NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03765918,Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689),https://clinicaltrials.gov/study/NCT03765918,,ACTIVE_NOT_RECRUITING,"This is a randomized, active-controlled, open-label study of pembrolizumab (Pembro) given prior to surgery and pembrolizumab in combination with standard of care radiotherapy (with or without cisplatin), as post-surgical therapy in treatment naÃ¯ve participants with newly diagnosed Stage III/IVA, resectable, locoregionally advanced, head and neck squamous cell carcinoma (LA-HNSCC). Efficacy outcomes will be stratified by programmed cell death ligand 1 (PD-L1) combined positive score (CPS) status. The primary hypothesis is that pembrolizumab given before surgery and after surgery in combination with radiotherapy (with or without cisplatin) improves event-free survival compared to radiotherapy (with or without cisplatin) given after surgery alone.",NO,Head and Neck Neoplasms,BIOLOGICAL: Pembrolizumab 200 mg|RADIATION: Radiotherapy 60 Gray|RADIATION: Radiotherapy 66 Gray|RADIATION: Radiotherapy 70 Gray|DRUG: Cisplatin 100 mg/m^2,"Event-free Survival (EFS), EFS is the time from the date of randomization to the date of first record of any of the following events: radiographic disease progression; local or distant progression or recurrence as assessed with imaging or biopsy as indicated; or death due to any cause. Radiographic disease progression during neoadjuvant phase that precludes surgery will be considered an event; a secondary malignancy will not be considered an event., Up to ~80 months","Major Pathological Response (mPR), The percentage of participants with a major pathological response (mPR) as assessed by the Central Pathologist at the time of definitive surgery. mPR is defined as â¤10% invasive squamous cell carcinoma within the resected primary tumor specimen and all the sampled regional lymph nodes., Up to ~64 months|Overall Survival (OS), OS is the time from randomization to death due to any cause., Up to ~92 months|Pathological Complete Response (pCR), Pathological complete response (pCR) is measured as the percentage of participants with a pathological complete response as assessed by the central pathologist at the time of definitive surgery. pCR is defined as having no residual invasive squamous cell carcinoma within the resected primary tumor specimen and all sampled regional lymph nodes., Up to ~64 months|Change From Baseline in Global Health Status/Quality of Life Scale (GHS/QoL), Change from baseline in the combined score of global health status (GHS)/quality of life (QoL) using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core Questionnaire (EORTC QLQ-C30) items 29 and 30. Participant responses to questions regarding overall health/QoL will be scored on a 7-point scale (1=Very poor to 7=Excellent) with a higher score indicating better overall health status., Prior to the first dose of study therapy (Baseline) and at the time of last follow-up (up to ~92 months)|Change From Baseline in Global Health Status/Physical Functioning Scales, Change from baseline in the combined score of physical functioning scale using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core Questionnaire (EORTC QLQ-C30) items 1 through 5. Participant responses to questions regarding their physical functioning will be scored on a 4-point scale (1=Not at All to 4=Very Much) with a higher score indicating worse physical functioning., Prior to the first dose of study therapy (Baseline) and at the time of last follow-up (up to ~92 months)|Change from Baseline in Swallowing, Speech, and Pain Symptoms, Change from baseline in the combined score of swallowing, speech, and pain symptoms using the European Organization for Research and Treatment of Cancer Head and Neck Questionnaire (EORTC QLQ-H\&N35) items 31-38, 46, and 53-54. Participant responses to questions regarding problems with swallowing, speech and pain in the mouth will be scored on a 4-point scale (1=Not at all to 4=Very much) with a higher score indicating more problems., Prior to the first dose of study therapy (Baseline) and at the time of last follow-up (up to ~92 months)|Percentage of Participants Experiencing An Adverse Event (AEs), Percentage of participants experiencing any sign, symptom, disease, or worsening of preexisting condition temporally associated with study therapy and irrespective of causality to study therapy, From time of first dose of study treatment until the end of follow-up (up to ~92 months)|Percentage of Participants Discontinuing Study Drug Due to AEs, Percentage of participants discontinuing study drug due to an AE, From time of first dose of study treatment until the end of treatment (up to 12 months)",,Merck Sharp & Dohme LLC,,ALL,"ADULT, OLDER_ADULT",PHASE3,714,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2018-12-17,2024-07-25,2026-09-10,2018-12-05,,2025-02-07,"Moores Cancer Center ( Site 1885), La Jolla, California, 92093-0698, United States|University of Southern California Norris Comprehensive Cancer Center ( Site 1850), Los Angeles, California, 90033, United States|Hoag Memoriall Hospital Presbyterian ( Site 2056), Newport Beach, California, 92688, United States|UC Davis Health System ( Site 1864), Sacramento, California, 95817, United States|St. Joseph Heritage Healthcare ( Site 1806), Santa Rosa, California, 95403, United States|University of Colorado Cancer Center ( Site 1838), Aurora, Colorado, 80045, United States|MedStar Washington Hospital Center ( Site 2062), Washington, District of Columbia, 20010, United States|George Washington University Medical Faculty Associates ( Site 2035), Washington, District of Columbia, 20037, United States|University of Florida ( Site 1832), Gainesville, Florida, 32608, United States|University of Miami, Sylvester Comprehensive Cancer Center ( Site 2008), Miami, Florida, 33136, United States|AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlando ( Site 2054), Orlando, Florida, 32804, United States|Orlando Health Cancer Institute ( Site 2061), Orlando, Florida, 32806, United States|Saint Alphonsus Regional Medical Center ( Site 2021), Boise, Idaho, 83706, United States|Beacon Cancer Care ( Site 2052), Post Falls, Idaho, 83854, United States|Rush University Medical Center ( Site 1823), Chicago, Illinois, 60607, United States|NorthShore University HealthSystem ( Site 1812), Evanston, Illinois, 60201, United States|Loyola University Medical Center [Maywood, IL] ( Site 1817), Maywood, Illinois, 60153, United States|University of Kansas Cancer Center ( Site 2004), Westwood, Kansas, 66205, United States|University of Kentucky Chandler Medical Center-Medical Oncology ( Site 2069), Lexington, Kentucky, 40536, United States|Ochsner Cancer Institute ( Site 2045), New Orleans, Louisiana, 70121, United States|University of Maryland ( Site 2031), Baltimore, Maryland, 21201, United States|Dana Farber Cancer Center ( Site 1873), Boston, Massachusetts, 02215, United States|University of Massachusetts Memorial Medical Center ( Site 1875), Worcester, Massachusetts, 01655, United States|Karmanos Cancer Institute ( Site 1870), Detroit, Michigan, 48201, United States|Henry Ford Health System ( Site 1803), Detroit, Michigan, 48202, United States|Southdale Cancer Care, University of Minnesota Medical Center- Edina ( Site 2016), Edina, Minnesota, 55435, United States|University of Missouri Hospital-Otolaryngology - Head and Neck Surgery ( Site 2058), Columbia, Missouri, 65212, United States|Washington University School of Medicine ( Site 1800), Saint Louis, Missouri, 63110, United States|Mercy Clinic Cancer and Hematology - Chub O'Reilly Cancer Center ( Site 1897), Springfield, Missouri, 65804, United States|St. Vincent Healthcare Frontier Cancer Center ( Site 1818), Billings, Montana, 59102, United States|Memorial Sloan Kettering Cancer Center Basking Ridge ( Site 2036), Basking Ridge, New Jersey, 07920, United States|Memorial Sloan Kettering Cancer Center- Monmouth ( Site 2039), Middletown, New Jersey, 07748, United States|MSKCC-Bergen ( Site 2037), Montvale, New Jersey, 07645, United States|Rutgers Cancer Institute of New Jersey ( Site 2071), New Brunswick, New Jersey, 08901, United States|Rutgers New Jersey Medical School-department of Hematology oncology ( Site 2053), Newark, New Jersey, 07103, United States|The University of New Mexico Comprehensive Cancer Center ( Site 1882), Albuquerque, New Mexico, 87131-0001, United States|Montefiore Einstein Center ( Site 2028), Bronx, New York, 10467, United States|Erie County Medical Center ( Site 2047), Buffalo, New York, 14215, United States|Memorial Sloan-Kettering Cancer Center at Commack ( Site 2038), Commack, New York, 11725, United States|Memorial Sloan-Kettering Cancer Center at West Harrison ( Site 2041), Harrison, New York, 10604, United States|Monter Cancer Center ( Site 2060), Lake Success, New York, 11042, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 2014), New York, New York, 10016, United States|Memorial Sloan Kettering Cancer Center ( Site 1857), New York, New York, 10065, United States|Weill Cornell Medical College ( Site 2050), New York, New York, 10065, United States|Northwell Health Cancer Institute ( Site 2030), New York, New York, 10075, United States|Stony Brook University ( Site 2063), Stony Brook, New York, 11794, United States|Memorial Sloan Kettering Cancer Center - Nassau ( Site 2040), Uniondale, New York, 11553, United States|Levine Cancer Institute ( Site 2003), Charlotte, North Carolina, 28204, United States|Wake Forest Compenhensive Cancer Center ( Site 2029), Winston-Salem, North Carolina, 27357, United States|Sanford Health Roger Maris Cancer Center ( Site 2034), Fargo, North Dakota, 58122, United States|University Hospitals ( Site 2032), Cleveland, Ohio, 44106, United States|The Ohio State University ( Site 2012), Columbus, Ohio, 43210, United States|Providence Portland Medical Center ( Site 1843), Portland, Oregon, 97220, United States|Kaiser Permanente Center for Health Research-Kaiser Permanente Medical Center ( Site 2022), Portland, Oregon, 97227, United States|Oregon Health Science University ( Site 1871), Portland, Oregon, 97239, United States|St. Luke's University Health Network ( Site 1801), Bethlehem, Pennsylvania, 18015, United States|Sidney Kimmel Cancer Center - Jefferson Health ( Site 2059), Philadelphia, Pennsylvania, 19107, United States|Allegheny General Hospital ( Site 1833), Pittsburgh, Pennsylvania, 15212, United States|Sanford Cancer Center Oncology Clinic ( Site 1859), Sioux Falls, South Dakota, 57104, United States|Avera Cancer Institute- Research ( Site 2070), Sioux Falls, South Dakota, 57105, United States|Henry Joyce Cancer Clinic ( Site 1827), Nashville, Tennessee, 37232, United States|UT Southwestern Medical Center ( Site 1841), Dallas, Texas, 75390, United States|USA Clinical Trials ( Site 2068), San Antonio, Texas, 78229, United States|University of Utah, Huntsman Cancer Institute ( Site 1855), Salt Lake City, Utah, 84112-5550, United States|University of Vermont Medical Center ( Site 2009), Burlington, Vermont, 05401, United States|UVA Health System - Emily Couric Cancer Center ( Site 1826), Charlottesville, Virginia, 22908, United States|Inova Schar Cancer Institute ( Site 2026), Fairfax, Virginia, 22031, United States|Seattle Cancer Care Alliance/Univ of Washington Medical Center ( Site 1865), Seattle, Washington, 98109, United States|Hospital Universitario Austral ( Site 0009), Pilar, Buenos Aires, B1629AHJ, Argentina|Centro de EducaciÃ³n MÃ©dica e Investigaciones ClÃ­nicas (CEMIC)-Medical Oncology ( Site 0019), Buenos Aires, Caba, C1431FWO, Argentina|Hospital Britanico de Buenos Aires ( Site 0012), Ciudad de Buenos Aires, Caba, C1280AEB, Argentina|Fundacion Estudios Clinicos-Oncology ( Site 0017), Rosario, Santa Fe, 2000, Argentina|Sanatorio Britanico ( Site 0013), Rosario, Santa Fe, S2000CVB, Argentina|Instituto de Oncologia de Rosario ( Site 0002), Rosario, Santa Fe, S2000KZE, Argentina|Hospital Provincial del Centenario ( Site 0008), Rosario, Santa Fe, S2002KDS, Argentina|IDIM - Instituto de DiagnÃ³stico e Investigaciones MetabÃ³licas ( Site 0016), Buenos Aires, 1012, Argentina|Hospital Aleman Buenos Aires Argentina ( Site 0004), Buenos Aires, C1118AAT, Argentina|Instituto de OncologÃ­a Angel Roffo ( Site 0003), Buenos Aires, C1417DTB, Argentina|CER San Juan Centro Polivalente de Asistencia e Investigacion Clinica ( Site 0010), San Juan, J5402DIL, Argentina|The Crown Princess Mary Cancer Centre - Westmead Hospital ( Site 0051), Westmead, New South Wales, 2145, Australia|Royal Brisbane and Women s Hospital ( Site 0050), Herston, Queensland, 4029, Australia|Ordensklinikum Linz Gmbh - Barmherzige Schwestern ( Site 1901), Linz, Oberosterreich, 4010, Austria|Landeskrankenhaus - Universitatsklinikum Graz ( Site 1902), Graz, Steiermark, 8036, Austria|Landeskrankenhaus Salzburg - Universitatklinikum der PMU ( Site 1900), Salzburg, 5020, Austria|Medizinische UniversitÃ¤t Wien ( Site 1903), Wien, 1090, Austria|Hopital de Jolimont ( Site 0103), Haine Saint Paul, Hainaut, 7100, Belgium|UZ Gent ( Site 0101), Gent, Oost-Vlaanderen, 9000, Belgium|AZ Nikolaas ( Site 0104), Sint-Niklaas, Oost-Vlaanderen, 9100, Belgium|Hospital Santa Izabel - Santa Casa de Misericordia da Bahia ( Site 0155), Salvador, Bahia, 40050-410, Brazil|Centro Regional Integrado de Oncologia ( Site 0160), Fortaleza, Ceara, 60336-232, Brazil|Hospital Marcio Cunha-Unidade de Pesquisa ClÃ­nica ( Site 0177), Ipatinga, Minas Gerais, 35162-189, Brazil|Liga Norte Riograndense Contra o Cancer ( Site 0171), Natal, Rio Grande Do Norte, 59075-740, Brazil|Hospital Nossa Senhora da Conceicao ( Site 0165), Porto Alegre, Rio Grande Do Sul, 91359-200, Brazil|Hospital de Base de Sao Jose de Rio Preto ( Site 0153), Sao Jose do Rio Preto, Sao Paulo, 15090-000, Brazil|Instituto Nacional do Cancer Jose Alencar Gomes da Silva INCA ( Site 0169), Rio de Janeiro, 20231-050, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0167), Sao Paulo, 01246-000, Brazil|BP - A Beneficencia Portuguesa de SÃ£o Paulo-Medical Oncology ( Site 0175), Sao Paulo, 01321-001, Brazil|Cross Cancer Institute ( Site 0201), Edmonton, Alberta, T6G 1Z2, Canada|Sunnybrook Research Institute ( Site 0211), Toronto, Ontario, M4N 3M5, Canada|Princess Margaret Cancer Centre ( Site 0202), Toronto, Ontario, M5G 2M9, Canada|McGill University Health Centre ( Site 0210), Montreal, Quebec, H4A 3J1, Canada|CIUSSS de l'Estrie-CHUS ( Site 0209), Sherbrooke, Quebec, J1H 5N4, Canada|Fundacion Arturo Lopez Perez FALP ( Site 0251), Santiago, Region M. De Santiago, 7500921, Chile|Clinica de la Costa S.A.S. ( Site 0307), Barranquilla, Atlantico, 080020, Colombia|Centro de Investigacion Clinica del Country ( Site 0304), Bogota, Distrito Capital De Bogota, 110221, Colombia|Oncologos del Occidente S.A. ( Site 0310), Pereira, Risaralda, 661002, Colombia|Centro Medico Imbanaco de Cali S.A ( Site 0300), Cali, Valle Del Cauca, 760042, Colombia|Centre Antoine Lacassagne ( Site 0351), Nice, Alpes-Maritimes, 06189, France|Hopital de la Timone ( Site 0356), Marseille, Bouches-du-Rhone, 13385, France|Institut Claudius Regaud IUCT Oncopole ( Site 0355), Toulouse, Haute-Garonne, 31059, France|Institut Gustave Roussy ( Site 0353), Villejuif, Val-de-Marne, 94800, France|Institut Sainte Catherine ( Site 0352), Avignon, Vaucluse, 84918, France|Hopital Europeen Georges Pompidou ( Site 0358), Paris, 75015, France|Institut Curie ( Site 0350), Paris, 75248, France|Universitaetsklinikum Tuebingen - Medizinische Klinik ( Site 0401), Tuebingen, Baden-Wurttemberg, 72076, Germany|Universitaetsklinikum Ulm ( Site 0402), Ulm, Baden-Wurttemberg, 89075, Germany|Universitaetsklinikum Erlangen-Strahlenklinik ( Site 0412), Erlangen, Bayern, 91054, Germany|Klinikum rechts der Isar der Technischen Universitaet ( Site 0409), Muenchen, Bayern, 81675, Germany|Klinikum rechts der Isar der Technischen UniversitÃ¤t MÃ¼nchen-HNO Klinik ( Site 0405), MÃ¼nchen, Bayern, 81675, Germany|Universitaetsklinikum Frankfurt ( Site 0403), Frankfurt, Hessen, 60590, Germany|Klinikum Kassel GmbH ( Site 0404), Kassel, Hessen, 34125, Germany|Universitaetsklinikum Koeln ( Site 0413), KÃ¶ln, Nordrhein-Westfalen, 50937, Germany|UniversitÃ¤tsklinikum Schleswig-Holstein ( Site 0411), Luebeck, Schleswig-Holstein, 23538, Germany|SRH Wald-Klinikum Gera GmbH ( Site 0406), Gera, Thuringen, 07548, Germany|Charite UniversitÃ¤tsmedizin Berlin Campus Benjamin Franklin ( Site 0414), Berlin, 12203, Germany|Universitaetsklinikum Hamburg Eppendorf ( Site 0407), Hamburg, 20246, Germany|Pecsi Tudomanyegyetem Onkoterapias Intezet ( Site 0452), Pecs, Baranya, 7621, Hungary|JÃ¡sz-Nagykun-Szolnok VÃ¡rmegyei HetÃ©nyi GÃ©za KÃ³rhÃ¡z ( Site 0450), Szolnok, Jasz-Nagykun-Szolnok, 5000, Hungary|Eszak-Pesti Centrumkorhaz-Honvedkorhaz ( Site 0453), Budapest, 1062, Hungary|Orszagos Onkologiai Intezet ( Site 0454), Budapest, 1122, Hungary|St. James s Hospital ( Site 0500), Dublin, Dublin 8, Ireland|Rambam Health Care Campus-Oncology Division ( Site 0550), Haifa, 3109601, Israel|Hadassah Medical Center. Ein Kerem ( Site 0554), Jerusalem, 9112001, Israel|Rabin Medical Center ( Site 0552), Petah Tikva, 4963211, Israel|Chaim Sheba Medical Center. ( Site 0553), Ramat Gan, 5265601, Israel|Sourasky Medical Center ( Site 0551), Tel Aviv, 6423906, Israel|Aichi Cancer Center Hospital ( Site 0658), Nagoya, Aichi, 464-8681, Japan|National Cancer Center Hospital East ( Site 0661), Kashiwa, Chiba, 277-8577, Japan|Hyogo Cancer Center ( Site 0656), Akashi, Hyogo, 673-8558, Japan|Kagawa University Hospital ( Site 0651), Kita-gun, Kagawa, 761-0793, Japan|Yokohama City University Hospital ( Site 0657), Yokohama, Kanagawa, 236-0004, Japan|Chiba Cancer Center ( Site 0652), Chiba, 260-8717, Japan|National Hospital Organization Kyushu Cancer Center ( Site 0660), Fukuoka, 811-1395, Japan|Hiroshima University Hospital ( Site 0655), Hiroshima, 734-8551, Japan|National Cancer Center Hospital ( Site 0650), Tokyo, 104-0045, Japan|Tokyo Medical and Dental University Hospital ( Site 0654), Tokyo, 113-8519, Japan|Tokyo Medical University Hospital ( Site 0659), Tokyo, 160-0023, Japan|Chonnam National University Hwasun Hospital ( Site 0705), Hwasun Gun, Jeonranamdo, 58128, Korea, Republic of|National Cancer Center ( Site 0702), Goyang-si, Kyonggi-do, 10408, Korea, Republic of|The Catholic University of Korea St. Vincent s Hospital ( Site 0704), Gyeonggi-do, Kyonggi-do, 16247, Korea, Republic of|Seoul National University Bundang Hospital ( Site 0703), Seongnam-si, Kyonggi-do, 13620, Korea, Republic of|Severance Hospital, Yonsei University Health System ( Site 0701), Seoul, 03722, Korea, Republic of|Wojewodzki Szpital Specjalistyczny im. M. Kopernika w Lodzi ( Site 0920), Lodz, Lodzkie, 93-513, Poland|Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie ( Site 0905), Krakow, Malopolskie, 31-826, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (, Warszawa, Mazowieckie, 02-781, Poland|Szpitale Pomorskie Sp. z o.o. ( Site 0935), Gdynia, Pomorskie, 81-159, Poland|Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 0901), Gliwice, Slaskie, 44101, Poland|Hospital de Braga ( Site 0951), Braga, 4710-243, Portugal|CHLN Hospital Santa Maria ( Site 0952), Lisboa, 1649-035, Portugal|Hospital CUF Descobertas ( Site 0953), Lisboa, 1998-018, Portugal|Inst. Portugues de Oncologia de Porto Francisco Gentil EPE ( Site 0950), Porto, 4200-072, Portugal|N.N. Blokhin NMRCO ( Site 1005), Moscow, Moskva, 115522, Russian Federation|Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 1000), Kazan, Tatarstan, Respublika, 420029, Russian Federation|Yaroslavl Regional SBIH Clinical Oncology Hospital ( Site 1001), Yaroslavl, Yaroslavskaya Oblast, 150054, Russian Federation|Hospital Germans Trias i Pujol. ICO de Badalona ( Site 1204), Badalona, Barcelona, 08916, Spain|ICO L Hospitalet ( Site 1208), Hospitalet de Llobregat, Barcelona, 08908, Spain|Hospital Clinico Universitario de Santiago ( Site 1207), Santiago de Compostela, La Coruna, 15706, Spain|Hospital Vall D Hebron ( Site 1200), Barcelona, 08035, Spain|Hospital Universitario La Paz ( Site 1201), Madrid, 28046, Spain|Hospital Universitario Virgen del Rocio ( Site 1206), Sevilla, 41013, Spain|Universitaetsspital Zurich ( Site 1923), Zuerich, Aargau, 8091, Switzerland|Istituto Oncologica della Svizzera Italiana (IOSI) ( Site 1921), Bellinzona, Ticino, 6500, Switzerland|Hopitaux Universitaires de Geneve HUG ( Site 1920), Geneve, 1211, Switzerland|Chang Gung Medical Foundation. Kaohsiung Branch ( Site 1303), Kaohsiung, 833, Taiwan|Taichung Veterans General Hospital ( Site 1301), Taichung, 40705, Taiwan|National Cheng Kung University Hospital ( Site 1302), Tainan, 704, Taiwan|National Taiwan University Hospital ( Site 1300), Taipei, 10002, Taiwan|Dnipropetrovsk Regional Hospital n.a. I.I. Mechnikov ( Site 1709), Dnipropetrovsk, Dnipropetrovska Oblast, 49005, Ukraine|Clinical oncology dispensary of Dnipro ( Site 1706), Dnipro, Dnipropetrovska Oblast, 49055, Ukraine|Municipal Non-Profit Enterprise City Clinical Hospital 4 of Dnipro City Council ( Site 1705), Dnipro, Dnipropetrovska Oblast, 49102, Ukraine|Ukrainian Center of Tomotherapy ( Site 1708), Kropyvnitskiy, Kirovohradska Oblast, 25011, Ukraine|PP PPC Acinus Medical and Diagnostic Centre ( Site 1704), Kropyvnytskyi, Kirovohradska Oblast, 25006, Ukraine|Medical Center of Yuriy Spizhenko LLC.-Clinical Trial ( Site 1703), Kapitanivka Village, Kyivska Oblast, 08111, Ukraine|National Cancer Institute of the MoH of Ukraine ( Site 1702), Kyiv, Kyivska Oblast, 03022, Ukraine|LISOD. Hospital ( Site 1707), Pliuty, Kyiv, 08720, Ukraine|Kyiv City Clinical Oncology Centre ( Site 1701), Kyiv, 03115, Ukraine|Addenbrooke's Hospital ( Site 1610), Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom|Castle Hill Hospital ( Site 1601), Cottingham-Hull, Kingston Upon Hull, HU16 5JQ, United Kingdom|Guy s & St Thomas NHS Foundation Trust ( Site 1604), London, London, City Of, SE1 9RT, United Kingdom|Royal Marsden Hospital - Fulham Road London ( Site 1609), London, London, City Of, SW3 6JJ, United Kingdom|Imperial Healthcare NHS Trust Charing Cross Hospital ( Site 1603), London, London, City Of, W6 8RF, United Kingdom|Weston Park Hospital ( Site 1607), Sheffield, S10 2SJ, United Kingdom",
NCT05572515,"A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma",https://clinicaltrials.gov/study/NCT05572515,MajesTEC-9,RECRUITING,The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd in Part 1 and to further characterize safety and efficacy of an alternative dosing for teclistamab in Part 2 in participants with relapsed or refractory multiple myeloma.,NO,Relapsed or Refractory Multiple Myeloma,DRUG: Teclistamab|DRUG: Pomalidomide|DRUG: Bortezomib|DRUG: Dexamethasone|DRUG: Carfilzomib,"Part 1: Progression-free Survival (PFS), PFS is defined as the time from the date of randomization to the date of first documented disease progression, as defined in the International myeloma working group (IMWG) 2016 response criteria, or death due to any cause, whichever occurs first., Up to 9 years|Part 2: Number of Participants Reporting Cytokine Release Syndrome (CRS) Cases by Severity, Severity for CRS will be graded as follows: Grade 1: Fever (Temperature greater than or equal to \[\>=\] 38Â°C); Grade 2: Fever (Temperature \>=38Â°C) with either: hypotension and/or hypoxia requiring low-flow nasal cannula or blow-by; Grade 3: Fever (Temperature \>=38Â°C) with either: hypotension and/or hypoxia requiring high-flow nasal cannula, facemask, nonrebreather mask, or Venturi mask; Grade 4: Fever (Temperature \>=38Â°C) with either: hypotension requiring multiple vasopressors (excluding vasopressin), and/or hypoxia requiring positive pressure and Grade 5: Death., Up to 9 years","Part 1 and 2: Overall Response (Partial Response [PR] or Better), Overall response (PR or better) is defined as participants who have a PR or better prior to subsequent antimyeloma therapy in accordance with the IMWG 2016 criteria., Up to 9 years|Part 1 and 2: Very Good Partial Response (VGPR) or Better Response, VGPR or better (Stringent Complete Response \[sCR\]+Complete Response \[CR\]+VGPR) is defined as participants who achieve a VGPR or better response prior to subsequent antimyeloma therapy in accordance with the IMWG 2016 criteria., Up to 9 years|Part 1 and 2: Complete Response (CR) or Better Response, CR or better response is defined as participants who achieve a CR or better response prior to subsequent antimyeloma therapy in accordance with the IMWG 2016 criteria., Up to 9 years|Part 1: Duration of Response (DOR), DOR is defined as the time interval between the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease according to the IMWG 2016 response criteria or death due to any cause, whichever occurs first., Up to 9 years|Part 1: Time to Next Treatment (TTNT), TTNT is defined as the time from randomization to the start of subsequent antimyeloma treatment., Up to 9 years|Part 1: Progression-free Survival on Next-line Therapy (PFS2), PFS2 is defined as the time interval between the date of randomization and date of event, which is defined as progressive disease as assessed by investigator on the first subsequent line of antimyeloma therapy, or death from any cause, whichever occurs first., Up to 9 years|Part 1: Overall Survival (OS), OS is defined as the time from the date of randomization to the date of the participant's death due to any cause., Up to 9 years|Part 1 and 2: Number of Participants with Adverse Events (AEs) by Severity, Number of participants with AEs by Severity will be reported., Up to 9 years|Part 1 and 2: Number of Participants with Serious Adverse Events (SAEs) by Severity, Number of participants with SAEs by Severity will be reported., Up to 9 years|Part 1 and 2: Number of Participants with Abnormal Laboratory Results, Number of participants with abnormal laboratory results (such as hematology and chemistry) will be reported., Up to 9 years|Part 1 and 2: Serum Concentrations of Teclistamab, Serum concentrations of teclistamab will be reported., Up to 9 years|Part 1 and 2: Number of Participants with Anti-drug Antibodies (ADAs) to Teclistamab, Number of participants with ADAs to teclistamab will be reported., Up to 9 years|Part 1: Change from Baseline in Symptoms, Functioning, and Overall Health-related Quality of Life (HRQoL) as Assessed by European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC-QLQ-C30), Change from baseline in symptoms, functioning, and overall HRQoL assessed by EORTC QLQ-C30 score version 3 will be reported. The EORTC- QLQ-C30 Version 3 includes 30 items that make up 5 functional scales (physical, role, emotional, cognitive, and social), 1 global health status scale, 3 symptom scales (pain, fatigue, and nausea/vomiting), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The item and scale scores are transformed to a 0 to 100 scale. A high scale score represents a higher response level. Thus, a high score for a functional scale represents a high/healthy level of functioning and a high score for the global health status represents high HRQoL, but a high score for a symptom scale/item represents a high level of symptomatology/problems., Baseline up to 9 years|Part 1: Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) Scale Score, Change from baseline in symptoms, functioning, and overall HRQoL assessed by MySIm-Q will be reported. The MySIm-Q is a disease-specific PRO assessment complementary to the EORTC-QLQ-C30. It includes 17 items resulting in a symptom subscale and an impact subscale. The recall period is the ""past 7 days"", and responses are reported on a 5-point verbal rating scale., Baseline up to 9 years|Part 1: Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), Change from baseline in symptoms, functioning, and overall HRQoL assessed by PRO-CTCAE will be reported. The National Cancer Institute's (NCI's) PRO-CTCAE is an item library of common adverse events experienced by people with cancer that are appropriate for self-reporting of treatment tolerability. Each symptom selected for inclusion can be rated by up to 3 attributes characterizing the presence/frequency, severity, and/or interference of the AEs. It ranges from 0 to 4 with higher scores indicating higher frequency or greater severity/impact., Baseline up to 9 years|Part 1: Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by EuroQol Five Dimension Questionnaire 5-Level (EQ-5D-5L), Change from baseline in symptoms, functioning, and overall HRQoL assessed by EQ-5D-5L will be reported. The EQ-5D-5L is a generic measure of health status. The EQ-5D-5L is a 5-item questionnaire that assesses 5 domains including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression plus a visual analog scale rating ""health today"" with anchors ranging from 0 (worst imaginable health state) to 100 (best imaginable health state)., Baseline up to 9 years|Part 1: Time to Worsening in Symptoms, Functioning, and Overall HRQoL, Time to worsening in symptoms, functioning, and overall HRQoL will be measured as the interval from the date of randomization to the start date of meaningful change., Up to 9 years|Part 1: PFS in Participants in High-risk Molecular Features, PFS in participants in high-risk molecular features will be reported. PFS is defined as the time from the date of randomization to the date of first documented disease progression, as defined in the IMWG 2016 response criteria, or death due to any cause, whichever occurs first., Up to 9 years|Part 1: Depth of Response in Participants in High-risk Molecular Features, Depth of response in participants in high-risk molecular features will be reported., Up to 9 years",,"Janssen Research & Development, LLC",,ALL,"ADULT, OLDER_ADULT",PHASE3,650,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-03-29,2026-02-13,2031-08-31,2022-10-07,,2025-05-23,"Alaska Oncology and Hematology LLC, Anchorage, Alaska, 99508, United States|Banner MD Anderson Cancer Center, Gilbert, Arizona, 85234, United States|Alta Bates Comprehensive Cancer Center, Berkeley, California, 94704, United States|MemorialCare Long Beach Medical Center, Long Beach, California, 90806, United States|University of California Irvine, Orange, California, 92868, United States|PIH Health Hospital, Whittier, California, 90602, United States|Rocky Mountain Cancer Centers, Aurora, Colorado, 80012, United States|University of Connecticut, Farmington, Connecticut, 06030, United States|University of Miami Sylvester Cancer Center, Miami, Florida, 33136, United States|Orlando Health Cancer Institute, Orlando, Florida, 32806, United States|Cleveland Clinic Florida, Weston, Florida, 33331, United States|Mission Cancer Blood, Des Moines, Iowa, 50309, United States|East Jefferson General Hospital Bone Marrow Transport Clinic, Metairie, Louisiana, 70006, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, 20889, United States|Maryland Oncology Hematology P A, Silver Spring, Maryland, 20904, United States|Boston University Medical Center, Boston, Massachusetts, 02118, United States|Saint Lukes Hospital Saint Lukes Cancer Specialists, Chesterfield, Missouri, 63017, United States|Cooper Health System MD Anderson Cancer Center at Cooper, Camden, New Jersey, 08103, United States|Herbert Irving Comprehensive Cancer Center Columbia University Medical Center, New York, New York, 10032, United States|Durham VAMC, Durham, North Carolina, 27705, United States|Penn Medicine Lancaster General Health, Lancaster, Pennsylvania, 17601, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, 78234, United States|Baylor College of Medicine, Houston, Texas, 77030, United States|Michael E DeBakey VA Medical Center, Houston, Texas, 77030, United States|Harris Health Smith Clinic, Houston, Texas, 77054, United States|Utah Cancer Specialists, Salt Lake City, Utah, 84106, United States|Alexander T. Augusta Military Medical Center, Fort Belvoir, Virginia, 22060, United States|Virginia Oncology Associates, Norfolk, Virginia, 23502, United States|NorthWest Medical Specialties, PLLC, Tacoma, Washington, 98405, United States|Blacktown Hospital, Blacktown, 2148, Australia|St Vincents Hospital Melbourne, Fitzroy, 3065, Australia|Box Hill Hospital, Melbourne, 3128, Australia|Fiona Stanley Hospital, Murdoch, 6150, Australia|Sir Charles Gairdner Hospital, Nedlands, 6009, Australia|LKH - UniversitÃ¤tsklinikum der PMU Salzburg, Salzburg, 5020, Austria|Medical University Vienna MUV, Vienna, A-1090, Austria|Algemeen Ziekenhuis Klina, Brasschaat, 2930, Belgium|Jolimont, Haine-St-Paul, 7100, Belgium|Az Groeninge, Kortrijk, 8500, Belgium|Universitair Ziekenhuis Gasthuisberg, Leuven, 3000, Belgium|CHR de la Citadelle, Liege, 4000, Belgium|Hospitais Integradaos da Gavea S/A - DF Star, Brasilia, 70390-140, Brazil|Fundacao Universidade de Caxias do Sul, Caxias do Sul, 95070 560, Brazil|Liga Paranaense de Combate ao Cancer, Curitiba, 81520 060, Brazil|Instituto Joinvilense de Hematologia e Oncologia Ltda Centro de Hematologia e Oncologia, Joinville, 89201-260, Brazil|Liga Norte Riograndense Contra O Cancer, Natal, 59062 000, Brazil|Complexo Hospitalar de Niteroi, Niteroi, 24020-073, Brazil|Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI), Rio de Janeiro, 22775-001, Brazil|Hospital Sao Rafael, Salvador, 41253-190, Brazil|Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto Hospital de Base, Sao Jose do Rio Preto, 15090-000, Brazil|Sociedade Beneficente de Senhoras Hospital Sirio Libanes, Sao Paulo, 01308-901, Brazil|Instituto D Or de Pesquisa e Ensino IDOR, Sao Paulo, 01401 002, Brazil|Fundacao Antonio Prudente A C Camargo Cancer Center, Sao Paulo, 01509 900, Brazil|Clinica Medica Sao Germano LTDA, Sao Paulo, 04537 081, Brazil|Real e BenemÃ©rita AssociaÃ§Ã£o Portuguesa de BeneficÃªncia, SÃ£o Paulo, 01321-001, Brazil|Hospital Alemao Oswaldo Cruz, SÃ£o Paulo, 01323-001, Brazil|Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein, SÃ£o Paulo, 05652-900, Brazil|Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta, T2N 5G2, Canada|Saint John Regional Hospital, Saint John, New Brunswick, E2L 4L2, Canada|Brampton Civic Hospital, Brampton, Ontario, L6R 3J7, Canada|Lakeridge Health Oshawa, Oshawa, Ontario, L1G2B9, Canada|CIUSSS de l Est de l Ile de Montreal Installation Hopital Maisonneuve Rosemont, Montreal, Quebec, H1T 2M4, Canada|Beijing Chaoyang Hospital, Beijing, 100020, China|BeiJing JiShuiTan Hospital, Beijing, 102208, China|The First Bethune Hospital of Jilin University, Changchun, 130021, China|The Third Xiangya Hospital, Central South University, Changsha, 410013, China|Sichuan Provincial Peoples Hospital, Chengdu, 610032, China|Chongqing University Cancer Hospital, Chongqing, 400030, China|Fujian Meidical University Union Hospital, Fu Zhou, 350001, China|Sun Yat -Sen University Cancer Center, Guangzhou, 510060, China|First affiliated Hospital of Zhejiang University, Hangzhou, 310003, China|Harbin medical university cancer hospital, Harbin, 150000, China|The First Affiliated Hospital of NanChang University, Nanchang, 330006, China|Nanjing Drum Tower Hospital, Nanjing, 210008, China|First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, China|Shanghai Fourth People s Hospital, Shanghai, 200434, China|Shengjing Hospital Of China Medical University, Shenyang, 110055, China|Shenzhen 2nd People's Hospital, Shenzhen, 518025, China|Institute of Hematology and Blood Diseases Hospital, Tian Jin, 300020, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China|The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China|Wuhan Union Hospital, Wuhan, 430023, China|Wuxi People s Hospital, Wuxi, 214023, China|The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710004, China|Henan Cancer Hospital, Zhengzhou, 450008, China|Fakultni nemocnice Brno, Brno, 625 00, Czechia|Fakultni nemocnice Olomouc, Olomouc, 779 00, Czechia|Fakultni Nemocnice Ostrava, Ostrava - Poruba, 708 52, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, 128 08, Czechia|Aalborg University Hospital, Aalborg, 9000, Denmark|Aarhus University Hospital, Aarhus, 8200, Denmark|Rigshospitalet, Copenhagen, DK-2100, Denmark|Regionshospitalet Godstrup, Herning, 7400, Denmark|Odense Universitetshospital, Odense C, 5000, Denmark|Vejle Sygehus, Vejle, 7100, Denmark|CHU Amiens - Hopital Sud, AMIENS cedex 1, 80000, France|HÃ´pital CÃ´te de Nacre, Caen cedex 9, 14003, France|CHU Grenoble, Grenoble, 38700, France|Centre Hospitalier du Mans, Le Mans, 72000, France|Hopital Saint Vincent de Paul, Lille, 59020, France|CHU de Montpellier Hopital Saint Eloi, Montpellier, 34090, France|CHU Nantes, Nantes Cedex 1, 44000, France|Hopital Saint-Antoine, Paris, 75012, France|Hopital de la Pitie Salpetriere, Paris, 75013, France|Hopital Necker Enfants Malades, Paris, 75743, France|Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, 31100, France|CHU de Nancy - Hopital de Brabois, VandÅuvre-lÃ¨s-Nancy, 54500, France|Medizinische Universitat Lausitz Carl Thiem, Cottbus, 03048, Germany|Universitatsklinikum Carl Gustav Carus Dresden, Dresden, 01307, Germany|UniversitÃ¤tsmedizin Greifswald, Greifswald, 17475, Germany|Asklepios Klinik Altona, Hamburg, 22763, Germany|Universitaetsklinikum Heidelberg, Heidelberg, 69120, Germany|Universitaetsklinikum Giessen und Marburg GmbH, Marburg, 35043, Germany|Universitatsklinikum Tubingen, TÃ¼bingen, 72076, Germany|Universitatsklinikum Ulm, Ulm, 89070, Germany|Heinrich-Braun-Klinikum gGmbH, Zwickau, 08060, Germany|Alexandra General Hospital of Athens, Athens Attica, 115 28, Greece|Agios Andreas General Hospital of Patra, Patra, 263 35, Greece|G Papanikolaou Hospital of Thessaloniki, Thessaloniki, 570 10, Greece|Fortis Memorial Research Institute, Gurgaon, 122002, India|Bhagwan Mahaveer Cancer Hospital & Research Centre, Jaipur, 302017, India|Deenanath Mangeshkar Hospital and Research Centre, Pune, 411004, India|Hillel Yaffe Medical Center, Hadera, 3810101, Israel|Bnai Zion Medical Center, Haifa, 31048, Israel|Carmel Medical Center, Haifa, 3436212, Israel|Rabin Medical Center, Petah Tikva, 49100, Israel|Sheba Medical Center, Ramat Gan, 52621, Israel|Tel Aviv Sourasky Medical Center, Tel-Aviv, 64239, Israel|A O U Sant Orsola Malpighi, Bologna, 40138, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, 20133, Italy|Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone, Palermo, 90127, Italy|Ospedale Santa Chiara AO Universitaria Pisana, Pisa, 56126, Italy|Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, 42123, Italy|Campus Bio Medico di Roma, Roma, 00128, Italy|A O Universitaria Senese Ospedale Santa Maria alle Scotte, Siena, 53100, Italy|A.O.U. Citta della Salute e della Scienza di Torino - Presidio Molinette, Turin, 10126, Italy|ASUI Santa Maria della Misericordia di Udine, Udine, 33100, Italy|Ospedale di Circolo e Fondazione Macchi, Varese, 21100, Italy|Institute of Science Tokyo Hospital, Bunkyo ku, 113 8519, Japan|Chiba Cancer Center, Chiba, 260-8717, Japan|Ogaki Municipal Hospital, Gifu, 503-8502, Japan|National Hospital Organization Shibukawa Medical Center, Gunma, 377-0280, Japan|Kansai Medical University Hospital, Hirakata, 573 1191, Japan|Hitachi General Hospital, Hitachi, 317-0077, Japan|Saitama Medical University Hospital, Iruma-gun, 350-0495, Japan|Kameda Medical Center, Kamogawa City, 296-8602, Japan|National Cancer Center Hospital East, Kashiwa, 277 8577, Japan|Kurashiki Central Hospital, Kurashiki, 710-8602, Japan|Matsuyama Red Cross Hospital, Matsuyama, 790-8524, Japan|Aichi Medical University Hospital, Nagakute, 480-1195, Japan|JRC Nagasaki Genbaku Hospital, Nagasaki-Shi, 852-8511, Japan|Niigata University Medical And Dental Hospital, Niigata, 951 8520, Japan|National Hospital Organization Okayama Medical Center, Okayama, 701-1192, Japan|Osaka Metropolitan University Hospital, Osaka, 545 8586, Japan|Hokkaido University Hospital, Sapporo, 060-8648, Japan|Juntendo University Hospital, Tokyo, 113-0033, Japan|The Cancer Institute Hospital of JFCR, Tokyo, 135 8550, Japan|Yamagata University Hospital, Yamagata, 990 2331, Japan|Yamanashi Prefectural Central Hospital, Yamanashi, 400-8506, Japan|Hospital Pulau Pinang, Georgetown, 10450, Malaysia|Hospital Queen Elizabeth, Kota Kinabalu, 88200, Malaysia|University Malaya Medical Centre, Kuala Lumpur, 59100, Malaysia|Subang Jaya Medical Centre, Subang Jaya, 47500, Malaysia|Meander Medisch Centrum, Amersfoort, 3813 TZ, Netherlands|VUMC Amsterdam, Amsterdam, 1081 HV, Netherlands|Universitair Medisch Centrum Groningen, Groningen, 9700 RB, Netherlands|UMC Utrecht, Utrecht, 3584 CX, Netherlands|Uniwersyteckie Centrum Kliniczne, Gdansk, 80 214, Poland|Pratia Onkologia Katowice, Katowice, 40 519, Poland|Swietokrzyskie Centrum Onkologii SPZOZ w Kielcach, Kielce, 25 734, Poland|Uniwersytecki Szpital Kliniczny Nr 1 w Lublinie, Lublin, 20-081, Poland|Uls Almada Seixal - Hosp. Garcia de Orta, Almada, 2805-267, Portugal|Uls Braga - Hosp. Braga, Braga, 4710-243, Portugal|Champalimaud Foundation Champalimaud Centre, Lisbon, 1400-038, Portugal|Instituto Portugues de Oncologia, Porto, 4200072, Portugal|Uls Gaia Espinho, Vila Nova de Gaia, 4434-502, Portugal|Hosp. Univ. Germans Trias I Pujol, Badalona, 08916, Spain|Institut Catala d Oncologia L Hospitalet, Hospitalet de Llobregat, 08908, Spain|Hosp. de Jerez de La Frontera, Jerez de la Frontera, 11407, Spain|Hosp. de Leon, Leon, 24008, Spain|Hosp. Univ. Infanta Leonor, Madrid, 28031, Spain|Hosp. Univ. Ramon Y Cajal, Madrid, 28034, Spain|Hosp. Univ. 12 de Octubre, Madrid, 28041, Spain|Hosp. Gral. Univ. J.M. Morales Meseguer, Murcia, 30008, Spain|Hospital Universitario Central de Asturias, Oviedo, 33011, Spain|Hosp. Son Llatzer, Palma de Mallorca, 07198, Spain|Hosp. Montecelo, Pontevedra, 36071, Spain|Hosp. Quiron Madrid Pozuelo, Pozuelo de Alarcon, 28223, Spain|Hospital Universitari i Politecnic La Fe, ValÃ¨ncia, 46026, Spain|Falu Lasarett Medicinkliniken Falun, Falun, 791 82, Sweden|Helsingborgs lasarett, Helsingborg, 25287, Sweden|Akademiska Sjukhuset, Uppsala, 751 85, Sweden|Ankara Gulhane Training and Research Hospital, Ankara, 06010, Turkey|Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, 06200, Turkey|Ankara University Medical Faculty, Ankara, 06620, Turkey|Liv Hospital Ankara, Ankara, 06680, Turkey|Antalya Training And Research Hospital, Antalya, 07100, Turkey|Ondokuz Mayis University, Atakum, 55280, Turkey|Pamukkale University Medical Faculty, Denizli, 20070, Turkey|Medipol University Hospital, Istanbul, 34214, Turkey|Aberdeen Royal Infirmary, Aberdeen, AB25 2ZN, United Kingdom|University Hospitals Birmingham NHS Foundation Trust, Birmingham, B15 2GW, United Kingdom|Colchester Hospital University NHS, Colchester, CO4 5JL, United Kingdom|The Clatterbridge Cancer Centre, Liverpool, L7 8YA, United Kingdom|Chelsea And Westminster Hospital, London, SW10 9NH, United Kingdom|St George's Hospital, London, SW17 0QT, United Kingdom|James Cook University Hospital, Middlesborough, Ts4 3Bw, United Kingdom|Norfolk and Norwich University Hospital, Norwich, NR4 7UY, United Kingdom|Royal Stoke University Hospital, Staffordshire, ST4 6QG, United Kingdom",
NCT05057494,A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,https://clinicaltrials.gov/study/NCT05057494,MAJIC,ACTIVE_NOT_RECRUITING,A study of acalabrutinib plus venetoclax (AV) versus venetoclax plus obinutuzumab (VO) in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.,NO,Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,DRUG: Acalabrutinib|DRUG: Venetoclax|DRUG: Obinutuzumab,"Progression-free Survival (PFS), To assess whether minimal residual disease (MRD)-driven finite AV treatment is NI to MRD-driven finite VO treatment with respect to PFS. PFS is defined as the time from the date of randomization until date of objective progressive disease per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 criteria as assessed by the investigator or death from any cause in the absence of progression., Until progressive disease (PD) [assessed Up to 6.6 Years].","Rate of peripheral blood (PB) undetectable minimal residual disease (uMRD) based on a clonoSEQ^Â®, To assess the effect of AV treatment compared with VO treatment on uMRD at sequential time points. Rate of PB uMRD is defined as proportion of participants achieving remission based on a clonoSEQ\^Â® assay result of \< 1 CLL cell per 100,000 leukocytes (\< 10 \^-5 ), after completion of 6 and 12 cycles of venetoclax (assessed at approximately 7/13 and 9/15 months for VO and AV, respectively), and at 24, 36, 48 and 60 months., Screening (Days -45 through -1); Arm A (AV): Day 28 of Cycles 8, 14 and 24 and post treatment follow up visits; Arm B (VO): Day 28 of Cycles 6, 12 and 24 and post treatment follow up visits|Rate of peripheral blood (PB) and Bone marrow (BM) undetectable minimal residual disease (uMRD) by flow cytometry, To assess the effect of AV treatment compared with VO treatment on uMRD at sequential timepoints. Rate of PB and BM uMRD is defined as \< 1 CLL cell per 10,000 leukocytes (\< 10\^-4) by flow cytometry, after completion of 12 cycles of venetoclax (assessed at approximately 13 and 15 months for VO and AV, respectively) and at 36 months., Cycle 14 (each Cycle length 28 days) Day 28 for Arm A (AV); Cycle 12 Day 28 for Arm B (VO) and Post treatment follow-up visits (assessed Up to 6.6 Years)|Overall Survival (OS), To assess the effect of AV treatment compared with VO treatment on OS. OS is defined as the time from the date of randomization until death from any cause., Date of randomization until death from any cause (Assessed Up to 6.6 Years)|Event-free Survival (EFS), To assess the effect of AV treatment compared with VO treatment on EFS. EFS is defined as the time from the date of randomization to the first occurrence of disease progression, initiation of subsequent CLL therapy, or death from any cause., Date of randomization until first occurrence of disease progression (Assessed Up to 6.6 Years)|Overall Response Rate (ORR), To assess the effect of AV treatment compared with VO treatment on ORR. ORR is defined as the proportion of participants who achieve best response of Complete Response (CR), complete response with incomplete marrow recovery (Cri), nodular partial remission (nPR), or partial remission (PR) per iwCLL 2018 criteria as assessed by the investigator., Date of randomization until PD (Assessed Up to 6.6 Years)|Complete Response (CR) rate, To assess the effect of AV treatment compared with VO treatment on ORR. CR rate (uMRD per iwCLL guidelines 2018) after completion of 12 cycles of venetoclax., Date of randomization until PD (Assessed Up to 6.6 Years)|Change from baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 scales, To assess symptoms, functional status and global health status/quality of life (QoL), in participants treated with AV versus VO using the EORTC QLQ-C30.

EORTC QLQ-C30 consists of 30 items and measures symptoms, functioning, and global health status/QoL for all cancer types. Questions are grouped into 5 multi-item functional scales, 3 multi-item symptom scales, a 2-item global QoL scale, 5 single items assessing additional symptoms commonly reported by cancer participants, and 1 item on the financial impact of the disease.

The EORTC QLQ-C30 will be scored according to the EORTC QLQ-C30 Scoring Manual. An outcome variable consisting of a score from 0 to 100 will be derived for each of the symptom scales, each of the functional scales, and the global measure of health status scale. Higher scores on the global measure of health status and functional scales indicate better health status/function, but higher scores on symptom scales represent greater symptom severity., For AV: Cycle 1-Cycle 2, Cycle 3-Cycle 14; After End of Treatment (EoT); Post treatment follow-up For VO: Cycle 1 Day 1-21, Cycle 1 Day 22-Cycle 6, Cycle 7-Cycle 24 (Each cycle is 28 days); After EoT, Post treatment follow-up (assessed Up to 6.6 years)|Change from baseline in EORTC QLQ-CLL17 scales, To assess symptoms, functional status, and global health status/QoL, participants treated with AV versus VO using the EORTC QLQ-CLL17.

EORTC QLQ-CLL17 comprises 17 items grouped into 3 multi-item scales: 1) symptom burden, 2) physical condition/fatigue, and 3) worries/fears about health and functioning.

The EORTC QLQ-CLL17 will be scored according to the EORTC QLQ-C30 Scoring Manual. An outcome variable consisting of a score from 0 to 100 will be derived for each of the symptom scales, each of the functional scales, and the global measure of health status scale. Higher scores on the global measure of health status and functional scales indicate better health status/function, but higher scores on symptom scales represent greater symptom severity., For AV: Cycle 1-Cycle 2, Cycle 3-Cycle 14; After End of Treatment (EoT); Post treatment follow-up For VO: Cycle 1 Day 1-21, Cycle 1 Day 22-Cycle 6, Cycle 7-Cycle 24 (Each cycle is 28 days); After EoT, Post treatment follow-up (assessed Up to 6.6 years)|Proportion of participants experiencing bruising as measured by the National Cancer Institute (NCI) Patient Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) item for Bruising, To assess symptomatic toxicities patient perceived benefit-risk in participants treated with AV versus VO using the NCI PRO-CTCAE item for Bruising.

It was designed to be used as a companion to the Common Terminology Criteria for Adverse Events (CTCAE), the standard lexicon for adverse event reporting in cancer trials. The bruising item, which has a dichotomous yes/no response option, will be included in this study to capture patient-reported bruising., For AV: Cycle 1-Cycle 2, Cycle 3-Cycle 14; After End of Treatment (EoT); Post treatment follow-up For VO: Cycle 1 Day 1-21, Cycle 1 Day 22-Cycle 6, Cycle 7-Cycle 24 (Each cycle is 28 days); After EoT, Post treatment follow-up (assessed Up to 6.6 years)|Proportion of participants reporting each response option of the Patient Global Impression of Benefit-Risk (PGI-BR), To assess patient perceived benefit-risk of treatment in participants treated with AV versus VO using the PGI-BR.

PGI-BR consists of 4 study medication-related questions, one each on efficacy, side effects, convenience of use, and overall benefit-risk. Each item is scored separately, with the final item providing a single metric of a participant's overall benefit-risk assessment.

The response from each question will be semi-quantitative. Each question ranges from Very (negative, Somewhat \[negative\]), Neutral, Somewhat \[positive\], Very \[positive\]., For AV: Cycle 1-Cycle 2, Cycle 3-Cycle 14 (Each cycle is 28 days); and End of treatment, E/D, disease progression, and post-treatment follow-up visits (assessed up to 6.6 years)|Number of participants with adverse events (AEs), To assess the safety and tolerability of AV treatment versus VO treatment in participants with previously untreated CLL/SLL., From screening (Days -45 through -1) until survival follow-up (Up to 6.6 years)",,AstraZeneca,,ALL,"ADULT, OLDER_ADULT",PHASE3,607,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-09-12,2027-07-15,2029-04-10,2021-09-27,,2025-03-04,"Research Site, Tucson, Arizona, 85710, United States|Research Site, La Jolla, California, 92093-0052, United States|Research Site, Longmont, Colorado, 80501, United States|Research Site, Jacksonville, Florida, 32256, United States|Research Site, Boston, Massachusetts, 02115, United States|Research Site, Saint Louis, Missouri, 63110, United States|Research Site, Buffalo, New York, 14263, United States|Research Site, New Hyde Park, New York, 11040, United States|Research Site, New York, New York, 10065, United States|Research Site, Rochester, New York, 14642, United States|Research Site, Charlotte, North Carolina, 28204, United States|Research Site, Cleveland, Ohio, 44195, United States|Research Site, Eugene, Oregon, 97401, United States|Research Site, Philadelphia, Pennsylvania, 19104, United States|Research Site, Nashville, Tennessee, 37203, United States|Research Site, Salt Lake City, Utah, 84112, United States|Research Site, Charlottesville, Virginia, 22908, United States|Research Site, Seattle, Washington, 98104, United States|Research Site, Seattle, Washington, 98109, United States|Research Site, Clayton, 3168, Australia|Research Site, Geelong, 3220, Australia|Research Site, Nedlands, 6009, Australia|Research Site, Waratah, 2298, Australia|Research Site, Hradec Kralove, 500 05, Czechia|Research Site, Ostrava - Poruba, 708 52, Czechia|Research Site, Pilsen, 30460, CZ, Czechia|Research Site, Montpellier, 34295, France|Research Site, Tours, 37044, France|Research Site, Budapest, 1097, Hungary|Research Site, Debrecen, 4032, Hungary|Research Site, Bydgoszcz, 85-168, Poland|Research Site, Gdansk, 80-219, Poland|Research Site, Katowice, 40-519, Poland|Research Site, KrakÃ³w, 30-727, Poland|Research Site, Lublin, 20-090, Poland|Research Site, LÃ³dz, 93-513, Poland|Research Site, Barcelona, 08025, Spain|Research Site, Palma de Mallorca, 07010, Spain",
NCT05020236,A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments,https://clinicaltrials.gov/study/NCT05020236,MAGNETISMM-5,RECRUITING,"The purpose of this clinical trial is to (1) learn whether the BCMA-CD3 bispecific antibody elranatamab can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab, pomalidomide, and dexamethasone, and (2) learn about the safety and activity of elranatamab in combination with the anti-CD38 monoclonal antibody daratumumab. People with multiple myeloma who have received previous treatment including lenalidomide will be enrolled in the study.

Part 1 of the study will assess the safety and activity of different doses of elranatamab in combination with daratumumab.

People participating in Part 2 of the study will be randomly assigned to receive either elranatamab alone, elranatamab plus daratumumab, or daratumumab, pomalidomide, and dexamethasone. Part 2 will evaluate the safety and activity of (1) elranatamab alone compared to daratumumab, pomalidomide, and dexamethasone, and (2) elranatamab plus daratumumab.

Part 3 will assess the effect of increased measures to protect against infection in people treated with either elranatamab alone or together with daratumumab.

All people participating in the study will receive study treatment until their disease progresses, they experience unacceptable side effects, or they choose to no longer participate in the study.",NO,Multiple Myeloma,DRUG: Elranatamab|DRUG: Daratumumab|DRUG: Pomalidomide|DRUG: Dexamethasone,"Part 1 Safety Lead-In: Incidence of dose limiting toxicities, First 42 days after first elranatamab dose|Part 2 Randomized: Progression free survival per International Myeloma Working Group criteria, From date of randomization to date of progressive disease, discontinuation from the study, death, or censoring, whichever occurs first, assessed up to 51 months|Part 3: Frequency of treatment-emergent adverse events, First 84 days after first elranatamab dose","Part 1 Safety Lead-In: Progression free survival per International Myeloma Working Group criteria, From date of randomization to date of progressive disease, discontinuation from study, death, or censoring, whichever occurs first, assessed up to 51 months|Overall survival, From date of randomization to date of discontinuation from study, death, or censoring, whichever occurs first, assessed up to 51 months|Objective response rate per International Myeloma Working Group criteria, From date of randomization to date of progressive disease, discontinuation from study, death, or start of new anticancer therapy, whichever occurs first, assessed up to 51 months|Duration of response per International Myeloma Working Group criteria, From date of confirmed objective response to date of progressive disease, discontinuation from study, death, or censoring, whichever occurs first, assessed up to 51 months|Time to response per International Myeloma Working Group criteria, From date of randomization to date of confirmed objective response, assessed up to 51 months|Complete response rate per International Myeloma Working Group criteria, From date of randomization to date of progressive disease, discontinuation from study, death, or start of new anticancer therapy, whichever occurs first, assessed up to 51 months|Duration of complete response per International Myeloma Working Group criteria, From date of confirmed complete response to date of progressive disease, discontinuation from study, death, or censoring, whichever occurs first, assessed up to 51 months|Minimal residual disease negativity rate per International Myeloma Working Group criteria, From date of randomization to date of progressive disease, discontinuation from study, death, or start of new anticancer therapy, whichever occurs first, assessed up to 51 months|Sustained minimal residual disease negativity rate per International Myeloma Working Group criteria, From date of randomization to date of progressive disease, discontinuation from study, death, or start of new anticancer therapy, whichever occurs first, assessed up to 51 months|Progression free survival on next-line treatment per International Myeloma Working Group criteria, From date of randomization to date of second objective disease progression, discontinuation from the study, death, or censoring, whichever occurs first, assessed up to 51 months|Frequency of treatment-emergent adverse events, From date of first dose of study intervention through minimum of 90 days after last study intervention administration. Reporting of non-serious AEs ends at start of new anti-cancer therapy.|Frequency of abnormal laboratory results, From date of first dose of study intervention through minimum of 90 days after last study intervention administration. Reporting of non-serious AEs ends at start of new anti-cancer therapy.|Rate of Grade â¥2 cytokine release syndrome, First 28 days after first elranatamab dose|Elranatamab pharmacokinetics by pre- and post-dose concentrations, From date of first dose through up to 14 days after date of last dose of elranatamab|Elranatamab immunogenicity by anti-drug antibodies against elranatamab, From date of first dose through up to 14 days after date of last dose of elranatamab|Daratumumab pharmacokinetics by pre-dose concentrations, From date of first dose through up to 14 days after date of last dose of daratumumab|Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30, From date of informed consent through up to 35 days after date of last dose of study intervention|Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Myeloma 20, From date of informed consent through up to 35 days after date of last dose of study intervention",,Pfizer,,ALL,"ADULT, OLDER_ADULT",PHASE3,944,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-10-04,2025-12-09,2027-05-31,2021-08-25,,2025-06-11,"Clovis Community Medical Center, Clovis, California, 93611, United States|Community Cancer Institute, Clovis, California, 93611, United States|University of California San Francisco, Fresno, California, 93701, United States|Community Regional Medical Center, Fresno, California, 93721, United States|UCHealth Poudre Valley Hospital, Fort Collins, Colorado, 80524, United States|UCHealth Harmony, Fort Collins, Colorado, 80528, United States|UCHealth Greeley Hospital, Greeley, Colorado, 80634, United States|UCHealth - Medical Center of the Rockies, Loveland, Colorado, 80538, United States|Sylvester Comprehensive Cancer Center - Aventura, Aventura, Florida, 33180, United States|Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center, Coral Gables, Florida, 33146, United States|Sylvester Comprehensive Cancer Center - Coral Springs, Coral Springs, Florida, 33065, United States|University of Miami Hospital and Clinics - Deerfield Beach, Deerfield Beach, Florida, 33442, United States|Sylvester Comprehensive Cancer Center - Hollywood, Hollywood, Florida, 33021, United States|Sylvester Comprehensive Cancer Center, Miami, Florida, 33136, United States|University of Miami Hospital And Clinics, Miami, Florida, 33136, United States|Sylvester Comprehensive Cancer Center - Kendall, Miami, Florida, 33176, United States|Sylvester Comprehensive Cancer Center - Plantation, Plantation, Florida, 33324, United States|East Jefferson General Hospital Bone Marrow Transplant Clinic, Metairie, Louisiana, 70006, United States|East Jefferson General Hospital, Metairie, Louisiana, 70006, United States|MSK Basking Ridge, Basking Ridge, New Jersey, 07920, United States|MSK Monmouth, Middletown, New Jersey, 07748, United States|MSK Bergen, Montvale, New Jersey, 07645, United States|MSK Commack, Commack, New York, 11725, United States|MSK Westchester, Harrison, New York, 10604, United States|Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York, New York, 10021, United States|Memorial Sloan Kettering Cancer Center - Main Campus, New York, New York, 10065, United States|MSK Nassau, Uniondale, New York, 11553, United States|Alexander Fleming S.A (Instituto Medico Especializado Alexander Fleming), Ciudad Autonoma de Buenos Aires, Buenos Aires, 1426, Argentina|FUNDALEU - Fundacion para combatir la Leucemia, Ciudad Autonoma de Buenos Aires, Buenos Aires, C1114AAN, Argentina|FUNDALEU -FundaciÃ³n para combatir la leucemia, Ciudad AutÃ³noma de Buenos Aires, Buenos Aires, C1114AAP, Argentina|FUNDALEU, Ciudad AutÃ³noma de Buenos Aires, Buenos Aires, C1114AAP, Argentina|Hospital Universitario Austral, Derqui, Buenos Aires, B1629AHJ, Argentina|Hospital Italiano de La Plata, La Plata, Buenos Aires, B1900XI, Argentina|Sanatorio de La Mujer, Rosario, Santa FE, S2000ORE, Argentina|Pindara Private Hospital, Benowa, Queensland, 4217, Australia|QScan Radiology Clinics, Clayfield, Queensland, 4011, Australia|Gallipoli Medical Research Foundation, Greenslopes, Queensland, 4120, Australia|Greenslopes Private Hospital, Greenslopes, Queensland, 4120, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, 4102, Australia|Epworth Freemasons, East Melbourne, Victoria, 3002, Australia|St Vincent's Hospital (Melbourne), Fitzroy, Victoria, 3065, Australia|Barwon Health, Geelong, Victoria, 3220, Australia|The Alfred Hospital, Melbourne, Victoria, 3004, Australia|Epworth Healthcare, Richmond, Victoria, 3121, Australia|Slade Pharmacy, Richmond, Victoria, 3121, Australia|Linear Clinical Research, Perth, Western Australia, 6009, Australia|UniversitÃ¤tsklinikum Krems, Krems, NiederÃ¶sterreich, 3500, Austria|Klinik Ottakring, Vienna, Wien, 1160, Austria|UniversitÃ¤tsklinik fÃ¼r Innere Medizin V Innsbruck, Innsbruck, 6020, Austria|Uniklinikum Salzburg, Salzburg, 5020, Austria|Medizinische UniversitÃ¤t Wien, Wien, 1090, Austria|Grand HÃ´pital de Charleroi, Gilly, Hainaut, 6060, Belgium|CHU UCL Namur (site Godinne), Yvoir, Namur, 5530, Belgium|Instituto D'Or de Pesquisa e Ensino (IDOR) - Filial Salvador, Salvador, Bahia, 41253-190, Brazil|Centro Gaucho Integrado De Oncologia, Hematologia, Ensino E Pesquisa, Porto Alegre, RIO Grande DO SUL, 90110-270, Brazil|Centro de Pesquisa ClÃ­nica - Ãrea Administrativa, Porto Alegre, RIO Grande DO SUL, 90850-170, Brazil|Hospital Mae de Deus, Porto Alegre, RIO Grande DO SUL, 90880-480, Brazil|BP - A Beneficencia Portuguesa de SÃ£o Paulo, Sao Paulo, SÃO Paulo, 01321-001, Brazil|ClÃ­nica MÃ©dica SÃ£o Germano LTDA, SP, SÃO Paulo, 04537-080, Brazil|Hospital AmÃ©ricas Medical City, Rio de Janeiro, 22775001, Brazil|Instituto de EducaÃ§Ã£o, Pesquisa e GestÃ£o em SaÃºde, Rio de Janeiro, 22793-080, Brazil|ESHO Empresa de ServiÃ§os Hospitalares S.A/ Hospital Samaritano de HigienÃ³polis, SÃ£o Paulo, 01232-010, Brazil|IDOR Ensino e Pesquisa, SÃ£o Paulo, 01401-002., Brazil|HU UNIFESP / SPDM - Hospital SÃ£o Paulo, SÃ£o Paulo, 04024-002, Brazil|Universidade Federal de Sao Paulo, SÃ£o Paulo, 04024-002, Brazil|ClÃ­nica MÃ©dica SÃ£o Germano S/S Ltda, SÃ£o Paulo, 04537-080, Brazil|Instituto D'Or de Pesquisa e Ensino (IDOR), SÃ£o Paulo, 04543-000, Brazil|Instituto D'Or de Pesquisa e Ensino (IDOR), SÃ£o Paulo, 04544-000, Brazil|Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta, T2N 5G2, Canada|Cross Cancer Institute, Edmonton, Alberta, T6G 1Z2, Canada|QEII Health Sciences Centre - Victoria General Site, Halifax, Nova Scotia, B3H 2Y9, Canada|Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario, L8V5C2, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, M5G 2M9, Canada|Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada|CIUSSS de l'Est-de-l'Ãle-de-MontrÃ©al, MontrÃ©al, Quebec, H1T2M4, Canada|Saskatoon Cancer Center, Saskatoon, Saskatchewan, S7N4H4, Canada|Peking University Third Hospital, Beijing, Beijing, 100191, China|Beijing Peking Union Medical College Hospital, Beijing, Beijing, 100730, China|Fujian Medical University Union Hospital, Fuzhou, Fujian, 350001, China|Guangdong Provincial People's Hospital, Guangzhou, Guangdong, 510080, China|Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, 510515, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510555, China|Shenzhen Second People's Hospital, Shenzhen, Guangdong, 518035, China|The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050000, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China|Henan Cancer Hospital, Zhengzhou, Henan, 450008, China|Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China|Nanjing Drum Tower Hospital ï¼ The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, 210008, China|The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221006, China|The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, China|Jilin Province Cancer Hospital, Changchun, Jilin, 130000, China|The First Hospital of Jilin University, Changchun, Jilin, 130021, China|Shandong Provincial Hospital, Jinan, Shandong, 250021, China|Jinan Central Hospital, Jinan, Shandong, 250100, China|Institute of hematology&blood disease hospital, Tianjin, Tianjin, 301636, China|The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, 310003, China|The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China|Beijing Boren Hospital, Beijing, 100070, China|Chongqing University Cancer Hospital, Chongqing, 400030, China|FakultnÃ­ nemocnice Brno Bohunice, Brno, Brno-m?sto, 625 00, Czechia|Fakultni Nemocnice Plzen, Plzen - Lochotin, PlzeÅskÃ½ KRAJ, 304 60, Czechia|Fakultni poliklinika, Praha, Praha 2, 120 00, Czechia|Fakultni nemocnice Hradec Kralove, Hradec Kralove, 500 05, Czechia|Fakultni nemocnice Olomouc, Olomouc, 779 00, Czechia|Fakultni nemocnice Ostrava, Ostrava-Poruba, 708 52, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, 12808, Czechia|Tampereen yliopistollinen sairaala, Tampere, Pirkanmaa, 33520, Finland|Oulun yliopistollinen sairaala, Oulu, Pohjois-pohjanmaa, 90220, Finland|Kuopion Yliopistollinen Sairaala, Kuopio, Pohjois-savo, 70210, Finland|Turku University Hospital, Turku, Varsinais-suomi, 20520, Finland|Helsinki University Hospital - Comprehensive Cancer Center (HYKS - SyÃ¶pÃ¤keskus), Helsinki, 00029, Finland|Tampereen yliopistollinen sairaala, Tampere, 33520, Finland|Centre Hospitalier Universitaire de Limoges - HÃ´pital Dupuytren, Limoges, Limousin, 87042, France|Hopital Claude Huriez - CHU de Lille, Lille, Nord, 59000, France|Centre Hospitalier Universitaire de Nantes - L' Hopital l'hÃ´tel-Dieu, Nantes Cedex 1, 44093, France|HÃ´pital Saint Antoine, Paris Cedex 12, 75571, France|Hopital Necker, Paris, 75015, France|Centre Hospitalier Lyon Sud - Service d'Hematologie Clinique, Pierre Benite Cedex, 69495, France|CHU de Poitiers, HÃ´pital de la MilÃ©trie, PÃ´le RÃ©gional de CancÃ©rologie, Poitiers Cedex, 86021, France|Institut Universitaire du Cancer Toulouse - Oncopole - CHU de TOULOUSE, Toulouse, 31059, France|Universitaetsklinikum Ulm, Ulm, Baden-wÃ¼rttemberg, 89081, Germany|UniversitÃ¤tsklinikum WÃ¼rzburg, WÃ¼rzburg, Bayern, 97080, Germany|CharitÃ© UniversitÃ¤tsmedizin Berlin, Berlin, 12200, Germany|Staedtisches Klinikum Braunschweig gGmbH, Braunschweig, 38114, Germany|Klinikum Chemnitz gGMbH, Chemnitz, 09116, Germany|UniversitÃ¤tsklinikum rechts der Isar, Technische UniversitÃ¤t MÃ¼nchen (TUM), Muenchen, 81675, Germany|Evangelismos General Hospital of Athens, Athens, AttikÃ­, 106 76, Greece|Alexandra General Hospital of Athens, Athens, AttikÃ­, 115 28, Greece|Radiology vendor, Athina, AttikÃ­, 115 25, Greece|Theageneio Cancer Hospital of Thessaloniki, Thessaloniki, KentrikÃ­ MakedonÃ­a, 546 39, Greece|University General Hospital of Ioannina, Ioannina, Greece|IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) ""Dino Amadori"", Meldola, Emilia-romagna, 47014, Italy|Ospedale San Martino, Genova, Liguria, 16132, Italy|Fondazione IRCCS CÃ  Granda Ospedale Maggiore Policlinico, Milano, Lombardia, 20122, Italy|Fondazione IRCCS San Gerardo dei Tintori, Monza, Lombardia, 20900, Italy|ASST Santi Paolo e Carlo Ospedale San Carlo Borromeo SSD di Onco-Ematologia (Edificio C-piano terra), Milano, Milan, 20153, Italy|Policlinico ""G. Rodolico"", Catania, Sicilia, 95123, Italy|IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola, Bologna, 40138, Italy|AOU Policlinico Umberto I, Roma, 00161, Italy|Fondazione Policlinico Universitario Agostino Gemelli, Roma, 00168, Italy|Nagoya City University Hospital, Nagoya, Aichi, 467-8602, Japan|University of Fukui Hospital, Yoshida-gun, Fukui, 910-1193, Japan|National Hospital Organization Shibukawa Medical Center, Shibukawa, Gunma, 377-0280, Japan|Iwate Medical University Hospital, Yahaba-cho, Iwate, 028-3695, Japan|Tohoku University Hospital, Sendai, Miyagi, 980-8574, Japan|Shizuoka Cancer Center, Sunto-gun, Shizuoka, 411-8777, Japan|Japanese Red Cross Medical Center, Shibuya-ku, Tokyo, 150-8935, Japan|Akita University Hospital, Akita, 010-8543, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, 811-1395, Japan|Kagoshima University Hospital, Kagoshima, 890-8520, Japan|National Hospital Organization Kumamoto Medical Center, Kumamoto, 860-0008, Japan|Nagasaki University Hospital, Nagasaki, 852-8501, Japan|National Hospital Organization Okayama Medical Center, Okayama, 701-1192, Japan|Osaka Metropolitan University Hospital, Osaka, 545-8586, Japan|Tokushima University Hospital, Tokushima, 770-8503, Japan|Yamagata University Hospital, Yamagata, 990-9585, Japan|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, 13620, Korea, Republic of|Chonnam National University Hwasun Hospital, Hwasun-gun, Jeonranamdo, 58128, Korea, Republic of|Pusan National University Hospital, Busan, Pusan-kwangyÇkshi, 49241, Korea, Republic of|Seoul National University Hospital, Seoul, Seoul-teukbyeolsi [seoul], 03080, Korea, Republic of|Samsung Medical Center, Seoul, Seoul-teukbyeolsi [seoul], 06351, Korea, Republic of|The Catholic Univ. of Korea Seoul St. Mary's Hospital, Seoul, Seoul-teukbyeolsi [seoul], 06591, Korea, Republic of|Kyungpook National University Hospital, Daegu, Taegu-kwangyÇkshi, 41944, Korea, Republic of|Gachon University Gil Medical Center, Incheon, 21565, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|HematolÃ³gica Alta Especialidad SC, consultorio 830, Colonia Valle De Las Palmas, MÃ©xico, 52787, Mexico|Hospital Universitario ""Dr. Jose Eleuterio Gonzalez"", Monterrey, Nuevo LEÃN, 66460, Mexico|Centro de Investigacion Clinica de Oaxaca, Oaxaca, 68020, Mexico|Instituto Veracruzano en InvestigaciÃ³n ClÃ­nica S.C., Veracruz, 91851, Mexico|Erasmus Universitair Medisch Centrum, Rotterdam, Zuid-holland, 3015 GD, Netherlands|Maastricht University Medical Center, Maastricht, 6229 HX, Netherlands|North Shore Hospital, Auckland, 0622, New Zealand|Labtests Auckland Ltd., Auckland, 1060, New Zealand|Aotearoa Clinical Trials, Auckland, 2025, New Zealand|Waikato District Health Board, Waikato Hospital, Hamilton, 3204, New Zealand|TRG Imaging, Milford, 0620, New Zealand|Pacific Radiology, Newtown, 6021, New Zealand|Broadway Radiology, Palmerston North, 4410, New Zealand|Palmerston North Hospital, Roslyn, 4414, New Zealand|Pharmacy on Shakespeare, Takapuna, 0620, New Zealand|Capital, Coast and Hutt Valley District - Wellington Regional Hospital, Wellington, 6021, New Zealand|Haukeland Universitetssjukehus, Bergen, Hordaland, 5021, Norway|Stavanger Universitetssykehus, Stavanger, Rogaland, 4011, Norway|Oslo Universitetssykehus UllevÃ¥l, Oslo, 0450, Norway|St Olavs Hospital, Trondheim, 7030, Norway|Szpital Uniwersytecki nr 2 im. dr Jana Biziela w Bydgoszczy Klinika Hematologii, Bydgoszcz, 85-168, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, 80-214, Poland|Pratia Onkologia Katowice, Katowice, 40-519, Poland|Uniwersytecki Szpital Kliniczny w Poznaniu, Poznan, 60-569, Poland|Centrum Medyczne Pratia Poznan, Skorzewo, 60-185, Poland|Uniwersyteckie Centrum Kliniczne WUM Centralny Szpital Kliniczny, Warszawa, 02-097, Poland|Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu, Wroclaw, 50-367, Poland|Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, A Coruna, 15706, Spain|Institut CatalÃ  d'Oncologia - L'Hospitalet, L'Hospitalet Del Llobregat, Barcelona [barcelona], 08908, Spain|Hospital Universitari Mutua Terrassa, Terrassa, Barcelona, 08221, Spain|Hospital Universitario MarquÃ©s de Valdecilla, Santander, Cantabria, 39008, Spain|Clinica Universidad de Navarra, Pamplona, Navarra, 31008, Spain|Hospital Universitario de Toledo, Toledo, Other, 45007, Spain|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital Clinic Barcelona, Barcelona, 08036, Spain|Hospital Universitari De Girona Doctor Josep Trueta, Girona, 17007, Spain|Hospital Universitario La Princesa, Madrid, 28006, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, 28050, Spain|Hospital Universitario de Salamanca, Salamanca, 37007, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, 41013, Spain|Hospital Universitario y Politecnico La Fe, Valencia, 46026, Spain|SkÃ¥nes Universitetssjukhus Lund, Lund, SkÃ¥ne LÃN [se-12], 22185, Sweden|SÃ¶dra Ãlvsborg Sjukhus, BorÃ¥s, 501 82, Sweden|Falu Lasarett, Falun, 791 82, Sweden|Sahlgrenska Universitetssjukhuset, GÃ¶teborg, 41345, Sweden|Sunderby Sjukhus, LuleÃ¥, 971 80, Sweden|Universitetssjukhuset Ãrebro, Ãrebro, Ãrebro LÃN [se-18], 701 85, Sweden|LÃ¤kemedelsberedningen, LinkÃ¶ping, ÃstergÃ¶tlands LÃN [se-05], 581 85, Sweden|Universitetssjukhuset i LinkÃ¶ping, LinkÃ¶ping, ÃstergÃ¶tlands LÃN [se-05], 581 85, Sweden|Chang Gung Memorial Hospital at Kaohsiung, Kaohsiung, 83301, Taiwan|China Medical University Hospital, Taichung, 40447, Taiwan|National Cheng Kung University Hospital, Tainan, 704, Taiwan|National Taiwan University Hospital, Taipei, 10002, Taiwan|Taipei Veterans General Hospital, Taipei, 11217, Taiwan|Istanbul Universitesi Istanbul TÄ±p Fakultesi Hastanesi, Istanbul, Ä°Ìstanbul, 34093, Turkey|Medipol Mega Universite Hastanesi, Ä°stanbul, Ä°Ìstanbul, 34214, Turkey|Acibadem Universitesi Atakent Hastanesi, Istanbul, Ä°Ìstanbul, 34303, Turkey|Sisli Florence Nightingale Hastanesi, Ä°stanbul, Ä°Ìstanbul, 34381, Turkey|Ege Universitesi Hastanesi, Ä°zmir, Ä°Ìzmir, 35100, Turkey|Dokuz Eylul Universitesi Hastanesi, Ä°zmir, Ä°Ìzmir, 35340, Turkey|Baskent Universitesi Adana Dr. Turgut Noyan Uygulama ve Arastirma Merkezi, Adana, 01240, Turkey|Ankara University Health Practice and Research Hospitals, Ankara, 06100, Turkey|Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve ArastÄ±rma Hastanesi, Ankara, 06200, Turkey|Akdeniz Universitesi Hastanesi, Antalya, 07070, Turkey|Gaziantep Universitesi Sahinbey Arastirma ve Uygulama Hastanesi, Gaziantep, 27310, Turkey|Erciyes Universitesi TÄ±p Fakultesi Hastaneleri, Kayseri, 38030, Turkey|Ãzel Anadolu SaÄlÄ±k Merkezi, Kocaeli, 41400, Turkey|Inonu Universitesi Turgut Ozal TÄ±p Merkezi, Malatya, 44280, Turkey|Royal Bournemouth Hospital, Bournemouth, Dorset, BH7 7DW, United Kingdom|Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, Oxfordshire, OX3 7LE, United Kingdom|University Hospital of Wales, Cardiff, South Glamorgan, CF14 4XW, United Kingdom|Bristol Haematology and Oncology Centre, Bristol, BS2 8ED, United Kingdom|Kent and Canterbury Hospital, Canterbury, CT1 3NG, United Kingdom|The Christie NHS Foundation Trust, Manchester, M20 4BX, United Kingdom",
NCT06091865,"A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Patients With Previously Untreated Diffuse Large B-cell Lymphoma",https://clinicaltrials.gov/study/NCT06091865,OLYMPIA-3,ACTIVE_NOT_RECRUITING,"This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy. The study is focused on patients with diffuse large B-cell lymphoma (DLBCL) that have not been treated before (called ""previously untreated""). Patients with DLBCL that have come back after treatment (called ""relapsed""), or have not responded to treatment (called ""refractory""), can also participate in this study.

This study will be made up of Part 1A, Part 1B, and Part 2.The aim of Part 1A and Part 1B of the study is to see how safe and tolerable the study drug in combination with chemotherapy is and to determine the dose and schedule of the study drug to be combined with chemotherapy in Part 2 of the study.

The aim of Part 2 of the study is to see how effective the combination of the study drug with chemotherapy is in comparison with the combination of rituximab (the comparator drug), and chemotherapy, the current standard of care treatment approved for DLBCL. Standard of care means the usual medication expected and used when receiving treatment for a condition.

The study is looking at several other research questions, including:

* What side effects may happen from taking the study drug when combined with chemotherapy
* How much study drug is in the blood at different times
* Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
* The impact from the study drug on quality of life and ability to complete routine daily activities",NO,Diffuse Large B-cell Lymphoma (DLBCL),DRUG: Odronextamab|DRUG: Rituximab|DRUG: Cyclophosphamide|DRUG: Doxorubicin|DRUG: Vincristine|DRUG: Prednisone/Prednisolone,"Incidence of dose limiting toxicities (DLTs), Part 1A, Up to 35 days|Incidence of treatment emergent adverse events (TEAEs), Part 1, Up to 2 years|Severity of TEAEs, Part 1, Up to 2 years|Progression free survival (PFS), assessed by independent central review (ICR), Part 2, Up to 5 years","Event-free survival (EFS) assessed by ICR, Part 2, Up to 5 years|Complete response (CR) assessed by ICR, Part 2, Up to 22 weeks|Overall survival (OS), Part 2, Up to 5 years|Best Overall response (BOR) as assessed by local investigators, Part 1 and Part 2, Up to 22 weeks|CR as assessed by local investigators, Part 1 and Part 2, Up to 22 weeks|Duration of response (DOR) as assessed by local investigators, Part 1 and Part 2, Up to 5 years|Odronextamab concentrations in serum when administered with CHOP, Part 1 and Part 2, Up to 22 weeks|Incidence of anti-drug antibodies (ADA) to odronextamab over the study duration, Part 1 and Part 2, Up to 22 weeks|Titer of ADA to odronextamab over the study duration, Part 1 and Part 2, Up to 22 weeks|Incidence of neutralizing antibodies (NAb) to odronextamab over the study duration, Part 1 and Part 2, Up to 22 weeks|PFS assessed by local investigator review, Part 2, Up to 5 years|EFS assessed by local investigator review, Part 2, Up to 5 years|BOR assessed by ICR, Part 2, Up to 22 weeks|DOR assessed by ICR, Part 2, Up to 5 years|Incidence of TEAEs, Part 2, Up to 2 years|Severity of TEAEs, Part 2, Up to 2 years|Measurable Residual Disease (MRD) status, Part 2, Up to 22 weeks|Duration of MRD-negativity, Part 2, Up to 5 years|Change in physical functioning as measured by European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C) 30, Part 2 The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a GHS/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and global health status / QoL, scores range from 1 = ""very poor"" to 7 = ""excellent"" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = ""not at all"" to 4 = ""very much"" higher scores indicate higher symptom burden., Up to 5 years|Change in patient reported outcomes, as measured by EORTC QLQ-C30, Part 2 The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a GHS/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and global health status / QoL, scores range from 1 = ""very poor"" to 7 = ""excellent"" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = ""not at all"" to 4 = ""very much"" higher scores indicate higher symptom burden., Up to 5 years|Change in patient reported outcomes, as measured by Functional Assessment of Cancer Therapy - Lymphoma Subscale (FACT-LymS), Part 2 The FACT-Lym lymphoma subscale (LymS) includes 15 items to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from ""not at all"" (0) to ""very much"" (4). Higher scores are associated with a worse quality of life., Up to 5 years|Change in patient reported outcomes, as measured by Patient Global Impression of Severity (PGIS), Part 2 The PGIS includes a single-item to assess how a patient perceives the overall severity of cancer symptoms over the past 7 days. Patients will choose the response that best describes the severity of their overall cancer symptoms with options on a 5-point scale ranging from 1 (No symptoms) to 4 (Very Severe)., Up to 5 years|Change in patient reported outcomes, as measured by Patient Global Impression of Change (PGIC), Part 2 The PGIC item includes a single-item to assess how a patient perceives their overall change in health status since the start of study treatment. Patients will choose from response options on a 7-point scale ranging from 1 (Much Better) to 7 (Much worse); 1- Much Better, 2-Moderately Better, 3-A Little Better, 4-About the Same, 5-A Little Worse, 6-Moderately Worse, 7-Much Worse., Up to 5 years|Change in patient reported outcomes, as measured by EuroQol-5 Dimension-5 Level Scale (EQ-5D-5L), Part 2 The EQ-5D-5L consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: ""no problems"", ""slight problems"", ""moderate problems"", ""severe problems"" and ""extreme problems"". The EQ VAS records the participant's self-rated health on a vertical visual analogue scale where the endpoints are labeled ""Best imaginable health state"" and ""Worst imaginable health state""., Up to 5 years|Change in score of the Functional Assessment of Cancer Therapy-General (FACT-G ) GP5 item, Part 2 A single item (GP5) of the validated FACT-G questionnaire will be used to assess from the participant perspective the overall impact of treatment side-effect. The question item is on a 5-point scale ranging from ""not at all"" (0) to ""very much"" (4)., Up to 5 years",,Regeneron Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,904,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-12-13,2028-03-30,2029-04-30,2023-10-19,,2025-05-15,"David Geffen School of Medicine at UCLA, Los Angeles, California, 90095, United States|University of California Irvine Medical Center, Orange, California, 92868, United States|University of California (UC) Davis, Sacramento, California, 95817-2229, United States|Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, 46202, United States|St Vincent Ascension at Peyton Manning Childrens Hospital, Indianapolis, Indiana, 46260, United States|Investigative Clinical Research of Indiana, Noblesville, Indiana, 46062, United States|University of Kentucky, Lexington, Kentucky, 40536, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States|Henry Ford Health System, Detroit, Michigan, 48202, United States|Cancer and Hematology Centers of Western Michigan, Grand Rapids, Michigan, 49503, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, 08901, United States|Stony Brook University Hospital, Stony Brook, New York, 11794, United States|Clinical Research Alliance Inc, Westbury, New York, 11590, United States|Duke University Medical Center, Durham, North Carolina, 27710, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, 44106, United States|Center for Oncology and Blood Disorders, Houston, Texas, 77030, United States|Community Cancer Trials of Utah, Ogden, Utah, 84405, United States|Prohealth Care Inc, Waukesha, Wisconsin, 53188, United States|Liverpool Hospital, Liverpool, New South Wales, 2170, Australia|Calvary Mater Newcastle, Waratah, New South Wales, 2298, Australia|Icon Cancer Centre - Wesley, Auchenflower, Queensland, 4066, Australia|Pindara Private Hospital, Benowa, Queensland, 4217, Australia|Epworth Freemasons, East Melbourne, Victoria, 3121, Australia|Landeskrankenhaus Hochsteiermark, Leoben, Styria, 8700, Austria|Kepler University Hospital, Linz, Upper Austria, 4020, Austria|Medical University Graz, Graz, 8036, Austria|Medical University of Vienna, Vienna, 1090, Austria|Hanusch Krankenhaus, Vienna, 1140, Austria|Klinikum Wels-Grieskirchen, Wels, 4600, Austria|AZ St.-Elisabeth Herentals vzw, Herentals, Antwerp, 2200, Belgium|Universitair Ziekenhuis (UZ) Gent/ Ghent University Hospital, Gent, Oost-Vlaanderen, 9000, Belgium|Az Delta, Roeselare, West Vlaanderen, 8800, Belgium|Institut Jules Bordet, Brussels, 1000, Belgium|Centre Hospitalier Regional de Verviers, Verviers, 4800, Belgium|Hospital Clinico Universidad de Los Andes, Santiago, Las Condes, 7620157, Chile|Inmunocel, Santiago, Region Metropolitana, 7580206, Chile|Clinica Alemana de Santiago, Santiago, 7650568, Chile|University Hospital Hradec Kralove, Hradec Kralove, East Bohemia, 50005, Czechia|University Hospital Kralovske Vinohrady, Prague, 10034, Czechia|Vseobecna Fakultni Nemocnice V Praze, Praha, 12808, Czechia|Centre Hospitalier Universitaire (CHU) Rennes, Rennes, Bretagne, 35033, France|CHRU de Tours, Tours, Centre Val De Loire, 37044, France|Polyclinique Bordeaux Nord Aquitaine, Bordeaux Cedex, Gironde, 33077, France|Hopital Victor Dupouy Argenteuil, Argenteuil, Ile De France, 95100, France|Avicenne Hospital, Bobigny, Ile De France, 93000, France|Hopital Saint Vincent-de-Paul, Lille, Nord, 5900, France|CHU de Poitiers, Poitiers, Nouvelle Aquitaine, 86000, France|Centre Hospitalier Universitaire (CHU) de Bordeaux, Pessac, Nouvelle-Aquitaine, F33600, France|Nantes University Hospital, Nantes, Pays De La Loire, 44093, France|Centre Hospitalier Metropole Savoie, Chambery, Savoie, 73000, France|Gustave Roussy, Villejuif, Val De Marne / Ile De France, 94805, France|Centre Hospitalier Universitaire Angers, Angers, 49933, France|Change Annecy, Metz Tessy, 74374, France|CHU Nimes Institut de Cancerologie, Nimes, 30029, France|Assistance Publique-Hopitaux de Paris (AP-HP), Paris, 75571, France|CHU de Saint-Etienne, Saint-Etienne, 42055, France|Robert-Bosch-Krankenhaus, Stuttgart, Baden-Wurttemberg, 70376, Germany|Kliniken Ostalb Stauferklinikum Schwab Gmund, Mutlangen, Gmund, D-73557, Germany|Clinic Frankfurt (Oder), Frankfurt, Hesse, 15236, Germany|University Hospital Essen, Essen, Nordrhein Westfalen, 45122, Germany|Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz KoeR, Mainz, Rheinland-Pfalz, 55131, Germany|Hematological Praxis Dresden, Dresden, Sachsen, 01307, Germany|University Hospital Carl Gustav Carus, Dresden, 01307, Germany|Stadtisches Krankenhaus Kiel, Kiel, 24116, Germany|Beaumont Hospital, Dublin, Leinster, D09V2N0, Ireland|St James Hospital and Trinity College Dublin, Dublin, D08, Ireland|The Chaim Sheba Medical Center, Tel-Hashomer, Tel Aviv, 5265601, Israel|Samson Assuta Ashdod University Hospital, Ashdod, 7747629, Israel|Bnai Zion Medical Center, Haifa, 31048, Israel|Hadassah Medical Center, Jerusalem, 91200, Israel|Galilee Medical Center, Nahariya, 2210001, Israel|The Tel Aviv Sourasky Medical Center, Tel Aviv, 64239, Israel|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (fc), Forli Cesena, 47014, Italy|ASST Monza Ospedale San Gerardo, Monza, Lombardy, 20900, Italy|Istituto Europeo di Oncologia, Milano, 20141, Italy|A.O.U. di Modena, Modena, 41124, Italy|Federico II University, Napoli, 80131, Italy|AOU Maggiore della Carita, Novara, 28100, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, 27100, Italy|Azienda Ospedaliera di Perugia, Perugia, 06132, Italy|Ospedale Santa Maria delle Croci, Ravenna, 48121, Italy|Hematology - CittÃ  della Salute e della Scienza di Torino, Turin, 10126, Italy|Santa Maria della Misericordia, Udine, 33100, Italy|St. Vincent Hospital - The Catholic University of Korea, Suwon-si, Gyeonggi-do, 16247, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Namdong-Gu, 21565, Korea, Republic of|Inje University Busan Paik Hospital, Busan, 47392, Korea, Republic of|Dong-A University Hospital, Busan, 49201, Korea, Republic of|Pusan National University Hospital, Busan, 49241, Korea, Republic of|Yeyungnam University Medical Center, Daegu, 42415, Korea, Republic of|Keimyung University Dongsan Hospital, Daegu, 42601, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|Yeouido St. Marys Hospital, Seoul, 07345, Korea, Republic of|Seoul St Marys Hospital, Seoul, 137-701, Korea, Republic of|Hospital Ampang, Ampang, Pahang, 68000, Malaysia|Hospital Tg Ampuan Afzan, Kuantan, Pahang, 25100, Malaysia|Hospital Queen Elizabeth, Kota Kinabalu, Sabah, 88200, Malaysia|Subang Jaya Medical Center, Subang Jaya, Selangor, 47500, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, 59100, Malaysia|Uniwersytecki Szpital Kliniczny, Wroclaw, Dolnoslaskie, 50-367, Poland|Matopolskie Centrum Medyczne S.C., Krakow, Malopolskie, 30-510, Poland|Pratia Poznan Medical Center, Poznan, Wielkopolska, 60185, Poland|Szpital Uniwersytecki Nr2 Bydgoszcz, Bydgoszcz, 85-168, Poland|Uniwersyteckie Centrum Kliniczne, Building of the Non-Invasive Medicine Center, Gdansk, 80-952, Poland|Centrum Innowacyjnych Terapii Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie, Lublin, 20-954, Poland|Szpital Szpecjalistyczny w Walbrzychu, Walbrzych, 58-300, Poland|National University Hospital Singapore, Singapore, 119074, Singapore|National Cancer Centre of Singapore, Singapore, 168583, Singapore|Tan Tock Seng Hospital, Singapore, 308433, Singapore|Hospital Clinico Universitario Santiago de Compostela, Santiago de Compostela, A Coruna, 15706, Spain|Hospital Universitario Central De Asturias, Oviedo, Asturias, 33011, Spain|Son Espases University Hospital, Palma, Balearic Islands, 07120, Spain|Hospital Universitari Parc Tauli, Sabadell, Barcelona, 08208, Spain|Hospital Universitari Mutua Terrassa, Terrassa, Barcelona, 08221, Spain|Hospital Universitario Marques de Valdecilla, Santander, Cantabria, 39008, Spain|Hospital Universitario Quironsalud Madrid, Pozuelo de Alarcon, Madrid, 28223, Spain|Hospital Universitario de Navarra, Pamplona, Navarra, 31008, Spain|Hospital Sant Pau, Barcelona, 08041, Spain|Hospital Virgen De Las Nieves De Granada, Granada, 18014, Spain|Hospital Universitario Infanta Leonor, Madrid, 28031, Spain|Hospital Universitario Ramon y Cajal, Madrid, 28034, Spain|Fundacion Jimenez Diaz University Hospital, Madrid, 28040, Spain|Hospital Universitario HM Sanchinarro, Servicio de Hematologia, Madrid, 28050, Spain|Hospital Universitario Virgen Macarena, Sevilla, 41009, Spain|Hospital Universitario Virgen del Rocio, Sevilla, 41013, Spain|Hospital General Universitario de Toledo, Toledo, 45007, Spain|Instituto Valenciano de Oncologia, Valencia, 46009, Spain|University Hospital Doctor Peset, Valencia, 46017, Spain|Changhua Christian Hospital, Changhua City, 50006, Taiwan|Taipei Medical University - Shuang Ho Hospital, New Taipei City, 23561, Taiwan|Chang Gung Medical Foundation Chia Yi Branch, Puzi City, 613, Taiwan|National Taiwan University Hospital, Taipei City, 10002, Taiwan|Wanfang Hospital, Taipei, 00116, Taiwan|Chang Gung Memorial Hospital- Linkou Branch, Taoyuan, 333, Taiwan|Chulalongkorn University, Bangkok, Krung Thep Maha Nakhon [Bangko], 10330, Thailand|Sriraj Hospital, Bangkok, 10700, Thailand|Chaing Mai University, Chiang Mai, 50200, Thailand|Faculty of Medicine, Khon Kaen, 40002, Thailand|Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Yenimahalle, Ankara, 06200, Turkey|VM Medical Park Mersin Hospital, Mezitli, Mersin, 33200, Turkey|Tekirdag Namik Kemal University Hospital, Tekirdag, Suleymanpasa, 59100, Turkey|Gazi Universitesi, Besevler, 6500, Turkey|Istanbul University Istanbul Faculty of Medicine, Istanbul, 34418, Turkey|Ege University, Izmir, 35100, Turkey|Dokuz Eylul University, Izmir, 35340, Turkey|Sakarya Universty Medical Faculty, Sakarya, 54290, Turkey|Ondokuz Mayis Universitesi Tip Fakultesi Hastanesi, Samsun, 55239, Turkey|NHS Grampian: Aberdeen Royal Infirmary, Aberdeen, AB25 2ZN, United Kingdom|The Hillingdon Hospitals NHS Foundation Trust, Uxbridge, UB8 3NN, United Kingdom",
NCT05566795,DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2),https://clinicaltrials.gov/study/NCT05566795,,RECRUITING,"This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in participants with pediatric low-grade glioma (LGG) harboring an activating rapidly accelerated fibrosarcoma (RAF) alteration requiring first-line systemic therapy.",NO,Low-grade Glioma|Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma|Pediatric Low-grade Glioma,DRUG: Tovorafenib|DRUG: Chemotherapeutic Agent,"Objective response rate (ORR) of tovorafenib monotherapy versus SoC chemotherapy, ORR assessed per Response Assessment in Pediatric Neuro Oncology (RAPNO) criteria by Independent Review Committee (IRC), and defined as the proportion of participants with overall confirmed response of complete response (CR), partial response (PR), or minor response (MR)., Up to 60 months","Progression-free survival (PFS) of tovorafenib monotherapy versus SoC chemotherapy, PFS assessed per RAPNO criteria by IRC, and deï¬ned as time from randomization to PD or death from any cause, whichever comes first., Up to 60 months|Event-free survival (EFS) of tovorafenib monotherapy versus SoC chemotherapy, EFS assessed per RAPNO criteria by IRC, deï¬ned as time from randomization to PD, death from any cause, or initiation of any new anticancer therapy, whichever comes first., Up to 60 months|Overall survival (OS) of tovorafenib monotherapy versus SoC chemotherapy, Overall survival is defined as time from randomization up to death from any cause., Up to 60 months|Number of participants with any treatment-emergent adverse events, and Serious adverse events, Type, frequency, and severity of adverse events of tovorafenib monotherapy versus SoC chemotherapy will be assessed., Up to 60 months|. Number of participants with clinically significant vital signs and laboratory abnormalities findings, Type, frequency, and severity of vital signs and laboratory abnormalities of tovorafenib monotherapy versus SoC chemotherapy will be assessed., Up to 60 months|Change from baseline in Adaptive Behavior Composite Score (ABS) of tovorafenib monotherapy versus SoC chemotherapy, Adaptive behavior Composite Score will be evaluated using domain scores collected from the comprehensive Vineland III Adaptive Behavior Scale (VABS)., Baseline, Year 1, 2 and 5|Change from baseline in the Motor Skills Domain Score of tovorafenib monotherapy versus SoC chemotherapy, The motor skills (gross and fine) will be assessed using the Motor Skills Score domain of the VABS in pediatric participants., Baseline, Year 1, 2 and 5|Change from baseline in the Daily Living Domain Score of tovorafenib monotherapy versus SoC chemotherapy, The daily living (personal, domestic and community) will be assessed using Daily Living Domain Score of VABS., Baseline, Year 1, 2 and 5|Change from baseline in the Communication Domain Score of tovorafenib monotherapy versus SoC chemotherapy, The communication skills (receptive, expressive and written) will be assessed using Communication Domain Score of VABS., Baseline, Year 1, 2 and 5|Change from baseline in the Socialization Domain Score of tovorafenib monotherapy versus SoC chemotherapy, The socialization skills (Interpersonal relationships, play and leisure time and coping skills) will be assessed using Socialization Domain Score of VABS., Baseline, Year 1, 2 and 5|Change in age-adjusted visual acuity (VA) of tovorafenib monotherapy versus SoC chemotherapy in optic pathway glioma (OPG) participants aged < 3 years, Visual acuity testing using current age-appropriate testing methodology will be performed for all participants at Screening. For participants with OPG or an underlying visual deficit related to the primary malignancy, visual acuity testing will be performed every time participants have a radiographic response assessment. Assessments will be performed in each eye separately at a recommended testing distance of 3 meters., Baseline and up to 5 years|Change in best corrected visual acuity of tovorafenib monotherapy versus SoC chemotherapy in OPG participants aged â¥ 3 years, Visual acuity assessments to be performed by an ophthalmologist or another qualified site clinical personnel., Baseline and up to 5 years|Visual progression-free survival (v-PFS) of tovorafenib monotherapy versus SoC chemotherapy, Visual progression-free survival is defined as the time from start of treatment to visual event for OPG participants aged â¥ 3 years., Up to 60 months|ORR of tovorafenib monotherapy versus SoC chemotherapy, ORR, defined as the proportion of participants with overall confirmed response per Response Assessment in Neuro-Oncology for High-Grade Glioma (RANO-HGG) criteria (CR or PR) and RANO-LGG criteria (CR, PR, or MR), as applicable., Up to 60 months|Clinical beneï¬t rate (CBR) of tovorafenib monotherapy versus SoC chemotherapy, CBR, deï¬ned as the proportion of participants with radiological tumor stabilization or regression per RANO-LGG (CR, PR, MR, or SD lasting 12 months or more), RANO-HGG (CR, PR, or SD lasting 12 months or more) or RAPNO criteria (CR, PR, MR or SD lasting 12 months or more), as applicable., Up to 60 months|Time to response (TTR) of tovorafenib monotherapy versus SoC chemotherapy, TTR, measured by the time following randomization to ï¬rst imaging of tumor response that was subsequently conï¬rmed per RANO-HGG criteria (CR or PR), RANO-LGG criteria (CR, or PR, or MR), or RAPNO criteria (CR, PR, or MR), as applicable., Up to 60 months|PFS of tovorafenib monotherapy versus SoC chemotherapy, PFS per RANO-HGG or RANO-LGG criteria (as applicable), deï¬ned as time from randomization to PD or death from any cause, whichever occurs first., Up to 60 months|EFS of tovorafenib monotherapy versus SoC chemotherapy, EFS per RANO-HGG or RANO-LGG criteria (as applicable), defined as time from randomization to PD, death from any cause, or initiation of any new anticancer therapy, whichever comes first., Up to 60 months|Duration of response (DOR) of tovorafenib monotherapy versus SoC chemotherapy, DOR, deï¬ned as time from first imaging of tumor response per RANO-LGG, RANO-HGG or RAPNO criteria, as applicable, that was subsequently confirmed to radiographic PD or death from any cause, whichever comes first., Up to 60 months|Change from Baseline in health-related quality of life (HRQoL) total score of tovorafenib monotherapy versus SoC chemotherapy, The Patient-Reported Outcomes Measurement Information System (PROMISÂ®) Pediatric/Parent Proxy Profile 49 v2.0 will be used to assess mental and social HRQoL., Baseline, Year 1, 2 and 5",,"Day One Biopharmaceuticals, Inc.",SIOPe Brain Tumor Group LOGGIC Consortium,ALL,"CHILD, ADULT",PHASE3,400,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-02-27,2026-02,2030-03,2022-10-04,,2025-06-04,"Children's of Alabama, Birmingham, Alabama, 35233, United States|Phoenix Children's Hospital, Phoenix, Arizona, 85016, United States|Children's Hospital Los Angeles, Los Angeles, California, 90027, United States|Children's Hospital of Orange County Main Campus - Orange, Orange, California, 92868, United States|UCSF Benioff Children's Hospital, San Francisco, California, 94158, United States|Children's Hospital Colorado, Aurora, Colorado, 80045, United States|Connecticut Children's Medical Center, Hartford, Connecticut, 06106-3322, United States|Children's National Medical Center, Washington, District of Columbia, 20010, United States|University of Florida Health, Gainesville, Florida, 32610, United States|Arnold Palmer Hospital for Children, Orlando, Florida, 32806, United States|Johns Hopkins All Children's Hospital, St. Petersburg, Florida, 33701, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, 30322, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, 60611, United States|Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, 46202, United States|Maine Children's Cancer Program, Scarborough, Maine, 04074, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|University of Michigan - - C.S. Mott Children's Hospital, Ann Arbor, Michigan, 48109, United States|Children's Minnesota, Minneapolis, Minnesota, 55404, United States|St. Louis Children's Hospital, Saint Louis, Missouri, 63110, United States|University of Nebraska Medical Center, Omaha, Nebraska, 68198-6878, United States|New York University Langone Health, New York, New York, 10016, United States|University of Rochester, Rochester, New York, 14642, United States|Duke Cancer Institute, Durham, North Carolina, 27705, United States|Cleveland Clinic Main Campus, Cleveland, Ohio, 44195, United States|University of Texas Southwestern Medical Center, Dallas, Texas, 75390, United States|Texas Children's Hospital, Houston, Texas, 77030, United States|Seattle Children's Hospital, Seattle, Washington, 98105, United States|University of Wisconsin - Madison, Madison, Wisconsin, 53792, United States|Children's Health Queensland Hospital and Health Service, South Brisbane, Queensland, 4101, Australia|Perth Children's Hospital, Nedlands, 6009, Australia|Women's and Children's Health Network, North Adelaide, 5006, Australia|The Royal Children's Hospital - Children's Cancer Centre, Parkville, 3052, Australia|Sydney Children's Hospital - Randwick, Randwick, 2031, Australia|Children's Hospital at Westmead, Westmead, 2145, Australia|Medizinische UniversitÃ¤t Innsbruck, Innsbruck, Tirol, 6020, Austria|Medizinische UniversitÃ¤t Wien, Wien, 1090, Austria|Cliniques Universitaires Saint-Luc, Brussel, 1200, Belgium|Universitair Ziekenhuis Gent, Ghent, 9000, Belgium|Universitair Ziekenhuis Leuven - Campus Gasthuisberg, Leuven, 3000, Belgium|Grupo de Apoio ao Adolescente e Ã  CrianÃ§a com CÃ¢ncer (GRAACC), SÃ£o Paulo, 04039-001, Brazil|Alberta Children's Hospital, Calgary, Alberta, T3B 6A8, Canada|Stollery Children's Hospital, Edmonton, Alberta, T6G 2B7, Canada|British Columbia Children's Hospital, Vancouver, British Columbia, V6H 3N1, Canada|McMaster Children's Hospital, Hamilton, Ontario, L8S 4L8, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, K1H 8L1, Canada|CHU Sainte-Justine, MontrÃ©al, Quebec, H3T IC5, Canada|The Montreal Children's Hospital, MontrÃ©al, Quebec, H4A 3J1, Canada|Centre Hospitalier de l'UniversitÃ© Laval et Centre MÃ¨re-Enfant Soleil, QuÃ©bec, G1V 4G2, Canada|SickKids - The Hospital for Sick Children, Toronto, M5G 1X8, Canada|FakultnÃ­ Nemocnice Brno - D?tskÃ¡ Nemocnice, Brno, 625 00, Czechia|Motol University Hospital, Prague, 5 150 06, Czechia|Aarhus Universitetshospital, Aarhus, Midtjylland, 8200, Denmark|Rigshospitalet, Copenhagen, 2100, Denmark|Helsingin yliopistollinen sairaala (HUS), Helsinki, FI-00290, Finland|Tampereen Yliopistollinen Sairaala, Tampere, 33520, Finland|Centre de Lutte contre le Cancer - Centre Oscar Lambret, Lille, 59020, France|Centre LÃ©on BÃ©rard, Lyon, 69008, France|HÃ´pital de la Timone, Marseille, 13005, France|Institut Curie, Paris, 75248, France|Gustave Roussy, Villejuif, 94805, France|UniversitÃ¤tsklinikum Freiburg, Freiburg, Baden-WÃ¼rttemberg, 79106, Germany|UniversitÃ¤tsklinikum Augsburg, Augsburg, Bayern, 86156, Germany|UniversitÃ¤tsklinikum Erlangen, Erlangen, Bayern, 91054, Germany|UniversitÃ¤tsklinikum WÃ¼rzburg, WÃ¼rzburg, Bayern, 97080, Germany|UniversitÃ¤tsklinikum Frankfurt, Frankfurt, Hessen, 60590, Germany|Medizinische Hochschule Hannover, Hannover, Niedersachsen, 30625, Germany|Universitaetsklinikum Essen, Essen, Nordrhein-Westfalen, 45147, Germany|UniversitÃ¤tsklinikum Leipzig, Leipzig, Sachsen, 4103, Germany|CharitÃ© UniversitÃ¤tsmedizin Berlin, Berlin, 13353, Germany|Evangelische Klinikum Bethel (EvKB), Bielefeld, 33617, Germany|UniversitÃ¤tsklinikum Hamburg-Eppendorf, Hamburg, 20246, Germany|UniversitÃ¤tsklinikum Heidelberg, Heidelberg, 69120, Germany|UniversitÃ¤tsklinikum TÃ¼bingen, TÃ¼bingen, 72076, Germany|Aghia Sofia General Children's Hospital, Athens, 11527, Greece|Athens General Children's Hospital, Athens, 11527, Greece|Semmelweis Egyetem TÅ±zoltÃ³ utcai II. Sz. GyermekgyÃ³gyÃ¡szati KlinikÃ¡, Budapest, 1094, Hungary|Children's Health Ireland at Crumlin, Crumlin, Dublin, D12 N512, Ireland|Schneider Children's Medical Center of Israel, Petah tikva, 49202, Israel|The Edmond and Lily Safra Children's Hospital, Ramat Gan, 5265601, Israel|Fondazione IRCCS - Istituto Nazionale dei Tumori, Milano, Milan, 20133, Italy|Ospedale Pediatrico Bambino GesÃ¹, Roma, Rome, 00165, Italy|Ospedale Infantile Regina Margherita, Torino, Turin, 10126, Italy|Azienda Universitaria Ospedaliera Consorziale - Policlinico di Bari, Bari, 70124, Italy|Istituto Giannina Gaslini, Genova, 16147, Italy|Azienda Ospedaliera di Rilievo Nazional Santobono Pausilipon, Napoli, 80131, Italy|Azienda Ospedale UniversitÃ  di Padova, Padova, 35128, Italy|Azienda Sanitaria Universitaria Friuli Centrale - P.O. Santa Maria della Misericordia, Udine, 33100, Italy|King Hussein Cancer Foundation - King Hussein Cancer Center, Amman, Muhafazat al-Asima, 11941, Jordan|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Severance Hospital, Seoul, 03722, Korea, Republic of|Prinses Maxima Centrum Kinderoncologie, Utrecht, 3584 CS, Netherlands|Starship Paediatric Blood & Cancer Center, Grafton, 1023, New Zealand|Universitetssykehuset Nord-Norge - TromsÃ¸, TromsÃ¸, Troms, 9038, Norway|Oslo Universitetssykehus, Oslo, 372, Norway|SingHealth Group - KK Women's and Children's Hospital, Singapore, 229899, Singapore|Univerzitetni Klinini Center Ljubljana, Ljubljana, 1000, Slovenia|Hospital Universitario Cruces, Barakaldo, 48903, Spain|Hospital Universitari Vall d'HebrÃ³n, Barcelona, 08035, Spain|Hospital Sant Joan de DÃ©u Barcelona, Barcelona, 08950, Spain|Hospital Infantil Universitario NiÃ±o JesÃºs, Madrid, 28009, Spain|Hospital Universitario La Paz, Madrid, 28046, Spain|Hospital Universitario Virgen del RocÃ­o, Sevilla, 41013, Spain|Hospital Universitari i PolitÃ¨cnic La Fe, Valencia, 46026, Spain|Drottning Silvias barn- och ungdomssjukhus, GÃ¶teborg, 416 85, Sweden|SkÃ¥nes Universitetssjukhus - Lund, Lund, 221 85, Sweden|Astrid Lindgrens Barnsjukhus Solna, Stockholm, 171 77, Sweden|Centre Hospitalier Universitaire Vaudois Lausanne, Lausanne, 1011, Switzerland|Universitaets - Kinderspital ZÃ¼rich, Zurich, 8032, Switzerland|Taipei Medical University Hospital, Taipei, 110, Taiwan|Chang Gung Memorial Hospital - Linkou Branch, Taoyuan, 333, Taiwan|Birmingham Women's and Children's NHS Foundation Trust, Birmingham, England, B4 6NH, United Kingdom|Leeds Teaching Hospital NHS Trust, Leeds, England, LS1 3EX, United Kingdom|Alder Hey Children's NHS Foundation Trust, Liverpool, England, L12 2AP, United Kingdom|Manchester University NHS Foundation Trust, Manchester, England, M13 PWL, United Kingdom|The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, England, NE1 4LP, United Kingdom|Great Ormond Street Hospital for Children, Oxford, England, WC1N 3JH, United Kingdom|Royal Belfast Hospital for Sick Children, Belfast, Northern Ireland, BT9 7AB, United Kingdom|NHS Greater Glasgow and Clyde, Glasgow, Scotland, G51 4TF, United Kingdom|Sheffield Children's Hospital, Sheffield, South Yorkshire, S10 2TH, United Kingdom|The Royal Marsden NHS Foundation Trust, Sutton, Surrey, SM2 5PT, United Kingdom|University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, BS2 8HW, United Kingdom|Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, United Kingdom",
NCT05629585,A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03),https://clinicaltrials.gov/study/NCT05629585,,ACTIVE_NOT_RECRUITING,"This is a Phase III, randomized, open-label, 3-arm, multicenter, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with ICT in participants with stage I to III TNBC with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvant systemic therapy.",NO,Breast Cancer,DRUG: Dato-DXd|DRUG: Durvalumab|DRUG: Capecitabine|DRUG: Pembrolizumab,"Invasive disease-free survival (iDFS) for Dato-DXd + durvalumab vs. ICT, iDFS is defined as time from randomisation until date of first occurrence of one of the following events: ipsilateral invasive breast tumour (local) recurrence, regional invasive breast cancer recurrence (axilla, regional lymph nodes, chest wall, and skin of ipsilateral breast), or distant recurrence (metastatic breast cancer that has either been biopsy-confirmed or clinically diagnosed as recurrent invasive breast cancer); contralateral invasive breast cancer; second primary non-breast invasive cancer (other than squamous or basal cell skin cancer); or death from any cause.

iDFS will be determined based on disease recurrence per investigator assessment based on all available clinical assessments. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anticancer therapy.

The measure of interest will be the HR (hazard ratio) of iDFS for Dato-DXd + durvalumab vs ICT., From randomisation to date of the event, up to 57 months from first subject in","Distant disease-free survival (DDFS) for Dato-DXd + durvalumab vs ICT, DDFS is defined as time from randomisation to date of first distant recurrence, occurrence of second primary non-breast invasive cancer, or death from any cause.

DDFS is determined based on disease recurrence per investigators assessment based on all available clinical assessments.

The analysis will include all randomised participants, as randomised regardless of whether the participant withdraws from randomised therapy or received another anticancer therapy. The measure of interest will be the HR (hazard ratio) of DDFS for Dato-DXd + durvalumab vs ICT., From randomisation to date of the event, up to 57 months from first subject in|DDFS for Dato-DXd vs ICT, DDFS is defined as time from randomisation to date of first distant recurrence, occurrence of second primary non-breast invasive cancer, or death from any cause. DDFS is determined based on disease recurrence per investigators assessment based on all available clinical assessments. The measure of interest will be the HR (hazard ratio) of DDFS for Dato-DXd vs ICT., From randomisation to date of the event, up to 57 months from first subject in|DDFS for Dato-DXd + durvalumab vs Dato-DXd, DDFS is defined as time from randomisation to date of first distant recurrence, occurrence of second primary non-breast invasive cancer, or death from any cause. DDFS is determined based on disease recurrence per investigators assessment based on all available clinical assessments. The measure of interest will be the HR (hazard ratio) of DDFS for Dato-DXd + durvalumab vs Dato-DXd., From randomisation to date of the event, up 57 months from first subject in|Overall Survival (OS) for Dato-DXd + durvalumab vs ICT, OS is defined as time from randomisation until date of death due to any cause.

The analysis will include all randomised participants, as randomised regardless of whether the participant withdraws from randomised therapy or received another anticancer therapy. The measure of interest will be the HR (hazard ratio) of OS for Dato-DXd + durvalumab vs ICT., From randomisation to date of death, due to any cause, up to 87 months from first subject in|OS for Dato-DXd vs ICT, OS is defined as time from randomisation until date of death due to any cause. The measure of interest will be the HR (hazard ratio) of OS for Dato-DXd vs ICT., From randomisation to date of death, due to any cause, up to 87 months from first subject in|iDFS for Dato-DXd vs ICT, iDFS is defined as time from randomisation until date of first occurrence of one of the following events: ipsilateral invasive breast tumour (local) recurrence, regional invasive breast cancer recurrence (axilla, regional lymph nodes, chest wall, and skin of ipsilateral breast), or distant recurrence (metastatic breast cancer that has either been biopsy-confirmed or clinically diagnosed as recurrent invasive breast cancer); contralateral invasive breast cancer; second primary non-breast invasive cancer (other than squamous or basal cell skin cancer); or death from any cause.

iDFS will be determined based on disease recurrence per investigator assessment based on all available clinical assessments. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anticancer therapy.

The measure of interest will be the HR (hazard ratio) of iDFS for Dato-DXd vs ICT., From randomisation to date of the event, up to 57 months from first subject in|iDFS for Dato-DXd + durvalumab vs Dato-DXd, iDFS is defined as time from randomisation until date of first occurrence of one of the following events: ipsilateral invasive breast tumour (local) recurrence, regional invasive breast cancer recurrence (axilla, regional lymph nodes, chest wall, and skin of ipsilateral breast), or distant recurrence (metastatic breast cancer that has either been biopsy-confirmed or clinically diagnosed as recurrent invasive breast cancer); contralateral invasive breast cancer; second primary non-breast invasive cancer (other than squamous or basal cell skin cancer); or death from any cause. The measure of interest will be the HR (hazard ratio) of iDFS for Dato-DXd + durvalumab vs Dato-DXd., From randomisation to date of the event, up to 57 months from first subject in|Participant-reported physical function in participants treated with Dato-DXd with or without durvalumab compared with ICT, Time to Deterioration (TTD) and actual scores in physical function as measured by the PROMIS Physical Function Short Form 8c.TTD is defined as time from the date of randomisation to the date of deterioration. Deterioration is defined as change from baseline that reaches a clinically meaningful deterioration threshold.

The analysis will include all dosed participants. The measure of interest is the HR (hazard ratio) of TTD and mean between-arm difference in physical function for Dato-DXd with or without durvalumab compared with ICT., From randomisation to date of the deterioration, up to 36 months after randomisation|Participant-reported in GHS/QoL in participants treated with Dato-DXd with or without durvalumab compared with ICT, Time to Deterioration (TTD) and actual scores in GHS/QoL as measured by the GHS/QoL scale from the EORTC IL172.

TTD is defined as time from the date of randomisation to the date of deterioration. Deterioration is defined as change from baseline that reaches a clinically meaningful deterioration threshold.

The analysis will include all randomised participants. The measure of interest is the HR (hazard ratio) of TTD and mean between-arm difference in GHS/QoL for Dato-DXd with or without durvalumab compared with ICT., From randomisation to date of the deterioration, up to 36 months after randomisation|Participant-reported fatigue in participants treated with Dato-DXd with or without durvalumab compared with ICT, Proportion of participants experiencing different levels of fatigue at 3 months (13weeks), 6 months (26 weeks), and 12 months (52 weeks) as measured by PROMIS Fatigue Short Form 7a.

The analysis will include all dosed participants. The measure of interest will be the proportion of participants reporting different levels of fatigue., From randomisation to 24 months after randomisation|Pharmacokinetics of Dato-DXd, Concentration of Dato- DXd, total anti-TROP2 antibody, and MAAA-1181 in plasma., Day 1 of cycles 1,2,4,6,8 (Each cycle is 21 days)|Immunogenicity of Dato-DXd, Presence of ADAs for Dato-DXd (confirmatory results: positive or negative; titres)., Day 1 of cycles 1,2,4,6,8 (Each cycle is 21 days) and within 35 days of completion of or discontinuation of study intervention (at an average of 6 months following randomization)|Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability), Safety and tolerability will be evaluated in terms of AEs (graded by CTCAE version 5.0)., Randomization to final safety follow-up visit, either 90 days after last dose of study intervention for those who complete planned study intervention or 90 days after date of discontinuation for those who discontinue study intervention prematurely",,AstraZeneca,Daiichi Sankyo|SWOG Clinical Trials Partnerships,ALL,"ADULT, OLDER_ADULT",PHASE3,1174,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-11-28,2027-09-20,2030-01-30,2022-11-29,,2025-04-14,"Research Site, Gilbert, Arizona, 85234, United States|Research Site, Tucson, Arizona, 85711, United States|Research Site, Tucson, Arizona, 85719, United States|Research Site, Hot Springs National Park, Arkansas, 71913, United States|Research Site, Little Rock, Arkansas, 72205, United States|Research Site, Springdale, Arkansas, 72762, United States|Research Site, Beverly Hills, California, 90211, United States|Research Site, Costa Mesa, California, 92627, United States|Research Site, Duarte, California, 91010, United States|Research Site, Fountain Valley, California, 92708, United States|Research Site, Irvine, California, 92618, United States|Research Site, La Jolla, California, 92093, United States|Research Site, Lakewood, California, 90805, United States|Research Site, Los Angeles, California, 90017, United States|Research Site, Los Angeles, California, 90095, United States|Research Site, Newport Beach, California, 92660, United States|Research Site, Newport Beach, California, 92663, United States|Research Site, Orange, California, 92868, United States|Research Site, Roseville, California, 95661, United States|Research Site, Upland, California, 91786, United States|Research Site, Vallejo, California, 94589, United States|Research Site, Denver, Colorado, 80220, United States|Research Site, New Haven, Connecticut, 06510, United States|Research Site, Newark, Delaware, 19713, United States|Research Site, Washington, District of Columbia, 20007, United States|Research Site, Altamonte Springs, Florida, 32701, United States|Research Site, Hollywood, Florida, 33021, United States|Research Site, Miami Beach, Florida, 33140, United States|Research Site, Tallahassee, Florida, 32308, United States|Research Site, West Palm Beach, Florida, 33401, United States|Research Site, Athens, Georgia, 30607, United States|Research Site, Atlanta, Georgia, 30318, United States|Research Site, Atlanta, Georgia, 30322, United States|Research Site, Chicago, Illinois, 60611, United States|Research Site, Maywood, Illinois, 60153, United States|Research Site, Westwood, Kansas, 66205, United States|Research Site, Lexington, Kentucky, 40503, United States|Research Site, Louisville, Kentucky, 40202, United States|Research Site, Louisville, Kentucky, 40207, United States|Research Site, Louisville, Kentucky, 40241, United States|Research Site, New Orleans, Louisiana, 70121, United States|Research Site, Annapolis, Maryland, 21401, United States|Research Site, Baltimore, Maryland, 21202, United States|Research Site, Columbia, Maryland, 21044, United States|Research Site, Boston, Massachusetts, 02114, United States|Research Site, Detroit, Michigan, 48201, United States|Research Site, Saint Louis, Missouri, 63110, United States|Research Site, Camden, New Jersey, 08103, United States|Research Site, Albuquerque, New Mexico, 87109, United States|Research Site, New York, New York, 10011, United States|Research Site, New York, New York, 10021, United States|Research Site, New York, New York, 10029, United States|Research Site, New York, New York, 10032, United States|Research Site, New York, New York, 10065, United States|Research Site, Charlotte, North Carolina, 28204, United States|Research Site, Canton, Ohio, 44710, United States|Research Site, Cleveland, Ohio, 44106, United States|Research Site, Cleveland, Ohio, 44111, United States|Research Site, Cleveland, Ohio, 44195, United States|Research Site, Columbus, Ohio, 43219, United States|Research Site, Portland, Oregon, 97227, United States|Research Site, Hershey, Pennsylvania, 17033, United States|Research Site, Philadelphia, Pennsylvania, 19111, United States|Research Site, Pittsburgh, Pennsylvania, 15213, United States|Research Site, Providence, Rhode Island, 02903, United States|Research Site, Germantown, Tennessee, 38138, United States|Research Site, Memphis, Tennessee, 38120, United States|Research Site, Nashville, Tennessee, 37203, United States|Research Site, Nashville, Tennessee, 37232, United States|Research Site, Bedford, Texas, 76022, United States|Research Site, Dallas, Texas, 75246, United States|Research Site, Denton, Texas, 76201, United States|Research Site, Fort Worth, Texas, 76104, United States|Research Site, Fort Worth, Texas, 76177, United States|Research Site, Houston, Texas, 77024, United States|Research Site, Houston, Texas, 77030, United States|Research Site, McAllen, Texas, 78503, United States|Research Site, Fairfax, Virginia, 22031, United States|Research Site, Gainesville, Virginia, 20155, United States|Research Site, Midlothian, Virginia, 23114, United States|Research Site, Norfolk, Virginia, 23502, United States|Research Site, Edmonds, Washington, 98026, United States|Research Site, Issaquah, Washington, 98029, United States|Research Site, Puyallup, Washington, 98373, United States|Research Site, Seattle, Washington, 98104, United States|Research Site, Seattle, Washington, 98133, United States|Research Site, Spokane Valley, Washington, 99216, United States|Research Site, Morgantown, West Virginia, 26506, United States|Research Site, Anderlecht, 1070, Belgium|Research Site, Brussel, 1090, Belgium|Research Site, Bruxelles, 1200, Belgium|Research Site, Charleroi, 6060, Belgium|Research Site, Edegem, 2650, Belgium|Research Site, Gent, 9000, Belgium|Research Site, Hasselt, 3500, Belgium|Research Site, LiÃ¨ge, 4000, Belgium|Research Site, Namur, 5000, Belgium|Research Site, Sint-Niklaas, 9100, Belgium|Research Site, Wilrijk, 2610, Belgium|Research Site, Brasilia, 71681-603, Brazil|Research Site, Porto Alegre, 90035-000, Brazil|Research Site, Recife, 52010-075, Brazil|Research Site, Salvador, 41253-190, Brazil|Research Site, Sao Paulo, 01321-001, Brazil|Research Site, Sao Paulo, 01508-010, Brazil|Research Site, SÃ£o Paulo, 03102-002, Brazil|Research Site, SÃ£o Paulo, 04532-030, Brazil|Research Site, VitÃ³ria, 29055-450, Brazil|Research Site, North Vancouver, British Columbia, V7L 2L7, Canada|Research Site, Barrie, Ontario, L4M 6M2, Canada|Research Site, Kingston, Ontario, K7L 2V7, Canada|Research Site, Oakville, Ontario, L9T 6G2, Canada|Research Site, Ottawa, Ontario, K1H 8L6, Canada|Research Site, Toronto, Ontario, M5G 1X5, Canada|Research Site, Toronto, Ontario, M5G 2M9, Canada|Research Site, Laval, Quebec, H7M 3L9, Canada|Research Site, Montreal, Quebec, H2X 0C1, Canada|Research Site, Montreal, Quebec, H3T 1E2, Canada|Research Site, Montreal, Quebec, H4A 3J1, Canada|Research Site, Quebec City, Quebec, G1S 4L8, Canada|Research Site, Saskatoon, Saskatchewan, S7N 4H4, Canada|Research Site, Beijing, 100044, China|Research Site, Beijing, 100142, China|Research Site, Bengbu, 233004, China|Research Site, Changchun, 130021, China|Research Site, Changsha, 410008, China|Research Site, Chengdu, 610000, China|Research Site, Chengdu, 610072, China|Research Site, Chongqing, 400030, China|Research Site, Fuzhou, 350011, China|Research Site, Guangzhou, 510060, China|Research Site, Guangzhou, 510100, China|Research Site, Guangzhou, 510120, China|Research Site, Guangzhou, 510700, China|Research Site, Haikou, 570311, China|Research Site, Hangzhou, 310009, China|Research Site, Hangzhou, 310020, China|Research Site, Harbin, 150081, China|Research Site, Hefei, 230001, China|Research Site, Jinan, 250030, China|Research Site, Nanchang, 330009, China|Research Site, Nanjing, 210008, China|Research Site, Nanjing, 210009, China|Research Site, Nanning, 530021, China|Research Site, Qingdao, 110016, China|Research Site, Shanghai, 200025, China|Research Site, Shanghai, 200032, China|Research Site, Shenzhen, 518020, China|Research Site, Shijiazhuang, 050020, China|Research Site, Tianjin, 300060, China|Research Site, Wuhan, 430022, China|Research Site, Wuhan, 430060, China|Research Site, Xi'an, 710038, China|Research Site, Xiamen, 361003, China|Research Site, Zhengzhou, 450052, China|Research Site, Copenhagen, 2100, Denmark|Research Site, Herning, 7400, Denmark|Research Site, NÃ¦stved, 4700, Denmark|Research Site, Odense, 5000, Denmark|Research Site, SÃ¸nderborg, 6400, Denmark|Research Site, Vejle, 7100, Denmark|Research Site, Angers Cedex 02, 49055, France|Research Site, Bordeaux, 33076, France|Research Site, Dijon, 21000, France|Research Site, Lyon, 69008, France|Research Site, Montpellier, 34070, France|Research Site, Nimes, 30029, France|Research Site, Paris Cedex 05, 75248, France|Research Site, Poitiers, 86021, France|Research Site, Rennes, 35000, France|Research Site, Saint Herblain Cedex, 44805, France|Research Site, Villejuif Cedex, 94805, France|Research Site, Frankfurt am Main, 65929, Germany|Research Site, Hamburg, 20357, Germany|Research Site, Hannover, 30177, Germany|Research Site, Heilbronn, 74078, Germany|Research Site, Kiel, 24105, Germany|Research Site, Langen, 63225, Germany|Research Site, Leipzig, 4103, Germany|Research Site, Ludwigsburg, 71640, Germany|Research Site, MÃ¶nchengladbach, 41061, Germany|Research Site, MÃ¼nchen, 80337, Germany|Research Site, Paderborn, 33098, Germany|Research Site, Regensburg, 93053, Germany|Research Site, Stuttgart, 70199, Germany|Research Site, Troisdorf, 53840, Germany|Research Site, TÃ¼bingen, 72076, Germany|Research Site, Wuppertal, 42283, Germany|Research Site, Athens, 115 22, Greece|Research Site, Athens, 11528, Greece|Research Site, Athens, 12462, Greece|Research Site, Heraklion, 71110, Greece|Research Site, Thessaloniki, 54639, Greece|Research Site, Thessaloniki, 54645, Greece|Research Site, Bologna, 40138, Italy|Research Site, Brescia, 25123, Italy|Research Site, Firenze, 50134, Italy|Research Site, Genova, 16132, Italy|Research Site, Livorno, 57124, Italy|Research Site, Meldola, 47014, Italy|Research Site, Messina, 98158, Italy|Research Site, Milano, 20132, Italy|Research Site, Milan, 20141, Italy|Research Site, Napoli, 80131, Italy|Research Site, Padova, 35128, Italy|Research Site, Roma, 00168, Italy|Research Site, Rozzano, 20089, Italy|Research Site, Akashi-shi, 673-8558, Japan|Research Site, Chiba-shi, 260-8717, Japan|Research Site, Chuo-ku, 104-0045, Japan|Research Site, Fukuoka, 811-1395, Japan|Research Site, Fukushima-shi, 960-1295, Japan|Research Site, Hiroshima-shi, 730-8518, Japan|Research Site, Isehara-shi, 259-1193, Japan|Research Site, Kashiwa, 277-8577, Japan|Research Site, Koto-ku, 135-8550, Japan|Research Site, Kyoto-shi, 606-8507, Japan|Research Site, Matsuyama-shi, 791-0280, Japan|Research Site, Nagoya-shi, 464-8681, Japan|Research Site, Nagoya-shi, 466-8560, Japan|Research Site, Niigata-shi, 951-8566, Japan|Research Site, Nishinomiya-shi, 663-8501, Japan|Research Site, Okayama-shi, 700-8558, Japan|Research Site, Osaka-shi, 541-8567, Japan|Research Site, Ota-shi, 373-8550, Japan|Research Site, Sapporo-shi, 003-0804, Japan|Research Site, Sendai-shi, 980-8574, Japan|Research Site, Shinagawa-ku, 142-8666, Japan|Research Site, Shinjuku-ku, 162-8655, Japan|Research Site, Tsukuba, 305-8577, Japan|Research Site, Yokohama-shi, 241-8515, Japan|Research Site, Busan, 49241, Korea, Republic of|Research Site, Daegu, 41404, Korea, Republic of|Research Site, Goyang-si, 10408, Korea, Republic of|Research Site, Seongnam-Si, 463-712, Korea, Republic of|Research Site, Seoul, 02841, Korea, Republic of|Research Site, Seoul, 03080, Korea, Republic of|Research Site, Seoul, 03722, Korea, Republic of|Research Site, Seoul, 05505, Korea, Republic of|Research Site, Seoul, 06273, Korea, Republic of|Research Site, Seoul, 06351, Korea, Republic of|Research Site, San Juan, 00918, Puerto Rico|Research Site, Barcelona, 08028, Spain|Research Site, Barcelona, 8035, Spain|Research Site, Bilbao (Vizcaya), 48013, Spain|Research Site, Elche(Alicante), 03202, Spain|Research Site, Madrid, 28040, Spain|Research Site, Madrid, 28041, Spain|Research Site, Malaga, 29010, Spain|Research Site, Palma de Mallorca, 07010, Spain|Research Site, Toledo, 45007, Spain|Research Site, Valencia, 46010, Spain|Research Site, Stockholm, 11281, Sweden|Research Site, Stockholm, 17176, Sweden|Research Site, Sundsvall, 851 86, Sweden|Research Site, Uppsala, 751 85, Sweden|Research Site, Hsinchu, 300, Taiwan|Research Site, Taichung, 40447, Taiwan|Research Site, Tainan City, 70403, Taiwan|Research Site, Taipei, 10002, Taiwan|Research Site, Taipei, 10449, Taiwan|Research Site, Taipei, 112, Taiwan|Research Site, Taoyuan, 333, Taiwan|Research Site, Yung Kang City, 71044, Taiwan|Research Site, Cambridge, CB2 0QQ, United Kingdom|Research Site, Cardiff, CF14 2TL, United Kingdom|Research Site, Derry, BT47 6SB, United Kingdom|Research Site, Edinburgh, EH4 2XU, United Kingdom|Research Site, Greater London, SW3 6JJ, United Kingdom|Research Site, London, EC1A 7BE, United Kingdom|Research Site, London, SE1 9RT, United Kingdom|Research Site, Manchester, M20 4BX, United Kingdom|Research Site, Newcastle upon Tyne, NE7 7AF, United Kingdom|Research Site, Portsmouth, PO6 3LY, United Kingdom|Research Site, Surrey, SM2 5PT, United Kingdom|Research Site, Taunton, TA1 5DA, United Kingdom",
NCT05625399,A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma,https://clinicaltrials.gov/study/NCT05625399,RELATIVITY-127,ACTIVE_NOT_RECRUITING,The purpose of this study is to demonstrate that the study drug exposure level of the nivolumab + relatlimab FDC subcutaneous (SC) formulation is not worse than nivolumab + relatlimab FDC intravenous (IV) administration in participants with previously untreated metastatic or unresectable melanoma.,NO,Melanoma,DRUG: Nivolumab + Relatlimab|DRUG: rHuPH20,"Time-averaged serum concentration over 28 days after the first dose (Cavgd28) of Nivolumab, Up to 28 days|Trough serum concentration at steady state (Cminss) of Nivolumab, Up to 4 months|Cavgd28 of Relatlimab, Up to 28 days|Cminss of Relatlimab, Up to 4 months","Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) per RECIST v1.1, Up to approximately 3 years|Trough serum concentration at Day 28 after the first dose (Cmind28) of Nivolumab and Relatlimab, Up to 28 days|Peak serum concentration after the first dose (Cmax1) of Nivolumab and Relatlimab, Up to 28 days|Time to Cmax1 (Tmax1) of Nivolumab and Relatlimab, Up to 28 days|Peak serum concentration at steady state (Cmaxss) of Nivolumab and Relatlimab, Up to 4 months|Time-averaged serum concentration at steady state (Cavgss) of Nivolumab and Relatlimab, Up to 4 months|Duration of Response (DOR) by BICR per RECIST v1.1, Up to approximately 3 years|Disease Control Rate (DCR) by BICR per RECIST v1.1, Up to approximately 3 years|Time to Response (TTR), by BICR per RECIST v1.1, Up to approximately 3 years|Objective Response Rate (ORR) by Investigator per RECIST v1.1, Up to approximately 3 years|DOR by Investigator per RECIST v1.1, Up to approximately 3 years|DCR by Investigator per RECIST v1.1, Up to approximately 3 years|TTR by Investigator per RECIST v1.1, Up to approximately 3 years|Progression Free Survival (PFS) by BICR and Investigator per RECIST v1.1, Up to approximately 3 years|Overall Survival, Up to approximately 3 years|Number of Participants with Adverse Events (AEs), Up to approximately 3 years|Change from Baseline in Functional Assessment of Cancer Therapy - Melanoma Subscale (FACT-MS), Up to approximately 3 years",,Bristol-Myers Squibb,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,570,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-03-06,2025-08-04,2027-11-18,2022-11-22,,2025-03-06,"Local Institution - 0125, Phoenix, Arizona, 85013, United States|Local Institution - 0189, Springdale, Arkansas, 72762, United States|Local Institution - 0098, Los Angeles, California, 90025, United States|Local Institution - 0093, Orange, California, 92868-3201, United States|Local Institution - 0123, Stanford, California, 94305, United States|Local Institution - 0113, Englewood, Colorado, 80113, United States|Local Institution - 0114, Jacksonville, Florida, 32224, United States|Local Institution - 0146, Baltimore, Maryland, 21201, United States|Local Institution - 0071, Rochester, Minnesota, 55905, United States|Local Institution - 0013, Omaha, Nebraska, 68130, United States|Local Institution - 0169, Cleveland, Ohio, 44195, United States|Local Institution - 0139, Easton, Pennsylvania, 18045, United States|Local Institution - 0124, Philadelphia, Pennsylvania, 19107, United States|Local Institution - 0122, Murray, Utah, 84107, United States|Local Institution - 0115, Fairfax, Virginia, 22031, United States|Local Institution - 0050, Coffs Harbour, New South Wales, 2450, Australia|Local Institution - 0175, Orange, New South Wales, 2800, Australia|Local Institution - 0172, Port Macquarie, New South Wales, 2444, Australia|Local Institution - 0118, Wagga Wagga, New South Wales, 2650, Australia|Local Institution - 0184, Waratah, New South Wales, 2298, Australia|Local Institution - 0033, Westmead, New South Wales, 2145, Australia|Local Institution - 0055, Wollstonecraft, New South Wales, 2065, Australia|Local Institution - 0090, Birtinya, Queensland, 4575, Australia|Local Institution - 0008, Bendigo, Victoria, 3550, Australia|Local Institution - 0059, Box Hill, Victoria, 3128, Australia|Local Institution - 0154, Heidelberg, Victoria, 3084, Australia|Local Institution - 0030, Melbourne, Victoria, 3004, Australia|Local Institution - 0109, Traralgon, Victoria, 3844, Australia|Local Institution - 0106, Nedlands, Western Australia, 6009, Australia|Local Institution - 0161, Nedlands, Western Australia, 6009, Australia|Local Institution - 0027, Graz, 8036, Austria|Local Institution - 0029, Salzburg, 5020, Austria|Local Institution - 0168, St. Polten, 3100, Austria|Local Institution - 0037, Wien, 1090, Austria|Local Institution - 0072, Brussels, 1200, Belgium|Local Institution - 0078, Charleroi, 6000, Belgium|Local Institution - 0016, Liege, 4000, Belgium|Local Institution - 0177, Fortaleza, Ce, 60135237, Brazil|Local Institution - 0180, Vitoria, ES, 29043-260, Brazil|Local Institution - 0107, Belo Horizonte, Minas Gerais, 30130-090, Brazil|Local Institution - 0025, Ijui, Rio Grande Do Sul, 98700-000, Brazil|Local Institution - 0002, Porto Alegrelegre, RIO Grande DO SUL, 91350-250, Brazil|Local Institution - 0031, Porto Alegre, RIO Grande DO SUL, 90035-903, Brazil|Local Institution - 0058, Porto Alegre, Rio Grande Do Sul, 90610-000, Brazil|Local Institution - 0009, Barretos, Sao Paulo, 14784-400, Brazil|Local Institution - 0018, Sao Jose do Rio Preto, Sao Paulo, 15090-000, Brazil|Local Institution - 0159, Blumenau, SC, 89010-340, Brazil|Local Institution - 0110, Rio De Janeiro, 20220-410, Brazil|Local Institution - 0130, Sao Paulo, 01321-001, Brazil|Local Institution - 0141, Calgary, Alberta, T2N 5G2, Canada|Local Institution - 0121, Hamilton, Ontario, L8V 5C2, Canada|Local Institution - 0096, Ottawa, Ontario, K1H 8L6, Canada|Local Institution - 0116, Toronto, Ontario, M4N 3M5, Canada|Local Institution - 0103, Quebec, G1J 1Z4, Canada|Local Institution - 0143, Temuco, Araucania, 4800827, Chile|Local Institution - 0178, Puerto Montt, Los Lagos, 5507642, Chile|Local Institution - 0140, Recoleta, Metropolitana, 8380455, Chile|Local Institution - 0144, Santiago, Metropolitana, 0101010, Chile|Local Institution - 0010, Santiago, Metropolitana, 7510032, Chile|Local Institution - 0074, Santiago, Metropolitana, 8150513, Chile|Local Institution - 0119, Santiago de Chile, Providencia, 7500653, Chile|Local Institution - 0028, Vina Del Mar, Valparaiso, 2520598, Chile|Local Institution - 0017, Santiago, 7500921, Chile|Local Institution - 0083, Prague, NY, 128 00, Czechia|Local Institution - 0094, Hradec Kralove, 500 05, Czechia|Local Institution - 0091, Olomouc, 77900, Czechia|Local Institution - 0082, Ostrava Poruba, 708 52, Czechia|Local Institution - 0095, Prague, 182 00, Czechia|Local Institution - 0164, Helsinki, 00029, Finland|Local Institution - 0167, Tampere, 33521, Finland|Local Institution - 0162, Turku, 20520, Finland|Local Institution - 0108, Toulouse, Cedex 9, 31059, France|Local Institution - 0034, Paris, Ile De France, 75475, France|Local Institution - 0127, Chambray-les-Tours, Indre-Et-Loire, 37044, France|Local Institution - 0111, Lille, Nord, 59000, France|Local Institution - 0063, Nantes Cedex 01, OH, 44093, France|Local Institution - 0061, Villejuif Cedex, Val-De-Marne, 94805, France|Local Institution - 0007, Amiens, 80054, France|Local Institution - 0128, Bayonne, 64100, France|Local Institution - 0022, Bordeaux, 33000, France|Local Institution - 0129, Clermont Ferrand Cedex 1, 63003, France|Local Institution - 0046, Dijon, 21079, France|Local Institution - 0117, Marseille, 13385, France|Local Institution - 0052, Pierre-Benite, 69310, France|Local Institution - 0089, Rennes Cedex, 35042, France|Local Institution - 0099, Rouen, 76031, France|Local Institution - 0101, Heidelberg, Baden-Wurttemberg, 69120, Germany|Local Institution - 0079, Ulm, Baden-Wurttemberg, 89081, Germany|Local Institution - 0011, Regensburg, Bayern, 93042, Germany|Local Institution - 0003, Luebeck, Schleswig-Holstein, 23538, Germany|Local Institution - 0060, Berlin, 10117, Germany|Local Institution - 0038, Buxtehude, 21614, Germany|Local Institution - 0136, Dortmund, 44137, Germany|Local Institution - 0039, Erfurt, 99089, Germany|Local Institution - 0049, Essen, 45147, Germany|Local Institution - 0166, Frankfurt am Main, 60590, Germany|Local Institution - 0065, Giessen, 35385, Germany|Local Institution - 0135, Goettingen, 37075, Germany|Local Institution - 0138, Hamburg, 20251, Germany|Local Institution - 0137, Ludwigshafen, 67063, Germany|Local Institution - 0165, Marburg, 35043, Germany|Local Institution - 0044, Minden, 32429, Germany|Local Institution - 0112, Nuernberg, 90419, Germany|Local Institution - 0053, Rostock, 18057, Germany|Local Institution - 0081, Tuebingen, 72076, Germany|Local Institution - 0026, Afula, 1834111, Israel|Local Institution - 0054, Jerusalem, 9112001, Israel|Local Institution - 0102, Petah-Tikvah, 4941492, Israel|Local Institution - 0035, Tel Hashomer, 5262100, Israel|Local Institution - 0173, Tel-Aviv, 6423906, Israel|Local Institution - 0051, Bari, 70124, Italy|Local Institution - 0077, Genova, 16132, Italy|Local Institution - 0170, Milan, 20133, Italy|Local Institution - 0084, Napoli, 80131, Italy|Local Institution - 0032, Perugia, 06132, Italy|Local Institution - 0064, Roma, 00168, Italy|Local Institution - 0014, Siena, 53100, Italy|Local Institution - 0163, Bodo, 8005, Norway|Local Institution - 0156, Gralum, 1714, Norway|Local Institution - 0158, LÃ¸renskog, 1474, Norway|Local Institution - 0155, Oslo, 0379, Norway|Local Institution - 0171, Bydgoszcz, Kujawsko-pomorskie, 85-796, Poland|Local Institution - 0021, Krakow, Malopolskie, 30727, Poland|Local Institution - 0005, Opole, Opolskie, 45-061, Poland|Local Institution - 0015, Poznan, Wiekopolskie, 60-780, Poland|Local Institution - 0066, Warszawa, 02-781, Poland|Local Institution - 0012, Donostia, Gipuzkoa, 20014, Spain|Local Institution - 0086, A Coruna, 15006, Spain|Local Institution - 0134, Badalona, 08916, Spain|Local Institution - 0047, Barcelona, 08035, Spain|Local Institution - 0024, Barcelona, 08036, Spain|Local Institution - 0153, Jaen, 23007, Spain|Local Institution - 0045, Las Palmas de Gran Canaria, 35016, Spain|Local Institution - 0040, Madrid, 28007, Spain|Local Institution - 0126, Madrid, 28009, Spain|Local Institution - 0004, Madrid, 28041, Spain|Local Institution - 0056, Madrid, 28050, Spain|Local Institution - 0006, Sevilla, 41009, Spain|Local Institution - 0041, Valencia, 46009, Spain|Local Institution - 0043, Valencia, 46009, Spain|Local Institution - 0151, Valencia, 46014, Spain|Local Institution - 0062, Solna, Stockholm, 171 64, Sweden|Local Institution - 0097, Lund, 222 42, Sweden|Local Institution - 0092, Bern, 3010, Switzerland|Local Institution - 0080, Chur, 7000, Switzerland|Local Institution - 0105, Lausanne, 1011, Switzerland|Local Institution - 0088, London, Greater London, SW3 6JJ, United Kingdom|Local Institution - 0068, Headington, Oxford, Oxfordshire, OX3 7LE, United Kingdom|Local Institution - 0120, Newcastle Upon Tyne, Tyne And Wear, NE7 7DN, United Kingdom",
NCT05051891,"A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naÑve Mantle Cell Lymphoma",https://clinicaltrials.gov/study/NCT05051891,,RECRUITING,To evaluate the efficacy of orelabrutinib combined with R-CHOP vs. R-CHOP alone in the treatment of treatment-naÑve mantle cell lymphoma.,NO,Treatment-naÑve Mantle Cell Lymphoma,DRUG: Orelabrutinib and R-CHOP|DRUG: R-CHOP,"PFS, To evaluate the Progression-free Survival (PFS) by the Independent Review Committee (IRC) according to the 2014 International Working Group Criteria for Non-Hodgkin Lymphoma (iwNHL)., Up to 6 years","ORR, Objective Response Rate, Up to 6 years|CRR, Complete Response Rate, Up to 6 years|OS, Overall Survival, Up to 6 years",,"Beijing InnoCare Pharma Tech Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,356,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-12-22,2024-12-31,2027-12-31,2021-09-21,,2022-10-12,"Anhui Province Cancer Hospital, Hefei, Anhui, 230009, China|Beijing Cancer Hospital, Beijing, Beijing, 100143, China|Tumor in Hunan Province, Hunan, Changsha, 410013, China|The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, 361003, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, China|Guangzhou First People's Hospital, Guangzhou, Guangdong, 510180, China|The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 50011, China|Henan Tumor Hospital, Zhengzhou, Henan, 450008, China|The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China|Wuhan Union Hospital, Wuhan, Hubei, 430022, China|Jiangsu Province Hospital, Nanjing, Jiangsu, 210029, China|The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 215006, China|The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 3300008, China|The First Hospital of Jilin University, Changchun, Jilin, 130021, China|The First Hospital of China Medical University, Shenyang, Liaojing, 110001, China|The First Affiliated Hospital of Guangxi Medical University, Guangxi, Nanning, 530021, China|Shandong Provincial Hospital, Jinan, Shandong, 250021, China|West China Hospital,Sichuan University, Chengdu, Sichuan, 610041, China|Hospital of Hematology, Chinese Academy of Medical Sciences, Tianjin, Tianjin, 300052, China|Tianjin Cancer Hospital, Tianjin, Tianjin, 300060, China|he First Affiliated Hospital of Zhengjiang University, Hangzhou, Zhejiang, 310003, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, 310022, China",
NCT05633654,Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63),https://clinicaltrials.gov/study/NCT05633654,,RECRUITING,"The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.",NO,Triple Negative Breast Cancer,DRUG: Sacituzumab govitecan-hziy (SG)|DRUG: Pembrolizumab|DRUG: Capecitabine,"Invasive Disease-free Survival (iDFS), iDFS is defined as the time from the date of randomization to death from any cause or one of the following events (whichever occurs first): invasive local, regional, or distant recurrence, invasive contralateral breast cancer., Up to 60 months","Overall Survival (OS), OS is defined as the time from the date of randomization until death due to any cause., Up to 96 months|Distant Disease-free Survival (dDFS), dDFS is defined as the time from the date of randomization to death from any cause or one of the following events (whichever occurs first): distant recurrence, or second primary invasive cancer., Up to 60 months|Recurrence-free Survival (RFS), RFS is defined as the time from the date of randomization to death from any cause or one of the following events (whichever occurs first): invasive local, regional, or distant recurrence., Up to 60 months|Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs), First dose date up to 38 months plus 30 days|Percentage of Participants Experiencing Laboratory Abnormalities, First dose date up to 38 months plus 30 days|Time to Worsening (TTW) of Quality of Life (QoL) Based on Functional Assessment of Cancer Therapy for Breast Cancer (FACT-B) Trial Outcome Index (TOI) Scores, TTW of FACT-B TOI scores will be analyzed for each index, the TTW of FACT-B scores will be measured from the randomization date and to the time the participants first experienced a first score of worsening., Up to 60 months",,Gilead Sciences,"Alliance Foundation Trials, LLC.|NSABP Foundation Inc|GBG Forschungs GmbH",ALL,"ADULT, OLDER_ADULT",PHASE3,1514,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-12-12,2027-06,2031-08,2022-12-01,,2025-04-23,"Alabama Oncology, Birmingham, Alabama, 35243, United States|Clearview Cancer Institute, Huntsville, Alabama, 35805, United States|Palo Verde Hematology Oncology, Glendale, Arizona, 85304, United States|Mayo Clinic Hospital, Phoenix, Arizona, 85054, United States|Arizona Oncology Associates, Prescott Valley, Arizona, 86314, United States|Alta Bates Summit Medical Center, Berkeley, California, 94704, United States|Community Cancer Institute, Clovis, California, 93611, United States|PIH Health Whittier Hospital, Downey, California, 90241, United States|Compassionate Cancer Care Medical Group - Inc, Fountain Valley, California, 92708, United States|Los Angeles Cancer Network, Los Angeles, California, 90017, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, 90033, United States|Cedars-Sinai Cancer at Beverly Hills, Los Angeles, California, 90048, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, 92663, United States|Emad Ibrahim, MD, INC, Redlands, California, 92373, United States|Sutter Institute for Medical Research, Sacramento, California, 95816, United States|UCSF Medical Center, San Francisco, California, 94143, United States|Sansum Clinic, Santa Barbara, California, 93105, United States|Stockton Hematology Oncology Medical Group, Stockton, California, 95204, United States|University of Colorado Cancer Center, Aurora, Colorado, 80045, United States|Norwalk Hospital, Danbury, Connecticut, 06810, United States|Stamford Hospital, Stamford, Connecticut, 06902, United States|Morton Plant Hospital - Bay Care, Clearwater, Florida, 00337, United States|University of Florida, Gainesville, Florida, 32610, United States|Mayo Clinic Florida, Jacksonville, Florida, 32224, United States|Cancer Specialists of North Florida, Jacksonville, Florida, 32256, United States|Jupiter Medical Center, Jupiter, Florida, 33458, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, 33140, United States|Midland Florida Clinical Research Center, L, Orange City, Florida, 32763, United States|Orlando Health, Orlando, Florida, 32806, United States|Cancer Care Centers of Brevard, Inc, Palm Bay, Florida, 32909, United States|Memorial Healthcare System, Pembroke Pines, Florida, 33028, United States|Sacred Heart Medical Oncology Group, Pensacola, Florida, 32504, United States|Sylvester Comprehensive Cancer Center, Plantation, Florida, 33324, United States|Cleveland Clinic Florida, Martin North Hospital, Stuart, Florida, 34994, United States|St. Joseph's Hospital, Tampa, Florida, 33614, United States|Weston Hospital, Weston, Florida, 33331, United States|University Cancer & Blood Center, LLC., Athens, Georgia, 30607, United States|Piedmont Cancer Institute, Atlanta, Georgia, 30318, United States|Northside Hospital, Atlanta, Georgia, 30342, United States|Northwest Georgia Oncology Centers, PC, Marietta, Georgia, 30060, United States|Pearlman Cancer Center, Valdosta, Georgia, 31602, United States|St Lukes Mountain States Tumor Institute, Boise, Idaho, 83712, United States|Kootenai Health, Coeur d'Alene, Idaho, 83814, United States|Northwestern Medicine, Chicago, Illinois, 60611, United States|Rush University Medical Center, Chicago, Illinois, 60612, United States|University of Illinois, Chicago, Illinois, 60612, United States|NorthShore University Healthsystem, Evanston, Illinois, 60201, United States|Edward Hospital, Naperville, Illinois, 60540, United States|West Suburban Medical Center- River Forest, River Forest, Illinois, 60305, United States|Edward H. Kaplan MD & Associates - Hematology/Oncology of the North Shore, Skokie, Illinois, 60076, United States|Springfield Clinic LLP, Springfield, Illinois, 62702, United States|Carle Cancer Center, Urbana, Illinois, 61801, United States|Franciscan Health Indianapolis, Indianapolis, Indiana, 46237, United States|Investigative Clinical Research of Indiana, LLC, Indianapolis, Indiana, 46260, United States|IU Health Arnett Hospital, Lafayette, Indiana, 47904, United States|Franciscan Health Munster, Munster, Indiana, 46321, United States|Mercy Medical Center, Cedar Rapids, Iowa, 52403, United States|Mission Cancer & Blood - John Stoddard Cancer Center, Des Moines, Iowa, 50309, United States|University of Iowa Hospitals and Clinics, Fairfield, Iowa, 52556, United States|University of Kentucky, Lexington, Kentucky, 40536, United States|Norton Healthcare, Inc., Louisville, Kentucky, 40207, United States|Mercy Health, Paducah, Kentucky, 42003, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, 70809, United States|University Medical Center New Orleans, New Orleans, Louisiana, 70112, United States|New England Cancer Specialists, Scarborough, Maine, 04074, United States|Sinai Hospital of Baltimore, Inc., Baltimore, Maryland, 21215, United States|St. Agnes Hospital, Baltimore, Maryland, 21229, United States|Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, 21231, United States|Medstar Franklin Square Medical Center, Baltimore, Maryland, 21237, United States|American Oncology Partners of Maryland, PA, Bethesda, Maryland, 20817, United States|James M Stockman Cancer Institute, Frederick, Maryland, 21702, United States|Greater Baltimore Medical Center, Towson, Maryland, 21204, United States|Tufts Medical Center, Boston, Massachusetts, 02111, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Baystate Medical Center Inc., Springfield, Massachusetts, 01199, United States|University of Massachusetts Worcester, Worcester, Massachusetts, 01655, United States|Henry Ford Health System, Detroit, Michigan, 48202, United States|Cancer and Hematology Centers of Western Michigan, Grand Rapids, Michigan, 49503, United States|Ascension, Grosse Pointe Woods, Michigan, 48236, United States|William Beaumont Hospital, Royal Oak, Michigan, 48073, United States|Ascension Providence Hospital Southfield Cancer Center, Southfield, Michigan, 48075, United States|Trinity Health St. Joseph Mercy Ann Arbor, Ypsilanti, Michigan, 48197, United States|Minnesota Oncology Hematology, PA, Maplewood, Minnesota, 55109, United States|Virginia Piper Cancer Center (Allina Health), Minneapolis, Minnesota, 55407, United States|University of Minnesota Medical Center, Fairview, Minneapolis, Minnesota, 55455, United States|Mayo Clinic Rochester, Rochester, Minnesota, 55905, United States|Metro Minnesota Community Oncology, Saint Louis Park, Minnesota, 55426, United States|Baptist Clinical Research Institute, Saint Louis, Missouri, 63131, United States|Mercy Hospital, Saint Louis, Missouri, 63141, United States|Mary Lanning Healthcare - Morrison Cancer Center, Hastings, Nebraska, 68901, United States|Oncology Hematology West - Methodist, Omaha, Nebraska, 68114, United States|Nebraska Methodist Hospital (change from Chi Health Bergan Mercy), Omaha, Nebraska, 68124, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, 89169, United States|Cancer Care & Hematology Specialists, Reno, Nevada, 89511, United States|Regional Cancer Care Associates LLC, East Brunswick, New Jersey, 08816, United States|Hunterdon Medical Center, Flemington, New Jersey, 08822, United States|Summit Medical Group, P.A., Florham Park, New Jersey, 07932, United States|Rutgers Health, New Brunswick, New Jersey, 08901, United States|Overlook Medical Center, Summit, New Jersey, 07901, United States|University of New Mexico, Albuquerque, New Mexico, 87131, United States|San Juan Oncology Associates, Farmington, New Mexico, 87401, United States|New York Oncology Hematology (NYOH), Amsterdam, New York, 12010, United States|Montefiore Medical Center, Bronx, New York, 10467, United States|Roswell Park Cancer Institute, Buffalo, New York, 14263, United States|Hematology Oncology Associates of Central New York, PC, East Syracuse, New York, 13057, United States|Northwell Health, Lake Success, New York, 11042, United States|Laura and Isaac Perlmutter Cancer Canter, New York, New York, 10016, United States|Lipson Cancer Institute - Linden Oaks, Rochester, New York, 14618, United States|New York Cancer and Blood Specialists, Shirley, New York, 11967, United States|Stony Brook Medicine, Stony Brook, New York, 11794, United States|SUNY Upstate Medical University, Syracuse, New York, 13210, United States|Clinical Research Alliance, Westbury, New York, 11590, United States|White Plains Hospital Physician Associates, White Plains, New York, 10601, United States|Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, 27514, United States|Duke Cancer Institute, Durham, North Carolina, 27710, United States|Cone Health Medical Group (Moses Cone Health System), Greensboro, North Carolina, 27403, United States|East Carolina University Health Medical Center, Greenville, North Carolina, 27834, United States|FirstHealth Outpatient Cancer Center, Pinehurst, North Carolina, 28374, United States|UNC Rex Cancer Center, Raleigh, North Carolina, 27607, United States|UNC Nash Cancer Center, Rocky Mount, North Carolina, 27804, United States|Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina, 27157, United States|Good Samaritan Hospital, Cincinnati, Ohio, 45220, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, 45242, United States|Ohio State University CRS, Columbus, Ohio, 43212, United States|Ohio Health Research Institute, Columbus, Ohio, 43214, United States|Anita Stewart Oncology Center, Columbus, Ohio, 43221, United States|Toledo Clinic Cancer Center, Toledo, Ohio, 43623, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, 73104, United States|St. Charles Health System, Inc. DBA St. Charles Medical Center, Bend, Oregon, 97701, United States|Samaritan Hospital, Corvallis, Oregon, 97330, United States|Willamette Valley Cancer Institute and Research Center, Eugene, Oregon, 97401, United States|Asante Rogue Regional Medical Center, Medford, Oregon, 97504, United States|Providence Cancer Institute - Oncology Clinical Trials, Portland, Oregon, 97213, United States|Oregon Health & Science University, Portland, Oregon, 97239, United States|Saint Luke's University Hospital, Bethlehem, Pennsylvania, 18015, United States|Lancaster General Health, Lancaster, Pennsylvania, 17601, United States|University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, 19104, United States|Guthrie Clinical Research, Sayre, Pennsylvania, 18840, United States|Reading Hospital and Medical Center, West Reading, Pennsylvania, 19611, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, 19106, United States|Cancer Care Associates of York, York, Pennsylvania, 17403, United States|Providence Health, Providence, Rhode Island, 02905, United States|Medical University of South Carolina, Charleston, South Carolina, 29425, United States|Spartanburg Medical Center, Spartanburg, South Carolina, 29303, United States|Monument Health Cancer Care Institute, Rapid City, South Dakota, 57701, United States|Avera Cancer Institute, Sioux Falls, South Dakota, 57105, United States|Ballad Health Cancer Care - Kingsport, Kingsport, Tennessee, 37660, United States|Center for Biomedical Research, LLC, Knoxville, Tennessee, 37909, United States|University of Tennessee, Knoxville, Tennessee, 37920, United States|Hendrick Health System, Abilene, Texas, 79601, United States|Texas Oncology, Austin, Texas, 78731, United States|Texas Oncology, El Paso, Texas, 79902, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, 79410, United States|Texas Oncology, San Antonio, Texas, 78240, United States|Huntsman Cancer Institute, Salt Lake City, Utah, 84112, United States|University of Virginia, Charlottesville, Virginia, 22908, United States|Virginia Commonwealth University Medical Center, Richmond, Virginia, 23298, United States|Oncology and Hematology Associates of Southwest Virginia, Inc, Wytheville, Virginia, 24382, United States|Providence Regional Cancer System, Lacey, Washington, 98503, United States|MultiCare Regional Cancer Center - Tacoma, Puyallup, Washington, 98372, United States|Northwest Medical Specialties, PLLC, Puyallup, Washington, 98373, United States|University of Washington, Renton, Washington, 98055, United States|Medical Oncology Associates, Spokane, Washington, 99208, United States|West Virginia University Hospital, Morgantown, West Virginia, 26505, United States|ThedaCare Regional Cancer Center, Appleton, Wisconsin, 54911, United States|Ascension St. Francis Reiman Cancer Center, Franklin, Wisconsin, 53132, United States|HSHS Saint Mary's Hospital Medical Center - Green Bay, Green Bay, Wisconsin, 54303, United States|University of Wisconsin, Madison, Wisconsin, 53792, United States|HÃ¤matologie-Onkologie im Zentrum MVZ GmbH, Augsburg, 86150, Germany|Studien GbR Braunschweig, Braunschweig, 38100, Germany|HÃ¤mato-Onkologische Praxis im Medicum, Bremen, 28209, Germany|St. Johannes Hospital, Dortmund, 44137, Germany|Klinikum Esslingen, Esslingen, 73730, Germany|MVZ II der Niels Stensen Kliniken, GeorgsmarienhÃ¼tte, 49124, Germany|Elisabeth Krankenhaus Brustzentrum, Kassel, 34117, Germany|InVO - Institut fÃ¼r Versorgungsforschung in der Onkologie GbR / Praxis fÃ¼r HÃ¤matologie und Onkologie, Koblenz, 56068, Germany|St. Elisabeth Krankenhaus GmbH, KÃ¶ln, 50935, Germany|UniversitÃ¤tsklinikum Mannheim, Mannheim, 68167, Germany|Klinikum Worms Frauenklinik, Worms, 67550, Germany|Medical Oncology Unit. A CoruÃ±a University Hospital, A CoruÃ±a, 15006, Spain|Hospital Universitary of Cruces, Barakaldo, 48903, Spain|Hospital Clinic de Barcelona, Barcelona, 08036, Spain|Consorcio Hospitalario Provincial de CastellÃ³n, CastellÃ³n, 12002, Spain|Hospital General Universitario De Elche, Elche, 03203, Spain|Althaia Xarxa Assistencial de Manresa, Manresa, 08242, Spain|Hospital Universitario Morales Meseguer, Murcia, 30008, Spain|HU MarquÃ©s de Valdecilla, Santander, 39008, Spain|Hospital Clinico Universitario de Valladolid, Valladolid, 47003, Spain|Isabel la Catolica nÂº 1-3, Zaragoza, 50009, Spain",
NCT04562389,Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis,https://clinicaltrials.gov/study/NCT04562389,SENTRY,RECRUITING,"This is a global, multicenter, 2-part study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naÃ¯ve myelofibrosis (MF) participants. The study will be conducted in two phases: Phase 1 (open-label) and Phase 3 (double-blind). Phase 1 (enrollment completed) was an open-label evaluation of the safety and recommended Phase 2 dose (RP2D) of selinexor in combination with ruxolitinib and included a dose escalation using a standard 3+3 design (Phase 1a) and a dose expansion part (Phase 1b). Phase 3 (ongoing), double-blind, placebo-controlled part of the study comparing the efficacy and safety of combination therapy of selinexor + ruxolitinib with combination of placebo + ruxolitinib.",NO,Myelofibrosis,DRUG: Selinexor|DRUG: Selinexor|OTHER: Placebo|DRUG: Ruxolitinib,"Phase 3: Proportion of Participants with Spleen Volume Reduction (SVR) of Greater than or Equal to (>=) 35 Percent (%) (SVR35) at Week 24 Measured by the Magnetic Resonance Imaging (MRI) or Computed Tomography (CT) Scan, At Week 24|Phase 3: Absolute mean change in TSS (Abs-TSS) from baseline to Week 24 as measured by the Myelofibrosis Symptom Assessment Form (MFSAF) v4.0, At Week 24|Phase 1: Maximum Tolerated Dose (MTD), Approximately within the first cycle (28 days) of therapy|Phase 1: Recommended Phase 2 Dose (RP2D), Approximately within the first cycle (28 days) of therapy|Phase 1: Number of Participants With Adverse Events (AEs) by Occurrence, Nature, and Severity, From start of drug administration up to 30 days after last dose of study treatment (approximately 48 months)","Phase 3: Overall survival (OS), From Baseline up to EoS (approximately 48 months)|Phase 3: Progression-free survival (PFS), Time from randomization until disease progression or death, whichever occurs first (approximately 48 months)",,Karyopharm Therapeutics Inc,,ALL,"ADULT, OLDER_ADULT",PHASE3,350,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-03-11,2025-09,2028-03,2020-09-24,,2025-02-05,"UAB Division of Hematology/Oncology, Birmingham, Alabama, 35294, United States|UCLA - Satellite Site, Beverly Hills, California, 90210, United States|City of Hope, Duarte, California, 91010, United States|UCLA - Satellite Site, Encino, California, 93003, United States|City of Hope - Irvine Lennar - Satellite, Irvine, California, 92618, United States|UCLA, Los Angles, California, 90095, United States|The Oncology Institute of Hope & Innovation, Pasadena, California, 91105, United States|USOR - Rocky Mountain Cancer Centers - Aurora, Aurora, Colorado, 80045, United States|Smilow Cancer Hospital - New Haven, New Haven, Connecticut, 06511, United States|Norton Cancer Institute - Saint Matthews, Louisville, Kentucky, 40207, United States|Maryland Oncology Hematology-Satellite, Annapolis, Maryland, 21401, United States|The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, 21205, United States|Maryland Oncology Hematology-Satellite, Brandywine, Maryland, 21004, United States|Maryland Oncology Hematology, Columbia, Maryland, 21044, United States|Maryland Oncology Hematology-Satellite, Rockville, Maryland, 20850, United States|Maryland Oncology Hematology-Satellite, Silver Spring, Maryland, 20904, United States|The Cancer & Hematology Centers -Satellite Site, Grand Rapids, Michigan, 49546, United States|The Cancer & Hematology Centers of Muskegon, Norton Shores, Michigan, 49444, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States|Mount Sinai Health System, New York, New York, 10029, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Duke Cancer Institue, Durham, North Carolina, 27705, United States|USOR - Oncology Hematology Care - Kenwood, Cincinnati, Ohio, 45242, United States|OhioHealth, Columbus, Ohio, 43214, United States|Vanderbilt Ingram Cancer Center, Nashville, Tennessee, 37232, United States|Texas Oncology, Dallas, Texas, 75246, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|Huntsman Cancer Institute, Salt Lake City, Utah, 84112, United States|USOR - Virginia Cancer Specialists - Gainesville Office, Gainesville, Virginia, 20155, United States|VCU Massey Cancer Center, Richmond, Virginia, 23298, United States|USOR - Virginia Oncology Associates - Virginia Beach, Virginia Beach, Virginia, 23456, United States|Fred Hutchinson Cancer Center - SCAA South Lake Union, Seattle, Washington, 98109, United States|West Virginia University Cancer Institute, Wheeling Hospital, Wheeling, West Virginia, 26003, United States|University of Wisconsin - Madison, Madison, Wisconsin, 53792, United States|Universitair Ziekenhuis Leuven - Campus Gasthuisberg, Leuven, Flemish Brabant, 3000, Belgium|Universitair Ziekenhuis Gent, Gent, Oost-Vlaanderen, 9000, Belgium|Algemeen Ziekenhuis Sint-Jan Brugge-Oostende - Campus Sint-Jan, Brugge, West-Vlaanderen, 8000, Belgium|ZNA Stuivenberg - Satelite, Antwerpen, 2030, Belgium|ZNA Stuivenberg, Antwerpen, 2060, Belgium|University Multiprofile Hospital for Active Treatment Sveti George - Base 1, Plovdiv, 4002, Bulgaria|University Multiprofile Hospital for Active Treatment Aleksandrovska, Sofia, 1431, Bulgaria|University Multiprofile Hospital for Active Treatment St. Ivan Rilski, Sofia, 1431, Bulgaria|Specialized Hospital for Active Treatment of Hematological Diseases - EAD Sofia, Sofia, 1797, Bulgaria|University Multiprofile Hospital for Active Treatment - Prof. Dr. Stoyan Kirkovich, Stara Zagora, 6003, Bulgaria|University of Alberta Hospital, Edmonton, Alberta, T6G 2G3, Canada|Research Institute of the McGill University Health Centre, Montreal, Quebec, H4A 3J1, Canada|Vseobecna Fakultni Nemocnice v Praze, Praha 2, Prague, 128 08, Czech Republic|FakultnÃ­ Nemocnice Hradec KrÃ¡lovÃ©, Hradec KrÃ¡lovÃ©, 500 05, Czechia|FakultnÃ­ Nemocnice Olomouc, Olomouc, 779 00, Czechia|Aarhus Universitetshospital, Aarhus N, Midtjylland, 8200, Denmark|Tang Severinsen, Marianne, Aalborg, Nordjylland, 9000, Denmark|Institut BergoniÃ©, Bordeaux, Aquitaine, 33000, France|Centre Hospitalier Universitaire Estaing, Clermont-Ferrand, Aubergne, 63003, France|HÃ´pital Morvan, Brest, Bretagne, 29200, France|Chu De NÃ®mes - Institut De CancÃ©rologie Du Gard, Nimes, Gard, 30029, France|HÃ´pital Emile Muller, Mulhouse, Grand Est, 68100, France|HÃ´pital Huriez, Lille, Hauts-de-France, 59037, France|HÃ´pital Universitaire PitiÃ© SalpÃªtriÃ¨re, Paris, Ile-de-France, 75013, France|HÃ´pital Bretonneau, Tours Cedex, Indre-et-Loire, 37044, France|Centre Hospitalier Universitaire de Saint-Ãtienne, Saint-Priest-en-Jarez, Loire, 42271, France|HÃ´pital l'Archet - CHU Nice, Nice Cedex 3, Paca, 06202, France|Centre Hospitalier Universitaire d'Angers, Angers, Pays de la Loire, 49 933, France|Centre Hospitalier Lyon-Sud, Pierre-BÃ©nite, Rhone-Alpes, 69495, France|HÃ´pital Saint-Louis, Paris, 75010, France|Kliniken Ostalb - Stauferklinikum SchwÃ¤bisch GmÃ¼nd, Mutlangen, Baden-WÃ¼rttemberg, 73557, Germany|Marien Hospital DÃ¼sseldorf, DÃ¼sseldorf, Nordrhein-Westfalen, 40479, Germany|UniversitÃ¤tsklinikum Halle, Halle, Sachsen-Anhalt, 6120, Germany|StÃ¤dtisches Krankenhaus Kiel, Kiel, Schleswig-Holstein, 24116, Germany|UniversitÃ¤tsklinikum Jena, Jena, Thuringen, 7747, Germany|Laiko General Hospital of Athens, Athens, Attica, 115 27, Greece|University General Hospital Attikon, Athens, Attica, 124 62, Greece|General Hospital of Thessaloniki George Papanikolaou, Thessaloniki, Central Macedonia, 570 10, Greece|University General Hospital of Larissa, Hematology Department, Larissa, Thessaly, 41110, Greece|GyÅr-Moson-Sopron VÃ¡rmegyei Petz AladÃ¡r Egyetemi OktatÃ³ KÃ³rhÃ¡z, GyÅr, Gyor-Moson-Sopron, 9023, Hungary|Semmelweis Egyetem, Budapest, 1088, Hungary|Shamir Medical Center (Assaf Harofeh), Be'er Ya'akov, Central District, 7030000, Israel|The Chaim Sheba Medical Center, Ramat Gan, Central District, 5265601, Israel|Rambam Health Care Campus, Haifa, Haifa District, 3109601, Israel|Carmel Medical Center, Haifa, Haifa District, 3436212, Israel|Hadassah University Hospital - Mount Scopus - Satellite Site, Jerusalem, Jerusalem District, 9112001, Israel|Hadassah University Hospital Ein Kerem, Jerusalem, Jerusalem District, 9112001, Israel|Emek Medical Center, Afula, Northern District, 1834111, Israel|Western Galilee Hospital-Nahariya, Nahariya, Northern District, 2210001, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, 6423906, Israel|Istituto Romagnolo per lo Studio dei Tumori ""Dino Amadori"" - IRST, Meldola, Forli-Cesena, 47014, Italy|IRCCS Ospedale Policlinico San Martino, Genova, Genoa, 16132, Italy|Fondazione IRCCS CÃ  Granda - Ospedale Maggiore Policlinico, Milano, Milan, 20122, Italy|Istituto Europeo di Oncologia, Milano, Milan, 20141, Italy|Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Milano, Milan, 20162, Italy|Fondazione IRCCS San Gerardo dei Tintori, Monza, Monza and Brianza, 20900, Italy|IRCCS Centro di Riferimento Oncologico di Basilicata, Rionero In Vulture, Potenza, 85028, Italy|Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino, Turin, 10126, Italy|UniversitÃ  Campus Bio-Medico di Roma, Rome, Viterbo, 00128, Italy|Azienda Ospedaliero-Universitaria di Bologna - Policlinico Sant Orsola-Malpighi, Bologna, 40138, Italy|Azienda Ospedaliero - Universitaria Careggi, Firenze, 50134, Italy|Azienda Ospedaliero-Universitaria Maggiore della CaritÃ  di Novara, Novara, 28100, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, 27100, Italy|Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, 00168, Italy|Azienda Ospedaliera Ordine Mauriziano di Torino, Torino, 10128, Italy|Centro Ricerche Cliniche di Verona, Verona, 37134, Italy|Pusan National University Hospital, Busan Gwang'yeogsi [Pusan-Kwangyokshi], 49241, Korea, Republic of|Kyungpook National University Hospital, Daegu, 41944, Korea, Republic of|Chonnam National University Hwasun Hospital, Hwasun-gun, 58128, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si Gyeonggido [Kyonggi-do], 13605, Korea, Republic of|Samsung Medical Center, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], 6351, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Severance Hospital, Seoul, 03722, Korea, Republic of|The Catholic University of Korea - Seoul St. Mary's Hospital, Seoul, 06591, Korea, Republic of|Universitair Medisch Centrum Groningen, Groningen, 9713 GZ, Netherlands|DolnoÅlÄskie Centrum Transplantacji KomÃ³rkowych z Krajowym Bankiem DawcÃ³w Szpiku, WrocÅaw, Dolnoslaskie, 53-439, Poland|Medicover Integrated Clinical Services (MICS) - Centrum Medyczne ToruÅ, ToruÅ, Kujawsko-Pomorskie, 87-100, Poland|Uniwersytecki Szpital Kliniczny Nr 4 w Lublinie, Lublin, Lubelskie, 20-093, Poland|Szpital Specjalistyczny w Brzozowie - Podkarpacki OÅrodek Onkologiczny im. Ks. B. Markiewicza, BrzozÃ³w, Podkarpackie, 36-200, Poland|Uniwersyteckie Centrum Kliniczne w GdaÅsku, GdaÅsk, Pomorskie, 80-952, Poland|Pratia Onkologia Katowice, Katowice, Slaskie, 40-519, Poland|Specjalistyczny Szpital im. dra Alfreda SokoÅowskiego w WaÅbrzychu, WaÅbrzych, Slaskie, 58-309, Poland|AIDPORT, SkÃ³rzewo, Wielkopolskie, 60-185, Poland|Institutul Oncologic Prof. Dr. Ion Chiricuta, Cluj-Napoca, Cluj, 400015, Romania|Spitalul Filantropia - Craiova, Craiova, Dolj, 200136, Romania|Institutul Regional De Oncologie Iasi, Moldova, Iasi, 700483, Romania|Spitalul Clinic Judetean De Urgenta TÃ¢rgu MureÈ, TÃ¢rgu MureÅ, MureÈ, 540136, Romania|Coltea - Spital Clinic, Bucuresti, 020125, Romania|Spitalul Clinic Colentina, Bucuresti, 20125, Romania|Hospital Universitario Central de Asturias, Oviedo, Asturias, 33011, Spain|Institut CatalÃ  d'Oncologia Badalona, Badalona, 08916, Spain|Hospital Universitari Vall d'HebrÃ³n, Barcelona, 08035, Spain|Hospital Clinic de Barcelona, Barcelona, 08036, Spain|Institut CatalÃ  d&#39;Oncologia Girona (ICO Girona), Girona, 17007, Spain|Hospital Universitario de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, 35010, Spain|Hospital Universitario Lucus Augusti, Lugo, 27003, Spain|Hospital General Universitario Gregorio MaraÃ±Ã³n, Madrid, 28007, Spain|Hospital Universitario RamÃ³n y Cajal, Madrid, 28034, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital ClÃ­nico Universitario Virgen de la Arrixaca, Murcia, 30120, Spain|Hospital Universitario Virgen de la Victoria, MÃ¡laga, 29010, Spain|Complejo Asistencial Universitario de Salamanca - Hospital ClÃ­nico, Salamanca, 37007, Spain|Hospital ClÃ­nico Universitario de Valencia, Valencia, 46010, Spain|China Medical University Hospital, Taichung City, Taichung, 40447, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, 80756, Taiwan|Chang Gung Memorial Hospital - Kaohsiung Branch, Kaohsiung, 83301, Taiwan|National Taiwan University Hospital, Taipei City, 10048, Taiwan|Chang Gung Memorial Hospital - Linkou Branch, Taoyuan, 33305, Taiwan|Guy's and St Thomas' NHS Foundation Trust, London, England, SE1 9RT, United Kingdom|Oxford University Hospitals NHS Foundation Trust, Oxford, England, OX3 7LE, United Kingdom|United Lincolnshire Hospitals NHS Trust-Satellite Site, Boston, PE21 9QS, United Kingdom|United Lincolnshire Hospitals NHS Trust, Boston, PE21 9QS, United Kingdom|The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, LZ 8XP, United Kingdom|Imperial College Healthcare NHS Trust, London, W12 0HS, United Kingdom|The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, NE7 7DN, United Kingdom",
NCT05317416,Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant,https://clinicaltrials.gov/study/NCT05317416,MagnetisMM-7,RECRUITING,"The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Part 1 and Part 2 of the study, participants in the study will either receive elranatamab (arm A and C) as an injection under the skin at the study clinic or lenalidomide orally once daily at home (arm B). Participation in the study will be approximately five years",NO,Multiple Myeloma,DRUG: Elranatamab|DRUG: Lenalidomide|DRUG: Lenalidomide|DRUG: Elranatamab,"Progression Free Survival, Progression Free Survival assessed by Blinded Independent Central review per IMWG response criteria, Assessed for up to approximately 5 years","Overall Survival, Defined as the time from randomization until death due to any cause, Assessed for up to approximately 5 years|Minimal Residual Disease negativity rate, Minimal Residual Disease negativity rate per IMWG criteria as assessed via Next Generation Sequencing, 12 months after randomization|Sustained MRD negativity rate, Sustained Minimal Residual Disease negativity rate per IMWG criteria as assessed via Next Generation Sequencing, 24 months after randomization|Progression Free Survival, Progression Free Survival by investigator per IMWG response criteria, Assessed for up to approximately 5 years|Overall minimal residual disease negativity rate, Minimal residual disease negativity rate per IMWG criteria, Assessed for up to approximately 5 years|Duration of minimal residual disease negativity, Minimal residual disease negativity per IMWG criteria, Assessed for up to approximately 5 years|Sustained minimal residual disease negativity rate, Minimal residual disease negativity per IMWG criteria that has lasted a minimum of 12 months, Assessed for up to approximately 5 years|Complete response rate, Complete response rate by blinded independent central review and by investigator per IMWG criteria, Assessed for up to approximately 5 years|Duration of complete response, Duration of complete response by blinded independent central review and by investigator per IMWG criteria, Assessed for up to approximately 5 years|Frequency of adverse events, Adverse event as characterized by type, frequency, severity per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5, seriousness and relationship to the study intervention, Up to 90 days after last dose|Frequency of laboratory abnormalities, Assessed for up to approximately 5 years|Pre-dose concentrations of elranatamab, Pharmacokinetics of elranatamab (trough concentrations of elranatamab), Assessed for up to approximately 5 years|Post-dose concentrations of elranatamab, Pharmacokinetics of elranatamab (Post-dose serum concentrations of elranatamab)"", Assessed for up to approximately 5 years|Incidence and titers of Anti-Drug Antibody and Neutralizing Antibody against elranatamab, Immunogenicity of elranatamab, Assessed for up to approximately 5 years|Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30, Higher scores on the functional scales represent higher levels of functioning. Higher scores on the global health status/quality of life scale represent higher health status/quality of life. Higher scores on symptom scales/items represent a greater presence of symptoms, Assessed for up to approximately 5 years|Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Myeloma 20, Higher scores on the functioning subscales (body image, future perspective) represent higher levels of functioning, whereas higher scores on the symptom subscales (disease symptoms, side effects) represent a greater presence of symptoms, Assessed for up to approximately 5 years|Progression Free Survival 2, Progression Free Survival to the date of second objective disease progression by investigator per IMWG response criteria, Assessed for up to approximately 5 years",,Pfizer,,ALL,"ADULT, OLDER_ADULT",PHASE3,760,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-03-25,2027-08-04,2029-10-31,2022-04-07,,2025-06-10,"Banner Gateway Medical Center, Gilbert, Arizona, 85234, United States|Banner MD Anderson Cancer Center, Gilbert, Arizona, 85234, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, 90095, United States|UCLA Hematology/Oncology - Westwood (Building 200 Suite 120), Los Angeles, California, 90095, United States|UCLA Hematology/Oncology - Santa Monica, Los Angeles, California, 90404, United States|Georgetown University Medical Center, Washington, District of Columbia, 20007, United States|Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, 33176, United States|Emory University Hospital Midtown, Atlanta, Georgia, 30308, United States|Emory University Hospital, Atlanta, Georgia, 30322, United States|Investigational Drug Service, Emory University Clinic, Atlanta, Georgia, 30322, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, 30322, United States|Loyola University Chicago, Maywood, Illinois, 60153, United States|Ascentist Doctor Hospital, Leawood, Kansas, 66211, United States|American Oncology Partners, P.A. dba MidAmerica Cancer Care, LLC, Merriam, Kansas, 66204, United States|O'Brien Pharmacy, Mission, Kansas, 66205, United States|University of Michigan, Ann Arbor, Michigan, 48109, United States|University Of Mississippi Medical Center, Jackson, Mississippi, 39213, United States|University of Mississippi Medical Center, Jackson, Mississippi, 39216, United States|American Oncology Partners, P.A. Dba MidAmerica Cancer Care, Kansas City, Missouri, 64132, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, 03756, United States|WMCHealth Advanced Physician Services, Hawthorne, New York, 10532, United States|Westchester Medical Center, Valhalla, New York, 10595, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|OhioHealth Arthur G.H. Bing, MD, Cancer Center, Columbus, Ohio, 43214, United States|OhioHealth Research Institute, Columbus, Ohio, 43214, United States|OhioHealth Riverside Methodist Hospital, Columbus, Ohio, 43214, United States|Baylor University Medical Center, Dallas, Texas, 75246, United States|Baylor Scott & White Medical Center - Temple, Temple, Texas, 76508, United States|Royal Prince Alfred Hospital, Camperdown, New South Wales, 2050, Australia|Shoalhaven District Memorial Hospital, Nowra, New South Wales, 2541, Australia|Westmead Hospital, Westmead, New South Wales, 2145, Australia|Wollongong Hospital, Wollongong, New South Wales, 2500, Australia|Pindara Private Hospital, Benowa, Queensland, 4217, Australia|QScan Radiology Clinics, Clayfield, Queensland, 4011, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, 4102, Australia|Epworth Healthcare, East Melbourne, Victoria, 3002, Australia|Precision Haematology, East Melbourne, Victoria, 3002, Australia|St Vincent's Hospital (Melbourne), Fitzroy, Victoria, 3065, Australia|Slade Pharmacy, Richmond, 3121, Australia|Medizinische UniversitÃ¤t Wien, Vienna, Wien, 1090, Austria|Hanusch-Krankenhaus, Vienna, 1140, Austria|Medizinische UniversitÃ¤t Wien, Wien, 1090, Austria|Institut Jules Bordet, Anderlecht, Bruxelles-capitale, RÃ©gion DE, 1070, Belgium|Grand HÃ´pital de Charleroi, Charleroi, Hainaut, 6060, Belgium|UniversitÃ© Catholique de Louvain-Namur - Centre Hospitalier Universitaire Dinant-Godinne - Site Godi, Yvoir, Namur, 5530, Belgium|UZ Gent, Gent, Oost-vlaanderen, 9000, Belgium|ZNA Middelheim, Antwerpen, 2020, Belgium|Zna Cadix, Antwerpen, 2030, Belgium|UZ Brussel, Brussel, 1090, Belgium|Instituto D'Or de Pesquisa e Ensino (IDOR) - Filial Salvador, Salvador, Bahia, 41253-190, Brazil|Centro Gaucho Integrado De Oncologia, Hematologia, Ensino E Pesquisa, Porto Alegre, RIO Grande DO SUL, 90110-270, Brazil|Centro de Pesquisa ClÃ­nica - Ãrea Administrativa, Porto Alegre, RIO Grande DO SUL, 90850-170, Brazil|Hospital Mae de Deus, Porto Alegre, RIO Grande DO SUL, 90880-480, Brazil|Hospital Amaral Carvalho, JaÃº, SÃO Paulo, 17210-080, Brazil|Hospital das ClÃ­nicas da Faculdade de Medicina de RibeirÃ£o Preto da Universidade de SÃ£o Paulo (USP), RibeirÃ£o Preto, SÃO Paulo, 14051-140, Brazil|BP - A Beneficencia Portuguesa de SÃ£o Paulo, Sao Paulo, SÃO Paulo, 01321-001, Brazil|ClÃ­nica MÃ©dica SÃ£o Germano LTDA, SP, SÃO Paulo, 04537-080, Brazil|FundaÃ§Ã£o Doutor Amaral Carvalho, JaÃº, 17210-080, Brazil|AmÃ©ricas Medical City, Rio de Janeiro, 22775-001, Brazil|Instituto de EducaÃ§Ã£o, Pesquisa e GestÃ£o em SaÃºde, Rio de Janeiro, 22775001, Brazil|ESHO Empresa de ServiÃ§os Hospitalares S.A/ Hospital Samaritano de HigienÃ³polis, SÃ£o Paulo, 01232-010, Brazil|HU UNIFESP / SPDM - Hospital SÃ£o Paulo, SÃ£o Paulo, 04024-002, Brazil|Universidade Federal de Sao Paulo, SÃ£o Paulo, 04024-002, Brazil|Hospital JaponÃªs Santa Cruz, SÃ£o Paulo, 04122-000, Brazil|ClÃ­nica MÃ©dica SÃ£o Germano S/S Ltda, SÃ£o Paulo, 04537-080, Brazil|Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta, T2N 5G2, Canada|Dr. Everett Chalmers Regional Hospital, Fredericton, New Brunswick, E3B 5N5, Canada|Saint John Regional Hospital, Saint John, New Brunswick, E2L 4L2, Canada|Hamilton Health Sciences Corporation, Hamilton, Ontario, L8L 8E7, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, M5G 2M9, Canada|Windsor Regional Hospital Cancer Program, Windsor, Ontario, N8W 1L9, Canada|Centre Integre Universitaire de la SantÃ© et de Services Sociaux de l'Est-de-l'ile-de-Montreal,, Montreal, Quebec, H1T 2M4, Canada|McGill University Health Centre, Montreal, Quebec, H4A 3J1, Canada|Centre intÃ©grÃ© universitaire de santÃ© et de services sociaux du Nord-de-l'Ãle-de-MontrÃ©al (CIUSSS NÃ, Montreal, Quebec, H4J 1C5, Canada|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, China|Institute of hematology&blood disease hospital, Tianjin, Tianjin, 300020, China|The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China|FakultnÃ­ nemocnice Brno Bohunice, Brno, Brno-mÄsto, 625 00, Czechia|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Hradec KrÃ¡lovÃ©, 500 05, Czechia|Fakultni nemocnice Ostrava, Ostrava, MoravskoslezskÃ½ KRAJ, 708 52, Czechia|Fakultni nemocnice Olomouc, Olomouc, 779 00, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, 12808, Czechia|Oulun yliopistollinen sairaala, Oulu, Pohjois-pohjanmaa, 90220, Finland|Helsinki University Hospital - Comprehensive Cancer Center (HYKS - SyÃ¶pÃ¤keskus), Helsinki, Uusimaa, 00029, Finland|Turku University Hospital, Turku, Varsinais-suomi, 20520, Finland|Institut Universitaire du Cancer Toulouse - Oncopole - CHU de TOULOUSE, Toulouse, Haute-garonne, 31100, France|Pitie Salpetriere University Hospital, Paris, Orne, 75013, France|Gustave Roussy, Villejuif, Val-de-marne, 94800, France|Centre Hospitalier Universitaire de Poitiers, Poitiers, Vienne, 86021, France|Chu Grenoble Alpes, La Tronche, 38700, France|Hopital Claude Huriez - CHU de Lille, Lille, 59037, France|HÃ´pital Saint Antoine, Paris Cedex 12, 75571, France|Hopital Lyon Sud, Pierre Benite, 69495, France|Centre Hospitalier RÃ©gional Universitaire de Tours - HÃ´pital Bretonneau, Tours, 37032, France|UniversitÃ¤tsklinikum WÃ¼rzburg, WÃ¼rzburg, Bayern, 97080, Germany|UniversitÃ¤tsmedizin Johannes Gutenberg UniversitÃ¤t Mainz, Mainz, Rheinland-pfalz, 55131, Germany|UniversitÃ¤tsklinikum Leipzig, Leipzig, Sachsen, 04103, Germany|Universitaetsklinikum Schleswig-Holstein Campus Kiel, Kiel, Schleswig-holstein, 24105, Germany|Charite UniversitÃ¤tsmedizin Berlin Campus Benjamin Franklin, Berlin, 12200, Germany|Klinikum Chemnitz gGMbH, Chemnitz, 09116, Germany|UniversitÃ¤tsklinikum Essen, Essen, 45147, Germany|Klinikum rechts der Isar der Technischen UniversitÃ¤t MÃ¼nchen, MÃ¼nchen, 81675, Germany|Alexandra General Hospital of Athens, Athens, AttikÃ­, 115 28, Greece|Theageneio Cancer Hospital of Thessaloniki, Thessaloniki, KentrikÃ­ MakedonÃ­a, 546 39, Greece|University Hospital of Ioannina, Ioannina, Ãpeiros, 455 00, Greece|Somogy Megyei Kaposi MÃ³r OktatÃ³ KÃ³rhÃ¡z, KaposvÃ¡r, Somogy, 7400, Hungary|Semmelweis University, Budapest, 1088, Hungary|DÃ©l-Pesti CentrumkÃ³rhÃ¡z, Budapest, 1097, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, 4032, Hungary|Szabolcs-SzatmÃ¡r-Bereg Megyei KÃ³rhÃ¡zak Ã©s Egyetemi OktatÃ³kÃ³rhÃ¡z, JÃ³sa AndrÃ¡s OktatÃ³kÃ³rhÃ¡z, NyÃ­regyhÃ¡za, 4400, Hungary|Artemis hospital, Gurugram, Haryana, 122001, India|Medanta-The Medicity, Gurugram, Haryana, 122001, India|Fortis Memorial Research Institute, Gurugram, Haryana, 122002, India|Himalayan Institute Hospital Trust University, Dehradun, Uttarakhand, 248140, India|Tata Medical Center, Kolkata, WEST Bengal, 700160, India|Rajiv Gandhi Cancer Institute And Research Centre, Delhi, 110085, India|Soroka Medical Center, Be'er Sheva, Hadarom, 8410101, Israel|Rabin Medical Center, Petah-Tikva, Hamerkaz, 4910021, Israel|Sheba Medical Center, Ramat Gan, Hamerkaz, 5262100, Israel|Rambam Health Care Campus, Haifa, Hatsafon, 3109601, Israel|Tel-Aviv Sourasky Medical Center Dana-Dwek Children's Hospital, Tel Aviv, Tell AbÄ«b, 6423906, Israel|Shaare Zedek Medical Center, Jerusalem, Yerushalayim, 9013102, Israel|Hadassah Medical Center, Jerusalem, Yerushalayim, 9112001, Israel|Hadassah Mount Scopus Medical Center, Jerusalem, Yerushalayim, 9124001, Israel|Shaare Zedek Medical Center, Jerusalem, 9013102, Israel|IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) ""Dino Amadori"", Meldola, Emilia-romagna, 47014, Italy|Fondazione Policlinico Universitario Agostino Gemelli, Roma, Lazio, 00168, Italy|Fondazione IRCCS CÃ  Granda Ospedale Maggiore Policlinico, Milano, Lombardia, 20122, Italy|Policlinico ""G. Rodolico"", Catania, Sicilia, 95123, Italy|Azienda Ospedaliero Universitaria Senese, Siena, Toscana, 53100, Italy|Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi, Ancona, 60126, Italy|IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola, Bologna, 40138, Italy|AOU Policlinico Umberto I, Roma, 00161, Italy|Nagoya City University Hospital, Nagoya, Aichi, 467-8602, Japan|Gunma University Hospital, Maebashi, Gunma, 371-8511, Japan|Kobe City Medical Center General Hospital, Kobe-city, Hyogo, 650-0047, Japan|Iwate Medical University Hospital, Yahaba-cho, Iwate, 028-3695, Japan|University Hospital,Kyoto Prefectural University of Medicine, Kyoto-shi, Kyoto, 602-8566, Japan|Tohoku University Hospital, Sendai, Miyagi, 980-8574, Japan|Hamamatsu University Hospital, Hamamatsu-shi, Shizuoka, 431-3192, Japan|Shizuoka Cancer Center, Sunto-gun, Shizuoka, 411-8777, Japan|Nippon Medical School Hospital, Bunkyo-ku, Tokyo, 113-8603, Japan|Kagoshima University Hospital, Kagoshima, 890-8520, Japan|National Hospital Organization Kumamoto Medical Center, Kumamoto, 860-0008, Japan|University Hospital,Kyoto Prefectural University of Medicine, Kyoto, 602-8566, Japan|National Hospital Organization Okayama Medical Center, Okayama, 701-1192, Japan|Osaka Metropolitan University Hospital, Osaka, 545-8586, Japan|Japanese Red Cross Medical Center, Tokyo, 150-8935, Japan|Yamagata University Hospital, Yamagata, 990-9585, Japan|Gachon University Gil Medical Center, Namdong-gu, Incheon-gwangyeoksi [incheon], 21565, Korea, Republic of|Chonnam National University Hwasun Hospital, Hwasun Gun, Jeonranamdo, 58128, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, KyÇnggi-do, 13620, Korea, Republic of|Pusan National University Hospital, Busan, Pusan-kwangyÇkshi, 49241, Korea, Republic of|Seoul National University Hospital, Seoul, Seoul-teukbyeolsi [seoul], 03080, Korea, Republic of|Samsung Medical Center, Seoul, Seoul-teukbyeolsi [seoul], 06351, Korea, Republic of|The Catholic Univ. of Korea Seoul St. Mary's Hospital(Seoul St. Mary's Hospital), Seoul, Seoul-teukbyeolsi [seoul], 06591, Korea, Republic of|The Catholic Univ. of Korea Seoul St. Mary's Hospital, Seoul, Seoul-teukbyeolsi [seoul], 06591, Korea, Republic of|Kyungpook National University, Daegu, Taegu-kwangyÇkshi, 41944, Korea, Republic of|Kyungpook National University Hospital, Jung-gu, Taegu-kwangyÇkshi, 41944, Korea, Republic of|HagaZiekenhuis, Den Haag, Zuid-holland, 2545 AA, Netherlands|Maastricht Universitair Medisch Centrum, Maastricht, 6229 HX, Netherlands|Isala, Zwolle, 8025 AB, Netherlands|Oslo Universitetssykehus UllevÃ¥l, Oslo, 0450, Norway|Stavanger Universitetssykehus, Stavanger, 4011, Norway|Centrum Medyczne Pratia PoznaÅ, Skorzewo, Wielkopolskie, 60-185, Poland|Uniwersyteckie Centrum Kliniczne,, Gdansk, 80-214, Poland|Uniwersytecki Szpital Kliniczny w Poznaniu, Poznan, 60-569, Poland|Uniwersyteckie Centrum Kliniczne WUM Centralny Szpital Kliniczny, Warszawa, 02-097, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Warszawa, 02-781, Poland|Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu, Wroclaw, 50-367, Poland|Pratia Onkologia Katowice, Katowice, ÅlÄskie, 40-519, Poland|Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, A Coruna, 15706, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Barcelona [barcelona], 08035, Spain|Institut CatalÃ  d'Oncologia - L'Hospitalet, L'Hospitalet Del Llobregat, Barcelona [barcelona], 08908, Spain|Hospital Universitari Mutua Terrassa, Terrassa, Barcelona [barcelona], 08221, Spain|Institut Catala d' Oncologia. Hospital Germans Trias i Pujol, Badalona, Barcelona, 08916, Spain|Hospital Universitari Mutua Terrassa, Terrassa, Barcelona, 08221, Spain|Hospital Universitario de Salamanca, Salamanca, Castilla Y LEÃN, 37007, Spain|Hospital ClÃ­nic de Barcelona, Barcelona, Catalunya [cataluÃ±a], 08036, Spain|Clinica Universidad de Navarra, Madrid, Madrid, Comunidad DE, 28027, Spain|Hospital Universitario La Paz, Madrid, Madrid, Comunidad DE, 28046, Spain|Hospital Universitario Quironsalud Madrid, Pozuelo de Alarcon, Madrid, 28223, Spain|Hospital San Pedro de AlcÃ¡ntara, CÃ¡ceres, 10003, Spain|Institut Catala Oncologia - Hospital Universitari de Girona Dr Josep Trueta, Gerona, 17007, Spain|Hospital La Princesa, Madrid, 28006, Spain|Hospital General Universitario Gregorio MaraÃ±on, Madrid, 28007, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital Universitario HM Sanchinarro, Madrid, 28050, Spain|Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca, Salamanca, 37007, Spain|Hospital Universitari i Politecnic La Fe, ValÃ¨ncia, 46026, Spain|Helsingborgs Lasarett, Helsingborg, SkÃ¥ne LÃN [se-12], 251 87, Sweden|Karolinska Universitetssjukhuset Huddinge, Stockholm, Stockholms LÃN [se-01], 141 86, Sweden|SÃ¶dra Ãlvsborgs Sjukhus BorÃ¥s, BorÃ¥s, VÃ¤stra GÃ¶talands LÃN [se-14], 501 82, Sweden|Falu Lasarett, Falun, 791 31, Sweden|Universitetssjukhuset Ãrebro, Ãrebro, Ãrebro LÃN [se-18], 701 85, Sweden|Universitetssjukhuset i LinkÃ¶ping, LinkÃ¶ping, ÃstergÃ¶tlands LÃN [se-05], 581 85, Sweden|CHUV (centre hospitalier universitaire vaudois), Lausanne, Vaud, 1011, Switzerland|UniversitÃ¤tsSpital ZÃ¼rich, ZÃ¼rich, ZÃ¼rich (DE), 8091, Switzerland|Kantonsspital Baden, Baden, 5404, Switzerland|Inselspital Bern, Berne, 3010, Switzerland|Kantonsspital Winterthur, Winterthur, 8401, Switzerland|China Medical University Hospital, Taichung, 40447, Taiwan|Taichung Veterans General Hospital, Taichung, 407, Taiwan|National Taiwan University Hospital, Taipei, 10002, Taiwan|Taipei Veterans General Hospital, Taipei, 11217, Taiwan|Chang Gung Medical Foundation-Linkou Branch, Taoyuan, 333, Taiwan|Medipol Mega Universite Hastanesi, Ä°stanbul, Ä°Ìstanbul, 34214, Turkey|Sisli Florence Nightingale Hastanesi, Ä°stanbul, Ä°Ìstanbul, 34381, Turkey|Ege Universitesi Hastanesi, Izmir, Ä°Ìzmir, 35100, Turkey|Dokuz Eylul Universitesi Hastanesi, Ä°zmir, Ä°Ìzmir, 35340, Turkey|Ankara University Health Practice and Research Hospitals, Ankara, 06100, Turkey|Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve ArastÄ±rma Hastanesi, Ankara, 06200, Turkey|AydÄ±n Adnan Menderes Universitesi Hastanesi, Aydin, 09100, Turkey|Erciyes Universitesi TÄ±p Fakultesi Hastaneleri, Kayseri, 38030, Turkey|Ãzel Anadolu SaÄlÄ±k Merkezi, Kocaeli, 41400, Turkey|Addenbrooke's Hospital, Cambridge, Cambridgeshire, CB2 2QQ, United Kingdom|Queen Elizabeth Hospital Birmingham, Birmingham, England, B15 2TH, United Kingdom|Dewsbury and District Hospital, Dewsbury, Wakefield, WF13 4HS, United Kingdom|Pontefract General Infirmary, Pontefract, Wakefield, WF8 1PL, United Kingdom|Belfast City Hospital, Belfast, BT9 7AB, United Kingdom|The Beatson West of Scotland Cancer Centre, Glasgow, G12 0YN, United Kingdom|Royal Berkshire Hospital, Reading, RG1 5AN, United Kingdom|Pinderfields General Hospital, Wakefield, WF1 4DG, United Kingdom|New Cross Hospital, Wolverhampton, WV10 0QP, United Kingdom",
NCT04622319,A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05),https://clinicaltrials.gov/study/NCT04622319,,ACTIVE_NOT_RECRUITING,Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher risk of disease recurrence. More effective treatment options are needed for this patient population. This study will examine the efficacy and safety of trastuzumab deruxtecan (T-DXd) compared with trastuzumab emtansine (T-DM1) in high-risk patients with residual invasive breast cancer following neoadjuvant therapy.,NO,HER2-Positive Primary Breast Cancer|Residual Invasive Breast Cancer,DRUG: DS-8201a|DRUG: T-DM1,"Invasive Disease-free Survival (IDFS) in Participants Who Were Administered Trastuzumab Deruxtecan (T-DXd) Compared With Trastuzumab Emtansine (T-DM1) Treatment, Randomization to date of invasive local, axillary or distant recurrence, invasive contralateral breast cancer or death from any cause (whichever occurs first), up to approximately 57 months postdose","Disease-free Survival (DFS) in Participants Who Were Administered Trastuzumab Deruxtecan (T-DXd) Compared With Trastuzumab Emtansine (T-DM1) Treatment, Randomization to date of the first occurrence of an IDFS event including second primary non-breast cancer event or contralateral or ipsilateral ductal carcinoma in situ (whichever occurs first), up to approximately 81 months postdose|Overall Survival (OS) in Participants Who Were Administered Trastuzumab Deruxtecan (T-DXd) Compared With Trastuzumab Emtansine (T-DM1) Treatment, Randomization to date of death from any cause, up to approximately 81 months postdose|Distant Recurrence-free Interval (DRFI) in Participants Who Were Administered Trastuzumab Deruxtecan (T-DXd) Compared With Trastuzumab Emtansine (T-DM1) Treatment, Randomization to date of distant recurrence, up to approximately 81 months postdose|Brain Metastases-free Interval (BMFI) in Participants Who Were Administered Trastuzumab Deruxtecan (T-DXd) Compared With Trastuzumab Emtansine (T-DM1) Treatment, Randomization to date of brain metastasis, up to approximately 81 months postdose|Percentage of Treatment-emergent Adverse Events in Participants Who Were Administered Trastuzumab Deruxtecan (T-DXd) Compared With Trastuzumab Emtansine (T-DM1) Treatment, Baseline up to approximately 81 months postdose|Serum Concentrations of Trastuzumab Deruxtecan (T-DXd), total anti-HER2 antibody, and Active Metabolite MAAA-1181a, Pre-dose on Day 1 of Cycles 1, 4 and 10 and within 15 minutes post-dose on Day 1 of Cycles 1 and 4 (each cycle is 21 days)|Percentage of Participants Positive for Treatment-emergent Anti-drug Antibodies (ADAs) in Participants Who Were Administered Trastuzumab Deruxtecan (T-DXd), Baseline up to approximately 81 months postdose",,Daiichi Sankyo,AstraZeneca|NSABP Foundation Inc|GBG Forschungs GmbH|Spanish Breast Cancer Research Group (SOLTI),ALL,"ADULT, OLDER_ADULT",PHASE3,1600,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-12-04,2025-12-31,2030-12-31,2020-11-09,,2025-05-09,"The Oncology Institute of Hope & Innovation, Anaheim, California, 92801, United States|Kaiser Permanente, Anaheim, California, 92806, United States|Kaiser Permanente, Baldwin Park, California, 91706, United States|Kaiser Permanente, Bellflower, California, 90706, United States|Kaiser Permanente, Fontana, California, 92335, United States|Orange Coast Blood and Cancer Care, Fountain Valley, California, 92708, United States|Kaiser Permanente, Harbor City, California, 90710, United States|Kaiser Permanente, Irvine, California, 92618, United States|Long Beach Memorial TCI, Long Beach, California, 90806, United States|Kaiser Permanente, Los Angeles, California, 90027, United States|Kaiser Permanente, Ontario, California, 90710, United States|Kaiser Permanente, Panorama City, California, 91402, United States|Kaiser Permanente, Riverside, California, 92505, United States|Kaiser Permanente, San Diego, California, 92120, United States|Kaiser Permanente, San Marcos, California, 92078, United States|Kaiser Permanente, West Los Angeles, California, 90034, United States|Kaiser Permanente, Woodland Hills, California, 91367, United States|SCRI FCS North- Altamonte, Altamonte Springs, Florida, 32701, United States|SCRI FCS South- Bonita, Bonita Springs, Florida, 34135, United States|SCRI FCS North- Brandon Cancer Center, Brandon, Florida, 33511, United States|SCRI FCS South- North Fort Myers, Cape Coral, Florida, 33909, United States|SCRI FCS North- Mease/Clearwater, Clearwater, Florida, 33761, United States|SCRI FCS South, Fort Myers, Florida, 33901, United States|SCRI FCS South- Colonial, Fort Myers, Florida, 33905, United States|SCRI FCS South- Gladiolus, Fort Myers, Florida, 33908, United States|SCRI FCS North- Gainesville Cancer Center, Gainesville, Florida, 32605, United States|Baptist MD Anderson Cancer Center, Jacksonville, Florida, 32207, United States|SCRI FCS North- Villages East, Lady Lake, Florida, 32159, United States|SCRI FCS South- Lakewood Ranch, Lakewood Ranch, Florida, 34211, United States|SCRI FCS North- Largo/Highland, Largo, Florida, 33770, United States|SCRI FCS North- Lecanto, Lecanto, Florida, 34461, United States|SCRI FCS South- Naples West, Naples, Florida, 34102, United States|SCRI FCS South- Naples/Goodlette, Naples, Florida, 34119, United States|SCRI FCS North- New Port Richey, New Port Richey, Florida, 34655, United States|SCRI FCS North- Ocala, Ocala, Florida, 34474, United States|Orlando Health, Ocoee, Florida, 34761, United States|SCRI FCS North- Orange City, Orange City, Florida, 32763, United States|Orlando Health, Orlando, Florida, 32806, United States|SCRI FCS North- Orlando Downtown, Orlando, Florida, 32806, United States|SCRI FCS South- Port Charlotte, Port Charlotte, Florida, 33980, United States|SCRI FCS North- St. Anthony's/St. Petersburg, Saint Petersburg, Florida, 33705, United States|SCRI FCS North, Saint Petersburg, Florida, 33705, United States|SCRI FCS South- Sarasota-Cattleman, Sarasota, Florida, 34232, United States|SCRI FCS South-Sarasota-Downtown, Sarasota, Florida, 34236, United States|SCRI FCS North- Spring Hill, Spring Hill, Florida, 34608, United States|SCRI FCS North- Tampa Cancer Center, Tampa, Florida, 33607, United States|SCRI FCS North- Tavares, Tavares, Florida, 32778, United States|SCRI FCS South- Venice Healthpark, Venice, Florida, 34292, United States|Cleveland Clinic-Weston, Weston, Florida, 33326, United States|SCRI FCS North- Winter Park, Winter Park, Florida, 32792, United States|Elmhurst Memorial Hospital- Nancy W. Knowles Cancer Center, Elmhurst, Illinois, 60126, United States|Edward Cancer Center, Naperville, Illinois, 60540, United States|Edward Cancer Center Plainfield, Plainfield, Illinois, 60585, United States|University of Kentucky, Markey Cancer Center, Clinical Research Organization, Lexington, Kentucky, 40536, United States|Baptist Health Louisville, Louisville, Kentucky, 40207, United States|LSU Health Baton Rouge North Clinic, Baton Rouge, Louisiana, 70805, United States|Our Lady of the Lake Physician Group-Medical Oncology, Baton Rouge, Louisiana, 70808, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, 70809, United States|Ochsner Hematology Oncology North Shore - Covington (West Region), Covington, Louisiana, 70433, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, 70121, United States|MedStar Franklin Square Medical Center-Harry and Jeanette Weinberg Cancer Institute, Baltimore, Maryland, 21237, United States|MedStar Franklin Square Cancer Center at Loch Raven Campus, Baltimore, Maryland, 21239, United States|Frederick Health-James M Stockman Cancer Center, Frederick, Maryland, 21702, United States|Maryland Oncology Hematology, Silver Spring, Maryland, 20904, United States|Holy Cross Hospital, Silver Spring, Maryland, 20910, United States|Montefiore Medical Center, Bronx, New York, 10461, United States|Waverly Hematology Oncology, Cary, North Carolina, 27518, United States|UNC Cancer Care at Nash, Rocky Mount, North Carolina, 27804, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, 27157, United States|Cleveland Clinic - Hillcrest, Cleveland, Ohio, 44195, United States|Cleveland Clinic-Fairview, Cleveland, Ohio, 44195, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|Cleveland Clinic South Pointe, Warrensville Heights, Ohio, 44195, United States|UPMC Upper St. Clair, Bethel Park, Pennsylvania, 15102, United States|UPMC Passavant Cranberry/North, Cranberry Township, Pennsylvania, 16066, United States|UPMC Erie, Erie, Pennsylvania, 16505, United States|AHN Cancer Inst at St Vincent, Erie, Pennsylvania, 16544, United States|UPMC Arnold Palmer-Mt View, Greensburg, Pennsylvania, 15601, United States|UPMC Pinnacle-Ortenzio Cancer Center, Harrisburg, Pennsylvania, 17050, United States|UMPC Pinnacle Pharmacy, Harrisburg, Pennsylvania, 17109, United States|AHN Cancer Insititute at Jefferson, Jefferson Hills, Pennsylvania, 15025, United States|AHN Cancer Institute at Forbes, Monroeville, Pennsylvania, 15146, United States|UPMC Monroeville, Monroeville, Pennsylvania, 15146, United States|UPMC Arnold Palmer-Mt Pleasant, Mount Pleasant, Pennsylvania, 15666, United States|UPMC Arnold Palmer-Norwin, N. Huntingdon, Pennsylvania, 15642, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, 15212, United States|Magee, Pittsburgh, Pennsylvania, 15213, United States|UPMC St. Margaret, Pittsburgh, Pennsylvania, 15215, United States|AHN Cancer Inst at West Penn, Pittsburgh, Pennsylvania, 15224, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, 15232, United States|UPMC Passavant HOA, Pittsburgh, Pennsylvania, 15237, United States|UPMC Passavant OHA, Pittsburgh, Pennsylvania, 15237, United States|UPMC Uniontown, Uniontown, Pennsylvania, 15401, United States|UPMC Washington, Washington, Pennsylvania, 15301, United States|Reading Hospital, McGlinn Cancer Institute, West Reading, Pennsylvania, 19611, United States|AHN Cancer Institute at Wexford, Wexford, Pennsylvania, 15090, United States|UPMC Pinnacle-Memorial Cancer Center, York, Pennsylvania, 17408, United States|SCRI TO Nashville- Franklin Tennessee Oncology, PLLC, Franklin, Tennessee, 37067, United States|SCRI TO Nashville- Gallatin Tennessee Oncology, PLLC, Gallatin, Tennessee, 37066, United States|SCRI TO Nashville- Hendersonville Tennessee Oncology, PLLC, Hendersonville, Tennessee, 37075, United States|SCRI TO Nashville- Summit Tennessee Oncology, PLLC, Hermitage, Tennessee, 37076, United States|Regional Cancer Center at Indian Path Community Hospital, Kingsport, Tennessee, 37660, United States|SCRI TO Nashville- Lebanon Tennessee Oncology, PLLC, Lebanon, Tennessee, 37090, United States|SCRI TO Nashville- St. Thomas Midtown Tennessee Oncology, PLLC, Nashville, Tennessee, 37203, United States|Tennessee Oncology Nashville / Sarah Cannon, Nashville, Tennessee, 37203, United States|SCRI TO Nashville- St. Thomas West Tennessee Oncology, PLLC, Nashville, Tennessee, 37205, United States|SCRI TO Nashville- Skyline Tennessee Oncology, PLLC, Nashville, Tennessee, 37207, United States|SCRI TO Nashville- Southern Hills Tennessee Oncology, PLLC, Nashville, Tennessee, 37211, United States|SCRI TO Nashville- Smyrna Tennessee Oncology, PLLC, Smyrna, Tennessee, 37167, United States|Houston Methodist Baytown, Baytown, Texas, 77521, United States|Houston Methodist, Houston, Texas, 77030, United States|Houston Methodist Willowbrook, Houston, Texas, 77070, United States|Houston Methodist West, Houston, Texas, 77094, United States|Houston Methodist Clear Lake, Nassau Bay, Texas, 77058, United States|Houston Methodist Sugarland, Sugar Land, Texas, 77479, United States|Houston Methodist Woodlands, The Woodlands, Texas, 77385, United States|Wellmont Medical Associates Oncology & Hematology, Bristol, Virginia, 24201, United States|University of Virginia, Charlottesville, Virginia, 22908, United States|Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia, 23298, United States|MultiCare Cancer Center Aurburn, Auburn, Washington, 98002, United States|MultiCare Regional Cancer Center - Gig Harbor, Gig Harbor, Washington, 98335, United States|MultiCare Cancer Center Puyallup, Puyallup, Washington, 98372, United States|MultiCare Institute for Research & Innovation, Spokane, Washington, 99204, United States|MultiCare Institute for Research & Innovation, Spokane, Washington, 99218, United States|MultiCare Cancer Center Tacoma, Tacoma, Washington, 98405, United States|West Virginia University, Morgantown, West Virginia, 26506, United States|Centro Oncologico Riojano Integral, Capital, La Rioja, 5300, Argentina|Sanatorio BritÃ¡nico de Rosario, Rosario, Santa Fe, 2000, Argentina|Instituto de OncologÃ­a de Rosario, Rosario, Santa Fe, S2000KZE, 2457, Argentina|COIBA, Buenos Aires, B1884BBF, Argentina|Instituto Alexander Fleming, Caba, 1426, Argentina|CER San Juan, San Juan, 5400, Argentina|Royal Adelaide Hospital, Adelaide, 5000, Australia|Chris O Brien Lifehouse, Camperdown, 2050, Australia|Monash Health, Clayton, 3168, Australia|Austin Hospital- Olivia Newto-John Cancer and Wellness Centre, Heidelberg, 3804, Australia|Peter MacCallum Cancer Centre, Melbourne, 3000, Australia|Breast Cancer Research Centre - WA, Nedlands, 6009, Australia|Genesis Care Northern Cancer, Saint Leonards, 2065, Australia|St John of God Hospital - Bendat Family Comprehensive Cancer Centre (BFCCC), Subiaco, 2050, Australia|Southern Medical Day Care Centre, Wollongong, 2500, Australia|Antwerp University Hospital, Edegem, Antwerpen, 2650, Belgium|UZ Gent, Gent, O. Vl., 9000, Belgium|Algemeen Ziekenhuis AZ Klina - Borstkliniek, Brasschaat, 2930, Belgium|Institut Jules Bordet Brussels Belgium, Brussels, 1000, Belgium|Cliniques Universitaires Saint-Luc, Brussels, 1200, Belgium|UZ Leuven - Campus Gasthuisberg, Leuven, 3000, Belgium|CHU Liege, LiÃ¨ge, 4000, Belgium|GZA Hospitals Campus Sint- Augustinus, Wilrijk, 2610, Belgium|Hospital Sirio-Libanes HSL - Centro de Oncologia - Brasilia, BrasÃ­lia, Federal District, 70200-730, Brazil|Hospital Erasto Gaertner, Curitiba, Parana, 81520-060, Brazil|FundaÃ§Ã£o Universidade de Caxias do Sul Instituto de Pesquisas em SaÃºde IPS-UCS, Caxias Do Sul, Rio Grande Do Sul, 95070-560, Brazil|Hospital Sao Lucas PUCRS, Porto Alegre, RS, 90610-000, Brazil|Fundacao Pio XII-Hospital de Cancer de Barretos, Barretos, SP, 14784-400, Brazil|CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia, Santo AndrÃ©, SP, 09060-650, Brazil|Hospital de Base de Sao Jose do Rio Preto, SÃ£o JosÃ© Do Rio Preto, SP, 15092415, Brazil|INCA - Instituto Nacional do Cancer / Hospital do Cancer HCIII, Rio De Janeiro, 20560-120, Brazil|Instituto do Cancer do Estado de Sao Paulo (ICESP), SÃ£o Paulo, 01246-000, Brazil|Tom Baker Cancer Centre, Calgary, Alberta, T2N4N2, Canada|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, K1H 8L6, Canada|CIUSSSS de l'Est-de-l'Ile-de-MontrÃ©al - Installation HÃ´pital Maisonneuve-Rosemont, MontrÃ©al, Quebec, H1T 2M4, Canada|CHUM, MontrÃ©al, Quebec, H2X3E4, Canada|Jewish General Hospital Segal Cancer Centre, MontrÃ©al, Quebec, H3T1E2, Canada|McGill University Health Centre - Cedars Cancer Centre, MontrÃ©al, Quebec, H4A 3J1, Canada|CHU de Quebec - Hopital du Saint-Sacrement, QuÃ©bec, Quebec, G1S 4L8, Canada|Hospital Clinico Universidad de Chile, Santiago, RM, 8380456, Chile|Fundacion Arturo Lopez Perez, Santiago, 7500921, Chile|SIM CRC, Temuco, 4780000, Chile|Peking University Cancer Hospital, Beijing, 100142, China|Peking University Third Hospital, Beijing, 100191, China|Jilin University JLU - First Affiliated Hospital, Changchun, 19512, China|Sichuan University - West China Hospital, Chengdu, 610041, China|Chongqing Medical University - The First Affiliated Hospital, Chongqing, 400016, China|Union Hospital of Fujian Medical University, Fuzhou, 35001, China|Sun Yat-sen Memorial Hospital, Guangzhou, 510030, China|Guangdong Academy of Medical Science, Guangzhou, 510080, China|Zhejiang Cancer Hospital, Hangzhou, 310002, China|Second Affiliated Hospital of Zhejiang University, Hangzhou, 310009, China|Harbin Medical University Cancer Hospital, Harbin, 150060, China|Shandong Cancer Hospital, Jinan, 250117, China|Nanchang University - The First Affiliated Hospital, Nanchang, 330006, China|Nanjing Medical University NMU - Jiangsu Province Hospital, Nanjing, 210029, China|Fudan University Cancer Hospital, Shanghai, 200032, China|The 4th Hospital of Heibei Medical University, Shijiazhuang, 50011, China|The First Affiliated Hospital of Xiamen University, Xiamen, 361003, China|University Hospital Brno, Brno, 62500, Czechia|Fakultni nemocnice Kralovske Vinohrady, Prague, 10034, Czechia|Aalborg University Hospital, Aalborg, 9000, Denmark|Aarhus University Hospital, Aarhus, 8210, Denmark|Rigshospitalet, Copenhagen, 2100, Denmark|Odense University Hospital, Odense, 5000, Denmark|Soenderborg sygehus, Syddanmark, 6400, Denmark|Clinique Tivoli Ducos - Centre dOncologie et de Radiotherapie a Bordeaux, Bordeaux, Gironde, 33000, France|Institut Claudius Regaud, Toulouse, Haute Garonne, 31059, France|Institut De Cancerologie De La Loire, Saint-Priest-en-Jarez, Loire, 42270, France|CHR Metz-Thionville, Metz cedex 03, Lorraine, 57085, France|Institut Bergonie, Bordeaux, 33000, France|Centre Georges FranÃ§ois Leclerc, Dijon, 21000, France|CHD Vendee, La Roche-sur-Yon, 85925 cedex 9, France|Centre Hosp Univ de Grenoble CHUG, La Tronche, 38700, France|Centre Oscar Lambret, Lille, 59000, France|Centre Leon Berard, Lyon, 69008, France|Institut Paoli-Calmettes, Marseille, 13009, France|Centre de CancÃ©rologie du Grand Montpellier, Montpellier, 34070, France|The Sel of Centre dOncologie de Gentilly, Nancy, 54000, France|Centre Antoine Lacassagne, Nice, 6189, France|Hospital St Louis, Paris, 75010, France|Hopital Georges Pompidou, Paris, 75015, France|IUC AP-HP. Sorbonne UniversitÃ©, HÃ´pital Tenon, Paris, 75020, France|CHU de Poitiers, Poitiers, 86021, France|Centre Eugene Marquis, Rennes, 35042, France|Institut de cancerologie de l'ouest, Saint-Herblain, 44360, France|Strasbourg Europe Cancer Institute, Strasbourg, 67033, France|Gemeinschaftspraxis Dres. Halder / Bangerter, Augsburg, 86150, Germany|CahritÃ© Campus Mitte, Berlin, 10117, Germany|Praxis Dr. med. J. Schilling, Berlin, 10317, Germany|MediOnko-Institut GbR, Praxisklinik Krebsheilkunde, Berlin, 10367, Germany|DRK Kliniken Berlin KÃ¶penick, Berlin, 12559, Germany|Helios Klinikum Berlin-Buch, Berlin, 13125, Germany|Onkologische Schwerpunktpraxis, Berlin, 13349, Germany|Onkologische Schwerpunktpraxis, Bielefeld, 13349, Germany|Studien GbR Braunschweig, Braunschweig, 38108, Germany|Klinikum Bremen Mitte, Bremen, 28205, Germany|Frauenklinik DIAKO Bremen, Bremen, 28239, Germany|Klinikverbund SÃ¼dwest Kliniken BÃ¶blingen Frauenklinik BÃ¶blingen, BÃ¶blingen, 71065, Germany|Klinikum Chemnitz gGmbH, Chemnitz, 09116, Germany|DONAUISAR Klinikum, Deggendorf, 94469, Germany|Klinikum Dortmund gGmbH, Dortmund, 44137, Germany|St.-Johannes-Hospital Dortmund, Dept. of Obstetrics/Gynecology, Dortmund, 44137, Germany|Onkologische Schwerpunktpraxis, Dresden, 01067, Germany|University Hospital Dresden, Dresden, 01069, Germany|Onkozentrum Dresden, Dresden, 01127, Germany|UniversitÃ¤tsklinikum DÃ¼sseldorf, Klinik fÃ¼r Frauenheilkunde & Geburtshilfe, DÃ¼sseldorf, 40225, Germany|Frauenklinik der UniversitÃ¤t Erlangen, Erlangen, 91054, Germany|Kliniken Essen-Mitte, Klinik fÃ¼r Senologie/ InterdisziplinÃ¤res Brustzentrum, Essen, 45136, Germany|UniversitÃ¤tsklinikum Essen, Frauenklinik, Essen, 45147, Germany|Klinikum Esslingen GmbH, Esslingen, 73730, Germany|AGAPLESION Markus Krankenhaus, Frankfurt am main, 60431, Germany|Frankfurt University Department of Gynecology and Obstetrics, Frankfurt, 60323, Germany|Centrum for Haematology and Oncology, Frankurt am Main, 60389, Germany|UniversitÃ¤tsklinik Freiburg, Klinik fÃ¼r Frauenheilkunde, Freiburg, 79106, Germany|Evangelische Kliniken Gelsenkirchen, Gelsenkirchen, 45879, Germany|MVZ II der Niels-Stensen-Kliniken, GeorgsmarienhÃ¼tte, 49074, Germany|SRH Waldklinikum Gera, Brustzentrum OstthÃ¼ringen, Gera, 07548, Germany|MVZ Onkologische Kooperation Harz, Goslar, 38642, Germany|Krankenhaus St. Elisabeth und St. Barbara Halle/Saale, Halle/saale, 06110, Germany|University Medical Center, Hamburg, 20251, Germany|Mammazentrum HH am Krankenhaus Jerusalem, Hamburg, 20357, Germany|Albertinen Krankenhaus, Hamburg, 22457, Germany|GynÃ¤kologisch-Ontologische Praxis Hannover, Hannover, 30177, Germany|DIAKOVERE Henriettenstift Frauenklinik, Hannover, 30559, Germany|Gemeinschaftspraxis FrauenÃ¤rzte am Bahnhofsplatz, Hildesheim, 31134, Germany|Department of Gyencology and Obstetrics, Saarland University Hospital, Homburg, 66424, Germany|ViDia Christliche Kliniken Karlsruhe, Karlsruhe, 76199, Germany|Elisabethkrankenhaus Kassel, Brustzentrum, Kassel, 34117, Germany|Klinikum Kassel, Kassel, 34125, Germany|University Hospital Schleswig-Holstein, Kiel, 24105, Germany|Institut fÃ¼r Versorgungsforschung in der Onkologie, Koblenz, 56068, Germany|Unifrauenklinik KÃ¶ln - Studienzentrum GynÃ¤kologie, KÃ¶ln, 50931, Germany|St. Elisabeth Hospital, KÃ¶ln, 50935, Germany|Kliniken der Stadt KÃ¶ln / Brustzentrum Holweide, KÃ¶ln, 51067, Germany|St. Vincenz KH Limburg, Limburg, 65549, Germany|UKSH Campus LÃ¼beck, Luebeck, 23562, Germany|UniversitÃ¤ts-Frauenklinik, Magdeburg, 69120, Germany|Department of Obstetrics and Gynecology, Mainz, 55131, Germany|Medzinische FakultÃ¤t Mannheim, UniversitÃ¤t Heidelberg, Mannheim, 68167, Germany|Klinikum Memmingen, Memmingen, 87700, Germany|Johannes Wesling Klinikum Minden, HÃ¤matologie-Onkologie/Brustzentrum, Minden, 32429, Germany|Rotkreuzklinikum MÃ¼nchen, Frauenklinik, Muenchen, 80637, Germany|Gynaekologie Arabella, Munich, 81925, Germany|Brustzentrum Niederrhein, MÃ¶nchengladbach, 41061, Germany|Medizinisches Versorgungszentrum fÃ¼r HÃ¤matologie und Onkologie MÃ¼nchen MVZ GmbH, MÃ¼nchen, 80639, Germany|LMU Klinikum/ Klinik und Poliklinik fÃ¼r Frauenheilkunde und Geburtshilfe, MÃ¼nchen, 81377, Germany|Dept. OB/GYN Johanna Etienne Krankenhaus, Neuss, 41462, Germany|Ortenau Klinikum Offenburg-Kehl, Offenburg, 77694, Germany|Klinikum Oldenburg AÃ¶R, Oldenburg, 26133, Germany|Frauenklinik St. Louise - St. Vincenz- Krankenhaus GmbH, Paderborn, 33098, Germany|Klinikum Ernst von Bergmann, Potsdam, 14467, Germany|Studienzentrum Onkologie Ravensburg, Ravensburg, 88212, Germany|Oncologianova GmbH, Recklinghausen, 45659, Germany|RoMed Klinikum Rosenheim, Rosenheim, 83022, Germany|Univ-Hospital, Dept Ob/Gyn, Rostock, 18059, Germany|CaritasKlinikum St. Theresia, SaarbrÃ¼cken, 66113, Germany|Onkologische Schwerpunktpraxis Speyer, Speyer, 67346, Germany|G.SUND GynÃ¤kologie Kompetenzzentrum, Stralsund, 18435, Germany|KKH Torgau, Torgau, 04860, Germany|Klinikum Mutterhaus, Trier, 54290, Germany|Praxisnetzwerk HÃ¤matologie/Internistische Onkologie, Troisdorf, 53840, Germany|Frauenklinik, Tuebingen, 91054, Germany|UniversitÃ¤tsfrauenklinik Ulm, Ulm, 89081, Germany|Schwarzwald - Baar Klinikum Frauenklinik, Villingen-Schwenningen, 78052, Germany|Harzklinikum Dorothea Christiane Erxleben, Wernigerode, 06484, Germany|St. Anna Hospital Brustzentrum, Witten, 44649, Germany|Klinikum Worms gGmbH, Worms, 67550, Germany|General Hospital of Athens Alexandra Clinic, Athens, Attiki, 11528, Greece|University General Hospital of Heraklion, Heraklion, Crete, 71110, Greece|University General Hospital of Patras, Patras, Western Greece, 265 04, Greece|General Hospital of Patras Agios Andreas, Patras, 26335, Greece|Pamela Youde Nethersole Eastern Hospital PYNEH, Hong Kong, 10101, Hong Kong|The Chinese University of Hong Kong (CUHK) - Prince of Wales Hospital (PWH), Hong Kong, 999077, Hong Kong|The University of Hong Kong (HKU) - Queen Mary Hospital (QMH), Pok Fu Lam, 10101, Hong Kong|Saint Vincents University Hospital, Dublin, Ie-d, 4, Ireland|St. James Hospital, Dublin, Leinster, D8, Ireland|University College Cork, Cork, T12 YN60, Ireland|Mater Misericordiae University Hospital, Dublin, 7, Ireland|University Hospital Limerick, Limerick, V94 F858, Ireland|Soroka MC, Be'er Sheva, Hadarom, 8410101, Israel|Sheba Medical Center, Ramat Gan, Tel Aviv, 5262100, Israel|Hadassah Medical Center, Jerusalem, 91120, Israel|Rabin Medical Center, Petah tikva, 49100, Israel|Azienda Ospedaliera Garibaldi-Nesima, Catania, CT, 95122, Italy|Istituto Europeo di Oncologia, Milan, MI, 20141, Italy|Clinica Oncologica, Ospedali Riuniti Umberto 1, Ancona, 60126, Italy|Centro di Riferimento Oncologico di Aviano - SOC Oncologia Medica e Prevenzione Oncologica, Aviano, 33081, Italy|Istituto Oncologico di Bari, Bari, 70124, Italy|Azienda ULSS n. 1 Dolomiti, Belluno, 32100, Italy|Policlinico S.Orsola-Malpighi SSD Oncologia Medica Addarii, Bologna, 40138, Italy|SSD Oncologia Medica, Bologna, 40138, Italy|Presidio Ospedaliero di Summa - Antonio Perrino, Brindisi, 72100, Italy|Istituto di Candiolo - IRCCS, Candiolo, 10060, Italy|Ospedale Poli SAN MARTINO, Genova, 16132, Italy|Area Vasta Sud Est Sede Operativa Grosseto, Grosseto, 58100, Italy|Azienda Usl Toscana sud est, Grosseto, 58100, Italy|IRCCS Ospedale San Raffaele, Milano, 20132, Italy|University Hospital of Modena, Modena, 41122, Italy|INT Fondazione Pascale, Napoli, 80131, Italy|Istituto Oncologico Veneto IRCCS, Padova, 35128, Italy|ICS Maugeri IRCCS, Pavia, 27100, Italy|Azienda Ospedaliera di Perugia, Perugia, 06132, Italy|A.O.U. Citta della Salute e della Scienza di Torino, Torino, 10126, Italy|Hyogo Cancer Center, Akashi City, 673-8558, Japan|National Cancer Center (NCC) - Tsukiji Campus - National Cancer Center Hospital (NCCH), Chuo-Ku, 104-0045, Japan|National Hospital Organization - National Kyushu Cancer Center, Fukuoka City, 811-1395, Japan|Hiroshima City Hiroshima Citizens Hospital, Hiroshima City, 730-8518, Japan|Tokai University Hospital - Isehara Campus, Isehara City, 253-0036, Japan|Sagara Hospital, Kagoshima City, 892-0833, Japan|National Cancer Center Hospital East (NCCHE) - Kashiwa Campus, Kashiwa City, 277-8577, Japan|Japanese Foundation for Cancer Research (JFCR) - The Cancer Institute Hospital - Breast Oncology Center, Koto-Ku, 135-8550, Japan|Kyoto University Hospital, Kyoto, 606-8507, Japan|National Hospital Organization (NHO) - Shikoku Cancer Center, Matsuyama City, 791-0280, Japan|Aichi Cancer Center Hospital, Nagoya City, 464-8681, Japan|Niigata Cancer Center Hospital, Niigata City, 951-8133, Japan|Hyogo College of Medicine Hospital, Nishinomiya City, 663-8501, Japan|Okayama University Hospital, Okayama City, 700-8558, Japan|National Hospital Organization - Osaka National Hospital (ONH), Osaka City, 540-0006, Japan|Osaka International Cancer Institute (OICI), Osaka City, 541-8567, Japan|Saitama Cancer Center, Saitama, 362-0806, Japan|National Hospital Organization - Hokkaido Cancer Center, Sapporo City, 003-0804, Japan|Kindai University (Kinki University) - Faculty of Medicine (Kinki University School of Medicine (KUSM)) - Kindai University Hospital (Kinki University Hospital) - Cancer Center, Sayama City, 589-8511, Japan|Tohoku University Hospital (TUH) - Clinical Research, Innovation and Education Center (CRIETO), Sendai City, 980-8574, Japan|Showa University Hospital - Breast Center, Shinagawa-Ku, 1428666, Japan|Tokyo Medical University Hospital, Shinjuku-Ku, 160-0023, Japan|Shizuoka Cancer Center (SCC), Shizuoka, 411-8777, Japan|Kanagawa Cancer Center Hospital - Kanagawa Cancer Center (Kanagawa Cancer Centre Research Institute), Yokohama City, 241-8515, Japan|Kyungpook National University Hospital, Daegu, 41944, Korea, Republic of|National Cancer Center, Gyeonggi-do, 10408, Korea, Republic of|CHA Bundang Medical Center CHA University, Gyeonggi-do, 13496, Korea, Republic of|Seoul National University Bundang Hospital, Gyeonggi-do, 13620, Korea, Republic of|Gachon University Gil Medical Center, Incheon, 21565, Korea, Republic of|Samsung Medical Center, Irwon-dong, 06351, Korea, Republic of|Korea University Anam Hospital, Seoul, 02841, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Severance Hospital, Seoul, 03722, Korea, Republic of|Asan Medical Center, Songpa-gu, 05505, Korea, Republic of|Soon Chun Hyang Central Medical Center (SCHMC), Yongsan, 330-721, Korea, Republic of|CIMAB S.A. de C.V, Torreon, Coahuila, 27000, Mexico|Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, JAL, 44280, Mexico|Consultorio del Dr. Joaqun Gabriel Reinoso Toledo, Monterrey, Nuevo Leon, 64320, Mexico|Amsterdam UMC - VU Medisch Centrum, Amsterdam, Noord-Holland, 1081 HZ, Netherlands|Amphia Hospital Breda, Breda, 4800 RK, Netherlands|Erasmus MC - Daniel den Hoed Oncologisch Centrum, Rotterdam, 3000 CA, Netherlands|Hospital Nacional Arzobispo Loayza, Lima, 15082, Peru|Clinica Ricardo Palma, Lima, Lima 27, Peru|Instituto Nacional de Enfermedades Neoplasicas INEN, Lima, Lima 34, Peru|Centro de InvestigaciÃ³n Clinica Trujillo EIRL, Trujillo, 13001, Peru|SP Zoz Opolskie Centrum Onkologii IM, Opole, Opolskie, 45-061, Poland|Uniwersyteckie Centrum Kliniczne, GdaÅsk, Pomorskie, 80-211, Poland|Centrum Medyczne HCP Sp. z o.o., PoznaÅ, Wielkopolskie, 61-485, Poland|MSCM Cancer Center and Institute of Oncology Department of Breast Cancer and Reconstructive Surgery, Warsaw, 02-781, Poland|Instytut Centrum Zdrowia Matki Polki, ÅÃ³dÅº, 93-338, Poland|Hospital da Senhora da Oliveira, GuimarÃ£es EPE, GuimarÃ£es, 4835-044, Portugal|Instituto PortuguÃªs de Oncologia de Lisboa Francisco Gentil, EPE, Lisboa, 1099-023, Portugal|FundaÃ§Ã£o Champalimaud, Lisboa, 1400-038, Portugal|Centro Hospitalar de Lisboa Ocidental, EPE, Lisboa, 1449-005, Portugal|Hospital da Luz, Lisboa, 1500-650, Portugal|Hospital CUF Descobertas, Lisboa, 1998-018, Portugal|Hospital Beatriz Ãngelo, Loures, 2674-514, Portugal|Unidade Local de SaÃºde de Matosinhos, EPE, Matosinhos, 4464-513, Portugal|Instituto PortuguÃªs de Oncologia do Porto Francisco Gentil, EPE, Porto, 4200-072, Portugal|Centro Hospitalar de Vila Nova de Gaia/Espinho, EPE, Vila Nova De Gaia, 4434-502, Portugal|Institutul Oncologic Prof. Dr. Ion Chiricuta, Cluj-Napoca, Cluj, 400015, Romania|Onco Clinic Consult SA, Craiova, Dolj, 200103, Romania|Centrul de Oncologie Sfantu Nectarie, Craiova, Dolj, 200347, Romania|Institutul Oncologic Bucuresti IOB, Bucharest, 22328, Romania|SBHI Arkhangelsk Region - Arkhangelsk Clinical Oncological Dispensary, Arkhangel'sk, 163045, Russian Federation|State Budgetary Healthcare Institution Oncological Dispensary No. 2 of the Ministry of Health of Krasnodar Region, Sochi, 354057, Russian Federation|National University Cancer Institute, Singapore, 119074, Singapore|National Cancer Center Singapore, Singapore, 169610, Singapore|Hospital Universitario de Basurto, Bilbao, Bizkaia, 48013, Spain|Hospital ClÃ­nico Universitario Virgen de la Arrixaca, El Palmar, Murcia, 30120, Spain|Hospital Universitario Sant Joan Reus, Reus, Tarragona, 43204, Spain|Hospital Universitario FundaciÃ³n AlcorcÃ³n, AlcorcÃ³n, 28922, Spain|Hospital General Universitario de Alicante, Alicante, 03010, Spain|Hospital de San Juan de Alicante, Alicante, 03550, Spain|Hospital Universitario de Badajoz, Badajoz, Spain|Hospital del Mar, Barcelona, 08003, Spain|IOB Institute Of Oncology-Hospital Quironsalud Barcelona, Barcelona, 08023, Spain|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital ClÃ­nic de Barcelona, Barcelona, 08036, Spain|Hospital Universitari MÃºtua Terrassa, Barcelona, 08221, Spain|ALTHAIA, Xarxa Assistencial UniversitÃ ria de Manresa F.P., Barcelona, 08243, Spain|Hospital de MatarÃ³, Barcelona, 08304, Spain|ICO Hospitalet, Barcelona, 08907, Spain|ICO Badalona, Barcelona, 2050, Spain|Consorcio Hospitalario Provincial de CastellÃ³, CastellÃ³n, 12002, Spain|Complejo Hospitalario Universitario A CoruÃ±a (CHUA), CoruÃ±a, 15006, Spain|Hospital Universitario San Pedro de Alcantara, CÃ¡ceres, 10001, Spain|ICO Girona, Girona, 17007, Spain|Hospital Universitario ClÃ­nico San Cecilio, Granada, 18016, Spain|Complejo Hospitalario de Jaen, JaÃ©n, 23007, Spain|Complejo Asistencial Universitario de LeÃ³n, LeÃ³n, 24001, Spain|Hospital Arnau de Vilanova de Lleida, Lleida, 25198, Spain|Clinica Universidad De Navarra, Madrid, Madrid, 28027, Spain|Hospital MD Anderson Cancer Center Madrid, Madrid, 28033, Spain|Hospital Universitario RamÃ³n y Cajal, Madrid, 28034, Spain|Hospital Universitario FundaciÃ³n JimÃ©nez DÃ­az, Madrid, 28040, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital Universitario La Paz, Madrid, 28046, Spain|HM Sanchinarro (CIOCC), Madrid, 28050, Spain|Hospital Universitario Puerta de Hierro de Majadahonda, Madrid, 28222, Spain|Hospital Universitario HM Puerta del Sur, Madrid, 28938, Spain|Hospital Universitario de Fuenlabrada, Madrid, 28942, Spain|Hospital General Universitario Morales Meseguer, Murcia, 30008, Spain|Hospital Universitario Virgen de la Victoria, MÃ¡laga, 29010, Spain|Hospital Universitario Rey Juan Carlos, MÃ³stoles, 28933, Spain|Complejo Hospitalario de Navarra, Navarro, 31008, Spain|Hospital Universitari Son Espases, Palma De Mallorca, 07120, Spain|Hospital Son Llatzer, Palma De Mallorca, 07198, Spain|Hospital Universitario de Canarias, San Cristobal de la Laguna, 38320, Spain|Hospital General de Catalunya, Sant Cugat Del VallÃ¨s, 08195, Spain|Complejo Hospitalario ClÃ­nico Universitario de Santiago de Compostela (CHUS), Santiago De Compostela, 15706, Spain|Hospital Universitario Virgen Macarena, Sevilla, 41009, Spain|Hospital QuirÃ³n Salud Sagrado CorazÃ³n, Sevilla, 41013, Spain|Hospital Universtiario Virgen del Rocio, Sevilla, 41013, Spain|FundaciÃ³n Instituto Valenciano de Oncologia (IVO), Valencia, 46009, Spain|Hospital ClÃ­nico Universitario de Valencia, Valencia, 46010, Spain|Hospital Arnau de Vilanova de Valencia, Valencia, 46015, Spain|Hospital ClÃ­nico Universitario Lozano Blesa, Zaragoza, 50009, Spain|E-Da Cancer Hospital, Kaohsiung, Yanchao District, 82445, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center, Beitou, 112, Taiwan|Changhua Christian Hospital (CCH), Chang Hua, 50006, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, 80756, Taiwan|China Medical University Hospital, Taichung, 40447, Taiwan|Taichung Veterans General Hospital, Taichung, 40705, Taiwan|National Cheng Kung University Hospital, Tainan, 704, Taiwan|Chi Mei Medical Center CMMC - Yongkang Branch, Tainan, 71004, Taiwan|National Taiwan University Hospital NTUH, Taipei, 10002, Taiwan|MacKay Memorial Hospital, Taipei, 10449, Taiwan|Taipei Veterans General Hospital TPVGH, Taipei, 111217, Taiwan|Tri-Service General Hospital, Taipei, 114, Taiwan|Chang Gung Memorial Hospital CGMH, Taipei, 33305, Taiwan|Hacettepe University Cancer Institute, Ankara, Ä°Ã§ Anadolu, 6100, Turkey|Trakya University Medical Faculty, Edirne, 22030, Turkey|Istanbul Medeniyet University Medical Faculty, Istanbul, 34093, Turkey|Medical Park - Izmir Hastanesi, Ä°zmir, 35575, Turkey|Peterborough City Hospital, Peterborough, Cambridgeshire, PE3 9NZ, United Kingdom|Kent Oncology Centre Maidstone Hospital, Maidstone, Kent, ME16 9QQ, United Kingdom|The Christie Hospital, Manchester, Lancashire, M20 4XB, United Kingdom|Clatterbridge Cancer Centre, Wirral, Merseyside, CH63 4JY, United Kingdom|Nottingham University Hospitals, Nottingham, Nottinghamshire, NG5 1PB, United Kingdom|Royal United Hospital Bath NHS Trust - Royal United Hospital RUH, Bath, Somerset, BA1 3NG, United Kingdom|Somerset NHS Foundation Trust, Taunton, Somerset, TA1 5DA, United Kingdom|St. James University Hospital, Leeds, West Yorkshire, LS9 7TF, United Kingdom|Univeristy Hospitals Bristol NHS Foundation Trust, Bristol, BS2 8ED, United Kingdom|Colchester Hospital, East Suffolk & North Essex NHS Foundation Trust, Colchester, CO4 5JL, United Kingdom|Royal Devon Exeter NHS Foundation Trust, Exeter, EX2 5DW, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, G12 0YN, United Kingdom|Guys and St Thomas NHS Foundation Trust, London, SE1 9RT, United Kingdom|Charing Cross Hospital, London, W6 8RF, United Kingdom|Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LJ, United Kingdom|Blackpool Victoria Hospital, Peterborough, FY3 8NR, United Kingdom",
NCT06152575,MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide),https://clinicaltrials.gov/study/NCT06152575,,RECRUITING,"The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer).

This study is seeking participants who:

* Are 18 years of age or older and have MM.
* Have received treatments before for MM.
* Have MM that has returned or not responded to their most recent treatment.

Half of the participants will receive elranatamab. The other half of participants will receive a combination therapy selected by the study doctor. The selected combination therapy will include 2 to 3 different medicines commonly used to treat MM.

Elranatamab will be given as a shot under the skin at the study clinic about once a week. This may change to a smaller number of shots later in the study.

The medicines in the combination therapy will be taken by mouth (at home or at the study clinic) AND will be given either as:

* a shot under the skin at the study clinic
* through a needle in the vein at the study clinic The number of times these medicines will be taken depends on what combination therapy the study doctor selects.

Participants may continue to receive elranatamab or a combination therapy until their MM is no longer responding. The study team will see how each participant is doing with the study treatment during regular visits at the study clinic. The study team will continue to follow-up with participants after study treatment with telephone contacts (or visits).

The study will compare the experiences of people receiving elranatamab to those people receiving a combination therapy. This will help learn about the safety and how effective elranatamab is.",NO,Multiple Myeloma,DRUG: Elranatamab|DRUG: Elotuzumab|DRUG: Pomalidomide|DRUG: Dexamethasone|DRUG: Bortezomib|DRUG: Carfilzomib,"Progression free survival per International Myeloma Working Group criteria, From date of randomization to date of progressive disease, discontinuation from study, death, or censoring, whichever occurs first, Up to approximately 5 years","Overall survival, From date of randomization to date of discontinuation from study, death, or censoring, whichever occurs first, Up to approximately 5 years|Progression free survival on next-line treatment per International Myeloma Working Group criteria, From date of randomization to date of second objective disease progression, discontinuation from the study, death, or censoring, whichever occurs first, Up to approximately 5 years|Objective response rate per International Myeloma Working Group criteria, From date of randomization to date of progressive disease, discontinuation from study, death, or start of new anticancer therapy, Up to approximately 5 years|Duration of response per International Myeloma Working Group criteria, From date of confirmed objective response to date of progressive disease, discontinuation from study, death, or censoring, whichever occurs first, Up to approximately 5 years|Very good partial response or better response rate per International Myeloma Working Group criteria, From date of randomization to date of progressive disease, discontinuation from study, death, or start of new anticancer therapy, whichever occurs first, Up to approximately 5 years|Complete response rate per International Myeloma Working Group criteria, From date of randomization to date of progressive disease, discontinuation from study, death, or start of new anticancer therapy, whichever occurs first, Up to approximately 5 years|Duration of complete response per International Myeloma Working Group criteria, From date of confirmed complete response to date of progressive disease, discontinuation from study, death, or censoring, whichever occurs first, Up to approximately 5 years|Time to response per International Myeloma Working Group criteria, From date of randomization to date of confirmed objective response, Up to approximately 5 years|Minimal residual disease negativity rate per International Myeloma Working Group criteria, From date of randomization to date of progressive disease, discontinuation from study, death, or start of new anticancer therapy, whichever occurs first, Up to approximately 5 years|Sustained minimal residual disease negativity rate per International Myeloma Working Group criteria, From date of randomization to date of progressive disease, discontinuation from study, death, or start of new anticancer therapy, whichever occurs first, Up to approximately 5 years|Duration of minimal residual disease negativity rate per International Myeloma Working Group criteria, From date of minimal residual disease negativity to date of relapse, death, or censoring, whichever occurs first, Up to approximately 5 years|Frequency of treatment-emergent adverse events, From date of first dose of study intervention up to 90 days after last study intervention administration|Frequency of abnormal laboratory results, From date of first dose of study intervention up to 90 days after last study intervention administration|Free elranatamab serum trough concentration [Ctrough], From date of first dose of elranatamab up to approximately 14 days after last dose of elranatamab|Elranatamab immunogenicity by anti-drug antibodies against elranatamab, From date of first dose of elranatamab up to approximately 14 days after last dose of elranatamab|Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30, Change from baseline scores, From date of informed consent up to approximately 35 days after last administration of study intervention|Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Myeloma 20, Change from baseline scores, From date of informed consent up to approximately 35 days after last administration of study intervention",,Pfizer,,ALL,"ADULT, OLDER_ADULT",PHASE3,492,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-02-08,2026-08-30,2027-12-30,2023-11-30,,2025-06-10,"Infirmary Cancer Care, Mobile, Alabama, 36607, United States|Beverly Hills Cancer Center, Beverly Hills, California, 90211, United States|Community Cancer Institute, Clovis, California, 93611, United States|Clinical Research Advisors (Encino Satellite Location), Encino, California, 91316, United States|Hoag Health Center Irvine, Irvine, California, 92618, United States|Hoag Hospital Irvine, Irvine, California, 92618, United States|Clinical Research Advisors (Korea Town Satellite Location), Los Angeles, California, 90020, United States|Clinical Research Advisors (West Hollywood Satellite Location), Los Angeles, California, 90048, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, 92663, United States|University of California Davis (UC Davis) Comprehensive Cancer Center, Sacramento, California, 95817, United States|University of California, Sacramento, California, 95817, United States|UCHealth Harmony, Fort Collins, Colorado, 80528, United States|Longs Peak Hospital, Longmont, Colorado, 80504, United States|Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, 33176, United States|BRCR Global, Plantation, Florida, 33322, United States|BRCR Global - Tamarac, Tamarac, Florida, 33321, United States|Community Health Network, Inc., Indianapolis, Indiana, 46227, United States|Community Health Network, Inc., Indianapolis, Indiana, 46250, United States|Community Health Network, Inc., Indianapolis, Indiana, 46256, United States|Bryan Medical Center, Lincoln, Nebraska, 68506, United States|NHO Revive Research Institute, LLC, Lincoln, Nebraska, 68506, United States|Atlantic Health System Morristown Medical Center, Morristown, New Jersey, 07960, United States|WMCHealth Advanced Physician Services, Hawthorne, New York, 10532, United States|Cayuga Cancer Center at Cayuga Park, Ithaca, New York, 14850, United States|Cayuga Medical Center, Ithaca, New York, 14850, United States|Westchester Medical Center, Valhalla, New York, 10595, United States|Brody school of Medicine at East Carolina University, Greenville, North Carolina, 27834, United States|ECU Health Medical Center, Greenville, North Carolina, 27834, United States|Oncology Hematology Care Clinical Trials, LLC, Cincinnati, Ohio, 45211, United States|TriHealth Cancer Institute-Good Samaritan Hospital, Cincinnati, Ohio, 45220, United States|Oncology Hematology Care Clinical Trials, LLC, Cincinnati, Ohio, 45236, United States|The Jewish Hospital, Cincinnati, Ohio, 45236, United States|Oncology Hematology Care Clinical Trials, LLC, Cincinnati, Ohio, 45242, United States|Oncology Hematology Care Clinical Trials, LLC, Cincinnati, Ohio, 45245, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|St Francis Cancer Center, Greenville, South Carolina, 29607, United States|Baylor University Medical Center, Investigational Drug Services, Department of Pharmacy, Dallas, Texas, 75246, United States|Baylor University Medical Center, Dallas, Texas, 75246, United States|Houston Methodist Hospital, Houston, Texas, 77030, United States|Houston Methodist Willowbrook Hospital, Houston, Texas, 77070, United States|US Oncology Investigational Products Center (IPC), Irving, Texas, 75063, United States|Houston Methodist Sugar Land Hospital, Sugar Land, Texas, 77479, United States|Baylor Scott & White Medical Center - Temple, Temple, Texas, 76508, United States|WVU Cancer Institute, Morgantown, West Virginia, 26506, United States|University of Wisconsin Carbone Cancer Center-University Hospital, Madison, Wisconsin, 53572, United States|University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison, Wisconsin, 53718, United States|Instituto Alexander Fleming, Ciudad AutÃ³noma de Buenos Aires, Buenos Aires, C1426ANZ, Argentina|Hospital Universitario Austral, Pilar, Buenos Aires, 1629, Argentina|Hospital Italiano de Buenos Aires, Ciudad de Buenos Aires, Ciudad AutÃ³noma DE Buenos Aires, C1199ABB, Argentina|Hospital Italiano de La Plata, La Plata, 1900, Argentina|Concord Repatriation General Hospital, Concord, New South Wales, 2139, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, 4575, Australia|St Vincent's Hospital (Melbourne), Fitzroy, Victoria, 3065, Australia|UZ Brussel, Brussels, Bruxelles-capitale, RÃ©gion DE, 1090, Belgium|Grand HÃ´pital de Charleroi, Gilly, Hainaut, 6060, Belgium|Centre Hospitalier Epicura, Hornu, Hainaut, 7301, Belgium|CHR Verviers - La Tourelle, Verviers, LiÃ¨ge, 4800, Belgium|UniversitÃ© Catholique de Louvain-Namur - Centre Hospitalier Universitaire Dinant-Godinne - Site Godi, Yvoir, Namur, 5530, Belgium|UZ Gent, Gent, Oost-vlaanderen, 9000, Belgium|Centro Gaucho Integrado De Oncologia, Hematologia, Ensino E Pesquisa, Porto Alegre, RIO Grande DO SUL, 90110-270, Brazil|Centro de Pesquisa ClÃ­nica - Ãrea Administrativa, Porto Alegre, RIO Grande DO SUL, 90850-170, Brazil|Hospital Mae de Deus, Porto Alegre, RIO Grande DO SUL, 90880-480, Brazil|Instituto D'Or de Pesquisa e Ensino (IDOR), Sao Paulo, SÃO Paulo, 04543-000, Brazil|ClÃ­nica MÃ©dica SÃ£o Germano LTDA, SP, SÃO Paulo, 04537-080, Brazil|Instituto de EducaÃ§Ã£o, Pesquisa e GestÃ£o em SaÃºde, Rio de Janeiro, 20775-001, Brazil|Americas Centro de Oncologia Integrado, Rio de Janeiro, 22775001, Brazil|Instituto de EducaÃ§Ã£o, Pesquisa e GestÃ£o em SaÃºde, Rio de Janeiro, 22793-080, Brazil|ESHO Empresa de ServiÃ§os Hospitalares S.A/ Hospital Samaritano de HigienÃ³polis, SÃ£o Paulo, 01232-010, Brazil|Instituto D'Or de Pesquisa e Ensino (IDOR), SÃ£o Paulo, 01401-002, Brazil|Hospital do Coracao, SÃ£o Paulo, 04004-030, Brazil|HU UNIFESP / SPDM - Hospital SÃ£o Paulo, SÃ£o Paulo, 04024-002, Brazil|Universidade Federal de Sao Paulo, SÃ£o Paulo, 04024-002, Brazil|ClÃ­nica MÃ©dica SÃ£o Germano S/S Ltda, SÃ£o Paulo, 04537-080, Brazil|Cross Cancer Institute, Edmonton, Alberta, T6G 1Z2, Canada|The Moncton Hospital, Moncton, New Brunswick, E1C 6Z8, Canada|Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada|Centre intÃ©grÃ© universitaire de santÃ© et de services sociaux du Nord-de-l'Ãle-de-MontrÃ©al (CIUSSS NÃ, Montreal, Quebec, H4J 1C5, Canada|FakultnÃ­ nemocnice Brno Bohunice, Brno, Brno-mÄsto, 625 00, Czechia|Fakultni nemocnice Olomouc, Olomouc, OlomouckÃ½ KRAJ, 779 00, Czechia|Fakultni nemocnice Kralovske Vinohrady, Prague, Praha 10, 100 34, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, 12808, Czechia|Rigshospitalet, Copenhagen, Hovedstaden, 2100, Denmark|Aarhus Universitetshospital, Skejby, Aarhus, Midtjylland, 8200, Denmark|Aalborg Universitetshospital, Syd, Aalborg, Nordjylland, 9000, Denmark|Tampereen yliopistollinen sairaala, Tampere, Pirkanmaa, 33520, Finland|Oulun yliopistollinen sairaala, Oulu, Pohjois-pohjanmaa, 90220, Finland|Kuopion Yliopistollinen Sairaala, Kuopio, Pohjois-savo, 70210, Finland|Helsinki University Hospital - Comprehensive Cancer Center (HYKS - SyÃ¶pÃ¤keskus), Helsinki, Uusimaa, 00029, Finland|Turku University Hospital, Turku, Varsinais-suomi, 20520, Finland|Centre Hospitalier Universitaire de Nice - HÃ´pital l'Archet, Nice, Alpes-maritimes, 06202, France|CHU Bordeaux Haut-Leveque, Pessac, Aquitaine, 33600, France|Centre Hospitalier RÃ©gional Universitaire de Nancy - HÃ´pitaux de Brabois, Vandoeuvre lÃ¨s Nancy, Lorraine, 54511, France|Centre Hospitalier de Dunkerque, Dunkirk, Nord-pas-de-calais, 59385, France|Centre Hospitalier Universitaire de Nantes - L' Hopital l'hÃ´tel-Dieu, Nantes, Pays-de-la-loire, 44000, France|HÃ´pital NOVO, Cergy Pontoise, Val-d'oise, 95303, France|HÃ´pital NOVO, Pontoise, Val-d'oise, 95300, France|Henri Mondor Hospital, CrÃ©teil, Val-de-marne, 94010, France|CHD Vendee, La Roche-sur-Yon, VendÃ©e, 85000, France|Centre Hospitalier de la CÃ´te Basque, Bayonne, 64109, France|Centre Hospitalier du Mans, Le Mans, 72037, France|HÃ´pital Universitaire Necker Enfants Malades, Paris, 75015, France|Hopitaux Universitaires Paris Centre-Hopital Cochin, Paris, 75679, France|Centre Hospitalier de Cornouaille, Quimper, 29107, France|Centre Hospitalier RÃ©gional Universitaire de Tours - HÃ´pital Bretonneau, Tours, 37032, France|Centre Hospitalier Bretagne Atlantique, Vannes, 56000, France|Centre Hospitalier Bretagne Atlantique, Vannes, 56017, France|Universitaetsklinikum Freiburg, Freiburg, Baden-wÃ¼rttemberg, 79106, Germany|Robert Bosch Krankenhaus GmbH, Stuttgart, Baden-wÃ¼rttemberg, 70376, Germany|Universitaetsklinikum Ulm, Ulm, Baden-wÃ¼rttemberg, 89081, Germany|Klinikum NÃ¼rnberg Nord, NÃ¼rnberg, Bayern, 90419, Germany|UniversitÃ¤tsklinikum Jena, Jena, ThÃ¼ringen, 07747, Germany|Vivantes Klinikum Am Urban, Berlin, 10249, Germany|Vivantes Klinikum Am Urban, Berlin, 10967, Germany|Medizinische UniversitÃ¤t Lausitz - Carl Thiem, Cottbus, 03048, Germany|Asklepios Altona, Hamburg, 22763, Germany|St. Barbara-Klinik Hamm-Heessen, Hamm, 59073, Germany|Diakonissen-Stiftungs-Krankenhaus Speyer, Speyer, 67346, Germany|University Hospital of Alexandroupolis, Alexandroupolis, AnatolikÃ­ MakedonÃ­a KAI ThrÃ¡ki, 681 00, Greece|Evangelismos General Hospital of Athens, Athens, AttikÃ­, 106 76, Greece|Alexandra General Hospital of Athens, Athens, AttikÃ­, 115 28, Greece|""Theagenio"" Cancer Hospital of Thessaloniki, Thessaloniki, KentrikÃ­ MakedonÃ­a, 540 07, Greece|G. Papanikolaou General Hospital, Thessaloniki, ThessalonÃ­ki, 570 10, Greece|University Hospital of Ioannina, Ioannina, Ãpeiros, 455 00, Greece|Rabin Medical Center, Petah-Tikva, Hamerkaz, 4910021, Israel|Sheba Medical Center, Ramat Gan, Hamerkaz, 5265601, Israel|Sourasky Medical Center, Tel Aviv, Tell AbÄ«b, 6423906, Israel|Hadassah Medical Center, Jerusalem, Yerushalayim, 9112001, Israel|IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) ""Dino Amadori"", Meldola, Emilia-romagna, 47014, Italy|P.O. San Carlo Borromeo- ASST SANTI PAOLO E CARLO, Milano, Lombardia, 20153, Italy|Azienda Ospedaliero Universitaria delle Marche, Ancona, Marche, 60126, Italy|Azienda Socio Sanitaria Ovest milanese, Legnano, Milano, 20025, Italy|Azienda Ospedaliero-Universitaria CittÃ  della Salute e della Scienza di Torino, Torino, Piemonte, 10126, Italy|A.O.U. Policlinico Paolo Giaccone, Palermo, Sicilia, 90127, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Toscana, 50134, Italy|IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola, Bologna, 40138, Italy|Istituto Europeo di Oncologia IRCCS, Milano, 20141, Italy|Ospedale Civile dello Spirito Santo, Pescara, 65124, Italy|Nagoya City University Hospital, Nagoya, Aichi, 467-8602, Japan|Toyohashi Municipal Hospital, Toyohashi, Aichi, 441-8570, Japan|Ehime Prefectural Central Hospital, Matsuyama, Ehime, 790-0024, Japan|Ogaki Municipal Hospital, Ogaki, Gifu, 503-8502, Japan|Gunma University Hospital, Maebashi, Gunma, 371-8511, Japan|National Hospital Organization Shibukawa Medical Center, Shibukawa, Gunma, 377-0280, Japan|Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan|Iwate Medical University Hospital, Shiwa-gun Yahaba-cho, Iwate, 028-3695, Japan|Shizuoka Cancer Center, Nagaizumi-cho, Shizuoka, 411-8777, Japan|Nippon Medical School Hospital, Bunkyo-ku, Tokyo, 113-8603, Japan|Japanese Foundation for Cancer Research, Koto, Tokyo, 135-8550, Japan|Yamanashi Prefectural Central Hospital, Kofu-shi, Yamanashi, 400-8506, Japan|Kagoshima University Hospital, Kagoshima, 890-8520, Japan|University Hospital,Kyoto Prefectural University of Medicine, Kyoto, 602-8566, Japan|National Hospital Organization Okayama Medical Center, Okayama, 701-1192, Japan|Okayama Rosai Hospital, Okayama, 702-8055, Japan|Yamagata University Hospital, Yamagata, 990-9585, Japan|Seoul National University Hospital, Seoul, Seoul-teukbyeolsi [seoul], 03080, Korea, Republic of|Samsung Medical Center, Seoul, Seoul-teukbyeolsi [seoul], 06351, Korea, Republic of|Maastricht UMC+, Maastricht, Limburg, 6229 HX, Netherlands|Albert Schweitzer Ziekenhuis, locatie Dordwijk, Dordrecht, Zuid-holland, 3318 AT, Netherlands|Akershus Universitetssykehus, LÃ¸renskog, Akershus, 1474, Norway|St. Olavs Hospital, Trondheim, SÃ¸r-trÃ¸ndelag, 7030, Norway|Sykehuset i Vestfold, TÃ¸nsberg, Vestfold, 3103, Norway|Oslo Universitetssykehus UllevÃ¥l, Oslo, 0450, Norway|Institut CatalÃ  d'Oncologia (ICO) - Badalona, Badalona, Barcelona [barcelona], 08916, Spain|Cetir-Ascires, Barcelona, Barcelona [barcelona], 08029, Spain|Hospital Universitari Mutua Terrassa, Terrassa, Barcelona [barcelona], 08221, Spain|Hospital ClÃ­nic de Barcelona, Barcelona, Catalunya [cataluÃ±a], 08036, Spain|Hospital General Universitario Morales Meseguer, Murcia, Galicia [galicia], 30008, Spain|Institut CatalÃ  d'Oncologia (ICO) - Girona, Girona, Girona [gerona], 17007, Spain|Hospital Universitario Infanta Leonor, Madrid, Madrid, Comunidad DE, 28031, Spain|ASCIRES ECG MÃ©dica S.L, ValÃ¨ncia, Valenciana, Comunitat, 46004, Spain|Hospital General Universitario Gregorio MaraÃ±on, Madrid, 28007, Spain|Hospital Universitario HM Sanchinarro, Madrid, 28050, Spain|H.R.U MÃ¡laga - Hospital General, MÃ¡laga, 29010, Spain|Centro de DiagnÃ³stico y Resonancia MagnÃ©tica, Salamanca, 37004, Spain|Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca, Salamanca, 37007, Spain|Hospital Universitari i Politecnic La Fe, ValÃ¨ncia, 46026, Spain|Falu Lasarett, Falun, 791 31, Sweden|Universitetssjukhuset Ãrebro, Ãrebro, Ãrebro LÃN [se-18], 701 85, Sweden|China Medical University Hospital, Taichung, 404332, Taiwan|Royal Bournemouth Hospital, Bournemouth, Dorset, BH7 7DW, United Kingdom|Poole Hospital, Poole, Dorset, BH15 2JB, United Kingdom|Eastbourne District General Hospital, Eastbourne, EAST Sussex, BN21 2UD, United Kingdom|Queen Elizabeth Hospital Birmingham, Birmingham, England, B15 2TH, United Kingdom|Maidstone Hospital, Maidstone, Kent, ME16 9QQ, United Kingdom|St Bartholomew's Hospital, London, London, CITY OF, EC1A 7BE, United Kingdom|Guy's & St Thomas' NHS Foundation Trust, London, London, CITY OF, SE1 9RT, United Kingdom|King's College Hospital, London, London, CITY OF, SE5 9RL, United Kingdom|Hammersmith Hospital, London, London, CITY OF, W12 0HS, United Kingdom|Churchill Hospital, Oxford, Oxfordshire, OX3 7LE, United Kingdom|Royal Stoke University Hospital, Stoke-on-Trent, Staffordshire, ST4 6QG, United Kingdom|Royal Marsden Hospital (Sutton), London, Sutton, SM2 5PT, United Kingdom|Kent and Canterbury Hospital, Canterbury, CT1 3NG, United Kingdom|New Cross Hospital, Wolverhampton, WV10 0QP, United Kingdom",
NCT04384484,Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma,https://clinicaltrials.gov/study/NCT04384484,LOTIS 5,ACTIVE_NOT_RECRUITING,The purpose of this study is to evaluate the efficacy of loncastuximab tesirine (ADCT-402) combined with rituximab compared to standard immunochemotherapy.,NO,Relapsed Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma,DRUG: Loncastuximab Tesirine|DRUG: Rituximab|DRUG: Gemcitabine|DRUG: Oxaliplatin,"Progression-free Survival (PFS), Up to 4 years","Overall Survival (OS), Up to 4 years|Overall Response Rate (ORR), Up to 4 years|Complete Response Rate (CRR), Up to 4 years|Duration of Response (DOR), Up to 4 years|Number of Participants Who Experience At Least One Treatment-Emergent Adverse Event (TEAE), Day 1 up to a maximum of Week 39|Number of Participants Who Experience At Least One Serious Adverse Event (SAE), Up to 4 years|Number of Participants Who Experience a Clinically Significant Change From Baseline in Clinical Laboratory Results, Day 1 up to a maximum of Week 25|Number of Participants Who Experience a Clinically Significant Change From Baseline in Vital Sign Measurements, Day 1 up to a maximum of Week 25|Number of Participants Who Experience a Clinically Significant Change From Baseline in Physical Examinations, Day 1 up to a maximum of Week 25|Number of Participants Who Experience a Clinically Significant Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status, Day 1 up to a maximum of Week 25|Number of Participants Who Experience a Clinically Significant Change From Baseline in Electrocardiogram (ECG) Results, Day 1 up to a maximum of Week 25|Average Concentration of Loncastuximab Tesirine at the End of Infusion, Day 1 of Cycles 1 through 6 (each cycle is 3 weeks)|Average Concentration of Loncastuximab Tesirine Before Infusion, Day 1 of Cycles 1 through 6 (each cycle is 3 weeks)|Number of Participants With Anti-Drug Antibody (ADA) Titers to Loncastuximab Tesirine, Day 1 up to a maximum of Week 25|Part 2: Change from Baseline in Health-Related Quality of Life (HRQoL) as Measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire -Core 30 (EORTC QLQ-C30), Baseline up to a maximum of Week 25|Part 2: Change from Baseline in Health-Related Quality of Life (HRQoL) as Measured by the Lymphoma Subscale of Functional Assessment of Cancer Therapy- Lymphoma (LymS of FACT-Lym), Baseline up to a maximum of Week 25|Part 2: Change from Baseline in Health-Related Quality of Life (HRQoL) as Measured by GP5 Item of the Functional Assessment of Cancer Therapy- Lymphoma (FACT-Lym), Baseline up to a maximum of Week 25|Part 2: Change from Baseline in Health-Related Quality of Life (HRQoL) as Measured by EuroQol-5 Dimensions-5 Levels (EQ-5D-5L), Baseline to up to 4 years",,ADC Therapeutics S.A.,,ALL,"ADULT, OLDER_ADULT",PHASE3,440,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-16,2025-06-30,2028-06-30,2020-05-12,,2025-05-30,"University of California San Diego Moores Cancer Center, La Jolla, California, 92093, United States|Redlands Community Hospital, Redlands, California, 92373, United States|The Oncology Institute of Hope and Innovation, Whittier, California, 90603, United States|Baptist MD Anderson Cancer Center, Jacksonville, Florida, 32207, United States|UnityPoint Health - Iowa Oncology Research Association (IORA), Des Moines, Iowa, 50309, United States|Norton Cancer Institute, Louisville, Kentucky, 40207, United States|Comprehensive Cancer Centers of Nevada - Henderson, Las Vegas, Nevada, 89169, United States|Kaiser Permanente Interstate Medical Office Central, Portland, Oregon, 97227, United States|Hollings Cancer Center, Charleston, South Carolina, 29425, United States|Virginia Cancer Specialists, Gainesville, Virginia, 20155, United States|Medical College of Wisconsin Cancer Center Clinical Trials Office, Milwaukee, Wisconsin, 53226, United States|Clinica Adventista Belgrano, Belgrano, Buenos Aires, C1430EGF, Argentina|ClÃ­nica de NefrologÃ­a, UrologÃ­a y Enfermedades Cardiovasculares S.A., Santa Fe, Buenos Aires, 3000, Argentina|Instituto MÃ©dico Especializado Alexander Fleming, Buenos Aires, Distrito Federal, C1426ANZ, Argentina|Grupo Gamma - Hospital Privado Rosario, Rosario, Santa Fe, S2000GAP, Argentina|Algemeen Ziekenhuis Sint-Jan Brugge-Oostende - Campus Sint-Jan, Brugge, 8000, Belgium|Cliniques Universitaires Saint-Luc, Brussels, 1200, Belgium|Centre Hospitalier Universitaire Universite Catholique de Louvain, Namur, B-5530, Belgium|Algemeen Ziekenhuis Delta - Campus Rumbeke, Roeselare, 8800, Belgium|Hospital Erasto Gaertner - Liga Paranaense de Combate ao CÃ¢ncer, Curitiba, ParanÃ¡, 81520-060, Brazil|Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, 90035-001, Brazil|Hospital de ClÃ­nicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, 90035-903, Brazil|Hospital MÃ£e de Deus - Centro Integrado de Oncologia, Porto Alegre, Rio Grande Do Sul, 90110-270, Brazil|Hospital do CÃ¢ncer, Rio De Janeiro, 20230-130, Brazil|Hemomed Instituto de Oncologia e Hematologia, SÃ£o Paulo, 01236-030, Brazil|A BeneficÃªncia Portuguesa de SÃ£o Paulo - Unidade Mirante, SÃ£o Paulo, 01321-001, Brazil|Hospital das ClÃ­nicas da Faculdade de Medicina da Universidade de SÃ£o Paulo, SÃ£o Paulo, 05403-010, Brazil|Hospital Israelita Albert Einstein, SÃ£o Paulo, 05652-900, Brazil|Hospital Santa Marcelina, SÃ£o Paulo, 08270-120, Brazil|Cross Cancer Institute, Edmonton, T6G 1Z2, Canada|Research Institute of the McGill University Health Centre, MontrÃ©al, H4A 3J1, Canada|HÃ´pital Fleurimont, Sherbrooke, J1H 5H3, Canada|Centro de Estudios ClÃ­nicos SAGA, Santiago, RegiÃ³n Metropolitana De Santiago, 7500653, Chile|Instituto OncolÃ³gico FundaciÃ³n Arturo LÃ³pez PÃ©rez, Santiago, RegiÃ³n Metropolitana De Santiago, 8320000, Chile|CeCim - Centro de Estudios ClÃ­nicos e Investigaciones MÃ©dicas, Santiago, RegiÃ³n Metropolitana De Santiago, 8330109, Chile|Peking University Third Hospital, Beijing, Beijing, 100191, China|The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, 361001, China|Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, China|Guangdong Provincial People's Hospital, Guangzhou, Guangdong, 510080, China|Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, 510280, China|Henan Cancer Hospital - Zhengzhou University, Zhengzhou, Henan, 450008, China|Jilin Cancer Hospital, Changchun, Jilin, 130021, China|The First Hospital of Jilin University, Changchun, Jilin, 130021, China|Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, 116000, China|Shanghai Cancer Center, Shanghai, Shanghai, 200025, China|West China School of Medicine - West China Hospital of Sichuan University, Chengdu, Sichuan, 610041, China|Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, 300060, China|The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310003, China|Chongqing University Cancer Hospital - Chongqing Cancer Hospital, Chongqing, 400030, China|Huizhou Municipal Central Hospital, Huizhou, 516001, China|The First Affiliated Hospital of Nanchang University, Nanchang, 330006, China|Institute of Hematology and Blood Diseases Hospital of CAMS - PUMC, Tianjin, 300020, China|Wuhan Union Hospital, Wuhan, 430023, China|Tongji Hospital, Wuhan, 430030, China|Fakultni nemocnice Ostrava, Ostrava, 708 52, Czechia|Fakultni Nemocnice Kralovske Vinohrady, Prague, 100 34, Czechia|Fakultni nemocnice v Motole, Prague, 150 06, Czechia|Centre Hospitalier Regional Universitaire Brest, Brest, Bretagne, 29200, France|HÃ´pital Avicenne, Bobigny, 93000, France|Centre Hospitalier Regional Universitaire Brest, Brest, 29200, France|HÃ´pital FranÃ§ois Mitterrand, Dijon, 21000, France|HÃ´pital PrivÃ© du Confluent, Nantes, 44200, France|Hopital Universitaire Pitie Salpetriere, Paris, 75651, France|HÃ´pital Haut-LÃ©vÃªque, Pessac, 33604, France|Centre de Lutte Contre le Cancer - Centre Henri-Becquerel, Rouen, 76038, France|Heves Varmegyei Markhot Ferenc Oktatokorhaz es Rendelointezet, Heves, Budapest, 3300, Hungary|DÃ©l-pesti CentrumkÃ³rhÃ¡z - OrszÃ¡gos HematolÃ³giai Ã©s InfektolÃ³giai IntÃ©zet - Szent LÃ¡szlÃ³, Budapest, Pest, 1097, Hungary|Semmelweis Egyetem, Budapest, 1088, Hungary|Orszagos Onkologiai Intezet, Budapest, 1122, Hungary|Samson Assuta Ashdod University Hospital, Ashdod, 7747629, Israel|Soroka Medical Center, Be'er Sheva, 8410101, Israel|Shamir Medical Center (Assaf Harofeh), Be'er Ya'aqov, 7030000, Israel|Carmel Medical Center, Haifa, 3436212, Israel|Rabin Medical Center - Beilinson Hospital, Petah tikva, 4941492, Israel|The Chaim Sheba Medical Center, Tel Aviv, 52621, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, 6423906, Israel|Presidio Ospedaliero Universitario Santa Maria della Misericordia, Udine, Friuli Venezia Giulia, 33100, Italy|Azienda Socio Sanitaria Territoriale (ASST) degli Spedali Civili di Brescia, Brescia, 25123, Italy|Azienda Ospedaliero - Universitaria Careggi, Florence, 50134, Italy|Ospedale Casa Sollievo della Sofferenza, Foggia, 71013, Italy|Istituto Romagnolo per lo Studio dei Tumori ""Dino Amadori"" - IRST, Meldola, 47014, Italy|Istituto Europeo di Oncologia, Milano, 20141, Italy|Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Istituto Clinico Humanitas, Milan, 20089, Italy|Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele, Milan, 20132, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, 27100, Italy|Sanitaria Locale della Romagna, Ravenna, 48121, Italy|National Hospital Organization - Nagoya Medical Center, Nagoya, Aichi, 460-0001, Japan|Toyohashi Municipal Hospital, Toyohashi, Aichi, 441-8570, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, 277-8577, Japan|Matsuyama Red Cross Hospital, Matsuyama, Ehime, 790-8524, Japan|Gunma Prefectural Cancer Center, Ota, Gunma, 373-8550, Japan|Sapporo Hokuyu Hospital, Sapporo, Hokkaido, 003-0006, Japan|Hokkaido Cancer Center, Sapporo, Hokkaido, 003-0804, Japan|Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan|Kanagawa Cancer Center, Yokohama, Kanagawa, 241-8515, Japan|Tohoku University Hospital, Sendai, Miyagi, 980-8574, Japan|Nagasaki University Hospital, Nagasaki-city, Nagasaki, 852-8501, Japan|Saitama Medical University - International Medical Center, Hidaka-Shi, Saitama, 350-1298, Japan|Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, 113-8677, Japan|National Hospital Organization Disaster Medical Center, Tachikawa, Tokyo, 190-0014, Japan|Fukushima Medical University Hospital, Fukushima, 960-1295, Japan|Gifu Municipal Hospital, Gifu, 500-8323, Japan|Kagoshima University Hospital, Kagoshima, 890-8520, Japan|Niigata University Medical and Dental Hospital, Niigata, 951-8520, Japan|National Hospital Organization Okayama Medical Center, Okayama, 701-1192, Japan|Osaka Prefectural Hospital Organization - Osaka International Cancer Institute, Osaka, 541-8567, Japan|Boca Raton Clinical Research (BRCR) Global Mexico - Guadalajara, Guadalajara, Jalisco, 44600, Mexico|PanAmerican Clinical Research Mexico - Guadalajara, Guadalajara, Jalisco, 44670, Mexico|PanAmerican Clinical Research Mexico - Cuernavaca, Cuernavaca, Morelos, 62290, Mexico|Hospital Universitario Dr. JosÃ© Eleuterio GonzÃ¡lez, Monterrey, Nuevo Leon, 64460, Mexico|HematolÃ³gica Alta Especialidad, Huixquilucan, 52787, Mexico|Boca Raton Clinical Research (BRCR) Global Mexico - Ciudad de MÃ©xico, Mexico City, 1120, Mexico|Hagaziekenhuis Van Den Haag - Leyweg, Den Haag, South Holland, 2545 AA, Netherlands|Elisabeth-TweeSteden Ziekenhuis - Elisabeth, Tilburg, 5022 GC, Netherlands|Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we WrocÅawiu, Wroclaw, Dolnoslaskie, 50-367, Poland|Pratia MCM KrakÃ³w, KrakÃ³w, Malopolskie, 30-510, Poland|Szpitale Pomorskie SpÃ³Åka Z OgraniczonÄ OdpowiedzialnoÅciÄ, Gdynia, 81-519, Poland|Pratia Onkologia Katowice, Katowice, 40-519, Poland|Szpital WojewÃ³dzki w Opolu, Opole, 45-061, Poland|Centrum Medyczne Pratia PoznaÅ, Skorzewo, 60-185, Poland|Instytut Hematologii I Transfuzjologii, Warszawa, 02-776, Poland|Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi, ÅÃ³dÅº, 93-510, Poland|Hospital EspaÃ±ol Auxilio Mutuo, San Juan, 00919, Puerto Rico|Hospital del Mar - Parc de Salut Mar, Barcelona, 08003, Spain|Institut CatalÃ  d'Oncologia - Hospital Duran i Reynals (ICO L'Hospitalet), Barcelona, 08908, Spain|Hospital San Pedro de Alcantara, CÃ¡ceres, 10003, Spain|Hospital Universitario RamÃ³n y Cajal, Madrid, 28034, Spain|Hospital Universitario FundaciÃ³n JimÃ©nez DÃ­az, Madrid, 28040, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital Universitario La Paz, Madrid, 28046, Spain|Hospital Universitario MarquÃ©s de Valdecilla, Santander, 39008, Spain|Hospital Universitario Virgen del RocÃ­o, Sevilla, 41013, Spain|Hospital Arnau de Vilanova, Valencia, 25198, Spain|Istituto Oncologico della Svizzera Italiana, Bellinzona, 6500, Switzerland|Ãzel Koru Hastanesi, Ãukurambar, Ankara, 6510, Turkey|VKV Amerikan Hastanesi, ÅiÅli, Istanbul, 34365, Turkey|Ege Universitesi Tip Fakultesi Hastanesi, Bornova, Izmir, 35100, Turkey|Ondokuz Mayis Ãniversitesi, Kurupelit, Samsun, 55270, Turkey|Karadeniz Teknik Ãniversitesi Tip FakÃ¼ltesi, Ortahisar, Trabzon, 61080, Turkey|Ankara Universitesi Tip Fakultesi - Cebeci Arastirma ve Uygulama Hastanesi, Ankara, 06100, Turkey|Mehmet Kemal Dedeman Hematoloji Hastanesi, Kayseri, 38039, Turkey|The Royal Marsden NHS Foundation Trust, Sutton, England, SM2 5PT, United Kingdom|NHS Greater Glasgow and Clyde, Glasgow, G12 0XH, United Kingdom|The Christie NHS Foundation Trust, Manchester, M20 4BX, United Kingdom",
NCT04578613,ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL,https://clinicaltrials.gov/study/NCT04578613,,RECRUITING,"This is a randomized, multicenter, open-label, Phase 3 study to evaluate the efficacy and safety of ICP-022 versus Chlorambucil plus Rituximab in subjects with Previously Untreated Chronic Lymphocytic Leukemia.",NO,Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,DRUG: ICP-022|DRUG: Chlorambucil|DRUG: Rituximab,"Progression Free Survival (PFS), Progress-free survival (PFS) was evaluated by the independent review board (IRC) against the IWCLL2018 criteria (Hallek et al., 2018) and the revised lymphoma mitigation assessment criteria (Cheson et al., 2014)., Up to 5 years","Objective Response Rate (ORR), Up to 5 years|Duration Of Response (DOR), Up to 5 years|Overall Survival (OS), Up to 5 years",,"Beijing InnoCare Pharma Tech Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,218,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-01-08,2024-12-30,2025-06-30,2020-10-08,,2023-06-05,"The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China|Anhui Provincial Cancer Hospital, Hefei, Anhui, China|The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China|The Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China|The First Affiliated Hospital of Congqing Medical University, Chongqing, Chongqing, 400000, China|The Second Affiliated Hospital of Army Medical University, Chongqing, Chongqing, China|The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China|Lanzhou University Second Hospital, Lanzhou, Gansu, China|Dongguan People's Hospital, Dongguan, Guangdong, 523058, China|Cancer Prevention and Treatment Center, Sun Yat-sen University, Guangzhou, Guangdong, China|Guangzhou First People's Hospital, Guangzhou, Guangdong, China|Shenzhen People's Hospital, Shenzhen, Guangdong, China|Affiliated Hospital of Guilin Medical College, Guilin, Guangxi Zhuang Autonomous Region, 541000, China|Affiliated Hospital of Hebei University, Baoding, Hebei, China|Hebei Medical University Second Hospital, Shijiazhuang, Hebei, h, China|The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|Affiliated Tumor Hospital of Harbin Medical University, Ha'erbin, Heilongjiang, China|The first Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China|First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China|Henan Cancer Hospital, Zhengzhou, Henan, China|Henan Province Hospital, Zhengzhou, Henan, China|Zhongnan Hospital of WuHan University, Wuhan, Hubei, 430071, China|Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China|Yichang Central People's Hospital, Yichang, Hubei, China|Yichang First People's Hospital, Yichang, Hubei, China|The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410000, China|The Third Xiangya Hospital of Central South University, Changsha, Hunan, China|Zhuzhou Central Hospital, Zhuzhou, Hunan, 412007, China|Jiangsu Province Hospital, Nanjing, Jiangsu, China|The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China|Wuxi People's Hospital, Wuxi, Jiangsu, China|Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China|Subei People's Hospital, Yangzhou, Jiangsu, China|The First Affiliated Hospital of Gannan Medical College, Ganzhou, Jiangxi, 341004, China|Jiangxi Cancer Hospital, Nanchang, Jiangxi, China|The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China|Shengjing Hospital of China Medical University, Dalian, Liaoning, China|The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China|Affiliated Hospital of Binzhou Medical College, Binzhou, Shandong, China|Shandong Cancer Hospita, Jinan, Shandong, 250117, China|Shandong Provincial Hospital, Jinan, Shandong, China|Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, 200025, China|The Second Affiliated Hospital of XiÂ´an Jiaotong University, Xi'an, Shanxi, 710000, China|Sichuan Provincial People's Hospital, Chengdu, Sichuan, China|West China Hospital of Sichuan University, Chengdu, Sichuan, China|Yibin Second People's Hospital, Yibin, Sichuan, China|General Hospital of Tianjin Medical University, Tianjin, Tianjin, China|Hospital of Hematology, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China|Tianjin Cancer Hospital, Tianjin, Tianjin, China|The First Affiliated Hospital of Xinjiang Medical University, ÃrÃ¼mqi, Xinjiang Uygur Autonomous Region, 830011, China|The first Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China|Dongyang People's Hospital, Dongyang, Zhejiang, 322199, China|Shaoyifu Hospital Affiliated to Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310026, China|The First Affiliated Hospital of Zhejiang University Medical College, Hangzhou, Zhejiang, China|Jinhua Central Hospital, Jinhua, Zhejiang, 321000, China|Ningbo First Hospital, Ningbo, Zhejiang, China",
NCT05113251,"Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer",https://clinicaltrials.gov/study/NCT05113251,,ACTIVE_NOT_RECRUITING,"This study will look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast cancer.",NO,Breast Neoplasms|Breast Cancer|HER2-positive Early Breast Cancer,DRUG: Trastuzumab Deruxtecan|DRUG: Paclitaxel|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Doxorubicin|DRUG: cyclophosphamide,"rate of pathologic complete response (pCR), Proportion of participants who have no evidence by H\&E staining of residual invasive disease, Up to 39 months after study start","Event-Free Survival, Up to 72 months after study start|Invasive Disease-Free Survival (IDFS), Up to 72 months after study start|Overall Survival, Up to 72 months after study start",,AstraZeneca,Daiichi Sankyo,ALL,"ADULT, OLDER_ADULT",PHASE3,927,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-10-25,2025-03-12,2027-04-30,2021-11-09,,2025-05-06,"Research Site, Springdale, Arkansas, 72762, United States|Research Site, Beverly Hills, California, 90211, United States|Research Site, Glendale, California, 91204, United States|Research Site, Los Alamitos, California, 90720, United States|Research Site, Orange, California, 92868, United States|Research Site, New Haven, Connecticut, 06510, United States|Research Site, Fort Wayne, Indiana, 46804, United States|Research Site, Lexington, Kentucky, 40503, United States|Research Site, Louisville, Kentucky, 40202, United States|Research Site, Shreveport, Louisiana, 71101, United States|Research Site, Minneapolis, Minnesota, 55407, United States|Research Site, Las Vegas, Nevada, 89102, United States|Research Site, East Brunswick, New Jersey, 08816, United States|Research Site, Summit, New Jersey, 07901, United States|Research Site, Commack, New York, 11725, United States|Research Site, Durham, North Carolina, 27710, United States|Research Site, Greenville, South Carolina, 29607, United States|Research Site, Germantown, Tennessee, 38138, United States|Research Site, Nashville, Tennessee, 37203, United States|Research Site, Fort Worth, Texas, 76104, United States|Research Site, Ogden, Utah, 84405, United States|Research Site, Tacoma, Washington, 98405, United States|Research Site, GoiÃ¢nia, 74000-000, Brazil|Research Site, IjuÃ­, 98700-000, Brazil|Research Site, Natal, 59075-740, Brazil|Research Site, Porto Alegre, 90610-000, Brazil|Research Site, Porto Alegre, 91350-200, Brazil|Research Site, SÃ£o Paulo, 01221-020, Brazil|Research Site, SÃ£o Paulo, 01229-010, Brazil|Research Site, Panagyurishte, 4500, Bulgaria|Research Site, Sofia, 1330, Bulgaria|Research Site, Edmonton, Alberta, T6G 1Z2, Canada|Research Site, Toronto, Ontario, M5G 1X5, Canada|Research Site, Montreal, Quebec, H4A-3J1, Canada|Research Site, Quebec City, Quebec, G1S 4L8, Canada|Research Site, Sherbrooke, Quebec, J1H 5N4, Canada|Research Site, Montreal, H3T 1E2, Canada|Research Site, Beijing, 100039, China|Research Site, Changsha, 410008, China|Research Site, Changsha, 410013, China|Research Site, Chongqing, 400030, China|Research Site, Guangzhou, 510060, China|Research Site, Guangzhou, 510080, China|Research Site, Guangzhou, 510700, China|Research Site, Kunming, 650118, China|Research Site, Nanning, 530021, China|Research Site, Qingdao, 266100, China|Research Site, Shanghai, 200032, China|Research Site, Shenyang, 110001, China|Research Site, Tianjin, 300060, China|Research Site, Wuhan, 430060, China|Research Site, Wuhan, 430079, China|Research Site, Zhengzhou, 450008, China|Research Site, Augsburg, 86156, Germany|Research Site, Berlin, 10117, Germany|Research Site, Erlangen, 91054, Germany|Research Site, Hamburg, 20357, Germany|Research Site, Heidelberg, 69120, Germany|Research Site, Kiel, 24105, Germany|Research Site, Leipzig, 4103, Germany|Research Site, Muenster, 48149, Germany|Research Site, MÃ¶nchengladbach, 41061, Germany|Research Site, MÃ¼nchen, 81377, Germany|Research Site, Paderborn, 33098, Germany|Research Site, TÃ¼bingen, 72076, Germany|Research Site, Gurgaon, 122001, India|Research Site, Howrah, 711103, India|Research Site, Nagpur, 440001, India|Research Site, Nashik, 422002, India|Research Site, New Delhi, 110 085, India|Research Site, New Delhi, 110029, India|Research Site, Raipur, 492001, India|Research Site, Rishikesh, 249203, India|Research Site, Surat, 395002, India|Research Site, Thiruvananthapuram, 695011, India|Research Site, Bologna, 40138, Italy|Research Site, Candiolo, 10060, Italy|Research Site, Livorno, 57100, Italy|Research Site, Milano, 20132, Italy|Research Site, Naples, 80131, Italy|Research Site, Napoli, 80131, Italy|Research Site, Negrar, 37024, Italy|Research Site, Padova, 35128, Italy|Research Site, Roma, 00168, Italy|Research Site, Rozzano, 20089, Italy|Research Site, Chuo-ku, 104-8560, Japan|Research Site, Chuo-ku, 862-8655, Japan|Research Site, Hidaka-shi, 350-1298, Japan|Research Site, Hiroshima-shi, 734-8551, Japan|Research Site, Kawasaki-shi, 216-8511, Japan|Research Site, Koto-ku, 135-8550, Japan|Research Site, Nagoya-shi, 466-8560, Japan|Research Site, Nagoya-shi, 467-0001, Japan|Research Site, Ota-shi, 373-8550, Japan|Research Site, Shinjuku-ku, 162-8655, Japan|Research Site, Goyang-si, 10408, Korea, Republic of|Research Site, Seoul, 03080, Korea, Republic of|Research Site, Seoul, 03722, Korea, Republic of|Research Site, Seoul, 05505, Korea, Republic of|Research Site, Seoul, 06273, Korea, Republic of|Research Site, Seoul, 06351, Korea, Republic of|Research Site, Lima, 15033, Peru|Research Site, Lima, LIMA 29, Peru|Research Site, Lima, Lima 32, Peru|Research Site, Lima, LIMA 34, Peru|Research Site, Bacolod, 6100, Philippines|Research Site, Cebu City, 6000, Philippines|Research Site, Davao City, 8000, Philippines|Research Site, Iloilo, 5000, Philippines|Research Site, Quezon City, 1112, Philippines|Research Site, San Juan, Philippines|Research Site, BiaÅa Podlaska, 21-500, Poland|Research Site, BiaÅystok, 15-027, Poland|Research Site, Bydgoszcz, 85-796, Poland|Research Site, Koszalin, 75-581, Poland|Research Site, Lublin, 20-090, Poland|Research Site, RzeszÃ³w, 30-055, Poland|Research Site, Warszawa, 02-781, Poland|Research Site, Moscow, 117997, Russian Federation|Research Site, Moscow, 143423, Russian Federation|Research Site, Saint Petersburg, 190020, Russian Federation|Research Site, Saint Petersburg, 197758, Russian Federation|Research Site, Ar RiyÄá¸, 11426, Saudi Arabia|Research Site, Dammam, 31444, Saudi Arabia|Research Site, Jeddah, 21423, Saudi Arabia|Research Site, Jeddah, 23214, Saudi Arabia|Research Site, Riyadh, 3354, Saudi Arabia|Research Site, Barcelona, 08028, Spain|Research Site, Barcelona, 08035, Spain|Research Site, Madrid, 28007, Spain|Research Site, Madrid, 28040, Spain|Research Site, Sevilla, 41013, Spain|Research Site, Vigo, 36312, Spain|Research Site, Kaohsiung, 82445, Taiwan|Research Site, Taichung, 40443, Taiwan|Research Site, Tainan, 710, Taiwan|Research Site, Taipei City, 114, Taiwan|Research Site, Taipei, 100, Taiwan|Research Site, Taipei, 11217, Taiwan|Research Site, Taoyuan, 333, Taiwan|Research Site, Bangkok, 10210, Thailand|Research Site, Bangkok, 10330, Thailand|Research Site, Bangkok, 10400, Thailand|Research Site, Chiang Mai, 50200, Thailand|Research Site, Hat Yai, 90110, Thailand|Research Site, Khon Kaen, 40002, Thailand",
NCT06464991,A Phase III Study of Eque-cel in Subjects with Len-refractory RRMM (FUMANBA-03),https://clinicaltrials.gov/study/NCT06464991,FUMANBA-03,RECRUITING,"This is a multicenter, randomized, controlled, open-label, phase III clinical study to evaluate the efficacy of Equecabtagene Autoleucel Injection versus standard therapy in subjects with lenalidomid-refractory RRMM who have received 1-2 lines of prior therapy.",NO,Multiple Myeloma,DRUG: Equecabtagene Autoleucel Injection|DRUG: Daratumumab|DRUG: Pomalidomide|DRUG: Bortezomib|DRUG: Dexamethasone,"Progression-Free Survival (PFS) as assessed by Independent Review Committee (IRC), The time from randomization to the first documented disease progression as determined by IRC or death due to any cause, up to 5 years from randomization","Minimal Residual Disease (MRD) negativity rate at 12 months, The proportion of subjects who achieve MRD negativity (using next-generation flow cytometry according to EuroFlow standard operating procedures) and complete response (CR) or better, as assessed by IRC, 12 months (Â±3 months) post-randomization, up to 5 years from randomization|Overall MRD negativity rate, The proportion of subjects who achieve MRD negativity at any time after the date of randomization and before the initiation of subsequent therapy, up to 5 years from randomization|Duration of MRD negativity, The time from first achievement of MRD negativity to the first subsequent positive MRD status, up to 5 years from randomization|Complete Response Rateï¼CRRï¼, The proportion of subjects who achieve CR or better post-randomization among all randomized subjects, up to 5 years from randomization|Very good partial response or better response (â¥VGPR) rate, The proportion of subjects who achieve sCR, CR, or VGPR post-randomization among all randomized subjects, up to 5 years from randomization|Overall Response Rateï¼ORRï¼, The proportion of subjects who achieve sCR, CR, VGPR, or PR post-randomization among all randomized subjects., up to 5 years from randomization|Duration of Response (DOR), The time from the first date of initial documented response (â¥PR) to the date of first disease progression or death from any cause, whichever occurs first, post-randomization, up to 5 years from randomization|Event-Free Survival (EFS), Time from randomization to the first occurrence of any of the following events: death, disease progression, initiation of a new anti-myeloma therapy, addition of other treatments, or occurrence of fatal or intolerable adverse effects, up to 5 years from randomization|Overall Survivalï¼OSï¼, Defined as the time from randomization to death due to any cause, up to 5 years from randomization|Time to Next Treatmentï¼TTNTï¼, Time from randomization to the initiation of a new subsequent anti-myeloma therapies, up to 5 years from randomization|Incidence of Adverse events, Safety Endpoint, up to 5 years from randomization|Pharmacokinetic Endpoint-Cmax, The maximum concentration (Cmax) of CAR VCN and BCMA CAR-T in peripheral blood after CAR-T infusion, up to 5 years from Eque-cel infusion|Pharmacokinetic Endpoint-Tmax, the time for CAR VCN and BCMA CAR-T to reach the maximum concentration (Tmax) after CAR-T infusion, up to 5 years from Eque-cel infusion|Pharmacokinetic Endpoint-AUC, Area under the curve of 29, 85, 169 days and the last time point of PK detection (AUC0-29d, AUC0-85d, AUC0-169d, AUC0-last) for CAR VCN; Area under the curve of 29 days (AUC0-29) for BCMA CAR-T., up to 5 years from Eque-cel infusion|Pharmacodynamic Endpoint, The concentration of soluble BCMA in peripheral blood of experimental group at each time point, up to 5 years from Eque-cel infusion|Health Related Quality of Life Endpoint, Symptoms, function, and overall HRQoL were collected using the validated Patient-Reported Outcomes (PRO) questionnaire, up to 5 years from randomization",,"Nanjing IASO Biotechnology Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,240,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-03-27,2027-08,2030-12,2024-06-18,,2025-02-21,"Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China|Beijing GoBoard Boren Hospital, Beijing, China|Fu Xing Hospital, Capital Medical University, Beijing, China|Peking Union Medical College Hospital, Beijing, China|Peking University First Hospital, Beijing, China|Peking University Third Hospital, Beijing, China|People's Hospital of Peking University, Beijing, China|The first hospital of Jilin University, Chang chun, China|West China School of Medicine, West China Hospital of Sichuan University, Chengdu, China|Xinqiao Hospital of AMU, Chongqing, China|Nanfang Hospital, Southern Medical University, Guangzhou, China|Sun Yat-sen University Cancer Centre, Guangzhou, China|Zhujiang Hospital of Southern Medical University Guangdong, Guangzhou, China|The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China|The Second Affiliated Hospital,Zhejiang University School of Medicine, Hangzhou, China|Qilu Hospital of Shangdong University, Jinan, China|The First Affiliated Hospital of Nanchang University, Nanchang, China|Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China|Jiangsu Province Hospital, Nanjing, China|The Affiliated People's Hospital of Ningbo University, Ningbo, China|Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China|The First Affiliated Hospital of Soochow University, Suzhou, China|Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjing, China|Tianjin Medical University General Hospital, Tianjing, China|The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China|Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China|Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China|Henan Cancer Hospital Affilated Cancer Hospital of Zhengzhou University, Zhengzhou, China",
NCT05780567,Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer,https://clinicaltrials.gov/study/NCT05780567,,RECRUITING,"This is a Phase III, randomized, double-blind, parallel, multi-center trail to evaluate the efficacy and safety of TQB3616 capsule combined with endocrine compared to placebo compared with endocrine in HR-positive and HER2-negative breast cancer adjuvant therapy. Approximately 1946 female subjects will be randomized to either TQB3616 combined with endocrine group or TQB3616-matching placebo combined endocrine group. Randomization will follow a 2:1 ratio, 1297 subjects in experimental group and 649 in the the Placebo Comparator group.",NO,Breast Cancer,"DRUG: TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen|DRUG: Placebo capsules, Letrozole, Anastrozole, Tamoxifen","Invasive Disease-Free Survival (IDFS), The time from the date of randomization to the first occurrence of the following events, including ipsilateral or contralateral recurrence of invasive breast cancer, regional or distant recurrence of invasive breast cancer, secondary primary malignancy outside the breast, and death from any cause., Baseline up to 60 months","Overall survival (OS), The time from first administration to death of any cause., Baseline up to 60 months|Disease Relapse Free Survival (DRFS), The time from the date of randomization to the first occurrence of distant recurrence or death from any cause., Baseline up to 60 months|Incidence of adverse events, Incidence of adverse events assessed according to the common terminology criteria for adverse events (CTCAE)., Baseline up to 60 months|Severity of adverse events, Severity of adverse events assessed according to the common terminology criteria for adverse events (CTCAE)., Baseline up to 60 months|Incidence of abnormal laboratory test values, Incidence of abnormal laboratory test values assessed according to the common terminology criteria for adverse events (CTCAE)., Baseline up to 60 months|Severity of abnormal laboratory test values, Severity of abnormal laboratory test values assessed according to the common terminology criteria for adverse events (CTCAE)., Baseline up to 60 months|Incidence of serious adverse events, Incidence of serious adverse events assessed according to the common terminology criteria for adverse events (CTCAE)., Baseline up to 60 months|Severity of serious adverse events, Severity of serious adverse events assessed according to the common terminology criteria for adverse events (CTCAE)., Baseline up to 60 months",,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,1946,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-03-30,2026-12,2027-01,2023-03-22,,2023-04-21,"Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, 100021, China|Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, 300020, China|Suining Central Hospital, Suining, Sichuan, 629099, China",
NCT05382286,"Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer",https://clinicaltrials.gov/study/NCT05382286,ASCENT-04,ACTIVE_NOT_RECRUITING,"The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).",NO,Triple Negative Breast Cancer|PD-L1 Positive,DRUG: Sacituzumab Govitecan-hziy|DRUG: Pembrolizumab|DRUG: Paclitaxel|DRUG: nab-Paclitaxel|DRUG: Gemcitabine|DRUG: Carboplatin,"Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, PFS is defined as the time from the date of randomization until the date of objective progressive disease (PD) or death (whichever comes first)., Randomization up to approximately 33 months","Overall Survival (OS), OS is defined as the time from the date of randomization until death due to any cause., Randomization up to approximately 53 months|Objective Response Rate (ORR) as Assessed by BICR per RECIST Version 1.1, ORR is defined as the proportion of participants who achieve complete response (CR) or partial response (PR) that is confirmed at least 4 weeks after initial documentation of response., Randomization up to approximately 53 months|Duration of Response (DOR) as Assessed by BICR per RECIST Version 1.1, DOR is defined as the time from the first documentation of CR or PR to the earlier of the first documentation of objective PD or death from any cause (whichever comes first)., Randomization up to approximately 53 months|Time to Response (TTR) as Assessed by BICR per RECIST Version 1.1, TTR is defined as the time from the date of randomization until the first documentation of CR or PR., Randomization up to approximately 53 months|Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs), First dose date up to 53 months plus 30 days|Percentage of Participants Experiencing Clinical Laboratory Abnormalities, First dose date up to 53 months plus 30 days|Time to Deterioration (TTD) in Global Health Status/Quality of Life (QoL) Scale as Measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, Core Questionnaire, Version 3.0 (EORTC QLQ-C30), The EORTC QLQ-C30 is a questionnaire to assess quality of life of cancer patients, it is composed of 30 questions (items) resulting in 5 functional scales, 1 global health status scale, 3 symptom scales, and 6 single items. Scoring of the QLQ-C30 is performed according to QLQ-C30 Scoring manual. All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status denote a better level of functioning (i.e. a better state of the participant), while higher scores on the symptom and single-item scales indicate a higher level of symptoms (i.e. a worse state of the participant)., Randomization up to approximately 53 months|TTD of Pain Score as Measured by EORTC QLQ-C30, The EORTC QLQ-C30 is a questionnaire to assess quality of life of cancer patients, it is composed of 30 questions (items) resulting in 5 functional scales, 1 global health status scale, 3 symptom scales, and 6 single items. Scoring of the QLQ-C30 is performed according to QLQ-C30 Scoring manual. All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status denote a better level of functioning (i.e. a better state of the participant), while higher scores on the symptom and single-item scales indicate a higher level of symptoms (i.e. a worse state of the participant)., Randomization up to approximately 53 months|TTD of Fatigue Score as Measured by EORTC QLQ-C30, The EORTC QLQ-C30 is a questionnaire to assess quality of life of cancer patients, it is composed of 30 questions (items) resulting in 5 functional scales, 1 global health status scale, 3 symptom scales, and 6 single items. Scoring of the QLQ-C30 is performed according to QLQ-C30 Scoring manual. All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status denote a better level of functioning (ie, a better state of the participant), while higher scores on the symptom and single-item scales indicate a higher level of symptoms (ie, a worse state of the participant)., Randomization up to approximately 53 months|TTD of Physical Functioning Domain Score as Measured by EORTC QLQ-C30, The EORTC QLQ-C30 is a questionnaire to assess quality of life of cancer patients, it is composed of 30 questions (items) resulting in 5 functional scales, 1 global health status scale, 3 symptom scales, and 6 single items. Scoring of the QLQ-C30 is performed according to QLQ-C30 Scoring manual. All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status denote a better level of functioning (ie, a better state of the participant), while higher scores on the symptom and single-item scales indicate a higher level of symptoms (ie, a worse state of the participant)., Randomization up to approximately 53 months|TTD of Role Functioning Score as Measured by EORTC QLQ-C30, The EORTC QLQ-C30 is a questionnaire to assess quality of life of cancer patients, it is composed of 30 questions (items) resulting in 5 functional scales, 1 global health status scale, 3 symptom scales, and 6 single items. Scoring of the QLQ-C30 is performed according to QLQ-C30 Scoring manual. All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status denote a better level of functioning (ie, a better state of the participant), while higher scores on the symptom and single-item scales indicate a higher level of symptoms (ie, a worse state of the participant)., Randomization up to approximately 53 months",,Gilead Sciences,Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE3,443,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-07-25,2027-02,2027-02,2022-05-19,,2024-12-24,"Alaska Oncology and Hematology, Anchorage, Alaska, 99508, United States|Arizona Oncology Associates, PC-Hope,1845 W Orange Grove Rd, Tucson, Arizona, 85704, United States|Arizona Oncology Associates, PC-Hope,2070 W. Rudasill Rd., Tucson, Arizona, 85704, United States|Arizona Oncology Associates, PC-Hope, Tucson, Arizona, 85711, United States|Arizona Oncology Associates, PC-Hope,1620 West St. Mary's Road, Tucson, Arizona, 85745, United States|Genesis Cancer and Blood Institute, Hot Springs, Arkansas, 71913, United States|Genesis Cancer and Blood Institute,1456 Higdon Ferry Road Suite B., Hot Springs, Arkansas, 71914, United States|Saint Bernards Medical Center, Jonesboro, Arkansas, 72401, United States|Saint Bernards Medical Center,4000 Linwood Drive, Paragould, Arkansas, 72450, United States|University of California Los Angeles - Jonsson Comprehensive Cancer Center,201 S. Buena Vista Street, Suite 200, Burbank, California, 91505, United States|University of California Irvine Health Chao Family,1640 Newport Blvd, Costa Mesa, California, 92627, United States|City of Hope, Duarte, California, 91010, United States|University of California San Diego Moores Cancer, La Jolla, California, 92093, United States|University of California Los Angeles - Jonsson Comprehensive Cancer Center,24302 Paseo de Valencia, Suite 200, Laguna Hills, California, 91505, United States|Cancer and Blood Specialty Clinic, Los Alamitos, California, 90720, United States|City of Hope,1601 Avocado Ave, Newport, California, 92660, United States|University of California Irvine Health Chao Family, Orange, California, 92868, United States|City of Hope,209 Fair Oaks Ave, Pasadena, California, 91030, United States|University of California Los Angeles - Jonsson Comprehensive Cancer Center,892 Aerovista Place, Suite 240, San Luis Obispo, California, 93401, United States|Sansum Clinic, Santa Barbara, California, 93105, United States|University of California Los Angeles - Jonsson Comprehensive Cancer Center,2020 Santa Monica Blvd, Suite 600, Santa Monica, California, 90404, United States|University of California Los Angeles - Jonsson Comprehensive Cancer Center,2336 Santa Monica, Suites 302 and 304, Santa Monica, California, 90404, United States|University of California Los Angeles - Jonsson Comprehensive Cancer Center, Santa Monica, California, 90404, United States|St. Jude Hospital Yorba dba St. Joseph Heritage Healthcare, Santa Rosa, California, 95403, United States|Sansum Clinic,2040 Viborg Road, Solvang, California, 93463, United States|City of Hope,5215 Torrance Blvd, Torrance, California, 90503, United States|Torrance Memorial Physician Network - Cancer Care, Torrance, California, 90505, United States|City of Hope,1100 San Bernardino Rd, Upland, California, 91786, United States|University of California Los Angeles - Jonsson Comprehensive Cancer Center,1250 La Venta Dr, Suite 100, Westlake Village, California, 91361, United States|Rocky Mountain Cancer Centers,1700 South Potomac Street, Aurora, Colorado, 80012, United States|Rocky Mountain Cancer Centers, Boulder, Colorado, 80303, United States|Rocky Mountain Cancer Centers,2312 N. Nevada Avenue, Colorado Springs, Colorado, 80907, United States|Rocky Mountain Cancer Centers,6031 E. Woodman Rd., Colorado Springs, Colorado, 80923, United States|Rocky Mountain Cancer Centers,4700 E. Hale Parkway, Denver, Colorado, 80220, United States|Rocky Mountain Cancer Centers,11750 West 2nd Place, Lakewood, Colorado, 80228, United States|Rocky Mountain Cancer Centers,22 West Dry Creek Circle, Littleton, Colorado, 80120, United States|Rocky Mountain Cancer Centers,10107 Ridge Gate Parkway, Lone Tree, Colorado, 80124, United States|Rocky Mountain Cancer Centers,2030 Mountain View Ave Ste 210, Longmont, Colorado, 80124, United States|Rocky Mountain Cancer Centers,3676 Parker Blvd, Pueblo, Colorado, 81008, United States|Rocky Mountain Cancer Centers,525 W. 15th Street, Pueblo, Colorado, 81008, United States|Rocky Mountain Cancer Centers,8820 Huron Street, Thornton, Colorado, 80260, United States|Eastern Connecticut Hematology and Oncology Associates, Norwich, Connecticut, 06360, United States|Advent Health Medical Group, Altamonte Springs, Florida, 32701, United States|SCRI - Florida Cancer Specialists - North Region R,750 Orienta Ave, Altamonte Springs, Florida, 32701, United States|University of Miami - Sylvester Comprehensive Cancer Center,2801 NE 213th St, Aventura, Florida, 33180, United States|Florida Cancer Specialists,9776 Bonita Beach Road Southeast Suite 201 A, Bonita Springs, Florida, 34135, United States|Florida Cancer Specialists,3630 Manatee Avenue West, Bradenton, Florida, 34205, United States|Florida Cancer Specialists,5985 Silver Falls Run, Bradenton, Florida, 34211, United States|SCRI - Florida Cancer Specialists - North Region R,403 S. Kings Ave., Brandon, Florida, 33511, United States|Florida Cancer Specialists,1030 Commerce Creek Blvd, Cape Coral, Florida, 33909, United States|SCRI - Florida Cancer Specialists - North Region R,3280 McMullen Booth Road, Clearwater, Florida, 33761, United States|University of Miami - Sylvester Comprehensive Cancer Center,5555 Ponce De Leon Blvd, Coral Gables, Florida, 33146, United States|SCRI - Florida Cancer Specialists - West Palm Beach,224 Memorial Medical Parkway, Suite 300, Daytona Beach, Florida, 32117, United States|University of Miami - Sylvester Comprehensive Cancer Center,1192 East Newport Center Drive, Deerfield Beach, Florida, 33442, United States|Florida Cancer Specialists, Fort Myers, Florida, 33901, United States|Florida Cancer Specialists,8981 Colonial Center Drive, Fort Myers, Florida, 33905, United States|Florida Cancer Specialists,8260 Gladiolus Dr, Fort Myers, Florida, 33908, United States|SCRI - Florida Cancer Specialists - North Region R,6420 W. Newberry Road, Gainesville, Florida, 32605, United States|University of Miami - Sylvester Comprehensive Cancer Center,3850 Hollywood Blvd, Hollywood, Florida, 33021, United States|SCRI - Florida Cancer Specialists - North Region R,100 Highland Avenue, Largo, Florida, 33770, United States|SCRI - Florida Cancer Specialists - North Region R,521 North Lecanto Highway, Lecanto, Florida, 34461, United States|University of Miami - Sylvester Comprehensive Cancer Center,1400 NW 12th Ave, Miami, Florida, 33136, United States|University of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida, 33136, United States|University of Miami - Sylvester Comprehensive Cancer Center,8932 S.W. 97 Ave, Miami, Florida, 33176, United States|Florida Cancer Specialists,1100 Goodlette Road, Naples, Florida, 34102, United States|SCRI - Florida Cancer Specialists - North Region R,4945 SW 49th Place, Ocala, Florida, 34474, United States|SCRI - Florida Cancer Specialists - North Region R,2824 Enterprise Rd, Orange City, Florida, 32763, United States|Advent Health Medical Group,2501 North Orange Ave, Orlando, Florida, 32804, United States|SCRI - Florida Cancer Specialists - North Region R,70 W. Gore Street, Orlando, Florida, 32806, United States|University of Miami - Sylvester Comprehensive Cancer Center,8100 SW 10 Street, Plantation, Florida, 33324, United States|Florida Cancer Specialists,22395 Edgewater Drive, Port Charlotte, Florida, 33980, United States|SCRI - Florida Cancer Specialists - North Region R,1201 Fifth Avenue North, Saint Petersburg, Florida, 33705, United States|SCRI - Florida Cancer Specialists - North Region R, Saint Petersburg, Florida, 33705, United States|Florida Cancer Specialists,600 North Cattlemen Road, Sarasota, Florida, 34232, United States|Florida Cancer Specialists,1970 Golf Street, Sarasota, Florida, 34236, United States|SCRI - Florida Cancer Specialists - North Region R,7154 Medical Center Drive, Spring Hill, Florida, 34608, United States|SCRI - Florida Cancer Specialists - West Palm Beach,301 SE Ocean Blvd, Suite 102, Stuart, Florida, 34994, United States|SCRI - Florida Cancer Specialists - North Region R,3402 West Dr. Martin Luther King Jr. Boulevard, Tampa, Florida, 33607, United States|SCRI - Florida Cancer Specialists - North Region R,4100 Waterman Way, Tavares, Florida, 32778, United States|SCRI - Florida Cancer Specialists - North Region R,1400 US Highway 441 N, The Villages, Florida, 32159, United States|SCRI - Florida Cancer Specialists - North Region R,9320 State Road 54, Trinity, Florida, 34655, United States|Florida Cancer Specialists,836 Sunset Lake Blvd, Venice, Florida, 34292, United States|SCRI - Florida Cancer Specialists - West Palm Beach,3730 7th Terrace, Suite 101, Vero Beach, Florida, 32960, United States|SCRI - Florida Cancer Specialists - West Palm Beach,1037 S. State Road 7, Bldg B, Suite 303, Wellington, Florida, 33414, United States|SCRI - Florida Cancer Specialists - West Palm Beach, West Palm Beach, Florida, 33401, United States|SCRI - Florida Cancer Specialists - North Region R,460 N Orlando Ave, Winter Park, Florida, 32789, United States|Northside Hospital,125 King Avenue, Athens, Georgia, 30606, United States|Piedmont Cancer Institute - Atlanta,1267 Hwy 54W, Atlanta, Georgia, 30214, United States|Winship Cancer Institute of Emory University,550 Peachtree St NE, Atlanta, Georgia, 30308, United States|Piedmont Cancer Institute - Atlanta, Atlanta, Georgia, 30318, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, 30322, United States|Northside Hospital,5670 Peachtree Dunwoody Rd., Atlanta, Georgia, 30342, United States|Northside Hospital, Atlanta, Georgia, 30342, United States|Winship Cancer Institute of Emory University,5665 Peachtree Dunwoody Road, Atlanta, Georgia, 30342, United States|Northside Hospital,308 Deep South Farm Rd, Suite 200, Blairsville, Georgia, 30512, United States|Northside Hospital,228 Riverstone Dr., Canton, Georgia, 30114, United States|Northside Hospital,1505 Northside Blvd, Suite 4600, Cumming, Georgia, 30041, United States|Northside Hospital,3855 Pleasant Hill Rd., Suite 480, Duluth, Georgia, 30096, United States|Northside Hospital,308 Coliseum Dr., Macon, Georgia, 31217, United States|Piedmont Cancer Institute - Atlanta,775 Poplar Road, Newnan, Georgia, 30265, United States|Piedmont Cancer Institute - Atlanta,1240 Eagles Landing Pkwy, Stockbridge, Georgia, 30281, United States|Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, 60611, United States|University of Illinois Hospital and Health Sciences System (Outpatient Cancer Center), Chicago, Illinois, 60612, United States|Orchard Healthcare Research Inc,2845 North Sheridan Road, 1st Floor, Chicago, Illinois, 60657, United States|Robert H. Lurie Comprehensive Cancer Center of Northwestern University,1 Kish Hospital Drive, DeKalb, Illinois, 60115, United States|Robert H. Lurie Comprehensive Cancer Center of Northwestern University,10 Health Services Drive, DeKalb, Illinois, 60115, United States|Orchard Healthcare Research Inc,800 Austin Street, Suite 360, East Tower, Evanston, Illinois, 60202, United States|Robert H. Lurie Comprehensive Cancer Center of Northwestern University,300 Randall Road, Geneva, Illinois, 60134, United States|Robert H. Lurie Comprehensive Cancer Center of Northwestern University,304 Randall Road, Geneva, Illinois, 60134, United States|Robert H. Lurie Comprehensive Cancer Center of Northwestern University,1000 N. Westmoreland Road, Lake Forest, Illinois, 60045, United States|Orchard Healthcare Research Inc, Skokie, Illinois, 60077, United States|Robert H. Lurie Comprehensive Cancer Center of Northwestern University,4405 Weaver Parkway, Warrenville, Illinois, 25731, United States|Robert H. Lurie Comprehensive Cancer Center of Northwestern University,4455 Weaver Parkway, Warrenville, Illinois, 60555, United States|Robert H. Lurie Comprehensive Cancer Center of Northwestern University,25 N Winfield Road, Winfield, Illinois, 60190, United States|Regulatory Management Only: TRIO-US Central Administration, Fort Wayne, Indiana, 46845, United States|The University of Kansas Cancer Center,2000 Olathe Blvd, Kansas City, Kansas, 66160, United States|The University of Kansas Cancer Center,12200 W. 110th Street, Overland Park, Kansas, 66210, United States|The University of Kansas Cancer Center,10710 Nall Avenue, Overland Park, Kansas, 66211, United States|The University of Kansas Cancer Center,10730 Nall Avenue, Overland Park, Kansas, 66211, United States|The University of Kansas Cancer Center, Westwood, Kansas, 66205, United States|Norton Cancer Institute - Saint Matthews,234 E. Gray Strret, Louisville, Kentucky, 40202, United States|Norton Cancer Institute - Saint Matthews,676 S. Floyd Street, Louisville, Kentucky, 40202, United States|Norton Cancer Institute - Saint Matthews, Louisville, Kentucky, 40207, United States|Norton Cancer Institute - Saint Matthews,4955 Norton Healthcare Blvd, Louisville, Kentucky, 40241, United States|Hematology Oncology Clinic - Baton Rouge, Baton Rouge, Louisiana, 70809, United States|Hematology Oncology Clinic - Baton Rouge,1673 E Mount Please Drive, Zachary, Louisiana, 70791, United States|Cancer Institute Ascension Saint Agnes, Baltimore, Maryland, 21229, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Massachusetts General Hospital, Boston, Massachusetts, 02215, United States|Massachusetts General Hospital,102 Endicott Street, Danvers, Massachusetts, 01923, United States|Massachusetts General Hospital,2014 Washington St, Newton, Massachusetts, 02462, United States|University of Michigan, Ann Arbor, Michigan, 48109, United States|Ascension St. John Hospital, Grosse Pointe Woods, Michigan, 48236, United States|Ascension Providence Hospital Southfield Cancer Center, Southfield, Michigan, 48075, United States|Mayo Clinic, Rochester, Minnesota, 55905, United States|The West Clinic, PLLC dba West Cancer Center,7668 Airways Blvd, Southaven, Mississippi, 38671, United States|The University of Kansas Cancer Center,2750 Clay Edwards Drive, Kansas City, Missouri, 64116, United States|The University of Kansas Cancer Center,8700 North Green Hills Road, Kansas City, Missouri, 64154, United States|The University of Kansas Cancer Center,4881 N.E. Goodview Circle, Lee's Summit, Missouri, 64064, United States|Nebraska Cancer Specialists,2730 W. Faidley Ave, Grand Island, Nebraska, 68803, United States|Nebraska Cancer Specialists,8303 Dodge Street, Omaha, Nebraska, 68114, United States|Nebraska Cancer Specialists, Omaha, Nebraska, 68130, United States|Nebraska Cancer Specialists,611 Fenwick Dr, Papillion, Nebraska, 68046, United States|Comprehensive Cancer Centers of Nevada - Central V,10001 S. Eastern Avenue, Suite 108, Henderson, Nevada, 89052, United States|Comprehensive Cancer Centers of Nevada - Central V,2460 W. Horizon Ridge Parkway, Henderson, Nevada, 89052, United States|Comprehensive Cancer Centers of Nevada - Central V,1501 Wigwam Parkway, Suite 1300, Henderson, Nevada, 89074, United States|Comprehensive Cancer Centers of Nevada - Central V,653 North Town Center Drive, Suite 402, Las Vegas, Nevada, 89144, United States|Comprehensive Cancer Centers of Nevada - Central V,9280 W. Sunset Road Suite 100, Las Vegas, Nevada, 89148, United States|Comprehensive Cancer Centers of Nevada - Central V,7445 Peak Drive, Las Vegas, Nevada, 89169, United States|Comprehensive Cancer Centers of Nevada - Central V, Las Vegas, Nevada, 89169, United States|Summit Medical Group,1 Diamond Hill Road, Berkeley Heights, New Jersey, 07922, United States|Regional Cancer Care Associates - East Brunswick, East Brunswick, New Jersey, 08816, United States|Summit Medical Group, Florham Park, New Jersey, 07932, United States|John Theurer Cancer Center, Hackensack, New Jersey, 07601, United States|Rutgers Cancer Institute of New Jersey,2575 Klockner Road, Hamilton, New Jersey, 08690, United States|Rutgers Cancer Institute of New Jersey,414 Grand Street, Jersey City, New Jersey, 07302, United States|Rutgers Cancer Institute of New Jersey,600 River Avenue, Lakewood, New Jersey, 08701, United States|Rutgers Cancer Institute of New Jersey,94 Old Short Hills Road, Livingston, New Jersey, 07039, United States|Rutgers Cancer Institute of New Jersey,300 Second Ave, Long Branch, New Jersey, 07740, United States|Regional Cancer Care Associates - East Brunswick,9 Centre Drive, Monroe, New Jersey, 08831, United States|Regional Cancer Care Associates - East Brunswick,34-36 Progress Street, New Brunswick, New Jersey, 08820, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, 08901, United States|Rutgers Cancer Institute of New Jersey,150 Bergen St., Newark, New Jersey, 07103, United States|Rutgers Cancer Institute of New Jersey,201 Lyons Avenue, Newark, New Jersey, 07112, United States|Regional Cancer Care Associates - East Brunswick,75 Veronica Avenue, Somerset, New Jersey, 08873, United States|Rutgers Cancer Institute of New Jersey,110 Rehill Ave, Somerville, New Jersey, 08876, United States|Rutgers Cancer Institute of New Jersey,99 Highway 37 West, Toms River, New Jersey, 08755, United States|Rutgers Cancer Institute of New Jersey,100 State Route 36, West Long Branch, New Jersey, 07764, United States|New York Cancer & Blood Specialists - Port Jeffers,72 East Main St., Babylon, New York, 11702, United States|New York Cancer & Blood Specialists - Port Jeffers,12 East 86th St, Suite 4, Bronx, New York, 10028, United States|Montefiore Medical Center - Montefiore Medical Park, Bronx, New York, 10467, United States|New York Cancer & Blood Specialists - Port Jeffers,2330 Eastchester Road, Suite 360, Bronx, New York, 10469, United States|Perlmutter Cancer Center - Manhattan - 34th Street,259 First Street, Mineola, New York, 11501, United States|New York Cancer & Blood Specialists - Port Jeffers,1 Delaware Dr., New Hyde Park, New York, 11042, United States|Perlmutter Cancer Center - Manhattan - 34th Street, New York, New York, 10016, United States|NYP/Columbia Univeresity Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, 10032, United States|New York Cancer & Blood Specialists - Port Jeffers,365 East Main St., Patchogue, New York, 11772, United States|New York Cancer & Blood Specialists - Port Jeffers,49 Rte. 347, Newconset Hwy, Port Jefferson Station, New York, 11776, United States|New York Cancer & Blood Specialists - Port Jeffers, Port Jefferson Station, New York, 11776, United States|New York Cancer & Blood Specialists - Port Jeffers,1500 Rte, 112, Building 4, Port Jefferson, New York, 11776, United States|New York Cancer & Blood Specialists - Port Jeffers,750 Old County Rd. Suite 4, Riverhead, New York, 11901, United States|The Ohio State University Wexner Medical Center Clinical Laboratories, Columbus, Ohio, 43212, United States|Zangmeister Cancer Center, Columbus, Ohio, 43219, United States|Northwest Cancer Specialists, PC,5050 NE Hoyt St., Portland, Oregon, 97213, United States|Northwest Cancer Specialists, PC,265 N. Broadway, Portland, Oregon, 97227, United States|Northwest Cancer Specialists, PC, Tigard, Oregon, 97223, United States|Magee-Womens Hospital of UPMC,200 Oxford Drive, Bethel Park, Pennsylvania, 15102, United States|Magee-Womens Hospital of UPMC,3 St. Francis Way, Cranberry Township, Pennsylvania, 16066, United States|Magee-Womens Hospital of UPMC,2500 West 12th Street, Erie, Pennsylvania, 16505, United States|Magee-Womens Hospital of UPMC,201 State Street, 6 Main, Erie, Pennsylvania, 16550, United States|Magee-Womens Hospital of UPMC,200 Village Drive, Greensburg, Pennsylvania, 15601, United States|Magee-Womens Hospital of UPMC,400 Oxford Drive, Monroeville, Pennsylvania, 15146, United States|University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, 19104, United States|Magee-Womens Hospital of UPMC,300 Halket Street, Pittsburgh, Pennsylvania, 15213, United States|Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, 15213, United States|Magee-Womens Hospital of UPMC,5115 Centre Avenue, Pittsburgh, Pennsylvania, 15232, United States|Magee-Womens Hospital of UPMC,9100 Babcock Boulevard, Pittsburgh, Pennsylvania, 15237, United States|Magee-Womens Hospital of UPMC,100 Fairfield Dr, Seneca, Pennsylvania, 16346, United States|Magee-Womens Hospital of UPMC,470 Johnson Road, Washington, Pennsylvania, 15301, United States|Magee-Womens Hospital of UPMC,1703 Innovation Drive, York, Pennsylvania, 17408, United States|Rhode Island Hospital, Providence, Rhode Island, 02903, United States|Rhode Island Hospital,164 Summit Ave, Fain 275A, Providence, Rhode Island, 02906, United States|Tennessee Oncology, PLLC,103 Natchez Park Drive, Dickson, Tennessee, 37055, United States|Tennessee Oncology, PLLC,4488 Carothers Parkway, Franklin, Tennessee, 37067, United States|Tennessee Oncology, PLLC,225 Big Station Camp Blvd, Gallatin, Tennessee, 37066, United States|The West Clinic, PLLC dba West Cancer Center, Germantown, Tennessee, 38138, United States|Tennessee Oncology, PLLC,353 New Shackle Island Road, Hendersonville, Tennessee, 37075, United States|Tennessee Oncology, PLLC,5653 First Blvd., Hermitage, Tennessee, 37076, United States|Tennessee Oncology, PLLC,103 Physicians Way, Lebanon, Tennessee, 37090, United States|Tennessee Oncology, PLLC,1840 Medical Center Parkway, Murfreesboro, Tennessee, 37129, United States|Tennessee Oncology, PLLC,2004 Hayes Street, Nashville, Tennessee, 37203, United States|Tennessee Oncology, PLLC,SCRI Oncology Partners, Nashville, Tennessee, 37203, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, 37203, United States|Tennessee Oncology, PLLC,4220 Harding Rd, Nashville, Tennessee, 37205, United States|Tennessee Oncology, PLLC,3443 Dickerson Road, Nashville, Tennessee, 37207, United States|Tennessee Oncology, PLLC,397 Wallace Road, Nashville, Tennessee, 37211, United States|Tennessee Oncology, PLLC,120 Frank Martin Road, Shelbyville, Tennessee, 37160, United States|Tennessee Oncology, PLLC,300 Stonecrest Blvd, Smyrna, Tennessee, 37167, United States|The Center for Cancer and Blood Disorders - Magnolia,515 W. Mayfield Rd., Arlington, Texas, 76104, United States|Texas Oncology-Austin,901 West 38th Street, Austin, Texas, 78705, United States|Texas Oncology-Austin, Austin, Texas, 78731, United States|Texas Oncology-Austin,4101 James Casey, Suite 100, Austin, Texas, 78745, United States|The Center for Cancer and Blood Disorders - Magnolia,11805 South Freeway, Burleson, Texas, 76028, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, 75246, United States|Texas Oncology-Denison, Denison, Texas, 75020, United States|The Center for Cancer and Blood Disorders - Magnolia, Fort Worth, Texas, 76104, United States|Oncology Consultants,1631 North Loop West, Houston, Texas, 77008, United States|Oncology Consultants,925 Gessner, Houston, Texas, 77024, United States|Oncology Consultants, Houston, Texas, 77030, United States|University of Texas MD Anderson Cancer Center,1155 Pressler St, Houston, Texas, 77030, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|Mays Cancer Center, San Antonio, Texas, 78229, United States|The Center for Cancer and Blood Disorders - Magnolia,920 Santa Fe Drive, Weatherford, Texas, 76086, United States|Huntsman Cancer Institute, University of Utah,165 North University Avenue, Farmington, Utah, 84025, United States|Huntsman Cancer Institute, University of Utah,1280 E. Stringham Avenue, Salt Lake City, Utah, 84106, United States|Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, 84112, United States|Huntsman Cancer Institute, University of Utah,5126 West Daybreak Parkway, South Jordan, Utah, 84009, United States|Virginia Oncology Associates,744 N. Battlefield Blvd, Chesapeake, Virginia, 23320, United States|Virginia Cancer Institute,7501 Right Flank Road, Mechanicsville, Virginia, 23116, United States|Virginia Oncology Associates,1051 Loftis Blvd Suite 100, Newport News, Virginia, 23606, United States|Virginia Oncology Associates, Norfolk, Virginia, 23502, United States|Virginia Cancer Institute,210 Medical Park Boulevard, Petersburg, Virginia, 23805, United States|Virginia Cancer Institute,1401 Johnston-Willis Drive, Richmond, Virginia, 23235, United States|Virginia Cancer Institute, Richmond, Virginia, 23298, United States|Virginia Oncology Associates,1950 Glenn Mitchell Drive, Virginia Beach, Virginia, 23456, United States|Northwest Cancer Specialists, PC,210 SE 136th Avenue, Vancouver, Washington, 98684, United States|Hospital BritÃ¡nico de Buenos Aires, Buenos Aires, 1426, Argentina|Instituto de OncologÃ­a Ãngel H. Roffo, Caba, 1417, Argentina|Fundacion CORI para la Investigacioy y PrevenciÃ³n del Cancer, Capital, F5300COE, Argentina|Instituto de Oncologia de Rosario, Rosario, 2000, Argentina|CAIPO Centro Para La AtenciÃ³n Integral Del Pacient, San Miguel de TucumÃ¡n, 4000, Argentina|Clinica Viedma, Viedma, 8500, Argentina|Border Medical Oncology, Albury, New South Wales, 2640, Australia|Saint George Hospital - Australia, Kogarah, New South Wales, 2217, Australia|Mater Hospital - North Sydney, North Sydney, New South Wales, 2060, Australia|GenesisCare - North Shore, St Leonards, New South Wales, 2065, Australia|Mater Misericordiae Limited and Mater Research Limited, South Brisbane, Queensland, 4101, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, 4102, Australia|Cancer Research SA (CRSA), Adelaide, South Australia, 5000, Australia|Icon Cancer Centre Hobart, Hobart, Tasmania, 7000, Australia|Monash Medical Centre, Clayton, Victoria, 3168, Australia|Austin Hospital, Melbourne, Victoria, 3084, Australia|Peter MacCallum Cancer Centre, Parkville, Victoria, 3050, Australia|Breast Cancer Research Center - Western Australia, Nedlands, Western Australia, 6009, Australia|Medizinische UniversitÃ¤t Innsbruck, Innsbruck, 06020, Austria|Ordensklinikum Linz GmbH Barmherzige Schwestern, Linz, 4010, Austria|Landeskrankenhaus Salzburg, Salzburg, A-5020, Austria|UniversitÃ¤tsklinikum Sankt PÃ¶lten, Sankt Poelten, 3100, Austria|Medizinische UniversitÃ¤t Wien, Wien, 1090, Austria|Institut Jules Bordet, Anderlecht, 1070, Belgium|Algemeen Ziekenhuis Klina, Brasschaat, 2930, Belgium|Cliniques Universitaires Saint-Luc, Brussels, 1200, Belgium|Universitair Ziekenhuis Brussel, Brussels, Belgium|Grand Hopital de Charleroi - Notre Dame, Charleroi, 6000, Belgium|Universitair Ziekenhuis Gent, Gent, 9000, Belgium|UZ Leuven, Leuven, 3000, Belgium|Centre Hospitalier Universitaire UniversitÃ© Cathol, Namur, 5000, Belgium|Hospital AraÃºjo Jorge - Associacao de Combate ao Cancer em Goias - ACCG, GoiÃ¢nia, 74605-070, Brazil|Centro de Pesquisa Clinica Em Oncologia - ONCOSITE, Ijui, 98700-000, Brazil|Hospital de Clinicas de Porto Alegre - HCPA, Itajai, 88301-220, Brazil|Centro de Pesquisas Clinicas da Fundacao Doutor Amaral Carvalho - Hospital Amarval Carvalho, Jau, 17210080, Brazil|Associacao Hosptialar Moinos de Vento - Hospital Moinhos de Vento, Porto Alegre, 90035-00, Brazil|Hospital de ClÃ­nicas de Porto Alegre, Porto Alegre, 90035-903, Brazil|Hospital Sao Lucas da PUCRS, Porto Alegre, 90610001, Brazil|Instituto Nacional de CÃ¢ncer - Brazil, Rio de Janeiro, Brazil|NÃºcleo de Oncologia da Bahia, Salvador, 40170170, Brazil|CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia - Centro UniversitÃ¡rio FMABC, Santo Andre, 09060-650, Brazil|Real e Benemerita Associacao Portuguesa de Beneficencia - Hospital Beneficencia Portuguesa (BP) - Unidade Paulista, SÃ£o Paulo, 01323-001, Brazil|Clinica de Pesquisas e Centro de Estudos em Oncolo, SÃ£o Paulo, 1317000, Brazil|FundaÃ§Ã£o Pio XII - Hospital de CÃ¢ncer de Barretos, SÃ£o Paulo, 14784400, Brazil|Nucleo de Pesquisa Clinica da Rede Sao Camilo, SÃ£o Paulo, 4014002, Brazil|Tom Baker Cancer Centre, Calgary, T2N 5G2, Canada|Cross Cancer Institute, Edmonton, T6G 1Z2, Canada|QEII Health Sciences Centre, Halifax, B3H 1V7, Canada|Grand River Regional Cancer Centre at Grand River Hospital, Kitchener, N2G 1G3, Canada|London Health Sciences Centre, London, N6A 5W9, Canada|McGill University Health Centre, Montreal, H4A 3J1, Canada|Jewish General Hospital, MontrÃ©al, H3T 1E2, Canada|Princess Margaret Cancer Centre - University Health Network, Ontario, M5G 2M9, Canada|Ottawa Hospital - General Campus, Ottawa, K1H 8L6, Canada|Sunnybrook Research Institute, Toronto, M4N 3M5, Canada|Mount Sinai Hospital, Toronto, M5G 1X5, Canada|British Columbia Cancer - Vancouver, Vancouver, V5Z 4E6, Canada|Oncovida - Santiago, Providencia, 7510035, Chile|ClÃ­nica IRAM, Santiago DE CHILE, Chile|Centro de Cancer Pontificia Universidad Catolica, Santiago Region, 8330032, Chile|ClÃ­nica Alemana, Santiago, 7630000, Chile|James Lind Centro de Investigacion del Cancer, Temuco, Chile|Masarykuv Onkologicky Ustav, Klinika Komplexni Onkologicke Pece, Brno, 65653, Czechia|FakultnÃ­ Thomayerova nemocnice, Hradec Kralove, 50005, Czechia|FakultnÃ­ Nemocnice Hradec KrÃ¡lovÃ©, Hradec KrÃ¡lovÃ©, 500 05, Czechia|Fakultni nemocnice Olomouc, Onkologicka klinika, Olomouc, 77520, Czechia|Vseobecna Fakultni Nemocnice v Praze, Onkologicka klinika, Prague, 12808, Czechia|FakultnÃ­ Nemocnice KrÃ¡lovskÃ© Vinohrady, Radioterapeuticka a onkologicka klinika, Praha, 100 34, Czechia|Sainte Catherine Institut du Cancer Avignon Provence, Avignon, 84918, France|Centre Hospitalier RÃ©gional et Universitaire de Be, Besancon, 25030, France|Polyclinique Bordeaux Nord Aquitaine, Bordeaux, 33000, France|HÃ´pital Morvan, Institut de cancÃ©rologie, Brest, 29200, France|Centre de Lutte contre le Cancer - FranÃ§ois Bacles, Caen, 14000, France|Centre Jean Perrin, Clermont Ferrand, 63011, France|Centre Leon Berard, Lyon, 69373, France|Institut Paoli-Calmettes, Marseille CEDEX 9, 13273, France|Institut RÃ©gional du Cancer de Montpellier, Montpellier Cedex 5, 34298, France|Centre de CancÃ©rologie du Grand Montpellier, Montpellier, 34070, France|HÃ´pital PrivÃ© du Confluent, Nantes, 44202, France|Hospices Civils de Lyon, HÃ´pital Lyon Sud, Pierre-Benite, 69495, France|Centre Armoricain de RadiothÃ©rapie, dImagerie MÃ©d, Plerin, 22190, France|Centre EugÃ¨ne Marquis, Rennes Cedex, 35042, France|Institut Claudius Regaud - IUCT-O, Toulouse, France|Institut Gustave Roussy, Villejuif, 94800, France|Helios Klinikum Berlin-Buch, Berlin, 13125, Germany|: Gynakologisches Zentrum Bonn, Schwerpunkt Gyn. Onkologie,, Bonn, 53111, Germany|Marienhospital Bottrop, Bottrop, 46236, Germany|UniversitÃ¤tsklinikum Erlangen, Frauen klinik, Erlangen, 91054, Germany|Kliniken Essen-Mitte - Evangelische Huyssens-Stift, Essen, 45136, Germany|Praxis fÃ¼r interdisziplinÃ¤re Onkologie & HÃ¤matolog, Freiburg, 79110, Germany|: UniversitÃ¤tsklinikum Hamburg-Eppendorf, Hamburg, 20246, Germany|Facharztzentrum Eppendorf, Hamburg, 20249, Germany|Nationales Centrum fÃ¼r Tumorerkrankungen, Heidelberg, 69120, Germany|Klinik Frauenheilkunde, Uniklinik ClO, Studienzentrale, KÃ¶ln, 50937, Germany|UniversitÃ¤tsklinikum Schleswig-Holstein Institut fur Klinische Chermie, LÃ¼beck, 23538, Germany|Universitatsklinikum Mannheim GmBH, Frauenklinik, Mannheim, 68167, Germany|UniversitÃ¤tsklinikum MÃ¼nster, Bereich Senologie an der klinik fur Frauenheilkunde und Gerburtschilfe, Munster, 48149, Germany|EV. Krankenhaus Bethesda - Johanniter GmbH, Station 1 Brustzentrum Niederrhein, MÃ¶nchengladbach, 41061, Germany|Rotkreuzklinikum Munchen Frauenklinik, MÃ¼nchen, 80637, Germany|Klinik und Poliklinik fÃ¼r Frauenheilkunde, MÃ¼nchen, 81675, Germany|Universitatsklinikum Tubingen, TÃ¼bingen, 72076, Germany|St. Josefs-Hospital Wiesbaden GmbH, Gynakologie und Geburtshilfe, Wiesbaden, 65189, Germany|Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong|Hong Kong Sanatorium and Hospital, Hong Kong, Hong Kong|Tuen Mun Hospital, Hong Kong, Hong Kong|Prince of Wales Hospital - Hong Kong, New Territories, Hong Kong|Orszagos Onkologiai Intezet, Budapest, 1122, Hungary|Uzsoki Utcai KÃ³rhÃ¡z, Budapest, 1145, Hungary|Debreceni Egyetem Klinikai KÃ¶zpont, Debrecen, 4032, Hungary|Petz AladÃ¡r Egyetemi OktatÃ³ KÃ³rhÃ¡z - Gy?r, Gyor, 9024, Hungary|Soroka Medical Center, Beer-Sheva, 8410101, Israel|Rambam Health Care Campus, Haifa, 3109601, Israel|Shaare Zedek Medical Center, Jerusalem, 9103102, Israel|Hadassah - Hebrew University Medical Center, Jerusalem, Israel|Meir Medical Center, Kfar Saba, 4428164, Israel|Rabin Medical Center, Petah Tikva, 4941492, Israel|Kaplan Medical Center, Rehovot, 7661041, Israel|Sheba Medical Center Hospital - Tel Hashomer, Tel Aviv, 52621, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, 64239, Israel|IRCCS Istituto Tumori ""Giovanni Paolo II"", Bari, 70124, Italy|SSD Oncologia Medica Addarii-Zamagni, IRCSS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola, Bologna, Italy|UO Oncologia, ASST degli Spedali Civili di Brescia, Brescia, 25123, Italy|IRCCS Ospedale Policlinico San Martino, Genova GE, 16132, Italy|S.C. Oncologia medica, ASST di Lecco, Lecco, 23900, Italy|Presidio Ospedaliero di Lucca, Lucca, 55100, Italy|Ospedale Generale Provinciale - Macerata, Macerata, 62100, Italy|Ospedale San Raffaele, Milano, 20132, Italy|Fondazione IRCCS - Istituto Nazionale dei Tumori, Milano, 20133, Italy|Istituto Europeo di Oncologia, Milan, 20141, Italy|Centro Ricerca Fase I, Fondazione IRCSS San Gerado dei Tintori, Monza, 20090, Italy|AOU ""Luigi Vanvitelli"", Napoli, 80131, Italy|Oncologia Medica Senologica Sperimentale - Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, 80131, Italy|AOU Maggiore della Carita, Novara, 28100, Italy|Istituto Oncologico Veneto - IRCCS, Padova, 35128, Italy|S.O.C Oncologia Medica, Nuovo Ospedale di Prato Santo Stefano, Prato, 59100, Italy|Policlinico di Roma, Roma, 00161, Italy|Fondazione Policlinico Universitario Agostino Geme, Rome, 00168, Italy|Azienda Ospedaliera Universitaria Senese - Losped, Siena, 53100, Italy|Aichi Cancer Center Hospital, Aichi, 464-8681, Japan|Tohoku University Hospital, Aoba-ku, 980-8574, Japan|Juntendo University Hospital, Bunkyo-ku, 113-8431, Japan|Chiba Cancer Center, Chuo-ku, 260-8717, Japan|Osaka Prefectural Hospital Organization Osaka International Cancer Institute, Chuo-ku, 541-8567, Japan|NHO Shikoku Cancer Center, Ehime, 791-0280, Japan|Fukushima Medical University Hospital, Fukushima, Japan|Saitama Cancer Center, Inamachi, 362-0806, Japan|Hakuaikai Sagara Hospital, Kagoshima-shi, 892-0833, Japan|Tokai University Hospital, Kanagawa, 259-1193, Japan|National Cancer Center Hospital East, Kashiwa, 277-8577, Japan|The Cancer Institute Hospital of JFCR, Koto-ku, 135-8550, Japan|Kumamoto University Hospital, Kumamoto- shi, 860-8556, Japan|Kure Medical Center And Chugoku Cancer Center, Kure, 737-0023, Japan|Mie University Hospital, Mie, 514-8507, Japan|Nagoya University Hospital, Nagoya, 466-8560, Japan|Nagoya City University Hospital, Nagoya, 467-8602, Japan|Hiroshima City Hiroshima Citizens Hospital, Naka-ku, 730-8518, Japan|NIigata Cancer Center Hospital, Niigata-shi, 951-8566, Japan|Okayama University Hospital, Okayama, 700-8558, Japan|Gunma Prefectural Cancer Center, Ota, 373-8550, Japan|Kyoto University Hospital, Sakyo-ku, 606-8507, Japan|Hokkaido Cancer Center, Sapporo, 003-0804, Japan|Shizuoka General Hospital, Shizuoka-city, 420-8527, Japan|Shizuoka Cancer Center, Shizuoka, 411-8777, Japan|Osaka University Hospital, Suita, 565-0871, Japan|Showa University Hospital, Tokyo, 142-8555, Japan|Kanagawa Cancer Center, Yokohama, 241-8515, Japan|National Cancer Center - Korea, Goyang-si Gyeonggi-do, 10408, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, 13620, Korea, Republic of|Severance Hospital, Seoul, 03722, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|Korea University Anam Hospital, Seoul, 2841, Korea, Republic of|Seoul National University Hospital, Seoul, 3080, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, 6591, Korea, Republic of|Hospital Pulau Pinang, Georgetown, 10450, Malaysia|Hospital Sultan Ismail, Johor Bahru, 81100, Malaysia|Hospital Kuala Lumpur, Kuala Lumpur, 47500, Malaysia|Pantai Hospital Kuala Lumpur, Kuala Lumpur, 59100, Malaysia|University Malaya Medical Centre (UMMC), Kuala Lumpur, 59100, Malaysia|Institut Kanser Negara, Putrajaya, 62250, Malaysia|Hospital Wanita dan Kanak-Kanak Sabah, Sabah, 88996, Malaysia|Sarawak General Hospital, Sarawak, 93586, Malaysia|Icaro Investigaciones en Medicina S.A. de C.V., Chihuahua, 31000, Mexico|Cryptex InvestigaciÃ³n ClÃ­nica, Ciudad de Mexico, 06100, Mexico|Centro para el Desarrollo de la Medicina, Culiacan, 80230, Mexico|Panamerican Clinical Research Mexico - Guadalajara, Guadalajara, 44670, Mexico|Medical Care and Research S.A. de C.V, Merida, 97070, Mexico|Avix Investigacion Clinica S.C., Monterrey, 64710, Mexico|Fucam A.C., MÃ©xico, 4980, Mexico|OncolÃ³gico Potosino, San Luis Potosi, 78209, Mexico|FAICIC ClÃ­nical Research, Veracruz, 91900, Mexico|iBiomed - Investigacion Biomedica para el Desarrol, Zapopan, 45070, Mexico|Amphia Ziekenhuis - Breda Langendijk, Breda, 4818 CK, Netherlands|Universitair Medisch Centrum Groningen, Groningen, 9700 RB, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, 8934 AD, Netherlands|Erasmus Medisch Centrum, Rotterdam, Netherlands|Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii, Gdansk, 80-952, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej, Gliwice, 44-102, Poland|SP ZOZ Opolskie Centrum Onkologii im. prof. Tadeusza Koszarowskiego, Opole, 45-061, Poland|Wielkopolskie Centrum Onkologii im. Marii Sklodowskiej-Curie, Poznan, 61- 866, Poland|Mazowiecki Szpital WojewÃ³dzki im. w. Jana Pawa II w, Siedlce, 08-110, Poland|Wojskowy Instytut Medyczny, Warsaw, 04-141, Poland|Narodowy Instytut Onkologii im.Marii Marii Sklodowskiejs, Warszawa, 02-781, Poland|Ponce Medical School Foundation Inc., Ponce, 00716, Puerto Rico|Hopelands Cancer Centre, Hilton, 3245, South Africa|The Medical Oncology Centre of Rosebank, Johannesburg, 2196, South Africa|University of Pretoria, Pretoria, 0002, South Africa|Hospital Teresa Herrera - Materno Infantil, A CoruÃ±a, 15006, Spain|Hospital Universitari Dexeus, Barcelona, 08028, Spain|Hospital Clinic Barcelona, Barcelona, 08036, Spain|Hospital ClÃ­nic de Barcelona, Barcelona, 08036, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, 8023, Spain|Hospital Universitari Vall d'HebrÃ³n, Barcelona, 8035, Spain|Hospital Universitario de Basurto, Bilbo, 48013, Spain|Hospital Universitari Arnau de Vilanova, Lleida, 25198, Spain|Hospital General Universitario Gregorio MaraÃ±Ã³n, Madrid, 28007, Spain|MD Anderson Cancer Centre Madrid, Madrid, 28033, Spain|Hospital Universitario FundaciÃ³n JimÃ©nez DÃ­az, Madrid, 28040, Spain|Hospital Universitario Virgen de la Victoria, Malaga, 29010, Spain|Hospital General Universitario Morales Meseguer, Murcia, 30008, Spain|Hospital Unviersitario Virgen del Rocio, Sevilla, 41013, Spain|Hospital Universitario Virgen Macarena, Sevilla, 41071, Spain|Hospital Universitario de Canarias, Tenerife, 38320, Spain|Hospital ClÃ­nico Universitario de Valencia, Valencia, 46010, Spain|Kantonsspital Baden, Baden, 5404, Switzerland|Kantonsspital Baselland - Standort Liestal, Liestal, 4410, Switzerland|Kantonsspital Sankt Gallen, St. Gallen, 9007, Switzerland|Kantonsspital Winterthur, Winterthur, 8401, Switzerland|Brust-Zentrum Zurich, ZÃ¼rich, 8008, Switzerland|Changhua Christian Hospital, Changhua, 50006, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, 807, Taiwan|Taipei Medical University-Shuang Ho Hospital, New Taipei City, 235, Taiwan|Chi Mei Hospital, Liouying, Tainan City, 73657, Taiwan|National Cheng Kung University Hospital, Tainan, 704, Taiwan|Taipei Veterans General Hospital, Taipei City, 11217, Taiwan|National Taiwan University Hospital, Taipei, 100, Taiwan|Linkou Chang Gung Memorial Hospital, Taoyuan, 333, Taiwan|Baskent Uni. Dr Turgut Noyan Uyg. ve Aras. Merkezi, Adana, 1120, Turkey|Ankara Il Saglik Mudurlugu SBU Gulhane Egitim Ve A, Ankara, 6010, Turkey|Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, 6200, Turkey|Memorial Ankara Hastanesi, Ankara, 6520, Turkey|Hacettepe Ãniversitesi Hastanesi, Ankara, Turkey|Trakya Universitesi Tip Fakultesi Hastanesi, Edirne, 22030, Turkey|Istanbul Il Saglik Mudurlugu Goztepe Prof. Dr. Sul, Istanbul, 34000, Turkey|Medipol Mega Universite Hastanesi, Istanbul, 34214, Turkey|Ege Universitesi Hastanesi, Izmir, 35100, Turkey|Medicana International Izmir Hastanesi, Ä°zmir, 35575, Turkey|Acibadem Maslak Hastanesi, Sariyer, Turkey|VKV Amerikan Hastanesi, Sisli, 34365, Turkey|NHS Lothian, Edinburgh, EH4 2XU, United Kingdom|Clinical Trials Unit Lvl 0 Cancer Research UK Beatson Institute, Glasgow, G12 0YN, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, LS9 7TF, United Kingdom|: Barts Health NHS Trust, St Hospital, London, EC1M 6BQ, United Kingdom|Royal Free London NHS Foundation Trust, London, NW2 2QG, United Kingdom|Guy's and Saint Thomas' NHS Foundation Trust, London, SE1 9RT, United Kingdom|University College London Hospitals, London, WC1E 6BT, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, NG5 1PB, United Kingdom",
NCT05623020,"A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135), Daratumumab, Lenalidomide or Elranatamab and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant",https://clinicaltrials.gov/study/NCT05623020,MagnetisMM-6,RECRUITING,"Elranatamab is a bispecific antibody: binding of elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity. The main purpose of the study is to evaluate if the combination of Elranatamab, Daratumumab and Lenalidomide or Elranatamab and Lenalidomide offers superior clinical benefit compared with the combination of Daratumumab, Lenalidomide and Dexamethasone in people with multiple myeloma.

There are 2 parts to this study. Part 1 will characterize the safety and tolerability of elranatamab in combination with daratumumab and lenalidomide or in combination with lenalidomide and will identify the optimal dose(s) of the combination regimen. Part 2 of the study will evaluate the minimal residual disease (MRD) negativity rate and the progression free survival (PFS) of the combination of elranatamab, daratumumab, and lenalidomide or elranatamab and lenalidomide compared with the combination of daratumumab, lenalidomide, and dexamethasone in participants with newly diagnosed transplant-ineligible multiple myeloma.",NO,Multiple Myeloma,DRUG: Elranatamab|DRUG: Daratumumab|DRUG: Lenalidomide|DRUG: Dexamethasone,"Part 1 Dose Limiting Toxicity, From the first dose of elranatamab/first full dose in combination with EDR until 28 days (+/- visit window) from the first administration of elranatamab with daratumumab and lenalidomide|Part 2: Progression free survival by blinded independent central review, From randomization up to 79 months.|Part 2: Minimal Residual Disease negativity rate, At 12 months after randomization","Overall Survival, From date of randomization up to 79 months|Overall minimal residual disease negativity rate, From date of randomization up to 79 months|Sustained MRD negativity rate (Part 2), From date of randomization up to 79 months|Duration of minimal residual disease negativity (Part 2), From date of minimal residual disease negative status up to 79 months|PFS by investigator, From date of randomization up to 79 months|PFS2 by investigator (Part 2), From the date of randomization up to 79 months|Objective Response Rate, From the date of randomization up to 79 months|Complete Response Rate, From the date of randomization up to 79 months|Time to Response, From the date of randomization to date of confirmed objective response up to 79 months|Duration of Response, From the date of confirmed objective response up to 79 months|Duration of Complete Response, From the date of confirmed complete response up to 79 months|Frequency of treatment-emergent adverse events, From the date of first dose of study intervention up to 79 months|Frequency of abnormal laboratory results, From the date of first dose of study intervention up to 79 months|Pharmacokinetics of elranatamab when used in the elranatamab + daratumumab + lenalidomide or elranatamab + lenalidomide combinations, Predose and post dose concentrations of elranatamab, From date of first dose of study intervention up to 79 months|Incidence of Anti-Drug Antibody and Neutralizing Antibody against elranatamab, Immunogenicity of elranatamab, From date of first dose of study intervention up to 79 months|Pharmacokinetics of daratumumab and lenalidomide when used in the elranatamab+daratumumab+lenalidomide or elranatamab+lenalidomide combinations (Part 1), Predose concentrations of daratumumab and lenalidomide, From date of first dose of study intervention up to 79 months|Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (Part 2), Higher scores on the functional scales represent higher levels of functioning. Higher scores on the global health status/quality of life scale represent higher health status/quality of life. Higher scores on the symptom scales/items represent a greater presence of symptoms., From date the informed consent is signed up to 79 months|Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire -Myeloma 20 (Part 2), Higher scores on the functioning subscales (body image, future perspective) represent higher levels of functioning, whereas higher scores on the symptom subscales (disease symptoms, side effects) represent a greater presence of symptoms, From date the informed consent is signed up to 79 months",,Pfizer,,ALL,"ADULT, OLDER_ADULT",PHASE3,966,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-11-10,2028-03-31,2031-11-29,2022-11-21,,2025-06-10,"Pindara Private Hospital, Benowa, Queensland, 4217, Australia|St Vincent's Hospital Melbourne, Fitzroy, Victoria, 3065, Australia|Epworth Freemasons, Melbourne, Victoria, 3002, Australia|The Alfred Hospital, Melbourne, Victoria, 3004, Australia|QEII Health Sciences Centre, Halifax, Nova Scotia, B3H 2Y9, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, M5G 2M9, Canada|FakultnÃ­ nemocnice Brno Bohunice, Brno, Brno-mÄsto, 625 00, Czechia|Fakultni nemocnice Ostrava, Ostrava, MoravskoslezskÃ½ KRAJ, 708 52, Czechia|Fakultni nemocnice Olomouc, Olomouc, 779 00, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, 12808, Czechia|Institut Universitaire du Cancer Toulouse - Oncopole - CHU de TOULOUSE, Toulouse, Haute-garonne, 31100, France|Centre Hospitalier Universitaire de Poitiers, Poitiers, Vienne, 86021, France|Centre Hospitalier Universitaire de Nantes - L' Hopital l'hÃ´tel-Dieu, Nantes, 44093 Cedex 1, France|Universitaetsklinikum Tuebingen, TÃ¼bingen, Baden-wÃ¼rttemberg, 72076, Germany|Klinikum Chemnitz, Chemnitz, 09116, Germany|Evangelismos General Hospital of Athens, Athens, AttikÃ­, 106 76, Greece|Alexandra General Hospital of Athens, Athens, AttikÃ­, 115 28, Greece|University Hospital of Ioannina, Ioannina, Ãpeiros, 455 00, Greece|Soroka Medical Center, Be'er Sheva, Hadarom, 8410101, Israel|Rabin Medical Center, Petah-Tikva, Hamerkaz, 4910021, Israel|The Edmond and Lily Safra Children's Hospital The Chaim Sheba Medical Center Department of Pediatric, Ramat Gan, Hamerkaz, 5265601, Israel|Sourasky Medical Center, Tel Aviv, Tell AbÄ«b, 6423906, Israel|Hadassah Medical Center, Jerusalem, Yerushalayim, 9112001, Israel|AUSL di Piacenza, Piacenza, Emilia-romagna, 29121, Italy|Ospedale Santa Maria delle Croci, Ravenna, Emilia-romagna, 48121, Italy|IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, 71013, Italy|Cro-Irccs, Aviano, Friuli-venezia Giulia, 33081, Italy|Fondazione IRCCS San Gerardo dei Tintori, Monza, Lombardia, 20900, Italy|Azienda Ospedaliero-Universitaria CittÃ  della Salute e della Scienza di Torino, Torino, Piemonte, 10126, Italy|A.O.U. Policlinico Paolo Giaccone, Palermo, Sicilia, 90127, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, Toscana, 56126, Italy|Istituto Europeo di Oncologia IRCCS, Milano, 20141, Italy|ASL PESCARA-Presidio Ospedaliero Pescara, Pescara, 65124, Italy|AOU Policlinico Umberto I, Roma, 00161, Italy|University of Fukui Hospital, Yoshida-gun, Fukui, 910-1193, Japan|Gunma University Hospital, Maebashi, Gunma, 371-8511, Japan|Iwate Medical University Hospital, Yahaba-cho, Iwate, 028-3695, Japan|Tohoku University Hospital, Sendai, Miyagi, 980-8574, Japan|Shizuoka Cancer Center, Nagaizumi-cho, Shizuoka, 411-8777, Japan|Japanese Red Cross Medical Center, Shibuya-ku, Tokyo, 150-8935, Japan|Kyushu University Hospital, Fukuoka, 812-8582, Japan|National Hospital Organization Okayama Medical Center, Okayama, 701-1192, Japan|Osaka Metropolitan University Hospital, Osaka, 545-0051, Japan|Yamagata University Hospital, Yamagata, 990-9585, Japan|Gachon University Gil Medical Center, Namdong-gu, Incheon-gwangyeoksi [incheon], 21565, Korea, Republic of|Chonnam National University Hwasun Hospital, Hwasun-gun, Jeonranamdo, 58128, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, KyÇnggi-do, 13620, Korea, Republic of|Seoul National University Hospital, Seoul, Seoul-teukbyeolsi [seoul], 03080, Korea, Republic of|Albert Schweitzer Ziekenhuis, locatie Dordwijk, Dordrecht, Zuid-holland, 3318 AT, Netherlands|Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we WrocÅawiu, Wroclaw, DolnoÅlÄskie, 50-367, Poland|Uniwersyteckie Centrum Kliniczne, GdaÅsk, Pomorskie, 80-214, Poland|Pratia Onkologia Katowice, Katowice, ÅlÄskie, 40-519, Poland|Institut CatalÃ  d'Oncologia (ICO) - Badalona, Badalona, Barcelona [barcelona], 08916, Spain|Institut CatalÃ  d'Oncologia - L'Hospitalet, L'Hospitalet Del Llobregat, Barcelona [barcelona], 08908, Spain|Hospital ClÃ­nic de Barcelona, Barcelona, Catalunya [cataluÃ±a], 08036, Spain|Institut CatalÃ  d'Oncologia (ICO) - Girona, Girona, Girona [gerona], 17007, Spain|Clinica Universidad de Navarra, Madrid, Madrid, Comunidad DE, 28027, Spain|Clinica Universidad de Navarra, Pamplona, Navarra, 31008, Spain|Hospital Universitario Doctor Peset, Valencia, ValÃ¨ncia, 46017, Spain|Hospital San Pedro de AlcÃ¡ntara, CÃ¡ceres, 10003, Spain|Hospital La Princesa, Madrid, 28006, Spain|Hospital Universitario FundaciÃ³n JimÃ©nez DÃ­az, Madrid, 28040, Spain|China Medical University Hospital, Taichung, 404332, Taiwan|National Taiwan University Hospital, Taipei, 10002, Taiwan|Chang Gung Medical Foundation-Linkou Branch, Taoyuan, 333, Taiwan",
NCT04821622,Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC,https://clinicaltrials.gov/study/NCT04821622,,ACTIVE_NOT_RECRUITING,The purpose of the study is to evaluate the safety and efficacy of talazoparib in combination with enzalutamide compared with placebo in combination with enzalutamide in participants with DDR-deficient mCSPC.,NO,Prostate Cancer,DRUG: talazoparib plus enzalutamide|DRUG: Placebo plus enzalutamide,"radiological Progression-Free Survival, time from the date of randomization to first objective evidence of radiographic progression or death, whichever occurs first, randomization up to 3 years","Overall Survival, time from randomization to death from any cause, randomization up to 4 years|Objective response in measurable soft tissue disease, proportion of patients with measurable soft tissue disease at baseline with objective response per RECIST 1.1, randomization up to 3 years|Duration of response in measurable soft tissue disease, duration of responses in patients with measurable soft tissue disease at baseline per RECIST 1.1, randomization up to 3 years|Prostate Specific Antigen (PSA) response, proportion of patients with PSA response grater than or equal to 50%, randomization up to 3 years|Time to PSA progression, time from baseline to PSA progression, randomization up to 3 years|Time to initiation of antineoplastic therapy, Time from randomization to initiation of antineoplastic therapy, randomization up to 3 years|Time to first symptomatic skeletal event, time from randomization to first symptomatic skeletal event (symptomatic fractures, spinal cord compression, surgery or radiation to the bone whichever is first), randomization up to 3 years|Opiate use for prostate cancer pain, time from randomization to opiate use for prostate cancer pain, randomization up to 3 years|Incidence of adverse events, AEs and SAEs incidence by type and severity (graded by NCI CTCAE version 4.03), randomization up to 3 years|Pharmacokinetic assessment of talazoparib, plasma concentrations of talazoparib, Weeks 5, 9, 13, and 17|Pharmacokinetic assessment of enzalutamide and its metabolite, plasma concentrations of enzalutamide and its metabolite, Weeks 5, 9, 13, and 17|Relationship between ctDNA burden and outcome, ctDNA burden at baseline and on study, randomization up to 3 years|Patient-reported outcomes in pain symptoms - change from baseline, change from baseline in patient-reported pain symptoms per Brief Pain Inventory Short Form (BPI-SF), randomization up to 3 years|Patient-reported outcomes in pain symptoms - time to deterioration, time to deterioration in patient-reported pain symptoms per Brief Pain Inventory Short Form (BPI-SF), randomization up to 3 years|Patient-reported outcomes in cancer specific general health status - change from baseline, change from baseline in participant-reported general health status per EQ-5D-5L, randomization up to 3 years|Patient-reported outcomes in cancer specific global health status/QoL - change from baseline, change from baseline in patient-reported Global health status/QoL per EORTC QLQ-C30, randomization up to 3 years|Patient-reported outcomes in cancer specific global health status/QoL - time to definitive deterioration, time to definitive deterioration in patient-reported global health status/QoL per EORTC QLQ-C30, randomization up to 3 years|Patient-reported outcomes in cancer specific symptoms - time to definitive deterioration, time to definitive deterioration in disease specific urinary symptoms per EORTC QLQ-PR25, randomization up to 3 years|Patient-reported outcome: cancer specific functioning, and symptoms - change from baseline, change from baseline in PGI-S, randomization up to 3 years",,Pfizer,Astellas Pharma Inc,MALE,"ADULT, OLDER_ADULT",PHASE3,599,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-05-12,2025-09-18,2027-08-07,2021-03-29,,2025-06-10,"University of Alabama at Birmingham, Birmingham, Alabama, 35233, United States|University of Alabama at Birmingham, Birmingham, Alabama, 35249, United States|Arizona Institute of Urology, PLLC, Tucson, Arizona, 85704, United States|Beverly Hills Cancer Center, Beverly Hills, California, 90211, United States|Adventist Health Glendale, Glendale, California, 91206, United States|VA Long Beach Healthcare System, Long Beach, California, 90822, United States|Yale-New Haven Hospital, New Haven, Connecticut, 06510, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, 20007, United States|Washington Cancer Institute at MedStar Washington Hospital Center, Washington, District of Columbia, 20010, United States|AdventHealth Medical Group Hematology and Oncology, Orlando, Florida, 32804, United States|Investigational Drug Services, Advent Health Orlando, Orlando, Florida, 32804, United States|Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital, Austell, Georgia, 30106, United States|Wellstar Cobb Hospital, Austell, Georgia, 30106, United States|Northwest Georgia Oncology Centers, a Service of Tanner Medical Center Villa Rica, Carrollton, Georgia, 30117, United States|West Georgia Infusion Center, a Service of Tanner Medical Center Villa Rica, Carrollton, Georgia, 30117, United States|Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital, Cartersville, Georgia, 30121, United States|Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital, Douglasville, Georgia, 30134, United States|Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital, Marietta, Georgia, 30060, United States|Comprehensive Urologic Care, SC, Lake Barrington, Illinois, 60010, United States|Mid-Illinois Hematology & Oncology Associates, Ltd, Normal, Illinois, 61761, United States|Henry Ford Health System, Detroit, Michigan, 48202, United States|Henry Ford Medical Center - New Center One, Detroit, Michigan, 48202, United States|Revive Research Institute, Inc., Farmington Hills, Michigan, 48334, United States|David C. Pratt Cancer Center, Saint Louis, Missouri, 63141, United States|New Jersey Cancer Care, P.A., Belleville, New Jersey, 07109, United States|Premier Medical Group of the Hudson Valley PC, Poughkeepsie, New York, 12603, United States|Providence Cancer Institute Franz Clinic, Portland, Oregon, 97213, United States|Keystone Urology Specialists, Lancaster, Pennsylvania, 17604, United States|Carolina Urologic Research Center, LLC, Myrtle Beach, South Carolina, 29572, United States|Parkway Surgery Center, Myrtle Beach, South Carolina, 29572, United States|Bristol Regional Medical Center, Bristol, Tennessee, 37620, United States|Ballad Health Cancer Care - Kingsport, Kingsport, Tennessee, 37660, United States|Holston Valley Hospital and Medical Center, Kingsport, Tennessee, 37660, United States|Indian Path Community Hospital, Kingsport, Tennessee, 37660, United States|Kelsey Research Foundation, Houston, Texas, 77005, United States|Oncology Consultants, P.A., Houston, Texas, 77008, United States|Kelsey-Seybold Clinic, Houston, Texas, 77014, United States|oncology Consultants, P.A., Houston, Texas, 77024, United States|Kelsey-Seybold Clinic, Houston, Texas, 77025, United States|Houston Metro Urology, Houston, Texas, 77027, United States|Oncology Consultants P.A., Houston, Texas, 77030, United States|Kelsey-Seybold Clinic, Houston, Texas, 77055, United States|Urology San Antonio, San Antonio, Texas, 78229, United States|Texas Oncology-Deke Slayton Cancer Center, Webster, Texas, 77598, United States|Huntsman Cancer Institute - University of Utah, Salt Lake City, Utah, 84112, United States|COIBA, Berazategui, Buenos Aires, B1884BBF, Argentina|Centro de Investigacion Pergamino SA - Clinica Pergamino SA, Pergamino, Buenos Aires, B2700CPM, Argentina|Centro de Investigaciones ClÃ­nicas - ClÃ­nica Viedma, Viedma, RÃO Negro, R8500ACE, Argentina|Centro Medico San Roque, San Miguel de Tucuman, Tucuman, T4000IAK, Argentina|Centro Oncologico Korben, Caba, C1426AGE, Argentina|Instituto MÃ©dico Especializado Alexander Fleming, Caba, C1426ANZ, Argentina|Centro Medico Privado CEMAIC, CÃ³rdoba, X5008HHW, Argentina|Chris O'Brien Lifehouse, Camperdown, New South Wales, 2050, Australia|Cancer Care Wollongong Pty Limited, Wollongong, New South Wales, 2500, Australia|Gallipoli Medical Research Foundation, Greenslopes Private Hospital, Brisbane, Queensland, 4120, Australia|Gold Coast University Hospital, Southport, Queensland, 4215, Australia|The Queen Elizabeth Hospital, Woodville South, South Australia, 5011, Australia|Epworth Freemasons-Epworth HealthCare, East Melbourne, Victoria, 3002, Australia|Cabrini Hospital, Malvern, Victoria, 3144, Australia|Western Health, Sunshine Hospital, St Albans, Victoria, 3021, Australia|Onze Lieve Vrouw Ziekenhuis Aalst, Aalst, 9300, Belgium|Institut Jules Bordet, Anderlecht, 1070, Belgium|Cliniques universitaires Saint-Luc, Brussels, 1200, Belgium|AZ (Algemeen Ziekenhuis) Maria Middelares, Gent, 9000, Belgium|AZ (Algemeen Ziekenhuis) Sint-Lucas, Gent, 9000, Belgium|AZ (Algemeen Ziekenhuis) Groeninge, Kortrijk, 8500, Belgium|CHU de Liege, Liege, 4000, Belgium|ZNA Jan Palfijn, Merksem, 2170, Belgium|Multiprofile Hospital for Active Treatment - Uni Hospital OOD, Panagyurishte, 4500, Bulgaria|Complex Oncology Center - Plovdiv EOOD, Plovdiv, 4000, Bulgaria|Independent medical-diagnostic laboratory ""Medisken"" EOOD, Plovdiv, 4000, Bulgaria|Complex Oncology Center - Shumen EOOD, Shumen, 9700, Bulgaria|Acibadem City Clinic University Multiprofile Hospital for Active Treatment Tokuda EAD, Sofia, 1407, Bulgaria|Acibadem City Clinic University Multiprofile Hospital for Active Treatment EOOD, Sofia, Bulgaria|Complex Oncology Center - Stara Zagora Ltd., Stara Zagora, 6003, Bulgaria|MRI SMDLOD ""Mediscan"" Ltd, Stara Zagora, 6003, Bulgaria|UMHAT ""Prof. Dr. Stoyan Kirkovich"", Stara Zagora, 6003, Bulgaria|Prostate Cancer Centre, Calgary, Alberta, T2V 1P9, Canada|Centre of Applied Urology Research, Nova Scotia Health Authority, Halifax, Nova Scotia, B3H 2Y9, Canada|London Health Sciences Centre, London, Ontario, N6A 5W9, Canada|The Ottawa Hospital Cancer Center, Ottawa, Ontario, K1H 8L6, Canada|University Health Network-Princess Margaret Cancer Centre, Toronto, Ontario, M5G 2M9, Canada|CIUSSS- saguenay-Lac-Saint-Jean, Chicoutimi, Quebec, G7H 5H6, Canada|Urology South Shore Research, Greenfield Park, Quebec, J4V 2H3, Canada|CHUM - Centre Hospitalier de l'UniversitÃ© de MontrÃ©al, Montreal, Quebec, H2X 0A9, Canada|Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada|McGill University Health Center, Montreal, Quebec, H4A 3J1, Canada|The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230022, China|Peking University First Hospital, Beijing, Beijing, 100034, China|Lanzhou university second hospital, Lanzhou, Gansu, 730030, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510120, China|Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, 510515, China|Henan Cancer Hospital, Zhengzhou, Henan, 450008, China|Union Hospital, Tongji Medical College of Huazhong University of Science & Technology, Wuhan, Hubei, 430022, China|Tongji Hospital, Tongji Medical College,Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China|Hubei Cancer Hospital, Wuhan, Hubei, 430079, China|Hunan Cancer Hospital, Changsha, Hunan, 410013, China|The Third Xiangya Hospital of Central South University, Changsha, Hunan, 410013, China|Zhongda Hospital Southeast University, Nanjing, Jiangsu, 210009, China|Nantong Tumor Hospital, Nantong, Jiangsu, 226000, China|The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 215004, China|Jiangxi Provincial Cancer Hospital, Nanchang, Jiangxi, 330029, China|The First hospital of Jilin University, Changchun, Jilin, 130021, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China|Fudan University Cancer Hospital, Shanghai, Shanghai, 200032, China|West China Hospital of Sichuan University, Chengdu, Sichuan, 610041, China|The Second Hospital of Tianjin Medical University, Tianjin, Tianjin, 300211, China|Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, 310014, China|The first affiliated hospital of Ningbo university, Ningbo, Zhejiang, 315010, China|The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China|The First Affiliated Hospital Chongqing Medical University, Chongqing, 400042, China|Fakultni nemocnice Olomouc, Olomouc, 779 00, Czechia|Fakultni nemocnice Ostrava, Ostrava - Poruba, 708 52, Czechia|Fakultni nemocnice Kralovske Vinohrady, Praha 10, 100 34, Czechia|Fakultni nemocnice v Motole, Praha 5, 150 06, Czechia|Fakultni nemocnice Bulovka, Praha 8- Liben, 180 81, Czechia|Helsinki University Hospital, Helsinki, 00029, Finland|Docrates Cancer Center, Helsinki, 00180, Finland|Kuopio University Hospital, Kuopio, 70210, Finland|Tampere University Hospital, Tampere, 33520, Finland|Turku University Hospital, Turku, 20520, Finland|CHU Morvan de Brest, Brest, Bretagne, 29200, France|Hopital Henri Mondor, Creteil, ILE DE France, 94010, France|Clinique Victor Hugo Le Mans, Le Mans, Pays-de-la-loire, 72000, France|Centre Hospitalier Universitaire d'Angers, Angers Cedex 9, 49933, France|Clinique Belharra, Bayonne, 64100, France|CHU Morvan de Brest, Brest, 29200, France|Hopital Prive le Bois, Lille, 59000, France|Centre Leon Berard, LYON Cedex 08, 69373, France|Hopital Bichat - Claude Bernard, Paris cedex 18, 75877, France|Hopital Bichat - Claude Bernard, Paris, 75018, France|Hopital Lyon Sud, Pierre-Benite, 69310, France|Clinique La Croix du Sud - Ramsay Sante, Quint Fonsegrives, 31130, France|Institut Jean Godinot, Reims Cedex, 51726, France|CHP Saint-GrÃ©goire, Saint Gregoire, 35760, France|Hopitaux Universitaires de Strasbourg - ICANS (Institut de Cancerologie Strasbourg Europe), Strasbourg, 67200, France|Institut de cancerologie de Lorraine, Vandoeuvre-Les-Nancy, 54519, France|Gustave Roussy, Villejuif Cedex, 94805, France|Universitaetsmedizin Goettingen, GÃ¶ttingen, Niedersachsen, 37075, Germany|Urologische Gemeinschaftspraxis Wesel, Wesel, Nordrhein-westfalen, 46483, Germany|UniversitÃ¤tsklinikum Jena, Jena, ThÃ¼ringen, 07747, Germany|Charite Universitaetsmedizin Berlin - Campus Mitte, Berlin, 10117, Germany|Urologicum Duisburg, Duisburg, 47169, Germany|Universitaetsklinikum Frankfurt, Frankfurt, 60590, Germany|Institut fuer Diagnostische und Interventionelle Radiologie, Goettingen, 37075, Germany|Universitaetsklinik Heidelberg, Heidelberg, 69120, Germany|Uro-/Onkologisches Zentrum, Leipzig, 04105, Germany|Studienpraxis Urologie, Nuertingen, 72622, Germany|Universitaetsklinikum Tuebingen, Tuebingen, 72076, Germany|PÃ©terfy KÃ³rhÃ¡z-RendelÅintÃ©zet Ã©s Manninger JenÅ OrszÃ¡gos TraumatolÃ³giai IntÃ©zet, Budapest, 1076, Hungary|OrszÃ¡gos OnkolÃ³giai IntÃ©zet, Budapest, 1122, Hungary|Uzsoki Utcai Korhaz, Budapest, 1145, Hungary|Jahn Ferenc Del-pesti Korhaz es Rendelointezet, Budapest, 1204, Hungary|Indraprastha Apollo Hospital, New Delhi, Delhi, 110076, India|Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, Delhi, 110085, India|Gujarat Hospital - Gastro and Vascular Centre, Surat, Gujarat, 395009, India|Artemis hospital, Gurugram, Haryana, 122001, India|Medanta- The Medicity hospital, Gurugram, Haryana, 122001, India|Bhaktivedanta Hospital and Research Institute, Mumbai, Maharashtra, 401107, India|Sahyadri Clinical Research & Development Centre, Pune, Maharashtra, 411004, India|Sahyadri Super Speciality Hospital, Pune, Maharashtra, 411004, India|Valentis Cancer Hospital, Meerut, Uttar Pradesh, 250001, India|Netaji Subhas Chandra Bose Cancer Hospital, Kolkata, WEST Bengal, 700094, India|Azienda Ospedaliero-Universitaria Policlinico S. Orsola Malpighi, Bologna, BO, 40138, Italy|ASST Cremona, Cremona, CR, 26100, Italy|Istituto Romagnolo per lo Studio dei Tumori ""Dino Amadori"" (IRST), Meldola, FC, 47014, Italy|Fondazione Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, 71013, Italy|Istituto Nazionale Tumori IRCCS Fondazione G. Pascale - Napoli, Napoli, Naples, 80131, Italy|Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, PN, 33081, Italy|Ospedale Santa Chiara, Trento, TN, 38122, Italy|AOU San Luigi Gonzaga, Orbassano, TO, 10043, Italy|Ospedale San Donato, Arezzo, 52100, Italy|IRCCS Istituto Tumori ""Giovanni Paolo II"" di Bari, Bari, 70124, Italy|ASST Papa Giovanni XXIII, Bergamo, 24127, Italy|ASST degli Spedali Civili de Brescia, Brescia, 25123, Italy|Azienda Ospedaliera Universitaria Integrata Verona, Verona, 37134, Italy|Nagoya University Hospital, Nagoya, Aichi, 466-8560, Japan|Hirosaki University School of Medicine & Hospital, Hirosaki, Aomori, 036-8563, Japan|Chiba cancer center, Chiba City, Chiba, 2608717, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, 277-8577, Japan|National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, 791-0280, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka-shi, Fukuoka, 811-1395, Japan|National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Hiroshima, 737-0023, Japan|National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, 003-0804, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, 060-8648, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, 920-8641, Japan|Yokohama City University Medical Center, Yokohama, Kanagawa, 232-0024, Japan|Yokosukakyosai, Yokosuka, Kanagawa, 238-8558, Japan|Osaka International Cancer Institute, Osaka-shi, Osaka, 5418567, Japan|Kindai University Hospital, Osakasayama, Osaka, 589-8511, Japan|The University of Osaka Hospital, Suita, Osaka, 565-0871, Japan|Hamamatsu University Hospital, Hamamatsu, Shizuoka, 431-3192, Japan|National Hospital Organization Tokyo Medical Center, Meguro-Ku, Tokyo, 152-8902, Japan|Keio university hospital, Shinjuku-ku, Tokyo, 160-8582, Japan|Kagoshima University Hospital, Kagoshima, 890-8520, Japan|National Hospital Organization Kumamoto Medical Center, Kumamoto, 860-0008, Japan|Tokushima University Hospital, Tokushima, 770-8503, Japan|Yamagata University Hospital, Yamagata, 990-9585, Japan|National Cancer Center, Goyang-si, Gyeonggi-do, 10408, Korea, Republic of|Chonnam National University Hwasun Hospital, Hwasun-gun, Jeollanam-do, 58128, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, KyÇnggi-do, 13620, Korea, Republic of|Kyungpook National University Chilgok Hospital, Daegu, 41404, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, 03722, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Gangnam Severance Hospital, Yonsei University Health System, Seoul, 06273, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|The Catholic Univ. of Korea Seoul St. Mary's Hospital, Seoul, 06591, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, 07985, Korea, Republic of|Oncologia Integral Satelite SA de CV, Naucalpan de Juarez, Estado DE Mexico, 53100, Mexico|Preparaciones OncolÃ³gicas S.C., Leon, Guanajuato, 37178, Mexico|Axis Heilsa S. de R.L. de C.V., Monterrey, Nuevo LEÃN, 64040, Mexico|Hospital Universitario ""Dr. Jose Eleuterio Gonzalez"", Monterrey, Nuevo LEÃN, 64460, Mexico|Oaxaca Site Management Organization, Oaxaca de Juarez, Oaxaca, 68000, Mexico|Centro de Investigacion Clinica de Oaxaca, Oaxaca, 68020, Mexico|Instituto Veracruzano en InvestigaciÃ³n ClÃ­nica S.C., Veracruz, 91851, Mexico|Meander Medisch Centrum, Amersfoort, Utrecht, 3813 TZ, Netherlands|Stichting HagaZiekenhuis, Den Haag, 2545 AA, Netherlands|Sykehuset Innlandet Gjoevik, Gjoevik, 2819, Norway|MRRC n.a. A.F. Tsyb - branch of FSBI ""NMRC of Radiology"" Minzdrav Russia, Obninsk, Kaluga Region, 249036, Russian Federation|Private Medical Institution ""Euromedservice"", Pushkin, Saint-petersburg, 196603, Russian Federation|Limited Liability Company ""4D Ultrasound Clinic"" (LLC ""4D Ultrasound Clinic""), Pyatigorsk, Stavropol Region, 357502, Russian Federation|Evimed Llc, Chelyabinsk, 454048, Russian Federation|SBIH ""Chelyabinsk Regional Clinical Centre of Oncology and Nuclear Medicine"", Chelyabinsk, 454087, Russian Federation|Regional Budgetary Healthcare Institution ""Ivanovskiy Regional Oncology Dispensary"" (RBHI ""IvROD""), Ivanovo, 153040, Russian Federation|Federal State Budgetary Institution ""Russian Research Center of Roentgenology and Radiology"" of the, Moscow, 117997, Russian Federation|Branch of the Limited Liability Company ""Hadassah Medical Ltd."", Moscow, 121205, Russian Federation|Federal State Budgetary Institution ""Central Clinical Hospital with ambulance"", Moscow, 121359, Russian Federation|BHI of Omsk region ""Clinical Oncological Dispensary"", Omsk, 644013, Russian Federation|LLC ""Medicina Severnoy Stolitsy"", Saint-Petersburg, 191025, Russian Federation|LLC ""Severo-Zapadny Medical Center"", Saint-Petersburg, 192007, Russian Federation|Private Institution Educational Organization of Higher Education ""Medical University ""REAVIZ"", Samara, 443011, Russian Federation|SAHI Republican Clinical Oncology Dispensary under the Ministry of Health, Republic of Bashkortostan, Ufa, 450054, Russian Federation|Budgetary Healthcare Institution of Vologda region ""Vologda Regional Clinical Hospital"", Vologda, 160002, Russian Federation|Budgetary Healthcare Institution of Vologda region ""Vologda Regional Clinical Hospital"", Vologda, 160022, Russian Federation|State Budgetary Institution of Healthcare of Yaroslavl Region ""Regional Clinical Oncology Hospital"", Yaroslavl, 150054, Russian Federation|Fakultna nemocnica s poliklinikou F.D. Roosevelta Banska Bystrica, Banska Bystrica, 975 17, Slovakia|Narodny onkologicky ustav, Bratislava, 833 10, Slovakia|Vychodoslovensky onkologicky ustav, a.s., Kosice, 041 91, Slovakia|UROEXAM, spol. s r.o., Nitra, 949 01, Slovakia|POKO Poprad s.r.o., Poprad, 058 21, Slovakia|MILAB s.r.o., Presov, 08 001, Slovakia|Privatna urologicka ambulancia, s.r.o., Trencin, 911 01, Slovakia|15 Eton Road, Johannesburg, Gauteng, 2193, South Africa|Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, Gauteng, 2193, South Africa|WCR Office, Johannesburg, Gauteng, 2193, South Africa|Sandton Oncology Medical Group (Pty) Ltd, Johannesburg, Gauteng, 2196, South Africa|Wits Clinical Research, Parktown, Gauteng, 2193, South Africa|Clinical Research Unit, University of Pretoria, Pretoria, Gauteng, 0002, South Africa|Hospital General Universitario de Elche, Elche, Alicante, 03203, Spain|Hospital Universitario Central de Asturias, Oviedo, Asturias, 33011, Spain|Hospital Germans Trias i Pujol, Badalona, Barcelona [barcelona], 08916, Spain|Althaia, Xarxa Assistencial UniversitÃ ria de Manresa, Manresa, Barcelona, 08243, Spain|Hospital Universitario Lucus Augusti, Lugo, Galicia, 27003, Spain|Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Comunidad DE, 28222, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, 31008, Spain|Hospital Universitari Sant Joan de Reus, Reus, Tarragona, 43204, Spain|FundaciÃ³n Instituto Valenciano de OncologÃ­a, Valencia, Valenciana, Comunitat, 46009, Spain|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital ClÃ­nic de Barcelona, Barcelona, 08036, Spain|Hospital Universitario Reina SofÃ­a, Cordoba, 14004, Spain|Hospital Universitario Gregorio MaraÃ±Ã³n, Madrid, 28009, Spain|MD Anderson Cancer Center, Madrid, 28033, Spain|Hospital Clinico San Carlos, Madrid, 28040, Spain|Hospital Universitario Virgen de la Macarena, Sevilla, 41009, Spain|Hospital Politecnic Universitari La Fe, Valencia, 46026, Spain|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, 807, Taiwan|Taichung Veterans General Hospital, Taichung, 40705, Taiwan|National Cheng Kung University Hospital, Tainan, 704, Taiwan|National Taiwan University Hospital, Taipei, 10002, Taiwan|Taipei Veterans General Hospital, Taipei, 11217, Taiwan|Linkou Chang Gung Memorial Hospital, Taoyuan City, 333, Taiwan|Adana City Training and Research Hospital, Adana, 01415, Turkey|Ankara University Faculty of Medicine, Ankara, 06620, Turkey|Ankara City Hospital, Ankara, 06800, Turkey|Trakya University Medical Faculty, Edirne, 22030, Turkey|Istanbul University, Cerrahpasa Faculty of Medicine, Istanbul, 34098, Turkey|Goztepe Prof. Dr. Suleyman Yalcin City Hospital, Istanbul, 34722, Turkey|Inonu University, Faculty of Medicine, Malatya, 44280, Turkey|MI Kryvyi Rih Oncology Dispensary of Dnipropetrovsk Regional Council; Chemotherapy Department, Kryviy Rih, Dnipropetrovska Oblast, 50048, Ukraine|Medical & diagnostic center of LISOD-Israeli Oncological Hosp ""MedX-ray International Group"", Pliuty Village, KYIV Region, 08720, Ukraine|Asklepion Medical Center, Khodosivka, Kyivska Oblast, 08173, Ukraine|National Cancer Institute, Kyiv, Kyivska Oblast, 03022, Ukraine|Municipal Ent ""Dnipropetrovsk Regional Clinical Hosp (I.I.Mechnikov Dnipropetrovsk Regional council), Dnipro, 49005, Ukraine|Municipal Non-profit Enterprise ""City Clinical Hospital #4"" of Dnipro City Council, Dnipro, 49102, Ukraine|Municipal Non-Commercial Enterprise of Kharkiv Regional Council Regional Medical Clinical Center of, Kharkiv, 61037, Ukraine|Communal Non-Profit Enterprise ""Regional Center of Oncology"", Kharkiv, 61070, Ukraine|Comm Noncommerc Entp Lviv Reg Council ""Lviv Oncological Regional Therapeutical and Diagnostic Cntre, Lviv, 79031, Ukraine|Royal Devon and Exeter NHS Foundation Trust, Exeter, Devon, EX2 5DW, United Kingdom|Maidstone and Tunbridge Wells NHS Trust, Maidstone, Kent, ME16 9QQ, United Kingdom|Lancashire Teaching Hospitals NHS Foundation Trust, Preston, Lancashire, PR2 9HT, United Kingdom|NHS Lothian, Edinburgh, Midlothian, EH4 2XU, United Kingdom|Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, South Yorkshire, S10 2SJ, United Kingdom|University Hospitals Birmingham NHS Foundation Trust, Birmingham, B9 5SS, United Kingdom|NHS Greater Glasgow and Clyde, Glasgow, G12 0YN, United Kingdom|The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, United Kingdom|Imperial College Healthcare NHS Trust, London, W6 8RF, United Kingdom|The Christie NHS Foundation Trust, Manchester, M20 4BX, United Kingdom",
NCT05840211,Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy,https://clinicaltrials.gov/study/NCT05840211,ASCENT-07,ACTIVE_NOT_RECRUITING,"The goal of this clinical study is to see if sacituzumab govitecan-hziy (SG) can improve life spans of people with HR+/HER2- metastatic breast cancer and their tumor does not grow or spread when compared to currently available standard treatments, such as paclitaxel, nab-paclitaxel or capecitabine. The primary objective is to compare the effect of SG relative to the treatment of physician's choice (TPC) on progression-free survival (PFS).",NO,Locally Advanced or Unresectable Metastatic Breast Cancer|Stage IV Breast Cancer,DRUG: Sacituzumab Govitecan-hziy|DRUG: Paclitaxel|DRUG: Nab-paclitaxel|DRUG: Capecitabine,"Progression Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), PFS is defined as time from date of randomization until the date of first objective progressive disease (PD) or death from any cause, whichever comes first., Up to approximately 29 months","Overall Survival (OS), OS is defined as the time from randomization until the date of death from any cause., Until death, up to approximately 60 months|Objective Response Rate (ORR) as Assessed by BICR per RECIST Version 1.1, ORR is defined as the proportion of participants who achieve a complete response (CR) or partial response (PR) that is confirmed at least 4 weeks after initial documentation of response., Until progression, up to approximately 60 months|Change from Baseline in the Physical Functioning Domain Using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Version 3.0 (EORTC QLQ-C30) at Week 16, The EORTC QLQ-C30 is composed of global health status/QoL scale; five functional domains (physical, role, emotional, cognitive, and social); three symptom domains (fatigue, nausea and vomiting, and pain); and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties).

The Physical Functioning domain includes 5 questions in which participants will be asked to rate their overall health and overall quality of life as it relates to physical functioning during the past week on a scale from 1 (very poor) to 4 (excellent), with a higher score representing a high QoL., Baseline, Week 16|Time to Deterioration in Version 3.0 EORTC-QLQ-C30 Scores, Time to deterioration from baseline in European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) scores. Scale scores range from 0-100. For functioning and global health status/QoL scales, higher scores indicate better functioning or global health status/QoL. For symptom scales, higher scores indicate greater symptom burden., Up to approximately 60 months|Progression Free Survival (PFS) as Assessed by Investigator per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), PFS is defined as time from date of randomization until the date of first objective progressive disease (PD) by investigator assessment according to RECIST v1.1 or death from any cause, whichever comes first., Until progression or death, up to approximately 60 months|Objective Response Rate (ORR) as Assessed by Investigator per RECIST Version 1.1, ORR is defined as the proportion of participants who achieve a complete response (CR) or partial response (PR) that is confirmed at least 4 weeks after initial documentation of response., Up to approximately 60 months|Duration of Response (DOR) as Assessed by BICR and Investigator per RECIST Version 1.1, DOR is defined as the time from the first documentation of CR or PR to the earlier of the first documentation of objective PD or death from any cause (whichever comes first)., Until progression or death, up to approximately 60 months|Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), First dose date up to 30 days post last dose, up to approximately 60 months|Percentage of Participants Experiencing Clinically Significant Laboratory and/or Vital Sign Abnormalities, First dose date up to 30 days post last dose, up to approximately 60 months",,Gilead Sciences,,ALL,"ADULT, OLDER_ADULT",PHASE3,654,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-05-08,2025-09,2028-12,2023-05-03,,2024-08-29,"Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers, Chandler, Arizona, 85224, United States|Los Angeles Hematology Oncology Medical Group, Los Angeles, California, 90017, United States|Stanford Cancer Institute, Palo Alto, California, 94305, United States|University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, San Francisco, California, 94143, United States|Rocky Mountain Cancer Centers, LLP, Littleton, Colorado, 80120, United States|Yale-New Haven Hospital-Yale Cancer Center, New Haven, Connecticut, 06510, United States|Investigational Drug Services, AdventHealth Orlando, Altamonte Springs, Florida, 32701, United States|Florida Cancer Specialists, Brooksville, Florida, 34613, United States|Florida Cancer Specialist, Leesburg, Florida, 34748, United States|Florida Cancer Specialist, Saint Petersburg, Florida, 33705, United States|Piedmont Cancer Institute, Atlanta, Georgia, 30318, United States|Georgia Cancer Specialist - Annex, Atlanta, Georgia, 30341, United States|Northwest Georgia Oncology Centers, Marietta, Georgia, 30060, United States|The University of Kansas Hospital, Kansas City, Kansas, 66160, United States|Hematology Oncology Clinic, Baton Rouge, Louisiana, 70809, United States|Saint Luke's Cancer Institute, Kansas City, Missouri, 64110, United States|David C. Pratt Cancer Center, Saint Louis, Missouri, 63141, United States|Astera Cancer Care, East Brunswick, New Jersey, 08816, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, 08901, United States|Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York, New York, 10065, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|Stefanie Spielman Comprehensive Breast Center, Columbus, Ohio, 43210, United States|Penn State Cancer Institute, Hershey, Pennsylvania, 17033, United States|Magee-Womens of UPMC, Pittsburgh, Pennsylvania, 15213, United States|Prisma Health - Upstate, Greenville, South Carolina, 29605, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, 37203, United States|Vanderbilt University Medical Center - Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, 37203, United States|US Oncology Investigational Products Center (IPC), Fairfax, Virginia, 22031, United States|US Oncology Investigational Products Center (IPC), Norfolk, Virginia, 23502, United States|MultiCare Regional Cancer Center - Auburn, Auburn, Washington, 98001, United States|Hospital Britanico de Buenos Aires, Buenos Aires, 1426, Argentina|Instituto de Investigaciones Clinicas de Mar del Plata, Buenos Aires, B7600, Argentina|Instituto Alexander Fleming, C.a.b.a., 1426ANZ, Argentina|Hospital AlemÃ¡n, Caba, 1118, Argentina|Centro Privado de RMI Rio Cuarto S.A., Cordoba, 5800, Argentina|Instituto de OncologÃ­a de Rosario, Rosario, 2000, Argentina|CER San Juan Centro Polivalente de Asistencia e InvestigaciÃ³n ClÃ­nica, San Juan, 5400, Argentina|Royal Brisbane and Women's Hospital, Queensland, ME, 4029, Australia|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, 2010, Australia|Liverpool Hospital, Liverpool, New South Wales, 2170, Australia|GenesisCare North Shore (Oncology), St Leonards, New South Wales, 2065, Australia|Icon Cancer Centre Wesley, Auchenflower, Queensland, 4066, Australia|Flinders Medical Centre, Bedford Park, South Australia, 5042, Australia|Icon Cancer Centre Hobart, Hobart, Tasmania, 7000, Australia|Austin Health, Melbourne, Victoria, 3084, Australia|Sunshine Hospital (Western Health), St Albans, Victoria, 3021, Australia|Breast Cancer Research Centre - WA, Nedlands, Western Australia, 6009, Australia|University Hospital Innsbruck, Innsbruck, 06020, Austria|UniversitÃ¤tsklinik fÃ¼r Innere Medizin 3 der PMU, Salzburg, A-5020, Austria|Klinikum Wels-Grieskirchen, Wels, 4710, Austria|Medizinische Universitat Wien, Univ. Klinik fur Innere Medizin I Klinische Abteilung fur Onkologie, Wien, 1090, Austria|GZA Ziekenhuizen - Campus Sint-Augustinus, Antwerpen, 2610, Belgium|AZ Klina, Brasschaat, 2930, Belgium|Cliniques Universitaires Saint-Luc, Brussels, 1200, Belgium|Universitaire Ziekenhuis Leuven, Leuven, 3000, Belgium|CHU UCL Namur-Site STE. Elisabeth, Namur, 5000, Belgium|Hospital Haroldo JuaÃ§aba - Instituto do CÃ¢ncer do CearÃ¡, Fortaleza, 60430-230, Brazil|Hospital Araujo Jorge - Associacao de Combate ao Cancer em Goias, GoiÃ¢nia, 74605-070, Brazil|Oncosite - Centro de Pesquisa Clinica e Oncologia, Ijui, 98700-000, Brazil|Catarina Pesquisa Clinica, Itajai, 88301-220, Brazil|Oncoclinicas do Brasil Servicos Medicos AS, Minas Gerais, 30360-680, Brazil|Liga Norte-Rio-Grandense Contra o CÃ¢ncer, Natal, 59062-000, Brazil|CIONC-Centro Integrado de Oncologia de Curitiba, Paraana, 80810050, Brazil|Hospital Erasto Gaertner, ParanÃ¡, 81.520-060, Brazil|IMIP - Instituto de Medicina Integral Professor Fernando Figueira, Pernambuco, 50070550, Brazil|Irmandade da Santa Casa de MisericÃ³rdia de Porto Alegre, Porto Alegre, 90020-090, Brazil|Hospital de ClÃ­nicas de Porto Alegre - HCPA, Porto Alegre, 90035-903, Brazil|HGB - Hospital Giovanni Battista/MÃ£e de Deus Center, Porto Alegre, 90110-270, Brazil|Hospital SÃ£o Lucas da PUCRS, Porto Alegre, 90610001, Brazil|Instituto Americas, Rio de Janeiro, 22775-001, Brazil|ClÃ­nica de Oncologia de Porto Alegre Ltda - CLINIONCO, Rio Grande Do Sul, 90430-090, Brazil|Unidade de PesquisasClinicas em Oncologia - UPCO, Rio Grande Do Sul, 96020-080, Brazil|Instituto do CÃ¢ncer - Hospital SÃ£o Vicente de Paulo, Rio Grande Do Sul, 99010-090, Brazil|CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia, Santo Andre, 09060-650, Brazil|Instituto Hemomed Oncologia e Hematologia, SÃ£o Paulo, 01236-030, Brazil|Clinica de pesquisa e centro de estudos em oncologia ginecolÃ³gica e mamaria, SÃ£o Paulo, 1317000, Brazil|BC Cancer - Kelowna, Kelowna, V1Y 5L3, Canada|The Ottawa Hospital Cancer Centre, Ottawa, K1H 8L6, Canada|CHU de QuÃ©bec-UniversitÃ© Laval, HÃ´pital du Saint-Sacrement, Quebec, G1S 4L8, Canada|Humber River Hospital, Toronto, M3M 0B2, Canada|BC Cancer-Victoria, Victoria, V8R 6V5, Canada|Centro de Investigacion Clinica Bradford Hill, Recoleta, Chile|Centro del Cancer UC, Region Metropolitana, 7550000, Chile|Centro de OncologÃ­a de PrecisiÃ³n (COP), Santiago Region, 8330032, Chile|James Lind Centro de Investigacion del Cancer, Temuco, Chile|Oncocentro APYS, Vina del Mar, 2520612, Chile|The First Affiliated Hospital of USTC (Anhui Provincial Hospital), Anhui, 230001, China|Peking University People's Hospital, Beijing, 100044, China|The First Hospital of Jilin University, Changchun, 130021, China|Xiangya Hospital Central South University, Changsha, 410008, China|West China Hospital Sichuan University, Chengdu, 610041, China|Chongqing University Cancer Hospital, Chongqing, 404100, China|Fujian Cancer Hospital, Fujian, 350015, China|Fujian Medical University Union Hospital, Fuzhou, 350001, China|Sun Yat-Sen University Cancer Center, Guangdong, 510060, China|Guangdong Provincial People's Hospital, Guangzhou, 510080, China|The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China|Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China|Sir Run Run Shaw Hospital,Zhejiang University School of Medicine, Hangzhou, 310000, China|Zhejiang Cancer Hospital, Hangzhou, 310022, China|Harbin Medical University Cancer Hospital, Heilongjiang, 150081, China|Jiangsu Province Hospital, Jiangsu, 210029, China|The First Affiliated Hospital of Soochow University, Jiangsu, 215004, China|The Nanchang Third Hospital, Jiangxi, 330009, China|The Second Hospital of Jilin University, Jilin Sheng, 130041, China|Affiliated Cancer Hospital of Shandong First Medical University, Jinan, 250117, China|The First Affiliated Hospital of Nanchang University, Nanchang, 330006, China|General Hospital of Ningxia Medical University, Ningxia Hui, 750004, China|The Affiliated Hospital Of Qingdao University, Qingdao, 266071, China|Fudan University Shanghai Cancer Center, Shanghai, 200030, China|Tianjin Medical University Cancer Institute & Hospital, Tianjin, 453000, China|Hubei Cancer Hospital, Wuhan, 430079, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang, 310009, China|Henan Cancer Hospital, Zhengzhou, 450003, China|Fakultni Nemocnice Brno, Brno, 62500, Czechia|Masaryk Memorial Cancer Institute, Brno, 656 53, Czechia|University Hospital Olomouc, Olomouc, 779 00, Czechia|Multiscan s.r.o, Pardubice, 532 01, Czechia|Fakultni nemocnice v Motole, Prague 4, 14059, Czechia|Charles General University Hospital, Prague, Prague, 12808, Czechia|Krajska nemocnice Tomase Bati Zlin, Zlin, 760 01, Czechia|CHU Jean Minjoz, Besancon, 25030, France|Institut BergoniÃ©, Bordeaux, 33076, France|Centre Georges FranÃ§ois Leclerc, Dijon, 21000, France|Centre Oscar Lambret, Lille, 59000, France|Clinique Francois Chenieux, Limoges, 87039, France|Ico RenÃ© Gauducheau, Loire Atlantique, 44 805, France|Centre Leon Berard, Lyon, 69373, France|Institut Paoli Calmettes, Marseille, 13009, France|Institut Regional du Cancer de Montpellier, Montpellier Cedex 5, 34298, France|Institut Curie, Paris, 75248, France|Centre Hospitalier Lyon-Sud, Pierre-benite, 69310, France|Hopital PrivÃ© des Cotes d'Armor, Plerin, 22190, France|Centre Jean Bernard Service d'Oncologie MÃ©dicale, Rennes Cedex, 35042, France|Centre Henri Becquerel, Rouen, France|Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse Cedex 9, 31059, France|Institut Gustave Roussy, Villejuif, 94800, France|Universitaetsklinikum Freiburg, Klinik fuer Frauenheilkunde, Baden-WÃ¼rttemberg, 79106, Germany|University Hospital rechts der Isar Technical University of Munich, Bayern, 81675, Germany|Vivantes Klinikum am Urban, Berlin, 10967, Germany|HELIOS Klinikum Berlin-Buch, Berlin, 13125, Germany|Marienhospital Bottrop, Bottrop, 46236, Germany|UniversitÃ¤tsklinik Erlangen, Erlangen, 91054, Germany|SRH Wald-Klinikum Gera GmbH, Gera, 07548, Germany|Universitatsklinikum Hamburg-Eppendorf, Hamburg, 20246, Germany|Medizinische Hochschule Hannover, Hannover, D-30625, Germany|Nationales Centrum fÃ¼r Tumorerkrankungen Heidelberg, Heidelberg, 69120, Germany|UniversitÃ¤tsklinikum Mannheim, Mannheim, 68167, Germany|Universitatsklinikum Munster, Munster, 48149, Germany|LMU Klinikum der Universitat MÃ¼nchen, MÃ¼nchen, 81377, Germany|UniversitÃ¤ts - Frauenklinik, TÃ¼bingen, 72076, Germany|Alexandra General Hospital, Athens, 11528, Greece|Attikon Hospital, Athens, 124 62, Greece|University Hospital of Heraklion, Heraklion, Greece|University Hospital of Larissa, Larissa, 41110, Greece|University Hospital of Patras, Patras, 26 500, Greece|Bioclinic of Thessaloniki, Thessaloniki, 546 22, Greece|Euromedica General Clinic of Thessaloniki, Thessaloniki, 546 45, Greece|Hong Kong Integrated Oncology Centre, Hong Kong, 0, Hong Kong|Prince of Wales Hospital, New Territories, Hong Kong|Queen Mary Hospital, Pok Fu Lam, 0, Hong Kong|Semmelweis Egyetem, Belgyogyaszati es Onkologiai Klinika, Budapest, 1083, Hungary|Debreceni Egyetem Klinikai KÃ¶zpont, Debrecen, 4032, Hungary|BÃ¡cs-Kiskun Varmegyei Oktatokorhaz, Onkaradiologiai Kozpont, KecskemÃ©t, 6000, Hungary|Szabolcs-Szatmar-Bereg Varmegyei Oktatokorhaz, Onkoradiologia, Nyiregyhaza, 4400, Hungary|Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont, Szeged, 6720, Hungary|Oncology Institute Rambam Health Care Campus, Haifa, 31096, Israel|Shaare Zedek Medical Center, Jerusalem, 9103102, Israel|Hadassah Medical Center, Jerusalem, Israel|Rabin Medical Center, Petah Tikva, 4941492, Israel|Sheba Medical Center, Ramat Gan, 52621, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, 64239, Israel|Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona, Ancona AN, 60126, Italy|Centro di Riferimento Oncologico - IRCCS, Aviano, 33081, Italy|Humanitas Gavazzeni, Bergamo, 24125, Italy|ASST Papa Giovanni XXIII, Bergamo, 24127, Italy|IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico di Sant'Orsola, Bologna, Italy|Humanitas Istituto Clinico Catanese, Catania, 95045, Italy|Azienda Ospedaliera Mater Domini, Catanzaro, 88100, Italy|IRCCS Ospedale Policlinico San Martino, Genova GE, 16132, Italy|Fondazione IRCCS San Raffaele del Monte Tabor, Milano, 20132, Italy|Istituto Europeo di Oncologia, Milan, 20141, Italy|Azienda Ospedaliera San Gerardo, Monza, 20090, Italy|Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, 80131, Italy|Istituto Oncologico Veneto IOV, Padova, 35128, Italy|Irccs Crob, Rionero in Vulture, 85028, Italy|Azienda Ospedaliero-Universitaria Policlinico Umberto I, Roma, 161, Italy|Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, 168, Italy|Istituto Clinico Humanitas, Rozzano, 20089, Italy|Aichi Cancer Center Hospital, Aichi, 464-8681, Japan|Tohoku University Hospital, Aoba-ku, 980-8574, Japan|Juntendo University Hospital, Bunkyo-ku, 113-8431, Japan|Chiba Cancer Center, Chiba, 260-8717, Japan|National Cancer Center Hospital, Chuo-ku, 1040045, Japan|Osaka Prefectural Hospital Organization Osaka International Cancer Institute, Chuo-ku, 541-8567, Japan|National Hospital Organization Shikoku Cancer Center, Ehime, 791-0280, Japan|Fukushima Medical University Hospital, Fukushima, Japan|Social Medical Corporation Hakuaikai Sagara Hospital, Kagoshima-shi, 892-0833, Japan|Tokai University Hospital, Kanagawa, 259-1193, Japan|National Cancer Center Hospital East, Kashiwa, 277-8577, Japan|Saitama Cancer Center, Kitaadachi-gun, 362-0806, Japan|Cancer Institute Hospital of JFCR, Koto-Ku, 135-8550, Japan|Kumamoto University Hospital, Kumamoto- shi, 860-8556, Japan|Kyoto University Hospital, Kyoto-shi, 606-8507, Japan|National Hospital Organization Kyushu Cancer Center, Minami-ku, 811-1395, Japan|Nagoya University Hospital, Nagoya, 466-8560, Japan|Hiroshima City Hiroshima Citizens Hospital, Naka-ku, 730-8518, Japan|Hyogo Medical University Hospital, Nishinomiya-shi, 663-8501, Japan|Okayama University Hospital, Okayama, 700-8558, Japan|Gunma Prefectural Cancer Center, Ota, 373-8550, Japan|National Hospital Organization Hokkaido Cancer Center, Sapporo, 003-0804, Japan|Center Hospital of the National Center for Global Health and Medicine, Shinjuku-ku, 162-8655, Japan|Showa University Hospital, Tokyo, 142-8555, Japan|Kanagawa Cancer Center, Yokohama, 241-8515, Japan|Samsung Medical Center, Gangnam-Gu, 06351, Korea, Republic of|National Cancer Center, Goyang-si Gyeonggi-do, 10408, Korea, Republic of|Kyungpook National University Chilgok Hospital, Gyeongsangbuk-do, 41404, Korea, Republic of|Gachon University Gil Medical Center, Incheon, 21565, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, 13620, Korea, Republic of|Korea University Anam Hospital, Seoul, 02841, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, 03722, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Hospital Kuala Lumpur, Kuala Lumpur, 50586, Malaysia|University Malaya Medical Centre, Kuala Lumpur, 59100, Malaysia|Sarawak General Hospital, Kuching, 93586, Malaysia|Institut Kanser Negara, Putrajaya, 62250, Malaysia|Centro de Investigacion y Avances Medicos Especializados, CancÃºn, 77550, Mexico|COI Centro Oncologico Internacional S.A.P.I. de C.V., Mexico City, 04700, Mexico|Hospital Universitario Dr. JosÃ© Eleuterio GonzÃ¡lez, Monterrey, 64460, Mexico|FUCAM, MÃ©xico, 4980, Mexico|Clinica Integral Internacional de Oncologia S de RL de CV, Puebla, 72530, Mexico|Centro Medico Zambrano Hellion, San Pedro Garza GarcÃ­a, 64710, Mexico|Centro de AtenciÃ³n e InvestigaciÃ³n ClÃ­nica en OncologÃ­a, YucatÃ¡n, 97134, Mexico|Copemicus Podmiot Leczniczy Wojewodzkie Centrum Okologii w Gdansku, Gdansk, 80-219, Poland|Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie Sp. z.o.o, Krakow, 31-826, Poland|Instytut MSF Sp. z o.o., Lodz, 90-302, Poland|Wojewodzki Szpital Specjalistyczny lm. Stefana Kardynala Wyszynsklego SPZOZ w Lublinie, Lublin, 19713, Poland|LUX MED Onkologia Sp. Zo.o., Warszawa, 01-748, Poland|Maria Sklodowska - Curie Institute of Oncology, Warszawa, 02-781, Poland|Centro Clinico Academico - Hospital de Braga, Braga, Portugal|Hospital da Senhora da Oliveira Guimaraes, GuimarÃ£es, 4835-044, Portugal|Centro Hospitalar de Lisboa Central, E.P.E . - Hospital de Santo Antonio dos Capuchos, Lisbon, 1153-302, Portugal|Fundacao Champalimaud, Lisbon, 1400-038, Portugal|Centro Hospitalar Lisboa Norte, EPE, Lisbon, 1649-035, Portugal|Unidade Local de Saude de Matosinhos EPE - Hospital Pedro Hispano, Matosinhos, 4464-513, Portugal|National University Hospital, Singapore, 119228, Singapore|National Cancer Centre Singapore, Singapore, 169610, Singapore|Tan Tock Seng Hospital, Singapore, 308433, Singapore|Wilgers Oncology Centre, Gauteng, 0081, South Africa|Wits Clinical Research, Johannesburg, 2192, South Africa|The Medical Oncology Centre of Rosebank, Johannesburg, 2196, South Africa|Cape Town Oncology Trials, Kraaifontein, 7570, South Africa|Hospital Universitari Dexeus, Barcelona, 08028, Spain|Hospital Clinic de Barcelona, Barcelona, 08036, Spain|Hospital Universitari Vall D'Hebron, Barcelona, 8035, Spain|Hospital de Basurto, Bilbo, 48013, Spain|Hospital Universitario Reina Sofia, CÃ³rdoba, 14004, Spain|Hospital General Universitario De Elche, Elche, 3203, Spain|Hospital Universitario de Jaen, Jaen, 23007, Spain|Hospital Beata MarÃ­a Ana, Madrid, 28007, Spain|Hospital General Universitario Gregorio MaraÃ±Ã³n, Madrid, 28007, Spain|MD Anderson Cancer Center, Madrid, 28033, Spain|Hospital Universitario RamÃ³n y Cajal, Madrid, 28034, Spain|Hospital Clinico San Carlos, Madrid, 28040, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital Universitario de Salamanca, Salamanca, 37002, Spain|Hospital ClÃ­nico Universitario de Santiago de Compostela - CHUS, Santiago de Compostela, 15706, Spain|Hospital Universitario Virgen Macarena, Sevilla, 41071, Spain|Hospital Universitario Virgen del Rocio, Seville, 41013, Spain|Instituto Valenciano De Oncologia (IVO), Valencia, 46009, Spain|Hospital ClÃ­nico Universitario de Valencia, Valencia, 46010, Spain|Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, 83301, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, 807, Taiwan|Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare, New Taipei City, 235, Taiwan|Chi Mei Hospital, Liouying, Tainan City, 73657, Taiwan|National Cheng Kung University Hospital, Tainan, 704, Taiwan|Taipei Veterans General Hospital, Taipei City, 11217, Taiwan|National Taiwan University Hospital, Taipei, 10048, Taiwan|Tri-Service General Hospital, Taipei, 11490, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center, Taipei, 999999, Taiwan|Chang Gung Memorial Hospital, Linkou, Taoyuan City, 33305, Taiwan|Barts Cancer Institute, London, EC1A 7BE, United Kingdom|University College London Hospitals, London, NW1 2PG, United Kingdom|The Royal Marsden NHS Foundation Trust, London, SW10 9NH, United Kingdom|The Christie NHS Foundation Trust, Manchester, M20 4BX, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, NG5 1PB, United Kingdom",
NCT04161885,A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML),https://clinicaltrials.gov/study/NCT04161885,VIALE-T,ACTIVE_NOT_RECRUITING,"The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Overall Survival (OS) in Acute Myeloid Leukemia (AML) participants compared to Best Supportive Care (BSC) when given as maintenance therapy following allogeneic stem cell transplantation (SCT).

This study will have 2 parts: Part 1 (Dose Confirmation), which may include participants who are greater than or equal to 18 years old; Part 2 (Randomization) which may include participants who are greater than or equal to 12 years old. During Part 1, recommended Phase 3 dose of venetoclax in combination with azacitidine will be determined and during Part 2, the efficacy and safety of venetoclax with azacitidine (Part 2 Arm A) will be compared with BSC (Part 2 Arm B).",NO,Acute Myeloid Leukemia (AML)|Cancer,DRUG: Venetoclax|DRUG: Azacitidine|OTHER: Best Supportive Care (BSC),"Number of Participants With Dose-Limiting Toxicities (DLTs) Following Administration of Venetoclax and Azacitidine (Part 1), DLTs are any of the hematologic, nonhematologic toxicities, adverse events (AEs) occurring following administration of venetoclax and AZA as described in the protocol and evaluated by the Investigator and the sponsor., Up to the first treatment cycle (28 days)|Overall Survival (OS) (Part 2), OS is defined as the number of days from the date of randomization to the date of death from any cause., Up to 45 months after the first participant is randomized","Morphologic Relapse-Free Survival (RFS) (Part 2), Morphologic relapse from AML defined as bone marrow blasts of \>= 5% or reappearance of blasts in the peripheral blood not attributable to any other cause (e.g., bone marrow regeneration) in at least 2 peripheral blood samples at least one week apart or development of extramedullary disease after achieving a complete remission (CR) or complete remission with incomplete count recovery (CRi); or the date of death from any cause, whichever comes first as determined by Independent Review Committee (IRC)., Up to 39 months after the first participant is randomized|Composite Relapse-Free Survival (RFS) (Part 2), Morphologic relapse from AML, non-morphologic relapse from AML, which is defined as increase in disease burden determined by standard methods with reappearance or acquisition of new findings with or without change in anti-leukemic treatment per investigator decision due to cytogenetic abnormalities or change in molecular marker or measurable residual disease by multiparameter flow with sensitivity to at least 10\^-3; or the date of death from any cause, whichever comes first as determined by IRC., Up to 39 months after the first participant is randomized|Graft-versus-Host Disease (GvHD)-free, Relapse Free Survival (GRFS) (Part 2), GRFS is defined as number of days from the date of randomization to occurrence of disease relapse OR incidence of GvHD OR death from any cause., Up to 39 months after the first participant is randomized|Graft-versus-Host Disease (GvHD) Rate (Part 2), GvHD rate is defined as grade 2 or higher for acute graft-versus-host disease (aGvHD) and moderate/severe for chronic graft-versus-host disease (cGvHD) assessed by investigator., Up to 39 months after the first participant is randomized|Change from Baseline in Physical Functioning as Measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) (Part 2), The EORTC-QLQ-C30 is a 30-item patient-reported questionnaire composed of both multi-item and single scales including 5 functional scales (physical, role, emotional, social, and cognitive), 3 symptom scales (fatigue, nausea and vomiting, and pain), a global health status/QoL scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Participantts rate items on a 4-point scale ranging from 1 to 4 (1 = Not at All, 2 = A Little, 3 = Quite a Bit, and 4 = Very Much)., Up to 39 months after the first participant is randomized|Change From Randomization in Fatigue in Adult Participants (Part 2), Fatigue is measured as Patient Reported Outcome (PRO) using Patient Reported Outcomes Measurement Information System (PROMIS) Cancer Fatigue SF 7a., Up to 39 months after the first participant is randomized|Measurable Residual Disease (MRD) Response Rate in Participants With MRD >= 10^-3 at Randomization (Part 2), MRD conversion rate is defined as percentage of participants who convert to MRD \< 10\^-3 after initiation of treatment., Up to 39 months after the first participant is randomized|Time to Deterioration in Global Health Status (GHS)/Quality of Life (QoL) in Adult Participants (Part 2), Time to deterioration defined as number of days from randomization to either deterioration of \>= 5 points based on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) version 3 or death due to any cause., Up to 39 months after the first participant is randomized|Change in Patient Reported Signs, Symptoms and Impact of Acute Myeloid Leukemia (AML) as Measured by the European Quality-of-Life-5 Dimensional-5-Level (EQ-5D-5L), The EQ-5D-5L is a generic preference instrument that has been validated in numerous population and has 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. These dimensions are measured on a 5-point scale: with higher scores representing better functioning/quality of life and greater symptom burden., Up to 39 months after the first participant is randomized",,AbbVie,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,465,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-02-26,2025-04,2026-11,2019-11-13,,2025-04-22,"Arizona Oncology - Scottsdale - Cancer Transplant Institute /ID# 239711, Scottsdale, Arizona, 85258-4547, United States|University of Arizona Cancer Center - Tucson /ID# 242507, Tucson, Arizona, 85724, United States|University of Arkansas for Medical Sciences /ID# 239804, Little Rock, Arkansas, 72205, United States|City of Hope /ID# 213681, Duarte, California, 91010, United States|UCHSC Anschultz Cancer Pavilion /ID# 215618, Aurora, Colorado, 80045-2517, United States|Colorado Blood Cancer Institute /ID# 215980, Denver, Colorado, 80218, United States|Mayo Clinic /ID# 239710, Jacksonville, Florida, 32224, United States|AdventHealth Medical Group Blood & Marrow Transplant at Orlando /ID# 213985, Orlando, Florida, 32804-5505, United States|Ann & Robert H Lurie Children's Hospital of Chicago /ID# 215840, Chicago, Illinois, 60611, United States|The University of Chicago Medical Center /ID# 215616, Chicago, Illinois, 60637-1443, United States|Loyola University Medical Ctr /ID# 215617, Maywood, Illinois, 60153, United States|Indiana Blood & Marrow Transpl /ID# 215842, Indianapolis, Indiana, 46237, United States|Duplicate_Ochsner Clinic Foundation-New Orleans /ID# 213834, New Orleans, Louisiana, 70121, United States|University of Maryland, Baltimore /ID# 213855, Baltimore, Maryland, 21201, United States|Massachusetts General Hospital /ID# 215765, Boston, Massachusetts, 02114, United States|Karmanos Cancer Institute - Dresner Clinic /ID# 214581, Detroit, Michigan, 48201-2013, United States|Masonic Cancer Center /ID# 239492, Minneapolis, Minnesota, 55455, United States|Mayo Clinic - Rochester /ID# 214685, Rochester, Minnesota, 55905-0001, United States|University of Mississippi Medical Center /ID# 239343, Jackson, Mississippi, 39216-4500, United States|The John Theurer Cancer /ID# 215251, Hackensack, New Jersey, 07601, United States|Montefiore Medical Center - Moses Campus /ID# 241669, Bronx, New York, 10467, United States|Roswell Park Cancer Institute /ID# 217857, Buffalo, New York, 14263, United States|Columbia University Medical Center /ID# 240875, New York, New York, 10032-3729, United States|Memorial Sloan Kettering Cancer Center-Koch Center /ID# 240680, New York, New York, 10065-6007, United States|Weill Cornell Medical College /ID# 214887, New York, New York, 10065, United States|University of North Carolina /ID# 215814, Chapel Hill, North Carolina, 27514, United States|Wake Forest Univ HS /ID# 239210, Winston-Salem, North Carolina, 27157, United States|UC Health - Cincinnati /ID# 239263, Cincinnati, Ohio, 45267-2800, United States|University Hospitals - Seidman Cancer Center /ID# 239260, Cleveland, Ohio, 44106-1716, United States|University of Oklahoma, Stephenson Cancer Center /ID# 215611, Oklahoma City, Oklahoma, 73104-5418, United States|Oregon Health and Science University /ID# 215874, Portland, Oregon, 97239, United States|Penn State Hershey Medical Ctr /ID# 217120, Hershey, Pennsylvania, 17033-2360, United States|Children's Hospital of Philadelphia - Main /ID# 215410, Philadelphia, Pennsylvania, 19104-4319, United States|Perelman Center for Advanced Medicine /ID# 214518, Philadelphia, Pennsylvania, 19104, United States|Duplicate_Allegheny General Hospital /ID# 216756, Pittsburgh, Pennsylvania, 15212, United States|UPMC Hillman Cancer Ctr /ID# 213715, Pittsburgh, Pennsylvania, 15232, United States|TriStar Centennial Medical Center /ID# 218750, Nashville, Tennessee, 37203-1551, United States|Texas Oncology - Medical City Dallas /ID# 216720, Dallas, Texas, 75230, United States|Texas Oncology- Baylor Charles A. Sammons Cancer Center /ID# 213735, Dallas, Texas, 75246-2003, United States|Texas Transplant Institute /ID# 214691, San Antonio, Texas, 78229, United States|Virginia Commonwealth University Medical Center Main Hospital /ID# 239203, Richmond, Virginia, 23219, United States|Fred Hutchinson Cancer Research Center /ID# 214436, Seattle, Washington, 98109-1024, United States|Univ of Wisconsin Hosp/Clinics /ID# 216096, Madison, Wisconsin, 53792-0001, United States|The Kinghorn Cancer Centre /ID# 214660, Darlinghurst, New South Wales, 2010, Australia|Royal Adelaide Hospital /ID# 215678, Adelaide, South Australia, 5000, Australia|Peter MacCallum Cancer Ctr /ID# 214653, Melbourne, Victoria, 3000, Australia|The Alfred Hospital /ID# 240931, Melbourne, Victoria, 3004, Australia|Hospital de Clinicas de Porto Alegre /ID# 215042, Porto Alegre, Rio Grande Do Sul, 90035-903, Brazil|Hospital Amaral Carvalho - Fundacao Doutor Amaral Carvalho /ID# 215145, JaÃº, Sao Paulo, 17210-070, Brazil|Hospital Nove de Julho /ID# 242359, SÃ£o Paulo, Sao Paulo, 01409-001, Brazil|Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao /ID# 239516, Sao Paulo, 05403-000, Brazil|Vancouver Coastal Health Research Institute (VCHRI) /ID# 215363, Vancouver, British Columbia, V5Z 1M9, Canada|University Health Network_Princess Margaret Cancer Centre /ID# 215344, Toronto, Ontario, M5G 2M9, Canada|CIUSSS de l'est de l'Ile-de-Montreal - Hopital Maisonneuve-Rosemont /ID# 214591, Montreal, Quebec, H1T 2M4, Canada|Royal Victoria Hospital / McGill University Health Centre /ID# 215253, Montreal, Quebec, H4A 3J1, Canada|Saskatoon Cancer Centre /ID# 238821, Saskatoon, Saskatchewan, S7N 4H4, Canada|Peking University People's Hospital /ID# 215551, Beijing, Beijing, 100044, China|Chinese PLA General Hospital /ID# 216287, Beijing, Beijing, 100853, China|Aerospace Center Hospital /ID# 217018, Beijing, Beijing, 861059, China|Fujian Medical University Union Hospital /ID# 215555, Fuzhou, Fujian, 350001, China|Guangdong Provincial People's Hospital /ID# 218666, Guangzhou, Guangdong, 510080, China|Zhujiang Hospital of Southern Medical University /ID# 216333, Guangzhou, Guangdong, 510280, China|Nanfang Hospital of Southern Medical University /ID# 215553, Guangzhou, Guangdong, 510515, China|Shenzhen Second People's Hospital /ID# 239401, Shenzhen, Guangdong, 518039, China|Henan Cancer Hospital /ID# 215554, Zhengzhou, Henan, 450008, China|Tongji Hospital Tongji Medical College Huazhong University of Science and Techno /ID# 215552, Wuhan, Hubei, 430022, China|Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 238373, Wuhan, Hubei, 430022, China|Xiangya Hospital Central South University /ID# 219025, Changsha, Hunan, 410008, China|Zhongda Hospital Southeast University /ID# 218926, Nanjing, Jiangsu, 210009, China|The First Affiliated Hospital of Soochow University /ID# 216605, Suzhou, Jiangsu, 215006, China|The Affiliated Hospital of Xuzhou Medical College /ID# 239098, Xuzhou, Jiangsu, 221006, China|The First Affiliated Hospital of Nanchang University /ID# 239168, Nanchang, Jiangxi, 330006, China|Shanghai Changhai Hospital /ID# 216334, Shanghai, Shanghai, 200433, China|Tangdu Hospital of The Fourth Military Medical University, PLA /ID# 216282, Xi'an, Shanxi, 710038, China|Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc /ID# 215546, Tianjin, Tianjin, 300020, China|The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 215550, Hangzhou, Zhejiang, 310003, China|FakultnÃ­ Nemocnice Brno - JihlavskÃ¡ /ID# 214811, Brno, Brno-mesto, 625 00, Czechia|FakultnÃ­ nemocnice Hradec KrÃ¡lovÃ© - SokolskÃ¡ /ID# 214814, Hradec KrÃ¡lovÃ©, Hradec Kralove, 500 05, Czechia|Fakultni Nemocnice Ostrava /ID# 239922, Ostrava, Ostrava-mesto, 708 52, Czechia|Ustav hematologie a krevni transfuze /ID# 215133, Praha, 128 00, Czechia|Duplicate_CHU de Nice - HÃ´pital Archet 1 /ID# 214056, Nice, Alpes-Maritimes, 06200, France|CHU de Besancon - Jean Minjoz /ID# 241171, Besancon, Doubs, 25030, France|Duplicate_CHU Bordeaux - Hopital Haut Leveque /ID# 214055, Pessac, Gironde, 33604, France|Hopital Pitie Salpetriere /ID# 241072, Paris Cedex 13, Ile-de-France, 75013, France|CHRU Lille - Hopital Claude Huriez /ID# 217916, Lille, Nord, 59037, France|CHU de Nantes, Hotel Dieu -HME /ID# 214060, Nantes, Pays-de-la-Loire, 44000, France|HÃ´pital Saint-Louis /ID# 214054, Paris, 75010, France|AP-HP - Hopital Saint-Antoine /ID# 216957, Paris, 75012, France|Universitaetsklinik Heidelberg /ID# 216623, Heidelberg, Baden-Wuerttemberg, 69120, Germany|Klinikum Augsburg /ID# 239583, Augsburg, Bayern, 86156, Germany|Universitaetsklinikum Wuerzburg /ID# 215212, Wuerzburg, Bayern, 97080, Germany|Universitaetsklinikum Muenster /ID# 215213, Muenster, Nordrhein-Westfalen, 48149, Germany|Universitaetsklinikum Carl Gustav Carus Dresden /ID# 214244, Dresden, Sachsen, 01307, Germany|Universitaetsklinikum Leipzig /ID# 245892, Leipzig, Sachsen, 04103, Germany|Universitaetsklinikum Halle (Saale) /ID# 239585, Halle (Saale), 06120, Germany|Medizinische Hochschule Hannover /ID# 214243, Hannover, 30625, Germany|General Hospital of Athens Evangelismos /ID# 238810, Athens, Attiki, 10676, Greece|University General Hospital Attikon /ID# 238812, Athens, Attiki, 12462, Greece|University General Hospital of Patras /ID# 238811, RION Patras Achaia, 26504, Greece|Debreceni Egyetem-Klinikai Kozpont /ID# 241123, Debrecen, Hajdu-Bihar, 4032, Hungary|Rambam Health Care Campus /ID# 214507, Haifa, H_efa, 3109601, Israel|Schneider Children's Medical Center /ID# 224326, Petah Tikva, HaMerkaz, 4920235, Israel|Sheba Medical Center /ID# 239571, Ramat Gan, Tel-Aviv, 52621, Israel|The Chaim Sheba Medical Center /ID# 214305, Ramat Gan, Tel-Aviv, 5265601, Israel|Tel Aviv Sourasky Medical Center /ID# 214508, Tel Aviv, Tel-Aviv, 6423906, Israel|Hadassah Medical Center-Hebrew University /ID# 218697, Jerusalem, Yerushalayim, 91120, Israel|Rabin Medical Center /ID# 214509, Petah Tikva, 4941492, Israel|IRCCS Ospedale San Raffaele /ID# 214311, Milan, Milano, 20132, Italy|Istituto Europeo Di Oncologia /ID# 242579, Milan, Milano, 20141, Italy|A.O.U. CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO - Ospedale Molinette /ID# 216148, Torino, Piemonte, 10126, Italy|Azienda Ospedaliero-Universitaria Policlinico Umberto I /ID# 254964, Rome, Roma, 00161, Italy|Fondazione Policlinico Universitario Agostino Gemelli IRCCS-UniversitÃ  Cattolica /ID# 214910, Rome, Roma, 00168, Italy|ASST degli Spedali Civili di Brescia /ID# 215997, Brescia, 25123, Italy|Anjou Kousei Hospital /ID# 215857, Anjo-shi, Aichi, 446-8602, Japan|Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital /ID# 215679, Nagoya-shi, Aichi, 453-8511, Japan|University of Fukui Hospital /ID# 253383, Yoshida-gun, Fukui, 910-1104, Japan|Kyushu University Hospital /ID# 215285, Fukuoka-shi, Fukuoka, 812-8582, Japan|Fukushima Medical University Hospital /ID# 252293, Fukushima-shi, Fukushima, 960-1295, Japan|Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital /ID# 217522, Hiroshima-shi, Hiroshima, 730-8619, Japan|Hokkaido University Hospital /ID# 215937, Sapporo-shi, Hokkaido, 060-8648, Japan|Kobe City Medical Center General Hospital /ID# 215388, Kobe-shi, Hyogo, 650-0047, Japan|Hyogo Medical University Hospital /ID# 215389, Nishinomiya-shi, Hyogo, 663-8501, Japan|Kanazawa University Hospital /ID# 242955, Kanazawa-shi, Ishikawa, 920-8641, Japan|Imamura General Hospital /ID# 215688, Kagoshima-shi, Kagoshima, 890-0064, Japan|Tokai University Hospital /ID# 250086, Isehara, Kanagawa, 259-1193, Japan|Kanagawa Cancer Center /ID# 215029, Yokohama-shi, Kanagawa, 241-8515, Japan|Kyoto University Hospital /ID# 243209, Kyoto-shi, Kyoto, 606-8507, Japan|Tohoku University Hospital /ID# 214670, Sendai-shi, Miyagi, 9808574, Japan|Okayama University Hospital /ID# 214842, Okayama-shi, Okayama, 700-8558, Japan|Osaka Metropolitan University Hospital /ID# 215227, Osaka-shi, Osaka, 545-8586, Japan|Kindai University Hospital /ID# 214917, Osakasayama-shi, Osaka, 589-8511, Japan|Jichi Medical University Saitama Medical Center /ID# 216092, Saitama-shi, Saitama, 330-8503, Japan|Jichi Medical University Hospital /ID# 216091, Shimotsuke-shi, Tochigi, 329-0498, Japan|Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital /ID# 215939, Bunkyo-ku, Tokyo, 113-8677, Japan|National Cancer Center Hospital /ID# 242639, Chuo-ku, Tokyo, 104-0045, Japan|Toranomon Hospital /ID# 215311, Minato-ku, Tokyo, 105-8470, Japan|National Center for Child Health and Development /ID# 242479, Setagaya-ku, Tokyo, 157-8535, Japan|Keio University Hospital /ID# 243549, Shinjuku-ku, Tokyo, 160-8582, Japan|Yamagata University Hospital /ID# 253304, Yamagata-shi, Yamagata, 990-9585, Japan|Seoul National University Hospital /ID# 214891, Seoul, Seoul Teugbyeolsi, 03080, Korea, Republic of|Asan Medical Center /ID# 214893, Seoul, Seoul Teugbyeolsi, 05505, Korea, Republic of|Samsung Medical Center /ID# 239087, Seoul, Seoul Teugbyeolsi, 06351, Korea, Republic of|The Catholic University of Korea, Seoul St. Marys Hospital /ID# 214892, Seoul, Seoul Teugbyeolsi, 06591, Korea, Republic of|Hospital Clinic de Barcelona /ID# 215108, Barcelona, 08036, Spain|Hospital Santa Creu i Sant Pau /ID# 240397, Barcelona, 08041, Spain|Hospital General Universitario Gregorio Maranon /ID# 215107, Madrid, 28007, Spain|Hospital Universitario Ramon y Cajal /ID# 218102, Madrid, 28034, Spain|Hospital Universitario La Paz /ID# 218103, Madrid, 28046, Spain|Hospital Universitario Virgen del Rocio /ID# 215463, Sevilla, 41013, Spain|Hospital Clinico Universitario de Valencia /ID# 215106, Valencia, 46010, Spain|Duplicate_UniversitÃ¤tsspital Basel /ID# 215892, Basel, Basel-Stadt, 4031, Switzerland|University Hospital Zurich /ID# 215891, Zurich, Zuerich, 8006, Switzerland|National Taiwan University Hospital /ID# 215245, Taipei City, Taipei, 100, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 215197, Kaohsiung, 807, Taiwan|China Medical University Hospital /ID# 215198, Taichung, 40447, Taiwan|Taichung Veterans General Hospital /ID# 239288, Taichung, 40705, Taiwan|Taipei Veterans General Hosp /ID# 239289, Taipei, 11217, Taiwan|Linkou Chang Gung Memorial Hospital /ID# 215319, Taoyuan City, 333, Taiwan|Hammersmith Hospital /ID# 215665, London, England, W12 0HS, United Kingdom|Gartnavel General Hospital /ID# 215663, Glasgow, Glasgow City, G12 0YN, United Kingdom|University College London Hospital /ID# 215662, London, Greater London, NW1 2BU, United Kingdom|University Hospitals Birmingham NHS Foundation Trust /ID# 215120, Birmingham, B15 2TH, United Kingdom|King's College Hospital NHS Foundation Trust /ID# 215338, London, SE5 9RS, United Kingdom|The Royal Marsden NHS Foundation Trust /ID# 215124, London, SW3 6JJ, United Kingdom|The Newcastle Upon Tyne Hospitals NHS Foundation Trust /ID# 248359, Newcastle upon Tyne, NE3 3HD, United Kingdom",
NCT06051409,A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL.,https://clinicaltrials.gov/study/NCT06051409,,RECRUITING,"A global multicenter, open-label, randomized and registrational Phase 3 study to evaluate efficacy and safety of Olverembatinib combined with chemotherapy versus Imatinib combined with chemotherapy in subjects with newly diagnosed Ph+ALL.",NO,Ph+ ALL,DRUG: Olverembatinib|DRUG: Imatinib,"Minimal residual disease negativity rate, The minimal residual disease negativity rate of olverembatinib combined chemotherapy versus imatinib combined chemotherapy in subjects with newly diagnosed Ph+ALL., Cycles 1 to cycle 3 (each cycle is 28 days)","Number of participants with treatment-related adverse events as assessed by CTCAE v5.0., According to CTCAE v5.0, the number and frequency of adverse events of test drug were assessed., Through study completion,an average of 2 years.|Plasma concentrations of olverembatinib, Blood samples will be collected to measure the plasma concentration of olverembatinib., Cycle 1 to Cycle 3 (each cycle is 28 days)|The patients' score of EORTC(The European Organization for Research and Treatment of Cancer) QLQ-C30., To evaluate patient-reported outcome in patients treated with olverembatinib plus chemotherapy.ï¼The scale ranges from 0 to 100, with a lower score indicating better quality of life and a higher score on the scale indicating worse symptoms.ï¼, Through study completion,an average of 2 years.",,Ascentage Pharma Group Inc.,HealthQuest Pharma Inc.,ALL,"ADULT, OLDER_ADULT",PHASE3,350,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-08-31,2024-12-31,2028-10-31,2023-09-22,,2024-11-07,"Royal North Shore Hospital, St. Leonards, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, 5000, Australia|Alfred Health, Melbourne, Victoria, 3004, Australia|Royal Perth Hospital, Perth, Washington, 6000, Australia|The First Affiliated Hospitalo of Bengbu Medical School, Bengbu, Anhui, 233000, China|Xinqiao Hospital of Army Medical University, Chongqing, Chongqing, 214426, China|Guangdong Province People's Hospital, Guangdong, Guangzhou, 510080, China|Nanfang Hospital of Southern Medical University, Guangdong, Guangzhou, 510515, China|Henan Cancer Hospital, Zhengzhou, Henan, 450003, China|Wuhan Union Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, 430022, China|The first affiliated hospital of Suzhou University, Suzhou, Jiangsu, 215006, China|Shanghai Jiao Tong University School of Medicine Ruijin Hospital, Shanghai, Shanghai, 200025, China|West China Hospital of Sichuan University, Chengdu, Sichuan, 610044, China|Institute of blood transfusion of Chinese Academy of Medical Sciences, Tianjin, Tianjin, 215127, China",
NCT06136559,A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011),https://clinicaltrials.gov/study/NCT06136559,,RECRUITING,The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior therapy. The primary hypotheses are that (1) nemtabrutinib is non-inferior to ibrutinib or acalabrutinib with respect to objective response rate (ORR) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria 2018 by blinded independent central review (BICR) and (2) nemtabrutinib is superior to ibrutinib or acalabrutinib with respect to progression free survival (PFS) per iwCLL Criteria 2018 by BICR.,NO,Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,DRUG: Nemtabrutinib|DRUG: Ibrutinib|DRUG: Acalabrutinib,"Objective Response Rate (ORR) per Chronic Lymphocytic Leukemia (iwCLL) Criteria 2018 as assessed by Blinded Independent Central Review (BICR), ORR is defined as the percentage of participants with complete response (CR), complete response with an incomplete recovery of the participant's bone marrow (CRi), nodular partial response (nPR), or partial response (PR), per iwCLL Criteria 2018 as assessed by BICR., Up to ~33 months|Progression-Free Survival (PFS) per iwCLL Criteria 2018 as assessed by BICR, PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. PD is evaluated per iwCLL Criteria 2018 as assessed by BICR., Up to ~104 months","Overall Survival (OS), OS is defined as the time from randomization to death due to any cause., Up to ~104 months|Duration of Response (DOR) per iwCLL Criteria 2018 as assessed by BICR, For participants who demonstrate a complete response (CR), complete response with an incomplete recovery of the participant's bone marrow (CRi), nodular partial response (nPR), or partial response (PR) per iwCLL Criteria 2018 as assessed by BICR, DOR is defined as the time from the first documented evidence of CR, CRi, nPR, or PR that led to response until disease progression or death due to any cause, whichever occurs first., Up to ~104 months|Number of Participants Who Experience One or More Adverse Events (AEs), An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention., Up to ~104 months|Number of Participants Who Discontinue Study Treatment Due to an AE, An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention., Up to ~104 months",,Merck Sharp & Dohme LLC,,ALL,"ADULT, OLDER_ADULT",PHASE3,1200,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-12-13,2032-09-30,2032-09-30,2023-11-18,,2025-06-13,"USA Mitchell Cancer Institute ( Site 0014), Mobile, Alabama, 36604, United States|Arizona Oncology Associates - NAHOA ( Site 8007), Prescott, Arizona, 86301, United States|Alta Bates Summit Medical Center ( Site 0004), Berkeley, California, 94704, United States|Moores Cancer Center ( Site 0003), La Jolla, California, 92093-0698, United States|Saint Joseph Hospital ( Site 0026), Denver, Colorado, 80218, United States|Lutheran Medical Center ( Site 0027), Golden, Colorado, 80401, United States|Intermountain Health St. Mary's Regional Hospital ( Site 0025), Grand Junction, Colorado, 81501, United States|Eastern CT Hematology & Oncology Associates ( Site 0033), Norwich, Connecticut, 06360, United States|Florida Cancer Specialists - South ( Site 7001), Fort Myers, Florida, 33901, United States|Florida Cancer Specialists - East ( Site 7002), West Palm Beach, Florida, 33401, United States|Parkview Research Center at Parkview Regional Medical Center ( Site 0002), Fort Wayne, Indiana, 46845, United States|University of Iowa-Holden Comprehensive Cancer Center ( Site 0017), Iowa City, Iowa, 52242, United States|Saint Elizabeth Healthcare ( Site 0041), Edgewood, Kentucky, 41017, United States|Corewell Health-Lemmon Holton Cancer Pavilion ( Site 0011), Grand Rapids, Michigan, 49503, United States|Regions Hospital ( Site 0042), Saint Louis Park, Minnesota, 55416, United States|Summit Medical Group Cancer Center ( Site 0007), Florham Park, New Jersey, 07932, United States|John Theurer Cancer Center at Hackensack University Medical Center ( Site 0016), Hackensack, New Jersey, 07601, United States|Roswell Park Cancer Institute ( Site 0023), Buffalo, New York, 14263, United States|Consultants in Medical Oncology and Hematology (CMOH) ( Site 8002), Broomall, Pennsylvania, 19008, United States|Cancer Care Associates Of York ( Site 0005), York, Pennsylvania, 17403, United States|Texas Oncology - Central/South Texas ( Site 8008), Austin, Texas, 78705, United States|The Center for Cancer and Blood Disorders ( Site 0032), Fort Worth, Texas, 76104, United States|Texas Oncology - San Antonio ( Site 8006), San Antonio, Texas, 78217, United States|Texas Oncology - Northeast Texas ( Site 8012), Tyler, Texas, 75702, United States|Inova Schar Cancer Institute ( Site 0015), Fairfax, Virginia, 22031, United States|Virginia Commonwealth University (VCU) Medical Center ( Site 0030), Richmond, Virginia, 23298, United States|Medical Oncology Associates, PS (dba Summit Cancer Centers) ( Site 0010), Spokane, Washington, 99208, United States|University Hospital and UW Health Clinics ( Site 0006), Madison, Wisconsin, 53792, United States|Royal North Shore Hospital ( Site 2806), St Leonards, New South Wales, 2065, Australia|AZ Sint-Maarten, Campus Leopoldstraat 2 ( Site 0205), Mechelen, Antwerpen, 2800, Belgium|UZ Leuven-Hematology ( Site 0200), Leuven, Vlaams-Brabant, 3000, Belgium|Hospital 9 De Julho ( Site 2206), SÃ£o Paulo, Sao Paulo, 01409-001, Brazil|Instituto Nacional de CÃ¢ncer - INCA ( Site 2201), Rio de Janeiro, 20230-130, Brazil|Hospital Paulistano-Americas Oncologia ( Site 2202), Sao Paulo, 01321-001, Brazil|BC Cancer Victoria ( Site 0109), Victoria, British Columbia, V8R 6V5, Canada|William Osler Health System ( Site 0103), Brampton, Ontario, L6R 3J7, Canada|The Ottawa Hospital - General Campus ( Site 0102), Ottawa, Ontario, K1H 8L6, Canada|McGill University Health Centre ( Site 0106), MontrÃ©al, Quebec, H4A 3J1, Canada|Centre intÃ©grÃ© de santÃ© et de services sociaux du Bas Saint-Laurent- HÃ´pital rÃ©gional de Rimouski ( Site 0100), Rimouski, Quebec, G5L 5T1, Canada|Bradfordhill-Clinical Area ( Site 2310), Santiago., Region M. De Santiago, 8420383, Chile|FALP-UIDO ( Site 2300), Santiago, Region M. De Santiago, 7500921, Chile|ClÃ­nica Alemana de Santiago-Unidad de Investigaciones ( Site 2306), Santiago, Region M. De Santiago, 7650568, Chile|Anhui Provincial Cancer Hospital ( Site 2001), Hefei, Anhui, 230000, China|Peking University First Hospital ( Site 2022), Beijing, Beijing, 100034, China|Peking University Third Hospital-Hematology ( Site 2011), Beijing, Beijing, 100191, China|Chongqing University Cancer Hospital ( Site 2041), Chongqing, Chongqing, 400030, China|Southern Medical University Nanfang Hospital-Department of Hematopathology ( Site 2006), Guangzhou, Guangdong, 510515, China|Sun Yat-sen University Cancer Center ( Site 2028), Guangzhou, Guangdong, 510700, China|Liuzhou People's Hospital ( Site 2029), Liuzhou, Guangxi, 545006, China|Guangxi Medical University Affiliated Tumor Hospital ( Site 2004), Nanning, Guangxi, 530200, China|The Affiliated Hospital of Guizhou Medical University ( Site 2024), Guiyang, Guizhou, 550004, China|Hainan General Hospital ( Site 2018), Haikou, Hainan, 570311, China|Wuhan Union Hospital ( Site 2015), Wuhan, Hebei, 4730056, China|Henan Cancer Hospital-hematology department ( Site 2025), Zhengzhou, Henan, 450008, China|Tongji Hospital Affiliated to Tongji Medical College of HUST ( Site 2016), Wuhan, Hubei, 430000, China|Hunan Cancer Hospital ( Site 2020), Changsha, Hunan, 410006, China|The Second Xiangya Hospital of Central South University ( Site 2010), Changsha, Hunan, 410011, China|Jiangsu Province Hospital ( Site 2000), Nanjing, Jiangsu, 210029, China|The First Affliated Hospital of Suzhou University ( Site 2027), Suzhou, Jiangsu, 215000, China|The Affiliated Hospital of Xuzhou Medical College ( Site 2013), Xuzhou, Jiangsu, 221006, China|The First Affiliated Hospital of Nanchang University ( Site 2023), Nanchang, Jiangxi, 330006, China|Jiangxi Provincial Cancer Hospital ( Site 2009), Nanchang, Jiangxi, 330029, China|The First Hospital of Jilin University-Hematology ( Site 2030), Changchun, Jilin, 130021, China|Shaanxi provincial people's hospital ( Site 2012), Xian, Shaanxi, 710068, China|Shandong Cancer Hospital ( Site 2003), Jinan, Shandong, 250117, China|Shanxi Cancer Hospital ( Site 2033), Taiyuan, Shanxi, 030000, China|West China Hospital, Sichuan University-Head and Neck Oncology ( Site 2026), Cheng Du, Sichuan, 610041, China|Tianjin Medical University Cancer Institute & Hospital-lymphoma ( Site 2019), Tianjin, Tianjin, 300060, China|Institute of hematology&blood disease hospital-Lymphoma ( Site 2005), Tianjin, Tianjin, 301617, China|Xinjiang Medical University Cancer Hospital - Urumqi ( Site 2014), Urumqi, Xinjiang, 830000, China|The first Affiliated Hospital, Zhejiang University School of Medicine-Hematology ( Site 2002), Hangzhou, Zhejiang, 310003, China|Zhejiang Cancer Hospital ( Site 2017), Hangzhou, Zhejiang, 310022, China|Sociedad De OncologÃ­a y HematologÃ­a Del Cesar SAS-Oncology ( Site 2405), Valledupar, Cesar, 200001, Colombia|IMAT S.A.S ( Site 2401), Monteria, Cordoba, 230002, Colombia|Fundacion Valle del Lili- CIC-Oncology CIC ( Site 2402), Cali, Valle Del Cauca, 760032, Colombia|Fakultni nemocnice Hradec Kralove-IV. interni hematologicka klinika ( Site 0301), Hradec Kralove, 500 05, Czechia|Fakultni nemocnice Olomouc ( Site 0303), Olomouc, 779 00, Czechia|Vseobecna fakultni nemocnice v Praze-I. InternÃ­ klinika - klinika hematologie ( Site 0302), Praha 2, 128 08, Czechia|Aalborg Universitetshospital, Syd ( Site 0403), Aalborg, Nordjylland, 9000, Denmark|Roskilde Sygehus-Department of Hematology ( Site 0402), Roskilde, Sjaelland, 4000, Denmark|Odense Universitetshospital-Department of Hematology ( Site 0401), Odense C, Syddanmark, 5000, Denmark|Universitaetsklinikum Ulm. ( Site 0601), Ulm, Baden-Wurttemberg, 89081, Germany|VK&K Studien GbR ( Site 0607), Landshut, Bayern, 84036, Germany|Kliniken Maria Hilf ( Site 0603), MÃ¶nchengladbach, Nordrhein-Westfalen, 41063, Germany|InVO Institut fÃ¼r Versorgungsforschung in der Onkologie ( Site 0606), Koblenz, Rheinland-Pfalz, 56068, Germany|UniversitÃ¤tsklinikum Halle ( Site 0604), Halle, Sachsen-Anhalt, 06120, Germany|Onkologische Schwerpunktpraxis Kurfuerstendamm ( Site 0600), Berlin, 10707, Germany|University Hospital of Alexandroupolis ( Site 0701), Alexandroupolis, Anatoliki Makedonia Kai Thraki, 681 00, Greece|Evangelismos General Hospital of Athens ( Site 0700), Athens, Attiki, 106 76, Greece|General Hospital of Athens ""Laiko"" ( Site 0704), Athens, Attiki, 115 26, Greece|University Hospital of Ioannina ( Site 0702), Ioannina, 455 00, Greece|Queen Mary Hospital ( Site 3300), Hong Kong, Hong Kong|Rambam Health Care Campus-Hematology and Bone Marrow Transplantation ( Site 1503), Haifa, 3109601, Israel|Bnai Zion Medical Center ( Site 1505), Haifa, 3339419, Israel|Hadassah Medical Center-Hemato-Oncology ( Site 1500), Jerusalem, 9112001, Israel|Rabin Medical Center ( Site 1504), Petah Tikva, 4941492, Israel|Sheba Medical Center-Hemato Oncology ( Site 1501), Ramat Gan, 5265601, Israel|Yitzhak Shamir Medical Center. ( Site 1506), Zerifin, 70300, Israel|Nagoya University Hospital ( Site 1907), Nagoya, Aichi, 466-8560, Japan|Gunma University Hospital ( Site 1903), Maebashi, Gunma, 371-8511, Japan|Hokkaido University Hospital ( Site 1900), Sapporo, Hokkaido, 060-8648, Japan|Kobe City Medical Center General Hospital ( Site 1910), Kobe, Hyogo, 650-0047, Japan|Tohoku University Hospital ( Site 1901), Sendai, Miyagi, 980-8574, Japan|Kindai University Hospital ( Site 1909), Sayama, Osaka, 589-8511, Japan|Shimane University Hospital ( Site 1911), Izumo, Shimane, 693-8501, Japan|Cancer Institute Hospital of JFCR ( Site 1906), Koto, Tokyo, 135-8550, Japan|Chiba Cancer Center ( Site 1905), Chiba, 260-8717, Japan|Kyushu University Hospital ( Site 1914), Fukuoka, 812-8582, Japan|Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital ( Site 1913), Hiroshima, 730-0052, Japan|Okayama University Hospital ( Site 1912), Okayama, 700-8558, Japan|Japanese Red Cross Osaka Hospital ( Site 1908), Osaka, 543-8555, Japan|Yamagata University Hospital ( Site 1902), Yamagata, 990-9585, Japan|University Malaya Medical Centre ( Site 1604), Lembah Pantai, Kuala Lumpur, 59100, Malaysia|Hospital Pulau Pinang ( Site 1602), George Town, Pulau Pinang, 10450, Malaysia|Queen Elizabeth Hospital ( Site 1603), Kota Kinabalu, Sabah, 88586, Malaysia|Centro de Infusion Superare ( Site 2602), Ciudad de MÃ©xico, Distrito Federal, 03100, Mexico|Health Pharma Professional Research S.A. de C.V: ( Site 2608), Ciudad de MÃ©xico, Distrito Federal, 03100, Mexico|Waikato Hospital-Haematology ( Site 3202), Hamilton, Waikato, 3240, New Zealand|North Shore Hospital-Department of Haematology ( Site 3200), Auckland, 0622, New Zealand|Aotearoa Clinical Trials ( Site 3201), Auckland, 2025, New Zealand|Akershus Universitetssykehus ( Site 0902), LÃ¸renskog, Akershus, 1474, Norway|Oslo Universitetssykehus Rikshospitalet-Avdeling for blodsykdommer ( Site 0901), Oslo, 0372, Norway|Centro Medico Monte Carmelo-Oncology ( Site 2706), Arequipa, Ariqipa, 054, Peru|ClÃ­nica Anglo Americana ( Site 2701), Lima, 15073, Peru|Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublinie-OddziaÅ Hematoonkologii, Transplantacji Szp ( Site 1006), Lublin, Lubelskie, 20-081, Poland|Pratia MCM Krakow ( Site 1007), Krakow, Malopolskie, 30-727, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Kilinka Onkologii I Hematologii ( Site 1004), Warszawa, Mazowieckie, 02-781, Poland|Uniwersyteckie Centrum Kliniczne-Klinika Hematologii i Transplantologii ( Site 1011), Gdansk, Pomorskie, 80-214, Poland|WojewÃ³dzki Szpital Specjalistyczny im. J. Korczaka w SÅupsku-OddziaÅ Hematologii i Transplantacji ( Site 1013), SÅupsk, Pomorskie, 76-200, Poland|Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 1000), Gliwice, Slaskie, 44-101, Poland|Pratia Onkologia Katowice ( Site 1009), Katowice, Slaskie, 40-519, Poland|Samodzielny Publiczny ZakÅad Opieki Zdrowotnej MSWiA w Olsztynie-Oddzial Kliniczny Hematologii ( Site 1005), Olsztyn, Warminsko-mazurskie, 10-228, Poland|Instituto PortuguÃªs de Oncologia de Lisboa Francisco Gentil ( Site 3103), Lisbon, Lisboa, 1099-023, Portugal|Champalimaud Foundation ( Site 3102), Lisbon, Lisboa, 1400-038, Portugal|Unidade Local de Saude Gaia/Espinho - Hospital Eduardo Santos Silva ( Site 3107), Vila Nova de Gaia, Porto, 4434-502, Portugal|Unidade Local de Saude Lisboa Ocidental - Hospital de SÃ£o Francisco Xavier ( Site 3104), Lisboa, 1449-005, Portugal|Unidade Local de Saude de Santa Maria - Hospital de Santa Maria ( Site 3106), Lisboa, 1649-035, Portugal|Instituto PortuguÃªs de Oncologia do Porto Francisco Gentil, EPE ( Site 3100), Porto, 4200-072, Portugal|Netcare Pretoria East Hospital-Alberts Cellular Therapy ( Site 1101), Centurion, Gauteng, 0181, South Africa|Wits Clinical Research ( Site 1102), Johannesburg, Gauteng, 1864, South Africa|Groote Schuur Hospital-Clinical Haematology ( Site 1100), Cape Town, Western Cape, 7925, South Africa|Haemalife ( Site 1105), Kuilsriver, Western Cape, 7580, South Africa|Constantiaberg Haematology ( Site 1106), Plumstead, Western Cape, 7800, South Africa|Institut CatalÃ  d'Oncologia - L'Hospitalet-Haematology Department ( Site 1207), L'Hospitalet Del Llobregat, Barcelona, 08908, Spain|HOSPITAL CLÃNIC DE BARCELONA ( Site 1202), Barcelona, Cataluna, 08036, Spain|HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA ( Site 1208), Majadahonda, Madrid, Comunidad De, 28222, Spain|HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID ( Site 1209), Pozuelo de Alarcon, Madrid, 28223, Spain|hospital universitario de canarias ( Site 1205), La Laguna, Santa Cruz De Tenerife, 38320, Spain|Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 1206), Barcelona, 08035, Spain|Hospital Universitario de Salamanca - Complejo Asistencial U-Servicio de Hematologia ( Site 1201), Salamanca, 37007, Spain|Karolinska Universitetssjukhuset Solna ( Site 1302), Stockholm, Stockholms Lan, 171 64, Sweden|Chang Gung Memorial Hospital at Kaohsiung-Division of Hematology and Oncology ( Site 1702), Kaohsiung, 83301, Taiwan|National Cheng Kung University Hospital ( Site 1700), Tainan, 704, Taiwan|National Taiwan University Hospital ( Site 1701), Taipei, 10048, Taiwan|Chang Gung Medical Foundation-Linkou Branch ( Site 1703), Taoyuan, 33305, Taiwan|Maharaj Nakorn Chiang Mai Hospital ( Site 1800), Muang, Chiang Mai, 50200, Thailand|Chulalongkorn University ( Site 1802), Bangkok, Krung Thep Maha Nakhon, 10330, Thailand|Faculty of Medicine Siriraj Hospital-Division of Hematology, Department of Medicine ( Site 1801), Bangkok, Krung Thep Maha Nakhon, 10700, Thailand|Naresuan University Hospital ( Site 1804), Muang, Phitsanulok, 65000, Thailand|Songklanagarind hospital ( Site 1803), HatYai, Songkhla, 90110, Thailand|Ankara Universitesi Tip Fakultesi Hastanesi-hematology ( Site 1401), Ankara, 06100, Turkey|Ankara Bilkent Åehir Hastanesi-Medical Oncology ( Site 1407), Ankara, 06800, Turkey|Antalya Egitim ve ArastÄ±rma Hastanesi ( Site 1409), Antalya, 7100, Turkey|Trakya University-Balkan Onkoloji Hastanesi ( Site 1403), Edirne, 22030, Turkey|Marmara Universitesi Pendik Egitim Arastirma Hastanesi ( Site 1408), Istanbul, 34899, Turkey|Ege Universitesi Hastanesi ( Site 1404), Ä°zmir, 35100, Turkey|Ondokuz Mays Ãniversitesi ( Site 1410), Samsun, 55280, Turkey|Southmead Hospital ( Site 3010), Bristol, Bristol, City Of, BS10 5NB, United Kingdom|St Bartholomew's Hospital-Centre for Experimental Cancer Medicine ( Site 3006), London, London, City Of, EC1A 7BE, United Kingdom|The Churchill Hospital ( Site 3007), Oxford, Oxfordshire, OX3 7LE, United Kingdom|GenesisCare - Cambridge ( Site 3001), Newmarket, Suffolk, CB8 7XN, United Kingdom|GenesisCare - Windsor ( Site 3002), Windsor, Windsor And Maidenhead, SL4 3HD, United Kingdom|Barnet Hospital ( Site 3005), Barnet, EN5 3DJ, United Kingdom|St James's University Hospital ( Site 3004), Leeds, LS9 7TF, United Kingdom|City Hospital, Nottingham University Hospitals NHS Trust ( Site 3003), Nottingham, NG5 1PB, United Kingdom",
NCT05239728,A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022),https://clinicaltrials.gov/study/NCT05239728,,ACTIVE_NOT_RECRUITING,"The purpose of this study is to assess the efficacy and safety of oral belzutifan (MK-6482) plus intravenous (IV) pembrolizumab (MK-3475) compared to placebo plus pembrolizumab, in the adjuvant treatment of Clear Cell Renal Cell Carcinoma (ccRCC) post nephrectomy.

The primary study hypothesis is that belzutifan plus pembrolizumab is superior to placebo plus pembrolizumab with respect to disease-free survival (DFS).",NO,"Carcinoma, Renal Cell",DRUG: Belzutifan|BIOLOGICAL: Pembrolizumab|DRUG: Placebo,"Disease-Free Survival (DFS), DFS is defined as the time from randomization to the first documented local recurrence, or occurrence of distant kidney cancer metastasis(es) as assessed by investigator, or death due to any cause, whichever occurs first. The DFS for all participants will be presented., Up to approximately 54 months","Overall Survival (OS), OS is defined as the time from randomization to death due to any cause., Up to approximately 89 months|Number of Participants Who Experience at Least One Adverse Event (AE), An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experienced an AE will be reported., Up to approximately 66 weeks|Number of Participants Who Discontinue Study Treatment Due to an AE, An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued the study due to an AE will be reported., Up to approximately 54 weeks|Disease Recurrence-Specific Survival 1 (DRSS1), DRSS1 is defined as the time from randomization to the first documented local recurrence of RCC as assessed by the investigator. For DRSS1, only local recurrence is counted as an event., Up to approximately 54 months|Disease Recurrence-Specific Survival 2 (DRSS2), DRSS2 is defined as the time from randomization to the first documented local recurrence with visceral lesion or occurrence of distant kidney cancer metastasis(es) with visceral lesion, whichever occurs first, as assessed by investigator., Up to approximately 54 months|Change From Baseline in Health-Related Quality-of-Life (HRQoL) Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Items 29 and 30 Score, The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of participants with cancer. Participant responses to the questions ""How would you rate your overall health during the past week?"" and ""How would you rate your overall quality of life during the past week?"" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status. The change from baseline in EORTC QLQ-C30 Items 29 and 30 combined scores will be presented., Baseline (Day 1) and up to approximately 36 months|Change From Baseline in Physical Functioning Using the EORTC QLQ-C30 Items 1- 5 Score, The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Higher scores indicate a worse level of function. Change from baseline in the score of EORTC QLQ-C30 Items 1-5 will be presented., Baseline (Day 1) and up to approximately 36 months|Change From Baseline in Role Functioning Using the EORTC QLQ-C30 Items 6 and 7 Score, The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to questions about their role functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Higher score indicate a worse level of function. Change from baseline in the score of EORTC QLQ-C30 Items 6-7 will be presented., Baseline (Day 1) and up to approximately 36 months|Change From Baseline in Disease Symptoms Using the Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-related Symptoms (FKSI-DRS) Items 1-9 Score, The FKSI-DRS index consists of a 9-item questionnaire that assesses the extent of participant symptoms from kidney cancer. Responses are scored on a 5-point scale (0=Not at all to 4=Very much) and summed to generate an index symptom score. These scores can range from 0 to 36, with a higher score indicating more favorable kidney cancer symptom status. Change from baseline in the score of FKSI-DRS Items 1-9 will be presented., Baseline (Day 1) and up to approximately 36 months",,Merck Sharp & Dohme LLC,,ALL,"ADULT, OLDER_ADULT",PHASE3,1800,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-03-15,2026-10-28,2029-09-28,2022-02-15,,2025-01-20,"Mayo Clinic in Arizona - Phoenix ( Site 3554), Phoenix, Arizona, 85054, United States|City of Hope Comprehensive Cancer Center ( Site 3567), Duarte, California, 91010, United States|Moores Cancer Center-Clinical Trials Office- Genitourinary ( Site 3516), La Jolla, California, 92093, United States|UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro, Los Angeles, California, 90095, United States|University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 3518), Orange, California, 92868, United States|Stanford Cancer Center ( Site 3523), Palo Alto, California, 94304, United States|University of Colorado Anschutz Medical Campus ( Site 3514), Aurora, Colorado, 80045, United States|St. Marys Hospital and Regional Medical Center-SCL Health Cancer Centers of Colorado ( Site 3562), Grand Junction, Colorado, 81501, United States|Georgetown University Medical Center ( Site 3534), Washington, District of Columbia, 20007, United States|University of Miami Hospital and Clinics, Sylvester Cancer Center-Cancer Research Services ( Site 35, Miami, Florida, 33136, United States|Moffitt Cancer Center ( Site 3540), Tampa, Florida, 33612, United States|Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 3515), Marietta, Georgia, 30060, United States|Parkview Research Center at Parkview Regional Medical Center ( Site 3526), Fort Wayne, Indiana, 46845, United States|Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center- GU Oncology ( Site 3549), Baltimore, Maryland, 21231, United States|Massachusetts General Hospital ( Site 3571), Boston, Massachusetts, 02114, United States|Beth Israel Deaconess Medical Center-Cancer Clinical Trials Office ( Site 3572), Boston, Massachusetts, 02215, United States|Dana-Farber Cancer Institute-GU ( Site 3505), Boston, Massachusetts, 02215, United States|Cancer and Hematology Centers of Western Michigan ( Site 3502), Grand Rapids, Michigan, 49503, United States|Washington University-Internal Medicine/Oncology ( Site 3531), Saint Louis, Missouri, 63110, United States|St. Vincent Frontier Cancer Center-Research ( Site 3506), Billings, Montana, 59102, United States|Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 3550), Omaha, Nebraska, 68130, United States|Englewood Hospital and Medical Center ( Site 3557), Englewood, New Jersey, 07631, United States|Rutgers Cancer Institute of New Jersey ( Site 3541), New Brunswick, New Jersey, 08903, United States|Monter Cancer Center ( Site 3560), Lake Success, New York, 11042, United States|Icahn School of Medicine at Mount Sinai ( Site 3539), New York, New York, 10029, United States|Memorial Sloan Kettering Cancer Center ( Site 3568), New York, New York, 10065, United States|University of Rochester Medical Center ( Site 3528), Rochester, New York, 14642, United States|The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C, Columbus, Ohio, 43210, United States|MidLantic urology ( Site 3501), Bala-Cynwyd, Pennsylvania, 19004, United States|Fox Chase Cancer Center-GU Oncology ( Site 3535), Philadelphia, Pennsylvania, 19111, United States|Sanford Cancer Center ( Site 3551), Sioux Falls, South Dakota, 57104, United States|The West Clinic, PLLC dba West Cancer Center ( Site 3522), Germantown, Tennessee, 38138, United States|Urology Associates ( Site 3512), Nashville, Tennessee, 37209, United States|UT Southwestern Medical Center ( Site 3529), Dallas, Texas, 75390, United States|University of Texas MD Anderson Cancer Center-Urology ( Site 3569), Houston, Texas, 77030, United States|Inova Schar Cancer Institute ( Site 3525), Fairfax, Virginia, 22031, United States|Seattle Cancer Care Alliance-Renal/Melanoma/MCC ( Site 3524), Seattle, Washington, 98109, United States|Blacktown Hospital-Blacktown Cancer and Haematology Centre - Medical Oncology ( Site 0002), Blacktown, New South Wales, 2148, Australia|Macquarie University-MQ Health Clinical Trials Unit ( Site 0003), Macquarie University, New South Wales, 2109, Australia|Tamworth Hospital-North West Cancer Centre ( Site 0006), North Tamworth, New South Wales, 2340, Australia|Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Si, Brisbane, Queensland, 4029, Australia|Lyell McEwin Hospital-Oncology Clinical Trials Unit ( Site 0008), Elizabeth Vale, South Australia, 5112, Australia|Austin Health-Cancer Clinical Trials Centre ( Site 0005), Heidelberg, Victoria, 3084, Australia|Fiona Stanley Hospital-Medical Oncology ( Site 0004), Murdoch, Western Australia, 6150, Australia|Hospital SÃ£o Carlos-Oncocentro Ce ( Site 0104), Fortaleza, Ceara, 60135-237, Brazil|Centro AvanÃ§ado de Tratamento OncolÃ³gico- CENANTRON-Clinical Research ( Site 0105), Belo Horizonte, Minas Gerais, 30130090, Brazil|Instituto do CÃ¢ncer e Transplante de Curitiba ( Site 0102), Curitiba, Parana, 80510-130, Brazil|Liga Norte Riograndense Contra o CÃ¢ncer-Centro de Pesquisa ClÃ­nica ( Site 0103), Natal, Rio Grande Do Norte, 59075-740, Brazil|Hospital Nossa Senhora da ConceiÃ§Ã£o-Centro Integrado de Pesquisa em Oncologia ( Site 0101), Porto Alegre, Rio Grande Do Sul, 91350-200, Brazil|Hospital de ClÃ­nicas de RibeirÃ£o Preto ( Site 0112), RibeirÃ£o Preto, Sao Paulo, 14048900, Brazil|BP - A Beneficencia Portuguesa de SÃ£o Paulo ( Site 0111), Sao Paulo, 01321-001, Brazil|MBAL Uni Hospital-Department of Medical Oncology ( Site 0204), Panagyurishte, Pazardzhik, 4500, Bulgaria|MHAT Serdika-Second Department of Medical Oncology ( Site 0203), Sofia, Sofia (stolitsa), 1301, Bulgaria|Complex Cancer Center Plovdiv-First Medical Oncology Department ( Site 0205), Plovdiv, 4004, Bulgaria|Tom Baker Cancer Center ( Site 3706), Calgary, Alberta, T2N 4N2, Canada|BC Cancer Vancouver-Clinical Trials Unit ( Site 3707), Vancouver, British Columbia, V5Z 4E6, Canada|Hamilton Health Sciences-Juravinski Cancer Centre ( Site 3710), Hamilton, Ontario, L8V 5C2, Canada|Victoria Hospital & Children's Hospital - London Health Scie-London Regional Cancer Program ( Site 3, London, Ontario, N6A 5W9, Canada|Princess Margaret Cancer Centre ( Site 3703), Toronto, Ontario, M5G 2M9, Canada|CIUSSS de l'Est-de-l'Ãle-de-MontrÃ©al ( Site 3708), Montreal, Quebec, H1T 2M4, Canada|McGill University Health Centre ( Site 3709), MontrÃ©al, Quebec, H4A 3J1, Canada|Centre intÃ©grÃ© de cancÃ©rologie du CHU de QuÃ©bec UniversitÃ© Laval, HÃ´pital de l'Enfant-JÃ©sus ( Site 3, Quebec, G1J 1Z4, Canada|James Lind Centro de InvestigaciÃ³n del CÃ¡ncer ( Site 0307), Temuco, Araucania, 4800827, Chile|ClÃ­nica Puerto Montt ( Site 0309), Puerto Montt, Los Lagos, 5500243, Chile|Oncocentro Valdivia ( Site 0312), Valdivia, Los Rios, 5112129, Chile|FALP-UIDO ( Site 0302), Santiago, Region M. De Santiago, 7500921, Chile|Oncovida ( Site 0306), Santiago, Region M. De Santiago, 7510032, Chile|Bradfordhill ( Site 0305), Santiago, Region M. De Santiago, 8420383, Chile|ONCOCENTRO APYS-ACEREY ( Site 0301), ViÃ±a del Mar, Valparaiso, 2520598, Chile|Bradford Hill Norte ( Site 0303), Antofagasta, 1240000, Chile|Afflilated Hospital of Bengbu Medical College-Urology Surgery ( Site 0438), Bengbu, Anhui, 233004, China|Second Affiliated hospital of Anhui Medical University-Urology ( Site 0416), Hefei, Anhui, 230000, China|Cancer Hospital Chinese Academy of Medical Science-Urinary Surgery ( Site 0435), Beijing, Beijing, 100021, China|Peking University First Hospital-Urology ( Site 0407), Beijing, Beijing, 100034, China|Beijing Cancer hospital-Urinary Surgery ( Site 0406), Beijing, Beijing, 100142, China|First Medical Center of Chinese PLA General Hospital ( Site 0415), Beijing, Beijing, 100853, China|Chongqing University Cancer Hospital ( Site 0414), Chongqing, Chongqing, 400030, China|Army Medical Center of People's Liberation Army ( Site 0439), Chongqing, Chongqing, 400042, China|The First Affiliated Hospital Of Fujian Medical University-Urology ( Site 0445), Fuzhou, Fujian, 350005, China|SUN YAT-SEN UNIVERSITY CANCER CENTRE-Urology Surgery ( Site 0417), Guangzhou, Guangdong, 510060, China|The First Affiliated Hospital of Guangzhou Medical University-Urology ( Site 0403), Guangzhou, Guangdong, 510120, China|Sun Yat-sen Memorial Hospital, Sun Yat-sen University-Urology Surgery ( Site 0402), Guangzhou, Guangdong, 510289, China|Henan Cancer Hospital-Urology ( Site 0441), Zhengzhou, Henan, 450008, China|Tongji Hospital Tongji Medical,Science & Technology-oncology ( Site 0423), Wuhan, Hubei, 430000, China|Wuhan Union Hospital ( Site 0430), Wuhan, Hubei, 430022, China|Hubei Cancer Hospital-Urinary surgery ( Site 0419), Wuhan, Hubei, 430079, China|Hunan Cancer Hospital ( Site 0421), Changsha, Hunan, 410013, China|Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Urology ( S, NanJing, Jiangsu, 210000, China|The First Affiliated Hospital of Nanchang University ( Site 0432), Nanchang, Jiangxi, 330006, China|The Second Affiliated Hospital of Nanchang University ( Site 0443), Nanchang, Jiangxi, 330006, China|The First Affiliated Hospital of Xi'an Jiaotong University ( Site 0431), Xi'an, Shaanxi, 710061, China|Fudan University Shanghai Cancer Center-Urology department ( Site 0401), Shanghai, Shanghai, 200000, China|Renji Hospital Shanghai Jiao Tong University School of Medicine ( Site 0418), Shanghai, Shanghai, 200001, China|Huadong Hospital Affiliated to Fudan University ( Site 0405), Shanghai, Shanghai, 200040, China|West China Hospital of Sichuan University-Urology Surgery ( Site 0410), Cheng Du, Sichuan, 610041, China|Tianjin Medical University Cancer Institute and Hospital ( Site 0422), Tianjin, Tianjin, 300060, China|The First Affiliated Hospital, Zhejiang University ( Site 0428), Hangzhou, Zhejiang, 310003, China|Zhejiang Provincial People's Hospital-Urology ( Site 0426), Hangzhou, Zhejiang, 310014, China|Ningbo First Hospital-Urology ( Site 0433), Ningbo, Zhejiang, 315010, China|The First Affiliated Hospital of Wenzhou Medical University-Urology Surgery ( Site 0425), Wenzhou, Zhejiang, 325000, China|Clinica de la Costa S.A.S. ( Site 0506), Barranquilla, Atlantico, 080020, Colombia|Sociedad De Oncologia Y Hematologia Del Cesar-Oncology ( Site 0505), Valledupar, Cesar, 200001, Colombia|OncomÃ©dica S.A.S ( Site 0501), Monteria, Cordoba, 230001, Colombia|Administradora Country S.A. - Clinica del Country ( Site 0504), BogotÃ¡, Distrito Capital De Bogota, 110221, Colombia|Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 0605), Brno, Brno-mesto, 656 53, Czechia|Fakultni Nemocnice u sv. Anny v Brne-Onkologicko-chirurgicke oddeleni ( Site 0603), Brno, Brno-mesto, 656 91, Czechia|Fakultni nemocnice Ostrava-Klinika onkologicka ( Site 0606), Ostrava, Moravskoslezsky Kraj, 708 52, Czechia|Fakultni nemocnice Olomouc-Onkologicka klinika ( Site 0601), Olomouc, Olomoucky Kraj, 779 00, Czechia|Fakultni Thomayerova nemocnice-Onkologicka klinika 1. LF UK ( Site 0602), Prague, Praha 4, 140 59, Czechia|Fakultni nemocnice v Motole-Onkologicka klinika 2. LF UK a FN Motol ( Site 0607), Praha, Praha 5, 150 06, Czechia|Fakultni nemocnice Hradec Kralove-Klinika onkologie a radioterapie ( Site 0604), Hradec Kralove, 500 05, Czechia|Tampereen yliopistollinen sairaala ( Site 0805), Tampere, Pirkanmaa, 33520, Finland|Oulun yliopistollinen sairaala ( Site 0802), Oulu, Pohjois-Pohjanmaa, 90220, Finland|Kuopion Yliopistollinen Sairaala-SyÃ¶pÃ¤keskus ( Site 0804), Kuopio, Pohjois-Savo, 70210, Finland|Helsinki University Hospital - Comprehensive Cancer Center (HYKS - SyÃ¶pÃ¤keskus) ( Site 0803), Helsinki, Uusimaa, 00290, Finland|Turku University Hospital ( Site 0801), Turku, Varsinais-Suomi, 20520, Finland|Institut de cancÃ©rologie Strasbourg Europe (ICANS) ( Site 0903), Strasbourg, Alsace, 67200, France|ROC37 ( Site 0910), Chambray Les Tours, Centre, 37170, France|CHU BesanÃ§on-Medical oncology ( Site 0904), BesanÃ§on, Doubs, 25000, France|Gustave Roussy ( Site 0907), Villejuif, Ile-de-France, 94800, France|Centre Hospitalier Universitaire de Rennes - HÃ´pital Pontchaillou ( Site 0908), Rennes, Ille-et-Vilaine, 35000, France|Centre Hospitalier Universitaire d'Angers-Urology ( Site 0901), Angers, Maine-et-Loire, 49933, France|CENTRE LEON BERARD-Medical oncology ( Site 0902), Lyon, Rhone-Alpes, 69008, France|HÃ´pital Saint-Louis ( Site 0905), Paris, 75010, France|HÃ´pital EuropÃ©en Georges Pompidou-Service d'Oncologie MÃ©dicale ( Site 0906), Paris, 75015, France|Hegau-Bodensee-Klinikum Singen ( Site 1016), Singen, Baden-Wurttemberg, 78224, Germany|Universitaetsklinikum Tuebingen ( Site 1002), TÃ¼bingen, Baden-Wurttemberg, 72076, Germany|klinikum rechts der isar der technischen universitÃ¤t mÃ¼nchen-Urologische Klinik und Poliklinik ( Sit, Munich, Bayern, 81675, Germany|UniversitÃ¤tsklinikum Aachen ( Site 1024), Aachen, Nordrhein-Westfalen, 52074, Germany|UniversitÃ¤tsklinikum Bonn ( Site 1006), Bonn, Nordrhein-Westfalen, 53127, Germany|Universitaetsklinikum Duesseldorf ( Site 1017), DÃ¼sseldorf, Nordrhein-Westfalen, 40225, Germany|Universitaetsklinikum Essen ( Site 1004), Essen, Nordrhein-Westfalen, 45147, Germany|UniversitÃ¤tsklinikum MÃ¼nster - Albert Schweitzer Campus ( Site 1005), MÃ¼nster, Nordrhein-Westfalen, 48149, Germany|Universitaetsklinikum des Saarlandes-Klinik fuer Urologie und Kinderurologies ( Site 1020), Homburg, Saarland, 66421, Germany|Krankenhaus Martha-Maria Halle-DÃ¶lau-Klinik fÃ¼r Urologie, Kinderurologie und urologische Onkologie (, Halle, Sachsen-Anhalt, 06120, Germany|Universitaetsklinikum Carl Gustav Carus Dresden-Klinik und Poliklinik fÃ¼r Urologie ( Site 1021), Dresden, Sachsen, 01307, Germany|SRH Wald-Klinikum Gera ( Site 1015), Gera, Thuringen, 07548, Germany|UniversitÃ¤tsklinikum Jena ( Site 1007), Jena, Thuringen, 07747, Germany|CharitÃ© Universitaetsmedizin Berlin - Campus Mitte ( Site 1022), Berlin, 10117, Germany|Helios Klinikum Berlin-Buch ( Site 1011), Berlin, 13125, Germany|Universitaetsklinikum Hamburg-Eppendorf-Onkologisches Zentrum ( Site 1001), Hamburg, 20246, Germany|Alexandra Hospital-ONCOLOGY DEPT. ( Site 1102), Athens, Attiki, 115 28, Greece|Metropolitan Hospital-2nd Oncology Dept ( Site 1104), Athens, Attiki, 185 47, Greece|ATTIKON GENERAL UNIVERSITY HOSPITAL ( Site 1101), Chaidari, Attiki, 124 62, Greece|Euromedica General Clinic Thessaloniki-Oncology Unit ( Site 1103), Thessaloniki, 546 45, Greece|European Interbalkan Medical Center-Oncology Department ( Site 1105), Thessaloniki, 57001, Greece|Szegedi TudomÃ¡nyegyetem Szent-GyÃ¶rgyi Albert Klinikai KÃ¶zpont ( Site 1319), Szeged, Csongrad, 6725, Hungary|Petz Aladar Egyetemi Oktato Korhaz-OnkolÃ³giai OsztÃ¡ly ( Site 1321), Gyor, Gyor-Moson-Sopron, 9024, Hungary|OrszÃ¡gos OnkolÃ³giai IntÃ©zet-UrogenitÃ¡lis Tumorok Ã©s Klinikai FarmakolÃ³giai OsztÃ¡ly ( Site 1316), Budapest, Pest, 1122, Hungary|Somogy Megyei Kaposi MÃ³r OktatÃ³ KÃ³rhÃ¡z-Oncology center ( Site 1311), KaposvÃ¡r, Somogy, 7400, Hungary|Debreceni Egyetem Klinikai Kozpont-OnkolÃ³giai Klinika ( Site 1310), Debrecen, 4032, Hungary|Tallaght University Hospital ( Site 1402), Dublin 24, Dublin, D24 NR0A, Ireland|St. Vincent's University Hospital ( Site 1401), Dublin 4, Dublin, Ireland|Cork University Hospital ( Site 1404), Cork, T12 E8YV, Ireland|Beaumont Hospital, Dublin-Cancer Clinical Trials & Research Unit ( Site 1403), Dublin, Dublin 9, Ireland|Soroka Medical Center ( Site 1505), Be'er Sheva, 8410101, Israel|Rambam Health Care Campus-Oncology ( Site 1502), Haifa, 3109601, Israel|Hadassah Medical Center-Oncology ( Site 1506), Jerusalem, 9112001, Israel|Rabin Medical Center-Oncology ( Site 1503), Petah-Tikva, 4941492, Israel|Sheba Medical Center-ONCOLOGY ( Site 1504), Ramat Gan, 5265601, Israel|Sourasky Medical Center-Oncology ( Site 1501), Tel Aviv, 6423906, Israel|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori-Oncologia Medica ( Site 1603), Meldola, Emilia-Romagna, 47014, Italy|Fondazione Policlinico Universitario Agostino Gemelli-Medical Oncology ( Site 1604), Roma, Lazio, 00168, Italy|Ospedale San Raffaele-Oncologia Medica ( Site 1606), Milano, Lombardia, 20132, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1608), Milan, Lombardia, 20133, Italy|Azienda Sanitaria Ospedaliera S Luigi Gonzaga-SCDU Oncologia Medica ( Site 1602), Orbassano, Piemonte, 10043, Italy|A.O.U.C. Policlinico di Bari ( Site 1607), Bari, Puglia, 70124, Italy|Azienda Ospedaliera Universitaria Careggi-SOD ONCOLOGIA MEDICA ( Site 1601), Firenze, Toscana, 50134, Italy|Azienda USL 8 di Arezzo-Medical Oncology ( Site 1610), Arezzo, 52100, Italy|IRCCS - AOU di Bologna-Oncologia Medica Ardizzoni ( Site 1605), Bologna, 40138, Italy|Azienda Ospedaliera Santa Maria Terni-SC Oncologia ( Site 1609), Terni, 05100, Italy|Fujita Health University ( Site 1709), Toyoake, Aichi, 470-1192, Japan|National Cancer Center Hospital East ( Site 1704), Kashiwa, Chiba, 277-8577, Japan|Toho University Sakura Medical Center ( Site 1718), Sakura, Chiba, 285-8741, Japan|Ehime University Hospital ( Site 1714), Toon, Ehime, 791-0295, Japan|Sapporo Medical University Hospital ( Site 1702), Sapporo, Hokkaido, 060-8543, Japan|Hokkaido University Hospital ( Site 1701), Sapporo, Hokkaido, 060-8648, Japan|Kanagawa cancer center ( Site 1703), Yokohama, Kanagawa, 241-8515, Japan|Nara Medical University Hospital ( Site 1712), Kashihara, Nara, 634-0813, Japan|Bell Land General Hospital ( Site 1710), Sakai, Osaka, 599-8247, Japan|Osaka University Hospital ( Site 1711), Suita, Osaka, 565-0871, Japan|Hamamatsu University Hospital ( Site 1708), Hamamatsu, Shizuoka, 431-3192, Japan|Toranomon Hospital ( Site 1706), Minato-ku, Tokyo, 105-8470, Japan|Toyama University Hospital ( Site 1713), Toyoma, Toyama, 930-0194, Japan|Kyushu University Hospital ( Site 1715), Fukuoka, 812-8582, Japan|Kagoshima University Hospital ( Site 1719), Kagoshima, 890-8520, Japan|Kumamoto University ( Site 1716), Kumamoto, 860-8556, Japan|Okayama University Hospital ( Site 1720), Okayama, 700-8558, Japan|Nippon Medical School Hospital ( Site 1705), Tokyo, 113-8603, Japan|Tokyo Women's Medical University Adachi Medical Center ( Site 1717), Tokyo, 123-8558, Japan|Keio university hospital ( Site 1707), Tokyo, 160-8582, Japan|Wakayama Medical University Hospital ( Site 1721), Wakayama, 641-8510, Japan|National Cancer Center-Center for Urologic Cancer ( Site 2604), Goyang-si, Kyonggi-do, 10408, Korea, Republic of|Seoul National University Bundang Hospital-Urology ( Site 2602), Seongnam, Kyonggi-do, 13620, Korea, Republic of|Asan Medical Center-Oncology ( Site 2601), Songpagu, Seoul, 05505, Korea, Republic of|Samsung Medical Center ( Site 2603), Seoul, 06351, Korea, Republic of|University Malaya Medical Centre ( Site 1804), Lembah Pantai, Kuala Lumpur, 59100, Malaysia|Hospital Pulau Pinang ( Site 1806), George Town, Pulau Pinang, 10450, Malaysia|Sarawak General Hospital-Radiotherapy Unit ( Site 1805), Kuching, Sarawak, 93586, Malaysia|INSTITUTO NACIONAL DE CANCEROLOGIA ( Site 1902), Mexico City, Distrito Federal, 14070, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran-Oncologia y Hematologia ( Site 1, Mexico City, Distrito Federal, 14080, Mexico|Terapias Integrales del RiÃ±on SA de CV ( Site 1910), Guadalajara, Jalisco, 44260, Mexico|Hospital Civil Fray Antonio Alcalde-Oncology ( Site 1906), Guadalajara, Jalisco, 44280, Mexico|BRCR Global Mexico - Guadalajara-Research ( Site 1908), Guadalajara, Jalisco, Mexico|Filios Alta Medicina ( Site 1903), Monterrey, Nuevo Leon, 64460, Mexico|iCan Oncology Center Centro Medico AVE ( Site 1901), Monterrey, Nuevo Leon, 64710, Mexico|Hospital H+ Queretaro-Cuidados OncolÃ³gicos ( Site 1905), Santiago de Queretaro, Queretaro, 76000, Mexico|BRCR Global Mexico - Queretaro-SMIQ ( Site 1907), Santiago de QuerÃ©taro, Queretaro, 76070, Mexico|Centro de OncologÃ­a Personalizada ( Site 1911), CuliacÃ¡n, Sinaloa, 80040, Mexico|Centro de Investigacion Clinica de Oaxaca ( Site 1904), Oaxaca, 68020, Mexico|Oncocenter ( Site 1909), Puebla, 72530, Mexico|Ziekenhuis Rijnstate-Rijnstate Centrum Oncologisch Onderzoek ( Site 3113), Arnhem, Gelderland, 6815 AD, Netherlands|Radboudumc ( Site 3120), Nijmegen, Gelderland, 6525 GA, Netherlands|Maastricht UMC+ ( Site 3104), Maastricht, Limburg, 6229 HX, Netherlands|Amphia Ziekenhuis, locatie Breda Molengracht ( Site 3103), Breda, Noord-Brabant, 4818 CK, Netherlands|Maxima Medisch Centrum, locatie Eindhoven ( Site 3116), Eindhoven, Noord-Brabant, 5600 PD, Netherlands|Amsterdam UMC, locatie AMC ( Site 3105), Amsterdam, Noord-Holland, 1105 AZ, Netherlands|Tergooiziekenhuizen, locatie Hilversum ( Site 3102), Hilversum, Noord-Holland, 1213 XZ, Netherlands|Spaarne Gasthuis - Hoofddorp-Oncology ( Site 3107), Hoofddorp, Noord-Holland, 2134 TM, Netherlands|Isala, locatie Zwolle-Oncology ( Site 3111), Zwolle, Overijssel, 8025 AB, Netherlands|Haga Ziekenhuis locatie Leyweg-Oncology ( Site 3108), Den Haag, Zuid-Holland, 2545 AA, Netherlands|Haaglanden MC - locatie Antoniushove ( Site 3117), Leidschendam, Zuid-Holland, 2501 ck, Netherlands|Franciscus Gasthuis & Vlietland, Locatie Vlietland ( Site 3101), Schiedam, Zuid-Holland, 3118 JH, Netherlands|University Medical Center Groningen ( Site 3121), Groningen, 9700RB, Netherlands|St. Antonius Ziekenhuis, locatie Utrecht-Interne geneeskunde ( Site 3112), Utrecht, 3543 AZ, Netherlands|Universitair Medisch Centrum Utrecht-Medical Oncology ( Site 3106), Utrecht, 3584 CX, Netherlands|Auckland City Hospital-Cancer & Blood Research ( Site 2003), Auckland, 1023, New Zealand|Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we WrocÅawiu ( Site 2309), WrocÅaw, Dolnoslaskie, 50-556, Poland|Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 2307), Bydgoszcz, Kujawsko-pomorskie, 85-796, Poland|MICS Centrum Medyczne Torun ( Site 2305), Torun, Kujawsko-pomorskie, 87-100, Poland|Szpital WojewÃ³dzki im. ÅwiÄtego Lukasza SP ZOZ w Tarnowie ( Site 2311), Tarnow, Malopolskie, 33-100, Poland|Mazowiecki Szpital WojewÃ³dzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 2313), Siedlce, Mazowieckie, 08-110, Poland|Luxmed Onkologia sp. z o. o. ( Site 2303), Warszawa, Mazowieckie, 01-748, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (, Warszawa, Mazowieckie, 02-781, Poland|Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 2306), Przemysl, Podkarpackie, 37-700, Poland|Przychodnia Lekarska KOMED ( Site 2304), Konin, Wielkopolskie, 62-500, Poland|Szpital Kliniczny im. Przemienienia Panskiego Uniwersytetu M-chemotherapy department ( Site 2312), PoznaÅ, Wielkopolskie, 60-569, Poland|Szpital WojewÃ³dzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 2302), Koszalin, Zachodniopomorskie, 75-581, Poland|Twoja Przychodnia - Szczecinskie Centrum Medyczne ( Site 2315), Szczecin, Zachodniopomorskie, 71-434, Poland|Centrul medical Focus ( Site 2407), BucureÈti, Bucuresti, 022548, Romania|Cardiomed SRL Cluj-Napoca ( Site 2406), Cluj-Napoca, Cluj, 400015, Romania|Amethyst Radiotherapy Center-Oncologie Medicala ( Site 2405), FloreÈti, Cluj, 407280, Romania|Centrul de Oncologie ""SfÃ¢ntul Nectarie""-Medical Oncology ( Site 2401), Craiova, Dolj, 200746, Romania|Radiology Therapeutic Center-Oncology ( Site 2404), Otopeni, Ilfov, 075100, Romania|Cabinet Medical Oncomed ( Site 2403), TimiÈoara, Timis, 300239, Romania|National Cancer Centre Singapore ( Site 3601), Singapore, Central Singapore, 168583, Singapore|National University Hospital ( Site 3602), Singapore, South West, 119074, Singapore|Institut CatalÃ  d'Oncologia (ICO) - Girona ( Site 2707), Girona, Gerona, 17007, Spain|Hospital Universitario RamÃ³n y Cajal-Medical Oncology ( Site 2710), Madrid, Madrid, Comunidad De, 28034, Spain|Hospital Universitario 12 de Octubre-Medical Oncology ( Site 2708), Madrid, Madrid, Comunidad De, 28041, Spain|FundaciÃ³n Instituto Valenciano de OncologÃ­a ( Site 2705), Valencia, Valenciana, Comunitat, 46009, Spain|Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 2702), Barcelona, 08035, Spain|Hospital Lucus Augusti-Oncology ( Site 2706), Lugo, 27003, Spain|Hospital Clinico San Carlos-Oncology Department ( Site 2703), Madrid, 28040, Spain|Hospital Universitario Virgen de la Victoria-Phase II-III-IV Trials ( Site 2709), Malaga, 29010, Spain|Karolinska Universitetssjukhuset Solna ( Site 2802), Stockholm, Stockholms Lan, 171 76, Sweden|Akademiska sjukhuset-Blod- och tumÃ¶rsjukdomar ( Site 2803), Uppsala, Uppsala Lan, 751 85, Sweden|Sahlgrenska Universitetssjukhuset ( Site 2801), Gothenburg, Vastra Gotalands Lan, 413 45, Sweden|Chang Gung Memorial Hospital at Kaohsiung-Oncology and Hematology ( Site 2905), Kaohsiung Niao Sung Dist, Kaohsiung, 83301, Taiwan|Tri-Service General Hospital ( Site 2908), Taipei City, Taipei, 114, Taiwan|Kaohsiung Veterans General Hospital ( Site 2901), Kaohsiung, 81362, Taiwan|China Medical University Hospital-Department of Urology ( Site 2907), Taichung, 40447, Taiwan|Taichung Veterans General Hospital ( Site 2902), Taichung, 407, Taiwan|National Taiwan University Hospital ( Site 2904), Taipei, 100225, Taiwan|Taipei Veterans General Hospital ( Site 2903), Taipei, 112, Taiwan|Chang Gung Medical Foundation-Linkou Branch-Urology ( Site 2906), Taoyuan, 333, Taiwan|Chulalongkorn University ( Site 3005), Bangkok, Krung Thep Maha Nakhon, 10330, Thailand|Ramathibodi Hospital ( Site 3001), Bangkok, Krung Thep Maha Nakhon, 10400, Thailand|Faculty of Medicine Siriraj Hospital ( Site 3002), Bangkok, Krung Thep Maha Nakhon, 10700, Thailand|Songklanagarind hospital ( Site 3004), Hatyai, Songkhla, 90110, Thailand|Ankara Bilkent Åehir Hastanesi-oncology ( Site 3206), Yenimahalle, Ankara, 06200, Turkey|Istanbul Universitesi Cerrahpasa-Internal Diseases ( Site 3204), Istanbul- Fatih, Istanbul, 34098, Turkey|Baskent University Dr. Turgut Noyan Research and Training Center-ONCOLOGY ( Site 3208), Adana, 01250, Turkey|Ankara GÃ¼lhane Eitim ve Aratrma Hastanesi-Oncology ( Site 3207), Ankara, 06010, Turkey|Ankara University Hospital Cebeci ( Site 3209), Ankara, 06100, Turkey|Hacettepe Universitesi-oncology hospital ( Site 3203), Ankara, 06230, Turkey|TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 3201), Istanbul, 34722, Turkey|Ege University Medicine of Faculty-Medical Oncology ( Site 3202), Izmir, 35100, Turkey|Royal Free Hospital ( Site 3304), London, England, NW32QG, United Kingdom|The Christie NHS Foundation Trust ( Site 3301), Manchester, England, M20 4BX, United Kingdom|City Hospital, Nottingham University Hospitals ( Site 3303), Nottingham, England, NG5 1PF, United Kingdom|Beatson West of Scotland Cancer Centre-Clinical Trials Unit ( Site 3305), Glasgow, Glasgow City, G12 0YN, United Kingdom|Charing Cross Hospital ( Site 3302), London, Hammersmith And Fulham, W6 8RF, United Kingdom|St Bartholomew's Hospital-Centre for Experimental Cancer Medicine ( Site 3307), London, London, City Of, EC1A 7BE, United Kingdom|Singleton Hospital ( Site 3306), Swansea, Wales, SA2 8QA, United Kingdom",
NCT05794906,A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies,https://clinicaltrials.gov/study/NCT05794906,ARASTEP,RECRUITING,"Researchers are looking for a better way to treat men at high-risk of biochemical recurrence (BCR) of prostate cancer.

BCR means that in men who had prostate cancer and were treated by either surgery and/ or radiation therapy, the blood level of a specific protein called PSA rises. PSA is a marker of prostate cancer cells activity. The PSA increase means that the cancer has come back even though conventional imaging such as computed tomography (CT) scans, magnetic resonance imaging (MRI) and bone scans does not show any lesion of prostate cancer. Recently a more sensitive imaging method called prostate-specific membrane antigen \[PSMA\] positron emission tomography \[PET\]) /computed tomography \[CT\]) scan may identify prostate cancer lesions not detectable by conventional imaging. Men with BCR have a higher risk of their cancer spreading to other parts of the body, particularly when PSA levels raised to a certain limit within a short period of time after local therapies. Once the cancer spreads to other parts of the body, it can become even harder to treat.

In men with prostate cancer, male sex hormones (also called androgens) like testosterone can help the cancer grow and spread. To reduce androgens levels in these patients, there are treatments that block androgens production in the body called androgen deprivation therapy (ADT). ADT is often used to stop prostate cancer. Another way to stop prostate cancer growth and spread is to block the action of androgen receptors on prostate cancer cells called androgen receptor inhibitors (ARIs). The new generation ARIs including darolutamide can block the action of androgens receptors and are available for the treatment of prostate cancer in addition to ADT. It is already known that men with prostate cancer benefit from these treatments.

The main objective of this study is to learn if the combination of darolutamide and ADT prolongs the time that the participants live without their cancer getting worse, or to death due to any cause, compared to placebo (which is a treatment that looks like a medicine but does not have any medicine in it) and ADT given for a pre-specified duration of 24 months.

To do this, the study team will measure the time from the date of treatment allocation to the finding of new cancer spread in the participants by using PSMA PET/CT, or death due to any cause. The PSMA PET/CT scans is performed using a radioactive substance called a ""tracer"" that specifically binds to the prostate-specific membrane antigen (PSMA) which is a protein often found in large amounts on prostate cancer cells.

To avoid bias in treatment, the study participants will be randomly (by chance) allocated to one of two treatment groups. Based on the allocated treatment group, the participants will either take darolutamide plus ADT or placebo plus ADT twice daily as tablets by mouth. The study will consist of a test (screening) phase, a treatment phase and a follow-up phase. The treatment duration is pre-specified to be 24 months unless the cancer gets worse, the participants have medical problems, or they leave the study for any reason. In addition, image guided radiotherapy (IGRT) or surgery is allowed and your doctor will explain the benefits and risks of this type of therapy.

During the study, the study team will:

* take blood and urine samples.
* measure PSA and testosterone levels in the blood samples
* do physical examinations
* check the participants' overall health
* examine heart health using electrocardiogram (ECG)
* check vital signs
* check cancer status using PSMA PET/CT scans, CT, MRI and bone scans
* take tumor samples (if required)
* ask the participants if they have medical problems

About 30 days after the participants have taken their last treatment, the study doctors and their team will check the participants' health and if their cancer worsened. The study team will continue to check this and regularly ask the participants questions about medical problems and subsequent therapies until they leave the study for any reason or until they leave the study for any reason or until the end of the study, whatever comes first.",NO,Biochemically Recurrent Prostate Cancer,"DRUG: Darolutamide (BAY1841788, Nubeqa)|OTHER: Placebo matching darolutamide|OTHER: ADT","Radiological progression-free survival (rPFS) by Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) assessed by Blinded independent central review (BICR), After randomization to after last treatment, approximately 24 months","Metastasis-free survival (MFS) by Conventional imaging (CI) assessed by BICR, After randomization to after last treatment, approximately 46 months|Time to Castration-resistant prostate cancer (CRPC), After randomization to after last treatment, approximately 46 months|Time to initiation of first subsequent systemic antineoplastic therapy, After randomization to after last treatment, approximately 46 months|Time to loco-regional progression by PSMA PET/CT, After randomization to after last treatment, approximately 46 months|Time to first Symptomatic skeletal event (SSE), After randomization to after last treatment, approximately 46 months|Overall survival (OS), After randomization to after last treatment, approximately 46 months|Prostate-specific antigen (PSA) undetectable rates (<0.2 ng/mL), After randomization to after last treatment, approximately 46 months|Time to deterioration in the Functional Assessment of Cancer Therapy-Prostate (FACT-P) total score, FACT-P is a multidimension, selfreport QoL instrument specifically designed for patients with prostate cancer. It consists of 39 questions items, made up by 2 parts: the 27 questions for functional assessment of cancer therapy general (FACT-G) and 12 prostate cancer subscale questions. It assesses 4 main domains which are: physical (n=7), social/family (n=7), emotional (n=6) and functional wellbeing (n=7)., After randomization to after last treatment, approximately 24 months|Time to symptomatic progression, After randomization to after last treatment, approximately 46 months|Number of participants with Treatment-emergent adverse events (TEAEs) and Treatment-emergent serious adverse events (TESAEs) categorized by severity, After the first treatment until 30 days (+7 days) after the last treatment, up to 25 months|Number of participants who discontinue study treatment due to a TEAE, After the first treatment until 30 days (+7 days) after the last treatment, up to 25 months",,Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE3,970,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-04-03,2027-07-30,2030-03-29,2023-04-03,,2025-06-06,"City of Hope - Phoenix Cancer Center, Goodyear, Arizona, 85338, United States|Mayo Clinic Hospital - Phoenix - Cardiology, Phoenix, Arizona, 85054, United States|Arizona Institute of Urology, Tucson, Arizona, 85704, United States|City of Hope - Duarte Cancer Center, Duarte, California, 91010, United States|University of Southern California, Los Angeles, California, 90033, United States|Tower Urology, Inc, Los Angeles, California, 90048, United States|University of California, Los Angeles, Los Angeles, California, 90095, United States|University of California Irvine Medical Center, Orange, California, 92868-3201, United States|UCSF Med Center Helen Diller Family Comp Cancer Center, San Francisco, California, 94143, United States|Colorado Urology - St. Anthony Hospital Campus, Lakewood, Colorado, 80228, United States|Clermont Oncology Center, Clermont, Florida, 34711, United States|University of Florida - Jacksonville, Jacksonville, Florida, 32209, United States|Mid Florida Cancer Centers, Orange City, Florida, 32763-8316, United States|Northwestern Medicine - Urology, Chicago, Illinois, 60611, United States|Jesse Brown VA Medical Center, Chicago, Illinois, 60612, United States|Comprehensive Cancer Center, Chicago, Illinois, 60637, United States|Urology of Indiana, LLC, Greenwood, Indiana, 46143, United States|First Urology PSC, Jeffersonville, Indiana, 47130, United States|University of Kansas, Kansas City, Kansas, 66160, United States|Chesapeake Urology Associates - Towson, Baltimore, Maryland, 21204, United States|Sidney Kimmel Comprehensive Cancer Center - Johns Hopkins, Baltimore, Maryland, 21231, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|UMass Memorial Medical Center - University Campus, Worcester, Massachusetts, 01655-0002, United States|Barbara Ann Karmanos Cancer Institute - Detroit Headquarters, Detroit, Michigan, 48201, United States|Michigan Institute of Urology - Troy - Town Center Building, Troy, Michigan, 48084, United States|University of Minnesota Medical Center, Minneapolis, Minnesota, 55455, United States|Washington University School of Medicine - Center for Advanced Medicine (CAM), Saint Louis, Missouri, 63110-1032, United States|Urology Cancer Center, PC, Omaha, Nebraska, 68130, United States|New Jersey Urology (NJU), Saddle Brook, New Jersey, 07663-5227, United States|New Jersey Urology - Voorhees, Voorhees, New Jersey, 08043, United States|NYU Langone Health, Mineola, New York, 11501, United States|Icahn School of Medicine at Mount Sinai - Oncology, New York, New York, 10029, United States|Associated Medical Professionals of NY, PLLC, Syracuse, New York, 13210, United States|White Plains Hospital, White Plains, New York, 10601, United States|Alliance Urology Specialists, Greensboro, North Carolina, 27403, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, 27157, United States|The Urology Group, Cincinnati, Ohio, 45212, United States|Ohio State University Wexner Medical Center, Columbus, Ohio, 43210, United States|MidLantic Urology - Bala Cynwyd, Bala-Cynwyd, Pennsylvania, 19004, United States|Urological Associates of Lancaster, Lancaster, Pennsylvania, 17604, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, 15212, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, 15232, United States|VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, 15240, United States|Bon Secours St. Francis Hospital, Greenville, South Carolina, 29607, United States|Carolina Urological Research Center, Myrtle Beach, South Carolina, 29579, United States|Urology Austin, PLLC (an affiliate of Urology America), Austin, Texas, 78745, United States|University of Texas Southwestern Medical Center-Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas, 75235, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|Urology San Antonio, PA dba USA Clinical Trials, San Antonio, Texas, 78229, United States|The Urology Place, San Antonio, Texas, 78240, United States|Spokane Urology PS, Spokane, Washington, 99202, United States|Blacktown Hospital, Blacktown, New South Wales, 2148, Australia|Chris O'Brien Lifehouse, Camperdown, New South Wales, 2050, Australia|University of New South Wales (UNSW) - Liverpool Hospital - Liverpool Cancer Therapy Centre, Liverpool, New South Wales, NSW 2170, Australia|GenesisCare Newcastle, Newcastle, New South Wales, 2290, Australia|Port Macquarie Base Hospital, Port Macquarie, New South Wales, 2444, Australia|St Vincents Hospital Sydney, Sydney, New South Wales, 2010, Australia|Prince of Wales Hospital NSW, Sydney, New South Wales, 2031, Australia|Macquarie University Hospital, Sydney, New South Wales, 2109, Australia|Sydney Adventist Hospital, Wahroonga, New South Wales, 2076, Australia|Westmead Hospital, Westmead, New South Wales, 2145, Australia|Royal Brisbane & Women's Hospital, Brisbane, Queensland, 4029, Australia|Bundaberg Hospital, Genesis Cancer Care - Bundaberg, Bundaberg, Queensland, 4670, Australia|Wide Bay Hospital and Health Service - Hervey Bay Hospital, Pialba, Queensland, 4655, Australia|Tasman Health Care, Southport, Queensland, 4215, Australia|Royal Adelaide Hospital, Adelaide, South Australia, 5000, Australia|Eastern Clinical Research Unit - Box Hill, Box Hill, Victoria, 3128, Australia|Epworth HealthCare, East Melbourne, Victoria, 3002, Australia|Northern Hospital, Epping, Victoria, 3076, Australia|Barwon Health, Geelong, Victoria, 3220, Australia|Austin Health, Heidelberg, Victoria, 3084, Australia|Cabrini Malvern, Malvern, Victoria, 3144, Australia|Western Urology, Maribyrnong, Victoria, 3032, Australia|Australian Prostate Centre, North Melbourne, Victoria, 3051, Australia|Royal Melbourne Hospital, Parkville, Victoria, 3050, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, 6009, Australia|Ordensklinikum Linz GmbH Elisabethinen, Linz, OberÃ¶sterreich, 4020, Austria|Medizinische UniversitÃ¤t Innsbruck, Innsbruck, Tirol, 6020, Austria|Krankenhaus der Barmherzigen BrÃ¼der, Vienna, Wien, 1020, Austria|Medizinische Universitaet Graz - Klinische Abteilung fÃ¼r Onkologie - Innere Medizin, Graz, 8036, Austria|Uniklinikum Salzburg - Landeskrankenhaus, Salzburg, 5020, Austria|Medizinische UniversitÃ¤t Wien- UniversitÃ¤tsklinik fÃ¼r Urologie, Wien, 1090, Austria|Institut Jules Bordet/Jules Bordet Instituut, Bruxelles, 1070, Belgium|Maria Middelares General Hospital | Medical Oncology Department, Gent, 9000, Belgium|UZ Gent - department Urology, Gent, 9000, Belgium|Jessa Hospital | Campus Virga Jesse - Data Management Oncology and Hematology Department, Hasselt, 3500, Belgium|AZ Groeninge Campus Kennedylaan - Urology, Kortrijk, 8500, Belgium|Hopital de La LouviÃ¨re - Site Jolimont - Oncology department, La LouviÃ¨re, 7100, Belgium|Universitair Ziekenhuis Leuven | Gasthuisberg Campus - Urology Department, Leuven, 3000, Belgium|Hospital SÃ£o Rafael, Salvador, Bahia, 41253-190, Brazil|AssistÃªncia Multidisciplinar em Oncologia (AMO), Salvador, Bahia, 41950-640, Brazil|Oncocentro - Fortaleza, Fortaleza, CearÃ¡, 60135-237, Brazil|Hospital EvangÃ©lico de Cachoeiro de Itapemirim, VitÃ³ria, EspÃ­rito Santo, 29047-660, Brazil|Liga Paranaense de Combate ao Cancer-Hosp Erasto Gaertner, Curitiba, Parana, 81520-060, Brazil|Real Hospital PortuguÃªs, Recife, Pernambuco, 50070-160, Brazil|Liga Norte Riograndense Contra o Cancer | Centro de Pesquisa ClÃ­nica, Natal, Rio Grande Do Norte, 59040-000, Brazil|Hospital Moinhos de Vento-Centro ClÃ­nico, Porto Alegre, Rio Grande Do Sul, 90035-001, Brazil|Hospital Mae de Deus, Porto Alegre, Rio Grande Do Sul, 90850-170, Brazil|Instituto D'Or Pesquisa e Ensino (IDOR) (D'Or Institute for Research & Education) - Rio de Janeiro, Rio de Janeiro, RJ, 22281-100, Brazil|Faculdade de Medicina do ABC, Santo AndrÃ©, Sao Paulo, 09060-650, Brazil|Instituto do Cancer do Estado de Sao Paulo, SÃ£o Paulo, Sao Paulo, 01246-000, Brazil|Real e BenemÃ©rita AssociaÃ§Ã£o Portuguesa de BeneficÃªncia, SÃ£o Paulo, Sao Paulo, 01323-001, Brazil|Inst. de AssistÃªncia MÃ©dica ao SÃ©rvidor PÃºblico Estadual, SÃ£o Paulo, Sao Paulo, 04039-004, Brazil|Hospital das ClÃ­nicas da Universidade de Campinas - UNICAMP, SÃ£o Paulo, Sao Paulo, 13083-888, Brazil|NAIC - Instituto do Cancer, Bauru, 17033-490, Brazil|Hospital Sirio LibanÃªs - Hospital Base de Brasilia, Brasilia, 70200-730, Brazil|Universidade Estadual do Rio de Janeiro, Rio de Janeiro, 20551-030, Brazil|Hospital Sirio Libanes, Sao Paulo, 01308-050, Brazil|Hospital Alemao Oswaldo Cruz, Sao Paulo, 01327-001, Brazil|Hospital do Cancer de Sao Paulo - A. C. Camargo, Sao Paulo, 01525-001, Brazil|Hospital Israelita Albert Einstein | Morumbi - Clinical Research Department, Sao Paulo, 05651-901, Brazil|Prostate Cancer Centre, Calgary, Alberta, T2V 1P9, Canada|Kaye Edmonton Clinic - Dianne and Irving Kipnes Urology Centre, Edmonton, Alberta, T6G 1Z1, Canada|Vancouver Prostate Centre, Vancouver, British Columbia, V5Z 1M9, Canada|BC Cancer - Victoria, Victoria, British Columbia, V8R 6V5, Canada|Nova Scotia Health Authority, Halifax, Nova Scotia, B3H 2Y9, Canada|St. Joseph's Healthcare - Hamilton, Hamilton, Ontario, L8N 4A6, Canada|London Health Sciences Centre (LHSC) - London Regional Cancer Program (LRCP), London, Ontario, N6A 5W9, Canada|Princess Margaret Cancer Centre - UHN, Toronto, Ontario, M5G 2M9, Canada|CISSS de l'Outaouais - Hopital de Gatineau - Centre de cancerolgie, Gatineau, Quebec, J8P 7H2, Canada|Urology South Shore Research - Research Department, Greenfield Park, Quebec, J4V 2H3, Canada|Hopital Maisonneuve-Rosemont, Montreal, Quebec, H1T 2M4, Canada|Sir Mortimer B. Davis Jewish General Hospital - Radiation Oncology, Montreal, Quebec, H3T 1E2, Canada|Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-Centre-du-Quebec - Radio-oncologie, Trois-rivieres, Quebec, G8Z 3R9, Canada|BC Cancer - Abbotsford, Abbotsford, V2S 0C2, Canada|HÃ´tel-Dieu de LÃ©vis - Urology, Quebec, G6V 3Z1, Canada|Centre Hospitalier Universitaire de Sherbrooke (CHUS) - Hopital Fleurimont, Sherbrooke, J1H 5N4, Canada|Peking University First Hospital, Beijing, Beijing, 100034, China|Zhongnan hospital ,Wuhan University, Wuhan, Hubei, 430071, China|Hunan Cancer Hospital, Changsha, Hunan, 410013, China|The Affiliated Hospital of Inner Mongolia Medical University, Hohehot, Inner Mongolia, 010030, China|Nanjing First Hospital, Nanjing, Jiangsu, 210006, China|Fudan University Shanghai Cancer Center, Shanghai, Jiangsu, 200000, China|West China Hospital,Sichuan University, Chengdu, Sichuan, 610041, China|The 1st Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, 310003, China|Peking Union Medical College Hospital (PUMCH) - East Location, Beijing, 100730, China|Jiangsu Provincial People's Hospital - The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China|Ruijin Hosp. Shanghai Jiaotong Univ.School of Medicine, Shanghai, 200025, China|Tianjin Cancer Hospital, Airport Hospital, Tianjin, 300308, China|Fakultni nemocnice u Sv. Anny, Onkologicko-chirurgicke oddeleni, Brno, 602 00, Czechia|Masarykova Univerzita - Masarykuv Onkologicky Ustav (MOU) - Klinika Komplexni Onkologicke Pece (KKOP), Brno, 602 00, Czechia|Multiscan s.r.o., Department: Ambulance klinickÃ© onkologie Nemocnice Horovice, Horovice, 26801, Czechia|Fakultni Nemocnice Olomouc (FNOL) - Onkologicka Klinika, Olomouc, 779 00, Czechia|Thomayerova Nemocnice (TN) (Thomayers Hospital) - Onkologicka Klinika 1. LF UK A TN, Prague, 140 59, Czechia|Fakultni nemocnice v Motole, Onkologicka klinika 2. LF UK a FN Motol, Prague, 15006, Czechia|VÅ¡eobecnÃ¡ fakultnÃ­ nemocnice v Praze - UrologickÃ¡ klinika, Praha 2, 128 08, Czechia|Aalborg University Hospital, Aalborg, 9000, Denmark|Aarhus Universitetshospital, Aarhus N, 8200, Denmark|Rigshospitalet - KrÃ¦ftbehandling, KÃ¸benhavn Ã, 2100, Denmark|SjÃ¦llands University hospital NÃ¦stved, NÃ¦stved, 4700, Denmark|HUS, Meilahden sairaala, Helsinki, Uusimaa, 00029, Finland|Docrates Klinikka, Helsinki, 00180, Finland|Oulun yliopistollinen sairaala, Oulu, 90220, Finland|Tampereen yliopistollinen sairaala, Tampere, 33520, Finland|Turun yliopistollinen keskussairaala, Turku, 20520, Finland|Center Hospitalier Michallon - Grenoble - Service d Urologie et de la transplantation Renale, La Tronche, Grenoble Cedex 9, 38700, France|Centre d' Oncologie du Pays Basque Clinique Belharra - Bayonne - Oncologie medicale, Bayonne, 64100, France|CHRU Besancon - Hopital Jean Minjoz, Besancon, 25000, France|CHU Bordeaux - Hopital Pellegrin - Service urologie, Bordeaux, 33000, France|Hopital La Cavale Blanche - CHU de Brest - institut de cancerologie et d'imagerie, Brest, 29200, France|Centre Hospitalier Universitaire de Clermont Ferrand - Gabriel Montpied - Service Urologie, Clermont- Ferrand, 63000, France|APHP - Hopital Henri Mondor - Departement Urologie, Creteil, 94000, France|Institut de cancerologie de Bourgogne - Departement radiotherapie, Dijon, 21000, France|Centre Georges Francois Leclerc Dijon - service de radiotherapie, Dijon, 21079, France|Hopital Claude Huriez - Lille - Urologie, Lille, 59000, France|Hopital Prive Le Bois - Centre Bourgogne - Service radiotherapie oncologie, Lille, 59000, France|UNICANCER - Centre Leon-Berard (CLB) - Medical oncology, Lyon, 69008, France|AP-HM - Hopital de la Timone, Marseille, 13005, France|Clinique Clementville, Montpellier, 34070, France|Institut Curie - Paris - Oncologie Radiotherapie, Paris, 75005, France|Hopital Bichat - Paris, Paris, 75018, France|HCL - Centre Hospitalier Lyon Sud, Pierre Benite, 69495, France|Institut de Cancerologie Jean Godinot - Departement oncologie medicale, Reims, 51056, France|CHU Rennes - Hopital Pontchaillou, Rennes Cedex, 35033, France|Institut de Cancerologie de l'Ouest - Saint Herblain - Unite de therapie precoce, Saint Herblain, 44800, France|Institut Curie - Saint-Cloud, Saint-Cloud, 92210, France|ICANS - Institut de Cancerologie de Strasbourg Europe, Strasbourg, 67033, France|Institut Claudius Regaud - iUCT Oncopole - Service oncologie, Toulouse, 31100, France|Hopital Bretonneau, Tours, 37044, France|Institut de CancÃ©rologie de Lorraine - Alexis Vautrin, Vandoeuvre-les-Nancy, 54519, France|Gustave Roussy - Departement Oncologie-Radiotherapie, Villejuif, 94800, France|Klinikum Mannheim GmbH, Mannheim, Baden-WÃ¼rttemberg, 68135, Germany|Studienpraxis Urologie, NÃ¼rtingen, Baden-WÃ¼rttemberg, 72622, Germany|Klinikum rechts der Isar, MÃ¼nchen, Bavaria, 81675, Germany|Klinikum der UniversitÃ¤t WÃ¼rzburg, Wurzburg, Bayern, 97080, Germany|UniversitÃ¤tsklinikum der Johann Wolfgang Goethe UniversitÃ¤t, Frankfurt, Hessen, 60590, Germany|StÃ¤dtisches Klinikum Braunschweig gGmbH, Brunswick, Lower Saxony, 38126, Germany|UniversitÃ¤tsmedizin der Georg-August-UniversitÃ¤t GÃ¶ttingen, GÃ¶ttingen, Lower Saxony, 37075, Germany|Urologicum Duisburg, Duisburg, Nordrhein-Westfalen, 47169, Germany|UniversitÃ¤tsklinikum KÃ¶ln, KÃ¶ln, Nordrhein-Westfalen, 50937, Germany|Universitaetsklinikum Muenster, MÃ¼nster, Nordrhein-Westfalen, 48149, Germany|Marienhospital Herne UniversitÃ¤tsklinik, Herne, NRW, 44625, Germany|Medizinische FakultÃ¤t der Otto-von-Guericke UniversitÃ¤t, Magdeburg, Sachsen-Anhalt, 39120, Germany|UniversitÃ¤tsklinikum Carl Gustav Carus an der Technischen UniversitÃ¤t Dresden, Dresden, Sachsen, 1307, Germany|UniversitÃ¤tsklinikum Aachen / Klinik und Poliklinik fÃ¼r Urologie und Kinderurologie, Aachen, 52074, Germany|Marien-Krankenhaus Bergisch Gladbach, Bergisch Gladbach, 51465, Germany|Vivantes Klinikum Am Urban, Berlin, 10967, Germany|CharitÃ© Campus Benjamin Franklin (CBF), Berlin, 12203, Germany|UniversitÃ¤tsklinikum Hamburg-Eppendorf - Martini-Klinik am UKE GmbH, Hamburg, 20246, Germany|Universitaetsklinikum Jena - Klinik fuer Urologie, Jena, 7747, Germany|UniversitÃ¤tsklinikum Schleswig-Holstein/ Klinik fÃ¼r Urologie, Kiel, 24105, Germany|Johannes Gutenberg-UniversitÃ¤t Mainz - Urologie, Mainz, 55131, Germany|Klinikum Stuttgart / Klinik fÃ¼r Urologie und Transplantationschirurgie, Stuttgart, 70174, Germany|Urologische Gemeinschaftspraxis Wesel, Wesel, 46483, Germany|Semmelweis Egyetem, Altalanos Orvostudomanyi Kar, Urologiai Klinika, Budapest, 1082, Hungary|Orszagos Onkologiai Intezet, Budapest, 1122, Hungary|Budapesti Uzsoki Utcai KÃ³rhÃ¡z, Budapest, 1145, Hungary|Budapesti Jahn Ferenc Del-pesti Korhaz es Rendelointezet, Budapest, 1204, Hungary|Gyor-Moson-Sopron Varmegyei Petz Aladar Egyetemi Oktato Korhaz, Gyor, 9024, Hungary|Szabolcs-Szatmar-Bereg Varmegyei Oktatokorhaz Nyiregyhazi Josa Andras Tagkorhaz, Nyiregyhaza, 4400, Hungary|Rambam Health Corporation, Haifa, 3109601, Israel|Hadassah Hebrew University Hospital Ein Kerem, Jerusalem, 9112001, Israel|Shaare Zedek Medical Center, Jerusalem, 9372212, Israel|Rabin Medical Center | Beilinson Hospital - Internal Medicine C Department, Petah Tikva, 4941492, Israel|Sheba Medical Center, Tel Hashomer, 52621, Israel|Sourasky Medical Center, Tel-Aviv, 64239, Israel|IRCCS Istituto Nazionale Tumori Fondazione Pascale - S. C. Oncologia Clinica Sperimentale Uro-Ginecologica, Napoli, Campania, 80131, Italy|Azienda Unita Sanitaria Locale Di Bologna_Ospedale Bellaria - Oncologia Medica, Bologna, Emilia-Romagma, 40139, Italy|Azienda Ospedaliero-Universitaria Di Bologna IRCCS_Policlinico Sant'Orsola - Urologia, Bologna, Emilia-Romagna, 40138, Italy|Azienda Ospedaliero Universitaria di Modena_Policlinico - Oncologia, Modena, Emilia-Romagna, 41124, Italy|Azienda USL IRCCS di Reggio Emilia_Arcispedale Santa Maria Nuova - S.C. Oncologia Provinciale, Reggio Emilia, Emilia-Romagna, 42123, Italy|Centro di Riferimento Oncologico di Aviano - Oncologia Radioterapica, Aviano, Friuli-Venezia Giulia, 33081, Italy|I.F.O. Istituti Fisioterapici Ospitalieri_Ospedale Regina Elena - Urologia, Roma, Lazio, 00128, Italy|Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Degenza di Radioterapia Oncologica, Roma, Lazio, 00168, Italy|IRCCS Ospedale Policlinico San Martino - Oncologia Medica 1, Genova, Liguria, 16132, Italy|Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII - Oncologia, Bergamo, Lombardia, 24127, Italy|Ospedale San Raffaele s.r.l - Urologia, Milano, Lombardia, 20132, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, 20133, Italy|Humanitas Mirasole S.p.A. - Oncologia Medica ed Ematologia, Rozzano, Lombardia, 20089, Italy|A.O.U. CittÃ  della Salute e della Scienza di Torino_Molinette - Urologia U, Torino, Piemonte, 10126, Italy|Azienda Universitaria Ospedaliera Consorziale Policlinico Bari, Bari, Puglia, 70124, Italy|Azienda Ospedaliero Universitaria Ospedali Riuniti_Foggia - Oncologia Medica e Terapia Biomolecolare Universitaria, Foggia, Puglia, 71122, Italy|Azienda Provinciale Per I Servizi Sanitari_Ospedale Santa Chiara - UO Oncologia Medica, Trento, Trentino, 38122, Italy|A.O. di Perugia_Hospital Santa Maria della Misericordia - S.C. Radioterapia Oncologica, Perugia, Umbria, 06129, Italy|Istituto Oncologico Veneto_Castelfranco Veneto - UOC Urologia Oncologica, Castelfranco Veneto, Veneto, 31033, Italy|Azienda Ospedaliera Policlinico Universitario Tor Vergata - UOC Radioterapia, Roma, Veneto, 00133, Italy|IRCCS Ospedale Sacro Cuore Don Calabria, Verona, Veneto, 37024, Italy|A.O.U.I. Verona, Verona, Veneto, 37134, Italy|Cliniche Gavazzeni S.p.A - Dipartimento Area Chirurgia UnitÃ  Operativa di Urologia, Bergamo, 24125, Italy|Azienda Ospedaliera Santa Croce e Carle - Oncologia, Cuneo, 12100, Italy|Hokkaido University Hospital, Sapporo, Hokkaido, 060-8648, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, 920-8641, Japan|Yokohama City University Hospital, Yokohama, Kanagawa, 236-0004, Japan|The University of Osaka Hospital, Suita, Osaka, 565-0871, Japan|Institute of Science Tokyo Hospital, Bunkyo-ku, Tokyo, 113-8519, Japan|Kagoshima University Hospital, Kagoshima, 890-8520, Japan|Kyoto University Hospital, Kyoto, 606-8507, Japan|Catharina Ziekenhuis, Eindhoven, Noord-Brabant, 5623 EJ, Netherlands|Albert Schweitzer Hospital | Internal Medicine - Oncology Department, Dordrecht, 3300 AK, Netherlands|University Medical Center Groningen | Urology Department, Groningen, 9713 GZ, Netherlands|Tergooi MC | Hilversum - Wetenschapsbureau, Hilversum, 1213 VG, Netherlands|St. Antonius Ziekenhuis | Utrecht - R&D Interne Geneeskunde, Nieuwegein, 3435 CM, Netherlands|St. Franciscus Gasthuis, Rotterdam, 3045 PM, Netherlands|HagaZiekenhuis van Den Haag, The Hague, 2545, Netherlands|Canterbury Urology Research Trust, Christchurch, Canterbury, 8013, New Zealand|Auckland City Hosptial, Auckland, 1023, New Zealand|MidCentral District Health Board (MDHB) - Palmerston North Hospital (PNH), Palmerston North, 4414, New Zealand|Tauranga Urology Research Limited, Tauranga, 3112, New Zealand|Centrum Onkologii im. Prof. Franciszka Lukaszczyka, Bydgoszcz, 85-796, Poland|Swietokrzyskie Centrum Onkologii, Kielce, 25-734, Poland|Centrum Medyczne iMed24, Krakow, 31-864, Poland|Medrise Sp. z o.o. Centrum Badan Klinicznych, Lublin, 20-582, Poland|Szpital Grochowski im. dr.med. Rafala Masztaka, Warszawa, 04-073, Poland|EMC Instytut Medyczny SA, Wroclaw, 54-144, Poland|Instituto Portugues de Oncologia de Lisboa | Unidade de Investigacao Clinica - Departamento de Urologia, Lisbon, Lisboa, 1099-023, Portugal|Centro Clinico Academico Braga | Braga, Portugal, Braga, 4710-243, Portugal|Centro Hospitalar e Universitario de Coimbra EPE (CHUC), Coimbra, 3004-561, Portugal|Companhia Uniao Fabril | Hospital CUF Tejo - Academic Center - Research Center, Lisboa, 1350-352, Portugal|Fundacao Champalimaud | Centro Clinico Champalimaud - Unidade Investigacao Clinica, Lisboa, 1400-038, Portugal|Luz Saude | Hospital da Luz Lisboa - Centro de Investigacao Clinica, Lisboa, 1500-650, Portugal|Hospital Santa Maria | Centro de Investigacao Clinica, Lisboa, 1649-035, Portugal|Centro Hospitalar Universitario do Porto, Porto, 4099-001, Portugal|Hospital ClÃ­nico Universitario de Santiago de Compostela, Santiago de Compostela, A CoruÃ±a, 15706, Spain|Hospital Universitario Marques De Valdecilla - Urologia, Santander, Cantabria, 39008, Spain|Hospital Universitario Virgen De La Victoria - Urologia, Malaga, MÃ¡laga, 20910, Spain|Hospital del Mar, Barcelona, 08003, Spain|Fundacio Puigvert - Urologia, Barcelona, 08025, Spain|Ciutat Sanitaria i Universitaria de la Vall d'Hebron, Barcelona, 08035, Spain|Hospital ClÃ­nic i Provincial de Barcelona, Barcelona, 8036, Spain|Hospital Universitario Puerta del Mar - Urologia, Cadiz, 11009, Spain|MD Anderson International Espanya, S.A. - Oncologia Radioterapica, Madrid, 28033, Spain|Hospital Universitario Ramon Y Cajal - Oncologia Radioterapica, Madrid, 28034, Spain|Centro Integral OncolÃ³gico Clara Campal, Madrid, 28050, Spain|Hospital General Universitario Morales Meseguer - Urologia, Murcia, 30008, Spain|Hospital Universitario Virgen Del Rocio S.L. - Urologia, Sevilla, 41013, Spain|Hospital Universitario Y Politecnico La Fe - Oncologia Radioterapica, Valencia, 46009, Spain|Instituto Valenciano de OncologÃ­a, Valencia, 46009, Spain|Goteborgs Universitet, Gothenburg, 413 45, Sweden|Skane University Hospital - Department of Urology, Malmo, 20502, Sweden|Uppsala University Hospital, Urology Department, Uppsala, SE-751, Sweden|Tungs' Taichung MetroHarbor Hospital, Taichung, 435403, Taiwan|National Taiwan University Hospital, Taipei, 100, Taiwan|Koo Foundation Sun Yet-Sen Cancer Centre, Taipei, 112019, Taiwan|Chang Gung Memorial Hospital at Linkou, Taoyuan, 33305, Taiwan|Bedford Hospital - Bedfordshire Hospitals NHS Foundation Tru, Bedford, Bedfordshire, MK42 9DJ, United Kingdom|East and North Hertfordshire NHS Trust - Mount Vernon Hospital - Mount Vernon Cancer Centre (MVCC), Northwood, Middlesex, HA6 2RN, United Kingdom|Royal Surrey NHS Foundation Trust | Royal Surrey County Hospital - Cancer Centre, Guildford, Surrey, GU2 7XX, United Kingdom|University College London Hospitals NHS Foundation Trust | University College Hospital (UCLH) - Cancer Clinical Trials Unit, London, NW1 2PG, United Kingdom|The Royal Marsden NHS Foundation Trust | The Royal Marsden Hospital - The Royal Marsden Clinical Trials Unit (CTU), London, SW3 6JJ, United Kingdom|Imperial College Healthcare NHS Trust | Charing Cross Hospital - Cancer Services, London, W68RF, United Kingdom",
NCT05132582,A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer,https://clinicaltrials.gov/study/NCT05132582,HER2CLIMB-05,ACTIVE_NOT_RECRUITING,"This study is being done to see if tucatinib works better than placebo when given with other drugs to treat participants with HER2-positive breast cancer. A placebo is a pill that looks the same as tucatinib but has no medicine in it. This study will also test what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease.

Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic).

In this study, all participants will get either tucatinib or placebo. Participants will be assigned randomly to a group. This is a blinded study, so patients and their doctors will not know which group a participant is in.

All participants will also get trastuzumab and pertuzumab. These are 2 drugs used to treat this type of cancer.",NO,HER2 Positive Breast Cancer,DRUG: Tucatinib|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Combination product: Trastuzumab + Pertuzumab|DRUG: Placebo,"Progression-free survival (PFS) by investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, The time from the date of randomization to the investigator assessment of disease progression according to RECIST v1.1 or death from any cause, Up to approximately 3 years","Overall survival (OS), The time from randomization to death from any cause., Up to approximately 5 years|PFS by blinded independent central review (BICR) per RECIST v1.1, The time from the date of randomization to the documented disease progression assessed by BICR according to RECIST v1.1 or death from any cause, Up to approximately 3 years|Time to deterioration of health-related quality of life (HRQoL), Will be measured based on patient reported outcomes (PROs) according to the European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ C30)., Up to approximately 3 years|Central nervous system (CNS) PFS, The time from randomization to investigator assessed disease progression in brain (RECIST v1.1), or death from any cause, Up to approximately 3 years|Incidence of adverse events (AEs), Any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment., Through 30 days after last study treatment, approximately 18 months|Incidence of laboratory abnormalities, To be summarized using descriptive statistics., Through 30 days after last study treatment, approximately 18 months|Incidence of tucatinib dose alterations, To be summarized using descriptive statistics., Through 30 days after last study treatment, approximately 18 months|Incidence of trastuzumab dose alterations, To be summarized using descriptive statistics., Through 30 days after last study treatment, approximately 18 months|Incidence of pertuzumab dose alterations, To be summarized using descriptive statistics., Through 30 days after last study treatment, approximately 18 months|Maximum concentration (Cmax), To be summarized using descriptive statistics., Through 30 days after last study treatment, approximately 18 months|Trough concentration (Ctrough), To be summarized using descriptive statistics., Through 30 days after last study treatment, approximately 18 months",,"Seagen, a wholly owned subsidiary of Pfizer",,ALL,"ADULT, OLDER_ADULT",PHASE3,654,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-03-07,2026-02-28,2027-09-28,2021-11-24,,2025-06-03,"Mayo Clinic Hospital, Phoenix, Arizona, 85054, United States|Mayo Clinic, Scottsdale, Arizona, 85259, United States|CARTI Cancer Center,Central Arkansas Radiation Therapy Institute, Little Rock, Arkansas, 72205, United States|CARTI Cancer Center, Little Rock, Arkansas, 72205, United States|UCLA Hematology/Oncology - Beverly Hills, Beverly Hills, California, 90212, United States|UCLA Hematology/Oncology - Burbank, Burbank, California, 91505, United States|UCSD Medical Center - Encinitas, Encinitas, California, 92024, United States|Koman Family Outpatient Pavilion, La Jolla, California, 92037, United States|Sulpizio Cardiovascular Center at UC San Diego Health, La Jolla, California, 92037, United States|UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion), La Jolla, California, 92037, United States|UCSD Perlman Medical Offices, La Jolla, California, 92037, United States|UC San Diego Moores Cancer Center, La Jolla, California, 92093, United States|UCLA Hematology/Oncology - Laguna Hills, Laguna Hills, California, 92653, United States|UCLA Hematology/Oncology, Los Angeles, California, 90095, United States|UC San Diego Medical Center - Hillcrest, San Diego, California, 92103, United States|UCLA Hematology/Oncology - San Luis Obispo, San Luis Obispo, California, 93401, United States|UCLA Hematology/Oncology- Santa Barbara, Santa Barbara, California, 93105, United States|UCLA Hematology/Oncology - Santa Monica, Santa Monica, California, 90404, United States|UCLA Hematology/Oncology Parkside, Santa Monica, California, 90404, United States|Clinical And Translational Research Center, Torrance, California, 90502, United States|Investigational Drug Service, Torrance, California, 90502, United States|Lundquist Institute/Harbor-UCLA, Torrance, California, 90502, United States|The Lundquist Institute for Biomedical Innovation at H arbor-UCLA M edical Center, Torrance, California, 90502, United States|Harbor-UCLA Medical Center, Torrance, California, 90509, United States|UCLA Hematology/Oncology - Santa Clarita, Valencia, California, 91355, United States|UCSD Medical Center - Vista, Vista, California, 92081, United States|UCLA Hematology/Oncology- Westlake, Westlake Village, California, 91361, United States|AdventHealth Altamonte Infusion Center, Altamonte Springs, Florida, 32701, United States|AdventHealth Medical Group Altamonte(second location), Altamonte Springs, Florida, 32701, United States|AdventHealth Medical Group Altamonte, Altamonte Springs, Florida, 32701, United States|Mayo Clinic Florida, Jacksonville, Florida, 32224, United States|AdventHealth Medical Group Orlando, Orlando, Florida, 32804, United States|AdventHealth Orlando Infusion Center, Orlando, Florida, 32804, United States|Emory University Hospital Midtown, Atlanta, Georgia, 30308, United States|Winship Cancer Institute, Atlanta, Georgia, 30322, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, 30342, United States|University of Illinois Hospital and Health Systems (Outpatient Cancer Center), Chicago, Illinois, 60612, United States|University of Illinois Hospital and Health Systems, Chicago, Illinois, 60612, United States|Norton Cancer Institute - Downtown, Louisville, Kentucky, 40202, United States|Norton Hospital, Louisville, Kentucky, 40202, United States|Brownsboro Diagnostic Center, Louisville, Kentucky, 40207, United States|Norton Cancer Institute, St Matthews Campus, Louisville, Kentucky, 40207, United States|Norton Cancer Institute, St. Matthews Campus, Louisville, Kentucky, 40207, United States|Norton Diagnostic Center - Dupont, Louisville, Kentucky, 40207, United States|Norton Women's & Children's Hospital, Louisville, Kentucky, 40207, United States|Norton Brownsboro Hospital, Louisville, Kentucky, 40241, United States|Norton Cancer Institute, Brownsboro Hospital Campus, Louisville, Kentucky, 40241, United States|Norton Cancer Institute, Louisville, Kentucky, 40241, United States|Norton Diagnostic Center - Fern Creek, Louisville, Kentucky, 40291, United States|Mercy Medical Center, Baltimore, Maryland, 21202, United States|Mayo Clinic Rochester, Rochester, Minnesota, 55905, United States|Saint Luke's Cancer Institute., Kansas City, Missouri, 64111, United States|Oncology Hematology West PC dba Nebraska Cancer Specialists, Grand Island, Nebraska, 68803, United States|Oncology Hematology West, PC dba Nebraska Cancer Specialists - Grand Island, Grand Island, Nebraska, 68803, United States|Oncology Hematology West PC dba Nebraska Cancer Specialists, Omaha, Nebraska, 68114, United States|Oncology Hematology West PC dba Nebraska Cancer Specialists, Omaha, Nebraska, 68124, United States|Oncology Hematology West PC dba Nebraska Cancer Specialists, Omaha, Nebraska, 68130, United States|Oncology Hematology West PC dba Nebraska Cancer Specialists, Papillion, Nebraska, 68046, United States|RWJBarnabas Health- Jersey City Medical Center, Jersey City, New Jersey, 07302, United States|RWJBarnabas Health- Monmouth Medical Center-Southern Campus, Lakewood, New Jersey, 08701, United States|RWJBarnabas Health- Cooperman Barnabas Medical Center, Livingston, New Jersey, 07039, United States|RWJBarnabas Health- Monmouth Medical Center, Long Branch, New Jersey, 07740, United States|Newark Beth Israel Medical Center, Newark, New Jersey, 07112, United States|RWJBarnabas Health-Robert Wood Johnson University Hospital, Somerset, Somerville, New Jersey, 08876, United States|Steeplechase Cancer Center, Somerville, New Jersey, 08876, United States|RWJBarnabas Health - Community Medical Center, Toms River, New Jersey, 08755, United States|Satellite Infusion Center-Monmouth Medical Center Vantage Point Infusion Center, West Long Branch, New Jersey, 07764, United States|Montefiore Einstein Comprehensive Cancer Center, Bronx, New York, 10461, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|Cleveland Clinic Cancer Center - Strongsville, Strongsville, Ohio, 44136, United States|Tennessee Oncology, PLLC, Gallatin, Tennessee, 37066, United States|Tennessee Oncology, PLLC, Murfreesboro, Tennessee, 37129, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, 37203, United States|Tennessee Oncology, PLLC, Shelbyville, Tennessee, 37160, United States|University of Washington Medical Center, Seattle, Washington, 98195, United States|Froedtert Hospital/Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States|Chris O'Brien Lifehouse, Camperdown, New South Wales, 2050, Australia|Macquarie University Clinical Trials Unit., Macquarie University, New South Wales, 2109, Australia|Macquarie University Hospital, Macquarie University, New South Wales, 2109, Australia|Baxter Healthcare Pty Limited, Old Tonggabbie, New South Wales, 2146, Australia|Pharmacy Macquarie University Hospital, Sydney, New South Wales, 2109, Australia|Westmead Hospital, Sydney, New South Wales, 2145, Australia|Western Sydney Local Health District (WSLHD), Westmead Hospital, Westmead, New South Wales, 2145, Australia|Cancer Research SA, Adelaide, South Australia, 5000, Australia|HPS Pharmacies -Adelaide (South Tee) (lnvestigational Product storage and dispensing), Adelaide, South Australia, 5000, Australia|St Andrews Medical Centre, Adelaide, South Australia, 5000, Australia|Flinders Medical Centre, Bedford Park, South Australia, 5042, Australia|Box Hill Hospital, Box Hill, Victoria, 3128, Australia|Austin Health, Heidelberg, Victoria, 3084, Australia|St John of God Subiaco Hospital Clinical Trials Unit Bendat Family Comprehensive Cancer Centre, Subiaco, Washington, 6008, Australia|St John of God Subiaco Hospital, Subiaco, Western Australia, 6008, Australia|Ordination Priv.-Doz. Dr. Michael Hubalek, Schwaz, Other, A-6130, Austria|Anstaltsapotheke des Landeskrankenhauses, Graz, 8036, Austria|Medizinische Universitat Graz, Graz, A-8036, Austria|Ordensklinikum Linz GmbH Barmherzige Schwestern, Linz, A-4010, Austria|Marien Apotheke Schwaz, Schwaz, A-6130, Austria|Anstaltsapotheke des Allgemeinen Krankenhauses der Stadt Wien, Wien, A-1090, Austria|Medizinische Universitat Wien Universitatsklinik Fur Frauenheilkunde, Wien, A-1090, Austria|Institut Jules Bordet, Anderlecht, Brussels, B-1070, Belgium|Universitair Ziekenhuis Brussel, Bruxelles-Capitale, Oost-vlaanderen, 1090, Belgium|Clinique Saint Pierre, Ottignies, Walloon Brabant, 1340, Belgium|Jules Bordet lnstituut, Anderlecht, 1070, Belgium|Cliniques Universitaires Saint-Luc, Brussels, 1200, Belgium|UCL Saint-Luc, Brussels, 1200, Belgium|Universitair Ziekenhuis Brussel (UZ Brussel), Brussel, 1090, Belgium|Clinique St Pierre, Ottignies, 1340, Belgium|Centro Regional Integrado de Oncologia, Fortaleza, Ceara, 60336-045, Brazil|CRIO - Centro Regional lntegrado de Oncologia, Fortaleza, Ceara, 60336-232, Brazil|Hospital Araujo Jorge, Goiania, Goias, 74605-070, Brazil|Clinica de Pesquisas e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda., Bela Vista, Other, 01317-001, Brazil|Hospital Araujo Jorge - Associacao de Combate ao Cancer em Goias, Goiania, Other, 74605-070, Brazil|Centro Gaucho Integrado de Oncologia, Hematologia, Ensino e Pesquisa, Porto Alegre, Other, 90110-270, Brazil|Hospital Do Cancer De Londrina, Londrina, Parana, 86015-520, Brazil|Liga Norte-Rio Grandense Contra o Cancer, Natal, RIO Grande DO Norte, 59075-740, Brazil|Liga Norte-Rio-Grandense Contra o Cancer, Natal, RIO Grande DO Norte, 59151-600, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, RIO Grande DO SUL, 90020-090, Brazil|Hospital de Clinicas de Porto Alegre, Porto Alegre, RIO Grande DO SUL, 90035-903, Brazil|Centro Gaucho Integrado de Oncologia, Hematologia, Ensino e Pesquisa - Hospital do Cancer Mae de Deu, Porto Alegre, RIO Grande DO SUL, CEP 90110-270, Brazil|Centro Gaucho Integrado de Oncologia, Hematologia, Ensino e Pesquisa - Hospital do Cancer Mae de Deu, Porto Alegre, RIO Grande DO SUL, CEP 90850-170, Brazil|Hospital de Cancer de Barretos - Fundacao Pio XII, Barretos, SAO Paulo, 14784-400, Brazil|Fundacao Pio XII, Hospital do Amor de Barretos, Barretos, SAO Paulo, CEP: 14784-400, Brazil|Fundacao Dr Amaral Carvalho, Jau, SAO Paulo, CEP: 17210-080, Brazil|Fundacao Doutor Amaral Carvalho, JaÃº, SAO Paulo, 17210-120, Brazil|CEPHO- Centro de Estudos e Pesquisas de Hematologia e Oncologia, Santo Andre, SAO Paulo, 09060-650, Brazil|CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia, Santo Andre, SAO Paulo, 09060-870, Brazil|Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto, Sao Jose Rio Preto, SAO Paulo, 15090-000, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre centro Multidisciplinar de pesquisa clinica, Porto Alegre/RS, 90050-170, Brazil|Faculdade Regional de Medicina de Sao Jose do Rio Preto, Sao Jose do Rio Preto, 15090-000, Brazil|ICESP- Instituto do Cancer do Estado de Sao Paulo Octavio Frias de Oliveira, Sao Paulo, 01246-000, Brazil|Fundacao Antonio Prudente (AC Camargo Cancer Center), Sao Paulo, 01509-010, Brazil|Sao Camilo Oncologia, Sao Paulo, 04014-002, Brazil|Clinica de Pesquisas e Centro de Estudos em Oncologia Ginecologica e MamÃ¡ria Ltda., Sao Paulo, CEP: 01317-000, Brazil|A.C. Camargo CÃ¢ncer Center, SÃ£o Paulo/SP, 01.509-010, Brazil|ICESP - Instituto do Cancer do Estado de Sao Paulo Octavio Frias de Oliveira, SÃ£o Paulo, 01246-000, Brazil|Cross Cancer Institute, Edmonton, Alberta, T6G 1Z2, Canada|BC Cancer Agency, Kelowna, British Columbia, V1Y 5L3, Canada|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, K1H 8L6, Canada|Sunnybrook Research Institute, Toronto, Ontario, M4N 3M5, Canada|Mount Sinai Hospital - Toronto, Toronto, Ontario, M5G1X2, Canada|Centre integre universitaire de sante et de services sociaux du Saguenay-Lac-Saint-Jean, Chicoutimi, Quebec, G7H 5H6, Canada|Centre Hospitalier de l'Universite de Motreal (CHUM), Montreal, Quebec, H2X 3E4, Canada|Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada|Sociedad de Investigaciones Medicas Limitada, Temuco, Cautin, 4810469, Chile|Centro de Investigacion ClÃ­nica Bradford Hill, Recoleta, Santiago, Chile|Oncocentro Apys, ViÃ±a del Mar, ValparaÃ­so, Chile|Centro de Investigacion Clinica Bradford Hill, Santiago, 13127, Chile|Clinica Universidad Catolica del Maule, Talca, 3460000, Chile|James Lind Centro De Investigacion Del Cancer, Temuco, 4810469, Chile|The Second Hospital of Anhui Medical University, Hefei City, Anhui, 230601, China|Guangdong Provincial People's Hospital, Guangzhou, Guangdong, 510080, China|Meizhou People's Hospital - Guangdong Province, Meizhou, Guangdong, 514031, China|Meizhou People's Hospital, Meizhou, Guangdong, 514031, China|Liuzhou People's Hospital, Liuzhou, Guangxi, 545006, China|Guangxi Medical University Affiliated Tumor Hospital, Nanning, Guangxi, 530021, China|The first Affiliated Hospital of Hainan Medical University, Haikou, Hainan, 570102, China|Affiliated Hospital of Hebei University, Baoding City, Hebei, 071000, China|Henan Cancer Hospital, Zhengzhou City, Henan, 450003, China|Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan City, Hubei, 430022, China|Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei, 430030, China|Hubei Cancer Hospital, Wuhan, Hubei, 430079, China|The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011, China|Jiangsu Province Hospital, Nanjing City, Jiangsu, 210029, China|The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330008, China|The First Hospital of Jilin University, Changchun, Jilin, 130021, China|The First Hospital of China Medical University, Shenyang City, Liaoning, 110001, China|Liaoning Cancer Hospital & Insitute, Shenyang City, Liaoning, China|Liaoning Cancer Hospital and Institute, Shenyang, Liaoning, 110042, China|Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine, Hangzhou, Other, 310016, China|Ruijin Hospital of Shanghai Jiaotong University School of Medicine, Shanghai, Other, 200025, China|Shaanxi Provincial People's Hospital, Xi'an City, Shaanxi, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China|Jinan Central Hospital, Jinan, Shandong, 250013, China|Linyi Cancer Hospital, Linyi City, Shandong, 276034, China|Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou City, Zhejiang, 310016, China|Zhejiang Cancer Hospital, Hangzhou City, Zhejiang, 310022, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310009, China|Beijing Hospital, Beijing, 100730, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Binjiang District, 310052, China|The First Bethune Hospital of Jilin University, Changchun, 130021, China|Nanjing Medical University (NMU) - Jiangsu Province Hospital, Nanjing, 210029, China|The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530016, China|Guangxi Medical University Affiliated Tumor Hospital, Nanning, 530021, China|Fudan University Shanghai Cancer Center, Shanghai, 200032, China|Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China|Tianjin Medical University Cancer Institute & Hospital, Tianjin City, 300181, China|Lekarna Vseobecne fakultni nemocnice v Praze, Praha, Praha 2, 128 08, Czechia|Masarykuv Onkologicky Ustav, Brno, 656 53, Czechia|Ustavni lekarna Masarykuv onkologicky ustav, Brno, 656 53, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, 128 08, Czechia|Lekarna FTN, Praha 4 - Krc, 140 59, Czechia|Fakultni Thomayerova nemocnice Onkologicka klinika 1. LF UK a FTN, Praha 4 - Krc, 14059, Czechia|Fakultni nemocnice v Motole Onkologicka klinika 2. LF UK a FN Motol, Praha 5 - Motol, 15006, Czechia|Tampere University Hospital pharmacy, Tampere, 33520, Finland|Tampere University Hospital, FONK/RSYO, Tampere, 33520, Finland|Tampere University Hospital, Tampere, Finland|Centre Henri Becquerel / Centre Regional de Lutte Contre le Cancer, Rouen, Bretagne, 76038, France|Institut Bergonie, Bordeaux, Cedex, 33076, France|Centre de CancÃ©rologie du Grand Montpellier, Montpellier, Languedoc-roussillon, 34070, France|Institut de Cancerologie de lOuest-Saint Herblain, Saint Herblain, Loire-atlantique, 44805, France|Centre de Lutte contre le Cancer (CLCC) - Centre Antoine Lacassagne, Nice Cedex 2, Lyon, 06189, France|Institut de Cancerologie de lOuest - Site Rene Gauducheau, Saint Herblain cedex, Mainet-et-loire, 44800, France|Institut Sainte-Catherine., Avignon Cedex 9, 84918, France|CHU Besancon - Pole Pharmaceutique - Unite essais cliniques, Besancon, 25000, France|CHU Besancon, Besangon, 25000, France|Centre Hospitalier Universitaire Hopital Avicenne, Bobigny, 93000, France|Hopital Avicenne, Bobigny, 93009 Cedex, France|Centre de Lutte contre le Cancer - FranÃ§ois Baclesse, Caen Cedex 5, 14076, France|CENTRE FRANCOIS BACLESSE - Service lmagerie medicale, Caen, 14076 Cedex 5, France|Centre Jean Perrin, Clermont Ferrand, 63000, France|Centre Jean Perrin - Pharmacy, Clermont-Ferrand, 63011, France|Center Georges-Francois Leclerc, Dijon, 21079 Cedex, France|Centre de Lutte contre le Cancer (CLCC) - Centre Oscar Lambret, Lille, 59000, France|Centre Oscar Lambret, Lille, 59020 Cedex, France|Center Leon Berard, Lyon, 69373 Cedex 08, France|Institut RÃ©gional du Cancer de Montpellier, Montpellier Cedex 5, 34298, France|Institut Regional du Cancer de Montpellier Service lmagerie medicale, Montpellier, 34298 Cedex 5, France|lnstitut Regional du Cancer de Montpellier- Service Pharmacie, Montpellier, 34298 Cedex 5, France|Centre Antoine Lacassagne, Nice cedex 2, 06189, France|Pharmacy :Centre Antoine Lacassagne, Nice, 06189 Cedex 2, France|Institut Curie - site de Paris - Pharmacy, Paris, 75005, France|Institut Curie - site de Paris, UnitÃ©d Investigation Clinique, Paris, 75005, France|Hopitaux Civils de Lyon, Pierre Benite, 69310, France|Hospices Civils de Lyon, Pierre Benite, 69310, France|""CARIO - Centre Armoricain de Radiotherapie lmagerie medicate et d'Oncologie -Hopital Prive des, Plerin, 22190, France|Centre Eugene Marquis Pharmacie - Essais Cliniques, Rennes, cedex 35042, France|Centre Eugene Marquis, Rennes, cedex 35042, France|Centre Henri Becquerel, Rouen, 76038 Cedex 1, France|Institut Curie - site St-Cloud, Saint-Cloud, 92210, France|Institut de Cancerologie Strasbourg Europe, Strasbourg, 67033, France|Centre Paul Strauss Pharmacie - Essais cliniques, Strasbourg, 67065, France|Institut Curie, Saint-Cloud, Ãle-de-france, 92210, France|Universitaetsklinikum Hamburg-Eppendorf (UKE), Hamburg, North Rhine-westphalia, 20246, Germany|Pharmacy:Fortuna Herstellung GmbH, Mannheim, Other, 68167, Germany|""Universitatsklinikum Augsburg Klinik fur Frauenheilkunde und Geburtshilfe"", Augsburg, 86156, Germany|Charite Universtitatsmedizin Berlin Klinik fur Gynakologie mit Brustzentrum, Berlin, 10117, Germany|""Pharmacy: Universitatsklinikum Hamburg-Eppendorf Apotheke (Gebaude N19)"", Hamburg, 20246, Germany|UniversitÃ¤tsmedizin Mannheim UniversitÃ¤tsfrauenklinik, Manheim, 68167, Germany|Klinikum Rechts der Isar der Technischen Universitaet Muenchen, Muenchen, 81675, Germany|University Hospital Muenster Senology, Munster, 48148, Germany|Universitatsklinikum Ulm Klinik fur Frauenheilkunde und Geburtshilfe, Ulm, 89075, Germany|Apotheke des Universitatsklinikums Ulm, Ulm, 89081, Germany|Universitatsklinikum Wurzburg Apotheke, Wurzburg, 97080, Germany|Universitatsklinikum Wurzburg Frauenklinik und Poliklinik, Wurzburg, 97080, Germany|Universitatsklinikum Wurzburg, Comprehensive Cancer Center - Mainfranken (CCCMF), Wurzburg, 97080, Germany|General Hospital of Athens ""Alexandra"" Clinical Therapeutics Department, Hematology/Oncology Unit, Athens, Attica, 11528, Greece|University General Hospital of Patras, Oncology Department, Internal Medicine Clinic, Patra, Peloponnese, 26504, Greece|University General Hospital of Larissa, Oncology Clinic, Larissa, 41110, Greece|IASO, Maroussi, 15123, Greece|Metaxa Anticancer Hospital of Piraeus, Pireaus, 18537, Greece|Azienda Ospedaliera Universitaria (AOU) Federico II, Napoli, Campania, 80131, Italy|Azienda Ospedaliera Universitaria Federico II, Napoli, Campania, 80131, Italy|Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Campania, 80131, Italy|lstituto Nazionale Tumori IRCCS - Fondazione Pascale U.O.C. Oncologia Medica Senologica, Napoli, Campania, 80131, Italy|Farmacia centrale, Genova, Liguria, 16132, Italy|IRCCS Ospedale Policlinico, San Martino, Genova, Liguria, 16132, Italy|Istituto Clinico Humanitas-Humanitas Cancer Center, Rozzano (Milano), Lombardia, 20089, Italy|ASST Monza Ospedale San Gerardo Centro Ricerca di Fase 1, Monza (MB), Lombardy, 20900, Italy|Azienda Ospedaliero Universitaria delle Marche SOD Clinica Oncologica, Torrette, Marche, 60126, Italy|U.O. Farmacia Asst Monza, Monza, Monza AND Brianza, 20900, Italy|Humanitas lstituto Clinico Catanese, Catania (CT), Sicily, 95045, Italy|Divisione Oncologia Medica, Ospedale di Trento - Presidio Ospedaliero (PO) Santa Chiara, Trento, Trentino, 38122, Italy|SOC Farmacia, Ospedale di Trento - Presidio Ospedaliero (PO), Trento, Trentino, 38122, Italy|Oncologia Medica Azienda Usl Toscana Nord Ovest - Ospedali Riuniti di Livor, Livorno, Tuscany, 57124, Italy|S.O.C. Oncologia Medica - Nuovo Ospedale di Prato Santo Stefano, Prato, Tuscany, 59100, Italy|Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi, Bologna, 40138, Italy|SSD Oncologia Medica Addarii - Zamagni, Policlinico Sant'Orsola - Malpighi, Bologna, 40138, Italy|Azienda Ospedaliera Universitaria San Martino, Genova, 16132, Italy|Divisione di Senologia Medica; Istituto Europeo di Oncologia, Milano, 20141, Italy|Farmacia Istituto Clinico Humanitas, Milan, 20089, Italy|UOC di Oncologia Medica, Azienda Ospedaliero Universitaria (AOU) di Parma, Parma, 43126, Italy|Istituti Clinici Scientifici Maugeri IRCCS, Pavia, 27100, Italy|Tesshokai Kameda General Hospital, Kamogawa-shi, Chiba-ken, 296-8602, Japan|Medical Corporation Tesshokai Kameda Medical Center, Kamogawa, Chiba, 296-8602, Japan|National Cancer Center Hospital East, Kashiwa-Shi, Chiba, 277-8577, Japan|Shikoku Cancer Center, Matsuyama-shi, Ehime-ken, 791-0280, Japan|NHO Shikoku Cancer Center, Matsuyama, Ehime, 791-0280, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka-city, Fukuoka, 811-1395, Japan|Fukushima Medical University Hospital, Fukushima-shi, Fukushima, 960-1295, Japan|National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, 003-0804, Japan|Ishikawa Prefectural Central Hospital, Kanazawa-shi, Ishikawa, 920-8530, Japan|Kanagawa Cancer Center, Yokohama, Kanagawa, 241-8515, Japan|University of Tsukuba Hospital, Tsukuba-shi, Lbaraki-ken, 305-8576, Japan|Naha Nishi Clinic, Naha-shi, Okinawa-ken, 901-0154, Japan|Medical Corporation Nahanishikai Nahanishi Clinic, Naha-shi, Okinawa, 901-0154, Japan|Kindai University Hospital, Osakasayama-shi, Osaka-fu, 589-8511, Japan|St. Luke's International Hospital, Chuo-ku, Tokyo-to, 104-8560, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, 104-0045, Japan|St. Luke's International Hospital., Chuo-ku, Tokyo, 104-8560, Japan|Toranomon Hospital, Minato-ku, Tokyo, 105-8470, Japan|Showa University Hospital, Shinagawa-ku, Tokyo, 142-8666, Japan|Chungbuk Nationl University Hospital, Cheongju-si, Chungcheongbuk-do, 28644, Korea, Republic of|Severance Hospital, Yonsei University Health System, Wonju-si, Gangwon-do, 26426, Korea, Republic of|Yonsei University Wonju Severance Christian Hospital, Wonju-si, Gangwon-do, 26426, Korea, Republic of|National Cancer Center, Goyang-Si, Gyeonggi-do, 10408, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, 13620, Korea, Republic of|The Catholic University of Korea, St. Vincent's Hospital, Suwon-si, Gyeonggi-do, 16247, Korea, Republic of|Ajou University Hospital, Suwon-si, Gyeonggi-do, 16499, Korea, Republic of|St. Vincent's Hospital, The Catholic University of Korea, Suwon-si, Gyeonggido [kyonggi-do], 16247, Korea, Republic of|Dong-A University Hospital, Busan, 49201, Korea, Republic of|Gachon University Gil Medical Center, Incheon, 21565, Korea, Republic of|Korea University Anam Hospital, Seoul, 02841, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Severance Hospital Yonsei University Health System, Seoul, 03722, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, 03722, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Gangnam Severance Hospital, Yonsei University Health System, Seoul, 06273, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, 06591, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, 07985, Korea, Republic of|Albert Schweitzer Hospital, Doedrecht, Zuid-holland, 3318AT, Netherlands|Albert Schweitzer Ziekenhuis, Dordrecht, 3318 AT, Netherlands|St. Antonius Hospital, Utrecht, 3543 AZ, Netherlands|VieCuri Medsich Centrum, Venlo, 5912 BL, Netherlands|Uniwersyteckie Centrum Kliniczne, Gdansk, 80-214, Poland|Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi, Lodz, 93-513, Poland|SP ZOZ Opolskie Centrum Onkologii im. Prof. Tadeusza Koszarowskiego w Opolu, Opole, 45-061, Poland|Narodowy lnstytut Onkologii im. Marii Sklodowskiej-Curie-Panstwowy lnstytut Badawczy, Gliwice, ÅlÄskie, 44-102, Poland|Centro Clinico Academico Braga Hospital de Braga, Braga, 4710-243, Portugal|Hospital de Braga, Braga, 4710-243, Portugal|Instituto Portugues de Oncologia de Coimbra Francisco Gentil, EPE (IPO, Coimbra), Coimbra, 3000-075, Portugal|Fundacao Champalimaud, Lisboa, 1400-038, Portugal|Hospital CUF Descobertas, Lisboa, 1998-018, Portugal|Champalimaud Clinical Center, Lisbon, 1400-038, Portugal|The Champalimaud Centre for the Unknown, Lisbon, Portugal|Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, 03010, Spain|Hospital Universitario Son Espases, Palma de Mallorca, Islas Baleares, 07120, Spain|Hospital Universitario Virgen De La Arrixaca, EI Palmar, Murcia, 30120, Spain|Hospital Universitario de Canarias, La Laguna Tenerife, Santa CRUZ DE Tenerife, 38320, Spain|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, 08041, Spain|Hospital Universitario de Basurto, Bilbao, 48013, Spain|Hospital San Pedro de Alcantara, Caceres, 10003, Spain|Institut Catala d'Oncologia Girona - ICO Girona, Girona, 17007, Spain|Hospital Universitario Virgen de las Nieves, Granada, 18014, Spain|Hospital Universitari Arnau de Vilanova, Lleida, 25198, Spain|Hospital General Universitario Gregorio Maranon, Madrid, 28007, Spain|Hospital Universitario Ramon y Cajal, Madrid, 28034, Spain|Hospital Universitario Virgen de la Victoria, Malaga, 29010, Spain|Hospital Universitario de Salamanca (Spain Salamanca), Salamanca, 37007, Spain|Hospital Universitario Virgen del Rocio, Sevilla, 41013, Spain|Fundacion lnstituto Valenciano de Oncologia, Valencia, 46009, Spain|Hospital Clinico Universitario de Valencia, Valencia, 46010, Spain|Kantonsspital Winterthur, Winterthur, Zurich, 8401, Switzerland|Kantonsspital Baden., Baden, 5404, Switzerland|Brust-Zentrum AG, ZÃ¼rich, 8008, Switzerland|Changhua Christian Medical Foundation Changhua Christian Hospital, Changhua City, 500 (R.O.C.), Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, 807, Taiwan|Taipei Medical University-Shuang Ho Hospital, Ministry of Health and Welfare, New Taipei City, 23561 (R.O.C.), Taiwan|China Medical University Hospital, Taichung, 40447 (R.O.C.), Taiwan|Chi Mei Medical Center, Tainan City, 710, Taiwan|National Cheng Kung University Hospital, Tainan, 704, Taiwan|MacKay Medical Foundation The Presbyterian Church in Taiwan MacKay Memorial Hospital, Taipei City, 10449, Taiwan|National Taiwan University Hospital, Taipei, 100, Taiwan|Taipei Veterans General Hospital, Taipei, 11217, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center, Taipei, 112, Taiwan|Tri-Service General Hospital, Taipei, 11490, R.O.C., Taiwan|Chang Gung Memorial Hospital LinKou, Taoyuan City, 333, Taiwan|Academic Oncology, London, England, NW3 2QG, United Kingdom|The Royal Marsden, Sutton, Surrey, SM2 5PT, United Kingdom|Finchley Memorial Hospital, London, N12 0JE, United Kingdom|University College London Hospital (UCLH) NHS Foundation Trust, London, NW1 2PG, United Kingdom|University College London Hospitals NHS Foundation Trust, London, NW1 2PG, United Kingdom|The Royal Marsden NHS Foundation Trust (RM), London, SW3 6JJ, United Kingdom|The Royal Marsden, London, SW3 6JJ, United Kingdom|Christie Hospital NHS Foundation Trust, Manchester, M20 4BX, United Kingdom|The Christie NHS Foundation Trust, Manchester, M20 4BX, United Kingdom",
NCT06765109,Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC,https://clinicaltrials.gov/study/NCT06765109,ALKAZAR,RECRUITING,"Multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with treatment-naÃ¯ve, Anaplastic Lymphoma Kinase (ALK) positive, advanced Non-Small Cell Lung Cancer (NSCLC).",NO,Non-small Cell Lung Cancer|Anaplastic Lymphoma Kinase-positive,DRUG: Neladalkib (NVL-655)|DRUG: Alectinib,"Progression-free survival (PFS) per blinded independent central review (BICR), Time from randomization to BICR-assessed radiographic disease progression or death, Up to 5 years after first patient dosed","Overall survival (OS), Time from randomization to death, Up to 5 years after first patient dosed|Progression-free survival (PFS) per investigator assessment, Time from randomization to investigator-assessed radiographic disease progression or death, Up to 5 years after first patient dosed|Time to intracranial progression per BICR, Time from randomization to the first BICR-assessed occurrence of disease progression in the central nervous system (CNS), Up to 5 years after first patient dosed|Intracranial objective response rate (IC-ORR), Proportion of patients with a confirmed intracranial response (intracranial complete response \[IC-CR\] or intracranial partial response \[IC-PR\]) among patients with measurable CNS disease at baseline, Up to 5 years after first patient dosed|Intracranial duration of response (IC-DOR), Time from first intracranial response (IC-CR or IC-PR) to radiographic intracranial disease progression or death, Up to 5 years after first patient dosed|Objective response rate (ORR), Proportion of patients with a complete response or partial response, Up to 5 years after first patient dosed|Duration of response (DOR), Time from first response (complete or partial) to radiographic disease progression or death, Up to 5 years after first patient dosed|Intracranial progression per investigator assessment, Time to investigator-assessed intracranial progression, Up to 5 years after first patient dosed|Treatment-emergent adverse events (TEAEs) and changes in clinically relevant laboratory parameters, Incidence and severity of TEAEs and changes in clinically relevant laboratory parameters, Up to 5 years after first patient dosed|Patient-reported measures in health-related quality of life (QoL), Changes in patient-reported outcomes (PROs) assessed by the European Organization for Research and Treatment of Cancer QoL core questionnaire - Cancer (EORTC QLQ-C30), Up to 5 years after first patient dosed|Patient-reported measures in lung cancer symptoms and side effects of treatment, Changes in PROs assessed by the European Organization for Research and Treatment of Cancer QoL - Lung Cancer module (EORTC QLQ-LC29), Up to 5 years after first patient dosed|Patient-reported measures in patient functioning, Changes in PROs assessed by the European Quality of Life (EuroQol) 5-dimension questionnaire (EQ-5D-5L), Up to 5 years after first patient dosed",,Nuvalent Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE3,450,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2025-03,2029-12,2029-12,2025-01-09,,2025-03-12,"Washington University Center for Advanced Medicine, Saint Louis, Missouri, 63110, United States|Clinical Research Alliance Inc., New Hyde Park, New York, 11042, United States",
NCT05382299,Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer,https://clinicaltrials.gov/study/NCT05382299,ASCENT-03,RECRUITING,"The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumors do express PD-L1.",NO,Triple Negative Breast Cancer|PD-L1 Negative,DRUG: Sacituzumab Govitecan-hziy|DRUG: Paclitaxel|DRUG: nab-Paclitaxel|DRUG: Gemcitabine|DRUG: Carboplatin,"Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, PFS is defined as the time from the date of randomization until the date of objective progressive disease (PD), or death (whichever comes first)., Randomization up to approximately 57 months","Overall Survival (OS), OS is defined as the time from the date of randomization until death due to any cause., Randomization up to approximately 57 months|Objective Response Rate (ORR) as Assessed by BICR per RECIST Version 1.1, ORR is defined as the proportion of participants who achieve a complete response (CR) or partial response (PR) that is confirmed at least 4 weeks after initial documentation of response., Randomization up to approximately 57 months|Duration of Response (DOR) as Assessed by BICR per RECIST Version 1.1, DOR is defined as the time from the first documentation of CR or PR to the earlier of the first documentation of definitive PD or death from any cause (whichever comes first)., Randomization up to approximately 57 months|Time to Response (TTR) as Assessed by BICR per RECIST Version 1.1, TTR is defined as the time from the date of randomization until the first documentation of CR or PR., Randomization up to approximately 57 months|Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs), First dose date up to approximately 57 months plus 30 days|Percentage of Participants Experiencing Clinical Laboratory Abnormalities, First dose date up to approximately 57 months plus 30 days|Change from Baseline in the Physical Functioning Domain as Measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, Core Questionnaire, Version 3.0 (EORTC QLQ-C30)., The EORTC QLQ-C30 is a questionnaire to assess quality of life of cancer patients, it is composed of 30 questions (items) to assess 15 scales; 1 global health status/quality of life (QOL), 5 functional scales (physical, role, cognitive, emotional, and social), and 9 symptom/item scales(fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus, a high score for a functional scale represents a high/healthy level of function, a high score for the global health status/QOL represents a high QOL, but a high score for a symptom scale/item represents a high level of symptomatology/problems., Randomization up to approximately 57 months|Time to Deterioration (TTD) of Fatigue Scale of the EORTC QLQ-C30, TTD is defined as the time between the date of randomization and the date of assessment at which a patient experienced a deterioration (â¥ 10 points deterioration from baseline in the fatigue scale) or death., Randomization up to approximately 57 months",,Gilead Sciences,,ALL,"ADULT, OLDER_ADULT",PHASE3,540,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-07-20,2028-07,2028-07,2022-05-19,,2025-05-18,"Alaska Oncology and Hematology, Anchorage, Alaska, 99508, United States|Arizona Oncology Associates, PC-Hope,1845 W Orange Grove Rd, Tucson, Arizona, 85704, United States|Arizona Oncology Associates, PC-Hope,2070 W. Rudasill Rd., Tucson, Arizona, 85704, United States|Arizona Oncology Associates, PC-Hope, Tucson, Arizona, 85711, United States|Arizona Oncology Associates, PC-Hope,1620 West St. Mary's Road, Tucson, Arizona, 85745, United States|Genesis Cancer and Blood Institute,1455 Higdon Ferry Road Suite B., Hot Springs, Arkansas, 71913, United States|Genesis Cancer and Blood Institute, Hot Springs, Arkansas, 71913, United States|Saint Bernards Medical Center, Jonesboro, Arkansas, 72401, United States|Saint Bernards Medical Center,4000 Linwood Drive, Paragould, Arkansas, 72450, United States|University of California Los Angeles - Jonsson Comprehensive Cancer Center,201 S. Buena Vista Street, Suite 200, Burbank, California, 91505, United States|University of California San Diego Moores Cancer, La Jolla, California, 92093, United States|University of California Los Angeles - Jonsson Comprehensive Cancer Center,24302 Paseo de Valencia, Suite 200, Laguna Hills, California, 91505, United States|Cancer and Blood Specialty Clinic, Los Alamitos, California, 90720, United States|University of California Los Angeles - Jonsson Comprehensive Cancer Center,892 Aerovista Place, Suite 240, San Luis Obispo, California, 93401, United States|Sansum Clinic, Santa Barbara, California, 93105, United States|University of California Los Angeles - Jonsson Comprehensive Cancer Center,2020 Santa Monica Blvd, Suite 600, Santa Monica, California, 90404, United States|University of California Los Angeles - Jonsson Comprehensive Cancer Center,2336 Santa Monica, Suites 302 and 304, Santa Monica, California, 90404, United States|University of California Los Angeles - Jonsson Comprehensive Cancer Center, Santa Monica, California, 90404, United States|Sansum Clinic,2040 Viborg Road, Solvang, California, 93463, United States|Torrance Memorial Physician Network - Cancer Care, Torrance, California, 90505, United States|University of California Los Angeles - Jonsson Comprehensive Cancer Center,1250 La Venta Dr, Suite 100, Westlake Village, California, 91361, United States|Rocky Mountain Cancer Centers,1700 South Potomac Street, Aurora, Colorado, 80012, United States|Rocky Mountain Cancer Centers, Boulder, Colorado, 80303, United States|Rocky Mountain Cancer Centers,2312 N. Nevada Avenue, Colorado Springs, Colorado, 80907, United States|Rocky Mountain Cancer Centers,6031 E. Woodman Rd., Colorado Springs, Colorado, 80923, United States|Rocky Mountain Cancer Centers,4700 E. Hale Parkway, Denver, Colorado, 80220, United States|Rocky Mountain Cancer Centers,11750 West 2nd Place, Lakewood, Colorado, 80228, United States|Rocky Mountain Cancer Centers,22 West Dry Creek Circle, Littleton, Colorado, 80120, United States|Rocky Mountain Cancer Centers,10107 Ridge Gate Parkway, Lone Tree, Colorado, 80124, United States|Rocky Mountain Cancer Centers,2030 Mountain View Ave Ste 210, Longmont, Colorado, 80124, United States|Rocky Mountain Cancer Centers,3676 Parker Blvd, Pueblo, Colorado, 81008, United States|Rocky Mountain Cancer Centers,525 W. 15th Street, Pueblo, Colorado, 81008, United States|Rocky Mountain Cancer Centers,8820 Huron Street, Thornton, Colorado, 80260, United States|Eastern Connecticut Hematology and Oncology Associates, Norwich, Connecticut, 06360, United States|AdventHealth Medical Group, Altamonte Springs, Florida, 32701, United States|Florida Cancer Specialists - North Region Research Office,750 Orienta Ave, Altamonte Springs, Florida, 32701, United States|Florida Cancer Specialists,9776 Bonita Beach Road Southeast Suite 201 A, Bonita Springs, Florida, 34135, United States|Florida Cancer Specialists,3630 Manatee Avenue West, Bradenton, Florida, 34205, United States|Florida Cancer Specialists,5985 Silver Falls Run, Bradenton, Florida, 34211, United States|Florida Cancer Specialists - North Region Research Office,403 S. Kings Ave., Brandon, Florida, 33511, United States|Florida Cancer Specialists,1030 Commerce Creek Blvd, Cape Coral, Florida, 33909, United States|Florida Cancer Specialists - North Region Research Office,3280 McMullen Booth Road, Clearwater, Florida, 33761, United States|Florida Cancer Specialists - West Palm Beach,224 Memorial Medical Parkway, Suite 300, Daytona Beach, Florida, 32117, United States|Holy Cross Hospital, Inc, Fort Lauderdale, Florida, 33308, United States|Florida Cancer Specialists, Fort Myers, Florida, 33901, United States|Florida Cancer Specialists,8981 Colonial Center Drive, Fort Myers, Florida, 33905, United States|Florida Cancer Specialists,8260 Gladiolus Dr, Fort Myers, Florida, 33908, United States|Florida Cancer Specialists - North Region Research Office,6420 W. Newberry Road, Gainesville, Florida, 32605, United States|Florida Cancer Specialists - North Region Research Office,100 Highland Avenue, Largo, Florida, 33770, United States|Florida Cancer Specialists - North Region Research Office,521 North Lecanto Highway, Lecanto, Florida, 34461, United States|Florida Cancer Specialists,1100 Goodlette Road, Naples, Florida, 34102, United States|Florida Cancer Specialists,681 4th Avenue North, Naples, Florida, 34102, United States|Florida Cancer Specialists - North Region Research Office,4945 SW 49th Place, Ocala, Florida, 34474, United States|Florida Cancer Specialists - North Region Research Office,2824 Enterprise Rd, Orange City, Florida, 32763, United States|AdventHealth Medical Group,2501 North Orange Ave, Orlando, Florida, 32804, United States|Florida Cancer Specialists - North Region Research Office,70 W. Gore Street, Orlando, Florida, 32806, United States|Sacred Heart Heatlh System, Inc., d/b/a Ascension Sacred Heart, Pensacola, Florida, 32504, United States|Florida Cancer Specialists,22395 Edgewater Drive, Port Charlotte, Florida, 33980, United States|Florida Cancer Specialists - North Region Research Office,1201 Fifth Avenue North, Saint Petersburg, Florida, 33705, United States|Florida Cancer Specialists - North Region Research Office, Saint Petersburg, Florida, 33705, United States|Sacred Heart Heatlh System, Inc., d/b/a Ascension Sacred Heart,27 Mack Bayou Loop, Santa Rosa Beach, Florida, 32549, United States|Florida Cancer Specialists,600 North Cattlemen Road, Sarasota, Florida, 34232, United States|Florida Cancer Specialists,1970 Golf Street, Sarasota, Florida, 34236, United States|Florida Cancer Specialists - North Region Research Office,7154 Medical Center Drive, Spring Hill, Florida, 34608, United States|Florida Cancer Specialists - West Palm Beach,301 SE Ocean Blvd, Suite 102, Stuart, Florida, 34994, United States|Florida Cancer Specialists - North Region Research Office,3402 West Dr. Martin Luther King Jr. Boulevard, Tampa, Florida, 33607, United States|Florida Cancer Specialists - North Region Research Office,4100 Waterman Way, Tavares, Florida, 32778, United States|Florida Cancer Specialists - North Region Research Office,1400 US Highway 441 N, The Villages, Florida, 32159, United States|Florida Cancer Specialists - North Region Research Office,9320 State Road 54, Trinity, Florida, 34655, United States|Florida Cancer Specialists,901 South Tamiami Trail, Venice, Florida, 34285, United States|Florida Cancer Specialists,836 Sunset Lake Blvd, Venice, Florida, 34292, United States|Florida Cancer Specialists - West Palm Beach,3730 7th Terrace, Suite 101, Vero Beach, Florida, 32960, United States|Florida Cancer Specialists - West Palm Beach,1037 S. State Road 7, Bldg B, Suite 303, Wellington, Florida, 33414, United States|Florida Cancer Specialists - West Palm Beach, West Palm Beach, Florida, 33401, United States|Florida Cancer Specialists - North Region Research Office,460 N Orlando Ave, Winter Park, Florida, 32789, United States|Northside Hospital,125 King Avenue, Athens, Georgia, 30606, United States|Piedmont Cancer Institute - Atlanta,1267 Hwy 54W, Atlanta, Georgia, 30214, United States|Piedmont Cancer Institute - Atlanta, Atlanta, Georgia, 30318, United States|Northside Hospital,5670 Peachtree Dunwoody Rd., Atlanta, Georgia, 30342, United States|Northside Hospital, Atlanta, Georgia, 30342, United States|Northside Hospital,308 Deep South Farm Rd, Suite 200, Blairsville, Georgia, 30512, United States|Northside Hospital,228 Riverstone Dr., Canton, Georgia, 30114, United States|Northwest Georgia Oncology Northwest Georgia Oncology Centers, PCCenters, PC,157 Clinic Avenue, Carrollton, Georgia, 30117, United States|Northwest Georgia Oncology Northwest Georgia Oncology Centers, PCCenters, PC,100 Market Place Blvd, Cartersville, Georgia, 30121, United States|Northside Hospital,1505 Northside Blvd, Suite 4600, Cumming, Georgia, 30041, United States|Northside Hospital,3855 Pleasant Hill Rd., Suite 480, Duluth, Georgia, 30096, United States|Northside Hospital,308 Coliseum Dr., Macon, Georgia, 31217, United States|Northwest Georgia Oncology Northwest Georgia Oncology Centers, PCCenters, PC, Marietta, Georgia, 30060, United States|Piedmont Cancer Institute - Atlanta,775 Poplar Road, Newnan, Georgia, 30265, United States|Piedmont Cancer Institute - Atlanta,1240 Eagles Landing Pkwy, Stockbridge, Georgia, 30281, United States|Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, 60611, United States|Rush University Medical Center, Chicago, Illinois, 60612, United States|University of Illinois Hospital and Health Sciences System (Outpatient Cancer Center), Chicago, Illinois, 60612, United States|Orchard Healthcare Research Inc,2845 North Sheridan Road, 1st Floor, Chicago, Illinois, 60657, United States|Robert H. Lurie Comprehensive Cancer Center of Northwestern University,1 Kish Hospital Drive, DeKalb, Illinois, 60115, United States|Robert H. Lurie Comprehensive Cancer Center of Northwestern University,10 Health Services Drive, DeKalb, Illinois, 60115, United States|Orchard Healthcare Research Inc,800 Austin Street, Suite 360, East Tower, Evanston, Illinois, 60202, United States|Robert H. Lurie Comprehensive Cancer Center of Northwestern University,300 Randall Road, Geneva, Illinois, 60134, United States|Robert H. Lurie Comprehensive Cancer Center of Northwestern University,304 Randall Road, Geneva, Illinois, 60134, United States|Robert H. Lurie Comprehensive Cancer Center of Northwestern University,1000 N. Westmoreland Road, Lake Forest, Illinois, 60045, United States|Rush University Medical Center,520 South Maple Ave, Oak Park, Illinois, 60304, United States|Orchard Healthcare Research Inc, Skokie, Illinois, 60077, United States|Robert H. Lurie Comprehensive Cancer Center of Northwestern University,4405 Weaver Parkway, Warrenville, Illinois, 25731, United States|Robert H. Lurie Comprehensive Cancer Center of Northwestern University,4455 Weaver Parkway, Warrenville, Illinois, 60555, United States|Robert H. Lurie Comprehensive Cancer Center of Northwestern University,25 N Winfield Road, Winfield, Illinois, 60190, United States|Fort Wayne Medical Oncology and Hematology - Fort, Fort Wayne, Indiana, 46845, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, 52242, United States|The University of Kansas Cancer Center,2000 Olathe Blvd, Kansas City, Kansas, 66160, United States|The University of Kansas Cancer Center,12200 W. 110th Street, Overland Park, Kansas, 66210, United States|The University of Kansas Cancer Center,10710 Nall Avenue, Overland Park, Kansas, 66211, United States|The University of Kansas Cancer Center,10730 Nall Avenue, Overland Park, Kansas, 66211, United States|The University of Kansas Cancer Center, Westwood, Kansas, 66205, United States|Norton Cancer Institute - Saint Matthews,234 E. Gray Strret, Louisville, Kentucky, 40202, United States|Norton Cancer Institute - Saint Matthews,676 S. Floyd Street, Louisville, Kentucky, 40202, United States|Norton Cancer Institute - Saint Matthews, Louisville, Kentucky, 40207, United States|Norton Cancer Institute - Saint Matthews,4955 Norton Healthcare Blvd, Louisville, Kentucky, 40241, United States|Hematology Oncology Clinic - Baton Rouge, Baton Rouge, Louisiana, 70809, United States|Hematology Oncology Clinic - Baton Rouge,1673 E Mount Please Drive, Zachary, Louisiana, 70791, United States|Mercy Medical Center, Baltimore, Maryland, 21202, United States|Cancer Institute Ascension Saint Agnes, Baltimore, Maryland, 21229, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Massachusetts General Hospital, Boston, Massachusetts, 02215, United States|Massachusetts General Hospital,102 Endicott Street, Danvers, Massachusetts, 01923, United States|Massachusetts General Hospital,2014 Washington St, Newton, Massachusetts, 02462, United States|University of Michigan, Ann Arbor, Michigan, 48109, United States|Ascension St. John Hospital, Grosse Pointe Woods, Michigan, 48236, United States|Ascension Providence Hospital, Southfield, Michigan, 48075, United States|The West Clinic, PLLC dba West Cancer Center,7668 Airways Blvd, Southaven, Mississippi, 38671, United States|The University of Kansas Cancer Center,2750 Clay Edwards Drive, Kansas City, Missouri, 64116, United States|The University of Kansas Cancer Center,8700 North Green Hills Road, Kansas City, Missouri, 64154, United States|The University of Kansas Cancer Center,4881 N.E. Goodview Circle, Lee's Summit, Missouri, 64064, United States|Nebraska Cancer Specialists,2730 W. Faidley Ave, Grand Island, Nebraska, 68803, United States|Nebraska Cancer Specialists,8303 Dodge Street, Omaha, Nebraska, 68114, United States|Nebraska Cancer Specialists, Omaha, Nebraska, 68130, United States|Nebraska Cancer Specialists,611 Fenwick Dr, Papillion, Nebraska, 68046, United States|Summit Medical Group Eastside Clinic,1 Diamond Hill Road, Berkeley Heights, New Jersey, 07922, United States|Summit Medical Group Eastside Clinic, Florham Park, New Jersey, 07932, United States|Rutgers Cancer Institute of New Jersey,414 Grand Street, Jersey City, New Jersey, 07302, United States|Rutgers Cancer Institute of New Jersey,600 River Avenue, Lakewood, New Jersey, 08701, United States|Rutgers Cancer Institute of New Jersey,94 Old Short Hills Road, Livingston, New Jersey, 07039, United States|Rutgers Cancer Institute of New Jersey,300 Second Ave, Long Branch, New Jersey, 07740, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, 08901, United States|Rutgers Cancer Institute of New Jersey,150 Bergen St., Newark, New Jersey, 07103, United States|Rutgers Cancer Institute of New Jersey,201 Lyons Avenue, Newark, New Jersey, 07112, United States|Capital Health Medical Center - Hopewell, Pennington, New Jersey, 08534, United States|Rutgers Cancer Institute of New Jersey,110 Rehill Ave, Somerville, New Jersey, 08876, United States|Rutgers Cancer Institute of New Jersey,99 Highway 37 West, Toms River, New Jersey, 08755, United States|Rutgers Cancer Institute of New Jersey,100 State Route 36, West Long Branch, New Jersey, 07764, United States|New York Cancer & Blood Specialists - Port Jeffers,72 East Main St., Babylon, New York, 11702, United States|New York Cancer & Blood Specialists - Port Jeffers,12 East 86th St, Suite 4, Bronx, New York, 10028, United States|Montefiore Medical Center - Montefiore Medical Park, Bronx, New York, 10467, United States|New York Cancer & Blood Specialists - Port Jeffers,2330 Eastchester Road, Suite 360, Bronx, New York, 10469, United States|Hematology Oncology Associates of Central New York, East Syracuse, New York, 13057, United States|Queens Hospital Center, Jamaica, New York, 11042, United States|New York Cancer & Blood Specialists - Port Jeffers,1 Delaware Dr., New Hyde Park, New York, 11042, United States|NYP/Columbia Univeresity Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, 10032, United States|New York Cancer & Blood Specialists - Port Jeffers,365 East Main St., Patchogue, New York, 11772, United States|New York Cancer & Blood Specialists - Port Jeffers,49 Rte. 347, Newconset Hwy, Port Jefferson Station, New York, 11776, United States|New York Cancer & Blood Specialists - Port Jeffers, Port Jefferson Station, New York, 11776, United States|New York Cancer & Blood Specialists - Port Jeffers,1500 Rte, 112, Building 4, Port Jefferson, New York, 11776, United States|New York Cancer & Blood Specialists - Port Jeffers,750 Old County Rd. Suite 4, Riverhead, New York, 11901, United States|Novant Health Cancer Institute - Forsyth,125 Queens Road, Suite 650, Charlotte, North Carolina, 28204, United States|Novant Health Cancer Institute - Forsyth,2131 S. 17th Street, Wilmington, North Carolina, 28401, United States|Novant Health Cancer Institute - Forsyth, Winston-Salem, North Carolina, 27103, United States|Zangmeister Cancer Center, Columbus, Ohio, 43219, United States|Northwest Cancer Specialists, P.C,5050 NE Hoyt St., Portland, Oregon, 97213, United States|Northwest Cancer Specialists, P.C,265 N. Broadway, Portland, Oregon, 97227, United States|Northwest Cancer Specialists, P.C, Tigard, Oregon, 97223, United States|Magee-Womens Hospital of UPMC,2500 West 12th Street, Erie, Pennsylvania, 16505, United States|Magee-Womens Hospital of UPMC,201 State Street, 6 Main, Erie, Pennsylvania, 16550, United States|Magee-Womens Hospital of UPMC,4300 Londonberry Road, Harrisburg, Pennsylvania, 17109, United States|Magee-Womens Hospital of UPMC,2035 Technology Parkway, Mechanicsburg, Pennsylvania, 17050, United States|University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, 19104, United States|Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, 15213, United States|Magee-Womens Hospital of UPMC,5115 Centre Avenue, Pittsburgh, Pennsylvania, 15232, United States|Magee-Womens Hospital of UPMC,1703 Innovation Drive, York, Pennsylvania, 17408, United States|Tennessee Oncology, PLLC,103 Natchez Park Drive, Dickson, Tennessee, 37055, United States|Tennessee Oncology, PLLC,4488 Carothers Parkway, Franklin, Tennessee, 37067, United States|Tennessee Oncology, PLLC,225 Big Station Camp Blvd, Gallatin, Tennessee, 37066, United States|The West Clinic, PLLC dba West Cancer Center, Germantown, Tennessee, 38138, United States|Tennessee Oncology, PLLC,353 New Shackle Island Road, Hendersonville, Tennessee, 37075, United States|Tennessee Oncology, PLLC,5653 First Blvd., Hermitage, Tennessee, 37076, United States|Tennessee Oncology, PLLC,103 Physicians Way, Lebanon, Tennessee, 37090, United States|Tennessee Oncology, PLLC,1840 Medical Center Parkway, Murfreesboro, Tennessee, 37129, United States|Tennessee Oncology, PLLC,2004 Hayes Street, Nashville, Tennessee, 37203, United States|Tennessee Oncology, PLLC,SCRI Oncology Partners, Nashville, Tennessee, 37203, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, 37203, United States|Tennessee Oncology, PLLC,4220 Harding Rd, Nashville, Tennessee, 37205, United States|Tennessee Oncology, PLLC,3443 Dickerson Road, Nashville, Tennessee, 37207, United States|Tennessee Oncology, PLLC,397 Wallace Road, Nashville, Tennessee, 37211, United States|Tennessee Oncology, PLLC,120 Frank Martin Road, Shelbyville, Tennessee, 37160, United States|Tennessee Oncology, PLLC,300 Stonecrest Blvd, Smyrna, Tennessee, 37167, United States|The Center for Cancer & Blood Disorders - Magnolia,515 W. Mayfield Rd., Arlington, Texas, 76104, United States|Texas Oncology PA,901 West 38th Street, Austin, Texas, 78705, United States|Texas Oncology PA, Austin, Texas, 78731, United States|Texas Oncology PA,4101 James Casey, Suite 100, Austin, Texas, 78745, United States|The Center for Cancer & Blood Disorders - Magnolia,11805 South Freeway, Burleson, Texas, 76028, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, 75246, United States|Texas Oncology-Denison, Denison, Texas, 75020, United States|The Center for Cancer & Blood Disorders - Magnolia, Fort Worth, Texas, 76104, United States|Oncology Consultants,1631 North Loop West, Houston, Texas, 77008, United States|Oncology Consultants,925 Gessner, Houston, Texas, 77024, United States|Oncology Consultants, Houston, Texas, 77030, United States|Mays Cancer Center, San Antonio, Texas, 78229, United States|The Center for Cancer & Blood Disorders - Magnolia,920 Santa Fe Drive, Weatherford, Texas, 76086, United States|Virginia Oncology Associates,744 N. Battlefield Blvd, Chesapeake, Virginia, 23320, United States|Virginia Cancer Specialists, PC,7501 Right Flank Road, Mechanicsville, Virginia, 23116, United States|Virginia Oncology Associates,1051 Loftis Blvd Suite 100, Newport News, Virginia, 23606, United States|Virginia Oncology Associates, Norfolk, Virginia, 23502, United States|Virginia Cancer Specialists, PC,210 Medical Park Boulevard, Petersburg, Virginia, 23805, United States|Virginia Cancer Specialists, PC,1401 Johnston-Willis Drive, Richmond, Virginia, 23235, United States|Virginia Cancer Specialists, PC, Richmond, Virginia, 23298, United States|Virginia Oncology Associates,1950 Glenn Mitchell Drive, Virginia Beach, Virginia, 23456, United States|Swedish Cancer Institute-First Hill,21632 Highway 99, Edmonds, Washington, 98026, United States|Swedish Cancer Institute-First Hill,751 NE Blakely Drive, Issaquah, Washington, 98029, United States|Swedish Cancer Institute-First Hill, Seattle, Washington, 98104, United States|Swedish Cancer Institute-First Hill,747 Broadway, Seattle, Washington, 98122, United States|Northwest Cancer Specialists, P.C,210 SE 136th Avenue, Vancouver, Washington, 98684, United States|Hospital BritÃ¡nico de Buenos Aires, Buenos Aires, 1426, Argentina|Instituto de Oncologia Angel H.Roffo, Caba, 1417, Argentina|Fundacion CORI para la Investigacion y Prevencion del Cancer, Capital, F5300COE, Argentina|Instituto de OncologÃ­a de Rosario, Rosario, 2000, Argentina|Centro para la Atencion Integral del Paciente Oncologico Centro MÃ©dico C.A.I.P.O, San Miguel de TucumÃ¡n, 4000, Argentina|Clinica Viedma, Viedma, 8500, Argentina|Border Medical Oncology, Albury, New South Wales, 2640, Australia|Saint George Hospital - Australia, Kogarah, New South Wales, 2217, Australia|Mater Hospital - North Sydney, North Sydney, New South Wales, 2060, Australia|GenesisCare - North Shore, St Leonards, New South Wales, 2065, Australia|Mater Misericordiae Limited and Mater Research Limited, South Brisbane, Queensland, 4101, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, 4102, Australia|Cancer Research SA (CRSA), Adelaide, South Australia, 5000, Australia|Icon Cancer Centre Hobart, Hobart, Tasmania, 7000, Australia|Monash Medical Centre, Clayton, Victoria, 3168, Australia|Austin Hospital, Melbourne, Victoria, 3084, Australia|Breast Cancer Research Center - Western Australia, Nedlands, Western Australia, 6009, Australia|UniversitÃ¤tsklinikum Graz, Graz, 8036, Austria|Medizinische UniversitÃ¤t Innsbruck, Innsbruck, 06020, Austria|Ordensklinikum Linz GmbH Barmherzige Schwestern, Linz, 4010, Austria|Landeskrankenhaus Salzburg, Salzburg, A-5020, Austria|UniversitÃ¤tsklinikum Sankt PÃ¶lten, Sankt Poelten, 3100, Austria|Landesklinikum Wiener Neustadt, Wiener Neustadt, 2700, Austria|Medizinische UniversitÃ¤t Wien, Wien, 1090, Austria|Algemeen Ziekenhuis Klina, Brasschaat, 2930, Belgium|Cliniques Universitaires Saint-Luc, Brussels, 1200, Belgium|Universitair Ziekenhuis Brussel, Brussels, Belgium|Grand Hopital de Charleroi - Notre Dame, Charleroi, 6000, Belgium|Universitair Ziekenhuis Gent, Gent, 9000, Belgium|UZ Leuven, Leuven, 3000, Belgium|Centre Hospitalier Universitaire UniversitÃ© Cathol, Namur, 5000, Belgium|Hospital AraÃºjo Jorge - AssociaÃ§Ã£o de Combate ao CÃ¢ncer em GoiÃ¡s - ACCG, GoiÃ¢nia, 74605-070, Brazil|ONCOSITE - Centro de Pesquisa Clinica em Oncologia, Ijui, 98700-000, Brazil|Catarina Pesquisa ClÃ­nica, Itajai, 88301-220, Brazil|Hospital Moinhos de Vento, Porto Alegre, 90035-00, Brazil|Hospital de Clinicas de Porto Alegre - HCPA, Porto Alegre, 90035-903, Brazil|Hospital Sao Lucas da PUCRS, Porto Alegre, 90610001, Brazil|Instituto Nacional de CÃ¢ncer - INCA - HCIII, Rio de Janeiro, Brazil|NÃºcleo de Oncologia da Bahia, Salvador, 40170170, Brazil|CEPHO - Centro de Estudos e PesquisaS de Hematologia e Oncologia, Santo Andre, 09060-650, Brazil|Hospital Amaral Carvalho, Sao Paolo, 17210080, Brazil|Real e Portuguesa de BeneficÃ©ncia - Hospital BeneficÃ©ncia Portuguesa (BP) - Unidade Paulista, SÃ£o Paulo, 01323-001, Brazil|Clinica de Pesquisas e Centro de Estudos em Oncolo, SÃ£o Paulo, 1317000, Brazil|FundaÃ§Ã£o Pio XII - Hospital de Amor de Barretos, SÃ£o Paulo, 14784400, Brazil|Nucleo de Pesquisa Clinica da Rede Sao Camilo, SÃ£o Paulo, 4014002, Brazil|Cross Cancer Institute, Edmonton, T6G 1Z2, Canada|QEII Health Sciences Centre, Halifax, B3H 1V7, Canada|Grand River Regional Cancer Centre at Grand River Hospital, Kitchener, N2G 1G3, Canada|London Health Sciences Centre, London, N6A 5W9, Canada|McGill University Health Centre, Montreal, H4A 3J1, Canada|Jewish General Hospital Department of Medical Oncology, MontrÃ©al, H3T 1E2, Canada|Ottawa Hospital - General Campus, Ottawa, K1H 8L6, Canada|CISSS du Bas-Saint-Laurent - HÃ´pital rÃ©gional de Rimouski, Rimouski, G5L 5T1, Canada|Sunnybrook Research Institute, Toronto, M4N 3M5, Canada|Mount Sinai Hospital, Toronto, M5G 1X5, Canada|British Columbia Cancer - Vancouver, Vancouver, V5Z 4E6, Canada|Oncovida - Santiago, Providencia, 7510035, Chile|ClÃ­nica IRAM, Santiago DE CHILE, Chile|Centro de OncologÃ­a de PrecisiÃ³n, Santiago Region, 8330032, Chile|ClÃ­nica Alemana, Santiago, 7630000, Chile|James Lind Centro de Investigacion del Cancer, Temuco, Chile|Cancer Hospital Chinese Academy of Medical Sciences, Beijing, 100021, China|Peking University People's Hospital, Beijing, 100044, China|Beijing Cancer Hospital, Beijing, 100142, China|The First Medical Center of Chinese PLA General Hospital, Beijing, 100853, China|The Second Xiangya Hospital of Central South University, Changsha, 410011, China|Sichuan Cancer Hospital, Chengdu, 610041, China|West China Hospital, Sichuan University, Chengdu, 610041, China|The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China|Chongqing University Cancer Hospital, Chongqing, 404100, China|Deyang People's Hospital, Deyang, 618000, China|Sun Yat-Sen University Cancer Center, Guangzhou, 510000, China|Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 31006, China|Harbin Medical University Cancer Hospital, Harbin, 150081, China|Anhui Provincial Cancer Hospital, Hefei, 230031, China|The Second Hospital of Anhui Medical University, Hefei, 230601, China|The Second Hospital of Jilin University, Jilin Sheng, 130041, China|The Second Hospital of Shandong University, Jinan, 250033, China|Shandong Cancer Hospital, Jinan, 250117, China|Nanchang People's hospital, Nanchang, 330200, China|The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, China|Tianjin Medical University Cancer Institute& Hospital, Tianjin, 453000, China|Weihai Municipal Hospital, Weihai, 264299, China|Hubei Cancer Hospital, Wuhan, 430000, China|Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China|Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang, 310009, China|The First Affiliated Hospital of Wenzhou Medical University, Zhejiang, 325000, China|Masarykuv onkologicky ustav, klinika komplexni onkologickie pece, Brno, 65653, Czechia|FakultnÃ­ Thomayerova nemocnice, Hradec Kralove, 50005, Czechia|Fakultni nemocnice Hradec Kravlove, Klinika onkologie a radioterapie, Hradec KrÃ¡lovÃ©, 500 05, Czechia|Fakultni nemocnice Olomouc, Onkologicka klinika, Olomouc, 77520, Czechia|Vseobecna Fakultni Nemocnice v Praze, Prague, 12808, Czechia|Fakultni nemocnice Karlovske Vinohrady, Radioterapeuticka a onkologicka klinika, Praha, 100 34, Czechia|Sainte Catherine Institut du Cancer Avignon Provence, Avignon, 84918, France|Centre Hospitalier RÃ©gional et Universitaire de Be, Besancon, 25030, France|HÃ´pital Morvan, Institut de cancÃ©rologie, Brest, 29200, France|Centre francois Baclesse, Caen, 14000, France|Centre Jean Perrin, Clermont Ferrand, 63011, France|Centre de CancÃ©rologie du Grand Montpellier, Montpellier, 34070, France|HÃ´pital PrivÃ© du Confluent, Nantes, 44202, France|Hospices Civils de Lyon HÃ´pital Lyon Sud, Pierre-benite, 69310, France|Centre Armoricain de RadiothÃ©rapie, dImagerie MÃ©d, Plerin, 22190, France|Centre EugÃ¨ne Marquis, Rennes Cedex, 35042, France|Institut Claudius Regaud - IUCT-O, Toulouse, France|Institut Gustave Roussy, Villejuif, 94800, France|Helios Klinikum Berlin-Buch, Berlin, 13125, Germany|Gynakologisches Zentrum Bonn, Schwerpunkt Gyn. Onkologie,, Bonn, 53111, Germany|UniversitÃ¤tsklinikum Erlangen, Frauen klinik, Erlangen, 91054, Germany|Kliniken Essen-Mitte - Evangelische Huyssens-Stift Breast Unit, Essen, 45136, Germany|Praxis fÃ¼r interdisziplinÃ¤re Onkologie & HÃ¤matolog, Freiburg, 79110, Germany|Universitatsklinikum Hamburg-Eppendorf, Hamburg, 20246, Germany|Facharztzentrum Eppendorf, Hamburg, 20249, Germany|Nationales Centrum fÃ¼r Tumorerkrankungen - Heidelb, Heidelberg, 69120, Germany|Klinik Frauenheilkunde, Uniklinik ClO, Studienzentrale, KÃ¶ln, 50937, Germany|UniversitÃ¤tsklinikum Schleswig-Holstein Institut fur Klinische Chermie, LÃ¼beck, 23538, Germany|Universitatsklinikum Mannheim GmBH, Frauenklinik, Mannheim, 68167, Germany|UniversitÃ¤tsklinikum MÃ¼nster, Bereich Senologie an der klinik fur Frauenheilkunde und Gerburtschilfe, Munster, 48149, Germany|Evangelisches Krankenhaus Bethesda MÃ¶nchengladbach, MÃ¶nchengladbach, 41061, Germany|Rotkreuzklinikum Munchen, MÃ¼nchen, 80637, Germany|Klinik und Poliklinik fÃ¼r Frauenheilkunde, MÃ¼nchen, 81675, Germany|UniversitÃ¤tsklinikum TÃ¼bingen, TÃ¼bingen, 72076, Germany|St. Josefs-Hospital Wiesbaden GmbH , GynÃ¤kologie und Geburtshilfe, Wiesbaden, 65189, Germany|Hong Kong Integrated Oncology Centre, Hong Kong, 0, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|Tuen Mun Hospital, Hong Kong, Hong Kong|Prince of Wales Hospital - Hong Kong, New Territories, 999077, Hong Kong|Queen Mary Hospital, Pok Fu Lam, 0, Hong Kong|Uzsoki Utcai Kornaz, Onkoradiologiai Osztaly, Budapest, 1145, Hungary|Debreceni Egyetem Klinikai KÃ¶zpont, Debrecen, 4032, Hungary|Petz Aladar Egyetemi OktatÃ© KÃ©rhaz - Osztaly, Gyor, 9024, Hungary|Soroka Medical Center, Beer-Sheva, 8410101, Israel|Rambam Health Care Campus, Haifa, 3109601, Israel|Shaare Zedek Medical Center, Jerusalem, 9103102, Israel|Hadassah - Hebrew University Medical Center, Jerusalem, Israel|Meir Medical Center, Kfar Saba, 4428164, Israel|Rabin Medical Center, Petah Tikva, 4941492, Israel|Kaplan Medical Center, Rehovot, 7661041, Israel|Sheba Medical Center Hospital - Tel Hashomer, Tel Aviv, 52621, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, 64239, Israel|IRCCS Istituto Tumori ""G.Paolo II"", Bari, 70124, Italy|SSD Oncologia Medica Addarii-Zamagni, IRCSS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola, Bologna, Italy|UO Oncologia, ASST degli Spedali Civili di Brescia, Brescia, 25123, Italy|IRCSS Ospedale Policlinico San Martino, Genova GE, 16132, Italy|S.C. Oncologia medica, ASST di Lecco, Lecco, 23900, Italy|Presidio Ospedaliero di Lucca, Lucca, 55100, Italy|Ospedale Generale Provinciale - Macerata, Macerata, 62100, Italy|Fondazione IRCCS - Istituto Nazionale dei Tumori, Milano, 20133, Italy|Istituto Europeo di Oncologia, Milan, 20141, Italy|Azienda Socio Sanitaria Territoriale, Monza, 20090, Italy|Oncologia Medica Senologica Sperimentale - Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, 80131, Italy|Azienda Ospedaliero-Universitaria Maggiore della C, Novara, 28100, Italy|Istituto Oncologico Veneto - IRCCS, Padova, 35128, Italy|S.O.C Patologia Clinica (Laboratorio Analisi), Nuovo Ospedale di Prato - Santo Stefano, Prato, 59100, Italy|AOU Policlinico Umberto I, Roma, 00161, Italy|Fondazione Policlinico Universitario Agostino Geme, Rome, 00168, Italy|Azienda Ospedaliera Universitaria Senese - Losped, Siena, 53100, Italy|Aichi Cancer Center Hospital, Aichi, 464-8681, Japan|Tohoku University Hospital, Aoba-ku, 980-8574, Japan|Juntendo University Hospital, Bunkyo-ku, 113-8431, Japan|Chiba Cancer Center, Chuo-ku, 260-8717, Japan|Osaka Prefectural Hospital Organization - Osaka In, Chuo-ku, 541-8567, Japan|Shikoku Cancer Center, Ehime, 791-0280, Japan|Fukushima Medical University Hospital, Fukushima, Japan|Saitama Cancer Center, Inamachi, 362-0806, Japan|Hakuaikai Sagara Hospital, Kagoshima-shi, 892-0833, Japan|Tokai University Hospital, Kanagawa, 259-1193, Japan|National Cancer Center Hospital East, Kashiwa, 277-8577, Japan|Cancer Institute Hospital of JFCR, Koto-ku, 135-8550, Japan|Kumamoto University Hospital, Kumamoto- shi, 860-8556, Japan|Kure Medical Center And Chugoku Cancer Center, Kure, 737-0023, Japan|Mie University Hospital, Mie, 514-8507, Japan|National Hospital Organization Kyushu Cancer Center, Minami-ku, 811-1395, Japan|Nagoya University Hospital, Nagoya, 466-8560, Japan|Nagoya City University Hospital, Nagoya, 467-8602, Japan|Hiroshima City Hiroshima Citizens Hospital, Naka-ku, 730-8518, Japan|Niigata Cancer Center Hospital, Niigata-shi, 951-8566, Japan|Okayama University Hospital, Okayama, 700-8558, Japan|Gunma Prefectural Cancer Center, Ota, 373-8550, Japan|Kyoto University Hospital, Sakyo-ku, 606-8507, Japan|Hokkaido Cancer Center, Sapporo, 003-0804, Japan|Shizuoka General Hospital, Shizuoka-city, 420-8527, Japan|Shizuoka Cancer Center, Shizuoka, 411-8777, Japan|Osaka University Hospital, Suita, 565-0871, Japan|Showa University Hospital, Tokyo, 142-8555, Japan|Kanagawa Cancer Center, Yokohama, 241-8515, Japan|National Cancer Center, Goyang-si Gyeonggi-do, 10408, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, 13620, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, 03722, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, 06591, Korea, Republic of|Korea University Anam Hospital, Seoul, 2841, Korea, Republic of|Seoul National University Hospital, Seoul, 3080, Korea, Republic of|Hospital Pulau Pinang, Georgetown, 10450, Malaysia|Hospital Sultan Ismail, Johor Bahru, 81100, Malaysia|Hospital Kuala Lumpur, Kuala Lumpur, 47500, Malaysia|Pantai Hospital Kuala Lumpur, Kuala Lumpur, 59100, Malaysia|University Malaya Medical Centre (UMMC), Kuala Lumpur, 59100, Malaysia|Institut Kanser Negara, Putrajaya, 62250, Malaysia|Hospital Wanita dan Kanak-Kanak Sabah, Sabah, 88996, Malaysia|Sarawak General Hospital, Sarawak, 93586, Malaysia|Icaro Investigaciones en Medicina, Chihuahua, 31000, Mexico|Cryptex InvestigaciÃ³n ClÃ­nica, Ciudad de Mexico, 06100, Mexico|Sinacor - Centro para el Desarrollo de la Medicina, Culiacan, 80230, Mexico|Panamerican Clinical Research Mexico - Guadalajara, Guadalajara, 44670, Mexico|Medical Care and Research S.A. de C.V., Merida, 97070, Mexico|Avix Investigacion Clinica S.C., Monterrey, 64710, Mexico|Fucam A.C., MÃ©xico, 4980, Mexico|OncolÃ³gico Potosino, San Luis Potosi, 78209, Mexico|FAICIC ClÃ­nical Research, Veracruz, 91900, Mexico|iBiomed - Investigacion Biomedica para el Desarrol, Zapopan, 45070, Mexico|Amphia Ziekenhuis - Breda Langendijk, Breda, 4818 CK, Netherlands|Universitair Medisch Centrum Groningen, Groningen, 9700 RB, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, 8934 AD, Netherlands|Maastricht Universitair Medisch Centrum, Maastricht, 6229HX, Netherlands|Erasmus Medisch Centrum, Rotterdam, Netherlands|Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii, Gdansk, 80-952, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej, Gliwice, 44-102, Poland|SP ZOZ Opolskie Centrum Onkologii im. prof. Tadeusza Koszarowskiego, Opole, 45-061, Poland|Wielkopolskie Centrum Onkologii im. Marii Sklodowskiej-Curie, Poznan, 61- 866, Poland|Mazowiecki Szpital WojewÃ³dzki im. w. Jana Pawa II, Siedlce, 08-110, Poland|Wojskowy Instytut Medyczny, Warsaw, 04-141, Poland|Narodowy Instytut Onkologii im.Marii Marii Sklodowskiej, Warszawa, 02-781, Poland|Ponce Medical School Foundation Inc., Ponce, 00732, Puerto Rico|Clinical Research Puerto Rico, San Juan, 00909-1711, Puerto Rico|Spitalul Clinic Filantropia, Bucharest, 11171, Romania|SC Medisprof SRL, Cluj-Napoca, 400058, Romania|Institutal Oncologic, Prof. Dr Ion Chiricuta, Cluj-Napoca, 400150, Romania|Centrul De Oncologie Sf Nectarie, Craiova, 200642, Romania|S.C. Oncomed S.R.L, Timisoara, 300239, Romania|National University Hospital, Singapore, 119074, Singapore|Raffles Hospital, Singapore, 188770, Singapore|Curie Oncology, Singapore, 329563, Singapore|Onkologicky Ustav Sv. Alzbety, Bratislava, 81250, Slovakia|NÃ¡rodnÃ½ onkologickÃ½ Ãºstav, Bratislava, 83310, Slovakia|Vychodoslovensky onkologicky ustav, a.s., Oddelenie klinickej onkologie, KoÅ¡ice, 041 90, Slovakia|Nemocnica PartizÃ¡nske, PartizÃ¡nske, 95801, Slovakia|Hopelands Cancer Centre, Hilton, 3245, South Africa|Wits Clinical Research, Johannesburg, 2192, South Africa|The Medical Oncology Centre of Rosebank, Johannesburg, 2196, South Africa|University of Pretoria, Pretoria, 0002, South Africa|Hospital Teresa Herrera - Materno Infantil, A CoruÃ±a, 15006, Spain|Hospital Universitari Dexeus, Barcelona, 08028, Spain|CEIm Hospital General Universitario Gregorio Maranon, Barcelona, 08036, Spain|Hospital Clinic Barcelona, Barcelona, 08036, Spain|Hospital Universitari Vall d'HebrÃ³n, Barcelona, 8035, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, 8041, Spain|Hospital Universitario de Basurto, Bilbo, 48013, Spain|Hospital Universitari Arnau de Vilanova, Lleida, 25198, Spain|Hospital General Universitario Gregorio Maranon, Madrid, 28007, Spain|MD Anderson Cancer Center Madrid, Madrid, 28033, Spain|Hospital Universitario FundaciÃ³n JimÃ©nez DÃ­az, Madrid, 28040, Spain|Hospital Universitario Virgen de la Victoria, Malaga, 29010, Spain|Hospital General Universitario Morales Meseguer, Murcia, 30008, Spain|Hospital Unviersitario Virgen del Rocio, Sevilla, 41013, Spain|Hospital Universitario Virgen Macarena, Sevilla, 41071, Spain|Hospital Universitario de Canarias, Tenerife, 38320, Spain|Hospital ClÃ­nico Universitario de Valencia, Valencia, 46010, Spain|Kantonsspital Baden, Baden, 5404, Switzerland|Kantonsspital Baselland - Standort Liestal, Liestal, 4410, Switzerland|Kantonsspital St.Gallen, St. Gallen, 9007, Switzerland|Kantonsspital Winterthur, Winterthur, 8401, Switzerland|Brust-Zentrum AG, ZÃ¼rich, 8008, Switzerland|Changhua Christian Hospital, Changhua, 50006, Taiwan|Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien City, 970, Taiwan|E-DA Cancer Hospital, Kaohsiung City, 82445, Taiwan|Kaohsiung, Kaohsiung City, 83301, Taiwan|Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare, New Taipei City, 235, Taiwan|Taichung, Taichung, 404327, Taiwan|Taichung Veterans General Hospital, Taichung, 40705, Taiwan|National Cheng Kung University Hospital, Tainan City, 704, Taiwan|Chi Mei Hospital, Lioying, Tainan City, 73657, Taiwan|National Taiwan University Hospital, Taipei, 10048, Taiwan|MacKay Medical Foundation The Presbyterian Church in Taiwan MacKay Memorial Hospital, Taipei, 104217, Taiwan|Tri-Service General Hospital, Taipei, 11490, Taiwan|Chang Gung Memorial Hospital, Linkou, Taoyuan City, 33305, Taiwan|Baskent Uni. Dr Turgut Noyan Uyg. ve Aras. Merkezi, Adana, 1120, Turkey|Memorial Ankara Hastanesi, Ankara, 06520, Turkey|Ankara Il Saglik Mudurlugu SBU Gulhane Egitim Ve A, Ankara, 6010, Turkey|Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastirma Hastanesi, Ankara, 6200, Turkey|Hacettepe Ãniversitesi Hastanesi, Ankara, Turkey|Trakya Universitesi Tip Fakultesi Hastanesi, Edirne, 22030, Turkey|Istanbul Il Saglik Mudurlugu Goztepe Prof. Dr. Sul, Istanbul, 34000, Turkey|Medipol Mega Universite Hastanesi, Istanbul, 34214, Turkey|Ege Universitesi Hastanesi, Izmir, 35100, Turkey|Medicana International Izmir Hastanesi, Ä°zmir, 35575, Turkey|Acibadem Maslak Hastanesi, Sariyer, Turkey|VKV Amerikan Hastanesi, Sisli, 34365, Turkey|Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, GL53 7AN, United Kingdom|Cancer Research UK Beatson Institute, Glasgow, G12 0YN, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, LS9 7TF, United Kingdom|Barts Health NHS Trust, London, EC1M 6BQ, United Kingdom|Royal Free London NHS Foundation Trust, London, NW2 2QG, United Kingdom|Guy's and Saint Thomas' NHS Foundation Trust, London, SE1 9RT, United Kingdom|University College London Hospitals NHS Foundation, London, WC1E 6BT, United Kingdom",
NCT06759857,FHND9041 Versus Afatinib for Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT06759857,FHND9041,ENROLLING_BY_INVITATION,"The goal of this clinical trial is to evaluate the effectiveness and safety of FHND9041 compared to afatinib as first-line treatments for epidermal growth factor receptor mutation-positive (EGFRm+) locally advanced or metastatic non-small cell lung cancer (NSCLC). The main questions it aims to answer are:

* Does FHND9041 improve progression-free survival (PFS) compared to afatinib?
* Are there differences in safety profiles between FHND9041 and afatinib?

Researchers will compare FHND9041 (80 mg, orally, once daily) with afatinib (40 mg, orally, once daily) in a randomized, open-label, parallel-controlled, multicenter Phase III trial.

Participants who meet the inclusion criteria, including having EGFR mutations (L858R and/or Exon 19 deletion) and no prior treatment, will be randomly assigned in a 1:1 ratio to either the FHND9041 group or the afatinib group. Treatment will continue until disease progression, intolerable drug-related toxicity, or other pre-specified treatment discontinuation criteria are met.

Study Procedures:

Participants will:

* Be screened for eligibility and randomly assigned to one of two groups.
* Receive study drugs per their assigned group.
* Undergo regular tumor assessments by Response Evaluation Criteria in Solid Tumors, version 1.1( RECIST 1.1) every six weeks during the first 18 cycles, then every nine weeks until disease progression. For intracranial efficacy, Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM ) criteria will be applied.
* Participate in pharmacokinetic studies (FHND9041 group only) with blood samples collected pre-dose at specified cycles and on the day of discontinuation.

After disease progression, participants will be followed for survival every three months.",NO,Non Small Cell Lung Cancer,DRUG: FHND9041|DRUG: Afatinib,"Progression-Free Survival (PFS), The time from randomization to the first documented disease progression ( assessed by investigators) or death due to any cause, whichever occurs first., 24 months","Objective Response Rate (ORR), The proportion of participants with confirmed complete response (CR) or partial response (PR), 24 months|Overall Survival (OS), The time from randomization to death due to any cause., 36 months|Duration of Response (DoR), The time from the first documented CR or PR to the first documented disease progression or death, whichever occurs first., 24 months|Disease Control Rate (DCR), The proportion of participants with confirmed CR, PR, or stable disease (SD) for at least 6 weeks, 24 months|Depth of Response (DepOR), The maximum percentage change in the sum of target lesion diameters from baseline, 24 months|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 ( EQRTC-C30), Change from baseline in quality of life (QoL) scores using the EQRTC-C30 questionnaire. The scale ranges from 0 to 100, where higher scores indicate better quality of life., 24 months|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer Module 13(LC13), Change from baseline in quality of life (QoL) scores using the LC13 questionnaire. The scale ranges from 0 to 100, where higher scores indicate better quality of life., 36 months|Lung Cancer Symptom Scale(LCSS), Change from baseline in quality of life (QoL) scores using the LCSS questionnaire. The scale ranges from 0 to 100, where higher scores indicate better quality of life., 36 months",,"Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.",,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,350,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-08-01,2025-03-04,2025-05-01,2025-01-06,,2025-01-06,"Cancer Hospital Chinese Academy of Medical Sciences, Beijing, 100021, China",
NCT06968585,A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy,https://clinicaltrials.gov/study/NCT06968585,A166,ACTIVE_NOT_RECRUITING,Evaluation of the efficacy of A166 versus trastuzumab emtansine (T-DM1) in Patients with HER2-Positive unresectable or metastatic breast cancer previously treated with trastuzumab and taxane therapy,NO,HER2-positive Breast Cancer,DRUG: A166|DRUG: T-DM1,"Progression-free survival (PFS), PFS as assessed by BICR according to RECIST v 1.1, Randomization up to approximately 39 months","Overall survival (OS), OS, 1-year survival rate, 2-year survival rate, and 3-year survival rate., Randomization up to approximately 48 months|Objective response rate(ORR), ORR is defined as the percentage of patients who achieve complete response(CR) or partial response (PR), as assessed by BICR/investigator per RECIST 1.1, Randomization up to approximately 39 months|Disease control rate(DCR), DCR is defined as the percentage of patients who achieve CR, PR or stable disease (SD), as assessed by BICR/investigator per RECIST 1.1, Randomization up to approximately 39 months|Duration of response(DOR), DoR is defined as the time from the date of first documented CR or PR until date of documented disease progression per RECIST 1.1, as assessed by BICR/investigator or death due to any cause, whichever occurs first., Randomization up to approximately 39 months",,"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,365,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-07-18,2025-11-30,2028-03-31,2025-05-13,,2025-05-13,"Fudan University Shanghai Cancer Center, Shanghai, Shanghai, 200032, China",
NCT06614192,A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT06614192,,RECRUITING,"Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide and in China. The purpose of this study is to assess adverse events disease activity when comparing intravenously (IV) infused ABBV-400 to trifluridine and tipiracil (LONSURF) oral tablets plus IV infused bevacizumab in adult participants with c-Met over-expressed refractory metastatic colorectal cancer (mCRC).

ABBV-400 is an investigational drug being developed for the treatment of CRC. Participants are put into treatment arms as part of 2 stages. Each treatment arm in stage 1 receives a different dose of ABBV-400. Each treatment arm in stage 2 receives the optimal dose of ABBV-400 or LONSURF plus bevacizumab. Up to approximately 460 adult participants with c-Met over-expressed (OE) refractory mCRC, will be enrolled in the study in approximately 160 sites in 15-20 countries.

In stage 1, participants will receive intravenously (IV) infused ABBV-400 dose A or B. In stage 2, participants will receive the optimal dose of IV infused ABBV-400 or the standard of care (SOC), LONSURF oral tablets plus IV infused bevacizumab. The total study duration will be approximately 4 years.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.",NO,Metastatic Colorectal Cancer,DRUG: ABBV-400|DRUG: Trifluridine/Tipiracil|DRUG: Bevacizumab,"Stage 1: Percentage of Participants with Adverse Events (AE)s, An AE is defined as any untoward medical occurrence, inappropriate patient management decision, unintended disease or injury or any untoward clinical signs (including an abnormal laboratory finding) in participants, users or other persons whether or not related to the investigational drug., Up to a Maximum of 4 Years|Stage 1: Percentage of Participants with Clinically Significant Vital Sign Measurements as Assessed by the Investigator, Vital signs are defined as determinations of systolic and diastolic blood pressure, pulse rate, respiratory rate, oxygen saturation (SpO2), and body temperature will be obtained at visits., Up to a Maximum of 4 Years|Stage 1: Percentage of Participants with Clinically Significant Electrocardiograms (ECGs) Findings as Assessed by the Investigator, Percentage of participants with clinically significant ECGs findings as assessed by the investigator., Up to a Maximum of 4 Years|Stage 1: Percentage of Participants with Clinically Significant Laboratory Values (Chemistry, Hematology, Coagulation, and Urinalysis) as Assessed by the Investigator, Percentage of participants with clinically significant laboratory values (hematology, chemistry, coagulation, and urinalysis) as assessed by the investigator., Up to a Maximum of 4 Years|Stage 1 and Stage 2: Objective Response (OR) as Assessed by Blinded Independent Central Review (BICR), OR is defined as confirmed complete response (CR) or confirmed partial response (PR) as assessed by BICR per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1., Up to a Maximum of 4 Years|Stage 2: Overall Survival (OS), OS is defined as the time from randomization to the event of death from any cause., Up to a Maximum of 4 Years","Stage 1 and Stage 2: Progression Free Survival (PFS) as Assessed by BICR, PFS is defined as the time from randomization to the first occurrence of radiographic progression based on RECIST version 1.1 as determined by BICR or death from any cause, whichever occurs earlier., Up to a Maximum of 4 Years|Stage 1: OS, OS is defined as the time from randomization to the event of death from any cause, Up to a Maximum of 4 Years|Stage 1 and Stage 2: Duration of Response (DOR) as Assessed by BICR, DOR is defined as the time from the first documented CR or PR to the first occurrence of radiographic progression per RECIST v1.1 as determined by BICR or death from any cause, whichever occurs first. DOR is defined for participants with confirmed CR/PR., Up to a Maximum of 4 Years|Stage 1 and Stage 2: Disease Control (DC) as Assessed by BICR, DC is defined as best overall response of confirmed CR or confirmed PR, or stable disease (SD) based on RECIST, version 1.1 as determined by BICR., Up to a Maximum of 4 Years|Stage 1 and Stage 2: OR as Assessed by Investigator, OR is defined as confirmed CR or confirmed PR as assessed by investigator per RECIST, version 1.1., Up to a Maximum of 4 Years|Stage 1 and Stage 2: PFS as Assessed by Investigator, PFS is defined as the time from randomization to the first occurrence of radiographic progression based on RECIST version 1.1 as determined by investigator or death from any cause, whichever occurs earlier., Up to a Maximum of 4 Years|Stage 1 and Stage 2: DOR as Assessed by Investigator, DOR is defined as the time from the first documented CR or PR to the first occurrence of radiographic progression per RECIST v1.1 as determined by BICR or death from any cause, whichever occurs first. DOR is defined for participants with confirmed CR/PR., Up to a Maximum of 4 Years|Stage 1: Maximum Observed Serum (or Plasma, for Payload) Concentration (Cmax) for ABBV-400, Maximum observed serum (or plasma, for payload) concentration for ABBV-400., Up to a Maximum of 4 Years|Stage 1: Time to Cmax (Tmax) for ABBV-400, Time to Cmax for ABBV-400., Up to a Maximum of 4 Years|Stage 1: Terminal Elimination Half-Life (t1/2) for ABBV-400, Terminal elimination half-life for ABBV-400., Up to a Maximum of 4 Years|Stage 1: Area Under the Serum (or Plasma, for Payload) Concentration Versus Time Curve (AUC) for ABBV-400, Area under the serum (or plasma, for payload) concentration versus time curve will be determined using noncompartmental methods for total antibody for ABBV-400., Up to a Maximum of 4 Years|Stage 1: Antibody Drug Conjugate (ADC) for ABBV-400, Antibody drug conjugate for ABBV-400., Up to a Maximum of 4 Years|Stage 1: Unconjugated Topoisomerase 1 (Top1) Inhibitor Payload for ABBV-400, Unconjugated Top1 inhibitor payload for ABBV-400., Up to a Maximum of 4 Years|Stage 1: Incidence of Anti-Drug Antibodies (ADAs) for ABBV-400, Incidence of anti-drug antibodies for ABBV-400., Up to a Maximum of 4 Years|Stage 1: Neutralizing Anti-Drug Antibodies (nADAs) for ABBV-400, Neutralizing anti-drug antibodies for ABBV-400., Up to a Maximum of 4 Years|Stage 2: Change from Baseline at C5D1 (ABBV-400 Arm) in Physical Functioning as Measured by the Physical Functioning Domain of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), The EORTC QLQ-C30 is a 30-item patient-reported questionnaire composed of both multi-item and single scales including 5 functional scales (physical, role, emotional, social, and cognitive), 3 symptom scales (fatigue, nausea and vomiting, and pain), a global health status/Quality of Life (QoL) scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Participants rate items on a 4-point scale ranging from 1 to 4 (1 = Not at All, 2 = A Little, 3 = Quite a Bit, and 4 = Very Much)., Up to a Maximum of 4 Years|Stage 2: Change from Baseline at C7D1 (Standard of Care [SOC] Arm) in Physical Functioning as Measured by the Physical Functioning Domain of the EORTC QLQ-C30, The EORTC QLQ-C30 is a 30-item patient-reported questionnaire composed of both multi-item and single scales including 5 functional scales (physical, role, emotional, social, and cognitive), 3 symptom scales (fatigue, nausea and vomiting, and pain), a global health status/QoL scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Participants rate items on a 4-point scale ranging from 1 to 4 (1 = Not at All, 2 = A Little, 3 = Quite a Bit, and 4 = Very Much)., Up to a Maximum of 4 Years|Stage 2: Change from Baseline at C5D1 (ABBV-400 Arm) in in Diarrhea as Measured by the Physical Functioning Domain of the EORTC QLQ-C30, The EORTC QLQ-C30 is a 30-item patient-reported questionnaire composed of both multi-item and single scales including 5 functional scales (physical, role, emotional, social, and cognitive), 3 symptom scales (fatigue, nausea and vomiting, and pain), a global health status/Quality of Life (QoL) scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Participants rate items on a 4-point scale ranging from 1 to 4 (1 = Not at All, 2 = A Little, 3 = Quite a Bit, and 4 = Very Much)., Up to a Maximum of 4 Years|Stage 2: Change from Baseline at C7D1 (SOC Arm) in Diarrhea as Measured by the Physical Functioning Domain of the EORTC QLQ-C30, The EORTC QLQ-C30 is a 30-item patient-reported questionnaire composed of both multi-item and single scales including 5 functional scales (physical, role, emotional, social, and cognitive), 3 symptom scales (fatigue, nausea and vomiting, and pain), a global health status/QoL scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Participants rate items on a 4-point scale ranging from 1 to 4 (1 = Not at All, 2 = A Little, 3 = Quite a Bit, and 4 = Very Much)., Up to a Maximum of 4 Years|Stage 2: Change from Baseline at C5D1 (ABBV-400 Arm) in in Global Health Status (GHS)/QoL as Measured by the Physical Functioning Domain of the EORTC QLQ-C30, The EORTC QLQ-C30 is a 30-item patient-reported questionnaire composed of both multi-item and single scales including 5 functional scales (physical, role, emotional, social, and cognitive), 3 symptom scales (fatigue, nausea and vomiting, and pain), a global health status/Quality of Life (QoL) scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Participants rate items on a 4-point scale ranging from 1 to 4 (1 = Not at All, 2 = A Little, 3 = Quite a Bit, and 4 = Very Much)., Up to a Maximum of 4 Years|Stage 2: Change from Baseline at C7D1 (SOC Arm) in GHS/QoL as Measured by the Physical Functioning Domain of the EORTC QLQ-C30, The EORTC QLQ-C30 is a 30-item patient-reported questionnaire composed of both multi-item and single scales including 5 functional scales (physical, role, emotional, social, and cognitive), 3 symptom scales (fatigue, nausea and vomiting, and pain), a global health status/QoL scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Participants rate items on a 4-point scale ranging from 1 to 4 (1 = Not at All, 2 = A Little, 3 = Quite a Bit, and 4 = Very Much)., Up to a Maximum of 4 Years",,AbbVie,,ALL,"ADULT, OLDER_ADULT",PHASE3,460,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2024-11-08,2029-04,2029-04,2024-09-26,,2025-04-10,"City of Hope National Medical Center /ID# 267875, Duarte, California, 91010, United States|City of Hope Orange County Lennar Foundation Cancer Center /ID# 270655, Irvine, California, 92618, United States|USC Norris Comprehensive Cancer Center /ID# 268131, Los Angeles, California, 90033, United States|Lutheran Medical Center- Cancer Centers of Colorado /ID# 268175, Golden, Colorado, 80401, United States|Yale New Haven Hospital /ID# 269125, New Haven, Connecticut, 06510, United States|AdventHealth Orlando /ID# 267970, Orlando, Florida, 32803, United States|Winship Cancer Institute of Emory University /ID# 266884, Atlanta, Georgia, 30322, United States|St. Luke's Cancer Institute: Boise /ID# 268095, Boise, Idaho, 83712, United States|Northwestern University Robert H. Lurie Comprehensive Cancer Center /ID# 268610, Chicago, Illinois, 60611-2927, United States|Hope And Healing Cancer Services /ID# 268541, Hinsdale, Illinois, 60521, United States|Springfield Clinic /ID# 268666, Springfield, Illinois, 62702-3749, United States|Community Cancer Center North /ID# 267965, Indianapolis, Indiana, 46250, United States|Hattiesburg Clinic /ID# 267860, Hattiesburg, Mississippi, 39401, United States|Washington University /ID# 267872, Saint Louis, Missouri, 63110, United States|Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana /ID# 268185, Billings, Montana, 59102, United States|Rutgers Cancer Institute of New Jersey /ID# 268056, New Brunswick, New Jersey, 08901, United States|University of North Carolina Medical Center /ID# 266879, Chapel Hill, North Carolina, 27514, United States|Duke University Medical Center /ID# 267966, Durham, North Carolina, 27710, United States|Avera Cancer Institute - Sioux Falls /ID# 268074, Sioux Falls, South Dakota, 57105, United States|West Cancer Center and Research Institute - Germantown /ID# 268619, Germantown, Tennessee, 38138, United States|The University of Texas MD Anderson Cancer Center /ID# 268098, Houston, Texas, 77030, United States|Millennium Research & Clinical Development /ID# 268400, Houston, Texas, 77090, United States|University of Virginia /ID# 268108, Charlottesville, Virginia, 22908, United States|Mater Hospital Brisbane /ID# 268360, South Brisbane, Queensland, 4101, Australia|Rambam Health Care Campus /ID# 267739, Haifa, H_efa, 3525408, Israel|The Chaim Sheba Medical Center /ID# 267741, Ramat Gan, Tel-Aviv, 5265601, Israel|Tel Aviv Sourasky Medical Center /ID# 267578, Tel Aviv, Tel-Aviv, 6423906, Israel|Hadassah Medical Center-Hebrew University /ID# 267579, Jerusalem, 91120, Israel|Rabin Medical Center /ID# 267740, Petah Tikva, 4941492, Israel|Assuta Medical Center /ID# 267745, Tel Aviv, 6789140, Israel|Aichi Cancer Center /ID# 268237, Nagoya-shi, Aichi, 464-8681, Japan|National Cancer Center Hospital East /ID# 268236, Kashiwa-shi, Chiba, 277-8577, Japan|The University of Osaka Hospital /ID# 268743, Suita-shi, Osaka, 565-0871, Japan|Saitama Cancer Center /ID# 268706, Kitaadachi-gun, Saitama, 362-0806, Japan|National Cancer Center Hospital /ID# 268713, Chuo-Ku, Tokyo, 104-0045, Japan|Seoul National University Bundang Hospital /ID# 268592, Seongnam-si, Gyeonggido, 13620, Korea, Republic of|Seoul National University Hospital /ID# 268719, Seoul, Seoul Teugbyeolsi, 03080, Korea, Republic of|Yonsei University Health System Severance Hospital /ID# 268718, Seoul, Seoul Teugbyeolsi, 03722, Korea, Republic of|Asan Medical Center /ID# 268717, Seoul, Seoul Teugbyeolsi, 05505, Korea, Republic of|Samsung Medical Center /ID# 268720, Seoul, Seoul Teugbyeolsi, 06351, Korea, Republic of|Pan American Center for Oncology Trials /ID# 267888, Rio Piedras, 00935, Puerto Rico|Kaohsiung Chang Gung Memorial Hospital /ID# 267638, Kaohsiung City, Kaohsiung, 833, Taiwan|National Taiwan University Hospital /ID# 267627, Taipei City, Taipei, 100, Taiwan|Changhua Christian Hospital /ID# 270464, Changhua City, Changhua County, 50006, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 267635, Kaohsiung, 807, Taiwan|China Medical University Hospital /ID# 267631, Taichung, 404, Taiwan|Taichung Veterans General Hospital /ID# 270467, Taichung, 407, Taiwan|National Cheng Kung University Hospital /ID# 270468, Tainan, 704, Taiwan|Taipei Veterans General Hospital /ID# 267628, Taipei City, 112, Taiwan|Linkou Chang Gung Memorial Hospital /ID# 267637, Taoyuan City, 333, Taiwan",
NCT05827016,A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma,https://clinicaltrials.gov/study/NCT05827016,,RECRUITING,The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (NDMM).,NO,Multiple Myeloma,DRUG: Iberdomide|DRUG: Lenalidomide,"Progression-free survival (PFS), Up to 6 years","Achieving minimal residual disease (MRD) negativity in participants with complete response (CR) or better at 12 (Â± 3) months of maintenance treatment, Up to 6 years|Overall Survival, Up to 12 years|Recommended iberdomide dose for Stage 2, Up to 1 year|Area under the iberdomide plasma concentration-time curve from time zero to tau, Up to 1 year|Area under the iberdomide plasma concentration-time curve within a dosing interval AUC (TAU), Up to 1 year|Maximum iberdomide concentration (Cmax), Up to 1 year|Time to maximum iberdomide plasma concentration (Tmax), Up to 1 year|Number of participants with adverse events (AEs), Up to 6 years|Progression-free survival on next line of treatment (PFS2), Up to 6 years|Achieving MRD negativity in participants with CR or better at any time after the date of randomization, Up to 6 years|Conversion from MRD positive to MRD negative in participants with CR or better, Up to 6 years|Achievement of CR or better and maintaining MRD-negative status in 2 bone marrow aspirate assessments that are a minimum of 1 year apart, without any examination showing MRD positive status in between assessments, Up to 6 years|Time to progression (TTP), Up to 6 years|Time to next treatment (TTNT), Up to 6 years|Best response achieved prior to progressive disease (PD), Up to 6 years|Patient-reported health-related quality of life (HRQoL) outcomes and multiple myeloma-related symptoms as measured by the European Organization for Research and Treatment of Cancer [EORTC] Quality of Life C30 questionnaire (QLQ-C30), Up to 6 years|Patient-reported HRQoL outcomes and multiple myeloma-related symptoms as measured by the EORTC Quality of Life Multiple Myeloma Module (QLQ-MY20), Up to 6 years",,Bristol-Myers Squibb,,ALL,"ADULT, OLDER_ADULT",PHASE3,1216,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-06-22,2029-03-15,2036-01-01,2023-04-24,,2025-06-04,"Rocky Mountain Cancer Centers, Aurora, Colorado, 80012-5405, United States|Mayo Clinic Florida, Jacksonville, Florida, 32224, United States|Tampa General Hospital, Tampa, Florida, 33606, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, 33612-9416, United States|Cleveland Clinic, Weston, Florida, 33331-3609, United States|University Cancer Blood Ctr, Athens, Georgia, 30607-1465, United States|The Winship Cancer Institute of Emory University, Atlanta, Georgia, 30322-1013, United States|Augusta University - Georgia Cancer Center, Augusta, Georgia, 30912, United States|The University of Chicago Medical Center - Duchossois Center for Advanced Medicine, Chicago, Illinois, 60637-1426, United States|University of Kansas Cancer Center - The Richard and Annette Bloch Cancer Care Pavilion, Westwood, Kansas, 66205-2003, United States|Maryland Oncology Hematology, PA- Clinton, Clinton, Maryland, 20735-4230, United States|UMass Memorial Medical Center, Worcester, Massachusetts, 01655, United States|University of Michigan - Rogel Cancer Center, Ann Arbor, Michigan, 48109-5000, United States|Henry Ford Health System - The Henry Ford Cancer Institute (HFCI) - Detroit, Detroit, Michigan, 48202-2610, United States|Cancer & Hematology Centers of Western Michigan (CHCWM), Grand Rapids, Michigan, 49503, United States|Mayo Clinic Cancer Center (MCCC) - Rochester, Rochester, Minnesota, 55905, United States|Hattiesburg Clinic - Hematology & Oncology, Hattiesburg, Mississippi, 39401, United States|Morristown Medical Center, Morristown, New Jersey, 07960, United States|Perlmutter Cancer Center at NYU Langone Hematology Oncology Associates-Mineola, Mineola, New York, 11501, United States|NYU Langone Health, New York, New York, 10016-6402, United States|Columbia University Medical Center - Herbert Irving Pavilion Location, New York, New York, 10032-3729, United States|Clinical Research Alliance, Westbury, New York, 11590, United States|Novant Health Cancer Institute - Elizabeth, Charlotte, North Carolina, 28803-2493, United States|Duke University Hospital, Durham, North Carolina, 27705-3976, United States|Novant Health Cancer Institute Hematology - Forsyth, Winston-Salem, North Carolina, 27103, United States|Local Institution - 0322, Winston-Salem, North Carolina, 27157, United States|Oncology Hematology Care, Inc. - Cincinnati - Galbraith Rd, Cincinnati, Ohio, 45236-2725, United States|Cleveland Clinic - Fairview Hospital - Cancer Center (Moll Cancer Center), Cleveland, Ohio, 44111, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|Midwest Oncology Associates - Kansas City, Kansas, Ohio, 64132, United States|Cleveland Clinic - Hillcrest Hospital - Hillcrest Cancer Center, Mayfield Heights, Ohio, 44124, United States|Toledo Clinic Cancer Centers, Toledo, Ohio, 43623, United States|Wooster Milltown Specialty and Surgery Center, Wooster, Ohio, 44691, United States|Willamette Valley Cancer Institute, Eugene, Oregon, 97401, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, 19107, United States|Fox Chase Cancer Center - Jeanes Campus, Philadelphia, Pennsylvania, 19111-2433, United States|University of Pittsburgh - Hillman Cancer Center, Pittsburgh, Pennsylvania, 15232, United States|West Cancer Center, Germantown, Tennessee, 38138-1762, United States|Tennessee Oncology, Nashville, Tennessee, 37203-1625, United States|Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, 75246, United States|UT Southwestern-Harold C. Simmons Cancer Center, Dallas, Texas, 75390-0001, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, 77030-4000, United States|Local Institution - 0259, Mar del Plata, B, 7600, Argentina|Hospital Universitario Austral, Pilar, B, B1629AHJ, Argentina|Hospital Italiano de Buenos Aires, Ciudad Autonoma Buenos Aires, Caba, C1199ABB, Argentina|""Centro de EducaciÃ³n MÃ©dica e Investigaciones ClÃ­nicas """"Norberto Quirno"""""", Ciudad Autonoma Buenos Aires, Caba, C1430EFA, Argentina|Sanatorio Allende, CÃ³rdoba, X5000JHGQ, Argentina|Calvary Mater Newcastle, Waratah, New South Wales, 2298, Australia|Royal Adelaide Hospital, Adelaide, South Australia, 5000, Australia|Box Hill Hospital, Box Hill, Victoria, 3128, Australia|Monash Health, Clayton, Victoria, 3800, Australia|Ordensklinikum Linz Elisabethinen, Linz, 4020, Austria|UniversitÃ¤tsklinikum St. PÃ¶lten, St. PÃ¶lten, 3100, Austria|Medizinische Universitaet Wien - Universitaetsklinik fuer Augenheilkunde und Optometrie, Vienna, 1090, Austria|Hanusch-Krankenhaus, Vienna, 1140, Austria|Grand Hopital de Charleroi - Les Viviers, Charleroi, WHT, 6060, Belgium|AZ Groeninge - Campus Kennedylaan, Kortrijk, 8500, Belgium|Local Institution - 0245, Curitiba, PR, 80520-174, Brazil|Local Institution - 0214, NiterÃ³i, RJ, 24020-096, Brazil|Local Institution - 0082, Rio de Janeiro, RJ, 20230-130, Brazil|Local Institution - 0081, RibeirÃ£o Preto, SP, 14051-140, Brazil|Local Institution - 0277, Sao Paulo, SP, 04537-080, Brazil|Local Institution - 0194, SÃ£o Paulo, SP, 05403-000, Brazil|Local Institution - 0241, SÃ£o Paulo, SP, 08270-070, Brazil|Local Institution - 0190, Barretos, 14784-400, Brazil|Local Institution - 0083, Porto Alegre, 90880-480, Brazil|Local Institution - 0096, Rio de Janeiro, 21941-913, Brazil|Local Institution - 0098, Salvador, 40110-150, Brazil|Cross Cancer Institute, Edmonton, Alberta, T6G 1Z2, Canada|The Ottawa Hospital - General Campus, Ottawa, Ontario, K1H 8L6, Canada|Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada|CHUQ - The HÃ´tel-Dieu de QuÃ©bec, Quebec, Canada|FundaciÃ³n Arturo LÃ³pez PÃ©rez, Santiago, 7500691, Chile|Local Institution - 0258, Temuco, 4800827, Chile|Clinica Alemana - Vitacura, Vitacura, 7650567, Chile|Anhui Provincial Hospital, Hefei, AH, 230001, China|Local Institution - 0326, Beijing, Beijing, 100038, China|The Fifth Medical Center of People's Liberation Army General Hospital, Beijing, Beijing, 100071, China|The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, 400016, China|Local Institution - 0321, Chongqing, CQ, 400030, China|Guangdong Provincial People's Hospital, Guangzhou Shi, Guangdong, 510080, China|Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, 510515, China|Shenzhen Second People's Hospital, Shenzhen, Guangdong, 518028, China|Henan Cancer Hospital, Zhengzhou City, Henan, 450003, China|The Third Xiangya Hospital of Central South University, Changsha, Hunan, 410013, China|Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China|Nanjing Drum Tower Hospital - The Comprehensive Cancer Center, Nanjing, Jiangsu, 210008, China|The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221000, China|The First Affiliated Hospital of Nanchang University - Donghu District, Nanchang, Jiangxi, 330200, China|The First Hospital of Jilin University, Changchun, Jilin, 130021, China|Shengjing Hospital of China Medical University, Shenyang, Liaoning, 110022, China|The First Affiliated Hospital of the Air Force Medical University, Xi'an City, Shaanxi, 710032, China|Local Institution - 0318, Xi'an, Shaanxi, 710061, China|Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China|Local Institution - 0271, Shanghai, Shanghai, 200003, China|Local Institution - 0319, Shanghai, Shanghai, 200434, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, 300060, China|The First Affiliated Hospital - Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310003, China|Local Institution - 0320, Ningbo, Zhejiang, 315010, China|Beijing Chaoyang Hospital, Capital Medical University, Beijing, 100020, China|Peking University People's Hospital, Beijing, 100044, China|The Second Xiangya Hospital of Central South University, Changsha, 400011, China|Fujian Medical University Union Hospital, Fuzhou, 350001, China|Sun Yat-sen University Cancer Center, Guangzhou, 511363, China|Shandong Provincial Hospital, Jinan, 250021, China|Jiangsu Province Hospital, Nanjing, 210029, China|Qingdao Municipal Hospital, Qingdao, 266071, China|Ruijin Hospital Affiliated to The Shanghai Jiao Tong University Medical School, Shanghai, 200025, China|The First Affiliated Hospital of Soochow University, Suzhou Shi, 215006, China|Wenzhou Medical University - The First Affiliated Hospital, Wenzhou Shi, 325000, China|Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan Shi, 430022, China|Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, 430030, China|Local Institution - 0302, Monteria, COR, 230002, Colombia|Instituto Nacional de CancerologÃ­a - Bogota, Bogota, 110111, Colombia|Fundacion Centro de Tratamiento e Investigacion sobre Cancer Luis Carlos Sarmiento Angulo - CTIC, Bogota, 110131, Colombia|Fundacion Oftalmologica de Santander - FOSCAL, Floridablanca, 681004, Colombia|Hospital Pablo Tobon Uribe, Medellin, 050034, Colombia|Sociedad de Oncologia y Hematologia del Cesar S.A.S, Valledupar, 200001, Colombia|FakultnÃ­ Nemocnice Brno, Brno, 625 00, Czechia|FakultnÃ­ Nemocnice Olomouc, Olomouc, 779 00, Czechia|VÅ¡eobecnÃ¡ fakultnÃ­ nemocnice v Praze, Prague 2, 128 08, Czechia|FakultnÃ­ nemocnice KrÃ¡lovskÃ© Vinohrady, Prague, 100 34, Czechia|Odense Universitetshospital, Odense, 5000, Denmark|Helsingin Yliopistollinen Sairaala (HUS) - Syopakeskus (Comprehensive Cancer Center), Helsinki, 00290, Finland|Kuopio University Hospital, Kuopio, 70211, Finland|CHU HÃ´pital Sud, Amiens Cedex 1, 80000, France|Institut d'HÃ©matologie de Basse-Normandie (IHBN), Caen, 14033, France|CHU HÃ´pital Henri Mondor, Creteil, 94000, France|Centre Hospitalier DÃ©partemental VendÃ©e - HÃ´pital de la Roche-sur-Yon, La Roche Sur Yon, 85000, France|Centre Hospitalier RÃ©gional Universitaire de Lille (CHRU) - HÃ´pital Claude Huriez, Lille, 59037, France|CHU Limoges - HÃ´pital Dupuytren, Limoges, 87042, France|Centre Hospitalier Universitaire de Nantes (CHU de Nantes) - Hotel-Dieu, Nantes, 44093, France|HÃ´pital Saint-Antoine, Paris, 75012, France|Hopital Pitie-Salpetriere, Paris, 75013, France|Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, 31059, France|Local Institution - 0314, Cottbus, BB, 03048, Germany|Charite-Universitaetsmedizin Berlin - Campus Benjamin Franklin (CBF), Berlin, BE, 12203, Germany|UniversitÃ¤tsklinikum Ulm, Ulm, BW, 89081, Germany|Local Institution - 0324, Augsburg, BY, 86156, Germany|Local Institution - 0312, Bayreuth, BY, 95445, Germany|Universitaetsklinikum Erlangen - Medizinische Klinik 5, Erlangen, BY, 91054, Germany|Local Institution - 0311, Muenchen, BY, 81377, Germany|Local Institution - 0315, Hamburg, HH, 22763, Germany|Local Institution - 0313, Hildesheim, NI, 31134, Germany|Local Institution - 0316, Chemnitz, SN, 09116, Germany|UniversitÃ¤tsklinikum Freiburg, Freiburg, 79106, Germany|Local Institution - 0310, Gottingen, 37075, Germany|UniversitÃ¤tsklinikum Hamburg-Eppendorf (UKE), Hamburg, 20246, Germany|St. Barbara-Klinik Hamm-Heessen GmbH, Hamm, 59073, Germany|UniversitÃ¤tsklinikum Jena, Jena, 07747, Germany|Local Institution - 0323, Marburg, 35033, Germany|UniversitÃ¤tsklinikum TÃ¼bingen, TÃ¼bingen, 72076, Germany|""General Hospital of Thessaloniki """"G. Papanikolaou"""""", Thessaloniki, B, 570 10, Greece|University of Patras - Rio Regional University Hospital, Rio, G, 265 04, Greece|Evangelismos General Hospital of Athens, Athina, I, 106 76, Greece|Alexandra General Hospital of Athens, Athens, 115 28, Greece|University of Thessaly- General University Hospital of Larissa, Larisa, 411 10, Greece|Theageneio Cancer Hospital of Thessaloniki, Thessaloniki, 546 39, Greece|Queen Mary Hospital, Hong Kong, HK, 999077, Hong Kong|Debreceni Egyetem Klinikai KÃ¶zpont III. sz. BelgyÃ³gyÃ¡szati Klinika, Debrecen, HB, 4032, Hungary|Postgraduate Institute of Medical Education & Research (PGIMER), Chandigarh, CH, 160012, India|HCG Cancer Center - Kalinga Rao Road, Bangalore, Karnataka, 560027, India|Aster Medcity, Cochin, KL, 68202, India|Dr. Bafnas Star Superspecaility Clinic and Hospital, Kolhapur, MH, 416005, India|Alexis Multispeciality Hospital, Nagpur, MH, 440030, India|Deenanath Mangeshkar Hospital & Research Center, Pune, MH, 411 004, India|Sahyadri Speciality Hospital Deccan Gymkhana, Pune, MH, 411004, India|Sparsh Hospitals & Critical Care, Bhubaneswar, Odisha, 751007, India|Tata Medical Center, Kolkata, WB, 700 020, India|Local Institution - 0135, Navi Mumbai, 410 210, India|Assuta Medical Center, Ashdod, 7747629, Israel|Assaf Harofeh Medical Center, Beer Ya'Aqov, 70300, Israel|Hillel Yaffe Medical Center, Hadera, 38100, Israel|Rambam Medical Center, Haifa, 3109601, Israel|Shaare Zedek Medical Center, Jerusalem, 91031, Israel|Hadassah University Medical Center, Jerusalem, 9112001, Israel|Rabin Medical Center - Davidoff Center, Petah Tikva, 49100, Israel|The Chaim Sheba Medical Center, Ramat Gan, 52621, Israel|Local Institution - 0136, Tel Aviv-Yafo, 64239, Israel|Azienda Ospedaliero Universitaria Policlinico G. Rodolico San Marco - Ospedale San Marco, Catania, CT, 95123, Italy|Local Institution - 0306, Firenze, FI, 50134, Italy|Ospedale Policlinico San Martino, Genova, GE, 16132, Italy|Fondazione IRCCS CÃ  Granda Ospedale Maggiore Policlinico, Milano, MI, 20122, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, MI, 20162, Italy|Azienda Ospedaliero Universitaria Pisana - Ospedale Santa Chiara, Pisa, PI, 56127, Italy|Fondazione Policlinico Universitario Agostino Gemelli, Roma, RM, 00168, Italy|Azienda Ospedaliera Universitaria Citta della Salute e della Scienza di Torino - Ospedale Molinette, Torino, TO, 10126, Italy|""Azienda Ospedaliera Universitaria """"Federico II"""""", Naples, 80131, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, 27100, Italy|Policlinico Umberto I, Rome, 00161, Italy|National Hospital Organization (NHO) - Shibukawa Medical Center, Shibukawa-shi, Gunma, 3770280, Japan|Shonan Kamakura General Hospital, Kamakura-Shi, Kanagawa, 2478533, Japan|Kumamoto University Hospital, Kumamoto-shi, Kumamoto, 860-8556, Japan|Chiba University Hospital, Chiba-shi, 260-8677, Japan|Gifu Municipal Hospital, Gifu-Shi, 500-8513, Japan|Local Institution - 0133, Higashiibaraki-Gun, 311-3193, Japan|Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital, Hiroshima-shi, 730-8619, Japan|Tokai University Hospital IRB, Isehara-shi, 259-1193, Japan|Kagoshima University Hospital, Kagoshima-Shi, 890-8520, Japan|Kanazawa University Hospital, Kanazawa-shi, 920-8641, Japan|Local Institution - 0134, Kobe-Shi, 650-0047, Japan|The Cancer Institute Hospital of Japanese Foundation for Cancer Research (JFCR), Koto-Ku, 135-8550, Japan|Gunma University Hospital, Maebashi-Shi, 371-8511, Japan|The Jikei University Hospital, Minato-Ku, 105-8471, Japan|The Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki-Shi, 852-8511, Japan|Nagoya City University Hospital, Nagoya-Shi, 467-8602, Japan|Kindai University Hospital, Osakasayama-Shi, 589-8511, Japan|Jichi Medical University Saitama Medical Center, Saitama-shi, 330-8503, Japan|Sapporo Hokuyu Hospital, Sapporo-shi, 003-0006, Japan|National Hospital Organization Sendai Medical Center, Sendai-shi, 983-8520, Japan|Japanese Red Cross Medical Center, Shibuya-ku, 150-8935, Japan|Shizuoka Cancer Center, Sunto-gun, 411-8777, Japan|Pusan National University Hospital, Busan, 49241, Korea, Republic of|National Cancer Center, Goyang-si, 410-769, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, 13620, Korea, Republic of|Yonsei University Health System, Severance Hospital, Seoul, 03722, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|Ulsan University Hospital (UUH), Ulsan, 44033, Korea, Republic of|Local Institution - 0127, Mexico, CMX, 14080, Mexico|Local Institution - 0146, Toluca De Lerdo, MEX, 50090, Mexico|Local Institution - 0283, Monterrey, NL, 64460, Mexico|Local Institution - 0107, Mexico city, 04100, Mexico|VU University Medical Center, Amsterdam, NH, 1081 HV, Netherlands|Local Institution - 0325, Almere, 1315 RA, Netherlands|Albert Schweitzer Hospital - Locatie Dordwijk, Dordrecht, 3300 AK, Netherlands|Szpital Uniwersytecki Nr. 2 im Dr. Jana Biziela w Bydgoszczy, Bydgoszcz, KP, 85-168, Poland|WojewÃ³dzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Åodzi, Lodz, LD, 93-510, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, PM, 80-211, Poland|Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology Gliwice Branch, Gliwice, 44-102, Poland|Pratia Onkologia Katowice, Katowice, 40-519, Poland|Office of Dr n. Med. Wojciech Legiec, Lublin, 20-134, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Warsaw, 02-781, Poland|Unidade Local de Saude Braga, Braga, 4710-243, Portugal|Unidade Local de Saude de Coimbra, EPE - Hospitais da Universidade de Coimbra, Coimbra, 3000-075, Portugal|Instituto PortuguÃªs Oncologia do Porto Francisco Gentil, EPE, Porto, 4200-072, Portugal|Institutul Clinic Fundeni, BucureÅti, B, 022328, Romania|Spitalul Clinic Municipal Filantropia Craiova, Craiova, Dolj, 200143, Romania|Institutul Regional de Oncologie IaÈi, Iasi, IS, 700483, Romania|""Institutul Oncologic """"Prof. Dr. Ion ChiricuÅ£Ä"""" Cluj Napoca"", Cluj-Napoca, Jud. Cluj, 400015, Romania|""Institutul Oncologic """"Prof. Dr. Ion ChiricuÅ£Ä"""" Cluj Napoca"", Cluj-Napoca, 400015, Romania|National University Hospital (S) Pte Ltd, Singapore, 119074, Singapore|Singapore General Hospital, Singapore, 169608, Singapore|Hospital Universitario Central de Asturias, Oviedo, Asturias, 33011, Spain|Hospital ClÃ­nic de Barcelona, Barcelona, B, 08036, Spain|Hospital San Pedro de AlcÃ¡ntara, CÃ¡ceres, CC, 10003, Spain|Hospital Universitario de Gran Canaria Doctor NegrÃ­n, Las Palmas de Gran Canaria, Las Palmas, 35019, Spain|Hospital Universitario Virgen Arrixaca, Murcia, MU, 30120, Spain|Hospital Universitari i PolitÃ¨cnic La Fe, Valencia, VC, 46026, Spain|Hospital Universitari Germans Trias i Pujol, Badalona, 08916, Spain|ClÃ­nica Universidad de Navarra -Madrid, Madrid, 28022, Spain|Hospital Universitari Son Espases, Palma de Mallorca, 07120, Spain|ClÃ­nica Universidad de Navarra, Pamplona, 31008, Spain|Local Institution - 0171, LuleÃ¥, BD, 971 80, Sweden|SÃ¶dra Ãlvsborgs Sjukhus, BorÃ¥s, 501 82, Sweden|Vastra Goetalandsregionen - Uddevalla Sjukhus (US), Uddevalla, 451 51, Sweden|Local Institution - 0168, Aarau 1, 5001, Switzerland|Chang Gung Medical Foundation - Kaohsiung Branch, Kao-Hsiung, 83301, Taiwan|E-DA Cancer Hospital, Kaohsiung, 82445, Taiwan|Far Eastern Memorial Hospital, New Taipei City, 220, Taiwan|National Cheng Kung University Hospital, Tainan, 704, Taiwan|National Taiwan University Hospital, Taipei, 10002, Taiwan|Chang Gung Memorial Hospital, Taoyuan, 333, Taiwan|Ankara Bilkent City Hospital, Ankara, 06230, Turkey|Liv Hospital Ankara, Cankaya, 06680, Turkey|Trakya Ãniversitesi TÄ±p FakÃ¼ltesi, Edirne, 22030, Turkey|Local Institution - 0068, Istanbul, 34214, Turkey|T.C. Istanbul Bilim Universitesi - lstanbul Florence Nightingale Hastanesi, Istanbul, 34381, Turkey|Ege Universitesi Tip Fakultesi Hastanesi (Ege University Medical Faculty Hospital), Izmir, 35100, Turkey|Local Institution - 0073, Izmir, 35575, Turkey|Erciyes Ãniversitesi TÄ±p FakÃ¼ltesi, Kayseri, 38039, Turkey|Dr. Abdurrahman Yurtaslan Ankara Onkoloji EÄitim ve AraÅtÄ±rma Hastanesi, Yenimahalle, 06200, Turkey|NHS Grampian - Aberdeen Royal Infirmary, Aberdeen, ABD, AB25 2ZN, United Kingdom|GenesisCare -Windosr, Windsor, Berkshire, SL4 3HD, United Kingdom|University Hospitals of Derby and Burton NHS Foundation Trust - Royal Derby Hospital, Derby, DBY, DE22 3NE, United Kingdom|University Hospitals Dorset NHS Foundation Trust (UHD) - Royal Bournemouth Hospital (RBH), Bournemouth, DOR, BH7 7DW, United Kingdom|Portsmouth Hospitals NHS Trust - Queen Alexandra Hospital, Portsmouth, HAM, PO6 3LY, United Kingdom|University Hospitals of North Midlands NHS Trust (UHNM) - Royal Stoke University Hospital, Stoke-on-Trent, Staffordshire, ST4 6QG, United Kingdom|NHS Lothian - Western General Hospital, Edinburgh, EH4 2XU, United Kingdom|Barts Health NHS Trust - St Bartholomew's Hospital, London, W1G 6AF, United Kingdom|GenesisCare-Oxford, Oxford, OX4 6LB, United Kingdom",
NCT04923893,"A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy",https://clinicaltrials.gov/study/NCT04923893,CARTITUDE-5,ACTIVE_NOT_RECRUITING,"The purpose of this study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administration of ciltacabtagene autoleucel (cilta-cel) versus VRd induction followed by Lenalidomide and Dexamethasone (Rd) maintenance in newly diagnosed multiple myeloma participants for whom ASCT is not planned as initial therapy in terms of Progression Free Survival (PFS).",NO,Multiple Myeloma,DRUG: Bortezomib|DRUG: Dexamethasone|DRUG: Lenalidomide|DRUG: Cilta-cel|DRUG: Cyclophosphamide|DRUG: Fludarabine,"Progression Free Survival (PFS), Progression-free survival is defined as the time from the date of randomization to the date of first documented Progressive Disease (PD), as defined in the International Myeloma Working Group (IMWG) criteria, or death due to any cause, whichever occurs first., Up to 4 years and 5 months","Sustained Minimal Residual Disease (MRD) Negative CR, Sustained MRD negative complete response (CR) as determined by next generation sequencing (NGS) with sensitivity of 10\^-5, and defined by MRD negative CR plus at least 12 months durability of the MRD negative CR status., Up to 12 years and 5 months|MRD Negative CR at 9 Months, MRD negative CR rate at 9 months is defined as the percentage of participants who achieve MRD negative CR status at 9Â±3 months after the randomization date., 9 months|Overall MRD Negative CR, Overall MRD negative is defined as the percentage of participants who achieve MRD negativity at any time after the date of randomization before initiation of subsequent therapy., Up to 12 years and 5 months|Overall Survival (OS), Overall survival is measured from the date of randomization to the date of the participant's death., Up to 12 years and 5 months|Complete Response or Better, CR or better is defined as percentage of participants who achieve a CR response or Stringent Complete Response (sCR) response according to the IMWG criteria., Up to 12 years and 5 months|Time to Subsequent Anti-myeloma Therapy, Time to subsequent anti-myeloma therapy is defined as the time from randomization to the start of subsequent anti-myeloma therapy., Up to 12 years and 5 months|Progression Free Survival on Next-line Therapy (PFS2), PFS2 is defined as the time interval between the date of randomization and date of event, which is defined as PD as assessed by investigator that starts after the next line of subsequent therapy, or death from any cause, whichever occurs first., Up to 12 years and 5 months|Number of Participants with Adverse Events (AEs), Abnormalities in Laboratory Parameters, 12-Lead Electrocardiogram (ECG), Physical Examination, and Vital Signs, Number of participants with AEs, abnormalities in laboratory parameters (complete blood count \[CBC\] with differential, coagulation, chimeric antigen receptor T cell \[CAR-T\] chemistry, full metabolic panel etc.), 12-lead ECG, physical examination, and vital signs will be reported., Up to 12 years and 5 months|Arm B: Systemic Cytokine Concentrations, Serum or plasma proteomic profiling of cytokines (such as interleukin \[IL\] 6, IL-15, and IL 10) concentrations will be measured for biomarker assessment., Up to Day 112|Arm B: Levels of Chimeric Antigen Receptor T cell (CAR-T) Cell Activation Markers, CAR-T cell activation markers including, but not limited to, CD4+, CD8+, CD25+, central memory, effector memory cells will be reported. An evaluation of cell populations may be performed by flow cytometry, cytometry by time of flight (CyTOF), single cell RNA sequencing (scRNAseq) or similar technologies and be correlated with response., Up to 12 years and 5 months|Arm B: Levels of Soluble B-cell Maturation Antigen (BCMA), Levels of soluble BCMA will be reported., Up to 1 year|Arm B: Levels of Cilta-cel Expansion (proliferation), and Persistence, Levels of cilta-cel expansion (proliferation), and persistence via monitoring CAR-T positive cell counts and CAR transgene level will be reported., Up to 12 years and 5 months|Arm B: Number of Participants with Anti-cilta-cel Antibodies, Number of participants with anti-cilta-cel antibodies will be reported., Up to 12 years and 5 months|Arm B: Number of Participants with Presence of Replication Competent Lentivirus, Number of participants with presence of replication competent lentivirus will be reported., Up to 12 years and 5 months|Change from Baseline in Health-Related Quality of Life (HRQoL) as Assessed by European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC-QLQ-C30) Scale Score, The EORTC QLQ-C30 includes 30 items in 5 functional scales (physical, role, emotional, cognitive, and social), 1 global health status scale, 3 symptom scales (pain, fatigue, nausea/vomiting), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The responses are reported using a verbal rating scale. The item and scale scores are transformed to a 0 to 100 scale. A higher score represents greater HRQoL, better functioning, and more (worse) symptoms., Baseline up to 12 years and 5 months|Change from Baseline in Health-Related Quality of Life as Assessed by MySIm-Q Scale Score, The MySIm-Q is a disease-specific PRO assessment complementary to the EORTC-QLQ-C30. It includes 17 items with recall period of ""7 days"" and responses are reported on a 5-point verbal rating scale. Item responses are scored from 0 to 4. Higher scores indicate greater severity/impact., Baseline up to 12 years and 5 months|Change from Baseline in Health-Related Quality of Life as Assessed by European Quality of Life - 5 Dimensions-5 Levels (EQ-5D-5L) Scale Score, The EQ-5D-5L is a generic measure of health status. The EQ-5D-5L is a 5-item questionnaire that assesses 5 domains including mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of the 5 dimensions is divided into 5 levels of perceived problems, where Level 1: no problem, Level 2: slight problems, Level 3: moderate problems, Level 4: severe problems and Level 5: extreme problems, plus a visual analog scale rating ""health today"" with anchors ranging from 0 (worst imaginable health state) to 100 (best imaginable health state)., Baseline up to 12 years and 5 months|Change from Baseline in Health-Related Quality of Life as Assessed by Patient Global Impression of Symptom Severity (PGIS) Scale Score, The PGIS uses 2 items to assess the participant's perception of the severity of their disease symptoms and impact using a 5-point verbal rating scale. Score ranges from 1 (None) to 5 (Very Severe)., Baseline up to 12 years and 5 months|Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Items, The National Cancer Institute's PRO-CTCAE is an item library of common adverse events experienced by people with cancer that are appropriate for self-reporting. Each symptom selected for inclusion can be rated by up to 3 attributes characterizing the presence/frequency, severity, and/or interference that ranges from 0 to 4 with higher scores indicating higher frequency or greater severity/impact., Up to 161 days|Time to Worsening of Symptoms, Functioning and Overall Well-being, Time to worsening is measured as the interval from the date of randomization to the start date of worsening in MySIm-Q symptom, impact, or total scores., Up to 12 year and 5 months",,"Janssen Research & Development, LLC",,ALL,"ADULT, OLDER_ADULT",PHASE3,743,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-08-19,2026-06-11,2034-12-13,2021-06-11,,2025-05-23,"UCSF, San Francisco, California, 94143, United States|Yale Cancer Center, New Haven, Connecticut, 06510, United States|University of Miami Health System, Miami, Florida, 33136, United States|AdventHealth Cancer Institute, Orlando, Florida, 32832, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, 52242, United States|University of Kentucky, Lexington, Kentucky, 40536-0293, United States|Norton Cancer Institute, Louisville, Kentucky, 40207, United States|University Of Maryland Medical Center, Baltimore, Maryland, 21201-1595, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, 48201, United States|Henry Ford Cancer Institute, Detroit, Michigan, 48202-2608, United States|Columbia University Medical Center, New York, New York, 10032, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, 10065, United States|New York Presbyterian-Weill Cornell Medical College, New York, New York, 10065, United States|Levine Cancer Institute, Charlotte, North Carolina, 28204, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, 19107, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, 15232, United States|University of Virginia, Charlottesville, Virginia, 22903, United States|Medical College Of Wisconsin, Milwaukee, Wisconsin, 53226, United States|Hospital Aleman, Buenos Aires, C1118AAT, Argentina|Hospital Italiano de Buenos Aires, Buenos Aires, C1199ABD, Argentina|Hospital Privado Universitario De Cordoba, Cordoba, 5016, Argentina|Royal Prince Alfred Hospital, Camperdown, 2050, Australia|St Vincents Hospital Melbourne, Fitzroy, 3065, Australia|Austin Health, Heidelberg, 3084, Australia|Royal Brisbane and Womens Hospital, Herston, 4029, Australia|Alfred Health, Melbourne, 3004, Australia|Peter MacCallum Cancer Centre, Melbourne, 8006, Australia|Fiona Stanley Hospital, Murdoch, 6150, Australia|Calvary Mater Newcastle Hospital, Waratah, 2298, Australia|Western Sydney Local Health District, Westmead, 2145, Australia|Medizinische UniversitÃ¤t Graz, LKH-Univ.Klinikum Graz, Klinische Abteilung fÃ¼r HÃ¤matologie, Graz, 8036, Austria|Krankenhaus der Elisabethinen Linz, Linz, 4020, Austria|LKH - UniversitÃ¤tsklinikum der PMU Salzburg, Salzburg, 5020, Austria|Medical University of Vienna Universitatsklinik fur Innere Medizin I, Vienna, 1090, Austria|Universitair Ziekenhuis - Antwerpen, Antwerp, 2650, Belgium|AZ St.-Jan Brugge-Oostende AV, Brugge, 8000, Belgium|UZ Gent, Gent, 9000, Belgium|UZ Leuven, Leuven, 3000, Belgium|Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman, Liege, B-4000, Belgium|Hospital Sao Rafael, Salvador, 41253-190, Brazil|Fundacao Antonio Prudente A C Camargo Cancer Center, Sao Paulo, 01509 900, Brazil|Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein, Sao Paulo, 05652 900, Brazil|Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta, T2N 5G2, Canada|Vancouver General Hospital, Vancouver, British Columbia, V5Z 1M9, Canada|Juravinski Cancer Centre, Hamilton, Ontario, L8V5C2, Canada|Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, M5G2M9, Canada|Hopital Maisonneuve Rosemont, Montreal, Quebec, H1T 2M4, Canada|Fakultni nemocnice Brno, Brno, 625 00, Czechia|Fakultni nemocnice Hradec Kralove, Hradec Kralove, 500 05, Czechia|Fakultni Nemocnice Ostrava, Ostrava - Poruba, 708 52, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, 128 08, Czechia|Aarhus University Hospital, Aarhus C, 8000, Denmark|Rigshospitalet, Copenhagen, 2100, Denmark|Odense Universitetshospital, Odense C, 5000, Denmark|Helsinki University Hospital, Helsinki, 00029 HUS, Finland|Oulu University Hospital, Oulu, 90220, Finland|Turku University Hospital, Turku, 20520, Finland|Centre Hospitalier RÃ©gional Universitaire de Lille, HÃ´pital Claude Huriez, Lille Cedex, 59000, France|C.H.U. Hotel Dieu - France, Nantes, 44093, France|Hopital Saint Louis, Paris cedex 10, 75475, France|CHU Poitiers - Hopital la Miletrie, Poitiers, 86021, France|Institut Universitaire du cancer de Toulouse-Oncopole, Toulouse cedex 9, 31059, France|CharitÃ© - UniversitÃ¤tsmedizin Berlin, Campus Benjamin Franklin, Berlin, 12203, Germany|Universitaetsklinikum Carl Gustav Carus TU Dresden, Dresden, 01307, Germany|Universitatsklinikum Freiburg, Freiburg, 79106, Germany|Universitaetsklinikum Hamburg Eppendorf, Hamburg, 20246, Germany|Universitaetsklinikum Heidelberg, Heidelberg, 69120, Germany|Universitaetsklinikum Leipzig, Leipzig, 04103, Germany|Universitatsmedizin der Johannes Gutenberg Universitat Mainz, Mainz, 55131, Germany|Klinikum GroÃhadern der Ludwig-Maximilians-UniversitÃ¤t, MÃ¼nchen, 81377, Germany|Universitaetsklinikum Regensburg, Regensburg, 93053, Germany|Klinikum der Eberhard Karls Universitaet Abt fur innere Med II Haematologie Onkologie Germany, Tubingen, 72076, Germany|Universitatsklinikum Wurzburg, Wuerzburg, 97080, Germany|Alexandra General Hospital of Athens, Athens, 11528, Greece|Attikon University General Hospital of Attica, Athens, 12462, Greece|G.Papanikolaou, Thessaloniki, 57010, Greece|Del Pesti Centrumkorhaz Orszagos Hematologiai es Infektologiai Intezet Szent Laszlo Telephely, Budapest, 1097, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, 4032, Hungary|St James Hospital, Dublin, D08 NHY1, Ireland|Hadassah University Hospita Ein Kerem, Jerusalem, P.O.B. 12000, Israel|Sheba Medical Center Tel Hashomer, Ramat Gan, 52621, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, 64239, Israel|Juntendo University Hospital, Bunkyo Ku, 113 8431, Japan|Kyushu University Hospital, Fukuoka, 812 8582, Japan|Hyogo Medical University Hospital, HyÃ´go, 663-8501, Japan|Kanazawa University Hospital, Kanazawa, 920 8641, Japan|University Hospital Kyoto Prefectural University of Medicine, Kyoto, 602-8566, Japan|Nagoya City University Hospital, Nagoya, 467 8602, Japan|Okayama University Hospital, Okayama, 700 8558, Japan|Hokkaido University Hospital, Sapporo, 060-8648, Japan|Tohoku University Hospital, Sendai, 980 8574, Japan|Japanese Red Cross Medical Center, Shibuya, 150-8935, Japan|Chonnam National University Hwasun Hospital, Jeollanam-do, 58128, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Severance Hospital Yonsei University Health System, Seoul, 03722, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|The Catholic University of Korea Seoul St Marys Hospital, Seoul, 06591, Korea, Republic of|VU Medisch Centrum, Amsterdam, 1081 HV, Netherlands|University Medical Center Groningen, Groningen, 9713 GZ, Netherlands|UMC Radboud, Nijmegen, 6500 HB, Netherlands|Erasmus MC, Rotterdam, 3075 EA, Netherlands|Oslo universitetssykehus HF, Rikshospitalet, Oslo, 0372, Norway|Uniwersyteckie Centrum Kliniczne, Gdansk, 80 214, Poland|Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut BadawczyOddz w Gliwicach, Gliwice, 44102, Poland|Centrum Onkologii Ziemi Lubelskiej im sw Jana z Dukli, Lublin, 20 090, Poland|Uniwersytecki Szpital Kliniczny w Poznaniu, Poznan, 60-569, Poland|Instytut Hematologii i Transfuzjologii, Warszawa, 02 776, Poland|Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we Wroclawiu, Wroclaw, 50 367, Poland|Instituto Portugues de Oncologia, Lisboa, 1099-023, Portugal|Instituto Portugues de Oncologia, Porto, 4200072, Portugal|Hosp. de La Santa Creu I Sant Pau, Barcelona, 08025, Spain|Hosp Univ Vall D Hebron, Barcelona, 8035, Spain|Instituto Catalan Deoncologia Hospital Duran I Reynals, L'Hospitalet de Llobregat, 08908, Spain|Hosp. Gral. Univ. Gregorio Maranon, Madrid, 28007, Spain|Hosp. Univ. 12 de Octubre, Madrid, 28041, Spain|Hosp. Univ. Virgen de La Arrixaca, Murcia, 30120, Spain|Clinica Univ. de Navarra, Pamplona, 31008, Spain|Hosp Clinico Univ de Salamanca, Salamanca, 37007, Spain|Hosp. Univ. Marques de Valdecilla, Santander, 39008, Spain|Hosp. Virgen Del Rocio, Sevilla, 41013, Spain|Hosp. Univ. I Politecni La Fe, Valencia, 46026, Spain|Sahlgrenska University Hospital, Goteborg, 413 45, Sweden|Universitetssjukhuset, LinkÃ¶ping, 58185, Sweden|Skane University Hospital, Lund, 221 85, Sweden|Universitatsspital Basel, Basel, 4031, Switzerland|Inselspital Universitatsspital Bern, Bern, 3010, Switzerland|Kantonsspital St Gallen, St. Gallen, 9007, Switzerland|University Hospitals Birmingham NHS Trust,, Birmingham, B15 2TH, United Kingdom|Bristol Royal Infirmary, Bristol, BS2 8BJ, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, LS9 7TF, United Kingdom|University College Hospital, London, NW1 2BU, United Kingdom|Kings College Hospital, London, SE5 9RS, United Kingdom|Manchester Royal Infirmary, Manchester, M13 9WL, United Kingdom|The Royal Marsden NHS Trust Sutton, Surrey, SM2 5PT, United Kingdom",
NCT05774951,A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy,https://clinicaltrials.gov/study/NCT05774951,CAMBRIA-1,RECRUITING,This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.,NO,"Breast Cancer, Early Breast Cancer",DRUG: Camizestrant|DRUG: Tamoxifen|DRUG: Anastrozole|DRUG: Letrozole|DRUG: Exemestane,"Invasive breast cancer-free survival (IBCFS), IBCFS is defined as time from randomisation until date of first occurrence of:

* Invasive ipsilateral breast tumour recurrence (invasive IBTR)
* Locoregional invasive breast cancer recurrence
* Distant recurrence
* Invasive contralateral breast cancer
* Death attributable to any cause., Up to 10 years","Invasive disease-free survival (IDFS), IDFS is defined as time from randomisation until date of first occurrence of one of the following events:

* Invasive ipsilateral breast tumor recurrence (invasive IBTR)
* Locoregional invasive breast cancer recurrence
* Distant recurrence
* Invasive contralateral breast cancer
* Second primary non-breast invasive cancer
* Death attributable to any cause., Up to 10 years|Distant relapse-free survival (DRFS), DRFS is defined as time from randomisation until date of first distant recurrence or death from any cause, whichever occurs first., Up to 10 years|Overall survival (OS), OS is defined as time from randomisation until death from any cause., Up to 10 years|Incidence and Severity of Adverse Events, with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI-CTCAE v5.0), Until 28 days after the final dose of study treatment (up to 5 years)|Absolute and percent change from baseline in Clinical Laboratory Parameters, Until 28 days after the final dose of study treatment (up to 5 years)|Absolute and percent change from baseline in Vital Sign Parameters, Until 28 days after the final dose of study treatment (up to 5 years)|Number of participants with abnormal physical examinations, Until 28 days after the final dose of study treatment (up to 5 years)|Change from baseline of arthralgia as measured by the EORTC-IL-194 (European Organisation for Research and Treatment of Cancer) item 10. EORTC-IL-194 uses 0 - 4 scale (higher score is worse), Until 28 days after the final dose of study treatment (up to 5 years)|Change from baseline of hot flush as measured by the EORTC-IL-194 item 4. EORTC-IL-194 uses 0 - 4 scale (higher score is worse), Until 28 days after the final dose of study treatment (up to 5 years)|Change from baseline of vaginal dryness as measured by the EORTC-IL-194 item 15. EORTC-IL-194 uses 0 - 4 scale (higher score is worse), Until 28 days after the final dose of study treatment (up to 5 years)|Proportion of patients experiencing each level of symptomatic AEs of arthralgia as measured by the EORTC-IL-194 item 10. EORTC-IL-194 uses 0 - 4 scale (higher score is worse), Until 28 days after the final dose of study treatment (up to 5 years)|Proportion of patients experiencing each level of symptomatic AEs of hot flush as measured by the EORTC-IL-194 item 4. EORTC-IL-194 uses 0 - 4 scale (higher score is worse), Until 28 days after the final dose of study treatment (up to 5 years)|Proportion of patients experiencing each level of symptomatic AEs of vaginal dryness as measured by the EORTC-IL-194 item 15. EORTC-IL-194 uses 0 - 4 scale (higher score is worse), Until 28 days after the final dose of study treatment (up to 5 years)|Change from baseline and TTD (time to deterioration ) of health-related QoL (quality of life) as measured by the 2 global QoL items from the EORTC-QLQ-C30 items 11 and 12. EORTC-QLQ-C30 uses 0 - 4 scale (higher score is worse), Until 28 days after the final dose of study treatment (up to 5 years)|Pharmacokinetics (PK), â¢ Plasma concentrations of camizestrant pre-dose (Ctrough)( trough concentration), Until 6 months from treatment start",,AstraZeneca,,ALL,"ADULT, OLDER_ADULT",PHASE3,4300,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-03-31,2027-04-20,2036-05-29,2023-03-20,,2025-05-18,"Research Site, Birmingham, Alabama, 35205, United States|Research Site, Dothan, Alabama, 36303, United States|Research Site, Anchorage, Alaska, 99508, United States|Research Site, Chandler, Arizona, 85224, United States|Research Site, Hot Springs National Park, Arkansas, 71913, United States|Research Site, Anaheim, California, 92801, United States|Research Site, Beverly Hills, California, 90211, United States|Research Site, Concord, California, 94520, United States|Research Site, Corona, California, 92882, United States|Research Site, Fountain Valley, California, 92708, United States|Research Site, Greenbrae, California, 94904, United States|Research Site, Los Alamitos, California, 90720, United States|Research Site, Palo Alto, California, 94304, United States|Research Site, San Diego, California, 92121, United States|Research Site, San Diego, California, 92123, United States|Research Site, Whittier, California, 90603, United States|Research Site, Aurora, Colorado, 80045, United States|Research Site, Hartford, Connecticut, 06102, United States|Research Site, Fort Myers, Florida, 33901, United States|Research Site, Gainesville, Florida, 32603, United States|Research Site, Miami Beach, Florida, 33140, United States|Research Site, Orlando, Florida, 32806, United States|Research Site, Plantation, Florida, 33324, United States|Research Site, Port Saint Lucie, Florida, 34952, United States|Research Site, Saint Augustine, Florida, 32086, United States|Research Site, Saint Petersburg, Florida, 33705, United States|Research Site, Saint Petersburg, Florida, 33709, United States|Research Site, Tallahassee, Florida, 32308, United States|Research Site, West Palm Beach, Florida, 33401, United States|Research Site, Winter Haven, Florida, 33880, United States|Research Site, Atlanta, Georgia, 30310, United States|Research Site, Atlanta, Georgia, 30318, United States|Research Site, Columbus, Georgia, 31904, United States|Research Site, Honolulu, Hawaii, 96813, United States|Research Site, Chicago, Illinois, 60608, United States|Research Site, Chicago, Illinois, 60637, United States|Research Site, Decatur, Illinois, 62526, United States|Research Site, Elmhurst, Illinois, 60126, United States|Research Site, Hinsdale, Illinois, 60521, United States|Research Site, Park Ridge, Illinois, 60068, United States|Research Site, Fort Wayne, Indiana, 46804, United States|Research Site, Iowa City, Iowa, 52242, United States|Research Site, Fort Mitchell, Kentucky, 41017, United States|Research Site, Lexington, Kentucky, 40536, United States|Research Site, Louisville, Kentucky, 40202, United States|Research Site, Baton Rouge, Louisiana, 70809, United States|Research Site, Brewer, Maine, 04412, United States|Research Site, Scarborough, Maine, 04074, United States|Research Site, Frederick, Maryland, 21702, United States|Research Site, Glenn Dale, Maryland, 20769, United States|Research Site, Silver Spring, Maryland, 20910, United States|Research Site, Towson, Maryland, 21204, United States|Research Site, Boston, Massachusetts, 02111, United States|Research Site, Hyannis, Massachusetts, 02601, United States|Research Site, Ann Arbor, Michigan, 48109, United States|Research Site, Detroit, Michigan, 48202, United States|Research Site, East Lansing, Michigan, 48824, United States|Research Site, Lansing, Michigan, 48910, United States|Research Site, Royal Oak, Michigan, 48073, United States|Research Site, Independence, Missouri, 64057, United States|Research Site, Lincoln, Nebraska, 68506, United States|Research Site, Las Vegas, Nevada, 89148, United States|Research Site, Laconia, New Hampshire, 03246, United States|Research Site, Belleville, New Jersey, 07109, United States|Research Site, Farmington, New Mexico, 87401, United States|Research Site, Santa Fe, New Mexico, 87505, United States|Research Site, Bronx, New York, 10461, United States|Research Site, East Syracuse, New York, 13057, United States|Research Site, New Hyde Park, New York, 11042, United States|Research Site, New York, New York, 10011, United States|Research Site, New York, New York, 10019, United States|Research Site, New York, New York, 10029, United States|Research Site, Stony Brook, New York, 11794, United States|Research Site, White Plains, New York, 10601, United States|Research Site, Charlotte, North Carolina, 28204, United States|Research Site, Durham, North Carolina, 27710-0001, United States|Research Site, Greensboro, North Carolina, 27403, United States|Research Site, Raleigh, North Carolina, 27607, United States|Research Site, Rocky Mount, North Carolina, 27804, United States|Research Site, Winston-Salem, North Carolina, 27103, United States|Research Site, Winston-Salem, North Carolina, 27104, United States|Research Site, Cincinnati, Ohio, 45219, United States|Research Site, Cincinnati, Ohio, 45255, United States|Research Site, Cleveland, Ohio, 44106, United States|Research Site, Cleveland, Ohio, 44195, United States|Research Site, Youngstown, Ohio, 44504, United States|Research Site, Clairton, Pennsylvania, 15025, United States|Research Site, Philadelphia, Pennsylvania, 19106, United States|Research Site, Philadelphia, Pennsylvania, 19111, United States|Research Site, Pittsburgh, Pennsylvania, 15213, United States|Research Site, Reading, Pennsylvania, 19611, United States|Research Site, State College, Pennsylvania, 16803, United States|Research Site, Providence, Rhode Island, 02903, United States|Research Site, Lancaster, South Carolina, 29720, United States|Research Site, Spartanburg, South Carolina, 29303, United States|Research Site, Aberdeen, South Dakota, 57401, United States|Research Site, Mitchell, South Dakota, 57301, United States|Research Site, Pierre, South Dakota, 57501, United States|Research Site, Sioux Falls, South Dakota, 57105, United States|Research Site, Yankton, South Dakota, 57078, United States|Research Site, Chattanooga, Tennessee, 37404, United States|Research Site, Knoxville, Tennessee, 37920, United States|Research Site, Nashville, Tennessee, 37203, United States|Research Site, Nashville, Tennessee, 37204, United States|Research Site, Dallas, Texas, 75230, United States|Research Site, Denton, Texas, 76201, United States|Research Site, Houston, Texas, 77024, United States|Research Site, Houston, Texas, 77030, United States|Research Site, Irving, Texas, 75063, United States|Research Site, Ogden, Utah, 84405, United States|Research Site, Salt Lake City, Utah, 84106, United States|Research Site, Fairfax, Virginia, 22031, United States|Research Site, Lynchburg, Virginia, 24501, United States|Research Site, Midlothian, Virginia, 23114, United States|Research Site, Reston, Virginia, 20190, United States|Research Site, Richmond, Virginia, 23235, United States|Research Site, Seattle, Washington, 98101, United States|Research Site, Seattle, Washington, 98104, United States|Research Site, Spokane, Washington, 99202, United States|Research Site, Tacoma, Washington, 98405, United States|Research Site, Charleston, West Virginia, 25304, United States|Research Site, Morgantown, West Virginia, 26505, United States|Research Site, Appleton, Wisconsin, 54911, United States|Research Site, Madison, Wisconsin, 53792, United States|Research Site, Milwaukee, Wisconsin, 53226, United States|Research Site, Buenos Aires, C1426ANZ, Argentina|Research Site, Buenos Aires, C1430EGF, Argentina|Research Site, Caba, C1119ACN, Argentina|Research Site, Capital Federal, C1417DTB, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, C1118AAT, Argentina|Research Site, Ciudad AutÃ³noma Buenos Aires, 1125, Argentina|Research Site, Ciudad de Buenos Aires, 1280, Argentina|Research Site, Cordoba, 5000, Argentina|Research Site, Cordoba, 5001, Argentina|Research Site, La Plata, 1900, Argentina|Research Site, Mar del Plata, 7600, Argentina|Research Site, Salta, A4400EMI, Argentina|Research Site, San Juan, 5400, Argentina|Research Site, San Miguel de Tucuman, T4000IAK, Argentina|Research Site, San Miguel de TucumÃ¡n, 4000, Argentina|Research Site, Viedma, R8500ACE, Argentina|Research Site, Birtinya, 4575, Australia|Research Site, Brighton, 3186, Australia|Research Site, Concord, 2139, Australia|Research Site, Nedlands, 6009, Australia|Research Site, Nedlands, 6009, Australia|Research Site, Randwick, 2031, Australia|Research Site, Tweed Heads, 2485, Australia|Research Site, Waratah, 2298, Australia|Research Site, Wendouree, 3355, Australia|Research Site, Graz, 8036, Austria|Research Site, Innsbruck, 6020, Austria|Research Site, Klagenfurt, 9020, Austria|Research Site, Kufstein, 6330, Austria|Research Site, Linz, 4010, Austria|Research Site, Ried, 4910, Austria|Research Site, St. Veit an der Glan, 9300, Austria|Research Site, Steyr, 4400, Austria|Research Site, Vienna, 1090, Austria|Research Site, Voecklabruck, 4840, Austria|Research Site, Wein, 1130, Austria|Research Site, Wels, 4600, Austria|Research Site, Wien, 1090, Austria|Research Site, Wien, 1180, Austria|Research Site, Brasschaat, 2930, Belgium|Research Site, Brussel, 1090, Belgium|Research Site, Edegem, 2650, Belgium|Research Site, Gent, 9000, Belgium|Research Site, Leuven, 8500, Belgium|Research Site, Liege, 4000, Belgium|Research Site, Mons, 7000, Belgium|Research Site, Ottignies, 1340, Belgium|Research Site, Wilrijk, 2610, Belgium|Research Site, Yvoir, 5530, Belgium|Research Site, Alfenas, 37130-000, Brazil|Research Site, Barretos, 14784-400, Brazil|Research Site, Belo Horizonte, 30130-100, Brazil|Research Site, Belo Horizonte, 30150-274, Brazil|Research Site, Brasilia, 70390-700, Brazil|Research Site, Brasilia, 71681-603, Brazil|Research Site, Chapeco, 89812-220, Brazil|Research Site, CuiabÃ¡, 78040-400, Brazil|Research Site, Curitiba, 80810-050, Brazil|Research Site, Curitiba, 81520-060, Brazil|Research Site, Fortaleza, 60170-170, Brazil|Research Site, Fortaleza, 60430-230, Brazil|Research Site, Lajeado, 95900000, Brazil|Research Site, Londrina, 86015-520, Brazil|Research Site, Natal, 59075-740, Brazil|Research Site, NiterÃ³i, 24020-096, Brazil|Research Site, Piracicaba, 13419-155, Brazil|Research Site, Porto Alegre, 90035-001, Brazil|Research Site, Porto Alegre, 90035-903, Brazil|Research Site, Porto Alegre, 90050-170, Brazil|Research Site, Porto Alegre, 90610000, Brazil|Research Site, Porto Alegre, 90880-480, Brazil|Research Site, Pouso Alegre, 37554-216, Brazil|Research Site, Recife, 50070-070, Brazil|Research Site, RibeirÃ£o Preto, 14051-140, Brazil|Research Site, Rio de Janeiro, 20560-120, Brazil|Research Site, Rio de Janeiro, 22250-905, Brazil|Research Site, Rio De Janeiro, 22290-160, Brazil|Research Site, Salvador, 40110-060, Brazil|Research Site, Salvador, 41253-190, Brazil|Research Site, Sao Paulo, 01246-000, Brazil|Research Site, Sao Paulo, 01317-001, Brazil|Research Site, Sao Paulo, 01508-010, Brazil|Research Site, Sao Paulo, 01509-900, Brazil|Research Site, SÃ£o Paulo, 01236-030, Brazil|Research Site, SÃ£o Paulo, 01321-001, Brazil|Research Site, SÃ£o Paulo, 01323-001, Brazil|Research Site, SÃ£o Paulo, 03102-002, Brazil|Research Site, SÃ£o Paulo, 08270-070, Brazil|Research Site, TaubatÃ©, 12030-200, Brazil|Research Site, Tres Lagoas, 79601-001, Brazil|Research Site, VitÃ³ria, 29055-450, Brazil|Research Site, Dobrich, 9300, Bulgaria|Research Site, Plovdiv, 4002, Bulgaria|Research Site, Plovdiv, 4002, Bulgaria|Research Site, Plovdiv, 4004, Bulgaria|Research Site, Sofia, 1330, Bulgaria|Research Site, Sofia, 1407, Bulgaria|Research Site, Sofia, 1431, Bulgaria|Research Site, Sofia, 1606, Bulgaria|Research Site, Sofia, 1784, Bulgaria|Research Site, Vratsa, 3000, Bulgaria|Research Site, Calgary, Alberta, T2N 4N2, Canada|Research Site, Kelowna, British Columbia, V1Y 5L3, Canada|Research Site, Winnipeg, Manitoba, R3E 0V9, Canada|Research Site, Barrie, Ontario, L4M 6M2, Canada|Research Site, Ottawa, Ontario, K1H 8L6, Canada|Research Site, Sault Ste. Marie, Ontario, P6A 0A8, Canada|Research Site, Toronto, Ontario, M5G 1X5, Canada|Research Site, Windsor, Ontario, N8W 2X3, Canada|Research Site, Chicoutimi, Quebec, G7H 5H6, Canada|Research Site, Greenfield Park, Quebec, J4V 2H1, Canada|Research Site, Montreal, Quebec, H1T 2M4, Canada|Research Site, Montreal, Quebec, H2X 3E4, Canada|Research Site, Montreal, Quebec, H4A 3J1, Canada|Research Site, Saint-Jerome, Quebec, J7Z 5T3, Canada|Research Site, Concepcion, 4070196, Chile|Research Site, La Serena, 1720430, Chile|Research Site, Puerto Montt, 5500243, Chile|Research Site, Santiago, 8150215, Chile|Research Site, Santiago, 8330032, Chile|Research Site, Santiago, 8330336, Chile|Research Site, Talca, 3460000, Chile|Research Site, Temuco, 4780000, Chile|Research Site, Vina del Mar, 2520000, Chile|Research Site, Baoding, 071000, China|Research Site, Beijing, 100005, China|Research Site, Beijing, 100021, China|Research Site, Beijing, 100044, China|Research Site, Beijing, 100142, China|Research Site, Beijing, China|Research Site, Changchun, 130021, China|Research Site, Changsha, 410008, China|Research Site, Chengdu, 610000, China|Research Site, Chengdu, 610041, China|Research Site, Chengdu, 610072, China|Research Site, Chifeng, 024000, China|Research Site, Dalian, 116023, China|Research Site, Foshan, 528000, China|Research Site, Fuzhou, 350001, China|Research Site, Fuzhou, 350011, China|Research Site, Guangzhou Shi, 510168, China|Research Site, Guangzhou, 510060, China|Research Site, Guangzhou, 510120, China|Research Site, Haikou, 570102, China|Research Site, Haikou, 570311, China|Research Site, Hangzhou, 310003, China|Research Site, Hangzhou, 310009, China|Research Site, Hangzhou, 310020, China|Research Site, Hangzhou, 310022, China|Research Site, Harbin, 150081, China|Research Site, Hefei, 230001, China|Research Site, Hefei, 230012, China|Research Site, Hefei, 230601, China|Research Site, Hohhot, 010010, China|Research Site, Huangpu District, 200025, China|Research Site, Ji Nan, 2501117, China|Research Site, Lanzhou, 730050, China|Research Site, Liuzhou, 545005, China|Research Site, Nanchang, 330009, China|Research Site, Nanjing, 210009, China|Research Site, Nanjing, 210029, China|Research Site, Nanning, 530021, China|Research Site, Nanning, 530021, China|Research Site, Neijiang, 641000, China|Research Site, Qingdao, 266100, China|Research Site, Shanghai, 200032, China|Research Site, Shanghai, 200127, China|Research Site, Shantou, 515031, China|Research Site, Shaoguan, 512027, China|Research Site, Shenyang, 110016, China|Research Site, Shenyang, China|Research Site, Shijiazhuang, 050020, China|Research Site, Suining, 629000, China|Research Site, Suzhou, 215006, China|Research Site, Taiyuan, 030000, China|Research Site, Taizhou, 317000, China|Research Site, Tianjin, 300060, China|Research Site, Weifang, 261000, China|Research Site, Wuhan, 430022, China|Research Site, Wuhan, 430070, China|Research Site, Wuhan, 430079, China|Research Site, Xiangfan, 441021, China|Research Site, Xining, 810001, China|Research Site, Xinxiang, 453100, China|Research Site, Xuzhou, 221000, China|Research Site, Xuzhou, 221009, China|Research Site, Yanji, 133000, China|Research Site, Yantai, 264000, China|Research Site, Zhengzhou, 450052, China|Research Site, Barranquilla, 080020, Colombia|Research Site, Barranquilla, 80020, Colombia|Research Site, Bogota, 110221, Colombia|Research Site, Bogota, 111511, Colombia|Research Site, Cali, 760042, Colombia|Research Site, Floridablanca, 681004, Colombia|Research Site, Medellin, 50030, Colombia|Research Site, Monteria, 23001, Colombia|Research Site, Pereira, Colombia|Research Site, Valledupar, 200001, Colombia|Research Site, Horovice, 268 31, Czechia|Research Site, Pardubice, 532 03, Czechia|Research Site, Pragues, 18081, Czechia|Research Site, Praha 4, 140 00, Czechia|Research Site, Praha, 15006, Czechia|Research Site, Pribram, 261 01, Czechia|Research Site, Angers Cedex 01, 49055, France|Research Site, Argenteuil, 95100, France|Research Site, Avignon, 84918, France|Research Site, Bordeaux Cedex, 33000, France|Research Site, Bordeaux CÃ©dex, 33077, France|Research Site, Bourg en Bresse, 01012, France|Research Site, Caen cedex 05, 14076, France|Research Site, Cholet, 49300, France|Research Site, Clermont Ferrand, 63011, France|Research Site, Dijon, 21079, France|Research Site, Epagny Metz-Tessy, 74370, France|Research Site, Lille, 59000, France|Research Site, Lorient cedex, 56322, France|Research Site, Lyon, 69008, France|Research Site, Marseille, 13273, France|Research Site, Metz Cedex 03, 57085, France|Research Site, Montpellier, 34070, France|Research Site, Montpellier, 34298, France|Research Site, Nantes, 44202, France|Research Site, Nimes, 30029, France|Research Site, Paris, 75010, France|Research Site, Paris, 75013, France|Research Site, Pierre Benite, 69310, France|Research Site, Plerin SUR MER, 22190, France|Research Site, Poitiers, 86021, France|Research Site, Quimper Cedex, 29107, France|Research Site, Rennes, 35042, France|Research Site, Saint Cloud, 92210, France|Research Site, Saint Herblain Cedex, 44805, France|Research Site, St-Priest-en-Jarez, 42270, France|Research Site, Suresnes Cedex, 92151, France|Research Site, Toulouse, 31059, France|Research Site, Tours CEDEX, 37044, France|Research Site, Villejuif, 94805, France|Research Site, Batumi, 6400, Georgia|Research Site, Tbilisi, 0179, Georgia|Research Site, Tbilisi, 112, Georgia|Research Site, Tbilisi, 160, Georgia|Research Site, Tbilisi, 186, Georgia|Research Site, Aachen, 52074, Germany|Research Site, Augsburg, 86150, Germany|Research Site, Bayreuth, 95445, Germany|Research Site, Berlin, 10317, Germany|Research Site, Berlin, 12623, Germany|Research Site, Bonn, 53111, Germany|Research Site, Deggendorf, 94469, Germany|Research Site, Dessau-Rosslau, 6847, Germany|Research Site, Dresden, 01307, Germany|Research Site, DÃ¼sseldorf, 40225, Germany|Research Site, DÃ¼sseldorf, 40235, Germany|Research Site, Eggenfelden, 84307, Germany|Research Site, Esslingen, 73730, Germany|Research Site, Georgsmarienhuette, 49124, Germany|Research Site, Guetersloh, 33332, Germany|Research Site, Hamburg, 20259, Germany|Research Site, Hamburg, 21073, Germany|Research Site, Heidelberg, 69120, Germany|Research Site, Kiel, 24105, Germany|Research Site, Landshut, 84036, Germany|Research Site, Luebeck, 23562, Germany|Research Site, Mainz, 55131, Germany|Research Site, Memmingen, 87700, Germany|Research Site, MÃ¼nchen, 80637, Germany|Research Site, Ravensburg, 88212, Germany|Research Site, RÃ¼sselsheim am Main, 65428, Germany|Research Site, Stralsund, 18439, Germany|Research Site, Torgau, 4860, Germany|Research Site, Trier, 54290, Germany|Research Site, Ulm, 89075, Germany|Research Site, Velbert, 42551, Germany|Research Site, Wiesbaden, 65189, Germany|Research Site, Wiesbaden, 65199, Germany|Research Site, Worms, 67550, Germany|Research Site, Wuppertal, 42283, Germany|Research Site, Athens, 11528, Greece|Research Site, Athens, 15123, Greece|Research Site, Athens, 18537, Greece|Research Site, Chaidari, 124 62, Greece|Research Site, Heraklion, 71110, Greece|Research Site, Ioannina, 45500, Greece|Research Site, Rio, 265 04, Greece|Research Site, Thessaloniki, 546 39, Greece|Research Site, Thessaloniki, 54631, Greece|Research Site, Thessaloniki, 54645, Greece|Research Site, Thessaloniki, 57001, Greece|Research Site, Budapest, 1083, Hungary|Research Site, Budapest, 1106, Hungary|Research Site, Budapest, 1115, Hungary|Research Site, Budapest, 1122, Hungary|Research Site, Debrecen, 4032, Hungary|Research Site, Gyula, 5700, Hungary|Research Site, GyÅr, 9024, Hungary|Research Site, KaposvÃ¡r, 7400, Hungary|Research Site, Miskolc, 3526, Hungary|Research Site, NyÃ­regyhÃ¡za, 4400, Hungary|Research Site, SzekszÃ¡rd, 7100, Hungary|Research Site, Szolnok, 5000, Hungary|Research Site, Bangalore, 560027, India|Research Site, Bangalore, 560076, India|Research Site, Belagavi, 590010, India|Research Site, Bhubaneswar, 751019, India|Research Site, Hubli, 580029, India|Research Site, Hyderabad, 500082, India|Research Site, Jaipur, 302017, India|Research Site, Kolkata, 700020, India|Research Site, Mumbai, 400 012, India|Research Site, Nagpur, 440026, India|Research Site, Nashik, 422005, India|Research Site, New Delhi, 110 085, India|Research Site, New Delhi, 110005, India|Research Site, New Delhi, 110076, India|Research Site, Pune, 411001, India|Research Site, Pune, 411004, India|Research Site, Thane, 401107, India|Research Site, Visakhapatnam, 530040, India|Research Site, West Bengal, 700 156, India|Research Site, Afula, 1834111, Israel|Research Site, Ashdod, 7747629, Israel|Research Site, Haifa, 31096, Israel|Research Site, Jerusalem, 00000, Israel|Research Site, Jerusalem, 9103102, Israel|Research Site, Kfar-Saba, 4428164, Israel|Research Site, Nahariya, 22100, Israel|Research Site, Ramat Gan, 52621, Israel|Research Site, Rehovot, 7661041, Israel|Research Site, Tel Aviv, 69710, Israel|Research Site, Bari, 70124, Italy|Research Site, Catania, 95126, Italy|Research Site, Catanzaro, 88100, Italy|Research Site, Firenze, 50134, Italy|Research Site, Genova, 16132, Italy|Research Site, Grosseto, 58100, Italy|Research Site, Milano, 20132, Italy|Research Site, Milan, 20141, Italy|Research Site, Modena, 41125, Italy|Research Site, Napoli, 80131, Italy|Research Site, Pisa, 56126, Italy|Research Site, Reggio Emilia, 42122, Italy|Research Site, Roma, 00168, Italy|Research Site, Rozzano, 20089, Italy|Research Site, Turin, 10128, Italy|Research Site, Chiba-shi, 260-8717, Japan|Research Site, Chuo-ku, 104-8560, Japan|Research Site, Fukuoka-shi, 811-1395, Japan|Research Site, Fukushima-shi, 960-1295, Japan|Research Site, Hidaka-shi, 350-1298, Japan|Research Site, Hirakata-shi, 573-1191, Japan|Research Site, Hiroshima-shi, 730-0011, Japan|Research Site, Isehara-shi, 259-1193, Japan|Research Site, Kagoshima-shi, 892-0833, Japan|Research Site, Kashiwa, 227-8577, Japan|Research Site, Kitaadachi-gun, 362-0806, Japan|Research Site, Koto-ku, 135-8550, Japan|Research Site, Kumamoto-shi, 860-8556, Japan|Research Site, Kurume-shi, 830-0013, Japan|Research Site, Kyoto-shi, 606-8507, Japan|Research Site, Matsuyama-shi, 791-0280, Japan|Research Site, Nagoya-shi, 464-8681, Japan|Research Site, Nagoya-shi, 466-8560, Japan|Research Site, Nagoya-shi, 467-0001, Japan|Research Site, Niigata-shi, 951-8566, Japan|Research Site, Oita-shi, 870-8511, Japan|Research Site, Osaka-shi, 533-0024, Japan|Research Site, Osaka-shi, 540-0006, Japan|Research Site, Osaka-shi, 541-8567, Japan|Research Site, Ota-shi, 373-8550, Japan|Research Site, Sagamihara-shi, 252-0375, Japan|Research Site, Sapporo, 060-8648, Japan|Research Site, Sendai-shi, 980-8574, Japan|Research Site, Shinagawa-ku, 142-8666, Japan|Research Site, Suita-shi, 565-0871, Japan|Research Site, Sunto-gun, 411-8777, Japan|Research Site, Takasaki-shi, 370-0829, Japan|Research Site, Tsu-shi, 514-8507, Japan|Research Site, Yokohama-shi, 241-8515, Japan|Research Site, Busan, 48108, Korea, Republic of|Research Site, Daegu, 42601, Korea, Republic of|Research Site, Donggu, 44033, Korea, Republic of|Research Site, Goyang-si, 10408, Korea, Republic of|Research Site, Jeonnam, 58128, Korea, Republic of|Research Site, Seongbuk-Gu, 2841, Korea, Republic of|Research Site, Seoul, 03080, Korea, Republic of|Research Site, Seoul, 03722, Korea, Republic of|Research Site, Seoul, 06273, Korea, Republic of|Research Site, Seoul, 06351, Korea, Republic of|Research Site, Seoul, 06591, Korea, Republic of|Research Site, Seoul, 08308, Korea, Republic of|Research Site, Seoul, 158-710, Korea, Republic of|Research Site, George Town, 10350, Malaysia|Research Site, Georgetown, 10450, Malaysia|Research Site, Johor Bahru, 81100, Malaysia|Research Site, Kota Bharu, 16150, Malaysia|Research Site, Kuala Lumpur, 50300, Malaysia|Research Site, Kuala Lumpur, 50450, Malaysia|Research Site, Kuala Lumpur, 50603, Malaysia|Research Site, Kuching, 93586, Malaysia|Research Site, Melaka, 75000, Malaysia|Research Site, Sabah, 88996, Malaysia|Research Site, Aguascalientes, 20230, Mexico|Research Site, Alc. CuauhtÃ©moc, 06100, Mexico|Research Site, Colonia Lindavista, 7300, Mexico|Research Site, Mexico City, 03310, Mexico|Research Site, Mexico, 14080, Mexico|Research Site, Mexico, 14080, Mexico|Research Site, Mexico, 6700, Mexico|Research Site, Monterrey, 64060, Mexico|Research Site, Monterrey, 64460, Mexico|Research Site, Monterrey, 64460, Mexico|Research Site, MÃ©rida, 97300, Mexico|Research Site, San Luis PotosÃ­, 78250, Mexico|Research Site, Toluca, 50180, Mexico|Research Site, Veracruz, 91900, Mexico|Research Site, Veracruz, 91910, Mexico|Research Site, Dirksland, 3247 BW, Netherlands|Research Site, Geleen, 6162 BG, Netherlands|Research Site, Groningen, 9728 NT, Netherlands|Research Site, Hoofddorp, 2134 TM, Netherlands|Research Site, Rotterdam, 3079 DZ, Netherlands|Research Site, Rotterdam, 3083 AN, Netherlands|Research Site, Arequipa, 04001, Peru|Research Site, Arequipa, 04001, Peru|Research Site, Arequipa, 4001, Peru|Research Site, Arequipa, AREQUIPA01, Peru|Research Site, Callao, 7021, Peru|Research Site, La Libertad, 13013, Peru|Research Site, Lima, 0051, Peru|Research Site, Lima, 15076, Peru|Research Site, Lima, Lima 32, Peru|Research Site, Lima, Lima 34, Peru|Research Site, Trujillo, Peru|Research Site, Bacolod, 6100, Philippines|Research Site, Cebu, 6000, Philippines|Research Site, Iloilo city, 5000, Philippines|Research Site, Manila, 1000, Philippines|Research Site, Quezon City, 0870, Philippines|Research Site, Quezon City, 1101, Philippines|Research Site, Quezon City, 1112, Philippines|Research Site, BiaÅystok, 15-027, Poland|Research Site, Grudziadz, 86-300, Poland|Research Site, Koszalin, 75-581, Poland|Research Site, Lublin, 20-718, Poland|Research Site, Opole, 45-061, Poland|Research Site, PoznaÅ, 61-485, Poland|Research Site, RacibÃ³rz, 47-400, Poland|Research Site, RzeszÃ³w, 35-021, Poland|Research Site, Warszawa, 02-781, Poland|Research Site, Wieliszew, 05-135, Poland|Research Site, ÅÃ³dÅº, 90-302, Poland|Research Site, Amadora, 2720-276, Portugal|Research Site, Braga, 4710-243, Portugal|Research Site, GuimarÃ£es, 4835-044, Portugal|Research Site, Lisboa, 1649-035, Portugal|Research Site, Lisboa, 1998-018, Portugal|Research Site, Matosinhos, 4454-509, Portugal|Research Site, Porto, 4100-180, Portugal|Research Site, Porto, 4200-072, Portugal|Research Site, Porto, 4200-319, Portugal|Research Site, Vila Nova de Gaia, 4434-502, Portugal|Research Site, Baia Mare, 430031, Romania|Research Site, Brasov, 500283, Romania|Research Site, Cluj Napoca, 400015, Romania|Research Site, Cluj-Napoca, 400641, Romania|Research Site, Constanta, 900591, Romania|Research Site, Craiova, 200094, Romania|Research Site, Craiova, 200347, Romania|Research Site, Craiova, 200385, Romania|Research Site, Floresti, 407280, Romania|Research Site, Iasi, 700106, Romania|Research Site, Oradea, 410167, Romania|Research Site, Pitesti, 110283, Romania|Research Site, Sibiu, 550245, Romania|Research Site, Timisoara, 300166, Romania|Research Site, Timisoara, 300239, Romania|Research Site, Belgrade, 11080, Serbia|Research Site, Belgrad, 11000, Serbia|Research Site, Beograd, 11010, Serbia|Research Site, Kragujevac, 34000, Serbia|Research Site, Nis, 18000, Serbia|Research Site, Sremska Kamenica, 21204, Serbia|Research Site, Valjevo, 14000, Serbia|Research Site, Zrenjanin, 23000, Serbia|Research Site, Singapore, 119074, Singapore|Research Site, Singapore, 228510, Singapore|Research Site, Singapore, 308433, Singapore|Research Site, Singapore, 329563, Singapore|Research Site, Amanzimtoti, 4126, South Africa|Research Site, Bloemfontein, 9301, South Africa|Research Site, Bloemfontein, 9301, South Africa|Research Site, George, 6529, South Africa|Research Site, Johannesburg, 2193, South Africa|Research Site, Johannesburg, 2196, South Africa|Research Site, Pietermaritzburg, 3201, South Africa|Research Site, Pretoria, 0084, South Africa|Research Site, Pretoria, 31, South Africa|Research Site, Soweto, 2193, South Africa|Research Site, A CoruÃ±a, 15006, Spain|Research Site, A CoruÃ±a, 15009, Spain|Research Site, Albacete, 02006, Spain|Research Site, Alcoy, 3804, Spain|Research Site, Alicant, 3015, Spain|Research Site, Alzira, 46600, Spain|Research Site, Badajoz, 06080, Spain|Research Site, Badalona, 08003, Spain|Research Site, Badalona, 08916, Spain|Research Site, Barakaldo, 48903, Spain|Research Site, Barcelona, 08028, Spain|Research Site, Barcelona, 08036, Spain|Research Site, Barcelona, 8035, Spain|Research Site, CÃ¡ceres, 10003, Spain|Research Site, Elche(Alicante), 03202, Spain|Research Site, Galdakao, 48960, Spain|Research Site, Gerona, 17007, Spain|Research Site, Granada, 18007, Spain|Research Site, Granada, 18014, Spain|Research Site, Jerez De La Frontera (CÃ¡diz), 11407, Spain|Research Site, L'Hospitalet de Llobregat, 08908, Spain|Research Site, LeganÃ©s, 28911, Spain|Research Site, LÃ©rida, 25198, Spain|Research Site, Madrid, 28033, Spain|Research Site, Madrid, 28040, Spain|Research Site, Madrid, 28050, Spain|Research Site, Majadahonda, 28222, Spain|Research Site, Manresa, 8242, Spain|Research Site, Murcia, 30008, Spain|Research Site, Oviedo, 33011, Spain|Research Site, Parla, 28981, Spain|Research Site, Puerto De Sagunto, 46520, Spain|Research Site, Reus,Tarragona, 43204, Spain|Research Site, Salamanca, 37007, Spain|Research Site, San Juan de Alicante, 03550, Spain|Research Site, San SebastiÃ¡n, 20014, Spain|Research Site, Santander, 39008, Spain|Research Site, Sevilla, 41009, Spain|Research Site, Sevilla, 41013, Spain|Research Site, Teruel, 44001, Spain|Research Site, Toledo, 45007, Spain|Research Site, Valencia, 46009, Spain|Research Site, Valencia, 46015, Spain|Research Site, Valencia, 46017, Spain|Research Site, Hsinchu, 300, Taiwan|Research Site, Kaohsiung, 82445, Taiwan|Research Site, Taichung, 40447, Taiwan|Research Site, Tainan City, 70403, Taiwan|Research Site, Tainan, 710, Taiwan|Research Site, Taipei City, 110, Taiwan|Research Site, Taipei, 10002, Taiwan|Research Site, Taipei, 11259, Taiwan|Research Site, Bangkok, 10400, Thailand|Research Site, Bangkok, 10700, Thailand|Research Site, Khon Kaen, 40002, Thailand|Research Site, Phisanulok, 65000, Thailand|Research Site, Phitsanulok, 65000, Thailand|Research Site, Rachathewi, 10400, Thailand|Research Site, Songkla, 90110, Thailand|Research Site, Ankara, 06100, Turkey|Research Site, Ankara, 06200, Turkey|Research Site, Ankara, 06520, Turkey|Research Site, Ankara, 06620, Turkey|Research Site, Ankara, 6800, Turkey|Research Site, Aydin, 9010, Turkey|Research Site, Bursa, 16059, Turkey|Research Site, Dinar, 03400, Turkey|Research Site, Istambul, 34218, Turkey|Research Site, Istanbul, 34010, Turkey|Research Site, Istanbul, 34899, Turkey|Research Site, Ä°zmir, 35120, Turkey|Research Site, Izmir, 35150, Turkey|Research Site, Izmir, 35530, Turkey|Research Site, Izmir, 35575, Turkey|Research Site, Samsun, 55200, Turkey|Research Site, Brighton, BN2 5BE, United Kingdom|Research Site, Burton-on-Trent, DE13 0RB, United Kingdom|Research Site, Cambridge, CB2 0QQ, United Kingdom|Research Site, Derby, DE22 3NE, United Kingdom|Research Site, Edinburgh, EH4 2XU, United Kingdom|Research Site, Guildford, United Kingdom|Research Site, Ipswich, IP4 5PD, United Kingdom|Research Site, Keighley, BD20 6TD, United Kingdom|Research Site, London, SE1 9RT, United Kingdom|Research Site, London, SW3 6JJ, United Kingdom|Research Site, Manchester, M20 4BX, United Kingdom|Research Site, Oxford, OX3 7LJ, United Kingdom|Research Site, Peterborough, PE3 9GZ, United Kingdom|Research Site, Stoke on Trent, ST4 6QG, United Kingdom|Research Site, Sutton, SM2 5PT, United Kingdom|Research Site, Hanoi, 100000, Vietnam|Research Site, Ho Chi Minh city, 700000, Vietnam|Research Site, Ho Chi Minh, 700000, Vietnam|Research Site, Ho Chi Minh, 70000, Vietnam|Research Site, Hue, 530000, Vietnam",
NCT05207514,Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer,https://clinicaltrials.gov/study/NCT05207514,,TERMINATED,"Phase III Clinical Trial to Compare the Efficacy and the Safety of AC(Doxorubicin, Cyclophosphamide) Followed by 4 Cycles Taxotere Versus AC(Doxorubicin, Cyclophosphamide) Followed by 4 Cycles Nanoxel M as Neoadjuvant Chemotherapy in Patients With Breast Cancer",NO,Breast Cancer,DRUG: Nanoxel M|DRUG: Taxotere|DRUG: Doxorubicin|DRUG: Cyclophosphamide,"Pathological complete response (pCR) rate using the definition of ypT0/Tis ypN0, H \& E staining of tissues obtained from breast and axillary lymph nodes was defined as the absence of invasive cancer, and the proportion of subjects was determined., at the time of definitive surgery",,,Samyang Biopharmaceuticals Corporation,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,26,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-03-31,2024-02-07,2024-05-09,2022-01-26,,2024-05-17,"Sevrance Hospital, Seoul, Korea, Republic of",
NCT04956692,Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86),https://clinicaltrials.gov/study/NCT04956692,,ACTIVE_NOT_RECRUITING,"The purpose of this study is to evaluate pembrolizumab (MK-3475) subcutaneous (SC) administration as the first-line therapy in the treatment of metastatic squamous and nonsquamous NSCLC by assessing the pharmacokinetics (PK), safety, and efficacy of pembrolizumab SC injection in combination with standard-of-care chemotherapy. The primary hypothesis of the study is Pembrolizumab SC is noninferior to pembrolizumab intravenous (IV) for Cycle 1 Area Under Curve (AUC) and Cycle 6 minimal concentration (Ctrough) at steady state.

Participants who discontinue study treatment after receiving the first course of 35 administrations of pembrolizumab (approximately up to 2 years) for reasons other than disease progression or intolerability, may be eligible for a second course of pembrolizumab for up to approximately 1 additional year if they have experienced radiographic disease progression per RECIST 1.1 as assessed by BICR after stopping first course treatment.",YES,Non-Small Cell Lung Cancer,BIOLOGICAL: Pembrolizumab SC|BIOLOGICAL: Pembrolizumab IV|DRUG: Paclitaxel|DRUG: Nab-Paclitaxel|DRUG: Carboplatin|DRUG: Cisplatin|DRUG: Pemetrexed,"Cycle 1 Area Under The Curve From 0-3 Weeks (AUC 0-3wks) of Pembrolizumab, Cycle 1 AUC0-3wks is defined as the area under the concentration-time curve for pembrolizumab in plasma over a 3-week dosing interval in Cycle 1. Each cycle is 21 days., Cycle 1: predose and postdose day 1; days 2, 3, 4, 5, 6, 7, 10, and 15. Cycle 2: predose day 1. Each cycle is 21 days.|Cycle 6 Model-Based Minimal Concentration (Ctrough) of Pembrolizumab, Cycle 6 model-based Ctrough is defined as the lowest concentration of pembrolizumab in plasma at the end of the dosing interval in Cycle 6, as predicted by the pharmacokinetic (PK) model based on historical intravenous pembrolizumab PK data. Each cycle is 21 days., Cycle 6: predose day 1; days 2, 3, 4, 5, 6, 7, 10, and 15. Cycle 7: predose day 1. Each cycle is 21 days.","Objective Response (OR) Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR), The OR rate is defined as the percentage of participants who achieve a confirmed complete response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by BICR., Up to approximately 5 years|Cycle 1 Observed Ctrough of Pembrolizumab, Cycle 1 observed Ctrough is defined as the lowest observed concentration of pembrolizumab in plasma at the end of the dosing interval in Cycle 1. Each cycle is 21 days., Predose Cycle 2 day 1. Each cycle is 21 days.|Cycle 1 Maximum Concentration (Cmax) of Pembrolizumab, Cycle 1 Cmax is defined as the observed peak concentration of pembrolizumab in plasma over the dosing interval in Cycle 1. Each cycle is 21 days., Cycle 1: predose day 1; days 2, 3, 4, 5, 6, 7, 10, and 15. Cycle 2: predose day 1. Each cycle is 21 days.|Cycle 6 AUC 0-3wks of Pembrolizumab, Cycle 6 AUC0-3wks is defined as the area under the concentration-time curve for pembrolizumab in plasma over a 3-week dosing interval in Cycle 6. Each cycle is 21 days., Cycle 6: predose and postdose day 1; days 2, 3, 4, 5, 6, 7, 10, and 15. Cycle 7: predose day 1. Each cycle is 21 days.|Cycle 6 Cmax of Pembrolizumab, Cmax in Cycle 6 is defined as the observed peak concentration of pembrolizumab in plasma over the dosing interval in Cycle 6. Each cycle is 21 days., Cycle 6: predose and postdose day 1; days 2, 3, 4, 5, 6, 7, 10, and 15. Cycle 7: predose day 1. Each cycle is 21 days.|Cycle 6 Observed Ctrough of Pembrolizumab, Cycle 6 observed Ctrough is defined as the lowest observed concentration of pembrolizumab in plasma at the end of the dosing interval in Cycle 6. Each cycle is 21 days., Predose Cycle 7 day 1. Each cycle is 21 days.|Number of Participants Who Experienced an Adverse Event (AE), An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experience an AE will be reported., Up to approximately 28 months|Number of Participants Who Discontinued Study Treatment Due to an AE, An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. The number of participants who discontinue study treatment due to an AE will be presented., Up to approximately 25 months|Progression-Free Survival (PFS) Per RECIST 1.1 as Assessed by BICR, PFS is defined as the time from randomization to the first documented PD per RECIST 1.1 by BICR or death due to any cause, whichever occurs first. PD is defined as â¥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of â¥5 mm. The appearance of one or more new lesions is also considered PD., Up to approximately 5 years|Overall Survival (OS), OS is defined as the time from randomization to death due to any cause., Up to approximately 5 years|Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR, For participants who show confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, duration of response is defined as the time from the first documented evidence of CR or PR until disease progression (PD) per RECIST 1.1 by BICR or death due to any cause, whichever occurs first. PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD., Up to approximately 5 years|Anti-Drug Antibodies (ADAs) Incidence After Administration of Pembrolizumab, ADA incidence will be assessed by analyzing the development of ADAs following administration of pembrolizumab SC and pembrolizumab IV., Up to approximately 26 months",,Merck Sharp & Dohme LLC,,ALL,"ADULT, OLDER_ADULT",PHASE3,531,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-08-05,2023-04-04,2026-10-14,2021-07-09,2024-05-17,2024-12-03,"St. Bernards Medical Center ( Site 0103), Jonesboro, Arkansas, 72401, United States|St Joseph Heritage Healthcare-Oncology ( Site 0102), Fullerton, California, 92835, United States|Cancer Blood and Specialty Clinic ( Site 0105), Los Alamitos, California, 90720, United States|PIH Health Hematology Medical Oncology ( Site 0106), Whittier, California, 90602, United States|Holy Cross Hospital ( Site 0017), Fort Lauderdale, Florida, 33308, United States|Memorial Regional Hospital-Memorial Cancer Institute ( Site 0104), Hollywood, Florida, 33021, United States|Advent Health ( Site 0013), Orlando, Florida, 32804, United States|Fort Wayne Medical Oncology and Hematology ( Site 0101), Fort Wayne, Indiana, 46804, United States|Baptist Health Lexington ( Site 0099), Lexington, Kentucky, 40503, United States|St Luke's Hospital - Kansas City ( Site 0033), Kansas City, Missouri, 64111, United States|St. Vincent Frontier Cancer Center ( Site 0058), Billings, Montana, 59102, United States|Montefiore Medical Center [Bronx, NY] ( Site 0040), Bronx, New York, 10461, United States|The University of Tennessee Medical Center ( Site 0050), Knoxville, Tennessee, 37920, United States|Tennessee Oncology ( Site 0051), Nashville, Tennessee, 37203, United States|Oncology Consultants, PA ( Site 0052), Houston, Texas, 77030, United States|Millennium Physicians - Oncology ( Site 0097), Houston, Texas, 77090, United States|Oncology & Hematology Assoc. SW Virginia, Inc., DBA Blue Ridge Cancer Care ( Site 0100), Blacksburg, Virginia, 24060, United States|West Virginia University ( Site 0056), Morgantown, West Virginia, 26506, United States|HOSPITAL EVANGÃLICO DE CACHOEIRO DE ITAPEMIRIM ( Site 0307), Cachoeiro de Itapemirim, Espirito Santo, 29308-065, Brazil|Hospital Sao Vicente de Paulo ( Site 0311), Passo Fundo, Rio Grande Do Sul, 99010-080, Brazil|Instituto Joinvilense de Hematologia e Oncologia ( Site 0308), Joinville, Santa Catarina, 89201260, Brazil|Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto ( Site 0305), Sao Jose do Rio Preto, Sao Paulo, 15090-000, Brazil|NÃºcleo de Pesquisa ClÃ­nica da Rede SÃ£o Camilo ( Site 0304), SÃ£o Paulo, Sao Paulo, 04014-002, Brazil|Nouvel HÃ´pital Civil (NHC) ( Site 1018), Strasbourg, Bas-Rhin, 67091, France|CHU Limoges CHU Dupuytren ( Site 1011), Limoges, Haute-Vienne, 87042, France|HÃ´pital Foch ( Site 1019), Suresnes, Hauts-de-Seine, 92150, France|Institut Regional du Cancer de Montpellier - ICM ( Site 1003), Montpellier, Herault, 34298, France|Centre Hospitalier Sud RÃ©union ( Site 1020), Saint-Pierre, La Reunion, 97448, France|Hopital Guillaume & Rene Laennec ( Site 1007), Saint-Herblain, Loire-Atlantique, 44800, France|Centre Hospitalier de Pau ( Site 1016), Pau, Pyrenees-Atlantiques, 64000, France|CHU de Rouen ( Site 1013), Rouen, Seine-Maritime, 76031, France|Hopital Cochin ( Site 1002), Paris, 75014, France|Centro de Investigaciones Clinicas de Latinoamerica S.A. - CELAN ( Site 0602), Guatemala, 01010, Guatemala|Clinica Privada Dr. Rixci Ramirez ( Site 0601), Guatemala, 01010, Guatemala|INTERVASC ( Site 0605), Guatemala, 01010, Guatemala|Grupo Angeles SA ( Site 0604), Guatemala, 01015, Guatemala|Centro Regional de Sub Especialidades MÃ©dicas SA ( Site 0600), Quetzaltenango, 09001, Guatemala|Bacs-Kiskun Megyei Korhaz-Onkoradiologiai Kozpont ( Site 1106), KecskemÃ©t, Bacs-Kiskun, 6000, Hungary|Petz Aladar Megyei Oktato Korhaz ( Site 1110), Gyor, Gyor-Moson-Sopron, 9023, Hungary|Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ( Site 1103), Szolnok, Jasz-Nagykun-Szolnok, 5000, Hungary|Tudogyogyintezet Torokbalint ( Site 1105), Torokbalint, Pest, 2045, Hungary|Veszprem Megyei Tudogyogyintezet ( Site 1108), Farkasgyepu, Veszprem, 8582, Hungary|Zala Megyei Szent Rafael Korhaz ( Site 1111), Zalagerszeg, Zalaegerszeg, 8900, Hungary|Semmelweis University-PulmonolÃ³giai Klinika ( Site 1114), Budapest, 1083, Hungary|Orszagos Koranyi Pulmonologiai Intezet ( Site 1104), Budapest, 1121, Hungary|Fujita Health University Hospital ( Site 3007), Toyoake, Aichi, 4701192, Japan|Ehime University Hospital ( Site 3005), Toon, Ehime, 791-0295, Japan|Kurume University Hospital ( Site 3006), Kurume, Fukuoka, 830-0011, Japan|National Hospital Organization Hokkaido Cancer Center ( Site 3014), Sapporo, Hokkaido, 003-0804, Japan|Kanazawa University Hospital ( Site 3004), Kanazawa, Ishikawa, 920-8641, Japan|Kanagawa Cardiovascular and Respiratory Center ( Site 3003), Yokohama, Kanagawa, 236-0051, Japan|Miyagi Cancer Center ( Site 3000), Natori, Miyagi, 981-1293, Japan|Sendai Kousei Hospital ( Site 3015), Sendai, Miyagi, 980-0873, Japan|Kurashiki Central Hospital ( Site 3013), Kurashiki, Okayama, 710-8602, Japan|Kansai Medical University Hospital ( Site 3016), Hirakata, Osaka, 573-1191, Japan|National Hospital Organization Kinki-chuo Chest Medical Center ( Site 3009), Sakai, Osaka, Japan|Osaka Medical and Pharmaceutical University Hospital ( Site 3017), Takatsuki, Osaka, 569-8686, Japan|Chiba University Hospital ( Site 3008), Chiba, 260-8677, Japan|National Hospital Organization Kyushu Medical Center ( Site 3001), Fukuoka, 810-8563, Japan|National Hospital Organization Kyushu Cancer Center ( Site 3002), Fukuoka, 811-1395, Japan|Okayama University Hospital ( Site 3012), Okayama, 7008558, Japan|Osaka International Cancer Institute ( Site 3018), Osaka, 541-8567, Japan|Tokushima University Hospital ( Site 3019), Tokushima, 770-8503, Japan|Juntendo University Hospital ( Site 3011), Tokyo, 113-8431, Japan|Showa University Hospital ( Site 3010), Tokyo, 142-8666, Japan|Chungnam National University Hospital ( Site 2002), Daejeon, Chungnam, 35015, Korea, Republic of|Chonnam National University Hwasun Hospital-Pulmonology ( Site 2000), Hwasun, Jeonranamdo, 58128, Korea, Republic of|Korea University Guro Hospital ( Site 2003), Seoul, 08308, Korea, Republic of|Hospital Nacional Carlos Alberto Seguin Escobedo ESSALUD ( Site 0704), Arequipa, Ariqipa, 04001, Peru|ClÃ­nica Peruano-Americana de Trujillo ( Site 0701), Trujillo, La Libertad, 13007, Peru|Oncosalud ( Site 0706), Lima, Muni Metro De Lima, 15036, Peru|Clinica Internacional Sede San Borja ( Site 0705), Lima, 15036, Peru|Instituto Nacional de Enfermedades Neoplasicas ( Site 0703), Lima, 15038, Peru|Hospital Nacional Cayetano Heredia ( Site 0700), Lima, 15102, Peru|Centrum Onkologii im prof Franciszka Lukaszczyka ( Site 1201), Bydgoszcz, Kujawsko-pomorskie, 85-796, Poland|Mazowiecki Szpital WojewÃ³dzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 1206), Siedlce, Mazowieckie, 08-110, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (, Warszawa, Mazowieckie, 02-781, Poland|Centrum Pulmonologii i Torakochirurgii w Bystrej ( Site 1205), Bystra, Slaskie, 43-360, Poland|Przychodnia Lekarska KOMED ( Site 1202), Konin, Wielkopolskie, 62-500, Poland|Szpital Wojewodzki im. Mikolaja Kopernika ( Site 1200), Koszalin, Zachodniopomorskie, 75-581, Poland|Cardiomed SRL Cluj-Napoca ( Site 1313), Cluj-Napoca, Cluj, 400015, Romania|Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 1303), Cluj-Napoca, Cluj, 400015, Romania|SC Radiotherapy Center Cluj SRL ( Site 1307), Comuna Floresti, Cluj, 407280, Romania|S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 1304), Craiova, Dolj, 200347, Romania|Centrul de Oncologie Oncolab-Medical Oncology ( Site 1312), Craiova, Dolj, 200385, Romania|Spitalul Municipal Ploiesti ( Site 1308), Ploiesti, Prahova, 100337, Romania|Policlinica Oncomed SRL ( Site 1302), Timisoara, Timis, 300239, Romania|S.C.Focus Lab Plus S.R.L ( Site 1301), Bucuresti, 022548, Romania|Spitalul Universitar de Urgenta Bucuresti ( Site 1305), Bucuresti, 050098, Romania|SPBU Clinic of Advanced medical technologies n.a. N. I. Pirogov ( Site 1406), Saint-Petersburg, Sankt-Peterburg, 190103, Russian Federation|National Medical Research Center of Oncology N.A. N.N. Petrov ( Site 1407), Saint-Petersburg, Sankt-Peterburg, 197758, Russian Federation|Saint-Petersburg Scientific-Practical Center of Specialized Kinds of Medical Care (o) ( Site 1424), Saint-Petersburg, Sankt-Peterburg, 197758, Russian Federation|Republican Clinical Oncology Dispensary-Chemotherapy #1 ( Site 1425), Kazan, Tatarstan, Respublika, 420029, Russian Federation|SPb SBHI City Clinical Oncological Dispensary ( Site 1409), Sankt-Peterburg, 198255, Russian Federation|Wits Clinical Research ( Site 1510), Johannesburg, Gauteng, 2193, South Africa|Steve Biko Academic Hospital ( Site 1506), Pretoria, Gauteng, 0002, South Africa|Marry Potter Oncology Centre ( Site 1502), Pretoria, Gauteng, 0181, South Africa|Sandton Oncology Medical Group PTY LTD ( Site 1505), Sandton, Gauteng, 2196, South Africa|Chris Hani Baragwanath Academic Hospital-Wits Clinical Research Bara ( Site 1513), Soweto, Gauteng, 2013, South Africa|The Oncology Centre ( Site 1507), Durban, Limpopo, 4001, South Africa|Cape Town Oncology Trials Pty Ltd ( Site 1500), Kraaifontein, Western Cape, 7570, South Africa|Hospital Insular de Gran Canaria-Oncology ( Site 1604), Las Palmas de Gran Canaria, Las Palmas, 35001, Spain|H.U. Vall de Hebron ( Site 1600), Barcelona, 08035, Spain|Hospital Juan Ramon Jimenez ( Site 1602), Huelva, 21005, Spain|Hospital Universitario Lucus Augusti ( Site 1603), Lugo, 27003, Spain|Hospital Universitario La Paz ( Site 1601), Madrid, 28046, Spain|Changhua Christian Hospital ( Site 2104), Changhua, 50006, Taiwan|National Taiwan University Hospital Hsin-Chu Branch ( Site 2103), Hsinchu, 300, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital ( Site 2107), Kaohsiung, 807, Taiwan|National Cheng Kung University Hospital ( Site 2105), Tainan, 704, Taiwan|National Taiwan University Hospital ( Site 2101), Taipei, 10048, Taiwan|Taipei Veterans General Hospital ( Site 2106), Taipei, 11217, Taiwan|Chang Gung Medical Foundation-Linkou Branch ( Site 2102), Taoyuan, 333, Taiwan|Gulhane Egitim ve Arastirma Hastanesi ( Site 1704), Ankara, 06010, Turkey|Ankara Sehir Hastanesi ( Site 1702), Ankara, 06800, Turkey|TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 1701), Istanbul, 34722, Turkey|Ege Universitesi Tip Fakultesi Hastanesi ( Site 1703), Izmir, 35040, Turkey|Inonu Universitesi Turgut Ozal Tip Merkezi ( Site 1707), Malatya, 44280, Turkey|Medical Center Mriya Med-Service ( Site 1805), Kryvyi Rih, Dnipropetrovska Oblast, 50000, Ukraine|Communal non profit enterprise Regional Clinical Oncology Center ( Site 1806), Kharkiv, Kharkivska Oblast, 61070, Ukraine|Ukrainian Center of Tomotherapy ( Site 1807), Kropyvnytskyi, Kirovohradska Oblast, 25011, Ukraine|Medical Center Asklepion LLC ( Site 1804), Khodosivka, Kyivska Oblast, 08173, Ukraine|Municipal non-profit enterprise'Odesa Regional Clinical Hosp-Thoracic surgery department. ( Site 181, Odesa, Odeska Oblast, 65025, Ukraine|Kremenchuk Regional Oncology Center ( Site 1811), Kremenchuk, Poltavska Oblast, 39617, Ukraine|Kyiv City Clinical Oncology Centre ( Site 1809), Kyiv, 03115, Ukraine|Medical Center Dobrobut Clinic ( Site 1808), Kyiv, 03151, Ukraine","Study Protocol and Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/92/NCT04956692/Prot_SAP_000.pdf"
NCT05624554,"A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)",https://clinicaltrials.gov/study/NCT05624554,,ACTIVE_NOT_RECRUITING,"Researchers are looking for new ways to treat people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are types of blood cancer. Researchers want to know if people who take nemtabrutinib compared to those who take the standard treatments in this study will live longer without their cancer growing, spreading or returning (progression free survival).",NO,Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,DRUG: Nemtabrutinib|DRUG: Fludarabine|DRUG: Cyclophosphamide|DRUG: Bendamustine|BIOLOGICAL: Rituximab|BIOLOGICAL: Truxima|BIOLOGICAL: Ruxience|BIOLOGICAL: Riabni,"Progression-Free Survival (PFS) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria 2018 as Assessed by Blinded Independent Central Review (BICR), PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. PD is evaluated per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria 2018 as assessed by blinded independent central review (BICR)., Up to approximately 49 months","Overall Survival (OS), OS is defined as the time from randomization to death due to any cause., Up to approximately 94 months|Objective Response Rate (ORR) per iwCLL Criteria 2018 as Assessed by BICR, ORR is defined as the percentage of participants with complete response (CR), complete response with an incomplete recovery of the participant's bone marrow (CRi), nodular partial response (nPR), or Partial response (PR), per iwCLL criteria 2018 as assessed by BICR., Up to approximately 36 months|Duration of Response (DOR) per iwCLL Criteria 2018 as Assessed by BICR, For participants who demonstrate a CR, CRi, nPR, or PR per iwCLL criteria as assessed by BICR, DOR is defined as the time from the first documented evidence of CR, CRi, nPR, or PR that led to response until disease progression or death due to any cause, whichever occurs first., Up to approximately 94 months|Number of Participants Who Experience an Adverse Event (AE), An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention., Up to approximately 94 months|Number of Participants Who Discontinue Study Treatment Due to an AE, An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention., Up to approximately 94 months",,Merck Sharp & Dohme LLC,,ALL,"ADULT, OLDER_ADULT",PHASE3,300,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-03-16,2027-05-19,2031-03-17,2022-11-22,,2024-12-24,"Highlands Oncology Group ( Site 5205), Springdale, Arkansas, 72762, United States|Clermont Oncology Center ( Site 5224), Clermont, Florida, 34711, United States|Hattiesburg Clinic Hematology/Oncology ( Site 5216), Hattiesburg, Mississippi, 39401, United States|Medical Oncology Associates, PS ( Site 5206), Spokane, Washington, 99208, United States|Royal Adelaide Hospital ( Site 1105), Adelaide, South Australia, 5000, Australia|Hospital Erasto Gaertner-CEPEP - Pesquisa ClÃ­nica ( Site 1317), Curitiba, Parana, 81520060, Brazil|Hospital Amaral Carvalho-Centro de Pesquisas ( Site 1304), JaÃº, Sao Paulo, 17210-120, Brazil|A. C. Camargo Cancer Center ( Site 1318), SÃ£o Paulo, Sao Paulo, 01509-010, Brazil|Instituto Nacional de CÃ¢ncer - INCA-DivisÃ£o de Pesquisa ClÃ­nica e Desenvolvimento TecnolÃ³gico HC1 (, Rio de Janeiro, 20231-050, Brazil|ICESP - INSTITUTO DO CÃNCER DO ESTADO DE SÃO PAULO-Pesquisa Clinica ( Site 1308), Sao Paulo, 01246-000, Brazil|Hospital Paulistano-Americas Oncologia ( Site 1302), Sao Paulo, 01321-001, Brazil|Specialized Hospital for Active Treatment of Haematology Diseases ( Site 6403), Sofia, Sofia (stolitsa), 1797, Bulgaria|University Multiprofile Hospital for Active Treatment ""Sveti Georgi"" EAD ( Site 6404), Plovdiv, 4002, Bulgaria|Medical Centre Pratia Clinic EOOD ( Site 6406), Plovdiv, 4003, Bulgaria|UMHAT ""Prof. Dr. Stoyan Kirkovich""AD-Clinical Hematology ( Site 6400), Stara Zagora, 6003, Bulgaria|Multriprofile Hospital for Active Treatment ""Hristo Botev"" ( Site 6402), Vratsa, 3000, Bulgaria|James Lind Centro de Investigacion del Cancer ( Site 1503), Temuco, Araucania, 4800827, Chile|Biocenter ( Site 1507), Concepcion, Biobio, 4070196, Chile|IC La Serena Research ( Site 1506), La Serena., Coquimbo, 1720430, Chile|Centro de Estudios ClÃ­nicos SAGA-CECSAGA ( Site 1509), Santiago, Region M. De Santiago, 7500653, Chile|FALP-UIDO ( Site 1500), Santiago, Region M. De Santiago, 7500921, Chile|ClÃ­nica Inmunocel ( Site 1511), Santiago, Region M. De Santiago, 7580206, Chile|Peking University Third Hospital ( Site 1602), Beijing, Beijing, 100191, China|Chongqing University Cancer Hospital ( Site 1605), Chongqing, Chongqing, 400030, China|Chongqing University Three Gorges Hospital ( Site 1609), Wanzhou, Chongqing, 404000, China|Southern Medical University Nanfang Hospital-Department of Hematopathology ( Site 1607), Guangzhou, Guangdong, 510515, China|Sun Yat-sen University Cancer Center ( Site 1608), Guangzhou, Guangdong, 510700, China|The Affiliated Hospital of Guizhou Medical University ( Site 1625), Guiyang, Guizhou, 550004, China|Hainan General Hospital ( Site 1603), Haikou, Hainan, 570311, China|Henan Cancer Hospital-hematology department ( Site 1613), Zhengzhou, Henan, 450008, China|Tongji Hospital Tongji Medical,Science & Technology ( Site 1619), Wuhan, Hubei, 430000, China|Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 1618), Wuhan, Hubei, 430010, China|Xiangya Hospital Central South University-Hematology department ( Site 1616), Changsha, Hunan, 410008, China|Hunan Cancer Hospital ( Site 1615), Changsha, Hunan, 410013, China|The First Affiliated Hospital of Soochow University-hematology department ( Site 1612), Suzhou, Jiangsu, 215006, China|The First Affiliated Hospital of Nanchang University ( Site 1614), Nanchang, Jiangxi, 330006, China|Jiangxi Provincial Cancer Hospital ( Site 1628), Nanchang, Jiangxi, 330029, China|The First Hospital of Jilin University-Hematology ( Site 1621), Changchun, Jilin, 130021, China|The First Affiliated Hospital of Xi'an Jiaotong University ( Site 1617), Xi'an, Shaanxi, 710061, China|Shaanxi provincial people's hospital ( Site 1626), Xi'an, Shaanxi, 710068, China|Fudan University Shanghai Cancer Center ( Site 1606), Shanghai, Shanghai, 200032, China|Shanxi Cancer Hospital ( Site 1629), Taiyuan, Shanxi, 030013, China|Institute of hematology&blood disease hospital ( Site 1600), Tianjin, Tianjin, 300020, China|Tianjin Medical University Cancer Institute & Hospital-lymphoma ( Site 1604), Tianjin, Tianjin, 300060, China|The First Affiliated Hospital, Zhejiang University-Hematology ( Site 1611), Hangzhou, Zhejiang, 310003, China|Clini Salud ( Site 1700), Envigado, Antioquia, 055422, Colombia|Fundacion Colombiana de CancerologÃ­a Clinica Vida ( Site 1707), Medellin, Antioquia, 050030, Colombia|Sociedad De Oncologia Y Hematologia Del Cesar-Oncology ( Site 1704), Valledupar, Cesar, 200001, Colombia|Oncologos del Occidente ( Site 1706), Pereira, Risaralda, 660001, Colombia|Aarhus Universitetshospital, Skejby-Blodsygdomme ( Site 1902), Aarhus, Midtjylland, 8200, Denmark|Aalborg Universitetshospital, Syd ( Site 1901), Aalborg, Nordjylland, 9000, Denmark|Odense Universitetshospital ( Site 1900), Odense C, Syddanmark, 5000, Denmark|Vejle Sygehus ( Site 1903), Vejle, Syddanmark, 7100, Denmark|MEDI-K ( Site 2401), Guatemala, 01009, Guatemala|CELAN,S.A ( Site 2403), Guatemala, 01010, Guatemala|Oncomedica-Guatemala ( Site 2402), Guatemala, 01010, Guatemala|Queen Mary Hospital ( Site 2500), Hksar, Hong Kong|FejÃ©r Megyei Szent GyÃ¶rgy Egyetemi OktatÃ³ KÃ³rhÃ¡z ( Site 2609), SzÃ©kesfehÃ©rvÃ¡r, Fejer, 8000, Hungary|Heves VÃ¡rmegyei Markhot Ferenc OktatÃ³kÃ³rhÃ¡z Ã©s RendelÅintÃ©zet ( Site 2608), Eger, Heves, 3300, Hungary|Szabolcs-SzatmÃ¡r-Bereg Megyei KÃ³rhÃ¡zak Ã©s Egyetemi OktatÃ³kÃ³r-HaematolÃ³gia osztÃ¡ly ( Site 2602), Nyiregyhaza, Szabolcs-Szatmar-Bereg, 4400, Hungary|Hospital of Lithuanian University of Health Sciences Kauno klinikos-Oncology and Hematology ( Site 3, Kaunas, Kauno Apskritis, 50161, Lithuania|Hospital Sultanah Aminah ( Site 3203), Johor Bahru, Johor, 80100, Malaysia|Hospital Ampang ( Site 3202), Ampang, Selangor, 68000, Malaysia|Centro de Infusion Superare ( Site 3314), Ciudad de MÃ©xico, Distrito Federal, 03100, Mexico|Health Pharma Professional Research S.A. de C.V: ( Site 3301), Ciudad de MÃ©xico, Distrito Federal, 03100, Mexico|Centro de Investigacion Clinica Chapultepec ( Site 3309), Morelia, Michoacan, 58260, Mexico|Oaxaca Site Management Organization ( Site 3313), Oaxaca, 68000, Mexico|Samodzielny Publiczny Szpital Kliniczny nr 1-Department of Haematooncology and Bone Marrow Transpla, Lublin, Lubelskie, 20-081, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika NowotworÃ³w UkÅadu ChÅonnego ( S, Warszawa, Mazowieckie, 02-781, Poland|Uniwersyteckie Centrum Kliniczne-Klinika Hematologii i Transplantologii ( Site 3702), Gdansk, Pomorskie, 80-952, Poland|Pratia Onkologia Katowice ( Site 3705), Katowice, Slaskie, 40-519, Poland|Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zakl-Klinika Hematologii i Transplantacji S, Kielce, Swietokrzyskie, 25-734, Poland|Samodzielny Publiczny Zaklad Opieki Zdrowotnej MSWiA z Warmi-Oddzial Kliniczny Hematologii ( Site 37, Olsztyn, Warminsko-mazurskie, 10-228, Poland|Spitalul Clinic ColÈea ( Site 4000), BucureÈti, Bucuresti, 030171, Romania|Spitalul Clinic ColÈea ( Site 4001), BucureÈti, Bucuresti, 030171, Romania|Institutul Oncologic Cluj ( Site 4002), Cluj, 400015, Romania|National Cancer Centre Singapore ( Site 4200), Singapore, Central Singapore, 168583, Singapore|Tan Tock Seng Hospital ( Site 4202), Singapore, Central Singapore, 308433, Singapore|Netcare Pretoria East Hospital-Albert Alberts Stem Cell Transplant Centre ( Site 4401), Centurion, Gauteng, 0181, South Africa|Wits Clinical Research ( Site 4403), Johannesburg, Gauteng, 1864, South Africa|Groote Schuur Hospital-Clinical Haematology ( Site 4400), Cape Town, Western Cape, 7925, South Africa|Haemalife ( Site 4407), Kuilsriver, Western Cape, 7580, South Africa|Constantiaberg Haematology ( Site 4408), Plumstead, Western Cape, 7800, South Africa|Chang Gung Memorial Hospital at Kaohsiung-Division of Hematology and Oncology ( Site 4700), Kaohsiung, 83301, Taiwan|National Cheng Kung University Hospital ( Site 4701), Tainan, 704, Taiwan|National Taiwan University Hospital ( Site 4704), Taipei, 10002, Taiwan|Mega Medipol-Hematology ( Site 4904), Stanbul, Istanbul, 34214, Turkey|Namik Kemal University Medical Faculty-Hematology ( Site 4912), Suleymanpasa, Tekirdas, 59100, Turkey|Ankara Universitesi Tip Fakultesi Hastanesi-hematology ( Site 4913), Ankara, 06100, Turkey|TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi ( Site 4906), Istanbul, 34722, Turkey|Ege Universitesi Hastanesi ( Site 4902), Ä°zmir, 35100, Turkey|MNPE ClinCenter of Oncology,Hematology,Transplantology and Palliative Care of CherkasyRegCouncil ( S, Cherkassy, Cherkaska Oblast, 18009, Ukraine|Communal non-profit enterprise ""Regional clinical hospital o-Hematology Department ( Site 5113), Ivano-Frankivsk, Ivano-Frankivska Oblast, 76008, Ukraine|Nonprofit Organization National Cancer Institute ( Site 5103), Kyiv, Kyivska Oblast, 03022, Ukraine|Institute of Blood Pathology and Transfusion Medicine of National AÑademy of Medical Sciences of Ukr, Lviv, Lvivska Oblast, 79057, Ukraine|National Research Center for Radiation Medicine of National Academy of Medical Sciences of Ukraine (, Kyiv, 03115, Ukraine|Public Non-Profit Enterprise Kyiv City Clinical Hospital #9 -Hematology department #1 ( Site 5111), Kyiv, 04112, Ukraine",
NCT05048797,"A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations",https://clinicaltrials.gov/study/NCT05048797,,RECRUITING,DESTINY-Lung04 will investigate the efficacy and safety of Trastuzumab Deruxtecan (T-DXd) versus Standard of Care (SoC) as first-line treatment of Non-Small Cell Lung Cancer (NSCLC) with HER2 Exon 19 or 20 mutations,NO,Locally Advanced or Metastatic Non-Small Cell Lung Cancer,DRUG: Trastuzumab Deruxtecan|DRUG: Cisplatin|DRUG: Carboplatin|DRUG: Pembrolizumab|DRUG: Pemetrexed,"Progression Free Survival (PFS) by Blinded Independent Central Review (BICR), Defined as time from randomization until progression per RECIST 1.1 as assessed by Blinded Independent Central Review (BICR), or death due to any cause., Until progression or death, assessed up to approximately 12 months","Overall Survival (OS), Defined as time from randomization until the date of death due to any cause., Until death, assessed up to approximately 28 months.|Progression Free Survival (PFS) by investigator assessment, Defined as time from randomization until progression per RECIST 1.1 as assessed by the investigator, or death due to any cause., Until progression, assessed up to approximately 12 months|Objective Response Rate (ORR), Defined as the proportion of participants who have a complete response (CR) or partial response (PR) as assessed by Blinded Independent Central Review (BICR) and investigator according to RECIST 1.1, Until progression, assessed up to approximately 12 months|Duration of Response (DoR), Defined as the time from the date of first documented response until date of documented progression as assessed by Blinded Independent Central Review (BICR) and investigator assessment according to RECIST 1.1., Until progression, assessed up to approximately 12 months|Time to second progression or death (PFS2), Defined as the time from randomization until second progression on next-line of treatment as assessed by investigator at the local site using assessments conducted per local standard clinical practice, or death due to any cause., Assessed up to approximately 20 months|Landmark analysis of PFS (PFS12), Defined as proportion of participants alive and progression-free at 12 months, as assessed by Blinded Independent Central Review (BICR) and investigator., Assessed up to approximately 12 months|Landmark analysis of OS (OS24), Defined as proportion of participants alive at 24 months, Assessed up to approximately 24 months|Central Nervous System (CNS) - Progression Free Survival (PFS), Defined as time from randomization until Central Nervous System (CNS) progression per RECIST 1.1 as assessed by Blinded Independent Central Review (BICR) or death due to any cause in the absence of CNS progression., Until CNS progression or death, assessed up to approximately 12 months|Safety and tolerability of T-DXd versus Standard of Care treatment, Assessed by the occurrence of AEs, SAEs, and changes from baseline in laboratory parameters, vital signs, ECG, and ECHO/MUGA scan results., Until progression or death, assessed up to approximately 28 months|Pharmacokinetics (PK) of T-DXd, total anti-HER2 antibody and DXd in serum, Serum concentration of T-DXd, total anti-HER2 antibody and DXd., Up to cycle 4, approximately 12 weeks|Immunogenicity of T-DXd, Presence of anti-drug antibodies (ADAs) for T-DXd., Until progression, assessed up to approximately 13 months|Patient-reported pulmonary symptoms associated with Non-Small Cell Lung Cancer, Time to sustained deterioration in pulmonary symptoms (cough, dyspnea, chest pain) while on treatment using the Non-Small Cell Lung Cancer-Symptom Assessment Questionnaire (NSCLC-SAQ)., Until progression, assessed up to approximately 13 months|Patient-reported tolerability of T-DXd described using symptomatic AEs, Symptomatic AEs: Descriptive summary of the proportion of participants reporting symptomatic AEs while on treatment, as assessed by the Patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) and items from the European Organisation for Research and Treatment of Cancer (EORTC) Item Library., Until progression, assessed up to approximately 13 months|Patient-reported tolerability of T-DXd described using overall side-effect bother, Overall side-effect bother: Descriptive summary of the proportion of participants reporting overall side-effect bother on the Patient's Global Impression of Treatment Tolerability (PGI-TT) while on treatment., Until progression, assessed up to approximately 13 months|Patient-reported tolerability of T-DXd described using physical function, Physical Function: The proportion of participants with maintained or improved physical function while on treatment, based on the European Organisation for Research and Treatment of Cancer 30-item core quality of life questionnaire (EORTC-QLQ-C30) physical functioning scale., Until progression, assessed up to approximately 13 months",,AstraZeneca,Daiichi Sankyo,ALL,"ADULT, OLDER_ADULT",PHASE3,450,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-10-28,2026-03-31,2027-07-30,2021-09-17,,2025-06-08,"Research Site, Anchorage, Alaska, 99508, United States|Research Site, Los Alamitos, California, 90720, United States|Research Site, Los Angeles, California, 90048, United States|Research Site, Orange, California, 92868, United States|Research Site, San Francisco, California, 94143, United States|Research Site, Santa Monica, California, 90404, United States|Research Site, Santa Rosa, California, 95403, United States|Research Site, Silver Spring, Maryland, 20910, United States|Research Site, Boston, Massachusetts, 02118, United States|Research Site, Boston, Massachusetts, 02215, United States|Research Site, Ann Arbor, Michigan, 48109, United States|Research Site, Basking Ridge, New Jersey, 07920, United States|Research Site, East Brunswick, New Jersey, 08816, United States|Research Site, Middletown, New Jersey, 07748, United States|Research Site, Montvale, New Jersey, 07645, United States|Research Site, New Brunswick, New Jersey, 08901, United States|Research Site, Commack, New York, 11725, United States|Research Site, Harrison, New York, 10604, United States|Research Site, New York, New York, 10065, United States|Research Site, Uniondale, New York, 11553, United States|Research Site, Canton, Ohio, 44710, United States|Research Site, Columbus, Ohio, 43201, United States|Research Site, Pittsburgh, Pennsylvania, 15232, United States|Research Site, Dallas, Texas, 75246, United States|Research Site, Kennewick, Washington, 99336, United States|Research Site, La Crosse, Wisconsin, 54601, United States|Research Site, Milwaukee, Wisconsin, 53226, United States|Research Site, Graz, 8036, Austria|Research Site, Innsbruck, 6020, Austria|Research Site, Linz, 4020, Austria|Research Site, Rankweil, 6830, Austria|Research Site, Wien, 1210, Austria|Research Site, Gent, 9000, Belgium|Research Site, Hasselt, 3500, Belgium|Research Site, Leuven, 3000, Belgium|Research Site, Barretos, 14784-400, Brazil|Research Site, Blumenau, 89010-340, Brazil|Research Site, BrasÃ­lia, 70200-730, Brazil|Research Site, FlorianÃ³polis, 88034-000, Brazil|Research Site, Natal, 59075-740, Brazil|Research Site, Salvador, 40170-110, Brazil|Research Site, Sao Paulo, 01327-001, Brazil|Research Site, SÃ£o Paulo, 01321-001, Brazil|Research Site, UberlÃ¢ndia, 38408-150, Brazil|Research Site, Vancouver, British Columbia, V5Z 4E6, Canada|Research Site, Brampton, Ontario, L6R 3J7, Canada|Research Site, Toronto, Ontario, M5G 1Z5, Canada|Research Site, Montreal, Quebec, H4A 3J1, Canada|Research Site, Beijing, 100142, China|Research Site, Beijing, 100730, China|Research Site, Changchun, 130021, China|Research Site, Changsha, 410008, China|Research Site, Changsha, 410013, China|Research Site, Chengdu, 610041, China|Research Site, Fuzhou, 350014, China|Research Site, Guangzhou, 510080, China|Research Site, Hangzhou, 310020, China|Research Site, Harbin, 150049, China|Research Site, Jinan, 250117, China|Research Site, Kunming, 650101, China|Research Site, Kunming, 650118, China|Research Site, Linhai, 317000, China|Research Site, Nanchang, 330006, China|Research Site, Nanjing, 210029, China|Research Site, Shanghai, 200030, China|Research Site, Shanghai, 200032, China|Research Site, Shenyang, 110001, China|Research Site, Shenyang, 110016, China|Research Site, ShenZhen, 518020, China|Research Site, Wenzhou, CN-325000, China|Research Site, Wuhan, 430022, China|Research Site, Xi'an, 710061, China|Research Site, Xiamen, 361003, China|Research Site, Yangzhou, 225001, China|Research Site, Zhengzhou City, 450008, China|Research Site, Vejle, 7100, Denmark|Research Site, Bordeaux, 33000, France|Research Site, Dijon, 21079, France|Research Site, Le Mans Cedex, 72037, France|Research Site, Lyon, 69373, France|Research Site, Marseille cedex, 13915, France|Research Site, Nantes, 44093, France|Research Site, Rennes Cedex 9, 35033, France|Research Site, Toulouse Cedex 9, 31059, France|Research Site, Villejuif Cedex, 94805, France|Research Site, Berlin-Zehlendorf, 14165, Germany|Research Site, Dresden, 01307, Germany|Research Site, Erfurt, 99089, Germany|Research Site, Heidelberg, 69126, Germany|Research Site, Immenhausen, 34376, Germany|Research Site, KÃ¶ln, 50937, Germany|Research Site, Mainz, 55131, Germany|Research Site, Mannheim, 68167, Germany|Research Site, MÃ¼nchen, 81377, Germany|Research Site, Oldenburg, 26121, Germany|Research Site, Ravensburg, 88212, Germany|Research Site, WÃ¼rzburg, 97080, Germany|Research Site, Hong Kong, HKG, Hong Kong|Research Site, Hong Kong, Hong Kong|Research Site, Jordan, HKG, Hong Kong|Research Site, Shatin, 00000, Hong Kong|Research Site, Bangalore, 560027, India|Research Site, Delhi, 110085, India|Research Site, Hyderabad, 500032, India|Research Site, Mumbai, 400012, India|Research Site, Nashik, 422002, India|Research Site, Milan, 20141, Italy|Research Site, Monza, 20090, Italy|Research Site, Orbassano, 10043, Italy|Research Site, Parma, 43100, Italy|Research Site, Roma, 00168, Italy|Research Site, Verona, 37126, Italy|Research Site, Chuo-ku, 104-0045, Japan|Research Site, Fukuoka-shi, 812-8582, Japan|Research Site, Kashiwa, 277-8577, Japan|Research Site, Matsuyama-shi, 791-0280, Japan|Research Site, Niigata-shi, 951-8566, Japan|Research Site, Okayama-shi, 700-8558, Japan|Research Site, Osaka-shi, 541-8567, Japan|Research Site, Osakasayama-shi, 589-8511, Japan|Research Site, Sapporo-shi, 060-8638, Japan|Research Site, Sendai-shi, 980-0873, Japan|Research Site, Sunto-gun, 411-8777, Japan|Research Site, Yokohama-shi, 241-8515, Japan|Research Site, Yonago-shi, 683-8504, Japan|Research Site, Cheongju-si, 28644, Korea, Republic of|Research Site, Goyang-si, 10408, Korea, Republic of|Research Site, Gyeonggi-do, 13620, Korea, Republic of|Research Site, Seoul, 03080, Korea, Republic of|Research Site, Seoul, 05505, Korea, Republic of|Research Site, Seoul, 06351, Korea, Republic of|Research Site, Cdmx, 03810, Mexico|Research Site, CuliacÃ¡n, 80230, Mexico|Research Site, Guadalajara Jalisco, 44280, Mexico|Research Site, Merida, 97000, Mexico|Research Site, Mexico City, '14080, Mexico|Research Site, Oaxaca, 68020, Mexico|Research Site, San Luis PotosÃ­, 78200, Mexico|Research Site, Amsterdam, 1081 HV, Netherlands|Research Site, Groningen, 9700 RB, Netherlands|Research Site, Leiden, 2333 ZA, Netherlands|Research Site, Nijmegen, 6525 GA, Netherlands|Research Site, Bystra, 43-360, Poland|Research Site, GdaÅsk, 80-952, Poland|Research Site, Olsztyn, 10-357, Poland|Research Site, Przemysl, 37-700, Poland|Research Site, Warszawa, 02-781, Poland|Research Site, L'Hospitalet de Llobregat, 08908, Spain|Research Site, Madrid, 28041, Spain|Research Site, Malaga, 29730, Spain|Research Site, Valencia, 46026, Spain|Research Site, Kaohsiung, 833, Taiwan|Research Site, Taichung, 40201, Taiwan|Research Site, Taichung, 40705, Taiwan|Research Site, Tainan, 70403, Taiwan|Research Site, Taipei, 10048, Taiwan|Research Site, Taipei, 235, Taiwan|Research Site, Taipei, TAIWAN, Taiwan|Research Site, Taoyuan, 333, Taiwan|Research Site, Edirne, 22030, Turkey|Research Site, Izmir, 35040, Turkey|Research Site, KadÄ±koy/Istanbul, 34722, Turkey|Research Site, Ãankaya, 06680, Turkey",
NCT04720157,"An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC",https://clinicaltrials.gov/study/NCT04720157,PSMAddition,ACTIVE_NOT_RECRUITING,"The purpose of this study is to evaluate the efficacy and safety of 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with mHSPC. In this study, the SoC is defined as a combination of Androgen Receptor Directed Therapy + Androgen Deprivation Therapy. Approximately 1126 patients will be randomized in this study. As of 31-Jan-2024, 1144 participants have been enrolled in 20 countries.",NO,Prostatic Neoplasms,DRUG: 177Lu-PSMA-617|DRUG: 68Ga-PSMA-11|DRUG: ARDT|DRUG: ADT,"Radiographic Progression Free Survival (rPFS), rPFS is defined as the time of radiographic progression by Prostate Cancer Working Group 3 (PCWG3)-modified RECIST V1.1 as assessed by blinded independent central review, or death, From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to 50 months (estimated final OS analysis)","Overall Survival (OS), OS is defined as time to death for any cause, From date of randomization until date of death from any cause, assessed up to 50 months (estimated final OS analysis)|Prostate-specific antigen 90 (PSA90) response, PSA90 response is defined as the proportion of patients who have a more/equal 90% decrease in PSA from baseline, it will be calculated at 12, 24 and 48 months, From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)|time to development of mCRPC, Time to development of mCRPC is defined as the time from date of randomization to disease progression despite androgen deprivation therapy (ADT) presenting as either a continuous rise in serum prostate-specific antigen (PSA) levels, the progression of pre existing disease, and/or the appearance of new metastases., From date of randomization till End Of Treatment (EOT) or death, which ever happen first, assessed up to 50 months (estimated final OS analysis)|Progression Free Survival (PFS), PFS is defined as the time from date of randomization to the date of first documented progression by investigator assessment (radiographic progression, clinical progression, PSA progression) or death from any cause, whichever occurs first, From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to 50 months (estimated final OS analysis)|second Progression Free Survival (PFS2), PFS2 is defined as time from date of randomization to the first documented progression by investigator assessment (radiographic progression, clinical progression, PSA progression) on next-line therapy or death from any cause, whichever occurs first., From date of randomization until date of second progression or date of death from any cause, whichever comes first, assessed up to 50 months (estimated final OS analysis)|Change in nadir level of PSA lower than 0.2 ng/ml, Proportion of patients with PSA \< 0.2 ng/mL at months 12, 24 and 48 months, From date of randomization till 30 days safety fup, whichever occur first, assessed up to 50 months (estimated final OS analysis)|Time to radiographic soft tissue progression (TTSTP), TTSTP is defined as time from randomization to radiographic soft tissue progression per PCWG3-modified RECIST v1.1 (Soft Tissue Rules of Prostate Cancer Working Group modified Response Evaluation Criteria in Solid Tumors Version 1.1) as assessed by Blinded Independent Central Review (BICR), From date of randomization until date of soft tissue radiographic progression or date of death from any cause, whichever comes first, assessed up to 50 months (estimated final OS analysis)|Time to first symptomatic skeletal event (SSE)., Time to SSE (TTSSE) is defined as date of randomization to the date of first new symptomatic pathological bone fracture, spinal cord compression, tumor-related orthopedic surgical intervention, requirement for radiation therapy to relieve bone pain or death from any cause, whichever occurs first, From date of randomization till EOT or death, whichever happens first, assessed up to 50 months (estimated final OS analysis)|Overall Response Rate (ORR), ORR is defined as the proportion of participants with best overall response of complete response or partial response in soft tissue as per BIRC and according to PCWG3 modified RECIST 1.1, From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)|Disease Control Rate (DCR), DCR is defined as the proportion of participants with best overall response of complete response or partial response or Stable disease in soft tissue as per BIRC and according to PCWG3 modified RECIST 1.1, From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)|Duration of Response (DOR), DOR is defined as the duration of time between the date of first documented response (CR or PR) in soft tissue as per BIRC and according to PCWG3 modified RECIST 1.1, and the date of first documented progression or death due to any cause, From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to 50 months (estimated final OS analysis)|Time to Response (TTR), TTR is defined as the time from the date of randomization to the date of first documented response (CR or PR)., From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)|Functional Assessment of Cancer Therapy - Prostate (FACT-P) Questionnaire, FACT-P assesses symptoms/problems related to prostate carcinoma and its treatment. It is a combination of the FACT-General + the Prostate Cancer Subscale (PCS). The FACT-General (FACT-G) is a 27 item Quality of Life (QoL) measure that provides a total score as well as subscale scores: Physical (0-28), Functional (0-28), Social (0-28), and Emotional Well-being (0-24). The total score range is between 1-108, higher scores indicates better for total score and subscale scores. PCS is a 12-item prostate cancer subscale that asks about symptoms and problems specific to prostate cancer (Range 0-48, higher scores better). The FACT-P total score is the sum of all 5 subscale scores of the FACT-P questionnaire and ranges from 0-156. Higher scores indicate higher degree of functioning and better quality of life., From randomization up till 30 day safety Follow-up or week 48 of long term Follow-up for patients prematurely discontinued, assessed up to 50 months (estimated final OS analysis)|European Quality of Life ( EuroQoL) -5 Domain 5 Level Scale (EQ-5D-5L), EQ-5D-5L is a standardized participant completed questionnaire that measures health-related quality of life and translates that score into an index value or utility score. EQ-5D-5L consists of two components: a health state profile and an optional visual analogue scale (VAS). EQ-5D health state profile is comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1= no problems, 2= slight problems, 3=moderate problems, 4= severe problems, and 5= extreme problems. Higher scores indicated greater levels of problems across each of the five dimensions., From screening up till 30 day safety follow-up or week 48 of long term follow up for patient prematurely discontinued, assessed up to 50 months (estimated final OS analysis)|Brief Pain Inventory-short Form (PBI-SF), The BPI-SF is a publicly available instrument to assess the pain and includes severity and interference scores. BPI-SF is an 11-item self report questionnaire that is designed to assess the severity and impact of pain on daily functions of a participant. Pain severity score is a mean value for BPI-SF questions 3, 4, 5 and 6 (questions inquiring about the extent of pain, where the extent is ranked from 0 \[no pain\] to 10 \[pain as bad as you can imagine\]). Pain severity progression is defined as an increase in score of 30% or greater from baseline without decrease in analgesic use., From screening up till 30 day safety follow-up or week 48 of long term follow up for patient prematurely discontinued, assessed up to 50 months (estimated final OS analysis)|Number of participants with Treatment Emergent Adverse Events, The distribution of adverse events (AE) will be done via the analysis of frequencies for treatment emergent Adverse Event (TEAEs), Serious Adverse Event (TESAEs) and Deaths due to AEs, through the monitoring of relevant clinical and laboratory safety parameters., From randomization till 30 days safety follow-up, assessed up to 50 months (estimated final OS analysis)",,Novartis Pharmaceuticals,"Alliance Foundation Trials, LLC.|RTOG Foundation, Inc.",MALE,"ADULT, OLDER_ADULT",PHASE3,1145,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-06-09,2025-01-13,2026-02-11,2021-01-22,,2025-06-11,"Mayo Clinic - Arizona Mayo Clinic Hospital, Scottsdale, Arizona, 85259, United States|University of California San Diego - Moores Cancer Center, La Jolla, California, 92093-0658, United States|VA Greater LA Healthcare System, Los Angeles, California, 90073, United States|University of California LA, Los Angeles, California, 90095, United States|St. Joseph Hospital, Orange, California, 92686, United States|Univ Cali Irvine ALS Neuromuscular, Orange, California, 92868, United States|VA Palo Alto Health Care System, Palo Alto, California, 94304-1207, United States|Sansum Clinic, Santa Barbara, California, 93105, United States|Providence Saint Johns Health Ctr, Santa Monica, California, 90404, United States|Stanford University Medical Center, Stanford, California, 94305, United States|Anschutz Medical Center, Aurora, Colorado, 80011, United States|Rocky Mountain Cancer Centers, Denver, Colorado, 80218, United States|Hartford Hospital, Hartford, Connecticut, 06102, United States|Georgetown University-Lombardi Cancer Center, Washington, District of Columbia, 20007, United States|VA Medical Center, Washington, District of Columbia, 20422, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, 32224, United States|Cancer Specialists of North Florida, Jacksonville, Florida, 32256, United States|University Of Miami, Miami, Florida, 33136, United States|Baptist Health Medical Group, Miami, Florida, 33173, United States|Florida Cancer Affiliates, Panama City, Florida, 32405, United States|University Cancer and Blood Center LLC, Athens, Georgia, 30607, United States|The Queens Medical Centre, Honolulu, Hawaii, 96813, United States|Northwestern University, Chicago, Illinois, 60611, United States|Rush University Medical Center, Chicago, Illinois, 60612, United States|University of Chicago, Chicago, Illinois, 60637, United States|Hines VA Hospital, Hines, Illinois, 60141, United States|Parkview Research Center, Fort Wayne, Indiana, 46845, United States|Indiana University, Indianapolis, Indiana, 46202, United States|Tulane Cancer Center, New Orleans, Louisiana, 70112, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, 70121, United States|Sidney Kimmel CCC At JH, Baltimore, Maryland, 21231, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States|Uni Of Michigan Health System, Ann Arbor, Michigan, 48109, United States|Corewell Health William Beaum Hosp, Royal Oak, Michigan, 48073-6769, United States|University of Minnesota, Minneapolis, Minnesota, 55455, United States|Mayo Clinic, Rochester, Minnesota, 55905, United States|University of Mississippi Med Ctr, Jackson, Mississippi, 39216, United States|St. Louis University, Saint Louis, Missouri, 63104, United States|VA St Louis Health Care System, Saint Louis, Missouri, 63106, United States|Wash U School of Medicine, Saint Louis, Missouri, 63110, United States|Nebraska Cancer Specialists, Omaha, Nebraska, 68130, United States|Urology Cancer Center PC, Omaha, Nebraska, 68130, United States|University of New Mexico, Albuquerque, New Mexico, 87131 0001, United States|Montefiore Medical Center, Bronx, New York, 10467, United States|Weill Cornell Medical College, New York, New York, 10021, United States|Memorial Sloan Kettering Cancer Ctr, New York, New York, 10065, United States|Univ Of Rochester Cancer Ctr, Rochester, New York, 14642, United States|Levine Cancer Institute, Charlotte, North Carolina, 28203, United States|Duke Univ Medical Center, Durham, North Carolina, 27710, United States|Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States|The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, 43221, United States|Oregon Health Sciences University, Portland, Oregon, 97239, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, 17033, United States|Thomas Jefferson Univ Hosp, Philadelphia, Pennsylvania, 19107, United States|Univ of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, 15232, United States|Carolina Urologic Research Center, LLC, Myrtle Beach, South Carolina, 29572, United States|Dallas VA Medical Center, Dallas, Texas, 75216, United States|Texas Oncology, Dallas, Texas, 75246, United States|Univ of Texas Southwest Med Center, Dallas, Texas, 75390-9034, United States|MD Anderson, Houston, Texas, 77030, United States|UT Health Science Center, Houston, Texas, 77030, United States|UT Health San Antonio Mays Cancer Center, San Antonio, Texas, 78229, United States|University of Virginia Medical Center, Charlottesville, Virginia, 22908, United States|Virginia Oncology Associates, Norfolk, Virginia, 23502, United States|Onco Hemato Asso of SE Virginia, Roanoke, Virginia, 24014, United States|Swedish Medical Center, Seattle, Washington, 98122-4379, United States|Medical College Of Wisconsin, Milwaukee, Wisconsin, 53226, United States|Novartis Investigative Site, Innsbruck, Tyrol, 6020, Austria|Novartis Investigative Site, Linz, 4020, Austria|Novartis Investigative Site, Wien, 1090, Austria|Novartis Investigative Site, Bruxelles, 1200, Belgium|Novartis Investigative Site, Gent, 9000, Belgium|Novartis Investigative Site, Vancouver, British Columbia, V5Z 1M9, Canada|Novartis Investigative Site, Hamilton, Ontario, L8V 5C2, Canada|Novartis Investigative Site, Toronto, Ontario, M4N 3M5, Canada|Novartis Investigative Site, Montreal, Quebec, H2W 1T8, Canada|Novartis Investigative Site, Montreal, Quebec, H3T 1E2, Canada|Novartis Investigative Site, Montreal, Quebec, H4A 3J1, Canada|Novartis Investigative Site, Sherbrooke, Quebec, J1H 5N4, Canada|Novartis Investigative Site, Quebec, G1R 2J6, Canada|Novartis Investigative Site, Nanjing, Jiangsu, 210006, China|Novartis Investigative Site, Nanjing, Jiangsu, 210029, China|Novartis Investigative Site, Shanghai, Shanghai, 200032, China|Novartis Investigative Site, Xian, Shanxi, 710032, China|Novartis Investigative Site, Chengdu, Sichuan, 610041, China|Novartis Investigative Site, Beijing, 100036, China|Novartis Investigative Site, Guangzhou, 510060, China|Novartis Investigative Site, Shanghai, 200025, China|Novartis Investigative Site, Shanghai, 200032, China|Novartis Investigative Site, Shanghai, 200080, China|Novartis Investigative Site, Tianjin, 300308, China|Novartis Investigative Site, Olomouc, 779 00, Czechia|Novartis Investigative Site, Praha 5, 150 06, Czechia|Novartis Investigative Site, Copenhagen, DK-2100, Denmark|Novartis Investigative Site, Bordeaux Cedex, 33075, France|Novartis Investigative Site, Clermont-Ferrand, 63011, France|Novartis Investigative Site, Lyon, 69373, France|Novartis Investigative Site, Montpellier, 34298, France|Novartis Investigative Site, Nantes, 44093, France|Novartis Investigative Site, Paris, 75015, France|Novartis Investigative Site, Paris, 75018, France|Novartis Investigative Site, Strasbourg, 67200, France|Novartis Investigative Site, Vandoeuvre Les Nancy, 54511, France|Novartis Investigative Site, Villejuif, 94800, France|Novartis Investigative Site, Essen, 45147, Germany|Novartis Investigative Site, Koeln, 50937, Germany|Novartis Investigative Site, Muenchen, 80377, Germany|Novartis Investigative Site, Muenster, 48149, Germany|Novartis Investigative Site, Rostock, 18057, Germany|Novartis Investigative Site, Wuerzburg, 97080, Germany|Novartis Investigative Site, Nagoya, Aichi, 466 8560, Japan|Novartis Investigative Site, Fukuoka city, Fukuoka, 812-8582, Japan|Novartis Investigative Site, Fukushima city, Fukushima, 960 1295, Japan|Novartis Investigative Site, Sapporo city, Hokkaido, 060 8648, Japan|Novartis Investigative Site, Kobe, Hyogo, 650-0047, Japan|Novartis Investigative Site, Yokohama-city, Kanagawa, 236-0004, Japan|Novartis Investigative Site, Okayama-city, Okayama, 700-8558, Japan|Novartis Investigative Site, Suita, Osaka, 565 0871, Japan|Novartis Investigative Site, Kitaadachi-gun, Saitama, 362-0806, Japan|Novartis Investigative Site, Bunkyo ku, Tokyo, 113-8431, Japan|Novartis Investigative Site, Chuo ku, Tokyo, 104 0045, Japan|Novartis Investigative Site, Chiba, 260-8717, Japan|Novartis Investigative Site, Fukuoka, 812-0033, Japan|Novartis Investigative Site, Kumamoto, 860-8556, Japan|Novartis Investigative Site, Kyoto, 606 8507, Japan|Novartis Investigative Site, Yamagata, 990 9585, Japan|Novartis Investigative Site, Seoul, 03080, Korea, Republic of|Novartis Investigative Site, Seoul, 03722, Korea, Republic of|Novartis Investigative Site, Seoul, 05505, Korea, Republic of|Novartis Investigative Site, Delft, 2625 AD, Netherlands|Novartis Investigative Site, Maastricht, 6229 HX, Netherlands|Novartis Investigative Site, Nijmegen, 6500HB, Netherlands|Novartis Investigative Site, Utrecht, 3584, Netherlands|Novartis Investigative Site, Gliwice, Slaskie, 44-101, Poland|Novartis Investigative Site, Krakow, 31-501, Poland|Novartis Investigative Site, Warszawa, 02 781, Poland|Novartis Investigative Site, Singapore, 119228, Singapore|Novartis Investigative Site, Singapore, 168583, Singapore|Novartis Investigative Site, Sabadell, Barcelona, 08208, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08035, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08036, Spain|Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, 08907, Spain|Novartis Investigative Site, El Palmar, Murcia, 30120, Spain|Novartis Investigative Site, Madrid, 28034, Spain|Novartis Investigative Site, Madrid, 28040, Spain|Novartis Investigative Site, Madrid, 28041, Spain|Novartis Investigative Site, Madrid, 28046, Spain|Novartis Investigative Site, Madrid, 28222, Spain|Novartis Investigative Site, Valencia, 46026, Spain|Novartis Investigative Site, Goteborg, 413 45, Sweden|Novartis Investigative Site, Lund, 221 85, Sweden|Novartis Investigative Site, Stockholm, 17176, Sweden|Novartis Investigative Site, Bern, 3010, Switzerland|Novartis Investigative Site, Lausanne, 1011, Switzerland|Novartis Investigative Site, Taipei, 10002, Taiwan|Novartis Investigative Site, Taoyuan, 33305, Taiwan|Novartis Investigative Site, Sutton, Surrey, SM2 5PT, United Kingdom|Novartis Investigative Site, Belfast, BT9 7AB, United Kingdom|Novartis Investigative Site, Cambridge, CB2 0QQ, United Kingdom|Novartis Investigative Site, Glasgow, G12 0YN, United Kingdom|Novartis Investigative Site, London, EC1A 7BE, United Kingdom|Novartis Investigative Site, London, NW1 2BU, United Kingdom|Novartis Investigative Site, London, NW3 2QG, United Kingdom|Novartis Investigative Site, Middlesbrough, TS4 3BW, United Kingdom",
NCT05042375,A Trial of Camrelizumab Combined With Famitinib Malate in Treatment NaÃ¯ve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT05042375,,RECRUITING,"The study is being conducted to evaluate the efficacy, and safety of camrelizumab combined with famitinib malate vs. pembrolizumab in treatment naÃ¯ve subjects with programmed death-ligand 1(PD-L1)-positive recurrent or metastatic non-small cell lung cancer (NSCLC).",NO,Non-small Cell Lung Cancer,DRUG: camrelizumab + famitinib|DRUG: pembrolizumab|DRUG: camrelizumab,"PFS assessed by BIRC, Progression-Free-Survival, defined as the time from randomization to the first occurrence of disease progression as determined by IRC with use of RECIST v1.1 or death from any cause, whichever occurs first., up to 3 years","PFS assessed by investigator, Progression-Free-Survival, up to 3 years|ORR, Objective Response Rate, determined using RECIST v1.1 criteria, defined as best overall response (CR or PR) across all assessment time points, up to 3 years|DCR, Disease Control Rate, determined using RECIST v1.1 criteria, up to 3 years|DoR, Duration of Response, determined using RECIST v1.1 criteria, up to 3 years|TTF, Time to Treatment Failure, defined as the time from randomization to treatment discontinuation., up to 3 years|AEs+SAEs, Adverse Events and Serious Adverse Events, from the first drug administration to within 90 days for the last SHR-1210 dose|OS, OS is the time interval from the date of randomization to death due to any reason or lost of follow-up, up to 4 years",,"Jiangsu HengRui Medicine Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,450,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-09-08,2023-12-31,2025-12-31,2021-09-13,,2022-11-17,"The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, 233000, China|Anhui Chest Hospital, Hefei, Anhui, 230000, China|Anhui Provincial Cancer Hospital, Hefei, Anhui, 230000, China|Anhui Provincial Hospital, Hefei, Anhui, 230000, China|The First Affiliated Hospital Of Anhui Medical University, Hefei, Anhui, 230000, China|Beijing Cancer Hospital, Beijing, Beijing, 100000, China|Beijing Chest Hospital,Capital Medical University, Beijing, Beijing, 100000, China|Peking University Third Hospital, Beijing, Beijing, 100000, China|ChongQing University Cancer Hospital, Chongqing, Chongqing, 400000, China|Fujian Medical University Union Hospital, Fuzhou, Fujian, 350000, China|Fujian Provincial Cancer Hospital, Fuzhou, Fujian, 350000, China|The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, 361000, China|The Second Affiliated Hospital of Xiamen Medical College, Xiamen, Fujian, 361000, China|The People's Hospital of Gaozhou, Gaozhou, Guangdong, 525200, China|Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, Guangdong, 510000, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510000, China|The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, 510000, China|Meizhou People's Hospital (Huangtang Hospital), Meizhou, Guangdong, 514000, China|Shantou Central Hospital, Shantou, Guangdong, 515000, China|Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, 524000, China|Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, 541000, China|Guangxi Medical University Affiliated Tumor Hospital, Nanning, Guangxi, 530000, China|The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530000, China|Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, 563000, China|Hainan General Hospital, Haikou, Hainan, 570100, China|The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050000, China|North China University Of Science And Technology Affiliated Hospital, Tangshan, Hebei, 063000, China|Xingtai People's Hospital, Xingtai, Hebei, 054000, China|Haerbin Medical University Cancer Hospital, Ha'erbin, Heilongjiang, 150000, China|Anyang Cancer Hospital, Anyang, Henan, 455000, China|The First Affiliated Hosptial of Henan University of Science & Technology, Luoyang, Henan, 471000, China|Henan Cancer Hospital, Zhengzhou, Henan, 450000, China|The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450000, China|Shiyan Taihe Hospital, Shiyan, Hubei, 442000, China|Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, 430000, China|Xiangyang Central Hospital, Xiangyang, Hubei, 441000, China|Army Medical Center of PLA, Changsha, Hunan, 410000, China|Hunan Cancer Hospital-Thoracic Medicine Department I, Changsha, Hunan, 410000, China|Hunan Cancer Hospital-Thoracic Medicine Department â¡, Changsha, Hunan, 410000, China|Xiangya Hospital Central South University, Changsha, Hunan, 410000, China|Shaoyang Central Hospital, Shaoyang, Hunan, 422000, China|Zhuzhou Central Hospital, Zhuzhou, Hunan, 412000, China|Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, 210000, China|Zhongda Hospital Southeast University, Nanjing, Jiangsu, 210000, China|Nantong Tumor Hospital, Nantong, Jiangsu, 226000, China|Affiliated Hospital of JiangNan University, Wuxi, Jiangsu, 214000, China|The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221000, China|Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, 225000, China|First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, 341000, China|The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330000, China|The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330000, China|Liaoning Cancer Hospital, Shenyang, Liaoning, 110000, China|Shengjing Hospital Affiliated to China Medical University, Shenyang, Liaoning, 110000, China|The First Hospital of China Medical University, Shenyang, Liaoning, 110000, China|Chifeng City Hospital, Chifeng, Neimenggu, 024000, China|The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Neimenggu, 010000, China|Qilu Hospital of Shandong University, Jinan, Shandong, 250000, China|Shandong Cancer Hospital&Institute, Jinan, Shandong, 250000, China|The Affiliated of Qingdao University, Qingdao, Shandong, 266000, China|LinYi Cancer Hospital, Linyi, Shangdong, 276000, China|Fudan University Shanghai Cancer Center, Shanghai, Shanghai, 200000, China|Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, 200000, China|Shanghai Chest Hospital, Shanghai, Shanghai, 200000, China|Shanghai Pulmonary Hospital, Shanghai, Shanghai, 200000, China|Baoji Central Hospital, Baoji, Shanxi, 721000, China|Changzhi People's Hospital, Changzhi, Shanxi, 046000, China|General Hospital of TISCO, Taiyuan, Shanxi, 030000, China|Shanxi Bethune Hospital, Taiyuan, Shanxi, 030000, China|Shanxi Provincial Cancer Hospital, Taiyuan, Shanxi, 030000, China|The Second Affiliated Hospital of Air Force Military University Tangdu Hospital, Xi'an, Shanxi, 710000, China|Sichuan Cancer Hospital, Chengdu, Sichuan, 610000, China|The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, China|Mianyang Central Hospital, Mianyang, Sichuan, 621000, China|Yibin Second People's Hospital, Yibin, Sichuan, 644000, China|Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, 300000, China|Yunnan Cancer Hospital, Kunming, Yunnan, 650000, China|Hangzhou Cancer Hospital, Hangzhou, Zhejiang, 310000, China|The First Affiliated Hospital, College of Medicine, Zhejiang University of Medicine, Hangzhou, Zhejiang, 310000, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310000, China|ZheJiang Cancer Hospital, Hangzhou, Zhejiang, 310000, China",
NCT06522737,A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype,https://clinicaltrials.gov/study/NCT06522737,TERZO,RECRUITING,The study will evaluate the progression-free survival benefit of duvelisib monotherapy as compared to investigator's choice of gemcitabine or bendamustine in participants with relapsed/refractory nodal T cell lymphoma with TFH phenotype.,NO,Lymphoma,DRUG: Duvelisib|DRUG: Gemcitabine|DRUG: Bendamustine,"Progression-free Survival (PFS) as assessed by the Independent Review Committee (IRC), Up to 3 years","Overall Survival (OS), Up to 3 years|PFS as assessed by the investigator, Up to 3 years|Objective Response Rate (ORR) as assessed by the IRC, Up to 3 years|Complete Response Rate (CRR) as assessed by the IRC, Up to 3 years|Duration of Response (DOR) as assessed by the IRC, Up to 3 years|Proportion of participants who proceed to Stem Cell Transplantation (SCT), Up to 3 years|Investigator-assessed PFS in participants who proceed to SCT, Up to 3 years|Number of participants with Adverse Events (AEs), Up to 3 years|Quality of Life (QoL): European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 Score, Up to 3 years|QoL: EQ5D Score, Up to 3 years|QoL: QLQ-NHL-HG29 Score, Up to 3 years",,SecuraBio,,ALL,"ADULT, OLDER_ADULT",PHASE3,124,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2025-05-19,2028-02,2028-12,2024-07-26,,2025-05-23,"The Christie NHS Foundation Trust, Manchester, M20 4BX, United Kingdom",
NCT06319456,A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.,https://clinicaltrials.gov/study/NCT06319456,,RECRUITING,"This is a global, multicenter, randomized, open-label, Phase III confirmatory study to investigate the efficacy and safety of Lisaftoclax (APG-2575) in combination with Acalabrutinib in patients with newly diagnosed CLL/SLL.",NO,CLL/SLL,DRUG: Lisaftoclax (APG-2575)|DRUG: Acalabrutinib|DRUG: Fludarabine|DRUG: Cyclophosphamideï¼CTX|DRUG: Rituximab|DRUG: Chlorambucil,"Progress Free Survival (PFS), PFS is defined as the time from randomization to disease progression(PD) or death from any cause., Up to 1 year","Objective Response Rate (ORR), ORR is defined as the proportion of patients who have achieved CR, CRi or PR., Up to 1 year|Minimal Residual Disease (MRD) negativity rate, To observe the proportion of patients with MRD negativity in bone marrow, peripheral blood, either or both., Up to 1 year|Safety evaluation based on the adverse event concurrence, Number of treatment emergent adverse events (TEAEs) and treatment related adverse events (TRAEs) will be evaluated., Up to 1 year",,Ascentage Pharma Group Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE3,344,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-04-07,2027-08,2028-08,2024-03-20,,2024-05-29,"The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, 233004, China|Guangdong Provincial People's Hospital, Guangzhou, Guangdong, 510080, China|Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, 510515, China|Henan Provincial Cancer Hospital, Zhengzhou, Henan, 450003, China|Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430023, China|Hematology Hospital of the Chinese Academy of Medical Sciences, Tianjin, Tianjin, 300020, China",
NCT03671044,A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients,https://clinicaltrials.gov/study/NCT03671044,,RECRUITING,"The Nanosomal Docetaxel Lipid Suspension (NDLS) consists of uniformly sized micro particles of docetaxel suspended in a lipid based formulation. The advantage of such a Lipid Based formulation of Docetaxel is an improvement of the safety profile by eliminating excipients, polysorbate 80 and ethanol which are present in conventional Docetaxel formulations (TaxotereÂ®). This randomized, open-label study is designed to assess the efficacy and safety of Nanosomal Docetaxel Lipid Suspension at the dose of 75 mg/m2 and at the dose of 100 mg/m2 compared to TaxotereÂ® at the dose of 100 mg/m2 in triple-negative breast cancer patients with Locally Advanced or Metastatic Breast Cancer. Patients will continue the treatment in the absence of disease progression and unacceptable toxicity. Disease status and tumor response will be assessed using Response Evaluation Criteria in Solid Tumors (RECIST 1.1) guidelines. 657 patients (219 patients per arm) will be randomized in the study. The trial will be conducted as per the ICH GCP Guidelines E6 (R1), Schedule Y (Amended Version 2013), Declaration of Helsinki (Fortaleza, Brazil, October 2013), ICMR Guidelines for Biomedical Research on Human subjects and in accordance with other applicable guidelines.",NO,Triple Negative Breast Cancer,DRUG: Nanosomal Docetaxel Lipid Suspension (75 mg/m2)|DRUG: Nanosomal Docetaxel Lipid Suspension (100 mg/m2)|DRUG: TaxotereÂ® (100 mg/m2),"Proportion of the patients with Objective Response Rate (i.e., CR + PR) as the Best Overall Response Rate (i.e., CR + PR) in the test arm (NDLS) compared to reference arm (Taxotere), Non-inferiority of NDLS (75 mg/m2, 100 mg/m2) compared to Taxotere (100 mg/m2), Approximately 2 years after study initiation","Progression free survival (PFS), PFS will be evaluated from the date of first dosing to the date of tumor progression (as per the RECIST 1.1 Criteria) or death (due to any cause) whichever occurred first, Approximately 2 years after study initiation|To evaluate the overall survival (OS) of the patients, OS will be evaluated from the date of first dosing to the date of tumor progression (as per the RECIST 1.1 Criteria) or death (due to any cause) whichever occurred first, Approximately 2 years after study initiation|Incidence of adverse events as assessed by clinical examination, and/or laboratory parameters, adverse events as assessed by CTCAE v4.0, Approximately 2 years after study initiation",,Jina Pharmaceuticals Inc.,"Intas Pharmaceuticals, Ltd.|Lambda Therapeutic Research Ltd.",FEMALE,"ADULT, OLDER_ADULT",PHASE3,657,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2018-07-10,2025-05-31,2025-12-31,2018-09-14,,2025-03-21,"Columbus Regional Research Institute, LLC, Columbus, Georgia, 31904, United States|Cox Medical Center, Springfield, Missouri, 65807, United States|Gabrail Cancer Center, Canton, Ohio, 44718, United States|Kailash Cancer Hospital & Research Centre, Vadodara, Gujarat, 391760, India",
NCT06841354,"A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)",https://clinicaltrials.gov/study/NCT06841354,,RECRUITING,Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sacituzumab tirumotecan alone or with pembrolizumab live longer overall or without the cancer growing or spreading compared to people treated with chemotherapy.,NO,Triple Negative Breast Neoplasms,BIOLOGICAL: Sacituzumab tirumotecan|BIOLOGICAL: Pembrolizumab|DRUG: Rescue Medication|DRUG: Paclitaxel|DRUG: Nab-paclitaxel|DRUG: Gemcitabine|DRUG: Carboplatin,"Progression-Free Survival (PFS) (sac-TMT versus treatment of physician's choice (TPC); sac-TMT plus pembrolizumab versus TPC), PFS is defined as the time from randomization to the first documented progressive disease (PD) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) based on blinded independent central review (BICR) or death due to any cause, whichever occurs first. PD is defined as â¥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of â¥5 mm. The appearance of one or more new lesions is also considered PD., Up to ~37 months|Overall Survival (OS) (sac-TMT versus TPC), OS is defined as the time from randomization to death due to any cause., Up to ~61 months","Overall Survival (OS) (sac-TMT plus pembrolizumab versus treatment of physician's choice (TPC); sac-TMT plus pembrolizumab versus sac-TMT), OS is defined as the time from randomization to death due to any cause., Up to ~61 months|Progression-Free Survival (PFS) (sac-TMT plus pembrolizumab versus sac-TMT), PFS is defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 based on BICR or death due to any cause, whichever occurs first. PD is defined as â¥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of â¥5 mm. The appearance of one or more new lesions is also considered PD., Up to ~37 months|Objective Response Rate (ORR) (sac-TMT versus TPC; sac-TMT plus pembrolizumab versus TPC), ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 based on BICR., Up to ~37 months|Duration of Response (DOR), For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 based on BICR, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death, whichever occurs first. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD., Up to ~37 months|Change from baseline in global health status/quality of life scores, on the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) (sac-TMT versus TPC; sac-TMT plus pembrolizumab versus TPC), The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions ""How would you rate your overall health during the past week?"" and ""How would you rate your overall quality of life during the past week?"" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status., Baseline and up to ~61 months|Change from baseline in physical functioning score, on the EORTC QLQ-C30 (sac-TMT versus TPC; sac-TMT plus pembrolizumab versus TPC), The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better level of physical functioning., Baseline and up to ~61 months|Change from baseline in emotional functioning score, on the EORTC QLQ-C30 (sac-TMT versus TPC; sac-TMT plus pembrolizumab versus TPC), The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to questions about their emotional functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better level of emotional functioning., Baseline and up to ~61 months|Change from baseline in fatigue score, on the EORTC QLQ-C30 (sac-TMT versus TPC; sac-TMT plus pembrolizumab versus TPC), The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to questions about their fatigue are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better level of function., Baseline and up to ~61 months|Change from baseline in diarrhea score, on the EORTC QLQ-C30 (sac-TMT versus TPC; sac-TMT plus pembrolizumab versus TPC), The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to the question ""Have you had diarrhea?"" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better level of function., Baseline and up to ~61 months|Number of participants who experience one or more adverse events (AEs), An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention., Up to ~61 months|Number of participants who discontinue study treatment due to an AE, An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention., Up to ~61 months",,Merck Sharp & Dohme LLC,,ALL,"ADULT, OLDER_ADULT",PHASE3,1000,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2025-03-16,2030-05-18,2030-05-18,2025-02-24,,2025-06-13,"Ironwood Cancer & Research Centers ( Site 0036), Chandler, Arizona, 85224, United States|Yale New Haven Hospital ( Site 0001), New Haven, Connecticut, 06510, United States|Comprehensive Cancer Centers of Nevada ( Site 0015), Las Vegas, Nevada, 89119, United States|Renown Regional Medical Center ( Site 0005), Reno, Nevada, 89502, United States|New Mexico Oncology Hematology Consultants Ltd. ( Site 0019), Albuquerque, New Mexico, 87109, United States|Fundacion Estudios Clinicos ( Site 2405), Rosario, Santa Fe, S2000DEJ, Argentina|Rambam Health Care Campus ( Site 3700), Haifa, 3109601, Israel|Shaare Zedek Medical Center ( Site 3704), Jerusalem, 9103102, Israel|Rabin Medical Center ( Site 3702), Petah Tikva, 4941492, Israel|Sheba Medical Center ( Site 3701), Ramat Gan, 5265601, Israel|Sourasky Medical Center ( Site 3703), Tel Aviv, 6423906, Israel|Mie University Hospital ( Site 5109), Tsu, Mie, 514-8507, Japan|Showa Medical University Hospital ( Site 5103), Shinagawa, Tokyo, 142-8666, Japan|Seoul National University Bundang Hospital ( Site 5204), Seongnam, Kyonggi-do, 13620, Korea, Republic of|Kyungpook National University Chilgok Hospital ( Site 5205), Daegu, Kyongsangbuk-do, 41404, Korea, Republic of|Seoul National University Hospital ( Site 5200), Seoul, 03080, Korea, Republic of|Severance Hospital Yonsei University Health System ( Site 5201), Seoul, 03722, Korea, Republic of|Samsung Medical Center ( Site 5203), Seoul, 06351, Korea, Republic of|Taichung Veterans General Hospital ( Site 5303), Taichung, 407, Taiwan|National Cheng Kung University Hospital ( Site 5304), Tainan, 70403, Taiwan|Mackay Memorial Hospital ( Site 5301), Taipei, 104, Taiwan",
NCT06855069,HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer,https://clinicaltrials.gov/study/NCT06855069,,NOT_YET_RECRUITING,"This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of HS-20089 versus investigator's choice of chemotherapy in patients with platinum-resistant recurrent epithelial ovarian cancer.",NO,Ovarian Cancer,DRUG: HS-20089|DRUG: Paclitaxel|DRUG: Doxorubicin|DRUG: Topotecan,"Progression-free Survival (PFS) assessed by Blinded Independ Review Committee (BIRC) as per RECIST 1.1, Screening up to study completion, an average of 1 year","Overall Survival (OS), Screening up to study completion, an average of 1 year|Objective Response Rate (ORR), assessed by site investigator as per RECIST 1.1, Screening up to study completion, an average of 1 year|Duration of Response (DoR), assessed by site investigator as per RECIST 1.1, Screening up to study completion, an average of 1 year|Disease Control Rate (DCR), assessed by site investigator as per RECIST 1.1, Screening up to study completion, an average of 1 year|Objective Response Rate (ORR), assessed by BIRC as per RECIST 1.1, Screening up to study completion, an average of 1 year|Duration of Response (DoR), assessed by BIRC as per RECIST 1.1, Screening up to study completion, an average of 1 year|Disease Control Rate (DCR), assessed by BIRC as per RECIST 1.1, Screening up to study completion, an average of 1 year|Adverse Events, Screening up to study completion, an average of 1 year",,Hansoh BioMedical R&D Company,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,468,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2025-03-07,2027-03-07,2029-03-07,2025-03-03,,2025-03-03,"Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China",
NCT04224493,"A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.",https://clinicaltrials.gov/study/NCT04224493,SYMPHONY-1,RECRUITING,"The participants of this study would have relapsed/refractory follicular lymphoma.

Follicular lymphoma is a type of blood cancer. It is referred to as 'relapsed' when the disease has come back after a period of improvement after that follows a treatment regimen and 'refractory' when treatment no longer works.

Stage 1 of this trial will study the safety and the level that adverse effects of each of the study drug combinations can be tolerated (known as tolerability). It is also designed to establish a recommended study drug dosage for stage 2 and 3. Stage 1 of the study is completed.

Stages 2 and 3 will evaluate and compare how long participants live without their disease getting worse when receiving the study drug in combination with other drug treatment versus the placebo (dummy drug) in combination with other drug treatment.",NO,Relapsed/Refractory Follicular Lymphoma|Follicular Lymphoma|Refractory Follicular Lymphoma,DRUG: Tazemetostat|DRUG: Tazemetostat|DRUG: Placebo oral tablet|COMBINATION_PRODUCT: Lenalidomide|COMBINATION_PRODUCT: Rituximab,"Recommended Phase 3 Dose (RP3D) of tazemetostat in combination with rituximab and lenalidomide (R2), The safety and tolerability of tazemetostat in combination with R2 in subjects with R/R FL will be evaluated. RP3D of tazemetostat for further evaluation in phase 3 will be selected as assessed by the occurrence of treatment-emergent dose-limiting toxicities (DLTs) and adverse events (AEs)., Subjects are evaluated for DLTs during the first 28-day cycle. The RP3D for Phase 3 was selected at the end of Stage 1|Progression-Free Survival (PFS) in the Intent-to-treat wild-type (ITT-WT) population, PFS is defined as the time from the date of randomization to the time of confirmed disease progression per the 2014 Lugano Classification or death, whichever occurs first, as assessed by Investigators., Stage 2: Up to 72 months|PFS in the Intent-to-treat mutant-type (ITT-MT) population, PFS is defined as the time from the date of randomization to the time of confirmed disease progression per the 2014 Lugano Classification or death, whichever occurs first, as assessed by Investigators., Stage 2: Up to 72 months","Pharmacokinetics (PK) of tazemetostat: Maximum (peak) Observed Plasma Drug Concentration (Cmax)., Cmax will be recorded from the PK blood samples collected., Stage 1: In cycles 1 and 2 on days 1 and 15 (28 days cycle)|PK of tazemetostat, EPZ 6930 (desethyl metabolite), and lenalidomide as data permit: Time to Maximum Observed Drug Concentration (Tmax), Stage 1: In cycles 1 and 2 on days 1 and 15 (28 days cycle)|PK of tazemetostat: area under the plasma concentration-time curve (AUC) from time 0 to the time of the last quantifiable concentration [AUC(0-t)],, Stage 1: In cycles 1 and 2 on days 1 and 15 (28 days cycle)|PK of tazemetostat: area under the plasma concentration-time curve (AUC) from time 0 to infinity [AUC(0-â)], Stage 1: In cycles 1 and 2 on days 1 and 15 (28 days cycle)|The apparent terminal elimination half-life (t1/2) of tazemetostat, EPZ 6930 (desethyl metabolite), and lenalidomide as data permit, Stage 1: In cycles 1 and 2 on days 1 and 15 (28 days cycle)|Complete Response Rate (CRR) in ITT-WT population, CRR is defined as the proportion of participants achieving CR according to the 2014 Lugano Classification, as assessed by the Investigator and a blinded Independent Review Committee (IRC)., Stage 2: Up to 96 months|CRR in ITT-MT population, CRR is defined as the proportion of participants achieving CR according to the 2014 Lugano Classification, as assessed by the Investigator and a blinded IRC., Stage 2: Up to 96 months|CRR in the Relapsed/Refractory (R/R) Follicular Lymphoma (FL) population regardless of mutation status, CRR is defined as the proportion of participants achieving CR according to the 2014 Lugano Classification, as assessed by the Investigator and a blinded IRC., Stage 2: Up to 96 months|Objective Response Rate (ORR) in the ITT-WT population, ORR is defined as the proportion of participants achieving a best overall response (BOR) of partial response (PR) or complete response (CR) according to the 2014 Lugano Classification, as assessed by the Investigator and a blinded IRC., Stage 2: Up to 96 months|ORR in the ITT-MT population, ORR is defined as the proportion of participants achieving a best overall response (BOR) of partial response (PR) or complete response (CR) according to the 2014 Lugano Classification, as assessed by the Investigator and a blinded IRC., Stage 2: Up to 96 months|ORR in the R/R FL population regardless of mutation status, ORR is defined as the proportion of participants achieving a best overall response (BOR) of partial response (PR) or complete response (CR) according to the 2014 Lugano Classification, as assessed by the Investigator and a blinded IRC., Stage 2: Up to 96 months|Overall Survival (OS) in the ITT-WT population, OS is defined as the time from the date of randomization until death due to any cause., Stage 2: Up to 96 months|OS in the ITT-MT population, Stage 2: Up to 96 months|OS in the R/R FL population regardless of mutation status, Stage 2: Up to 96 months|PFS in the ITT-WT population, assessed by a blinded IRC, Stage 2: Up to 96 months|PFS in the ITT-MT population, assessed by a blinded IRC, Stage 2: Up to 96 months|PFS in the R/R FL population regardless of mutation status, assessed by a blinded IRC, Stage 2: Up to 96 months|PFS in the R/R FL population regardless of mutation status, assessed by the Investigator, Stage 2: Up to 96 months|Duration Of Response (DOR) in the ITT-WT population, DOR is defined as the time from initial CR or PR to documented progression or death due to any cause, whichever occurs first, for those participants with a CR or PR, as assessed by the Investigator and by a blinded IRC., Stage 2: Up to 96 months|DOR in the ITT-MT population, DOR is defined as the time from initial CR or PR to documented progression or death due to any cause, whichever occurs first, for those participants with a CR or PR, as assessed by the Investigator and by a blinded IRC., Stage 2: Up to 96 months|DOR in the R/R FL population regardless of mutation status, DOR is defined as the time from initial CR or PR to documented progression or death due to any cause, whichever occurs first, for those participants with a CR or PR, as assessed by the Investigator and by a blinded IRC., Stage 2: Up to 96 months|Duration Of Complete Response (DOCR) in the ITT-WT population, DOCR is defined as the time from initial CR to documented progression or death due to any cause, whichever occurs first, for those participants with CR, assessed by the Investigator and by a blinded IRC., Stage 2: Up to 96 months|DOCR in the ITT-MT population, DOCR is defined as the time from initial CR to documented progression or death due to any cause, whichever occurs first, for those participants with CR, assessed by the Investigator and by a blinded IRC., Stage 2: Up to 96 months|DOCR in the R/R FL population regardless of mutation status, DOCR is defined as the time from initial CR to documented progression or death due to any cause, whichever occurs first, for those participants with CR, assessed by the Investigator and by a blinded IRC., Stage 2: Up to 96 months|Disease Control Rate (DCR) in the ITT-WT population, DCR, defined as the proportion of participants with best overall response of CR, PR, or stable disease (SD) lasting 12 or more months, as assessed by the Investigator and by a blinded IRC., Stage 2: Up to 96 months|DCR in the ITT-MT population, DCR, defined as the proportion of participants with best overall response of CR, PR, or stable disease (SD) lasting 12 or more months, as assessed by the Investigator and by a blinded IRC., Stage 2: Up to 96 months|DCR in the R/R FL population regardless of mutation status, DCR, defined as the proportion of participants with best overall response of CR, PR, or stable disease (SD) lasting 12 or more months, as assessed by the Investigator and by a blinded IRC., Stage 2: Up to 96 months|Population PK parameters of oral clearance (CL/F) of tazemetostat, CL/F will be used to generate estimates of tazemetostat AUC, Stage 2: In cycles 2, 4, 6, and 12 at Day 1 (28 days cycle)|Population PK parameters of oral volume of distribution (Vd/F) of tazemetostat., Stage 2: In cycles 2, 4, 6, and 12 at Day 1 (28 days cycle)|Population PK parameters of first-order absorption rate constant (Ka) for tazemetostat., Stage 2: In cycles 2, 4, 6, and 12 at Day 1 (28 days cycle)|Percentage of Participants Experiencing Adverse Events (AEs), An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention., Up to 36 months|Percentage of Participants with Clinically Significant Changes in Physical Examination, Percentage of participants with clinically significant changes in physical examination findings will be reported. The clinical significance will be graded by the investigator according to the National Cancer Institute Common Terminology Criteria for AEs (CTCAE) Version 5.0., Up to 36 months|Percentage of Participants with Clinically Significant Changes in Vital Signs, Percentage of participants with clinically significant changes in vital signs findings will be reported. The clinical significance will be graded by the investigator according to the National Cancer Institute Common Terminology Criteria for AEs (CTCAE) Version 5.0., Up to 36 months|Percentage of Participants with Clinically Significant Changes in Electrocardiogram (ECG) Readings, Percentage of participants with clinically significant changes in ECG Readings will be reported. The clinical significance will be graded by the investigator according to the National Cancer Institute Common Terminology Criteria for AEs (CTCAE) Version 5.0., Up to 72 months|Performance status evaluated by Eastern Cooperation Oncology Group (ECOG), ECOG is a 6-point performance status scale used to assess performance using PA as a key indicator (e.g., 0 = fully active, 2 = up and about more than 50% of walking hours, 5 = dead) Performance status will be assessed per usual clinical practice and will be recorded in the medical record., Up to 72 months|Duration of Study Drug Exposure, Duration of exposure to study drug will be reported., Up to 36 months|Percentage of study drug taken by participants, Up to 36 months|Quality of life questionnaires evaluation, Evaluate and compare health-related quality of life as measured by the EuroQOL 5-Dimension 5-Level (EQ-5D-5L) instrument and the Functional Assessment of Cancer Therapy -Lymphoma (FACT-Lym), Up to 36 months",,"Epizyme, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE3,612,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-06-11,2026-03-01,2029-03-01,2020-01-13,,2025-05-28,"Southern Cancer Center, Mobile, Alabama, 36608, United States|Arizona Oncology Associates - Tuscon-Rusadill Road, Tucson, Arizona, 85704, United States|TOI - Clinical Research, Cerritos, California, 90703, United States|UCSF Fresno, Clovis, California, 93611, United States|UC San Diego Health Sciences, La Jolla, California, 92093, United States|UCLA Clinical Research Unit Hematology/Oncology, Santa Monica, California, 90404, United States|Rocky Mountain Cancer Centers (RMCC) - Boulder, Boulder, Colorado, 80303, United States|St. Mary's Hospital and Regional Medical Center - St. Mary's, Grand Junction, Colorado, 81501, United States|SCL Health Lutheran Medical Center, Greeley, Colorado, 80033, United States|Cancer Specialists of North Florida, Fleming Island, Florida, 32003, United States|Florida Cancer Specialists & Research Institute (FCS) - Fort Myers Cancer Center, Fort Myers, Florida, 33908, United States|Mayo Clinic - Cancer Clinical Research Office, Jacksonville, Florida, 32224, United States|Mayo Clinic, Jacksonville, Florida, 32224, United States|Miami Cancer Institute, Miami, Florida, 33176, United States|Florida Cancer Affiliates/Ocala Oncology - Clinic, Ocala, Florida, 34474, United States|BRCR Medical Center, INC, Plantation, Florida, 33322, United States|Florida Cancer Specialists, Saint Petersburg, Florida, 33705, United States|Florida Cancer Specialists - Panhandle, Tallahassee, Florida, 32308, United States|H Lee Moffitt Cancer Center and Research Institute I, Tampa, Florida, 33612, United States|Florida Cancer Specialists & Research Institute (FCS) - Atlantis, West Palm Beach, Florida, 33401, United States|Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii, 96819, United States|University of Chicago, Chicago, Illinois, 60637, United States|Illinois Cancer Specialists, Niles, Illinois, 60714, United States|June E. Nylen Cancer Center, Sioux City, Iowa, 51101, United States|The University of Kansas Cancer Center, Overland Park, Kansas, 66210, United States|University of Maryland, Baltimore, Maryland, 21201, United States|The office of Frederick P. Smith, MD, P.C., Chevy Chase, Maryland, 20815-6908, United States|Mass General Cancer Center at Newton-Wellesley, Newton, Massachusetts, 02462, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, 48109, United States|St. Joseph Mercy Hospital, Ypsilanti, Michigan, 48197, United States|Mayo Clinic - Rochester, Rochester, Minnesota, 55901, United States|Saint Louis University Cancer Center, Saint Louis, Missouri, 63110, United States|University Of Nebraska Medical Center, Omaha, Nebraska, 68198, United States|Astera Cancer Care, East Brunswick, New Jersey, 08816, United States|Astera Cancer Center, East Brunswick, New Jersey, 08816, United States|Regional Cancer Care Associates-Freehold, Freehold, New Jersey, 07728, United States|Hackensack University Medical John Theurer Cancer Center, Hackensack, New Jersey, 07601, United States|Regional Cancer Care Associates LLC - Howell, Howell, New Jersey, 07731, United States|Regional Cancer Care Associates LLC - Little Silver, Little Silver, New Jersey, 07739, United States|New Mexico Cancer Care Alliance, Albuquerque, New Mexico, 87131-0001, United States|New York Oncology Hematology, P.C., Albany, New York, 12206, United States|Northwell Health/Monter Cancer Center, Lake Success, New York, 11042, United States|Weill Cornell Medicine-New York Presbyterian Hospital, New York, New York, 10021, United States|Columbia U - Herbert Irving Comprehensive Cancer Center, New York, New York, 10032, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, 10065, United States|Hematology Oncology Associates of Rockland, P.C., Nyack, New York, 10960, United States|Messino Cancer Center, Asheville, North Carolina, 28806, United States|Levine Cancer Institute - Concord, Concord, North Carolina, 28205, United States|FirstHealth of the Carolinas, Pinehurst, North Carolina, 28374, United States|Gabrail Cancer Center Research, Canton, Ohio, 44718, United States|Oncology Hematology Care (OHC), Inc. - Kenwood Office, Cincinnati, Ohio, 45236, United States|Willamette Valley Cancer Institute and Research Center - Oncology, Eugene, Oregon, 97401, United States|University of Pittsburgh Medical Center - Oncology, Pittsburgh, Pennsylvania, 15232, United States|Western Pennsylvania Hospital Hematology & Cellular Therapy, Pittsburgh, Pennsylvania, 15524, United States|Tennessee Oncology, PLLC, Chattanooga, Tennessee, 37404, United States|University of Tennessee Medical Center - Cancer Institute, Knoxville, Tennessee, 37920, United States|Sarah Cannon Research Institute, Nashville, Tennessee, 37203, United States|Texas Oncology - Amarillo, Amarillo, Texas, 79124, United States|Texas Oncology-Austin Midtown, Austin, Texas, 78705, United States|Texas Oncology - Medical City Dallas Pediatric Hematology, Dallas, Texas, 75230, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, 75246, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|Millennium Physicians - Oncology, Houston, Texas, 77090, United States|Texas Oncology, Plano, Texas, 75075, United States|Mays Cancer Center, San Antonio, Texas, 78229, United States|UT Health East Texas HOPE Cancer Center - Tyler, Tyler, Texas, 75701, United States|USO Texas Oncology - Tyler, Tyler, Texas, 75702, United States|Texas Oncology- Weslaco, Weslaco, Texas, 78596, United States|Utah Cancer Specialists/ IHO Corp, Salt Lake City, Utah, 84106, United States|Huntsman Cancer Institute; The University of Utah, Salt Lake City, Utah, 84112, United States|Peninsula Cancer Institute, Chesapeake, Virginia, 23320, United States|Virginia Cancer Specialists, Gainesville, Virginia, 22155, United States|Oncology and Hematology Associates of Southwest Virginia Inc., Roanoke, Virginia, 24014, United States|MC Rockwood Cancer Bl Specialty Ctr - North, Spokane, Washington, 99218, United States|Yakima Valley Memorial Hospital - North Star Lodge Cancer Center, Yakima, Washington, 98902, United States|Wheeling Hospital, Wheeling, West Virginia, 26003, United States|Royal Adelaide Hospital, Adelaide, South Australia, 5000, Australia|Flinders Medical Centre, Bedford Park, South Australia, 5042, Australia|Monash Health, Clayton, Victoria, 3168, Australia|Barwon Health, University Hospital Geelong, Geelong, Victoria, 3220, Australia|Hollywood Private Hospital, Nedlands, Western Australia, 6009, Australia|GenesisCare - St Andrew's, Adelaide, Australia|Peninsula Health - Frankston, Frankston, Australia|Royal Hobart Hospital, Hobart, Australia|Gold Coast University Hosptial, Southport, Australia|CHU Dinant Godinne UCL Namur, Yvoir, Namur, 5530, Belgium|Universitair Ziekenhuis Gent, Gent, Oost-Vlaanderen, 9000, Belgium|UZ Leuven - Campus Gasthuisberg, Leuven, Vlaams Brabant, 3000, Belgium|University Health Network Princess Margaret Hospital, Toronto, Ontario, M5G 2M9, Canada|Centre Hospitalier de l'Universite de Montreal (CHUM), MontrÃ©al, Quebec, H2X 3E4, Canada|Sir Mortimer B Davis/Jewish General Hospital, MontrÃ©al, Quebec, H3T 1E2, Canada|Fujian Medical University Union Hospital, Fuzhou, Fujian, 350001, China|The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, 361003, China|The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, 550004, China|The Second Affiliated Hospital Zhejiang University School of Medicine, Zhejiang, Hangzhou, 310000, China|The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, China|Henan Provincial People's Hospital, Zhengzhou, Henan, 450008, China|Henan Cancer Hospital, Zhengzhou, Henan, 45008, China|Hunan Cancer Hospital, Changsha, Hunan, 410013, China|The First Bethune Hospital of Jilin University, Changchun, Jinlin, 130021, China|The Affiliated Hospital of Qingdao University, Qingdao, Shandong, 266071, China|Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, 20025, China|Shanxi Bethune Hospital, Taiyuan, Shanxi, 30032, China|Peking University Third Hospital, Beijing, 100191, China|Tongji Hospital of Tongji Medical College of HUST, Hangzhou, China|Jiangxi Cancer Hospital, Nanchang, China|Tongji Hospital of Tongji University, Shanghai, China|Sichuan Provincial People's Hospital, Sichuan, China|Tianjin Medical University Cancer Institute & Hospital, Tianjin, 300060, China|Centre Hospitalier Universitaire de Bordeaux-Hopital du Haut Leveque, Pessac Cedex, Aquitaine, 33600, France|CHRU Brest HÃ´p Morvan, Brest, Bretagne, 29609, France|Institut Bergonie, Bordeaux, Gironde, 33000, France|Centre Hosp Mulh Hop Emile Muller, Mulhouse, Haut-Rhin, 68100, France|Centre Henri Becquerel, Rouen, Haute-Normandie, 76038, France|CHU de Limoges Dupuytren, Limoges, Haute-Vienne, 87042, France|CHU de Grenoble - Hopital Albe, La Tronche, Isere, 38700, France|CHU de Nantes - Hematologie, Nantes, Loire-Atlantique, 44000, France|CHRU de Lille Hop Claude Huriez, Lille, Nord, 59037, France|Centre Hospitalier Le Mans, Le Mans, Sarthe, 72000, France|Centre Hospitalier Universitaire D'Angers - HÃ©matologie Clinique, Angers, France|CHRU de BesanÃ§on- Hopital Jean Minjoz, Besancon, 25000, France|CHU Caen, Caen, 14000, France|CHU de Clermont-Ferrand, site Estaing, Clermont-Ferrand, 63000, France|Centre Hospitalier Docteur Schaffner, Lens, France|L'HÃ´pital PrivÃ© Confluent, Nantes, 44202, France|L'hÃ´pital PrivÃ© du Concluent, Nantes, France|Hopital Saint Louis, Paris, 75010, France|Centre Hospitalier Universitaire de Poitiers, Poitiers, France|Centre Hospitalier - HÃ´pital de jour d'HÃ©matologie, PÃ©rigueux, France|CHU de Nancy Brabois, VandÅuvre-lÃ¨s-Nancy, 54511, France|Centre Hospitalier Bretagne Atlantique, Vannes, 56017, France|Institut Gustave Roussy, Villejuif, France|Hopital Henri Mondor - Hemopathies Lymphoides, CrÃ©teil, Ãle-de-France, 94010, France|Diakoneo Diak Schwaebisch Hall gGmbH, SchwÃ¤bisch Hall, Baden-WÃ¼rttemberg, 74523, Germany|Klinikum Der UniversitÃ¤t MÃ¼nchen AÃ¶R, MÃ¼nchen, Bayern, 81377, Germany|Klinikum rechts der Isar der Technischen Universitat Muenche, MÃ¼nchen, Bayern, 81675, Germany|UniversitÃ¤tsmedizin Mainz, Mainz, Hessen, 55131, Germany|Universitaetsklinikum Bonn AÃ¶R, Bonn, Nordrhein-Westfalen, 53127, Germany|Kliniken Maria Hilf GmbH, Moenchengladbach, Nordrhein-Westfalen, 41063, Germany|StÃ¤dt. Krankenhaus Kiel, Kiel, Schleswig-Holstein, 24116, Germany|Vivantes Klinikum am Urban HÃ¤matologie und Onkologie, Berlin, Germany|University Medical Center Schleswig Holstein, Kiel, Germany|Debreceni Egyetem Klinikai KÃ¶zpont, Debrecen, HajdÃº-Bihar, 4032, Hungary|Semmelweis Egyetem ÃltalÃ¡nos OrvostudomÃ¡nyi Kar, Budapest, 1088, Hungary|OrszÃ¡gos OnkolÃ³giai IntÃ©zet, Budapest, 1122, Hungary|Del-pesti Centrumkorhaz Orszagos Hematologiai Ã©s Infektologiai Intezet, Budapest, H-1097, Hungary|AOU Federico II, Napoli, Campania, 80122, Italy|Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori IRCCS, Meldola, Forli-Cesena, 47014, Italy|ASST Spedali Civili di Brescia, Brescia, 25123, Italy|PO Garibaldi-Nesima, ARNAS Garibaldi, Catania, 95122, Italy|AOU Careggi, Firenze, 50134, Italy|Ospedale Vito Fazzi, ASL Lecce, Lecce, Italy|IEO - Istituto Europeo di Oncologia, IRCCS, Milano, Italy|Ospedale Maggiore Policlinico, Fondazione IRCCS Ca' Granda, Milano, Italy|Ospedale Niguarda, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy|Ospedale San Gerardo, ASST di Monza, Monza, Italy|Ospedale Civile S.Spirito, PO di Pescara, AUSL Pescara, Pescara, Italy|Ospedale Infermi di Rimini, AUSL Rimini, Distretto di Rimini, Presidio di Rimini, Santarcangelo di Romagna e Novafeltria, Rimini, Italy|Catholic University Of Sacred Heart, Roma, 00168, Italy|PU Campus Bio-Medico di Roma, Roma, Italy|Regina Elena, Istituto Nazionale dei Tumori , IFO, IRCCS, Roma, Italy|Azienda Ospedaliera Santa Maria di Terni, Terni, 05100, Italy|Azienda Ospedaliera Ordine Mauriziano di Torino, Ospedale Umberto I di Torino, Torino, Italy|Ospedale S.Giacomo Apostolo, PO Castelfranco Veneto, AULSS 2 Marca Trevigiana, Treviso, Italy|Azienda Sanitaria Universitaria Giuliano Isontina (ASU GI), Ospedale Maggiore, Trieste, Italy|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Seoul Teugbyeolsi [Seoul-T'ukp], 06591, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Seoul Teugbyeolsi [Seoul-T'ukp, 03722, Korea, Republic of|Samsung Medical Center, Seoul, Seoul Teugbyeolsi [Seoul-T'ukp, 06351, Korea, Republic of|Seoul National University Hospital, Seoul, Seoul Teugbyeolsi, 03080, Korea, Republic of|Pusan National University Hospital, Busan, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Ajou University Hospital, Suwon, Korea, Republic of|Narodowy Instytut Onkologii im. Marii SkÅodowskiej-Curie - PaÅstwowy Instytut Badawczy, Warszawa, Mazowieckie, 02-781, Poland|Centrum Medyczne Pratia Poznan, Skorzewo, Wielkopolskie, 60-185, Poland|Pratia Onkologia Katowice, Katowice, Poland|Pratia MCM Krakow, KrakÃ³w, 30-727, Poland|Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka w Slupsku Sp. z o.o., SÅupsk, 76-200, Poland|MICS Centrum Medyczne Torun, Torun, 87-100, Poland|MTZ Clinical Research powered by Pratia, Warszawa, Poland|Uniwersytecki Szpital Kliniczny im. J. Mikulicza-Radeckiego we Wroclawiu, Wroclaw, 50-367, Poland|Hospital Universitari Vall d'HebrÃ³n, Barcelona, Cataluny, 08035, Spain|Hospital Costa del Sol, Marbella, MÃ¡laga, 29603, Spain|Hospital Del Mar, Barcelona, 08003, Spain|Hospital Univ. Infanta Leonor, Madrid, 28031, Spain|Hospital Universitario La Paz, Madrid, 28046, Spain|C.H. de Navarra, Pamplona, Spain|Hospital Universitario de Salamanca, Salamanca, 37007, Spain|Hospital Universitario Nuestra SeÃ±ora de Valme, Sevilla, 41014, Spain|Hospital Universitario Virgen De La Macarena, Sevilla, Spain|Buddihist Tzu Chi Medical Foundation- Hualien Tzu Chi Hospital, Hualien City, Taiwan|Chang Gung Medical Foundation - Kaohsiung Chang Gung Memorial Hospital - Hemato-Oncology, Kaohsiung, 833, Taiwan|Taichung Veterans General Hospital, Taichung, 40705, Taiwan|National Cheng Kung University Hospital, Tainan, 704, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Ankara University Medical Faculty - Hematology, Ankara, Turkey|Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research, Ankara, Turkey|Gazi University Medical Faculty, Ankara, Turkey|Medipol Bagcilar Mega Hospital, Istanbul, Turkey|Ondokuz Mayis University Medical Faculty - Hematology, Samsun, Turkey|Western General Hospital - Haematology, Edinburgh, Edinburgh, City Of, EH4 2XU, United Kingdom|Imperial College Healthcare NHS Trust - Hammersmith Hospital, London, London City, W12 0HS, United Kingdom|St Bartholomew's Hospital Barts Health NHS Trust, London, London, City Of, EC1A 7BE, United Kingdom|The Clatterbridge Cancer Centre NHS Foundation Trust - Clatterbridge Cancer Centre, Bebington, United Kingdom|Royal Cornwall Hospitals NHS Trust - Royal Cornwall Hospital, Cornwell, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, G12 0YN, United Kingdom|Northwick Park Hospital Middlesex, United Kindgom, HA1 3UJ, Middlesex, United Kingdom",
NCT04951648,A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation,https://clinicaltrials.gov/study/NCT04951648,,UNKNOWN,To assess the efficacy and safety of Almonertinib versus platinum-based chemotherapy as first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutation.,NO,Non-small Cell Lung Cancer,DRUG: Almonertinib|DRUG: chemotherapy,"Progression-free survival (PFS) assessed by IRC (Independent Review Committee), PFS is defined as the time from randomization until the date of objective disease progression or death regardless of whether the patient withdraws from randomised therapy or receives another anti-cancer therapy prior to progression, based on blinded independent central review assessment according to RECIST 1.1., Tumor scans performed at baseline then every ~6 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression; up to a maximum of approximately 2 years.","PFS assessed by INVs (Investigators), PFS is defined as the time from randomization until the date of disease progression as assessed by INVs according to RECIST 1.1 or death from any cause on study., Tumor scans performed at baseline then every ~6 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression; up to a maximum of approximately 2 years.|Objective response rate (ORR) assessed by IRC, ORR is defined as the number (%) of patients with at least 1 visit response of CR (Complete response) or PR (Partial response) based on blinded independent central review assessment according to RECIST 1.1., Tumor scans performed at baseline then every ~6 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression; up to a maximum of approximately 2 years.|Duration of response (DoR) assessed by IRC, DoR is defined as the time from date for first documented response of until the documented response of progression per RECIST 1.1 or death in the absence of progression based on blinded independent central review assessment., Tumor scans performed at baseline then every ~6 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression; up to a maximum of approximately 2 years.|Disease control rate (DCR) assessed by IRC, DCR is defined as the percentage of patients who have a best overall response of CR or PR or SD based on blinded independent central review assessment according to RECIST 1.1., Tumor scans performed at baseline then every ~6 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression; up to a maximum of approximately 2 years.|Depth of response (DepOR) assessed by IRC, DepOR is defined as the change amount of the sum of the lengths of the longest diameters of the target lesions on blinded independent central review assessment according to RECIST 1.1 in the absence of New Lesions (NLs) or progression of Non-Target Lesions when compared to baseline., Tumor scans performed at baseline then every ~6 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression; up to a maximum of approximately 3 years.|Proportion of patients alive and progression free at 6 months (APF6) assessed by IRC, APF6 is defined as the percentage (%) of patients who were alive and progression free per RECIST 1.1 at 6 months after randomization., Tumor scans performed at baseline then every ~6 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 6 months post-randomization.|Proportion of patients alive and progression free at 9 months (APF9) assessed by IRC, APF9 is defined as the percentage (%) of patients who were alive and progression free per RECIST 1.1 at 9 months after randomization., Tumor scans performed at baseline then every ~6 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 9 months post-randomization.|Proportion of patients alive and progression free at 12 months (APF12) assessed by IRC, APF12 is defined as the percentage (%) of patients who were alive and progression free per RECIST 1.1 at 12 months after randomization., Tumor scans performed at baseline then every ~6 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 12 months post-randomization.|Proportion of patients alive and progression free at 24 months (APF24) assessed by IRC, APF24 is defined as the percentage (%) of patients who were alive and progression free per RECIST 1.1 at 24 months after randomization., Tumor scans performed at baseline then every ~6 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 24 months post-randomization.|Overall survival (OS), OS is deï¬ned as the time from the date of randomization until death due to any cause., From the date of randomization until death due to any cause; up to a maximum of approximately 3 years.|Percentage of patients alive at 36 months (OS36), OS36 was defined as the percentage (%) of patients who were alive at 36 months after randomization per the Kaplan-Meier estimate of OS at 36 months., From randomization until death due to any cause, up to a maximum of approximately 3 years.|Incidence of Adverse Events (AEs), AEs are graded according to CTCAE v5.0 and recorded in the case report form., From the screening period to 28 days after treatment completion, approximately 3 years.",,"Jiangsu Hansoh Pharmaceutical Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,220,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-07-15,2023-10-04,2024-09-06,2021-07-07,,2021-07-07,"Sun yat-sen Univerisity Cancer Center, Guangzhou, Guangdong, China",
NCT05950945,Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer,https://clinicaltrials.gov/study/NCT05950945,,RECRUITING,This study will evaluate the safety and efficacy of trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor receptor 2 (HER2)-low or HER2 immunohistochemistry (IHC) 0 (who are both hormone receptor \[HR\]-negative and HR-positive) unresectable and/or metastatic breast cancer.,NO,Breast Cancer,DRUG: Trastuzumab Deruxtecan,"Time From the Start of T-DXd to Initiation of Subsequent Anticancer Treatment (TTNT), TTNT is defined as the time interval from the date of first dose of T-DXd to the initiation of the next anticancer treatment or death due to any cause., Until subsequent therapy or death, assessed up to 24 months","Real-World Progression Free Survival (PFS), Real-world PFS is defined as time from date of first dose of T-DXd to time of disease progression per investigator assessment based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or death due to any cause., Until progression or death, assessed up to 24 months|Time From Start of T-DXd to Discontinuation of T-DXd or Death (TTD), TTD is defined as the time interval from the date of first dose of T-DXd to the date of discontinuation of T-DXd or death due to any cause., Until treatment discontinuation or death, up to 24 months|Objective Response Rate (ORR), ORR is defined as the proportion of participants with a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) according to the investigator and per RECIST version 1.1 criteria., Until progression, assessed up to 24 months|Number of Participants With Treatment-emergent Adverse Events (TEAEs), TEAEs are graded according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0. A TEAE is defined as an adverse event (AE) that occurs, having been absent before the first dose of study drug, or has worsened in severity or seriousness after initiating the study drug until 47 days after the last dose of the study drug., Up to follow up period, up to 24 months|Mean Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaires (EORTC-QLQ)-C30 Score, Change from baseline in the EORTC-QLQ-C30 scale scores range from 0-100. For functioning and global health status/ QoL scales, higher scores indicate better functioning or global health status/QoL. For symptom scales, higher scores indicate greater symptom burden., Assessed up to 24 months|Mean Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaires (EORTC-QLQ)-BR45 Score, Change from baseline in the EORTC QLQ-BR45 scale scores range from 0-100. For functioning and global health status/ QoL scales, higher scores indicate better functioning or global health status/QoL. For symptom scales, higher scores indicate greater symptom burden., Assessed up to 24 months|Time to First and Definitive Deterioration in European Organization for Research and Treatment of Cancer Quality of Life Questionnaires (EORTC-QLQ) Scales, Time to first and definitive deterioration in EORTC-QLQ scales. Scale scores range from 0-100. For functioning and global health status/ QoL scales, higher scores indicate better functioning or global health status/QoL. For symptom scales, higher scores indicate greater symptom burden., Assessed up to 24 months|Mean Change from Baseline in EuroQol Questionnaire-5 Dimensions-5 Levels (EQ-5D-5L), Change from baseline in EQ-5D-5L. The EQ-5D-5L is a health-related QoL questionnaire based on five dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension contains five levels: no problems, slight, moderate, severe, and extreme problems. The EQ-5D-5L results can be converted into a single utility value. Utility values range from 0 to 1, with 1 corresponding to perfect health and 0 corresponding to a health status equivalent to death. In addition, participants can provide an overall rating of their current health status using a visual analog scale ranging from 0 (worse) to 100 (better)., Assessed up to 24 months|Mean Change From Baseline in EuroQol Questionnaire-5 Dimensions-5 Levels (EQ-5D-5L) Index Score, Change from baseline in EQ-5D-5L index score. The EQ-5D-5L index score ranges from less than 0 (worse) to 1 (better), with higher scores representing a better health status., Assessed up to 24 months|Mean Change From Baseline in EuroQol Questionnaire-5 Dimensions-5 Levels (EQ-5D-5L) Visual Analog Scale (VAS), Change from baseline in EQ-5D-5L VAS. The EQ-5D-5L VAS ranging from 0 (worse) to 100 (better) is used to assess an overall rating of participant's current health status. Higher scores indicate better clinical outcomes., Assessed up to 24 months|Time to First and Definitive Deterioration in EuroQol Questionnaire-5 Dimensions-5 Levels (EQ-5D-5L) Visual Analog Scale (VAS), Time to first and definitive deterioration in EQ-5D-5L VAS. The EQ-5D-5L VAS ranging from 0 (worse) to 100 (better) is used to assess an overall rating of participant's current health status. Higher scores indicate better clinical outcomes., Assessed up to 24 months|Patient's Global Impression of Change (PGI-C) Response, The PGI-C is a single-item questionnaire asking for the participant's overall impression of changes in clinical condition from baseline (prior to study drug initiation), where 1 is ""Normal"" and 7 is ""Severely ill"". Lower scores indicate better clinical outcome., Assessed up to 24 months|Patient's Global Impression of Severity (PGI-S) Response, The PGI-S is a single-item questionnaire asking for the subject's overall impression of symptoms assessed over the past week, where 1 is ""Normal"" and 4 is ""Severe"". Lower scores indicate better clinical outcome., Assessed up to 24 months|Patient's Global Impression of Treatment Tolerability (PGI-TT) Response, The PGI-TT is a single-item questionnaire asking for the subject's overall impression of treatment tolerability over the past week, where 1 is ""Not at all"" and 5 is ""Very much"". Higher scores indicate a worse outcome., Assessed up to 24 months",,Daiichi Sankyo,AstraZeneca,ALL,"ADULT, OLDER_ADULT",PHASE3,250,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-12-30,2027-10-01,2027-10-01,2023-07-18,,2025-04-29,"Mount Sinai Medical Center, Miami Beach, Florida, 33140, United States|USF College of Medicine, Tampa, Florida, 33602, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Beth Israel Lahey Health, Burlington, Massachusetts, 01805, United States|Overlook Medical Center, Summit, New Jersey, 07901, United States|Mater Hospital Sydney, North Sydney, New South Wales, 2065, Australia|Monash Medical Centre Moorabbin, East Bentleigh, Victoria, 3165, Australia|Institut Jules Bordet, Anderlecht, 1070, Belgium|GZA Ziekenhuizen, Antwerpen, 2610, Belgium|Universitair Ziekenhuis Brussel, Bruxelles, 1090, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, 1200, Belgium|UZ Leuven, Leuven, 3000, Belgium|Centre Hospitalier Universitaire de Liege Sart-Tilman, Liege, 4000, Belgium|GZA Ziekenhuizen, Wilrijk, 2610, Belgium|Centro de Oncologia - Unidade BrasÃ­lia - Hospital SÃ­rio LibanÃªs, Brasilia, 71635-610, Brazil|CIONC-Centro Integrado de Oncologia de Curitiba, Curitiba, 80810-050, Brazil|Hospital Erasto Gaertner - Liga Paranaense de Combate ao CÃ¢ncer, Curitiba, 81520-060, Brazil|CEPON - Centro de Pesquisas OncolÃ³gicas de Santa Catarina, Florianopolis, 88034-000, Brazil|Oncosite - Centro de Pesquisa Clinica e Oncologia, IjuÃ­, 98700-000, Brazil|FundaÃ§Ã£o Doutor Amaral Carvalho, JaÃº, 17.210 - 080, Brazil|Instituto de Cancer de Londrina, Londrina, 86015-520, Brazil|Hospital das ClÃ­nicas FMRP-USP, RiberÃ£o Preto, 14015-010, Brazil|Hospital Nossa Senhora da Conceicao, Rio Grande Do Sul, 88701-160, Brazil|Ensino e Terapia de InovaÃ§Ã£o ClÃ­nica AMO-ETICA, Salvador, 41810-570, Brazil|Catarina Pesquisa Clinica, Santa Catarina, 88301-220, Brazil|CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia, Santo AndrÃ©, 09060-650, Brazil|Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto, Sao Jose do Rio Preto, 15090-000, Brazil|ICESP - Instituto do CÃ¢ncer do Estado de SÃ£o Paulo Octavio Frias de Oliveira, SÃ£o Paulo, 01246-000, Brazil|ClÃ­nica de Pesquisas e Centro de Estudos em Oncologia GinecolÃ³gica e MamÃ¡ria Ltda, SÃ£o Paulo, 01317-001, Brazil|Beijing Hospital, Beijing, 100006, China|307 Hospital of PLA, Beijing, 100161, China|Fujian Cancer Hospital, Fujian, 350011, China|Sun Yat sen University Cancer Center, Guangzhou, 510060, China|Zhejiang Cancer Hospital, Hangzhou, 310022, China|Anhui Provincial Cancer Hospital, Hefei, 230031, China|Shandong Cancer Hospital, Jinan, 250117, China|Yunnan Cancer Hospital, Kunming, 650107, China|Nanchang People's Hospital, Nanchang, 330006, China|Jiangxi Cancer Hospital, Nanchang, 330029, China|The Affiliated Hospital of Qingdao University, Qingdao, 266000, China|Fudan University Shanghai Cancer Center, Shanghai, 200032, China|Henan Cancer Hospital, Zhengzhou, 450008, China|Cork University Hospital, Cork, T12 EC8P, Ireland|St Vincent's University Hospital, Dublin, D04 T6F4, Ireland|St James Hospital, Dublin, D08 NHY1, Ireland|Beaumont Hospital, Dublin, Dublin 9, Ireland|Galway University Hospital, Galway, H91 YR71, Ireland|Istituto Tumori Giovanni Paolo II IRCCS Ospedale Oncologico Bari, Bari, 70124, Italy|Azienda Ospedaliera Universitaria Policlinico Sant Orsola Malpighi IRCCS, Bologna, 40138, Italy|Istituto Nazionale per la Ricerca sul Cancro di Genova, Genova, 16132, Italy|Ospedale San Raffaele, Milano, 20132, Italy|Humanitas Istituto Clinico Catanese, Misterbianco, 95045, Italy|Istituto Nazionale Tumori Fondazione G Pascale, Naples, 80131, Italy|IOV - Istituto Oncologico Veneto IRCCS, Padova, 35128, Italy|Nuovo Ospedale di Prato, Prato, 59100, Italy|Azienda Ospedaliera Universitaria Policlinico Umberto I - UniversitÃ  di Roma La Sapienza, Rome, 00161, Italy|Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, 00168, Italy|Ospedale Santa Chiara, Trento, 38123, Italy|Amsterdam UMC, Locatie VUMC, Amsterdam, 1081 HV, Netherlands|Amphia Ziekenhuis Molengracht, Breda, 4818 CK, Netherlands|Haga Ziekenhuis, Den Haag, 2545 AA, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, 8934 AD, Netherlands|Alrijne Ziekenhuis Leiden, Leiden, 2334, Netherlands|Maastricht University Medical Center, Maastricht, 6229 HX, Netherlands|Elisabeth TweeSteden Ziekenhuis, Tilburg, 5022 GC, Netherlands|Bernhoven Uden, Uden, 5406, Netherlands|Hospital de Braga, Braga, 4710-243, Portugal|Instituto PortuguÃªs de Oncologia de Lisboa Francisco Gentil, EPE, Lisboa, 1099-023, Portugal|Centro Hospitalar de Lisboa Norte E P E Hospital de Santa Maria, Lisboa, 1649-028, Portugal|Hospital de la Santa Creu i Sant Pau, Barcelona, 08025, Spain|ICO l'Hospitalet - Hospital Duran i Reynals, Barcelona, 08908, Spain|Hospital Universitario Virgen de las Nieves, Granada, 18014, Spain|Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas de Gran Canaria, 35016, Spain|Hospital Beata Maria Ana, Madrid, 28007, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, 28222, Spain|Hospital General Universitario Morales Meseguer, Murcia, 30008, Spain|Clinica Universidad de Navarra, Pamplona, 31008, Spain|Hospital Universitario Donostia, San Sebastian, 20014, Spain|Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, 15706, Spain|Hospital Universitario Virgen Macarena, Sevilla, 41009, Spain|Hospital Clinico Universitario de Valencia, Valencia, 46010, Spain|Hospital Arnau de Vilanova de Valencia, Valencia, 46015, Spain",
NCT06767514,Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1,https://clinicaltrials.gov/study/NCT06767514,HARMONi-7,RECRUITING,Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.,NO,Non-Small Cell Lung Cancer,BIOLOGICAL: Ivonescimab Injection|BIOLOGICAL: Pembrolizumab Injection,"Overall Survival (OS), Up to approximately 36 months|Progression free survival (PFS), Up to approximately 36 months","Objective response rate (ORR), Up to approximately 36 months|Disease control rate ( DCR), Up to approximately 36 months|Duration of response (DoR), Up to approximately 36 months|Adverse Events (AE): incidence and severity of adverse events (AEs) and clinically significant abnormal laboratory test results, [Time Frame: From the subject signs the ICF to 30 days (AE) and 90 days (SAE related to ivonescimab/pembrolizumab ) after the last dose of study treatment or initiation of other anticancer therapy, whichever occurs first, Up to approximately 24 months.",,Summit Therapeutics,,ALL,"ADULT, OLDER_ADULT",PHASE3,780,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2025-02-27,2028-04,2029-06,2025-01-10,,2025-04-29,"Clinical Study Site, Hot Springs, Arkansas, 71913, United States|Clinical Study Site, Cerritos, California, 90703, United States|Clinical Study Site, Los Angeles, California, 90067, United States|Clinical Study Site, Lone Tree, Colorado, 80124, United States|Clinical Study Site, Fort Lauderdale, Florida, 33316, United States|Clinical Study Site, Fort Myers, Florida, 33901, United States|Clinical Study Site, Hialeah, Florida, 33013, United States|Clinical Study Site, Jacksonville, Florida, 32256, United States|Clinical Study Site, Miami, Florida, 33155, United States|Clinical Study Site, Plantation, Florida, 33322, United States|Clinical Study Site, Saint Petersburg, Florida, 33705, United States|Clinical Study Site, Tamarac, Florida, 33321, United States|Clinical Study Site, West Palm Beach, Florida, 33401, United States|Clinical Study Site, Atlanta, Georgia, 30318, United States|Clinical Study Site, Boston, Massachusetts, 02215, United States|Clinical Study Site, Saint Paul, Minnesota, 55101, United States|Clinical Study Site, Kansas City, Missouri, 64132, United States|Clinical Study Site, Mullica Hill, New Jersey, 08062, United States|Clinical Study Site, Columbus, Ohio, 43219, United States|Clinical Study Site, Eugene, Oregon, 97401, United States|Clinical Study Site, Austin, Texas, 78745, United States|Clinical Study Site, Dallas, Texas, 75246, United States|Clinical Study Site, Webster, Texas, 77598, United States",
NCT05952557,An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2),https://clinicaltrials.gov/study/NCT05952557,CAMBRIA-2,RECRUITING,This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm within the study will be 7 years.,NO,"Breast Cancer, Early Breast Cancer",DRUG: Camizestrant|DRUG: Tamoxifen|DRUG: Anastrozole|DRUG: Letrozole|DRUG: Exemestane|DRUG: Abemaciclib,"Invasive breast cancer-free survival (IBCFS), IBCFS is defined as time from randomisation until date of first occurrence of:

* Invasive ipsilateral breast tumour recurrence
* Locoregional invasive breast cancer recurrence
* Distant recurrence
* Contralateral invasive breast cancer
* Death attributable to any cause., Up to 14 years","Invasive disease-free survival (IDFS), IDFS is defined as time from randomisation until date of first occurrence of one of the following events:

* Invasive ipsilateral breast tumor recurrence
* Locoregional invasive breast cancer recurrence
* Distant recurrence
* Contralateral invasive breast cancer
* Second primary non-breast invasive cancer
* Death attributable to any cause., Up to 14 years|Distant relapse-free survival (DRFS), DRFS is defined as time from randomisation until date of first distant recurrence or death from any cause, whichever occurs first., Up to 14 years|Overall survival (OS), OS is defined as time from randomisation until death from any cause., Up to 14 years|Incidence and Severity of Adverse Events, with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI-CTCAE v5.0), Until 28 days after the final dose of study treatment (up to 7 years)|Proportion of time on study treatment with high side-effect burden as measured by the PGI-TT., Until 28 days after the final dose of study treatment (up to 7 years)|Change from baseline and time to deterioration of health-related quality of life as measured by the 2 global QoL items from the EORTC IL-311, Until 28 days after the final dose of study treatment (up to 7 years)|Pharmacokinetics (PK), Plasma concentrations of camizestrant pre-dose (trough concentration), Until 6 months from treatment start",,AstraZeneca,Austrian Breast and Colorectal Cancer Study Group (ABCSG),ALL,"ADULT, OLDER_ADULT",PHASE3,5500,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-10-05,2030-03-04,2037-05-06,2023-07-19,,2025-05-21,"Research Site, Dothan, Alabama, 36303, United States|Research Site, Phoenix, Arizona, 85054, United States|Research Site, Tucson, Arizona, 85745, United States|Research Site, Fayetteville, Arkansas, 72703, United States|Research Site, Duarte, California, 91010, United States|Research Site, Fountain Valley, California, 92708, United States|Research Site, Greenbrae, California, 94904, United States|Research Site, Irvine, California, 92618, United States|Research Site, La Jolla, California, 92093, United States|Research Site, Los Angeles, California, 90017, United States|Research Site, Monterey, California, 93940, United States|Research Site, Walnut Creek, California, 94598, United States|Research Site, West Hollywood, California, 90048, United States|Research Site, Aurora, Colorado, 80045, United States|Research Site, Littleton, Colorado, 80120, United States|Research Site, Littleton, Colorado, 80129, United States|Research Site, New Haven, Connecticut, 06510, United States|Research Site, Newark, Delaware, 19713, United States|Research Site, Washington, District of Columbia, 20016, United States|Research Site, Clearwater, Florida, 33756, United States|Research Site, Fort Myers, Florida, 33901, United States|Research Site, Gainesville, Florida, 32610, United States|Research Site, Jacksonville, Florida, 32224, United States|Research Site, Orlando, Florida, 32806, United States|Research Site, Pembroke Pines, Florida, 33028, United States|Research Site, Plantation, Florida, 33322, United States|Research Site, Plantation, Florida, 33324, United States|Research Site, Saint Petersburg, Florida, 33705, United States|Research Site, Saint Petersburg, Florida, 33709, United States|Research Site, Tallahassee, Florida, 32308, United States|Research Site, West Palm Beach, Florida, 33401, United States|Research Site, Atlanta, Georgia, 30318, United States|Research Site, Atlanta, Georgia, 30322, United States|Research Site, Columbus, Georgia, 31904, United States|Research Site, Marietta, Georgia, 30060, United States|Research Site, Savannah, Georgia, 31404, United States|Research Site, Thomasville, Georgia, 31792, United States|Research Site, Chicago, Illinois, 60637, United States|Research Site, Elmhurst, Illinois, 60126, United States|Research Site, Naperville, Illinois, 60540, United States|Research Site, Park Ridge, Illinois, 60068, United States|Research Site, Plainfield, Illinois, 60585, United States|Research Site, Urbana, Illinois, 61801, United States|Research Site, Fort Wayne, Indiana, 46804, United States|Research Site, Des Moines, Iowa, 50309, United States|Research Site, Fairway, Kansas, 66205, United States|Research Site, Louisville, Kentucky, 40202, United States|Research Site, New Orleans, Louisiana, 70121, United States|Research Site, Scarborough, Maine, 04074, United States|Research Site, Annapolis, Maryland, 21401, United States|Research Site, Baltimore, Maryland, 21201, United States|Research Site, Baltimore, Maryland, 21287, United States|Research Site, Bethesda, Maryland, 20817, United States|Research Site, Lutherville, Maryland, 21093, United States|Research Site, Towson, Maryland, 21204, United States|Research Site, Boston, Massachusetts, 02111, United States|Research Site, Boston, Massachusetts, 02115, United States|Research Site, Hyannis, Massachusetts, 02601, United States|Research Site, Worcester, Massachusetts, 01655, United States|Research Site, Detroit, Michigan, 48202, United States|Research Site, Flint, Michigan, 48503, United States|Research Site, Ypsilanti, Michigan, 48197, United States|Research Site, Minneapolis, Minnesota, 55416, United States|Research Site, Rochester, Minnesota, 55905, United States|Research Site, Kansas City, Missouri, 64111, United States|Research Site, Saint Louis, Missouri, 63110, United States|Research Site, Saint Louis, Missouri, 63131, United States|Research Site, Lincoln, Nebraska, 68506, United States|Research Site, Omaha, Nebraska, 68124, United States|Research Site, Omaha, Nebraska, 68198, United States|Research Site, Hooksett, New Hampshire, 03106, United States|Research Site, Lebanon, New Hampshire, 03756, United States|Research Site, Manchester, New Hampshire, 03103, United States|Research Site, New Brunswick, New Jersey, 08901, United States|Research Site, Albuquerque, New Mexico, 87109, United States|Research Site, Farmington, New Mexico, 87401, United States|Research Site, Bay Shore, New York, 11706, United States|Research Site, East Syracuse, New York, 13057, United States|Research Site, Greenlawn, New York, 11740, United States|Research Site, New Hyde Park, New York, 11042, United States|Research Site, New York, New York, 10029, United States|Research Site, New York, New York, 10065, United States|Research Site, New York, New York, 10065, United States|Research Site, Stony Brook, New York, 11794, United States|Research Site, White Plains, New York, 10601, United States|Research Site, Charlotte, North Carolina, 28204, United States|Research Site, Durham, North Carolina, 27710, United States|Research Site, Greensboro, North Carolina, 27403, United States|Research Site, Greenville, North Carolina, 27834, United States|Research Site, Pinehurst, North Carolina, 28374, United States|Research Site, Raleigh, North Carolina, 27607, United States|Research Site, Winston-Salem, North Carolina, 27103, United States|Research Site, Blue Ash, Ohio, 45242, United States|Research Site, Cincinnati, Ohio, 45255, United States|Research Site, Cleveland, Ohio, 44106, United States|Research Site, Columbus, Ohio, 43212, United States|Research Site, Toledo, Ohio, 43623, United States|Research Site, Youngstown, Ohio, 44504, United States|Research Site, Oklahoma City, Oklahoma, 73104, United States|Research Site, Portland, Oregon, 97210, United States|Research Site, Portland, Oregon, 97213, United States|Research Site, Portland, Oregon, 97225, United States|Research Site, Gettysburg, Pennsylvania, 17325, United States|Research Site, Hershey, Pennsylvania, 17033, United States|Research Site, Philadelphia, Pennsylvania, 19104, United States|Research Site, Pittsburgh, Pennsylvania, 15213, United States|Research Site, Sayre, Pennsylvania, 18840, United States|Research Site, York, Pennsylvania, 17403, United States|Research Site, Charleston, South Carolina, 29425, United States|Research Site, Greenville, South Carolina, 29605, United States|Research Site, Rock Hill, South Carolina, 29732, United States|Research Site, Spartanburg, South Carolina, 29303, United States|Research Site, Aberdeen, South Dakota, 57401, United States|Research Site, Sioux Falls, South Dakota, 57105, United States|Research Site, Chattanooga, Tennessee, 37404, United States|Research Site, Knoxville, Tennessee, 37909, United States|Research Site, Knoxville, Tennessee, 37920, United States|Research Site, Memphis, Tennessee, 38120, United States|Research Site, Nashville, Tennessee, 37203, United States|Research Site, Nashville, Tennessee, 37232, United States|Research Site, Austin, Texas, 78731, United States|Research Site, Bedford, Texas, 76022, United States|Research Site, Dallas, Texas, 75230, United States|Research Site, Dallas, Texas, 75231, United States|Research Site, Dallas, Texas, 75246, United States|Research Site, El Paso, Texas, 79902, United States|Research Site, Flower Mound, Texas, 75028, United States|Research Site, Houston, Texas, 77024, United States|Research Site, Houston, Texas, 77030, United States|Research Site, Plano, Texas, 75075, United States|Research Site, San Antonio, Texas, 78217, United States|Research Site, Tyler, Texas, 75702, United States|Research Site, Salt Lake City, Utah, 84112, United States|Research Site, Charlottesville, Virginia, 22908, United States|Research Site, Fairfax, Virginia, 22031, United States|Research Site, Midlothian, Virginia, 23114, United States|Research Site, Norfolk, Virginia, 23502, United States|Research Site, Richmond, Virginia, 23219, United States|Research Site, Roanoke, Virginia, 24014, United States|Research Site, Winchester, Virginia, 22601, United States|Research Site, Puyallup, Washington, 98373, United States|Research Site, Spokane, Washington, 99202, United States|Research Site, Vancouver, Washington, 98684, United States|Research Site, Charleston, West Virginia, 25304, United States|Research Site, Morgantown, West Virginia, 26505, United States|Research Site, Appleton, Wisconsin, 54911, United States|Research Site, Madison, Wisconsin, 53792, United States|Research Site, Milwaukee, Wisconsin, 53215, United States|Research Site, Buenos Aires, C1025ABI, Argentina|Research Site, Buenos Aires, C1417, Argentina|Research Site, Buenos Aires, C1426ANZ, Argentina|Research Site, Caba, C1061, Argentina|Research Site, Capital Federal, 1118, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, 1426, Argentina|Research Site, Ciudad de CÃ³rdoba, X5800HHW, Argentina|Research Site, Cordoba, 5001, Argentina|Research Site, La Plata, 1900, Argentina|Research Site, Rosario, 2123, Argentina|Research Site, San Juan, 5400, Argentina|Research Site, San Miguel de Tucuman, T4000IAK, Argentina|Research Site, Viedma, R8500ACE, Argentina|Research Site, Adelaide, 5081, Australia|Research Site, Bankstown, 2200, Australia|Research Site, Bendigo, 3550, Australia|Research Site, Bowral, 2576, Australia|Research Site, Brighton, 3186, Australia|Research Site, Clayton, 3168, Australia|Research Site, Coffs Harbour, 2450, Australia|Research Site, Fitzroy, 3065, Australia|Research Site, Frankston, 3199, Australia|Research Site, Garran, 2605, Australia|Research Site, Gateshead, 2290, Australia|Research Site, Heidelberg, 3084, Australia|Research Site, Liverpool, 2170, Australia|Research Site, Melbourne, 3004, Australia|Research Site, Murdoch, WA6150, Australia|Research Site, Randwick, 2031, Australia|Research Site, Richmond, 3121, Australia|Research Site, Shepparton, 3630, Australia|Research Site, South Brisbane, 4101, Australia|Research Site, St Leonards, 2065, Australia|Research Site, Subiaco, 6008, Australia|Research Site, Traralgon, 3844, Australia|Research Site, Wangaratta, 3677, Australia|Research Site, Waratah, 2298, Australia|Research Site, Warnnambool, 3280, Australia|Research Site, Wollongong, 2500, Australia|Research Site, Graz, 8036, Austria|Research Site, Innsbruck, 6020, Austria|Research Site, Klagenfurt, 9020, Austria|Research Site, Linz, 4010, Austria|Research Site, Linz, 4021, Austria|Research Site, Salzburg, 5020, Austria|Research Site, St. Veit an der Glan, 9300, Austria|Research Site, Steyr, 4400, Austria|Research Site, Vienna, 1090, Austria|Research Site, Wels, 4600, Austria|Research Site, Wiener Neustadt, 2700, Austria|Research Site, Wien, 1090, Austria|Research Site, Wien, 1130, Austria|Research Site, Wien, 1160, Austria|Research Site, Wien, 1180, Austria|Research Site, Aalst, 9300, Belgium|Research Site, Anderlecht, 1070, Belgium|Research Site, Brasschaat, 2930, Belgium|Research Site, Bruxelles, 1200, Belgium|Research Site, Charleroi, 6000, Belgium|Research Site, Edegem, 2650, Belgium|Research Site, Gent, 9000, Belgium|Research Site, Leuven, 3000, Belgium|Research Site, Namur, 5000, Belgium|Research Site, Wilrijk, 2610, Belgium|Research Site, Alfenas, 37130-000, Brazil|Research Site, Belo Horizonte, 30130-100, Brazil|Research Site, Blumenau, 89010-340, Brazil|Research Site, BrasÃ­lia, 71615-907, Brazil|Research Site, Curitiba, 80730-380, Brazil|Research Site, Curitiba, 80810-050, Brazil|Research Site, Fortaleza, 60135-237, Brazil|Research Site, Fortaleza, 60430-230, Brazil|Research Site, GoiÃ¢nia, 74000-000, Brazil|Research Site, Itajai, 88301-220, Brazil|Research Site, Joao Pessoa, 58013-140, Brazil|Research Site, Natal, 59075-740, Brazil|Research Site, Porto Alegre, 90035-001, Brazil|Research Site, Porto Alegre, 90050-170, Brazil|Research Site, Porto Alegre, 90610000, Brazil|Research Site, Porto Velho, 76834-899, Brazil|Research Site, Pouso Alegre, 37554-216, Brazil|Research Site, Recife, 50070-480, Brazil|Research Site, RibeirÃ£o Preto, 14015-130, Brazil|Research Site, Rio de Janeiro, 20560-120, Brazil|Research Site, Rio De Janeiro, 22793-080, Brazil|Research Site, Salvador, 40170-110, Brazil|Research Site, Santo AndrÃ©, 09060-650, Brazil|Research Site, Sao Paulo, 01327-001, Brazil|Research Site, Sao Paulo, 03102-006, Brazil|Research Site, SÃ£o Paulo, 01246-000, Brazil|Research Site, SÃ£o Paulo, 01409-902, Brazil|Research Site, TaubatÃ©, 12030-200, Brazil|Research Site, Teresina, 64049-200, Brazil|Research Site, Tres Lagoas, 79601-001, Brazil|Research Site, VitÃ³ria, 29043-260, Brazil|Research Site, Dobrich, 9300, Bulgaria|Research Site, Haskovo, 6300, Bulgaria|Research Site, Plovdiv, 4002, Bulgaria|Research Site, Plovdiv, 4004, Bulgaria|Research Site, Shumen, 9700, Bulgaria|Research Site, Sofia, 1330, Bulgaria|Research Site, Sofia, 1404, Bulgaria|Research Site, Sofia, 1407, Bulgaria|Research Site, Sofia, 1431, Bulgaria|Research Site, Varna, 9010, Bulgaria|Research Site, Vratsa, 3000, Bulgaria|Research Site, Calgary, Alberta, T2N 4N2, Canada|Research Site, Edmonton, Alberta, t6G1Z2, Canada|Research Site, Kelowna, British Columbia, V1Y 5L3, Canada|Research Site, North Vancouver, British Columbia, V7L 2L7, Canada|Research Site, Halifax, Nova Scotia, B3H 2Y9, Canada|Research Site, Barrie, Ontario, L4M 6M2, Canada|Research Site, Kingston, Ontario, K7L 2V7, Canada|Research Site, Sault Ste. Marie, Ontario, P6A 0A8, Canada|Research Site, Sudbury, Ontario, P3E 5J1, Canada|Research Site, Thunder Bay, Ontario, P7B 6V4, Canada|Research Site, Windsor, Ontario, N8W 2X3, Canada|Research Site, Chicoutimi, Quebec, G7H 5H6, Canada|Research Site, Levis, Quebec, G6V 3Z1, Canada|Research Site, Montreal, Quebec, H1T 2M4, Canada|Research Site, Montreal, Quebec, H2X 3E4, Canada|Research Site, Montreal, Quebec, H4A 3J1, Canada|Research Site, Saskatoon, Saskatchewan, S7N 4H4, Canada|Research Site, Quebec, G1S 4L8, Canada|Research Site, Concepcion, 4070196, Chile|Research Site, La Serena, 1720430, Chile|Research Site, Providencia, 7510032, Chile|Research Site, Puerto Montt, 5500243, Chile|Research Site, Santiago, 7620157, Chile|Research Site, Santiago, 8150215, Chile|Research Site, Santiago, 8330032, Chile|Research Site, Santiago, 8330336, Chile|Research Site, Temuco, 4810218, Chile|Research Site, Vina del Mar, 2520000, Chile|Research Site, Baoding, 071000, China|Research Site, Beijing, 100021, China|Research Site, Beijing, 100039, China|Research Site, Beijing, 100142, China|Research Site, Beijing, 100191, China|Research Site, Beijing, 100730, China|Research Site, Bengbu, 233004, China|Research Site, Binzhou, 256606, China|Research Site, Cangzhou, 061001, China|Research Site, Changchun, 130021, China|Research Site, Changsha, 410008, China|Research Site, Chengdu, 610042, China|Research Site, Chengdu, 610072, China|Research Site, Chifeng, 024000, China|Research Site, Dalian, 116011, China|Research Site, Foshan, 528000, China|Research Site, Fuzhou, 350014, China|Research Site, Guangzhou Shi, 510168, China|Research Site, Guangzhou, 510060, China|Research Site, Guangzhou, 510080, China|Research Site, Haikou, 570311, China|Research Site, Haikou, 570311, China|Research Site, Hangzhou, 310000, China|Research Site, Hangzhou, 310009, China|Research Site, Hangzhou, 310016, China|Research Site, Hangzhou, 310022, China|Research Site, Harbin, 150081, China|Research Site, Hefei, 230001, China|Research Site, Hefei, 230012, China|Research Site, Hefei, 230022, China|Research Site, Hefei, 230601, China|Research Site, Hohhot, 010017, China|Research Site, Huizhou, 516001, China|Research Site, Jinzhou, 121001, China|Research Site, Lanzhou, 730050, China|Research Site, Linyi, 276000, China|Research Site, Liuzhou, 545005, China|Research Site, Liuzhou, 545006, China|Research Site, Nanchang, 330009, China|Research Site, Nanjing, 210009, China|Research Site, Nanjing, 210029, China|Research Site, Nanning, 530021, China|Research Site, Nantong, 226001, China|Research Site, Neijiang, 641000, China|Research Site, Shandong, 250117, China|Research Site, Shangqiu, 476100, China|Research Site, Shantou, 515031, China|Research Site, Shaoguan Shi, 512025, China|Research Site, Shenyang, 110001, China|Research Site, Shenyang, 110042, China|Research Site, Shenzhen, 518020, China|Research Site, Shenzhen, 518116, China|Research Site, Shijiazhuang, 050011, China|Research Site, Suining Shi, 629000, China|Research Site, Suzhou, 215004, China|Research Site, Suzhou, 215006, China|Research Site, Suzhou, 215600, China|Research Site, Taizhou, 317000, China|Research Site, Tianjin, 300060, China|Research Site, Weifang, 261000, China|Research Site, Wuhan, 430030, China|Research Site, Wuhan, 430060, China|Research Site, Wuhan, 430079, China|Research Site, Xiangfan, 441021, China|Research Site, Xian, 710004, China|Research Site, Xinxiang, 453100, China|Research Site, Xuzhou, 221002, China|Research Site, Xuzhou, 221009, China|Research Site, Zunyi, 563100, China|Research Site, Barranquilla, 080020, Colombia|Research Site, Bogota, 110221, Colombia|Research Site, Cali, 760042, Colombia|Research Site, Medellin, 050030, Colombia|Research Site, Monteria, 23001, Colombia|Research Site, Valledupar, 200001, Colombia|Research Site, Osijek, 31000, Croatia|Research Site, Rijeka, 51000, Croatia|Research Site, Split, 21000, Croatia|Research Site, Zadar, 23000, Croatia|Research Site, Zagreb, 10000, Croatia|Research Site, Brno, 625 00, Czechia|Research Site, Horovice, 26831, Czechia|Research Site, Liberec, 46063, Czechia|Research Site, Pardubice, 532 03, Czechia|Research Site, Praha 5, 150 06, Czechia|Research Site, Tallinn, 11619, Estonia|Research Site, Tallin, 10138, Estonia|Research Site, Tartu, 50406, Estonia|Research Site, Angers, 49100, France|Research Site, Bordeaux, 33076, France|Research Site, Caen cedex 05, 14076, France|Research Site, Clermont-Ferrand, 63000, France|Research Site, Dijon, 21000, France|Research Site, Epagny Metz-Tessy, 74370, France|Research Site, Lille, 59000, France|Research Site, Lyon, 75004, France|Research Site, Marseille, 13273, France|Research Site, Montpellier, 34298, France|Research Site, Nantes, 44277, France|Research Site, Nimes, 30029, France|Research Site, Paris, 75005, France|Research Site, Pierre Benite, 69495, France|Research Site, Plerin SUR MER, 22190, France|Research Site, Rennes, 35000, France|Research Site, Rouen, 76021, France|Research Site, Saint Herblain, 44800, France|Research Site, Saint-cloud, 92210, France|Research Site, Saint-Priest-En-Jarez, 42270, France|Research Site, Strasbourg, 67033, France|Research Site, Toulouse, 31059, France|Research Site, Vandoeuvre les Nancy, 54519, France|Research Site, Villejuif Cedex, 94805, France|Research Site, Batumi, 6000, Georgia|Research Site, Tbilisi, 0102, Georgia|Research Site, Tbilisi, 0112, Georgia|Research Site, Tbilisi, 0179, Georgia|Research Site, Tbilisi, 0186, Georgia|Research Site, Tbilisi, 114, Georgia|Research Site, Tbilisi, 160, Georgia|Research Site, Aachen, 52074, Germany|Research Site, Berlin, 12559, Germany|Research Site, Darmstadt, 64283, Germany|Research Site, Deggendorf, 94469, Germany|Research Site, Dessau-Rosslau, 6847, Germany|Research Site, Dresden, 01127, Germany|Research Site, DÃ¼sseldorf, 40235, Germany|Research Site, Essen, 45130, Germany|Research Site, Freudenstadt, 72250, Germany|Research Site, Georgsmarienhuette, 49124, Germany|Research Site, Hamburg, 20357, Germany|Research Site, Hamburg, 22457, Germany|Research Site, Hamm, 59073, Germany|Research Site, Hanau, 63450, Germany|Research Site, Hannover, 30177, Germany|Research Site, Hannover, 30559, Germany|Research Site, Heidelberg, 69120, Germany|Research Site, Karlsruhe, 76135, Germany|Research Site, Koblenz, 56068, Germany|Research Site, KÃ¶ln, 51067, Germany|Research Site, Mainz, 55131, Germany|Research Site, Nurtingen, 72622, Germany|Research Site, Offenburg, 77654, Germany|Research Site, Rostock, 18057, Germany|Research Site, SaarbrÃ¼cken, 66113, Germany|Research Site, Schweinfurt, 97421, Germany|Research Site, Speyer, 67346, Germany|Research Site, Torgau, 4860, Germany|Research Site, Wiesbaden, 65189, Germany|Research Site, Wiesbaden, 65199, Germany|Research Site, Witten, 58452, Germany|Research Site, Worms, 67550, Germany|Research Site, Wuppertal, 42283, Germany|Research Site, Athens, 115 22, Greece|Research Site, Athens, 11527, GR, Greece|Research Site, Athens, 11528, Greece|Research Site, Athens, 11528, Greece|Research Site, Athens, 12462, Greece|Research Site, Heraklion, 71110, Greece|Research Site, Ioannina, 455 00, Greece|Research Site, Larissa, 41335, GR, Greece|Research Site, Marousi, 151 23, Greece|Research Site, Marousi, 151 23, Greece|Research Site, Piraeus, 185 37, Greece|Research Site, Rio, 265 04, Greece|Research Site, Thessaloniki, 546 39, Greece|Research Site, Thessaloniki, 54645, Greece|Research Site, Thessaloniki, 552 36, Greece|Research Site, Thessaloniki, 56403, Greece|Research Site, Budapest, 1082, Hungary|Research Site, Budapest, 1122, Hungary|Research Site, Debrecen, 4032, Hungary|Research Site, Gyula, 5700, Hungary|Research Site, GyÅr, 9024, Hungary|Research Site, KaposvÃ¡r, 7400, Hungary|Research Site, KecskemÃ©t, 6000, Hungary|Research Site, Miskolc, 3526, Hungary|Research Site, NyÃ­regyhÃ¡za, 4400, Hungary|Research Site, Salgotarjan, 3100, Hungary|Research Site, Szeged, 6725, Hungary|Research Site, SzekszÃ¡rd, 7100, Hungary|Research Site, Zalaegerszeg, 8900, Hungary|Research Site, Ansari Nagar, 110 029, India|Research Site, Bangalore, 560064, India|Research Site, Belgavi, 590010, India|Research Site, Dehradun, 248016, India|Research Site, Delhi, 110088, India|Research Site, Dhanvantari Nagar, 605006, India|Research Site, Gurgaon, 122001, India|Research Site, Hyderabad, 500082, India|Research Site, JAipur, 302022, India|Research Site, Kanpur, 208005, India|Research Site, Kolkata, 700099, India|Research Site, Kolkata, 700160, India|Research Site, Kozhikode, 673 601, India|Research Site, Mumbai, 400012, India|Research Site, Mumbai, 400612, India|Research Site, Mysuru, 570017, India|Research Site, Nagpur, 440001, India|Research Site, Nashik, 422 009, India|Research Site, Nashik, 422002, India|Research Site, New Delhi, 110 085, India|Research Site, New Delhi, 110029, India|Research Site, New Delhi, 110075, India|Research Site, Surat, 395002, India|Research Site, Cork, T12 DV56, Ireland|Research Site, Dublin, 7, Ireland|Research Site, Dublin, 7, Ireland|Research Site, Dublin, D09V2N0, Ireland|Research Site, Dublin, DO4YN63, Ireland|Research Site, Galway, H91 YR71, Ireland|Research Site, Waterford, X91 ER8E, Ireland|Research Site, Afula, 18101, Israel|Research Site, Ashdod, 7747629, Israel|Research Site, Beer Sheva, 84101, Israel|Research Site, Haifa, 31096, Israel|Research Site, Jerusalem, 9103102, Israel|Research Site, Jerusalem, 91120, Israel|Research Site, Kfar Saba, 49281, Israel|Research Site, Nahariya, 22100, Israel|Research Site, Ramat Gan, 5262000, Israel|Research Site, Bergamo, 24127, Italy|Research Site, Bologna, 40138, Italy|Research Site, Brindisi, 72100, Italy|Research Site, Firenze, 50134, Italy|Research Site, Genoa, 16132, Italy|Research Site, Meldola, 47014, Italy|Research Site, Milano, 20132, Italy|Research Site, Milan, 20141, Italy|Research Site, Misterbianco, 95045, Italy|Research Site, Modena, 41124, Italy|Research Site, Monza, 20900, Italy|Research Site, Napoli, 80131, Italy|Research Site, Novara, 28100, Italy|Research Site, Padova, 35128, Italy|Research Site, Roma, 00161, Italy|Research Site, Roma, 00168, Italy|Research Site, Rozzano, 20089, Italy|Research Site, Torino, 10126, Italy|Research Site, Trento, 38100, Italy|Research Site, Bunkyo-ku, 113-8431, Japan|Research Site, Chiba-shi, 260-8717, Japan|Research Site, Chuo-ku, 104-8560, Japan|Research Site, Fukuoka-shi, 811-1395, Japan|Research Site, Fukushima-shi, 960-1295, Japan|Research Site, Hirakata-shi, 573-1191, Japan|Research Site, Hiroshima-shi, 730-8518, Japan|Research Site, Iruma-Gun, 350-0495, Japan|Research Site, Isehara-shi, 259-1193, Japan|Research Site, Kagoshima-shi, 892-0833, Japan|Research Site, Kashiwa, 277-8577, Japan|Research Site, Koto-ku, 135-8550, Japan|Research Site, Kumamoto-shi, 860-8556, Japan|Research Site, Kurume-shi, 830-0013, Japan|Research Site, Kyoto-shi, 606-8507, Japan|Research Site, Matsuyama-shi, 791-0280, Japan|Research Site, Nagoya-shi, 464-8681, Japan|Research Site, Nagoya-shi, 466-8550, Japan|Research Site, Nagoya-shi, 467-0001, Japan|Research Site, Niigata-shi, 951-8566, Japan|Research Site, Osaka-shi, 541-8567, Japan|Research Site, Ota-shi, 373-8550, Japan|Research Site, Sapporo-shi, 003-0804, Japan|Research Site, Sapporo-shi, 060-8638, Japan|Research Site, Sendai-shi, Japan|Research Site, Shinagawa-ku, 142-8666, Japan|Research Site, Suita-shi, 565-0871, Japan|Research Site, Sunto-gun, 411-8777, Japan|Research Site, Takasaki-shi, 370-0829, Japan|Research Site, Tsu-shi, 514-8507, Japan|Research Site, Yokohama-shi, 241-8515, Japan|Research Site, Cheonan-si, 31151, Korea, Republic of|Research Site, Daegu, 41404, Korea, Republic of|Research Site, Goyang-si, 10408, Korea, Republic of|Research Site, Seongnam-si, 13620, Korea, Republic of|Research Site, Seoul, 02841, Korea, Republic of|Research Site, Seoul, 03080, Korea, Republic of|Research Site, Seoul, 03722, Korea, Republic of|Research Site, Seoul, 06273, Korea, Republic of|Research Site, Seoul, 06351, Korea, Republic of|Research Site, Seoul, 06591, Korea, Republic of|Research Site, Seoul, 5505, Korea, Republic of|Research Site, Johor Bahru, 81100, Malaysia|Research Site, Kota Bharu, 16150, Malaysia|Research Site, Kuala Lumpur, 50586, Malaysia|Research Site, Kuala Lumpur, 50603, Malaysia|Research Site, Kuching, 93200, Malaysia|Research Site, Melaka, 75000, Malaysia|Research Site, Pulau Pinang, 10450, Malaysia|Research Site, Alc. CuauhtÃ©moc, 06100, Mexico|Research Site, Alc. CuauhtÃ©moc, 06700, Mexico|Research Site, CancÃºn, 77500, Mexico|Research Site, Colonia Lindavista, 7300, Mexico|Research Site, Estado de MÃ©xico, 50090, Mexico|Research Site, Mexico, 14080, Mexico|Research Site, Monterrey, 64460, Mexico|Research Site, Monterrey, 66220, Mexico|Research Site, MÃ©rida, 97300, Mexico|Research Site, San Luis PotosÃ­, 78209, Mexico|Research Site, Tuxtla GutiÃ©rrez, 29000, Mexico|Research Site, Veracruz, 91851, Mexico|Research Site, Auckland, 1023, New Zealand|Research Site, Hamilton, 3204, New Zealand|Research Site, Palmerston North, 4414, New Zealand|Research Site, Arequipa, AREQUIPA01, Peru|Research Site, La Libertad, 13013, Peru|Research Site, Lima, 15023, Peru|Research Site, Lima, 15073, Peru|Research Site, Lima, 15076, Peru|Research Site, Lima, LIMA 01, Peru|Research Site, Lima, Lima 13, Peru|Research Site, Lima, LIMA 29, Peru|Research Site, Lima, Lima 34, Peru|Research Site, San Isidro, Peru|Research Site, Trujillo, 044, Peru|Research Site, Bacolod, 6100, Philippines|Research Site, Cebu City, 6000, Philippines|Research Site, Iloilo City, 5000, Philippines|Research Site, Manila, 1000, Philippines|Research Site, Quezon, 1102, Philippines|Research Site, BiaÅa Podlaska, 21-500, Poland|Research Site, BiaÅystok, 15-027, Poland|Research Site, Bydgoszcz, 85-796, Poland|Research Site, GdaÅsk, 80-952, Poland|Research Site, Gdynia, 81-519, Poland|Research Site, Grudziadz, 86-300, Poland|Research Site, Koszalin, 75-581, Poland|Research Site, KrakÃ³w, 31-501, Poland|Research Site, Lublin, 20-090, Poland|Research Site, Lublin, 20-718, Poland|Research Site, Opole, 45-061, Poland|Research Site, PoznaÅ, 61-485, Poland|Research Site, RacibÃ³rz, 47-400, Poland|Research Site, Rzeszow, 35-055, Poland|Research Site, RzeszÃ³w, 35-021, Poland|Research Site, Szczecin, 71-730, Poland|Research Site, TomaszÃ³w Mazowiecki, 97-200, Poland|Research Site, Warszawa, 02-781, Poland|Research Site, Wroclaw, 53-413, Poland|Research Site, ÅÃ³dÅº, 90-302, Poland|Research Site, Amadora, 2720-276, Portugal|Research Site, Braga, 4710-243, Portugal|Research Site, Lisboa, 1649-035, Portugal|Research Site, Lisboa, 1998-018, Portugal|Research Site, Matosinhos, 4454-509, Portugal|Research Site, Porto, 4100-180, Portugal|Research Site, Porto, 4200-072, Portugal|Research Site, Viana do Castelo, 4904-858, Portugal|Research Site, Vila Nova de Gaia, 4434-502, Portugal|Research Site, Vila Real, 5000-508, Portugal|Research Site, Rio Piedras, 00935, Puerto Rico|Research Site, Bucuresti, 011171, Romania|Research Site, Bucuresti, 013812, Romania|Research Site, Cluj Napoca, 400015, Romania|Research Site, Cluj-Napoca, 400641, Romania|Research Site, Craiova, 200094, Romania|Research Site, Craiova, 200385, Romania|Research Site, Craiova, 200542, Romania|Research Site, Floresti, 407280, Romania|Research Site, Iasi, 700106, Romania|Research Site, Oradea, 410469, Romania|Research Site, Otopeni, 075100, Romania|Research Site, Ovidiu, 905900, Romania|Research Site, Pitesti, 110283, Romania|Research Site, Sibiu, 550245, Romania|Research Site, Timisoara, 300166, Romania|Research Site, Timisoara, 300239, Romania|Research Site, Riyadh/MENA, 11426, Saudi Arabia|Research Site, Riyadh, 12713, Saudi Arabia|Research Site, Riyadh, 12713, Saudi Arabia|Research Site, Belgrade, 11000, Serbia|Research Site, Belgrade, 11080, Serbia|Research Site, Belgrad, 11000, Serbia|Research Site, Beograd, 11010, Serbia|Research Site, Kragujevac, 34000, Serbia|Research Site, Nis, 18000, Serbia|Research Site, Novi Sad, 21000, Serbia|Research Site, Valjevo, 14000, Serbia|Research Site, Zrenjanin, 23000, Serbia|Research Site, Amanzimtoti, 4126, South Africa|Research Site, Bloemfontein, 9301, South Africa|Research Site, Cape Town, 7925, South Africa|Research Site, George, 6529, South Africa|Research Site, Johannesburg, 2193, South Africa|Research Site, Johannesburg, 2196, South Africa|Research Site, Pietermaritzburg, 3245, South Africa|Research Site, Port Elizabeth, 6045, South Africa|Research Site, Pretoria, 31, South Africa|Research Site, A CoruÃ±a, 15009, Spain|Research Site, Albacete, 02006, Spain|Research Site, Alicante, 03010, Spain|Research Site, Badalona, 08916, Spain|Research Site, Barakaldo, 48903, Spain|Research Site, Barcelona, 08003, Spain|Research Site, Barcelona, 08035, Spain|Research Site, Barcelona, 08036, Spain|Research Site, Barcelona, 08041, Spain|Research Site, Burgos, 09006, Spain|Research Site, Caceres, 10003, Spain|Research Site, Castello de la Plana, 12002, Spain|Research Site, Cordoba, 14004, Spain|Research Site, El Palmar, 30120, Spain|Research Site, Elche(Alicante), 03202, Spain|Research Site, Fuenlabrada, 28942, Spain|Research Site, Girona, 17007, Spain|Research Site, Granada, 18012, Spain|Research Site, Granada, 18016, Spain|Research Site, Jerez de la Frontera, 11407, Spain|Research Site, La CoruÃ±a, 15006, Spain|Research Site, La Laguna (Tenerife), 38320, Spain|Research Site, Leon, 24008, Spain|Research Site, LÃ©rida, 25198, Spain|Research Site, Madrid, 28007, Spain|Research Site, Madrid, 28009, Spain|Research Site, Madrid, 28033, Spain|Research Site, Madrid, 28034, Spain|Research Site, Madrid, 28040, Spain|Research Site, Madrid, 28041, Spain|Research Site, Madrid, 28050, Spain|Research Site, Malaga, 29010, Spain|Research Site, Manresa, 08243, Spain|Research Site, Murcia, 30008, Spain|Research Site, MÃ¡laga, 29016, Spain|Research Site, Palma de Mallorca, 07120, Spain|Research Site, Reus,Tarragona, 43204, Spain|Research Site, Sabadell, 08208, Spain|Research Site, Salamanca, 37007, Spain|Research Site, San Sebastian, 20014, Spain|Research Site, Sant Joan DespÃ­, 08970, Spain|Research Site, Sevilla, 41009, Spain|Research Site, Sevilla, 41014, Spain|Research Site, Sevilla, 41015, Spain|Research Site, Toledo, 45007, Spain|Research Site, Valencia, 46009, Spain|Research Site, Valencia, 46010, Spain|Research Site, Valencia, 46015, Spain|Research Site, Vigo, 36312, Spain|Research Site, Zaragoza, 50009, Spain|Research Site, Baden, CH-5405, Switzerland|Research Site, Basel, 4031, Switzerland|Research Site, Bellinzona, 6500, Switzerland|Research Site, Chur, 7000, Switzerland|Research Site, Frauenfeld, 8501, Switzerland|Research Site, La Chaux-De-Fonds, 2300, Switzerland|Research Site, Lausanne, 1011, Switzerland|Research Site, Luzern, 6000, Switzerland|Research Site, Luzern, 6006, Switzerland|Research Site, St. Gallen, 9016, Switzerland|Research Site, Winterthur, 8401, Switzerland|Research Site, ZÃ¼rich, 8008, Switzerland|Research Site, Hsinchu, 300, Taiwan|Research Site, Kaohsiung, 833589, Taiwan|Research Site, New Taipei City, 23561, Taiwan|Research Site, Taichung, 404, Taiwan|Research Site, Taichung, 40705, Taiwan|Research Site, Tainan, 70403, Taiwan|Research Site, Taipei, 10048, Taiwan|Research Site, Taipei, 11259, Taiwan|Research Site, Yong Kang City, 71004, Taiwan|Research Site, Bangkok, 10210, Thailand|Research Site, Bangkok, 10330, Thailand|Research Site, Bangkok, 10400, Thailand|Research Site, Bangkok, 10700, Thailand|Research Site, Hat Yai, 90110, Thailand|Research Site, Khon Kaen, 40002, Thailand|Research Site, Ankara, 06010, Turkey|Research Site, Ankara, 06200, Turkey|Research Site, Ankara, 06250, Turkey|Research Site, Ankara, 06530, Turkey|Research Site, Antalya, 07100, Turkey|Research Site, Bursa, 16059, Turkey|Research Site, Cigli, 35620, Turkey|Research Site, Edirne, 22030, Turkey|Research Site, Istanbul, 34010, Turkey|Research Site, Istanbul, 34093, Turkey|Research Site, Istanbul, 34180, Turkey|Research Site, Ä°stanbul, 34457, Turkey|Research Site, Istanbul, 34722, Turkey|Research Site, Istanbul, 34899, Turkey|Research Site, Karsiyaka, 35575, Turkey|Research Site, Malatya, 44280, Turkey|Research Site, Samsun, 55200, Turkey|Research Site, Ãankaya, 06680, Turkey|Research Site, Abu Dhabi, 11241, United Arab Emirates|Research Site, Al Ain, 15258, United Arab Emirates|Research Site, Dubai, 0000, United Arab Emirates|Research Site, Dubai, 505004, United Arab Emirates|Research Site, Aberdeen, AB25 2ZN, United Kingdom|Research Site, Bath, BA1 3NG, United Kingdom|Research Site, Brighton, BN2 5BD, United Kingdom|Research Site, Burton-on-Trent, DE13 0RB, United Kingdom|Research Site, Cambridge, CB2 2QQ, United Kingdom|Research Site, Derby, DE22 3NE, United Kingdom|Research Site, Guilford, GU27XX, United Kingdom|Research Site, Ipswich, IP4 5PD, United Kingdom|Research Site, Lancaster, LA1 4RP, United Kingdom|Research Site, Leeds, LS9 7TF, United Kingdom|Research Site, Leicester, LE1 5WW, United Kingdom|Research Site, Liverpool, L7 8YA, United Kingdom|Research Site, London, EC1M 6BQ, United Kingdom|Research Site, London, NW3 2QG, United Kingdom|Research Site, London, SE1 9RT, United Kingdom|Research Site, London, SW2 6JJ, United Kingdom|Research Site, Manchester, M20 4BX, United Kingdom|Research Site, Northampton, NN1 5BD, United Kingdom|Research Site, Oxford, OX3 7LE, United Kingdom|Research Site, Reading, RG1 5AN, United Kingdom|Research Site, Shrewsbury, SY3 8XQ, United Kingdom|Research Site, Stockton, TS19 8PE, United Kingdom|Research Site, Sutton In Ashfield, NG17 4JL, United Kingdom|Research Site, Sutton, SM2 5PT, United Kingdom|Research Site, Taunton, TA1 5DA, United Kingdom|Research Site, Warwick, CV34 5BW, United Kingdom|Research Site, Whitchurch, CF14 2TL, United Kingdom",
NCT05253651,A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT05253651,MOUNTAINEER-03,RECRUITING,"This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease.

Participants in this study have colorectal cancer that has spread through the body (metastatic) and/or cannot be removed with surgery (unresectable).

Participants will be assigned randomly to the tucatinib group or standard of care group. The tucatinib group will get tucatinib, trastuzumab, and mFOLFOX6. The standard of care group will get either:

* mFOLFOX6 alone,
* mFOLFOX6 with bevacizumab, or
* mFOLFOX6 with cetuximab mFOLFOX6 is a combination of multiple drugs. All of the drugs given in this study are used to treat this type of cancer.",NO,Colorectal Neoplasms,DRUG: tucatinib|DRUG: trastuzumab|DRUG: bevacizumab|DRUG: cetuximab|DRUG: oxaliplatin|DRUG: leucovorin|DRUG: levoleucovorin|DRUG: fluorouracil,"Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) by Blinded Independent Central Review (BICR), The time from the date of randomization to the BICR assessment of disease progression according to RECIST v1.1 or death from any cause, Up to approximately 3 years","Overall survival (OS), The time from randomization to death from any cause, Up to approximately 6 years|Confirmed objective response rate (cORR) per RECIST v1.1 by BICR, The proportion of participants with confirmed complete response (CR) or partial response (PR) according to RECIST v1.1, as assessed by BICR, Up to approximately 3 years|PFS per RECIST v1.1 by investigator assessment, The time from the date of randomization to the investigator assessment of disease progression according to RECIST v1.1 or death from any cause, Up to approximately 3 years|cORR per RECIST v1.1 by investigator assessment, The proportion of participants with confirmed CR or PR according to RECIST v1.1, as assessed by investigators, Up to approximately 3 years|Duration of response (DOR) per RECIST v1.1 by BICR, The time from first documentation of objective response (CR or PR that is subsequently confirmed) to the first documentation of disease progression per RECIST v1.1 or death from any cause, Up to approximately 3 years|DOR per RECIST v1.1 by investigator assessment, The time from first documentation of objective response (CR or PR that is subsequently confirmed) to the first documentation of disease progression per RECIST v1.1 or death from any cause, Up to approximately 3 years|Time to second progression or death (PFS2), The time from randomization to disease progression on the next-line of therapy, or death from any cause, Up to approximately 3 years|Incidence of adverse events (AEs), Any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment., Through 30 days after the last study treatment; approximately 1 year|Incidence of dose alterations, Through 30 days after the last study treatment; approximately 1 year|Trough concentration (Ctrough), PK parameter, Approximately 4 months|Change from baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQC30) score, Change from baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) scores. Scale scores range from 0-100. For functioning and global health status/quality of life (QoL) scales, higher scores indicate better functioning or global health status/quality of life (QoL). For symptom scales, higher scores indicate greater symptom burden., Through 30-37 days after the last study treatment; approximately 1 year|Time to meaningful change in EORTC QLQ30 score, The time from baseline to the first onset of a â¥10-point changes in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) scores. Scale scores range from 0-100.

For functioning and global health status/QoL scales, higher scores indicate better functioning or global health status/QoL. For symptom scales, higher scores indicate greater symptom burden., Through 30-37 days after the last study treatment; approximately 1 year",,"Seagen, a wholly owned subsidiary of Pfizer",,ALL,"ADULT, OLDER_ADULT",PHASE3,400,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-10-24,2026-04-03,2029-07-27,2022-02-24,,2025-05-20,"Palo Verde Hematology Oncology, Glendale, Arizona, 85304, United States|Mayo Clinic Building - Phoenix, Phoenix, Arizona, 85054, United States|Mayo Clinic Hospital, Phoenix, Arizona, 85054, United States|Mayo Clinic, Scottsdale, Arizona, 85259, United States|Pacific Cancer Medical Center Inc., Anaheim, California, 92801, United States|Kaiser Permanente Anaheim Kraemer Medical Offices, Anaheim, California, 92806, United States|Kaiser Permanente Baldwin Park Medical Center, Baldwin Park, California, 91706, United States|Kaiser Permanente Bellflower Medical Offices, Bellflower, California, 90706, United States|Kaiser Permanente Fontana Medical Center, Fontana, California, 92335, United States|Los Angeles Hematology Oncology Medical Group, Glendale, California, 91204, United States|Los Angeles Hematology Oncology Medical Group, Glendale, California, 91206, United States|Kaiser Permanente South Bay Medical center, Harbor City, California, 90710, United States|Kaiser Permanente Alton/Sand Canyon Medical Offices, Irvine, California, 92618, United States|Los Angeles Hematology Oncology Medical Group, Los Angeles, California, 90017, United States|USC Norris Koreatown - Medical Oncology, Los Angeles, California, 90020, United States|Kaiser Permanente Los Angeles Medical Offices, Los Angeles, California, 90027, United States|Keck Hospital of USC, Los Angeles, California, 90033, United States|USC/Norris Comprehensive Cancer Center / Investigational Drug Services, Los Angeles, California, 90033, United States|USC/Norris Comprehensive Cancer Center, Los Angeles, California, 90033, United States|Kaiser Permanente West Los Angeles Medical Center, Los Angeles, California, 90034, United States|USC Norris Oncology/Hematology - Newport Beach, Newport Beach, California, 92663, United States|Kaiser Permanente Ontario Medical Center, Ontario, California, 91761, United States|Kaiser Permanente Panorama City Medical Center, Panorama City, California, 91402, United States|Keck Medical Center of USC Pasadena, Pasadena, California, 91105, United States|Los Angeles Hematology Oncology Medical Group, Pasadena, California, 91105, United States|Kaiser Permanente Riverside Medical Center, Riverside, California, 92505, United States|Kaiser Permanente San Diego Mission Road (Regulatory and Lab Supplies), San Diego, California, 92108, United States|Kaiser Permanente Zion Medical Center, San Diego, California, 92120, United States|Kaiser Permanente San Marcos Medical Offices, San Marcos, California, 92078, United States|Los Angeles Hematology Oncology Medical Group, Van Nuys, California, 91405, United States|Kaiser Permanente Woodland Hills Medical Center, Woodland Hills, California, 91367, United States|Rocky Mountain Cancer Centers, LLP, Aurora, Colorado, 80012, United States|Rocky Mountain Cancer Centers, LLP, Boulder, Colorado, 80303, United States|Rocky Mountain Cancer Centers, LLP, Colorado Springs, Colorado, 80907, United States|Rocky Mountain Cancer Centers, LLP, Denver, Colorado, 80218, United States|Rocky Mountain Cancer Centers, LLP, Denver, Colorado, 80220, United States|Rocky Mountain Cancer Centers, LLP, Lakewood, Colorado, 80228, United States|Rocky Mountain Cancer Centers, LLP, Littleton, Colorado, 80120, United States|Rocky Mountain Cancer Centers, LLP, Lone Tree, Colorado, 80124, United States|Rocky Mountain Cancer Centers, LLP, Longmont, Colorado, 80504, United States|Rocky Mountain Cancer Centers, LLP, Pueblo, Colorado, 81003, United States|Rocky Mountain Cancer Centers, LLP, Thornton, Colorado, 80260, United States|Mount Sinai Medical Center Aventura ER, Aventura, Florida, 33180, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, 33140, United States|Mount Sinai Medical Center, Miami Beach, Florida, 33140, United States|Grady Health System, Atlanta, Georgia, 30303, United States|Grady Memorial Hospital Investigational Drug Service, Atlanta, Georgia, 30303, United States|Emory University Hospital Midtown, Atlanta, Georgia, 30308, United States|Emory University Hospital, Atlanta, Georgia, 30322, United States|Investigational Drug Service, Atlanta, Georgia, 30322, United States|Winship Cancer Institute, Atlanta, Georgia, 30322, United States|Alliance for Multispecialty Research LLC., Merriam, Kansas, 66204, United States|Baptist Health Lexington, Lexington, Kentucky, 40503, United States|Norton Cancer Institute - Downtown, Louisville, Kentucky, 40202, United States|Norton Cancer Institute, Downtown, Louisville, Kentucky, 40202, United States|Norton Hospital, Louisville, Kentucky, 40202, United States|Norton Audubon Hospital, Louisville, Kentucky, 40217, United States|Norton Cancer Institute, Audubon Hospital Campus, Louisville, Kentucky, 40217, United States|Norton Brownsboro Hospital, Louisville, Kentucky, 40241, United States|Norton Cancer Institute, Brownsboro Hospital Campus, Louisville, Kentucky, 40241, United States|Minnesota Oncology Hematology, PA, Burnsville, Minnesota, 55337, United States|Allina Health Cancer institute, Coon Rapids, Minnesota, 55433, United States|Minnesota Oncology Hematology, PA, Coon Rapids, Minnesota, 55433, United States|M Health Fairview Cancer Clinic-Edina, Edina, Minnesota, 55435, United States|Minnesota Oncology Hematology, PA, Edina, Minnesota, 55435, United States|Minnesota Oncology Hematology, PA, Fridley, Minnesota, 55432, United States|Minnesota Oncology Hematology, PA, Maple Grove, Minnesota, 55369, United States|M Health Fairview St. John's Hospital, Maplewood, Minnesota, 55109, United States|Minnesota Oncology Hematology, PA, Maplewood, Minnesota, 55109, United States|Allina Health Cancer Institute (Virginia Piper Cancer Institute), Minneapolis, Minnesota, 55404, United States|Minnesota Oncology Hematology, PA, Minneapolis, Minnesota, 55404, United States|Hennepin County Medical Center, Minneapolis, Minnesota, 55415, United States|North Memorial Health Cancer Center, Robbinsdale, Minnesota, 55422, United States|Mayo Clinic Cancer Center Outpatient Pharmacy, Rochester, Minnesota, 55905, United States|Mayo Clinic, Rochester, Minnesota, 55905, United States|Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, 55416, United States|Park Nicollet Frauenshuh Cancer Center, Saint Louis Park, Minnesota, 55426, United States|Regulatory Location: MMCORC, Saint Louis Park, Minnesota, 55426, United States|Regions Hospital, Saint Paul, Minnesota, 55101, United States|Minnesota Oncology Hematology, PA St. Paul Cancer Center, Saint Paul, Minnesota, 55102, United States|Minnesota Oncology Hematology, PA Cornerstone Medical Specialty Center, Woodbury, Minnesota, 55125, United States|MSK Basking Ridge, Basking Ridge, New Jersey, 07920, United States|MSK Monmouth, Middletown, New Jersey, 07748, United States|MSK Bergen, Montvale, New Jersey, 07645, United States|MSK Commack, Commack, New York, 11725, United States|MSK Westchester, Harrison, New York, 10604, United States|Rockefeller Outpatient Pavilion (53rd Street), New York, New York, 10022, United States|Memorial Solan Kettering Cancer Center- Main Campus, New York, New York, 10065, United States|MSK Nassau, Uniondale, New York, 11553, United States|Duke University Hospital, Durham, North Carolina, 27710, United States|Duke University Medical Center, Duke Cancer Center, Durham, North Carolina, 27710, United States|Duke University Medical Center, Durham, North Carolina, 27710, United States|FirstHealth Cancer Center, Pinehurst, North Carolina, 28374, United States|FirstHealth Moore Regional Hospital, Pinehurst, North Carolina, 28374, United States|Gabrail Cancer Center Research, Canton, Ohio, 44718, United States|Providence Cancer Institute Newberg Clinic, Newberg, Oregon, 97132, United States|Providence Cancer Institute Willamette Falls Clinic, Oregon City, Oregon, 97045, United States|Northwest Cancer Specialists, P.C., Portland, Oregon, 97213, United States|Providence Cancer Institute Franz Clinic, Portland, Oregon, 97213, United States|Providence Portland Medical Center, Portland, Oregon, 97213, United States|Providence Oncology and Hematology Care Clinic - Westside, Portland, Oregon, 97225, United States|Providence St. Vincent Medical Center- Investigational Drug Services, Portland, Oregon, 97225, United States|Providence St. Vincent Medical Center, Portland, Oregon, 97225, United States|Northwest Cancer Specialists, P.C., Portland, Oregon, 97227, United States|Northwest Cancer Specialists, P.C., Tigard, Oregon, 97223, United States|Avera Cancer Institute, Sioux Falls, South Dakota, 57105, United States|Henry-Joyce Cancer Clinic, Nashville, Tennessee, 37232, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|US Oncology Investigational Product Center (IPC), Irving, Texas, 75063, United States|US Oncology Investigational Products Center (IPC), Irving, Texas, 75063, United States|US Oncology Investigational Products Center(IPC), Irving, Texas, 75063, United States|Oncology & Hematology Associates of Southwest Virginia, Inc. D.B.A Blue Ridge Cancer Care, Blacksburg, Virginia, 24060, United States|Oncology & Hematology Associates of Southwest Virginia, Low Moor, Virginia, 24457, United States|Oncology & Hematology Associates of Southwest Virginia Inc dba Blue Ridge Cancer Care, Roanoke, Virginia, 24014, United States|Oncology & Hematology Associates of Southwest Virginia, Inc. D.B.A Blue Ridge Cancer Care, Salem, Virginia, 24153, United States|Oncology & Hematology Associates of Southwest Virginia, Wytheville, Virginia, 24382, United States|Providence Regional Cancer Partnership, Everett, Washington, 98201, United States|Providence Regional Medical Center Everett, Everett, Washington, 98201, United States|Northwest Cancer Specialists, P.C., Vancouver, Washington, 98684, United States|Centro de Investigacion Pergamino SA, Pergamino, Buenos Aires, 2700, Argentina|Instituto Medico de la Fundacion Estudios Clinicos, Rosario, Santa FE, S2000DEJ, Argentina|Hospital Britanico de Buenos Aires, Caba, 1280, Argentina|Instituto Medico Especializado Alexander Fleming, Ciudad AutÃ³noma de Buenos Aires, 1426, Argentina|IONC Instituto Oncologico de Cordoba Fundacion Richardet Longo, Cordoba, X5001 HWE, Argentina|CEMAIC - Centro Medico Privado, Cordoba, Argentina|Townsville Hospital and Health Service, Townsville, Queensland, 4814, Australia|St Vincent's Hospital, Fitzroy, Victoria, 3065, Australia|Alfred Health, Melbourne, Victoria, 3004, Australia|Klinikum Wels-Grieskirchen GmbH Austria, Wels, Upper Austria, A-4600, Austria|Landesapotheke Salzburg, Salzburg, 5020, Austria|Uniklinikum Salzburg, Landeskrankenhaus, Salzburg, 5020, Austria|Klinikum Wels-Grieskirchen GmbH Austria, Wels, 4600, Austria|Landesklinikum Wiener Neustadt, Wiener Neustadt, 2700, Austria|Institut Jules Bordet, Anderlecht, 1070, Belgium|Cliniques Universitaires Saint-Luc, Brussels, 1200, Belgium|UZA, Edegem, 2650, Belgium|CHU HELORA - Hopital de Jolimont, Haine-Saint-Paul, 7100, Belgium|Centre Hospitalier Chretien - Clinique MontLegia, LiÃ¨ge, 4000, Belgium|Maag-,Darm- en Leverziekten AZ Turnhout, Turnhout, 2300, Belgium|Oncologisch Dagziekenhuis AZ Turnhout Campus Sint-Elisabeth, Turnhout, 2300, Belgium|CIONC-Centro Integrado de Oncologia de Curitiba, Curitiba, Parana, 80810-050, Brazil|Centro Integrado de Pesquisa em Oncologia CIPO-GHC / Hospital Nossa Senhora da Conceicao, Porto Alegre, RIO Grande DO SUL, 91350-200, Brazil|Institute de Educacao, Pesquisa e Gestao em Saude - Instituto COI, Rio de Janeiro, RJ, 22775-001, Brazil|Institute de Educacao, Pesquisa e Gestao em Saude - Instituto COI, Rio de Janeiro, RJ, 22793-080, Brazil|Hospital de Cancer de Barretos/Fundacao Pio XII, Barretos, SAO Paulo, 14784-400, Brazil|Centro de Pesquisas Clinicas da FundaÃ§Ã£o Doutor Amaral Carvalho, Jau, SAO Paulo, Brazil|CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia., Santo Andre, SAO Paulo, 09060-650, Brazil|FundaÃ§Ã£o Faculdade Regional de Medicina de SÃ£o JosÃ© do Rio Preto, Sao Jose do Rio Preto, SP, CEP 15090-000, Brazil|ICESP - Instituto do CÃ¢ncer do Estado de SÃ£o Paulo Octavio Frias de Oliveira., Sao Paulo, 01245-000, Brazil|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, K1H 8L6, Canada|Sunnybrook Research Institute, Toronto, Ontario, M4N 3M5, Canada|Mount Sinai Hospital, Toronto, Ontario, M5G 1X5, Canada|Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, S7N 4H4, Canada|Oncocentro Apys, ViÃ±a del Mar, ValparaÃ­so, Chile|Biocenter, Concepcion, Chile|Centro de estudios clinicos SAGA, Santiago, Chile|Fujian Medical University Union Hospital, Fuzhou, Fujian, 350001, China|The 900th Hospital of The Chinese People's Liberation Army Joint Logistics Support Force, Fuzhou, Fujian, 350025, China|The First hospital of LanZhou university, Lanzhou, Gansu, 730000, China|The Sixth Affiliated hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510655, China|Meizhou People's Hospital - Guangdong Province, Meizhou, Guangdong, 514031, China|Meizhou People's hospital, Meizhou, Guangdong, 514031, China|The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan, 570216, China|Hainan General Hospital, Haikou, Hainan, 570311, China|Affiliated Hospital of Chengde Medical University, Chengde City, Hebei, 067055, China|Affiliated Hospital of Chengde Medical University, Chengde, Hebei, 067000, China|Tangshan People's Hospital, Tangshan, Hebei, 063001, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China|Nanyang Second General Hospital, Nanyang, Henan, 473009, China|Henan Provincial People's Hospital, Zhengzhou, Henan, 450003, China|Hubei Cancer Hospital, Wuhan, Hubei, 430000, China|The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011, China|The First People's Hospital of Changzhou, Changzhou, Jiangsu, 213003, China|Changzhou Cancer Hospital, Changzhou, Jiangsu, 213032, China|The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 215004, China|Xuzhou Central Hospital, Xuzhou, Jiangsu, 221009, China|The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, China|The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, China|The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, 121001, China|The First Hospital of China Medical University, Shenyang, Liaoning, 110001, China|Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China|Jinan Central Hospital, Jinan, Shandong, 250013, China|Shandong Cancer Hospital, Jinan, Shandong, 250117, China|LinYi Cancer Hospital, Linyi, Shandong, 276034, China|Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, 200092, China|Shanxi Province Cancer Hospital, Taiyuan, Shanxi, 30013, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310009, China|Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310016, China|Beijing Cancer Hospital, Beijing, 100142, China|Hunan Cancer Hospital, Changsha, 410013, China|Army Specialty Medical Center of The Chinese People's Liberation Army, Chongqing, 400042, China|Shanghai General Hospital, Shanghai, 201620, China|Centre Hospitalier Regional et Universitaire de Besancon - Hopital Jean-Minjoz, Besancon Cedex, Other, 25000, France|Institut Sainte Catherine, Avignon cedex 9, 84918, France|CHU Brest Hopital Cavale Blanche, Brest, 29200, France|Hopital Henri Mondor, Creteil, 94000, France|Center Georges-Francois Leclerc, Dijon, 21079, France|Hopital Edouard Herriot, LYON Cedex 3, 69437, France|HÃ¶pital Saint-Joseph, Marseille CEDEX 8, 13285, France|Centre Hospitalier Universitaire Nantes-Hotel Dieu, Nantes Cedex 1, 44093, France|Centre Antoine Lacassagne, Nice cedex 2, 06189, France|Hopital Saint-Louis, Paris, 75010, France|Pharmacy Address:Hopital Saint-Louis, Paris, 75010, France|Hopital Saint-Antoine, Paris, 75012, France|Hopital Europeen Georges Pompidou, Paris, 75015, France|CHU Bordeaux Hopital Haut Leveque, Pessac, 33604, France|CHU Poitiers, Poitiers, 86000, France|CHU de Rouen, ROUEN Cedex, 76031, France|Institut de CancÃ©rologie de l'Ouest - Saint-Herblain, Saint Herblain, 44805 Cedex, France|Centre Hospitalier Universitaire Sainte-Etienne - Hopital Nord, Saint Priest En Jarez, 42270, France|Institut de Cancerologie Strasbourg Europe, Strasbourg, 67033, France|CCC Muenchen TUM, Muenchen, Bavaria, D-81675, Germany|LMU Klinikum - Campus GroÃhadern, MÃ¼nchen, Bayern, D-81377, Germany|Regierung von Oberfranken, Bayreuth, LudwigstraÃe, 95444, Germany|RegierungsprÃ¤sidium Darmstadt, Darmstadt, Luisenplatz, 64283, Germany|Klinikum St. Marien Amberg, Amberg, Mariahilfbergweg, 92224, Germany|Medizinische Hochschule Hannover (MHH), Hannover, Niedersachsen, 30625, Germany|UniversitÃ¤tsklinikum Leipzig, Leipzig, Sachsen, 04103, Germany|Landesdirektion Sachsen Dienststelle Leipzig, Leipzig, Saxony, 04107, Germany|Klinikum St. Marien Amberg, Amberg, 92224, Germany|CharitÃ© - UniversitÃ¤tsmedizin Berlin, Berlin, 13353, Germany|Apotheke Johannstadt, Dresden, 01307, Germany|Gemeinschaftspraxis HÃ¤matologie - Onkologie, Dresden, 01307, Germany|Technische UniversitÃ¤t Dresden, Medizinische FakultÃ¤t Carl Gustav Carus, Dresden, 01307, Germany|UniversitÃ¤tsklinikum Carl Gustav Carus Dresden, Dresden, 01307, Germany|Agaplesion Frankfurter Diakonie Kliniken gGmbH, Frankfurt, 60431, Germany|Agaplesion Markus Krankenhaus, Frankfurt, 60431, Germany|HÃ¤matologisch Onkologische Praxis Eppendorf (HOPE), Hamburg, 20249, Germany|ZytoService Deutschland GmbH, Hamburg, 22045, Germany|Asklepios Kliniken Hamburg GmbH, Hamburg, 22453, Germany|Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg, 22763, Germany|Medizinische Hochschule Hannover (MHH), Hannover, 30625, Germany|UniversitÃ¤tsklinikum Leipzig, Leipzig, 04103, Germany|Klinikum rechts der Isar der TU MÃ¼nchen, Krankenhausapotheke, Muenchen, 81675, Germany|Klinikum Rechts der Isar der Technischen Universitaet Muenchen, Munchen, 81675, Germany|Klinik fÃ¼r HÃ¤matologie, Onkologie und Gastroenterologie, MÃ¶nchengladbach, 41063, Germany|Klinikum rechts der Isar der Technischen Universitaet Muenchen, MÃ¼nchen, 81675, Germany|Zentrale Apotheke - Rheinland Klinikum Lukaskrankenhaus Neuss, Neuss, 41464, Germany|Universitaetsklinikum Ulm, Ulm, 89081, Germany|Athens Medical Group Psychiko Hospital, Psychiko, Athens, 11525, Greece|Athens Medical Center - Psychikon branch, Athens, AttikÃ­, 11525, Greece|University General Hospital ""Attikon"", Athens, Chaidari, 124 62, Greece|""University General Hospital of Heraklion Oncology Unit "", Heraklion, Crete, 71500, Greece|""Papageorgiou"" General Hospital of Thessaloniki 2nd Internal Medicine/Oncology Clinic of Aristotle, Nea Efkarpia, Thessaloniki, 56403, Greece|Evgenidion Clinic Agia Trias Oncology Department, Athens, 11528, Greece|Athens Medical Group, Psychiko Hospital, Psychiko, 11525, Greece|Tolna Megyei Balassa Janos Korhaz, Szekszard, 7100, Hungary|Cork University Hospital,Department of Medical Onncology, Cork, T12 DC4A, Ireland|Bon Secours Hospital, Cork, T12 DV56, Ireland|St Vincents University Hospital, Dublin, D04 T6F4, Ireland|Mater Misericordiae University Hospital, Dublin, D07 R2WY, Ireland|Mater Private Hospital, Dublin, D07 WKW8, Ireland|Beaumont Hospital, Dublin, D09 V2N0, Ireland|University Hospital Waterford, Waterford, X91 ER8E, Ireland|Azienda Ospedaliera Universitaria Cagliari, Monserrato, Cagliari, 09042, Italy|Farmacia AOU Cagliari - Presidio Ospedaliero ' Duilio Casula' di Monserrate, Monserrato, Cagliari, 09042, Italy|UOC Oncologia Medica - Dipartimento Onco Ematologico AORN San Giuseppe Moscati di Avellino, Avellino, Campania, 83100, Italy|IRCCS Ospedale Policlinico San Martino Farmacia, Genova, GE, 16132, Italy|Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Lazio, 00168, Italy|UOC Oncologia, Azienda Ospedaliera Cardinale Giovanni Panico, Tricase, Lecce, 73039, Italy|Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Lombardia, 25124, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardy, 20133, Italy|lstituto Europeo di Oncologia, Milano, Lombardy, 20141, Italy|Niguarda Cancer Center Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Milano, Lombardy, 20162, Italy|UMaCA U.O.S.D. Farmacia Ospedaliera, Napoli, Naples, 80131, Italy|IRCCS Ospedale Policlinico San Martino, Genova, Other, 16132, Italy|Ospedale S Chiara Farmacia, Pisa, Other, 56126, Italy|Servizio Farmacia Azienda Ospedaliera Universitaria lntegrata (AOUI) di Verona, Verona, Other, 37134, Italy|Farmacia Sperimentazioni, Reggio Emilia, RE, 42123, Italy|UOC Oncologia Medica, ARNAS GARIBALDI - PRESIDIO OSPEDALIERO NESIMA, Catania, Sicily, 95122, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, Toscana, 56126, Italy|SODc Oncologia Medica e Clinica, AOU Careggi, Firenze, Tuscany, 50134, Italy|Istituto Oncologico Veneto - IRCCS, Padova, Veneto, 35128, Italy|Struttura Semplice Dipartimentale di Oncologia Medica e Terapia Biomolecolare Azienda Ospedaliero, Foggia, 71122, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori Farmacia, Milano, 20133, Italy|lstituto Europeo di Oncologia Servizio Farmacia, Milan, 20141, Italy|Istituto Oncologico Veneto-IRCCS Farmacia, Padova, 35128, Italy|Fondazione IRCCS Policlinico San Matteo Farmacia, Pavia, 27100, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, 27100, Italy|Farmacia UFA, Reggio Emilia, 42123, Italy|S.C Oncologia Arcispedale Santa Maria Nuova, Reggio Emilia, 42123, Italy|Farmacia degli Sperimentali Policlinico Gemelli IRCCS, Roma, 00168, Italy|ASST della Valtellina e dell'alto Lario - Presidio Ospedaliero di Sondrio, Sondrio, 23100, Italy|ASST della Valtellina e dell'alto Lario- Presidio Ospedaliero di Sondrio Farmacia, Sondrio, 23100, Italy|U.O.C. Oncologia Azienda Ospedaliera Universitaria lntegrata (AOUI) di Verona, Verona, 37134, Italy|Chiba Cancer Center, Chiba-shi, Chiba-ken, 260-8717, Japan|National Cancer Center Hospital East, Kashiwa-shi, Chiba-ken, 277-8577, Japan|NHO Shikoku Cancer Center, Matsuyama-shi, Ehime-ken, 791-0280, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka-City, Fukuoka, 811-1395, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, 060-8648, Japan|Kobe City Hospital Organization Kobe City Medical Center General Hospital, Kobe-shi, HyÅgo, 650-0047, Japan|Kagawa University Hospital, Kita-gun, Kagawa, 761-0793, Japan|St. Marianna University Hospital, Kawasaki-shi, Kanagawa, 216-8511, Japan|Kanagawa Cancer Center, Yokohama-shi, Kanagawa, 241-8515, Japan|Osaka University Hospital, Suita-shi, Osaka-fu, 565-0871, Japan|National Hospital Organization Osaka National Hospital, Chuo-Ku, Osaka, 540-006, Japan|Osaka General Medical Center, Osaka-shi, Osaka, 558-8558, Japan|Kindai University Hospital, Osakasayama-shi, Osaka, 589-8511, Japan|Osaka Medical and Pharmaceutical University Hospital, Takatsuki-shi, Osaka, 569-8686, Japan|Saitama Cancer Center, Kitaadachi-gun, Saitama, 362-0806, Japan|National Cancer Center Hospital, Chuo-Ku, Tokyo, 104-0045, Japan|Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, 135-8550, Japan|Gachon University Gil Medical Center, Incheon, 21565, Korea, Republic of|Korea University Anam Hospital, Seoul, 02841, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, 03722, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|Korea University Guro Hospital, Seoul, 08308, Korea, Republic of|St. Antonius Hospital, Nieuwegein, Other, 3435 CM, Netherlands|Netherlands Cancer Institute, Amsterdam, 1066 CX, Netherlands|Het Nederlands Kanker Instituut, Amsterdam, Netherlands|Klinische Farmacie, Nieuwegein, 3534 CM, Netherlands|St. Antonius Ziekenhuis - Ziekenhuis Utrecht, Utrecht, 3543 AZ, Netherlands|Viecuri Medisch Centrum, Venlo, 5912 BL, Netherlands|Sjukehusapoteket i Bergen [Bergen Hospital Pharmacy], Bergen, N0-5053, Norway|Helse Bergen HF, Haukeland University Hospital, Bergen, NO-5021, Norway|Oslo University Hospital (OUH) - The Norwegian Radium Hospital, Oslo, 0379, Norway|Sykehusapoteket Oslo, Radiumhospitalet - Avdeling Produksjon, Oslo, 0379, Norway|Narodowy lnstytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy lnstytut Badawczy, Warszawa, Mazowieckie, 02-034, Poland|Marii Sklodowskiej-Curie Panstwowy lnstytut Badawczy, Warszawa, Mazowieckie, 02-781, Poland|MRUK-MED | Sp. z.o.o Apteka szpitalna, Rzeszow, Podkarpackie, 35-021, Poland|MRUK-MED | Sp. z.o.o, Rzeszow, Podkarpackie, 35-021, Poland|Apteka Szpitalna Uniwersytie Centrum Kliniczne, Gdansk, Pomorskie, 80-214, Poland|Przychodnia Lekarska KOMED Roman Karaszewski, Konin, Wielkopolskie, 62-500, Poland|Salve Medica Apteka Szpitalna, Lodz, 91-211, Poland|Hospital Garcia de Orta, Almada, 2805-267, Portugal|Unidade Local de Saude da Guarda-Hospital Sousa Martins, Guarda, 6300-035, Portugal|Fundacao Champalimaud, Lisboa, 1400-038, Portugal|Centro Hospitalar UniversitÃ¡rio de Santo Antonio,E.P.E., Porto, 4099-001, Portugal|Narodny Onkologicky ustav II.Onkologicka Klinika LFUK a NOU, Bratislava, 833 10, Slovakia|Hospital Duran i Reynals - Institut Catala d'Oncologia L'Hospitalet (ICO L'Hospitalet), L'Hospitalet de Llobregat, Barcelona, 08908, Spain|CETIR Viladomat, Barcelona, Other, 08029, Spain|Hospital General Universitario de Alicante, Alicante, 03010, Spain|Radiology: CETIR Ascires, Barcelona, 08029, Spain|Data review: Vall d'Hebron institute of Oncology (VHIO)., Barcelona, 08035, Spain|Hospital Vall d'Hebron Unidad de Farmacia de Ensayos Clinicos Oncohematologia, Barcelona, 08035, Spain|Hospital Vall d'Hebron, Barcelona, 08035, Spain|Hospital Clinic de Barcelona, Barcelona, 08036, Spain|Hospital Universitario Reina Sofia, Cordoba, 14004, Spain|Hospital Universitari Arnau de Vilanova, Lleida, 25198, Spain|Hospital General Universitario Gregorio Maranon, Madrid, 28007, Spain|Hospital Universitario Ramon y Cajal, Madrid, 28034, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital Universitario La Paz, Madrid, 28046, Spain|Hospital Regional Universitario de Malaga (Hospital Civil), Malaga, 29011, Spain|Complejo Hospitalario Universitario de Ourense, Ourense, 32005,, Spain|Hospital Universitario Central de Asturias, Oviedo, 33011, Spain|Complejo Hospitalario de Navarra, Pamplona, 31008, Spain|Hospital Universitario Marques de Valdecilla, Santander, 39008, Spain|Hospital Universitario Virgen del Rocio, Sevilla, 41013, Spain|Hospital General Universitario de Valencia, Valencia, 46014, Spain|Hospital Quiron Salud Zaragoza, Zaragoza, 50006, Spain|Hospital Universitario Miguel Servet, Zaragoza, 50009, Spain|Pharmacy:Kantonsspital Winterthur, Winterthur, Other, 8401, Switzerland|Zuripharm AG, Schlieren, 8952, Switzerland|Kantonsspital Winterthur, Winterthur, 8401, Switzerland|Universitatsspital Zurich - Klinik fur Medizinische Onkologie und Hamatologie USZ, Zurich, 8091, Switzerland|Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, 833, (R.O.C.), Taiwan|National Cheng Kung University Hospital, Tainan, 704, R.O.C., Taiwan|National Cheng-Kung University Hospital, Tainan, 704, Taiwan|National Taiwan University Hospital, Taipei, 100 ROC, Taiwan|National Taiwan University Hospital Clinical Trial Pharmacy, Taipei, 10048, Taiwan|Taipei Veterans General Hospital, Taipei, 11217, Taiwan|Chang Gung Memorial Hospital LinKou, Taoyuan, 333 (R.O.C.), Taiwan|Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom|The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, Chelsea, NE7 7DN, United Kingdom|Cambridge University Hospitals NHS Foundation Trust, Oncology Centre, Cambridge, England, CB2 0QQ, United Kingdom|The Royal Marsden Hospital, Sutton, Surrey, SM2 5PT, United Kingdom|Leeds Teaching Hospitals Trust, Leeds, WEST Yorkshire, LS9 7TF, United Kingdom|University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, BS2 8ED, United Kingdom|Leeds Teaching Hospitals NHS Trust, st James's Institute of Oncology, Leeds, LS97TF, United Kingdom|Guy's and Saint Thomas' NHS Foundation Trust, London, SE1 9RT, United Kingdom|Guy's and St Thomas' NHS Foundation, London, SE1 9RT, United Kingdom|The Royal Marsden Hospital - Chelsea Site, London, SW3 6JJ, United Kingdom|Imperial College Healthcare NHS Trust, London, W12 0NN, United Kingdom|The Christie NHS Foundation Trust, Manchester, M20 4BX, United Kingdom|The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, NE7 7DN, United Kingdom",
NCT05204927,177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer,https://clinicaltrials.gov/study/NCT05204927,,ACTIVE_NOT_RECRUITING,"A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I\&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.",NO,Metastasis From Malignant Tumor of Prostate,DRUG: 177Lu-PSMA-I&T|DRUG: Abiraterone with Prednisone or Enzalutamide,"Radiographic Progression Free Survival, Radiographic progression free survival (rPFS), defined as the time from randomization to radiographic progression (using PCWG3 and RECIST 1.1 criteria as assessed by blinded independent central review \[BICR\]) or death due to any cause., 34 weeks","Overall Survival (OS), Time (weeks) from randomization to death due to any cause., 156 weeks|Second Radiographic Progression Free Survival (rPFS 2), Time from randomization to the second radiographic progression or death in participants who crossover., 156 weeks|Progression Free Survival, First occurrence of PCWG3 progression, clinical/symptomatic progression and/or pain progression, or death due to any cause., 156 weeks|Second Progression-Free Survival, Second occurrence of PCWG3 progression, clinical/symptomatic progression and/or pain progression, or death due to any cause., 156 weeks|PSA50 Response Rate, Response rate of patients who achieve a reduction of â¥50% in PSA from the baseline PSA assessment., 156 weeks|Time to First Symptomatic Skeletal Event (SSE), Occurrence of either bone-directed radiotherapy to relieve bone pain, new symptomatic pathologic fractures, spinal cord compression, or tumor-related orthopedic surgery., 156 weeks|Time to Soft Tissue Progression (STP), Occurrence of radiographic progression in soft tissue., 156 weeks|Time to Chemotherapy (TTC), Time from randomization to the initiation of chemotherapy or death., 156 weeks|Quality of Life Questionnaire- EORTC QLQ-C30, The Quality of Life (QoL) will be assessed via European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30). The EORTC QLQ-C30 is a questionnaire of thirty quality of life (QoL) questions developed to assess the QoL of cancer patients. The EORTC QLQ-C30 comprises 30 items, 24 of which are aggregated into nine multi-item scales, which are scored from 0 to 100., 22 weeks",,Curium US LLC,,MALE,"ADULT, OLDER_ADULT",PHASE3,439,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2022-02-14,2024-08-02,2029-02,2022-01-24,,2024-10-31,"Arizona Institute of Urology, PPLC, Tucson, Arizona, 85704, United States|Providence Medical Foundation, Fullerton, California, 92835, United States|Long Beach Memorial Center, Long Beach, California, 90806, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, 92663, United States|San Francisco VA Health Care System, San Francisco, California, 94121, United States|University of California, San Francisco, San Francisco, California, 94158, United States|Providence Saint John's Health Center, Santa Monica, California, 90404, United States|GenesisCare USA, Boca Raton, Florida, 33431, United States|Biogenix Molecular LLC, Miami, Florida, 33165, United States|Orlando Health Cancer Institute, Orlando, Florida, 32806, United States|GenesisCare USA, Plantation, Florida, 33324, United States|Florida Urology Partners, LLP, Tampa, Florida, 33607, United States|Northwestern Memorial Hospital, Chicago, Illinois, 60611, United States|NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, 60201, United States|John Hopkins Hospital, Baltimore, Maryland, 21287, United States|Kaiser Permanente Gaithersburg Medical Center, Gaithersburg, Maryland, 20879, United States|Henry Ford Hospital, Detroit, Michigan, 48202, United States|BAMF Health I PC, Grand Rapids, Michigan, 49503, United States|Michigan Institute of Urology, Troy, Michigan, 48084, United States|GenesisCare USA, Troy, Michigan, 48098, United States|M Health Fairview Ridges Cancer Clinic, Burnsville, Minnesota, 55337, United States|SSM Saint Louis University Hospital, Saint Louis, Missouri, 63104, United States|Center for Clinical Theranostics Research, Washington University, Saint Louis, Missouri, 63110, United States|Oncology Hematology West, PC dba Nebraska Cancer Specialists, Omaha, Nebraska, 68130, United States|XCancer Omaha / Urology Cancer Center, Omaha, Nebraska, 68130, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, 08993, United States|Icahn School of Medicine at Mount Sinai, New York, New York, 10029, United States|Columbia University Medical Center - Herbert Irving Pavilion, New York, New York, 10032, United States|SUNY Upstate Medical University, Syracuse, New York, 13210, United States|Central Ohio Urology Group, Gahanna, Ohio, 43230, United States|Hightower Clinical, Oklahoma City, Oklahoma, 73102, United States|OHSU - Center for health and healing, Portland, Oregon, 97239, United States|VA Portland Health Care System, Portland, Oregon, 97239, United States|MidLantic Urology, Bala-Cynwyd, Pennsylvania, 19004, United States|Houston Metro Urology, Houston, Texas, 77027, United States|Urology San Antonio, San Antonio, Texas, 78229, United States|Fred Hutchinson Cancer Center, Seattle, Washington, 98109, United States|CHU Brest, Brest, France|Jean Perrin Comprehensive Cancer Center, Clermont-Ferrand, France|Institute Paoli-Calmettes, Marseille, France|HÃ´pital de Brabois -CHU, Nancy, France|Institut de CancÃ©rologie de l'Ouest (ICO) St Herblain, Nantes, France|CHU Nimes, NÃ®mes, France|ICANS, Strasbourg, France|InstitutClaudius Regaud-IUCT-O, Toulouse, France|University Clinic Bologna, Bologna, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy|Istituto Europeo di Oncologia (IEO) -IRCCS, Milan, Italy|FundaciÃ³n JimÃ©nez DÃ­az, Madrid, Spain|Hospital Universitario HM Sanchinarro, Madrid, Spain|Hospital Regional Universitario de Malaga, MÃ¡laga, Spain|University Hospital of Salamanca, Salamanca, Spain",
NCT06492616,"A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence",https://clinicaltrials.gov/study/NCT06492616,ELEGANT,RECRUITING,"The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.",NO,Breast Cancer,DRUG: Elacestrant|DRUG: Anastrozole|DRUG: Letrozole|DRUG: Exemestane|DRUG: Tamoxifen,"Invasive Breast Cancer-Free Survival (IBCFS), Assessed by the time from date of randomization to the date of first occurrence of:

* Ipsilateral invasive breast tumor recurrence
* Local/regional invasive breast cancer recurrence
* Distant recurrence
* Contralateral invasive breast cancer, or
* Death attributable to any cause, Up to 5 years","Distant Relapse-Free Survival (DRFS), Assessed by the time from date of randomization to the date of first occurrence of:

* Distant recurrence, or
* Death attributable to any cause, Up to 5 years|Overall Survival (OS), Up to 5 years|Invasive Disease-Free Survival (IDFS), Assessed by the time from date of randomization to the date of first occurrence of:

* Local/regional recurrence
* Contralateral recurrence
* Second primary non-breast invasive cancer
* Distant recurrence, or
* Death attributable to any cause, Up to 5 years|Number of Participants With Adverse Events (AEs), Up to 5 years plus 28 days|Change from Baseline in Global Health Status Quality of Life Scale score, as Assessed by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), Baseline, Month 6, Annually at Years 1, 2, 3, 4, 5|Change from Baseline in the Physical Functioning Sub-Scale Score as Assessed by EORTC QLQ-C30, Baseline, Month 6, Annually at Years 1, 2, 3, 4, 5|Change From Baseline in the Breast Cancer Endocrine Therapy Symptoms Sub-Scale Score, as Assessed by the EORTC Quality of Life Breast Cancer Questionnaire module (EORTC QLQ-BR42), Baseline, Month 6, Annually at Years 1, 2, 3, 4, 5|Change From Baseline in Side Effects, as Assessed by the Question 168 of the European Organization for the Research and Treatment of Cancer Question Library (EORTC Q168), Baseline, Month 6, Annually at Years 1, 2, 3, 4, 5|Area Under the Plasma Concentration Versus Time Curve at Steady State (AUCss) of Elacestrant, Predose up to 4 hours postdose|Maximum Plasma Concentration at Steady State (Cmaxss) of Elacestrant, Predose up to 4 hours postdose",,"Stemline Therapeutics, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE3,4220,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-09-27,2029-08,2032-10,2024-07-09,,2025-06-08,"Southern Cancer Center, PC, Daphne, Alabama, 36526, United States|Banner MD Anderson Cancer Center, Gilbert, Arizona, 85234-2165, United States|Mayo Clinic, Scottsdale, Arizona, 85259-5452, United States|Arizona Clinical Research Center, Inc., Tucson, Arizona, 85715, United States|Highlands Oncology Group, PA, Springdale, Arkansas, 72762, United States|UC San Diego Moores Cancer Center, La Jolla, California, 92037, United States|Cancer and Blood Research Center, LLC, Los Alamitos, California, 90720, United States|UCLA Department of Medicine - Hematology/Oncology, Los Angeles, California, 90095, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, 92663, United States|Dignity Health dba Health Research Institute, Sacramento, California, 95816, United States|Sutter Institute for Medical Research, Sacramento, California, 95816, United States|Helen Diller Family Comprehensive Cancer Center, San Francisco, California, 94158, United States|Sansum Clinic, Solvang, California, 93463, United States|St.Joseph Hospital- Cancer Centers of Colorado, Denver, Colorado, 80218-1122, United States|Rocky Mountain Cancer Centers, LLP, Lone Tree, Colorado, 80124, United States|AHMG Hematology and Oncology, Parker, Colorado, 80138, United States|Cancer Care at CommonSpirit St. Anthony North Hospital, Westminster, Colorado, 80023, United States|Yale New Haven Hospital- Yale Cancer Center, New Haven, Connecticut, 06510, United States|Florida Cancer Specialists, Fort Myers, Florida, 33901, United States|Mayo Clinic, Jacksonville, Florida, 32224, United States|AdventHealth Orlando Infusion Center, Orlando, Florida, 32804, United States|Cancer Care Centers of Brevard (CCCB) - Palm Bay, Palm Bay, Florida, 32909, United States|Memorial Healthcare System, Pembroke Pines, Florida, 33026, United States|Florida Cancer Specialists, Saint Petersburg, Florida, 33705, United States|Florida Cancer Specialists, West Palm Beach, Florida, 33401, United States|University Blood & Cancer Center, LLC, Athens, Georgia, 30607, United States|Winship Cancer Institute, Atlanta, Georgia, 30322, United States|Northside Hospital, Atlanta, Georgia, 30341, United States|Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii, 96819, United States|Illinois Cancer Specialists, Arlington Heights, Illinois, 60005, United States|Northwest Cancer Centers, PC, Dyer, Indiana, 46311, United States|Mission Cancer and Blood, Des Moines, Iowa, 50309, United States|Cancer Center of Kansas, Wichita, Kansas, 67214, United States|Mercy Medical Center, Baltimore, Maryland, 21202, United States|Ascension St. Agnes Hospital, Baltimore, Maryland, 21229, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, 21287, United States|Maryland Oncology Hematology, P.A., Columbia, Maryland, 21044, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Boston Medical Center, Boston, Massachusetts, 02118, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|The Cancer & Hematology Centers, Grand Rapids, Michigan, 49503, United States|Allina Health Cancer Institute - Abbott Northwestern Hospital, Minneapolis, Minnesota, 55407, United States|Mayo Clinic, Rochester, Minnesota, 01842, United States|Siteman Cancer Center, Saint Louis, Missouri, 63108, United States|NHO Revive Research Institute LLC, Lincoln, Nebraska, 68506, United States|Oncology Hematology West, PC dba Nebraska Cancer Specialists - Legacy, Omaha, Nebraska, 68130, United States|Summit Medical Group, Florham Park, New Jersey, 07932, United States|John Theurer Ctr-Hackensack UMC, Hackensack, New Jersey, 07601, United States|Rutgers Cancer Institute, New Brunswick, New Jersey, 08903, United States|Exigent Research LLC/New Mexico Oncology Hematology Consultants Ltd., Albuquerque, New Mexico, 87109, United States|Cayuga Medical Center, Ithaca, New York, 14850, United States|Laura and Isaac Perlmutter Cancer Center/NYU Langone Health, New York, New York, 10016, United States|Columbia University Medical Center, New York, New York, 10032-3729, United States|Cape Fear Valley Medical Center, Fayetteville, North Carolina, 28304, United States|Miami Valley Hospital South, Centerville, Ohio, 45459, United States|Oncology_Hematology Care Clinical Trials, LLC, Fairfield, Ohio, 45014, United States|Oregon Oncology Specialists, Salem, Oregon, 97301, United States|Northwest Cancer Specialists, P.C., Tigard, Oregon, 97223, United States|Consultants In Medical Oncology and Hematology, P.C., Broomall, Pennsylvania, 19008, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, 17033, United States|Alliance Cancer Specialists, PC, Media, Pennsylvania, 19044-1134, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, 19096, United States|Hollings Cancer Center, Charleston, South Carolina, 29425, United States|SCRI Oncology Partners, Nashville, Tennessee, 37203, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, 37203, United States|Henry - Joyce Cancer Clinic, Nashville, Tennessee, 37232, United States|Hendrick Cancer Center, Abilene, Texas, 79601, United States|Texas Oncology - DFW, Dallas, Texas, 75246, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030-4009, United States|Texas Oncology - San Antonio, New Braunfels, Texas, 78130, United States|Mays Cancer Center, San Antonio, Texas, 78229, United States|Texas Oncology- Central South, Weslaco, Texas, 78596, United States|Inova Schar Cancer Institute, Fairfax, Virginia, 22031, United States|Virginia Oncology Associates, Newport News, Virginia, 23606, United States|Virginia Cancer Institute, Richmond, Virginia, 23229, United States|Oncology & Hematology Associates of Southwest Virginia, Inc, Wytheville, Virginia, 24382, United States|Virginia Mason Medical Center, Seattle, Washington, 98101, United States|Swedish Cancer Institute, Seattle, Washington, 98104, United States|Cancer Care Northwest, Spokane Valley, Washington, 99216, United States|Northwest Medical Specialties PLLC, Tacoma, Washington, 98405, United States|University of Wisconsin Carbone Cancer Center- University Hospital, Madison, Wisconsin, 53792, United States|UW Cancer Center at ProHealth Care, Waukesha, Wisconsin, 53188, United States|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, 2010, Australia|Lake Macquarie Private Hospital - Oncology, Gateshead, New South Wales, 2290, Australia|Lismore Base Hospital - Cancer Care , Haematology Unit, Lismore, New South Wales, 2480, Australia|Mater Hospital Sydney, North Sydney, New South Wales, 2060, Australia|Westmead Hospital, Westmead, New South Wales, 2145, Australia|Icon Cancer Centre Townsville, Hyde Park, Queensland, 4812, Australia|Icon Cancer Centre Southport, Southport, Queensland, 4215, Australia|Icon Cancer Centre Wesley, Auchenflower, Quuensland, 4066, Australia|Icon Cancer Centre Kurralta Park, Kurralta Park, South Australia, 5037, Australia|Goulburn Valley Health, Shepparton, Victoria, 3630, Australia|Breast Cancer Research Centre, Nedlands, Western Australia, 6009, Australia|Icon Cancer Centre Hobart, Hobart, 7000, Australia|Mid North Coast Cancer Institute, Port Macquarie, 2444, Australia|Hanusch Krankenhaus, Wien, 1140, Austria|Grand Hopital de Charleroi - Site Les Viviers, Charleroi, Hainaut, 6060, Belgium|Jessa Ziekenhuis - Campus Virga Jesse - Medische Oncologie, Hasselt, Limburg, 3500, Belgium|Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada|Regional Hospital Saint-Jerome, Saint-Jerome, Quebec, J7Z 5T3, Canada|Masarykuv onkologicky ustav - Klinika komplexni onkol. pece, Brno, Brno-mÄsto, 656 53, Czechia|FN Kralovske Vinohrady - Radioterapeuticka a onkologicka klinika, Praha 10, 100 34, Czechia|Fakultni Thomayerova nemocnice - Onkologicka klinika, Praha 4, 140 59, Czechia|Centre Hospitalier Regional et Universitaire (CHRU) de Besancon - L'Hopital Jean Minjoz, Besancon, Alpes-Maritimes, 25000, France|Institut de Cancerologie de l'Ouest - Oncology, St. Herblain, Loire-Atlantique, 44805, France|ICONE, Bezannes, Marne, 51430, France|Institut Gustave Roussy, Villejuif, Val-de-Marne, 94805, France|Institut Sainte Catherine, Avignon, Vaucluse, 84000, France|Centre Hospitalier Universitaire De Poitiers - PÃ´le RÃ©gional de CancÃ©rologie, Poitiers, 86000, France|Institut de CancÃ©rologie de Lorraine, VandÅuvre-LÃ¨s-Nancy Cedex 03, 54511, France|UniversitÃ¤tsmedizin Mannheim (UMM), Mannheim, Baden-WÃ¼rttemberg, 68167, Germany|Studienzentrale fÃ¼r das MVZ e.K, Eggenfelden, Bayern, 84307, Germany|Immanuel Klinik RÃ¼dersdorf, RÃ¼dersdorf, Brandenburg, 15562, Germany|'Klinikum Esslingen GmbH, Esslingen am Neckar, Esslingen a.N., 73730, Germany|'Schwerpunktpraxis Fuer Gynaekologie und Onkologie, Brandenburg, Fuerstenwalde /Spree, 15517, Germany|Klinikum Worms gGmbH, Worms, Rheinland-Pfalz, 67550, Germany|Bacs-Kiskun Varmegyei Oktatakorhaz, KecskemÃ©t, BÃ¡cs-Kiskun, H-6000, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, HajdÃº-Bihar, 4032, Hungary|Nograd Varmegyei Szent Lazar Korhaz, SalgÃ³tarjÃ¡n, Szabolcs-SzatmÃ¡r-Bereg, 3100, Hungary|Budapesti Uzsoki Utcai Korhaz, Budapest, H-1145, Hungary|IRST Dino Amadori IRCCS, Meldola, Forli-Cesena, 47014, Italy|IRCCS San Gerardo dei Tintori, Monza, Monza E Brianza, 20900, Italy|Azienda Sanitaria Locale Napoli 2 Nord, Frattamaggiore, Napoli, 80027, Italy|Centro di Riferimento Oncologico, IRCCS, Aviano, Pordenone, 33081, Italy|Ospedale Casa Sollievo della Sofferen IRCCS, Opera di San Pio da Pietrelcina, San Giovanni Rotondo, Puglia, 71013, Italy|SOD Radioterapia Oncologica, AOU Careggi, Firenze, 50134, Italy|Istituto Nazionale dei Tumori,IRCCS, Milano, 20133, Italy|Istituto Europeo di Oncologia IRCCS, Milano, 20141, Italy|Azienda Ospedaliera Universitaria Federico II, Napoli, 80131, Italy|IRCCS Istituto Nazionale Tumori Fondazione Pascale, Napoli, 80131, Italy|Azienda USL Toscana Centro, Prato, 59100, Italy|Azienda Unita Sanitaria Locale della Romagna, Rimini, 47923, Italy|Irccs Crob, Rionero In Vulture, 85028, Italy|Fondazione PU Campus Biomedico, Roma, 00128, Italy|U.O. Ginecologia Oncologica - Fondazione Policlinico A. Gemelli, Roma, 00136, Italy|IRCCS Istituto Nazionale Tumori Regina Elena,UOSD Sperimentazioni di fase IV, Roma, 00144, Italy|Azienda Ospedaliero Universitaria Di Sassari, Sassari, 07100, Italy|Ospedale Sacro cuore Don Calabria- Negrar di Valpolicella, Verona, 37024, Italy|Chungbuk National University Hospital, Cheongju-si, Chungcheongbugdo [Ch'ungch'ongbuk-do], 28644, Korea, Republic of|CHA Bundang Medical Center, CHA University, Seongnam-si, Gyeonggido, 13496, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Incheon Gwang'yeogsi [Inch'n-Kwangyokshi], 21565, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], 03722, Korea, Republic of|Asan Medical Center, Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], 05505, Korea, Republic of|Gangnam Severance Hospital - Oncology, Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], 06273, Korea, Republic of|Korea University Guro Hospital, Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], 08308, Korea, Republic of|Korea University Anam Hospital, Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], 2841, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], 7985, Korea, Republic of|Inje University Haeundae Paik Hospital, Busan, 48108, Korea, Republic of|National Cancer Center, Gyeonggi-do, 10408, Korea, Republic of|Ajou University Hospital, Gyeonggi-do, 16499, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, 06591, Korea, Republic of|Ulsan University Hospital, Ulsan, 44033, Korea, Republic of|Hospital Raja Permaisuri Bainun, Ipoh, Perak, 30990, Malaysia|Hospital Pulau Pinang - Rheumatology, George Town, Pulau Pinang, Malaysia|Pantai Hospital Kuala Lumpur, Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, 50603, Malaysia|UKM Medical Centre, Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, 56000, Malaysia|Beacon Hospital, Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, 59100, Malaysia|Universiti Malaya Medical Centre, Kuala Lumpur, Wilayah Persekutuan, 59100, Malaysia|Institut Kanser Negara, Putrajaya, Wilayah Persekutuan, 62250, Malaysia|Hospital Sultan Ismail, Johor Bahru, 81100, Malaysia|Hospital Kuala Lumpur, Kuala Lumpur, 50000, Malaysia|Mahkota Medical Center, Melaka, Malaysia|Elisabeth-TweeSteden Ziekenhuis, Tilburg, Noord-Brabant, 5022 GC, Netherlands|Catharina Ziekenhuis, Eindhoven, 5623 EJ, Netherlands|IP Clinic Sp. z o.o., ÅÃ³dÅº, Lodz, 90-752, Poland|Pratia Poznan, Poznan, Wielkopolskie, 60-192, Poland|Hospital Beatriz Ãngelo. Hospital de Loures - Oncologia Medica, Loures, Lisboa, 2674-514, Portugal|Instituto Portugues de Oncologia de Lisboa Francisco Gentil - Oncologia Medica, Lisboa, 1099-023, Portugal|Hospital CUF Descobertas, Lisboa, 1998-018, Portugal|Unidade Local de SaÃºde de ArrÃ¡bida, SetÃºbal, 2910-446, Portugal|Oncolab - Medical Oncology, Craiova, Dolj, 200385, Romania|Centrul de Oncologie Sf. Nectarie, Craiova, Dolj, 200746, Romania|Spitalul Clinic Filantropia, Bucuresti, 011171, Romania|Spitalul Clinic CF Nr 2 Bucuresti, Bucuresti, 011464, Romania|Memorial Healthcare International, Bucuresti, 13823, Romania|Radiotherapy Center Cluj, FloreÅti, 407280, Romania|Raffles Hospital, Singapore, 065001, Singapore|Hospital Alvaro Cunqueiro, Vigo, A CoruÃ±a, 36312, Spain|Hospital Universitario Virgen del RocÃ­o, Sevilla, Andalucia, 41013, Spain|H. Virgen de Valme, Sevilla, Andalucia, 41014, Spain|Hospital Universitario de Canarias, San Cristobal de la Laguna, Canarias, 38320, Spain|Hospital ClÃ­nico Universitario Virgen De La Arrixaca, El Palmar, Murcia, 30120, Spain|Complexo Hospitalario Universitario A CoruÃ±a, A CoruÃ±a, 15006, Spain|Hospital Universitari Vall D Hebron, Barcelona, 08035, Spain|Hospital de La Santa Creu i Sant Pau, Barcelona, 08041, Spain|Hospital Universitario Reina Sofia, CÃ³rdoba, 14004, Spain|H.U. Insular Gran Canaria, Las Palmas De Gran Canaria, 35010, Spain|H.U Arnau De Vilanova Lleida, Lleida, 25198, Spain|Hospital Beata Maria Ana, Madrid, 28007, Spain|Hospital Universitario RamÃ³n y Cajal, Madrid, 28034, Spain|Hospital ClÃ­nico San Carlos, Madrid, 28040, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital Universitario La Paz, Madrid, 28046, Spain|Hospital Universitario Virgen De La Victoria, MÃ¡laga, 29010, Spain|Hospital Universitario de Santiago, Santiago De Compostela, 15706, Spain|Hospital Universitario Virgen de la Macarena - OncologÃ­a MÃ©dica, Sevilla, 41009, Spain|Hospital Clinico Universitario De Valencia, Valencia, 46010, Spain|Hospital Quironsalud Valencia, Valencia, 46010, Spain|Tumor Zentrum Aarau, Aarau, Aargau (de), 5000, Switzerland|Brust-Zentrum AG Zurich, ZÃ¼rich, ZÃ¼rich (de), 8008, Switzerland|Spitaeler Schaffhausen Kantonspital, Schaffhausen, 8208, Switzerland|Changhua Christian Medical Foundation Changhua Christian Hospital, Changhua City, 500209, Taiwan|Royal Cornwall Hospital (RCH) - Sunrise Centre, Truro, Cornwall, TR1 3LJ, United Kingdom|Maidstone Hospital Kent Oncology Centre, Maidstone, ME16 9QQ, United Kingdom",
NCT06830889,A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy,https://clinicaltrials.gov/study/NCT06830889,,NOT_YET_RECRUITING,"This trial is a registered phase III, randomized, open-label, multicenter study designed to evaluate the efficacy and safety of BL-M07D1 in the adjuvant treatment of HER2-positive breast cancer with residual invasive cancer after neoadjuvant therapy.",NO,HER2-positive Breast Cancer,DRUG: BL-M07D1|DRUG: T-DM1,"Invasive Disease-free Survival (IDFS), IDFS refers to the absence of invasive cancer recurrence after breast cancer treatment., Up to approximately 77 months","Disease-free Survival(DFS), DFS is defined as the time from random occurrence of a tumor to recurrence., Up to approximately 77 months|Distant Recurrence-free Interval (DRFI), DRFI is defined as the interval from the date of randomization to the first occurrence of distant recurrence of breast cancer or death due to breast cancer., Up to approximately 77 months|Overall Survival (OS), Overall survival (OS) is defined as the time between the subject's randomization date and subject's death., Up to approximately 77 months|Treatment Emergent Adverse Event (TEAE), TEAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally emerging, or any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition during the treatment of BL-M07D1. The type, frequency and severity of TEAE will be evaluated during the treatment of BL-M07D1., Up to approximately 77 months",,"Sichuan Baili Pharmaceutical Co., Ltd.","Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.",FEMALE,"ADULT, OLDER_ADULT",PHASE3,1450,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2025-05,2031-10,2031-12,2025-02-17,,2025-02-19,"Jiangsu Province Hospital, Nanjing, Jiangsu, China|Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China",
NCT06671379,"A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC",https://clinicaltrials.gov/study/NCT06671379,,RECRUITING,"This study was a randomized, controlled, open-label, multicenter phase III clinical study to compare the efficacy and safety of SHR-A2009 with platinum-based dual-agent chemotherapy in patients with EGFR-mutated advanced or metastatic non-small cell lung cancer who failed EGFR TKI treatment.",NO,Non-small Cell Lung Cancer,DRUG: SHR-A2009 monotherapy|DRUG: platinum-based dual-agent chemotherapy,"Progression-free survival (PFS) assessed by BICR according to RECIST v1.1, Up to approximately 32 months","overall survival (OS), Up to approximately 32 months|Progression Free Survival(PFS by investigator), Up to approximately 32 months|Duration of response(DoRï¼by BICR and investigator ), Up to approximately 32 months|Disease control rateï¼DCRï¼by BICR and investigatorï¼, Up to approximately 32 months|Incidence of AEs, from Day1 to 40 days after last dose",,"Suzhou Suncadia Biopharmaceuticals Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,500,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-11-29,2026-12,2027-06,2024-11-04,,2024-12-31,"Guangdong Provincial People's Hospital, Guangzhou, Guangdong, 510000, China",
NCT05855200,Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer,https://clinicaltrials.gov/study/NCT05855200,AZUR-2,RECRUITING,"The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon cancer.",NO,"Colonic Neoplasms|Neoplasms, Colon",BIOLOGICAL: Dostarlimab|DRUG: CAPEOX|DRUG: FOLFOX,"Event-free Survival (EFS) Assessed by Blinded Independent Central Review (BICR), EFS is defined as the time from randomization to either disease recurrence or death due to any cause or treatment related toxicity that results in the participant not being suitable for surgery, Up to approximately 5 years","Overall Survival (OS), OS is defined as time from randomization to death from any cause, Up to approximately 5 years|Number of Participants with Pathological Response, Pathological response will be categorized as a complete pathologic response, major pathologic response, partial pathologic response, or negligible pathologic response., Up to approximately 5 years|Event-free Survival (EFS) assessed by local assessment, EFS is defined as the time from randomization to either disease recurrence or death due to any cause or treatment related toxicity that results in the participant not being suitable for surgery, Up to approximately 5 years|Number of Participants with treatment emergent adverse events (AEs), serious adverse events (SAEs), Immune-mediated Adverse Event (imAEs), AEs leading to death and AEs leading to discontinuation of study treatment, Up to approximately 5 years|Number of Participants with AEs and SAEs by Severity, Up to approximately 5 years|Serum Concentration of Dostarlimab, Predose and End of Infusion (EoI) of Cycle 1 and EoI of Cycle 2 to Cycle 10 (each cycle is of 21 days)|Serum Concentration of Dostarlimab at End of Infusion (C-EoI), End of Infusion (EoI) of Cycle 1 to Cycle 10 (each cycle is of 21 days)|Serum Predose trough concentration (Ctrough) of Dostarlimab, Predose of Cycle 1 to Cycle 10 (each cycle is of 21 days)|Number of Participants with Anti-Drug Antibodies against Dostarlimab, Up to approximately 5 years",,GlaxoSmithKline,,ALL,"ADULT, OLDER_ADULT",PHASE3,711,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-08-01,2028-12-15,2030-12-25,2023-05-11,,2024-08-27,"GSK Investigational Site, Tucson, Arizona, 85715, United States|GSK Investigational Site, Los Angeles, California, 90027, United States|GSK Investigational Site, New Haven, Connecticut, 06520, United States|GSK Investigational Site, Washington, District of Columbia, 20010, United States|GSK Investigational Site, Deerfield Beach, Florida, 33064, United States|GSK Investigational Site, Fort Lauderdale, Florida, 33316, United States|GSK Investigational Site, Marietta, Georgia, 30060, United States|GSK Investigational Site, Chicago, Illinois, 60611, United States|GSK Investigational Site, Chicago, Illinois, 60612, United States|GSK Investigational Site, Chicago, Illinois, 60637, United States|GSK Investigational Site, Naperville, Illinois, 60126, United States|GSK Investigational Site, Naperville, Illinois, 60540, United States|GSK Investigational Site, Westwood, Kansas, 66205, United States|GSK Investigational Site, Lexington, Kentucky, 40503, United States|GSK Investigational Site, Louisville, Kentucky, 40206, United States|GSK Investigational Site, Baton Rouge, Louisiana, 70809, United States|GSK Investigational Site, Bethesda, Maryland, 20817, United States|GSK Investigational Site, Ann Arbor, Michigan, 48109, United States|GSK Investigational Site, Detroit, Michigan, 48202, United States|GSK Investigational Site, Minneapolis, Minnesota, 55455, United States|GSK Investigational Site, Joplin, Missouri, 64804, United States|GSK Investigational Site, Saint Louis, Missouri, 63128, United States|GSK Investigational Site, Saint Louis, Missouri, 63141, United States|GSK Investigational Site, Omaha, Nebraska, 68130, United States|GSK Investigational Site, Omaha, Nebraska, 68198, United States|GSK Investigational Site, Omaha, Nebraska, 68803, United States|GSK Investigational Site, Lebanon, New Hampshire, 03756, United States|GSK Investigational Site, Bronx, New York, 10461, United States|GSK Investigational Site, New York, New York, 10028, United States|GSK Investigational Site, New York, New York, 10065, United States|GSK Investigational Site, New York, New York, 10469, United States|GSK Investigational Site, New York, New York, 11042, United States|GSK Investigational Site, New York, New York, 11967, United States|GSK Investigational Site, Durham, North Carolina, 27710, United States|GSK Investigational Site, Greenville, North Carolina, 27834, United States|GSK Investigational Site, Akron, Ohio, 44304, United States|GSK Investigational Site, Cincinnati, Ohio, 45220, United States|GSK Investigational Site, Cleveland, Ohio, 44111, United States|GSK Investigational Site, Cleveland, Ohio, 44142, United States|GSK Investigational Site, Cleveland, Ohio, 44196, United States|GSK Investigational Site, Oklahoma City, Oklahoma, 73104, United States|GSK Investigational Site, Oklahoma City, Oklahoma, 73120, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, 15212, United States|GSK Investigational Site, Wynnewood, Pennsylvania, 19096, United States|GSK Investigational Site, Sioux Falls, South Dakota, 57078, United States|GSK Investigational Site, Sioux Falls, South Dakota, 57105, United States|GSK Investigational Site, Sioux Falls, South Dakota, 57401, United States|GSK Investigational Site, Sioux Falls, South Dakota, 57501, United States|GSK Investigational Site, Nashville, Tennessee, 37232, United States|GSK Investigational Site, Dallas, Texas, 75235, United States|GSK Investigational Site, Dallas, Texas, 75390-8565, United States|GSK Investigational Site, Richmond, Virginia, 23229, United States|GSK Investigational Site, Appleton, Wisconsin, 54911, United States|GSK Investigational Site, Buenos Aires, 1093, Argentina|GSK Investigational Site, Buenos Aires, C1181ACH, Argentina|GSK Investigational Site, Capital Federal, C1426ANZ, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aire, C1431FWO, Argentina|GSK Investigational Site, Cordoba, 5000, Argentina|GSK Investigational Site, Mar del Plata, 7600, Argentina|GSK Investigational Site, Rosario, S2002, Argentina|GSK Investigational Site, Santa Fe, S3000FUJ, Argentina|GSK Investigational Site, Heidelberg, 3084, Australia|GSK Investigational Site, Melbourne, VIC 3004, Australia|GSK Investigational Site, Newcastle, 2298, Australia|GSK Investigational Site, St Leonards, 2065, Australia|GSK Investigational Site, Woolangabba, 4102, Australia|GSK Investigational Site, Aalst, 9300, Belgium|GSK Investigational Site, Bruxelles, 1070, Belgium|GSK Investigational Site, Bruxelles, 1200, Belgium|GSK Investigational Site, Edegem, 2650, Belgium|GSK Investigational Site, Gent, 9000, Belgium|GSK Investigational Site, Leuven, 3000, Belgium|GSK Investigational Site, LiEge, 4000, Belgium|GSK Investigational Site, Roeselare, 8800, Belgium|GSK Investigational Site, Barretos, 14784-400, Brazil|GSK Investigational Site, Lages, 88501-001, Brazil|GSK Investigational Site, Natal, 59075-740, Brazil|GSK Investigational Site, Porto Alegre, 90610-000, Brazil|GSK Investigational Site, Salvador, 40414-120, Brazil|GSK Investigational Site, Sao Jose do Rio Preto, 15090-000, Brazil|GSK Investigational Site, Sao Paulo, 01509-010, Brazil|GSK Investigational Site, Sao Paulo, 04312903, Brazil|GSK Investigational Site, Teresina, 64049-200, Brazil|GSK Investigational Site, VitOria, 29043-260, Brazil|GSK Investigational Site, Edmonton, T6G 1Z2, Canada|GSK Investigational Site, Halifax, B3H 1V7, Canada|GSK Investigational Site, Montreal, H4A 3J1, Canada|GSK Investigational Site, Ottawa, K1H 8L6, Canada|GSK Investigational Site, Toronto, M5G 2M9, Canada|GSK Investigational Site, Beijing, 100036, China|GSK Investigational Site, Beijing, 100083, China|GSK Investigational Site, Beijing, 100730, China|GSK Investigational Site, Changchun, 130021, China|GSK Investigational Site, Changsha, 410013, China|GSK Investigational Site, Chengdu, 610041, China|GSK Investigational Site, Chongqing, 400042, China|GSK Investigational Site, Chongqing, 400042, China|GSK Investigational Site, Guangzhou, 510060, China|GSK Investigational Site, Guangzhou, 510655, China|GSK Investigational Site, Hangzhou, 310003, China|GSK Investigational Site, Hangzhou, 310016, China|GSK Investigational Site, Hangzhou, 310022, China|GSK Investigational Site, Hangzhou, 310052, China|GSK Investigational Site, Harbin, 150000, China|GSK Investigational Site, Jinan, 250117, China|GSK Investigational Site, Kunming, 650106, China|GSK Investigational Site, Meizhou, 514700, China|GSK Investigational Site, Nanchang, 330006, China|GSK Investigational Site, Nanchang, 330029, China|GSK Investigational Site, Shanghai, 200032, China|GSK Investigational Site, Shanghai, 200032, China|GSK Investigational Site, Shenyang, 110001, China|GSK Investigational Site, Shenzhen, 518036, China|GSK Investigational Site, Taiyuan, 030013, China|GSK Investigational Site, Tianjin, China|GSK Investigational Site, Wuhan, 430030, China|GSK Investigational Site, Xiamen, 361004, China|GSK Investigational Site, Yangzhou, 225001, China|GSK Investigational Site, Zhengzhou, 450052, China|GSK Investigational Site, Tallinn, 11312, Estonia|GSK Investigational Site, Tallinn, 13419, Estonia|GSK Investigational Site, Tartu, 50501, Estonia|GSK Investigational Site, Helsinki, 00029, Finland|GSK Investigational Site, Tampere, 33520, Finland|GSK Investigational Site, Turku, 20521, Finland|GSK Investigational Site, Lyon, 69008, France|GSK Investigational Site, Marseille Cedex 5, 13385, France|GSK Investigational Site, Nantes cedex 1, 44093, France|GSK Investigational Site, Paris, 75015, France|GSK Investigational Site, Pessac cedex, 33604, France|GSK Investigational Site, Rennes Cedex, 35042, France|GSK Investigational Site, Rouen Cedex, 76000, France|GSK Investigational Site, Saint-Priest en Jarez, 42270, France|GSK Investigational Site, Suresnes, 92150, France|GSK Investigational Site, Toulouse Cedex 9, 31059, France|GSK Investigational Site, Villejuif Cedex, 94805, France|GSK Investigational Site, Berlin, 13353, Germany|GSK Investigational Site, Duesseldorf, 40225, Germany|GSK Investigational Site, Frankfurt, 60488, Germany|GSK Investigational Site, Halle, 06120, Germany|GSK Investigational Site, Luebeck, 23562, Germany|GSK Investigational Site, Mannheim, 68167, Germany|GSK Investigational Site, MUnchen, 81377, Germany|GSK Investigational Site, Munchen, 81737, Germany|GSK Investigational Site, Athens, 11528, Greece|GSK Investigational Site, Thessaloniki, 54639, Greece|GSK Investigational Site, Thessaloniki, 570 10, Greece|GSK Investigational Site, Cagliari, 09042, Italy|GSK Investigational Site, Genova, 16132, Italy|GSK Investigational Site, Milano, 20162, Italy|GSK Investigational Site, Napoli, 80131, Italy|GSK Investigational Site, Padova, 35128, Italy|GSK Investigational Site, Pisa, 56126, Italy|GSK Investigational Site, Reggio Emilia, 40123, Italy|GSK Investigational Site, Roma, 00152, Italy|GSK Investigational Site, Roma, 00168, Italy|GSK Investigational Site, Rozzano MI, 20089, Italy|GSK Investigational Site, Aichi, 464-8681, Japan|GSK Investigational Site, Chiba, 277-8577, Japan|GSK Investigational Site, Fukuoka, 812-8582, Japan|GSK Investigational Site, Hokkaido, 060-8648, Japan|GSK Investigational Site, Hyogo, 650-0047, Japan|GSK Investigational Site, Ibaraki, 309-1793, Japan|GSK Investigational Site, Kanagawa, 216-8511, Japan|GSK Investigational Site, Kanagawa, 232-0024, Japan|GSK Investigational Site, Kyoto, 606-8507, Japan|GSK Investigational Site, Okayama, 710-8602, Japan|GSK Investigational Site, Osaka, 540-0006, Japan|GSK Investigational Site, Osaka, 541-8567, Japan|GSK Investigational Site, Osaka, 558-8558, Japan|GSK Investigational Site, Osaka, 565-0871, Japan|GSK Investigational Site, Shizuoka, 411-8777, Japan|GSK Investigational Site, Tokyo, 104-0045, Japan|GSK Investigational Site, Daegu, 41404, Korea, Republic of|GSK Investigational Site, Gyeonggi-do, 463712, Korea, Republic of|GSK Investigational Site, Seoul, 03722, Korea, Republic of|GSK Investigational Site, Seoul, 06351, Korea, Republic of|GSK Investigational Site, Seoul, 06591, Korea, Republic of|GSK Investigational Site, Seoul, 138-736, Korea, Republic of|GSK Investigational Site, DF, 14000, Mexico|GSK Investigational Site, Guadalajara, 44280, Mexico|GSK Investigational Site, Guadalajara, 44650, Mexico|GSK Investigational Site, Mexico City, 03100, Mexico|GSK Investigational Site, Oaxaca, 68020, Mexico|GSK Investigational Site, San Pedro Garza Garcia, 66220, Mexico|GSK Investigational Site, Tijuana, 22010, Mexico|GSK Investigational Site, Breda, 4818 CK, Netherlands|GSK Investigational Site, Maastricht, 6229 HX, Netherlands|GSK Investigational Site, Nijmegen, 6525 GA, Netherlands|GSK Investigational Site, Utrecht, 3584 CX, Netherlands|GSK Investigational Site, Bergen, 5021, Norway|GSK Investigational Site, Drammen, N-3004, Norway|GSK Investigational Site, Kristiansand, 4604, Norway|GSK Investigational Site, Lrenskog, 1478, Norway|GSK Investigational Site, Oslo, 0407, Norway|GSK Investigational Site, Stavanger, 4011, Norway|GSK Investigational Site, Tromsoe, 9019, Norway|GSK Investigational Site, Punta Pacifica Panama City Panama, Panama|GSK Investigational Site, Almada, 2805-267, Portugal|GSK Investigational Site, Coimbra, 3000-075, Portugal|GSK Investigational Site, Lisboa, 1649-035, Portugal|GSK Investigational Site, BaracaldoVizcaya, 48903, Spain|GSK Investigational Site, Barcelona, 08026, Spain|GSK Investigational Site, Barcelona, 08035, Spain|GSK Investigational Site, Barcelona, 08036, Spain|GSK Investigational Site, COrdoba, 14004, Spain|GSK Investigational Site, Elche Alicante, 03203, Spain|GSK Investigational Site, Granada, 18014, Spain|GSK Investigational Site, JaEn, 23007, Spain|GSK Investigational Site, L'Hospitalet De Llobrega, 08908, Spain|GSK Investigational Site, Las Palmas De Gran Canar, 35016, Spain|GSK Investigational Site, Madrid, 28006, Spain|GSK Investigational Site, Madrid, 28009, Spain|GSK Investigational Site, Madrid, 28034, Spain|GSK Investigational Site, Madrid, 28041, Spain|GSK Investigational Site, Madrid, 28046, Spain|GSK Investigational Site, Madrid, 28050, Spain|GSK Investigational Site, Madrid, 28222, Spain|GSK Investigational Site, MAlaga, 29010, Spain|GSK Investigational Site, Oviedo, 33011, Spain|GSK Investigational Site, Pamplona, 31008, Spain|GSK Investigational Site, San Sebastian, 20080, Spain|GSK Investigational Site, Santander, 39011, Spain|GSK Investigational Site, Sevilla, 41013, Spain|GSK Investigational Site, Valencia, 46009, Spain|GSK Investigational Site, Valencia, 46010, Spain|GSK Investigational Site, Zaragoza, 50009, Spain|GSK Investigational Site, Eskilstuna, 63349, Sweden|GSK Investigational Site, Goteborg, SE-413 45, Sweden|GSK Investigational Site, Linkoping, SE-581 85, Sweden|GSK Investigational Site, Malmo, 20502, Sweden|GSK Investigational Site, Stockholm, 11219, Sweden|GSK Investigational Site, Stockholm, 11883, Sweden|GSK Investigational Site, Stockholm, 17164, Sweden|GSK Investigational Site, Umea, SE-901 85, Sweden|GSK Investigational Site, Uppsala, SE-751 85, Sweden|GSK Investigational Site, Kaohsiung, 833, Taiwan|GSK Investigational Site, Tainan, 704, Taiwan|GSK Investigational Site, Taipei, 100, Taiwan|GSK Investigational Site, Taoyuan, 333, Taiwan|GSK Investigational Site, Ankara, 06010, Turkey|GSK Investigational Site, Ankara, 06230, Turkey|GSK Investigational Site, Istanbul, 34722, Turkey|GSK Investigational Site, Birmingham, B9 5SS, United Kingdom|GSK Investigational Site, Chelmsford, CM1 7ET, United Kingdom|GSK Investigational Site, Cheltenham, GL53 7AN, United Kingdom|GSK Investigational Site, Edinburgh, EH4 2XU, United Kingdom|GSK Investigational Site, Hull, HU16 5JQ, United Kingdom|GSK Investigational Site, Leeds West Yorkshire, LS9 7TF, United Kingdom|GSK Investigational Site, London, NW3 2QG, United Kingdom|GSK Investigational Site, London, SW3 6JJ, United Kingdom|GSK Investigational Site, Manchester, M20 4BX, United Kingdom|GSK Investigational Site, Sutton, SM2 5PT, United Kingdom",
NCT06313086,DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer,https://clinicaltrials.gov/study/NCT06313086,,RECRUITING,A Clinical Study to Evaluate the Efficacy and Safety of DP303c versus trastuzumab emtansine in patients with HER2-positive Advanced Breast Cancer,NO,HER2-positive Breast Cancer,DRUG: DP303c|DRUG: trastuzumab emtansine,"Progression-free survival (PFS) by BIRC, PFS is evaluated by a Blinded Independent Review Committee (BIRC) according to the Response Evaluation Criteria for Solid Tumors (RECIST) V1.1., Up to approximately 4 years","Progression-free survival (PFS) by investigator, PFS is evaluated by investigator according to the Response Evaluation Criteria for Solid Tumors (RECIST) V1.1., Up to approximately 4 years|Overall Survival (OS), Overall Survival, Up to approximately 4 years|Objective response rate (ORR), ORR is evaluated by investigator and BIRC according to the Response Evaluation Criteria for Solid Tumors (RECIST) V1.1., Up to approximately 4 years|Duration of response (DoR), Duration of Response, Up to approximately 4 years|Incidence and severity of adverse events (AEs), Incidence and severity of adverse events, Up to approximately 4 years",,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,442,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-03-13,2025-12,2028-02,2024-03-15,,2024-05-10,"Fudan University Shanghai Cancer Center, Shanghai, Shanghai, 200032, China",
NCT05424835,"A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane",https://clinicaltrials.gov/study/NCT05424835,,ACTIVE_NOT_RECRUITING,"The study is being conducted to evaluate whether the efficacy of SHR-A1811 is better than Pyrotinib in combination with Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane.",NO,"HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane",DRUG: SHR-A1811|DRUG: Pyrotinib in combination with Capecitabine.,"PFSï¼BIRC assessmentï¼, 6 weeks after the first study drug administrationï¼about 2 years.",,,"Jiangsu HengRui Medicine Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,381,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-08-04,2026-12-31,2027-12-31,2022-06-21,,2024-09-20,"Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, 510120, China",
NCT06065748,"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)",https://clinicaltrials.gov/study/NCT06065748,,RECRUITING,"This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant endocrine therapy.",NO,"Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer",DRUG: Giredestrant|DRUG: Fulvestrant|DRUG: Abemaciclib|DRUG: Palbociclib|DRUG: Ribociclib|DRUG: LHRH Agonist|DIAGNOSTIC_TEST: FoundationOne Liquid CDx Assay (F1LCDx),"Progression-Free Survival (PFS) in the ESR1 mutation (ESR1m) Subgroup, PFS is defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), or death from any cause during the study., From randomization to first occurrence of progressive disease (PD) or death (up to 5 years)|PFS in the Full Analysis Set (FAS) Population, From randomization to first occurrence of PD or death (up to 5 years)","PFS in the ESR1 no-mutation-detected (ESR1nmd) Subgroup, From randomization to first occurrence of PD or death (up to 5 years)|Overall Survival (OS), OS is defined as the time from randomization to death from any cause. It will be analyzed in the FAS and in the ESR1m and ESR1nmd subgroups., From randomization until death from any cause (up to 5 years)|Confirmed Objective Response Rate (cORR), The cORR is defined as the percentage of participants with a complete response (CR) or partial response (PR) on two consecutive occasions at least 4 weeks apart, as determined by the investigator according to RECIST v1.1. It will be analyzed in the FAS and in the ESR1m and ESR1nmd subgroups., From randomization until treatment discontinuation (up to 5 years)|Duration of Response (DOR), DOR is defined as the time from the first occurrence of a documented objective response to PD, as determined by the investigator according to RECIST v1.1, or death from any cause (whichever occurs first). It will be analyzed in the FAS and in the ESR1m and ESR1nmd subgroups., From the first occurrence of a documented objective response to PD or death (up to 5 years)|Clinical Benefit Rate (CBR), The CBR is defined as the percentage of participants with stable disease for at least (â¥)24 weeks or a CR or PR, as determined by the investigator according to RECIST v1.1. It will be analyzed in the FAS and in the ESR1m and ESR1nmd subgroups., From randomization until treatment discontinuation (up to 5 years)|Time to Chemotherapy, Time to chemotherapy is defined as the time from randomization until the start date of the first chemotherapy or death from any cause (whichever occurs first). It will be analyzed in the FAS and in the ESR1m and ESR1nmd subgroups., From randomization until the start of chemotherapy or death (up to 5 years)|Time to Confirmed Deterioration (TTCD) in Pain Severity, TTCD in pain severity is defined as the time from randomization to the first documentation of â¥2-point increase from baseline on the ""worst pain"" item score of the Brief Pain Inventory-Short Form (BPI-SF). It will be analyzed in the FAS and in the ESR1m and ESR1nmd subgroups., From randomization until end of follow-up (up to 5 years)|TTCD in Pain Presence and Interference, TTCD in pain presence and interference is defined as the time from randomization to the first documentation of â¥10-point increase in pain score, as determined using the European Organisation for Research and Treatment of Cancer Quality of Life-Core 30 (EORTC QLQ-C30) questionnaire. It will be analyzed in the FAS and in the ESR1m and ESR1nmd subgroups., From randomization until end of follow-up (up to 5 years)|TTCD in Physical Functioning, TTCD in physical functioning (PF) is defined as the time from randomization to the first documentation of â¥10-point decrease in PF score, as determined using the EORTC QLQ-C30 questionnaire. It will be analyzed in the FAS and in the ESR1m and ESR1nmd subgroups., From randomization until end of follow-up (up to 5 years)|TTCD in Role Functioning, TTCD in role functioning (RF) is defined as the time from randomization to the first documentation of â¥10-point decrease in RF score, as determined using the EORTC QLQ-C30 questionnaire. It will be analyzed in the FAS and in the ESR1m and ESR1nmd subgroups., From randomization until end of follow-up (up to 5 years)|TTCD in Global Health Status/Quality of Life, TTCD in in Global Health Status/Quality of Life (GHS/QoL) is defined as the time from randomization to the first documentation of â¥10-point decrease in GHS/QoL score, as determined using the EORTC QLQ-C30 questionnaire. It will be analyzed in the FAS and in the ESR1m and ESR1nmd subgroups., From randomization until end of follow-up (up to 5 years)|Incidence and Severity of Adverse Events, Incidence will be reported as the number of participants with at least one adverse event, with severity determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5 (NCI CTCAE v5.0)., From Baseline until 28 days after the final dose of study treatment (up to 5 years)|Number of Participants with Vital Sign Abnormalities Over the Course of the Study, Vital signs include respiratory rate, pulse rate, systolic and diastolic blood pressure, and temperature., From Baseline until 28 days after the final dose of study treatment (up to 5 years)|Number of Participants with Clinical Laboratory Test Abnormalities for Hematology and Biochemistry Parameters Over the Course of the Study, From Baseline until 28 days after the final dose of study treatment (up to 5 years)",,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE3,1050,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-12-11,2026-07-30,2028-12-30,2023-10-04,,2025-05-31,"Southern Cancer Center, Daphne, Alabama, 36526, United States|Sutter Auburn Faith Hospital, Auburn, California, 95602, United States|La Hematology Oncology Medical Group, Glendale, California, 91260, United States|Marin Cancer Care Inc, Greenbrae, California, 94904, United States|Kaiser Permanente - Harbor City, Harbor City, California, 90710, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, 90033, United States|USC Norris Cancer Center, Newport Beach, California, 92663, United States|Sutter Medical Group, Roseville Clinic, Roseville, California, 95661, United States|Sutter Health Medical Center, Sacramento, California, 95816, United States|The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Cente, Torrance, California, 90502, United States|Rocky Mountain Cancer Centers, Littleton, Colorado, 80120-4413, United States|Georgetown University Medical Center, Washington, District of Columbia, 20007, United States|MedStar Washington Hosp Center, Washington, District of Columbia, 20010, United States|AdventHealth Altamonte, Altamonte Springs, Florida, 32701, United States|Florida Cancer Specialists - Fort Myers (Gladiolus Dr), Fort Myers, Florida, 33908, United States|Cancer Specialists of North Florida, Jacksonville, Florida, 32256, United States|Comprehensive Hematology Oncology, Saint Petersburg, Florida, 33709, United States|Florida Cancer Specialists - Tampa, Tampa, Florida, 33603, United States|Florida Cancer Specialists - EAST - SCRI - PPDS, West Palm Beach, Florida, 33401-3406, United States|Grady Health System, Atlanta, Georgia, 30303, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, 30329, United States|Advocate Lutheran General Hospital, Park Ridge, Illinois, 60068, United States|Springfield Clinic, Springfield, Illinois, 62702, United States|Mission Cancer + Blood - IMMC, Des Moines, Iowa, 50309, United States|Baptist Health Lexington, Lexington, Kentucky, 40503, United States|Baptist Health Hamburg, Lexington, Kentucky, 40509, United States|Baptist Health Louisville, Louisville, Kentucky, 40207, United States|New England Cancer Specialists, Scarborough, Maine, 04074, United States|Maryland Oncology Hematology, Annapolis, Maryland, 21401, United States|Frederick Health Hospital, Frederick, Maryland, 21702, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Henry Ford Hospital, Detroit, Michigan, 48202, United States|HCA Midwest Division, Kansas City, Missouri, 64132, United States|Cancer Care Center of O'Fallon, O'Fallon, Missouri, 62269, United States|Oncology Hematology West - Legacy, Omaha, Nebraska, 68130-2042, United States|Astera Cancer Care East Brunswick, East Brunswick, New Jersey, 08816, United States|Capital Health Regional Medical Center, Pennington, New Jersey, 08534, United States|Queens Hospital Cancer Center, Jamaica, New York, 11432, United States|Duke Women Cancer Care, Raleigh, North Carolina, 27607, United States|Oncology Hematology Care, Cincinnati, Ohio, 45242, United States|Asante Rogue Regional Medical Center, Medford, Oregon, 97504-8332, United States|Alliance Cancer Specialists, Bensalem, Pennsylvania, 19020, United States|Ann B. Barshinger Cancer Institute, Lancaster, Pennsylvania, 17604, United States|Abramson Cancer Center; Univ of Pennsylvania; Clinical Research Unit, Philadelphia, Pennsylvania, 19106, United States|WellSpan Oncology Research, York, Pennsylvania, 17403, United States|Brown University Health, Providence, Rhode Island, 02905, United States|Medical University of South Carolina, Charleston, South Carolina, 29425, United States|Avera Cancer Institute - Aberdeen, Aberdeen, South Dakota, 57401, United States|Avera Cancer Institute, Sioux Falls, South Dakota, 57105, United States|West Cancer Center, Germantown, Tennessee, 38138, United States|SCRI Oncology Partners, Nashville, Tennessee, 37203, United States|Texas Oncology Cancer Center, Austin, Texas, 78731, United States|JPS Oncology & Infusion Center, Fort Worth, Texas, 76104, United States|Texas Oncology - DFW, Irving, Texas, 75063, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, 22031, United States|Virginia Commonwealth University - Massey Cancer Center, Richmond, Virginia, 23219, United States|Northwest Medical Specialties, Tacoma, Washington, 98405, United States|West Virginia University Hospitals Inc, Morgantown, West Virginia, 26056, United States|Aurora BayCare Medical Center, Green Bay, Wisconsin, 54311, United States|Aurora St Lukes Medical Center, Milwaukee, Wisconsin, 53215, United States|Inst. de Oncologia Angel H. Roffo, Buenos aires, C1417DTB, Argentina|FundaciÃ³n CENIT para la InvestigaciÃ³n en Neurociencias, Ciudad Autonoma Buenos Aires, C1125ABD, Argentina|Centro Oncologico Korben, Ciudad Autonoma Buenos Aires, C1426AGE, Argentina|Sanatorio Allende, Cordoba, X5000JHQ, Argentina|Centro Oncologico Riojano Integral (CORI), La Rioja, F5300COE, Argentina|Hospital AlemÃ¡n, Recoleta, C1118AAT, Argentina|Instituto de OncologÃ­a de Rosario, Rosario, S2000KZE, Argentina|Sanatorio Parque S.A., Rosario, S2000QGB, Argentina|Hospital Provincial del Centenario, Rosario, S2002KDS, Argentina|Centro OncolÃ³gico de Excelencia, San Juan, J5400, Argentina|Northern Beaches Hospital, Frenchs Forest, New South Wales, 2086, Australia|Nepean Hospital, Kingswood, New South Wales, 2747, Australia|Mater Hospital, North Sydney, New South Wales, 2060, Australia|University of the Sunshine Coast, Sippy Downs, Queensland, 4556, Australia|Mater Misericordiae Limited, South Brisbane, Queensland, 4101, Australia|Cancer Research SA, Adelaide, South Australia, Australia|Barwon Health, Geelong, Victoria, 3220, Australia|Sunshine Hospital, St Albans, Victoria, 3021, Australia|South West Healthcare, Warrnambool, Victoria, 3280, Australia|Lkh-Univ. Klinikum Graz, Graz, 8036, Austria|Medical University Innsbruck, Innsbruck, 6020, Austria|Ordensklinikum Linz Barmherzige Schwestern, Linz, 4010, Austria|OÃ¶. Gesundheits- und Spitals-AG/LKH Steyr, Steyr, 4400, Austria|Medizinische UniversitÃ¤t Wien, Wien, 1090, Austria|Cliniques Universitaires St-Luc, Bruxelles, 1200, Belgium|UZ Gent, Gent, 9000, Belgium|UZ Leuven Gasthuisberg, Leuven, 3000, Belgium|CHU Sart-Tilman, LiÃ¨ge, 4000, Belgium|Clinique Ste-Elisabeth, Namur, 5000, Belgium|Sint Augustinus Wilrijk, Wilrijk, 2610, Belgium|Obras Sociais Irma Dulce - Osid, Salvador, Bahia, 40415-006, Brazil|Crio - Centro Regional Integrado de Oncologia, Fortaleza, CearÃ¡, 60336-232, Brazil|Hospital SÃ­rio-LibanÃªs, Brasilia, Distrito Federal, 70200-730, Brazil|CEDOES - DiagnÃ³stico e Pesquisa, Vitoria, EspÃ­rito Santo, 29055-450, Brazil|Hospital Araujo Jorge, Goiania, GoiÃ¡s, 74605-070, Brazil|Hospital Sao Domingos, Sao Luis, MaranhÃ£o, 65060-645, Brazil|Hospital do Cancer de Pernambuco - HCP, Recife, Pernambuco, 50040-000, Brazil|Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda, Ijui, Rio Grande Do Sul, 98700-000, Brazil|Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, 90020-090, Brazil|Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, 90035-000, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, Rio Grande Do Sul, 90610-000, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, Rio Grande Do Sul, 91350-200, Brazil|Hospital de Cancer de Barretos, Barretos, SÃ£o Paulo, 14784-400, Brazil|Hospital Amaral Carvalho, Jau, SÃ£o Paulo, 17210-120, Brazil|Hospital SÃ­rio-LibanÃªs, Sao Paulo, SÃ£o Paulo, 01308-050, Brazil|Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda, Sao Paulo, SÃ£o Paulo, 01317-001, Brazil|Hospital A. C. Camargo, Sao Paulo, SÃ£o Paulo, 01509-010, Brazil|Instituto D'Or de Pesquisa e Ensino, Rio de Janeiro, 22281-100, Brazil|Cross Cancer Institute, Edmonton, Alberta, T6G 1Z2, Canada|Royal Victoria Regional Health Centre, Barrie, Ontario, L4M 6M2, Canada|Credit Valley Hospital/Carlo Fidani Peel Regional Cancer Centre, Mississauga, Ontario, L5M 2N1, Canada|Lakeridge Health Oshawa, Oshawa, Ontario, L1G 2B9, Canada|Thunder Bay Regional Health Sciences Centre, Thunder Bay, Ontario, P7B 6V4, Canada|North York General Hospital, Toronto, Ontario, M2K 1E1, Canada|Princess Margaret Cancer Center, Toronto, Ontario, M5G 2M9, Canada|CIUSSS du Saguenay Lac-Saint-Jean, Chicoutimi Hospital, Chicoutimi, Quebec, G7H 5H6, Canada|CISSS ChaudiÃ¨re-Appalaches, Levis, Quebec, G6V 3Z1, Canada|Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal, Quebec, H2X 0C2, Canada|McGill University Health Centre - Glen Site, Montreal, Quebec, H4A 3J1, Canada|CHU de QuÃ©bec - HÃ´pital du Saint-Sacrement, Quebec City, Quebec, G1S 4L8, Canada|Hopital regional de saint jerome, Saint-jerome, Quebec, J7Z 5T3, Canada|Centre hospitalier regional de Trois-Rivieres, Trois-Rivieres, Quebec, G8Z 3R9, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, S4T 7T1, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, SK S7N 4H4, Canada|Oncovida, Providencia, 750000, Chile|ClÃ­nica Puerto Montt, Puerto Montt, 5500243, Chile|Centro De Cancer Universidad Catolica, Santiago, 8330032, Chile|Instituto Nacional del Cancer, Santiago, 8380000, Chile|Icegclinic, Santiago, Chile|Beijing Cancer Hospital, Beijing, 100142, China|the First Hospital of Jilin University, Changchun City, 130021, China|Hunan Cancer Hospital, Changsha CITY, 410013, China|West China Hospital of Sichuan University, Chengdu City, 610041, China|Sichuan Provincial People's Hospital, Chengdu, 610072, China|The First Affiliated Hospital, Chongqing Medical University, Chongqing, 400016, China|Fujian Medical University Union Hospital, Fuzhou City, 350001, China|No. 900 Hospital (Fuzhou General Hospital), Fuzhou City, 350009, China|Cancer Center, Sun Yat-sen University of Medical Sciences, Guangzhou City, 510060, China|The Second Affiliated Hospital of Zhejiang University College, Hangzhou, 310009, China|Harbin Medical University Cancer Hospital, Harbin, 150081, China|Jinan Central Hospital, Jinan City, 250013, China|Shandong Cancer Hospital, Jinan, 250117, China|The First People's Hospital of Yunnan Province, Kunming City, 650034, China|The First Affiliated Hospital to Henan University of Science and Technology, Luoyang, 471003, China|Guangxi Cancer Hospital of Guangxi Medical University, Nanning, 530021, China|Fudan University Shanghai Cancer Center, Shanghai City, 200120, China|Zhongshan Hospital Fudan University, Shanghai, 200032, China|Shanxi Province Cancer Hospital, Taiyuan City, 030013, China|Taizhou Hospital of Zhejiang Province, Taizhou, China|Tianjin Cancer Hospital, Tianjin, China|The Tumor Hospital of Xinjiang Medical University, Urumqi, 830000, China|Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan City, 430022, China|Hubei Cancer Hospital, Wuhan, 430079, China|The Second Affiliated Hospital of Xi'an Jiao Tong University, Xi'an City, 710004, China|Xi'an International Medical Center Hospital, Xian, 710100, China|The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China|Zhejiang Cancer Hospital, Zhejiang, 310022, China|The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China|FundaciÃ³n CTIC - Centro de Tratamiento e InvestigaciÃ³n sobre CÃ¡ncer Luis Carlos Sarmiento Angulo, Bogota, D.C., 110131, Colombia|IPS Salud SURA Chipichape Cali, Cali, Colombia|Oncomedica S.A., Monteria, 230002, Colombia|Sociedad de OncologÃ­a y hematologÃ­a del Cesar Ltda, Valledupar, 200001, Colombia|Clinica CIMCA, San JosÃ©, 10103, Costa Rica|ICIMED Instituto de InvestigaciÃ³n en Ciencias MÃ©dicas, San JosÃ©, 10108, Costa Rica|Proclinical Pharma, San JosÃ©, 11303, Costa Rica|Kuopio Uni Hospital, Kuopio, 70211, Finland|Tampere University Hospital, Tampere, 33520, Finland|ICO Paul Papin, Angers, 49055, France|Institut Sainte Catherine, Avignon, 84082, France|Hopital Jean Minjoz, Besancon, 25030, France|Centre Francois Baclesse, Caen, 14076, France|Centre Jean Perrin, Clermont Ferrand, 63011, France|Centre Hospitalier Saint Louis, La Rochelle, 17019, France|Centre Oscar Lambret, Lille, 59020, France|Centre Leon Berard, Lyon, 69373, France|Centre Cancerologie Grand Montpellier, Montpellier, 34070, France|Institut Jean Godinot, Reims CEDEX, 51056, France|Centre Eugene Marquis, Rennes, 35042, France|IUCT Oncopole, Toulouse, 31100, France|Gustave Roussy, Villejuif, 94805, France|Sozialstiftung Bamberg, Klinikum am Bruderwald, GynÃ¤kologie, Bamberg, 96049, Germany|DONAU ISAR Klinikum Deggendorf, Deggendorf, 94469, Germany|Gynonco DÃ¼sseldorf, MVZ Medical Center GmbH, DÃ¼sseldorf, 40235, Germany|UniversitÃ¤tsklinikum Erlangen, Erlangen, 91054, Germany|Kliniken Essen-Mitte, Essen, 45136, Germany|Praxis fÃ¼r InterdisziplinÃ¤re Onkologie und HÃ¤matologie GbR, Freiburg, 79110, Germany|Nationales Centrum fÃ¼r Tumorerkrankungen (NCT), Heidelberg, 69120, Germany|UniversitÃ¤tsklinikum des Saarlandes, Homburg/Saar, 66424, Germany|St. Elisabeth Krankenhaus KÃ¶ln GmbH, Koeln, 50935, Germany|Rotkreuzklinikum MÃ¼nchen, Muenchen, 80637, Germany|Brustzentrum Rhein-Ruhr Servicegesellschaft mbH, MÃ¶nchengladbach, 41061, Germany|Anticancer Hospital Ag. Savas, Athens, 115 22, Greece|Aretaieio Hospital of Athens, Athina, 115 28, Greece|University Hospital of Larissa, Larissa, 411 10, Greece|University Hospital of Patras Medical Oncology, Patras, 265 04, Greece|Celan S.A., Ciudad de Guatemala, 01010, Guatemala|INTEGRA Cancer Institute, Ciudad de Guatemala, 01010, Guatemala|Onco Go, S.A., Ciudad de Guatemala, 01010, Guatemala|Medi-k, ciudad de Guatemala, 01016, Guatemala|Grupo Angeles, Guatemala City, 01015, Guatemala|Oncomedica, Guatemala, 01009, Guatemala|Centro Medico Integral de Cancerologia CEMIC, SalcajÃ¡, 09002, Guatemala|Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|Orszagos Onkologiai Intezet, Budapest, 1122, Hungary|BÃ¡cs-Kiskun VÃ¡rmegyei OktatÃ³kÃ³rhÃ¡z, KecskemÃ©t, 6000, Hungary|B-A-Z VÃ¡rmegyei KÃ¶zponti KÃ³rhÃ¡z Ã©s Egyetemi OktatÃ³kÃ³rhÃ¡z, Miskolc, 3526, Hungary|Nograd Varmegyei Szent Lazar Korhaz, SalgÃ³tarjÃ¡n, 3100, Hungary|Max Super Speciality Hospital, New Delhi, Delhi, 110017, India|HealthCare Global Enterprises Limited, Banglore, Karnataka, 560027, India|MVR Cancer Centre and Research Institute, Kozhikode, Kerala, 673601, India|Regional Cancer Centre, Trivandrum, Kerala, 695011, India|Sir H. N. Reliance Foundation Hospital and Research Centre, Mumbai, Maharashtra, 400004, India|Grant Medical Foundation, Ruby Hall Clinic, Pune, Maharashtra, 411001, India|Sunact Cancer Institute, Thane, Maharashtra, 400615, India|Hadassah Ein Karem Hospital, Jerusalem, 9112000, Israel|Rabin Medical Center, Petah Tikva, 4910000, Israel|Sheba MC, Ramat Gan, 5265601, Israel|Sourasky Medical Center, Tel-Aviv, 6423900, Israel|Azienda Ospedaliera di Rilievo Nazionale e di Alta Specialita San Giuseppe Moscati, Avellino, Campania, 83100, Italy|Azienda Ospedaliera Universitaria Federico II, Napoli, Campania, 80131, Italy|Policlinico S.Orsola-Malpighi, Bologna, Emilia-Romagna, 40138, Italy|I.R.S.T Srl IRCCS, Meldola, Emilia-Romagna, 47014, Italy|A.O. Universitaria Di Parma, Parma, Emilia-Romagna, 43100, Italy|RCCS - Centro di Riferimento, Aviano (PN), Friuli-Venezia Giulia, 33081, Italy|A.O. Universitaria S. Maria Della Misericordia Di Udine, Udine, Friuli-Venezia Giulia, 33100, Italy|Policlinico Universitario Agostino Gemelli, Roma, Lazio, 00168, Italy|UniversitÃ  Campus Bio-Medico di Roma, Roma, Lazio, 128, Italy|Asst Papa Giovanni XXIII, Bergamo, Lombardia, 24127, Italy|Asst Degli Spedali Civili Di Brescia, Brescia, Lombardia, 25123, Italy|Irccs Istituto Nazionale Dei Tumori (Int), Milano, Lombardia, 20133, Italy|Istituto Clinico Humanitas, Rozzano, Lombardia, 20089, Italy|Ospedale Di Macerata, Macerata, Marche, 62100, Italy|A.O.U. Maggiore della CaritÃ , Novara, Piemonte, 28100, Italy|Presidio Ospedaliero di Summa-Perrino, Brindisi, Puglia, 72100, Italy|Humanitas Centro Catanese Di Oncologia, Misterbianco (CT), Sicilia, 95045, Italy|Azienda Ospedaliera Universitaria Careggi, Florence, Toscana, 50134, Italy|IOV - Istituto Oncologico Veneto - IRCCS, Padova, Veneto, 35128, Italy|University of Nairobi - Institute of Tropical and Infectious Diseases, Nairobi, Kenya|Kyungpook National University Chilgok Hospital, Daegu, 41404, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, 13620, Korea, Republic of|Korea University Anam Hospital, Seoul, 02841, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, 03722, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Gangnam Severance Hospital, Seoul, 06273, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, 07985, Korea, Republic of|Samsung Medical Center, Seoul, 135-710, Korea, Republic of|Ulsan University Hosiptal, Ulsan, 44033, Korea, Republic of|Panamerican Clinical Research S.A de C.V., Guadalajara, Jalisco, 44670, Mexico|RENATI INNOVATION S.A.P.I. de C.V, Guadalajara, Jalisco, 44680, Mexico|Productos y Servicios Oncologicos Acacias SA de CV, Ciudad de MÃ©xico, Mexico CITY (federal District), 03240, Mexico|Centro OncolÃ³gico HematolÃ³gico Roma, Mexico City, Mexico CITY (federal District), 06700, Mexico|Hospital Zambrano Hellion TecSalud, Monterrey, Nuevo LEON, Mexico|Centro de Investigacion Clinica de Oaxaca, Oaxaca de JuÃ¡rez, Oaxaca, 68020, Mexico|PanAmerican Clinical Research, QuerÃ©taro, QuerÃ©aro, Queretaro, 76230, Mexico|CENEIT Oncologicos, Mexico City, 03100, Mexico|Centro Medico Dalinde, Mexico City, 06700, Mexico|Christchurch Hospital, Christchurch, New Zealand|Palmerston North Hospital, Palmerston North, 4442, New Zealand|Whangarei Hospital, Whangarei, 0110, New Zealand|Centro Medico Monte Carmelo, Arequipa, 04001, Peru|ClÃ­nica Santa Beatriz, Lima, 15072, Peru|Hospital Nacional Arzobispo Loayza, Lima, 1, Peru|Oncosalud Sac, Lima, 41, Peru|Instituto Nacional de Enfermedades Neoplasicas, Lima, Lima 34, Peru|Clinica Internacional, Sede San Borja, Lima, Lima 41, Peru|Instituto Peruano de OncologÃ­a y Radioterapia, Lima, Peru|Clinica Peruana Americana, Trujillo, 13011, Peru|Instytut ""Centrum Zdrowia Matki Polki"", ?Ã³d?, 93-338, Poland|Centrum Onkologii im. Prof. Franciszka ?ukaszczyka, Bydgoszcz, 85-796, Poland|Szpital Morski Im. Pck, Gdynia, 81-519, Poland|Narodowy Instytut Onkologii Odzia? w Gliwicach, Gliwice, 44-102, Poland|?wi?tokrzyskie Centrum Onkologii, Kielce, 25-734, Poland|Przychodnia Lekarska KOMED, Roman Karaszewski, Konin, 62-500, Poland|Szpital WojewÃ³dzki im. Miko?aja Kopernika, Koszalin, 75-581, Poland|Centrum Onkologii Ziemi Lubelskiej im. sw. Jana z Dukli, Lublin, 20-090, Poland|Mazowiecki Szpital WojewÃ³dzki im. ?w. Jana Paw?a II, Siedlce, 08-110, Poland|Zachodniopomorskie Centrum Onkologii, Szczecin, 71-730, Poland|Narodowy Inst.Onkologii im.Sklodowskiej-Curie Panstw.Inst.Bad, Warszawa, 02-781, Poland|IPO de Coimbra, Coimbra, 3000-075, Portugal|Hospital de S. Francisco Xavier, Lisboa, 1495-005, Portugal|Hospital da Luz, Lisboa, 1500-650, Portugal|IPO do Porto, Porto, 4200-072, Portugal|CHVNG/E_Unidade 1, Vila Nova de Gaia, 4434-502, Portugal|PanOncology Trials, San Juan, 00935, Puerto Rico|Spitalul Clinic Filantropia, Bucuresti, 011171, Romania|Amethyst Cluj, Cluj County, 407280, Romania|Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj Napoca, Cluj Napoca, 400015, Romania|Centrul de Oncologie Sfantul Nectarie, Craiova, 200347, Romania|Institutul Regional de Oncologie Iasi, Iasi, 700483, Romania|Centrul de Oncologie Oncohelp, Timisoara, 300239, Romania|National University Hospital, Singapore, 119228, Singapore|National Cancer Centre, Singapore, 168583, Singapore|Icon Cancer Centre Gleneagles, Singapore, 258499, Singapore|Institute of Oncology Ljubljana, Ljubljana, 1000, Slovenia|Cancercare Rondebosch Oncology, Cape Town, 7700, South Africa|Cancercare, Port Elizabeth, 6045, South Africa|Institut Catala d?Oncologia Hospital Germans Trias i Pujol, Badalona, Barcelona, 08916, Spain|Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Sant Andreu de La Barca, Barcelona, 08740, Spain|Hospital de Jerez de la Frontera, Jerez de La Frontera, Cadiz, 11407, Spain|Hospital Quiron de Madrid, Pozuelo de Alarcon, Madrid, 28223, Spain|Hospital Universitario Virgen de La Arrixaca, EL Palmar (EL Palmar), Murcia, 30120, Spain|Hospital Alvaro Cunqueiro, Vigo, Pontevedra, 36213, Spain|Hospital Universitari Dexeus - Grupo Quironsalud, Barcelona, 08028, Spain|Hospital Juan Ramon Jimenez, Huelva, 21005, Spain|Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico, Jaen, 23007, Spain|Centro Oncologico MD Anderson Internacional, Madrid, 28033, Spain|Hospital de Madrid Norte Sanchinarro- Centro Integral Oncologico Clara Campal, Madrid, 28050, Spain|Hospital Universitario Virgen Macarena, Sevilla, 41009, Spain|Hospital Universitario Virgen del Rocio, Sevilla, 41013, Spain|Instituto Valenciano Oncologia, Valencia, 46009, Spain|Hospital Arnau de Vilanova (Valencia) Servicio de Oncologia, Valencia, 46015, Spain|Hsin-Chu Branch of National Taiwan University Hospital, Hsinchu City, 300, Taiwan|China Medical University Hospital, Taichung, 404, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center, Taipei City, 11259, Taiwan|Veterans General Hospital, Taipei, 00112, Taiwan|National Taiwan Uni Hospital, Taipei, 100, Taiwan|Veterans General Hospital - Taichung, Xitun Dist., 40705, Taiwan|Chulalongkorn Hospital, Bangkok, 10330, Thailand|National Cancer Institute, Bangkok, 10400, Thailand|Rajavithi Hospital, Bangkok, 10400, Thailand|Chulabhorn Hospital, Lak Si, 10210, Thailand|Maharaj Nakorn Chiang Mai Hospital;Depart of Radiology, Muang Chiang MAI Delivery Branch 3, 50200, Thailand|Songklanagarind Hospital, Songkhla, 90110, Thailand|Ankara City Hospital, Ankara, 06800, Turkey|Bakirkoy Dr. Sadi Konuk Egitim ve Arastirma Hastanesi, Tibbi Onkoloji, Bakirkoy / Istanbul, 34147, Turkey|Katip Celebi University Ataturk Training and Research Hospital, Izmir, 35360, Turkey|Goztepe Prof.Dr. Suleyman Yalcin City Hospital, KadikÃ¶y, 34722, Turkey|Mersin City Education and Research Hospital, Mersin, 33240, Turkey|Medikal Park Samsun, Samsun, 55200, Turkey|Hacettepe Uni Medical Faculty Hospital, Sihhiye/Ankara, 06230, Turkey",
NCT05751850,"HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer",https://clinicaltrials.gov/study/NCT05751850,,RECRUITING,The purpose of this study is to look at the efficacy and safety of HR070803 in combination with 5 fluorouracil/leucovorin (5FU/LV) plus oxaliplatin compared to nab-paclitaxel + gemcitabine treatment in improving the overall survival of patients not previously treated for metastatic pancreatic cancer.,NO,First-line Treatment of Advanced Pancreatic Cancer,DRUG: HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate|DRUG: nab-paclitaxel; gemcitabine,"Overall survival (OS), From study start until 399 OS events have occurred (approximately 15 months after last patient enrollment)","Objective Response rate (ORR), ORR is defined as the percentage of participants who have a best overall response of complete response (CR) or partial response (PR), per RECIST 1.1., up to 6 months following the date the last patient was randomized|Disease Control Rate, The study is designed to evaluate the disease control rate with advanced pancreatic cancer. DCR is defined as the percentage of patients with a best response of CR, PR, or stable disease (SD)., up to 6 months following the date the last patient was randomized|Duration of Response, DoR is defined as the time from first documentation of response (CR or PR whichever occurred first, as per RECIST version 1.1) to disease progression or death, whichever is earlier., up to 6 months following the date the last patient was randomized|Progression free survival (PFS), PFS is defined as the time from the date of first dose of study drug to the date of the first documentation of disease progression or date of death, whichever occurs first., From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months",,"Jiangsu HengRui Medicine Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,778,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-06-13,2024-12-30,2025-12-30,2023-03-02,,2024-05-09,"Peking Union Medical College Hospital, Beijing, Beijing, 100142, China",
NCT04949256,Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014),https://clinicaltrials.gov/study/NCT04949256,,ACTIVE_NOT_RECRUITING,"The purpose of this study is to assess the efficacy and safety of pembrolizumab plus lenvatinib plus chemotherapy compared with pembrolizumab plus chemotherapy as first-line intervention in participants with metastatic esophageal carcinoma.

The primary hypotheses are that pembrolizumab plus lenvatinib plus chemotherapy is superior to pembrolizumab plus chemotherapy with respect to overall survival (OS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).",NO,Metastatic Esophageal Squamous Cell Carcinoma,BIOLOGICAL: Pembrolizumab|DRUG: Lenvatinib|DRUG: Cisplatin|DRUG: 5-FU|DRUG: Oxaliplatin|DRUG: Leucovorin|DRUG: Levoleucovorin|DRUG: Paclitaxel,"Part 1 (FP and TP Safety Run-in): Number of Participants With Dose Limiting Toxicities (DLTs), Hematologic DLTs are defined as Grade 4 neutropenia lasting for â¥7 days, Grade 3 or Grade 4 febrile neutropenia, Grade 3 thrombocytopenia with bleeding, Grade 4 thrombocytopenia, or Grade 4 anemia. Other nonhematologic toxicities considered a DLT include any other Grade 4 or Grade 5 toxicity, Grade 3 toxicities lasting \>3 days (excluding nausea, vomiting, and diarrhea controlled by medical intervention within 72 hours, and Grade 3 rash in the absence of desquamation with no mucosal involvement), Grade 3 hypertension not able to be controlled by medication, â¥Grade 3 gastrointestinal perforation, â¥Grade 3 wound dehiscence requiring medical or surgical intervention, any grade thromboembolic event or any Grade 3 nonhematologic laboratory value requiring medical intervention or hospitalization. The number of participants in Part 1 with DLTs will be presented., Up to ~21 days|Part 1 (FP and TP Safety Run-in): Number of Participants With Adverse Events (AEs), An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants in Part 1 with AEs will be presented., Up to ~53 months|Part 1 (FP and TP Safety Run-in): Number of Participants who Discontinued Study Treatment Due to an AE, An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants in Part 1 who discontinue study treatment due to an AE will be presented., Up to ~53 months|Part 2 (Main Study): Overall Survival (OS) in all Participants, OS is defined as the time from randomization to death due to any cause. OS in Part 2 for all randomized participants will be presented., Up to ~48 months","Part 2 (Main Study): Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in all Participants, PFS is defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 by BICR or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as â¥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of â¥5 mm. The appearance of one or more new lesions is also considered PD. RECIST 1.1 has been adjusted to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ. PFS in Part 2 for all randomized participants will be presented., Up to ~42 months|Part 2 (Main Study): Objective Response Rate (ORR) per RECIST 1.1 as Assessed by BICR in all Participants, ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions), per RECIST 1.1 adjusted to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, as assessed by BICR. ORR in Part 2 for all randomized participants will be presented., Up to ~42 months|Part 2 (Main Study): Duration of Response (DOR) per RECIST 1.1 as Assessed by BICR in all Participants, For participants who demonstrate a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions), per RECIST 1.1 by BICR, DOR is defined as the time from first documented evidence of CR or PR until PD or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. RECIST 1.1 has been adjusted to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ. DOR in Part 2 for all randomized participants will be presented., Up to ~42 months|Part 2 (Main Study): OS in Participants With Programmed Cell Death-Ligand 1 (PD-L1) Combined Positive Score (CPS) â¥10, OS is defined as the time from randomization to death due to any cause. OS in Part 2 for randomized participants with PD-L1 CPS â¥10 will be presented., Up to ~48 months|Part 2 (Main Study): PFS per RECIST 1.1 as Assessed by BICR in Participants With PD-L1 CPS â¥10, PFS is defined as the time from randomization to the first documented PD per RECIST 1.1 by BICR or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as â¥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of â¥5 mm. The appearance of one or more new lesions is also considered PD. RECIST 1.1 has been adjusted to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ. PFS in Part 2 for randomized participants with PD-L1 CPS â¥10 will be presented., Up to ~42 months|Part 2 (Main Study): ORR per RECIST 1.1 as Assessed by BICR in Participants With PD-L1 CPS â¥10, ORR is defined as the percentage of participants with CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions), per RECIST 1.1 adjusted to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, as assessed by BICR. ORR in Part 2 for randomized participants with PD-L1 CPS â¥10 will be presented., Up to ~42 months|Part 2 (Main Study): DOR per RECIST 1.1 as Assessed by BICR in Participants With PD-L1 CPS â¥10, For participants who demonstrate a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions), per RECIST 1.1 by BICR, DOR is defined as the time from first documented evidence of CR or PR until PD or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. RECIST 1.1 has been adjusted to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ. DOR in Part 2 for randomized participants with PD-L1 CPS â¥10 will be presented., Up to ~42 months|Part 2 (Main Study): Number of Participants With AEs, An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants in Part 2 with AEs will be presented., Up to ~53 months|Part 2 (Main Study): Number of Participants who Discontinued Study Treatment Due to an AE, An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants in Part 2 who discontinue study treatment due to an AE will be presented., Up to ~53 months|Part 2 (Main Study): Change From Baseline in Health-related Quality of life (HRQoL) Score Using European Organization for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30), The EORTC QLQ-C30 is a questionnaire to assess the overall HRQoL. Participant responses to the question "" How would you rate your overall quality of life (QoL) during the past week?"" are scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall QoL. The change from baseline in HRQoL EORTC QLQ-C30 score in participants in Part 2 will be presented., Baseline and ~53 months|Part 2 (Main Study): Change From Baseline in HRQoL Score Using EORTC Quality of Life Questionnaire-Oesophageal Module (QLQ-OES18), The EORTC QLQ-OES18 is a disease-specific questionnaire to assess measurements specific to esophageal cancer. It contains 18 items and is based on four subscales-dysphagia, eating, reflux and pain. All items are scored using a four-point scale that offers these response choices: 1=not at all, 2=a little, 3=quite a bit, 4=very much. Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates worse level of symptoms. The change from baseline in HRQoL QLQ-OES18 score in participants in Part 2 will be presented., Baseline and ~53 months|Part 2 (Main Study): Time to Deterioration (TTD) in HRQoL Score Using EORTC QLQ-C30, TTD is defined as the time from baseline to the first onset of a â¥10-point change from baseline in the HRQoL EORTC QLQ-C30 score. The EORTC QLQ-C30 is a questionnaire to assess the overall HRQoL. Participant responses to the question "" How would you rate your overall QoL during the past week?"" are scored on a 7-point scale (1=Very Poor to 7=Excellent). A higher score indicates a better overall QoL. Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A longer TTD indicates a better outcome. The TTD in HRQoL EORTC QLQ-C30 score in participants in Part 2 will be presented., Up to ~ 53 months|Part 2 (Main Study): TTD in HRQoL Score Using EORTC QLQ-OES18, TTD is defined as the time from baseline to the first onset of a â¥10-point change from baseline in the HRQoL EORTC QLQ-OES18 score. The EORTC QLQ-OES18 is a disease-specific questionnaire to assess measurements specific to esophageal cancer. It contains 18 items and is based on four subscales-dysphagia, eating, reflux and pain. All items are scored using a four-point scale that offers these response choices: 1=not at all, 2=a little, 3=quite a bit, 4=very much. A higher score indicates worse level of symptoms. Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A longer TTD indicates a better outcome. The TTD in HRQoL QLQ-OES18 score in participants in Part 2 will be presented., Up to ~ 53 months",,Merck Sharp & Dohme LLC,Eisai Inc.,ALL,"ADULT, OLDER_ADULT",PHASE3,862,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-07-28,2027-01-31,2027-01-31,2021-07-02,,2025-03-07,"City of Hope ( Site 0102), Duarte, California, 91010, United States|MedStar Washington Hospital Center ( Site 0186), Washington, District of Columbia, 20010, United States|James Graham Brown Cancer Center ( Site 0117), Louisville, Kentucky, 40202, United States|Norton Cancer Institute ( Site 0116), Louisville, Kentucky, 40217, United States|Johns Hopkins Bayview Medical Center ( Site 0152), Baltimore, Maryland, 21224, United States|UMASS Memorial Medical Center ( Site 0120), Worcester, Massachusetts, 01655, United States|Capital Health Medical Center - Hopewell ( Site 0189), Pennington, New Jersey, 08534, United States|Hematology-Oncology Associates of CNY ( Site 0173), East Syracuse, New York, 13057, United States|Memorial Sloan Kettering Cancer Center ( Site 0132), New York, New York, 10065, United States|Weill Cornell Medical College ( Site 0133), New York, New York, 10065, United States|St. Luke's University Health Network ( Site 0185), Bethlehem, Pennsylvania, 18015, United States|AHN Allegheny General Hospital ( Site 0164), Pittsburgh, Pennsylvania, 15212, United States|Medical University of South Carolina-Hollings Cancer Center ( Site 0177), Charleston, South Carolina, 29425, United States|VCU Health Adult Outpatient Pavillion ( Site 0160), Richmond, Virginia, 23219, United States|Seattle Cancer Care Alliance ( Site 0145), Seattle, Washington, 98109, United States|Centro de Oncologia e Investigacion Buenos Aires COIBA ( Site 0203), Berazategui, Buenos Aires, B1884BBF, Argentina|IDIM Instituto de Diagnostico e Investigaciones Metabolicas ( Site 0202), Caba, Buenos Aires, C1012AAR, Argentina|Instituto de Investigaciones Clinicas Mar del Plata ( Site 0205), Mar del Plata., Buenos Aires, B7600FZO, Argentina|Fundacion Estudios Clinicos-Oncology ( Site 0215), Rosario, Santa Fe, S2000DEJ, Argentina|Sanatorio Parque ( Site 0206), Rosario, Santa Fe, S2000DSV, Argentina|Hospital Provincial del Centenario ( Site 0217), Rosario, Santa Fe, S2002KDS, Argentina|Fundacion Favaloro ( Site 0201), Buenos Aires, C1093AAS, Argentina|FundaciÃ³n Respirar ( Site 0216), Buenos Aires, C1426ABP, Argentina|Hospital Italiano de CÃ³rdoba ( Site 0218), Cordoba, X5004BAL, Argentina|FundaciÃ³n CORI para la InvestigaciÃ³n y PrevenciÃ³n del CÃ¡ncer ( Site 0221), La Rioja, F5300COE, Argentina|Instituto San Marcos ( Site 0213), San Juan, J5400EBB, Argentina|CancerCare Manitoba ( Site 0001), Winnipeg, Manitoba, R3E 0V9, Canada|Princess Margaret Cancer Centre ( Site 0004), Toronto, Ontario, M5G 2M9, Canada|Hotel-Dieu de Levis ( Site 0013), Levis, Quebec, G6V 3Z1, Canada|Centro de Investigacion y desarrollo Oncologico SpA - CIDO SpA ( Site 0401), Temuco., Araucania, 4810218, Chile|James Lind Centro de Investigacion del Cancer ( Site 0412), Temuco, Araucania, 4800827, Chile|Fundacion Arturo Lopez Perez FALP ( Site 0403), Santiago, Region M. De Santiago, 7500836, Chile|Oncovida ( Site 0413), Santiago, Region M. De Santiago, 7510032, Chile|ClÃ­nica San Carlos de Apoquindo Red Salud UC Christus ( Site 0407), Santiago, Region M. De Santiago, 7550000, Chile|Bradford Hill Centro de Investigaciones Clinicas ( Site 0404), Santiago, Region M. De Santiago, 8420383, Chile|Anhui Provincial Cancer Hospital ( Site 8058), Hefei, Anhui, 230031, China|The Second Affiliated Hospital of Anhui Medical University ( Site 8026), Hefei, Anhui, 230031, China|Beijing Cancer Hospital ( Site 8001), Beijing, Beijing, 100142, China|Fujian Provincial Cancer Hospital ( Site 8029), Fuzhou, Fujian, 350014, China|The First Affiliated Hospital of Xiamen University ( Site 8003), Xiamen City, Fujian Province, Fujian, 361003, China|Zhongshan Hospital Affiliated to Xiamen University ( Site 8055), Xiamen, Fujian, 361004, China|The First Affiliated Hospital.Sun Yat-sen University ( Site 8047), Guangzhou, Guangdong, 510080, China|Southern Medical University Nanfang Hospital ( Site 8031), Guangzhou, Guangdong, 510515, China|The Third Xiangya Hospital of Central South University ( Site 8046), Changsha, Hainan, 410013, China|The First Affiliated Hospital of Hainan Medical University ( Site 8042), Haikou, Hainan, 570102, China|Affiliated Hospital of Chengde Medical Univeristy ( Site 8053), Chengde, Hebei, 067055, China|Harbin Medical University Cancer Hospital ( Site 8009), Harbin, Heilongjiang, China|Anyang Cancer Hospital ( Site 8006), Anyang, Henan, 455000, China|The First Affiliated Hospital of Henan University of Science &Technology-Tumor ( Site 8036), Luoyang, Henan, 471003, China|The First Affiliated Hospital of Xinxiang Medical University ( Site 8018), Xinxiang, Henan, 453100, China|Tongji Medical College Huazhong Uinversity Of Science and Technology ( Site 8025), Wuhan, Hubei, 430030, China|Hubei Cancer Hospital ( Site 8014), Wuhan, Hubei, 430079, China|Affiliated hospital of Jiangnan university ( Site 8049), Wuxi, Jiangsu, 214122, China|The Affiliated Hospital of Xuzhou Medical University ( Site 8015), Xuzhou, Jiangsu, 221000, China|Jilin Cancer Hospital ( Site 8016), Changchun, Jilin, 130012, China|Jinan Central Hospital ( Site 8052), Jinan, Shandong, 250013, China|Shandong Cancer Hospital ( Site 8060), Jinan, Shandong, 250117, China|Affiliated Hospital of Jining Medical University ( Site 8017), Jining, Shandong, 272000, China|Linyi Cancer Hospital- Medical Oncology Department ( Site 8051), Linyi, Shandong, 276000, China|Shanxi Provincial Cancer Hospital ( Site 8019), Taiyuan, Shanxi, 030000, China|West China Hospital of Sichuan University ( Site 8048), Chengdu, Sichuan, 610041, China|Tianjin Medical University Cancer Institute & Hospital ( Site 8035), Tianjin, Tianjin, 300060, China|The Affiliated Cancer Hospital of Xinjiang Medical University. ( Site 8041), Urumqi, Xinjiang, 830000, China|Sir Run Run Shaw Hospital ( Site 8021), Hangzhou, Zhejiang, 310016, China|ICIMED-Oncology Research Unit ( Site 0903), San JosÃ©, San Jose, 10108, Costa Rica|PROCLINICAL Pharma ( Site 0904), San JosÃ©, San Jose, 11303, Costa Rica|CIMCA Centro de Investigacion y Manejo del Cancer ( Site 0902), San Jose, 10103, Costa Rica|Onco Tech S A ( Site 0901), San Jose, 10103, Costa Rica|Rigshospitalet ( Site 2102), Copenhagen, Hovedstaden, 2100, Denmark|Odense University Hospital ( Site 2101), Odense, Syddanmark, 5000, Denmark|Institut De Cancerologie De Lorraine ( Site 1010), Vandoeuvre les Nancy, Ain, 54519, France|Institut de cancÃ©rologie Strasbourg Europe (ICANS) ( Site 1014), Strasbourg, Alsace, 67200, France|Centre FranÃ§ois Baclesse ( Site 1009), Caen, Calvados, 14076, France|Centre Georges Francois Leclerc ( Site 1008), Dijon, Cote-d Or, 21000, France|C.H. regional Unv. de Brest - Hopital La Cavale Blanche - Institut de Cancerologie et d Imagerie ( S, Brest, Finistere, 29200, France|CHU BesanÃ§on ( Site 1015), BesanÃ§on, Franche-Comte, 25000, France|CHU Bordeaux Haut-Leveque ( Site 1012), Pessac, Gironde, 33604, France|Institut du Cancer de Montpellier ( Site 1002), Montpellier, Herault, 34298, France|CHRU de Tours - Hopital Bretonneau ( Site 1018), Tours, Indre-et-Loire, 37044, France|Institut De Cancerologie De L Ouest ( Site 1003), Saint Herblain, Loire-Atlantique, 44805, France|HÃ´pital Claude Huriez ( Site 1030), Lille, Nord, 59000, France|Hopital Henri Mondor ( Site 1007), Creteil, Val-de-Marne, 94010, France|Hopital Saint Louis ( Site 1029), Paris, 75010, France|Centro Regional de Sub Especialidades Medicas SA ( Site 0604), Guatemala, Quetzaltenango, 09001, Guatemala|MEDI-K ( Site 0601), Guatemala, 01009, Guatemala|Oncomedica ( Site 0602), Guatemala, 01010, Guatemala|Soluciones Gastrointestinales S.A. ( Site 0607), Guatemala, 01010, Guatemala|Queen Mary Hospital ( Site 4001), Hong Kong, Hong Kong|Queen Elizabeth Hospital. ( Site 4004), Kowloon, Hong Kong|Pecsi Tudomanyegyetem AOK ( Site 1204), Pecs, Baranya, 7624, Hungary|Petz Aladar Egyetemi Oktato Korhaz ( Site 1210), Gyor, Gyor-Moson-Sopron, 9024, Hungary|JÃ¡sz-Nagykun-Szolnok VÃ¡rmegyei HetÃ©nyi GÃ©za KÃ³rhÃ¡z ( Site 1203), Szolnok, Jasz-Nagykun-Szolnok, 5000, Hungary|Orszagos Onkologiai Intezet ( Site 1207), Budapest, 1122, Hungary|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori-Oncologia Medica ( Site 1313), Meldola, Emilia-Romagna, 47014, Italy|A.O.U. Santa Maria della Misericordia di Udine ( Site 1302), Udine, Friuli-Venezia Giulia, 33100, Italy|Humanitas Research Hospital ( Site 1309), Rozzano, Lombardia, 20089, Italy|Azienda Ospedaliera Universitaria Pisana ( Site 1312), Pisa, Toscana, 56126, Italy|Istituto Oncologico Veneto IRCCS-Oncologia Medica 1 ( Site 1311), Padova, Veneto, 35128, Italy|Azienda Ospedaliera Mater Domini-Translational Oncology Unit ( Site 1314), Catanzaro, 88100, Italy|Azienda Ospedaliero Universitaria Careggi ( Site 1301), Firenze, 50134, Italy|IRCCS Ospedale San Raffaele di Milano ( Site 1304), Milano, 20132, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 1306), Milano, 20133, Italy|A.O. Universitaria di Modena ( Site 1307), Modena, 41124, Italy|A.O.U. Universita degli Studi della Campania-Luigi Vanvitelli ( Site 1305), Napoli, 80131, Italy|Universita Cattolica del Sacro Cuore - Policlinico Gemelli ( Site 1310), Roma, 00168, Italy|Aichi Cancer Center Hospital ( Site 9006), Nagoya, Aichi, 464-8681, Japan|Chiba Cancer Center ( Site 9023), Chiba-shi, Chiba, 260-8717, Japan|National Cancer Center Hospital East ( Site 9002), Kashiwa, Chiba, 277-8577, Japan|National Hospital Organization Shikoku Cancer Center ( Site 9019), Matsuyama, Ehime, 791-0280, Japan|Hyogo Cancer Center ( Site 9014), Akashi, Hyogo, 673-8558, Japan|Ibaraki Prefectural Central Hospital ( Site 9007), Kasama, Ibaraki, 309-1793, Japan|Kagawa University Hospital ( Site 9015), Kita-gun, Kagawa, 761-0793, Japan|Kanagawa Cancer Center ( Site 9004), Yokohama, Kanagawa, 241-8515, Japan|Tohoku University Hospital ( Site 9013), Sendai-shi, Miyagi, 980-8574, Japan|Niigata Cancer Center Hospital ( Site 9022), Niigata-shi, Niigata, 951-8566, Japan|Kindai University Hospital ( Site 9017), Sayama, Osaka, 589-8511, Japan|Osaka University Hospital ( Site 9021), Suita, Osaka, 565-0871, Japan|Osaka Medical and Pharmaceutical University Hospital ( Site 9008), Takatsuki, Osaka, 569-8686, Japan|Saitama Prefectural Cancer Center ( Site 9003), Kitaadachi-gun, Saitama, 362-0806, Japan|Shizuoka Cancer Center ( Site 9016), Nagaizumi, Shizuoka, 411-8777, Japan|Tokyo Metropolitan Komagome Hospital ( Site 9028), Bunkyo ku, Tokyo, 113-8677, Japan|Toranomon Hospital ( Site 9026), Minato-ku, Tokyo, 105-8470, Japan|Showa University Hospital ( Site 9025), Shinagawa, Tokyo, 142-8666, Japan|National Hospital Organization Kyushu Cancer Center ( Site 9010), Fukuoka, 811-1395, Japan|University Hospital,Kyoto Prefectural University of Medicine ( Site 9027), Kyoto, 602-8566, Japan|Kyoto University Hospital ( Site 9011), Kyoto, Japan|Okayama University Hospital ( Site 9024), Okayama, 700-8558, Japan|Osaka International Cancer Institute ( Site 9009), Osaka, 541-8567, Japan|Osaka General Medical Center ( Site 9018), Osaka, 558-8558, Japan|National Cancer Center Hospital ( Site 9001), Tokyo, 104-0045, Japan|The Cancer Institute Hospital of JFCR ( Site 9005), Tokyo, 135-8550, Japan|Keio University Hospital ( Site 9020), Tokyo, 160-8582, Japan|Seoul National University Bundang Hospital ( Site 5006), Seongnam-si, Kyonggi-do, 13605, Korea, Republic of|Asan Medical Center ( Site 5002), Songpagu, Seoul, 05505, Korea, Republic of|Severance Hospital ( Site 5003), Seoul, 03722, Korea, Republic of|Samsung Medical Center ( Site 5005), Seoul, 06351, Korea, Republic of|Korea University Guro Hospital ( Site 5001), Seoul, 08308, Korea, Republic of|University Malaya Medical Centre ( Site 9101), Lembah Pantai, Kuala Lumpur, 59100, Malaysia|Sarawak General Hospital-Radiotherapy Unit ( Site 9100), Kuching, Sarawak, 93586, Malaysia|Hospital Kuala Lumpur ( Site 9104), Kuala Lumpur, 50586, Malaysia|MEMORIAL HEALTHCARE INTERNATIONAL S.R.L. ( Site 2201), Bucharest, Bucuresti, 013812, Romania|Cardiomed SRL Cluj-Napoca-Medical Oncology ( Site 2207), Cluj-Napoca, Cluj, 400015, Romania|SC Radiotherapy Center Cluj SRL ( Site 2202), Comuna Floresti, Cluj, 407280, Romania|Ovidius Clinical Hospital OCH-Oncology and Hematology ( Site 2203), Ovidiu, Constanta, 905900, Romania|S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 2204), Craiova, Dolj, 200542, Romania|Policlinica Oncomed SRL ( Site 2206), Timisoara, Timis, 300239, Romania|Republican Clinical Oncology Dispensary of Republic of Bashkortostan ( Site 1507), Ufa, Baskortostan, Respublika, 450054, Russian Federation|GBUZ LOKB ( Site 1502), Saint-Petersburg, Leningradskaya Oblast, 194291, Russian Federation|FSBI National Medical Oncology Research Center n.a. N.N. Blokhina ( Site 1510), Moscow, Moskva, 115478, Russian Federation|Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 1503), Saint Petersburg, Sankt-Peterburg, 197758, Russian Federation|Academician I.P. Pavlov First St. Petersburg State Medical University ( Site 1519), Saint-Petersburg, Sankt-Peterburg, 197022, Russian Federation|Republican Clinical Oncology Dispensary of Tatarstan MoH named after professor M.Z. Sigal ( Site 150, Kazan, Tatarstan, Respublika, 420029, Russian Federation|SAIH of Tyumen reg ""Multifield clinical medical center ""Medical city"" ( Site 1520), Tyumen, Tyumenskaya Oblast, 625041, Russian Federation|National Cancer Centre Singapore ( Site 9201), Singapore, Central Singapore, 168583, Singapore|Wits Clinical Research ( Site 9502), Johannesburg, Gauteng, 2193, South Africa|The Oncology Centre ( Site 9505), Durban, Kwazulu-Natal, 4091, South Africa|Hospital Universitario General de Asturias ( Site 1601), Oviedo, Asturias, 33011, Spain|Hospital Universitario Marques de Valdecilla ( Site 1602), Santander, Cantabria, 39008, Spain|Complexo Hospitalario Universitario de Ourense-MEDICAL ONCOLOGY ( Site 1609), Ourense, Orense, 32005, Spain|Hospital General Universitari Vall d Hebron ( Site 1607), Barcelona, 08035, Spain|Hospital General Universitario Gregorio Maranon ( Site 1604), Madrid, 28007, Spain|Hospital Virgen del Rocio ( Site 1606), Sevilla, 41013, Spain|Chi Mei Hospital - Liouying Branch-Clinical Trial Center ( Site 6007), Tainan City, Tainan, 73657, Taiwan|Chang Gung Med Foundation. Kaohsiung Branch ( Site 6005), Kaohsiung, 833, Taiwan|China Medical University Hospital ( Site 6003), Taichung, 40447, Taiwan|National Cheng Kung University Hospital ( Site 6004), Tainan, 704, Taiwan|National Taiwan University Hospital ( Site 6001), Taipei, 10002, Taiwan|Taipei Veterans General Hospital ( Site 6006), Taipei, 11217, Taiwan|Faculty of Medicine Siriraj Hospital ( Site 7002), Bangkok, Krung Thep Maha Nakhon, 10700, Thailand|Songklanagarind hospital ( Site 7001), HatYai, Songkhla, 90110, Thailand|Adana Medical Park Seyhan Hastanesi-Medikal Onkoloji ( Site 1714), Adana, 01140, Turkey|Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 1701), Ankara, 06230, Turkey|Memorial Ankara Hastanesi ( Site 1702), Ankara, 06520, Turkey|Ankara Bilkent Åehir Hastanesi-Medical Oncology ( Site 1715), Ankara, 06800, Turkey|AtatÃ¼rk Ãniversitesi-onkoloji ( Site 1712), Erzurum, 25070, Turkey|Acibadem Universitesi Atakent Hastanesi-Medical Oncology ( Site 1716), Istanbul, 34303, Turkey|Istanbul OkmeydanÄ± Egitim ve Arastirma Hastanesi ( Site 1711), Istanbul, 34384, Turkey|Medeniyet Universitesi Tip Fakultesi ( Site 1703), Ä°stanbul, 34732, Turkey|Chernihiv Medical Center of Modern Oncology ( Site 1811), Chernihiv, Chernihivska Oblast, 14029, Ukraine|Regional Municipal Non-profit Enterprise ""Bukovinian Clinical Oncology Center"" ( Site 1819), Chernivtsi, Chernivetska Oblast, 58013, Ukraine|MI Kryvyi Rih Oncology Dispensary of Dnipropetrovsk Regional Council ( Site 1804), Kryviy Rih, Dnipropetrovska Oblast, 50048, Ukraine|Kharkiv Regional Clinical Oncology Center ( Site 1812), Kharkiv, Kharkivska Oblast, 61000, Ukraine|Institute of General and Emergency Surgery n.a Zaitsev NAMS of Ukraine ( Site 1813), Kharkiv, Kharkivska Oblast, 61103, Ukraine|Communal nonprofit enterprise ""Kherson Regional Oncology Dispensary"" of Kherson Regional Council (, Antonivka Village, Khersonska Oblast, 73000, Ukraine|SNPE National Cancer Institute ( Site 1806), Kyiv, Kyivska Oblast, 03022, Ukraine|Rivne Regional Clinical Hospital ( Site 1817), Rivne, Rivnenska Oblast, 33007, Ukraine|Podillya Regional Center of Oncology ( Site 1809), Vinnytsia, Vinnytska Oblast, 21029, Ukraine|Volyn Regional Oncological Dispensary ( Site 1816), Lutsk, Volynska Oblast, 43018, Ukraine|Shalimov Institute of Surgery and Transplantation ( Site 1818), Kyiv, 03126, Ukraine|Cambridge University Hospitals NHSFT ( Site 1908), Cambridge, Cambridgeshire, CB2 2QQ, United Kingdom|Ninewells Hospital and Medical School ( Site 1907), Dundee, Dundee City, DD2 1SG, United Kingdom|Nottingham University Hospital NHS Trust ( Site 1910), Nottingham, England, NG5 1PF, United Kingdom|St Bartholomew's Hospital-Centre for Experimental Cancer Medicine ( Site 1915), London, London, City Of, EC1A 7BE, United Kingdom|University College London Hospitals NHS Foundation Trust ( Site 1901), London, London, City Of, NW1 2BU, United Kingdom|Royal Marsden NHS Foundation Trust ( Site 1905), London, London, City Of, SW3 6JJ, United Kingdom|Royal Marsden NHS Trust. ( Site 1906), Sutton, London, City Of, SM2 5PT, United Kingdom|Western General Hospital ( Site 1912), Edinburgh, Midlothian, EH4 2XU, United Kingdom|The Christie NHS Foundation Trust ( Site 1909), Manchester, M20 4BX, United Kingdom",
NCT04884360,D9319C00001- 1L OC Mono Global RCT,https://clinicaltrials.gov/study/NCT04884360,MONO-OLA1,ACTIVE_NOT_RECRUITING,"This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of maintenance olaparib compared with placebo in BRCAwt participants with Stage III to IV high grade serous or endometroid ovarian cancer (including fallopian tube cancer or primary peritoneal cancer) who are in complete or partial response following treatment with standard first-line platinum-based chemotherapy.",NO,Ovarian Cancer,DRUG: Olaparib|OTHER: Matching placebo,"Superiority of olaparib as maintenance treatment relative to placebo by assessment of PFS in participants with Stage III/IV ovarian cancer with a BRCAwt HRD positive tumour and a CR/PR following standard 1st line platinum based chemotherapy treatment., PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by the investigator at the local site, or death due to any cause., Approximately 3 years|Superiority of olaparib as maintenance treatment relative to placebo by assessment of PFS in participants with Stage III/IV ovarian cancer with a BRCAwt tumour and a CR/PR following standard 1st line platinum-based chemotherapy treatment., PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by the investigator at the local site, or death due to any cause., Approximately 3 years","Superiority of olaparib as maintenance treatment relative to placebo by assessment of OS in participants with Stage III/IV ovarian cancer with a BRCAwt HRD positive tumour and a CR/PR following standard first line platinum based chemotherapy treatment., OS is defined as time from randomisation until the date of death due to any cause., Approximately 4 years|Superiority of olaparib as maintenance treatment relative to placebo by assessment of OS in participants with Stage III/IV ovarian cancer with a BRCAwt tumour and a CR/PR following standard first-line platinum-based chemotherapy treatment., OS is defined as time from randomisation until the date of death due to any cause., Approximately 4 years|Superiority of olaparib as maintenance treatment relative to placebo by assessment of TFST in participants with a BRCAwt HRD positive tumour and a CR or PR following standard first-line platinum-based chemotherapy treatment., TFST is defined as time from randomisation until the start date of the first subsequent anti-cancer therapy after discontinuation of randomised treatment, or death due to any cause., Approximately 4 years|Superiority of olaparib as maintenance treatment relative to placebo by assessment of TFST in participants with a BRCAwt tumour and a CR or PR following standard first line platinum based chemotherapy treatment., TFST is defined as time from randomisation until the start date of the first subsequent anti-cancer therapy after discontinuation of randomised treatment, or death due to any cause., Approximately 4 years|Superiority of olaparib as maintenance treatment relative to placebo by assessment of PFS2 in participants with a BRCAwt HRD positive tumour and a CR or PR following standard first-line platinum based chemotherapy treatment., PFS2 is defined as the time from the randomisation to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death., Approximately 4 years|Superiority of olaparib as maintenance treatment relative to placebo by assessment of PFS2 in participants with a BRCAwt tumour and a CR or PR following standard first-line platinum based chemotherapy treatment., PFS2 is defined as the time from the randomisation to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death., Approximately 4 years|Superiority of olaparib as maintenance treatment relative to placebo by assessment of TSST in participants with a BRCAwt HRD positive tumour and a CR or PR following standard first-line platinum based chemotherapy treatment., TSST is defined as time from randomisation until the start date of the second subsequent anti-cancer therapy after discontinuation of first subsequent treatment, or death due to any cause., Approximately 4 years|Superiority of olaparib as maintenance treatment relative to placebo by assessment of TSST in participants with a BRCAwt tumour and a CR or PR following standard first-line platinum based chemotherapy treatment., TSST is defined as time from randomisation until the start date of the second subsequent anti-cancer therapy after discontinuation of first subsequent treatment, or death due to any cause., Approximately 4 years|Superiority of olaparib as maintenance treatment relative to placebo by assessment of time to TDT in participants with a BRCAwt HRD positive tumour and a CR/PR following standard first-line platinum based chemotherapy treatment., TDT is defined as time from randomisation until discontinuation of treatment for any reason, including disease progression, toxicity and death., Approximately 3 years|To demonstrate superiority of olaparib as maintenance treatment relative to placebo by assessment of time to TDT in participants with a BRCAwt tumour and a CR or PR following standard first-line platinum based chemotherapy treatment., TDT is defined as time from randomisation until discontinuation of treatment for any reason, including disease progression, toxicity and death., Approximately 3 years|Superiority of olaparib as maintenance treatment relative to placebo by assessment of time to earliest progression by RECIST 1.1/CA 125/death in participants with a BRCAwt HRD positive tumour and a CR/PR following 1st line platinum based chemotherapy, Time to earliest progression by RECIST 1.1/CA 125 or death will be measured from time of randomisation to the earlier date of RECIST 1.1/CA-125 progression or death by any cause., Approximately 3 years|Superiority of olaparib as maintenance treatment relative to placebo by assessment of time to earliest progression by RECIST 1.1/CA 125/death in participants with a BRCAwt tumour and a CR/PR following first-line platinum based chemotherapy., Time to earliest progression by RECIST 1.1 or CA 125 or death will be measured from time of randomisation to the earlier date of RECIST 1.1 or CA-125 progression or death by any cause., Approximately 3 years|Assess Health-related quality of life in participants treated with olaparib compared with placebo in participants with a BRCAwt HRD positive tumour and a CR or PR following standard first-line platinum based chemotherapy treatment, Change from baseline in EORTC QLQ C30., Approximately 3 years|Assess Health-related quality of life in participants treated with olaparib compared with placebo in participants with BRCAwt tumour and a CR or PR following standard first-line platinum based chemotherapy treatment, Change from baseline in EORTC QLQ C30., Approximately 3 years","Assess the safety and tolerability of olaparib in terms of AEs/SAEs as compared with placebo in participants with a BRCAwt tumour and a CR or PR following standard first-line platinum-based chemotherapy treatment., Graded according to the National Cancer Institute (NCI CTCAE), Approximately 3 years",AstraZeneca,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,366,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-05-31,2025-04-30,2026-04-30,2021-05-13,,2024-11-08,"Research Site, Santiago, 8241479, Chile|Research Site, Santiago, 8420383, Chile|Research Site, Temuco, 4800827, Chile|Research Site, Temuco, 4810218, Chile|Research Site, ViÃ±a del Mar, 2540488, Chile|Research Site, Baoji, 721008, China|Research Site, Beijing, 100034, China|Research Site, Beijing, 100142, China|Research Site, Changchun, 130021, China|Research Site, Changsha, 410013, China|Research Site, Chengdu, 610041, China|Research Site, Chengdu, 610072, China|Research Site, Chongqing, 400038, China|Research Site, Chongqing, 400042, China|Research Site, Guangzhou, 510095, China|Research Site, Guangzhou, 510120, China|Research Site, Guiyang, 550004, China|Research Site, Haikou, 570311, China|Research Site, Hangzhou, 310022, China|Research Site, Hefei, 230001, China|Research Site, Hefei, 230601, China|Research Site, Jiaxing, 314001, China|Research Site, Jining, 272029, China|Research Site, Lanzhou, 730030, China|Research Site, Linyi, 276000, China|Research Site, Nanjing, 210009, China|Research Site, Qingdao, 266034, China|Research Site, Rui'an, 325200, China|Research Site, Shanghai, 200011, China|Research Site, Shanghai, 200032, China|Research Site, Shenyang, 110042, China|Research Site, Suzhou, 215004, China|Research Site, Tianjin, 300052, China|Research Site, Tianjin, 300060, China|Research Site, Urumqi, 830000, China|Research Site, Urumqi, China|Research Site, Wenzhou, 325027, China|Research Site, Wenzhou, CN-325000, China|Research Site, Wuhan, 430000, China|Research Site, Wuhan, 430022, China|Research Site, Wuxi, 214062, China|Research Site, Xuzhou, 221000, China|Research Site, Xuzhou, 221009, China|Research Site, Yanji, 133000, China|Research Site, Zibo, 255200, China|Research Site, Zunyi, 563100, China|Research Site, BogotÃ¡, 110221, Colombia|Research Site, BogotÃ¡, Colombia|Research Site, Medellin, 50030, Colombia|Research Site, Gurgaon, 122001, India|Research Site, Jaipur, 302017, India|Research Site, Kolkata, 700160, India|Research Site, Madurai, 625107, India|Research Site, Namakkal, 637001, India|Research Site, Nashik, 422002, India|Research Site, New Delhi, 110085, India|Research Site, New Delhi, 11029, India|Research Site, Arequipa, AREQUIPA01, Peru|Research Site, Lima, 15036, Peru|Research Site, Lima, LIMA 29, Peru|Research Site, Lima, LIMA 34, Peru|Research Site, San Isidro, 27, Peru|Research Site, Arkhangelsk, 163045, Russian Federation|Research Site, Chelyabinsk, 454087, Russian Federation|Research Site, Ekaterinburg, 620905, Russian Federation|Research Site, Moscow, 115478, Russian Federation|Research Site, Moscow, 117997, Russian Federation|Research Site, Saint Petersburg, 197758, Russian Federation|Research Site, Saint-Petersburg, 198255, Russian Federation|Research Site, Tomsk, 634028, Russian Federation|Research Site, Port Elizabeth, 6045, South Africa|Research Site, Adana, 01120, Turkey|Research Site, Ankara, 06100, Turkey|Research Site, Ankara, 06800, Turkey|Research Site, Istanbul, 34010, Turkey|Research Site, Karsiyaka, 35575, Turkey|Research Site, Samsun, 55139, Turkey|Research Site, Chernihiv, 14029, Ukraine|Research Site, Dnipro, 49102, Ukraine|Research Site, Ivano-Frankivsk, 76018, Ukraine|Research Site, Kharkiv, 61103, Ukraine|Research Site, Kryvyi Rih, 50048, Ukraine|Research Site, Kyiv, 03022, Ukraine|Research Site, Kyiv, 04050, Ukraine|Research Site, Zaporizhzhia, Ukraine|Research Site, Ha noi, 100000, Vietnam|Research Site, Hanoi, 100000, Vietnam|Research Site, Ho Chi Minh city, Vietnam|Research Site, Ho Chi Minh, 700000, Vietnam",
NCT06357533,"Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC â¥ 50%) and Without Actionable Genomic Alterations",https://clinicaltrials.gov/study/NCT06357533,TROPION-Lung10,RECRUITING,The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC â¥ 50%) and without actionable genomic alterations.,NO,Non-Small Cell Lung Cancer,DRUG: Datopotamab Deruxtecan|DRUG: Rilvegostomig|DRUG: Pembrolizumab,"Progression-Free Survival (PFS) in TROP2 biomarker positive participants., PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause.

The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy, receives another anti-cancer therapy or clinically progresses prior to RECIST 1.1 progression, in the following population:

â¢ TROP2 biomarker positive population

The measure of interest is the HR of PFS. PFS by investigator will be reported as a sensitivity analysis., Approximately 4 years|Overall Survival (OS) in TROP2 biomarker positive participants., OS is defined as the time from randomisation until the date of death due to any cause.

The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anti-cancer therapy, in the following population:

â¢ TROP2 biomarker positive population The measure of interest is the HR of OS., Approximately 6 years","Progression-Free Survival (PFS) in the FAS population., PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause.

The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy, receives another anti cancer therapy or clinically progresses prior to RECIST 1.1 progression, in the following population:

â¢ FAS population

The measure of interest is the HR of PFS. PFS by investigator will be reported as a sensitivity analysis., Approximately 4 years|Overall Survival (OS) in the FAS population., OS is defined as the time from randomisation until the date of death due to any cause.

The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anti-cancer therapy, in the following population:

â¢ FAS population The measure of interest is the HR of OS., Approximately 6 years|Assessment of Objective Response Rate (ORR) by BICR in TROP2 biomarker positive and FAS populations, ORR is defined as the proportion of participants who have a CR or PR, as determined by BICR per RECIST 1.1.

The analyses will include all randomised participants, as randomised, with measurable disease at baseline, in the following populations:

* TROP2 biomarker positive population
* FAS population Data obtained from randomisation up until progression, or the last evaluable assessment in the absence of progression, will be included in the assessment of ORR, regardless of whether the participant withdraws from therapy. Participants who go off treatment without a response or progression, receive a subsequent therapy, and then respond will not be included as responders in the ORR.

The measure of interest is the OR of the ORR. ORR by investigator will be reported as a sensitivity analysis., Approximately 4 years|Assessment of Duration of Response (DoR) by BICR in TROP2 biomarker positive and FAS populations, DoR is defined as the time from the date of first documented response until date of documented progression per RECIST 1.1, as assessed by BICR and investigator assessment or death due to any cause.

The analyses will include all randomised participants who have a response, as randomised, regardless of whether the participant withdraws from randomised therapy, receives another anti cancer therapy or clinically progresses prior to RECIST 1.1 progression, in the following populations:

* TROP2 biomarker positive population
* FAS population The measure of interest is the median of DoR. DoR by investigator will be reported as a sensitivity analysis., Approximately 4 years|Participant-reported lung cancer symptoms of NSCLC and participant-reported GHS/QOL in participants treated with Dato-DXd in combination with rilvegostomig relative to pembrolizumab., Time to deterioration in: pulmonary symptoms (dyspnoea, cough, and chest pain) as measured by the NSCLC-SAQ, in overall lung cancer symptoms as measured by the NSCLC-SAQ, and in GHS/QoL as measured by the GHS/QoL scale from EORTC IL172.

Time to deterioration is defined as the time from randomisation until the date of deterioration. Deterioration is defined as change from baseline that reaches a clinically meaningful deterioration threshold. The analyses will include all randomised participants, in the following populations:

* TROP2 biomarker positive population
* FAS population The measure of interest is the HR of time to deterioration in pulmonary symptoms, HR of time to deterioration in overall lung cancer symptoms, and HR of time to deterioration in GHS/QoL., Approximately 6 years|Participant-reported physical functioning in participants treated with Dato DXd in combination with rilvegostomig relative to pembrolizumab., Time to deterioration in physical functioning as measured by PROMIS Physical Function short form 8c.

Time to deterioration is defined as the time from randomisation until the date of deterioration. Deterioration is defined as change from baseline that reaches a clinically meaningful deterioration threshold. The analyses will include all randomised participants, in the following populations:

* TROP2 biomarker positive population
* FAS population The measure of interest is the HR of time to deterioration in physical functioning., Approximately 6 years|Pharmacokinetics (PK), Concentration of rilvegostomig, Dato-DXd, total anti TROP2 antibody, and MAAA 1181a (payload deruxtecan) in plasma or serum and PK parameters (peak and trough concentrations)., Approximately 6 years|Immunogenicity, Presence of ADA for Dato-DXd and rilvegostomig (confirmatory results, titres and neutralising antibodies for confirmed positive samples)., Approximately 6 years|Second Progression-Free Survival (PFS2)., PFS2 is defined as the time from randomisation to the earliest of the progression events (following the initial progression), subsequent to first subsequent therapy, or death. Progression event includes radiological (RECIST 1.1) or clinical disease progression.

The date of second progression will be recorded by the investigator in the eCRF and defined according to local standard practice.

The analyses will include all randomised participants, as randomised, regardless of whether the participant withdraws from subsequent therapy and regardless of missed visits, in the following populations:

* TROP2 biomarker positive population
* FAS population The measure of interest is the HR of PFS2., Approximately 6 years","Safety of Dato-DXd in combination with rilvegostomig and rilvegostomig monotherapy as compared with pembrolizumab., Safety and tolerability will be evaluated in terms of AEs (graded by CTCAE Version 5.0)., Approximately 6 years",AstraZeneca,Daiichi Sankyo,ALL,"ADULT, OLDER_ADULT",PHASE3,675,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2024-04-11,2028-04-24,2030-05-24,2024-04-10,,2025-06-04,"Research Site, Anchorage, Alaska, 99508, United States|Research Site, Tucson, Arizona, 85719, United States|Research Site, Little Rock, Arkansas, 72205, United States|Research Site, Springdale, Arkansas, 72762, United States|Research Site, Anaheim, California, 92801, United States|Research Site, Beverly Hills, California, 90211, United States|Research Site, Fountain Valley, California, 92708, United States|Research Site, Newport Beach, California, 92663, United States|Research Site, Gainesville, Florida, 32608, United States|Research Site, Miami Beach, Florida, 33140, United States|Research Site, Orange City, Florida, 32763, United States|Research Site, Orlando, Florida, 32827, United States|Research Site, Punta Gorda, Florida, 33980, United States|Research Site, Atlanta, Georgia, 30303, United States|Research Site, Atlanta, Georgia, 30318, United States|Research Site, Atlanta, Georgia, 30322, United States|Research Site, Atlanta, Georgia, 30342, United States|Research Site, Noblesville, Indiana, 46062, United States|Research Site, Annapolis, Maryland, 21401, United States|Research Site, Boston, Massachusetts, 02114, United States|Research Site, Boston, Massachusetts, 02215, United States|Research Site, Dearborn, Michigan, 48126, United States|Research Site, Farmington Hills, Michigan, 48334, United States|Research Site, Grand Rapids, Michigan, 49503, United States|Research Site, Traverse City, Michigan, 49684, United States|Research Site, Hattiesburg, Mississippi, 39401, United States|Research Site, Bozeman, Montana, 59715, United States|Research Site, Grand Island, Nebraska, 68803, United States|Research Site, Omaha, Nebraska, 68130, United States|Research Site, Las Vegas, Nevada, 89102, United States|Research Site, Reno, Nevada, 89502, United States|Research Site, Voorhees, New Jersey, 08043, United States|Research Site, Stony Brook, New York, 11794, United States|Research Site, Greenville, North Carolina, 27834, United States|Research Site, Salisbury, North Carolina, 28144, United States|Research Site, Cincinnati, Ohio, 45219, United States|Research Site, Columbus, Ohio, 43210, United States|Research Site, Portland, Oregon, 97213, United States|Research Site, Greenville, South Carolina, 29607, United States|Research Site, Sioux Falls, South Dakota, 57105, United States|Research Site, Chattanooga, Tennessee, 37404, United States|Research Site, Knoxville, Tennessee, 37920, United States|Research Site, Fort Worth, Texas, 76104, United States|Research Site, Houston, Texas, 77030, United States|Research Site, Houston, Texas, 77030, United States|Research Site, Houston, Texas, 77090, United States|Research Site, Kingwood, Texas, 77339, United States|Research Site, Odessa, Texas, 79761, United States|Research Site, Fort Belvoir, Virginia, 22060, United States|Research Site, Leesburg, Virginia, 20176, United States|Research Site, Richmond, Virginia, 23230, United States|Research Site, Tacoma, Washington, 98405, United States|Research Site, Vancouver, Washington, 98684, United States|Research Site, Wenatchee, Washington, 98801, United States|Research Site, Birtinya, 4575, Australia|Research Site, Blacktown, 2148, Australia|Research Site, Clayton, 3168, Australia|Research Site, Gosford, 2250, Australia|Research Site, Melbourne, 3000, Australia|Research Site, South Brisbane, QL 4101, Australia|Research Site, Southport, 4215, Australia|Research Site, Wodonga, 3690, Australia|Research Site, Innsbruck, 6020, Austria|Research Site, Krems, 3500, Austria|Research Site, Linz, 4020, Austria|Research Site, Rankweil, 6830, Austria|Research Site, Wels, 4600, Austria|Research Site, Wien, 1140, Austria|Research Site, Wien, 1210, Austria|Research Site, Anderlecht, 1070, Belgium|Research Site, Hasselt, 3500, Belgium|Research Site, La LouviÃ¨re, 7100, Belgium|Research Site, LiÃ¨ge, 4000, Belgium|Research Site, Barretos, 14784-400, Brazil|Research Site, Curitiba, 80730-150, Brazil|Research Site, FlorianÃ³polis, 88034-000, Brazil|Research Site, Ipatinga, 35162-189, Brazil|Research Site, Natal, 59075-740, Brazil|Research Site, Porto Alegre, 91350-200, Brazil|Research Site, Rio de Janeiro, 22211-230, Brazil|Research Site, Santa Maria, 97015-450, Brazil|Research Site, SÃ£o Paulo, 01221-020, Brazil|Research Site, TaubatÃ©, 12030-200, Brazil|Research Site, Vancouver, British Columbia, VSZ 4E6, Canada|Research Site, Winnipeg, Manitoba, R3E 0V9, Canada|Research Site, St. John's, Newfoundland and Labrador, A1B 3V6, Canada|Research Site, London, Ontario, N6A 4L6, Canada|Research Site, Newmarket, Ontario, L3Y 2P9, Canada|Research Site, Oshawa, Ontario, L1G 2B9, Canada|Research Site, Toronto, Ontario, M4N 3M5, Canada|Research Site, LÃ©vis, Quebec, G6V 0B8, Canada|Research Site, Montreal, Quebec, H3T 1E2, Canada|Research Site, Montreal, Quebec, H3T 1M5, Canada|Research Site, Montreal, Quebec, H4J 1C5, Canada|Research Site, Rimouski, Quebec, G5L 5T1, Canada|Research Site, Trois-Rivieres, Quebec, G8Z 3R9, Canada|Research Site, Saskatoon, Saskatchewan, S7N 4H4, Canada|Research Site, Chicoutimi, G7H 5H6, Canada|Research Site, Beijing, 100142, China|Research Site, Beijing, 101149, China|Research Site, Changsha, 410013, China|Research Site, Chengdu, 610000, China|Research Site, Chengdu, 610041, China|Research Site, Chongqing, 400030, China|Research Site, Fuzhou, 350014, China|Research Site, Guangzhou, 510080, China|Research Site, Hangzhou, 310006, China|Research Site, Hangzhou, 310016, China|Research Site, Hangzhou, 310022, China|Research Site, Harbin, 150049, China|Research Site, Hefei, 230031, China|Research Site, Hefei, 230601, China|Research Site, Jinan, 250117, China|Research Site, Jining, 272011, China|Research Site, Kunming, 650118, China|Research Site, Lanzhou, 730000, China|Research Site, Linhai, 317000, China|Research Site, Linyi, 276001, China|Research Site, Nanjing, 210009, China|Research Site, Nanning, 530000, China|Research Site, Nanning, 530021, China|Research Site, Shanghai, 200030, China|Research Site, Shanghai, 200032, China|Research Site, Shanghai, 200433, China|Research Site, Shenyang, 110022, China|Research Site, Taiyuan, 030000, China|Research Site, Tianjin, 300060, China|Research Site, Wenzhou, 325000, China|Research Site, Wuhan, 430000, China|Research Site, Wuhan, 430010, China|Research Site, Wuhan, 430022, China|Research Site, Wuhan, 430030, China|Research Site, Xi'an, 710061, China|Research Site, Yangzhou, 225001, China|Research Site, Zhengzhou City, 450000, China|Research Site, Zhengzhou, 450008, China|Research Site, Bonn, 53113, Germany|Research Site, DÃ¼sseldorf, 40489, Germany|Research Site, Essen, 45136, Germany|Research Site, Freiburg, 79106, Germany|Research Site, Gauting, 82131, Germany|Research Site, GeorgsmarienhÃ¼tte, 49124, Germany|Research Site, Gera, 07548, Germany|Research Site, GÃ¼tersloh, 33332, Germany|Research Site, Hamburg, 20251, Germany|Research Site, Hamburg, 22087, Germany|Research Site, Heidelberg, 69126, Germany|Research Site, Kempten, 87439, Germany|Research Site, Koblenz, 56068, Germany|Research Site, Ludwigsburg, 71640, Germany|Research Site, MÃ¼nchen, 81925, Germany|Research Site, NÃ¼rnberg, 90419, Germany|Research Site, Ravensburg, 88212, Germany|Research Site, Budapest, 1121, Hungary|Research Site, Gyula, 5700, Hungary|Research Site, GyÃ¶ngyÃ¶s, 3200, Hungary|Research Site, GyÅr, 9024, Hungary|Research Site, KecskemÃ©t, 6000, Hungary|Research Site, SalgÃ³tarjÃ¡n, 3100, Hungary|Research Site, SzekszÃ¡rd, 7100, Hungary|Research Site, SzÃ©kesfehÃ©rvÃ¡r, 8000, Hungary|Research Site, TÃ¶rÃ¶kbÃ¡lint, 2045, Hungary|Research Site, Chennai, 600031, India|Research Site, Dwarka, 110075, India|Research Site, Jaipur, 302004, India|Research Site, Kolkata, 700099, India|Research Site, Marg Jaipur, 302004, India|Research Site, Nagpur, 440001, India|Research Site, Nashik, 422011, India|Research Site, New Delhi, 110085, India|Research Site, New Delhi, 11029, India|Research Site, Thiruvananthapuram, 695011, India|Research Site, Bergamo, 24125, Italy|Research Site, Genoa, 16132, Italy|Research Site, Milano, 20141, Italy|Research Site, Milano, 20162, Italy|Research Site, Monza, 20052, Italy|Research Site, Padova, 35128, Italy|Research Site, Pavia, 27100, Italy|Research Site, Ravenna, 48100, Italy|Research Site, Roma, 00128, Italy|Research Site, Rozzano, 20089, Italy|Research Site, Fukuoka-shi, 812-8582, Japan|Research Site, Fukuoka-shi, 814-0180, Japan|Research Site, Hidaka-shi, 350-1298, Japan|Research Site, Hirosaki-shi, 036-8563, Japan|Research Site, Hiroshima-shi, 730-8518, Japan|Research Site, Kashiwa, 227-8577, Japan|Research Site, Kawasaki-shi, 216-8511, Japan|Research Site, Kumamoto-shi, 860-8556, Japan|Research Site, Nagoya-shi, 460-0001, Japan|Research Site, Okayama, 700-8558, Japan|Research Site, Osakasayama-shi, 589-8511, Japan|Research Site, Osaka, 545-8586, Japan|Research Site, Sagamihara-shi, 252-0375, Japan|Research Site, Sapporo-shi, 003-0804, Japan|Research Site, Takaoka-shi, 933-8555, Japan|Research Site, Takatsuki-shi, 569-8686, Japan|Research Site, Tokushima-shi, 770-8503, Japan|Research Site, Tokyo, 104-0045, Japan|Research Site, Utsunomiya-shi, 320-0834, Japan|Research Site, Yokohama-shi, 221-0855, Japan|Research Site, Changwon, 51353, Korea, Republic of|Research Site, Incheon, 21565, Korea, Republic of|Research Site, Seongnam-si, 13496, Korea, Republic of|Research Site, Seoul, 03080, Korea, Republic of|Research Site, Seoul, 03722, Korea, Republic of|Research Site, Suwon-si, 16499, Korea, Republic of|Research Site, Suwon, 16247, Korea, Republic of|Research Site, Olsztyn, 10-357, Poland|Research Site, PoznaÅ, 60-569, Poland|Research Site, Przemysl, 37-700, Poland|Research Site, Warszawa, 01-138, Poland|Research Site, Warszawa, 02-781, Poland|Research Site, San Juan, 00909, Puerto Rico|Research Site, Alicante, 03010, Spain|Research Site, Barcelona, 08003, Spain|Research Site, Barcelona, 08036, Spain|Research Site, Jerez de la Frontera, 11407, Spain|Research Site, Reus,Tarragona, 43204, Spain|Research Site, Salamanca, 37007, Spain|Research Site, Kaohsiung, 80756, Taiwan|Research Site, New Taipei, 220, Taiwan|Research Site, Taichung, 40447, Taiwan|Research Site, Tainan, 704, Taiwan|Research Site, Taipei, 10002, Taiwan|Research Site, Taipei, 112, Taiwan|Research Site, Taipei, TAIWAN, Taiwan|Research Site, Taoyuan, 333, Taiwan|Research Site, Bangkok, 10400, Thailand|Research Site, Hat Yai, 90110, Thailand|Research Site, Mueang, 20000, Thailand|Research Site, Mueang, 32000, Thailand|Research Site, AdapazarÄ±, 54100, Turkey|Research Site, Ankara, 06560, Turkey|Research Site, Ankara, 6200, Turkey|Research Site, Antalya, 07070, Turkey|Research Site, Diyarbakir, 21280, Turkey|Research Site, Istanbul, 34030, Turkey|Research Site, Istanbul, 34890, Turkey|Research Site, Cheltenham, GL53 7AN, United Kingdom|Research Site, Inverness, IV2 3UJ, United Kingdom|Research Site, London, SE1 9RT, United Kingdom|Research Site, London, SW10 9NH, United Kingdom|Research Site, London, SW17 0QT, United Kingdom|Research Site, Preston, PR2 9HT, United Kingdom|Research Site, Truro, TR1 3LJ, United Kingdom",
NCT05091567,"A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer",https://clinicaltrials.gov/study/NCT05091567,IMforte,ACTIVE_NOT_RECRUITING,"Study GO43104 is a Phase III, randomized, open-label, multicenter study of lurbinectedin in combination with atezolizumab compared with atezolizumab alone administered as maintenance therapy in participants with extensive-stage small-cell lung cancer (ES-SCLC) after first-line induction therapy with carboplatin, etoposide, and atezolizumab. The study consists of 2 phases: an induction phase and a maintenance phase. Participants need to have an ongoing response or stable disease per the Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 criteria after completion of 4 cycles of carboplatin, etoposide, and atezolizumab induction treatment in order to be considered for eligibility screening for the maintenance phase. Eligible participants will be randomized in a 1:1 ratio to receive either lurbinectedin plus atezolizumab or atezolizumab in the maintenance phase.",NO,Small-Cell Lung Cancer,DRUG: Atezolizumab|DRUG: Lurbinectedin|DRUG: Carboplatin|DRUG: Etoposide,"IRF-Assessed Progression-Free Survival (PFS), IRF-assessed progression-free survival (PFS) is defined as the time from randomization to the date of first documented disease progression (as assessed by the IRF according to RECIST v1.1), or death whichever occurs first., Randomization to the date of first documented disease progression or death, whichever occurs first (up to approximately 60 months)|Overall Survival (OS), Overall survival (OS) is defined as the time from randomization to the date of death from any cause., Randomization to the date of death from any cause (up to approximately 60 months)","Investigator-Assessed PFS, Investigator-assessed PFS is defined as the time from randomization to the first occurrence of disease progression as determined by the investigator according to RECIST v1.1, or death from any cause (whichever occurs first)., Randomization to the first occurrence of disease progression or death from any cause (whichever occurs first) (up to approximately 60 months)|Confirmed Objective Response Rate (ORR) as Determined by the IRF, Confirmed objective response rate (ORR) is defined as the proportion of randomized participants with a CR or PR on two consecutive occasions \>= 4 weeks apart after randomization, as determined by the IRF according to RECIST v1.1., Up to approximately 60 months|Confirmed Objective Response Rate (ORR) as Determined by the Investigator, Confirmed objective response rate (ORR) is defined as the proportion of randomized participants with a CR or PR on two consecutive occasions \>= 4 weeks apart after randomization, as determined by the Investigator according to RECIST v1.1., Up to approximately 60 months|Duration of Response (DOR) as Determined by the IRF, Duration of Response (DOR) (for participants with a confirmed objective response) is defined as the time from the first occurrence of a documented confirmed objective response after randomization until disease progression as determined by the IRF according to RECIST v1.1, or death from any cause, whichever occurs first., Up to approximately 60 months|Duration of Response (DOR) as Determined by the Investigator, Duration of Response (DOR) (for participants with a confirmed objective response) is defined as the time from the first occurrence of a documented confirmed objective response after randomization until disease progression as determined by the investigator according to RECIST v1.1, or death from any cause, whichever occurs first., Up to approximately 60 months|PFS Rates as Determined by the IRF, PFS rates at 6 months and 12 months is defined as the proportion of participants who have not experienced disease progression or death from any cause at 6 months and 12 months after randomization, as determined by the IRF according to RECIST v1.1., 6 months and 12 months after randomization|PFS Rates as Determined by the Investigator, PFS rates at 6 months and 12 months is defined as the proportion of participants who have not experienced disease progression or death from any cause at 6 months and 12 months after randomization, as determined by the investigator according to RECIST v1.1., 6 months and 12 months after randomization|OS Rates, OS rates at 12 months and 24 months is defined as the proportion of participants who have not experienced death from any cause at 12 months and 24 months after randomization., 12 months and 24 months after randomization|Percentage of Participants With Adverse Events, Percentage of participants with adverse events., Up to approximately 60 months|Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab, Percentage of participants with ADAs to atezolizumab after drug administration., Up to approximately 60 months|Time to Confirmed Deterioration (TTCD), Time to confirmed deterioration (TTCD) from randomization in participant-reported physical functioning and global health status as measured by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30)., Up to approximately 60 months",,Hoffmann-La Roche,Jazz Pharmaceuticals,ALL,"ADULT, OLDER_ADULT",PHASE3,660,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-11-18,2025-02-12,2026-08-13,2021-10-25,,2025-04-24,"Florida Cancer Specialists, West Palm Beach, Florida, 33401, United States|Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital, Marietta, Georgia, 30060, United States|Illinois Cancer Care, Peoria, Illinois, 61615, United States|New England Cancer Specialists, Scarborough, Maine, 04074, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Cancer & Hematology Centers of Western Michigan, Grand Rapids, Michigan, 49503, United States|Mercy Research - St. Louis, Saint Louis, Missouri, 63141, United States|Clinical Research Alliance, Westbury, New York, 11590, United States|The Mark H. Zangmeister Ctr, Columbus, Ohio, 43219, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States|Rhode Island Hospital, Providence, Rhode Island, 02903, United States|Hollings Cancer Center, Charleston, South Carolina, 29425, United States|Greco-Hainesworth Centers for Research, Chattanooga, Tennessee, 37403, United States|West Clinic, Germantown, Tennessee, 38138, United States|Sarah Cannon Research Institute / Tennessee Oncology, Nashville, Tennessee, 37203, United States|Institut Jules Bordet, Anderlecht, 1070, Belgium|Jessa Zkh (Campus Virga Jesse), Hasselt, 3500, Belgium|UZ Leuven Gasthuisberg, Leuven, 3000, Belgium|AZ St Maarten Campus Leopoldstr, Mechelen, 2800, Belgium|CHU UCL Mont-Godinne, Mont-godinne, 5530, Belgium|Vitaz, Sint Niklaas, 9100, Belgium|Zentralklinik Bad Berka GmbH, Bad Berka, 99437, Germany|Evang. Lungenklinik Berlin Klinik fÃ¼r Pneumologie, Berlin, 13125, Germany|Helios Klinikum Emil von Behring GmbH, Berlin, 14165, Germany|Klinikum Chemnitz gGmbH, Chemnitz, 09116, Germany|KEM/Evang. Kliniken Essen Mitte gGmbH, Essen, 45136, Germany|Niels-Stensen-Kliniken Franziskus-Hospital Harderberg GmbH, GeorgsmarienhÃ¼tte, 49124, Germany|LungenClinic GroÃhansdorf GmbH, GroÃhansdorf, 22927, Germany|Krankenhaus Martha-Maria Halle-Doelau gGmbH, Halle, 06120, Germany|Fachklinik fÃ¼r Lungenerkrankungen, Immenhausen, 34376, Germany|UniversitÃ¤tsklinikum Schleswig-Holstein, LÃ¼beck, 23538, Germany|Asklepios Klinik Gauting, MÃ¼nchen-Gauting, 82131, Germany|Sotiria Thoracic Diseases Hospital of Athens, Athens, 115 27, Greece|Errikos Dynan Hospital, Athens, 11526, Greece|University Hospital of Larissa, Larissa, 411 10, Greece|Euromedical General Clinic of Thessaloniki, Thessaloniki, 546 45, Greece|Diavalkaniko Hospital, Thessaloniki, 570 01, Greece|Orszagos Koranyi Pulmonologiai Intezet, Budapest, 1121, Hungary|PÃ©csi TudomÃ¡nyegyetem, PÃ©cs, 7623, Hungary|Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rend.Int., Szolnok, 5000, Hungary|Tudogyogyintezet Torokbalint, Torokbalint, 2045, Hungary|AUSL della Romagna, Ravenna, Emilia-Romagna, 48121, Italy|ASL 3 Genovese, Genova, Liguria, 16125, Italy|Irccs Istituto Europeo di Oncologia (IEO), Milano, Lombardia, 20141, Italy|Azienda Socio Sanitaria Territoriale Niguarda (Ospedale Niguarda Ca' Granda), Milano, Lombardia, 20162, Italy|Azienda Ospedaliero Universitaria Ospedali Riuniti, Torrette Di Ancona, Marche, 60126, Italy|Chungbuk National University Hospital, Cheongju-si, 28644, Korea, Republic of|Chilgok Kyungpook National University Medical Center, Daegu, 702-210, Korea, Republic of|Samsung Changwon Hospital, Gyeongsangnam-do, 51353, Korea, Republic of|Gyeongsang National University Hospital, Gyeongsangnam-do, 52727, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, 13605, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|Ulsan University Hosiptal, Ulsan, 44033, Korea, Republic of|Health Pharma Professional Research, Cdmx, Mexico CITY (federal District), 03100, Mexico|Antiguo Hospital Civil de Guadalajara Fray Antonio Alcalde, Morelia, 58260, Mexico|Uniwersyteckie Centrum Kliniczne, Gda?sk, 80-214, Poland|Krakowski Szpital Specjalistyczny im sw. Jana Paw?a II, KrakÃ³w, 31-202, Poland|Warminsko-Mazurskie Centrum ChorÃ³b P?uc w Olsztynie, Olsztyn, 10-357, Poland|Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy, Otwock, 05-400, Poland|Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu, Poznan, 60-569, Poland|Centrum Onkologii Instytut im.Marii Sklodowskiej-Curie, Warszawa, 02-781, Poland|Complejo Hospitalario Universitario A CoruÃ±a (CHUAC), A CoruÃ±a, LA Coruna, 15006, Spain|Hospital del Mar, Barcelona, 08003, Spain|Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Barcelona, 08035, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, 08041, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital Clinico Universitario Virgen de la Victoria, Malaga, 29010, Spain|Hospital Universitario Virgen del Rocio, Sevilla, 41013, Spain|E-DA Hospital, Kaohsiung, 824, Taiwan|Taichung Veterans General Hospital, Taichung, 407, Taiwan|National Cheng Kung University Hospital, Tainan, 00704, Taiwan|Taipei Veterans General Hospital, Taipei, 112, Taiwan|Adana Baskent University Hospital, Adana, 01120, Turkey|Memorial Ankara Hastanesi, Ankara, 06520, Turkey|Uludag Uni Hospital, Bursa, 16059, Turkey|Pamukkale University School Of Medicine, Denizli, 20070, Turkey|Dicle University Faculty of Medicine, Diyarbakir, 21280, Turkey|Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi, Edirne, 22030, Turkey|Ba?c?lar Medipol Mega Ãniversite Hastanesi, Istanbul, 34214, Turkey|Istanbul Uni Cerrahpasa Medical Faculty Hospital, Istanbul, 34300, Turkey|Ac?badem Altunizade Hastanesi, Istanbul, 34660, Turkey|Izmir Medical Point Hospital, Izmir, 35101, Turkey|Kocaeli University Faculty of Medicine, Izmit, 31380, Turkey|Goztepe Prof.Dr. Suleyman Yalcin City Hospital, KadikÃ¶y, 34722, Turkey|Medikal Park Samsun, Samsun, 55200, Turkey|TC Necmettin Erbakan University Meram Medical Faculty Hospital, SelÃ§uklu, 42080, Turkey|Blackpool Victoria Hospital, Blackpool, FY3 8NR, United Kingdom|Christie NHS Foundation Trust, GB Manchester, M20 4BX, United Kingdom|Castle Hill Hospital, Hull, HU16 5JQ, United Kingdom|St James University Hospital, Leeds, LS9 7TF, United Kingdom|Leicester Royal Infirmary, Leicester, LE1 5WW, United Kingdom|Guy's Hospital, London, SE1 9RT, United Kingdom",
NCT04919226,Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE,https://clinicaltrials.gov/study/NCT04919226,COMPOSE,ACTIVE_NOT_RECRUITING,"The purpose of the study is to evaluate the efficacy, safety \& patient-reported outcomes of peptide receptor radionuclide therapy (PRRT) with 177Lu-Edotreotide as 1st or 2nd line of treatment compared to best standard of care in patients with well-differentiated aggressive grade 2 and grade 3, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin.",NO,Neuroendocrine Tumors,DRUG: 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT|DRUG: CAPTEM (Capecitabine and Temozolomide)|OTHER: Amino-Acid Solution|DRUG: Everolimus|DRUG: FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin),"Progression-Free Survival, PFS (Progression-Free Survival), defined as the time from randomization until documented RECIST v1.1 (Response evaluation criteria in solid tumors) progression., Every 12 weeks from randomization until disease progression or death whichever occurs earlier, during the time necessary to observe 148 Progression Free Survival (PFS) events.","Overall Survival, OS (Overall Survival), defined as the time from randomization until death;, Up to 2 years after disease progression",,ITM Solucin GmbH,,ALL,"ADULT, OLDER_ADULT",PHASE3,259,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-12-21,2027-06,2027-09,2021-06-09,,2025-05-29,"Stanford Cancer Center, Palo Alto, California, 94305, United States|University of Colorado Hospital, Nuclear Medicine, Aurora, Colorado, 80045, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, 33612, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Mayo Clinic - Rochester, Department of Oncology, Rochester, Minnesota, 55905, United States|Washington University Alvin J. Siteman Cancer Center, Saint Louis, Missouri, 63110, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, 10065, United States|ICAHN School of Medicine at Mount Sinai, Tish Cancer Institute, New York, New York, 10128, United States|Duke University School of Medicine, Duke Cancer Institute, Durham, North Carolina, 27710, United States|Oregon Health and Science University, Portland, Oregon, 97239-3098, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111-2497, United States|Texas Oncology, Dallas, Texas, 75246, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, 84112, United States|Royal North Shore Hospital, St. Leonards, New South Wales, 2065, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, VIC 3000, Australia|Fudan University Shanghai Cancer Center, Shanghai, 200000, China|Affiliated Hospital of Jiangnan University, Wuxi, 214122, China|Haut-Leveque Hospital, Department of Hepatogastroenterology and Digestive Tract Oncology, Pessac, Bordeaux, 33604, France|Nantes University Hospital Center - Hotel Dieu Hospital, Nantes, Cedex, 44093, France|Edouard Herriot Hospital, Medical Oncology Unit, Lyon, 69003, France|IUCT Oncopole - Institut Universitaire du Cancer de Toulouse, Toulouse, 31059, France|Charite - University Hospital Berlin, Berlin, 13353, Germany|University Hospital Bonn, Department of Nuclear Medicine, Bonn, 53127, Germany|University Hospital Erlangen, Department of Internal Medicine I - Endocrinology, Erlangen, 91054, Germany|University Duisburg-Essen, University Hospital Essen, Clinic for Nuclear Medicine, Essen, 45147, Germany|All India Institute Of Medical Sciences, Nuclear Medicine, New Delhi, Delhi, 110029, India|HCG Cancer Centre, Medical Oncology, Bangalore, Karnataka, 560027, India|Tata Memorial Hospital, Nuclear Medicine & Molecular Imaging, Mumbai, 400012, India|University Polyclinic Hospital ""G. Martino"", Department of Biomedical Sciences, Dentistry and Morphological and Functional Imaging, Complex Operational Unit of Nuclear Medicine, Messina, 98125, Italy|European Institute of Oncology (IEO), IRCCS, Milan, 20141, Italy|University Polyclinic Foundation ""Agostino Gemelli"" - IRCCS, Complex Operative Unit of Medical Oncology, Rome, 00168, Italy|VU Medical Center (VUMC), Department of Medical Oncology, Amsterdam, 1081-HV, Netherlands|Erasmus University Medical Center Rotterdam, Rotterdam, 3015 GD, Netherlands|University Hospital Vall d'Hebron, Department of Medical Oncology, Barcelona, 08035, Spain|ICO Hospitalet, Catalan Institute of Oncology, Barcelona, 199-203, Spain|University General Hospital Gregorio Maranon, Madrid, 28007, Spain|University Hospital 12 de Octubre, Department of Gastroenterology, Madrid, 28041, Spain|Central University Hospital de Asturias (HUCA), IUOPA - Universitary Institute of Oncology, Oviedo, 33011, Spain|University Hospital Complex of Santiago (CHUS), Santiago De Compostela, 15706, Spain|University and Polytechnic Hospital La Fe, Endocrinology, Valencia, 46026, Spain|King's College Hospital, London, SE5 9RS, United Kingdom",
NCT06380751,"Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer",https://clinicaltrials.gov/study/NCT06380751,EvoPAR-BR01,RECRUITING,"The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+, 2+/ ISH non-amplified) advanced breast cancer",NO,Advanced Breast Cancer,DRUG: Saruparib (AZD5305)|DRUG: Camizestrant|DRUG: Abemaciclib|DRUG: Ribociclib|DRUG: Palbociclib|DRUG: Fulvestrant|DRUG: Letrozole|DRUG: Anastrozole|DRUG: Exemestane,"Progression-Free Survival, PFS is defined as time from randomisation until progression per RECIST v1.1 as assessed by BICR, or death due to any cause., Up to approximately 59 months","Overall Survival, OS is defined as the time from randomisation until the date of death due to any cause., Up to approximately 88 months|Progression Free Survival 2, PFS2 is defined as the time from randomisation to the earliest of the progression event (following the initial investigator-assessed progression), after first subsequent therapy, or death., Up to approximately 59 months|Time to chemotherapy, Time to chemotherapy is defined as time from randomisation until the start date of the first subsequent chemotherapy treatment after discontinuation of randomised treatment (censoring participants who died prior to initiation of chemotherapy)., Up to approximately 59 months|Objective Response Rate, ORR is defined as the proportion of participants who have a complete or parial response, as determined by BICR per RECIST v1.1., Up to approximately 59 months|Duration of Response, DoR is defined as the time from the date of first documented response until date of documented progression per RECIST v1.1 as assessed by BICR, or death due to any cause., Up to approximately 59 months|Participant-reported tolerability, Proportion of all dosed participants reporting different levels of severity of diarrhoea as measured by the diarrhoea single item (EORTC IL237/IL239/IL240) and different levels of severity of abdominal pain as measured by the abdominal pain single item (EORTC IL237/IL239/IL240)., Up to approximately 59 months|Time to deterioration in patient-reported global health status/QoL as measured by the global health status/QoL scale within the The European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ), This scale includes 2 items asking participants to report overall health and overall quality of life in the past week. Both items are measured on a 6-point verbal rating scale ranging from Very Poor to Excellent. Single item scores are averaged to calculate a subscale score that is transformed to range from 0 to 100, where higher scores indicate better global health status/QoL., Up to approximately 59 months|Change from baseline in patient-reported global health status/QoL as measured by the global health status/QoL scale within the The European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ), This scale includes 2 items asking participants to report overall health and overall quality of life in the past week. Both items are measured on a 6-point verbal rating scale ranging from Very Poor to Excellent. Single item scores are averaged to calculate a subscale score that is transformed to range from 0 to 100, where higher scores indicate better global health status/QoL., Up to approximately 59 months|Plasma concentrations of saruparib (AZD5305), Up to approximately 59 months|Plasma concentrations of camizestrant, Up to approximately 59 months|Samples will be used to develop companion diagnostics by analyzing their performance characteristics and calculate their consistency with clinical trial assays used for enrolment onto the study., Samples will be tested by a CDx to confirm BRCA1/2 and PALB2 gene mutation status, Up to approximately 59 months",,AstraZeneca,,ALL,"ADULT, OLDER_ADULT",PHASE3,500,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-08-01,2029-03-30,2030-10-18,2024-04-24,,2025-05-15,"Research Site, Gilbert, Arizona, 85234, United States|Research Site, Glendale, California, 91206, United States|Research Site, Los Angeles, California, 90089, United States|Research Site, Newport Beach, California, 92663, United States|Research Site, Aurora, Colorado, 80045, United States|Research Site, Grand Junction, Colorado, 81501, United States|Research Site, Hollywood, Florida, 33021, United States|Research Site, Jacksonville, Florida, 32224, United States|Research Site, Orlando, Florida, 32806, United States|Research Site, Chicago, Illinois, 60611, United States|Research Site, Evanston, Illinois, 60201, United States|Research Site, Park Ridge, Illinois, 60068, United States|Research Site, Urbana, Illinois, 61801, United States|Research Site, Winfield, Illinois, 60190, United States|Research Site, Indianapolis, Indiana, 46227, United States|Research Site, Louisville, Kentucky, 40207, United States|Research Site, Silver Spring, Maryland, 20902, United States|Research Site, Boston, Massachusetts, 02215, United States|Research Site, Dearborn, Michigan, 48126, United States|Research Site, Detroit, Michigan, 48202, United States|Research Site, Royal Oak, Michigan, 48073, United States|Research Site, Royal Oak, Michigan, 48073, United States|Research Site, Rochester, Minnesota, 55905, United States|Research Site, Camden, New Jersey, 08103, United States|Research Site, New Brunswick, New Jersey, 08901, United States|Research Site, Bronx, New York, 10469, United States|Research Site, Brooklyn, New York, 11220, United States|Research Site, Mineola, New York, 11501, United States|Research Site, New Hyde Park, New York, 11042, United States|Research Site, New York, New York, 10016, United States|Research Site, New York, New York, 10028, United States|Research Site, New York, New York, 10065, United States|Research Site, Shirley, New York, 11967, United States|Research Site, Stony Brook, New York, 11790, United States|Research Site, Westbury, New York, 11590, United States|Research Site, Hershey, Pennsylvania, 17033, United States|Research Site, Philadelphia, Pennsylvania, 19104, United States|Research Site, Pittsburgh, Pennsylvania, 15215, United States|Research Site, West Columbia, South Carolina, 29169, United States|Research Site, Nashville, Tennessee, 37219, United States|Research Site, Houston, Texas, 77030, United States|Research Site, Houston, Texas, 77030, United States|Research Site, Houston, Texas, 77054, United States|Research Site, Norfolk, Virginia, 23502, United States|Research Site, Tacoma, Washington, 98405, United States|Research Site, Morgantown, West Virginia, 26506, United States|Research Site, Milwaukee, Wisconsin, 53215, United States|Research Site, Caba, C1280AEB, Argentina|Research Site, Ciudad AutÃ³noma Buenos Aires, 1125, Argentina|Research Site, Ciudad de Buenos Aires, 1015, Argentina|Research Site, Cordoba, 5008, Argentina|Research Site, Rosario, S2000KZE, Argentina|Research Site, Salta, A4400EMI, Argentina|Research Site, San Miguel de TucumÃ¡n, 4000, Argentina|Research Site, Darlinghurst, 2010, Australia|Research Site, Darlinghurst, 2139, Australia|Research Site, Malvern, 3144, Australia|Research Site, Melbourne, VIC 3000, Australia|Research Site, Graz, 8036, Austria|Research Site, Linz, 4010, Austria|Research Site, Wien, 1090, Austria|Research Site, Cachoeira De Itapemirim, 29308-055, Brazil|Research Site, Curitiba, 80060-900, Brazil|Research Site, Fortaleza, 60336-045, Brazil|Research Site, GoiÃ¢nia, 74000-000, Brazil|Research Site, JaÃº, 17210-120, Brazil|Research Site, Porto Alegre, 91350-200, Brazil|Research Site, RibeirÃ£o Preto, 14049-901, Brazil|Research Site, Salvador, 41253-190, Brazil|Research Site, Sao Paulo, 01509-900, Brazil|Research Site, SÃ£o Paulo, 03102-002, Brazil|Research Site, Plovdiv, 4002, Bulgaria|Research Site, Sofia, 1527, Bulgaria|Research Site, Stara Zagora, 6003, Bulgaria|Research Site, Vratza, 3000, Bulgaria|Research Site, Toronto, Ontario, M5G 2M9, Canada|Research Site, Greenfield Park, Quebec, J4V 2G9, Canada|Research Site, Montreal, Quebec, H3T 1E2, Canada|Research Site, Montreal, Quebec, H4A 3J1, Canada|Research Site, MontrÃ©al, Quebec, H2X 0A9, Canada|Research Site, Saskatoon, Saskatchewan, S7N 4H4, Canada|Research Site, Toronto, M4N 3M5, Canada|Research Site, Providencia, 7500994, Chile|Research Site, Recoleta, 8420391, Chile|Research Site, Santiago, 8330034, Chile|Research Site, Talca, 3461341, Chile|Research Site, Vina del Mar, 2520000, Chile|Research Site, Beijing, 100044, China|Research Site, Bengbu, 233004, China|Research Site, Changchun, 130012, China|Research Site, Changchun, 130021, China|Research Site, Changsha, 410008, China|Research Site, Changsha, 410013, China|Research Site, Chengdu, 610000, China|Research Site, Chengdu, 610072, China|Research Site, Chongqing, 400042, China|Research Site, Foshan, 528000, China|Research Site, Fuzhou, 350014, China|Research Site, Guangzhou, 510060, China|Research Site, Guangzhou, 510062, China|Research Site, Guangzhou, 510289, China|Research Site, Hangzhou, 310016, China|Research Site, Hangzhou, 310022, China|Research Site, Harbin, 150081, China|Research Site, Hefei, 230031, China|Research Site, Hohhot, 010017, China|Research Site, Jining, 272029, China|Research Site, Liuzhou, 545006, China|Research Site, Luoyang, 471000, China|Research Site, Nanchang, 330006, China|Research Site, Nanchang, 330009, China|Research Site, Nanjing, 210029, China|Research Site, Shandong, 250117, China|Research Site, Shanghai, 200025, China|Research Site, Shanghai, 200120, China|Research Site, Shenyang, 110016, China|Research Site, Shijiazhuang, 050000, China|Research Site, Tianjin, 300000, China|Research Site, Wuhan, 430030, China|Research Site, Wuhan, 430040, China|Research Site, Wuhan, 430079, China|Research Site, Xi'an, 710006, China|Research Site, Xi'an, 710061, China|Research Site, Xiamen, 361003, China|Research Site, Xiangfan, 441021, China|Research Site, Xinxiang, 453100, China|Research Site, Zhengzhou, 450008, China|Research Site, Brno, 656 53, Czechia|Research Site, Horovice, 26831, Czechia|Research Site, Hradec KrÃ¡lovÃ©, 500 05, Czechia|Research Site, Olomouc, 77900, Czechia|Research Site, Praha 2, 120 00, Czechia|Research Site, Praha 8, 180 00, Czechia|Research Site, Angers, 49100, France|Research Site, BesanÃ§on Cedex, 25030, France|Research Site, Lille, 59000, France|Research Site, Lyon, 69373, France|Research Site, Marseille, 13273, France|Research Site, Paris, 75005, France|Research Site, Rouen, 76021, France|Research Site, Saint-Herblain, 44805, France|Research Site, Toulouse, 31059, France|Research Site, Villejuif Cedex, 94805, France|Research Site, Aachen, 52074, Germany|Research Site, Augsburg, 86150, Germany|Research Site, Berlin, 13125, Germany|Research Site, Dessau-RoÃlau, 06847, Germany|Research Site, DÃ¼sseldorf, 40225, Germany|Research Site, Erlangen, 91054, Germany|Research Site, Goettingen, DE-37099, Germany|Research Site, Hamburg, 20357, Germany|Research Site, Hannover, 30625, Germany|Research Site, Heidelberg, 69120, Germany|Research Site, Kiel, 24105, Germany|Research Site, KÃ¶ln, 50937, Germany|Research Site, Leipzig, 04103, Germany|Research Site, Ludwigsburg, 71640, Germany|Research Site, MÃ¼nchen, 81675, Germany|Research Site, MÃ¼nster, 48149, Germany|Research Site, Budapest, 1082, Hungary|Research Site, Budapest, 1122, Hungary|Research Site, Budapest, 1145, Hungary|Research Site, Miskolc, 3526, Hungary|Research Site, Zalaegerszeg, 8900, Hungary|Research Site, Fort Myers, 33905, India|Research Site, Jodhpur, 342005, India|Research Site, Kolkata, 700160, India|Research Site, Luknow, 226003, India|Research Site, Mumbai, 400012, India|Research Site, Mumbai, 400052, India|Research Site, Mysuru, 570017, India|Research Site, Nagpur, 440001, India|Research Site, Nashik, 422002, India|Research Site, New Delhi, 110085, India|Research Site, Surat, 396007, India|Research Site, Jerusalem, 9103102, Israel|Research Site, Jerusalem, 9112001, Israel|Research Site, Petah Tikva, 49100, Israel|Research Site, Ramat Gan, 52621, Israel|Research Site, Tel Aviv, 64239, Israel|Research Site, Bergamo, 24127, Italy|Research Site, Bologna, 40138, Italy|Research Site, Milano, 20132, Italy|Research Site, Milano, 20141, Italy|Research Site, Modena, 41124, Italy|Research Site, Napoli, 80131, Italy|Research Site, Padova, 35128, Italy|Research Site, Reggio Emilia, 422122, Italy|Research Site, Rome, 00168, Italy|Research Site, Rozzano, 20089, Italy|Research Site, Chiba-shi, 260-8717, Japan|Research Site, Hidaka-shi, 350-1298, Japan|Research Site, Hirakata-shi, 573-1191, Japan|Research Site, Isehara-shi, 259-1193, Japan|Research Site, Kagoshima-shi, 892-0833, Japan|Research Site, Kashiwa, 227-8577, Japan|Research Site, Koto-ku, 135-8550, Japan|Research Site, Kumamoto-shi, 860-8556, Japan|Research Site, Kyoto-shi, 606-8507, Japan|Research Site, Matsuyama-shi, 791-0280, Japan|Research Site, Nagoya-shi, 464-8681, Japan|Research Site, Nagoya-shi, 466-8560, Japan|Research Site, Nagoya-shi, 467-8602, Japan|Research Site, Osaka-shi, 541-8567, Japan|Research Site, Ota-shi, 373-8550, Japan|Research Site, Sapporo-shi, 003-0804, Japan|Research Site, Sendai-shi, 980-8574, Japan|Research Site, Shinagawa-ku, 142-8666, Japan|Research Site, Suita-shi, 565-0871, Japan|Research Site, Sunto-gun, 411-8777, Japan|Research Site, Takasaki-shi, 370-0829, Japan|Research Site, Tsu-shi, 514-8507, Japan|Research Site, Yokohama-shi, 241-8515, Japan|Research Site, Daegu, 41404, Korea, Republic of|Research Site, Seongnam-si, 13620, Korea, Republic of|Research Site, Seoul, 02841, Korea, Republic of|Research Site, Seoul, 03080, Korea, Republic of|Research Site, Seoul, 06351, Korea, Republic of|Research Site, Seoul, 3722, Korea, Republic of|Research Site, Seoul, 5505, Korea, Republic of|Research Site, Johor Bahru, 81100, Malaysia|Research Site, Kuala Lumpur, 59100, Malaysia|Research Site, Melaka, 75000, Malaysia|Research Site, Puncak Alam, 42300, Malaysia|Research Site, Selangor, 62250, Malaysia|Research Site, Bellavista, CALLAO 2, Peru|Research Site, Jesus Maria, Lima, LIMA 11, Peru|Research Site, Lima, 15036, Peru|Research Site, Lima, LIMA 29, Peru|Research Site, BiaÅa Podlaska, 21-500, Poland|Research Site, PoznaÅ, 61-485, Poland|Research Site, Warszawa, 02-781, Poland|Research Site, ÅÃ³dÅº, 93-338, Poland|Research Site, Coimbra, 3000-075, Portugal|Research Site, Lisboa, 1099-023, Portugal|Research Site, Lisboa, 1998-018, Portugal|Research Site, Matosinhos, 4454-509, Portugal|Research Site, Porto, 4050-115, Portugal|Research Site, Vila Real, 5000-508, Portugal|Research Site, San Juan, 00918, Puerto Rico|Research Site, Barcelona, 08035, Spain|Research Site, Caceres, 10003, Spain|Research Site, Granada, 18007, Spain|Research Site, L'Hospitalet de Llobregat, 08908, Spain|Research Site, Madrid, 28040, Spain|Research Site, Madrid, 28041, Spain|Research Site, Malaga, 29010, Spain|Research Site, Pamplona, 31008, Spain|Research Site, Sevilla, 41013, Spain|Research Site, Valencia, 46006, Spain|Research Site, New Taipei City, 23561, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, 704, Taiwan|Research Site, Taipei, 100, Taiwan|Research Site, Taipei, 10449, Taiwan|Research Site, Taipei, 112, Taiwan|Research Site, Taoyuan, 00333, Taiwan|Research Site, Bangkok, 10210, Thailand|Research Site, Bangkok, 10330, Thailand|Research Site, Dusit, 10300, Thailand|Research Site, Hat Yai, 90110, Thailand|Research Site, Ratchathewi, 10400, Thailand|Research Site, Adapazari, 54290, Turkey|Research Site, AltÄ±ndaÄ-Ankara, 06230, Turkey|Research Site, Istanbul, 34214, Turkey|Research Site, Kayseri, 38039, Turkey|Research Site, Ãankaya, 06680, Turkey|Research Site, Cambridge, CB2 2QQ, United Kingdom|Research Site, Guildford, GU2 7XX, United Kingdom|Research Site, London, SE1 9RT, United Kingdom|Research Site, Manchester, M20 4BX, United Kingdom|Research Site, Oxford, OX3 7LE, United Kingdom|Research Site, Taunton, TA1 5DA, United Kingdom",
NCT04002297,A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation,https://clinicaltrials.gov/study/NCT04002297,MANGROVE,ACTIVE_NOT_RECRUITING,This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated participants with mantle cell lymphoma (MCL) who are not eligible for stem cell transplantation.,NO,Mantle Cell Lymphoma; Non-Hodgkin Lymphoma,DRUG: zanubrutinib|DRUG: bendamustine|DRUG: rituximab,"Progression-free survival (PFS) determined by independent central review, PFS is defined as the time from randomization to the date of first documentation of disease progression or death, whichever occurs first., Up to approximately 7 years","PFS by investigator assessment, PFS is defined as the time from randomization to the date of first documentation of disease progression or death, whichever occurs first., Up to approximately 7 years|Overall response rate (ORR), ORR is defined as the percentage of participants who achieve a complete response (CR) or partial response (PR), determined by independent central review and by investigator assessment., Up to approximately 7 years|Duration of response (DOR), DOR, as determined by independent central review and by investigator assessment, and defined as the time from the date that response criteria are first met to the date that disease progression is objectively documented or death, whichever occurs first., Up to approximately 7 years|Overall survival (OS), OS is defined as the time from randomization to the date of death due to any reason., Up to approximately 7 years|Time to Response (TTR), TTR, as determined by independent central review and by investigator assessment, and defined as the time from randomization to the first documentation of response., Up to approximately 7 years|Rate of complete response (CR) or complete metabolic response, Rate of CR or complete metabolic response is defined as the percentage of participants who achieve a CR or complete metabolic response, determined by independent central review and by investigator assessment., Up to approximately 7 years|Participant-reported outcomes (PROs) as assessed by the European Quality of Life 5-Dimension 5 Level Questionnaire (EQ-5D-5L), EuroQoL-Five Dimensions, Five Levels (EQ-5D-5L) is a generic, self-reported measure of utility that consists of a five-item descriptive system and a visual analogue scale (EQ VAS). The descriptive system involves five health dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Participants may choose from the following response levels: no problems=1; slight problems=2; moderate problems=3; severe problems=4; and unable to/extreme problems=5. Higher values indicate worst health., Up to approximately 7 years|PROs as assessed by the European Organization for Research on Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 =Not at all (best) to 4 =Very Much (worst) and 2 questions answered on a 7-point scale where 1 =Very poor (worst) to 7 =Excellent (best)., Up to approximately 7 years|Number of participants with adverse events and serious adverse events, Number of participants with adverse events and serious adverse events, including laboratory values, vital signs, and physical examination findings., Up to approximately 7 years",,BeiGene,,ALL,"ADULT, OLDER_ADULT",PHASE3,510,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2019-08-20,2027-03,2027-12,2019-06-28,,2025-02-21,"Chao Family Comprehensive Cancer Center, Orange, California, 92868, United States|Rush University Medical Center, Chicago, Illinois, 60612, United States|Beth Israel Deaconess Medical Center (Bidmc), Boston, Massachusetts, 02215-5400, United States|University of Michigan Health System, Ann Arbor, Michigan, 48109, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, 89169, United States|Icahn School of Medicine At Mount Sinai, New York, New York, 10029, United States|Clinical Research Alliance, Inc, Westbury, New York, 11590, United States|Providence Portland Medical Center, Portland, Oregon, 97213, United States|West Penn Hospital, Pittsburgh, Pennsylvania, 15224, United States|The University of Texas Md Anderson Cancer Center, Houston, Texas, 77030-4009, United States|Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, 79410, United States|Seattle Cancer Care Alliance, Seattle, Washington, 98109, United States|Canberra Hospital, Garran, Australian Capital Territory, 2605, Australia|Concord Repatriation General Hospital, Concord, New South Wales, 2139, Australia|The Tweed Valley Hospital, Cudgen, New South Wales, 2487, Australia|Saint Vincents Hospital Sydney, Darlinghurst, New South Wales, 2010, Australia|Gosford Hospital, Gosford, New South Wales, 2250, Australia|Calvary Mater Newcastle, Waratah, New South Wales, 2298, Australia|Sunshine Coast Hospital and Health Service, Birtinya, Queensland, 4575, Australia|Icon Cancer Foundation, South Brisbane, Queensland, 4101, Australia|Flinders Medical Centre, Bedford PK, South Australia, 5042, Australia|Royal Hobart Hospital, Hobart, Tasmania, 7000, Australia|Monash Health, Clayton, Victoria, 3168, Australia|St Vincents Hospital Melbourne, Fitzroy, Victoria, 3065, Australia|Peninsula Private Hospital, Frankston, Victoria, 3199, Australia|Barwon Health the Geelong Hospital, Geelong, Victoria, 3220, Australia|Royal Perth Hospital, Perth, Western Australia, 6000, Australia|Ordensklinikum Linz Gmbh Elisabethinen, Linz, 4020, Austria|Universitatsklinik Fur Innere Medizin Iii Universitatsklinikum Der Pmu Landeskrankenhaus Salzburg, Salzburg, 5020, Austria|Medical University Vienna Oncology, Vienna, 1090, Austria|Az Sint Jan Brugge, Brugge, 8000, Belgium|Universitair Ziekenhuis Brussel, Brussels, 1090, Belgium|Uz Antwerpen, Edegem, 2650, Belgium|Az Groeninge Campus Loofstraat, Kortrijk, 8500, Belgium|Centre Hospitalier Universitaire (Chu) de Liege Site Du Sart Tilman, Liege, 4000, Belgium|Centre Hospitalier Universitaire Universite Catholique de Louvain Site Godinne, Yvoir, 5530, Belgium|The Ottawa Hospital, Ottawa, Ontario, K1H 8M2, Canada|Ciusss de Lestrie Chus, Sherbrooke, Quebec, J1H 5N4, Canada|Peking University Peoples Hospital, Beijing, Beijing, 100044, China|Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, 100050, China|Fujian Medical University Union Hospital, Fuzhou, Fujian, 350001, China|Quanzhou First Affliated Hospital of Fujian Medical University, Quanzhou, Fujian, 362000, China|Sun Yat Sen University Cancer Center, Guangzhou, Guangdong, 510060, China|Guangdong Provincial Peoples Hospital, Guangzhou, Guangdong, 510080, China|Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, 510515, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150000, China|Henan Cancer Hospital, Zhengzhou, Henan, 450000, China|Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China|Hunan Cancer Hospital, Changsha, Hunan, 410013, China|Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, 210008, China|Jiangsu Province Hospital, Nanjing, Jiangsu, 210029, China|The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221000, China|The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang, Jiangxi, 330006, China|Jilin Cancer Hospital, Changchun, Jilin, 130021, China|The First Hospital of Jilin University, Changchun, Jilin, 130021, China|Shengjing Hospital of China Medical University, Shenyang, Liaoning, 110004, China|Fudan University Shanghai Cancer Center, Shanghai, Shanghai, 200000, China|Shanghai East Hospital, Shanghai, Shanghai, 200120, China|West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China|Institute of Hematology and Hospital of Blood Disease, Tianjin, Tianjin, 300020, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, 300060, China|Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, Xinjiang, 830000, China|The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310003, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, 310022, China|Hwa Mei Hospital, University of Chinese Academy of Sciences (Ningbo No Hospital), Ningbo, Zhejiang, 315000, China|Centre de Lutte Contre Le Cancer Institut Bergonie, Bordeaux, 33076, France|Chru de Brest Hospital Morvan, Brest, 29200, France|Chu Dijon, Dijon, J4V 2H1, France|Chu Grenoble Alpes, Grenoble Cedex, 38043, France|Centre Hospitalier Le Mans, Le Mans, 72037, France|Hopital Claude Huriez Chu Lille, Lille, 59000, France|Institut Paoli Calmettes, Marseille, 13009, France|Centre Hospitalier Universitaire Nantes Hotel Dieu, Nantes Cedex, 44093, France|Institut Curie, Paris, 75005, France|Necker University Hospital, Paris, 75015, France|Chu Hopital Lyon Sud, PierreBenite, 69495, France|Centre Hospitalier Universitaire de Poitier Hopital de La Miletrie Hopital Jean Bernard, Poitiers, 86000, France|Ch Cornouaille, Quimper, 29000, France|Iuc Toulouse Oncopole, Toulouse, 31059, France|Universitatsklinikum Heidelberg, Heidelberg, 69120, Germany|Uniklinik Koln (Aor), Koln, 50937, Germany|Dept of Medicine Iii, University Hospitallmu, Munich, 81377, Germany|Universitaetsklinikum Ulm, Innere Medizin Iii, Ulm, 89081, Germany|Petrus Krankenhaus Wuppertal, Wuppertal, 42283, Germany|Cork University Hospital, Cork, t12DC4A, Ireland|Mater Misericordiae University Hospital, Dublin, D7, Ireland|St Jamess Hospital, Dublin, D8, Ireland|University Hospital Galway, Galway, H91 YR71, Ireland|University Hospital Limerick, Limerick, V94F858, Ireland|University Hospital Waterford, Waterford, X91 ER8E, Ireland|Azienda Ospedaliera Nazionale Ssantonio E Biagio E Cesare Arrigo, Alessandria, 15121, Italy|Policlinico Sorsola Malpighi, Aou Di Bologna, Bologna, 40138, Italy|Azienda Ospedaliera Universitaria San Martino, Genova, 16132, Italy|Niguarda Cancer Center Division of Hematology, Milano, 20162, Italy|Aou Maggiore Della Carita, Novara, 28100, Italy|Aoor Villa Sofia Cervello, Palermo, 90146, Italy|Aou Pisana, Stabilimento Di Santa Chiara, Pisa, 56126, Italy|Unita Di Ematologia, Dipartimento Di Ematologia Ed Oncologia, Ravenna, 48121, Italy|Azienda Unita Sanitaria Locale Irccs, Reggio Emilia, 42123, Italy|Universita Degli Studi La Sapienza, Roma, 00161, Italy|Aou Senese Policlinico Santa Maria Alle Scotte, Siena, 53100, Italy|Ao Citta Della Salute E Della Scienza Di Torino Presidio O, Torino, 10126, Italy|University of Verona, Verona, 37142, Italy|National Hospital Organization Nagoya Medical Center, Nagoyashi, Aichi, 460-0001, Japan|Toyohashi Municipal Hospital, Toyohashi, Aichi, 441-8570, Japan|Chiba Cancer Center, Chibashi, Chiba, 260-8717, Japan|Kurume University Hospital, Kurume, Fukuoka, 830-0011, Japan|Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital, Hiroshimashi, Hiroshima, 730-8619, Japan|Kanagawa Cancer Center, Yokohamashi, Kanagawa, 241-8515, Japan|National Hospital Organization Kumamoto Medical Center, Kumamotoshi, Kumamoto, 860-0008, Japan|Tohoku University Hospital, Sendaishi, Miyagi, 980-8574, Japan|Kurashiki Central Hospital, Kurashikishi, Okayama, 710-8602, Japan|Osaka Red Cross Hospital, Osakashi, Osaka, 543-8555, Japan|National Cancer Center Hospital, Chuoku, Tokyo, 104-0045, Japan|University Hospital, Kyoto Prefectural Univ of Medicine, Kyoto, 602-8566, Japan|National Hospital Organization Okayama Medical Center, Okayama, 701-1192, Japan|Osaka Metropolitan University Hospital, Osaka, 545-8586, Japan|Tokyo Medical and Dental University Hospital, Tokyo, 113-8519, Japan|Yokohama Municipal Citizens Hospital, Yokohamashi, 221-0855, Japan|Hagaziekenhuis, Den Haag, 2545 CH, Netherlands|Admiraal de Ruijter Ziekenhuis, Goes, 4462 RA, Netherlands|University of Medical Center Groningen (Umcg), Groningen, 9713 GZ, Netherlands|St Antonius Ziekenhuis, Randd Interne Geneeskunde (F), Nieuwegein, 3435 CM, Netherlands|Albert Schweitzer Ziekenhuis, Nijmegen, 6525 GA, Netherlands|Erasmus Mc, Rotterdam, 3015 GD, Netherlands|Christchurch Hospital (Canterbury Health Laboratories), Christchurch, 8011, New Zealand|Tauranga Hospital, Tauranga, 3112, New Zealand|Szpital Uniwersytecki Nr Im Dr Jana Biziela, Bydgoszcz, 85-168, Poland|Silesian Healthy Blood Clinic, Chorzow, 41-503, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, 80-952, Poland|Copernicus Podmiot Leczniczy Sp Z Oo Wojewodzkie Centrum Onkologii, Gdask, 80-219, Poland|Szpitale Pomorskie Spolka Z Ograniczona Odpowiedzialnoscia, Gdynia, 81-519, Poland|Pratia McM Krakow, Krakow, 30-727, Poland|Wojewodzki Szpital Specjalistyczny W Legnicy, Legnica, 59-220, Poland|Wielospecjalistyczne Centrum Onkologii I Traumatologii Im M Kopernika W Lodzi, Lodz, 93-510, Poland|Centrum Onkologii Ziemi Lubelskiej, Lublin, 20-090, Poland|Specjalistyczny Szpital Im Dr Alfreda Sokolowskiego, Walbrzych, 58-309, Poland|Instytut Hematologii I Transfuzjologii W Warszawie, Warszawa, 02-776, Poland|Uniwersytecki Szpital Kliniczny Im Jana Mikulicza Radeckiego We Wroclawiu, Wroclaw, 50-556, Poland|Chuln Hospital de Santa Maria, Lisboa, 1649-035, Portugal|Instituto Portugues Oncologia de Lisboa Francisco Gentil, Epe, Lisbon, 1099-023, Portugal|Centro Hospitalar Universitario Porto, Porto, 4099-001, Portugal|Instituto Portugues de Oncologia Do Porto Francisco Gentil, Epe, Porto, 4200-072, Portugal|Institutul Clinic Fundeni, Bucuresti, 022328, Romania|Institutul Regional de Oncologie Iasi, Iasi, 700483, Romania|Clinical Hospital, Sp Botkin, Moscow, Moskva, 125284, Russian Federation|Fgu Russian Scientific Research Institute of Hematology and Transfusiology, Saint Petersburg, Sankt-Peterburg, 191024, Russian Federation|Leningrad Regional Clinic and Hospital, Saint Petersburg, Sankt-Peterburg, 194291, Russian Federation|Gbuz Mmcc Kommunarka Dzm, Moscow, 142770, Russian Federation|Hospital Universitario Vall Dhebron, Barcelona, 08035, Spain|Institut Catala Doncologia, Barcelona, 08908, Spain|Ico Hug Trias I Pujol, Barcelona, 08916, Spain|Ico Girona, Girona, 17007, Spain|Hospital Universitario Gregorio Maranon, Madrid, 28009, Spain|Md Anderson Cancer Center Madrid Spain, Madrid, 28033, Spain|Start Madrid Fundacion Jimenez Diaz, Madrid, 28040, Spain|Hospital Universitario La Paz, Madrid, 28046, Spain|Hospital Regional Universitario de Malaga, Malaga, 29010, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, 41013, Spain|National Cheng Kung University Hospital, Tainan, 704, Taiwan|Chi Mei Hospital Liouying, Tainan, 736, Taiwan|Tri Service General Hospital, Taipei, 114, Taiwan|Dr Abdurrahman Yurtaslan Oncology Teaching and Research Hospital, Ankara, 06620, Turkey|Hematoloji Ve Hematolik Onkoloji Tani Ve Tedavi Merezi, Ankara, 06700, Turkey|Gazi University, Ankara, 6500, Turkey|Tr Trakya University Health Research and Application Center (Hospital), Edirne, 22030, Turkey|Vkv American Hospital, Istanbul, 34365, Turkey|Mersin Universitesi Tip Fakultesi Hastanesi, Mersin, 33000, Turkey|Cherkasy Regional Oncology Dispensary, Cherkasy, 18009, Ukraine|Municipal Non Profit Enterprise City Clinical Hospital, Dnipro, 49102, Ukraine|National Cancer Institute, Kiev, 3022, Ukraine|Si Institute of Blood Pathology and Transfusion Medicine Nams of Ukraine, Hematology Department, Lviv, 79044, Ukraine|Aneurin Bevan University Health Board, Abergavenny, NP7 7EG, United Kingdom|Birmingham Heartlands Hospital, Birmingham, B9 5SS, United Kingdom|Russells Hall Hopsital, Dudley, DY1 2HQ, United Kingdom|Royal Marsden Nhs Foundation Royal Marsden Hospital, Sutton, SM2 5PT, United Kingdom",
NCT05173987,Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15),https://clinicaltrials.gov/study/NCT05173987,,ACTIVE_NOT_RECRUITING,"The purpose of this study is to assess the safety and efficacy of treatment with pembrolizumab (MK-3475) compared to a combination of carboplatin and paclitaxel in women with mismatch repair deficient (dMMR) advanced or recurrent endometrial carcinoma who have not previously been treated with prior systemic chemotherapy.

The primary study hypotheses are that pembrolizumab is superior to the combination of carboplatin and paclitaxel with respect to Progression Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and Overall Survival (OS).",NO,Endometrial Neoplasms,BIOLOGICAL: pembrolizumab|DRUG: carboplatin|DRUG: paclitaxel|DRUG: docetaxel|DRUG: cisplatin,"Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR), PFS is defined as the time from randomization to the first documented disease progression (PD) per RECIST 1.1 or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as â¥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of â¥5 mm. Note: The appearance of one or more lesions and the unequivocal progression of non-target lesions is also considered PD. The PFS per RECIST 1.1 as assessed by BICR will be reported for participants., Up to approximately 45 months|Overall Survival, OS is defined as the time from randomization to death due to any cause. The OS will be reported for all participants., Up to approximately 59 months","Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR), ORR is defined as the percentage of participants who have a best response of confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience CR or PR as assessed by BICR will be presented., Up to approximately 45 months|Disease Control Rate (DCR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR), DCR is defined, per RECIST 1.1, as the percentage of participants who have achieved Complete Response (CR: Disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) or demonstrated Stable Disease (SD) for at least 24 weeks. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD: At least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD.) The DCR as assessed by BICR will be presented., Up to approximately 45 months|Duration of Response (DOR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR), DOR is defined as the time from first documented evidence of CR or PR until the first documented date of disease progression (PD) or death due to any cause, whichever occurs first, for participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by BICR will be presented., Up to approximately 45 months|Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Investigator, PFS is defined as the time from randomization to the first documented disease progression (PD) per RECIST 1.1 or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as â¥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of â¥5 mm. Note: The appearance of one or more lesions and the unequivocal progression of non-target lesions is also considered PD. The PFS per RECIST 1.1 as assessed by investigator will be reported for participants., Up to approximately 45 months|Progression-Free Survival 2 (PFS2) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Investigator, PFS2 is defined as the time from randomization to subsequent disease progression (PD) per RECIST 1.1 after initiation of a new anticancer therapy, or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as â¥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of â¥5 mm. Note: The appearance of one or more lesions and the unequivocal progression of non-target lesions is also considered PD. The PFS2 per RECIST 1.1 as assessed by investigator will be reported for participants., Up to approximately 45 months|Number of Participants Who Experience at Least One Adverse Event (AE), An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experience an AE will be reported., Up to approximately 27 months|Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE), An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinue study treatment due to an AE will be reported., Up to approximately 24 months|Change From Baseline in European Organization for Research And Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (GHS) (Item 29) And Quality of Life (QoL) (Item 30) Combined Score, The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions ""How would you rate your overall health during the past week?"" and ""How would you rate your overall quality of life during the past week?"" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status. The change from baseline in EORTC QLQ-C30 Items 29 and 30 combined score will be presented., Baseline and up to approximately 25 months|Change From Baseline in European Organization for Research And Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Physical Functioning (Items 1-5) Combined Score, The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The change from baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) score will be presented. A higher score indicates a better quality of life., Baseline and up to approximately 25 months",,Merck Sharp & Dohme LLC,European Network of Gynaecological Oncological Trial Groups (ENGOT)|GOG Foundation,FEMALE,"ADULT, OLDER_ADULT",PHASE3,280,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-02-03,2027-05-27,2027-05-27,2021-12-30,,2024-11-21,"HonorHealth-USOR HonorHealth ( Site 8000), Phoenix, Arizona, 85016, United States|Moores Cancer Center ( Site 0037), La Jolla, California, 92093-0698, United States|Kaiser Permanente Riverside Medical Center ( Site 0045), Riverside, California, 92505, United States|Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0013), New Haven, Connecticut, 06511, United States|Mount Sinai Cancer Center ( Site 0018), Miami Beach, Florida, 33140, United States|Sarasota Memorial Hospital ( Site 0005), Sarasota, Florida, 34239, United States|Northside Hospital ( Site 0017), Atlanta, Georgia, 30342, United States|Southeastern Regional Medical Center ( Site 0046), Newnan, Georgia, 30265, United States|Midwestern Regional Medical Center,Inc. DBA CTCA, Chicago ( Site 0003), Zion, Illinois, 60099, United States|St. Vincent Hospital and Health Care Center, Inc ( Site 0006), Indianapolis, Indiana, 46260, United States|Baptist Health Lexington ( Site 0042), Lexington, Kentucky, 40503, United States|Maryland Oncology Hematology, P.A.-USOR Maryland Oncology Hematology, P.A. ( Site 8002), Rockville, Maryland, 20850, United States|University of Massachusetts Medical School-Division of Gynecologic Oncology ( Site 0008), Worcester, Massachusetts, 01605, United States|Karmanos Cancer Institute ( Site 0029), Detroit, Michigan, 48201, United States|St. Dominic's Hospital ( Site 0024), Jackson, Mississippi, 39216, United States|John Theurer Cancer Center at Hackensack University Medical Center ( Site 0026), Hackensack, New Jersey, 07601, United States|The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 0023), New York, New York, 10011, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0016), New York, New York, 10016, United States|Icahn School of Medicine at Mount Sinai ( Site 0052), New York, New York, 10029, United States|Memorial Sloan Kettering Cancer Center ( Site 0009), New York, New York, 10065, United States|FirstHealth Clinical Trials ( Site 0050), Pinehurst, North Carolina, 28374, United States|Sanford Medical Center ( Site 0054), Bismarck, North Dakota, 58501, United States|Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0055), Fargo, North Dakota, 58122, United States|University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0039), Cincinnati, Ohio, 45219, United States|The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C, Columbus, Ohio, 43210, United States|Providence Portland Medical Center ( Site 0031), Portland, Oregon, 97213, United States|Sidney Kimmel Cancer Center - Jefferson Health ( Site 0053), Philadelphia, Pennsylvania, 19107, United States|University of Pittsburgh Medical Center Magee-Womens Hospital ( Site 0034), Pittsburgh, Pennsylvania, 15213, United States|AHN West Penn Hospital ( Site 0011), Pittsburgh, Pennsylvania, 15224, United States|Asplundh Cancer Pavilion ( Site 0014), Willow Grove, Pennsylvania, 19090, United States|Sanford Cancer Center-Gynecologic Oncology ( Site 0002), Sioux Falls, South Dakota, 57104, United States|Texas Oncology - Austin-USOR Texas Oncology - Austin ( Site 8003), Austin, Texas, 78731, United States|Texas Oncology - Dallas-USOR Texas Oncology - Dallas (Sammons) ( Site 8005), Dallas, Texas, 75246, United States|Texas Oncology - Tyler-USOR Texas Oncology - Northeast Texas ( Site 8004), Tyler, Texas, 75702, United States|VCU Health Adult Outpatient Pavillion ( Site 0022), Richmond, Virginia, 23219, United States|Northern Cancer Institute ( Site 0206), St Leonards, New South Wales, 2065, Australia|Westmead Hospital-Department of Gynaecological Oncology ( Site 0201), Westmead, New South Wales, 2145, Australia|Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Si, Brisbane, Queensland, 4029, Australia|Monash Health ( Site 0202), Clayton, Victoria, 3168, Australia|Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 0207), Melbourne, Victoria, 3000, Australia|Epworth Freemasons ( Site 0203), Melbourne, Victoria, 3002, Australia|St. John of God Subiaco Hospital-Oncology Clinical Trials Unit ( Site 0204), Subiaco, Western Australia, 6008, Australia|Institut Jules Bordet-Medicine Oncology ( Site 0321), Bruxelles, Bruxelles-Capitale, Region De, 1000, Belgium|Grand HÃ´pital de Charleroi-Oncology & Hematology ( Site 0323), Charleroi, Hainaut, 6000, Belgium|Centre Hospitalier Universitaire de LiÃ¨ge - Domaine Universitaire du Sart Tilman ( Site 0320), LiÃ¨ge, Liege, 4000, Belgium|Liga Norte Riograndense Contra o CÃ¢ncer-Centro de Pesquisa ClÃ­nica ( Site 3005), Natal, Rio Grande Do Norte, 59075-740, Brazil|ICESP - INSTITUTO DO CÃNCER DO ESTADO DE SÃO PAULO ( Site 3001), SÃ£o Paulo, Sao Paulo, 01246-000, Brazil|A. C. Camargo Cancer Center-CAPEC ( Site 3003), Sao Paulo, 01509-010, Brazil|Cross Cancer Institute ( Site 0513), Edmonton, Alberta, T6G 1Z2, Canada|BC Cancer Kelowna ( Site 0517), Kelowna, British Columbia, V1Y 5L3, Canada|BC Cancer Vancouver-Clinical Trials Unit ( Site 0518), Vancouver, British Columbia, V5Z 4E6, Canada|Sunnybrook Health Sciences - Odette Cancer Centre ( Site 0509), Toronto, Ontario, M4N 3M5, Canada|Princess Margaret Cancer Centre ( Site 0510), Toronto, Ontario, M5G 2M9, Canada|Jewish General Hospital ( Site 0504), Montreal, Quebec, H3T 1E2, Canada|Centre Hospitalier de l'UniversitÃ© de MontrÃ©al ( Site 0519), MontrÃ©al, Quebec, H2X 3E4, Canada|McGill University Health Centre ( Site 0505), MontrÃ©al, Quebec, H4A 3J1, Canada|Saskatoon Cancer Center-Clinical Research Department ( Site 0520), Saskatoon, Saskatchewan, S7N4H4, Canada|FALP-UIDO ( Site 0602), Santiago, Region M. De Santiago, 7500921, Chile|Pontificia Universidad Catolica de Chile-Centro del CÃ¡ncer ( Site 0604), Santiago, Region M. De Santiago, 8330032, Chile|Bradfordhill-Clinical Area ( Site 0603), Santiago, Region M. De Santiago, 8420383, Chile|Anhui Provincial Hospital-Obstetrics and Gynecology ( Site 0730), Hefei, Anhui, 230001, China|Beijing Obstetric and Gynecology Hospital ( Site 0740), Beijing, Beijing, 100026, China|Peking University First Hospital ( Site 0723), Beijing, Beijing, 100034, China|Beijing Cancer hospital ( Site 0715), Beijing, Beijing, 100142, China|Southwest Hospital of Third Military Medical University ( Site 0719), Chongqing, Chongqing, 400038, China|2nd Affiliated Hospital Chongqing Medical Universi ( Site 0745), Chongqing, Chongqing, 400072, China|Fuling Central Hospital ( Site 0733), Fulingqu, Chongqing, 408000, China|Fujian Provincial Cancer Hospital ( Site 0720), Fuzhou, Fujian, 350014, China|SUN YAT-SEN UNIVERSITY CANCER CENTRE ( Site 0710), Guangzhou, Guangdong, 510060, China|Cancer Hospital of Shantou University Medical College ( Site 0732), Shantou, Guangdong, 515041, China|Affiliated Hospital of Guangdong Medical College ( Site 0731), Zhanjiang, Guangdong, 524004, China|Guangxi Medical University Affiliated Tumor Hospital-Gynecological oncology ( Site 0704), Nanning, Guangxi, 530021, China|Hainan General Hospital ( Site 0703), Haikou, Hainan, 570311, China|Harbin Medical University Cancer Hospital ( Site 0711), Harbin, Heilongjiang, 150081, China|Henan Cancer Hospital ( Site 0713), Zhengzhou, Henan, 450008, China|Wuhan Union Hospital-Medical Oncology ( Site 0716), Wuhan, Hubei, 430022, China|Xiangya Hospital Central South University-Gynecology ( Site 0708), Changsha, Hunan, 410008, China|Hunan Cancer Hospital ( Site 0709), Changsha, Hunan, 410013, China|Jiangsu Province Hospital-Oncology Department ( Site 0707), Nanjing, Jiangsu, 210003, China|The First Affiliated Hospital of Nanchang University ( Site 0729), Nanchang, Jiangxi, 330006, China|The First Hospital of Jilin University ( Site 0705), Changchun, Jilin, 130021, China|Shaanxi Provincial Cancer Hospital ( Site 0714), XI An, Shaanxi, 710061, China|Binzhou Medical University Hospital-Oncology department ( Site 0735), Binzhou, Shandong, 256603, China|Obstetrics & Gynecology Hospital of Fudan University ( Site 0702), Shanghai, Shanghai, 200011, China|Shanghai First Maternity and Infant Hospital-Gynecology department ( Site 0717), Shanghai, Shanghai, 201204, China|West China Second University Hospital Sichuan University ( Site 0701), Chengdu, Sichuan, 610066, China|Tianjin Medical University Cancer Institute and Hospital ( Site 0706), Tianjin, Tianjin, 300060, China|Yunnan Province Cancer Hospital-Gynecology Department ( Site 0721), Kunming, Yunnan, 650118, China|The Affiliated Women's Hospital of Zhejiang University-Obstetrics and Gynecology ( Site 0726), Hangzhou, Zhejiang, 310006, China|Zhejiang Cancer Hospital-Oncology ( Site 0700), Hangzhou, Zhejiang, 310022, China|The First Affiliated Hospital of Wenzhou Medical University-Gynecology ( Site 0725), Wenzhou, Zhejiang, 325000, China|FakultnÃ­ nemocnice Brno Bohunice-Gynekologicko-porodnicka klinika ( Site 0404), Brno, Brno-mesto, 62500, Czechia|Fakultni nemocnice Ostrava-Gynekologicko-porodnicka klinika ( Site 0403), Ostrava, Moravskoslezsky Kraj, 708 52, Czechia|Nemocnice AGEL Novy Jicin a.s.-Oddeleni radioterapie a onkologie ( Site 0406), NovÃ½ JiÃ­n, Novy Jicin, 741 01, Czechia|Fakultni nemocnice Olomouc-Onkologicka klinika ( Site 0402), Olomouc, Olomoucky Kraj, 779 00, Czechia|Vseobecna fakultni nemocnice v Praze-Gynekologicko-porodnicka klinika 1.LF a VFN ( Site 0405), Praha, Praha 2, 12808, Czechia|Fakultni nemocnice Bulovka-Gynekologicko-porodnicka klinika ( Site 0401), Praha, Praha 8, 180 00, Czechia|Nemocnice Tomase Bati ve Zline-OnkologickÃ© oddÄlenÃ­ ( Site 0407), ZlÃ­n, Zlinsky Kraj, 762 75, Czechia|Fakultni nemocnice Kralovske Vinohrady-Gynekologicko-porodnickÃ¡ klinika ( Site 0408), Praha 10, 10034, Czechia|Rigshospitalet ( Site 0903), Copenhagen, Hovedstaden, 2100, Denmark|Herlev and Gentofte Hospital ( Site 0902), Copenhagen, Hovedstaden, 2730, Denmark|Aalborg Universitetshospital, Syd ( Site 0905), Aalborg, Nordjylland, 9000, Denmark|Roskilde Sygehus-Oncology department ( Site 0904), Roskilde, Sjaelland, DK-4000, Denmark|Tampereen yliopistollinen sairaala-Gynecology and Obstetrics ( Site 1001), Tampere, Pirkanmaa, 33520, Finland|Kuopion Yliopistollinen Sairaala ( Site 1002), Kuopio, Pohjois-Savo, 70210, Finland|Helsinki University Hospital - Comprehensive Cancer Center (HYKS - SyÃ¶pÃ¤keskus) ( Site 1003), Helsinki, Uusimaa, 00290, Finland|Universitaetsklinikum Ulm ( Site 1106), Ulm, Baden-Wurttemberg, 89081, Germany|UniversitÃ¤tsklinikum Bonn-Gynaecological oncology ( Site 1105), Bonn, Nordrhein-Westfalen, 53127, Germany|Universitaetsklinikum Carl Gustav Carus Dresden-Klinik und Poliklinik fÃ¼r Frauenheilkunde und Gebur, Dresden, Sachsen, 01307, Germany|CharitÃ© Campus Virchow-Klinikum ( Site 1103), Berlin, 13353, Germany|OrszÃ¡gos OnkolÃ³giai IntÃ©zet-NgyÃ³gyÃ¡szat ( Site 1201), Budapest, 1122, Hungary|Bon Secours Cork Hospital ( Site 1305), Cork, T12 DV56, Ireland|St. James's Hospital-Cancer clinical trials office ( Site 1301), Dublin, D08 E9P6, Ireland|Soroka Medical Center ( Site 1403), Be'er Sheva, 8410101, Israel|Rambam Health Care Campus-Gyneco-oncology unit ( Site 1402), Haifa, 3109601, Israel|Edith Wolfson Medical Center-Obstetrics & Gynecology ( Site 1405), Holon, 5822012, Israel|Shaare Zedek Medical Center ( Site 1404), Jerusalem, 9103102, Israel|Sheba Medical Center ( Site 1401), Ramat Gan, 5265601, Israel|Istituto Nazionale Tumori IRCCS Fondazione Pascale-S.C. Oncologia Sperimentale Uro-Genitale ( Site 1, Napoli, Campania, 80131, Italy|IRCCS - AOU di Bologna-SSD Oncologia medica Addarii ( Site 1503), Bologna, Emilia-Romagna, 40138, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori-Oncologia Medica ( Site 1513), Meldola, Emilia-Romagna, 47014, Italy|Fondazione Policlinico Universitario Agostino Gemelli-Ginecologia Oncologica ( Site 1502), Roma, Lazio, oo168, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Chirurgia Ginecologica ( Site 150, Milan, Lombardia, 20133, Italy|Ospedale Mauriziano-SCDU ONCOLOGIA MEDICA ( Site 1514), Torino, Piemonte, 10128, Italy|Istituto Nazionale Tumori Regina Elena-Oncologia Medica 1 ( Site 1504), Rome, Roma, 00144, Italy|Azienda Ospedaliera Universitaria Careggi-SOD ONCOLOGIA MEDICA ( Site 1509), Firenze, Toscana, 50134, Italy|AULSS8 Berica-Ospedale S.Bortolo-ONCOLOGIA CLINICA ( Site 1510), Vicenza, Veneto, 36100, Italy|Istituto Europeo di Oncologia IRCCS-Divisione di Ginecologia Oncologica ( Site 1506), Milano, 20141, Italy|National Cancer Center Hospital East ( Site 1604), Kashiwa, Chiba, 277-8577, Japan|National Hospital Organization Shikoku Cancer Center ( Site 1611), Matsuyama, Ehime, 791-0280, Japan|Ehime University Hospital ( Site 1614), Toon, Ehime, 791-0295, Japan|Kurume University Hospital ( Site 1612), Kurume, Fukuoka, 830-0011, Japan|Gunma Prefectural Cancer Center-Gynecology ( Site 1603), Ota, Gunma, 373-8550, Japan|Hokkaido University Hospital ( Site 1601), Sapporo, Hokkaido, 060-8648, Japan|Tsukuba University Hospital ( Site 1618), Tsukuba, Ibaraki, 305-8576, Japan|Iwate Medical University Hospital ( Site 1602), Shiwa-gun Yahaba-cho, Iwate, 028-3695, Japan|Niigata University Medical & Dental Hospital ( Site 1613), Chuo-ku, Niigata, Niigata, 951-8520, Japan|Saitama Medical University International Medical Center ( Site 1605), Hidaka-shi, Saitama, 350-1200, Japan|Shizuoka Cancer Center ( Site 1609), Nagaizumi-cho,Sunto-gun, Shizuoka, 411-8777, Japan|National Cancer Center Hospital ( Site 1607), Chuo-ku, Tokyo, 104-0045, Japan|Japanese Foundation for Cancer Research ( Site 1616), Koto, Tokyo, 135-8550, Japan|The Jikei University Hospital ( Site 1615), Minato-ku, Tokyo, 105-8471, Japan|Keio university hospital ( Site 1606), Shinjyuku-ku, Tokyo, 160-8582, Japan|National Hospital Organization Kyushu Cancer Center ( Site 1608), Fukuoka, 811-1395, Japan|Osaka International Cancer Institute ( Site 1617), Osaka, 541-8567, Japan|Seoul National University Hospital ( Site 2302), Seoul, 03080, Korea, Republic of|Severance Hospital, Yonsei University Health System-Gynecologic cancer center ( Site 2301), Seoul, 03722, Korea, Republic of|Asan Medical Center-Division of Gynecologic Oncology, Dept. of Obstetrics & Gynecology ( Site 2303), Seoul, 05505, Korea, Republic of|Gangnam Severance Hospital ( Site 2304), Seoul, 06273, Korea, Republic of|Radboudumc-Medical Oncology ( Site 1703), Nijmegen, Gelderland, 6525 GA, Netherlands|Maastricht UMC+ ( Site 1709), Maastricht, Limburg, 6229 HX, Netherlands|Catharina Ziekenhuis-Oncology ( Site 1704), Eindhoven, Noord-Brabant, 5623 EJ, Netherlands|Amsterdam UMC, locatie AMC ( Site 1706), Amsterdam, Noord-Holland, 1105 AZ, Netherlands|Leids Universitair Medisch Centrum-Medical Oncology ( Site 1702), Leiden, Zuid-Holland, 2333 ZA, Netherlands|Erasmus Medisch Centrum-Medical Oncology ( Site 1701), Rotterdam, Zuid-Holland, 3015 GD, Netherlands|University Medical Center Groningen ( Site 1707), Groningen, 9713 GZ, Netherlands|Universitair Medisch Centrum Utrecht-Medical Oncology ( Site 1705), Utrecht, 3584 CX, Netherlands|Auckland City Hospital-Cancer & Blood Research ( Site 1801), Auckland, 1023, New Zealand|Oslo universitetssykehus, Radiumhospitalet ( Site 1901), Oslo, 0379, Norway|Centrum Onkologii Ziemi Lubelskiej ( Site 2006), Lublin, Lubelskie, 20-090, Poland|Mazowiecki Szpital WojewÃ³dzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 2007), Siedlce, Mazowieckie, 08-110, Poland|Szpital Kliniczny im. KsiÄÅ¼nej Anny Mazowieckiej ( Site 2009), Warsaw, Mazowieckie, 00-315, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Ginekologii Onkologicznej ( Sit, Warszawa, Mazowieckie, 02-781, Poland|Bialostockie Centrum Onkologii-Oddzial Onkologii Ginekologicznej ( Site 2003), Bialystok, Podlaskie, 15-027, Poland|Narodowy Instytut Onkologii - Oddzial w Gliwicach-III Klinika Radioterapii i Chemioterapii ( Site 20, Gliwice, Slaskie, 44-102, Poland|Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zaklad Opieki Zdrowotnej ( Site 2010), Kielce, Swietokrzyskie, 25-734, Poland|Szpital Kliniczny im. Heliodora ÅwiÄcickiego Uniwersytetu Me-Oddzial Ginekologii Onkologicznej ( Sit, Poznan, Wielkopolskie, 61-848, Poland|Moscow City Oncology Hospital #62 ( Site 2204), Krasnogorsk, Moskovskaya Oblast, 143423, Russian Federation|Yaroslavl Regional Cancer Hospital-Oncology ( Site 2202), Yaroslavl, Yaroslavskaya Oblast, 150054, Russian Federation|Institut CatalÃ  d'Oncologia - L'Hospitalet-Medical Oncology ( Site 2406), Hospitalet, Barcelona, 08907, Spain|CHUAC-Complejo Hospitalario Universitario A CoruÃ±a ( Site 2405), A CoruÃ±a, La Coruna, 15006, Spain|Hospital Universitario RamÃ³n y Cajal-Medical Oncology ( Site 2402), Madrid, Madrid, Comunidad De, 28034, Spain|COMPLEJO HOSPITALARIO DE NAVARRA ( Site 2407), Pamplona, Navarra, 31009, Spain|FundaciÃ³n Instituto Valenciano de OncologÃ­a-Oncologico ( Site 2404), Valencia, Valenciana, Comunitat, 46009, Spain|Hospital Universitari Vall d'Hebron ( Site 2403), Barcelona, 08035, Spain|HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO ( Site 2401), Sevilla, 41013, Spain|SkÃ¥nes Universitetssjukhus Lund-Department of Hematology ( Site 2504), Lund, Skane Lan, 22185, Sweden|Karolinska Universitetssjukhuset Solna ( Site 2502), Solna, Stockholms Lan, 171 64, Sweden|Norrlands universitetssjukhus-Cancercentrum ( Site 2503), UmeÃ¥, Vasterbottens Lan, 901 85, Sweden|Taichung Veterans General Hospital ( Site 2602), Taichung, 407, Taiwan|NATIONAL CHENG-KUNG UNI. HOSP. ( Site 2604), Tainan, 704, Taiwan|National Taiwan University Hospital ( Site 2603), Taipei, 10002, Taiwan|Mackay Memorial Hospital ( Site 2601), Taipei, 10449, Taiwan|Taipei Veterans General Hospital ( Site 2605), Taipei, 11217, Taiwan|Istanbul Universitesi Cerrahpasa ( Site 2702), Fatih, Istanbul, 34098, Turkey|Hacettepe Universite Hastaneleri-oncology hospital ( Site 2704), Ankara, 06230, Turkey|Ankara Bilkent Åehir Hastanesi-Medical Oncology ( Site 2706), Ankara, 06800, Turkey|Akdeniz Universitesi Hastanesi ( Site 2701), Antalya, 07070, Turkey|Istanbul University Capa Campus-department of obstetrics and gynaecology ( Site 2705), Istanbul, 34093, Turkey|T.C. Saglik Bakanligi Turkiye Kamu Hastaneleri Kurumu - Bakirkoy Dr. Sadi Konuk Egitim ve Arastirma, Istanbul, 34440, Turkey|St Bartholomew's Hospital ( Site 2804), London, England, EC1A 7BE, United Kingdom|The Christie ( Site 2807), Manchester, England, M20 4BX, United Kingdom|The Beatson West of Scotland Cancer Centre ( Site 2805), Glasgow, Glasgow City, G12 0YN, United Kingdom|ROYAL MARSDEN HOSPITAL (CHELSEA) ( Site 2806), London, London, City Of, SW3 6JJ, United Kingdom|Hammersmith Hospital-Medical Oncology ( Site 2808), London, London, City Of, W12 OHS, United Kingdom",
NCT06561386,A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression â¥ 1%,https://clinicaltrials.gov/study/NCT06561386,RELATIVITY1093,RECRUITING,The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression â¥ 1%,NO,Non-small Cell Lung Cancer,DRUG: Nivolumab|DRUG: Relatlimab|DRUG: Pembrolizumab|DRUG: Carboplatin|DRUG: Pemetrexed|DRUG: Cisplatin,"Overall survival (OS) in randomized participants with PD-L1 1% to 49%, Up to 5 years","OS in randomized participants with PD-L1 â¥ 1%, Up to 5 years|Progression-free survival (PFS) as assessed by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) per blinded independent central review (BICR), Up to 5 years|Overall response rate (ORR), Up to 5 years|Duration of response (DoR), Up to 5 years|Number of participants with adverse events (AEs), Up to 2.5 years|Number of participants with serious adverse events (SAEs), Up to 2.5 years|Number of participants with immune-mediated adverse events (IMAEs), Up to 2.5 years|The time until definitive deterioration based on non-small cell lung cancer - symptom assessment questionnaire (NSCLC-SAQ) total score, Up to 2 years",,Bristol-Myers Squibb,,ALL,"ADULT, OLDER_ADULT",PHASE3,1000,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-10-07,2030-07-30,2033-11-11,2024-08-20,,2025-05-29,"Local Institution - 0368, Tucson, Arizona, 85723, United States|Local Institution - 0112, Los Angeles, California, 90404, United States|Local Institution - 0304, Sacramento, California, 95817, United States|San Francisco Oncology Associates, San Francisco, California, 94115, United States|UCLA Hematology/Oncology - Santa Monica, Santa Monica, California, 90404, United States|University of Miami Hospital and Clinics, Sylvester Cancer Center, Miami, Florida, 33136, United States|Memorial Hospital West, Pembroke Pines, Florida, 33028, United States|Florida Cancer Specialists - North, Saint Petersburg, Florida, 33705, United States|Florida Cancer Specialists - East, West Palm Beach, Florida, 33401, United States|Affiliated Oncologists, LLC, Chicago Ridge, Illinois, 60415, United States|Saint Elizabeth Medical Center Edgewood, Edgewood, Kentucky, 41017, United States|Hattiesburg Clinic Hematology/Oncology, Hattiesburg, Mississippi, 39401-7233, United States|Bozeman Health Deaconess Hospital, Bozeman, Montana, 59715, United States|Renown Regional Medical Center, Reno, Nevada, 89502, United States|St. Joseph's Regional Medical Center, Paterson, New Jersey, 07503, United States|New Mexico VA Healthcare System, Albuquerque, New Mexico, 87108, United States|Local Institution - 0357, Bronx, New York, 10468, United States|Local Institution - 0356, Hawthorne, New York, 10532, United States|Local Institution - 0392, New York, New York, 10016, United States|Local Institution - 0380, Northport, New York, 11768, United States|Local Institution - 0325, Rochester, New York, 14642, United States|Local Institution - 0324, Syracuse, New York, 13210, United States|Messino Cancer Centers, Asheville, North Carolina, 28806, United States|Local Institution - 0351, Greenville, North Carolina, 27858, United States|Local Institution - 0369, Canton, Ohio, 44708, United States|Local Institution - 0141, Cincinnati, Ohio, 45219, United States|Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio, 44106, United States|Local Institution - 0366, Massillon, Ohio, 44646, United States|Lancaster General Hospital - Ann B Barshinger Cancer Institute, Lancaster, Pennsylvania, 17601, United States|Texas Oncology - West Texas, Abilene, Texas, 79606-5208, United States|Local Institution - 0305, Harlingen, Texas, 78550, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|The University of Texas Health Science Center at Tyler dba UT Health East Texas HOPE Cancer Center, Tyler, Texas, 75701, United States|Local Institution - 0302, Salt Lake City, Utah, 84112, United States|Local Institution - 0379, Ciudad autÃ³noma de Buenos Aires, Buenos Aires, 1280, Argentina|Instituto Alexander Fleming, Ciudad AutÃ³noma de Buenos Aires, Buenos Aires, C1426ANZ, Argentina|Hospital Italiano de Buenos Aires, ABB, Ciudad AutÃ³noma De Buenos Aires, C1199ABB, Argentina|Instituto MÃ©dico RÃ­o Cuarto, RÃ­o Cuarto, CÃ³rdoba, X5800AEV, Argentina|Sanatorio Parque, Rosario, Santa Fe, S2000DSV, Argentina|Hospital Privado Universitario de CÃ³rdoba, CÃ³rdoba, 5016, Argentina|Local Institution - 0370, CÃ³rdoba, X5000HWE, Argentina|Hospital Privado de Comunidad, Mar del Plata, 7600, Argentina|Gosford Hospital, Gosford, New South Wales, 2250, Australia|GenesisCare North Shore, St Leonards, New South Wales, 2065, Australia|The Prince Charles Hospital, Brisbane, Queensland, 4032, Australia|Gallipoli Medical Research Ltd, Brisbane, Queensland, 4120, Australia|Local Institution - 0057, Elizabeth Vale, South Australia, 5112, Australia|Box Hill Hospital, Box Hill, Victoria, 3128, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, 6150, Australia|St. John of God Murdoch Hospital, Murdoch, Western Australia, 6150, Australia|Local Institution - 0314, Krems, NiederÃ¶sterreich, 3500, Austria|Local Institution - 0292, Wels, OberÃ¶sterreich, 4600, Austria|Local Institution - 0293, Wien, 1210, Austria|Local Institution - 0396, Edegem, Antwerpen, 2650, Belgium|Local Institution - 0039, Brussels, Bruxelles-Capitale, RÃ©gion De, 1090, Belgium|Local Institution - 0187, Hasselt, Limburg, 3500, Belgium|Local Institution - 0038, Yvoir, Namur, 5530, Belgium|Local Institution - 0041, Roeselare, West-Vlaanderen, 8800, Belgium|Local Institution - 0185, LiÃ¨ge, 4000, Belgium|Pronutrir, Fortaleza, CearÃ¡, 60810180, Brazil|Cetus Oncologia - Unidade Belo Horizonte, Belo Horizonte, Minas Gerais, 30110-022, Brazil|Local Institution - 0375, Belem, ParÃ¡, 66063-495, Brazil|Local Institution - 0151, Natal, Rio Grande Do Norte, 59075-740, Brazil|Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, 90035-903, Brazil|Hospital SÃ£o Lucas da PUCRS, Porto Alegre, Rio Grande Do Sul, 90610-000, Brazil|ClÃ­nica de Neoplasias Litoral, ItajaÃ­, Santa Catarina, 88301-220, Brazil|FundaÃ§Ã£o Pio XII - Hospital de CÃ¢ncer de Barretos, Barretos, SÃ£o Paulo, 14784400, Brazil|NAIC - Instituto do CÃ¢ncer, Bauru, SÃ£o Paulo, 17033-490, Brazil|Centro de Oncologia - CEON+ - Unidade SÃ£o Caetano do Sul, SÃ£o Caetano do Sul, SÃ£o Paulo, 09541-270, Brazil|Instituto Nacional de CÃ¢ncer - INCA, Rio de Janeiro, 20231-050, Brazil|Icesp - Instituto Do CÃ¢ncer Do Estado de SÃ£o Paulo, SÃ£o Paulo, 01246-000, Brazil|Orlandi Oncologia, Santiago, RegiÃ³n Metropolitana De Santiago, 0, Chile|Fundacion Arturo Lopez Perez (FALP), Santiago, RegiÃ³n Metropolitana De Santiago, 7500921, Chile|Pontificia Universidad Catolica de Chile, Santiago, RegiÃ³n Metropolitana De Santiago, 8330032, Chile|Bradfordhill, Santiago, RegiÃ³n Metropolitana De Santiago, 8420383, Chile|Local Institution - 0452, ViÃ±a del Mar, ValparaÃ­so, 2520598, Chile|Local Institution - 0182, Hefei, Anhui, 230031, China|Beijing Cancer hospital, Beijing, Beijing, 100142, China|Chongqing University Cancer Hospital, Chongqing, Chongqing, 400030, China|Chongqing Three Gorges Central Hospital, Wanzhou, Chongqing, 404000, China|Fujian Cancer Hospital, Fuzhou, Fujian, 350014, China|Local Institution - 0307, Guangzhou, Guangdong, 510080, China|The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510080, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510140, China|Huizhou Central People's Hospital, Huizhou, Guangdong, 516001, China|Liuzhou People's Hospital, Liuzhou, Guangxi, 545006, China|Guangxi Medical University Affiliated Tumor Hospital, Nanning, Guangxi, 530201, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China|Local Institution - 0420, Xinxiang, Henan, 453100, China|The First Affiliated Hospital of Zhengzhou Universtiy, Zhengzhou, Henan, 450000, China|Local Institution - 0235, Wuhan, Hubei, 430079, China|Hunan Cancer Hospital, Changsha, Hunan, 410013, China|First Huai'an Hospital Affiliated to Nanjing Medical University, Huai'an, Jiangsu, 223300, China|Local Institution - 0451, Nanchang, Jiangxi, 330209, China|Liaoning Cancer Hospital, Shenyang, Liaoning, 110042, China|Xi'an International Medical Center Hospital, Xi'an, Shaanxi, 710126, China|Shandong Cancer Hospital, Jinan, Shandong, 250117, China|Shanghai Chest Hospital, Shanghai, Shanghai, 200030, China|Shanghai Chest Hospital, Shanghai, Shanghai, 200030, China|Zhongshan Hospital,Fudan University, Shanghai, Shanghai, 200032, China|Local Institution - 0435, Taiyuan, Shanxi, 030000, China|Sichuan Cancer hospital, Chengdu, Sichuan, 610041, China|Local Institution - 0424, Neijiang, Sichuan, 641000, China|Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, 300060, China|The first Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310003, China|Sir Run Run Shaw Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310016, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, 310022, China|Taizhou Hospital of Zhejiang Province, Linhai, Zhejiang, 317000, China|Local Institution - 0415, MedellÃ­n, Antioquia, 0, Colombia|Local Institution - 0417, Valledupar, Cesar, 200001, Colombia|Local Institution - 0443, BogotÃ¡, Distrito Capital De BogotÃ¡, 0, Colombia|Local Institution - 0418, BogotÃ¡, Distrito Capital De BogotÃ¡, 110131, Colombia|Local Institution - 0416, Pereira, Risaralda, 660001, Colombia|Local Institution - 0442, Cali, Valle Del Cauca, 760032, Colombia|Local Institution - 0198, Aarhus, Midtjylland, 8200, Denmark|Local Institution - 0124, Soenderborg, Syddanmark, 6400, Denmark|Local Institution - 0125, Copenhagen, 2100, Denmark|Local Institution - 0090, Toulouse, Haute-Garonne, 31059, France|Local Institution - 0092, Montpellier, HÃ©rault, 34298, France|Local Institution - 0093, Rennes, Ille-et-Vilaine, 35033, France|Local Institution - 0395, Vandoeuvre lÃ¨s Nancy, Meurthe-et-Moselle, 54511, France|Local Institution - 0096, Lille, Nord-Pas-de-Calais, 59037, France|Local Institution - 0091, Toulon, Provence-Alpes-CÃ´te-d'Azur, 83100, France|Local Institution - 0157, Pierre-BÃ©nite, RhÃ´ne, 69310, France|Local Institution - 0421, Bayonne, 64109, France|Local Institution - 0158, Marseille, 13915, France|Local Institution - 0089, Paris, 75014, France|Local Institution - 0095, Paris, 75248, France|Local Institution - 0284, Esslingen, Baden-WÃ¼rttemberg, 73730, Germany|Local Institution - 0439, Ulm, Baden-WÃ¼rttemberg, 89081, Germany|Local Institution - 0287, Kempten, Bayern, 87439, Germany|Local Institution - 0347, MÃ¼nchen, Bayern, 81377, Germany|Local Institution - 0313, Marburg, Hessen, 35033, Germany|Local Institution - 0436, Hannover, Niedersachsen, 30161, Germany|Local Institution - 0397, Herne, Nordrhein-Westfalen, 44651, Germany|Local Institution - 0438, MÃ¼nster, Nordrhein-Westfalen, 48149, Germany|Local Institution - 0437, Chemnitz, Sachsen, 09116, Germany|Local Institution - 0316, Grosshansdorf, Schleswig-Holstein, 22927, Germany|Local Institution - 0285, Berlin, 13353, Germany|Local Institution - 0282, Bonn, 53127, Germany|Local Institution - 0288, Essen, 45122, Germany|Local Institution - 0286, Gauting, 82131, Germany|Local Institution - 0329, New Delhi, Delhi, 110029, India|Local Institution - 0448, New Delhi, Delhi, 110029, India|Local Institution - 0337, New Delhi, Delhi, 110085, India|Local Institution - 0333, Bengaluru, Karnataka, 560017, India|Local Institution - 0331, Thiruvananthapuram, Kerala, 695011, India|Local Institution - 0446, Mumbai, Maharashtra, 400 057, India|Local Institution - 0336, Mumbai, Maharashtra, 400012, India|Local Institution - 0453, Secunderabad, Telangana, 500003, India|Local Institution - 0328, Howrah, West Bengal, 711103, India|Local Institution - 0367, Dublin, D08 E9P6, Ireland|Local Institution - 0028, Dublin, D18 AK68, Ireland|Local Institution - 0029, Dublin, D24 NR0A, Ireland|Local Institution - 0027, Dublin, D9, Ireland|Local Institution - 0400, Ravenna, Emilia-Romagna, 48121, Italy|Local Institution - 0045, Monza, Lombardia, 20900, Italy|Local Institution - 0046, Naples, Napoli, 80131, Italy|Local Institution - 0049, Naples, Napoli, 80131, Italy|Local Institution - 0043, Bari, Puglia, 70124, Italy|Local Institution - 0250, Rome, Roma, 00144, Italy|Local Institution - 0221, Peschiera del Garda, Verona, 37019, Italy|Local Institution - 0222, Ravenna, 48121, Italy|Local Institution - 0312, Kashiwa, Chiba, 277-8577, Japan|University of Occupational and Enviromental Health, Kitakyushu, Fukuoka, 807-8556, Japan|Kurume University Hospital, Kurume, Fukuoka, 830-0011, Japan|Chugoku Central Hospital, Fukuyama-shi, Hiroshima, 720-0001, Japan|National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, 003-0804, Japan|Local Institution - 0449, Yokohama, Kanagawa, 236-0051, Japan|Kanagawa cancer center, Yokohama, Kanagawa, 2418515, Japan|Local Institution - 0444, Nankoku, Kochi, 783-8505, Japan|Sendai Kousei Hospital, Sendai, Miyagi, 9810914, Japan|Nara Medical University Hospital, Kashihara, Nara, 634-0813, Japan|Niigata Cancer Center Hospital, Niigata-shi, Niigata, 951-8566, Japan|Kurashiki Central Hospital, Kurashiki, Okayama, 710-8602, Japan|Kansai Medical University Hospital, Hirakata, Osaka, 573-1191, Japan|Kindai University Hospital- Osakasayama Campus, Osaka-sayama, Osaka, 589-8511, Japan|Saitama Medical University International Medical Center, Hidaka, Saitama, 350-1298, Japan|Hamamatsu University Hospital, Hamamatsu, Shizuoka, 431-3192, Japan|Shizuoka Cancer Center, Nagaizumi-cho,Sunto-gun, Shizuoka, 411-8777, Japan|The Cancer Institute Hospital of JFCR, Koto, Tokyo, 135-8550, Japan|Hyogo Cancer Center, Akashi, 6738558, Japan|Fukushima Medical University, Fukushima, 960-1295, Japan|Osaka International Cancer Institute, Osaka, 541-8567, Japan|Chungbuk National University Hospital, Cheongju-si, Chungcheongbuk-do [Chungbuk], 28644, Korea, Republic of|Gachon University Gil Medical Center, Namdong-gu, Incheon-gwangyeoksi [Incheon], 21565, Korea, Republic of|Local Institution - 0458, Hwasun, Jeonranamdo, 58128, Korea, Republic of|National Cancer Center, Goyang-si, KyÇnggi-do, 10408, Korea, Republic of|Local Institution - 0450, Seongnam-si, KyÇnggi-do, 13496, Korea, Republic of|Local Institution - 0454, Busan, Pusan-KwangyÇkshi, 49241, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Seoul-teukbyeolsi [Seoul], 03722, Korea, Republic of|Asan Medical Center, Seoul, Seoul-teukbyeolsi [Seoul], 05505, Korea, Republic of|Samsung Medical Center, Seoul, Seoul-teukbyeolsi [Seoul], 06351, Korea, Republic of|Local Institution - 0170, Guadalajara, Jalisco, 44260, Mexico|Local Institution - 0168, Santiago de Queretaro, QuerÃ©taro, 76000, Mexico|Local Institution - 0172, Mexico, 06700, Mexico|Local Institution - 0169, San Luis PotosÃ­, 78250, Mexico|Local Institution - 0030, Harderwijk, Gelderland, 3844 DG, Netherlands|Local Institution - 0193, Heerlen, Limburg, 6419 PC, Netherlands|Local Institution - 0196, Den Bosch, Noord-Brabant, 5223 GZ, Netherlands|Local Institution - 0195, Zwolle, Overijssel, 8025 AB, Netherlands|Local Institution - 0036, Leiden, Zuid-Holland, 2333 ZA, Netherlands|Local Institution - 0315, The Hague, Zuid-Holland, 2512 VA, Netherlands|Local Institution - 0033, Arnhem, 6815 AD, Netherlands|Local Institution - 0032, Groningen, 9700 RB, Netherlands|Local Institution - 0407, Tauranga, Bay Of Plenty, 3112, New Zealand|Local Institution - 0447, Tauranga, Bay Of Plenty, 3112, New Zealand|Local Institution - 0405, Auckland, 1023, New Zealand|Local Institution - 0425, Dunedin, 9016, New Zealand|Local Institution - 0406, Wellington, 6021, New Zealand|Local Institution - 0259, Warsaw, Mazowieckie, 04-125, Poland|Local Institution - 0258, Prabuty, Pomorskie, 82-550, Poland|Local Institution - 0255, Konin, Wielkopolskie, 62-500, Poland|Local Institution - 0261, Poznan, Wielkopolskie, 60-693, Poland|Local Institution - 0256, PoznaÅ, Wielkopolskie, 60-192, Poland|Local Institution - 0257, Koszalin, Zachodniopomorskie, 75-581, Poland|Local Institution - 0260, Bydgoszcz, 85796, Poland|Local Institution - 0254, ÅÃ³dÅº, ÅÃ³dzkie, 93-338, Poland|Local Institution - 0402, Lisbon, Lisboa, 1099-023, Portugal|Local Institution - 0404, Coimbra, 3040, Portugal|Local Institution - 0403, Porto, 4200-072, Portugal|Local Institution - 0401, Porto, 4200-319, Portugal|Local Institution - 0296, Bucharest, BucureÈti, 013812, Romania|Local Institution - 0298, Bucharest, BucureÈti, 022338, Romania|Local Institution - 0299, FloreÈti, Cluj, 407280, Romania|Local Institution - 0295, Craiova, Dolj, 200542, Romania|Local Institution - 0297, PloieÈti, Prahova, 100337, Romania|Local Institution - 0301, Cluj, 400015, Romania|Local Institution - 0300, IaÈi, 700483, Romania|Local Institution - 0408, Riyadh, Ar RiyÄá¸, 11426, Saudi Arabia|Local Institution - 0440, Dammam, Ash SharqÄ«yah, 31444, Saudi Arabia|Local Institution - 0409, Jeddah, Makkah Al Mukarramah, 23433, Saudi Arabia|Local Institution - 0429, Johannesburg, GP, 2193, South Africa|Local Institution - 0432, Pretoria, GP, 0181, South Africa|Local Institution - 0427, Sandton, GP, 2196, South Africa|Local Institution - 0431, Soweto, GP, 2013, South Africa|Local Institution - 0428, Cape Town, Western Cape, 7570, South Africa|Local Institution - 0270, A CoruÃ±a, A CoruÃ±a [La CoruÃ±a], 15006, Spain|Local Institution - 0264, Barcelona, Barcelona [Barcelona], 08035, Spain|Local Institution - 0434, Barcelona, Catalunya [CataluÃ±a], 08041, Spain|Local Institution - 0267, L'Hospitalet de Llobregat, Catalunya [CataluÃ±a], 08908, Spain|Local Institution - 0414, Palma, Illes Balears [Islas Baleares], 07198, Spain|Local Institution - 0413, Madrid, Madrid, Comunidad De, 28034, Spain|Local Institution - 0265, Madrid, Madrid, Comunidad De, 28041, Spain|Local Institution - 0426, Majadahonda, Madrid, Comunidad De, 28222, Spain|Local Institution - 0411, Valencia, ValÃ¨ncia, 46015, Spain|Local Institution - 0266, MÃ¡laga, 29011, Spain|Local Institution - 0268, Sevilla, 41013, Spain|Local Institution - 0269, ValÃ¨ncia, 46026, Spain|Local Institution - 0341, Bellinzona, Ticino, 6500, Switzerland|Local Institution - 0291, Lausanne, Vaud, 1011, Switzerland|Local Institution - 0290, Basel, 4031, Switzerland|Local Institution - 0398, MÃ¼nsterlingen, 8596, Switzerland|Local Institution - 0445, Kaohsiung Niao Sung Dist, Kaohsiung, 83301, Taiwan|Taipei Medical University Shuang Ho Hospital, New Taipei, 235, Taiwan|Taichung Veterans General Hospital, Taichung, 407, Taiwan|National Taiwan University Hospital, Taipei, 10002, Taiwan|Taipei Veterans General Hospital, Taipei, 11217, Taiwan|Local Institution - 0361, Adana, 01140, Turkey|Local Institution - 0365, Adana, 01370, Turkey|Local Institution - 0383, Ankara, 06230, Turkey|Local Institution - 0362, Ankara, 06800, Turkey|Local Institution - 0410, Istanbul, 34214, Turkey|Local Institution - 0364, Istanbul, 34722, Turkey|Local Institution - 0441, Exeter, Devon, EX2 5DW, United Kingdom|Ninewells Hospital and Medical School, Dundee, Dundee City, DD1 9SY, United Kingdom|Forth Valley Royal Hospital, Larbert, Falkirk, FK5 4WR, United Kingdom|Local Institution - 0189, Glasgow, Glasgow City, g12OYN, United Kingdom|Local Institution - 0021, London, Kensington And Chelsea, SW3 6JJ, United Kingdom|St Bartholomew's Hospital, London, London, City Of, EC1A 7BE, United Kingdom|Local Institution - 0001, London, London, City Of, SE1 9RT, United Kingdom|Local Institution - 0020, Manchester, M20 4BX, United Kingdom|Local Institution - 0024, Wirral, CH63 4JY, United Kingdom",
NCT04765059,A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT04765059,COMPEL,ACTIVE_NOT_RECRUITING,The study will evaluate the efficacy and safety of treatment with chemotherapy in combination with osimertinib compared to chemotherapy in combination with placebo in patients whose disease has progressed extracranially following first-line osimertinib treatment.,NO,Non-small Cell Lung Cancer,DRUG: Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin|DRUG: Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin,"Progression free survival(PFS):time from randomization until progression(intra- or extracranial whichever occurs first)per RECIST 1.1(for extracranial)and CNS RECIST 1.1(for intracranial progression)as assessed by Investigator or death due to any cause, To compare the efficacy of chemotherapy plus osimertinib treatment relative to chemotherapy plus placebo based on PFS, At Screening,every 6 weeks for the first 13 cycles (each cycle is 21 days),then every 12 weeks, relative to randomization,and upto intracranial or extracranial disease progression or end of survival follow-up,whichever comes first (approximately 3 years)","Intracranial PFS is defined as time from randomization until intracranial progression per CNS RECIST 1.1 as assessed by the Investigator at local site or death due to any cause, To compare the efficacy of chemotherapy plus osimertinib treatment relative to chemotherapy plus placebo based on intracranial PFS in patients with baseline brain metastases and patients without baseline brain metastases, At Screening,every 6 weeks for the first 13 cycles (each cycle is 21 days), then every 12 weeks, relative to randomization, and upto intracranial disease progression or end of survival follow-up, whichever comes first (approximately 3 years)|Extracranial PFS is defined as time from randomization until extracranial progression per RECIST 1.1 as assessed by the Investigator at local site or death due to any cause, To compare the efficacy of chemotherapy plus osimertinib treatment relative to chemotherapy plus placebo based on extracranial PFS, At Screening,every 6 weeks for the first 13 cycles (each cycle is 21 days), then every 12 weeks, relative to randomization, and upto extracranial disease progression or end of survival follow-up, whichever comes first (approximately 3 years)|OS: the length of time from randomization until the date of death due to any cause, To compare the efficacy of chemotherapy plus osimertinib treatment relative to chemotherapy plus placebo based on OS, From randomization through post progression survival follow-up (up to approximately 3 years)|Number of patients with serious and non-serious adverse events, To assess the safety and tolerability of chemotherapy plus osimertinib treatment relative to chemotherapy plus placebo in patients with locally advanced or metastatic EGFRm NSCLC whose disease has progressed extracranially on first-line osimertinib treatment., From screening through post progression survival follow-up (at least once every 12 weeks relative to randomization)",,AstraZeneca,Parexel,ALL,"ADULT, OLDER_ADULT",PHASE3,98,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-09-12,2024-10-28,2025-12-29,2021-02-21,,2025-04-06,"Research Site, Silver Spring, Maryland, 20910, United States|Research Site, Boston, Massachusetts, 02114, United States|Research Site, Beijing, 100005, China|Research Site, Beijing, 100142, China|Research Site, Ganzhou, 341099, China|Research Site, Guangzhou, 510080, China|Research Site, Hohhot, 010017, China|Research Site, Jinan, 250013, China|Research Site, Shenyang, 110001, China|Research Site, Tianjin, 300060, China|Research Site, Zhengzhou City, 450008, China|Research Site, Berlin, 12351, Germany|Research Site, Hannover, 30625, Germany|Research Site, KÃ¶ln, 50937, Germany|Research Site, KÃ¶ln, 51109, Germany|Research Site, MÃ¼nchen, D-80336, Germany|Research Site, Beer Sheva, 84101, Israel|Research Site, Jerusalem, 9103102, Israel|Research Site, Jerusalem, 9112001, Israel|Research Site, Kfar Saba, 4428164, Israel|Research Site, Tel Aviv, 6423906, Israel|Research Site, Tel Hashomer, 52621, Israel|Research Site, Firenze, 50134, Italy|Research Site, Meldola, 47014, Italy|Research Site, Messina, 98158, Italy|Research Site, Napoli, 80131, Italy|Research Site, Padova, 35128, Italy|Research Site, Roma, 00168, Italy|Research Site, Terni, 05100, Italy|Research Site, Verona, 37124, Italy|Research Site, Alicante, 03010, Spain|Research Site, Barcelona, 08907, Spain|Research Site, Cordoba, 14004, Spain|Research Site, LeÃ³n, 24071, Spain|Research Site, Madrid, 28040, Spain|Research Site, Murcia, 30008, Spain|Research Site, MÃ¡laga, 29010, Spain|Research Site, Oviedo, 33011, Spain|Research Site, Palma de Mallorca, 07010, Spain|Research Site, Sevilla, 41013, Spain|Research Site, Valencia, 46010, Spain",
NCT05652894,A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT05652894,,NOT_YET_RECRUITING,"The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS), achieved by HX008 or Investigator's Choice Chemotherapy in participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer (mCRC).",NO,Metastatic Colorectal Cancer,DRUG: HX008|DRUG: Investigator's Choice Chemotherapy,"Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Independent Review Committee(IRC), PFS, defined as the time from randomization to the first documented disease progression per RECIST 1.1 assessed by IRC or death due to any cause, whichever occurs first., 2 years","Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Investigators, PFS, defined as the time from randomization to the first documented disease progression per RECIST 1.1 assessed by investigators or death due to any cause, whichever occurs first., 2 years|Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by IRC or investigators, ORR, defined as the percentage of subjects achieving complete response (CR) and partial response (PR)., 2 years|Disease Control Rate (DCR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by IRC or investigators, DCR, defined as the proportion of subjects achieving CR, PR, and Stable disease(SD) after treatment., 2 years|Duration of Response (DOR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by IRC or investigators, DOR, defined as the duration from the initial recording of objective disease response to the first onset of tumor progression, or death of any cause., 2 years|Overall Survival (OS), OS, defined as the duration from the start of treatment to death of any cause., 2 years|Immune Progression-free Survival (iPFS)-Experimental group per iRECIST assessed by IRC/investigators, iPFS, defined as the time from randomization to the first documented disease immune progression per iRECIST assessed by IRC/investigators or death due to any cause, whichever occurs first., 2 years|Immune Objective Response Rate (iORR)-Experimental group per iRECIST assessed by IRC/investigators, iORR, defined as the proportion of subjects with a best overall response (BOR) of immune complete response (iCR) or immune partial response (iPR) based on the immunotherapy Response Evaluation Criteria in Solid Tumors (iRECIST) by IRC/investigators., 2 years|Immune Disease Control Rate (iDCR) -Experimental group per iRECIST assessed by IRC/investigators, response, a partial response or stable disease according to immune Response Evaluation Criteria In Solid Tumors (iRECIST) criteria by IRC/investigators over the the total number of evaluable patients., 2 years|Immune Duration of Response (iDOR)-Experimental group per iRECIST assessed by IRC/investigators, iDOR, defined as the time from the date of the first immune response (iCR or iPR) to the date of immune confirmed progressive disease (iCPD) based on the immunotherapy Response Evaluation Criteria in Solid Tumors (iRECIST) by IRC/investigators., 2 years|Objective tumor response rate 2 (ORR2) (crossover phase) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by IRC or investigators, ORR2, defined as proportion of subjects with best overall response of CR or PR, in progressors who continue to receive HX008 in crossover group., 2 years|Disease Control Rate 2 (DCR 2) (crossover phase) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by IRC or investigators, DCR2, defined as the proportion of subjects achieving CR, PR, and SD after treatment who continue to receive HX008 in crossover group., 2 years|Duration of Response 2 (DOR2) (crossover phase) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by IRC or investigators, DOR2, defined as the duration from the initial recording received HX008 in crossover group of objective disease response to the second onset of tumor progression, or death of any cause., 2 years|Progression-free Survival 2 (PFS2) (crossover phase) per Response Evaluation Criteria in Solid Tumors, PFS2, defined as duration of time until 2nd confirmed objective disease progression or death (or last documentation of being alive)., 2 years|Immune Objective Response Rate 2 (iORR2) (crossover phase) per iRECIST assessed by IRC/investigators, iORR2, defined as the proportion of subjects with a best overall response (BOR) of immune complete response (iCR) or immune partial response (iPR) in progressors who continue to receive HX008 in crossover group based on the immunotherapy Response Evaluation Criteria in Solid Tumors (iRECIST) by IRC/investigators., 2 years|Immune Disease Control Rate 2 (iDCR2) (crossover phase) per iRECIST assessed by IRC/investigators, iDCR 2, defined as the percentage of patients whose best overall response is either a complete response, a partial response or stable disease who continue to receive HX008 in crossover group according to immune Response Evaluation Criteria In Solid Tumors (iRECIST) criteria by IRC/investigators over the the total number of evaluable patients., 2 years|Immune Duration of Response 2 (iDOR2) (crossover phase) per iRECIST assessed by IRC/investigators, iDOR2, defined as the time from the date of the first immune response (iCR or iPR) to the date of immune confirmed progressive disease (iCPD) who continue to receive HX008 in crossover group based on the immunotherapy Response Evaluation Criteria in Solid Tumors (iRECIST) by IRC/investigators., 2 years|Immune Progression-free Survival 2 (iPFS2) (crossover phase) per iRECIST assessed by IRC/investigators, iPFS2, defined as duration of time until 2nd confirmed objective disease progression or death (or last documentation of being alive) who continue to receive HX008 in crossover group based on the immunotherapy Response Evaluation Criteria in Solid Tumors (iRECIST) by IRC/investigators., 2 years|Adverse events, Number of participants with treatment-related adverse events as assessed by CTCAE v5.0, etc., 2 years",,Taizhou Hanzhong biomedical co. LTD,,ALL,"ADULT, OLDER_ADULT",PHASE3,190,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-12-20,2026-01-19,2028-10-20,2022-12-15,,2022-12-15,"Anhui Provincial Cancer Hospital, Hefei, Anhui, China|Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China|Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China|Henan Cancer Hospital, Zhengzhou, Henan, China|Hubei Cancer Hospital, Wuhan, Hubei, China|Hunan Cancer Hospital, Changsha, Hunan, China|The First Hospital of China Medical University, Shenyang, Liaoning, 110010, China|Tianjin People's Hospital, Tianjin, Tianjin, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Xi'an, China",
NCT06899126,"Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT06899126,DESTINY-Lung06,NOT_YET_RECRUITING,"This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; EnhertuÂ®) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants with no prior therapy for locally advanced unresectable or metastatic non-squamous NSCLC, whose tumors have HER2-overexpressing and PD-L1 TPS \<50% without known AGA that have locally available therapies targeting their AGAs in first-line advanced/metastatic setting.",NO,Non-small Cell Lung Cancer,DRUG: Trastuzumab Deruxtecan|DRUG: pembrolizumab|DRUG: Pemetrexed|DRUG: Chemotherapy,"Progression Free Survival by Blinded Independent Central Review, PFS is defined as the time interval from the date of randomization to the date of radiographic disease progression or death due to any cause. Tumor response will be determined by BICR assessment of tumor scans using RECIST v1.1., From date of randomization to the date of radiographic disease progression or death due to any cause, up to 54 months","Overall Survival, OS is defined as the time interval from the date of randomization to the date of death due to any cause., From date of randomization to the date of death due to any cause, up to 85 months",,Daiichi Sankyo,Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE3,686,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2025-09-07,2030-03-05,2032-07-05,2025-03-27,,2025-05-06,,
NCT06646276,A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).,https://clinicaltrials.gov/study/NCT06646276,,RECRUITING,The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer.,NO,Extensive-Stage Small Cell Lung Cancer,BIOLOGICAL: BMS-986489 (BMS-986012+Nivolumab)|BIOLOGICAL: Atezolizumab|DRUG: Carboplatin|DRUG: Etoposide,"Overall Survival (OS), Up to 5 years","Time to definitive deterioration (TTDD)based on the LCSS ASBI defined as the time from randomization until a definitive clinically meaningful decline (â¥ 10 point increase from baseline in LCSS ASBI score)., Up to 5 years|Number of participants with Adverse Events (AEs), Up to 135 days after last treatment|Number of Participants with Serious Adverse Events (SAEs), Up to 135 days after last treatment|Number of Participants with Adverse Events (AEs) leading to discontinuation and death, Up to 135 days after last treatment|Objective Response (OR), Up to 5 years|Duration of Response (DOR), Up to 5 years|Progression Free Survival (PFS), Up to 5 years",,Bristol-Myers Squibb,,ALL,"ADULT, OLDER_ADULT",PHASE3,530,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2025-02-25,2028-04-06,2031-09-05,2024-10-17,,2025-06-10,"Local Institution - 0337, Daphne, Alabama, 36526, United States|Local Institution - 0283, Hot Springs, Arkansas, 71913, United States|Florida Cancer Specialists - South, Fort Myers, Florida, 33901, United States|Mid Florida Hematology and Oncology Center, Orange City, Florida, 32763, United States|Florida Cancer Specialists - North, Saint Petersburg, Florida, 33705, United States|Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital, Marietta, Georgia, 30060, United States|Illinois Cancer Care, Peoria, Illinois, 61615, United States|Local Institution - 0037, Minneapolis, Minnesota, 55407, United States|University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, 87106, United States|Local Institution - 0029, Durham, North Carolina, 27710, United States|Oncology Hematology Care, Cincinnati, Ohio, 45242, United States|Local Institution - 0239, Cleveland, Ohio, 44106, United States|Sanford Cancer Center, Sioux Falls, South Dakota, 57104, United States|Local Institution - 0307, Knoxville, Tennessee, 37909, United States|SCRI Oncology Partners, Nashville, Tennessee, 37203, United States|Texas Oncology - Central/South Texas, Austin, Texas, 78705, United States|Texas Oncology - Northeast Texas, Tyler, Texas, 75702, United States|Oncology & Hematology Associates of Southwest Virginia, Inc., Roanoke, Virginia, 24014, United States|Swedish Medical Center, Seattle, Washington, 98104, United States|Local Institution - 0007, Tacoma, Washington, 98405, United States|Instituto Alexander Fleming, Ciudad AutÃ³noma de Buenos Aires, Buenos Aires, C1426ANZ, Argentina|Hospital Italiano de Buenos Aires, ABB, Ciudad AutÃ³noma De Buenos Aires, C1199ABB, Argentina|Local Institution - 0100, Buenos Aires, Ciudad AutÃ³noma De Buenos Aires, C1417DTB, Argentina|Clinica Adventista Belgrano, Caba, Ciudad AutÃ³noma De Buenos Aires, C1430EGF, Argentina|Instituto MÃ©dico RÃ­o Cuarto, RÃ­o Cuarto, CÃ³rdoba, X5800AEV, Argentina|GenesisCare - Campbelltown, Campbelltown, New South Wales, 2560, Australia|Nepean Hospital, Penrith, New South Wales, 2750, Australia|Gallipoli Medical Research Ltd, Brisbane, Queensland, 4120, Australia|Grampians Health, Ballarat Central, Victoria, 3350, Australia|St. John of God Murdoch Hospital, Murdoch, Western Australia, 6150, Australia|Klinikum Wels-Grieskirchen GmbH, Wels, OberÃ¶sterreich, 4600, Austria|Medizinische UniversitÃ¤t Graz, Graz, Steiermark, 8036, Austria|Kepler UniversitÃ¤tsklinikum, Linz, 4021, Austria|Landeskrankenhaus Rankweil, Rankweil, 6830, Austria|Local Institution - 0250, Wien, 1210, Austria|Local Institution - 0198, Brussels, Bruxelles-Capitale, RÃ©gion De, 1200, Belgium|Local Institution - 0091, Gent, Oost-Vlaanderen, 9000, Belgium|Local Institution - 0187, Sint-Niklaas, Oost-Vlaanderen, B-9100, Belgium|Local Institution - 0180, Leuven, Vlaams-Brabant, 3000, Belgium|Local Institution - 0092, LiÃ¨ge, 4000, Belgium|Local Institution - 0166, Fortaleza, CearÃ¡, 60135-237, Brazil|Local Institution - 0165, Porto Alegre, Rio Grande Do Sul, 90035-903, Brazil|Local Institution - 0169, Porto Alegre, Rio Grande Do Sul, 90610-000, Brazil|Local Institution - 0170, Santa Cruz do Sul, Rio Grande Do Sul, 96830-180, Brazil|Local Institution - 0163, ItajaÃ­, Santa Catarina, 88301-220, Brazil|Local Institution - 0178, Barretos, SÃ£o Paulo, 14784400, Brazil|Local Institution - 0111, Sao Paulo, SÃ£o Paulo, 01509-010, Brazil|Local Institution - 0289, Edmonton, Alberta, T6G 1Z2, Canada|CIUSSS- saguenay-Lac-Saint-Jean, Chicoutimi, Quebec, G7H 5H6, Canada|Centre intÃ©grÃ© de santÃ© et de services sociaux du Bas Saint-Laurent- HÃ´pital rÃ©gional de Rimouski, Rimouski, Quebec, G5L 5T1, Canada|IUCPQ, Quebec, G1V 4G5, Canada|Orlandi Oncologia, Santiago, RegiÃ³n Metropolitana De Santiago, 0, Chile|Fundacion Arturo Lopez Perez (FALP), Santiago, RegiÃ³n Metropolitana De Santiago, 7500921, Chile|Pontificia Universidad Catolica de Chile, Santiago, RegiÃ³n Metropolitana De Santiago, 8330032, Chile|Bradfordhill, Santiago, RegiÃ³n Metropolitana De Santiago, 8420383, Chile|Oncocentro Apys, ViÃ±a del Mar, ValparaÃ­so, 2520598, Chile|Local Institution - 0204, Beijing, Beijing, 100142, China|Local Institution - 0336, Beijing, Beijing, 101149, China|Chongqing University Cancer Hospital, Chongqing, Chongqing, 400030, China|Local Institution - 0308, Fuzhou, Fujian, 350014, China|Local Institution - 0212, Xiamen, Fujian, 361003, China|Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, 515000, China|Local Institution - 0227, Harbin, Heilongjiang, 150081, China|Local Institution - 0208, Wuhan, Hubei, 430030, China|Local Institution - 0209, Wuhan, Hubei, 430079, China|Local Institution - 0216, Changsha, Hunan, 410013, China|Local Institution - 0233, Nanchang, Jiangxi, 330006, China|Local Institution - 0244, Changchun, Jilin, 132000, China|Local Institution - 0235, Shenyang, Liaoning, 110042, China|Xi'an International Medical Center Hospital, Xi'an, Shaanxi, 710126, China|Shandong Cancer Hospital, Jinan, Shandong, 250117, China|Local Institution - 0206, Shanghai, Shanghai, 200030, China|Local Institution - 0210, Shanghai, Shanghai, 200032, China|Sichuan Cancer hospital, Chengdu, Sichuan, 610041, China|Local Institution - 0213, Tianjin, Tianjin, 300060, China|Sir Run Run Shaw Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310016, China|Local Institution - 0237, Hangzhou, Zhejiang, 310022, China|Taizhou Hospital of Zhejiang Province, Linhai, Zhejiang, 317000, China|Shanghai East Hospital, Shanghai, 200120, China|Masarykuv onkologicky ustav, Brno, Brno-mÄsto, 656 53, Czechia|Nemocnice AGEL Ostrava - Vitkovice a.s., Ostrava, Ostrava MÄsto, 703 00, Czechia|Local Institution - 0113, Prague, Praha 4, 14059, Czechia|Local Institution - 0116, Olomouc, 779 00, Czechia|HÃ´pital Arnaud de Villeneuve - CHU Montpellier, Montpellier, HÃ©rault, 34090, France|Chu Grenoble Alpes, La Tronche, IsÃ¨re, 38700, France|CHU Lille - Institut Coeur Poumon, Lille Cedex, Nord, 59037, France|L Hopital Nord Ouest, Gleize, RhÃ´ne, 69400, France|Centre Hospitalier Lyon Sud, Pierre-BÃ©nite, RhÃ´ne, 69310, France|Centre Hospitalier Intercommunal de CrÃ©teil, CrÃ©teil, Val-de-Marne, 94010, France|Gustave Roussy, Villejuif, Val-de-Marne, 94800, France|Assistance Publique HÃ´pitaux de Marseille - HÃ´pital Nord, Marseille, 13915, France|Institut Curie, Paris, 75248, France|Centre Hospitalier de Cornouaille Quimper - Concarneau, Quimper, 29000, France|Institut fÃ¼r Klinisch Onkologische Forschung, Frankfurt, Hessen, 60488, Germany|Pius Hospital Oldenburg, Oldenburg, Niedersachsen, 26121, Germany|Klinikum KÃ¶ln-Merheim, KÃ¶ln, Nordrhein-Westfalen, 51109, Germany|Krankenhaus Martha-Maria Halle-DÃ¶lau, Halle, Sachsen-Anhalt, 06120, Germany|Local Institution - 0257, Bad Berka, ThÃ¼ringen, 99437, Germany|Local Institution - 0263, Berlin, 14165, Germany|Asklepios Klinik Gauting GmbH, Gauting, 82131, Germany|LungenClinic Grosshansdorf, Grosshansdorf, 22927, Germany|Local Institution - 0260, Heidelberg, 69126, Germany|Robert Bosch Krankenhaus GmbH, Stuttgart, 70736, Germany|Errikos Dunant Hospital Center, Athens, AttikÃ­, 115 26, Greece|Local Institution - 0064, Athens, AttikÃ­, 115 27, Greece|Local Institution - 0062, Thessaloniki, KentrikÃ­ MakedonÃ­a, 540 07, Greece|European Interbalkan Medical Center, Thessaloniki, ThessalonÃ­ki, 570 01, Greece|Local Institution - 0059, Larissa, ThessalÃ­a, 41110, Greece|Local Institution - 0278, New Delhi, Delhi, 110029, India|Local Institution - 0274, Bengaluru, Karnataka, 560017, India|Local Institution - 0271, Madurai, Tamil Nadu, 625107, India|Local Institution - 0277, Varanasi, Uttar Pradesh, 221005, India|Local Institution - 0273, Kolkata, West Bengal, 700094, India|Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, 80131, Italy|Local Institution - 0068, Milan, Lombardia, 20133, Italy|Istituto Nazionale Tumori Regina Elena, Rome, Roma, 00144, Italy|Local Institution - 0110, Perugia, Umbria, 06132, Italy|Casa di Cura Dott. Pederzoli, Peschiera del Garda, Verona, 37019, Italy|Local Institution - 0074, Bologna, 40138, Italy|Istituto Europeo di Oncologia IRCCS, Milano, 20141, Italy|National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, 791-0280, Japan|Kurume University Hospital, Kurume, Fukuoka, 830-0011, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, 0608648, Japan|Kobe City Medical Center General Hospital, Kobe-shi, Hyogo, 650-0047, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, 920-8641, Japan|Kanagawa Cardiovascular and Respiratory Center, Yokohama, Kanagawa, 236-0051, Japan|Sendai Kousei Hospital, Sendai, Miyagi, 9810914, Japan|Nara Medical University Hospital, Kashihara city, Nara, 634-8522, Japan|Kurashiki Central Hospital, Kurashiki, Okayama, 710-8602, Japan|Kansai Medical University Hospital, Hirakata, Osaka, 573-1191, Japan|Local Institution - 0314, Osakasayama, Osaka, 589-8511, Japan|Osaka Medical and Pharmaceutical University Hospital, Takatsuki, Osaka, 569-8686, Japan|Saitama Medical University International Medical Center, Hidaka, Saitama, 350-1298, Japan|Local Institution - 0318, Ina-machi, Saitama, 362-0806, Japan|Hamamatsu University Hospital, Hamamatsu, Shizuoka, 431-3192, Japan|Nippon Medical School Hospital, Bunkyo-ku, Tokyo, 1138603, Japan|The Cancer Institute Hospital of JFCR, Koto, Tokyo, 135-8550, Japan|Fukushima Medical University, Fukushima, 960-1295, Japan|Local Institution - 0305, Cheongju-si, Chungcheongbuk-do [Chungbuk], 28644, Korea, Republic of|Local Institution - 0286, Seongnam, KyÇnggi-do, 13620, Korea, Republic of|Local Institution - 0304, Suwon-si, KyÇnggi-do, 16499, Korea, Republic of|Local Institution - 0285, Seoul, Seoul-teukbyeolsi [Seoul], 03722, Korea, Republic of|Local Institution - 0293, Seoul, Seoul-teukbyeolsi [Seoul], 05505, Korea, Republic of|Local Institution - 0309, Daegu, Taegu-KwangyÇkshi, 42601, Korea, Republic of|Local Institution - 0311, Kuching, Sarawak, 93586, Malaysia|Local Institution - 0310, Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, 50586, Malaysia|Local Institution - 0312, Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, 50603, Malaysia|Local Institution - 0148, Pachuca, Hidalgo, 42000, Mexico|Local Institution - 0146, Guadalajara, Jalisco, 44630, Mexico|Local Institution - 0147, Monterrey, Nuevo LeÃ³n, 66460, Mexico|Local Institution - 0145, Puebla, 72424, Mexico|Local Institution - 0097, Amsterdam, Noord-Holland, 1081 HV, Netherlands|Local Institution - 0099, Arnhem, 6815 AD, Netherlands|University Medical Center Groningen, Groningen, 9713 GZ, Netherlands|Szpital Specjalistyczny w Prabutach Spolka z o.o., Prabuty, Pomorskie, 82-550, Poland|Przychodnia Lekarska KOMED, Konin, Wielkopolskie, 62-500, Poland|Pratia PoznaÅ, PoznaÅ, Wielkopolskie, 60-192, Poland|Centrum Onkologii im. Prof. Franciszka Lukaszczyka, Bydgoszcz, 85796, Poland|Instytut Centrum Zdrowia Matki Polki, ÅÃ³dÅº, ÅÃ³dzkie, 93-338, Poland|SC Memorial Healthcare International SRL, Bucharest, BucureÈti, 013812, Romania|Institutul Oncologic Bucuresti, Bucharest, BucureÈti, 022328, Romania|SC Radiotherapy Center Cluj SRL, FloreÈti, Cluj, 407280, Romania|Centrul de Oncologie ""SfÃ¢ntul Nectarie"", Craiova, Dolj, 200542, Romania|Institutul Oncologic Cluj, Cluj, 400015, Romania|S.C. Centrul de Oncologie Euroclinic S.R.L., IaÈi, 700106, Romania|Institutul Regional de Oncologie, IaÈi, 700483, Romania|CHUS - Hospital Clinico Universitario, Santiago de Compostela, A CoruÃ±a [La CoruÃ±a], 15706, Spain|Hospital ClÃ­nic de Barcelona, Barcelona, Catalunya [CataluÃ±a], 08036, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Catalunya [CataluÃ±a], 08041, Spain|Hospital Universitario de Jaen, Jaen, JaÃ©n, 23007, Spain|Hospital Universitario RamÃ³n y Cajal, Madrid, Madrid, Comunidad De, 28034, Spain|Hospital Universitario 12 de Octubre, Madrid, Madrid, Comunidad De, 28041, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Comunidad De, 28222, Spain|Hospital General Universitario de Valencia, Valencia, Valenciana, Comunitat, 46014, Spain|Local Institution - 0299, Sevilla, 41009, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, 41013, Spain|Kantonsspital GraubÃ¼nden, Chur, 7000, Switzerland|Kantonsspital Winterthur, Winterthur, 8401, Switzerland|UniversitÃ¤tsSpital ZÃ¼rich, ZÃ¼rich, 8091, Switzerland|Local Institution - 0158, Cigli, Ä°zmir, 35620, Turkey|Local Institution - 0154, Adana, 01370, Turkey|Local Institution - 0157, Ankara, 06010, Turkey|Local Institution - 0177, Ankara, 06280, Turkey|Local Institution - 0153, Istanbul, 34732, Turkey|Local Institution - 0197, London, London, City Of, SE1 9RT, United Kingdom|Local Institution - 0183, Central Middlesbrough, Middlesbrough, TS4 3BW, United Kingdom|Aberdeen Royal Infirmary, Aberdeen, AB9 2ZB, United Kingdom|Local Institution - 0108, Leicester, LE1 5WW, United Kingdom|The Christie NHS Foundation Trust, Manchester, M20 4BX, United Kingdom|The Clatterbridge Cancer Centre, Wirral, CH63 4JY, United Kingdom",
NCT04210115,Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975),https://clinicaltrials.gov/study/NCT04210115,,ACTIVE_NOT_RECRUITING,"The purpose of this study is to assess the efficacy and safety of treatment with definitive chemoradiotherapy (dCRT) + pembrolizumab (MK-3475) compared to treatment with dCRT + placebo with respect to Event-free Survival (EFS) and Overall Survival (OS) in:

* participants whose tumors express Programmed Death-Ligand 1 (PD-L1) Combined Positive Score (CPS) â¥10
* participants whose tumors express PD-L1 CPS â¥1
* all participants

The primary study hypotheses are that dCRT+ pembrolizumab is better than dCRT + placebo with respect to:

* EFS in participants whose tumors express PD-L1 CPS â¥10
* EFS in participants whose tumors express PD-L1 CPS â¥1
* EFS in all participants
* OS in participants whose tumors express PD-L1 CPS â¥10
* OS in participants whose tumors express PD-L1 CPS â¥1
* OS in all participants",NO,Esophageal Squamous Cell Carcinoma (ESCC)|Gastroesophageal Junction Carcinoma (GEJC)|Esophageal Adenocarcinoma (EAC),BIOLOGICAL: pembrolizumab|DRUG: placebo|DRUG: cisplatin|DRUG: 5-FU|RADIATION: radiotherapy|DRUG: leucovorin|DRUG: levoleucovorin|DRUG: oxaliplatin,"Event-free Survival (EFS), EFS is defined as the time from randomization to an event defined as local, regional, or distant radiological recurrence as assessed by the investigator; clinical recurrence as assessed by the investigator with histopathologic confirmation (in the absence of radiological disease recurrence by investigator assessment); or death from any cause, whichever occurs first., Up to ~60 months|Overall Survival (OS), OS is defined as the time from randomization to death from any cause., Up to ~72 months","Number of participants with an adverse event (AE), An AE is any untoward medical occurrence in a participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment., Up to ~15 months|Number of participants discontinuing study treatment due to an adverse event (AE), An AE is any untoward medical occurrence in a participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment., Up to ~12 months",,Merck Sharp & Dohme LLC,,ALL,"ADULT, OLDER_ADULT",PHASE3,703,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-02-28,2027-02-01,2027-02-01,2019-12-24,,2024-11-15,"MemorialCare Health System - Long Beach Medical Center-Oncology ( Site 0691), Long Beach, California, 90806, United States|Columbus Regional Research Institute ( Site 0047), Columbus, Georgia, 31904, United States|University of Kansas Cancer Center ( Site 0023), Westwood, Kansas, 66205, United States|Cancer Center of Kansas ( Site 0058), Wichita, Kansas, 67214, United States|University Medical Center ( Site 0035), New Orleans, Louisiana, 70112, United States|Greater Baltimore Medical Center ( Site 0031), Baltimore, Maryland, 21204, United States|Dana Farber Cancer Center ( Site 0034), Boston, Massachusetts, 02215, United States|Henry Ford Hospital ( Site 0685), Detroit, Michigan, 48202, United States|University of Missouri ( Site 0688), Columbia, Missouri, 65212, United States|Renown Regional Medical Center ( Site 0706), Reno, Nevada, 89502, United States|Rutgers Cancer Institute of New Jersey ( Site 0695), New Brunswick, New Jersey, 08903, United States|Weill Cornell Medical College ( Site 0053), New York, New York, 10065, United States|Stephenson Cancer Center ( Site 0044), Oklahoma City, Oklahoma, 73104, United States|Oregon Health & Science University Center for Health & Healing 2- CHH2 ( Site 0060), Portland, Oregon, 97239, United States|Allegheny Health Network ( Site 0042), Pittsburgh, Pennsylvania, 15212, United States|Thompson Cancer Survival Center ( Site 0696), Knoxville, Tennessee, 37916, United States|Utah Cancer Specialists ( Site 0697), Salt Lake City, Utah, 84106, United States|Cancer Care Northwest - Spokane Valley ( Site 0036), Spokane Valley, Washington, 99216, United States|University of Wisconsin Hospital and Clinics ( Site 0033), Madison, Wisconsin, 53792, United States|Instituto Medico Alexander Fleming ( Site 0063), Buenos Aires, Caba, C1426ANZ, Argentina|Fundacion Favaloro ( Site 0061), Ciudad de Buenos Aires, Caba, C1093AAS, Argentina|Hospital Municipal de Gastroenterologia Dr. Bonorino Udaondo ( Site 0066), Buenos Aires, C1264AAA, Argentina|CEMIC ( Site 0064), Buenos Aires, C1431FWO, Argentina|UCL Saint Luc ( Site 0162), Brussels, Bruxelles-Capitale, Region De, 1200, Belgium|UZ Gent ( Site 0163), Gent, Oost-Vlaanderen, 9000, Belgium|UZ Leuven ( Site 0161), Leuven, Vlaams-Brabant, 3000, Belgium|AZ Delta ( Site 0165), Roeselare, West-Vlaanderen, 8800, Belgium|ONCOSITE - Centro de Pesquisa Clinica em Oncologia ( Site 0088), Ijui, Rio Grande Do Sul, 98700-000, Brazil|Hospital Nossa Senhora da Conceicao ( Site 0087), Porto Alegre, Rio Grande Do Sul, 91350-200, Brazil|Clinica de Oncologia Reichow ( Site 0085), Blumenau, Santa Catarina, 89010-340, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0081), Sao Paulo, 01246-000, Brazil|Cross Cancer Institute ( Site 0010), Edmonton, Alberta, T6G 1Z2, Canada|CancerCare Manitoba ( Site 0002), Winnipeg, Manitoba, R3E 0V9, Canada|The Ottawa Hospital - Cancer Care ( Site 0008), Ottawa, Ontario, K1H 8L6, Canada|Sunnybrook Research Institute ( Site 0012), Toronto, Ontario, M4N 3M5, Canada|Princess Margaret Cancer Centre ( Site 0011), Toronto, Ontario, M5G 2M9, Canada|Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0005), Montreal, Quebec, H2X 0A9, Canada|Centro InvestigaciÃ³n del CÃ¡ncer James Lind ( Site 0106), Temuco, Araucania, 4800827, Chile|Centro de Investigacion y desarrollo Oncologico SpA - CIDO SpA ( Site 0103), Temuco, Araucania, 4810218, Chile|Hospital Regional de Concepcion ( Site 0105), Concepcion, Biobio, 4070038, Chile|Centro de Cancer Nuestra Senora de la Esperanza ( Site 0104), Santiago, Region M. De Santiago, 8330024, Chile|Anhui Provincial Hospital-Oncology Radiotherapy Department ( Site 0531), Hefei, Anhui, 230071, China|The 900th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army ( Si, Fuzhou, Fujian, 350025, China|The First Affiliated Hospital of Xiamen University ( Site 0538), Xiamen, Fujian, 361003, China|Hubei Cancer Hospital ( Site 0514), Wuhan, Hubei, 430079, China|Hunan Cancer Hospital ( Site 0515), Changsha, Hunan, 410006, China|Huai an First People s Hospital ( Site 0526), Huai An, Jiangsu, 223001, China|Jiangsu Cancer Hospital ( Site 0519), Nanjing, Jiangsu, 210000, China|The Affiliated Hospital of Xuzhou Medical University ( Site 0522), Xuzhou, Jiangsu, 221002, China|Affiliated Hospital of Jiangsu University ( Site 0524), Zhenjiang, Jiangsu, 212000, China|Jiangxi Cancer Hospital ( Site 0512), Nanchang, Jiangxi, 330029, China|Shanghai Chest Hospital ( Site 0503), Shangai, Shanghai, 200030, China|Shanghai Chest Hospital ( Site 0501), Shanghai, Shanghai, 200030, China|Zhongshan Hospital Fudan University ( Site 0502), Shanghai, Shanghai, 200032, China|Sichuan Cancer Hospital ( Site 0527), Chengdu, Sichuan, 610041, China|Tianjin Medical University Cancer Institute & Hospital ( Site 0505), Tianjin, Tianjin, 300060, China|Hangzhou First People's Hospital ( Site 0530), Hangzhou, Zhejiang, 310002, China|Sir Run Run Shaw Hospital ( Site 0523), Hangzhou, Zhejiang, 310018, China|Zhejiang Cancer Hospital ( Site 0529), Hangzhou, Zhejiang, 310022, China|Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 0721), Brno, Brno-mesto, 656 53, Czechia|Fakultni nemocnice Ostrava-Klinika onkologicka ( Site 0719), Ostrava, Moravskoslezsky Kraj, 708 52, Czechia|Fakultni nemocnice Olomouc-Onkologicka klinika ( Site 0720), Olomouc, Olomoucky Kraj, 779 00, Czechia|Fakultni nemocnice v Motole-Onkologicka klinika 2. LF UK a FN Motol ( Site 0718), Praha, Praha 5, 150 06, Czechia|Rigshospitalet ( Site 0199), Copenhagen, Hovedstaden, 2100, Denmark|Odense Universitetshospital ( Site 0200), Odense, Syddanmark, 5000, Denmark|SA Pohja-Eesti Regionaalhaigla ( Site 0201), Tallinn, Harjumaa, 13419, Estonia|SA Tartu Ulikooli Kliinikum ( Site 0202), Tartu, Tartumaa, 50406, Estonia|Institut De Cancerologie De Lorraine ( Site 0222), Vandoeuvre les Nancy, Ain, 54519, France|Centre Francois Baclesse ( Site 0236), Caen, Calvados, 14075, France|Centre Georges Francois Leclerc ( Site 0223), Dijon, Cote-d Or, 21079, France|CHU Limoges Hopital Dupuytren ( Site 0225), Limoges, Haute-Vienne, 87042, France|Institut Curie - Centre Rene Huguenin ( Site 0237), Saint-Cloud, Hauts-de-Seine, 92210, France|Institut Jean Godinot ( Site 0238), Reims, Marne, 51726 CEDEX, France|CHU Hotel Dieu Nantes ( Site 0230), Nantes, Pays-de-la-Loire, 44093, France|Institut Sainte Catherine ( Site 0228), Avignon, Provence-Alpes-Cote-d Azur, 84918, France|CHU Amiens Picardie Site Sud Amiens ( Site 0235), Amiens, Somme, 80054, France|CHD Vendee ( Site 0227), La Roche sur Yon, Vendee, 85925, France|Marienhospital Stuttgart Vincenz von Paul Kliniken gGmbH ( Site 0253), Stuttgart, Baden-Wurttemberg, 70199, Germany|Universitaetsklinikum Koeln ( Site 0251), Koeln, Nordrhein-Westfalen, 50937, Germany|Universitaetsklinikum Muenster ( Site 0248), Muenster, Nordrhein-Westfalen, 48149, Germany|Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz ( Site 0247), Mainz, Rheinland-Pfalz, 55131, Germany|Charite Campus Virchow Klinikum ( Site 0250), Berlin, 13353, Germany|Facharztzentrum Eppendorf ( Site 0242), Hamburg, 20249, Germany|Centro de Investigaciones Clinicas de Latinoamerica S.A. - CELAN ( Site 0122), Guatemala, 01010, Guatemala|Gastrosoluciones ( Site 0126), Guatemala, 01010, Guatemala|Oncomedica ( Site 0125), Guatemala, 01010, Guatemala|Grupo Medico Angeles ( Site 0121), Guatemala, 01015, Guatemala|Medi-K Cayala ( Site 0124), Guatemala, 01016, Guatemala|Centro Medico Integral De CancerologÃ­a (CEMIC) ( Site 0123), Quetzaltenango, 09002, Guatemala|Pamela Youde Nethersole Eastern Hospital ( Site 0543), Hong Kong, Hong Kong|Princess Margaret Hospital. ( Site 0542), Hong Kong, Hong Kong|Queen Mary Hospital ( Site 0541), Pokfulam, Hong Kong|Pecsi Tudomanyegyetem AOK ( Site 0265), Pecs, Baranya, 7624, Hungary|Bekes Megyei Kozponti Korhaz - Pandy Kalman Tagkorhaza ( Site 0262), Gyula, Bekes, 5700, Hungary|Orszagos Onkologiai Intezet ( Site 0263), Budapest, 1122, Hungary|Debreceni Egyetem Klinikai Kozpont ( Site 0261), Debrecen, 4032, Hungary|Fondazione IRCCS Policlinico San Matteo-Oncology ( Site 0300), Pavia, Lombardia, 27100, Italy|IRCCS Policlinico San Donato ( Site 0295), San Donato Milanese, Milano, 20097, Italy|Azienda Ospedaliero Universitaria Pisana - Presidio Santa Chiara ( Site 0294), Pisa, Toscana, 56126, Italy|ASST Papa Giovanni XXIII ( Site 0296), Bergamo, 24127, Italy|Azienda Socio Sanitaria Territoriale di Cremona ( Site 0299), Cremona, 26100, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 0292), Milano, 20133, Italy|Istituto Nazionale Tumori IRCCS Fondazione Pascale-SC Oncologia Clinica Sperimentale Addome ( Site 0, Napoli, 80131, Italy|IRCCS Istituto Oncologico Veneto ( Site 0298), Padova, 35128, Italy|Policlinico Universitario A. Gemelli ( Site 0297), Roma, 00168, Italy|Aichi Cancer Center Hospital ( Site 0563), Nagoya, Aichi, 464-8681, Japan|National Cancer Center Hospital East ( Site 0562), Kashiwa, Chiba, 2778577, Japan|Kanagawa Cancer Center ( Site 0565), Yokohama, Kanagawa, 241-8515, Japan|Saitama Cancer Center ( Site 0564), Kitaadachi-gun, Saitama, 362-0806, Japan|Shizuoka Cancer Center Hospital and Research Institute ( Site 0566), Sunto-gun, Shizuoka, 411-8777, Japan|National Cancer Center Hospital ( Site 0561), Tokyo, 104-0045, Japan|Chonnam National University Hwasun Hospital ( Site 0625), Hwasun Gun, Jeonranamdo, 58128, Korea, Republic of|National Cancer Center ( Site 0626), Goyang-si, Kyonggi-do, 10408, Korea, Republic of|Asan Medical Center ( Site 0623), Songpagu, Seoul, 05505, Korea, Republic of|Severance Hospital Yonsei University Health System ( Site 0624), Seoul, 03722, Korea, Republic of|Samsung Medical Center ( Site 0622), Seoul, 06351, Korea, Republic of|Korea University Guro Hospital ( Site 0621), Seoul, 08308, Korea, Republic of|Cryptex InvestigaciÃ³n ClÃ­nica S.A. de C.V. ( Site 0729), CuauhtÃ©moc, Ciudad De MÃ©xico, Distrito Federal, 06100, Mexico|CENTRO HEMATO ONCOLOGICO PRIVADO-CHOP ( Site 0728), Toluca de Lerdo, 50120, Mexico|Instituto Nacional de Enfermedades Neoplasicas ( Site 0141), Lima, Muni Metro De Lima, Lima 34, Peru|Detecta ClÃ­nica ( Site 0146), Surquillo, Muni Metro De Lima, 15038, Peru|Hospital Nacional Arzobispo Loayza ( Site 0143), Lima, 15082, Peru|Clinica San Gabriel ( Site 0142), Lima, 15087, Peru|Baguio General Hospital and Medical Center ( Site 0603), Baguio City, Benguet, 2600, Philippines|Cebu Doctors University Hospital ( Site 0604), Cebu City, Cebu, 6000, Philippines|The Medical City-Iloilo ( Site 0602), Iloilo City, Iloilo, 5000, Philippines|St. Luke s Medical Center ( Site 0601), Quezon, National Capital Region, 1102, Philippines|Hospital Beatriz Angelo ( Site 0374), Loures, Lisboa, 2674-514, Portugal|Inst. Portugues de Oncologia de Lisboa Francisco Gentil EPE ( Site 0372), Lisboa, 1099-023, Portugal|Hospital da Luz ( Site 0373), Lisboa, 1500 650, Portugal|CHLN Hospital Santa Maria ( Site 0376), Lisboa, 1649-035, Portugal|Inst. Portugues de Oncologia de Porto Francisco Gentil EPE ( Site 0371), Porto, 4200-072, Portugal|MedEuropa Bucuresti - Centru de Radioterapie-Oncology ( Site 0400), BucureÈti, Bucuresti, 022343, Romania|Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 0392), Cluj-Napoca, Cluj, 400015, Romania|S.C. Radiotherapy Center Cluj S.R.L ( Site 0391), Cluj-Napoca, Cluj, 407280, Romania|Ovidius Clinical Hospital OCH-Oncology and Hematology ( Site 0393), Ovidiu, Constanta, 905900, Romania|S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 0394), Craiova, Dolj, 200542, Romania|Centrul Medical Topmed ( Site 0398), Targu-Mures, Mures, 540156, Romania|S.C.Focus Lab Plus S.R.L ( Site 0395), Bucuresti, 022548, Romania|GBUZ Republican Clinical Oncological Dispensary-Antitumor drug therapy department ( Site 0430), Ufa, Baskortostan, Respublika, 450054, Russian Federation|Kaluga Regional Clinical Oncology Center ( Site 0424), Kaluga, Kaluzskaja Oblast, 248007, Russian Federation|Main Military Clinical Hospital n.a. N.N.Burdenko ( Site 0421), Moscow, Moskva, 105229, Russian Federation|FSAI Treatment and Rehabilitation Centre of the MoH and SD of RF ( Site 0429), Moscow, Moskva, 125367, Russian Federation|SBHI Samara Regional Clinical Oncology Dispensary ( Site 0420), Samara, Samarskaya Oblast, 443031, Russian Federation|Pavlov First Saint Petersburg State Medical University ( Site 0426), St. Petersburg, Sankt-Peterburg, 197022, Russian Federation|Medical institute named after Berezin Sergey ( Site 0417), St. Petersburg, Sankt-Peterburg, 197758, Russian Federation|Sverdlovsk Regional Oncology Hospital ( Site 0411), Ekaterinburg, Sverdlovskaya Oblast, 620036, Russian Federation|Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 0412), Kazan, Tatarstan, Respublika, 420029, Russian Federation|Chang Gung Med Foundation. Kaohsiung Branch ( Site 0643), Kaohsiung, 833, Taiwan|China Medical University Hospital ( Site 0646), Taichung, 40447, Taiwan|Taichung Veterans General Hospital-Radiation Oncology ( Site 0647), Taichung, 407, Taiwan|National Cheng Kung University Hospital ( Site 0645), Tainan, 70457, Taiwan|National Taiwan University Hospital ( Site 0641), Taipei, 10002, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center ( Site 0644), Taipei, 11259, Taiwan|Chang Gung Medical Foundation. Linkou ( Site 0642), Taoyuan, 33305, Taiwan|Istanbul University Cerrahpasa Medical Faculty ( Site 0452), Istambul, Istanbul, 34098, Turkey|Memorial Ankara Hastanesi ( Site 0461), Ankara, 06520, Turkey|GÃ¶ztepe Prof. Dr. SÃ¼leyman YalÃ§Ä±n Åehir Hastanesi-oncology ( Site 0451), Istanbul, 34722, Turkey|Ege Universitesi Tip Fakultesi ( Site 0457), Izmir, 35040, Turkey|Izmir Katip Celebi Universitesi Ataturk Egitim ve Arastirma Hastanesi ( Site 0458), Izmir, 35360, Turkey|Aberdeen Royal Infirmary ( Site 0474), Aberdeen, Aberdeen City, AB25 2ZN, United Kingdom|Cambridge University Hospitals NHS Trust ( Site 0477), Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom|Royal Free Hospital ( Site 0702), London, England, NW32QG, United Kingdom|ROYAL MARSDEN HOSPITAL (CHELSEA) ( Site 0283), London, London, City Of, SW3 6JJ, United Kingdom|Hammersmith Hospital-Medical Oncology ( Site 0471), London, London, City Of, W12 OHS, United Kingdom|Nottingham University Hospitals NHS Trust ( Site 0476), Nottingham, Nottinghamshire, NG5 1PB, United Kingdom|Royal Marsden Hospital (Sutton) ( Site 0281), Sutton, Surrey, SM2 5PT, United Kingdom|University College Hospital NHS Foundation Trust ( Site 0701), London, Worcestershire, NW1 2PG, United Kingdom|The Christie NHS Foundation Trust ( Site 0282), Manchester, M20 4BX, United Kingdom|Mount Vernon Hospital ( Site 0478), Northwood, HA6 2RN, United Kingdom",
NCT05100862,A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma,https://clinicaltrials.gov/study/NCT05100862,MAHOGANY,RECRUITING,"The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R\^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.",NO,Relapsed/Refractory Follicular Lymphoma|Marginal Zone Lymphoma,DRUG: Zanubrutinib|DRUG: Rituximab|DRUG: Lenalidomide|DRUG: Obinutuzumab,"Progression-free Survival As Determined By A Blinded Independent Review Committee (BIRC), Approximately 78 months","Progression-free Survival As Determined By Investigator Assessment, Approximately 87 months|Duration Of Response As Determined By BIRC And By Investigator Assessment, Approximately 87 months|Overall Response Rate As Determined By BIRC And By Investigator Assessment, Approximately 87 months|Complete Response Rate As Determined By BIRC And By Investigator Assessment, Approximately 87 months|Time To Response As Determined By BIRC And By Investigator Assessment, Approximately 87 months|Time to Next Ant-Lymphoma Treatment, Approximately 87 months|Overall Survival, Approximately 87 months|Health-related Quality Of Life (HRQoL) Using EORTC QLQ-C30), HRQ0L assessed by The European Organization For Research On Treatment Of Cancer Quality Of Life Questionnaire-core 30 (EORTC QLQ-C30) consists of 30 questions that are associated with 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea and vomiting), and 6 single symptom items ( dyspnoea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The scores range from 0 to 100 and higher score indicates better quality of life., Approximately 87 months|HRQoL Using European Quality of Life 5 Dimension 5 Level Questionnaire [EQ 5D 5L), The EQ-5D-5L is comprised of a descriptive module and a visual analogue scale. The EQ-5D-5L descriptive module comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The visual analogue scale records the respondent's self-rated health on a 0 to 100 scale, with 100 labeled ""the best health you can imagine"" and 0 labeled ""the worst health you can imagine. Higher scores indicate better quality of life., Approximately 87 months|HRQoL Using National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Lymphoma Symptom Index-18 [FLymSI 18), The FLymSI-18 is comprised of 18 questions which cover 4 sub-scales: physical symptoms, emotional symptoms, side effects, and functional well-being. Scores are based on the 5-level Likert scale with 5 possible responses ranging from 0 'Not at all' to 4 'Very much' and is divided into a total score. Higher score indicates better quality of life., Approximately 87 months|Number of Participants Experiencing Adverse Events (AEs), From first dose to 28 days after the last dose of zanubrutinib or lenalidomide, 90 days after the last dose of obinutuzumab or rituximab, or until the date of confirmed disease progression, whichever comes later (Approximately 87 months)",,BeiGene,,ALL,"ADULT, OLDER_ADULT",PHASE3,780,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-03-10,2028-07,2030-06,2021-10-29,,2025-06-05,"Ucsf Fresno University of California San Francisco Fresno, Fresno, California, 93730-3595, United States|Kaiser Permanente Southern California, Irvine, California, 92618-3734, United States|Cancer and Blood Specialty Clinic, Los Alamitos, California, 90720-3302, United States|Los Angeles Cancer Network, Los Angeles, California, 90017-4803, United States|Valkyrie Clinical Trials, Los Angeles, California, 90067-2011, United States|UCLA Hematologyoncology, Los Angeles, California, 90095-3075, United States|Scripps Health, San Diego, California, 92103-2106, United States|Sharp Healthcare Sharp Memorial Hospital, San Diego, California, 92123-2701, United States|Baptist Md Anderson Cancer Center, Jacksonville, Florida, 32207-8432, United States|Memorial Cancer Institute, Memorial Healthcare System, Pembroke Pines, Florida, 33026-4119, United States|Ascension Sacred Heart, Pensacola, Florida, 32504-8615, United States|Northwest Georgia Oncology Centers Marietta, Marietta, Georgia, 30060-1152, United States|Cancer Care Specialists of Illinois, Decatur, Illinois, 62526-5858, United States|Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, 46804, United States|Mission Cancer and Blood, Waukee, Iowa, 50263, United States|Cotton Oneil Cancer Center, Topeka, Kansas, 66606-1535, United States|Cancer Center of Kansas, Wichita, Kansas, 67214-3728, United States|Baptist Health Lexington, Lexington, Kentucky, 40503-1466, United States|Christus Highland Cancer Treatment Center, Shreveport, Louisiana, 71105-6800, United States|Luminis Health Anne Arundel Medical Center, Annapolis, Maryland, 21401, United States|University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, 21201-1544, United States|Ascension St Agnes Hospital, Baltimore, Maryland, 21229-5201, United States|American Oncology Partners of Maryland Pa, Bethesda, Maryland, 20817-7847, United States|Henry Ford Hospital, Detroit, Michigan, 48202-2608, United States|Corewell Health the Michigan Cancer Consortium, Grand Rapids, Michigan, 49503-2560, United States|Ascension St John Hospital, Grosse Pointe Woods, Michigan, 48236-2891, United States|Hattiesburg Hematology and Oncology Clinic, Hattiesburg, Mississippi, 39401-7233, United States|University of Missouri Hospital, Ellis Fischel Cancer Center, Columbia, Missouri, 65212-1000, United States|Oncology Hematology Associates, Springfield, Missouri, 65807-5288, United States|St Vincent Frontier Cancer Center, Billings, Montana, 59102, United States|Nebraska Cancer Specialists (Satellite Site), Omaha, Nebraska, 68130-2042, United States|Nebraska Cancer Specialists, Omaha, Nebraska, 68130-2042, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, 89169-3321, United States|Iyengar Hematology Oncology Medical Center Pa, Bayonne, New Jersey, 07002-4654, United States|North Shore Hematology Oncology Associates Eccc Bronx, Bronx, New York, 10469-5930, United States|New York Cancer and Blood Specialists, East Setauket, New York, 11733-3538, United States|North Shore Hematology Oncology Associates New Hyde Park, New Hyde Park, New York, 11042-1116, United States|North Shore Hematology Oncology Associates Dba New York Cancer and Blood Specialists (New York), New York, New York, 10028-0517, United States|Suny Upstate Medical University, Syracuse, New York, 13210-2306, United States|Clinical Research Alliance, Inc, Westbury, New York, 11590-5119, United States|Levine Cancer Institute Wake Forest, Charlotte, North Carolina, 28204-2990, United States|Oncology Hematology Care Clinical Trials, Llc, Cincinnati, Ohio, 45245-1995, United States|Mainline Health Lankenau Institute For Medical Research, Wynnewood, Pennsylvania, 19096, United States|Cancer Care Associates of York, York, Pennsylvania, 17403-5049, United States|Prairie Lakes Healthcare System, Watertown, South Dakota, 57201-1548, United States|Texas Oncology Baylorcharles A Sammons Cancer Center, Dallas, Texas, 75246-2003, United States|Harris Health Lyndon B Johnson Hospital, Houston, Texas, 77026-1967, United States|Md Anderson Cancer Center, Houston, Texas, 77030-3907, United States|Texas Oncology Longview Cancer Center, Longview, Texas, 75601-4717, United States|Texas Oncology Palestine Cancer Center, Palestine, Texas, 75801-6981, United States|Texas Oncology Paris, Paris, Texas, 75460, United States|Northeast Texas Cancer and Research Institute, Tyler, Texas, 75702-7522, United States|Northwest Medical Specialties, Puyallup, Washington, 98373-1659, United States|University of Washington, Seattle, Washington, 98195, United States|Medical Oncology Associates, Spokane, Washington, 99208-1129, United States|Hospital Aleman, Caba, 1425, Argentina|Hospital Italiano de Buenos Aires, Ciudad Autonoma Buenos Aires, 1413, Argentina|Concord Repatriation General Hospital, Concord, New South Wales, 2139, Australia|Gosford Hospital, Gosford, New South Wales, 2250, Australia|St George Hospital, Kogarah, New South Wales, 2217, Australia|Orange Health Hospital, Orange, New South Wales, 2800, Australia|Port Macquarie Base Hospital, Port Macquarie, New South Wales, 2444, Australia|Westmead Hospital, Westmead, New South Wales, 2145, Australia|Sunshine Coast Hospital and Health Service, Birtinya, Queensland, 4575, Australia|Townsville University Hospital, Douglas, Queensland, 4814, Australia|Genesiscare North Adelaide, North Adelaide, South Australia, 5006, Australia|Monash Health, Clayton, Victoria, 3168, Australia|Epworth Freemasons, East Melbourne, Victoria, 3002, Australia|St Vincents Hospital Melbourne, Fitzroy, Victoria, 3065, Australia|Austin Health, Heidelberg, Victoria, 3084, Australia|Cabrini Hospital Malvern, Malvern East, Victoria, 3144, Australia|The Alfred Hospital, Melbourne, Victoria, 3004, Australia|Royal Perth Hospital, Perth, Western Australia, 6000, Australia|Perth Blood Institute, West Perth, Western Australia, 6005, Australia|La Trobe Regional Hospital, Melbourne, 3844, Australia|Medizinische Universitatsklinik Innsbruck, Innsbruck, 6020, Austria|Uk St Poelten, St Polten, 3100, Austria|Medical Univeristy Vienna, Wien, 1090, Austria|Hanusch Krankenhaus, Wien, 1140, Austria|Wiener Gesundheitsverbund Klinik Ottakring, Wien, 1160, Austria|Institut Jules Bordet, Anderlecht, 1070, Belgium|Az Sint Jan Brugge, Brugge, 8000, Belgium|Universitair Ziekenhuis Gent, Gand, 9000, Belgium|University Hospitals Leuven, Leuven, 3000, Belgium|Hospital de Amor Barretos, Barretos, 14784-400, Brazil|Clinica de Oncologia Reichow, Blumenau, 89010-340, Brazil|Unesp Faculdade de Medicina Da Universidade Estadual Paulista Campus Botucatu, Botucatu, 18618687, Brazil|Instituto Dor de Pesquisa E Ensino Distrito Federal, Brasilia, 70390140, Brazil|Universidade de Campinas Centro de Hematologia E Hemoterapia, Campinas, 13083-878, Brazil|Fundacao Universidade de Caxias Do Sul, Caxias do Sul, 95070-560, Brazil|Centro Integrado de Oncologia de Curitiba Ss Cionc, Curitiba, 80810-050, Brazil|Hospital Erasto Gaertner, Curitiba, 81520-060, Brazil|Centro de Ensino E Pesquisa Em Oncologia de Santa Catarina (Cepen), Florianopolis, 88020-210, Brazil|Complexo Hospitalar de Niteroi, Niteroi, 24020-096, Brazil|Centro Gaucho Integrado de Oncologia Hospital Mae de Deus, Porto Alegre, 90110-270, Brazil|Instituto Dor de Pesquisa E Ensino Pernambuco, Recife, 50070-170, Brazil|Instituto Dor de Pesquisa E Ensino, Recife, 50070-170, Brazil|Hospital Das Clinicas Da Faculdade de Medicina de Ribeirao Preto Usp, Ribeirao Preto, 14051-140, Brazil|Instituto Americas Ensino, Pesquisa E Inovacao, Rio de Janeiro, 22775-001, Brazil|Hospital Sao Rafaelinstituto Dor de Pesquisa E Ensino, Salvador, 41253-190, Brazil|Ensino E Terapia de Inovacao Clinica Amo Etica, Salvador, 41950-640, Brazil|Hospital Nove de Julho Dasa, Sao Paulo, 01409-001, Brazil|Instituto Dor de Pesquisa E Ensino Sao Paulo, Sao Paulo, 04501-000, Brazil|Hcfmusp Servico de Hematologia, Hemoterapia E Terapia Celular, Sao Paulo, 05402-000, Brazil|Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein, Sao Paulo, 05653-120, Brazil|Hospital Santa Rita de Cassia Afecc, Vitoria, 29043-260, Brazil|Umhat Svgeorgi Ead, Plovdiv, 4002, Bulgaria|Acibadem City Clinic Tokuda Umhat Ead, Department of Medical Oncology, Sofia, 1407, Bulgaria|University Multiprofile Hospital For Active Treatment Saint Ivan Rilski, Sofia, 1407, Bulgaria|NHATHD, Sofia, 1756, Bulgaria|British Columbia Cancer Agency the Vancouver Centre, Vancouver, British Columbia, V5Z 4E6, Canada|Newfoundland and Labrador Health Services, St Johns, Newfoundland and Labrador, A1B 3V6, Canada|Queen Elizabeth Ii Health Sciences Centre, Halifax, Nova Scotia, B3H 2Y9, Canada|Juravinski Cancer Centre, Hamilton, Ontario, L8V 5C2, Canada|London Health Sciences Centre, London, Ontario, N6A 5W9, Canada|Ciusss Du Saguenay Lac St Jean, Chicoutimi, Quebec, G7H 5H6, Canada|Centre Integre de Sante Et de Services Sociaux de Chaudiere Appalaches, Levis, Quebec, G6V 3Z1, Canada|Ciusss de Lest de Lile de Montreal Hopital Maisonneuve Rosemont, Montreal, Quebec, H1T 2M4, Canada|Unite de Recherche Clinique Du Cisss Des Laurentides, SaintJerome, Quebec, J7Z 5T3, Canada|Ciusss de Lestrie Chus, Sherbrooke, Quebec, J1H 5N4, Canada|Chu de Quebec Universite Laval, Hopital de Lenfant Jesus, Centre Integre de Cancerologie (Cic), Quebec, G1J 1Z4, Canada|The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, 241001, China|Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, 100050, China|Beijing Cancer Hospital, Beijing, Beijing, 100142, China|Beijing Friendship Hospital, Capital Medical University(Tongzhou), Beijing, Beijing, 101100, China|Chongqing Cancer Hospital, Chongqing, Chongqing, 400030, China|Fujian Medical University Union Hospital, Fuzhou, Fujian, 350001, China|The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, 361003, China|The First Peoples Hospital of Foshan, Foshan, Guangdong, 528000, China|Sun Yat Sen University Cancer Center, Guangzhou, Guangdong, 510060, China|Huizhou Central Peoples Hospital, Huizhou, Guangdong, 516001, China|Meizhou People Hospital, Meizhou, Guangdong, 514031, China|Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, 524000, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150000, China|Anyang Tumor Hospital, Anyang, Henan, 455001, China|Henan Cancer Hospital, Zhengzhou, Henan, 450000, China|Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, China|Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China|The First Peoples Hospital of Changde City, Changde, Hunan, 415000, China|Jiangsu Province Hospital, Nanjing, Jiangsu, 210029, China|Affiliated Hospital of Nantong University, Nantong, Jiangsu, 201203, China|The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 215006, China|Wuxi Peoples Hospital, Wuxi, Jiangsu, 214023, China|The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang, Jiangxi, 330006, China|Jiangxi Province Cancer Hospital, Nanchang, Jiangxi, 330029, China|The First Affiliated Hospital of Nanchang University Branch Xianghu, Nanchang, Jiangxi, 332000, China|The First Hospital of Jilin University, Changchun, Jilin, 130021, China|Shengjing Hospital of China Medical University, Shenyang, Liaoning, 110004, China|Liaoning Cancer Hospital and Institute, Shenyang, Liaoning, 110042, China|Peoples Hospital of Rizhao, Rizhao, Shandong, 276827, China|The Second Affiliated Hospital of Shandong First Medical University, Taian, Shandong, 271099, China|Fudan University Shanghai Cancer Center, Shanghai, Shanghai, 200000, China|Shanxi Provincial Cancer Hospital, Taiyuan, Shanxi, 030013, China|West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China|Dongyang Peoples Hospital, Dongyang, Zhejiang, 322103, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, 310022, China|The First Hospital of Jiaxing, Jiaxing, Zhejiang, 314001, China|Jinhua Municipal Central Hospital, Jinhua, Zhejiang, 321000, China|The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China|Fakultni Nemocnice Hradec Kralove, Hradec Kralove, 500 03, Czechia|Fakultni Nemocnice Olomouc, Olomouc, 77900, Czechia|Hopital Prive Dantony, Departement Dhemathologie, Antony, 92160, France|Centre Hospitalier Le Mans, Le Mans, 72037, France|Chu Montpellier Hopital Saint Eloi, Montpellier, 34090, France|Hopital Larchet Chu Nice, Nice, 06200, France|Institut Curie, Paris, 75005, France|Necker University Hospital, Paris, 75015, France|Icans Institut de Cancerologie Strasbourg Europe, Strasbourg, 67200, France|Chu Nancy Hopital Brabois, VandoeuvrelesNancy, 54511, France|High Technology Hospital Medcenter Ltd, Batumi, 6000, Georgia|JSC VIAN, Kutaisi, 4600, Georgia|K Eristavi National Center of Experimental and Clinical Surgery Jsc, Tbilisi, 0159, Georgia|Oncology Research Center Ltd, Tbilisi, 0186, Georgia|Universitaetsklinikum Essen, Essen, 45147, Germany|Universitaetsklinikum Ulm, Ulm, 89081, Germany|University Hospital of Alexandroupolis, Alexandroupolis, 68100, Greece|Evaggelismos, Athens, 106 76, Greece|General Hospital of Athens Alexandra, Athens, 115 28, Greece|University Hospital of Patra, Patras, 26504, Greece|St Jamess Hospital, Dublin, D8, Ireland|University Hospital Waterford, Waterford, X91 ER8E, Ireland|Haemek Medical Center, Afula, 1834111, Israel|Assuta Ashdod Medical Center, Ashdod, 7747629, Israel|Shaare Zedek Medical Center, Jerusalem, 9103102, Israel|Hadassah En Karem Medical Center, Jerusalem, 9112001, Israel|Rabin Medical Center, Petach Tikva, 49100, Israel|Chaim Sheba Medical Center, Ramat gan, 5265601, Israel|Assuta Medical Center, Tel Aviv Jaffa, 60000, Israel|Sourasky Tel Aviv Medical Center, Tel Aviv Jaffa, 6423906, Israel|Cro Irccs Aviano, Aviano, 33081, Italy|Irccs Azienda Ospedaliero Universitaria Bologna, Bologna, 40138, Italy|Aou Careggi, Servizio Sanitario Toscana, Firenze, 50134, Italy|Istituto Europeo Di Oncologia, Milano, 20141, Italy|Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Milano, 20162, Italy|Aou Maggiore Della Carita, Novara, 28100, Italy|Azienda Ospedaliera Di Padova, Padova, 35128, Italy|Irccs Policlinico San Matteo, Universita Degli Studi Di Pavi, Pavia, 27100, Italy|Arcispedale S Maria Nuova Ausl Reggio Emilia Hematology Unit, Reggio Emilia, 42123, Italy|Aou Santa Maria Della Misericordia Di Udine, Udine, 33100, Italy|Ospedale Di Circolo E Fondazione Macchi, Varese, 21100, Italy|Aichi Cancer Center Hospital Clinical Oncology, Nagoya, Aichi, 464-8681, Japan|Matsuyama Red Cross Hospital, Matsuyamashi, Ehime, 790 8524, Japan|Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital, Hiroshimashi, Hiroshima, 730-8619, Japan|National Hospital Organization Hokkaido Cancer Center, SapporoShi, Hokkaido, 003-0804, Japan|Aiiku Hospital, SapporoShi, Hokkaido, 064-0804, Japan|Kanagawa Cancer Center, Yokohamashi, Kanagawa, 241-8515, Japan|University Hospital, Kyoto Prefectural Univ of Medicine, KyotoShi, Kyoto, 602-8566, Japan|Tohoku University Hospital, Sendaishi, Miyagi, 980-8574, Japan|Kurashiki Central Hospital, Kurashikishi, Okayama, 710-8602, Japan|Kansai Medical University Hospital, Hirakata, Osaka, 573-1191, Japan|Kindai University Hospital, Osakasayama, Osaka, 589-8511, Japan|Tokyo Metropolitan Komagome Hospital, Bunkyoku, Tokyo, 113-8677, Japan|National Cancer Center Hospital, ChuoKu, Tokyo, 104-0045, Japan|Cancer Institute Hospital of Jfcr, Kotoku, Tokyo, 135-8550, Japan|Yamagata University Hospital, Yamagatashi, Yamagata, 990-9585, Japan|Kumamoto University Hospital, Kumamoto, 860-8556, Japan|National Hospital Organization Okayama Medical Center, Okayama, 701-1192, Japan|Yokohama Municipal Citizens Hospital, YokohamaShi, 221-0855, Japan|Inje University Busan Paik Hospital, BusanjinGu, Busan Gwang'yeogsi, 47392, Korea, Republic of|Dong A University Hospital, SeoGu, Busan Gwang'yeogsi, 49201, Korea, Republic of|Pusan National University Hospital, SeoGu, Busan Gwang'yeogsi, 49241, Korea, Republic of|Seoul National University Bundang Hospital, BundangGu SeongnamSi, Gyeonggi-do, 13620, Korea, Republic of|Kyungpook National University Chilgok Hospital, BukGu, Gyeongsangbukdo, 41404, Korea, Republic of|Gyeongsang National University Hospital, JinjuSi, Gyeongsangnamdo, 52727, Korea, Republic of|Chonnam National University Hwasun Hospital, HwasunGun, Jeollanam-do, 58128, Korea, Republic of|Samsung Medical Center, GangnamGu, Seoul Teugbyeolsi, 06351, Korea, Republic of|The Catholic University of Korea, Seoul St Marys Hospital, SeochoGu, Seoul Teugbyeolsi, 06591, Korea, Republic of|Severance Hospital Yonsei University Health System, SeodaemunGu, Seoul Teugbyeolsi, 03722, Korea, Republic of|Seoul National University Hospital, Seoul, Seoul Teugbyeolsi, 03080, Korea, Republic of|Asan Medical Center, SongpaGu, Seoul Teugbyeolsi, 05505, Korea, Republic of|Soon Chun Hyang University Hospital Seoul, YongsanGu, Seoul Teugbyeolsi, 04401, Korea, Republic of|Szpital Uniwersytecki Nr Im Dr Jana Biziela, Bydgoszcz, 85-168, Poland|Uniwersyteckie Centrum Kliniczne Klinika Hematologii I Transplantologii, Gdask, 80-214, Poland|Pratia Onkologia Katowice, Katowice, 40-519, Poland|Pratia McM Krakow, Krakow, 30-727, Poland|Uniwersytecki Szpital Kliniczny W Poznaniu, Oddzial Hematologii I Transplantacji Szpiku, Poznan, 60-569, Poland|Wojewodzki Szpital Zespolony Im L Rydygiera W Toruniu, Torun, 87-100, Poland|Centralny Szpital Kliniczny Uck Wum, Warszawa, 02-097, Poland|Instytut Hematologii I Transfuzjologii, Warszawa, 02-776, Poland|Narodowy Instytut Onkologii Im Marii Skodowskiej Curie Hematology Unit, Warszawa, 02-781, Poland|Hospital de Braga, Braga, 4710-243, Portugal|Instituto Portugues de Oncologia Do Porto Francisco Gentil, Epe, Porto, 4200-072, Portugal|Unidade Local de Saude Gaia E Espinho, VILA NOVA DE GAIA Porto, 4434-502, Portugal|Auxilio Mutuo Cancer Center, San Juan, 00917, Puerto Rico|Coltea Clinical Hospital, Bucharest, 30171, Romania|Institutul Oncologic Prof Dr Ion Chiricuta Cluj Napoca, ClujNapoca, 400015, Romania|Institutul Regional de Oncologie Iasi, Iasi, 700483, Romania|Spitalul Clinic Judetean de Urgenta Bihor, Oradea, 410469, Romania|University of Cape Town, Cape Town, 7925, South Africa|Haemalife, Kuils River, 7579, South Africa|Alberts Cellular Therapy, Pretoria, O181, South Africa|Ico Badalona, Badalona, 08916, Spain|Hospital Universitario de Burgos, Burgos, 09006, Spain|Hospital Universitario Puerta Del Mar, Cadiz, 11009, Spain|Hospital Universitario Virgen de Las Nieves, Granada, 18014, Spain|Institut Catala Doncologia Hospital Duran I Reynals, Hospitalet de LLobregat, 8908, Spain|Complejo Asistencial Universitario de Leon, Leon, 24071, Spain|Hospital de La Princesa, Madrid, 28006, Spain|Clinica Universidad de Navarra, Madrid, 28027, Spain|Hospital Universitario Infanta Leonor, Madrid, 28031, Spain|Hospital Universitario Ramon Y Cajal, Madrid, 28048, Spain|H Puerta de Hierro Majadahonda, Majadahonda, 28222, Spain|Hospital Clinico Universitario Virgen de La Arrixaca, Murcia, 30120, Spain|Clinica Universidad de Navarra Pamplona, Pamplona, 31008, Spain|Hospital Universitario Quironsalud Madrid, Pozuelo de Alarcon, 28223, Spain|Hospital Universitario de Salamanca, Salamanca, 37007, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, 41013, Spain|Hospital Universitari Mutua Terrassa, Terrassa, 8221, Spain|St Claraspital, Basel, 4058, Switzerland|Hfr Fribourg, Fribourg, 1708, Switzerland|Reseau Hospitalier Neuchatelois, La ChauxdeFonds, 2300, Switzerland|Universitatsspital Zurich, Zurich, 8091, Switzerland|Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, 06200, Turkey|Ankara University Medical Faculty, Ankara, 06620, Turkey|Gazi University Medical School, AOCiftlii, 06560, Turkey|Ondokuz Mayis University Medicine Faculty Hospital, Atakum Samsun, 55200, Turkey|Dokuz Eylul University, Balcova, 35330, Turkey|Bagcilar Medipol Mega Hospital, Istanbul, 34214, Turkey|Kocaeli Universitesi Tip Fakultesi, Kocaeli, 41380, Turkey|Vkv American Hospital, Tevikiye, 34365, Turkey|Beatson West of Scotland Cancer Centre, Glasgow, G12 0YN, United Kingdom|The Christie Hospital, Greater Manchester, M20 4BX, United Kingdom|Huddersfield Royal Infirmary, Huddersfield, HD3 3EA, United Kingdom|Nhs Highland, Inverness, IV2 3BW, United Kingdom|The Leeds Teaching Hospitals Nhs Trust, Leeds, LS9 7TF, United Kingdom|Barts Health Nhs Trust, London, EC1A 7BE, United Kingdom|University College Hospital, London, NW1 2PG, United Kingdom|Derriford Hospital, Plymouth, PL6 8DH, United Kingdom|Southampton General Hospital, Southampton, SO16 6YD, United Kingdom",
NCT04994717,Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT04994717,,RECRUITING,The safety run-in part of the study aims to evaluate the safety and tolerability of blinatumomab alternating with low-intensity chemotherapy. The phase 3 part of the study aims to compare event-free survival (EFS) and overall survival (OS) of participants receiving blinatumomab alternating with low-intensity chemotherapy to EFS and (OS) of participants receiving standard of care (SOC) chemotherapy.,NO,Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL),DRUG: Blinatumomab|DRUG: Low-intensity chemotherapy regimen|DRUG: SOC chemotherapy regimen,"Safety run-in: Number of Participants who Experience Treatment-emergent Adverse Events (TEAEs), Number and percentage of participants who experience one or more TEAE, serious TEAE, treatment-related adverse events, and adverse events of interest., Up to approximately 5 years|Phase 3: Event-free Survival (EFS), Time from randomization (enrollment) until treatment failure, relapse or death from any cause, whichever is earlier.

Treatment failure is defined as not achieving a hematological complete CR with MRD response \<10-4 by the end of the initial disease assessment period.

Relapse is defined as hematologic relapse, extramedullary relapse, and/or molecular relapse (MRD positivity \>= 10\^-3), whichever occurs earlier, in participants with prior achievement of hematologic CR with MRD response \<10\^-4.

Participants without an event will be censored at their last evaluable disease assessment date., Up to approximately 5 years|Phase 3: Overall Survival (OS), OS is defined as time from randomization (enrollment) until death due to any cause., Up to approximately 5 years","Safety run-in: Complete Remission (CR) Rate by the End of Initial Disease Assessment Period, Baseline to Week 14|Safety run-in: Minimal Residual Disease (MRD) Response by the End of Initial Disease Assessment Period, MRD response is defined as the percentage of participants who achieve a response of \< 10\^-4 measured by polymerase chain reaction (PCR)., Baseline to Week 14|Safety run-in: Relapse-free Survival (RFS), RFS: In participants who achieve CR, the time from first achievement of this response until date of the first relapse including hematologic relapse, extramedullary relapse, or death due to any cause, whichever occurs first., Up to approximately 5 years|Safety run-in: Minimal Residual Disease (MRD) Relapse Free Survival (RFS), MRD RFS: In participants who achieve CR with MRD response, the time from first achievement of this response until date of of the first relapse including molecular relapse, hematological relapse, and/or extramedullary relapse, or death due to any cause, whichever occurs first. (Molecular relapse will be defined 2 ways: MRD\>= 10\^-3 and MRD\>=10\^-4. Participants without an event will be censored at their last evaluable disease assessment date., Up to approximately 5 years|Safety run-in: Steady State Concentration (Css) of Blinatumomab, Up to approximately 34 weeks|Safety run-in: Clearance (CL) of Blinatumomab, Up to approximately 34 weeks|Phase 3: Change from Baseline to End of Initial Disease Assessment Period in Fatigue Score, Fatigue score will be measured by Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue - Short Form 7a., Baseline to Week 14|Phase 3: Change from Baseline to End of Initial Disease Assessment Period in Pain Score, Pain score will be measured by Brief Pain Inventory - Short Form (BPI-SF); Item 3: pain at its worst in the last 24 hours., Baseline to Week 14|Phase 3: Change from Baseline to End of Initial Disease Assessment Period in Global Health Status, Global health status will be measured by the Quality of Life Questionnaire (QLQ)-C30 global health status quality of life scale., Baseline to Week 14|Phase 3: Change from Baseline to End of Initial Disease Assessment Period in Physical Function, Physical function will be measured by the QLQ-C30 functional scale., Baseline to Week 14|Phase 3: Change from Baseline to End of Initial Disease Assessment Period in Nausea and Vomiting, Nausea and vomiting will be measured by the QLQ-C30 symptom scale., Baseline to Week 14|Phase 3: Complete Remission (CR) Rate by the End of Initial Disease Assessment Period, Baseline to Week 14|Phase 3: Minimal Residual Disease (MRD) Response by the End of Initial Disease Assessment Period, MRD response is defined as the percentage of participants who achieve a response of \< 10\^4 measured by polymerase chain reaction (PCR)., Baseline to Week 14|Phase 3: Relapse-free Survival (RFS), RFS: In participants who achieve CR, the time from first achievement of this response until the date of the first relapse including hematologic relapse, extra medullary relapse, or death due to any cause, whichever occurs first. Participants without an event will be censored at their last evaluable disease assessment date., Up to approximately 5 years|Phase 3: Minimal Residual Disease (MRD) Relapse Free Survival (RFS), In participants who achieve CR with MRD response, the time from first achievement of this response until date of the first relapse including molecular relapse, hematologic relapse, and/or extramedullary relapse, or death due to any cause, whichever occurs first. Molecular relapse will be defined 2 ways: MRD\>= 10\^-3 and MRD\>= 10\^-4. Participants without an event will be censored at their last evaluable disease assessment date, Up to approximately 5 years|Phase 3: Minimal Residual Disease (MRD) Over Time, Up to approximately 5 years|Phase 3: Number of Participants who Experience Treatment-emergent Adverse Events (TEAEs), Number and percentage of participants who experience one or more TEAE, serious TEAE, treatment-related adverse events, and adverse events of interest., Up to approximately 5 years|Phase 3: Number of Participants who Experience Cluster of Differentiation (CD) 19 Positive and Negative Relapse by Flow Cytometry for Bone Marrow, Up to approximately 5 years|Phase 3: Number of Participants who Experience Cluster of Differentiation (CD) 19 Positive and Negative Relapse Identified by Immunohistochemistry or Flow Cytometry for Cerebrospinal Fluid, Up to end of safety follow up (approximately 44 months)|Phase 3: Number of Participants who Experience Cluster of Differentiation (CD) 19 Positive and Negative Relapse for Extramedullary Sites other than Cerebrospinal Fluid, Up to end of safety follow up (approximately 44 months)|Phase 3: Rate of Lineage Switch to Acute Myeloid Leukemia (AML), Up to end of safety follow up (approximately 44 months)|Phase 3: Localization of Relapse by Clinical Assessment, Up to end of safety follow up (approximately 44 months)|Phase 3: Mortality Rate in Participants who Experience Complete Remission (CR), Up to approximately 5 years|Phase 3: Number of Participants who have Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT) in Participants who Experience Continuous First Complete Remission (CR), Up to approximately 5 years|Phase 3: Mortality Rate in Participants who Experience Complete Remission (CR) after Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT), Up to approximately 5 years|Phase 3: Relapse Rate Following Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT), Up to approximately 5 years|Phase 3: Time to Deterioration using the Fatigue Score, Fatigue score will be measured by PROMIS Fatigue-Short Form 7a., Up to approximately 5 years|Phase 3: Time to Improvements using the Fatigue Score, Fatigue score will be measured by PROMIS Fatigue-Short Form 7a., Up to approximately 5 years|Phase 3: Time to Deterioration using the Pain Score, Pain score will be measured by BPI-SF; Item 3: pain at its worst in the last 24 hours., Up to approximately 5 years|Phase 3: Time to Improvements using the Pain Score, Pain score will be measured by BPI-SF; Item 3: pain at its worst in the last 24 hours., Up to approximately 5 years|Phase 3: Change from Baseline in Global Health Status, Physical Function, Nausea/Vomiting, and All Other Subscales of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), EORTC QLQ-C30 will include global health status, physical functioning, emotional functioning, cognitive functioning, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, diarrhea, and financial difficulties will be measured by EORTC QLQ-C30., Baseline to end of study (up to approximately 5 years)|Phase 3: Time to Deterioration for Global Health Status, Physical Function, Nausea/Vomiting, and All Other Subscales of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), Global health status, physical functioning, role functioning, emotional functioning, cognitive functioning, social functioning, fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, diarrhea, and financial difficulties will be measured by EORTC QCQ-C30., Up to approximately 5 years|Phase 3: Time to Improvements for Global Health Status, Physical Function, Nausea/Vomiting, and All Other Subscales of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), Global health status, physical functioning, role functioning, emotional functioning, cognitive functioning, social functioning, fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, diarrhea, and financial difficulties will be measured by EORTC QCQ-C30., Up to approximately 5 years|Steady State Concentration of Blinatumomab, Up to approximately Day 36|Clearance of Blinatumomab, Up to approximately Day 36",,Amgen,,ALL,"ADULT, OLDER_ADULT",PHASE3,284,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-11-02,2027-06-24,2031-09-30,2021-08-06,,2025-06-05,"City of Hope National Medical Center, Duarte, California, 91010, United States|University of California Irvine, Orange, California, 92868-3201, United States|University of California San Francisco, San Francisco, California, 94143, United States|Adventist Health System/Sunbelt, Inc d/b/a AdventHealth Orlando, Orlando, Florida, 32804, United States|Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States|Saint Francis Hospital, Inc, Greenville, South Carolina, 29607, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|Canberra Hospital, Garran, Australian Capital Territory, 2605, Australia|Royal Prince Alfred Hospital, Camperdown, New South Wales, 2050, Australia|Liverpool Hospital, Liverpool, New South Wales, 2170, Australia|Royal North Shore Hospital, St Leonards, New South Wales, 2065, Australia|Westmead Hospital, Westmead, New South Wales, 2145, Australia|Royal Brisbane and Womens Hospital, Herston, Queensland, 4029, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, 4102, Australia|Royal Adelaide Hospital, Adelaide, South Australia, 5000, Australia|Monash Medical Centre, Clayton, Victoria, 3168, Australia|Austin Health, Austin Hospital, Heidelberg, Victoria, 3084, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, 3000, Australia|The Alfred Hospital, Melbourne, Victoria, 3004, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, 6150, Australia|Medizinische Universitaet Graz, Graz, 8036, Austria|Medizinische Universitaet Innsbruck, Innsbruck, 6020, Austria|Ordensklinikum Linz Elisabethinen, Linz, 4020, Austria|Hanusch Krankenhaus, Wien, 1140, Austria|Institut Jules Bordet, Anderlecht, 1070, Belgium|AZ Sint-Jan Brugge-Oostende AV, Brugge, 8000, Belgium|Universite Catholique de Louvain Cliniques Universitaires Saint Luc, Bruxelles, 1200, Belgium|Universitair Ziekenhuis Antwerpen, Edegem, 2650, Belgium|Universitair Ziekenhuis Gent, Ghent, 9000, Belgium|Jessa Ziekenhuis - Campus Virga Jesse, Hasselt, 3500, Belgium|Centre Hospitalier Universitaire de Liege - Sart Tilman, Liege, 4000, Belgium|AZ Delta Campus Rumbeke, Roeselare, 8800, Belgium|Centre Hospitalier Universitaire Dinant Godinne - Universite Catholique de Louvain Namur, Yvoir, 5530, Belgium|Hospital das Clinicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, 90035-003, Brazil|Fundacao Amaral Carvalho, Jau, SÃ£o Paulo, 17210-120, Brazil|Instituto do Cancer do Estado de Sao Paulo Octavio Frias de Oliveira Icesp, SÃ£o Paulo, 01246-000, Brazil|University Multiprofile Hospital for Active Treatment Sveti Georgi EAD, Plovdiv, 40002, Bulgaria|Specialized Hospital for Active Treatment of Hematology Diseases EAD, Sofia, 1797, Bulgaria|Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta, T2N 5G2, Canada|Vancouver General Hospital, Gordon and Leslie Diamond Health Care Centre, Vancouver, British Columbia, V5Z 1M9, Canada|Cancer Care Manitoba, Winnipeg, Manitoba, R3H 0V9, Canada|Queen Elizabeth II, Health Sciences Centre, Halifax, Nova Scotia, B3H 1V8, Canada|Hamilton Health Sciences - Juravinski Hospital and Cancer Centre, Hamilton, Ontario, L8V 5C2, Canada|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, K1H 8L6, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, M5G 2M9, Canada|CEMTL Hopital Maisonneuve Rosemont, Montreal, Quebec, H1T 2M4, Canada|Fundacion Arturo Lopez Perez, Santiago, 7500921, Chile|Inmunocel, Santiago, 7580206, Chile|Clinica Alemana de Santiago, Santiago, 7650729, Chile|Aalborg Universitetshospital, Aalborg, 9000, Denmark|Aarhus Universitetshospital, Aarhus N, 8200, Denmark|Rigshospitalet, KÃ¸benhavn Ã, 2100, Denmark|Odense Universitetshospital, Odense, 5000, Denmark|Helsinki University Hospital, Helsinki, 00029, Finland|Turku University Hospital, Turku, 20521, Finland|Hopital Henri Mondor, Creteil, 94010, France|Centre Hospitalier Universitaire de Dijon - Hopital du Bocage, Dijon, 21000, France|Centre Hospitalier de Versailles - Hopital Andre Mignot, Le Chesnay Cedex, 78157, France|Centre Hospitalier Regional Universitaire de Lille - Hopital Claude Huriez, Lille, 59000, France|Institut Paoli Calmettes, Marseille, 13009, France|Centre Hospitalier Universitaire de Nantes - Hopital Hotel Dieu, Nantes, 44000, France|Centre Hospitalier Universitaire Archet 2, Nice cedex 3, 06202, France|Hopital Saint Louis, Paris, 75010, France|Hopital Saint Antoine, Paris, 75012, France|Centre Hospitalier Universitaire de Bordeaux - Hopital Haut Leveque, Pessac Cedex, 33604, France|Hopital Lyon Sud, Pierre Benite, 69645, France|Centre Hospitalier Universitaire de Rennes, Rennes Cedex 9, 35000, France|Institut Universitaire du Cancer Toulouse Oncopole, Toulouse cedex 9, 31059, France|Centre Hospitalier Universitaire de Nancy - Hopital de Brabois, Vandoeuvre les Nancy Cedex, 54511, France|Universitaetsklinikum Augsburg, Augsburg, 86156, Germany|Charite - Universitaetsmedizin Berlin, Campus Benjamin Franklin, Berlin, 12203, Germany|Universitaetsklinikum Dresden, Dresden, 01307, Germany|Universitaetsklinikum Duesseldorf, Duesseldorf, 40225, Germany|Universitaetsklinikum Heidelberg, Heidelberg, 69120, Germany|Universitaetsklinikum Jena, Jena, 07747, Germany|Universitaetsklinikum Schleswig-Holstein, Kiel, 24105, Germany|Klinikum der LMU Muenchen, Muenchen, 81377, Germany|Evangelismos Hospital, Athens, 10676, Greece|Laiko General Hospital of Athens, Athens, 11527, Greece|Attiko General University Hospital, Athens, 12462, Greece|University Hospital of Heraklion, Heraklion, 71500, Greece|University Hospital of Ioannina, Ioannina, 45500, Greece|University Hospital of Larissa, Larissa, 41110, Greece|University Hospital of Patras, Patras, 26504, Greece|General Hospital of Thessaloniki Georgios Papanikolaou, Thessaloniki, 57010, Greece|Queen Mary Hospital, The University of Hong Kong, Hong Kong, Hong Kong|Princess Margaret Hospital, Kowloon, Hong Kong|Semmelweis Egyetem, Budapest, 1088, Hungary|Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet, Budapest, 1097, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, 4032, Hungary|Heves Varmegyei Markhot Ferenc Oktatokorhaz es Rendelointezet, Eger, 3300, Hungary|Szabolcs-Szatmar-Bereg Varmegyei Oktatokorhaz Nyiregyhazi Josa Andras Tagkorhaz, Nyiregyhaza, 4400, Hungary|Azienda Ospedaliera Universitaria Consorziale Policlinico di Bari, Bari, 70124, Italy|Azienda Socio Sanitaria Territoriale Papa Giovanni xxiii, Bergamo, 24127, Italy|IRCCS Azienda Ospedaliero Universitaria di Bologna Policlinico di Sant Orsola, Bologna, 40138, Italy|Ospedale Policlinico San Martino IRCCS, Genova, 16132, Italy|Azienda Unita Sanitaria Locale LE Presidio Ospedaliero Vito Fazzi Polo Oncologico Giovanni Paolo II, Lecce, 73100, Italy|Azienda UnitÃ  Locale Socio Sanitaria 3 Ospedale Dell Angelo, Mestre (VE), 30174, Italy|Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milano, 20122, Italy|Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli, Napoli, 80131, Italy|Azienda Ospedaliera di Perugia Ospedale Santa Maria della Misericordia, Perugia, 06156, Italy|Azienda Unita Sanitaria Locale Pescara Ospedale Civile Santo Spirito, Pescara, 65124, Italy|Azienda Ospedaliera Policlinico Umberto I, Roma, 00161, Italy|Azienda Ospedaliera Universitaria Integrata di Verona Ospedale G B Rossi Borgo Roma, Verona, 37134, Italy|Nagoya University Hospital, Nagoya-shi, Aichi, 466-8560, Japan|Akita University Hospital, Akita-shi, Akita, 010-8543, Japan|Tesshokai Kameda General Hospital, Kamogawa-shi, Chiba, 296-8602, Japan|University of Fukui Hospital, Yoshida-gun, Fukui, 910-1193, Japan|Kyushu University Hospital, Fukuoka-shi, Fukuoka, 812-8582, Japan|Kurume University Hospital, Kurume-shi, Fukuoka, 830-0011, Japan|Fukushima Medical University Hospital, Fukushima-shi, Fukushima, 960-1295, Japan|Gunma Saiseikai Maebashi Hospital, Maebashi-shi, Gunma, 371-0821, Japan|Sapporo Hokuyu Hospital, Sapporo-shi, Hokkaido, 003-0006, Japan|Kobe City Medical Center General Hospital, Kobe-shi, Hyogo, 650-0047, Japan|Kanazawa University Hospital, Kanazawa-shi, Ishikawa, 920-8641, Japan|Tokai University Hospital, Isehara-shi, Kanagawa, 259-1193, Japan|Yokohama City University Medical Center, Yokohama-shi, Kanagawa, 232-0024, Japan|Kyoto University Hospital, Kyoto-shi, Kyoto, 606-8507, Japan|Tohoku University Hospital, Sendai-shi, Miyagi, 980-8574, Japan|Nagasaki University Hospital, Nagasaki-shi, Nagasaki, 852-8501, Japan|National Hospital Organization Okayama Medical Center, Okayama-shi, Okayama, 701-1192, Japan|Osaka Metropolitan University Hospital, Osaka-shi, Osaka, 545-8586, Japan|Kindai University Hospital, Osakasayama-shi, Osaka, 589-8511, Japan|Jichi Medical University Hospital, Shimotsuke-shi, Tochigi, 329-0498, Japan|Nihon University Itabashi Hospital, Itabashi-ku, Tokyo, 173-8610, Japan|Yamagata University Hospital, Yamagata-shi, Yamagata, 990-9585, Japan|Pusan National University Hospital, Busan, 49241, Korea, Republic of|Chonnam National University Hwasun Hospital, Hwasun, 58128, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Severance Hospital Yonsei University Health System, Seoul, 03722, Korea, Republic of|The Catholic University of Korea Seoul St Marys Hospital, Seoul, 06591, Korea, Republic of|Boca Clinical Trials Mexico SC, Ciudad de Mexico, Distrito Federal, 01120, Mexico|Centro Oncologico Internacional, Mexico City, Distrito Federal, 01330, Mexico|Hospital Universitario Dr Jose Eleuterio Gonzalez, Monterrey, Nuevo LeÃ³n, 64460, Mexico|Hematologica Alta Especialidad, Huixquilucan, 52787, Mexico|Universitair Medisch Centrum Groningen, Groningen, 9713 GZ, Netherlands|Unidade Local de Saude de Coimbra, EPE, Coimbra, 3004-561, Portugal|Instituto Portugues de Oncologia de Lisboa Francisco Gentil, EPE, Lisboa, 1099-023, Portugal|Unidade Local de Saude de Sao Jose, EPE - Hospital de Santo Antonio dos Capuchos, Lisboa, 1169-050, Portugal|Unidade Local de Saude de Santa Maria, EPE - Hospital de Santa Maria, Lisboa, 1649-035, Portugal|Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE, Porto, 4200-072, Portugal|Institutul Clinic Fundeni, Bucharest, 022328, Romania|Institutul Oncologic Prof Dr Ion Chiricuta, Cluj-Napoca, 400015, Romania|Institutul Regional de Oncologie Iasi, Iasi, 700483, Romania|Spitalul Clinic Judetean de Urgenta Sibiu, Sibiu, 550245, Romania|Hospital Universitario Reina Sofia, Cordoba, AndalucÃ­a, 14004, Spain|Hospital Universitario Virgen del Rocio, Sevilla, AndalucÃ­a, 41013, Spain|Hospital Universitario Marques de Valdecilla, Santander, Cantabria, 39008, Spain|Complejo Asistencial Universitario de Salamanca Hospital Universitario de Salamanca, Salamanca, Castilla LeÃ³n, 37007, Spain|Institut Catala d Oncologia Badalona Hospital Universitari Germans Trias i Pujol, Badalona, CataluÃ±a, 08916, Spain|Hospital Universitari Vall d Hebron, Barcelona, CataluÃ±a, 08035, Spain|Institut Catala d Oncologia Hospitalet Hospital Duran i Reynals, Hospitalet de Llobregat, CataluÃ±a, 08908, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Comunidad Valenciana, 46026, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Sahlgrenska Universitetssjukhuset, Goteborg, 413 45, Sweden|Inselspital Bern, Bern, 3010, Switzerland|China Medical University Hospital, Taichung, 40458, Taiwan|Taichung Veterans General Hospital, Taichung, 40705, Taiwan|National Cheng Kung University Hospital, Tainan, 70403, Taiwan|National Taiwan University Hospital, Taipei, 10002, Taiwan|Linkou Chang Gung Memorial Hospital of Chang Gung Medical Foundation, Taoyuan, 33305, Taiwan|Hacettepe Universitesi Tip Fakultesi Hastanesi, Ankara, 06100, Turkey|Ankara Bilkent Sehir Hastanesi, Ankara, 06800, Turkey|Memorial Antalya Hastanesi, Antalya, 07025, Turkey|Bagcilar Medipol Mega Universite Hastanesi, Istanbul, 34214, Turkey|Dokuz Eylul Universitesi Tip Fakultesi Hastanesi, Izmir, 35340, Turkey|Ondokuz Mayis Universitesi Tip Fakultesi Hastanesi, Samsun, 55139, Turkey|University College London, London, NW1 2PG, United Kingdom|Kings College Hospital, London, SE5 9RS, United Kingdom",
NCT06117774,Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC),https://clinicaltrials.gov/study/NCT06117774,DeLLphi-306,RECRUITING,The primary objective of this study is to compare the efficacy of tarlatamab with placebo as assessed by progression free survival (PFS).,NO,Limited Stage Small Cell Lung Cancer|Small Cell Lung Cancer,DRUG: Tarlatamab|DRUG: Placebo,"PFS as Determined by Blinded Independent Central Review (BICR), Up to approximately 6 years","Overall Survival (OS) Over the Whole Trial, Up to approximately 6 years|PFS Determined by Investigator Assessment, Up to approximately 6 years|Objective Response (OR) Rate, Up to approximately 6 years|Disease Control (DC) Rate, Up to approximately 6 years|Duration of Response (DOR), Up to approximately 6 years|PFS at 6 months, 1 year, 2 years, 6 months, 1 year, 2 years|OS at 6 months, 1 year, 2 years, 3 years, 6 months, 1 year, 2 years, 3 years|Time to Progression (TTP), Up to approximately 6 years|Number of Participants with Treatment-emergent Adverse Events (TEAEs), Up to approximately 6 years|Serum Concentration of Tarlatamab, Up to approximately 4 months|Incidence of Anti-tarlatamab Antibody Formation, Up to approximately 1 year",,Amgen,,ALL,"ADULT, OLDER_ADULT",PHASE3,400,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2024-02-20,2029-10-31,2029-10-31,2023-11-07,,2025-06-13,"Valkyrie Clinical Trials, Los Angeles, California, 90067, United States|University of California Los Angeles, Santa Monica, California, 90404, United States|Yale New Haven Hospital, New Haven, Connecticut, 06510, United States|Boca Raton Clinical Research Global South Florida, Plantation, Florida, 33322, United States|University of Louisville James Graham Brown Cancer Center, Louisville, Kentucky, 40202, United States|Our Lady of the Lake Cancer Institute, Baton Rouge, Louisiana, 70808, United States|Morristown Medical Center, Morristown, New Jersey, 07960, United States|Montefiore Einstein Center for Cancer Care, Bronx, New York, 10461, United States|New York University Grossman School of Medicine and New York University Langone Hospitals, New York, New York, 10016, United States|Perlmutter Cancer Center at New York University Langone Hospital - Long Island, New York, New York, 10016, United States|FirstHealth Cancer Center, Pinehurst, North Carolina, 28374, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, 18103, United States|Spokenword Clinical Trials, Easton, Pennsylvania, 18045, United States|Renovatio Clinical, The Woodlands, Texas, 77380, United States|US Oncology Research Investigational Products Center, The Woodlands, Texas, 77380, United States|University of Virginia Health System, Charlottesville, Virginia, 22908, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, 22031, United States|West Virginia University Health Sciences Center, Morgantown, West Virginia, 26506, United States|Fundacion Respirar, Ciudad Autonoma de Buenos Aires, Buenos Aires, C1426ABP, Argentina|Hospital Italiano de La Plata, La Plata, Buenos Aires, 1900, Argentina|Hospital Universitario Austral, Pilar, Buenos Aires, B1629ODT, Argentina|Instituto Oncologico de Cordoba Ionc Fundacion Richardet Longo, Cordoba, CÃ³rdoba, 5003, Argentina|Hospital Aleman Buenos Aires, Caba, Distrito Federal, C1118AAT, Argentina|Clinica Viedma, Viedma, RÃ­o Negro, R8500ACE, Argentina|Sanatorio 9 de Julio Cice 9 de Julio, San Miguel de Tucuman, Tucuman, 4000, Argentina|Instituto Argentino de DiagnÃ³stico y Tratamiento, Buenos Aires, C1122AAL, Argentina|Port Macquarie Base Hospital, Port Macquarie, New South Wales, 2444, Australia|Westmead Hospital, Westmead, New South Wales, 2145, Australia|Flinders Medical Centre, Bedford Park, South Australia, 5042, Australia|Monash Medical Centre, Clayton, Victoria, 3168, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, 6150, Australia|Medizinische Universitaet Graz, Graz, 8036, Austria|Universitaetsklinikum Allgemeines Krankenhaus Wien, Wien, 1090, Austria|Institut Jules Bordet, Brussels, B-1070, Belgium|Universitair Ziekenhuis Gent, Gent, 9000, Belgium|Oncoclinicas Onco Vida Distrito Federal, Brasilia, Distrito Federal, 70200-730, Brazil|Hospital Santa Rita, Vitoria, EspÃ­rito Santo, 29043-260, Brazil|Liga Paranaense do Combate ao Cancer - Hospital Erasto Gaertner, Curitba, ParanÃ¡, 81520-060, Brazil|Londrina Cancer Hospital, Londrina, ParanÃ¡, 86015-520, Brazil|Liga Norte-Riograndense Contra O Cancer, Natal, Rio Grande Do Norte, 59075-740, Brazil|Hospital Sao Lucas da Pontificia Universidade Catolica do Rio Grande do Sul, Porto Alegre, Rio Grande Do Sul, 90610-000, Brazil|Cipo - Centro Integrado de Pesquisa em Oncologia, Porto Alegre, Rio Grande Do Sul, 91350-200, Brazil|Centro de pesquisa em oncologia Hospital Ana Nery, Santa Cruz do Sul, Rio Grande Do Sul, 96835-090, Brazil|Centro Catarinense de Pesquisa LTDA, Blumenau, Santa Catarina, 89015-200, Brazil|Fundacao Pio 12 Hospital de Amor de Barretos, Barretos, SÃ£o Paulo, 14784-400, Brazil|Fundacao Amaral Carvalho, Jau, SÃ£o Paulo, 17210-120, Brazil|Cepho, Santo Andre, SÃ£o Paulo, 09060-650, Brazil|Instituto Dor de Pesquisa e Ensino, Rio de Janeiro, 22793-080, Brazil|Instituto do Cancer do Estado de Sao Paulo Octavio Frias de Oliveira Icesp, SÃ£o Paulo, 01246-000, Brazil|Multiprofile Hospital for Active Treatment - Uni Hospital OOD, Panagyurishte, 4500, Bulgaria|Complex Oncology Center Plovdiv EOOD, Plovdiv, 4004, Bulgaria|Complex Oncology Center Shumen EOOD, Shumen, 9700, Bulgaria|University Multiprofile Hospital for Active Treatment Sofiamed OOD, Sofia, 1113, Bulgaria|University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna - ISUL EAD, Sofia, 1527, Bulgaria|Military Medical Academy Multiprofile Hospital for Active Treatment - Sofia, Sofia, 1606, Bulgaria|Multiprofile Hospital for Active Treatment Serdika EOOD, Sofia, 1632, Bulgaria|Beijing Cancer Hospital, Beijing, Beijing, 100142, China|Chongqing University Cancer Hospital, Chongqing, Chongqing, 400030, China|Fujian Cancer Hospital, Fuzhou, Fujian, 350014, China|Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, 350025, China|Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, China|Henan Cancer Hospital, Zhengzhou, Henan, 450003, China|Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China|Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, China|Hubei Cancer Hospital, Wuhan, Hubei, 430070, China|Hunan Cancer Hospital, Changsha, Hunan, 410013, China|Northern Jiangsu Peoples hospital, Yangzhou, Jiangsu, 225009, China|Jiangxi Cancer hospital, Nanchang, Jiangxi, 330029, China|The First Bethune Hospital of Jilin University, Changchun, Jilin, 130021, China|Cancer Hospital of Shandong First Medical University, Jinan, Shandong, 250117, China|Qingdao Municipal Hospital, Qingdao, Shandong, 266000, China|Fudan University Shanghai Cancer Center, Shanghai, Shanghai, 200032, China|Shanxi Provincial Cancer Hospital, Taiyuan, Shanxi, 030009, China|Shanxi Bethune Hospital, Taiyuan, Shanxi, 030032, China|Tianjin Cancer Hospital, Tianjin, Tianjin, 300060, China|The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, 830011, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310003, China|Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang, 315016, China|Zhejiang Taizhou Hospital, Taizhou, Zhejiang, 317099, China|Centro de Tratamiento e InvestigaciÃ³n sobre Cancer Luis Carlos Sarmiento Angulo Ctic, Bogota, Cundinamarca, 0129, Colombia|Instituto Medico de Alta Tecnologia sas - Imat sas, Monteria, CÃ³rdoba, Colombia|Oncologos del Occidente SAS, Pereira, Risaralda, 660001, Colombia|Fundacion cardiovascular de Colombia, Bucaramanga, Santander, 681017, Colombia|Centre Hospitalier RÃ©gional Universitaire de Lille - Institut Coeur Poumon, Lille, 59037, France|Centre Hospitalier Universitaire Nord, Marseille Cedex 20, 13915, France|Centre Hospitalier Universitaire de Nice - Hopital Pasteur, Nice Cedex 01, 06002, France|Hopital Bichat Claude Bernard, Paris, 75018, France|Hopital Nord Ouest Villefranche sur Saone, Villefranche Sur Saone Cedex, 69400, France|Universitaetsklinikum Essen, Essen, 45147, Germany|Universitaetsmedizin Goettingen, Goettingen, 37075, Germany|Universitaetsklinikum Wuerzburg, Wuerzburg, 97078, Germany|Agios Savvas Anticancer Hospital, Athens, 11522, Greece|Henry Dunant Hospital Center, Athens, 11526, Greece|Sotiria General Hospital, Athens, 11527, Greece|Attikon University Hospital, Athens, 12462, Greece|Metropolitan Hospital, Athens, 18547, Greece|Saint Lukes Hospital SA, Thessaloniki, 55236, Greece|European Interbalkan Medical Center, Thessaloniki, 57001, Greece|Queen Mary Hospital, The University of Hong Kong, Hong Kong, Hong Kong|Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, New Territories, Hong Kong|Centro di Riferimento Oncologico di Aviano, Aviano PN, 33081, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, 20133, Italy|IRCCS Istituto Oncologico Europeo, Milano, 20141, Italy|Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano, 10043, Italy|Istituto Oncologico Veneto IRCCS, Padova, 35128, Italy|Azienda Ospedaliera di Perugia Ospedale Santa Maria della Misericordia, Perugia, 06156, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, 56124, Italy|Azienda Unita Sanitaria Locale di Reggio Emilia Arcispedale Santa Maria Nuova, Reggio Emilia, 42123, Italy|IRCCS Istituto Clinico Humanitas, Rozzano MI, 20089, Italy|Ospedale San Giuseppe Moscati, Statte, 74010, Italy|National Hospital Organization Nagoya Medical Center, Nagoya-shi, Aichi, 460-0001, Japan|National Cancer Center Hospital East, Kashiwa-shi, Chiba, 277-8577, Japan|National Hospital Organization Shikoku Cancer Center, Matsuyama-shi, Ehime, 791-0280, Japan|Kurume University Hospital, Kurume-shi, Fukuoka, 830-0011, Japan|National Hospital Organization Hokkaido Cancer Center, Sapporo-shi, Hokkaido, 003-0804, Japan|Kanagawa Prefectural Hospital Organization Kanagawa Cancer Center, Yokohama-shi, Kanagawa, 241-8515, Japan|Sendai Kousei Hospital, Sendai-shi, Miyagi, 981-0914, Japan|Niigata Cancer Center Hospital, Niigata-shi, Niigata, 951-8566, Japan|Okayama University Hospital, Okayama-shi, Okayama, 700-8558, Japan|Kansai Medical University Hospital, Hirakata-shi, Osaka, 573-1191, Japan|Osaka International Cancer Institute, Osaka-shi, Osaka, 541-8567, Japan|Kindai University Hospital, Osakasayama-shi, Osaka, 589-8511, Japan|Saitama Medical University International Medical Center, Hidaka-Shi, Saitama, 350-1298, Japan|Saitama Cancer Center, Kitaadachi-gun, Saitama, 362-0806, Japan|Shizuoka Cancer Center, Sunto-gun, Shizuoka, 411-8777, Japan|Dokkyo Medical University Hospital, Shimotsuga-gun, Tochigi, 321-0293, Japan|Juntendo University Hospital, Bunkyo-ku, Tokyo, 113-8431, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, 104-0045, Japan|The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Tokyo, 135-8550, Japan|Wakayama Medical University Hospital, Wakayama, 641-8509, Japan|Chungbuk National University Hospital, Cheongju Chungbuk, 28644, Korea, Republic of|National Cancer Center, Goyang-si Gyeonggi-do, 10408, Korea, Republic of|Gachon University Gil Hospital, Incheon, 405-760, Korea, Republic of|Gyeongsang National University Hospital, Jinju-si, 52727, Korea, Republic of|Cha Bundang Medical Center, Cha University, Seongnam-si, Gyeonggi-do, 13496, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, 13620, Korea, Republic of|Severance Hospital Yonsei University Health System, Seoul, 03722, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|Seoul National University Hospital, Seoul, 110-744, Korea, Republic of|Oncare, Ciudad de MÃ©xico, Distrito Federal, 03810, Mexico|Centro Oncologico Personalizado, Cuauhtemoc, Distrito Federal, 06760, Mexico|Phylasis Clinicas Research Toluca, Toluca, 50090, Mexico|Uniwersytecki Szpital Kliniczny w Bialymstoku, Bialystok, 15-540, Poland|Centrum Pulmonologii i Torakochirurgii w Bystrej, Bystra, 43-360, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, 80-214, Poland|Uniwerystecki Szpital Kliniczny Nr 4 w Lublinie, Lublin, 20-090, Poland|Wielkopolskie Centrum Pulmonologii i Torakochirurgii imienia Eugenii i Janusza Zeylandow, Poznan, 60-569, Poland|Szpital Specjalistyczny w Prabutach Spolka z OgraniczonÄ Odpowiedzialnoscia, Prabuty, 82-550, Poland|Wojewodzki Szpital im Sw Ojca Pio w Przemyslu, Przemysl, 37-700, Poland|Narodowy Instytut Onkologii im Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Warszawa, 02-781, Poland|Unidade Local de Saude de Braga, EPE, Braga, 4710-243, Portugal|Hospital da Luz, SA, Lisboa, 1500-650, Portugal|Hospital Cuf porto, Porto, 4100-180, Portugal|Institutul Oncologic, Prof Dr Alexandru Trestioreanu, Bucuresti, 022328, Romania|Institutul Oncologic Prof Dr Ion Chiricuta Cluj-Napoca, Cluj Napoca, 400015, Romania|Centrul de Oncologie Sf Nectarie SRL, Craiova, 200542, Romania|Institutul Regional de Oncologie Iasi, Iasi, 700483, Romania|Spitalul Municipal Ploiesti, Ploiesti, 100337, Romania|SC Oncomed SRL, Timisoara, 300239, Romania|National Cancer Centre Singapore, Singapore, 168583, Singapore|Icon - Mount Alvernia, Singapore, 217562, Singapore|Hospital Regional Universitario de Malaga, Malaga, AndalucÃ­a, 29011, Spain|Hospital Universitario Virgen del Rocio, Sevilla, AndalucÃ­a, 41013, Spain|Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Canarias, 35016, Spain|Institut Catala d Oncologia Badalona Hospital Universitari Germans Trias i Pujol, Badalona, CataluÃ±a, 08916, Spain|Hospital del Mar, Barcelona, CataluÃ±a, 08003, Spain|Hospital Universitari Vall d Hebron, Barcelona, CataluÃ±a, 08035, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, CataluÃ±a, 08036, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, CataluÃ±a, 08041, Spain|Instituto Valenciano de Oncologia, Valencia, Comunidad Valenciana, 46009, Spain|Hospital Clinico Universitario de Santiago, Santiago de Compostela, Galicia, 15706, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, 28222, Spain|Clinica Universidad de Navarra, Pamplona, Navarra, 31008, Spain|Hospital General Universitario Gregorio Maranon, Madrid, 28009, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Sahlgrenska Universitetssjukhuset, Goteborg, 413 45, Sweden|Norrlands Universitetssjukhus, Umea, 901 85, Sweden|Kantonsspital Baden, Baden, 5404, Switzerland|Universitaetsspital Basel, Basel, 4052, Switzerland|Ospedale Regionale di Bellinzona e Vali, Mendrisio, 6850, Switzerland|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, 80756, Taiwan|National Taiwan University Hospital, Taipei, 10002, Taiwan|Taipei Veterans General Hospital, Taipei, 11217, Taiwan|Memorial Ankara Hastanesi, Ankara, 06520, Turkey|Ankara Bilkent Sehir Hastanesi, Ankara, 06800, Turkey|Bagcilar Medipol Mega Universite Hastanesi, Istanbul, 34214, Turkey|Goztepe Prof Dr Suleyman Yalcin Sehir Hastanesi, Istanbul, 34722, Turkey|Marmara Universitesi Tip Fakultesi Hastanesi, Istanbul, 34890, Turkey|Izmir Ekonomi Universitesi Medical Point Hastanesi, Izmir, 35575, Turkey|Kocaeli Universitesi Tip Fakultesi Hastanesi, Kocaeli, 41380, Turkey|Medical Park Seyhan Hastanesi, Mersin, 33200, Turkey|Ondokuz Mayis Universitesi Tip Fakultesi Hastanesi, Samsun, 55200, Turkey|Guys Hospital, London, SE1 9RT, United Kingdom|Christie Hospital, Manchester, M20 4BX, United Kingdom",
NCT06465446,A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT06465446,,NOT_YET_RECRUITING,The purpose of this study is to compare efficacy of IMM01 plus Tiselizumab with physician's choice chemotherapy of bendamustine or gemcitabine in participants with PD-(L)1-refractory classical Hodgkin Lymphoma. The study will also assess the safety and tolerability of IMM01 plus Tiselizumab. The primary study hypotheses are that IMM01 plus Tiselizuma is superior to physician's choice chemotherapy with respect to progression-free survival (PFS) and overall survival (OS).,NO,Classic Hodgkin Lymphoma,BIOLOGICAL: Tislelizumab|BIOLOGICAL: IMM01|DRUG: Bendamustine|DRUG: Gemcitabine,"Progression Free Survival (PFS) per Lugano 2014 as Assessed by Independent Review Committee (IRC), PFS is defined as the time from randomization to the first documented disease progression or death due to any cause, whichever occurs first., approximately 24 months","Overall Survival (OS), OS is defined as the time from randomization to death due to any cause., approximately 36 months|Duration of Response (DOR), DOR is defined as the time from the first documented evidence of complete response or partial response until disease progression or death due to any cause, whichever occurs first., approximately 24 months|Number of Participants Who Experienced At Least One Adverse Event (AE), An AE is any untoward medical occurrence in a clinical study participant temporally associated with the use of study intervention, whether or not considered related to the study intervention., approximately 18 months",,ImmuneOnco Biopharmaceuticals (Shanghai) Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE3,202,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-06,2026-06,2029-07,2024-06-18,,2024-06-24,,
NCT06976190,A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma,https://clinicaltrials.gov/study/NCT06976190,Magic-C002,NOT_YET_RECRUITING,"This is a randomized, open-label, multi-center, phase III study to evaluate the efficacy and safety, and immunogenicity of MRG003 in combination with pucotenlimab in patients with recurrent or metastatic nasopharyngeal carcinoma.",NO,Recurrent or Metastatic Nasopharyngeal Carcinoma,"DRUG: MRG003 + Pucotenlimab|DRUG: Gemcitabine, Docetaxel, or Capecitabine","Progression Free Survival (PFS) as assessed by BIRC, PFS is defined as the duration from the start of treatment to the onset of tumor progression or death of any cause., Baseline to study completion (up to 33 months)|Overall Survival (OS), OS is defined as the duration from the start of treatment to death of any cause., Baseline to study completion (up to 48 months)","Objective Response Rate (ORR), ORR is defined as the proportions of patients with a complete response (CR) and partial response (PR). ORR will be assessed according to RECIST v1.1., Baseline to study completion (up to 48 months)|Disease Control Rate (DCR), DCR is defined as the proportion of subjects achieving CR, PR, and stable disease (SD) after treatment., Baseline to study completion (up to 48 months)|Progression Free Survival (PFS) as assessed by investigator, PFS is defined as the duration from the start of treatment to the onset of tumor progression or death of any cause., Baseline to study completion (up to 33 months)|Immunogenicity (ADA), The proportion of patients with positive ADA results., Baseline to 14 days after the last dose.|Adverse Events (AEs), Any reaction, side effect, or untoward event that occurs during the course of the clinical trial whether or not the event is considered related to the study drug., Baseline to 30 days after the last dose of study treatment|Serious Adverse Events (SAEs), Adverse events that are fatal, life-threatening, or result in hospitalization or prolonged hospitalization, persistent or significant disability/incapacity/substantial disruption of the ability to lead a normal life, congenital anomaly/birth defect or major medical events or reactions., Baseline to 30 days after the last dose of study treatment",,Shanghai Miracogen Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE3,446,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2025-05,2029-05,2030-12,2025-05-16,,2025-05-16,"Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, China",
NCT05050942,A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients with GEP-NET,https://clinicaltrials.gov/study/NCT05050942,SORENTO,ACTIVE_NOT_RECRUITING,"The purpose of this study is to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-differentiated GEP-NET. Patients who experience progressive disease in the randomized part of the study may proceed to an open-label extension part with intensified treatment with CAM2029.",NO,Gastro-enteropancreatic Neuroendocrine Tumor,DRUG: CAM2029|DRUG: Octreotide LAR|DRUG: Lanreotide ATG,"Progression-free survival (PFS) as assessed by a Blinded Independent Review Committee (BIRC), PFS is defined as time from the date of randomization to the date of the first documented disease progression as per RECIST 1.1 or death due to any cause (whichever occurs first), From date of randomization until disease progression or death due to any cause, whichever comes first, assessed up to 48 months","Overall survival, The time from the date of randomization to the date of death due to any cause, Up to 2 years following the primary efficacy analysis|PFS as assessed by local Investigators, PFS is defined as time from the date of randomization to the date of the first documented disease progression as per RECIST 1.1 or death due to any cause (whichever occurs first), From date of randomization until disease progression or death due to any cause, whichever comes first, assessed up to 48 months|Overall response rate, The proportion of patients with best overall response of complete response (CR) or partial response (PR), as per BIRC according to RECIST 1.1, From date of randomization until disease progression, assessed up to 48 months|Disease control rate, The proportion of patients with a best overall response of CR, PR or stable disease (SD), as per BIRC according to RECIST 1.1, From date of randomization until disease progression, assessed up to 48 months|Time to tumor response, The time from the date of randomization to the first documented response of CR or PR, as per BIRC according to RECIST 1.1, From date of randomization until disease progression, assessed up to 48 months|Duration of response, The time from the date of the first documented response of CR or PR to the date of the first documented progression or death due to underlying cancer, as per BIRC according to RECIST 1.1, From date of randomization until disease progression or death due to underlying cancer, whichever comes first, assessed up to 48 months|Incidence of treatment-emergent adverse events, From screening to the safety follow-up, assessed up to 6 years",,Camurus AB,,ALL,"ADULT, OLDER_ADULT",PHASE3,332,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-10-22,2025-12,2027-12,2021-09-21,,2024-12-13,"Mayo Clinic Cancer Center (MCCC) - Phoenix, Phoenix, Arizona, 85054, United States|UCLA Ahmanson Biological Imaging Center, Santa Monica, California, 90404, United States|Rocky Mountain Cancer Centers - Denver - Midtown, Denver, Colorado, 80218, United States|Mayo Clinic Hospital - Florida, Jacksonville, Florida, 32224, United States|Anderson Family Cancer Institute, Jupiter, Florida, 33469, United States|University of Kentucky (UK) - Markey Cancer Center, Lexington, Kentucky, 40536, United States|East Jefferson General Hospital, Metairie, Louisiana, 70065, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Mayo Clinic Rochester, Rochester, Minnesota, 55905, United States|The Mount Sinai Hospital, Bronx, New York, 10461, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, 10065, United States|White Plains Hospital - Center for Cancer Care, White Plains, New York, 10601, United States|Texas Oncology - Austin, Austin, Texas, 78705, United States|Texas Oncology - Dallas, Dallas, Texas, 75246, United States|Texas Oncology - Denton North, Denton, Texas, 76201, United States|The University of Texas - MD Anderson Cancer Center, Houston, Texas, 77030, United States|Texas Oncology - McAllen, McAllen, Texas, 78503, United States|Texas Oncology - San Antonio Northeast, San Antonio, Texas, 78240, United States|Huntsman Cancer Institute, Salt Lake City, Utah, 84112, United States|The Queen Elizabeth Hospital (TQEH), Adelaide, Australia|GenesisCare - North Shore, Alexandria, Australia|Blacktown Hospital, Blacktown, Australia|Peter MacCallum Cancer Centre, Melbourne, Australia|Fiona Stanley Hospital, Murdoch, Australia|Cliniques Universitaires Saint-Luc, Brussels, Belgium|HÃ´pital Erasme, Brussels, Belgium|Antwerp University Hospital, Edegem, Belgium|Algemeen Ziekenhuis Maria Middelares, Gent, Belgium|Universitair Ziekenhuis Leuven, Leuven, Belgium|AZ Nikolaas, Sint-Niklaas, Belgium|London Health Sciences Centre, London, Canada|Centre Hospitalier de l'Universite de Montreal - Notre-Dame Hospital, MontrÃ©al, Canada|Jewish General Hospital, MontrÃ©al, Canada|The Ottawa Hospital - General Campus, Ottawa, Canada|Niagara Health System - St. Catharines General Site, St. Catharines, Canada|Princess Margaret Cancer Centre, Toronto, Canada|Sunnybrook Health Sciences Centre, Toronto, Canada|BC Cancer Agency Vancouver Centre, Vancouver, Canada|CHU Hopitaux de Bordeaux - HÃ´pital Haut-LÃ©vÃªque, Bordeaux, France|CHRU de Tours - Hopital Trousseau, Chambray-lÃ¨s-Tours, France|Centre Hospitalier Universitaire Dijon Bourgogne - L'Hopital General, Dijon, France|Groupe Hospitalier de l'Institut Catholique de Lille - Hopital Saint Vincent de Paul, Lille, France|CHU de Lyon - Groupement Hospitalier Edouard Herriot, Lyon, France|CHU de Nantes - HÃ´tel-Dieu, Nantes, France|Centre EugÃ¨ne Marquis, Rennes, France|HÃ´pitaux Universitaires de Strasbourg - HÃ´pital de Hautepierre, Strasbourg, France|Charite - UB - CVK - Medizinische Klinik, Berlin, Germany|Universitaetsklinikum Erlangen - Hautklinik, Erlangen, Germany|UniversitÃ¤tsklinikum Essen, Essen, Germany|Asklepios Klinik St. Georg, Hamburg, Germany|UniversitÃ¤tsklinikum Hamburg-Eppendorf (UKE), Hamburg, Germany|Nationales Centrum fÃ¼r Tumorerkrankungen (NCT) Heidelberg, Heidelberg, Germany|Medizinischen FakultÃ¤t Mannheim der UniversitÃ¤t Heidelberg, Mannheim, Germany|UniversitÃ¤tsklinikum Ulm, Ulm, Germany|SE ÃOK I. sz. BelgyÃ³gyÃ¡szati Klinika, Budapest, Hungary|Petz AladÃ¡r Megyei OktatÃ³ KÃ³rhÃ¡z, GyÅr, Hungary|BÃ¡cs-Kiskun Megyei KÃ³rhÃ¡z, KecskemÃ©t, Hungary|Szegedi TudomÃ¡nyegyetem; I.BelgyÃ³gyÃ¡szati Klinika, Szeged, Hungary|Rambam Medical Center, Haifa, Israel|Hadassah Medical Center (HMC) - Hadassah University Hospital (HUH) - Ein Kerem, Jerusalem, Israel|The Chaim Sheba Medical Center, Ramat Gan, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Centro di Riferimento Oncologico (CRO), Aviano, Italy|Universita degli Studi di Bari - Aldo Moro, Bari, Italy|Azienda Ospedaliero - Universitaria di Bologna Policlinico S. Orsola - Malpighi, Bologna, Italy|ASST degli Spedali Civili di Brescia, Brescia, Italy|Universita degli Studi di Firenze - Azienda Ospedaliero - Universitaria Careggi - SC di Oncologia Medical, Firenze, Italy|Universita Degli Studi di Genova - Center of Excellence for Biomedical Research (CEBR), Genova, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - IRST IRCCS, Meldola, Italy|Istituto Clinico Humanitas, Milan, Italy|Azienda Ospedaliero - Universitaria di Modena Policlinico, Modena, Italy|IRCCS - Istituto Nazionale dei Tumori di Napoli Fondazione G. Pascale - Oncologia Addominale, Napoli, Italy|Istituto Oncologico Veneto - IRCCS, Padova, Italy|Azienda Ospedaliera Sant'Andrea, Roma, Italy|Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Trento, Verona, Italy|Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands|Rijnstate Ziekenhuis - Arnhem, Arnhem, Netherlands|Maastricht UMC+, Maastricht, Netherlands|Erasmus MC, Rotterdam, Netherlands|Institutul Clinic Fundeni, Bucharest, Romania|Institutul Oncologic ""Prof. Dr. Ion ChiricuÅ£Ä"" Cluj Napoca, Cluj-Napoca, Romania|Medisprof SRL, Cluj-Napoca, Romania|Sigmedical Services S.R.L., Suceava, Romania|Complexo Hospitalario Universitario A CoruÃ±a, A CoruÃ±a, Spain|Hospital Universitari Vall d'Hebron - Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona, Spain|Institut Catala d'Oncologia Hospitalet, Barcelona, Spain|Hospital General Universitario de Elche, Elche, Spain|Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain|Facultad de Medicina - Hospital Universitario Fundacion Jimenez Diaz (UAM-FJD) (Clinica de la Concepcion), Madrid, Spain|Hospital Universitario FundaciÃ³n AlcorcÃ³n, Madrid, Spain|Hospital Universitario La Paz (HULP), Madrid, Spain|Hospital Universitario RamÃ³n y Cajal, Madrid, Spain|MD Anderson Cancer Center - Madrid, Madrid, Spain|Hospital General Universitario Morales Meseguer, Murcia, Spain|Hospital Universitario Virgen de la Victoria, MÃ¡laga, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Parc TaulÃ­ Sabadell Hospital Universitari, Sabadell, Spain|Hospital Universitario Marques de Valdecilla (HUMV), Santander, Spain",
NCT05580562,ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study),https://clinicaltrials.gov/study/NCT05580562,ACTION,RECRUITING,"This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with ONC201 following frontline radiotherapy will extend overall survival and progression-free survival in this population. Eligible participants will have histologically diagnosed H3 K27M-mutant diffuse glioma and have completed standard frontline radiotherapy.",NO,H3 K27M|Glioma,DRUG: Dordaviprone (ONC201)|DRUG: Dordaviprone (ONC201) + Placebo|OTHER: Placebo,"Overall survival (OS), Overall Survival is defined as the time from randomization to death due to any cause., From date of randomization until date of death from any cause, assessed up to approximately 44 months|Progression free survival (PFS) as assessed by using RANO-HGG criteria, PFS is defined as time from randomization to disease progression (PD) or death., From date of randomization until the date of first documented progression assessed up to approximately 44 months","Incidence of adverse events, Incidence of overall, treatment-related, Grade 3 or higher in severity, serious, fatal, those resulting in treatment discontinuation, and events of special interest, From date of randomization up to 44 months|Change from baseline in clinical laboratory parameters, Percentage of participants with clinically significant laboratory results, From date of randomization up to 44 months|PFS using RANO-HGG criteria, PFS using RANO-HGG criteria for participants with measurable contrast-enhancing disease, From date of randomization up to 44 months|Corticosteroid response, Corticosteroid response will be measured by a confirmed 50% decrease in use of dexamethasone or equivalent, From date of randomization up to 44 months|Performance status response, Performance status response will be measured by confirmed increase in Karnofsky Performance Status (KPS) or Lansky Performance Status (LPS), From date of randomization up to 44 months",,Chimerix,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,450,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-01-23,2026-08,2026-08,2022-10-14,,2025-06-06,"Barrow Neurological Institute, Phoenix, Arizona, 085013, United States|Banner MD Anderson Cancer Center, Phoenix, Arizona, 85006, United States|Phoenix Childrens Hospital, Phoenix, Arizona, 85016, United States|Mayo Clinic Arizona, Phoenix, Arizona, 85054, United States|University of California Irvine, Costa Mesa, California, 92628, United States|UC San Diego Moores Cancer Center, La Jolla, California, 92093, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, 90027, United States|UCLA University of California Los Angeles, Los Angeles, California, 90095, United States|Children's Hospital of Orange County, Orange, California, 92868, United States|UCSF Benioff Children's Hospital, San Francisco, California, 94143, United States|University of California San Francisco, San Francisco, California, 94143, United States|Providence Saint John's Cancer Institute, Santa Monica, California, 90404, United States|Stanford Cancer Center, Stanford, California, 94350, United States|Yale University, Fairfield, Connecticut, 06824, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, 20007, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, 32224, United States|Miami Cancer Institute, Miami, Florida, 33176, United States|St Joseph's Children's Hospital of Tampa, Tampa, Florida, 33607, United States|Moffitt Cancer Center, Tampa, Florida, 33612, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, 30342, United States|Kapi'olani Medical Center for Women and Children, Honolulu, Hawaii, 96826, United States|Feinberg School of Medicine Northwestern University, Chicago, Illinois, 60611, United States|Indiana University School of Medicine - Indianapolis, Indianapolis, Indiana, 46202, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, 52242, United States|Norton Healthcare, Louisville, Kentucky, 40241, United States|Ochsner Medical Center - New Orleans, New Orleans, Louisiana, 70121, United States|University of Maryland School of Medicine, Baltimore, Maryland, 21201, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, 02114, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|University of Michigan Hospital, Ann Arbor, Michigan, 48109, United States|University of Minnesota, Minneapolis, Minnesota, 55455, United States|Mayo Clinic - Cancer Center - Rochester, Rochester, Minnesota, 55905, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|Benefis Hospital Sletten Cancer Institute, Great Falls, Montana, 59405, United States|University of Nebraska Medical Center, Omaha, Nebraska, 68114, United States|Jersey Shore University Medical Center, Neptune, New Jersey, 07753, United States|Overlook Medical Center, Summit, New Jersey, 07901, United States|Albany Medical Center, Albany, New York, 12208, United States|Children's Hospital at Montefiore Medical Center, New York, New York, 10029, United States|Montefiore Medical Park, New York, New York, 10029, United States|Laura & Isaac Perlmutter Cancer Center - NYU ACC, New York, New York, 10032-3726, United States|Columbia University Medical Center, New York, New York, 10032, United States|Lenox Hill Hospital, New York, New York, 10075, United States|University of Rochester Medical Center, Rochester, New York, 14642, United States|Levine Cancer Institute/ Atrium Health, Charlotte, North Carolina, 28204, United States|Duke Cancer Institute, Durham, North Carolina, 27710, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 45229, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|Ohio State University, Columbus, Ohio, 43210, United States|University of Oklahoma Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma, 73104, United States|Providence Health and Services St. Vincent Medical Center, Portland, Oregon, 97239, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, 19107, United States|UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, 15232, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, 15232, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, 78723, United States|Neuro-Oncology Associates, Dallas, Texas, 75246, United States|University of Texas Southwestern Medical Center, Dallas, Texas, 75390, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|UT Health Science Center Houston Department of Neurosurgery, Houston, Texas, 77030, United States|University of Texas - San Antonio - Health Science Center, San Antonio, Texas, 78229, United States|University of Utah - Huntsman Cancer Institute, Salt Lake City, Utah, 84112, United States|Inova Schar Cancer Institute, Fairfax, Virginia, 22031, United States|Children's Hospital of The King's Daughter, Norfolk, Virginia, 23507, United States|University of Washington, Seattle, Washington, 98195, United States|University Of Wisconsin - Madison, Madison, Wisconsin, 53792, United States|FLENI Neurologia, Ciudad AutÃ³noma de Buenos Aires, C1426ABP, Argentina|Sydney Children's Hospital, Randwick, New South Wales, 2031, Australia|Royal North Shore Hospital, Sydney, New South Wales, 2065, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Royal Hobart Hospital, Hobart, Tasmania, 7000, Australia|Olivia Newton-John Cancer Research Institute (ONJCRI), Heidelberg, Victoria, 3084, Australia|Perth Children's Hospital, Nedlands, Western Australia, 6009, Australia|Medical University of Vienna - Adults, Vienna, Wien, 01090, Austria|Medical University of Vienna - Pediatrics, Vienna, Wien, Austria|Hospital do GRAACC, SÃ£o Paulo, 04023-062, Brazil|Hcor Research Institute, SÃ£o Paulo, Brazil|Instituto Do Cancer Do Estado De SÃ£o Paulo, SÃ£o Paulo, Brazil|Tom Baker Cancer Cetre, Calgary, Alberta, T2N 2T9, Canada|BC Cancer - The Vancouver Center, Vancouver, British Columbia, V5Z 4E6, Canada|Children's & Women's Health Care of BC, Vancouver, British Columbia, V6H 0B3, Canada|London Health Sciences Centre, London, Ontario, N6A 5W9, Canada|Childrens Hospital of Eastern Ontario, Ottawa, Ontario, K1H 8L1, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, M4N 3M5, Canada|Princess Margaret Hospital, Toronto, Ontario, M5G 1X8, Canada|Hopital Notre Dame, Lachapelle, MontrÃ©al, Quebec, H2X 3E4, Canada|Copenhagen University Hospital, Copenhagen, Capital, 2100, Denmark|Aalborg Universitetshospital, Aalborg, Nordjylland, 9000, Denmark|F345 H.C. Andersen's Children's Hospital, Odense, South Denmark, 5000, Denmark|Odense Universitetshospital, Odense, South Denmark, 5000, Denmark|University Clinic Heidelberg, Heidelberg, Baden-WÃ¼rttemberg, 69120, Germany|UniversitÃ¤tsklinikum Heidelberg, Heidelberg, Baden-WÃ¼rttemberg, 69120, Germany|UniversitÃ¤tsklinikum Augsburg, Augsburg, Bayern, 86156, Germany|University Clinic Regensburg, Regensburg, Bayern, 93053, Germany|Klinikum der Johann-Wolfgang Goethe-Universitat, Frankfurt am Main, Hessen, 60528, Germany|UniversitÃ¤tsklinikum Bonn, Bonn, Nordrhein-Westfalen, 53127, Germany|UniversitÃ¤tsklinikum Essen, Essen, Nordrhein-Westfalen, 45147, Germany|Uniklinik KÃ¶ln, KÃ¶ln, Nordrhein-Westfalen, 50937, Germany|Vivantes Klinikum NeukÃ¶lln, Berlin, 12351, Germany|Klinikum Mannheim UniversitÃ¤tsklinikum gGmbH, Manheim, 68167, Germany|UniversitÃ¤tsklinikum TÃ¼bingen, TÃ¼bingen, 72076, Germany|Queen Mary Hospital, Hong Kong, 999077, Hong Kong|Sheba Medical Center, Ramat Gan, Tel-Aviv, 5262100, Israel|Soroka University Medical Centre, Be'er Sheva, 50937, Israel|Rambam Medical Center, Haifa, 31096, Israel|Hadassah Ein Kerem Medical Center, Jerusalem, 91120, Israel|Schneider Children's Medical Center of Israel, Petah Tikvah, 4920235, Israel|Rabin Medical Center, Petah Tikva, 49372, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, 64239, Israel|Ospedale Bellaria, Bologna, Emilia-Romagna, 40139, Italy|Istituto Nazionale Tumori Regina Elena, Roma, Lazio, 00144, Italy|Ospedale San Raffaele S.r.l., Milano, Lombardia, 20132, Italy|Fondazione IRCCS Di Rilievo Nazionale Istituto Nazionale Neurologico Carlo Besta, Milano, Lombardia, 20133, Italy|Istituto Clinico Humanitas, Rozzano, Lombardia, 20089, Italy|Azienda Ospedaliera CittÃ  della Salute e della Scienza di Torino, Torino, Piemonte, 10126, Italy|Istituto Oncologico Veneto, Padova, Veneto, 35128, Italy|National Cancer Center Hospital, Chuo City, 104-0045, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, 812-8582, Japan|Kyoto University Hospital, Kyoto, 606-8507, Japan|Osaka City General Hospital, Osaka, 534-0021, Japan|Hokkaido University Hospital, Sapporo, 060-8648, Japan|CHA Bundang Medical Center, Bundang-Gu, Seongnam-Si, Gyeonggido, 13496, Korea, Republic of|Seoul National University Bundang Hospital, Bundang-gu, Seongnam-si, Gyeonggido, 13620, Korea, Republic of|National Cancer Center, Ilsandong-Gu, Goyang-Si, Gyeonggido, 10408, Korea, Republic of|Samsung Medical Center, Gangnam-Gu, Seoul Teugbyeolsi, 06351, Korea, Republic of|Gangnam Severance Hospital, Yonsei University Health System, Gangnam, Seoul Teugbyeolsi, 06273, Korea, Republic of|Seoul National University Hospital, Jongno-Gu, Seoul Teugbyeolsi, 03080, Korea, Republic of|Asan Medical Center, Seoul, Seoul Teugbyeolsi, 5505, Korea, Republic of|Severance Hospital Yonsei University Health System, Seoul, 03722, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, 6591, Korea, Republic of|Erasmus MC, Rotterdam, Zuid-Holland, 3015 GD, Netherlands|Universitair Medisch Centrum Utrecht Cancer Center, Utrecht, 3584 CX, Netherlands|KK Women's and Children's Hospital, Singapore, 229899, Singapore|National Cancer Centre, Singapore, 308433, Singapore|National Neuroscience Institute, Singapore, 308433, Singapore|Hospital Sant Joan de Deu, Esplugues De Llobregat, Barcelona, 8950, Spain|Clinica Universidad Navarra, Pamplona, Navarra, 31008, Spain|Hospital Clinic de Barcelona, Barcelona, 08036, Spain|Hospital Universitario Vall d'Hebron, Barcelona, 8035, Spain|Hospital Infantil Universitario NiÃ±o Jesus, Madrid, 28009, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital Universitario HM Sanchinarro, Madrid, 28050, Spain|Complejo Asistencial Universitario de Salamanca - H. Clinico, Salamanca, 37007, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, 46026, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, 46026, Spain|Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, 1011, Switzerland|UniversitÃ¤tsspital ZÃ¼rich, ZÃ¼rich, 8091, Switzerland|Addenbrooke's Hospital, Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, Lanarkshire, G12 0YN, United Kingdom|Royal Hospital for Children (Glasgow), Glasgow, Lanarkshire, G51 4TF, United Kingdom|Clatterbridge Cancer Centre - Liverpool, Liverpool, Lancashire, L7 8YA, United Kingdom|The Christie NHS Foundation Trust, Manchester, Lancashire, M20 4BX, United Kingdom|The Royal Marsden in Sutton, Surrey, Sutton, Surrey, SM2 5PT, United Kingdom|Royal Victoria Infirmary, Newcastle Upon Tyne, Tyne And Wear, NE1 4LP, United Kingdom|Freeman Hospital, Newcastle Upon Tyne, Tyne And Wear, NE7 7DN, United Kingdom|St James University Hospital, Leeds, West Yorkshire, LS9 7TF, United Kingdom|The Leeds Teaching Hospitals NHS Trust, Leeds General Infimary, Leeds, LS1 3EX, United Kingdom|Guy's Hospital, London, SE19RT, United Kingdom|Churchill Hospital, Oxford, Ox3 7LE, United Kingdom",
NCT04853342,"To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy",https://clinicaltrials.gov/study/NCT04853342,FORWARD,RECRUITING,"This is a phase 3 double-blind, randomized, placebo-controlled, study to assess the efficacy and safety of Furmonertinib (AST2818) versus placebo in patients with stage II-IIIA non-small cell lung cancer (NSCLC) with centrally confirmed, most common sensitising EGFR mutations (Ex19Del and L858R) either alone or in combination with other EGFR mutations as confirmed by a central test, who have had complete tumour resection, with or without postoperative adjuvant chemotherapy.",NO,Non-small Cell Lung Carcinoma,DRUG: Drug: Furmonertinib 80 mg|DRUG: Furmonertinib 80 mg placebo,"DFS, Disease free survival, From date of randomization until date of disease recurrence or death (by any cause in the absence of recurrence). Estimated median time to event of 60 months for those treatment) [ Time Frame: Up to 5 years]","Disease free survival (DFS) rate, Disease free survival (DFS) rate at 2, 3 and 5 years, Time Frame: From date of randomization until date of disease recurrence or death (by any cause in the absence of recurrence)Estimated median time to event of 60 months for those treatment[ Time Frame: Up to 5 years]|Overall Survival (OS), Defined as the time from the date of randomization until date of death due to any cause, Time Frame: From date of randomization until date of death due to any cause Estimated median time to event of 60 months for those treatment[ Time Frame: Up to 5 years]|Overall Survival rate at 5 years, Defined as the proportion of patients alive at 5 years, estimated from a Kaplan Meier plot of OS at the time of the primary analysis, Time Frame: From date of randomization until date of death due to any cause about 5years[ Time Frame: Up to 5 years]",,"Allist Pharmaceuticals, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE3,318,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-06-07,2026-01,2030-01,2021-04-21,,2025-04-04,"First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 215000, China",
NCT07008976,Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer,https://clinicaltrials.gov/study/NCT07008976,,NOT_YET_RECRUITING,"This study adopted a randomized, open-label, positive drug-controlled, multi-center trial design. The primary endpoint was PFS evaluated by the Independent Review Committee (IRC). Eligible subjects were randomly assigned in a 1:1 ratio to receive either TQB2102 for injection or trastuzumab emtansine for injection.",NO,Metastatic Breast Cancer,DRUG: TQB2102 Injection|DRUG: Trastuzumab Emtansine for Injection,"The Progression-Free Survival (PFS) evaluated by Independent Review Committee (IRC), The PFS evaluation of TQB2102 for injection compared with Trastuzumab Emtansine for injection in HER2-positive, unresectable locally advanced or metastatic breast cancer patients who had previously received anti-HER2 monoclonal antibodies and taxane drugs was assessed by the Independent Imaging Review Committee (IRC)., Up 30 months","The PFS evaluated by the researchers, The efficacy of injectable TQB2102 compared to injectable Trastuzumab Emtansine in evaluating the progression-free survival (PFS) in HER2-positive, unresectable locally advanced or metastatic breast cancer patients who had previously received anti-HER2 monoclonal antibodies and taxane drugs was assessed by the researchers., Up 30 months|The Overall Survival (OS) evaluated by the researchers, The efficacy of injectable TQB2102 compared to injectable Trastuzumab Emtansine, as evaluated by the researchers, in HER2-positive, unresectable locally advanced or metastatic breast cancer patients who had previously received anti-HER2 monoclonal antibodies and taxane drugs., Up to 5 years|The Duration of Response (DOR) evaluated by the researchers, The efficacy of injectable TQB2102 compared to injectable Trastuzumab Emtansine as evaluated by the researchers in HER2-positive, unresectable locally advanced or metastatic breast cancer patients who had previously received anti-HER2 monoclonal antibodies and taxane drugs was studied., Up to 5 years|The Partial Response (PR) evaluated by the researchers, The efficacy of PR-assessed TQB2102 injection compared with Trastuzumab Emtansine injection in HER2-positive, unresectable locally advanced or metastatic breast cancer patients who had previously received anti-HER2 monoclonal antibodies and taxane drugs was evaluated by the researchers., Up to 5 years|The Objective Response Rate (ORR)evaluated by the researchers, The efficacy of injectable TQB2102 compared to injectable Trastuzumab Emtansine in evaluating the objective response rate (ORR) was assessed in HER2-positive, unresectable locally advanced or metastatic breast cancer patients who had previously received anti-HER2 monoclonal antibodies and taxane drugs., Up to 5 years|The Clinical Benefit Rate (CBR) evaluated by the researchers, The efficacy of CBR evaluated injection TQB2102 compared to injection Trastuzumab Emtansine in HER2-positive, unresectable locally advanced or metastatic breast cancer patients who had previously received anti-HER2 monoclonal antibodies and taxane drugs was assessed by the researchers., Up to 5 years|The incidence and severity of adverse events, The proportion of patients experiencing adverse events, and these adverse events are defined by the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0., Sign the informed consent form, and until 28 days after the last medication administration / before starting a new anti-tumor treatment (which ever occurs first))|Antibody-drug conjugate (ADC), Evaluate the population pharmacokinetic (PK) characteristics of TOB2102 for injection in patients with HER2-positive, unresectable, locally advanced or metastatic breast cancer who have previously received anti-HER2 monoclonal antibodies and taxane drugs., Cycle 2, Cycle 4, Cycle 8, Cycle 16 (Each cycle is 3 weeks)|Total antibodies, Evaluate the population pharmacokinetic (PK) characteristics of TOB2102 for injection in patients with HER2-positive, unresectable, locally advanced or metastatic breast cancer who have previously received anti-HER2 monoclonal antibodies and taxane drugs., Cycle 2, Cycle 4, Cycle 8, Cycle 16 (Each cycle is 3 weeks)|The small molecule toxin TO22723, The blood concentration of the small molecule toxin TO22723 in TOB2102., Cycle 2, Cycle 4, Cycle 8, Cycle 16 (Each cycle is 3 weeks)|The incidence rate of Anti-Drug Antibody (ADA), Evaluate the immunogenicity of injectable TQB2102 in conditions such as ADA incidence rate. Subjects with HER2-positive, unresectable, locally advanced or metastatic breast cancer who have previously received anti-HER2 monoclonal antibodies and taxane drugs., Cycle 1, Cycle 2, Cycle 4, Cycle 8, Cycle 16, 28 days (Â±7 days) after the last administration (Each cycle is 3 weeks)",,"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,246,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2025-06,2028-03,2028-12,2025-06-06,,2025-06-06,"The First Affiliated Hospital of Anhui Medical University, Bengbu, Anhui, 233099, China|Anhui Provincial Cancer Hospital, Hefei, Anhui, 230000, China|The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230000, China|Peking University First Hospital, Beijing, Beijing, 100034, China|Beijing Shunyi Hospital, Beijing, Beijing, 101300, China|Fujian Cancer Hospital, Fuzhou, Fujian, 350000, China|The First Hospital Of Lanzhou University, Lanzhou, Gansu, 730000, China|Jiangmen Central Hospital, Jiangmen, Guangdong, 529000, China|Affiliated Cancer Hospital Of Guangxi Medical University, Nanning, Guangxi, 530028, China|Cancer Hospital Of Guizhou Medical University, Guiyang, Guizhou, 550001, China|Hainan General Hospital, Haikou, Hainan, 570311, China|The Fourth Hospital Of Hebei Medical University, Shijiazhuang, Hebei, 050035, China|Affiliated Cancer Hospital Of Harbin Medical University, Harbin, Heilongjiang, 150000, China|Jiamusi Tuberculosis Hospital (Jiamusi Tumor Hospital), Jiamusi, Heilongjiang, 154007, China|Anyang Cancer Hospital, Anyang, Henan, 455001, China|The First Affiliated Hospital Of Henan University Of Science & Technology, Luoyang, Henan, 471000, China|Henan Cancer Hospital, Zhengzhou, Henan, 450000, China|Hunan Cancer Hospital, Changsha, Hunan, 410013, China|Chifeng Municipal Hospital, Chifeng, Inner Mongolia, 024000, China|Jiangxi Cancer Hospital, Nanchang, Jiangxi, 330029, China|Jilin Cancer Hospital, Changchun, Jilin, 130000, China|The First Hospital of Jilin University, Changchun, Jilin, 130021, China|The Second Hospital Of Dalian Medical University, Dalian, Liaoning, 116000, China|Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, 110041, China|Affiliated Hospital Of Jining Medical University, Jining, Shandong, 272029, China|Linyi Cancer Hospital, Linyi, Shandong, 276000, China|Fudan University Shanghai Cancer Center, Shanghai, Shanghai, 201321, China|Dazhopu Central Hospital, Dazhou, Sichuan, 635000, China|Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, 637000, China|Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, 300060, China|Hangzhou Cancer Hospital, Hangzhou, Zhejiang, 310002, China",
NCT04497844,A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC),https://clinicaltrials.gov/study/NCT04497844,AMPLITUDE,ACTIVE_NOT_RECRUITING,The purpose of the study is to determine if the combination of niraparib with Abiraterone Acetate (AA) plus prednisone compared with AA plus prednisone in participants with deleterious germline or somatic Homologous Recombination Repair (HRR) gene-mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) provides superior efficacy in improving radiographic progression-free survival (rPFS).,NO,Metastatic Castration-sensitive Prostate Cancer,DRUG: Niraparib|DRUG: Abiraterone acetate (AA)|DRUG: Prednisone|DRUG: Placebo for Niraparib,"Radiographic Progression-free Survival (rPFS), rPFS is defined as time from randomization date to date of radiographic progression or death, whichever occurs first. Radiographic progression will be evaluated by Prostate Cancer Working Group 3 (PCWG3) criteria and Response Evaluation Criteria in Solid Tumors (RECIST 1.1)., Up to 47 months","Overall Survival (OS), OS is defined as the time from date of randomization to date of death from any cause., Up to 78 months|Time to Symptomatic Progression, Time to symptomatic progression is defined as time from the date of randomization to the date of any of the following (whichever occurs first): a) the use of external beam radiation therapy for skeletal or pelvic symptoms; b) the need for tumor-related orthopedic surgical intervention; c) other cancer-related procedures; d) cancer-related morbid events; e) initiation of a new systemic anti-cancer therapy because of cancer symptoms., Up to 47 months|Time to Subsequent Therapy, Time to Subsequent Therapy is defined as the time from date of randomization to the date of initiation of subsequent therapy for prostate cancer., Up to 47 months|Number of Participants with Adverse Events as a Measure of Safety and Tolerability, An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. AE does not necessarily have a causal relationship with intervention., Up to 78 months",,"Janssen Research & Development, LLC",,MALE,"ADULT, OLDER_ADULT",PHASE3,696,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-09-23,2025-01-07,2027-11-01,2020-08-04,,2025-05-23,"Urology Centers Of Alabama, Homewood, Alabama, 35209, United States|Mayo Clinic Arizona, Phoenix, Arizona, 85054, United States|Urological Associates of Southern Arizona, P.C., Tucson, Arizona, 85741, United States|Greater Los Angeles VA Healthcare System, Los Angeles, California, 90073, United States|University of California Irvine Medical Center Chao Family Comprehensive Cancer Center, Orange, California, 92868, United States|San Bernardino Urological Associates, San Bernardino, California, 92404, United States|University of San Francisco California, San Francisco, California, 94158, United States|Rocky Mountain Cancer Centers, Colorado Springs, Colorado, 80907, United States|AdventHealth Medical Group Urology of Denver, Denver, Colorado, 80210, United States|Colorado Clinical Research, Lakewood, Colorado, 80228, United States|Eastern Connecticut Hematology & Oncology Assoc., Norwich, Connecticut, 06360, United States|Advanced Urology Institute, Daytona Beach, Florida, 32114, United States|Holy Cross Hospital - Michael and Dianne Bienes Comprehensive Cancer Center, Fort Lauderdale, Florida, 33308, United States|University of Florida Health Jacksonville, Jacksonville, Florida, 32209, United States|Cancer Specialists of North Florida, Jacksonville, Florida, 32256, United States|Urology of Indiana, Greenwood, Indiana, 46143, United States|First Urology, Jeffersonville, Indiana, 47130, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, 70121, United States|Baltimore VA Medical Center, Baltimore, Maryland, 21201, United States|Maryland Oncology Hematology, PA, Columbia, Maryland, 21044, United States|Chesapeake Urology Associates, Towson, Maryland, 21204, United States|Michigan Institute of Urology, Troy, Michigan, 48084, United States|Mosaic Life Care, Saint Joseph, Missouri, 64507, United States|St. Louis VA Medical Center, Saint Louis, Missouri, 63109, United States|GU Research Network, Omaha, Nebraska, 68130, United States|New York Oncology Hematology, Albany, New York, 12206, United States|Montefiore Medical Center, Bronx, New York, 10461, United States|Manhattan VAMC, New York, New York, 10010, United States|Mount Sinai, New York, New York, 10029, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Associated Medical Professionals, Syracuse, New York, 13210, United States|Durham VAMC, Durham, North Carolina, 27705, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, 73104, United States|VA Portland Health Care System, Portland, Oregon, 97239, United States|Oregon Oncology Specialists, Salem, Oregon, 97301, United States|Keystone Urology Specialists, Lancaster, Pennsylvania, 17604, United States|Philadelphia VA Medical Center, Philadelphia, Pennsylvania, 19104, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, 15232, United States|Ralph H. Johnson Veterans Affairs Medical Center, Charleston, South Carolina, 29401, United States|Prisma Health, Seneca, South Carolina, 29672, United States|Urology Associates, Nashville, Tennessee, 37209, United States|Texas Oncology-Austin, Austin, Texas, 78731, United States|Texas Oncology - Northeast, Denton, Texas, 76201, United States|Houston Metro Urology, Houston, Texas, 77027, United States|Texas Oncology P A, New Braunfels, Texas, 78130, United States|Texas Oncology - Northeast, Tyler, Texas, 75702, United States|University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, 84112, United States|Virginia Oncology Associates, Norfolk, Virginia, 23502, United States|Virginia Commonwealth University - Massey Cancer Center, Richmond, Virginia, 23298, United States|VA Puget Sound Healthcare System, Seattle, Washington, 98108, United States|Seattle Cancer Care Alliance, Seattle, Washington, 98109, United States|MultiCare Health System, Tacoma, Washington, 98405, United States|Sociedade Beneficente de Senhoras Hospital Sirio Libanes, Buenos Aires, C1419AHN, Argentina|Centro OncolÃ³gico Korben, Buenos Aires, C1426AGE, Argentina|Hospital Militar Cosme Argerich, C.a.b.a., C1426BOR, Argentina|CINME Centro de Investigaciones Metabolicas, Caba, C1056ABI, Argentina|CIPREC Arenales, Caba, C1061AAS, Argentina|Centro de Urologia (CDU), Ciudad Automoma Buenos Aires, C1120AAT, Argentina|Hospital Italiano de Buenos Aires, Ciudad Autonoma de, C1199ABB, Argentina|Clinica Adventista Belgrano, Ciudad De Buenos Aires, C1430EGF, Argentina|Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica, Cordoba, 5000, Argentina|Centro Urologico Profesor Bengio, Cordoba, X5000KPH, Argentina|Instituto MÃ©dico de RÃ­o Cuarto, Cordoba, X5800, Argentina|Hospital Privado de Cordoba, Cordoba, XX5016KEH, Argentina|Hospital Privado de Comunidad, Mar Del Plata, B7602CBM, Argentina|Centro de Investigacion Pergamino SA, Pergamino, B2700CPM, Argentina|ARS MÃ©dica, San Salvador De Jujuy, Y4600AFW, Argentina|Sunshine Coast University Hospital, Birtinya, 4575, Australia|St Vincent s Hospital Sydney, Darlinghurst, 2010, Australia|Cancer Care Services Clinical Research Unit, Herston, 4029, Australia|Royal Hobart Hospital, Hobart, 7000, Australia|Icon Cancer Centre Kurralta Park, Kurralta Park, 5037, Australia|Liverpool Hospital, Liverpool, 2170, Australia|Peter MacCallum Cancer Centre, Melbourne, 3000, Australia|Fiona Stanley Hospital, Murdoch, 6150, Australia|Macquarie University Hospital, North Ryde, 2109, Australia|ICON Cancer Care, South Brisbane, 4101, Australia|St John of God Subiaco Hospital, Subiaco, 6008, Australia|Bobruisk Interregional Oncology Dispensary, Bobruisk, 213825, Belarus|Brest Regional Oncology Dispensary, Brest, 224027, Belarus|Gomel Regional Clinical Oncology Dispensary, Gomel, 246012, Belarus|Grodno University Hospital, Grodno, 230017, Belarus|N N Alexandrov National Cancer Centre of Belarus, Lesnoy, 223040, Belarus|Minsk city Clinical Oncological Dispensary, Minsk, 220013, Belarus|Mogilev Regional Oncology Dispensary, Mogilev, 212018, Belarus|Vitebsk Regional Clinical Oncology Dispensary, Vitebsk, 210603, Belarus|ZNA Middelheim, Antwerp, 2020, Belgium|Grand Hopital De Charleroi Site Les Viviers, Charleroi, 6060, Belgium|Jolimont, Haine-St-Paul, 7100, Belgium|CHC MontLegia, Liege, 4000, Belgium|CHU UCL Namur - Site Sainte Elisabeth, Namur, 5000, Belgium|Clinique St Pierre, Ottignies, 1340, Belgium|Algemeen Ziekenhuis Delta, Roeselare, 8800, Belgium|GZA Ziekenhuizen, Wilrijk, 2610, Belgium|Fundacao Pio XII, Barretos, 14784-400, Brazil|Cetus Oncologia, Belo Horizonte, 30110-022, Brazil|PERSONAL Oncologia de Precisao e Personalizada, Belo Horizonte, 30130-090, Brazil|CIONC Centro Integrado de Oncologia de Curitiba, Curitiba, 80810 050, Brazil|Centro de Pesquisa e Ensino em Oncologia de Santa Catarina CEPEN, Florianopolis, 88034-000, Brazil|Pronutrir, Fortaleza, 60 810180, Brazil|Associacao de Combate ao Cancer em Goias - Hospital de Cancer Araujo Jorge, Goiania, 74605-070, Brazil|Fundacao Sao Francisco Xavier, Ipatinga, 35162 189, Brazil|Instituto Joinvilense de Hematologia e Oncologia Ltda Centro de Hematologia e Oncologia, Joinville, 89201-260, Brazil|Liga Norte Riograndense Contra O Cancer, Natal, 59075-740, Brazil|UPCO Unidade de Pesquisa Clinica em Oncologia, Pelotas, 96020 080, Brazil|Irmandade Santa Casa de Misericordia de Porto Alegre, Porto Alegre, 90020-090, Brazil|Hospital Ernesto Dornelles, Porto Alegre, 90160-093, Brazil|MultiHemo Servicos Medicos S.A, Recife, CEP: 50070-460, Brazil|Ministerio da Saude Instituto Nacional do Cancer, Rio de Janeiro, 20230-130, Brazil|Universidade do Estado do Rio de Janeiro - UERJ, Rio de Janeiro, 20551-030, Brazil|Oncoclinicas Rio de Janeiro S A, Rio de Janeiro, 22250 905, Brazil|Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI), Rio de Janeiro, 22775 001, Brazil|Nucleo de Oncologia da Bahia, Salvador, 40170 110, Brazil|Hospital Sao Rafael, Salvador, 41253 190, Brazil|Fundacao do ABC Centro Universitario FMABC, Santo Andre, 09060 870, Brazil|Irmandade Santa Casa de Misericordia de Sao Paulo, Sao Paulo, 01221-020, Brazil|Instituto de Ensino e Pesquisa SÃ£o Lucas, Sao Paulo, 01236-030, Brazil|Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, 01246 000, Brazil|Real e Benemerita Associacao Portuguesa de Beneficencia, Sao Paulo, 01323 900, Brazil|Hospital Alemao Oswaldo Cruz, Sao Paulo, 01421-000, Brazil|Instituto de Assistencia Medica ao Servidor Publico Estadual IAMSPE, Sao Paulo, 04039-004, Brazil|IOS - Instituto de Oncologia de Sorocaba Dr. Gilson Delgado, Sorocaba, 18030-005, Brazil|Instituto do Cancer Arnaldo Vieira de Carvalho, SÃ£o Paulo, 01221 020, Brazil|NÃºcleo de Pesquisa SÃ£o Camilo, SÃ£o Paulo, 04014-002, Brazil|Centro OncolÃ³gico do TriÃ¢ngulo, UberlÃ¢ndia, 38408-150, Brazil|MHAT Deva Maria, Burgas, 8001, Bulgaria|UMHAT 'Dr. Georgi Stranski', EAD, Pleven, 5800, Bulgaria|Complex Oncology Center - Plovdiv EOOD, Plovdiv, 4004, Bulgaria|Multifunctional Hospital for Active Treatment for Women Health Nadezhda, Sofia, 1330, Bulgaria|Specialized Hospital for Active Treatment in Oncology, Sofia, 1756, Bulgaria|UMHAT Sofia Med, Sofia, 1797, Bulgaria|Comprehensive Cancer Center, Vratsa, 3001, Bulgaria|Prostate Cancer Centre, Calgary, Alberta, T2V 1P9, Canada|Cross Cancer Institute, Edmonton, Alberta, T6G 1Z2, Canada|British Columbia Cancer Agency(BCCA)-Sindi Ahluwalia Hawkins Centre for the Southern Interior(CSI), Kelowna, British Columbia, V1Y 5L3, Canada|British Columbia Cancer Agency BCCA Vancouver Centre, Vancouver, British Columbia, V5Z 4E6, Canada|British Columbia Cancer Agency Vancouver Island Centre, Victoria, British Columbia, V8R 6V5, Canada|McMaster Institute of Urology, Hamilton, Ontario, L8N 4A6, Canada|Kingston Health Sciences Centre, Kingston General Health Research Institute, Kingston, Ontario, K7L2V7, Canada|Sunnybrook Health Sciences Center, Toronto, Ontario, M4N 3M5, Canada|Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, M5G2M9, Canada|Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, H2X 0A9, Canada|McGill University - Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada|Cancer Hospital Chinese Academy of Medical Sciences, Beijing, 100021, China|Peking University First Hospital, Beijing, 100034, China|Beijing Friendship Hospital Capital Medical University, Beijing, 100050, China|Beijing Cancer Hospital, Beijing, 100142, China|Beijing University Third Hospital, Beijing, 100191, China|Beijing Hospital, Beijing, 100730, China|West China Hospital of Sichuan University, Chengdu, 610041, China|Sichuan Provincial Peoples Hospital, Chengdu, 610072, China|Western Theater General Hospital of the Chinese People's Liberation Army, Chengdu, 610083, China|Chongqing University Cancer Hospital, Chongqing, 400030, China|Southwest Hospital, The Third Military Medical University, Chongqing, 400038, China|Sun Yat Sen University Cancer Center, GuangZhou, 430030, China|Guangzhou First Municipal People's Hospital, Guangzhou, 510180, China|Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510289, China|Zhejiang Provincial People's Hospital, Hangzhou, 310014, China|The First Affiliated Hospital of NanChang University, Nanchang, 330006, China|Jiangsu Province Cancer Hospital, Nanjing, 210000, China|Nanjing Drum Tower Hospital, Nanjing, 210008, China|The First Affiliated Hospital of Ningbo University, Ningbo, 315010, China|Fudan University Shanghai Cancer Center, Shanghai, 200032, China|Huashan Hospital Fudan University, Shanghai, 200040, China|Renji Hospital Affiliated to Medical College of Shanghai Jiaotong University, Shanghai, 200127, China|The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, 200240, China|Huadong Hospital Affiliated to Fudan University, Shanghai, 200400, China|Shengjing Hospital Of China Medical University, Shenyang, 110004, China|Second Affiliated Hospital of Soochow University, SuZhou, 200233, China|The First Affliated Hospital of Soochow University, Suzhou, 215006, China|The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China|TongJi Hospital of TongJi Medical College of Huazhong University of Science & Technology, Wuhan, 430030, China|The First Affiliated Hospital of Xian Jiaotong University, XI An, 710061, China|Fakultni nemocnice u sv. Anny v Brne, Brno, 656 91, Czechia|FN Hradec Kralove, Urologicka klinika, Hradec Kralove, 500 05, Czechia|KrajskÃ¡ nemocnice Liberec, Liberec, 460 63, Czechia|Uromedical Center s.r.o., Olomouc, 77900, Czechia|Urologicka klinika 1 LF UK a VFN, Praha 2, 128 00, Czechia|Aalborg University Hospital, Aalborg, 9000, Denmark|Copenhagen University Hospital, Copenhagen, 2100, Denmark|Herlev Hospital, Herlev, DK-2730, Denmark|NÃ¦stved Hospital, Naestved, 4700, Denmark|Odense Universitetshospital, Odense, DK-5000, Denmark|Vejle Hospital, Vejle, DK-7100, Denmark|Institut de Cancerologie de l Ouest ICO, Angers Cedex 9, 49933, France|Institut Sainte Catherine, Avignon Cedex 9, 84918, France|CHRU De Besancon, Besancon, 25030, France|Institut Bergonie, Bordeaux, 33000, France|Centre Jean Perrin, Clermont Ferrand, 63011, France|Centre Georges Francois Leclerc, Dijon, 21000, France|Centre Oscar Lambret, Lille, 59020, France|Centre Leon Berard, Lyon, 69008, France|Hopital Prive Jean Mermoz, Lyon, 69008, France|Institut Regional du Cancer de Montpellier Val d'Aurelle, Montpellier, 34298, France|Polyclinique de Gentilly, Nancy, 54100, France|CHU De Poitiers, Poitiers Cedex, 86021, France|Centre Hopitalier Inter-Communal De Cornouaille, Quimper, 29000, France|HIA Begin, Saint Mande, 94163, France|Institut de CancÃ©rologie de Loire, Saint-Priest-en-Jarez, 42271, France|Clinique Sainte Anne, Strasbourg, 67000, France|Hopital Foch, Suresnes, 32151, France|CHRU de Tours, Tours, 37044, France|StÃ¤dtisches Klinikum Braunschweig gGmbH - Standort Salzdahlumer, Braunschweig, 38126, Germany|UniversitÃ¤tsklinik Carl Gustav Carus, Med. Klinik u. Poliklinik I, Dresden, 01307, Germany|Urologicum Duisburg, Duisburg, 47169, Germany|Medizinische Hochschule Hannover, Hannover, 30625, Germany|Universitaetsklinikum Koelnt, Koeln, 50937, Germany|Universitaetsklinikum Muenster, Muenster, 48149, Germany|Klinikum rechts der Isar - III. Med. Klinik und Poliklinik, MÃ¼nchen, 81675, Germany|Studienpraxis Urologie Drs. Feyerabend, Nuertingen, 72622, Germany|Jahn Ferenc Del-pesti Korhaz es Rendelointezet, Budapest, 1204, Hungary|Debreceni Egyetem, Debrecen, 4032, Hungary|Petz Aladar Megyei Oktato Korhaz, Gyor, 9024, Hungary|Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaz, Gyula, 5700, Hungary|Borsod Abauj Zemplen Varmegyei Kozponti Korhaz es Egyetemi Oktato Korhaz, Miskolc, 3526, Hungary|Szegedi Tudomanyegyetem, Szeged, 6720, Hungary|Szent Borbala Hospital Tatabanya, Tatabanya, 2800, Hungary|Haemek Medical Center - Afula, Afula, 1834111, Israel|Soroka Hospital, Beer-Sheva, 85101, Israel|Rambam Medical Center, Haifa, 31096, Israel|Hadassah Hospital, Jerusalem, 91200, Israel|Rabin Medical Center, Beilinson Hospital, Petach Tikvah, 49100, Israel|Sheba Medical Center Tel Hashomer, Ramat Gan, 52621, Israel|Tel Aviv Sourasky Medical Center, Tel-Aviv, 64239, Israel|Ospedale S. Donato - Asl 8 Arezzo, Arezzo, 52100, Italy|Divisione di Oncologia - Istituto per la ricerca e cura del cancro, Candiolo, 10060, Italy|Istituti Ospitalieri di Cremona, AO di Cremona, Cremona, 26100, Italy|Azienda Ospedaliera ''Vito Fazzi'', Lecce, 73100, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, 47014, Italy|Ospedale San Raffaele, Milano, 20132, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, 20133, Italy|European Institute of Oncology, Milano, 20141, Italy|Fondazione G Pascale Istituto Nazionale Tumori IRCCS, Napoli, 80138, Italy|Aou San Luigi Gonzaga, Orbassano, 10043, Italy|Istituto Oncologico Veneto Iov Irccs Padova, Padova, 35128, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, 56126, Italy|ASL Napoli 2 Nord-SM delle Grazie Hospital, Pozzuoli, 80078, Italy|Casa Sollievo Della Sofferenza IRCCS, San Giovanni Rotondo, 71013, Italy|Ospedale S. Chiara, Trento, Italy|Ospedale San Bortolo, Vicenza, Italy|Pusan National University Hospital, Busan, 49241, Korea, Republic of|Kyungpook National University Chilgok Hospital, Daegu, 41404, Korea, Republic of|Keimyung University Dongsan Hospital, Daegu, 42601, Korea, Republic of|Chungnam National University Hospital, Daejeon, 35015, Korea, Republic of|Chonnam National University Hospital, Gwangju, 61469, Korea, Republic of|National Cancer Center, Gyeonggi-do, 10408, Korea, Republic of|Ajou University Hospital, Gyeonggi-do, 16499, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, 13620, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Severance Hospital Yonsei University Health System, Seoul, 03722, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Gangnam Severance Hospital, Yonsei University Health System, Seoul, 06273, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|The Catholic University of Korea Seoul St Mary s Hospital, Seoul, 06591, Korea, Republic of|Hospital Pulau Pinang, George Town, 10990, Malaysia|Hospital Sultan Ismail, Johor Bahru, 81100, Malaysia|Hospital Kuala Lumpur, Kuala Lumpur, 50586, Malaysia|University Malaya Medical Centre, Kuala Lumpur, 59100, Malaysia|Sarawak General Hospital, Kuching, 93586, Malaysia|Institut Kanser Negara Clinical Research Center, Putrajaya, 62250, Malaysia|Centro de InvestigaciÃ³n ClÃ­nica Gramel S.C., Ciudad de Mexico, 3720, Mexico|Consultorio de Especialidad en Urologia Privado, Durango, 34000, Mexico|Consultorio Privado, Leon, 37000, Mexico|Avix Investigacion Clinica S C, Monterrey, 64710, Mexico|i Can Oncology Center, Monterrey, 64710, Mexico|Oncologia Integral Satelite, Naucalpan, 53100, Mexico|Consultorio de OncologÃ­a MÃ©dica, Oaxaca, 68020, Mexico|Consultorio Privado, Zapopan, 45040, Mexico|Reinier de Graaf Gasthuis, Delft, 2625 AD, Netherlands|Tergooiziekenhuizen, Hilversum, 1213XZ, Netherlands|Canisius-Wilhelminaziekenhuis, Nijmegen, 6532 SZ, Netherlands|Elisabeth-TweeSteden Ziekenhuis, Tilburg, 5022 GC, Netherlands|Auckland City Hospital, Auckland, 1023, New Zealand|Canterbury Urology Research Trust, Christchurch, 8013, New Zealand|Dunedin Hospital, Dunedin Central, 9016, New Zealand|Tauranga Hospital, Tauranga, 3112, New Zealand|IN VIVO Sp. z o.o, Bydgoszcz, 85 048, Poland|Szpital Uniwersytecki NR 1 IM Dr Antoniego Jurasza, Bydgoszcz, 85 094, Poland|Centrum Onkologii im Prof F Lukaszczyka, Bydgoszcz, 85 796, Poland|Szpitale Pomorskie Sp z o o, Gdynia, 81 519, Poland|Przychodnia Lekarska KOMED Roman Karaszewski, Konin, 62-500, Poland|Klinika MedTrials, Krakow, 30 539, Poland|Wojewodzki Szpital Specjalistyczny im. M. Kopernika w Lodzi, Lodz, 93-509, Poland|Medisport, Lublin, 20-223, Poland|Urologica Praktyka Lekarska Adam Marcheluk, Siedlce, 08-110, Poland|Szpital Grochowski Im Dr Med Rafala Masztaka Sp Z O O, Warszawa, 04 073, Poland|Specjalistyczna przychodnia lekarska POLIMED, Wroclaw, 53-329, Poland|Uls Almada Seixal - Hosp. Garcia de Orta, Almada, 2805-607, Portugal|Instituto PortuguÃªs de Oncologia Francisco Gentil - Centro Regional de Oncologia de Coimbra, S.A., Coimbra, 3000075, Portugal|Fund. Champalimaud, Lisboa, 1400-038, Portugal|Uls Santa Maria - Hosp. Santa Maria, Lisboa, 1649 035, Portugal|Puerto Rico Medical Research Center, Hato Rey, 00917, Puerto Rico|Altai Regional Oncology Dispensary, Barnaul, 656045, Russian Federation|Chelyabinsk Regional Clinical Center Of Oncology And Nuclear Medicine, Chelyabinsk, 454087, Russian Federation|Ivanovo Regional Oncology Dispensary, Ivanovo, 153040, Russian Federation|Moscow City Clinical Hospital # 62, Moscow, 125130, Russian Federation|Hertzen Oncology Research Institute, Moscow, 125284, Russian Federation|Privolzhsky District Medical Centre, Nizhny Novgorod, 603001, Russian Federation|Clinical Oncology Dispensary, Omsk, 644013, Russian Federation|LLC Novaya Clinica, Pyatigorsk, 357500, Russian Federation|Pyatigorsk Interdistrict Oncology Dispensary, Pyatigorsk, 357502, Russian Federation|Private Medical Institution Euromedservice, Saint Petersburg, 196603, Russian Federation|Leningrad Regional Oncology Dispensary, Saint-Petersburg, 191104, Russian Federation|Republican Oncology Dispensary, Saransk, 430032, Russian Federation|Tomsk Cancer Research Institute, Tomsk, 634050, Russian Federation|Multifunctional clinical medical center 'Medical city', Tyumen, 625041, Russian Federation|Bashkir State Medical University, Ufa, 450083, Russian Federation|CancerCare Rondebosch, Cape Town, 7700, South Africa|Steve Biko Academic Hospital, Pretoria, 0001, South Africa|East Rand Urology Research Unit, Vosloorus, 1475, South Africa|Hosp Univ A Coruna, A Coruna, 15006, Spain|Hosp. de La Santa Creu I Sant Pau, Barcelona, 08025, Spain|Hosp Clinic de Barcelona, Barcelona, 08036, Spain|Hosp. Gral. Univ. de Castellon, Castellon, 12004, Spain|Institut CatalÃ  D'Oncologia Girona, Girona, 17007, Spain|Hosp. de Jerez de La Frontera, Jerez de la Frontera, 11407, Spain|Hosp. Univ. de La Princesa, Madrid, 28006, Spain|Hosp. Univ. Ramon Y Cajal, Madrid, 28034, Spain|Hosp. Univ. 12 de Octubre, Madrid, 28041, Spain|Hosp. Univ. La Paz, Madrid, 28046, Spain|Hosp. Univ. Hm Monteprincipe, Madrid, 28660, Spain|Hosp Virgen de La Victoria, MÃ¡laga, 29010, Spain|Corporacio Sanitari Parc Tauli, Sabadell, 08208, Spain|Hosp. Univ. Marques de Valdecilla, Santander, 39008, Spain|Hosp. Virgen Del Rocio, Sevilla, 41013, Spain|Hosp. Clinico Univ. de Valencia, Valencia, 46010, Spain|Salgrenska University hospital, GÃ¶teborg, 413 45, Sweden|Urologiska Mottagningen, MalmÃ¶, 205 02, Sweden|Sodersjukhuset, Stockholm, 11883, Sweden|Karolinska Universitetssjukhuset Solna, Stockholm, 17164, Sweden|Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, 83301, Taiwan|Kaohsiung Medical University Chung Ho Memorial Hospital, Kaohsiung, 807, Taiwan|China Medical University Hospital, Taichung, 40447, Taiwan|Taichung Veterans General Hospital, Taichung, 40705, Taiwan|Tungs' Taichung MetroHarbor Hospital, Taichung, 435, Taiwan|National Taiwan University Hospital., Taipei, 10002, Taiwan|Taipei Veterans General Hospital, Taipei, 11217, Taiwan|Chang-Gung Memorial Hospital, LinKou Branch, Taoyuan, 333, Taiwan|King Chulalongkorn Memorial Hospital, Bangkok, 10330, Thailand|Ramathibodi Hospital, Bangkok, 10400, Thailand|Siriraj Hospital, Bangkok, 10700, Thailand|Adana Baskent Yuregir Hospital, Adana, 01250, Turkey|Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, 06200, Turkey|Memorial Ankara Hastanesi, Ankara, 06520, Turkey|Gazi University Hospital, Ankara, 06560, Turkey|Ankara University Medical Faculty, Ankara, 06590, Turkey|Ankara Bilkent City Hospital, Ankara, 06800, Turkey|Bursa Yuksek lhtisas EAH Medikal Onkoloji Klinigi, Bursa, 16310, Turkey|Trakya University Medical Faculty, Edirne, 22030, Turkey|Istanbul University Istanbul Medical Faculty, Istanbul, 34000, Turkey|Istanbul Universitesi Cerrahpasa Tip Fakultesi Ic Hastaliklari Anabilim Dali Medikal Onkoloji Bd, Istanbul, 34098, Turkey|Bakirkoy Training and Research Hospital, Istanbul, 34147, Turkey|T C Saglik BakanlÄ±gi Goztepe Prof Dr Suleyman YalcÄ±n Sehir Hastanesi, Istanbul, 34722, Turkey|Dokuz Eylul University Medical Faculty, Izmir, 35340, Turkey|Izmir Medical Point Hospital, Izmir, 35530, Turkey|Sakarya University Training and Research Hospital, Sakarya, 54100, Turkey|Medical Park Samsun Hastanesi, Samsun, 55200, Turkey|CNE Clinical Center of Oncology Hematology Transplantology and Palliative Care of the Cherkasy RC, Cherkasy, 18009, Ukraine|Municipal Non-profit enterprise 'Bukovinian clinical oncology center', Chernivtsi, 58013, Ukraine|Ce 'Dnipropetrovsk Regional Clinical Hospital N.A. Mechnikov' of Dnipropetrovsk Rc, Dnipro, 49005, Ukraine|Municipal Institution 'Clinical Oncology Dispensary' Under Dnipropetrovsk Regional Council, Dnipro, 49100, Ukraine|Dnipropetrovsk State Medical Academy, Dnipropetrovsk City Multifield Clinical Hospital # 4, Dnipro, 49102, Ukraine|Ivano-Frankivsk Regional Clinical Hospital, Ivano-Frankivsk, 76008, Ukraine|Communal Institution 'City hospital â7 of Kamianske' of Dnepropetrov'sk Regional Council, Kamianske, 51900, Ukraine|Municipal non-profit enterprise 'Regional Center of Oncology', Khakhiv, 61070, Ukraine|Regional Medical Clinical Center for Urology and Nephrology named after V.I. Shapoval, Kharkiv, 61037, Ukraine|Kherson Regional Oncological Dispensary, Kherson, 73035, Ukraine|Nonprofit Organization National Cancer Institute, Kyiv, 03022, Ukraine|State Institution Institute of Urology NAMS of Ukraine based on Kyiv City Clinical Oncology Center, Kyiv, 03115, Ukraine|Kyiv Regional Oncological Dispensary, Kyiv, 04107, Ukraine|Communal Noncommercial Enterprise of Lviv Regional Council 'Lviv Regional Clinical Hospital', Lviv, 79010, Ukraine|Podilskiy Regional Center of Oncology, Vinnitsa, 21029, Ukraine|Communal Institution 'Regional Oncology Dispensary' of Zhytomyr Region Council, Zhytomyr, 10002, Ukraine|Ysbyty Gwynedd, Bangor, LL57 2PW, United Kingdom|Belfast City Hospital, Belfast, BT9 7AB, United Kingdom|Brighton and Sussex University Hospitals NHS Trust, Brighton, BN2 5BE, United Kingdom|Bristol Haematology and Oncology Centre, Bristol, BS2 8ED, United Kingdom|Guy's Hospital, Great Maze Pond, SE1 9RT, United Kingdom|Prince Of Wales Hospital, Grimsby, DN33 2BA, United Kingdom|Marie Curie Research Wing - Mount Vernon Hospital, Hillingdon, HA6 2RN, United Kingdom|Raigmore Hospital, Inverness, IV2 3UJ, United Kingdom|University College London Hospitals NHSFT, London, NW1 2PG, United Kingdom|Churchill Hospital, Oxford, OX3 7LE, United Kingdom|Royal Preston Hospital, Preston, PR2 9HT, United Kingdom|Royal Marsden Hospital, Sutton, SM2 5PT, United Kingdom|Royal Cornwall Hospitals NHS Trust - Royal Cornwall Hospital, Truro, TR1 3LJ, United Kingdom",
NCT03767244,"A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy",https://clinicaltrials.gov/study/NCT03767244,PROTEUS,ACTIVE_NOT_RECRUITING,The purpose of this study is to determine if treatment with apalutamide plus androgen deprivation therapy (ADT) before and after radical prostatectomy (RP) with pelvic lymph node dissection (pLND) in participants with high-risk localized or locally advanced prostate cancer results in an improvement in pathological complete response (pCR) rate and metastasis-free survival (MFS) as compared to placebo plus ADT.,NO,Prostatic Neoplasms,DRUG: Apalutamide|DRUG: Androgen Deprivation Therapy (ADT)|DRUG: Placebo,"Percentage of Participants with Pathologic complete response (pCR), pCR is assessed by a pathology blinded independent central radiology review (BICR) as defined in the pathology charter., Approximately 4 years|Metastasis-Free Survival (MFS), MFS is defined as the time from randomization to the date of the first occurrence of radiographic distant metastasis evaluated by radiology BICR, incidental pathologic finding of distant metastasis, or death from any cause, whichever occurs first., Up to 7 years and 5 months","Prostate Specific Antigen (PSA)-Free Survival, PSA-free survival with testosterone recovery defined as the time from randomization to the first detectable serum PSA level with recovered testosterone levels after undetectable PSA post-radical prostatectomy with pelvic lymph node dissection or death, whichever occurs first., Approximately 4 years|Event Free Survival (EFS), EFS defined as time from randomization to any of the following events: biochemical failure (BCF); or local or regional recurrence by BICR or histopathological assessment; or distant metastasis by BICR or histopathological assessment; or death., Up to 7 years and 5 months|Time to Subsequent First Treatments (TTST-1), TTST-1 is defined as the time from randomization to the date of first subsequent therapy., Up to 7 years and 5 months|Time to Distant Metastasis (TTDM), TTDM is defined as the time from the date of enrollment until the first date of distant metastasis., Up to 7 years and 5 months|MFS Based on Conventional Imaging, MFS based on conventional imaging, defined as the time from randomization to the date of the first occurrence of radiographic distant metastasis on CT/MRI and bone scan by radiology BICR, pathologic finding of distant metastasis, or death from any cause, whichever occurs first., Up to 7 years and 5 months|Number of Participants with No Evidence of Disease (NED) at 4 Years, Number of participants with NED at 4 years will be reported. NED at 4 years is defined as: (a) alive, (b) Undetectable prostate-specific antigen (PSA), (c) No distant metastasis, (d) No local or regional recurrence, (e) No subsequent therapy for prostate cancer, (f) Testosterone recovery to physiological testosterone levels, defined as 200 nanograms per deciliter (ng/dL)., Up to 4 years|Number of Participants with Vital Signs Abnormalities as a Measure of Safety and Tolerability, Number of participants with vital signs (including body temperature, heart rate, respiratory rate, and blood pressure) abnormalities will be reported., Up to 30 days after last dose of study drug (Approximately 8 years)|Number of Participants with Physical Examinations Abnormalities as a Measure of Safety and Tolerability, Number of participants with physical examinations (including general appearance of the participant, height, weight, and examination of the skin, ears, nose, throat, lungs, heart, abdomen, extremities, musculoskeletal system, lymphatic system, and nervous system) abnormalities will be reported., Up to 30 days after last dose of study drug (Approximately 8 years)|Number of Participants with Laboratory Abnormalities as a Measure of Safety and Tolerability, Blood samples for serum chemistry and hematology will be collected at predefined time points for clinical laboratory testing., Up to 30 days after last dose of study drug (Approximately 8 years)|Number of Participants with Treatment Compliance Rate, Number of participants who are complaint with study treatment will be assessed., Up to 30 days after last dose of study drug (Approximately 8 years)",,"Janssen Research & Development, LLC",,MALE,"ADULT, OLDER_ADULT",PHASE3,2517,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-06-11,2026-02-10,2029-07-19,2018-12-06,,2025-05-23,"UC San Diego Moores Cancer Center, La Jolla, California, 92093, United States|University of Southern California, Los Angeles, California, 90033, United States|Cedars Sinai Medical Center, Los Angeles, California, 90048, United States|University of California Los Angeles, Los Angeles, California, 90095, United States|University of California Irvine Medical Center Chao Family Comprehensive Cancer Center, Orange, California, 92868, United States|UC Davis Medical Center, Sacramento, California, 95817, United States|AdventHealth Medical Group Urology of Denver, Denver, Colorado, 80210, United States|Colorado Clinical Research, Lakewood, Colorado, 80228, United States|Stamford Hospital, Stamford, Connecticut, 06904, United States|Urology Specialists LLC, Hialeah, Florida, 33002, United States|Mayo Clinic - Division Of Hematology/oncology, Jacksonville, Florida, 32224, United States|Miami Cancer Institute at Baptist Health / Baptist Health Medical Group, Miami, Florida, 33176, United States|Florida Hospital, Orlando, Florida, 32804, United States|Emory University Winship Cancer Institute, Atlanta, Georgia, 30322-1013, United States|University of Chicago, Chicago, Illinois, 60637, United States|Ochsner LSU Health Shreveport - Regional Urology, Shreveport, Louisiana, 71106, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States|Beth Isreal Deaconess Medical Center, Boston, Massachusetts, 02215, United States|Michigan Institute of Urology, PC, Troy, Michigan, 48084, United States|Saint Louis University, Saint Louis, Missouri, 63110, United States|Urology Cancer Center, PC, Omaha, Nebraska, 68130, United States|Albany Medical College, Albany, New York, 12208, United States|Great Lakes Physician PC d/b/a Western New York Urology Associates, Cheektowaga, New York, 14225, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, 10065, United States|Weill Cornell Medical College, New York, New York, 10065, United States|SUNY Upstate Medical University, Syracuse, New York, 13210, United States|University of North Carolina, Chapel Hill, North Carolina, 27599, United States|Duke University School of Medicine, Durham, North Carolina, 27705, United States|Medication Management LLC, Greensboro, North Carolina, 27403, United States|Carolina Urology Partners, PLLC, Huntersville, North Carolina, 28078, United States|Cleveland VA Medical Center, Cleveland, Ohio, 44106, United States|Oklahoma City VAMC, Oklahoma City, Oklahoma, 73104, United States|MidLantic Urology, Bala-Cynwyd, Pennsylvania, 19004, United States|Omega Medical Research, Warwick, Rhode Island, 02886, United States|Medical University of South Carolina, Charleston, South Carolina, 29403, United States|Ralph H. Johnson Veterans Affairs Medical Center, Charleston, South Carolina, 29425, United States|Greenville Health, Greenville, South Carolina, 29605, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, 29572, United States|Vanderbilt University Medical Center, Nashville, Tennessee, 37232, United States|VA North Texas Health Care System, Dallas, Texas, 75216, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|Virginia Urology, Richmond, Virginia, 23235, United States|Urology of Virginia, PLCC, Virginia Beach, Virginia, 23462, United States|CAMC Memorial Hospital, Charleston Area Medical Center Physicians, Charleston, West Virginia, 25304, United States|Hospital Aleman, Caba, 1118, Argentina|Hospital Italiano de Buenos Aires, Ciudad Autonoma de, C1199ABB, Argentina|Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica, Cordoba, 5000, Argentina|Centro Urologico Profesor Bengio, Cordoba, X5000KPH, Argentina|Uroclinica, Mendoza, 5500, Argentina|Clinica Mayo de UMCB, San Miguel de Tucuman, 4000, Argentina|Epworth Eastern Hospital, Box Hill, 3128q, Australia|St Vincent s Hospital Sydney, Darlinghurst, 2010, Australia|Austin Health, Heidelberg, 3084, Australia|Australian Urology Associates Pty Ltd, Malvern, 3144, Australia|Royal Melbourne Hospital, Parkville, 3052, Australia|Northern Cancer Institute, St Leonards, 2065, Australia|Australian Clinical Trials - SAN Clinic, Wahroonga, 2076, Australia|Westmead Hospital, Westmead, 2145, Australia|Princess Alexandra Hospital, Woolloongabba, 4102, Australia|Associacao de Combate ao Cancer em Goias - Hospital de Cancer Araujo Jorge, Goiania, 74605-070, Brazil|Oncosite - Centro de Pesquisa ClÃ­nica em Oncologia Ltda, Ijui, 98700-000, Brazil|Liga Norte Riograndense Contra O Cancer, Natal, 59075-740, Brazil|Irmandade Santa Casa de Misericordia de Porto Alegre, Porto Alegre, 90020-090, Brazil|Universidade do Estado do Rio de Janeiro - UERJ, Rio de Janeiro, 20551-030, Brazil|Associacao Umane, Sao Paulo, 01232-910, Brazil|Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, 01246 000, Brazil|Instituto Do Cancer Brasil, Tres Lagoas, 79601-001, Brazil|Prostate Cancer Centre, Calgary, Alberta, T2V 1P9, Canada|Vancouver Prostate Centre, Gordon and Leslie Diamond Health Care Centre, Vancouver, British Columbia, V5Z 1M9, Canada|Nova Scotia Health Authority, Halifax, Nova Scotia, B3H 2Y9, Canada|London Health Sciences Center, London, Ontario, N6A 5W9, Canada|Sunnybrook Health Sciences Center, Toronto, Ontario, M4N 3M5, Canada|Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, M5G2M9, Canada|CHUM - Centre hospitalier universitaire de Montreal, Montreal, Quebec, H2X 0A9, Canada|CHU de Quebec Universite Laval Hopital de l Enfant Jesus, Quebec, G1R 2J6, Canada|Fakultni nemocnice Hradec Kralove, Hradec KrÃ¡love, 500 05, Czechia|KrajskÃ¡ nemocnice Liberec, Liberec, 460 63, Czechia|Uromedical Center s.r.o., Olomouc, 77200, Czechia|Fakultni nemocnice Plzen, Urologicka klinika, Plzen, 305 99, Czechia|Thomayerova nemocnice, Praha 4, 140 59, Czechia|Vseobecna fakultni nemocnice v Praze, Praha, 120 00, Czechia|CHU d'Angers, Angers, 49933, France|CHRU Besancon Hopital Jean Minjoz, Besancon Cedex, 25030, France|Hopital Pellegrin CHU Bordeaux, Bordeaux N/a, 33076, France|APHP - Hopital Henri Mondor, CrÃ©teil, 94010, France|Hopital Edouard Herriot - CHU Lyon, Lyon cedex 03, 69437, France|CHU de Nantes hotel Dieu, Nantes, 44000, France|Institut Mutualiste Montsouris, Paris, 75014, France|Clinique de la Croix du Sud, Quint-Fonsegrives, 31130, France|Chu Rennes Hopital Pontchaillou, Rennes Cedex, 35033, France|CHU de Toulouse - HÃ´pital Rangueil, Toulouse Cedex 9, 31059, France|CHRU Tours Hopital Bretonneau, Tours, 37000, France|Universitaetsklinikum der RWTH Aachen, Aachen, 52074, Germany|StÃ¤dtisches Klinikum Braunschweig gGmbH - Standort Salzdahlumer, Braunschweig, 38126, Germany|Universitatsklinikum Essen, Essen, 45147, Germany|Universitatsklinikum Frankfurt, Frankfurt am Main, 60590, Germany|Prostata zentrum Nordwest, Gronau, 48599, Germany|Martini-Klinik am UniversitÃ¤tsklinikum Hamburg-Eppendorf Urologie, Hamburg, 20246, Germany|UniversitÃ¤tsklinikum des Saarlandes, Homburg/Saar, 66421, Germany|Universitaetsklinikum Koelnt, Koeln, 50937, Germany|Universitatsklinikum Schleswig Holstein Campus Lubeck, Lubeck, 23538, Germany|Praxis Dr. med. Ralf Eckert, Lutherstadt Eisleben, 06295, Germany|Klinikum St. Elisabeth Straubing GmbH, Straubing, 94315, Germany|Kliniken Nordoberpfalz, Klinik fÃ¼r Urologie, Weiden/Opf, 92637, Germany|Praxisgemeinschaft f. Onkologie u. Urologie - Germany, Wilhelmshaven, 26389, Germany|Asaf Harofe Medical Center, Beer Yaakov, 60930, Israel|Rambam Health Care Campus, Haifa, 31096, Israel|Tel Aviv University Sackler School of Medicine - Meir Medical Center (MMC), Kfar Saba, 4428164, Israel|Rabin Medical Center, Petach Tikva, 49100, Israel|The Chaim Sheba Medical Center, Ramat Gan, 52621, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, 64239, Israel|Policlinico Abano Terme, Abano Terme, 35031, Italy|Generale Regionale F. Miulli, Acquaviva delle Fonti, 70021, Italy|Ospedale di Bassano del Grappa, Bassano del Grappa, 36061, Italy|ASST Spedali Civili Brescia, Brescia, 25123, Italy|ASL2 Lanciano - Vasto - Chieti - Ospedale 'SS Annunziata' di Chieti, Chieti, 66100, Italy|Azienda Ospedaliero Universitaria Careggi, Firenze, 50134, Italy|San Raffaele Turro - Istituto di Ricovero e Cura a Carattere Scientifico, MIlano, 20127, Italy|Ospedale San Raffaele, Milano, 20132, Italy|Istituto Europeo di Oncologia, Milano, 20141, Italy|Clinica di Urologia Policlinico di Modena - Universita di Modena e reggio Emilia, Modena, 41100, Italy|UniversitÃ  del Piemonte Orientale - Ospedale Maggiore della CaritÃ  di Novara, Novara, 28100, Italy|Universita degli Studi di Torino - Azienda Ospedaliero-Universitaria San Luigi Gonzaga, Orbassano, 10043, Italy|Universita Campus Bio-Medico di Roma, Roma, 00128, Italy|Istituto Nazionale Tumori Regina Elena, Roma, 00144, Italy|Azienda Ospedaliera Sant Andrea, Roma, 00189, Italy|Ospedale Molinette, AO CittÃ  della Salute e della Scienza di, Torino, 10126, Italy|UOC di Urologia AOU Integrata di Verona - Polo Chirurgico Confortini - Ospedale Borgo Trento, Verona, 37126, Italy|Akita University Hospital, Akita, 010-8543, Japan|Chiba University Hospital, Chiba, 260 8677, Japan|Chiba Cancer Center, Chuo-ku, 260-8717, Japan|Hakodate Goryoukaku Hospital, Hakodate, 040 8611, Japan|Hirosaki University Hospital, Hirosaki, 036-8203, Japan|Kanazawa University Hospital, Kanazawa, 920 8641, Japan|Kobe City Medical Center General Hospital, Kobe, 650-0047, Japan|Dokkyo Medical University Saitama Medical Center, Koshigaya, 343-8555, Japan|Kurume University Hospital, Kurume, 830-0011, Japan|Kyoto University Hospital, Kyoto, 606-8507, Japan|National Hospital Organization Shikoku Cancer Center, Matsuyama, 791-0280, Japan|Kitasato University Hospital, Minami-Ku, 252-0375, Japan|University of Miyazaki Hospital, Miyazaki, 889-1692, Japan|Nagano Municipal Hospital, Nagano, 381-8551, Japan|Osaka International Cancer Institute, Osaka City, 541 8567, Japan|Kindai University Hospital, Osaka Sayama shi, 589 8511, Japan|Toho University Sakura Medical Center, Sakura, 285-8741, Japan|Hokkaido University Hospital, Sapporo-shi, 060-8648, Japan|Iwate Medical University Hospital, Shiwa-gun, 028-3695, Japan|Nippon Medical School Hospital, Tokyo, 113 8603, Japan|Juntendo University Hospital, Tokyo, 113-8421, Japan|Yamaguchi University Hospital, Ube, 755-8505, Japan|Yokohama City University Medical Center, Yokohama, 232 0024, Japan|Chonnam National University Hospital, Gwangju, 61469, Korea, Republic of|Seoul National University Bundang Hospital, Gyeonggi-do, 13605, Korea, Republic of|Severance Hospital Yonsei University Health System, Seoul, 03722, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|The Catholic University of Korea Seoul St Marys Hospital, Seoul, 06591, Korea, Republic of|Antoni van Leeuwenhoek, Amsterdam, 1066 CX, Netherlands|Catharinaziekenhuis, Eindhoven, 5623 EJ, Netherlands|St. Antonius Ziekenhuis (St. Antonius Hospital), Nieuwegein, 3430EM, Netherlands|Canisius-Wilhelmina Ziekenhuis, Nijmegen, 6524 KD, Netherlands|Samodzielny Publiczny Wielospecjalistyczny Zaklad Opieki Zdrowotnej Mswia W Bydgoszczy, Bydgoszcz, 85 015, Poland|Szpital Uniwersytecki NR 1 IM Dr Antoniego Jurasza, Bydgoszcz, 85 094, Poland|Szpital Wojewodzki im Mikolaja Kopernika w Koszalinie, Koszalin, 75 581, Poland|Pratia MCM Krakow, Krakow, 30 727, Poland|City Clinic Sp. z o.o., Warszawa, 02-473, Poland|Dolnoslaskie Centrum Onkologii, Oddzial Chirurgii Onkologicznej II - Urologia, Wroclaw, 53-413, Poland|Altai Regional Oncology Dispensary, Barnaul, 656049, Russian Federation|Chelyabinsk Regional Clinical Center Of Oncology And Nuclear Medicine, Chelyabinsk, 454087, Russian Federation|Moscow City Clinical Hospital # 62, Moscow, 125130, Russian Federation|Hertzen Oncology Research Institute, Moscow, 125284, Russian Federation|Clinical Oncology Dispensary, Omsk, 644013, Russian Federation|Medical-sanitary unit 'Neftyanik', Tyumen, 625000, Russian Federation|Vologda Regional Oncological Dispensary, Vologda, 160012, Russian Federation|Hosp Univ A Coruna, A Coruna, 15006, Spain|Hosp Univ Vall D Hebron, Barcelona, 8035, Spain|Hosp. Puerta Del Mar, Cadiz, 11009, Spain|Hosp. Gral. Univ. de Castellon, CastellÃ³n, 12004, Spain|Hosp. de Jerez de La Frontera, Jerez de la Frontera, 11407, Spain|Hosp. Univ. Ramon Y Cajal, Madrid, 28034, Spain|Hosp. Univ. 12 de Octubre, Madrid, 28041, Spain|Hosp. Univ. La Paz, Madrid, 28046, Spain|Fund. Hosp. de Manacor, Manacor, 07500, Spain|Hosp Virgen de La Victoria, MÃ¡laga, 29010, Spain|Hosp. Univ. Marques de Valdecilla, Santander, 39008, Spain|Hosp. Virgen Del Rocio, Sevilla, 41013, Spain|Inst. Valenciano de Oncologia, Valencia, 46009, Spain|Hosp. Clinico Univ. de Valencia, Valencia, 46010, Spain|Kaohsiung Medical University Chung Ho Memorial Hospital, Kaohsiung, 807, Taiwan|China Medical University Hospital, Taichung, 40447, Taiwan|Taichung Veterans General Hospital, Taichung, 40705, Taiwan|Tungs' Taichung MetroHarbor Hospital, Taichung, 435, Taiwan|Chi Mei Medical Center Yong Kang, Tainan, 710, Taiwan|National Taiwan University Hospital., Taipei, 10002, Taiwan|Southmead Hospital, Bristol, BS10 5NB, United Kingdom|University Hospital of Wales, Cardiff, CF14 4XW, United Kingdom|Ninewells Hospital, Dundee, DD2 1UB, United Kingdom|The Royal Marsden NHS Trust, London, SW3 6JJ, United Kingdom|University College London, London, WC1E 6BT, United Kingdom|Lancashire Teaching Hospitals NHS Foundation Trust Royal Preston Hospital, Preston, PR2 9HT, United Kingdom|Royal Marsden Hospital, Sutton, SM2 5PT, United Kingdom|Mid Yorkshire NHS Trust, Wakefield, WF1 4DG, United Kingdom|New Cross Hospital, Wolverhampton, WV10 0QP, United Kingdom",
NCT06519370,"FDA018-ADC Vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer",https://clinicaltrials.gov/study/NCT06519370,,RECRUITING,"This is a Phase III, randomized, open-label, 2-arm, multicentre, international study assessing the efficacy and safety of FDA018-ADC compared with Investigator's Choice Chemotherapy(ICC) in participants with locally recurrent inoperable or metastatic Triple-negative Breast Cancer(TNBC) who are resistant to, or recurring during or after taxane therapy.",NO,Triple Negative Breast Cancer,DRUG: FDA018-ADC|DRUG: Eribulin|DRUG: Capecitabine|DRUG: Gemcitabine|DRUG: Vinorelbine,"Progression-free survival (PFS), PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause, up to 24 months|Overall Survival (OS), OS is defined as the time from randomisation until the date of death due to any cause., up to 24 months","Progression-Free Survival (PFS) by Investigator assessment, PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by the investigator, or death due to any cause, up to 24 months|Objective Response Rate (ORR), ORR is defined as the proportion of participants who have a confirmed CR or PR, as determined by BICR/investigator assessment, per RECIST 1.1., up to 24 months|Duration of Response Duration of Response (DoR), DoR is defined as the time from the date of first documented confirmed response until date of documented progression per RECIST 1.1, as assessed by BICR/investigator assessment or death due to any cause., up to 24 months|Disease Control Rate (DCR), DCR is defined as the proportion of patients who have achieved complete responseï¼partial response and stable disease assessed by BICR/investigator according to RECIST v 1.1, up to 24 months|Incidence of Treatment-Emergent Adverse Events, Incidence and severity of AEs and SAEs (graded by CTCAE version 5.0)., up to 24 months|Immunogenicity of FDA018-ADC, Presence of ADAs for FDA018-ADC, up to 24 months",,"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,350,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-08-09,2026-08-18,2027-06-20,2024-07-25,,2024-09-26,"Fudan University Shanghai Cancer Center, Shanghai, Shanghai, 200000, China",
NCT06549595,A Study of AZD0486 Plus Rituximab in Previously Untreated Follicular Lymphoma Patients,https://clinicaltrials.gov/study/NCT06549595,,RECRUITING,"This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the AZD0486 plus rituximab combination compared to Investigator's choice of 3 standard immunochemotherapy regimen, conducted in participants with untreated FL.",NO,Untreated Follicular Lymphoma,DRUG: AZD0486|DRUG: R-CHOP|DRUG: R-CVP|DRUG: BR,"SRI Primary: Incidence, nature and severity of AEs and SAEs. Incidence and nature of study drug discontinuations, dose reductions, and dose delays due to AEs, Frequency, severity, and relationship to study drug of AEs and SAEs; dose modifications; changes in physical examination and safety procedures., Up to 10 years|SRI Primary: Determination of the recommended Phase III dose (RP3D), The RP3D will be the dose of AZD0486 selected for the Phase 3 part based on safety data compiled during the safety run-in part, Up to 1 year|Phase 3 Primary: To demonstrate the superiority of AZD0486 plus rituximab compared to Investigator's choice of SoC chemoimmunotherapy, PFS, based on Lugano 2014 Response Criteria, as assessed by BICR., Up to 10 years","Safety Run in and Phase 3: ORR, ORR defined as the proportion of participants achieving either a PR or CR at any time based on Lugano 2014 Response Criteria, Up to 10 years|Safety Run In and Phase 3: CR Rate, CR rate is defined as the proportion of participants achieving a CR at any time as based on Lugano 2014 Response Criteria, Up to 10 years|Safety Run In and Phase 3: CR at EoI, Proportion of participants achieving CR at End of Induction based on Lugano 2014 Response Criteria, Up to 10 years|Safety Run In and Phase 3: DoR, DoR will be defined as the time from the time of first response until progression based on Lugano 2014 criteria, up to 10 years|Safety Run In and Phase 3: PFS, PFS is defined as time until disease progression based on Lugano 2014 Response Criteria, Up to 10 years|Safety Run In and Phase 3: OS, OS is defined as time until the date of death, Up to 10 years|Phase 3: CR rate at 30 months, Proportion of participants in CR rate at 30 months (CR30) based on Lugano 2014 Response Criteria, Up to 10 Years",,AstraZeneca,,ALL,"ADULT, OLDER_ADULT",PHASE3,1015,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-08-07,2031-11-26,2031-11-26,2024-08-12,,2025-05-18,"Research Site, Macquarie University, 2109, Australia|Research Site, Nedlands, 6009, Australia|Research Site, Brussels, 1070, Belgium|Research Site, Brussels, 1090, Belgium|Research Site, Gent, 9000, Belgium|Research Site, Mechelen, 2800, Belgium|Research Site, Hamilton, Ontario, L8V 5C2, Canada|Research Site, Oshawa, Ontario, L1G 2B9, Canada|Research Site, Chicoutimi, Quebec, G7H 5H6, Canada|Research Site, Montreal, Quebec, H4J 1C5, Canada|Research Site, Beijing, 100142, China|Research Site, Beijing, 100730, China|Research Site, Changsha, 410013, China|Research Site, Fuzhou, 350001, China|Research Site, Guangzhou, 510000, China|Research Site, Nanning, 530021, China|Research Site, Tianjin, 300020, China|Research Site, Wuhan, 430079, China|Research Site, Xiamen, 361003, China|Research Site, Zhengzhou, 450008, China|Research Site, Helsinki, 00029, Finland|Research Site, Kuopio, 70029, Finland|Research Site, Tampere, 33520, Finland|Research Site, Hong Kong, 999077, Hong Kong|Research Site, Shatin, 00000, Hong Kong|Research Site, Budapest, 1122, Hungary|Research Site, Koto-ku, 135-8550, Japan|Research Site, Okayama-shi, 700-8558, Japan|Research Site, Seoul, 05505, Korea, Republic of|Research Site, Seoul, 06351, Korea, Republic of|Research Site, Seoul, 13620, Korea, Republic of|Research Site, Gliwice, 44-102, Poland|Research Site, Barcelona, 08035, Spain|Research Site, Barcelona, 8036, Spain|Research Site, El Palmar, 30120, Spain|Research Site, Girona, 17007, Spain|Research Site, Las Palmas de Gran Canaria, 35020, Spain|Research Site, Madrid, 28040, Spain|Research Site, Madrid, 28041, Spain|Research Site, Oviedo, 33011, Spain|Research Site, Pamplona, 31008, Spain|Research Site, Santander, 39008, Spain|Research Site, Falun, 79182, Sweden|Research Site, Uppsala, 75185, Sweden|Research Site, Changhua, 50006, Taiwan|Research Site, Kaohsiung City, 80756, Taiwan|Research Site, Kaohsiung city, 833, Taiwan|Research Site, Lukang Township, 505029, Taiwan|Research Site, Tainan City, 704, Taiwan|Research Site, Taipei City, 106, Taiwan|Research Site, Ankara, 06620, Turkey|Research Site, Ankara, 6200, Turkey|Research Site, London, EC1M6BQ, United Kingdom|Research Site, Norwich, NR4 7UY, United Kingdom",
NCT05714202,A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-GuÃ©rin (BCG) in Participants With BCG-naÃ¯ve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC),https://clinicaltrials.gov/study/NCT05714202,SunRISe-3,ACTIVE_NOT_RECRUITING,"The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle invasive bladder cancer (HR-NMIBC), including high-grade papillary Ta, any T1, or carcinoma in situ (CIS), between TAR-200 plus cetrelimab (Group A) and TAR-200 alone (Group C) versus intravesical BCG (Group B).",NO,Bladder Cancer,DRUG: TAR-200|BIOLOGICAL: Cetrelimab|BIOLOGICAL: BCG Vesiculture,"Event-free Survival (EFS), EFS is defined as the time from randomization to either the time of the first recurrence of high-risk disease, progression, or death due to any cause, whichever occurs first. For participants with carcinoma In-situ (CIS), persistent disease at 6 months (Week 24) is also considered an EFS event. Progression is defined as: an increase of stage from Ta to T1 or from CIS to T1 or progression to muscle invasive bladder cancer (MIBC) (T greater than or equal to \[\>=\] 2) or to lymph node (N+) or to distant disease (M+), whichever occurs first., Up to 5 years 2 months","Overall Complete Response (CR) Rate, Overall CR will be measured by determining the percentage of participants with CIS who have no presence of high-risk disease at 6 months., Up to 5 years 2 months|Duration of CR, Duration of CR is defined from the time of first CR achieved to first evidence of recurrence, progression or death due to any cause (whichever occurs first) for participants who achieve a CR., Up to 5 years 2 months|Recurrence-Free Survival (RFS), RFS is defined as the time from randomization to the time of the first recurrence of high-risk disease, or death due to any cause, whichever occurs first., Up to 5 years 2 months|Time to Progression (TTP), TTP is defined as the time from randomization to the date of first documented evidence of disease progression or death due to disease progression, whichever occurs first., Up to 5 years 2 months|Overall Survival (OS), OS is defined as the time from randomization to death, due to any cause., Up to 5 years 2 months|Cancer Specific Survival (CSS), CSS is defined as the time from randomization to the date of death due to bladder cancer., Up to 5 years 2 months|Number of Participants with Adverse Events (AEs) by Grades According to Common Terminology Criteria for Adverse Events (CTCAE), Number of participants with AEs by severity grade as assessed by CTCAE version 5 will be reported. Grade refers to the severity of AE as follows: Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe; Grade 4- Life-threatening; Grade 5- Death related to adverse event., Up to 5 years 2 months|Number of Participants with Adverse Events (AEs), Number of participants with AEs will be reported. An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product., Up to 5 years 2 months|Number of Participants with Change from Baseline in Laboratory Abnormalities, Number of participants with change from baseline in laboratory abnormalities will be reported. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1- Mild, Grade 2- Moderate, Grade 3- Severe, Grade 4- Life-threatening, and Grade 5- Death related to adverse event., Up to 5 years 2 months|Number of Participants with Change from Baseline in Vital Signs Abnormalities, Number of participants with change from baseline in vital signs (blood pressure \[systolic and diastolic\], heart rate, temperature, and weight) abnormalities will be reported., Up to 5 years 2 months|Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of life Questionnaire - Non-muscle Invasive Bladder Cancer EORTC QLQ- NMIBC 24, EORTC QLQ-NMIBC 24 is a 24-item questionnaire for evaluating the Health-related quality of life (HRQoL) of participants with superficial (non-muscle-invasive) bladder cancer. The questionnaire is designed to supplement the quality of life questionnaire (QLQ-C30) and incorporates 6 multi-item scales and 5 single items. Ratings for each item range from 1 (not at all) to 4 (very much)., Up to 5 years 2 months|Time to Symptom Deterioration as Assessed by EORTC-QLQ-NMIBC 24 Scores, EORTC QLQ-NMIBC 24 is a 24-item questionnaire for evaluating the HRQoL of participants with superficial (non-muscle-invasive) bladder cancer. The questionnaire is designed to supplement the QLQ-C30 and incorporates 6 multi-item scales and 5 single items. Ratings for each item range from 1 (not at all) to 4 (very much)., Up to 5 years 2 months",,"Janssen Research & Development, LLC",,ALL,"ADULT, OLDER_ADULT",PHASE3,1135,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-03-23,2029-09-18,2029-09-18,2023-02-06,,2025-05-23,"Mayo Clinic, Scottsdale, Arizona, 85259, United States|Arkansas Urology, Little Rock, Arkansas, 72211, United States|VA Long Beach Health Care System, Long Beach, California, 90822, United States|Genesis Research, LLC - West Coast Urology, Los Alamitos, California, 90720, United States|Cedars Sinai Medical Center, Los Angeles, California, 90048, United States|UC Davis Comprehensive Cancer Center, Sacramento, California, 95630, United States|Genesis Research, San Diego, California, 92123, United States|Providence Saint Johns Cancer Institute, Santa Monica, California, 90404, United States|Providence Medical Foundation, Santa Rosa, California, 95403, United States|Colorado Clinical Research, Lakewood, Colorado, 80228, United States|Urological Research Network, Hialeah, Florida, 33016, United States|Orlando Health Cancer Institute, Orlando, Florida, 32806, United States|Sarasota Memorial Hospital, Sarasota, Florida, 34239, United States|Grady Memorial Hospital, Atlanta, Georgia, 30303, United States|The Emory Clinic Department of Urology, Atlanta, Georgia, 30322, United States|Northwestern University, Chicago, Illinois, 60611, United States|Duly Health and Care, Lisle, Illinois, 60532, United States|Blessing Hospital, Quincy, Illinois, 62301, United States|Urology of Indiana, Carmel, Indiana, 46032, United States|First Urology, Jeffersonville, Indiana, 47130, United States|AMR Kansas City Oncology, Merriam, Kansas, 66204, United States|Wichita Urology Group, Wichita, Kansas, 67226, United States|Chesapeake Urology Research Associates, Hanover, Maryland, 21076, United States|Lahey Hospital & Medical Center, Burlington, Massachusetts, 01805, United States|University of Michigan, Ann Arbor, Michigan, 48109, United States|University Of Minnesota, Minneapolis, Minnesota, 55455, United States|Mayo Clinic Rochester, Rochester, Minnesota, 55905, United States|The Urology Center, PC, Omaha, Nebraska, 68114, United States|Cooper Health System MD Anderson Cancer Center at Cooper, Camden, New Jersey, 08103, United States|VA NY Harbor Healthcare System, New York, New York, 10010, United States|Icahn School of Medicine at Mt. Sinai, New York, New York, 10029, United States|Associated Medical Professionals of Ny, Syracuse, New York, 13210, United States|SUNY Upstate Med Univ, Syracuse, New York, 13210, United States|Vidant Urology - Greenville, Greenville, North Carolina, 27834, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|Central Ohio Urology Group, Gahanna, Ohio, 43230, United States|Centers for Advanced Urology LLC d b a MidLantic Urology, Bala-Cynwyd, Pennsylvania, 19004, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, 19107, United States|UPMC Shadyside Hospital, Pittsburgh, Pennsylvania, 15232, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, 29572, United States|Urology Associates, Nashville, Tennessee, 37209, United States|Vanderbilt University Medical Center, Nashville, Tennessee, 37232, United States|Urology Austin, Austin, Texas, 78745, United States|Urology Clinics of North Texas, Dallas, Texas, 75231, United States|Houston Metro Urology, Houston, Texas, 77027, United States|Houston Methodist Hospital, Houston, Texas, 77030, United States|Urology San Antonio Research, San Antonio, Texas, 78229, United States|Huntsman Cancer Institute, Salt Lake City, Utah, 84112, United States|George E. Wahlen VAMC, Salt Lake City, Utah, 84148, United States|Urology Of Virginia, Pllc, Virginia Beach, Virginia, 23462, United States|Spokane Urology, Spokane, Washington, 99202, United States|Hospital Italiano de Buenos Aires, Buenos Aires, C1199, Argentina|Sociedade Beneficente de Senhoras Hospital Sirio Libanes, Buenos Aires, C1417, Argentina|Centro Urologico Profesor Bengio, Cordoba, X5000KPH, Argentina|Hospital Privado Centro Medico de Cordoba, Cordoba, X5016KEH, Argentina|Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica, CÃ³rdoba, 5000, Argentina|Hospital Privado de la Comunidad, Mar del Plata, B7602CBM, Argentina|Instituto Medico Rio Cuarto, Rio Cuarto, 5800, Argentina|Austin Health, Heidelberg, 3084, Australia|Macquarie University Hospital, Macquarie University, 2109, Australia|Hollywood Private Hospital, Nedlands, 6009, Australia|Mater Hospital Brisbane, South Brisbane, 4101, Australia|ZNA Middelheim, Antwerpen, 2020, Belgium|AZ Sint-Jan, Brugge, 8000, Belgium|AZ Sint-Lucas, Brugge, 8310, Belgium|AZ Maria Middelares, Gent, 9000, Belgium|UZ Gent, Gent, 9000, Belgium|Centre Hospitalier de l'Ardenne, Libramont-Chevigny, 6800, Belgium|AZ Delta, Roeselare, 8800, Belgium|Vitaz, Sint Niklaas, 9100, Belgium|GZA Ziekenhuizen- Campus St Augustinus, Wilrijk, 2610, Belgium|Fundacao Pio XII, Barretos, 14784-400, Brazil|NAIC Nair Antunes Instituto do Cancer, Bauru, 17033-495, Brazil|Universidade Estadual De Campinas, Campinas, 13083-888, Brazil|Liga Paranaense de Combate ao Cancer, Curitiba, 81520 060, Brazil|Liga Norte Riograndense Contra O Cancer, Natal, 59075-740, Brazil|Irmandade Santa Casa de Misericordia de Porto Alegre, Porto Alegre, 90050-170, Brazil|Hospital Regional do Cancer - Hospital de EsperanÃ§a, Presidente Prudente, 19013-050, Brazil|Hospital Sao Rafael, Salvador, 41253 190, Brazil|Hospital Ana Nery Santa Cruz do Sul, Santa Cruz Do Sul, 96835-090, Brazil|CEPHO Centro de Estudos e Pesquisa de Hematologia e Oncologia, Santo Andre, 09060-870, Brazil|Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, 01246 000, Brazil|Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein, Sao Paulo, 05652 900, Brazil|Real e Benemerita Associacao Portuguesa de Beneficencia, Sao Paulo, 1321 001, Brazil|Fundacao Antonio Prudente A C Camargo Cancer Center, SÃ£o Paulo, 01508-010, Brazil|Nova Scotia Health Authority, Halifax, Nova Scotia, B3H 2Y9, Canada|St Josephs Healthcare Hamilton, Hamilton, Ontario, L8N 4A6, Canada|Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, M5G 1Z5, Canada|CHUM - Centre hospitalier universitaire de Montreal, MontrÃ©al, Quebec, H2X 3E4, Canada|Unite de Recherche Clinique du CISSS des Laurentides, Saint Jerome Quebec, Quebec, J7Z 2V4, Canada|CHU de Quebec Universite Laval Hopital de l Enfant Jesus, Quebec, G1J1Z4, Canada|Peking University First Hospital, Beijing, 100034, China|Beijing Hospital, Beijing, 100730, China|Beijing Luhe Hospital, Capital Medical University, Beijing, 101100, China|Hunan Province Cancer Hospital, Chang Sha, 410013, China|The First Bethune Hospital of Jilin University, Changchun, 130499, China|West China Hospital Sichuan University, Chengdu, 610044, China|Chongqing University Cancer Hospital, Chongqing, 400000, China|People's Hospital of Deyang City, Deyang City, 618000, China|Sun Yat Sen University Cancer Center, GuangZhou, 430030, China|Zhejiang Provincial People's Hospital, Hangzhou, 310000, China|Sir Run Run Shaw Hospital Zhejiang University School of Medicine, Hangzhou, 310016, China|Nanjing Drum Tower Hospital, Nanjing, 210008, China|The First Affiliated Hospital of Ningbo University, Ningbo, 315010, China|Ruijing Hospital Affiliated To Shanghai Jiaotong University School Of Medicine, Shanghai, 200025, China|Huadong Hospital Affiliated to Fudan University, Shanghai, 200400, China|Shengjing Hospital Of China Medical University, Shenyang, 110004, China|The Second Hospital Of Tianjin Medical University, Tianjin, 300211, China|The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China|TongJi Hospital of TongJi Medical College of Huazhong University of Science & Technology, Wuhan, 430030, China|First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xian, 710061, China|Yantai Yuhuangding Hospital, Yantai, 264000, China|Henan Cancer Hospital, Zhengzhou, 450008, China|Fakultni nemocnice u sv. Anny v Brne, Brno, 65691, Czechia|Fakultni nemocnice Hradec Kralove, Hradec KrÃ¡lovÃ©, 500 05, Czechia|KrajskÃ¡ nemocnice Liberec a.s., Liberec, 460 01, Czechia|Fakultni nemocnice Olomouc, Olomouc, 779 00, Czechia|Fakultni nemocnice v Motole, Prague, 15006, Czechia|Thomayerova nemocnice, Onkologicka klinika, Praha 4, 140 59, Czechia|Fakultni nemocnice Kralovske Vinohrady, Praha, 100 34, Czechia|Polyclinique Bordeaux Nord Acquitaine, Bordeaux, 33000, France|CHU Gabriel-Montpied, Clermont-Ferrand, 63003, France|CHU Grenoble, Grenoble, 38043, France|Polyclinique de Limoges - Francois Chenieux, Limoges, 87000, France|HÃ´pital Edouard Herriot, Lyon, 69437, France|CHU de Nantes hotel Dieu, Nantes, 44093, France|CHU Nimes, Nimes, 30029, France|Centre Hospitalier Regional d'Orleans (CHRO) - Hopital La Source, OrlÃ©ans, 45067, France|Groupe Hospitalier Diaconesses Croix Saint Simon, PARIS cedex 20, 75960, France|HÃ´pital Universitaire PitiÃ©-SalpÃªtriÃ¨re, Paris, 75013, France|Hopital Europeen Georges-Pompidou, Paris, 75015, France|APHP - Hopital Bichat - Claude Bernard, Paris, 75018, France|Clinical La Croix Du Sud - Ramsay SantÃ©, Quint-Fonsegrives, 31130, France|Chu Rennes Hopital Pontchaillou, Rennes, 35000, France|Institut de Cancerologie Strasbourg Europe ICANS, Strasbourg, 67200, France|CHU Rangueil, Toulouse, 31059, France|Urologicum Duisburg, Duisburg, 47169, Germany|Universitatsklinikum Erlangen, Erlangen, 91054, Germany|Universitatsklinikum Essen, Essen, 45147, Germany|Universitaetsklinikum Frankfurt, Frankfurt am Main, 60590, Germany|Universitaetsklinikum Freiburg, Freiburg, 79106, Germany|Urologische Partnerschaft Koln UPK, KÃ¶ln, 50968, Germany|Matthias Schulze - Germany, Markkleeberg, 04416, Germany|Urologie Neandertal Praxis Mettmann, Mettmann, 40822, Germany|Universitatsklinikum Munster, Muenster, 48149, Germany|Klinikum rechts der Isar an der Technischen Universitat Munchen, MÃ¼nchen, 81675, Germany|Klinikum Nurnberg Nord, Nuernberg, 90419, Germany|Medizinisches Versorgungszentrum - Urologie, Nurnberg, 90491, Germany|Studienpraxis Urologie Nurtingen, NÃ¼rtingen, 72622, Germany|Caritas-Krankenhaus St. Josef, Regensburg, 93053, Germany|Universitat Tubingen, TÃ¼bingen, 72076, Germany|Health Care Global Enterprises pvt Ltd, Bangalore, 560027, India|Post Graduate Institute of Medical Education And Research PGIMER, Chandigarh, 160012, India|Artemis Hospital, Gurugram, 122001, India|Netaji Subhas chandra Bose Cancer Research Institute, Kolkata, 700094, India|Tata Memorial Hospital, Mumbai, 400012, India|CIMET s Inamdar Multispeciality Hospital, Pune, 411040, India|Generale Regionale F. Miulli, Acquaviva delle Fonti, 70021, Italy|Ospedale Cardinal Massaia, Asti, 14100, Italy|Ospedale San Giuseppe Moscati di Avellino, Avellino, 83100, Italy|Ospedale San Giacomo Apostolo, Guardia pediatrica territoriale, Castelfranco Veneto, 31033, Italy|Ospedale San Raffaele di Milano, Milano, 20132, Italy|Istituto Europeo di Oncologia, Milano, 20141, Italy|Fondazione G Pascale Istituto Nazionale Tumori IRCCS, Napoli, 80138, Italy|Ospedale S. Maria Delle Croci, Ravenna, 48121, Italy|Istituto Nazionale Tumori Regina Elena, Rome, 00128, Italy|Fuji City General Hospital, Fuji-shi, 417-8567, Japan|Kanazawa University Hospital, Kanazawa, 920 8641, Japan|Nara Medical University Hospital, Kashihara-shi, 634-8522, Japan|Kimitsu Chuo Hospital, Kisarazu-shi, 292-8535, Japan|Kobe City Medical Center General Hospital, Kobe City, 650 0047, Japan|National Hospital Organization Kumamoto Medical Center, Kumamoto shi, 860-0008, Japan|Nagano Municipal Hospital, Nagano-shi, 381-8551, Japan|Nagasaki University Hospital, Nagasaki-shi, 852-8501, Japan|JRC Nagasaki Genbaku Hospital, Nagasaki-Shi, 852-8511, Japan|Saiseikai Narashino Hospital, Narashino-shi, 275-8580, Japan|Ehime University Hospital, Toon-shi, 791-0295, Japan|Toyama University Hospital, Toyama-shi, 930 0194, Japan|Yamaguchi University Hospital, Ube, 755-8505, Japan|Yokohama City University Medical Center, Yokohama, 232 0024, Japan|Pusan National University Hospital, Busan, 49241, Korea, Republic of|Chungbuk National University Hospital, Cheongju, 28644, Korea, Republic of|Kyungpook National University Chilgok Hospital, Daegu, 41404, Korea, Republic of|Keimyung University Dongsan Hospital, Daegu, 42601, Korea, Republic of|National Cancer Center, Gyeonggi-do, 10408, Korea, Republic of|Chonnam National University Hwasun Hospital, Jeollanam-do, 58128, Korea, Republic of|Korea University Anam Hospital, Seoul, 02841, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Kangbuk Samsung Hospital, Seoul, 03181, Korea, Republic of|Severance Hospital Yonsei University Health System, Seoul, 03722, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|The Catholic University of Korea Seoul St Marys Hospital, Seoul, 06591, Korea, Republic of|Consultorio Medico dentro del Hospital Angeles Acoxpa, Ciudad de MÃ©xico, 14308, Mexico|Hospital Universitario Dr Jose Eleuterio Gonzalez, Monterrey, 64460, Mexico|Avix Investigacion Clinica S C, Monterrey, 64710, Mexico|Eme Red Hospitalaria, MÃ©rida, 97000, Mexico|Oncologico Potosino, San Luis PotosÃ­, 78260, Mexico|Spaarne Ziekenhuis, Hoofddorp, 2134 TM, Netherlands|Canisius-Wilhelmina Ziekenhuis, Nijmegen, 6524 KD, Netherlands|Radboud Umcn, Nijmegen, 6525 GA, Netherlands|Uniwersytecki Szpital Kliniczny w Bialymstoku, Bialystok, 15 276, Poland|IN VIVO Sp. z o.o, Bydgoszcz, 85 048, Poland|Wojewodzki Szpital Specjalistyczny im Stefana Kardynala Wyszynskiego SPZOZ, Lublin, 20 708, Poland|Centrum Medyczne, Piotrkow Trybunalski, 97 300, Poland|Clinical Research Center sp z o o MEDIC R s k, Poznan, 61 731, Poland|Wojewodzki Szpital Specjalistyczny im Janusza Korczaka, Slupsk, 76-200, Poland|Provita Poliklinika, Warszawa, 02-647, Poland|Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy, Warszawa, 02-781, Poland|Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we Wroclawiu, Wroclaw, 50 556, Poland|Ipo Coimbra, Coimbra, 3000-075, Portugal|Uls Santa Maria - Hosp. Santa Maria, Lisboa, 1649 028, Portugal|Uls Gaia Espinho, Vila Nova de Gaia, 4434 502, Portugal|Hosp Univ A Coruna, A CoruÃ±a, 15006, Spain|Hosp. Punta de Europa, Algeciras, 11207, Spain|Fund. Puigvert, Barcelona, 08025, Spain|Hosp. Gral. Univ. de Castellon, Castellon, 12004, Spain|Hosp. Puerta Del Mar, CÃ¡diz, 11009, Spain|Hosp. Univ. de Bellvitge, L'Hospitalet de Llobregat, 08907, Spain|Hosp. Univ. Lucus Augusti, Lugo, 27003, Spain|Clinica Univ. de Navarra, Madrid, 28027, Spain|Hosp. Univ. 12 de Octubre, Madrid, 28041, Spain|Hosp. Univ. La Paz, Madrid, 28046, Spain|Hosp Virgen de La Victoria, MÃ¡laga, 29010, Spain|Hosp. Univ. Marques de Valdecilla, Santander, 39008, Spain|Hosp. Clinico Univ. de Valencia, Valencia, 46010, Spain|Kaohsiung Medical University Chung Ho Memorial Hospital, Kaohsiung City, 807, Taiwan|Chang Kung Memorial Hospital, Kaohsiung, 833, Taiwan|China Medical University Hospital, Taichung City, 404, Taiwan|Taichung Veterans General Hospital, Taichung, 40705, Taiwan|Taipei Veterans General Hospital, Taipei, 11217, Taiwan|Linkou Chang Gung Memorial Hospital, Taoyuan, 33382, Taiwan|Western General Hospital, Edinburgh, EH4 2XU, United Kingdom|St Bartholomews Hospital, London, EC1A 7BE, United Kingdom|The Royal Marsden NHS Trust, London, SW3 6JJ, United Kingdom|Charing Cross Hospital, London, W6 8RF, United Kingdom|Derriford Hospital, Plymouth, PL6 8DH, United Kingdom|Scunthorpe General Hospital, Scunthorpe, DN15 7BH, United Kingdom|Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, S10 2JF, United Kingdom|Lister Hospital, Stevenage, SG1 4AB, United Kingdom|Royal Cornwall Hospitals NHS Trust - Royal Cornwall Hospital, Truro, TR1 3LJ, United Kingdom",
NCT06041776,Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations,https://clinicaltrials.gov/study/NCT06041776,,RECRUITING,"This multicenter, randomized, controlled, double-blind, double-simulated, Phase III study is designed to evaluate the efficacy and safety of Befotertinib compared with Icotinib as adjuvant treatment in EGFR-sensitive mutation-positive stage IB-IIIB (T3N2M0) non-small cell lung cancer after surgical resection.",NO,Non-Small Cell Lung Cancer|EGFR Sensitive Mutation|Adjuvant Therapy,DRUG: Befotertinib + Icotinib placebo|DRUG: Icotinib + Befotertinib placebo,"Disease free survival (DFS) evaluated by investigator in patients with stage II-IIIB (T3N2M0), up to 5 years","DFS evaluated by investigator in patients with stage IB-IIIB (T3N2M0), up to 5 years","DFS rate at 2 years, Assessed at 2 years|DFS rate at 3 years, Assessed at 3 years|DFS rate at 5 years, Assessed at 5 years|Overall survival (OS), Assessed at 5 years|OS rate at 5 years, up to 5 years|Treatment-Emergent Adverse Event (TEAE), Until 28 days after the last dosing","Betta Pharmaceuticals Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,570,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-03-28,2028-04-30,2029-11-30,2023-09-18,,2023-09-22,"Peking University International Hospital, Beijing, China|Jiangsu Cancer Hospital, Nanjing, China|Shanghai chest hospital, Shanghai, China",
NCT06561607,A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer,https://clinicaltrials.gov/study/NCT06561607,,NOT_YET_RECRUITING,"The study is a Phase III, randomized, multicenter, open-label study in HER2-low, HR+ metastatic breast cancer subjects who are patients with locally advanced or metastatic breast cancer with low HER2 expression in the recurrent metastatic stage who have not received chemotherapy. The primary objective of the study is to determine the efficacy and safety of TQB2102 compared to investigator-selected single-agent chemotherapy in the target population. 542 subjects with HER2 immunohistochemistry (IHC )2+/ in situ hybridization (ISH)- and IHC 1+ (HER2-low) expression will be enrolled in 1:1 randomized groups to receive TQB2102 or investigator's choice of single-agent chemotherapy (capecitabine, paclitaxel, or albumin-paclitaxel) until progression of disease (PD), as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1. 1, unless there are unacceptable toxicity, withdrawal of consent, or meeting other discontinuation criteria.",NO,Breast Cancer,DRUG: TQB2102 for Injection|DRUG: Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel),"Progression-free survival (PFS) in subjects with HR-positive, HER2 low-expressing recurrent/metastatic breast cancer as assessed by Independent Review Committee (IRC), Designed to demonstrate that in subjects with HR-positive, HER2 low-expressing recurrent/metastatic breast cancer, TQB2102 for injection significantly prolongs progression-free survival in subjects compared to investigator-selected chemotherapy., Up to 25 months","Progression-free survival (PFS) in subjects with HER2 low-expressing recurrent/metastatic breast cancer as assessed by IRC, Designed to demonstrate that in subjects with HER2 low-expressing recurrent/metastatic breast cancer, TQB2102 for injection significantly prolongs progression-free survival in subjects compared to investigator-selected chemotherapy., Up to 25 months|Progression-free survival (PFS) as assessed by investigators in the HR-positive, HER2 low-expressing population, To evaluate progression-free survival (PFS) of TQB2102 for injection versus investigator-selected chemotherapy in subjects with HR-positive, HER2 low-expressing recurrent/metastatic breast cancer., Up to 25 months|Investigator-assessed overall survival (OS) in HR-positive, low HER2-expressing population., To evaluate the overall survival (OS) of TQB2102 for injection versus investigator-selected chemotherapy in subjects with HR-positive, HER2 low-expressing recurrent/metastatic breast cancer., Up to 25 months|Overall survival (OS) as assessed by investigators in the HR-positive, HER2 low-expressing population, To evaluate the objective remission rate (ORR) of TQB2102 for injection versus investigator-selected chemotherapy in subjects with HR-positive, HER2 low-expressing recurrent/metastatic breast cancer., Up to 25 months|Duration of remission (DOR) as assessed by investigators in the HR-positive, HER2 low-expressing population, To evaluate the duration of remission (DOR) of injectable TQB2102 compared to investigator-selected chemotherapy in subjects with HR-positive, HER2 low-expressing recurrent/metastatic breast cancer., Up to 25 months|Investigator-assessed clinical benefit rate (CBR) in the HR-positive, low HER2-expressing population, To evaluate the clinical benefit rate (CBR) of TQB2102 for injection versus investigator-selected chemotherapy in subjects with HR-positive, HER2 low-expressing recurrent/metastatic breast cancer., Up to 25 months|Progression-free survival (PFS) as assessed by investigators in the HER2 low expression population, To evaluate progression-free survival (PFS) of TQB2102 for injection versus investigator-selected chemotherapy in subjects with HER2 low-expressing recurrent/metastatic breast cancer., Up to 25 months|Overall survival (OS) as assessed by investigators in the HER2 low expression population, To evaluate the overall survival (OS) of TQB2102 for injection versus investigator-selected chemotherapy in subjects with HER2 low-expressing recurrent/metastatic breast cancer., Up to 25 months|Duration of remission (DOR) as assessed by investigators in the HER2 low expression population, To evaluate the duration of remission (DOR) of injectable TQB2102 compared to investigator-selected chemotherapy in subjects with HER2 low-expressing recurrent/metastatic breast cancer., Up to 25 months|Objective remission rate (ORR) as assessed by investigators in the HER2 low expression population, To evaluate the objective remission rate (ORR) of TQB2102 for injection versus investigator-selected chemotherapy in subjects with HER2 low-expressing recurrent/metastatic breast cancer., Up to 25 months|Clinical benefit rate (CBR) as assessed by investigators in the HER2 low expression population, To evaluate the clinical benefit rate (CBR) of TQB2102 for injection versus investigator-selected chemotherapy in subjects with HER2 low-expressing recurrent/metastatic breast cancer., Up to 25 months|Incidence and severity of adverse events (AEs) and serious adverse events (SAEs), and indicators of abnormal laboratory tests, To evaluate the safety of TQB2102 for Injection compared to investigator-selected chemotherapy in subjects with HER2 low-expressing recurrent/metastatic breast cancer, including: the incidence and severity of adverse events (AEs), abnormal laboratory test values, and serious adverse events (SAEs)., Up to 52 months|Blood concentrations of the ADC drug TQB2102, total antibodies, and the small molecule toxin TQ22723, To evaluate the pharmacokinetic (PK) profile of TQB2102 for injection in subjects with HER2 low-expressing recurrent/metastatic breast cancer.

Within 1 hour prior to the start of infusion for Cycle 1, Cycle 2, Cycle 3, Cycle 4, Cycle 7, and Cycle 12, and 0.5 to 2 hours after the end of infusion for Cycle 2, Cycle 3, Cycle 4, Cycle 7, and Cycle 12 ., Within 1 hour prior to the start of infusion for Cycle 1, Cycle 2, Cycle 3, Cycle 4, Cycle 7, and Cycle 12, and 0.5 to 2 hours after the end of infusion for Cycle 2, Cycle 3, Cycle 4, Cycle 7, and Cycle 12 (21 days as a treatment cycle).|Immunogenicity of TQB2102: ADA incidence, To evaluate the immunogenicity (ADA) of TQB2102 for injection in subjects with HER2 low expression recurrent/metastatic breast cancer., Prior to (-60 min) the first day of dosing in Cycle 1, Cycle 2, Cycle 4, Cycle 7, and Cycle 12 (21 days as a treatment cycle), and at follow-up 30 days (Â±7 days) after the last dosing.",,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,542,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-08,2027-01,2028-12,2024-08-20,,2024-08-20,"The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, 233004, China|AnHui Province Hospital West District, Hefei, Anhui, 230000, China|The first Affiliated hospital of anhui medical university, Hefei, Anhui, 230000, China|Beijing Cancer Hospital, Beijing, Beijing, 100142, China|Fujian Medical University 2nd Affiliated Hospital, Quanzhou, Fujian, 362000, China|Zhangzhou Hospital in Fujian Province, Zhangzhou, Fujian, 363000, China|Gansu Provincial Hospital, Lanzhou, Gansu, 730000, China|Gansu Provincial Cancer Hospital, Lanzhou, Gansu, 730050, China|Gansu Wuwei Tumour Hospital, Wuwei, Gansu, 730000, China|Sun Yet-Sen University Cancer Certer, Guangzhou, Guangdong, 510000, China|Affiliated Hospital of Guangdong Medical University, ZhanJiang, Guangdong, 524001, China|Guigang City People'S Hospital, Guigang, Guangxi, 537100, China|Cancer Hospital Affiliated to Guangxi Medical University, Nanning, Guangxi, 530021, China|The First affiliated hospital of GuangXi medical university, Nanning, Guangxi, 530021, China|The Affiliated Cancer Hospital of Guizhou Medical University Co., LTD, Guiyang, Guizhou, 550000, China|Guizhou Provincial People's Hospital, Guiyang, Guizhou, 550002, China|The First Affiliated Hospital of Hainan Medical College, Haikou, Hainan, 570102, China|Hainan General Hospital, Haikou, Hainan, 570311, China|Affiliated Hospital of Hebei University, Baoding, Hebei, China|Chengde Central Hospital, Chengde, Hebei, 067024, China|Affiliated Cancer Hospital of Harbin Medical University, Harbin, Heilongjiang, 150081, China|AnYang Tumor Hospital, Anyang, Henan, 455100, China|Henan Cancar Hospital, Zhengzhou, Henan, 450000, China|The First Affiliated Hospital of Henan University of Science & Technology, Luoyang, Hennan, 471003, China|Tongji Hospital Tongji Medical College of HUST, Wuhan, Hubei, 430034, China|Hubei Cancer Hospital, Wuhan, Hubei, 430079, China|Chifeng Municipal Hospital, Chifeng, Inner Mongolia, 24099, China|The Second Hospital of DALIAN Medical University, Dalian, Liaoning, 116000, China|Binzhou Medical College Affiliated Hospital, Binzhou, Shandong, 256699, China|Binzhou People's Hospital, Binzhou, Shandong, 310053, China|Obstetrics & Gynecology Hospital of Fudan University, Shanghai, Shanghai, 200082, China|Baoji Central Hospital, Baoji, Shanxi, 721008, China|Affiliated Hospital of North Scichuan Medical College, Nanchong, Sichuan, 637000, China|Affiliated Hangzhou First People's Hospital, Hangzhou, Zhejiang, 310004, China",
NCT06126640,"A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy",https://clinicaltrials.gov/study/NCT06126640,,RECRUITING,"This study aims to Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants with Residual Invasive Disease Following Neoadjuvant Therapyï¼This study will examine SHR-A1811versus trastuzumab emtansine (T-DM1) in patients with HER2-positive primary breast cancer who have residual invasive disease in breast or axillary lymph nodes after neoadjuvant therapy.The primary objective is to compare invasive disease-free survival (IDFS) between SHR-A1811 and T-DM1 treatment arms in this population. The key secondary objective of the study is to evaluate disease-free survival (DFS), overall survival (OS) and distant recurrence-free interval (DRFI).",NO,HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy,DRUG: SHR-A1811|DRUG: Trastuzumab Emtansine,"Invasive disease-free survival (IDFS), Randomization until the disease progressed, up to approximately 77 months postdose","Disease-free survival (DFS), Randomization until the disease progressed, up to approximately 77 months postdose|Overall survival(OS), Randomization until death from any cause, up to approximately 101 months postdose.|Distant recurrence-free interval (DRFI), Randomization until distant recurrence or death from any cause, up to approximately 101 months postdose.|Safety endpointPercentage of Adverse Events in Participants, Baseline up to approximately 101 months postdose",,"Jiangsu HengRui Medicine Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,1600,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-11-20,2030-04,2032-04,2023-11-13,,2025-05-02,"Fudan University Shanghai Cancer Center, Shanghai, Shanghai, 200030, China|Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, 300060, China",
NCT06911502,A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma (GOLSEEK-4),https://clinicaltrials.gov/study/NCT06911502,,NOT_YET_RECRUITING,"The study is designed as a multicenter, randomized, open label Phase 3 study to compare the efficacy and safety of golcadomide in combination with rituximab vs investigator's choice in participants with relapsed/refractory follicular lymphoma who have received at least one line of prior systemic therapy.",NO,Follicular Lymphoma,DRUG: Golcadomide|DRUG: Rituximab|DRUG: Lenalidomide|DRUG: Cyclophosphamide|DRUG: Doxorubicin|DRUG: Vincristine|DRUG: Prednisone/Prednisolone|DRUG: Bendamustine,"Progression free survival (PFS) assessed by Independent Review Adjudication committee (IRAC), Up to approximately 32 Months","Overall response rate (ORR) assessed by IRAC, Up to approximately 32 Months|Overall survival (OS), Up to approximately 83 Months|PFS as assessed by investigator, Up to approximately 32 Months|ORR as assessed by investigator, Up to approximately 32 Months|Number of participants who achieve complete metabolic response (CMR), Up to approximately 32 Months|Duration of Response (DoR), Up to approximately 32 Months|Event free survival (EFS), Up to approximately 32 Months|Time to next anti-lymphoma treatment (TTNT), Up to approximately 32 Months|PFS on next anti-lymphoma treatment (PFS2), Up to approximately 32 Months|Time from randomization to meaningful improvement in primary domains of interest in the European Organization for Research and Treatment of Cancer - Quality of Life C30 (EORTC QLQ-C30) Questionnaire, Up to approximately 32 Months|Time from randomization to meaningful improvement in primary domains of interest in the European Organization for Research and Treatment of Cancer - Non- Hodgkin Lymphoma- Low Grade- 20 items (EORTC QLQNHL- LG20) Questionnaire, Up to approximately 32 Months|Minimal residual disease (MRD) negativity, Up to approximately 32 Months",,Celgene,,ALL,"ADULT, OLDER_ADULT",PHASE3,400,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2025-07-08,2028-04-24,2030-07-31,2025-04-04,,2025-05-31,"Local Institution - 0225, Birmingham, Alabama, 35205, United States|Local Institution - 0014, Mobile, Alabama, 36607, United States|Local Institution - 0074, Anchorage, Alaska, 99508, United States|Local Institution - 0215, Little Rock, Arkansas, 72205, United States|Local Institution - 0072, Duarte, California, 91010, United States|Local Institution - 0119, San Francisco, California, 94143, United States|Local Institution - 0008, Jacksonville, Florida, 32256, United States|Local Institution - 0214, Tampa, Florida, 33606, United States|Local Institution - 0217, Tampa, Florida, 33612, United States|Local Institution - 0021, Marietta, Georgia, 30060, United States|Local Institution - 0245, Newnan, Georgia, 30265, United States|Local Institution - 0240, Arlington Heights, Illinois, 60005, United States|Local Institution - 0243, Waukee, Iowa, 50309, United States|Local Institution - 0216, Westwood, Kansas, 66205, United States|Local Institution - 0218, Lexington, Kentucky, 40536, United States|Local Institution - 0023, Baltimore, Maryland, 21201, United States|Local Institution - 0010, Towson, Maryland, 21204, United States|Local Institution - 0145, Boston, Massachusetts, 02114, United States|Local Institution - 0244, Boston, Massachusetts, 02215, United States|Local Institution - 0247, Boston, Massachusetts, 02215, United States|Local Institution - 0013, Hattiesburg, Mississippi, 39401-7233, United States|Local Institution - 0144, Providence, Rhode Island, 02903, United States|Local Institution - 0237, Austin, Texas, 78705, United States|Local Institution - 0212, Fort Worth, Texas, 76104, United States|Local Institution - 0230, San Antonio, Texas, 78240, United States|Local Institution - 0236, Tyler, Texas, 75702, United States|Local Institution - 0030, Fredericksburg, Virginia, 22408, United States|Local Institution - 0146, Roanoke, Virginia, 24014, United States|Local Institution - 0143, Vancouver, Washington, 98684, United States|Local Institution - 0134, Westmead, New South Wales, 2145, Australia|Local Institution - 0132, Adelaide, South Australia, 5042, Australia|Local Institution - 0131, Hobart, Tasmania, 7000, Australia|Local Institution - 0128, Heidelberg, Victoria, 3084, Australia|Local Institution - 0198, Malvern, Victoria, 3144, Australia|Local Institution - 0127, Perth, Western Australia, 6000, Australia|Local Institution - 0224, Perth, Western Australia, 6000, Australia|Local Institution - 0159, Vitoria, EspÃ­rito Santo, 29041-295, Brazil|Local Institution - 0088, NiterÃ³i, Rio De Janeiro, 24220-070, Brazil|Local Institution - 0087, Porto Alegre, Rio Grande Do Sul, 90110-270, Brazil|Local Institution - 0079, Sao Paulo, SÃ£o Paulo, 04543-000, Brazil|Local Institution - 0089, Rio de Janeiro, 22250-905, Brazil|Local Institution - 0066, SÃ£o Paulo, 01246-000, Brazil|Local Institution - 0092, SÃ£o Paulo, 05652-900, Brazil|Local Institution - 0200, Victoria, British Columbia, V8R 6V5, Canada|Local Institution - 0035, Toronto, Ontario, M5G 2M9, Canada|Local Institution - 0192, Sherbrooke, Quebec, J1H 5N4, Canada|Local Institution - 0226, Sherbrooke, Quebec, J1H 5N4, Canada|Local Institution - 0154, Santiago, RegiÃ³n Metropolitana De Santiago, 7580206, Chile|Local Institution - 0155, Santiago, RegiÃ³n Metropolitana De Santiago, 8320325, Chile|Local Institution - 0153, Santiago, RegiÃ³n Metropolitana De Santiago, 8420383, Chile|Local Institution - 0246, Beijing, Beijing, 100038, China|Local Institution - 0171, Beijing, Beijing, 100142, China|Local Institution - 0172, Fuzhou Fujian, Fujian, 350001, China|Local Institution - 0173, Guangzhou, Guangdong, 511400, China|Local Institution - 0241, Harbin, Heilongjiang, 150081, China|Local Institution - 0176, Wuhan, Hubei, 430022, China|Local Institution - 0175, Changsha, Hunan, 410008, China|Local Institution - 0235, Hohhot, Inner Mongolia, 010020, China|Local Institution - 0233, Suzhou, Jiangsu, 215006, China|Local Institution - 0178, Nanchang, Jiangxi, 330006, China|Local Institution - 0239, Changchun, Jilin, 130000, China|Local Institution - 0177, Changchun, Jilin, 130021, China|Local Institution - 0179, Shenyang, Liaoning, 110004, China|Local Institution - 0242, Shenyang, Liaoning, 110042, China|Local Institution - 0180, Jinan, Shandong, 250117, China|Local Institution - 0181, Shanghai, Shanghai, 200032, China|Local Institution - 0249, Shanghai, Shanghai, 200065, China|Local Institution - 0234, Sichuan, Sichuan, 646000, China|Local Institution - 0182, Tianjin, Tianjin, 300060, China|Local Institution - 0227, Tianjin, Tianjin, 300121, China|Local Institution - 0248, Kunming, Yunnan, 650118, China|Local Institution - 0184, Hangzhou, Zhejiang, 310022, China|Local Institution - 0174, Zhengzhou, 450008, China|Local Institution - 0151, Oulu, Pohjois-Pohjanmaa, 90220, Finland|Local Institution - 0152, Turku, Varsinais-Suomi, 20521, Finland|Local Institution - 0150, Helsinki, 00029, Finland|Local Institution - 0100, Pessac, Aquitaine, 33600, France|Local Institution - 0121, Toulouse, Haute-Garonne, 31059, France|Local Institution - 0044, Saint-Cloud, Hauts-de-Seine, 92210, France|Local Institution - 0047, Montpellier, HÃ©rault, 34090, France|Local Institution - 0120, Nantes, Loire-Atlantique, 44093 Cedex 1, France|Local Institution - 0048, Lille, Nord, 59037, France|Local Institution - 0042, Pierre-BÃ©nite, RhÃ´ne, 69310, France|Local Institution - 0191, Paris, 75010, France|Local Institution - 0163, Ulm, Baden-WÃ¼rttemberg, 89081, Germany|Local Institution - 0161, Augsburg, Bayern, 86156, Germany|Local Institution - 0220, GÃ¶ttingen, Niedersachsen, 37075, Germany|Local Institution - 0166, Dortmund, Nordrhein-Westfalen, 44263, Germany|Local Institution - 0193, DÃ¼sseldorf, Nordrhein-Westfalen, 40225, Germany|Local Institution - 0231, MÃ¼nster, Nordrhein-Westfalen, 48153, Germany|Local Institution - 0232, MÃ¼nster, Nordrhein-Westfalen, 48153, Germany|Local Institution - 0164, Homburg, Saarland, 66424, Germany|Local Institution - 0165, Chemnitz, Sachsen, 09116, Germany|Local Institution - 0222, Erfurt, ThÃ¼ringen, 99089, Germany|Local Institution - 0167, Jena, ThÃ¼ringen, 07747, Germany|Local Institution - 0187, Dresden, 01307, Germany|Local Institution - 0162, MÃ¼nchen, 81337, Germany|Local Institution - 0221, Wuerzburg, 97080, Germany|Local Institution - 0109, Athens, AttikÃ­, 106 76, Greece|Local Institution - 0107, Îthens, AttikÃ­, 11526, Greece|Local Institution - 0110, Thessaloniki, ThessalonÃ­ki, 570 10, Greece|Local Institution - 0197, Thessaloniki, ThessalonÃ­ki, 570 10, Greece|Local Institution - 0111, Alexandroupolis, 08100, Greece|Local Institution - 0108, Ioannina, Ãpeiros, 455 00, Greece|Local Institution - 0142, New Delhi, Delhi, 110029, India|Local Institution - 0139, Bengaluru, Karnataka, 560099, India|Local Institution - 0141, Mumbai, Maharashtra, 400 057, India|Local Institution - 0140, Hyderabad, Telangana, 500033, India|Local Institution - 0138, Hyderabad, Telangana, 500082, India|Local Institution - 0104, Bologna, Emilia-Romagna, 40138, Italy|Local Institution - 0101, Meldola, Emilia-Romagna, 47014, Italy|Local Institution - 0103, Rozzano, Milano, 20089, Italy|Local Institution - 0106, Pisa, Toscana, 56126, Italy|Local Institution - 0102, Alessandria, 15121, Italy|Local Institution - 0105, Napoli, 80131, Italy|Local Institution - 0157, Torino, 10126, Italy|Local Institution - 0059, Seoul, Seoul-teukbyeolsi [Seoul], 03080, Korea, Republic of|Local Institution - 0060, Seoul, Seoul-teukbyeolsi [Seoul], 05505, Korea, Republic of|Local Institution - 0061, Seoul, Seoul-teukbyeolsi [Seoul], 06351, Korea, Republic of|Local Institution - 0058, Seoul, Seoul-teukbyeolsi [Seoul], 07345, Korea, Republic of|Local Institution - 0050, Amsterdam, Noord-Holland, 1081 HV, Netherlands|Local Institution - 0046, Groningen, 9713 GZ, Netherlands|Local Institution - 0053, Utrecht, 3584 CX, Netherlands|Local Institution - 0188, Warszawa, Mazowieckie, 02-781, Poland|Local Institution - 0186, KrakÃ³w, MaÅopolskie, 30-727, Poland|Local Institution - 0190, Gdynia, Pomorskie, 81-519, Poland|Local Institution - 0185, SkÃ³rzewo, Wielkopolskie, 60-185, Poland|Local Institution - 0189, ÅÃ³dÅº, ÅÃ³dzkie, 93-513, Poland|Local Institution - 0099, Dammam, Ash SharqÄ«yah, 31444, Saudi Arabia|Local Institution - 0054, Riyadh, 11426, Saudi Arabia|Local Institution - 0052, Riyadh, 12713, Saudi Arabia|Local Institution - 0158, Sabadell, Barcelona [Barcelona], 08208, Spain|Local Institution - 0122, Santander, Cantabria, 39008, Spain|Local Institution - 0124, Madrid, Madrid, Comunidad De, 28031, Spain|Local Institution - 0125, Valencia, Valenciana, Comunitat, 46010, Spain|Local Institution - 0126, Granada, 18012, Spain|Local Institution - 0123, Madrid, 28040, Spain|Local Institution - 0195, Istanbul- Fatih, Ä°stanbul, 34098, Turkey|Local Institution - 0194, Ankara, 06100, Turkey|Local Institution - 0196, Antalya, 07059, Turkey|Local Institution - 0223, Mersin, 33343, Turkey|Local Institution - 0148, Cringleford, England, NR4 7UY, United Kingdom|Local Institution - 0147, Canterbury, Kent, CT1 3NG, United Kingdom|Local Institution - 0213, London, London, City Of, W12 0HS, United Kingdom|Local Institution - 0149, Manchester, M20 4BX, United Kingdom",
NCT06112379,A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer,https://clinicaltrials.gov/study/NCT06112379,,RECRUITING,"This is a Phase III, 2-arm, randomised, open-label, multicentre, global study assessing the efficacy and safety of neoadjuvant Dato-DXd plus durvalumab followed by adjuvant durvalumab with or without chemotherapy compared with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab with or without chemotherapy in participants with previously untreated TNBC or hormone receptor-low/HER2-negative breast cancer.",NO,Breast Cancer,DRUG: Dato-DXd|DRUG: Durvalumab|DRUG: Pembrolizumab|DRUG: Doxorubicin|DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Capecitabine|DRUG: Olaparib,"Pathologic Complete Response (pCR) in the experimental vs control arms, pCR rate is defined as the proportion of participants who have no evidence by haematoxylin and eosin staining of residual invasive disease or lymphovascular invasion at the time of definitive surgery in the complete resected breast specimen and all sampled regional lymph nodes (ypT0/Tis ypN0) by blinded central evaluation.

The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anticancer therapy.

The measure of interest will be the difference between the pCR rates., At the time of definitive surgery|Event-free survival (EFS) in the experimental vs control arms, EFS is defined as the time from the date of randomisation until the date of the first occurrence of any of the following events: disease progression precluding surgery, disease recurrence (local, regional, distant, or contralateral), second primary invasive cancer (other than squamous or basal cell skin cancer), or relapse from prior malignancy, or death by any cause (in the absence of recurrence).

The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anticancer therapy.

The measure of interest will be the Hazard Ratio of EFS., Date of randomization to date of the EFS event, up to 68 months after the first subject randomized","Overall Survival (OS) in the experimental vs control arms, Key Secondary - OS is defined as the time from the date of randomisation until the date of death due to any cause.

The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anticancer therapy.

The measure of interest will be the Hazard Ratio of OS., Date of randomization to date of death due to any cause, up to 82 months after the first subject randomized|Distant disease-free survival (DDFS) in the experimental vs control arms, DDFS is defined as the time from the date of randomisation until the date of the first occurrence of any of the following events: distant metastasis, occurrence of second primary invasive cancer (other than squamous or basal cell skin cancer), relapse from prior malignancy or death by any cause (in the absence of recurrence).

The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anticancer therapy.

The measure of interest will be the Hazard Ratio of DDFS., Date of randomization to date of the DDFS event, up to 68 months after the first subject randomized|Participant-reported breast and arm symptoms in the experimental vs. control arms, Breast and arm symptoms measured by the EORTC IL116. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anticancer therapy.

The measure of interest is the mean between-arm difference in breast and arm symptom scores., From Cycle 1 Day 1 of neoadjuvant treatment until pre-surgery safety FU visit (for approximately 24 weeks) or EOT - whichever occurs first.|Participant-reported physical function in the experimental vs. control arms, Physical function measured by the PROMIS Physical Function Short Form 8c. The analysis will include all dosed participants. The measure of interest is the mean between-arm difference in physical function scores., From Cycle 1 Day 1 of neoadjuvant treatment until pre-surgery safety FU visit (for approximately 24 weeks) or EOT - whichever occurs first, and then from Cycle 1 Day 1 of adjuvant treatment until EOT (for approximately 27 weeks).|Participant-reported fatigue in the experimental vs. control arms, Fatigue measured by the PROMIS Fatigue Short Form 7a. The analysis will include all dosed participants. The measure of interest will be the difference on the proportions of participants reporting different levels of fatigue and mean between-arm difference in the fatigue scores., From Cycle 1 Day 1 of neoadjuvant treatment until pre-surgery safety FU visit (for approximately 24 weeks) or EOT - whichever occurs first, and then from Cycle 1 Day 1 of adjuvant treatment until EOT (for approximately 27 weeks).|Participant-reported Global health status/Quality of life (GHS/QoL)in the experimental vs. control arms, Global health status/Quality of life measured by EORTC IL172. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anticancer therapy.

The measure of interest is the mean between-arm difference in GHS/QoL scores., From Cycle 1 Day 1 of neoadjuvant treatment until pre-surgery safety FU visit (for approximately 24 weeks) or EOT - whichever occurs first, and then from Cycle 1 Day 1 of adjuvant treatment until EOT (for approximately 27 weeks).|Pharmacokinetics of Dato-DXd (in combination with durvalumab), Plasma concentrations of Dato-DXd (ug/ml ), Day 1 of cycles 1,2,4,8 (Each cycle is 21 days) and at pre-surgery safety follow up visit|Pharmacokinetics of Dato-DXd (in combination with durvalumab), Plasma concentrations of total anti-TROP2 antibody (ug/ml ), Day 1 of cycles 1,2,4,8 (Each cycle is 21 days) and at pre-surgery safety follow up visit|Pharmacokinetics of Dato-DXd (in combination with durvalumab), Plasma concentrations of DXd (MAAA-1181a) (ng/ml), Day 1 of cycles 1,2,4,8 (Each cycle is 21 days) and at pre-surgery safety follow up visit|Immunogenicity of Dato-DXd (in combination with durvalumab), Presence of antidrug antibodies (ADAs) for Dato-DXd (confirmatory results: positive or negative, titres)., Day 1 of cycles 1,2,4,8 (Each cycle is 21 days) and at pre-surgery safety follow up visit|Safety of Dato-DXd (in combination with durvalumab), Safety and tolerability will be evaluated in terms of AEs graded by CTCAE version 5.0, Randomization to final safety follow-up visit, either 90 days after last dose of study intervention for those who complete planned study intervention or 90 days after date of discontinuation for those who discontinue study intervention prematurely",,AstraZeneca,Daiichi Sankyo,ALL,"ADULT, OLDER_ADULT",PHASE3,1900,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-11-14,2028-11-20,2032-11-03,2023-11-01,,2025-06-03,"Research Site, Daphne, Alabama, 36526, United States|Research Site, Goodyear, Arizona, 85395, United States|Research Site, Phoenix, Arizona, 85054, United States|Research Site, Tucson, Arizona, 85711, United States|Research Site, Jonesboro, Arkansas, 72401, United States|Research Site, Rogers, Arkansas, 72758, United States|Research Site, Bakersfield, California, 93309, United States|Research Site, Fullerton, California, 92835, United States|Research Site, Irvine, California, 92612, United States|Research Site, Los Angeles, California, 90033, United States|Research Site, Los Angeles, California, 90095, United States|Research Site, Newport Beach, California, 92663, United States|Research Site, Orange, California, 92868, United States|Research Site, Santa Barbara, California, 93105, United States|Research Site, Santa Rosa, California, 92805, United States|Research Site, Sylmar, California, 91342, United States|Research Site, Torrance, California, 90505, United States|Research Site, Van Nuys, California, 91405, United States|Research Site, Aurora, Colorado, 80045, United States|Research Site, Fort Collins, Colorado, 80528, United States|Research Site, Longmont, Colorado, 80504, United States|Research Site, Bridgeport, Connecticut, 06606, United States|Research Site, New Haven, Connecticut, 06510, United States|Research Site, Newark, Delaware, 19713, United States|Research Site, Fort Myers, Florida, 33901, United States|Research Site, Jacksonville, Florida, 32224, United States|Research Site, Jacksonville, Florida, 32256, United States|Research Site, Port Saint Lucie, Florida, 34952, United States|Research Site, Saint Petersburg, Florida, 33705, United States|Research Site, Tallahassee, Florida, 32308, United States|Research Site, West Palm Beach, Florida, 33401, United States|Research Site, Atlanta, Georgia, 30322, United States|Research Site, Atlanta, Georgia, 30342, United States|Research Site, Chicago Ridge, Illinois, 60415, United States|Research Site, Dyer, Indiana, 46311, United States|Research Site, Des Moines, Iowa, 50309, United States|Research Site, Edgewood, Kentucky, 41017, United States|Research Site, Louisville, Kentucky, 40202, United States|Research Site, Baton Rouge, Louisiana, 70817, United States|Research Site, Annapolis, Maryland, 21401, United States|Research Site, Boston, Massachusetts, 02215, United States|Research Site, Detroit, Michigan, 48202, United States|Research Site, Grand Rapids, Michigan, 49503, United States|Research Site, Traverse City, Michigan, 49684, United States|Research Site, Burnsville, Minnesota, 55337, United States|Research Site, Minneapolis, Minnesota, 55407, United States|Research Site, Columbia, Missouri, 65212, United States|Research Site, Saint Louis, Missouri, 63110, United States|Research Site, Omaha, Nebraska, 68130, United States|Research Site, Henderson, Nevada, 89074, United States|Research Site, Camden, New Jersey, 08103, United States|Research Site, East Brunswick, New Jersey, 08816, United States|Research Site, New Brunswick, New Jersey, 08901, United States|Research Site, Santa Fe, New Mexico, 87505, United States|Research Site, Commack, New York, 11725, United States|Research Site, New York, New York, 10065, United States|Research Site, Charlotte, North Carolina, 28204, United States|Research Site, Durham, North Carolina, 27710, United States|Research Site, Winston-Salem, North Carolina, 27103, United States|Research Site, Blue Ash, Ohio, 45242, United States|Research Site, Canton, Ohio, 44710, United States|Research Site, Eugene, Oregon, 97401, United States|Research Site, Portland, Oregon, 97223, United States|Research Site, Horsham, Pennsylvania, 19044, United States|Research Site, Philadelphia, Pennsylvania, 19104, United States|Research Site, Pittsburgh, Pennsylvania, 15212, United States|Research Site, Providence, Rhode Island, 02903, United States|Research Site, Chattanooga, Tennessee, 37404, United States|Research Site, Nashville, Tennessee, 37203, United States|Research Site, Nashville, Tennessee, 37232, United States|Research Site, Austin, Texas, 78731, United States|Research Site, Dallas, Texas, 75230, United States|Research Site, Dallas, Texas, 75231, United States|Research Site, Dallas, Texas, 75235, United States|Research Site, Dallas, Texas, 75246, United States|Research Site, Dallas, Texas, 75390-8843, United States|Research Site, El Paso, Texas, 79902, United States|Research Site, Flower Mound, Texas, 75028, United States|Research Site, Fort Worth, Texas, 76104, United States|Research Site, Houston, Texas, 77030, United States|Research Site, Irving, Texas, 75063, United States|Research Site, San Antonio, Texas, 78240, United States|Research Site, Webster, Texas, 77598, United States|Research Site, Fairfax, Virginia, 22031, United States|Research Site, Norfolk, Virginia, 23502, United States|Research Site, Richmond, Virginia, 23298, United States|Research Site, Roanoke, Virginia, 24014, United States|Research Site, Winchester, Virginia, 22601, United States|Research Site, Tacoma, Washington, 98405, United States|Research Site, Madison, Wisconsin, 53715, United States|Research Site, Darlinghurst, 2010, Australia|Research Site, East Melbourne, 3002, Australia|Research Site, Heidelberg, 3084, Australia|Research Site, Herston, 4029, Australia|Research Site, Nedlands, 6009, Australia|Research Site, Waratah, 2298, Australia|Research Site, Feldkirch, 6807, Austria|Research Site, Graz, 8036, Austria|Research Site, Innsbruck, 6020, Austria|Research Site, Linz, 4010, Austria|Research Site, Salzburg, 5020, Austria|Research Site, Brasschaat, 2930, Belgium|Research Site, Charleroi, 6060, Belgium|Research Site, Gent, 9000, Belgium|Research Site, Leuven, 3000, Belgium|Research Site, Libramont-Chevigny, 6800, Belgium|Research Site, Wilrijk, 2610, Belgium|Research Site, Brasilia, 71681-603, Brazil|Research Site, Curitiba, 80440-220, Brazil|Research Site, Fortaleza, 60336-045, Brazil|Research Site, Londrina, 86015-520, Brazil|Research Site, Natal, 59075-740, Brazil|Research Site, Porto Alegre, 90035-000, Brazil|Research Site, Porto Alegre, 90035-903, Brazil|Research Site, RibeirÃ£o Preto, 14051-140, Brazil|Research Site, Santo Andre, 09060-650, Brazil|Research Site, SÃ£o Paulo, 01246-000, Brazil|Research Site, TaubatÃ©, 12030-200, Brazil|Research Site, VitÃ³ria, 29043-260, Brazil|Research Site, Plovdiv, 4004, Bulgaria|Research Site, Shumen, 9700, Bulgaria|Research Site, Sofia, 1330, Bulgaria|Research Site, Sofia, 1431, Bulgaria|Research Site, Sofia, 1797, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Vratza, 3000, Bulgaria|Research Site, Calgary, Alberta, T2N 5G2, Canada|Research Site, Abbotsford, British Columbia, V2S0C2, Canada|Research Site, Vancouver, British Columbia, VSZ 4E6, Canada|Research Site, St. John's, Newfoundland and Labrador, A1B 3V6, Canada|Research Site, Barrie, Ontario, L4M 6M2, Canada|Research Site, London, Ontario, N6A 5W9, Canada|Research Site, Oshawa, Ontario, L1G 2B9, Canada|Research Site, Toronto, Ontario, M5G 2M9, Canada|Research Site, Levis, Quebec, G6V 3Z1, Canada|Research Site, Montreal, Quebec, H1T 2M4, Canada|Research Site, Montreal, Quebec, H2X 0C1, Canada|Research Site, Montreal, Quebec, H4A-3J1, Canada|Research Site, Sherbrooke, Quebec, J1H 5N4, Canada|Research Site, St-Jerome, Quebec, J7Z 5T3, Canada|Research Site, Saskatoon, Saskatchewan, S7N 4H4, Canada|Research Site, Montreal, H3T 1E2, Canada|Research Site, Ottawa, K1H 8L6, Canada|Research Site, Beijing, 100044, China|Research Site, Beijing, 211405, China|Research Site, Bengbu, 233004, China|Research Site, Changchun, 130021, China|Research Site, Changsha, 410008, China|Research Site, Changsha, 410013, China|Research Site, Chengdu, 610000, China|Research Site, Chongqing, 400030, China|Research Site, Guangzhou, 510060, China|Research Site, Guangzhou, 510120, China|Research Site, Hangzhou, 310009, China|Research Site, Hangzhou, 310022, China|Research Site, Harbin, 150049, China|Research Site, Hefei, 230012, China|Research Site, Jinan, 250117, China|Research Site, Kunming, 650118, China|Research Site, Linhai, 317000, China|Research Site, Nanchang, 330009, China|Research Site, Nanchang, 330029, China|Research Site, Nanjing, 210008, China|Research Site, Nanjing, 210029, China|Research Site, Nanning, 530021, China|Research Site, Shanghai, 200025, China|Research Site, Shenyang, 110004, China|Research Site, Shenyang, 110042, China|Research Site, Shijiazhuang, 050020, China|Research Site, Suining, 629000, China|Research Site, Suzhou, 215004, China|Research Site, Tianjin, 300000, China|Research Site, Urumqi, 830000, China|Research Site, Wuhan, 430022, China|Research Site, Xi'an, 710061, China|Research Site, Xintai, 54031, China|Research Site, Zhaoqing, 526000, China|Research Site, Zhengzhou, 450008, China|Research Site, Avignon, 84918, France|Research Site, Bayonne, 64100, France|Research Site, Caen Cedex 5, 41076, France|Research Site, Clermont Ferrand, 63011, France|Research Site, Limoges, 87000, France|Research Site, Lyon, 69373, France|Research Site, Marseille, 13273, France|Research Site, Montpellier, 34298, France|Research Site, Nice, 06100, France|Research Site, Paris, 75010, France|Research Site, Reims Cedex, 51056, France|Research Site, Saint Herblain, 44805, France|Research Site, Toulouse, 31100, France|Research Site, Vandoeuvre les Nancy, 54519, France|Research Site, Villejuif Cedex, 94805, France|Research Site, Augsburg, 86150, Germany|Research Site, Berlin, 10967, Germany|Research Site, Berlin, 13125, Germany|Research Site, Dessau-RoÃlau, 06847, Germany|Research Site, Dresden, 01307, Germany|Research Site, Erlangen, 91054, Germany|Research Site, Essen, 45130, Germany|Research Site, Esslingen am Neckar, 73730, Germany|Research Site, Frankfurt am Main, 60431, Germany|Research Site, Freiburg, 79106, Germany|Research Site, Freiburg, 79110, Germany|Research Site, Hamburg, 20246, Germany|Research Site, Hannover, 30559, Germany|Research Site, Hannover, 30625, Germany|Research Site, Heidelberg, 69120, Germany|Research Site, Kiel, 24105, Germany|Research Site, Mainz, 55131, Germany|Research Site, Mannheim, 68167, Germany|Research Site, MÃ¼nchen, 80637, Germany|Research Site, MÃ¼nchen, 81675, Germany|Research Site, MÃ¼nster, 48149, Germany|Research Site, Trier, 54290, Germany|Research Site, Ulm, 89075, Germany|Research Site, Hong Kong, 00000, Hong Kong|Research Site, Hong Kong, 999077, Hong Kong|Research Site, Kwai Chung, 999077, Hong Kong|Research Site, Budapest, 1122, Hungary|Research Site, KecskemÃ©t, 6000, Hungary|Research Site, Miskolc, 3526, Hungary|Research Site, NyÃ­regyhÃ¡za, 4400, Hungary|Research Site, SalgÃ³tarjÃ¡n, 3100, Hungary|Research Site, SzekszÃ¡rd, 7100, Hungary|Research Site, Bengaluru, 560085, India|Research Site, Dehradun, 248016, India|Research Site, Delhi, 110029, India|Research Site, Delhi, 110085, India|Research Site, Kolkata, 700016, India|Research Site, Kolkata, 700099, India|Research Site, Marg Jaipur, 302004, India|Research Site, Nagpur, 440001, India|Research Site, Nashik, 422011, India|Research Site, Puducherry, 605006, India|Research Site, Thiruvananthapuram, 695011, India|Research Site, Vadodara, 391760, India|Research Site, Empoli, 50053, Italy|Research Site, Lucca, 55100, Italy|Research Site, Macerata, 62100, Italy|Research Site, Milano, 20132, Italy|Research Site, Modena, 41124, Italy|Research Site, Napoli, 80131, Italy|Research Site, Padova, 35128, Italy|Research Site, Roma, 00168, Italy|Research Site, Rozzano, 20089, Italy|Research Site, Torino, 10126, Italy|Research Site, Tricase, 73039, Italy|Research Site, Udine, 33100, Italy|Research Site, Akashi-shi, 673-8558, Japan|Research Site, Akita-shi, 010-8543, Japan|Research Site, Bunkyo-ku, 113-8431, Japan|Research Site, Chiba-shi, 260-8717, Japan|Research Site, Chuo-ku, 104-8560, Japan|Research Site, Fukuoka-shi, 811-1395, Japan|Research Site, Fukushima-shi, 960-1295, Japan|Research Site, Gifu-shi, 501-1194, Japan|Research Site, Hidaka-shi, 350-1298, Japan|Research Site, Hirakata-shi, 573-1191, Japan|Research Site, Hiroshima-shi, 730-0011, Japan|Research Site, Hiroshima-shi, 734-8551, Japan|Research Site, Isehara-shi, 259-1193, Japan|Research Site, Kashiwa, 227-8577, Japan|Research Site, Koto-ku, 135-8550, Japan|Research Site, Kumamoto-shi, 860-8556, Japan|Research Site, Kurume-shi, 830-0011, Japan|Research Site, Kyoto-shi, 606-8507, Japan|Research Site, Matsuyama-shi, 791-0280, Japan|Research Site, Nagoya-shi, 460-0001, Japan|Research Site, Nagoya-shi, 466-8560, Japan|Research Site, Nagoya-shi, 467-0001, Japan|Research Site, Niigata-shi, 951-8566, Japan|Research Site, Okayama, 700-8558, Japan|Research Site, Osaka-shi, 541-8567, Japan|Research Site, Sapporo-shi, 003-0804, Japan|Research Site, Sapporo-shi, 060-8648, Japan|Research Site, Sendai-shi, 980-8574, Japan|Research Site, Shinagawa-ku, 142-8666, Japan|Research Site, Shinjuku-ku, 160-0023, Japan|Research Site, Shinjuku-ku, 162-8655, Japan|Research Site, Sunto-gun, 411-8777, Japan|Research Site, Tokyo, 104-0045, Japan|Research Site, Tsu-shi, 514-8507, Japan|Research Site, Yokohama-shi, 241-8515, Japan|Research Site, Daegu, 41404, Korea, Republic of|Research Site, Goyang-si, 10408, Korea, Republic of|Research Site, Seongnam, 13620, Korea, Republic of|Research Site, Seoul, 02841, Korea, Republic of|Research Site, Seoul, 03080, Korea, Republic of|Research Site, Seoul, 03722, Korea, Republic of|Research Site, Seoul, 05505, Korea, Republic of|Research Site, Seoul, 06273, Korea, Republic of|Research Site, Seoul, 06351, Korea, Republic of|Research Site, Seoul, 06591, Korea, Republic of|Research Site, George Town, 10990, Malaysia|Research Site, Kuala Lumpur, 50586, Malaysia|Research Site, Kuala Lumpur, 59100, Malaysia|Research Site, Kuching, 93586, Malaysia|Research Site, Selangor, 62250, Malaysia|Research Site, Bialystok, 15-027, Poland|Research Site, Bydgoszcz, 85-796, Poland|Research Site, GdaÅsk, 80-214, Poland|Research Site, Gdynia, 81-519, Poland|Research Site, KrakÃ³w, 31-501, Poland|Research Site, TomaszÃ³w Mazowiecki, 97-200, Poland|Research Site, Warszawa, 02-781, Poland|Research Site, Wroclaw, 53-413, Poland|Research Site, ÅÃ³dÅº, 93-338, Poland|Research Site, Singapore, 168583, Singapore|Research Site, Barcelona, 08036, Spain|Research Site, Barcelona, 8035, Spain|Research Site, Granada, 18016, Spain|Research Site, Hospitalet deLlobregat, 08907, Spain|Research Site, Madrid, 28007, Spain|Research Site, Madrid, 28034, Spain|Research Site, Santiago de Compostela, 15706, Spain|Research Site, Sevilla, 41009, Spain|Research Site, Zaragoza, 50009, Spain|Research Site, Baden, CH-5405, Switzerland|Research Site, Basel, 4031, Switzerland|Research Site, Bern, 3010, Switzerland|Research Site, Frauenfeld, 8501, Switzerland|Research Site, Rennaz, 1847, Switzerland|Research Site, Changhua, 500, Taiwan|Research Site, Kaohsiung, 82445, Taiwan|Research Site, Taichung, 40447, Taiwan|Research Site, Tainan, 704, Taiwan|Research Site, Taipei, 10002, Taiwan|Research Site, Taipei, 10449, Taiwan|Research Site, Taipei, 112, Taiwan|Research Site, Taoyuan, 333, Taiwan|Research Site, Bangkok, 10210, Thailand|Research Site, Bangkok, 10330, Thailand|Research Site, Dusit, 10300, Thailand|Research Site, Muang, 50200, Thailand|Research Site, Songkhla, 90110, Thailand|Research Site, Adapazari, 54290, Turkey|Research Site, Ankara, 06010, Turkey|Research Site, Ankara, 06340, Turkey|Research Site, Ankara, 06520, Turkey|Research Site, Istanbul, 34722, Turkey|Research Site, Kayseri, 38039, Turkey|Research Site, Samsun, 55200, Turkey|Research Site, Birmingham, B15 2TG, United Kingdom|Research Site, Cardiff, CF14 2TL, United Kingdom|Research Site, Edinburgh, EH1 3EG, United Kingdom|Research Site, Guildford, United Kingdom|Research Site, Lancaster, LA1 4RP, United Kingdom|Research Site, London, EC1A 7BE, United Kingdom|Research Site, Northampton, NN1 5BD, United Kingdom|Research Site, Oxford, OX3 7LE, United Kingdom|Research Site, Taunton, TA1 5DA, United Kingdom|Research Site, Hanoi, 100000, Vietnam|Research Site, Ho Chi Minh city, 700000, Vietnam|Research Site, Vinh, 460000, Vietnam",
NCT06801834,Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT06801834,EVOKE-SCLC-04,RECRUITING,"The goal of this clinical study is to learn more about the study drug sacituzumab govitecan (SG; TrodelvyÂ®; GS-0132; IMMU 132), versus standard of care (SOC) in participants with previously treated extensive stage small cell lung cancer (ES-SCLC).

The primary objectives of this study are to compare the effect of SG to SOC on objective response rate (ORR) as assessed by blinded independent central review (BICR) according to the Response Evaluation Criteria in Solid Tumors and to compare the effect of SG to SOC on overall survival (OS).",NO,Extensive Stage Small Cell Lung Cancer (ES-SCLC),DRUG: Sacituzumab Govitecan (SG)|DRUG: Topotecan|DRUG: Amrubicin (Japan only),"Objective Response Rate (ORR), ORR is defined as the percentage of participants who have achieved a complete response (CR) or partial response (PR) as assessed by BICR according to RECIST v1.1, Up to 4.5 years|Overall Survival (OS), OS is defined as length of time from randomization until the date of death from any cause., Up to 4.5 years","Progression-free Survival (PFS), PFS is defined as the time from date of randomization until disease progression as assessed by BICR according to RECIST v1.1 or death from any cause, whichever comes first., Up to 4.5 years|Duration of Response (DOR), DOR is defined as is measured from the time of first response (CR or PR) as assessed by BICR according to RECIST v1.1, until the date of first documented disease progression or death, whichever comes first, Up to 4.5 years|Time to First Deterioration in Shortness of Breath Domain, Time to first deterioration is defined as the time from the date of randomization to the first time a participant experienced change from baseline equal to or greater than the prespecified threshold value for deterioration or death., Up to 4.5 years|Time to First Deterioration in Physical Functioning Domain, Time to first deterioration is defined as the time from the date of randomization to the first time a participant experienced change from baseline equal to or greater than the prespecified threshold value for deterioration or death., Up to 4.5 years|Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs), TEAE is defined as any AEs occurred during the treatment-emergent period. The treatment-emergent period is defined as the time period from the first dose of study treatment to the earlier of 30 days following the last dose of study treatment or the initiation of subsequent anticancer therapy., First dose date up to 4.5 years|Percentage of Participants Experiencing Clinical Laboratory abnormalities, Laboratory abnormality is defined as any value that increases at least 1 toxicity grade from baseline., First dose date up to 4.5 years",,Gilead Sciences,,ALL,"ADULT, OLDER_ADULT",PHASE3,695,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2025-04-04,2029-10,2029-10,2025-01-30,,2025-05-07,"Hope and Healing Cancer Services, Hinsdale, Illinois, 60521, United States|Taylor Cancer Research Foundation, Toledo, Ohio, 43617, United States|Spoknwrd Clinical Trials Inc., Easton, Pennsylvania, 18045, United States|The University of Texas Health Science Center at Tyler, Tyler, Texas, 75708, United States|Cancer Care Wollongong, New South Wales, 2500, Australia",
NCT05468489,To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC,https://clinicaltrials.gov/study/NCT05468489,,RECRUITING,"This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC.

Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows:

* Arm A (Serplulimab): Serplulimab + chemotherapy (carboplatin-etoposide)
* Arm B (control): Atezolizumab + chemotherapy (carboplatin-etoposide)",NO,Extensive Stage Small Cell Lung Cancer,DRUG: Serplulimab + chemotherapy (carboplatin-etoposide)|DRUG: Atezolizumab + chemotherapy (carboplatin-etoposide),"OS, Overall assessment, A period from randomization through death regardless of causality (approximately up to 24 months).","ORR, Objective response rate, approximately up to 14 months|PFS, Progression-free survival, approximately up to 24 months|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0, Adverse events are described and graded using the grading categories defined in CTCAE, Version 5.0, approximately up to 24 months|Maximum Plasma Concentration (Cmax), The maximum concentration (Cmax) of Serplulimab will be measured, approximately up to 24 months|Minimum Plasma Concentration (Cmin), The minimum concentration (Cmin) of Serplulimab will be measured, approximately up to 24 months|Average Plasma Concentration (Cavg), The average Plasma Concentration (Cavg) of Serplulimab will be measured, approximately up to 24 months",,Shanghai Henlius Biotech,,ALL,"ADULT, OLDER_ADULT",PHASE3,200,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-11-18,2025-09-30,2025-12-31,2022-07-21,,2025-05-23,"Alabama Oncology, Birmingham, Alabama, 35223, United States|O'Neal Comprehensive Cancer Center, Birmingham, Alabama, 352942, United States|City of Hope - Phoenix, Goodyear, Arizona, 85338, United States|Arizona Clinical Research Center (ACRC), Tucson, Arizona, 85715, United States|Highlands Oncology Group, Springdale, Arkansas, 72762, United States|OPN - Oncology Physician Network, Arcadia, California, 91107, United States|Compassionate Care Research Group, Fountain Valley, California, 92708, United States|Providence Medical Foundation, Fullerton, California, 92835, United States|Los Angeles Cancer Network, Glendale, California, 91204, United States|Long Beach Memorial Medical Center, Long Beach, California, 90806, United States|OPN - Oncology Physician Network, Los Alamitos, California, 90720, United States|California Research Institute, Los Angeles, California, 90027, United States|Kaiser Permanente Research (Southern California), Los Angeles, California, 90034, United States|UC Davis, Sacramento, California, 95817, United States|Providence Medical Group, Santa Rosa, California, 95403, United States|UCHealth Memorial Hospital North, Colorado Springs, Colorado, 80920, United States|Saint Joseph Hospital, Denver, Colorado, 80218, United States|Lutheran Medical Cancer Center, Golden, Colorado, 80401, United States|Banner MD Anderson Cancer Center (BMDACC), Greeley, Colorado, 80631, United States|MD Anderson- North Colorado Medical Center, Greeley, Colorado, 80631, United States|Eastern Connecticut Hematology and Oncology Associates, Norwich, Connecticut, 06360, United States|The Stamford Hospital, Stamford, Connecticut, 06904, United States|Advanced Cancer Treatment Centers, Brooksville, Florida, 34613, United States|Clermont Oncology Center, Clermont, Florida, 34711, United States|Cancer Specialists North Florida, Jacksonville, Florida, 32256, United States|United Medical Group, Miami, Florida, 33135, United States|Mount Sinai Comprehensive Cancer Center, Miami, Florida, 33140, United States|Florida Cancer Affiliates- (Ocala Oncology - Main), Ocala, Florida, 34473, United States|Mid Florida Hematology and Oncology Center, Orange City, Florida, 32763, United States|BRCR Global, Plantation, Florida, 33322, United States|Napa Research, Pompano Beach, Florida, 33064, United States|Advanced Research, Tamarac, Florida, 33321, United States|City of Hope- Chicago, Chicago, Illinois, 60099, United States|Cancer Center of Decatur, Decatur, Illinois, 62526, United States|NorthShore University Health System, Evanston, Illinois, 60201, United States|Northwest Oncology and Hematology, Rolling Meadows, Illinois, 60008, United States|Accellacare of Duly, Tinley Park, Illinois, 60487, United States|Northwest Cancer Centers, Dyer, Indiana, 46311, United States|Cancer Center of Kansas, Wichita, Kansas, 67214, United States|Baptist Health Lexington, Lexington, Kentucky, 40503, United States|Norton Healthcare - Norton Cancer Institute - Downtown Women's Cancer Center, Louisville, Kentucky, 40202, United States|Pikeville Hospital, Pikeville, Kentucky, 41501, United States|CHRISTUS St. Frances Cabrini Cancer Center, Alexandria, Louisiana, 71301, United States|Pontchartrain Cancer Center, Covington, Louisiana, 70433, United States|Pontchartrain Cancer Center, Hammond, Louisiana, 70433, United States|Tulane Medical Center, New Orleans, Louisiana, 70112, United States|Willis-Knighton Cancer Center, Shreveport, Louisiana, 71103, United States|Sandra and Malcolm Berman Cancer Institute at Greater Baltimore Medical Center, Baltimore, Maryland, 21204, United States|American Oncology Partners of Maryland, PA, Bethesda, Maryland, 20817, United States|Tufts Medicine, Boston, Massachusetts, 02111, United States|Lahey Hospital & Medical Center, Burlington, Massachusetts, 01805, United States|Henry Ford Health Providence Southfield Hospital, Southfield, Michigan, 48075, United States|Health Partners Cancer Center at Regions Hospital, Saint Paul, Minnesota, 55101, United States|Hattiesburg Clinic Hematology/Oncology, Hattiesburg, Mississippi, 39401, United States|North Mississippi Medical Center Hematology and Oncology Clinic, Tupelo, Mississippi, 38801, United States|Saint Luke's Hospital Cancer Institute, Kansas City, Missouri, 64111, United States|MidAmerica Division Inc., c/o Research Medical Center, Kansas City, Missouri, 64132, United States|Lake Regional, Osage Beach, Missouri, 65065, United States|Oncology Hematology Associates, Springfield, Missouri, 65807, United States|St. Vincent Frontier Cancer Center, Billings, Montana, 59102, United States|Cancer Partners of Nebraska, Lincoln, Nebraska, 68510, United States|University of Nebraska Medical Center, Omaha, Nebraska, 68106, United States|Nebraska Methodist Hospital, Omaha, Nebraska, 68114, United States|Renown Health, Reno, Nevada, 89502, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, 03756, United States|Summit Medical Group, Florham Park, New Jersey, 07932, United States|Regional Cancer Care Associates LLC RCCA, Freehold, New Jersey, 03756, United States|Jersey Shore University Medical Center, Neptune, New Jersey, 07753, United States|CHRISTUS St. Vincent, Santa Fe, New Mexico, 87505, United States|Elmhurst (BRANY site), Elmhurst, New York, 11373, United States|Northwell Health, Lake Success, New York, 11042, United States|Stony Brook Cancer Center, Stony Brook, New York, 11794, United States|Great Lakes Cancer Care (Kaleida Health), Williamsville, New York, 14221, United States|Summa Health, Akron, Ohio, 44304, United States|Cleveland Clinic Mercy Hospital, Canton, Ohio, 44708, United States|Aultman Cancer Center, Canton, Ohio, 44710, United States|Gabrail Cancer Center (GCC) Research- Canton Facility, Canton, Ohio, 44718, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, 44106, United States|MetroHealth, Cleveland, Ohio, 44109, United States|Tricounty Hematology and Oncology Associates, Massillon, Ohio, 44646, United States|The Toledo Clinic, Toledo, Ohio, 43623, United States|CharterCARE (Roger Williams), Providence, Rhode Island, 02908, United States|Monument Health, Rapid City, South Dakota, 57701, United States|CHRISTUS Institute for Innovation & Advanced Clinical Care, Corpus Christi, Texas, 78404, United States|DHR Research, Edinburg, Texas, 78539, United States|The Center for Cancer and Blood Disorders, Fort Worth, Texas, 76104, United States|Valley Cancer Associates, Harlingen, Texas, 78550, United States|Millennium Research and Clinical Development, Houston, Texas, 77090, United States|Lumi Research, Kingwood, Texas, 77339, United States|Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, 79410, United States|The University of Texas Health Science Center at Tyler/HOPE Cancer Center, Tyler, Texas, 75701, United States|Utah Cancer Specialists, Salt Lake City, Utah, 84106, United States|Huntsman Cancer Institute, Salt Lake City, Utah, 84112, United States|American Oncology Network Vista Oncology Division, Olympia, Washington, 98502, United States|Medical Oncology Associates, PS (dba Summit Cancer Centers), Spokane Valley, Washington, 99216, United States|Northwest Medical Specialties, PLLC, Tacoma, Washington, 98405, United States|West Virginia University Cancer Institute, Morgantown, West Virginia, 26505, United States|University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, 53792, United States|Froedtert Hospital- Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States",
NCT06868277,A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT06868277,ARTEMIDELung04,RECRUITING,The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.,NO,"Carcinoma, Non-Small Cell Lung",BIOLOGICAL: Rilvegostomig|BIOLOGICAL: Pembrolizumab,"Overall Survival (OS), OS is defined as the time from randomization until the date of death due to any cause., Up to approximately 5 years|Progression-Free Survival (PFS), PFS is defined as the time from randomization until radiological progression per RECIST 1.1 or death due to any cause (in the absence of progression)., Up to approximately 5 years","Landmark Overall Survival (OS) rates, OS is defined as the time from randomization until the date of death due to any cause., Up to approximately 5 years|Landmark Progression-Free Survival (PFS) rates, PFS is defined as the time from randomization until radiological progression per RECIST 1.1 or death due to any cause (in the absence of progression)., Up to approximately 5 years|Objective Response Rate (ORR), ORR is defined as the proportion of participants who have a confirmed CR or confirmed PR, using RECIST 1.1., Up to approximately 5 years|Duration of Response (DoR), DoR is defined as the time from the date of first documented response until the date of documented progression using RECIST 1.1 or death due to any cause (in the absence of progression)., Up to approximately 5 years|Time to second progression or death (PFS2), PFS2 is defined as the time from randomization until the earliest of the progression event (following the initial investigator-assessed progression event), after the start of the first subsequent therapy, or death from any cause, whichever occurs first., Up to approximately 5 years|Pharmakokinetics (PK) of rilvegostomig, Concentration of rilvegostomig in serum, Up to approximately 5 years|Immunogenicity of rilvegostomig, Presence of antidrug antibodies (ADAs), titer, and neutralizing antibodies for rilvegostomig., Up to approximately 5 years|Patient-reported physical functioning, Proportion of participants with maintained or improved physical functioning as measured by Patient-Reported Outcomes Measurement Information System Physical Function - Short Form 8c - 7 day (PROMIS PF-SF 8c - 7 day) at each time point., Up to approximately 5 years|Patient-reported global health status (GHS)/quality of life (QoL), Time to deterioration (TTD) of GHS/QoL as measured by the European Organization for Research and Treatment of Cancer Item Library 172 (EORTC IL172). TTD is defined as time from randomization to the date of first deterioration., Up to approximately 5 years|Patient-reported lung cancer symptoms of non-small cell lung cancer (NSCLC), Time to deterioration (TTD) in pulmonary symptoms as measured by the Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ).

TTD is defined as time from randomization to the date of first deterioration., Up to approximately 5 years",,AstraZeneca,,ALL,"ADULT, OLDER_ADULT",PHASE3,830,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2025-04-10,2030-01-17,2030-12-02,2025-03-10,,2025-05-14,"Research Site, Bay Pines, Florida, 33744, United States|Research Site, Clearwater, Florida, 33756, United States|Research Site, Saint Petersburg, Florida, 33705, United States|Research Site, Decatur, Illinois, 62526, United States|Research Site, Des Moines, Iowa, 50309, United States|Research Site, Leawood, Kansas, 66209, United States|Research Site, Frederick, Maryland, 21702, United States|Research Site, Silver Spring, Maryland, 20910, United States|Research Site, Towson, Maryland, 21204, United States|Research Site, Westbury, New York, 11590, United States|Research Site, Canton, Ohio, 44718, United States|Research Site, Philadelphia, Pennsylvania, 19104, United States|Research Site, Cordoba, 5000, Argentina|Research Site, Hobart, 7000, Australia|Research Site, Edegem, 2650, Belgium|Research Site, LiÃ¨ge, 4000, Belgium|Research Site, Mechelen, 2800, Belgium|Research Site, Roeselaere, 8800, Belgium|Research Site, Blumenau, 89010-340, Brazil|Research Site, Fortaleza, 60336-550, Brazil|Research Site, Ijui, 98700-000, Brazil|Research Site, Itajai, 88301-220, Brazil|Research Site, Passo Fundo, 99010-260, Brazil|Research Site, Porto Alegre, 90035-903, Brazil|Research Site, Porto Alegre, 90610-000, Brazil|Research Site, Porto Velho, 76834-899, Brazil|Research Site, Burgas, 8000, Bulgaria|Research Site, Panagyurishte, 4500, Bulgaria|Research Site, Sofia, 1407, Bulgaria|Research Site, Sofia, 1618, Bulgaria|Research Site, Sofia, 1756, Bulgaria|Research Site, Baoding, 071000, China|Research Site, Beijing, 100021, China|Research Site, Beijing, 101149, China|Research Site, Changchun, 130000, China|Research Site, Changchun, 130033, China|Research Site, Changsha, 410008, China|Research Site, Changsha, 410013, China|Research Site, Chongqing, 400030, China|Research Site, Fuzhou, 350001, China|Research Site, Fuzhou, 350014, China|Research Site, Guangzhou, 510080, China|Research Site, Jiamusi, 154007, China|Research Site, Jinan, 250117, China|Research Site, Lanzhou, 730050, China|Research Site, Linyi, 276001, China|Research Site, Nanchang, 330029, China|Research Site, Nanjing, 210008, China|Research Site, Ningbo, 315010, China|Research Site, Shanghai, 200092, China|Research Site, Shenyang, 110042, China|Research Site, Suzhou, 215004, China|Research Site, Wuhan, 430030, China|Research Site, Wuhan, 430060, China|Research Site, Xuzhou, 221002, China|Research Site, Yantai, 264000, China|Research Site, Valledupar, 200001, Colombia|Research Site, Avignon, 84000, France|Research Site, Caen, 14000, France|Research Site, Dijon, 21000, France|Research Site, La Tronche, 38700, France|Research Site, Paris, 75020, France|Research Site, Pau Cedex, 64046, France|Research Site, Toulouse, 31300, France|Research Site, Tbilisi, 0112, Georgia|Research Site, Tbilisi, 0159, Georgia|Research Site, Amberg, 92224, Germany|Research Site, Bad Saarow, 15526, Germany|Research Site, Berlin, 13359, Germany|Research Site, Bonn, 53127, Germany|Research Site, Essen, 45147, Germany|Research Site, Frankfurt am Main, 60431, Germany|Research Site, Heilbronn, 74078, Germany|Research Site, Immenhausen, 34376, Germany|Research Site, Koblenz, 56073, Germany|Research Site, Leipzig, 04103, Germany|Research Site, MÃ¼nchen, 80336, Germany|Research Site, Oldenburg, 26121, Germany|Research Site, Rotenburg, 27356, Germany|Research Site, Schweinfurt, 97421, Germany|Research Site, Velbert, 42551, Germany|Research Site, WÃ¼rselen, 52146, Germany|Research Site, WÃ¼rzburg, 97080, Germany|Research Site, Athens, 11527, Greece|Research Site, Athens, 12462, Greece|Research Site, Peiraias, 185 47, Greece|Research Site, Thessaloniki, 55236, Greece|Research Site, Thessaloniki, 56429, Greece|Research Site, Thessaloniki, 57001, Greece|Research Site, Afula, 1834111, Israel|Research Site, Beer-Sheva, 8410101, Israel|Research Site, Hadera, 38100, Israel|Research Site, Jerusalem, 91031, Israel|Research Site, Jerusalem, 91120, Israel|Research Site, Ramat Gan, 52621, Israel|Research Site, Candiolo, 10060, Italy|Research Site, Lucca, 55100, Italy|Research Site, Pisa, 56126, Italy|Research Site, Udine, 33100, Italy|Research Site, Verona, 37126, Italy|Research Site, Akashi, 673-8558, Japan|Research Site, Bunkyo-ku, 113-8603, Japan|Research Site, Bunkyo-ku, 113-8677, Japan|Research Site, Fukuoka-shi, 811-1395, Japan|Research Site, Fukuoka-Shi, 812-8582, Japan|Research Site, Hamamatsu-shi, 431-3192, Japan|Research Site, Iwakuni-shi, 740-8510, Japan|Research Site, Izumi-shi, 594-0073, Japan|Research Site, Kobe, 650-0046, Japan|Research Site, Koto-ku, 135-8550, Japan|Research Site, Kurume-shi, 830-0011, Japan|Research Site, Kyoto-shi, 602-8566, Japan|Research Site, Matsuyama-shi, 791-0280, Japan|Research Site, Nankoku-shi, 783-8505, Japan|Research Site, Niigata-shi, 951-8566, Japan|Research Site, Osaka-shi, 534-0021, Japan|Research Site, Osakasayama, 589-8511, Japan|Research Site, Sakai-shi, 591-8555, Japan|Research Site, Sendai-shi, 980-0873, Japan|Research Site, Shinagawa-ku, 142-8666, Japan|Research Site, Toyoake-shi, 470-1192, Japan|Research Site, Toyonaka-shi, 560-8552, Japan|Research Site, Kuala Lumpur, 50586, Malaysia|Research Site, Perai, 13700, Malaysia|Research Site, Selangor, 62250, Malaysia|Research Site, Alcabideche, 2755-009, Portugal|Research Site, Lisboa, 1400-038, Portugal|Research Site, Lisboa, 1500-650, Portugal|Research Site, Lisbon, 1769-001, Portugal|Research Site, Porto, 4100-180, Portugal|Research Site, Porto, 4200-072, Portugal|Research Site, Bucuresti, 013812, Romania|Research Site, Bucuresti, 022328, Romania|Research Site, Craiova, 200385, Romania|Research Site, Craiova, 200542, Romania|Research Site, Iasi, 700106, Romania|Research Site, Pitesti, 110283, Romania|Research Site, Badalona, 8916, Spain|Research Site, CastellÃ³n, 12002, Spain|Research Site, Granada, 18016, Spain|Research Site, Madrid, 28040, Spain|Research Site, Madrid, 28050, Spain|Research Site, MÃ¡laga, 29010, Spain|Research Site, Oviedo, 33006, Spain|Research Site, Izmit, 41380, Turkey|Research Site, YÃ¼reÄir, 01240, Turkey|Research Site, Blackpool, FY3 8NR, United Kingdom",
NCT03456063,"A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)",https://clinicaltrials.gov/study/NCT03456063,,ACTIVE_NOT_RECRUITING,"This is a randomized, double-blinded study designed to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of neoadjuvant treatment with atezolizumab (MPDL3280A) or placebo in combination with platinum-based chemotherapy in participants with resectable Stage II, IIIA, or select IIIB non-small cell lung cancer (NSCLC) followed by open-label adjuvant/postoperative atezolizumab or best supportive care and monitoring.",NO,Non-Small-Cell Lung,"DRUG: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|DRUG: Placebo Comparator|DRUG: Nab-paclitaxel|DRUG: Pemetrexed|DRUG: Carboplatin|DRUG: Cisplatin|DRUG: Gemcitabine","Independent Review Facility (IRF)-Assessed Event Free Survival (EFS), IRF-assessed EFS is defined as the time from randomization to the first documented disease progression per RECIST v1.1 that precludes surgery, local or distant disease recurrence, or death from any cause, whichever occurs first., Up to approximately 96 months","Pathological Complete Response (pCR), pCR is defined as the absence of any viable primary tumor cells at the time of surgical resection in the primary tumor and all sampled lymph nodes as assessed by central and local pathology laboratory., At time of surgery|Major Pathological Response (MPR), MPR is defined as â¤ 10% residual viable tumor cells at the time of surgical resection in the primary tumor, as assessed by central and local pathology laboratory., At time of surgery|Objective Response (OR), Objective response is defined as a complete response or partial response, as determined by the investigator according to RECIST v1.1, Prior to surgery, up to approximately 84 days|Overall Survival (OS), OS is defined as the time from randomization to death from any cause during the course of the study., Up to approximately 96 months|Investigator-Assessed EFS, EFS is defined as the time from randomization to the first documented disease progression per RECIST v1.1 that precludes surgery, local or distant disease recurrence, as assessed by the investigator; or death from any cause, whichever occurs first., Up to approximately 96 months|Disease-Free Survival (DFS), DFS is defined as the time from the first date of no disease to local or distant recurrence (including occurrence of new primary NSCLC) or death due to any cause, whichever occurs first, as determined by the investigator during the adjuvant treatment and observation follow-up, Up to approximately 96 months|2-Year and 3-Year OS, The 2-year and 3-year OS rate is defined as the probability that a participant will be alive 2 years and 3 years after randomization, respectively., Up to approximately 96 months|2-Year and 3-Year Independent Review Facility-Assessed EFS, EFS is defined as the probability that a participant will be event-free 2 years and 3 years after randomization, respectively, as assessed by the Independent Review Facility., Up to approximately 96 months|2-Year and 3-Year Investigator-Assessed EFS, EFS is defined as the probability that a participant will be event-free 2 years and 3 years after randomization, respectively, as assessed by the Investigator., Up to approximately 96 months|Change from baseline in HRQoL scores, Change from baseline in HRQoL scores as assessed through use of the two-item GHS/HRQoL subscale (Questions 29 and 30) of the EORTC QLQ-C30 at each assessment time point during the study through the completion of adjuvant treatment and observation follow-up assessments, Up to approximately 96 months|Percentage of Participants With Adverse Events (AEs), Up to approximately 96 months|Number and Severity of Surgical Related Adverse Events, Up to approximately 96 months|Number of Surgical Delays, Number of surgical delays., Up to approximately 96 months|Length of Surgical Delays, Length of surgical delays., Up to approximately 96 months|Number of Operative and Post-Operative Complications, Number of operative and post-operative complications., Up to approximately 96 months|Reasons for Surgical Cancellations, Reasons for surgical cancellations., Up to approximately 96 months|Minimum Observed Serum Atezolizumab Concentration (Cmin), Cmin is the minimum (or trough) concentration that a study drug achieves in the body., Pre-dose on Day 1 of Cycles 1 and 3 (each cylce is 21 days) for Neoadjuvant Treatment; pre-dose on Day 1 of Cycles 5, 7, 9, 11 and 19 (each cycle is 21 days) for Arm A; at treatment or observation follow-up discontinuation (up to approximately 96 months)|Maximum Observed Serum Atezolizumab Concentration (Cmax), Cmax is the maximum (or peak) concentration that a study drug achieves in the body., Pre-dose on Day 1 of Cycles 1 and 3 for Neoadjuvant Treatment; Pre-dose on Day 1 of Cycles 5, 7, 9, 11 and 19 for Arm A. Each cycle is 21 days; at treatment or observation follow-up discontinuation (up to approximately 96 months)|Percentage of Participants With Anti-Drug Antibody (ADA) to Atezolizumab, Pre-dose on Day 1 of Cycles 1 and 3 for Neoadjuvant Treatment; Pre-dose on Day 1 of Cycles 5, 7, 9, 11 and 19 for Arm A. Each cycle is 21 days; at treatment or observation follow-up discontinuation (up to approximately 96 months)",,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE3,453,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2018-04-24,2025-12-31,2025-12-31,2018-03-07,,2025-05-20,"Arizona Oncology, Tucson, Arizona, 85711, United States|USC Norris Cancer Center, Los Angeles, California, 90033, United States|The Center for Cancer Prevention and Treatment at St.Joseph Hospital of Orange, Orange, California, 92868, United States|UC Davis Cancer Center, Sacramento, California, 95817, United States|Scripps Clinic, San Diego, California, 92037, United States|National Jewish Health, Denver, Colorado, 80206, United States|Rocky Mountain Cancer Center, Denver, Colorado, 80218, United States|Georgetown University, Washington, District of Columbia, 20007, United States|Washington Cancer Institute, Washington, District of Columbia, 20010, United States|Illinois Cancer Care, Peoria, Illinois, 61615, United States|Uni of Maryland Cancer Center, Baltimore, Maryland, 21201, United States|University of Michigan, Ann Arbor, Michigan, 48109, United States|Brighton Center for Specialty Care, Brighton, Michigan, 48116, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, 48201, United States|Minnesota Oncology Minneapolis, Minneapolis, Minnesota, 55404, United States|Mayo Clinic - Rochester, Rochester, Minnesota, 55905, United States|Mercy Clinic Cancer & Hematology, Springfield, Missouri, 65804, United States|Nebraska Methodist Estabrook Cancer Center, Omaha, Nebraska, 68114, United States|Northwell Health, Lake Success, New York, 11042, United States|NYU Winthrop Hospital, Mineola, New York, 11501, United States|NYU Langone Medical Center, New York, New York, 10016, United States|Columbia University Medical Center, New York, New York, 10032, United States|Levine Cancer Institute, Charlotte, North Carolina, 28204, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, 18103, United States|Sarah Cannon Research Institute / Tennessee Oncology, Nashville, Tennessee, 37203, United States|Texas Oncology - South Austin, Austin, Texas, 78745, United States|UT Health East Texas HOPE Cancer Center, Tyler, Texas, 75701, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, 22031, United States|Northwest Cancer Specialists - Vancouver, Vancouver, Washington, 98684, United States|St George Hospital, Kogarah, New South Wales, 2217, Australia|Box Hill Hospital, Box Hill, Victoria, 3128, Australia|Peter MacCallum Cancer Center, Melbourne, Victoria, 3000, Australia|Kepler UniversitÃ¤tskliniken GmbH - Med Campus III, Linz, 4020, Austria|Ordensklinikum Linz Elisabethinen, Linz, 4020, Austria|Klinik Penzing, Wien, 1140, Austria|Krankenhaus Nord - Klinik Floridsdorf, Wien, 1210, Austria|Cenantron - Centro Avancado de Tratamento Oncologico, Belo Horizonte, Minas Gerais, 30130-090, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, Rio Grande Do Sul, 91350-200, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SÃ£o Paulo, 01246-000, Brazil|Shanghai Chest Hospital, Shanghai, 200030, China|CHU Angers, Angers, 49933, France|Centre LÃ©on BÃ©rard, Lyon, 69008, France|Centre Hospitalier Saint Quentin, Saint Quentin, 02321, France|Hopital d'Instruction des Armees de Begin, Saint-Mande, 94160, France|CHU Strasbourg - Nouvel Hopital Civil, Strasbourg, 67091, France|HÃ´pital d'Instruction des ArmÃ©es de Sainte Anne, Toulon, 83000, France|UniversitÃ¤tsklinikum Freiburg, Freiburg, 79106, Germany|Asklepios-Fachkliniken Muenchen-Gauting, Gauting, 82131, Germany|Krankenhaus Martha-Maria Halle-Doelau gGmbH, Halle, 06120, Germany|Pius-Hospital Oldenburg, Oldenburg, 26121, Germany|Klinikum der Univer Regenburg, Regensburg, 93053, Germany|Robert Bosch Krankenhaus, Stuttgart, 70376, Germany|MissionsÃ¤rztliche Klinik, GemeinnÃ¼tzige Gesellschaft mbH, WÃ¼rzburg, 97074, Germany|Semmelweis Egyetem X, Budapest, 1083, Hungary|Soroka Medical Center, Beer Sheva, 8410101, Israel|Rambam Health Care Campus, Haifa, 3109601, Israel|Meir Medical Center, Kfar-Saba, 4428164, Israel|Sourasky / Ichilov Hospital, Tel Aviv, 6423906, Israel|Policlinico Universitario Campus Biomedico, Roma, Lazio, 00128, Italy|Irccs Istituto Nazionale Dei Tumori (Int), Milano, Lombardia, 20133, Italy|Irccs Istituto Europeo Di Oncologia (IEO), Milano, Lombardia, 20141, Italy|A.O. Universitaria Pisana-Ospedale Cisanello, Pisa, Toscana, 56124, Italy|IOV - Istituto Oncologico Veneto - IRCCS, Padova, Veneto, 35128, Italy|National Hospital Organization Kyushu Cancer Center, Fukuoka, 811-1395, Japan|Hiroshima City Hiroshima Citizens Hospital, Hiroshima, 730-8518, Japan|Hiroshima University Hospital, Hiroshima, 734-8551, Japan|Kobe University Hospital, Hyogo, 650-0017, Japan|Hyogo Medical University Hospital, Hyogo, 663-8501, Japan|Kyoto University Hospital, Kyoto, 606-8507, Japan|Fukushima Medical University Hospital, Miyagi, 960-1295, Japan|Sendai Kousei Hospital, Miyagi, 981-0914, Japan|Okayama University Hospital, Okayama, 700-8558, Japan|Kurashiki Central Hospital, Okayama, 710-8602, Japan|Osaka City General Hospital, Osaka, 534-0021, Japan|Osaka International Cancer Institute, Osaka, 541-8567, Japan|Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, 113-8677, Japan|The Cancer Institute Hospital of JFCR, Tokyo, 135-8550, Japan|Tokyo Medical University Hospital, Tokyo, 160-0023, Japan|Kosin University Gospel Hospital, Busan, 49267, Korea, Republic of|St. Vincent's Hospital, Gyeonggi-do, 16247, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Gangnam Severance Hospital, Seoul, 06273, Korea, Republic of|Korea University Guro Hospital, Seoul, 08308, Korea, Republic of|Uniwersyteckie Centrum Kliniczne, Gda?sk, 80-214, Poland|Krakowski Szpital Specjalistyczny im sw. Jana Paw?a II, KrakÃ³w, 31-202, Poland|Narod.Inst.Onkol. im. M.Sklodowskiej - Curie-Panst.Inst.Bad, Warszawa, 02-781, Poland|FSBI Russian Oncology Research Center n.a. Blokhin of MOH RF, Moscow, Moskovskaja Oblast, 115478, Russian Federation|S-Pb clinical scientific practical center of specialized kinds of medical care (oncological), Saint-Petersburg, Sankt Petersburg, 197758, Russian Federation|Scientific Research Oncology Institute named after N.N. Petrov, St. Petersburg, Sankt Petersburg, 197758, Russian Federation|University Hospital Medical Center Bezanijska kosa, Belgrade, 11080, Serbia|University Clinic Golnik, Golnik, 4204, Slovenia|Medical Oncology Centre of Rosebank, Johannesburg, 2196, South Africa|Eugene Marais Hospital, Pretoria, South Africa|Corporacio Sanitaria Parc Tauli, Sabadell, Barcelona, 08208, Spain|Hospital Son Llatzer, Palma de Mallorca, Islas Baleares, 07198, Spain|Clinica Universitaria de Navarra, Pamplona, Navarra, 31008, Spain|Hospital de Basurto, Bilbao, Vizcaya, 48013, Spain|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital Clinico San Carlos, Madrid, 28040, Spain|Hospital Regional Universitario Carlos Haya, Malaga, 29010, Spain|Hospital Universitario Virgen Macarena, Sevilla, 41009, Spain|Hospital Clinico Universitario de Valencia, Valencia, 46010, Spain|Hospital Universitario la Fe, Valencia, 46026, Spain|Lungmedicinska kliniken, Centrum fÃ¶r kirurgi, ortopedi och cancervÃ¥rd, Universitetssjukhuset, LinkÃ¶ping, 58185, Sweden|Uni Hospital in Lund, Lund, 22185, Sweden|Karolinska Universitetssjukhuset, Solna, Solna, 171 64, Sweden|Uppsala University Hospital, Uppsala, SE-75185, Sweden|CHUV, Lausanne, 1011, Switzerland|UniversitÃ¤tsSpital ZÃ¼rich, ZÃ¼rich, 8091, Switzerland|Taichung Veterans General Hospital, Xitun Dist., 40705, Taiwan|Chulalongkorn Hospital, Bangkok, 10330, Thailand|Maharaj Nakorn Chiang Mai Hospital, ChiangMai, 50200, Thailand|Chemotherapy SI Dnipropetrovsk MA of MOHU, Dnipropetrovsk, 49102, Ukraine|Queen Elizabeth Hospital, Birmingham, B15 2TH, United Kingdom|Barts and the London NHS Trust., London, EC1A 7BE, United Kingdom|The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, CH63 4JY, United Kingdom",
NCT06564844,"A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features",https://clinicaltrials.gov/study/NCT06564844,TROPION-Lung12,RECRUITING,"This is a Phase III, randomised, open-label, multicentre, global study assessing the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig compared with SoC, after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponsor-designated ctDNA assay, or have at least one high-risk pathological feature.",NO,Non-small Cell Lung Cancer,DRUG: Datopotamab Deruxtecan|DRUG: Rilvegostomig|DRUG: Carboplatin|DRUG: Cisplatin|DRUG: Etoposide|DRUG: Pemetrexed|DRUG: Vinorelbine|DRUG: UFT,"Disease-Free Survival (DFS) using BICR in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoC, The analysis will include all randomised participants as randomised. All events will be included, regardless of whether the participant withdraws from randomised therapy or receives another anti-cancer therapy.

The measure of interest is the HR of DFS.

Descriptive analyses of Dato-DXd in combination with rilvegostomig versus rilvegostomig monotherapy and rilvegostomig monotherapy versus SoC will be performed to assess contribution of components., From date of randomisation up to approximately 10 years.","Overall Survival (OS) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoC, The analysis will include all randomised participants as randomised. All deaths will be included, regardless of whether the participant withdraws from therapy or receives another anti-cancer therapy.

The measure of interest is the HR of OS.

Descriptive analyses of Dato-DXd in combination with rilvegostomig versus rilvegostomig monotherapy and rilvegostomig monotherapy versus SoC will be performed to assess contribution of components., From date of randomisation up to approximately 10 years.|Participant-reported physical function in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoC, The analysis will include all randomised participants as randomised. The physical function will be measured by the PROMIS SF PF 8c. Data from PROMIS SF PF 8c will capture participants' perceived ability to perform specific activities from daily life and will be scored on a 5-point rating scale.

The measure of interest will be the between treatment group difference in adjusted mean in physical function scores.

Descriptive analyses of Dato-DXd in combination with rilvegostomig versus rilvegostomig monotherapy and rilvegostomig monotherapy versus SoC will be performed to assess contribution of components., Measured at weeks 12, 24 and 48.|Participant-reported GHS/QoL in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoC, The analysis will include all randomised participants as randomised. The GHS/QoL scores will be measured by the GHS/QoL scale from EORTC IL172.

The measure of interest will be the between treatment group difference in adjusted mean in GHS/QoL scores.

Descriptive analyses of Dato-DXd in combination with rilvegostomig versus rilvegostomig monotherapy and rilvegostomig monotherapy versus SoC will be performed to assess contribution of components., Measured at weeks 12, 24 and 48.|Pharmacokinetics (PK), Concentration of Dato-DXd, total anti-TROP2 antibody, and MAAA-1181a (payload deruxtecan) in plasma or serum., Up to 30 or 90 days post-last dose of study intervention.|Pharmacokinetics (PK), Concentration of rilvegostomig in plasma or serum., Up to 30 or 90 days post-last dose of study intervention.|Pharmacokinetics (PK), PK parameters (peak and through concentrations)., Up to 30 or 90 days post-last dose of study intervention.|Immunogenicity, Presence of ADAs for Dato-DXd and rilvegostomig (confirmatory results: titres and neutralising antibodies for confirmed positive samples)., Up to 30 or 90 days post-last dose of study intervention.",,AstraZeneca,Daiichi Sankyo,ALL,"ADULT, OLDER_ADULT",PHASE3,660,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2024-10-15,2033-05-19,2035-01-19,2024-08-21,,2025-05-09,"Research Site, Gilbert, Arizona, 85234, United States|Research Site, Phoenix, Arizona, 85054, United States|Research Site, Tucson, Arizona, 85710, United States|Research Site, Tucson, Arizona, 85719, United States|Research Site, Duarte, California, 91010, United States|Research Site, Fountain Valley, California, 92708, United States|Research Site, Glendale, California, 91204, United States|Research Site, Los Angeles, California, 90089, United States|Research Site, Los Angeles, California, 90095, United States|Research Site, Newport Beach, California, 92663, United States|Research Site, Orange, California, 92868, United States|Research Site, San Diego, California, 92123, United States|Research Site, Santa Barbara, California, 93105, United States|Research Site, Aurora, Colorado, 80045, United States|Research Site, Lone Tree, Colorado, 80124, United States|Research Site, Newark, Delaware, 19713, United States|Research Site, Washington, District of Columbia, 20007, United States|Research Site, Washington, District of Columbia, 20422, United States|Research Site, Clermont, Florida, 34711, United States|Research Site, Fort Myers, Florida, 33901, United States|Research Site, Jacksonville, Florida, 32224, United States|Research Site, Miami Beach, Florida, 33140, United States|Research Site, Miami, Florida, 33136, United States|Research Site, Orange City, Florida, 32763, United States|Research Site, Orlando, Florida, 32803, United States|Research Site, Saint Petersburg, Florida, 33705, United States|Research Site, Saint Petersburg, Florida, 33709, United States|Research Site, West Palm Beach, Florida, 33401, United States|Research Site, Boise, Idaho, 83702, United States|Research Site, Chicago, Illinois, 60637, United States|Research Site, Evanston, Illinois, 60201, United States|Research Site, Zion, Illinois, 60099, United States|Research Site, Fort Wayne, Indiana, 46804, United States|Research Site, Kansas City, Kansas, 66160, United States|Research Site, Lexington, Kentucky, 40503, United States|Research Site, Annapolis, Maryland, 21401, United States|Research Site, Baltimore, Maryland, 21201, United States|Research Site, Baltimore, Maryland, 21202, United States|Research Site, Baltimore, Maryland, 21231, United States|Research Site, Frederick, Maryland, 21702, United States|Research Site, Silver Spring, Maryland, 20902, United States|Research Site, Boston, Massachusetts, 02111, United States|Research Site, Boston, Massachusetts, 02114, United States|Research Site, Boston, Massachusetts, 02115, United States|Research Site, Worcester, Massachusetts, 01655, United States|Research Site, Ann Arbor, Michigan, 48109, United States|Research Site, Dearborn, Michigan, 48126, United States|Research Site, Detroit, Michigan, 48202, United States|Research Site, Farmington Hills, Michigan, 48334, United States|Research Site, Grand Rapids, Michigan, 49503, United States|Research Site, Ypsilanti, Michigan, 48197, United States|Research Site, Duluth, Minnesota, 55805, United States|Research Site, Minneapolis, Minnesota, 55407, United States|Research Site, Rochester, Minnesota, 55905, United States|Research Site, Saint Louis, Missouri, 63110, United States|Research Site, Billings, Montana, 59102, United States|Research Site, Omaha, Nebraska, 68105, United States|Research Site, Omaha, Nebraska, 68130, United States|Research Site, Las Vegas, Nevada, 89102, United States|Research Site, Camden, New Jersey, 08103, United States|Research Site, Bronx, New York, 10467, United States|Research Site, East Syracuse, New York, 13057, United States|Research Site, Mineola, New York, 11501, United States|Research Site, New York, New York, 10016, United States|Research Site, New York, New York, 10065, United States|Research Site, New York, New York, 10065, United States|Research Site, Durham, North Carolina, 27710, United States|Research Site, Cincinnati, Ohio, 45219, United States|Research Site, Cincinnati, Ohio, 45245, United States|Research Site, Cleveland, Ohio, 44106, United States|Research Site, Cleveland, Ohio, 44111, United States|Research Site, Cleveland, Ohio, 44124, United States|Research Site, Cleveland, Ohio, 44195, United States|Research Site, Independence, Ohio, 44131, United States|Research Site, Portland, Oregon, 97213, United States|Research Site, Portland, Oregon, 97239, United States|Research Site, Bethlehem, Pennsylvania, 18015, United States|Research Site, Philadelphia, Pennsylvania, 19107, United States|Research Site, Pittsburgh, Pennsylvania, 15212, United States|Research Site, Pittsburgh, Pennsylvania, 15213, United States|Research Site, Knoxville, Tennessee, 37920, United States|Research Site, Memphis, Tennessee, 38120, United States|Research Site, Nashville, Tennessee, 37203, United States|Research Site, Austin, Texas, 78745, United States|Research Site, Dallas, Texas, 75204, United States|Research Site, Dallas, Texas, 75231, United States|Research Site, Dallas, Texas, 75390, United States|Research Site, Houston, Texas, 77030, United States|Research Site, Houston, Texas, 77090, United States|Research Site, San Antonio, Texas, 78217, United States|Research Site, Webster, Texas, 77598, United States|Research Site, Salt Lake City, Utah, 84132, United States|Research Site, Fairfax, Virginia, 22031, United States|Research Site, Fairfax, Virginia, 22031, United States|Research Site, Norfolk, Virginia, 23502, United States|Research Site, Seattle, Washington, 98108, United States|Research Site, Seattle, Washington, 98109, United States|Research Site, Seattle, Washington, 98122, United States|Research Site, Silverdale, Washington, 98383, United States|Research Site, Vancouver, Washington, 98684, United States|Research Site, Madison, Wisconsin, 53792, United States|Research Site, Edegem, 2650, Belgium|Research Site, Hasselt, 3500, Belgium|Research Site, Barretos, 14784-057, Brazil|Research Site, BrasÃ­lia, 70200-730, Brazil|Research Site, FlorianÃ³polis, 88034-000, Brazil|Research Site, Sao Paulo, 01323-903, Brazil|Research Site, Teresina, 64049-200, Brazil|Research Site, St. John's, Newfoundland and Labrador, A1B 3V6, Canada|Research Site, Halifax, Nova Scotia, B3H 2Y9, Canada|Research Site, Newmarket, Ontario, L3Y 2R2, Canada|Research Site, Oshawa, Ontario, L1G 2B9, Canada|Research Site, Greenfield Park, Quebec, J4V 2H1, Canada|Research Site, Montreal, Quebec, H2X 3J4, Canada|Research Site, Angers, 49933, France|Research Site, Marseille, 13915, France|Research Site, Paris Cedex 5, 75248, France|Research Site, Rouen, 76031, France|Research Site, Suresnes, 92150, France|Research Site, Toulon, 83000, France|Research Site, Bonn, 53127, Germany|Research Site, Erfurt, 99089, Germany|Research Site, Essen, 45239, Germany|Research Site, Esslingen, 73730, Germany|Research Site, Gauting, 82131, Germany|Research Site, GeorgsmarienhÃ¼tte, 49124, Germany|Research Site, Gera, 07548, Germany|Research Site, Giessen, 35392, Germany|Research Site, Karlsruhe, 76137, Germany|Research Site, Kempten, 87439, Germany|Research Site, Luebeck, 23538, Germany|Research Site, MÃ¼nster, 48163, Germany|Research Site, WÃ¼rzburg, 97067, Germany|Research Site, Hong Kong, 999077, Hong Kong|Research Site, Budapest, 1033, Hungary|Research Site, Budapest, 1083, Hungary|Research Site, Budapest, 1121, Hungary|Research Site, Budapest, 1122, Hungary|Research Site, Debrecen, 4032, Hungary|Research Site, PÃ©cs, 7624, Hungary|Research Site, TÃ¶rÃ¶kbÃ¡lint, 2045, Hungary|Research Site, Zalaegerszeg, 8000, Hungary|Research Site, Firenze, 50134, Italy|Research Site, Monza, 20090, Italy|Research Site, Padova, 35128, Italy|Research Site, Roma, 00144, Italy|Research Site, Roma, 00168, Italy|Research Site, Rozzano, 20089, Italy|Research Site, Bunkyo-ku, 113-8603, Japan|Research Site, Chiba-shi, 260-0877, Japan|Research Site, Chuo-ku, 104-0045, Japan|Research Site, Fukuoka-shi, 812-8582, Japan|Research Site, Hidaka-shi, 350-1298, Japan|Research Site, Hiroshima-shi, 730-8518, Japan|Research Site, Hiroshima-shi, 734-8551, Japan|Research Site, Iwakuni-shi, 740-8510, Japan|Research Site, Kashiwa, 277-8577, Japan|Research Site, Kitaadachi-gun, 362-0806, Japan|Research Site, Kobe-shi, 650-0017, Japan|Research Site, Koto-ku, 135-8550, Japan|Research Site, Kumamoto-shi, 860-8556, Japan|Research Site, Nagoya-shi, 464-8681, Japan|Research Site, Niigata-shi, 951-8566, Japan|Research Site, Osakasayama-shi, 589-8511, Japan|Research Site, Sapporo-shi, 003-0804, Japan|Research Site, Sendai-shi, 980-0873, Japan|Research Site, Sendai-shi, 980-8574, Japan|Research Site, Wakayama-shi, 641-8510, Japan|Research Site, Yokohama-shi, 241-8515, Japan|Research Site, Incheon, 21565, Korea, Republic of|Research Site, Seoul, 03722, Korea, Republic of|Research Site, Seoul, 05505, Korea, Republic of|Research Site, Seoul, 06351, Korea, Republic of|Research Site, Suwon, 16247, Korea, Republic of|Research Site, George Town, 10450, Malaysia|Research Site, Kuala Lumpur, 50586, Malaysia|Research Site, Kuala Lumpur, 59100, Malaysia|Research Site, Kuala Lumpur, 59100, Malaysia|Research Site, Kuching, 93586, Malaysia|Research Site, Selangor, 62250, Malaysia|Research Site, Rotterdam, 3015 GD, Netherlands|Research Site, Olsztyn, 10-357, Poland|Research Site, PoznaÅ, 60-569, Poland|Research Site, Warszawa, 01-138, Poland|Research Site, Alicante, 03010, Spain|Research Site, Badalona, 08003, Spain|Research Site, Barcelona, 8035, Spain|Research Site, Madrid, 28040, Spain|Research Site, Malaga, 29004, Spain|Research Site, Zaragoza, 50009, Spain|Research Site, Solna, 171 76, Sweden|Research Site, Zurich, 8091, Switzerland|Research Site, Kaohsiung, 80756, Taiwan|Research Site, Taipei, 10002, Taiwan|Research Site, Taipei, 112, Taiwan|Research Site, Taipei, 114, Taiwan|Research Site, Taoyuan, 333, Taiwan|Research Site, Bangkoknoi, 10700, Thailand|Research Site, Bangkok, 10400, Thailand|Research Site, Banphaeo, 74120, Thailand|Research Site, Dusit, 10300, Thailand|Research Site, Hat Yai, 90110, Thailand|Research Site, Muang, 40002, Thailand|Research Site, Muang, 50200, Thailand|Research Site, Ratchathewi, 10400, Thailand|Research Site, Ankara, 06010, Turkey|Research Site, Ankara, 06280, Turkey|Research Site, Istanbul, 34214, Turkey|Research Site, Mersin, 33240, Turkey|Research Site, Leeds, LS9 7TF, United Kingdom|Research Site, London, SE1 9RT, United Kingdom|Research Site, Nottingham, NG5 1PB, United Kingdom|Research Site, Da Nang, 550000, Vietnam|Research Site, Ha noi, 100000, Vietnam|Research Site, Hanoi, 100000, Vietnam|Research Site, Ho Chi Minh, 700000, Vietnam|Research Site, Ho Chi Minh, 70000, Vietnam|Research Site, Vinh, 460000, Vietnam",
NCT06072131,To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL,https://clinicaltrials.gov/study/NCT06072131,CRESCENDO,RECRUITING,"Part 1: This is a 5 Arm study primarily to determine the best dose out of the two dose levels of Belinostat and Pralatrexate combined with CHOP/COP in newly diagnosed PTCL patients based on Safety for part 2 study.

Part 2 (Efficacy and Safety): This is a 3 Arm study. Patients with previously untreated PTCL will be randomized 1:1:1 into 1 of 3 treatment groups: 2 experimental treatment groups (Bel-CHOP or Fol-COP) or 1 active comparator treatment group (CHOP). Patients will be treated for up to 6 cycles. The primary objective is to compare the Progression Free Survival of patients with newly diagnosed PTCL treated for up to 6 cycles with Beleodaq (belinostat) in combination with CHOP (Bel-CHOP) or Folotyn (pralatrexate injection) in combination with COP (Fol-COP) to CHOP alone.",NO,Peripheral T Cell Lymphoma,DRUG: Belinostat Injection|DRUG: Pralatrexate Injection|DRUG: CHOP|DRUG: COP,"PFS, Progression-free survival is determined from randomization to the first documented Progression of Disease or death, whichever occurs first., 4.5 years","Overall survival, It is the time from randomization to the death, 8 years",,Acrotech Biopharma Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE3,504,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-10-04,2030-07,2030-11,2023-10-10,,2025-06-04,"University of California, San Francisco Fresno, Clovis, California, 93611, United States|University of California, Los Angeles Hem/ Onc Clinical Research Unit, Suite 600, Santa Monica, California, 90404, United States|Moffitt Malignant Hematology &amp; Cellular Therapy at Memorial Healthcare System Memorial Cancer Institute, Pembroke Pines, Florida, 33026, United States|Norton Cancer Institute, Louisville, Kentucky, 40207, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, 08901, United States|University of Texas, MD Anderson Cancer Center, Houston, Texas, 77030, United States|Baylor Scott & White Medical Center - Temple, Temple, Texas, 76508, United States|The Ottawa Hospital, Ottawa, Ontario, K1H 8L6, Canada|Princess Margaret Hospital, Toronto, Ontario, M5G 2C4, Canada|Universitaetsklinikum Halle (Saale), Halle, 06120, Germany|University of Debrecen Clinical Center, Debrecen, Nagyerdei Krt. 98, 4032, Hungary|Andras Josa University Teaching Hospital, NyÃ­regyhÃ¡za, Szent Istvan Utca, 68, Hungary|Semmelweis Egyetem, Budapest, 1088, Hungary|National Institute of Oncology, Budapest, 1122, Hungary|Markhot Ferenc Oktato Korhaz, Eger, 3300, Hungary|Belgyogyaszati Klinika es Kardiologiai Kozpont, Szeged, 6725, Hungary|University of Milano Bicocca, Milano, Bicocca, 20126, Italy|Servizio Sanitario Regionale Emilia-Romagna-Istituto Scientifico Romagnolo per lo Studio dei Tumori ""Dino Amadori"" Srl (IRST), Meldola, Province Of ForlÃ¬-Cesena, 47014, Italy|Azienda Ospedaliera Cardinale Giovanni Panico, Tricase, Puglia, 73039, Italy|Policlinico GB Rossi Borgo Roma, Borgo Roma, Verona, 37134, Italy|Ospedale Policlinico San Martino, IRCCS, Genova, 16132, Italy|Azienda Ospedaliera Universitaria di Parma, Parma, 43126, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, 27100, Italy|Azienda USL di Ravenna, Ravenna, 41800, Italy|Inje University Busan Paik Hospital, Busan, Busanjin District, Korea, Republic of|Ulsan University Hospital, Ulsan, Dong-gu, Korea, Republic of|Ajou University Hospital, Suwon-si, Gyenoggi-do, 16499, Korea, Republic of|The Catholic University of Korea - St. Vincents Hospital, Suwon-si, Gyeonggi-do, Korea, Republic of|Gyeongsang National University Hospital, Jinju-si, Gyeongsangnam-do, Korea, Republic of|Jeonbuk National University Hospital, Jeonju, Jeollabuk-do, Korea, Republic of|Yeungnam University Medical Center, Daegu, Nam-gu, Korea, Republic of|Asan Medical Center, Songpa-dong, Seoul, 05505, Korea, Republic of|Daegu Catholic University Medical Center, Daegu, 42472, Korea, Republic of|Samsung Medical Center, Seoul, 6351, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Pratia MCM Krakow, Krakow, 30-727, Poland|Hospital Universitario Basurto, Bilbao, Bizkaia, 48013, Spain|Hospital Universitario FundaciÃ³n JimÃ©nez DÃ­az, Moncloa-Aravaca, Madrid, 28040, Spain|Hospital Universitario de Navarra, Pamplona, Navarra, 31008, Spain|Hospital del Mar Medical Research Institute, Barcelona, 08003, Spain|Clinica Universidad de Navarra - Madrid, Madrid, 28027, Spain|Clinica Universidad de Navarra, Pamplona, 31008, Spain|Hospital Universitario de Salamanca, Salamanca, 37007, Spain|Hospital Universitario y Politecnico La Fe, Valencia, 46026, Spain|Hospital Universitario Miguel Servet, Zaragoza, 50009, Spain|Changhua Christian Hospital CCH, Changhua City, Changhua County, Taiwan|Hualien Tzu Chi Medical Center, Hualien City, Hualien, 970, Taiwan|National Cheng Kung University Hospital NCKUH, Tainan City, Southern Taiwan, 704, Taiwan|Chang Bing Show Chwan Memorial Hospital, Changhua, 505, Taiwan|Hematology Oncology Taipei Medical University - Shuang-Ho Hospital, New Taipei City, Taiwan|Chang Gung Memorial Hospital Linkou Branch, Taoyuan, 333, Taiwan|Gazi University Faculty of Medicine, Yenimahalle, Ankara, 06560, Turkey|VKV AMERICAN HOSPITAL, Medical Oncology Outpatient Clinic, ÅiÅli, Istanbul, 34365, Turkey|Adana City Education and Research Hospital, Adana, 4522, Turkey",
NCT06363994,A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL,https://clinicaltrials.gov/study/NCT06363994,,RECRUITING,Compare the efficacy and safety of Orelabrutinib plus bendamustine+ rituximab versus bendamustine + rituximab in previously untreated patients with mantle cell lymphoma (MCL),NO,Mantle Cell Lymphoma,DRUG: Orelabrutinib|DRUG: Bendamustine Injection|DRUG: Rituximab|DRUG: Orelabrutinib Placebo,"Dose-limiting toxicity (DLT), 28 days|Progression-free Survival (PFS) for Arm A vs. Arm B, Approximately 7 years",,,InnoCare Pharma Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE3,476,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-05-29,2031-06-25,2032-06-25,2024-04-12,,2024-12-27,"Beijing Cancer Hospital, Beijing, China|Peking University Third Hospital, Beijing, China|The First Affiliated Hospital of Bengbu Medical University, Bengbu, China|First Hospital of Jilin University, Changchun, China|Hunan Cancer Hospital, Changsha, China|The First People's Hospital of Changzhou, Changzhou, China|Sichuan Provincial People's Hospital, Chengdu, China|West China Hospital of Sichuan University, Chengdu, China|Chongqinq Cancer Hospital, Chongqing, China|The First Affiliated Hospital of Chongqing Medical University, Chongqing, China|The second Hospital of Dalian Medical University, Dalian, China|Fujing Cancer Hospital, Fuzhou, China|Union Hospital Affiliated to Fujian Medical University, Fuzhou, China|Guangdong Provincial People's Hospital, Guangzhou, China|Sun Yat-sen University Cancer Center, Guangzhou, China|The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China|Zhejiang University Medical School affiliated to the first Hospital, Hangzhou, China|The First Affiliated Hospital of Anhui Medical University, Hefei, China|Shandong Provincial Hospital, Jinan,, China|Cancer Hospital of Shandong First Medical University, Jinan, China|The First Affiliated Hospital of Ningbo University, Jinan, China|The First Affiliated Hospital of Henan University of Science & Technology, Luoyang, China|The First Affiliated Hospital of Nanchang University, Nanchang, China|Nanjing Drum Tower Hospital Affiliated to Medical School of Nanjing University, Nanjing, China|Cancer Hospital Affiliated to Fudan University, Shanghai, China|Huashan Hospital of Fudan University, Shanghai, China|Shengjing Hospital of China Medical University, Shenyang, China|The First Affiliated Hospital of China Medical University, Shenyang, China|The Fourth Hospital of Hebei Medical University, Shijiazhuang, China|Shanxi Cancer Hospital, Taiyuan, China|Tianjin Cancer Hospital, Tianjin, China|Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and, Wuhan, China|Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and, Wuhan, China|The Tumor Hospital Affiliated to Xinjiang Medical University, Wulumuqi, China|The First Affiliated Hospital of the PLA Air Force Military Medical University (Xijing Hospital), Xi'an, China|The Second Affiliated Hospital Of Xi'an Jiaotong University, Xi'an, China|Yibin Second People's Hospital, Yibin, China|Henan Cancer Hospital, Zhengzhou, China|Henan Provincial People's Hospital, Zhengzhou, China",
NCT05155254,IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18),https://clinicaltrials.gov/study/NCT05155254,,ACTIVE_NOT_RECRUITING,"Phase 3, multicenter, international, open-label, randomized, 2-arm trial investigating the safety and efficacy of IO102-IO103 in combination with pembrolizumab as first-line treatment for patients with previously untreated unresectable or metastatic (advanced) melanoma.

Patients will be stratified on the basis of the following factors; Disease stage: Stage III (unresectable) and IV M1a-b versus stage IV M1c-d and BRAFV600 mutation status: mutated vs wild type.

All patients will receive pembrolizumab 200 mg intravenously every 3 weeks for a maximum of 35 cycles (up to 2 years treatment). Patients randomized to IO102-IO103 dual-antigen, immunotherapeutic arm will also be given IO102-IO103 Q3W with an additional dose given during the induction period on Day 8 of cycles 1 and 2. IO102 IO103 will thereafter be administered subcutaneous every 3 weeks during the maintenance period. Each patient can be treated for a maximum of 37 administrations in total (up to 2 years of treatment).

The primary objective is to investigate the efficacy of IO102-IO103 in combination with pembrolizumab (compared with pembrolizumab alone) in terms of progression free survival.",NO,Metastatic Melanoma|Unresectable Melanoma,DRUG: IO102-IO103|DRUG: Pembrolizumab,"Progression Free Survival (PFS), PFS defined as the time from randomization to the first documented disease progression ((based on Independent Review Committee in accordance with RECIST v1.1) or death from any cause., Approximately 3.5 years","Overall Response Rate (ORR), ORR defined as the percentage of patients achieving a confirmed PR or CR. ORR will be determined by an IRC in accordance with RECIST v1.1., Approximately 2.5 years|Overall survival (OS), OS defined as the time from randomisation until death from any cause. months. This will be determined by an IRC in accordance with RECIST v1.1., Approximately 5.5 years|Durable Objective response rate (DRR), DRR is defined as the percentage of patients achieving a PR or CR \> 6 months. This will be determined by an IRC in accordance with RECIST v1.1., Approximately 3.5 years|Complete response rate (CRR), Percentage of patients with a visit response of CR, which will be determined by the IRC in accordance with RECIST v1.1., Approximately 3.5 years|Duration of response (DoR), DoR will be measured from the date of first observed objective response until disease progression or death (whichever is earlier) (based on IRC)., Approximately 3.5 years|Time to response (TTR), TTR is defined as the time from the date of randomization to the date of first observed PR or CR (based on IRC)., Approximately 3.5 years|Time to complete response (TTCR), TTCR is defined as the time from the date of randomization to the date of first observed CR (based on IRC)., Approximately 3.5 years|Disease control rate (DCR), DCR is defined as the percentage of patients achieving a PR or CR or SD (based on IRC)., Approximately 3.5 years|Incidence of e.g. AEs and SAEs (Safety and Tolerability), Incidence of AEs and SAEs, and treatment related AEs and SAEs. Incidence of AEs causing discontinuation of trial treatment., Approximately 3.5 years",,IO Biotech,Syneos Health|Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE3,407,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-05-17,2025-07,2027-09,2021-12-13,,2024-01-09,"Mid Florida Hematology and Oncology Center, Orange City, Florida, 32763, United States|Orlando Health Cancer Institute, Orlando, Florida, 32806, United States|Roswell Park Cancer Institute, Buffalo, New York, 14221, United States|VCU Massey Cancer Center, Richmond, Virginia, 23219, United States|Border Medical Oncology Research Unit, Albury, New South Wales, 2640, Australia|Westmead Hospital, Westmead, New South Wales, 2145, Australia|Southern Medical Day Care Centre, Wollongong, New South Wales, 2500, Australia|Cairns Hospital, Cairns, Queensland, 4870, Australia|Flinders Medical Centre, Bedford Park, South Australia, 5042, Australia|The Queen Elizabeth Hospital, Woodville South, South Australia, 5011, Australia|Sunshine Coast University Hospital, Birtinya, 4575, Australia|Peter MacCallum Cancer Centre PMCC - East Melbourne, Melbourne, 3052, Australia|Universitair Ziekenhuis Gent UZ Gent, Gent, Oost-Vlaanderen, 9000, Belgium|AZ Nikolaas, Sint-Niklaas, 9100, Belgium|FNHK Klinika onkologie a radioterapie, Hradec KrÃ¡lovÃ©, 500 05, Czechia|Fakultni Nemocnice Olomouc, Olomouc, 779 00, Czechia|FN Ostrava, Ostrava, 708 52, Czechia|FNKV Department of Dermatology, Praha, 10034, Czechia|Aalborg University Hospital, Aalborg, 9000, Denmark|Aarhus University Hospital, Aarhus, 8200, Denmark|Herlev og Gentofte Hospital, Herlev, 2730, Denmark|Odense University Hospital, Odense, 5000, Denmark|Centre Hospitalier Universitaire de BesanÃ§on Jean Minjoz, Besancon, 25000, France|Centre Hospitalier Universitaire de Bordeaux Hospital Saint Andre, Bordeaux, 33075, France|Hopital Ambroise, Boulogne Billancourt, 92100, France|Centre Georges Francois Leclerc, Dijon, 21079, France|Chu Grenoble - Hopital Albert Michallon, La Tronche, 38700, France|Centre Hospitalier Universitaire de Lille, Lille, 59000, France|HÃ´pital de La Timone, Marseille cedex 05, 13385, France|CHU de Nice Hpital de lArchet 2, Nice, 6200, France|Centre Hospitalier Lyon Sud, Pierre Benite, 69495, France|Centre Eugene Marquis, Rennes Cedex, 35042, France|Institut de CancÃ©rologie de L'Ouest, Saint Herblain, 44805, France|Centre Hospitalier de Valence (CHV), Valence, 26 953, France|Gustave Roussy, Villejuif Cedex, 94805, France|Universitatsklinikum Augsburg Medizincampus Sued, Augsburg, 86179, Germany|Charite Universitaetsmedizin Berlin, Berlin, 13353, Germany|St. Josef Hospital - Ruhr-Universitt Bochum, Bochum, 44791, Germany|University Hospital Erlangen, Erlangen, 90054, Germany|Universitaetsklinikum Essen, Essen, 45147, Germany|University Hospital Frankfurt Theodor-Stern-Kai, Frankfurt, 60590, Germany|Universitatsklinik fur Dermatologie und Venerologie der MLU Halle-Wittenberg, Halle (Saale), 6120, Germany|Elbe Klinikum Buxtehude, Hamburg, 22045, Germany|Nationales Centrum fr Tumorerkrankungen NCT, Heidelberg, 69120, Germany|SLK-Kliniken Heilbronn GmbH, Heilbronn, 74078, Germany|Universitaetsklinikum Schleswig-Holstein, Kiel, 24105, Germany|Department of Dermatology University of Mainz, Mainz, 55131, Germany|Universitatsmedizin Mannheim Dermatologie, Mannheim, 68167, Germany|MÃ¼hlenkreiskliniken AÃ¶R, University Hospital Ruhr University Bochum Campus Minden, Minden, 32429, Germany|LMU Muenchen, Muenchen, 80337, Germany|Universitaetsklinikum Muenster, MÃ¼nster, 48149, Germany|Hospital Tubingen, Tubingen, 72076, Germany|Universittsklinikum Wuerzburg, Wuerzburg, 97080, Germany|Orszagos Onkologiai Intezet, Budapest, 1122, Hungary|Bor, -Nemikortani es Onkodermatologiai Klinika, Pecs, 7632, Hungary|Hetenyi G Korhaz, Onkologiai Kozpont, Szolnok, 5000, Hungary|Emek Medical Center, Afula, Israel|Ben-Gurion University of the Negev - Soroka University Medical Center - Soroka Clinical Research Center, Beer Sheva, 84101, Israel|Hadassah University Hospital, Jerusalem, 91120, Israel|Rabin Medical Center, Petah Tikva, 4941492, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv-Yafo, Israel|The Chaim Sheba Medical Center - The Ella Lemelbaum Institute for Immuno-Oncology, Tel Hashomer, 5262100, Israel|Clinica Oncologica, AOU Riuniti ancona, Ancona, 60126, Italy|Centro di Riferimento Oncologico, Aviano, 33081, Italy|Istituto Tumori Giovanni Paolo II IRCCS Ospedale Oncologico Bari, Bari, 70124, Italy|IRCCS Ospedale San Raffaele, Candiolo, 10060, Italy|IRCCS Ospedale Policlinico San Martino, Genova, 16132, Italy|Istituto Romagnolo per lo Studio dei Tumori "" DINO AMADORI"", Meldola, 47014, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, 20133, Italy|Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, 80131, Italy|Veneto Oncology Institute, Padova, 35128, Italy|Ospedale S. Maria della Misericordia, Perugia, 6156, Italy|IRCCS Istituti Fisioterapici Ospitalieri, Roma, 144, Italy|Idi-Irccs, Rome, 00167, Italy|Azienda Ospedaliera Universitaria Senese Policlinico Le Scotte, Siena, 53100, Italy|The Netherlands Cancer Institute, Amsterdam, 1066, Netherlands|AMC Amsterdam, locatie VUMC, Amsterdam, 1081, Netherlands|LUMC, Leiden, 2300 RC, Netherlands|UMC Maastricht, Maastricht, 6229HX, Netherlands|Erasmus MC, Rotterdam, 1054 ZG, Netherlands|University Medical Center Utrecht, Utrecht, 3584, Netherlands|Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Masovian, 02-781, Poland|Szpital Kliniczny im. Heliodora ÅwiÄcickiego UM w Poznaniu, Poznan, 60-780, Poland|Cape Town Oncology Trials (Pty) Ltd., Cape Town, 7570, South Africa|Mary Potter Oncology Centre Groenkloof, Pretoria, 0181, South Africa|Hospital Universitario Virgen Macarena, Seville, Andalusia, 41009, Spain|CH Universitario de A CoruÃ±a (CHUAC), A CoruÃ±a, 15006, Spain|Hospital Clinic i Provincial, Barcelona, 08036, Spain|Instituto Oncologico Dr. Rosell IOR - Hospital Universitari Quiron Dexeus, Barcelona, 8028, Spain|Hospital Universitari Germans Trias i Pujol HUGTP, ICO-Badalona, Barcelona, 8916, Spain|Hospital Vall d'hebron, Barcelona, Spain|Hospital General Universitario Gregorio MaraÃÂ±on, Madrid, 28007, Spain|Clinica Universidad de Navarra, Madrid, 28027, Spain|Hospital Universitario Ramon y Cajal, Madrid, 28034, Spain|Hospital Universitario HM Sanchinarro, Madrid, 28050, Spain|Hospital Regional Universitario de Malaga, Malaga, 29010, Spain|Hospital Universitario Central de Asturias (HUCA), Oviedo, 33011, Spain|Clinica Universidad de Navarra, Pamplona, 31008, Spain|Hospital General Universitario de Valencia, Valencia, 46014, Spain|Hospital Universitari i Politecnic La Fe, Valencia, 46026, Spain|Miguel Servet University Hospital, Zaragoza, 50009, Spain|Adana City Education and Research Hospital, Adana, 1060, Turkey|Gulhane School of Medicine, Ankara, 6010, Turkey|Memorial Ankara Hospital, Ankara, 6520, Turkey|Akdeniz University Medical Faculty, Antalya, 7059, Turkey|Ege university Faculty of Medicine, T. Aktas Oncology Hospital, Bornova, Bornova, 35100, Turkey|Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Istanbul, 34098, Turkey|Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi, Istanbul, 34722, Turkey|Guy's Hospital, London, SE1 9RT, United Kingdom|Christie Hospital NHS Trust, Manchester, M20 4BX, United Kingdom|Christie Hospital NHS Trust, Manchester, M20 4XB, United Kingdom|Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE, United Kingdom",
NCT06312176,A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010),https://clinicaltrials.gov/study/NCT06312176,,RECRUITING,"The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unresectable locally advanced, or metastatic, breast cancer.

The primary hypotheses are that sacituzumab tirumotecan as a single agent and sacituzumab tirumotecan plus pembrolizumab are superior to TPC with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR) in all participants.",NO,Breast Neoplasms,DRUG: Sacituzumab tirumotecan|BIOLOGICAL: Pembrolizumab|DRUG: Paclitaxel|DRUG: Nab-paclitaxel|DRUG: Capecitabine|DRUG: Liposomal doxorubicin,"Progression-Free Survival (PFS) ( sacituzumab tirumotecan versus treatment of physician's choice [TPC]; pembrolizumab + sacituzumab tirumotecan versus TPC), PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as â¥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of â¥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review (BICR) will be presented., Up to ~38 months","Overall Survival (OS), OS is defined as the time from randomization to death due to any cause., Up to ~77 months|Progression-Free Survival (PFS) (pembrolizumab + sacituzumab tirumotecan + versus sacituzumab tirumotecan), PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as â¥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of â¥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review (BICR) will be presented., Up to ~57 months|Objective Response Rate (ORR), ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented., Up to ~57 months|Duration of Response (DOR), For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1), DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by Blinded Independent Central Review (BICR) will be presented., Up to ~57 months|Change from baseline in global health status/quality of life scores, on the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions ""How would you rate your overall health during the past week?"" and ""How would you rate your overall quality of life during the past week?"" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status., Baseline and up to ~77 months|Change from baseline in physical functioning score, on the EORTC QLQ-C30, The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better level of physical functioning., Baseline and up to ~77 months|Change from baseline in emotional functioning score, on the EORTC QLQ-C30, The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to questions about their emotional functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better level of emotional functioning., Baseline and up to ~77 months|Change from baseline in fatigue score, on the EORTC QLQ-C30, The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to questions about their fatigue are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better level of function., Baseline and up to ~77 months|Change from baseline in diarrhea score, on the EORTC QLQ-C30, The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to the question ""Have you had diarrhea?"" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better level of function., Baseline and up to ~77 months|Time to first Deterioration (TTD) in global health status/quality of life scores, on the EORTC QLQ-C30, The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions ""How would you rate your overall health during the past week?"" and ""How would you rate your overall quality of life during the past week?"" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status. TTD is defined as the time from baseline to the first onset of a 10-point deterioration from baseline in global health status/quality of life combined score., Up to ~77 months|TTD in physical functioning score, on the EORTC QLQ-C30, The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better level of physical functioning. TTD is defined as the time from baseline to the first onset of a 10-point deterioration from baseline in the physical functioning score., Up to ~77 months|TTD in emotional functioning score, on the EORTC QLQ-C30, The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to questions about their emotional functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better level of emotional functioning. TD is defined as the time from baseline to the first onset of a 10-point deterioration from baseline in the emotional functioning score., Up to ~77 months|TTD in fatigue score, on the EORTC QLQ-C30, The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to questions about their fatigue are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better level of function. TTD is defined as the time from baseline to the first onset of a 10-point deterioration from baseline in the fatigue score., Up to ~77 months|TTD in diarrhea score, on the EORTC QLQ-C30, The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to the question about their diarrhea are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better level of function. TTD is defined as the time from baseline to the first onset of a 10-point deterioration from baseline in the diarrhea score., Up to ~77 months|Number of participants who experience one or more adverse events (AEs), An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention., Up to ~77 months|Number of participants who discontinue study treatment due to an AE, An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention., Up to ~77 months",,Merck Sharp & Dohme LLC,,ALL,"ADULT, OLDER_ADULT",PHASE3,1200,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-04-14,2027-07-11,2031-04-12,2024-03-15,,2025-06-13,"Ironwood Cancer & Research Centers ( Site 0066), Chandler, Arizona, 85224, United States|Providence Medical Foundation-Oncology ( Site 0020), Fullerton, California, 92835, United States|Moores Cancer Center ( Site 0059), La Jolla, California, 92093-0698, United States|Cancer and Blood Specialty Clinic ( Site 0001), Los Alamitos, California, 90720, United States|Yale Cancer Center ( Site 0060), New Haven, Connecticut, 06510, United States|Stamford Hospital ( Site 0049), Stamford, Connecticut, 06904, United States|AdventHealth Altamonte Springs ( Site 0021), Altamonte Springs, Florida, 32701, United States|University of Florida College of Medicine ( Site 0063), Gainesville, Florida, 32610, United States|Orlando Health Cancer Institute ( Site 0011), Orlando, Florida, 32806, United States|Archbold Memorial Hospital-Lewis Hall Singletary Oncology Center ( Site 0032), Thomasville, Georgia, 31792, United States|University of Chicago Medical Center ( Site 0067), Chicago, Illinois, 60637, United States|Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 0053), Edgewood, Kentucky, 41017, United States|Mary Bird Perkins Cancer Center-Breast & GYN Pavilion ( Site 0042), Baton Rouge, Louisiana, 70817, United States|Greenebaum Comprehensive Cancer Center ( Site 0036), Baltimore, Maryland, 21201, United States|Mercy Medical Center - Baltimore-Medical Oncology and Hematology ( Site 0028), Baltimore, Maryland, 21202, United States|Dana-Farber Cancer Institute-Breast Oncology Center ( Site 0037), Boston, Massachusetts, 02215, United States|Washington University School of Medicine ( Site 0076), Saint Louis, Missouri, 63110, United States|Hematology Oncology Associates of Rockland ( Site 0054), Nyack, New York, 10960, United States|Stony Brook University-Cancer Center ( Site 0034), Stony Brook, New York, 11794, United States|Providence Portland Medical Center ( Site 0044), Portland, Oregon, 97213, United States|Providence St. Vincent Medical Center ( Site 0081), Portland, Oregon, 97225, United States|Thomas Jefferson University - Clinical Research Institute ( Site 0056), Philadelphia, Pennsylvania, 19107, United States|The Center for Cancer and Blood Disorders ( Site 0041), Fort Worth, Texas, 76104, United States|The University of Texas Health Science Center at Tyler dba UT Health East Texas HOPE Cancer Center ( Site 0057), Tyler, Texas, 75701, United States|Inova Schar Cancer Institute ( Site 0025), Fairfax, Virginia, 22031, United States|Bon Secours St. Francis Medical Center-Oncology Research ( Site 0015), Midlothian, Virginia, 23114, United States|VCU Health Adult Outpatient Pavillion ( Site 0070), Richmond, Virginia, 23219, United States|University Hospital and UW Health Clinics-Carbone Cancer Center ( Site 0040), Madison, Wisconsin, 53792, United States|Instituto Alexander Fleming-Alexander Fleming ( Site 0382), Ciudad AutÃ³noma de Buenos Aires, Caba, 1426ANZ, Argentina|Fundacion Estudios Clinicos-Oncology ( Site 0384), Rosario, Santa Fe, S2000DEJ, Argentina|Hospital Aleman-Oncology ( Site 0386), Buenos Aires, C1118AAT, Argentina|Centro de EducaciÃ³n MÃ©dica e Investigaciones clÃ­nicas ""Dr. Norberto Quirno"" (CEMIC) ( Site 0383), Buenos Aires, C1431FWO, Argentina|Hospital Italiano de CÃ³rdoba ( Site 0385), Cordoba, X5004BAL, Argentina|FundaciÃ³n CORI para la InvestigaciÃ³n y PrevenciÃ³n del CÃ¡ncer ( Site 0387), La Rioja, F5300COE, Argentina|Macquarie University-MQ Health Clinical Trials Unit ( Site 2002), Macquarie University, New South Wales, 2109, Australia|Westmead Hospital ( Site 2000), Westmead, New South Wales, 2145, Australia|Frankston Hospital-Oncology and Haematology ( Site 2003), Frankston, Victoria, 3199, Australia|Fiona Stanley Hospital-Medical Oncology ( Site 2004), Murdoch, Western Australia, 6150, Australia|Institut Jules Bordet-Medicine Oncology ( Site 1104), Anderlecht, Bruxelles-Capitale, Region De, 1070, Belgium|Cliniques universitaires Saint-Luc-Medical Oncology ( Site 1103), Brussels, Bruxelles-Capitale, Region De, 1200, Belgium|Jessa Ziekenhuis-Limburgs Oncologisch Centrum ( Site 1105), Hasselt, Limburg, 3500, Belgium|AZ Maria Middelares-IKG ( Site 1106), Gent, Oost-Vlaanderen, 9000, Belgium|UniversitÃ© Catholique de Louvain-Namur - Centre Hospitalier -Oncology ( Site 1107), Namur, 5530, Belgium|OncoclÃ­nica Oncologistas Associados-Clinical Research ( Site 0407), Teresina, Piaui, 64049-200, Brazil|Hospital Moinhos de Vento ( Site 0403), Porto Alegre, Rio Grande Do Sul, 90035-001, Brazil|Hospital do CÃ¢ncer MÃ£e de Deus ( Site 0404), Porto Alegre, Rio Grande Do Sul, 90110-270, Brazil|Instituto de Oncologia Saint Gallen ( Site 0412), Santa Cruz do Sul, Rio Grande Do Sul, 96830-180, Brazil|Instituto do CÃ¢ncer Brasil - Unidade TaubatÃ© ( Site 0408), TaubatÃ©, Sao Paulo, 12030-200, Brazil|IBCC - NÃºcleo de Pesquisa e Ensino ( Site 0401), Sao Paulo, 04014-012, Brazil|BC Cancer Surrey ( Site 0315), Surrey, British Columbia, V3V 1Z2, Canada|Southlake Regional Health Centre ( Site 0311), Newmarket, Ontario, L3Y 2P9, Canada|Princess Margaret Cancer Centre ( Site 0310), Toronto, Ontario, M5G 2M9, Canada|CIUSSS de l'Est-de-l'Ãle-de-MontrÃ©al ( Site 0301), Montreal, Quebec, H1T 2M4, Canada|Jewish General Hospital ( Site 0303), Montreal, Quebec, H3T 1E2, Canada|Centre intÃ©grÃ© de santÃ© et de services sociaux du Bas Saint-Laurent- HÃ´pital rÃ©gional de Rimouski ( Site 0308), Rimouski, Quebec, G5L 5T1, Canada|CHU de Quebec Universite Laval - Hopital du Saint-Sacrement ( Site 0302), Quebec, G1S 4L8, Canada|Oncovida ( Site 0453), Santiago., Region M. De Santiago, 7500994, Chile|ClÃ­nica RedSalud Vitacura ( Site 0455), Santiago., Region M. De Santiago, 7650018, Chile|FALP-UIDO ( Site 0451), Santiago, Region M. De Santiago, 7500921, Chile|Pontificia Universidad Catolica de Chile-Centro del CÃ¡ncer ( Site 0454), Santiago, Region M. De Santiago, 8330024, Chile|Bradfordhill ( Site 0452), Santiago, Region M. De Santiago, 8420383, Chile|Bradford Hill Norte ( Site 0456), Antofagasta, 1263521, Chile|Fundacion Colombiana de CancerologÃ­a Clinica Vida ( Site 0506), MedellÃ­n, Antioquia, 050030, Colombia|Sociedad De OncologÃ­a y HematologÃ­a Del Cesar SAS-Oncology ( Site 0501), Valledupar, Cesar, 200001, Colombia|IMAT S.A.S ( Site 0502), Monteria., Cordoba, 23002, Colombia|FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 0507), Bogota, Distrito Capital De Bogota, 110131, Colombia|FundaciÃ³n Valle del Lili ( Site 0508), Cali, Valle Del Cauca, 760032, Colombia|CIMCA ( Site 0551), San JosÃ©, San Jose, 10103, Costa Rica|Hospital Metropolitano - Sede Lindora ( Site 0550), Santa Ana, San Jose, 10903, Costa Rica|ICIMED ( Site 0552), San Jose, 10108, Costa Rica|Nemocnice Ceske Budejovice-Onkologicke oddeleni ( Site 1138), Ceske Budejovice, Jihocesky Kraj, 370 01, Czechia|Fakultni nemocnice Olomouc-Onkologicka klinika ( Site 1132), Olomouc, Olomoucky Kraj, 779 00, Czechia|Fakultni nemocnice v Motole-Onkologicka klinika 2. LF UK a FN Motol ( Site 1136), Praha, Praha 5, 150 06, Czechia|Rigshospitalet ( Site 1180), Copenhagen, Hovedstaden, 2100, Denmark|NordsjÃ¦llands Hospital - HillerÃ¸d ( Site 1184), Hillerod, Hovedstaden, 3400, Denmark|NÃ¦stved Sygehus ( Site 1182), Naestved, Sjaelland, 4700, Denmark|Odense Universitetshospital ( Site 1181), Odense C, Syddanmark, 5000, Denmark|Vejle Sygehus ( Site 1183), Vejle, Syddanmark, 7100, Denmark|Centre FranÃ§ois Baclesse ( Site 1250), Caen, Calvados, 14076, France|Centre de CancÃ©rologie du Grand Montpellier ( Site 1244), Montpellier, Languedoc-Roussillon, 34070, France|HÃ´pital privÃ© du Confluent SAS-Service d'oncologie mÃ©dicale ( Site 1242), Nantes, Loire-Atlantique, 44277, France|Pitie Salpetriere University Hospital ( Site 1249), Paris, Orne, 75013, France|Hopital Prive Jean Mermoz-Oncology ( Site 1246), Lyon, Rhone-Alpes, 69008, France|Centre Hospitalier Universitaire de Poitiers-PÃ´le rÃ©gional de cancÃ©rologie ( Site 1243), Poitiers, Vienne, 86021, France|Institut Curie-Oncology medical Department ( Site 1240), Paris, 75248, France|Errikos Dunant Hospital Center ( Site 1348), Athens, Attiki, 115 26, Greece|Aretaieio Hospital Oncology Unit ( Site 1345), Athens, Attiki, 115 28, Greece|Hygeia Hospital ( Site 1346), Marousi, Attiki, 151 23, Greece|Agios Loukas Clinic ( Site 1347), Thessaloniki, Kentriki Makedonia, 552 36, Greece|University General Hospital of Larissa ( Site 1343), Larissa, Thessalia, 411 10, Greece|European Interbalkan Medical Center ( Site 1341), Thessaloniki, 57001, Greece|Queen Mary Hospital ( Site 2040), Hksar, Hong Kong|Prince of Wales Hospital ( Site 2041), Shatin, Hong Kong|Szegedi TudomÃ¡nyegyetem Szent-GyÃ¶rgyi Albert Klinikai KÃ¶zpont-OnkoterÃ¡piÃ¡s Klinika ( Site 1379), Szeged, Csongrad, 6720, Hungary|Somogy VÃ¡rmegyei Kaposi MÃ³r OktatÃ³ KÃ³rhÃ¡z-Oncology center ( Site 1371), KaposvÃ¡r, Somogy, 7400, Hungary|Zala VÃ¡rmegyei Szent Rafael KÃ³rhÃ¡z-OnkolÃ³giai osztÃ¡ly ( Site 1372), Zalaegerszeg, Zala, 8900, Hungary|Budapesti Uzsoki Utcai KÃ³rhÃ¡z-OnkoradiolÃ³giai OsztÃ¡ly ( Site 1373), Budapest, 1145, Hungary|Debreceni Egyetem Klinikai Kozpont-OnkolÃ³giai Klinika ( Site 1375), Debrecen, 4032, Hungary|All India Institute of Medical Sciences ( Site 2051), New Delhi, Delhi, 110029, India|Rajiv Gandhi Cancer Institute And Research Centre-Department of Clinical Research ( Site 2052), New Delhi, Delhi, 110085, India|Tata Memorial Hospital-Medical Oncology ( Site 2053), Mumbai, Maharashtra, 400012, India|Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute-Centre for cancer ( Site 2056), Mumbai, Maharashtra, 400053, India|Bon Secours Cork Hospital ( Site 1422), Cork, T12 DV56, Ireland|St. Vincent's University Hospital-Medical Oncology Research Department ( Site 1420), Dublin, D04 T6F4, Ireland|Mater Misericordiae University Hospital-Clinical Trials Research Unit ( Site 1423), Dublin, D07 R2WY, Ireland|Rambam Health Care Campus-Oncology Division ( Site 1452), Haifa, 3109601, Israel|Hadassah Medical Center ( Site 1451), Jerusalem, 9112001, Israel|Rabin Medical Center ( Site 1453), Petah Tikva, 4941492, Israel|Sheba Medical Center ( Site 1450), Ramat Gan, 5265601, Israel|IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) ""Dino Amadori"" ( Site 1480), Meldola, Forli-Cesena, 47014, Italy|CRO-IRCCS ( Site 1478), Aviano, Friuli-Venezia Giulia, 33081, Italy|Istituto Europeo di Oncologia IRCCS-Divisione di Senologia Medica ( Site 1475), Milano, Lombardia, 20141, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1472), Milan, Lombardia, 20133, Italy|Istituto Clinico Humanitas ( Site 1476), Rozzano, Milano, 20089, Italy|IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 1474), Bologna, 40138, Italy|Ospedale San Martino ( Site 1479), Genova, 16132, Italy|Ospedale San Raffaele-Oncologia Medica ( Site 1471), Milano, 20132, Italy|Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UniversitÃ  Cattolica del Sacro Cuore ( Site 1477), Roma, 00168, Italy|Nagoya City University Hospital ( Site 2474), Nagoya, Aichi, 467-8602, Japan|Hokkaido University Hospital ( Site 2460), Sapporo, Hokkaido, 060-8648, Japan|Tokai University Hospital ( Site 2473), Isehara, Kanagawa, 259-1193, Japan|St. Marianna University Hospital ( Site 2465), Kawasaki, Kanagawa, 216-8511, Japan|Kitasato University Hospital ( Site 2471), Sagamihara, Kanagawa, 252-0375, Japan|Kanagawa Cancer Center ( Site 2472), Yokohama, Kanagawa, 241-8515, Japan|Mie University Hospital ( Site 2483), Tsu, Mie, 514-8507, Japan|Tohoku University Hospital ( Site 2482), Sendai, Miyagi, 980-8574, Japan|The University of Osaka Hospital ( Site 2476), Suita, Osaka, 565-0871, Japan|Saitama Medical University International Medical Center ( Site 2462), Hidaka, Saitama, 350-1298, Japan|Juntendo University Hospital ( Site 2468), Bunkyo, Tokyo, 113-8431, Japan|Cancer Institute Hospital of JFCR ( Site 2464), Koto, Tokyo, 135-8550, Japan|Showa Medical University Hospital ( Site 2466), Shinagawa, Tokyo, 142-8666, Japan|Tokyo Medical University Hospital ( Site 2467), Shinjuku, Tokyo, 160-0023, Japan|National Center for Global Health and Medicine ( Site 2469), Shinjuku, Tokyo, 162-8655, Japan|Fukushima Medical University Hospital ( Site 2461), Fukushima, 960-1295, Japan|Gifu University Hospital ( Site 2486), Gifu, 501-1194, Japan|Hiroshima City Hiroshima Citizens Hospital ( Site 2478), Hiroshima, 730-8518, Japan|Social medical corporation Hakuaikai Sagara Hospital ( Site 2481), Kagoshima, 892-0833, Japan|Kumamoto University Hospital ( Site 2480), Kumamoto, 860-8556, Japan|Kyoto University Hospital ( Site 2475), Kyoto, 606-8507, Japan|Okayama University Hospital ( Site 2485), Okayama, 700-8558, Japan|Osaka International Cancer Institute ( Site 2477), Osaka, 541-8567, Japan|Seoul National University Hospital-Internal Medicine ( Site 2353), Seoul, 03080, Korea, Republic of|Severance Hospital, Yonsei University Health System-Medical oncology ( Site 2350), Seoul, 03722, Korea, Republic of|Asan Medical Center-Department of Oncology ( Site 2352), Seoul, 05505, Korea, Republic of|Samsung Medical Center-Division of Hematology/Oncology ( Site 2351), Seoul, 06351, Korea, Republic of|Hospital Sultan Ismail ( Site 2153), Johor Bahru, Johor, 81100, Malaysia|Sarawak General Hospital ( Site 2154), Kuching, Sarawak, 93586, Malaysia|Pantai Hospital Kuala Lumpur ( Site 2151), Kuala Lumpur, 59100, Malaysia|Health Pharma Professional Research S.A. de C.V: ( Site 0598), Ciudad de MÃ©xico, Distrito Federal, 03100, Mexico|Grupo MÃ©dico ASSET-Clinical Research ( Site 0596), Mexico City, Distrito Federal, 03100, Mexico|CIO - Centro de Inmuno-OncologÃ­a de Occidente ( Site 0592), Guadalajara, Jalisco, 44630, Mexico|Hospital Universitario ""Dr. Jose Eleuterio Gonzalez""-Servicio de OncologÃ­a ( Site 0590), Monterrey, Nuevo Leon, 64460, Mexico|CENTRO MEDICO ZAMBRANO HELLION-Centro de CÃ¡ncer de Mama ( Site 0595), San Pedro Garza Garcia, Nuevo Leon, 66278, Mexico|Ziekenhuis Rijnstate-Rijnstate Centrum Oncologisch Onderzoek ( Site 1524), Arnhem, Gelderland, 6815 AD, Netherlands|Maastricht UMC+-Medical Oncology ( Site 1522), Maastricht, Limburg, 6229 HX, Netherlands|Amphia Ziekenhuis, locatie Breda Molengracht-oncologie ( Site 1523), Breda, Noord-Brabant, 4800 RK, Netherlands|Catharina Ziekenhuis ( Site 1526), Eindhoven, Noord-Brabant, 5623 EJ, Netherlands|Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL)-medical oncology ( Site 1520), Amsterdam, Noord-Holland, 1066 CX, Netherlands|Isala, locatie Zwolle ( Site 1525), Zwolle, Overijssel, 8025 AB, Netherlands|Meander Medisch Centrum ( Site 1521), Amersfoort, Utrecht, 3813TZ, Netherlands|Auckland City Hospital ( Site 2031), Auckland, 1023, New Zealand|Clinica Vallesur - AUNA ( Site 0652), Arequipa, Ariqipa, 15036, Peru|Hospital Militar Central Luis Arias Schereiber ( Site 0651), JesÃºs MarÃ­a, Lima, 18, Peru|Oncosalud ( Site 0650), Lima, Muni Metro De Lima, 15036, Peru|IPOR Instituto Peruano de OncologÃ­a & Radioterapia ( Site 0653), Lima, 15036, Peru|Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 1582), Bydgoszcz, Kujawsko-pomorskie, 85-796, Poland|Mazowiecki Szpital WojewÃ³dzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 1584), Siedlce, Mazowieckie, 08-110, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika NowotworÃ³w Piersi i Chirurgii ( Site 1580), Warszawa, Mazowieckie, 02-781, Poland|Mazowiecki Szpital Onkologiczny ( Site 1581), Wieliszew, Mazowieckie, 05-135, Poland|Mrukmed-Mrukmed ( Site 1592), Rzeszow, Podkarpackie, 35-021, Poland|Bialostockie Centrum Onkologii ( Site 1585), Bialystok, Podlaskie, 15-027, Poland|Szpitale Pomorskie Sp. z o. o.-OddziaÅ Onkologii Klinicznej ( Site 1593), Gdynia, Pomorskie, 81-519, Poland|Narodowy Instytut Onkologii - Oddzial w Gliwicach-Centrum Diagnostyki i Leczenia Chorob Piersi ( Site 1590), Gliwice, Slaskie, 44-102, Poland|Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zakl-Klinika Onkologii Klinicznej, Dzial Ch ( Site 1595), Kielce, Swietokrzyskie, 25-734, Poland|Szpital WojewÃ³dzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 1583), Koszalin, Zachodniopomorskie, 75-581, Poland|Zachodniopomorskie Centrum Onkologii ( Site 1588), Szczecin, Zachodniopomorskie, 71-730, Poland|Unidade Local de Saude Amadora/Sintra - Hospital Prof Dr Fernando Fonseca ( Site 1663), Lisbon, Lisboa, 2720-276, Portugal|Unidade Local de Saude de Santa Maria - Hospital de Santa Maria ( Site 1661), Lisboa, 1649-035, Portugal|Instituto PortuguÃªs de Oncologia do Porto Francisco Gentil, EPE ( Site 1662), Porto, 4200-072, Portugal|Puerto Rico Medical Research Center LLC ( Site 0675), Hato Rey, 00917, Puerto Rico|UPR Comprehensive Cancer Center-Comprehensive Cancer Center Hospital ( Site 0677), San Juan, 00935, Puerto Rico|Spitalul Clinic Filantropia ( Site 1703), BucureÈti, Bucuresti, 011171, Romania|SC Radiotherapy Center Cluj SRL-Oncologie Medicala ( Site 1702), FloreÈti, Cluj, 407280, Romania|Centrul Medical Neolife- Baneasa ( Site 1704), Bucuresti, 077190, Romania|Institutul Oncologic Cluj ( Site 1701), Cluj, 400015, Romania|National University Hospital ( Site 2250), Singapore, Central Singapore, 119074, Singapore|Mount Alvernia ICON Cancer Center ( Site 2251), Singapore, North East, 574623, Singapore|CANCERCARE LANGENHOVEN DRIVE ONCOLOGY CENTRE ( Site 2905), Port Elizabeth, Eastern Cape, 6055, South Africa|Curo Oncology ( Site 2908), Pretoria, Gauteng, 0084, South Africa|Sandton Oncology Medical Group (Pty) Ltd ( Site 2911), Sandton, Gauteng, 2196, South Africa|Cancercare Rondebosch Oncology-Clinical trials ( Site 2904), Rondebosch, Western Cape, 7700, South Africa|HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID ( Site 1758), Pozuelo de Alarcon, Madrid, 28223, Spain|HOSPITAL CLINICO DE VALENCIA-Oncology ( Site 1752), Valencia, Valenciana, Comunitat, 46010, Spain|Hospital Universitari Vall d'Hebron-Oncology ( Site 1750), Barcelona, 08035, Spain|Hospital Universitario Reina Sofia-Oncologia Medica ( Site 1754), Cordoba, 14004, Spain|Hospital Beata MarÃ­a Ana-oncology ( Site 1755), Madrid, 28007, Spain|HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÃON-ONCOLOGY ( Site 1756), Madrid, 28009, Spain|Hospital Universitario Virgen Macarena ( Site 1757), Sevilla, 41009, Spain|Karolinska Universitetssjukhuset Solna ( Site 1801), Stockholm, Stockholms Lan, 171 76, Sweden|Akademiska sjukhuset ( Site 1802), Uppsala, Uppsala Lan, 75185, Sweden|SÃ¶dra Ãlvsborgs Sjukhus BorÃ¥s ( Site 1803), BorÃ¥s, Vastra Gotalands Lan, 501 82, Sweden|University Hospital Basel-Gynecology & Gynecologic Oncology ( Site 1844), Basel, Basel-Stadt, 4031, Switzerland|Spital Thun ( Site 1840), Thun, Berne, 3600, Switzerland|Brust-Zentrum ( Site 1841), ZÃ¼rich, Zurich, 8008, Switzerland|Changhua Christian Hospital ( Site 2410), Changhua, 50006, Taiwan|Chang Gung Memorial Hospital at Kaohsiung-Oncology and Hematology ( Site 2413), Kaohsiung, 83301, Taiwan|National Cheng Kung University Hospital-Surgery ( Site 2411), Tainan, 704, Taiwan|National Taiwan University Hospital-Oncology ( Site 2415), Taipei, 10002, Taiwan|Mackay Memorial Hospital ( Site 2412), Taipei, 10449, Taiwan|Chang Gung Medical Foundation-Linkou Branch-General Surgery ( Site 2414), Taoyuan, 333, Taiwan|Medipol Mega Universite Hastanesi-oncology ( Site 1875), Stanbul, Istanbul, 34214, Turkey|Adana Medical Park Seyhan Hastanesi-Medikal Onkoloji ( Site 1876), Adana, 01140, Turkey|Hacettepe Universite Hastaneleri-oncology hospital ( Site 1870), Ankara, 06230, Turkey|Memorial Ankara Hastanesi-Medical Oncology ( Site 1874), Ankara, 06520, Turkey|Ankara Bilkent Åehir Hastanesi-Medical Oncology ( Site 1871), Ankara, 06800, Turkey|TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 1872), Istanbul, 34722, Turkey|Samsun Medical Park Hastanesi-medical oncology ( Site 1873), Samsun, 55200, Turkey|North West Cancer Centre ( Site 1944), Londonderry, Derry And Strabane, BT47 6SB, United Kingdom|The Royal Cornwall Hospital ( Site 1943), Truro, England, TR1 3LJ, United Kingdom|St Bartholomew's Hospital-Centre for Experimental Cancer Medicine ( Site 1940), London, London, City Of, EC1A 7BE, United Kingdom|University College London Hospital-Cancer Clinical Trials Unit ( Site 1942), London, London, City Of, NW1 2PG, United Kingdom|Blackpool Victoria Hospital ( Site 1941), Blackpool, FY3 8NR, United Kingdom|City Hospital, Nottingham University Hospitals NHS Trust ( Site 1945), Nottingham, NG5 1PB, United Kingdom",
NCT06256588,A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma,https://clinicaltrials.gov/study/NCT06256588,JADE,RECRUITING,The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with HNSCC (Head and Neck Squamous Cell Carcinoma),NO,"Neoplasms, Head and Neck",DRUG: Dostarlimab|DRUG: Placebo,"Event-free Survival (EFS) Assessed by Blinded Independent Central Review (BICR), Event Free Survival (EFS) is defined as the time from the date of randomization to the date of an event, where an event is defined as locoregional progression or recurrence, or distant metastasis per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as per BICR; Salvage surgery at the primary tumor site; Neck dissection or surgery performed \>20 weeks after completion of or Death from any cause., Up to approximately 5 years","Overall Survival (OS), OS is defined as the time from date of randomization to the date of death by any cause., Up to approximately 5 years|Event-free Survival (EFS) assessed by investigator, Event Free Survival (EFS) is defined as the time from the date of randomization to the date of an event as per primary endpoint, however with investigator assessment per RECIST 1.1, Up to approximately 5 years|Number of Participants with treatment emergent adverse events (TEAEs), Immune-mediated TEAEs, and serious adverse events (SAEs) by severity, Up to approximately 5 years|Number of Participants with TEAEs and SAEs leading to dose delays, withdrawals or death, Up to approximately 5 years|Number of participants with clinically significant changes in laboratory, vital signs, and safety assessment parameters, Up to approximately 5 years|Serum Concentration of Dostarlimab, Up to approximately 15 months|Serum Concentration of Dostarlimab at End of Infusion (C-EoI), Up to approximately 15 months|Serum Predose trough concentration (Ctrough) of Dostarlimab, Up to approximately 15 months|Number of Participants with Anti-Drug Antibodies against Dostarlimab, Up to approximately 15 months",,GlaxoSmithKline,,ALL,"ADULT, OLDER_ADULT",PHASE3,864,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-03-21,2028-05-04,2029-07-13,2024-02-13,,2025-05-30,"GSK Investigational Site, Jonesboro, Arkansas, 72401, United States|GSK Investigational Site, Los Angeles, California, 90095, United States|GSK Investigational Site, Solvang, California, 93463, United States|GSK Investigational Site, Stockton, California, 95204, United States|GSK Investigational Site, Torrance, California, 90505, United States|GSK Investigational Site, Farmington, Connecticut, 06030-1628, United States|GSK Investigational Site, New Haven, Connecticut, 06520, United States|GSK Investigational Site, Washington, District of Columbia, 20010, United States|GSK Investigational Site, Tamarac, Florida, 33321, United States|GSK Investigational Site, Fort Wayne, Indiana, 46804, United States|GSK Investigational Site, Iowa City, Iowa, 52242-1009, United States|GSK Investigational Site, Lexington, Kentucky, 40536, United States|GSK Investigational Site, Columbia, Maryland, 21044, United States|GSK Investigational Site, Worcester, Massachusetts, 01655-0002, United States|GSK Investigational Site, Saint Louis, Missouri, 63110, United States|GSK Investigational Site, Omaha, Nebraska, 68114, United States|GSK Investigational Site, New York, New York, 10032, United States|GSK Investigational Site, Cincinnati, Ohio, 45219, United States|GSK Investigational Site, Charleston, South Carolina, 29425, United States|GSK Investigational Site, Greenville, South Carolina, 29607, United States|GSK Investigational Site, Chattanooga, Tennessee, 37404, United States|GSK Investigational Site, Germantown, Tennessee, 38138, United States|GSK Investigational Site, Nashville, Tennessee, 37203, United States|GSK Investigational Site, Fort Worth, Texas, 76104, United States|GSK Investigational Site, Fredericksburg, Virginia, 22408, United States|GSK Investigational Site, Wytheville, Virginia, 24382, United States|GSK Investigational Site, Tacoma, Washington, 98405, United States|GSK Investigational Site, Buenos Aires, 1023, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, C1425, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, C1437GZT, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aire, 1426, Argentina|GSK Investigational Site, Cordoba, 5000, Argentina|GSK Investigational Site, Rosario, S2002, Argentina|GSK Investigational Site, San Juan, J5400, Argentina|GSK Investigational Site, San Miguel de TucumAn, T4000GTB, Argentina|GSK Investigational Site, Viedma, R8500ACE, Argentina|GSK Investigational Site, Blacktown, New South Wales, 2148, Australia|GSK Investigational Site, Douglas, Queensland, 4814, Australia|GSK Investigational Site, Herston, Queensland, 4029, Australia|GSK Investigational Site, Ballarat, Victoria, 3350, Australia|GSK Investigational Site, Geelong, Victoria, 3220, Australia|GSK Investigational Site, Melbourne, Victoria, 3004, Australia|GSK Investigational Site, Bruxelles, 1200, Belgium|GSK Investigational Site, Charleroi, 6060, Belgium|GSK Investigational Site, Edegem, 2650, Belgium|GSK Investigational Site, Gent, 9000, Belgium|GSK Investigational Site, Yvoir, 5530, Belgium|GSK Investigational Site, Barretos, 14784-400, Brazil|GSK Investigational Site, Belo Horizonte, 30110-022, Brazil|GSK Investigational Site, Florianopolis, 88020-210, Brazil|GSK Investigational Site, Joinville, 89201-260, Brazil|GSK Investigational Site, Porto Alegre, 90610-000, Brazil|GSK Investigational Site, Salvador, 41253-190, Brazil|GSK Investigational Site, Salvador, 41950-640, Brazil|GSK Investigational Site, Sao Jose Do Rio Preto, 15090-200, Brazil|GSK Investigational Site, SAo Paulo, 01246-000, Brazil|GSK Investigational Site, VitOria, 29043-260, Brazil|GSK Investigational Site, Hamilton, Ontario, L8V 5C2, Canada|GSK Investigational Site, Toronto, Ontario, M5G 2M9, Canada|GSK Investigational Site, Montreal, Quebec, H3T 1E2, Canada|GSK Investigational Site, Chongqing, Chongqing, 400030, China|GSK Investigational Site, Beijing, 100036, China|GSK Investigational Site, Changzhou, 213032, China|GSK Investigational Site, Chengdu, 610000, China|GSK Investigational Site, Chengdu, 610041, China|GSK Investigational Site, Dongguan, 523059, China|GSK Investigational Site, Fuzhou, 350005, China|GSK Investigational Site, Fuzhou, 350014, China|GSK Investigational Site, Guangzhou, 510503, China|GSK Investigational Site, Hangzhou, 310003, China|GSK Investigational Site, Hangzhou, 310022, China|GSK Investigational Site, Hefei, 230001, China|GSK Investigational Site, Hengyang, 421000, China|GSK Investigational Site, Jinan, 250117, China|GSK Investigational Site, Linyi, 276002, China|GSK Investigational Site, Nanchang, 330006, China|GSK Investigational Site, Nanchang, 330029, China|GSK Investigational Site, Nanning, 530021, China|GSK Investigational Site, Shanghai, 200032, China|GSK Investigational Site, Taiyuan, 030013, China|GSK Investigational Site, Wuhan, 430030, China|GSK Investigational Site, Wuhan, 430079, China|GSK Investigational Site, Xiamen, 361004, China|GSK Investigational Site, Zhengzhou, 450052, China|GSK Investigational Site, Zhuhai, 519001, China|GSK Investigational Site, Olomouc, 779 00, Czechia|GSK Investigational Site, Prague, 10034, Czechia|GSK Investigational Site, Praha 8, 180 81, Czechia|GSK Investigational Site, Praha, 150 08, Czechia|GSK Investigational Site, Zlin, 76275, Czechia|GSK Investigational Site, Caen Cedex 5, 14075, France|GSK Investigational Site, Dijon Cedex, 21079, France|GSK Investigational Site, Marseille cedex 5, 13005, France|GSK Investigational Site, Poitiers, 86021, France|GSK Investigational Site, Quimper cedex, 29000, France|GSK Investigational Site, Rennes Cedex, 35042, France|GSK Investigational Site, Rouen Cedex 1, 76038, France|GSK Investigational Site, Vandoeuvre Les Nancy Cedex, 54519, France|GSK Investigational Site, Augsburg, 86156, Germany|GSK Investigational Site, Berlin, 12351, Germany|GSK Investigational Site, Berlin, 13353, Germany|GSK Investigational Site, Erlangen, 91054, Germany|GSK Investigational Site, Essen, 45147, Germany|GSK Investigational Site, Giessen, 35392, Germany|GSK Investigational Site, Hamburg, 22087, Germany|GSK Investigational Site, Straubing, 94315, Germany|GSK Investigational Site, Athens, 115 22, Greece|GSK Investigational Site, Athens, 12462, Greece|GSK Investigational Site, Larissa, 41100, Greece|GSK Investigational Site, Thessaloniki, 564 29, Greece|GSK Investigational Site, GyÅr, 9023, Hungary|GSK Investigational Site, Kaposvar, 7400, Hungary|GSK Investigational Site, Nyiregyhaza, H-4400, Hungary|GSK Investigational Site, Bengaluru, 560066, India|GSK Investigational Site, Bhubaneswar, 751019, India|GSK Investigational Site, Hyderabad, 500004, India|GSK Investigational Site, Mumbai, 400012, India|GSK Investigational Site, Nashik, 422002, India|GSK Investigational Site, Nehru Nagar Belagavi Karnataka 590010, 590010, India|GSK Investigational Site, Surat, 395002, India|GSK Investigational Site, Vijayawada, 520002, India|GSK Investigational Site, Haifa, 3109601, Israel|GSK Investigational Site, Jerusalem, 9112001, Israel|GSK Investigational Site, Tel Aviv, 64239, Israel|GSK Investigational Site, Milano, 20133, Italy|GSK Investigational Site, Milano, 20141, Italy|GSK Investigational Site, Napoli, 80131, Italy|GSK Investigational Site, Pavia, 27100, Italy|GSK Investigational Site, Prato, 59100, Italy|GSK Investigational Site, Roma, 00161, Italy|GSK Investigational Site, Roma, 00168, Italy|GSK Investigational Site, Rozzano MI, 20089, Italy|GSK Investigational Site, Savona, 17100, Italy|GSK Investigational Site, Aichi, 464-8681, Japan|GSK Investigational Site, Chiba, 260-8717, Japan|GSK Investigational Site, Chiba, 277-8577, Japan|GSK Investigational Site, Ehime, 791-0280, Japan|GSK Investigational Site, Fukuoka, 812-8582, Japan|GSK Investigational Site, Hokkaido, 060-8648, Japan|GSK Investigational Site, Hyogo, 650-0017, Japan|GSK Investigational Site, Iwate, 028-3695, Japan|GSK Investigational Site, Kanagawa, 236-0004, Japan|GSK Investigational Site, Kanagawa, 259-1193, Japan|GSK Investigational Site, Kyoto, 612-8555, Japan|GSK Investigational Site, Miyagi, 981-1293, Japan|GSK Investigational Site, Niigata, 951-8520, Japan|GSK Investigational Site, Osaka, 541-8567, Japan|GSK Investigational Site, Saitama, 350-1298, Japan|GSK Investigational Site, Shizuoka, 411-8777, Japan|GSK Investigational Site, Tokyo, 113-8519, Japan|GSK Investigational Site, Tokyo, 152-8902, Japan|GSK Investigational Site, Tokyo, 160-0023, Japan|GSK Investigational Site, Tottori, 683-8504, Japan|GSK Investigational Site, Busan, 602-030, Korea, Republic of|GSK Investigational Site, Pusan, 49241, Korea, Republic of|GSK Investigational Site, Seoul, 03722, Korea, Republic of|GSK Investigational Site, Seoul, 06351, Korea, Republic of|GSK Investigational Site, Seoul, 110 744, Korea, Republic of|GSK Investigational Site, Suwon Gyeonggi-do, 16247, Korea, Republic of|GSK Investigational Site, Ciudad de Mexico, 06760, Mexico|GSK Investigational Site, Ciudad de Mexico, 11510, Mexico|GSK Investigational Site, Guadalajara, 44650, Mexico|GSK Investigational Site, Oaxaca, 68020, Mexico|GSK Investigational Site, Bergen, 5021, Norway|GSK Investigational Site, Oslo, 0379, Norway|GSK Investigational Site, Troms, 9038, Norway|GSK Investigational Site, Bielsko-Biala, 43-300, Poland|GSK Investigational Site, Gliwice, 44-102, Poland|GSK Investigational Site, Katowice, 40-514, Poland|GSK Investigational Site, Koszalin, 75-581, Poland|GSK Investigational Site, Olsztyn, 10-228, Poland|GSK Investigational Site, Przemysl, 37-700, Poland|GSK Investigational Site, Siedlce, 08-110, Poland|GSK Investigational Site, Warszawa, 04-141, Poland|GSK Investigational Site, Coimbra, 3000-075, Portugal|GSK Investigational Site, Faro, 8000-386, Portugal|GSK Investigational Site, Lisboa, 1649-035, Portugal|GSK Investigational Site, Lisboa, 1998-018, Portugal|GSK Investigational Site, Matosinhos, 4464-509, Portugal|GSK Investigational Site, Porto, 4200-072, Portugal|GSK Investigational Site, Porto, 4200-319, Portugal|GSK Investigational Site, Vila Nova de Gaia, 4434-502, Portugal|GSK Investigational Site, Bucharest, 020142, Romania|GSK Investigational Site, Bucuresti, 013823, Romania|GSK Investigational Site, Craiova, 200508, Romania|GSK Investigational Site, Craiova, 200542, Romania|GSK Investigational Site, Floresti, 407280, Romania|GSK Investigational Site, Iasi, 700483, Romania|GSK Investigational Site, Oradea, 410469, Romania|GSK Investigational Site, Pitesti, 110283, Romania|GSK Investigational Site, Suceava, 720214, Romania|GSK Investigational Site, Timisoara, 300239, Romania|GSK Investigational Site, BaracaldoVizcaya, 48903, Spain|GSK Investigational Site, Barcelona, 08023, Spain|GSK Investigational Site, Cartagena Murcia, 30202, Spain|GSK Investigational Site, HebrOn, 08035, Spain|GSK Investigational Site, Jerez, 11407, Spain|GSK Investigational Site, L'Hospitalet De Llobrega, 08908, Spain|GSK Investigational Site, Lugo, 27003, Spain|GSK Investigational Site, Madrid, 28040, Spain|GSK Investigational Site, Madrid, 28041, Spain|GSK Investigational Site, Madrid, 28046, Spain|GSK Investigational Site, Pamplona, 31008, Spain|GSK Investigational Site, Salamanca, 37007, Spain|GSK Investigational Site, Santander, 39008, Spain|GSK Investigational Site, Zaragoza, 50009, Spain|GSK Investigational Site, Goteborg, SE-413 45, Sweden|GSK Investigational Site, Stockholm, SE-171 64, Sweden|GSK Investigational Site, Uppsala, SE-751 85, Sweden|GSK Investigational Site, Changhua, 500, Taiwan|GSK Investigational Site, Kaohsiung, 833, Taiwan|GSK Investigational Site, Taichung, 40447, Taiwan|GSK Investigational Site, Taipei, 100, Taiwan|GSK Investigational Site, Adapazari, Turkey|GSK Investigational Site, Ankara, 06010, Turkey|GSK Investigational Site, Ankara, 06100, Turkey|GSK Investigational Site, Ankara, 06520, Turkey|GSK Investigational Site, Istanbul, 34010, Turkey|GSK Investigational Site, Istanbul, 34662, Turkey|GSK Investigational Site, Istanbul, ÅiÅli, 34384, Turkey|GSK Investigational Site, Edinburgh, EH4 2XU, United Kingdom|GSK Investigational Site, Gloucester, GL1 3NN, United Kingdom|GSK Investigational Site, London, SW3 6JJ, United Kingdom|GSK Investigational Site, Nottingham, NG5 1PB, United Kingdom|GSK Investigational Site, Sutton, SM2 5PT, United Kingdom|GSK Investigational Site, Wolverhampton, WV10 0QP, United Kingdom",
NCT05753865,A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound),https://clinicaltrials.gov/study/NCT05753865,,UNKNOWN,The main purpose of this study is to evaluate the efficacy and safety in patients with advanced breast cancer treated with SYHX2011 versus paclitaxel for injection (albumin-bound).,NO,Advanced Breast Cancer,DRUG: SYHX2011|DRUG: Paclitaxel for injection (albumin-bound),"Objective Response Rate (ORR) by IRC, Up to approximately 2 years","ORR by investigator, Up to approximately 2 years|Progression-Free-Survival (PFS), Up to approximately 2 years|Time to progression (TTP), Up to approximately 2 years|Overall survival (OS), Up to approximately 2 years|Incidence of adverse events, Up to approximately 2 years",,"CSPC Ouyi Pharmaceutical Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,454,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-05-01,2024-09-01,2024-09-01,2023-03-03,,2023-03-03,"The Fourth Hospital of Hebei Medical University, Shijia Zhuang, Hebei, China",
NCT06658353,Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors,https://clinicaltrials.gov/study/NCT06658353,,RECRUITING,"This Study is a single arm, open label, multicenter phase III clinical trial to evaluate the safety and efficacy of VC004 in patients with locally advanced/metastatic solid tumors.",NO,Locally Advanced Solid Tumor,DRUG: VC004 Capsules,"Objective response rate(ORR), 6 months",,,"Jiangsu vcare pharmaceutical technology co., LTD",,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,54,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2025-03-17,2026-12-30,2026-12-30,2024-10-26,,2025-03-20,"Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China",
NCT05502237,Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT05502237,STAR-121,RECRUITING,The primary objective of this study is to compare the effect of zimberelimab (ZIM) and domvanalimab (DOM) in combination with chemotherapy relative to pembrolizumab (PEMBRO) in combination with chemotherapy on overall survival (OS) in patients with untreated metastatic non-small cell lung cancer with no actionable genomic alteration.,NO,Non-small Cell Lung Cancer,DRUG: Zimberelimab|DRUG: Domvanalimab|DRUG: Pembrolizumab|DRUG: Carboplatin|DRUG: Cisplatin|DRUG: Paclitaxel|DRUG: Nab-paclitaxel|DRUG: Pemetrexed,"Overall Survival (OS) in Participants With Positive Programmed Cell Death-Ligand 1 (PD-L1) Expression (â¥1%Tumor Cells) and in all Randomized Participants., OS is defined as the time from the date of randomization to the date of death from any cause., Up to 68 months","Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, PFS is defined as the time from the date of randomization until disease progression (PD) or death from any cause, whichever comes first., Upt to 50 months|Objective Response Rate (ORR) as Assessed by BICR per RECIST Version 1.1, ORR is defined as the proportion of participants who have achieved a complete response (CR) or partial response (PR) that is confirmed at least 4 weeks later., Up to 50 Months|Duration of Response (DOR) as Assessed by BICR per RECIST Version 1.1, DOR is defined as the time from the first response (CR or PR), to the first documented PD or death from any cause, whichever comes first., Up to 50 Months|Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs), First dose date up to 50 months plus 30 days|Percentage of Participants Experiencing Clinical Laboratory Abnormalities, First dose date up to 50 months plus 30 days|Time to First Symptom Deterioration in Non-small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) Total Score, The NSCLC-SAQ is a patient reported outcome measure with seven items assessing five symptom concepts of NSCLC: cough, pain, dyspnea, fatigue, and appetite. Each item is rated using a five-point verbal rating scale from ""No \<symptom\> At All"" to ""Very severe \<symptom\>"" or from ""Never to Always,"" corresponding to a score of 0 to 4. The sum of all 5 domain scores will be computed, if any scores are missing, a total score will not be computed. The total score ranges between 0 and 20 with higher scores indicating more severe symptoms., Baseline, Up to 50 Months",,Gilead Sciences,"Arcus Biosciences, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE3,1069,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-10-12,2028-06,2028-06,2022-08-16,,2025-05-18,"Palo Verde Hematology Oncology Ltd, Glendale, Arizona, 85304, United States|California Cancer Associates for Research and Excellence, San Marcos, California, 92069, United States|Texas Oncology, Santa Barbara, California, 93105, United States|Innovative Clinical Research Institute, Whittier, California, 90606, United States|Eastern CT Hematology and Oncology Associates, Norwich, Connecticut, 06360, United States|Lake City Cancer Care, Lake City, Florida, 32024, United States|Florida Cancer Specialists, Sarasota, Florida, 34232, United States|Moffitt Cancer Center, Tampa, Florida, 33612, United States|Peachtree Hematology Oncology Consultants, Atlanta, Georgia, 30318, United States|Illinois Cancer Care, Peoria, Illinois, 61615, United States|Messino Cancer Centers, Asheville, North Carolina, 28806, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, 45242, United States|Hematology & Oncology Associates, Eugene, Oregon, 97401, United States|AHN Allegheny General Hospital, Pittsburgh, Pennsylvania, 15212, United States|Arlington Cancer Center, Arlington, Texas, 76012, United States|Texas Oncology - Austin, Austin, Texas, 78745, United States|Texas Oncology, Dallas, Texas, 75246, United States|Texas Oncology- Denison, Sherman, Texas, 75090, United States|US Oncology Investigational Products Center (IPC), Arlington, Virginia, 22205, United States|Oncology and Hematology Associates of Southwest Virginia, Inc, Blacksburg, Virginia, 24060, United States|Northwest Cancer Specialists, PC, Vancouver, Washington, 98684, United States|Investigaciones CORI S.R.L., Capital, F5300COE, Argentina|Centro MÃ©dico Privado Centro de Especialidades MÃ©dicas Ambulatorias e InvestigaciÃ³n ClÃ­nica, Cardoba, X5008HHW, Argentina|Centro Medico Barrio Parque, Ciudad Autanoma Buenos Aires, 1426, Argentina|Sanatorio Allende, Cordoba, 5000, Argentina|Sanatorio Britanico de Rosario, Rosario, 2000, Argentina|Sanatorio Parque de Rosario, Rosario, S2000DSV, Argentina|Hospital Provincial del Centenario, Rosario, S2002KDS, Argentina|Instituto Medico de la Fundacion Estudios Clinicos, Rosario, S2013DTC, Argentina|CAIPO - Centro para la AtenciÃ³n Integral del Paciente OncolÃ³gico, San Miguel de TucumÃ¡n, 4000, Argentina|ClÃ­nica Viedma, Viedma, 8500, Argentina|Klinikum Klagenfurt am Woerthersee, Klagenfurt Am Woerthersee, Austria|Ordensklinikum Linz GmbH, Elisabethinen, Linz, 4020, Austria|Klinikum Wels-Grieskirchen, Wels, 4600, Austria|Krankenhaus Nord - Klinik Floridsdorf, Wien, A-1140, Austria|Algemeen Ziekenhuis Sint-Lucas, Aalst, 9300, Belgium|Grand Hopital de Charleroi asbl (GHdC), Charleroi, 6000, Belgium|AZ Sint-Maarten, Mechelen, 2800, Belgium|CHU UCL Namur / Site Sainte Elisabeth, Namur, 5000, Belgium|Cenantron Centro AvanÃ§ado de Tratamento Oncologico Ltda, Belo Horizonte, 30130-090, Brazil|Hospital Evangelico de Cachoeiro de Itapemirim, Cachoeiro De Itapemirim, 29308-014, Brazil|Fundacao Universidade De Caxias Do Sul - FUCS/RS, Caxias Do Sul, 95070-560, Brazil|Instituto do CÃ¢ncer do CearÃ¡ - ICC, Fortaleza, 60430-230, Brazil|Oncosite - Centro de Pesquisa Clinica em Oncologia LTDA, Ijui, 98700-000, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, 90020-090, Brazil|Hospital de ClÃ­nicas de Porto Alegre, Porto Alegre, 90035-903, Brazil|Hospital SÃ£o Lucas da PUCRS, Porto Alegre, 90610-000, Brazil|Hospital Ana Nery Santa Cruz do Sul, Santa Cruz Do Sul, 96810-110, Brazil|Centro Des Pesquisas Clinicas da Fundacao Doutor Amaral Carvalho, Sao Paolo, 17210080, Brazil|Instituto Brasiliero de Controle do Cancer IBCC, Sao Paulo, 03102002, Brazil|Centre Integre de sante et de services sociaux de la Monteregie Centre, Greenfield Park, J4V 2H1, Canada|Moncton Hospital, Moncton, E1C 6Z8, Canada|CISSS des Laurentides, Quebec, J7Z 2V4, Canada|Centre de santÃ© et services sociaux de Rimouski-Neigette, Rimouski, G5L5T1, Canada|BC Cancer - Victoria, Victoria, V8R 6V5, Canada|Clinica Alemana de Santiago, Las Condes, 7550000, Chile|Orlandioncologia, Providencia, 7500006, Chile|Oncovida- Santiago, Providencia, 7510035, Chile|Clinica Puerto Montt, Puerto Montt, 5500243, Chile|Biocinetic, Santiago, 8331143, Chile|James Lind Centro de Investigacion del Cancer, Temuco, 4800827, Chile|Oncocentro APYS, Vina del Mar, 2520612, Chile|West China Hospital Sichuan University, Chengdu, 610041, China|Chongqing University Cancer Hospital, Chongqing, 400030, China|Deyang People's Hospital, Deyang, 618000, China|Fujian Cancer Hospital, Fuzhou, 350014, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China|Guangzhou First People's Hospital, Guangzhou, 510180, China|Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China|Zhejiang Cancer Hospital, Hangzhou, 310005, China|Anhui Chest Hospital, Hefei, 230022, China|The Second Affiliated Hospital of Nanchang University, Jiangxi, 330006, China|Shandong Cancer Hospital, Jinan, 250021, China|Jiangxi Chest Hospital, Nanchang, 330006, China|Nanjing Drum Tower Hospital, Nanjing, 210008, China|Guangxi Medical University Cancer Hospital, Nanning, 530021, China|Shanghai Chest Hospital, Shanghai, 200030, China|Shanghai Pulmonary Hospital, Shanghai, 200433, China|Cancer Hospital of Shantou University Medical College, Shantou, 0754-88555844, China|Tianjin Medical University Cancer Institute & Hospital, Tianjin, 300181, China|Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, 430022, China|Tongji Hospital Tongji Medical College of Hust, Wuhan, 430030, China|The First Affiliated Hospital of Xian Jiaotong University, Xi'an, 710049, China|The First Affiliated Hospital of Xinxiang Medical College, Xinxiang, 453100, China|Henan Cancer Hospital, Zhengzhou, 450008, China|Ambroise-Pare Hospital, Assistance Publique - Hopitaux de Paris, Boulogne-Billancourt, 92100, France|CHU de Caen, Caen, 14000, France|Clinique Victor Hugo, Centre de Cancerologie de la Sarthe, Le Mans, 72000, France|Hopital Nord, Marseille, 13005, France|Institut de Cancer de Montpellier (ICM) - Val d'Aurelle, Montpellier, 34928, France|Centre Antoine Lacassagne, Nice, 6189, France|Institut de cancerologie de l'ouest (ICO), Saint-Herblain, 44805, France|Hopital d'Instruction des Armees (HIA) Begin, Saint-MandÃ©, 94160, France|Centre Hospitalier de Saint-Quentin, Saint-Quentin, 2100, France|Institut de Cancerologie Strasbourg Europe (ICANS), Strasbourg, 67033, France|HÃ´pital Foch, Suresnes, 92150, France|CHI de Toulon la Seyne-sur-Mer Hopital Sainte Musse, Toulon cedex, 83056, France|Augusta-Kranken-Anstalt gGmbh Klinik fÃ¼r HÃ¤matologie Onkologie und Palliativmedizin, Bochum, 44791, Germany|Klinikum Chemnitz gGmbH, Chemnitz, 9116, Germany|Universitatsklinikum Essen / Westdeutsches Tumorzentrum, Innere Klinik (Tumorforschung), Essen, 45122, Germany|UniversitÃ¤tsklinikum Freiburg, Klinik fÃ¼r Innere Medizin I HÃ¤matologie, Onkologie und Stammzelltransplantation, Freiburg, 79106, Germany|LungenClinic Grosshansdorf, Grosshansdorf, 22927, Germany|Krankenhaus Martha-Maria Halle DÃ¶lau, Halle, 06120, Germany|Asklepios Kliniken Hamburg, Hamburg, 21075, Germany|Katholisches Marienkrankenhaus gGmbH, Hamburg, 22087, Germany|Lungenklinik Hemer, Zentrum fur Pneumologie and Thoraxchirurgie, Hemer, 58675, Germany|Vincentius-Diakonissen-Kliniken gAG, St. Vincentius-Kliniken, Medizinische Klinik 2, Karlsruhe, 76137, Germany|Klinikum Kassel, Kassel, 34125, Germany|Kliniken der Stadt KÃ¶ln ggmbh, Krankenhaus Koln-Merheim/Lungenklinik, KÃ¶ln, 51109, Germany|Universitatsklinikum Schleswig-Holstein, Lubeck, 23538, Germany|Johannes Wesling Klinikum Minden, Minden, 32429, Germany|Munchen Klinik Bogenhausen, Klinik fur Pneumologie und Pneumologische Onkologie, Munchen, 81925, Germany|Sana Klinikum Offenbach GmbH, Medizinische Klinik IV, HÃ¤matologie und Internistische Onkologie, Offenbach, 63069, Germany|Queen Elizabeth Hospital, Hong Kong, 999077, Hong Kong|Queen Mary Hospital, Hong Kong, 999077, Hong Kong|Prince of Wales Hospital, New Territories, Hong Kong|Soroka University Medical Center, Itzchak Rager Blvd., Beer Seva, 84101, Israel|Shaare Zedek Medical Center, Jerusalem, 9103102, Israel|Oncology Institute, Galilee Medical Center, Route 89 Nahariya-Cabri, Nahariya, Israel|Rabin Medical Center, Petah Tiqva, 49100, Israel|Kaplan Medical Center, Rehovot, 76100, Israel|Tel-Aviv Sourasky Medical Center, Tel Aviv, 64239, Israel|Azienda Ospedaliera San Giuseppe Moscati, Avellino, Italy|IRCCS Fondazoine del Piemonte per l'Oncologia, Candiolo, 10060, Italy|Azienda Socio Sanitaria Territoriale di Cremona, Cremona, 26100, Italy|Ospedale Policlinico San Martino, Genova, 16132, Italy|Ospedale San Raffaele, Milano, 20132, Italy|Azienda Ospedaliero Universitaria di Modena, Modena, 41124, Italy|AORN Cardarelli, Naples, 80131, Italy|Azienda Ospedaliera dei Colli, Napoli, 80131, Italy|IRCCS Policlinico S. Matteo, Dipartimento Oncologia Ematologia-Oncologia Medica, Pavia, 27100, Italy|Azienda Sanitaria Territoriale Pesaro e Urbino (AST), Pesaro, 61122, Italy|Ospedale Guglielmo da Saliceto AUSL di Piacenza, Piacenza, 29100, Italy|Centro di Riferimento Oncologico, Pordenone, 33081, Italy|Regina Elena Institute for Cancer Research, Rome, 00144, Italy|ASST Bergamo Ovest- ospedale di Treviglio, Treviglio, 24047, Italy|National Cancer Center Hospital East, Chiba, 277-0882, Japan|National Hospital Organization Shikoku Cancer Center, Ehime, 791-0280, Japan|Kyushu University Hospital, Fukuoka, 812-8582, Japan|Kurume University Hospital, Fukuoka, 830-0011, Japan|National Hospital Organization Himeji Medical Center, Hyogo, 670-8520, Japan|Hyogo Cancer Center, Hyogo, 673-8558, Japan|Kanazawa University Hospital, Ishikawa, 920-8641, Japan|Kanagawa Cancer Center, Kanagawa, 241-0815, Japan|Sendai Kousei Hospital, Miyagi, 981-0914, Japan|Niigata Cancer Center Hospital, Niigata, 951-8566, Japan|Osaka Metropolitan University Hospital, Osaka, 545-8586, Japan|Osaka Medical and Pharmaceutical University Hospital, Osaka, 569-8686, Japan|Kindai University Hospital, Osaka, 589-8511, Japan|National Hospital Organization Kinki Chuo Chest Medical Center, Osaka, 591-8555, Japan|Saitama Medical University, Saitama, 350-1298, Japan|SMG - SNU Boramae Medical Center, Dongjak-Gu, 07061, Korea, Republic of|Samsung Medical Center, Gangnam-Gu, 6351, Korea, Republic of|National Cancer Center, Goyang, 410769, Korea, Republic of|Chungbuk National University Hospital, Heungdeok-Gu, 361-711, Korea, Republic of|Inha University Hospital, Incheon, 22332, Korea, Republic of|Gachon University Gil Medical Center, Inchon, 21565, Korea, Republic of|Kosin University Gospel Hospital, Seo-gu, 49267, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, 03722, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, 06591, Korea, Republic of|Ajou University Hospital, Suwon-si, 16499, Korea, Republic of|The Catholic University of Korea, Saint Vincent's Hospital, Suwon, 16247, Korea, Republic of|Health Pharma Professional Research S.A. de C.V., Mexico, 3100, Mexico|Hospital Universitario Dr. Jose Eleuterio Gonzalez, Mitras Centro, 64460, Mexico|Oaxaca Site Management Organization, Oaxaca, 68000, Mexico|Centro de Investigacion Clinica de Oaxaca, Oaxaca, 68020, Mexico|Clinical Medical Research SC., Orizaba Centro, 94300, Mexico|Clinica Integral Internacional de Oncologia S de RL de CV, Puebla, 72530, Mexico|FAICIC ClÃ­nical Research, Veracruz, 91900, Mexico|Amphia Ziekenhuis, Breda, 4818 CK, Netherlands|Ziekenhuis Gelderse Vallei, Ede, 6716 RP, Netherlands|Universitair Medisch Centrum Groningen, Groningen, 9713 GZ, Netherlands|Ziekenhuis St Jansdal, Harderwijk, 3844 DG, Netherlands|TweeSteden Ziekenhuis, Tilburg, Netherlands|Hospital Prof. Doutor Fernando Fonseca, Amadora, 2720276, Portugal|Instituto PortuguÃªs de Oncologia de Lisboa Francisco Gentil, Lisboa, 1089, Portugal|Fundacao Champalimaud, Lisboa, 1400-038, Portugal|Centro Hospitalar UniversitÃ¡rio Lisboa Norte - Hospital Pulido Valente, Lisboa, Portugal|Hospital Beatriz Angelo. Hospital de Loures., Lisbon, 2674-514, Portugal|Centro Hospitalar Universitario Sao Joao, EPE, Porto, 4202-451, Portugal|Unidade Local de Saude de Matosinhos EPE - Hospital Pedro Hispano SA, Senhora da Hora, 4464-513, Portugal|Raffles Hospital, Singapore, 188770, Singapore|Tang Tock Seng Hospital, Singapore, 308433, Singapore|Hospital Clinic de Barcelona, Barcelona, 08036, Spain|Hospital de la Santa Creu i de Sant Pau, Barcelona, 08041, Spain|Hospital Universitari Dexeus (USP Institut Universitari Dexeus/Hospital Universitari Quiron Dexeus), Barcelona, 8028, Spain|Hospital Universitari Vall D'Hebron, Barcelona, 8035, Spain|Hospital Parc Tauli, Barcelona, 8208, Spain|Hospital Universitario Reina Sofia, Cordoba, 14004, Spain|Hospital Doctor Josep Trueta, Girona, 17007, Spain|Hospital Universitario de Jaen, Jaen, 23007, Spain|Hospital Universitario de Canarias, Las Palmas de G.C., 35016, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, 28020, Spain|Clinica Universidad de Navarra, Madrid, 28027, Spain|Hospital Universitario La Paz, Madrid, 28046, Spain|Hospital Universitario Puerta de Hierro de Majadahonda, Majadahonda, 28222, Spain|Hospital Sant Joan de Reus, Reus, 43204, Spain|Hospital Regional Universitario de Malaga, Rincon de la Victoria, 29011, Spain|Hospital Universitario Virgen Macarena, Sevilla, 41009, Spain|Hospital Universitario Virgen del Rocio, Seville, 41014, Spain|Instituto Valenciano De Oncologia (IVO), Valencia, 46009, Spain|Hospital Universitari i Politecnic La Fe, Valencia, 46015, Spain|Hospital Vithas Valencia 9 de Octubre, Valencia, 46015, Spain|Changhua Christian Hospital, Changhua City, 500-06, Taiwan|E-DA Hospital, Kaohsiung City, 824, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, 807, Taiwan|Chang Gung Memorial Hospital Kaohsiung, Kaohsiung, 83301, Taiwan|National Cheng Kung University Hospital, Tainan, 70403, Taiwan|Chi Mei Hospital, Liouying, Tainan, Taiwan|National Taiwan University Hospital, Taipei City, 100, Taiwan|Taipei Veterans General Hospital, Taipei, 10002, Taiwan|Chang Gung Memorial Hospital Linkou Branch of the Chang Gung Medical Foundation, Taoyuan City, 33305, Taiwan|Ankara Bilkent Sehir Hastanesi, Ankara, 06550, Turkey|Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastirma Hastanesi, Ankara, 6200, Turkey|Trakya University Faculty of Medicine, Edirne, 22030, Turkey|Istanbul University Cerrahpasa Medical Faculty Hospital, Fatih, 34098, Turkey|Goztepe Prof. Dr. Suleyman YalcÄ±n Sehir Hastanesi, Istanbul, 34093, Turkey|Medipol Mega University Hospital, Istanbul, Turkey|Acibadem Mehmet Ali Aydinlar Universitesi Atakent Hastanesi, Kaakaekmece, 34303, Turkey|Turgut Ozal Medical Faculty, Malatya, 44300, Turkey|Colchester General Hospital, Colchester, CO4 5JL, United Kingdom|St Bartholomew's Hospital, Barts Health NHS Trust, London, EC1A 7BE, United Kingdom|The Christie NHS Foundation Trust, Department of Medical Oncology, Manchester, M20 4BX, United Kingdom|University Hospital Southampton Nhs Foundation Trust, Southampton, SO16 6YD, United Kingdom",
NCT04557059,A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer,https://clinicaltrials.gov/study/NCT04557059,PRIMORDIUM,ACTIVE_NOT_RECRUITING,The main purpose of this study is to determine if the addition of apalutamide to radiotherapy (RT) plus luteinizing hormone-releasing hormone agonist (LHRHa) delays metastatic progression as assessed by prostate specific membrane antigen-positron emission tomography (PSMA-PET) or death compared with RT plus LHRHa alone.,NO,Prostatic Neoplasms,RADIATION: Radiotherapy|DRUG: LHRHa|DRUG: Apalutamide,"Prostate specific Membrane Antigen-Positron Emission Tomography (PSMA-PET) Metastatic Progression-free Survival (ppMPFS), ppMPFS is defined as the appearance of at least one new PSMA-PET-positive distant lesion compared with the previous scan as assessed by blinded independent central review (BICR) or death., Up to 9 years","Time to Prostate-Specific Antigen (PSA) Progression, Time to PSA progression is defined as the time from randomization to the date of first documentation of PSA progression. PSA progression is defined as a PSA concentration above the nadir of more than 0.5 nanogram per milliliter (ng/mL), confirmed by additional measurement at least 3 Weeks later., Up to 9 years|PSA Response Rate, PSA response rate is defined as the percentage of participants with a PSA decrease of \>= 50 percent (%), \>= 90% or undetectable from baseline., Up to 9 years|PSA Levels at Week 26, PSA levels at week 26 will be reported., Week 26|Time to Loco-Regional Progression by PSMA-PET, Time to loco-regional progression by PSMA-PET as assessed by blinded independent central review (BCIR) is defined as the time from randomization to the date of the first occurrence of PSMA-PET loco-regional progression. Criteria for PSMA-PET loco-regional progression: Appearance of at least one new PSMA-PET-positive loco-regional lesion compared with the previous scan., Up to 9 years|Overall Survival, Overall survival is defined as the time from randomization to date of death from any cause., Up to 9 years|Prostate Cancer-Specific Survival, Prostate cancer-specific survival is defined as the time from randomization to date of death due to prostate cancer., Up to 9 years|Number of Participants With Adverse Event (AE) and Serious Adverse Events (SAEs), An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the study vaccine. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. An SAE is any AE that results in: death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect and is a suspected transmission of any infectious agent via a medicinal product., Up to 9 years",,"Janssen Pharmaceutica N.V., Belgium",,MALE,"ADULT, OLDER_ADULT",PHASE3,694,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-11-12,2029-08-27,2029-08-27,2020-09-21,,2025-05-23,"Arizona Urology Specialists, Tucson, Arizona, 85741, United States|Arkansas Urology, Little Rock, Arkansas, 72211, United States|Colorado Clinical Research, Lakewood, Colorado, 80228, United States|Urological Research Network, Hialeah, Florida, 33016, United States|First Urology, PSC, Jeffersonville, Indiana, 47130, United States|Michigan Institute of Urology, Troy, Michigan, 48084, United States|Associated Medical Professionals of Ny, Syracuse, New York, 13210, United States|The Urology Group, Cincinnati, Ohio, 45212, United States|Oregon Urology Institute, Springfield, Oregon, 97477, United States|MidLantic Urology, Bala-Cynwyd, Pennsylvania, 19004, United States|Urology Austin, Austin, Texas, 78745, United States|Houston Metro Urology, Houston, Texas, 77027, United States|Spokane Urology, Spokane, Washington, 99202, United States|Bundaberg Hospital, Bundaberg, 4670, Australia|Hervey Bay Hospital, Bundaberg, 4670, Australia|Epworth Healthcare, East Melbourne, 3002, Australia|St Vincent's Hospital - Melbourne, Fitzroy, 3065, Australia|Genesis Care Hurstville, Hurstville, 2220, Australia|Macquarie University Hospital, North Ryde, 2109, Australia|Calvary Mater Newcastle, Waratah, 2298, Australia|GenesisCare Wembley, Wembley, 6014, Australia|Ordensklinikum Linz GmbH Elisabethinen, Linz, 4020, Austria|Universitaetsklinikum Salzburg Landeskrankenhaus, Salzburg, 5020, Austria|Medizinische Universitaet Wien, Wien, 1090, Austria|A.Z. Sint Jan, Brugge, 8000, Belgium|UZ Gent, Gent, 9000, Belgium|Az Groeninge, Kortrijk, 8500, Belgium|GZA Ziekenhuis, Wilrijk, 2610, Belgium|Empresa Brasileira de Servicos Hospitalares - EBSERH - Hospital das Clinicas da UFMG, Belo Horizonte, 30130-100, Brazil|Liga Paranaense de Combate ao Cancer, Curitiba, 81520 060, Brazil|Liga Norte Riograndense Contra O Cancer, Natal, 59075-740, Brazil|Associacao Hospitalar Moinhos de Vento, Porto Alegre, 90035-001, Brazil|Irmandade Santa Casa de Misericordia de Porto Alegre, Porto Alegre, 90050-170, Brazil|Oncoclinicas Rio de Janeiro S A, Rio de Janeiro, 22250-905, Brazil|Hospital Sao Rafael, Salvador, 41253 190, Brazil|Hospital Alemao Oswaldo Cruz, Sao Paulo, 01421-000, Brazil|Hospital Sao Camilo Unidade Vila Mariana, Sao Paulo, 04014-002, Brazil|Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein, Sao Paulo, 05652 900, Brazil|Sociedade Beneficente de Senhoras Hospital Sirio Libanes, SÃ£o Paulo, 01308 901, Brazil|Fakultni nemocnice Plzen, Urologicka klinika, Plzen, 305 99, Czechia|Urocentrum Praha, Praha 2, 120 00, Czechia|Urologicka klinika 1 LF UK a VFN, Praha 2, 120 00, Czechia|Fakultni nemocnice v Motole, Praha 5, 15006, Czechia|Aalborg University Hospital, Aalborg, 9000, Denmark|Aarhus University Hospital, Aarhus N., 8200, Denmark|Rigshospitalet, Copenhagen N, 2200, Denmark|Gentofte Herlev Hospital, Herlev, 2730, Denmark|Helsinki University Hospital, Helsinki, 00290, Finland|Oulu University Hospital, Oulu, 90220, Finland|Tampere University Hospital, Tampere, 33521, Finland|Turku University Hospital, Turku, 20520, Finland|Vaasa Central Hospital, Vaasa, 65130, Finland|Vivantes Klinikum Am Urban, Berlin, 10967, Germany|StÃ¤dtisches Klinikum Braunschweig gGmbH - Standort Salzdahlumer, Braunschweig, 38126, Germany|Universitatsklinikum Carl Gustav Carcus Dresden, Dresden, 01307, Germany|Universitatsklinikum Essen, Essen, D-45147, Germany|Universitaetsklinikum Muenster, Muenster, 48149, Germany|Klinikum rechts der Isar - der Technischen UniversitÃ¤t MÃ¼nchen, Munchen, 81675, Germany|PÃ©terfy SÃ¡ndor utcai KÃ³rhÃ¡z, Budapest, 1076, Hungary|Budapesti Bajcsy Zsilinszky Korhaz es Rendelointezet, Budapest, 1106, Hungary|Orszagos Onkologiai Intezet, Budapest, 1122, Hungary|Eszak Budai Szent Janos Centrumkorhaz, Budapest, 1125, Hungary|Budapesti Uzsoki Utcai Korhaz, Budapest, 1145, Hungary|Jahn Ferenc Del-pesti Korhaz es Rendelointezet, Budapest, 1204, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, 4032, Hungary|Radioterapia Oncologica, A.O.U. San'T Orsola, Bologna, 40138, Italy|Azienda Ospedaliero Universitaria Careggi, Firenze, 50134, Italy|Ospedale San Raffaele, Milano, 20132, Italy|Fondazione Policlinico Tor Vergata, Roma, 00133, Italy|Istituto Nazionale Tumori Regina Elena, Roma, 00144, Italy|Azienda Ospedaliera Sant Andrea, Roma, 00189, Italy|King Hussein Cancer Center, Amman, 0000, Jordan|St Georges Hospital university medical centre, Beirut, 11 00 2807, Lebanon|American Universitty of Beirut Medical Center, Beirut, 1107 2020, Lebanon|Notre Dame De Secours, Jbeil, 3, Lebanon|Centre Hospitalier du Nord, Zgharta, 100, Lebanon|Consultorio de Especialidad en Urologia Privado, Durango, 34000, Mexico|Hospital Aranda de la Parra S A de C V, Leon, 37000, Mexico|Avix Investigacion Clinica S C, Monterrey, 64623, Mexico|Oncologia Integral Satelite, Naucalpan, 53100, Mexico|Centro de Investigacion Clinica de Oaxaca, Oaxaca de JuÃ¡rez, 68020, Mexico|Oncocenter, Puebla, 72530, Mexico|Cuidados Oncologicos, Queretaro, 76000, Mexico|Centrum Onkologii im Prof F Lukaszczyka w Bydgoszczy, Bydgoszcz, 85 796, Poland|NU-MED Grupa S.A Centrum Radioterapii i Onkologii, Elblag, 82-300, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, 80 952, Poland|Szpitale Pomorskie Sp z o o, Gdynia, 81 519, Poland|Swietokrzyskie Centrum Onkologii SPZOZ w Kielcach, Kielce, 25 734, Poland|Szpital Wojewodzki im Mikolaja Kopernika w Koszalinie, Koszalin, 75 581, Poland|Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im M Kopernika w Lodzi, Lodz, 93 513, Poland|Radomskie Centrum Onkologii, Radom, 26-600, Poland|Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy, Warszawa, 02 781, Poland|Ipo Lisboa, Lisboa, 1099-023, Portugal|Hosp. Cuf Tejo, Lisboa, 1350-352, Portugal|Fund. Champalimaud, Lisboa, 1400-038, Portugal|Uls Lisboa Ocidental - Hosp. Sao Francisco Xavier, Lisboa, 1449-005, Portugal|Hosp. Da Luz Lisboa, Lisboa, 1500 650, Portugal|Uls Santa Maria - Hosp. Santa Maria, Lisboa, 1649 035, Portugal|Uls Santo Antonio - Hosp. Santo Antonio, Porto, 4099-001, Portugal|Uls de Entre Douro E Vouga - Hosp. Sao Sebastiao, Santa Maria da Feira, 4520-211, Portugal|SHI Sverdlovsk Regional Clinical Hospital #1, Ekaterinburg, 620102, Russian Federation|Ivanovo Regional Oncology Dispensary, Ivanovo, 153040, Russian Federation|City Clinical Hospital #57, Moscow, 105077, Russian Federation|I.M. Sechenov First Moscow State Medical University, Moscow, 119991, Russian Federation|Hertzen Oncology Research Institute, Moscow, 125284, Russian Federation|SPb SBIH 'City Clinical Oncological Dispensary', Saint Petersburg, 197022, Russian Federation|Leningrad Regional Oncology Dispensary, Saint-Petersburg, 191104, Russian Federation|Multifunctional clinical medical center 'Medical city', Tyumen, 625041, Russian Federation|CUIMED - urologickÃ¡ ambulancia, Bratislava, 851 05, Slovakia|VÃ½chodoslovenskÃ½ OnkologickÃ½ Ãstav, KoÅ¡ice, 04191, Slovakia|UniverzitnÃ¡ nemocnica Martin, Martin, 036 59, Slovakia|Uroexam s.r.o., Nitra, 94901, Slovakia|Urologicka ambulancia e.cho Poprad, s.r.o, Poprad, 05801, Slovakia|MILAB s.r.o., PreÅ¡ov, 08001, Slovakia|PrivÃ¡tna urologickÃ¡ ambulancia, Trencin, 911 01, Slovakia|Hospital Universitario Puerto Del Mar, Cadiz, 11009, Spain|Hosp. Arquitecto Marcide, Ferrol, 15405, Spain|Hosp. de Jerez de La Frontera, Jerez de la Frontera, 11407, Spain|Hosp. Univ. 12 de Octubre, Madrid, 28041, Spain|Hosp. Univ. de La Paz, Madrid, 28046, Spain|Hosp Virgen de La Victoria, MÃ¡laga, 29010, Spain|Complejo Hosp. de Navarra, Navarra, 31008, Spain|Clinica Univ. de Navarra, Pamplona, 31008, Spain|Hosp. Virgen Del Rocio, Sevilla, 41013, Spain|Hosp. Univ. I Politecni La Fe, Valencia, 46026, Spain|Hosp. Clinico Univ. Lozano Blesa, Zaragoza, 50009, Spain|Urologiska Mottagningen, MalmÃ¶, 205 02, Sweden|Prostatacancercentrum, Stockholm, 112 19, Sweden|Sodersjukhuset, Stockholm, 11883, Sweden|Adana Baskent Yuregir Hospital, Adana, 01250, Turkey|Hacettepe University Medical Faculty, Ankara, 06230, Turkey|Memorial Ankara Hastanesi, Ankara, 06520, Turkey|Ankara University Medical Faculty, Ankara, 06590, Turkey|Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, 6200, Turkey|Koc University, School of Medicine, Koc University Hospital, Istanbul, 34010, Turkey|Istanbul University Cerrahpasa Medical Faculty, Istanbul, 34096, Turkey|Bakirkoy Training and Research Hospital, Istanbul, 34147, Turkey|Goztepe Prof Dr Suleyman Yalcin Sehir Hastanesi, Istanbul, 34722, Turkey|Kartal Dr Lutfi Kirdar Egitim ve Arastirma Hastanesi, Istanbul, 34890, Turkey|Dokuz Eylul Universitesi Tip Fakultesi, Izmir, 35340, Turkey|Sakarya Ãniversitesi TÄ±p FakÃ¼ltesi Hastanesi, Sakarya, 54187, Turkey",
NCT05120349,A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection,https://clinicaltrials.gov/study/NCT05120349,ADAURA2,ACTIVE_NOT_RECRUITING,This is a global study to assess the effects of osimertinib in participants with EGFRm stage IA2-IA3 non-small cell lung cancer following complete tumour resection.,NO,Non-Small Cell Lung Cancer,DRUG: Osimertinib|DRUG: Placebo,"Disease-Free Survival (DFS) in high-risk stratum, DFS is defined as the time from the date of randomisation until the date of disease recurrence or date of death (by any cause in the absence of recurrence), whichever occurs first.

Stratification to the high risk stratum will be based on pathologic features assessed by central pathology review during screening., From date of randomisation up to approximately 10 years","Disease-Free Survival (DFS) in overall population, DFS is defined as the time from the date of randomisation until the date of disease recurrence or date of death (by any cause in the absence of recurrence), whichever occurs first., From date of randomisation up to approximately 10 years|Overall Survival (OS) in high-risk stratum and the overall population, OS is defined as the time from the date of randomisation until death due to any cause., From date of randomization up to approximately 10 years|PK plasma concentrations of osimertinib and of metabolite AZ5104 in overall population, Ratio of metabolite-to-osimertinib to be calculated at predose, and at 0.5-2 hours postdose., From date of randomisation up to approximately 10 years|Impact of osimertinib versus placebo on physical functioning, Assess the impact of osimertinib versus placebo on physical functioning in both the high-risk stratum and the overall population as measured by SF-36 V2 health survey, From date of randomisation up to approximately 10 years|Central Nervous System (CNS) Disease-Free Survival (DFS) in both the high-risk stratum and the overall population, CNS DFS is defined as the time from randomisation to the time of a CNS lesion (as assessed by investigator) or death due to any cause, regardless of whether the participant withdraws from study intervention or receives other anti-cancer therapy., From date of randomisation up to approximately 10 years|Safety and tolerability in overall population, AEs graded by CTCAE version 5.0, From date of randomisation up to approximately 10 years",,AstraZeneca,,ALL,"ADULT, OLDER_ADULT",PHASE3,390,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-02-21,2027-08-02,2032-11-01,2021-11-15,,2025-04-13,"Research Site, Anchorage, Alaska, 99508, United States|Research Site, Los Angeles, California, 90024, United States|Research Site, Orange, California, 92868, United States|Research Site, Grand Junction, Colorado, 81501, United States|Research Site, Newark, Delaware, 19713, United States|Research Site, Atlanta, Georgia, 30322, United States|Research Site, Chicago, Illinois, 60612, United States|Research Site, Frederick, Maryland, 21702, United States|Research Site, Morristown, New Jersey, 07960, United States|Research Site, Flushing, New York, 11355, United States|Research Site, New York, New York, 10032, United States|Research Site, New York, New York, 10065, United States|Research Site, White Plains, New York, 10601, United States|Research Site, Houston, Texas, 77030, United States|Research Site, Fort Belvoir, Virginia, 22060, United States|Research Site, Buenos Aires, C1431FWO, Argentina|Research Site, Caba, C1012AAR, Argentina|Research Site, Cipolletti, 8234, Argentina|Research Site, La Plata, 1900, Argentina|Research Site, Rosario, 2000, Argentina|Research Site, Rosario, S2000CVB, Argentina|Research Site, S.C. De Bariloche, 8400, Argentina|Research Site, Barretos, 14784-400, Brazil|Research Site, Belo Horizonte, 30380-090, Brazil|Research Site, Porto Alegre, 90610-000, Brazil|Research Site, Recife, 52010-075, Brazil|Research Site, Rio de Janeiro, 22271-110, Brazil|Research Site, Sao Paulo, 01327-001, Brazil|Research Site, SÃ£o Paulo, 04501-000, Brazil|Research Site, Vancouver, British Columbia, V5Z 1M9, Canada|Research Site, Montreal, Quebec, H4A 3J1, Canada|Research Site, Toronto, M5G 2M9, Canada|Research Site, Beijing, 100005, China|Research Site, Beijing, 100029, China|Research Site, Beijing, 100142, China|Research Site, Beijing, 100210, China|Research Site, Beijing, 100730, China|Research Site, Beijing, 102218, China|Research Site, Changchun, 130012, China|Research Site, Changsha, 410013, China|Research Site, Changsha, 430033, China|Research Site, Chengdu, 610000, China|Research Site, Fuzhou, 350014, China|Research Site, Guangzhou, 510060, China|Research Site, Guangzhou, 510100, China|Research Site, Hangzhou, 310022, China|Research Site, Harbin, 150049, China|Research Site, Jinan, 250117, China|Research Site, Nanjing, 210029, China|Research Site, Shanghai, 200030, China|Research Site, Shanghai, 200032, China|Research Site, Shenzhen, 518116, China|Research Site, Suzhou, 215006, China|Research Site, Taiyuan, 030000, China|Research Site, Xi'an, 710061, China|Research Site, Xintai, 54031, China|Research Site, Yangzhou, 225001, China|Research Site, Zhengzhou, 450008, China|Research Site, Berlin, 13125, Germany|Research Site, Esslingen, 73730, Germany|Research Site, Georgsmarienhuette, 49124, Germany|Research Site, LÃ¼beck, 23538, Germany|Research Site, MÃ¼nchen, 81377, Germany|Research Site, WÃ¼rzburg, 97067, Germany|Research Site, Bari, 70124, Italy|Research Site, Catania, 95100, Italy|Research Site, Firenze, 50134, Italy|Research Site, Genova, 16132, Italy|Research Site, Milan, 20141, Italy|Research Site, Napoli, 80131, Italy|Research Site, Padova, 35128, Italy|Research Site, Parma, 43100, Italy|Research Site, Roma, 00144, Italy|Research Site, Chiba-shi, 260-0877, Japan|Research Site, Fukuoka-shi, 812-8582, Japan|Research Site, Hiroshima-shi, 734-8551, Japan|Research Site, Kashiwa, 227-8577, Japan|Research Site, Koto-ku, 135-8550, Japan|Research Site, Kyoto-shi, 606-8507, Japan|Research Site, Niigata-shi, 951-8566, Japan|Research Site, Osaka-shi, 541-8567, Japan|Research Site, Osakasayama-shi, 589-8511, Japan|Research Site, Sendai-shi, 981-0914, Japan|Research Site, Shinjuku-ku, 160-0023, Japan|Research Site, Sunto-gun, 411-8777, Japan|Research Site, Wakayama-shi, 641-8510, Japan|Research Site, Daegu, 42415, Korea, Republic of|Research Site, Jinju-si, 52727, Korea, Republic of|Research Site, Seoul, 03082, Korea, Republic of|Research Site, Seoul, 05505, Korea, Republic of|Research Site, Seoul, 07061, Korea, Republic of|Research Site, Suwon, 16247, Korea, Republic of|Research Site, Suwon, 16499, Korea, Republic of|Research Site, Kuala Lumpur, 59100, Malaysia|Research Site, Kuching, 93586, Malaysia|Research Site, Pulau Pinang, 10450, Malaysia|Research Site, Selangor, 46050, Malaysia|Research Site, PoznaÅ, 60-569, Poland|Research Site, Warszawa, 01-138, Poland|Research Site, Bucharest, 050098, Romania|Research Site, Bucuresti, 022328, Romania|Research Site, Perm, 614990, Russian Federation|Research Site, Saint Petersburg, 191036, Russian Federation|Research Site, Singapore, 169610, Singapore|Research Site, Singapore, 308433, Singapore|Research Site, Barcelona, 08041, Spain|Research Site, MÃ¡laga, 29010, Spain|Research Site, Valencia, 46010, Spain|Research Site, Vigo, 36312, Spain|Research Site, Zaragoza, 50009, Spain|Research Site, Taichung, 40201, Taiwan|Research Site, Taichung, 40705, Taiwan|Research Site, Tainan, 70403, Taiwan|Research Site, Taipei City, 114, Taiwan|Research Site, Taipei, 100, Taiwan|Research Site, Taipei, 11217, Taiwan|Research Site, Taipei, 235, Taiwan|Research Site, Taoyuan, 333, Taiwan|Research Site, Bangkok, 10300, Thailand|Research Site, Bangkok, 10330, Thailand|Research Site, Bangkok, 10700, Thailand|Research Site, Hat Yai, 90110, Thailand|Research Site, Khon Kaen, 40002, Thailand|Research Site, Muang, 50200, Thailand|Research Site, Ankara, 06010, Turkey|Research Site, Bursa, 16059, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, 35040, Turkey|Research Site, KadÄ±koy/Istanbul, 34722, Turkey|Research Site, Birmingham, B9 5SS, United Kingdom|Research Site, Blackpool, FY3 8NR, United Kingdom|Research Site, London, SE1 9RT, United Kingdom|Research Site, London, SW10 9NH, United Kingdom|Research Site, London, SW3 6NP, United Kingdom|Research Site, Nottingham, NG5 1PB, United Kingdom|Research Site, Wythenshawe, M23 9LT, United Kingdom|Research Site, Hanoi, 100000, Vietnam|Research Site, Ho Chi Minh city, 700000, Vietnam|Research Site, Ho Chi Minh, 700000, Vietnam",
NCT06435429,"A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer",https://clinicaltrials.gov/study/NCT06435429,,RECRUITING,"The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous T-DXd treatment.",NO,Metastatic HER2-positive Breast Cancer,DRUG: Zanidatamab|DRUG: Trastuzumab|DRUG: Eribulin|DRUG: Vinorelbine|DRUG: Gemcitabine|DRUG: Capecitabine,"Progression-free Survival (PFS) Per RECIST Version 1.1 As Assessed by Blinded Independent Central Review (BICR), PFS is defined as the time in months from randomization to the date of first documented disease progression (as assessed by BICR according to RECIST v1.1) or death from any cause, whichever occurs first., Until disease progression or death, up to approximately 44 months","Overall Survival (OS), OS is defined as the time in months from randomization to the date of death due to any cause., Until death, up to approximately 80 months|Confirmed Objective Response Rate (ORR) Per RECIST Version 1.1, As Assessed by BICR, The BICR-assessed confirmed ORR is defined as the proportion of participants who had a best overall response of BICR-assessed Complete Response (CR) or Partial Response (PR) after randomization., Until disease progression or death, up to approximately 44 months|Duration of Response (DOR) Per RECIST Version 1.1, As Assessed by BICR, BICR-assessed DOR is defined as the time in months from the first objective response (CR or PR) that is subsequently confirmed to documented progressive disease (PD) as assessed by BICR per RECIST v1.1 or death from any cause., Until disease progression or death, up to approximately 44 months|PFS Per RECIST Version 1.1, As Assessed By Investigator, Investigator-assessed PFS is defined as the time in months from randomization to the date of first documented disease progression (as assessed by investigator according to RECIST v1.1) or death from any cause, whichever occurs first, Until disease progression or death, up to approximately 44 months|Confirmed ORR Per RECIST Version 1.1, As Assessed By Investigator, The investigator-assessed confirmed ORR is defined as the proportion of participants who had a best overall response of investigator-assessed confirmed CR or PR after randomization., Until disease progression or death, up to approximately 44 months|DOR Per RECIST Version 1.1, As Assessed By Investigator, Investigator-assessed DOR is defined as the time in months from the first objective response (CR or PR) that is subsequently confirmed to documented PD as assessed by the investigator per RECIST v1.1 or death from any cause., Until disease progression or death, up to approximately 44 months|Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events As Graded by NCI CTCAE Version 5.0, Up to approximately 44 months|Number of Participants With Dose Reductions, Up to approximately 44 months|Number of Participants Discontinuing Study Treatment Due to TEAEs, Up to approximately 44 months|Serum Concentrations of Zanidatamab, Up to approximately 44 months|Number of Participants Positive for Anti-drug Antibodies to Zanidatamab, Up to approximately 44 months|Proportion of All Treated Participants, As Treated, Reporting Symptomatic Adverse Events While On Treatment Based on Patient-reported Outcome-Common Terminology Criteria for AEs and European Organisation for Research and Treatment of Cancer Item Library, Up to approximately 44 months|Proportion of All Treated Participants, As Treated, Reporting Overall Side-effect Bother on the Functional Assessment of Chronic Illness Therapy General Physical Item 5 (FACIT-GP5), The Functional Assessment of Chronic Illness Therapy (FACIT) GP5 Item score ranges from 0 (Not at all) to 4 (Very Much), where higher scores reflect greater bother from treatment side effects., Up to approximately 44 months|Proportion of Treated Participants, As Treated, With Maintained or Improved Physical Function While On Treatment Based On The Physical Functioning Subscale of the EORTC Quality of Life Questionnaire Core Module (EORTC QLQ-C30), The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core Module Physical Functioning score ranges from 0 to 100, where higher scores reflect better functioning., Up to approximately 44 months",,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,550,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-08-13,2028-09-26,2031-11-26,2024-05-30,,2025-06-08,"Arizona Oncology Tucson - Wilmot, Tucson, Arizona, 85711, United States|University of Arizona Cancer Center, Tucson, Arizona, 85719, United States|The Oncology Institute Of Hope And Innovation, Cerritos, California, 90703, United States|USC-Norris Comprehensive Cancer Center - Investigational Drug Service IDS, Los Angeles, California, 90033, United States|University of Colorado-Cancer Center-PPDS, Aurora, Colorado, 80045-2517, United States|Rocky Mountain Cancer Centers, Denver, Colorado, 80218, United States|Medstar Georgetown University Hospital, Washington, District of Columbia, 20007, United States|Washington Cancer Center, Washington, District of Columbia, 20010, United States|Florida Cancer Specialists Research South, Fort Myers, Florida, 33901, United States|Florida Cancer Specialists Research North, Saint Petersburg, Florida, 33705, United States|Florida Cancer Specialists Research East, West Palm Beach, Florida, 33401, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215-5418, United States|Minnesota Oncology Hematology, Coon Rapids, Minnesota, 55433, United States|Saint Luke's Cancer Institute, Kansas City, Missouri, 64111, United States|Hackensack Meridian Health, Hackensack, New Jersey, 07601, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, 08901, United States|Perlmutter Cancer Center 160 E 34th St, New York, New York, 10016-4744, United States|The Mount Sinai Hospital, New York, New York, 10029, United States|Columbia University Medical Center 161 Fort Washington, New York, New York, 10032-3729, United States|Messino Cancer Center, Asheville, North Carolina, 28806, United States|Oncology Hematology Care (OHC), Cincinnati, Ohio, 45226, United States|University Hospitals Cleveland Medical Center 11100 Euclid Ave, Cleveland, Ohio, 44106-1716, United States|Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States|Sarah Cannon Research Institute, Nashville, Tennessee, 37203, United States|Texas Oncology - Fort Worth, Fort Worth, Texas, 76104, United States|U.T. MD Anderson Cancer Center, Investigational Pharmacy Services, Houston, Texas, 77030, United States|Millennium Research and Clinical Development, Houston, Texas, 77090, United States|Maryland Oncology Hematology Healing Way - USOR, Irving, Texas, 75063, United States|Medical Oncology Hematology Consultants, Irving, Texas, 75063, United States|Nexus Health, Irving, Texas, 75063, United States|Sansum Clinic 540 W - USOR, Irving, Texas, 75063, United States|Texas Oncology Gulf Coast, Irving, Texas, 75063, United States|Texas Oncology West, Irving, Texas, 75063, United States|Virginia Cancer Specialists, Fairfax, Virginia, 22031, United States|Virginia Oncology Associates, Sentara Health, Norfolk, Virginia, 23502, United States|Blue Ridge Cancer Care, Roanoke, Virginia, 24014, United States|Fred Hutchinson Cancer Center, Seattle, Washington, 98109, United States|Sunshine Coast University Private Hospital, Birtinya, Queensland, 4575, Australia|Box Hill Hospital, Melbourne, Victoria, 3128, Australia|Peninsula and South Eastern Haematology and Oncology Group, Mount Waverly, Victoria, 3149, Australia|HPS Pharmacies - Adelaide, Adelaide, 5000, Australia|The Kinghorn Cancer Centre, Mt Kuring-gai, 2080, Australia|St John of God Hospital Subiaco, Subiaco, 6008, Australia|Ordensklinikum Barmherzige Schwestern, Linz, 4010, Austria|Klinikum Wels-Grieskirchen GmbH - Abteilung fÃ¼r Innere Medizin IV, Wels, 4600, Austria|Medizinische Universitat Wien, Wien, 1090, Austria|Institute Jules Bordet, Anderlecht, 1070, Belgium|UZ Antwerpen, Edegem, 2650, Belgium|Grand HÃ´pital de Charleroi, Gilly, 6060, Belgium|CHU UCL Namur - Site Sainte-Elisabeth, Namur, 5000, Belgium|AZ Delta- Campus Rumbeke, Roeselare, 8800, Belgium|DASA Hospital Brasilia, Brasilia, 71.635-610, Brazil|Centro Regional Integrado de Oncologia, Ceara, 60336-232, Brazil|Real Hospital Portugues de Beneficiencia Em Pernambuco, Recife, 52.010-075, Brazil|Ceon Pesquisas Ltda, SÃ£o Caetano do Sul, 09541-270, Brazil|Jewish General Hospital, Montreal, H3T 1E2, Canada|The Ottawa Hospital Cancer Centre, Ottawa, K1H 8L6, Canada|CHU de QuÃ©bec UniversitÃ© Laval HÃ´pital du Saint Sacrement, Quebec, G1S 4L8, Canada|Sunnybrook Research Institute, Toronto, M4N 3M5, Canada|BC Cancer-Vancouver Center, Vancouver, V5Z 4E6, Canada|Institut Bergonie, Bordeaux Cedex, 33076, France|Centre FranÃ§ois Baclesse, Caen, 14000, France|Centre Georges FranÃ§ois Leclerc, Dijon, 21000, France|Pharmacie Centre de Cancerologie de la Sarthe, Le Mans, 72000, France|Centre Oscar Lambret, Lille Cedex, 59020, France|AP HM Hopital de La Timone, Marseille, 13005, France|Pharmacie ICM Val d'Aurelle, Montpellier, 34298, France|ICANS - Institut de cancÃ©rologie Strasbourg Europe, Strasbourg, 67000, France|OncopÃ´le Claudius Regaud Pharmacie, Toulouse, 31059, France|Gustave Roussy, Villejuif, 94800, France|Helios Klinikum Berlin Buch GmbH Klinik fÃ¼r GynÃ¤kologie und Geburtshilfe, Berlin, 13125, Germany|Marienhospital Bottrop gGmbH, Dortmund, 44263, Germany|Aretaieio Hospital, Athens, 11528, Greece|Athens Medical Center, Athens, 15125, Greece|University General Hospital of Patras, Patra, 26504, Greece|European Interbalkan Medical Center, Thessaloniki, 57001, Greece|IRCCS Centro di Riferimento Oncologico di Aviano CRO, Aviano, 33081, Italy|Asst Papa Giovanni Xxiii, Bergamo, 24127, Italy|Azienda Ospedaliero Universitaria Di Bologna Policlinico S Orsola Malpighi Via Massarenti, Bologna, 40138, Italy|Ospedale San Raffaele S.r.l PPDS, Milano, 20132, Italy|Istituto Europeo di Oncologia, Milano, 20141, Italy|Fondazione IRCCS San Gerardo dei Tintori, Monza, 20900, Italy|Istituto Oncologico Veneto - I.R.C.C.S., Padova, 35128, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, 27100, Italy|Chiba Cancer Center, Chiba-shi, 260-8717, Japan|National Cancer Center Hospital, Chuo-ku, 104-0045, Japan|Osaka International Cancer Institute, Chuo-Ku, 541-8567, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka-shi, 811-1395, Japan|Fukushima Medical University Hospital, Fukushima, 960-1295, Japan|Saitama Medical University International Medical Center, Hidaka-shi, 350-1298, Japan|Tokai University Hospital, Isesaki-shi, 259-1193, Japan|Sagara Hospital, Kagoshima-Shi, 892-0833, Japan|Kyoto University Hospital, Kyoto, 606-8507, Japan|Aichi Cancer Center, Nagoya-shi, 464-8681, Japan|Nagoya City University Hospital, Nagoya-shi, 467-8602, Japan|Okayama University Hospital, Okayama, 700-8558, Japan|National Hospital Organization Osaka National Hospital, Osaka-Shi, 540-0006, Japan|National Hospital Organization Hokkaido Cancer Center, Sapporo-shi, 003-0804, Japan|Showa University Hospital, Tokyo, 142-8666, Japan|Kanagawa Cancer Center, Yokohama-shi, 241-8515, Japan|Soon Chun Hyang University Cheonan Hospital, Cheonan-si, 330721, Korea, Republic of|Gachon University Gil Medical Center, Namdong-gu, 21565, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, 13605, Korea, Republic of|Severance Hospital Yonsei University Health System, Seoul, 03722, Korea, Republic of|Gangnam Severance Hospital, Yonsei University Health System, Seoul, 06273, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, 137-701, Korea, Republic of|WojewÃ³dzki Szpital Specjalistyczny W BiaÅej Podlaskiej, Biala Podlaska, 21-500, Poland|BiaÅostockie Centrum Onkologii im. Marii SkÅodowskiej-Curie w BiaÅymstoku, Bialystok, 15-027, Poland|Pratia MCM KrakÃ³w, KrakÃ³w, 30-727, Poland|Pratia Poznan, Poznan, 60-192, Poland|Uniwersytecki Szpital Kliniczny w Poznaniu, Poznan, 60-569, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy w Warszawie, Warszawa, 02-781, Poland|Hospital Universitario A CoruÃ±a, A CoruÃ±a, 15006, Spain|Hospital Universitario de Badajoz, Badajoz, 06006, Spain|Hospital Universitari Vall d Hebron, Barcelona, 08035, Spain|Hospital Clinic de Barcelona, Barcelona, 08036, Spain|ICO Badalona-H.U. Germans Trias i Pujol, Barcelona, 08916, Spain|Hospital General Universitario de Elche, Elche, 03203, Spain|Hospital Universitario Clinico San Cecilio, Granada, 18016, Spain|Hospital Beata Maria Ana, Madrid, 28007, Spain|MD Anderson Cancer Center, Madrid, 28033, Spain|Hospital Clinico San Carlos, Madrid, 28040, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, 28040, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital Universitario de Canarias, San CristÃ³bal de La Laguna, 38320, Spain|Hospital Universitario Virgen del Rocio, Sevilla, 41013, Spain|Hospital ClÃ­nico Universitario de Valencia, Valencia, 46010, Spain|CHUVI - H.U. Alvaro Cunqueiro, Vigo, 36312, Spain|Beatson West Of Scotland Cancer Centre, Glasgow, G12 0YN, United Kingdom|Guy's Hospital, London, SE1 9RT, United Kingdom|Charring Cross Hospital, London, W6 8RF, United Kingdom|The Christie - PPDS, Manchester, M20 4BX, United Kingdom|Churchill Hospital, Oxford, OX3 7LJ, United Kingdom|New Cross Hospital, Wolverhampton, WV10 0QP, United Kingdom",
NCT05371093,Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma,https://clinicaltrials.gov/study/NCT05371093,ZUMA-22,ACTIVE_NOT_RECRUITING,"The goal of this clinical study is test how well the study drug, axicabtagene ciloleucel, works in participants with relapsed/refractory follicular lymphoma",NO,Relapsed/Refractory Follicular Lymphoma,BIOLOGICAL: Axicabtagene Ciloleucel|DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Lenalidomide|DRUG: Rituximab|DRUG: Doxorubicin|DRUG: Vincristine|DRUG: Prednisone|DRUG: Bendamustine,"Progression-free Survival (PFS) as Assessed by Blinded Central Assessment per Lugano Classification, PFS is defined as the time from randomization to disease progression or death due to any cause., Up to 5 years","Overall Survival (OS), OS is defined as the time from randomization to death from any cause., Up to 5 years|Complete Response (CR) Rate as Assessed by Blinded Central Assessment per Lugano Classification, CR rate is defined as the proportion of participants with best overall response of CR during the study prior to any subsequent off-protocol anti-follicular lymphoma (FL) therapy., Up to 5 years|Objective Response Rate (ORR) as Assessed by Blinded Central Assessment per Lugano Classification, Objective response rate is defined as the proportion of participants with best overall response of either a complete response or a partial response during the study prior to any subsequent off-protocol anti-FL therapy., Up to 5 years|Duration of Response (DOR) as Assessed by Blinded Central Assessment per Lugano Classification, DOR is defined as the time from first objective response to disease progression or death from any cause., Up to 5 years|Duration of CR as Assessed by Blinded Central Assessment per Lugano Classification, Duration of CR is defined as the time from first CR to disease progression or death from any cause., Up to 5 years|Event Free Survival (EFS) as Assessed by Blinded Central Assessment per Lugano Classification, EFS is defined as the time from randomization to the earliest date of disease progression, the initiation of subsequent off-protocol anti-FL therapy, or death from any cause., Up to 5 years|Time to Next Treatment (TTNT), TTNT is defined as the time from randomization to the start of subsequent off-protocol anti-lymphoma therapy or death from any cause., Up to 5 years|Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs), Randomization up to 5 years plus 30 days|Percentage of Participants Experiencing Clinically Significant Changes in Safety Laboratory Values, Randomization up to 5 years plus 30 days|Percentage of Participants with Replication-competent Retrovirus in Blood Over time, Up to 5 years|Change From Baseline in the Global Health Status Quality of Life Scale of the European Organisation for Research and Treatment of Cancer-Quality of Life Questionnaire-30 (EORTC QLQ-C30), The EORTC-QLQ-C30 is a multi-item questionnaire measuring the following content five (5) multi-item functional scales, three (3) multi-item symptom scales, one (1) global health status scale, and one (1) global health-related quality of life (HRQoL) each scale is measured from 0 to 100 after a linear transformation. Higher scores for functioning scales and for the Global Health Status or Global HRQoL scales indicate a higher level of functioning and a better HRQoL respectively, whereas higher scores in symptom scales represent a higher level of symptoms., Baseline, up to 5 years|Change From Baseline in the Physical Functioning Domain of the EORTC QLQ-C30, The EORTC-QLQ-C30) is a multi-item questionnaire measuring the following content five (5) multi-item functional scales, three (3) multi-item symptom scales, one (1) global health status scale, and one (1) global health-related quality of life (HRQoL) each scale is measured from 0 to 100 after a linear transformation. Higher scores for functioning scales and for the Global Health Status or Global HRQoL scales indicate a higher level of functioning and a better HRQoL respectively, whereas higher scores in symptom scales represent a higher level of symptoms., Baseline, up to 5 years|Change From Baseline in the Global Health Status Quality of Life Scale of the Low Grade Non-Hodgkin Lymphoma-20 (NHL-LG20), The NHL-LG20 is is a 20-item supplement questionnaire that was specifically developed to assess HRQoL in participants with low-grade non-Hodgkin lymphomas (such as follicular lymphoma). The NHL-LG20 includes multi-item scales of symptom burden, physical condition/fatigue, worries/fears on health and functioning, and emotional impact; and is administered in conjunction with the EORTC QLQ-C30. Each scale is measured from 0 to 100 after a linear transformation. Higher scores for functional scales and for the global health status or global HRQoL scales indicate a higher level of functioning and a better HRQoL, whereas higher scores in symptom scales represent a higher level of symptoms., Baseline, up to 5 years|Change From Baseline in the Physical Functioning Domain of the NHL-LG20, The NHL-LG20 is is a 20-item supplement questionnaire that was specifically developed to assess HRQoL in participants with low-grade non-Hodgkin lymphomas (such as follicular lymphoma). The NHL-LG20 includes multi-item scales of symptom burden, physical condition/fatigue, worries/fears on health and functioning, and emotional impact; and is administered in conjunction with the EORTC QLQ-C30. Each scale is measured from 0 to 100 after a linear transformation. Higher scores for functional scales and for the global health status or global HRQoL scales indicate a higher level of functioning and a better HRQoL, whereas higher scores in symptom scales represent a higher level of symptoms., Baseline, up to 5 years|Changes From Baseline in the European Quality of Life Five Dimensions Five Levels Scale (EQ-5D-5L), The EQ-5D-5L questionnaire is a generic measure of health status that provides a simple descriptive profile and a single index value. The EQ-5D-5L comprises 2 components: a questionnaire covering 5 dimensions and a tariff of values based upon direct valuations of health states using a visual analog scale (VAS). Rating gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ VAS indicate better health., Baseline, up to 5 years|Changes From Baseline in the Visual Analog Scale (VAS) Scores, The EQ-5D-5L VAS is a 20-cm VAS for recording self-rated current HRQoL state and is used to describe the participants health status on the day of the assessment. The EQ-5D-5L VAS score is recorded by each participant for his or her current HRQoL state and scored 0 (""the worst health you can imagine"") to 100 (""the best health you can imagine""). Higher scores indicate better health., Baseline, up to 5 years",,"Kite, A Gilead Company",,ALL,"ADULT, OLDER_ADULT",PHASE3,230,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-09-12,2030-10,2030-10,2022-05-12,,2025-05-09,"City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California, 91010, United States|Stanford Health Care, Stanford, California, 94305, United States|Moffitt Cancer Center, Tampa, Florida, 33612, United States|The University of Kansas Hospital, Westwood, Kansas, 66205, United States|University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, 21201, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Novant Health Cancer Institute Hematology - Charlotte, Charlotte, North Carolina, 28204, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, 17033, United States|TriStar Centennial Medical Center - Cell Processing, Nashville, Tennessee, 37203, United States|Henry-Joyce Cancer Clinic, Nashville, Tennessee, 37232, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|Virginia Commonwealth University, Richmond, Virginia, 23298, United States|Hopital Henri Mondor, CrÃ©teil, 94010, France|CHU de Dijon, Dijon, 21079, France|HÃ´pital Claude Huriez-CHU de Lille, Lille cedex, 59037, France|Institut Paoli-Calmettes, Marseille, 13273, France|Hopital Saint Eloi, Montpellier, 34295, France|Hopital Pitie-Salpetriere, Paris, 75013, France|CHU Bordeaux - Hospital Haut-Leveque - Centre Francois Magendie, Pessac, 33604, France|Centre Hospitalier Lyon Sud, Pierre Benite, 69495, France|CHU de Poitiers, Poitiers, 86021, France|Hopital Pontchaillou - CHU Rennes, Rennes, 35033, France|Centre Henri Becquerel, Rouen, 76038, France|Universitatsmedizin Gottingen, GÃ¶ttingen, 37075, Germany|Universitatsklinikum Koln Klinik I fur Innere Medizin, Wuerzburg, 97080, Germany|ASST Papa Giovanni XXIII, Bergamo, 24128, Italy|Azienda Ospedallero-Universitaria di Bologna Policlinico Sant'Orsola-Malpighi, Bologna, 40138, Italy|Fondazione IRCCS - Istituto Nazionale Tumori, Milano, 20100, Italy|Ospedale San Raffaele, Milano, 20132, Italy|Arcispedale Santa Maria Nuova, Reggio Emilia, 42123, Italy|Istituto Clinico Humanitas-IRCCS, Rozzano, 20089, Italy|Hyogo Medical University Hospital, Hyogo, 663-8501, Japan|University Hospital Kyoto Prefectural University of Medicine, Kyoto, 602-8566,, Japan|Tohoku University Hospital, Miyagi, 980-8574, Japan|Okayama University Hospital, Okayama, 700-8558, Japan|Osaka University Hospital, Osaka, 565-0871, Japan|Hospital Universitari Vall d'HebrÃ³n, Barcelona, 08035, Spain|Hospital Clinic de Barcelona, Barcelona, 08036, Spain|Instituto Catalan de Oncologia - Hospital Duran i Reynolds (ICO L'Hospitalet), Barcelona, 08908, Spain|Hospital General Universitario Gregorio Maranon, Madrid, 28009, Spain|Hospital 12 de Octubre, Madrid, 28041, Spain|Hospital Universitario de Salamanca, Salamanca, 37007, Spain|Hospital Universitario Virgen del Rocio, Sevilla, 41013, Spain|Hospital ClÃ­nico Universitario de Valencia, Valencia, 46010, Spain|University Hospital Birmingham NHS Foundation Trust, Birmingham, B15 2GW, United Kingdom|Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 2QQ, United Kingdom|University College London Hospitals NHS Foundation Trust, London, NW2 2QG, United Kingdom|King's College Hospital NHS Foundation Trust, London, SE5 9RS, United Kingdom|The Christie NHS Foundation Trust, Manchester, M20 4BX, United Kingdom|Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE, United Kingdom|The University Hospital Southampton NHS Foundation Trust, Southampton, SO16 6YD, United Kingdom|The Royal Marsden NHS Foundation Trust, Sutton, SM2 5PT, United Kingdom",
NCT04523493,Phase III Study of Toripalimabï¼JS001ï¼ Combined With Lenvatinib for Advanced HCC,https://clinicaltrials.gov/study/NCT04523493,,ACTIVE_NOT_RECRUITING,"This is a prospective, randomized, placebo-controlled, double-blind, multicenter phase III registration clinical study to observe, compare and evaluate the efficacy and safety of Toripalimab combined with Lenvatinib versus placebo combined with Lenvatinib as the 1st-line therapy for advanced HCC.

Eligible subjects will be randomized at a ratio of 2:1 to receive Toripalimab combined with Lenvatinib (experimental group) or Placebo combined with Lenvatinib (control group).",NO,Advanced Hepatocellular Carcinoma (HCC),COMBINATION_PRODUCT: Toripalimab combined with Lenvatinib|COMBINATION_PRODUCT: Placebo combined with Lenvatinib,"Overall survival (OS), The time from randomization to death for any reason., Up to 3 years","ORR, Defined as the proportion of subjects with the best overall response of complete response (CR) or partial response (PR)., Up to 3 years|Duration of Response (DOR), Defined as the time from the first evaluation of CR or PR to the first evaluation of PD or death for any reason., Up to 3 years|DCR, Defined as the proportion of subjects with the best overall response (BOR) of CR, PR or SD., Up to 3 years|TTP, Defined as the time from randomization to objective tumor progression., Up to 3 years|Progression-free survival (PFS), The time from randomization to progression of disease or death for any reason, whichever comes first. Progression of disease will be evaluated, Up to 3 years|PFS rate, The PFS rate on 6 months and 1year in both groups., Up to 3 years|OS rate, The OS rate on 1year and 2years in both groups., Up to 3 years|Incidence,severity and prognosis of AEs/SAEs as assessed by NCI-CTCAE v5.0, Verbatim descriptions of adverse events will correspond to MedDRA synonymous terms, and AEs will be graded in accordance with NCI-CTCAE version 5.0. All the adverse events during or after the first dose of study drug will be summarized by treatment groups and NCI CTCAE grade. In addition, serious adverse events, adverse events (grade 3 or above) and the adverse events leading to discontinuation or suspension of study drug will be summarized correspondingly. Multiple occurrence of the same event will be counted once in accordance with the highest severity. The proportion of subjects with at least one adverse event will be reported by term of toxicity and treatment groups., From date of consent informed until 90 days after the last investigational product administration. Up to 2 approximately years.|PK, According to the test of blood samples, the pharmacokinetic parameters of Toripalimab, mainly trough concentration, will be analyzed., To be collected once within 60 minutes prior to administration each for Toripalimab/placebo on Day 1 of Cycle (each cycle is 21 days). but the no-china sites not collection the sample|Immunogenicity, Plasma level of anti-Toripalimab injection (JS001) antibody, immunoglobulin and Toripalimab injection (JS001) will be summarized descriptively., Up to 3 years","Assessment of the correlation between tumor cell PD-L1 expression level/ percentage and efficacy, Tumor biopsy specimen collected before the treatment and tumor specimen collected at progression of tumor will be used for immunohistochemical staining test to determine the expression of PD-L1, Up to 3 years|Tumor mutation burden (TMB), Correlation between TMB of tumor tissue and the efficacy, Up to 3 years","Shanghai Junshi Bioscience Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,530,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-06-29,2025-05-31,2026-09-01,2020-08-21,,2025-02-19,"Qinhuai Medical Area, General Hospital of PLA Eastern Theater Command, Nanjing, Jiangsu, 21000, China|Azienda Ospedaliera Universitaria Careggi, Firenze, 50134, Italy|Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico,Oncologia Medica, Milan, 20122, Italy|IRCCS Fondazione Giovanni Pascale, Istituto Nazionale Dei Tumori, Napoli, 80131, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, 56126, Italy|A.O.U. Citta della Salute e della Scienza di Torino, Tortona, Italy|AOUI Verona - Policlinico ""G.B. Rossi"" di Borgo Roma, Verona, 37134, Italy|Copernicus Podmiot Leczniczy sp. z o.o., Wojewodzkie Centrum Onkologii, Oddzial Onkologii Klinicznej/Chemioterapii, Gdansk, 80-219, Poland|Szpital WojewÃ³dzki im. MikoÅaja Kopernika w Koszalinie, Oddzial Dzienny Chemioterapii, Koszalin, 75-581, Poland|PRATIA MCM KrakÃ³w, ul. Pana Tadeusza 2,, Krakow, 30-727, Poland|ID Clinic, MysÅowice, 41-400, Poland|Wielkopolskie Centrum Onkologii, OddziaÅ Onkologii Klinicznej i Immunoonkologii z PododdziaÅem Dziennym i IzbÄ PrzyjÄÄ, Poznan, 61-866, Poland|Centrum Medyczne Pratia PoznaÅ, SkÃ³rzewo, 60-185, Poland|Narodowy Instytut Onkologii im. Marii SkÅodowskiej-Curie - PaÅstwowy Instytut Badawczy, Klinika Onkologii i Radioterapii, Warszawa, 02-034, Poland|National Cancer Centre Singapore, Singapore, 168583, Singapore|Communal Non-commercial Enterprise City Clinical Hospital #4 of Dnipro City Council, Department of Chemotherapy, Dnipro, 49102, Ukraine|Communal Non-profit Enterprise ""Regional Center of Oncology"", Department of Abdominal Organs Oncosurgery, Kharkiv, 61070, Ukraine|Communal Non-Profit Institution of Kharkiv Regional Council Regional Clinical Specialized Dispensary of Radiation Protection of Population, Kharkiv, 61166, Ukraine|State Inst. O.O.Shalimov Nat. scientific certer of Surgery and Transplantology of Nat. Academy of Med.Sciences of Ukraine, Dep.of Oncology, Kyiv, 03126, Ukraine|Communal Enterprise Volyn Regional Clinical Hospital of Volyn Regional Council, Luts'k, 43018, Ukraine|Communal Non-commercial Enterprise Odesa Regional Clinical Hospital of Odesa Regional Council, Department of General Surgery, Odesa, 65025, Ukraine|Communal Non-commercial Enterprise of Sumy Regional Council, Sumy Regional Clinical Oncological Dispensar, Sumy, 40022, Ukraine|Communal Non-commercial Enterprise Zaporizhzhia Regional Antitumor Center of Zaporizhzhia Regional Council, Zaporizhzhia, 69040, Ukraine",
NCT06510374,Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer,https://clinicaltrials.gov/study/NCT06510374,ABLE-32,RECRUITING,"A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)",NO,Intermediate Risk Non-Muscle Invasive Bladder Cancer,DRUG: Nadofaragene Firadenovec,"Recurrence Free survival, Recurrence-free survival, defined as the time from the date of randomization to the date of first documented recurrence, progression or death (due to any cause), whichever occurs first during the treatment period., 24 months","Adverse Events, Frequency and intensity of adverse events will be recorded from the signed informed consent for participation in the trial up to month 24, up to 24 months|Recurrence Free Survival at 12 Months, Recurrence free survival at 12 months defined as whether a subject is alive and is documented recurrence and progression-free for up to 12 months, 12 months|Recurrence Free Survival at 24 Months, Recurrence free survival at 24 months defined as whether a subject is alive and is documented recurrence and progression-free for up to 24 months, 24 Months",,Ferring Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,454,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-10-01,2030-03-31,2030-03-31,2024-07-19,,2025-06-03,"Ferring Investigational Site, Mobile, Alabama, 36606, United States|Ferring Investigational Site, Fresno, California, 93720, United States|Ferring Investigational Site, Los Angeles, California, 90017, United States|Ferring Investigational Site, Murrieta, California, 92563, United States|Ferring Investigational Site, Largo, Florida, 33771, United States|Ferring Investigational Site, Atlanta, Georgia, 30322, United States|Ferring Investigational Site, Lexington, Kentucky, 40536, United States|Ferring Investigational Site, Creve Coeur, Missouri, 63141, United States|Ferring Investigational Site, Omaha, Nebraska, 68114, United States|Ferring Investigational Site, Albany, New York, 10461, United States|Ferring Investigational Site, Bronx, New York, 10468, United States|Ferring Investigational Site, Garden City, New York, 11530, United States|Ferring Investigational Site, New York, New York, 10016, United States|Ferring Investigational Site, Poughkeepsie, New York, 12603, United States|Ferring Investigational Site, Bala-Cynwyd, Pennsylvania, 19004, United States|Ferring Investigational Site, Myrtle Beach, South Carolina, 29572, United States|Ferring Investigational Site, Virginia Beach, Virginia, 23462, United States|Ferring Investigational Site, Burlington, Ontario, L7N 3V2, Canada|Ferring Investigational Site, Nankoku, Kochi, 783-8505, Japan",
NCT03383458,A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation,https://clinicaltrials.gov/study/NCT03383458,CheckMate 9DX,ACTIVE_NOT_RECRUITING,"This study will investigate if nivolumab will improve recurrence-free survival (RFS) compared to placebo in participants with HCC who have undergone complete resection or have achieved a complete response after local ablation, and who are at high risk of recurrence",NO,Hepatocellular Carcinoma|Liver Cancer,BIOLOGICAL: Nivolumab|OTHER: Placebo,"Recurrence-free Survival (RFS), Up to 49 months","Overall Survival (OS), Up to 7 years|Time to recurrence (TTR), Up to 49 months",,Bristol-Myers Squibb,Ono Pharmaceutical Co. Ltd,ALL,"ADULT, OLDER_ADULT",PHASE3,545,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-04-18,2025-04-28,2025-12-16,2017-12-26,,2023-11-18,"Local Institution - 0081, Anniston, Alabama, 36207, United States|Mayo Clinic in Arizona - Phoenix, Phoenix, Arizona, 85054, United States|Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, 85711, United States|Local Institution - 0135, Los Angeles, California, 90095, United States|Local Institution - 0088, Palo Alto, California, 94304, United States|Local Institution - 0085, San Francisco, California, 94115, United States|Local Institution - 0235, Aurora, Colorado, 80045, United States|Miami VA Healthcare System, Miami, Florida, 33125, United States|Sylvester Comprehensive Cancer Center/ UMHC, Miami, Florida, 33136, United States|Local Institution - 0163, Tampa, Florida, 33612, United States|Local Institution - 0009, Atlanta, Georgia, 30322, United States|Local Institution - 0025, Westwood, Kansas, 66205, United States|Local Institution - 0086, New Orleans, Louisiana, 70112, United States|University of Michigan, Ann Arbor, Michigan, 48109, United States|Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota, 55404, United States|Local Institution - 0209, Saint Louis, Missouri, 63110, United States|Local Institution - 0075, New York, New York, 10016, United States|Local Institution - 0208, New York, New York, 10029, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Local Institution - 0219, White Plains, New York, 10601, United States|MetroHealth Medical Center, Cleveland, Ohio, 44109, United States|Local Institution - 0206, Portland, Oregon, 97225, United States|Local Institution - 0272, Austin, Texas, 78705, United States|Texas Oncology Sammons Cancer Center, Dallas, Texas, 75246, United States|Local Institution - 0156, Dallas, Texas, 75390, United States|Local Institution - 0273, Tyler, Texas, 75702, United States|McGuire VA Medical Center, Richmond, Virginia, 23249, United States|Local Institution - 0154, Seattle, Washington, 98109, United States|Local Institution - 0243, Gorriti, Buenos Aires, 5737, Argentina|Local Institution - 0254, Pilar, Buenos Aires, 1629, Argentina|Local Institution - 0244, Rosario, Santa FE, 2000, Argentina|Local Institution - 0239, Blacktown, New South Wales, 2148, Australia|Local Institution - 0166, Camperdown, New South Wales, 2050, Australia|Local Institution - 0141, Concord, New South Wales, 2139, Australia|Local Institution - 0220, Herston, Queensland, 4029, Australia|Local Institution - 0164, Adelaide, South Australia, 5000, Australia|Local Institution - 0224, Heidelberg, Victoria, 3084, Australia|Local Institution - 0124, Nedlands, Western Australia, 6009, Australia|Local Institution - 0012, Graz, 8036, Austria|Local Institution - 0001, Vienna, 1100, Austria|Local Institution - 0003, Wien, 1090, Austria|Local Institution - 0033, Brussels, 1070, Belgium|Local Institution - 0064, Bruxelles, 1200, Belgium|Local Institution - 0068, Edegem, 2650, Belgium|Local Institution - 0071, Gent, 9000, Belgium|Local Institution - 0108, Leuven, 3000, Belgium|Local Institution - 0090, Belo Horizonte, Minas Gerais, 30130-090, Brazil|Local Institution - 0275, Barretos, Sao Paulo, 14780-070, Brazil|Local Institution - 0237, Cerqueira Cesar, SAO Paulo, 01246-000, Brazil|Local Institution, Sao Jose Do Rio Preto, Sao Paulo, 15090-000, Brazil|Local Institution, SÃ£o Paulo, SAO Paulo, 08270-120, Brazil|Local Institution - 0023, Sao Paulo, 01308-050, Brazil|Local Institution - 0236, Sao Paulo, 01509-010, Brazil|Local Institution, Calgary, Alberta, T2N 4Z6, Canada|Local Institution - 0116, Edmonton, T6G 1Z2, Canada|Local Institution - 0248, Santiago de Chile, Metropolitana, 0, Chile|Local Institution - 0246, Santiago, Metropolitana, 7710007, Chile|Local Institution - 0245, Santiago, RegiÃ³n Metropolitana De Santiago, 8380420, Chile|Local Institution - 0247, Vina del Mar, Valparaiso, 2520598, Chile|Local Institution - 0256, Bogota, 0, Colombia|Local Institution - 0057, Bobigny, 93000, France|Local Institution - 0052, Brest, 29200, France|CHU Estaing, Clermont Ferrand, 63003, France|Local Institution - 0046, Clichy, 92110, France|Local Institution - 0061, Creteil Cedex, 94010, France|Local Institution - 0013, Grenoble Cedex 09, 38043, France|Local Institution - 0222, Lille, 59037, France|Local Institution - 0051, Lyon Cedex 04, 69317, France|Local Institution - 0043, Montpellier Cedex, 34295, France|Local Institution - 0037, Nice, 06202, France|Local Institution, Poitiers, 86021, France|Local Institution - 0098, Reims, 51100, France|Local Institution - 0212, Rennes Cedex 9, 35033, France|Local Institution - 0044, Saint-Priest-en-Jarez, 42270, France|Local Institution - 0011, Vandoeuvre Les Nancy Cedex, 54511, France|Local Institution - 0054, Villejuif, 94800, France|Local Institution - 0024, Aachen, 52057, Germany|Local Institution - 0258, Berlin, 13353, Germany|Local Institution - 0020, Bonn, 53127, Germany|Local Institution - 0026, Essen, 45147, Germany|Local Institution - 0093, Frankfurt am Main, 60590, Germany|Local Institution - 0040, Hannover, 30625, Germany|Local Institution - 0019, Homburg, 66421, Germany|Local Institution - 0050, Koln, 50937, Germany|Local Institution, Leipzig, 04103, Germany|Local Institution - 0036, Magdeburg, 39104 Magdeburg, Germany|Local Institution - 0048, Mainz, 55131, Germany|Universitatsmedizin Mannheim, Mannheim, 68167, Germany|Local Institution - 0096, Muenchen, 81377, Germany|Local Institution - 0008, Tuebingen, 72076, Germany|Local Institution, Wuerzburg, 97078, Germany|Local Institution - 0120, Hong Kong, 999077, Hong Kong|Local Institution - 0076, Hong Kong, Hong Kong|Local Institution - 0136, Messina, ME, 98125, Italy|Local Institution - 0102, Bologna, 40138, Italy|Local Institution - 0077, Firenze, 50134, Italy|Local Institution - 0104, Meldola, 47014, Italy|Local Institution - 0091, Milano, 20133, Italy|Local Institution, Modena, 41124, Italy|Local Institution - 0134, Monserrato, 09042, Italy|Azienda Ospedaliera Specialistica dei Colli Monaldi-Cotugno-CTO, Napoli, 80131, Italy|Local Institution - 0119, Napoli, 80131, Italy|Local Institution - 0103, Padova, 35128, Italy|Fondazione Policlinico Gemelli - Universita Cattolica del Sacro Cuore, Rome, 00168, Italy|Local Institution - 0187, Chiba-shi, Chiba, 2608677, Japan|Local Institution - 0183, Kashiwa-shi, Chiba, 2778577, Japan|Local Institution - 0201, Kurume-shi, Fukuoka, 8300011, Japan|Local Institution - 0184, Sapporo-shi, Hokkaido, 0600033, Japan|Local Institution - 0200, Sapporo-shi, Hokkaido, 0608648, Japan|Local Institution - 0216, Nishinomiya-shi, Hyogo, 6638501, Japan|Local Institution - 0180, Kanazawa-shi, Ishikawa, 9208641, Japan|Local Institution - 0257, Morioka-shi, Iwate, 0208505, Japan|Local Institution - 0202, Kumamoto-shi, Kumamoto, 8608556, Japan|Local Institution, Osaka-sayama, Osaka, 5898511, Japan|Local Institution - 0203, Osaka-shi, Osaka, 5438555, Japan|Local Institution - 0198, Osaka-shi, Osaka, 5458586, Japan|Local Institution - 0214, Suita-shi, Osaka, 565-0871, Japan|Local Institution - 0185, Tokushima-shi, Tokushima, 770-8503, Japan|Local Institution - 0215, Bunkyo-ku, Tokyo, 1138655, Japan|Local Institution - 0196, Chuo-ku, Tokyo, 1040045, Japan|Local Institution - 0182, Mitaka-shi, Tokyo, 181-8611, Japan|Local Institution - 0210, Musashino-shi, Tokyo, 1808610, Japan|Local Institution - 0186, Shinjuku-ku, Tokyo, 162-8655, Japan|Local Institution - 0179, Hiroshima, 734-8551, Japan|Local Institution - 0197, Kanagawa, 213-8587, Japan|Local Institution - 0191, Suwon-si, Gyeonggi-do, 16499, Korea, Republic of|Local Institution - 0127, Seoul, Seoul-teukbyeolsi [Seoul], 06351, Korea, Republic of|Local Institution - 0177, Daegu, 41944, Korea, Republic of|Local Institution - 0190, Goyang-si, 10408, Korea, Republic of|Local Institution - 0188, Gyeongsangnam-do, 50612, Korea, Republic of|Local Institution - 0178, Jeollanam-do, 58128, Korea, Republic of|Local Institution - 0169, Seongnam-si, 13620, Korea, Republic of|Local Institution - 0128, Seoul, 03080, Korea, Republic of|Local Institution - 0168, Seoul, 03722, Korea, Republic of|Local Institution - 0167, Seoul, 05505, Korea, Republic of|Local Institution - 0195, Seoul, 06591, Korea, Republic of|Local Institution - 0189, Seoul, 08308, Korea, Republic of|Local Institution - 0148, Cuauhtemoc, Durango, 06700, Mexico|Local Institution - 0264, Monterrey, Nuevo Leon, 64460, Mexico|Local Institution - 0121, Monterrey, Nuevo LeÃ³n, 64000, Mexico|Local Institution - 0226, San Luis Potosi, 78250, Mexico|Local Institution - 0263, Maastricht, 6229 HX, Netherlands|Local Institution - 0260, Utrecht, 3584CX, Netherlands|Local Institution - 0240, Auckland, 1023, New Zealand|Local Institution - 0231, San Juan, 00927, Puerto Rico|Local Institution, Brasov, 500091, Romania|Local Institution - 0078, Bucharest, 022328, Romania|Local Institution - 0232, Cluj-Napoca, 400015, Romania|Local Institution - 0242, Constanta, 900591, Romania|Local Institution - 0074, Craiova, 200542, Romania|Local Institution - 0070, Timisoara, 300166, Romania|Local Institution - 0032, St. Petersburg, Sankt-Peterburg, 198255, Russian Federation|Arkhangelsk Clinical Oncological Dispensary, Arkhangelsk, 163045, Russian Federation|Local Institution, Leningrad Region, 188663, Russian Federation|Local Institution - 0230, Moscow, 115478, Russian Federation|Local Institution - 0042, Singapore, 119228, Singapore|Local Institution - 0067, Singapore, 169610, Singapore|Local Institution - 0039, Singapore, 308433, Singapore|Local Institution - 0069, Barcelona, 08035, Spain|Local Institution - 0031, Barcelona, 08036, Spain|Local Institution - 0016, CÃ³rdoba, 14004, Spain|Local Institution - 0072, Donostia-San Sebastian, 20014, Spain|Local Institution - 0199, Madrid, 28007, Spain|Local Institution - 0109, Madrid, 28046, Spain|Local Institution - 0100, Pamplona, 31008, Spain|Local Institution - 0010, Sabadell (Barcelona), 08208, Spain|Local Institution - 0028, Sevilla, 41013, Spain|Local Institution - 0082, Valencia, 46026, Spain|Local Institution - 0097, Zaragoza, 50009, Spain|Local Institution - 0131, Tainan, TNN, 704, Taiwan|Local Institution - 0204, Kaohsiung, 883, Taiwan|Local Institution - 0130, Taichung, 40447, Taiwan|Local Institution - 0140, Taichung, 40705, Taiwan|Local Institution - 0174, Tainan, 736, Taiwan|Local Institution - 0207, Taipei, 100, Taiwan|Local Institution - 0173, Taipei, 105, Taiwan|Local Institution - 0129, Taipei, 11217, Taiwan|Local Institution - 0175, Taoyuan, 333, Taiwan|Local Institution - 0176, Yunlin, 632, Taiwan|Local Institution - 0111, London, NW3 2QG, United Kingdom|Local Institution - 0092, London, SE5 9RS, United Kingdom|Local Institution - 0153, London, W12 0HS, United Kingdom|Local Institution - 0114, Manchester, M20 4BX, United Kingdom|Local Institution - 0142, Wirral, CH63 4JY, United Kingdom",
NCT04819100,A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT04819100,LIBRETTO-432,ACTIVE_NOT_RECRUITING,"The reason for this study is to see if the study drug, selpercatinib, compared to placebo is effective and safe in delaying cancer return in participants with early-stage non-small cell lung cancer (NSCLC), who have already had surgery or radiation. Participants who are assigned to placebo and stop the study drug because their disease comes back or gets worse have the option to potentially crossover to selpercatinib. Participation could last up to three years.",NO,"Carcinoma, Non-Small-Cell Lung",DRUG: Selpercatinib|DRUG: Placebo,"Event-Free Survival (EFS), EFS by Investigator Assessment in the Primary Analysis Population, Randomization to disease recurrence/progression or death from any cause (estimated as up to 7 years)","EFS, EFS by investigator assessment in the overall population, Randomization to disease recurrence/progression or death from any cause (estimated as up to 7 years)|Overall Survival (OS), OS, Randomization to death from any cause (estimated as up to 9 years)]|EFS, EFS by blinded independent central review (BICR), Randomization to disease recurrence/progression or death from any cause (estimated as up to 7 years)]|Time to Distant Disease Recurrence in the Central Nervous System (CNS), Time to distant disease recurrence in the CNS by investigator assessment and BICR, Randomization to disease recurrence/progression or death from any cause (estimated as up to 7 years)|Progression Free Survival on the Next Line of Treatment (PFS2), PFS2 by investigator assessment, Randomization to disease progression on the next line of treatment or death from any cause (estimated as up to 9 years)|Positive Predictive Value (PPV) of Rearranged during Transfection (RET) Tests from Investigator-Identified Laboratories with Respect to the Lilly-Designated RET Test, PPV of RET Tests from Investigator-Identified Laboratories with Respect to the Lilly-Designated RET Test, Baseline|Mean Change from Baseline over Time in NSCLC Symptoms, NSCLC symptoms will be measured using the 7-item NSCLC Symptom Assessment Questionnaire (NSCLC-SAQ). The NSCLC-SAQ measures the severity/frequency of the following core symptoms: Cough, pain, dyspnea, fatigue, and appetite. Raw scores range from 0 to 4 and the total score ranges from 0-20. Higher scores represent worse symptoms., Baseline to treatment discontinuation (estimated as up to 3 years)|Mean Change from Baseline over Time in Physical Function, Physical function will be measured by the 5 physical function items in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30) (also known as the EORTC IL 19 questionnaire). Raw scores range from 0-20. Higher scores indicate worst function., Baseline to treatment discontinuation (estimated as up to 3 years)",,Eli Lilly and Company,"Loxo Oncology, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE3,152,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-12-20,2026-05,2028-05,2021-03-26,,2025-04-25,"UCLA Hematology/Oncology - Santa Monica, Los Angeles, California, 90404, United States|Stockton Hematology Oncology Group, Stockton, California, 95204, United States|Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, 90502, United States|GenesisCare, Aventura, Florida, 33180, United States|GenesisCare - Boca Raton, Boca Raton, Florida, 33431, United States|USO-Cancer Care Center of Brevard, Inc., Palm Bay, Florida, 32909, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Mayo Clinic in Rochester, Minnesota, Rochester, Minnesota, 55905, United States|USO-New York Oncology Hematology, P.C, Latham, New York, 12110, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|USO - Alliance Cancer Specialists, PC, Horsham, Pennsylvania, 19044, United States|Sarah Cannon Research Institute SCRI, Nashville, Tennessee, 37203, United States|Tennessee Oncology Nashville, Nashville, Tennessee, 37203, United States|USO-Texas Oncology-Central/South Texas, Austin, Texas, 78705, United States|US Oncology, The Woodlands, Texas, 77380, United States|Sunshine Coast University Hospital, Birtinya, Queensland, 4575, Australia|Rockhampton Hospital, Rockhampton, Queensland, 4700, Australia|The Townsville Hospital, Townsville, Queensland, 4814, Australia|Ballarat Health Services, Ballarat Central, Victoria, 3350, Australia|Bendigo Health Care Group, Bendigo, Victoria, 3550, Australia|Goulburn Valley Health, Shepparton, Victoria, 3630, Australia|South West Healthcare, Warrnambool, Victoria, 3280, Australia|Border Medical Oncology, Wodonga, Victoria, 3690, Australia|Landeskrankenhaus Feldkirch, Feldkirch, Vorarlberg, 6800, Austria|Klinik Floridsdorf, Wien, 1210, Austria|Antwerp University Hospital, Edegem, Antwerpen, 2650, Belgium|Cliniques universitaires Saint-Luc, Brussels, Bruxelles-Capitale, RÃ©gion De, 1200, Belgium|UniversitÃ© Catholique de Louvain-Namur - Centre Hospitalier Universitaire Dinant-Godinne - Site Godinne, Yvoir, Namur, 5530, Belgium|Clinique Saint Pierre, Ottignies, Wallonne, RÃ©gion, 1340, Belgium|AZ Delta vzw, Roeselare, West-Vlaanderen, 8800, Belgium|CHU UCL Namur/Site Sainte Elisabeth, Namur, 5000, Belgium|Nucleo de Oncologia da Bahia, Salvador, Bahia, 40170-070, Brazil|Sirio-Libanes Brasilia - Centro de Oncologia - Asa Sul, Brasilia, Distrito Federal, 70200-730, Brazil|Oncocentro de Minas Gerais, Belo Horizonte, Minas Gerais, 30180-060, Brazil|Centro OncolÃ³gico do TriÃ¢ngulo, UberlÃ¢ndia, Minas Gerais, 38408-150, Brazil|Multihemo, Recife, Pernambuco, 50070-170, Brazil|Hospital SÃ£o Lucas da PUCRS, Porto Alegre, Rio Grande Do Sul, 90610-000, Brazil|Hospital BP, Sao Paulo, SÃ£o Paulo, 01321-001, Brazil|Instituto D'Or de Pesquisa e Ensino (IDOR), Sao Paulo, SÃ£o Paulo, 04543-000, Brazil|Instituto de EducaÃ§Ã£o, Pesquisa e GestÃ£o em SaÃºde, Rio de Janeiro, 22775001, Brazil|Centro Paulista de Oncologia ClÃ­nica, SÃ£o Paulo, 01452-000, Brazil|NÃºcleo de Pesquisa ClÃ­nica da Rede SÃ£o Camilo, SÃ£o Paulo, 04014-002, Brazil|Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein, SÃ£o Paulo, 05652-900, Brazil|Princess Margaret Cancer Centre, Toronto, Ontario, M5G 2M9, Canada|Beijing Friendship Hospital, Beijing, Beijing, 100050, China|Beijing Cancer hospital, Beijing, Beijing, 100142, China|Fujian Provincial Hospital, Fuzhou, Fujian, 350001, China|Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, 510515, China|Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China|Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China|Hunan Cancer Hospital, Changsha, Hunan, 410013, China|Jilin Cancer Hospital, Changchun, Jilin, 130000, China|Tangdu Hospital of Fourth Military Medical University of Chinese People's Liberation Army, Xi'an, Shaanxi, 710038, China|Jinan Central Hospital, Jinan, Shandong, 250013, China|Shanghai Chest Hospital, Shanghai, Shanghai, 200030, China|Zhongshan Hospital, Fudan University, Shanghai, Shanghai, 200032, China|Shanghai Pulmonary Hospital, Shanghai, Shanghai, 200433, China|West China Hospital, Sichuan University, Cheng Du, Sichuan, 610041, China|the Third People's Hospital of Chengdu, Chengdu, Sichuan, 610031, China|First Affiliated Hosp of College of Med, Zhejiang University, Hangzhou, Zhejiang, 310003, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, 310022, China|Tongji Medical College of Huazhong University of Science and Technology, Wuhan, 430030, China|Masarykuv onkologicky ustav, Brno, Brno-mÄsto, 656 53, Czechia|Nemocnice AGEL Ostrava - Vitkovice a.s., Ostrava, Ostrava MÄsto, 703 84, Czechia|Fakultni nemocnice Bulovka, Prague, Praha 8, 180 81, Czechia|Odense Universitetshospital, Odense, Syddanmark, 5000, Denmark|Assistance Publique HÃ´pitaux de Marseille - HÃ´pital de la Timone, Marseille, Bouches-du-RhÃ´ne, 13385, France|CHU Charles Nicolle, Rouen, Haute-Normandie, 76031, France|Centre Chirurgical Marie Lannelongue, Le Plessis-Robinson, Hauts-de-Seine, 92350, France|Centre Leon Berard, Lyon CEDEX 08, RhÃ´ne-Alpes, 69373, France|Hospices Civils de Lyon - Hopital Louis Pradel, Lyon, RhÃ´ne, 69677, France|Gustave Roussy, Villejuif, Val-de-Marne, 94800, France|Hopitaux Universitaires Paris Centre-Hopital Cochin, Paris, 75014, France|Thoraxklinik-Heidelberg gGmbH, Heidelberg, Baden-WÃ¼rttemberg, 69126, Germany|Klinik LÃ¶wenstein, LÃ¶wenstein, Baden-WÃ¼rttemberg, 74245, Germany|Asklepios Fachkliniken MÃ¼nchen-Gauting, Gauting, Bayern, 82131, Germany|Klinikum der Ludwig-Maximilians-Universitaet Muenchen, MÃ¼nchen, Bayern, 80336, Germany|Lungenfachklinik Immenhausen, Immenhausen, Hessen, 34376, Germany|Franziskus-Hospital Harderberg, GeorgsmarienhÃ¼tte, Niedersachsen, 49124, Germany|KRH, Klinikum Siloah, Hannover, Niedersachsen, 30459, Germany|UniversitÃ¤tsklinikum MÃ¼nster - Albert Schweitzer Campus, MÃ¼nster, Nordrhein-Westfalen, 48149, Germany|LungenClinic Grosshansdorf, Grosshansdorf, Schleswig-Holstein, 22927, Germany|Charite UniversitÃ¤tsmedizin Berlin Campus Benjamin Franklin, Berlin, 12203, Germany|Evangelische Lungenklinik Berlin, Berlin, 13125, Germany|Asklepios Klinik Harburg, Hamburg, 21075, Germany|University Hospital of Patras, Patras, Achaá¸¯a, 26504, Greece|Agios Savvas Regional Cancer Hospital, Athens, AttikÃ­, 115 22, Greece|Errikos Dunant Hospital Center, Athens, AttikÃ­, 115 26, Greece|Sotiria Thoracic Diseases Hospital of Athens, Athens, AttikÃ­, 11527, Greece|University General Hospital of Heraklion, Heraklion, IrakleÃ­o, 711 10, Greece|European Interbalkan Medical Center, Thessaloniki, ThessalonÃ­ki, 570 01, Greece|G. Papanikolaou General Hospital, Thessaloniki, ThessalonÃ­ki, 570 10, Greece|Hong Kong United Oncology Centre, Hong Kong, 000000, Hong Kong|Princess Margaret Hospital, Lai Chi Kok, 999077, Hong Kong|Queen Elizabeth Hospital, Yau Ma Tei, Hong Kong|Rajiv Gandhi Cancer Institute And Research Centre, New Delhi, Delhi, 110085, India|Regional Cancer Centre - Thiruvananthapuram, Thiruvananthapuram, Kerala, 695011, India|Tata Memorial Hospital, Mumbai, Maharashtra, 400012, India|Rashtrasant Tukdoji Regional Cancer Hospital, Nagpur, Maharashtra, 440027, India|HCG Manavata Cancer Centre, Nashik, Maharashtra, 422001, India|Sheba Medical Center, Ramat Gan, HaMerkaz, 5265601, Israel|Hadassah Medical Center, Jerusalem, Yerushalayim, 9112001, Israel|Rambam Health Care Campus, Haifa, á¸¤eifÄ, 3109601, Israel|ASST Grande Ospedale Metropolitano Niguarda, Milan, Milano, 20162, Italy|Humanitas, Rozzano, Milano, 20089, Italy|Azienda Ospedaliera Dei Colli, Naples, Napoli, 80131, Italy|Instituto Tumori Giovanni Paolo II, Bari, Puglia, 70124, Italy|Azienda Sanitaria Ospedaliera S Luigi Gonzaga, Orbassano, Torino, 10043, Italy|Istituto Oncologico Veneto IRCCS, Padova, 35128, Italy|Aichi Cancer Center Hospital, Nagoya, Aichi, 464-8681, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, 277-8577, Japan|Himeji Medical Center, Himeji, Hyogo, 670-8520, Japan|Kanagawa cancer center, Yokohama, Kanagawa, 241-8515, Japan|Niigata Cancer Center Hospital, Niigata-shi, Niigata, 951-8566, Japan|Shizuoka Cancer Center, Nagaizumi, Shizuoka, 411-8777, Japan|Japanese Foundation for Cancer Research, Koto, Tokyo, 135-8550, Japan|Tottori University Hospital, Yonago, Tottori, 683-8504, Japan|Hiroshima University Hospital, Hiroshima, 734-8551, Japan|Osaka International Cancer Institute, Osaka, 541-8567, Japan|Chonnam National University Hwasun Hospital, Hwasun, Jeonranamdo, 58128, Korea, Republic of|National Cancer Center, Goyang-si, KyÇnggi-do, 10408, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, KyÇnggi-do, 13620, Korea, Republic of|Pusan National University Hospital, Busan, Pusan-KwangyÇkshi, 49241, Korea, Republic of|Seoul National University Hospital, Seoul, Seoul-teukbyeolsi [Seoul], 3080, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Seoul-teukbyeolsi [Seoul], 3722, Korea, Republic of|Asan Medical Center, Seoul, Seoul-teukbyeolsi [Seoul], 5505, Korea, Republic of|Samsung Medical Center, Seoul, Seoul-teukbyeolsi [Seoul], 6351, Korea, Republic of|Korea University Guro Hospital, Seoul, Seoul-teukbyeolsi [Seoul], 8308, Korea, Republic of|Kyungpook National University Chilgok Hospital, Deagu, Taegu-KwangyÇkshi, 41404, Korea, Republic of|Actualidad Basada en la InvestigaciÃ³n del CÃ¡ncer, Guadalajara, Jalisco, 44680, Mexico|Oncare Viaducto Napoles, Cdmx, MÃ©xico, 03810, Mexico|Avix InvestigaciÃ³n Clinica, S.C., Monterrey, Nuevo LeÃ³n, 64710, Mexico|Hospital Universitario ""Dr. Jose Eleuterio Gonzalez"", Monterrey, Nuevo LeÃ³n, 66460, Mexico|Ziekenhuis St. Jansdal, Harderwijk, Gelderland, 3844 DG, Netherlands|Radboudumc, Nijmegen, Gelderland, 6500HB, Netherlands|Oslo Universitetssykehus UllevÃ¥l, Oslo, 0450, Norway|Krakowski Szpital Specjalistyczny im. Jana Pawa II, Krakow, MaÅopolskie, 30-002, Poland|Pan American Center for Oncology Trials, Rio Piedras, 00935, Puerto Rico|Institutul Oncologic, Cluj, 400015, Romania|Arkhangelsk Clinical Oncological Dispensary, Arkhangelsk, Arkhangel'skaya Oblast', 163045, Russian Federation|Hadassah Medical, Moscow, Moskva, 121205, Russian Federation|First Pavlov State Medical University of Saint Petersburg, Saint Petersburg, Sankt-Peterburg, 197022, Russian Federation|Scientific research institution of oncology named after N.N. Petrov, Sankt-Peterburg, 197758, Russian Federation|Parkway Cancer Centre - Gleneagles Hospital, Singapore, Central Singapore, 258500, Singapore|Tan Tock Seng Hospital, Singapore, Central Singapore, 308433, Singapore|CHUS - Hospital Clinico Universitario, Santiago de Compostela, A CoruÃ±a [La CoruÃ±a], 15706, Spain|Hospital Universitario Reina Sofia, Cordoba, AndalucÃ­a, 14004, Spain|Hospital Universitario Puerta del Mar, CÃ¡diz, AndalucÃ­a, 11009, Spain|Hospital Universitario Central de Asturias, Oviedo, Asturias, 33011, Spain|Institut CatalÃ  d'Oncologia (ICO) - Badalona, Badalona, Barcelona [Barcelona], 08916, Spain|Parc de Salut Mar - Hospital del Mar, Barcelona, Barcelona [Barcelona], 8003, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Barcelona [Barcelona], 8035, Spain|Instituto Catalan de Oncologia - Hospital Duran i Reynals, L'Hospitalet Del Llobregat, Barcelona [Barcelona], 8907, Spain|Hospital de MatarÃ³, MatarÃ³, Barcelona [Barcelona], 8304, Spain|Complejo Asistencial Universitario de LeÃ³n - Hospital de LeÃ³n, LeÃ³n, Castilla Y LeÃ³n, 24071, Spain|Hospital Universitari Dexeusa, Barcelona, Catalunya [CataluÃ±a], 8028, Spain|Hospital ClÃ­nic de Barcelona, Barcelona, Catalunya [CataluÃ±a], 8036, Spain|Hospital Son LlÃ tzer, Palma, Illes Balears [Islas Baleares], 7198, Spain|Hospital Lucus Augusti, Lugo, Lugo [Lugo], 27003, Spain|Hospital Universitario RamÃ³n y Cajal, Madrid, Madrid, Comunidad De, 28034, Spain|Hospital Universitario 12 de Octubre, Madrid, Madrid, Comunidad De, 28041, Spain|Hospital ClÃ­nico Universitario Virgen de la Arrixaca, El Palmar, Murcia, Murcia, RegiÃ³n De, 30120, Spain|Complexo Hospitalario Universitario de Ourense, Ourense, Ourense [Orense], 32005, Spain|CHUVI- Hospital Alvaro Cunqueiro, Pontevedra, Pontevedra [Pontevedra], 36312, Spain|Hospital Universitario de Canarias, La Laguna, Santa Cruz De Tenerife, 38320, Spain|Hospital Universitari Sant Joan de Reus, Reus, Tarragona [Tarragona], 43204, Spain|Hospital General Universitario de Albacete, Albacete, 2006, Spain|MD Anderson Cancer Center, Madrid, 28033, Spain|Hospital Clinico San Carlos, Madrid, 28040, Spain|H.R.U MÃ¡laga - Hospital General, MÃ¡laga, 29011, Spain|Hospital Universitario Virgen Macarena, Sevilla, 41009, Spain|Hospital Universitari i Politecnic La Fe, ValÃ¨ncia, 46026, Spain|Sahlgrenska Universitetssjukhuset, Gothenburg, VÃ¤stra GÃ¶talands LÃ¤n [se-14], 413 45, Sweden|Changhua Christian Hospital, Changhua County, Changhua, 50006, Taiwan|Chang Gung Memorial Hospital at Kaohsiung, Kaohsiung Niao Sung Dist, Kaohsiung, 83301, Taiwan|Chung Shan Medical University Hospital, Taichung City, Taichung, 402, Taiwan|Chi Mei Hospital - Liouying Branch, Tainan City, Tainan, 73657, Taiwan|National Taiwan University Cancer Center (NTUCC), Taipei City, Taipei, 106, Taiwan|Taipei Veterans General Hospital, Taipei City, Taipei, 112, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, 80756, Taiwan|Taichung Veterans General Hospital, Taichung, 40705, Taiwan|National Taiwan University Hospital, Taipei, 10002, Taiwan|Chang Gung Medical Foundation-Linkou Branch, Taoyuan, 333, Taiwan|Ege Universitesi Hastanesi, Bornova, Ä°zmir, 35100, Turkey|Izmir Medical Park Hospital, Izmir, Karsiyaka, Ä°zmir, 009035575, Turkey|Baskent University Dr. Turgut Noyan Research and Training Center, Adana, 1250, Turkey|Adana City Hospital, Adana, 1370, Turkey|Abdurrahman Yurtaslan Ankara Oncology, education and Research Hospital, Ankara, 6200, Turkey|Ankara Bilkent Åehir Hastanesi, Ankara, 6800, Turkey|Memorial Antalya Hospital, Antalya, 7090, Turkey|Uludag Universitesi, Bursa, 16059, Turkey|Dicle Ãniversitesi, Diyarbakir, 21100, Turkey|Trakya University, Edirne, 22030, Turkey|Medipol Mega Universite Hastanesi, Istanbul, 34214, Turkey|AcÄ±badem Maslak Hastanesi, Ä°stanbul, 34457, Turkey|TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi, Istanbul, 34722, Turkey|Izmir Katip Celebi Ataturk Egitim Arastirma Hastanesi, Izmir, 35620, Turkey|Ä°nÃ¶nÃ¼ Ãniversitesi Turgut Ãzal TÄ±p Merkezi EÄitim ve AraÅtÄ±rma Hastanesi, Malatya, 44280, Turkey|Medical Center ""Mriya Med-Service"", Kryvyi Rih, Dnipropetrovska Oblast, 50000, Ukraine|CNPE ""Regional Center of Oncology"", Kharkiv, Kharkivska Oblast, 61070, Ukraine|Municipal non-profit enterprise'Odesa Regional Clinical Hospital'of Odesa Regional Council, Odesa, Odeska Oblast, 65025, Ukraine|Sumy regional clinical oncological dispensary, Sumy, Sumska Oblast, 40022, Ukraine|Communal Noncommercial Enterprise ""Podillia Regional Oncology Center Of Vinnytsia Regional Council"", Vinnytsia, Vinnytska Oblast, 21029, Ukraine|""Oncolife"" LLC, Zaporizhzhia, Zaporizka Oblast, 69059, Ukraine|Municipal non-profit enterprise ""Kyiv City Clinical Oncology Center"" of executive body of Kyiv City Counci -T, Kyiv, 3115, Ukraine|Chelsea and Westminster Hospital NHS Foundation Trust, London, England, SW10 9NH, United Kingdom|Royal Brompton Hospital, London, Kensington And Chelsea, SW3 6NP, United Kingdom|University College London Hospital, London, London, City Of, NW1 2PG, United Kingdom|City Hospital, Nottingham University Hospitals, Nottingham, NG5 1PB, United Kingdom|New Cross Hospital, Wolverhampton, WV10 0QP, United Kingdom",
NCT06679101,"A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)",https://clinicaltrials.gov/study/NCT06679101,DREAMM-10,RECRUITING,The purpose of this Phase 3 study is to evaluate if BRd prolongs progression free survival (PFS) and/or improves minimal residual disease (MRD) negative status compared with DRd in participants with TI-NDMM.,NO,Multiple Myeloma|Newly Diagnosed Multiple Myeloma,DRUG: Belantamab mafodotin|DRUG: Lenalidomide|DRUG: Dexamethasone|DRUG: Daratumumab,"PFS, Defined as the time from the date of randomization to the date of first documented PD per International Myeloma Working Group (IMWG) criteria by Independent Review Committee (IRC) or death from any cause in the absence of progression, whichever occurs first., Up to approximately 7 years|Number of Participants Achieving MRD Negative Status, Defined as achieving MRD negativity at 10\^-5 sensitivity threshold (1 nucleated tumor cell in 100,000 normal cells) assessed by next-generation sequencing (NGS) at least once during the time of confirmed complete response (CR) or better response per IMWG criteria by IRC., Up to approximately 7 years","PFS2, Defined as the time from the date of randomization to the date of documented PD following the first subsequent anti-myeloma therapy or death from any cause, whichever is earlier., Up to approximately 7 years|Overall Survival (OS), Up to approximately 7 years|Number of Participants Achieving CR or Better (CR+), Up to approximately 7 years|Number of Participants Achieving Very Good Partial Response (VGPR) or Better, Up to approximately 7 years|Number of Participants Achieving Sustained MRD Negative Status, Defined as achieving MRD negative status at 10\^-5 sensitivity threshold (1 nucleated tumor cell in 100,000 normal cells) assessed by NGS at least twice, a minimum of 1 year apart and with no MRD positive result in between, during the time of confirmed CR+ response per IMWG criteria by IRC., Up to approximately 7 years|Duration of Response (DoR), Up to approximately 7 years|Time to Second Next Line Therapy (TTST), Up to approximately 7 years|Number of Participants With Adverse Events (AEs), Up to approximately 7 years|Number of Participants With Ocular Findings on Ophthalmic Exam, Up to approximately 7 years|Maximum Post-baseline Patient-Reported Outcomes Version of the Common Term Criteria for Adverse Events (PRO-CTCAE) Score, Up to approximately 7 years|Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30, Up to approximately 7 years|Change From Baseline in EORTC QLQ-MY20, Up to approximately 7 years|Plasma Concentrations of Belantamab Mafodotin, Up to approximately 7 years|Number of Participants With Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin, Up to approximately 7 years|Titers of ADAs Against Belantamab Mafodotin, Up to approximately 7 years",,GlaxoSmithKline,,ALL,"ADULT, OLDER_ADULT",PHASE3,520,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-12-27,2030-12-23,2032-04-06,2024-11-07,,2025-05-15,"GSK Investigational Site, Capital Federal, C1426ANZ, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aire, 1414, Argentina|GSK Investigational Site, Rosario, S2002, Argentina|GSK Investigational Site, Viedma, R8500ACE, Argentina|GSK Investigational Site, Gosford NSW, New South Wales, 2250, Australia|GSK Investigational Site, Fitzroy, Australia|GSK Investigational Site, Beijing, 100191, China|GSK Investigational Site, Shanghia, 200080, China|GSK Investigational Site, Tianjin, 300020, China|GSK Investigational Site, Aichi, 467-8602, Japan|GSK Investigational Site, Ehime, 790-0024, Japan|GSK Investigational Site, Ehime, 790-8524, Japan|GSK Investigational Site, Fukushima, 960-1295, Japan|GSK Investigational Site, Gunma, 371-8511, Japan|GSK Investigational Site, Hyogo, 660-8550, Japan|GSK Investigational Site, Hyogo, 670-8540, Japan|GSK Investigational Site, Ibaraki, 300-0028, Japan|GSK Investigational Site, Iwate, 028-3695, Japan|GSK Investigational Site, Miyagi, 983-8520, Japan|GSK Investigational Site, Nara, 632-8552, Japan|GSK Investigational Site, Sapporo, 003-0006, Japan|GSK Investigational Site, Suita, 565-0871, Japan|GSK Investigational Site, Tokyo, 105-8471, Japan|GSK Investigational Site, Yamagata, 990-9585, Japan|GSK Investigational Site, Hwasun, 519-763, Korea, Republic of|GSK Investigational Site, Jeonju, 561-712, Korea, Republic of|GSK Investigational Site, Seoul, 03080, Korea, Republic of|GSK Investigational Site, Seoul, 03722, Korea, Republic of|GSK Investigational Site, Seoul, 06591, Korea, Republic of|GSK Investigational Site, Seoul, 138-736, Korea, Republic of|GSK Investigational Site, Ulsan, 44033, Korea, Republic of|GSK Investigational Site, Lublin, Poland|GSK Investigational Site, Madrid, 28041, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Murcia, 30120, Spain|GSK Investigational Site, Valladolid, 47003, Spain|GSK Investigational Site, Kaohsiung, 807, Taiwan",
NCT06875310,A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4),https://clinicaltrials.gov/study/NCT06875310,,RECRUITING,"This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C mutation",NO,"Carcinoma, Non-Small-Cell Lung",DRUG: Adagrasib|DRUG: Pembrolizumab|DRUG: Carboplatin|DRUG: Pemetrexed|DRUG: Placebo|DRUG: Cisplatin,"Progression Free Survival (PFS) as Assessed per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Blinded Independent Central Review (BICR), Up to 7 years|Overall Survival (OS), Up to 7 years","Overall Response (OR) as Assessed per RECIST v1.1 by BICR, Up to 7 years|Duration of Response (DOR) as Assessed per RECIST 1.1 by BICR, Up to 7 years|PFS as Assessed per RECIST v1.1 by Investigator, Up to 7 years|Number of Participants With Adverse Events (AEs), Up to 90 days from last dose|Number of Participants With Serious Adverse Events (SAEs), Up to 90 days from last dose|Number of Participants With AEs Leading to Dose Interruption, Up to 90 days from last dose|Number of Participants With AEs Leading to Dose Reduction, Up to 90 days from last dose|Number of Participants With AEs Leading to Treatment Discontinuation, Up to 90 days from last dose|Number of Deaths, Up to 90 days from last dose|Time to Definitive Deterioration by Non-Small Cell Lung Cancer-Symptom Assessment Questionnaire (NSCLC-SAQ) Total Score, Up to 7 years|Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-30) Scale/item Score, Up to 90 days from last dose",,Mirati Therapeutics Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE3,630,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2025-04-24,2029-09-07,2032-04-30,2025-03-13,,2025-06-04,"Local Institution - 0347, Birmingham, Alabama, 35294-3300, United States|Local Institution - 0581, Fullerton, California, 92835, United States|Local Institution - 0202, Long Beach, California, 90805, United States|Local Institution - 0643, Newport Beach, California, 92663, United States|Local Institution - 0666, Orange, California, 92868, United States|Local Institution - 0623, Santa Barbara, California, 93105, United States|Local Institution - 0442, Denver, Colorado, 80206, United States|Local Institution - 0651, Gainesville, Florida, 32610, United States|Local Institution - 0621, Palm Bay, Florida, 32901, United States|Local Institution - 0377, Tamarac, Florida, 33321, United States|Local Institution - 0647, Tampa, Florida, 33612, United States|Local Institution - 0392, Fort Eisenhower, Georgia, 30905, United States|Local Institution - 0031, Marietta, Georgia, 30060, United States|Local Institution - 0665, Arlington Heights, Illinois, 60005, United States|Local Institution - 0423, Munster, Indiana, 46321, United States|Local Institution - 0366, Edgewood, Kentucky, 41017, United States|Local Institution - 0566, Louisville, Kentucky, 40202, United States|Local Institution - 0644, Shreveport, Louisiana, 71103, United States|Local Institution - 0385, Columbia, Maryland, 21044, United States|Local Institution - 0019, Boston, Massachusetts, 02215, United States|Local Institution - 0437, Worcester, Massachusetts, 01655, United States|Local Institution - 0618, White Plains, New York, 10601, United States|Local Institution - 0624, Asheville, North Carolina, 28806, United States|Local Institution - 0672, Salisbury, North Carolina, 28144, United States|Local Institution - 0620, Columbus, Ohio, 43219, United States|Local Institution - 0657, York, Pennsylvania, 17403, United States|Local Institution - 0658, Greenville, South Carolina, 29607, United States|Local Institution - 0652, Laredo, Texas, 78041, United States|Local Institution - 0622, San Antonio, Texas, 78217, United States|Local Institution - 0575, Ciudad AutÃ³noma de Buenos Aires, Buenos Aires, C1426ANZ, Argentina|IDIM - Instituto de Investigaciones MetabÃ³licas, Ciudad de Buenos Aires, Buenos Aires, C1012AAR, Argentina|Local Institution - 0584, Pilar, Buenos Aires, 1629, Argentina|Hospital Italiano de Buenos Aires, ABB, Ciudad AutÃ³noma De Buenos Aires, C1199ABB, Argentina|Local Institution - 0571, Buenos Aires, Ciudad AutÃ³noma De Buenos Aires, C1417DTB, Argentina|Local Institution - 0573, Caba, Ciudad AutÃ³noma De Buenos Aires, C1430EGF, Argentina|Sanatorio Plaza, Rosario, Santa Fe, 2000, Argentina|Local Institution - 0126, Canberra, Australian Capital Territory, 2605, Australia|Tamworth Hospital, North Tamworth, New South Wales, 2340, Australia|Orange Hospital, Orange, New South Wales, 2800, Australia|Local Institution - 0127, Brisbane, Queensland, 4102, Australia|Lyell McEwin Hospital, Elizabeth Vale, South Australia, 5112, Australia|Frankston Hospital, Frankston, Victoria, 3199, Australia|Local Institution - 0121, Melbourne, Victoria, 3076, Australia|Local Institution - 0160, Traralgon, Victoria, 3844, Australia|Joondalup Health Campus, Joondalup, Western Australia, 6027, Australia|Local Institution - 0532, Wels, OberÃ¶sterreich, 4600, Austria|Local Institution - 0539, Graz, Steiermark, 8036, Austria|Local Institution - 0530, Linz, 4021, Austria|Local Institution - 0533, Wien, 1090, Austria|Local Institution - 0673, Wien, 1210, Austria|Local Institution - 0114, Brussels, Bruxelles-Capitale, RÃ©gion De, 1090, Belgium|Local Institution - 0113, Brussels, Bruxelles-Capitale, RÃ©gion De, 1200, Belgium|Local Institution - 0215, Hasselt, Limburg, 3500, Belgium|Local Institution - 0216, Gent, Oost-Vlaanderen, 9000, Belgium|Local Institution - 0107, Leuven, Vlaams-Brabant, 3000, Belgium|Local Institution - 0109, LiÃ¨ge, 4000, Belgium|Local Institution - 0257, Salvador, Bahia, 40170-110, Brazil|Local Institution - 0242, VitÃ³ria, EspÃ­rito Santo, 29055450, Brazil|Local Institution - 0244, Belo Horizonte, Minas Gerais, 30110-022, Brazil|Local Institution - 0235, Ijui, Rio Grande Do Sul, 98700-000, Brazil|Local Institution - 0233, Porto Alegre, Rio Grande Do Sul, 90610-000, Brazil|Local Institution - 0238, Santa Cruz do Sul, Rio Grande Do Sul, 96830-180, Brazil|Local Institution - 0243, Porto Velho, Rondonia, 76834-899, Brazil|Local Institution - 0237, Blumenau, Santa Catarina, 89010-340, Brazil|Local Institution - 0245, ItajaÃ­, Santa Catarina, 88301-220, Brazil|Local Institution - 0240, Barretos, SÃ£o Paulo, 14784400, Brazil|Local Institution - 0254, Sao Paulo, SÃ£o Paulo, 01509-010, Brazil|Local Institution - 0241, SÃ£o Carlos, SÃ£o Paulo, 13561-130, Brazil|Local Institution - 0239, SÃ£o JosÃ© do Rio Preto, SÃ£o Paulo, 15090-000, Brazil|Local Institution - 0236, Rio de Janeiro, 20230-130, Brazil|Local Institution - 0258, SÃ£o Paulo, 01246-000, Brazil|Local Institution - 0629, Panagyurishte, Pazardzhik, 4500, Bulgaria|Local Institution - 0628, Sofia, Sofia (stolitsa), 1632, Bulgaria|Local Institution - 0627, Ruse, 7002, Bulgaria|Local Institution - 0635, Stara Zagora, 6000, Bulgaria|Local Institution - 0074, Halifax, Nova Scotia, B3H 2Y9, Canada|Local Institution - 0559, Montreal, Quebec, H3T 1M5, Canada|Bradfordhill, Recoleta, RegiÃ³n Metropolitana De Santiago, 8420391, Chile|FALP, Santiago, RegiÃ³n Metropolitana De Santiago, 7500921, Chile|Local Institution - 0482, Bengbu, Anhui, 233004, China|Local Institution - 0475, Hefei, Anhui, 230071, China|Local Institution - 0355, Beijing, Beijing, 100142, China|Local Institution - 0491, Beijing, Beijing, 100730, China|Local Institution - 0397, Beijing, Beijing, 101149, China|Local Institution - 0490, Chongqing, Chongqing, 400030, China|Local Institution - 0362, Fuzhou Fujian, Fujian, 350001, China|Local Institution - 0383, Xiamen, Fujian, 361003, China|Local Institution - 0469, Guangzhou, Guangdong, 0, China|Local Institution - 0625, Guangzhou, Guangdong, 0, China|Local Institution - 0356, Shantou, Guangdong, 515041, China|Local Institution - 0461, Shenzhen, Guangdong, 0, China|Local Institution - 0352, Shenzhen, Guangdong, 518020, China|Local Institution - 0464, Nanning, Guangxi, 530021, China|Local Institution - 0472, Shijiazhuang, Hebei, 050035, China|Local Institution - 0465, Harbin, Heilongjiang, 150081, China|Local Institution - 0626, Nanyang, Henan, 473009, China|Local Institution - 0494, Xinxiang, Henan, 453100, China|Local Institution - 0373, Wuhan, Hubei, 430030, China|Local Institution - 0398, Changsha, Hunan, 410013, China|Local Institution - 0371, Nanjing, Jiangsu, 210000, China|Local Institution - 0382, Suzhou, Jiangsu, 215006, China|Local Institution - 0378, Yangzhou, Jiangsu, 225001, China|Local Institution - 0467, Nanchang, Jiangxi, 330006, China|Local Institution - 0483, Changchun, Jilin, 130021, China|Local Institution - 0473, Shenyang, Liaoning, 110001, China|Local Institution - 0479, Shenyang, Liaoning, 110004, China|Local Institution - 0493, Shenyang, Liaoning, 110042, China|Local Institution - 0474, Jinan, Shandong, 250117, China|Local Institution - 0359, Linyi, Shandong, 276001, China|Local Institution - 0470, Shanghai, Shanghai, 200030, China|Local Institution - 0381, Shanghai, Shanghai, 200032, China|Local Institution - 0353, Taiyuan, Shanxi, 030000, China|Local Institution - 0384, Cheng Du, Sichuan, 610041, China|Local Institution - 0667, Chengdu, Sichuan, 610041, China|Local Institution - 0460, Tianjin, Tianjin, 300052, China|Local Institution - 0462, Hangzhou, Zhejiang, 310003, China|Local Institution - 0492, Hangzhou, Zhejiang, 310016, China|Local Institution - 0463, Hangzhou, Zhejiang, 310022, China|Local Institution - 0374, Linhai, Zhejiang, 317000, China|Local Institution - 0354, Shanghai, 200120, China|Local Institution - 0580, MedellÃ­n, Antioquia, 050030, Colombia|Local Institution - 0171, Rionegro, Antioquia, 054040, Colombia|Local Institution - 0191, Puerto Colombia, AtlÃ¡ntico, 81001, Colombia|Local Institution - 0253, Valledupar, Cesar, 200001, Colombia|Local Institution - 0167, MonterÃ­a, COR, 230002, Colombia|Local Institution - 0671, Bogota, Cundinamarca, 111151, Colombia|Local Institution - 0189, BogotÃ¡, Distrito Capital De BogotÃ¡, 110131, Colombia|Local Institution - 0170, Floridablanca, Santander, 681004, Colombia|Local Institution - 0173, Cali, Valle Del Cauca, 760032, Colombia|Local Institution - 0619, Dubrovnik, DubrovaÄko-neretvanska Å½upanija, 20000, Croatia|Local Institution - 0664, Rijeka, Primorsko-goranska Å½upanija, 51000, Croatia|Local Institution - 0639, Split, Splitsko-dalmatinska Å½upanija, 21000, Croatia|Local Institution - 0567, Osijek, 31000, Croatia|Local Institution - 0585, Zagreb, 10000, Croatia|Local Institution - 0159, Mulhouse, Alsace, 68100, France|Local Institution - 0296, Caen, Calvados, 14076, France|Local Institution - 0605, Dijon, CÃ´te-d'Or, 21079, France|Local Institution - 0512, Brest, FinistÃ¨re, 29609, France|Local Institution - 0558, Montpellier, HÃ©rault, 34298, France|Local Institution - 0220, La Tronche, IsÃ¨re, 38700, France|Local Institution - 0139, Saint-Herblain, Loire-Atlantique, 44800, France|Local Institution - 0560, Angers, Maine-et-Loire, 49933, France|Local Institution - 0589, Vandoeuvre lÃ¨s Nancy, Meurthe-et-Moselle, 54511, France|Local Institution - 0636, Marseille, Provence-Alpes-CÃ´te-d'Azur, 13273, France|Local Institution - 0552, Amiens, Somme, 80054, France|Local Institution - 0213, Villejuif, Val-de-Marne, 94800, France|Local Institution - 0134, Clermont-Ferrand, 63000, France|Local Institution - 0604, Limoges, 87042, France|Local Institution - 0164, Marseille, 13915, France|Local Institution - 0133, Paris, 75248, France|Local Institution - 0158, Paris, 75679, France|Local Institution - 0513, Boulogne-Billancourt, Ãle-de-France, 92100, France|Local Institution - 0534, Esslingen, Baden-WÃ¼rttemberg, 73730, Germany|Local Institution - 0670, Ulm, Baden-WÃ¼rttemberg, 89081, Germany|Local Institution - 0557, MÃ¼nchen, Bayern, 81377, Germany|Local Institution - 0518, Frankfurt, Hessen, 60389, Germany|Local Institution - 0535, GieÃen, Hessen, 35392, Germany|Local Institution - 0520, Hannover, Niedersachsen, 30161, Germany|Local Institution - 0527, Oldenburg, Niedersachsen, 26121, Germany|Local Institution - 0603, Herne, Nordrhein-Westfalen, 44651, Germany|Local Institution - 0523, KÃ¶ln, Nordrhein-Westfalen, 51109, Germany|Local Institution - 0522, Halle, Sachsen-Anhalt, 06120, Germany|Local Institution - 0521, Flensburg, Schleswig-Holstein, 24939, Germany|Local Institution - 0524, Gera, ThÃ¼ringen, 07548, Germany|Local Institution - 0551, Jena, ThÃ¼ringen, 07747, Germany|Local Institution - 0526, Berlin, 12351, Germany|Local Institution - 0537, Berlin, 13125, Germany|Local Institution - 0528, Hemer, 58675, Germany|Local Institution - 0517, Stuttgart, 70174, Germany|Local Institution - 0525, Wuerzburg, 97080, Germany|Local Institution - 0608, Athens, AttikÃ­, 115 26, Greece|Local Institution - 0612, Athens, AttikÃ­, 115 27, Greece|Local Institution - 0609, Larissa, ThessalÃ­a, 41110, Greece|Local Institution - 0379, Hksar, 0, Hong Kong|Local Institution - 0466, Hksar, 0, Hong Kong|Local Institution - 0601, Gyor, GyÅr-Moson-Sopron, 9024, Hungary|Local Institution - 0144, GyÃ¶ngyÃ¶s, Heves, 3200, Hungary|Local Institution - 0157, TatabÃ¡nya, KomÃ¡rom-Esztergom, 2800, Hungary|Local Institution - 0593, KaposvÃ¡r, Somogy, 7400, Hungary|Local Institution - 0143, Farkasgyepu, VeszprÃ©m, 8582, Hungary|Local Institution - 0151, Budapest, 1083, Hungary|Local Institution - 0140, Budapest, 1121, Hungary|Local Institution - 0222, Visakhapatnam, Andhra Pradesh, 530040, India|Local Institution - 0312, New Delhi, Delhi, 110029, India|Local Institution - 0511, New Delhi, Delhi, 110029, India|Local Institution - 0135, New Delhi, Delhi, 110085, India|Local Institution - 0136, Ahmedabad, Gujarat, 380054, India|Local Institution - 0230, Ahmedabad, Gujarat, 380060, India|Local Institution - 0155, Thiruvananthapuram, Kerala, 695011, India|Local Institution - 0154, Mumbai, Maharashtra, 400012, India|Local Institution - 0226, Bhubaneswar, Odisha, 751003, India|Local Institution - 0224, Madurai, Tamil Nadu, 625107, India|Local Institution - 0663, Hyderabad, Telangana, 500084, India|Local Institution - 0153, Varanasi, Uttar Pradesh, 221005, India|Local Institution - 0161, Howrah, West Bengal, 711103, India|Local Institution - 0221, Kolkata, West Bengal, 700094, India|Local Institution - 0661, Hyderabad, 500034, India|Local Institution - 0102, Cork, T12 E8YV, Ireland|Local Institution - 0476, Dublin, D07 WKW8, Ireland|Local Institution - 0101, Dublin, D08 E9P6, Ireland|Local Institution - 0100, Dublin, D18 AK68, Ireland|Local Institution - 0106, Dublin, D9, Ireland|Local Institution - 0597, Petah Tikva, HaMerkaz, 4941492, Israel|Local Institution - 0596, Ramat Gan, HaMerkaz, 5265601, Israel|Local Institution - 0600, Zerifin, HaMerkaz, 70300, Israel|Local Institution - 0544, Jerusalem, Yerushalayim, 9112001, Israel|Local Institution - 0613, Haifa, á¸¤eifÄ, 3436212, Israel|Local Institution - 0067, Meldola, Emilia-Romagna, 47014, Italy|Local Institution - 0066, Naples, Napoli, 80131, Italy|Local Institution - 0070, Orbassano, Piemonte, 10043, Italy|Local Institution - 0071, Bari, Puglia, 70124, Italy|Local Institution - 0068, Rome, Roma, 00144, Italy|Local Institution - 0069, Firenze, Toscana, 50134, Italy|Local Institution - 0588, Genova, 16132, Italy|Local Institution - 0073, Padova, 35128, Italy|Local Institution - 0156, Parma, 43126, Italy|Local Institution - 0543, Pavia, 27100, Italy|Local Institution - 0556, Varese, 21100, Italy|Local Institution - 0607, Nagoya, Aichi, 457-8510, Japan|Local Institution - 0305, Nagoya, Aichi, 460-0001, Japan|Local Institution - 0298, Sapporo, Hokkaido, 0608648, Japan|Local Institution - 0304, Kanazawa, Ishikawa, 920-8641, Japan|Local Institution - 0302, Sagamihara, Kanagawa, 252-0375, Japan|Local Institution - 0369, Yokohama, Kanagawa, 221-0855, Japan|Local Institution - 0301, Sendai, Miyagi, 9810914, Japan|Local Institution - 0306, Kashihara, Nara, 634-0813, Japan|Local Institution - 0368, Kurashiki, Okayama, 710-8602, Japan|Local Institution - 0642, Hirakata, Osaka, 573-1191, Japan|Local Institution - 0303, Hidaka, Saitama, 350-1298, Japan|Local Institution - 0300, Ina-machi, Saitama, 362-0806, Japan|Local Institution - 0606, Hamamatsu, Shizuoka, 431-3192, Japan|Local Institution - 0299, Shimotsuga, Tochigi, 321-0293, Japan|Local Institution - 0343, Toyoma, Toyama, 930-0194, Japan|Local Institution - 0542, Iwakuni, Yamaguchi, 740-8510, Japan|Local Institution - 0307, Akashi, 6738558, Japan|Local Institution - 0346, Aomori, 030-8553, Japan|Local Institution - 0310, Fukuoka, 812-8582, Japan|Local Institution - 0367, Fukushima, 960-1295, Japan|Local Institution - 0308, Kumamoto, 861-4193, Japan|Local Institution - 0297, Osaka, 534-0021, Japan|Local Institution - 0309, Osaka, 541-8567, Japan|Chungbuk National University Hospital, Cheongju-si, Chungcheongbuk-do [Chungbuk], 28644, Korea, Republic of|Gachon University Gil Medical Center, Namdong-gu, Incheon-gwangyeoksi [Incheon], 21565, Korea, Republic of|Pusan National University Yangsan Hospital, Yangsan, KyÇngsangnam-do, 50612, Korea, Republic of|Pusan National University Hospital, Busan, Pusan-KwangyÇkshi, 49241, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Seoul-teukbyeolsi [Seoul], 03722, Korea, Republic of|Konkuk University Medical Center, Seoul, Seoul-teukbyeolsi [Seoul], 05030, Korea, Republic of|The Catholic Univ. of Korea Seoul St. Mary's Hospital, Seoul, Seoul-teukbyeolsi [Seoul], 06591, Korea, Republic of|Korea University Guro Hospital, Seoul, Seoul-teukbyeolsi [Seoul], 08308, Korea, Republic of|Local Institution - 0583, Saltillo, Coahuila, 25279, Mexico|Local Institution - 0176, Mexico City, DIF, 11510, Mexico|Local Institution - 0579, Pachuca, Hidalgo, 42000, Mexico|Local Institution - 0178, Guadalajara, Jalisco, 44280, Mexico|Local Institution - 0591, Monterrey, Nuevo LeÃ³n, 64040, Mexico|Local Institution - 0175, Chihuahua, 31217, Mexico|Local Institution - 0181, Puebla, 72424, Mexico|Local Institution - 0638, Puebla, 72530, Mexico|Local Institution - 0180, Veracruz, 91900, Mexico|Local Institution - 0615, Maastricht, Limburg, 6229 HX, Netherlands|Local Institution - 0594, Amsterdam, Noord-Holland, 1066 CX, Netherlands|Local Institution - 0205, WrocÅaw, DolnoÅlÄskie, 53-439, Poland|Local Institution - 0080, Lublin, Lubelskie, 20-954, Poland|Local Institution - 0206, Gorlice, MaÅopolskie, 38-300, Poland|Local Institution - 0079, KrakÃ³w, MaÅopolskie, 30-727, Poland|Local Institution - 0077, Prabuty, Pomorskie, 82-550, Poland|Local Institution - 0209, Poznan, Wielkopolskie, 60-693, Poland|Local Institution - 0076, Bydgoszcz, 85796, Poland|Local Institution - 0078, Katowice, 40-519, Poland|Local Institution - 0509, Lisbon, Lisboa, 1099-023, Portugal|Local Institution - 0510, Coimbra, 3000-075, Portugal|Local Institution - 0553, Porto, 4099-001, Portugal|Local Institution - 0272, Bucharest, BucureÈti, 013812, Romania|Local Institution - 0261, Bucharest, BucureÈti, 022338, Romania|Local Institution - 0276, Cluj-Napoca, Cluj, 400015, Romania|Local Institution - 0268, FloreÈti, Cluj, 407280, Romania|Local Institution - 0275, Ovidiu, ConstanÈa, 905900, Romania|Local Institution - 0271, Craiova, Dolj, 200542, Romania|Local Institution - 0269, PloieÈti, Prahova, 100337, Romania|Local Institution - 0592, TimiÈoara, TimiÈ, 300239, Romania|Local Institution - 0270, Cluj, 400015, Romania|Local Institution - 0273, Cluj, 400015, Romania|Local Institution - 0590, ConstanÈa, 900591, Romania|Local Institution - 0266, IaÈi, 700106, Romania|Local Institution - 0260, IaÈi, 700483, Romania|Local Institution - 0614, Jeddah, Makkah Al Mukarramah, 23433, Saudi Arabia|Local Institution - 0602, Riyadh, 11426, Saudi Arabia|Local Institution - 0562, Riyadh, 12713, Saudi Arabia|Local Institution - 0499, A CoruÃ±a, A CoruÃ±a [La CoruÃ±a], 15006, Spain|Local Institution - 0506, Santiago de Compostela, A CoruÃ±a [La CoruÃ±a], 15706, Spain|Local Institution - 0501, Barcelona, Barcelona [Barcelona], 08035, Spain|Local Institution - 0497, Hospitalet, Barcelona [Barcelona], 08907, Spain|Local Institution - 0505, Barcelona, Catalunya [CataluÃ±a], 08036, Spain|Local Institution - 0508, Palma, Illes Balears [Islas Baleares], 07198, Spain|Local Institution - 0500, Madrid, Madrid, Comunidad De, 28009, Spain|Local Institution - 0503, Madrid, Madrid, Comunidad De, 28034, Spain|Local Institution - 0496, Madrid, Madrid, Comunidad De, 28041, Spain|Local Institution - 0498, Majadahonda, Madrid, Comunidad De, 28222, Spain|Local Institution - 0669, Pontevedra, Pontevedra [Pontevedra], 36312, Spain|Local Institution - 0640, Valencia, ValÃ¨ncia, 46015, Spain|Local Institution - 0504, Madrid, 28040, Spain|Local Institution - 0502, MÃ¡laga, 29011, Spain|Local Institution - 0507, Sevilla, 41013, Spain|Local Institution - 0495, ValÃ¨ncia, 46026, Spain|Local Institution - 0536, MÃ¼nsterlingen, 8596, Switzerland|Chi Mei Hospital - Liouying Branch, Tainan City, Tainan, 73657, Taiwan|Tri-Service General Hospital, Taipei City, Taipei, 114, Taiwan|Taipei Medical University Shuang Ho Hospital, New Taipei, 235, Taiwan|National Cheng Kung University Hospital, Tainan, 704, Taiwan|National Taiwan University Hospital, Taipei, 10002, Taiwan|Local Institution - 0565, Muang, Khon Kaen, 40002, Thailand|Local Institution - 0563, Bangkok, Krung Thep Maha Nakhon, 10330, Thailand|Local Institution - 0564, Hatyai, Songkhla, 90110, Thailand|Local Institution - 0548, Stanbul, Ä°stanbul, 34214, Turkey|Local Institution - 0199, Izmir, Karsiyaka, Ä°zmir, 009035575, Turkey|Local Institution - 0197, Adana, 01250, Turkey|Local Institution - 0201, Ankara, 06230, Turkey|Local Institution - 0198, Ankara, 06800, Turkey|Local Institution - 0194, Ankara, 0, Turkey|Local Institution - 0549, Istanbul, 34722, Turkey|Local Institution - 0200, Izmir, 35100, Turkey|Local Institution - 0550, Malatya, 44280, Turkey|University College London Hospital, London, London, City Of, NW1 2PG, United Kingdom|Guy's & St Thomas' NHS Foundation Trust, London, London, City Of, SE1 9RT, United Kingdom|Local Institution - 0092, Birmingham, B9 5SS, United Kingdom|Local Institution - 0090, Guildford, GU2 7XX, United Kingdom|Local Institution - 0545, Guildford, GU2 7XX, United Kingdom|Local Institution - 0093, Manchester, M20 4BX, United Kingdom",
NCT05894239,A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer,https://clinicaltrials.gov/study/NCT05894239,INAVO122,RECRUITING,"This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcutaneous use) compared with placebo in combination with Phesgo, as maintenance therapy, after induction therapy in participants with previously untreated HER2-positive advanced breast cancer (ABC).",NO,Metastatic Breast Cancer,DRUG: Inavolisib|DRUG: Phesgo|DRUG: Placebo|DRUG: Taxane-based Chemotherapy|DRUG: Optional Endocrine Therapy of Investigator's Choice,"Investigator-Assessed Progression-Free Survival (PFS), Up to approximately 40 months","Overall Survival (OS), Up to approximately 111 months|Investigator-Assessed Objective Response Rate (ORR), Up to approximately 111 months|Investigator-Assessed Duration of Response (DOR), Up to approximately 111 months|Investigator-Assessed Clinical Benefit Rate (CBR), Up to approximately 111 months|Investigator-Assessed PFS2, Up to approximately 111 months|Mean and Mean Changes from Baseline Score in Function and Health-Related Quality of Life (HRQoL), Assessed through the use of the Functional (Role, Physical) and Global Health Status (GHS)/Quality of Life (QoL) scales of the European Organisation for Research and Treatment of Cancer Quality of Life-Core 30 Questionnaire (EORTC QLQ-C30), Day 1 of Cycles 1 and 2 and beyond, 30-day safety follow up visit, post-treatment tumor assessment follow-up with PRO collection and survival follow up visit every 6 months (up to 111 months). Each cycle is 21 days.|Percentage of Participants with Adverse Events, Day 1 until 30 days after the final dose of study treatment (up to approximately 111 months). Each cycle is 21 days.|Plasma Concentration of Inavolisib at Specified Timepoints, Day 1 of Cycles 1 and 4. Each cycle is 21 days.",,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE3,230,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-09-08,2026-09-28,2032-12-28,2023-06-08,,2025-06-05,"Banner Health MD Anderson AZ, Gilbert, Arizona, 85234, United States|Disney Family Cancer Center, Burbank, California, 91505, United States|Ellison Institute of Technology, Los Angeles, California, 90064, United States|Georgetown Uni Hospital, Washington, District of Columbia, 20007, United States|Medstar Research Institute, Hyattsville, Maryland, 20783, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Henry Ford Hospital, Detroit, Michigan, 48202, United States|Renown Regional Medical Center, Reno, Nevada, 89502, United States|Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States|Atrium Health, Charlotte, North Carolina, 28209, United States|Hightower Clinical, Oklahoma City, Oklahoma, 73102, United States|Renovatio Clinical - El Paso, El Paso, Texas, 79915, United States|JPS Health Network, Fort Worth, Texas, 76104, United States|Lumi Research, Kingwood, Texas, 77339, United States|Renovatio Clinical, The Woodlands, Texas, 77380, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, 99336-7774, United States|Swedish Medical Center, Seattle, Washington, 98104-1360, United States|FundaciÃ³n CENIT para la InvestigaciÃ³n en Neurociencias, Buenos Aires, C1125ABD, Argentina|Centro Oncologico Korben, Ciudad Autonoma Buenos Aires, C1426AGE, Argentina|Instituto de OncologÃ­a de Rosario, Rosario, S2000KZE, Argentina|Hospital Provincial del Centenario, Rosario, S2002KDS, Argentina|CER San Juan Centro Polivalente de Asistencia e Investigacion Clinica, San Juan, J5400DIL, Argentina|ClÃ­nica Viedma, Viedma Rio Negro, R8500ACE, Argentina|Blacktown Hospital, Blacktown, New South Wales, 2148, Australia|Kinghorn Cancer Centre, Darlinghurst, New South Wales, 2010, Australia|Gosford Hospital, Gosford, New South Wales, 2250, Australia|University of the Sunshine Coast, Sippy Downs, Queensland, 4556, Australia|Monash Health, Clayton, Victoria, 3168, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, 6009, Australia|Cliniques Universitaires St-Luc, Bruxelles, 1200, Belgium|GHdC Site Les Viviers, Charleroi, 6000, Belgium|Jessa Zkh (Campus Virga Jesse), Hasselt, 3500, Belgium|Clinique Ste-Elisabeth, Namur, 5000, Belgium|Hospital Sao Rafael - HSR, Salvador, Bahia, 41253-190, Brazil|Crio - Centro Regional Integrado de Oncologia, Fortaleza, CearÃ¡, 60336-232, Brazil|Hospital Araujo Jorge, Goiania, GoiÃ¡s, 74605-070, Brazil|Hospital do CÃ¢ncer de Londrina, Londrina, ParanÃ¡, 86015-520, Brazil|Hospital do Cancer de Pernambuco - HCP, Recife, Pernambuco, 50040-000, Brazil|Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, 90050-170, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, Rio Grande Do Sul, 90610-000, Brazil|Hospital de Amor AmazÃ´nia, Porto Velho, RondÃ´nia, 76834-899, Brazil|Hospital de Cancer de Barretos, Barretos, SÃ£o Paulo, 14784-400, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SÃ£o Paulo, 01246-000, Brazil|Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda, Sao Paulo, SÃ£o Paulo, 01317-001, Brazil|Arthur J.E. Child Comprehensive Cancer Center-Calgary, Calgary, Alberta, T2N 5G2, Canada|The Moncton Hospital, Moncton, New Brunswick, E1C 6Z8, Canada|Eastern Health - General Hospital, St. John's, Newfoundland and Labrador, A1B 3V6, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, M4N 3M5, Canada|Centre Hospitalier de l?UniversitÃ© de MontrÃ©al (CHUM), Montreal, Quebec, H2X 0C2, Canada|Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada|HÃ´pital du SacrÃ©-Coeur de Montreal, Montreal, Quebec, H4J 1C5, Canada|Hopital du Saint Sacrement, Quebec City, Quebec, G1S 4L8, Canada|Allan Blair Cancer Center, Regina, Saskatchewan, S4T 7T1, Canada|Affiliated Hospital of Hebei University, Baoding, 071000, China|Beijing Cancer Hospital, Beijing, 100142, China|The First Hospital of Jilin University, Changchun City, 130021, China|Sichuan Provincial Cancer Hospital, Chengdu, 610041, China|Sichuan Provincial People's Hospital, Chengdu, 610072, China|Fujian Cancer Hospital, Fuzhou, 350014, China|Zhejiang Cancer Hospital, Hangzhou City, 310022, China|Harbin Medical University Tumor Hospital, Harbin, 150049, China|Shandong Cancer Hospital, Jinan, 250117, China|The First Affiliated Hospital to Henan University of Science and Technology, Luoyang, 471003, China|The Second Affiliated Hospital to Nanchang University, Nanchang, 330006, China|Guangxi Cancer Hospital of Guangxi Medical University, Nanning, 530021, China|Shantou Center Hospital, Shantou City, 515031, China|Tianjin Cancer Hospital, Tianjin, 300000, China|Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan City, 430022, China|Hubei Cancer Hospital, Wuhan, 430079, China|Clinica De La Costa, Barranquilla, 080020, Colombia|FundaciÃ³n CTIC - Centro de Tratamiento e InvestigaciÃ³n sobre CÃ¡ncer Luis Carlos Sarmiento Angulo, Bogota, D.C., 110131, Colombia|Oncomedica S.A., Monteria, 230002, Colombia|Sociedad de OncologÃ­a y hematologÃ­a del Cesar Ltda, Valledupar, 200001, Colombia|Tampere University Hospital, Tampere, 33520, Finland|Turku Uni Central Hospital, Turku, 20520, Finland|Institut Sainte Catherine, Avignon, 84082, France|Centre Hospitalier de La Cote Basque, Bayonne, 64109, France|Polyclinique Bordeaux Nord Aquitaine, Bordeaux, 33300, France|Centre Oscar Lambret, Lille, 59020, France|Klinikum St. Marien, Amberg, 92224, Germany|Marienhospital Bottrop gGmbH, Bottrop, 46236, Germany|Gynonco DÃ¼sseldorf, MVZ Medical Center GmbH, DÃ¼sseldorf, 40235, Germany|Frauenarztpraxis Dr. Apel, Dr. Kolpin, Erfurt, 99084, Germany|Praxis fÃ¼r InterdisziplinÃ¤re Onkologie und HÃ¤matologie GbR, Freiburg, 79110, Germany|Klinik & Poliklinik fÃ¼r Frauenheilkunde und Geburtshilfe, Campus Innenstadt, MÃ¼nchen, 80336, Germany|Caritas Klinik St. Theresia -Frauenklinik Brustzentrum, Saarbruecken, 66113, Germany|GynÃ¤kologie Kompetenzzentrum, Stralsund, 18439, Germany|Queen Mary Hospital, Hong Kong, Hong Kong|Tuen Mun Hospital, Hong Kong, Hong Kong|Max Super Speciality Hospital, NEW Delhi Delhi, Delhi, 110092, India|Gujarat Cancer & Research Inst., Ahmadabad CITY, Gujarat, 380016, India|Sunshine Global Hospital (A unit of Baroda Medicare Pvt Ltd), Surat CITY, Gujarat, 395007, India|Artemis Hospital, Gurugram, Haryana, 122001, India|National Cancer Institute, Nagpur, Maharashtra, 441108, India|Tata Medical Center, Kolkata, WEST Bengal, 700160, India|I.R.S.T Srl IRCCS, Meldola, Emilia-Romagna, 47014, Italy|Ospedale San Giovanni Addolorata, Roma, Lazio, 00185, Italy|Ospedale San Raffaele, Milano, Lombardia, 20132, Italy|Irccs Istituto Nazionale Dei Tumori (Int), Milano, Lombardia, 20133, Italy|Irccs Istituto Europeo Di Oncologia (IEO), Milano, Lombardia, 20141, Italy|Ospedale San Gerardo, Monza, Lombardia, 20900, Italy|A.O.U. Maggiore della CaritÃ , Novara, Piemonte, 28100, Italy|Casa di Cura La Maddalena, Palermo, Sicilia, 90146, Italy|Ospedale Santa Maria Annunziata, Bagno a Ripoli, Toscana, 50012, Italy|""Azienda Ospedaliera Universitaria Integrata Verona Ospedale Borgo Trento"", Verona, Veneto, 37124, Italy|King Hussein Cancer Center, Amman, 11941, Jordan|University of Nairobi - Institute of Tropical and Infectious Diseases, Nairobi, Kenya|National Cancer Center, Goyang-si, 10408, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, 03722, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Gangnam Severance Hospital, Seoul, 06273, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|Seoul St Mary's Hospital, Seoul, 06591, Korea, Republic of|Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, 44280, Mexico|OncoMed, Ciudad de MÃ©xico, Mexico CITY (federal District), 03100, Mexico|Centro OncolÃ³gico HematolÃ³gico Roma, Mexico City, Mexico CITY (federal District), 06700, Mexico|Hospital Universitario, Monterrey, Nuevo LEON, 64460, Mexico|CENEIT Oncologicos, Mexico City, 03100, Mexico|Sultan Qaboos Comprehensive Cancer Care & Research Center, Muscat, Oman|Centrum Onkologii im. Prof. Franciszka ?ukaszczyka, Bydgoszcz, 85-796, Poland|Uniwersyteckie Centrum Kliniczne, Gda?sk, 80-214, Poland|Szpital Morski im.PCK, Gdynia, 81-519, Poland|Narodowy Instytut Onkologii Odzia? w Gliwicach, Gliwice, 44-102, Poland|Przychodnia Lekarska KOMED, Roman Karaszewski, Konin, 62-500, Poland|Szpital WojewÃ³dzki im. Miko?aja Kopernika, Koszalin, 75-581, Poland|Wielkopolskie Centrum Onkologii im. Marii Sk?odowskiej-Curie, Pozna?, 61-866, Poland|Centrum Onkologii Instytut im.M. Sklodowskiej-Curie, Warszawa, 02-781, Poland|National University Hospital, Singapore, 119228, Singapore|National Cancer Centre, Singapore, 169610, Singapore|Icon Cancer Centre Farrer Park, Singapore, 217562, Singapore|Tan Tock Seng Hospital, Singapore, 308433, Singapore|Hopelands Cancer Centre, Hilton, 3245, South Africa|Charlotte Maxeke Academic Hospital, Johannesburg, 2193, South Africa|Medical Oncology Centre of Rosebank, Johannesburg, 2196, South Africa|Limpopo Cancer Research Institute, Polokwane, 0700, South Africa|Steve Biko Academic Hospital, Pretoria, 0002, South Africa|Chris Hani Baragwanath Clinical Trial Site, Soweto, 2013, South Africa|Complejo Hospitalario Universitario A CoruÃ±a (CHUAC), A CoruÃ±a, LA Coruna, 15006, Spain|Hospital Universitari Dexeus - Grupo Quironsalud, Barcelona, 08028, Spain|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital General Universitario Gregorio MaraÃ±on, Madrid, 28007, Spain|Hospital Ramon y Cajal, Madrid, 28034, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital Clinico Universitario Virgen de la Victoria, Malaga, 29010, Spain|Hospital Universitario Virgen Macarena, Sevilla, 41009, Spain|National Taiwan Uni Hospital, Taipei, 100, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital-Linkou, Taoyuan County, 333, Taiwan|Abderrahmen Mami Hospital, Ariana, 2080, Tunisia|Taher Maamouri Hospital, Nabeul, 8000, Tunisia|Habib Bourguiba Hospital, Sfax, 3029, Tunisia|Farhat Hached Hospital, Sousse, 4031, Tunisia|Institut Salah Azeiz, Tunis, 1006, Tunisia|Sakarya Training and Research Hospital, Adapazar?, 54290, Turkey|Gulhane Training and Research Hospital, Ankara, 06010, Turkey|Gazi University Medical Faculty, Ankara, 06500, Turkey|Bakirkoy Dr. Sadi Konuk Egitim ve Arastirma Hastanesi, Tibbi Onkoloji, Bakirkoy / Istanbul, 34147, Turkey|Dicle University Faculty of Medicine, Diyarbakir, 21280, Turkey|Medipol Mega Ãniversite Hastanesi GÃ¶ztepe, Istanbul, 34214, Turkey|Katip Celebi University Ataturk Training and Research Hospital, Izmir, 35360, Turkey|Medical Park Seyhan Hospital, Seyhan, 01140, Turkey|Hacettepe Uni Medical Faculty Hospital, Sihhiye/Ankara, 06230, Turkey|Uganda Cancer Institute, Kampala, 00256, Uganda|Blackpool Victoria Hospital, Blackpool, FY3 8NR, United Kingdom|Colchester General Hospital, Colchester, Essex, CO4 5JL, United Kingdom|Mount Vernon Hospital, Northwood, HA6 2RN, United Kingdom|Nottingham City Hospital, Nottingham, NG5 1PB, United Kingdom|Churchill Hospital, Oxford, OX3 7LJ, United Kingdom",
NCT06521255,Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma,https://clinicaltrials.gov/study/NCT06521255,,RECRUITING,"This is a Randomized, Multi-center, Phase 3 Study of Tafasitamab and Lenalidomide in Combination with Gemcitabine and Oxaliplatin versus Rituximab in Combination with Gemcitabine and Oxaliplatin in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphom",NO,DLBCL,DRUG: Tafasitamab|DRUG: Lenalidomide|DRUG: Gemcitabine|DRUG: Oxaliplatin|DRUG: Rituximab,"Dose limiting toxicityï¼DLTï¼and other adverse events (AEs) of tafasitamab and lenalidomide in combination with GemOx (TL-GemOx) assessed using CTCAE v5.0, within 28 days after therapy initiation|PFS assessed by IRC according to Lugano 2014, 1-3 years approximately","Objective Response Rate (ORR) according to investigator., 1-3 years approximately|Complete Response Rate (CRR) according to investigator., 1-3 years approximately|Duration of Response (DOR) according to investigator., 1-3 years approximately|Progression free survival (PFS) assessed by investigator according to the Lugano 2014, 1-3 years approximately|Time to response (TTR), 1-3 years approximately|Overall Survival (OS), 1-3 years approximately|Time to next treatment (TTNT), 1-3 years approximately|Adverse events assessed by CTCAE version 5.0 criteria., 1-3 years approximately|Quality of life assessment: Patient-reported outcomes (PROs) on happiness and general health status based on Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym), 1-3 years approximately|Quality of life assessment: Patient-reported outcomes (PROs) on happiness and general health status based on EuroQol five dimensions questionnaire (EQ-5D-5L), 1-3 years approximately",,"Beijing InnoCare Pharma Tech Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,244,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-05-07,2028-09,2029-12,2024-07-25,,2024-07-25,"Beijing Hospital, Beijing, China|The First Hospital Of Jilin University, Changchun, China|Hunan Cancer Hospital, Changsha, China|Chenzhou No.1 People's Hospital, Chaozhou, China|Sichuan Province People's Hospital, Chengdu, China|The First Affiliated Hospital of Chongqing Medical University, Chongqing, China|Guangdong General Hospital, Guangzhou, China|Sun Yat-sen University Cancer Center, Guangzhou, China|Hangzhou First People's Hospital, Hangzhou, China|The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China|Shandong Cancer Hospital and Institute, Jinan, China|Jiangxi Cancer Hospital, Nanchang, China|The First Affiliated Hospital of Nanchang University, Nanjing, China|Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China|The Second Affiliated Hospital of Soochow University, Suzhou, China|Tianjin First Central Hospital, Tianjin, China|Xinjiang Medical University Affiliated Cancer Hospital, Urumqi, China|The First Affiliated Hospital Wenzhou Medical University, Wenzhou, China|Union Hospital Tongji Medical College, Wuhan, China|Henan Cancer Hospital, Zhengzhou, China",
NCT05647954,A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver,https://clinicaltrials.gov/study/NCT05647954,,NOT_YET_RECRUITING,"The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS) and Overall Survival(OS), achieved by HX008 Plus Transcatheter Arterial Chemoembolization (TACE) or Temozolomide Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver.",NO,Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms,DRUG: HX008 + TACE|DRUG: Temozolomide + TACE|DRUG: Pembrolizumab,"Progression-free Survival (PFS) by Independent Review Committee(IRC), PFS, defined as the time from randomization to the first documented disease.(HX008 + TACE vs Temozolomide + TACE), 2 years|Overall Survival (OS), OS, defined as the duration from the start of treatment to death of any cause.(HX008 + TACE vs Temozolomide + TACE), 2 years","Progression-free Survival (PFS) by Investigators, PFS, defined as the time from randomization to the first documented disease.(HX008 + TACE vs Temozolomide + TACE), 2 years|Objective Response Rate (ORR), ORR, defined as the percentage of subjects achieving complete response (CR) and partial response (PR)., 2 years|Disease Control Rate (DCR), DCR, defined as the proportion of subjects achieving CR, PR, and Stable diseaseï¼SD) after treatment., 2 years|Duration of Response (DOR), DOR, defined as the duration from the initial recording of objective disease response to the first onset of tumor progression, or death of any cause., 2 years|Progression-free Survival (PFS) by IRC or investigators, PFS, defined as the time from randomization to the first documented disease.(HX008 + TACE vs Pembrolizumab), 2 years|Overall Survival (OS), OS, defined as the duration from the start of treatment to death of any cause.(HX008 + TACE vs Pembrolizumab), 2 years|Adverse events, Number of subjects with treatment-related adverse events as assessed by CTCAE v5.0,etc., 2 years",,Taizhou Hanzhong biomedical co. LTD,,ALL,"ADULT, OLDER_ADULT",PHASE3,350,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-12-31,2024-12-30,2025-06-30,2022-12-13,,2022-12-13,"Beijing Cancer hospital, Beijing, Beijing, 100142, China",
NCT05687266,"Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations",https://clinicaltrials.gov/study/NCT05687266,AVANZAR,ACTIVE_NOT_RECRUITING,"This is a Phase III, randomized, open-label, multicenter, global study to compare the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd) in combination with durvalumab and carboplatin compared with pembrolizumab in combination with histology-specific platinum-based chemotherapy as first-line treatment of adults with stage IIIB, IIIC, or IV NSCLC without actionable genomic alterations (including sensitizing EGFR mutations, and ALK and ROS1 rearrangements).",NO,NSCLC,DRUG: Datopotamab deruxtecan|DRUG: Durvalumab|DRUG: Carboplatin|DRUG: Pembrolizumab|DRUG: Cisplatin|DRUG: Pemetrexed|DRUG: Paclitaxel,"Progression-Free Survival (PFS) by blinded independent central review (BICR) in the non-squamous TROP2 biomarker positive population, PFS is deï¬ned as time from randomisation until progression per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1) as assessed by BICR, or death due to any cause., Approximately 3 years|Overall Survival (OS) in the non-squamous TROP2 biomarker positive population, OS is defined as the time from randomisation until the date of death due to any cause., Approximately 4 years|PFS by BICR in the non-squamous population, PFS is deï¬ned as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause., Approximately 3 years|OS in the non-squamous population, OS is deï¬ned as the time from randomisation until the date of death due to any cause., Approximately 4 years","PFS by BICR in ITT and TROP2 biomarker-defined populations, PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause., Approximately 3 years|OS in ITT and TROP2 biomarker-defined populations, OS is defined as the time from randomisation until the date of death due to any cause., Approximately 4 years|Objective Response Rate (ORR) in ITT, non-squamous and TROP2 biomarker-defined populations, ORR is deï¬ned as the proportion of participants who have a conï¬rmed Complete Response (CR) or conï¬rmed Partial Response (PR), as determined by BICR per RECIST 1.1., Approximately 4 years|Duration of Response (DoR) in ITT, non-squamous and TROP2 biomarker-defined populations, DoR is deï¬ned as the time from the date of ï¬rst documented conï¬rmed response until date of documented progression per RECIST 1.1, as assessed by BICR and investigator clinical assessment or death due to any cause., Approximately 4 years|PFS by investigator in ITT, non-squamous and TROP2 biomarker-defined populations, PFS is deï¬ned as time from randomisation until progression per RECIST 1.1 as assessed by investigator clinical assessment, or death due to any cause., Approximately 3 years|Pharmacokinetics of Dato-DXd when combined with durvalumab and carboplatin., Concentration of Dato-DXd, total anti-TROP2 antibody, and DXd (payload deruxtecan) in plasma and pharmacokinetic (PK) parameters (such as peak and trough concentrations, as data allow; sparse sampling)., Approximately 4 years|Anti-Drug Antibody (ADA) for Dato-DXd, The immunogenicity of Dato-DXd when combined with durvalumab and carboplatin., Approximately 4 years|Time to Second Progression or Death (PFS2) in ITT, non-squamous and TROP2 biomarker-defined populations, PFS2 is defined as the time from randomisation to the earliest of the progression events (following the initial progression), subsequent to first subsequent therapy, or death., Approximately 4 years|Clinical Outcome Assessments in ITT, non-squamous and TROP2 biomarker-defined populations, Clinical Outcome Assessments, such as TTD in pulmonary symptoms (dyspnoea, cough and chest pain) as measured by the NSCLC-SAQ, and TTD in physical functioning as measured by PROMIS Physical Function short form 8c, Approximately 4 years","Safety of Dato-DXd in combination with durvalumab and carboplatin, Safety and tolerability will be evaluated in terms of AEs (graded by CTCAE Version 5.0)., Approximately 4 years",AstraZeneca,,ALL,"ADULT, OLDER_ADULT",PHASE3,1350,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-12-29,2027-11-01,2027-11-01,2023-01-18,,2025-01-30,"Research Site, Phoenix, Arizona, 85054, United States|Research Site, Tucson, Arizona, 85704, United States|Research Site, Hot Springs National Park, Arkansas, 71913, United States|Research Site, Little Rock, Arkansas, 72205, United States|Research Site, Springdale, Arkansas, 72762, United States|Research Site, Fountain Valley, California, 92708, United States|Research Site, Los Angeles, California, 90017, United States|Research Site, Orange, California, 92868, United States|Research Site, Boulder, Colorado, 80303, United States|Research Site, Fort Myers, Florida, 33901, United States|Research Site, Jacksonville, Florida, 32224, United States|Research Site, Lakeland, Florida, 33812, United States|Research Site, Saint Petersburg, Florida, 33705, United States|Research Site, West Palm Beach, Florida, 33401, United States|Research Site, Hinsdale, Illinois, 60521, United States|Research Site, Fort Wayne, Indiana, 46845, United States|Research Site, Bettendorf, Iowa, 52722, United States|Research Site, Des Moines, Iowa, 50309, United States|Research Site, Iowa City, Iowa, 52242, United States|Research Site, Baton Rouge, Louisiana, 70808, United States|Research Site, Covington, Louisiana, 70433, United States|Research Site, Duluth, Minnesota, 55805, United States|Research Site, Rochester, Minnesota, 55905, United States|Research Site, Hannibal, Missouri, 63401, United States|Research Site, Lincoln, Nebraska, 68506, United States|Research Site, Lincoln, Nebraska, 68516, United States|Research Site, Clifton Park, New York, 12065, United States|Research Site, Asheville, North Carolina, 28806, United States|Research Site, Canton, Ohio, 44710, United States|Research Site, Columbus, Ohio, 43219, United States|Research Site, Maumee, Ohio, 43537, United States|Research Site, Tulsa, Oklahoma, 74134, United States|Research Site, Portland, Oregon, 97239, United States|Research Site, Salem, Oregon, 97301, United States|Research Site, Philadelphia, Pennsylvania, 19104, United States|Research Site, Philadelphia, Pennsylvania, 19107, United States|Research Site, Philadelphia, Pennsylvania, 19111, United States|Research Site, York, Pennsylvania, 17403, United States|Research Site, Watertown, South Dakota, 57201, United States|Research Site, Memphis, Tennessee, 38120, United States|Research Site, Dallas, Texas, 75246, United States|Research Site, Fort Worth, Texas, 76104, United States|Research Site, Houston, Texas, 77030, United States|Research Site, Houston, Texas, 77090, United States|Research Site, Irving, Texas, 75063, United States|Research Site, Fairfax, Virginia, 22031, United States|Research Site, Henrico, Virginia, 23229, United States|Research Site, Norfolk, Virginia, 23502, United States|Research Site, Renton, Washington, 98055, United States|Research Site, Spokane, Washington, 99202, United States|Research Site, Tacoma, Washington, 98405, United States|Research Site, Appleton, Wisconsin, 54911, United States|Research Site, La Crosse, Wisconsin, 54601, United States|Research Site, Graz, 8036, Austria|Research Site, Rankweil, 6830, Austria|Research Site, Wien, 1090, Austria|Research Site, Wien, 1210, Austria|Research Site, Blumenau, 89010-340, Brazil|Research Site, FlorianÃ³polis, 88034-000, Brazil|Research Site, Fortaleza, 60336-045, Brazil|Research Site, Londrina, 86015-520, Brazil|Research Site, Porto Alegre, 90035-903, Brazil|Research Site, Sao Paulo, 01327-001, Brazil|Research Site, Sao Paulo, 01509-900, Brazil|Research Site, Sao Paulo, 09323-900, Brazil|Research Site, SÃ£o Paulo, 01246-000, Brazil|Research Site, TaubatÃ©, 12030-200, Brazil|Research Site, Vitoria, 29043-260, Brazil|Research Site, Sofia, 1113, Bulgaria|Research Site, Sofia, 1330, Bulgaria|Research Site, Varna, 9010, Bulgaria|Research Site, Saint John, New Brunswick, E2L 4L2, Canada|Research Site, Brampton, Ontario, L6R 3J7, Canada|Research Site, Kitchener, Ontario, N2G 1G3, Canada|Research Site, Newmarket, Ontario, L3Y 2P9, Canada|Research Site, Sudbury, Ontario, P3E 5J1, Canada|Research Site, Montreal, Quebec, H1T 2M4, Canada|Research Site, Montreal, Quebec, H4A 3J1, Canada|Research Site, Montreal, Quebec, H4J 1C5, Canada|Research Site, St-Jerome, Quebec, J7Z 5T3, Canada|Research Site, Saskatoon, Saskatchewan, S7N 4H4, Canada|Research Site, Beijing, 100010, China|Research Site, Beijing, 100029, China|Research Site, Beijing, 100037, China|Research Site, Beijing, 100039, China|Research Site, Beijing, 100853, China|Research Site, Beijing, CN-100730, China|Research Site, Changsha, 410008, China|Research Site, Changsha, 410013, China|Research Site, Chengdu, 610041, China|Research Site, Chengdu, 610072, China|Research Site, Chongqing, 400037, China|Research Site, Guangzhou, 510000, China|Research Site, Guangzhou, 510100, China|Research Site, Hefei, 230601, China|Research Site, Jinan, 250021, China|Research Site, Kunming, 650101, China|Research Site, Lanzhou, 730000, China|Research Site, Liuzhou, 545006, China|Research Site, Shandong, China|Research Site, Shanghai, 200030, China|Research Site, Shanghai, 200032, China|Research Site, Shanghai, 200080, China|Research Site, Shantou, 515041, China|Research Site, Shenyang, 110004, China|Research Site, Shenzhen, 517108, China|Research Site, Taiyuan, 030000, China|Research Site, Tianjin, 300060, China|Research Site, Wenzhou, 325000, China|Research Site, Wuhan, 430030, China|Research Site, Wuhan, 430060, China|Research Site, Xiamen, 361004, China|Research Site, Yangzhou, 225001, China|Research Site, Zhengzhou, 450052, China|Research Site, Brest, 29200, France|Research Site, Creteil, 94010, France|Research Site, Gleize, 69400, France|Research Site, Montpellier, 34070, France|Research Site, Nimes, 30029, France|Research Site, Paris CEDEX 14, 75674, France|Research Site, Paris, 75018, France|Research Site, Rouen, 76031, France|Research Site, Saint-Quentin, 02321, France|Research Site, Strasbourg Cedex, 67091, France|Research Site, Toulon Cedex 9, 83800, France|Research Site, Toulouse, 31059, France|Research Site, Tours, 37000, France|Research Site, Bad Berka, 99437, Germany|Research Site, Berlin, 14109, Germany|Research Site, Frankfurt A. Main, 60590, Germany|Research Site, Gauting, 82131, Germany|Research Site, GÃ¼tersloh, 33332, Germany|Research Site, Hamburg, 20251, Germany|Research Site, Kassel, 34125, Germany|Research Site, Kiel, 24116, Germany|Research Site, Koblenz, 56073, Germany|Research Site, Minden, 32429, Germany|Research Site, Rosenheim, 83022, Germany|Research Site, Velbert, 42551, Germany|Research Site, WÃ¼rzburg, 97074, Germany|Research Site, Athens, 11526, Greece|Research Site, Athens, 11527, Greece|Research Site, Athens, 155 62, Greece|Research Site, Peiraias, 185 47, Greece|Research Site, Thessaloniki, 55236, Greece|Research Site, Thessaloniki, 57001, Greece|Research Site, Budapest, 1121, Hungary|Research Site, Budapest, 1122, Hungary|Research Site, GyÃ¶ngyÃ¶s - MÃ¡trahÃ¡za, 3200, Hungary|Research Site, KaposvÃ¡r, 7400, Hungary|Research Site, PÃ©cs, 7624, Hungary|Research Site, SzekszÃ¡rd, 7100, Hungary|Research Site, Szolnok, 5000, Hungary|Research Site, TÃ¶rÃ¶kbÃ¡lint, 2045, Hungary|Research Site, Calicut, 673601, India|Research Site, Delhi, 110029, India|Research Site, Delhi, 110085, India|Research Site, Jaipur, 302017, India|Research Site, Kolkata, 700160, India|Research Site, Madurai, 625107, India|Research Site, Puducherry, 605006, India|Research Site, Firenze, 50134, Italy|Research Site, Lecco, 23900, Italy|Research Site, Messina, 98158, Italy|Research Site, Napoli, 80131, Italy|Research Site, Orbassano, 10043, Italy|Research Site, Padova, 35128, Italy|Research Site, Parma, 43126, Italy|Research Site, Peschiera Del Garda, 37019, Italy|Research Site, Rozzano, 20089, Italy|Research Site, Bunkyo-ku, 113-8603, Japan|Research Site, Chuo-ku, 104-0045, Japan|Research Site, Hamamatsu-shi, 431-3192, Japan|Research Site, Hamamatsu-shi, 432-8580, Japan|Research Site, Hidaka-shi, 350-1298, Japan|Research Site, Hirosaki-shi, 036-8563, Japan|Research Site, Hiroshima-shi, 730-8518, Japan|Research Site, Kumamoto-shi, 860-8556, Japan|Research Site, Nagoya-shi, 464-8681, Japan|Research Site, Nagoya-shi, 466-8560, Japan|Research Site, Okayama-shi, 700-8558, Japan|Research Site, Osaka-shi, 545-8586, Japan|Research Site, Osakasayama-shi, 589-8511, Japan|Research Site, Sapporo-shi, 060-8638, Japan|Research Site, Sunto-gun, 411-8777, Japan|Research Site, Wakayama-shi, 641-8510, Japan|Research Site, Yokohama-shi, 221-0855, Japan|Research Site, Yokohama-shi, 241-8515, Japan|Research Site, Busan, 48108, Korea, Republic of|Research Site, Cheongju-si, 28644, Korea, Republic of|Research Site, Jinju-si, 52727, Korea, Republic of|Research Site, Seoul, 03080, Korea, Republic of|Research Site, Seoul, 03722, Korea, Republic of|Research Site, Seoul, 05505, Korea, Republic of|Research Site, Seoul, 06351, Korea, Republic of|Research Site, Seoul, 07061, Korea, Republic of|Research Site, Suwon-si, 16499, Korea, Republic of|Research Site, Suwon, 16247, Korea, Republic of|Research Site, Cdmx, 03810, Mexico|Research Site, Del. Cuauhtemoc, 06700, Mexico|Research Site, Mexico, 14080, Mexico|Research Site, San Luis PotosÃ­, 78209, Mexico|Research Site, Arequipa, 04002, Peru|Research Site, ConcepciÃ³n, 12125, Peru|Research Site, Lima, 15036, Peru|Research Site, Lima, 34, Peru|Research Site, Lima, LIMA 27, Peru|Research Site, Lima, LIMA 29, Peru|Research Site, Bydgoszcz, 85-796, Poland|Research Site, Bystra, 43-360, Poland|Research Site, GrudziÄdz, 86-300, Poland|Research Site, Kielce, 25-734, Poland|Research Site, Koszalin, 75-581, Poland|Research Site, Olsztyn, 10-357, Poland|Research Site, PoznaÅ, 60-569, Poland|Research Site, Przemysl, 37-700, Poland|Research Site, RacibÃ³rz, 47-400, Poland|Research Site, Radom, 26-600, Poland|Research Site, Siedlce, 08-110, Poland|Research Site, Las Palmas de Gran Canaria, 35016, Spain|Research Site, Lugo, 27003, Spain|Research Site, Madrid, 28041, Spain|Research Site, Santander, 39008, Spain|Research Site, Sevilla, 41013, Spain|Research Site, Valencia, 46010, Spain|Research Site, Zaragoza, 50009, Spain|Research Site, GÃ¤vle, 801 88, Sweden|Research Site, LinkÃ¶ping, 581 85, Sweden|Research Site, Lund, 221 85, Sweden|Research Site, Stockholm, 17176, Sweden|Research Site, Uppsala, 751 85, Sweden|Research Site, Hsinchu, 300, Taiwan|Research Site, Taichung, 40705, Taiwan|Research Site, Tainan City, 73657, Taiwan|Research Site, Taipei City, 11217, Taiwan|Research Site, Taipei, 235, Taiwan|Research Site, Taoyuan City, 333, Taiwan|Research Site, Adana, 01060, Turkey|Research Site, Ankara, 06800, Turkey|Research Site, Edirne, 22030, Turkey|Research Site, Istanbul, 34098, Turkey|Research Site, Izmir, 35110, Turkey|Research Site, Aberdeen, AB25 2ZN, United Kingdom|Research Site, Cambridge, CB2 0QQ, United Kingdom|Research Site, Cardiff, CF14 2TL, United Kingdom|Research Site, Cheltenham, GL53 7AN, United Kingdom|Research Site, Edinburgh, EH4 2XU, United Kingdom|Research Site, London, SE1 9RT, United Kingdom|Research Site, London, W6 8RF, United Kingdom|Research Site, Manchester, M20 4BX, United Kingdom|Research Site, Middlesborough, TS4 3BW, United Kingdom|Research Site, Newcastle-Upon-Tyne, NE7 7DN, United Kingdom|Research Site, Taunton, TA1 5DA, United Kingdom|Research Site, Hanoi, 100000, Vietnam|Research Site, Ho Chi Minh city, 700000, Vietnam|Research Site, Ho Chi Minh, 700000, Vietnam",
NCT04624204,"Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-NaÃ¯ve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)",https://clinicaltrials.gov/study/NCT04624204,,ACTIVE_NOT_RECRUITING,"Researchers are looking for new ways to treat Limited-Stage Small Cell Lung Cancer (LS-SCLC), a type of lung cancer that has not spread from the lung to other parts of the body. The purpose of this study is to learn if pembrolizumab and olaparib, when given with chemotherapy and radiation treatment (CRT), can be effective in treating LS-SCLC. The researchers want to know if participants who receive CRT and pembrolizumab, with or without olaparib, have a longer overall survival compared to participants who only receive CRT.",NO,Small Cell Lung Cancer,"BIOLOGICAL: Pembrolizumab 200 mg|BIOLOGICAL: Pembrolizumab 400 mg|DRUG: Pembrolizumab placebo (saline)|DRUG: Pembrolizumab placebo (saline)|DRUG: Olaparib 300 mg BID|DRUG: Olaparib matching placebo|DRUG: Etoposide 100 mg/m^2|DRUG: Platinum, investigator's choice|RADIATION: Standard Thoracic Radiotherapy|RADIATION: Prophylactic Cranial Irradiation (PCI)","Progression-free Survival Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1); the time from randomization to progression or death due to any cause, whichever occurs first, Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) is the time from randomization to progression or death due to any cause, whichever occurs first., Up to approximately 59 months|Overall Survival: the time from randomization to death due to any cause, Overall Survival (OS) is the time from randomization to death due to any cause., Up to approximately 82 months","Number of Participants Experiencing an Adverse Events (AEs), An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study., Up to approximately 82 months|Number of Participants Discontinuing Study Treatment Due to Adverse Events (AEs), An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study., Up to approximately 82 months|Objective Response (OR): Complete Response (CR) or Partial Response (PR), Percentage of participants in the analysis population who have a best overall response of either confirmed CR or a PR per RECIST 1.1., Up to approximately 82 months|Duration of Response (DOR): the time from the earliest date of first documented evidence of confirmed CR or PR until the earliest date of disease progression or death from any cause, whichever comes first, DOR is the time from the earliest date of first documented evidence of confirmed CR or PR until the earliest date of disease progression or death from any cause, whichever comes first., Up to approximately 82 months|Change from Baseline at Cycle 1 in European Organization for Research and Treatment (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status / Quality of Life (Items 29 & 30) Scale Score, The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the question ""How would you rate your overall health during the past week?"" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status. The change from baseline in EORTC QLQ-C30 Items 29 and 30 scores will be presented., Baseline and 82 months post randomization|Change from Baseline at Cycle 1 in EORTC Quality of Life Questionnaire Lung Cancer Module 13 (QLQ-LC13) Cough (Item 1) Scale Score, The EORTC QLQ-LC13 is a lung cancer specific supplemental questionnaire used in combination with the EORTC QLQC30 questionnaire. Participant responses to the question ""How much did you cough?"" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. The change from baseline in EORTC QLQ-LC13 cough (Item 1) score will be presented., Baseline and 82 months post randomization|Change from Baseline at Cycle 1 in EORTC QLQ-LC13 Chest Pain (Item 10) Scale Score, The EORTC QLQ-LC13 is a lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQC30 questionnaire. Participant responses to the question ""How was your chest pain?"" are scored on a 4 point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. The change from baseline in EORTC QLQ-LC13 chest pain (Item 10) score will be presented., Baseline and 82 months post randomization|Change from Baseline at Cycle 1 in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score, The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the question ""Were you short of breath?"" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. The change from baseline in EORTC QLQ-LC13 dyspnea (Item 8) score will be presented., Baseline and 82 months post randomization|Change from Baseline at Cycle 1 in EORTC QLQ-C30 Physical Functioning (Items 1 to 5) Scale Score, The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better quality of life. The change from baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) score will be presented., Baseline and 82 months post randomization|Time to True Deterioration (TTD) in EORTC QLQ-C30 Global Health Status / Quality of Life (Items 29 & 30) Scale Score, The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the question ""How would you rate your overall health during the past week?"" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status. TTD was defined as the time from baseline (at randomization) to the first onset of a â¥10-point decrease with confirmation by the subsequent visit of a â¥10-point decrease in EORTC QLQ-C30 Items 29 and 30 scale scores., Up to approximately 82 months post randomization|Time to True Deterioration (TTD) in Cough (LC13/Item 1) Scale Score, The EORTC QLQ-LC13 is a lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQC30 questionnaire. Participant responses to the question ""How much did you cough?"" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. TTD was defined as the time from baseline (at randomization) to the first onset of a â¥10-point decrease with confirmation by the subsequent visit of a â¥10-point decrease in cough EORTC QLQLC13 cough (Item 1) scale score., Up to approximately 82 months post randomization|Time to True Deterioration (TTD) in Chest Pain (LC13/Item 10) Scale Score, The EORTC QLQ-LC13 is a lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQC30 questionnaire. Participant responses to the question ""How was your chest pain?"" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. TTD was defined as the time from baseline (at randomization) to the first onset of a â¥10-point decrease with confirmation by the subsequent visit of a â¥10-point decrease in EORTC QLQ-LC13 chest pain (Item 10) scale score., Up to approximately 82 months post randomization|Time to True Deterioration (TTD) in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score, The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the question ""Were you short of breath?"" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. TTD was defined as the time from baseline (at randomization) to the first onset of a â¥10-point decrease with confirmation by the subsequent visit of a â¥10-point decrease in EORTC QLQ-C30 dyspnea (Item 8) scale score., Up to approximately 82 months post randomization|Time to True Deterioration (TTD) in EORTC QLQ-C30 Physical Functioning (Items 1 to 5) Scale Score, The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better quality of life. TTD was defined as the time from baseline (at randomization) to the first onset of a â¥10-point decrease with confirmation by the subsequent visit of a â¥10-point decrease in EORTC QLQ-C30 physical functioning (Items 1 to 5) scale scores., Up to approximately 82 months post randomization|Objective Response (OR, according to RECIST 1.1 by BICR) assessed by programmed cell death ligand 1 (PD-L1) expression levels, Percentage of participants in the analysis population who have a best overall response of either confirmed CR or a PR per RECIST 1.1, analyzed by programmed cell death ligand 1 (PD-L1) expression levels., Up to approximately 82 months|Duration of Response (DOR, according to RECIST 1.1 by BICR) assessed by programmed cell death ligand 1 (PD-L1) expression levels, DOR is the time from the earliest date of first documented evidence of confirmed CR or PR until the earliest date of disease progression or death from any cause, whichever comes first, analyzed by programmed cell death ligand 1 (PD-L1) expression levels., Up to approximately 82 months|Progression-free Survival (PFS, according to RECIST 1.1 by BICR) assessed by programmed cell death ligand 1 (PD-L1) expression levels, Progression-free Survival Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1); the time from randomization to progression or death due to any cause, whichever occurs first, analyzed by programmed cell death ligand 1 (PD-L1) expression levels., Up to approximately 59 months|Overall Survival (OS) assessed by programmed cell death ligand 1 (PD-L1) expression levels, Overall Survival: the time from randomization to death due to any cause, analyzed by programmed cell death ligand 1 (PD-L1) expression levels., Up to approximately 82 months",,Merck Sharp & Dohme LLC,,ALL,"ADULT, OLDER_ADULT",PHASE3,672,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-12-08,2027-10-28,2027-10-28,2020-11-10,,2024-11-19,"Ironwood Cancer & Research Centers ( Site 0007), Chandler, Arizona, 85224, United States|Loma Linda University Cancer Center ( Site 0011), Loma Linda, California, 92350, United States|Georgetown University ( Site 0017), Washington, District of Columbia, 20007, United States|Moffitt Cancer Center ( Site 0137), Tampa, Florida, 33612, United States|University of Chicago Medical Center ( Site 0136), Chicago, Illinois, 60637, United States|Fort Wayne Medical Oncology and Hematology ( Site 0034), Fort Wayne, Indiana, 46804, United States|University of Kentucky Chandler Medical Center ( Site 0138), Lexington, Kentucky, 40536, United States|Overton Brooks VAMC ( Site 0041), Shreveport, Louisiana, 71101, United States|Harry & Jeanette Weinberg Cancer Institute ( Site 0045), Baltimore, Maryland, 21237, United States|VA Ann Arbor Healthcare System ( Site 0050), Ann Arbor, Michigan, 48105, United States|St. Vincent Healthcare Frontier Cancer Center ( Site 0056), Billings, Montana, 59102, United States|Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0061), Omaha, Nebraska, 68130, United States|Memorial Sloan Kettering - Basking Ridge ( Site 0133), Basking Ridge, New Jersey, 07920, United States|John Theurer Cancer Center ( Site 0064), Hackensack, New Jersey, 07601, United States|Memorial Sloan Kettering - Monmouth ( Site 0135), Middletown, New Jersey, 07748, United States|Memorial Sloan Kettering - Bergen ( Site 0130), Montvale, New Jersey, 07645, United States|Rutgers Cancer Institute of New Jersey ( Site 0123), New Brunswick, New Jersey, 08903, United States|Memorial Sloan Kettering- Commack ( Site 0132), Commack, New York, 11725, United States|Memorial Sloan Kettering - Westchester-Thoracic Oncology ( Site 0134), Harrison, New York, 10604, United States|Memorial Sloan Kettering Cancer Center ( Site 0069), New York, New York, 10021, United States|Memorial Sloan Kettering - Nassau ( Site 0131), Uniondale, New York, 11553, United States|Fairview Hospital-Moll Cancer Center ( Site 0141), Cleveland, Ohio, 44111, United States|Cleveland Clinic Main ( Site 0139), Cleveland, Ohio, 44195, United States|Cleveland Clinic - Hillcrest Hospital-Hillcrest Hospital Cancer Center ( Site 0140), Mayfield Heights, Ohio, 44124, United States|Penn State Hershey Cancer Institute ( Site 0081), Hershey, Pennsylvania, 17033, United States|Saint Francis Cancer Center ( Site 0087), Greenville, South Carolina, 29607, United States|The University of Tennessee Medical Center ( Site 0116), Knoxville, Tennessee, 37920, United States|Texas Oncology - Dallas (Presbyterian)_McIntyre ( Site 0098), Dallas, Texas, 75231, United States|Texas Oncology - Dallas (Sammons) ( Site 0093), Dallas, Texas, 75246, United States|MD Anderson Cancer Center ( Site 0100), Houston, Texas, 77030, United States|Millennium Research & Clinical Development ( Site 0143), Houston, Texas, 77090, United States|Providence Regional Cancer Partnership ( Site 0106), Everett, Washington, 98201, United States|Medical Oncology Associates, PS ( Site 0142), Spokane, Washington, 99208, United States|Multicare Institute For Research And Innovation ( Site 0108), Tacoma, Washington, 98405, United States|Virginia Mason Memorial- North Star Lodge Cancer Center ( Site 0112), Yakima, Washington, 98902, United States|Campbelltown Hospital ( Site 3002), Campbelltown, New South Wales, 2560, Australia|Nepean Hospital ( Site 3001), Kingswood, New South Wales, 2747, Australia|Calvary Mater Newcastle ( Site 3000), Waratah, New South Wales, 2298, Australia|Gold Coast University Hospital ( Site 3003), Southport, Queensland, 4215, Australia|Frankston Hospital-Oncology and Haematology ( Site 3007), Frankston, Victoria, 3199, Australia|Austin Health-Austin Hospital ( Site 3006), Heidelberg, Victoria, 3084, Australia|Western Health-Sunshine Hospital ( Site 3004), St Albans, Victoria, 3021, Australia|Saint-Luc UCL ( Site 1005), Brussels, Bruxelles-Capitale, Region De, 1200, Belgium|Grand Hopital de Charleroi ( Site 1003), Charleroi, Hainaut, 6000, Belgium|C.I.U. Hopital Ambroise Pare ( Site 1001), Mons, Hainaut, 7000, Belgium|CHU UCL Namur Site de Godinne ( Site 1004), Yvoir, Namur, 5530, Belgium|UZ Leuven ( Site 1002), Leuven, Vlaams-Brabant, 3000, Belgium|AZ Delta ( Site 1000), Roeselare, West-Vlaanderen, 8800, Belgium|MHAT ""Uni Hospital"" OOD ( Site 2507), Panagyurishte, Pazardzhik, 4500, Bulgaria|Cross Cancer Institute ( Site 0206), Edmonton, Alberta, T6G 1Z2, Canada|Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0212), Hamilton, Ontario, L8V 5C2, Canada|CIUSSS Ouest de l Ile - St-Mary s Hospital ( Site 0202), Montreal, Quebec, H3T 1M5, Canada|McGill University Health Centre ( Site 0210), MontrÃ©al, Quebec, H4A 3J1, Canada|CIUSSS de la Mauricie et du Centre du Quebec ( Site 0200), Trois-Rivieres, Quebec, G8Z 3R9, Canada|Peking Union Medical College Hospital ( Site 3102), Beijing, Beijing, 100006, China|Cancer Hospital Chinese Academy of Medical Sciences ( Site 3104), Beijing, Beijing, 100021, China|Beijing Cancer Hospital ( Site 3127), Beijing, Beijing, 100142, China|Beijing Cancer hospital-Oncology Radiotherapy Department ( Site 3140), Beijing, Beijing, 100142, China|Chongqing Cancer Hospital ( Site 3135), Chongqing, Chongqing, 400030, China|Daping Hospital,Third Military Medical University ( Site 3136), Chongqing, Chongqing, 400042, China|Fujian Provincial Cancer Hospital ( Site 3126), Fuzhou, Fujian, 350014, China|The First Affiliated Hospital of Xiamen University ( Site 3121), Xiamen, Fujian, 361003, China|Peking University Shenzhen Hospital ( Site 3118), Shenzhen, Guangdong, 518036, China|Cancer Hospital Chinese Academy Of Medical Sciences. Shenzhen Center ( Site 3113), Shenzhen, Guangdong, 518116, China|Henan Cancer Hospital ( Site 3105), Zhengzhou, Henan, 450008, China|Wuhan Union Hospital ( Site 3123), Wuhan, Hubei, 430022, China|Tongji Medical College Huazhong University of Science and Technology ( Site 3138), Wuhan, Hubei, 430030, China|Hubei Cancer Hospital ( Site 3120), Wuhan, Hubei, 430079, China|Hunan Cancer Hospital ( Site 3133), Changsha, Hunan, 410006, China|Xiangya Hospital of Central South University ( Site 3137), Changsha, Hunan, 410008, China|Second Xiangya Hospital of Central-South University ( Site 3128), Changsha, Hunan, 410011, China|Jiangsu Cancer Hospital ( Site 3139), Nanjing, Jiangsu, 210000, China|The Second Affiliated Hospital of Nanchang University ( Site 3106), Nanchang, Jiangxi, 330006, China|The First Hospital of Jilin University ( Site 3132), Changchun, Jilin, 130021, China|Shandong Province Cancer Hospital ( Site 3100), Jinan, Shandong, 250117, China|Shanghai Chest Hospital ( Site 3107), Shangai, Shanghai, 200030, China|Shanghai Pulmonary Hospital ( Site 3101), Shanghai, Shanghai, 200443, China|West China Hospital of Sichuan University ( Site 3114), Chengdu, Sichuan, 510115, China|Tianjin Medical University Cancer Institute & Hospital ( Site 3103), Tianjin, Tianjin, 300060, China|Hangzhou Cancer Hospital ( Site 3129), Hanghzou, Zhejiang, 310002, China|The 1st Affil Hosp of College of Medicine, Zhejiang Univ ( Site 3131), Hangzhou, Zhejiang, 310003, China|Zhejiang Cancer Hospital.... ( Site 3108), Hangzhou, Zhejiang, 310022, China|SA Pohja-Eesti Regionaalhaigla ( Site 2201), Tallinn, Harjumaa, 13419, Estonia|SA Tartu Ulikooli Kliinikum ( Site 2200), Tartu, Tartumaa, 50406, Estonia|C.H. de Saint Quentin ( Site 1111), Saint Quentin, Aisne, 02321, France|CHU de Bordeaux Hop St ANDRE ( Site 1115), Bordeaux, Aquitaine, 33075, France|Clinique Clairval ( Site 1108), Marseille, Bouches-du-Rhone, 13009, France|Hopitaux Universitaires Paris Centre-Hopital Cochin ( Site 1105), Paris, Ile-de-France, 75014, France|CHU Grenoble -Hop Michallon ( Site 1102), Grenoble, Isere, 38043, France|Institut De Cancerologie De L Ouest ( Site 1110), Saint Herblain, Loire-Atlantique, 44805, France|Institut de Cancerologie de l Ouest Site Paul Papin ( Site 1103), Angers, Maine-et-Loire, 49000, France|Hopital Avicenne ( Site 1106), Bobigny, Seine-Saint-Denis, 93000, France|H.I.A. Sainte-Anne ( Site 1101), Toulon, Var, 83800, France|Henry Dunant Hospital ( Site 1205), Athens, Attiki, 115 26, Greece|Sotiria Regional Chest Diseases Hospital of Athens ( Site 1200), Athens, Attiki, 115 27, Greece|University General Hospital of Herakleion ( Site 1202), Heraklion, Irakleio, 711 10, Greece|Anti-Cancer Hospital of Thessaloniki Theagenio ( Site 1204), Thessaloniki, Kentriki Makedonia, 54007, Greece|University General Hospital of Larisa ( Site 1201), Larissa, Thessalia, 411 10, Greece|Bacs-Kiskun Megyei Korhaz-Onkoradiologiai Kozpont ( Site 1306), KecskemÃ©t, Bacs-Kiskun, 6000, Hungary|Petz Aladar Megyei Oktato Korhaz ( Site 1312), Gyor, Gyor-Moson-Sopron, 9024, Hungary|Reformatus Pulmonologiai Centrum ( Site 1304), Torokbalint, Pest, 2045, Hungary|Orszagos Koranyi Pulmonologiai Intezet ( Site 1301), Budapest, 1121, Hungary|Orszagos Onkologiai Intezet ( Site 1310), Budapest, 1122, Hungary|Uzsoki Utcai Korhaz ( Site 1303), Budapest, 1145, Hungary|Rambam Health Care Campus-Oncology Division ( Site 1401), Haifa, 3109601, Israel|Chaim Sheba Medical Center ( Site 1400), Ramat Gan, 5262000, Israel|A O U Policlinico di Modena ( Site 1503), Modena, Emilia-Romagna, 41125, Italy|Azienda Ospedaliero Universitaria Careggi ( Site 1509), Florence, Firenze, 50134, Italy|Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Trento-Oncology Unit ( Site 1513, Verona, Veneto, 37126, Italy|Azienda Ospedaliera Spedali Civili di Brescia ( Site 1512), Brescia, 25123, Italy|IRCCS Ospedale San Raffaele ( Site 1500), Milano, 20132, Italy|Istituto Nazionale dei Tumori ( Site 1504), Milano, 20133, Italy|Istituto Europeo di Oncologia ( Site 1501), Milano, 20141, Italy|IRCCS Istituto Oncologico Veneto ( Site 1506), Padova, 35128, Italy|Policlinico Universitario Agostino Gemelli ( Site 1505), Roma, 00168, Italy|Aichi Cancer Center Hospital ( Site 4010), Nagoya, Aichi, 464-8681, Japan|Kobe Minimally Invasive Cancer Center ( Site 4003), Kobe, Hyogo, 650-0046, Japan|Takarazuka City Hospital ( Site 4013), Takarazuka, Hyogo, 665-0827, Japan|Kanagawa Cancer Center ( Site 4001), Yokohama, Kanagawa, 241-8515, Japan|Kansai Medical University Hospital ( Site 4009), Hirakata, Osaka, 573-1191, Japan|Osaka Medical and Pharmaceutical University Hospital ( Site 4007), Takatsuki, Osaka, 5698686, Japan|Shizuoka Cancer Center ( Site 4014), Nagaizumi, Shizuoka, 411-8777, Japan|National Hospital Organization Kyushu Cancer Center ( Site 4000), Fukuoka, 811-1395, Japan|Niigata Cancer Center Hospital ( Site 4004), Niigata, 951-8566, Japan|Okayama University Hospital ( Site 4012), Okayama, 700-8558, Japan|Osaka International Cancer Institute ( Site 4005), Osaka, 541-8567, Japan|National Cancer Center Hospital ( Site 4015), Tokyo, 104-0045, Japan|Juntendo University Hospital ( Site 4008), Tokyo, 113-0033, Japan|Tokyo Metropolitan Komagome Hospital ( Site 4011), Tokyo, 113-8677, Japan|The Cancer Institute Hospital of JFCR ( Site 4006), Tokyo, 135-8550, Japan|Showa University Hospital ( Site 4002), Tokyo, 142-8666, Japan|National Cancer Center ( Site 3306), Goyang-si, Kyonggi-do, 10408, Korea, Republic of|Seoul National University Bundang Hospital ( Site 3301), Seongnam-si, Kyonggi-do, 13620, Korea, Republic of|The Catholic University of Korea St. Vincent s Hospital ( Site 3303), Suwon-si, Kyonggi-do, 16247, Korea, Republic of|Inje University Haeundae Paik Hospital ( Site 3307), Busan, Pusan-Kwangyokshi, 48108, Korea, Republic of|Asan Medical Center ( Site 3308), Songpagu, Seoul, 05505, Korea, Republic of|Keimyung University Dongsan Hospital CRC room 1 ( Site 3302), Daegu, Taegu-Kwangyokshi, 42601, Korea, Republic of|Severance Hospital Yonsei University Health System ( Site 3304), Seoul, 03722, Korea, Republic of|Samsung Medical Center ( Site 3300), Seoul, 06351, Korea, Republic of|Nacionalinis Vezio Institutas ( Site 2300), Vilnius, Vilniaus Miestas, 08660, Lithuania|LSMUL Kauno Klinikos ( Site 2301), Kaunas, 50161, Lithuania|Hospital Civil de Guadalajara Fray Antonio Alcalde ( Site 0401), Guadalajara, Jalisco, 44280, Mexico|Hospital Universitario ""Dr. Jose Eleuterio Gonzalez"" ( Site 0404), Monterrey, Nuevo Leon, 64460, Mexico|Inst. Portugues de Oncologia de Lisboa Francisco Gentil EPE ( Site 1705), Lisboa, 1099-023, Portugal|Centro Hospitalar Lisboa Norte E.P.E. - Hospital Pulido Valente ( Site 1704), Lisboa, 1769-001, Portugal|Instituto Portugues de Oncologia Do Porto Francisco Gentil E.P.E. ( Site 1701), Porto, 4200-072, Portugal|Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 2803), Cluj-Napoca, Cluj, 400015, Romania|Amethyst Radiotherapy Center-Oncologie Medicala ( Site 2805), FloreÈti, Cluj, 407280, Romania|Spitalul Municipal Ploiesti ( Site 2801), Ploiesti, Prahova, 100337, Romania|Cabinet Medical Oncomed ( Site 2802), Timisoara, Timis, 300239, Romania|S.C.Focus Lab Plus S.R.L ( Site 2804), Bucuresti, 022548, Romania|Moscow Regional Oncological Dispensary-Oncology (thoracic surgery) Department â1 ( Site 1815), Balashikha, Moskovskaya Oblast, 143900, Russian Federation|Main Military Clinical Hospital n.a. N.N.Burdenko ( Site 1812), Moscow, Moskva, 105094, Russian Federation|MROI n.a. P.A. Herzen - branch of FSBI NMICR of MoH of Russia ( Site 1800), Moscow, Moskva, 125284, Russian Federation|Nizhniy Novgorod Region Oncology Dispensary ( Site 1811), Nizhny Novgorod, Nizhegorodskaya Oblast, 603081, Russian Federation|Omsk Clinical Oncology Dispensary ( Site 1806), Omsk, Omskaya Oblast, 644013, Russian Federation|Sverdlovsk Regional Oncology Hospital ( Site 1807), Ekaterinburg, Sverdlovskaya Oblast, 620036, Russian Federation|Republican Clinical Oncology Dispensary-Chemotherapy #1 ( Site 1814), Kazan, Tatarstan, Respublika, 420029, Russian Federation|Institute for Oncology and Radiology of Serbia ( Site 2995), Belgrade, Beograd, 11000, Serbia|Institut za plucne bolesti Vojvodine Sremska Kamenica ( Site 2991), Sremska Kamenica, Sremski Okrug, 21204, Serbia|Steve Biko Academic Hospital ( Site 5000), Pretoria, Gauteng, 0002, South Africa|Groote Schuur Hospital ( Site 5002), Cape Town, Western Cape, 7925, South Africa|Hospital Universitario Central de Asturias ( Site 1900), Oviedo, Asturias, 33011, Spain|Hospital Duran i Reynals ( Site 1903), Hospitalet de Llobregat, Barcelona, 08908, Spain|Hospital Universitari Vall d Hebron ( Site 1904), Barcelona, 08035, Spain|Hospital Universitario 12 de Octubre ( Site 1902), Madrid, 28041, Spain|Hospital Regional Universitario de Malaga ( Site 1905), Malaga, 29010, Spain|Hospital Universitario Virgen Macarena-Unidad de InvestigaciÃ³n OncolÃ³gica ( Site 1907), Sevilla, 41009, Spain|Ankara Bilkent Sehir Hastanesi ( Site 2007), Ankara, 06800, Turkey|Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 2009), Istanbul, 34098, Turkey|Medipol Universite Hastanesi ( Site 2005), Istanbul, 34214, Turkey|GÃ¶ztepe Prof. Dr. SÃ¼leyman YalÃ§Ä±n Åehir Hastanesi-oncology ( Site 2003), Istanbul, 34722, Turkey|Ege Universitesi Tip Fakultesi Hastanesi ( Site 2001), Izmir, 35040, Turkey|Medical center Medikal Plaza of Ecodnipro LLC ( Site 2107), Dnipro, Dnipropetrovska Oblast, 49055, Ukraine|Grigoriev Institute for medical Radiology NAMS of Ukraine ( Site 2110), Kharkiv, Kharkivska Oblast, 61024, Ukraine|Municipal non-profit Enterprise ""Khmelnytskyi Regional Antitumor Center"" ( Site 2115), Khmelnytskyi, Khmelnytska Oblast, 29009, Ukraine|Medical Center of Yuriy Spizhenko LLC.-Clinical Trial ( Site 2104), Kapitanivka Village, Kyivska Oblast, 08111, Ukraine|Clinic of National Cancer Institute ( Site 2101), Kyiv, Kyivska Oblast, 03022, Ukraine|Medical Center Verum ( Site 2106), Kyiv, Kyivska Oblast, 03039, Ukraine|LISOD. Hospital ( Site 2111), Pliuty, Kyiv, 08720, Ukraine|Communal Noncommercial Enterprise ""Podillia Regional Oncolog-Chemotherapy Department ( Site 2114), Vinnytsia, Vinnytska Oblast, 21029, Ukraine|Kyiv City Clinical Oncology Center ( Site 2100), Kyiv, 03115, Ukraine|Royal Infirmary Aberdeen ( Site 2403), Aberdeen, Aberdeen City, AB25 2ZN, United Kingdom|Ninewells Hospital and Medical School ( Site 2401), Dundee, Dundee City, DD1 9SY, United Kingdom|Taunton and Somerset Hospital ( Site 2404), Taunton, England, TA1 5DA, United Kingdom|Barts Health NHS Trust ( Site 2409), London, London, City Of, EC1A 7BE, United Kingdom|Guy s & St Thomas NHS Foundation Trust ( Site 2408), London, London, City Of, SE1 9RT, United Kingdom|The Christie NHS Foundation Trust ( Site 2405), Manchester, M20 4GJ, United Kingdom",
NCT04204941,Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma,https://clinicaltrials.gov/study/NCT04204941,,RECRUITING,"The participants of this study will have advanced epithelioid sarcoma. Sarcoma is a cancer of the connective tissues, such as nerves, muscles and bones. Epithelioid sarcoma is an ultra-rare sarcoma of the soft-tissue.

Part 1 of this trial will evaluate the safety and the level of the study drug that the study drug combinations can be tolerated (known as tolerability). It is also designed to establish a recommended study drug dosage for the next part of the study.

Part 2 will evaluate and compare for each of the study drug combinations how long participants live without their disease getting worse.

The study drug is called tazemetostat. The study will test tazemetostat in combination with doxorubicin compared to placebo (dummy treatment) in combination with doxorubicin. Doxorubicin is a current front line treatment for epithelioid sarcoma",NO,Advanced Soft-tissue Sarcoma|Advanced Epithelioid Sarcoma,DRUG: Tazemetostat|DRUG: Doxorubicin HCl|DRUG: Tazemetostat|DRUG: Placebo|DRUG: Doxorubicin HCl,"Dose Limiting Toxicities (DLTs), Determined by Adverse Events (AEs) and clinical laboratory tests., 1 Cycle/21 days|Progression free survival (PFS), Phase 3: Assessed by Independent Review Committee., Through study completion, an average of two years.","Phase 1b: Pharmacokinetics (PK) of tazemetostat when administered in combination with doxorubicin in participants with soft tissue sarcoma (STS): Area under the Plasma Concentration Time Curve from time 0 to 24 hours (AUC0-24), Cycles 1, 2, 3, and 5 of the first continuous 21-day cycles of combination therapy|Phase 1b: PK of tazemetostat when administered in combination with doxorubicin in participants with STS: Area under the Plasma Concentration Time Curve From time 0 to the last observable concentration (AUC0- last), Cycles 1, 2, 3, and 5 of the first continuous 21-day cycles of combination therapy|Phase 1b: PK of tazemetostat when administered in combination with doxorubicin in Pparticipants with STS: The maximum observed concentration (Cmax)., Cycles 1, 2, 3, and 5 of the first continuous 21-day cycles of combination therapy|Phase 3: Overall Survival (OS), Through study completion, an average of two years.|Phase 3: Incidence of Adverse Events (AEs), All AEs, including clinically significant laboratory parameters will be graded by the investigator according to the Common Terminology Criteria for Adverse Events (CTCAE), Through study completion, an average of two years.|Phase 3: PFS, Assessed by the investigator, Through study completion, an average of two years.|Disease control rate (DCR), Defined as the number of participants who achieve response complete response (CR) + partial response (PR) or who have stable disease (SD), Through study completion, an average of two years|Objective response rate (ORR), ORR is defined as the proportion of participants achieving complete or partial response. Determined based on the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, Through study completion, an average of two years|Duration of treatment (DOR), Defined as the time from first documented evidence of CR or PR to the time of first documented disease progression or death, whichever occurs first, Through study completion, an average of two years|Change from baseline in European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQC-30), The EORTC QLQC-30 physical function, role function, and global health status domains will be assessed, Through study completion, an average of two years|PFS2, Defined as time from randomization to objective tumor progression on next-line treatment or death, whichever occurs first, Through study completion, an average of two years|Time to first subsequent anti-cancer therapy ((TFST, Defined as the time from randomization to the time to first subsequent therapy, Through study completion, an average of two years|Population PK parameters of tazemetostat when administered in combination with doxorubicin: Oral clearance (CL/F), CL/F is defined as the apparent oral clearance following administration of tazemetostat when administered in combination with doxorubicin, Cycles 1, 2, 3, and 5 of the first continuous 21-day cycles of combination therapy|Population PK parameters of tazemetostat when administered in combination with doxorubicin: oral volume of distribution (Vss)., Cycles 1, 2, 3, and 5 of the first continuous 21-day cycles of combination therapy|Population PK parameters of tazemetostat when administered in combination with doxorubicin: Area Under the Curve at steady state (AUCss), Cycles 1, 2, 3, and 5 of the first continuous 21-day cycles of combination therapy|Population PK parameters of tazemetostat when administered in combination with doxorubicin: trough concentration (Ctrough), Cycles 1, 2, 3, and 5 of the first continuous 21-day cycles of combination therapy|Population PK parameters of tazemetostat when administered in combination with doxorubicin: Cmax, Cycles 1, 2, 3, and 5 of the first continuous 21-day cycles of combination therapy",,"Epizyme, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE3,164,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-12-19,2029-01-28,2030-01-01,2019-12-19,,2025-05-01,"City of Hope Comprehensive Cancer Center, Duarte, California, 91010, United States|Sarcoma Oncology Research Center, Santa Monica, California, 90403, United States|University of Colorado Hospital - Anschutz Cancer Pavilion, Aurora, Colorado, 80045, United States|Sarah Cannon Research Institute at HealthONE, Denver, Colorado, 80218, United States|Mayo Clinic-Jacksonville, Jacksonville, Florida, 32224, United States|Massachusetts General Hospital, Boston, Massachusetts, 02214, United States|Dana Farber Cancer Insititute, Boston, Massachusetts, 02215, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|University of Michigan Medical Center, Ann Arbor, Michigan, 48109, United States|Washington University, Saint Louis, Missouri, 63110, United States|Columbia University Irving Medical Center, New York, New York, 10032, United States|Duke University Medical Center, Durham, North Carolina, 27710, United States|The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, 43210, United States|Oregon Health and Science University, Portland, Oregon, 97239, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, 19107, United States|University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh, Pennsylvania, 15232, United States|Sarah Cannon and HCA Research Institute, Nashville, Tennessee, 37203, United States|Fred Hutchinson Research Center, Seattle, Washington, 98109, United States|McGill University Faculty of Medicine - Royal Victoria Hospital, MontrÃ©al, Quebec, H4A 3J1, Canada|National Taiwan University Hospital, Taipei, 100, Taiwan|Royal Marsden Foundation Trust, London, SW3 6JJ, United Kingdom",
NCT03969004,Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma,https://clinicaltrials.gov/study/NCT03969004,,ACTIVE_NOT_RECRUITING,"The primary objective of the study is to compare disease-free survival (DFS) of patients with high-risk cutaneous squamous cell carcinoma (CSCC) treated with adjuvant cemiplimab, versus those treated with placebo, after surgery and radiation therapy (RT).

The secondary objectives of the study are:

* To compare the overall survival (OS) of high-risk CSCC patients treated with adjuvant cemiplimab, versus those treated with placebo, after surgery and RT
* To compare the effect of adjuvant cemiplimab with that of placebo on patients' freedom from locoregional recurrence (FFLRR) after surgery and RT
* To compare the effect of adjuvant cemiplimab with that of placebo on patients' freedom from distant recurrence (FFDR) after surgery and RT
* To compare the effect of adjuvant cemiplimab with that of placebo on the cumulative incidence of second primary CSCC tumors (SPTs) after surgery and RT
* To evaluate the safety of adjuvant cemiplimab and that of placebo in high-risk CSCC patients after surgery and RT
* To assess cemiplimab pharmacokinetics and immunogenicity in human serum",NO,Cutaneous Squamous Cell Carcinoma,DRUG: Cemiplimab|DRUG: Placebo,"DFS defined as time from randomization to the first documented disease recurrence (local, regional and/or distant); or death due to any cause., For patients who do not have a tumor recurrence or death, DFS will be censored on the date of last disease assessment., Up to 54 months","Overall survival (OS), defined as time from randomization to the date of death. A patient who has not died will be censored on the last known date as alive., Up to 78 months|FFLRR defined as time from randomization to the date of first locoregional recurrence (LRR). Patients who died without a preceding LRR will be censored on the date of death., For patients who do not have a LRR or death, FFLRR will be censored on the date of last disease assessment., Up to 54 months|Freedom from distant recurrence (FFDR), defined as time from randomization to the date of first distant recurrence (DR). Patients who died without a preceding DR will be censored on the date of death., For patients who do not have a DR or death, FFDR will be censored on the date of last disease assessment., Up to 54 months|Cumulative occurrence of second primary cutaneous squamous cell carcinoma tumor (SPTs) for each patient from randomization to occurrence of first primary endpoint event or end of study., Up to 54 months|Incidence and severity of treatment-emergent adverse events (TEAE), Up to 78 months|Incidence of deaths, Up to 78 months|Incidence of laboratory abnormalities, Up to 78 months|Cemiplimab concentrations in serum, Up to 78 months|Anti-drug antibodies (ADA) in serum, Up to 78 months",,Regeneron Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,415,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-06-04,2026-11-03,2028-03-26,2019-05-31,,2024-09-19,"Banner MD Anderson Cancer Center, Gilbert, Arizona, 85234, United States|Mayo Clinic Hospital, Phoenix, Arizona, 85054, United States|Regeneron Study Site, Tucson, Arizona, 85724-5024, United States|The Angeles Clinic, Los Angeles, California, 90025, United States|University of Southern California (USC), Los Angeles, California, 90033, United States|Stanford Cancer Institute, Stanford Medicine at Stanford University, Palo Alto, California, 94304, United States|University Of California San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, San Francisco, California, 94143-0981, United States|George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, 20037, United States|University of Florida Health, Gainesville, Florida, 032608, United States|Sylvester Comprehensive Cancer Center, Miami, Florida, 33136, United States|Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, 33176, United States|University of South Florida (USF) - H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, 33612, United States|Regeneron Study Site, Atlanta, Georgia, 30342, United States|Regeneron Study Site, Chicago, Illinois, 60611, United States|Regeneron Study Site, Louisville, Kentucky, 40202, United States|Regeneron Study Site, Baltimore, Maryland, 21287, United States|Massachusetts General Cancer Center, Boston, Massachusetts, 02114, United States|Dana Farber/Harvard Cancer Center, Boston, Massachusetts, 02215, United States|Michigan Medicine- University of Michigan, Ann Arbor, Michigan, 48109, United States|University of Missouri Health Care - University Physicians - Medicine Specialty Clinic, Columbia, Missouri, 65212, United States|Washington University in Saint Louis, Saint Louis, Missouri, 63110, United States|Nebraska Methodist Hospital, Omaha, Nebraska, 68114, United States|Memorial Sloan Kettering, Basking Ridge, New Jersey, 07920, United States|Memorial Sloan Kettering, Middletown, New Jersey, 07748, United States|Memorial Sloan Kettering, Montvale, New Jersey, 07645, United States|Memorial Sloan Kettering, New Brunswick, New Jersey, 08903, United States|Memorial Sloan Kettering, Commack, New York, 11725, United States|Memorial Sloan Kettering, Harrison, New York, 10604, United States|NYU Langone Health, New York, New York, 10016, United States|Columbia University, New York, New York, 10032, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Memorial Sloan Kettering, Uniondale, New York, 11553, United States|Regeneron Research Site, Cincinnati, Ohio, 45267, United States|The Ohio State University, Gahanna, Ohio, 43230, United States|Penn State Hershey Children's Hospital, Hershey, Pennsylvania, 17025, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|Sarah Cannon Research Institute - Tennessee Oncology, Nashville, Tennessee, 37203, United States|Texas Oncology - Baylor Charles A. Simmons Cancer Center, Dallas, Texas, 75246, United States|UT Southwestern Medical Center, Dallas, Texas, 75390, United States|University Of Virginia Health System, Charlottesville, Virginia, 22908, United States|The Border Cancer Hospital Dispensary - Albury Wodonga Regional Cancer Centre, Albury, New South Wales, 2640, Australia|Coffs Harbour Health Campus, Coffs Harbour, New South Wales, 2450, Australia|Central Coast Cancer Centre-Gosford and Wyong Hospitals, Gosford, New South Wales, 2250, Australia|St George Hospital, Kogarah, New South Wales, 2217, Australia|North Shore Private Hospital, St Leonards, New South Wales, 2065, Australia|Cancer Care Associates (CCA) Riverina Cancer Care Centre (RCCC), Wagga Wagga, New South Wales, 2650, Australia|Calvary Mater Newcastle, Waratah, New South Wales, 2298, Australia|Westmead Hospital, Westmead, New South Wales, 2145, Australia|Illawarra Cancer Care Centre (ICCC), Wollongong, New South Wales, 2500, Australia|Melanoma Institute, Sydney, North South Wales, 2060, Australia|Wide Bay Hospital and Health Service - Cancer Care Services, Bundaberg, Queensland, 4670, Australia|Cairns Hospital, Cairns, Queensland, 4870, Australia|The Royal Brisbane and Women's Hospital, Herston, Queensland, 4029, Australia|ICON Cancer Care, Southport, Queensland, 4215, Australia|Toowoomba Hospital, Toowoomba, Queensland, 4350, Australia|Genesis Care Tugun - John Flynn Private Hospital, Tugun, Queensland, 4224, Australia|Wide Bay Hospital and Health Service - Cancer Care Services - Hervey Bay, Urraween, Queensland, 4655, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, 4102, Australia|Ashford Cancer Centre Research-Adelaide Cancer Centre, Kurralta Park, South Australia, 5037, Australia|Royal Hobart Hospital-Hobart Hospital, Hobart, Tasmania, 7000, Australia|Royal Hobart Hospital, Hobart, Tasmania, 7000, Australia|Bendigo Health, Bendigo, Victoria, 3550, Australia|St. Vincent's Hospital, Fitzroy, Victoria, 3065, Australia|Olivia Newton -John Cancer Wellness & Research Centre, Heidelberg, Victoria, 3084, Australia|Peter Maccallum Cancer Centre (PMCC), Melbourne, Victoria, 3000, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, 6009, Australia|Royal Adelaide Hospital, Adelaide, 5000, Australia|Liverpool Cancer Therapy Center, Liverpool, 2170, Australia|University of New South Wales (UNSW) - Liverpool Hospital - Liverpool Cancer Therapy Centre, Liverpool, 2170, Australia|The Townsville Hospital and Health Service, Townsville, 4814, Australia|Universitair Ziekenhuis Leuven Gasthuisberg Campus, Leuven, Vlaams-Brabant, 3000, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, 1200, Belgium|Fundacao Sao Francisco Xavier - Hospital Marcio Cunha (HMC) - Unidade I, Ipatinga, Minas Gerais, 35160-158, Brazil|Fundacao Pio XII - Hospital de Cancer de Barretos, Barretos, Porte Alegre, 90610-000, Brazil|Instituto Nacional de Cancer Jose Alencar Gomes da Silva Â¿ INCA, Santo Cristo, Rio De Janiero, 20220-410, Brazil|Hospital Sao Vicente de Paulo (HSVP), Passo Fundo, Rio Grande Do Sul, 99010-080, Brazil|Centro de Pesquisa em Oncologia - Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da PUCRS, Porto Alegre, Rio Grande Do Sul, 90610-000, Brazil|Centro De Novos Tratamentos Itajai, Itajai, Santa Catarina, 88301-220, Brazil|ANIMI, Lajes, Santa Catarina, 88501-001, Brazil|Centro Oncologico Mogi das Cruzes, Mogi das Cruzes, Sao Paulo, 08730-500, Brazil|Hospital das Clinicas da Faculdade de Medician de Ribeirao Preto FMRP USP, Ribeirao Preto, Sao Paulo, 14049-900, Brazil|Ynova pesquisa clinica, Florianopolis, 88020-210, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, 05403-000, Brazil|University Health Network- Princess Margaret Cancer Center, Toronto, Ontario, M5G 2M9, Canada|Centre Hospitalier Universitaire (CHU) de Dijon - Hopital du Bocage, Dijon, Dijon Cedex, 21079, France|Hopital Saint Andre - CHU de Bordeaux, Bordeaux, 33604, France|Hopital Ambroise Pare, Boulogne Billancourt, 92100, France|Centre Hospitalier Universitaire De Grenoble- Hopital Albert Michallon, La Tronche, 38700, France|Centre Hospitalier Regional Universitaire de Lille - Hopital Claude Huriez, Lille, 59037, France|Centre Leon-Berard (CLB) - Centre de Recherche en Cancerologie Lyon-Est (CRCL), Lyon, 69008, France|Centre Hospitalier Universitaire de Nantes (CHU de Nantes) - Hopital Hotel Dieu, Nantes, 44093, France|Centre Hospitalier Universitaire de Nice,Hopital l Archet, Nice, 06202, France|Hospital Saint-Louis - APHP, Paris Cedex 10, 75475, France|CIC Cochin Pasteur, Hopital Cochin, Paris, 7504, France|Centre Hospitalier Lyon Sud, Pierre Benite Cedex, 69495, France|Centre Hospitalier Universitaire de Rouen-Hopital Charles Nicolle, Rouen cedex, 76031, France|Institut Gustave Roussy-Gustave Roussy Cancer Center -DITEP, Villejuif Cedex, 94805, France|NCT Dermatoonkologie -Hautklinik Heidelberg, Heidelberg, Baden-WÃ¼rttemberg, 69120, Germany|Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz KoeR, Mainz, Rheinland-Pfalz, 55131, Germany|Charite- Universitaetsmedizin Berlin, Berlin, 10117, Germany|Universitaetsklinikum der Ruhr Universitaet Bochum (UKRUB), St. Josef Hospital, Bochum, 44791, Germany|Elbekliniken Buxtehude, Buxtehude, 21614, Germany|University Hospital Dresden, Dresden, 01307, Germany|Universitaetsklinikum Essen (AoR), Essen, 45147, Germany|SLK-Kliniken Heilbronn GmbH, Heilbronn, 74078, Germany|Universitaetsklinikum Schleswig-Holstein, Campus Kiel, Kiel, 24105, Germany|Klinikum der Universitaet zu Koeln, Koeln, 50937, Germany|LMU Munchen, Muenchen, 80337, Germany|University Hospital Tuebingen, Tuebingen, 72076, Germany|University of Athens - Hospital of Venereology Dermatology Diseases Andreas Syggros, Athens, Attiki, 16121, Greece|Office of Dr. Aimilios Lallas MD, Thessaloniki, 546 23, Greece|St. Vincent's University Hospital, Dublin, Leinster, DO4 YN63, Ireland|University College Cork-Cork University Maternity Hospital, Cork, Ireland|University Hospital Galway, Galway, H91 YR71, Ireland|ASST Papa Giovanni XXIII, Bergamo, 24128, Italy|Policlinico S.Orsola-Malpighi U.O. Dermatologia - University of Bologna, Bologna, 40138, Italy|ASST Spedali Civili Brescia, Brescia, 089263, Italy|University of Brescia, Brescia, 25121, Italy|Universita di Firenze - Azienda Sanitaria Firenze, Firenze, 50125, Italy|University L'Aquila, L'Aquila, 67100, Italy|IRCCS-Istituto Europeo di Oncologia, Milan, 20141, Italy|UOC Oncoematologia AOU Luigi Vanvitelli, Naples, 80131, Italy|U.O.S.C Di Oncologia Medica E Terapie Innovative, Napoli, 43100, Italy|A. Gemelli University Hospital, Catholic University of the Sacred Heart, Rome, 00168, Italy|IRCCS Istituto Clinico Humanitas, Rozzano, 20089, Italy|AOU Citta della Salute e della Scienza di Torino, Torino, 10126, Italy|Sapporo Medical University Hospital, Sapporo, Hokkaido, 060-8543, Japan|Shizuoka Cancer Center - Oncology, Nagaizumi-Cho, Shizuoka, 411-8777, Japan|National Cancer Center Hospital - Gastrointestinal Oncology, Chuo-ku, Tokyo, 104-0045, Japan|Niigata Cancer Center Hospital, Niigata, 951-8566, Japan|Osaka International Cancer Institute - Clinical Oncology, Osaka, 541-8567, Japan|Regeneron Study Site, Auckland, 1023, New Zealand|Palmerston North Hospital, Palmerston North, 4410, New Zealand|Narodowy Instytut Onkologii im. Marii SkÂ¿odowskiej-Curie - Panstwowy Instytut Badawczy, Oddzial w Gliwicach, Gliwice, 44-102, Poland|Regeneron Study Site, Krakow, 30-820, Poland|Regeneron Study Site, Poznan, 61-306, Poland|Regeneron Study Site, Warsaw, 04-141, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy, Warszawa, 20-090, Poland|State Healthcare Institution Oncology Dispensary 2 Ministry of Healthcare of Krasnodar Region, Sochi, Krasnodar Krai, 354057, Russian Federation|SBHI of Stavropol Region Pyatigorsk Interdistrict Oncology Dispensary, Pyatigorsk, Stavropol Region, 357502, Russian Federation|Regeneron Study Site, Magnitogorsk, 455001, Russian Federation|N.N.Blokhin Cancer Research Center, Moscow, 33756, Russian Federation|Regeneron Research Site, Omsk, 644013, Russian Federation|Federal State Budgetary Institution Rostov Research Institute of Oncology of the Ministry of Healthcare of the Russian Federation, Rostov-Na-Donu, 344037, Russian Federation|Regeneron Study Site, Saint Petersburg, 198255, Russian Federation|Hospital Universitari Vall d'Hebron, Barcelona, Cataluna, 08035, Spain|Hospital Universitario Fundacion Alcorcon, Alcorcon, Madrid, 28922, Spain|Hospital Universitario de Torrejon, Torrejon de Ardoz, Madrid, 28850, Spain|Catalan institute of Oncology Badalona, Badalona, 8916, Spain|Hospital Clinic de Barcelona - Institut Clinic de Malalties Hematologiques i Oncologiques (ICMHO), Barcelona, 08036, Spain|Genesis Care hospital San Francisco de Asis, Madrid, 28002, Spain|Hospital General Universitario Gregorio Maranon (HGUGM), Madrid, 28007, Spain|Clinica Universidad de Navarra, Madrid, 28027, Spain|Hospital Universitario 12 de Octubre-Centro de Actividades Ambulatorias, Madrid, 28041, Spain|Hospital Universitario Puerta de Hierro de Majadahonda, Majadahonda, 28222, Spain|Hospital Clinico Universitario de Salamanca, Salamanca, 37007, Spain|Hospital Universitario Virgen Macarena-merge, Sevilla, 41009, Spain|Instituto Valenciano de OncologÃ­a, Valencia, 46009, Spain|Hospital Universitario y Politecnico La Fe-merge, Valencia, 46026, Spain|Derriford Hospital, Plymouth, Devon, PL6 8DH, United Kingdom|University Hospitals Bristol NHS Foundation Trust - Bristol Haematology And Oncology Centre (BHOC) - Bristol Cancer Institute, Bristol, Somerset, BS2 8ED, United Kingdom|Velindre NHS Trust, Velindre Cancer Centre, Cardiff, CF14 2TL, United Kingdom|The Lothian University Hospitals NHS Lothian - Western General Hospital (WGH), Edinburgh, EH4 2XU, United Kingdom|Beatson West of Scotland Cancer Centre - Greater Glasgow Health Board, Glasgow, G12 0YN, United Kingdom|St George's Hospital - St George's University Hospitals NHS Foundation Trust, London, SW17 0QT, United Kingdom|The Christie - The Christie NHS Foundation Trust, Manchester, M20 4QL, United Kingdom",
NCT06929624,A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma,https://clinicaltrials.gov/study/NCT06929624,,RECRUITING,"This is a multicenter, randomized, open-label, phase 3 clinical study to evaluate the efficacy of SHR-A1912 combined with R-GemOx in relapsed refractory diffuse large B-cell lymphoma.",NO,Diffuse Large B-cell Lymphoma,DRUG: SHR-A1912 Injection|DRUG: Rituximab Injection|DRUG: Gemcitabine Hydrochloride for Injection|DRUG: Oxaliplatin Injection,"Complete response rate (CRR), Up to 1 years following the first dose of the last enrolled patient.|Overall survival (OS), Up to 5 years following the first dose of the last enrolled patient.","Adverse events (AEs), Up to 5 years following the first dose of the last enrolled patient.",,"Suzhou Suncadia Biopharmaceuticals Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,280,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2025-04-24,2027-03,2028-01,2025-04-16,,2025-05-13,"Beijing Cancer Hospital, Beijing, Beijing, 100142, China",
NCT04940052,"Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer",https://clinicaltrials.gov/study/NCT04940052,,ACTIVE_NOT_RECRUITING,"150 adults patients with locally advanced or metastatic BRAFV600E mutation-positive, differentiated thyroid carcinoma who are refractory to radioactive iodine and have progressed following prior VEGFR targeted therapy will enter in the trial. Patients will be randomized in a 2:1 ratio to either dabrafenib plus trametinib or placebo. Patients will be stratified by number of prior VEGFR targeted therapy (1versus2) and prior lenvatinib treatment (yes versus no)",NO,Differentiated Thyroid Cancer,DRUG: Dabrafenib|DRUG: Trametinib|DRUG: Trametinib placebo|DRUG: Dabrafenib placebo,"Progression Free Survival, Progression Free Survival is based on the blinded independent review committee assessment using RECIST 1.1, From randomization to first documented progression or deaths, whichever comes first, assessed up to approximately 2 years","Overall Response Rate, overall response rate is defined as the proportion of patients with best overall response of complete response or partial response assessed per blinded independent review committee using RECIST 1.1 criteria, From randomization up to approximately 2 years|Overall Survival, Overall survival is defined as the time from the date of randomization to the date of death to any cause., From randomization to death assessed up to approximately 5 years|Duration of response, Duration of response only applies to patients whose best overall response is complete response or partial response according to RECIST 1.1 and based on blinded independent review committee., Duration of response from the start date of the first documented response of complete response or partial response and the date defined as the date of the first documented progression or death due to any cause up to 2 years|Number of participants with trametinib associated serous retinopathy ocular events, Standard ophthalmic examination will by done by an ophthalmologist and optical coherence tomography conducted at mandated visit. Analysis using optical coherence tomography data will be done to assess the incidence, type and severity of ocular events, screening, week 4, week 8, week 12, week 20 and every 12 weeks after week 20, up to approximately 2 years",,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,153,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-11-15,2025-01-22,2027-05-26,2021-06-25,,2025-06-11,"Northwestern University Med School, Chicago, Illinois, 60611, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Novartis Investigative Site, Caba, Buenos Aires, C1417DTB, Argentina|Novartis Investigative Site, Rio De Janiero, RJ, 20231-050, Brazil|Novartis Investigative Site, Blumenau, Santa Catarina, 89015-200, Brazil|Novartis Investigative Site, Sao Paulo, SP, 01246-000, Brazil|Novartis Investigative Site, Edmonton, Alberta, T6G 1Z2, Canada|Novartis Investigative Site, London, Ontario, N6A 5W9, Canada|Novartis Investigative Site, Fuzhou, Fujian, 350014, China|Novartis Investigative Site, Zhengzhou, Henan, 450008, China|Novartis Investigative Site, Wuhan, Hubei, 430022, China|Novartis Investigative Site, Changsha, Hunan, 410013, China|Novartis Investigative Site, Nanjing, Jiangsu, 210006, China|Novartis Investigative Site, Nanjing, Jiangsu, 210009, China|Novartis Investigative Site, Xuzhou, Jiangsu, 221003, China|Novartis Investigative Site, Changchun, Jilin, 130033, China|Novartis Investigative Site, Chengdu, Sichuan, 610041, China|Novartis Investigative Site, Tianjin, Tianjin, 300121, China|Novartis Investigative Site, Beijing, 100036, China|Novartis Investigative Site, Beijing, 100730, China|Novartis Investigative Site, Guangzhou, 510060, China|Novartis Investigative Site, Shanghai, 200233, China|Novartis Investigative Site, Tianjin, 300052, China|Novartis Investigative Site, Tianjin, 300480, China|Novartis Investigative Site, Hisar, Haryana, 125005, India|Novartis Investigative Site, Chennai, 600 020, India|Novartis Investigative Site, New Delhi, 110029, India|Novartis Investigative Site, Seoul, Seocho Gu, 06591, Korea, Republic of|Novartis Investigative Site, Seoul, 03080, Korea, Republic of|Novartis Investigative Site, Seoul, 05505, Korea, Republic of|Novartis Investigative Site, Seoul, 06351, Korea, Republic of|Novartis Investigative Site, Kuching, Sarawak, 93586, Malaysia|Novartis Investigative Site, Kuala Lumpur, 59100, Malaysia|Novartis Investigative Site, Pulau Pinang, 10990, Malaysia|Novartis Investigative Site, Tainan, 70403, Taiwan|Novartis Investigative Site, Taipei, 10002, Taiwan|Novartis Investigative Site, Istanbul, TUR, 34098, Turkey|Novartis Investigative Site, Adana, 01250, Turkey|Novartis Investigative Site, Ankara, 06500, Turkey|Novartis Investigative Site, Edirne, 22030, Turkey|Novartis Investigative Site, Hanoi, 100000, Vietnam",
NCT06467357,Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer,https://clinicaltrials.gov/study/NCT06467357,DESTINY-BTC01,RECRUITING,The purpose of this study is to measure the efficacy and safety of T-DXd with rilvegostomig or T-DXd monotherapy compared with gemcitabine plus cisplatin and durvalumab in patients with advanced treatment naÃ¯ve HER2-expressing BTC.,NO,Biliary Tract Cancer,DRUG: Gemcitabine|DRUG: Cisplatin|DRUG: Durvalumab|DRUG: Trastuzumab deruxtecan|DRUG: Rilvegostomig|DIAGNOSTIC_TEST: Agilent HercepTestâ¢ mAb pharmDx|DIAGNOSTIC_TEST: Ventana PD-L1 SP263 assay,"Safety Run In: To evaluate the safety and tolerability of T-DXd with rilvegostomig, Safety and tolerability will be evaluated by the proportion of treated patients with occurrence of AEs, SAEs and AESIs, as assessed by CTCAE v5.0., Until all patients have completed at least 1 full Cycle (each cycle is 21 days)|Randomized Portion: To evaluate the efficacy of T-DXd with rilvegostomig vs Standard of Care (SoC) in terms of Overall Survival in the FAS (HER2 IHC 3+) population, Overall survival (OS) in FAS (HER2 IHC 3+) population OS is defined as time from randomization date until the date of death due to any cause. The comparison will include all randomized patients, regardless of whether the patient withdraws from therapy or receives another anticancer therapy. The measure of interest is the hazard ratio of OS., From date of treatment randomization until the date of death from any cause (estimated to be assessed up to 50 months after first subject randomized)","To evaluate the efficacy of T-DXd with rilvegostomig vs Standard of Care in terms of Overall Survival in the FAS (HER2 IHC 3+/2+) population, Overall Survival (OS) in FAS (HER2 IHC 3+/2+) population. OS definition as above., From date of randomization until the date of death from any cause (estimated to be assessed up to 50 months after first subject randomized)|To evaluate the efficacy of T-DXd monotherapy vs Standard of Care in terms of Overall Survival in the FAS (HER2 IHC 3+) population, Overall Survival (OS) in FAS (HER2 IHC 3+) population. OS definition as above., From date of randomization until the date of death from any cause (estimated to be assessed up to 50 months after first subject randomized)|To evaluate the efficacy of T-DXd monotherapy vs Standard of Care in terms of Overall Survival in the FAS (HER2 IHC 3+/2+) population, Overall Survival (OS) in FAS (HER2 IHC 3+/2+) population. OS definition as above., From date of randomization until the date of death from any cause (estimated to be assessed up to 50 months after first subject randomized)|To further evaluate efficacy of T-DXd with rilvegostomig vs Standard of Care in terms of Progression Free Survival in FAS (HER2 IHC 3+) and FAS (HER2 IHC 3+/2+) populations, Progression free survival (PFS) in FAS (HER2 IHC 3+) and FAS (HER2 IHC 3+/2+) populations.

PFS is defined as time from randomization until progression per RECIST v1.1, or death due to any cause. The analysis will include all randomized patients, regardless of whether the patient withdraws from randomized therapy, receives another anticancer therapy or clinically progresses prior to RECIST v1.1 progression.

The measure of interest is the hazard ratio of PFS., From date of randomization until the date of first documented progression or date of death from any cause, whichever occurs first (estimated to be assessed up to 50 months)|To further evaluate efficacy of T-DXd monotherapy vs Standard of Care in terms of Progression Free Survival in FAS (HER2 IHC 3+) and FAS (HER2 IHC 3+/2+) populations, Progression free survival (PFS) in FAS (HER2 IHC 3+) and FAS (HER2 IHC 3+/2+) populations.

PFS is defined as time from randomization until progression per RECIST v1.1, or death due to any cause. The analysis will include all randomized patients, regardless of whether the patient withdraws from randomized therapy, receives another anticancer therapy or clinically progresses prior to RECIST v1.1 progression.

The measure of interest is the hazard ratio of PFS., From date of randomization until the date of first documented progression or date of death from any cause, whichever occurs first (estimated to be assessed up to 50 months)|To further evaluate the efficacy of T-DXd with rilvegostomig vs Standrad of Care in terms of objective response rate in the FAS (HER2 IHC 3+) and FAS (HER2 IHC 3+/2+) populations, Objective response rate (ORR) in FAS (HER2 IHC 3+) and FAS (HER2 IHC 3+/2+) populations.

ORR is defined as the proportion of patients who achieved CR or PR per RECIST 1.1, as assessed by the investigator. The analysis will include objective response data for all randomized patients from randomization until progression, or up to the last evaluable assessment in the absence of progression.

Patients who go off-treatment without a response or progression and then respond while receiving a subsequent therapy will not be included as responders in the ORR calculation.

The measure of interest is the risk difference of ORR., From date of randomization until the date of first documented progression or date of death from any cause, whichever occurs first (estimated to be assessed up to 50 months)|To further evaluate the efficacy of T-DXd monotherapy vs Standrad of Care in terms of objective response rate in the FAS (HER2 IHC 3+) and FAS (HER2 IHC 3+/2+) populations, Objective response rate (ORR) in FAS (HER2 IHC 3+) and FAS (HER2 IHC 3+/2+) populations.

ORR is defined as the proportion of patients who achieved CR or PR per RECIST 1.1, as assessed by the investigator. The analysis will include objective response data for all randomized patients from randomization until progression, or up to the last evaluable assessment in the absence of progression.

Patients who go off-treatment without a response or progression and then respond while receiving a subsequent therapy will not be included as responders in the ORR calculation.

The measure of interest is the risk difference of ORR., From date of randomization until the date of first documented progression or date of death from any cause, whichever occurs first (estimated to be assessed up to 50 months)|To further evaluate efficacy of T-DXd with rilvegostomig vs Standard if Care in terms of duration of response in patients with HER2-expressing BTC in the FAS (HER2 IHC 3+) and FAS (HER2 IHC 3+/2+) populations, Duration of response (DoR) in FAS (HER2 IHC 3+) and FAS (HER2 IHC 3+/2+) populations.

DoR will be defined as the time from the date of first documented response until date of documented progression per RECIST v1.1, or death due to any cause. The analysis will include all randomized patients who have a response, regardless of whether the patient withdraws from randomized therapy, receives another anti-cancer therapy or clinically progresses prior to RECIST v1.1 progression.

The measure of interest is the median DoR., From the date of first documented response until date of documented progression or death due to any cause, whichever occurs first (estimated up to 50 months)|To further evaluate efficacy of T-DXd monotherapy vs Standard if Care in terms of duration of response in patients with HER2-expressing BTC in the FAS (HER2 IHC 3+) and FAS (HER2 IHC 3+/2+) populations, Duration of response (DoR) in FAS (HER2 IHC 3+) and FAS (HER2 IHC 3+/2+) populations.

DoR will be defined as the time from the date of first documented response until date of documented progression per RECIST v1.1, or death due to any cause. The analysis will include all randomized patients who have a response, regardless of whether the patient withdraws from randomized therapy, receives another anti-cancer therapy or clinically progresses prior to RECIST v1.1 progression.

The measure of interest is the median DoR., From the date of first documented response until date of documented progression or death due to any cause, whichever occurs first (estimated up to 50 months)|To further evaluate the efficacy of T-DXd with rilvegostomig versus T-DXd monotherapy in terms of Overall survival in FAS (HER2 IHC 3+) and FAS (HER2 IHC 3+/2+) populations., Overall survival (OS) in FAS (HER2 IHC 3+) and FAS (HER2 IHC 3+/2+) populations.

OS is defined as time from randomization date until the date of death due to any cause. The comparison will include all randomized patients, regardless of whether the patient withdraws from therapy or receives another anticancer therapy. The measure of interest is the hazard ratio of OS., From date of randomization until the date of death from any cause (estimated to be assessed up to 50 months after first subject randomized)|To further evaluate the efficacy of T-DXd with rilvegostomig versus T-DXd monotherapy in terms of PFS in FAS (HER2 IHC 3+) and FAS (HER2 IHC 3+/2+) populations, Progression free survival (PFS) in FAS (HER2 IHC 3+) and FAS (HER2 IHC 3+/2+) populations.

PFS is defined as time from randomization until progression per RECIST v1.1, or death due to any cause. The analysis will include all randomized patients, regardless of whether the patient withdraws from randomized therapy, receives another anticancer therapy or clinically progresses prior to RECIST v1.1 progression.

The measure of interest is the hazard ratio of PFS., From the date of randomisation until progression or death due to any cause, whichever occurs first (estimated up to 50 months)|To further evaluate the efficacy of T-DXd with rilvegostomig versus T-DXd monotherapy in terms of Duration of response in FAS (HER2 IHC 3+) and FAS (HER2 IHC 3+/2+) populations, Duration of response (DoR) in FAS (HER2 IHC 3+) and FAS (HER2 IHC 3+/2+) populations.

DoR will be defined as the time from the date of first documented response until date of documented progression per RECIST v1.1, or death due to any cause. The analysis will include all randomized patients who have a response, regardless of whether the patient withdraws from randomized therapy, receives another anti-cancer therapy or clinically progresses prior to RECIST v1.1 progression.

The measure of interest is the median DoR., From the date of first response until progression or death due to any cause, whichever occurs first (estimated up to 50 months)|To further evaluate the efficacy of T-DXd with rilvegostomig versus T-DXd monotherapy in terms of Objective response rate in FAS (HER2 IHC 3+) and FAS (HER2 IHC 3+/2+) populations, Objective response rate (ORR) in FAS (HER2 IHC 3+) and FAS (HER2 IHC 3+/2+) populations.

ORR is defined as the proportion of patients who achieved CR or PR per RECIST 1.1, as assessed by the investigator. The analysis will include objective response data for all randomized patients from randomization until progression, or up to the last evaluable assessment in the absence of progression.

Patients who go off-treatment without a response or progression and then respond while receiving a subsequent therapy will not be included as responders in the ORR calculation.

The measure of interest is the risk difference of ORR., From date of randomization until the date of first documented progression or date of death from any cause, whichever occurs first (estimated to be assessed up to 50 months)|To assess the safety and tolerability of T-DXd with rilvegostomig vs Standard of Care, Safety and tolerability will be evaluated by the proportion of treated patients with occurrence of AEs, SAEs and AESIs, as assessed by CTCAE v5.0., From date of randomization until the date of first documented progression or date of death from any cause, whichever occurs first (estimated to be assessed up to 50 months)|To assess the safety and tolerability of T-DXd monotherapy vs Standard of Care, Safety and tolerability will be evaluated by the proportion of treated patients with occurrence of AEs, SAEs and AESIs, as assessed by CTCAE v5.0., From date of randomization until the date of first documented progression or date of death from any cause, whichever occurs first (estimated to be assessed up to 50 months)|To describe patient-reported tolerability of T-DXd with rilvegostomig in comparison to Standard of Care based on a summary of symptomatic AEs, Patient-reported tolerability will be described using the Symptomatic adverse events: Descriptive summary of the proportion of patients reporting symptomatic AEs while on treatment using items from the EORTC Item Library (on EORTC IL form 322)., Until End of Study (estimated up to 50 months)|To describe patient-reported tolerability of T-DXd monotherapy in comparison to SoC based on a summary of symptomatic AEs, Patient-reported tolerability will be described using the Symptomatic adverse events: Descriptive summary of the proportion of patients reporting symptomatic AEs while on treatment using items from the EORTC Item Library (on EORTC IL form 322), Until End of Study (estimated up to 50 months)|To describe patient-reported tolerability of T-DXd with rilvegostomig in comparison to T-DXd monotherapy based on a summary of symptomatic AEs, Patient-reported tolerability will be described using the Symptomatic adverse events: Descriptive summary of the proportion of patients reporting symptomatic AEs while on treatment using items from the EORTC Item Library (on EORTC IL form 322)., Until End of Study (estimated up to 50 months)|To assess time to deterioration in physical functioning in patients treated with T-DXd with rilvegostomig vs Standard of Care, Time to deterioration (TTD) in physical function as measured by the PROMIS Short Form v2.0 - Physical Function 8c - TTD is defined as time from the date of randomization to the date of deterioration.

Deterioration is defined as the change from baseline that reaches a clinically meaningful deterioration threshold.

- The measure of interest is the HR of TTD in physical function. The analysis will include all randomized patients as randomized., Until End of Study (estimated up to 50 months)|To assess time to deterioration in physical functioning in patients treated with T-DXd monotherapy vs Standard of care, Time to deterioration (TTD) in physical function as measured by the PROMIS Short Form v2.0 - Physical Function 8c - TTD is defined as time from the date of randomization to the date of deterioration.

Deterioration is defined as the change from baseline that reaches a clinically meaningful deterioration threshold.

- The measure of interest is the HR of TTD in physical function. The analysis will include all randomized patients as randomized., Until End of Study (estimated up to 50 months)|To assess time to deterioration in physical functioning in patients treated with T-DXd with rilvegostomig vs T-DXd monotherapy, Time to deterioration (TTD) in physical function as measured by the PROMIS Short Form v2.0 - Physical Function 8c - TTD is defined as time from the date of randomization to the date of deterioration.

Deterioration is defined as the change from baseline that reaches a clinically meaningful deterioration threshold.

- The measure of interest is the HR of TTD in physical function. The analysis will include all randomized patients as randomized., Until End of Study (estimated up to 50 months)|To assess the pharmacokinetics of T-DXd, total anti- HER2 antibody, DXd and rilvegostomig in serum, Descriptive analysis of serum concentration of T-DXd, total anti-HER2 antibody, DXd and rilvegostomig in all applicable arms., From the time of informed consent until 90 days after the last dose of T-DXd and rilvegostomig|To investigate the immunogenicity of T-DXd and of rilvegostomig, Descriptive summary of presence of ADAs for T-DXd and rilvegostomig in all applicable arms., From the time of informed consent until 30 and 90 days after the last dose of T-DXd and rilvegostomig, respectively|To describe patient-reported tolerability of T-DXd with rilvegostomig in comparison to Standard of Care based on overall side-effect bother, Patient-reported tolerability will be described using the Overall side-effect bother that will be mesured using PGI-TT, Until End of Study (estimated up to 50 months)|To describe patient-reported tolerability of T-DXd monotherapy in comparison to SoC based on overall side-effect bother, Patient-reported tolerability will be described using the Overall side-effect bother that will be assessed will be mesured using PGI-TT, Until End of Study (estimated up to 50 months)|To assess the safety and tolerability of T-DXd with rilvegostomig vs T-DXd monotherapy, Safety and tolerability will be evaluated by the proportion of treated patients with occurrence of AEs, SAEs and AESIs, as assessed by CTCAE v5.0., From date of randomization until the date of first documented progression or date of death from any cause, whichever occurs first (estimated to be assessed up to 50 months)|To describe patient-reported tolerability of T-DXd with rilvegostmog in comparison to T-DXd monotherapy based on overall side-effect bother, Patient-reported tolerability will be described using the Overall side-effect bother that will be assessed will be mesured using PGI-TT., Until End of Study (estimated up to 50 months)",,AstraZeneca,,ALL,"ADULT, OLDER_ADULT",PHASE3,620,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-08-12,2028-06-12,2029-05-16,2024-06-21,,2025-05-25,"Research Site, Scottsdale, Arizona, 85259, United States|Research Site, Tucson, Arizona, 85704, United States|Research Site, Tucson, Arizona, 85719, United States|Research Site, Fullerton, California, 92835, United States|Research Site, La Jolla, California, 92093, United States|Research Site, Los Alamitos, California, 90720, United States|Research Site, Los Angeles, California, 90017, United States|Research Site, Los Angeles, California, 90089, United States|Research Site, San Francisco, California, 94143, United States|Research Site, Fort Myers, Florida, 33901, United States|Research Site, Jacksonville, Florida, 32224, United States|Research Site, Saint Petersburg, Florida, 33705, United States|Research Site, Tampa, Florida, 33606, United States|Research Site, West Palm Beach, Florida, 33401, United States|Research Site, Atlanta, Georgia, 30309, United States|Research Site, Coeur d'Alene, Idaho, 83814, United States|Research Site, Chicago, Illinois, 60612, United States|Research Site, Niles, Illinois, 60714, United States|Research Site, Towson, Maryland, 21204, United States|Research Site, Worcester, Massachusetts, 01655, United States|Research Site, Detroit, Michigan, 48202, United States|Research Site, Grand Rapids, Michigan, 49503, United States|Research Site, Rochester, Minnesota, 55905, United States|Research Site, Kansas City, Missouri, 64132, United States|Research Site, Saint Louis, Missouri, 63110, United States|Research Site, Albuquerque, New Mexico, 87102, United States|Research Site, New York, New York, 10032, United States|Research Site, Columbus, Ohio, 43210, United States|Research Site, Greenville, South Carolina, 29605, United States|Research Site, Nashville, Tennessee, 37203, United States|Research Site, Austin, Texas, 78705, United States|Research Site, Dallas, Texas, 75246, United States|Research Site, Fort Worth, Texas, 76104, United States|Research Site, Fort Worth, Texas, 76104, United States|Research Site, Houston, Texas, 77030, United States|Research Site, Pearland, Texas, 77584, United States|Research Site, San Antonio, Texas, 78217, United States|Research Site, San Antonio, Texas, 78258, United States|Research Site, Fairfax, Virginia, 22031, United States|Research Site, Clayton, 3168, Australia|Research Site, Nedlands, 6009, Australia|Research Site, Graz, 8036, Austria|Research Site, Linz, 4010, Austria|Research Site, Salzburg, 5020, Austria|Research Site, Wiener Neustadt, 2700, Austria|Research Site, Wien, 1090, Austria|Research Site, Anderlecht, 1070, Belgium|Research Site, Edegem, 2650, Belgium|Research Site, Gent, 9000, Belgium|Research Site, Leuven, 3000, Belgium|Research Site, LiÃ¨ge, 4000, Belgium|Research Site, Roeselare, 8800, Belgium|Research Site, Natal, 59012-300, Brazil|Research Site, Porto Alegre, 90035-000, Brazil|Research Site, Porto Alegre, 91350-200, Brazil|Research Site, Sao Paulo, 01246-000, Brazil|Research Site, Sao Paulo, 05652-9000, Brazil|Research Site, VitÃ³ria, 29043-272, Brazil|Research Site, Edmonton, Alberta, T6G 1Z2, Canada|Research Site, Halifax, Nova Scotia, B3H 1V7, Canada|Research Site, Brampton, Ontario, L6R 3J7, Canada|Research Site, Toronto, Ontario, M5G 2M9, Canada|Research Site, Montreal, Quebec, H3A 1A1, Canada|Research Site, Beijing, 100021, China|Research Site, Beijing, 100142, China|Research Site, Beijing, China|Research Site, Bengbu, 233004, China|Research Site, Changchun, 130021, China|Research Site, Changde, 415003, China|Research Site, Changsha, 410013, China|Research Site, Chengdu, 610041, China|Research Site, Chongqing, 400030, China|Research Site, Fuzhou, 350005, China|Research Site, Guangzhou, 510080, China|Research Site, Guangzhou, 510515, China|Research Site, Guiyang, 550044, China|Research Site, Hangzhou, 310016, China|Research Site, Harbin, 150081, China|Research Site, Hefei, 230001, China|Research Site, Hefei, 230601, China|Research Site, Hohhot, 610078, China|Research Site, Jinan, 250117, China|Research Site, Luoyang, 471000, China|Research Site, Nanchang, 330029, China|Research Site, Nanning, 530021, China|Research Site, Nantong, 226001, China|Research Site, Shanghai, 200001, China|Research Site, Shanghai, 201114, China|Research Site, Shenyang, 110004, China|Research Site, Shenzhen, 518116, China|Research Site, Tianjin, 300060, China|Research Site, Wuhan, 430079, China|Research Site, Xi'an, 710061, China|Research Site, Zhengzhou, 450008, China|Research Site, Zhengzhou, 450052, China|Research Site, Brno, 625 00, Czechia|Research Site, Brno, 656 53, Czechia|Research Site, Hradec Kralove, 500 05, Czechia|Research Site, Olomouc, 77900, Czechia|Research Site, Praha 10, 100 34, Czechia|Research Site, Praha 5, 150 06, Czechia|Research Site, Brest, 29609, France|Research Site, Clichy Cedex, 92118, France|Research Site, Dijon, 21079, France|Research Site, Lille, 59037, France|Research Site, Lyon, 69008, France|Research Site, Marseille, 13008, France|Research Site, Montpellier, 34295, France|Research Site, Nimes, 30029, Cedex, France|Research Site, Pessac, 33604, France|Research Site, Villejuif, 94800, France|Research Site, Berlin, 13353, Germany|Research Site, Bonn, 53127, Germany|Research Site, Dresden, 01370, Germany|Research Site, Frankfurt, 60488, Germany|Research Site, Freiburg, 79106, Germany|Research Site, GÃ¶ttingen, 37075, Germany|Research Site, Hamburg, 22763, Germany|Research Site, KÃ¶ln, 50937, Germany|Research Site, Leipzig, 4103, Germany|Research Site, LÃ¼beck, 23538, Germany|Research Site, Munchen, 81377, DE, Germany|Research Site, Ulm, 89081, Germany|Research Site, Wuerzburg, 97080, Germany|Research Site, Hong Kong, 999077, Hong Kong|Research Site, Shatin, 00000, Hong Kong|Research Site, Dehradun, 248016, India|Research Site, Delhi, 110029, India|Research Site, Kolkata, 700054, India|Research Site, Kolkata, 700094, India|Research Site, Mumbai, 400012, India|Research Site, Vadodara, 391760, India|Research Site, Varanasi, 221005, India|Research Site, Firenze, 50134, Italy|Research Site, Milano, 20132, Italy|Research Site, Milano, 20162, Italy|Research Site, Naples, 80131, Italy|Research Site, Napoli, 80128, Italy|Research Site, Padova, 35128, Italy|Research Site, Roma, 00133, Italy|Research Site, Rozzano, 20089, Italy|Research Site, Tricase, 73039, Italy|Research Site, Bunkyo-ku, 113-8431, Japan|Research Site, Bunkyo-ku, 113-8603, Japan|Research Site, Bunkyo-ku, 113-8677, Japan|Research Site, Chiba-shi, 260-0877, Japan|Research Site, Fukuyama-shi, 721-8511, Japan|Research Site, Hirakata-shi, 573-1191, Japan|Research Site, Hiroshima-shi, 734-8551, Japan|Research Site, Kanazawa, Japan|Research Site, Kashiwa, 227-8577, Japan|Research Site, Kawasaki-shi, 216-8511, Japan|Research Site, Kita-gun, 761-0793, Japan|Research Site, Kitaadachi-gun, 362-0806, Japan|Research Site, Koto-ku, 135-8550, Japan|Research Site, Kumamoto-shi, 860-8556, Japan|Research Site, Kyoto-shi, 606-8507, Japan|Research Site, Maebashi-shi, 371-8511, Japan|Research Site, Mitaka-shi, 181-8611, Japan|Research Site, Nagoya-shi, 464-8681, Japan|Research Site, Nagoya-shi, 466-8560, Japan|Research Site, Osaka-shi, 541-8567, Japan|Research Site, Osaka, 545-8586, Japan|Research Site, Sakai-shi, 591-8025, Japan|Research Site, Sapporo-shi, 060-8543, Japan|Research Site, Sendai-shi, 980-8574, Japan|Research Site, Shinjuku-ku, 160-8582, Japan|Research Site, Suita-city, 565-0871, Japan|Research Site, Sunto-gun, 411-8777, Japan|Research Site, Ube-shi, 755-8505, Japan|Research Site, Wakayama-shi, 641-8510, Japan|Research Site, Yokohama-shi, 241-8515, Japan|Research Site, Busan, 48108, Korea, Republic of|Research Site, Gyeonggi-do, 13620, Korea, Republic of|Research Site, Hwasun-gun, 58128, Korea, Republic of|Research Site, Seongnam-si, 13496, Korea, Republic of|Research Site, Seoul, 03080, Korea, Republic of|Research Site, Seoul, 05505, Korea, Republic of|Research Site, Seoul, 06351, Korea, Republic of|Research Site, Seoul, 06591, Korea, Republic of|Research Site, Seoul, 120-752, Korea, Republic of|Research Site, George Town, 10990, Malaysia|Research Site, Johor Bahru, 81100, Malaysia|Research Site, Kuala Lumpur, 50586, Malaysia|Research Site, Kuala Lumpur, 59100, Malaysia|Research Site, Kuching, 93586, Malaysia|Research Site, Rotterdam, 3015 GD, Netherlands|Research Site, Cebu City, 6000, Philippines|Research Site, Makati, 1229, Philippines|Research Site, Pasig City, 1605, Philippines|Research Site, Quezon City, 1112, Philippines|Research Site, BiaÅystok, 15-027, Poland|Research Site, Katowice, 40-514, Poland|Research Site, KrakÃ³w, 31-501, Poland|Research Site, Lublin, 20-080, Poland|Research Site, Warszawa, 02-034, Poland|Research Site, WrocÅaw, 50-556, Poland|Research Site, Ar RiyÄá¸, 11426, Saudi Arabia|Research Site, Dammam, 31444, Saudi Arabia|Research Site, Riyadh, 11525, Saudi Arabia|Research Site, Riyadh, 12713, Saudi Arabia|Research Site, Banska Bystrica, 974 01, Slovakia|Research Site, Bratislava, 833 10, Slovakia|Research Site, Kosice, 041 91, Slovakia|Research Site, Martin, 036 59, Slovakia|Research Site, Trnava, 917 75, Slovakia|Research Site, Barcelona, 08035, Spain|Research Site, Madrid, 28007, Spain|Research Site, Madrid, 28040, Spain|Research Site, Madrid, 28041, Spain|Research Site, MÃ¡laga, 29010, Spain|Research Site, Santander, 39008, Spain|Research Site, Kaohsiung City, 824, Taiwan|Research Site, Kaohsiung, 00807, Taiwan|Research Site, Kaohsiung, 833, Taiwan|Research Site, Taichung, 40447, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taipei, 10002, Taiwan|Research Site, Taipei, 112, Taiwan|Research Site, Taoyuan, 333, Taiwan|Research Site, Bangkok, 10400, Thailand|Research Site, Hat Yai, 90110, Thailand|Research Site, Khon Kaen, 40002, Thailand|Research Site, Muang, 50200, Thailand|Research Site, Mueang, 47000, Thailand|Research Site, Naimuang, 30000, Thailand|Research Site, Ongkharak, 26120, Thailand|Research Site, Sisaket, 33000, Thailand|Research Site, AltÄ±ndaÄ, 06230, Turkey|Research Site, Antalya, 07100, Turkey|Research Site, Istanbul, 34218, Turkey|Research Site, Izmir, 35340, Turkey|Research Site, Mezitli, 33200, Turkey|Research Site, Yakutiye, 25040, Turkey|Research Site, Birmingham, B15 2GW, United Kingdom|Research Site, Dundee, DD1 9SY, United Kingdom|Research Site, Glasgow, G12 0YN, United Kingdom|Research Site, Greater London, SW3 6JJ, United Kingdom|Research Site, Leeds, LS9 7TF, United Kingdom|Research Site, London, EC1A 7BE, United Kingdom|Research Site, Hanoi, 100000, Vietnam|Research Site, Ho Chi Minh city, 700000, Vietnam|Research Site, Ho Chi Minh City, 70000, Vietnam|Research Site, Ho Chi Minh, 700000, Vietnam|Research Site, Vinh, 460000, Vietnam",
NCT03856697,Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation,https://clinicaltrials.gov/study/NCT03856697,,UNKNOWN,To compare efficacy and safety of Abivertinib maleate alone versus standard first-line EGFR-TKIs for the treatment of patients with advanced non-small cell lung cancer with sensitive EGFR mutation,NO,Advanced Non-small Cell Lung Cancer,DRUG: Abivertinib Maleate Capsules|DRUG: Placebo Gefitinib Tablets|DRUG: Gefitinib Tablets|DRUG: Placebo Abivertinib Maleate Capsules,"Assess the efficacy of Abivertinib: Progression Free Survival (PFS), Progression-free survival (PFS) of Abivertinib maleate alone versus standard first-line EGFR-TKI for the treatment of treatment-naÃ¯ve patients with advanced non-small cell lung cancer with sensitive EGFR mutation (Investigator's evaluation according to RECIST1.1 criteria), From baseline, then every 6 weeks, until disease progression or discontinuation from study. From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months","Objective Response Rate (ORR), Objective Response Rate (ORR) of Abivertinib maleate alone versus standard first-line EGFR-TKI for the treatment of treatment-naÃ¯ve patients with advanced non-small cell lung cancer with sensitive EGFR mutation, At baseline and every 6 weeks until the date of first documented progression or date of death from any cause ( approximately 12 months)|Disease Control Rate (DCR), Disease Control Rate (DCR) of Abivertinib maleate alone versus standard first-line EGFR-TKI for the treatment of treatment-naÃ¯ve patients with advanced non-small cell lung cancer with sensitive EGFR mutation, At baseline and every 6 weeks until the date of first documented progression or date of death from any cause ( approximately 12 months)|Duration of Response (DoR), Duration of Response (DoR) of Abivertinib maleate alone versus standard first-line EGFR-TKI for the treatment of treatment-naÃ¯ve patients with advanced non-small cell lung cancer with sensitive EGFR mutation, At baseline and every 6 weeks until the date of first documented progression or date of death from any cause ( approximately 12 months)|Overall Survival (OS), Overall Survival (OS) of Abivertinib maleate alone versus standard first-line EGFR-TKI for the treatment of treatment-naÃ¯ve patients with advanced non-small cell lung cancer with sensitive EGFR mutation, From first dose to end of study or date of death from any cause, whichever comes first, assessed every 6 weeks (approximately 36 months)|Safety and Resistance: Number and severity of AEs/SAEs, Number and severity of AEs/SAEs of Abivertinib maleate alone versus standard first-line EGFR-TKI for the treatment of treatment-naÃ¯ve patients with advanced non-small cell lung cancer with sensitive EGFR mutation, From screening to the end of survival follow-up, which is assessed through study completion until 30 days after discontinuation|Safety and Resistance: Drug exposure, The mean, standard deviation, maximum, minimum, and median of drug exposures in the two groups are described, Continuously throughout the study until 30days after discontinuation|Safety and Resistance: General physical examination status, A general physical examination includes: general status, skin, head and neck (includes: eyes, ears, nose, throat), respiratory system, cardiovascular system, abdomen,superficial lymph nodes, thyroid, musculoskeletal system (including spine and limbs), and nervous system, and any other physical signs of clinical significance. During the treatment, physical examination of the potentially affected organs will be performed., Continuously throughout the study until 30days after discontinuation|Safety and Resistance: Electrocardiogram(ECG test), Descriptive statistical analysis of clinical diagnosis results of ECG examination and changes compared with baseline are performed at planned time points, and abnormal ECG examination results are listed., Continuously throughout the study until 30days after discontinuation|Safety and Resistance: Eastern Clinical Oncology Group Scores, ECOG (Eastern Clinical Oncology Group) Performance Status Grading Criteria: Range from 0-5, 0 considered to be the best outcome and 5 to be the worst outcome, Continuously throughout the study until 30days after discontinuation|Questionnaire: Health-related quality of life (HRQoL), Quality of life questionnaire of Abivertinib maleate alone versus standard which includes 5 functional domains, 3 symptom domains, 1 overall health status/quality of life domain and 6 single entries. Standardized scores of the domains/single entries in the questionnaire are used to statistically describe the absolute values and changes from baseline at each evaluation time point; t test is used to compare changes from baseline in overall quality of life score at each evaluation time point in both groups; analysis of variance is used to compare changes in overall health status score at each evaluation time point between the two groups. first-line EGFR-TKI for the treatment of treatment-naÃ¯ve patients with advanced non-small cell lung cancer with sensitive EGFR mutation, At baseline and every 6 weeks until the date of first documented progression or date of death from any cause ( approximately 12 months)",,"Hangzhou ACEA Pharmaceutical Research Co., Ltd.",Guangdong Provincial People's Hospital,ALL,"ADULT, OLDER_ADULT",PHASE3,406,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-03,2022-03,2024-03,2019-02-27,,2019-02-27,"Guangdong Provicial People's Hospital, Guangzhou, Guangdong, China",
NCT06956001,Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation,https://clinicaltrials.gov/study/NCT06956001,,RECRUITING,"This study is a randomized, open, multicenter phase III clinical study, which aims to evaluate the efficacy and safety of firmonertinib mesylate compared with platinum based chemotherapy for patients with locally advanced or metastatic NSCLC who have not been treated with systemic antitumor therapy and carry EGFR PaCC mutation or EGFR l861q mutation.

Eligible patients were stratified by EGFR mutation type and CNS metastasis at the time of enrollment. Approximately 300 patients would be randomly assigned 1:1 to receive either firmonertinib mesylate (240mg, orally on an empty stomach daily) or platinum containing dual agent chemotherapy.",NO,EGFR|NSCLC (Advanced Non-small Cell Lung Cancer),DRUG: Firmonertinib Mesilate Tablets|DRUG: Pemetrexed Disodium for Injection|DRUG: Cisplatin for injection|DRUG: Carboplatin Injection,"Progression-free survival (PFS) assessed by the Independent Review Committee (BICR) according to RECIST v1.1., The time from the date of randomization to the date of first documentation of disease progression (assessed according to RECIST v1.1 criteria) or death from any cause, whichever occurred first., Up to 3 years","Overall survival (OS), Up to 3 years|The incidence and severity of adverse events (AES) were determined according to NCI CTCAE V5.0, Up to 3 years|Patient Reported Outcomes by EORTC QLQ LC13 questionnaire, To assess the impact of firmonertinib on patients' disease-related symptoms and health related quality of life (HRQoL)., Up to 3 years|Patient Reported Outcomes by EORTC QLQ-C30 questionnaire, To assess the impact of firmonertinib on patients' disease-related symptoms and health related quality of life (HRQoL)., Up to 3 years|Plasma concentrations of firmonertinib and its major metabolite (ast5902) in patients treated with firmonertinib at the indicated sampling time points, Up to 3 years",,"Allist Pharmaceuticals, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE3,300,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-11-19,2027-12,2028-07,2025-05-02,,2025-05-02,"Ethics Committee of cancer hospital, Chinese Academy of Medical Sciences, BeiJing, Beijing, 100021, China|Shandong Tumor Hospital, Shandong, Jinan, China",
NCT03520686,QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC.,https://clinicaltrials.gov/study/NCT03520686,,ACTIVE_NOT_RECRUITING,"This is a phase 3, open-label, 4-cohort study (3 randomized cohorts and 1 single-arm cohort). Participants enrolled in each cohort will be treated as detailed below. Each study cohort will be analyzed separately. Treatment will continue for up to 2 years, or until the patient experiences confirmed progressive disease or unacceptable toxicity, withdraws consent, or if the investigator feels that it is no longer in the patient's best interest to continue treatment. Patients will be followed for disease progression, post-therapies, and survival through 24 months after the first dose of study drug.",NO,Non Small Cell Lung Cancer,DRUG: N-803 + Pembrolizumab|DRUG: N-803 + Carboplatin + Nab-paclitaxel + Pembrolizumab|DRUG: N-803 + Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed|DRUG: Pembrolizumab|DRUG: Carboplatin + Nab-paclitaxel or Paclitaxel + Pembrolizumab|DRUG: Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed|DRUG: N-803 + Carboplatin + Nab-paclitaxel + Ipilimumab + Nivolumab,"Progression Free Survival (PFS), Defined by RECIST Version 1.1 based on BICR, 24 Months","Overall Survival (OS), 24 Months|Overall Response Rate (ORR), Defined by RECIST Version 1.1 based on BICR, 24 Months|Duration of Response (DOR), Defined by RECIST Version 1.1 based on BICR., 24 Months|PFS, Defined by iRECIST based on BICR., 24 Months|Overall Response Rate (ORR), Defined by iRECIST based on BICR., 24 Months|Duration of Response (DOR), Defined by iRECIST based on BICR., 24 Months|Disease Control Rate (DCR), Confirmed CR, PR, or SD lasting for at least 2 months by RECIST Version 1.1 based on BICR, 2 Months|Quality of Life based on Patient Reported Outcomes Questionnaires (Cohorts A, B, C only), FACT-L, 24 Months","Incidence of treatment-emergent AEs and SAEs, Graded using the NCI CTCAE Version 5.0, 24 Months|Immunogenicity profile of N-803 in combination with pembrolizumab (Cohorts A, B, C only)., Detection of anti-drug antibodies, 24 Months|Tumor molecular profiles and correlations with subject outcomes (Cohorts A, B, C only)., Genomic sequencing of tumor cells from tissue, 9 Weeks","ImmunityBio, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE3,1538,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2018-05-18,2025-10-01,2026-04-01,2018-05-11,,2024-08-14,"Alaska Urological Institute - Alaska Clinical Research Center, Anchorage, Alaska, 99503, United States|Genesis Cancer Center, Hot Springs, Arkansas, 71913, United States|Chan Soon-Shiong Institute for Medicine, El Segundo, California, 90245, United States|Adventist Health Glendale, Glendale, California, 92106, United States|MemorialCare Health System, Long Beach, California, 90806, United States|Adventist Health White Memorial, Los Angeles, California, 90033, United States|Hoag Memorial Hospital, Newport Beach, California, 92663, United States|Desert Hematology Oncology Medical Group, Rancho Mirage, California, 92270, United States|Memorial Healthcare, Hollywood, Florida, 33021, United States|Baptist Health South Florida - Miami Cancer Institute, Miami, Florida, 33176, United States|Healthcare Research Network, Tinley Park, Illinois, 60487, United States|Baptist Health - Lexington, Lexington, Kentucky, 40503, United States|Baptist Health Louisville, Louisville, Kentucky, 40503, United States|Karmanos Cancer Center, Detroit, Michigan, 48201, United States|Mercy Research Joplin, Joplin, Missouri, 64804, United States|St. Vincent Frontier Cancer Center, Billings, Montana, 59102, United States|Astera Cancer Care, East Brunswick, New Jersey, 08816, United States|University of Rochester, Rochester, New York, 14642, United States|Stony Brooke Medicine, Stony Brook, New York, 11794, United States|Mercy Research Oklahoma City, Oklahoma City, Oklahoma, 73120, United States|LeHigh Valley, Allentown, Pennsylvania, 18103, United States|Gettysburg Cancer Center, Gettysburg, Pennsylvania, 17325, United States|Medical University of South Carolina (MUSC) - Hollings Cancer Center (HCC), Charleston, South Carolina, 29425, United States|Saint Francis Cancer Center/Bon Secours St. Francis Health System, Greenville, South Carolina, 29607, United States|Avera Cancer Institute, Sioux Falls, South Dakota, 57105, United States|University of Tennessee Medical Center, Knoxville, Tennessee, 37920, United States|Baptist Cancer Center, Memphis, Tennessee, 38120, United States|Texas Oncology-Austin, Austin, Texas, 78745, United States|Texas Oncology-Bedford, Bedford, Texas, 76002, United States|Oncology Consultants, PA, Houston, Texas, 77030, United States|Bon Secours Richmond, Richmond, Virginia, 23114, United States",
NCT05301842,Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC,https://clinicaltrials.gov/study/NCT05301842,EMERALD-3,ACTIVE_NOT_RECRUITING,"A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab, tremelimumab and lenvatinib therapy in patients with locoregional hepatocellular carcinoma",NO,Hepatocellular Carcinoma,DRUG: Tremelimumab|DRUG: Durvalumab|PROCEDURE: Transarterial Chemoembolization (TACE)|DRUG: Lenvatinib,"Progression Free Survival (PFS) for Arm A vs Arm C, PFS is defined as time from randomization until progression per RECIST 1.1 as assessed by BICR or death due to any cause, Approximately 5 years","Overall Survival (OS) for Arm A vs Arm C, OS is defined as the time from the date of randomization until death due to any cause, Approximately 5 years|Progression Free Survival (PFS) for Arm B vs Arm C, PFS is defined as time from randomization until progression per RECIST 1.1 as assessed by BICR or death due to any cause, Approximately 5 years|Overall Survival (OS) for Arm B vs Arm C, OS is defined as the time from the date of randomization until death due to any cause, Approximately 5 years",,AstraZeneca,,ALL,"ADULT, OLDER_ADULT",PHASE3,760,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-03-28,2025-12-31,2027-02-26,2022-03-31,,2025-01-15,"Research Site, Birmingham, Alabama, 35233, United States|Research Site, Mobile, Alabama, 36607, United States|Research Site, Yuma, Arizona, 85364, United States|Research Site, Glendale, California, 91204, United States|Research Site, Atlanta, Georgia, 30318, United States|Research Site, Baltimore, Maryland, 21201, United States|Research Site, Santa Fe, New Mexico, 87505, United States|Research Site, Commack, New York, 11725, United States|Research Site, New York, New York, 10029, United States|Research Site, Memphis, Tennessee, 38104, United States|Research Site, Dallas, Texas, 75235, United States|Research Site, Houston, Texas, 77030, United States|Research Site, Brussels, 1070, Belgium|Research Site, Gent, 9000, Belgium|Research Site, Barretos, 14784-400, Brazil|Research Site, Brasilia, 71681-603, Brazil|Research Site, NiterÃ³i, 24020-096, Brazil|Research Site, Porto Alegre, 91350-200, Brazil|Research Site, Rio de Janeiro, 20231-050, Brazil|Research Site, Santa Maria, 97015-450, Brazil|Research Site, Santo Andre, 09060-650, Brazil|Research Site, SÃ£o Paulo, 04014-002, Brazil|Research Site, VitÃ³ria, 29043-272, Brazil|Research Site, Calgary, Alberta, T2N 5G2, Canada|Research Site, Halifax, Nova Scotia, B3H 2Y9, Canada|Research Site, Kingston, Ontario, K7L 5P9, Canada|Research Site, Ottawa, Ontario, K1H 8L6, Canada|Research Site, Toronto, Ontario, M4N 3M5, Canada|Research Site, Toronto, Ontario, M5G 2M9, Canada|Research Site, Montreal, Quebec, H2X 3E4, Canada|Research Site, Montreal, Quebec, H4A 3J1, Canada|Research Site, Beijing, 100021, China|Research Site, Beijing, 100069, China|Research Site, Beijing, 100142, China|Research Site, Changchun, 130021, China|Research Site, Changsha, 410013, China|Research Site, Chengdu, 610041, China|Research Site, Fuzhou, 350001, China|Research Site, Fuzhou, 350011, China|Research Site, Guangzhou, 510060, China|Research Site, Guangzhou, 510515, China|Research Site, Haikou, 570311, China|Research Site, Hangzhou, 310022, China|Research Site, Harbin, 150081, China|Research Site, Hefei, 230031, China|Research Site, Lanzhou, 730030, China|Research Site, Lishui, 323000, China|Research Site, Nanchang, 330006, China|Research Site, Nanjing, 210002, China|Research Site, Nantong, 226361, China|Research Site, Neijiang, 641000, China|Research Site, Shanghai, 200032, China|Research Site, Suzhou, 215004, China|Research Site, Tianjin, 300170, China|Research Site, Wenzhou, 325000, China|Research Site, Wuhan, 430010, China|Research Site, Wuhan, 430022, China|Research Site, Xi'an, 710000, China|Research Site, Zhengzhou, 450008, China|Research Site, Zhuhai, 519000, China|Research Site, Cairo, 11451, Egypt|Research Site, Mansoura, 7650001, Egypt|Research Site, Shebeen El Kom, 32511, Egypt|Research Site, Angers, 49933, France|Research Site, Clichy, 92110, France|Research Site, Creteil, 94010, France|Research Site, MONTPELLIER Cedex 5, 34295, France|Research Site, Nantes cedex 1, 44093, France|Research Site, Nice, 06200, France|Research Site, Paris, 75013, France|Research Site, Strasbourg, 67091, France|Research Site, Toulouse, 31059, France|Research Site, Vandoeuvre Les Nancy, 54511, France|Research Site, Bonn, 53127, Germany|Research Site, Chemnitz, 09116, Germany|Research Site, Dresden, 01307, Germany|Research Site, DÃ¼sseldorf, 40225, Germany|Research Site, Frankfurt, 60596, Germany|Research Site, GÃ¶ttingen, 37075, Germany|Research Site, Hamburg, 22291, Germany|Research Site, Hannover, 30625, Germany|Research Site, Heidelberg, 69120, Germany|Research Site, Kiel, 24105, Germany|Research Site, Leipzig, 04103, Germany|Research Site, Magdeburg, 39120, Germany|Research Site, Ulm, 89081, Germany|Research Site, Ahmedabad, 380054, India|Research Site, Ahmedabad, 380060, India|Research Site, Bangalore, 560027, India|Research Site, Delhi, 110029, India|Research Site, Hyderabad, 500032, India|Research Site, JAipur, 302022, India|Research Site, Kolkata, 700099, India|Research Site, Mumbai, 400012, India|Research Site, New Delhi, 110 085, India|Research Site, New Delhi, 110005, India|Research Site, Arezzo, 52100, Italy|Research Site, Firenze, 50134, Italy|Research Site, Milano, 20132, Italy|Research Site, Milano, 20133, Italy|Research Site, Roma, 00128, Italy|Research Site, Rozzano, 20089, Italy|Research Site, Tricase, 73039, Italy|Research Site, Chuo-ku, 104-0045, Japan|Research Site, Fukuoka-shi, 810-8563, Japan|Research Site, Hiroshima-shi, 734-8551, Japan|Research Site, Kashihara-shi, 634-8522, Japan|Research Site, Kashiwa, 277-8577, Japan|Research Site, Kumamoto-shi, 860-8556, Japan|Research Site, Mitaka-shi, 181-8611, Japan|Research Site, Morioka-shi, 028-3695, Japan|Research Site, Musashino-shi, 180-8610, Japan|Research Site, Okayama-shi, 700-8558, Japan|Research Site, Osaka-shi, 543-8555, Japan|Research Site, Osaka-shi, 545-8586, Japan|Research Site, Osakasayama-shi, 589-8511, Japan|Research Site, Sapporo-shi, 006-8555, Japan|Research Site, Sendai-shi, 981-0914, Japan|Research Site, Sunto-gun, 411-8777, Japan|Research Site, Tokushima-shi, 770-8503, Japan|Research Site, Tsu-shi, 514-8507, Japan|Research Site, Yokohama-shi, 241-8515, Japan|Research Site, Busan, 49241, Korea, Republic of|Research Site, Daegu, 42601, Korea, Republic of|Research Site, Goyang-si, 10408, Korea, Republic of|Research Site, Jung-gu, 41944, Korea, Republic of|Research Site, Seoul, 03080, Korea, Republic of|Research Site, Seoul, 03722, Korea, Republic of|Research Site, Seoul, 06351, Korea, Republic of|Research Site, George Town, 10450, Malaysia|Research Site, Kuala Lumpur, 59100, Malaysia|Research Site, Kuching, 93586, Malaysia|Research Site, Puncak Alam, 42300, Malaysia|Research Site, Selangor, 62250, Malaysia|Research Site, Guadalajara, Jalisco, 44280, Mexico|Research Site, MÃ©xico, 1400, Mexico|Research Site, San Luis PotosÃ­, 78209, Mexico|Research Site, Tuxtla Gutierrez, 29090, Mexico|Research Site, Davao City, 8000, Philippines|Research Site, Makati, 1229, Philippines|Research Site, Manila, 1003, Philippines|Research Site, Pasig City, 1600, Philippines|Research Site, Quezon City, 1112, Philippines|Research Site, Lisboa, 1649-035, Portugal|Research Site, Vila Real, 5000-508, Portugal|Research Site, Hato Rey Central, 00917, Puerto Rico|Research Site, San Juan, 00927, Puerto Rico|Research Site, Jeddah, 22384, Saudi Arabia|Research Site, Riyadh, 12713, Saudi Arabia|Research Site, Barcelona, 08036, Spain|Research Site, Cordoba, 14004, Spain|Research Site, Madrid, 28007, Spain|Research Site, Madrid, 28034, Spain|Research Site, San Sebastian, 20014, Spain|Research Site, Taichung, 40447, Taiwan|Research Site, Taichung, 40705, Taiwan|Research Site, Tainan City, 70403, Taiwan|Research Site, Taipei, 100, Taiwan|Research Site, Taipei, TAIWAN, Taiwan|Research Site, Taoyuan, 333, Taiwan|Research Site, Bangkok, 10210, Thailand|Research Site, Bangkok, 10300, Thailand|Research Site, Bangkok, 10400, Thailand|Research Site, Bangkok, 10700, Thailand|Research Site, Chiang Mai, 50200, Thailand|Research Site, Hat Yai, 90110, Thailand|Research Site, Khon Kaen, 40002, Thailand|Research Site, Ha Noi, 100000, Vietnam|Research Site, Hanoi, 100000, Vietnam|Research Site, Hcmc, 700000, Vietnam|Research Site, Hcmc, 70000, Vietnam|Research Site, Ho Chi Minh, 700000, Vietnam",
NCT04961996,"A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)",https://clinicaltrials.gov/study/NCT04961996,,RECRUITING,"This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with endocrine therapy of physician's choice in participants with medium- and high-risk Stage I-III histologically confirmed estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.

In addition, an open-label exploratory substudy will explore the safety and efficacy of giredestrant in combination with abemaciclib in a subset of the primary study population.",NO,Early Breast Cancer,DRUG: Giredestrant|DRUG: Endocrine Therapy of Physician's Choice|DRUG: LHRH Agonist|DRUG: Abemaciclib,"Invasive Disease-Free Survival (IDFS), Excluding Second Primary Non-Breast Cancers, From randomization to first occurrence of an IDFS event (up to 10 years)","Overall Survival, From randomization to death from any cause (up to 10 years)|Invasive Disease-Free Survival (IDFS), Including Second Primary Non-Breast Cancers, From randomization to first occurrence of an IDFS event (up to 10 years)|Disease-Free Survival (DFS), From randomization to first occurrence of a DFS event (up to 10 years)|Distant Recurrence-Free Interval (DRFI), From randomization to first occurrence of a DFRI event (up to 10 years)|Locoregional Recurrence-Free Interval (LRRFI), From randomization to first occurrence of a LRRFI event (up to 10 years)|Mean Physical Functioning Scale Score at Specified Timepoints, Assessed Using the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), Baseline (Cycle 1) and Cycles 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54, and 60 (1 cycle is 28 days) of treatment, once every 6 months during the first 2 years of post-treatment follow-up and annually for 3 years thereafter (up to 10 years)|Change from Baseline in the Mean Physical Functioning Scale Score at Specified Timepoints, Assessed Using the EORTC QLQ-C30, Baseline (Cycle 1) and Cycles 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54, and 60 (1 cycle is 28 days) of treatment, once every 6 months during the first 2 years of post-treatment follow-up and annually for 3 years thereafter (up to 10 years)|Mean Role Functioning Scale Score at Specified Timepoints, Assessed Using the EORTC QLQ-C30, Baseline (Cycle 1) and Cycles 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54, and 60 (1 cycle is 28 days) of treatment, once every 6 months during the first 2 years of post-treatment follow-up and annually for 3 years thereafter (up to 10 years)|Change from Baseline in the Mean Role Functioning Scale Score at Specified Timepoints, Assessed Using the EORTC QLQ-C30, Baseline (Cycle 1) and Cycles 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54, and 60 (1 cycle is 28 days) of treatment, once every 6 months during the first 2 years of post-treatment follow-up and annually for 3 years thereafter (up to 10 years)|Mean Global Health Status/Quality of Life (QoL) Scale Score at Specified Timepoints, Assessed Using the EORTC QLQ-C30, Baseline (Cycle 1) and Cycles 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54, and 60 (1 cycle is 28 days) of treatment, once every 6 months during the first 2 years of post-treatment follow-up and annually for 3 years thereafter (up to 10 years)|Change from Baseline in the Mean Global Health Status/Quality of Life (QoL) Scale Score at Specified Timepoints, Assessed Using the EORTC QLQ-C30, Baseline (Cycle 1) and Cycles 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54, and 60 (1 cycle is 28 days) of treatment, once every 6 months during the first 2 years of post-treatment follow-up and annually for 3 years thereafter (up to 10 years)|Change from Baseline in the EQ 5D-5L Index-Based Score at Specified Timepoints, Baseline (Cycle 1) and Cycles 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54, and 60 (1 cycle is 28 days) of treatment, once every 6 months during the first 2 years of post-treatment follow-up and annually for 3 years thereafter (up to 10 years)|Change from Baseline in the EQ 5D-5L Visual Analogue Scale (VAS) Score at Specified Timepoints, Baseline (Cycle 1) and Cycles 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54, and 60 (1 cycle is 28 days) of treatment, once every 6 months during the first 2 years of post-treatment follow-up and annually for 3 years thereafter (up to 10 years)|Incidence and Severity of Adverse Events, with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI-CTCAE v5.0), From start of treatment until 28 days after the final dose of study treatment (up to 5 years)|Plasma Concentrations of Giredestrant at Specified Timepoints, Predose and 3-4 hours postdose on Day 1 of Cycles 1 and 2, and predose on Day 1 of Cycles 3 and 6 (1 cycle is 28 days)|Substudy: Incidence of Grade â¥3 Adverse Events with Giredestrant in Combination with Abemaciclib, From first dose of study treatment until 28 days after the last dose of treatment with the combination of giredestrant and abemaciclib or until the end of Year 2, whichever occurs first (up to 2 years)|Substudy: Incidence and Severity of Adverse Events with Giredestrant in Combination with Abemaciclib, with Severity Determined According to NCI-CTCAE v5.0, From first dose of study treatment until 28 days after the last dose of treatment with the combination of giredestrant and abemaciclib or until the end of Year 2, whichever occurs first (up to 2 years)",,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE3,4200,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-08-27,2026-03-31,2033-11-21,2021-07-14,,2025-05-18,"Southern Cancer Center, Daphne, Alabama, 36526, United States|CBCC Global Research Inc., at Comprehensive Blood and Cancer Center, Bakersfield, California, 93309, United States|Arrowhead Regional Medical Center, Colton, California, 92324, United States|Cancer and Blood Specialty Clinic, Fountain Valley, California, 92708, United States|St Joseph Heritage Healthcare, Fullerton, California, 92835, United States|Long Beach Memorial Medical Center, Long Beach, California, 90806, United States|UCLA Hematology/Oncology, Los Angeles, California, 90095, United States|Keck Medicine of USC ? Newport Beach, Newport Beach, California, 92663-4121, United States|The Center for Cancer Prevention and Treatment at St.Joseph Hospital of Orange, Orange, California, 92868, United States|Stanford University Medical Center, Palo Alto, California, 94304, United States|Kaiser Permanente - Roseville, Roseville, California, 95661, United States|Kaiser Permanente - San Diego, San Diego, California, 92120, United States|Kaiser Permanente - San Francisco (2238 Geary), San Francisco, California, 94115, United States|Stanford Cancer Center South Bay, San Jose, California, 95124, United States|Sansum Clinic, Santa Barbara, California, 93105, United States|Kaiser Permanente - Santa Clara, Santa Clara, California, 95051, United States|Torrance Memorial Physician Network/Cancer Care, Torrance, California, 90505, United States|Kaiser Permanente - Vallejo, Vallejo, California, 94589, United States|Valley Breast Care and Women's Health Center, Van Nuys, California, 91405, United States|Rocky Mountain Cancer Centers (Longmont) - USOR, Longmont, Colorado, 80501, United States|Stamford Hospital, Stamford, Connecticut, 06902, United States|University of Florida, Gainesville, Florida, 32608, United States|Memorial Healthcare System - Memorial Regional Hospital, Hollywood, Florida, 33021, United States|Baptist - MD Anderson Cancer Center, Jacksonville, Florida, 32207, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, 33140, United States|Miami Cancer Institute of Baptist Health, Inc., Miami, Florida, 33176, United States|Orlando Health Cancer Institute, Orlando, Florida, 32806, United States|Miami Cancer Institute-Plantation, Plantation, Florida, 33324, United States|Memorial Health University Cancer Center, Savannah, Georgia, 31404, United States|University of Illinois at Chicago, Chicago, Illinois, 60612, United States|University of Chicago Hospital, Chicago, Illinois, 60637, United States|Elmhurst Cancer Center, Elmhurst, Illinois, 60126, United States|Joliet Oncology Hematology Associates, Ltd., Joliet, Illinois, 60435, United States|Edward Cancer Center Naperville, Naperville, Illinois, 60540, United States|Edward Cancer Center Plainfield, Plainfield, Illinois, 60585, United States|Oncology Associates at Mercy Medical Center, Cedar Rapids, Iowa, 52403, United States|University of Iowa, Iowa City, Iowa, 52242-1086, United States|Cancer Center of Kansas - Kingman, Kingman, Kansas, 67068, United States|University of Kentucky, Lexington, Kentucky, 40536, United States|Norton Cancer Institute - MDC, Louisville, Kentucky, 40202, United States|Hematology/Oncology Clinic, LLP, Baton Rouge, Louisiana, 70809, United States|University Medical Center New Orleans, New Orleans, Louisiana, 70112, United States|UPMC Western Maryland - Schwab Family Cancer Center, Cumberland, Maryland, 21502, United States|University of Maryland, Towson, Maryland, 21204, United States|Lahey Clinic Med Ctr, Burlington, Massachusetts, 01805, United States|Massachusetts General Hospital, Lexington, Massachusetts, 02421, United States|University Of Michigan, Ann Arbor, Michigan, 48109, United States|Metro-Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, 55426, United States|University of Missouri-Columbia, Columbia, Missouri, 65203, United States|St. Vincent Frontier Cancer Center, Billings, Montana, 59102, United States|Nebraska Cancer Specialists, Omaha, Nebraska, 68130-2042, United States|University of Nebraska Medical Center, Omaha, Nebraska, 68198-0600, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, 89135, United States|MD Anderson Cancer Center at Cooper, Camden, New Jersey, 08103, United States|Hunterdon Hematology Oncology, Flemington, New Jersey, 08822, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, 08901, United States|Roswell Park Cancer Institute, Buffalo, New York, 14263, United States|NYU Winthrop Hospital, Mineola, New York, 11501, United States|New York University Cancer Cen, New York, New York, 10016, United States|Stony Brook Univ Cancer Ctr, Stony Brook, New York, 11794, United States|Messino Cancer Centers, Asheville, North Carolina, 28806, United States|Levine Cancer Institute, Charlotte, North Carolina, 28204, United States|First Health of the Carolinas, Pinehurst, North Carolina, 28374, United States|Rex Cancer Center, Raleigh, North Carolina, 27607, United States|UNC Cancer Care at Nash, Rocky Mount, North Carolina, 27804, United States|Atrium Health Wake Forest Baptist Medical Center - PPDS, Winston-Salem, North Carolina, 27157, United States|Aultman Hospital, Canton, Ohio, 44710, United States|Oncology Hematology Care Inc, Cincinnati, Ohio, 45242, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, 44106, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|Columbus NCORP, Columbus, Ohio, 43125, United States|Stefanie Spielman Comprehensive Breast Center, Columbus, Ohio, 43212, United States|SCRI Mark H. Zangmeister Center, Columbus, Ohio, 43219, United States|Oncology Associates of Oregon, P.C., Eugene, Oregon, 97401, United States|Kaiser Permanente-Northwest Region, Portland, Oregon, 97227, United States|Pinnacle Health, Harrisburg, Pennsylvania, 17109, United States|Penn State Univ. Milton S. Hershey Medical Center, Hershey, Pennsylvania, 17033, United States|Allegheny Cancer Center, Pittsburgh, Pennsylvania, 15212-4737, United States|Magee Womens Hospital, Pittsburgh, Pennsylvania, 15213, United States|Reading Hospital, West Reading, Pennsylvania, 19611, United States|UPMC Williamsport, Divine Providence Campus, Williamsport, Pennsylvania, 17701, United States|Women & Infants Hospital, Providence, Rhode Island, 02905, United States|Avera Cancer Institute, Sioux Falls, South Dakota, 57105, United States|West Cancer Center & Research Institute, Germantown, Tennessee, 38138-1762, United States|Sarah Cannon Research Institute / Tennessee Oncology, Nashville, Tennessee, 37203, United States|Texas Oncology, P.A. - El Paso, El Paso, Texas, 79902, United States|Texas Oncology (Flower Mound) - USOR, Flower Mound, Texas, 75028, United States|Texas Oncology-Fort Worth Cancer Center, Fort Worth, Texas, 76104, United States|Baylor College of Medicine Medical Center, Houston, Texas, 77030, United States|Houston Methodist Cancer Center, Houston, Texas, 77030, United States|Joe Arrington Cancer Research & Treatment Center, Lubbock, Texas, 79410, United States|Texas Oncology (McAllen) - USOR, McAllen, Texas, 78503, United States|Texas Oncology McKinney, McKinney, Texas, 75071, United States|USOR - Texas Oncology - San Antonio Northeast, San Antonio, Texas, 78217, United States|US Oncology Research, Inc., The Woodlands, Texas, 77380, United States|Texas Oncology (Tyler) - USOR, Tyler, Texas, 75702-8363, United States|Texas Oncology (Waco) - USOR, Waco, Texas, 76712, United States|Centra Alan B. Pearson Regional Cancer Center, Lynchburg, Virginia, 24501, United States|Bon Secours Mercy Health, Midlothian, Virginia, 23114, United States|Virginia Oncology Associates, Norfolk, Virginia, 23502, United States|Virginia Commonwealth University - Massey Cancer Center, Richmond, Virginia, 23298, United States|Oncology and Hematology Associates of Southwest Virginia, Inc.,-Blacksburg, Roanoke, Virginia, 24014, United States|Swedish Cancer Institute, Seattle, Washington, 98104, United States|West Virginia University Hospitals Inc, Morgantown, West Virginia, 26056, United States|University of Wisconsin, Madison, Wisconsin, 53792, United States|Froedtert and The Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States|Hospital Italiano Regional del Sur, Bahia Blanca, 8000, Argentina|Fundacion Intectus, Bariloche, 8400, Argentina|Instituto de Investigaciones Clinicas-Mar del Plata, Buenos Aires, B7600FZN, Argentina|Instituto de Investigaciones MetabÃ³licas (IDIM), Buenos Aires, C1012, Argentina|FundaciÃ³n CENIT para la InvestigaciÃ³n en Neurociencias, Buenos Aires, C1125ABD, Argentina|Centro Oncologico Korben, Caba, C1426AGE, Argentina|Fundacion Medica de Rio Negro Y Nuequen, Cipoletti, 8324, Argentina|Consultorios MÃ©dicos Dr. Doreski, Ciudad Autonoma Buenos Aires, C1426ABP, Argentina|Sanatorio Allende Servicio NefrologÃ­a, CÃ³rdoba, 5000, Argentina|Centro Medico Privado CEMAIC, CÃ³rdoba, 5008, Argentina|FundaciÃ³n Ars Medica, Jujuy, Argentina|Centro Oncologico Riojano Integral (CORI), La Rioja, F5300COE, Argentina|Centro de Investigaciones Medicas Mar Del Plata, Mar Del Plata, B7600FYK, Argentina|Hospital Privado de La Comunidad, Mar Del Plata, B7603CBM, Argentina|Centro de Investigacion Pergamino SA, Pergamino, B2700CPM, Argentina|Hospital AlemÃ¡n, Recoleta, C1118AAT, Argentina|Instituto Medico de la Fundacion Estudios Clinicos, Rosario, 2000, Argentina|Instituto de Especialidades de la Salud Rosario - ClÃ­nica del TÃ³rax, Rosario, S2000DBS, Argentina|Sanatorio Parque de Rosario, Rosario, S2000DSV, Argentina|Instituto de Oncologia de Rosario, Rosario, S2013KZE, Argentina|Centro Polivalente de Asistencia e Investigacion Clinica - CER San Juan, San Juan, J5402DIL, Argentina|Centro MÃ©dico Privado de ReumatologÃ­a, San Miguel de Tucuman, T4000AXL, Argentina|Centro Medico San Roque, San Miguel de Tucuman, T4000IAK, Argentina|Organizacion Medica de Investigacion, San NicolÃ¡s, C1015ABO, Argentina|Centro de InvestigaciÃ³n ClÃ­nica ? ClÃ­nica Viedma, Viedma, R8500ACE, Argentina|Border Medical Oncology Research Unit, Albury, New South Wales, 2640, Australia|Bankstown-Lidcombe Hospital, Bankstown, New South Wales, 2200, Australia|Campbelltown Hospital, Campbelltown, New South Wales, 2560, Australia|Liverpool Hospital, Liverpool, New South Wales, 2170, Australia|Westmead Hospital, Northmead, New South Wales, 2152, Australia|North Coast Cancer Institute - Port Macquarie, Port Macquarie, New South Wales, 2444, Australia|Mater Hospital, Wollstonecraft, New South Wales, 2065, Australia|Wesley Medical Centre, Auchenflower, Queensland, 4066, Australia|Mater Cancer Care Centre, Brisbane, Queensland, 4101, Australia|Cairns Hospital, Cairns, Queensland, 4870, Australia|Townsville Hospital, Townsville, Queensland, 4810, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, 4102, Australia|Royal Adelaide Hospital, Adelaide, South Australia, 5000, Australia|St Andrews Medical Centre, Adelaide, South Australia, 5000, Australia|Flinders Medical Centre, Bedford Park, South Australia, 5042, Australia|Ashford Cancer Centre Research, Kurralta Park, South Australia, 5037, Australia|ICON Cancer Care Hobart, Hobart, Tasmania, 7000, Australia|Bendigo Hospital, Bendigo, Victoria, 3550, Australia|Northern Hospital, Epping, Victoria, 3076, Australia|Frankston Hospital, Frankston, Victoria, 3199, Australia|Maroondah Hospital, Ringwood East, Victoria, 3135, Australia|Goulburn Valley Health, Shepparton, Victoria, 3630, Australia|Sunshine Hospital, St Albans, Victoria, 3021, Australia|South West Healthcare, Warrnambool, Victoria, 3280, Australia|Ballarat Oncology & Haematology, Wendouree, Victoria, 3355, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, 6009, Australia|LKH-UniversitÃ¤tsklinikum Klinikum Graz, Graz, 8036, Austria|Medizinische Universitat Innsbruck, Innsbruck, 6020, Austria|Ordensklinikum Linz GmbH, Linz, 4010, Austria|LKH Rankweil, Interne E, Rankweil, 6830, Austria|UniversitÃ¤tsklinikum Salzburg, Salzburg, 5020, Austria|UniversitÃ¤tsklinikum St. PÃ¶lten, St. PÃ¶lten, 3100, Austria|A.Ã¶. Krankenhaus der Barmherzigen BrÃ¼der, St. Veit, 9300, Austria|OÃ¶. Gesundheits- und Spitals-AG/LKH Steyr, Steyr, 4400, Austria|Klinikum Wels-Grieskirchen GmbH, Wels, 4600, Austria|Medizinische Universitat Wien Medical University of Vienna, Wien, 1090, Austria|Institute Jules Bordet, Belgium, 1000, Belgium|Grand Hopital de Charleroi asbl, Charleroi, 6000, Belgium|UZ Leuven, Leuven, 3000, Belgium|CH de l'Ardenne (Libramont), Libramont, 6800, Belgium|Chu Sart Tilman, Liege, 4000, Belgium|Centre Hospitalier ChrÃ©tien MontLÃ©gia, LiÃ¨ge, 4000, Belgium|CHR de la Citadelle, Pharmacie, LiÃ¨ge, 4000, Belgium|Clinique Sainte-Elisabeth, Namur, 5000, Belgium|Cliniques Universitaires UCL de Mont-Godinne, Namur, 5530, Belgium|GZA Ziekenhuizen Antwerpen campus Sint-Augustinus, Wilrijk, 2610, Belgium|Clinical Center Banja Luka, Banja Luka, 78000, Bosnia and Herzegovina|Clinical Hospital Mostar, Mostar, 88000, Bosnia and Herzegovina|Clinical Center University of Sarajevo, Sarajevo, 71000, Bosnia and Herzegovina|University Clinical Center Tuzla, Tuzla, 75000, Bosnia and Herzegovina|Nucleo de Oncologia da Bahia - NOB, Salvador, Bahia, Bahia, 40170-380, Brazil|Centro de Oncologia da Bahia, Salvador/BA, Bahia, 41820-021, Brazil|Centro Odonito Medico Linus Pauling - Clinica de O, Salvador, Bahia, 41830-907, Brazil|Terapia de InovaÃ§Ã£o ClÃ­nica AssistÃªncia Multidiciplinar Em Oncologia Ãtica, Salvador, Bahia, 41950-640, Brazil|Centro de Pesquisas Clinicas em Oncologia - CPCO, Cachoeiro de Itapemirim, EspÃ­rito Santo, 29308-014, Brazil|Hospital Araujo Jorge, Goiania, GoiÃ¡s, 74605-070, Brazil|Cenantron - Centro Avancado de Tratamento Oncologico, Belo Horizonte, Minas Gerais, 30130-090, Brazil|Oncoclinicas do Brasil Servicos Medicos As, Belo Horizonte, Minas Gerais, 30360-680, Brazil|Hospital de Clinicas de Porto Alegre HCPA PPDS, Porto Alegre, ParÃ¡, 90035-903, Brazil|Hospital do Cancer de Pernambuco - HCP, Recife, Pernambuco, 50040-000, Brazil|Universidade de Caxias do Sul - Rio Grande do Sul, Caixas Do Sul, Rio Grande Do Sul, 95070-560, Brazil|ONCOSITE Centro de Pesquisa ClÃ­nica Em Oncologia, Ijui, Rio Grande Do Sul, 98700-000, Brazil|Hospital Bruno Born, Lajeado, Rio Grande Do Sul, 95900-000, Brazil|Hospital SÃ£o Vicente de Paulo X, Passo Fundo, Rio Grande Do Sul, 99001-970, Brazil|Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, 90035-001, Brazil|Irmandade Da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, 90050-170, Brazil|Hospital Mae de Deus, Porto Alegre, Rio Grande Do Sul, 90470-340, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, Rio Grande Do Sul, 90610-000, Brazil|Hospital Nossa Senhora da ConceiÃ§Ã£o, Porto Alegre, Rio Grande Do Sul, 91350-200, Brazil|Clinica de Neoplasias Litoral, Itajai, Santa Catarina, 88301-220, Brazil|*X*FundaÃ§Ã£o Pio XII Hospital de CÃ¢ncer de Barretos, Barretos, SÃ£o Paulo, 14784-400, Brazil|Hospital Amaral Carvalho, Jau, SÃ£o Paulo, 17210-120, Brazil|Instituto de Oncologia ClÃ­nica de Piracicaba, Piracicaba, SÃ£o Paulo, 13419-160, Brazil|Faculdade de Medicina do ABC - FMABC, Santo Andre, SÃ£o Paulo, 09060-650, Brazil|FundaÃ§Ã£o Faculdade Regional de Medicina de SÃ£o JosÃ© do Rio Preto, Sao Jose Do Rio Preto, SÃ£o Paulo, 15090-000, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SÃ£o Paulo, 01246-000, Brazil|Instituto de Oncologia de Sorocaba - CEPOS, Sorocaba, SÃ£o Paulo, 18030-005, Brazil|Instituto Nacional de Cancer - INCa, Rio de Janeiro, 20560-120, Brazil|Instituto Brasileiro De Controle Do CÃ¢ncer - IBCC, SÃ£o Paulo, 03102-002, Brazil|Clinica de Pesquisas e Centro de Estudos Oncologia Ginecologica e Mamaria Ltda, SÃ£o Paulo, 0317-0001, Brazil|Onco Star Sp Oncologia Ltda, SÃ£o Paulo, 04543-000, Brazil|Complex Oncology Center Burgas, Burgas, 8000, Bulgaria|Multiprofile Hospital for Active Treatment Uni Hospital, Panagyurishte, 4500, Bulgaria|Arthur J.E. Child Comprehensive Cancer Center-Calgary, Calgary, Alberta, T2N 4N2, Canada|Cross Cancer Institute, Edmonton, Alberta, T6G 1Z2, Canada|British Columbia Cancer Agency, Vancouver, British Columbia, V5Z 4R2, Canada|The Moncton Hospital, Moncton, New Brunswick, E1C 6Z8, Canada|Sault Area Hospital, Sault Ste. Marie, Ontario, P6B 0A8, Canada|Centre Integre Universitaire de Sante et de Services Sociaux du Saguenay Lac Saint Jean, Chicoutimi, Quebec, G7H 5H6, Canada|Hopital Charles Le Moyne, Greenfield Park, Quebec, J4V 2H1, Canada|CIUSSS-de-l?Est-de-l?Ãle-de-MontrÃ©al, Montreal, Quebec, H1T 2M4, Canada|CHUM, Montreal, Quebec, H2X 3E4, Canada|Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada|McGill University Health Center, Montreal, Quebec, H4A 3J1, Canada|St-JÃ©rome Medical Research, Inc., Saint-Jerome, Quebec, H7Z 5T3, Canada|Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, J1H 5N4, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, S4T 7T1, Canada|CHU de Quebec-Universite Laval, Quebec, G1S 4L8, Canada|IC La Serena Research SpA, La Serena, 1700000, Chile|BIOCINETIC SpA, PeÃ±alolen, 7910000, Chile|Centro de Estudios ClÃ­nicos SAGA SpA, Providencia, 7500000, Chile|Fundacion Arturo Lopez Perez, Providencia, 7500921, Chile|Oncovida - Santiago, Providencia, 7510035, Chile|Patagonia Research, Puerto Montt, 5480000, Chile|Servicios MÃ©dicos URUMED SpA, Rancagua, Chile|Meditek Ltda, Santiago, 8320000, Chile|Icegclinic, Santiago, Chile|Medwal, Santiago, Chile|Clinica Universidad Catolica del Maule, Talca, 3460000, Chile|James Lind Centro de InvestigaciÃ³n Del CÃ¡ncer, Temuco, 4800827, Chile|Oncocentro Apys, Vina Del Mar, 2520598, Chile|Centro de Investigaciones Clinicas ViÃ±a del Mar, ViÃ±a del Mar, 2540333, Chile|Henan Cancer Hospital, Zhengzhou, Henan, 450008, China|Hunan Cancer Hospital, Changsha, Hunan, 410013, China|Jiangxi Cancer Hospital, Nanchang, Jiangxi, 330006, China|The First Hospital of Jilin University, Changchun, Jilin, 130021, China|West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China|Peking University People's Hospital, Beijing, 100044, China|Jilin Cancer Hospital, Changchun, 132013, China|The Second Affiliated Hospital of Dalian Medical University, Dalian, 116027, China|Fujian Provincial Cancer Hospital, Fuzhou City, 350014, China|Guangdong Provincial Maternity and Child Care Cent, Guangzhou, 510010, China|Sun yat-sen University Cancer Center, Guangzhou, 510060, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou City, 310009, China|Sir Run Run Shaw Hospital Zhejiang University, Hangzhou City, 310016, China|The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, 310003, China|Zhejiang Cancer Hospital, Hangzhou, 310022, China|Harbin Medical University Cancer Hospital, Harbin City, 150040, China|Anhui Province Cancer Hospital, Hefei, 230001, China|Jinan Central Hospital, Jinan City, 250013, China|Yunnan Cancer Hospital, Kunming, 650118, China|Linyishi Cancer Hospital, Linyi, 273316, China|The Third Hospital of Nanchang, Nanchang City, 330009, China|Guangxi Cancer Hospital of Guangxi Medical University, Nanning, 530021, China|The Second People's Hospital of Neijiang, Neijiang, 641000, China|Fudan University Shanghai Cancer Center, Shanghai City, 200032, China|Shengjing Hospital of China Medical University, ShenYang, 110004, China|The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000, China|Tianjin Medical University Cancer Institute & Hospital, Tianjin City, 300060, China|Wenzhou Medical College - The First Affiliated Hospital GCP, Wenzhou City, 325000, China|Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan City, 430023, China|Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan City, 430030, China|Hubei Cancer Hospital, Wuhan, 430079, China|Air Force Military Medical University Xijing Hospital, Xi'an City, 710032, China|First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, 710061, China|The First Affiliated Hospital of Xiamen University, Xiamen, 361003, China|The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China|Hemato OncÃ³logos S.A, Cali, 760042, Colombia|FOSCAL, Floridablanca, Colombia|Oncomedica S.A., MonterÃ­a, 000000, Colombia|OncÃ³logos Del Occidente SA, Pereira, 660003, Colombia|Sociedad de OncologÃ­a y hematologÃ­a del Cesar Ltda, Valledupar, 200001, Colombia|Consultorio Oncologico-Hospital Metropolitano Linc, Moravia, 11401, Costa Rica|Instituto de InvestigaciÃ³n en Ciencias MÃ©dicas S.A., San Jose, Costa Rica|Oncotech S.A., San JosÃ©, 10103, Costa Rica|Metropolitano Research Institute Lindora, San JosÃ©, 10903, Costa Rica|Centro de CÃ¡ncer y HematologÃ­a, San JosÃ©, Costa Rica|Clinical Hospital Centre Osijek, Osijek, 31000, Croatia|General Hospital Pula, Pula, 52100, Croatia|University Hospital of Split, Split, 21000, Croatia|General Hospital Varazdin, Varazdin, 42000, Croatia|Clinical Hospital Sestre Milosrdnice, Zagreb, 10000, Croatia|Clinical Hospital Sestre Milosrdnice, Zagreb, 10000, Croatia|Klinicki bolnicki centar Zagreb, Zagreb, 10000, Croatia|Fakultni nemocnice Olomouc, Ostrava - Poruba, 708 52, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, 121 11, Czechia|Fakultni nemocnice v Motole, Praha 5, 150 06, Czechia|Fakultni nemocnice Kralovske Vinohrady, Praha, 100 34, Czechia|Fakultni Thomayerova Nemocnice, Praha, 140 59, Czechia|Alexandria Uni, Alexandria, Egypt|Medical Technology Center for Research and Services, Alexandria, Egypt|Kasr Al Ainy School of Medicine-Cairo University, Cairo, 11562, Egypt|Ain Shams University Hospital, Cairo, 11566, Egypt|Mansoura University Hospital, El Mansura, 35516, Egypt|Sohag Oncology Center, Markaz Sohag, 82511, Egypt|Dar ElSalam Cancer City, Old Cairo, 11632, Egypt|Helsingin yliopistollinen keskussairaala, Helsinki, 00290, Finland|Tampereen yliopistollinen sairaala, Tampere, 33520, Finland|Turun Yliopistollinen Keskussairaala, Turku, 20540, Finland|Centre Francois Baclesse, Caen, Calvados, 14000, France|Sas Clinique De L Europe - Amiens, Amiens, 80090, France|Hopital d'Argenteuil, Argenteuil, 95100, France|Centre Hospitalier Regional Universitaire de Brest - Hopital de la Cavale Blanche, Brest, 29200, France|Institut Daniel Hollard, Grenoble, 38000, France|Centre Hospitalier Departemental de Vendee, La Roche Sur Yon, 85925, France|Centre de cancÃ©rologie de la Sarthe - Aile B, Le Mans, 72015, France|Centre Oscar Lambret, Lille, 59020, France|CHU Dupuytren, Limoges, 87042, France|HÃ´pital PrivÃ© Clairval, Marseille, 13273, France|Clinique ClÃ©mentville, Montpellier, 34070, France|Clinique Catherine de Sienne, Nantes, 44202, France|Institut Curie, Paris, 75005, France|Hopital Universitaire Pitie Salpetriere, Paris, 75013, France|Hopital Tenon, Paris, 75020, France|Hopital Saint Louis, Paris, 75475, France|HÃ´pital EuropÃ©en Georges Pompidou, Paris, 75908, France|Hopital privÃ© des CÃ´tes Armor, PlÃ©rin, 22190, France|EDOG - Centre Eugene Marquis Centre Regional de Lutte Contre Le Cancer - PPDS, Rennes Cedex, 35042, France|Centre Henri Becquerel, Rouen, 76038, France|Curie Saint Cloud, St Cloud, 92210, France|Institut de CancÃ©rologie Strasbourg Europe, Strasbourg, 67033, France|Institut Gustave Roussy, Villejuif, 94805, France|High Technology Hospital MedCenter Ltd, Batumi, 6000, Georgia|Acad. F. Todua Medical Center, Tbilisi, 0112, Georgia|Ltd Israel-Georgia Medical Research Clinic Helsicore, Tbilisi, 0112, Georgia|LTD Health House, Tbilisi, 0144, Georgia|Institute of Clinical Oncology LTD, Tbilisi, 0159, Georgia|Tbilisi Oncology Dispensary, Tbilisi, 0159, Georgia|LTD TIM, Tbilisi Institute of Medicine, Tbilisi, 0160, Georgia|Multiprofile Clinic Consilium Medulla, Tbilisi, 0186, Georgia|S Khechinashvili University Clinic Ltd, Tbilisi, 179, Georgia|HÃ¤matologisch/onkologische Gemeinschaftspraxis, Augsburg, 86150, Germany|Ambulantes Tumorzentrum Spandau, Berlin, 13581, Germany|LÃ¼becker Onkologische Schwerpunktpraxis, Bonn, 53111, Germany|Marienhospital Bottrop, Bottrop, 46236, Germany|Klinikum Chemnitz gGmbH, Chemnitz, 09116, Germany|Universitatsklinikum Erlangen, Erlangen, 91054, Germany|KEM/Evang. Kliniken Essen Mitte gGmbH, Essen, 45136, Germany|Franziskus-Hospital Harderberg, Georgsmarienhutte, 49124, Germany|SRH Wald-Klinikum Gera, Gera, 07548, Germany|Mammazentrum Hamburg am Krankenhaus Jerusalem, Hamburg, 20357, Germany|GynÃ¤kologisch Onkologische Praxis Hannover, Hannover, 30177, Germany|Vincentius-Diakonissen-Kliniken gAG, Karlsruhe, 76137, Germany|Facharztpraxis fÃ¼r GynÃ¤kologie und Geburtshilfe PD Dr. med. Christian Kurbacher, LÃ¼beck, 23562, Germany|UniversitÃ¤tsmedizin Mainz, Mainz, 55131, Germany|Klinikum Mannheim GmbH UniversitÃ¤tsklinikum, Mannheim, 68167, Germany|Praxis fuer gynaekologische onkologie Prof. Dr. me, MÃ¶nchengladbach, 41061, Germany|HÃ¤matologie und Onkologie Ravensburg / Wangen, Ravensburg, 88212, Germany|Leopoldina Krankenhaus Schweinfurt, Schweinfurt, 97422, Germany|Praxis fur Haematologie und Internistische Onkologie, Velbert, 42551, Germany|Henry Dunant Hospital, Athens, 115 26, Greece|University of Athens, Hematological Clinic,, Athens, 115 27, Greece|Sotiria Chest Hospital of Athens, Athens, 11527, Greece|General Oncology Hospital Kifissias ""Oi Agioi Anargyroi"", Athens, 145 64, Greece|Aretaieio Hospital of Athens, Athina, 115 28, Greece|Attikon University General Hospital, Chaidari, 124 62, Greece|Metropolitan General Hospital, Cholargos, 155 62, Greece|Metropolitan Hospital First Oncology Clinic, Faliro, 185 47, Greece|Metropolitan Hospital Fourth Oncology Clinic, Faliro, 185 47, Greece|University General Hospital of Heraklion, Herakleion, 711 10, Greece|University General Hospital of Ioannina, Ioannina, 455 00, Greece|University General Hospital of Larissa, Larissa, 412 21, Greece|IASO Obstetrics Gynecology Clinic, Marousi, 151 23, Greece|Medical Center of Athens, Marousi, 151 25, Greece|Agios Loucas Clinic SA, Panorama, 552 36, Greece|Olympion Clinic, Patras, 264 43, Greece|University General Hospital of Patras, Patras, 265 00, Greece|Bioclinic Thessaloniki, Thessaloniki, 546 22, Greece|Interbalkan Medical Center of Thessaloniki, Thessaloniki, 546 39, Greece|Euromedica PPDS, Thessaloniki, 546 45, Greece|Papageorgiou General Hospital of Thessaloniki, Thessaloniki, 564 29, Greece|Celan S.A., Ciudad de Guatemala, 01010, Guatemala|INTEGRA Cancer Institute, Ciudad de Guatemala, 01010, Guatemala|Grupo Medico Angeles, Ciudad de Guatemala, 01015, Guatemala|Oncomedica, Guatemala, 01010, Guatemala|ClÃ­nica MÃ©dica Especializada en HematologÃ­a, Guatemala, 01234, Guatemala|Centro Medico Integral de Cancerologia CEMIC, SalcajÃ¡, 09002, Guatemala|Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|Tuen Mun Hospital, Hong Kong, Hong Kong|Semmelweis Egyetem, Budapest, 1082, Hungary|Tolna Megyei Balassa JÃ¡nos KÃ³rhÃ¡z, Budapest, 1136, Hungary|Budapesti Uzsoki Utcai KÃ³rhÃ¡z, Budapest, 1145, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, 4032, Hungary|Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz, Miskolc, 3526, Hungary|Szent Borbala Korhaz, TatabÃ¡nya, 2800, Hungary|Zala Megyei Szent Rafael Korhaz, Zalaegersteg, 8900, Hungary|HCG City Cancer Centre, Vijayawada, Andhra Pradesh, 520002, India|State Cancer Institute, Indira Gandhi Institute of Medical Sciences (IGIMS), Patna, Bihar, 800014, India|Gujarat Cancer & Research Inst., Ahmadabad CITY, Gujarat, 380016, India|Nirmal Hospital, Surat, Gujarat, 395002, India|Kiran Hospital Multi Super Speciality Hospital and Research Center, Surat, Gujarat, 395004, India|Himalaya Cancer Hospital & Research Institute, Vadodara, Gujarat, 390020, India|Kailash Cancer Hospital and Research Center, Vadodara, Gujarat, 391760, India|KLES Dr Prabhakar Kore Hospital and Medical Research Centre, Belagavi, Karnataka, 590010, India|Sujan Surgical Cancer Hospital And Amravati Cancer Foundation, Amravati, Maharashtra, 444606, India|Kolhapur Cancer Centre, Kolhapur, Maharashtra, 416234, India|Tata Memorial Hospital, Mumbai, Maharashtra, 400013, India|Government Medical College, Nagpur, Maharashtra, 440003, India|HCG NCHRI Cancer Center, Nagpur, Maharashtra, 440026, India|Shalinitai Meghe Medical College and Hospital, Nagpur, Maharashtra, 441110, India|HCG Manavata Cancer Centre, Nashik, Maharashtra, 422002, India|Chopda Medicare & Research Centre pvt. Ltd, Nashik, Maharashtra, 422005, India|Apex Wellness Hospital, Nashik, Maharashtra, 422009, India|Sahyadri Speciality Hospital, Pune City, Maharashtra, 411004, India|Sahyadri Super Specialty Hospital Hadapsar, Pune, Maharashtra, 411028, India|Lokmanya Holistic Cancer Care and Research Center (LMRC), Pune, Maharashtra, 411033, India|All India Institute of Medical Sciences, Bhubaneswar, Bhubaneswar, Odisha, 751019, India|Erode Cancer Centre, Erode, Tamil NADU, 638012, India|Christian Medical College-Ranipet Campus, Ratnagiri Kilminnal, Tamil NADU, 632517, India|King George Medical University (KGMU), Lucknow, Uttar Pradesh, 226003, India|Institute of Post Graduate Medical Education and Research (IPGMER) and SSKM Hospital, Kolkata, WEST Bengal, 700020, India|Health Point Hospital - Kolkata, Kolkata, WEST Bengal, 700025, India|Cork University Hospital, Cork, T12 DC4A, Ireland|Bon Secours Hospital, Cork, T12 DV56, Ireland|St Vincents University Hospital, Dublin, D04 T6F4, Ireland|Beaumont Hospital, Dublin, D09 V2N0, Ireland|Galway University Hospital, Galway, H91 YR71, Ireland|Mid- Western Regional Hospital Limerick, Limerick, V94 F858, Ireland|Waterford Regional Hospital, Waterford, X91 ER8E, Ireland|Shamir Medical Center Assaf Harofeh, Beer Jacob, 0073100, Israel|Soroka University Medical Centre, Beer Sheba, 84101, Israel|Sheba Medical Center - PPDS, Ramat Gan, 52621, Israel|Tel-Aviv Sourasky Medical Center, Tel Aviv, 6423906, Israel|Azienda Ospedaliera Universitaria Senese, Siena, Abruzzo, 53100, Italy|Azienda Ospedaliera di Rilievo Nazionale e di Alta Specialita San Giuseppe Moscati, Avellino, Campania, 83100, Italy|Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale, Napoli, Campania, 80131, Italy|Azienda Ospedaliero Universitaria di BolognaPoliclinico S.Orsola-Malpighi, Bologna, Emilia-Romagna, 40138, Italy|Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori IRST - PPDS, Meldola, Emilia-Romagna, 47014, Italy|Arcispedale Santa Maria Nuova, Reggio Emilia, Emilia-Romagna, 42100, Italy|Fondazione Policlinico Universitario A Gemelli, Roma, Emilia-Romagna, 00168, Italy|Ospedale San Raffaele S.r.l. - PPDS, Milano, Lombardia, 20132, Italy|Istituto Nazionale Tumori Regina Elena, Milano, Lombardia, 20133, Italy|ASST Grande Ospedale Metropolitano Niguarda - Presidio Ospedaliero Ospedale Niguarda Ca' Granda, Milano, Lombardia, 20162, Italy|Istituto Clinico Humanitas, Rozzano (MI), Lombardia, 20089, Italy|Ospedale San Giuseppe, Empoli, Toscana, 50053, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Toscana, 50134, Italy|Ospedale Civile - Livorno, Livorno, Toscana, 57124, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, Toscana, 56126, Italy|IRCCS Ospedale Sacro Cuore Don Calabria, Negrar, Veneto, 37024, Italy|Fukushima Medical University Hospital, Fukushima, 960-1295, Japan|Hiroshima University Hospital, Hiroshima, 734-8551, Japan|Social Medical Corporation Hakuaikai Sagara Hospital, Kagoshima, 892-0833, Japan|Tokai University Hospital, Kanagawa, 259-1193, Japan|Saitama Cancer Center, Kitaadachi-gun, 362-0806, Japan|Kumamoto University Hospital, Kumamoto-Shi Chuo-Ku, 860-8555, Japan|Nahanishi Clinic, Naha-shi, 901-0154, Japan|National Hospital Organization Osaka National Hospital, Osaka, 540-0006, Japan|Osaka International Cancer Institute, Osaka, 541-8567, Japan|National Hospital Organization Hokkaido Cancer Center, Sapporo-shi, 003-0804, Japan|St. Luke's International Hospital, Tokyo, 104-0044, Japan|The Cancer Institute Hospital of Japanese Foundation For Cancer Research, Tokyo, 135-8550, Japan|International Cancer Institute (ICI), Eldoret, 30100, Kenya|Aga Khan University Hospital, Nairobi, 00100, Kenya|Chungbuk National University Hospital, Cheongju-si, 361-711, Korea, Republic of|Soon Chun Hyang University Cheonan Hospital, Dongnam-gu, Cheonan-si, 31151, Korea, Republic of|Yonsei University Wonju Severance Christian Hospital, Gangwon-do, 26426, Korea, Republic of|National Cancer Centre, Gyeonggi-do, 10408, Korea, Republic of|CHA Bundang Medical Center, Gyeonggi-do, 13496, Korea, Republic of|Inha University Hospital, Incheon, 22332, Korea, Republic of|Gachon University Gil Medical Center, Namdong-Gu, 21565, Korea, Republic of|Korea University Anam Hospital, Seongbuk-Gu, 02841, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, 13620, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Asan Medical Center - PPDS, Seoul, 05505, Korea, Republic of|Gangnam Severance Hospital, Yonsei University Health System, Seoul, 06273, Korea, Republic of|Korea University Guro Hospital, Seoul, 08308, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, 3722, Korea, Republic of|The Catholic University of Korea Seoul St. Mary?s Hospital, Seoul, 6591, Korea, Republic of|Samsung Medical Center - PPDS, Seoul, Korea, Republic of|Ulsan University Hosiptal, Songpa-Gu, 05505, Korea, Republic of|Ajou University Hospital, Suwon City, 443-721, Korea, Republic of|Pauls Stradins Clinical University Hospital, R?ga, LV-1002, Latvia|Hospital Kuala Lumpur, Kuala Lumpur, FED. Territory OF Kuala Lumpur, 50586, Malaysia|University Malaya Medical Centre, Kuala Lumpur, FED. Territory OF Kuala Lumpur, 59100, Malaysia|National Cancer Institute IKN, Putrajaya, Federal Territory OF Putrajaya, 62250, Malaysia|Pantai Hospital Sungai Petani, Sungai Petani, Kedah, 08000, Malaysia|Sarawak General Hospital, Buzia?, Sarawak, 305100, Malaysia|Beacon International Specialist Centre, Petaling Jaya, Selangor, Selangor, 46050, Malaysia|Hospital Pulau Pinang, Penang, 10990, Malaysia|Centro de InvestigaciÃ³n en Artritis y Osteoporosis - PPDS, Mexicali, BAJA California, 21200, Mexico|Office of Alma Magdalena Astorga-Ramos, MD, GÃ³mez Palacio, Durango, 35000, Mexico|Dr. JosÃ© Luis GonzÃ¡lez Trujillo, LeÃ³n de Los Aldama, Guanajuato, 37000, Mexico|Hospital Civil Fray Antonio Alcalde, Guadalajara, Jalisco, 44280, Mexico|Health Pharma Professional Research, Cdmx, Mexico CITY (federal District), 03100, Mexico|ClÃ­nica Integral Internacional de OncologÃ­a S de RL de CV, Puebla, Mexico CITY (federal District), Mexico|Accelerium S. de R.L. de C.V., Monterrey, Nuevo LEON, 64000, Mexico|Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, Nuevo LEON, Mexico|Centro de Investigacion Clinica de Oaxaca, Oaxaca de JuÃ¡rez, Oaxaca, 68020, Mexico|Unidad MÃ©dica Onco-HematolÃ³gica, Heroica Puebla de Zaragoza, Puebla, 72424, Mexico|InvestigaciÃ³n MÃ©dica de Alta Especialidad, QuerÃ©taro, Queretaro, 76000, Mexico|Neurociencias Estudios Clinicos S.C., CuliacÃ¡n, Sinaloa, 80020, Mexico|Merida | Investigacion Clinica, MÃ©rida, Yucatan, 97125, Mexico|Centro de Investigacion Medica Aguascalientes, Aguascalientes, 20116, Mexico|Centro Oncologico Alianza XXI, Mexico, Mexico|Oaxaca Site Management Organization, Oaxaca, 68000, Mexico|OncolÃ³gico Potosino, San Luis PotosÃ­, 78250, Mexico|Centro Hemato-Oncologico Privado CHOP, Toluca, 50080, Mexico|Hagaziekenhuis, 'S-Gravenhage, 2545 AA, Netherlands|Catharina Hospital, Eindhoven, 5623 EJ, Netherlands|Viecuri Medisch Centrum, Venlo, 5912 BL, Netherlands|PHI Clinical Hospital Dr Trifun Panovski Bitola, Bitola, 7000, North Macedonia|Acibadem Sistina Hospital, Skopje, 1000, North Macedonia|PHI University Clinic of Radiotherapy and Oncology, Skopje, 1000, North Macedonia|Hospital Nacional Daniel A Carrion, Bellavista, 7016, Peru|Hospital Militar Central, Jesus Maria, Lima 11, Peru|Hospital Central Fuerza Aerea Del Peru, Lima, 15046, Peru|ClÃ­nica Santa Beatriz, Lima, 15072, Peru|Oncologia S.A.C. - Instituto Peruano de OncologÃ­a & Radioterapia, Lima, 27, Peru|Oncosalud Sac, Lima, 41, Peru|Clinica Peruana Americana, Trujillo, 13011, Peru|University of Santo Tomas Hospital, Manila, National Capital Region, 1015, Philippines|Riverside Medical Center, Inc., Bacolod City, Western Visayas (Region VI), 6100, Philippines|Baguio General Hospital and Medical Center, Baguio City, 2600, Philippines|Saint Louis University Hospital of Sacred Heart, Baguio City, 2600, Philippines|Metro Davao Medical and Research Center, Davao City, 8000, Philippines|St. Paul's Hospital, Iloilo City, 5000, Philippines|Cardinal Santos Medical Center, Manila, 1503, Philippines|The Medical City, Pasig City, 1605, Philippines|East Avenue Medical Center, Quezon City, 1101, Philippines|St. Luke's Medical Center - Quezon City, Quezon City, 1102, Philippines|Centrum Onkologii im. Prof. F. Lukaszczyka w Bydgoszczy, Bydgoszcz, 85-796, Poland|Szpital Morski Im. Pck, Gdynia, 81-519, Poland|Narodowy Instytut Onkologii im. M.Sk?odowskiej-Curie - Pa?stwowy Instytut Badawczy Oddzia? Gliwice, Gliwice, 44-101, Poland|Regionalny Szpital Specjalistyczny im. W. Bieganskiego, Grudziadz, 86-300, Poland|Narodowy Instytut Onkologii - Panstwowy Instytut Badawczy, Oddzia? w Krakowie, KrakÃ³w, 31-115, Poland|Centrum Terapii Wspolczesnej, Lodz, 90-338, Poland|Centrum Onkologii Ziemi LUBELSKIEJ im. Sw Jana z Dukli, I oddz. Chemioterapii, Lublin, 20-090, Poland|Centrum Medyczne Pratia, Poznan, 60-192, Poland|Narodowy Instytut Onkologii im. Marii Sk?odowskiej-Curie - Pa?stwowy Instytut Badawczy, Warszawa, 02-781, Poland|Unidade Local de Saude de Santa Maria, E.P.E. - Hospital de Santa Maria, Lisbon, Lisboa, 1649-035, Portugal|Hospital Senhora da Oliveira ? Guimaraes, E.P.E, GuimarÃ£es, 4835-044, Portugal|Champalimaud Cancer Center, Lisboa, 1400-038, Portugal|Hospital da Luz, Lisboa, 1500-650, Portugal|Instituto PortuguÃªs de Oncologia de Lisboa Francisco Gentil, E.P.E., Lisbon, 1050-034, Portugal|Hospital Beatriz Angelo, Loures, 2674-514, Portugal|Centro Hospitalar do Porto ? Hospital de Santo AntÃ³nio, Porto, 4099-001, Portugal|Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe, Porto, 4200-072, Portugal|Centro Hospitalar de Vila Nova de Gaia / Espinho E.P.E, Vila Nova de Gaia, 4434-502, Portugal|Centro Hospitalar TrÃ¡s Os Montes E Alto Douro EPE, Vila Real, 5000-508, Portugal|Spitalul Clinic de Obstetrica si Ginecologie Filantropia, Bucure?ti, 011171, Romania|Prof Dr I Chiricuta Institute of Oncology, Cluj-napoca, 400015, Romania|Medisprof SRL, Cluj-Napoca, 400641, Romania|Oncology Center Sf. Nectarie, Craiova, 200347, Romania|Onco Clinic Consult SA, Craiova, 200516, Romania|Institutul Regional de Oncologie Iasi, Iasi, 700483, Romania|Timisoara Emergency County Clinical Hospital, Timi?oara, 300595, Romania|Institute for Oncology and Radiology of Serbia, Belgrade, 11000, Serbia|University Hospital Medical Center Bezanijska kosa, Belgrade, 11080, Serbia|Health Center Kladovo, Kladovo, 19320, Serbia|Oncology Institute of Vojvodina, Sremska Kamenica, 21204, Serbia|General Hospital Djordje Joanovic - Zrenjanin, Zrenjanin, 23000, Serbia|Univerzitna nemocnica s poliklinikou Milosrdni bratia spol s r o, Bratislava, 811 06, Slovakia|Onkologicky ustav sv. Alzbety, s.r.o., Bratislava, 812 50, Slovakia|Narodny onkologicky ustav, Bratislava, 833 10, Slovakia|Vychodoslovensky onkologicky ustav, KoÅ¡ice, 040 01, Slovakia|Institute of Oncology Ljubljana, Ljubljana, 1000, Slovenia|Cape Town Oncology Trials, Cape Town, 7570, South Africa|Cancercare Rondebosch Oncology, Cape Town, 7700, South Africa|WITS Clinical Research Site PPDS, City Of Johannesburg, 2193, South Africa|Sandton Oncology Medical Group (Pty) Ltd, City Of Johannesburg, 2196, South Africa|Excellentis Clinical Trial Consultants, George, 6530, South Africa|Medical Oncology Centre of Rosebank, Johannesburg, 2196, South Africa|Southern Cross Research South Africa (PTY) LTD, Mogale City, 1724, South Africa|Langenhoven Drive Oncology Centre, Port Elizabeth, 6045, South Africa|Wilgers Oncology Centre, Pretoria, 0001, South Africa|Eastleigh Breast Care Centre, Pretoria, 0081, South Africa|Hospital General Universitario de Elche, Elche, Alicante, 03203, Spain|ICO Badalona-H.U. Germans Trias i Pujol, Badalona, Barcelona, 08916, Spain|ALTHAIA Xarxa Assistencial de Manresa, Manresa, Barcelona, 08243, Spain|Corporacio Sanitaria Parc Tauli, Sabadell, Barcelona, 08208, Spain|Hospital HM Nuestra SeÃ±ora de la Esperanza, Santiago de Compostela, Burgos, 15705, Spain|Hospital de Jerez, Jerez De La Frontera, Cadiz, 11407, Spain|Consorcio Hospitalario Provincial de Castellon, Castellon DE LA Plana/castello DE LA Plana, Castellon, 12002, Spain|Hospital Universitario Reina Sofia, CÃ³rdoba, Cordoba, 14004, Spain|Hospital Universitario de Donostia, Donostia, Guipuzcoa, 20080, Spain|Hospital Son Llatzer, Palma de Mallorca, Islas Baleares, 07198, Spain|Hospital Universitario A CoruÃ±a, Coruna, LA Coruna, 15006, Spain|CHUS H Clinico U de Santiago, Santiago de Compostela, LA Coruna, 15706, Spain|Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, LAS Palmas, 35016, Spain|Hospital Universitari Arnau de Vilanova, Lleida, Lerida, 25198, Spain|Hospital Universitario FundaciÃ³n AlcorcÃ³n, Alcorcon, Madrid, 28922, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, 31008, Spain|CHUVI ? H.U. Alvaro Cunqueiro, Vigo, Pontevedra, 36312, Spain|Hospital Nuestra Senora de Valme, Seville, Sevilla, 41014, Spain|Hospital Universitario Virgen Macarena, Seville, Sevilla, 41071, Spain|Hospital Universitari Sant Joan de Reus, Reus, Tarragona, 43204, Spain|Hospital Universitario de Canarias, S. Cristobal De La Laguna, Tenerife, 38320, Spain|Hospital Universitario Basurto, Bilbao, Vizcaya, 48013, Spain|Complejo Hospitalario Universitario de Albacete, Albacete, 2006, Spain|Hospital General Universitario de Alicante, Alicante, 03010, Spain|Hospital Universitario San Juan, Alicante, 03550, Spain|Hospital Nuestra SeÃ±ora de Sonsoles, Avila, 05004, Spain|Hospital del Mar, Barcelona, 08003, Spain|Clinica Tres Torres, Barcelona, 08017, Spain|Hospital Universitario Quiron Dexeus, Barcelona, 08028, Spain|Hospital Clinic de Barcelona, Barcelona, 08036, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, 8041, Spain|Hospital de San Pedro de Alcantara, Caceres, 10003, Spain|Hospital Puerta del Mar, Cadiz, 11009, Spain|Institut Catala d'Oncologia Girona, Girona, 17007, Spain|Hospital Universitario ClÃ­nico San Cecilio, Granada, 18007, Spain|Hospital Universitario Virgen de Las Nieves, Granada, 18012, Spain|Hospital Universitario Juan Ramon Jimenez, Huelva, 21005, Spain|Hospital Universitario de Jaen, Jaen, 23007, Spain|Hospital General Universitario Gregorio MaraÃ±on, Madrid, 28007, Spain|IOB Madrid Institute of Oncology Hospital Beata Maria Ana de Jesus, Madrid, 28007, Spain|Hospital Universitario La Paz, Madrid, 280146, Spain|Clinica Universidad Navarra, Madrid, 28027, Spain|Hospital Universitario Infanta Leonor, Madrid, 28031, Spain|MD Anderson Cancer Center Madrid ? Espana, Madrid, 28033, Spain|Hospital Universitario Ramon y Cajal, Madrid, 28034, Spain|Hospital Clinico San Carlos, Madrid, 28040, Spain|Hospital Universitario Fundacion Jimenez Diaz., Madrid, 28040, Spain|Hospital Universitario 12 De Octubre, Madrid, 28041, Spain|Hospital Universitario HM Sanchinarro ? CIOCC, Madrid, 28050, Spain|Hospital Universitario Puerta de Hierro - Majadahonda, Madrid, 28222, Spain|Hospital Universitario de Fuenlabrada, Madrid, 28942, Spain|Hospital Universitario Virgen de la Victoria, Malaga, 29010, Spain|Hospital General Universitario Morales Meseguer, Murcia, 30008, Spain|Hospital Universitario Virgen de La Arrixaca, Murcia, 30120, Spain|Hospital Universitario Son Espases, Palma de Mallorca, 07120, Spain|Hospital Universitario Virgen del RocÃ­o, Sevilla, 41013, Spain|Fundacion Instituto Valenciano de Oncologia (IVO), Valencia, 46009, Spain|Hospital Clinico Universitario de Valencia, Valencia, 46010, Spain|Consorcio Hospital General Universitario de Valencia, Valencia, 46014, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, 46026, Spain|Hospital Clinico Universitario de Valladolid, Valladolid, 47005, Spain|Hospital Universitario Miguel Servet, Zaragoza, 50009, Spain|LÃ¤nssjukhuset Ryhov, JÃ¶nkÃ¶ping, 553 05, Sweden|SÃ¶dersjukhuset, Stockholm, 11883, Sweden|Sundsvalls sjukhus, Sundsvall, 851 86, Sweden|Akademiska Sjukhuset, Uppsala, 751 85, Sweden|VÃ¤stmanlands sjukhus VÃ¤sterÃ¥s, VÃ¤sterÃ¥s, 721 89, Sweden|Tumorzentrum Aarau, Aarau, 5000, Switzerland|Kantonsspital Baden, Baden, 5404, Switzerland|UniversitÃ¤tsspital Basel, Basel, 4031, Switzerland|UniversitÃ¤tsspital Bern, Bern, 3010, Switzerland|Hirslanden Salem-Spital, Bern, 3013, Switzerland|Kantonsspital GraubÃ¼nden KSGR, Chur, 7000, Switzerland|Luzerner Kantonsspital LUKS, Luzern, 6000, Switzerland|Hirslanden Klinik St. Anna, Luzern, 6006, Switzerland|Kantonsspital St. Gallen, St. Gallen, 9007, Switzerland|Spital STS AG Thun - Berner Oberland, Thun, 3600, Switzerland|Kantonsspital Winterthur Medizin Pneumologie, Winterthur, 8400, Switzerland|Brust-Zentrum ZÃ¼rich AG Seefeldstrasse 214 ZÃ¼rich, ZÃ¼rich, 8008, Switzerland|Changhua Christian Medical Foundation Changhua Christian Hospital, Changhua County, 50006, Taiwan|Hsin-Chu Branch of National Taiwan University Hospital, Hsinchu City, 300, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, 807, Taiwan|Taipei Medical University Shuang Ho Hospital, New Taipei City, 23561, Taiwan|China Medical University Hospital, Taichung, 40447, Taiwan|National Cheng Kung University Hospital, Tainan, 70457, Taiwan|Chi Mei Medical Cente, Tainan, 71044, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center, Taipei City, 112, Taiwan|National Taiwan University Hospital, Taipei, 100, Taiwan|Mackay Memorial Hospital - Taipei Branch, Taipei, 10449, Taiwan|Taipei Veterans General Hospital, Taipei, 11217, Taiwan|Chang Gung Memorial Hospital - Linkou, Taoyuan City, 33305, Taiwan|Taichung Veterans General Hospital, Xitun Dist., 40705, Taiwan|Siriraj Hospital, Mahidol University, Bangkok Noi, 10700, Thailand|Chulalongkorn Hospital, Bangkok, 10330, Thailand|Ramathibodi Hospital, Bangkok, 10400, Thailand|Hacettepe Universitesi Tip Fakultesi Hastanesi, Ankara, 06100, Turkey|Ankara City Hospital, Ankara, 06800, Turkey|Akdeniz University Medical Faculty, Antalya, 07059, Turkey|Trakya University Medical Faculty, Edirne, 22030, Turkey|Istanbul University Cerrahpasa Medical Faculty Hospital, Fat?h, 34096, Turkey|T.C. Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin City Hospital, Istanbul, 34722, Turkey|Izmir Medical Point Hospital, Izmir, 35101, Turkey|Katip Celebi University- Izmir Ataturk Egitim ve Arastirma Hastanesi, Izmir, 35360, Turkey|Kocaeli Universitesi Tip Fakultesi Arastirma ve Uygulama Hastanesi, Kocaeli, 41380, Turkey|Ondokuz Mayis Universitesi Tip Fakultesi Hastanesi, Samsun, 55239, Turkey|Baskent Universitesi - Adana Uygulama Ve Arastirma Merkezi, SariÃ§am, 01250, Turkey|Ac?badem Adana Hospital, Oncology Department, Seyhan/Adana, 01130, Turkey|Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastirma Hastanesi, Yen?mahalle, 06200, Turkey|Acibadem Altunizade Hospital, ÃskÃ¼dar, 34662, Turkey|Uganda Cancer Institute, Kampala, 99999, Uganda|St Francis Hospital Nsambya, Kampala, Uganda|SI Institute for general and urgent surgery n.a. V.T.Zaitseva of NAMS of Ukraine, Kharkiv, Kharkiv Governorate, 61103, Ukraine|Municipal Non-profit Enterprise Odessa Regional Clinical Hospital of Odessa Regional Council, Odesa, Kherson Governorate, 65025, Ukraine|Communal Non-Profit Enterprise Chernihiv Medical Center of Modern Oncology of CRC, Chernihiv, KIEV Governorate, 14029, Ukraine|Regional Municipal Non-Commercial Enterprise Bukovynian Clinical Oncology Center, Chernivtsi, KIEV Governorate, 58000, Ukraine|Clinic Verum Expert LLC, Kyiv, KIEV Governorate, 03039, Ukraine|Communal Nonprofit Enterprise Kyiv City Clinical Oncological Center, Kyiv, KIEV Governorate, Ukraine|Kyiv Regional Oncological Dispensary, Kyiv, 04107, Ukraine|Medical Clinical Research Center of Medical Center LLC Health Clinic, Vinnytsia, 21009, Ukraine|Royal Sussex County Hospital, Brighton, BN2 5BE, United Kingdom|Leicester Royal Infirmary, Leicester, LE2 7LX, United Kingdom|University College London Hospitals, London, United Kingdom|Nottingham City Hospital, Nottingham, NG5 1PB, United Kingdom|Royal Preston Hospital, Preston, PR2 9HT, United Kingdom",
NCT06952803,A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation,https://clinicaltrials.gov/study/NCT06952803,EvoPAR-PR02,NOT_YET_RECRUITING,The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in participants with high-risk and very high-risk localised/locally advanced prostate cancer with a breast cancer gene mutation (BRCAm).,NO,Prostate Cancer,DRUG: Saruparib|DRUG: Placebo|DRUG: Abiraterone + Prednisolone/Prednisone|DRUG: Androgen Deprivation Therapy (ADT),"Metastasis-free survival (MFS), MFS is defined as the time from randomisation until the date of first appearance of distant metastases, confirmed by standard clinical imaging \[computed tomography (CT)/ magnetic resonance imaging (MRI) and bone scan, or prostate-specific membrane antigen-positron emission tomography (PSMA-PET)\], as assessed by blinded independent central review (BICR) or death due to any cause., Up to approximately 93 months","Overall Survival (OS), OS is defined as the time from randomisation until the date of death due to any cause., Up to approximately 11 years|MFS (CT/MRI and bone scan), MFS is defined as the time from randomisation until the date of distant metastases, confirmed by conventional imaging (CT/MRI and bone scan), or death due to any cause., Up to approximately 93 months|MFS (PSMA-PET), MFS is defined as the time from randomisation until the date of distant metastases, confirmed by PSMA-PET imaging or death due to any cause., Up to approximately 93 months|MFS (standard clinical imaging), MFS is defined as the time from randomisation until the date of distant metastases, confirmed by standard clinical imaging (CT/MRI and bone scan or PSMA-PET), histology, or death due to any cause., Up to approximately 93 months|Time from randomisation to Progression Free Survival 2 (PFS2), Time from randomisation to PFS2 is defined as the time from randomisation to the earliest of progression \[defined as radiographic progression, clinical progression, or prostate-specific antigen (PSA) progression\] after initiation of first subsequent systemic treatment following the initial investigator-assessed progression or death. The date of second progression will be investigator assessed according to local standard clinical practice., Up to approximately 93 months|Time to PSA progression, Time to PSA progression is defined as the time from randomisation to PSA progression per Phoenix criteria., Up to approximately 93 months|Prostate cancer-specific survival (PCSS), PCSS is defined as the time from randomisation until the date of death due to the underlying prostate cancer., Up to approximately 11 years|Time to deterioration in urinary symptoms (TTDUS), TTDUS is defined as the time from randomisation to deterioration in EORTC-QLQ-PR25 (US) subscale scores., Up to approximately 93 months|Time to deterioration in physical function (TTDPF), TTDPF is defined as the time from randomisation to deterioration in EORTC-QLQ-C30 Physical Function subscale scores., Up to approximately 93 months|Plasma concentrations of saruparib, To assess the PK of saruparib in plasma either with or without abiraterone and explore the relationship between the PK concentration/parameters and selected endpoints (which may include pharmacodynamic parameters, efficacy, and/or safety)., Day 1 of Cycle 1, Cycle 3 and Cycle 6 (each cycle is of 28 days)|Area under the curve (AUC), To assess the PK of saruparib in plasma either with or without abiraterone and explore the relationship between the PK concentration/parameters and selected endpoints (which may include pharmacodynamic parameters, efficacy, and/or safety)., Day 1 of Cycle 1, Cycle 3 and Cycle 6 (each cycle is of 28 days)|Maximum observed concentration (Cmax), To assess the PK of saruparib in plasma either with or without abiraterone and explore the relationship between the PK concentration/parameters and selected endpoints (which may include pharmacodynamic parameters, efficacy, and/or safety)., Day 1 of Cycle 1, Cycle 3 and Cycle 6 (each cycle is of 28 days)|Time to Cmax (Tmax), To assess the PK of saruparib in plasma either with or without abiraterone and explore the relationship between the PK concentration/parameters and selected endpoints (which may include pharmacodynamic parameters, efficacy, and/or safety)., Day 1 of Cycle 1, Cycle 3 and Cycle 6 (each cycle is of 28 days)|Number of participants with adverse events (AEs), To assess the safety and tolerability of saruparib administered in combination with ADT alone (Cohort A) and in combination with ADT + abiraterone (Cohort B)., Up to approximately 11 years",,AstraZeneca,Parexel,MALE,"ADULT, OLDER_ADULT",PHASE3,700,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2025-05-30,2033-03-31,2036-04-30,2025-05-01,,2025-05-30,"Research Site, Tucson, Arizona, 85741, United States|Research Site, La Jolla, California, 92037, United States|Research Site, Hialeah, Florida, 33016, United States|Research Site, Jeffersonville, Indiana, 47130, United States|Research Site, Voorhees, New Jersey, 08043, United States|Research Site, Hershey, Pennsylvania, 17033, United States|Research Site, Nashville, Tennessee, 37209, United States|Research Site, Austin, Texas, 78745, United States|Research Site, Salt Lake City, Utah, 84112, United States|Research Site, Seattle, Washington, 98109, United States|Research Site, Kingswood, 2747, Australia|Research Site, St Leonards, 2065, Australia|Research Site, Graz, 8036, Austria|Research Site, Innsbruck, 6020, Austria|Research Site, Vienna, 1020, Austria|Research Site, Bruxelles, 1200, Belgium|Research Site, Kortrijk, 8500, Belgium|Research Site, Roeselare, 8800, Belgium|Research Site, Wilrijk, 2610, Belgium|Research Site, Curitiba, 80810-050, Brazil|Research Site, Londrina, 86015-520, Brazil|Research Site, Pelotas, 96020-080, Brazil|Research Site, Porto Alegre, 90035-000, Brazil|Research Site, Porto Alegre, 91350200, Brazil|Research Site, Salvador, 41950640, Brazil|Research Site, Sao Paulo, 01246-000, Brazil|Research Site, Sao Paulo, 01327-001, Brazil|Research Site, Barrie, Ontario, L4M 6M2, Canada|Research Site, Brampton, Ontario, L6R 3J7, Canada|Research Site, Toronto, M4N 3M5, Canada|Research Site, Temuco, 4781156, Chile|Research Site, Hangzhou, 310022, China|Research Site, Ningbo, 315010, China|Research Site, Sichuan, 610041, China|Research Site, Xiamen, 361003, China|Research Site, Tampere, FI-33521, Finland|Research Site, Angers, 49100, France|Research Site, Bordeaux Cedex, 33000, France|Research Site, Clermont Ferrand, 63011, France|Research Site, Le Mans, 72000, France|Research Site, Marseille, 13273, France|Research Site, Montpellier, 34070, France|Research Site, Nice, 06100, France|Research Site, NÃ®mes, 30029, France|Research Site, Pierre-Benite, 69310, France|Research Site, Suresnes Cedex, 92151, France|Research Site, Vandoeuvre-lÃ¨s-nancy, 54511, France|Research Site, Villejuif, 94805, France|Research Site, Braunschweig, 38126, Germany|Research Site, Dresden, 1307, Germany|Research Site, Duisburg, 47169, Germany|Research Site, Essen, 45147, Germany|Research Site, Giessen, 35392, Germany|Research Site, Goettingen, 37075, Germany|Research Site, Hamburg, 20246, Germany|Research Site, Herne, 44625, Germany|Research Site, Marburg, 35043, Germany|Research Site, NÃ¼rnberg, 90419, Germany|Research Site, NÃ¼rtingen, 72622, Germany|Research Site, Regensburg, 93053, Germany|Research Site, Ulm, 89081, Germany|Research Site, WÃ¼rzburg, 97080, Germany|Research Site, Budapest, H-1145, Hungary|Research Site, Debrecen, 4032, Hungary|Research Site, Ansari Nagar, 110 029, India|Research Site, Delhi, 110085, India|Research Site, Nagpur, 440001, India|Research Site, Genoa, 16132, Italy|Research Site, Milano, 20132, Italy|Research Site, Milano, 20133, Italy|Research Site, Napoli, 80131, Italy|Research Site, Roma, 00144, Italy|Research Site, Roma, 00168, Italy|Research Site, Rozzano, 20089, Italy|Research Site, Verona, 37134, Italy|Research Site, Busan, 49241, Korea, Republic of|Research Site, Daegu, 41404, Korea, Republic of|Research Site, Goyang-si, 10408, Korea, Republic of|Research Site, Seoul, 03080, Korea, Republic of|Research Site, Seoul, 06273, Korea, Republic of|Research Site, Seoul, 06591, Korea, Republic of|Research Site, Seoul, 3722, Korea, Republic of|Research Site, Seoul, 5505, Korea, Republic of|Research Site, Batu Caves, 68100, Malaysia|Research Site, Kuala Lumpur, 59100, Malaysia|Research Site, Pulau Pinang, 10450, Malaysia|Research Site, Lima, 15036, Peru|Research Site, Lima, LIMA 29, Peru|Research Site, Lima, Lima 34, Peru|Research Site, Gdynia, 81-519, Poland|Research Site, Gliwice, 44-101, Poland|Research Site, Koszalin, 75-581, Poland|Research Site, Krakow, 30-727, Poland|Research Site, PiotrkÃ³w Trybunalski, 97-300, Poland|Research Site, Barcelona, 08041, Spain|Research Site, Girona, 17007, Spain|Research Site, Madrid, 28040, Spain|Research Site, Madrid, 28046, Spain|Research Site, MÃ¡laga, 29010, Spain|Research Site, Sabadell, 08208, Spain|Research Site, Santander, 39008, Spain|Research Site, Valencia, 46009, Spain|Research Site, Valencia, 46014, Spain|Research Site, Stockholm, 112 81, Sweden|Research Site, Stockholm, 141 86, Sweden|Research Site, Kaohsiung, 83301, Taiwan|Research Site, Tainan, 704, Taiwan|Research Site, Taoyuan, 333, Taiwan|Research Site, Khon Kaen, 40002, Thailand|Research Site, Muang, 50200, Thailand|Research Site, Songkhla, 90110, Thailand|Research Site, Ankara, 06520, Turkey|Research Site, Istanbul, 34010, Turkey|Research Site, Karsiyaka, 35575, Turkey",
NCT04380636,Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012),https://clinicaltrials.gov/study/NCT04380636,,ACTIVE_NOT_RECRUITING,"The purpose of this study is to assess the efficacy and safety of pembrolizumab in combination with concurrent chemoradiation therapy followed by either pembrolizumab with olaparib placebo (Arm 1) or with olaparib (Arm 2) compared to concurrent chemoradiation therapy followed by durvalumab (Arm 3) in participants with unresectable, locally advanced NSCLC. Arms 1 and 2 will be studied in a double-blind design and Arm 3 will be open-label. The primary hypotheses are:

1. Pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab with olaparib is superior to concurrent chemoradiation therapy followed by durvalumab with respect to progression-free survival (PFS) and overall survival (OS)
2. Pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab is superior to concurrent chemoradiation therapy followed by durvalumab with respect to PFS and OS",NO,"Lung Neoplasms|Carcinoma, Non-Small-Cell Lung",BIOLOGICAL: Pembrolizumab|DRUG: Olaparib|DRUG: Placebo for olaparib|DRUG: Etoposide|DRUG: Carboplatin|DRUG: Cisplatin|DRUG: Paclitaxel|DRUG: Pemetrexed|RADIATION: Thoracic Radiotherapy|DRUG: Durvalumab,"Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR), PFS is defined as the time from randomization to the first documented disease progression or death due to any cause, whichever occurs first., Up to approximately 48 months|Overall Survival (OS), OS is the time from randomization to death due to any cause., Up to approximately 72 months","Incidence of Adverse Events (AE), An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention., Up to approximately 72 months|Discontinuation Rate of Study Intervention Due to an Adverse Event (AE), An AE is defined as as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention., Up to approximately 72 months|Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR), ORR is defined as the percentage of participants who have achieved a Complete Response (CR) or a Partial Response (PR)., Up to approximately 72 months|Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR), DOR is defined as the time from first documented evidence of Complete Response (CR) or a Partial Response (PR) until disease progression or death due to any cause, whichever occurs first., Up to approximately 72 months|Change from Baseline in EORTC Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status/Quality of Life (Items 29 and 30) Scale Score, The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions ""How would you rate your overall health during the past week?"" and ""How would you rate your overall quality of life during the past week?"" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status. The change from baseline in EORTC QLQ-C30 Items 29 and 30 scale scores will be presented., Baseline (at randomization) and at the end of study (approximately 72 months post randomization)|Change From Baseline in Cough Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer Module 13 (EORTC QLQ-LC13) Item 1 Score, The EORTC QLQ-LC13 is a supplemental lung cancer-specific questionnaire that includes a single-item scale score for cough (Item 1). For this item, individual responses to the question ""How much did you cough?"" are given on a 4-point scale (1=Not at all; 4=Very much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100, with a lower score indicating a better outcome. The change from baseline in the EORTC QLQ-LC13 cough scale score will be presented., Baseline (at randomization) and at the end of study (approximately 72 months post randomization)|Change From Baseline in Chest Pain Using the EORTC QLQ-LC13 Item 10 Score, The EORTC QLQ-LC13 is a supplemental lung cancer-specific questionnaire that includes a single-item scale score for chest pain (Item 10). For this item, individual responses to the question ""Have you had pain in your chest?"" are given on a 4-point scale (1=Not at all; 4=Very much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100, with a lower score indicating a better outcome. The change from baseline in the EORTC QLQ-LC13 chest pain scale score will be presented., Baseline (at randomization) and at the end of study (approximately 72 months post randomization)|Change From Baseline in Dyspnea Using the EORTC QLQ-C30 Item 8 Score, The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients and includes a single-item scale score for dyspnea (Item 8). Participant responses to the question ""Were you short of breath? are scored on a 4-point scale (1=not at all to 4=very much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100, with a lower score indicating a better outcome. The change from baseline in the EORTC QLQ-C30 dyspnea scale score will be presented., Baseline (at randomization) and at the end of study (approximately 72 months post randomization)|Change From Baseline in Physical Functioning Using the EORTC QLQ-C30 Items 1- 5 Score, The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. The physical functioning scale consists of participant responses to 5 questions regarding performance of daily activities \[1) strenuous activities; 2) long walks; 3) short walks; 4) bed/chair rest; and 5) needing help with eating, dressing, washing themselves or using the toilet\]. Participant responses are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100, with a higher score indicating a better quality of life. The change from baseline in the EORTC QLQ-C30 physical functioning scale score will be presented., Baseline (at randomization) and at the end of study (approximately 72 months post randomization)|Change from Baseline in Role Functioning Using the EORTC QLQ-C30 Items 6-7 Score, The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. The role functioning scale consists of participant responses to 2 questions regarding limitations in doing work or other activities and pursuing hobbies or leisure activities. Participant responses are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100, with a higher score indicating a better quality of life. The change from baseline in the EORTC QLQ-C30 role functioning scale score will be presented., Baseline (at randomization) and at the end of study (approximately 72 months post randomization)|Time to Deterioration (TTD) in HRQoL Using the EORTC QLQ-C30 Items 29 and 30 Score, TTD is defined as the time to first onset of a â¥10-point decrease from baseline for EORTC QLQ-C30 Items 29 and 30 scale scores. The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions ""How would you rate your overall health during the past week?"" and ""How would you rate your overall quality of life during the past week?"" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status., Up to approximately 72 months post randomization|TTD in Cough Using the EORTC QLQ-LC13 Item 1 Score, TTD is defined as the time to first onset of a â¥10-point decrease from baseline for EORTC QLQ-LC13 Item 1 scale score. The EORTC QLQ-LC13 is a supplemental lung cancer-specific questionnaire that includes a single-item scale score for cough (Item 1). For this item, individual responses to the question ""How much did you cough?"" are given on a 4-point scale (1=Not at all; 4=Very much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100, with a lower score indicating a better outcome., Up to approximately 72 months post randomization|TTD in Chest Pain Using the EORTC QLQ-LC13 Item 10 Score, TTD is defined as the time to first onset of a â¥10-point decrease from baseline for EORTC QLQ-LC13 Item 10 scale score. The EORTC QLQ-LC13 is a supplemental lung cancer-specific questionnaire that includes a single-item scale score for chest pain (Item 10). For this item, individual responses to the question ""Have you had pain in your chest?"" are given on a 4-point scale (1=Not at all; 4=Very much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100, with a lower score indicating a better outcome., Up to approximately 72 months post randomization|TTD in Dyspnea Using the EORTC QLQ-C30 Item 8 Score, TTD is defined as the time to first onset of a â¥10-point decrease from baseline for EORTC QLQ-C30 Item 8 scale score. The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients and includes a single-item scale score for dyspnea (Item 8). Participant responses to the question ""Were you short of breath? are scored on a 4-point scale (1=not at all to 4=very much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100, with a lower score indicating a better outcome., Up to approximately 72 months post randomization|TTD in Physical Functioning Using the EORTC QLQ-C30 Items 1- 5 Score, TTD is defined as the time to first onset of a â¥10-point decrease from baseline for EORTC QLQ-C30 Items 1-5 scale scores. The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. The physical functioning scale consists of participant responses to 5 questions regarding performance of daily activities \[1) strenuous activities; 2) long walks; 3) short walks; 4) bed/chair rest; and 5) needing help with eating, dressing, washing themselves or using the toilet\]. Participant responses are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100, with a higher score indicating a better quality of life., Up to approximately 72 months post randomization|TTD in Role Functioning Using the EORTC QLQ-C30 Items 6-7 Score, TTD is defined as the time to first onset of a â¥10-point decrease from baseline for EORTC QLQ-C30 Items 6-7 scale scores. The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. The role functioning scale consists of participant responses to 2 questions regarding limitations in doing work or other activities and pursuing hobbies or leisure activities. Participant responses are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100, with a higher score indicating a better quality of life., Up to approximately 72 months post randomization",,Merck Sharp & Dohme LLC,,ALL,"ADULT, OLDER_ADULT",PHASE3,870,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-07-06,2026-07-06,2027-02-15,2020-05-08,,2024-11-19,"University of South Alabama, Mitchell Cancer Institute ( Site 0003), Mobile, Alabama, 36604, United States|St. Bernards Medical Center ( Site 0089), Jonesboro, Arkansas, 72401, United States|St Joseph Heritage Healthcare-Oncology ( Site 0088), Fullerton, California, 92835, United States|Long Beach Memorial Medical Center ( Site 0006), Long Beach, California, 90806, United States|UCLA Hematology/Oncology - Santa Monica ( Site 0013), Los Angeles, California, 90404, United States|St. Joseph Heritage Healthcare Local Lab ( Site 0011), Santa Rosa, California, 95403, United States|Torrance Memorial Physician Network / Cancer Center ( Site 0093), Torrance, California, 90505, United States|Memorial Regional Hospital-Memorial Cancer Institute ( Site 0095), Hollywood, Florida, 33021, United States|Miami VA Healthcare System ( Site 0024), Miami, Florida, 33125, United States|Mid Florida Hematology and Oncology Center ( Site 0022), Orange City, Florida, 32763, United States|Orlando Health, UF Health Cancer Center Inc ( Site 0092), Orlando, Florida, 32806, United States|Fort Wayne Medical Oncology and Hematology ( Site 0094), Fort Wayne, Indiana, 46804, United States|Parkview Research Center ( Site 0032), Fort Wayne, Indiana, 46845, United States|Franciscan Health Lafayette East ( Site 0031), Lafayette, Indiana, 47905, United States|University of Kentucky ( Site 0096), Lexington, Kentucky, 40536, United States|Norton Brownsboro Hospital-Norton Cancer Institute - Brownsboro ( Site 0035), Louisville, Kentucky, 40241, United States|Pikeville Medical Center ( Site 0036), Pikeville, Kentucky, 41501, United States|Massachusetts General Hospital ( Site 0038), Boston, Massachusetts, 02114, United States|Henry Ford Hospital ( Site 0045), Detroit, Michigan, 48202, United States|VA St. Louis Health Care System ( Site 0047), Saint Louis, Missouri, 63106, United States|Washington University Siteman Cancer Center ( Site 0046), Saint Louis, Missouri, 63110, United States|CHI Health St. Francis ( Site 0053), Grand Island, Nebraska, 68803, United States|Rutgers Cancer Institute of New Jersey ( Site 0054), New Brunswick, New Jersey, 08901, United States|The Valley Hospital ( Site 0056), Paramus, New Jersey, 07652, United States|Montefiore Einstein Center ( Site 0083), Bronx, New York, 10467, United States|Novant Health Presbyterian ( Site 0081), Charlotte, North Carolina, 28204, United States|Duke University Medical Center ( Site 0050), Durham, North Carolina, 27710, United States|Piedmont Hematology-Oncology Associates ( Site 0080), Winston-Salem, North Carolina, 27103, United States|The Lindner Center for Research and Education at The Christ Hospital ( Site 0060), Cincinnati, Ohio, 45219, United States|Fox Chase Cancer Center ( Site 0063), Philadelphia, Pennsylvania, 19111, United States|Sanford Cancer Center Oncology Clinic ( Site 0066), Sioux Falls, South Dakota, 57104, United States|Veterans Affairs Puget Sound Health Care System [Seattle, WA] ( Site 0075), Seattle, Washington, 98108, United States|Cancer Care Northwest ( Site 0074), Spokane Valley, Washington, 99216, United States|Instituto MÃ©dico RÃ­o Cuarto ( Site 4003), RÃ­o Cuarto, Cordoba, X5800AEV, Argentina|Clinica Adventista Belgrano-Oncology ( Site 4002), Caba, 1430, Argentina|Queen Elizabeth II Health Sciences Centre ( Site 0100), Halifax, Nova Scotia, B3H 1V7, Canada|Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0102), Montreal, Quebec, H2X 3E4, Canada|CIUSSS Ouest de l Ile - St-Mary s Hospital ( Site 0108), Montreal, Quebec, H3T 1M5, Canada|McGill University Health Center - Research Institute ( Site 0114), Montreal, Quebec, H4A 3J1, Canada|Centre intÃ©grÃ© de cancÃ©rologie du CHU de QuÃ©bec UniversitÃ© Laval, HÃ´pital de l'Enfant-JÃ©sus ( Site 0, Quebec, G1J 1Z4, Canada|Centro InvestigaciÃ³n del CÃ¡ncer James Lind ( Site 0202), Temuco, Araucania, 4800827, Chile|OrlandiOncologia ( Site 0201), Santiago, Region M. De Santiago, 7500713, Chile|Bradfordhill ( Site 0200), Santiago, Region M. De Santiago, 8420383, Chile|Oncocentro ( Site 0203), Vina del Mar, Valparaiso, 2520598, Chile|Bradford Hill Norte ( Site 0204), Antofagasta, 1240000, Chile|Beijing Cancer Hospital ( Site 3224), Beijing, Beijing, 100001, China|Peking Union Medical College Hospital ( Site 3201), Beijing, Beijing, 100006, China|Cancer Hospital Chinese Academy of Medical Sciences ( Site 3213), Beijing, Beijing, 100021, China|Beijing Cancer Hospital ( Site 3212), Beijing, Beijing, 100142, China|Daping Hospital,Third Military Medical University ( Site 3235), Chongqing, Chongqing, 400042, China|Fujian Provincial Cancer Hospital ( Site 3226), Fuzhou, Fujian, 350014, China|The First Affiliated Hospital of Xiamen University ( Site 3219), Xiamen, Fujian, 361003, China|Peking University Shenzhen Hospital ( Site 3216), Shenzhen, Guangdong, 518036, China|Cancer Hospital Chinese Academy Of Medical Sciences. Shenzhen Center ( Site 3200), Shenzhen, Guangdong, 518116, China|Henan Cancer Hospital ( Site 3205), Zhengzhou, Henan, 450008, China|Wuhan Union Hospital ( Site 3222), Wuhan, Hubei, 430022, China|Hubei Cancer Hospital ( Site 3218), Wuhan, Hubei, 430079, China|Hunan Cancer Hospital ( Site 3238), Changsha, Hunan, 410006, China|Xiangya Hospital of Central South University ( Site 3637), Changsha, Hunan, 410008, China|Second Xiangya Hospital of Central-South University ( Site 3227), Changsha, Hunan, 410011, China|Hunan Cancer Hospital ( Site 3225), Changsha, Hunan, 410013, China|Jiangsu Cancer Hospital ( Site 3234), Nanjing, Jiangsu, 210000, China|The Second Affiliated Hospital of Nanchang University ( Site 3206), Nanchang, Jiangxi, 330006, China|Jilin Cancer Hospital ( Site 3230), Changchun, Jilin, 130000, China|Shanghai Chest Hospital ( Site 3207), Shangai, Shanghai, 200030, China|Zhongshan Hospital Fudan University ( Site 3220), Shanghai, Shanghai, 200032, China|Shanghai Pulmonary Hospital ( Site 3203), Shanghai, Shanghai, 200443, China|West China Hospital of Sichuan University ( Site 3202), Chengdu, Sichuan, 510115, China|Tianjin Medical University Cancer Institute & Hospital ( Site 3204), Tianjin, Tianjin, 300060, China|The 1st Affil Hosp of College of Medicine, Zhejiang Univ ( Site 3232), Hangzhou, Zhejiang, 310003, China|Masarykuv onkologicky ustav ( Site 2206), Brno, Brno-mesto, 656 53, Czechia|Fakultni nemocnice Ostrava ( Site 2201), Ostrava, Ostrava Mesto, 708 52, Czechia|Fakultni nemocnice Kralovske Vinohrady-Radioterapeuticka a onkologicka klinika ( Site 2200), PRague, Praha 10, 10034, Czechia|Fakultni nemocnice v Motole ( Site 2210), Praha, Praha, Hlavni Mesto, 150 06, Czechia|Nemocnice Na Plesi s.r.o. ( Site 2202), Nova Ves pod Plesi, Pribram, 262 04, Czechia|Krajska nemocnice Liberec, a.s. ( Site 2209), Liberec, 468 63, Czechia|Vseobecna fakultni nemocnice v Praze ( Site 2208), Praha 2, 128 08, Czechia|Nemocnice Na Bulovce ( Site 2205), Praha 8, 180 81, Czechia|North Estonia Medical Centre Foundation ( Site 1601), Tallin, Harjumaa, 13419, Estonia|Tartu University Hospital ( Site 1600), Tartu, Tartumaa, 50406, Estonia|Clinique Clairval ( Site 0802), Marseille, Bouches-du-Rhone, 13009, France|C.H.R.U. de Brest - Hopital Morvan ( Site 0806), Brest, Bretagne, 29200, France|Centre Hospitalier Annecy Genevois ( Site 0811), Epagny Metz Tessy, Haute-Savoie, 74730, France|Clinique Teissier Groupe ( Site 0808), Valenciennes, Nord, 59304, France|Hopital Avicenne ( Site 0803), Bobigny, Seine-Saint-Denis, 93000, France|Clinique de l'Europe-Service de pneumologie ( Site 0816), Amiens, Somme, 80000, France|H.I.A. Sainte-Anne ( Site 0815), Toulon, Var, 83800, France|CHD Vendee ( Site 0807), La Roche sur Yon, Vendee, 85925, France|UniversitÃ¤tsmedizin GÃ¶ttingen - Georg-August-UniversitÃ¤t ( Site 0917), GÃ¶ttingen, Niedersachsen, 37075, Germany|Johannes Wesling Klinikum Minden ( Site 0908), Minden, Nordrhein-Westfalen, 32429, Germany|GEHO Muenster ( Site 0910), Muenster, Nordrhein-Westfalen, 48153, Germany|Johanna Etienne Hospital-Klinik fÃ¼r Onkologie ( Site 0916), Neuss, Nordrhein-Westfalen, 41462, Germany|LungenClinic Grosshansdorf GmbH ( Site 0901), Grosshansdorf, Schleswig-Holstein, 22927, Germany|Zentralklinik Bad Berka GmbH ( Site 0905), Bad Berka, Thuringen, 99437, Germany|Universitaetsklinikum Jena ( Site 0911), Jena, Thuringen, 07747, Germany|Charite-Universitaetsmedizin Berlin Campus Virchow-Klinikum ( Site 0900), Berlin, 13353, Germany|Katholisches Marienkrankenhaus gGmbH ( Site 0902), Hamburg, 22087, Germany|Bacs-Kiskun Megyei Korhaz-Onkoradiologiai Kozpont ( Site 2302), KecskemÃ©t, Bacs-Kiskun, 6000, Hungary|Bekes Megyei Kozponti Korhaz - Pandy Kalman Tagkorhaza ( Site 2303), Gyula, Bekes, 5700, Hungary|Petz Aladar Megyei Oktato Korhaz ( Site 2306), Gyor, Gyor-Moson-Sopron, 9024, Hungary|Orszagos Koranyi Pulmonologiai Intezet ( Site 2305), Budapest, 1121, Hungary|OrszÃ¡gos KorÃ¡nyi PulmonolÃ³giai IntÃ©zet-VI. TÃ¼dÃ¶belosztÃ¡ly Ã©s BroncholÃ³gia ( Site 2309), Budapest, 1121, Hungary|Azienda Ospedaliera Umberto I- Torrette ( Site 1009), Torrette, Ancona, 60126, Italy|Azienda Ospedaliero Universitaria Careggi ( Site 1001), Florence, Firenze, 50134, Italy|Istituto Clinico Humanitas Research Hospital ( Site 1000), Rozzano, Lombardia, 20089, Italy|Azienda Ospedaliera Vito Fazzi ( Site 1003), Lecce, 73100, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 1008), Milano, 20133, Italy|Policlinico di Modena ( Site 1007), Modena, 41124, Italy|Policlinico Agostino Gemelli ( Site 1002), Roma, 00168, Italy|A.O.U. Santa Maria della Misericordia di Udine ( Site 1004), Udine, 33100, Italy|Kurume University Hospital ( Site 3112), Kurume, Fukuoka, 830-0011, Japan|Kobe Minimally Invasive Cancer Center ( Site 3100), Kobe, Hyogo, 650-0046, Japan|Kanagawa Cancer Center ( Site 3101), Yokohama, Kanagawa, 241-8515, Japan|Kansai Medical University Hospital ( Site 3103), Hirakata, Osaka, 573-1191, Japan|Osaka Medical and Pharmaceutical University Hospital ( Site 3110), Takatsuki, Osaka, 5698686, Japan|National Hospital Organization Kyushu Cancer Center ( Site 3104), Fukuoka, 811-1395, Japan|Niigata Cancer Center Hospital ( Site 3109), Niigata, 951-8566, Japan|Osaka International Cancer Institute ( Site 3106), Osaka, 540-0008, Japan|Juntendo University Hospital ( Site 3111), Tokyo, 113-0033, Japan|Tokyo Metropolitan Komagome Hospital ( Site 3108), Tokyo, 113-8677, Japan|The Cancer Institute Hospital of JFCR ( Site 3107), Tokyo, 135-8550, Japan|Showa University Hospital ( Site 3105), Tokyo, 142-8666, Japan|Chungbuk National University Hospital ( Site 2802), Cheongju-si, Chungbuk, 28644, Korea, Republic of|National Cancer Center ( Site 2800), Goyang-si, Kyonggi-do, 10408, Korea, Republic of|The Catholic University of Korea St. Vincent s Hospital ( Site 2805), Gyeonggi-do, Kyonggi-do, 16247, Korea, Republic of|Seoul National University Bundang Hospital ( Site 2801), Seongnam-si, Kyonggi-do, 13620, Korea, Republic of|Ajou University Hospital ( Site 2803), Suwon-si, Kyonggi-do, 16499, Korea, Republic of|Gyeongsang National University Hospital ( Site 2804), Jinju-si, Kyongsangnam-do, 52727, Korea, Republic of|Keimyung University Dongsan Hospital ( Site 2807), Daegu, Taegu-Kwangyokshi, 42601, Korea, Republic of|Kangbuk Samsung Hospital ( Site 2806), Seoul, 03181, Korea, Republic of|Severance Hospital Yonsei University Health System ( Site 2808), Seoul, 03722, Korea, Republic of|Pauls Stradins Clinical University Hospital ( Site 1501), Riga, 1002, Latvia|Riga East Clinical University Hospital ( Site 1500), Riga, 1079, Latvia|Hospital of Lithuanian University of Health Sciences Kauno klinikos-Pulmonology ( Site 4201), Kaunas, Kauno Apskritis, 50161, Lithuania|National Cancer Institute-Department of Thoracic Surgery and Oncology ( Site 4200), Vilnius, Vilniaus Miestas, 08660, Lithuania|Hospital Civil de Guadalajara Fray Antonio Alcalde ( Site 0500), Guadalajara, Jalisco, 44280, Mexico|Hospital Universitario ""Dr. Jose Eleuterio Gonzalez"" ( Site 0508), Monterrey, Nuevo Leon, 64460, Mexico|CLIMERS Clinical Medical Research ( Site 0506), Orizaba, Veracruz, 94300, Mexico|Instituto Nacional de Cancerologia ( Site 0502), Tlalpan, 14080, Mexico|Akershus Universitetssykehus HF ( Site 1106), Lorenskog, Akershus, 1478, Norway|Vestre Viken HF Drammen Sykehus ( Site 1101), Drammen, Buskerud, 3004, Norway|Sykehuset Oestfold ( Site 1107), Gralum, Ostfold, 1714, Norway|Helse Stavanger HF Stavanger Universitetssjukehus ( Site 1103), Stavanger, Rogaland, 4011, Norway|Oslo Universitetssykehus HF. Ulleval ( Site 1100), Oslo, 0450, Norway|Hospital Nacional Carlos Alberto Seguin Escobedo ESSALUD ( Site 0604), Arequipa, Ariqipa, 04001, Peru|Oncosalud ( Site 0605), Lima, Muni Metro De Lima, 15036, Peru|Detecta ClÃ­nica ( Site 0607), Surquillo, Muni Metro De Lima, 15038, Peru|IPOR Instituto Peruano de OncologÃ­a & Radioterapia ( Site 0606), Lima, 15036, Peru|Clinica San Gabriel ( Site 0601), Lima, 15088, Peru|Hospital Nacional Cayetano Heredia ( Site 0602), Lima, 15102, Peru|Mazowiecki Szpital WojewÃ³dzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 2404), Siedlce, Mazowieckie, 08-110, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (, Warszawa, Mazowieckie, 02-781, Poland|Szpital Morski im. PCK. Szpitale Pomorskie Sp. Z o.o ( Site 2400), Gdynia, Pomorskie, 81-519, Poland|SPZOZ MSWIA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie ( Site 2401), Olsztyn, Warminsko-mazurskie, 10-228, Poland|Spitalul Universitar de Urgenta Bucuresti ( Site 2508), Bucharest, Bucuresti, 050098, Romania|Gral Medical SRL-Medical Oncology ( Site 2511), BucureÈti, Bucuresti, 031422, Romania|Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 2506), Cluj Napoca, Cluj, 400015, Romania|S.C. Radiotherapy Center Cluj S.R.L ( Site 2503), Comuna Floresti, Cluj, 407280, Romania|Centrul de Oncologie ""SfÃ¢ntul Nectarie""-Medical Oncology ( Site 2510), Craiova, Dolj, 200746, Romania|Radiology Therapeutic Center-Oncology ( Site 2502), Otopeni, Ilfov, 075100, Romania|Policlinica Oncomed SRL ( Site 2504), Timisoara, Timis, 300239, Romania|S C Oncocenter Oncologie Clinica S R L-Medical Oncology ( Site 2509), TimiÈoara, Timis, 300166, Romania|S.C.Focus Lab Plus S.R.L ( Site 2500), Bucuresti, 022548, Romania|Spitalul Clinic Judetean De Urgenta Constanta ( Site 2501), Constanta, 900591, Romania|Institutul Regional de Oncologie Iasi ( Site 2505), Iasi, 700483, Romania|Chelyabinsk Regional Clinical Oncological Dispensary ( Site 1913), Chelyabinsk, Chelyabinskaya Oblast, 454087, Russian Federation|MSROI named after P.A. Hertsen branch of FSBI NMRC Radiology ( Site 1903), Moscow, Moskva, 125284, Russian Federation|Nizhniy Novgorod Region Oncology Dispensary ( Site 1914), Nizhniy Novgorod, Nizhegorodskaya Oblast, 603081, Russian Federation|Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 1905), Saint-Petersburg, Sankt-Peterburg, 197758, Russian Federation|Medical institute named after Berezin Sergey ( Site 1906), St. Petersburg, Sankt-Peterburg, 197758, Russian Federation|Sverdlovsk Regional Oncology Hospital ( Site 1909), Ekaterinburg, Sverdlovskaya Oblast, 620036, Russian Federation|Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 1911), Kazan, Tatarstan, Respublika, 420029, Russian Federation|Yaroslavl Regional SBIH Clinical Oncology Hospital ( Site 1910), Yaroslavl, Yaroslavskaya Oblast, 150054, Russian Federation|Hospital Universitario Puerta de Hierro (Majadahonda) ( Site 1202), Majadahonda, Madrid, 28222, Spain|Hospital Universitario Quiron Madrid ( Site 1200), Pozuelo de Alarcon, Madrid, 28223, Spain|H.R.U MÃ¡laga - Hospital General ( Site 1206), MÃ¡laga, Malaga, 29011, Spain|H.U. Vall de Hebron ( Site 1201), Barcelona, 08035, Spain|Hospital Clinic de Barcelona ( Site 1204), Barcelona, 08036, Spain|Hospital Universitario Virgen Macarena ( Site 1205), Sevilla, 41009, Spain|Hospital Universitario La Fe ( Site 1203), Valencia, 46026, Spain|Chulalongkorn University ( Site 3003), Bangkok, Krung Thep Maha Nakhon, 10330, Thailand|Ramathibodi Hospital. ( Site 3000), Bangkok, Krung Thep Maha Nakhon, 10400, Thailand|Chiang Mai University Maharaj Nakorn Chiang Mai Hospital ( Site 3001), Chiang Mai, 50200, Thailand|Srinagarind Hospital. Khon Kaen University ( Site 3002), Khon Kaen, 40002, Thailand|Ankara Bilkent Sehir Hastanesi ( Site 2002), Ankara, Adana, 06800, Turkey|Memorial Ankara Hastanesi ( Site 2006), Ankara, 06520, Turkey|Istanbul Uni. Cerrahpasa Tip Fakultesi ( Site 2000), Istanbul, 34098, Turkey|Medipol Universite Hastanesi ( Site 2003), Istanbul, 34214, Turkey|GÃ¶ztepe Prof. Dr. SÃ¼leyman YalÃ§Ä±n Åehir Hastanesi-oncology ( Site 2001), Istanbul, 34722, Turkey|Ege University Medical Faculty ( Site 2005), Izmir, 35100, Turkey|Medical center Medikal Plaza of Ecodnipro LLC ( Site 2107), Dnipro, Dnipropetrovska Oblast, 49055, Ukraine|SOGrigoriev Inst for Med Radiolgy and Oncology of NAMS of Ukraine-Clinical oncology and hematology (, Kharkiv, Kharkivska Oblast, 61024, Ukraine|Communal nonprofit enterprise ""Kherson Regional Oncology Dispensary"" of Kherson Regional Council (, Antonivka Village, Khersonska Oblast, 73000, Ukraine|LLC Ukrainian Center of Tomotherapy ( Site 2105), Kropyvnytskyi, Kirovohradska Oblast, 25011, Ukraine|Medical Center of Yuriy Spizhenko LLC.-Clinical Trial ( Site 2104), Kapitanivka Village, Kyivska Oblast, 08111, Ukraine|SNPE National Cancer Institute ( Site 2101), Kyiv, Kyivska Oblast, 03022, Ukraine|Medical Center Verum ( Site 2106), Kyiv, Kyivska Oblast, 03039, Ukraine|Kyiv City Clinical Oncology Center ( Site 2100), Kyiv, 03115, Ukraine|Weston Park Hospital ( Site 1406), Sheffield, Derbyshire, S10 2SJ, United Kingdom|University College Hospital NHS Foundation Trust ( Site 1403), London-Camden, London, City Of, NW1 2PG, United Kingdom|Guys and St Thomas NHS Foundation Trust ( Site 1410), London, London, City Of, SE1 9RT, United Kingdom|Royal Marsden Hospital (Sutton) ( Site 1407), London, Surrey, SM2 5PT, United Kingdom|Southampton General Hospital ( Site 1400), Southampton, Worcestershire, SO16 6YD, United Kingdom|Leeds Teaching Hospitals NHS Trust ( Site 1401), Leeds, LS9 7TF, United Kingdom|Christie NHS Foundation Trust ( Site 1409), Manchester, M20 4BX, United Kingdom",
NCT04139135,A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer,https://clinicaltrials.gov/study/NCT04139135,,UNKNOWN,"This is a two-arm, randomized, double-blinded, multicenter phase III clinical study to evaluate the efficacy of HLX10 combined with chemotherapy versus placebo combined with chemotherapy for neoadjuvant/adjuvant treatment of gastric cancer.

Subjects will be randomized to the following two arms at 1: 1 ratio:

* Arm A (HLX10 arm): HLX10 combined with chemotherapy will be adopted in the neoadjuvant treatment phase, and HLX10 monotherapy will be administered in the adjuvant treatment phase;
* Arm B (control arm): Placebo combined with chemotherapy will be given in the neoadjuvant treatment phase, and chemotherapy alone will be administered during the adjuvant treatment phase.

Chemotherapy regimen SOX (oxaliplatin + tegafor gimeracil oteracil potassium (S-1)) will be used in the neoadjuvant treatment phase in Arm A and B, and in the adjuvant treatment phase in Arm B.

After randomization, subjects will receive a total of 3 cycles of neoadjuvant treatment with the mentioned treatment regimen.Surgery will be performed within 3-6 weeks after the last cycle of neoadjuvant treatment.All subjects who have completed the surgery will be unblinded after surgery, and adjuvant treatment will be started 3 to 12 weeks after surgery. Subjects randomized to Arm A (HLX10 arm) will continue to receive HLX10 monotherapy for up to 17 cycles (12 months).Subjects in Arm B after surgery (control arm) will continue to use chemotherapy alone (oxaliplatin + S-1) for 5 cycles.",NO,Gastric Cancer,DRUG: HLX10|DRUG: Placebos,"EFS, event-free survival (assessed by independent radiological review committee (IRRC) based on RECIST v1.1), from randomizationuntil firstly confirmed and recorded disease progression or death (whichever occurs earlier),assessed up to 3 years","EFS, Event-free survival (assessed by the investigator per RECIST v1.1 criteria), from randomizationuntil firstly confirmed and recorded disease progression or death (whichever occurs earlier)ï¼assessed up to 3 years|DFS, Disease-free survival (assessed by the investigator per RECIST v1.1 criteria), from the start of surgery to disease recurrence or death (for any reason)ï¼assessed up to 3 years|pCR rate, Pathological complete response (pCR) rate (assessed by central pathology laboratory and the site), after surgeryï¼an average of 6 months|5-year OS rate, 5-year overall survival (OS) rate, OS is the time from randomization to death (of any cause)ï¼assessed up to 5 years",,Shanghai Henlius Biotech,,ALL,"ADULT, OLDER_ADULT",PHASE3,642,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-12-12,2023-10,2024-10,2019-10-25,,2022-06-06,"Peking University shenzhen hospital, Shenzhen, Guangdong, China|Affiliated Hospital of Hebei University, Baoding, China|Beijing Cancer Hospital, Beijing, China|China PLA General Hospital, Beijing, China|Peking University International Hospital, Beijing, China|Peking University Third Hospital, Beijing, China|The First Affiliated Hospital of Bengbu Medical College, Bengbu, China|Cangzhou People's Hospital, Cangzhou, China|Anhui Provincial Hospital, Hefei, China|The First Affiliated Hospital of Anhui Medical University, Hefei, China|Linyi Cancer Hospital, Linyi, China|The Fourth Hospital of Hebei Medical University, Shijia Zhuang, China|Shanxi Provincial People's Hospital, Taiyuan, China|Tianjin Medical University Institute & Hospital, Tianjin, China|Xingtai People's Hospital, Xingtai, China",
NCT03924856,Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866),https://clinicaltrials.gov/study/NCT03924856,KEYNOTE-866,ACTIVE_NOT_RECRUITING,A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eligible patients.,NO,Bladder Cancer,DRUG: Pembrolizumab|DRUG: Gemcitabine|DRUG: Cisplatin|PROCEDURE: Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])|DRUG: Placebo,"Event-Free Survival (EFS), EFS is defined as the time from randomization to the first occurrence of any of the following events: progression of disease that precludes RC surgery; failure to undergo RC surgery in participants with residual disease and any radiographical disease present; gross residual disease left behind at the time of surgery; local or distant recurrence based on investigator assessments and/or biopsy, or death due to any cause., Up to approximately 60 months","Pathologic Complete Response (pCR) Rate, pCR rate is defined as the percentage of participants having pCR. pCR is defined as absence of viable tumor (pT0N0) in examined tissue from RC and PLND, as assessed by blinded independent central review (BICR)., Up to approximately 72 months|Overall Survival (OS), Overall survival is defined as the time from randomization to death due to any cause., Up to approximately 72 months|Disease-Free Survival (DFS), DFS is defined as the time from post-surgery baseline scan until the first occurrence of either local or distant recurrence as assessed by investigator by CT or MRI and/or computerized tomography (CT) or magnetic resonance imaging (MRI) and or biopsy or death from any cause., From approximately 20 weeks up to approximately 72 months|Pathologic Downstaging (pDS) Rate, pDS rate is defined as the percentage of participants having pDS. pDS is defined as participants with a tumor classification of \<pT2 (includes pT0, pTis, pTa, pT1) and N0 in examined tissue from RC plus PLND as assessed by BICR., Up to approximately 72 months|Number of Participants Who Experienced an Adverse Event (AE), An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study., Up to approximately 72 months|Number of Participants Who Discontinued Study Treatment Due to an AE, An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study., Up to approximately 12 months|Number of Participants Who Experienced Perioperative Complications, An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study., Up to approximately 12 months|Change in Patient-Reported Outcomes from Baseline in Total Score of Functional Assessment of Cancer Therapy - General (FACT-G), The FACT-G is a health-related quality of life (HRQoL) 27-item questionnaire in patients being treated for cancer. The FACT-G subscales include Physical Well-Being (PWB), Social/Family Well-Being (SWB), Emotional Well-Being (EWB), and Functional Well-Being (FWB). All items are scored on a 5-point Likert scale of 0 to 4, with higher scores indicating higher HRQoL. The total score can range from 0 to 108., Baseline, Up to approximately 72 months|Change in Patient-Reported Outcomes from Baseline in Total Score of FACT-Bladder- (FACT-BI-Cys), Total Score of FACT BI-Cys is the sum of FACT-G total score and FACT-Bl-Cys score. FACT-Bl-Cys contains 17 items on the bowel, bladder, and sexual symptoms following cystectomy. The FACT-G is a health-related quality of life (HRQoL) 27-item questionnaire in patients being treated for cancer. The FACT-G subscales include Physical Well-Being (PWB), Social/Family Well-Being (SWB), Emotional Well-Being (EWB), and Functional Well-Being (FWB). All items are scored on a 5-point Likert scale of 0 to 4, with higher scores indicating higher HRQoL. The total score of FACT-Bl-Cys can range from 0 to 168., Baseline, Up to approximately 72 months|Change in Patient-Reported Outcomes from Baseline in FACT-BI-Cys-Trial Outcome Index (TOI), FACT-Bl-Cys Trial Outcome Index (TOI) is the sum of FACT-G PWB score, FWB score, and FACT-Bl-Cys score. FACT-Bl-Cys contains 17 items on the bowel, bladder, and sexual symptoms following cystectomy. The FACT-G is a health-related quality of life (HRQoL) 27-item questionnaire in patients being treated for cancer. The FACT-G subscales include Physical Well-Being (PWB), Social/Family Well-Being (SWB), Emotional Well-Being (EWB), and Functional Well-Being (FWB). All items are scored on a 5-point Likert scale of 0 to 4, with higher scores indicating higher HRQoL. The total score of FACT-Bl-Cys TOI can range from 0 to 116., Baseline, Up to approximately 72 months|Change in Patient-Reported Outcomes from Baseline in EuroQol Five-Dimensional Questionnaire (EQ-5D-5L) Visual Analog Score (VAS), The EQ-5D-5L is a standardized instrument for use as a measure of health outcome. In the EQ-5D-5L VAS, the participant rates his or her general state of health at the time of the assessment on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state., Baseline, Up to approximately 72 months|Time to Deterioration (TTD) in the Total Score of FACT-G, The FACT-G is a health-related quality of life (HRQoL) 27-item questionnaire in patients being treated for cancer. The FACT-G subscales include Physical Well-Being (PWB), Social/Family Well-Being (SWB), Emotional Well-Being (EWB), and Functional Well-Being (FWB). All items are scored on a 5-point Likert scale of 0-4, with higher scores indicating higher HRQoL. TTD is defined as the time from baseline to the first onset of patient-reported outcomes (PRO) deterioration. For the FACT-G questionnaire, deteriorations are defined as a decrease of 7 points or more (out of 108) from baseline in total score., Up to approximately 72 months|TTD in EQ-5D-5L VAS, The EQ-5D-5L is a standardized instrument for use as a measure of health outcome and includes 5 health state dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. In the EQ-5D-5L VAS, the participant rates his or her general state of health at the time of the assessment on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. TTD is defined as the time from baseline to the first onset of PRO deterioration. For the EQ 5D-5L, deterioration is defined as a decrease of 7 points or more from baseline in the VAS., Up to approximately 72 months",,Merck Sharp & Dohme LLC,,ALL,"ADULT, OLDER_ADULT",PHASE3,907,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-06-13,2025-09-02,2026-09-01,2019-04-23,,2025-03-24,"Scripps MD Anderson ( Site 0010), La Jolla, California, 92037, United States|Providence Saint John's Health Center ( Site 0075), Santa Monica, California, 90404, United States|Georgetown University Medical Center ( Site 0022), Washington, District of Columbia, 20007, United States|AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlando ( Site 0005), Orlando, Florida, 32804, United States|Parkview Cancer Institute ( Site 0077), Fort Wayne, Indiana, 46845, United States|Indiana University Melvin and Bren Simon Cancer Center ( Site 0004), Indianapolis, Indiana, 46202, United States|Ochsner Medical Center ( Site 0049), New Orleans, Louisiana, 70121, United States|New England Cancer Specialists ( Site 0070), Scarborough, Maine, 04074, United States|UMass Memorial Medical Center ( Site 0051), Worcester, Massachusetts, 01655, United States|Henry Ford Hospital ( Site 0039), Detroit, Michigan, 48202, United States|Mercy Hospital Saint Louis ( Site 0064), Saint Louis, Missouri, 63141, United States|Morristown Medical Center ( Site 0015), Morristown, New Jersey, 07960, United States|UNM Comprehensive Cancer Center-Clinical Research Office ( Site 0045), Albuquerque, New Mexico, 87106, United States|New York University Perlmutter Cancer Center ( Site 0008), New York, New York, 10016, United States|University Hospitals Cleveland Medical Center ( Site 0038), Cleveland, Ohio, 44106, United States|Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0021), Tulsa, Oklahoma, 74146, United States|Portland VA Medical Center ( Site 0084), Portland, Oregon, 97239, United States|Allegheny General Hospital ( Site 0048), Pittsburgh, Pennsylvania, 15212, United States|MD Anderson Cancer Center ( Site 0063), Houston, Texas, 77030, United States|Central Texas Veterans Healthcare System ( Site 0057), Temple, Texas, 76504, United States|Inova Schar Cancer Institute ( Site 0007), Fairfax, Virginia, 22031, United States|Northwest Medical Specialties, PLLC ( Site 0061), Puyallup, Washington, 98373, United States|Seattle Cancer Care Alliance/Univ of Washington Medical Center ( Site 0033), Seattle, Washington, 98109, United States|Charleston Area Medical Center ( Site 0023), Charles Town, West Virginia, 25304, United States|Mid North Coast Cancer Institute ( Site 1256), Port Macquarie, New South Wales, 2444, Australia|Southside Cancer Care Centre ( Site 1252), Sydney, New South Wales, 2228, Australia|Cairns Base Hospital ( Site 1257), Cairns, Queensland, 4870, Australia|Eastern Health ( Site 1255), Box Hill, Victoria, 3128, Australia|Peninsula Health Frankston Hospital ( Site 1258), Frankston, Victoria, 3199, Australia|UZ Brussel ( Site 0358), Brussels, Bruxelles-Capitale, Region De, 1090, Belgium|Jessa Ziekenhuis ( Site 0360), Hasselt, Limburg, 3500, Belgium|CHU UCL Namur Site de Godinne ( Site 0354), Yvoir, Namur, 5530, Belgium|O.L.V. Ziekenhuis Aalst ( Site 0356), Aalst, Oost-Vlaanderen, 9300, Belgium|AZ Maria Middelares Gent ( Site 0353), Gent, Oost-Vlaanderen, 9000, Belgium|Tom Baker Cancer Centre ( Site 0100), Calgary, Alberta, T2N 4N2, Canada|Nova Scotia Health Authority ( Site 0109), Halifax, Nova Scotia, B3H 1V7, Canada|Kingston Health Sciences Centre ( Site 0103), Kingston, Ontario, K7L 2V7, Canada|Lakeridge Health ( Site 0104), Oshawa, Ontario, L1G 2B9, Canada|Sunnybrook Research Institute ( Site 0110), Toronto, Ontario, M4N 3M5, Canada|Princess Margaret Cancer Centre ( Site 0107), Toronto, Ontario, M5G 2M9, Canada|CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0105), Montreal, Quebec, H1T 2M4, Canada|Centre intÃ©grÃ© de cancÃ©rologie du CHU de QuÃ©bec UniversitÃ© Laval, HÃ´pital de l'Enfant-JÃ©sus ( Site 0, Quebec City, Quebec, G1J 1Z4, Canada|Herlev og Gentofte Hospital. ( Site 0402), Herlev, Hovedstaden, 2730, Denmark|Rigshospitalet University Hospital ( Site 0401), Kobenhavn, Hovedstaden, 2100, Denmark|Odense Universitetshospital ( Site 0403), Odense, Syddanmark, 5000, Denmark|CHU de Bordeaux- Hopital Saint Andre ( Site 0456), Bordeaux, Aquitaine, 33075, France|Centre Leon Berard ( Site 0465), Lyon, Auvergne, 69373, France|Centre Francois Baclesse ( Site 0459), Caen, Calvados, 14075, France|Centre Armoricain de Radiotherapie Imagerie medicale et Oncologie ( Site 0457), Plerin, Cotes-d Armor, 22190, France|Hopital Foch ( Site 0483), Suresnes, Hauts-de-Seine, 92150, France|CHU de Montpellier - Hopital Saint-Eloi ( Site 0469), Montpellier, Languedoc-Roussillon, 34295, France|Institut de Cancerologie de l Ouest Site Paul Papin ( Site 0453), Angers, Maine-et-Loire, 49000, France|Hopital Robert Schuman ( Site 0452), Metz, Moselle, 57070, France|Centre Jean Perrin ( Site 0460), Clermont-Ferrand, Puy-de-Dome, 63011, France|Clinique Victor Hugo ( Site 0463), Le Mans, Sarthe, 72000, France|CHU de Rouen ( Site 0493), Rouen, Seine-Maritime, 76031, France|Institut Sainte Catherine ( Site 0454), Avignon, Vaucluse, 84918, France|Klinikum der Eberhard-Karls-Universitaet Tuebingen ( Site 0502), Tuebingen, Baden-Wurttemberg, 72076, Germany|Universitaetsklinikum Erlangen ( Site 0505), Erlangen, Bayern, 91058, Germany|Universitaetsklinikum Magdeburg A.o.R. ( Site 0516), Magdeburg, Sachsen-Anhalt, 39120, Germany|Universitaetsklinikum Carl Gustav Carus ( Site 0519), Dresden, Sachsen, 01307, Germany|Universitaetsklinikum Schleswig-Holstein-Campus Lubeck ( Site 0512), Luebeck, Schleswig-Holstein, 23538, Germany|Charite Universitaetsmedizin Berlin ( Site 0515), Berlin, 10117, Germany|Vivantes Klinikum am Urban ( Site 0522), Berlin, 10967, Germany|Pecsi Tudomanyegyetem AOK ( Site 1009), Pecs, Baranya, 7624, Hungary|SZTE Szent-Gyorgyi Albert Klinikai Kozpont ( Site 1010), Szeged, Csongrad, 6720, Hungary|Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ( Site 1002), Szolnok, Jasz-Nagykun-Szolnok, 5004, Hungary|Bajcsy Zsilinszki Korhaz es Rendelointezet ( Site 1001), Budapest, 1106, Hungary|Debreceni Egyetem Klinikai Kozpont ( Site 1006), Debrecen, 4032, Hungary|Petz Aladar Megyei Oktato Korhaz ( Site 1012), Gyor, 9023, Hungary|Somogy Megyei Kaposi Mor Oktato Korhaz ( Site 1007), Kaposvar, 7400, Hungary|Cork University Hospital ( Site 0722), Cork, T12 DC4A, Ireland|Tallaght University Hospital ( Site 0710), Dublin, D24 DH74, Ireland|University Hospital Waterford ( Site 0723), Waterford, X91ER8E, Ireland|Ha Emek Medical Center ( Site 0808), Afula, 1834111, Israel|Soroka Medical Center ( Site 0806), Beer Sheva, 8410101, Israel|Rambam Health Care Campus-Oncology Division ( Site 0802), Haifa, 3109601, Israel|Shaare Zedek Medical Center ( Site 0809), Jerusalem, 9103102, Israel|Hadassah Ein Kerem Medical Center ( Site 0810), Jerusalem, 9112001, Israel|Meir Medical Center ( Site 0803), Kfar Saba, 4428164, Israel|Rabin Medical Center ( Site 0804), Petach Tikva, 4941492, Israel|Sheba Medical Center ( Site 0801), Ramat Gan, 5265601, Israel|Sourasky Medical Center ( Site 0807), Tel Aviv, 6423906, Israel|Yitzhak Shamir Medical Center ( Site 0805), Zerifin, 7030001, Israel|Policlinico Gemelli di Roma ( Site 0558), Roma, Abruzzo, 00168, Italy|Policlinico di Modena ( Site 0553), Modena, Emilia-Romagna, 41124, Italy|A.O.U. Policlinico Vittorio Emanuele - Presidio Gaspare Rodolico ( Site 0559), Catania, 95123, Italy|Istituto Nazionale Studio e Cura dei Tumori ( Site 0551), Milano, 20133, Italy|Istituto Nazionale Per Lo Studio E La Cura Dei Tumori ( Site 0552), Napoli, 80131, Italy|Fondazione Salvatore Maugeri IRCCS. ( Site 0554), Pavia, 27100, Italy|Azienda Ospedaliera San Camillo Forlanini ( Site 0560), Roma, 00152, Italy|Azienda Ospedaliera Santa Maria Terni ( Site 0557), Terni, 05100, Italy|Hirosaki University Hospital ( Site 1502), Hirosaki, Aomori, 036-8563, Japan|National Cancer Center Hospital East ( Site 1504), Kashiwa, Chiba, 2778577, Japan|Ehime University Hospital ( Site 1508), Toon, Ehime, 791-0295, Japan|Sapporo Medical University Hospital ( Site 1501), Sapporo, Hokkaido, 060-8543, Japan|University of Tsukuba Hospital ( Site 1503), Tsukuba, Ibaraki, 305-8576, Japan|Yokosuka Kyosai Hospital ( Site 1509), Yokosuka, Kanagawa, 238-8558, Japan|Nara Medical University Hospital ( Site 1510), Kashihara, Nara, 634-8522, Japan|Saitama Medical University International Medical Center ( Site 1505), Hidaka, Saitama, 350-1298, Japan|Chiba Cancer Center ( Site 1506), Chiba, 260-8717, Japan|Harasanshin Hospital ( Site 1515), Fukuoka, 812-0033, Japan|Hiroshima City Hiroshima Citizens Hospital ( Site 1513), Hiroshima, 730-8518, Japan|Nagano Municipal Hospital ( Site 1516), Nagano, 381-8551, Japan|Osaka Metropolitan University Hospital ( Site 1512), Osaka, 545-8586, Japan|Tokushima University Hospital ( Site 1514), Tokushima, 770-8503, Japan|Tokyo Medical and Dental University Hospital ( Site 1517), Tokyo, Japan|National Cancer Center ( Site 1354), Goyang-si, Kyonggi-do, 10408, Korea, Republic of|Seoul National University Bundang Hospital ( Site 1356), Seongnam-si, Kyonggi-do, 13620, Korea, Republic of|Korea University Anam Hospital ( Site 1351), Seoul, 02841, Korea, Republic of|Seoul National University Hospital ( Site 1352), Seoul, 03080, Korea, Republic of|Asan Medical Center ( Site 1355), Seoul, 05505, Korea, Republic of|Samsung Medical Center ( Site 1353), Seoul, 06351, Korea, Republic of|Centro de Urologia Avanzada del Noreste S.A. de C.V. ( Site 0254), Monterrey, Nuevo Leon, 66269, Mexico|Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V. ( Site 0300), Aguascalientes, 20010, Mexico|Centro Estatal de Cancerologia de Chihuahua ( Site 0253), Chihuahua, 31000, Mexico|Instituto Nacional de Cancerologia ( Site 0256), Tlalpan, 14080, Mexico|Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego ( Site 1062), Wroclaw, Dolnoslaskie, 50-556, Poland|Centrum Onkologii im.prof. F. Lukaszczyka w Bydgoszczy ( Site 1068), Bydgoszcz, Kujawsko-pomorskie, 85-796, Poland|Europejskie Centrum Zdrowia Otwock ( Site 1057), Otwock, Mazowieckie, 05-400, Poland|Luxmed Onkologia sp. z o. o. ( Site 1051), Warszawa, Mazowieckie, 01-748, Poland|Beskidzkie Centrum Onkologii im. Jana Pawla II ( Site 1060), Bielsko-Biala, Slaskie, 43-300, Poland|Clinic of Bashkortostan State Medical University ( Site 0869), Ufa, Baskortostan, Respublika, 450081, Russian Federation|Ivanovo Regional Oncology Dispensary ( Site 0852), Ivanovo, Ivanovskaya Oblast, 153040, Russian Federation|Krasnoyarsk Regional Clinical Oncological Dispensary ( Site 0861), Krasnoyarsk, Krasnoyarskiy Kray, 660133, Russian Federation|Kursk Regional Clinical Oncology Dispensary ( Site 0854), Kursk, Kurskaya Oblast, 305524, Russian Federation|FSBI """"United Hospital with Polyclinic"""" of the Administrative Department of the President of the Ru, Moscow, Moskva, 119285, Russian Federation|Central Clinical Hospital with outpatient Clinic ( Site 0856), Moscow, Moskva, 121359, Russian Federation|Bayandin Murmansk Regional Clinical Hospital ( Site 0859), Murmansk, Murmanskaya Oblast, 183057, Russian Federation|Volga District Medical Center Federal Medical and Biological Agency ( Site 0857), Nizhny Novgorod, Nizhegorodskaya Oblast, 603074, Russian Federation|Omsk Clinical Oncology Dispensary ( Site 0865), Omsk, Omskaya Oblast, 644013, Russian Federation|Leningrad Regional Oncology Center ( Site 0868), Saint Petersburg, Sankt-Peterburg, 188663, Russian Federation|Clinical Hospital Saint Luka ( Site 0867), St. Petersburg, Sankt-Peterburg, 194044, Russian Federation|Saratov State Medical University n.a. V.I.Razumovskiy ( Site 0866), Saratov, Saratovskaya Oblast, 410012, Russian Federation|Hospital San Pedro de Alcantara ( Site 0654), Caceres, Extremadura, 10003, Spain|H. de Gerona Dr. Josep Trueta ( Site 0651), Girona, Gerona, 17007, Spain|Hospital Universitario Ramon y Cajal ( Site 0660), Madrid, Madrid, Comunidad De, 28034, Spain|Hospital Universitario Quiron Madrid ( Site 0657), Pozuelo de Alarcon, Madrid, Comunidad De, 28223, Spain|Instituto Valenciano de Oncologia - IVO ( Site 0662), Valencia, Valenciana, Comunitat, 46009, Spain|Hospital del Mar ( Site 0653), Barcelona, 08003, Spain|Hospital Universitario San Carlos ( Site 0663), Madrid, 28040, Spain|Hospital Universitario La Paz ( Site 0661), Madrid, 28046, Spain|Hospital Nuestra Sra. de Valme ( Site 0658), Sevilla, 41014, Spain|Laenssjukhuset Ryhov ( Site 1205), Jonkoping, Jonkopings Lan, 551 85, Sweden|Akademiska Sjukhuset ( Site 1201), Uppsala, Uppsala Lan, 751 85, Sweden|Cancercentrum ( Site 1204), Umea, Vasterbottens Lan, 901 85, Sweden|Ramathibodi Hospital. ( Site 1451), Bangkok, Krung Thep Maha Nakhon, 10400, Thailand|Faculty of Medicine Siriraj Hospital ( Site 1452), Bangkok, Krung Thep Maha Nakhon, 10700, Thailand|Maharaj Nakorn Chiangmai Hospital ( Site 1453), Chiang Mai, 50200, Thailand|Srinagarind Hospital ( Site 1454), Khon Kaen, 40002, Thailand|Hacettepe Universitesi TÄ±p Fakultesi ( Site 0911), Ankara, 06100, Turkey|Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 0910), Istanbul, 34096, Turkey|TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 0906), Istanbul, 34722, Turkey|Universitesi Pendik Egitim ve Arastirma Hastanesi ( Site 0901), Istanbul, 34899, Turkey|Necmettin Erbakan Universitesi Meram Tip Fakultesi Hastanesi ( Site 0909), Konya, 42080, Turkey|Sakarya Universitesi Tip Fakultesi ( Site 0913), Sakarya, 54290, Turkey|Karadeniz Teknik Universitesi Tip Fakultesi Farabi Hastanesi ( Site 0904), Trabzon, 61080, Turkey|Cherkasy Regional Oncology Dispensary ( Site 0959), Cherkasy, Cherkaska Oblast, 18009, Ukraine|MI Dnipr Regional Clinical Hospital named after I.I. Mechnikov ( Site 0963), Dnipropetrovsk, Dnipropetrovska Oblast, 49005, Ukraine|Regional Oncological Hospital ( Site 0956), Dnipro, Dnipropetrovska Oblast, 49055, Ukraine|Dnipropetrovsk City Multidiscipline Clinical Hosp. 4 of DRC ( Site 0951), Dnipro, Dnipropetrovska Oblast, 49102, Ukraine|Reg. Clinical Center of Urology and Nephrology n.a. V. I. Shapoval ( Site 0969), Kharkiv, Kharkivska Oblast, 61037, Ukraine|CNPE ""Regional Center of Oncology"" ( Site 0958), Kharkiv, Kharkivska Oblast, 61070, Ukraine|National Cancer Institute of the MoH of Ukraine ( Site 0962), Kyiv, Kyivska Oblast, 03022, Ukraine|Lviv Regional Clinical Hospital ( Site 0955), Lviv, Lvivska Oblast, 79000, Ukraine|Lviv State Oncology Regional Treatment and Diagnostic Center ( Site 0967), Lviv, Lvivska Oblast, 79000, Ukraine|Kyiv City Clinical Oncology Center ( Site 0960), Kyiv, 03115, Ukraine|Aberdeen Royal Infirmary ( Site 0708), Aberdeen, Aberdeen City, AB25 2ZN, United Kingdom|Torbay Hospital ( Site 0704), Torquay, Devon, TQ2 7AA, United Kingdom|Kent and Canterbury Hospital ( Site 0709), Canterbury, England, CT1 3NG, United Kingdom|Lister Hospital ( Site 0715), Stevenage, Hertfordshire, SG1 4AB, United Kingdom|The Royal Marsden Foundation Trust ( Site 0702), London, London, City Of, SW3 6JJ, United Kingdom|Imperial College Healthcare NHS Trust ( Site 0721), London, London, City Of, W6 8RF, United Kingdom|Norfolk & Norwich University Hospital NHS Foundation Trust ( Site 0725), Norwich, Norfolk, NR4 7UY, United Kingdom|Royal Cornwall Hospital ( Site 0703), Truro, TR1 3LJ, United Kingdom",
NCT06943872,A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL),https://clinicaltrials.gov/study/NCT06943872,,RECRUITING,The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The study will also compare how well sonrotoclax plus rituximab works versus venetoclax plus rituxumab in treating adults with R/R CLL/SLL. The safety of these treatments will also be assessed.,NO,Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,DRUG: Sonrotoclax|DRUG: Obinutuzumab|DRUG: Rituximab|DRUG: Venetoclax,"Progression-Free Survival (PFS) as assessed by Blinded Independent Review Committee (BIRC) for Arm A versus Arm D, PFS is defined as the time from randomization to the date of progression or death, whichever occurs first., Up to approximately 51 months","Progression-Free Survival (PFS) as assessed by BIRC for Arm B versus Arm D, PFS is defined as the time from randomization to the date of progression or death, whichever occurs first., Up to approximately 69 months|Rate of uMRD4 for Arm A versus Arm D, The rate of undetectable minimal residual disease (uMRD4) in peripheral blood based on next-generation sequencing (NGS), Up to approximately 12 months|Complete Response Rate as assessed by BIRC for Arm A versus Arm D, Complete Response Rate (CRR) is defined as the percentage of participants that achieve a best response of complete response (CR) or complete response with incomplete hematopoietic recovery (CRi), Up to approximately 25 months|Overall Survival for Arm A versus Arm D, Overall survival (OS) is defined as the time from the date of randomization to the date of death, Up to approximately 84 months|PFS per Investigator Assessment (INV) for Arm B versus Arm D, PFS is defined as the time from randomization to the date of progression or death, whichever occurs first., Up to approximately 69 months|CRR per BIRC and by INV for Arm B versus Arm D, CRR is defined as the percentage of participants that achieve a best response of CR or CRi, Up to approximately 25 months|OS for Arm B versus Arm D, OS is defined as the time from the date of randomization to the date of death, Up to approximately 84 months|Rate of uMRD4 for Arm B versus Arm D, The rate of uMRD4 in peripheral blood based on NGS, Up to approximately 25 months|PFS per BIRC and by INV for Arm A versus Arm B, PFS is defined as the time from randomization to the date of progression or death, whichever occurs first., Up to approximately 69 months|CRR per BIRC and by INV for Arm A versus Arm B, CRR is defined as the percentage of participants that achieve a best response of CR or CRi, Up to approximately 25 months|OS for Arm A versus Arm B, OS is defined as the time from the date of randomization to the date of death, Up to approximately 84 months|Rate of uMRD4 for Arm A versus Arm B, The rate of uMRD4 in peripheral blood based on NGS, Up to approximately 25 months|Rate of uMRD4 for Arm A versus Arm D, The rate of uMRD4 in peripheral blood based on NGS, Up to approximately 25 months|CRR per INV for Arm A versus Arm D, CRR is defined as the percentage of participants that achieve a best response of CR or CRi, Up to approximately 25 months|PFS per INV for Arm A versus Arm D, PFS is defined as the time from randomization to the date of progression or death, whichever occurs first., Up to approximately 51 months|PFS per INV for Arm C versus Arm D, PFS is defined as the time from randomization to the date of progression or death, whichever occurs first., Up to approximately 69 months|CRR per INV for Arm C versus Arm D, CRR is defined as the percentage of participants that achieve a best response of CR or CRi, Up to approximately 25 months|OS for Arm C versus Arm D, OS is defined as the time from the date of randomization to the date of death, Up to approximately 84 months|Rate of uMRD4 for Arm C versus Arm D, The rate of uMRD4 in peripheral blood based on NGS, Up to approximately 25 months|Overall Response Rate (ORR) per BIRC and by INV, ORR is defined as the percentage of participants that achieve a best response of partial response (PR) or better, Up to approximately 25 months|Duration of Response (DOR) per BIRC and by INV, DOR is defined as the time from the date that response criteria were first met to the date of first documentation of disease progression or death, whichever occurs first, Up to approximately 69 months|Time to Response (TTR) per BIRC and by INV, TTR is defined as the time from the date of randomization to the date response criteria were first met, Up to approximately 25 months|Time to Next Anti-CLL/SLL Treatment (TTNT), TTNT is defined as the time from the date of randomization to the date of next anti-CLL/SLL treatment, Up to approximately 84 months|Rate of uMRD4, The rate of uMRD4 in peripheral blood based on NGS, Up to approximately 25 months|Change from Baseline in the European Organisation of Research and Treatment of Cancer-Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30) Global Health Status/Quality of Life and Physical Functioning Scales, The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 =Not at all (best) to 4 =Very Much (worst) and 2 questions answered on a 7-point scale where 1 =Very poor (worst) to 7 =Excellent (best). Higher scores in global health status (GHS) and functional scales indicate better health-related quality of life (HRQoL)., Baseline and up to approximately 69 months|Change from Baseline in EORTC QLQ for Chronic Lymphocytic Leukemia (EORTC QLQ-CLL17) Symptom Burden and Fatigue Scales, The EORTC QLQ-CLL17 is the CLL module of QLQ-C30 consisting of 17 items and comprising 3 scales: symptom burden due to disease and/or treatment (6 items), physical condition/fatigue (4 items), and worries/fears about health and functioning (7 items) Items are rated using a 4-point response scale (""not at all,"" ""a little,"" ""quite a bit,"" and ""very much"") and the recall period for all items is the past 7 days. Lower scores indicate better HRQoL., Baseline and up to approximately 69 months|Number of Participants with Treatment-Emergent Adverse Events (TEAEs), Number of participants with TEAEs, including laboratory values, vital signs, and physical examination findings, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0., From the first dose of study drug(s) to 30 days after the last dose of sonrotoclax or venetoclax, or 90 days after the last dose of obinutuzumab or rituximab; up to approximately 26 months",,BeiGene,German CLL Study Group,ALL,"ADULT, OLDER_ADULT",PHASE3,630,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2025-06,2029-09-30,2032-12-31,2025-04-24,,2025-06-13,"Chao Family Comprehensive Cancer Center, Orange, California, 92868-3201, United States|Stanford Cancer Institute, Palo Alto, California, 94304-2205, United States|Scripps Prebys Cancer Center, San Diego, California, 92103-2106, United States|Rocky Mountain Cancer Centers (Williams) Usor, Aurora, Colorado, 80012-5405, United States|Yale University, Yale Cancer Center, New Haven, Connecticut, 06520-8028, United States|Eastern Connecticut Hematology and Oncology, Norwich, Connecticut, 06360-2700, United States|University of Miami, Miami, Florida, 33136-2107, United States|Northwestern University, Chicago, Illinois, 60611, United States|Illinois Cancer Specialists (Niles) Usor, Niles, Illinois, 60714-5905, United States|Mission Cancer and Blood, Waukee, Iowa, 50263, United States|University of Louisville, Brown Cancer Center, Louisville, Kentucky, 40202, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, 70809-3738, United States|University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, 21201-1544, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215-5418, United States|The Cancer and Hematology Centers, Grand Rapids, Michigan, 49503-2563, United States|Mayo Clinic Rochester, Rochester, Minnesota, 55905-0001, United States|Memorial Sloan Kettering Cancer Center Mskcc, New York, New York, 10065-6800, United States|Clinical Research Alliance, Inc, Westbury, New York, 11590-5119, United States|University of North Carolina At Chapel Hill, Chapel Hill, North Carolina, 27514-4220, United States|Levine Cancer Center, Charlotte, North Carolina, 28204-2990, United States|Oncology Hematology Care Clinical Trials, Llc, Cincinnati, Ohio, 45245-1995, United States|Oncology Associates of Oregon Willamette Valley Cancer Center, Eugene, Oregon, 97401, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, 17033, United States|Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh, Pennsylvania, 15232-1309, United States|Tennessee Oncology, Nashville, Tennessee, 37205, United States|Texas Oncology Baylorcharles A Sammons Cancer Center, Dallas, Texas, 75246-2003, United States|Ut Southwestern Medical Center, Dallas, Texas, 75390-7208, United States|Texas Oncology San Antonio Medical Center Usor, San Antonio, Texas, 78240-5251, United States|Texas Oncology Tyler, Tyler, Texas, 75702-7522, United States|Northwest Cancer Specialist, Pc(Us Oncology Research), Vancouver, Washington, 98684-6930, United States|Hospital Aleman, Caba, 1425, Argentina|FUNDALEU, Caba, CP1114, Argentina|Instituto Alexander Fleming (Iaf), Ciudad Autonoma Buenos Aires, 1426, Argentina|Blacktown Cancer and Haematology Centre, Blacktown, New South Wales, 2148, Australia|St George Hospital, Kogarah, New South Wales, 2217, Australia|Northern Nsw Health District, Lismore, New South Wales, 2480, Australia|Macquarie University, North Ryde, New South Wales, 2109, Australia|Genesiscare North Shore, St Leonards, New South Wales, 2065, Australia|Wollongong Private Hospital, Wollongong, New South Wales, 2500, Australia|Sunshine Coast Hospital and Health Service, Birtinya, Queensland, 4575, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, 4102, Australia|Monash Health, Clayton, Victoria, 3168, Australia|St Vincents Hospital Melbourne, Fitzroy, Victoria, 3065, Australia|Peter Maccallum Cancer Centre, Melbourne, Victoria, 3000, Australia|The Alfred Hospital, Melbourne, Victoria, 3004, Australia|Rockingham Hospital, Cooloongup, Western Australia, 6168, Australia|Perth Blood Institute, West Perth, Western Australia, 6005, Australia|Landeskrankenhaus Universitaetskliniken Innsbruck, Innsbruck, 6020, Austria|Medical University Vienna Oncology, Wien, 1090, Austria|Hanusch Krankenhaus, Wien, 1140, Austria|Cliniques Universitaires Saint Luc, Brussels, 1200, Belgium|Uz Antwerpen, Edegem, 2650, Belgium|University Hospitals Leuven, Leuven, 3000, Belgium|CETUS, Belo Horizonte, 30110-022, Brazil|Universidade de Campinas Centro de Hematologia E Hemoterapia, Campinas, 13083-878, Brazil|Hospital Erasto Gaertner, Curitiba, 81520-060, Brazil|Complexo Hospitalar de Niteroi, Niteroi, 24020-096, Brazil|Irmandade Da Santa Casa de Misericordia Hospital Porto Alegre, Porto Alegre, 90020-090, Brazil|Hospital Sao Lucas, Rio de Janeiro, 22061-080, Brazil|Instituto Dor de Pesquisa E Ensino Rio de Janeiro, Rio de Janeiro, 22281-100, Brazil|Hospital Santa Izabel, Salvador, 40050-410, Brazil|Hospital Samaritano Sao Paulo, Sao Paulo, 01232-010, Brazil|Hospital Nove de Julho Dasa, Sao Paulo, 01409-001, Brazil|Instituto Brasileiro de Controle Do Cancer, Sao Paulo, 04014-002, Brazil|Instituto Dor de Pesquisa E Ensino Sao Paulo, Sao Paulo, 04501-000, Brazil|Hcfmusp Servico de Hematologia, Hemoterapia E Terapia Celular, Sao Paulo, 05402-000, Brazil|Hospital Santa Rita de Cassia Afecc, Vitoria, 29043-260, Brazil|Cross Cancer Institute, Edmonton, Alberta, T6G 1Z2, Canada|British Columbia Cancer Agency the Vancouver Centre, Vancouver, British Columbia, V5Z 4E6, Canada|Cancercare Manitoba, Winnipeg, Manitoba, R3E 0V9, Canada|Newfoundland and Labrador Health Services, St Johns, Newfoundland and Labrador, A1B 3V6, Canada|The Ottawa Hospital, Ottawa, Ontario, K1H 8L6, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, M5G 2M9, Canada|Ciusss Nim Hscm, Montreal, Quebec, H4J 1C5, Canada|Arthur Je Child Comprehensive Cancer Centre, Calgary, T2N 5G2, Canada|Affiliated Zhongshan Hospital of Fudan University, Shanghai, Shanghai, 200032, China|Fakultni Nemocnice Brno, Brno, 625 00, Czechia|Fakultni Nemocnice Hradec Kralove, Hradec Kralove, 500 03, Czechia|Vseobecna Fakultni Nemocnice V Praze, Praha, 10000, Czechia|Ustav Hematologie A Krevni Transfuze (Uhkt), Praha, 128 00, Czechia|University Hospital of Aalborg, Denmark, Aalborg, 9000, Denmark|Rigshospitalet, Copenhagen, 2100, Denmark|Odense University Hospital, Odense C, 5000, Denmark|Zealand University Hospital, Roskilde, Roskilde, 4000, Denmark|Chu Clermont Ferrand Therapie Cellulaire and Hematolo, Clermontferrand, 63100, France|Centre Hospitalier Universitaire Nantes Hotel Dieu, Nantes, 44000, France|Hopital de La Pitie Salpetriere, Paris, 75013, France|Chu Hopital Lyon Sud, PierreBenite, 69495, France|Hopital Robert Debre, Reims, 51100, France|Chu Rennes, Rennes Cedes, 35000, France|Centre Henri Becquerel, Rouen Cedex, 76038, France|Icans Institut de Cancerologie Strasbourg Europe, Strasbourg, 67200, France|Iuct Oncopole, Toulouse, 31100, France|Chu Nancy Hopital Brabois, VandoeuvrelesNancy, 54511, France|Osp Kurfuerstendamm, Berlin, 10707, Germany|Gokos Gmbh, Dresden, 01307, Germany|Universitatsklinikum Jena Klinik Fur Innere Medizin Ii, Jena, 07747, Germany|Universitatsklinikum Schleswig Holstein, Campus Kiel, Kiel, 24105, Germany|Uniklinik Koeln (Aoer), Koln, 50937, Germany|Klinikum Der Universitat Munchen Medizinische Klinik Und Poliklinik Iii, Munchen, 81377, Germany|Stauferklinikum Schwabisch Gmund Kliniken Ostalb, Mutlangen, 73557, Germany|Dietrich Bonhoeffer Klinikum Neubrandenburg, Neubrandenburg, 17036, Germany|Medizinische Universitaetsklinik, Tubingen, 72076, Germany|Universitaetsklinikum Ulm, Ulm, 89081, Germany|Haematologisch Onkologische Schwerpunktpraxis, Wurzburg, 97080, Germany|Mater Misericordiae University Hospital, Dublin, D7, Ireland|St Jamess Hospital, Dublin, D8, Ireland|University Hospital Galway, Galway, H91 YR71, Ireland|University Hospital Limerick, Limerick, V94F858, Ireland|Azienda Ospedaliera Policlinico Di Bari, Bari, 70124, Italy|Ao Brotzu Ospedale Oncologico Armando Businco, Cagliari, 09121, Italy|Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele, Catania, 95123, Italy|Azienda Ospedaliero Universitaria Di Ferrara, Ferrara, 44124, Italy|Ospedale San Raffaele, Milano, 20132, Italy|Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Milano, 20162, Italy|Universita Degli Studi Di Modena Azienda Ospedaliere Policlinco, Modena, 41124, Italy|Asl Salerno Andrea Tortora, Pagani, 84014, Italy|Pusan National University Hospital, SeoGu, Busan Gwang'yeogsi, 49241, Korea, Republic of|Seoul National University Bundang Hospital, BundangGu SeongnamSi, Gyeonggi-do, 13620, Korea, Republic of|National Cancer Center (Korea), IlsandongGu GoyangSi, Gyeonggi-do, 10408, Korea, Republic of|Samsung Medical Center, GangnamGu, Seoul Teugbyeolsi, 06351, Korea, Republic of|The Catholic University of Korea, Seoul St Marys Hospital, SeochoGu, Seoul Teugbyeolsi, 06591, Korea, Republic of|Severance Hospital Yonsei University Health System, SeodaemunGu, Seoul Teugbyeolsi, 03722, Korea, Republic of|Seoul National University Hospital, Seoul, Seoul Teugbyeolsi, 03080, Korea, Republic of|Flevoziekenhuis, Almere, 1315 RA, Netherlands|Rijnstate, Arnhem, 6815 AD, Netherlands|Albert Schweitzer Ziekenhuis, Dordrecht, 3318 AT, Netherlands|Tergooi Mc, Hilversum, 1212 VG, Netherlands|North Shore Hospital, Auckland, 0622, New Zealand|Auckland City Hospital, Auckland, 1023, New Zealand|Uniwersyteckie Centrum Kliniczne, Gdask, 80-214, Poland|Wielospecjalistyczne Centrum Onkologii I Traumatologii Im M Kopernika W Lodzi, OD, 93-513, Poland|Wojewodzki Szpital Zespolony Im L Rydygiera W Toruniu, Torun, 87-100, Poland|Centralny Szpital Kliniczny Uck Wum, Warszawa, 02-097, Poland|Uniwersytecki Szpital Kliniczny Hematology, Wrocaw, 50-367, Poland|Vall D Hebron Institute of Oncology Vhio, Barcelona, 08035, Spain|Hospital Clinic de Barcelona, Barcelona, 8036, Spain|Ico Lhospitalet Hospital Duran I Reynals, Lhospitalet de Llobregat, 08908, Spain|Hospital de La Princesa, Madrid, 28006, Spain|Hospital Universitario Infanta Leonor, Madrid, 28031, Spain|Costa Del Sol (Marbella, Malaga), Marbella, 29603, Spain|Hospital Universitario de Salamanca, Salamanca, 37007, Spain|Hospital Universitario Marques de Valdecilla, Santander, 39008, Spain|Hospital Virgen de Valme (Sevilla), Sevilla, 41014, Spain|Sahlgrenska University Hospital Hematology, Goteborg, 413 46, Sweden|Skanes Universitetssjukhus I Lund, Lund, 221 85, Sweden|Karolinska Universitetssjukhuset Solna, Stockholm, 171 76, Sweden|Uppsala Akademiska Sjukhus, Uppsala, 751 85, Sweden|University Hospitals Dorset Royal Bournemouth Hospital, Bournemouth, BH7 7DW, United Kingdom|Churchill Hospital Oxford University Hospital Nhs Trust, Headington, OX3 7LE, United Kingdom|St Jamess University Hospital, Leeds, LS9 7TF, United Kingdom|Kings College Hospital, London, SE5 9RS, United Kingdom|Freeman Hospital, NewCastle Upon Tyne, NE7 7DN, United Kingdom|Clatterbridge Cancer Centre, Wirral, CH63 4JY, United Kingdom",
NCT03867084,Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937),https://clinicaltrials.gov/study/NCT03867084,,ACTIVE_NOT_RECRUITING,This study will evaluate the safety and efficacy of pembrolizumab (MK-3475) versus placebo as adjuvant therapy in participants with hepatocellular carcinoma (HCC) and complete radiological response after surgical resection or local ablation. The primary hypotheses of this study are that adjuvant pembrolizumab is superior to placebo with respect to: 1) recurrence-free survival (RFS) as assessed by blinded independent central review (BICR); and 2) overall survival (OS).,NO,Hepatocellular Carcinoma,BIOLOGICAL: Pembrolizumab|DRUG: Placebo,"Recurrence-Free Survival (RFS), RFS is defined as the time from randomization to first documentation of disease recurrence (local, regional, or distant) as assessed by BICR or by pathology consistent with HCC if required per the site's standard of care, or death due to any cause (both cancer and non-cancer causes of death), whichever occurs first., Up to ~6 years|Overall Survival (OS), OS is defined as the time from randomization to death due to any cause., Up to ~8 years","Percentage of Participants who Experience an Adverse Event (AE), An AE is defined as any unfavorable and unintended sign, symptom, or disease (new or worsening) temporally associated with the use of study therapy, regardless of whether or not a causal relationship with the study therapy can be determined., Up to ~8 years|Percentage of Participants who Discontinue Study Treatment Due to an AE, An AE is defined as any unfavorable and unintended sign, symptom, or disease (new or worsening) temporally associated with the use of study therapy, regardless of whether or not a causal relationship with the study therapy can be determined., Up to ~1 year|Change from Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Combined Global Health Status (GHS) / Quality of Life (QoL) Scale Score, The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients, including a combined GHS/QoL (Items 29 and 30) scale. Per protocol, the change from baseline in the combined GHS/QoL score (range: 0-100) will be reported. Higher overall GHS/QoL scores indicate higher GHS/QoL., Baseline and time of last patient reported outcome (PRO) assessment (up to ~5 years)|Change from Baseline in EORTC QLQ-Hepatocellular Carcinoma Module (EORTC QLQ-HCC18) Scale Score, The EORTC QLQ-HCC18 is an HCC-specific questionnaire, administered in addition to the EORTC QLQ-C30, with scores ranging from 0-100. Higher scores indicate more severe symptoms/problems. Change from baseline in the EORTC QLQ-HCC18 scale score will be reported., Baseline and time of last PRO assessment (up to ~5 years)|Change from Baseline in European Quality of Life (EuroQoL)-5 Dimensions, 5-level Questionnaire (EQ-5D-5L) Health Utility Score, The EQ-5D-5L measured health-related outcomes, assessing 5 health state dimensions (mobility, selfcare, usual activities, pain/discomfort, and anxiety/depression) on a 5-point scale from 1 (no problem) to 5 (extreme problems). The EQ-5D-5L also includes a graded (0 to 100) vertical visual analog scale on which the participant rates their general state of health., Baseline and time of last PRO assessment (up to ~5 years)",,Merck Sharp & Dohme LLC,,ALL,"ADULT, OLDER_ADULT",PHASE3,950,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2019-05-28,2027-10-31,2029-08-31,2019-03-07,,2024-11-14,"Banner MD Anderson Cancer Center ( Site 0026), Gilbert, Arizona, 85234, United States|The University of Arizona Cancer Center - North Campus ( Site 0039), Tucson, Arizona, 85719, United States|City of Hope Medical Center ( Site 0027), Duarte, California, 91010, United States|Smilow Cancer Hospital at Yale New Haven ( Site 0042), New Haven, Connecticut, 06510, United States|Regional Cancer Center ( Site 0054), Fort Myers, Florida, 33905, United States|Indiana University Simon Cancer Center ( Site 0075), Indianapolis, Indiana, 46202, United States|University of Iowa ( Site 0067), Iowa City, Iowa, 52242, United States|James Graham Brown Cancer Center ( Site 0088), Louisville, Kentucky, 40202, United States|University of Louisville ( Site 0059), Louisville, Kentucky, 40202, United States|University Medical Center New Orleans ( Site 0014), New Orleans, Louisiana, 70112, United States|Massachusetts General Hospital ( Site 0062), Boston, Massachusetts, 02114, United States|Boston Medical Center ( Site 0025), Boston, Massachusetts, 02118, United States|Beth Israel Deaconess Medical Ctr. ( Site 0033), Boston, Massachusetts, 02215, United States|University of Massachusetts Worcester ( Site 0017), Worcester, Massachusetts, 01655, United States|Henry Ford Hospital-GI/Hepatology Research ( Site 0047), Detroit, Michigan, 48202, United States|University of New Mexico ( Site 0041), Albuquerque, New Mexico, 87131, United States|North Shore-Long Island Jewish Health System ( Site 0068), Lake Success, New York, 11042, United States|Miami Valley Hospital South ( Site 0093), Centerville, Ohio, 45459, United States|University of Cincinnati Medical Center ( Site 0084), Cincinnati, Ohio, 45219, United States|ProMedica Flower Hospital ( Site 0090), Sylvania, Ohio, 43560, United States|Stephenson Cancer Center ( Site 0045), Oklahoma City, Oklahoma, 73104, United States|Vanderbilt Ingram Cancer Center ( Site 0006), Nashville, Tennessee, 37232, United States|Baylor Scott & White Medical Center - Temple ( Site 0089), Temple, Texas, 76508, United States|Virginia Mason Medical Center ( Site 0028), Seattle, Washington, 98101, United States|Hospital Universitario Austral ( Site 0795), Pilar, Buenos Aires, B1629AHJ, Argentina|FundaciÃ³n favaloro para la Docencia e InvestigaciÃ³n MÃ©dica ( Site 0808), Buenos Aires, Caba, C1096AAS, Argentina|Hospital Provincial del Centenario ( Site 0794), Rosario, Santa Fe, S2002KDS, Argentina|Hospital Aleman ( Site 0806), Buenos Aires, C1118AAT, Argentina|Hospital Italiano ( Site 0793), Buenos Aires, C1181ACH, Argentina|Hospital Britanico de Buenos Aires ( Site 0792), Buenos Aires, C1280AEB, Argentina|Clinica de nefrologia urologia y enfermedades cardiovasculares ( Site 0802), Santa Fe, S3000BPJ, Argentina|Royal Prince Alfred Hospital AW ( Site 0225), Camperdown, New South Wales, 2050, Australia|Liverpool Hospital ( Site 0226), Liverpool, New South Wales, 2170, Australia|Princess Alexandra Hospital ( Site 0228), Woollongabba, Queensland, 4102, Australia|Royal Adelaide Hospital ( Site 0234), Adelaide, South Australia, 5000, Australia|Monash Health ( Site 0233), Clayton, Victoria, 3168, Australia|St Vincents Hospital Melbourne ( Site 0227), Fitzroy, Victoria, 3065, Australia|Alfred Health ( Site 0230), Melbourne, Victoria, 3004, Australia|Royal Perth Hospital ( Site 0229), Perth, Western Australia, 6000, Australia|University Hospital Antwerp (UZA) ( Site 0374), Edegem, Antwerpen, 02650, Belgium|Erasme Hospital ( Site 0376), Bruxelles, Bruxelles-Capitale, Region De, 1070, Belgium|UZ Gent ( Site 0375), Gent, Oost-Vlaanderen, 9000, Belgium|UZ Leuven ( Site 0377), Leuven, Vlaams-Brabant, 3000, Belgium|CIONC - Centro Integrado de Oncologia de Curitiba ( Site 0813), Curitiba, Parana, 80810-050, Brazil|Hospital de Cancer de Pernambuco ( Site 0815), Recife, Pernambuco, 50040-000, Brazil|Hospital de Clinicas de Porto Alegre ( Site 0824), Porto Alegre, Rio Grande Do Sul, 90035-903, Brazil|Clinica de Oncologia Reichow ( Site 0818), Blumenau, Santa Catarina, 89010-340, Brazil|Centro de Novos Tratamentos Itajai - Clinica de Neoplasias Litoral ( Site 0820), Itajai, Santa Catarina, 88301-220, Brazil|Hospital Paulistano ( Site 0829), SÃ£o Paulo, Sao Paulo, 01321-001, Brazil|Instituto COI de Pesquisa Educacao e Gestao ( Site 0825), Rio de Janeiro, 22793-080, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0826), Sao Paulo, 01246-000, Brazil|Real e Benemerita Associacao Portuguesa de Beneficencia ( Site 0828), Sao Paulo, 01321-001, Brazil|A.C. Camargo Cancer Center ( Site 0827), Sao Paulo, 01509-900, Brazil|Casa de Saude Santa Marcelina ( Site 0821), Sao Paulo, 08270120, Brazil|Complex Cancer Center Plovdiv-First Medical Oncology Department ( Site 0982), Plovdiv, 4004, Bulgaria|Nova Scotia Health Authority QEII-HSC ( Site 0208), Halifax, Nova Scotia, B3H 2Y9, Canada|Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0211), Montreal, Quebec, H2X 3E4, Canada|McGill University Health Centre ( Site 0207), Montreal, Quebec, H4A 3J1, Canada|Anhui Provincil Hospital South District ( Site 0181), Hefei, Anhui, 230036, China|Cancer Hospital Chinese Academy of Medical Sciences ( Site 0156), Beijing, Beijing, 100021, China|Peking University People's Hospital ( Site 0191), Beijing, Beijing, 100044, China|Beijing Cancer Hospital ( Site 0155), Beijing, Beijing, 100142, China|Fujian Provincial Cancer Hospital ( Site 0165), Fuzhou, Fujian, 350014, China|900 Hospital of the Joint ( Site 0197), Fuzhou, Fujian, 350025, China|Guangdong General Hospital ( Site 0166), Guangzhou, Guangdong, 510080, China|Southern Medical University Nanfang Hospital ( Site 0172), Guangzhou, Guangdong, 510515, China|Wuhan Union Hospital ( Site 0173), Wuhan, Hubei, 430022, China|Hubei Cancer Hospital ( Site 0189), Wuhan, Hubei, 430079, China|The Third Xiangya Hospital of Central South University ( Site 0167), Changsha, Hunan, 410000, China|Hunan Provincial People Hospital ( Site 0192), Changsha, Hunan, 410005, China|Hunan Cancer Hospital ( Site 0168), Changsha, Hunan, 410013, China|Fudan University Shanghai Cancer Center ( Site 0161), Shanghai, Shanghai, 200032, China|Zhongshan Hospital Fudan University ( Site 0193), Shanghai, Shanghai, 200032, China|Renji Hospital Shanghai Jiaotong University School of Medicine ( Site 0174), Shanghai, Shanghai, 200127, China|Zhongshan Hospital affiliated to Fudan University ( Site 0153), Shanghai, Shanghai, 210000, China|The First Affiliated Hospital of Xi an Jiaotong University ( Site 0164), XI An, Shanxi, 710061, China|West China Hospital of Sichuan University ( Site 0162), Chengdu, Sichuan, 610041, China|Affiliated Tumor Hospital of Xinjiang Medical University ( Site 0157), Urumqi, Xinjiang, 830001, China|Zhejiang Cancer Hospital ( Site 0171), Hangzhou, Zhejiang, 310022, China|Herlev Hospital ( Site 0421), Herlev, Hovedstaden, 2730, Denmark|Aarhus Universitets hospital ( Site 0420), Aarhus N, Midtjylland, 8200, Denmark|Odense Universitets Hospital ( Site 0422), Odense C, Syddanmark, 5000, Denmark|HUS Hopital Hautepierre ( Site 0445), Strasbourg, Bas-Rhin, 67098, France|Hopital de la Timone ( Site 0442), Marseille, Bouches-du-Rhone, 13005, France|CHU Bordeaux Haut-Leveque ( Site 0437), Pessac, Gironde, 33604, France|CHU Rangueil ( Site 0441), Toulouse, Haute-Garonne, 31059, France|Hopital Beaujon ( Site 0439), Clichy, Hauts-de-Seine, 92118, France|CHU Montpellier. ( Site 0443), Montpellier, Herault, 34295, France|Hopital Claude Huriez CHRU LILLE ( Site 0440), Lille, Nord, 59037, France|Hopital Paul Brousse ( Site 0447), Villejuif, Val-de-Marne, 94800, France|SLK-Kliniken Heilbronn GmbH ( Site 0460), Heilbronn, Baden-Wurttemberg, 74078, Germany|Universitaetsklinikum Tuebingen ( Site 0466), Tuebingen, Baden-Wurttemberg, 72076, Germany|Klinikum rechts der Isar der Technischen Universitaet ( Site 0470), Muenchen, Bayern, 81675, Germany|Universitaetsklinikum Wuerzburg ( Site 0468), Wuerzburg, Bayern, 97080, Germany|Krankenhaus Nord-West GmbH ( Site 0472), Frankfurt am Main, Hessen, 60488, Germany|Universitaetsklinikum Frankfurt ( Site 0467), Frankfurt, Hessen, 60596, Germany|Medizinische Hochschule Hannover ( Site 0458), Hannover, Niedersachsen, 30625, Germany|Universitaetsklinikum Duesseldorf ( Site 0461), Duesseldorf, Nordrhein-Westfalen, 40225, Germany|Universitaetsklinikum Koeln ( Site 0463), Koeln, Nordrhein-Westfalen, 50937, Germany|Staedtisches Klinikum Dresden ( Site 0471), Dresden, Sachsen, 01067, Germany|Universitatsklinikum Carl Gustav Carus ( Site 0459), Dresden, Sachsen, 01307, Germany|Charite - Campus Virchow Klinikum ( Site 0457), Berlin, 13353, Germany|Universitaetsklinikum Hamburg-Eppendorf ( Site 0469), Hamburg, 20246, Germany|Prince of Wales Hospital ( Site 0268), Hong Kong, 000, Hong Kong|Pamela Youde Nethersole Eastern Hospital ( Site 0271), Hong Kong, Hong Kong|Queen Mary Hospital ( Site 0267), Hong Kong, Hong Kong|Tuen Mun Hospital ( Site 0272), Tuen Mun, Hong Kong|Bacs-Kiskun Megyei Korhaz-Onkoradiologiai Kozpont ( Site 0483), KecskemÃ©t, Bacs-Kiskun, 6000, Hungary|SZTE Szent-Gyorgyi Albert Klinikai Kozpont ( Site 0482), Szeged, Csongrad, 6720, Hungary|Somogy Megyei Kaposi MÃ³r OktatÃ³ KÃ³rhÃ¡z-Oncology center ( Site 0484), KaposvÃ¡r, Somogy, 7400, Hungary|Semmelweis University ( Site 0480), Budapest, 1085, Hungary|Debreceni Egyetem Klinikai Kozpont Onkologiai Tanszek ( Site 0481), Debrecen, 4032, Hungary|St Vincent's University Hospital ( Site 0498), Dublin, D04 T6F4, Ireland|Tallaght University Hospital ( Site 0499), Dublin, D24 NR0A, Ireland|Rambam Medical Center ( Site 0524), Haifa, 3109601, Israel|Haddassah Medical Organization - Ein Kerem ( Site 0519), Jerusalem, 9112001, Israel|Rabin Medical Center ( Site 0520), Petah Tikva, 4941492, Israel|Chaim Sheba Medical Center ( Site 0523), Ramat Gan, 5262000, Israel|Sourasky Medical Center ( Site 0522), Tel Aviv, 6423906, Israel|A O U Policlinico di Modena ( Site 0548), Modena, Abruzzo, 41025, Italy|Azienda Ospedaliera Ordine Mauriziano di Torino ( Site 0542), Torino, Piemonte, Italy|Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello ( Site 0547), Palermo, Sicilia, 90146, Italy|Istituto Tumori Giovanni Paolo II ( Site 0543), Bari, 70124, Italy|AOU di Bologna Policliico S. Orsola-Malpighi ( Site 0541), Bologna, 40138, Italy|Azienda Ospedaliero Universitaria Careggi ( Site 0549), Firenze, 50134, Italy|Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico ( Site 0550), Milano, 20122, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 0540), Milano, 20133, Italy|Ospedale del Mare ( Site 0545), Napoli, 80147, Italy|Azienda Ospedaliero Universitaria Pisana ( Site 0546), Pisa, 56126, Italy|Ehime University Hospital ( Site 0123), Toon, Ehime, 791-0295, Japan|Kurume University Hospital ( Site 0119), Kurume, Fukuoka, 830-0011, Japan|Hokkaido P.W.F.A.C Sapporo-Kosei General Hospital ( Site 0102), Sapporo, Hokkaido, 060-0033, Japan|Kanazawa University Hospital ( Site 0111), Kanazawa, Ishikawa, 920-8641, Japan|Kagawa University Hospital ( Site 0121), Kita-gun, Kagawa, 761-0793, Japan|Kagawa Prefectural Central Hospital ( Site 0122), Takamatsu, Kagawa, 760-8557, Japan|Toranomon Hospital Kajigaya ( Site 0109), Kawasaki, Kanagawa, 213-8587, Japan|Yokohama City University Medical Center ( Site 0110), Yokohama, Kanagawa, 232-0024, Japan|Kindai University Hospital ( Site 0116), Osakasayama, Osaka, 5898511, Japan|Saitama Medical University Hospital ( Site 0104), Iruma-gun, Saitama, 350-0495, Japan|Kyorin University Hospital ( Site 0106), Mitaka, Tokyo, 181-8611, Japan|Musashino Red Cross Hospital ( Site 0107), Musashino, Tokyo, 180-8610, Japan|Chiba University Hospital ( Site 0103), Chiba, 260-8677, Japan|National Hospital Organization Kyushu Medical Center ( Site 0118), Fukuoka, 810-8563, Japan|Hiroshima University Hospital ( Site 0117), Hiroshima, 7348551, Japan|University Hospital, Kyoto Prefectural University of Medicine ( Site 0112), Kyoto, 602-8566, Japan|Japanese Red Cross Osaka Hospital ( Site 0113), Osaka, 543-8555, Japan|Osaka Metropolitan University Hospital. ( Site 0114), Osaka, 545-8586, Japan|Saga-Ken Medical Centre Koseikan ( Site 0120), Saga, 840-8571, Japan|Toranomon Hospital ( Site 0108), Tokyo, 105-8470, Japan|The University of Tokyo Hospital ( Site 0105), Tokyo, 113-8655, Japan|Wakayama Medical University Hospital ( Site 0115), Wakayama, 641-8510, Japan|National Cancer Center ( Site 0314), Goyang-si, Kyonggi-do, 10408, Korea, Republic of|Seoul National University Bundang Hospital ( Site 0313), Seongnam-si, Kyonggi-do, 13605, Korea, Republic of|Seoul National University Hospital ( Site 0312), Seoul, 03080, Korea, Republic of|Severance Hospital Yonsei University Health System ( Site 0309), Seoul, 03722, Korea, Republic of|Asan Medical Center ( Site 0310), Seoul, 05505, Korea, Republic of|Samsung Medical Center ( Site 0311), Seoul, 06351, Korea, Republic of|The Catholic University of Korea. Seoul St. Mary s Hospital ( Site 0315), Seoul, 06591, Korea, Republic of|Hospital Universiti Sains Malaysia ( Site 0295), Kubang Kerian, Kelantan, 16150, Malaysia|Penang Adventist Hospital ( Site 0289), George Town, Pulau Pinang, 10350, Malaysia|Gleneagles Penang ( Site 0290), Penang, Pulau Pinang, 10050, Malaysia|Sarawak General Hospital ( Site 0293), Kuching, Sarawak, 93586, Malaysia|Institut Kanser Negara - National Cancer Institute ( Site 0294), Putrajaya Wilayah Persekutuan, Wilayah Persekutuan Putrajaya, 62250, Malaysia|University Malaya Medical Centre ( Site 0288), Kuala Lumpur, 59100, Malaysia|Christchurch Hospital ( Site 0247), Christchurch, Canterbury, 8011, New Zealand|Auckland City Hospital ( Site 0246), Auckland, 1142, New Zealand|Oslo Universitetssykehus HF. Ulleval ( Site 0433), Oslo, 0450, Norway|Izerskie Centrum Pulmonologii i Chemioterapii IZER-MED Spolka z o.o. ( Site 0607), Szklarska Poreba, Dolnoslaskie, 58-580, Poland|Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublinie ( Site 0620), Lublin, Lubelskie, 20-081, Poland|MTZ Clinical Research Sp. z o. o. ( Site 0608), Warsaw, Mazowieckie, 02-106, Poland|Copernicus PL Sp. z o.o. ( Site 0603), Gdansk, Pomorskie, 80-219, Poland|ID Clinic ( Site 0619), Myslowice, Slaskie, 41-400, Poland|SPZOZ MSWIA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie ( Site 0606), Olsztyn, Warminsko-mazurskie, 10-228, Poland|Szpital Wojewodzki im. Mikolaja Kopernika ( Site 0604), Koszalin, Zachodniopomorskie, 75-581, Poland|Altay Regional Oncology Dispensary ( Site 0919), Barnaul, Altayskiy Kray, 656045, Russian Federation|Siberian Clinical Center of FMBA ( Site 0918), Krasnoyarsk, Krasnoyarskiy Kray, 660037, Russian Federation|Krasnoyarsk Regional Clinical Oncological Dispensary ( Site 0648), Krasnoyarsk, Krasnoyarskiy Kray, 660133, Russian Federation|Blokhin National Medical Oncology ( Site 0645), Moscow, Moskva, 115478, Russian Federation|City Clinical Hospital 1 na. NI. Pirogov ( Site 0662), Moscow, Moskva, 119049, Russian Federation|First Moscow State Medical University n.a. I.M.Sechenov ( Site 0661), Moscow, Moskva, 119881, Russian Federation|Hadassah Medical-Clinical Research Department ( Site 0920), Moscow, Moskva, 121205, Russian Federation|National Medical Research Radiological Centre ( Site 0660), Moscow, Moskva, 125284, Russian Federation|Privolzhsky District Medical Center ( Site 0655), Nizhniy Novgorod, Nizhegorodskaya Oblast, 603109, Russian Federation|Samara Regional Clinical Oncology Center ( Site 0656), Samara, Samarskaya Oblast, 443031, Russian Federation|Road Hospital JSC Russian railways ( Site 0649), Saint Petersburg, Sankt-Peterburg, 195271, Russian Federation|Russian Scientific Center of Radiology and Surgical Technologies ( Site 0665), Saint Petersburg, Sankt-Peterburg, 197758, Russian Federation|City Clinical Oncology Center ( Site 0646), Saint Petersburg, Sankt-Peterburg, 198255, Russian Federation|Tomsk Scientific Research Institute of Oncology ( Site 0657), Tomsk, Tomskaya Oblast, 634028, Russian Federation|Hospital Central de Asturias ( Site 0667), Oviedo, Asturias, 33011, Spain|Hospital Universitari Parc Tauli ( Site 0681), Sabadell, Barcelona, 08208, Spain|Hospital Universitario de Donostia ( Site 0671), San Sebastian, Gipuzkoa, 20014, Spain|Complejo Hospitalario Universitario de Santiago ( Site 0668), Santiago de Compostela, La Coruna, 15706, Spain|Hospital Universitario Puerta de Hierro ( Site 0678), Majadahonda, Madrid, 28222, Spain|Hospital Universitari Vall d Hebron ( Site 0674), Barcelona, 08035, Spain|Hospital General Universitario Gregorio Maranon ( Site 0676), Madrid, 28007, Spain|Hospital Ramon y Cajal ( Site 0673), Madrid, 28034, Spain|Hospital Universitario La Paz ( Site 0677), Madrid, 28046, Spain|Hospital Universitario Virgen del Rocio ( Site 0670), Sevilla, 41013, Spain|Hospital Universitario Miguel Servet-Gastroenterology ( Site 0682), Zaragoza, 50009, Spain|Skane University Hospital ( Site 0692), Malmo, Skane Lan, 205 02, Sweden|Karolinska Universitetssjukhuset, Huddinge ( Site 0689), Stockholm, Stockholms Lan, 141 86, Sweden|Norrlands Universitetssjukhus ( Site 0687), Umea, Vasterbottens Lan, 901 85, Sweden|Sahlgrenska Universitetssjukhuset ( Site 0691), Goteborg, Vastra Gotalands Lan, 413 46, Sweden|Universitaetsspital Bern ( Site 0710), Bern, Aargau, 3010, Switzerland|University Hospital Basel ( Site 0709), Basel, Basel-Stadt, 4056, Switzerland|Kantonsspital St. Gallen ( Site 0708), St. Gallen, Sankt Gallen, 9007, Switzerland|CHUV (centre hospitalier universitaire vaudois) ( Site 0712), Lausanne, Vaud, 1011, Switzerland|Kantonsspital Winterthur ( Site 0714), Winterthur, Zurich, 8401, Switzerland|Hopitaux Universitaires de Geneve HUG ( Site 0711), Geneve, 1211, Switzerland|Universitaetsspital Zurich ( Site 0713), Zurich, 8091, Switzerland|Chang Gung Medical Foundation. Kaohsiung Branch ( Site 0335), Kaohsiung, 833, Taiwan|China Medical University Hospital ( Site 0333), Taichung, 40447, Taiwan|National Cheng Kung University Hospital ( Site 0334), Tainan, 704, Taiwan|National Taiwan University Hospital ( Site 0330), Taipei, 100, Taiwan|Taipei Veterans General Hospital ( Site 0331), Taipei, 112, Taiwan|Chang Gung Medical Foundation. Linkou ( Site 0332), Taoyuan, 333, Taiwan|Ramathibodi Hospital. ( Site 0352), Bangkok, Krung Thep Maha Nakhon, 10400, Thailand|Siriraj Hospital ( Site 0351), Bangkok, Krung Thep Maha Nakhon, 10700, Thailand|Maharaj Nakorn Chiangmai Hospital ( Site 0353), Chiang Mai, 50200, Thailand|Srinagarind Hospital ( Site 0354), Khon Kaen, 40002, Thailand|Namik Kemal Universitesi Tip Fakultesi ( Site 0738), Tekirdag, Tekirdas, 59100, Turkey|Baskent Unv. Adana Uyg. ve Arast. Hastanesi ( Site 0733), Adana, 01120, Turkey|Gulhane Egitim ve Arastirma Hastanesi ( Site 0741), Ankara, 06010, Turkey|Ankara Sehir Hastanesi ( Site 0731), Ankara, 06800, Turkey|Adnan Menderes University Medical Faculty ( Site 0737), Aydin, 09010, Turkey|Bezmialem Vakif University School of Medicine ( Site 0732), Istanbul, 34093, Turkey|AcÄ±badem Maslak Hastanesi ( Site 0742), Istanbul, 34457, Turkey|GÃ¶ztepe Prof. Dr. SÃ¼leyman YalÃ§Ä±n Åehir Hastanesi-oncology ( Site 0730), Istanbul, 34722, Turkey|Dokuz Eylul Universitesi ( Site 0740), Izmir, 35340, Turkey|Konya Necmettin Erbakan University Medical Faculty ( Site 0736), Konya, 42080, Turkey|Inonu University Faculty of Medicine ( Site 0729), Malatya, 44280, Turkey|VM Medical Park Hastanesi ( Site 0739), Mersin, 33440, Turkey|Regional Clinical Onco Dispensary_ State Medical University ( Site 0782), Chernivtsi, Chernivetska Oblast, 58000, Ukraine|Regional Oncology Center of Kharkiv ( Site 0777), Kharkiv, Kharkivska Oblast, 61000, Ukraine|National Cancer Institute of the MoH of Ukraine ( Site 0779), Kyiv, Kyivska Oblast, 03022, Ukraine|Shalimov s NI of Surgery and Transplantation ( Site 0781), Kyiv, Kyivska Oblast, 03126, Ukraine|MI Odessa Regional Oncological Centre ( Site 0776), Odesa, Odeska Oblast, 65055, Ukraine|CI City Clinical Hospital # 3 ( Site 0783), Zaporizhzhia, Zaporizka Oblast, 69032, Ukraine|Universal Clinic Oberig-Oncology Center ( Site 0786), Kyiv, 03057, Ukraine|Medical Center Dobrobut Clinic ( Site 0785), Kyiv, 03151, Ukraine|Cambridge University Hospitals NHS Trust ( Site 0755), Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom|Weston Park Hospital ( Site 0753), Sheffield, Derbyshire, S10 2SJ, United Kingdom|The Beatson West of Scotland Cancer Centre ( Site 0750), Glasgow, Glasgow City, G12 0YN, United Kingdom|Kings College Hospital NHS Foundation Trust ( Site 0758), London, London, City Of, SE5 9RS, United Kingdom|Belfast City Hospital ( Site 0752), Belfast, Northern Ireland, BT9 7AB, United Kingdom|The Clatterbridge Cancer Centre NHS Foundation Trust ( Site 0757), Birkenhead, Wirral, CH63 4JY, United Kingdom|University Hospital Coventry and Warwickshire NHS Trust ( Site 0754), Coventry, CV3 2DX, United Kingdom|Leeds Teaching Hospitals NHS Trust ( Site 0751), Leeds, LS9 7TF, United Kingdom|Nottingham University Hospitals NHS Trust ( Site 0756), Nottingham, NG5 1PB, United Kingdom",
NCT02531516,An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS,https://clinicaltrials.gov/study/NCT02531516,,ACTIVE_NOT_RECRUITING,"The purpose of this study is to determine if apalutamide plus gonadotropin releasing hormone (GnRH) agonist in participants with high-risk, localized or locally advanced prostate cancer receiving primary radiation therapy (RT) results in an improvement of metastasis-free survival based on conventional or prostate specific membrane antigen-positron emission tomography (PSMA-PET) imaging evaluated by blinded independent central review (BICR).",NO,Prostatic Neoplasms,DRUG: Apalutamide|DRUG: Bicalutamide|DRUG: Bicalutamide Placebo|DRUG: Apalutamide Placebo|DRUG: GnRH (agonist)|RADIATION: 74-80 Grays (units of radiation),"Metastasis-free Survival, Metastasis-free survival is defined as the time from randomization to the date of the first occurrence of radiographic bone or soft tissue distant metastasis based on conventional imaging or prostate specific membrane antigen-positron emission tomography (PSMA-PET) imaging by blinded independent central review (BICR), histopathologic diagnosis of distant metastasis, or death from any cause, whichever occurs first., 108 Months","Event-free Survival on Conventional Imaging or PSMA-PET Imaging, Event-free survival is defined as the time from randomization to the date of the first occurrence of prostate specific antigen (PSA) failure by the Phoenix definition, local or regional disease recurrence on conventional imaging or PSMA-PET imaging by BICR or histopathologic diagnosis, distant metastasis on conventional imaging or PSMA-PET imaging by BICR or histopathologic diagnosis, or death., 108 Months|Time to Prostate Specific Antigen (PSA) Progression, Time to PSA progression is defined as time from randomization to the date of PSA nadir plus (+) 0.5 nanograms per milliliter (ng/mL) and rising., 108 Months|Metastasis-free Survival (MFS) on Conventional Imaging by Blinded Independent Central Review (BICR), MFS is defined as the time from randomization to the date of the first occurrence of radiographic bone or soft tissue distant metastasis based on conventional imaging by BICR, histopathologic diagnosis of distant metastasis, or death from any cause, whichever occurs first., 108 Months|No Evidence of Disease (NED), NED is defined as: alive; no prostate specific antigen (PSA) progression; no distant metastasis on conventional imaging or PSMA-PET imaging by BICR; no local or regional recurrence on conventional imaging or PSMA-PET imaging by BICR; no subsequent therapy for prostate cancer; testosterone recovery to age-related pre-androgen deprivation therapy (pre-ADT)/baseline or greater than (\>) 200 nanogram per deciliter (ng/dL)., 108 Months|Overall Survival (OS), OS is defined as the time from randomization to date of death from any cause., 108 Months|Time to Distant Metastasis, Time to distant metastasis is defined as the time from randomization to the date of the first occurrence of radiographic or pathological bone or soft tissue distant metastasis on conventional imaging or PSMA-PET imaging by BICR or histopathologic diagnosis of distant metastasis., 108 Months|Event-free Survival on Conventional Imaging, EFS is defined as the time from randomization to the date of the first occurrence of prostate specific antigen (PSA) failure by the Phoenix definition, local or regional disease recurrence on conventional imaging by BICR or histopathologic diagnosis, distant metastasis on conventional imaging by BICR or histopathologic diagnosis, or death., 108 Months|Time to Next Local or Systemic Treatment, Time to next local or systemic treatment defined as time from randomization to first subsequent therapy, including re-initiation of androgen deprivation therapy (ADT) and local treatments for local-regional recurrence or distant metastasis., 108 Months",,"Aragon Pharmaceuticals, Inc.",,MALE,"ADULT, OLDER_ADULT",PHASE3,1503,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2015-11-19,2026-06-30,2028-12-29,2015-08-24,,2025-05-23,"Homewood, Alabama, United States|Chandler, Arizona, United States|Scottsdale, Arizona, United States|Tucson, Arizona, United States|Bakersfield, California, United States|Los Angeles, California, United States|Orange, California, United States|San Bernardino, California, United States|San Diego, California, United States|San Francisco, California, United States|Aurora, Colorado, United States|Denver, Colorado, United States|Middlebury, Connecticut, United States|Bradenton, Florida, United States|Daytona Beach, Florida, United States|Fort Myers, Florida, United States|Hialeah, Florida, United States|Lakewood Ranch, Florida, United States|Naples, Florida, United States|Plantation, Florida, United States|Meridian, Idaho, United States|Evergreen Park, Illinois, United States|Harvey, Illinois, United States|Jeffersonville, Indiana, United States|Wichita, Kansas, United States|Ashland, Kentucky, United States|New Orleans, Louisiana, United States|Shreveport, Louisiana, United States|Scarborough, Maine, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Saint Louis, Missouri, United States|Morristown, New Jersey, United States|Albany, New York, United States|Bronx, New York, United States|Brooklyn, New York, United States|New York, New York, United States|Poughkeepsie, New York, United States|Rochester, New York, United States|Syracuse, New York, United States|Cary, North Carolina, United States|Raleigh, North Carolina, United States|Portland, Oregon, United States|Springfield, Oregon, United States|Bala-Cynwyd, Pennsylvania, United States|Bryn Mawr, Pennsylvania, United States|Lancaster, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|East Greenwich, Rhode Island, United States|Charleston, South Carolina, United States|Myrtle Beach, South Carolina, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Fairfax, Virginia, United States|Virginia Beach, Virginia, United States|Burien, Washington, United States|Spokane, Washington, United States|Morgantown, West Virginia, United States|Buenos Aires, Argentina|C.a.b.a., Argentina|Caba, Argentina|Ciudad Autonoma de Buenos Aires, Argentina|Pergamino, Argentina|Rosario, Argentina|San Salvador De Jujuy, Argentina|Aalst, Belgium|Bonheiden, Belgium|Brussel, Belgium|Haine-St-Paul, Belgium|Leuven, Belgium|LiÃ¨ge, Belgium|Namur, Belgium|Roeselare, Belgium|Sint-Niklaas, Belgium|Turnhout, Belgium|Wilrijk, Belgium|Barretos, Brazil|Belo Horizonte, Brazil|Campinas, Brazil|Curitiba, Brazil|Florianopolis, Brazil|Goiania, Brazil|Ijui, Brazil|Natal, Brazil|Porto Alegre, Brazil|Ribeirao Preto, Brazil|Rio de Janeiro, Brazil|Salvador, Brazil|Santo Andre, Brazil|Sao Jose do Rio Preto, Brazil|Sao Paulo, Brazil|Sorocaba, Brazil|SÃ£o Paulo, Brazil|Calgary, Alberta, Canada|Surrey, British Columbia, Canada|Vancouver, British Columbia, Canada|Victoria, British Columbia, Canada|London, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Gatineau, Quebec, Canada|Laval, Quebec, Canada|Montreal, Quebec, Canada|MontrÃ©al, Quebec, Canada|Sherbrooke, Quebec, Canada|Quebec, Canada|Beijing, China|ChengDu, China|ChongQing, China|GuangZhou, China|Hangzhou, China|Nanchang, China|Nanjing, China|Ningbo, China|Shanghai, China|Wuhan, China|Xi'An, China|Hradec KrÃ¡love, Czechia|Liberec, Czechia|NovÃ½ Jicin, Czechia|Olomouc, Czechia|Opava, Czechia|Pardubice, Czechia|Praha 10, Czechia|Praha 2, Czechia|Praha 4, Czechia|Praha 5, Czechia|Praha 8, Czechia|Zlin, Czechia|Amiens, France|Angers Cedex 02, France|Avignon Cedex 9, France|Bayonne, France|Besancon, France|Bordeaux, France|Brest, France|Dijon, France|HyÃ¨res, France|La Tronche, France|Le Mans, France|Lille, France|Marseille cedex 05, France|Marseilli, France|Montpellier, France|Neuilly-sur-Seine, France|Paris, France|Ris Orangis, France|Saint Herblain, France|Saint-Brieuc, France|Saint-Mande, France|Saint-Priest-en-Jarez, France|Strasbourg, France|Toulouse, France|Tours, France|Vandoeuvre les Nancy, France|Villejuif Cedex, France|Ãvry-Courcouronnes, France|Braunschweig, Germany|Chemnitz, Germany|Dessau, Germany|Frankfurt, Germany|Gronau, Germany|Jena, Germany|MÃ¼nster, Germany|NÃ¼rtingen, Germany|Ulm, Germany|Weiden, Germany|Beer Yaakov, Israel|Beer-Sheva, Israel|Haifa, Israel|Jerusalem, Israel|Kfar Saba, Israel|Petach-Tikva, Israel|Ramat-Gan, Israel|Tel-Aviv, Israel|Daegu, Korea, Republic of|Gyeonggi-do, Korea, Republic of|Jeollanam-do, Korea, Republic of|Seoul, Korea, Republic of|Georgetown, Malaysia|Kuala Lumpur, Malaysia|Kuching, Malaysia|Putrajaya, Malaysia|Culiacan, Mexico|Guadalajara, Mexico|Leon, Mexico|Mexico, Mexico|Morelia, Mexico|Zapopan, Mexico|Alkmaar, Netherlands|Amsterdam, Netherlands|Den Haag, Netherlands|Nijmegen, Netherlands|Rotterdam, Netherlands|Bialystok, Poland|Bydgoszcz, Poland|Gdynia, Poland|Gliwice, Poland|Kielce, Poland|Lodz, Poland|Olsztyn, Poland|Poznan, Poland|Walbrzych, Poland|Bucuresti, Romania|Cluj-Napoca, Romania|Floresti, Romania|Iasi, Romania|Otopeni, Romania|Ploiesti, Romania|Sibiu, Romania|Targu Mures, Romania|Timisoara, Romania|Barnaul, Russian Federation|Ivanovo, Russian Federation|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|Obninsk, Russian Federation|Omsk, Russian Federation|Pyatigorsk, Russian Federation|Rostov-on-Don, Russian Federation|Ryazan, Russian Federation|Saint Petersburg, Russian Federation|Saint-Petersburg, Russian Federation|Saransk, Russian Federation|St Petersburg, Russian Federation|Tambov, Russian Federation|Tyumen, Russian Federation|Ufa, Russian Federation|Vologda, Russian Federation|Barakaldo, Spain|Barcelona, Spain|Castellon, Spain|Hospitalet de Llobregat, Spain|Las Palmas de Gran Canaria, Spain|Madrid, Spain|MÃ¡laga, Spain|Reus, Spain|Santiago de Compostela, Spain|Sevilla, Spain|Stockholm, Sweden|UmeÃ¥, Sweden|Ãrebro, Sweden|Kaohsiung, Taiwan|Taichung, Taiwan|Tainan, Taiwan|Taipei City, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Adana, Turkey|Ankara, Turkey|Edirne, Turkey|Istanbul, Turkey|Izmir, Turkey|Kayseri, Turkey|Kocaeli, Turkey|Dnipro, Ukraine|Khakhiv, Ukraine|Kyiv, Ukraine|Lviv, Ukraine|Aberdeen, United Kingdom|Birmingham, United Kingdom|Bristol, United Kingdom|Derby, United Kingdom|Glasgow, United Kingdom|Oxford, United Kingdom|Plymouth, United Kingdom|Preston, United Kingdom|Sheffield, United Kingdom|Sutton, United Kingdom|Wolverhampton, United Kingdom",
NCT05234684,A Study of Orelabrutinib Plus R-CHOP in Treatment-naÃ¯ve Patients With MCD Subtype Diffuse Large B-cell Lymphoma,https://clinicaltrials.gov/study/NCT05234684,BELIEVE-01,RECRUITING,The purpose of this study is to evaluate the safety and efficacy of orelabrutinib combined with R-CHOP regimen versus placebo with R-CHOP in the treatment of treatment-naÃ¯ve patients with MCD subtype DLBCL.,NO,Diffuse Large B Cell Lymphoma (DLBCL),DRUG: Orelabrutinib + R-CHOP|DRUG: Placebo + R-CHOP,"Progression free survival (PFS), Progression free survival (PFS) accessed by independent review committee (IRC), Up to 3 years and 9 months|Complete response rate (CRR) by independent review committee (IRC), Complete response rate (CRR) at the completion of combination therapy accessed by independent review committee (IRC), Up to 3 years and 9 months","Complete response rate (CRR) by investigator, Complete response rate (CRR) at the completion of combination therapy accessed by investigator, Up to 3 years and 9 months|Overall response rate (ORR) by independent review committee (IRC) and investigator, Overall response rate (ORR) accessed by independent review committee (IRC) and investigator, Up to 3 years and 9 months|Overall response rate (ORR) at the completion of combination therapy by independent review committee (IRC) and investigator, Overall response rate (ORR) at the completion of combination therapy accessed by independent review committee (IRC) and investigator, Up to 3 years and 9 months|Duration of Response (DOR), Duration of Response (DOR) accessed by independent review committee (IRC) and investigator, Up to 3 years and 9 months|Disease free survival (DFS) rate and event free survival (EFS) rate, 2-year disease free survival (DFS) rate and 2-year event free survival (EFS) rate, Up to 2 years|Overall survival (OS) rate, 2-year overall survival (OS) rate Accessed by independent review committee (IRC) and investigator, Up to 2 years|Occurrence of adverse events and serious adverse events according to CTCAE V5.0., The safety of Orelabrutinib measured by the occurrence of adverse events and serious adverse events according to CTCAE V5.0., Up to 3 years and 9 months",,"Beijing InnoCare Pharma Tech Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,150,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-11-02,2024-07-30,2025-12-30,2022-02-10,,2024-02-07,"The first affiliated hospital of bengbu medical college, Bengbu, Anhui, 233000, China|Anhui Provincal Cancer Hospital, Hefei, Anhui, 230031, China|Beijing Hospital, Beijing, Beijing, 100730, China|Chongqing University Cancer Hospital, Chongqing, Chongqing, 400000, China|The Southwest Hospital of AMU, Chongqing, Chongqing, 400000, China|Fujian Medical University Union Hospital, Fuzhou, Fujian, 350001, China|The First Affiliated Hospital Of XIAMEN University, Xiamen, Fujian, 361003, China|Gansu Provincial Cancer Hospital, Lanzhou, Gansu, 730050, China|The First People's Hospital of Foshan, Foshan, Guangdong, 528000, China|Guangdong General Hospital, Guangzhou, Guangdong, 510180, China|ZhuJiang Hospital of Southern Medical University, Guangzhou, Guangdong, 510280, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510700, China|PEKING University SHENZHEN Hospital, Shenzhen, Guangdong, 518036, China|Sun Yat-sen University Cancer Center Internal medicine department, Guandong, Guangzhou, 510060, China|Affiliated Hospital of Hebei University, Baoding, Hebei, 050031, China|The Second Hospital of Hebei Medical University, Shijia Zhuang, Hebei, 050000, China|The First Affiliated Hospital of Henan University of science and Technology, Luoyang, Henan, 450052, China|Henan Cancer Hospital, Zhengzhou, Henan, 450008, China|The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China|Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430023, China|Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China|The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011, China|Hunan Cancer Hospital, Changsha, Hunan, 410013, China|Chenzhou first people's Hospital, Chenzhou, Hunan, 423099, China|The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, 210008, China|Wuxi People's Hospital, Wuxi, Jiangsu, 214043, China|Jiangxi Cancer Hospital, Nanchang, Jiangxi, 330001, China|The First Affiliated Hospital Of Nanchang University, Nanchang, Jiangxi, 330006, China|The Second Hospital of Dalian Medical University, Dalian, Liaoning, 116023, China|The First Hospital of China Medical University, Shenyang, Liaoning, 110002, China|Qilu Hospital Of Shandong University, Jinan, Shandong, 250000, China|Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China|The Affiliated Hospital of Qingdao University, Qingdao, Shandong, 266400, China|Shanghai Changzheng Hospital, Shanghai, Shanghai, 200003, China|Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, 200025, China|Shanghai 6th People's Hospital, Shanghai, Shanghai, 201306, China|The first Affiliated Hospital Of Xi'an Jiaotong University, Xi'an, Shanxi, 710004, China|The Second Affiliated Hospital Of Xi'an Jiaotong University, Xi'an, Shanxi, 710004, China|West China Hospital Sichuan University, Chengdu, Sichuan, 610000, China|Tianjin Cancer Hospital, Tianjin, Tianjin, 300060, China|Affiliated Cancer Hospital of Xinjiang Medical University, ÃrÃ¼mqi, Xinjiang, 830000, China|The first affiliated Hospital Zhejiang University School Of Medicine, Hangzhou, Zhejiang, 310003, China|Sir Run Run Shaw Hospital Zhejiang University School Of Medicine, Hangzhou, Zhejiang, 310016, China|Shaoxing People's Hospital, Shaoxing, Zhejiang, 312000, China",
NCT06350097,"Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT06350097,TROPION-Lung14,RECRUITING,"The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Datopotamab Deruxtecan (i.v. infusion) compared with osimertinib (tablet) monotherapy as a first-line therapy in participants with locally advanced or metastatic EGFRm (Ex19del and/or L858R) NSCLC.

Study details include:

1. The study duration will be event-driven, with an estimated duration of approximately 9 years.
2. Participants may receive study treatment until disease progression, unacceptable toxicity, or other specific discontinuation criteria are met.
3. The visit frequency will be every 3 weeks during the treatment period.

Note: Participants on osimertinib treatment (osimertinib only arm or who have discontinued Datopotamab Deruxtecan while are still receiving osimertinib) are required to attend visits to perform assessments every 6 weeks from Cycle 7 until Cycle 17 and then visits every 12 weeks until disease progression, IP discontinuation or primary PFS DCO. Participants who are receiving osimertinib + Datopotamab Deruxtecan are still required to attend visit to perform assessment every 3 weeks (q3w) per SoA.",NO,Non-small Cell Lung Cancer,DRUG: Osimertinib|DRUG: Datopotamab Deruxtecan,"To demonstrate the superiority of osimertinib in combination with Datopotamab Deruxtecan relative to osimertinib by assessment of PFS by BICR in all randomised participants., PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause (in the absence of progression)., It is anticipated that it will be performed approximately 3 years after the first participant is randomised.","To demonstrate the superiority of osimertinib in combination with Datopotamab Deruxtecan relative to osimertinib by assessment of OS in all randomised participants., OS defined as the time from randomisation until the date of death due to any cause., It is anticipated that it will be performed approximately 7 years after the first participant has been randomised.|To demonstrate the effectiveness of osimertinib in combination with Datopotamab Deruxtecan relative to osimertinib by assessment of PFS on CNS metastases in participants with CNS metastases at baseline, Central nervous system progression-free survival (CNS PFS) is defined as the time from randomisation until the date of objective CNS progression assessed by CNS BICR or death (by any cause in absence of CNS progression)., It is anticipated that it will be performed approximately 3 years after the first participant is randomised.|To demonstrate the effectiveness of osimertinib in combination with Datopotamab Deruxtecan relative to osimertinib by assessment of PFS by investigator in all randomised participants., PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by investigator, or death due to any cause (in the absence of progression)., It is anticipated that it will be performed approximately 3 years after the first participant is randomised.|To demonstrate the effectiveness of osimertinib in combination with Datopotamab Deruxtecan relative to osimertinib by assessment of ORR in all randomised participants with measurable disease at baseline., ORR is defined as the proportion of participants who have a confirmed CR or confirmed PR, as determined by BICR (and investigator) per RECIST 1.1., It is anticipated that it will be performed approximately 3 years after the first participant is randomised.|To demonstrate the effectiveness of osimertinib in combination with Datopotamab Deruxtecan relative to osimertinib by assessment of DoR in all randomised participants with measurable disease at baseline., DoR is defined as the time from the date of first documented confirmed response until date of documented progression per RECIST 1.1, as assessed by BICR (and investigator) assessment or death due to any cause.

The measure of interest is the median of DoR., It is anticipated that it will be performed approximately 3 years after the first participant is randomised.|To demonstrate the effectiveness of osimertinib in combination with Datopotamab Deruxtecan relative to osimertinib on the prevention of CNS metastases, Neuro-radiologist assessments according to CNS RECIST 1.1 to determine the presence/absence of CNS lesions at progression in participants without CNS metastases at baseline., It is anticipated that it will be performed approximately 3 years after the first participant is randomised.|To demonstrate the effectiveness of osimertinib in combination with Datopotamab Deruxtecan relative to osimertinib by assessment of PFS2 in all randomised participants, PFS2 will be defined as the time from randomisation to the earliest of the progression event (following the initial progression) subsequent to first subsequent anti-cancer therapy, or death., It is anticipated that it will be performed approximately 7 years after the first participant has been randomised.|To assess the PK of osimertinib and Datopotamab Deruxtecan, Concentration of osimertinib and its metabolite AZ5104, Datopotamab Deruxtecan, total anti-TROP2 antibody and DXd in plasma., It is anticipated that it will be performed approximately 7 years after the first participant has been randomised.|To investigate the immunogenicity of Datopotamab Deruxtecan, Presence of ADAs for Datopotamab Deruxtecan (confirmatory results: positive or negative, titres, and neutralizing antibodies)., It is anticipated that it will be performed approximately 7 years after the first participant has been randomised.|To compare the local EGFR mutation test result used for patient selection with the retrospective central cobasÂ® EGFR Mutation Test v2 results from baseline tumour samples, Concordance of EGFR mutation status between the local EGFR mutation test and the central cobasÂ® EGFR Mutation Test v2 results from tumour samples with evaluable results., It is anticipated that it will be performed approximately 3 years after the first participant is randomised.|To demonstrate the effectiveness of osimertinib in combination with Datopotamab Deruxtecan vs. osimertinib monotherapy based on the cobasÂ® EGFR Mutation Test v2 plasma screening test result for Ex19del or L858R EGFR mutations, PFS by Investigator by plasma EGFR mutation status PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by investigator, or death due to any cause (in the absence of progression)., It is anticipated that it will be performed approximately 7 years after the first participant has been randomised.",,AstraZeneca,Daiichi Sankyo,ALL,"ADULT, OLDER_ADULT",PHASE3,582,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-04-29,2028-03-21,2032-05-25,2024-04-05,,2025-04-09,"Research Site, Fountain Valley, California, 92708, United States|Research Site, Los Alamitos, California, 90720, United States|Research Site, Los Angeles, California, 90017, United States|Research Site, Los Angeles, California, 90033, United States|Research Site, Los Angeles, California, 90095, United States|Research Site, Orange, California, 92868, United States|Research Site, San Diego, California, 92123, United States|Research Site, Walnut Creek, California, 94598, United States|Research Site, New Haven, Connecticut, 06510, United States|Research Site, Washington, District of Columbia, 20037, United States|Research Site, Jacksonville, Florida, 32256, United States|Research Site, Ocala, Florida, 34474, United States|Research Site, Honolulu, Hawaii, 96819, United States|Research Site, North Chicago, Illinois, 60064, United States|Research Site, Fort Wayne, Indiana, 46845, United States|Research Site, Bethesda, Maryland, 20817, United States|Research Site, Detroit, Michigan, 48201, United States|Research Site, Saint Paul, Minnesota, 55102, United States|Research Site, Saint Louis, Missouri, 63110, United States|Research Site, New York, New York, 10065, United States|Research Site, Houston, Texas, 77030, United States|Research Site, Houston, Texas, 77090, United States|Research Site, Webster, Texas, 77598, United States|Research Site, Woodway, Texas, 76712, United States|Research Site, Fairfax, Virginia, 22031, United States|Research Site, Fort Belvoir, Virginia, 22060, United States|Research Site, Midlothian, Virginia, 23114, United States|Research Site, Seattle, Washington, 98104, United States|Research Site, Clayton, 3168, Australia|Research Site, Kogarah, 2217, Australia|Research Site, South Brisbane, 4101, Australia|Research Site, Westmead, 2145, Australia|Research Site, Barretos, 14784-400, Brazil|Research Site, Natal, 59075-740, Brazil|Research Site, Porto Alegre, 91350-200, Brazil|Research Site, Salvador, 41253-190, Brazil|Research Site, Sao Paulo, 01246-000, Brazil|Research Site, Edmonton, Alberta, T6G 1Z2, Canada|Research Site, Montreal, Quebec, H4A 3J1, Canada|Research Site, Beijing, 100029, China|Research Site, Beijing, 100034, China|Research Site, Beijing, 100142, China|Research Site, Changchun, 130000, China|Research Site, Changsha, 410013, China|Research Site, Chengdu, 610000, China|Research Site, Chengdu, 610042, China|Research Site, Chengdu, 610072, China|Research Site, Chongqing, 400030, China|Research Site, Chongqing, 402260, China|Research Site, Guangzhou, 510100, China|Research Site, Hangzhou, 310006, China|Research Site, Hangzhou, 31000, China|Research Site, Hangzhou, 310022, China|Research Site, Hankou,Wuhan, 430022, China|Research Site, Harbin, 150049, China|Research Site, Hefei, 230031, China|Research Site, Hefei, 230601, China|Research Site, Jinan, 250021, China|Research Site, Jinan, 250117, China|Research Site, Kunming, 650118, China|Research Site, Linhai, 317000, China|Research Site, Ningbo, 315010, China|Research Site, Shanghai, 200030, China|Research Site, Shanghai, 200433, China|Research Site, Shenyang, 110004, China|Research Site, Wenzhou, 325000, China|Research Site, Wuhan, 430030, China|Research Site, Xi'an, 710061, China|Research Site, Xuzhou, 221000, China|Research Site, Yangzhou, 225001, China|Research Site, Zhengzhou City, 450000, China|Research Site, Zhengzhou, 450008, China|Research Site, Berlin, 13125, Germany|Research Site, Erfurt, 99089, Germany|Research Site, Frankfurt, 60488, Germany|Research Site, Goettingen, 37075, Germany|Research Site, Immenhausen, 34376, Germany|Research Site, Kiel, 24105, Germany|Research Site, KÃ¶ln, 51109, Germany|Research Site, Mainz, 55131, Germany|Research Site, MÃ¼nchen, 81925, Germany|Research Site, Hong Kong, 999077, Hong Kong|Research Site, Hong Kong, Hong Kong|Research Site, Jordan, HKG, Hong Kong|Research Site, Lai Chi Kok, Hong Kong|Research Site, Bangalore, 560027, India|Research Site, Delhi, 110085, India|Research Site, Hyderabad, 500032, India|Research Site, Kolkata, 700054, India|Research Site, Mysuru, 570017, India|Research Site, Nashik, 422011, India|Research Site, New Delhi, 100049, India|Research Site, Vadodara, 391760, India|Research Site, Varanasi, 221005, India|Research Site, Milano, 20141, Italy|Research Site, Monza, 20900, Italy|Research Site, Orbassano, 10043, Italy|Research Site, Padova, 35128, Italy|Research Site, Parma, 43100, Italy|Research Site, Chuo-ku, 104-0045, Japan|Research Site, Fukuoka-shi, 812-8582, Japan|Research Site, Kashiwa, 277-8577, Japan|Research Site, Koto-ku, 135-8550, Japan|Research Site, Niigata-shi, 951-8566, Japan|Research Site, Osaka-shi, 541-8567, Japan|Research Site, Osakasayama-shi, 589-8511, Japan|Research Site, Sendai-shi, 981-0914, Japan|Research Site, Wakayama-shi, 641-8510, Japan|Research Site, Yokohama-shi, 241-8515, Japan|Research Site, Erie, 16544, Korea, Republic of|Research Site, Goyang-si, 410-769, Korea, Republic of|Research Site, Namdong-gu, 21565, Korea, Republic of|Research Site, Seoul, 06351, Korea, Republic of|Research Site, Seoul, 120-752, Korea, Republic of|Research Site, Seoul, 13620, Korea, Republic of|Research Site, Bystra, 43-360, Poland|Research Site, Olsztyn, 10-357, Poland|Research Site, PoznaÅ, 60-569, Poland|Research Site, Warszawa, 02-781, Poland|Research Site, Rio Piedras, 00935, Puerto Rico|Research Site, San Juan, 00918, Puerto Rico|Research Site, Barcelona, 8036, Spain|Research Site, Granada, 18007, Spain|Research Site, La CoruÃ±a, 15006, Spain|Research Site, Madrid, 28040, Spain|Research Site, Majadahonda, 28222, Spain|Research Site, Valencia, 46009, Spain|Research Site, Taichung, 40705, Taiwan|Research Site, Tainan, 704, Taiwan|Research Site, Taipei City, 106, Taiwan|Research Site, Taipei, 10002, Taiwan|Research Site, Taipei, TAIWAN, Taiwan|Research Site, Taoyuan, 333, Taiwan|Research Site, Bangkok, 10400, Thailand|Research Site, Bangkok, 10700, Thailand|Research Site, Dusit, 10300, Thailand|Research Site, Hat Yai, 90110, Thailand|Research Site, Mueang Udon Thani, 41000, Thailand|Research Site, AdapazarÄ±, 54100, Turkey|Research Site, Ankara, 06530, Turkey|Research Site, Goztepe Istanbul, Turkey|Research Site, Izmir, 35100, Turkey|Research Site, KÃ¼Ã§Ã¼kÃ§ekmece, 34295, Turkey|Research Site, Seyhan, 1060, Turkey|Research Site, Ha noi, 100000, Vietnam|Research Site, Hanoi, 100000, Vietnam|Research Site, Ho Chi Minh City, Vietnam|Research Site, Ho Chi Minh, 700000, Vietnam|Research Site, Ho Chi Minh, 70000, Vietnam|Research Site, Vinh, 460000, Vietnam",
NCT05320692,A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma,https://clinicaltrials.gov/study/NCT05320692,,RECRUITING,A study to evaluate efficacy and safety of transarterial chemoembolization (TACE) in combination with Camrelizumab and Rivoceranib (Apatinib) therapy in patients with incurable hepatocellular carcinoma.,NO,Hepatocellular Carcinoma,DRUG: TACE+Camrelizumab+Apatinib mesylate|PROCEDURE: TACE,"PFS assessed by BIRC, PFS is defined as the time from the date of randomization until the date of first objective disease progression or death (whichever occurs first)., approximately 5 years","OS, OS is defined as the time from the date of randomization until death due to any cause., approximately 5 years|ORR, ORR is defined as the percentage of participants in the analysis population who have a CR or PR., approximately 5 years|DCR, DCR is defined as the percentage of participants in the analysis population who have a CR, PR or SD., approximately 5 years|DoR, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first., approximately 5 years|The incidence and severity of adverse events (AEs) and serious adverse events (SAEs) as assessed by CTCAE v5.0, approximately 5 years",,"Jiangsu HengRui Medicine Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,425,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-08-09,2026-07-30,2026-07-30,2022-04-11,,2025-02-18,"Zhongshan Hospital, Fudan University, Shanghai, Shanghai, 200032, China",
NCT06901531,A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer,https://clinicaltrials.gov/study/NCT06901531,LUCERNA,NOT_YET_RECRUITING,"Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer. Zolbetuximab with chemotherapy may be used to treat stomach and GEJ cancer when the cancer cells do not have a protein called HER2 (human epidermal growth factor receptor 2) on their surface (HER2-negative) but do have a protein called Claudin 18.2 (Claudin 18.2-positive). Zolbetuximab is thought to work by attaching to the Claudin 18.2 protein in their tumor, which switches on the body's immune system to attack the tumor. Certain stomach and GEJ cancers may be treated with immunotherapy, which helps the body's immune system fight cancer. This study will give more information about how well zolbetuximab works when given with an immunotherapy medicine called pembrolizumab and chemotherapy. In this study, adults with stomach cancer or GEJ cancer will either be given zolbetuximab with pembrolizumab and chemotherapy or a placebo with pembrolizumab and chemotherapy. A placebo looks like zolbetuximab but doesn't have any medicine in it.

The main aim of the study is to check how long people with stomach cancer and GEJ cancer live after treatment with zolbetuximab with pembrolizumab and chemotherapy compared to placebo with pembrolizumab and chemotherapy.

Adults with locally advanced unresectable or metastatic stomach cancer or GEJ cancer can take part. Locally advanced means the cancer has spread to nearby tissue. Unresectable means the cancer cannot be removed by surgery. Metastatic means the cancer has spread to other parts of the body. A tumor sample (biopsy) of their cancer will have the Claudin 18.2 protein, PD-L1 protein, and be HER2-negative. They may have been previously treated with certain standard therapies. People cannot take part if they need to take medicines to suppress their immune system, have blockages or bleeding in their gut, have specific uncontrollable cancers such as symptomatic or untreated cancers in the nervous system, or have a specific heart condition, or infections.

The study treatments are either zolbetuximab with pembrolizumab and chemotherapy, or placebo with pembrolizumab and chemotherapy. People who take part will receive just 1 of the study treatments by chance. The people in the study and the study doctors will not know who takes which of the study treatments. Study treatment will be given in 6-week (42-day) cycles. The study treatment is mainly given to people slowly through a tube into a vein. This is called an infusion. People will receive study treatment as follows: Zolbetuximab or placebo: 1 infusion every 2 or 3 weeks (2 or 3 infusions in a cycle) together with: Chemotherapy (1 of the following types of chemotherapy): 1. CAPOX (capecitabine and oxaliplatin): 1 infusion of oxaliplatin every 3 weeks (2 infusions in a cycle). People will also take 1 tablet of capecitabine twice a day for 2 weeks (14 days) at the start of each cycle (Day 1) and again in the middle of each cycle (Day 22). After 8 study treatments people will receive capecitabine only. 2. Modified FOLFOX6 or mFOLFOX6 (5-fluorouracil, folinic acid and oxaliplatin): 1 infusion every 2 weeks (3 infusions in a cycle). After 12 study treatments people will receive folinic acid and fluorouracil only, instead of mFOLFOX6. Pembrolizumab: 1 infusion every 3 or 6 weeks (1 or 2 infusions in a cycle). People can be in the study and will receive study treatment until their cancer worsens, they cannot tolerate the study treatment, or they need to start another cancer treatment. People may receive pembrolizumab for up to 2 years. People will visit the clinic on certain days to receive their study treatment and have health checks. The study doctors will check if people had any medical problems from taking zolbetuximab or the other study treatments. On some visits they will have scans to check for any changes in their cancer. People will have the option of giving a tumor sample if they stop treatment because their cancer has worsened. People will visit the clinic after they stop their study treatment. People will be asked about any medical problems and will have a health check. People will continue to have scans every 9 or 12 weeks to check for any changes in their cancer. They will have telephone health checks every 3 months. The number of visits and checks done at each visit will depend on the health of each person and whether they completed their study treatment or not.",NO,Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer|Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer|Metastatic Gastric Adenocarcinoma or Cancer|Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma,DRUG: zolbetuximab|DRUG: Pembrolizumab|DRUG: Capecitabine|DRUG: Oxaliplatin|DRUG: Folinic acid (leucovorin or local equivalent)|DRUG: 5-fluorouracil (5-FU)|DRUG: Placebo,"Overall Survival (OS), OS is defined as the time from the date of randomization until the date of death from any cause., Up to 72 months","Progression Free Survival (PFS), Defined as the time from the date of randomization until the date of radiologic PD \[investigator-assessed per Response Evaluation Criteria in Solid Tumors (RECIST) V1.1\] or death from any cause, whichever is earlier., Up to 72 Months|Objective Response Rate (ORR), Defined as the proportion of participants who have a Best Overall Response (BOR) or Complete Response (CR) or Partial Response (PR) as investigator assessed per RECIST V1.1., Up to 57 Months|Duration of Response (DOR), Defined as the time from the date of the first response (CR/PR) until the date of PD as investigator-assessed per RECIST V1.1 or date of death from any cause, whichever is earlier., Up to 72 Months|Number of participants with adverse Events (AEs), Adverse events (AEs) will coded using MedDRA. An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. This includes events related to the comparator, if applicable, and events related to the (study) procedures., Up to 57 Months|Number of participants with electrocardiograms (ECG) abnormalities and/or AEs, Number of participants with potentially clinically significant ECG values., Up to 57 Months|Number of Participants with Vital Sign abnormalities and/or AEs, Number of participants with potentially clinically significant vital sign values., Up to 57 Months|Number of participants at each grade of Eastern Cooperative Oncology Group (ECOG) performance status score, The ECOG scale will be used to assess performance status. Grades range from 0 (fully active) to 5 (dead). Negative change scores indicate an improvement. Positive scores indicate a decline in performance., Up to 57 Months|Number of participants with laboratory assessments abnormalities and/ or AEs, Number of participants with potentially clinically significant laboratory values., Up to 57 Months|Pharmacokinetics (PK) of zolbetuximab in serum: End of Infusion Concentration, Concentration will be derived from the PK serum samples collected at time of end of infusion., Up to 57 Months|Pharmacokinetics (PK) of zolbetuximab in serum: Concentration Immediately Prior to Dosing at multiple dosing (Ctrough), Ctrough will be derived from the PK serum samples collected., Up to 57 Months|Number of participants with positive antidrug antibodies (ADA) to zolbetuximab, Up to 57 Months",,"Astellas Pharma Global Development, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE3,500,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2025-05-31,2029-12-31,2029-12-31,2025-03-30,,2025-05-14,,
NCT06927986,A Study of SYS6010 and Platinum-based Chemotherapy in Patients With EGFR-mutated NSCLC.,https://clinicaltrials.gov/study/NCT06927986,,NOT_YET_RECRUITING,To evaluate the efficacy and safety of SYS6010 versus platinum-based chemotherapy in participants with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC),NO,EGFR-mutated Locally Advanced or Metastatic NSCLC,DRUG: SYS6010|DRUG: Pemetrexed|DRUG: Cisplatin|DRUG: Carboplatin,"Progression-free survival (PFS) assessed by independent review committee (IRC), Defined as the time from randomisation until the date of objective disease progression or death was assessed by IRC according to RECIST 1.1, Up to approximately 1.5 years","Investigator-assessed PFS, Defined as the time from randomisation until the date of objective disease progression or death was assessed by investigator according to RECIST 1.1, Up to approximately 1.5 years|Disease Control Rate (DCR), Defined as the percentage of subjects who have a best overall response of CR or PR or SD based on IRC and investigator according to RECIST 1.1, Up to approximately 2 years|Objective response rate (ORR), : Defined as the proportion of patients with response (including CR and PR) assessed by the investigator and the IRC according to RECIST v1.1., Up to approximately 1.5 years|Overall Survival (OS), Defined as the time from randomization until death from any cause, Up to approximately 2 years|Incidence of adverse events (AEs), AEs graded by CTCAE version 5.0, Up to approximately 2 years|Serious adverse events (SAEs), SAEs graded by CTCAE version 5.0, Up to approximately 2 years|EORTC QLQ-LC13 questionnaire, EORTC QLQ-LC13 incorporates one multi-item scale to assess dyspnoea, and a series of single items assessing pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and haemoptysis., Up to approximately 2 years|EORTC QLQ-30 questionnaire, EORTC QLQ-C30 is designed to measure cancer patients' physical, psychological and social functions., Up to approximately 2 years|Plasma concentrations of toxin-bound antibodies, Tests are conducted after single and continuous administration of SYS6010., Up to approximately 2 years|Plasma concentrations of total antibodies, Tests are conducted after single and continuous administration of SYS6010., Up to approximately 2 years|Plasma concentrations of free toxin (JS-1), Tests are conducted after single and continuous administration of SYS6010., Up to approximately 2 years|anti-SYS6010 antibodies (ADA), Incidence of SYS6010 anti-drug antibodies, Up to approximately 2 years",,"CSPC Megalith Biopharmaceutical Co.,Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,380,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2025-04-30,2026-07-30,2026-08-30,2025-04-15,,2025-04-15,,
NCT06452277,"A Study to Learn More About How Well BAY 2927088 Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)",https://clinicaltrials.gov/study/NCT06452277,SOHO-02,RECRUITING,"Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations.

Advanced NSCLC is a group of lung cancers that have spread to nearby tissues or to other parts of the body or that are unlikely to be cured or controlled with currently available treatments. HER2 is a protein that helps cells to grow and divide. A damage (also called mutation) to the building plans (genes) for this protein in cancer cells leads to a production of abnormal HER2 and therefore abnormal cell growth and division.

The study treatment, BAY 2927088, is expected to block the mutated HER2 protein which may stop the spread of NSCLC.

The main purpose of this study is to learn how well BAY 2927088 works and how safe it is compared with standard treatment, in participants who have advanced NSCLC with specific genetic changes called HER2 mutations.

The study participants will receive one of the study treatments:

* BAY 2927088 twice every day as a tablet by mouth, or
* Standard treatment in cycles of 21 days via infusion (""drip"") into the vein. The treatment will continue for as long as participants benefit from it without any severe side effects or until they or their doctor decide to stop the treatment.

During the study, the doctors and their study team will:

* take imaging scans, including CT, PET, MRI, and X-rays, of different parts of the body to study the spread of cancer
* check the overall health of the participants by performing tests such as blood and urine tests, and checking
* heart health using an electrocardiogram (ECG)
* perform pregnancy tests for women
* ask the participants questions about how they are feeling and what adverse events they are having.

An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment.",NO,Advanced Non-small Cell Lung Cancer|HER2 Mutation,DRUG: BAY2927088|DRUG: Pembrolizumab|DRUG: Cisplatin|DRUG: Carboplatin|DRUG: Pemetrexed,"Progression free survival (PFS) per RECIST 1.1 as assessed by BICR, RECIST 1.1 = Response Evaluation Criteria in Solid Tumors, version 1.1; BICR = blinded independent central review (BICR), Up to approximately 2 years","Overall survival (OS), Up to approximately 4 years.|Objective response rate (ORR) per RECIST 1.1 as assessed by BICR, RECIST 1.1 = Response Evaluation Criteria in Solid Tumors, version 1.1; BICR = blinded independent central review (BICR), Up to approximately 4 years|Progression free survival (PFS) per RECIST 1.1 as assessed by the investigator, RECIST 1.1 = Response Evaluation Criteria in Solid Tumors, version 1.1, Up to approximately 4 years|Objective Response Rate (ORR) per RECIST 1.1 as assessed by the investigator, Up to approximately 4 years|Disease control rate (DCR) per RECIST 1.1 as assessed by BICR, RECIST 1.1 = Response Evaluation Criteria in Solid Tumors, version 1.1; BICR = blinded independent central review (BICR), Up to approximately 4 years|Disease control rate (DCR) per RECIST 1.1 as assessed by the investigator, RECIST 1.1 = Response Evaluation Criteria in Solid Tumors, version 1.1, Up to approximately 4 years|Duration of response (DOR) as assessed by BICR, BICR = blinded independent central review (BICR), Up to approximately 4 years|Duration of response (DOR) as assessed by the investigator, Up to approximately 4 years|Adverse events per CTCAE v 5.0 (eg. TEAEs, TESAEs) categorized by severity, CTCAE = common terminology criteria for adverse events; TEAE = treatment-emergent adverse event; TESAE = treatment-emergent serious adverse event, Up to approximately 4 years|Change from baseline in NSCLC-SAQ total score, NSCLC-SAQ = Non-small cell lung cancer Symptom Assessment Questionnaire, Up to approximately 4 years|Change from baseline in NSCLC-SAQ individual domain scores, NSCLC-SAQ = Non-small cell lung cancer Symptom Assessment Questionnaire; Domains: cough, pain, dyspnea, fatigue, appetite, Up to approximately 4 years|Time to deterioration in NSCLC-SAQ total score, NSCLC-SAQ = Non-small cell lung cancer Symptom Assessment Questionnaire, Up to approximately 4 years|Time to deterioration in NSCLC-SAQ individual domain scores, NSCLC-SAQ = Non-small cell lung cancer Symptom Assessment Questionnaire; Domains: cough, pain, dyspnea, fatigue, appetite, Up to approximately 4 years|Time to deterioration in EORTC QLQ-C30 physical functioning domain score, EORTC QLQ-C30: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30, Up to approximately 4 years|Change from baseline in EORTC QLQ-C30 physical functioning domain score, EORTC QLQ-C30: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; QoL: quality of life, Up to approximately 4 years|Change from baseline in EORTC QLQ-C30 global health status/QoL, EORTC QLQ-C30: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; QoL: quality of life, Up to approximately 4 years",,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,278,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-08-28,2027-04-26,2029-04-26,2024-06-11,,2025-06-08,"Patty & George Hoag Cancer Center, Newport Beach, California, 92663, United States|UC San Diego Health - Moores Cancer Center, San Diego, California, 92093-1503, United States|University of California San Francisco (UCSF) - Thoracic Surgery and Oncology Clinic, San Francisco, California, 94115-3010, United States|University of California Los Angeles (UCLA) - Cancer Care - Santa Monica, Santa Monica, California, 90404-2023, United States|The Oncology Institute of Hope and Innovation, Whittier, California, 90602, United States|Memorial Cancer Institute at Miramar, Miramar, Florida, 33029, United States|AdventHealth Cancer Institute, Orlando, Florida, 32804, United States|Moffitt Cancer Center - Magnolia Campus, Tampa, Florida, 33612, United States|Moffitt Cancer Center, Tampa, Florida, 33612, United States|Piedmont Cancer Institute - Atlanta, Atlanta, Georgia, 30318, United States|John B. Amos Cancer Center, Columbus, Georgia, 31904, United States|University of Illinois at Chicago, Chicago, Illinois, 60607, United States|The U Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, 60805, United States|University of Maryland, Baltimore, Maryland, 21201, United States|UMass Memorial Medical Center - University Campus, Worcester, Massachusetts, 01655-0002, United States|Profound Research -OMG - TriAtria Cancer Center, Farmington Hills, Michigan, 48334, United States|Profound Research - OMG - Royal Oak Cancer Center, Royal Oak, Michigan, 48073, United States|University of Minnesota Medical Center, Minneapolis, Minnesota, 55455, United States|R.J. Zuckerberg Cancer Center, New Hyde Park, New York, 11042, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, 45219-2316, United States|Providence Cancer Institute - Franz Clinic, Portland, Oregon, 97213, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, 15212, United States|UT Southwestern, Dallas, Texas, 75235, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|Virginia Commonwealth University, Richmond, Virginia, 23298, United States|FundaciÃ³n Cenit para la InvestigaciÃ³n en Neurociencias, Caba, Ciudad Auton. De Buenos Aires, C1125 ABD, Argentina|Hospital Italiano de Buenos Aires, Buenos Aires, C1199ABB, Argentina|Centro de Educacion Medica e Investigaciones Clinicas ""Norberto Quirno"" (CEMIC), Buenos Aires, C1431FWO, Argentina|Centro MÃ©dico Privado CEMAIC, CÃ³rdoba, X5008HHW, Argentina|Instituto Argentino de Diagnostico y Tratamiento (IADT), TBC, TBC, Argentina|Centro de Investigaciones ClÃ­nicas, ClÃ­nica Viedma, Viedma, R8500, Argentina|Blacktown Cancer & Haematology Centre, Blacktown, New South Wales, 2148, Australia|Concord Repatriation General Hospital - Medical Oncology Clinical Trials Unit, Concord, New South Wales, 2139, Australia|Calvary Mater Hospital Newcastle, Waratah, New South Wales, 2298, Australia|University of the Sunshine Coast, Buderim, 4556, Australia|The Canberra Hospital (TCH) - Canberra Region Cancer Centre (CRCC), Garran, 2605, Australia|Austin Hospital - Olivia Newton John Cancer Research Institute, Heidelberg, 3084, Australia|Uniklinikum Salzburg, UniversitÃ¤tsklinik fÃ¼r Innere Medizin III, Salzburg, 5020, Austria|Uniklinikum Salzburg, UniversitÃ¤tsklinik fÃ¼r Pneumologie/ Lungenheilkunde, Salzburg, 5020, Austria|Medizinische UniversitÃ¤t Wien UniversitÃ¤tsklinik f. Innere Medizin I Klinische Abteilung fÃ¼r Onkologie, Wien, 1090, Austria|Klinik Floridsdorf, Pneumo-onkologische Ambulanz und Tagesklinik, Wien, 1210, Austria|UZ Leuven Gasthuisberg - Pneumology Department, Leuven, Vlaams-Brabant, 3000, Belgium|AZ Delta | Clinical Trial Center - Pneumology, Roeselare, West-Flanders, 8800, Belgium|Antwerp University Hospital | Oncology Department, Antwerpen, 2650, Belgium|Rede DoR Recife - PE, Recife, Pernambuco, 50070-480, Brazil|Liga Norte Riograndense Contra o Cancer | Centro de Pesquisa ClÃ­nica, Natal, Rio Grande Do Norte, 59040-000, Brazil|Irmandade Santa Casa de Misericordia de Porto Alegre | Oncology, Porto Alegre, Rio Grande Do Sul, 90020-090, Brazil|Centro de Pesquisa da ClÃ­nica de Oncologia Reichow, Blumenau, Santa Catarina, 89010-340, Brazil|Fundacao Pio XII - Hospital de Cancer de Barretos, Barretos, Sao Paulo, 14784-400, Brazil|Hospital de Base | Integrated Research Center, SÃ£o JosÃ© do Rio Preto, Sao Paulo, 15090-000, Brazil|NAIC - Instituto do Cancer, Bauru, 17033-490, Brazil|Hospital Sirio-Libanes (HSL) - Centro de Oncologia - Brasilia, Brasilia, 71635-610, Brazil|Pronutrir Fortaleza - CE, Fortaleza, 60810-180, Brazil|Hospital Sirio Libanes, Sao Paulo, 01308-050, Brazil|A Beneficencia Portuguesa de Sao Paulo - Hospital BP Mirante, Sao Paulo, 01323-030, Brazil|Centro Paulista de Oncologia (CPO) - Sao Paulo - Faria Lima, Sao Paulo, 04538-132, Brazil|MHAT Uni Hospital, Panagyurishte, Pazardzhik, 4500, Bulgaria|MHAT ""Heart and brain"" Pleven, Pleven, 5804, Bulgaria|Complex Oncology Center - Plovdiv EOOD, Plovdiv, 4004, Bulgaria|MHAT Park Hospital EOOD, Plovdiv, 4109, Bulgaria|Multiprofile Hospital for Active Treatment ""Sveta Sofia"", Sofia, 1404, Bulgaria|MHAT Serdika, Sofia, 1632, Bulgaria|Specialized Hospital for Active Treatment of Oncology, Sofia, 1797, Bulgaria|University Multiprofile Hospital For Active Treatment Sofiamed OOD, Sofia, Sofia, 1797, Bulgaria|MHAT Sveta Marina EAD, Varna, 9010, Bulgaria|Brampton Civic Hospital - Oncology, Brampton, Ontario, L6R 3J7, Canada|Princess Margaret Cancer Centre - University Health Network - Department of Medical Oncology and Hematology, Toronto, Ontario, M5G 2C4, Canada|Jewish General Hospital - Department of Pulmonary Oncology, Montreal, Quebec, H3T 1E2, Canada|BC Cancer - Vancouver, Vancouver, V5Z 4E6, Canada|Beijing Cancer Hospital, Beijing, Beijing, 100142, China|Beijing Hospital, Beijing, Beijing, 100730, China|Fujian Cancer Hospital, Fuzhou, Fujian, 350014, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150000, China|Union Hospi, Tongji Med College, Huazhong Univ. Scien&Tech, Wuhan, Hubei, 430023, China|Hubei Cancer Hospital, Wuhan, Hubei, 430079, China|Hunan Cancer Hospital, Changsha, Hunan, 410013, China|NJ Drum Tower Hospital, the Affil Hos of NJ Univ Med School, Nanjing, Jiangsu, 210008, China|Jilin Cancer Hospital, Changchun, Jilin, 130000, China|Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, Shanghai, 200030, China|West China Hospital Sichuan University, Chengdu, Sichuan, 610041, China|Sir Run Run Shaw Hospital, Zhejiang Univ. School of Medicine, Hangzhou, Zhejiang, 310016, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, 310022, China|Zhejiang University School of Medicine - Taizhou Hospital of Zhejiang Province, Taizhou, Zhejiang, 317000, China|Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, 100000, China|The People's Liberation Army General Hospital (Beijing 301 Hospital), Beijing, 100853, China|Beijing chest hospital, Capital Medical University, Beijing, 101149, China|University of Electronic Science & Technology of China - Sichuan Cancer Hospital & Institute (Sichuan Provincial Tumor Hospital), Chengdu, 610041, China|Guangzhou Medical University - The First Affiliated Hospital, Guangzhou, 510230, China|Shandong University - Shandong Cancer Hospital, Jinan, 250117, China|LinYi Cancer Hospital (Linyi Tumor Hospital), Linyi, 276001, China|Jiangsu Provincial People's Hospital - The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China|Guangxi Medical University (GXMU) - Affiliated Tumor Hospital, Nanning, 530021, China|Fudan University - Zhongshan Hospital, Shanghai, 200032, China|Xiamen University - The First Affiliated Hospital, Xiamen, 361003, China|KrajskÃ¡ nemocnice T. Bati - PneumoonkologickÃ¡ a klinickÃ¡ onkologie, Zlin, Zlinsky Kraj, 762 75, Czechia|Masarykova Univerzita - Masarykuv Onkologicky Ustav (MOU) - Klinika Komplexni Onkologicke Pece (KKOP), Brno, 602 00, Czechia|Nemocnice AGEL NovÃ½ JicÃ­n a.s. - OddelenÃ­ radioterapie a onkologie, NovÃ½ JicÃ­n, 741 01, Czechia|FakultnÃ­ Nemocnice Olomouc - Klinika plicnÃ­ch nemocÃ­ a tuberkulÃ³zy, Olomouc, 77900, Czechia|Nemocnice AGEL Ostrava-VÃ­tkovice a. s. - PlicnÃ­ oddelenÃ­, Ostrava - VÃ­tkovice, 703 00, Czechia|Aalborg University hospital - oncology department, Aalborg, 9000, Denmark|Aarhus Universitetshospital, Aarhus N, 8200, Denmark|Rigshospitalet - KrÃ¦ftbehandling, Copenhagen OE, 2100, Denmark|Regionshospitalet GÃ¸dstrup - Medicinsk afdeling, Herning, 7400, Denmark|Odense University Hospital - Oncology Department, Odense C, 5000, Denmark|Docrates MehilÃ¤inen SyÃ¶pÃ¤sairaala, Helsinki, FIN-00180, Finland|Turun yliopistollinen keskussairaala, Turku, 20520, Finland|Institut Bergonie - Unicancer Nouvelle Aquitaine, Bordeaux, 33076, France|Hopital La Cavale Blanche - CHU de Brest - institut de cancerologie et d'imagerie, Brest, 29200, France|Centre Hospitalier Intercommunal Creteil - Service de pneumologie, CrÃ©teil, 94010, France|Centre Hospitalier Michallon Grenoble - Service pneumologie, La Tronche, 38700, France|Institut Coeur Poumon CHRU Lille - Pole Cardio-vasculaire et pulmonaire, Lille, 59000, France|Centre Hospitalier Universitaire de Limoges - unite oncologie thoracique, Limoges, 87000, France|hopital Arnaud de Villeneuve CHU Montpellier - service oncologie thoracique, Montpellier, 34091, France|hopital Emile Muller - Service Pneumologie, Mulhouse, 68100, France|Hopital Nord Laennec - Oncologie medicale thoracique et digestive, Nantes, 44093, France|Centre Antoine Lacassagne - Departement Oncologie, Nice, 06100, France|hopital cochin APHP - service de pneumologie, Paris, 75014, France|Institut Curie - Paris - Oncologie medicale, Paris, 75248, France|hopital Lyon sud HCL - Pneumologie aigue specialisee et cancerologie thoracique, Pierre BÃ©nite, 69310, France|CHU de Rouen - Hopital Charles Nicolle - Service de Pneumologie, Rouen, 76031, France|Institut de Cancerologie Ouest - Saint-Herblain, Saint-Herblain, 44800, France|Hopital Foch - Oncologie digestive et thoracique, Suresnes, 92150, France|Gustave Roussy - Departement Oncologie-Radiotherapie, Villejuif Cedex, 94805, France|Universitaetsklinikum Giessen und Marburg - Medizinische Klinik IV Organonkologie, Giessen, Hessen, 35392, Germany|Kliniken der Stadt KÃ¶ln gGmbH - Krankenhaus Merheim - Lungenklinik, KÃ¶ln, Nordrhein-Westfalen, 51109, Germany|Universitaetsklinikum Essen - Innere Klinik (Tumorforschung), Essen, North Rhine-Westphalia, 45122, Germany|CharitÃ© UniversitÃ¤tsmedizin Berlin CBF - Med. Klinik mit Schwerpunkt HÃ¤matologie, Onkologie und Tumorimmunologie, Berlin, 12203, Germany|UniversitÃ¤tsklinikum Frankfurt - Medizinische Klinik II, HÃ¤matologie und Onkologie, Frankfurt, 60590, Germany|Lungenklinik Hemer, Thorakale Onkologie und onkologische Palliativmedizin, Hemer, 58675, Germany|Klinikum NÃ¼rnberg - Klinik fÃ¼r Innere Medizin 3, Schwerpunkt Pneumologie (Lungenheilkunde), NÃ¼rnberg, 90419, Germany|Robert Bosch Krankenhaus - Haematologie, Onkologie und Palliativmedizin, Stuttgart, 70376, Germany|?enry Durant Hospital Center-4th Oncology Department and Clinical Trials Unit, Athens, 115 26, Greece|University of Athens Medical School-Sotiria General Hospital - 3rd Dept of Medicine & Medical Oncology, Athens, 11527, Greece|General Hospital of Athens ""Alexandra''-Plasma Cell Dyscrasias,Department of Clinical Therapeutics,School of Medicine,NKUA, Athens, 11528, Greece|University General Hospital ATTIKON, Department of Internal Medicine IV, Chaidari, 12462, Greece|University General Hospital of Athens ""ATTIKON"", Chaidari, 12462, Greece|University General Hospital of Larissa, Larissa, 41110, Greece|Metropolitan Hospital- 4th Oncology Clinic, Piraeus, 18547, Greece|Bioclinic Thessaloniki, Thessaloniki, 54622, Greece|PAPANIKOLAOU General Hospital of Thessaloniki, Thessaloniki, 57010, Greece|Prince of Wales Hospital, Hong Kong, MISSING, Hong Kong|Queen Mary Hospital, Hong Kong, MISSING, Hong Kong|Queen Elizabeth Hospital Hong Kong, Hong Kong, Hong Kong|Hong Kong United Oncology Centre, Kowloon, 0, Hong Kong|Budapesti Uzsoki Utcai Korhaz - TÃ¼dogyÃ³gyÃ¡szati OsztÃ¡ly, Budapest, 1145, Hungary|Komarom-Esztergom Varmegyei Szent Borbala Korhaz, Tatabanya, 2800, Hungary|Assuta Ashdod Public Hospital (R.A), Ashdod, 7747629, Israel|Soroka Medical Center- Legacy Heritage Cancer Center, Be'er Sheva, 8410101, Israel|Shaare Zedek Medical Center (SZMC), Jerusalem, 91031, Israel|Tel-Aviv Sourasky Medical Center, Tel Aviv, 6423906, Israel|AORN San Giuseppe Moscati Avellino - U.O.C. Oncologia Medica, Avellino, Campania, 83100, Italy|Azienda Ospedaliero-Universitaria Di Bologna IRCCS_Policlinico Sant'Orsola - UOC Oncologia Medica, Bologna, Emilia-Romagna, 40138, Italy|Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l. - GDP Toracica, Meldola, Emilia-Romagna, 47014, Italy|Centro di Riferimento Oncologico di Aviano - Oncologia Medica e dei Tumori Immuno-Correlati, Aviano, Friuli-Venezia Giulia, 33081, Italy|I.F.O. Istituti Fisioterapici Ospitalieri_Ospedale Regina Elena -- Oncologia Medica 2, Roma, Lazio, 00128, Italy|Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOSD Oncologia Toraco-Polmonare, Roma, Lazio, 00168, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori - S. C. Oncologia Medica 1, Milano, Lombardia, 20133, Italy|Istituto Europeo di Oncologia s.r.l - Oncologia Toracica, Milano, Lombardia, 20141, Italy|Humanitas Mirasole S.p.A. - Oncologia Medica ed Ematologia, Rozzano, Lombardia, 20089, Italy|Azienda Ospedaliero-Universitaria San Luigi Gonzaga - Oncologia Medica, Orbassano, Piemonte, 10043, Italy|Istituto Oncologico Veneto_Padova - UOC Oncologia 2, Padova, Veneto, 35128, Italy|Careggi University Hospital - Oncologia Clinica, Firenze, 50134, Italy|Ospedale Vito Fazzi Lecce - Oncologia, Lecce, 73100, Italy|Ospedale San Raffaele s.r.l. - Oncologia Medica, Milano, 20132, Italy|Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello - Oncologia Medica, Palermo, 90146, Italy|ASST Sette Laghi_Ospedale Macchi - Oncologia, Varese, 21100, Italy|Centro Ricerche Cliniche Di Verona S.r.l. - Oncologia, Verona, 37134, Italy|National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, 460-0001, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, 277-8577, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, 060-8648, Japan|National Hospital Organization Himeji Medical Center, Himeji, Hyogo, 670-8520, Japan|Kobe University Hospital, Kobe, Hyogo, 650-0017, Japan|Kitasato University Hospital, Sagamihara, Kanagawa, 252-0375, Japan|Sendai Kousei Hospital, Sendai, Miyagi, 980-0873, Japan|Kansai Medical University Hospital, Hirakata, Osaka, 573-1191, Japan|Kindai University Hospital, Osakasayama, Osaka, 589-8511, Japan|Saitama Cancer Center, Kitaadachi-gun, Saitama, 362-0806, Japan|Nippon Medical School - Nippon Medical School Hospital - Cancer Center, Bunkyo-ku, Tokyo, 113-8603, Japan|Tottori University Hospital, Yonago, Tottori, 683-8504, Japan|National Hospital Organization-Yamaguchi-Ube Medical Center (Sanyo Hospital), Ube, Yamaguchi, 755-0241, Japan|National Hospital Organization Kyushu Medical Center, Fukuoka, 810-8563, Japan|Niigata Cancer Center Hospital, Niigata, 951-8566, Japan|Osaka International Cancer Institute, Osaka, 541-8567, Japan|Chungbuk National University Hospital, Cheongju-si, Chungcheongbugdo, 28644, Korea, Republic of|Gyeongsang National University Hospital, Jinju-si, Gyeongsangnam-do, 52727, Korea, Republic of|Pusan National University Yangsan Hospital, Yangsan-si, Gyeongsangnamdo, 50612, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Seoul Teugbyeolsi, 03722, Korea, Republic of|Seoul National University Hospital, Seoul, Seoul Teugbyeolsi, 3080, Korea, Republic of|Chonnam National University Hwasun Hospital, Hwasun Gun, 58128, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|Beacon Hospital, Petaling Jaya, Selangor, 46050, Malaysia|Columbia Asia Hospital Bukit Rimau, Shah Alam, Selangor, 40460, Malaysia|Sunway Medical Centre, Subang Jaya, Selangor, 47500, Malaysia|University Hospital Kebangsaan Malaysia, Cheras, 56000, Malaysia|Gleneagles Penang Medical Center, George Town,, 10050, Malaysia|University Malaya Medical Centre, Kuala Lumpur, 59100, Malaysia|Sunway Medical Centre Penang, Perai, 13700, Malaysia|Instituto Nacional de CancerologÃ­a, Mexico, Distrito Federal, 14080, Mexico|Oncare Viaducto NÃ¡poles, Cdmx, 3810, Mexico|OncologÃ­a Integral SatÃ©lite, Naucalpan, 53100, Mexico|Hospital Universitrio Dr. JosÃ© Eleuterio GonzÃ¡lez. Servicio de Oncologia, Nuevo LeÃ³n, 64460, Mexico|Clinica Integral Internacional de Oncologia S. de R.L. de C.V., Puebla, 72530, Mexico|ONCARE Treatment Center, San Pedro Garza GarcÃ­a, 66220, Mexico|Nederlands Kanker Instituut, Amsterdam, 1066 CX, Netherlands|Radboud University Medical Center | Afdeling Interne Geneeskunde, Nijmegen, 6500 HB, Netherlands|Narodowy Instytut Onkologii-im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy - Nowotworow Pluca i Klatki Piersiowej, Warsaw, Mazowieckie, 02-781, Poland|Narodowy Instytut Onkologii-im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy - Nowotworow Pluca i Klatki Piersiowej, Warsaw, Mazowieckie, 02-781, Poland|Uniwersytecki Szpital Kliniczny w Bialymstoku, Bialystok, 15-276, Poland|Swietokrzyskie Centrum Onkologii, Kielce, 25-734, Poland|Uniwersytecki Szpital Kliniczny Nr 2 Uniwersytetu Medycznego w Lodzi, Lodz, 92-213, Poland|Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy w Otwocku, Otwock, 05-400, Poland|Wielkopolskie Centrum Pulmonologii i Torakochirurgii, Poznan, 60-569, Poland|Dolnoslaskie Centrum Onkologii, Pulmonologii i Hematologii, Wroclaw, 53-413, Poland|Hospital Pedro Hispano | Clinical Research Center, Matosinhos, Porto, 4464-513, Portugal|Centro Hospitalar e Universitario de Coimbra EPE (CHUC), Coimbra, 3004-561, Portugal|Fundacao Champalimaud | Centro Clinico Champalimaud - Unidade Investigacao Clinica, Lisboa, 1400-038, Portugal|CHULN - Hospital Pulido Valente, Lisboa, 1769-001, Portugal|IPO Porto, Porto, 4200-072, Portugal|Radiotherapy Center Cluj SRL, Flore?ti, Comuna Floresti, 407280, Romania|Institutul Oncologic Prof. Dr. Alexandru Trestioreanu (IOB); Oncologie Medicala II, Bucuresti, 22328, Romania|Spitalul Clinic Coltea, Bucuresti, 30171, Romania|CardioMed S.R.L., Cluj-Napoca, 400015, Romania|Institutul Oncologic Prof. Dr. Ion Chiricuta, Cluj-Napoca, 400015, Romania|Sc Oncolab Srl, Craiova, 200385, Romania|Centrul de Oncologie Sfantul Nectarie, Craiova, 200745, Romania|S.C Ovidius Clinical Hospital SRL - Oncology Department, Ovidiu, 905900, Romania|Oncocenter, Timisoara, 300166, Romania|Raffles Cancer Centre, Singapore, 188770, Singapore|OncoCare Cancer Centre | Gleneagles Medical Centre, Singapore, 258499, Singapore|Tan Tock Seng Hospital, Singapore, 308433, Singapore|Curie Oncology | Farrer, Singapore, 329563, Singapore|POKO Poprad s.r.o., Poprad, 058 01, Slovakia|Fakultna nemocnica Trnava, Trnava, 91775, Slovakia|Hospital Universitario Puerta De Hierro De Majadahonda - Oncologia, Majadahonda, Madrid, 28222, Spain|Complejo Hospitalario Universitario A Coruna (CHUAC), A Coruna, 15006, Spain|Institut Catala d'Oncologia (ICO) - Hospital Universitari Germans Trias i Pujol (HUGTP) Location, Badalona, 8916, Spain|Hospital Quiron Dexeus - Oncologia, Barcelona, 08028, Spain|Ciutat Sanitaria i Universitaria de la Vall d'Hebron, Barcelona, 08035, Spain|Hospital Clinic de Barcelona (Hospital Clinic i Provincial), Barcelona, 08036, Spain|Hospital General Universitario Gregorio Maranon | Oncologia, Madrid, 28009, Spain|Hospital Universitario Ramon Y Cajal - Oncologia, Madrid, 28034, Spain|Fundacion Jimenez Diaz (Clinica de la Concepcion), Madrid, 28040, Spain|Hospital Universitario De Navarra - Oncologia, Pamplona, 31008, Spain|Fundacion Instituto Valenciano de Oncologia (IVO, Valencia, 46009, Spain|Hospital Universitario Y Politecnico La Fe - Oncologia, Valencia, 46026, Spain|SkÃ¥ne University Hospital, Lund, 221 85, Sweden|Norrland University Hospital - Cancercentrum, UmeÃ¥, 90185, Sweden|Kantonsspital Baden, Baden, Aargau, 5404, Switzerland|HFR Freiburg - Kantonsspital, Fribourg, 1708, Switzerland|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Kaohsiung, 807377, Taiwan|National Cheng Kung University Hospital, Tainan, TNN, 704, Taiwan|Chung Shan Medical University Hospital, Taichung, 402306, Taiwan|Taichung Veterans General Hospital, Taichung, 40705, Taiwan|Chi-Mei Medical Center, Liouyine, Tainan, 73657, Taiwan|National Taiwan University Hospital (NTUH) - Cancer Research Center, Taipei, 100225, Taiwan|National Taiwan University Hospital, Taipei, 100, Taiwan|Taipei Veterans General Hospital, Taipei, 11217, Taiwan|Ankara Bilkent Sehir Hastanesi, Bilkent Ankara, 6800, Turkey|Marmara University Hospital, Istanbul, 34899, Turkey|Ege Universitesi Tip Fakultesi, Izmir, 35100, Turkey|Istanbul Medeniyet Ãniversitesi GÃ¶ztepe SÃ¼leyman YalÃ§in Sehir Hastanesi, Kadikoy, 34722, Turkey|I.A.Ã. VM Medical Park Florya Hastanesi, Kucukcekmece, 34295, Turkey|Sakarya Universitesi Egitim ve Arastirma Hastanesi, Sakarya, 54100, Turkey|Ankara Etlik Sehir Hastanesi, Yenimahalle, 6170, Turkey|Adana Sehir Egitim ve Arastirma Hastanesi, Yuregir, 1370, Turkey|LLC ""RDP Ukraine"" - Medical Department, Dnipro, 49102, Ukraine|Private Enterprise Private Production Company ""Acinus"", Treatment and Diagnostic Center, Kropyvnytskyi, 25006, Ukraine|Kyiv City Clinical Oncology Center - Department of Chemotherapy #1, Kyiv, 03115, Ukraine|Limited Liability Company ""MedOffice Group Medical Center"", Kyiv, 03189, Ukraine|Medical Center LLC ""Verum Expert Clinic"", Kyiv, 3039, Ukraine|Volyn Regional Oncology Center, Lutsk, 43018, Ukraine|Municipal Enterprise 'Rivne Regional Antitumor Center"" of the Rivne Regional Council"", Rivne, 33007, Ukraine|MNCE ""Uzhhorod City Multidisciplinary Clinical Hospital"" -Oncology Department, Uzhhorod, 88000, Ukraine|Torbay Hospital, Torquay, Devon, TQ2 7AA, United Kingdom|Belfast City Hospital, Belfast, North Ireland, BT12 7AB, United Kingdom|Royal Surrey County Hospital, Guildford, Surrey, GU2 7XX, United Kingdom|Velindre University NHS Trust | Velindre Cancer Centre - Clinical Trials Unit, Cardiff, CF14 2TL, United Kingdom",
NCT06698042,A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84),https://clinicaltrials.gov/study/NCT06698042,,RECRUITING,"Researchers are looking for new ways to treat non-small cell lung cancer (NSCLC) that is metastatic, which means cancer has spread to other parts of the body.

Some people with metastatic NSCLC are treated with pembrolizumab, an immunotherapy treatment that is given into a vein as an intravenous (IV) infusion. Pembrolizumab (+) Berahyaluronidase alfa is pembrolizumab that is given under the skin as a subcutaneous (SC) injection. The goal of this study is to compare what happens to pembrolizumab in a person's body over time when it is given as an IV infusion or SC injection.",NO,Lung Cancer|Non-Small Cell Lung Cancer,BIOLOGICAL: Pembrolizumab (+) Berahyaluronidase alfa|BIOLOGICAL: Pembrolizumab,"Area Under the Curve (AUC) of Pembrolizumab Measured After the First Dose, AUC is defined as area under curve exposure. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine AUC., At designated time points (up to approximately 14 months)|Trough Concentration (Ctrough) of Pembrolizumab Measured at Steady State, Ctrough is defined as the trough concentration at steady-state. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine Ctrough, At designated time points (Up to ~18 months)","Maximum Serum Concentration (Cmax) of Pembrolizumab Measured After the First Dose, Cmax is defined as the peak concentration over the dosing interval. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine Cmax., At designated time points (Up to ~28 months)|Trough Concentration (Ctrough) of Pembrolizumab Measured After the First Dose, Ctrough is defined as the trough concentration. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine Ctrough., At designated time points (Up to ~28 months)|AUC of Pembrolizumab Measured at Steady State, AUC is defined as area under curve exposure at steady state. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine AUC., At designated time points (Up to ~28 months)|Maximum Serum Concentration (Cmax) of Pembrolizumab Measured at Steady State, Cmax is defined as the peak concentration over the dosing interval in steady-state. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine Cmax, At designated time points (Up to ~28 months)|Model-based Ctrough of Pembrolizumab Measured After the First Dose, Model-based Ctrough is defined as the value of trough concentration at the end of the dosing interval, as predicted by the population PK model., At designated time points (Up to ~28 monhts|Model-based Ctrough of Pembrolizumab Measured at Steady State, Model-based steady-state Ctrough is defined as the value of trough concentration at the end of the dosing interval at steady-state, as predicted by the population PK model., At designated time points (Up to ~28 months)|Number of participants with antipembrolizumab antibodies, Blood samples are to be collected at designated time points for the determination of the presence or absence of anti-pembrolizumab antibodies. The percentage of participants who develop anti pembrolizumab antibodies will be reported., Baseline and up to approximately 28 months|Objective Response Rate (ORR), ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented., Up to approximately 60 months|Progression-free Survival (PFS), PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as â¥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of â¥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review (BICR) will be presented., Up to approximately 60 months|Overall survival (OS), OS is defined as time from randomization to death due to any cause., Up to approximately 60 months|Duration of Response (DOR), For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1), DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by Blinded Independent Central Review (BICR) will be presented, Up to approximately 60 months|Number of Participants Who Experience an AE- All Participants, An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment., Up to approximately 28 months|Number of Participants Who Discontinue Study Intervention Due to an AE, An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment., Up to approximately 25 months|Change in Score from Baseline: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)Global Health Status/Quality of Life (QoL)- Items 29 and 30, The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions ""How would you rate your overall health during the past week?"" and ""How would you rate your overall quality of life during the past week?"" are scored on a 7- point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status. The change from baseline in EORTC QLQ-C30 Items 29 and 30 combined score will be presented., Baseline and up to approximately 26 months|Change in Score from Baseline: EORTC QLQ-C30 Physical Functioning (Items 1 to 5), Change from baseline in the score of EORTC QLQ-C30 Items 1-5 will be presented. The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Higher scores indicate a worse level of function., Baseline and up to approximately 26 months|Change in Score from Baseline: EORTC QLQ-C30 Role functioning (Items 6 and 7), Change from baseline in the score of EORTC QLQ-C30 Items 6-7 will be presented. The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to questions about their role functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Higher scores indicate a worse level of function., Baseline and up to approximately 26 months",,Merck Sharp & Dohme LLC,,ALL,"ADULT, OLDER_ADULT",PHASE3,160,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-11-21,2026-06-22,2030-02-11,2024-11-20,,2025-06-13,"Providence Medical Foundation ( Site 0117), Fullerton, California, 92835, United States|Illinois Cancer Care ( Site 0101), Peoria, Illinois, 61615, United States|Montefiore Medical Center ( Site 0104), Bronx, New York, 10461, United States|University of Cincinnati Medical Center ( Site 0112), Cincinnati, Ohio, 45219, United States|Beijing Peking Union Medical College Hospital ( Site 5000), Beijing, Beijing, 100730, China|Chongqing University Three Gorges Hospital ( Site 5018), Chongqing, Chongqing, 404000, China|Fujian Province Cancer Hospital ( Site 5007), Fuzhou, Fujian, 350014, China|The First Affiliated hospital of Xiamen University ( Site 5008), XiaMen, Fujian, 361003, China|The first affiliated hospital, Sun Yat-Sen university ( Site 5011), Guangzhou, Guangdong, 510080, China|Southern Medical University Nanfang Hospital ( Site 5003), Guangzhou, Guangdong, 510515, China|Huizhou Central People's Hospital ( Site 5004), Huizhou, Guangdong, 516001, China|Jiangmen Center Hospital ( Site 5001), Jiangmen, Guangdong, 529030, China|Liuzhou People's Hospital ( Site 5009), Liuzhou, Guangxi, 545006, China|Wuhan Union Hospital Cancer Center-Cancer Center ( Site 5015), Wuhan, Hubei, 430048, China|The First Affiliated Hospital of Nanchang University ( Site 5019), Nanchang, Jiangxi, 330006, China|Jilin Province Tumor Hospital ( Site 5014), Changchun, Jilin, 130000, China|Jinan Central Hospital ( Site 5012), Jinan, Shandong, 250013, China|Shanghai Pulmonary Hospital ( Site 5010), Shanghai, Shanghai, 200433, China|West China Hospital of Sichuan University ( Site 5016), Chengdu, Sichuan, 610041, China|Sichuan Cancer Hospital. ( Site 5006), Chengdu, Sichuan, 610213, China|Sir Run Run Shaw Hospital of Zhejiang University School of Medicine ( Site 5021), Hangzhou, Zhejiang, 310016, China|Taizhou Hospital of Zhejiang Province ( Site 5002), Linhai, Zhejiang, 317000, China|CELAN,S.A ( Site 1104), Guatemala., 01010, Guatemala|MEDI-K ( Site 1101), Guatemala, 01009, Guatemala|Private Practice- Dr. Rixci Augusto Lenin RamÃ­rez ( Site 1102), Guatemala, 01010, Guatemala|Centro Medico Integral De CancerologÃ­a (CEMIC) ( Site 1103), Quetzaltenango, 09002, Guatemala|Fujita Health University Hospital ( Site 4004), Toyoake, Aichi, 470-1192, Japan|Ehime University Hospital ( Site 4007), Toon, Ehime, 791-0295, Japan|Takarazuka City Hospital ( Site 4006), Takarazuka, Hyogo, 665-0827, Japan|Kanagawa Cardiovascular and Respiratory Center ( Site 4002), Yokohama, Kanagawa, 236-0051, Japan|Miyagi Cancer Center ( Site 4000), Natori, Miyagi, 981-1293, Japan|National Hospital Organization Kinki-chuo Chest Medical Center ( Site 4009), Sakai, Osaka, 591-8555, Japan|Saitama Prefectural Cancer Center ( Site 4001), Kitaadachi-gun, Saitama, 362-0806, Japan|Tochigi Cancer Center ( Site 4008), Utsunomiya, Tochigi, 320-0834, Japan|Juntendo University Hospital ( Site 4003), Bunkyo, Tokyo, 113-8431, Japan|Osaka International Cancer Institute ( Site 4005), Osaka, 541-8567, Japan|Pusan National University Hospital ( Site 3002), Pusan Kwangyokshi, Pusan-Kwangyokshi, 49241, Korea, Republic of|Chungnam National University Hospital ( Site 3003), Daejeon, Taejon-Kwangyokshi, 35015, Korea, Republic of|Korea University Guro Hospital ( Site 3001), Seoul, 8308, Korea, Republic of|ClÃ­nica Internacional - Sede San Borja ( Site 1002), Lima, 15036, Peru|IPOR Instituto Peruano de OncologÃ­a & Radioterapia ( Site 1004), Lima, 15036, Peru|Oncosalud ( Site 1000), Lima, 15036, Peru|Mazowiecki Szpital WojewÃ³dzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 2305), Siedlce, Mazowieckie, 08-110, Poland|Narodowy Instytut Onkologii ( Site 2303), Warsaw, Mazowieckie, 02-781, Poland|SC Radiotherapy Center Cluj SRL ( Site 2203), Floresti, Cluj, 407280, Romania|S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 2201), Craiova, Dolj, 200746, Romania|Institutul Oncologic ( Site 2202), Cluj, 400015, Romania|Onkologikoa - Instituto Oncologico de San Sebastian ( Site 2454), San Sebastian, Gipuzkoa, 20014, Spain|Hospital General Universitari Vall d Hebron ( Site 2450), Barcelona, 08035, Spain|INSTITUTO CATALAN DE ONCOLOGIA- LÂ´HOSPITALET DE LLOBREGAT ( Site 2451), Barcelona, 08908, Spain|Hospital Universitario Juan Ramon Jimenez ( Site 2453), Huelva, 21005, Spain|Hospital Universitario Virgen Macarena ( Site 2455), Sevilla, 41009, Spain|Ege Universitesi Hastanesi-Chest Diseases Department ( Site 2501), Bornova, Izmir, 35100, Turkey|Gulhane Egitim Arastirma Hastanesi ( Site 2504), Ankara, 06010, Turkey|Hacettepe Universite Hastaneleri-oncology hospital ( Site 2500), Ankara, 06230, Turkey|Gazi University Health Research and Application Center Gazi Hospital-Oncology ( Site 2502), Ankara, 06560, Turkey|Ankara Bilkent Sehir Hastanesi ( Site 2503), Ankara, 06800, Turkey|TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi ( Site 2506), Ä°stanbul, 34722, Turkey|Torbay Hospital ( Site 2100), Torquay, England, TQ2 7AA, United Kingdom|The Royal Cornwall Hospital ( Site 2102), Truro, England, TR1 3LJ, United Kingdom",
NCT03049189,Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients,https://clinicaltrials.gov/study/NCT03049189,COMPETE,ACTIVE_NOT_RECRUITING,"The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).",NO,Neuroendocrine Tumors,DRUG: 177Lu-edotreotide PRRT|DRUG: Everolimus|OTHER: Amino-Acid Solution,"progression-free survival (PFS), PFS will be assessed individually per patient from date of randomization until the date of first documented progression or death, assessed up to 30 months, primary outcome will be measured by CT/MRI every 12 weeks +/- 14 days, 12 weeks +/- 14 days, up to 30 months","objective response rates (ORR), ORR will be assessed, defined as the proportion of patients achieving partial response (PR) or complete response (CR) as best outcome, after treatment with 177Lu-edotreotide compared to everolimus, 12 weeks +/- 14 days, up to 30 months|overall survival (OS), OS as secondary outcome measure will be assessed per patient from date of randomization until the date of death, 12 weeks +/- 14 days, up to 90 months",,ITM Solucin GmbH,ABX CRO|PSI CRO,ALL,"ADULT, OLDER_ADULT",PHASE3,309,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2017-02-02,2024-11-27,2029-11,2017-02-09,,2025-05-30,"Banner Health d.b.a. Banner MD Anderson Cancer Center, Gilbert, Arizona, 85234, United States|Stanford University, Stanford, California, 94305, United States|Moffitt Cancer Center & Research Institute, Tampa, Florida, 33612, United States|Northwestern Memorial Hospital, Chicago, Illinois, 60611, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, 48109, United States|Excel Diagnostics & Nuclear Oncology Center, Houston, Texas, 77042, United States|Royal North Shore Hospital, Saint Leonards, New South Wales, 2065, Australia|Olivia Newton-John Cancer & Wellness Centre, Austin Hospital, Heidelberg, Victoria, 3084, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, 3000, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, 6150, Australia|Allgemeines Krankenhaus Wien, Wien, 1090, Austria|Institut Jules Bordet, Brussels, 1000, Belgium|Universitaire Ziekenhuizen Leuven, Leuven, 3000, Belgium|University Hospital Olomouc, Olomouc, 775 20, Czechia|University Hospital Motol, Prague, 150 06, Czechia|Hospices civils de Lyon, Bron, 69677, France|Centre Jean Perrin, Clermont-Ferrand, 63011, France|HP HÃ´pital Beaujon, Clichy, 92110, France|Institut de Recherche en CancÃ©rologie de Montpellier (IRCM), Montpellier, 34298, France|CHU de Nantes - HÃ´tel Dieu, Nantes, 44093, France|IUCT-Oncopole, Toulouse, 31059, France|Zentralklinik Bad Berka GmbH, Bad Berka, 99437, Germany|CharitÃ© - UniversitÃ¤tsmedizin Berlin, Berlin, 10117, Germany|UniversitÃ¤tsklinikum Bonn, Bonn, 53127, Germany|UniversitÃ¤tsklinikum Erlangen, Erlangen, 91054, Germany|UniversitÃ¤tsklinikum Essen, Essen, 45147, Germany|University Medical Center, Abteilung fÃ¼r Nuklearmedizin, Hamburg, 20251, Germany|UniversitÃ¤tsklinikum Magdeburg A.Ã¶.R., Otto-von-Guericke UniversitÃ¤t, Magdeburg, 39120, Germany|Philipps UniversitÃ¤t Marburg, Marburg, 35043, Germany|Klinikum rechts der Isar Technische UniversitÃ¤t MÃ¼nchen, Munich, 81675, Germany|UniversitÃ¤tsklinikum Ulm, Ulm, 89081, Germany|UniversitÃ¤tsklinikum WÃ¼rzburg, Wurzburg, 97080, Germany|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Srl, Meldola, 47014, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, 20133, Italy|European Institute of Oncology (EIO), Milano, 20141, Italy|Academic Medical Center, University of Amsterdam, Amsterdam, 1100DD, Netherlands|MSC Memorial Cancer Centre, Gliwice, 44-100, Poland|""Gammed"" Izabela Chuchrowksa, Warsaw, 02-351, Poland|University Cape Town (UCT), Groote Schuur Hospital, Cape Town, 7925, South Africa|University of Pretoria & Steve Biko Academic Hospital, Pretoria, 0001, South Africa|Vall d'Hebron University Hospital, Barcelona, 08035, Spain|ICO Hospitalet, Granvia de l'Hospitalet, Barcelona, 08909, Spain|MD Anderson Cancer Center Madrid, Madrid, 28033, Spain|University Hospital 12 de Octubre, Madrid, 28041, Spain|Central University Hospital de Asturias (HUCA), Oviedo, 33011, Spain|University and Polytechnic Hospital La Fe, Valencia, 46026, Spain|UniversitÃ¤tsspital Basel, Basel, 4031, Switzerland|Inselspital, UniversitÃ¤tsspital Bern, Bern, 3010, Switzerland|UniversitÃ¤tsSpital ZÃ¼rich, ZÃ¼rich, 8091, Switzerland|Royal Free NHS Foundation Trust, London, NW3 2QG, United Kingdom|Kings College Hospital, London, SE5 9RS, United Kingdom|The Christie NHS Foundation Trust, Manchester, M20 4BX, United Kingdom",
NCT04960709,"Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin",https://clinicaltrials.gov/study/NCT04960709,VOLGA,ACTIVE_NOT_RECRUITING,"A global phase 3, multicenter, randomized, trial, to Determine the Efficacy and Safety of Durvalumab in combination with Tremelimumab and Enfortumab Vedotin or Durvalumab in combination with Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or who refuse Cisplantin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer.

The goal of the study is to explore the triplet combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or the duplet combination of Durvalumab and Enfortumab vedotin in terms of efficacy and safety compared to the current Standard Of Care (SOC).

Volga trial consists of two parts: Safety Run-In and Main Study. In total the study aims to enroll approximately 677 patients, who will receive triplet combination, duplet combination or currently approved SOC in the main trial. In the main part of the trial there is two out of three chances of being on a treatment arm and the treatment is assigned at random by a computer system.

In this trial patients in the two treatment arms will receive either 3 cycles of neoadjuvant Durvalumab + Tremelimumab + Enfortumab Vedotin or Durvalumab + Enfortumab vedotin and after surgery both treatment arms will continue with adjuvant Durvalumab.",NO,Muscle Invasive Bladder Cancer,DRUG: Durvalumab|DRUG: Tremelimumab|DRUG: Enfortumab Vedotin|PROCEDURE: Radical Cystectomy,"To assess the safety and tolerability as evaluated by adverse events occurring throughout the study (Safety Run-In part), Frequency of Adverse Events., At completion of study treatment by the last patient and at 3 months.|To assess the safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin as assessed by vital signs (blood pressure in mmHg) (Safety Run-In part), Up to 84 months|To assess the safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin as assessed by vital signs (pulse rate) in beats per minute (Safety Run-In part), Up to 84 months|To assess the safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin as assessed by vital signs (respiration rate) in breaths per minute (Safety Run-In part), Up to 84 months|To assess the safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin as assessed by vital signs (temperature) in degrees Celsius (Safety Run-In part), Up to 84 months|To assess the safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin as assessed by abnormality in clinical chemistry by liver function (Safety Run-In part), Clinical chemistry will be assessed by liver function assessment (ALT, AST, albumin, total bilirubin measured in units per dL), Up to 84 months|Safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin or who refuse cisplatin as assessed by abnormality in clinical chemistry by kidney function (Safety Run-In part), Clinical chemistry will be assessed by kidney function assessment in mg/dL, Up to 84 months|To assess the safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin as assessed by abnormality in clinical chemistry by thyroid function (Safety Run-In part), Clinical chemistry will be assessed by thyroid function assessment in units per mL., Up to 84 months|To assess the safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin as assessed by abnormality in haematology (Safety Run-In part), Hematology will be assessed by white cell count, platelet count, absolute neutrophil count and absolute lymphocyte count., Up to 84 months|To assess the safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin as as assessed by ECG (pulse rate) (Safety Run-In part), Up to 84 months|Changes in WHO/ECOG performance status (Safety Run-In part), Eastern Cooperative Oncology Group (ECOG) performance status scale range 0 to 5, where 0 is fully active, able to carry on all pre disease performance without restriction - best outcome and 5 -death - worst outcome., Up to 84 months|Compare efficacy of durvalumab + tremelimumab + EV (Arm 1) relative to cystectomy (Arm 3) and durvalumab + EV (Arm 2) relative to cystectomy (Arm 3) on EFS (Main Study), Event-free survival (EFS;) is defined as the time from randomization to the first occurrence of any of the following events: recurrence of disease post-radical cystectomy, the first documented progression in participants who did not receive radical cystectomy, failure to undergo radical cystectomy in participants with residual disease, or death due to any cause, up to 3 years., Up to 3 years","1. To evaluate the efficacy of durvalumab + tremelimumab + EV on pCR rate (Safety Run-in part), Pathologic complete response (pCR) rate is defined as the number of participants whose pathological staging was T0N0M0 as assessed per local pathological review using specimens obtained via cystectomy, at 3 years., 3 years|2. To evaluate the efficacy of durvalumab + tremelimumab + EV on EFS (Safety Run-in part), Event-free survival (EFS;) is defined as the time from randomization to the first occurrence of any of the following events: recurrence of disease post-radical cystectomy, the first documented progression in participants who did not receive radical cystectomy, failure to undergo radical cystectomy in participants with residual disease, or death due to any cause, up to 3 years., 3 years|3. Pathologic complete response (pCR) rates at time of cystectomy in Arm1 vs Arm3 and Arm 2 vs Arm 3 (Main Study part), Pathologic complete response (pCR) rate is defined as the number of participants whose pathological staging was T0N0M0 as assessed per local pathological review using specimens obtained via cystectomy, at 3 years., 3 years|4. Overall survival (Safety Run-in and Main Study part), Overall Survival is defined as length of time from randomization until the date of death due to any cause, whichever came first, assessed up to 5 years., Up to 5 years|5. EFS at 24 months (EFS24) (Safety Run-in and Main Study part), EFS24 is defined as proportion of participants alive and event-free at 24 months, Up to 24 months|6. Overall survival rate at 5 years (Safety Run-in and Main Study part), The proportion of participants alive at 5 years (OS5) is defined as the Kaplan-Meier estimate of OS at 5 years after randomization, At 5 years|7. Disease-free survival (DFS) (Safety Run-in and Main Study part), DFS is defined as time from radical cystectomy to recurrence or death, whichever came first, assessed up to 5 years., Up to first recurrence of disease or death up to 5 years|8. Pathologic downstaging (pDS) rate-to < pT2 (Safety Run-in and Main Study part), pDS rate is defined as the rate of downstaging to \< pT2, including pT0, pTis, pTa, pT1, and N0, 3 years|9. Disease-specific survival (DSS) (Safety Run-in and Main Study part), DSS is defined as time from randomization until death due to bladder cancer, assessed up to 5 years., from randomization until death due to bladder cancer up to 5 year.|10. EORTC QLQ-C30 European Organisation for Research and Treatment of Cancer 30-item Core Quality of Life Questionnaire) (Safety Run-in and Main Study part), from baseline and time to definitive clinically, assessed up to 5 years|11. Immunogenicity of durvalumab when used in combination with Tremelimumab as measured by presence of antidrug antibodies (ADA) (Safety Run-in and Main Study part), At 3 months after last dose of durvalumab and tremelimumab|12. Time to maximum observed serum concentration (tmax) of durvalumab and tremelimumab (Safety Run-in and Main Study part), At 3 months after last dose of durvalumab and tremelimumab|13. Metastasis-free survival (MFS) (Safety Run-in and Main Study part), MFS is defined as the time from date of randomization until the first recognition of distant metastases or death, whichever occurs first, up to approximately 48 months., From randomization until the first recognition of distant metastases or death, up to approximately 48 months.",,AstraZeneca,,ALL,"ADULT, OLDER_ADULT",PHASE3,712,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-08-05,2025-07-18,2028-09-08,2021-07-14,,2025-04-29,"Research Site, Orange, California, 92868, United States|Research Site, Santa Monica, California, 90404, United States|Research Site, New Haven, Connecticut, 06510, United States|Research Site, Washington, District of Columbia, 20010, United States|Research Site, Fort Myers, Florida, 33901, United States|Research Site, Coeur d'Alene, Idaho, 83814, United States|Research Site, Maywood, Illinois, 60153, United States|Research Site, Indianapolis, Indiana, 46250, United States|Research Site, Iowa City, Iowa, 52242, United States|Research Site, Louisville, Kentucky, 40207, United States|Research Site, Scarborough, Maine, 04074, United States|Research Site, Boston, Massachusetts, 02111, United States|Research Site, Brighton, Michigan, 48114, United States|Research Site, Jackson, Mississippi, 39213, United States|Research Site, Las Vegas, Nevada, 89102, United States|Research Site, Saddle Brook, New Jersey, 07663, United States|Research Site, Brooklyn, New York, 11219, United States|Research Site, Buffalo, New York, 14263, United States|Research Site, New York, New York, 10040, United States|Research Site, Syracuse, New York, 13210, United States|Research Site, Portland, Oregon, 97239, United States|Research Site, Hershey, Pennsylvania, 17033, United States|Research Site, Pittsburgh, Pennsylvania, 15212, United States|Research Site, Knoxville, Tennessee, 37932, United States|Research Site, Austin, Texas, 78731, United States|Research Site, Dallas, Texas, 75246, United States|Research Site, Fort Worth, Texas, 76104, United States|Research Site, Houston, Texas, 77030, United States|Research Site, Irving, Texas, 75063, United States|Research Site, Norfolk, Virginia, 23502, United States|Research Site, Spokane, Washington, 99208, United States|Research Site, Buenos Aires, C1431FWO, Argentina|Research Site, Caba, C1280AEB, Argentina|Research Site, Caba, C1426ANZ, Argentina|Research Site, Ciudad de Buenos Aires, C1419AHL, Argentina|Research Site, Pergamino, B2700CPM, Argentina|Research Site, Pilar, B1629AHJ, Argentina|Research Site, Graz, 8036, Austria|Research Site, Krems, 3500, Austria|Research Site, Linz, 4020, Austria|Research Site, Salzburg, 5020, Austria|Research Site, Wiener Neustadt, 2700, Austria|Research Site, Wien, 1020, Austria|Research Site, Wien, 1090, Austria|Research Site, Barretos, 14784-400, Brazil|Research Site, Curitiba, 81520-060, Brazil|Research Site, Fortaleza, 60135-237, Brazil|Research Site, Porto Alegre, 90035-001, Brazil|Research Site, Porto Alegre, 90035-003, Brazil|Research Site, Porto Alegre, 90610-000, Brazil|Research Site, Porto Alegre, 91350200, Brazil|Research Site, Rio de Janeiro, 22250-905, Brazil|Research Site, Santa Maria, 97015-450, Brazil|Research Site, Santo AndrÃ©, 09060-650, Brazil|Research Site, Sao Paulo, 01246-000, Brazil|Research Site, Sao Paulo, 01323-903, Brazil|Research Site, SÄo Paulo, 03162-065, Brazil|Research Site, UberlÃ¢ndia, 38408-150, Brazil|Research Site, Abbotsford, British Columbia, V2S 3N5, Canada|Research Site, Toronto, Ontario, M4N 3M5, Canada|Research Site, Toronto, Ontario, M5G 2C1, Canada|Research Site, Montreal, Quebec, H4A 3J1, Canada|Research Site, Sherbrooke, Quebec, J1H 5N4, Canada|Research Site, Quebec, G1R 2J6, Canada|Research Site, Santiago, 7500653, Chile|Research Site, Santiago, 7500921, Chile|Research Site, Amiens, 80090, France|Research Site, Bayonne, 64100, France|Research Site, Clermont Ferrand, 63011, France|Research Site, Lille, 59000, France|Research Site, Lyon, 69008, France|Research Site, Marseille CEDEX, 13273, France|Research Site, Marseille, 13385, France|Research Site, Montpellier, 34070, France|Research Site, Nice, 06189, France|Research Site, Pierre Benite, 69495, France|Research Site, Quint-Fonsegrives, 31130, France|Research Site, Saint-Priez En Jarez, 42270, France|Research Site, Strasbourg, 67091, France|Research Site, Suresnes Cedex, 92151, France|Research Site, Vandoeuvre les Nancy, 54519, France|Research Site, Bielefeld, 33611, Germany|Research Site, Bochum, 44791, Germany|Research Site, DÃ¼sseldorf, 40225, Germany|Research Site, Giessen, 35392, Germany|Research Site, Hannover, 30625, Germany|Research Site, Herne, 44625, Germany|Research Site, KÃ¶ln, 50937, Germany|Research Site, Magdeburg, 39120, Germany|Research Site, Mainz, 55131, Germany|Research Site, Mannheim, 68167, Germany|Research Site, Muenchen, 81377, Germany|Research Site, MÃ¼nster, 48149, Germany|Research Site, Regensburg, 93053, Germany|Research Site, Reutlingen, 72766, Germany|Research Site, Ulm, 89075, Germany|Research Site, Athens, 11528, Greece|Research Site, Athens, 12462, Greece|Research Site, Maroussi, Athens, 15125, Greece|Research Site, Shatin, 00000, Hong Kong|Research Site, Hadera, 38100, Israel|Research Site, Haifa, 31096, Israel|Research Site, Jerusalem, 9103102, Israel|Research Site, Jerusalem, 9112001, Israel|Research Site, Tel Aviv, 64239, Israel|Research Site, Bari, 70124, Italy|Research Site, Firenze, 50134, Italy|Research Site, Meldola, 47014, Italy|Research Site, Milano, 20132, Italy|Research Site, Milan, 20141, Italy|Research Site, Padova, 35128, Italy|Research Site, Pozzuoli, 80078, Italy|Research Site, Reggio Emilia, 42100, Italy|Research Site, Roma, 00128, Italy|Research Site, Roma, 00137, Italy|Research Site, Roma, 00144, Italy|Research Site, Terni, 05100, Italy|Research Site, Tricase, 73039, Italy|Research Site, Verona, 37124, Italy|Research Site, Bunkyo-ku, 113-8431, Japan|Research Site, Fukuoka-shi, 811-1395, Japan|Research Site, Hamamatsu-shi, 431-3192, Japan|Research Site, Hirosaki-shi, 036-8563, Japan|Research Site, Ichikawa-shi, 272-8516, Japan|Research Site, Kanazawa-shi, 920-8641, Japan|Research Site, Kashihara-shi, 634-8522, Japan|Research Site, Kawasaki-shi, 216-8511, Japan|Research Site, Kita-gun, 761-0793, Japan|Research Site, Kobe-shi, 650-0017, Japan|Research Site, Kumamoto-shi, 860-0008, Japan|Research Site, Matsuyama-shi, 791-0288, Japan|Research Site, Miyazaki-shi, 889-1692, Japan|Research Site, Niigata-shi, 951-8566, Japan|Research Site, Okayama-shi, 700-8558, Japan|Research Site, Osaka-shi, 541-8567, Japan|Research Site, Osaka-shi, 545-8586, Japan|Research Site, Osakasayama-shi, 589-8511, Japan|Research Site, Toyama-shi, 930-0194, Japan|Research Site, Tsukuba-shi, 305-8576, Japan|Research Site, Yokohama-shi, 241-8515, Japan|Research Site, Busan, 47392, Korea, Republic of|Research Site, Goyang-si, 10408, Korea, Republic of|Research Site, Incheon, 405-760, Korea, Republic of|Research Site, Seongnam-si, 13620, Korea, Republic of|Research Site, Seoul, 02841, Korea, Republic of|Research Site, Seoul, 03080, Korea, Republic of|Research Site, Seoul, 06351, Korea, Republic of|Research Site, Seoul, 06591, Korea, Republic of|Research Site, Seoul, 07985, Korea, Republic of|Research Site, Colima, 28018, Mexico|Research Site, Monterrey, 64000, Mexico|Research Site, Arnhem, 6815 AD, Netherlands|Research Site, Breda, 4818 CK, Netherlands|Research Site, Groningen, 9713 GZ, Netherlands|Research Site, Hoofddorp, 2134 TM, Netherlands|Research Site, Leiden, 2333 ZA, Netherlands|Research Site, Utrecht, 3508 GA, Netherlands|Research Site, GdaÅsk, 80-214, Poland|Research Site, Nowa Sol, 67-106, Poland|Research Site, SkÃ³rzewo, 60-185, Poland|Research Site, Warszawa, 02-781, Poland|Research Site, Braga, 4710, Portugal|Research Site, Coimbra, 3000-075, Portugal|Research Site, Faro, 8000-386, Portugal|Research Site, Lisboa, 1350-352, Portugal|Research Site, Lisboa, 1500-458, Portugal|Research Site, Lisboa, 1500-650, Portugal|Research Site, Lisboa, 1649-035, Portugal|Research Site, Lisbon, 1169-050, Portugal|Research Site, Porto, 4200-072, Portugal|Research Site, Vila Nova de Gaia, 4434-502, Portugal|Research Site, Belgrade, 11000, Serbia|Research Site, Belgrad, 11000, Serbia|Research Site, Sremska Kamenica, 21204, Serbia|Research Site, Barcelona, 08035, Spain|Research Site, Barcelona, 08036, Spain|Research Site, Barcelona, 08041, Spain|Research Site, Barcelona, 08208, Spain|Research Site, L'Hospitalet de Llobregat, 08907, Spain|Research Site, Las Palmas de Gran Canaria, 35016, Spain|Research Site, Madrid, 28033, Spain|Research Site, Madrid, 28040, Spain|Research Site, Madrid, 28046, Spain|Research Site, Pamplona, 31008, Spain|Research Site, Sevilla, 41009, Spain|Research Site, Taichung, 40447, Taiwan|Research Site, Taichung, 40705, Taiwan|Research Site, Tainan, 70403, Taiwan|Research Site, Tainan, 710, Taiwan|Research Site, Bangkok, 10330, Thailand|Research Site, Dusit, 10300, Thailand|Research Site, Songkhla, 90110, Thailand|Research Site, Adana, 01060, Turkey|Research Site, Ankara, 06560, Turkey|Research Site, Ankara, 06620, Turkey|Research Site, Ankara, 5000, Turkey|Research Site, Ankara, Turkey|Research Site, Antalya, 07025, Turkey|Research Site, Edirne, 22030, Turkey|Research Site, Istanbul, 32098, Turkey|Research Site, Istanbul, 34722, Turkey|Research Site, Karsiyaka, 35575, Turkey|Research Site, London, EC1A 7BE, United Kingdom|Research Site, London, NW1 2PG, United Kingdom|Research Site, Ha Noi, 100000, Vietnam|Research Site, Hanoi, 100000, Vietnam|Research Site, Ho Chi Minh, 700000, Vietnam|Research Site, Hue, 530000, Vietnam",
NCT06112314,IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301),https://clinicaltrials.gov/study/NCT06112314,PRISM-MEL-301,RECRUITING,"This is a phase 3, randomized, controlled study of brenetafusp (IMC-F106C) plus nivolumab compared to standard nivolumab regimens in HLA-A\*02:01-positive participants with previously untreated advanced melanoma.",NO,Advanced Melanoma,DRUG: Brenetafusp|DRUG: Nivolumab|DRUG: Nivolumab + Relatlimab,"Progression-Free Survival (PFS), PFS as assessed by blinded independent central review (BICR) according to Response Evaluation Criteria in Solid Tumours (RECIST 1.1)., Up to ~45 months","Overall Survival (OS), OS is the time from randomization to time of death from any cause., Up to ~57 months|Overall Response Rate (ORR), ORR as assessed by BICR according to RECIST 1.1., Up to ~45 months|Number of Participants Experiencing â¥1 Adverse Event (AE), An AE is defined as the appearance of (or worsening of any pre-existing) undesirable sign, symptom, or medical condition that occur in the study., Up to ~57 months|Number of Participants Experiencing â¥1 Serious Adverse Event (SAE), An SAE is any untoward medical consequence that results in death; requires inpatient hospitalization or prolongs existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or any other important medical event in the opinion of the Investigator., Up to ~57 months|Number of Participants Experiencing a Dose Interruption, Reduction, or Discontinuation, The number of participants with a dose interruption, reduction, or discontinuation due to AE will be reported., Up to ~45 months|Maximum Plasma Concentration (Cmax) of IMC-F106C, The Cmax of IMC-F106C will be reported., Day 1 of Weeks 1, 2, and 3: Predose and 0.5 and 4 hours postdose|Incidence of anti-IMC-F106C Antibodies, The incidence of anti-IMC-F106C antibodies, including neutralizing antibodies, will be reported., Up to ~45 months|Association between PFS and Intra-Tumor Immune Cells, The potential association between the effect of IMC-F106C on efficacy and intra-tumor environment will be explored. Intra-tumor environment is estimated as the ratio of CD3+ to CD163+ cells and the correlation with PFS will be estimated by the hazard ratio (+/- 95% CI) from a Cox model. This analysis will be restricted to subjects randomized to receive IMC-F106C., Up to ~45 months|Health-Related Quality of Life, The change from baseline over time and between treatments of health-related quality of life will be reported., Up to ~45 months",,Immunocore Ltd,,ALL,"ADULT, OLDER_ADULT",PHASE3,680,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-06-05,2027-10-16,2027-10-16,2023-11-01,,2025-06-04,"University of California - San Diego, La Jolla, California, 92093-0698, United States|The Angeles Clinic and Research Institute- West Los Angeles, Los Angeles, California, 90025, United States|ESC Norris Comprehensive Cancer Center, Los Angeles, California, 90033, United States|UCLA Hematology/Oncology, Los Angeles, California, 90095, United States|Stanford Cancer Institute - Stanford Cancer Center Palo Alto, Palo Alto, California, 94304, United States|Saint John's Health Center - John Wayne Cancer Institute (JWCI), Santa Monica, California, 90404, United States|University of Colorado, Anschutz Medical Campus, Aurora, Colorado, 80045, United States|UConn Health-Farmington (University of Connecticut Health Center (UCHC)), Farmington, Connecticut, 06030-2205, United States|Mayo Clinic Florida, Jacksonville, Florida, 32224, United States|University of Miami Health System-Sylvester Comprehensive Cancer Center-Miami, Miami, Florida, 33136, United States|Northwestern University - Robert H. Lurie Comprehensive Cancer Center - NMDTI, Chicago, Illinois, 60611, United States|St. Elizabeth Healthcare - Edgewood, Edgewood, Kentucky, 41017, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States|Northwell Health Cancer Institute, Lake Success, New York, 11042, United States|Columbia University Medical Center, New York, New York, 10032, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, 19107, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, 15232, United States|Prisma Health Cancer Institute, Greenville, South Carolina, 29605, United States|UVA Health-UVA Emily Couric Clinical Cancer Center, Charlottesville, Virginia, 22903, United States|Swedish Medical Center - Swedish Cancer Institute (SCI) - First Hill Campus, Seattle, Washington, 98104, United States|Sanatorio Finochietto, Caba, Buenos Aires, 1213, Argentina|ClÃ­nica Adventista Belgrano - Sector InvestigaciÃ³n, Caba, Buenos Aires, C1430EGF, Argentina|Instituto Alexander Fleming, Caba, CP1426ANZ, Argentina|Clinica Viedma, Viedma, R8500ACE, Argentina|Calvary Mater Newcastle Hospital, Waratah, New South Wales, 02298, Australia|Gallipoli Medical Research Foundation (Greenslopes Private Hospital), Greenslopes, Queensland, 4120, Australia|Linear Clinical Research, Nedlands, Western Australia, 06009, Australia|One Clinical Research - Nedlands, Nedlands, Western Australia, 06009, Australia|Austin Hospital, Heidelberg, 3084, Australia|Peter MacCallum Cancer Centre, North Melbourne, 3051, Australia|University of Sydney - Melanoma Institute Australia (MIA) - The Poche Centre, Wollstonecraft, Australia|The University of Queensland (UQ) - Princess Alexandra Hospital (PAH), Woolloongabba, Australia|UniversitÃ¤tsklinikum St. PÃ¶lten, PÃ¶lten, Austria|Paracelsus Medizinischen Privatuniversitaet - SALK - Universitaetsklinik fuer Dermatologie - EB-Haus Austria, Salzburg, 5020, Austria|Universite Libre de Bruxelles (ULB)-Institut Jules Bordet, Anderlecht, 01070, Belgium|AZ Sint-Jan Brugge-Oostende AV-Campus Sint-Jan, Brugge, 8000, Belgium|UZ Leuven, Leuven, 03000, Belgium|Centro Gaucho Integrado de Oncologia, Hematologia, Ensino e Pesquisa Ltda, Porto Alegre, RS, 90110-270, Brazil|Fundacao Pio XII - Hospital de Cancer de Barretos - Hospital de Amor, Barretos, 14784, Brazil|Hospital Sirio-Libanes (HSL) - Centro de Oncologia - Brasilia, BrasÃ­lia, DF CEP 70200-730, Brazil|Centro de Pesquisas Oncologicas (CEPON), FlorianÃ³polis, 88034-000, Brazil|Oncocentro Sao Carlos Hospital, Fortaleza, 60135-237, Brazil|A.C.Camargo Cancer Center - Centro Internacional de Pesquisa (CIPE), Liberdade, 01509-010, Brazil|Hospital de Clinicas de Porto Alegre (HCPA), Porto Alegre, 90035-903, Brazil|Pontificia Universidade Catolica do Rio Grande do Sul (PUCRS) - Hospital Sao Lucas - Centro de Pesquisa Clinica (CPC), Porto Alegre, 90610-000, Brazil|National Cancer Institute, Rio De Janeiro, 20220-410, Brazil|Instituto AmÃ©ricas - Instituto de EducaÃ§Ã£o Pesquisa e GestÃ£o em SaÃºde Oncosite, Rio De Janeiro, 22775-001, Brazil|Instituto do Cancer do Estado de Sao Paulo (ICESP), SÃ£o Paulo, 01246-000, Brazil|Hospital 9 de Julho, SÃ£o Paulo, 01308-070, Brazil|Faculdade de Medicina de Sao Jose do Rio Preto-SP (FAMERP) - Hospital de Base (HB) - Centro Integrado de Pesquisa (CIP), SÃ£o Paulo, 15090-000, Brazil|Uni Hospital, Panagyurishte, 4500, Bulgaria|Complex Oncology Center - Plovdiv Ltd., Plovdiv, 4000, Bulgaria|University Hospital Tsaritsa Yoanna (ISUL) (Queen Giovanna University Hospital), Sofia, 1527, Bulgaria|Regina Life Clinic, Sofia, Bulgaria|Cross Cancer Institute, Edmonton, T6G 1Z2, Canada|Fakultni Nemocnice Hradec Kralove (FNHK) - Klinika Onkologie a Radioterapie, Hradec KrÃ¡lovÃ©, 500 05, Czechia|Fakultni Nemocnice Olomouc (FNOL), Olomouc, 77900, Czechia|Sanatorium Profesora Arenbergera, Praha, 110 00, Czechia|Kobenhavns Universitet - Herlev Hospital (Amtssygehuset i Herlev), Herlev, 2730, Denmark|HÃ´pital de la Timone, Marseille, Cedex, 13385, France|Oncopole Claudius Regaud- Institut Universitaire du Cancer de Toulouse, Toulouse, Cedex, 31059, France|Assistance Publique-Hopitaux de Paris (AP-HP) - Hopitaux Universitaires Paris Seine-Saint-Denis - Hopital Avicenne, Bobigny, 93000, France|Assistance Publique-Hopitaux de Paris (AP-HP) - Hopital Ambroise-Pare, Boulogne-Billancourt, 92104, France|UNICANCER-Centre Francois Baclesse (CFB), Caen, 14000, France|CHU de Dijon Bourgogne - HÃ´pital FranÃ§ois Mitterrand, Dijon, France|Centre Hospitalier Universitaire de Lille (CHU Lille)-Hopital Claude Huriez, Lille, 59037, France|Centre Hospitalier Universitaire de Nantes (CHU de Nantes) - Hotel-Dieu, Nantes, France|Hospital Saint Louis, Paris, 75010, France|Hospices Civils de Lyon (HCL) - Centre Hospitalier Lyon-Sud, Pierre-Benite, 69310, France|Centre Hospitalier Universitaire de Rouen (CHU de Rouen) - Hopital Charles-Nicolle, Rouen, 76031, France|Hopital Robert Debre, Valence, 26000, France|Institut Gustave Roussy (IGR) Service de Dermatolgie, Villejuif, 94800, France|Charite-Universitaetsmedizin Berlin - Campus Charite Mitte (CCM) - Klinik fuer Dermatologie Venerologie und Allergologie - Hauttumorcentrum Charite (HTCC), Berlin, 10115, Germany|UniversitÃ¤tsklinikum Carl Gustav Carus, Dresden, 01307, Germany|Helios Klinikum Erfurt - Klinik fuer Hautkrankheiten und Allergologie, Erfurt, 99089, Germany|Universitaetsklinikum Essen, Essen, 45122, Germany|Johann Wolfgang Goethe-Universitaet Frankfurt am Main - Klinik fuer Dermatologie, Venerologie und Allergologie, Frankfurt, 60590, Germany|Justus-Liebig-Universitaet Giessen - Klinik fuer Dermatologie und Andrologie, GieÃen, D-35392, Germany|University of Hamburg, Hamburg, 20246, Germany|Elbe Kliniken Stade - Hautkrebszentrum Buxtehude, Hamburg, 22045, Germany|Universitaetsklinikum Heidelberg (UKHD) - Hautklinik, Heidelberg, 69120, Germany|Universitaetsklinikum Leipzig - Klinik fuer Dermatologie, Venerologie und Allergologie, Leipzig, 4103, Germany|Johannes Wesling Klinikum Minden, Minden, 32429, Germany|LMU Klinikum - Klinik und Poliklinik fur Dermatologie und Allergologie, Munich, 81377, Germany|Universitaetsklinikum Tuebingen (UKT) - Zentrum fuer Dermatoonkologie - Hautklinik, TÃ¼bingen, 72076, Germany|Universitaetsklinikum Wuerzburg - Klinik und Poliklinik fuer Dermatologie Venerologie und Allergologie, WÃ¼rzburg, 97080, Germany|Semmelweis Egyetem ÃltalÃ¡nos OrvostudomÃ¡nyi Kar, Budapest, 1085, Hungary|Pecsi Tudomanyegyetem (PTE) (University of Pecs), PÃ©cs, 7624, Hungary|Szegedi Tudomanyegyetem (University of Szeged), Szeged, 6720, Hungary|Istituto Tumori Giovanni Paolo II - Ospedale Oncologico di Bari, Bari, 70124, Italy|Humanitas Gavazzeni (Cliniche Gavazzeni S.p.A), Bergamo, 24125, Italy|IRCCS Istituto Scientifico Romagnolo per lo Studio dei Tumori ""Dino Amadori"" Srl (IRST), Meldola, 47014, Italy|Fondazione IRCCS - Istituto Nazionale dei Tumori - Milano, Milano, 20133, Italy|Istituto Europeo di Oncologia (IEO) (European Institute of Oncology), Milan, 20141, Italy|Istituto Nazionale Tumori (INT) ""Fondazione G. Pascale"" di Napoli, Napoli, 80131, Italy|Istituto Oncologico Veneto (IOV) IRCCS, Padova, 35128, Italy|Istituto Oncologico Veneto (IOV) IRCCS, Padova, I-35128, Italy|Azienda Ospedaliera di Perugia - Ospedale Santa Maria della Misericordia, Perugia, 06129, Italy|Azienda Sanitaria Locale di Biella (ASL BI) - Ospedale degli Infermi, Ponderano, 13875, Italy|Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, 0168, Italy|"" Azienda Ospedaliera Universitaria Senese - Policlinico Santa Maria Alle Scotte - Clinica Immunoterapia Oncologica"", Siena, 53100, Italy|Haukeland University Hospital, Bergen, 05009, Norway|Oslo University Hospital, Oslo, 0379, Norway|Centrum Onkologii im. Prof. Franciszka Åukaszczyka, Bydgoszcz, 85796, Poland|Klinika Onkologii i Radioterapii Uniwersyteckie Centrum Kliniczne, Gdansk, 80-214, Poland|Centrum Medyczne Pratia PoznaÅ - Skorzewo, Skorzewo, 60185, Poland|Klinika NowotworÃ³w Tkanek MiÄkkich, KoÅci i CzerniakÃ³w, Warszawa, 02-781, Poland|L'Institute Oncologique Prof. Dr. Ion Chiricuta (IOCN) (The Oncology Institute Prof. Dr. Ion. Chiricuta), Cluj-Napoca, 400015, Romania|Sf Nectarie Oncology Center, Craiova, 200542, Romania|Universidad de Cantabria (UC) - Hospital Universitario Marques de Valdecilla (HUMV), Santander, Cantabria, 39008, Spain|Universidad de Murcia - Hospital Universitario Virgen de la Arrixaca (HUVA), El Palmar, Murcia, 30120, Spain|Complejo Hospitalario Universitario A Coruna (CHUAC), A CoruÃ±a, 15006, Spain|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital Universitario Dexeus, Barcelona, 08035, Spain|Hospital Duran i Reynals, Barcelona, 08908, Spain|Hospital Clinic de Barcelona, Barcelona, 8036, Spain|Hospital Universitario Reina Sofia, CÃ³rdoba, 14004, Spain|Hospital Universitario Virgen de las Nieves (HUVN), Granada, 18014, Spain|Hospital Universitario Ramon y Cajal, Madrid, 28034, Spain|Universidad Complutense de Madrid (UCM)-Hospital Universitario 12 de Octubre (H12O), Madrid, 28041, Spain|Hospital Universitario La Paz, Madrid, 28046, Spain|Centro Integral Oncologico Clara Campal (CIOCC), Madrid, 28050, Spain|Universidad de Navarra - Clinica Universidad de Navarra (CUN) - Pamplona, Pamplona, 31008, Spain|Hospital Universitario Virgen del Rocio, Sevilla, 41013, Spain|Hospital Universitario Virgen Macarena, Seville, 41009, Spain|Hospital Clinico Universitario de Valencia, Valencia, 46014, Spain|Universitat de Valencia - Hospital Universitari i Politecnic La Fe de Valencia (Hospital La Fe Bulevar Sur), Valencia, 46026, Spain|Sahlgrenska Akademin - Institutionen for Kliniska Vetenskaper (Institute of Clinical Sciences), GÃ¶teborg, SE41345, Sweden|Lanssjukhuset Ryhov - Onkologiska Kliniken, JÃ¶nkÃ¶ping, 553 05, Sweden|Skanes Universitetssjukhus - Lund - Onkologiska Klinik, Lund, 22185, Sweden|Karolinska Universitetssjukhuset, Stockholm, 171 76, Sweden|Uppsala Universitet - Akademiska Sjukhuset (Uppsala University Hospital), Uppsala, SE75185, Sweden|UniversitaetsSpital Zuerich - Dermatologische Klinik, Zurich, 8901, Switzerland|Memorial Saglik Grubu - Memorial Ankara Hastanesi, Ãankaya, Ankara, 06520, Turkey|Medical Park Hastaneler Grubu - I.A.U. VM Medical Park Florya, Antalya, Campus, 07070, Turkey|Memorial Saglik Grubu - Memorial Bahcelievler Hastanesi, BahÃ§elievler, Istanbul, 34180, Turkey|Kanser Enstitusu (Hacettepe University Cancer Institute), AltÄ±ndaÄ, 6230, Turkey|T.C. Saglik Bakanligi - SBU Gulhane Egitim ve Arastirma Hastanesi, Ankara, 6100, Turkey|Inonu Universitesi - Turgut Ozal Tip Merkezi, Malatya, 44280, Turkey|Ondokuz Mayis Universitesi (OMU) - Tip Facultesi, Samsun, 55270, Turkey|Medical Park Seyhan Hastanesi, Seyhan, 1140, Turkey|T.C. Saglik Bakanligi - Ankara Etlik sehir Hastanesi, Yenimahalle, 06170, Turkey|Ankara Bilkent City Hospital, Oncology Department, Ãankaya, 6800, Turkey|Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital (AH) - Oncology Centre, Cambridge, CB20QQ, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, G12 0YN, United Kingdom|The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, L78YA, United Kingdom|Sarah Cannon Research Institute (SCRI) - London (SCRI-UK), London, W1G 6AD, United Kingdom|The Christie NHS Foundation Trust, Manchester, M204BX, United Kingdom|Royal Marsden Hospital - Sutton, Surrey Quays, SM2 5PT, United Kingdom",
NCT06819007,Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01),https://clinicaltrials.gov/study/NCT06819007,,RECRUITING,"This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry \[IHC\] 3+/2+/1+) advanced high-grade epithelial ovarian cancer.",NO,Ovarian Cancer,DRUG: Trastuzumab Deruxtecan|DRUG: Bevacizumab,"Progression Free Survival by Blinded Independent Central Review (BICR) in the HER2 IHC 3+/2+ population, Time from randomization to time of objective radiographic disease progression as assessed by BICR based on RECIST v1.1 or death due to any cause., From date of randomization to radiographic disease progression or death due to any cause, up to approximately 35 months","Overall Survival in the HER2 IHC 3+/2+ population, Time interval from the date of randomization to the date of death due to any cause., From date of randomization to death due to any cause, up to approximately 72 months|Progression Free Survival by BICR in the HER2 IHC 3+/2+/1+ population, Time from randomization to time of objective radiographic disease progression as assessed by BICR based on RECIST v1.1 or death due to any cause., From date of randomization to radiographic disease progression or death due to any cause, up to approximately 35 months|Overall Survival in the HER2 IHC 3+/2+/1+ population, Time interval from the date of randomization to the date of death due to any cause., From date of randomization to death due to any cause, up to approximately 72 months|Progression Free Survival by the investigator in HER2 IHC 3+/2+ population, Time from randomization to time of objective radiographic disease progression as assessed by the investigator based on RECIST v1.1 or death due to any cause., From date of randomization to radiographic disease progression or death due to any cause, up to approximately 35 months|Progression Free Survival by the investigator in HER2 IHC 3+/2+/1+ population, Time from randomization to time of objective radiographic disease progression as assessed by the investigator based on RECIST v1.1 or death due to any cause., From date of randomization to radiographic disease progression or death due to any cause, up to approximately 35 months",,Daiichi Sankyo,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,582,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2025-03-19,2028-11-01,2032-01-31,2025-02-11,,2025-05-31,"Miami Valley Hospital South, Centerville, Ohio, 45459, United States|Fudan University Shanghai Cancer Center, Shanghai Shi, 200032, China|Hyogo Cancer Center, Akashi, 673-8558, Japan|National Cancer Center Hospital, Chuo-Ku, 104-0045, Japan|Fukushima Medical University Hospital, Fukushima-Shi, 960-1295, Japan|Saitama Medical University International Medical Center, Hidaka-Shi, 350-1298, Japan|Cancer Institute Hospital of JFCR, Koto-Ku, 135-8550, Japan|Okayama University Hosptial, Okayama, 700-8558, Japan|NHO Hokkaido Cancer Center, Sapporo-Shi, 003-0804, Japan|Iwate Medical University Hospital, Shiwa-Gun, 028-3695, Japan|Mie University Hospital, Tsu-Shi, 514-8507, Japan|Yamagata University Hospital, Yamagata-Shi, 990-9585, Japan",
NCT03847428,Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment,https://clinicaltrials.gov/study/NCT03847428,EMERALD-2,ACTIVE_NOT_RECRUITING,A global study to assess the efficacy and safety of durvalumab in combination with bevacizumab or durvalumab alone in patients with hepatocellular carcinoma who are at high risk of recurrence.,NO,Hepatocellular Carcinoma,DRUG: Durvalumab|DRUG: Bevacizumab|OTHER: Placebo,"Recurrence-free survival (RFS) for Arm A vs Arm C, RFS (per RECIST 1.1 criteria as assessed by BICR) will be defined as the time from the date of randomization until the date of the first objective radiologic recurrence or death due to any cause, whichever occurs first., Up to 49 months after first patient randomized","Recurrence-free survival (RFS) Arm B vs Arm C, RFS (per RECIST 1.1 criteria as assessed by BICR) will be defined as the time from the date of randomization until the date of the first objective radiologic recurrence or death due to any cause, whichever occurs first., Up to 49 months after first patient randomized|Overall Survival (OS) for Arm A vs Arm C and Arm B vs Arm C, OS is defined as the time from the date of randomization until death due to any cause, No timeframe|Recurrence-free survival at 24 months (RFS24) and 36 months (RFS36) for Arm A vs Arm C and Arm B vs Arm C, Proportion of RFS at 24 months and at 36 months, At 24 and at 36 months|Time to recurrence (TTR) for Arm A vs Arm C and Arm B vs Arm C, TTR is defined as the time from the date of randomization until the date of disease recurrence, Up to 49 months after first patient randomized|Time from randomization to recurrence/progression on next therapy (RFS2/PFS2) for Arm A vs Arm C and Arm B vs Arm C, Time from randomization to recurrence/progression on next therapy (RFS2/PFS2), Up to 49 months after first patient randomized",,AstraZeneca,,ALL,"ADULT, OLDER_ADULT",PHASE3,908,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-04-29,2026-05-29,2027-05-31,2019-02-20,,2025-05-29,"Research Site, Birmingham, Alabama, 35233, United States|Research Site, Mobile, Alabama, 36604, United States|Research Site, Phoenix, Arizona, 85054, United States|Research Site, Costa Mesa, California, 92627, United States|Research Site, La Jolla, California, 92093-0698, United States|Research Site, Long Beach, California, 90806, United States|Research Site, Orange, California, 92868, United States|Research Site, Sacramento, California, 95817, United States|Research Site, Washington, District of Columbia, 20007, United States|Research Site, Miami, Florida, 33176, United States|Research Site, Tampa, Florida, 33606, United States|Research Site, Honolulu, Hawaii, 96819, United States|Research Site, Chicago, Illinois, 60637, United States|Research Site, Westwood, Kansas, 66205, United States|Research Site, Louisville, Kentucky, 40206, United States|Research Site, Shreveport, Louisiana, 71103, United States|Research Site, Detroit, Michigan, 48201, United States|Research Site, Grand Rapids, Michigan, 49503, United States|Research Site, Rochester, Minnesota, 55905, United States|Research Site, Omaha, Nebraska, 68198, United States|Research Site, New Brunswick, New Jersey, 08903, United States|Research Site, Albuquerque, New Mexico, 87109, United States|Research Site, New York, New York, 10021, United States|Research Site, Stony Brook, New York, 11794, United States|Research Site, Durham, North Carolina, 27710, United States|Research Site, Winston-Salem, North Carolina, 27157, United States|Research Site, Cleveland, Ohio, 44106, United States|Research Site, Philadelphia, Pennsylvania, 19104, United States|Research Site, Pittsburgh, Pennsylvania, 15212, United States|Research Site, Spartanburg, South Carolina, 29303, United States|Research Site, Knoxville, Tennessee, 37916, United States|Research Site, Memphis, Tennessee, 38104, United States|Research Site, Dallas, Texas, 75216, United States|Research Site, Madison, Wisconsin, 53715, United States|Research Site, Kogarah, 2217, Australia|Research Site, Melbourne, 3004, Australia|Research Site, Nedlands, 6009, Australia|Research Site, Westmead, 2145, Australia|Research Site, Innsbruck, 6020, Austria|Research Site, Linz, 4010, Austria|Research Site, St. PÃ¶lten, 3100, Austria|Research Site, FlorianÃ³polis, 88034-000, Brazil|Research Site, Porto Alegre, 90020-090, Brazil|Research Site, Porto Alegre, 90035-003, Brazil|Research Site, Rio de Janeiro, 20231-050, Brazil|Research Site, Santa Maria, 97015-450, Brazil|Research Site, Santo Andre, 09060-870, Brazil|Research Site, SÃ£o JosÃ© do Rio Preto, 15090-000, Brazil|Research Site, VitÃ³ria, 29043-272, Brazil|Research Site, Hamilton, Ontario, L8V 5C2, Canada|Research Site, Kingston, Ontario, K7L 2V7, Canada|Research Site, Ottawa, Ontario, K1H 8L6, Canada|Research Site, Toronto, Ontario, M4N 3M5, Canada|Research Site, Toronto, Ontario, M5G 2M9, Canada|Research Site, Quebec, G1R 2J6, Canada|Research Site, Beijing, 100021, China|Research Site, Beijing, 100142, China|Research Site, Beijing, 100730, China|Research Site, Bengbu, 233004, China|Research Site, Changchun, 130021, China|Research Site, Changsha, 410013, China|Research Site, Chengdu, 610041, China|Research Site, Fuzhou, 350005, China|Research Site, Guangzhou, 510000, China|Research Site, Guangzhou, 510080, China|Research Site, Guangzhou, 510515, China|Research Site, Hangzhou, 310003, China|Research Site, Hangzhou, 310016, China|Research Site, Hangzhou, 310022, China|Research Site, Harbin, 150049, China|Research Site, Hefei, 230001, China|Research Site, Hohhot, 010010, China|Research Site, Nanjing, 2100008, China|Research Site, Nanjing, 210002, China|Research Site, Ningbo, 315100, China|Research Site, Shanghai, 200032, China|Research Site, Shanghai, 201114, China|Research Site, Shanghai, 201318, China|Research Site, Tianjin, 300170, China|Research Site, Urumqi, 830000, China|Research Site, Wuhan, 430079, China|Research Site, Xi'an, 710061, China|Research Site, Zhengzhou, 450052, China|Research Site, Alexandria, 21131, Egypt|Research Site, Assiut, 71511, Egypt|Research Site, Cairo, 11451, Egypt|Research Site, Cairo, 11588, Egypt|Research Site, Cairo, 11796, Egypt|Research Site, Dakahlia, 35516, Egypt|Research Site, New Cairo, 11566, Egypt|Research Site, Shebeen El Kom, 32511, Egypt|Research Site, Amiens Cedex 1, 88054, France|Research Site, ANGERS Cedex 9, 49933, France|Research Site, BesanÃ§on, 25000, France|Research Site, Clichy, 92110, France|Research Site, Dijon Cedex, 21079, France|Research Site, Nantes, 44093, France|Research Site, Nice, 06200, France|Research Site, PARIS Cedex 12, 75571, France|Research Site, Pessac, 33604, France|Research Site, Toulouse Cedex 9, 31059, France|Research Site, TOURS Cedex 9, 37049, France|Research Site, Berlin, 13353, Germany|Research Site, Bonn, 53105, Germany|Research Site, Chemnitz, 09116, Germany|Research Site, Freiburg, 79106, Germany|Research Site, Heidelberg, 69120, Germany|Research Site, KÃ¶ln, 50937, Germany|Research Site, Leipzig, 04103, Germany|Research Site, LÃ¼beck, 23538, Germany|Research Site, MÃ¼nchen, 81377, Germany|Research Site, Tuebingen, 72076, Germany|Research Site, Hong Kong, 0000, Hong Kong|Research Site, Hong Kong, 150001, Hong Kong|Research Site, Hong Kong, HKG, Hong Kong|Research Site, HongKong, Hong Kong|Research Site, Kwai Chung, 999077, Hong Kong|Research Site, Shatin, 00000, Hong Kong|Research Site, Bangalore, 560027, India|Research Site, Bangalore, 560092, India|Research Site, Hyderabad, 500032, India|Research Site, Kolkata, 700160, India|Research Site, Mumbai, 400012, India|Research Site, New Delhi, 110017, India|Research Site, New Delhi, 110076, India|Research Site, New Delhi, 110085, India|Research Site, Bologna, 40138, Italy|Research Site, Milano, 20132, Italy|Research Site, Milano, 20162, Italy|Research Site, Napoli, 80131, Italy|Research Site, Roma, 00168, Italy|Research Site, Tricase, Lecce, 73039, Italy|Research Site, Verona, 37134, Italy|Research Site, Bunkyo-ku, 113-8655, Japan|Research Site, Fukuoka-shi, 810-8563, Japan|Research Site, Gifu-shi, 500-8513, Japan|Research Site, Hiroshima-shi, 734-8551, Japan|Research Site, Koto-ku, 135-8550, Japan|Research Site, Kumamoto-shi, 860-8556, Japan|Research Site, Kurume-shi, 830-0011, Japan|Research Site, Kyoto-shi, 606-8507, Japan|Research Site, Kyoto-shi, 612-8555, Japan|Research Site, Matsuyama-shi, 790-8524, Japan|Research Site, Mitaka-shi, 181-8611, Japan|Research Site, Musashino-shi, 180-8610, Japan|Research Site, Nagasaki-shi, 852-8501, Japan|Research Site, Nagoya-shi, 466-8560, Japan|Research Site, Nagoya-shi, 467-8602, Japan|Research Site, Osaka-shi, 534-0021, Japan|Research Site, Osaka-shi, 541-8567, Japan|Research Site, Osaka-shi, 543-8555, Japan|Research Site, Osakasayama-shi, 589-8511, Japan|Research Site, Sapporo-shi, 006-8555, Japan|Research Site, Sapporo-shi, 060-0033, Japan|Research Site, Sendai-shi, 980-0872, Japan|Research Site, Shinagawa-ku, 142-8666, Japan|Research Site, Shinjuku-ku, 160-0023, Japan|Research Site, Shinjuku-ku, 162-8655, Japan|Research Site, Shiwa-gun, 028-3695, Japan|Research Site, Takasaki-shi, 370-0829, Japan|Research Site, Tsu-shi, 514-8507, Japan|Research Site, Wakayama-shi, 641-8510, Japan|Research Site, Yokohama-shi, 241-8515, Japan|Research Site, Yokohama-shi, 245-8575, Japan|Research Site, Busan, 49241, Korea, Republic of|Research Site, Daegu, 41944, Korea, Republic of|Research Site, Seoul, 03080, Korea, Republic of|Research Site, Seoul, 03722, Korea, Republic of|Research Site, Seoul, 05505, Korea, Republic of|Research Site, Seoul, 06351, Korea, Republic of|Research Site, Lima, LIMA 31, Peru|Research Site, Lima, LIMA 34, Peru|Research Site, Lima, LIMA 41, Peru|Research Site, San Isidro, 27, Peru|Research Site, Manila, 1000, Philippines|Research Site, Muntinlupa City, 1780, Philippines|Research Site, Pasig City, 1605, Philippines|Research Site, Bydgoszcz, 85-796, Poland|Research Site, GdaÅsk, 80-952, Poland|Research Site, PoznaÅ, 61-866, Poland|Research Site, Warszawa, 02-034, Poland|Research Site, Ponce, 00716, Puerto Rico|Research Site, Barnaul, 656049, Russian Federation|Research Site, Ekaterinburg, 620905, Russian Federation|Research Site, Moscow, 119421, Russian Federation|Research Site, Moscow, 125284, Russian Federation|Research Site, Obninsk, 249031, Russian Federation|Research Site, Saint Petersburg, 197044, Russian Federation|Research Site, Saint-Petersburg, 197022, Russian Federation|Research Site, Saint-Petersburg, 197758, Russian Federation|Research Site, Singapore, 119074, Singapore|Research Site, Singapore, 308433, Singapore|Research Site, Singapore, 329563, Singapore|Research Site, Changhua, 500, Taiwan|Research Site, Tainan, 710, Taiwan|Research Site, Taipei, 10002, Taiwan|Research Site, Taipei, 11217, Taiwan|Research Site, Taoyuan City, 333, Taiwan|Research Site, Yunlin, 640, Taiwan|Research Site, Bangkok, 10210, Thailand|Research Site, Bangkok, 10300, Thailand|Research Site, Bangkok, 10330, Thailand|Research Site, Bangkok, 10700, Thailand|Research Site, Chiang Mai, 50200, Thailand|Research Site, Hat Yai, 90110, Thailand|Research Site, Khon Kaen, 40002, Thailand|Research Site, Pathumthani, 12120, Thailand|Research Site, Ankara, 06100, Turkey|Research Site, Ankara, 6200, Turkey|Research Site, Istanbul, 34098, Turkey|Research Site, Izmir, 35100, Turkey|Research Site, Malatya, 44100, Turkey|Research Site, Hanoi, 100000, Vietnam|Research Site, Hanoi, 123, Vietnam|Research Site, Ho Chi Minh city, Vietnam|Research Site, Ho Chi Minh, 700000, Vietnam|Research Site, Hochiminh, 70000, Vietnam",
NCT06417814,A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT06417814,TROPION-Lung15,RECRUITING,This study will assess the effect of Dato-DXd in combination with osimertinib or Dato-DXd monotherapy versus platinum-based doublet chemotherapy in terms of progression-free survival (PFS).,NO,Metastatic Non-small Cell Lung Cancer,DRUG: Dato-DXd|DRUG: Osimertinib|DRUG: Pemetrexed|DRUG: Carboplatin|DRUG: Cisplatin,"Progression free Survival (PFS), PFS is defined as the time from randomization to Blinded Independent Central Review (BICR)-assessed progression using RECIST v1.1 or death due to any cause, regardless of whether the participant withdraws from study therapy, receives other anti-cancer therapy, or clinical progression., Up to 2.5 years","Overall Survival (OS), OS is defined as time from randomization until the date of death due to any cause., Up to 3.5 years|Central Nervous System Progression-free Survival (CNS PFS), CNS PFS is defined as the time from randomization to BICR confirmed progression in the CNS or death due to any cause, regardless of whether the participant withdraws from study therapy, receives other anti-cancer therapy, or clinically progresses prior to BICR confirmed CNS modified RECIST v1.1 progression., Up to 2.5 years|Objective Response Rate (ORR), ORR is defined as the percentage of participants who have a confirmed complete response (CR) or confirmed partial response (PR), as determined by BICR per RECIST v1.1., Up to 2.5 years|Duration of Response (DoR), DoR is defined as the time from the date of first documented response until date of documented progression per RECIST v1.1, as assessed by BICR or death due to any cause., Up to 2.5 years|Progression-free Survival-2 (PFS-2), PFS2 is defined as the time from randomization to the earliest of the progression event (following the initial investigator assessed progression), after first subsequent therapy, or death., Up to 3.5 years|Objective Response Rate (ORR) Using CNS Modified RECIST v1.1, ORR is defined as the percentage of participants who have a confirmed CR or confirmed PR, using CNS modified RECIST v1.1., Up to 2.5 years|Duration of Response (DoR) Using CNS Modified RECIST v1.1, DoR is defined as the time from the date of first documented response until date of documented progression or death due to any cause using CNS modified RECIST v1.1., Up to 2.5 years|Time to Deterioration in Pulmonary Symptoms, Time to deterioration (in pulmonary symptoms \[dyspnea, cough, and chest pain\]) is defined as the time from randomization until the date of deterioration. Deterioration is defined as change from baseline that reaches a meaningful change threshold., Up to 3.5 years|Time to Deterioration in Physical Functioning, Time to deterioration in physical functioning as measured by Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function short form 8c will be evaluated. Time to deterioration (in physical functionating) is defined as the time from randomization until the date of deterioration. Deterioration is defined as change from baseline that reaches a meaningful change threshold., Up to 3.5 years|Time to Deterioration in Global Health Status (GHS)/Quality of Life (QoL), Time to deterioration in GHS/QoL as measured by the GHS/QoL scale from EORTC IL172 will be reported. Time to deterioration (in GHS/QoL) is defined as the time from randomization until the date of deterioration. Deterioration is defined as change from baseline that reaches a meaningful change threshold., Up to 3.5 years|Pharmacokinetics (PK) of Dato-DXd, Concentration of Dato-DXd, total anti-TROP2 antibody and DXd in plasma., Up to 3.5 years|Immunogenicity of Dato-DXd, Presence of antidrug antibody (ADAs) for Dato-DXd (confirmatory results: positive or negative, titers)., Up to 3.5 years",,AstraZeneca,Daiichi Sankyo,ALL,"ADULT, OLDER_ADULT",PHASE3,630,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-10-04,2026-06-11,2027-11-29,2024-05-16,,2025-06-05,"Research Site, Fayetteville, Arkansas, 72703, United States|Research Site, Duarte, California, 91010, United States|Research Site, Fountain Valley, California, 92708, United States|Research Site, La Jolla, California, 92093, United States|Research Site, Los Angeles, California, 90048, United States|Research Site, San Diego, California, 92123, United States|Research Site, Fort Collins, Colorado, 80528, United States|Research Site, Jacksonville, Florida, 32256, United States|Research Site, Athens, Georgia, 30607, United States|Research Site, Chicago, Illinois, 60611, United States|Research Site, Evanston, Illinois, 60201-1718, United States|Research Site, Baltimore, Maryland, 21201, United States|Research Site, Bethesda, Maryland, 20817, United States|Research Site, Boston, Massachusetts, 02114, United States|Research Site, Boston, Massachusetts, 02215, United States|Research Site, Detroit, Michigan, 48202, United States|Research Site, Omaha, Nebraska, 68124, United States|Research Site, Morristown, New Jersey, 07960, United States|Research Site, Northfield, New Jersey, 08225, United States|Research Site, Bronx, New York, 10461, United States|Research Site, New York, New York, 10016, United States|Research Site, New York, New York, 10065, United States|Research Site, Philadelphia, Pennsylvania, 19107, United States|Research Site, Pittsburgh, Pennsylvania, 15232, United States|Research Site, Chattanooga, Tennessee, 37404, United States|Research Site, Nashville, Tennessee, 37203, United States|Research Site, Fairfax, Virginia, 22031, United States|Research Site, Fitzroy, VIC3065, Australia|Research Site, Heidelberg, 3084, Australia|Research Site, Kogarah, 2217, Australia|Research Site, Liverpool, 2170, Australia|Research Site, Nedlands, 6009, Australia|Research Site, Port Macquarie, 2444, Australia|Research Site, St Leonards, 2065, Australia|Research Site, Westmead, 2145, Australia|Research Site, Woodville, 5011, Australia|Research Site, Woolloongabba, 4102, Australia|Research Site, Charleroi, 6060, Belgium|Research Site, Edegem, 2650, Belgium|Research Site, Gent, 9000, Belgium|Research Site, Ghent, 9000, Belgium|Research Site, Hasselt, 3500, Belgium|Research Site, Jette, 1090, Belgium|Research Site, La LouviÃ¨re, 7100, Belgium|Research Site, Leuven, 3000, Belgium|Research Site, Namur, 5000, Belgium|Research Site, Roeselare, 8800, Belgium|Research Site, Barretos, 14784-400, Brazil|Research Site, Betim, 32671-550, Brazil|Research Site, Blumenau, 89010-340, Brazil|Research Site, FlorianÃ³polis, 88040-970, Brazil|Research Site, Itajai, 88301-220, Brazil|Research Site, Pelotas, 96020-080, Brazil|Research Site, Porto Alegre, 90035-074, Brazil|Research Site, Porto Alegre, 90470-340, Brazil|Research Site, Porto Alegre, 90610-000, Brazil|Research Site, Rio de Janeiro, 22250-905, Brazil|Research Site, Rio de Janeiro, 22281-100, Brazil|Research Site, Rio de Janeiro, 22775-001, Brazil|Research Site, Sao Paulo, 01327-001, Brazil|Research Site, SÃ£o Paulo, 01323-900, Brazil|Research Site, Brampton, Ontario, L6R 3J7, Canada|Research Site, Newmarket, Ontario, L3Y 2P9, Canada|Research Site, Toronto, Ontario, M4N 3M5, Canada|Research Site, Toronto, Ontario, M5G 1Z5, Canada|Research Site, Montreal, Quebec, H4A 3J1, Canada|Research Site, Quebec, G1R 2J6, Canada|Research Site, Baoding, 071000, China|Research Site, Beijing, 100005, China|Research Site, Beijing, 100034, China|Research Site, Beijing, 100044, China|Research Site, Beijing, 100050, China|Research Site, Beijing, 100142, China|Research Site, Beijing, 100730, China|Research Site, Beijing, 101199, China|Research Site, Bengbu, 233004, China|Research Site, Changchun, 130012, China|Research Site, Changchun, 130021, China|Research Site, Changsha, 410013, China|Research Site, Changsha, 410013, China|Research Site, Chengdu, 610041, China|Research Site, Deyang, 618000, China|Research Site, Ganzhou, 341099, China|Research Site, Guangzhou, 510180, China|Research Site, Hangzhou, 310003, China|Research Site, Hangzhou, 310022, China|Research Site, Hefei, 230001, China|Research Site, Hengyang, 421001, China|Research Site, Huaian, 223399, China|Research Site, Jinan, 250013, China|Research Site, Linyi, 276000, China|Research Site, Luoyang, 471003, China|Research Site, Luzhou, 646000, China|Research Site, Nanchang, 330006, China|Research Site, Nanjing, 210009, China|Research Site, Shanghai, 200433, China|Research Site, Shantou, China|Research Site, Shenyang, 110004, China|Research Site, Shenyang, 110042, China|Research Site, Tianjin, 300201, China|Research Site, Tianjin, CN-300052, China|Research Site, Weifang, 261000, China|Research Site, Wuhan, 430060, China|Research Site, Zhengzhou, 450000, China|Research Site, Zhengzhou, 450001, China|Research Site, Zhengzhou, 450008, China|Research Site, ANGERS Cedex 9, 49933, France|Research Site, Avignon, 84902, France|Research Site, Bordeaux, 33076, France|Research Site, Caen, 14000, France|Research Site, Lille Cedex, 59037, France|Research Site, Montpellier, 34298, France|Research Site, Nantes, 44093, France|Research Site, Paris Cedex 14, 75014, France|Research Site, Paris, 75970, France|Research Site, Pessac, 33604, France|Research Site, Quimper, 29000, France|Research Site, Toulon Armees, 83800, France|Research Site, Toulouse Cedex 9, 31400, France|Research Site, Villejuif Cedex, 94805, France|Research Site, Berlin-Zehlendorf, 14165, Germany|Research Site, Berlin, 12351, Germany|Research Site, Bonn, 53127, Germany|Research Site, Essen, 45122, Germany|Research Site, Georgsmarienhuette, 49124, Germany|Research Site, GroÃhansdorf, 22927, Germany|Research Site, Hamburg, 20251, Germany|Research Site, Hamburg, 21075, Germany|Research Site, Heidelberg, 69126, Germany|Research Site, Kempten, 87439, Germany|Research Site, LÃ¶wenstein, 74245, Germany|Research Site, NÃ¼rnberg, 90419, Germany|Research Site, Oldenburg, 26121, Germany|Research Site, Athens, 11526, Greece|Research Site, Athens, 11527, Greece|Research Site, Athens, 12462, Greece|Research Site, Athens, 18547, Greece|Research Site, Heraklion, 71110, Greece|Research Site, Thessaloniki, 552 36, Greece|Research Site, Thessaloniki, 56249, Greece|Research Site, Thessaloniki, 57001, Greece|Research Site, Thessaloniki, 57010, Greece|Research Site, Hong Kong, 999077, Hong Kong|Research Site, Hong Kong, Hong Kong|Research Site, Shatin, 00000, Hong Kong|Research Site, Amravati, 444606, India|Research Site, Bhubaneswar, 751019, India|Research Site, Hyderabad, 500034, India|Research Site, Kolhapur, 416234, India|Research Site, Mumbai, 400012, India|Research Site, Mysuru, 570017, India|Research Site, Namakkal, 637001, India|Research Site, Pune, 411001, India|Research Site, Raipur, 492001, India|Research Site, Rajasthan, 313001, India|Research Site, Ranchi, 834001, India|Research Site, Thane, 401107, India|Research Site, Trivandrum, 695011, India|Research Site, Varanasi, 221005, India|Research Site, Beer Sheva, 8410101, Israel|Research Site, Haifa, 3109601, Israel|Research Site, Haifa, 34362, Israel|Research Site, Jerusalem, 91031, Israel|Research Site, Jerusalem, 91120, Israel|Research Site, Kfar-Saba, 4428164, Israel|Research Site, Petach Tikva, 49100, Israel|Research Site, Ramat Gan, 52621, Israel|Research Site, Tel Aviv, 62748, Israel|Research Site, Bari, 70124, Italy|Research Site, Milano, 20141, Italy|Research Site, Misterbianco, 95045, Italy|Research Site, Monza, 20090, Italy|Research Site, Napoli, 80131, Italy|Research Site, Orbassano, 10043, Italy|Research Site, Padova, 35128, Italy|Research Site, Parma, 43126, Italy|Research Site, Perugia, 06100, Italy|Research Site, Roma, 00144, Italy|Research Site, Rozzano, 20089, Italy|Research Site, Verona, 37134, Italy|Research Site, Bunkyo-ku, 113-8431, Japan|Research Site, Fukuoka-shi, 812-8582, Japan|Research Site, Hiroshima-shi, 734-8551, Japan|Research Site, Iruma-Gun, 350-0495, Japan|Research Site, Iwakuni-shi, 740-8510, Japan|Research Site, Kobe, 650-0046, Japan|Research Site, Koto-ku, 135-8550, Japan|Research Site, Kumamoto-shi, 860-8556, Japan|Research Site, Kyoto-shi, 602-8566, Japan|Research Site, Matsuyama-shi, 791-0280, Japan|Research Site, Nagoya-shi, 464-8681, Japan|Research Site, Nagoya-shi, 466-8560, Japan|Research Site, Niigata-shi, 951-8566, Japan|Research Site, Osaka-Sayama, 589-8511, Japan|Research Site, Osaka-shi, 534-0021, Japan|Research Site, Osaka-shi, 541-8567, Japan|Research Site, Sendai-shi, 981-0914, Japan|Research Site, Sunto-gun, 411-8777, Japan|Research Site, Toyoake-shi, 470-1192, Japan|Research Site, Utsunomiya-shi, 320-0834, Japan|Research Site, Wakayama-shi, 641-8510, Japan|Research Site, Yokohama-shi, 236-0051, Japan|Research Site, Yokohama-shi, 241-8515, Japan|Research Site, Busan, 48108, Korea, Republic of|Research Site, Chungcheongbuk-do, 28644, Korea, Republic of|Research Site, Goyang-si, 10408, Korea, Republic of|Research Site, Gyeonggi-do, 13620, Korea, Republic of|Research Site, Jinju-si, 52727, Korea, Republic of|Research Site, Seoul, 03080, Korea, Republic of|Research Site, Seoul, 03722, Korea, Republic of|Research Site, Seoul, 06351, Korea, Republic of|Research Site, Seoul, 06591, Korea, Republic of|Research Site, Seoul, 5505, Korea, Republic of|Research Site, Suwon-si, 16247, Korea, Republic of|Research Site, Alor Setar, 05460, Malaysia|Research Site, Cheras, 56000, Malaysia|Research Site, Johor Bahru, 81100, Malaysia|Research Site, Kuala Lumpur, 59100, Malaysia|Research Site, Kuching, 93586, Malaysia|Research Site, Perai, 13700, Malaysia|Research Site, Petaling Jaya, 47500, Malaysia|Research Site, Selangor, 46050, Malaysia|Research Site, Amersfoort, 3813 TZ, Netherlands|Research Site, Harderwijk, 3844 DG, Netherlands|Research Site, Rotterdam, 3015 GD, Netherlands|Research Site, Zutphen, 7207 AE, Netherlands|Research Site, Bacolod, 6100, Philippines|Research Site, Cebu City, 6000, Philippines|Research Site, Davao City, 8000, Philippines|Research Site, Manila, 1000, Philippines|Research Site, Quezon, 1102, Philippines|Research Site, Quezon, 1104, Philippines|Research Site, San Juan, 1500, Philippines|Research Site, Katowice, 40-519, Poland|Research Site, Krakow, 30-727, Poland|Research Site, Olsztyn, 10-357, Poland|Research Site, Poznan, 60-569, Poland|Research Site, ÅÃ³dÅº, 90-302, Poland|Research Site, Braga, 4710, Portugal|Research Site, Porto, 4099-001, Portugal|Research Site, Porto, 4200-072, Portugal|Research Site, Craiova, 200385, Romania|Research Site, Craiova, 200542, Romania|Research Site, Singapore, 168583, Singapore|Research Site, Singapore, 217562, Singapore|Research Site, Singapore, 308433, Singapore|Research Site, Barakaldo, 48903, Spain|Research Site, Barcelona, 08003, Spain|Research Site, Barcelona, 08041, Spain|Research Site, El Palmar, 30120, Spain|Research Site, L'Hospitalet de Llobregat, 08908, Spain|Research Site, La Coruna, 15006, Spain|Research Site, Madrid, 28046, Spain|Research Site, Majadahonda, 28222, Spain|Research Site, Malaga, 29004, Spain|Research Site, Palma de Mallorca, 7120, Spain|Research Site, Pamplona, 31008, Spain|Research Site, Santander, 39008, Spain|Research Site, Santiago De Compostela-CoruÃ±a, 15706, Spain|Research Site, Sevilla, 41014, Spain|Research Site, Valencia, 46010, Spain|Research Site, Valencia, 46026, Spain|Research Site, Valladolid, 47003, Spain|Research Site, Changhua City, 50006, Taiwan|Research Site, Kaohsiung City, 80756, Taiwan|Research Site, New Taipei, 23561, Taiwan|Research Site, Taichung, 404, Taiwan|Research Site, Taichung, 40705, Taiwan|Research Site, Tainan City, 73657, Taiwan|Research Site, Tainan, 70403, Taiwan|Research Site, Taipei City, 110, Taiwan|Research Site, Taipei, 100, Taiwan|Research Site, Taipei, 112, Taiwan|Research Site, Bangkok, 10330, Thailand|Research Site, Bangkok, 10400, Thailand|Research Site, Bangkok, 10700, Thailand|Research Site, Chiang Mai, 50200, Thailand|Research Site, Hat Yai, 90110, Thailand|Research Site, Khon-Kaen, 40002, Thailand|Research Site, Pathumthani, 12120, Thailand|Research Site, Birmingham, B9 5SS, United Kingdom|Research Site, Cambridge, CB2 0QQ, United Kingdom|Research Site, Glasgow, G12 0YN, United Kingdom|Research Site, Leicester, LE1 5WW, United Kingdom|Research Site, London, EC1A 7BE, United Kingdom|Research Site, Manchester, M20 4BX, United Kingdom|Research Site, Middlesbrough, TS4 3BW, United Kingdom|Research Site, Hanoi, 100000, Vietnam",
NCT06508983,A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients,https://clinicaltrials.gov/study/NCT06508983,,RECRUITING,The purpose of this study is to evaluate the effects of the addition of SG301 injection to pomalidomide and dexamethasone in subjects with relapsed or refractory multiple myeloma.,NO,Relapsed/Refractory Multiple Myeloma,DRUG: SG301 Injection|DRUG: SG301 placebo|DRUG: pomalidomide|DRUG: dexamethasone,"Adverse events ï¼stage 1ï¼, AEs, DLTs, laboratory abnormality, Vital signs or ECG abnormalities, ECOG scores, abnormal physical examination, From date of first dose of study intervention through approximately 30 days after last study intervention administration, assessed up to approximately 4 years.|Recommended stage 2 dose of SG301 (Stage 1), Recommended stage 2 dose of SG301 will be determined based on the DLTs and safety data, Up to approximately 6 months.|Progression Free Survival (Stage 2), Comparison of Progression Free Survival between treatment arms (SG301/Pomalidomide/Dexamethasone vs Placebo/Pomalidomide/Dexamethasone)., From baseline through the end of study. Assessed every 4 weeks after randomization until C19D1, and every 8 weeks thereafter until disease progression (IMWG criteria) or death whichever occurs first, assessed up to approximately 4 years.","Pharmacokinetics (PK): AUC, The area under the curve (AUC) of serum concentration of the drug after the administration., From date of first dose of study intervention through approximately 30 days after last study intervention administration, assessed up to approximately 4 years.|Pharmacokinetics (PK): Cmax, Cmax to maximum drug concentration., From date of first dose of study intervention through approximately 30 days after last study intervention administration, assessed up to approximately 4 years.|Pharmacokinetics (PK):limination half-life (T1/2), Limination half-life (T1/2) of the drug after administration., From date of first dose of study intervention through approximately 30 days after last study intervention administration, assessed up to approximately 4 years.|Immunogenicity endpoints, Anti-SG301 antibody, neutralizing antibody (to be detected only in case of the presence of anti-SG301 antibody., From date of first dose of study intervention through approximately 30 days after last study intervention administration, assessed up to approximately 4 years.|Overall Response Rate, ORR (IMWG criteria): percentage of participants with stringent complete response(sCR), complete response (CR), very good partial response (VGPR), and partial response (PR) as best overall response, From baseline through the end of study. It is measured from the start of treatment until disease progression, death, initiation of further anti-myeloma treatment, or cut-off date, whichever occurs first, assessed up to approximately 4 years.|Percentage of Participants With Very Good Partial Response (VGPR) or Better (â¥VGPR Rate), â¥VGPR Rate (IMWG criteria): percentage of participants with stringent complete response(sCR), complete response (CR), and very good partial response (VGPR) as best overall response., From baseline through the end of study. It is measured from the start of treatment until disease progression, death, initiation of further anti-myeloma treatment, or cut-off date, whichever occurs first, assessed up to approximately 4 years.|Duration of Response, Duration of response will be restricted to subjects who achieve a best objective response of PR or better., From baseline through the end of study. It is measured from the time that the criteria for objective response are first met until the date of a progression event, assessed up to approximately 4 years.|Overall Survival, Overall survival is defined as the time, in months, from randomization to the date of death from any cause., From baseline through the end of study, assessed up to approximately 4 years.|Percentage of Participants With Minimal Residual Disease (MRD), MRD was assessed by next-generation sequencing in bone marrow samples from participants who achieved CR or sCR, to determine the depth of response at the molecular level., From baseline through the end of study. It is measured from the time that the criteria for CR are first met until the date of a progression event, assessed up to approximately 4 years.",,"Hangzhou Sumgen Biotech Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,360,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-06-14,2027-03-31,2028-03-31,2024-07-19,,2024-07-23,"Beijing Chaoyang Hospital of Capital Medical University, Beijing, Beijing, 100024, China|Guangzhou First People's Hospital, Guangzhou, Guangdong, 510000, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510000, China|First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, 471000, China|Henan Cancer Hospital, Zhengzhou, Henan, 450000, China|Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430000, China|The First Affiliated Hospital Of Soochow University, Suzhou, Jiangsu, 215006, China|Shanxi Provincial Hospital, Taiyuan, Shanxi, 030000, China|The Second Affiliated Hospital Of Xi an Jiaotong University (Xibei Hospital), Xi'an, Shanxi, 710000, China|Tianjin Cancer University Airport Hospital, Tianjin, Tianjin, 300060, China|Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, 300060, China|The Second Affiliated Hospital Zhejiang University School Of Medicine, Hangzhou, Zhejiang, 310056, China",
NCT04475939,Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT04475939,ZEAL-1L,ACTIVE_NOT_RECRUITING,"This is a multicenter, randomized, double-blind, placebo-controlled study of niraparib plus pembrolizumab versus placebo plus pembrolizumab as maintenance therapy in participants with advanced or metastatic non-small cell lung cancer (NSCLC) who have achieved stable disease (SD), partial response (PR), or complete response (CR) following completion of standard of care first-line (SoC 1L) platinum-based induction chemotherapy with pembrolizumab. The primary hypotheses are: participants with confirmed diagnosis of NSCLC could benefit from niraparib plus pembrolizumab versus placebo plus pembrolizumab with respect to Progression-free survival (PFS) and Overall survival (OS).",NO,"Lung Cancer, Non-Small Cell",DRUG: Niraparib|BIOLOGICAL: Pembrolizumab|DRUG: Placebo,"Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR) using Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 in complete and partial response (CR/PR) population, PFS in CR/PR population is defined as the time from the date of randomization to the date of first radiographic progression as determined by BICR or death from any cause in the absence of progression, whichever occurs first., Up to approximately 3 years","PFS assessed by BICR using RECIST v 1.1 in intent to treat (ITT) population, PFS in the ITT Population is defined as the time from the date of randomization to the date of first radiographic progression as determined by BICR or death from any cause in the absence of progression, whichever occurs first., Up to approximately 3 years|OS in CR/PR population, OS in CR/PR population defined as the time from randomization to the date of death due to any cause., Up to approximately 3 years|OS in overall population, OS is defined as the time from randomization to the date of death due to any cause., Up to approximately 5 years|Time to progression (TTP), TTP in the Central nervous system (CNS) is defined as the time from the date of randomization until the earliest date of documented PD in the CNS, based on BICR assessment using response assessment in neuro-oncology brain metastases (RANO-BM) criteria., Up to approximately 3 years|PFS by investigator assessment using RECIST v1.1, PFS is defined as the time from the date of randomization to the date of first radiographic progression as determined by the Investigator using RECIST v1.1 or death from any cause in the absence of progression, whichever occurs first., Up to approximately 3 years|CNS PFS as assessed by BICR using RANO-BM, PFS is defined as the time from the date of randomization to the date of first radiographic progression as determined by BICR using RANO-BM criteria or until death due to any cause (whichever occurs first)., Up to approximately 3 years|PFS as assessed by BICR using RECIST v1.1 by programmed cell death-ligand 1 (PD-L1) status, PFS is defined as the time from the date of randomization to the date of first radiographic progression as determined by BICR using RECIST v1.1 or death from any cause in the absence of progression, whichever occurs first. PFS will be assessed by PD-L1 status (PD-L1 tumor cells \[TCs\] less than \[\<\]1% and not evaluable (NE) versus more than or equal to \[\>=\]1%)., Up to approximately 3 years|OS by PD-L1 status, OS is defined as the time from randomization to the date of death due to any cause. OS will be assessed by PD-L1 status (PD-L1-TCs \<1% and NE versus \>=1%)., Up to approximately 5 years|Time to Deterioration (TTD) in Lung Symptoms, TTD is defined as the time from randomization to meaningful deterioration as measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 13-item lung cancer-specific module (EORTC QLQ-LC13) questionnaire, Up to approximately 3 years|Change from Baseline in Health-related quality of life (HRQoL), functioning and symptoms by EORTC QLQ-C30-item Core module (EORTC QLQ-C30) (Scores on a scale), EORTC QLQ-C30 is a validated questionnaire to assess overall health-related quality of life in participants with cancer., Baseline, Day 1 in Cycles 1, 2, 3, 4, 5 (Each cycle is of 21 Days); thereafter every 2 cycles until 90 days after last treatment dose (up to approximately 3 years)|Change from Baseline in HRQoL functioning and symptoms by EORTC QLQ-LC13 (Scores on a scale), The EORTC QLQ-LC13 is a clinically valid and useful tool for assessing disease- and treatment-specific symptoms in lung cancer participants., Baseline, Day 1 in Cycles 1, 2, 3, 4, 5 (Each cycle is of 21 Days); thereafter every 2 cycles until 90 days after last treatment dose (up to approximately 3 years)|Number of participants with adverse events (AEs), serious adverse events (SAEs) and adverse events of special interest (AESIs), AEs, SAEs and AESIs will be collected., Up to approximately 3 years|Plasma concentrations of niraparib, Blood samples will be collected to assess the plasma concentrations of niraparib., Up to approximately 3 years",,GlaxoSmithKline,,ALL,"ADULT, OLDER_ADULT",PHASE3,666,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-10-26,2025-02-26,2025-09-24,2020-07-17,,2025-05-31,"GSK Investigational Site, Fullerton, California, 92835, United States|GSK Investigational Site, Los Angeles, California, 90017, United States|GSK Investigational Site, Lone Tree, Colorado, 80128, United States|GSK Investigational Site, Norwich, Connecticut, 06360, United States|GSK Investigational Site, Tallahassee, Florida, 32003, United States|GSK Investigational Site, Atlanta, Georgia, 30322, United States|GSK Investigational Site, Newnan, Georgia, 30265, United States|GSK Investigational Site, Niles, Illinois, 60714, United States|GSK Investigational Site, Iowa City, Iowa, 52242, United States|GSK Investigational Site, Worcester, Massachusetts, 01655, United States|GSK Investigational Site, Mineola, New York, 10016, United States|GSK Investigational Site, New York, New York, 10016-4744, United States|GSK Investigational Site, Charlotte, North Carolina, 28207, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, 15212, United States|GSK Investigational Site, Chattanooga, Tennessee, 37404, United States|GSK Investigational Site, Nashville, Tennessee, 37203, United States|GSK Investigational Site, Dallas, Texas, 75246, United States|GSK Investigational Site, San Antonio, Texas, 78217, United States|GSK Investigational Site, Sugar Land, Texas, 77479, United States|GSK Investigational Site, Waco, Texas, 76712, United States|GSK Investigational Site, Fairfax, Virginia, 22031, United States|GSK Investigational Site, Buenos Aires, C1125ABD, Argentina|GSK Investigational Site, Buenos Aires, C1426ABP, Argentina|GSK Investigational Site, Cipoletti Rio Negro, R8324CVE, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aire, C1012AAR, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aire, C1426AGE, Argentina|GSK Investigational Site, Cordoba, X5004FHP, Argentina|GSK Investigational Site, Florida, 1602, Argentina|GSK Investigational Site, La Plata, 1900, Argentina|GSK Investigational Site, Rosario, S2000DSV, Argentina|GSK Investigational Site, Blacktown, New South Wales, 2148, Australia|GSK Investigational Site, Hobart, Tasmania, 7000, Australia|GSK Investigational Site, Ballarat, Victoria, 3350, Australia|GSK Investigational Site, Heidelberg, Victoria, 3084, Australia|GSK Investigational Site, Bruxelles, 1200, Belgium|GSK Investigational Site, Edegem, 2650, Belgium|GSK Investigational Site, Leuven, 3000, Belgium|GSK Investigational Site, Roeselare, 8800, Belgium|GSK Investigational Site, Belo Horizonte, 30110-022, Brazil|GSK Investigational Site, Cachoeiro Do Itapemirim, 29308-014, Brazil|GSK Investigational Site, Curitiba, 80040-170, Brazil|GSK Investigational Site, Porto Alegre, 90610-000, Brazil|GSK Investigational Site, Rio de Janeiro, 22250-905, Brazil|GSK Investigational Site, SAo Paulo, 01308-901, Brazil|GSK Investigational Site, Sao Paulo, 01509-010, Brazil|GSK Investigational Site, UberlAndia, 38408-150, Brazil|GSK Investigational Site, Panagyurishte, 4500, Bulgaria|GSK Investigational Site, Pleven, 5800, Bulgaria|GSK Investigational Site, Plovdiv, 4004, Bulgaria|GSK Investigational Site, Ruse, 7002, Bulgaria|GSK Investigational Site, Sofia, 1632, Bulgaria|GSK Investigational Site, Santiago, 7500653, Chile|GSK Investigational Site, Santiago, 7500921, Chile|GSK Investigational Site, Temuco, 5360000, Chile|GSK Investigational Site, Bogota, 5600520, Colombia|GSK Investigational Site, Monteria, 230018, Colombia|GSK Investigational Site, Brest cedex, 29609, France|GSK Investigational Site, CrEteil cedex, 94010, France|GSK Investigational Site, Grenoble Cedex 9, 38043, France|GSK Investigational Site, Lille, 59037, France|GSK Investigational Site, Paris, 75014, France|GSK Investigational Site, Paris, 75018, France|GSK Investigational Site, Rennes, 35033, France|GSK Investigational Site, Saint-Herblain, 44093, France|GSK Investigational Site, Strasbourg, 67200, France|GSK Investigational Site, Toulon cedex, 83056, France|GSK Investigational Site, Toulouse cedex 9, 31059, France|GSK Investigational Site, Berlin, 13125, Germany|GSK Investigational Site, Bonn, 53113, Germany|GSK Investigational Site, Essen, 45147, Germany|GSK Investigational Site, Frankfurt, 60488, Germany|GSK Investigational Site, Gauting, 82131, Germany|GSK Investigational Site, Grosshansdorf, 22927, Germany|GSK Investigational Site, Halle, 06120, Germany|GSK Investigational Site, Hamburg, 20251, Germany|GSK Investigational Site, Hannover, 30459, Germany|GSK Investigational Site, Heidelberg, 69126, Germany|GSK Investigational Site, Hemer, 58675, Germany|GSK Investigational Site, Jena, 07747, Germany|GSK Investigational Site, Muenchen, 81925, Germany|GSK Investigational Site, MUnchen, 80336, Germany|GSK Investigational Site, Stuttgart, 70376, Germany|GSK Investigational Site, Velbert, 42551, Germany|GSK Investigational Site, Athens, 115 27, Greece|GSK Investigational Site, Athens, 11526, Greece|GSK Investigational Site, Athens, 11528, Greece|GSK Investigational Site, Athens, 12462, Greece|GSK Investigational Site, Athens, 15125, Greece|GSK Investigational Site, Athens, 15562, Greece|GSK Investigational Site, Athens, 185 37, Greece|GSK Investigational Site, Heraklion Crete, 71110, Greece|GSK Investigational Site, Larissa, 41110, Greece|GSK Investigational Site, Neo Faliro, 185 47, Greece|GSK Investigational Site, Patras, 26500, Greece|GSK Investigational Site, Pylaia Thessaloniki, 57001, Greece|GSK Investigational Site, Rio Patras, 26500, Greece|GSK Investigational Site, Thessaloniki, 54007, Greece|GSK Investigational Site, Thessaloniki, 54622, Greece|GSK Investigational Site, Thessaloniki, 54645, Greece|GSK Investigational Site, Thessaloniki, 57010, Greece|GSK Investigational Site, Budapest, 1083, Hungary|GSK Investigational Site, Budapest, H-1122, Hungary|GSK Investigational Site, GyOngyOs, 3200, Hungary|GSK Investigational Site, TatabAnya, 2800, Hungary|GSK Investigational Site, TOrOkbAlint, 2045, Hungary|GSK Investigational Site, Cork, T12 DFK4, Ireland|GSK Investigational Site, Dublin, 8, Ireland|GSK Investigational Site, Avellino, 83100, Italy|GSK Investigational Site, Aviano PN, 33081, Italy|GSK Investigational Site, Bari, 70124, Italy|GSK Investigational Site, Catania, 95123, Italy|GSK Investigational Site, Firenze, 50134, Italy|GSK Investigational Site, Milano, 20122, Italy|GSK Investigational Site, Milano, 20132, Italy|GSK Investigational Site, Milano, 20133, Italy|GSK Investigational Site, Monza, 20900, Italy|GSK Investigational Site, Napoli, 80131, Italy|GSK Investigational Site, Orbassano TO, 10043, Italy|GSK Investigational Site, Pisa, 56124, Italy|GSK Investigational Site, Roma, 00168, Italy|GSK Investigational Site, Verona, 37045, Italy|GSK Investigational Site, Seongnam-si Gyeonggi-do, 13620, Korea, Republic of|GSK Investigational Site, Seongnam-si, 463-712, Korea, Republic of|GSK Investigational Site, Seoul, 05505, Korea, Republic of|GSK Investigational Site, Seoul, 08308, Korea, Republic of|GSK Investigational Site, Suwon Kyunggi-do, 443-721, Korea, Republic of|GSK Investigational Site, Mexico City, 03100, Mexico|GSK Investigational Site, Mexico City, 06700, Mexico|GSK Investigational Site, Mexico City, CP 14080, Mexico|GSK Investigational Site, Monterrey, 64460, Mexico|GSK Investigational Site, Puebla Puebla, 72560, Mexico|GSK Investigational Site, Amersfoort, 3813 TZ, Netherlands|GSK Investigational Site, Amsterdam, 1066 CX, Netherlands|GSK Investigational Site, Den Bosch, 5223 GZ, Netherlands|GSK Investigational Site, Enschede, 7512 KZ, Netherlands|GSK Investigational Site, Maastricht, 6229 HX, Netherlands|GSK Investigational Site, Utrecht, 3543 AZ, Netherlands|GSK Investigational Site, Zwolle, 8025 AB, Netherlands|GSK Investigational Site, Drammen, N-3004, Norway|GSK Investigational Site, Lrenskog, 1470, Norway|GSK Investigational Site, Oslo, N-0450, Norway|GSK Investigational Site, Lima, Lima 34, Peru|GSK Investigational Site, Bialystok, 15-540, Poland|GSK Investigational Site, Lodz, 90-338, Poland|GSK Investigational Site, Olsztyn, 10-357, Poland|GSK Investigational Site, Bucuresti, 011654, Romania|GSK Investigational Site, Bucuresti, 022328, Romania|GSK Investigational Site, Cluj-Napoca, 400015, Romania|GSK Investigational Site, Craiova, 200542, Romania|GSK Investigational Site, Iasi, 700483, Romania|GSK Investigational Site, Satu Mare, 440055, Romania|GSK Investigational Site, Timisoara, 300239, Romania|GSK Investigational Site, Moscow, 105 229, Russian Federation|GSK Investigational Site, Moscow, 121309, Russian Federation|GSK Investigational Site, Nizhniy Novgorod, 603081, Russian Federation|GSK Investigational Site, Omsk, 644013, Russian Federation|GSK Investigational Site, Saint-Petersburg, 197022, Russian Federation|GSK Investigational Site, Saint-Petersburg, 197758, Russian Federation|GSK Investigational Site, A CoruNa, 15006, Spain|GSK Investigational Site, Barcelona, 08025, Spain|GSK Investigational Site, Barcelona, 08035, Spain|GSK Investigational Site, Barcelona, 08036, Spain|GSK Investigational Site, Cordoba, 140044, Spain|GSK Investigational Site, Gerona, 17007, Spain|GSK Investigational Site, Las Palmas De Gran Canar, 35016, Spain|GSK Investigational Site, Madrid, 28009, Spain|GSK Investigational Site, Madrid, 28027, Spain|GSK Investigational Site, Madrid, 28041, Spain|GSK Investigational Site, Madrid, 28046, Spain|GSK Investigational Site, Madrid, 28050, Spain|GSK Investigational Site, Madrid, 28222, Spain|GSK Investigational Site, Malaga, 29010, Spain|GSK Investigational Site, PamplonaNavarra, 31008, Spain|GSK Investigational Site, Santander, 39008, Spain|GSK Investigational Site, Zaragoza, 50009, Spain|GSK Investigational Site, Gavle, SE-801 87, Sweden|GSK Investigational Site, Stockholm, SE-171 76, Sweden|GSK Investigational Site, Uppsala, SE-751 85, Sweden|GSK Investigational Site, Lausanne, 1011, Switzerland|GSK Investigational Site, Ankara, 06010, Turkey|GSK Investigational Site, Ankara, 06100, Turkey|GSK Investigational Site, Ankara, 06520, Turkey|GSK Investigational Site, Edirne, 22030, Turkey|GSK Investigational Site, Istanbul, 34662, Turkey|GSK Investigational Site, Bournemouth, BH7 7DW, United Kingdom|GSK Investigational Site, Dundee, DD1 9SY, United Kingdom|GSK Investigational Site, Middlesex, HA6 2RN, United Kingdom|GSK Investigational Site, Oxford, OX3 7LJ, United Kingdom|GSK Investigational Site, Wrexham, LL13 7TD, United Kingdom",
NCT04325763,A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC),https://clinicaltrials.gov/study/NCT04325763,,UNKNOWN,"This study is a randomized, double-blind, double-dummy,placebo parallel controlled, multi-centre,phase III clinical trial to evaluate the efficacy and safety of TQB2450 with or without anlotinib compared with placebo as consolidation treatment in subjects with locally advanced/unresectable (Stage III) Non-Small Cell Lung Cancer that has not progressed after prior concurrent/sequential chemoradiotherapy.",NO,Stage III Non-small-cell Lung Cancer,DRUG: TQB2450|DRUG: Anlotinib|DRUG: TQB2450(blank)|DRUG: Anlotinib(blank),"Progression Free Survival (PFS) evaluated by Independent Review Committee(IRC), PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause, based on IRC., up to 33 months","PFS evaluated by Investigator, PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause, based on investigator., up to 33 months|Overall survival (OS), OS defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive., up to 5 years|Overall response rate (ORR), Percentage of participants achieving complete response (CR) and partial response (PR)., up to 33 months|Disease control rateï¼DCRï¼, Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD)., up to 33 months|Duration of responseï¼DORï¼, The time when the participants first achieved complete or partial remission to disease progression., up to 33 months|PFS rate at month 6, The percentage of PFS at month 6, up to 6 months|PFS rate at month 12, The percentage of PFS at month 12, up to 12 months|Biomarkers, such as PD-L1 expression, etc., Tissue samples were collected during the screening period for pd-l1 analysis. Blood samples were collected for Tumor Mutation Burden (TMB) test before enrollment (within 7 days before medication) and after exit (Â±3 days)., up to 33 months|Immunogenicity, such as the incidence of ADA, Degree of the immune response caused by the drug., on day 1, 42, 105, 189 and 90 days after the last administration.",,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,315,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-05-27,2022-12,2025-03,2020-03-30,,2022-03-31,"Anhui Chest Hospital, Hefei, Anhui, 230000, China|Peking Union Medical College Hospital, Beijing, Beijing, 100730, China|Chongqing University Cancer Hospital, Chongqing, Chongqing, 400000, China|The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, 400000, China|Fujian Cancer Hospital, Fuzhou, Fujian, 350000, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, China|The First Affiliated Hospital Sun Yat-Sen University, Guangzhou, Guangdong, 510080, China|Yuebei People's Hospital, Shaoguan, Guangdong, 512025, China|Affiliated Hospital of Guangdong Medical University, Zhangjiang, Guangdong, 524000, China|The Fifth Affiliated Hospital Sun Yat-Sen University, Zhuhai, Guangdong, 519000, China|Guangxi Medical University Affiliated Tumor Hospital, Nanning, Guangxi, 530200, China|The Fourth Hospital of Hebei medical University, Shijiazhuang, Hebei, 050019, China|Anyang Cancer Hospital, Anyang, Henang, 455000, China|Henan Cancer Hospital, Zhengzhou, Henan, 450008, China|Hubei Cancer Hospital, Wuhan, Hubei, 430079, China|Hunan Cancer Hospital, Changsha, Hunan, 410006, China|Xiangya Hospital Central South University, Changsha, Hunan, 410008, China|The Third Xiangya Hospital of Central South University, Changsha, Hunan, 410013, China|Huaian First People's Hospital, Huai'an, Jiangsu, 223300, China|Jiangsu Cancer Hospital, Nanjing, Jiangsu, 210029, China|Jiangsu People's Hospital, Nanjing, Jiangsu, 210029, China|The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330012, China|Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China|Baoji Central Hospital, Baoji, Shanxi, 721008, China|Shanxi Cancer Hospital, Taiyuan, Shanxi, 030000, China|Xijing Hospital of Airforce Medical University, Xi'an, Shanxi, 710000, China|First Affiliated Hospital of Xi'anjiantong University, Xi'an, Shanxi, 710061, China|Tianjin Cancer Hospital, Tianjin, Tianjin, 300060, China|The first Hospital of Zhengjiang Province, Hangzhou, Zhejiang, 310000, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, 310005, China|Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310006, China|Zhejiang Hospital, Hangzhou, Zhejiang, 310013, China|Zhejiang People's Hospital, Hangzhou, Zhejiang, 310014, China|Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang, 315000, China|Taizhou Hospital of Zhejiang Province, Taizhou, Zhejiang, 317000, China|Taizhou Central Hospital, Taizhou, Zhejiang, 318000, China",
NCT03980054,A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer,https://clinicaltrials.gov/study/NCT03980054,,UNKNOWN,"This is a randomised, double-blind multicenter Phase III study for evaluating the efficacy and safety of pyrotinib in women with early stage high-risk breast cancer after adjuvant trastuzumab. The main purpose of this study is to investigate whether pyrotinib can further reduce the risk of recurrence from previously diagnosed HER-2 positive breast cancer after adjuvant treatment with trastuzumab.",NO,Breast Cancer,DRUG: Pyrotinib|DRUG: Placebo,"Invasive Disease-free Survival (iDFS), Invasive disease-free survival time is defined as the time from date of randomization until the first invasive disease recurrence of the following events: invasive ipsilateral breast tumor recurrence, invasive contralateral breast cancer, local/regional invasive recurrence, distant recurrence and death from any cause., From randomization until time of event up to 2 years","Disease-free Survival (DFS), Disease-free survival time is defined as the time from date of randomization until the first disease recurrence of the following events: invasive ipsilateral breast tumor recurrence, invasive contralateral breast cancer, local/regional invasive recurrence, non-breast primary invasive cancer, ductal carcinoma in situ(DCIS),or distant recurrence and death from any cause., From randomization until time of event up to 2 years|Overall Survival (OS), Overall survival is defined as the time from randomization to death from any cause., up to 2 years|Distance Disease-free Survival (DDFS), Distance Disease-free Survival is defined as the time from date of randomization until the first distant recurrence and death from any cause., distant recurrence From randomization until time of event up to 2 years",,"Jiangsu HengRui Medicine Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,1192,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-07-12,2022-07-31,2024-07-31,2019-06-10,,2021-05-24,"Fudan University Cancer Hospital, Shanghai, China",
NCT05342194,Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study,https://clinicaltrials.gov/study/NCT05342194,,RECRUITING,"This is a Phase III, prospective, randomized, three-arm, double-blind, placebo-controlled, international multicenter study to evaluate the efficacy and safety of toripalimab in combination with lenvatinib and gemcitabine-based chemotherapy compared with gemcitabine-based chemotherapy as first-line treatment for unresectable advanced ICC.

This study will enroll approximately 480 patients with unresectable advanced ICC who have received no prior systemic therapy. Patients who meet the requirements will be randomly assigned to Treatment Arm A: Toripalimab, lenvatinib, and gemcitabine-based chemotherapy or Treatment Arm B: Toripalimab, oral placebo, and gemcitabine-based chemotherapy or Treatment Arm C: Intravenous placebo, oral placebo, and gemcitabine-based chemotherapy.

All patients will receive standard chemotherapy (GEMOX or GC per Investigator decision) for a maximum of 8 cycles. After the completion of standard chemotherapy, all patients continue to receive maintenance therapy with toripalimab injection or its placebo in combination with lenvatinib mesylate capsule or its placebo until unacceptable toxicity, confirmed disease progression and loss of clinical benefit as determined by the investigators, start of new anti-cancer therapy, death, other conditions requiring termination of study treatment, or the patient meets the criteria for study withdrawal, whichever occurs first.

In the absence of unacceptable toxicity, patients who meet criteria for unconfirmed disease progression per RECIST v1.1 while receiving toripalimab, lenvatinib, or their placebos will be permitted to continue treatment if their clinical status or symptoms are stable or improved (as determined by the investigators) or until loss of clinical benefit. Patients with confirmed disease progression should discontinue toripalimab, lenvatinib, or their placebos.

Tumor assessments will be performed at screening and during the study treatment per protocol. In the absence of progression, tumor assessments will continue as scheduled, regardless of whether study treatment ends, until confirmed disease progression or other criteria for study withdrawal are met, whichever occurs first. Patients who meet RECIST v1.1 criteria for progression should undergo tumor assessments as scheduled if clinical benefits of continuing study treatment are determined by investigators until progression is confirmed per iRECIST (iCPD), or the criteria for study withdrawal are met, whichever occurs first.

Computerized tomography (CT)/magnetic resonance imaging (MRI) scans for efficacy evaluation will be performed at baseline, every 6 weeks (Q6W) in the first year (52 weeks), and every 9 weeks (Q9W) in the second year (after week 52).

All AEs and concomitant medications during the study will be recorded. An end-of-treatment (EOT) visit will be performed within 30 days after the last dose of study treatment or termination of study treatment is confirmed by the investigator. After the EOT visit, follow-up for survival (telephone visit is allowed) will be conducted and AEs and subsequent anti-cancer therapy will be collected.",NO,Intrahepatic Cholangiocarcinoma,DRUG: Toripalimab|DRUG: Lenvatinib mesylate capsules|DRUG: Placebo IV|DRUG: Oral placebo|DRUG: Oxaliplatin for injection|DRUG: Gemcitabine hydrochloride|DRUG: Cisplatin,"Overall survival (OS) in Arm A compared with Arm C (OS A vs. C), OS is defined as the time from randomization to death due to any cause. Overall survival will be compared between Arm A and Arm C, Until 2 years after the last subject was enrolled","OS in Arm B compared with Arm C (OS B vs. C), OS is defined as the time from randomization to death due to any cause. Overall survival will be compared between Arm B and Arm C, Until 2 years after the last subject was enrolled|Investigator-determined progression-free survival (PFS), Investigator-determined progression-free survival (PFS) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1) in Arm A compared with Arm C (PFS A vs. C);, Until 2 years after the last subject was enrolled|Investigator-determined progression-free survival (PFS), Investigator-determined PFS according to RECIST v1.1 in Arm B compared with Arm C (PFS B vs. C);, Until 2 years after the last subject was enrolled|Investigator-determined objective response rate (ORR), Investigator-determined objective response rate (ORR) according to RECIST v1.1 in Arm A compared with Arm C (ORR A vs. C), Until 2 years after the last subject was enrolled|Investigator-determined objective response rate (ORR), Investigator-determined ORR according to RECIST v1.1 in Arm B compared with Arm C (ORR B vs. C), Until 2 years after the last subject was enrolled","OS rates, 1-year and 2-year OS rates between Arm A and Arm C, Until 2 years after the last subject was enrolled|OS rates, 1-year and 2-year OS rates between Arm B and Arm C, Until 2 years after the last subject was enrolled|adverse events (AE), immune-related adverse events (irAE) and serious adverse events (SAE), To evaluate incidence, severity and outcome of adverse events (AE), immune-related adverse events (irAE) and serious adverse events (SAE), Until 2 years after the last subject was enrolled","Shanghai Junshi Bioscience Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,480,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-06-19,2027-05-31,2027-05-31,2022-04-22,,2025-04-23,"Zhongshan Hospital affiliated to Fudan University, Shanghai, Shanghai, 130061, China",
NCT06966700,"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)",https://clinicaltrials.gov/study/NCT06966700,,NOT_YET_RECRUITING,"Researchers are looking for new ways to treat types of breast cancer that are both:

* High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment
* Early-stage, which means the cancer is in the breast or the lymph nodes around the breast The 2 types of breast cancer in this study are triple-negative breast cancer (TNBC) and hormone receptor (HR)-low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. These cancers have zero or a low amount of a protein called HER2 and other proteins that attach to the hormones estrogen or progesterone.

Sacituzumab tirumotecan (also known as sac-TMT or MK-2870), the study medicine, is a type of targeted therapy. A targeted therapy is a treatment that works to control how specific types of cancer cells grow and spread.

The main goals of this study are to learn if people who receive sac-TMT, pembrolizumab, and chemotherapy:

* Have fewer cancer cells found in the tumors and lymph nodes removed during surgery compared to those who receive only pembrolizumab and chemotherapy
* Live longer without the cancer growing, spreading, or coming back compared to people who receive only pembrolizumab with chemotherapy",NO,Breast Neoplasms|Triple Negative Breast Neoplasms|HR Low-Positive/HER2-Negative Breast Neoplasms,BIOLOGICAL: Sacituzumab tirumotecan|BIOLOGICAL: Pembrolizumab|DRUG: Rescue Medication|DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Doxorubicin|DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: Capecitabine|DRUG: Olaparib,"Percentage of Participants with Pathological Complete Response (pCR) at the Time of Definitive Surgery, pCR (ypT0/Tis ypN0) is defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes after completion of neoadjuvant systemic therapy per current American Joint Committee on Cancer (AJCC) staging criteria assessed by the local pathologist at the time of definitive surgery., Up to approximately 30 weeks|Event-Free Survival (EFS), EFS is defined as the time from randomization to disease progression that precludes surgery, local or distant recurrence, or death due to any cause, whichever occurs first., Up to approximately 92 months","Overall Survival (OS), OS is defined as the time from randomization to death due to any cause., Up to approximately 115 months|Percentage of Participants with pCR with No Ductal Carcinoma in Situ (pCR-no DCIS) at the Time of Definitive Surgery, pCR-no ductal carcinoma in situ (DCIS) (ypT0 ypN0) is defined as the absence of residual invasive and in situ cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes after completion of neoadjuvant systemic therapy per current AJCC staging criteria assessed by the local pathologist at the time of definitive surgery., Up to approximately 30 weeks|Percentage of Participants with pCR at the Time of Definitive Surgery (High-risk, early-stage, TNBC subset), pCR (ypT0/Tis ypN0) is defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes after completion of neoadjuvant systemic therapy per current American Joint Committee on Cancer (AJCC) staging criteria assessed by the local pathologist at the time of definitive surgery. The pCR will be presented for the subset of participants who enrolled with high-risk, early-stage, TNBC., Up to approximately 30 weeks|Event-Free Survival (EFS) (High-risk, early-stage, TNBC subset), EFS is defined as the time from randomization to disease progression that precludes surgery, local or distant recurrence, or death due to any cause, whichever occurs first. The EFS will be presented for the subset of participants who enrolled with high-risk, early-stage, TNBC., Up to approximately 92 months|Overall Survival (OS) (High-risk, early-stage, TNBC subset), OS is defined as the time from randomization to death due to any cause., Up to approximately 115 months|Distant Progression or Distant Recurrence-Free Survival (DPDRFS), DPDRFS is defined as the time from randomization to first distant progression or distant recurrence event as assessed by investigator, or death due to any cause, whichever occurs first., Up to approximately 92 months|Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status-Quality of Life Score, The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients. Participant responses to Item 30 (""""How would you rate your overall quality of life during the past week?"") is scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher value indicates a better level of function. The change from baseline in EORTC QLQ-C30 Item 30 score will be reported., Baseline and up to approximately 3 years|Change from Baseline in EORTC QLQ-C30 Physical Functioning Score, The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better level of physical functioning., Baseline and up to approximately 3 years|Change from Baseline in EORTC QLQ-C30 Role Functioning Score, The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to questions about their role functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better level of physical functioning., Baseline and up to approximately 3 years|Change from Baseline in EORTC QLQ-C30 Fatigue Score, The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to questions about their fatigue are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better level of function., Baseline and up to approximately 3 years|Change from Baseline in EORTC QLQ Breast Cancer 42 (BR42) Systemic Therapy Side Effects Score, The EORTC QLQ-BR42 is a 42-item questionnaire to assess the overall quality of life of breast cancer patients. Participant responses to questions about their systemic therapy side effects are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a lower level of side effects., Baseline and up to approximately 3 years|Number of Participants Who Experience One or More Adverse Events (AEs), An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention., Up to approximately 67 weeks|Number of Participants Who Discontinue Study Treatment Due to an AE, An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention., Up to approximately 54 weeks",,Merck Sharp & Dohme LLC,,ALL,"ADULT, OLDER_ADULT",PHASE3,2400,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2025-06-19,2033-03-23,2035-02-04,2025-05-13,,2025-05-13,,
NCT03833154,Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation,https://clinicaltrials.gov/study/NCT03833154,PACIFIC-4,ACTIVE_NOT_RECRUITING,"This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab with SoC SBRT versus placebo with SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3N0M0) NSCLC.

An additional cohort will assess Osimertinib following SBRT in patients with early stage unresected T1 to T3N0M0 NSCLC harbouring an EGFR mutation.",NO,"Carcinoma, Non-Small-Cell Lung","DRUG: Durvalumab|OTHER: Placebo|DRUG: (Osimertinib cohort, single-arm, open-label separate cohort)","Progression-Free Survival (PFS) assessed by Blinded Independent Central Review (BICR) according to RECIST 1.1 in subpopulation of patients with Stage I/II NSCLC, Main Cohort, from randomization up to 6 years|4-year Progression-Free Survival (4y-PFS) by ICR according to RECIST 1.1 criteria, Osimertinib Cohort, from treatment start up to 5 years","Progression-Free Survival (PFS) assessed by BICR per RECIST 1.1 in all randomised patients with Stage I/II NSCLC, Main Cohort, from randomization up to 6 years|Overall Survival (OS), Main Cohort, from randomization up to 7 years|Concentration of durvalumab in serum such as peak concentration and trough, Main Cohort, 12 weeks after last dose|Detection of ADA neutralising antibodies titers, Main Cohort, up to 6 months after last dose|Health-related quality of life in patients treated with durvalumab with SoC SBRT compared to placebo with SoC SBRT using the EORTC QLQ-C30, Main Cohort, from randomization up to 7 years|Proportion of patients alive and progression free at 24 months from randomisation (PFS24) assessed by BICR according to RECIST 1.1, Main Cohort, at 24 months following randomization|Time to progression (TTP) assessed by BICR according to RECIST 1.1, Main Cohort, from randomization up to 6 years|Time to death or distant metastasis (TTDM) assessed by BICR according to RECIST 1.1, Main Cohort, from randomization up to 6 years|Time from randomisation to second progression (PFS2) as defined by local standard clinical practice, Main Cohort, from randomization up to 7 years|Assessment of AEs by CTCAE v 5.0 as measures of the safety and tolerability of Durvalumab with SoC SBRT compared to placebo with SoC SBRT, Main Cohort, up to 3 months after last dose|Assessment of AEs by CTCAE v 5.0 as measures of the safety, tolerability and compliance of osimertinib with SoC SBRT therapy, Osimertinib Cohort, Up to 35 days after last dose|WHO performance status, Osimertinib Cohort, from treatment start up to 5 years|ECG QT interval, Osimertinib Cohort, Up to 156 weeks of treatment or treatment discontinuation|Overall Survival, Osimertinib Cohort, from treatment start up to 5 years|Time To Progression (TTP), Osimertinib Cohort, from treatment start up to 5 years|Time to CNS progression, Osimertinib Cohort, from treatment start up to 5 years|PFS2, Osimertinib Cohort, from treatment start up to 5 years|Site(s) of disease progression, Osimertinib Cohort, from treatment start up to 5 years|PFS by ICR using RECIST 1.1, Osimertinib Cohort, from treatment start up to 5 years","Lung cancer mortality, Osimertinib Cohort, from treatment start up to 5 years|Lung Cancer Mortality, Main Cohort, from randomization Up to 5 years",AstraZeneca,,ALL,"ADULT, OLDER_ADULT",PHASE3,724,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-03-06,2027-04-16,2028-04-04,2019-02-06,,2025-04-09,"Research Site, Tuscaloosa, Alabama, 35401, United States|Research Site, Chandler, Arizona, 85224, United States|Research Site, Phoenix, Arizona, 85004, United States|Research Site, Tucson, Arizona, 85719, United States|Research Site, Duarte, California, 91010, United States|Research Site, Long Beach, California, 90806, United States|Research Site, Los Angeles, California, 90095, United States|Research Site, San Diego, California, 92123, United States|Research Site, Newark, Delaware, 10709, United States|Research Site, Washington, District of Columbia, 20010, United States|Research Site, Bay Pines, Florida, 33744, United States|Research Site, Jacksonville, Florida, 32256, United States|Research Site, Miami Beach, Florida, 33140, United States|Research Site, Orlando, Florida, 32804, United States|Research Site, Atlanta, Georgia, 30322, United States|Research Site, Atlanta, Georgia, 30342, United States|Research Site, Chicago, Illinois, 60611, United States|Research Site, Chicago, Illinois, 60612, United States|Research Site, Chicago, Illinois, 60637, United States|Research Site, Decatur, Illinois, 62526, United States|Research Site, Elmhurst, Illinois, 60126, United States|Research Site, Naperville, Illinois, 60540, United States|Research Site, Fort Wayne, Indiana, 46845, United States|Research Site, Cedar Rapids, Iowa, 52403, United States|Research Site, Iowa City, Iowa, 52242, United States|Research Site, Elizabethtown, Kentucky, 42701, United States|Research Site, Lexington, Kentucky, 40503, United States|Research Site, Louisville, Kentucky, 40202, United States|Research Site, Metairie, Louisiana, 70006, United States|Research Site, New Orleans, Louisiana, 70121, United States|Research Site, South Portland, Maine, 04106, United States|Research Site, Annapolis, Maryland, 21401, United States|Research Site, Baltimore, Maryland, 21201, United States|Research Site, Rosedale, Maryland, 21237, United States|Research Site, Silver Spring, Maryland, 20910, United States|Research Site, Towson, Maryland, 21204, United States|Research Site, Boston, Massachusetts, 02215, United States|Research Site, Ann Arbor, Michigan, 48197, United States|Research Site, Detroit, Michigan, 48201, United States|Research Site, Royal Oak, Michigan, 48073, United States|Research Site, Duluth, Minnesota, 55805, United States|Research Site, Rochester, Minnesota, 55905, United States|Research Site, Saint Louis, Missouri, 63110, United States|Research Site, Omaha, Nebraska, 68105, United States|Research Site, Las Vegas, Nevada, 89135, United States|Research Site, Lebanon, New Hampshire, 03756, United States|Research Site, Camden, New Jersey, 08103, United States|Research Site, Paramus, New Jersey, 07652, United States|Research Site, Albany, New York, 12206, United States|Research Site, Bronx, New York, 10461, United States|Research Site, Bronx, New York, 10467, United States|Research Site, East Syracuse, New York, 13057, United States|Research Site, New Hyde Park, New York, 11042, United States|Research Site, New York, New York, 10016, United States|Research Site, Rochester, New York, 14642, United States|Research Site, Stony Brook, New York, 11794, United States|Research Site, Syracuse, New York, 13210, United States|Research Site, Winston-Salem, North Carolina, 27157, United States|Research Site, Grand Forks, North Dakota, 58201, United States|Research Site, Akron, Ohio, 44304, United States|Research Site, Cincinnati, Ohio, 45219, United States|Research Site, Cincinnati, Ohio, 45242, United States|Research Site, Cleveland, Ohio, 44106, United States|Research Site, Portland, Oregon, 97210, United States|Research Site, Portland, Oregon, 97213, United States|Research Site, Philadelphia, Pennsylvania, 19107, United States|Research Site, Pittsburgh, Pennsylvania, 15212, United States|Research Site, Charleston, South Carolina, 29425, United States|Research Site, Sioux Falls, South Dakota, 57105, United States|Research Site, Watertown, South Dakota, 57201, United States|Research Site, Austin, Texas, 78745, United States|Research Site, Dallas, Texas, 75235, United States|Research Site, Houston, Texas, 77030, United States|Research Site, Sherman, Texas, 75090, United States|Research Site, Burlington, Vermont, 05401, United States|Research Site, Richmond, Virginia, 23249, United States|Research Site, Bellingham, Washington, 98225, United States|Research Site, Seattle, Washington, 98195, United States|Research Site, Spokane Valley, Washington, 99216, United States|Research Site, Milwaukee, Wisconsin, 53226, United States|Research Site, Clayton, 3168, Australia|Research Site, Aalst, 9300, Belgium|Research Site, Charleroi, 6000, Belgium|Research Site, Edegem, 2650, Belgium|Research Site, Gent, 9000, Belgium|Research Site, Leuven, 3000, Belgium|Research Site, Barretos, 14784-400, Brazil|Research Site, Porto Alegre, 90110-270, Brazil|Research Site, Recife, 52010-075, Brazil|Research Site, Rio de Janeiro, 22271-110, Brazil|Research Site, Sao Paulo, 01327-001, Brazil|Research Site, Volta Redonda, 27258-000, Brazil|Research Site, Edmonton, Alberta, T6G 1Z2, Canada|Research Site, London, Ontario, N6A 5W9, Canada|Research Site, Toronto, Ontario, M4N 3M5, Canada|Research Site, Toronto, Ontario, M5G 2M9, Canada|Research Site, Montreal, Quebec, H2X 3E4, Canada|Research Site, Beijing, 100021, China|Research Site, Beijing, 100142, China|Research Site, Changchun, 130021, China|Research Site, Changsha, 410013, China|Research Site, Chengdu, 610042, China|Research Site, Fuzhou, 350005, China|Research Site, Hangzhou, 310002, China|Research Site, Hangzhou, 310022, China|Research Site, Hefei, 230031, China|Research Site, Jinan, 250117, China|Research Site, Nanjing, 210009, China|Research Site, Shanghai, 200002, China|Research Site, Shanghai, 200030, China|Research Site, Shanghai, 200032, China|Research Site, Shanghai, 200433, China|Research Site, Shenyang, 100003, China|Research Site, Suzhou, 215006, China|Research Site, Wenzhou, 325000, China|Research Site, Wuhan, 430022, China|Research Site, Wuhan, 430030, China|Research Site, Zhengzhou, 450008, China|Research Site, Bron, 69677, France|Research Site, Dijon, 21079, France|Research Site, Lyon Cedex 04, 69317, France|Research Site, Nantes, 44202, France|Research Site, Pierre Benite, 69310, France|Research Site, Toulouse, 31000, France|Research Site, Villejuif, 94805, France|Research Site, Dresden, 01307, Germany|Research Site, GÃ¶ttingen, 37075, Germany|Research Site, Halle, 06120, Germany|Research Site, Hannover, 30459, Germany|Research Site, Heidelberg, 69126, Germany|Research Site, Homburg, 66424, Germany|Research Site, Regensburg, 93053, Germany|Research Site, Trier, 54292, Germany|Research Site, Athens, 11526, Greece|Research Site, Athens, 11527, Greece|Research Site, Athens, 18547, Greece|Research Site, Thessaloniki, 55236, Greece|Research Site, Haifa, 31096, Israel|Research Site, Jerusalem, 91120, Israel|Research Site, Kfar Saba, 95847, Israel|Research Site, Petah Tikva, 49100, Israel|Research Site, Ramat Gan, 52621, Israel|Research Site, Tel Aviv, 64239, Israel|Research Site, Firenze, 50134, Italy|Research Site, Genova, 16132, Italy|Research Site, Milano, 20132, Italy|Research Site, Orbassano, 10043, Italy|Research Site, Padova, 35128, Italy|Research Site, Pavia, 27100, Italy|Research Site, Roma, 00128, Italy|Research Site, Rozzano, 20089, Italy|Research Site, Akashi-shi, 673-8558, Japan|Research Site, Bunkyo-ku, 113-8677, Japan|Research Site, Chuo-ku, 104-0045, Japan|Research Site, Fukuoka-shi, 812-8582, Japan|Research Site, Hirosaki-shi, 036-8563, Japan|Research Site, Hiroshima-shi, 734-8551, Japan|Research Site, Kobe-shi, 650-0047, Japan|Research Site, Niigata-shi, 951-8566, Japan|Research Site, Osaka-shi, 541-8567, Japan|Research Site, Sakai-shi, 591-8555, Japan|Research Site, Sapporo-shi, 060-8648, Japan|Research Site, Sunto-gun, 411-8777, Japan|Research Site, Toyoake-shi, 470-1192, Japan|Research Site, Yokohama-shi, 241-8515, Japan|Research Site, Cheongju-si, 28644, Korea, Republic of|Research Site, Goyang-si, 10408, Korea, Republic of|Research Site, Gyeonggi-do, 13620, Korea, Republic of|Research Site, Seoul, 03722, Korea, Republic of|Research Site, Seoul, 05505, Korea, Republic of|Research Site, Seoul, 06351, Korea, Republic of|Research Site, Amsterdam, 1081 HV, Netherlands|Research Site, Groningen, 9713 GZ, Netherlands|Research Site, Utrecht, 3584 CX, Netherlands|Research Site, Bydgoszcz, 85-796, Poland|Research Site, ElblÄg, 02-300, Poland|Research Site, GdaÅsk, 80-952, Poland|Research Site, Katowice, 40-514, Poland|Research Site, Warszawa, 02-781, Poland|Research Site, ÅÃ³dÅº, 93-513, Poland|Research Site, Hato Rey, 00917, Puerto Rico|Research Site, Ekaterinburg, 620905, Russian Federation|Research Site, Kazan, Tatarstan, 420029, Russian Federation|Research Site, Moscow, 105229, Russian Federation|Research Site, Moscow, 115478, Russian Federation|Research Site, Moscow, 119421, Russian Federation|Research Site, Saint Petersburg, 197758, Russian Federation|Research Site, Ufa, 450054, Russian Federation|Research Site, Badajoz, 6006, Spain|Research Site, Barcelona, 08041, Spain|Research Site, L'Hospitalet de Llobregat, 08907, Spain|Research Site, Madrid, 28034, Spain|Research Site, Madrid, 28040, Spain|Research Site, Madrid, 28041, Spain|Research Site, Madrid, 28046, Spain|Research Site, Malaga, 29010, Spain|Research Site, San SebastiÃ¡n, 20014, Spain|Research Site, Santiago de Compostela, 15706, Spain|Research Site, Sevilla, 41013, Spain|Research Site, Valencia, 46010, Spain|Research Site, Zaragoza, 50009, Spain|Research Site, Ankara, 06010, Turkey|Research Site, Ankara, 06520, Turkey|Research Site, Istanbul, 34214, Turkey|Research Site, Izmir, 35340, Turkey|Research Site, Kocaeli, 41400, Turkey|Research Site, Birmingham, B9 5SS, United Kingdom|Research Site, Leeds, LS9 7TF, United Kingdom|Research Site, London, EC1A 7BE, United Kingdom|Research Site, Manchester, M20 4BX, United Kingdom",
NCT03682068,"Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer",https://clinicaltrials.gov/study/NCT03682068,NILE,ACTIVE_NOT_RECRUITING,"This is a randomized, open-label, controlled, multi-center, global Phase III study to determine the efficacy and safety of combining durvalumab Â± tremelimumab with standard of care (SoC) chemotherapy (cisplatin + gemcitabine or carboplatin + gemcitabine doublet) followed by durvalumab monotherapy versus SoC alone as first-line chemotherapy in patients with histologically or cytologically documented, unresectable, locally advanced or metastatic transitional cell carcinoma of the urothelium (including renal pelvis, ureters, urinary bladder, and urethra).",NO,Unresectable Locally Advanced Urothelial Cancer|Metastatic Urothelial Cancer,DRUG: Durvalumab|DRUG: Tremelimumab|DRUG: Cisplatin + Gemcitabine|DRUG: Carboplatin + Gemcitabine,"Overall Survival (OS), OS is defined as the time from the date of randomization until death due to any cause, approximately 5 years","Overall Survival (OS), Additional analysis beyond the primary endpoint, approximately 5 years|Overall Survival at 24 months (OS24), The OS24 will be defined as the Kaplan-Meier estimate of OS at 24 months, 24 months|Progression Free Survival (PFS), PFS (per RECIST 1.1) will be defined as the time from the date of randomization until the date of first objective disease progression or death, approximately 5 years|Alive and Progression Free Survival at 12 months (APF12), The APF12 will be defined as the Kaplan-Meier estimate of PFS (per RECIST 1.1) at 12 months, 12 months|Objective Response Rate (ORR), ORR (per RECIST 1.1) is defined as the number (%) of patients with at least 1 visit response of complete response or partial response and will be based on a subset of all randomized patients, approximately 5 years|Duration of Response (DoR), DoR (per RECIST 1.1) will be defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression, approximately 5 years|Disease Control Rate (DCR), DCR is defined as the proportion of subjects with the best overall response of complete response, partial response or stable disease per RECIST 1.1, approximately 5 years|Time from randomization to second (PFS2), PFS2 will be defined as the time from the date of randomization to the earliest of the progression events subsequent to that used for the PFS endpoint or death, approximately 5 years|To assess disease-related symptoms, physical functioning, and other Health-related quality of life, Collection of patient reported outcome questionnaires, approximately 5 years","To assess safety using a summary of adverse events., Adverse Events (both in terms of MedDRA preferred terms and CTCAE grade) will be listed individually by patient. The number of patients experiencing each Adverse Event will be summarized by treatment arm and CTCAE grade, approximately 5 years|To assess pharmacokinetics of Durvalumab and Tremelimumab, Serum concentrations of Durvalumab and Tremelimumab, approximately 5 years|To assess immunogenicity of Durvalumab and Tremelimumab, Presence of anti-drug antibodies for Durvalumab and Tremelimumab, approximately 5 years",AstraZeneca,,ALL,"ADULT, OLDER_ADULT",PHASE3,1246,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2018-09-27,2025-06-30,2025-06-30,2018-09-24,,2025-02-06,"Research Site, Birmingham, Alabama, 35294, United States|Research Site, Bakersfield, California, 93309, United States|Research Site, Fullerton, California, 92835, United States|Research Site, Los Angeles, California, 90095, United States|Research Site, Salinas, California, 93901, United States|Research Site, Santa Barbara, California, 93105, United States|Research Site, Truckee, California, 96161, United States|Research Site, New Haven, Connecticut, 06520, United States|Research Site, Washington, District of Columbia, 20007, United States|Research Site, Orlando, Florida, 32806, United States|Research Site, Chicago, Illinois, 60611, United States|Research Site, Fort Wayne, Indiana, 46804, United States|Research Site, Kansas City, Kansas, 66160, United States|Research Site, Louisville, Kentucky, 40202, United States|Research Site, New Orleans, Louisiana, 70112, United States|Research Site, Grand Rapids, Michigan, 49503, United States|Research Site, Bozeman, Montana, 59715, United States|Research Site, New Hyde Park, New York, 11042, United States|Research Site, New York, New York, 10029, United States|Research Site, New York, New York, 10065, United States|Research Site, Rochester, New York, 14642, United States|Research Site, Germantown, Tennessee, 38138, United States|Research Site, Fort Worth, Texas, 76104, United States|Research Site, Buenos Aires, C1120AAT, Argentina|Research Site, Buenos Aires, C1426ANZ, Argentina|Research Site, Ciudad de Buenos Aires, 1280, Argentina|Research Site, Ciudad de Buenos Aires, C1419AHL, Argentina|Research Site, Rosario, S2000DEJ, Argentina|Research Site, Box Hill, 3128, Australia|Research Site, Elizabeth Vale, 5112, Australia|Research Site, Kogarah, 2217, Australia|Research Site, Macquarie University, 2109, Australia|Research Site, Murdoch, 6150, Australia|Research Site, Orange, 2800, Australia|Research Site, South Brisbane, 4101, Australia|Research Site, St Albans, 3021, Australia|Research Site, Curitiba, 80810-050, Brazil|Research Site, Fortaleza, 60336-232, Brazil|Research Site, Porto Alegre, 90020-090, Brazil|Research Site, Porto Alegre, 90610-000, Brazil|Research Site, Porto Alegre, 91350-200, Brazil|Research Site, RibeirÃ£o Preto, 14048-900, Brazil|Research Site, Rio de Janeiro, 20231-050, Brazil|Research Site, Rio de Janeiro, 22793-080, Brazil|Research Site, Salvador, 41.950-610, Brazil|Research Site, Santa Maria, 97015-450, Brazil|Research Site, Sao Paulo, 01327-001, Brazil|Research Site, SÃ£o JosÃ© do Rio Preto, 15090-000, Brazil|Research Site, SÃ£o Paulo, 01246-000, Brazil|Research Site, Pleven, 5800, Bulgaria|Research Site, Plovdiv, 4000, Bulgaria|Research Site, Sofia, 1303, Bulgaria|Research Site, Sofia, 1431, Bulgaria|Research Site, Sofia, 1527, Bulgaria|Research Site, Sofia, 1797, Bulgaria|Research Site, Varna, 9010, Bulgaria|Research Site, Calgary, Alberta, T2N 5G2, Canada|Research Site, Edmonton, Alberta, T6G 1Z2, Canada|Research Site, Vancouver, British Columbia, V5Z 4E6, Canada|Research Site, Hamilton, Ontario, L8V 5C2, Canada|Research Site, Ottawa, Ontario, K1H 8L6, Canada|Research Site, Toronto, Ontario, M5G IX6, Canada|Research Site, Montreal, Quebec, H3T 1E2, Canada|Research Site, Beijing, 100034, China|Research Site, Beijing, 100191, China|Research Site, Beijing, 100730, China|Research Site, Changchun, 130021, China|Research Site, Changsha, 410008, China|Research Site, Changsha, 410013, China|Research Site, Chongqing, 400038, China|Research Site, Chongqing, 400042, China|Research Site, Dalian, 116027, China|Research Site, Guangzhou, 510000, China|Research Site, Guangzhou, 510060, China|Research Site, Hangzhou, 310003, China|Research Site, Hangzhou, 310009, China|Research Site, Hangzhou, 310014, China|Research Site, Hangzhou, 310022, China|Research Site, Jinan, 250012, China|Research Site, Nanchang, 330006, China|Research Site, Nanjing, 2100008, China|Research Site, Shanghai, 200032, China|Research Site, Shanghai, 200072, China|Research Site, Shenyang, 110001, China|Research Site, Suzhou, 215006, China|Research Site, Tianjin, 300211, China|Research Site, Tianjin, China|Research Site, Urumqi, 830000, China|Research Site, Wuhan, 430022, China|Research Site, Xi'an, 710061, China|Research Site, Brno, 656 91, Czechia|Research Site, Hradec Kralove, 500 05, Czechia|Research Site, Olomouc, 77900, Czechia|Research Site, Ostrava, 708 52, Czechia|Research Site, Praha 2, 128 08, Czechia|Research Site, Praha 8, 180 81, Czechia|Research Site, Praha, 140 59, Czechia|Research Site, Budapest, 1062, Hungary|Research Site, Budapest, 1122, Hungary|Research Site, Budapest, 1145, Hungary|Research Site, Debrecen, 4032, Hungary|Research Site, GyÅr, 9024, Hungary|Research Site, KecskemÃ©t, 6000, Hungary|Research Site, Szolnok, 5000, Hungary|Research Site, Gurgaon, 122001, India|Research Site, Hubli, 580025, India|Research Site, Kolkata, 700160, India|Research Site, Mysuru, 570017, India|Research Site, Nagpur, 440012, India|Research Site, Nasik, 422005, India|Research Site, New Delhi, 110085, India|Research Site, New Delhi, 11029, India|Research Site, Pune, 411004, India|Research Site, Haifa, 31096, Israel|Research Site, Jerusalem, 91120, Israel|Research Site, Kfar Saba, 95847, Israel|Research Site, Petach-Tikva, 4941492, Israel|Research Site, Ramat Gan, 52621, Israel|Research Site, Arezzo, 52100, Italy|Research Site, Milano, 20132, Italy|Research Site, Milano, 20133, Italy|Research Site, Napoli, 80131, Italy|Research Site, Orbassano, 10043, Italy|Research Site, Parma, 43126, Italy|Research Site, Pavia, 27100, Italy|Research Site, Roma, 00100, Italy|Research Site, Terni, 05100, Italy|Research Site, Verona, 37134, Italy|Research Site, Bunkyo-ku, 113-8603, Japan|Research Site, Chuo-ku, 104-0045, Japan|Research Site, Fukuoka-shi, 811-1347, Japan|Research Site, Hirosaki-shi, 036-8563, Japan|Research Site, Kanazawa-shi, 920-8641, Japan|Research Site, Kita-gun, 761-0793, Japan|Research Site, Koshigaya-shi, 343-8555, Japan|Research Site, Koto-ku, 135-8550, Japan|Research Site, Kumamoto-shi, 860-0008, Japan|Research Site, Kumamoto-shi, 860-8556, Japan|Research Site, Kyoto-shi, 606-8507, Japan|Research Site, Miyazaki-city, 889-1692, Japan|Research Site, Nagasaki-shi, 852-8501, Japan|Research Site, Nagoya-shi, 466-8560, Japan|Research Site, Nagoya-shi, 467-0001, Japan|Research Site, Niigata-shi, 951-8520, Japan|Research Site, Osaka-shi, 541-8567, Japan|Research Site, Osaka-shi, 545-8586, Japan|Research Site, Osakasayama-shi, 589-8511, Japan|Research Site, Shinjuku-ku, 160-8582, Japan|Research Site, Suita-shi, 565-0871, Japan|Research Site, Toyama-shi, 930-0194, Japan|Research Site, Yokohama-shi, 232-0024, Japan|Research Site, Yokohama-shi, 241-8515, Japan|Research Site, Goyang-si, 10408, Korea, Republic of|Research Site, Incheon, 21565, Korea, Republic of|Research Site, Seoul, 02841, Korea, Republic of|Research Site, Seoul, 03722, Korea, Republic of|Research Site, Seoul, 05505, Korea, Republic of|Research Site, Seoul, 06351, Korea, Republic of|Research Site, Suwon, 16247, Korea, Republic of|Research Site, Bacolod, 6100, Philippines|Research Site, Baguio City, 2600, Philippines|Research Site, Cebu, 6000, Philippines|Research Site, Davao City, 8000, Philippines|Research Site, Makati, 1229, Philippines|Research Site, Manila, 1015, Philippines|Research Site, Quezon City, 1101, Philippines|Research Site, Quezon City, 1104, Philippines|Research Site, Bialystok, 15-027, Poland|Research Site, GdaÅsk, 80-214, Poland|Research Site, GrudziÄdz, 86-300, Poland|Research Site, Koszalin, 75-581, Poland|Research Site, KrakÃ³w, 31-501, Poland|Research Site, Olsztyn, 10-228, Poland|Research Site, Poznan, 60-693, Poland|Research Site, Radom, 26-600, Poland|Research Site, Warszawa, 02-781, Poland|Research Site, Ivanovo, 153040, Russian Federation|Research Site, Krasnoyarsk, 660133, Russian Federation|Research Site, Moscow, 105077, Russian Federation|Research Site, Moscow, 105229, Russian Federation|Research Site, Moscow, 115280, Russian Federation|Research Site, Moscow, 125284, Russian Federation|Research Site, Nizhniy Novgorod, 603074, Russian Federation|Research Site, Nizhniy Novgorod, 603137, Russian Federation|Research Site, Omsk, 644013, Russian Federation|Research Site, Rostov-on-Don, 344037, Russian Federation|Research Site, Saint-Petersburg, 195067, Russian Federation|Research Site, St. Petersburg, 197758, Russian Federation|Research Site, St. Petersburg, 199178, Russian Federation|Research Site, Tyumen, 625041, Russian Federation|Research Site, Vologda, 160012, Russian Federation|Research Site, Barcelona, 08908, Spain|Research Site, Barcelona, 8003, Spain|Research Site, Barcelona, 8035, Spain|Research Site, Lugo, 27003, Spain|Research Site, Madrid, 28007, Spain|Research Site, Madrid, 28034, Spain|Research Site, Madrid, 28040, Spain|Research Site, Malaga, 29010, Spain|Research Site, Santander, 39008, Spain|Research Site, Sevilla, 41013, Spain|Research Site, Taichung, 404, Taiwan|Research Site, Taichung, 40705, Taiwan|Research Site, Tainan, 704, Taiwan|Research Site, Taipei City, 10050, Taiwan|Research Site, Taipei, 11217, Taiwan|Research Site, Taoyuan, 333, Taiwan|Research Site, Bangkok, 10300, Thailand|Research Site, Bangkok, 10400, Thailand|Research Site, Khon Kaen, 40002, Thailand|Research Site, Mueang, 50200, Thailand|Research Site, Songkla, 90110, Thailand|Research Site, Adana, 1260, Turkey|Research Site, Adapazari, 54290, Turkey|Research Site, Ankara, 06590, Turkey|Research Site, Edirne, 22030, Turkey|Research Site, Istanbul, 34030, Turkey|Research Site, Izmir, Turkey|Research Site, Ha Noi, 100000, Vietnam|Research Site, Hanoi, 100000, Vietnam|Research Site, Hanoi, 10000, Vietnam|Research Site, Ho Chi Minh, 70000, Vietnam",
NCT03924895,Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303),https://clinicaltrials.gov/study/NCT03924895,,ACTIVE_NOT_RECRUITING,"This is a study of perioperative pembrolizumab or enfortumab vedotin in combination with pembrolizumab in participants who are cisplatin-ineligible or decline cisplatin with muscle-invasive bladder cancer (MIBC).

The primary hypothesis is that perioperative pembrolizumab plus radical cystectomy (RC) plus pelvic lymph node dissection (PLND) and perioperative enfortumab vedotin in combination with pembrolizumab plus RC+PLND will achieve superior event-free survival (EFS) compared with RC+PLND alone.

With Amendment 5, outcome measures for programmed cell death ligand 1 (PD-L1) combined positive score (CPS) were removed.

With Amendment 8, the primary outcome measure of pathologic complete response (pCR) rates was changed to a secondary outcome measure.",NO,"Urinary Bladder Cancer, Muscle-invasive",DRUG: Pembrolizumab|PROCEDURE: Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])|DRUG: Enfortumab Vedotin,"Event-Free Survival (EFS) between Arm C and Arm B, EFS is defined as the time from randomization to the first occurrence of any of the following events: progression of disease that precludes RC surgery or failure to undergo RC surgery in participants with residual disease (biopsy-proven muscle-invasive bladder cancer \[MIBC\] will be considered an event regardless of radiographic findings), gross residual disease left behind at the time of surgery, local or distant recurrence as assessed by imaging and/or biopsy, or death due to any cause., Up to approximately 6.75 years","EFS between Arm A and Arm B, EFS is defined as the time from randomization to the first occurrence of any of the following events: progression of disease that precludes RC surgery or failure to undergo RC surgery in participants with residual disease (biopsy-proven muscle-invasive bladder cancer \[MIBC\] will be considered an event regardless of radiographic findings), gross residual disease left behind at the time of surgery, local or distant recurrence as assessed by imaging and/or biopsy, or death due to any cause., Up to approximately 6.75 years|Overall Survival (OS) between Arm C and Arm B, OS is defined as the time from randomization to death due to any cause., Up to approximately 7.6 years|OS between Arm A and Arm B, OS is defined as the time from randomization to death due to any cause., Up to approximately 7.6 years|Pathologic Complete Response (pCR) Rate between Arm C and Arm B, Pathologic complete response rate is defined as the percentage of participants having pCR. pCR is defined as absence of viable tumor (pT0N0) in examined tissue from RC and PLND, as determined centrally., Up to approximately 5.7 years|pCR Rate between Arm A and Arm B, Pathologic complete response rate is defined as the percentage of participants having pCR. pCR is defined as absence of viable tumor (pT0N0) in examined tissue from RC and PLND, as determined centrally., Up to approximately 5.7 years|Disease-Free Survival (DFS), DFS is defined as the time from first post-surgery baseline scan until:

* local or distant recurrence as assessed by imaging and/or biopsy
* Death due to any cause, Up to approximately 6.75 years|Pathologic Downstaging (pDS) Rate between Arm A and Arm B, Pathologic downstaging rate is defined as the percentage of participants having pDS. pDS is defined as participants with a tumor classification of \<pT2 (includes pT0, pTis, pTa, pT1) and N0 in examined tissue from RC and PLND., Up to approximately 5.7 years|pDS Rate between Arm C and Arm B, Pathologic downstaging rate is defined as the percentage of participants having pDS. pDS is defined as participants with a tumor classification of \<pT2 (includes pT0, pTis, pTa, pT1) and N0 in examined tissue from RC and PLND., Up to approximately 5.7 years|Number of Participants Experiencing Adverse Events (AEs), An AE is defined as any unfavorable and unintended sign, symptom, or disease (new or worsening) temporally associated with the use of study therapy, regardless of whether or not a causal relationship with the study therapy can be determined., Up to approximately 7.6 years|Number of Participants Discontinuing Study Drug Due to Adverse Events (AEs), An AE is defined as any unfavorable and unintended sign, symptom, or disease (new or worsening) temporally associated with the use of study therapy, regardless of whether or not a causal relationship with the study therapy can be determined., Up to approximately 1 year|Number of Participants Experiencing Perioperative Complications, The number of participants who experience perioperative complications will be presented., Up to approximately 1 year",,Merck Sharp & Dohme LLC,"Seagen Inc.|Astellas Pharma Global Development, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE3,595,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2019-07-24,2027-05-31,2027-12-15,2019-04-23,,2025-01-29,"University of South Alabama, Mitchell Cancer Institute ( Site 1582), Mobile, Alabama, 36604, United States|CARTI Cancer Center ( Site 1577), Little Rock, Arkansas, 72205, United States|St. Joseph Heritage Healthcare ( Site 0046), Fullerton, California, 92835, United States|Scripps MD Anderson ( Site 0010), La Jolla, California, 92037, United States|Hoag Memorial Hospital Presbyterian ( Site 1595), Newport Beach, California, 92663, United States|John Wayne Cancer Institute ( Site 0075), Santa Monica, California, 90404, United States|University of Colorado Hospital ( Site 0098), Aurora, Colorado, 80045, United States|Georgetown University Medical Center ( Site 0022), Washington, District of Columbia, 20007, United States|Emory School of Medicine ( Site 0006), Atlanta, Georgia, 30322, United States|John H. Stroger Jr. Hospital of Cook County ( Site 1551), Chicago, Illinois, 60612, United States|University of Chicago ( Site 0068), Chicago, Illinois, 60637, United States|Parkview Cancer Institute ( Site 0077), Fort Wayne, Indiana, 46845, United States|Indiana University Melvin and Bren Simon Comprehensive Cancer Center ( Site 0004), Indianapolis, Indiana, 46202, United States|Wichita Urology Group ( Site 0059), Wichita, Kansas, 67226, United States|Tulane University School of Medicine ( Site 0088), New Orleans, Louisiana, 70112, United States|New England Cancer Specialists ( Site 0070), Scarborough, Maine, 04074, United States|Greater Baltimore Medical Center ( Site 0014), Baltimore, Maryland, 21204, United States|Dana-Farber Cancer Institute ( Site 1596), Boston, Massachusetts, 02215, United States|M Health Fairview Ridges Hospital ( Site 1555), Burnsville, Minnesota, 55337, United States|Morristown Medical Center ( Site 0015), Morristown, New Jersey, 07960, United States|UNM Comprehensive Cancer Center-Clinical Research Office ( Site 0045), Albuquerque, New Mexico, 87106, United States|Northwell Health - Monter Cancer Center ( Site 0083), Lake Success, New York, 11042, United States|New York University Perlmutter Cancer Center ( Site 0008), New York, New York, 10016, United States|Icahn School of Medicine at Mount Sinai ( Site 0031), New York, New York, 10029, United States|Cleveland Clinic Main ( Site 1576), Cleveland, Ohio, 44195, United States|Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0021), Tulsa, Oklahoma, 74146, United States|Providence Portland Medical Center [Portland, OR] ( Site 0095), Portland, Oregon, 97213, United States|MidLantic Urology ( Site 0089), Bala-Cynwyd, Pennsylvania, 19004, United States|Abramson Cancer Center of the University of Pennsylvania ( Site 0074), Philadelphia, Pennsylvania, 19104, United States|Thomas Jefferson University ( Site 1579), Philadelphia, Pennsylvania, 19107, United States|Fox Chase Cancer Center ( Site 0055), Philadelphia, Pennsylvania, 19111, United States|Allegheny General Hospital ( Site 0048), Pittsburgh, Pennsylvania, 15212, United States|Bon Secours St. Francis Health System ( Site 1572), Greenville, South Carolina, 29607, United States|Carolina Urologic Research Center ( Site 0062), Myrtle Beach, South Carolina, 29572, United States|Urology Associates [Nashville, TN] ( Site 0053), Nashville, Tennessee, 37209, United States|Vanderbilt University Medical Center ( Site 0017), Nashville, Tennessee, 37232, United States|Texas Oncology-Baylor Sammons Cancer Center ( Site 1552), Dallas, Texas, 75246, United States|Inova Schar Cancer Institute ( Site 0007), Fairfax, Virginia, 22031, United States|Charleston Area Medical Center ( Site 0023), Charleston, West Virginia, 25304, United States|AsociaciÃ³n de Beneficencia Hospital Sirio LibanÃ©s ( Site 2102), Buenos Aires, Caba, C1419AHN, Argentina|Western Sydney Local Health District ( Site 1259), Blacktown, New South Wales, 2148, Australia|Macquarie University ( Site 1251), Macquarie Park, New South Wales, 2109, Australia|Cairns Base Hospital ( Site 1257), Cairns, Queensland, 4870, Australia|Mater Misericordiae Ltd ( Site 1258), South Brisbane, Queensland, 4101, Australia|Eastern Health ( Site 1255), Box Hill, Victoria, 3128, Australia|Monash Health ( Site 1260), Clayton, Victoria, 3168, Australia|UCL Saint-Luc - Oncologie Medicale ( Site 0357), Bruxelles, Bruxelles-Capitale, Region De, 1200, Belgium|CHU UCL Namur Site de Godinne ( Site 0354), Yvoir, Namur, 5530, Belgium|AZ Maria Middelares Gent ( Site 0353), Gent, Oost-Vlaanderen, 9000, Belgium|UZ Leuven ( Site 0361), Leuven, Vlaams-Brabant, 3000, Belgium|AZ Sint-Jan Brugge ( Site 0352), Brugge, West-Vlaanderen, 8000, Belgium|AZ Delta vzw-Oncology ( Site 0362), Roeselare, West-Vlaanderen, 8800, Belgium|Tom Baker Cancer Centre ( Site 0100), Calgary, Alberta, T2N 4N2, Canada|BC Cancer Vancouver-Clinical Trials Unit ( Site 0121), Vancouver, British Columbia, V5Z 4E6, Canada|Silverado Resarch Inc. ( Site 0111), Victoria, British Columbia, V8T 2C1, Canada|Moncton Hospital - Horizon Health Network ( Site 0112), Moncton, New Brunswick, E1C 6Z8, Canada|Sunnybrook Research Institute ( Site 0110), Toronto, Ontario, M4N 3M5, Canada|Princess Margaret Cancer Centre ( Site 0107), Toronto, Ontario, M5G 2M9, Canada|CIUSSS du Saguenay-Lac-St-Jean ( Site 0116), Chicoutimi, Quebec, G7H 5H6, Canada|CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0105), Montreal, Quebec, H1T 2M4, Canada|Jewish General Hospital ( Site 0120), Montreal, Quebec, H3T 1E2, Canada|McGill University Health Centre ( Site 0123), MontrÃ©al, Quebec, H4A 3J1, Canada|CIUSSS de l'Estrie-CHUS ( Site 0106), Sherbrooke, Quebec, J1H 5N4, Canada|FundaciÃ³n Colombiana de CancerologÃ­a ClÃ­nica Vida ( Site 2003), Medellin, Antioquia, 050030, Colombia|OncomÃ©dica S.A.S ( Site 2001), MonterÃ­a, Cordoba, 230002, Colombia|Clinica Colsanitas S.A, Sede ClÃ­nica Universitaria Colombia-Center Investigator ( Site 2002), Bogota, Distrito Capital De Bogota, 111321, Colombia|FundaciÃ³n Cardiovascular de Colombia ( Site 2004), Piedecuesta, Santander, 681017, Colombia|Fundacion Valle del Lili- CIC-Fundacion Valle del Lili ( Site 2005), Cali, Valle Del Cauca, 760032, Colombia|Herlev og Gentofte Hospital. ( Site 0412), Herlev, Hovedstaden, 2730, Denmark|Rigshospitalet University Hospital ( Site 0411), Kobenhavn, Hovedstaden, 2100, Denmark|Aarhus University Hospital Skejby ( Site 0418), Aarhus, Midtjylland, 8200, Denmark|Odense Universitetshospital ( Site 0413), Odense, Syddanmark, 5000, Denmark|Hopital de la Timone ( Site 0489), Marseille, Bouches-du-Rhone, 13005, France|Centre Francois Baclesse ( Site 0459), Caen, Calvados, 14075, France|Centre Georges Francois Leclerc ( Site 0488), Dijon, Cote-d Or, 21000, France|CHU Jean Minjoz ( Site 0455), Besancon, Doubs, 25000, France|Institut de Cancerologie du Gard - CHU Caremeau ( Site 0490), Nimes, Gard, 30029, France|CHU de Bordeaux- Hopital Saint Andre ( Site 0456), Bordeaux, Gironde, 33075, France|Institut Claudius Regaud IUCT Oncopole ( Site 0486), Toulouse, Haute-Garonne, 31059, France|C.H.R.U. de Rennes. Hopital de Pontchaillou ( Site 0492), Rennes, Ille-et-Vilaine, 35033, France|CHU de Montpellier - Hopital Saint-Eloi ( Site 0469), Montpellier, Languedoc-Roussillon, 34295, France|CHU Hotel Dieu Nantes ( Site 0458), Nantes, Loire-Atlantique, 44093, France|Hopital Belle Isle ( Site 0452), Vantoux, Moselle, 57070, France|C.H.U. Lyon Sud ( Site 0466), Pierre Benite, Rhone, 69310, France|Institut Gustave Roussy ( Site 0487), Villejuif, Val-de-Marne, 94805, France|CHU Cochin ( Site 0475), Paris, 75014, France|Hopital Europeen Georges Pompidou ( Site 0476), Paris, 75015, France|Hopital Bichat du Paris ( Site 0462), Paris, 75018, France|Klinikum Stuttgart - Katharinenhospital ( Site 0520), Stuttgart, Baden-Wurttemberg, 70174, Germany|Klinikum der Eberhard-Karls-Universitaet Tuebingen ( Site 0549), Tuebingen, Baden-Wurttemberg, 72076, Germany|Universitaetsklinikum Erlangen ( Site 0546), Erlangen, Bayern, 91058, Germany|Klinikum der Universitaet Muenchen - Grosshadern ( Site 0548), Muenchen, Bayern, 81377, Germany|Universitaetsklinikum Wuerzburg ( Site 0547), Wuerzburg, Bayern, 97080, Germany|Universitaetsklinikum Bonn ( Site 0550), Bonn, Nordrhein-Westfalen, 53127, Germany|Universitaetsklinikum Magdeburg A.o.R. ( Site 0535), Magdeburg, Sachsen-Anhalt, 39120, Germany|Universitaetsklinikum Carl Gustav Carus ( Site 0532), Dresden, Sachsen, 01307, Germany|SRH Wald-Klinikum Gera-Zentrum fÃ¼r klinische Studien ( Site 0533), Gera, Thuringen, 07548, Germany|Vivantes Klinikum am Urban ( Site 0529), Berlin, 10967, Germany|Universitaetsklinikum Hamburg-Eppendorf-Onkologisches Zentrum ( Site 0528), Hamburg, 20246, Germany|SZTE Szent-Gyorgyi Albert Klinikai Kozpont ( Site 1010), Szeged, Csongrad, 6720, Hungary|Bajcsy Zsilinszki Korhaz es Rendelointezet ( Site 1001), Budapest, 1106, Hungary|Debreceni Egyetem Klinikai Kozpont ( Site 1006), Debrecen, 4032, Hungary|Petz Aladar Megyei Oktato Korhaz ( Site 1012), Gyor, 9023, Hungary|Somogy Megyei Kaposi Mor Oktato Korhaz ( Site 1007), Kaposvar, 7400, Hungary|Tallaght University Hospital ( Site 0734), Dublin, D24 NR0A, Ireland|University Hospital Waterford ( Site 0747), Waterford, X91ER8E, Ireland|Ha Emek Medical Center ( Site 0843), Afula, 1834111, Israel|Soroka Medical Center ( Site 0849), Beer Sheva, 8410101, Israel|Rambam Health Care Campus-Oncology Division ( Site 0845), Haifa, 3109601, Israel|Shaare Zedek Medical Center ( Site 0842), Jerusalem, 9103102, Israel|Hadassah Ein Kerem Medical Center ( Site 0841), Jerusalem, 9112001, Israel|Meir Medical Center ( Site 0846), Kfar Saba, 4428164, Israel|Rabin Medical Center ( Site 0847), Petach Tikva, 4941492, Israel|Sheba Medical Center ( Site 0844), Ramat Gan, 5265601, Israel|Sourasky Medical Center ( Site 0850), Tel Aviv, 6423906, Israel|Yitzhak Shamir Medical Center. ( Site 0848), Zerifin, 70300, Israel|Policlinico Gemelli di Roma ( Site 0558), Roma, Abruzzo, 00168, Italy|Ospedale San Raffaele-Oncologia Medica ( Site 0561), Milano, Lombardia, 20132, Italy|Azienda Sanitaria Ospedaliera S Luigi Gonzaga-SCDU Oncologia Medica ( Site 0563), Orbassano, Piemonte, 10043, Italy|AULSS8 Berica-Ospedale S.Bortolo-ONCOLOGIA CLINICA ( Site 0562), Vicenza, Veneto, 36100, Italy|Azienda USL 8 di Arezzo-Medical Oncology ( Site 0565), Arezzo, 52100, Italy|A.O.U. Policlinico Vittorio Emanuele - Presidio Gaspare Rodolico ( Site 0559), Catania, 95123, Italy|Istituto Nazionale Studio e Cura dei Tumori ( Site 0551), Milano, 20133, Italy|Istituto Nazionale Per Lo Studio E La Cura Dei Tumori ( Site 0552), Napoli, 80131, Italy|Fondazione Salvatore Maugeri IRCCS ( Site 0554), Pavia, 27100, Italy|Azienda Ospedaliera Santa Maria Terni-S.C. Oncologia Medica e Traslazionale ( Site 0564), Terni, 05100, Italy|National Cancer Center Hospital East ( Site 2305), Kashiwa, Chiba, 277-8577, Japan|Tsukuba University Hospital ( Site 2302), Tsukuba, Ibaraki, 305-8576, Japan|St. Marianna University Hospital ( Site 2321), Kawasaki, Kanagawa, 216-8511, Japan|Kitasato University Hospital ( Site 2306), Sagamihara, Kanagawa, 252-0375, Japan|Yokosukakyosai ( Site 2307), Yokosuka, Kanagawa, 238-8558, Japan|Tohoku University Hospital ( Site 2301), Sendai-shi, Miyagi, 980-8574, Japan|Nagano Municipal Hospital ( Site 2309), Tomitake, Nagano, 381-8551, Japan|Nara Medical University Hospital ( Site 2312), Kashihara, Nara, 634-0813, Japan|Osaka Rosai Hospital ( Site 2320), Sakai, Osaka, 591-8025, Japan|Saitama Prefectural Cancer Center ( Site 2319), Ina-machi, Saitama, 362-0806, Japan|Dokkyo Medical University Saitama Medical Center ( Site 2304), Koshigaya, Saitama, 3438555, Japan|Hamamatsu University Hospital ( Site 2311), Hamamatsu, Shizuoka, 431-3192, Japan|Tokyo Medical and Dental University Hospital ( Site 2303), BunkyÅ, Tokyo, 113-8519, Japan|Toranomon Hospital ( Site 2322), Minato-ku, Tokyo, 105-8470, Japan|Toyama University Hospital ( Site 2308), Toyoma, Toyama, 930-0194, Japan|Gifu University Hospital ( Site 2310), Gifu, 501-1112, Japan|Kagoshima University Hospital ( Site 2317), Kagoshima, 890-8520, Japan|Nagasaki University Hospital ( Site 2315), Nagasaki, 852-8501, Japan|National Cancer Center ( Site 1354), Goyang-si, Kyonggi-do, 10408, Korea, Republic of|Seoul National University Bundang Hospital ( Site 1356), Seongnam-si, Kyonggi-do, 13620, Korea, Republic of|Asan Medical Center ( Site 1355), Songpagu, Seoul, 05505, Korea, Republic of|Kyungpook National University Chilgok Hospital-Urology ( Site 1357), Deagu, Taegu-Kwangyokshi, 41404, Korea, Republic of|Korea University Anam Hospital ( Site 1351), Seoul, 02841, Korea, Republic of|Seoul National University Hospital ( Site 1352), Seoul, 03080, Korea, Republic of|Samsung Medical Center ( Site 1353), Seoul, 06351, Korea, Republic of|University Malaya Medical Centre ( Site 1702), Lembah Pantai, Kuala Lumpur, 59100, Malaysia|Hospital Pulau Pinang ( Site 1703), Georgetown, Pulau Pinang, 10990, Malaysia|Sarawak General Hospital ( Site 1701), Kuching, Sarawak, 93586, Malaysia|Centro de Urologia Avanzada del Noreste S.A. de C.V. ( Site 0253), Monterrey, Nuevo Leon, 66269, Mexico|Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V. ( Site 0300), Aguascalientes, 20010, Mexico|Centro Estatal de Cancerologia de Chihuahua ( Site 0254), Chihuahua, 31000, Mexico|Instituto Nacional de Cancerologia. ( Site 0256), Ciudad de Mexico, 14080, Mexico|Centro de Tratamiento de Cancer ( Site 0266), Metepec, 52140, Mexico|Hospital Angeles Roma ( Site 0262), Mexico City, 06700, Mexico|THE MEDICAL CITY ILOILO ( Site 1756), Iloilo City, Iloilo, 5000, Philippines|The Medical City ( Site 1752), Pasig City, National Capital Region, 1605, Philippines|St. Luke s Medical Center ( Site 1751), Quezon City, National Capital Region, 1112, Philippines|Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego ( Site 1063), Wroclaw, Dolnoslaskie, 50-556, Poland|Centrum Onkologii im.prof. F. Lukaszczyka w Bydgoszczy ( Site 1068), Bydgoszcz, Kujawsko-pomorskie, 85-796, Poland|Szpital Wojewodzki ( Site 1062), Tarnow, Malopolskie, 33-100, Poland|Europejskie Centrum Zdrowia Otwock ( Site 1058), Otwock, Mazowieckie, 05-400, Poland|Luxmed Onkologia sp. z o. o. ( Site 1051), Warszawa, Mazowieckie, 01-748, Poland|Bialostockie Centrum Onkologii ( Site 1072), Bialystok, Podlaskie, 15-027, Poland|Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka w Slupsku ( Site 1057), Slupsk, Pomorskie, 76-200, Poland|Beskidzkie Centrum Onkologii im. Jana Pawla II ( Site 1061), Bielsko-Biala, Slaskie, 43-300, Poland|Clinical Research Center Medic-R ( Site 1073), PoznaÅ, Wielkopolskie, 60-848, Poland|Clinic of Bashkortostan State Medical University ( Site 0873), Ufa, Baskortostan, Respublika, 450081, Russian Federation|Ivanovo Regional Oncology Dispensary ( Site 0852), Ivanovo, Ivanovskaya Oblast, 153040, Russian Federation|Krasnoyarsk Regional Clinical Oncological Dispensary ( Site 0861), Krasnoyarsk, Krasnoyarskiy Kray, 660133, Russian Federation|Kursk Regional Clinical Oncology Dispensary ( Site 0854), Kursk, Kurskaya Oblast, 305524, Russian Federation|Russian Oncological Research Center n.a. N.N.Blokhin of MoH ( Site 0878), Moscow, Moskva, 115478, Russian Federation|First Moscow State Medical University n.a. I.M.Sechenov ( Site 0884), Moscow, Moskva, 119991, Russian Federation|Central Clinical Hospital with outpatient Clinic ( Site 0856), Moscow, Moskva, 121359, Russian Federation|Bayandin Murmansk Regional Clinical Hospital ( Site 0859), Murmansk, Murmanskaya Oblast, 183057, Russian Federation|Volga District Medical Center Federal Medical and Biological Agency ( Site 0857), Nizhny Novgorod, Nizhegorodskaya Oblast, 603074, Russian Federation|Omsk Clinical Oncology Dispensary ( Site 0865), Omsk, Omskaya Oblast, 644013, Russian Federation|Leningrad Regional Oncology Center ( Site 0868), Saint Petersburg, Sankt-Peterburg, 188663, Russian Federation|First St. Petersburg State Medical University n.a. acad. I.P. Pavlov ( Site 0872), Saint-Petersburg, Sankt-Peterburg, 197022, Russian Federation|National Medical Research Center of Oncology N.A. N.N. Petrov ( Site 0860), Saint-Petersburg, Sankt-Peterburg, 197758, Russian Federation|Clinical Hospital Saint Luka ( Site 0867), St. Petersburg, Sankt-Peterburg, 194044, Russian Federation|Saratov State Medical University n.a. V.I.Razumovskiy ( Site 0866), Saratov, Saratovskaya Oblast, 410012, Russian Federation|Sverdlovsk Regional Oncology Hospital ( Site 0874), Ekaterinburg, Sverdlovskaya Oblast, 620036, Russian Federation|Medical Sanitary Unit Neftyannik ( Site 0888), Tyumen, Tyumenskaya Oblast, 625000, Russian Federation|National University Hospital ( Site 1802), Singapore, Central Singapore, 119074, Singapore|Tan Tock Seng Hospital ( Site 1804), Singapore, Central Singapore, 398442, Singapore|Steve Biko Academic Hospital-Medical Oncology ( Site 1601), Pretoria, Gauteng, 0001, South Africa|Groote Schuur Hospital ( Site 1602), Cape Town, Western Cape, 7925, South Africa|Hosp. Gral. Universitari Germans Trias i Pujol ( Site 0675), Badalona, Barcelona, 08916, Spain|Hospital Clinic i Provincial ( Site 0674), Barcelona, Cataluna, 08036, Spain|Hospital San Pedro de Alcantara ( Site 0697), Caceres, Extremadura, 10003, Spain|Institut CatalÃ  d'Oncologia (ICO) - Girona ( Site 0700), Girona, Gerona, 17007, Spain|Hospital Universitario Quiron Madrid ( Site 0694), Pozuelo de Alarcon, Madrid, Comunidad De, 28223, Spain|Instituto Valenciano de Oncologia - IVO ( Site 0679), Valencia, Valenciana, Comunitat, 46009, Spain|Hospital del Mar ( Site 0698), Barcelona, 08003, Spain|Hospital Universitario Ramon y Cajal ( Site 0691), Madrid, 28034, Spain|Hospital Universitario San Carlos ( Site 0678), Madrid, 28040, Spain|Hospital Universitario la Paz ( Site 0690), Madrid, 28046, Spain|Hospital de Nuestra Senora de Valme ( Site 0693), Sevilla, 41014, Spain|Laenssjukhuset Ryhov ( Site 1215), Jonkoping, Jonkopings Lan, 551 85, Sweden|Karolinska Universitetssjukhuset Solna ( Site 1212), Stockholm, Stockholms Lan, 171 76, Sweden|Akademiska Sjukhuset ( Site 1211), Uppsala, Uppsala Lan, 751 85, Sweden|Cancercentrum ( Site 1214), Umea, Vasterbottens Lan, 901 85, Sweden|Onkologiska kliniken ( Site 1217), Goteborg, Vastra Gotalands Lan, 413 45, Sweden|Ramathibodi Hospital. ( Site 1451), Bangkok, Krung Thep Maha Nakhon, 10400, Thailand|Faculty of Medicine Siriraj Hospital ( Site 1452), Bangkok, Krung Thep Maha Nakhon, 10700, Thailand|Maharaj Nakorn Chiangmai Hospital ( Site 1453), Chiang Mai, 50200, Thailand|Srinagarind Hospital ( Site 1454), Khon Kaen, 40002, Thailand|Hacettepe Universitesi TÄ±p Fakultesi ( Site 0931), Ankara, 06100, Turkey|Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 0930), Istanbul, 34096, Turkey|TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 0926), Istanbul, 34722, Turkey|Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi ( Site 0921), Istanbul, 34899, Turkey|Necmettin Erbakan Universitesi Meram Tip Fakultesi Hastanesi ( Site 0929), Konya, 42080, Turkey|Sakarya Universitesi Tip Fakultesi ( Site 0933), Sakarya, 54290, Turkey|Karadeniz Teknik Universitesi Tip Fakultesi Farabi Hastanesi ( Site 0924), Trabzon, 61080, Turkey|Cherkasy Regional Oncology Dispensary ( Site 0959), Cherkasy, Cherkaska Oblast, 18009, Ukraine|ME Ð.Ð. Mechnykov Dnipro Regional Clinical Hospital ( Site 0963), Dnipropetrovsk, Dnipropetrovska Oblast, 49005, Ukraine|MNPE City Clinical Hospital #4 of Dnipro Regional Council ( Site 0951), Dnipro, Dnipropetrovska Oblast, 49102, Ukraine|Regional Oncology Center of Kharkiv ( Site 0958), Kharkiv, Kharkivska Oblast, 61000, Ukraine|MNPE V.I. Shapoval Regional Medical Clinical Urology and Nephrology Center of KharkivRegCouncil ( Si, Kharkiv, Kharkivska Oblast, 61037, Ukraine|Municipal Non-profit Enterprise of Kharkiv Regional Council RCSDRPP ( Site 0973), Kharkiv, Kharkivska Oblast, 61166, Ukraine|Communal nonprofit enterprise ""Kherson Regional Oncology Dispensary"" of Kherson Regional Council (, Antonivka Village, Khersonska Oblast, 73000, Ukraine|SNPE National Cancer Institute ( Site 0962), Kyiv, Kyivska Oblast, 03022, Ukraine|MNPE Lviv Regional Clinical Hospital of Lviv Regional Council ( Site 0955), Lviv, Lvivska Oblast, 79010, Ukraine|Lviv State Regional Oncological Center ( Site 0967), Lviv, Lvivska Oblast, 79031, Ukraine|Zhytomyr Regional Oncology Center ( Site 0971), Zhytomyr, Zhytomyrska Oblast, 10002, Ukraine|Kyiv City Clinical Oncology Center ( Site 0960), Kyiv, 03115, Ukraine|Kent and Canterbury Hospital ( Site 0733), Canterbury, England, CT1 3NG, United Kingdom|The James Cook University Hospital ( Site 0730), Middlesbrough, England, TS4 3BW, United Kingdom|Lister Hospital ( Site 0739), Stevenage, Hertfordshire, SG1 4AB, United Kingdom|Barts Health NHS Trust - St Bartholomew s Hospital ( Site 0725), London, London, City Of, EC1A 7BE, United Kingdom|The Royal Marsden Foundation Trust ( Site 0726), London, London, City Of, SW3 6JJ, United Kingdom|Imperial College Healthcare NHS Trust ( Site 0745), London, London, City Of, W6 8RF, United Kingdom|Western General Hospital ( Site 0749), Edinburgh, Midlothian, EH4 2XU, United Kingdom|Royal Cornwall Hospital ( Site 0727), Truro, TR1 3LJ, United Kingdom|Walsall Manor Hospital-Oncology ( Site 0743), Walsall, WS2 9PS, United Kingdom|Clatterbridge Oncology Centre ( Site 0731), Wirral, CH63 4JY, United Kingdom",
NCT05715840,"Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy Â± Bevacizumab Versus Placebo Plus Chemotherapy Â±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPSâ¥1)",https://clinicaltrials.gov/study/NCT05715840,,NOT_YET_RECRUITING,"This study is a randomised, double-blind, placebo-controlled, multicentre phase 3 clinical study to evaluate the efficacy and safety of SG001 plus chemotherapyÂ±bevacizumab versus placebo plus chemotherapyÂ±bevacizumab, as first-line treatment, in patients with PD-L1 positive (CPSâ¥1), Recurrent or Metastatic Cervical Cancer. The study contains a Safety Lead-in Phase in which the safety and tolerability of SG001ï¼ChemotherapyÂ±Bevacizumab will be assessed prior to the Phase 3 portion of the study.",NO,"Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPSâ¥1)",DRUG: SG001 injection|DRUG: Paclitaxel|DRUG: Cisplatin|DRUG: Carboplatin|DRUG: Bevacizumab injection|DRUG: SG001 placebo,"Safety Lead-in, Incidence and grade of the TRAEãSAE and irAE, Up to 42 days after the last patient of the lead-in phase|PFS per RECIST 1.1, Phase 3, Up to approximately 3 years|Overall survival (OS), Phase 3, Up to approximately 3 years","Safety Lead-in and phase 3, ORR per RECIST 1.1, Up to approximately 3 years|Peak Plasma Concentrationï¼Cmaxï¼, Safety Lead-in and phase 3, Up to approximately 2 years|DOR per RECIST 1.1, Safety Lead-in and phase 3, Up to approximately 3 years|DCR per RECIST 1.1, Safety Lead-in and phase 3, Up to approximately 3 years|TTR per RECIST 1.1, Safety Lead-in and phase 3, Up to approximately 3 years|Area under the plasma concentration versus time curve (AUC), Safety Lead-in and phase 3, Up to approximately 2 years|half-timeï¼t1/2ï¼, Safety Lead-in and phase 3, Up to approximately 2 years|Plasma clearanceï¼CLï¼, Safety Lead-in and phase 3, Up to approximately 2 years|Volume of Distribution at Steady Stateï¼Vssï¼, Safety Lead-in and phase 3, Up to approximately 2 years|PFS per iRECIST 1.1, phase 3, Up to approximately 3 years|Incidence and grade of the TRAEãSAE and irAE, phase 3, Up to approximately 3 years",,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,368,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-01-31,2024-07-31,2026-05-31,2023-02-08,,2023-02-08,,
NCT06617416,A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC,https://clinicaltrials.gov/study/NCT06617416,,RECRUITING,"This study compares the efficacy and safety of AK104 versus Sugemalimab as consolidation therapy in patients with unresectable, locally advanced NSCLC who have not progressed following concurrent or sequential chemoradiotherapy.",NO,NSCLC (Non-small Cell Lung Cancer),DRUG: Cadonilimab (AK104)|DRUG: Sugemalimab,"Progression-free survival (PFS) assessed by INV, PFS is defined as the time from randomization until the first documentation of disease progression or death due to any cause, whichever occurs first (based on RECIST Version 1.1)., 3 years","OS, Time from randomization to death, 5 years|6-month PFS rate assessed by INV, PFS rate at 6 months, 3 years|AEs, Adverse events incidence and severity, clinically significant abnormal laboratory test results., 3 years",,Akeso,,ALL,"ADULT, OLDER_ADULT",PHASE3,560,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-11-12,2026-10-28,2028-12-30,2024-09-27,,2025-03-12,"Cancer Hospital of Shandong First Medical University, Jinan, China",
NCT06393374,Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012),https://clinicaltrials.gov/study/NCT06393374,,RECRUITING,"This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery. The primary objective is to compare sacituzumab tirumotecan plus pembrolizumab to TPC (pembrolizumab or pembrolizumab plus capecitabine) with respect to invasive disease-free survival (iDFS) per investigator assessment. It is hypothesized that sacituzumab tirumotecan plus pembrolizumab is superior to TPC with respect to iDFS per investigator assessment.",NO,Triple-Negative Breast Cancer,BIOLOGICAL: Pembrolizumab|BIOLOGICAL: Sacituzumab tirumotecan|DRUG: Capecitabine,"Invasive Disease-Free Survival (iDFS), iDFS is the time from randomization to invasive local, regional, or distant recurrence, invasive contralateral breast cancer, or death due to any cause, whichever occurs first., Up to ~77 months","Overall Survival (OS), OS is the time from randomization to death due to any cause., Up to ~101 months|Distant recurrence-free survival (DRFS), DRFS is the time from randomization to distant recurrence or death due to any cause, whichever occurs first., Up to ~101 months|Change from baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score, EORTC QLQ-C30 is a 30-item scale to assess the overall quality of life in cancer patients. The overall functioning score is based on participant responses that are scored on a 7-point scale (1 = ""Very poor"" to 7 = ""Excellent""). Higher scores indicate better overall health status., Baseline and up to ~60 months|Change from baseline in EORTC QLQ-C30 Physical Functioning (Items 1-5) Combined Score, EORTC QLQ-C30 is a 30-item scale to assess the overall quality of life of cancer patients. The physical functioning score is based on participant responses to questions that scored on a 4-point scale (1 = 'Not at All' to 4 = 'Very Much'). Higher scores indicate better physical functioning., Baseline and up to ~60 months|Change from baseline in EORTC QLQ-C30 Role Functioning (Items 6 and 7) Combined Score, EORTC QLQ-C30 is a 30-item scale to assess the overall quality of life of cancer patients. The role functioning score is based on participant responses to questions that scored on a 4-point scale (1 = 'Not at All' to 4 = 'Very Much'). Higher scores indicate better role functioning., Baseline and up to ~60 months|Change from baseline in EORTC QLQ-C30 Fatigue (Items 10, 12, and 18) Combined Score, EORTC QLQ-C30 is a 30-item scale to assess the overall quality of life of cancer patients. Participant responses to questions about their fatigue are scored on a 4-point scale (1 = ""Not at All"" to 4 = ""Very Much""). Lower scores indicate a better level of fatigue., Baseline and up to ~60 months|Number of participants who experience one or more adverse events (AEs), An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention., Up to ~42 weeks|Number of participants who discontinue study intervention due to an AE, An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention., Up to 24 weeks",,Merck Sharp & Dohme LLC,,ALL,"ADULT, OLDER_ADULT",PHASE3,1530,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-06-24,2030-12-16,2037-12-14,2024-05-01,,2025-06-13,"Infirmary Cancer Care ( Site 0001), Mobile, Alabama, 36607, United States|Ironwood Cancer & Research Centers-Research ( Site 0054), Chandler, Arizona, 85224, United States|Scripps Cancer Center ( Site 0052), La Jolla, California, 92037, United States|Cancer and Blood Specialty Clinic ( Site 0008), Los Alamitos, California, 90720, United States|Kaiser Permanente - Oakland ( Site 0079), Oakland, California, 94611, United States|Kaiser Permanente - Roseville ( Site 0081), Roseville, California, 95661, United States|Kaiser Permanente - San Francisco ( Site 0080), San Francisco, California, 94115, United States|Kaiser Permanente - Santa Clara ( Site 0082), Santa Clara, California, 95051, United States|Kaiser Permanente Vallejo Medical Center ( Site 0060), Vallejo, California, 94589, United States|Kaiser Permanente - Walnut Creek ( Site 0078), Walnut Creek, California, 94596, United States|Bass Medical Group ( Site 0089), Walnut Creek, California, 94598, United States|Yale Cancer Center ( Site 0053), New Haven, Connecticut, 06510, United States|Comprehensive Hematology Oncology ( Site 0091), Saint Petersburg, Florida, 33709, United States|Archbold Memorial Hospital-Lewis Hall Singletary Oncology Center ( Site 0040), Thomasville, Georgia, 31792, United States|Orchard Healthcare Research Inc. ( Site 0014), Skokie, Illinois, 60077, United States|Parkview Research Center at Parkview Regional Medical Center ( Site 0011), Fort Wayne, Indiana, 46845, United States|Cancer Center of Kansas ( Site 0004), Wichita, Kansas, 67214, United States|Ochsner LSU Health - Monroe Medical Center, Family Medicine Clinic ( Site 0063), Monroe, Louisiana, 71202, United States|Louisiana State University Health Sciences Shreveport ( Site 0029), Shreveport, Louisiana, 71103, United States|Holy Cross Hospital ( Site 0069), Silver Spring, Maryland, 20910, United States|Profound Research LLC ( Site 0074), Royal Oak, Michigan, 48073, United States|SSM Health Cancer Care - Fenton ( Site 0088), Fenton, Missouri, 63026, United States|Lake Regional Hospital ( Site 0009), Osage Beach, Missouri, 65065, United States|New Mexico Oncology Hematology Consultants Ltd. ( Site 0090), Albuquerque, New Mexico, 87109, United States|Memorial Sloan Kettering Cancer Center ( Site 0067), New York, New York, 10065, United States|Clinical Research Alliance ( Site 0086), Westbury, New York, 11590, United States|Sanford Cancer Center Bismarck ( Site 0058), Bismarck, North Dakota, 58501, United States|Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0056), Fargo, North Dakota, 58122, United States|Altru Cancer Center ( Site 0104), Grand Forks, North Dakota, 58201, United States|Cleveland Clinic - Mercy Hospital ( Site 0057), Canton, Ohio, 44708, United States|Tri-County Hematology & Oncology Associates, Inc. ( Site 0076), Massillon, Ohio, 44646, United States|Genesis Healthcare System ( Site 0025), Zanesville, Ohio, 43701, United States|Hightower Clinical, LLC ( Site 0085), Oklahoma City, Oklahoma, 73102, United States|Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0041), Tulsa, Oklahoma, 74146, United States|Sidney Kimmel Cancer Center at Jefferson ( Site 0049), Philadelphia, Pennsylvania, 19107, United States|Sanford Cancer Center ( Site 0059), Sioux Falls, South Dakota, 57104, United States|West Cancer Center and Research Institute ( Site 0084), Germantown, Tennessee, 38138, United States|Nashville General Hospital ( Site 0072), Nashville, Tennessee, 37208, United States|Harrington Cancer Center ( Site 0061), Amarillo, Texas, 79106, United States|Parkland Health & Hospital System ( Site 0096), Dallas, Texas, 75390, United States|University of Texas Southwestern Medical Center ( Site 0032), Dallas, Texas, 75390, United States|Texas Oncology - Northeast Texas ( Site 8005), Flower Mound, Texas, 75028, United States|The University of Texas Health Science Center at Tyler dba UT Health East Texas HOPE Cancer Center ( Site 0055), Tyler, Texas, 75701, United States|Bon Secours Memorial Regional Medical Center-Oncology Research Department ( Site 0020), Midlothian, Virginia, 23114, United States|Virginia Cancer Institute ( Site 0034), Richmond, Virginia, 23229, United States|Northwest Medical Specialties, PLLC ( Site 0093), Tacoma, Washington, 98405, United States|SSM Health Dean Medical Group ( Site 0087), Madison, Wisconsin, 53715, United States|Hospital Aleman-Oncology ( Site 0501), Capital Federal, Buenos Aires, C1118AAT, Argentina|Hospital BritÃ¡nico de Buenos Aires-Oncology ( Site 0502), Ciudad autÃ³noma de Buenos Aires, Buenos Aires, C1280AEB, Argentina|Instituto de OncologÃ­a Angel H. Roffo ( Site 0503), Buenos Aires, Caba, C1417, Argentina|Instituto Alexander Fleming-Alexander Fleming ( Site 0509), Ciudad AutÃ³noma de Buenos Aires, Caba, 1426ANZ, Argentina|Sanatorio Parque ( Site 0512), Rosario, Santa Fe, S2000DVC, Argentina|Sanatorio Finochietto ( Site 0513), Buenos Aires, C1187AAN, Argentina|Centro de EducaciÃ³n MÃ©dica e Investigaciones clÃ­nicas ""Dr. Norberto Quirno"" (CEMIC) ( Site 0508), Buenos Aires, C1431FWO, Argentina|Macquarie University-MQ Health Clinical Trials Unit ( Site 2703), Macquarie University, New South Wales, 2109, Australia|Westmead Hospital ( Site 2700), Westmead, New South Wales, 2145, Australia|Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Site 2701), Brisbane, Queensland, 4029, Australia|Frankston Hospital-Oncology and Haematology ( Site 2704), Frankston, Victoria, 3199, Australia|Kepler UniversitÃ¤tsklinikum-Department for Oncology and Hematology ( Site 1206), Linz, Oberosterreich, 4020, Austria|Klinikum Wels-Grieskirchen GmbH ( Site 1205), Wels, Oberosterreich, 4600, Austria|Medizinische Universitaet Innsbruck ( Site 1200), Innsbruck, Tirol, 6020, Austria|Uniklinikum Salzburg-UniversitÃ¤tsklinik fÃ¼r Innere Medizin III der PMU mit HÃ¤matologie, internistis ( Site 1202), Salzburg, 5020, Austria|Medizinische UniversitÃ¤t Wien-UniversitÃ¤tsklinik fÃ¼r Innere Medizin I, Klinische Abteilung fÃ¼r Onko ( Site 1201), Wien, 1090, Austria|Cliniques universitaires Saint-Luc-Medical Oncology ( Site 0901), Brussels, Bruxelles-Capitale, Region De, 1200, Belgium|AZ Maria Middelares-IKG ( Site 0903), Gent, Oost-Vlaanderen, 9000, Belgium|UniversitÃ© Catholique de Louvain-Namur - Centre Hospitalier -Oncology ( Site 0902), Namur, 5530, Belgium|PRONUTRIR-CLINICAL RESEARCH ( Site 0609), Fortaleza, Ceara, 60810-180, Brazil|OncoclÃ­nica Oncologistas Associados-Clinical Research ( Site 0607), Teresina, Piaui, 64049-200, Brazil|Hospital do CÃ¢ncer MÃ£e de Deus ( Site 0604), Porto Alegre, Rio Grande Do Sul, 90110-270, Brazil|Instituto de Oncologia Saint Gallen ( Site 0614), Santa Cruz do Sul, Rio Grande Do Sul, 96830-180, Brazil|Instituto do CÃ¢ncer Brasil - Unidade TaubatÃ© ( Site 0608), TaubatÃ©, Sao Paulo, 12030-200, Brazil|IBCC - NÃºcleo de Pesquisa e Ensino ( Site 0601), Sao Paulo, 04014002, Brazil|Cross Cancer Institute ( Site 0407), Edmonton, Alberta, T6G 1Z2, Canada|BC Cancer Vancouver ( Site 0404), Vancouver, British Columbia, V5Z 4E6, Canada|CancerCare Manitoba ( Site 0411), Winnipeg, Manitoba, R2H 2A6, Canada|The Moncton Hospital ( Site 0401), Moncton, New Brunswick, E1C 6Z8, Canada|QEII Health Sciences Centre - Victoria General Site ( Site 0418), Halifax, Nova Scotia, B3H 2Y9, Canada|Southlake Regional Health Centre ( Site 0413), Newmarket, Ontario, L3Y 2P9, Canada|The Ottawa Hospital - General Campus ( Site 0414), Ottawa, Ontario, K1H 8L6, Canada|North York General Hospital ( Site 0415), Toronto, Ontario, M2K 1E1, Canada|Princess Margaret Cancer Centre ( Site 0400), Toronto, Ontario, M5G 2M9, Canada|Centre IntÃ©grÃ© de SantÃ© et de Services Sociaux de la MontÃ©rÃ©gie-Centre ( Site 0417), Greenfield Park, Quebec, J4V 2H1, Canada|CIUSSS de l'Est-de-l'Ãle-de-MontrÃ©al ( Site 0419), Montreal, Quebec, H1T 2M4, Canada|Jewish General Hospital ( Site 0416), Montreal, Quebec, H3T 1E2, Canada|Centre Hospitalier de l'UniversitÃ© de MontrÃ©al ( Site 0403), MontrÃ©al, Quebec, H2X 3E4, Canada|Centre intÃ©grÃ© de santÃ© et de services sociaux du Bas Saint-Laurent- HÃ´pital rÃ©gional de Rimouski ( Site 0409), Rimouski, Quebec, G5L 5T1, Canada|Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-centre-du-quebec ( Site 0406), Trois-RiviÃ¨res, Quebec, G8Z 3R9, Canada|Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 1005), Brno, Brno-mesto, 656 53, Czechia|Nemocnice Ceske Budejovice-Onkologicke oddeleni ( Site 1007), Ceske Budejovice, Jihocesky Kraj, 37001, Czechia|Fakultni nemocnice Olomouc-Onkologicka klinika ( Site 1006), Olomouc, Olomoucky Kraj, 779 00, Czechia|Vseobecna fakultni nemocnice v Praze-OnkologickÃ¡ klinika VFN ( Site 1002), Praha, Praha 2, 128 08, Czechia|Fakultni nemocnice v Motole-Onkologicka klinika 2. LF UK a FN Motol ( Site 1000), Praha, Praha 5, 150 06, Czechia|Tampereen yliopistollinen sairaala ( Site 1102), Tampere, Pirkanmaa, 33520, Finland|Helsinki University Hospital - Comprehensive Cancer Center (HYKS - SyÃ¶pÃ¤keskus) ( Site 1100), Helsinki, Uusimaa, 00029, Finland|Turku University Hospital-Department of Oncology ( Site 1103), Turku, Varsinais-Suomi, 20520, Finland|Centre Antoine-Lacassagne ( Site 1308), Nice, Alpes-Maritimes, 06189, France|Centre Hospitalier de la CÃ´te Basque ( Site 1315), Bayonne, Aquitaine, 64109, France|Centre Jean Perrin - Centre RÃ©gional de Lutte contre le Cancer d'Auvergne ( Site 1307), Clermont-Ferrand, Auvergne, 63011, France|Institut Paoli-Calmettes ( Site 1309), Marseille, Bouches-du-Rhone, 13009, France|Centre FranÃ§ois Baclesse ( Site 1318), Caen, Calvados, 14076, France|Centre Georges FranÃ§ois Leclerc ( Site 1312), Dijon, Cote-d Or, 21079, France|CHU BesanÃ§on ( Site 1311), BesanÃ§on, Doubs, 25000, France|HÃ´pital PrivÃ© DrÃ´me-ArdÃ¨che ( Site 1301), Valence, Drome, 26000, France|CHRU Brest - Hopital Cavale Blanche ( Site 1304), Brest, Finistere, 29200, France|Clinique Tivoli Ducos ( Site 1322), Bordeaux, Gironde, 33000, France|HÃ´pital Franco-Britannique - Fondation Cognacq-Jay ( Site 1321), Levallois-Perret, Hauts-de-Seine, 92300, France|Institut de CancÃ©rologie de l'Ouest ( Site 1305), Saint Herblain, Loire-Atlantique, 44805, France|Institut de CancÃ©rologie de l'Ouest ( Site 1316), ANGERS cedex 02, Maine-et-Loire, 49055, France|Centre de Cancerologie Les Dentellieres ( Site 1306), Valenciennes, Nord, 59300, France|Centre Hospitalier de Pau ( Site 1302), Pau, Pyrenees-Atlantiques, 64046, France|CENTRE LEON BERARD ( Site 1300), Lyon Cedex08, Rhone-Alpes, 69373, France|Centre Henri Becquerel ( Site 1319), Rouen, Seine-Maritime, 76038, France|HÃ´pital Tenon ( Site 1303), Paris, 75020, France|Klinikum Ludwigsburg-Klinik fÃ¼r Geburtshilfe und Frauenheilkunde ( Site 1405), Ludwigsburg, Baden-Wurttemberg, 71640, Germany|Universitaetsklinikum Erlangen-Klinik fÃ¼r GynÃ¤kologie und Geburtshilfe ( Site 1400), Erlangen, Bayern, 91054, Germany|Klinikum der Ludwig-Maximilians-Universitaet Muenchen-Frauenklinik Brustzentrum ( Site 1402), Muenchen, Bayern, 80336, Germany|Klinikum Ernst von Bergmann-Frauenklinik ( Site 1408), Potsdam, Brandenburg, 14467, Germany|Universitaetsklinikum Duesseldorf-Klinik fÃ¼r Frauenheilkunde & Geburtshilfe ( Site 1409), DÃ¼sseldorf, Nordrhein-Westfalen, 40225, Germany|Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung-Klinik fÃ¼r Senologie/ Brustzentrum ( Site 1401), Essen, Nordrhein-Westfalen, 45136, Germany|Evangelisches Krankenhaus Bethesda MÃ¶nchengladbach-Brustzentrum Niederrhein ( Site 1406), MÃ¶nchengladbach, Nordrhein-Westfalen, 41061, Germany|UniversitÃ¤tsmedizin Johannes Gutenberg UniversitÃ¤t Mainz-Klinik und Poliklinik fÃ¼r Geburtshilfe und ( Site 1418), Mainz, Rheinland-Pfalz, 55131, Germany|CaritasKlinikum SaarbrÃ¼cken St. Theresia ( Site 1410), SaarbrÃ¼cken, Saarland, 66113, Germany|UniversitÃ¤tsklinikum Schleswig-Holstein ( Site 1411), LÃ¼beck, Schleswig-Holstein, 23538, Germany|Helios Klinikum Berlin-Buch-Klinik fÃ¼r GynÃ¤kologie und Geburtshilfe ( Site 1413), Berlin, 13125, Germany|UNIVERSITY HOSPITAL OF PATRAS-DIVISION OF ONCOLOGY ( Site 1509), Patras, Achaia, 26504, Greece|Errikos Dunant Hospital Center-1st Medical Oncology Dept. ( Site 1508), Athens, Attiki, 115 26, Greece|Aretaieio Hospital Oncology Unit ( Site 1505), Athens, Attiki, 115 28, Greece|Agios Loukas Clinic ( Site 1507), Thessaloniki, Kentriki Makedonia, 552 36, Greece|University General Hospital of Larissa ( Site 1503), Larissa, Thessalia, 411 10, Greece|Euromedica General Clinic of Thessaloniki-Oncology Unit ( Site 1502), Thessaloniki, 546 45, Greece|Queen Mary Hospital ( Site 3600), Hong Kong, Hong Kong|Hong Kong United Oncology Centre ( Site 3601), Kowloon, Hong Kong|Bon Secours Cork Hospital ( Site 1600), Cork, T12 DV56, Ireland|St. Vincent's University Hospital-Medical Oncology Research Department ( Site 1601), Dublin, D04 T6F4, Ireland|Soroka Medical Center-Oncology ( Site 1704), Beer Sheva, 8410101, Israel|Hadassah Medical Center ( Site 1700), Jerusalem, 9112001, Israel|Rabin Medical Center ( Site 1702), Petah Tikva, 4941492, Israel|Sheba Medical Center-ONCOLOGY ( Site 1701), Ramat Gan, 5265601, Israel|Sourasky Medical Center ( Site 1705), Tel Aviv, 6423906, Israel|University of Naples Federico II-Dipartimento di Medicina Clinica e Chirurgia ( Site 1803), Naples, Campania, 80100, Italy|Istituto Nazionale Tumori IRCCS Fondazione Pascale-S.C. Oncologia Clinica Sperimentale di Senologia ( Site 1800), Napoli, Campania, 80131, Italy|Humanitas Istituto Clinico Catanese ( Site 1811), Misterbianco, Catania, 95045, Italy|IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) ""Dino Amadori"" ( Site 1807), Meldola (FC), Forli-Cesena, 47014, Italy|CRO-IRCCS ( Site 1808), Aviano, Friuli-Venezia Giulia, 33081, Italy|Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Medical Oncology ( Site 1802), Roma, Lazio, 00168, Italy|Azienda Ospedaliera Spedali Civili di Brescia ( Site 1812), Brescia, Lombardia, 25123, Italy|Istituto Europeo di Oncologia IRCCS-Divisione di Senologia Medica ( Site 1809), Milano, Lombardia, 20141, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1801), Milan, Lombardia, 20133, Italy|Fondazione IRCCS San Gerardo dei Tintori ( Site 1813), Monza, Lombardia, 20900, Italy|Azienda Ospedaliera Universitaria Careggi ( Site 1805), Firenze, Toscana, 50134, Italy|IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 1810), Bologna, 40138, Italy|Ospedale San Raffaele-Oncologia Medica ( Site 1814), Milano, 20132, Italy|Azienda Ospedaliero Universitaria Maggiore della CaritÃ -SCDU ONCOLOGIA ( Site 1804), Novara, 28100, Italy|Nagoya City University Hospital ( Site 3414), Nagoya, Aichi, 467-8602, Japan|Hokkaido University Hospital ( Site 3400), Sapporo, Hokkaido, 060-8648, Japan|Tokai University Hospital ( Site 3413), Isehara, Kanagawa, 259-1193, Japan|St. Marianna University Hospital ( Site 3405), Kawasaki, Kanagawa, 216-8511, Japan|Kitasato University Hospital ( Site 3411), Sagamihara, Kanagawa, 252-0375, Japan|Kanagawa Cancer Center ( Site 3412), Yokohama, Kanagawa, 241-8515, Japan|Mie University Hospital ( Site 3423), Tsu, Mie, 514-8507, Japan|Tohoku University Hospital ( Site 3422), Sendai, Miyagi, 980-8574, Japan|The University of Osaka Hospital ( Site 3416), Suita, Osaka, 565-0871, Japan|Saitama Medical University International Medical Center ( Site 3402), Hidaka, Saitama, 350-1298, Japan|Juntendo University Hospital ( Site 3408), Bunkyo, Tokyo, 113-8431, Japan|Showa Medical University Hospital ( Site 3406), Shinagawa, Tokyo, 142-8666, Japan|Tokyo Medical University Hospital ( Site 3407), Shinjuku, Tokyo, 160-0023, Japan|National Center for Global Health and Medicine ( Site 3409), Shinjuku, Tokyo, 162-8655, Japan|Fukushima Medical University Hospital ( Site 3401), Fukushima, 960-1295, Japan|Gifu University Hospital ( Site 3426), Gifu, 501-1194, Japan|Hiroshima City Hiroshima Citizens Hospital ( Site 3418), Hiroshima, 730-8518, Japan|Social medical corporation Hakuaikai Sagara Hospital ( Site 3421), Kagoshima, 892-0833, Japan|Kumamoto University Hospital ( Site 3420), Kumamoto, 860-8556, Japan|Kyoto University Hospital ( Site 3415), Kyoto, 606-8507, Japan|Okayama University Hospital ( Site 3425), Okayama, 700-8558, Japan|Osaka International Cancer Institute ( Site 3417), Osaka, 541-8567, Japan|Seoul National University Hospital-Internal Medicine ( Site 3102), Seoul, 03080, Korea, Republic of|Severance Hospital, Yonsei University Health System-Medical oncology ( Site 3100), Seoul, 03722, Korea, Republic of|Asan Medical Center-Department of Oncology ( Site 3103), Seoul, 05505, Korea, Republic of|Gangnam Severance Hospital, Yonsei University Health System-Medical Oncology, Internal Medicine ( Site 3104), Seoul, 06273, Korea, Republic of|Samsung Medical Center-Division of Hematology/Oncology ( Site 3101), Seoul, 06351, Korea, Republic of|Prince Court Medical Centre ( Site 2802), Kuala Lumpur, 50450, Malaysia|Pantai Hospital Kuala Lumpur ( Site 2801), Kuala Lumpur, 59100, Malaysia|CENEIT Oncologicos ( Site 0706), Ciudad de MÃ©xico, Distrito Federal, 03100, Mexico|Health Pharma Professional Research S.A. de C.V: ( Site 0709), Ciudad de MÃ©xico, Distrito Federal, 03100, Mexico|COI Centro Oncologico Internacional S.A.P.I. de C.V. ( Site 0712), Mexico City, Distrito Federal, 04700, Mexico|CENTRO MEDICO ZAMBRANO HELLION ( Site 0711), San Pedro Garza Garcia, Nuevo Leon, 66278, Mexico|Drammen Sykehus, Vestre Viken HF ( Site 2001), Drammen, Buskerud, 3004, Norway|Stavanger Universitetssykehus ( Site 2004), Stavanger, Rogaland, 4011, Norway|Oslo universitetssykehus, Radiumhospitalet ( Site 2002), Oslo, 0379, Norway|Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 2102), Bydgoszcz, Kujawsko-pomorskie, 85-796, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika NowotworÃ³w Piersi i Chirurgii ( Site 2100), Warszawa, Mazowieckie, 02-781, Poland|Mazowiecki Szpital Onkologiczny-BREAST CANCER ( Site 2101), Wieliszew, Mazowieckie, 05-135, Poland|Bialostockie Centrum Onkologii ( Site 2105), Bialystok, Podlaskie, 15-027, Poland|Szpitale Pomorskie Sp. z o. o.-OddziaÅ Onkologii Klinicznej ( Site 2113), Gdynia, Pomorskie, 81-519, Poland|Narodowy Instytut Onkologii - Oddzial w Gliwicach-Centrum Diagnostyki i Leczenia Chorob Piersi ( Site 2110), Gliwice, Slaskie, 44-102, Poland|Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zakl-Klinika Onkologii Klinicznej, Dzial Ch ( Site 2118), Kielce, Swietokrzyskie, 25-734, Poland|Zachodniopomorskie Centrum Onkologii ( Site 2108), Szczecin, Zachodniopomorskie, 71-730, Poland|Unidade Local de Saude Amadora/Sintra - Hospital Prof Dr Fernando Fonseca ( Site 2203), Amadora, Lisboa, 2720-276, Portugal|Unidade Local de Saude de Santa Maria - Hospital de Santa Maria ( Site 2201), Lisboa, 1649-035, Portugal|Instituto Portugues de Oncologia do Porto ( Site 2202), Porto, 4200-072, Portugal|National Cancer Centre Singapore-Medical Oncology ( Site 3002), Singapore, Central Singapore, 168583, Singapore|HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO-Medical Oncology ( Site 2304), Sevilla, Andalucia, 41013, Spain|Institut CatalÃ  d'Oncologia - L'Hospitalet-Medical Oncology ( Site 2305), L Hospitalet De Llobregat, Barcelona, 08908, Spain|CHUAC-Hospital Teresa Herrera-MEDICAL ONCOLOGY ( Site 2307), A CoruÃ±a, La Coruna, 15006, Spain|Hospital Universitario RamÃ³n y Cajal-Medical Oncology ( Site 2301), Madrid, Madrid, Comunidad De, 28034, Spain|HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA-Medical Oncology ( Site 2308), Majadahonda, Madrid, Comunidad De, 28222, Spain|FundaciÃ³n Instituto Valenciano de OncologÃ­a-Oncologico ( Site 2303), Valencia, Valenciana, Comunitat, 46009, Spain|Hospital Universitari Vall d'Hebron-Oncology ( Site 2300), Barcelona, 08035, Spain|Hospital Beata MarÃ­a Ana-oncology ( Site 2309), Madrid, 28007, Spain|Hospital Clinico San Carlos-Oncology Department ( Site 2306), Madrid, 28040, Spain|HOSPITAL CLINICO DE VALENCIA-Oncology ( Site 2302), Valencia, 46010, Spain|Spital Thun ( Site 2400), Thun, Berne, 3600, Switzerland|Clinique GÃ©nÃ©rale-Beaulieu ( Site 2406), Geneva, Geneve, 1206, Switzerland|Kantonsspital GraubÃ¼nden-Medizin ( Site 2404), Chur, Grisons, 7000, Switzerland|Brust-Zentrum ( Site 2401), ZÃ¼rich, Zurich, 8008, Switzerland|HFR Fribourg - HÃ´pital Cantonal ( Site 2402), Fribourg, 1708, Switzerland|Adana Medical Park Seyhan Hastanesi-Medikal Onkoloji ( Site 2501), Adana, 01140, Turkey|Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve ArastÄ±rma Hastanesi-oncology ( Site 2504), Ankara, 06200, Turkey|Memorial Ankara Hastanesi-Medical Oncology ( Site 2502), Ankara, 06520, Turkey|Medipol Mega Universite Hastanesi-oncology ( Site 2503), Istanbul, 34214, Turkey|Samsun Medical Park Hastanesi-medical oncology ( Site 2500), Samsun, 55200, Turkey|University Hospitals Bristol NHS Foundation Trust ( Site 2601), Bristol, Bristol, City Of, BS2 8ED, United Kingdom|The Royal Cornwall Hospital ( Site 2603), Truro, England, TR1 3LJ, United Kingdom|St Bartholomew's Hospital-Centre for Experimental Cancer Medicine ( Site 2602), London, London, City Of, EC1A 7BE, United Kingdom|University College London Hospital ( Site 2604), London, London, City Of, NW1 2PG, United Kingdom|Western General Hospital ( Site 2607), Edinburgh, Midlothian, EH4 2XU, United Kingdom|St James's University Hospital-Leeds Cancer Centre ( Site 2608), Leeds, LS9 7TF, United Kingdom",
NCT06952504,A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29),https://clinicaltrials.gov/study/NCT06952504,TroFuse-033,RECRUITING,"Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advanced or recurrent.

* EC is a type of cancer that starts in the tissues inside the uterus (womb)
* pMMR indicates that certain normal proteins are present in the cancer cells
* Advanced means the cancer has spread locally or to other parts of the body (metastatic) and cannot be removed with surgery
* Recurrent means the cancer came back after surgery

Sacituzumab tirumotecan (also known as sac-TMT) and pembrolizumab are the study medicines. Sac-TMT is an antibody drug conjugate (ADC). An ADC attaches to specific targets on cancer cells and delivers treatment to destroy those cells.

The goal of this study is to learn if people who receive sac-TMT with pembrolizumab live longer and without the cancer getting worse compared to people who receive pembrolizumab alone.",NO,Endometrial Cancer,BIOLOGICAL: Pembrolizumab|DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Docetaxel|BIOLOGICAL: Sacituzumab Tirumotecan,"Maintenance Treatment: Progression-Free Survival (PFS), PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as evaluated by the blinded independent central review (BICR). PD is defined as â¥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of â¥5 mm. The appearance of one or more new lesions is also considered PD., Up to approximately 44 months|Maintenance Treatment: Overall Survival (OS), OS is defined as time from randomization to death due to any cause., Up to approximately 54 months","Maintenance Treatment: Progression-Free Survival 2 (PFS2) as Assessed by Investigator, PFS2 is defined as the time from randomization to the documented subsequent objective disease progression after initiation of new anticancer therapy or death due to any cause, whichever occurs first. PFS2 as assessed by the investigator will be presented., Up to approximately 54 months|Maintenance Treatment: Number of Participants Who Experience One or More Adverse Events (AEs), An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention., Up to approximately 27 months|Maintenance Treatment: Number of Participants Who Discontinue Study Intervention Due to an AE, An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention., Up to approximately 24 months|Maintenance Treatment: Change from baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Item Mean Score, EORTC QLQ-C30 is a 30-item scale to assess the overall quality of life of cancer patients. Participant responses to the questions ""How would you rate your overall health during the past week?"" and ""How would you rate your overall quality of life during the past week?"" are scored on a 7- point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status. The change from baseline in EORTC QLQ-C30 Items 29 and 30 mean score will be presented., Baseline and up to approximately 24 months|Maintenance Treatment: Change from baseline in EORTC QLQ-C30 Physical Functioning (Items 1-5) Combined Score, EORTC QLQ-C30 is a 30-item scale to assess the overall quality of life of cancer patients. The physical functioning score is based on participant responses to questions scored on a 4-point scale (1 = 'Not at All' to 4 = 'Very Much'). Higher scores indicate better physical functioning. The change from baseline in EORTC QLQ-C30 Physical Functioning (Items 1-5) combined score will be presented., Baseline and up to approximately 24 months|Maintenance Treatment: Change from baseline in EORTC QLQ-C30 Role Functioning (Items 6 and 7) Combined Score, EORTC QLQ-C30 is a 30-item scale to assess the overall quality of life of cancer patients. The role functioning score is based on participant responses to questions scored on a 4-point scale (1 = 'Not at All' to 4 = 'Very Much'). Higher scores indicate better role functioning. The change from baseline in EORTC QLQ-C30 Role Functioning (Items 6 and 7) combined score will be presented., Baseline and up to approximately 24 months|Maintenance Treatment: Change from baseline in EORTC QLQ Endometrial Cancer Symptom Score (QLQ-EN24), The EORTC-QLQ-EN24 is a 24-item questionnaire developed to be used in conjunction with the EORTC-QLQ-C30 to assess the quality of life of endometrial cancer patients. Participant responses are scored on a 4-point scale (1=not at all to 4=very much). A higher score indicates a better quality of life. The change from baseline in EORTC QLQ-E24 back and pelvis pain score will be presented., Baseline and up to approximately 24 months",,Merck Sharp & Dohme LLC,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,1123,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2025-05-22,2032-05-24,2032-05-24,2025-05-01,,2025-06-13,"Mount Sinai Cancer Center ( Site 6031), Miami Beach, Florida, 33140, United States|TRIALS 365 ( Site 6005), Shreveport, Louisiana, 71103, United States|Rambam Health Care Campus ( Site 2025), Haifa, 3109601, Israel|Carmel Hospital ( Site 2023), Haifa, 3436212, Israel|Shaare Zedek Medical Center ( Site 2020), Jerusalem, 9103102, Israel|Sourasky Medical Center ( Site 2022), Tel Aviv, 6423906, Israel|Puerto Rico Cancer Specialists Clinical Trials ( Site 4201), San Juan, 00917, Puerto Rico|Linkou Chang Gung Memorial Hospital ( Site 3705), Taoyuan, 333, Taiwan",
NCT06459180,A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20),https://clinicaltrials.gov/study/NCT06459180,,RECRUITING,"This study will have two phases: a sacituzumab tirumotecan safety run-in and a Phase 3 portion. The safety run-in phase will be used to evaluate the efficacy and safety of sacituzumab tirumotecan at the dose for evaluation in the Phase 3 portion. The purpose of this study is to compare the efficacy and safety of sacituzumab tirumotecan versus treatment of physician's choice as second-line treatment for participants with recurrent or metastatic cervical cancer in the Phase 3 portion.

The primary study hypotheses are that, in the Phase 3 portion, sacituzumab tirumotecan results in a superior overall survival compared to TPC in participants with high trophoblast cell surface antigen 2 (TROP2) expression level and in all participants.",NO,Cervical Cancer,BIOLOGICAL: Sacituzumab Tirumotecan|DRUG: Pemetrexed|BIOLOGICAL: Tisotumab Vedotin|DRUG: Topotecan|DRUG: Vinorelbine|DRUG: Gemcitabine|DRUG: Irinotecan,"Objective Response Rate (ORR) in Sacituzumab Tirumotecan Run-in, ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented., Up to approximately 51 months|Number of Participants Experiencing One or More Adverse Events (AEs) in Sacituzumab Tirumotecan Run-in, An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention., Up to approximately 51 months|Number of Participants Discontinuing Study Treatment Due to an AE in Sacituzumab Tirumotecan Run-in, An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention., Up to approximately 51 months|Overall Survival (OS) in Phase 3 Portion, OS is defined as the time from randomization to death due to any cause., Up to approximately 43 months","Progression-free Survival (PFS) in Phase 3 Portion, PFS is defined as the time from randomization to the first documented progressive disease (PD) or death from any cause, whichever occurs first. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented., Up to approximately 43 months|ORR in Phase 3 Portion, ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by BICR in the Phase 3 portion will be presented., Up to approximately 43 months|Duration of Response (DOR) in Phase 3 Portion, For participants who demonstrate CR (CR: disappearance of all target lesions) or PR (PR: at least a 30% decrease in the sum of diameters of target lesions), DOR is defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR will be presented as assessed by BICR and analyzed by the Kaplan-Meier method for censored data., Up to approximately 43 months|Number of Participants Experiencing One or More AEs in Phase 3 Portion, An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention., Up to approximately 51 months|Number of Participants Discontinuing Study Treatment Due to an AE in Phase 3 Portion, An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention., Up to approximately 51 months|Time to First Deterioration (TTD) in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score in Phase 3 Portion, The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients. Participant responses to Items 29 and 30 (""How would you rate your overall health during the past week?"" and ""How would you rate your overall quality of life during the past week?"") are scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher value indicates a better level of function. TTD in Global Health Status (GHS)/Quality of Life (QoL) is defined as the time from baseline to the first onset of a â¥10-point decrease from baseline in combined GHS/QoL score. The TTD in GHS/QoL (Items 29 and 30) combined score will be reported., Baseline and up to approximately 51 months|Change from Baseline in EORTC QLQ-C30 Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score in Phase 3 Portion, The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients. Participant responses to Items 29 and 30 (""How would you rate your overall health during the past week?"" and ""How would you rate your overall quality of life during the past week?"") are scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher value indicates a better level of function. The change from baseline in EORTC QLQ-C30 Items 29 and 30 combined score will be reported., Baseline and up to approximately 51 months|Change from Baseline in EORTC QLQ-C30 Physical Functioning Score in Phase 3 Portion, The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better level of physical functioning., Baseline and up to approximately 51 months|Change from Baseline in EORTC QLQ-C30 Role Functioning Score in Phase 3 Portion, The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions ""Were you limited in doing either your work or other daily activities during the past week?"" and "" Were you limited in pursuing your hobbies or other leisure time activities during the past week?"" will be scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. Higher scores indicate a more impaired level of role functioning. Change from baseline in the role functioning score will be presented., Baseline and up to approximately 51 months",,Merck Sharp & Dohme LLC,European Network of Gynaecological Oncological Trial Groups (ENGOT)|GOG Foundation,FEMALE,"ADULT, OLDER_ADULT",PHASE3,686,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-07-24,2028-10-23,2028-10-23,2024-06-14,,2025-06-13,"USA Mitchell Cancer Institute-Clinical Trials ( Site 4126), Mobile, Alabama, 36604, United States|Providence Alaska Medical Center ( Site 4137), Anchorage, Alaska, 99508, United States|HonorHealth (HH) ( Site 8002), Phoenix, Arizona, 85016, United States|Arizona Oncology Associates - HOPE ( Site 8001), Tucson, Arizona, 85711, United States|Moores Cancer Center-Clinical Trials Office - Gynecological Oncology ( Site 4125), La Jolla, California, 92093, United States|UCLA Hematology/Oncology - Westwood (Building 100)-Department of OBGYN, Division of Gynecologic Onc ( Site 4105), Los Angeles, California, 90095, United States|Hoag Memorial Hospital Presbyterian ( Site 4104), Newport Beach, California, 92663, United States|Mount Sinai Comprehensive Cancer Center ( Site 4143), Miami Beach, Florida, 33140, United States|Advent Health ( Site 4140), Orlando, Florida, 32804, United States|Florida Cancer Specialists East ( Site 7001), West Palm Beach, Florida, 33401, United States|Northside Hospital ( Site 4127), Atlanta, Georgia, 30342, United States|Georgia Cancer Center at Augusta University ( Site 4112), Augusta, Georgia, 30912, United States|Lewis Cancer and Research Pavilion ( Site 4114), Savannah, Georgia, 31405, United States|University Medical Center New Orleans ( Site 4132), New Orleans, Louisiana, 70112, United States|Willis Knighton Medical Center ( Site 4101), Shreveport, Louisiana, 71103, United States|The Center of Hope ( Site 4106), Reno, Nevada, 89511, United States|Holy Name Medical Center ( Site 4117), Teaneck, New Jersey, 07666, United States|Optimum Clinical Research Group ( Site 4138), Albuquerque, New Mexico, 87109, United States|Duke Cancer Institute ( Site 4120), Durham, North Carolina, 27710, United States|University of Cincinnati Medical Center ( Site 4128), Cincinnati, Ohio, 45219, United States|The Ohio State University ( Site 4103), Hilliard, Ohio, 43026, United States|Oklahoma Cancer Specialists and Research Institute, LLC-Clinical Research ( Site 4116), Tulsa, Oklahoma, 74146, United States|Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8007), Eugene, Oregon, 97401, United States|Legacy Good Samaritan Medical Center-Oncology Clinical Research ( Site 4115), Portland, Oregon, 97210, United States|Sidney Kimmel Cancer Center - Jefferson Health ( Site 4142), Philadelphia, Pennsylvania, 19107, United States|Asplundh Cancer Pavilion ( Site 4113), Willow Grove, Pennsylvania, 19090, United States|Texas Oncology - DFW ( Site 8003), Fort Worth, Texas, 76104, United States|Houston Methodist Hospital OB/GYN ( Site 4102), Houston, Texas, 77030, United States|Texas Oncology - San Antonio ( Site 8006), San Antonio, Texas, 78240, United States|University of Virginia Cancer Center ( Site 4123), Charlottesville, Virginia, 22908, United States|Inova Schar Cancer Institute ( Site 4139), Fairfax, Virginia, 22031-4867, United States|Swedish Medical Center-Swedish Cancer Institute ( Site 4134), Seattle, Washington, 98104, United States|Hospital BritÃ¡nico de Buenos Aires-Oncology ( Site 0102), Ciudad autÃ³noma de Buenos Aires, Buenos Aires, C1280AEB, Argentina|Instituto de Investigaciones ClÃ­nicas Mar del Plata ( Site 0107), Mar del Plata, Buenos Aires, B7600FZO, Argentina|Instituto de OncologÃ­a Angel H. Roffo ( Site 0103), Buenos Aires, Caba, C1417, Argentina|Sanatorio Allende - Cerro-Oncology ( Site 0106), CÃ³rdoba, Cordoba, 5000, Argentina|Hospital Aleman-Oncology ( Site 0100), Buenos Aires, C1118AAT, Argentina|Instituto Alexander Fleming ( Site 0108), Caba, C1426ANZ, Argentina|Centro de EducaciÃ³n MÃ©dica e Investigaciones ClÃ­nicas (CEMIC) ( Site 0109), Caba, C1431FWO, Argentina|FundaciÃ³n CORI para la InvestigaciÃ³n y PrevenciÃ³n del CÃ¡ncer ( Site 0104), La Rioja, F5300COE, Argentina|Blacktown Hospital ( Site 3006), Sydney, New South Wales, 2148, Australia|Campbelltown Hospital-Macarthur Cancer Therapy Centre Medical Oncology ( Site 3000), Sydney, New South Wales, 2560, Australia|Royal Brisbane and Women's Hospital ( Site 3001), Herston, Queensland, 4029, Australia|Monash Health-Oncology Research ( Site 3002), Clayton, Victoria, 3168, Australia|Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 3005), Melbourne, Victoria, 3000, Australia|Sir Charles Gairdner Hospital ( Site 3003), Nedlands, Western Australia, 6009, Australia|Kepler UniversitÃ¤tsklinikum-Department for Oncology and Hematology ( Site 1002), Linz, Oberosterreich, 4020, Austria|Medizinische UniversitÃ¤t Graz-Abteilung fÃ¼r GynÃ¤kologie / Onkologie ( Site 1003), Graz, Steiermark, 8036, Austria|Medizinische Universitaet Innsbruck-Univ.-Klinik f. GynÃ¤kologie und Geburtshilfe ( Site 1000), Innsbruck, Tirol, 6020, Austria|Medizinische UniversitÃ¤t Wien ( Site 1001), Wien, 1090, Austria|AZORG Campus Aalst-Moorselbaan ( Site 2905), Aalst, Oost-Vlaanderen, 9300, Belgium|UZ Gent-Medical oncology ( Site 2901), Gent, Oost-Vlaanderen, 9000, Belgium|UZ Leuven-Gynecologic Oncology ( Site 2900), Leuven, Vlaams-Brabant, 3000, Belgium|Centre Hospitalier Universitaire de LiÃ¨ge - Domaine Universitaire du Sart Tilman-Medical Oncology ( Site 2904), Belgium, Wallonne, Region, 4000, Belgium|CHU UCL Namur/Site Sainte Elisabeth-Trial Office ( Site 2902), Namur, 5000, Belgium|Instituto do CÃ¢ncer e Transplante de Curitiba ( Site 0205), Curitiba, Parana, 80510130, Brazil|Hospital Moinhos de Vento-Centro de Pesquisa ClÃ­nica ( Site 0204), Porto Alegre, Rio Grande Do Sul, 90035-001, Brazil|Hospital do CÃ¢ncer MÃ£e de Deus ( Site 0201), Porto Alegre, Rio Grande Do Sul, 90110-270, Brazil|Centro de Hematologia e Oncologia ( Site 0203), Joinville, Santa Catarina, 89202-050, Brazil|IBCC - Instituto Brasileiro de Controle do CÃ¢ncer-Centro de Pesquisa ClÃ­nica ( Site 0200), SÃ£o Paulo, Sao Paulo, 04014-002, Brazil|Americas Centro de Oncologia Integrado ( Site 0202), Rio de Janeiro, 22775-001, Brazil|Hospital Paulistano ( Site 0209), Sao Paulo, 01321-001, Brazil|MBAL Uni Hospital-Department of Medical Oncology ( Site 1104), Panagyurishte, Pazardzhik, 4500, Bulgaria|MHAT - Heart and Brain ( Site 1100), Pleven, 5804, Bulgaria|Complex Oncology Center - Plovdiv EOOD ( Site 1102), Plovdiv, 4004, Bulgaria|BC Cancer Kelowna ( Site 4007), Kelowna, British Columbia, V1Y 5L3, Canada|BC Cancer Surrey ( Site 4006), Surrey, British Columbia, V3V 1Z2, Canada|BC Cancer Victoria ( Site 4008), Victoria, British Columbia, V8R 6V5, Canada|McGill University Health Centre ( Site 4000), Montreal, Quebec, H4A 3J1, Canada|Centre Hospitalier de l'UniversitÃ© de MontrÃ©al ( Site 4001), MontrÃ©al, Quebec, H2X 0C1, Canada|Centre intÃ©grÃ© de cancÃ©rologie du CHU de QuÃ©bec UniversitÃ© Laval, HÃ´pital de l'Enfant-JÃ©sus ( Site 4002), Quebec City, Quebec, G1J 1Z4, Canada|FALP-UIDO ( Site 0300), Santiago, Region M. De Santiago, 7500921, Chile|Pontificia Universidad Catolica de Chile-Centro del CÃ¡ncer ( Site 0302), Santiago, Region M. De Santiago, 8330024, Chile|ONCOCENTRO APYS-ACEREY ( Site 0303), ViÃ±a del Mar, Valparaiso, 2520598, Chile|Anhui Provincial Cancer Hospital-Gynecological Oncology ( Site 5040), Hefei, Anhui, 230000, China|Anhui Provincial Hospital ( Site 5011), Hefei, Anhui, 230071, China|Beijing Peking Union Medical College Hospital ( Site 5045), Beijing, Beijing, 100730, China|Chongqing University Cancer Hospital ( Site 5003), Chongqing, Chongqing, 400030, China|Fujian Provincial Cancer Hospial ( Site 5012), Fuzhou, Fujian, 350014, China|The First Affiliated hospital of Xiamen University-Obstetrics and gynecology department ( Site 5027), Xiamen, Fujian, 361003, China|Sun Yat-sen Memorial Hospital, Sun Yat-sen University ( Site 5001), Guangzhou, Guangdong, 510000, China|Sun Yat-sen University Cancer Center-Internal medicine ( Site 5006), Guangzhou, Guangdong, 511400, China|Affiliated Hospital of Guangdong Medical University ( Site 5004), Zhanjiang, Guangdong, 524004, China|Guangxi Medical University Affiliated Tumor Hospital ( Site 5016), Nanning, Guangxi, 530200, China|Hainan General Hospital ( Site 5032), Haikou, Hainan, 570311, China|The First Affiliated Hospital of Xinxiang Medical University-Oncology ( Site 5041), Xinxiang, Henan, 453100, China|Henan Cancer Hospital ( Site 5026), Zhengzhou, Henan, 450008, China|Wuhan Union Hospital ( Site 5020), Wuhan, Hubei, 430048, China|Hubei Cancer Hospital-Hubei Cancer Hospital ( Site 5019), Wuhan, Hubei, 430079, China|Hunan Cancer Hospital ( Site 5021), Changsha, Hunan, 410013, China|Xiangya Hospital Central South University ( Site 5009), Changsha, Hunan, 410028, China|Jiangsu Province Hospital-Oncology Department ( Site 5018), Nanjing, Jiangsu, 210036, China|Jiangxi Maternal and Child Health Hospital ( Site 5031), Nanchang, Jiangxi, 330077, China|Jilin Province Tumor Hospital ( Site 5036), Changchun, Jilin, 130000, China|The First Affiliated Hospital of Xi'an Jiaotong University ( Site 5007), Xi'an, Shaanxi, 710061, China|Shandong Cancer Hospital ( Site 5014), Jinan, Shandong, 250117, China|LinYi Cancer Hospital-Gastrology department ( Site 5039), Linyi, Shandong, 276000, China|Obstetrics & Gynecology Hospital of Fudan University ( Site 5015), Shanghai, Shanghai, 200011, China|Shanxi Cancer Hospital ( Site 5043), Taiyuan, Shanxi, 030000, China|West China Second University Hospital, Sichuan University ( Site 5017), Chengdu, Sichuan, 610000, China|Sichuan Cancer hospital-Oncology ( Site 5030), Chengdu, Sichuan, 610042, China|Yunnan Province Cancer Hospital-Gynecology Department ( Site 5005), Kunming, Yunnan, 650107, China|Women s Hospital School of Medicine Zhejiang University ( Site 5022), Hangzhou, Zhejiang, 310006, China|Zhejiang Cancer Hospital ( Site 5008), Hangzhou, Zhejiang, 310022, China|The First Affiliated Hospital of Wenzhou Medical University ( Site 5033), Wenzhou, Zhejiang, 325015, China|Sociedad De OncologÃ­a y HematologÃ­a Del Cesar SAS-Oncology ( Site 0401), Valledupar, Cesar, 200001, Colombia|IMAT S.A.S ( Site 0402), MonterÃ­a, Cordoba, 230002, Colombia|FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 0403), Bogota., Distrito Capital De Bogota, 110131, Colombia|Oncologos del Occidente ( Site 0405), Pereira., Risaralda, 660001, Colombia|FundaciÃ³n Valle del Lili ( Site 0406), Cali, Valle Del Cauca, 760032, Colombia|Rigshospitalet-Dept. of Oncology ( Site 1300), Kobenhavn, Hovedstaden, 2100, Denmark|Aarhus Universitetshospital, Skejby ( Site 1301), Aarhus, Midtjylland, 8200, Denmark|Odense Universitetshospital-Department of oncology ( Site 1302), Odense C, Syddanmark, 5000, Denmark|Tampereen yliopistollinen sairaala-Gynecology and Obstetrics ( Site 1404), Tampere, Pirkanmaa, 33520, Finland|Helsinki University Hospital - Comprehensive Cancer Center (HYKS - SyÃ¶pÃ¤keskus) ( Site 1400), Helsinki, Uusimaa, 00029, Finland|Turku University Hospital-Department of Obstetrics and Gynecology ( Site 1401), Turku, Varsinais-Suomi, 20520, Finland|Institut de cancÃ©rologie Strasbourg Europe (ICANS) ( Site 1501), Strasbourg, Alsace, 67200, France|Institut BergoniÃ© - Centre RÃ©gional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest ( Site 1503), Bordeaux, Aquitaine, 33076, France|Centre Jean Perrin - Centre RÃ©gional de Lutte contre le Cancer d'Auvergne ( Site 1508), Clermont-Ferrand, Auvergne, 63011, France|Institut Paoli-Calmettes ( Site 1504), Marseille, Bouches-du-Rhone, 13009, France|HÃ´pital PrivÃ© Des CÃ´tes d'Armor ( Site 1510), PlÃ©rin, Cotes-d Armor, 22190, France|CHU BesanÃ§on ( Site 1507), Besancon, Franche-Comte, 25030, France|Oncopole Claudius Regaud ( Site 1502), Toulouse, Haute-Garonne, 31059, France|Institut Regional du Cancer Montpellier ( Site 1511), Montpellier, Herault, 34298, France|Gustave Roussy ( Site 1512), Villejuif, Ile-de-France, 94805, France|HÃ´pital privÃ© du Confluent SAS ( Site 1509), Nantes, Loire-Atlantique, 44277, France|CENTRE LEON BERARD ( Site 1505), Lyon Cedex08, Rhone-Alpes, 69373, France|Groupe Hospitalier Diaconesses Croix Saint Simon ( Site 1506), Paris, 75020, France|Aretaieio Hospital ( Site 1700), Athens, Attiki, 115 28, Greece|Mitera Hospital ( Site 1702), Athens, Attiki, 151 23, Greece|ATTIKON GENERAL UNIVERSITY HOSPITAL ( Site 1703), Chaidari, Attiki, 124 62, Greece|Agios Andreas Hospital Patras ( Site 1701), Patras, Peloponnisos, 263 35, Greece|Cork University Hospital ( Site 1900), Cork, T12 E8YV, Ireland|Mater Misericordiae University Hospital ( Site 1901), Dublin, D07 R2WY, Ireland|St. James's Hospital-Cancer clinical trials office ( Site 1902), Dublin, D08 E9P6, Ireland|Rambam Health Care Campus ( Site 2002), Haifa, 3109601, Israel|Edith Wolfson Medical Center ( Site 2003), Holon, 5810001, Israel|Hadassah Medical Center ( Site 2000), Jerusalem, 9112001, Israel|Sheba Medical Center ( Site 2001), Ramat Gan, 5265601, Israel|IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlin-DEPARTMENT OF EXPERIMENTAL, DIAGNOSTIC ( Site 2105), Bologna, Emilia-Romagna, 40138, Italy|Istituto Europeo di Oncologia IRCCS ( Site 2108), Milano, Lombardia, 20141, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Chirurgia Ginecologica ( Site 2107), Milan, Lombardia, 20133, Italy|Ospedale Humanitas San Pio X ( Site 2113), Milan, Lombardia, 20159, Italy|Fondazione IRCCS San Gerardo dei Tintori-Oncologia ( Site 2111), Monza, Lombardia, 20900, Italy|Humanitas University ( Site 2112), Rozzano, Milano, 20089, Italy|Ospedale Mauriziano-SCDU ONCOLOGIA MEDICA ( Site 2100), Torino, Piemonte, 10128, Italy|Azienda Ospedaliera Spedali Civili di Brescia-Obstetrics anf gynecology ( Site 2110), Brescia, 25123, Italy|Ospedale Cannizzaro ( Site 2104), Catania, 95126, Italy|Ospedale San Raffaele. ( Site 2106), Milano, 20132, Italy|Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 2103), Napoli, 80131, Italy|Istituto Oncologico Veneto IRCCS ( Site 2109), Padova, 35128, Italy|Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Ginecologia Oncologica ( Site 2102), Roma, 00168, Italy|Aichi Cancer Center ( Site 5110), Nagoya, Aichi, 464-8681, Japan|National Hospital Organization Shikoku Cancer Center ( Site 5109), Matsuyama, Ehime, 791-0280, Japan|Ehime University Hospital ( Site 5102), Toon, Ehime, 791-0295, Japan|Kurume University Hospital ( Site 5105), Kurume, Fukuoka, 830-0011, Japan|Gunma Prefectural Cancer Center ( Site 5116), Ohta, Gunma, 373-8550, Japan|Hokkaido University Hospital ( Site 5106), Sapporo, Hokkaido, 060-8648, Japan|University of Tsukuba Hospital ( Site 5114), Tsukuba, Ibaraki, 305-8576, Japan|Iwate Medical University Hospital ( Site 5112), Shiwa-gun, Iwate, 028-3695, Japan|Saitama Medical University International Medical Center ( Site 5117), Hidaka, Saitama, 350-1298, Japan|Shizuoka Cancer Center ( Site 5107), Sunto-gun,, Shizuoka, 411-8777, Japan|National Cancer Center Hospital ( Site 5108), Chuo, Tokyo, 104-0045, Japan|Cancer Institute Hospital of JFCR ( Site 5111), Koto, Tokyo, 135-8550, Japan|Keio University Hospital ( Site 5101), Shinjyuku, Tokyo, 160-8582, Japan|National Hospital Organization Kyushu Cancer Center ( Site 5104), Fukuoka, 811-1395, Japan|Kagoshima City Hospital ( Site 5115), Kagoshima, 890-8760, Japan|Niigata Cancer Center Hospital ( Site 5100), Niigata, 951-8566, Japan|Osaka International Cancer Institute ( Site 5103), Osaka, 541-8567, Japan|Seoul National University Hospital ( Site 3403), Seoul, 03080, Korea, Republic of|Severance Hospital, Yonsei University Health System ( Site 3402), Seoul, 03722, Korea, Republic of|Asan Medical Center-Division of Gynecologic Oncology, Dept. of Obstetrics & Gynecology ( Site 3401), Seoul, 05505, Korea, Republic of|Samsung Medical Center ( Site 3400), Seoul, 06351, Korea, Republic of|University Malaya Medical Centre ( Site 3102), Lembah Pantai, Kuala Lumpur, 59100, Malaysia|Sunway Medical Centre ( Site 3105), Petaling Jaya, Selangor, 47500, Malaysia|Pantai Hospital Kuala Lumpur ( Site 3100), Kuala Lumpur, 59100, Malaysia|Penang Adventist Hospital ( Site 3101), Pulau Pinang, 10350, Malaysia|Radboudumc-Medical Oncology ( Site 2202), Nijmegen, Gelderland, 6525 GA, Netherlands|Catharina Ziekenhuis-Oncology ( Site 2203), Eindhoven, Noord-Brabant, 5623 EJ, Netherlands|Amsterdam UMC, locatie VUmc ( Site 2201), Amsterdam, Noord-Holland, 1081 HV, Netherlands|Erasmus Medisch Centrum-Medical Oncology ( Site 2200), Rotterdam, Zuid-Holland, 3015 GD, Netherlands|University Medical Center Groningen ( Site 2204), Groningen, 9713GZ, Netherlands|Oslo universitetssykehus, Radiumhospitalet ( Site 2300), Oslo, 0379, Norway|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Ginekologii Onkologicznej ( Site 2400), Warszawa, Mazowieckie, 02-781, Poland|Bialostockie Centrum Onkologii-Oddzial Onkologii Ginekologicznej ( Site 2402), Bialystok, Podlaskie, 15-027, Poland|Uniwersytecki Szpital Kliniczny w Poznaniu-Oddzial Ginekologii Onkologicznej ( Site 2404), Poznan, Wielkopolskie, 60-569, Poland|UPR Comprehensive Cancer Center-Comprehensive Cancer Center Hospital ( Site 0601), San Juan, 00935, Puerto Rico|National University Hospital ( Site 3301), Singapore, Central Singapore, 119228, Singapore|National Cancer Centre Singapore ( Site 3300), Singapore, Central Singapore, 168583, Singapore|HOSPITAL CLÃNIC DE BARCELONA-ICHMO- Clinic Institut of Haematological and Oncological diseases ( Site 2509), Barcelona, Cataluna, 08036, Spain|Institut CatalÃ  d'Oncologia - L'Hospitalet-Medical Oncology ( Site 2508), L Hospitalet De Llobregat, Cataluna, 08908, Spain|Institut CatalÃ  d'Oncologia (ICO) - Girona-OncologÃ­a MÃ©dica ( Site 2507), Girona, Gerona, 17007, Spain|Clinica Universidad de Navarra ( Site 2510), Madrid, Madrid, Comunidad De, 28027, Spain|Hospital Universitario RamÃ³n y Cajal-Medical Oncology ( Site 2502), Madrid, Madrid, Comunidad De, 28034, Spain|Hospital Universitario 12 de Octubre-Medical Oncology ( Site 2506), Madrid, Madrid, Comunidad De, 28041, Spain|FundaciÃ³n Instituto Valenciano de OncologÃ­a-Oncologico ( Site 2503), Valencia, Valenciana, Comunitat, 46009, Spain|HOSPITAL CLINICO DE VALENCIA ( Site 2505), Valencia, Valenciana, Comunitat, 46010, Spain|Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 2500), Barcelona, 08035, Spain|Hospital Universitario Reina Sofia-Oncologia Medica ( Site 2501), Cordoba, 14004, Spain|Hospital Universitario La Paz-OncologÃ­a MÃ©dica ( Site 2504), Madrid, 28046, Spain|Universitetssjukhuset i LinkÃ¶ping ( Site 2600), LinkÃ¶ping, Ostergotlands Lan, 581 85, Sweden|SkÃ¥nes Universitetssjukhus Lund-Department of Hematology ( Site 2602), Lund, Skane Lan, 221 85, Sweden|Karolinska Universitetssjukhuset Solna ( Site 2601), Stockholm, Stockholms Lan, 171 64, Sweden|Akademiska sjukhuset ( Site 2603), Uppsala, Uppsala Lan, 751 85, Sweden|University Hospital Basel-Gynecology & Gynecologic Oncology ( Site 2701), Basel, Basel-Stadt, 4031, Switzerland|Inselspital Bern-Oncology ( Site 2700), Berne, 3010, Switzerland|ROYAL MARSDEN HOSPITAL (CHELSEA)-Gynaecology Research Centre ( Site 2807), London, England, SW10 9NH, United Kingdom|Royal Marsden Hospital (Sutton)-Gynaecology Unit ( Site 2801), Sutton, England, SM2 5PT, United Kingdom|Gartnavel General Hospital-Clinical Trials Unit ( Site 2800), Glasgow, Glasgow City, G12 0YN, United Kingdom|University College London Hospital ( Site 2805), London, London, City Of, NW1 2PG, United Kingdom|St James's University Hospital ( Site 2804), Leeds, LS9 7TF, United Kingdom|The Christie NHS Foundation Trust-Research and Development ( Site 2802), Manchester, m20 4bx, United Kingdom",
NCT06793215,"A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer",https://clinicaltrials.gov/study/NCT06793215,Krascendo 2,NOT_YET_RECRUITING,"The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-mutated, advanced or metastatic non squamous non-small cell lung cancer (NSCLC).",NO,Non-Small Cell Lung Cancer|KRAS G12C Lung Cancer,DRUG: Divarasib|DRUG: Pembrolizumab|DRUG: Pemetrexed|DRUG: Carboplatin|DRUG: Cisplatin,"Progression-Free Survival (PFS), PFS is defined as the time from randomization to the first occurrence of disease progression, as determined by blinded independent central review (BICR) according to RECIST v1.1, or death from any cause (whichever occurs first), Up to approximately 5 years|Overall Survival (OS), OS is defined as the time from randomization to death from any cause, Up to approximately 5 years","Objective Response, Objective response is defined as complete response (CR) or partial response (PR) on two consecutive occasions \>=4 weeks apart, as determined by BICR according to RECIST v1.1, Up to approximately 5 years|Change from Baseline on the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire-Supplemental Lung Cancer Module (EORTC QLQ-LC13) Cough Scale, Baseline up to Cycle 5 Day 1 (each cycle is 21 days)|Change from Baseline on the EORTC Quality of Life Questionnaire (QLQ-C30) Dyspnea Item and Physical Functioning Scale, Baseline up to Cycle 5 Day 1 (each cycle is 21 days)|Duration of Response (DOR), DOR is defined as the time from the first occurrence of a documented objective response to disease progression, as determined by BICR according to RECIST v1.1, or death from any cause (whichever occurs first), Up to approximately 5 years|Percentage of Participants with Adverse Events (AEs), Up to approximately 5 years|Number of Participants Reporting Presence, Frequency, Severity, and/or Degree of Interference with Daily Function of Symptomatic Treatment Toxicities Assessed by NCI Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE), Up to approximately 5 years|Change from Baseline in the Severity of Selected Symptomatic Treatment Toxicities as Assessed Through use of the NCI PRO-CTCAE, Up to approximately 5 years|Frequency of Participants' Response of the Degree they are Troubled with Treatment Symptoms, as Assessed Through use of the single-item EORTC Item List (IL46), Up to approximately 5 years|Change from Baseline on the EORTC QLQ-C30 and QLQ-LC13 Functional and Global Health Status Score/Quality of Life Score (GHS/QoL), Up to approximately 5 years",,Hoffmann-La Roche,Chugai Pharmaceutical,ALL,"ADULT, OLDER_ADULT",PHASE3,600,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2025-12-01,2028-11-30,2030-10-01,2025-01-27,,2025-06-12,,
NCT06497556,A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT06497556,Krascendo 1,RECRUITING,The purpose of this study is to assess the safety and efficacy of divarasib compared to locally approved KRAS G12C inhibitors (sotorasib or adagrasib) in participants with KRAS G12C-positive (KRAS G12C +) advanced or metastatic non-small cell lung cancer (NSCLC).,NO,Non-Small Cell Lung Cancer|KRAS G12C Lung Cancer,DRUG: Divarasib|DRUG: Sotorasib|DRUG: Adagrasib,"Progression-Free Survival (PFS), PFS is defined as the time from randomization to the first occurrence of disease progression, as determined by blinded independent central review (BICR) according to RECIST v1.1, or death from any cause (whichever occurs first), Up to approximately 4 years","Overall Survival (OS), OS is defined as the time from randomization to death from any cause, Up to approximately 4 years|Objective Response, Objective response is defined as complete response (CR) or partial response (PR) as determined by BICR according to RECIST v1.1, Up to approximately 4 years|Time to Confirmed Deterioration (TTCD) on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Dyspnea Item and Physical Functioning Scale, Baseline up to approximately 4 years|TTCD on the EORTC Quality-of-Life Questionnaire-Supplemental Lung Cancer Module (QLQ-LC13) Cough Scale, Baseline up to approximately 4 years|Duration of Response (DOR), DOR is defined as the time from the first occurrence of a documented objective response to disease progression, as determined by BICR according to RECIST v1.1, or death from any cause (whichever occurs first), Up to approximately 4 years|Percentage of Participants with Adverse Events (AEs), Up to approximately 4 years|Number of Participants Reporting Presence, Frequency, Severity, and/or Degree of Interference with Daily Function of Symptomatic Treatment Toxicities Assessed by NCI Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE), Up to approximately 4 years|Change from Baseline in Diarrhea, Nausea, Vomiting, Anorexia, Alopecia, Dyspnea, Cough, Constipation, Myalgia, Headache, and Rash/Acne as Assessed Through use of the NCI PRO-CTCAE, Baseline up to approximately 4 years|Frequency of Participants' Response of the Degree they are Troubled with Treatment Symptoms, as Assessed Through use of the single-item EORTC Item List (IL46), Up to approximately 4 years|Change from Baseline in Cough, Chest Pain, Dyspnea, Physical and Role Functioning, and Global Health Status score/Quality of Life Score (GHS/QoL) at Each Timepoint as Assessed Through use of the EORTC QLQ-LC13 and QLQ-C30, Baseline up to approximately 4 years|TTCD on the EORTC QLQ-C30 Role Functioning and GHS/QoL scales, Up to approximately 4 years|TTCD on the Chest Pain Scale of the QLQ-LC13 Scales, Up to approximately 4 years",,Hoffmann-La Roche,Chugai Pharmaceutical,ALL,"ADULT, OLDER_ADULT",PHASE3,320,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-09-23,2026-09-23,2029-09-30,2024-07-11,,2025-06-04,"Banner Health MD Anderson AZ, Gilbert, Arizona, 85234, United States|University of Arkansas For Medical Sciences, Little Rock, Arkansas, 72205, United States|Los Angeles Cancer Network, Los Angeles, California, 90017-4803, United States|UCLA Hematology / Oncology Clinic, Los Angeles, California, 90095, United States|Community Clinical Trials, Orange, California, 92868, United States|Zuckerberg San Francisco General Hospital, San Francisco, California, 94110, United States|University of California, San Francisco, San Francisco, California, 94158, United States|UC Health Oncology Research, Colorado Springs, Colorado, 80909, United States|Yale Cancer Center, New Haven, Connecticut, 06519, United States|Bay Pines Foundation Inc, Bay Pines, Florida, 33744, United States|Florida Cancer Specialists, Fort Myers, Florida, 33901, United States|University of Miami, Miami, Florida, 33136, United States|Cancer Specialists of North Florida, Saint Augustine, Florida, 32086, United States|Florida Cancer Specialists., Saint Petersburg, Florida, 33705, United States|Florida Cancer Specialists, West Palm Beach, Florida, 33401, United States|University Cancer & Blood Center, LLC, Athens, Georgia, 30607, United States|Summit Cancer Care PC, Savannah, Georgia, 31405, United States|University of Chicago Medical Center, Chicago, Illinois, 60637, United States|IU Health Ball Memorial Hospital, Muncie, Indiana, 47303, United States|Mission Cancer + Blood - IMMC, Waukee, Iowa, 50263, United States|Baptist Health Lexington, Lexington, Kentucky, 40503, United States|Norton Cancer Institute- Poplar, Louisville, Kentucky, 40217, United States|VA Shreveport Healthcare System, Shreveport, Louisiana, 71101, United States|New England Cancer Specialists, Scarborough, Maine, 04074, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Dana Farber/Harvard Cancer Center (Foxborough), Foxboro, Massachusetts, 02035, United States|Dana-Farber Cancer Institute, Methuen, Massachusetts, 01844, United States|University of Michigan, Ann Arbor, Michigan, 48109-0934, United States|Henry Ford Health System;Clinical Trials Office, Detroit, Michigan, 48202, United States|Cancer and Hematology Centers of Western Michigan, Grand Rapids, Michigan, 49503, United States|Nebraska Methodist Estabrook Cancer Center, Omaha, Nebraska, 68114, United States|Renown Regional Medical Center Hospital, Reno, Nevada, 89502-1576, United States|New York Cancer & Blood Specialists, Bronx, New York, 10469, United States|New York Cancer & Blood Specialists - New Hyde Park, New Hyde Park, New York, 11042-1116, United States|New York Cancer and Blood Specialists-Central Park Hematology & Oncology, New York, New York, 10028, United States|Mount SInai Medical Center, New York, New York, 10029, United States|Columbia University Medical Center, New York, New York, 10032, United States|North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists, Shirley, New York, 11967, United States|University of North Carolina At Chapel Hill, Chapel Hill, North Carolina, 27514, United States|East Carolina University, Greenville, North Carolina, 27834, United States|Firsthealth of The Carolinas, Pinehurst, North Carolina, 28374, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, 43210, United States|SCRI Mark H. Zangmeister Center, Columbus, Ohio, 43219, United States|Taylor Cancer Research Center, Maumee, Ohio, 43537, United States|Oncology Associates of Oregon, P.C, Eugene, Oregon, 97401, United States|Oregon Health & Science University, Portland, Oregon, 97239, United States|Allegheny Cancer Center, Pittsburgh, Pennsylvania, 15212, United States|Gibbs Cancer Center & Research Institute, Spartanburg, South Carolina, 29303, United States|Avera Cancer Institute, Sioux Falls, South Dakota, 57105, United States|Tennessee Oncology, PLLC - Chattanooga, Chattanooga, Tennessee, 37404, United States|Baptist Clinical Research Institute, Memphis, Tennessee, 38120, United States|Tennessee Oncology, Nashville, Tennessee, 37203, United States|JPS Health Network, Fort Worth, Texas, 76104, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|Texas Oncology - Northeast Texas, Longview, Texas, 75601, United States|Virginia Commonwealth University - Massey Cancer Center, Richmond, Virginia, 23298-0042, United States|Hospital Britanico, Buenos Aires, C1280AEB, Argentina|Centro Oncologico Korben, Ciudad Autonoma Buenos Aires, C1426AGE, Argentina|Clinica Adventista Belgrano, Ciudad Autonoma Buenos Aires, C1430EGF, Argentina|Sanatorio Parque S.A., Rosario, S2000QGB, Argentina|Kinghorn Cancer Centre, Darlinghurst, New South Wales, 2010, Australia|Liverpool Hospital, Liverpool, New South Wales, 2170, Australia|GenesisCare North Shore, St Leonards, New South Wales, 2065, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, 4575, Australia|Lyell McEwin Hospital, Elizabeth Vale, South Australia, 5112, Australia|Peter Maccallum Cancer Centre, Melbourne, Victoria, 3000, Australia|Klinik Penzing, Wien, 1140, Austria|Institut fÃ¼r Lungenforschung Wien, Wien, 1160, Austria|Krankenhaus Nord - Klinik Floridsdorf, Wien, 1210, Austria|AZORG Campus Aalst-Moorselbaan, Aalst, 9300, Belgium|UZ Brussel, Brussel, 1090, Belgium|Cliniques Universitaires St-Luc, Bruxelles, 1200, Belgium|UZ Antwerpen, Edegem, 2650, Belgium|Jessa Zkh (Campus Virga Jesse), Hasselt, 3500, Belgium|CHU Sart-Tilman, LiÃ¨ge, 4000, Belgium|CHU UCL Mont-Godinne, Mont-godinne, 5530, Belgium|AZ Delta (Campus Rumbeke), Roeselare, 8800, Belgium|Vitaz, Sint Niklaas, 9100, Belgium|Sint Augustinus Wilrijk, Wilrijk, 2610, Belgium|Hospital Sao Rafael - HSR, Salvador, Bahia, 41253-190, Brazil|Hospital Brasilia, Brasilia, Distrito Federal, 71635580, Brazil|Clinica Onconeo, Campo Grande, Mato Grosso Do Sul, 79002-061, Brazil|Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, 90020-090, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, Rio Grande Do Sul, 90040-373, Brazil|Hospital Mae de Deus, Porto Alegre, Rio Grande Do Sul, 90110-000, Brazil|Hospital de Cancer de Barretos, Barretos, SÃ£o Paulo, 14784-400, Brazil|Hospital de Base de Sao Jose do Rio Preto, Sao Jose do Rio Preto, SÃ£o Paulo, 15090-000, Brazil|Hospital SÃ­rio-LibanÃªs, Sao Paulo, SÃ£o Paulo, 01308-050, Brazil|Hospital Alemao Oswaldo Cruz, Sao Paulo, SÃ£o Paulo, 01323-903, Brazil|Oncoclinicas Rio de Janeiro S.A., Rio de Janeiro, 22250-905, Brazil|William Osler Health Centre - Brampton Civic Hospital, Brampton, Ontario, L6R 3J7, Canada|Princess Margaret Cancer Center, Toronto, Ontario, M5G 2M9, Canada|Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada|Aarhus Universitetshospital, Aarhus N, 8200, Denmark|Herlev Hospital, Herlev, 2730, Denmark|Regionshospitalet GÃ¸dstrup, Herning, 7400, Denmark|Helsinki University Central Hospital, Helsinki, 00029, Finland|Kuopio Uni Hospital, Kuopio, 70211, Finland|Turku Uni Central Hospital, Turku, 20520, Finland|CHU Angers, Angers, 49933, France|CHRU Brest, Brest, 29200, France|Chu Toulouse, Bron, 69500, France|Hopital Louis Pradel, Bron, 69677, France|CHRU Lille, Lille, 59037, France|Centre Leon Berard, Lyon, 69373, France|CHU Montpellier, Montpellier, 34295, France|Centre Antoine Lacassagne Centre RÃ©gional de Lutte Contre Le Cancer, Nice, 06100, France|Hopital Tenon, Paris, 75970, France|CHU Bordeaux, Pessac, 33604, France|CH de Saint Quentin, Saint Quentin, 2100, France|Chru de Strasbourg, Strasbourg, 67091, France|Hia Sainte Anne, Toulon, 83041, France|Evangelische Lungenklinik Berlin, Berlin, 13125, Germany|CharitÃ© UniversitÃ¤tsmedizin Berlin, Med Klinik Infekto und Pneumo, Berlin, 13353, Germany|Helios Klinikum Emil von Behring GmbH, Berlin, 14165, Germany|Klinikum Braunschweig, Braunschweig, 38114, Germany|KEM/Evang. Kliniken Essen Mitte gGmbH, Essen, 45136, Germany|UniversitÃ¤tsklinikum Essen, Essen, 45147, Germany|Klinikum Esslingen, Esslingen, 73730, Germany|Asklepios Fachkliniken GmbH, Gauting, 82131, Germany|LungenClinic GroÃhansdorf GmbH, GroÃhansdorf, 22927, Germany|Krankenhaus Martha-Maria Halle-Doelau gGmbH, Halle, 06120, Germany|Thoraxklinik Heidelberg gGmbH, Heidelberg, 69126, Germany|Lungenklinik Hemer, Hemer, 58675, Germany|UniversitÃ¤t Des Saarlandes, Homburg, 66421, Germany|Lungenfachklinik Immenhausen, Immenhausen, 34376, Germany|Uniklinik Schleswig-Holstein, Kiel, 24116, Germany|Klinikum Koeln-Merheim, KÃ¶ln, 51109, Germany|SLK Kliniken Heilbronn GmbH, Standort Fachklinik LÃ¶wenstein, LÃ¶wenstein, 74245, Germany|UniversitÃ¤tsklinikum Schleswig-Holstein, LÃ¼beck, 23538, Germany|UniversitÃ¤t Mannheim, Mannheim, 68167, Germany|Klinikum Bogenhausen, MÃ¼nchen, 81925, Germany|UniversitÃ¤tsklinikum MÃ¼nster, Medizinische Klinik A, Translationale Onkologie, MÃ¼nster, 48149, Germany|Pius Hospital Oldenburg, Oldenburg, 26121, Germany|UniversitÃ¤tsklinikum Regensburg, Regensburg, 93053, Germany|Klinikum WÃ¼rzburg Mitte gGmbH, WÃ¼rzburg, 97074, Germany|Uoa Sotiria Hospital, Athens, 115 27, Greece|Errikos Dynan Hospital, Athens, 11526, Greece|Metropolitan Hospital Fourth Oncology Clinic, Faliro, 185 47, Greece|University Hospital of Larissa, Larissa, 411 10, Greece|Theageneio Hospital, Thessaloniki, 546 39, Greece|Ag. Loukas Hospital, Thessaloniki, 55236, Greece|Hong Kong Integrated Oncology Centre, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|Tuen Mun Hospital, Hong Kong, Hong Kong|Prince of Wales Hosp, Shatin, Hong Kong|Az. Osp. Pugliese Ciaccio, Catanzaro, Calabria, 88100, Italy|AZ.Osp S. Orsola ? Malpighi-Reparto di Oncologia Medica, Bologna, Emilia-Romagna, 40138, Italy|A.O. Universitaria Di Parma, Parma, Emilia-Romagna, 43100, Italy|AUSL della Romagna, Ravenna, Emilia-Romagna, 48121, Italy|Azienda Sanitaria Universitaria Friuli Centrale ? PO Universitario Santa Maria della Misericordia, Udine, Friuli-Venezia Giulia, 33100, Italy|IRCCS Istituto Regina Elena (IFO), Roma, Lazio, 00144, Italy|Ospedale Policlinico San Martino, Genova, Liguria, 16132, Italy|Asst Papa Giovanni XXIII, Bergamo, Lombardia, 24100, Italy|IRCCS Istituto Clinico Humanitas, Rozzano (MI), Lombardia, 20089, Italy|A.O.U. Maggiore della CaritÃ , Novara, Piemonte, 28100, Italy|Irccs Ist. Tumori Giovanni Paolo Ii, Bari, Puglia, 70124, Italy|Ospedale Civile SS Annunziata, Sassari, Sardegna, 07100, Italy|AO Ospedali Riuniti Villa Sofia-Cervello-Presidio Ospedaliero Cervello, Palermo, Sicilia, 90146, Italy|Azienda Ospedaliero-Universitaria Careggi, Firenze, Toscana, 50139, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, Toscana, 56126, Italy|IRCCS Istituto Oncologico Veneto (IOV), Padova, Veneto, 35128, Italy|Shikoku Cancer Center, Ehime, 791-0280, Japan|Kyushu University Hospital, Fukuoka, 812-8582, Japan|Hokkaido University Hospital, Hokkaido, 060-8648, Japan|Sendai Kousei Hospital, Miyagi, 981-0914, Japan|Niigata Cancer Center Hospital, Niigata, 951-8566, Japan|Okayama University Hospital, Okayama, 700-8558, Japan|Kindai University Hospital, Osaka, 589-8511, Japan|Shizuoka Cancer Center, Shizuoka, 411-8777, Japan|National Cancer Center Hospital, Tokyo, 104-0045, Japan|The Cancer Institute Hospital of JFCR, Tokyo, 135-8550, Japan|Wakayama Medical University Hospital, Wakayama, 641-8510, Japan|Pusan National University Hospital, Busan, 602-739, Korea, Republic of|Chungbuk National University Hospital, Cheongju-si, 28644, Korea, Republic of|Kyungpook National University Chilgok Hospital, Daegu, 41404, Korea, Republic of|Keimyung University Dongsan Medical Center, Daegu, 41931, Korea, Republic of|St. Vincent's Hospital, Gyeonggi-do, 16247, Korea, Republic of|Pusan National University Yangsan Hospital, Gyeongsangnam-do, 50612, Korea, Republic of|Gachon University Gil Medical Center, Incheon, 21565, Korea, Republic of|Chonnam National University Hwasun Hospital, Jeollanam-do, 58128, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, 463-707, Korea, Republic of|Korea University Anam Hospital, Seoul, 02841, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|Korea University Guro Hospital, Seoul, 08308, Korea, Republic of|Centro de Infusion E Investigacion Oncologia de Saltillo Sc, Saltillo, Coahuila, 25230, Mexico|Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, 44280, Mexico|ClÃ­nica Integral Internacional de OncologÃ­a S de RL de CV, Heroica Puebla de Zaragoza, Puebla, 72530, Mexico|PanAmerican Clinical Research, QuerÃ©taro, Santiago de QuerÃ©taro, Queretaro, 76100, Mexico|ARKE Estudios ClÃ­nicos S.A. de C.V., Ciudad de MÃ©xico, 06700, Mexico|Jeroen Bosch Ziekenhuis, 'S Hertogenbosch, 5223 GZ, Netherlands|Ziekenhuis Rijnstate, Arnhem, 6815 AD, Netherlands|Amphia Ziekenhuis, Breda, 4818CK, Netherlands|Ziekenhuis St. Jansdal, Harderwijk, 3844 DG, Netherlands|Medisch Centrum Haaglanden, locatie Antoniushove, Leidschendam, 2262 BA, Netherlands|Isala, Zwolle, 8025 AB, Netherlands|Instytut ""Centrum Zdrowia Matki Polki"", ?Ã³d?, 93-338, Poland|Kujawsko-Pomorskie Centrum Pulmonologii, Bydgoszcz, 85-326, Poland|Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii, Gdansk, 80-214, Poland|Krakowski Szpital Specjalistyczny im sw. Jana Paw?a II, KrakÃ³w, 31-202, Poland|Uniwersytecki Szpital Kliniczny nr 4 w Lublinie, Lublin, 20-954, Poland|Warminsko-Mazurskie Centrum ChorÃ³b P?uc w Olsztynie, Olsztyn, 10-357, Poland|Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu, Poznan, 60-569, Poland|Radomskie Centrum Onkologii, Radom, 26-600, Poland|Instytut Gruzlicy I Chorob Pluc, Warszawa, 01-138, Poland|Narod.Inst.Onkol. im. M.Sklodowskiej - Curie-Panst.Inst.Bad, Warszawa, 02-781, Poland|Dolno?L?Skie Centrum Onkologii, Pulmonologii I Hematologii, Wroc?aw, 53-439, Poland|Hospital de Braga, Braga, 4710-243, Portugal|CHUC - Unidade de Pneumologia OncolÃ³gica, Coimbra, 3000-075, Portugal|Centro Clinico Champalimaud, Lisboa, 1400-038, Portugal|Centro Hospitalar do Porto ? Hospital de Santo AntÃ³nio, Porto, 4099-001, Portugal|IPO do Porto, Porto, 4200-072, Portugal|National Cancer Centre, Singapore, 168583, Singapore|Curie Oncology (Farrer), Singapore, 217562, Singapore|Institut Catala d Oncologia Hospitalet, Hospitalet de Llobregat, Barcelona, 08908, Spain|Hospital Nuestra Senora de Valme, Seville, Sevilla, 41014, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, 08025, Spain|Hospital Vall Hebron, Barcelona, Spain|Hospital General Universitario Gregorio MaraÃ±on, Madrid, 28007, Spain|Hospital Universitario La Paz, Madrid, 280146, Spain|Hospital Regional Universitario de Malaga, Malaga, 29010, Spain|Hospital Universitario la Fe, Valencia, 46026, Spain|Hospital Universitario Miguel Servet, Zaragoza, 50009, Spain|GÃ¤vle Sjukhus, GÃ¤vle, 80187, Sweden|Hsin-Chu Branch of National Taiwan University Hospital, Hsinchu City, 300, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, 807, Taiwan|Chung Shan Medical University Hospital, Taichung, 402306, Taiwan|National Taiwan University Hospital, Taipei, 00100, Taiwan|Taipei Veterans General Hospital, Taipei, 112, Taiwan|Chang Gung Medical Foundation - Linkou, Taoyuan, 333, Taiwan|Vajira Hospital, Bangkok, 10300, Thailand|Siriraj Hospital - Chulabhorn Bone Marrow Transplant Centre, Bangkok, 10700, Thailand|Srinagarind Hospital, Khon Kaen, 40002, Thailand|Songklanagarind Hospital, Songkhla, 90110, Thailand|Blackpool Victoria Hospital, Blackpool, FY3 8NR, United Kingdom|Addenbrooke's Hospital, Cambridge, CB2 0QQ, United Kingdom|Velindre NHS Trust - Velindre Cancer Centre, Cardiff, CF14 2TL, United Kingdom|Castle Hill Hospital, Cottingham, HU16 5JQ, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, G12 0YN, United Kingdom|St James University Hospital, Leeds, LS9 7TF, United Kingdom|Guy's Hospital - Cancer Centre, London, SE1 9RT, United Kingdom|Royal Marsden Hospital - London, London, SW3 6JJ, United Kingdom|The Christie NHS Foundation Trust, Manchester, M20 4BX, United Kingdom|Nottingham City Hospital, Nottingham, NG5 1PB, United Kingdom|University Hospitals of North Midlands NHS Trust-Royal Stoke University Hospital, Stoke-On-Trent, ST4 6QG, United Kingdom|Royal Marsden Hospital (Sutton), Sutton, SM2 5PT, United Kingdom|Torbay Hospital, Torquay, TQ27AA, United Kingdom",
NCT06545955,A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer,https://clinicaltrials.gov/study/NCT06545955,ABLE-22,RECRUITING,"The pivotal phase 3 trial (rAd-IFN-CS 003) evaluating the efficacy of nadofaragene firadenovec showed that 55 (53.4%) of 103 subjects with CIS Â± high-grade Ta/T1 achieved a complete response (CR) at 3 months. In this trial, the safety and efficacy of intravesical instillation of nadofaragene firadenovec alone or in combination with chemotherapy or immunotherapy will be evaluated in participants with NMIBC CIS (Â± high-grade Ta/T1).",NO,Non-muscle Invasive Bladder Cancer With Carcinoma in Situ,DRUG: Nadofaragene Firadenovec|DRUG: Gemcitabine|DRUG: Docetaxel|DRUG: Pembrolizumab,"Complete response, Complete response (CR) at any time from first treatment (defined as absence of high-grade (HG) recurrence)., up to 12 months","Complete response at month 3, Complete response 3 months from first treatment, 3 months|Complete response at month 6, Complete response 6 months from first treatment, 6 months|Durability of complete response, Durability of complete response (defined as time from achieved CR to HG recurrence, progression or death due to any cause)., Up to 24 months|Muscle-invasive progression of disease, Muscle-invasive progression of disease (defined as time from first treatment to first evidence of muscle-invasive disease or death), up to 36 months|Cystectomy-free survival, Cystectomy-free survival (defined as time from first treatment to either cystectomy or death due to any cause), up to 36 months|Pathological staging, Pathological staging (tumor, node, metastasis staging system) in participants at time of cystectomy, up to 36 months|Overall survival, Overall survival (defined as time from first treatment to death due to any cause), up to 36 months|Evidence of malignant lesions of the upper tract and/or prostatic urethra, Evidence of malignant lesions of the upper tract and/or prostatic urethra (defined as time from first treatment to first evidence of malignant lesions)., up to 36 months|Adverse events, Adverse events collected for nadofaragene firadenovec in combination with chemotherapy (gemcitabine and docetaxel) or immunotherapy (pembrolizumab), up to 36 months",,Ferring Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,250,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-10-01,2030-12-31,2030-12-31,2024-08-09,,2025-06-04,"Ferring Investigational Site, Fresno, California, 93720, United States|Ferring Investigational Site, Los Angeles, California, 90017, United States|Ferring Investigational Site, New Haven, Connecticut, 06519, United States|Ferring Investigational Site, Atlanta, Georgia, 30322, United States|Ferring Investigational Site, Atlanta, Georgia, 30328, United States|Ferring Investigational Site, Boise, Idaho, 83702, United States|Ferring Investigational Site, Troy, Michigan, 48084, United States|Ferring Investigational Site, Bronx, New York, 10468, United States|Ferring Investigational Site, Buffalo, New York, 14263, United States|Ferring Investigational Site, Poughkeepsie, New York, 12603, United States|Ferring Investigational Site, Bala-Cynwyd, Pennsylvania, 19004, United States|Ferring Investigational Site, Myrtle Beach, South Carolina, 29572, United States",
NCT05341583,Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT05341583,,RECRUITING,"This double-blind, randomized, placebo-controlled, multicenter, Phase III study is designed to evaluate the efficacy and safety of ensatinib compared with placebo as adjuvant treatment in ALK positive stage II-IIIB non-small cell lung cancer after surgical resection with or without chemotherapy.",NO,Non-small Cell Lung Cancer,DRUG: Ensartinib|DRUG: Placebo,"Disease free survival (DFS), From date of randomization until date of tumor recurrence or death, whichever occurs earlier, up to 5 years","DFS rate at 3 years, Assessed at 3 years|DFS rate at 5 years, Assessed at 5 years|Overall survival (OS), Assessed at 5 years|OS rate at 5 years, up to 5 years",,"Betta Pharmaceuticals Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,202,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-05-24,2025-06-01,2025-07-23,2022-04-22,,2024-08-23,"TianJin Medical University Cancer Institute & Hospital, Tianjin, China",
NCT05798819,"A Study of GLS-010 Plus Platinum-containing ChemotherapyÂ±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer",https://clinicaltrials.gov/study/NCT05798819,,NOT_YET_RECRUITING,"This is a randomized, double-blind, placebo-controlled phase III study to evaluate GLS-010 plus platinum-containing chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer.",NO,"Persistent, Recurrent, or Metastatic Cervical Cancer",DRUG: GLS-010|DRUG: Placebo|DRUG: paclitaxel|DRUG: cisplatin|DRUG: carboplatin|DRUG: bevacizumab,"overall survival (OS), OS is defined as the time from randomization to death due to any cause., Up to 2 years","progression-free survival (PFS), PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1., Up to 2 years|Objective Response Rate (ORR), Proportion of subjects who have a complete or partial response relative to baseline based on RECIST 1.1 criteria., Up to 2 years|Duration of Response (DOR), Measured from the date of partial or complete response to therapy until the cancer progresses based on RECIST v1.1 criteria., Up to 2 years|Disease Control Rate (DCR), DCR defined as the proportion of subjects' response of CR, PR, or SD based on RECIST v1.1 criteria., Up to 2 years|Time to Responseï¼TTRï¼, TTR defined as the time from the date of randomization to the date when the response criteria are first met, based on RECIST v1.1 criteria., Up to 2 years|Number of subjects with adverse events (AEs), An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment, From the time of signed informed consent to 90 days after end of treatment.|Quality of life (QoL), EORTC QLQ-C30 will be used., Up to 2 years",,"Guangzhou Gloria Biosciences Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,424,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-05-01,2025-05-01,2026-12-01,2023-04-05,,2023-04-05,"Fudan University Shanghai Cancer Hospital, Shanghai, Shanghai, China",
NCT06282575,Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer,https://clinicaltrials.gov/study/NCT06282575,,RECRUITING,"The purpose of this study is to evaluate the efficacy and safety of Zanidatamab plus CisGem (Cisplatin and Gemcitabine) with or without the addition of a programmed death protein 1/ligand-1 (PD-1/L1) inhibitor (physician's choice of either Durvalumab or Pembrolizumab, where approved under local regulations) as first line of treatment for participants with human epidermal growth factor receptor 2 (HER2)-positive biliary tract cancer.",NO,Biliary Tract Cancer,DRUG: Zanidatamab|DRUG: Cisplatin|DRUG: Gemcitabine|DRUG: Pembrolizumab|DRUG: Durvalumab,"Progression Free Survival (PFS) in participants with Immunohistochemistry (IHC) 3+ tumors, PFS is defined as the time from the date of randomization to the date of documented disease progression, or death from any cause., Up to 52 months","Overall survival (OS) in participants with IHC 3+ tumors, OS is defined as the time from randomization to death, due to any cause., Up to 68 months|Progression Free Survival for all participants, PFS is defined as the time from the date of randomization to the date of documented disease progression, or death from any cause., Up to 68 months|OS for all participants, OS is defined as the time from randomization to death, due to any cause., Up to 68 months|Number of participants achieving Confirmed objective response rate (cORR), Confirmed objective response rate is defined as achieving a confirmed best overall response of Complete Response (CR) or Partial Response (PR), Up to 68 months|Duration of response (DOR), Duration of response is defined as the time from the first objective response (CR or PR) to documented Progressive Disease (PD) or death, from any cause., Up to 68 months|Number of Patients reporting Treatment-Emergent Adverse Events (TEAE), Up to 68 months|Maximum serum concentration of Zanidatamab, Up to 68 months|Number of participants who develop Anti-drug antibodies (ADAs) to Zanidatamab, Up to 68 months|Time to definitive deterioration (TDD) for participants with IHC 3+ tumors in patient-reported Physical Functioning (PF) domain score as measured by the EORTC QLQ-C30, TDD is defined as the time from randomization to the first confirmed clinical meaningful deterioration or death. European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 (QLQ-C30) final scores range from 0 to 100, where higher scores reflect better functioning, Up to 68 months|TDD for all participants in patient-reported PF domain score as measured by the EORTC QLQ-C30, TDD is defined as the time from randomization to the first confirmed clinical meaningful deterioration or death. EORTC QLQ-C30 final scores range from 0 to 100, where higher scores reflect better functioning., Up to 68 months|TDD for participants with IHC 3+ tumors in patient-reported symptoms scores as measured by the EORTC QLQ-BIL21 (Pain, Jaundice, Abdominal Pain and Pruritis), TDD is defined as the time from randomization to the first confirmed clinical meaningful deterioration or death. EORTC Quality of Life Questionnaire - Cholangiocarcinoma and Gallbladder Cancer module (QLQ-BIL21) (Pain, Jaundice, Abdominal Pain, and Pruritis) final scores range from 0 to 100, where higher scores reflect better functioning., Up to 68 months|TDD for all participants in patient-reported symptoms scores as measured by the EORTC QLQ-BIL21 (Pain, Jaundice, Abdominal Pain, and Pruritis), TDD is defined as the time from randomization to the first confirmed clinical meaningful deterioration or death. EORTC QLQ-BIL21 (Pain, Jaundice, Abdominal Pain, and Pruritis) final scores range from 0 to 100, where higher scores reflect better functioning., Up to 68 months",,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,286,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-07-19,2028-12-01,2030-04-01,2024-02-28,,2025-05-13,"Rocky Mountain Cancer Centers, LLP, Lone Tree, Colorado, 80124, United States|AdventHealth Hematology and Oncology, Orlando, Florida, 32804, United States|Winship Cancer Institute, Atlanta, Georgia, 30322, United States|The University of Kansas Cancer Center - Westwood, Westwood, Kansas, 66205, United States|Norton Cancer Institute - Audubon, Louisville, Kentucky, 40217, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, 70121, United States|Tufts Medical Center, Boston, Massachusetts, 02111, United States|University of Michigan Hospital, Ann Arbor, Michigan, 48109, United States|Henry Ford Health System, Detroit, Michigan, 48202, United States|Minnesota Oncology Hematology, P.A., Maple Grove, Minnesota, 55369, United States|Atlantic Health System/Morristown Medical Center, Morristown, New Jersey, 07960, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone - Ambulatory Care Center, New York, New York, 10016, United States|Memorial Sloan Kettering Cancer Centers, New York, New York, 10022, United States|Saint Francis Cancer Center, Greenville, South Carolina, 29607, United States|SCRI Oncology Partners, Nashville, Tennessee, 37203, United States|Texas Oncology - DFW, Dallas, Texas, 75246, United States|University of Texas Southwestern Medical Center, Dallas, Texas, 75390, United States|The Univerrsity of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|Virginia Commonwealth University, VCU Health, Richmond, Virginia, 23219, United States|Hospital Italiano de Buenos Aires, Ciudad AutÃ³noma de Buenos Aires (CABA), Buenos Altes, C1199ABB, Argentina|FundaciÃ³n ARS MÃ©dica, San Salvador De Jujuy, Jujuy, 4600, Argentina|Centro de InvestigaciÃ³nes ClÃ­nicas - ClÃ­nica Viedma, Viedma, RÃ­o Negro, R8500ACE, Argentina|Hospital Provincial Del Centenario, Rosario, Santa Fe, 2000, Argentina|Instituto MÃ©dico de la FundaciÃ³n Estudios ClÃ­nicos, Rosario, Santa Fe, S2013DTC, Argentina|CAIPO Centro para la AtenciÃ³n Integral del Paciente OncolÃ³gico, San Miguel De TucumÃ¡n, TucumÃ¡n, 4000, Argentina|Centro MÃ©dico en OncologÃ­a ClÃ­nica EXELSUS S.R.L, San Miguel De TucumÃ¡n, TucumÃ¡n, 4000, Argentina|Centro MÃ©dico Privado CEMAIC, CÃ³rdoba, X5008HHW, Argentina|Imelda VZW, Bonheiden, Antwerpen, 2820, Belgium|UZ Antwerpen, Edegem, Antwerpen, 2650, Belgium|UZ Leuven, Leuven, Vlaams-Brabant, 3000, Belgium|Liga Norte Riograndense Contra O Cancer, Natal, Rio Grande Do Norte, 59062-000, Brazil|Irmandade Da Santa Casa de Misericordia de Porto Alegre - ISCMPA, Porto Alegrev, Rio Grande Do Sul, 90020-170, Brazil|FundaÃ§Ã£o Pio XII Hospital de Amor de Barretos, Barretos, SÃ£o Paulo, 14.784-400, Brazil|FundaÃ§Ã£o Faculdade Regional de Medicina de SÃ£o JosÃ© do Rio Preto (FUNFARME), SÃ£o JosÃ© do Rio Preto, SÃ£o Paulo, 15090-000, Brazil|Hospital Nossa Senhora Da ConceiÃ§Ã£o/Centro Integrado de Pesquisa em Oncologia CIPO-GHC, Porto Alegre, 91350-200, Brazil|London Health Sciences Centre, LondonO, Ontario, NGA 5W9, Canada|Princess Margaret Cancer Centre - University Health Network, Toronto, Ontario, M5G 2M9, Canada|James Lind Centro de Investigacion del Cancer, Temuco, AraucanÃ­a, 4800827, Chile|Servicios MÃ©dicos URUMED SpA, Rancagua, Libertador Gen Bernardo O Higgins, 2820000, Chile|Clinica Puerto Montt, Puerto Montt, Los Lagos, 5507642, Chile|FundaciÃ³n Arturo LÃ³pez PÃ©rez (FALP), Santiago, Metropolitana, 7500921, Chile|Oncovida, Santiago, Metropolitana, 7500994, Chile|Hospital Clinico Universidad de Chile, Santiago, Region Metropolitana, 8380494, Chile|Centro de Investigacion y Especialidades Medicas (CDIEM), Santiago, RegiÃ³n-Metropolitana, 7500859, Chile|Biocinetic Ltda, Santiago, RegiÃ³n-Metropolitana, 8320000, Chile|FakultnÃ­ nemocnice Brno, InternÃ­ hematologickÃ¡ a onkologickÃ¡ klinika, Brno, 625 00, Czechia|Fakultni nemocnice Hradec Kralove, Klinika onkologie a radioterapie, Hradec Kralove, 50005, Czechia|Fakultni nemocnice v Motole, Onkologicka klinika, Praha 5, 150 00, Czechia|Docrates Cancer Center, Helsinki, 180, Finland|Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, 290, Finland|Kuopio University Hospital, Kuopio, 70029, Finland|CHU de Toulouse- (Toulouse University Hospital Center), Toulouse, Cedex 9, 31059, France|CHU Besancon, BesanÃ§on, Cedex, 25030, France|CHU de Bordeaux - HÃ´pital Haut Leveque, Pessac, Cedex, 33604, France|CHU Brest HÃ´pital de la Cavale Blanche, Brest, 29200, France|CHU Estaing, Clermont-Ferrand, 63100, France|Hospital Beaujon University, Clichy, 92110, France|Hopital Henri Mondor, CrÃ©teil, 94010, France|CHU Montepellier - HÃ´pital Saint Eloi, Montpellier, 34000, France|CHU Poitiers, Poitiers, 86000, France|Institut de CancÃ©rologie de l'Ouest, Saint-Herblain Cedex, 44805, France|Gustave Roussy, Villejuif Cedex, 94805, France|UniversitÃ¤tsklinikum TÃ¼bingen - Medizinische UniversitÃ¤tsklinik, Innere Medizin I, Tuebingen, Baden-Wuttemberg, 72076, Germany|Nationales Centrum fÃ¼r Tumorerkrankungen (NCT) Heidelberg, Heidelberg, Baden-WÃ¼rttemberg, 69120, Germany|LMU UniversitÃ¤tsklinikum MÃ¼nchen, Campus GroÃhadern, Medizinische Klinik und Poliklinik III - HÃ¤matologie und Onkologie, MÃ¼nchen, Bayern, 81377, Germany|Krankenhaus Nordwest - Institut fÃ¼r Klinisch-Onkologische Forschung (IFK), Frankfurt, Hessen, 60488, Germany|Medizinische Hochschule Hannover - Klinik Fur Gastroenterologie, Hepatologie, Infektiologie und Endokrinologie, Hannover, Nieder-Sachsen, 30625, Germany|UniversitÃ¤tsklinikum Schleswig-Holstein - Campus LÃ¼beck, Medizinische Klinik I (MKI), Lubeck, Schleswig-Holstein, 23562, Germany|CharitÃ© - UniversitÃ¤tsmedizin Berlin - Campus Virchow Klinikum, Medizinische Klinik mit Schwerpunkt Hamatologie und Tumorimmunologie, Berlin, 13353, Germany|Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona - Onkologie und Palliativmedizin mit Sektionen Hamatologie und Rheumatologie, Hamburg, 22763, Germany|KLES Dr Prabhakar Kore Hospital and Medical Research Centre, Belagavi, Karnataka, 590010, India|Tata Memorial Hospital, Mumbai, Maharashtra, 4000012, India|Chopda Medicare & Research Centre Pvt. Ltd - Magnum Heart Institute, Nashik, Maharashtra, 422005, India|AIG Hospitals (A Unit of Asian Institute of Gastroenterology), Hyderabad, Telangana, 500032, India|Pi Health Cancer Hospital, Hyderabad, Telangana, 500032, India|Mahamana Pandit Madan Mohan Malviya Cancer Centre, Varanasi, Uttar Pradesh, 221005, India|Max Super Speciality Hospital - Saket (a unit of Devki Devi foundation), New Delhi, 110017, India|Rajiv Gandhi Cancer Institute And Research Centre, New Delhi, 110085, India|Rambam Health Care Campus, Haifa, 3109601, Israel|The Hadassah University Medical Center, Ein Kerem Hospital, Jerusalem, 91120, Israel|Rabin Medical Center, Bellinson Hospital, Petah-Tikva, 49100, Israel|The Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, HaMerkaz, 5265601, Israel|Tel Aviv Sourasky Medical Center (Ichilov), Tel Aviv, 6423906, Israel|Azienda Ospedaliero Universitaria di Cagliari Presidio Ospedaliero Duilio Casula, Monserrato, Cagliari, 9042, Italy|Instituo di Candiolo, Fondazione del Piemonte per l'Oncologia (IRCCS), Candiolo, Torino, 10060, Italy|IRCCS Ospedale Policlinico San Martino, Genova, 16132, Italy|Fondazione IRCCS Istituto Nazionale per lo studio e la cura dei Tumori, Milano, 20133, Italy|AOU dell'Universit~ degli Studi della Campania Luigi Vanvitelli, Napoli, 80131, Italy|Veneto Institute of Oncology IOV - I.R.C.C.S., Padova, 35128, Italy|Azienda Ospedaliero - Universitaria Pisana, Pisa, 56126, Italy|Istituto Clinico Humanitas, Rozzano, 20089, Italy|Azienda Sanitaria Universitaria Friuli Centrale - P.O. S. Maria della Misericordia, Udine, 33100, Italy|Azienda Ospedaliera Universitaria Integrata Verona, Verona, 37134, Italy|Aichi Cancer Center, Nagoya-shi, Aichi, 464-8681, Japan|Chiba Cancer Center, Chiba-shi, Chiba, 260-8717, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, 277-8577, Japan|National Hospital Organization Shikoku Cancer Center, Matsuyama-Shi, Ehime, 791-0280, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka-shi, Fukuoka, 811-1395, Japan|Hokkaido University Hospital, Sapporo-Shi, HokkaidÃ´, 060-8648, Japan|Kanazawa University Hospital, Kanazawa-shi, Isikawa, 9208641, Japan|Kagoshima University Hospital, Kagoshima-shi, Kagoshima, 890-8520, Japan|Kanagawa Cancer Center, Yokohama-shi, Kanagawa, 241-8515, Japan|Kyoto University Hospital, Kyoto City, KyÃ´to, 606-8507, Japan|Mie University Hospital, Tsu-Shi, Mie, 514-8507, Japan|Tohoku University Hospital, Sendai-Shi, Miyagi, 980-8574, Japan|Niigata University Medical and Dental Hospital, Niigata-shi, Niigata, 951-8520, Japan|Osaka Prefectural Hospital Organization Osaka International Cancer Institute, Osaka-shi, Osaka, 541-8567, Japan|The University of Tokyo Hospital, Bunkyo-ku, Tokyo, 113-8655, Japan|National Cancer Center Hospital, Chuo-Ku, Tokyo, 104-0045, Japan|The Cancer Institute Hospital of Japanese Foundation For Cancer Research, Koto-Ku, Tokyo, 135-8550, Japan|Kyorin University Hospital, Mitaka-shi, Tokyo, 181-8611, Japan|Yamaguchi University Hospital, Ube-Shi, Yamaguchi, 755-8505, Japan|Osaka University Hospital, Suita-Shi, Ãsaka, 565-0871, Japan|CHA Bundang Medical Center, CHA University, Bundang-Gu, Seongnam-Si, Gyeonggi-do, 13496, Korea, Republic of|National Cancer Center, Ilsandong-gu, Goyang-si, Gyeonggi-do, 10408, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, 13620, Korea, Republic of|Pusan National University Hospital, Busan, 49241, Korea, Republic of|Korea University Anam Hospital, Seoul, 2841, Korea, Republic of|Seoul National University Hospital, Seoul, 3080, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, 3722, Korea, Republic of|Hanyang University Seoul Hospital, Seoul, 4763, Korea, Republic of|Asan Medical Center, Seoul, 5505, Korea, Republic of|Samsung Medical Center, Seoul, 6351, Korea, Republic of|Korea University Guro Hospital, Seoul, 8308, Korea, Republic of|Unidade Local de Saude de Almada-Seixal, E.P.E. - Hospital Garcia de Orta, Almada, 2805-267, Portugal|Unidade Local de Saude de Coimbra, EPE - Hospitais da Universidade de Coimbra, Coimbra, 3004-561, Portugal|Unidade Local de SaÃºde de SÃ£o JosÃ© - Hospital de Santo AntÃ³nio dos Capuchos, Lisboa, 1150-314, Portugal|Champalimaud Clinical Center, Lisboa, 1400-038, Portugal|Instituto PortuguÃªs de Oncologia Do Porto Francisco Gentil, EPE, Porto, 4200-072, Portugal|Hospital Oncologico, Puerto Rico Medical Center, Rio Piedras, 935, Puerto Rico|Spital Clinic Judetean de Urgenta Bihor, Oradea, Bihor, 410169, Romania|Centrul De Oncologie ""SF. Nectarie"" S.R.L., Craiova, Dolj, 200542, Romania|Institutul Clinic Fundeni, Bucharest, 22328, Romania|Centrul de Oncologie Euroclinic SRL, Iasi, 700106, Romania|University Clinical Center of Serbia, Clinic for Gastroenterohepatology, Belgrade, 11000, Serbia|Military Medical Academy, Clinic for Gastroenterology and Hepatology, Belgrade, 11040, Serbia|Oncology Institute of Vojvodina, Internal Oncology Clinic, Sremska Kamenica, 21204, Serbia|Complejo Hospitalario Universitario de Santiago -Hospital Clinico Universitario de Santiago, Santiago de Compostela, A Coruna, 15706, Spain|Vall d'Hebron Institute of Oncology/Hospital Universitari de Vall d'Hebron, Barcelona, 8035, Spain|Hospital Universitario Reina Sofia, Cordoba, 14004, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, 28040, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital Universitario La Paz, Madrid, 28048, Spain|Hospital Regional Universitario de Malaga, Malaga, 29010, Spain|Clinica Universidad de Navarra, Pamplona, 31008, Spain|Hospital Universitario Virgen Macarena, Sevilla, 41009, Spain|Hospital Universitario y Politecnico La Fe, Valencia, 46026, Spain|Hospital Universitario Miguel Servet, Zaragoza, 50009, Spain|Onkologiska mottagningen, Sahlgrenska Universitetssjukhuset, GÃ¶teborg, 413 45, Sweden|Cancerstudieenheten Huddinge, Karolinska Universitetssjukhuset Huddinge, Huddinge, 14186, Sweden|Onkologiska mottagningen, SkÃ¥nes Universitetssjukhus MalmÃ¶, MalmÃ¶, 205 02, Sweden|Kaohsiung Medical University - Chung-Ho Memorial Hospital, Kaohsiung, 807, Taiwan|Chang Gung Memorial Hospital Kaohsiung Branch of the Chang Gung Medical Foundation, Kaohsiung, 833, Taiwan|National Cheng Kung University Hospital, Tainan, 704, Taiwan|National Taiwan University Cancer Center, Taipei, 106, Taiwan|Chang Gung Memorial Hospital Linkou Branch of the Chang Gung Medical Foundation, Taoyuan, 333, Taiwan|Hacettepe University Cancer Institute, Ankara, Sihhiye, 5230, Turkey|Trakya University Faculty of Medicine, Edirne, 22030, Turkey|Mount Vernon Cancer Centre, London, England, HA 6 2RN, United Kingdom|NHS Foundation Trust Royal Marsden Hospital, London, England, SW3 6JJ, United Kingdom|The Christie NHS Foundation Trust, Manchester, England, M20 4BX, United Kingdom|Royal Marsden Hospital NHS Foundation Trust, Surrey, England, SM2 5PT, United Kingdom|Western General Hospital, Edinburgh Cancer Centre, Edinburgh, Scotland, EH4 2XU, United Kingdom",
NCT06835400,Oral Paclitaxel + Encequidar vs IV Paclitaxel in Treatment of HER2 Negative Metastatic Breast Cancer,https://clinicaltrials.gov/study/NCT06835400,,NOT_YET_RECRUITING,The current study is being conducted to find an optimal Oral Paclitaxel + Encequidar dose and regimen based on prior experience with oral paclitaxel (stage 1) and to compare that dose to an accepted dose and regimen of intravenous (IV) paclitaxel in subjects with metastatic breast cancer (stage 2).,NO,Metastatic Breast Cancer,DRUG: Paclitaxel Capsule|DRUG: IV Paclitaxel|DRUG: Encequidar tablet,"Stage 1: Confirmed Tumor Response, Confirmed tumor response based on BICR timepoint evaluations of CT scans using RECIST v1.1 criteria, 6 months|Stage 2: Confirmed Tumor Response, Confirmed tumor response based on BICR timepoint evaluations of CT scans using RECIST v1.1 criteria, 1 Year",,,Health Hope Pharma,,ALL,"ADULT, OLDER_ADULT",PHASE3,340,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2025-04,2028-04,2029-05,2025-02-19,,2025-02-19,,
NCT05514054,A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer,https://clinicaltrials.gov/study/NCT05514054,EMBER-4,RECRUITING,The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years.,NO,Breast Neoplasms,DRUG: Imlunestrant|DRUG: Tamoxifen|DRUG: Anastrozole|DRUG: Letrozole|DRUG: Exemestane,"Invasive Disease-Free Survival (IDFS), IDFS excluding second non-breast primary invasive cancers, Randomization to recurrence or death from any cause (up to 10 years)","Distant Recurrence-Free Survival (DRFS), DRFS, Randomization to Distant Recurrence or Death from Any Cause (up to 10 Years)|Overall Survival (OS), OS, Randomization to Death from Any Cause (up to 10 Years)|Pharmacokinetics (PK): Steady State Plasma Concentrations of Imlunestrant, PK: steady state plasma concentrations of imlunestrant, Year 1, Month 2 to Month 4|Change from Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core Questionnaire (EORTC QLQ-C30) Physical Functioning, The EORTC QLQ-C30 is a 30-question patient reported instrument used to assess multidimensional quality of life (QOL) in cancer patients. It consists of 15 domains: 1 global QOL scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). Physical functioning was measured by items 1 to 5. The sum score was linearly transformed to the range 0 - 100 as recommended by the EORTC (higher score is better)., Visit 1 Day 1 up to end of Year 5|Change from Baseline in the EORTC QLQ-C30 Role Functioning, The EORTC QLQ-C30 is a 30-question patient reported instrument used to assess the multidimensional QOL in cancer patients. It consists of 15 domains: 1 global QOL scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). Role functioning was measured by items 6 and 7. The sum score was linearly transformed to the range 0 - 100 as recommended by the EORTC (higher score is better)., Visit 1 Day 1 up to end of Year 5|Change from Baseline in the EORTC QLQ-C30 Global QOL, The EORTC QLQ-C30 is a 30-question patient reported instrument used to assess the multidimensional QOL in cancer patients. It consists of 15 domains: 1 global QOL scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). Global QOL was measured by items 29 and 30. The sum score was linearly transformed to the range 0 - 100 as recommended by the EORTC (higher score is better)., Visit 1 Day 1 up to end of Year 5|Proportion of Time on Study Treatment with High Overall Adverse Event Burden, FACT GP5 = Functional Assessment of Cancer Therapy - General Physical Well-being Item 5 (FACT GP5). High overall adverse event burden is defined as a score of 3 or 4 on a 5-point Likert scale. Higher scores represent higher symptom burden., Visit 1 Day 1 up to end of Year 5",,Eli Lilly and Company,,ALL,"ADULT, OLDER_ADULT",PHASE3,8000,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-10-04,2027-10,2032-03,2022-08-24,,2025-05-23,"USO - Southern Cancer Center, Daphne, Alabama, 36526, United States|Clearview Cancer Institute, Huntsville, Alabama, 35805, United States|Infirmary Cancer Care, Mobile, Alabama, 36607, United States|Banner MD Anderson Cancer Center, Gilbert, Arizona, 85234, United States|USO - Arizona Oncology Associates - HAL, Glendale, Arizona, 85308, United States|St. Joseph's Hospital and Medical Center, Phoenix, Arizona, 85004, United States|Mayo Clinic in Arizona - Phoenix, Phoenix, Arizona, 85054, United States|USO - Arizona Oncology Associates - HOPE, Tucson, Arizona, 85711, United States|The University of Arizona Cancer Center - North Campus, Tucson, Arizona, 85719, United States|Highlands Oncology Group, Springdale, Arkansas, 72762, United States|UCSF - John Muir Health Cancer Center Berkeley, Berkeley, California, 94702, United States|Washington Hospital Healthcare System, Fremont, California, 94538, United States|Chao Family Comprehensive Cancer Center and Ambulatory Care (CIACC) - Irvine, Irvine, California, 92612, United States|Loma Linda University Cancer Center, Loma Linda, California, 92350-1700, United States|Pacific Cancer Care, Monterey, California, 93940, United States|St. Joseph Hospital, Orange, California, 92868, United States|University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange, California, 92868, United States|University of California Davis (UC Davis) Comprehensive Cancer Center, Sacramento, California, 95817, United States|Kaiser Permanente San Diego Mission Road, San Diego, California, 92108, United States|Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, California, 94110, United States|UCSF Medical Center at Mission Bay, San Francisco, California, 94158, United States|Saint Joseph's Medical Center, Stockton, California, 95204, United States|Anschutz Cancer Pavilion, Aurora, Colorado, 80045, United States|UCHealth Memorial Hospital, Colorado Springs, Colorado, 80909, United States|UCHealth Harmony, Fort Collins, Colorado, 80528, United States|Banner MD Anderson Cancer Center at North Colorado Medical Center, Greeley, Colorado, 80631, United States|USO - Rocky Mountain Cancer Centers, Lakewood, Colorado, 80228, United States|Banner MD Anderson Cancer Center at McKee Medical Center, Loveland, Colorado, 80538, United States|Yale-New Haven Hospital, New Haven, Connecticut, 06510, United States|Georgetown University Medical Center, Washington, District of Columbia, 20007, United States|MedStar Washington Hospital Center, Washington, District of Columbia, 20010, United States|AdventHealth Altamonte Springs, Altamonte Springs, Florida, 32701, United States|Memorial Regional Hospital, Hollywood, Florida, 33021, United States|Millennium Oncology Research Clinic, Hollywood, Florida, 33024, United States|Mayo Clinic in Florida, Jacksonville, Florida, 32224, United States|Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, 33176, United States|USO - Cancer Care Centers of Brevard, Palm Bay, Florida, 32901, United States|USO - Woodlands Medical Specialists, Pensacola, Florida, 32503, United States|Miami Cancer Institute - Plantation, Plantation, Florida, 33324, United States|Tampa General Hospital, Tampa, Florida, 33606, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, 30322, United States|Northside Hospital, Atlanta, Georgia, 30342, United States|Summit Cancer Care, PC, Savannah, Georgia, 31405, United States|Kaiser Permanente Moanalua Medical Center, Honolulu, Hawaii, 96819, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, 96826, United States|Northwestern Memorial Hospital, Chicago, Illinois, 60611, United States|University of Illinois at Chicago, Chicago, Illinois, 60612, United States|Illinois Cancer Care, Peoria, Illinois, 61615, United States|Simmons Cancer Institute at SIU, Springfield, Illinois, 62702, United States|The University of Kansas Cancer Center - Westwood, Westwood, Kansas, 66205, United States|Ochsner Clinic Foundation, Covington, Louisiana, 70433, United States|Pontchartrain Cancer Center, Hammond, Louisiana, 70403, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, 70121, United States|Central Maine Medical Center, Lewiston, Maine, 04240, United States|York Hospital, York, Maine, 03909, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, 20889, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Mass General/North Shore Cancer Center, Danvers, Massachusetts, 01923, United States|Southcoast Centers for Cancer Care, Fairhaven, Massachusetts, 02719, United States|Dana-Farber Cancer Institute - Foxborough, Foxboro, Massachusetts, 02035, United States|Dana-Farber Cancer Institute - Merrimack Valley, Methuen, Massachusetts, 01844, United States|Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center, Milford, Massachusetts, 01757, United States|Mass General Cancer Center at Newton-Wellesley, Newton, Massachusetts, 02462, United States|Dana-Farber/Brigham and Women's Cancer Center - South Shore Hospital, South Weymouth, Massachusetts, 02190, United States|University of Massachusetts Medical School, Worcester, Massachusetts, 01655, United States|M Health Fairview Cancer Clinic -Edina, Edina, Minnesota, 55435, United States|USO - Minnesota Oncology Hematology, Minneapolis, Minnesota, 55404, United States|Allina Health Cancer Institute, Minneapolis, Minnesota, 55407, United States|Mayo Clinic in Rochester, Minnesota, Rochester, Minnesota, 55905, United States|University of Missouri Hospital, Columbia, Missouri, 65212, United States|Washington University, Saint Louis, Missouri, 63108, United States|Nebraska Methodist Hospital, Omaha, Nebraska, 68114, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, 03756, United States|Dana-Farber - New Hampshire Oncology/Hematology, Londonderry, New Hampshire, 03053, United States|MD Anderson Cancer Center at Cooper, Camden, New Jersey, 08103, United States|Astera Cancer Care, East Brunswick, New Jersey, 08816, United States|Regional Cancer Care Associates, Little Silver, New Jersey, 07739, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, 08901, United States|Capital Health Medical Center - Hopewell, Pennington, New Jersey, 08534, United States|New Mexico Oncology Hematology Consultants Ltd., Albuquerque, New Mexico, 87109, United States|University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, 87131, United States|USO - New York Oncology Hematology, Albany, New York, 12206, United States|Maimonides Cancer Center, Brooklyn, New York, 11220, United States|NYU Langone Health - Brooklyn, Brooklyn, New York, 11220, United States|R.J. Zuckerberg Cancer Center, Lake Success, New York, 11042, United States|Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola, New York, 11501, United States|Northern Westchester Hospital, Mount Kisco, New York, 10549, United States|Laura and Isaac Perlmutter Cancer Center, New York, New York, 10016, United States|NYC Health + Hospitals / Bellevue, New York, New York, 10016, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Queens Medical Associates, Queens, New York, 11374, United States|University of Rochester - Wilmot Cancer Institute, Rochester, New York, 14642, United States|Phelps Hospital, Sleepy Hollow, New York, 10591, United States|Staten Island University Hospital, Staten Island, New York, 10305, United States|Clinical Research Alliance, Westbury, New York, 11590, United States|Messino Cancer Center, Asheville, North Carolina, 28806, United States|Aultman Hospital, Canton, Ohio, 44710, United States|The Christ Hospital Cancer Center, Cincinnati, Ohio, 45219, United States|USO - Oncology Hematology Care, Cincinnati, Ohio, 45242, United States|The Mark H Zangmeister Center, Columbus, Ohio, 43219, United States|Mercy Health - St. Vincent Medical Center, Toledo, Ohio, 43608, United States|St. Elizabeth Youngstown Hospital, Youngstown, Ohio, 44501, United States|Good Samaritan Regional Medical Center, Corvallis, Oregon, 97330, United States|USO - Oncology Associates of Oregon, Eugene, Oregon, 97401, United States|Oregon Health and Science University, Portland, Oregon, 97239, United States|USO - Compass Oncology, Tigard, Oregon, 97223, United States|St. Luke's University Health Network, Bethlehem, Pennsylvania, 18015, United States|USO - Alliance Cancer Specialists, PC, Horsham, Pennsylvania, 19044, United States|Thomas Jefferson University - Clinical Research Institute, Philadelphia, Pennsylvania, 19107, United States|Thomas Jefferson University, Aria Jefferson Health, Philadelphia, Pennsylvania, 19114, United States|Asplundh Cancer Pavilion, Willow Grove, Pennsylvania, 19090, United States|Lifespan Cancer Institute, Providence, Rhode Island, 02906, United States|St Francis Cancer Center, Greenville, South Carolina, 29607, United States|The West Clinic, PLLC dba West Cancer Center, Germantown, Tennessee, 38138, United States|University of Tennessee Medical Center, Knoxville, Tennessee, 37920, United States|Sarah Cannon Research Institute, Nashville, Tennessee, 37203, United States|USO - Texas Oncology, Austin, Texas, 78731, United States|USO - Texas Oncology, Dallas, Texas, 75231, United States|USO - Texas Oncology, Dallas, Texas, 75246, United States|USO - Texas Oncology, Denison, Texas, 75020, United States|Texas Oncology - West Texas, El Paso, Texas, 79902, United States|William Beaumont Army Medical Center, El Paso, Texas, 79918, United States|USO - Texas Oncology, Flower Mound, Texas, 75028, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, 78234, United States|John Peter Smith Hospital, Fort Worth, Texas, 76104, United States|The Center for Cancer and Blood Disorders, Fort Worth, Texas, 76104, United States|USO - Texas Oncology, Fort Worth, Texas, 76104, United States|USO - Texas Oncology, Fredericksburg, Texas, 78624, United States|USO - Texas Oncology, McAllen, Texas, 78503, United States|USO - Texas Oncology, Plano, Texas, 75075, United States|Scott & White Hospital - Round Rock, Round Rock, Texas, 78665, United States|Mays Cancer Center, San Antonio, Texas, 78229, United States|Baylor Scott & White Medical Center - Temple, Temple, Texas, 76508, United States|US Oncology Research Network, The Woodlands, Texas, 77380, United States|USO - Texas Oncology, Webster, Texas, 77598, United States|University of Virginia Health System, Charlottesville, Virginia, 22908, United States|Inova Schar Cancer Institute, Fairfax, Virginia, 22031, United States|Fort Belvoir Community Hospital, Fort Belvoir, Virginia, 22060, United States|Bon Secours St. Francis Medical Center, Midlothian, Virginia, 23114, United States|USO - Virginia Oncology Associates, Norfolk, Virginia, 23502, United States|USO - Virginia Cancer Specialists, Reston, Virginia, 20190, United States|USO - Oncology & Hematology Associates of Southwest Virginia, Roanoke, Virginia, 24014, United States|Centro de OncologÃ­a e InvestigaciÃ³n de Buenos Aires, Berazategui, Buenos Aires, B1884BBF, Argentina|Instituto Alexander Fleming, Ciudad AutÃ³noma de Buenos Aires, Buenos Aires, C1426ANZ, Argentina|Instituto de Investigaciones ClÃ­nicas Mar del Plata, Mar del Plata, Buenos Aires, B7600FZO, Argentina|Go Centro Medico San NicolÃ¡s, San Nicolas, Buenos Aires, 2900, Argentina|CIPREC, Buenos Aires, Ciudad AutÃ³noma De Buenos Aires, C1061AAS, Argentina|Mautalen Salud e InvestigaciÃ³n, Buenos Aires, Ciudad AutÃ³noma De Buenos Aires, C1128AAF, Argentina|FundaciÃ³n Cenit Para La InvestigaciÃ³n En Neurociencias, Caba, Ciudad AutÃ³noma De Buenos Aires, 1125, Argentina|Clinica Adventista Belgrano, Caba, Ciudad AutÃ³noma De Buenos Aires, C1430EGF, Argentina|Centro Medico Privado CEMAIC, Capital, CÃ³rdoba, X5008HHW, Argentina|Instituto MÃ©dico RÃ­o Cuarto, RÃ­o Cuarto, CÃ³rdoba, 5800, Argentina|Clinica Viedma S. A, Viedma, RÃ­o Negro, R8500ACE, Argentina|Fundacion Estudios Clinicos, Rosario, Santa Fe, S2000DEJ, Argentina|Centro Medico San Roque, San Miguel de TucumÃ¡n, TucumÃ¡n, 4000, Argentina|Investigaciones Clinicas Moleculares (ICM), Buenos Aires, 1425, Argentina|Centro Oncologico Korben, Buenos Aires, 1426, Argentina|FundaciÃ³n Respirar, Buenos Aires, C1426ABP, Argentina|FundaciÃ³n CORI para la InvestigaciÃ³n y PrevenciÃ³n del CÃ¡ncer, La Rioja, F5300COE, Argentina|Fundacion Scherbovsky, Mendoza, 5500, Argentina|Centro Polivalente de Asistencia e Investigacion Clinica - CER San Juan, San Juan, 5400, Argentina|Instituto San Marcos, San Juan, 5400, Argentina|Coffs Harbour Health Campus, Coffs Harbour, New South Wales, 2450, Australia|St Vincent's Hospital, Darlinghurst, New South Wales, 2010, Australia|Gosford Hospital, Gosford, New South Wales, 2250, Australia|Liverpool Hospital, Liverpool, New South Wales, 2170, Australia|Lake Macquarie Private Hospital, Newcastle, New South Wales, 2290, Australia|Mater Hospital Sydney, Sydney, New South Wales, 2060, Australia|Royal Darwin Hospital, Tiwi, Northern Territory, 0810, Australia|Mackay Base Hospital, Mackay, Queensland, 4740, Australia|Gold Coast University Hospital, Southport, Queensland, 4215, Australia|The Townsville Hospital, Townsville, Queensland, 4814, Australia|Hervey Bay Hospital, Urraween, Queensland, 4655, Australia|The Queen Elizabeth Hospital, Woodville, South Australia, 5011, Australia|Royal Hobart Hospital, Hobart, Tasmania, 7000, Australia|Launceston General Hospital, Launceston, Tasmania, 7250, Australia|Ballarat Health Services, Ballarat Central, Victoria, 3350, Australia|Box Hill Hospital, Box Hill, Victoria, 3128, Australia|Monash Health, Clayton, Victoria, 3168, Australia|Barwon Health, Geelong, Victoria, 3220, Australia|St Vincent's Hospital, Melbourne, Victoria, 3065, Australia|Northern Hospital, Melbourne, Victoria, 3076, Australia|Maroondah Hospital, Melbourne, Victoria, 3135, Australia|Goulburn Valley Health, Shepparton, Victoria, 3630, Australia|Breast Cancer Research Centre-WA, Nedlands, Western Australia, 6009, Australia|Medizinische UniversitÃ¤t Graz, Graz, Steiermark, 8036, Austria|Private Practice - Dr. Hubalek, Schwaz, Tirol, 6130, Austria|Universitaetsklinikum Allgemeines Krankenhaus Wien, Vienna, Wien, 1090, Austria|Klinik Hietzing, Vienna, Wien, 1130, Austria|Uniklinikum Salzburg, Salzburg, 5020, Austria|Medizinische UniversitÃ¤t Wien, Wien, 1090, Austria|Institut Jules Bordet, Anderlecht, Bruxelles-Capitale, RÃ©gion De, 1070, Belgium|CHIREC - site delta, Auderghem, Bruxelles-Capitale, RÃ©gion De, 1160, Belgium|CHU Saint-Pierre, Brussels, Bruxelles-Capitale, RÃ©gion De, 1000, Belgium|Centre Hospitalier Universitaire Brugmann, Brussels, Bruxelles-Capitale, RÃ©gion De, 1020, Belgium|Cliniques universitaires Saint-Luc, Brussels, Bruxelles-Capitale, RÃ©gion De, 1200, Belgium|Grand HÃ´pital de Charleroi, Charleroi, Hainaut, 6000, Belgium|Groupe Jolimont, La LouviÃ¨re, Hainaut, 7100, Belgium|Jessa Ziekenhuis, Hasselt, Limburg, 3500, Belgium|AZ Nikolaas, Sint-Niklaas, Oost-Vlaanderen, B-9100, Belgium|UZ Leuven, Leuven, Vlaams-Brabant, 3000, Belgium|AZ Groeninge Campus Kennedylaan, Kortrijk, West-Vlaanderen, 8500, Belgium|AZ Oostende vzw, Oostende, West-Vlaanderen, 8400, Belgium|Jan Yperman ziekenhuis, Ieper, 8900, Belgium|Centre Hospitalier Universitaire de LiÃ¨ge - Domaine Universitaire du Sart Tilman, LiÃ¨ge, 4000, Belgium|CHU UCL Namur/Site Sainte Elisabeth, Namur, 5000, Belgium|Clinique Saint Pierre, Ottignies, 1340, Belgium|CHR Verviers - La Tourelle, Verviers, 4800, Belgium|Nucleo de Oncologia da Bahia, Salvador, Bahia, 40170-110, Brazil|Centro de Pesquisa ClÃ­nica do Instituto do CÃ¢ncer do CearÃ¡, Fortaleza, CearÃ¡, 60430230, Brazil|CEDOES, VitÃ³ria, EspÃ­rito Santo, 29055450, Brazil|Hospital AraÃºjo Jorge, GoiÃ¢nia, GoiÃ¡s, 74605070, Brazil|Oncocentro de Minas Gerais, Belo Horizonte, Minas Gerais, 30180-060, Brazil|Centro Integrado de Oncologia de Curitiba, Curitiba, ParanÃ¡, 80810050, Brazil|Hospital de Cancer de Londrina, Londrina, ParanÃ¡, 86015-520, Brazil|CTO - Centro de Tratamento OncolÃ³gico, Belem, ParÃ¡, 66063-495, Brazil|Multihemo, Recife, Pernambuco, 50070-170, Brazil|ONCOSITE - Centro de Pesquisa Clinica em Oncologia, Ijui, Rio Grande Do Sul, 98700-000, Brazil|Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, 90035001, Brazil|Centro Gaucho Integrado De Oncologia, Hematologia, Ensino E Pesquisa, Porto Alegre, Rio Grande Do Sul, 90110-270, Brazil|Hospital SÃ£o Lucas da PUCRS, Porto Alegre, Rio Grande Do Sul, 90610-000, Brazil|Hospital de Amor AmazÃ´nia, Porto Velho, RondÃ´nia, 76834-899, Brazil|FundaÃ§Ã£o Pio XII - Hospital de CÃ¢ncer de Barretos, Barretos, SÃ£o Paulo, 14784400, Brazil|Hospital de ClÃ­nicas de RibeirÃ£o Preto, RibeirÃ£o Preto, SÃ£o Paulo, 14051-140, Brazil|Faculdade de Medicina do ABC, Santo AndrÃ©, SÃ£o Paulo, 09060-650, Brazil|Hospital SÃ­rio LibanÃªs, Sao Paulo, SÃ£o Paulo, 01308-060, Brazil|Hospital BP, Sao Paulo, SÃ£o Paulo, 01321-001, Brazil|A. C. Camargo Cancer Center, Sao Paulo, SÃ£o Paulo, 01509-010, Brazil|Instituto D'Or de Pesquisa e Ensino (IDOR), Sao Paulo, SÃ£o Paulo, 04543-000, Brazil|Hospital Santa Paula, Sao Paulo, SÃ£o Paulo, 04556-100, Brazil|FundaÃ§Ã£o Faculdade Regional de Medicina de SÃ£o JosÃ© do Rio Preto, SÃ£o JosÃ© do Rio Preto, SÃ£o Paulo, 15090000, Brazil|Hospital Sirio Libanes, Brasilia, 70200-730, Brazil|Instituto Nacional de CÃ¢ncer - INCA, Rio de Janeiro, 20560121, Brazil|Hospital SÃ£o Lucas de Copacabana, Rio de Janeiro, 22061-080, Brazil|Centro de Tratamento de Tumores Botafogo para Oncoclinicas Rio de Janeiro SA, Rio de Janeiro, 22250-905, Brazil|Instituto de EducaÃ§Ã£o, Pesquisa e GestÃ£o em SaÃºde, Rio de Janeiro, 22793080, Brazil|IPITEC, SÃ£o Paulo, 01221-020, Brazil|NotreDame Intermedica Saude S.A, SÃ£o Paulo, 01229-010, Brazil|Instituto de Ensino e Pesquisa SÃ£o Lucas, SÃ£o Paulo, 01236030, Brazil|Icesp - Instituto Do CÃ¢ncer Do Estado de SÃ£o Paulo, SÃ£o Paulo, 01246-000, Brazil|ClÃ­nica de Pesquisa e Centro de Estudos em Ginecologia OncolÃ³gica e MamÃ¡ria LTDA, SÃ£o Paulo, 01317-001, Brazil|Hospital Alemao Oswaldo Cruz, SÃ£o Paulo, 01327-001, Brazil|NÃºcleo de Pesquisa ClÃ­nica da Rede SÃ£o Camilo, SÃ£o Paulo, 04014-002, Brazil|Instituto de AssistÃªncia MÃ©dica ao Servidor PÃºblico Estadual - IAMSPE/HSPE-FMO Conhecer Centro de Oncolog -T, SÃ£o Paulo, 04039-901, Brazil|Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta, T2N 5G2, Canada|BC Cancer Surrey, Surrey, British Columbia, V3V 1Z2, Canada|Victoria Hospital & Children's Hospital - London Health Sciences Centre, London, Ontario, N6A 5W9, Canada|Humber River Hospital, Toronto, Ontario, M3M 0B2, Canada|Sunnybrook Research Institute - Odette Cancer Centre, Toronto, Ontario, M4N 3M5, Canada|Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada|Centre intÃ©grÃ© universitaire de santÃ© et de services sociaux du Nord-de-l'Ãle-de-MontrÃ©al (CIUSSS NÃM) - H -T, Montreal, Quebec, H4J 1C5, Canada|Centre Hospitalier de l'UniversitÃ© de MontrÃ©al, MontrÃ©al, Quebec, H2X 3E4, Canada|CHU de QuÃ©bec-UniversitÃ© Laval, HÃ´pital du Saint-Sacrement, Quebec City, Quebec, G1S 4L8, Canada|Wannan Medical College Yijishan Hospital, Wuhu Shi, Anhui, 241001, China|Beijing Hospital, Beijing, Beijing, 100005, China|Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, 100021, China|Peking University People's Hospital, Beijing, Beijing, 100034, China|Beijing Friendship Hospital Affiliate of Capital University, Beijing, Beijing, 100050, China|Fujian Medical University Union Hospital-1 Bingfanglou, Fuzhou, Fujian, 350001, China|The 900th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army, Fuzhou, Fujian, 350025, China|Dongguan People's Hospital, Dongguan, Guangdong, 523059, China|Shunde Hospital of Southern Medical Univesity, Foshan, Guangdong, 528399, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, China|Guangdong Maternity and Child Health Care Hospital, Guangzhou, Guangdong, 511400, China|Huizhou Municipal Central Hospital, Huizhou, Guangdong, 516001, China|Jiangmen Center Hospital, Jiangmen, Guangdong, 529000, China|Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, 515041, China|ShenZhen People's Hospital, Shenzhen, Guangdong, 518020, China|Shenzhen Second People's Hospital, Shenzhen, Guangdong, 518035, China|Cancer Hospital Chinese Academy of Medical Sciences. Shenzhen Center, Shenzhen, Guangdong, China|Central Hospital of Guangdong Provincial Agricutural Reclamation, Zhanjiang, Guangdong, 524002, China|Hainan General Hospital, Haikou, Hainan, 570311, China|Affiliated Hospital of Hebei University, Baoding, Hebei, 071000, China|Anyang Cancer Hospital, Anyang, Henan, 455000, China|The First Affiliated Hospital of Henan University of Science &Technology, Luoyang, Henan, 471003, China|Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, 430022, China|Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, China|Hubei Cancer Hospital, Wuhan, Hubei, 430079, China|Xiangyang Central Hospital, Xiangyang, Hubei, 441021, China|The First People's Hospital of Changde City, Changde, Hunan, 415003, China|Xiangya Hospital Central South University, Changsha, Hunan, 410008, China|Hunan Cancer Hospital, Changsha, Hunan, 421000, China|The Central Hospital of Yongzhou - North Campus, Yongzhou, Hunan, 425000, China|The First People's Hospital of Yueyang, Yueyang, Hunan, 414000, China|First Huai'an Hospital Affiliated to Nanjing Medical University, Huai'an, Jiangsu, 223300, China|Jiangsu Province Hospital, Nanjing, Jiangsu, 210029, China|The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 215006, China|The Third Hospital of Nanchang, Nanchang, Jiangxi, 330009, China|The First Hospital of Jilin University, Changchun, Jilin, 130021, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China|Jinan Central Hospital, Jinan, Shandong, 250013, China|Jining Medical University - Affiliated Hospital, Jining, Shandong, 272100, China|Fudan University Shanghai Cancer Center, Shanghai, Shanghai, 200032, China|Yuncheng Central Hospital - Eastern Hospital, Yuncheng Shi, Shanxi, 044000, China|Sichuan Cancer hospital, Chengdu, Sichuan, 610042, China|Deyang City People's Hospital, Deyang, Sichuan, 618000, China|The Second People's Hospital of Neijiang, Neijiang, Sichuan, 641000, China|Tianjin Medical University Cancer Institute & Hospital, Tianjing, Tianjin, 300060, China|Xinjiang Medical University Cancer Hospital - Urumqi, Urumqi, Xinjiang, 830000, China|The First People's Hospital of Hangzhou, Hangzhou, Zhejiang, 310000, China|Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, 310014, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, 310022, China|Hwa Mei Hospital University of Chinese Academy of Sciences, Ningbo, Zhejiang, 315010, China|Ningbo First Hospital, Ningbo, Zhejiang, 315010, China|Nemocnice Horovice, Horovice, Beroun, 268 31, Czechia|Masarykuv onkologicky ustav, Brno, Brno-mÄsto, 656 53, Czechia|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Hradec KrÃ¡lovÃ©, 500 05, Czechia|Fakultni nemocnice Ostrava, Ostrava, MoravskoslezskÃ½ Kraj, 708 52, Czechia|Multiscan, Pardubice, PardubickÃ½ Kraj, 53203, Czechia|Fakultni Thomayerova nemocnice, Prague, Praha 4, 14059, Czechia|Fakultni nemocnice Motol, Praha, Praha 5, 150 06, Czechia|Fakultni nemocnice Bulovka, Prague, Praha 8, 180 81, Czechia|Institut BergoniÃ© - Centre RÃ©gional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest, Bordeaux, Aquitaine, 33076, France|Polyclinique De Blois, La ChaussÃ©e-Saint-Victor, Centre, 41260, France|Groupe Hospitalier La Rochelle-RÃ©-Aunis - HÃ´pital Saint Louis, La Rochelle, Charente-Maritime, 17019, France|CHU BesanÃ§on, BesanÃ§on, Doubs, 25000, France|CHRU de Brest, Brest, FinistÃ¨re, 29609, France|Clinique Francois Chenieux, Limoges, Haute-Vienne, 87039, France|Institut Curie - site Saint-Cloud, Saint-Cloud, Hauts-de-Seine, 92210, France|Chu Grenoble Alpes, La Tronche, IsÃ¨re, 38700, France|Centre Hospitalier Intercommunal de Mont-de-Marsan et du Pays des Sources, Mont-de-Marsan, Landes, 40024, France|Centre de CancÃ©rologie du Grand Montpellier, Montpellier, Languedoc-Roussillon, 34070, France|Institut de CancÃ©rologie de l'Ouest, Saint Herblain, Loire-Atlantique, 44805, France|Institut de CancÃ©rologie de Lorraine Alexis Vautrin, Vandoeuvre-lÃ¨s-Nancy, Lorraine, 54519, France|Institut Jean Godinot, Reims, Marne, 51726, France|Polyclinique de Gentilly, Nancy, Meurthe-et-Moselle, 54100, France|Centre Hospitalier RÃ©gional Metz Thionville - HÃ´pital de Mercy, Metz, Moselle, 57085, France|Clinique Victor Hugo Le Mans, Le Mans, Pays-de-la-Loire, 72000, France|Centre Hospitalier de la CÃ´te Basque, Bayonne, PyrÃ©nÃ©es-Atlantiques, 64109, France|Centre Hospitalier de Pau, Pau, PyrÃ©nÃ©es-Atlantiques, 64000, France|Centre Catalan d'Oncologie, Perpignan, PyrÃ©nÃ©es-Orientales, 66000, France|Hopital Prive Jean Mermoz, Lyon, RhÃ´ne-Alpes, 69008, France|Sainte Catherine Institut du Cancer Avignon Provence, Avignon, Vaucluse, 84918, France|CHD Vendee, La Roche-sur-Yon, VendÃ©e, 85000, France|Centre Hospitalier Universitaire de Poitiers, Poitiers, Vienne, 86021, France|Pole SantÃ© RÃ©publique, Clermont-Ferrand, 63050, France|Centre Antoine-Lacassagne, Nice, 06189, France|HÃ´pital Saint-Louis, Paris, 75010, France|HÃ´pital EuropÃ©en Georges Pompidou, Paris, 75015, France|Groupe Hospitalier Diaconesses Croix Saint Simon, Paris, 75020, France|Institut Curie, Paris, 75248, France|HÃ´pital Tenon, Paris, 75970, France|Centre Hospitalier PrivÃ© Saint-GrÃ©goire, Saint-GrÃ©goire, 35768, France|Centre de cancÃ©rologie des DentelliÃ¨res, Valenciennes, 59300, France|Henri Mondor Hospital, CrÃ©teil, Ãle-de-France, France|Groupe hospitalier Paris saint Joseph, Paris, Ãle-de-France, 75014, France|Universitaetsklinikum Freiburg, Freiburg im Breisgau, Baden-WÃ¼rttemberg, 79106, Germany|Private Practice - Dr. Helmut Oettle und Prof.Dr.med. Frank Mayer, Friedrichshafen, Baden-WÃ¼rttemberg, 88045, Germany|UniversitÃ¤tsmedizin Mannheim, Mannheim, Baden-WÃ¼rttemberg, 68167, Germany|Robert-Bosch-Krankenhaus, Stuttgart, Baden-WÃ¼rttemberg, 70376, Germany|Universitaetsklinikum Tuebingen, TÃ¼bingen, Baden-WÃ¼rttemberg, 72076, Germany|Universitaetsklinikum Ulm, Ulm, Baden-WÃ¼rttemberg, 89075, Germany|Gemeinschaftspraxis hop-augsburg, Augsburg, Bayern, 86150, Germany|Universitaetsklinikum Augsburg, Augsburg, Bayern, 86156, Germany|Onkologiezentrum DonauwÃ¶rth, DonauwÃ¶rth, Bayern, 86609, Germany|Universitaetsklinikum Erlangen, Erlangen, Bayern, 91054, Germany|Klinikverbund AllgÃ¤u gGmbH, Kempten, Bayern, 87439, Germany|Klinikum der Ludwig-Maximilians-Universitaet Muenchen, MÃ¼nchen, Bayern, 80336, Germany|Klinikum Ernst von Bergmann, Potsdam, Brandenburg, 14467, Germany|Agaplesion Markus Krankenhaus, Frankfurt, Hessen, 60431, Germany|Helios HSK Wiesbaden, Wiesbaden, Hessen, 65199, Germany|HELIOS Kliniken Schwerin, Schwerin, Mecklenburg-Vorpommern, 19055, Germany|Marienhospital Bottrop, Bottrop, Nordrhein-Westfalen, 46236, Germany|St.-Johannes-Hospital Dortmund, Dortmund, Nordrhein-Westfalen, 44137, Germany|MVZ Medical Center DÃ¼sseldorf GmbH, DÃ¼sseldorf, Nordrhein-Westfalen, 40235, Germany|Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Essen, Nordrhein-Westfalen, 45136, Germany|St. Anna Hospital, Herne, Nordrhein-Westfalen, 44649, Germany|Zentrum fuer ambulante gynaekologische Onkologie (ZAGO), Krefeld, Nordrhein-Westfalen, 47805, Germany|Universitaetsklinikum Koeln, KÃ¶ln, Nordrhein-Westfalen, 50937, Germany|Onkologisch-hÃ¤matologisches Forschungsinstitut am Habsburgring, Mayen, Rheinland-Pfalz, 56727, Germany|Klinikum Mutterhaus der BorromÃ¤erinnen, Trier, Rheinland-Pfalz, 54290, Germany|Universitaetsklinikum des Saarlandes, Homburg, Saarland, 66421, Germany|StÃ¤dtisches Klinikum Dessau, Dessau, Sachsen-Anhalt, 06847, Germany|Universitaetsklinikum Schleswig-Holstein Campus Kiel, Kiel, Schleswig-Holstein, 24105, Germany|SRH Wald-Klinikum Gera, Gera, ThÃ¼ringen, 07548, Germany|SRH Zentralklinikum Suhl, Suhl, ThÃ¼ringen, 98527, Germany|Praxisklinik Krebsheilkunde fur Frauen, Berlin, 10367, Germany|Onkologische Schwerpunktpraxis Kurfuerstendamm, Berlin, 10707, Germany|Helios Klinikum Berlin-Buch, Berlin, 13125, Germany|OSP GÃ¶ttingen, Goettingen, 37073, Germany|Olympion General Clinic, Patras, Achaá¸¯a, 26443, Greece|University Hospital of Patras, Patras, Achaá¸¯a, 26504, Greece|Iaso Private General Obstetrics Gynecological & Pediatric Clinic Diagnostic Therapeutic & Research Center -T, Athens, AttikÃ­ (Region), 151 23, Greece|Agios Savvas Regional Cancer Hospital, Athens, AttikÃ­, 115 22, Greece|Alexandra Hospital, Athens, AttikÃ­, 115 28, Greece|IASO Obstetrics - Gynecology Clinic, Athens, AttikÃ­, 151 23, Greece|Attikon General University Hospital, Chaidari, AttikÃ­, 12462, Greece|General Oncology Hospital of Kifissia ""Agioi Anargiroi"", Nea Kifissia, AttikÃ­, 145 64, Greece|University Hospital of Ioannina, Ioannina, IoÃ¡nnina, 455 00, Greece|University General Hospital of Heraklion, Heraklion, IrakleÃ­o, 711 10, Greece|BioClinic Thessaloniki, Thessaloniki, KentrikÃ­ MakedonÃ­a, 546 22, Greece|Agios Loukas Clinic, Thessaloniki, KentrikÃ­ MakedonÃ­a, 552 36, Greece|Euromedica General Clinic of Thessaloniki, Thessaloniki, ThessalonÃ­ki, 546 45, Greece|European Interbalkan Medical Center, Thessaloniki, ThessalonÃ­ki, 570 01, Greece|University General Hospital of Larissa, Larissa, ThessalÃ­a, 41110, Greece|Queen Mary Hospital, Hksar, Hong Kong|Bacs-Kiskun Megyei Korhaz, KecskemÃ©t, BÃ¡cs-Kiskun, 6000, Hungary|Szabolcs SzatmÃ¡r Bereg VÃ¡rmegyei OktatÃ³kÃ³rhÃ¡z, Nyiregyhaza, Szabolcs-SzatmÃ¡r-Bereg, 4400, Hungary|OrszÃ¡gos OnkolÃ³giai IntÃ©zet, Budapest, 1122, Hungary|Uzsoki Utcai KÃ³rhÃ¡z, Budapest, 1145, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, 4032, Hungary|Mahatma Gandhi Cancer Hospital and Research Institute, Visakhapatnam, Andhra Pradesh, 530017, India|Delhi State Cancer Institute, New Delhi, Delhi, 110095, India|Hemato Oncology Clinic, Ahmedabad, Gujarat, 380054, India|KD Hospital, Ahmedabad, Gujarat, 382421, India|Medstar Speciality Hospital, Bangalore, Karnataka, 560092, India|KLES Dr. Prabhakar Kore Hospital & M.R.C, Belagavi, Karnataka, 590010, India|Regional Cancer Centre - Thiruvananthapuram, Thiruvananthapuram, Kerala, 695011, India|Krishna Institute of Medical Sciences - Karad, Karad, Maharashtra, 415539, India|Kolhapur Cancer Centre Private Limited, Kolhapur, Maharashtra, 416234, India|Tata Memorial Hospital, Mumbai, Maharashtra, 400012, India|Rashtrasant Tukdoji Regional Cancer Hospital, Nagpur, Maharashtra, 440027, India|Grant Medical Foundation - Ruby Hall Clinic, Pune, Maharashtra, 411001, India|Lifepoint Multispeciality Hospital, Pune, Maharashtra, 411057, India|All India Institute of Medical Sciences, Bhubaneswar, Odisha, 751019, India|Cancer Institute (WIA), Chennai, Tamil Nadu, 600036, India|Nizam's Institute of Medical Sciences, Hyderabad, Telangana, 500082, India|Regency Hospital, Kanpur, Uttar Pradesh, 208005, India|Postgraduate Institute of Medical Education & Research, Chandigarh, 160012, India|Galway University Hospital, Galway, Connaught, H91 YR71, Ireland|Bon Secours Cork Hospital, Cork, T12 DV56, Ireland|Cork University Hospital, Cork, T12 E8YV, Ireland|St. Vincent's University Hospital, Dublin, D04 N2E0, Ireland|St. James's Hospital, Dublin, D08 E9P6, Ireland|UCD School of Medicine Beacon Hospital, Dublin, D18 AK68, Ireland|Beaumont Hospital, Dublin, Dublin, D9, Ireland|Sligo General Hospital, Sligo, F91 H684, Ireland|Waterford Regional Hospital, Waterford, X91 ER8E, Ireland|Meir Medical Center, Kfar Saba, HaMerkaz, 4428164, Israel|Rabin Medical Center, Petah Tikva, HaMerkaz, 4941492, Israel|Sheba Medical Center, Ramat Gan, HaMerkaz, 5265601, Israel|Yitzhak Shamir Medical Center, Zerifin, HaMerkaz, 70300, Israel|Sourasky Medical Center, Tel Aviv, Tell AbÄ«b, 6423906, Israel|Shaare Zedek Medical Center, Jerusalem, Yerushalayim, 9013102, Israel|Hadassah Medical Center, Jerusalem, Yerushalayim, 9112001, Israel|Carmel Hospital, Haifa, á¸¤eifÄ, 3436212, Israel|University of Naples Federico II, Naples, Campania, 80100, Italy|Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, 80131, Italy|Humanitas Istituto Clinico Catanese, Misterbianco, Catania, 95045, Italy|IRCCS - AOU di Bologna, Bologna, Emilia-Romagna, 40138, Italy|Ospedale San Martino, Genova, Liguria, 16132, Italy|Ospedale San Gerardo-ASST Monza, Monza, Lombardia, 20900, Italy|Humanitas, Rozzano, Milano, 20089, Italy|Istituto Nazionale Tumori Regina Elena, Rome, Roma, 00144, Italy|Ospedale San Giovanni Moscati, Statte, Taranto, 74100, Italy|Istituto di Candiolo IRCCS - Fondazione del Piemonte per l'Oncologia, Candiolo, Torino, 10060, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Toscana, 50134, Italy|Aou Ospedali Riuniti Umberto I, Ancona, 60126, Italy|Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, 24127, Italy|Ospedale Antonio Perrino, Brindisi, 72100, Italy|Ospedale Generale Provinciale Macerata, Macerata, 62100, Italy|Istituto Europeo di Oncologia IRCCS, Milano, 20141, Italy|Azienda Ospedaliero Universitaria, Modena, 41125, Italy|Istituto Oncologico Veneto IRCCS, Padova, 35128, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, 43126, Italy|Azienda Ospedaliera Santa Maria Terni, Terni, 05100, Italy|Nagoya University Hospital, Nagoya, Aichi, 466-8560, Japan|Nagoya City University Hospital, Nagoya, Aichi, 467-8602, Japan|Chiba cancer center, Chiba-shi, Chiba, 260-8717, Japan|Kameda Clinic, Kamogawa, Chiba, 296-0041, Japan|National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, 791-0280, Japan|Gunma Prefectural Cancer Center, Otashi, Gunma, 373-8550, Japan|National Hospital Organization Takasaki General Medical Centar, Takasaki, Gunma, 370-0829, Japan|Fukuyama City Hospital, Fukuyama, Hiroshima, 721-8511, Japan|National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, 003-0804, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, 060-8648, Japan|Hyogo Medical University Hospital, Nishinomiya, Hyogo, 663-8501, Japan|Tsukuba University Hospital, Tsukuba, Ibaraki, 305-8576, Japan|Ishikawa Prefectural Central Hospital, Kanazawa, Ishikawa, 920-8530, Japan|Kanazawa Medical University Hospital, Uchinada, Ishikawa, 920-0265, Japan|Iwate Medical University Hospital, Yahaba-cho, Shiwa-gun, Iwate, 028-3695, Japan|St. Marianna University Hospital, Kawasaki, Kanagawa, 216-8511, Japan|Kitasato University Hospital, Sagamihara, Kanagawa, 252-0375, Japan|Yokohama City University Medical Center, Yokohama, Kanagawa, 232-0024, Japan|Kanagawa cancer center, Yokohama, Kanagawa, 2418515, Japan|Tohoku University Hospital, Sendai-shi, Miyagi, 980-8574, Japan|Shinshu University Hospital, Matsumoto, Nagano, 390-8621, Japan|Niigata Cancer Center Hospital, Niigata-shi, Niigata, 951-8566, Japan|Naha Nishi Clinic, Naha, Okinawa, 901-0154, Japan|Kansai Medical University Hospital, Hirakata, Osaka, 573-1191, Japan|Shimane University Hospital, Izumo, Shimane, 693-0021, Japan|Tochigi Cancer Center, Utsunomiya, Tochigi, 320-0834, Japan|Juntendo University Hospital, Bunkyo-ku, Tokyo, 113-8431, Japan|St. Luke's International Hospital, Chuo-ku, Tokyo, 104-8560, Japan|Tokai University Hachioji Hospital, Hachioji-shi, Tokyo, 192-0032, Japan|Japanese Foundation for Cancer Research, Koto, Tokyo, 135-8550, Japan|Showa University Hospital, Shinagawa, Tokyo, 142-8555, Japan|National Center for Global Health and Medicine, Shinjyuku-ku, Tokyo, 162-8655, Japan|Chiba University Hospital, Chiba, 260-8677, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, 811-1395, Japan|Fukushima Medical University, Fukushima, 960-1295, Japan|Gifu University Hospital, Gifu, 501-1194, Japan|Hiroshima City Hospital, Hiroshima, 730-8518, Japan|Hiroshima University Hospital, Hiroshima, 734-8551, Japan|Sagara Hospital, Kagoshima, 892-0833, Japan|Kumamoto Breast Surgical Hospital, Kumamoto, 860-0812, Japan|Kumamoto Shinto General Hospital, Kumamoto, 862-8655, Japan|University Hospital,Kyoto Prefectural University of Medicine, Kyoto, 602-8566, Japan|Kyoto University Hospital, Kyoto, 606-8507, Japan|Miyazaki Prefectural Miyazaki Hospital, Miyazaki, 880-8510, Japan|Okayama University Hospital, Okayama, 700-8558, Japan|Nakagami Hospital Okinawa, Okinawa, 904-2195, Japan|National Hospital Organization - Osaka National Hospital - Institute For Clinical Research, Osaka, 540-0006, Japan|Saitama Red Cross Hospital, Saitama, 330-8553, Japan|Shizuoka General Hospital, Shizuoka, 420-8527, Japan|Tokushima University Hospital, Tokushima, 770-8503, Japan|Chungbuk National University Hospital, Cheongju-si, Chungcheongbuk-do [Chungbuk], 28644, Korea, Republic of|Soon Chun Hyang University Cheonan Hospital, Cheonan-si, Chungcheongnam-do [Chungnam], 31151, Korea, Republic of|Inha University Hospital, Incheon, Incheon-gwangyeoksi [Incheon], 22332, Korea, Republic of|Gachon University Gil Medical Center, Namdong-gu, Incheon-gwangyeoksi [Incheon], 21565, Korea, Republic of|Chonnam National University Hwasun Hospital, Hwasun-gun, Jeonranamdo, 58128, Korea, Republic of|National Cancer Center, Goyang-si, KyÇnggi-do, 10408, Korea, Republic of|CHA Bundang Medical Center, CHA University, Seongnam-si, KyÇnggi-do, 13496, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, KyÇnggi-do, 13620, Korea, Republic of|Ajou University Hospital, Suwon-si, KyÇnggi-do, 16499, Korea, Republic of|Yeungnam Univeristy Medical Center, Gyeongsan-si, KyÇngsangbuk-do, 42415, Korea, Republic of|Dongnam Institute of Radiological and Medical Sciences, Busan, Pusan-KwangyÇkshi, 46033, Korea, Republic of|Korea University Anam Hospital, Seoul, Seoul-teukbyeolsi [Seoul], 02841, Korea, Republic of|Seoul National University Hospital, Seoul, Seoul-teukbyeolsi [Seoul], 03080, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Seoul-teukbyeolsi [Seoul], 03722, Korea, Republic of|Asan Medical Center, Seoul, Seoul-teukbyeolsi [Seoul], 05505, Korea, Republic of|Gangnam Severance Hospital, Seoul, Seoul-teukbyeolsi [Seoul], 06273, Korea, Republic of|Samsung Medical Center, Seoul, Seoul-teukbyeolsi [Seoul], 06351, Korea, Republic of|The Catholic Univ. of Korea Seoul St. Mary's Hospital, Seoul, Seoul-teukbyeolsi [Seoul], 06591, Korea, Republic of|Korea University Guro Hospital, Seoul, Seoul-teukbyeolsi [Seoul], 08308, Korea, Republic of|Kyungpook National University Chilgok Hospital, Daegu, Taegu-KwangyÇkshi, 41404, Korea, Republic of|Ulsan University Hospital, Ulsan, Ulsan-KwangyÇkshi, 44033, Korea, Republic of|Hospital Angeles, Tijuana, Baja California, 22010, Mexico|Centro de Estudios Y Prevencion Del Cancer, Tuxtla Gutierrez, Chiapas, 29038, Mexico|CENEIT OncolÃ³gicos. Centro Especializado en InvestigaciÃ³n y Tratamientos OncolÃ³gicos, Mexico City, Distrito Federal, 03100, Mexico|Grupo Medico Camino Sc, Mexico City, Distrito Federal, 03310, Mexico|Preparaciones Oncologicas, LeÃ³n, Guanajuato, 37178, Mexico|CIO - Centro de Inmuno-OncologÃ­a de Occidente, Guadalajara, Jalisco, 44630, Mexico|Clinica de Investigacion en Reumatologia y Obesidad S. C., Guadalajara, Jalisco, 44650, Mexico|Axis Heilsa S. de R.L. de C.V., Monterrey, Nuevo LeÃ³n, 64040, Mexico|Centro Regiomontano de InvestigaciÃ³n, Monterrey, Nuevo LeÃ³n, 64060, Mexico|Filios Alta Medicina, Monterrey, Nuevo LeÃ³n, 64460, Mexico|Centro Medico Zambrano Hellion, San Pedro Garza Garcia, Nuevo LeÃ³n, 66278, Mexico|Oncologico Potosino, S.C., San Luis Potosi, San Luis PotosÃ­, 78209, Mexico|Centro de Estudios de Investigacion Metabolicos y Cardiovasculares, Ciudad Madero, Tamaulipas, 89440, Mexico|Scientia Investigacion Clinica S.C., Chihuahua, 31207, Mexico|Oaxaca Site Management Organization, Oaxaca, 68000, Mexico|Centro de Investigacion Clinica de Oaxaca, Oaxaca, 68020, Mexico|Unidad MÃ©dica Onco-hematolÃ³gica, Puebla, 72424, Mexico|PanAmerican Clinical Research - QuerÃ©taro - Avenida Antea, QuerÃ©taro, 76100, Mexico|Centro Oncologico Estatal ISSEMyM ( COEI ), Toluca, 50180, Mexico|Wilhelmina Ziekenhuis Assen, Assen, Drenthe, 9401 RK, Netherlands|Maastricht UMC+, Maastricht, Limburg, 6229 HX, Netherlands|VieCuri Medisch Centrum, locatie Venlo, Venlo, Limburg, 5912 BL, Netherlands|Amphia Ziekenhuis, locatie Breda Molengracht, Breda, Noord-Brabant, 4818 CK, Netherlands|Spaarne Gasthuis - Hoofddorp, Hoofddorp, Noord-Holland, 2134 TM, Netherlands|Zaans Medisch Centrum, Zaandam, Noord-Holland, 1502 DV, Netherlands|Deventer Ziekenhuis, Deventer, Overijssel, 7416 SE, Netherlands|Ziekenhuisgroep Twente, locatie Almelo, Hengelo, Overijssel, 7555 DL Hengelo, Netherlands|Reinier de Graaf Ziekenhuis, locatie Delft, Delft, Zuid-Holland, 2625 AD, Netherlands|Haga Ziekenhuis locatie Leyweg, Den Haag, Zuid-Holland, 2545 AA, Netherlands|Albert Schweitzer Ziekenhuis, locatie Dordwijk, Dordrecht, Zuid-Holland, 3318 AT, Netherlands|MICS Centrum Medyczne Torun, Torun, Kujawsko-pomorskie, 87-100, Poland|Mazowiecki Szpital WojewÃ³dzki w Siedlcach, Siedlce, Mazowieckie, 08-110, Poland|Luxmed Onkologia sp. z o. o., Warszawa, Mazowieckie, 01-748, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie, Warszawa, Mazowieckie, 02-781, Poland|FORMED2, Oswiecim, MaÅopolskie, 32-600, Poland|Opolskie Centrum Onkologii w Opolu im. prof. Tadeusza Koszarowskiego, Opole, Opolskie, 45-061, Poland|Szpitale Pomorskie Sp. z o. o., Gdynia, Pomorskie, 81-519, Poland|Szpital WojewÃ³dzki im. Mikoaja Kopernika w Koszalinie, Koszalin, Zachodniopomorskie, 75-581, Poland|Salve Medica, Lodz, ÅÃ³dzkie, 91-211, Poland|Champalimaud Foundation, Lisbon, Lisboa, 1400-038, Portugal|Centro Hospitalar UniversitÃ¡rio Lisboa Norte, E.P.E. - Hospital de Santa Maria, Lisbon, Lisboa, 1649-035, Portugal|Centro Hospitalar de Vila Nova de Gaia/Espinho - Unidade I, Vila Nova de Gaia, Porto, 4434-502, Portugal|Hopital Garcia de Orta, Almada, SetÃºbal, 2805-267, Portugal|Hospital da Luz Lisboa, Lisboa, 1500-650, Portugal|Hospital Beatriz Ãngelo, Lisboa, 2674-514, Portugal|C.M.D.T.A. Neomed, Brasov, BraÈov, 500283, Romania|Onco Medint Srl, Bucharest, BucureÈti, 010644, Romania|Lotus-Med, Bucharest, BucureÈti, 012292, Romania|SC Memorial Healthcare International SRL, Bucharest, BucureÈti, 013812, Romania|Institutul Oncologic Cluj, Cluj-Napoca, Cluj, 400015, Romania|Ovidius Clinical Hospital OCH, Ovidiu, ConstanÈa, 905900, Romania|Centrul de Oncologie ""SfÃ¢ntul Nectarie"", Craiova, Dolj, 200542, Romania|Radiology Therapeutic Center, Otopeni, Ilfov, 075100, Romania|S C Oncocenter Oncologie Clinica S R L, TimiÈoara, TimiÈ, 300166, Romania|Spitalul Clinic ColÈea, BucureÈti, 030171, Romania|Gral Medical Diagnostic Center, BucureÈti, 031422, Romania|National Cancer Centre Singapore, Singapore, Central Singapore, 168583, Singapore|Raffles Hospital, Singapore, Central Singapore, 188770, Singapore|Onkologicky Ustav sv. Alzbety, Bratislava, BratislavskÃ½ Kraj, 812 50, Slovakia|Narodny onkologicky ustav, Bratislava, BratislavskÃ½ Kraj, 833 10, Slovakia|CHUAC-Hospital Teresa Herrera, A CoruÃ±a, A CoruÃ±a [La CoruÃ±a], 15006, Spain|Hospital Universitario TorrecÃ¡rdenas, Almeria, AndalucÃ­a, 04009, Spain|Hospital Mateu Orfila, Mahon, Balears [Baleares], 07703, Spain|Hospital Universitari Son Espases, Palma, Balears [Baleares], 07120, Spain|Parc de Salut Mar - Hospital del Mar, Barcelona, Barcelona [Barcelona], 08003, Spain|Hospital Quiron Barcelona, Barcelona, Barcelona [Barcelona], 08023, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Barcelona [Barcelona], 08035, Spain|Hospital Universitari General de Catalunya, Sant Cugat del VallÃ¨s, Barcelona [Barcelona], 08915, Spain|Hospital Universitari Dexeus, Barcelona, Catalunya [CataluÃ±a], 08028, Spain|Hospital ClÃ­nic de Barcelona, Barcelona, Catalunya [CataluÃ±a], 08036, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Catalunya [CataluÃ±a], 08041, Spain|Hospital San Pedro de AlcÃ¡ntara, CÃ¡ceres, Extremadura, 10003, Spain|Complejo Hospitalario de JaÃ©n, Jaen, JaÃ©n, 23007, Spain|Hospital San Pedro, LogroÃ±o, La Rioja, 26006, Spain|Hospital Universitario Arnau de Vilanova de Lleida, Lleida, Lleida [LÃ©rida], 25198, Spain|Hospital Lucus Augusti, Lugo, Lugo [Lugo], 27003, Spain|Hospital Universitario Getafe, Getafe, Madrid, Comunidad De, 28905, Spain|Hospital General Universitario Gregorio MaraÃ±on, Madrid, Madrid, Comunidad De, 28009, Spain|Hospital Universitario Infanta Leonor, Madrid, Madrid, Comunidad De, 28031, Spain|Hospital Universitario RamÃ³n y Cajal, Madrid, Madrid, Comunidad De, 28034, Spain|Hospital Universitario 12 de Octubre, Madrid, Madrid, Comunidad De, 28041, Spain|Hospital Universitario La Paz, Madrid, Madrid, Comunidad De, 28046, Spain|Hospital ClÃ­nico Universitario Virgen de la Arrixaca, El Palmar, Murcia, Murcia, RegiÃ³n De, 30120, Spain|H.R.U MÃ¡laga - Hospital Materno-infantil, Malaga, MÃ¡laga, 29011, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, 31009, Spain|Osi Bilbao-Basurto, Bilbao, PaÃ­s Vasco, 48013, Spain|Hospital Universitario de Canarias, La Laguna, Santa Cruz De Tenerife, 38320, Spain|Hospital Universitari Sant Joan de Reus, Reus, Tarragona [Tarragona], 43204, Spain|Hospital Clinico de Valencia, Valencia, Valenciana, Comunitat, 46010, Spain|Hospital QuirÃ³nsalud Valencia, Valencia, ValÃ¨ncia, 46010, Spain|Hospital General Universitario de Alicante, Alicante, 03010, Spain|Hospital Infanta Cristina, Badajoz, 06006, Spain|Hospital Universitario de Burgos, Burgos, 09006, Spain|Hospital Universitario San Cecilio, Granada, 18016, Spain|Hospital La Princesa, Madrid, 28006, Spain|Hospital Beata MarÃ­a Ana, Madrid, 28007, Spain|Hospital Ruber Internacional, Madrid, 28034, Spain|Hospital Clinico San Carlos, Madrid, 28040, Spain|Hospital Vithas MÃ¡laga, MÃ¡laga, 29016, Spain|Hospital Universitario Nuestra SeÃ±ora de Candelaria, Santa Cruz de Tenerife, 38010, Spain|Hospital General de Segovia, Segovia, 47002, Spain|Hospital Universitario Virgen Macarena, Sevilla, 41009, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, 41013, Spain|Hospital Universitario de Toledo, Toledo, 45007, Spain|Hospital ClÃ­nico Universitario de Valladolid, Valladolid, 47003, Spain|Hospital ClÃ­nico Universitario Lozano Blesa, Zaragoza, 50009, Spain|Changhua Christian Hospital, Changhua County, Changhua, 50006, Taiwan|Chi Mei Hospital - Liouying Branch, Tainan City, Tainan, 73657, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, 807, Taiwan|Taipei Tzu Chi General Hospital, New Taipei City, 231, Taiwan|Taichung Veterans General Hospital, Taichung, 407219, Taiwan|National Cheng Kung University Hospital, Tainan, 704, Taiwan|National Taiwan University Hospital, Taipei, 10002, Taiwan|Mackay Memorial Hospital, Taipei, 10449, Taiwan|Taipei Veterans General Hospital, Taipei, 11217, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center, Taipei, 112, Taiwan|Chang Gung Medical Foundation-Linkou Branch, Taoyuan, 333, Taiwan|Hacettepe Universitesi, AltindaÄ, Ankara, 06230, Turkey|Marmara Universitesi Pendik Egitim Arastirma Hastanesi, Istanbul, Pendik, Ä°stanbul, 34899, Turkey|Medipol Mega Universite Hastanesi, Stanbul, Ä°stanbul, 34214, Turkey|Izmir Medical Park Hospital, Izmir, Karsiyaka, Ä°zmir, 009035575, Turkey|Mugla Sitki Kocman Universitesi Egitim ve Arastirma Hastanesi, Mugla, MuÄla, 48000, Turkey|Sakarya Training and Research Hospital, AdapazarÄ±, Sakarya, 54290, Turkey|Adana Medical Park Seyhan Hastanesi, Adana, 01140, Turkey|Adana City Hospital, Adana, 01370, Turkey|Ankara GÃ¼lhane Eitim ve Aratrma Hastanesi, Ankara, 06010, Turkey|Ankara Etlik City Hospital, Ankara, 06170, Turkey|Memorial Ankara Hastanesi, Ankara, 06520, Turkey|Ankara Bilkent Åehir Hastanesi, Ankara, 06800, Turkey|Akdeniz Universitesi Hastanesi, Antalya, 07059, Turkey|Antalya Egitim ve ArastÄ±rma Hastanesi, Antalya, 07100, Turkey|Uludag Universitesi, Bursa, 16059, Turkey|Dicle Ãniversitesi, Diyarbakir, 21200, Turkey|Trakya University Medical Faculty Hospital, Edirne, 22030, Turkey|Gaziantep Universitesi Sahinbey Arastirma ve Uygulama Hastanesi, Gaziantep, 27310, Turkey|TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi, Istanbul, 34722, Turkey|Ege Universitesi Hastanesi, Izmir, 35100, Turkey|zmir Katip Ãelebi Ãniversitesi AtatÃ¼rk Eitim Ve Aratrma Hastanesi, Izmir, 35360, Turkey|Kocaeli Ãniversitesi, Kocaeli, 41380, Turkey|Ä°nÃ¶nÃ¼ Ãniversitesi Turgut Ãzal TÄ±p Merkezi EÄitim ve AraÅtÄ±rma Hastanesi, Malatya, 44280, Turkey|Mersin University, Mersin, 33110, Turkey|Ondokuz MayÄ±s Universitesi, Samsun, 55270, Turkey|Derriford Hospital, Plymouth, Devon, Pl6 8DH, United Kingdom|Panthera Biopartners - Preston, Preston, England, PR2 9QB, United Kingdom|Colchester General Hospital, Colchester, Essex, CO4 5JL, United Kingdom|Hairmyres Hospital, East Kilbride, Glasgow, Great Britain, G75 8RG, United Kingdom|Mount Vernon Hospital, Northwood, Hertfordshire, HA6 2RN, United Kingdom|Lister Hospital, Stevenage, Hertfordshire, SG1 4AB, United Kingdom|St Bartholomew's Hospital, London, London, City Of, EC1A 7BE, United Kingdom|Panthera Biopartners - Manchester, Rochdale, Manchester, OL11 4AU, United Kingdom|Oncology Research, Wigan, Manchester, WN1 2NN, United Kingdom|Western General Hospital, Edinburgh, Midlothian, EH4 2XU, United Kingdom|Clatterbridge Cancer Centre - Liverpool, Liverpool, L7 8YA, United Kingdom|The Christie NHS Foundation Trust, Manchester, M20 4BX, United Kingdom|Royal Berkshire Hospital, Reading, RG1 5AN, United Kingdom",
NCT05501886,Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1),https://clinicaltrials.gov/study/NCT05501886,VIKTORIA-1,RECRUITING,"This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy.",NO,Breast Cancer,DRUG: Gedatolisib|DRUG: Palbociclib|DRUG: Fulvestrant|DRUG: Alpelisib,"Progression Free Survival (PFS) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer, PFS is defined as the time from randomization to death or the first documented progression, whichever occurs first, confirmed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria, as determined based on blinded independent central review (BICR), Approximately 48 months","Overall Survival (OS) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer, OS is defined as the length of time from randomization until the date of death from any cause method, where PFS is defined as the time from randomization to death or the first documented progression, whichever occurs first, confirmed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria, as determined based on blinded independent central review (BICR), From date of randomization to the date of death due to any cause, up to approximately 48 months|Overall Response Rate (ORR) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer, Percentage of subjects who achieved an objective response according to RECIST v1.1 criteria (complete response \[CR\] or partial response \[PR\]) as assessed by BICR), Up to approximately 48 months|Duration of Response (DOR) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer, Time from the assessment of initial response (PR or better) to death or first documented disease progression as assessed by BICR, whichever occurs first, Up to approximately 48 months|Time to Response (TTR) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer, Time form randomization to the first assessment of PR or better as assessed by BICR, whichever comes first, Up to approximately 48 months|Clinical Benefit Rate (CBR) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer, Percentage of subjects with CR, PR, or stable disease (SD) \>24 weeks as assessed by BICR, Up to approximately 48 months|Quality of Life (QOL)Functional Assessment of Cancer Therapy - Breast Trial Outcome Index (FACT-B TOI) Questions in Patients with PIK3CA WT and PIK3CA MT Breast Cancer, The FACT-B TOI is an abbreviated (24-item) version of the full FACT-B which focuses only on the patient's Physical Well-being (PWB), Functional Well-being (FWB), and Breast Cancer Subscale (BCS) components using a 5-level scale, (Not at all, A little bit, Some-what, Quite a bit, Very much)., From baseline to 30 Day Safety Follow-up|Quality of Life (QOL) NCCN-FACT Breast Symptom Index -16 (NFBSI-16) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer, NCCN-FACT is derived from the FACT-B and only 4 additional items will be administered to enable optional scoring of the NFBSI subscales and total score using a 5-level scale (Not at all, A little bit, Some-what, Quite a bit, Very much)., From baseline to 30 Day Safety Follow-up|Patient-Reported Outcomes in Patients with PIK3CA WT and PIK3CA MT Breast Cancer, Patient-Reported Outcomes Measurement Information System (PROMISÂ®) Short Form v2.0 - Physical Function 8c using a 5-level scale (Without any difficulty, With a little difficulty, With some difficulty, With much difficulty, Unable to do), From baseline to 30 Day Safety Follow-up|EuroQol 5 in Patients with PIK3CA WT and PIK3CA MT Breast Cancer, EuroQol 5 Dimension 5 Level (EQ-5D-5L) - This is a 5 question, self-administered visual analog scale (VAS) where patients use 0 (worst health) to 100 (best health) to indicate how they view their health., From baseline to 30 Day Safety Follow-up|Adverse Events, Safety and tolerability will be evaluated by review of type, incidence, severity (as graded by the National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\] v5.0), seriousness, and relationship to study medications of adverse events (AEs) and any laboratory abnormalities, Up to approximately 48 months",,Celcuity Inc,,ALL,"ADULT, OLDER_ADULT",PHASE3,701,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-12-08,2025-03-31,2026-12-31,2022-08-16,,2024-12-19,"University of Alabama at Birmingham, Birmingham, Alabama, 35294, United States|Arizona Oncology (US Oncology/McKesson) - Goodyear, Goodyear, Arizona, 85395, United States|St. Bernards Medical Center, Jonesboro, Arkansas, 72401, United States|CARTI Cancer Center, Little Rock, Arkansas, 72205, United States|Pacific Cancer Medical Center Inc, Anaheim, California, 92801, United States|Kaiser Permanente South Bay Medical Center, Harbor City, California, 90710, United States|Cancer and Blood Specialty Clinic, Los Alamitos, California, 90720, United States|Pacific Cancer Care, Monterey, California, 93940, United States|University of California, Irvine Medical Center, Orange, California, 92868, United States|Ventura County Hematology Oncology Specialists, Oxnard, California, 93030, United States|Redlands Hematology Oncology, Redlands, California, 92373, United States|UCLA Hematology/Oncology-Santa Monica, Santa Monica, California, 90904, United States|Torrance Memorial Physician Network - Cancer Care, Torrance, California, 90505, United States|Kaiser Permanente Medical Center - Vallejo, Vallejo, California, 94589, United States|PIH Health Hospital Whittier, Whittier, California, 90602-1006, United States|Yale Cancer Center - New Haven, New Haven, Connecticut, 06520-8028, United States|South Broward Hospital District d/b/a Memorial Healthcare System, Hollywood, Florida, 33021, United States|Cancer Specialists of North Florida - Jacksonville, Jacksonville, Florida, 32256, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, 33612, United States|Bond & Steele Clinic, P.A. d/b/a Bond Clinic, P.A., Winter Haven, Florida, 33881, United States|John D. Archbold Memorial Hospital, Thomasville, Georgia, 31792, United States|Illinois Cancer Specialists - Arlington Heights, Arlington Heights, Illinois, 60005, United States|Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, 46845, United States|University of Kentucky Medical Center, Lexington, Kentucky, 40536-0293, United States|Mercy Health - Paducah, Paducah, Kentucky, 42003, United States|American Oncology Partners of Maryland, PA, Bethesda, Maryland, 20817-7847, United States|Maryland Oncology Hematology, P.A. - Rockville, Rockville, Maryland, 20850, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215-5450, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States|Henry Ford Hospital, Detroit, Michigan, 48202, United States|Nebraska Hematology - Oncology, P.C., Lincoln, Nebraska, 68506, United States|Oncology Hematology West PC dba Nebraska Cancer Specialists, Omaha, Nebraska, 68130, United States|University of Nebraska Medical Center, Omaha, Nebraska, 68198, United States|New York Oncology Hematology, P.C. - Albany, Albany, New York, 12206, United States|Montefiore Medical Center, Bronx, New York, 10467, United States|Queens Hospital Cancer Center, Jamaica, New York, 11432, United States|Coleman, Pasmantier & Decter, MDs, New York, New York, 10021-5302, United States|Weill Cornell Medicine/New York-Presbyterian Hospital, New York, New York, 10021, United States|University of Rochester Medical Center, Rochester, New York, 14642, United States|Hematology/Oncology Associates of Central New York, Syracuse, New York, 13057, United States|White Plains Hospital, White Plains, New York, 10601, United States|Cone Health Cancer Center at Alamance Regional, Hematology/Oncology, Greensboro, North Carolina, 27403, United States|Southeast Regional Cancer Center, Lumberton, North Carolina, 28359, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, 44106-1716, United States|The James Cancer Hospital and Solove Research Institute, Columbus, Ohio, 43210, United States|OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma, 73104, United States|Oregon Oncology Specialists, Salem, Oregon, 97301, United States|Northwest Cancer Specialists, PC - Tigard, Tigard, Oregon, 97223, United States|Consultants In Medical Oncology and Hematology, P.C., Broomall, Pennsylvania, 19008, United States|Alliance Cancer Specialists PC, Horsham, Pennsylvania, 19044, United States|Cancer Care Associates of York, York, Pennsylvania, 17403, United States|Sanford Gynecologic Oncology Clinic, Sioux Falls, South Dakota, 57104, United States|Texas Oncology - Austin, Austin, Texas, 78745, United States|Texas Oncology P.A. - Dallas, Dallas, Texas, 75230, United States|Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, 75246, United States|William Beaumont Army Medical Center, El Paso, Texas, 79920, United States|Oncology Consultants, Houston, Texas, 77030, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|Brooke Army Medical Center, Houston, Texas, 78234, United States|Texas Oncology - McKinney, McKinney, Texas, 75071, United States|Texas Oncology - Gulf Coast, Sugar Land, Texas, 77479, United States|Texas Oncology - Tyler, Tyler, Texas, 75702, United States|Fort Belvoir Community Hospital, Fort Belvoir, Virginia, 22060, United States|Bon Secours St. Francis Medical Oncology Center, Midlothian, Virginia, 23114, United States|Virginia Oncology Associates - Newport News, Newport News, Virginia, 23502, United States|VCU Massey Cancer Center, Richmond, Virginia, 23219, United States|Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care - Roanoke, Roanoke, Virginia, 24014, United States|Fred Hutchinson Cancer Center, Seattle, Washington, 98109-1023, United States|Northwest Medical Specialties, PLLC - Tacoma, Tacoma, Washington, 98405, United States|Alexander Fleming Institute, Buenos Aires, Argentina|Buenos Aires British Hospital, Buenos Aires, Argentina|CENIT Foundation, Buenos Aires, Argentina|Center for Medical Education and Clinical Research (CEMIC), Buenos Aires, Argentina|Fleischer Medical Center, Buenos Aires, Argentina|Medical Center Austral, Buenos Aires, Argentina|Pergamino Clinic, Buenos Aires, Argentina|Cordoba Oncology Institute (IONC), CÃ³rdoba, Argentina|Center of Nuclear and Molecular Medicine of Entre Rios (CEMENER), ParanÃ¡, Argentina|CEDIT Diagnostic and treatment center, Salta, Argentina|CER San Juan, San Juan, Argentina|Rosario's Oncology Institute and Medical Specialities (IOR), Santa Fe, Argentina|9 of July Sanatorium, TucumÃ¡n, Argentina|Adelaide Oncology & Haematology, Adelaide, Australia|St Vincent's Hospital (Melbourne) Ltd, Fitzroy, Australia|Peninsula & South Eastern Hematology and Oncology Group (PSEHOG), Frankston, Australia|Hollywood Private Hospital, Breast Cancer Research Centre, Nedlands, Australia|Mater Hospital Brisbane, Mater Cancer Care Centre, South Brisbane, Australia|Icon Cancer Centre- Southport, Southport, Australia|Sydney Adventist Hospital, Wahroonga, Australia|The Queen Elizabeth Hospital, Woodville, Australia|University Hospital Graz, Department of Gynecology and Obstetrics, Graz, Austria|University Hospital Innsbruck - Tyrolean Hospital, Department of Gynaecology and Obstetrics, Innsbruck, Austria|Order Hospital Linz Ltd. - Hospital of Sisters of Mercy, Department of Internal Medicine I, Linz, Austria|Salzburg Regional Hospital, Department of Internal Medicine III, Salzburg, Austria|University Hospital St. Poelten, Department of Internal Medicine I, St. Poelten, Austria|Hospital Hietzing, Department of Gynecology, Vienna, Austria|Medical University Vienna, Department of Gynecology and Obstetrics, Vienna, Austria|Saint Luc University Hospital, Brussels, Belgium|Charleroi Grand Hospital (GHDC), Charleroi, Belgium|University Hospital Antwerp (UZA), Edegem, Belgium|AZ Groeninge, Kortrijk, Belgium|University Hospitals Leuven, Campus Gasthuisberg, Leuven, Belgium|Citadelle Regional Hospital Center, LiÃ¨ge, Belgium|VITAZ, Sint-Niklaas, Belgium|Centre Hospitalier Peltzer-la-Tourelle, Verviers, Belgium|UCL Mont-Godinne University Hospitals, Yvoir, Belgium|Oncology Treatment Center, BelÃ©m, ParÃ¡, Brazil|Pronutrir, Fortaleza, Brazil|ONCOSITE - Clinical Research Center in Oncology, IjuÃ­, Brazil|Juiz de Fora Eurolatino Research Center, Minas Gerais, Brazil|Bahia Oncology Center, Salvador de Bahia, Brazil|D'OR Institute, SÃ£o Paulo, Brazil|Hospital A.C.Camargo, SÃ£o Paulo, Brazil|Multiprofile Hospital for Active Treatment - Uni Hospital, Panagyurishte, Panagyurishte, Bulgaria|MHAT for Women's Health ""Nadezhda"", Sofia, Bulgaria|Multiprofile Hospital for Active Treatment ""Serdika"", Sofia, Sofia, Bulgaria|Specialized Hospital for Active Treatment in Oncology, Clinic of Medicial Oncology (Chemotherapy), Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment ""Sveta Marina"", Varna, Bulgaria|BC Cancer - Vancouver, Medical Oncology, Vancouver, British Columbia, Canada|CIUSSS du Saguenay Lac St-Jean, Chicoutimi, Quebec, Canada|Hospital Notre-Dame, MontrÃ©al, Quebec, Canada|Maisonneuve-Rosemont Hospital, MontrÃ©al, Quebec, Canada|University Hospital Olomouc, Clinic of Oncology, Olomouc, Czechia|Thomayer University Hospital, Clinic of Oncology, Prague, Czechia|University Hospital Bulovka, Institute of Radiation Oncology, Prague, Czechia|University Hospital Motol, Clinic of Oncology, Prague, Czechia|Bergonie Institute, Bordeaux, France|Francois Baclesse Center, Caen, 14076, France|La Roche-sur-Yon Hospital, La Roche-sur-Yon, 85925, France|CHU La Timone - La Timone Children's Hospital, Marseille, France|University Hospital Center of Poitiers, Poitiers, France|Saint Anne Clinic, Strasbourg, France|Gustave Roussy, Villejuif, France|Hospital Bayreuth, Bayreuth, Germany|Vivantes Hospital Am Urban, Berlin, Germany|Private Practice with Focus on Oncology, Luebeck, Germany|University Hospital Johannes Gutenberg - University of Mainz, Mainz, Germany|Hospital Suedstadt Rostock, Mecklenburg, Germany|University Hospital Muenster, MÃ¼nster, Germany|Caritas Klinikum, SaarbrÃ¼cken, Germany|Helios Clinic Wuppertal, Wuppertal, Germany|Alexandra General Hospital, Athens, Greece|University General Hospital of Ioannina, IoÃ¡nnina, Greece|IASO Thessaly SA, Larissa, Greece|EUROMEDICA General Clinic of Thessaloniki, ThessalonÃ­ki, Greece|Theageneio Anticancer Hospital of Thessaloniki, ThessalonÃ­ki, Greece|University of Debrecen Clinical Center, Institute of Oncology, Debrecen, Hungary|Bacs-Kiskun County Hospital, Center for Oncoradiology, KecskemÃ©t, Hungary|Szabolcs-Szatmar-Bereg County Hospitals and University Teaching Hospital, Department of Oncology, NyÃ­regyhÃ¡za, Hungary|HCG Cancer Centre, Bangalore, India|Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India|Tata Medical Center, Kolkata, India|Tata Memorial Hospital, Navi Mumbai, India|Christian Medical College, Department of Medical Oncology, Vellore, India|European Institute of Oncology (IEO), IRCCS, Milan, Italy|University Polyclinic Hospital of Modena, Modena, Italy|Local Healthcare Company of Monza (ASST Monza), Monza, Italy|University Hospital of Parma, Parma, Italy|New Hospital of Prato (NOP), Prato, Italy|University Hospital Campus Bio-Medico, Rome, Italy|University Polyclinic Foundation ""Agostino Gemelli"" - IRCCS, Rome, Italy|Santa Maria della Misericordia University Hospital of Udine, Udine, Italy|Asan Medical Center, Seoul, Korea, Republic of|Gangnam Severance Hospital, Soeul, Korea, Republic of|Korea University Anam Hospital, Soeul, Korea, Republic of|Samsung Medical Center, Soeul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Soeul, Korea, Republic of|Ulsan University Hospital, Ulsan, Korea, Republic of|Clinical Research Center Chapultepec Mexico City, Mexico City, Mexico|CRYPTEX, Mexico City, Mexico|ProcliniQ Clinical Research, Mexico City, Mexico|Filios High Medicine, Monterrey, 64460, Mexico|Administrative Society of Health Services, SC, Morelia, Mexico|Avix Clinical Research, Nuevo LeÃ³n, Mexico|Zambrano Hellion Medical Center, Nuevo LeÃ³n, Mexico|Inbiomedyc, QuerÃ©taro, Mexico|ONCOR Life Medical Center, Saltillo, Mexico|Prof. Franciszek Lukaszczyk Oncology Center in Bydgoszcz, Chemotherapy Outpatient Clinic, Bydgoszcz, Poland|Medical Clinic ""Komed"", Konin, Poland|Maria Sklodowska-Curie Institute of Oncology, Branch in Krakow, KrakÃ³w, Poland|Independent Public Healthcare Facility Prof. Tadeusz Koszarowski Opole Oncology Center in Opole, Clinical Oncology Department and Day Hospitalization Unit, Opole, Poland|St. John Paul 2nd Mazovian Provincial Hospital in Siedlce Limited Liability Company, Siedlce Oncology Centre, Siedlce, Poland|West Pomeranian Oncology Center, Szczecin, Poland|LUX MED Oncology LLC, Szamocka Hospital, Department of Clinical Oncology/Chemotherapy, Warsaw, Poland|Maria Sklodowska-Curie - National Research Institute of Oncology, Warsaw, Poland|Provincial Specialist Hospital in Wroclaw, Department of Chemotherapy, Wroclaw, Poland|Polish Mother's Memorial Hospital-Research Institute, ÅÃ³dÅº, Poland|S.C. Oncopremium-Team SRL, Baia Mare, Romania|Prof. Dr. Alexandru Trestioreanu Institute of Oncology, Bucharest, Romania|Prof. Dr. Ion Chiricuta Institute of Oncology, Cluj-Napoca, Romania|Onco Clinic Consult S.A., Craiova, Romania|Oncology Center ""Sf. Nectarie"", Craiova, Romania|S.C. Topmed Medical Center SRL, TÃ¢rgu-MureÅ, Romania|Curie Oncology, Singapore, Singapore|ICON SOC Farrer Park Medical Clinic, Singapore, Singapore|OncoCare Cancer Centre, Singapore, Singapore|Raffles Hospital, Singapore, Singapore|Tan Tock Seng Hospital, Singapore, Singapore|Infanta Cristina Hospital, Badajoz, Spain|Catalan Institute of Oncology, Hospital Duran i Reynals, Barcelona, Spain|Caceres Hospital Complex - San Pedro de Alcantara General Hospital, CÃ¡ceres, Spain|Hospital Ruber Internacional, Madrid, Spain|University Hospital Foundation Jimenez Diaz, Madrid, Spain|University Clinical Hospital Virgen de la Arrixaca, Department of Oncology, Murcia, Spain|University Hospital Complex of Santiago (CHUS), Department of Oncology, Santiago De Compostela, Spain|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|Taipei Medical University - Shuang Ho Hospital, New Taipei City, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Royal United Hospital, Department of Oncology/Hematology, Bath, United Kingdom|Velindre Cancer Centre, Cardiff, United Kingdom|Guy's Hospital, London, United Kingdom|Royal Marsden Hospital - London, Department of Medical Oncology, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom",
NCT04711252,A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease,https://clinicaltrials.gov/study/NCT04711252,SERENA-4,ACTIVE_NOT_RECRUITING,"The study is intended to show superiority of AZD9833 in combination with palbociclib (a CDK4/6 inhibitor) versus anastrozole (an aromatase inhibitor) and palbociclib as the initial treatment of patients with hormone receptor-positive (ER-positive), human epidermal growth factor 2-negative (HER2-negative) advanced/metastatic breast cancer.

INFORMATION FOR TRIAL PARTICIPANTS

In this trial, the researchers will look at how well camizestrant with palbociclib works, compared with anastrozole with palbociclib, in participants with breast cancer that has either spread into other parts of the body at the time of diagnosis, or has come back after at least 2 years of standard endocrine treatment.

Participants in this trial will have breast cancer that has ER proteins but does not have overexpression of HER2 protein.",NO,ER-Positive HER2-Negative Breast Cancer,DRUG: AZD9833|DRUG: Anastrozole|DRUG: Anastrozole placebo|DRUG: AZD9833 placebo|DRUG: Palbociclib|DRUG: Luteinizing hormone-releasing hormone (LHRH) agonist,"Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST) version 1.1, PFS is defined as the time from randomization to objective disease progression (as assessed by RECIST) or death., From randomization until progression per RECIST 1.1 as assessed by the investigator at local site or death due to any cause (up to 5 years)","Overall survival (OS), The OS is defined as the time from randomization to death due to any cause., From randomization until the date of death due to any cause (up to 8 years)|Second progression-free survival (PFS2), Time to second progression or death (PFS2) will be defined as the time from randomisation to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death., From randomization to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death (up to 5 years)|Objective response rate (ORR) assessed by the Investigator as defined by RECIST version 1.1, ORR is defined as the proportion of patients who have a CR or partial response, as determined by the investigator at local site per RECIST 1.1., From randomization until a response or in the absence of a response from randomization up until progression, or the last evaluable assessment in the absence of progression (up to 5 years)|Duration of response (DoR) assessed by the Investigator as defined by RECIST version 1.1, The DoR will be defined as the time from the date of first documented response until date of documented progression or death in the absence of disease progression., From the date of first documented response until date of documented progression per RECIST 1.1 as assessed by the investigator at local site or death due to any cause (up to 5 years)|Time to chemotherapy (TTC), Time to chemotherapy is defined as the time from randomization until the earlier of the start date of chemotherapy or death due to any cause., From randomization until the earlier of the start date of chemotherapy or death due to any cause (up to 5 years)|Time to first subsequent anti-cancer therapy (TFST), TFST is defined as time from randomization until the earlier of start date of the first subsequent anti-cancer therapy after discontinuation of randomized treatment, or death due to any cause., From randomization until the earlier of start date of the first subsequent anti-cancer therapy after discontinuation of randomized treatment, or death due to any cause (up to 5 years)|Clinical benefit rate at 24 weeks (CBR24), CBR at 24 weeks is defined as the percentage of participants who have a complete response (CR) or partial response or who have stable disease (SD) per RECIST 1.1 as assessed by the investigator at local site for at least 23 weeks after randomization (to allow for an early assessment within the assessment window)., At least 23 weeks after randomisation|Time to second subsequent therapy (TSST), TSST is defined as time from randomization until the earlier of start date of the second subsequent anti-cancer therapy after discontinuation of first subsequent treatment, or death due to any cause., From randomization until the earlier of start date of the second subsequent anti-cancer therapy after discontinuation of first subsequent treatment, or death due to any cause (up to 5 years)|Plasma concentration of AZD9833 at specified timepoints, To assess the steady state PK of AZD9833 in combination with palbociclib in all participants who receive at least one dose of AZD9833 per the protocol, for whom there are at least one reportable PK concentration., on Day 15|Change from baseline in EORTC QLQ-C30 scale scores, Change from baseline in EORTC QLQ-C30 scale scores for each patient at each post-baseline visit. The comparison will include all randomised patients, as randomised, with baseline and at least one post-baseline visit score for the scale score., From baseline to 24 weeks post progression (up to approximately 5 years)|Change from baseline in EORTC QLQ-BR45 scale scores, Change from baseline in EORTC QLQ-BR45 scale scores for each patient at each post-baseline visit. The comparison will include all randomised patients, as randomised, with baseline and at least one post-baseline visit score for the scale score., From baseline to 24 weeks post progression (up to approximately 5 years)",,AstraZeneca,,ALL,"ADULT, OLDER_ADULT",PHASE3,1370,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-01-28,2026-08-24,2029-02-01,2021-01-15,,2025-03-24,"Research Site, Mobile, Alabama, 36604, United States|Research Site, Springdale, Arkansas, 72762, United States|Research Site, Harbor City, California, 90710, United States|Research Site, Solvang, California, 93463, United States|Research Site, Lone Tree, Colorado, 80124, United States|Research Site, Fort Myers, Florida, 33901-8101, United States|Research Site, Jacksonville, Florida, 32256, United States|Research Site, West Palm Beach, Florida, 33401, United States|Research Site, Indianapolis, Indiana, 46256, United States|Research Site, Baton Rouge, Louisiana, 70809, United States|Research Site, Silver Spring, Maryland, 20904, United States|Research Site, Boston, Massachusetts, 02114, United States|Research Site, Detroit, Michigan, 48202, United States|Research Site, Hattiesburg, Mississippi, 39401, United States|Research Site, Omaha, Nebraska, 68130, United States|Research Site, Cincinnati, Ohio, 45219, United States|Research Site, Cincinnati, Ohio, 45267, United States|Research Site, Portland, Oregon, 97239, United States|Research Site, West Columbia, South Carolina, 29169, United States|Research Site, Sioux Falls, South Dakota, 57105, United States|Research Site, Chattanooga, Tennessee, 37404, United States|Research Site, Nashville, Tennessee, 37203, United States|Research Site, Austin, Texas, 78731, United States|Research Site, Houston, Texas, 77030, United States|Research Site, Houston, Texas, 77090, United States|Research Site, Tyler, Texas, 75702, United States|Research Site, Fairfax, Virginia, 22031, United States|Research Site, Kennewick, Washington, 99336, United States|Research Site, Renton, Washington, 98055, United States|Research Site, Morgantown, West Virginia, 26505, United States|Research Site, Feldkirch, 6807, Austria|Research Site, Salzburg, 5020, Austria|Research Site, Wien, 1130, Austria|Research Site, Anderlecht, 1070, Belgium|Research Site, Edegem, 2650, Belgium|Research Site, Gent, 9000, Belgium|Research Site, Leuven, 3000, Belgium|Research Site, LiÃ¨ge, 4000, Belgium|Research Site, Namur, 5000, Belgium|Research Site, Sint-Niklaas, 9100, Belgium|Research Site, Plovdiv, 4000, Bulgaria|Research Site, Plovdiv, 4109, Bulgaria|Research Site, Shumen, 9700, Bulgaria|Research Site, Sofia, 1330, Bulgaria|Research Site, Sofia, 1431, Bulgaria|Research Site, Sofia, 1527, Bulgaria|Research Site, Edmonton, Alberta, T6G 1Z2, Canada|Research Site, Vancouver, British Columbia, V5Z 1H7, Canada|Research Site, Kitchener, Ontario, N2G 1G3, Canada|Research Site, London, Ontario, N6A 5W9, Canada|Research Site, Toronto, Ontario, M5G 2M9, Canada|Research Site, Montreal, H3T 1E2, Canada|Research Site, Concepcion, 4070196, Chile|Research Site, La Serena, 1720430, Chile|Research Site, Santiago, 7630370, Chile|Research Site, Santiago, 8241479, Chile|Research Site, Baoding, 071000, China|Research Site, Beijing, 100039, China|Research Site, Beijing, 100142, China|Research Site, Beijing, China|Research Site, Bengbu, 233060, China|Research Site, Changchun, 130000, China|Research Site, Changchun, 130021, China|Research Site, Changsha, 410013, China|Research Site, Chengdu, 610042, China|Research Site, Chongqing, 400042, China|Research Site, Dalian, 116011, China|Research Site, Guangzhou, 510060, China|Research Site, Guangzhou, 510100, China|Research Site, Guiyang, 550004, China|Research Site, Haikou, 570311, China|Research Site, Hangzhou, 310020, China|Research Site, Hangzhou, 310022, China|Research Site, Hefei, 230031, China|Research Site, Jinan, 250117, China|Research Site, Lanzhou, 730000, China|Research Site, Linyi, 276000, China|Research Site, Nanchang, 330009, China|Research Site, Nanjing, 210008, China|Research Site, Shanghai, 200025, China|Research Site, Shanghai, 200032, China|Research Site, Shenyang, 110001, China|Research Site, Tianjin, 300060, China|Research Site, Wuhan, 430000, China|Research Site, Wuhan, 430022, China|Research Site, Xi'an, 710061, China|Research Site, Zhengzhou, 450008, China|Research Site, Horovice, 268 01, Czechia|Research Site, Hradec Kralove, 500 05, Czechia|Research Site, Novy Jicin, 741 01, Czechia|Research Site, Praha 10, 100 34, Czechia|Research Site, Praha 4, 140 00, Czechia|Research Site, Praha 5, 150 06, Czechia|Research Site, Besancon Cedex, 25030, France|Research Site, Bordeaux, 33030, France|Research Site, Brest Cedex 2, 29609, France|Research Site, Caen Cedex 05, 14076, France|Research Site, Dijon, 21079, France|Research Site, Le Mans, 72000, France|Research Site, Lille, 59000, France|Research Site, Montpellier, 34070, France|Research Site, Pierre Benite Cedex, 69495, France|Research Site, Plerin SUR MER, 22190, France|Research Site, Saint-cloud, 92210, France|Research Site, Vandoeuvre Les Nancy, 54000, France|Research Site, Villejuif Cedex, 94805, France|Research Site, Berlin, 13125, Germany|Research Site, Dessau-RoBlau, 06847, Germany|Research Site, Essen, 45136, Germany|Research Site, Freiburg, 79110, Germany|Research Site, MÃ¶nchengladbach, 41061, Germany|Research Site, MÃ¼nchen, 81675, Germany|Research Site, MÃ¼nster, 48145, Germany|Research Site, Regensburg, 93053, Germany|Research Site, Velbert, 42551, Germany|Research Site, Budapest, 1062, Hungary|Research Site, Budapest, 1088, Hungary|Research Site, Budapest, 1122, Hungary|Research Site, GyÅr, 9024, Hungary|Research Site, Miskolc, 3526, Hungary|Research Site, NyÃ­regyhÃ¡za, 4400, Hungary|Research Site, SzekszÃ¡rd, 7100, Hungary|Research Site, Zalaegerszeg, 8900, Hungary|Research Site, Ahmedabad, 380060, India|Research Site, Calicut, 673601, India|Research Site, Delhi, 110085, India|Research Site, Faridabad, 121001, India|Research Site, Gurgaon, 122001, India|Research Site, Karamsad, 388325, India|Research Site, Kolkata, 700160, India|Research Site, Madurai, 625107, India|Research Site, Nagpur, 440001, India|Research Site, Nashik, 422009, India|Research Site, Nashik, 422011, India|Research Site, New Delhi, 11029, India|Research Site, Bergamo, 24127, Italy|Research Site, Firenze, 50139, Italy|Research Site, Milan, 20141, Italy|Research Site, Modena, 41124, Italy|Research Site, Napoli, 80131, Italy|Research Site, Novara, 28100, Italy|Research Site, Padova, 35128, Italy|Research Site, Parma, 43100, Italy|Research Site, Prato, 59100, Italy|Research Site, Roma, 00168, Italy|Research Site, Roma, 161, Italy|Research Site, Rozzano, 20089, Italy|Research Site, Chiba-shi, 260-8717, Japan|Research Site, Chuo-ku, 104-0045, Japan|Research Site, Chuo-ku, 862-8655, Japan|Research Site, Hidaka-shi, 350-1298, Japan|Research Site, Hirakata-shi, 573-1191, Japan|Research Site, Isehara-shi, 259-1193, Japan|Research Site, Kitaadachi-gun, 362-0806, Japan|Research Site, Koto-ku, 135-8550, Japan|Research Site, Kumamoto-shi, 860-8556, Japan|Research Site, Kurashiki shi, 701 0192, Japan|Research Site, Kurume-shi, 830-0013, Japan|Research Site, Kyoto-shi, 606-8507, Japan|Research Site, Nagoya-shi, 464-8681, Japan|Research Site, Nagoya-shi, 467-8602, Japan|Research Site, Nishinomiya-shi, 663-8501, Japan|Research Site, Osaka-shi, 540-0006, Japan|Research Site, Osaka-shi, 541-8567, Japan|Research Site, Ota-shi, 373-8550, Japan|Research Site, Sapporo-shi, 003-0804, Japan|Research Site, Sendai-shi, 980-8574, Japan|Research Site, Shimotsuke-shi, 329-0498, Japan|Research Site, Shinagawa-ku, 142-8666, Japan|Research Site, Shinjuku-ku, 162-8655, Japan|Research Site, Suita-shi, 565-0871, Japan|Research Site, Takasaki-shi, 370-0829, Japan|Research Site, Tsu-shi, 514-8507, Japan|Research Site, Tsukuba-shi, 305-8576, Japan|Research Site, Yokohama-shi, 241-8515, Japan|Research Site, Busan, 49201, Korea, Republic of|Research Site, Daegu, 41404, Korea, Republic of|Research Site, Goyang-si, 10408, Korea, Republic of|Research Site, Seoul, 03080, Korea, Republic of|Research Site, Seoul, 03722, Korea, Republic of|Research Site, Seoul, 05505, Korea, Republic of|Research Site, Seoul, 06273, Korea, Republic of|Research Site, Seoul, 06351, Korea, Republic of|Research Site, George Town, 10450, Malaysia|Research Site, Johor Bahru, 81100, Malaysia|Research Site, Kuala Lumpur, 50586, Malaysia|Research Site, Kuala Lumpur, 59100, Malaysia|Research Site, Kuching, 93586, Malaysia|Research Site, Selangor, 62250, Malaysia|Research Site, Del. Cuauhtemoc, 06700, Mexico|Research Site, Estado de MÃ©xico, 50080, Mexico|Research Site, La Paz, 23040, Mexico|Research Site, Mexico City, 0 3100, Mexico|Research Site, Monterrey, 64710, Mexico|Research Site, Puebla, 72424, Mexico|Research Site, Drammen, 3004, Norway|Research Site, Oslo, N-0379, Norway|Research Site, Gdynia, 81-519, Poland|Research Site, Konin, 62-500, Poland|Research Site, Koszalin, 75-581, Poland|Research Site, Lublin, 20-090, Poland|Research Site, Olsztyn, 10-513, Poland|Research Site, PoznaÅ, 60-192, Poland|Research Site, ÅÃ³dÅº, 90-302, Poland|Research Site, Braga, 4710, Portugal|Research Site, GuimarÃ£es, 4835-044, Portugal|Research Site, Lisboa, 1400-038, Portugal|Research Site, Lisboa, 1500-650, Portugal|Research Site, Lisboa, 1998-018, Portugal|Research Site, Loures, 2674-514, Portugal|Research Site, Porto, 4099-001, Portugal|Research Site, Porto, 4200-319, Portugal|Research Site, Vila Nova de Gaia, 4434-502, Portugal|Research Site, Kaluga, 248007, Russian Federation|Research Site, Kislino Village, Ryshkovsky Ru, 305524, Russian Federation|Research Site, Moscow, 111123, Russian Federation|Research Site, Moscow, 115478, Russian Federation|Research Site, Moscow, 117997, Russian Federation|Research Site, Moscow, 121467, Russian Federation|Research Site, Saint Petersburg, 197758, Russian Federation|Research Site, Saint-Petersburg, 190103, Russian Federation|Research Site, Saint-Petersburg, 195067, Russian Federation|Research Site, Sankt-Peterburg, 196603, Russian Federation|Research Site, BanskÃ¡ Bystrica, 974 01, Slovakia|Research Site, Bratislava, 81250, Slovakia|Research Site, Bratislava, 833 01, Slovakia|Research Site, PreÅ¡ov, 081 81, Slovakia|Research Site, Trencin, 91171, Slovakia|Research Site, Barcelona, 08908, Spain|Research Site, Barcelona, 8035, Spain|Research Site, JaÃ©n, 23007, Spain|Research Site, Lleida, 25198, Spain|Research Site, Madrid, 28040, Spain|Research Site, Madrid, 28046, Spain|Research Site, Malaga, 29010, Spain|Research Site, Pamplona, 31008, Spain|Research Site, Santander, 39008, Spain|Research Site, Sevilla, 41013, Spain|Research Site, Valencia, 46015, Spain|Research Site, Liestal, CH- 4410, Switzerland|Research Site, ZÃ¼rich, 8008, Switzerland|Research Site, Kaohsiung, 82445, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, 40443, Taiwan|Research Site, Tainan, 70403, Taiwan|Research Site, Taipei City, 110, Taiwan|Research Site, Taipei, 10048, Taiwan|Research Site, Taipei, 104, Taiwan|Research Site, Taipei, 235, Taiwan|Research Site, Taoyuan, 333, Taiwan|Research Site, Adana, 01120, Turkey|Research Site, Ankara, 06010, Turkey|Research Site, Ankara, 06230, Turkey|Research Site, Ankara, 06340, Turkey|Research Site, Ankara, 6100, Turkey|Research Site, Izmir, 35100, Turkey|Research Site, Izmir, 35620, Turkey|Research Site, Kayseri, 38039, Turkey|Research Site, Cambridge, CB2 2QQ, United Kingdom|Research Site, Colchester, CO4 5JL, United Kingdom|Research Site, Leeds, LS9 7TF, United Kingdom|Research Site, Nottingham, NG5 1PB, United Kingdom|Research Site, Surrey, GU2 7XX, United Kingdom",
NCT03661320,"A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer",https://clinicaltrials.gov/study/NCT03661320,,ACTIVE_NOT_RECRUITING,"The purpose of this study is to compare nivolumab plus neoadjuvant gemcitabine/cisplatin (GC) chemotherapy, followed by post-surgery continuation of immuno-oncology (IO) therapy, with neoadjuvant GC chemotherapy alone in adult participants with previously untreated muscle-invasive bladder cancer (MIBC).",NO,Urinary Bladder Neoplasms|Muscle-Invasive Bladder Cancer,BIOLOGICAL: Nivolumab|DRUG: Gemcitabine|DRUG: Cisplatin,"Pathological Complete Response (pCR) rate, in all randomized participants, Arm B vs. Arm A, Approximately 43 months|Event-Free Survival (EFS), in all randomized participants, Arm B vs. Arm A, Approximately 36 months","Overall Survival (OS) in all randomized participants, Arm B vs. Arm A, Approximately 60 months|Incidence of Adverse Events (AE) in participants who received at least one treatment dose, Approximately 60 months|Incidence of Serious Adverse Events (SAE) in participants who received at least one treatment dose, Approximately 60 months|Incidence of deaths in participants who received at least one treatment dose, Approximately 60 months|Incidence of laboratory abnormalities in participants who received at least one treatment dose, Approximately 60 months|pCR rate, descriptively in all concurrently randomized participants, Arm C vs. Arm B and Arm A, Approximately 43 months|EFS, descriptively in all concurrently randomized participants, Arm C vs. Arm B and Arm A, Approximately 36 months|OS, descriptively in all concurrently randomized participants, Arm C vs. Arm B and Arm A, Approximately 60 months",,Bristol-Myers Squibb,Ono Pharmaceutical Co. Ltd,ALL,"ADULT, OLDER_ADULT",PHASE3,855,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2018-11-06,2025-11-17,2027-12-30,2018-09-07,,2025-05-31,"Local Institution - 0022, Tucson, Arizona, 85711, United States|UC Davis Comprehensive Cancer Center, Sacramento, California, 95817, United States|Local Institution - 0021, Littleton, Colorado, 80120-4413, United States|Local Institution - 0036, Pensacola, Florida, 32503, United States|Local Institution - 0004, Tampa, Florida, 33612, United States|Local Institution - 0144, Atlanta, Georgia, 30342, United States|Local Institution - 0005, Chicago, Illinois, 60637, United States|Local Institution - 0006, Peoria, Illinois, 61615, United States|Local Institution - 0181, Columbia, Maryland, 21044, United States|Local Institution - 0009, Boston, Massachusetts, 02114, United States|Local Institution - 0166, Boston, Massachusetts, 02215, United States|Local Institution - 0209, Boston, Massachusetts, 02215, United States|Local Institution - 0025, Minneapolis, Minnesota, 55404, United States|Local Institution - 0129, Minneapolis, Minnesota, 55455, United States|Local Institution - 0183, Omaha, Nebraska, 68130, United States|Local Institution - 0001, Omaha, Nebraska, 68198-6840, United States|Local Institution - 0024, Las Vegas, Nevada, 89169, United States|Local Institution - 0029, Albany, New York, 12208, United States|Local Institution - 0069, Lake Success, New York, 11042, United States|Local Institution - 0047, New York, New York, 10065, United States|Local Institution - 0191, Cleveland, Ohio, 44195, United States|Local Institution - 0028, Tigard, Oregon, 97223, United States|Local Institution - 0189, Charleston, South Carolina, 29425, United States|Local Institution - 0007, Nashville, Tennessee, 37232, United States|Local Institution - 0030, Austin, Texas, 78731, United States|Local Institution - 0023, Norfolk, Virginia, 23502, United States|Local Institution - 0051, Capital Federal, Buenos Aires, 1426, Argentina|Local Institution - 0049, Ciudad AutÃ³noma de Buenos Aires, Buenos Aires, 1280, Argentina|Local Institution - 0151, Ciudad Autonoma Buenos Aires, Distrito Federal, 1118, Argentina|Local Institution - 0131, Garran, Australian Capital Territory, 2605, Australia|Local Institution - 0130, Kingswood, New South Wales, 2747, Australia|Local Institution - 0157, Macquarie University, New South Wales, 2109, Australia|Local Institution - 0043, St Leonards, New South Wales, 2065, Australia|Local Institution - 0143, North Adelaide, South Australia, 5006, Australia|Local Institution - 0037, Heidelberg, Victoria, 3084, Australia|Local Institution - 0038, Murdoch, Western Australia, 6150, Australia|Local Institution - 0090, Klagenfurt Am Woerthersee, 9020, Austria|Local Institution - 0091, Krems, 3500, Austria|Local Institution - 0011, Linz, 4020, Austria|Local Institution - 0012, Wien, 1090, Austria|Local Institution - 0060, Bruxelles, 1200, Belgium|Local Institution - 0063, Gent, 9000, Belgium|Local Institution - 0062, Wilrijk, 2610, Belgium|Local Institution - 0094, Fortaleza, Ceara, 60130-241, Brazil|Local Institution - 0099, Ipatinga, Minas Gerais, 35160-158, Brazil|Local Institution - 0092, Ijui, RIO Grande DO SUL, 98700-000, Brazil|Local Institution - 0212, Porto Alegre, RIO Grande DO SUL, 90035-001, Brazil|Local Institution - 0097, Porto Alegre, RIO Grande DO SUL, 90610000, Brazil|Local Institution - 0098, Barretos, Sao Paulo, 14780-070, Brazil|Local Institution - 0095, Jau, Sao Paulo, 17210-080, Brazil|Local Institution - 0093, Sao Jose Do Rio Preto, Sao Paulo, 15090-000, Brazil|Local Institution - 0164, Rio De Janeiro, 20231-050, Brazil|Local Institution - 0214, Sao Paulo, 01221-020, Brazil|Local Institution - 0159, Kelowna, British Columbia, V1Y 5L3, Canada|Local Institution - 0182, North York, Ontario, M2K 1E1, Canada|Local Institution - 0192, Chicoutimi, Quebec, G7H 5H6, Canada|Local Institution - 0190, Montreal, Quebec, H3T 1M5, Canada|Local Institution - 0053, Santiago, Metropolitana, 8330024, Chile|Local Institution - 0052, Santiago, Metropolitana, 8380456, Chile|Local Institution - 0210, Santiago, Metropolitana, 8420383, Chile|Local Institution - 0054, Santiago, Metropolitana, Chile|Local Institution - 0201, Colombia, Bogota, 0, Colombia|Local Institution - 0104, Bucaramanga, 681004, Colombia|Local Institution - 0103, Monteria, 230003, Colombia|Local Institution - 0148, Helsinki, 00029, Finland|Local Institution - 0145, Tampere, 33521, Finland|Local Institution - 0146, Turku, 20251, Finland|Local Institution - 0202, Brest, FinistÃ¨re, 29609, France|Local Institution - 0204, CrÃ©teil, Val-de-Marne, 94010, France|Local Institution - 0205, Amiens, 80054, France|Local Institution - 0198, Angers, 49100, France|Local Institution - 0101, Besancon, 25000, France|Local Institution - 0217, Bordeaux, 33076, France|Local Institution - 0199, Clermont-ferrand, 63000, France|Local Institution - 0206, La Tronche, 38043, France|Local Institution - 0075, Marseille, 13273, France|Local Institution - 0200, Montpellier Cedex 5, 34298, France|Local Institution - 0074, Nice, 06189, France|Local Institution - 0163, Paris, 75014, France|Local Institution - 0020, Pierre Benite Cedax, 69495, France|Local Institution - 0188, Saint Herblain Cedex, 44805, France|Local Institution - 0002, Strasbourg Cedex, 67091, France|Local Institution - 0003, TOULOUSE Cedex 9, 31059, France|Local Institution - 0100, Mainz, Rheinland-Pfalz, 55131, Germany|Local Institution - 0078, Aachen, 52074, Germany|Local Institution - 0015, Erfurt, 99028, Germany|Local Institution - 0081, Essen, 45136, Germany|Local Institution - 0086, Frankfurt Main, 60590, Germany|Local Institution - 0080, Goettingen, 37075, Germany|Local Institution - 0013, Herne, 44625, Germany|Local Institution - 0010, Jena, 07747, Germany|Local Institution - 0084, Luebeck, 23538, Germany|Local Institution - 0079, Magdeburg, 39120, Germany|Local Institution - 0082, Muenchen, 81675, Germany|Local Institution - 0016, Nuernberg, 90419, Germany|Local Institution - 0085, Trier, 54292, Germany|Local Institution - 0195, Athens, AttikÃ­, 155 62, Greece|Local Institution - 0031, Larissa, ThessalÃ­a, 411 10, Greece|Local Institution - 0194, Chaidari, 12462, Greece|Local Institution - 0196, Tel Aviv, Tel-Aviv, 6423906, Israel|Local Institution - 0068, Beer Sheva, 84101, Israel|Local Institution - 0066, Haifa, 3109601, Israel|Local Institution - 0067, Ramat Gan, 52621, Israel|Local Institution - 0064, Bari, 70124, Italy|Local Institution - 0193, Meldola (fc), 47014, Italy|Local Institution - 0032, Milano, 20133, Italy|Local Institution - 0065, Modena, 41012, Italy|Local Institution - 0033, Padova, 35128, Italy|Local Institution - 0034, Pisa, 56126, Italy|Local Institution - 0035, Roma, 00168, Italy|Local Institution - 0186, Komaki, Aichi, 485-8520, Japan|Local Institution - 0184, Sapporo, Hokkaido, 0030804, Japan|Local Institution - 0177, Sapporo, Hokkaido, 060-8543, Japan|Local Institution - 0185, Sapporo, Hokkaido, 0608604, Japan|Local Institution - 0179, Tsukuba-shi, Ibaraki, 3058576, Japan|Local Institution - 0171, Kita-gun, Kagawa, 761-0793, Japan|Local Institution - 0169, Yokohama, Kanagawa, 222-0036, Japan|Local Institution - 0168, Niigata-shi, Niigata, 9518520, Japan|Local Institution - 0173, Osakasayama, Osaka, 589-8511, Japan|Local Institution - 0175, Takatsuki City, Osaka, 569-8686, Japan|Local Institution - 0176, Hidaka-shi, Saitama, 3501298, Japan|Local Institution - 0170, Hamamatasu, Shizuoka, 431-3192, Japan|Local Institution - 0178, Minato-ku, Tokyo, 1058470, Japan|Local Institution - 0172, Shinjuku-ku, Tokyo, 160-8582, Japan|Local Institution - 0174, Fukuoka, 812-8582, Japan|Local Institution - 0180, Kyoto, 606-8507, Japan|Local Institution - 0137, Goyang-si, Gyeonggi-do, 10408, Korea, Republic of|Local Institution - 0203, Seongnam-si, KyÇnggi-do, 13620, Korea, Republic of|Local Institution - 0220, Busan, 48108, Korea, Republic of|Local Institution - 0218, Daegu, 41404, Korea, Republic of|Local Institution - 0208, Gyeongsangnam-do, 50612, Korea, Republic of|Local Institution - 0215, Seongnam-si,, 13496, Korea, Republic of|Local Institution - 0140, Seoul, 02841, Korea, Republic of|Local Institution - 0136, Seoul, 03080, Korea, Republic of|Local Institution - 0211, Seoul, 05505, Korea, Republic of|Local Institution - 0138, Seoul, 06351, Korea, Republic of|Local Institution - 0160, La Paz, BAJA Californa SUR, 23040, Mexico|Local Institution - 0102, Zapopan, Jalisco, 45050, Mexico|Local Institution - 0056, Monterrey, Nuevo LEON, 64460, Mexico|Local Institution - 0105, Colima, 28017, Mexico|Local Institution - 0070, Amsterdam, 1066 CX, Netherlands|Local Institution - 0072, Groningen, 9713 GZ, Netherlands|Local Institution - 0073, Sittard-Geleen, 6162 BG, Netherlands|Local Institution - 0087, Auckland, 1023, New Zealand|Local Institution - 0089, Christchurch, 8011, New Zealand|Local Institution - 0158, Gralum, 1714, Norway|Local Institution - 0132, Lorenskog, 1478, Norway|Local Institution - 0133, Oslo, 0379, Norway|Local Institution - 0153, Lisboa, 1649-035, Portugal|Local Institution - 0152, Porto, 4200-072, Portugal|Local Institution - 0219, Cluj-Napoca, 400015, Romania|Local Institution - 0076, Craiova, 200542, Romania|Local Institution - 0058, Sector 2, 022328, Romania|Local Institution, Saint-Petersburg, 194044, Russian Federation|Local Institution, St Petersburg, 197758, Russian Federation|Local Institution - 0154, Singapore, 168583, Singapore|Local Institution - 0113, Lugo, 27003, Spain|Local Institution - 0111, Madrid, 28007, Spain|Local Institution - 0112, Madrid, 28033, Spain|Local Institution - 0114, Madrid, 28041, Spain|Local Institution - 0156, Malaga, 29010, Spain|Local Institution - 0109, Sevilla, 41013, Spain|Local Institution - 0135, Kaohsiung, 833401, Taiwan|Local Institution - 0165, Taichung, 407219, Taiwan|Local Institution - 0141, Taipei City, 100229, Taiwan|Local Institution - 0139, Taipei, 11217, Taiwan|Local Institution - 0128, Chelmsford, Essex, CM1 7ET, United Kingdom|Local Institution - 0127, York, Yorkshire, YO31 8HE, United Kingdom|Local Institution - 0122, Glasgow, G12 0YN, United Kingdom|Local Institution - 0117, Lancaster, LA1 4RP, United Kingdom|Local Institution - 0121, London, SE1 9RT, United Kingdom|Local Institution - 0124, Oxford, OX3 7LE, United Kingdom",
NCT05947851,A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).,https://clinicaltrials.gov/study/NCT05947851,,RECRUITING,The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrutinib plus venetoclax is superior to VR with respect to progression-free survival (PFS) per 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria as assessed by blinded independent central review (BICR).,NO,"Leukemia, Lymphocytic, Chronic, B-Cell|Leukemia, Chronic Lymphocytic|Small-Cell Lymphoma|Lymphoma, Small Lymphocytic|CLL|SLL",DRUG: Nemtabrutinib|DRUG: Venetoclax|BIOLOGICAL: Rituximab,"Part 1: Number of participants experiencing dose-limiting toxicities (DLTs), DLT evaluation period is defined as 8 weeks after the first dose of the combination treatment of nemtabrutinib plus venetoclax Cycle 2 Day 1 in Part 1 + 4 weeks follow up. Each cycle is 4 weeks. DLTs are: Grade â¥3 nonhematologic toxicity (except Grade 3 nausea, vomiting, diarrhea, rash, fatigue, and uncontrolled hypertension which will not be considered a DLT unless lasting â¥72 hours despite optimal supportive care); Grade 4 hematologic toxicity lasting \>7 days (except Grade 3 lymphocytosis, Grade 4 platelet count decreased of any duration, or Grade 3 platelet count decreased if associated with bleeding); any Grade 3 or Grade 4 nonhematologic laboratory abnormality if values result in drug-induced liver injury, or medical intervention is required, or the abnormality leads to hospitalization, or the abnormality persists for \>1 week (with exceptions); missing \>25% of nemtabrutinib or venetoclax doses as a result of drug-related adverse events during the first 2 cycles; Grade 5 toxicity., Up to approximately 12 Weeks|Part 1: Number of participants experiencing adverse events (AEs), An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants experiencing AEs will be reported for Part 1., Up to approximately 28 months|Part 1: Number of participants discontinuing study treatment due to AEs, An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants discontinuing study treatment due to AEs will be reported for Part 1., Up to approximately 25 months|Part 2: PFS per the 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria as assessed by Blinded Independent Central Review (BICR), PFS is defined as the time from randomization to the first documented disease progression per iwCLL criteria 2018 as accessed by BICR, or death due to any cause, whichever occurs first. PFS will be presented., Up to approximately 71 months","Part 2: Undetectable minimal residual disease (MRD) rate in bone marrow as assessed by central laboratory, Undetectable MRD, defined as \<1 leukemic cell per 10,000 cells (MRD \<10-4) in bone marrow. The MRD rate will be presented., Month 14|Part 2: Overall Survival (OS), OS, defined as the time from randomization to death due to any cause. OS will be presented., Up to approximately 108 months|Part 2: Objective Response Rate (ORR) per iwCLL Criteria 2018 as assessed by BICR, OR, defined as complete response/remission (CR), complete response with incomplete count recovery (CRi), nodular partial remission (nPR), or partial remission (PR). CR is defined as meeting the following criteria: no lymph nodes \>1.5 cm, spleen size \<13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets â¥100 x 10\^9/L; hemoglobin â¥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as â¥50% decrease in â¥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS â¥1 of the following met: platelets â¥100 x 10\^9/L or â¥50% increase from screening, hemoglobin \>11 g/dL or â¥50% increase from screening, CLL cells or B lymphoid nodules in marrow. ORR will be presented., Up to approximately 108 months|Part 2: Duration of Response (DOR) per iwCLL Criteria 2018 as assessed by BICR, DOR, defined as the time from the first documented evidence of CR, CRi, nPR, or PR that led to response until disease progression or death due to any cause, whichever occurs first. CR is defined as meeting the following criteria: no lymph nodes \>1.5 cm, spleen size \<13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets â¥100 x 10\^9/L; hemoglobin â¥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as â¥50% decrease in â¥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS â¥1 of the following met: platelets â¥100 x 10\^9/L or â¥50% increase from screening, hemoglobin \>11 g/dL or â¥50% increase from screening, CLL cells or B lymphoid nodules in marrow. DOR will be presented., Up to approximately 108 months|Part 2: Number of participants experiencing AEs, An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants experiencing AEs will be reported for Part 2., Up to approximately 28 months|Part 2: Number of participants discontinuing study treatment due to AEs, An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants discontinuing study treatment due to AEs will be reported for Part 2., Up to approximately 25 months",,Merck Sharp & Dohme LLC,,ALL,"ADULT, OLDER_ADULT",PHASE3,720,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-08-08,2033-06-27,2033-06-27,2023-07-17,,2025-06-13,"Highlands Oncology Group ( Site 5405), Springdale, Arkansas, 72762, United States|MemorialCare Health System - Long Beach Medical Center ( Site 5421), Long Beach, California, 90806, United States|Memorial Hospital West ( Site 5410), Pembroke Pines, Florida, 33028, United States|Oregon Health and Science University ( Site 5425), Portland, Oregon, 97239-3011, United States|Medical Oncology Associates, PS ( Site 5406), Spokane, Washington, 99208, United States|University of Wisconsin Hospital and Clinics-Carbone Cancer Center ( Site 5423), Madison, Wisconsin, 53792, United States|Instituto Alexander Fleming ( Site 1005), Ciudad AutÃ³noma de Buenos Aires, Buenos Aires, C1426ANZ, Argentina|Instituto de Investigaciones ClÃ­nicas Mar del Plata ( Site 1007), Mar del Plata, Buenos Aires, B7600FZO, Argentina|Centro de EducaciÃ³n MÃ©dica e Investigaciones ClÃ­nicas (CEMIC)-Hematology ( Site 1002), Buenos Aires, Caba, C1431FWO, Argentina|Sanatorio Parque ( Site 1003), Rosario, Santa Fe, S2000DVC, Argentina|Centro Medico Fleischer ( Site 1006), Buenos Aires, 1414, Argentina|Hospital Aleman-oncohematologic diseases ( Site 1001), Buenos Aires, C1118AAT, Argentina|Royal Adelaide Hospital ( Site 1104), Adelaide, South Australia, 5000, Australia|Western Health-Sunshine & Footscray Hospitals-Cancer Services-Cancer Research ( Site 1103), Melbourne, Victoria, 3021, Australia|UZ Leuven-Hematology ( Site 1200), Leuven, Vlaams-Brabant, 3000, Belgium|ZAS Cadix ( Site 1203), Antwerpen, 2030, Belgium|ICESP - INSTITUTO DO CÃNCER DO ESTADO DE SÃO PAULO-Pesquisa Clinica ( Site 1308), Sao Paulo, 01246-000, Brazil|The Moncton Hospital ( Site 1414), Moncton, New Brunswick, E1C 6Z8, Canada|Centre IntÃ©grÃ© de SantÃ© et de Services Sociaux de la MontÃ©rÃ©gie-Centre ( Site 1402), Greenfield Park, Quebec, J4V 2H1, Canada|Centre intÃ©grÃ© universitaire de santÃ© et de services sociaux de l'Estrie - Centre Hospitalier Univer ( Site 1410), Sherbrooke, Quebec, J1H 5H4, Canada|Biocenter ( Site 1507), Concepcion., Biobio, 4070196, Chile|IC La Serena Research ( Site 1506), La Serena., Coquimbo, 1720430, Chile|Centro de Estudios ClÃ­nicos SAGA-CECSAGA ( Site 1509), Santiago., Region M. De Santiago, 7500653, Chile|FALP-UIDO ( Site 1500), Santiago, Region M. De Santiago, 7500921, Chile|ClÃ­nica Inmunocel ( Site 1511), Santiago, Region M. De Santiago, 7580206, Chile|FundaciÃ³n Valle del Lili ( Site 1703), Cali, Valle Del Cauca, 760032, Colombia|Hopital Claude Huriez - CHU de Lille ( Site 2107), Lille, Nord, 59037, France|Centre Hospitalier Universitaire Estaing ( Site 2105), Clermont-Ferrand, Puy-de-Dome, 63100, France|CHD Vendee ( Site 2100), La Roche-sur-Yon, Vendee, 85925, France|Klinikum Mutterhaus der BorromÃ¤erinnen-Innere Medizin I ( Site 2203), Trier, Rheinland-Pfalz, 54290, Germany|UniversitÃ¤tsklinikum Leipzig-Medical Department I - Hematology and Celltherapy ( Site 2201), Leipzig, Sachsen, 04103, Germany|Rambam Health Care Campus ( Site 2801), Haifa, 3109601, Israel|Hadassah Medical Center-Hemato-Oncology ( Site 2812), Jerusalem, 9112001, Israel|Sheba Medical Center-Hemato Oncology ( Site 2809), Ramat Gan, 5265601, Israel|Sourasky Medical Center ( Site 2811), Tel Aviv, 6423906, Israel|Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo ( Site 2906), Alessandria, Ancona, 15121, Italy|Ospedale San Raffaele-Programma di Ricerca Strategica sulla LLC ( Site 2902), Milano, 20132, Italy|Arcispedale Santa Maria Nuova-Hematology ( Site 2900), Reggio Emilia, 42123, Italy|Centro de Infusion Superare ( Site 3314), Ciudad de MÃ©xico, Distrito Federal, 03100, Mexico|Health Pharma Professional Research S.A. de C.V: ( Site 3301), Ciudad de MÃ©xico, Distrito Federal, 03100, Mexico|Centro de Investigacion Clinica Chapultepec ( Site 3309), Morelia, Michoacan, 58260, Mexico|Auxilio Mutuo Cancer Center ( Site 3900), San Juan, 00918, Puerto Rico|Netcare Pretoria East Hospital-Albert Alberts Stem Cell Transplant Centre ( Site 4401), Moreletta Park, Gauteng, 0181, South Africa|Groote Schuur Hospital ( Site 4400), Cape Town, Western Cape, 7925, South Africa|Haemalife ( Site 4407), Kuilsriver, Western Cape, 7580, South Africa|Instituto Catalan de Oncologia - Hospital Duran i Reynals-Haematology Department ( Site 4601), L'Hospitalet Del Llobregat, Barcelona, 08908, Spain|HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID ( Site 4602), Pozuelo de Alarcon, Madrid, 28223, Spain|HOSPITAL CLINICO DE VALENCIA-HEMATOLOGY ( Site 4603), Valencia, Valenciana, Comunitat, 46010, Spain|Namik Kemal University Medical Faculty-Hematology ( Site 4912), Tekirdag, Tekirdas, 59100, Turkey|Ankara Universitesi Tip Fakultesi Hastanesi-hematology ( Site 4913), Ankara, 06100, Turkey|Mega Medipol-Hematology ( Site 4904), Ä°stanbul, 34214, Turkey|TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi ( Site 4906), Istanbul, 34722, Turkey|Ege Universitesi Hastanesi ( Site 4902), Ä°zmir, 35100, Turkey|City Hospital, Nottingham University Hospitals-Hematology ( Site 5002), Nottingham, England, NG5 1PF, United Kingdom|University College London Hospital-Cancer Clinical Trials Unit ( Site 5001), London-Camden, London, City Of, NW1 2PG, United Kingdom",
NCT05673629,Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer,https://clinicaltrials.gov/study/NCT05673629,,RECRUITING,"The purpose of this clinical trial is to evaluate the efficacy and safety of Utidelone plus AC versus Docetaxel plus AC as neoadjuvant chemotherapy in high-risk HER2-negative early-stage or locally advanced breast cancer.

In this phase III, multi-center, open-label, randomized controlled study, 552 subjects will be enrolled and randomly assigned in a 1:1 ratio to either the Utidelone plus AC group or the docetaxel plus AC group, stratified by hormone receptor status (ER and/or PgR positive vs ER and PgR negative).",NO,Breast Cancer,DRUG: Utidelone Injection in combination with AC|DRUG: Docetaxel Injection in combination with AC,"Total Pathologic Complete Response, tpCR (ypT0/is, ypN0), percentage of patients with absence of invasive neoplastic cells in ipsilateral lymph nodes and the breast, 24 months","Breast Pathologic Complete Response, ypT0/is, percentage of patients whose pathological evaluation of hematoxylin and eosin-stained breast samples do not show any residual invasive carcinoma., 24 months|Objective Response Rate, Proportion of subjects who get to CR or PR during neoadjuvant therapy, 24 months|3-year Event Free Survival, Event of interest, which included preoperative disease progression, postoperative disease recurrence, and death from any cause., 36 months",,"Beijing Biostar Pharmaceuticals Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,552,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-05-30,2025-06-15,2025-12-31,2023-01-06,,2023-11-08,"Fudan University Shanghai Cancer Center, Shanghai, China",
NCT05296798,"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)",https://clinicaltrials.gov/study/NCT05296798,,RECRUITING,"This Phase III, randomized, two-arm, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus Phesgo compared with Phesgo after induction therapy with Phesgo plus taxane in participants with human epidermal growth factor receptor 2 (HER2)-positive, estrogen receptor (ER)-positive advanced breast cancer (metastatic or locally advanced disease not amenable to curative treatment) who have not previously received a systemic non-hormonal anti-cancer therapy in the advanced setting.",NO,Locally Advanced or Metastatic Breast Cancer,DRUG: Phesgo|DRUG: Giredestrant|DRUG: Docetaxel|DRUG: Paclitaxel|DRUG: LHRH Agonist|DRUG: Optional Endocrine Therapy of Investigator's Choice,"Progression-Free Survival, as Determined by the Investigator According to RECIST v1.1, From randomization for maintenance therapy to the first occurrence of disease progression or death from any cause, whichever occurs first (up to 53 months)","Overall Survival, From randomization for maintenance therapy to death from any cause (up to 98 months)|Objective Response Rate, as Determined by the Investigator According to RECIST v1.1, The objective response rate is defined as the percentage of participants with a complete response (CR) or partial response (PR) on two consecutive occasions at least 4 weeks apart., From randomization for maintenance therapy to disease progression or death (up to 53 months)|Duration of Response, as Determined by the Investigator According to RECIST v1.1, From first occurrence of documented objective response after randomization for maintenance therapy to disease progression or death from any cause, whichever occurs first (up to 53 months)|Clinical Benefit Rate, as Determined by the Investigator According to RECIST v1.1, The clinical benefit rate is defined as the percentage of participants with stable disease for â¥24 weeks or a complete response (CR) or partial response (PR)., From randomization for maintenance therapy to disease progression or death (up to 53 months)|Mean Role Functioning Score Over Time, as Assessed Using the European Organisation for Research and Treatment of Cancer Quality of Life-Core 30 (EORTC QLQ-C30) Questionnaire, Maintenance Cycles 1 (Baseline), 3, 6, 9, 12, 15, 18, once every 6 cycles from Cycles 24 to 90 (1 cycle is 21 days), treatment discontinuation, every 6 months and every year for Follow-up Years 1-2 and 3-5, respectively (up to 8 years)|Mean Change from Baseline in the Role Functioning Score Over Time, as Assessed Using the European Organisation for Research and Treatment of Cancer Quality of Life-Core 30 (EORTC QLQ-C30) Questionnaire, Maintenance Cycles 1 (Baseline), 3, 6, 9, 12, 15, 18, once every 6 cycles from Cycles 24 to 90 (1 cycle is 21 days), treatment discontinuation, every 6 months and every year for Follow-up Years 1-2 and 3-5, respectively (up to 8 years)|Mean Physical Functioning Score Over Time, as Assessed Using the European Organisation for Research and Treatment of Cancer Quality of Life-Core 30 (EORTC QLQ-C30) Questionnaire, Maintenance Cycles 1 (Baseline), 3, 6, 9, 12, 15, 18, once every 6 cycles from Cycles 24 to 90 (1 cycle is 21 days), treatment discontinuation, every 6 months and every year for Follow-up Years 1-2 and 3-5, respectively (up to 8 years)|Mean Change from Baseline in the Physical Functioning Score Over Time, as Assessed Using the European Organisation for Research and Treatment of Cancer Quality of Life-Core 30 (EORTC QLQ-C30) Questionnaire, Maintenance Cycles 1 (Baseline), 3, 6, 9, 12, 15, 18, once every 6 cycles from Cycles 24 to 90 (1 cycle is 21 days), treatment discontinuation, every 6 months and every year for Follow-up Years 1-2 and 3-5, respectively (up to 8 years)|Mean Global Health Status/Quality of Life Score Over Time, as Assessed Using the European Organisation for Research and Treatment of Cancer Quality of Life-Core 30 (EORTC QLQ-C30) Questionnaire, Maintenance Cycles 1 (Baseline), 3, 6, 9, 12, 15, 18, once every 6 cycles from Cycles 24 to 90 (1 cycle is 21 days), treatment discontinuation, every 6 months and every year for Follow-up Years 1-2 and 3-5, respectively (up to 8 years)|Mean Change from Baseline in the Global Health Status/Quality of Life Score Over Time, as Assessed Using the European Organisation for Research and Treatment of Cancer Quality of Life-Core 30 (EORTC QLQ-C30) Questionnaire, Maintenance Cycles 1 (Baseline), 3, 6, 9, 12, 15, 18, once every 6 cycles from Cycles 24 to 90 (1 cycle is 21 days), treatment discontinuation, every 6 months and every year for Follow-up Years 1-2 and 3-5, respectively (up to 8 years)|Number of Participants with at Least One Adverse Event, with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, version 5 (NCI CTCAE v5.0), From Baseline until 28 days after the final dose of study treatment (up to 8 years, 5 months)|Number of Participants with Abnormalities in Clinical Laboratory Test Results, From Baseline until 28 days after the final dose of study treatment (up to 8 years, 5 months)",,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE3,922,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-07-18,2027-12-31,2030-12-31,2022-03-25,,2025-05-28,"Arizona Clinical Research Center, Inc, Tucson, Arizona, 85715, United States|Genesis Cancer Center, Hot Springs, Arkansas, 71913, United States|Los Angeles Hematology Oncology Medical Group, Los Angeles, California, 90017, United States|St Mary's Hospital and Medical Center, Grand Junction, Colorado, 81502-1628, United States|Cancer Specialists of North Florida, Jacksonville, Florida, 32256, United States|Florida Cancer Specialists - EAST - SCRI - PPDS, West Palm Beach, Florida, 33401-3406, United States|Carle Cancer Center, Urbana, Illinois, 61801, United States|Maryland Oncology Hematology - Annapolis, Annapolis, Maryland, 21401, United States|St. Joseph Mercy Hospital, Ann Arbor, Michigan, 48106, United States|Henry Ford Hospital, Detroit, Michigan, 48202, United States|St. Joseph Mercy Oakland, Pontiac, Michigan, 48341, United States|Queens Hospital Cancer Center, Jamaica, New York, 11432, United States|Clinical Research Alliance, Westbury, New York, 11590, United States|Hightower Clinical, Oklahoma City, Oklahoma, 73102, United States|West Cancer Center, Germantown, Tennessee, 38138, United States|Texas Oncology - Austin, Austin, Texas, 78731, United States|CHRISTUS Spohn Cancer Center - Shoreline, Corpus Christi, Texas, 78404, United States|Texas Oncology - DFW, Dallas, Texas, 75246, United States|Texas Oncology - El Paso, El Paso, Texas, 79902, United States|Millennium Physicians, Houston, Texas, 77090, United States|CHRISTUS St. Michael Health System, Texarkana, Texas, 75503, United States|Virginia Oncology Associates, Norfolk, Virginia, 23502, United States|Swedish Cancer Institute - Edmonds Campus, Edmonds, Washington, 98026, United States|Swedish Cancer Institute - Issaquah, Issaquah, Washington, 98029, United States|Swedish Cancer Institute, Seattle, Washington, 98104, United States|FundaciÃ³n CENIT para la InvestigaciÃ³n en Neurociencias, Buenos Aires, C1125ABD, Argentina|Centro Oncologico Korben, Ciudad Autonoma Buenos Aires, C1426AGE, Argentina|Centro Oncologico Riojano Integral (CORI), La Rioja, F5300COE, Argentina|Fundacion Centro Oncologico de Integracion Regional (COIR), Mendoza, M5500AYB, Argentina|Instituto de OncologÃ­a de Rosario, Rosario, S2000KZE, Argentina|Hospital Provincial del Centenario, Rosario, S2002KDS, Argentina|CER San Juan Centro Polivalente de Asistencia e Investigacion Clinica, San Juan, J5400DIL, Argentina|Cliniques Universitaires St-Luc, Bruxelles, 1200, Belgium|GHdC Site Les Viviers, Charleroi, 6000, Belgium|UZ Gent, Gent, 9000, Belgium|Jessa Zkh (Campus Virga Jesse), Hasselt, 3500, Belgium|UZ Leuven Gasthuisberg, Leuven, 3000, Belgium|Clinique Ste-Elisabeth, Namur, 5000, Belgium|Hospital Sao Rafael - HSR, Salvador, Bahia, 41253-190, Brazil|Pronutrir - suporte nutricional e quimioterapia ltda., Fortaleza, CearÃ¡, 60810-180, Brazil|Hospital Araujo Jorge, Goiania, GoiÃ¡s, 74605-070, Brazil|Hospital do CÃ¢ncer de Londrina, Londrina, ParanÃ¡, 86015-520, Brazil|Hospital do Cancer de Pernambuco - HCP, Recife, Pernambuco, 50040-000, Brazil|Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda, Ijui, Rio Grande Do Sul, 98700-000, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, Rio Grande Do Sul, 91350-200, Brazil|Hospital de Amor AmazÃ´nia, Porto Velho, RondÃ´nia, 76834-899, Brazil|FundaÃ§Ã£o Pio XII Hospital de CÃ¢ncer de Barretos, Barretos, SÃ£o Paulo, 14784-400, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SÃ£o Paulo, 01246-000, Brazil|Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda, Sao Paulo, SÃ£o Paulo, 01317-001, Brazil|Affiliated Hospital of Hebei University, Baoding, 071000, China|Peking University People's Hospital, Beijing, 100044, China|the First Affiliated Hospital of Bengbu Medical College, Bengbu City, 233000, China|The First Hospital of Jilin University, Changchun City, 130021, China|Hunan Cancer Hospital, Changsha City, 410013, China|Sichuan Cancer Hospital, Chengdu City, 610041, China|West China Hospital - Sichuan University, Chengdu City, 610047, China|No. 900 Hospital (Fuzhou General Hospital), Fuzhou City, 350009, China|Fujian Cancer Hospital, Fuzhou, 350014, China|Zhejiang Cancer Hospital, Hangzhou City, 310022, China|Zhejiang Provincial People?s Hospital, Hangzhou, 310014, China|Shandong Cancer Hospital, Jinan, 250117, China|The First Affiliated Hospital Of Jinzhou Medical University, Jinzhou City, 121001, China|Yunnan Cancer Hospital, Kunming, 650118, China|The Third Hospital of Nanchang, Nanchang City, 330009, China|Jiangxi Cancer Hospital, Nanchang, 330006, China|Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University), Nanjing City, 210029, China|Jiangsu Cancer Hospital, Nanjing City, 211100, China|Guangxi Cancer Hospital of Guangxi Medical University, Nanning City, 530021, China|The First Affiliated Hospital of China Medical University, Shenyang City, 110001, China|Tianjin Cancer Hospital, Tianjin, 300060, China|The Tumor Hospital of Xinjiang Medical University, Urumqi, 830000, China|Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan City, 430023, China|The First Affiliated Hospital of Xian Jiao Tong University, Xi'an City, 710061, China|Clinica De La Costa, Barranquilla, 080020, Colombia|FundaciÃ³n CTIC - Centro de Tratamiento e InvestigaciÃ³n sobre CÃ¡ncer Luis Carlos Sarmiento Angulo, Bogota, D.C., 110131, Colombia|Clinica Colsanitas S.A. sede Clinica Universitaria Colombia, Bogota, 111321, Colombia|Oncomedica S.A., Monteria, 230002, Colombia|OncÃ³logos de Occidente, Pereira, 600004, Colombia|Dar El salam Cancer Centre, Cairo, Egypt|National Cancer Institute- Breast Cancer Treatment & Research Hospital - 5th settlement, Cairo, Egypt|Sohag Oncology Center, Cairo, Egypt|Institut Sainte Catherine, Avignon, 84918, France|CH de la CÃ´te Basque - HÃ´pital de Bayonne, Bayonne, 64109, France|CHU BesanÃ§on - HÃ´pital Jean Minjoz, BesanÃ§on Cedex, 25030, France|Polyclinique Bordeaux Nord Aquitaine, Bordeaux, 33077, France|CHU de GRENOBLE, Grenoble, 38043, France|CHD VendÃ©e, La Roche Sur Yon, 85025, France|Hopital Prive Jean Mermoz, Lyon, 69373, France|INSTITUT CURIE_Site Paris, Paris, 75005, France|Centre Catalan D' Oncologie, Perpignan, 66000, France|CHU Poitiers, Poitiers, 86000, France|Gesundheitszentrum Wetterau, Hochwaldkrankenhaus Bad Nauheim, Bad Nauheim, 61231, Germany|Sozialstiftung Bamberg, Klinikum am Bruderwald, GynÃ¤kologie, Bamberg, 96049, Germany|Onkologische Schwerpunktpraxis KurfÃ¼rstendamm, Berlin, 10707, Germany|GynÃ¤kologisches Zentrum Bonn, Bonn, 53111, Germany|Onkozentrum Dres. GÃ¶hler, Dresden, 01127, Germany|Kliniken Essen-Mitte, Essen, 45136, Germany|UniversitÃ¤tsklinikum Freiburg, Freiburg, 79106, Germany|HOPA MVZ GmbH, Hamburg, 22767, Germany|Nationales Centrum fÃ¼r Tumorerkrankungen (NCT), Heidelberg, 69120, Germany|Ãrztehaus am Bahnhofsplatz, Hildesheim, 31134, Germany|UniversitÃ¤tsklinikum des Saarlandes, Homburg/Saar, 66424, Germany|Dres. Andreas KÃ¶hler und Roswitha Fuchs, Langen, 63225, Germany|MVZ fÃ¼r HÃ¤matologie und Onkologie Ravensburg GmBH, Ravensburg, 88212, Germany|Caritas-Krankenhaus St. Josef, Regensburg, 93053, Germany|Klinikum Mutterhaus der Borromaeerinnen gGmbH, Trier, 54290, Germany|UniversitÃ¤tsklinik TÃ¼bingen, TÃ¼bingen, 72076, Germany|Budapesti Szent Margit Korhaz, Budapest, 1032, Hungary|Eszak-Pesti Centrumkorhaz - Honvedkorhaz, Budapest, 1062, Hungary|Semmelweis Egyetem;OnkolÃ³giai Profil (BelgyÃ³gyÃ¡szati Ã©s OnkolÃ³giai Klinika), Budapest, 1082, Hungary|Bekes Varmegyei KÃ¶zponti Korhaz, Pandy Kalman Tagkorhaz, Gyula, 5700, Hungary|Somogy Varmegyei Kaposi Mor Oktato Korhaz, KaposvÃ¡r, 7400, Hungary|Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet, Szolnok, 5004, Hungary|Komarom-Eszergom Varmegyei Szent Borbala Korhaz, Tatabanya, 2800, Hungary|Rajiv Gandhi Cancer Inst.&Research Center, New Delhi, Delhi, 110085, India|Fortis Hospital, New Delhi, Delhi, 110088, India|Manipal Hospital, Bangalore, Karnataka, 560017, India|Tata Memorial Hospital, Mumbai, Maharashtra, 400012, India|Sahyadri Super Specialty Hospital Hadapsar, Pune, Maharashtra, 411028, India|Netaji Subhas Chandra Bose Cancer Hospital, Kolkata, WEST Bengal, 700094, India|TATA Medical Centre, Kolkata, WEST Bengal, 700156, India|Azienda Ospedaliera Universitaria Federico II, Napoli, Campania, 80131, Italy|Istituto Nazionale Tumori Irccs Fondazione g. PASCALE, Napoli, Campania, 80131, Italy|AUSL della Romagna, Ravenna, Emilia-Romagna, 48121, Italy|Azienda UnitÃ  Sanitaria Locale di Reggio Emilia/IRCCS, Reggio Emilia, Emilia-Romagna, 42123, Italy|Ospedale Infermi AUSL della Romagna, Rimini, Emilia-Romagna, 47900, Italy|Policlinico Universitario Agostino Gemelli, Roma, Lazio, 00168, Italy|Asst Degli Spedali Civili Di Brescia, Brescia, Lombardia, 25123, Italy|Istituto Europeo Di Oncologia, Milano, Lombardia, 20141, Italy|Istituto Clinico Humanitas, Rozzano, Lombardia, 20089, Italy|Humanitas Centro Catanese Di Oncologia, Misterbianco (CT), Sicilia, 95045, Italy|Ospedale Civile, Livorno, Toscana, 57100, Italy|IOV - Istituto Oncologico Veneto - IRCCS, Padova, Veneto, 35128, Italy|King Hussein Cancer Center, Amman, 1269, Jordan|International Cancer Institute (ICI), Eldoret, 30100, Kenya|Aga Khan University Hospital, Nairobi, 00100, Kenya|Kyungpook National University Chilgok Hospital, Daegu, 41404, Korea, Republic of|National Cancer Center, Goyang-si, 10408, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, 03722, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Gangnam Severance Hospital, Seoul, 06273, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|Seoul St Mary's Hospital, Seoul, 06591, Korea, Republic of|Rizk Hospital, Beirut, 0, Lebanon|American University of Beirut - Medical Center, Beirut, 1107 2020, Lebanon|Hotel Dieu de France, Beirut, 2063 1111, Lebanon|Notre Dame Des Secours Hospital, Jbeil, 1401, Lebanon|Investigacion Oncofarmaceutica, La Paz, BAJA California SUR, 23040, Mexico|Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, 44280, Mexico|Health Pharma Professional Research, Cdmx, Mexico CITY (federal District), 03100, Mexico|Iem-Fucam, D.f., Mexico CITY (federal District), 04980, Mexico|Filios Alta Medicina, Monterrey, Nuevo LEON, 64460, Mexico|Hospital Universitario, Monterrey, Nuevo LEON, 64460, Mexico|Hospital Zambrano Hellion TecSalud, Monterrey, Nuevo LEON, Mexico|Cuidados oncologicos, QuerÃ©taro, Queretaro, 76000, Mexico|Oncologico Potosino, San Luis PotosÃ­, SAN LUIS Potosi, 78209, Mexico|Centro Estatal de Cancerologia de Chihuahua, Chihuahua, 31000, Mexico|Sultan Qaboos Comprehensive Cancer Care & Research Center, Muscat, Oman|Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii, Gdansk, 80-214, Poland|Szpital Morski im.PCK, Gdynia, 81-519, Poland|Przychodnia Lekarska KOMED, Roman Karaszewski, Konin, 62-500, Poland|Szpital WojewÃ³dzki im. Miko?aja Kopernika, Koszalin, 75-581, Poland|Opolskie Centrum Onkologii, Opole, 45-060, Poland|Ars Medical Sp. z o. o., Pi?a, 64-920, Poland|Szpital Kliniczny im. H.Swiecickiego UM w Poznaniu, Pozna?, 60-355, Poland|MRUKMED Lekarz Beata Madej-Mruk i Partner Spolka Partnerska Oddzial nr 1 w Rzeszowie, Rzeszow, 35-021, Poland|Centrum Onkologii ? Instytut im. Marii Sk?odowskiej-Curie Klinika NowotworÃ³w Piersi i Chirurgii, Warszawa, 02-781, Poland|IPO de Coimbra, Coimbra, 3000-075, Portugal|Hospital de S. Francisco Xavier, Lisboa, 1495-005, Portugal|Hospital da Luz, Lisboa, 1500-650, Portugal|Hospital Beatriz Angelo, Loures, 2674-514, Portugal|IPO do Porto, Porto, 4200-072, Portugal|Hamad Medical Corporation, Doha, 3050, Qatar|King Faisal Specialist Hospital & Research Centre, Riyadh, 11211, Saudi Arabia|National Guard King Abdulaziz Medical City, Riyadh, 11426, Saudi Arabia|King Fahad Medical City, Riyadh, 11525, Saudi Arabia|Wits Donald Gordon Clinical Trial Centre, Parktown, Johannesburg, 2193, South Africa|University of Pretoria Oncology Department, Pretoria, 0002, South Africa|Eastleigh Breast Care Centre, Pretoria, 0081, South Africa|Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Sant Andreu de La Barca, Barcelona, 08740, Spain|Complejo Hospitalario Universitario de Santiago (CHUS), Santiago de Compostela, LA Coruna, 15706, Spain|Hospital Universitario de Canarias, La Laguna, Tenerife, 38320, Spain|Hospital ClÃ­nic i Provincial, Barcelona, 08036, Spain|Hospital Universitario ClÃ­nico San Cecilio, Granada, 18016, Spain|Hospital Juan Ramon Jimenez, Huelva, 21005, Spain|Centro Oncologico MD Anderson Internacional, Madrid, 28033, Spain|Hospital Universitario La Paz, Madrid, 28046, Spain|Hospital Clinico Universitario Virgen de la Victoria, Malaga, 29010, Spain|Hospital Arnau de Vilanova (Valencia) Servicio de Oncologia, Valencia, 46015, Spain|Hospital Universitario Miguel Servet, Zaragoza, 50009, Spain|Changhua Christian Hospital, Changhua, 500, Taiwan|China Medical University Hospital, Taichung, 404, Taiwan|National Cheng Kung University Hospital, Tainan, 00704, Taiwan|National Taiwan University Hospital, Taipei 100, 100, Taiwan|Taipei Veterans General Hospital Office of General Surgery, Taipei, 11217, Taiwan|Rajavithi Hospital, Bangkok, 10400, Thailand|Ramathibodi Hospital, Bangkok, 10400, Thailand|Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, 50200, Thailand|Songklanagarind Hospital, Songkhla, 90110, Thailand|Adana Baskent University Hospital, Adana, 01120, Turkey|Ankara Oncology Hospital, Ankara, 06200, Turkey|Gazi Uni Medical Faculty Hospital, Ankara, 06500, Turkey|Ankara City Hospital, Ankara, 06800, Turkey|Uludag Uni Hospital, Bursa, 16059, Turkey|Dicle University Faculty of Medicine, Diyarbakir, 21280, Turkey|Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi, Edirne, 22030, Turkey|Ataturk University Medical Faculty Yakutiye Research Hospital Medical Oncology Department, Erzurum, 25240, Turkey|Medipol University Medical Faculty, Istanbul, 34214, Turkey|Prof. Dr. Cemil Tascioglu City Hospital, Istanbul, 34384, Turkey|Ac?badem Altunizade Hastanesi, Istanbul, 34662, Turkey|Ege Uni Medical Faculty, Izmir, 35100, Turkey|Katip Celebi University Ataturk Training and Research Hospital, Izmir, 35360, Turkey|Kocaeli University Faculty of Medicine, Izmit, 31380, Turkey|Erciyes Uni, Kayseri, 38039, Turkey|Antalya Memorial Hastanesi, Kepez, 07020, Turkey|Mersin City Education and Research Hospital, Mersin, 33240, Turkey|Ondokuz Mayis Univ. Med. Fac., Samsun, 55139, Turkey|Ac?badem Maslak Hastanesi BÃ¼yÃ¼kdere, Sar?yer/?stanbul, 34457, Turkey|Medical Park Seyhan Hospital, Seyhan, 01140, Turkey|Hacettepe Uni Medical Faculty Hospital, Sihhiye/Ankara, 06230, Turkey|Namik Kemal Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, 100, Tekirdag, 59030, Turkey|Karadeniz Tecnical University Medical Faculty, Trabzon, 61080, Turkey|Uganda Cancer Institute, Kampala, 88560, Uganda|Burjeel Medical City-Abu Dhabi, Abu Dhabi, United Arab Emirates|Tawam Hospital, Al Ain, 15258, United Arab Emirates|Ysbyty Gwynedd Hospital, Bangor, LL57 2PW, United Kingdom|Royal United Hospital, Bath, BA1 3NG, United Kingdom|Blackpool Victoria Hospital, Blackpool, FY3 8NR, United Kingdom|University Hospital North Tees, Cleveland, TS19 8PE, United Kingdom|Charing Cross Hospital, London, W6 8RF, United Kingdom|Maidstone Hospital, Maidstone, ME16 9QQ, United Kingdom|Nottingham University Hospitals NHS Trust - City Hospital, Nottingham, NG5 1PB, United Kingdom|Royal Preston Hosp, Preston, PR2 9HT, United Kingdom|North Wales Cancer Treatment Centre, Glan Clwyd Hospital, Rhyl, LL18 5UJ, United Kingdom|Queen's Hospital, Romford, RM7 0AG, United Kingdom|Singleton Hospital, Swansea, SA2 8QA, United Kingdom|Royal Cornwall Hospital, Truro, TR1 3LJ, United Kingdom",
NCT06984159,"The Study Will Evaluate if Leuprolide Mesylate is Safe and Effective in the Treatment of Subjects With Advanced Prostate Carcinoma, When Administered as Two Injections Six Months Apart.",https://clinicaltrials.gov/study/NCT06984159,,COMPLETED,"Evaluate the Safety, Efficacy and Pharmacokinetics of Leuprolide Injectable Emulsion in Advanced Prostate Cancer",NO,Advanced Prostate Cancer,DRUG: Leuprolide Injectable Emulsion (CAMCEVIÂ®),"Cumulative probability of maintaining serum testosterone at a castrate level (â¤ 50 ng/dL) from the end of 28 days after the first dose to the end of 168 days after the second dose., To evaluate the castrate level maintenance of Leuprolide Injectable Emulsion from the end of 28 days after the first dose to the end of 168 days after the second dose, with serum testosterone as a surrogate parameter for the assessment of efficacy and a castrate level of 50 ng/dL., from the end of 28 days after the first dose to the end of 168 days after the second dose.|including but not limited to:adverse events (AEs) and serious adverse events (SAEs), vital signs, physical examination, laboratory tests, 12-lead electrocardiogram (ECG), injection site reactions, local tolerance, etc., To evaluate the safety and tolerability of Leuprolide Injectable Emulsion after two subcutaneous injections in patients with advanced prostate cancer., 336 days",,,"Changchun GeneScience Pharmaceutical Co., Ltd.",,MALE,"ADULT, OLDER_ADULT",PHASE3,137,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-07-12,2023-11-30,2024-04-24,2025-05-22,,2025-05-22,"Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510000, China",
NCT06867562,Paclitaxel Lipid Suspension for Patients with Platinum-Resistant /Refractory Ovarian Cancer,https://clinicaltrials.gov/study/NCT06867562,,NOT_YET_RECRUITING,"This is a phase-3, open-label, multicenter, two-arm treatment study to evaluate the efficacy and safety of weekly Paclitaxel Lipid Suspension compared with weekly conventional paclitaxel in participants with platinum-resistant/refractory recurrent high-grade serous epithelial ovarian cancer.

Paclitaxel Lipid Suspension or conventional paclitaxel will be administered intravenously at a dose level of 80 mg/m2 on Day 1, Day 8 and Day 15 of each 28 days cycle.

The primary objective is to establish the non-inferiority of Paclitaxel Lipid Suspension in comparison with conventional paclitaxel for Injection in participants with platinum-resistant/refractory recurrent advanced high-grade serous epithelial ovarian cancer including fallopian tube and/or primary peritoneal cancer.

Participants in both arms will be dosed with the drug until disease progression as assessed by investigator and/or unacceptable toxicity.",NO,Platinum-Resistant Primary Peritoneal Carcinoma|Platinum Resistant High Grade Epithelial Ovarian Cancer|Platinum Resistant High Grade Serous Ovarian Cancer,DRUG: Paclitaxel Lipid Suspension|DRUG: Conventional paclitaxel or Taxol,"Confirmed Objective Response Rate, The proportion of participants whose Best Overall Response is a confirmed CR or PR as determined by blinded independent central review (BICR) based on RECIST v1.1, Minimum 6 months",,,Jina Pharmaceuticals Inc.,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,166,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2025-04,2025-12,2026-03,2025-03-10,,2025-03-10,,
NCT06082102,Efficacy and Safety of Orelabrutinib Plus Lenalidomide and Rituximab (R2) Compared to Placebo Plus R2 in r/r Marginal Zone Lymphoma,https://clinicaltrials.gov/study/NCT06082102,,RECRUITING,Evaluate the Efficacy and Safety of Orelabrutinib Plus Lenalidomide and Rituximab (R2) Versus Placebo Plus R2 in Relapsed/Refractory Marginal Zone Lymphoma.,NO,Relapsed/Refractory Marginal Zone Lymphoma,DRUG: Orelabrutinib|DRUG: Lenalidomide|DRUG: Rituximab|DRUG: Orelabrutinib Placebo,"IRC-assessed PFS, Through study completion, an average of 5 year.",,,"Beijing InnoCare Pharma Tech Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,324,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-12-19,2027-08-25,2030-02-25,2023-10-13,,2024-08-20,"Anqing Municipal Hospital, Anqing, Auhui, 246003, China|The First Affiliated Hospital of Bengbu Medical College, Bengbu, Auhui, 233000, China|Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, 100070, China|Beijing Tongren Hospital, Capital Medical University, Beijing, Beijing, 100730, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510055, China|Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong, 510120, China|Henan Cancer Hospital, Zhengzhou, Henan, 450003, China|Henan Provincial Peoples Hospital, Zhengzhou, Henan, 450003, China|Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, 430000, China|Hunan Cancer Hospital, Changsha, Hunan, 410000, China|The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, China|Jiangxi Cancer Hospital, Nanchang, Jiangxi, 330029, China|The Second Hospital of Dalian Medical University, Dalian, Liaoning, 116023, China|The first Hospital of China Medical University, Shenyang, Liaoning, 110002, China|The Affiliated Hospital Of Qingdao University, Qingdao, Shandong, 266000, China|Yantai Yuhuangding Hospital, Yantai, Shandong, 264099, China|Huashan Hospital, Fudan University, Shanghai, Shanghai, 200040, China|The Second Affiliated Hospital of Xi'an Jiaotong Universityï¼Xibei Hospitalï¼, Xi'an, Shanxi, 710004, China|West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China|The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310003, China",
NCT03952403,A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT03952403,,ACTIVE_NOT_RECRUITING,"This study involves a two-part design. Part 1 is designed to evaluate the safety and tolerability of the 4 drug (HLX10+HLX04+carboplatin+pemetrexed). Part 2 is a randomized, open-label study, which will evaluate the safety and efficacy of HLX10 in combination with carboplatin+pemetrexed with or without HLX04(biosimilar of avastin) compared with treatment with carboplatin+pemetrexed in 1st line Stage IIIB/IIIC or IV non-squamous NSCLC. Participants will be randomized in a 1:1:1 ratio to Arm A (HLX10+HLX04+Carboplatin+Pemetrexed), Arm B (HLX10+HLX04 placebo+Carboplatin+Pemetrexed), or Arm C (HLX10 placebo + HLX04 placebo+Carboplatin+Pemetrexed).",NO,Carcinoma|Non-Small-Cell Lung,"DRUG: HLX10, an engineered anti-PD-1 antibody|DRUG: HLX04, a bevacizumab biosimilar|DRUG: Carboplatin|DRUG: Pemetrexed","Part 1 Safety and tolerability of study treatment, baseline to 21 days|Part 2-Progression Free Survival (PFS) as Determined by the IRRC using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), Baseline until disease progression or death, whichever occurs first (up to approximately 24months)","Part 2-Overall survival (OS), as a major secondary endpoint, Baseline until death (up to approximately 36 months)|Part 1 and 2-Incidence rates of AEs and SAEs, Baseline up to approximately 36months|Part 1-Overall survival (OS), Baseline up to approximately 36months|Part 1 and Part 2-PFS (assessed by the investigator according to RECIST v1.1) in Part 1 and 2; PFS (assessed by IRRC according to RECIST v1.1) in Part 1, Baseline until disease progression or death, whichever occurs first (up to approximately 36months)|Part 1 and 2-Objective response rate (ORR, assessed by IRRC and investigator according to RECIST v1.1 criteria), Baseline up to approximately 36 months|Part 1 and 2-Duration of response (DOR, assessed by IRRC and investigator according to RECIST v1.1 criteria), Baseline up to approximately 36 months|Part 2-PFS2 (assessed by IRRC), Baseline up to approximately 36months|Part 1 and 2-Pharmacokinetics (PK): serum HLX10 concentration, Baseline up to approximately 36 months|Part 1 and 2-Immunogenicity evaluation: positive anti-drug antibody (ADA) rate, Baseline up to approximately 36 months|Part 1 and 2-PD-L1 expression level, Baseline|Part 1 and 2-Microsatellite instability(MSI), Baseline|Part 1 and 2-Tumor mutation burden(TMB), Baseline",,Shanghai Henlius Biotech,,ALL,"ADULT, OLDER_ADULT",PHASE3,643,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-12-02,2023-10-01,2024-03-15,2019-05-16,,2023-08-08,"Cancer Hospital Chinese Academy of Medical Sciences (CAMS), Beijing, Beijing, 100000, China",
NCT05989542,A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2),https://clinicaltrials.gov/study/NCT05989542,KUNPENG-2,RECRUITING,"The goal of this clinical trial is to test if PLB1001 works well and safely in Non-small cell lung cancer patients with MET exon 14 mutation. The main questions it aims to answer are:

* If it is works well in Non-small cell lung cancer patients with MET exon 14 mutation
* If it is safety and tolerant in Non-small cell lung cancer patients with MET exon 14 mutation

Participants will

1. be given PLB1001 200mg BID,oral.
2. be received hematology and urine and ECG examinations every 14 days (First 3 months) or every 28 days (After 3 months)
3. be received Image examination every 8 weeks(First year) or every 12 weeks(After one year)",NO,Non-small Cell Lung Cancer,DRUG: PLB1001,"Confirmed Objective Response Rate Evaluated by IRC, Objective response rate will be determined according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Objective response rate is defined as the percentage of patients who experienced either a complete response (CR) or partial response (PR) from first administration of trial treatment to first observation of progressive disease (PD). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD is defined as at least a 20% increase in the SLD, but at least increase 5mm, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions., 2 years","Confirmed Objective Response Rate evaluated by Investigator, Objective response rate will be determined according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Objective response rate is defined as the percentage of patients who experienced either a complete response (CR) or partial response (PR) from first administration of trial treatment to first observation of progressive disease (PD). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD is defined as at least a 20% increase in the SLD, but at least increase 5mm,taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions., 2 years|Disease Control Rate evaluated by IRC and Investigator, Disease Control Rate according to RECIST 1.1 is the percentage of patients who experienced either a complete response (CR), partial response (PR) or stable disease (SD)., 2 years|Duration Of Response evaluated by IRC and Investigator, Duration Of Response according to RECIST 1.1 is the time from when the CR/PR (whichever is first) criteria are first met until progression of disease (PD) or death due to any cause., 2 years|Time To Response evaluated by IRC and Investigator, Time To Response according to RECIST 1.1 is the time from the first trial treatment administration to the CR/PR (whichever is first) criteria are first met., 2 years|Progression Free Survival evaluated by IRC and Investigator, Progression Free Survival is defined as the time (in months) from the first administration of trial treatment to the date of the first documentation of PD or death due to any cause., 2 years|Intracranial Duration Of Response evaluated by IRC and Investigator, Duration Of Response according to RECIST 1.1 is the time from when the CR/PR (whichever is first) criteria are first met until progression of disease (PD) or death due to any cause., 2 years|Intracranial Disease Control Rate evaluated by IRC and Investigator, Disease Control Rate according to RECIST 1.1 is the percentage of patients who experienced either a complete response (CR), partial response (PR) or stable disease (SD)., 2 years|Intracranial Time To Response evaluated by IRC and Investigator, Time To Response according to RECIST 1.1 is the time from the first trial treatment administration to the CR/PR (whichever is first) criteria are first met., 2 years|Intracranial Progression Free Survival evaluated by IRC and Investigator, Progression Free Survival is defined as the time (in months) from the first administration of trial treatment to the date of the first documentation of PD or death due to any cause., 2 years|Occurrence of Treatment emergent adverse event (TEAEs), This outcome measure will be presented as the percentage of subjects with any (serious) adverse event (AE). Percentages are calculated using total number of subjects per treatment cohort as the denominator., 2 years","Minimum plasma concentration (Cmin) of drug and safety-analysis-set.etc, Subjects need collect PK sample within 2 hours prior to morning dose on day 1 (Â±7 days) of cycles 2, 3, and 5., Within 2 hours prior to morning dose on day 1 (Â±7) of Cycle 2,Cycle,3,Cycle5 (eash cycle is 28 days )",Beijing Pearl Biotechnology Limited Liability Company,,ALL,"ADULT, OLDER_ADULT",PHASE3,136,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-06-29,2026-09-30,2027-09-30,2023-08-14,,2025-02-06,"Guangdong Provincial People's Hospital, Guangzhou, Guangdong, 510080, China",
NCT06735391,A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations,https://clinicaltrials.gov/study/NCT06735391,,RECRUITING,"This is a Phase 3, randomized, positive-controlled, open-label clinical study. The primary objective is to evaluate the efficacy of JMT101 in combination with osimertinib versus osimertinib alone in patients with newly diagnosed locally advanced or metastatic non-squamous NSCLC harboring EGFR-sensitive mutations.",NO,Locally Advanced or Metastatic Non-squamous NSCLC|Harboring EGFR Sensitive Mutations NSCLC|Previously Untreated Systematically NSCLC,DRUG: JMT101|DRUG: Osimertinib,"PFS assessed by the independent review committee (IRC) based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, Up to approximately 44 months after the first participant is enrolled","Overall survival (OS), Up to approximately 44 months after the first participant is enrolled|Objective response rate (ORR) assessed by IRC based on RECIST 1.1, Up to approximately 44 months after the first participant is enrolled|duration of response (DOR) assessed by IRC based on RECIST 1.1, Up to approximately 44 months after the first participant is enrolled|disease control rate (DCR) assessed by IRC based on RECIST 1.1, Up to approximately 44 months after the first participant is enrolled|DOR assessed by the investigator based on RECIST 1.1, Up to approximately 44 months after the first participant is enrolled|ORR assessed by the investigator based on RECIST 1.1, Up to approximately 44 months after the first participant is enrolled|DCR assessed by the investigator based on RECIST 1.1, Up to approximately 44 months after the first participant is enrolled|Adverse events incidence and severity, Up to approximately 44 months after the first participant is enrolled|Serum concentration of JMT101, Up to approximately 44 months after the first participant is enrolled|Incidence and titer of anti-drug antibodies (ADAs), Up to approximately 44 months after the first participant is enrolled|The incidence of neutralising antibodies (NAbs), Up to approximately 44 months after the first participant is enrolled",,Shanghai JMT-Bio Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE3,516,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2024-10-23,2026-09-30,2029-05-30,2024-12-16,,2024-12-16,"Sun Yat sen University Cancer Prevention and Treatment Center, Guangzhou, China",
NCT04655976,Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy,https://clinicaltrials.gov/study/NCT04655976,COSTAR Lung,ACTIVE_NOT_RECRUITING,"This is a multi-center, parallel group treatment, Phase 2/3 open label study evaluating cobolimab in combination with dostarlimab and docetaxel in participants with advanced non-small cell Lung Cancer (NSCLC) who have progressed on prior anti-PD-(L)1 therapy and chemotherapy.",NO,"Lung Cancer, Non-Small Cell",BIOLOGICAL: Cobolimab|BIOLOGICAL: Dostarlimab|DRUG: Docetaxel,"Overall survival (OS) in participants receiving cobolimab + dostarlimab + docetaxel relative to participants receiving docetaxel alone, OS is defined as survival from the date of randomization to the date of death by any cause., Up to approximately 52 months|OS in participants receiving dostarlimab + docetaxel relative to participants receiving docetaxel alone, OS is defined as survival from the date of randomization to the date of death by any cause., Up to approximately 52 months","OS in participants receiving cobolimab + dostarlimab + docetaxel relative to participants receiving dostarlimab + docetaxel, OS is defined as survival from the date of randomization to the date of death by any cause., Up to approximately 52 months|Objective response rate (ORR), Confirmed ORR is defined as the proportion of participants who have achieved confirmed complete response (CR) or confirmed partial response (PR), evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 based on Investigator assessment., Up to approximately 52 months|Progression free survival (PFS), PFS is defined as the length of time until disease progression, from the time of randomization to the earliest date of assessment of disease progression based on RECIST version 1.1 by Investigator assessment or death by any cause., Up to approximately 52 months|Duration of response (DOR), DOR is defined as the time from first documented response (CR/PR) until the time of first documentation of disease progression based on RECIST version 1.1 by Investigator assessment or death, whichever occurs first., Up to approximately 52 months|Time to deterioration (TTD), TTD in lung cancer is defined as time from randomization to meaningful deterioration on a composite endpoint of dyspnea, chest pain, and cough, from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 13 item Lung Cancer Module (EORTC QLQ LC13)., Up to approximately 52 months|Change from Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30 item Core Module (EORTC QLQ-C30) assessment, EORTC QLQ-C30 is a questionnaire used to measure health related quality of life (HRQoL) in participants with cancer., Baseline (Day 1) and up to approximately 52 months|Change from Baseline in the EORTC QLQ LC13 assessment, EORTC QLQ LC13 is a lung cancer specific questionnaire module designed to supplement the EORTC QLQ C30., Baseline (Day 1) and up to approximately 52 months|Number of participants with serious adverse events (SAEs), From consent signature (Day -28) until the 90 day post last dose follow-up|Number of participants with treatment-emergent adverse events (TEAEs) and immune related adverse event (irAEs), From consent signature (Day -28) until the 30 day post last dose follow-up|Number of participants with TEAEs leading to death, From consent signature (Day -28) until the 90 day post last dose follow-up|Number of participants with adverse events (AEs) leading to discontinuation, From consent signature (Day -28) until the 30 day post last dose follow-up|Number of participants with clinically significant changes in hematology, clinical chemistry, thyroid function and urinalysis lab parameters, Blood and urine samples will be collected for the assessment of hematology, clinical chemistry, thyroid function and urinalysis lab parameters, From consent signature (Day -28) until the 90 day post last dose follow-up|Number of participants with clinically significant changes in vital signs and Electrocardiogram (ECG) Parameters, From consent signature (Day -28) until the 90 day post last dose follow-up|Number of participants with indicated Eastern Cooperative Oncology Group (ECOG) performance status, Performance status will be assessed using the ECOG performance status scale. Scales range from grade 0 to 4, grade 0 denoting fully active and grade 4 completely disabled., From consent signature (Day -28) until the 90 day post last dose follow-up|Number of participants with usage of concomitant medications, From consent signature (Day -28) until the 90 day post last dose follow-up|Number of participants with abnormal physical examinations, From consent signature (Day -28) until the 90 day post last dose follow-up",,GlaxoSmithKline,,ALL,"ADULT, OLDER_ADULT",PHASE3,758,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-12-08,2025-04-07,2025-10-31,2020-12-07,,2024-11-05,"GSK Investigational Site, Fountain Valley, California, 92708, United States|GSK Investigational Site, Walnut Creek, California, 94596, United States|GSK Investigational Site, Norwich, Connecticut, 06360, United States|GSK Investigational Site, Washington, District of Columbia, 20422, United States|GSK Investigational Site, Honolulu, Hawaii, 96819, United States|GSK Investigational Site, Iowa City, Iowa, 52242, United States|GSK Investigational Site, Edgewood, Kentucky, 41017, United States|GSK Investigational Site, Las Vegas, Nevada, 89144, United States|GSK Investigational Site, Mineola, New York, 11501, United States|GSK Investigational Site, New York, New York, 10016, United States|GSK Investigational Site, White Plains, New York, 10601, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, 15224, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, 15232, United States|GSK Investigational Site, Sioux Falls, South Dakota, 57105, United States|GSK Investigational Site, Houston, Texas, 77030, United States|GSK Investigational Site, Fredericksburg, Virginia, 22408, United States|GSK Investigational Site, Tacoma, Washington, 98405, United States|GSK Investigational Site, Buenos Aires, C1426ABP, Argentina|GSK Investigational Site, Cipoletti Rio Negro, R8324CVE, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aire, 1425, Argentina|GSK Investigational Site, Florida, 1602, Argentina|GSK Investigational Site, La Rioja, F5300COE, Argentina|GSK Investigational Site, Pergamino, B2700CPM, Argentina|GSK Investigational Site, Rosario, S2000DBS, Argentina|GSK Investigational Site, Viedma, R8500ACE, Argentina|GSK Investigational Site, South Brisbane, Queensland, 4101, Australia|GSK Investigational Site, Ashford, South Australia, 5037, Australia|GSK Investigational Site, Hobart, Tasmania, 7000, Australia|GSK Investigational Site, Ballarat, Victoria, 3350, Australia|GSK Investigational Site, Melbourne, Victoria, 3004, Australia|GSK Investigational Site, Mount Waverley, Victoria, 3350, Australia|GSK Investigational Site, Aalst, 9300, Belgium|GSK Investigational Site, Hasselt, 3500, Belgium|GSK Investigational Site, Kortrijk, 8500, Belgium|GSK Investigational Site, Blumenau, 89010340, Brazil|GSK Investigational Site, Fortaleza, 60336-232, Brazil|GSK Investigational Site, Porto Alegre, 90610000, Brazil|GSK Investigational Site, Rio de Janeiro, 22061080, Brazil|GSK Investigational Site, Rio de Janeiro, 22250-905, Brazil|GSK Investigational Site, Salvador, 40170-110, Brazil|GSK Investigational Site, SAo Paulo, 04014-002, Brazil|GSK Investigational Site, Kingston, Ontario, K7L 2V7, Canada|GSK Investigational Site, Oshawa, Ontario, L1G 2B9, Canada|GSK Investigational Site, Sudbury, Ontario, P3E 5J1, Canada|GSK Investigational Site, Greenfield Park, Quebec, J4V 2H1, Canada|GSK Investigational Site, Montreal, Quebec, H3T 1E2, Canada|GSK Investigational Site, Helsinki, 00180, Finland|GSK Investigational Site, Kuopio, 70210, Finland|GSK Investigational Site, CrEteil cedex, 94010, France|GSK Investigational Site, Grenoble cedex 9, 38043, France|GSK Investigational Site, Marseille, 13009, France|GSK Investigational Site, Nice Cedex 2, 06189, France|GSK Investigational Site, Quimper cedex, 29107, France|GSK Investigational Site, Rennes, 35033, France|GSK Investigational Site, Tours cedex 9, 37044, France|GSK Investigational Site, Augsburg, 86156, Germany|GSK Investigational Site, Bad Berka, 99437, Germany|GSK Investigational Site, Berlin, 12200, Germany|GSK Investigational Site, Bonn, 53113, Germany|GSK Investigational Site, Dresden, 01307, Germany|GSK Investigational Site, Essen, 45147, Germany|GSK Investigational Site, Frankfurt, 60488, Germany|GSK Investigational Site, Frankfurt, 60590, Germany|GSK Investigational Site, Halle, 06120, Germany|GSK Investigational Site, Heidelberg, 69126, Germany|GSK Investigational Site, Karlsruhe, 76137, Germany|GSK Investigational Site, Koeln, 51109, Germany|GSK Investigational Site, Muenchen, 81925, Germany|GSK Investigational Site, MUnchen, 80336, Germany|GSK Investigational Site, Oldenburg, 26121, Germany|GSK Investigational Site, Athens, 115 27, Greece|GSK Investigational Site, Athens, 11526, Greece|GSK Investigational Site, Athens, 11528, Greece|GSK Investigational Site, Athens, 12462, Greece|GSK Investigational Site, Larissa, 41100, Greece|GSK Investigational Site, Pylaia Thessaloniki, 570 01, Greece|GSK Investigational Site, Rio Patras, 26504, Greece|GSK Investigational Site, Thessaloniki, 55236, Greece|GSK Investigational Site, Thessaloniki, 57010, Greece|GSK Investigational Site, Ancona, 60126, Italy|GSK Investigational Site, Avellino, 83100, Italy|GSK Investigational Site, Firenze, 50134, Italy|GSK Investigational Site, Milano, 20132, Italy|GSK Investigational Site, Milano, 20133, Italy|GSK Investigational Site, Monza, 20900, Italy|GSK Investigational Site, Napoli, 80131, Italy|GSK Investigational Site, Orbassano TO, 10043, Italy|GSK Investigational Site, Perugia, 06156, Italy|GSK Investigational Site, Siena, 53100, Italy|GSK Investigational Site, Kyoto, 612-8555, Japan|GSK Investigational Site, Miyagi, 981-1293, Japan|GSK Investigational Site, Osaka, 591-8555, Japan|GSK Investigational Site, Yamaguchi, 755-0241, Japan|GSK Investigational Site, Cheongju Chungcheongbuk-do, 28644, Korea, Republic of|GSK Investigational Site, Daegu, 42601, Korea, Republic of|GSK Investigational Site, Gyeonggi-do, 10408, Korea, Republic of|GSK Investigational Site, Pusan, 49241, Korea, Republic of|GSK Investigational Site, Seongnam-si Gyeonggi-do, 13620, Korea, Republic of|GSK Investigational Site, Seoul, 03722, Korea, Republic of|GSK Investigational Site, Seoul, 05505, Korea, Republic of|GSK Investigational Site, Seoul, 06351, Korea, Republic of|GSK Investigational Site, Seoul, 08308, Korea, Republic of|GSK Investigational Site, Suwon Kyunggi-do, 443-721, Korea, Republic of|GSK Investigational Site, Guadalajara, 44280, Mexico|GSK Investigational Site, Mexico City, 03100, Mexico|GSK Investigational Site, Mexico City, 03810, Mexico|GSK Investigational Site, Mexico City, 06700, Mexico|GSK Investigational Site, Mexico City, CP 14080, Mexico|GSK Investigational Site, Monterrey, 64460, Mexico|GSK Investigational Site, Puebla Puebla, 72560, Mexico|GSK Investigational Site, Amersfoort, 3813 TZ, Netherlands|GSK Investigational Site, Enschede, 7512 KZ, Netherlands|GSK Investigational Site, Groningen, 9713 GZ, Netherlands|GSK Investigational Site, Harderwijk, 3844 DG, Netherlands|GSK Investigational Site, Nijmegen, 6525 GA, Netherlands|GSK Investigational Site, Utrecht, 3543 AZ, Netherlands|GSK Investigational Site, Zwolle, 8025 AB, Netherlands|GSK Investigational Site, Bydgoszcz, 85-796, Poland|GSK Investigational Site, Gdynia, 81-519, Poland|GSK Investigational Site, Lodz, 90-338, Poland|GSK Investigational Site, Olsztyn, 10-357, Poland|GSK Investigational Site, Pila, 64-920, Poland|GSK Investigational Site, Poznan, 60-693, Poland|GSK Investigational Site, Bucuresti, 013812, Romania|GSK Investigational Site, Craiova Dolj, 200385, Romania|GSK Investigational Site, Craiova, 200347, Romania|GSK Investigational Site, Otopeni, 075100, Romania|GSK Investigational Site, Timisoara, 300239, Romania|GSK Investigational Site, Chelyabinsk, 454048, Russian Federation|GSK Investigational Site, Moscow Region, 143423, Russian Federation|GSK Investigational Site, Pushkin, 196603, Russian Federation|GSK Investigational Site, Saint-Petersburg, 197022, Russian Federation|GSK Investigational Site, A CoruNa, 15006, Spain|GSK Investigational Site, Badalona, 08916, Spain|GSK Investigational Site, Barcelona, 08035, Spain|GSK Investigational Site, Barcelona, 08036, Spain|GSK Investigational Site, Burgos, 09006, Spain|GSK Investigational Site, Cordoba, 140044, Spain|GSK Investigational Site, Las Palmas De Gran Canar, 35016, Spain|GSK Investigational Site, Madrid, 28007, Spain|GSK Investigational Site, Madrid, 28034, Spain|GSK Investigational Site, Madrid, 28041, Spain|GSK Investigational Site, Madrid, 28046, Spain|GSK Investigational Site, Madrid, 28050, Spain|GSK Investigational Site, Madrid, 28222, Spain|GSK Investigational Site, Malaga, 29010, Spain|GSK Investigational Site, Valencia, 46026, Spain|GSK Investigational Site, Gavle, SE-801 87, Sweden|GSK Investigational Site, Stockholm, 171 64, Sweden|GSK Investigational Site, Uppsala, SE-751 85, Sweden|GSK Investigational Site, HsinChu, 300, Taiwan|GSK Investigational Site, Taichung, 407, Taiwan|GSK Investigational Site, Taipei, 11217, Taiwan|GSK Investigational Site, Taipei, 23561, Taiwan|GSK Investigational Site, Bangkok, 10210, Thailand|GSK Investigational Site, Dusit, 10300, Thailand|GSK Investigational Site, Kho Hong Hat Yai, 90110, Thailand|GSK Investigational Site, Khon Kaen, 40002, Thailand|GSK Investigational Site, Pathumthani, 12120, Thailand|GSK Investigational Site, Adana, 1120, Turkey|GSK Investigational Site, Antalya, 07020, Turkey|GSK Investigational Site, Izmir, 35600, Turkey|GSK Investigational Site, Cardiff, CF14 2TL, United Kingdom|GSK Investigational Site, Edinburgh, EH4 2XU, United Kingdom|GSK Investigational Site, London, SE1 9RT, United Kingdom|GSK Investigational Site, London, W1G 6AD, United Kingdom|GSK Investigational Site, Manchester, M20 4BX, United Kingdom",
NCT04842617,"Phase III Study ï¼SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative",https://clinicaltrials.gov/study/NCT04842617,,ACTIVE_NOT_RECRUITING,"The study is to evaluate the efficacy and safety of SHR6390 combined with endocrine therapy for the adjuvant treatment of hormone receptor positive,Human Epidermal Receptor 2 negative.

To observe the PK characteristics of SHR6390 combined with endocrine therapy for the adjuvant treatment of hormone receptor positive,Human Epidermal Receptor 2 negative.",NO,"Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stageï¼Female Breast Cancer",DRUG: SHR6390|DRUG: placebo,"IDFSï¼Invasive Disease-Free Survivalï¼, at least 5 years from the date of randomization .","DFS(Disease-Free Survival), The observation time is at least 5 years from the date of randomization . Evaluations were conducted every 26 weeks for the first 2 years and every 52 weeks thereafter, with a follow-up of at least 5 years.|OS(Overall Survival), up to approximately 5 years.|DDFS(Distant Disease-Free Survival), from randomization to distant recurrence or death from any cause, whichever occurs first. Evaluations were conducted every 26 weeks for the first 2 years and every 52 weeks thereafter, with a follow-up of at least 5 years.|Number of Participants With adverse events (AEs) and serious adverse events (SAEs) Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v5.0., To evaluate the safety and tolerability of SHR6390 combined with endocrine therapy for the adjuvant treatment of hormone receptor positive,Human Epidermal Receptor 2 negative female breast cancer., up to approximately 5 years|Plasma concentration of SHR6390 will be analyzed for PK samples, To explore the PK characteristics of SHR6390 combined with endocrine therapy for the adjuvant treatment of hormone receptor positive,Human Epidermal Receptor 2 negative female breast cancer., collected on day 1 of the 5th, 9th, 13th and 17th weeks, respectively.",,"Jiangsu HengRui Medicine Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,5274,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-04-30,2026-10-31,2031-10-31,2021-04-13,,2024-08-01,"Fudan University Shanghai Cancer Center, Shanghai, Shanghai, 200032, China",
NCT06852222,"A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Acute Myeloid Leukemia (AML)",https://clinicaltrials.gov/study/NCT06852222,cAMeLot-2,NOT_YET_RECRUITING,The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with Acute Myeloid Leukemia (AML).,NO,"Leukemia, Myeloid, Acute",DRUG: Bleximenib|DRUG: Venetoclax (VEN)|DRUG: Azacitidine (AZA)|DRUG: Placebo,"Percentage of Participants who Achieve Complete Remission (CR), CR is defined as Bone marrow blasts less than (\<) 5 percent (%); Absence of circulating blasts; Absence of extramedullary disease; Absolute neutrophil count (ANC) greater than or equal to (\>=) 1.0 \* 10\^9/Liter (1,000/microliter \[mcL\] ); Platelet count \>= 100 \* 10\^9/L (100,000/mcL)., Up to 4 years and 1 month|Overall Survival (OS), Overall survival time is defined as the time duration from the date of randomization to death due to any cause., Up to 4 years and 1 month","Event-free survival (EFS), EFS is defined as the time from randomization to treatment failure, relapse, or death due to any cause, whichever occurs first., Up to 4 years and 1 month|Duration of CR, Duration of CR will be estimated among responders from the date of initial documentation of CR, to the date of first documented evidence of relapse, or death due to any cause, whichever occurs first, respectively., Up to 4 years and 1 month|Time to CR, Time to CR is defined as time from randomization to first documented response., Up to 4 years and 1 month|Rate of CR-Measurable Residual Disease (MRD), Rate of CR-MRD is defined as percentage of participants who have achieved CR-MRD., Up to 4 years and 1 month|Percentage of Participants who Achieved Transfusion Independence, Transfusion independence is defined as lack of requirement for red blood cell (RBC) and platelet transfusions during any 56-day period., Up to 4 years and 1 month|Percentage of Participants with Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT), Allo-HSCT is defined as the percentage of participants who have undergone allo-HSCT after randomization., Up to 4 years and 1 month|Number of Participants with Adverse Events (AEs), An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event., Up to 4 years and 1 month|Number of Participants with Abnormalities in Clinical Laboratory Parameters, Participants with abnormalities in clinical laboratory parameters will be reported., Up to 4 years and 1 month|Serum Concentration of Bleximenib, Serum samples will be analyzed to determine concentrations of bleximenib., Up to 4 years and 1 month",,"Janssen Research & Development, LLC",,ALL,"ADULT, OLDER_ADULT",PHASE3,600,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2025-04-30,2029-06-22,2029-08-15,2025-02-28,,2025-05-04,"Hadassah University Hospita Ein Kerem, Jerusalem, 9112001, Israel",
NCT04301739,to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC),https://clinicaltrials.gov/study/NCT04301739,,NOT_YET_RECRUITING,"This study is a randomized, double-Blind,international multi-Centre, phase III clinical study to evaluate efficacy and safety of HLX10 in combination with chemotherapy versus placebo in combination with chemotherapy as neoadjuvant therapy and HLX10 versus placebo as adjuvant therapy in previously untreated and potentially resectable patients with TNBC and without distant metastasis.

Eligible subjects in this study will be randomized to Arm A or Arm B at 2:1 ratio as follows:

Arm A (HLX10 arm): HLX10 + chemotherapy (nab-paclitaxel carboplatin) (4 cycles) â HLX10 + chemotherapy (doxorubicin or epirubicin cyclophosphamide) (4 cycles) â surgery â HLX10 (9 cycles) Arm B (placebo arm): Placebo + chemotherapy (nab-paclitaxel carboplatin) (4 cycles) â Placebo + chemotherapy (doxorubicin or epirubicin cyclophosphamide) (4 cycles) â surgery â Placebo (9 cycles) The three stratification factors for randomization include: lymph node metastasis (yes or no), size of primary tumor lesion (T1/T2 or T3/T4), asian population (yes or no).",NO,Triple Negative Breast Cancer,"DRUG: HLX10|DRUG: nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide|DRUG: Placebo","tumor assessment, Pathological complete response (pCR) rate (ypT0/Tis, ypN0) (assessed by central pathology laboratory based on American Joint Committee on Cancer (AJCC) staging system), up till 5 years after the enroll",,,Shanghai Henlius Biotech,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,522,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-04-17,2022-09-07,2027-04-09,2020-03-10,,2020-03-12,,
NCT06752811,Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer,https://clinicaltrials.gov/study/NCT06752811,pompom,RECRUITING,"This trial is a multi-center, randomized, open, parallel-group and positive-controlled phase III trial to evaluate the efficacy and safety of paclitaxel polymeric micelles for injection plus gemcitabine as first-line treatment of metastatic pancreatic cancer compared with nab-Paclitaxel plus gemcitabine.",NO,Pancreatic Cancer Metastatic,DRUG: paclitaxel polymeric micelles for injection|DRUG: Gemcitabine Hydrochloride for Injection|DRUG: Paclitaxel for Injection (albumin bound )|DRUG: Gemcitabine Hydrochloride for Injection,"Progression-Free-Survival, PFS(Progression-Free-Survival) is the time from randomization until the date of objectively determined progressive disease (PD) or death due to any cause, whichever occurs first., Randomization to measured PD or date of death from any causeï¼up to 36 months)","Overall Survival(OS), The time from randomization to death., Randomization to date of death from any causeï¼up to 36 months)|Objective Response Rate(ORR), Proportion of subjects who have achieved complete response (CR) or partial response (PR) (RECIST 1.1), Baseline to measured PDï¼up to 36 months)|Disease Control Rateï¼DCRï¼, Proportion of subjects who have achieved complete response (CR), partial response (PR) or stable disease (SD) (RECIST 1.1), Baseline to measured PDï¼up to 36 months)|Incidence of adverse events, Number of participants with treatment-related adverse events as assessed by CTCAE v5.0""., up to 36 months",,"Shanghai Yizhong Pharmaceutical Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,416,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2025-02-05,2027-07-01,2027-12-31,2024-12-31,,2025-05-14,"Jiangsu Province Hospital, Nanjing, Jiangsu, 210029, China|Fudan University Shanghai Cancer Center, Shanghai, Shanghai, 201400, China",
NCT03602859,A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer,https://clinicaltrials.gov/study/NCT03602859,FIRST,ACTIVE_NOT_RECRUITING,"Ovarian cancer is a heterogeneous disease, characterized by complex molecular and genetic changes. The high expression of vascular endothelial growth factor (VEGF) receptor, programmed death receptor ligands 1 (PD-L1) expression, and deoxyribonucleic acid (DNA) damage in ovarian tumors provide several targets for treatment and maintenance of disease response. Given the unmet medical need of participants with advanced or metastatic ovarian cancer, this study design will enable investigators to provide participants with current SOC for ovarian cancer for the duration of the study. This is a global, multicenter, randomized, double-blind, controlled Phase 3 study that will primarily compare the progression-free survival (PFS) for participants receiving dostarlimab with SOC chemotherapy +/- bevacizumab followed by niraparib and dostarlimab maintenance +/- bevacizumab versus participants receiving SOC with chemotherapy followed by niraparib maintenance. This comparison will be investigated in participants of newly diagnosed stage III or IV advanced non-mucinous epithelial ovarian cancer participants and also to compare PFS of all participants with Stage III or IV high-grade non-mucinous epithelial ovarian cancer treated with platinum-based combination therapy, dostarlimab (TSR-042), and niraparib to SOC platinum-based combination therapy. The currently recommended SOC therapy for the first line treatment of Stage III or IV ovarian cancer is the combination of paclitaxel and carboplatin, with or without concurrent and maintenance bevacizumab. Participants will receive SOC during the chemotherapy Run-In period (cycle 1) before randomization to study treatment (cycle 2). Concurrent bevacizumab use must be determined prior to randomization at cycle 2.",NO,"Ovarian Neoplasms|Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma",DRUG: Niraparib|DRUG: Dostarlimab (TSR-042)|DRUG: Standard of care|DRUG: Dostarlimab-Placebo|DRUG: Niraparib-Placebo,"Progression Free Survival (PFS), To compare the PFS of all participants with Stage III or IV high-grade nonmucinous epithelial ovarian cancer given first-line treatment with the combination of dostarlimab with SOC chemotherapy +/- bevacizumab followed by niraparib and dostarlimab maintenance +/- bevacizumab versus SOC chemotherapy +/- bevacizumab followed by niraparib maintenance +/- bevacizumab. PFS is defined as the time from treatment randomization to the earlier date of assessment of progression or death by any cause in the absence of progression. PFS will be evaluated by investigator assessment per RECIST v1.1 criteria., Up to 6 years","Overall Survival (OS), OS is defined as the date of randomization to the date of death by any cause, Up to 7 years|PFS by Blinded Independent Central Review (BICR) per investigator-assessed Response Evaluation Criteria in Solid Tumors (RECIST) criteria, BICR determined PFS will be assessed as per RECIST criteria., Up to 6 years|Change from Baseline in the European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) assessment, EQ-5D-5L is a validated questionnaire to assess the overall health-related quality of life in participants across diseases. EQ-5D-5L consists of a descriptive section of 5 questions/dimensions, one related to each of: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is measured by 5-point Likert scale (no problems, slight problems, moderate problems, severe problems and extreme problems), Baseline and up to 6 years|Change from Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30) assessment, EORTC QLQ-C30 is a validated questionnaire to assess the overall health-related quality of life in participants with cancer and is composed of 30 questions including multi-item scales and single item measures. These include five functional scales (physical, role, emotional, cognitive and social), three symptom scales (fatigue, nausea/vomiting, and pain), a global health status/quality of life scale (GHS/QOL), and six single items (dyspnoea, insomnia, appetite loss, constipation, diarrhea and financial difficulties). Response options are 1 to 4. Higher score indicates better health-related quality of life., Baseline and up to 6 years|Change from Baseline in the EORTC-QLQ Ovarian Cancer Module OV28 (EORTC-QLQ-OV28) assessment, EORTC QLQ-OV28 is a validated questionnaire to assess the overall health-related quality of life in participants with local or advanced ovarian cancer. EORTC QLQ-OV28 consists of 28 questions evaluated across eight multi-item and 4 single item scales: abdominal/ gastrointestinal (GI) symptoms, peripheral neuropathy, hormonal symptoms, body image, attitude to disease/treatment, chemotherapy side effects, and sexuality, and single items scales for indigestion/heartburn, hair loss, upset due to hair loss, and taste. All questions are rated on a 4 point verbal rating scale: ""Not at all,"" ""A little,"" ""Quite a bit,"" and ""Very much."", Baseline and up to 6 years|Time to first subsequent therapy (TFST), TFST is defined as the time from randomization until the start date of the first subsequent anti-cancer therapy or death, whichever occurs first, Up to 6 years|Time to second subsequent therapy (TSST), TSST is defined as the time from randomization until the start date of the second subsequent anti-cancer therapy or death, whichever occurs first, Up to 6 years|Time to progression on next-line therapy (PFS2), PFS2 is defined as the time from randomization until PD per investigator's assessment after starting follow-up anti-cancer therapy or death due to any cause, whichever occurs first, Up to 6 years|Objective Response Rate (ORR), ORR, defined as the percentage of participants with complete response (CR) or partial response (PR) on study treatment as assessed by RECIST v1.1 criteria for participants with measurable disease., Up to 6 years|Duration of response (DOR), DOR, defined as the time from first documentation of CR or PR until the time of first documentation of PD as assessed by RECIST v1.1, or death by any cause in the absence of progression, whichever occurs first., Up to 6 years|Disease control rate (DCR), DCR, defined as the proportion of participants with a best overall response of CR, PR, or stable disease (SD), as assessed by RECIST v1.1 criteria., Up to 6 years|Plasma concentration of dostarlimab, Blood samples will be collected for pharmacokinetic analysis of dostarlimab, Up to 6 years|Number of participants with positive antidrug antibodies (ADAs) against dostarlimab, Serum samples will be collected for the analysis of the presence of ADAs using validated immunoassays., Up to 6 years|Plasma concentration of niraparib, Blood samples will be collected for pharmacokinetic analysis of niraparib., Up to 6 years|Number of participants with treatment-emergent adverse events (TEAEs), TEAEs are defined as, any event that was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment., Up to 6 years|Number of participants with serious adverse events (SAEs), SAEs are any adverse event that may result in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital abnormality or birth defect, is an important medical event., Up to 6 years|Number of participants with treatment discontinuations or dose delays or dose reductions due to adverse events, Adverse events are any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a medicinal product and which does not necessarily have to have a causal relationship with this treatment., Up to 6 years|Number participants with immune-related adverse events (irAEs), Following events are categorized as irAEs: Diarrhea/colitis, AST or ALT (\>3 and \<=5 X ULN), or increased bilirubin, T1DM or hyperglycemia, immune-related encephalitis, uveitis, myositis, hypophysitis, adrenal insufficiency, hypo- and hyperthyroidism, infusion-related reaction, pneumonitis, immune-related rash, renal failure or nephritis and recurrence of AEs after resolution to Grade \<=1., Up to 6 years|Number of participants with changes in Eastern Cooperative Oncology Group (ECOG) performance status, Performance status will be assessed using the ECOG performance status scale: ranging from Grade 0 to 5, Grade 0 denoting fully active and Grade 5 denoting death., Up to 6 years|Number of participants with abnormal hematology results, Blood samples will be collected for the analysis of hematologic parameters including: hemoglobin, platelet count, white blood cell count, differential white blood cell count, coagulation factors-International normalized ratio (INR) and activated partial thromboplastin time., Up to 6 years|Number of participants with abnormal clinical chemistry results, Blood samples will be collected for the analysis of clinical chemistry parameters including: amylase, thyroid function (thyroid stimulating hormone \[TSH\]), urea or blood urea nitrogen, creatinine, albumin, total protein, ALT, AST, total bilirubin, Glucose, Magnesium, Calcium, Chloride, Potassium and Sodium., Up to 6 years",,"Tesaro, Inc.",European Network of Gynaecological Oncological Trial Groups (ENGOT),FEMALE,"ADULT, OLDER_ADULT",PHASE3,1402,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2018-10-11,2024-10-31,2026-06-22,2018-07-27,,2025-03-13,"GSK Investigational Site, Anchorage, Alaska, 99508, United States|GSK Investigational Site, Phoenix, Arizona, 85016, United States|GSK Investigational Site, Tucson, Arizona, 85711, United States|GSK Investigational Site, Los Angeles, California, 90027, United States|GSK Investigational Site, Los Angeles, California, 90048, United States|GSK Investigational Site, Newport Beach, California, 92663, United States|GSK Investigational Site, Farmington, Connecticut, 06030, United States|GSK Investigational Site, Hartford, Connecticut, 06102, United States|GSK Investigational Site, Gainesville, Florida, 32608, United States|GSK Investigational Site, Jacksonville, Florida, 32256, United States|GSK Investigational Site, Geneva, Illinois, 60555, United States|GSK Investigational Site, Warrenville, Illinois, 60555, United States|GSK Investigational Site, Zion, Illinois, 60099, United States|GSK Investigational Site, Covington, Louisiana, 70433, United States|GSK Investigational Site, New Orleans, Louisiana, 70121, United States|GSK Investigational Site, Shreveport, Louisiana, 71103, United States|GSK Investigational Site, Scarborough, Maine, 04074, United States|GSK Investigational Site, Baltimore, Maryland, 21201, United States|GSK Investigational Site, Silver Spring, Maryland, 20910, United States|GSK Investigational Site, Boston, Massachusetts, 02215, United States|GSK Investigational Site, Springfield, Massachusetts, 01199, United States|GSK Investigational Site, Worcester, Massachusetts, 01605, United States|GSK Investigational Site, Maplewood, Minnesota, 55109, United States|GSK Investigational Site, Minneapolis, Minnesota, 55404, United States|GSK Investigational Site, Minneapolis, Minnesota, 55455, United States|GSK Investigational Site, Billings, Montana, 59101, United States|GSK Investigational Site, Neptune, New Jersey, 07753, United States|GSK Investigational Site, Teaneck, New Jersey, 07666, United States|GSK Investigational Site, Hawthorne, New York, 10532, United States|GSK Investigational Site, New York, New York, 10016, United States|GSK Investigational Site, New York, New York, 10029, United States|GSK Investigational Site, New York, New York, 10065, United States|GSK Investigational Site, Rochester, New York, 14620-4159, United States|GSK Investigational Site, Stony Brook, New York, 11794, United States|GSK Investigational Site, Syracuse, New York, 13210, United States|GSK Investigational Site, Charlotte, North Carolina, 28204, United States|GSK Investigational Site, Canton, Ohio, 44710, United States|GSK Investigational Site, Cincinnati, Ohio, 45219, United States|GSK Investigational Site, Oklahoma City, Oklahoma, 73104, United States|GSK Investigational Site, Eugene, Oregon, 97401, United States|GSK Investigational Site, Portland, Oregon, 97227, United States|GSK Investigational Site, Paoli, Pennsylvania, 19301, United States|GSK Investigational Site, Philadelphia, Pennsylvania, 19111, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, 15224, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, 15232, United States|GSK Investigational Site, Willow Grove, Pennsylvania, 19001-3788, United States|GSK Investigational Site, Wynnewood, Pennsylvania, 19096, United States|GSK Investigational Site, Providence, Rhode Island, 02905, United States|GSK Investigational Site, Charleston, South Carolina, 29425, United States|GSK Investigational Site, Sioux Falls, South Dakota, 57105, United States|GSK Investigational Site, Knoxville, Tennessee, 37920, United States|GSK Investigational Site, Nashville, Tennessee, 37203, United States|GSK Investigational Site, Nashville, Tennessee, 37205, United States|GSK Investigational Site, Austin, Texas, 78731, United States|GSK Investigational Site, Dallas, Texas, 75246, United States|GSK Investigational Site, Fort Worth, Texas, 76104, United States|GSK Investigational Site, Houston, Texas, 77030, United States|GSK Investigational Site, San Antonio, Texas, 78240, United States|GSK Investigational Site, The Woodlands, Texas, 77380, United States|GSK Investigational Site, Tyler, Texas, 75702, United States|GSK Investigational Site, Ogden, Utah, 84405, United States|GSK Investigational Site, Charlottesville, Virginia, 22903, United States|GSK Investigational Site, Norfolk, Virginia, 23502, United States|GSK Investigational Site, Kennewick, Washington, 99336, United States|GSK Investigational Site, Seattle, Washington, 98104, United States|GSK Investigational Site, Seattle, Washington, 98109, United States|GSK Investigational Site, Minsk, 223040, Belarus|GSK Investigational Site, Brasschaat, 2930, Belgium|GSK Investigational Site, Brugge, 8000, Belgium|GSK Investigational Site, Vancouver, British Columbia, V5Z 4E6, Canada|GSK Investigational Site, London, Ontario, N6A 4L6, Canada|GSK Investigational Site, Toronto, Ontario, M4N 3M5, Canada|GSK Investigational Site, Montreal, Quebec, H2X 3E4, Canada|GSK Investigational Site, Montreal, Quebec, H4A 3J1, Canada|GSK Investigational Site, Sherbrooke, Quebec, J1H 5N4, Canada|GSK Investigational Site, Windsor, 1000, Canada|GSK Investigational Site, Praha 8, 180 81, Czechia|GSK Investigational Site, Praha, 128 51, Czechia|GSK Investigational Site, Copenhagen, DK- 2100, Denmark|GSK Investigational Site, Herlev, 2730, Denmark|GSK Investigational Site, Roskilde, 4000, Denmark|GSK Investigational Site, Helsinki, 00029, Finland|GSK Investigational Site, Kuopio, 70210, Finland|GSK Investigational Site, Tampere, 33520, Finland|GSK Investigational Site, Turku, 20520, Finland|GSK Investigational Site, Angers cedex 9, 49055, France|GSK Investigational Site, Avignon, 84918, France|GSK Investigational Site, BesanCon, 25030, France|GSK Investigational Site, Bordeaux, 33000, France|GSK Investigational Site, Bron, 69495, France|GSK Investigational Site, Caen Cedex 5, 14000, France|GSK Investigational Site, Cholet, 69373, France|GSK Investigational Site, Clermont-Ferrand, 63011, France|GSK Investigational Site, Dijon Cedex, 21079, France|GSK Investigational Site, Grenoble Cedex 9, 38700, France|GSK Investigational Site, Grenoble, 38000, France|GSK Investigational Site, Le Mans, 72000, France|GSK Investigational Site, Lille, 59000, France|GSK Investigational Site, Lyon Cedex 08, 69373, France|GSK Investigational Site, Lyon, 69008, France|GSK Investigational Site, Lyon, 69495, France|GSK Investigational Site, Marseille, 13273, France|GSK Investigational Site, Montpellier Cedex, 34298, France|GSK Investigational Site, Montpellier, 34070, France|GSK Investigational Site, Nancy, 54100, France|GSK Investigational Site, Nantes cedex 2, 44227, France|GSK Investigational Site, Nice Cedex 2, 06189, France|GSK Investigational Site, Nimes Cedex 9, 30029, France|GSK Investigational Site, Paris Cedex 20, 75970, France|GSK Investigational Site, Paris cedex 5, 75248, France|GSK Investigational Site, Paris Cedex, 75020, France|GSK Investigational Site, Paris, 75014, France|GSK Investigational Site, Paris, 75908, France|GSK Investigational Site, Pierre Benite, 69495, France|GSK Investigational Site, Plerin-sur-mer, 22190, France|GSK Investigational Site, Poitiers, 86021, France|GSK Investigational Site, Reims, 51056, France|GSK Investigational Site, Rennes Cedex, 35042, France|GSK Investigational Site, Saint-Cloud, 75248, France|GSK Investigational Site, Saint-Priest-en-Jarez, 42271, France|GSK Investigational Site, Strasbourg, 67091, France|GSK Investigational Site, Toulouse Cedex 9, 31059, France|GSK Investigational Site, Tours cedex 9, 37044, France|GSK Investigational Site, Villejuif cedex, 94805, France|GSK Investigational Site, Berlin, 13125, Germany|GSK Investigational Site, Hamburg, 22457, Germany|GSK Investigational Site, Muenster, 48149, Germany|GSK Investigational Site, Ravensburg, 88212, Germany|GSK Investigational Site, Wolfsburg, 38440, Germany|GSK Investigational Site, Athens, 115 28, Greece|GSK Investigational Site, Athens, 11528, Greece|GSK Investigational Site, Athens, 12462, Greece|GSK Investigational Site, Haidari - Athens, 12462, Greece|GSK Investigational Site, Marousi, 15123, Greece|GSK Investigational Site, Beer-Sheva, 8410101, Israel|GSK Investigational Site, Haifa, 3109601, Israel|GSK Investigational Site, Haifa, 3436212, Israel|GSK Investigational Site, Holon, 5822012, Israel|GSK Investigational Site, Petach Tikva, 4941492, Israel|GSK Investigational Site, Rehovot, 76100, Israel|GSK Investigational Site, Bologna, 40138, Italy|GSK Investigational Site, Faenza, 48018, Italy|GSK Investigational Site, Lugo RA, 48018, Italy|GSK Investigational Site, Meldola FC, 47014, Italy|GSK Investigational Site, Napoli, 80131, Italy|GSK Investigational Site, Amsterdam, 1081 HV, Netherlands|GSK Investigational Site, Groningen, 9700 RB, Netherlands|GSK Investigational Site, Maastricht, 6229 HX, Netherlands|GSK Investigational Site, Nijmegen, 6525 GA, Netherlands|GSK Investigational Site, Rotterdam, 3015 GD, Netherlands|GSK Investigational Site, Utrecht, 3584 CX, Netherlands|GSK Investigational Site, Kristiansand, 4632, Norway|GSK Investigational Site, Oslo, 0310, Norway|GSK Investigational Site, Tromsoe, 9019, Norway|GSK Investigational Site, Olsztyn, 10-228, Poland|GSK Investigational Site, Szczecin, 70-111, Poland|GSK Investigational Site, Warszawa, 02-781, Poland|GSK Investigational Site, Bucuresti, 022328, Romania|GSK Investigational Site, Cluj-Napoca, 400015, Romania|GSK Investigational Site, Cluj-Napoca, 400051, Romania|GSK Investigational Site, Constanta, 900591, Romania|GSK Investigational Site, Craiova, 200347, Romania|GSK Investigational Site, Timisoara, 300239, Romania|GSK Investigational Site, Avila, 05071, Spain|GSK Investigational Site, Badalona, 08916, Spain|GSK Investigational Site, Barcelona, 08036, Spain|GSK Investigational Site, Gerona, 17007, Spain|GSK Investigational Site, JaEn, 23007, Spain|GSK Investigational Site, Madrid, 28046, Spain|GSK Investigational Site, Madrid, 28702, Spain|GSK Investigational Site, Santiago de Compostela, 15706, Spain|GSK Investigational Site, Toledo, 45007, Spain|GSK Investigational Site, Valencia, 46010, Spain|GSK Investigational Site, Chernihiv, 14029, Ukraine|GSK Investigational Site, Lviv, 79031, Ukraine|GSK Investigational Site, Glasgow, G12 0YN, United Kingdom|GSK Investigational Site, Portsmouth, PO6 3LY, United Kingdom|GSK Investigational Site, Sutton, SM2 5PT, United Kingdom|GSK Investigational Site, Truro, TR1 3LJ, United Kingdom|GSK Investigational Site, Wirral, CH63 4JY, United Kingdom",
NCT06331299,A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer,https://clinicaltrials.gov/study/NCT06331299,UTOPIA,RECRUITING,"This Phase 3, single-arm, multicenter study will evaluate the efficacy and safety of UGN-103, a novel formulation of UGN-102, instilled in the urinary bladder of patients with low-grade non-muscle invasive bladder cancer (LG-NMIBC).",NO,Bladder Cancer|Urothelial Carcinoma|Urothelial Carcinoma Bladder,DRUG: UGN-103,"Complete response rate (CRR), CRR is defined as the proportion of patients who achieved CR at the 3-month Visit., 3 months","Duration of response (DOR), DOR is defined as the time from the date of evidence of CR at the 3-month Visit to the earliest date of recurrence or progression or death due to any cause, whichever occurred first., Up to 21 months|Durable complete response (DCR) rate, DCR rate at scheduled disease assessment time points, defined as the proportion of patients who achieved CR at the 3-month Visit and maintained CR (ie, no detectable disease) up to that particular follow-up disease assessment., Up to 21 months|Incidence of treatment-emergent adverse events (TEAEs), serious TEAEs, TEAEs of special interest, and abnormal clinical laboratory test results (hematology and serum chemistry), The number of patients with each type of event will be summarized., Up to 21 months|Mitomycin plasma concentrations, Mitomycin plasma concentrations will be assessed in a subset of patients treated with UGN-103, 0 (pre-instillation), 0.5, 1, 2, 3, 4, 5, and 6 hours after the first instillation of UGN-103.|Mitomycin maximum plasma concentration (Cmax), Mitomycin Cmax will be assessed in a subset of patients treated with UGN-103, 0 (pre-instillation), 0.5, 1, 2, 3, 4, 5, and 6 hours after the first instillation of UGN-103.",,UroGen Pharma Ltd.,,ALL,"ADULT, OLDER_ADULT",PHASE3,92,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-08-29,2025-08,2026-08,2024-03-26,,2025-04-09,"Genesis Research, LLC, San Diego, California, 92123, United States|Peachtree Clinical Solutions, Powder Springs, Georgia, 30127, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, 46202, United States|Garden State Urology, Morristown, New Jersey, 07962, United States|Great Lakes Physician dba WNYU, Cheektowaga, New York, 14225, United States|AccuMed Research Associates, Garden City, New York, 11530, United States|Crystal Run Healthcare, Middletown, New York, 10941, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, 10016, United States|Perlmutter Cancer Center at NYU Langone Hospital - Long Island, New York, New York, 11501, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, 29572, United States|Urology Associates P.C. - Nashville, Nashville, Tennessee, 37209-4035, United States|Houston Metro Urology (HMU) - Southwest Location, Houston, Texas, 77027, United States|Houston Methodist Hospital, Houston, Texas, 77030, United States|Spokane Urology, P.S., Spokane, Washington, 99202, United States",
NCT06380348,"JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations",https://clinicaltrials.gov/study/NCT06380348,,NOT_YET_RECRUITING,"This is a multicenter, randomized, open-label, parallel-controlled phase 3 study. This study aims to evaluate the efficacy and safety of JMT101 combined with Osimertinib compared with Cisplatin combined with pemetrexed in participants with local advanced or metastatic non-small-cell lung cancer harboured EGFR 20ins mutation without prior systemic therapy.

Primary objective of this study is to assess the efficacy of JMT101 combined with Osimertinib versus Cisplatin combined with pemetrexed using by ï¼Independent Review Centerï¼IRC-assessed Progression Free Survival (PFS) per RECIST 1.1 as primary endpoint. Approximately 398 participants are estimated to be randomized into the study. Participants enrolled will be randomized to JMT101 or Cisplatin chemotherapy in a 1:1 manner, stratified by baseline brain metastasis (with/without) and Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) (0 versus 1).",NO,Local Advanced or Metastatic NSCLC,DRUG: JMT101 Injection|DRUG: Osimertinib tablet|DRUG: Cisplatin injection|DRUG: Pemetrexed injection,"Progression Free Survival (PFS) as assessed by Independent Review Center (IRC) per RECIST 1.1, Up to approximately 35 months after the first participant is randomized","Overall Survival (OS), Up to approximately 35 months after the first participant is randomized|Overall Response Rate (ORR) by IRC per RECIST 1.1, Up to approximately 35 months after the first participant is randomized|Duration of Response (DoR) by IRC per RECIST 1.1, Up to approximately 35 months after the first participant is randomized|PFS by investigator per RECIST 1.1, Up to approximately 35 months after the first participant is randomized|ORR by investigator per RECIST 1.1, Up to approximately 35 months after the first participant is randomized|DoR by investigator per RECIST 1.1, Up to approximately 35 months after the first participant is randomized",,Shanghai JMT-Bio Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE3,398,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-04-26,2027-03-26,2028-03-26,2024-04-23,,2024-04-23,,
NCT06312137,A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019),https://clinicaltrials.gov/study/NCT06312137,TroFuse-019,RECRUITING,This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tirumotecan plus pembrolizumab is superior to pembrolizumab monotherapy with respect to disease free survival (DFS) as assessed by blinded independent central review (BICR).,NO,Non Small Cell Lung Cancer,BIOLOGICAL: Sacituzumab tirumotecan|BIOLOGICAL: Pembrolizumab|DRUG: Cisplatin|DRUG: Pemetrexed|DRUG: Gemcitabine|DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Rescue medication,"Disease-free survival (DFS) as assessed by Blinded Independent Central Review (BICR), DFS is defined as the time from randomization to any recurrence (local, locoregional, regional or distant), occurrence of new primary NSCLC, or death due to any cause, whichever occurs first., Up to ~ 93 months","Overall Survival (OS), OS is defined as the time from randomization to death due to any cause., Up to ~ 118 months|Distant metastasis-free survival (DMFS) as assessed by investigator, DMFS is defined as the time from randomization to the first documented distant metastasis or death due to any cause, whichever occurs first. Distant metastasis refers to cancer that has spread from the original (primary) tumor to distant organs or distant lymph nodes., Up to ~ 118 months|Disease-Free Survival (DFS) as assessed by investigator, DFS is defined as the time from randomization to any recurrence (local, locoregional, regional or distant), occurrence of new primary NSCLC, or death due to any cause, whichever occurs first., Up to ~ 118 months|Lung Cancer Specific Survival (LCSS), LCSS is defined as the time from randomization to the date of death due to lung cancer., Up to ~ 118 months|Number of Participants Who Experience an Adverse Event (AE), An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention., Up to ~ 118 months|Number of Participants Who Discontinue Study Intervention Due to AEs, An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinue study treatment due to an AE will be presented., Up to ~ 118 months|Change from Baseline in Global Health Status/Quality of Life (QoL) score (Quality of Life Questionnaire (QLQ)-C30 Items 29 and 30), The European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ) is a psychometrically and clinically validated instrument appropriate for assessing the health-related quality of life (HRQoL) of cancer patients in oncology studies. Each scale or item is scored between 0 and 100, for the global health status or QoL a higher value indicates a better level of function., Baseline and up to ~118 months|Change from Baseline in Physical Functioning Score (QLQ-C30 Items 1 to 5), The EORTC-QLQ is a psychometrically and clinically validated instrument appropriate for assessing the HRQoL of cancer patients in oncology studies. Each scale or item is scored between 0 and 100, for all physical functional scales, a higher value indicates a better level of function., Baseline and up to ~118 months|Change from Baseline in Role Functioning Score (QLQ-C30 Items 6 and 7), The EORTC-QLQ is a psychometrically and clinically validated instrument appropriate for assessing the HRQoL of cancer patients in oncology studies. Each scale or item is scored between 0 and 100, for all role functional scales, a higher value indicates a better level of function., Baseline and up to ~118 months|Change from Baseline in Dyspnea scores (QLQ-C30 Item 8), The EORTC-QLQ is a psychometrically and clinically validated instrument appropriate for assessing the HRQoL of cancer patients in oncology studies. Each scale or item is scored between 0 and 100, for symptom scales such as dyspnea, a higher value indicates increased severity of symptoms., Baseline and up to ~118 months|Change from Baseline in Coughing scores (QLQ-LC24 Items 31 and 52), The lung cancer module of the EORTC, QLQ-LC24 is a revised and updated version of the Lung Cancer Module QLQ-LC13 and is a supplementary lung cancer specific module to be used along with EORTC QLQ C30. The QLQ-LC24 incorporates 4 multi-item scales to assess coughing, shortness of breath, hair problems, and fear of progression, for symptom scales as for cough, a higher value indicates increased severity of symptoms., Baseline and up to ~118 months|Change from Baseline in Chest pain scores (QLQ-LC24 Item 40), The lung cancer module of the EORTC, QLQ-LC24 is a revised and updated version of the Lung Cancer Module QLQ-LC13 and is a supplementary lung cancer specific module to be used along with EORTC QLQ C30. The QLQ-LC24 incorporates 4 multi-item scales to assess coughing, shortness of breath, hair problems, and fear of progression, for symptom scales as for chest pain, a higher value indicates increased severity of symptoms., Baseline and up to ~118 months",,Merck Sharp & Dohme LLC,,ALL,"ADULT, OLDER_ADULT",PHASE3,780,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2024-04-03,2034-02-21,2034-10-23,2024-03-15,,2025-06-13,"Highlands Oncology Group-Research Department ( Site 0062), Springdale, Arkansas, 72762, United States|Beverly Hills Cancer Center ( Site 0070), Beverly Hills, California, 90211, United States|The Angeles Clinic and Research Institute ( Site 0040), Los Angeles, California, 90025, United States|The Angeles Clinic and Research Institute- A Cedars-Sinai Affiliate ( Site 0079), Los Angeles, California, 90025, United States|San Francisco Oncology Associates ( Site 0066), San Francisco, California, 94115, United States|Stamford Hospital ( Site 0083), Stamford, Connecticut, 06904, United States|Mount Sinai Cancer Center ( Site 0038), Miami Beach, Florida, 33140, United States|Mid Florida Hematology and Oncology Center ( Site 0018), Orange City, Florida, 32763, United States|Emory University School of Medicine-Phase I ( Site 0056), Atlanta, Georgia, 30322, United States|Northside Hospital ( Site 0055), Atlanta, Georgia, 30342, United States|Centricity Research Columbus Cancer Center ( Site 0005), Columbus, Georgia, 31904, United States|Lewis Cancer and Research Pavilion ( Site 0063), Savannah, Georgia, 31405, United States|Archbold Cancer Center ( Site 0071), Thomasville, Georgia, 31792, United States|Edward-Elmhurst Healthcare, Elmhurst Hospital-Nancy W. Knowles Cancer Center ( Site 0017), Elmhurst, Illinois, 60126, United States|Edward-Elmhurst Healthcare, Edward Hospital-Edward Cancer Center ( Site 0078), Naperville, Illinois, 60540, United States|Indiana University Health Arnett Cancer Center ( Site 0076), Lafayette, Indiana, 47904, United States|Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 0061), Edgewood, Kentucky, 41017, United States|Allina Health Cancer Institute - Abbott Northwestern Hospital ( Site 0027), Minneapolis, Minnesota, 55407, United States|Mercy Research - David C. Pratt Cancer Center ( Site 0006), Saint Louis, Missouri, 63141, United States|Renown Regional Medical Center-Renown Health Medical Oncology ( Site 0037), Reno, Nevada, 89502, United States|Atlantic Health Morristown Medical Center ( Site 0077), Morristown, New Jersey, 07960, United States|Stony Brook University-Cancer Center ( Site 0054), Stony Brook, New York, 11794, United States|Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0057), Fargo, North Dakota, 58122, United States|Oregon Health and Science University ( Site 0052), Portland, Oregon, 97239, United States|Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0068), Lancaster, Pennsylvania, 17601, United States|Medical University of South Carolina-Hollings Cancer Center ( Site 0045), Charleston, South Carolina, 29425, United States|Sanford Cancer Center ( Site 0053), Sioux Falls, South Dakota, 57104, United States|Avera Cancer Institute- Research ( Site 0090), Sioux Falls, South Dakota, 57105, United States|University of Tennessee Medical Center Knoxville ( Site 0082), Knoxville, Tennessee, 37920, United States|Millennium Research & Clinical Development ( Site 0039), Houston, Texas, 77090, United States|Huntsman Cancer Institute ( Site 0042), Salt Lake City, Utah, 84112-5500, United States|Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 0213), Caba, Buenos Aires, C1199ABB, Argentina|Hospital BritÃ¡nico de Buenos Aires-Oncology ( Site 0207), Ciudad autÃ³noma de Buenos Aires, Buenos Aires, C1280AEB, Argentina|Sanatorio BritÃ¡nico-Clinical Oncology Department ( Site 0206), Rosario, Santa Fe, S2000CVB, Argentina|Sanatorio Parque ( Site 0205), Rosario, Santa Fe, S2000DVC, Argentina|Hospital Aleman-Oncology ( Site 0202), Buenos Aires, C1118AAT, Argentina|Hospital Privado Universitario de CÃ³rdoba-Hematology and Oncology ( Site 0204), Cordoba, X5016KEH, Argentina|Westmead Hospital ( Site 0701), Westmead, New South Wales, 2145, Australia|The Prince Charles Hospital ( Site 0700), Brisbane, Queensland, 4032, Australia|Fiona Stanley Hospital-Medical Oncology ( Site 0705), Murdoch, Western Australia, 6150, Australia|Ordensklinikum Linz GmbH Elisabethinen-Department of Pneumology ( Site 1402), Linz, Oberosterreich, 4020, Austria|Medizinische Universitaet Innsbruck-Department for Internal Medicine V ( Site 1403), Innsbruck, Tirol, 6020, Austria|Klinik Floridsdorf-Abteilung fÃ¼r Innere Medizin und Pneumologie ( Site 1400), Wien, 1210, Austria|Antwerp University Hospital-Thoracic Oncology ( Site 1503), Edegem, Antwerpen, 2650, Belgium|UniversitÃ© Catholique de Louvain-Namur - Centre Hospitalier Universitaire Dinant-Godinne - Site Godi ( Site 1502), Yvoir, Namur, 5530, Belgium|VITAZ ( Site 1500), Sint-Niklaas, Oost-Vlaanderen, 9100, Belgium|Liga Norte Riograndense Contra o CÃ¢ncer ( Site 0301), Natal., Rio Grande Do Norte, 59062-000, Brazil|Irmandade da Santa Casa de MisericÃ³rdia de Porto Alegre ( Site 0303), Porto Alegre, Rio Grande Do Sul, 90020-090, Brazil|Hospital Nossa Senhora da ConceiÃ§Ã£o ( Site 0302), Porto Alegre, Rio Grande Do Sul, 91350-200, Brazil|Instituto de Oncologia Saint Gallen ( Site 0319), Santa Cruz do Sul, Rio Grande Do Sul, 96830-180, Brazil|FundaÃ§Ã£o Pio XII - Hospital de CÃ¢ncer de Barretos ( Site 0304), Barretos, Sao Paulo, 14784400, Brazil|FundaÃ§Ã£o Faculdade Regional de Medicina de SÃ£o JosÃ© do Rio Preto ( Site 0313), SÃ£o JosÃ© do Rio Preto, Sao Paulo, 15090000, Brazil|Centre IntÃ©grÃ© de SantÃ© et de Services Sociaux de la MontÃ©rÃ©gie-Centre ( Site 0100), Greenfield Park, Quebec, J4V 2H1, Canada|St. Marys Hospital Center ( Site 0107), Montreal, Quebec, H3T 1M5, Canada|Centre Hospitalier de l'UniversitÃ© de MontrÃ©al ( Site 0104), MontrÃ©al, Quebec, H2X 3E4, Canada|FALP-UIDO ( Site 0401), Providencia, Region M. De Santiago, 7500921, Chile|Centro de Estudios ClÃ­nicos SAGA-CECSAGA ( Site 0404), Santiago., Region M. De Santiago, 7500653, Chile|Bradfordhill-Clinical Area ( Site 0400), Santiago, Region M. De Santiago, 8420383, Chile|ONCOCENTRO APYS-ACEREY ( Site 0410), ViÃ±a del Mar, Valparaiso, 2520598, Chile|Beijing Cancer hospital-Thoracic Surgery department I ( Site 1301), Beijing, Beijing, 100010, China|Beijing Peking Union Medical College Hospital-Thoracic surgery department ( Site 1302), Beijing, Beijing, 100730, China|Peking University People's Hospital. ( Site 1300), Beijing, Beijing, 101109, China|Fujian Cancer Hospital-oncology department ( Site 1314), Fuzhou, Fujian, 350014, China|The First Affiliated Hospital of Guangzhou Medical University-thoracic surgery department ( Site 1320), Guangzhou, Guangdong, 510120, China|Southern Medical University Nanfang Hospital-Thoracic surgery department ( Site 1313), Guangzhou, Guangdong, 510515, China|Henan Cancer Hospital-henan cancer hospital ( Site 1316), Zhengzhou, Henan, 450000, China|Union Hospital Tongji Medical College Huazhong University of Science and Technology-Thoracic Surgery ( Site 1306), Wuhan, Hubei, 430022, China|Hubei Cancer Hospital ( Site 1308), Wuhan, Hubei, 430079, China|Xiangya Hospital Central South University-Thoracic surgery ( Site 1311), Changsha, Hunan, 410008, China|Hunan Cancer Hospital ( Site 1312), Changsha, Hunan, 410013, China|Nanjing First Hospital ( Site 1310), Nanjing, Jiangsu, 210012, China|The First Affiliated Hospital of Soochow University-Thoracic Surgery Department ( Site 1318), Suzhou, Jiangsu, 215006, China|The First affiliated hospital of Nanchang University (Xianghu campus) ( Site 1330), Nanchang, Jiangxi, 330209, China|The First Hospital of Jilin University ( Site 1324), Changchun, Jilin, 130031, China|The Second Affiliated Hospital of Air Force Medical University ( Site 1332), Xian, Shaanxi, 710038, China|Shandong Cancer Hospital ( Site 1321), Jinan, Shandong, 250117, China|Zhongshan Hospital Fudan University ( Site 1325), Shangai, Shanghai, 200032, China|Shanghai Pulmonary Hospital-Thoracic Surgery department ( Site 1304), Shanghai, Shanghai, 200433, China|Sichuan Cancer hospital. ( Site 1327), Chengdu, Sichuan, 610042, China|The Second People's Hospital of Neijiang ( Site 1322), Neijiang, Sichuan, 641000, China|Yunnan Province Cancer Hospital ( Site 1315), Kunming, Yunnan, 650107, China|The first Affiliated Hospital, Zhejiang University School of-Thoracic Cardiovascular Surgery Ward ( Site 1303), Hangzhou, Zhejiang, 310003, China|Zhejiang Cancer Hospital ( Site 1309), Hangzhou, Zhejiang, 310005, China|Sir Run Run Shaw Hospital of Zhejiang University School of Medicine ( Site 1328), Hangzhou, Zhejiang, 31009, China|Taizhou Hospital of Zhejiang Province ( Site 1329), Linhai, Zhejiang, 317000, China|Ningbo No. 2 Hospital ( Site 1305), Ningbo, Zhejiang, 315010, China|Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 1600), Brno, Brno-mesto, 656 53, Czechia|Nemocnice AGEL Ostrava - Vitkovice a.s.-Plicni oddeleni ( Site 1601), Ostrava, Ostrava Mesto, 703 00, Czechia|CHRU de Brest ( Site 1804), Brest, Finistere, 29609, France|CHU de Toulouse - Hopital Larrey-service de pneumologie ( Site 1801), Toulouse, Haute-Garonne, 31400, France|CHU Charles Nicolle ( Site 1803), Rouen, Haute-Normandie, 76000, France|Centre Hospitalier Universitaire de Limoges - HÃ´pital Dupuytren ( Site 1805), Limoges, Haute-Vienne, 87042, France|Groupe hospitalier Paris saint Joseph. ( Site 1807), Paris, Ile-de-France, 75014, France|Clinique Teissier Groupe ( Site 1811), Valenciennes, Nord, 59304, France|Centre Jean Perrin - Centre RÃ©gional de Lutte contre le Cancer d'Auvergne-ONCOLOGY ( Site 1810), Clermont-Ferrand, Puy-de-Dome, 63003, France|Hospices Civils de Lyon - Hopital Louis Pradel ( Site 1809), Bron, Rhone, 69677, France|HIA Sainte Anne ( Site 1800), Toulon, Var, 83800 Cedex 9, France|HÃ´pital Tenon ( Site 1802), Paris, 75020, France|Klinikum Esslingen-Klinik fÃ¼r Kardiologie und Pneumologie ( Site 1914), Esslingen, Baden-Wurttemberg, 73730, Germany|Katholisches Klinikum Koblenz ( Site 1911), Koblenz, Rheinland-Pfalz, 56073, Germany|Krankenhaus Martha-Maria Halle-DÃ¶lau-Klinik fÃ¼r Innere Medizin II ( Site 1908), Halle, Sachsen-Anhalt, 06120, Germany|SRH Wald-Klinikum Gera-Lungenkrebszentrum ( Site 1900), Gera, Thuringen, 07548, Germany|Vivantes Hospital Spandau-Klinik fÃ¼r Innere Medizin, HÃ¤matologie, Onkologie und Gastroenterologie- ( Site 1912), Berlin, 13585, Germany|Helios Klinikum Emil von Behring Berlin-Zehlendorf ( Site 1916), Berlin, 14165, Germany|UNIVERSITY HOSPITAL OF PATRAS-DIVISION OF ONCOLOGY ( Site 2006), Patras, Achaia, 26504, Greece|251 Hellenic Air Force General Hospital ( Site 2003), Athens, Attiki, 115 25, Greece|THORACIC GENERAL HOSPITAL OF ATHENS ""I SOTIRIA""-3rd Dept of Internal Medicine and Laboratory, Oncol ( Site 2000), Athens, Attiki, 115 27, Greece|Athens Medical Center ( Site 2005), Athens, Attiki, 151 25, Greece|Metaxa Cancer Hospital of Piraeus ( Site 2002), Piraeus, Attiki, 185 37, Greece|University General Hospital of Heraklion-Internal Medicine-Oncology ( Site 2001), Heraklion, Irakleio, 715 00, Greece|University General Hospital of Larissa-Oncology Clinic ( Site 2004), Larissa, Thessalia, 411 10, Greece|European Interbalkan Medical Center ( Site 2007), Thessaloniki, 57001, Greece|Queen Mary Hospital ( Site 3400), Hksar, Hong Kong|Hong Kong United Oncology Centre ( Site 3403), Kowloon, Hong Kong|Queen Elizabeth Hospital ( Site 3402), Yau Ma Tei, 999077, Hong Kong|Rambam Health Care Campus-Oncology Division ( Site 2203), Haifa, 3109601, Israel|Shaare Zedek Medical Center ( Site 2206), Jerusalem, 9103102, Israel|Rabin Medical Center ( Site 2204), Petah Tikva, 4941492, Israel|Sheba Medical Center ( Site 2200), Ramat Gan, 5265601, Israel|IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) ""Dino Amadori""-Oncologia Medica ( Site 2302), Meldola, Emilia-Romagna, 47014, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 2300), Milan, Lombardia, 20133, Italy|Fondazione IRCCS San Gerardo dei Tintori-Oncologia ( Site 2301), Monza, Lombardia, 20900, Italy|Istituto Nazionale Tumori Regina Elena-Oncologia Medica 2 ( Site 2309), Rome, Roma, 00144, Italy|Azienda Ospedaliera Universitaria Careggi-SOD ONCOLOGIA MEDICA ( Site 2307), Firenze, Toscana, 50134, Italy|Humanitas Gavazzeni-ONCOLOGY ( Site 2310), Bergamo, 24125, Italy|Ospedale San Martino ( Site 2313), Genova, 16132, Italy|Ospedale San Raffaele-Oncologia Medica ( Site 2311), Milano, 20132, Italy|Azienda Ospedaliero Universitaria di Parma-UO Oncologia Medica ( Site 2312), Parma, 43126, Italy|Fondazione IRCCS Policlinico San Matteo-Oncology ( Site 2303), Pavia, 27100, Italy|Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Medical Oncology ( Site 2306), Roma, 00168, Italy|National Hospital Organization Shikoku Cancer Center ( Site 1216), Matsuyama, Ehime, 791-0280, Japan|Hospital of the University of Occupational and Environmental Health, Japan ( Site 1217), Kitakyushu, Fukuoka, 807-8556, Japan|Kobe City Medical Center General Hospital ( Site 1213), Kobe, Hyogo, 650-0047, Japan|St. Marianna University Hospital ( Site 1207), Kawasaki, Kanagawa, 216-8511, Japan|Kanagawa Cancer Center ( Site 1206), Yokohama, Kanagawa, 241-8515, Japan|Kansai Medical University Hospital ( Site 1211), Hirakata, Osaka, 573-1191, Japan|Kindai University Hospital ( Site 1212), Osakasayama, Osaka, 589-8511, Japan|Saitama Prefectural Cancer Center ( Site 1201), Kitaadachi-gun, Saitama, 3620806, Japan|Juntendo University Hospital ( Site 1204), Bunkyo-ku, Tokyo, 113-8431, Japan|Tokyo Medical University Hospital ( Site 1203), Shinjuku, Tokyo, 160-0023, Japan|National Hospital Organization Kyushu Cancer Center ( Site 1218), Fukuoka, 811-1395, Japan|Fukushima Medical University Hospital ( Site 1200), Fukushima, 960-1295, Japan|Hiroshima University Hospital ( Site 1215), Hiroshima, 734-8551, Japan|Niigata Cancer Center Hospital ( Site 1208), Niigata, 951-8566, Japan|Okayama University Hospital ( Site 1214), Okayama, 700-8558, Japan|Osaka International Cancer Institute ( Site 1210), Osaka, 541-8567, Japan|Nippon Medical School Hospital ( Site 1205), Tokyo, 113-8603, Japan|Chungbuk National University Hospital-Internal medicine ( Site 1000), Cheongju-si, Chungbuk, 28644, Korea, Republic of|National Cancer Center-Lung Cancer Center ( Site 1002), Goyang-si, Kyonggi-do, 10408, Korea, Republic of|Seoul National University Bundang Hospital-Medical Oncology ( Site 1003), Seongnam, Kyonggi-do, 13620, Korea, Republic of|The Catholic University Of Korea St. Vincent's Hospital-Medical Oncology ( Site 1001), Suwon-si, Kyonggi-do, 16247, Korea, Republic of|Keimyung University Dongsan Hospital CRC room 1 ( Site 1006), Daegu, Taegu-Kwangyokshi, 42601, Korea, Republic of|Asan Medical Center-Lung Cancer Center ( Site 1005), Seoul, 05505, Korea, Republic of|Samsung Medical Center-Division of Hematology/Oncology ( Site 1004), Seoul, 06351, Korea, Republic of|CIO - Centro de Inmuno-OncologÃ­a de Occidente ( Site 0506), Guadalajara, Jalisco, 44630, Mexico|Centro de Investigacion Clinica de Oaxaca ( Site 0509), Oaxaca de Juarez, Oaxaca, 68020, Mexico|Unidad de Mastologia Avanzada de Chihuahua S.A de C.V ( Site 0504), Chihuahua, 31123, Mexico|Mediadvance Clinical ( Site 0502), Chihuahua, 31203, Mexico|Oaxaca Site Management Organization S.C. ( Site 0507), Oaxaca, 68000, Mexico|Amphia Ziekenhuis, locatie Breda Molengracht-long oncologie ( Site 3453), Breda, Noord-Brabant, 4818 CK, Netherlands|Isala, locatie Zwolle-Poli Longziekten ( Site 3454), Zwolle, Overijssel, 8025 BK, Netherlands|Meander Medisch Centrum-Researchbureau Longgeneeskunde ( Site 3458), Amersfoort, Utrecht, 3813TZ, Netherlands|Erasmus Medisch Centrum ( Site 3452), Rotterdam, Zuid-Holland, 3015 GD, Netherlands|Sint Antonius Ziekenhuis ( Site 3455), Utrecht, 3543 AZ, Netherlands|Auckland City Hospital ( Site 0800), Auckland, 1023, New Zealand|Akershus Universitetssykehus ( Site 2501), LÃ¸renskog, Akershus, 1478, Norway|Drammen Sykehus, Vestre Viken HF ( Site 2502), Drammen, Buskerud, 3004, Norway|Sykehuset Innlandet HF GjÃ¸vik ( Site 2503), GjÃ¸vik, Oppland, 2819, Norway|IPOR Instituto Peruano de OncologÃ­a & Radioterapia-Centro de InvestigaciÃ³n ( Site 0604), Lima, 15036, Peru|Oncosalud ( Site 0602), Lima, 15036, Peru|INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS-Medical Oncology ( Site 0600), Lima, 15038, Peru|Instituto Neuro Cardiovascular de las Americas ( Site 0607), Lima, 15038, Peru|Hospital Nacional Edgardo Rebagliati Martins-medical oncology ( Site 0603), Lima, Lima11, Peru|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier ( Site 2600), Warszawa, Mazowieckie, 02-781, Poland|Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 2601), Przemysl, Podkarpackie, 37-700, Poland|Bialostockie Centrum Onkologii ( Site 2604), Bialystok, Podlaskie, 15-027, Poland|Uniwersyteckie Centrum Kliniczne ( Site 2610), Gdansk, Pomorskie, 80-214, Poland|Szpital Specjalistyczny w Prabutach Spolka z o.o. ( Site 2613), Prabuty, Pomorskie, 82-550, Poland|WarmiÅsko - Mazurskie Centrum ChorÃ³b PÅuc w Olsztynie-Oddzial Onkologii z Pododdzialem Chemioterapii ( Site 2606), Olsztyn, Warminsko-mazurskie, 10-357, Poland|Wielkopolskie Centrum Pulmonologii i Torakochirurgii-Oddzial Onkologii Klinicznej z Pododdzialem Dz ( Site 2602), Poznan, Wielkopolskie, 60-569, Poland|UNIDADE LOCAL DE SAUDE DE MATOSINHOS-ServiÃ§o de Oncologia ( Site 2705), Matosinhos, Porto, 4464-513, Portugal|Instituto PortugÃªs de Oncologia de Coimbra Francisco Gentil-Oncologia MÃ©dica ( Site 2704), Coimbra, 3000-075, Portugal|Instituto PortuguÃªs de Oncologia do Porto Francisco Gentil, EPE ( Site 2702), Porto, 4200-072, Portugal|MEMORIAL HEALTHCARE INTERNATIONAL S.R.L.. ( Site 2803), Bucharest, Bucuresti, 013823, Romania|Spitalul Universitar de UrgenÈÄ Elias ( Site 2804), BucureÈti, Bucuresti, 011461, Romania|Cardiomed SRL Cluj-Napoca-Medical Oncology ( Site 2801), Cluj-Napoca, Cluj, 400015, Romania|SC Radiotherapy Center Cluj SRL-Oncologie Medicala ( Site 2802), FloreÈti, Cluj, 407280, Romania|SC ONCO CARD SRL ( Site 2808), Brasov, 500052, Romania|Institut CatalÃ  d'Oncologia - L'Hospitalet-Medical Oncology ( Site 2901), L Hospitalet, Barcelona, 08908, Spain|CHUS - Hospital Clinico Universitario-Servicio de Oncologia ( Site 2905), Santiago de Compostela, La Coruna, 15706, Spain|Hospital Insular de Gran Canaria-Oncology ( Site 2903), Las Palmas de Gran Canaria, Las Palmas, 35016, Spain|HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID-ONCOLOGIA MEDICA ( Site 2902), Pozuelo de Alarcon, Madrid, 28223, Spain|Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 2900), Barcelona, 08035, Spain|Hospital Clinico San Carlos-Oncology Department ( Site 2904), Madrid, 28040, Spain|Kantonsspital GraubÃ¼nden-Medizin ( Site 3006), Chur, Grisons, 7000, Switzerland|Kantonsspital MÃ¼nsterlingen - Spital Thurgau AG ( Site 3005), Munsterlingen, Thurgau, 8596, Switzerland|CHUV (centre hospitalier universitaire vaudois) ( Site 3003), Lausanne, Vaud, 1011, Switzerland|HFR Fribourg - HÃ´pital Cantonal ( Site 3004), Fribourg, 1708, Switzerland|National Taiwan University Cancer Center (NTUCC) ( Site 1105), Taipei City, Taipei, 106, Taiwan|Tri-Service General Hospital ( Site 1100), Taipei City, Taipei, 114, Taiwan|Taoyuan General Hospital ( Site 1106), Taoyuan City, Taoyuan, 33004, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital ( Site 1103), Kaohsiung, 807, Taiwan|Taichung Veterans General Hospital-Chest ( Site 1101), Taichung, 40705, Taiwan|National Cheng Kung University Hospital-Clinical Trial Center ( Site 1102), Tainan, 704, Taiwan|National Taiwan University Hospital-Oncology ( Site 1104), Taipei, 10002, Taiwan|Adana Medical Park Seyhan Hastanesi-Medikal Onkoloji ( Site 3106), Adana, 01140, Turkey|Gulhane Egitim Arastirma Hastanesi-Onkoloji ( Site 3104), Ankara, 06010, Turkey|Hacettepe Universite Hastaneleri-oncology hospital ( Site 3101), Ankara, 06230, Turkey|Memorial Ankara Hastanesi-Medical Oncology ( Site 3110), Ankara, 06520, Turkey|Ankara Bilkent Åehir Hastanesi-Medical Oncology ( Site 3103), Ankara, 06800, Turkey|TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 3107), Istanbul, 34722, Turkey",
NCT05116189,Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65),https://clinicaltrials.gov/study/NCT05116189,,ACTIVE_NOT_RECRUITING,"The primary objective is to compare pembrolizumab plus paclitaxel with or without bevacizumab to placebo plus paclitaxel with or without bevacizumab, with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by the investigator. The hypotheses are that pembrolizumab plus paclitaxel with or without bevacizumab is superior to placebo plus paclitaxel with or without bevacizumab, with respect to PFS per RECIST 1.1 as assessed by the investigator for participants with programmed cell death ligand 1 (PD-L1) positive tumors (Combined Positive Score \[CPS\] â¥1) and that pembrolizumab plus paclitaxel with or without bevacizumab is superior to placebo plus paclitaxel with or without bevacizumab, with respect to PFS per RECIST 1.1 as assessed by the investigator for all participants.",NO,"Ovarian Cancer|Carcinoma, Ovarian Epithelial|Fallopian Tube Neoplasms",BIOLOGICAL: Pembrolizumab|DRUG: Paclitaxel|DRUG: Bevacizumab|OTHER: Placebo for pembrolizumab|DRUG: Docetaxel,"Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) by Investigator, PFS is defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 based on Investigator assessment or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as â¥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of â¥5 mm. Note: The appearance of one or more lesions and the unequivocal progression of non-target lesions is also considered PD. The PFS per RECIST 1.1 as assessed by the Investigator will be presented., Up to ~38 months","Overall Survival (OS), OS is defined as the time from the date of randomization to death due to any cause. The OS will be reported for all participants., Up to ~64 months|PFS per RECIST 1.1 by Blinded Independent Central Review (BICR), PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on blinded independent central review assessment or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as â¥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of â¥5 mm. Note: The appearance of one or more lesions and the unequivocal progression of non-target lesions is also considered PD. The PFS per RECIST 1.1 as assessed by blinded independent central review will be presented., Up to ~38 months|Number of Participants who Experience an Adverse Event (AE), An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported., Up to ~64 months|Number of Participants who Discontinue Study Treatment due to an AE, An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be reported., Up to ~64 months|Change From Baseline in Global Health Status/Quality of Life (GHS/Qol) Score (Items 29 and 30) Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions ""How would you rate your overall health during the past week?"" and ""How would you rate your overall quality of life during the past week?"" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status. The change from baseline in EORTC QLQ-C30 Items 29 and 30 combined score will be presented., Baseline and up to ~64 months|Time to Deterioration (TTD) in the GHS/Qol Score (Items 29 and 30) Using the EORTC QLQ-C30, TTD is defined as the time from Baseline to the first onset of a â¥10-point negative change (decrease) from Baseline in GHS (EORTC QLQ-C30 Items 29 and 30) score. Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a â¥10-point negative change (decrease) from Baseline in GHS score, will be presented. A longer TTD indicates a better outcome., Up to ~64 months|Change From Baseline in the Abdominal and Gastrointestinal (GI) Symptoms Score (Items 31 to 36) Using the EORTC Quality of Life Questionnaire-Ovarian Cancer (QLQ-OV28) Abdominal/GI Symptom Scale, The EORTC QLQ-OV28 is an abdominal and gastrointestinal questionnaire (items 31-36). Participant responses to the question ""Did you have abdominal pain ?"" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The change from baseline in abdominal and gastrointestinal symptoms (EORTC QLQ-LC28 Items 31-36) score will be presented. A lower score indicates a better outcome., Baseline and up to ~64 months|TTD in the Abdominal and GI Symptoms Score (Items 31 to 36) Using the EORTC QLQ-OV28 Abdominal/GI Symptom Scale, TTD is defined as the time from Baseline to the first onset of a â¥10-point negative change (decrease) from Baseline in GHS (EORTC QLQ-C28 Items 31-36) score. Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a â¥10-point negative change (decrease) from Baseline in GHS score, will be presented. A longer TTD indicates a better outcome., Up to ~64 months",,Merck Sharp & Dohme LLC,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,616,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-12-13,2025-06-30,2028-10-25,2021-11-10,,2025-06-13,"HonorHealth ( Site 0041), Phoenix, Arizona, 85016, United States|Marin Cancer Care ( Site 0055), Greenbrae, California, 94904, United States|Pacific Cancer Care ( Site 0028), Monterey, California, 93940, United States|Eisenhower Medical Center ( Site 0067), Rancho Mirage, California, 92270, United States|Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0004), New Haven, Connecticut, 06511, United States|University of Florida College of Medicine-UF Health Cancer Center/Clinical Trials Office ( Site 0054, Gainesville, Florida, 32610, United States|Sarasota Memorial Hospital ( Site 0018), Sarasota, Florida, 34239, United States|Moffitt Cancer Center ( Site 0033), Tampa, Florida, 33612, United States|Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0005), Marietta, Georgia, 30060, United States|Advocate Medical Group-Oncology ( Site 0049), Park Ridge, Illinois, 60068, United States|Parkview Research Center at Parkview Regional Medical Center ( Site 0027), Fort Wayne, Indiana, 46845, United States|St. Vincent Hospital and Health Care Center, Inc ( Site 0032), Indianapolis, Indiana, 46260, United States|Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 0040), Edgewood, Kentucky, 41017, United States|WK Physicians Network / Hematology Oncology Associates ( Site 0034), Shreveport, Louisiana, 71103, United States|Mercy Medical Center - Baltimore-Medical Oncology and Hematology ( Site 0015), Baltimore, Maryland, 21202, United States|University of Massachusetts Chan Medical School-Division of Gynecologic Oncology ( Site 0003), Worcester, Massachusetts, 01605, United States|John Theurer Cancer Center at Hackensack University Medical Center ( Site 0007), Hackensack, New Jersey, 07601, United States|Roswell Park Cancer Institute ( Site 0039), Buffalo, New York, 14263, United States|Columbia University Medical Center ( Site 0010), New York, New York, 10032, United States|Novant Health Presbyterian Medical Center ( Site 0029), Charlotte, North Carolina, 28204, United States|Duke Cancer Institute ( Site 0038), Durham, North Carolina, 27710, United States|Novant Health Forsyth Medical Center ( Site 0057), Winston-Salem, North Carolina, 27103, United States|Aultman Hospital-Oncology Clinical Trials ( Site 0009), Canton, Ohio, 44710, United States|MetroHealth Medical Center-Cancer Care Center ( Site 0047), Cleveland, Ohio, 44109, United States|Providence Portland Medical Center ( Site 0048), Portland, Oregon, 97213, United States|University of Pittsburgh Medical Center Magee-Womens Hospital ( Site 0024), Pittsburgh, Pennsylvania, 15219, United States|Sanford Cancer Center ( Site 0064), Sioux Falls, South Dakota, 57104, United States|The West Clinic, PLLC dba West Cancer Center ( Site 0058), Germantown, Tennessee, 38138, United States|Texas Oncology - Dallas (Presbyterian) ( Site 0065), Dallas, Texas, 75231, United States|Texas Oncology - The Woodlands_Lee ( Site 0043), The Woodlands, Texas, 77380, United States|Inova Schar Cancer Institute ( Site 0019), Fairfax, Virginia, 22031, United States|Westmead Hospital-Department of Gynaecological Oncology ( Site 0201), Westmead, New South Wales, 2145, Australia|Gallipoli Medical Research Foundation-GMRF CTU ( Site 0202), Brisbane, Queensland, 4120, Australia|Epworth Freemasons ( Site 0204), Melbourne, Victoria, 3002, Australia|St. John of God Subiaco Hospital ( Site 0203), Subiaco, Western Australia, 6008, Australia|Institut Jules Bordet-Medicine Oncology ( Site 0302), Bruxelles, Bruxelles-Capitale, Region De, 1000, Belgium|UZ Gent-Medical oncology ( Site 0301), Gent, Oost-Vlaanderen, 9000, Belgium|UZ Leuven ( Site 0303), Leuven, Vlaams-Brabant, 3000, Belgium|AZ Groeninge Campus Kennedylaan-Oncology ( Site 0305), Kortrijk, West-Vlaanderen, 8500, Belgium|Hospital AraÃºjo Jorge ( Site 0401), GoiÃ¢nia, Goias, 74605-070, Brazil|Liga Norte Riograndense Contra o CÃ¢ncer-Centro de Pesquisa ClÃ­nica ( Site 0404), Natal, Rio Grande Do Norte, 59075-740, Brazil|ANIMI - Unidade de Tratamento Oncologico ( Site 0408), Lages, Santa Catarina, 88501001, Brazil|BP - A Beneficencia Portuguesa de SÃ£o Paulo ( Site 0403), SÃ£o Paulo, Sao Paulo, 01323-001, Brazil|NÃºcleo de Pesquisa ClÃ­nica da Rede SÃ£o Camilo ( Site 0405), SÃ£o Paulo, Sao Paulo, 04014-002, Brazil|Instituto Nacional de CÃ¢ncer JosÃ© Alencar Gomes da Silva - INCA-Pesquisa Clinica HC II ( Site 0402), Rio de Janeiro, 20220-410, Brazil|Tom Baker Cancer Center ( Site 0511), Calgary, Alberta, T2N 4N2, Canada|BC Cancer Abbotsford ( Site 0512), Abbotsford, British Columbia, V2S 0C2, Canada|BC Cancer Victoria ( Site 0513), Victoria, British Columbia, V8R 6V5, Canada|Kingston Health Sciences Centre-Kingston General Hospital Si-Oncology and/or Hematology - Gynecolog, Kingston, Ontario, K7L 2V7, Canada|Sunnybrook Health Sciences - Odette Cancer Centre ( Site 0508), Toronto, Ontario, M4N 3M5, Canada|CIUSSS de l'Est-de-l'Ãle-de-MontrÃ©al ( Site 0501), Montreal, Quebec, H1T 2M4, Canada|Jewish General Hospital ( Site 0505), Montreal, Quebec, H3T 1E2, Canada|McGill University Health Centre ( Site 0502), MontrÃ©al, Quebec, H4A 3J1, Canada|Saskatoon Cancer Center ( Site 0510), Saskatoon, Saskatchewan, S7N 4H4, Canada|Centre intÃ©grÃ© de cancÃ©rologie du CHU de QuÃ©bec UniversitÃ© Laval, HÃ´pital de l'Enfant-JÃ©sus ( Site 0, Quebec, G1J 1Z4, Canada|James Lind Centro de InvestigaciÃ³n del CÃ¡ncer ( Site 0602), Temuco, Araucania, 4780000, Chile|CIDO SpA-Oncology ( Site 0608), Temuco, Araucania, 4810148, Chile|ClÃ­nica Puerto Montt ( Site 0601), Puerto Montt, Los Lagos, 5500243, Chile|Oncovida ( Site 0603), Santiago, Region M. De Santiago, 7510032, Chile|Instituto de Radiomedicina-hemato-oncologia ( Site 0604), Santiago, Region M. De Santiago, 7630370, Chile|ClÃ­nica Vespucio-Hemato - Ocology ( Site 0607), Santiago, Region M. De Santiago, 8241479, Chile|Pontificia Universidad Catolica de Chile-Centro del CÃ¡ncer ( Site 0609), Santiago, Region M. De Santiago, 8330032, Chile|Bradfordhill ( Site 0605), Santiago, Region M. De Santiago, 8420383, Chile|Anhui Provincial Hospital-Obstetrics and Gynecology ( Site 0709), Hefei, Anhui, 230001, China|Beijing Cancer hospital ( Site 0711), Beijing, Beijing, 100142, China|Beijing Peking Union Medical College Hospital-Gynecological center of tumor ( Site 0702), Beijing, Beijing, 100730, China|Fujian Provincial Cancer Hospital ( Site 0713), Fuzhou, Fujian, 350014, China|Lanzhou university second hospital ( Site 0734), Lanzhou, Gansu, 730030, China|Zhujiang Hospital ( Site 0739), Guangzhou, Guangdong, 510280, China|Affiliated Hospital of Guangdong Medical University ( Site 0743), Zhanjiang, Guangdong, 524004, China|Guangxi Medical University Affiliated Tumor Hospital ( Site 0717), Nanning, Guangxi, 530021, China|Hainan General Hospital ( Site 0736), Haikou, Hainan, 570311, China|Henan Cancer Hospital ( Site 0718), Zhengzhou, Henan, 450008, China|Wuhan Union Hospital-Medical Oncology ( Site 0735), Wuhan, Hubei, 430022, China|Hubei Cancer Hospital-Hubei Cancer Hospital ( Site 0708), Wuhan, Hubei, 430079, China|Xiangya Hospital Central South University-Gynecology ( Site 0705), Changsha, Hunan, 410008, China|Hunan Cancer Hospital ( Site 0704), Changsha, Hunan, 410013, China|Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Oncology (, Nanjing, Jiangsu, 210000, China|Zhongda Hospital Southeast University ( Site 0723), Nanjing, Jiangsu, China|Jiangxi Maternal and Child Health Hospital-Oncology Department ( Site 0716), Nanchang, Jiangxi, 330006, China|The First Hospital of Jilin University ( Site 0710), Changchun, Jilin, 130021, China|Shandong Cancer Hospital-Oncology Department ( Site 0733), Jinan, Shandong, 250117, China|LinYi Cancer Hospital ( Site 0731), Linyi, Shandong, 276001, China|Obstetrics & Gynecology Hospital of Fudan University ( Site 0715), Shanghai, Shanghai, 200011, China|Fudan University Shanghai Cancer Center-Gynecologic Oncology Department ( Site 0701), Shanghai, Shanghai, 200032, China|Shanghai First Maternity and Infant Hospital-Gynecology department ( Site 0744), Shanghai, Shanghai, 201204, China|West China Second University Hospital Sichuan University ( Site 0740), Chengdu, Sichuan, 610066, China|Tianjin Central Hosptial of Gynecology Obstetrics ( Site 0737), Tianjin, Tianjin, 300052, China|Tianjin Medical University Cancer Institute and Hospital ( Site 0720), Tianjin, Tianjin, 300060, China|Yunnan Province Cancer Hospital-Gynecology Department ( Site 0714), Kunming, Yunnan, 650106, China|The Affiliated Women's Hospital of Zhejiang University-Obstetrics and Gynecology ( Site 0741), Hangzhou, Zhejiang, 3100000, China|The First Affiliated Hospital of Wenzhou Medical University-Gynecology ( Site 0706), Wenzhou, Zhejiang, 325000, China|FundaciÃ³n Colombiana de CancerologÃ­a ClÃ­nica Vida ( Site 0808), Medellin, Antioquia, 050030, Colombia|Clinica de la Costa LTDA-Clinical Research Oncology & Hematology -Pediatric ( Site 0809), Barranquilla, Atlantico, 080020, Colombia|ClÃ­nica Universitaria Colombia ( Site 0806), BogotÃ¡, Distrito Capital De Bogota, 111221, Colombia|Oncologos del Occidente ( Site 0807), Pereira, Risaralda, 660001, Colombia|Hemato Oncologos SA ( Site 0801), Cali, Valle Del Cauca, 76001, Colombia|Aalborg Universitetshospital, Syd ( Site 0901), Aalborg, Nordjylland, 9000, Denmark|Turku University Hospital-Department of Obstetrics and Gynecology ( Site 1001), Turku, Varsinais-Suomi, 20521, Finland|Centre Hospitalier RÃ©gional Universitaire de Brest - HÃ´pital-Institut de cancÃ©rologie et hÃ©matologi, Brest, Bretagne, 29200, France|Centre FranÃ§ois Baclesse-Recherche clinique ( Site 2904), Caen, Calvados, 14076, France|Centre Hospitalier Universitaire de Limoges - HÃ´pital Dupuytren-oncologie ( Site 2907), Limoges, Haute-Vienne, 87042, France|Institut Curie - site Saint-Cloud ( Site 2909), Saint-Cloud, Hauts-de-Seine, 92210, France|Centre EugÃ¨ne Marquis Rennes - Centre de Lutte Contre le Cancer-Medical Oncology ( Site 2901), Rennes, Ille-et-Vilaine, 35042, France|Centre de CancÃ©rologie du Grand Montpellier ( Site 2908), Montpellier, Languedoc-Roussillon, 34070, France|HÃ´pital privÃ© du Confluent SAS-Service d'oncologie mÃ©dicale ( Site 2905), Nantes, Loire-Atlantique, 44277, France|Universitaetsklinikum Erlangen-Klinik fÃ¼r GynÃ¤kologie und Geburtshilfe ( Site 1205), Erlangen, Bayern, 91054, Germany|UniversitÃ¤tsklinikum Bonn-Gynaecological oncology ( Site 1203), Bonn, Nordrhein-Westfalen, 53127, Germany|Universitaetsklinikum Duesseldorf-Klinik fÃ¼r Frauenheilkunde & Geburtshilfe ( Site 1204), DÃ¼sseldorf, Nordrhein-Westfalen, 40225, Germany|Zentrum fuer ambulante gynaekologische Onkologie (ZAGO) ( Site 1207), Krefeld, Nordrhein-Westfalen, 47805, Germany|CaritasKlinikum SaarbrÃ¼cken St. Theresia ( Site 1211), SaarbrÃ¼cken, Saarland, 66113, Germany|Universitaetsklinikum Carl Gustav Carus Dresden-Klinik und Poliklinik fÃ¼r Frauenheilkunde und Gebur, Dresden, Sachsen, 01307, Germany|UniversitÃ¤tsklinikum Leipzig-Department of Gynecology and Obstetrics ( Site 1213), Leipzig, Sachsen, 04103, Germany|CharitÃ© Campus Virchow-Klinikum ( Site 1201), Berlin, 13353, Germany|Asklepios Kliniken Hamburg-Asklepios Klinik Barmbek ( Site 1214), Hamburg, 22307, Germany|St. James's Hospital-Cancer clinical trials office ( Site 2821), Dublin, D08 E9P6, Ireland|Emek Medical Center-Gyn-Onc ( Site 1406), Afula, 1834111, Israel|Soroka Medical Center ( Site 1404), Be'er Sheva, 8410101, Israel|Rambam Health Care Campus-Gyneco-oncology unit ( Site 1402), Haifa, 3109601, Israel|Shaare Zedek Medical Center ( Site 1405), Jerusalem, 9103102, Israel|Rabin Medical Center ( Site 1401), Petah-Tikva, 49100, Israel|Sheba Medical Center ( Site 1407), Ramat Gan, 5265601, Israel|Sourasky Medical Center ( Site 1403), Tel Aviv, 6423906, Israel|IRCCS - AOU di Bologna-SSD Oncologia medica Addarii ( Site 1501), Bologna, Emilia-Romagna, 40138, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 1503), Milan, Lombardia, 20133, Italy|Ospedale San Gerardo-ASST Monza-Oncologia ( Site 1508), Monza, Lombardia, 20900, Italy|ASST Grande Ospedale Metropolitano Niguarda ( Site 1505), Milan, Milano, 20162, Italy|Ospedale Mauriziano-Ginecologia e Ostetricia ( Site 1507), Torino, Piemonte, 10128, Italy|Azienda Ospedaliera Spedali Civili di Brescia ( Site 1504), Brescia, 25123, Italy|Istituto Europeo di Oncologia IRCCS-Divisione di Ginecologia Oncologica ( Site 1502), Milano, 20141, Italy|Aichi Cancer Center Hospital ( Site 1610), Nagoya, Aichi, 464-8681, Japan|National Cancer Center Hospital East ( Site 1609), Kashiwa, Chiba, 277-8577, Japan|National Hospital Organization Shikoku Cancer Center ( Site 1603), Matsuyama, Ehime, 791-0280, Japan|Ehime University Hospital ( Site 1606), Toon, Ehime, 791-0295, Japan|Kurume University Hospital ( Site 1607), Kurume, Fukuoka, 830-0011, Japan|Hokkaido University Hospital ( Site 1604), Sapporo, Hokkaido, 060-8648, Japan|Iwate Medical University Hospital ( Site 1613), Shiwa-gun Yahaba-cho, Iwate, 028-3695, Japan|Nippon Medical School Musashi Kosugi Hospital ( Site 1614), Kawasaki, Kanagawa, 211-8533, Japan|Saitama Medical University International Medical Center ( Site 1601), Hidaka-shi, Saitama, 350-1200, Japan|Shizuoka Cancer Center ( Site 1611), Nagaizumi, Shizuoka, 411-8777, Japan|National Cancer Center Hospital ( Site 1612), Chuo-ku, Tokyo, 104-0045, Japan|Japanese Foundation for Cancer Research ( Site 1605), Koto, Tokyo, 135-8550, Japan|Osaka International Cancer Institute ( Site 1602), Osaka, 541-8567, Japan|Seoul National University Hospital ( Site 2302), Seoul, 03080, Korea, Republic of|Severance Hospital, Yonsei University Health System-Gynecologic cancer center ( Site 2303), Seoul, 03722, Korea, Republic of|Asan Medical Center-Division of Gynecologic Oncology, Dept. of Obstetrics & Gynecology ( Site 2304), Seoul, 05505, Korea, Republic of|Gangnam Severance Hospital ( Site 2301), Seoul, 06273, Korea, Republic of|InvestigaciÃ³n OncofarmacÃ©utica-InvestigaciÃ³n clÃ­nica ( Site 1706), La Paz, Baja California Sur, 23040, Mexico|COI Centro Oncologico Internacional S.A.P.I. de C.V.-Investigation Unit COI ( Site 1703), Mexico City, Distrito Federal, 04700, Mexico|INSTITUTO NACIONAL DE CANCEROLOGIA ( Site 1701), Mexico City, Distrito Federal, 14070, Mexico|iCan Oncology Center Centro Medico AVE ( Site 1704), Monterrey, Nuevo Leon, 64710, Mexico|Centro de Investigacion Clinica de Oaxaca ( Site 1705), Oaxaca, 68020, Mexico|Radboudumc ( Site 1802), Nijmegen, Gelderland, 6525 GA, Netherlands|Leids Universitair Medisch Centrum-Medical Oncology ( Site 1801), Leiden, Zuid-Holland, 2333 ZA, Netherlands|Erasmus Medisch Centrum-Medical Oncology ( Site 1803), Rotterdam, Zuid-Holland, 3015 GD, Netherlands|Universitair Medisch Centrum Utrecht-Medical Oncology ( Site 1804), Utrecht, 3584 CX, Netherlands|Auckland City Hospital ( Site 1901), Auckland, 1023, New Zealand|Universitetssykehuset Nord-Norge HF-Kreftavdelingen ( Site 2001), TromsÃ¸, Troms, 9038, Norway|Szpital Kliniczny im. KsiÄÅ¼nej Anny Mazowieckiej ( Site 2103), Warsaw, Mazowieckie, 00-315, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Gynecological Oncology Department ( Sit, Warszawa, Mazowieckie, 02-781, Poland|Bialostockie Centrum Onkologii-Oddzial Onkologii Ginekologicznej ( Site 2106), Bialystok, Podlaskie, 15-027, Poland|Uniwersytecki Szpital Kliniczny w Bialymstoku-Uniwersyteckie Centrum Onkologii ( Site 2104), Bialystok, Podlaskie, 15-276, Poland|Uniwersyteckie Centrum Kliniczne-Klinika Ginekologii, Ginekologii Onkologicznej i Endokrynologii Gi, GdaÅsk, Pomorskie, 80-214, Poland|Narodowy Instytut Onkologii - Oddzial w Gliwicach-III Klinika Radioterapii i Chemioterapii ( Site 21, Gliwice, Slaskie, 44-101, Poland|Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zaklad Opieki Zdrowotnej ( Site 2107), Kielce, Swietokrzyskie, 25-734, Poland|Szpital Kliniczny im. Heliodora ÅwiÄcickiego Uniwersytetu Me-Oddzial Ginekologii Onkologicznej ( Sit, Poznan, Wielkopolskie, 61-848, Poland|Chelyabinsk Regional Clinical Oncology Dispensary-Chelyabinsk Regional Clinical Oncology Dispensary, Chelyabinsk, Chelyabinskaya Oblast, 454087, Russian Federation|Ogarev Mordovia State University ( Site 2209), Saransk, Mordoviya, Respublika, 430005, Russian Federation|Moscow City Oncology Hospital #62 ( Site 2214), Krasnogorsk D-t, Moskovskaya Oblast, 143423, Russian Federation|Fed State Budgetary Inst ""N.N. Blokhin Med Center of Oncology"" MHRF-Chemotherapy #2 ( Site 2211), Moscow, Moskva, 115478, Russian Federation|SVERDLOVSK REGIONAL ONCOLOGY DISPENSARY-Oncogynecology Department ( Site 2216), Ekaterinburg, Sverdlovskaya Oblast, 620905, Russian Federation|cukurova universty ( Site 2706), SarÃ§am, Adana, 01250, Turkey|Istanbul Universitesi Cerrahpasa ( Site 2709), Fatih, Istanbul, 34098, Turkey|Ege University Medicine of Faculty ( Site 2702), Bornova, Izmir, 35100, Turkey|Baskent University Dr. Turgut Noyan Research and Training Center-ONCOLOGY ( Site 2704), Adana, 01250, Turkey|Ankara University Hospital Cebeci ( Site 2701), Ankara, 06100, Turkey|Baskent Universitesi Ankara Hastanesi ( Site 2707), Ankara, 34180, Turkey|Bezmialem Vakf Ãniversitesi-Oncology ( Site 2705), Istanbul, 34093, Turkey|T.C. Saglik Bakanligi Turkiye Kamu Hastaneleri Kurumu - Bakirkoy Dr. Sadi Konuk Egitim ve Arastirma, Istanbul, 34440, Turkey|Brighton and Sussex University Hospitals NHS Trust ( Site 2803), East Sussex, Brighton And Hove, BN2 5BE, United Kingdom|Addenbrooke's Hospital ( Site 2808), Cambridge, Cambridgeshire, CB2 2QQ, United Kingdom|The Royal Cornwall Hospital ( Site 2804), Truro, Cornwall, TR1 3LJ, United Kingdom|Westmorland General Hospital ( Site 2815), Kendal, Cumbria, LA9 7RG, United Kingdom|Ninewells Hospital and Medical School ( Site 2826), Dundee, Dundee City, DD1 9SY, United Kingdom|Leicester Royal Infirmary-HOPE Clinical Trials Unit ( Site 2812), Leicester, England, United Kingdom|Hammersmith Hospital-Medical Oncology ( Site 2818), London, London, City Of, W12 0HS, United Kingdom|Velindre Cancer Centre ( Site 2805), Cardiff, CF14 2TL, United Kingdom",
NCT06824467,A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103),https://clinicaltrials.gov/study/NCT06824467,,RECRUITING,The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and If people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.,NO,Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer,BIOLOGICAL: Sacituzumab tirumotecan|BIOLOGICAL: Bevacizumab|DRUG: H1 receptor antagonist|DRUG: H2 receptor antagonist|DRUG: Acetaminophen (or equivalent)|DRUG: Dexamethasone (or equivalent)|DRUG: Steroid mouthwash (dexamethasone or equivalent),"Part 1: Number of participants with one or more adverse events (AEs), An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention., Up to 6 weeks|Part 1: Number of participants who discontinue study intervention due to an AE, An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention., Up to 6 weeks|Part 2: Progression-free Survival (PFS), PFS is defined as the time from randomization to the first documented progressive disease (PD) or death from any cause, whichever occurs first. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented., Up to approximately 4 years","Part 2: Overall Survival (OS), OS is defined as the time from randomization to death due to any cause, Up to approximately 4 years|Part 2: Number of participants with one or more AEs, An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention., Up to approximately 4 years|Part 2: Number of participants who discontinue study intervention due to an AE, An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention., Up to approximately 4 years|Part 2: Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status-Quality of Life Score, The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients. Participant responses to Item 30 (""""How would you rate your overall quality of life during the past week?"") is scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher value indicates a better level of function. The change from baseline in EORTC QLQ-C30 Item 30 score will be reported., Baseline and up to approximately 4 years|Part 2: Change from Baseline in EORTC QLQ-C30 Physical Functioning Score, The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better level of physical functioning., Baseline and up to approximately 4 years|Part 2: Change from Baseline in EORTC QLQ-C30 Role Functioning Score, The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions ""Were you limited in doing either your work or other daily activities during the past week?"" and "" Were you limited in pursuing your hobbies or other leisure time activities during the past week?"" will be scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. Higher scores indicate a more impaired level of role functioning. Change from baseline in the role functioning score will be presented., Baseline and up to approximately 4 years|Part 2: Change from Baseline in EORTC Quality of Life Questionnaire-Ovarian Cancer Module 28 (QLQ-OV28) abdominal/gastrointestinal (GI) symptom scale, The EORTC QLQ-OV28 is an OC-specific, and psychometrically and clinically validated module to supplement the EORTC QLQ-C30. The EORTC QLQ-OV28 abdominal/GI symptom scale is scored on a 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much)., Baseline and up to approximately 4 years",,Merck Sharp & Dohme LLC,European Network of Gynaecological Oncological Trial Groups (ENGOT)|GOG Foundation,FEMALE,"ADULT, OLDER_ADULT",PHASE3,770,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2025-04-09,2029-04-27,2032-10-15,2025-02-13,,2025-06-08,"Sarasota Memorial Hospital ( Site 0075), Sarasota, Florida, 34239, United States|St. Dominic's Hospital ( Site 0064), Jackson, Mississippi, 39216, United States|Nebraska Methodist Hospital ( Site 0053), Omaha, Nebraska, 68114, United States|Rutgers Cancer Institute of New Jersey ( Site 0071), New Brunswick, New Jersey, 08901, United States|University of Cincinnati Medical Center ( Site 0090), Cincinnati, Ohio, 45219, United States|Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0056), Tulsa, Oklahoma, 74146, United States|Women & Infants Hospital ( Site 0050), Providence, Rhode Island, 02905, United States|Gallipoli Medical Research Ltd ( Site 0214), Brisbane, Queensland, 4120, Australia|Epworth Freemasons ( Site 0217), East Melbourne, Victoria, 3002, Australia|Kurume University Hospital ( Site 1640), Kurume, Fukuoka, 830-0011, Japan|Saitama Medical University International Medical Center ( Site 1632), Hidaka, Saitama, 350-1298, Japan|Cancer Institute Hospital of JFCR ( Site 1639), Koto, Tokyo, 135-8550, Japan|Niigata Cancer Center Hospital ( Site 1633), Niigata, 951-8566, Japan|National Cancer Center ( Site 2305), Goyang-si, Kyonggi-do, 10408, Korea, Republic of|Severance Hospital ( Site 2302), Seodaemun-Gu, Seoul, 03722, Korea, Republic of|Asan Medical Center ( Site 2304), Songpa-gu, Seoul, 05505, Korea, Republic of|Seoul National University Hospital ( Site 2301), Seoul, 03080, Korea, Republic of|Samsung Medical Center ( Site 2303), Seoul, 06351, Korea, Republic of|Institut CatalÃ  d'Oncologia (ICO) - Girona ( Site 2402), Girona, Gerona, 17007, Spain|Clinica Universidad de Navarra ( Site 2407), Madrid, Madrid, Comunidad De, 28027, Spain|Hospital Vall D Hebron ( Site 2403), Barcelona, 08035, Spain|ICO L Hospitalet ( Site 2408), Barcelona, 08907, Spain|Hospital Universitario Reina Sofia ( Site 2406), Cordoba, 14004, Spain|Hospital Ramon y Cajal ( Site 2405), Madrid, 28034, Spain|Taichung Veterans General Hospital ( Site 2603), Taichung, 40705, Taiwan|National Cheng Kung University Hospital ( Site 2602), Tainan, 704, Taiwan|Mackay Memorial Hospital ( Site 2604), Taipei, 104, Taiwan",
NCT06774131,A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer,https://clinicaltrials.gov/study/NCT06774131,,NOT_YET_RECRUITING,"This study will evaluate the efficacy and safety of UGN-104, a new formulation of UGN-101 (approved in the United States and Israel as JELMYTO \[mitomycin\] for pyelocalyceal solution), instilled in the upper urinary tract (UUT) of patients with low-grade upper tract urothelial cancer (LG-UTUC).",NO,Upper Urinary Tract Urothelial Carcinoma|Urothelial Carcinoma,DRUG: UGN-104,"Complete response rate (CRR), CRR is defined as the proportion of patients who achieved CR at the PDE Visit., 3 months","Duration of response (DOR), DOR is defined as the time from the date of evidence of CR at the PDE Visit to the earliest date of recurrence, progression, or death due to any cause, whichever occurred first., 12 months|Durable complete response (DCR) rate, DCR rate at scheduled disease assessment time points, defined as the proportion of patients who achieved CR at the PDE Visit and maintained CR (ie, no detectable disease) up to that particular follow-up disease assessment., 12 months|Incidence of treatment-emergent adverse events (TEAEs), serious TEAEs, TEAEs of special interest, and abnormal clinical laboratory test results (hematology and serum chemistry), The number of patients with each type of event will be summarized., 15 months|Mitomycin plasma concentrations, Mitomycin plasma concentrations will be assessed in a subset of patients treated with UGN-104., 0 (pre-instillation), 0.5, 1, 2, 3, 4, 5, and 6 hours after the first instillation of UGN-104|Mitomycin maximum plasma concentration (Cmax), Mitomycin Cmax will be assessed in a subset of patients treated with UGN-104., 0 (pre-instillation), 0.5, 1, 2, 3, 4, 5, and 6 hours after the first instillation of UGN-104|Mitomycin time to maximum plasma concentration (tmax), Mitomycin tmax will be assessed in a subset of patients treated with UGN-104., 0 (pre-instillation), 0.5, 1, 2, 3, 4, 5, and 6 hours after the first instillation of UGN-104|Mitomycin area under the concentration-time curve (AUC), Mitomycin AUC will be assessed in a subset of patients treated with UGN-104., 0 (pre-instillation), 0.5, 1, 2, 3, 4, 5, and 6 hours after the first instillation of UGN-104|Mitomycin terminal half-life (t1/2), Mitomycin t1/2 will be assessed in a subset of patients treated with UGN-104., 0 (pre-instillation), 0.5, 1, 2, 3, 4, 5, and 6 hours after the first instillation of UGN-104",,UroGen Pharma Ltd.,,ALL,"ADULT, OLDER_ADULT",PHASE3,50,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2025-04-15,2026-03-31,2027-03-31,2025-01-14,,2025-01-14,"Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, 17033, United States",
NCT06929325,Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors,https://clinicaltrials.gov/study/NCT06929325,,NOT_YET_RECRUITING,"A randomized, double-blind, multicenter phase III clinical study to evaluate the efficacy and safety of sirolimus for injection (albumin-bound) combined with fulvestrant in patients with HR+ and HER2- advanced breast cancer.",NO,HR+/HER2- Advanced/Metastatic Breast Cancer,DRUG: Sirolimus for Injection (Albumin-bound)|DRUG: Fulvestrant Injection|DRUG: Placebo for Sirolimus for Injection (Albumin-bound),"Progression-free Survivalï¼PFSï¼, Up to ~24 months","Overall Survivalï¼OSï¼, Up to ~36 months|Overall response rateï¼ORRï¼, Up to ~24 months|Clinical benefit rateï¼CBRï¼, Up to ~24 months|Disease control rateï¼DCRï¼, Up to ~24 months|Duration of Responseï¼DORï¼, Up to ~24 months|Safety and Tolerabilityï¼the incidence and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs), Up to ~24 months|PK metricsï¼plasma concentration of sirolimus, Up to ~24 months",,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,312,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2025-04,2026-10,2027-12,2025-04-16,,2025-04-16,"Clinical Trials Information Group, Shijiazhuang, Hebei, China",
NCT04639180,A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation,https://clinicaltrials.gov/study/NCT04639180,,UNKNOWN,A Trial to Evaluate the Efficacy and Safety of Camrelizumab Plus Rivoceranib (Apatinib) Versus Active Surveillance as Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation.,NO,Hepatocellular Carcinoma (HCC),DRUG: Camrelizumab|DRUG: Rivoceranib (Apatinib),"Recurrence-Free Survival (RFS), as Determined by the blinded independent review committee (BIRC), RFS is defined as the time from randomization to the first documented occurrence of local, regional, or metastatic HCC as determined by BIRC, or death from any cause (whichever occurs first)., Randomization up to approximately 43 months","RFS Rate at 24 and 36 Months, as Assessed by the Investigator, Randomization up to 24 months and up to 36 months|Time to Recurrence (TTR) as determined by the investigator and by BIRC, TTR defined as the time from randomization to first documented occurrence of local, regional, or metastatic HCC, Randomization up to approximately 43 months|Overall Survival (OS), OS is defined as the time from randomization to death from any cause, Randomization up to approximately 43 months|The incidence and severity of adverse events (AEs) and serious adverse events (SAEs) as assessed by CTCAE v5.0, Baseline up to approximately 43 months",,"Jiangsu HengRui Medicine Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,687,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2021-04-01,2024-07-31,2024-07-31,2020-11-20,,2023-04-25,"The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China|Guangxi Medical University Affiliated Tumor Hospital, Nanjin, Guangzhou, China|Guizhou Cancer Hospital, Guiyang, Guizhou, China|Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China|Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China",
NCT03711032,Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676),https://clinicaltrials.gov/study/NCT03711032,,ACTIVE_NOT_RECRUITING,"Researchers are looking for new ways to treat high-risk non muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder but has not spread to the bladder muscle or outside of the bladder. High-risk means NMIBC may have a high chance of getting worse or coming back after treatment.

The goals of this study are to learn: 1. If more people who receive pembrolizumab with Bacillus Calmette-Guerin (BCG) have no signs of cancer in their body and live longer without the cancer growing, spreading, or coming back compared to people who receive BCG alone. 2. About the safety and how well people tolerate BCG alone or in combination with pembrolizumab.",NO,High-risk Non-muscle Invasive Bladder Cancer,BIOLOGICAL: Pembrolizumab|BIOLOGICAL: BCG,"Complete Response Rate (CRR) by Blinded Independent Central Review (BICR) (Cohort A), CRR is defined as the percentage of participants with carcinoma in situ (CIS) achieving a complete response (CR)., Up to ~3.5 years|Event-Free Survival (EFS) (Cohort B), EFS is defined as the time from randomization until urothelial carcinoma (UC)-defined event, or death due to any cause., Up to ~5 years","EFS (Cohort A), EFS is defined as the time from randomization until UC-defined event, or death due to any cause., Up to ~5 years|Recurrence-Free Survival (RFS) (Cohorts A and B), RFS is defined as the time from randomization until the first occurrence of any UC recurrence, progression, or death due to any cause., Up to ~5 years|Overall Survival (OS) (Cohorts A and B), OS is defined as the time from randomization to death due to any cause., Up to ~5 years|Disease Specific Survival (DSS) (Cohorts A and B), DSS is defined as the time from randomization to death due to bladder cancer., Up to ~5 years|Time to Cystectomy (Cohorts A and B), Time to cystectomy is defined as the time from a participant's randomization until the date of cystectomy., Up to ~5 years|12-Month EFS Rate (Cohort A), EFS is defined as the time from randomization until UC-defined event, or death due to any cause. The 12-month EFS rate is defined as the percentage of participants with EFS at 12 months., 12 months after EFS (up to ~5 years)|Duration of Response (DOR) (Cohorts A and B), DOR in participants with CIS is defined as the time from first documented CR until end of response or death due to any cause, whichever occurs first., Up to ~5 years|12-Month DOR Rate (Cohorts A and B), The 12-month DOR Rate in participants with CIS is defined as the percentage of participants with a CR of at least 12 months duration., 12 months after CR (up to ~4.5 years)|Percentage of Participants Experiencing Adverse Events (AEs) (Cohorts A and B), An AE is any untoward medical occurrence in a participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment., Up to ~5 years|Percentage of Participants Discontinuing Study Drug Due to AEs (Cohorts A and B), An AE is any untoward medical occurrence in a participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment., Up to ~5 years|Change from Baseline in the European Organization for Research and Treatment of Cancer (EORTC)-Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status/Quality of Life (Items 29 and 30) Combined Score (Cohorts A and B), The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to the questions ""How would you rate your overall health during the past week?"" and ""How would you rate your overall quality of life during the past week?"" are scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall outcome. The change from baseline in Global Health Status/Quality of Life (EORTC QLQ-C30 Items 29 and 30) combined score will be presented., Baseline, time of last PRO assessment (up to ~2 years)|Change from Baseline in EORTC-QLQ-C30 Physical Functioning (Items 1-5) Combined Score (Cohorts A and B), EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better quality of life. The change from baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) combined score will be presented., Baseline, time of last PRO assessment (up to ~2 years)|Change from Baseline in EORTC-QLQ-Non-muscle Invasive Bladder Cancer Module 24 (NMIBC24) Total Score (Cohorts A and B), The EORTC-QLQ-NMIBC24 is a 24-item questionnaire developed to supplement the EORTC QLQ-C30 in high-risk NMIBC patients. Each item is scored out of 4 total points (1=Not at All to 4=Very Much). All responses are transformed from 0 to 100, with a high score indicating more symptoms or problems. The change from baseline in EORTC-QLQ-NMIBC24 total score will be presented., Baseline, time of last PRO assessment (up to ~2 years)|Change from Baseline in European Quality of Life (EuroQoL)-5 Dimensions, 5-level Questionnaire (EQ-5D-5L) Visual Analogue Score (VAS) (Cohorts A and B), The EQ-5D-5L VAS records the respondent's self-rated health on a 10 cm vertical, visual analogue scale. It is rated by the respondent on a scale 0 to 100, with 0 being ""the worst health you can imagine"" and 100 being ""the best health you can imagine"". The change from baseline in EQ-5D-5L VAS will be presented., Baseline, time of last PRO assessment (up to ~2 years)|Time to Deterioration (TTD) in the EORTC-QLQ-C30 Global Health Status/Quality of Life (Items 29 and 30) Combined Score (Cohorts A and B), EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to the questions ""How would you rate your overall health during the past week?"" and ""How would you rate your overall quality of life during the past week?"" are scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall outcome. TTD in Global Health Status/Quality of Life is defined as the time from baseline to the first onset of a 10 point or greater decrease from baseline in the Global Health Status/Quality of Life (EORTC QLQ-C30 Items 29 and 30) combined score, with or without subsequent confirmation., Time of last PRO assessment (up to ~2 years)|TTD in the EQ-5D-5L VAS (Cohorts A and B), The EQ-5D-5L VAS records the respondent's self-rated health on a 20 cm vertical, visual analogue scale. It is rated by the respondent on a scale 0 to 100, with 0 being ""the worst health you can imagine"" and 100 being ""the best health you can imagine"". TTD in EQ-5D-5L VAS is defined as the time from baseline to the first onset of a 7 point or greater decrease from baseline in EQ-5D-5L VAS, with or without subsequent confirmation, under a right-censoring rule., Time of last PRO assessment (up to ~2 years)|CRR by BICR (Cohort B), CRR is defined as the percentage of participants with CIS achieving a CR., Up to ~3.5 years|24-Month EFS Rate (Cohort B), EFS is defined as the time from randomization until UC-defined event, or death due to any cause. The 24-month EFS rate is defined as the percentage of participants with EFS at 24 months., 24 months after EFS (Up to ~5 years)",,Merck Sharp & Dohme LLC,,ALL,"ADULT, OLDER_ADULT",PHASE3,1397,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2018-12-24,2025-12-31,2034-11-20,2018-10-18,,2024-12-11,"Alaska Urological Institute dba Alaska Clinical Research Center ( Site 1083), Anchorage, Alaska, 99503, United States|Mayo Clinic in Arizona - Phoenix ( Site 1094), Phoenix, Arizona, 85054, United States|Arizona Urology Specialists (AUS)-Professional Park ( Site 1096), Tucson, Arizona, 85704, United States|UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro, Los Angeles, California, 90095, United States|University of California Irvine Medical Center ( Site 1061), Orange, California, 92868, United States|Genesis Research LLC ( Site 1065), Torrance, California, 90505, United States|Colorado Clinical Research ( Site 1100), Lakewood, Colorado, 80228, United States|Urological Research Network ( Site 1106), Hialeah, Florida, 33016, United States|Mayo Clinic in Florida-Urology ( Site 1097), Jacksonville, Florida, 32224, United States|University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 1056), Miami, Florida, 33136, United States|Woodlands Medical Specialists, PA ( Site 8002), Pensacola, Florida, 32503, United States|Emory School of Medicine ( Site 1076), Atlanta, Georgia, 30322, United States|Advanced Urology ( Site 1092), Roswell, Georgia, 30076, United States|Northwestern Memorial Hospital ( Site 1101), Chicago, Illinois, 60611, United States|Wichita Urology Group ( Site 1086), Wichita, Kansas, 67226, United States|Ochsner LSU Health Shreveport - Regional Urology ( Site 1099), Shreveport, Louisiana, 71106, United States|Henry Ford Health System ( Site 1062), Detroit, Michigan, 48202, United States|Michigan Institute of Urology ( Site 1077), Troy, Michigan, 48084, United States|Coastal Urology Associates ( Site 1055), Brick, New Jersey, 08724, United States|Morristown Medical Center ( Site 1090), Morristown, New Jersey, 07960, United States|Rutgers Cancer Institute of New Jersey ( Site 1059), New Brunswick, New Jersey, 08903, United States|St. Peter's Hospital Cancer Care Center ( Site 1087), Albany, New York, 12208, United States|R.J. Zuckerberg Cancer Center ( Site 1080), Lake Success, New York, 11042, United States|Veterans Affairs New York Harbor Healthcare System-PCF COE ( Site 1112), New York, New York, 10010, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 1074), New York, New York, 10016, United States|Associated Medical Professionals of NY ( Site 1078), Syracuse, New York, 13210, United States|TriState Urologic Services PSC Inc. dba The Urology Group ( Site 1091), Cincinnati, Ohio, 45212, United States|University Hospitals Cleveland Medical Center ( Site 1066), Cleveland, Ohio, 44106, United States|Ohio State University Arthur G James Cancer Hospital & Richard J Solove Research Institute ( Site 10, Columbus, Ohio, 43210, United States|OHSU Knight Cancer Institute ( Site 1075), Portland, Oregon, 97210, United States|Oregon Urology Institute ( Site 1098), Springfield, Oregon, 97477, United States|MidLantic Urology ( Site 1071), Bala-Cynwyd, Pennsylvania, 19004, United States|Lancaster Urology ( Site 1079), Lancaster, Pennsylvania, 17604, United States|University of Pennsylvania ( Site 1088), Philadelphia, Pennsylvania, 19104, United States|Carolina Urologic Research Center ( Site 1085), Myrtle Beach, South Carolina, 29572, United States|Urology Associates [Nashville, TN] ( Site 1072), Nashville, Tennessee, 37209, United States|Urology Clinics of North Texas, PLLC ( Site 1064), Dallas, Texas, 75231, United States|University Of Texas Southwestern Medical Center ( Site 1053), Dallas, Texas, 75390, United States|Texas Oncology-Fort Worth Cancer Center ( Site 8003), Fort Worth, Texas, 76104, United States|Houston Metro Urology ( Site 1111), Houston, Texas, 77027, United States|Texas Oncology-Plano West ( Site 8001), Plano, Texas, 75093, United States|Urology San Antonio Research ( Site 1108), San Antonio, Texas, 78229, United States|University of Vermont Medical Center ( Site 1057), Burlington, Vermont, 05401, United States|Urology of Virginia ( Site 1070), Virginia Beach, Virginia, 23462, United States|GenesisCare North Shore ( Site 0010), St Leonards, New South Wales, 2065, Australia|Northern Cancer Institute. ( Site 0003), St Leonards, New South Wales, 2065, Australia|Sydney Adventist Hospital ( Site 0001), Wahroonga, New South Wales, 2076, Australia|Epworth Hospital ( Site 0009), Richmond, Victoria, 3121, Australia|Ordensklinikum Linz GmbH Elisabethinen ( Site 0052), Linz, Oberosterreich, 4020, Austria|Univ. Klinik f. Urologie Innsbruck ( Site 0051), Innsbruck, Tirol, 6020, Austria|Medizinische UniversitÃ¤t Wien ( Site 0054), Vienna, Wien, 1090, Austria|Universitaetsklinik Salzburg ( Site 0053), Salzburg, 5020, Austria|UZA University Hospital Antwerp ( Site 0105), Edegem, Antwerpen, 2650, Belgium|CHU UCL Namur Site de Godinne ( Site 0103), Yvoir, Namur, 5530, Belgium|O.L.V. Ziekenhuis Aalst ( Site 0106), Aalst, Oost-Vlaanderen, 9300, Belgium|AZ Maria Middelares Gent ( Site 0102), Gent, Oost-Vlaanderen, 9000, Belgium|UZ Gent ( Site 0101), Gent, Oost-Vlaanderen, 9000, Belgium|Hospital SÃ£o Carlos-Oncocentro Ce ( Site 1558), Fortaleza, Ceara, 60135-237, Brazil|Hospital Erasto Gaertner-CEPEP - Pesquisa ClÃ­nica ( Site 1551), Curitiba, Parana, 81520060, Brazil|FundaÃ§Ã£o Pio XII - Hospital de CÃ¢ncer de Barretos-Unidade de Pesquisa ClÃ­nica ( Site 1553), Barretos, Sao Paulo, 14784-400, Brazil|ICESP - INSTITUTO DO CÃNCER DO ESTADO DE SÃO PAULO ( Site 1560), Sao Paulo, 01246-000, Brazil|BP - A Beneficencia Portuguesa de SÃ£o Paulo ( Site 1559), Sao Paulo, 01321-001, Brazil|NÃºcleo de Pesquisa ClÃ­nica da Rede SÃ£o Camilo ( Site 1554), Sao Paulo, 04014-002, Brazil|Exdeo Clinical Research Inc. ( Site 0165), Abbotsford, British Columbia, V2T 1X8, Canada|Silverado Resarch Inc. ( Site 0155), Victoria, British Columbia, V8T 2C1, Canada|Horizon Health Network ( Site 0160), Moncton, New Brunswick, E1C 6Z8, Canada|Princess Margaret Cancer Centre ( Site 0153), Toronto, Ontario, M5G 2M9, Canada|CIUSSS du Saguenay-Lac-St-Jean ( Site 0164), Chicoutimi, Quebec, G7H 5H6, Canada|CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0157), Montreal, Quebec, H1T 2M4, Canada|CHUS - Hopital Fleurimont ( Site 0152), Sherbrooke, Quebec, J1H 5N4, Canada|Centre intÃ©grÃ© de cancÃ©rologie du CHU de QuÃ©bec UniversitÃ© Laval, HÃ´pital de l'Enfant-JÃ©sus ( Site 0, Quebec, G1J 1Z4, Canada|Cancer Hospital Chinese Academy of Medical Science-Urinary Surgery ( Site 1766), Beijing, Beijing, 100021, China|Peking University First Hospital ( Site 1759), Beijing, Beijing, 100034, China|Beijing Cancer hospital-Urinary Surgery ( Site 1755), Beijing, Beijing, 100142, China|Chongqing University Cancer Hospital ( Site 1784), Chongqing, Chongqing, 400030, China|The First Affiliated hospital of Xiamen University-Urology ( Site 1776), Xiamen, Fujian, 361003, China|SUN YAT-SEN UNIVERSITY CANCER CENTRE ( Site 1752), Guangzhou, Guangdong, 510060, China|The First Affiliated Hospital of Guangzhou Medical University-Urology ( Site 1777), Guangzhou, Guangdong, 510120, China|Sun Yat-sen Memorial Hospital, Sun Yat-sen University-Urology Surgery ( Site 1751), Guangzhou, Guangdong, 510289, China|ShenZhen People's Hospital ( Site 1778), Shenzhen, Guangdong, 518020, China|Harbin Medical University Cancer Hospital-urology ( Site 1772), Harbin, Heilongjiang, 150081, China|Henan Cancer Hospital-Urology ( Site 1770), Zhengzhou, Henan, 450008, China|Tongji Hospital Tongji Medical,Science & Technology ( Site 1768), Wuhan, Hubei, 430000, China|Wuhan Union Hospital ( Site 1771), Wuhan, Hubei, 430010, China|Hunan Cancer Hospital ( Site 1763), Changsha, Hunan, 410013, China|Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Urology ( S, NanJing, Jiangsu, 210008, China|The Second Affiliated Hospital of Soochow University-Urology ( Site 1773), Suzhou, Jiangsu, 215004, China|The First Affiliated Hospital of Xi'an Jiaotong University ( Site 1764), Xi'an, Shaanxi, 710061, China|West China Hospital Sichuan University ( Site 1767), Cheng Du, Sichuan, 610041, China|The Second Hospital of Tianjin Medical University ( Site 1769), Tianjin, Tianjin, 300211, China|Zhejiang Provincial People's Hospital-Urology ( Site 1762), Hangzhou, Zhejiang, 310014, China|The First Affiliated Hospital of Wenzhou Medical University-Urology Surgery ( Site 1774), Wenzhou, Zhejiang, 325000, China|Instituto de CancerologÃ­a-Oncology ( Site 1609), MedellÃ­n, Antioquia, 050024, Colombia|FundaciÃ³n Hospital San Vicente de PaÃºl - Rionegro - Centros Especializados o de Centros Especializad, Rionegro, Antioquia, 054047, Colombia|Oncomedica S.A.-Oncomedica S.A ( Site 1604), MonterÃ­a, Cordoba, 230002, Colombia|Clinica Colsanitas S.A, Sede ClÃ­nica Universitaria Colombia-Center Investigator ( Site 1605), Bogota, Distrito Capital De Bogota, 111321, Colombia|Administradora Country S.A. - Clinica del Country ( Site 1607), BogotÃ¡, Distrito Capital De Bogota, 110221, Colombia|Oncologos del Occidente ( Site 1608), Pereira, Risaralda, 661001, Colombia|Hemato Oncologos SA-Oncology ( Site 1601), Cali, Valle Del Cauca, 76001, Colombia|ClÃ­nica Imbanaco S.A.S ( Site 1611), Cali, Valle Del Cauca, 760042, Colombia|CIMCA ( Site 1550), San JosÃ©, San Jose, 10103, Costa Rica|Policlinico San Bosco ( Site 0600), San Jose, 10103, Costa Rica|Tampere University Hospital [Tampere Finland] ( Site 0201), Tampere, Pirkanmaa, 33520, Finland|Centre Hospitalier Universitaire Dijon Bourgogne - HÃ´pital FranÃ§ois Mitterrand-Urology ( Site 1355), Dijon, Bourgogne, 21000, France|HÃ´pital Foch-Urology department ( Site 1351), Suresnes, Hauts-de-Seine, 92150, France|Centre Hospitalier Universitaire de Rennes - HÃ´pital Pontchaillou ( Site 1353), Rennes, Ille-et-Vilaine, 35000, France|Hopital Claude Huriez - CHU de Lille ( Site 1360), Lille, Nord, 59037, France|HENRI MONDOR HOSPITAL ( Site 1357), CrÃ©teil, Seine-et-Marne, 94000, France|Klinikum Rechts der Isar. Technischen Universitaet Muenchen ( Site 0266), Munich, Bayern, 81675, Germany|Klinikum Weiden ( Site 0259), Weiden In Der Oberpfalz, Bayern, 92637, Germany|Universitaetsklinikum Wuerzburg ( Site 0265), Wuerzburg, Bayern, 97080, Germany|Krankenhaus der Barmherzigen BrÃ¼der Trier-Abteilung fÃ¼r Urologie und Kinderurologie ( Site 0262), Trier, Rheinland-Pfalz, 54292, Germany|Universitaetsklinikum Jena ( Site 0252), Jena, Thuringen, 07747, Germany|Olympion General Clinic ( Site 0306), Patras, Achaia, 264 43, Greece|General University Hospital of Patras ( Site 0302), Patra, Achaia, 265 04, Greece|ATTIKON GENERAL UNIVERSITY HOSPITAL ( Site 0304), Chaidari, Attiki, 124 62, Greece|Antikarkiniko Nosokomeio Thessalonikis THEAGENIO ( Site 0303), Thessaloniki, Kentriki Makedonia, 54007, Greece|University Hospital of Larissa ( Site 0301), Larissa, Thessalia, 411 10, Greece|Onco Go, S.A ( Site 1454), Guatemala City, 01010, Guatemala|INTEGRA Cancer Institute ( Site 1451), Guatemala, 01010, Guatemala|Grupo Medico Angeles ( Site 1453), Guatemala, 01015, Guatemala|PÃ©csi TudomÃ¡nyegyetem Klinikai KÃ¶zpont-UrolÃ³giai Klinika ( Site 1304), PÃ©cs, Baranya, 7621, Hungary|Szegedi TudomÃ¡nyegyetem Szent-GyÃ¶rgyi Albert Klinikai KÃ¶zpont-UrolÃ³giai Klinika ( Site 1303), Szeged, Csongrad, 6725, Hungary|Semmelweis University-UrolÃ³giai Klinika ( Site 1301), Budapest, 1082, Hungary|Debreceni Egyetem Klinikai Kozpont ( Site 1302), Debrecen, 4032, Hungary|Ospedale Clinicizzato Santissima Annunziata ( Site 0361), Chieti, Abruzzo, 66100, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 0353), Milan, Milano, 20133, Italy|Ospedale Mauriziano-SCDU ONCOLOGIA MEDICA ( Site 0366), Torino, Piemonte, 10128, Italy|Azienda Ospedaliero Universitaria Careggi ( Site 0360), Firenze, Toscana, 50134, Italy|Osp Generale Reg di Bolzano ( Site 0355), Bolzano, Trentino-Sudtirol, 39100, Italy|Azienda USL 8 di Arezzo-Medical Oncology ( Site 0363), Arezzo, 52100, Italy|Istituto Tumori Giovanni Paolo II ( Site 0357), Bari, 70124, Italy|Ospedale San Martino ( Site 0351), Genova, 16132, Italy|IRCCS Ospedale San Raffaele ( Site 0362), Milano, 20132, Italy|Ospedale Buccheri La Ferla Fatebenefratelli ( Site 0352), Palermo, 90123, Italy|Policlinico Universitario A. Gemelli ( Site 0358), Roma, 00168, Italy|A.O.U. di Verona - Ospedale Civile Maggiore Borgo Trento ( Site 0356), Verona, 37126, Italy|Hirosaki University Hospital ( Site 0407), Hirosaki, Aomori, 036-8563, Japan|Ehime University Hospital ( Site 0414), Toon, Ehime, 791-0295, Japan|University of Tsukuba Hospital ( Site 0412), Tsukuba, Ibaraki, 305-8576, Japan|St. Marianna University Hospital ( Site 0415), Kawasaki, Kanagawa, 216-8511, Japan|Kitasato University Hospital ( Site 0403), Sagamihara, Kanagawa, 252-0375, Japan|Yokosuka Kyosai Hospital ( Site 0406), Yokosuka, Kanagawa, 238-8558, Japan|Nara Medical University Hospital ( Site 0411), Kashihara, Nara, 634-8522, Japan|Hamamatsu University Hospital ( Site 0416), Hamamatsu, Shizuoka, 431-3192, Japan|Chiba Cancer Center ( Site 0401), Chiba, 260-8717, Japan|Harasanshin Hospital ( Site 0410), Fukuoka, 812-0033, Japan|Osaka International Cancer Institute ( Site 0413), Osaka, 541-8567, Japan|Osaka Metropolitan University Hospital ( Site 0404), Osaka, 545-8586, Japan|Institute of Science Tokyo Hospital ( Site 0409), Tokyo, 113-8519, Japan|Keio University Hospital ( Site 0405), Tokyo, 160-8582, Japan|Asan Medical Center ( Site 0804), Songpagu, Seoul, 05505, Korea, Republic of|Korea University Anam Hospital ( Site 0801), Seoul, 02841, Korea, Republic of|Seoul National University Hospital ( Site 0802), Seoul, 03080, Korea, Republic of|Samsung Medical Center ( Site 0803), Seoul, 06351, Korea, Republic of|University Malaya Medical Centre ( Site 1180), Kuala Lumpur, 59100, Malaysia|Maastricht University Medical Centre ( Site 0453), Maastricht, Limburg, 6229 HX, Netherlands|Erasmus MC ( Site 0451), Rotterdam, Zuid-Holland, 3015 GD, Netherlands|Universitair Medisch Centrum Utrecht-Medical Oncology ( Site 0455), Utrecht, 3584 CX, Netherlands|Akershus University Hospital ( Site 0553), Lorenskog, Akershus, 1478, Norway|Stavanger universitetssykehus ( Site 0555), Stavanger, Rogaland, 4011, Norway|Hospital Nacional Guillermo Almenara Irigoyen ( Site 0601), La Victoria, Lima, 15033, Peru|Oncosalud ( Site 0603), Lima, Muni Metro De Lima, 15036, Peru|Hospital Militar Central [Lima, Peru] ( Site 0604), Lima, 15076, Peru|Uniwesytecki Szpital Kliniczny we Wroclawiu ( Site 0669), Wroclaw, Dolnoslaskie, 50-556, Poland|MICS Centrum Medyczne Torun ( Site 0679), Torun, Kujawsko-pomorskie, 87-100, Poland|Pratia MCM Krakow ( Site 0668), Krakow, Malopolskie, 30-510, Poland|Szpital WojewÃ³dzki im. ÅwiÄtego Lukasza SP ZOZ w Tarnowie ( Site 0681), Tarnow, Malopolskie, 33-100, Poland|Urologica Praktyka Lekarska Adam Marcheluk ( Site 0654), Siedlce, Mazowieckie, 08-110, Poland|Medical Concierge Centrum Medyczne ( Site 0676), Warsaw, Mazowieckie, 02-798, Poland|Luxmed Onkologia sp. z o. o. ( Site 0653), Warszawa, Mazowieckie, 01-748, Poland|Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 0678), Przemysl, Podkarpackie, 37-700, Poland|Szpital Specjalistyczny w Koscierzynie Sp. z o.o. ( Site 0671), Koscierzyna, Pomorskie, 83-400, Poland|Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka w Slupsku ( Site 0655), Slupsk, Pomorskie, 76-200, Poland|LIFTMED ( Site 0652), Rybnik, Slaskie, 44-200, Poland|Clinical Research Center Sp. z o.o. ( Site 0674), Poznan, Wielkopolskie, 61-731, Poland|Unidade Local de Saude de Santa Maria - Hospital de Santa Maria ( Site 0702), Lisbon, Lisboa, 1649-035, Portugal|Unidade Local de Saude de Braga - Hospital de Braga ( Site 0705), Braga, 4710-243, Portugal|Inst. Portugues de Oncologia de Coimbra Francisco Gentil EPE ( Site 0704), Coimbra, 3000-075, Portugal|Inst. Portugues de Oncologia de Lisboa Francisco Gentil EPE ( Site 0708), Lisboa, 1099-023, Portugal|Hospital CUF Descobertas ( Site 0706), Lisboa, 1998-018, Portugal|Inst. Portugues de Oncologia de Porto Francisco Gentil EPE ( Site 0701), Porto, 4200-072, Portugal|Advance Urology and Laparoscopic Center ( Site 0757), Ponce, 00716, Puerto Rico|Ad-Vance Medical Research ( Site 0756), Ponce, 00717, Puerto Rico|Hospital Universitario Lucus Augusti ( Site 0852), Lugo, La Coruna, 27003, Spain|Hospital Universitario Quiron Madrid ( Site 0862), Pozuelo de Alarcon, Madrid, Comunidad De, 28223, Spain|Clinica Universitaria de Navarra ( Site 0863), Pamplona, Navarra, 31008, Spain|Fundacio Puigvert ( Site 0864), Barcelona, 08025, Spain|Hospital Universitario Gregorio Maranon ( Site 0854), Madrid, 28007, Spain|Clinica Universitaria Navarra - Madrid ( Site 0860), Madrid, 28027, Spain|MD Anderson Cancer Center Madrid ( Site 0859), Madrid, 28033, Spain|Hospital Universitario Ramon y Cajal ( Site 0857), Madrid, 28034, Spain|Hospital Universitario La Paz ( Site 0866), Madrid, 28046, Spain|Hospital La Fe de Valencia ( Site 0855), Valencia, 46026, Spain|Universitaetsspital Basel ( Site 1201), Basel, Basel-Stadt, 4031, Switzerland|Hopitaux Universitaires de Geneve HUG ( Site 1204), Geneve, 1205, Switzerland|Universitaetsspital Zurich ( Site 1203), Zurich, 8091, Switzerland|Ankara Universitesi Tip Fakultesi Hastanesi ( Site 0966), Ankara, 06590, Turkey|Eskisehir Osmangazi Universitesi Hastanesi ( Site 0953), Eskisehir, 26480, Turkey|Memorial Sisli Hastanesi-Medical Oncology ( Site 0965), Istanbul, 34385, Turkey|TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 0963), Istanbul, 34722, Turkey|Dokuz Eylul Universitesi ( Site 0959), Izmir, 35340, Turkey|Necmettin Erbakan Universitesi Meram Tip Fakultesi Hastanesi ( Site 0961), Konya, 42000, Turkey|Raigmore Hospital ( Site 1006), Inverness, Highland, IV2 3UJ, United Kingdom|St Bartholomew s Hospital ( Site 1008), London, London, City Of, EC1A 7BE, United Kingdom|St Georges University Hospitals NHS Foundation Trust. ( Site 1005), London, London, City Of, SW17 0QT, United Kingdom",
NCT06079671,Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical),https://clinicaltrials.gov/study/NCT06079671,eVOLVECervical,RECRUITING,"This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progressed following platinum-based CCRT.",NO,Locally Advanced Cervical Cancer,BIOLOGICAL: Volrustomig|OTHER: Placebo,"Progression-free Survival (PFS) based on the investigator assessment in all randomized participants (FAS), PFS is defined as the time from date of randomization until RECIST 1.1- defined radiological progression or histopathologically confirmed progression as assessed by the Investigator or death due to any cause, whichever occurs earlier., The study duration will be approximately 40 months.","Overall Survival (OS) in all randomized participants., OS defined as time from randomization until the date of death due to any cause., Regarding the demonstration OS in participants, the study duration will be approximately 6 years.|Objective Response Rate (ORR) in all randomized participants., ORR is defined as the proportion of participants who have a CR or PR, as determined by Investigator per RECIST 1.1, The study duration will be approximately 40 months.|Duration of Response (DoR) in all randomized participants., DoR in participants with a CR or PR: Time from date of first detection of CR or PR until the date of RECIST 1.1-defined radiological progression or histopathologically confirmed progression., The study duration will be approximately 40 months.|Time to First Subsequent Therapy or death (TFST) in all randomized participants., TFST: The time from randomization until the start date of the first subsequent anti-cancer therapy after discontinuation of randomized treatment, or death due to any cause., The study duration will be approximately 40 months.|Time to second progression or death (PFS2) in all randomized participants., PFS2: The time from randomization to the earliest of the progression event (following the initial Investigator-assessed progression), after first subsequent therapy, or death. The date of second progression will be recorded by the Investigator in the eCRF and defined according to local standard clinical practice., The study duration will be approximately 40 months.|PFS by BICR in all randomized participants., Endpoints based on the PFS by BICR assessment according to RECIST 1.1., The study duration will be approximately 40 months.|The incidence of local progression, and distant disease progression as the first documented progression event in all randomized participants., Incidence of Local Progression, and Distant Disease Progression: Number and percentage of participants who develop local progression, distant disease recurrence., The study duration will be approximately 40 months.|PK of Volrustomig, Concentration of Volrustomig in serum and PK parameters as data allow., The study duration will be approximately 40 months.|The immunogenicity of volrustomig, Incidence of ADAs against volrustomig in serum., The study duration will be approximately 40 months.|Incidence of adverse events of Volrustomig compared to placebo., An AE is defined as the development of any untoward medical occurrence (other than progression of the malignancy under evaluation) in a patient or clinical study participant administered a medicinal product, and which does not necessarily have a causal relationship with this treatment., The study duration will be approximately 40 months.|Participant-reported disease-related symptoms, Change from baseline as measured by the European Organization for Research and Treatment of Cancer IL318 (EORTC IL318, Symptom Experience subscale of the EORTC Quality of Life Questionnaire Symptom Specific Scale for Cervical Cancer (EORTC QLQ-CX24)). The score of scale for EORTC IL318 is from 1-4., The study duration will be approximately 40 months.|Participant-reported physical functioning, Change from baseline of physical functioning as measured by the Patient Reported Outcomes Measurement Information System - Short Form - Physical Functioning 8c (PROMIS SF-PF 8c). The score of scale for PROMIS SF-PF 8c is from 1-5., The study duration will be approximately 40 months.|Participant-reported global health status/Quality of Life., Change from baseline of Global Health Status/ Quality of Life (GHS/QoL) as measured by the European Organization for Research and Treatment of Cancer IL172 (EORTC IL172). The score of scale for EORTC IL172 is from 1-7., The study duration will be approximately 40 months.",,AstraZeneca,Gynecologic Oncology Group Foundation|European Network for Gynaecological Oncological Trial Groups,FEMALE,"CHILD, ADULT, OLDER_ADULT",PHASE3,800,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-09-22,2026-11-17,2029-10-18,2023-10-12,,2025-05-20,"Research Site, Birmingham, Alabama, 35233, United States|Research Site, Phoenix, Arizona, 85016, United States|Research Site, Tucson, Arizona, 85711, United States|Research Site, Little Rock, Arkansas, 72205, United States|Research Site, La Jolla, California, 92093, United States|Research Site, West Hollywood, California, 90048, United States|Research Site, Atlanta, Georgia, 30322, United States|Research Site, Augusta, Georgia, 30912, United States|Research Site, Savannah, Georgia, 31405, United States|Research Site, Melrose Park, Illinois, 60160, United States|Research Site, Indianapolis, Indiana, 46202, United States|Research Site, New Orleans, Louisiana, 70112, United States|Research Site, New Orleans, Louisiana, 70121, United States|Research Site, Shreveport, Louisiana, 71103, United States|Research Site, New York, New York, 10016, United States|Research Site, Syracuse, New York, 13210, United States|Research Site, Cleveland, Ohio, 44195, United States|Research Site, Columbus, Ohio, 43210, United States|Research Site, Eugene, Oregon, 97401, United States|Research Site, Philadelphia, Pennsylvania, 19107, United States|Research Site, Providence, Rhode Island, 02905, United States|Research Site, Dallas, Texas, 75390, United States|Research Site, Fort Worth, Texas, 76104, United States|Research Site, Houston, Texas, 77030, United States|Research Site, Tyler, Texas, 75702, United States|Research Site, Charlottesville, Virginia, 22908, United States|Research Site, Fairfax, Virginia, 22031, United States|Research Site, Richmond, Virginia, 23298, United States|Research Site, Barretos, 14784-400, Brazil|Research Site, Belo Horizonte, 30130-100, Brazil|Research Site, Curitiba, 80730-150, Brazil|Research Site, Fortaleza, 60336-045, Brazil|Research Site, Fortaleza, 60430-230, Brazil|Research Site, Natal, 59075-740, Brazil|Research Site, Porto Alegre, 90619-900, Brazil|Research Site, Porto Alegre, 98850-170, Brazil|Research Site, Porto Velho, 76834-899, Brazil|Research Site, Recife, 52010-075, Brazil|Research Site, Rio de Janeiro, 20231-050, Brazil|Research Site, Salvador, 40050 410, Brazil|Research Site, Sao Paulo, 1323001, Brazil|Research Site, SÃ£o Paulo, 01246-000, Brazil|Research Site, Teresina, 64049-200, Brazil|Research Site, Hamilton, Ontario, L8V 1C3, Canada|Research Site, London, Ontario, N6A 5W9, Canada|Research Site, Toronto, Ontario, M4N 3M5, Canada|Research Site, Toronto, Ontario, M5G 2M9, Canada|Research Site, Montreal, Quebec, H2X 0C1, Canada|Research Site, Montreal, Quebec, H3G 1A4, Canada|Research Site, Ste-Foy, Quebec, G1V 4G2, Canada|Research Site, Beijing, 100142, China|Research Site, Beijing, 100730, China|Research Site, Changde, 415003, China|Research Site, Changsha, 410008, China|Research Site, Changsha, 410013, China|Research Site, Chengdu, 610041, China|Research Site, Chongqing, 400030, China|Research Site, Fuzhou, 350014, China|Research Site, Guangzhou, 510060, China|Research Site, Guangzhou, 510120, China|Research Site, Hangzhou, 310022, China|Research Site, Harbin, 150081, China|Research Site, Kunming, 650118, China|Research Site, Lanzhou, 730000, China|Research Site, Lanzhou, 730050, China|Research Site, Linyi, 276001, China|Research Site, Luzhou, 646000, China|Research Site, Nanchang, 330006, China|Research Site, Nanchang, 330029, China|Research Site, Shandong, China|Research Site, Shanghai, 200032, China|Research Site, Shanghai, 200080, China|Research Site, Shenyang, 110004, China|Research Site, Shenzhen, 518116, China|Research Site, TianJin, 300060, China|Research Site, Wuhan, 430022, China|Research Site, Wuhan, 430030, China|Research Site, Xi'an, 710061, China|Research Site, Yibin, 610500, China|Research Site, Yinchuan, 750004, China|Research Site, Zhengzhou, 450008, China|Research Site, Zhengzhou, 450052, China|Research Site, Aarhus N, 8200, Denmark|Research Site, KÃ¸benhavn Ã, 2100, Denmark|Research Site, Odense, 5000, Denmark|Research Site, Berlin, 13353, Germany|Research Site, Bonn, 53127, Germany|Research Site, Hamburg, 20246, Germany|Research Site, Leipzig, 04103, Germany|Research Site, Calicut, 673601, India|Research Site, Jaipur, 302017, India|Research Site, Lucknow, 226003, India|Research Site, Madurai, 625107, India|Research Site, Mohali, 160055, India|Research Site, Nagpur, 440001, India|Research Site, Nashik, 422009, India|Research Site, Nashik, 422011, India|Research Site, New Delhi, 11029, India|Research Site, Vadodara, 391760, India|Research Site, Bari, 70124, Italy|Research Site, Bologna, 40138, Italy|Research Site, Catania, 95126, Italy|Research Site, Firenze, 50141, Italy|Research Site, Lecco, 23900, Italy|Research Site, Milano, 20133, Italy|Research Site, Milan, 20141, Italy|Research Site, Milan, 20159, Italy|Research Site, Monza, 20900, Italy|Research Site, Napoli, 80131, Italy|Research Site, Roma, 161, Italy|Research Site, Rome, 00168, Italy|Research Site, Turin, 10128, Italy|Research Site, Fukuoka-shi, 812-8582, Japan|Research Site, Hidaka-shi, 350-1298, Japan|Research Site, Kagoshima-shi, 890-8520, Japan|Research Site, Koto-ku, 135-8550, Japan|Research Site, Kurume-shi, 830-0011, Japan|Research Site, Maebashi-shi, 371-8511, Japan|Research Site, Matsuyama-shi, 791-0280, Japan|Research Site, Morioka-shi, 028-3695, Japan|Research Site, Nagoya-shi, 464-8681, Japan|Research Site, Nakagami-gun, 903-0215, Japan|Research Site, Osaka-shi, 541-8567, Japan|Research Site, Sapporo-shi, 003-0804, Japan|Research Site, Sapporo-shi, 060-8638, Japan|Research Site, Shinjuku-ku, 160-8582, Japan|Research Site, Suita-shi, 565-0871, Japan|Research Site, Sunto-gun, 411-8777, Japan|Research Site, Toon-Shi, 791-0295, Japan|Research Site, Seoul, 03080, Korea, Republic of|Research Site, Seoul, 03722, Korea, Republic of|Research Site, Seoul, 06351, Korea, Republic of|Research Site, Seoul, 5505, Korea, Republic of|Research Site, Ciudad de MÃ©xico, 03240, Mexico|Research Site, Coyoacan, 04380, Mexico|Research Site, Culiacan, 80040, Mexico|Research Site, Guadalajara, 44650, Mexico|Research Site, Guadalajra, 44260, Mexico|Research Site, Mexico, 14080, Mexico|Research Site, Monterrey, 64460, Mexico|Research Site, MÃ©xico, 04700, Mexico|Research Site, Oslo, 424, Norway|Research Site, Trondheim, 7030, Norway|Research Site, ConcepciÃ³n, 12125, Peru|Research Site, Lima, 15036, Peru|Research Site, Lima, 15038, Peru|Research Site, Lima, 15102, Peru|Research Site, Lima, LIMA 29, Peru|Research Site, BiaÅystok, 15-027, Poland|Research Site, GdaÅsk, 80-214, Poland|Research Site, Gliwice, 44-101, Poland|Research Site, KrakÃ³w, 30-348, Poland|Research Site, Poznan, 61-866, Poland|Research Site, Warszawa, 02-781, Poland|Research Site, Wroclaw, 53-413, Poland|Research Site, ÅÃ³dÅº, 90-513, Poland|Research Site, San Juan, 00927, Puerto Rico|Research Site, Barcelona, 08036, Spain|Research Site, Barcelona, 8035, Spain|Research Site, Cordoba, 14004, Spain|Research Site, Girona, 17007, Spain|Research Site, Hospitalet deLlobregat, 08907, Spain|Research Site, La Coruna, 15006, Spain|Research Site, Madrid, 28034, Spain|Research Site, Madrid, 28040, Spain|Research Site, Madrid, 28041, Spain|Research Site, Madrid, 28046, Spain|Research Site, Palma de Mallorca, 07010, Spain|Research Site, Valencia, 46009, Spain|Research Site, Valencia, 46010, Spain|Research Site, Changhua, 50006, Taiwan|Research Site, Kaohsiung city, 833, Taiwan|Research Site, Kaohsiung, 81362, Taiwan|Research Site, New Taipei, 220, Taiwan|Research Site, Taichung, 40447, Taiwan|Research Site, Taichung, 40705, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, 10449, Taiwan|Research Site, Taipei, 11217, Taiwan|Research Site, Taoyuan, 333, Taiwan|Research Site, Bangkok, 10330, Thailand|Research Site, Bangkok, 10400, Thailand|Research Site, Bangkok, 10700, Thailand|Research Site, Muang, 50200, Thailand|Research Site, Udon Thani, 41330, Thailand|Research Site, Adana, 01250, Turkey|Research Site, Ankara, 06100, Turkey|Research Site, Ankara, 06490, Turkey|Research Site, Istanbul, 32098, Turkey|Research Site, Istanbul, 34214, Turkey|Research Site, Karsiyaka, 35575, Turkey",
NCT04736394,A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naÃ¯ve Intermediate-risk NMIBC Patients,https://clinicaltrials.gov/study/NCT04736394,ASCERTAIN,RECRUITING,"A multi-center, randomized, open-label, parallel-controlled Phase â¢ clinical trial to evaluate the clinical safety and efficacy of APL-1202 as a single-agent oral treatment versus intravesical instillation of Epirubicin hydrochloride in naÃ¯ve intermediate-risk non-muscle invasive bladder cancer (NMIBC) patients",NO,Non-muscle Invasive Bladder Cancer,DRUG: APL-1202|DRUG: Epirubicin Hydrochloride,"Event-free survival (EFS), Event-free survival (EFS) based on the assessment of pathological report from the Independent Pathology Review Committee (IPRC), Up to 48 months","Event-free survival (EFS) based on the assessment of pathological report from each site, Event-free survival (EFS) based on the assessment of pathological report from each site, Up to 48 months|Overall survival (OS), Overall survival (OS), Up to 48 months|Recurrence-free rate, Recurrence-free rate at 12,18, and 24 months after enrollment, Up to 48 months|Progression-free rate, Progression-free rate at 12,18, and 24 months after enrollment, Up to 48 months|Clinical benefit rates, Clinical benefit rates at 12,18, 24 months after enrollment (clinical benefits are defined as the pathological improvement of the recurrence, no high-risk recurrence, progression-free recurrence, no radical therapy and no death), Up to 48 months|Change from Baseline in the European Organization for Research and Treatment of Cancer (EORTC)-Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status/Quality of Life Total Score, The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to the questions ""How would you rate your overall health during the past week?"" and ""How would you rate your overall quality of life during the past week?"" are scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall outcome, Up to 48 months|Change from Baseline in EORTC-QLQ-Non-muscle Invasive Bladder Cancer Module 24 (NMIBC24) Total Score, The EORTC-QLQ-NMIBC24 is a 24-item questionnaire developed to supplement the EORTC QLQ-C30 in high-risk NMIBC patients. Each item is scored out of 4 total points (1=Not at All to 4=Very Much). All responses are transformed from 0 to 100, with a high score indicating more symptoms or problems. The change from baseline in EORTC-QLQ-NMIBC24 total score will be presented., Up to 48 months","Cystectomy-free survival (CFS), Cystectomy-free survival (CFS), Up to 48 months","Jiangsu Yahong Meditech Co., Ltd aka Asieris",,ALL,"ADULT, OLDER_ADULT",PHASE3,800,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-09-29,2025-03-01,2025-12-31,2021-02-03,,2022-02-22,"Fudan University Shanghai Cancer Center, Shanghai, Shanghai, 201203, China",
NCT06828354,A Study of SHR-A1811 in Subjects With Ovarian Cancer,https://clinicaltrials.gov/study/NCT06828354,,RECRUITING,This is an open-label study to evaluate the safety and efficacy of SHR-A1811 for injection in subjects with ovarian cancer.,NO,Ovarian Cancer,DRUG: SHR-A1811|DRUG: Paclitaxel Injection|DRUG: Doxorubicin Hydrochloride Liposome Injection|DRUG: Gemcitabine Hydrochloride for Injection|DRUG: Topotecan Hydrochloride for Injection,"Progression free survival (PFS), From day 1 to 10 months.","Objective response rate (ORR), From day 1 to 12 months.|Disease control rate (DCR), From day 1 to 12 months.|Duration of response (DOR), From day 1 to 12 months.|Overall survival (OS), From day 1 to 12 months.|Response rate (RR), From day 1 to 12 months.|Adverse events (AEs), From day 1 to 40 days after the last dose.",,"Jiangsu HengRui Medicine Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,300,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2025-03-13,2027-05,2027-12,2025-02-14,,2025-03-24,"Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China|Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China",
NCT06623422,A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009),https://clinicaltrials.gov/study/NCT06623422,,RECRUITING,The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene and pembrolizumab after surgery can help prevent the cancer from coming back in people with non-small cell lung cancer (NSCLC) whose tumors did not respond completely to treatment before surgery (neoadjuvant treatment).,NO,"Carcinoma, Non-Small-Cell Lung",BIOLOGICAL: Pembrolizumab|DRUG: Cisplatin|DRUG: Carboplatin|DRUG: Pemetrexed|DRUG: Gemcitabine|DRUG: Paclitaxel|BIOLOGICAL: Intismeran autogene|OTHER: Placebo,"Disease-Free Survival (DFS), DFS is defined as the time from randomization to any recurrence (local, locoregional, regional or distant), occurrence of new primary NSCLC, as assessed by the investigator, or death due to any cause, whichever occurs first., Up to ~97 months","Overall Survival (OS), OS is defined as the time from randomization to death due to any cause., Up to ~129 months|Distant Metastasis-Free Survival (DMFS), DMFS is defined as the time from randomization to the first diagnosis of a distant metastasis as assessed by the investigator, or death due to any cause, whichever occurs first. Distant metastasis refers to cancer that has spread from the original (primary) tumor and beyond local tissues and lymph nodes to distant organs or distant lymph nodes., Up to ~129 months|Disease-Free Survival 2 (DFS2), DFS2 is defined as the time from randomization to subsequent recurrence or disease progression after initiation of next-line anticancer therapy as assessed by the investigator, or death due to any cause, whichever occurs first., Up to ~129 months|Lung Cancer Specific Survival (LCSS), LCSS is defined as the time from randomization to death due to lung cancer specifically as assessed by the investigator., Up to ~129 months|Change from Baseline in the European Organization for Research and Treatment of Cancer (EORTC)-Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status/Quality of Life (Items 29 and 30), The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions ""How would you rate your overall health during the past week?"" and ""How would you rate your overall quality of life during the past week?"" will be scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores will be standardized, so that scores range from 0 to 100. Higher scores indicate a better overall health status. The change from baseline in global health status/quality of life (EORTC QLQ-C30 Items 29 and 30) combined score will be presented., Baseline and up to ~129 months|Change from Baseline in the EORTC QLQ-C30 Physical Functioning (Items 1-5), The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning will be scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores will be standardized, so that scores range from 0 to 100. Higher scores indicate a worse level of physical functioning. The change from baseline in physical functioning (EORTC QLQ-C30 Items 1-5) combined score will be presented., Baseline and up to ~129 months|Change from Baseline in the EORTC QLQ-C30 Role Functioning (Items 6 and 7), The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions ""Were you limited in doing either your work or other daily activities during the past week?"" and "" Were you limited in pursuing your hobbies or other leisure time activities during the past week?"" will be scored on a 4-point scale (1=Not at All to 4=Very Much). Higher scores indicate a worse level of role functioning. Change from baseline in the role functioning (EORTC QLQ-C30 Items 6 and 7) combined score will be presented., Baseline and up to ~129 months|Number of participants with â¥1 adverse event (AE), An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention., Up to ~129 months|Number of participants discontinuing from study therapy due to AE(s), An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention., Up to ~129 months",,Merck Sharp & Dohme LLC,"ModernaTX, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE3,680,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2024-10-21,2033-05-16,2038-01-26,2024-10-02,,2025-06-08,"Providence St. Jude Medical Center ( Site 0106), Fullerton, California, 92835, United States|UCHealth Memorial Hospital Central ( Site 0125), Colorado Springs, Colorado, 80909, United States|Beacon Cancer Care ( Site 0127), Post Falls, Idaho, 83854, United States|The University of Chicago Medical Center ( Site 0118), Chicago, Illinois, 60637, United States|Massachusetts General Hospital ( Site 0136), Boston, Massachusetts, 02114, United States|Dana Farber Cancer Hospital ( Site 0155), Boston, Massachusetts, 02215, United States|Ellis Fischel Cancer Center ( Site 0133), Columbia, Missouri, 65212, United States|Lake Regional Hospital-Cancer Center ( Site 0123), Osage Beach, Missouri, 65065, United States|Montefiore Medical Center ( Site 0160), Bronx, New York, 10461, United States|Hematology-Oncology Associates of CNY ( Site 0164), East Syracuse, New York, 13057, United States|Icahn School of Medicine at Mount Sinai ( Site 0116), New York, New York, 10029, United States|Memorial Sloan Kettering Cancer Center ( Site 0137), New York, New York, 10065, United States|Westchester Medical Center ( Site 0196), Valhalla, New York, 10595, United States|University of Cincinnati Medical Center ( Site 0119), Cincinnati, Ohio, 45219, United States|St. Lukes Hospital and Health Network ( Site 0186), Bethlehem, Pennsylvania, 18015, United States|Thompson Cancer Survival Center ( Site 0168), Knoxville, Tennessee, 37916, United States|MD Anderson Cancer Center ( Site 0150), Houston, Texas, 77030, United States|The University of Texas Health Science Center at Tyler dba UT Health East Texas HOPE Cancer Center ( Site 0148), Tyler, Texas, 75701, United States|Swedish Cancer Institute ( Site 0143), Seattle, Washington, 98104, United States|CEMIC ( Site 2454), Caba., Buenos Aires, C1431FWO, Argentina|Fundacion Intecnus ( Site 2456), San Carlos de Bariloche, Rio Negro, R8402APU, Argentina|Centro MÃ©dico IPAM ( Site 2452), Rosario, Santa Fe, S2001SBK, Argentina|Instituto Medico Especializado Alexander Fleming ( Site 2457), Buenos Aires, C1426ANZ, Argentina|Instituto Oncologico de Cordoba -IONC ( Site 2455), Cordoba, X5001HWE, Argentina|Calvary Mater Newcastle ( Site 2106), Waratah, New South Wales, 2298, Australia|Tasman Oncology Research ( Site 2104), Southport, Queensland, 4215, Australia|Princess Alexandra Hospital ( Site 2102), Wooloongabba, Queensland, 4102, Australia|Grampians Health ( Site 2101), Ballarat, Victoria, 3350, Australia|One Clinical Research ( Site 2103), Nedlands, Western Australia, 6009, Australia|Cliniques Universitaires Saint-Luc ( Site 1203), Bruxelles, Bruxelles-Capitale, Region De, 1200, Belgium|Jessa Ziekenhuis ( Site 1204), Hasselt, Limburg, 3500, Belgium|UZ Gent ( Site 1201), Gent, Oost-Vlaanderen, 9000, Belgium|CRIO - CENTRO REGIONAL INTEGRADO DE ONCOLOGIA ( Site 2502), Fortaleza, Ceara, 60336-550, Brazil|Liga Norte Riograndense Contra o Cancer ( Site 2513), Natal, Rio Grande Do Norte, 59062-000, Brazil|Hospital Tacchini ( Site 2506), Bento Goncalves, Rio Grande Do Sul, 95700-000, Brazil|Hospital de ClÃ­nicas de Passo Fundo ( Site 2504), Passo Fundo, Rio Grande Do Sul, 99010-260, Brazil|Hospital Moinhos de Vento ( Site 2510), Porto Alegre, Rio Grande Do Sul, 90035-001, Brazil|Instituto de Oncologia Saint Gallen ( Site 2507), Santa Cruz do Sul, Rio Grande Do Sul, 96830-180, Brazil|Hospital de Amor - Barretos ( Site 2511), Barretos, Sao Paulo, 14784-400, Brazil|Queen Elizabeth II Health Sciences Centre ( Site 1101), Halifax, Nova Scotia, B3H 2Y9, Canada|Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 1105), Kingston, Ontario, K7L 2V7, Canada|Lakeridge Health ( Site 1107), Oshawa, Ontario, L1G 2B9, Canada|McGill University Health Centre ( Site 1103), MontrÃ©al, Quebec, H4A 3J1, Canada|FALP ( Site 2551), Santiago., Region M. De Santiago, 7500921, Chile|Orlandi Oncologia ( Site 2555), Santiago, Region M. De Santiago, 7500713, Chile|ClÃ­nica RedSalud Vitacura ( Site 2556), Santiago, Region M. De Santiago, 7650018, Chile|Bradfordhill ( Site 2552), Santiago, Region M. De Santiago, 8420383, Chile|ONCOCENTRO APYS ( Site 2554), ViÃ±a del Mar, Valparaiso, 2520598, Chile|IMAT S.A.S ( Site 2602), Monteria, Cordoba, 230002, Colombia|FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 2603), Bogota, Distrito Capital De Bogota, 110131, Colombia|Hospital Universitario San Ignacio ( Site 2610), Bogota, Distrito Capital De Bogota, 110231, Colombia|Clinica Colsanitas S.A, Sede ClÃ­nica Universitaria Colombia ( Site 2604), Bogota, Distrito Capital De Bogota, 111321, Colombia|Oncologos del Occidente ( Site 2608), Pereira, Risaralda, 660001, Colombia|Fundacion Valle del Lili- CIC ( Site 2601), Cali, Valle Del Cauca, 760032, Colombia|Oulun yliopistollinen sairaala ( Site 1301), Oulu, Pohjois-Pohjanmaa, 90220, Finland|Turku University Hospital ( Site 1303), Turku, Varsinais-Suomi, 20520, Finland|Marienhaus Klinikum Mainz ( Site 1403), Mainz, Rheinland-Pfalz, 55131, Germany|THORACIC GENERAL HOSPITAL OF ATHENS ""I SOTIRIA""-3rd Dept of Internal Medicine and Laboratory, Oncol ( Site 1451), Athens, Attiki, 115 27, Greece|University General Hospital of Larissa-Oncology Clinic ( Site 1453), Larissa, Thessalia, 411 10, Greece|MÃ¡trai GyÃ³gyintÃ©zet ( Site 1504), MÃ¡trahÃ¡za, Heves, 3233, Hungary|Reformatus Pulmonologiai Centrum-Onkopulmonologiai Jarobeteg Centrum ( Site 1505), TÃ¶rÃ¶kbÃ¡lint, Pest, 2045, Hungary|Rambam Health Care Campus ( Site 1603), Haifa, 3109601, Israel|Shaare Zedek Medical Center ( Site 1601), Jerusalem, 9103102, Israel|Hadassah Medical Center ( Site 1605), Jerusalem, 9112001, Israel|Sheba Medical Center ( Site 1602), Ramat Gan, 5265601, Israel|Hospital of the University of Occupational and Environmental Health, Japan ( Site 1166), Kitakyushu, Fukuoka, 807-8556, Japan|National Cancer Center Hospital ( Site 1156), Chuo, Tokyo, 104-0045, Japan|Tokyo Medical University Hospital ( Site 1157), Shinjuku, Tokyo, 160-0023, Japan|National Hospital Organization Kyushu Cancer Center ( Site 1167), Fukuoka, 811-1395, Japan|Fukushima Medical University Hospital ( Site 1151), Fukushima, 960-1295, Japan|Hiroshima University Hospital ( Site 1165), Hiroshima, 734-8551, Japan|Wakayama Medical University Hospital ( Site 1163), Wakayama, 641-8510, Japan|National Cancer Center ( Site 2305), Goyang-si, Kyonggi-do, 10408, Korea, Republic of|The Catholic University of Korea St. Vincent s Hospital ( Site 2301), Suwonsi, Kyonggi-do, 16247, Korea, Republic of|Ajou University Hospital ( Site 2306), Suwon, Kyonggi-do, 16499, Korea, Republic of|Seoul National University Hospital ( Site 2303), Seoul, 03080, Korea, Republic of|Severance Hospital Yonsei University Health System ( Site 2302), Seoul, 03722, Korea, Republic of|Samsung Medical Center ( Site 2304), Seoul, 06351, Korea, Republic of|Seoul St. Mary's Hospital ( Site 2307), Seoul, 06591, Korea, Republic of|Radboudumc ( Site 1706), Nijmegen, Gelderland, 6525 GA, Netherlands|Dunedin Hospital ( Site 2202), Dunedin, Otago, 9016, New Zealand|Krakowski Szpital Specjalistyczny im. Jana Pawla II ( Site 1756), Krakow, Malopolskie, 31-202, Poland|Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 1759), Przemysl, Podkarpackie, 37-700, Poland|Uniwersyteckie Centrum Kliniczne ( Site 1758), Gdansk, Pomorskie, 80-214, Poland|Swietokrzyskie Centrum Onkologii. ( Site 1754), Kielce, Swietokrzyskie, 25-734, Poland|WarmiÅsko - Mazurskie Centrum ChorÃ³b PÅuc w Olsztynie ( Site 1760), Olsztyn, Warminsko-mazurskie, 10-357, Poland|Wielkopolskie Centrum Pulmonologii i Torakochirurgii ( Site 1763), Poznan, Wielkopolskie, 60-569, Poland|Institutul Regional de Oncologie ( Site 1804), Iasi, 700483, Romania|National Cancer Centre Singapore ( Site 2251), Singapore, Central Singapore, 168583, Singapore|Tan Tock Seng Hospital ( Site 2252), Singapore, Central Singapore, 308433, Singapore|Complejo Hospitalario Universitario A Coruna ( Site 1916), A CoruÃ±a, La Coruna, 15006, Spain|Hospital General Universitario Gregorio Maranon ( Site 1912), Madrid, 28009, Spain|Hospital Quiron Malaga ( Site 1914), Malaga, 29004, Spain|Karolinska Universitetssjukhuset Solna ( Site 1951), Stockholm, Stockholms Lan, 171 64, Sweden|Chung Shan Medical University Hospital ( Site 2351), Taichung, 40201, Taiwan|China Medical University Hospital ( Site 2358), Taichung, 40447, Taiwan|National Cheng Kung University Hospital ( Site 2354), Tainan, 704, Taiwan|National Taiwan University Cancer Center (NTUCC) ( Site 2360), Taipei, 10002, Taiwan|Mackay Memorial Hospital ( Site 2355), Taipei, 104217, Taiwan|Taipei Medical University Hospital ( Site 2352), Taipei, 11030, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center ( Site 2359), Taipei, 112, Taiwan|Taipei Veterans General Hospital ( Site 2357), Taipei, 112, Taiwan|Chang Gung Memorial Hospital ( Site 2361), Taoyuan, 333, Taiwan|Hacettepe Universite Hastaneleri ( Site 2001), SÄ±hhiye, Ankara, 06230, Turkey|NamÄ±k Kemal University Medical Faculty ( Site 2007), Tekirdag, Tekirdas, 59100, Turkey|Bristol Haematology and Oncology Centre ( Site 2072), Bristol, Bristol, City Of, BS2 8ED, United Kingdom|St Bartholomews Hospital ( Site 2052), London, London, City Of, EC1A 7BE, United Kingdom|Nottingham City Hospital ( Site 2058), Nottingham, Nottinghamshire, NG5 1PB, United Kingdom|St James University Hospital ( Site 2055), Leeds, LS9 7TF, United Kingdom",
NCT06281964,Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.,https://clinicaltrials.gov/study/NCT06281964,,ENROLLING_BY_INVITATION,Efficacy and safety evaluation of PLB1004 in patients with locally advanced/metastatic non-squamous NSCLCharboring EGFR exon 20 insertion.,NO,Non-Small-Cell Lung Cancer,DRUG: PLB1004|DRUG: Pemetrexed+ï¼carboplatin or Cisplatinï¼with or without Sintilimab,"Progression-Free Survival (PFS) by BICR, Progression-free survival (PFS) as assessed by a Blind Independent Center Review Committee (BICR) with reference to RECIST v1.1 for Solid tumors, 3 years","Progression-Free Survival (PFS) by the investigator, Refer to RECIST v1.1, PFS assessed by the investigator, 2 years|Intracranial Overall Response Rateï¼ORRï¼, To evaluate the intracranial Overall Response Rateï¼ORRï¼which is defined by investigator as the proportion of subjects with Intracranial disease confirmed best overall response of complete response or partial response per RECIST v 1.1., 3 years|Duration of Response (DOR), DOR is defined as the time from the date of first documented response (CR or PR) until the date of documented progression or death, whichever comes first., 3 years|Disease Control Rate (DCR), DCR is defined as the percentage of participants achieving complete or partial response or stable disease as defined per RECIST v 1.1, 3 years|Overall Survival (OS), OS is defined as the time from the date of the first dose until the date of death due to any cause., 3 years|Incidence of Treatment-Emergent Adverse Events (TEAEs), A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug assessed by CTCAE v5.0, 3 years|Plasma concentrations of PLB1004 and metabolites may be combined with data from other clinical studies, Plasma concentrations of PLB1004 and metabolites may be combined with data from other clinical studies, 3 years","intracranial Progression-Free Survivalï¼PFSï¼, Reference RECIST v1.1, intracranial PFS assessed by BICR and investigator, 3 years|Time to second progression-free survival(PFS2), Time to second progression-free survival (PFS2) as assessed by the investigator, 3 years|Assess the Quality of Healthy Living About Patients, Use the EQ-5D-5L scale to measure patients' quality of healthy living. It has 5 items (Mobility, Self-care, Usual activities, Pain/discomfort, Depression/anxiety). Each item contains 5 levels: 1= no difficulty, 2= slight difficulty, 3= moderate difficulty, 4= serious difficulty, 5= extremely serious difficulty. The higher the score has the worse the health. Then, the score calculation of the European Five-Dimensional Health Scale is based on the calculation formula published by the EuroQol Group. Based on 5 combinations of different severity levels, a score of 0 to 1 is obtained. 0 is the least healthy and 1 is the most healthy., 3 years|EGFR Ex20ins status in tumor tissues and its relevance to the clinical efficacy of drugs, EGFR Ex20ins status in tumor tissues and its relevance to the clinical efficacy of drugs, 3 years|Gene mutation status in plasma ctDNA before and after medication, and its correlation with clinical efficacy, To assess the expression of circulating tumor DNA in ascites and blood, ctDNA was mesured at screen, cycle 3 and end of the study, 3 years","Avistone Biotechnology Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,327,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-12-01,2026-01-30,2026-12-30,2024-02-28,,2025-06-13,"Guangdong Provincial People's Hospital, Guangzhou, Guangzhou, 510080, China",
NCT04102020,A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy,https://clinicaltrials.gov/study/NCT04102020,VIALE-M,ACTIVE_NOT_RECRUITING,This study will be conducted in two parts. Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in combination with azacitidine (AZA). Part 3 will be the Dose Finding portion to determine RPTD of venetoclax in combination with AZA. Part 2 and Part 3 Randomization of the study were removed.,NO,Acute Myeloid Leukemia (AML),DRUG: Venetoclax|DRUG: Azacitidine|DRUG: Azacitidine,"Number of Participants With Dose-Limiting Toxicities (DLTs) of Venetoclax in Combination with Azacitidine (AZA) (Part 1), DLTs are any of the hematologic, nonhematologic toxicities, adverse events (AEs) occurring following administration of venetoclax as described in the protocol and evaluated by the Investigator and the sponsor., Time from treatment of first participant to 20th participant reaching end of cycle 1, approximately 7 Months|Number of Participants With DLTs of Venetoclax in Combination with Oral AZA (Part 3 Dose Finding Portion), DLTs are hematologic, nonhematologic toxicities, adverse events (AEs) occurring following administration of venetoclax in combination with oral AZA as described in the protocol and evaluated by the Investigator and the sponsor., Time from treatment of first participant to the 14th patient in Safety Expansion reaching the end of Cycle 1, approximately 16 months.",,,AbbVie,Roche-Genentech,ALL,"ADULT, OLDER_ADULT",PHASE3,112,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-03-26,2022-09-29,2025-05,2019-09-25,,2025-05-25,"Mitchell Cancer Institute /ID# 216443, Mobile, Alabama, 36604, United States|Compassionate Cancer Care Research Group - Fountain Valley /ID# 216156, Fountain Valley, California, 92708-7501, United States|University of California, Los Angeles /ID# 219149, Los Angeles, California, 90095, United States|Colorado Blood Cancer Institute /ID# 214280, Denver, Colorado, 80218, United States|St. Alphonsus Regional Medical /ID# 216424, Boise, Idaho, 83706, United States|Duplicate_Rush University Medical Center /ID# 218815, Chicago, Illinois, 60612, United States|University of Kentucky Markey Cancer Center /ID# 215048, Lexington, Kentucky, 40536-7001, United States|Duplicate_Norton Cancer Institute /ID# 216401, Louisville, Kentucky, 40202-3700, United States|Tulane Medical Center - New Orleans /ID# 218166, New Orleans, Louisiana, 70112-2600, United States|Ochsner Clinic Foundation-New Orleans /ID# 214583, New Orleans, Louisiana, 70121, United States|Tufts Medical Center /ID# 216110, Boston, Massachusetts, 02111-1552, United States|Massachusetts General Hospital /ID# 217307, Boston, Massachusetts, 02114, United States|Duplicate_UMass Chan Medical School /ID# 218163, Worcester, Massachusetts, 01655, United States|Saint Louis University Cancer Center /ID# 218164, Saint Louis, Missouri, 63110-2539, United States|Oncology Hematology Associates (OHA) - Springfield /ID# 216351, Springfield, Missouri, 65807-5287, United States|The John Theurer Cancer /ID# 215191, Hackensack, New Jersey, 07601, United States|Rutgers Cancer Institute of New Jersey /ID# 239708, New Brunswick, New Jersey, 08901, United States|Weill Cornell Medical College /ID# 214847, New York, New York, 10065, United States|Providence Portland Medical Ct /ID# 216231, Portland, Oregon, 97213-2933, United States|Fox Chase Cancer Center /ID# 239372, Philadelphia, Pennsylvania, 19111, United States|UPMC Hillman Cancer Ctr /ID# 214051, Pittsburgh, Pennsylvania, 15232, United States|Duplicate_Prisma Health Cancer Institute-Faris Road /ID# 216066, Greenville, South Carolina, 29605-4255, United States|St Francis Cancer Center /ID# 216115, Greenville, South Carolina, 29607-5253, United States|Gibbs Cancer Center & Research /ID# 216192, Spartanburg, South Carolina, 29303-3040, United States|Tennessee Oncology-Nashville Centennial /ID# 218757, Nashville, Tennessee, 37203-1632, United States|Texas Oncology- Baylor Charles A. Sammons Cancer Center /ID# 214584, Dallas, Texas, 75246-2003, United States|University of Texas MD Anderson Cancer Center /ID# 225201, Houston, Texas, 77030, United States|St George Hospital /ID# 215416, Kogarah, New South Wales, 2217, Australia|Liverpool Hospital /ID# 215415, Liverpool, New South Wales, 2170, Australia|Shoalhaven District Memorial Hospital /ID# 221973, Nowra, New South Wales, 2541, Australia|Wollongong Hospital /ID# 216071, Wollongong, New South Wales, 2500, Australia|Gold coast University Hospital /ID# 214650, SouthPort, Queensland, 4215, Australia|Toowoomba Hospital /ID# 217922, Toowoomba, Queensland, 4350, Australia|Princess Alexandra Hospital /ID# 238753, Woolloongabba, Queensland, 4102, Australia|Royal Adelaide Hospital /ID# 238754, Adelaide, South Australia, 5000, Australia|Box Hill Hospital /ID# 217622, Box Hill, Victoria, 3128, Australia|Barwon Health /ID# 217921, Geelong, Victoria, 3220, Australia|Perth Blood Institute Ltd /ID# 217531, Nedlands, Western Australia, 6009, Australia|Tom Baker Cancer Centre /ID# 214625, Calgary, Alberta, T2N 4N2, Canada|Duplicate_University of Alberta Hospital - Division of Hematology /ID# 215656, Edmonton, Alberta, T6G 2B7, Canada|Juravinski Cancer Centre /ID# 214623, Hamilton, Ontario, L8V 1C3, Canada|London Health Sciences Center- University Hospital /ID# 216055, London, Ontario, N6A 5W9, Canada|Ottawa Hospital Research Institute /ID# 214627, Ottawa, Ontario, K1H 8L6, Canada|Princess Margaret Cancer Centre /ID# 214624, Toronto, Ontario, M5G 2M9, Canada|McGill University Health Center Research Institute /ID# 215984, Montreal, Quebec, H4A 3J1, Canada|Beijing Friendship Hospital /ID# 216455, Beijing, Beijing, 100032, China|Chinese PLA General Hospital /ID# 216286, Beijing, Beijing, 100853, China|Guangdong Provincial People's Hospital /ID# 216284, Guangzhou, Guangdong, 510080, China|Nanfang Hospital of Southern Medical University /ID# 215565, Guangzhou, Guangdong, 510515, China|Peking University International Hospital /ID# 217439, Beijing, Guizhou, 102206, China|Henan Cancer Hospital /ID# 215566, Zhengzhou, Henan, 450008, China|Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 218046, Wuhan, Hubei, 430022, China|Tongji Hospital Tongji Medical College of HUST /ID# 216456, Wuhan, Hubei, 430030, China|Duplicate_Shanghai Tongji Hospital /ID# 218800, Shanghai, Shanghai, 200065, China|Tangdu Hospital of The Fourth Military Medical University, PLA /ID# 216283, Xi'an, Shanxi, 710038, China|West China Hospital, Sichuan University /ID# 216606, Chengdu, Sichuan, 610041, China|Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc /ID# 215558, Tianjin, Tianjin, 300020, China|The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 215564, Hangzhou, Zhejiang, 310003, China|Fakultni Nemocnice Ostrava /ID# 214809, Ostrava, Praha 17, 708 52, Czechia|Fakultni nemocnice Brno /ID# 214807, Brno, 613 00, Czechia|Ustav hematologie a krevni transfuze /ID# 215137, Praha, 128 00, Czechia|CHU de Nice - HÃ´pital Archet 1 /ID# 217368, Nice, Alpes-Maritimes, 06200, France|Duplicate_CHU Bordeaux - Hopital Haut Leveque /ID# 215150, Pessac, Gironde, 33604, France|Hopital Avicenne - APHP /ID# 215152, Bobigny, Ile-de-France, 93000, France|CHRU Tours - Hopital Bretonneau /ID# 216186, Tours CEDEX 9, Indre-et-Loire, 37044, France|CHRU Lille - Hopital Claude Huriez /ID# 217474, Lille, Nord, 59037, France|CHU de Nantes - Hotel Dieu /ID# 217367, Nantes, Pays-de-la-Loire, 44000, France|Centre Hospitalier de la Cote Basque /ID# 216185, Bayonne, Pyrenees-Atlantiques, 64100, France|Centre Hospitalier du Mans /ID# 215148, Le Mans CEDEX 9, Sarthe, 72037, France|Institut Gustave Roussy /ID# 215158, Villejuif Cedex, Val-de-Marne, 94805, France|Chu Angers /Id# 215151, Angers, 49933, France|Duplicate_Hopital Henri Mondor /ID# 215159, Creteil, 94000, France|Centre Hospitalier de Versailles AndrÃ© Mignot /ID# 215157, Le Chesnay, 78150, France|Klinikum Chemnitz gGmbH /ID# 216073, Chemnitz, Saarland, 09116, Germany|Universitaetsklinikum Giessen und Marburg /ID# 214734, Marburg, Saarland, 35043, Germany|Universitaetsklinikum Leipzig /ID# 214440, Leipzig, Sachsen, 04103, Germany|Universitaetsklinikum Schleswig-Holstein Campus Luebeck /ID# 215173, LÃ¼beck, Schleswig-Holstein, 23538, Germany|Universitaetsklinikum Halle (Saale) /ID# 221109, Halle (Saale), 06120, Germany|General Hospital of Athens Laiko /ID# 213869, Athens, Attiki, 11527, Greece|University General Hospital Attikon /ID# 214298, Athens, Attiki, 12462, Greece|University General Hospital of Heraklion PA.G.N.I /ID# 214075, Heraklion, Kriti, 71500, Greece|General University Hospital of Alexandroupolis /ID# 213870, Alexandroupolis, 68100, Greece|General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 213872, Athens, 10676, Greece|University General Hospital of Patras /ID# 213871, RION Patras Achaia, 26504, Greece|Debreceni Egyetem-Klinikai Kozpont /ID# 214422, Debrecen, Hajdu-Bihar, 4032, Hungary|Somogy Varmegyei Kaposi Mor Oktato Korhaz /ID# 214426, KaposvÃ¡r, Somogy, 7400, Hungary|Szabolcs-Szatmar-Bereg Varmegyei Oktatokorhaz /ID# 214425, Nyiregyhaza, Szabolcs-Szatmar-Bereg, 4400, Hungary|Vas Varmegyei Markusovszky Egyetemi Oktatokorhaz /ID# 215644, Szombathely, Vas, 9700, Hungary|Semmelweis Egyetem /ID# 214423, Budapest, 1085, Hungary|Tel Aviv Sourasky Medical Center /ID# 239698, Tel Aviv, Tel-Aviv, 6423906, Israel|Shaare Zedek Medical Center /ID# 239699, Jerusalem, Yerushalayim, 91031, Israel|Hadassah Medical Center-Hebrew University /ID# 239700, Jerusalem, Yerushalayim, 91120, Israel|Rabin Medical Center /ID# 239696, Haifa, 4941492, Israel|Azienda Ospedaliera Universitaria Federico II /ID# 214278, Napoli, L Aquila, 80131, Italy|ASST Grande Ospedale Metropolitano Niguarda /ID# 213946, Milan, Milano, 20162, Italy|AOU Citta della Salute e della Scienza di Torino /ID# 214505, Torino, Piemonte, 10126, Italy|Duplicate_Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona /ID# 213944, Ancona, 60126, Italy|IRCCS Azienda Ospedaliero-Universitaria di Bologna /ID# 213948, Bologna, 40138, Italy|ASST Spedali civili di Brescia /ID# 214580, Brescia, 25123, Italy|Duplicate_A.O.U. Policlinico G. Rodolico S.Marco- Presidio G.Rodolico /ID# 214802, Catania, 95123, Italy|Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 214826, Milan, 20122, Italy|Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli /ID# 213947, Napoli, 80131, Italy|Ospedale S.Eugenio /ID# 214277, Rome, 00144, Italy|Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital /ID# 215680, Nagoya-shi, Aichi, 453-8511, Japan|Aichi Cancer Center Hospital /ID# 215284, Nagoya-shi, Aichi, 464-8681, Japan|University of Fukui Hospital /ID# 215283, Yoshida-gun, Fukui, 910-1104, Japan|National Hospital Organization Kyushu Cancer Center /ID# 214841, Fukuoka-shi, Fukuoka, 811-1395, Japan|Kyushu University Hospital /ID# 215286, Fukuoka-shi, Fukuoka, 812-8582, Japan|Hokkaido University Hospital /ID# 215938, Sapporo-shi, Hokkaido, 060-8648, Japan|National Hospital Organization Mito Medical Center /ID# 214699, Higashi Ibaraki-gun, Ibaraki, 311-3193, Japan|Tohoku University Hospital /ID# 214669, Sendai-shi, Miyagi, 9808574, Japan|Nagasaki University Hospital /ID# 214916, Nagasaki-shi, Nagasaki, 852-8501, Japan|Duplicate_Okayama University Hospital /ID# 214840, Okayama-shi, Okayama, 700-8558, Japan|Osaka Metropolitan University Hospital /ID# 215225, Osaka-shi, Osaka, 545-8586, Japan|Kindai University Hospital /ID# 214915, Osakasayama-shi, Osaka, 589-8511, Japan|Saitama Medical University International Medical Center /ID# 214823, Hidaka-shi, Saitama, 350-1298, Japan|NTT Medical Center Tokyo /ID# 214959, Shinagawa-ku, Tokyo, 141-8625, Japan|Yamagata University Hospital /ID# 214698, Yamagata-shi, Yamagata, 990-9585, Japan|Pusan National University Hospital /ID# 213941, Busan, Busan Gwang Yeogsi, 49241, Korea, Republic of|Seoul National University Bundang Hospital /ID# 215549, Seongnam-si, Gyeonggido, 13620, Korea, Republic of|Seoul National University Hospital /ID# 213943, Seoul, Seoul Teugbyeolsi, 03080, Korea, Republic of|Samsung Medical Center /ID# 213940, Seoul, Seoul Teugbyeolsi, 06351, Korea, Republic of|Pan American Center for Oncology Trials, LLC /ID# 214953, Rio Piedras, 00935, Puerto Rico|Clinic of Immunopathology, SRIFCI /ID# 217937, Novosibirsk, Kurskaya Oblast, 630047, Russian Federation|Regional Clinical Hospital of Yaroslavl /ID# 214318, Yaroslavl, Kurskaya Oblast, 150062, Russian Federation|Nizhny Novgorod Regional Clinical Hospital named N.A. Semashko /ID# 214309, Nizhniy Novgorod, Nizhegorodskaya Oblast, 603126, Russian Federation|Academician I.P. Pavlov First St. Petersburg State Medical University /ID# 215393, St. Petersburg, Sankt-Peterburg, 197101, Russian Federation|P. Hertsen Moscow Oncology Research Institute /ID# 214312, Moscow, 125284, Russian Federation|MMCC Kommunarka /ID# 215223, Moscow, 129301, Russian Federation|Almazov National Medical Research Centre /ID# 214306, Sankt-Peterburg, 197341, Russian Federation|Duplicate_Instituto Catalan de Oncologia (ICO) L'Hospitalet /ID# 214715, Hospitalet de Llobregat, Barcelona, 08908, Spain|Hospital Universitario de Navarra /ID# 214788, Pamplona, Navarra, 31008, Spain|Hospital Santa Creu i Sant Pau /ID# 214714, Barcelona, 08041, Spain|Duplicate_Hospital Universitario Reina Sofia /ID# 214786, Cordoba, 14004, Spain|Hospital Universitario Infanta Leonor /ID# 214843, Madrid, 28031, Spain|MD Anderson Madrid /ID# 214477, Madrid, 28033, Spain|Hospital Universitario Ramon y Cajal /ID# 214684, Madrid, 28034, Spain|Hospital Universitario Fundacion Jimenez Diaz /ID# 214933, Madrid, 28040, Spain|Hospital Universitario 12 de Octubre /ID# 214789, Madrid, 28041, Spain|Hospital Universitario Virgen de la Victoria /ID# 214713, Malaga, 29010, Spain|Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 213953, Kaohsiung, Keelung, 807, Taiwan|National Taiwan University Hospital /ID# 213939, Taipei City, Taipei, 100, Taiwan|China Medical University Hospital /ID# 213952, Taichung, 40447, Taiwan|Linkou Chang Gung Memorial Hospital /ID# 213951, Taoyuan City, 333, Taiwan|Gulhane Askeri Tip Academy /ID# 214242, Ankara, Adana, 06010, Turkey|Karadeniz University /ID# 214241, Trabzon, Adana, 61000, Turkey|Ankara Univ Medical Faculty /ID# 214239, Ankara, 06590, Turkey|Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty /ID# 215525, Istanbul, 34098, Turkey|Erciyes University Medical Faculty /ID# 214240, Kayseri, 38039, Turkey|University Hospitals Bristol /ID# 215911, Bristol, Bristol, City Of, BS1 3NU, United Kingdom|Leicester Royal Infirmary /ID# 215924, Leicester, England, LE1 5WW, United Kingdom|Barts Health NHS Trust /ID# 215909, London, London, City Of, E1 2ES, United Kingdom|Guys and St Thomas NHS Foundation Trust /ID# 215908, London, London, City Of, SE1 9RT, United Kingdom|Cardiff & Vale University Health Board /ID# 215906, Cardiff, Wales, CF14 4XN, United Kingdom|University Hospitals Birmingham NHS Foundation Trust /ID# 215910, Birmingham, B15 2TH, United Kingdom|University College London Hospitals NHS Foundation Trust /ID# 215921, London, NW1 2PG, United Kingdom",
NCT05353257,A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT05353257,,ACTIVE_NOT_RECRUITING,"This study is a randomized, double-blind, multicenter, phase III clinical study to compare the clinical efficacy and safety of Serplulimab + chemotherapy+ concurrent radiotherapy vs chemotherapy+ concurrent radiotherapy in subjects with Limited-Stage Small Cell Lung Cancer.",NO,Limited-Stage Small Cell Lung Cancer,DRUG: HLX10|DRUG: carboplatin/cisplatin-etoposide|RADIATION: Thoracic radiotherapy|DRUG: Placebo|RADIATION: Prophylactic Cranial Irradiation (PCI),"Overall survival(OS, the time from randomization to death due to any cause, up to 36 months","Progression-free survival, PFS, assessed by the investigator as per RECIST v1.1, up to approximately 24months",,Shanghai Henlius Biotech,,ALL,"ADULT, OLDER_ADULT",PHASE3,511,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-05-17,2025-07-30,2026-12-30,2022-04-29,,2025-01-28,"OPN-Glendale, Arcadia, California, 91007, United States|OPN-Los Alamitos, Los Alamitos, California, 90720, United States|Southern California Permanente Group, Los Angeles, California, 90034, United States|Emad Ibrahim, MD, Inc, Redlands, California, 92373, United States|Providence Medical Foundation, Santa Rosa, California, 95403, United States|Lutheran Medical Center - Cancer Centers of Colorado, Golden, Colorado, 80401, United States|Eastern Connecticut Hematology & Oncology Associates, Norwich, Connecticut, 06360, United States|Cancer Specialists of North Florida, Jacksonville, Florida, 32257, United States|Mid Florida Hematology and Oncology Center, Orange City, Florida, 32763, United States|Advent Health Orlando, Orlando, Florida, 32804, United States|Napa Research, Pompano Beach, Florida, 33064, United States|Kansas University Mediacal Center, Fairway, Kansas, 66205, United States|Pontchartrain Cancer Center, Covington, Louisiana, 70433, United States|Tulane University, New Orleans, Louisiana, 70112, United States|Health Partners, Bloomington, Minnesota, 55425, United States|Renown Health, Reno, Nevada, 89502, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, 03756, United States|Montefiore Medical Center, Bronx, New York, 10467, United States|New York City Health+HospitalsCorporation Elmhurst Hospital Center, Elmhurst, New York, 11373, United States|Northwell Health, Queens, New York, 11040, United States|Cleveland Clinic Mercy Hospital, Canton, Ohio, 44708, United States|Gabrail Cancer Center, Canton, Ohio, 44718, United States|Tricounty Hematology and Oncology Associates, Massillon, Ohio, 44646, United States|Kaiser Permanente Northwest, Portland, Oregon, 97229, United States|The Center for Cancer and Blood Disorders, Fort Worth, Texas, 76104, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|Millennium Research & Clinical Development, Houston, Texas, 77090, United States|Pro Research Tools, INC DBA Lumi Research, Kingwood, Texas, 77339, United States|The University of Texas - Hope Cancer Center, Tyler, Texas, 75701, United States|Innova Schar Cancer Insitute, Fairfax, Virginia, 22031, United States|Northwest Medical Specialties, Tacoma, Washington, 98405, United States|Klinikum Klagenfurt am Worthersee, Klagenfurt am Worthersee, 9020, Austria|Klinikum Klagenfurt am WÃ¶rthersee, Klagenfurt am WÃ¶rthersee, 9020, Austria|Karl Landsteiner Institut fÃ¼r Lungenforschung und pneumologische Onkologie, c/o Klinik Floridsdorf Abteilung fÃ¼r Innere Medizin und Pneumologie, Wien, 1210, Austria|Karl Landsteiner Institute for Lung Research and Pneumological Oncology, c/o Klinik Floridsdorf Department for Inner Medicine und Pneumology, Wien, 1210, Austria|The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, 233099, China|Anhui Chest Hospital, Hefei, Anhui, 230031, China|Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, 100021, China|Beijing Cancer Hospital, Beijing, Beijing, 100142, China|The First Affiliated Hospital of Chongqing Medical, Chongqing, Chongqing, 400016, China|Chongqing University Cancer Hospital, Chongqing, Chongqing, 400030, China|Fujian Cancer Hospital, Fuzhou, Fujian, 350011, China|The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, 510000, China|Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510030, China|Peking University Shenzhen Hospital, Shenzhen, Guangdong, 518036, China|The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, 541100, China|Guangxi Medical University Cancer Hospital, Nanning, Guangxi, 530021, China|Gungzhouyikedaxuefushuzhongliuyiyuan, Guangzhou, Guangzhou, 510095, China|Affiliated Hospital of Hebei University, Baoding, Hebei, 071000, China|Cangzhou People's Hospital, Cangzhou, Hebei, 061019, China|Tangshan People's Hospital, Tangshan, Hebei, 063001, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150000, China|Jiamusi Cancer Hospital, Jiamusi, Heilongjiang, 154007, China|The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, 471000, China|The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, 453100, China|Henan Cancer Hospital, Zhengzhou, Henan, 450008, China|The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China|Hong Kong United Oncology Centre, Hong kong, Hong Kong, 999077, China|Queen Elizabeth Hospital, Hong Kong, Hong Kong, 999077, China|Queen Mary Hospital, Hong Kong, Hong Kong, 999077, China|TaiHe Hospital Affiliated Hospital of Hubei University of Medicine, Shiyan, Hubei, 442000, China|Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, Wuhan, Hubei, 430030, China|Zhongnan hospital of wuhan university, Wuhan, Hubei, 430071, China|Hubei Cancer Hospital, Wuhan, Hubei, 430079, China|The First People's Hospital Of Changde City, Changde, Hunan, 415000, China|The Second Xiangya Hospita, Changsha, Hunan, 410008, China|Hunan Cancer Hospital, Changsha, Hunan, 410013, China|Xiangya Hospital Central South University, Changsha, Hunan, 410013, China|Xuzhou Central Hospital, Xuzhou, Jiangsu, 221000, China|Northern Jiangsu people's Hospital, Yangzhou, Jiangsu, 210008, China|First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, 341001, China|Ganzhou Cancer Hospital, Ganzhou, Jiangxi, 341005, China|The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, China|Jilin Cancer Hospital, Changchun, Jilin, 130000, China|Liaoning Cancer Hospital & Institute, Shenyang, Liao Ning, 110042, China|Shenyang The Tenth People's Hospital, Shenyang, Liao Ning, 110044, China|Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China|Shandong Cancer Hospital, Jinan, Shandong, 250117, China|Linyi Tumor Hospital, Linyi, Shandong, 276002, China|Affiliated Hospital of Qingdao University, Qingdao, Shandong, 266031, China|Shanghai Chest Hospital, Shanghai, Shanghai, 200030, China|Fudan University Shanghai Cancer Center, Shanghai, Shanghai, 200032, China|Zhongshan Hospital of Fudan University, Shanghai, Shanghai, 200032, China|Wenzhou University Hospital, Wenzhou, Shanghai, 200032, China|Baoji Central Hospital, Baoji, Shanxi, 721008, China|Shanxi Provincial Cancer Hospital, TaiYuan, Shanxi, 030013, China|First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, 710061, China|West China Hospital of Sichuan University, Chengdu, Sichuan, 610041, China|Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, 300052, China|Tianjin Medical University General Hospital, Tianjin, Tianjin, 300052, China|The Second People's Hospital Of Yibin, Sichuan, Yibin, 644000, China|Yunnan Cancer Hospital, Kunming, Yunnan, 650118, China|Sir Run Run Shaw Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310000, China|Yuhang Branch of the First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, 310003, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, 310005, China|The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310009, China|Taizhou Hospital of Zhejiang Province, Taizhou, Zhejiang, 317000, China|The 1st Affiliated Hospital of WMU, Wenzhou, Zhejiang, 325000, China|University Hospital Brno (Clinic For Lung Diseases and Tuberculosis), Brno, 625 00, Czechia|University Hospital Brno, Brno, 625 00, Czechia|University Hospital Olomouc (Oncology Clinic), Olomouc, 775 20, Czechia|University Hospital Ostrava (oncology department), Ostrava-Poruba, 570852, Czechia|University Hospital Ostrava, Ostrava-Poruba, Czechia|Nemocnice AGEL Ostrava-VÃ­tkovice, Ostrava-Vitkovice, 703 00, Czechia|Nemocnice AGEL Ostrava-VÃ­tkovice, Ostrava-VÃ­tkovice, 703 00, Czechia|University Hospital Motol, Prague, 150 06, Czechia|University Hospital Motol (Pneumology Clinic 2.LF UK and FN Motol), Prague, Czechia|General University hospital in Prague (Oncology department), Praha 2, 128 08, Czechia|Kliniken der Stadt Cologne GmbH, Cologne, 51109, Germany|University hospital Schleswig-Holstein, LÃ¼beck-TravemÃ¼nde, 23538, Germany|""Sotiria"" Thoracic Diseases General Hospital of Athens, Athens, 115 27, Greece|General Hospital of Athens ""Alexandra"", Athens, 11528, Greece|Fejer County Szent Gyorgy University Teaching Hospital, Szekesfehervar, 8000, Hungary|Pulmonary Institute of Torokbalint, Torokbalint, 2045, Hungary|Riga East University Hospital, Latvian Oncology Center, Riga, LV 1079, Latvia|Clinic of Oncology, Pauls Stradins Clinical university hospital, Riga, LV-1002, Latvia|Hospital St. Jansdal, Harderwijk, 3844, Netherlands|Isala Hospital, Zwolle, 8025, Netherlands|MedPoloniaSp. z o.o., Poznan, 60-693, Poland|Lung and Chest Cancer Clinic, National Institute of Oncology, Warszawa, 02-781, Poland|Hospital Universitario de Badajoz, Badajoz, 6006, Spain|Hospital German Trias i Pujol/ ICO Badalona, Badalona, 8916, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, 8025, Spain|Hospital Universitario Reina SofÃ­a, Cordoba, 14004, Spain|Hospital Gregorio MaraÃ±on, Madrid, 28007, Spain|Hospital Universitario Puerta de Hierro, Madrid, 2822, Spain|Hospital Quironsalud Sagrado CorazÃ³n, Sevilla, 41013, Spain|Hospital Marques de Valdecilla, Valdecilla, 39008, Spain|University Hospital La Fe, Valencia, 46026, Spain",
NCT06119581,A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT06119581,SUNRAY-01,RECRUITING,"The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing.",NO,"Carcinoma, Non-Small-Cell Lung|Neoplasm Metastasis",DRUG: LY3537982|DRUG: Pembrolizumab|DRUG: Placebo|DRUG: Cisplatin|DRUG: Carboplatin|DRUG: Pemetrexed,"Dose Optimization and Safety Lead-In Part B: Number of Participants with a Treatment Emergent Adverse Event(s) (TEAE), Dose Optimization and Safety Lead-In Part B: Number of Participants with a TEAE, Randomization to first documented progression of disease or death from any cause. (Estimated as approximately 1 year)|Part A and Part B: Progression-Free Survival (PFS), PFS per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by blinded independent central review (BICR), Randomization to first documented progression of disease or death from any cause. (Estimated as approximately 1 year)","Part A and Part B: Overall Survival (OS), Part A and Part B: OS, Randomization to date of death from any cause. (Estimated as up to 3 years)|Part A and Part B: Overall Response Rate (ORR): Percentage of Participants who Achieve a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR), ORR per RECIST v1.1 by BICR, Randomization to disease progression or death. (Estimated as approximately 1 year)|Part A and Part B: Duration of Response (DOR), DOR per RECIST v1.1 by BICR, Date of first evidence of CR or PR to date of disease progression or death from any cause. (Estimated as approximately 1 year)|Part A and Part B: Disease Control Rate (DCR): Percentage of Participants who Achieve a BOR of CR, PR, or Stable Disease (SD), DCR per RECIST v1.1 by BICR, Randomization to disease progression or death from any cause. (Estimated as approximately 1 year)|Part A and Part B: Time to Response (TTR), TTR per RECIST v1.1 by BICR, Time from randomization until the date that measurement criteria for CR or PR (whichever is first recorded) are first met (Estimated as approximately 1 year)|Part A and Part B: Intracranial Overall Response Rate (ORR), Intracranial ORR per RECIST v1.1 by BICR, Randomization to intracranial disease progression or death. (Estimated as approximately 1 year)|Part A and Part B: Intracranial Duration of Response (DoR), Intracranial DoR per RECIST v1.1 by BICR, Date of first evidence of CR or PR to date of intracranial disease progression or death from any cause. (Estimated as approximately 1 year)|Part A and Part B: PFS2, Part A and Part B: PFS2 by Investigator, Randomization to disease progression on next line of treatment or death from any cause (Estimated as approximately 1 year|Part A and Part B: Changes in NSCLC-related symptoms as measured by NSCLC-SAQ, NSCLC-related symptoms are assessed by the NSCLC-SAQ total score, which is computed as the sum of the 5 domains (7 questions) and ranges from 0 to 20. The total score will be calculated if all 7 questions are completed. Higher scores indicate more severe symptomatology., Randomization through end of treatment (Estimated as approximately 1 year)]|Part A and Part B: Time to Worsening of NSCLC-related Symptoms as Measured by NSCLC Symptom Assessment Questionnaire (NSCLC-SAQ), NSCLC symptoms will be assessed using the 7-item NSCLC-SAQ. The NSCLC-SAQ measures overall symptom severity of NSCLC, including cough, pain, dyspnea, fatigue, and poor appetite. Response options range from 0) ""Not at all"" to 4) ""Always"" or from 0) ""Never"" to 4) ""Always."" The total score ranges from 0-20. Higher scores represent worse symptoms., Randomization through end of treatment (Estimated as approximately 1 year)|Part A and Part B: Changes in physical function, as measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core Questionnaire (EORTC QLQ-C30) Physical Functioning subscale and IL19, Physical function is assessed by EORTC-QLQ-C30 Physical Functioning scale or IL19. The physical function score is calculated by generating the raw score: (Q1+Q2+Q3+Q4+Q5)/5; and then generating the transformed score: (1-((raw score-1)/3)) x 100. The score ranges from 0 to 100. Higher scores indicate better physical function., Randomization through end of treatment (Estimated as approximately 1 year)|Part A and Part B: Time to Deterioration in Physical Function, as Measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core Questionnaire (EORTC QLQ-C30) Physical Functioning Subscale and IL19, The EORTC QLQ-C30 is a 30-question patient-reported instrument used to assess multidimensional health-related quality of life (HRQoL) in cancer patients. Physical functioning is measured by the EORTC-QLQ-30 Physical Function Scale (five items). Response options range from 1) ""Not at all"" to 4) ""Very much."" The sum score is linearly transformed to the range 0 - 100. Higher scores represent better physical function., Randomization through end of treatment (Estimated as approximately 1 year)|Part A and Part B: Proportion of Time with High Side-Effect Burden, as Measured by Functional Assessment of Cancer Therapy - General Item 5 (FACT-GP5), FACT-GP5 is a single-item, patient-reported instrument for assessing overall treatment side-effect burden. Response options range from 0) ""Not at all"" to 4) ""Very much."" Higher scores represent higher symptom burden., Randomization through end of treatment (Estimated as approximately 1 year)|Part A and Part B: Change from Baseline in Overall Health-related Quality of Life, as Measured by the EORTC QLQ-C30 Global Health Status/Quality of Life Subscale, The EORTC QLQ-C30 is a 30-question patient-reported instrument used to assess multidimensional HRQoL in cancer patients. Overall HRQoL is measured by the EORTC QLQ-30 Global Health Status/Quality of Life Subscale (two items). Response options range from 1) ""very poor"" to 7) ""excellent."" Scores are linearly transformed to the range 0 - 100. Higher scores represent better overall HRQoL., Randomization through end of treatment (Estimated as approximately 1 year)",,Eli Lilly and Company,,ALL,"ADULT, OLDER_ADULT",PHASE3,1016,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-12-21,2026-10,2029-10,2023-11-07,,2025-05-21,"Clearview Cancer Institute, Huntsville, Alabama, 35805, United States|Banner MD Anderson Cancer Center, Gilbert, Arizona, 85234, United States|Banner University Medical Center Phoenix, Phoenix, Arizona, 85006, United States|The University of Arizona Cancer Center - North Campus, Tucson, Arizona, 85719, United States|Highlands Oncology Group, Springdale, Arkansas, 72762, United States|Cedars-Sinai Medical Center, Los Angeles, California, 90048, United States|Mercy Cancer Center, Merced, California, 95340, United States|Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, 90502, United States|BASS Cancer Center, Walnut Creek, California, 94598, United States|USO - Rocky Mountain Cancer Centers, Lone Tree, Colorado, 80124, United States|Yale University School of Medicine, New Haven, Connecticut, 06510, United States|Sibley Memorial Hospital, Washington, District of Columbia, 20016, United States|Millennium Oncology Research Clinic, Hollywood, Florida, 33024, United States|University of Florida - Jacksonville, Jacksonville, Florida, 32209, United States|Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, 33176, United States|Ocala Oncology Center PL DBA Florida Cancer Affiliates - Ocala, Ocala, Florida, 34474, United States|Comprehensive Hematology Oncology, Saint Petersburg, Florida, 33709, United States|Tampa General Hospital, Tampa, Florida, 33606, United States|University Cancer & Blood Center, LLC, Athens, Georgia, 30607, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, 30322, United States|University of Illinois at Chicago, Chicago, Illinois, 60612, United States|University of Chicago Hospital, Chicago, Illinois, 60637, United States|Springfield Clinic Main Campus, Springfield, Illinois, 62702, United States|Parkview Research Center at Parkview Regional Medical Center, Fort Wayne, Indiana, 46845, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, 46202, United States|Franciscan Health, Indianapolis, Indiana, 46237, United States|Community Cancer Center North, Indianapolis, Indiana, 46250, United States|The University of Kansas Cancer Center - Westwood, Westwood, Kansas, 66205, United States|CHI Saint Joseph Cancer Center - East, Lexington, Kentucky, 40509, United States|University of Kentucky Chandler Medical Center, Lexington, Kentucky, 40536, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, 70809, United States|USO - Maryland Oncology Hematology, Annapolis, Maryland, 21401, United States|Johns Hopkins Bayview Medical Center, Baltimore, Maryland, 21224, United States|Boston Medical Center, Boston, Massachusetts, 02118, United States|Lahey Hospital & Medical Center, Burlington, Massachusetts, 01805, United States|University of Michigan, Ann Arbor, Michigan, 48109, United States|Karmanos Cancer Institute, Detroit, Michigan, 48201, United States|The Cancer & Hematology Centers, Grand Rapids, Michigan, 49503, United States|Allina Health Cancer Institute - Abbott Northwestern Hospital, Minneapolis, Minnesota, 55407, United States|HealthPartners Cancer Research Center, Saint Paul, Minnesota, 55101, United States|North Mississippi Hematology and Oncology Associates, Tupelo, Mississippi, 38801, United States|Saint Louis University Cancer Center, Saint Louis, Missouri, 63110, United States|Oncology Hematology Associates, Springfield, Missouri, 65807, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, 89169, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, 03756, United States|The Valley Hospital, Inc., Paramus, New Jersey, 07652, United States|University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, 87131, United States|Maimonides Cancer Center, Brooklyn, New York, 11220, United States|Northwell Health/ RJ Zuckerberg Cancer Center, Lake Success, New York, 11042, United States|Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola, New York, 11501, United States|Laura and Isaac Perlmutter Cancer Center, New York, New York, 10016, United States|Manhattan Eye, Ear and Throat Hospital, New York, New York, 10065, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Clinical Research Alliance, Westbury, New York, 11590, United States|University of North Carolina Medical Center, Chapel Hill, North Carolina, 27599, United States|Duke Cancer Institute, Durham, North Carolina, 27710, United States|UNC REX Cancer Center, Raleigh, North Carolina, 27607, United States|USO - Oncology Hematology Care, Cincinnati, Ohio, 45242, United States|The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer -T, Columbus, Ohio, 43210, United States|USO - Oncology Associates of Oregon, Eugene, Oregon, 97401, United States|Asante Rogue Regional Medical Center, Medford, Oregon, 97504, United States|Providence Portland Medical Center, Portland, Oregon, 97213, United States|Providence St. Vincent Medical Center, Portland, Oregon, 97225, United States|Kaiser Permanente Interstate Medical Office Central, Portland, Oregon, 97227, United States|USO - Alliance Cancer Specialists, PC, Horsham, Pennsylvania, 19044, United States|Thomas Jefferson University, Sidney Kimmel Cancer Center - Clinical Trials Office, Philadelphia, Pennsylvania, 19107, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, 15232, United States|Lifespan Cancer Institute, Providence, Rhode Island, 02903, United States|Medical University of South Carolina, Charleston, South Carolina, 29425, United States|Prisma Health Cancer Institute, Greenville, South Carolina, 29605, United States|Lexington Medical Center, West Columbia, South Carolina, 29169, United States|Tennessee Oncology Chattanooga, Chattanooga, Tennessee, 37404, United States|University of Tennessee Medical Center, Knoxville, Tennessee, 37920, United States|Baptist Memorial Hospital-Memphis, Memphis, Tennessee, 38120, United States|Tennessee Oncology, Nashville, Tennessee, 37203, United States|USO - US Oncology Research Network, Nashville, Tennessee, 37203, United States|USO - Texas Oncology, Austin, Texas, 78745, United States|William Beaumont Army Medical Center, Fort Bliss, Texas, 79918, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, 78234, United States|Houston Methodist Hospital, Houston, Texas, 77030, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|Baylor Scott & White Medical Center - Temple, Temple, Texas, 76508, United States|USO - Texas Oncology, Webster, Texas, 77598, United States|The University of Vermont Medical Center Inc., Burlington, Vermont, 05401, United States|University of Virginia Health System, Charlottesville, Virginia, 22903, United States|USO - Virginia Cancer Specialists, Fairfax, Virginia, 22031, United States|VCU Health Adult Outpatient Pavillion, Richmond, Virginia, 23219, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, 99336, United States|Swedish Medical Center, Seattle, Washington, 98104, United States|VA Puget Sound Health Care System, Seattle, Washington, 98108, United States|USO - Northwest Cancer Specialists, Vancouver, Washington, 98684, United States|SSM Health Dean Medical Group - South Madison Campus Health Research/Circuit Clinical, Madison, Wisconsin, 53715, United States|Gosford Hospital, Gosford, New South Wales, 2250, Australia|Icon Cancer Centre Wesley, Auchenflower, Queensland, 4066, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, 4575, Australia|Mackay Base Hospital, Mackay, Queensland, 4740, Australia|Gold Coast University Hospital, Southport, Queensland, 4215, Australia|The Townsville Hospital, Townsville, Queensland, 4814, Australia|Royal Adelaide Hospital, Adelaide, South Australia, 5000, Australia|Ballarat Health Services, Ballarat Central, Victoria, 3350, Australia|St Vincent's Hospital, Melbourne, Victoria, 3065, Australia|Goulburn Valley Health, Shepparton, Victoria, 3630, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, 6009, Australia|Ordensklinikum Linz GmbH Elisabethinen, Linz, OberÃ¶sterreich, 4020, Austria|Landeskrankenhaus Feldkirch, Feldkirch, Vorarlberg, 6800, Austria|Klinik Floridsdorf, Wien, 1210, Austria|ZNA Middelheim, Antwerp, Antwerpen, 2020, Belgium|AZ Sint-Maarten, Mechelen, Antwerpen, 2800, Belgium|Clinique Saint Pierre, Ottignies, Brabant Wallon, 1340, Belgium|CHIREC - site delta, Auderghem, Bruxelles-Capitale, RÃ©gion De, 1160, Belgium|UniversitÃ© Catholique de Louvain-Namur - Centre Hospitalier Universitaire Dinant-Godinne - Site Godinne, Yvoir, Namur, 5530, Belgium|UZ Gent, Gent, Oost-Vlaanderen, 9000, Belgium|UZ Leuven, Leuven, Vlaams-Brabant, 3000, Belgium|AZ Sint-Jan Brugge-Oostende AV, Brugge, West-Vlaanderen, 8000, Belgium|AZ Groeninge Campus Kennedylaan, Kortrijk, West-Vlaanderen, 8500, Belgium|AZ Glorieux Ronse, Ronse, 9600, Belgium|Clinica Amo - Rio Vermelho, Salvador, Bahia, 41950-640, Brazil|Centro de Pesquisa ClÃ­nica do Instituto do CÃ¢ncer do CearÃ¡, Fortaleza, CearÃ¡, 60430235, Brazil|Sirio-Libanes Brasilia - Centro de Oncologia - Asa Sul, Brasilia, Distrito Federal, 70200-730, Brazil|Hospital Brasilia, Lago sul, Distrito Federal, 71.635-610, Brazil|CEDOES, VitÃ³ria, EspÃ­rito Santo, 29055450, Brazil|Hospital SÃ£o Domingos, Bequimao, MaranhÃ£o, 65060-645, Brazil|Oncocentro de Minas Gerais, Belo Horizonte, Minas Gerais, 30180-060, Brazil|Oncominas, Pouso Alegre, Minas Gerais, 37554-216, Brazil|Hospital UniversitÃ¡rio EvangÃ©lico Mackenzie, Curitiba, ParanÃ¡, 80730-150, Brazil|Hospital de Cancer de Londrina, Londrina, ParanÃ¡, 86015-520, Brazil|Liga Norte Riograndense Contra o CÃ¢ncer, Natal, Rio Grande Do Norte, 59062-000, Brazil|Hospital Tacchini, Bento GonÃ§alves, Rio Grande Do Sul, 95700-084, Brazil|ONCOSITE - Centro de Pesquisa Clinica em Oncologia, Ijui, Rio Grande Do Sul, 98700-000, Brazil|Hospital SÃ£o Lucas da PUCRS, Porto Alegre, Rio Grande Do Sul, 90610-000, Brazil|FundaÃ§Ã£o Pio XII - Hospital de CÃ¢ncer de Barretos, Barretos, SÃ£o Paulo, 14784400, Brazil|Faculdade de Medicina do ABC, Santo AndrÃ©, SÃ£o Paulo, 09060-650, Brazil|Hospital SÃ­rio LibanÃªs, Sao Paulo, SÃ£o Paulo, 01308-060, Brazil|Hospital BP, Sao Paulo, SÃ£o Paulo, 01321-001, Brazil|Hospital Paulistano, Sao Paulo, SÃ£o Paulo, 01321-001, Brazil|Instituto D'Or de Pesquisa e Ensino (IDOR), Sao Paulo, SÃ£o Paulo, 04543-000, Brazil|FundaÃ§Ã£o Faculdade Regional de Medicina de SÃ£o JosÃ© do Rio Preto, SÃ£o JosÃ© do Rio Preto, SÃ£o Paulo, 15090000, Brazil|COE Ensino e Pesquisa, SÃ£o JosÃ© dos Campos, SÃ£o Paulo, 12242-660, Brazil|Instituto Nacional de CÃ¢ncer JosÃ© Alencar Gomes da Silva - INCA, Rio de Janeiro, 20231-050, Brazil|Centro de Tratamento de Tumores Botafogo para Oncoclinicas Rio de Janeiro SA, Rio de Janeiro, 22250-905, Brazil|Instituto D'Or Pesquisa e Ensino, Rio de Janeiro, 22271-110, Brazil|Icesp - Instituto Do CÃ¢ncer Do Estado de SÃ£o Paulo, SÃ£o Paulo, 01246-000, Brazil|Hospital Santa Catarina - Paulista, SÃ£o Paulo, 01310-000, Brazil|Centro Paulista de Oncologia ClÃ­nica, SÃ£o Paulo, 01452-000, Brazil|NÃºcleo de Pesquisa ClÃ­nica da Rede SÃ£o Camilo, SÃ£o Paulo, 04014-002, Brazil|Instituto de AssistÃªncia MÃ©dica ao Servidor PÃºblico Estadual - IAMSPE/HSPE-FMO Conhecer Centro de Oncolog -T, SÃ£o Paulo, 04039-901, Brazil|BC Cancer Abbotsford, Abbotsford, British Columbia, V2S 0C2, Canada|BC Cancer Vancouver, Vancouver, British Columbia, V5Z 4E6, Canada|CIUSSS- saguenay-Lac-Saint-Jean, Chicoutimi, Quebec, G7H 5H6, Canada|Wannan Medical College Yijishan Hospital, Wuhu, Anhui, 241001, China|Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, 100021, China|Beijing Cancer hospital, Beijing, Beijing, 100142, China|Fujian Cancer Hospital, Fuzhou, Fujian, 350014, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510170, China|Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, 524001, China|Liuzhou People's Hospital, Liuzhou, Guangxi, 545006, China|Hainan General Hospital, Haikou, Hainan, 570311, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China|Tongji Hospital Tongji Medical,Science & Technology, Wuhan, Hubei, 430030, China|Wuhan Union Hospital, Wuhan, Hubei, 430048, China|Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, China|Xiangyang Central Hospital, Xiangyang, Hubei, 441021, China|Hunan Cancer Hospital, Changsha, Hunan, 410013, China|Hunan Cancer Hospital, Changsha, Hunan, 410013, China|ZhuZhou Central Hospital, Zhuzhou, Hunan, 412007, China|The First People's Hospital of Changzhou, Changzhou, Jiangsu, 213003, China|Nanjing First Hospital, Nanjing, Jiangsu, 210012, China|Nantong Tumor Hospital, Nantong, Jiangsu, 226361, China|The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, China|Jilin Cancer Hospital, Changchun, Jilin, 132000, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China|Jinan Central Hospital, Jinan, Shandong, 250013, China|Shandong Cancer Hospital, Jinan, Shandong, 250117, China|LinYi Cancer Hospital, Linyi, Shandong, 276001, China|Shanghai Chest Hospital, Shanghai, Shanghai, 200030, China|West China Hospital, Sichuan University, Cheng Du, Sichuan, 610041, China|The Third People's Hospital of Chengdu (CDTPH), Chengdu, Sichuan, 610031, China|Sichuan Cancer hospital, Chengdu, Sichuan, 610041, China|Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, 300060, China|The First Affiliated Hospital of Xinjiang Medical University, Urumchi, Xinjiang, 830054, China|Xinjiang Medical University Cancer Hospital - Urumqi, Urumqi, Xinjiang, 830000, China|The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, 310003, China|Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, 310016, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, 310022, China|Taizhou Hospital of Zhejiang Province, Linhai, Zhejiang, 317099, China|Hwa Mei Hospital University of Chinese Academy of Sciences, Ningbo, Zhejiang, 315099, China|Yichang Central People's Hospital, Yichang, 443003, China|Nemocnice AGEL Ostrava - Vitkovice a.s., Ostrava, Ostrava MÄsto, 703 84, Czechia|Fakultni nemocnice Bulovka, Prague, Praha 8, 180 81, Czechia|Roskilde University Hospital, Roskilde, SjÃ¦lland, 4000, Denmark|Centre Antoine-Lacassagne, Nice, Alpes-Maritimes, 06189, France|Nouvel HÃ´pital Civil (NHC), Strasbourg, Alsace, 67091, France|CHU Bordeaux Haut-Leveque, Pessac, Aquitaine, 33600, France|CHU de Toulouse - Hopital Larrey, Toulouse, Haute-Garonne, 31059, France|HÃ´pital Foch, Suresnes, Hauts-de-Seine, 92151, France|Centre Hospitalier Universitaire de Rennes - HÃ´pital Pontchaillou, Rennes, Ille-et-Vilaine, 35033, France|Institut de CancÃ©rologie de l'Ouest, Saint Herblain, Loire-Atlantique, 44805, France|HÃ´pital Robert Schuman, Vantoux, Lorraine, 57070, France|Institut Jean Godinot, Reims, Marne, 51726, France|CHU Lille - Institut Coeur Poumon, Lille Cedex, Nord, 59037, France|Centre Hospitalier intercommunal de Toulon La Seyne sur Mer, Toulon, Provence-Alpes-CÃ´te-d'Azur, 83100, France|Centre Leon Berard, Lyon Cedex08, RhÃ´ne-Alpes, 69373, France|Hospices Civils de Lyon - Hopital Louis Pradel, Bron, RhÃ´ne, 69677, France|Gustave Roussy, Villejuif, Val-de-Marne, 94800, France|Sainte Catherine Institut du Cancer Avignon Provence, Avignon, Vaucluse, 84918, France|Centre Hospitalier Universitaire de Poitiers, Poitiers, Vienne, 86021, France|Institut Curie, Paris, 75248, France|Universitaetsklinikum Freiburg, Freiburg, Baden-WÃ¼rttemberg, 79106, Germany|Thoraxklinik-Heidelberg gGmbH, Heidelberg, Baden-WÃ¼rttemberg, 69126, Germany|Universitaetsklinikum Tuebingen, TÃ¼bingen, Baden-WÃ¼rttemberg, 72076, Germany|Onkologiezentrum DonauwÃ¶rth, DonauwÃ¶rth, Bayern, 86609, Germany|Asklepios Fachkliniken MÃ¼nchen-Gauting, Gauting, Bayern, 82131, Germany|Klinikum NÃ¼rnberg Nord, NÃ¼rnberg, Bayern, 90419, Germany|MV-Zentrum fÃ¼r Onkologie und HÃ¤matologie, Cologne, Nordrhein-Westfalen, 50677, Germany|UniversitÃ¤tsklinikum MÃ¼nster - Albert Schweitzer Campus, MÃ¼nster, Nordrhein-Westfalen, 48149, Germany|Krankenhaus Martha-Maria Halle-DÃ¶lau, Halle, Sachsen-Anhalt, 06120, Germany|Klinikum Chemnitz, Chemnitz, Sachsen, 09116, Germany|LungenClinic Grosshansdorf, Grosshansdorf, Schleswig-Holstein, 22927, Germany|HELIOS Klinikum Erfurt, Erfurt, ThÃ¼ringen, 99089, Germany|Evangelische Lungenklinik Berlin, Berlin, 13125, Germany|CharitÃ© Campus Virchow-Klinikum, Berlin, 13353, Germany|Helios Klinikum Emil von Behring Berlin-Zehlendorf, Berlin, 14165, Germany|Franziskus-Hospital Harderberg, GeorgsmarienhÃ¼tte, 49124, Germany|HÃ¤mato-Onkologie Hamburg, Prof. Laack und Partner, Hamburg, 20251, Germany|Asklepios Klinik Harburg, Hamburg, 21075, Germany|University Hospital of Patras, Patras, Achaá¸¯a, 26504, Greece|Agios Savvas Regional Cancer Hospital, Athens, AttikÃ­, 115 22, Greece|Errikos Dunant Hospital Center, Athens, AttikÃ­, 115 26, Greece|Sotiria Thoracic Diseases Hospital of Athens, Athens, AttikÃ­, 11527, Greece|Attikon General University Hospital, Chaidari, AttikÃ­, 12462, Greece|University General Hospital of Heraklion, Heraklion, IrakleÃ­o, 715 00, Greece|""Theagenio"" Cancer Hospital of Thessaloniki, Thessaloniki, KentrikÃ­ MakedonÃ­a, 540 07, Greece|European Interbalkan Medical Center, Thessaloniki, ThessalonÃ­ki, 570 01, Greece|G. Papanikolaou General Hospital, Thessaloniki, ThessalonÃ­ki, 570 10, Greece|Bacs-Kiskun Megyei Korhaz, KecskemÃ©t, BÃ¡cs-Kiskun, 6000, Hungary|OrszÃ¡gos KorÃ¡nyi PulmonolÃ³giai IntÃ©zet, Budapest, Pest, 1121, Hungary|Farkasgyepui Tudogyogyintezet, Farkasgyepu, VeszprÃ©m, 8582, Hungary|OrszÃ¡gos OnkolÃ³giai IntÃ©zet, Budapest, 1122, Hungary|Budapesti Uzsoki Utcai KÃ³rhÃ¡z, Budapest, 1145, Hungary|Mahatma Gandhi Cancer Hospital and Research Institute, Visakhapatnam, Andhra Pradesh, 530017, India|Hemato Oncology Clinic, Ahmedabad, Gujarat, 380054, India|KLES Dr. Prabhakar Kore Hospital & M.R.C, Belagavi, Karnataka, 590010, India|SRV Hospitals, Bengaluru, Karnataka, 560027, India|Regional Cancer Centre - Thiruvananthapuram, Thiruvananthapuram, Kerala, 695011, India|Krishna Institute of Medical Sciences - Karad, Karad, Maharashtra, 415539, India|Kolhapur Cancer Centre Private Limited, Kolhapur, Maharashtra, 416234, India|Tata Memorial Hospital, Mumbai, Maharashtra, 400012, India|HCG Manavata Cancer Centre, Nashik, Maharashtra, 422001, India|Grant Medical Foundation - Ruby Hall Clinic, Pune, Maharashtra, 411001, India|Sahyadri Super Speciality Hospital, Pune, Maharashtra, 411004, India|Lifepoint Multispeciality Hospital, Pune, Maharashtra, 411057, India|All India Institute of Medical Sciences, Bhubaneswar, Odisha, 751019, India|Pacific Medical College & Hospital, Udaipur, Rajasthan, 313001, India|Ashwin Hospital, Coimbatore, Tamil Nadu, 641012, India|Nizam's Institute of Medical Sciences, Hyderabad, Telangana, 500082, India|Tata Memorial Centre - Homi Bhabha Cancer Hospital, Varanasi, Uttar Pradesh, 221002, India|Jawaharlal Institute Of Postgraduate Medical Education And Research, Puducherry, 605006, India|Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, 80131, Italy|Fondazione Policlinico Universitario Agostino Gemelli, Roma, Lazio, 00168, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Lombardia, 20133, Italy|Instituto Tumori Giovanni Paolo II, Bari, Puglia, 70124, Italy|Istituto Nazionale Tumori Regina Elena, Rome, Roma, 00144, Italy|Policlinico ""G. Rodolico"", Catania, Sicilia, 95123, Italy|Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Trento, Verona, Veneto, 37126, Italy|IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola, Bologna, 40138, Italy|Istituto Oncologico Veneto IRCCS, Padova, 35128, Italy|Ospedale di Circolo e Fondazione Macchi Varese, Varese, 21100, Italy|Aichi Cancer Center Hospital, Nagoya, Aichi, 464-8681, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, 277-8577, Japan|National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, 791-0280, Japan|National Hospital Organization Asahikawa Medical Center, Asahikawa, Hokkaido, 0708644, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, 060-8648, Japan|Himeji Medical Center, Himeji, Hyogo, 670-8520, Japan|Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan|Ibaraki Prefectural Central Hospital, Kasama, Ibaraki, 309-1793, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, 920-8641, Japan|Kanagawa Cardiovascular and Respiratory Center, Yokohama, Kanagawa, 236-0051, Japan|Kanagawa cancer center, Yokohama, Kanagawa, 2418515, Japan|Miyagi Cancer Center, Natori, Miyagi, 981-1293, Japan|Niigata Cancer Center Hospital, Niigata-shi, Niigata, 951-8566, Japan|Kansai Medical University Hospital, Hirakata, Osaka, 573-1191, Japan|Kindai University Hospital- Osakasayama Campus, Osakasayama, Osaka, 589-8511, Japan|National Hospital Organization Kinki-chuo Chest Medical Center, Sakai, Osaka, 591-8555, Japan|Saitama Medical University International Medical Center, Hidaka, Saitama, 350-1298, Japan|Shizuoka Cancer Center, Nagaizumi-cho,Sunto-gun, Shizuoka, 411-8777, Japan|Tochigi Cancer Center, Utsunomiya, Tochigi, 320-0834, Japan|Tokyo Metropolitan Komagome Hospital, Bunkyo ku, Tokyo, 113-8677, Japan|Juntendo University Hospital, Bunkyo-ku, Tokyo, 113-8431, Japan|Japanese Foundation for Cancer Research, Koto, Tokyo, 135-8550, Japan|Tottori University Hospital, Yonago, Tottori, 683-8504, Japan|National Hospital Organization Yamaguchi Ube Medical Center, Ube, Yamaguchi, 755-0241, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, 811-1395, Japan|Kyushu University Hospital, Fukuoka, 812-8582, Japan|University Hospital,Kyoto Prefectural University of Medicine, Kyoto, 602-8566, Japan|Nagasaki University Hospital, Nagasaki, 852-8501, Japan|Okayama University Hospital, Okayama, 700-8558, Japan|Wakayama Medical University Hospital, Wakayama, 641-8510, Japan|Chungbuk National University Hospital, Cheongju-si, Chungcheongbuk-do [Chungbuk], 28644, Korea, Republic of|Chonnam National University Hwasun Hospital, Hwasun, Jeonranamdo, 58128, Korea, Republic of|National Cancer Center, Goyang-si, KyÇnggi-do, 10408, Korea, Republic of|The Catholic University Of Korea St. Vincent's Hospital, Suwon-si, KyÇnggi-do, 16247, Korea, Republic of|Pusan National University Yangsan Hospital, Yangsan, KyÇngsangnam-do, ASI|KR|KS011, Korea, Republic of|Gangnam Severance Hospital, Yonsei University Health System, Gangnam-gu, Seoul-teukbyeolsi [Seoul], 06273, Korea, Republic of|Korea University Anam Hospital, Seoul, Seoul-teukbyeolsi [Seoul], 02841, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Seoul-teukbyeolsi [Seoul], 03722, Korea, Republic of|Hanyang University Seoul Hospital, Seoul, Seoul-teukbyeolsi [Seoul], 04763, Korea, Republic of|Asan Medical Center, Seoul, Seoul-teukbyeolsi [Seoul], 05505, Korea, Republic of|Samsung Medical Center, Seoul, Seoul-teukbyeolsi [Seoul], 06351, Korea, Republic of|The Catholic University of Korea, Yeouido St. Mary's Hospital, Seoul, Seoul-teukbyeolsi [Seoul], 07345, Korea, Republic of|Korea University Guro Hospital, Seoul, Seoul-teukbyeolsi [Seoul], 08308, Korea, Republic of|Keimyung University Dongsan Hospital, Daegu, Taegu-KwangyÇkshi, 42601, Korea, Republic of|Kyungpook National University Chilgok Hospital, Deagu, Taegu-KwangyÇkshi, 41404, Korea, Republic of|Health Pharma Professional Research S.A. de C.V:, Ciudad de MÃ©xico, Distrito Federal, 03100, Mexico|Centro Onco-HematolÃ³gico Roma (COHR), Mexico City, Distrito Federal, 06700, Mexico|Higiea Oncologia, Mexico City, Distrito Federal, 11819, Mexico|Preparaciones OncolÃ³gicas S.C., LeÃ³n, Guanajuato, 37178, Mexico|CIO - Centro de Inmuno-OncologÃ­a de Occidente, Guadalajara, Jalisco, 44630, Mexico|PanAmerican Clinical Research - Guadalajara, Guadalajara, Jalisco, 44670, Mexico|Actualidad Basada en la InvestigaciÃ³n del CÃ¡ncer, Guadalajara, Jalisco, 44680, Mexico|Renati Innovation, Guadalajara, Jalisco, 44680, Mexico|Hospital Universitario ""Dr. Jose Eleuterio Gonzalez"", Monterrey, Nuevo LeÃ³n, 64460, Mexico|Avix InvestigaciÃ³n Clinica, S.C., Monterrey, Nuevo LeÃ³n, 64623, Mexico|Oncare - Unidad Valle, San Pedro Garza GarcÃ­a, Nuevo LeÃ³n, 66220, Mexico|Health Pharma QuerÃ©taro, Juriquilla, QuerÃ©taro, 76230, Mexico|Centro de Investigacion Clinica de Oaxaca, Oaxaca, 68020, Mexico|Clinica Integral Internacional de OncologÃ­a, Puebla, 72530, Mexico|ArkÃ© SMO S.A de C.V, Veracruz, 91900, Mexico|Medische Centrum Leeuwarden, Leeuwarden, FryslÃ¢n, 8934 AD, Netherlands|Ziekenhuis St. Jansdal, Harderwijk, Gelderland, 3844 DG, Netherlands|Jeroen Bosch Hospital, Den Bosch, Noord-Brabant, 5223 GZ, Netherlands|ETZ Elisabeth, Tilburg, Noord-Brabant, 5022 GC, Netherlands|Tergooiziekenhuizen, locatie Hilversum, Hilversum, Noord-Holland, 1213 XZ, Netherlands|Medisch Spectrum Twente, Enschede, Overijssel, 7512 KZ, Netherlands|Leids Universitair Medisch Centrum, Leiden, Zuid-Holland, 2333 ZA, Netherlands|Erasmus Medisch Centrum, Rotterdam, Zuid-Holland, 3015 GD, Netherlands|St. Antonius Ziekenhuis, locatie Utrecht, Utrecht, 3543 AZ, Netherlands|Akershus Universitetssykehus, LÃ¸renskog, Akershus, 1478, Norway|Drammen Sykehus, Vestre Viken HF, Drammen, Buskerud, 3004, Norway|Haukeland Universitetssjukehus, Bergen, Hordaland, 5021, Norway|Sykehuset Innlandet HF GjÃ¸vik, GjÃ¸vik, Oppland, 2819, Norway|Stavanger Universitetssykehus, Stavanger, Rogaland, 4011, Norway|St. Olavs Hospital, Trondheim, SÃ¸r-TrÃ¸ndelag, 7030, Norway|Oslo universitetssykehus, Radiumhospitalet, Oslo, 0379, Norway|MICS Centrum Medyczne Torun, Torun, Kujawsko-pomorskie, 87-100, Poland|One Day Med, Szczecin, Zachodniopomorskie, 70-419, Poland|Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Kielce, ÅwiÄtokrzyskie, 25-734, Poland|Champalimaud Foundation, Lisbon, Lisboa, 1400-038, Portugal|Hospital Pulido Valente, Lisbon, Lisboa, 1769-001, Portugal|Centro Hospitalar E UniversitÃ¡rio De Coimbra, Coimbra, 3004-561, Portugal|Hospital da Luz Lisboa, Lisboa, 1500-650, Portugal|Centro Hospitalar do Porto - Hospital de Santo AntÃ³nio, Porto, 4099-001, Portugal|Hospital CUF Porto, Porto, 4100-180, Portugal|Instituto PortuguÃªs de Oncologia do Porto Francisco Gentil, EPE, Porto, 4200-072, Portugal|Lotus-Med, Bucharest, BucureÈti, 012292, Romania|SC Memorial Healthcare International SRL, Bucharest, BucureÈti, 013812, Romania|Ovidius Clinical Hospital OCH, Ovidiu, ConstanÈa, 905900, Romania|Centrul de Oncologie ""SfÃ¢ntul Nectarie"", Craiova, Dolj, 200542, Romania|S C Oncocenter Oncologie Clinica S R L, TimiÈoara, TimiÈ, 300166, Romania|Cabinet Medical Oncomed, TimiÈoara, TimiÈ, 300239, Romania|Gral Medical Diagnostic Center, BucureÈti, 031422, Romania|Institutul Oncologic, Cluj, 400015, Romania|CHUAC-Hospital Teresa Herrera, A CoruÃ±a, A CoruÃ±a [La CoruÃ±a], 15006, Spain|CHUS - Hospital Clinico Universitario, Santiago de Compostela, A CoruÃ±a [La CoruÃ±a], 15706, Spain|Hospital Universitari Son Espases, Palma, Balears [Baleares], 07120, Spain|Parc de Salut Mar - Hospital del Mar, Barcelona, Barcelona [Barcelona], 08003, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Barcelona [Barcelona], 08035, Spain|Instituto Catalan de Oncologia - Hospital Duran i Reynals, Hospitalet, Barcelona [Barcelona], 08907, Spain|Complejo Asistencial Universitario de LeÃ³n - Hospital de LeÃ³n, LeÃ³n, Castilla Y LeÃ³n, 24071, Spain|Hospital Universitari Dexeus, Barcelona, Catalunya [CataluÃ±a], 08028, Spain|Hospital Jerez de la Frontera, Jerez de la Frontera, CÃ¡diz, 11407, Spain|Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Las Palmas, 35016, Spain|Hospital Universitario RamÃ³n y Cajal, Madrid, Madrid, Comunidad De, 28034, Spain|Hospital Universitario 12 de Octubre, Madrid, Madrid, Comunidad De, 28041, Spain|Hospital Universitario Quironsalud Madrid, Pozuelo de Alarcon, Madrid, 28223, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, 31009, Spain|Hospital Clinico de Valencia, Valencia, Valenciana, Comunitat, 46010, Spain|Hospital Infanta Cristina, Badajoz, 06006, Spain|H.R.U MÃ¡laga - Hospital General, MÃ¡laga, 29011, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, 41013, Spain|Hospital ClÃ­nico Universitario Lozano Blesa, Zaragoza, 50009, Spain|MÃ¤larsjukhuset, Eskilstuna, SÃ¶dermanlands LÃ¤n [se-04], 631 88, Sweden|VÃ¤stmanlands Sjukhus VÃ¤sterÃ¥s, VÃ¤sterÃ¥s, VÃ¤stmanlands LÃ¤n [se-19], 721 89, Sweden|CHUV (centre hospitalier universitaire vaudois), Lausanne, Vaud, 1011, Switzerland|Kantonsspital Winterthur, Winterthur, 8401, Switzerland|UniversitÃ¤tsSpital ZÃ¼rich, ZÃ¼rich, 8091, Switzerland|Changhua Christian Hospital, Changhua County, Changhua, 50006, Taiwan|National Taiwan University Hospital - Hsinchu branch, Zhu Bei City, Hsinchu, 302, Taiwan|Hualien Tzu Chi Medical Center, Hualien City, Hualien, 970, Taiwan|Chang Gung Memorial Hospital at Kaohsiung, Kaohsiung Niao Sung Dist, Kaohsiung, 83301, Taiwan|New Taipei Municipal TuCheng Hospital, New Taipei City, New Taipei, 236, Taiwan|Chung Shan Medical University Hospital, Taichung City, Taichung, 402, Taiwan|Chi Mei Medical Center, Tainan City, Tainan, 71004, Taiwan|Chi Mei Hospital - Liouying Branch, Tainan City, Tainan, 73657, Taiwan|National Taiwan University Cancer Center (NTUCC), Taipei City, Taipei, 106, Taiwan|National Taiwan University Hospital Yun-Lin Branch Dou-Liou Region, Douliu City, Yunlin, 640, Taiwan|Buddhist Dalin Tzu Chi General Hospital, Chiayi, 622, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, 807, Taiwan|Taichung Veterans General Hospital, Taichung, 407, Taiwan|National Cheng Kung University Hospital, Tainan, 704, Taiwan|National Taiwan University Hospital, Taipei, 10002, Taiwan|Taipei Veterans General Hospital, Taipei, 11217, Taiwan|Chang Gung Medical Foundation-Linkou Branch, Taoyuan, 333, Taiwan|Adana Medical Park Seyhan Hastanesi, Adana, 01140, Turkey|Adana City Hospital, Adana, 01370, Turkey|Ankara Etlik City Hospital, Ankara, 06170, Turkey|Abdurrahman Yurtaslan Ankara Oncology, education and Research Hospital, Ankara, 06200, Turkey|Ankara Bilkent Åehir Hastanesi, Ankara, 06800, Turkey|Akdeniz Universitesi Hastanesi, Antalya, 07059, Turkey|Memorial Antalya Hospital, Antalya, 07090, Turkey|Uludag Universitesi, Bursa, 16059, Turkey|Dicle Ãniversitesi, Diyarbakir, 21200, Turkey|Bezmialem Vakf Ãniversitesi, Istanbul, 34093, Turkey|Ä°.A.Ã VM Medical Park Florya Hastanesi, Istanbul, 34295, Turkey|TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi, Istanbul, 34722, Turkey|Ege Universitesi Hastanesi, Izmir, 35100, Turkey|zmir Katip Ãelebi Ãniversitesi AtatÃ¼rk Eitim Ve Aratrma Hastanesi, Izmir, 35360, Turkey|Kocaeli Ãniversitesi, Kocaeli, 41380, Turkey|Ondokuz MayÄ±s Universitesi, Samsun, 55270, Turkey|Aberdeen Royal Infirmary, Aberdeen, Aberdeen City, AB25 2ZN, United Kingdom|Ninewells Hospital and Medical School, Dundee, Dundee City, DD1 9SY, United Kingdom|Huddersfield Royal Infirmary, Huddersfield, England, HD3 3EA, United Kingdom|Weston Park Hospital, Sheffield, England, S10 2SJ, United Kingdom|Cheltenham General Hospital, Cheltenham, Gloucestershire, GL53 7AN, United Kingdom|Mount Vernon Hospital, Northwood, Hillingdon, HA6 2RN, United Kingdom|St James's University Hospital, Leeds, LS9 7TF, United Kingdom|The Christie NHS Foundation Trust, Manchester, M20 4BX, United Kingdom|New Cross Hospital, Wolverhampton, WV10 0QP, United Kingdom",
NCT06837896,Efficacy and Safety Study of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer,https://clinicaltrials.gov/study/NCT06837896,,NOT_YET_RECRUITING,The purpose of this study was to evaluate the efficacy and safety of QLG1080 in patients with hormone-sensitive advanced prostate cancer.,NO,Prostate Cancer,DRUG: QLG1080,"Sustained castration rate of serum testosterone, The cumulative probability of serum testosterone levels reaching and maintaining castration levels (â¤50 ng/dL or 1.7 nmol/L), From study day 29 to the end of the study",,,"Qilu Pharmaceutical Co., Ltd.",,MALE,"ADULT, OLDER_ADULT",PHASE3,110,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2025-02,2026-11,2026-12,2025-02-20,,2025-02-20,,
NCT06345729,"A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) â¥50% (MK-1084-004)",https://clinicaltrials.gov/study/NCT06345729,,RECRUITING,"This is a study evaluating the efficacy and safety of MK-1084 with pembrolizumab as first-line treatment in participants with metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation and programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) â¥50%. There are two primary study hypotheses:

Hypothesis 1: Combination of MK-1084 and pembrolizumab is superior to placebo plus pembrolizumab with respect to progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).

Hypothesis 2: Combination of MK-1084 plus pembrolizumab is superior to placebo plus pembrolizumab with respect to overall survival (OS).",NO,Non-small Cell Lung Cancer,DRUG: MK-1084|OTHER: Placebo|BIOLOGICAL: Pembrolizumab,"Progression-Free Survival (PFS), PFS is defined as the time from randomization until either documented disease progression per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) or death due to any cause, whichever occurs first. PFS as determined by blinded independent central review (BICR) will be presented., Up to approximately 42 months|Overall Survival (OS), OS is defined as the time from randomization to death due to any cause., Up to approximately 56 months","Objective Response Rate (ORR), ORR is defined as the percentage of participants with Complete Response or Partial Response per RECIST1.1. The percentage of participants who experience CR or PR as assessed by BICR will be presented., Up to approximately 42 months|Duration of Response (DOR), For participants who demonstrate confirmed CR or PR per RECIST 1.1 as assessed by BICR, duration of response is defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first., Up to approximately 42 months|Number of Participants Who Experience One or More Adverse Event (AEs), An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who experience an AE will be presented., Up to approximately 56 months|Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE), An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who discontinue study treatment due to an AE will be presented., Up to approximately 56 months|Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score, The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions ""How would you rate your overall health during the past week?"" and ""How would you rate your overall quality of life during the past week?"" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The change from baseline in the score of EORTC QLQ-C30 Items 29 and 30 will be presented. Higher scores indicate a better overall health status., Baseline and Up to approximately 24 months|Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Physical Functioning (Items 1-5) Score, The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). The change from baseline in the score of EORTC QLQ-C30 Items 1-5 will be presented. Higher scores indicate a better level of functioning., Baseline and Up to approximately 24 months|Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Role Functioning (Items 6 and 7) Score, The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 2 questions about their role functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). The change from baseline in the score of EORTC QLQ-C30 Items 6-7 will be presented. Higher scores indicate a better level of functioning., Baseline and Up to approximately 24 months|Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Dyspnea (Item 8) Score, The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant response to the question ""Were you short of breath?"" is scored on a 4-point scale (1=Not at All to 4=Very Much). The change from baseline in the score of EORTC QLQ-C30 Item 8 will be presented. A higher score indicates a worse level of dyspnea., Baseline and Up to approximately 24 months|Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Lung Cancer-Specific Questionnaire Module (EORTC QLQ-C13) Cough (Item 31) Score, The EORTC QLQ-C13 is a lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQ-C30. Participant response to the question ""Have you coughed?"" is scored on a 4-point scale (1=Not at All to 4=Very Much). The change from baseline in the score of EORTC QLQ-C13 Item 31 will be presented. A higher score indicates more frequent coughing., Baseline and Up to approximately 24 months|Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Lung Cancer-Specific Questionnaire Module (EORTC QLQ-LC13) Chest pain (Item 40) Score, The EORTC QLQ-C13 is lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQ-C30. Participant response to the question ""Have you had pain in your chest?"" is scored on a 4-point scale (1=Not at All to 4=Very Much). The change from baseline in the score of EORTC QLQ-C13 Item 40 will be presented. A higher score indicates a worse level of chest pain., Baseline and Up to approximately 24 months|Time to Deterioration (TTD) in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score, TTD is defined as the time from baseline to the first onset of a â¥10-point negative change (decrease) from baseline in global health status (GHS) and quality of life (QoL) (EORTC QLQ-C30 Items 29 and 30) score. Participant responses to the questions ""How would you rate your overall health during the past week?"" and ""How would you rate your overall quality of life during the past week?"" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a â¥10 point negative change (decrease) from baseline in GHS and QoL, will be presented. A longer TTD indicates a better outcome., Baseline and Up to approximately 24 months|Time to Deterioration (TTD) in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Physical Functioning (Items 1-5) Score, TTD is defined as the time from baseline to the first onset of a â¥10-point negative change (decrease) from baseline in physical functioning (EORTC QLQ-C30 Items 1-5) score. The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a â¥10 point negative change (decrease) from baseline in physical functioning score, will be presented. A longer TTD indicates a better outcome., Baseline and Up to approximately 24 months|Time to Deterioration (TTD) in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Role Functioning (Items 6 and 7) Score, TTD is defined as the time from baseline to the first onset of a â¥10-point negative change (decrease) from baseline in role functioning (EORTC QLQ-C30 Items 6 and 7) score. The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 2 questions about their role functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a â¥10 point negative change (decrease) from baseline in role functioning score, will be presented. A longer TTD indicates a better outcome., Baseline and Up to approximately 24 months|Time to Deterioration (TTD) in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Dyspnea (Item 8) Score, TTD is defined as the time from baseline to the first onset of a â¥10-point negative change (decrease) from baseline in dyspnea (EORTC QLQ-C30 Item 8) score. The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant response to the question ""Were you short of breath?"" is scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a â¥10 point negative change (decrease) from baseline in dyspnea score, will be presented. A longer TTD indicates a better outcome., Baseline and Up to approximately 24 months|Time to Deterioration (TTD) in European Organization for Research and Treatment of Cancer Quality of Life Lung Cancer-Specific Questionnaire Module (EORTC QLQ-C13) Cough (Item 31) Score, TTD is defined as the time from baseline to the first onset of a â¥10-point negative change (decrease) from baseline in cough (EORTC QLQ-C13 Item 31) score. The EORTC QLQ-C13 is lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQ-C30. Participant response to the question ""Have you coughed?"" is scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a â¥10 point negative change (decrease) from baseline in cough score, will be presented. A longer TTD indicates a better outcome., Baseline and Up to approximately 24 months|Time to Deterioration (TTD) in European Organization for Research and Treatment of Cancer Quality of Life Lung Cancer-Specific Questionnaire Module (EORTC QLQ-C13) Chest pain (Item 40) Score, TTD is defined as the time from baseline to the first onset of a â¥10-point negative change (decrease) from baseline in chest pain (EORTC QLQ-C13 Item 40) score. The EORTC QLQ-C13 is lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQ-C30. Participant response to the question ""Have you had pain in your chest?"" is scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a â¥10 point negative change (decrease) from baseline chest pain score, will be presented. A longer TTD indicates a better outcome., Baseline and Up to approximately 24 months",,Merck Sharp & Dohme LLC,,ALL,"ADULT, OLDER_ADULT",PHASE3,600,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-05-24,2029-02-19,2031-02-18,2024-04-03,,2025-06-13,"CBCC Global Research, Inc. ( Site 0123), Bakersfield, California, 93309, United States|Beverly Hills Cancer Center ( Site 0116), Beverly Hills, California, 90211, United States|Mount Sinai Cancer Center ( Site 0137), Miami Beach, Florida, 33140, United States|Orchard Healthcare Research Inc. ( Site 0115), Skokie, Illinois, 60077, United States|Truman Medical Center ( Site 0126), Kansas City, Missouri, 64108, United States|Cox Medical Center North ( Site 0133), Springfield, Missouri, 65807, United States|St. Vincent Frontier Cancer Center-Research ( Site 0105), Billings, Montana, 59102, United States|Atlantic Health System Morristown Medical Center ( Site 0121), Morristown, New Jersey, 07960, United States|New York Oncology Hematology, P.C. ( Site 0132), Albany, New York, 12206, United States|University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0103), Cincinnati, Ohio, 45219, United States|Kettering Health Main Campus-Kettering Health Cancer Center ( Site 0106), Kettering, Ohio, 45429, United States|Oncology Consultants P.A. ( Site 0113), Houston, Texas, 77030, United States|Circuit Clinical/SSM Health Dean Medical Group ( Site 0129), Madison, Wisconsin, 53715, United States|AUSTRAL MEDICAL CENTER ( Site 0302), Caba, Buenos Aires, C1019ABS, Argentina|Centro Oncologico Korben ( Site 0304), Caba, Buenos Aires, C1426AGE, Argentina|Instituto de Investigaciones ClÃ­nicas Mar del Plata ( Site 0300), Mar del Plata, Buenos Aires, B7600FZO, Argentina|Fundacion Estudios Clinicos ( Site 0306), Rosario, Santa Fe, S2000DEJ, Argentina|Sanatorio Parque ( Site 0301), Rosario, Santa Fe, S2000DVC, Argentina|Chris O'Brien Lifehouse ( Site 3000), Camperdown, New South Wales, 2050, Australia|Frankston Hospital ( Site 3002), Frankston, Victoria, 3199, Australia|One Clinical Research ( Site 3001), Nedlands, Western Australia, 6009, Australia|Medizinische UniversitÃ¤t Graz-Klinische Abteilung fÃ¼r Pulmonologie ( Site 2401), Graz, Steiermark, 8036, Austria|Klinik Floridsdorf-Abteilung fÃ¼r Innere Medizin und Pneumologie ( Site 2400), Wien, 1210, Austria|Hospital Mario Penna ( Site 0436), Belo Horizonte, Minas Gerais, 30380-472, Brazil|Hospital de CÃ¢ncer de Recife ( Site 0447), Recife, Pernambuco, 50040-000, Brazil|OncoclÃ­nica Oncologistas Associados ( Site 0441), Terezina, Piaui, 64049-200, Brazil|Liga Norte Riograndense Contra o CÃ¢ncer ( Site 0439), Natal., Rio Grande Do Norte, 59062-000, Brazil|Irmandade da Santa Casa de MisericÃ³rdia de Porto Alegre-Centro Multidisciplinar de Pesquisa ClÃ­nica ( Site 0435), Porto Alegre, Rio Grande Do Sul, 90050-170, Brazil|FundaÃ§Ã£o Pio XII - Hospital de CÃ¢ncer de Barretos-Unidade de Pesquisa ClÃ­nica ( Site 0437), Barretos., Sao Paulo, 14784-400, Brazil|Instituto Nacional de CÃ¢ncer - INCA ( Site 0446), Rio de Janeiro, 20230-130, Brazil|Americas ( Site 0431), Rio de Janeiro, 22775-001, Brazil|MBAL Uni Hospital-Department of Medical Oncology ( Site 1000), Panagyurishte, Pazardzhik, 4500, Bulgaria|MHAT - Heart and Brain ( Site 1006), Pleven, 5804, Bulgaria|CancerCare Manitoba ( Site 0210), Winnipeg, Manitoba, R3E 0V9, Canada|Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0205), Hamilton, Ontario, L8V 5C2, Canada|Sunnybrook Research Institute ( Site 0206), Toronto, Ontario, M4N 3M5, Canada|St. Marys Hospital Center ( Site 0204), Montreal, Quebec, H3T 1M5, Canada|Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-centre-du-quebec ( Site 0207), Trois-RiviÃ¨res, Quebec, G8Z 3R9, Canada|Clinica Universidad Catolica del Maule-Oncology ( Site 0500), Talca, Maule, 3465584, Chile|Orlandi Oncologia-Oncology ( Site 0503), Santiago, Region M. De Santiago, 7500713, Chile|FALP-UIDO ( Site 0501), Santiago, Region M. De Santiago, 7500921, Chile|Centro de OncologÃ­a de PrecisiÃ³n-Oncology ( Site 0502), Santiago, Region M. De Santiago, 7560908, Chile|Bradfordhill-Clinical Area ( Site 0504), Santiago, Region M. De Santiago, 8420383, Chile|Anhui Provincial Cancer Hospital ( Site 3136), Hefei, Anhui, 230000, China|Beijing Cancer hospital ( Site 3133), Beijing, Beijing, 100142, China|Beijing Cancer hospital ( Site 3134), Beijing, Beijing, 100142, China|Beijing Peking Union Medical College Hospital-pneumology department ( Site 3102), Beijing, Beijing, 100730, China|Beijing Chest Hospital,Capital Medical University ( Site 3104), Beijing, Beijing, 101149, China|Chongqing University Cancer Hospital ( Site 3119), Chongqing, Chongqing, 400030, China|Army Medical Center of People's Liberation Army ( Site 3142), Chongqing, Chongqing, 400042, China|Fujian Cancer Hospital ( Site 3127), Fuzhou, Fujian, 350014, China|The First Affiliated hospital of Xiamen University ( Site 3148), Xiamen, Fujian, 361003, China|The First Affiliated Hospital of Guangzhou Medical University ( Site 3108), Guangzhou, Guangdong, 510160, China|Southern Medical University Nanfang Hospital ( Site 3128), Guangzhou, Guangdong, 510515, China|Sun Yat-sen University Cancer Center ( Site 3137), Guangzhou, Guangdong, 510555, China|Harbin Medical University Cancer Hospital ( Site 3123), Harbin, Heilongjiang, 150000, China|JIAMUSI TUBERCULOSIS HOSPITAL(CANCER HOSPITAL) ( Site 3124), Jiamusi, Heilongjiang, 154007, China|Henan Cancer Hospital ( Site 3149), Zhengzhou, Henan, 450008, China|Tongji Hospital Tongji Medical,Science & Technology ( Site 3113), Wuhan, Hubei, 430000, China|Hubei Cancer Hospital ( Site 3126), Wuhan, Hubei, 430079, China|The Second Xiangya Hospital of Central South University ( Site 3130), Changsha, Hunan, 410011, China|Hunan Cancer Hospital ( Site 3141), Changsha, Hunan, 410013, China|Nanjing Gulou Hospital ( Site 3122), Nanjing, Jiangsu, 210008, China|Nanjing First Hospital ( Site 3154), Nanjing, Jiangsu, 210012, China|The First Affiliated Hospital of Soochow University ( Site 3146), Suzhou, Jiangsu, 215006, China|Affiliated Hospital of Jiangnan University(Wuxi Fourth People's Hospital ) ( Site 3155), Wuxi City, Jiangsu, 214122, China|The Second Affiliated Hospital of Nanchang University ( Site 3139), Nanchang, Jiangxi, 330000, China|The First affiliated hospital of Nanchang University (Xianghu campus) ( Site 3138), Nanchang, Jiangxi, 330209, China|Jilin Province Tumor Hospital ( Site 3107), Changchun, Jilin, 130000, China|The First Affiliated Hospital of Xi'an Jiaotong University ( Site 3150), Xian, Shaanxi, 710000, China|Shandong Cancer Hospital ( Site 3116), Jinan, Shandong, 250117, China|LinYi Cancer Hospital ( Site 3111), Linyi, Shandong, 276001, China|Shanghai Chest Hospital ( Site 3100), Shanghai, Shanghai, 200030, China|Fudan University Shanghai Cancer Center ( Site 3144), Shanghai, Shanghai, 200032, China|Zhongshan Hospital,Fudan University ( Site 3143), Shanghai, Shanghai, 200032, China|Shanxi Cancer Hospital ( Site 3131), Taiyuan, Shanxi, 030000, China|The Second Affiliated Hospital of Air Force Medical University ( Site 3117), Xian, Shanxi, 710038, China|The Second Affiliated Hospital of Air Force Medical University ( Site 3152), Xian, Shanxi, 710038, China|West China Hospital, Sichuan University ( Site 3140), Cheng Du, Sichuan, 610041, China|The Third People's Hospital of Chengdu (CDTPH) ( Site 3157), Chengdu, Sichuan, 610031, China|Sichuan Cancer hospital. ( Site 3109), Chengdu, Sichuan, 610042, China|The Second People's Hospital of Neijiang ( Site 3105), Neijiang, Sichuan, 641000, China|Xinjiang Medical University Cancer Hospital - Urumqi ( Site 3101), Urumqi, Xinjiang, 830000, China|Yunnan Province Cancer Hospital ( Site 3153), Kunming, Yunnan, 650107, China|The first Affiliated Hospital, Zhejiang University School of Medicine ( Site 3115), Hangzhou, Zhejiang, 310003, China|Sir Run Run Shaw Hospital of Zhejiang University School of Medicine ( Site 3121), Hangzhou, Zhejiang, 310016, China|Taizhou Hospital of Zhejiang Province ( Site 3145), Linhai, Zhejiang, 317000, China|The First Affiliated Hospital of Wenzhou Medical University ( Site 3151), Wenzhou, Zhejiang, 325015, China|Centre Hospitalier Universitaire Dijon Bourgogne - HÃ´pital FranÃ§ois Mitterrand ( Site 1103), Dijon, Bourgogne, 21000, France|HÃ´pital Ambroise ParÃ©-Department of Respiratory Diseases and Thoracic Oncology ( Site 1105), Boulogne-Billancourt, Ile-de-France, 92100, France|Clinique Teissier Groupe ( Site 1100), Valenciennes, Nord, 59304, France|Centre Jean Perrin - Centre RÃ©gional de Lutte contre le Cancer d'Auvergne-ONCOLOGY ( Site 1101), Clermont-Ferrand, Puy-de-Dome, 63003, France|Centre Hospitalier d'Avignon-Service d'Oncologie mÃ©dicale et d'hÃ©matologie clinique ( Site 1104), Avignon, Vaucluse, 84000, France|High Technology Hospital Medcenter ( Site 1203), Batumi, Ajaria, 6000, Georgia|American Hospital Network LLC ( Site 1208), Tbilisi, 0102, Georgia|Todua Clinic, LLC ( Site 1204), Tbilisi, 0112, Georgia|TSMU and Ingorokva High Medical Technology University Clinic LTD ( Site 1201), Tbilisi, 0144, Georgia|New Hospitals ( Site 1200), Tbilisi, 0162, Georgia|Cancer Research Centre. Mardaleishvili Medical Centre ( Site 1205), Tbilisi, 0177, Georgia|Caucasus Medical Centre ( Site 1202), Tbilisi, 0186, Georgia|Tbilisi Institute of Medicine ( Site 1206), Tbilisi, 1206, Georgia|Marienhospital Stuttgart ( Site 1302), Stuttgart, Baden-Wurttemberg, 70199, Germany|Krankenhaus Bethanien ( Site 1303), Solingen, Nordrhein-Westfalen, 42699, Germany|UNIVERSITY HOSPITAL OF PATRAS-DIVISION OF ONCOLOGY ( Site 1402), Patras, Achaia, 26504, Greece|THORACIC GENERAL HOSPITAL OF ATHENS ""I SOTIRIA""-3rd Dept of Internal Medicine and Laboratory, Oncol ( Site 1400), Athens, Attiki, 115 27, Greece|Agios Loukas Clinic ( Site 1404), Thessaloniki, Kentriki Makedonia, 552 36, Greece|University General Hospital of Larissa-Oncology Clinic ( Site 1403), Larissa, Thessalia, 411 10, Greece|G. Papanikolaou General Hospital-Pulmonary Clinic of Aristotle University of Thessaloniki ( Site 1405), Thessaloniki, 570 10, Greece|Istituto Nazionale Tumori IRCCS Fondazione Pascale-Oncologia clinica sperimentale Toraco-Polmonare ( Site 1607), Napoli, Campania, 80131, Italy|Ospedale Santa Maria delle Croci ( Site 1606), Ravenna, Emilia-Romagna, 48121, Italy|CRO-IRCCS-Clinical Oncology ( Site 1605), Aviano, Friuli-Venezia Giulia, 33081, Italy|Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Medical Oncology ( Site 1601), Roma, Lazio, 00168, Italy|Istituto Europeo di Oncologia IRCCS-Divisione di Oncologia Toracica ( Site 1604), Milano, Lombardia, 20141, Italy|Istituto Nazionale Tumori Regina Elena-Oncologia Medica 2 ( Site 1609), Rome, Roma, 00144, Italy|Azienda USL Toscana Nord Ovest_Ospedale Civile di Livorno-UOC Oncologia Medica Livorno ( Site 1608), Livorno, Toscana, 57124, Italy|Nagoya University Hospital ( Site 3309), Nagoya, Aichi, 466-8560, Japan|Fujita Health University Hospital ( Site 3310), Toyoake, Aichi, 470-1192, Japan|National Hospital Organization Shikoku Cancer Center ( Site 3315), Matsuyam, Ehime, 719-0280, Japan|National Hospital Organization Kyushu Cancer Center ( Site 3316), Fukuoka,, Fukuoka, 811-1395, Japan|Kurume University Hospital ( Site 3317), Kurume, Fukuoka, 830-0011, Japan|Gunma Prefectural Cancer Center ( Site 3302), Ota, Gunma, 373-8550, Japan|Kanazawa University Hospital ( Site 3308), Kanazawa, Ishikawa, 920-8641, Japan|St. Marianna University Hospital ( Site 3320), Kawasaki, Kanagawa, 216-8511, Japan|Matsusaka Municipal Hospital ( Site 3311), Matsusaka, Mie, 515-8544, Japan|Miyagi Cancer Center ( Site 3301), Natori, Miyagi, 981-1293, Japan|Sendai Kousei Hospital ( Site 3300), Sendai, Miyagi, 981-0914, Japan|Kansai Medical University Hospital ( Site 3312), Hirakata, Osaka, 573-1191, Japan|Osaka Medical and Pharmaceutical University Hospital ( Site 3313), Takatsuki, Osaka, 569-8686, Japan|Nippon Medical School Hospital ( Site 3306), Bunkyo, Tokyo, 113-8603, Japan|Toho University Omori Medical Center ( Site 3319), Ota, Tokyo, 143-8541, Japan|Tokyo Medical University Hospital ( Site 3307), Shinjuku, Tokyo, 160-0023, Japan|National Center for Global Health and Medicine ( Site 3305), Shinjuku, Tokyo, 162-8655, Japan|Chiba University Hospital ( Site 3322), Chiba, 260-8677, Japan|Hiroshima City Hiroshima Citizens Hospital ( Site 3314), Hiroshima, 730-8518, Japan|Saiseikai Kumamoto Hospital ( Site 3318), Kumamoto, 861-4193, Japan|Osaka Metropolitan University Hospital ( Site 3321), Osaka, 545-8586, Japan|The Catholic University of Korea, Incheon St. Mary's Hospital ( Site 3606), Bupyeong-gu, Incheon, 21431, Korea, Republic of|Chonnam National University Hwasun Hospital-Pulmonology ( Site 3604), Hwasun, Jeonranamdo, 58128, Korea, Republic of|The Catholic University Of Korea St. Vincent's Hospital-Medical Oncology ( Site 3600), Suwon-si, Kyonggi-do, 16247, Korea, Republic of|Pusan National University Yangsan Hospital-Lung Cancer Clinic ( Site 3603), Yangsan, Kyongsangnam-do, 50612, Korea, Republic of|Chungnam national university hospital ( Site 3602), Jung-gu, Taejon-Kwangyokshi, 35015, Korea, Republic of|Kyung Hee University Hospital ( Site 3605), Seoul, 02447, Korea, Republic of|Korea University Guro Hospital ( Site 3601), Seoul, 08308, Korea, Republic of|ArkÃ© SMO S.A. de C.V. ( Site 0602), Mexico, Distrito Federal, 06700, Mexico|Oaxaca Site Management Organization S.C. ( Site 0603), Oaxaca, 68000, Mexico|Ziekenhuis St. Jansdal-Poli Longziekten ( Site 1701), Harderwijk, Gelderland, 3844 DG, Netherlands|Isala, locatie Zwolle-Poli Longziekten ( Site 1700), Zwolle, Overijssel, 8025 AB, Netherlands|Universitair Medisch Centrum Utrecht ( Site 1704), Utrecht, 3584 CX, Netherlands|Auckland City Hospital ( Site 3400), Auckland, 1023, New Zealand|Lung Center of the Philippines-Pulmonary, Critical Care and Sleep Medicine ( Site 3503), Quezon City, National Capital Region, 1100, Philippines|Veterans Memorial Medical Center-Section of Oncology ( Site 3505), Quezon City, National Capital Region, 1100, Philippines|Centrul de Oncologie Sfantul Nectarie-Medical ( Site 1994), Craiova, Dolj, 200542, Romania|Cabinet Medical Oncomed ( Site 1998), TimiÈoara, Timis, 300239, Romania|SC ONCO CARD SRL ( Site 1995), Brasov, 500052, Romania|Institutul Oncologic Cluj-Oncologie Medicala ( Site 1999), Cluj, 400015, Romania|Sigmedical Services SRL ( Site 1997), Suceava, 720214, Romania|Hospital Insular de Gran Canaria-Oncology ( Site 2019), Las Palmas de Gran Canaria, Las Palmas, 35001, Spain|HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÃON-ONCOLOGY ( Site 2012), Madrid, Madrid, Comunidad De, 28009, Spain|H.R.U MÃ¡laga - Hospital General-Oncology ( Site 2014), MÃ¡laga, Malaga, 29011, Spain|Hospital Universitari Vall d Hebron ( Site 2010), Barcelona, 08035, Spain|Hospital Universitario FundaciÃ³n JimÃ©nez DÃ­az-Oncology & Hematology ( Site 2017), Madrid, 28040, Spain|Hospital Universitario Virgen Macarena-Unidad de InvestigaciÃ³n OncolÃ³gica ( Site 2015), Sevilla, 41009, Spain|Adana Medical Park Seyhan Hastanesi-Medikal Onkoloji ( Site 2107), Adana, 01140, Turkey|SBU GULHANE EGITIM VE ARASTIRMA HASTANESI Onkoloji ( Site 2104), Ankara, 06010, Turkey|Hacettepe Universite Hastaneleri-oncology hospital ( Site 2101), Ankara, 06230, Turkey|Memorial Ankara Hastanesi-Medical Oncology ( Site 2106), Ankara, 06520, Turkey|Medipol Mega Universite Hastanesi-oncology ( Site 2105), Istanbul, 34214, Turkey|COMMUNAL NONPROFIT ENTERPRISE ""CLINICAL CENTER OF ONCOLOGY, HEMATOLOGY, TRANSPLANTOLOGY AND PALLIATI ( Site 2209), Cherkasy, Cherkaska Oblast, 18009, Ukraine|Regional Municipal Non-profit Enterprise ""Bukovinian Clinica-structural unit of the clinical trials ( Site 2210), Chernivtsi, Chernivetska Oblast, 58013, Ukraine|Medical Center ""Mriya Med-Service""-Clinical Research Department ( Site 2215), Kryvyi Rih, Dnipropetrovska Oblast, 50000, Ukraine|Communal Non-Commercial Enterprise ""Prykarpatski Clinical On-Surgery department #2 ( Site 2202), Ivano-Frankivsk, Ivano-Frankivska Oblast, 76018, Ukraine|Kirovohrad Regional Oncology Center-Chemotherapy department ( Site 2204), Kropyvnytskyi, Kirovohradska Oblast, 25011, Ukraine|Medical Center ""MedOffice Group"" ( Site 2219), Kiev, Kyivska Oblast, 03022, Ukraine|Municipal non-profit enterprise ""Lviv Territorial Medical Union ""Multidisciplinary Clinical Hospital ( Site 2217), Lviv, Lvivska Oblast, 79059, Ukraine|Rivne Regional Clinical Hospital ( Site 2205), Rivne, Rivnenska Oblast, 33007, Ukraine|Communal Noncommercial Enterprise ""Podillia Regional Oncolog-Cardiothoracic department ( Site 2211), Vinnytsia, Vinnytska Oblast, 21029, Ukraine|ME Volyn Regional Clinical Hospital of the Volyn Regional Council ( Site 2216), Lutsk, Volynska Oblast, 43018, Ukraine",
NCT04848753,Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma,https://clinicaltrials.gov/study/NCT04848753,,ACTIVE_NOT_RECRUITING,"This is a randomized, placebo-controlled, multi-center, double-blinded, Phase III study to determine the efficacy and safety of patients with locally advanced squamous cell carcinoma of the thoracic esophagus treated with perioperative immunotherapy combined with neoadjuvant chemotherapy versus placebo combined with neoadjuvant chemotherapy.",NO,Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma,COMBINATION_PRODUCT: Toripalimab combined with cisplatin and paclitaxel|COMBINATION_PRODUCT: Placebo combined with cisplatin and paclitaxel,"To compare IRC-assessed events-free survival (EFS) in 2 arms, From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed approximately up to 60 months","pathologically complete remission (pCR) rate, To compare the percentage of patients who achieved pCR in the 2 arms, pCR rate was defined as the percentage of subjects who achieved a complete pathological response (PCR), From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed approximately up to 60 months|Investigator-assessed EFS according to RECIST v1.1, To compare Investigator-assessed events-free survival (EFS) in patients with locally advanced squamous cell carcinoma of the thoracic esophagus treated with perioperative immunotherapy combined with neoadjuvant chemotherapy versus placebo combined with neoadjuvant chemotherapy., From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed approximately up to 60 months|Overall survival, To compare Overall survival in patients with locally advanced squamous cell carcinoma of the thoracic esophagus treated with perioperative immunotherapy combined with neoadjuvant chemotherapy versus placebo combined with neoadjuvant chemotherapy., From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed approximately up to 60 months|1-year OS rate, To compare 1-year OS rates in patients with locally advanced squamous cell carcinoma of the thoracic esophagus treated with perioperative immunotherapy combined with neoadjuvant chemotherapy versus placebo combined with neoadjuvant chemotherapy, from randomization to death from any cause at 1 year|3- year OS rate, To compare 3-year OS rates in patients with locally advanced squamous cell carcinoma of the thoracic esophagus treated with perioperative immunotherapy combined with neoadjuvant chemotherapy versus placebo combined with neoadjuvant chemotherapy, from randomization to death from any cause at 3 year|5- year OS rate, To compare 5-year OS rates in patients with locally advanced squamous cell carcinoma of the thoracic esophagus treated with perioperative immunotherapy combined with neoadjuvant chemotherapy versus placebo combined with neoadjuvant chemotherapy, from randomization to death from any cause at 5 year",,"Shanghai Junshi Bioscience Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,663,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-06-23,2027-05-12,2027-05-12,2021-04-19,,2023-07-21,"The Firest Affiliated Hospital of bengbu Medical College, Bengbu, Anhui, China|Anhui provincial hospital, Hefei, Anhui, 230001, China|The Second Hospital of anhui Medical University, Hefei, Anhui, China|Jiangmen central Hospital, Jiangmen, Guangdong, China|Shenzhen people's hosptial, Shenzhen, Guangdong, 518040, China|The fourth hospital of hebei medical university, Shijiazhuang, Hebei, 050019, China|Anyang Cancer Hospital, Anyang, Henan, China|The First Affiliated Hospital of xinxiang Medical University, Xinxiang, Henan, China|Henan provincial pepples hospital, Zhengzhou, Henan, 450003, China|The first affilated hospital of zhengzhou university, Zhengzhou, Henan, 450052, China|Hunan provincial cancer hospital, Changsha, Hunan, 410013, China|China-Japan Union hosptial of Jilin university, Changchun, Jilin, 130031, China|The first affiliated hospital of jinzhou medical university, Jinzhou, Niaoning, 121001, China|Shanxi provincial cancer hosptial, Taiyuan, Shanxi, 030013, China|Affiliated Tumor Hospital of Xinjiang Medical University, ÃrÃ¼mqi, Xinjiang, China|Hwa Mei Hospital,University of Chinese Academy of sciences, Ningbo, Zhejiang, 315010, China|Taizhou hospital of zhejiang province, Taizhou, Zhejiang, 317000, China|Beijing Cancer Hospital, Beijing, China|Peking University Third Hospital, Beijing, China|The General Hospital of People's Liberation Army, Beijing, China|Heping Hospital Affiliated to changzhi Medical College, Changzhi, China|Sichuan Cancer Hospital & Institute, Chengdu, China|Fujian Cancer Hospital, Fuzhou, China|3201 Hospital, Hangzhou, China|Zhejiang Cancer Hospital, Hangzhou, China|The First Affiliated Hospital, Zhejiang University School of Medicine, Hanzhou, China|harbin medical university Cancer Hospital, Harbin, China|Anhui Provincial Cancer Hospital, Hefei, China|Huai'an First People's Hospital, Huai'an, China|The Affiliated Hospital of jining Medical University, Jining, China|The First Affiliated Hospital of nanchang University, Nanchang, China|Jiangsu Cancer Hospital, Nanjing, China|The Affiliated Hospital of Qingdao University, Qingdao, China|Zhongshan Hospital Fudan University, Shanghai, China|Shantou University Cancer Hospital, Shantou, China|Liaoning cancer hospital& Institute, Shenyang, China|Shengjing Hospital of China Medical University, Shenyang, China|The first Hospital of china Medical University, Shenyang, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, China|Hubei Cancer Hospital, Wuhan, China|Renmin Hospital of Wuhan University, Wuhan, China|Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China|The First Affiliated Hospital of Xiamen University, Xiamen, China|Zhongshan Hospital Affiliated to Xiamen University, Xiamen, China|Xinyang central Hospital, Xinyang, China|The Affiliated Hospital of xuzhou Medical University, Xuzhou, China|Yantai yuhuangding Hospital, Yantai, China|Henan Cancer Hospital, Zhengzhou, China",
NCT04862663,Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292),https://clinicaltrials.gov/study/NCT04862663,CAPItello-292,RECRUITING,"A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)",NO,Locally Advanced (Inoperable) or Metastatic Breast Cancer,DRUG: Capivasertib|DRUG: Fulvestrant|DRUG: Palbociclib|DRUG: Ribociclib|DRUG: Abemaciclib,"Phase Ib: 1. The number of participants with dose-limiting toxicity, as defined in the protocol., Dose-limiting toxicity as described in the protocol that is not related to disease progression, intercurrent illness or concomitant medications and that, despite optimal therapeutic intervention, meets protocol-defined criteria., Within the first 28 day cycle.|Phase Ib: 2. The number of participants with treatment-related adverse events., Data will include clinical observations, ECG parameters, clinical chemistry and haematology and vital signs assessed as the number of participants with treatment-related adverse events., From baseline up to approximately 36 months.|Phase Ib: 3. The number of participants with treatment-related serious adverse events., Data will include clinical observations, ECG parameters, clinical chemistry and haematology and vital signs assessed as the number of participants with treatment-related adverse events., From baseline up to approximately 36 months.|Phase III: 1. Progression Free Survival (PFS)., Progression Free Survival (PFS) is defined as time from randomization until progression per RECIST v1.1. as assessed by BICR or death due to any cause in the overall population, the altered population, and the confirmed non-altered population. RECIST related endpoints such as PFS, ORR, DoR, CBR will be collected., Up to approximately 47 months.","Phase Ib: 1. PK parameters for Palbociclib, Ribociclib, Abemaciclib: Cmax., Maximum observed plasma (peak) drug concentration., Cycle 0 (Cycle 0 is 3 days), Cycle 1 Day 11 and Cycle 1 Day 14 (Cycle 1 is 28 days).|Phase Ib: 2. PK parameters for Palbociclib, Ribociclib, Abemaciclib: AUC0-72h., Partial area under the plasma concentration-time curve from zero to 72 hours post-dose., Cycle 0 (Cycle 0 is 3 days).|Phase Ib: 3. PK parameters for Palbociclib, Ribociclib, Abemaciclib: AUC0-24h., Partial area under the plasma concentration-time curve from zero to 24 hours post-dose., Cycle 0 (Cycle 0 is 3 days), Cycle 1 Day 11 and Cycle 1 Day 14 (Cycle 1 is 28 days).|Phase Ib: 4. PK parameters for Palbociclib, Ribociclib, Abemaciclib: Cmin., Minimum observed plasma drug concentration., Cycle 1 Day 11 and Cycle 1 Day 14 (Cycle 0 is 3 days and Cycle 1 is 28 days).|Phase Ib: 5. PK parameters for capivasertib: Cmax., Maximum observed plasma (peak) drug concentration., Cycle 1 Day 11 (Cycle 0 is 3 days and Cycle 1 is 28 days).|Phase Ib: 6. PK parameters for capivasertib: AUC0-12h., Partial area under the plasma concentration-time curve from zero to 12 hours post-dose., Cycle 1 Day 11 (Cycle 0 is 3 days and Cycle 1 is 28 days).|Phase Ib: 7. PK parameters for capivasertib: Cmin., Minimum observed plasma drug concentration., Cycle 1 Day 11 (Cycle 0 is 3 days and Cycle 1 is 28 days).|Phase Ib: 8. Objective Response Rate (ORR)., Objective Response Rate (ORR) is defined as the proportion of patients with measurable disease at baseline who have a confirmed complete response (CR) or confirmed partial response (PR), as determined by the investigator at local site per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)., Up to approximately 36 months.|Phase Ib: 9. Clinical Benefit Rate (CBR) at 24 weeks., Clinical Benefit Rate (CBR) 24 weeks is defined as the percentage of patients who have a CR or PR or who have SD per RECIST v1.1 as assessed by the investigator at local site for at least 23 weeks after date of first dose., Up to approximately 36 months.|Phase Ib: 10. Duration of Response (DoR)., Duration of Response (DoR) will be defined as the time from the date of first documented confirmed response until date of documented progression per RECIST v1.1 as assessed by the investigator at local site or death due to any cause., Up to approximately 36 months.|Phase Ib: 11. Progression Free Survival (PFS)., Progression Free Survival (PFS) is defined as time from date of first dose until progression per RECIST v1.1. as assessed by the investigator at local site or death due to any cause., Up to approximately 36 months.|Phase III: 1. Overall Survival (OS)., Overall survival (OS) - time from randomization until the date of death due to any cause, secondary outcome measure in participants with HR+/HER2- locally advanced or metastatic breast cancer with gene alteration in PIK3CA/AKT1/PTEN - altered population, confirmed non-altered population and overall population., Up to approximately 69 months.|Phase III: 2. Objective Response Rate (ORR)., Objective Response Rate (ORR) - the proportion of patients who have a complete or partial response, as determined by BICR per RECIST v1.1 in participants with HR+/HER2- locally advanced or metastatic breast cancer with gene alteration in PIK3CA/AKT1/PTEN - altered population, confirmed non-altered population and overall population., Up to approximately 47 months.|Phase III: 3. Progression Free Survival 2 (PFS2), Progression Free Survival 2 (PFS2) - time from randomization to the earliest of the progression event, after first subsequent therapy or death., Up to approximately 69 months.|Phase III: 4. Duration of Response (DoR)., Duration of Response (DoR) - the time from the date of first documented response until the date of progression per RECIST v1.1 as assessed by BICR, or death due to any cause., Up to approximately 47 months.|Phase III: 5. Clinical Benefit Rate (CBR) at 24 weeks., Clinical Benefit Rate (CBR) at 24 weeks-the % of patients who have a CR or PR or who have SD per RECIST v1.1 as assessed by BICR for at least 23 weeks after randomisation., Up to approximately 47 months.|Phase III: 6. Participant-reported physical functioning, TTD of physical functioning as measured by the physical functioning subscale of the EORTC QLQ-C30., Up to approximately 69 months.|Phase III: 7. Participant-reported GHS/QoL in participants, TTD of GHS/QoL as measured by the GHS/QoL subscale of the EORTC QLQ-C30., Up to approximately 69 months.|Phase III: 8. Participant-reported overall side effect bother in participants in the capivasertib arm relative to control arm, Proportion of participants experiencing different levels of overall treatment tolerability as measured by the Patient Global Impression-Treatment Tolerability (PGI-TT)., Up to approximately 69 months.|Phase III: 9. Plasma concentration of capivasertib pre- and post-dose., Plasma concentration of capivasertib pre-, and post-dose., Up to approximately 69 months.|Phase III: 10. The number of participants with adverse events., Data will include clinical observations, ECG parameters, clinical chemistry / haematology / glucose metabolism parameters and vital signs assessed as the number of participants with adverse events., Up to approximately 69 months.|Phase III: 11. The number of participants with serious adverse events., Data will include clinical observations, ECG parameters, clinical chemistry / haematology / glucose metabolism parameters and vital signs assessed as the number of participants with serious adverse events., Up to approximately 69 months.",,AstraZeneca,,ALL,"ADULT, OLDER_ADULT",PHASE3,895,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-05-10,2027-11-01,2029-08-14,2021-04-28,,2025-03-25,"Research Site, Tucson, Arizona, 85719, United States|Research Site, Fountain Valley, California, 92708, United States|Research Site, Glendale, California, 91204, United States|Research Site, Los Angeles, California, 90033, United States|Research Site, Los Angeles, California, 90048, United States|Research Site, Napa, California, 94558, United States|Research Site, Newport Beach, California, 92663, United States|Research Site, San Francisco, California, 94158, United States|Research Site, Santa Barbara, California, 93105, United States|Research Site, Santa Rosa, California, 92805, United States|Research Site, Aurora, Colorado, 80045, United States|Research Site, New Haven, Connecticut, 06510, United States|Research Site, Newark, Delaware, 19713, United States|Research Site, Quincy, Illinois, 62305, United States|Research Site, Fort Wayne, Indiana, 46804, United States|Research Site, Louisville, Kentucky, 40202, United States|Research Site, Louisville, Kentucky, 40202, United States|Research Site, Baton Rouge, Louisiana, 70809, United States|Research Site, Covington, Louisiana, 70433, United States|Research Site, Annapolis, Maryland, 21401, United States|Research Site, Baltimore, Maryland, 21202, United States|Research Site, Baltimore, Maryland, 21229, United States|Research Site, Boston, Massachusetts, 02215, United States|Research Site, Detroit, Michigan, 48236, United States|Research Site, Grand Rapids, Michigan, 49503, United States|Research Site, Hannibal, Missouri, 63401, United States|Research Site, Saint Louis, Missouri, 63110, United States|Research Site, Omaha, Nebraska, 68130, United States|Research Site, Camden, New Jersey, 08103, United States|Research Site, Brooklyn, New York, 11220, United States|Research Site, Mineola, New York, 11501, United States|Research Site, New York, New York, 10016, United States|Research Site, New York, New York, 10065, United States|Research Site, Durham, North Carolina, 27710, United States|Research Site, Gresham, Oregon, 97030, United States|Research Site, Philadelphia, Pennsylvania, 19104, United States|Research Site, Pittsburgh, Pennsylvania, 15213, United States|Research Site, York, Pennsylvania, 17403, United States|Research Site, Providence, Rhode Island, 02903, United States|Research Site, Greenville, South Carolina, 29607, United States|Research Site, Chattanooga, Tennessee, 37404, United States|Research Site, Nashville, Tennessee, 37203, United States|Research Site, Dallas, Texas, 75246, United States|Research Site, Fort Worth, Texas, 76104, United States|Research Site, Houston, Texas, 77030, United States|Research Site, San Antonio, Texas, 78229, United States|Research Site, San Antonio, Texas, 78240, United States|Research Site, Falls Church, Virginia, 22042, United States|Research Site, Leesburg, Virginia, 20176, United States|Research Site, Midlothian, Virginia, 23114, United States|Research Site, Norfolk, Virginia, 23502, United States|Research Site, Tacoma, Washington, 98405, United States|Research Site, Buenos Aires, 1439, Argentina|Research Site, Buenos Aires, C1125ABD, Argentina|Research Site, Caba, 1414, Argentina|Research Site, Caba, 1425, Argentina|Research Site, Caba, C1425, Argentina|Research Site, Chivilcoy, B6620LUD, Argentina|Research Site, Rosario, 2000, Argentina|Research Site, Santa Fe, S2002RE, Argentina|Research Site, Darlinghurst, 2010, Australia|Research Site, Miranda, 2228, Australia|Research Site, Nedlands, 6009, Australia|Research Site, Nedlands, 6009, Australia|Research Site, Wahroonga, 2076, Australia|Research Site, Waratah, 2298, Australia|Research Site, Brasschaat, 2930, Belgium|Research Site, Bruxelles, 1200, Belgium|Research Site, Edegem, 2650, Belgium|Research Site, Haine-Saint-Paul, 7100, Belgium|Research Site, Leuven, 3000, Belgium|Research Site, Alfenas, 37130-000, Brazil|Research Site, Blumenau, 89010-340, Brazil|Research Site, Natal, 59075-740, Brazil|Research Site, Porto Alegre, 90035-903, Brazil|Research Site, Porto Velho, 76834-899, Brazil|Research Site, SÃ£o Paulo, 04014-002, Brazil|Research Site, TaubatÃ©, 12030-200, Brazil|Research Site, Teresina, 64049-200, Brazil|Research Site, Vitoria, 29043-260, Brazil|Research Site, Abbotsford, British Columbia, V2S0C2, Canada|Research Site, Kelowna, British Columbia, V1Y 5L3, Canada|Research Site, Winnipeg, Manitoba, R3E 0V9, Canada|Research Site, Moncton, New Brunswick, E1C 6Z8, Canada|Research Site, Halifax, Nova Scotia, B3H 1V7, Canada|Research Site, Brampton, Ontario, L6R 3J7, Canada|Research Site, Ottawa, Ontario, K1H 8L6, Canada|Research Site, Sault Ste. Marie, Ontario, P6A 2C4, Canada|Research Site, Toronto, Ontario, M5B 1W8, Canada|Research Site, Sherbrooke, Quebec, J1H 5N4, Canada|Research Site, Chicoutimi, G7H 5H6, Canada|Research Site, Montreal, H3T 1E2, Canada|Research Site, Beijing, 100039, China|Research Site, Beijing, 100044, China|Research Site, Beijing, 100191, China|Research Site, Beijing, 100210, China|Research Site, Bengbu, 233060, China|Research Site, Changchun, 130000, China|Research Site, Changsha, 410013, China|Research Site, Chengdu, 610041, China|Research Site, Chongqing, 400042, China|Research Site, Guangzhou, 510060, China|Research Site, Guangzhou, 510062, China|Research Site, Guangzhou, 510080, China|Research Site, Hangzhou, 31000, China|Research Site, Hangzhou, 310016, China|Research Site, Hangzhou, 310022, China|Research Site, Hefei, 230031, China|Research Site, Jinan, 250001, China|Research Site, Nanchang, 330006, China|Research Site, Nanchang, 330009, China|Research Site, Nanjing, 210029, China|Research Site, Nanning, 530021, China|Research Site, Shandong, China|Research Site, Shanghai, 200032, China|Research Site, Shenyang, 110001, China|Research Site, Shenyang, 110016, China|Research Site, Urumqi, 830000, China|Research Site, Urumqi, 830000, China|Research Site, Wuhan, 430060, China|Research Site, Xi'an, 710061, China|Research Site, Xiangyang City, 441000, China|Research Site, Xian, 710100, China|Research Site, Xuzhou, 221009, China|Research Site, Zhengzhou, 450008, China|Research Site, Aalborg, 9000, Denmark|Research Site, Aarhus N, 8200, Denmark|Research Site, HillerÃ¸d, 3400, Denmark|Research Site, Odense C, 5000, Denmark|Research Site, Bobigny, 93000, France|Research Site, Clermont Ferrand, 63011, France|Research Site, Limoges, 87042, France|Research Site, Lyon, 69008, France|Research Site, Plerin, 22190, France|Research Site, Rouen, 76021, France|Research Site, St Herblain, 44805, France|Research Site, Villejuif, 94805, France|Research Site, Augsburg, 86150, Germany|Research Site, Berlin, 10967, Germany|Research Site, Berlin, 13125, Germany|Research Site, Bottrop, 46236, Germany|Research Site, Dresden, 01307, Germany|Research Site, Erlangen, 91054, Germany|Research Site, Frankfurt am Main, 65929, Germany|Research Site, Freiburg, 79106, Germany|Research Site, GeorgsmarienhÃ¼tte, 49124, Germany|Research Site, Hamburg, 20357, Germany|Research Site, Hannover, 30625, Germany|Research Site, Heilbronn, 74078, Germany|Research Site, Kiel, 24105, Germany|Research Site, Leipzig, 04103, Germany|Research Site, Mannheim, 68167, Germany|Research Site, MÃ¶nchengladbach, 41061, Germany|Research Site, MÃ¼nster, 48149, Germany|Research Site, Regensburg, 93053, Germany|Research Site, Stade, 21680, Germany|Research Site, Trier, 54290, Germany|Research Site, Ulm, 89075, Germany|Research Site, Bangalore, 560004, India|Research Site, Jaipur, 302017, India|Research Site, JAipur, 302022, India|Research Site, Mohali, 160055, India|Research Site, Mysuru, 570017, India|Research Site, Nagpur, 440001, India|Research Site, New Delhi, 110075, India|Research Site, New Delhi, 110076, India|Research Site, Pondicherry, 605006, India|Research Site, Vadodara, 391760, India|Research Site, Varanasi, 221005, India|Research Site, Aviano, 33081, Italy|Research Site, Bologna, 40138, Italy|Research Site, Catanzaro, 88100, Italy|Research Site, Firenze, 50141, Italy|Research Site, Milano, 20132, Italy|Research Site, Milan, 20141, Italy|Research Site, Misterbianco, 95045, Italy|Research Site, Napoli, 80131, Italy|Research Site, Padova, 35128, Italy|Research Site, Prato, 59100, Italy|Research Site, Reggio Emilia, 422122, Italy|Research Site, Roma, 00168, Italy|Research Site, Rozzano, 20089, Italy|Research Site, Chiba-shi, 260-8717, Japan|Research Site, Chuo-ku, 104-0045, Japan|Research Site, Chuo-ku, 104-8560, Japan|Research Site, Hidaka-shi, 350-1298, Japan|Research Site, Hirakata-shi, 573-1191, Japan|Research Site, Hiroshima-shi, 730-8518, Japan|Research Site, Isehara-shi, 259-1193, Japan|Research Site, Kagoshima-shi, 892-0833, Japan|Research Site, Koto-ku, 135-8550, Japan|Research Site, Kyoto-shi, 606-8507, Japan|Research Site, Matsuyama-shi, 791-0280, Japan|Research Site, Nagoya-shi, 464-8681, Japan|Research Site, Naha-shi, 901-0154, Japan|Research Site, Okayama-shi, 700-8558, Japan|Research Site, Osaka-shi, 541-8567, Japan|Research Site, Ota-shi, 373-8550, Japan|Research Site, Sapporo-shi, 060-8638, Japan|Research Site, Sendai-shi, 980-8574, Japan|Research Site, Shimotsuke-shi, 329-0498, Japan|Research Site, Shinagawa-ku, 142-8666, Japan|Research Site, Shinjuku-ku, 162-8655, Japan|Research Site, Suita-shi, 565-0871, Japan|Research Site, Takasaki-shi, 370-0829, Japan|Research Site, Tsu-shi, 514-8507, Japan|Research Site, Yokohama-shi, 241-8515, Japan|Research Site, Goyang-si, 10408, Korea, Republic of|Research Site, Seoul, 02841, Korea, Republic of|Research Site, Seoul, 03080, Korea, Republic of|Research Site, Seoul, 03722, Korea, Republic of|Research Site, Seoul, 06273, Korea, Republic of|Research Site, Seoul, 06351, Korea, Republic of|Research Site, Seoul, 5505, Korea, Republic of|Research Site, George Town, 10350, Malaysia|Research Site, Kuala Lumpur, 50586, Malaysia|Research Site, Kuala Lumpur, 59100, Malaysia|Research Site, Kuching, 93586, Malaysia|Research Site, Pulau Pinang, 10450, Malaysia|Research Site, Selangor, 46050, Malaysia|Research Site, Selangor, 62250, Malaysia|Research Site, Bialystok, 15-027, Poland|Research Site, Bydgoszcz, 85-796, Poland|Research Site, GdaÅsk, 80-952, Poland|Research Site, Koszalin, 75-581, Poland|Research Site, KrakÃ³w, 31-501, Poland|Research Site, Lodz, 91-211, Poland|Research Site, Lublin, 20-090, Poland|Research Site, RzeszÃ³w, 35-326, Poland|Research Site, Warszawa, 02-781, Poland|Research Site, Warszawa, 02-781, Poland|Research Site, ÅÃ³dÅº, 90-302, Poland|Research Site, Barcelona, 8035, Spain|Research Site, Granada, 18014, Spain|Research Site, LÃ©rida, 25198, Spain|Research Site, Madrid, 28034, Spain|Research Site, Madrid, 28040, Spain|Research Site, Madrid, 28046, Spain|Research Site, MÃ¡laga, 29010, Spain|Research Site, Pamplona, 31008, Spain|Research Site, Santiago de Compostela, 15706, Spain|Research Site, Lund, 221 85, Sweden|Research Site, Solna, 17176, Sweden|Research Site, VÃ¤xjÃ¶, 35185, Sweden|Research Site, Kaohsiung, 80756, Taiwan|Research Site, Kaohsiung, 83301, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, 704, Taiwan|Research Site, Taipei, 10002, Taiwan|Research Site, Taipei, 10449, Taiwan|Research Site, Taoyuan, 333, Taiwan|Research Site, Bangkok, 10210, Thailand|Research Site, Bangkok, 10330, Thailand|Research Site, Bangkok, 10400, Thailand|Research Site, Bangkok, 10400, Thailand|Research Site, Bangkok, 10700, Thailand|Research Site, Chiang Mai, 50200, Thailand|Research Site, Dusit, 10300, Thailand|Research Site, Hat Yai, 90110, Thailand|Research Site, Khon Kaen, 40002, Thailand|Research Site, Lampang, 52000, Thailand|Research Site, Ratchathewi, 10400, Thailand|Research Site, Ankara, 6100, Turkey|Research Site, Antalya, 07070, Turkey|Research Site, Goztepe Istanbul, Turkey|Research Site, Karsiyaka, 35575, Turkey|Research Site, Kayseri, 38039, Turkey|Research Site, Malatya, 44280, Turkey|Research Site, Samsun, 55200, Turkey|Research Site, Derry, BT47 6SB, United Kingdom|Research Site, Guildford, CU2 7XX, United Kingdom|Research Site, London, SE1 9RT, United Kingdom|Research Site, Taunton, TA1 5DA, United Kingdom|Research Site, York, YO21 8HE, United Kingdom|Research Site, Hanoi, 100000, Vietnam|Research Site, Ho Chi Minh city, 700000, Vietnam|Research Site, Ho Chi Minh, 70000, Vietnam|Research Site, Vinh, 460000, Vietnam",
NCT05939414,An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.,https://clinicaltrials.gov/study/NCT05939414,PSMA-DC,RECRUITING,The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. The data generated from this study will provide evidence for the treatment of AAA617 in early-stage prostate cancer patients to control recurrent tumor from progressing to fatal metastatic disease while preserving quality of life by delaying treatment with androgen deprivation therapy (ADT).,NO,Oligometastatic Prostate Cancer (OMPC),DRUG: AAA617,"Blinded Independent Review Committee (BIRC) assessed Metastasis Free Survival (MFS), Blinded Independent Review Committee (BIRC) assessed Metastasis Free Survival (MFS) is defined as the time from randomization to first evidence of radiographically detectable bone or soft tissue distant metastasis by conventional imaging (i.e., Computed Tomography (CT)/Magnetic Resonance Imaging (MRI) and bone scans) as assessed by BIRC using RECIST 1.1 or death due to any cause, whichever occurs first.

Participants who are alive without distant metastasis at the analysis data cut-off or are lost to follow-up at the time of analysis will be censored for MFS at the time of their last adequate radiographic assessment. Clinical deterioration without objective radiographic evidence will not be considered as documented distant metastasis., From date of randomization until first evidence of radiographically detectable bone or soft tissue distant metastasis or death due to any cause, whichever occurs first, assessed up to approximately 30 months","Key secondary endpoint: Time to Hormonal Therapy (TTHT), Time to Hormonal Therapy (TTHT) is defined as the time from randomization to the time to Androgen Deprivation Therapy (ADT). The type of hormonal therapy will be at the discretion of the Investigator., From date of randomization until date of Androgen Deprivation Therapy (ADT), assessed up to approximately 74 months|Investigator assessed Metastasis Free Survival (MFS), Investigator assessed Metastasis Free Survival (MFS) is defined as the time from randomization to the first evidence of radiographically detectable bone or soft tissue distant metastasis by conventional imaging (i.e., CT/MRI and bone scans) as assessed by Investigator using RECIST 1.1 or death from any cause, whichever occurs first., From date of randomization until first evidence of radiographically detectable bone or soft tissue distant metastasis or death from any cause, whichever occurs first, assessed up to approximately 74 months|Time to prostate specific antigen (PSA) progression (TTPSAP), Time to prostate specific antigen (PSA) progression (TTPSAP) is defined as time from randomization to first PSA progression 1. First PSA progression 1 is defined as a rising PSA confirmed on repeated measurement at least 3 weeks later, and at least greater than 25% and \>= 2 ng/mL above nadir or baseline, whichever is lower. In the absence of PSA progression, TTPSAP will be censored at the last PSA measurement., From date of randomization until date of first PSA progression, assessed up to approximately 74 months|Radiographic Progression Free Survival (rPFS), Radiographic progression free survival (rPFS) is defined as the time from randomization to first documentation of confirmed radiographic progressive disease or death due to any cause (whichever occurs first) by conventional imaging (i.e., CT/MRI and bone scans) using RECIST 1.1. The rPFS will be analyzed based on BIRC and Investigator assessments respectively., From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to approximately 74 months|Time to next therapy (local or systemic), Time to next therapy (local or systemic) is defined as the time from randomization to initiation of the next line of therapy (local or systemic). Next-line therapy is defined as the first new (local or systemic) anti-neoplastic therapy initiated after discontinuation of study treatment regardless of end of treatment (EOT) reason., From date of randomization until initiation of the next line of therapy (local or systemic), assessed up to approximately 74 months|24-month prostate-specific antigen (PSA) progression free survival (PFS), 24-month PSA PFS is defined as PSA PFS at 24 months. PSA PFS is defined as the time from date of randomization to the date of first documented PSA progression 2 or death from any cause, whichever occurs first. PSA progression 2 is defined as a PSA concentration above the nadir (or baseline if lower) of \>= 0.5 ng/mL, confirmed by repeated measurement at least 3 weeks later. PSA PFS will be censored if no PSA PFS event is observed before the first to occur analysis cut-off date. The censoring date will be the date of the last adequate tumor assessment prior to cut-off., From date of randomization until date of first documented PSA progression 2 or death from any cause, whichever occurs first, assessed up to approximately 74 months|Time to symptomatic progression, Time to symptomatic progression is defined as time from randomization to the date of first documented event for any of the following, whichever occurs first: development of symptomatic skeletal event, escalation in cancer-related pain or worsening of disease-related symptoms leading to the initiation of a new systemic anticancer therapy, development of clinically significant symptoms due to local or regional tumor progression leading to surgery or radiation therapy., From date of randomization until date of first documented symptomatic progression, assessed up to approximately 74 months|Functional Assessment of Cancer Therapy - Prostate (FACT-P) Questionnaire, FACT-P assesses symptoms/problems related to prostate carcinoma and its treatment. It is a combination of the FACT- General + the Prostate Cancer Subscale (PCS). The FACTGeneral (FACT-G) is a 27 item Quality of Life (QoL) measure that provides a total score as well as subscale scores: Physical (0-28), Functional (0-28), Social (0-28), and Emotional Well-being (0-24). The total score range is between 1-108, higher scores indicates better for total score and subscale scores. PCS is a 12-item prostate cancer subscale that asks about symptoms and problems specific to prostate cancer (Range 0-48, higher scores better). The FACT-P total score is the sum of all 5 subscale scores of the FACT-P questionnaire and ranges from 0-156. Higher scores indicate higher degree of functioning and better quality of life., From date of randomization up till 42 day safety Follow-up, assessed up to approximately 74 months|Functional Assessment of Cancer Therapy - Radionuclide Therapy (FACT-RNT) Questionnaire, The FACT-RNT (Functional Assessment of Cancer Therapy - Radionuclide Therapy) is a Patient Reported Outcomes (PRO) new measure developed using FACIT specific questions (items), selected from FACIT item bank, to assess treatment-related symptoms of special interest associated with radioligand therapies.

The FACT-RNT contains items assessing dry mouth, dry eyes, vomiting, diarrhea, constipation, loss of appetite, fatigue, impact of fatigue, bone pain, and isolation due to illness or treatment. FACT-RNT score range 0 to 60, with higher score indicating better quality of life., From date of randomization up till 42 day safety Follow-up, assessed up to approximately 74 months|Brief Pain Inventory - Short Form (BPI-SF) Questionnaire, The BPI-SF is a publicly available instrument to assess the pain and includes severity and interference scores. BPI-SF is an 11-item selfreport questionnaire that is designed to assess the severity and impact of pain on daily functions of a participant. Pain severity score is a mean value for BPI-SF questions 3, 4, 5 and 6 (questions inquiring about the extent of pain, where the extent is ranked from 0 \[no pain\] to 10 \[pain as bad as you can imagine\]). Pain severity progression is defined as an increase in score of 30% or greater from baseline without decrease in analgesic use., From date of randomization up till 42 day safety Follow-up, assessed up to approximately 74 months|European Quality of Life (EuroQol) - 5 Domain 5 Level scale (EQ-5D- 5L), EQ-5D-5L is a standardized participant completed questionnaire that measures health-related quality of life and translates that score into an index value or utility score. EQ-5D-5L consists of two components: a health state profile and an optional visual analogue scale (VAS). EQ-5D health state profile is comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, and 5= extreme problems. Higher scores indicated greater levels of problems across each of the five dimensions., From date of randomization up till 42 day safety Follow-up, assessed up to approximately 74 months|Time to First Symptomatic Skeletal Event (TTSE), Time to first symptomatic skeletal event (TTSSE) is defined as date of randomization to the date of first new SSE or death from any cause, whichever occurs first. Symptomatic skeletal events (SSE) will be defined by the occurrence of any of the following (whichever occurs earlier): symptomatic pathological bone fracture, spinal cord compression, tumor-related orthopedic surgical intervention, requirement for radiation therapy to relieve bone pain., From date of randomization till end of treatment (EOT) or death, whichever happens first, assessed up to approximately 74 months|Incidence and severity of adverse events (AEs) and serious adverse events (SAEs), The distribution of adverse events will be done via the analysis of frequencies for treatment emergent Adverse Event (TEAEs), Serious Adverse Event (TESAEs) and Deaths due to AEs, through the monitoring of relevant clinical and laboratory safety parameters., From date of randomization up till 42 day safety Follow-up, assessed up to approximately 74 months|Dose modifications and intensity for AAA617, Dose modifications (dose interruptions and reductions) and dose intensity for AAA617 will be assessed and summarized using descriptive statistics., From date of randomization until end of treatment (EOT), assessed up to approximately 30 months|Overall survival (OS), Overall Survival (OS) is defined as the time from the date of randomization to the date of death due to any cause. OS time for participants who are alive at the end of the study or are lost to follow-up will be censored at the date of last contact., From date of randomization until date of death from any cause, assessed up to approximately 74 months",,Novartis Pharmaceuticals,,MALE,"ADULT, OLDER_ADULT",PHASE3,450,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-03-12,2027-12-21,2030-07-09,2023-07-11,,2025-06-13,"Highlands Oncology Group, Fayetteville, Arkansas, 72703, United States|VA Palo Alto Health Care System, Palo Alto, California, 94304-1207, United States|Stanford University, Palo Alto, California, 94304, United States|UCSF, San Francisco, California, 94115, United States|Rocky Mountain Cancer Centers, Denver, Colorado, 80218, United States|Cancer Specialists of North Florida, Jacksonville, Florida, 32256, United States|Woodlands Medical Specialists, Pensacola, Florida, 32503, United States|Piedmont Cancer Institute P C, Atlanta, Georgia, 30318, United States|University of Chicago, Chicago, Illinois, 60637, United States|The Cancer Institute of Alexian Brothers, Elk Grove, Illinois, 60007, United States|University of Kansas Hospital, Kansas City, Kansas, 66160, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, 70809, United States|University of Maryland Medical Ctr, Baltimore, Maryland, 21201, United States|Johns Hopkins Kimmel Com Cancer Ctr, Baltimore, Maryland, 21231, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States|BAMF Health, Grand Rapids, Michigan, 49503, United States|Profound Research LLC, Royal Oak, Michigan, 48073, United States|Mayo Clinic Rochester, Rochester, Minnesota, 55905, United States|VA St Louis Health Care System, Saint Louis, Missouri, 63106, United States|Wash U School of Medicine, Saint Louis, Missouri, 63110, United States|Memorial Sloane Ketterin Cancer Ctr, New York, New York, 10065, United States|Dayton Physicians, Kettering, Ohio, 45409, United States|Oregon Urology Institute, Springfield, Oregon, 97477, United States|Carolina Urologic Research Center, LLC, Myrtle Beach, South Carolina, 29572, United States|Vanderbilt University Medical Center, Nashville, Tennessee, 37232, United States|Univ of Texas Southwest Med Center, Dallas, Texas, 75390-9034, United States|Rio Grande Urology, El Paso, Texas, 79912, United States|Virginia Oncology Associates, Norfolk, Virginia, 23502, United States|Blue Ridge Cancer Center, Wytheville, Virginia, 24382, United States|Novartis Investigative Site, Caba, Buenos Aires, C1181ACH, Argentina|Novartis Investigative Site, Caba, C1431FWO, Argentina|Novartis Investigative Site, Darlinghurst, New South Wales, 2010, Australia|Novartis Investigative Site, Herston, Queensland, 4029, Australia|Novartis Investigative Site, Adelaide, South Australia, 5000, Australia|Novartis Investigative Site, Malvern, Victoria, 3144, Australia|Novartis Investigative Site, Linz, 4020, Austria|Novartis Investigative Site, Wien, 1090, Austria|Novartis Investigative Site, Aalst, 9300, Belgium|Novartis Investigative Site, Gent, 9000, Belgium|Novartis Investigative Site, Wilrijk, 2610, Belgium|Novartis Investigative Site, Sao Paulo, SP, 01246 000, Brazil|Novartis Investigative Site, Calgary, Alberta, T2N 5G2, Canada|Novartis Investigative Site, London, Ontario, N6A 4G5, Canada|Novartis Investigative Site, Ottawa, Ontario, K1H 8L6, Canada|Novartis Investigative Site, Toronto, Ontario, M5G 2M9, Canada|Novartis Investigative Site, Montreal, Quebec, H2X 1R9, Canada|Novartis Investigative Site, Montreal, Quebec, H3T 1E2, Canada|Novartis Investigative Site, Quebec, G1J 1Z4, Canada|Novartis Investigative Site, Beijing, 100036, China|Novartis Investigative Site, Guangzhou, 510060, China|Novartis Investigative Site, Shanghai, 200127, China|Novartis Investigative Site, Ostrava, Poruba, 708 52, Czechia|Novartis Investigative Site, Olomouc, 779 00, Czechia|Novartis Investigative Site, Praha 5, 150 06, Czechia|Novartis Investigative Site, Saint-Cloud, Hauts De Seine, 92210, France|Novartis Investigative Site, Bordeaux, 33076, France|Novartis Investigative Site, Bron, 69677, France|Novartis Investigative Site, Clermont-Ferrand, 63011, France|Novartis Investigative Site, Rouen, 76038, France|Novartis Investigative Site, Saint Herblain, 44805, France|Novartis Investigative Site, Berlin, 10249, Germany|Novartis Investigative Site, Essen, 45147, Germany|Novartis Investigative Site, Koeln, 50937, Germany|Novartis Investigative Site, Rostock, 18057, Germany|Novartis Investigative Site, Budapest, H 1122, Hungary|Novartis Investigative Site, Budapest, H-1083, Hungary|Novartis Investigative Site, Debrecen, 4032, Hungary|Novartis Investigative Site, Beer-Sheva, 8457108, Israel|Novartis Investigative Site, Haifa, 3109601, Israel|Novartis Investigative Site, Jerusalem, 9112001, Israel|Novartis Investigative Site, Petach Tikva, 4941492, Israel|Novartis Investigative Site, Tel Aviv, 6423906, Israel|Novartis Investigative Site, Brescia, BS, 25123, Italy|Novartis Investigative Site, Cona, FE, 44100, Italy|Novartis Investigative Site, Genova, GE, 16132, Italy|Novartis Investigative Site, Milano, MI, 20141, Italy|Novartis Investigative Site, Rozzano, MI, 20089, Italy|Novartis Investigative Site, Pisa, PI, 56124, Italy|Novartis Investigative Site, Roma, RM, 00168, Italy|Novartis Investigative Site, Negrar, VR, 37024, Italy|Novartis Investigative Site, Kashiwa, Chiba, 277 8577, Japan|Novartis Investigative Site, Fukuoka city, Fukuoka, 812-8582, Japan|Novartis Investigative Site, Fukushima city, Fukushima, 960 1295, Japan|Novartis Investigative Site, Sapporo city, Hokkaido, 060 8648, Japan|Novartis Investigative Site, Kobe, Hyogo, 650-0047, Japan|Novartis Investigative Site, Kanazawa, Ishikawa, 920 8641, Japan|Novartis Investigative Site, Yokohama-city, Kanagawa, 236-0004, Japan|Novartis Investigative Site, Chuo ku, Tokyo, 104 0045, Japan|Novartis Investigative Site, Fukuoka, 811-0213, Japan|Novartis Investigative Site, Fukuoka, 812-0033, Japan|Novartis Investigative Site, Kyoto, 606 8507, Japan|Novartis Investigative Site, Petaling Jaya, Selangor, 46050, Malaysia|Novartis Investigative Site, Amsterdam, 1066 CX, Netherlands|Novartis Investigative Site, Singapore, 119228, Singapore|Novartis Investigative Site, Singapore, 168583, Singapore|Novartis Investigative Site, Bratislava, Slovak Republic, 83310, Slovakia|Novartis Investigative Site, Kosice, 041 91, Slovakia|Novartis Investigative Site, Nitra, 94901, Slovakia|Novartis Investigative Site, Trencin, 91101, Slovakia|Novartis Investigative Site, Granada, Andalucia, 18014, Spain|Novartis Investigative Site, Sevilla, Andalucia, 41013, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08025, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08036, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, 46010, Spain|Novartis Investigative Site, El Palmar, Murcia, 30120, Spain|Novartis Investigative Site, Madrid, 28040, Spain|Novartis Investigative Site, Madrid, 28041, Spain|Novartis Investigative Site, Geneve 14, 1211, Switzerland|Novartis Investigative Site, Luzern, 6006, Switzerland|Novartis Investigative Site, Zuerich, 8063, Switzerland|Novartis Investigative Site, Taipei, 10002, Taiwan|Novartis Investigative Site, Taipei, 103616, Taiwan|Novartis Investigative Site, Taipei, 11217, Taiwan|Novartis Investigative Site, Taoyuan, 33305, Taiwan|Novartis Investigative Site, Bristol, Avon, BS2 8ED, United Kingdom|Novartis Investigative Site, Sutton, Surrey, SM2 5PT, United Kingdom|Novartis Investigative Site, Coventry, CV2 2DX, United Kingdom",
NCT06855277,Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC,https://clinicaltrials.gov/study/NCT06855277,AcTFirst,NOT_YET_RECRUITING,"The purpose of this study is to determine whether \[225Ac\]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus androgen receptor pathway inhibitor (ARPI), improves the radiographic progression free survival (rPFS) compared to investigator's choice of standard of care (SOC) (ARPI change or taxane-based chemotherapy) in adult participants with PSMA-positive metastatic castration resistant prostate cancer (mCRPC) treated with another ARPI as last treatment and who have not been exposed to a taxane-containing chemotherapy in the mCRPC setting nor have received any prior PSMA-targeting radioligand therapy.",NO,Prostate Cancer,DRUG: AAA817|DRUG: ARPI|DRUG: Standard of Care,"Radiographic Progression Free Survival (rPFS), Time to radiographic disease progression or death due to any cause., From the date of randomization to the date of the first documented radiographic disease progression using conventional imaging, or death due to any cause, whichever occurs first, assessed up to approximately 40.0 months.","Overall Survival (OS) (Key Secondary Endpoint), Time to death due to any cause., From the date of randomization to the date of death due to any cause, assessed up to approximately 40 months.|Radiographic Progression Free Survival by PSMA PET/CT and (rPSF-PET)(Key Secondary), Time to radiographic disease progression, using PSMA PET/CT and (rPSF-PET), or death due to any cause., From date of randomization to the date of the first documented radiographic disease progression or death due to any cause, whichever occurs first, assessed up to approximately 40.0 months.|Progression Free Survival (PFS), Time to first documented progression or death due to any cause., From date of randomization to the first documented progression by investigator's assessment or death due to any cause, whichever occurs first, assessed up to approximately 40.0 months.|Progression Free Survival (PFS2), Time to first documented progression on next line of antineoplastic therapy or death from any cause., From date of randomization until date of second progression or date of death from any cause, whichever comes first, assessed up to approximately 40.0 months.|Overall Response Rate (ORR), The proportion of participants with best overall response (BOR) of confirmed complete response (CR) or partial response (PR) in soft tissue., From the date of randomization to the date of the first documented radiographic disease progression, or death due to any cause, whichever occurs first, assessed up to approximately 40.0 months.|Disease Control Rate (DCR), The proportion of participants with BOR of confirmed CR, PR, stable disease (SD) or non-CR/non-progressive disease (PD) in soft tissue., From the date of randomization to the date of the first documented radiographic disease progression or death due to any cause, whichever occurs first, assessed up to approximately 40.0 months.|Duration of Response (DoR), Time between the date of first documented response and the date of first documented radiographic progression or death due to any cause., From the date of first documented response (CR or PR) for confirmed responders and the date of first documented radiographic progression in soft tissue or death due to any cause, whichever occurs first, assessed up to approximately 40.0 months.|Time to first radiographic soft tissue progression (TTSTP), Time to radiographic soft tissue progression., From the date of randomization to the date of radiographic soft tissue progression or death due to any cause, whichever occurs first, assessed up to approximately 40.0 months.|Time to first symptomatic skeletal event (TTSSE), Time to date of first new symptomatic skeletal event of death due to any cause., From the date of randomization to the date of the first documented radiographic disease progression, or death due to any cause, whichever occurs first, assessed up to approximately 40.0 months.|Prostate specific antigen response (PSA50 and PSA90), The percentage of participants who achieved â¥ 50% and â¥ 90% decrease from baseline, respectively., From the date of randomization to the date of safety follow up, assessed up to approximately 40.0 months.|Time-concentration profiles and PK parameters of AAA817, Time-concentration profiles and PK parameters of AAA817 (e.g. AUC, Cmax)., From Cycle 1 Day 1 up to approximately cycle 5 days 11 (each cycle is 8 weeks).|Change from baseline on FACT-P Prostate Cancer Subscale (PCS), Change from baseline on FACT-P Prostate Cancer Subscale (PCS). FACT-P assesses symptoms/problems related to prostate carcinoma and its treatment., From randomization to the first occurrence of worsening on the score or death due to any cause, whichever occurs first, assessed up to approximately 40.0 months.|Time to worsening on the Worst Pain, Time to worsening on the Worst Pain is defined as the time from randomization to the first occurrence of worsening on the Worst Pain item (BPI-SF) or death due to any cause, whichever occurs first., From randomization to the first occurrence of worsening from baseline, or death due to any cause, whichever occurs first, assessed up to approximately 40.0 months.|rPFS in participants treated with AAA817, rPFS time to the date of first documented radiographic disease progression or death due to any cause, whichever occurs first., From the date of randomization to the date of the first documented radiographic disease progression, or death due to any cause, whichever occurs first, assessed up to approximately 40.0 months.|OS in participants treated with AAA817, OS is time to death due to any cause., From the date of randomization to the date of death due to any cause assessed up to approximately 40.0 months.",,Novartis Pharmaceuticals,,MALE,"ADULT, OLDER_ADULT",PHASE3,605,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2025-08-20,2028-02-29,2032-11-04,2025-03-03,,2025-05-30,,
NCT06829459,A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs,https://clinicaltrials.gov/study/NCT06829459,,RECRUITING,"The is a randomized, controlled, open-label Phase III clinical study to evaluate the efficacy and safety of glumetinib combined with osimertinib mesylate versus platinum-based doublet chemotherapy in non-small cell lung cancer( NSCLC) patients with MET amplification and/or overexpression after resistance to EGFR-TKIs..

Approximately 350 NSCLC patients with MET amplification and/or overexpression after previous treatment with EGFR-TKIs are planned to be enrolled. After patients sign the informed consent form (ICF), those who are eligible for enrollment after screening examinations will be randomized to the investigational group or the control group in a 1:1 ratio by the central randomization system (IWRS).",NO,Non-Small Cell Lung Cancer,DRUG: Glumetinib|DRUG: Osimertinib mesylate|DRUG: Pemetrexed|DRUG: Cisplatin or carboplatin,"PFS as assessed by IRC, Progression-Free-Survival (PFS ) as assessed by IRC, Up to approximately 24 months after the first patient is enrolled","ORR as assessed by IRC, Objective response rate (ORR) as assessed by IRC, Up to approximately 24 months after the first patient is enrolled|DCRas assessed by IRC, Disease control rate (DCR) as assessed by IRC, Up to approximately 24 months after the first patient is enrolled|DOR as assessed by IRC, Duration of response (DOR) as assessed by IRC, Up to approximately 24 months after the first patient is enrolled|OS, Overall survival, Up to approximately 24 months after the first patient is enrolled",,Shanghai JMT-Bio Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE3,350,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2025-04-03,2028-02-15,2029-02-15,2025-02-17,,2025-04-08,"Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, 100021, China",
NCT05037279,Evaluating Safety and Efficacy of Verity-BCG in BCG-naÃ¯ve Patients with Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC),https://clinicaltrials.gov/study/NCT05037279,EVER,RECRUITING,"The aim of this study is to evaluate the effect of Verity-BCG in patients with intermediate and high-risk non-muscle-invasive bladder cancer (NMIBC) and to compare our findings to the standard of care BCG formulation, OncoTICE (BCG) in order to examine our hypothesis that Verity-BCG is at least non-inferior to OncoTICE in achieving 24-month Recurrence Free Survival in NMIBC patients who are at high risk of recurrence and have never been treated with intradermal or intravesical BCG before, with the exception of tuberculosis vaccination in childhood.",NO,Bladder Cancer|Bladder Cancer Recurrent|Neoplasm Recurrence|Urothelial Carcinoma Bladder|Urothelial Carcinoma Recurrent|Non-Invasive Bladder Urothelial Carcinoma,DRUG: Bacillus Calmette-Guerin: Strain Russian BCG-I|DRUG: Bacillus Calmette-Guerin: Strain TICE,"Recurrence Free Survival (RFS) at 24 months, Cumulative Recurrence Free Survival (RFS) at 24 months following 1st intravesical instillation as estimated using the Kaplan - Meier estimator of the survival function.

Recurrence will be defined as the reappearance of any of the NMIBC tumors as confirmed by cystoscopic biopsy or TURBT., 24 months","Recurrence Free Survival (RFS), Cumulative Recurrence Free Survival (RFS) at 36 months following 1st intravesical instillation as estimated using the Kaplan - Meier estimator of the survival function., 36 months|Progression Free Survival (PFS), Progression Free Survival (PFS) at 24 months as estimated using the Kaplan - Meier estimator of the survival function., 24 months|Progression Free Survival (PFS), Progression Free Survival (PFS) at 36 months as estimated using the Kaplan - Meier estimator of the survival function., 36 months|Overall Survival (OS), Overall Survival (OS) at 36 months as estimated using the Kaplan - Meier estimator of the survival function., 36 months|Change in Quality of Life, Change in Quality of Life as measured by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life questionnaire for NMIBC (EORTC-QLQ-NMIBC24) over 36 months.

The EORTC QLQ-NMIBC24 is a 24-item self-administered questionnaire that measures health-related quality of life in patients with intermediate to high-risk NMIBC. Items are ranked by the patient from 1 to 4 indicating the extent to which they have experienced those symptoms or problems. 1 = Not at All, 2 = A little, 3=Quite a bit, 4 = Very Much.

- High Score is equivalent to more problems, except for items on sexual function and sexual enjoyment for which a high score is interpreted as better function., 36 months|Change in functioning and symptom status, Change in functioning and symptom status as measured by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life questionnaire for Cancer Patients (EORTC-QLQ-C30) over 36 months.

The EORTC QLQ-C30 consists of 30 items and measures Health Related Quality of Life as well as presence of symptoms across all cancer types. The QLQ-C30 includes nine multi-item scales:

* 5 functional scales (physical, role, cognitive, emotional, and social)
* 3 symptom scales (fatigue, pain, and nausea and vomiting);
* A global health and quality-of-life scale\*
* Several single-item symptom measures

  28 Items are ranked 1 to 4. 1 = Not at All, 2 = A little, 3=Quite a bit, 4 = Very Much.

  \*2 items are ranked 1 to 7. 1=Very Poor, 7 = Excellent.

High score = More symptoms or worse problems

\*High Score = Better overall health or Quality of life., 36 months","Safety: Incidence of treatment-emergent AEs and SAEs, Incidence of treatment-emergent AEs and SAEs defined according to the CTCAE v5.0;, 36 months|Safety: Number of discontinued subjects, Number of subjects discontinuing study drug due to AEs, 36|Safety: concomitant medications, Usage of concomitant medications over time., 36 months",Verity Pharmaceuticals Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE3,540,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-04-24,2029-02,2029-02,2021-09-08,,2025-02-20,"Site 05, Vancouver, British Columbia, Canada|Site 04, Kingston, Ontario, Canada|Site 01, Toronto, Ontario, Canada|Site 02, Toronto, Ontario, Canada|Site 08, Toronto, Ontario, Canada|Site 10, Montreal, Quebec, Canada",
NCT05180734,PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer,https://clinicaltrials.gov/study/NCT05180734,,ACTIVE_NOT_RECRUITING,"This multicenter, randomized, double-blind phase III study intends to recruit about 878 patients, including PD-L1 positive 660 patients, who have received radical gastrectomy (R0 resection, D2 or more extended lymphadenectomy) with postoperative pathological stage IIB or III (AJCC Cancer Staging Manual, 8th Edition) gastric or EGJ adenocarcinoma to evaluate the efficacy and safety of JS001 combined with postoperative adjuvant chemotherapy versus placebo combined with postoperative adjuvant chemotherapy.",NO,Gastric or Esophagogastric Junction Adenocarcinoma,BIOLOGICAL: JS001/Placebo|BIOLOGICAL: JS001/placebo combine with Postoperative Adjuvant Chemotherapy,"DFS in the PD-L1-positive population evaluated by the BICR, To evaluate the disease-free survival (DFS) by the blind independent central review (BICR) for toripalimab combined with adjuvant chemotherapy versus placebo combined with adjuvant chemotherapy in PD-L1-positive patients with gastric or GEJ adenocarcinoma after radical gastrectomy., 5 years","OS in the PD-L1-positive population, To evaluate the OS for toripalimab combined with adjuvant chemotherapy versus placebo combined with adjuvant chemotherapy in PD-L1-positive patients with gastric or gastroesophageal junction adenocarcinoma after radical gastrectomy.Toripalimab Injection (JS001) combined with adjuvant chemotherapy versus placebo combined with adjuvant chemotherapy in patients with gastric or gastroesophageal junction adenocarcinoma after radical gastrectomy., 5 years|DFS in the PD-L1-positive population evaluated by the investigator, To evaluate the disease-free survival (DFS) by the investigator for toripalimab combined with adjuvant chemotherapy versus placebo combined with adjuvant chemotherapy in PD-L1-positive patients with gastric or GEJ adenocarcinoma after radical gastrectomy., 5 years|DFS in the ITT population evaluated by the BICR and investigator, respectively, To evaluate the disease-free survival (DFS) by the blind independent central review (BICR) and investigator,respectively, for toripalimab combined with adjuvant chemotherapy versus placebo combined with adjuvant chemotherapy in the ITT population., 5 years|OS in the ITT population, To evaluate the OS for toripalimab combined with adjuvant chemotherapy versus placebo combined with adjuvant chemotherapy in the ITT population., 5 years|DFS rate at 3 years in the PD-L1-positive population and the ITT population evaluated by the BICR and investigator, respectively, To evaluate the disease-free survival (DFS) rate at 3 years by the BICR and investigator, respevtively, for toripalimab combined with adjuvant chemotherapy versus placebo combined with adjuvant chemotherapy in the PD-L1-positive population and the ITT population., 3 years|DFS rate at 5 years in the PD-L1-positive population and the ITT population evaluated by the BICR and investigator, respectively, To evaluate the disease-free survival (DFS) rate at 5 years by the BICR and investigator, respevtively, for toripalimab combined with adjuvant chemotherapy versus placebo combined with adjuvant chemotherapy in the PD-L1-positive population and the ITT population., 5 years|OS rate at 3 years in the PD-L1-positive population and the ITT population, To evaluate the OS rate at 3 years for toripalimab combined with adjuvant chemotherapy versus placebo combined with adjuvant chemotherapy in the PD-L1-positive population and the ITT population., 3 years|OS rate at 5 years in the PD-L1-positive population and the ITT population, To evaluate the OS rate at 5 years for toripalimab combined with adjuvant chemotherapy versus placebo combined with adjuvant chemotherapy in the PD-L1-positive population and the ITT population., 5 years|Immunogenicity of toripalimab, To evaluate the incidence and titer of anti-drug antibody (ADA) of toripalimab, and further analyze ADA-positive samples for the presence of Neutralising antibodies (Nab)., Up to the 90 days from last dose of toripalimab|Blood trough concentration of toripalimab, To evaluate the blood trough concentration of toripalimab, Up to the 90 days from last dose of toripalimab",,"Shanghai Junshi Bioscience Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,878,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-02-10,2026-06-30,2028-07-31,2022-01-06,,2025-01-15,"The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, 233300, China|The Peple's Hospital of Chizhou, Chizhou, Anhui, China|Chinese PLA General Hospital, Beijing, Beijing, 100000, China|Beijing Hospital, Beijing, Beijing, 100005, China|Peking University People's hospital, Beijing, Beijing, 100044, China|Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, 100050, China|Beijing Cancer hospital, Beijing, Beijing, 510515, China|The first affiliated hospital of chongqing medical universit, Chongqing, Chongqing, 400016, China|Fujian Provincial Cancer Hospital, Fuzhou, Fujian, 350011, China|The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, 361003, China|Gansu Provincial People's Hospital, Lanzhou, Gansu, 730000, China|Lanzhou University Second Hospital, Lanzhou, Gansu, 730000, China|Gansu Provincial Cancer Hospital, Lanzhou, Gansu, 730050, China|The first Hospital of Lanzhou University, Lanzhou, Gansu, 750050, China|Wuwei Cancer Hospital of Gansu Province, Wuwei, Gansu, 733000, China|Guandong General Hospital, Guangzhou, Guandong, 510000, China|Zhujiang Hospital of Southern Medical University, Guangzhou, Guandong, 510280, China|The First People's Hospital of Foshan, Foshan, Guangdong, 528000, China|The First Affiliated Hospital of Sun yat-sen University, Guangzhou, Guangdong, 510080, China|Affiliated Cancer Hospital and Institute of Ghuangzhou Medical University, Guangzhou, Guangdong, 510095, China|Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, 510515, China|Yuebei People's Hospital, Shaoguan, Guangdong, 512099, China|Peking University Shenzhen Hospital, Shenzhen, Guangdong, 518000, China|Shenzhen People's Hospital, Shenzhen, Guangdong, 518000, China|Guangxi Medical University Affiliated Tumor Hospital, Nanning, Guangxi, 530021, China|Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, 563099, China|The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, China|The 2ed Affiliated Hospital of Harbin Medical University, Ha'erbin, Heilongjiang, 150086, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China|The First Affiliated Hospital of Henan University of science and Technology, Luoyang, Henan, 450052, China|Henan cancer hospital, Zhengzhou, Henan, 450003, China|The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China|Union Hospital, Tongji Medical College,Huazhong University of Science and Technology, Wuhan, Hubei, 430022, China|Hubei Cancer Hospital, Wuhan, Hubei, 430079, China|Xiangyang Central Hospital, Xiangyang, Hubei, 441021, China|Yichang Central People's Hospital, Yichang, Hubei, 443008, China|Xiangya Hospital Central South University, Changsha, Hunan, 410008, China|Hunan Cancer Hopital, Changsha, Hunan, 410031, China|The First People's Hospital of Changzhou, Changzhou, Jiangsu, 213004, China|Jiangsu cancer hospital, Nanjing, Jiangsu, 210000, China|Jiangsu Province Hospital, Nanjing, Jiangsu, 210029, China|Nantong Tumor Hospital, Nantong, Jiangsu, 226006, China|The Second People's Hospital of Wuxi, Wuxi, Jiangsu, 214001, China|Jiangmen Central Hospital, Nanchang, Jiangxi, 330006, China|The first Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, China|The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, China|The First Hospital of Jilin University, Changchun, Jilin, 130021, China|China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130033, China|The First Hospital of China Medical University, Shengyang, Liaoning, 110000, China|LiaoNing Cancer Hospital & Institute, Shenyang, Liaoning, 110000, China|General Hospital of Ningxia Medical University, Yinchuan, Ningxia, 750000, China|Qinghai University Affiliated Hosptial, Xining, Qinghai, 810000, China|Shandong Cancer Hospital, Jinan, Shandong, 250117, China|Linyi Cancer Hospital, Linyi, Shandong, 276002, China|The Affiliated Hospital of Qingdao University, Qingdao, Shandong, 266003, China|Qingdao central medical group, Qingdao, Shandong, 266042, China|Jinan Central Hospital, Jinan, Shangdong, 250012, China|Shandong Provincial Hospital, Jinan, Shangdong, 250031, China|Affiliated Hospital of Jining Medical University, Jining, Shangdong, 272007, China|Zhongshan Hospital, Fudan university, Shanghai, Shanghai, 200032, China|Shanghai General Hospital, Shanghai, Shanghai, 200080, China|Shanxi Provincial People's Hospital, Taiyuan, Shanxi, 030012, China|Tangdu hospital, Air force Military Medical University, Xian, Shanxi, 710000, China|Xijing hospital, Air force Military Medical University, Xian, Shanxi, 710000, China|SiChuan Cancer Hospital, Chengdu, Sichuan, 610000, China|Suining Central Hospital, Suining, Sichuan, 629000, China|Cancer Hospital affiliated to Xinjiang Medical University, Urumqi, Xinjiang, 830000, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310009, China|The first affiliated hospital of Zhejiang medical university, Hangzhou, Zhejiang, China|The First Hospital of Jiaxing, Jiaxing, Zhejiang, 314001, China|The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325024, China",
NCT03737643,"Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients",https://clinicaltrials.gov/study/NCT03737643,DUO-O,ACTIVE_NOT_RECRUITING,"This is a Phase III randomised, double-blind, multi-centre study to evaluate the efficacy and safety of durvalumab in combination with standard of care platinum based chemotherapy and bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer.",NO,Advanced Ovarian Cancer,DRUG: Bevacizumab|DRUG: Durvalumab|DRUG: Olaparib|DRUG: Placebo olaparib|DRUG: Durvalumab placebo|DRUG: Carboplatin+Paclitaxel,"Progression Free Survival (PFS) - in non-tBRCA HRD positive patients, Defined as time from randomisation to first progression by investigator assessment using modified RECIST 1.1 or death (by any cause in the absence of progression), Approximately 4 years|Progression Free Survival (PFS) - in all non-tBRCA patients, Defined as time from randomisation to first progression by investigator assessment using modified RECIST 1.1 or death (by any cause in the absence of progression), Approximately 4 years","Progression Free Survival (PFS) - in non-tBRCAm patients, Defined as time from randomisation to first progression by investigator assessment using modified RECIST 1.1 or death (by any cause in the absence of progression), Approximately 4 years|Overall Survival (OS) - in non-tBRCA HRD positive patients and in all non-tBRCA patients, Defined as the time from randomisation to death due to any cause, Approximately 7 years|Second Progression (PFS2) - in non-tBRCAm patients, Defined as time from randomisation to second progression by investigator assessment of radiological progression, symptomatic progression or death (by any cause in the absence of progression), Approximately 7 years|Health-related quality of life - in non-tBRCAm patients, Change from baseline in the physical functioning subscale of the EORTC-QLQ-C30, Approximately 4 years|Pathological Complete Response (pCR) - in non-tBRCAm patients, Defined as the proportion of patients with pCR in patients undergoing IDS, Approximately 4 years|The pharmacokinetics (PK) and immunogenicity of durvalumab and olaparib as determined by peak concentration - in non-tBRCAm patients, Determination of durvalumab concentration in serum and olaparib concentration in plasma in a subset of patients, Approximately 4 years|Objective Response Rate (ORR) - in non-tBRCAm patients, Defined as the number (%) of patients with at least one investigator-assessed visit response of CR or PR as per RECIST 1.1, Approximately 4 years|Duration of response (DoR) - in non-tBRCAm patients, Defined as the time form the date of first documented response (CR/PR) until the first progression or death in the absence of disease progression, Approximately 4 years|Time to first subsequent therapy (TFST) - in non-tBRCAm patients, Time elapsed from randomisation to first subsequent therapy or death, Approximately 7 years|Time to second subsequent therapy (TSST) - in non-tBRCAm patients, Time elapsed from randomisation to second subsequent therapy or death, Approximately 7 years|Time to discontinuation or death (TDT) - in non-tBRCAm patients, Time elapsed from randomisation to study treatment discontinuation or death, Approximately 4 years|PFS - in tBRCAm patients, To assess the potential additional clinical benefit of durvalumab added to SoC and olaparib in the first line treatment of tBRCAm patients, Approximately 4 years|PFS2 - in tBRCAm patients, To assess the potential additional clinical benefit of durvalumab added to SoC and olaparib in the first line treatment of tBRCAm patients, Approximately 7 years|ORR - in tBRCAm patients, To assess the potential additional clinical benefit of durvalumab added to SoC and olaparib in the first line treatment of tBRCAm patients, Approximately 4 years|ORR pre-surgery in IDS group - in tBRCAm patients, To assess the potential additional clinical benefit of durvalumab added to SoC and olaparib in the first line treatment of tBRCAm patients, Approximately 4 years|Duration of response (DoR) - in tBRCAm patients, To assess the potential additional clinical benefit of durvalumab added to SoC and olaparib in the first line treatment of tBRCAm patients, Approximately 4 years|Time to first subsequent therapy (TFST) - in tBRCAm patients, To assess the potential additional clinical benefit of durvalumab added to SoC and olaparib in the first line treatment of tBRCAm patients, Approximately 7 years|Time to second subsequent therapy (TSST) - in tBRCAm patients, To assess the potential additional clinical benefit of durvalumab added to SoC and olaparib in the first line treatment of tBRCAm patients, Approximately 7 years|Time to discontinuation or death (TDT) - in tBRCAm patients, To assess the potential additional clinical benefit of durvalumab added to SoC and olaparib in the first line treatment of tBRCAm patients, Approximately 4 years|Health-related quality of life - in tBRCAm patients, Change from baseline in the physical functioning subscale of the EORTC-QLQ-C30, Approximately 4 years|Proportion of patients with pCR in patients undergoing IDS - in tBRCAm patients, To assess the potential additional clinical benefit of durvalumab added to SoC and olaparib in the first line treatment of tBRCAm patients, Approximately 4 years","Safety and tolerability of drugs by assessment of AEs/SAEs, Graded according to the National Cancer Institute (NCI CTCAE), Approximately 4 years",AstraZeneca,"European Network of Gynaecological Oncological Trial Groups (ENGOT)|GOG Foundation, Inc. (GOG Foundation)|Myriad Genetic Laboratories, Inc.",FEMALE,"ADULT, OLDER_ADULT",PHASE3,1407,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-01-04,2025-03-28,2028-03-30,2018-11-09,,2025-01-29,"Research Site, Foothill Ranch, California, 92610, United States|Research Site, Los Angeles, California, 90095, United States|Research Site, Orange, California, 92868-3298, United States|Research Site, San Francisco, California, 94158, United States|Research Site, Tampa, Florida, 33612, United States|Research Site, Augusta, Georgia, 30912, United States|Research Site, Hinsdale, Illinois, 60521, United States|Research Site, Indianapolis, Indiana, 46202, United States|Research Site, Towson, Maryland, 21204, United States|Research Site, Detroit, Michigan, 48202, United States|Research Site, Springfield, Missouri, 65807, United States|Research Site, Middletown, New Jersey, 07748, United States|Research Site, Montvale, New Jersey, 07645, United States|Research Site, Albany, New York, 12208, United States|Research Site, New York, New York, 10065, United States|Research Site, Uniondale, New York, 11553, United States|Research Site, Durham, North Carolina, 27710, United States|Research Site, Cleveland, Ohio, 44195, United States|Research Site, Dayton, Ohio, 45429, United States|Research Site, Hilliard, Ohio, 43026, United States|Research Site, Tulsa, Oklahoma, 74134, United States|Research Site, Lancaster, Pennsylvania, 17601, United States|Research Site, Philadelphia, Pennsylvania, 19104, United States|Research Site, Philadelphia, Pennsylvania, 19107-5097, United States|Research Site, Pittsburgh, Pennsylvania, 15224, United States|Research Site, Salt Lake City, Utah, 84112, United States|Research Site, Graz, 8036, Austria|Research Site, Innsbruck, 6020, Austria|Research Site, Linz, 4020, Austria|Research Site, Wien, 1090, Austria|Research Site, Aalst, 9300, Belgium|Research Site, Leuven, 3000, Belgium|Research Site, Namur, 5000, Belgium|Research Site, Oostende, 8400, Belgium|Research Site, Sint-Niklaas, 9100, Belgium|Research Site, Barretos, 14784-400, Brazil|Research Site, FlorianÃ³polis, 88034-000, Brazil|Research Site, Fortaleza, 60810-180, Brazil|Research Site, Londrina, 86015-520, Brazil|Research Site, Porto Alegre, 90020-090, Brazil|Research Site, Porto Alegre, 90110-270, Brazil|Research Site, Rio de Janeiro, 20220-410, Brazil|Research Site, Sao Paulo, 01317-000, Brazil|Research Site, SÃ£o Paulo, 04014-002, Brazil|Research Site, Burgas, 8000, Bulgaria|Research Site, Plovdiv, 4004, Bulgaria|Research Site, Sofia, 1330, Bulgaria|Research Site, Varna, 9000, Bulgaria|Research Site, Calgary, Alberta, T2N 5G2, Canada|Research Site, Barrie, Ontario, L4M 6M2, Canada|Research Site, Sudbury, Ontario, P3E 5J1, Canada|Research Site, Toronto, Ontario, M5G 2M9, Canada|Research Site, Montreal, Quebec, H2X 3E4, Canada|Research Site, Montreal, Quebec, H3T 1E2, Canada|Research Site, Montreal, Quebec, H4A 3J1, Canada|Research Site, Rimouski, Quebec, G5L 5T1, Canada|Research Site, Quebec, G1J 1Z4, Canada|Research Site, Beijing, 100026, China|Research Site, Beijing, CN-100730, China|Research Site, Bengbu, 233060, China|Research Site, Changchun, 130021, China|Research Site, Changsha, 410008, China|Research Site, Changsha, 430033, China|Research Site, Chengdu, 610041, China|Research Site, Chongqing, 400030, China|Research Site, Dalian, 116001, China|Research Site, Guangzhou, 510060, China|Research Site, Guangzhou, 510080, China|Research Site, Hangzhou, 310009, China|Research Site, Hangzhou, 310022, China|Research Site, Harbin, 150081, China|Research Site, Hefei, 230031, China|Research Site, Jinhua, 321099, China|Research Site, Kunming, 650118, China|Research Site, Lanzhou, 730030, China|Research Site, Luzhou, 646099, China|Research Site, Nan Chong, 637000, China|Research Site, Nanjing, 2100008, China|Research Site, Nanning, 530021, China|Research Site, Nantong, 226361, China|Research Site, Shanghai, 200011, China|Research Site, Shanghai, 200032, China|Research Site, Wuhan, 430030, China|Research Site, Wuhan, 430060, China|Research Site, Xi'an, 710061, China|Research Site, Zhengzhou, 450002, China|Research Site, Zhengzhou, 450008, China|Research Site, Zhuhai, 519099, China|Research Site, Aalborg, 9000, Denmark|Research Site, Aarhus N, 8200, Denmark|Research Site, Odense, 5000, Denmark|Research Site, Roskilde, 4000, Denmark|Research Site, Vejle, 7100, Denmark|Research Site, Kuopio, 70210, Finland|Research Site, Oulu, 90029, Finland|Research Site, Turku, 20521, Finland|Research Site, BesanÃ§on, 25000, France|Research Site, Bordeaux, 33076, France|Research Site, Limoges Cedex, 87042, France|Research Site, Lyon Cedex 08, 69373, France|Research Site, Marseille, 13273, France|Research Site, Nantes, 44202, France|Research Site, Paris Cedex 14, 75674, France|Research Site, Paris, 75012, France|Research Site, Paris, 75015, France|Research Site, Saint Herblain Cedex, 44805, France|Research Site, Vandoeuvre les Nancy, 54519, France|Research Site, Bad Homburg, 61352, Germany|Research Site, Berlin, 10117, Germany|Research Site, Bielefeld, 33604, Germany|Research Site, Bonn, 53105, Germany|Research Site, Brandenburg, 14770, Germany|Research Site, Dresden, 1307, Germany|Research Site, DÃ¼sseldorf, 40489, Germany|Research Site, Essen, 45136, Germany|Research Site, Essen, 45147, Germany|Research Site, Esslingen am Neckar, 73730, Germany|Research Site, Frankfurt, 60590, Germany|Research Site, Freiburg, 79106, Germany|Research Site, FÃ¼rth, 90766, Germany|Research Site, Greifswald, 17475, Germany|Research Site, GÃ¼tersloh, 33332, Germany|Research Site, Hamburg, 20246, Germany|Research Site, Hamburg, 20357, Germany|Research Site, Hamburg, 22457, Germany|Research Site, Hannover, 30177, Germany|Research Site, Hannover, 30625, Germany|Research Site, Jena, 07747, Germany|Research Site, Karlsruhe, 76133, Germany|Research Site, Karlsruhe, 76135, Germany|Research Site, Kassel, 34125, Germany|Research Site, Kiel, 24105, Germany|Research Site, KÃ¶ln, 50935, Germany|Research Site, Leipzig, 04103, Germany|Research Site, Ludwigsburg, 71640, Germany|Research Site, LÃ¼beck, 23538, Germany|Research Site, Mainz, 55131, Germany|Research Site, Mannheim, 68167, Germany|Research Site, MÃ¼nchen, 81377, Germany|Research Site, Offenbach am Main, 63069, Germany|Research Site, Oldenburg, 26133, Germany|Research Site, Rosenheim, 83022, Germany|Research Site, Rostock, 18057, Germany|Research Site, Saalfeld, 07318, Germany|Research Site, Schweinfurt, 97422, Germany|Research Site, TÃ¼bingen, 72016, Germany|Research Site, Ulm, 89075, Germany|Research Site, Worms, 67550, Germany|Research Site, Budapest, 1062, Hungary|Research Site, Budapest, 1122, Hungary|Research Site, Debrecen, 4032, Hungary|Research Site, GyÅr, 9024, Hungary|Research Site, KaposvÃ¡r, 7400, Hungary|Research Site, Szeged, 6725, Hungary|Research Site, Zalaegerszeg, 8900, Hungary|Research Site, Brescia, 25123, Italy|Research Site, Lecce, 73100, Italy|Research Site, Lecco, 23900, Italy|Research Site, Milano, 20132, Italy|Research Site, Milano, 20141, Italy|Research Site, Mirano, 30035, Italy|Research Site, Napoli, 80131, Italy|Research Site, Reggio Calabria, 89100, Italy|Research Site, Reggio Emilia, 42100, Italy|Research Site, Roma, 00168, Italy|Research Site, Torino, 10126, Italy|Research Site, Torino, 10128, Italy|Research Site, Fukuoka-shi, 811-1395, Japan|Research Site, Kashiwa-shi, 277-8567, Japan|Research Site, Kobe-shi, 650-0047, Japan|Research Site, Koto-ku, 135-8550, Japan|Research Site, Kurume-shi, 830-0011, Japan|Research Site, Kyoto-shi, 606-8507, Japan|Research Site, Minato-ku, 105-8471, Japan|Research Site, Nagoya-shi, 464-8681, Japan|Research Site, Niigata-shi, 951-8520, Japan|Research Site, Okayama-shi, 700-8558, Japan|Research Site, Sapporo-shi, 003-0804, Japan|Research Site, Sendai-shi, 980-8574, Japan|Research Site, Shinjuku-ku, 160-8582, Japan|Research Site, Sunto-gun, 411-8777, Japan|Research Site, Toyoake-shi, 470-1192, Japan|Research Site, Goyang-si, 10408, Korea, Republic of|Research Site, Seongnam-si, 13620, Korea, Republic of|Research Site, Seoul, 03080, Korea, Republic of|Research Site, Seoul, 03722, Korea, Republic of|Research Site, Seoul, 06351, Korea, Republic of|Research Site, Suwon-si, 16499, Korea, Republic of|Research Site, Bellavista, CALLAO 2, Peru|Research Site, La Libertad, 13013, Peru|Research Site, Lima, LIMA 31, Peru|Research Site, Lima, Lima 32, Peru|Research Site, Lima, LIMA 34, Peru|Research Site, Lima, LIMA 41, Peru|Research Site, San Isidro, 27, Peru|Research Site, Gdynia, 81-519, Poland|Research Site, Szczecin, 70-111, Poland|Research Site, Warszawa, 02-781, Poland|Research Site, Warszawa, 04-141, Poland|Research Site, ÅÃ³dÅº, 93-513, Poland|Research Site, Floresti, 407280, Romania|Research Site, CÃ³rdoba, 14004, Spain|Research Site, Madrid, 28033, Spain|Research Site, Madrid, 28034, Spain|Research Site, Madrid, 28040, Spain|Research Site, Madrid, 28041, Spain|Research Site, Terrassa(Barcelona), 08221, Spain|Research Site, Vigo, 36312, Spain|Research Site, Adana, 1260, Turkey|Research Site, Ankara, 06230, Turkey|Research Site, Ankara, 06490, Turkey|Research Site, Istanbul, 34093, Turkey|Research Site, Istanbul, 34384, Turkey|Research Site, Izmir, 35100, Turkey",
NCT05346952,A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).,https://clinicaltrials.gov/study/NCT05346952,,UNKNOWN,"This is Phase 3, randomized, open-label, parallel controlled study designed to compare the efficacy and safety of TQB2450 in combination with platinum-containing chemotherapy followed by TQB2450 plus Anlotinib versus tislelizumab in combination with platinum-containing chemotherapy followed by tislelizumab in locally advanced (stage â¢B/â¢C), metastatic or recurrent ( Stage IV) non-squamous NSCLC cancer. The primary endpoint is Progression Free Survival (PFS) assessed by IRC.",NO,Advanced Non-squamous Non-small Cell Lung Cancer,"DRUG: TQB2450 injection, Tilelizumab injection, Anlotinib hydrochloride capsule, Pemetrexed disodium injection, Carboplatin injection","Progression Free Survival (PFS) assessed by IRC, The period from the first use of the drug to disease progression or death (whichever occurs first)., Up to 2 years|Overall survival (OS), Time from randomization to death, Up to 3 years|According to response evaluation criteria in solid tumours 1.1ï¼RECIST1.1ï¼standard and iRECIST ï¼Immune-related response evaluation criteria in solid tumours ï¼standard researcher's assessment of progression-free survival (PFS), The period from the first use of the drug to disease progression or death (whichever occurs first)., Up to 2 years|Objective Response Rate (ORR), Proportion of patients whose tumor volume shrinks to a predetermined value and maintains the minimum time limit, Up to 2 years|Disease Control Rate (DCRï¼, Proportion of subjects whose tumors shrink or remain stable for a certain period, including CR, PR and stable disease SD, Up to 2 years|Duration of Remission (DOR), The period from firstly-recorded objective tumor response (CR or PR) to firstly-recorded objective tumor progression or death due to any cause (whichever occurs first) ., Up to 2 years|TTR, Time from randomization to onset of remission (PR), Up to 2 years","Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)ï¼as well as abnormal laboratory examination indicators., The proportion of AEs and SAEs recorded afte signing the informed consent form(ICF)., Up to 2 years",,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,390,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-01-25,2023-12,2023-12,2022-04-26,,2022-04-26,"Chinese Academy of Medical Sciences Cancer Hospital, Beijing, Beijing, 100021, China",
NCT04158440,Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC,https://clinicaltrials.gov/study/NCT04158440,,ACTIVE_NOT_RECRUITING,"This is a randomized, double-blind, placebo-controlled, multi-center, phase III clinical study to evaluate the efficacy and safety of Toripalimab injection (JS001) combined with platinum-based doublet drug chemotherapy versus placebo combined with platinum-based doublet drug chemotherapy for subjects with resectable, stage II-III NSCLC.",NO,Stage II-III Non-small Cell Lung Cancer,DRUG: 4cycles(Toripalimab IV 240mg + platinum-based doublet chemotherapy)+13 cycles(Toripalimab IV 240mg); Biological: Toripalimab|DRUG: 4cycles(Placebo + platinum-based doublet chemotherapy)+13 cycles(Placebo ),"MPR rate in stage III population evaluated by BIPR, Major Pathological Response (MPR) Rate.MPR rate is defined as the percentage of participants having â¤10% viable tumor cells in the resected primary tumor and all resected lymph nodes in neoadjuvant therapy., up to 7 weeks after neoadjuvant|EFS in stage III population evaluated by investigators, Event Free Survival (EFS):EFS is defined as the time from randomization until radiographic disease progression, local progression precluding surgery, inability to resect the tumor, local or distant recurrence, or death due to any cause., up to 3 years|MPR rate in stage II-III population evaluated by BIPR, Major Pathological Response (MPR) Rate.MPR rate is defined as the percentage of participants having â¤10% viable tumor cells in the resected primary tumor and all resected lymph nodes in neoadjuvant therapy., up to 7 weeks after neoadjuvant|EFS in stage II-III population evaluated by investigators, Event Free Survival (EFS):EFS is defined as the time from randomization until radiographic disease progression, local progression precluding surgery, inability to resect the tumor, local or distant recurrence, or death due to any cause., EFS: up to 3 years","pCR rate in stage III population evaluated by BIPR and investigators, Pathological Complete Response (pCR) Rate :pCR rate is defined as the percentage of participants having an absence of residual invasive cancer in resected lung specimens and lymph nodes following completion of neoadjuvant therapy., pCR:up to 7 weeks after neoadjuvant;|EFS in stage III population evaluated by IRC, EFS is defined as the time from randomization until radiographic disease progression, local progression precluding surgery, inability to resect the tumor, local or distant recurrence, or death due to any cause. EFS determined either by biopsy assessed by blinded central pathologist or by imaging using RECIST 1.1 assessed by investigator., EFS by IRC:up to 3 years|Disease-free survival (DFS) in stage III evaluated by IRC and investigators, DFS is defined as the time from postoperation until radiographic disease progression, local or distant recurrence, or death due to any cause., DFS:up to 3 years|pCR rate in stage II-III population evaluated by BIPR and investigators, Pathological Complete Response (pCR) Rate :pCR rate is defined as the percentage of participants having an absence of residual invasive cancer in resected lung specimens and lymph nodes following completion of neoadjuvant therapy., pCR:up to 7 weeks after neoadjuvant|EFS in stage II-III population evaluated by IRC, EFS is defined as the time from randomization until radiographic disease progression, local progression precluding surgery, inability to resect the tumor, local or distant recurrence, or death due to any cause. EFS determined either by biopsy assessed by blinded central pathologist or by imaging using RECIST 1.1 assessed by investigator., EFS by IRC:up to 3 years|Disease-free survival (DFS) in stage II-III population evaluated by IRC and investigators, DFS is defined as the time from postoperation until radiographic disease progression, , local or distant recurrence, or death due to any cause., DFS:up to 3 years|Overall survival (OS) rate in stage III and II-III population, OS is defined as the time from randomization until death from any cause., OS up to 5 years|2-3 years overall survival (OS) rate in stage III and II-III population, OS rate is defined as survival probability n stage III and II-III population at a given time pointï¼2yï¼3yï¼, OS up to 5 years","Safety evaluation of subjects, Safety: adverse event (AE), abnormal laboratory examination, serious adverse event (SAE) related with the study drug judged using NCI-CTCAE V5.0; surgical feasibility: percentage of procedure delay or cancellation, change of surgical approach, operation timeï¼, Safety: 90 days after the last administration|Exploratory analysis of potential biomarkers related with the outcome, Exploratory analysis of potential biomarkers related to the outcome (including PD-L1 expression in tissue specimen, tumor mutation burden (TMB), whole exome sequencing (WES) and change of ctDNA in peripheral blood sample), Exploratory :withdrawal from study treatmentï¼up to 71 weeks|Pharmacokinetics: plasma concentration of Toripalimab in each cycle;, Pre-dose serum samples will be collected from subjects at cycles 1, 2, and 3 of the neoadjuvant therapy period, cycle 1 of the adjuvant therapy period, and cycles 1, 5, 9, and 13 of the consolidation therapy period for the determination of Toripalimab concentrations., Exploratory : withdrawal from study treatmentï¼up to 71 weeks|mmunogenicity: the incidence and titer of anti-drug antibody (ADA) and whether it is neutralizing antibody (if necessary);, Pre-dose serum samples will be collected from subjects at cycles 1, 2, and 3 of the neoadjuvant therapy period, cycle 1 of the adjuvant therapy period, and cycles 1, 5, 9, and 13 of the consolidation therapy period to detect the presence of anti-drug antibodies (ADAs). ADA-positive samples will be tested and analyzed for neutralizing antibodies (if necessary)., Exploratory : withdrawal from study treatmentï¼up to 71 weeks","Shanghai Junshi Bioscience Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,501,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-04-07,2025-06-30,2025-12-31,2019-11-08,,2024-07-09,"Shanghai Chest Hospital, Shanghai, China",
NCT03656536,A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma,https://clinicaltrials.gov/study/NCT03656536,FIGHT-302,ACTIVE_NOT_RECRUITING,The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.,NO,Unresectable Cholangiocarcinoma|Metastatic Cholangiocarcinoma,DRUG: Pemigatinib|DRUG: Gemcitabine|DRUG: Cisplatin,"Progression-free survival, Defined as the time from date of randomization until date of disease progression (according to Response Evaluation Criteria in Solid Tumors \[RECIST\] v1.1 and assessed by an independent central reviewer (ICR)) or death, whichever occurs first., Up to approximately 12 months","Overall response rate, Defined as the proportion of participants with best overall response of complete response (CR) or partial response (PR) per RECIST v1.1 as assessed by an ICR., Up to approximately 12 months|Overall survival, Defined as the time from date of randomization until death due to any cause., Up to approximately 12 months|Duration of response, Defined as the time from the date of the first assessment of CR or PR until the date of the first disease progression by an ICR per RECIST v1.1 or death, whichever occurs first., Up to approximately 12 months|Disease control rate, Defined as the proportion of participants who achieved best overall response of CR, PR, or stable disease (SD) per RECIST v1.1 as assessed by an ICR., Up to approximately 12 months|Number of treatment-emergent adverse events, Defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug., Up to approximately 12 months|Quality of Life impact as assessed by the EQ-5D-3L questionnaire, Up to 12 months|Quality of Life impact as assessed by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-30 questionnaire, Up to 12 months|Quality of Life impact as assessed by the EORTC QLQ-BIL21 questionnaire, Up to 12 months",,Incyte Corporation,,ALL,"ADULT, OLDER_ADULT",PHASE3,167,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2019-06-03,2027-10-26,2028-07-27,2018-09-04,,2024-12-30,"Mayo Clinic Arizona, Phoenix, Arizona, 85054, United States|Marin Cancer Care, Greenbrae, California, 94904, United States|UC Irvine Medical Center, Orange, California, 92868-3201, United States|Georgetown University-Lombardi Comprehensive Cancer Center, Washington, District of Columbia, 20007, United States|Mayo Clinic-Florida, Jacksonville, Florida, 32224, United States|Mount Sinai Medical Center Comprehensive Cancer Center, Miami Beach, Florida, 33140, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, 30322, United States|University of Chicago Medical Center, Chicago, Illinois, 60637-1447, United States|Parkview Research Center, Fort Wayne, Indiana, 46845, United States|University of Iowa Hospital and Clinics, Iowa City, Iowa, 52242, United States|The University of Kansas Cancer Center, Westwood, Kansas, 66205, United States|Ochsner Clinic Foundation Ocf Ochsner Cancer Institute Oci, New Orleans, Louisiana, 70121, United States|Johns Hopkins Oncology Center, Baltimore, Maryland, 21287, United States|Boston Medical Center, Boston, Massachusetts, 02118, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States|Barbara Ann Karmanos Cancer Hospital, Detroit, Michigan, 48201, United States|Henry Ford Hospital, Detroit, Michigan, 48202, United States|Karmanos Cancer Institute, Farmington Hills, Michigan, 48334, United States|Mayo Clinic, Rochester, Minnesota, 55905, United States|Comprehensive Cancer Centers of Nevada-Twain, Las Vegas, Nevada, 89169, United States|Summit Medical Group, Florham Park, New Jersey, 07932, United States|Icahn School of Medicine At Mount Sinai, New York, New York, 10029, United States|White Plains Hospital, White Plains, New York, 10601, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, 44106, United States|Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States|Providence Portland Med. Ctr, Portland, Oregon, 97213, United States|Oregon Health & Science University, Portland, Oregon, 97239, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States|Greenville Hospital System University Medical Center Institute For Translational Oncology Research, Greenville, South Carolina, 29605, United States|Baylor Scott and White Research Institute, Dallas, Texas, 75246, United States|Houston Methodist Research Institute, Houston, Texas, 77030, United States|Riverside Regional Medical Center, Newport News, Virginia, 23601, United States|Virginia Commonwealth University, Richmond, Virginia, 23229, United States|Virginia Mason Medical Center, Seattle, Washington, 98101, United States|West Virginia University Cancer Institute, Morgantown, West Virginia, 26506, United States|Aurora Research Institute, Wauwatosa, Wisconsin, 53226, United States|Landeskrankenhaus Universitatsklinikum Graz, Graz, 08036, Austria|Innsbruck University Hospital, Innsbruck, A-6020, Austria|Ordensklinikum Krankenhaus Der Barmherzigen Schwestern Linz, Linz, 04010, Austria|Salzburger Universitatsklinikum, Salzburg, 05020, Austria|Landeskrankenhaus Steyr, Steyr, 04400, Austria|Allgemeines Krankenhaus Der Stadt Wien, Vienna, 01090, Austria|Ulb Hospital Erasme, Bruxelles, 01070, Belgium|Universitair Ziekenhuis Brussel, Bruxelles, 01090, Belgium|Universitair Ziekenhuis Gent, Gent, 09000, Belgium|Hospital de Jolimont, Haine-st-paul, 07100, Belgium|Az Groeninge Campus Kennedylaan, Kortrijk, 08500, Belgium|Universitaire Ziekenhuis Leuven - Gasthuisberg, Leuven, 03000, Belgium|Chu Ucl Namur University Hospital Mont-Godinne, Yvoir, 05530, Belgium|Tom Baker Cancer Centre, Calgary, Alberta, T2N 4N2, Canada|Cancercare Manitoba, Winnipeg, Manitoba, R3E 0V9, Canada|Nova Scotia Health Authority/Qeii Health Sciences Centre, Halifax, Nova Scotia, B3H 4K4, Canada|Princess Margaret Cancer Center, Toronto, Ontario, MG5 2M9, Canada|McGill University Health Centre Research Institute, Montreal, Quebec, H4A 3J1, Canada|Peking Union Medical College Hospital, Beijing, 100032, China|West China Hospital Sichuan University, Chengdu, 610041, China|Fujian Cancer Hospital, Fuzhou, 350005, China|Sun Yat-Sen Memorial Hospital Sun Yat-Sen University, Guangdong, 510000, China|Sun Yat-Sen Memorial Hospital Sun Yat-Sen University, Guangzhou, 510000, China|Shulan Hangzhou Hospital Co Ltd, Hangzhou, 310000, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, 310009, China|Heilongjiang Province Cancer Hospital, Harbin, 150081, China|University of Science and Technology of China-First Affiliated Hospital (Anhui Provincial Hospital), Hefei, 230001, China|Kunming 1St People'S Hospital, Kunming, 650032, China|Jiangsu Province Hospital, Nanjing, 210029, China|The Affiliated Hospital of Qingdao University, Shandong, 266071, China|Zhongshan Hospital Fudan University, Shanghai, 200032, China|Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China|Xinhua Hospital, SHanghai, 200092, China|Sichuan Cancer Hospital, Sichuan, 610041, China|Tianjin Medical University Cancer Institute Hospital, Tianjin, 300060, China|Tongji Hospital Huazhong University of Science and Technology, Wuhan, 430030, China|Hubei Cancer Hospital, Wuhan, 430079, China|Northern Jiangsu Peoples Hospital, Yangzhou, 225001, China|Herlev Og Gentofte Hospital, Herlev, 02730, Denmark|Docrates Cancer Center, Helsinki, 00180, Finland|Helsinki University Central Hospital, Helsinki, 00290, Finland|Tampere University Hospital, Tampere, 33521, Finland|Institut Sainte Catherine, Avignon Cedex 9, 84918, France|Chu Besancon Hospital Jean Minjoz, BesanÃ§on, 25030, France|Institut Bergonie, Bordeaux Cedex, 33076, France|Hopital Beaujon, Clichy, 92110, France|Chu de Limoges - Hospital Dupuytren, Limoges Cedex, 87042, France|Hopital Prive Jean Mermoz, Lyon Cedex 08, 69373, France|Chu Hopital de La Timone, Marseille Cedex 5, 13385, France|Centre Hospitalier Universitaire de Nantes, Nantes, 44000, France|Centre Antoine Laccassagne, Nice Cedex 02, 06189, France|Hospital Universitaire Pitie-Salpetriere, Paris Cedex 13, 75013, France|Hopital Europeen Georges Pompidou (Hegp), Paris Cedex 15, 75015, France|Centre Hospitalier Universitaire de Bordeaux - Hospital Haut-Leveque, Pessac Cedex, 336600, France|Hospital de La Miletrie, Poitiers Cedex, 86021, France|Hopital Charles Nicolle Chu Rouen Hospital de Bois-Guillaume, Rouen Cedex, 76031, France|University Hospital of Saint Etienne, Saint Etienne, 42055, France|Centre de Lutte Contre Le Cancer - Institut de Cancerologie de L'Ouest - Rene Gauducheau, Saint Herblain, 44800, France|Chu Toulouse Hopital Rangueil, Toulouse Cedex 9, 31059, France|Chu Vandoeuvre-Les-Nancy Hopital Brabois, Vandoeuvre Les Nancy, 54511, France|Institut Gustave Roussy, Villejuif Cedex, 94805, France|University Medical Center Rwth Aachen, Aachen, 52074, Germany|Charite - Campus Virchow-Klinikum, Berlin, 13353, Germany|Charite Universitaetsmedizin Berlin - Campus Charite Mitte, Berlin, 13353, Germany|Universitatsklinikum Bonn Aoer, Bonn, 53127, Germany|Klinikum Bremen-Nord, Bremen, 28755, Germany|University Clinic Carl Gustav Carus Technical University Dresden, Dresden, 01307, Germany|Klinikum Der Johann Wolfgang Goethe University, Frankfurt Am Main, 60590, Germany|University Medical Center Freiburg, Freiburg, 79106, Germany|Universitatsklinikum Hamburg Eppendorf, Hamburg, 20246, Germany|Asklepios Klinik Altona, Hamburg, 22763, Germany|Hannover Medical School, Hannover, 30625, Germany|Universitaetsklinikum Des Saarlandes, Homburg / Saar, 66421, Germany|Universitatsklinikum Koln, Koln, 50937, Germany|Universitatsklinikum Leipzig Aor, Leipzig, 04103, Germany|Klinikum Ludwigsburg, Ludwigsburg, 71640, Germany|Otto-Von-Guericke-Universitat Magdeburg, Magdeburg, 39120, Germany|Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii, Mainz, 55131, Germany|University Hospital Grosshadern Munich, Munich, 81377, Germany|Klinikum Nuernberg, Nuernberg, 90419, Germany|Universitaetsklinikum in Tubingen, Tubingen, 72076, Germany|University Hospital Tuebingen, Tubingen, 72076, Germany|Universitatkinikums Ulm, ULM, 89081, Germany|St. Vincent'S University Hospital, Dublin 4, D04 Y8V0, Ireland|Soroka University Medical Center, Beer-sheva, 84001, Israel|Rambam Health Care Campus, Haifa, 3109601, Israel|Hadassah University Hospital, Jerusalem, 9112001, Israel|Rabin Medical Center - Beilinson Hospital, Petach Tikva, 4941492, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, 64239, Israel|Azienda Ospedaliero Universitaria Delle Marche, Ancona, 60126, Italy|Istituto Tumori Giovanni Paolo Ii Irccs Ospedale Oncologico Bari, Bari, 70124, Italy|Ospedale Papa Giovanni Xxiii, Bergamo, 24127, Italy|Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi, Bologna, 40138, Italy|Fondazione Del Piemonte Per L'Oncologia Ircc Candiolo, Candiolo, 10060, Italy|Presidio Ospedaliero Garibaldi Nesima, Catania, 95100, Italy|Ospedale Degli Infermi - Faenza, Faenza, 48018, Italy|Irccs Azienda Ospedaliera Universitaria San Martino, Genova, 16132, Italy|Comitato Etico Fondazione Irccs Istituto Nazionale Dei Tumori Milano, Milano, 20133, Italy|Istituto Di Ricovero E Cura A Carattere Scientifico (Irccs) Ospedale San Raffaele, Milan, 20132, Italy|European Institute of Oncology, Milan, 20141, Italy|Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Milan, 20162, Italy|A.O.U. Di Modena - Policlinico, Modena, 41124, Italy|Istituto Nazionale Tumori Irccs Fondazione Pascale, Napoli, 80131, Italy|Universita Degli Studi Della Campania Luigi Vanvitelli U.O.C. Oncologia Medica, Napoli, 80138, Italy|Azienda Ospedaliera Universitaria San Luigi Gonzaga Orbassano, Orbassano, 10043, Italy|Iov - Istituto Oncologico Veneto Irccs, Padova, 35128, Italy|Presidio Ospedaliero Pescara, Pescara, 65124, Italy|Azienda Ospedaliera Universitaria Pisana, Pisa, 56126, Italy|Fondazione Policlinico Universitario Agostino Gemelli Irccs, Roma, 00137, Italy|Istituto Nazionale Tumori Regina Elena Irccs, Roma, 00144, Italy|Universita Campus Bio Medico Di Roma, Rome, 00128, Italy|Azienda Ospedaliera San Camillo Forlanini, Rome, 00152, Italy|Irccs Istituto Clinico Humanitas, Rozzano, 20089, Italy|Azienda Ospedaliera Universitaria Senese Policlinico Santa Maria Alle Scotte, Siena, 53100, Italy|Centro Ricerche Cliniche Di Verona (Crc), Verona, 37134, Italy|San Bartolo Hospital, Vicenza, 36100, Italy|University of Tokyo Hospital, Bunkyo, 113-8655, Japan|Chiba Cancer Center, Chiba-shi, 260-8717, Japan|Chiba University Hospital, Chiba, 260-8677, Japan|Kyushu University Hospital, Fukuoka-shi, 812-8582, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, 811-1395, Japan|Hiroshima University Hospital, Hiroshima-shi, 734-8551, Japan|Hyogo College of Medicine Hospital, Hyogo, 663-8501, Japan|Kanazawa University Hospital, Ishikawa, 920-8641, Japan|Teikyo University Hospital, Itabashi-ku, 173-8606, Japan|Kobe University Hospital, Kobe-shi, 650-0017, Japan|Cancer Institute Hospital of Jfcr, Koto-ku, 135-8550, Japan|Kyoto University Hospital, Kyoto-shi, 606-8507, Japan|Nho Shikoku Cancer Center, Matsuyama-shi, 791-0280, Japan|Kyorin University Hospital, Mitaka-shi, 181-8611, Japan|Aichi Cancer Center Hospital, Nagoya-shi, 464-8681, Japan|Niigata Cancer Center Hospital, Niigata, 951-8566, Japan|Osaka International Cancer Institute, Osaka-shi, 541-8567, Japan|Kindai University Hospital, Osakasayama City, 589-8511, Japan|Saitama Cancer Center, Saitama, 362-0806, Japan|Hokkaido University Hospital, Sapporo-shi, 060-8648, Japan|Tohoku University Hospital, Sendai-shi, 980-8574, Japan|Jichi Medical University Hospital, Shimotsuke-shi, 329-0498, Japan|Keio University Hospital, Shinjuku-ku, 160-8582, Japan|Shizuoka Cancer Center, Shizuoka, 411-8777, Japan|Osaka University Hospital, Suita-shi, 565-0871, Japan|Toyama University Hospital, Toyama-shi, 930-0194, Japan|Yamaguchi University Hospital, UBE, 755-8505, Japan|Wakayama Medical University Hospital, Wakayama, 641-8509, Japan|Yokohama City University Medical Center, Yokohama-shi, 232-0024, Japan|Kanagawa Cancer Center, Yokohama-shi, 241-8515, Japan|Oita University Hospital, Yufu-shi, 879-5593, Japan|Amsterdam University Medical Centre, Amsterdam, 1100 DD, Netherlands|Maastricht Umc+, Maastricht, 6202 AZ, Netherlands|Erasmus Medical Center, Rotterdam, 3015 CE, Netherlands|Umc Utrecht, Utrecht, 3584 CX, Netherlands|Oslo University Hospital, Oslo, 00450, Norway|Hospital de La Santa Creu I Sant Pau, Barcelona, 08026, Spain|Hospital General Universitario Vall D Hebron, Barcelona, 08035, Spain|Hospital Clinic Barcelona Main, Barcelona, 08036, Spain|Hospital Universitario Reina Sofia, Cordoba, 14004, Spain|Hospital Universitario Reina Sofia, CÃ³rdoba, 14004, Spain|Hospital Materno Teresa Herrera, La CoruÃ±a, 15006, Spain|Hospital General Universitario Gregorio Maranon, Madrid, 28007, Spain|Hospital Universitario Ramon Y Cajal, Madrid, 28034, Spain|Hospital Universitario Hm Sanchinarro, Madrid, 28050, Spain|Hospital Regional Universitario de Malaga, MÃ¡laga, 29010, Spain|Clinica Universidad de Navarra (Cun), Pamplona, 31008, Spain|Hospital Universitari Parc Tauli, Sabadell, 08208, Spain|HOSPITAL UNiVERSITARIO DONOSTIA, San Sebastian, 20014, Spain|Hospital Universitario Marques de Valdecilla, Santander, 39008, Spain|Hospital General Universitario de Valencia, Valencia, 46014, Spain|Karolinska Institute Universitetssjukhuset Solna, Solna, 171 64, Sweden|Inselspital - Universitaetsspital Bern, Bern, 03010, Switzerland|Universitatsspital Zurich, Zuerich, 08091, Switzerland|Aberdeen Royal Infirmary, Aberdeen, AB25 2ZN, United Kingdom|Addenbrookes Hospital, Cambridge, CB2 0QQ, United Kingdom|Velindre Cancer Centre, Cardiff, CF14 2TL, United Kingdom|University Hospital Coventry and Warwickshire, Coventry, CV2 2DX, United Kingdom|The Royal Marsden Nhs Foundation Trust - Chelsea, London, SW3 6JJ, United Kingdom|Imperial College Healthcare Nhs Trust - Hammersmith Hospital, London, W12 0HS, United Kingdom|University College London Hospitals (Uclh), London, WC1E 6BT, United Kingdom|Kent Oncology Centre - Maidstone Hospital, Maidstone, ME16 9QQ, United Kingdom|The Christie Nhs Foundation Trust, Manchester, M20 4BV, United Kingdom|The Royal Marsden Nhs Foundation Trust - Sutton, Sutton, SM2 5PT, United Kingdom",
NCT05717764,Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment,https://clinicaltrials.gov/study/NCT05717764,,NOT_YET_RECRUITING,"This is a randomized, open-label, positive-controlled, multicenter Phase Ð¨ study to evaluate the efficacy and safety of mitoxantrone hydrochloride liposome injection combined with capecitabine versus capecitabine monotherapy in patients with recurrent metastatic nasopharyngeal carcinoma.",NO,Recurrent Metastatic Nasopharyngeal Carcinoma,DRUG: Mitoxantrone hydrochloride liposome injection|DRUG: Capecitabine,"Progression-free survival (PFS) assessed by the independent review committee (IRC), Progression-Free Survival PFS is defined as the time from randomization to progression or death, Throughout the study period, up to approximately 2 years|Overall survival (OS), Overall survival (OS) is defined as the duration from the date of diagnosis to death or last follow-up, with no restriction on the cause of death., Throughout the study period, up to approximately 2 years","Objective response rate (ORR) assessed by the investigator and IRC, Objective response rate (ORR) is defined as the proportion of patients with a complete response or partial response to treatment, Throughout the study period, up to approximately 2 years|Disease control rate (DCR) assessed by the investigator and IRC, Disease Control Rate (DCR) is defined as the percentage of patients who have achieved complete response, partial response and stable disease to a therapeutic intervention in clinical trials of anticancer agents, Throughout the study period, up to approximately 2 years|Duration of Response (DOR) assessed by the investigator and IRC, Duration of Response (DOR) is defined as time from the first assessment of CR or PR until the date of the first occurrence of PD, or until the date of death, Throughout the study period, up to approximately 2 years|Progression-free survival (PFS) assessed by the investigator, Progression-Free Survival PFS is defined as the time from randomization to progression or death, Throughout the study period, up to approximately 2 years|Frequency and severity of AE (NCI CTCAE 5.0), Throughout the study period, up to approximately 2 years|Blood concentrations of total and free mitoxantrone, At the end of Cycle 4 (each cycle is 28 days)",,"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,500,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-02,2026-09,2027-09,2023-02-08,,2023-02-08,,
NCT06890598,Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT06890598,SUNRAY-02,RECRUITING,The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant.,NO,"Carcinoma, Non-Small-Cell Lung",DRUG: Olomorasib|DRUG: Pembrolizumab|DRUG: Durvalumab|DRUG: Placebo,"Part A: Disease-Free Survival (DFS) by Investigator Assessment, DFS by Investigator Assessment, Randomization to disease recurrence or death from any cause (Estimated as approximately 48 months).|Part B: Progression-Free Survival (PFS), PFS per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by blinded independent central review (BICR), Randomization to disease progression or death from any cause (Estimated as approximately 3 years).","Part A & B: Overall Survival (OS), OS, Randomization to disease progression or death from any cause (Estimated as approximately 5 years).|Part A & B: Change from baseline in health-related quality of life (HRQoL), measured by European Organization for Research & Treatment of CancerQualityofLifeQuestionnaire-Core 30 (EORTC QLQ-C30), Change from baseline in HRQoL, measured by the EORTC QLQ-C30, Randomization through end of treatment (Estimated as approximately 3 years).|Part B: Objective Response Rate (ORR) per RECIST 1.1 by BICR, ORR per RECIST 1.1 by BICR, Randomization to disease progression or death from any cause (Estimated as approximately 3 years).|Part B: Duration of Response (DOR) per RECIST 1.1 by BICR, DOR per RECIST 1.1 by BICR, Randomization to disease progression or death from any cause (Estimated as approximately 3 years).|Part B: Disease Control Rate (DCR) per RECIST 1.1 by BICR, DCR per RECIST 1.1 by BICR, Randomization to disease progression or death from any cause (Estimated as approximately 3 years).|Part B: Time to Response (TTR) per RECIST 1.1 by BICR, TTR per RECIST 1.1 by BICR, Randomization until the date that measurement criteria for CR or PR (whichever is first recorded) are first met (Estimated as approximately 3 years).|Part B: Progression-Free Survival 2 (PFS2) by investigator assessment, PFS2 by investigator assessment, Randomization to disease progression on next line of treatment or death from any cause (Estimated as approximately 3 years).]|Part B: Changes in Non-Small Cell Lung Cancer (NSCLC)-related symptoms, measured by the NSCLC-Symptom Assessment Questionnaire (SAQ), Changes in NSCLC-related symptoms, measured by the NSCLC-SAQ, Randomization through end of treatment (Estimated as approximately 3 years).|Part B: Time to worsening of NSCLC-related symptoms, as measured by NSCLC-SAQ, Time to worsening of NSCLC-related symptoms, as measured by NSCLC-SAQ, Randomization through end of treatment (Estimated as approximately 3 years).|Part B: Changes in patient-reported pulmonary symptoms of cough, chest pain, and dyspnea, measured by NSCLC-SAQ, Changes in patient-reported pulmonary symptoms of cough, chest pain, and dyspnea, measured by NSCLC-SAQ, Randomization through end of treatment (Estimated as approximately 3 years).",,Eli Lilly and Company,AstraZeneca,ALL,"ADULT, OLDER_ADULT",PHASE3,700,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2025-03-27,2029-05,2032-02,2025-03-24,,2025-06-05,"University of Alabama at Birmingham, Birmingham, Alabama, 35294-3300, United States|Clearview Cancer Institute, Huntsville, Alabama, 35805, United States|The University of Arizona Cancer Center - North Campus, Tucson, Arizona, 85719, United States|Highlands Oncology Group, Springdale, Arkansas, 72762, United States|UCLA Hematology/Oncology - Santa Monica, Los Angeles, California, 90404, United States|Profound Research LLC, Oceanside, California, 92056, United States|University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange, California, 92868, United States|Stanford Cancer Center, Palo Alto, California, 94304, United States|Kaiser Permanente San Diego Mission Road, San Diego, California, 92108, United States|BASS Cancer Center, Walnut Creek, California, 94598, United States|Hartford Hospital (HH), Hartford, Connecticut, 06102, United States|Sibley Memorial Hospital, Washington, District of Columbia, 20016, United States|Boca Raton Regional Hospital, Boca Raton, Florida, 33486, United States|Florida Cancer Specialists - South, Fort Myers, Florida, 33901, United States|University of Florida - Jacksonville, Jacksonville, Florida, 32209, United States|Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, 33176, United States|Florida Cancer Specialists North, Saint Petersburg, Florida, 33705, United States|Comprehensive Hematology Oncology, Saint Petersburg, Florida, 33709, United States|Moffitt Cancer Center, Tampa, Florida, 33612, United States|Florida Cancer Specialists East, West Palm Beach, Florida, 33401, United States|University of Illinois at Chicago, Chicago, Illinois, 60612, United States|University of Chicago Medical Center, Chicago, Illinois, 60637, United States|Captain James A. Lovell Federal Health Care Center, North Chicago, Illinois, 60064, United States|Springfield Clinic Main Campus, Springfield, Illinois, 62703, United States|Parkview Research Center at Parkview Regional Medical Center, Fort Wayne, Indiana, 46845, United States|Franciscan Health, Indianapolis, Indiana, 46237, United States|The University of Kansas Cancer Center - Westwood, Westwood, Kansas, 66205, United States|Baptist Health Lexington, Lexington, Kentucky, 40503, United States|CHI Saint Joseph Cancer Center - East, Lexington, Kentucky, 40509, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, 70809, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, 70121, United States|University of Maryland, Baltimore, Maryland, 21201, United States|Johns Hopkins Bayview Medical Center, Baltimore, Maryland, 21224, United States|Reliant Medical Group, Worcester, Massachusetts, 01606, United States|Karmanos Cancer Institute, Detroit, Michigan, 48201, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, 63131, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States|Roswell Park Cancer Institute, Buffalo, New York, 14263, United States|Columbia University Irving Medical Center, New York, New York, 10032, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Northport VA Medical Center, Northport, New York, 11768, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|Providence Portland Medical Center, Portland, Oregon, 97213, United States|Providence St. Vincent Medical Center, Portland, Oregon, 97225, United States|Kaiser Permanente Interstate Medical Office Central, Portland, Oregon, 97227, United States|Oregon Health and Science University, Portland, Oregon, 97239, United States|Thomas Jefferson University, Sidney Kimmel Cancer Center - Clinical Trials Office, Philadelphia, Pennsylvania, 19107, United States|AHN Allegheny General Hospital, Pittsburgh, Pennsylvania, 15212, United States|Medical University of South Carolina, Charleston, South Carolina, 29425, United States|Lexington Medical Center, West Columbia, South Carolina, 29169, United States|Tennessee Oncology Chattanooga, Chattanooga, Tennessee, 37404, United States|University of Tennessee Medical Center, Knoxville, Tennessee, 37920, United States|Sarah Cannon Research Institute, Nashville, Tennessee, 37203, United States|SCRI Oncology Partners, Nashville, Tennessee, 37203, United States|Tennessee Oncology, Nashville, Tennessee, 37203, United States|The Center for Cancer and Blood Disorders, Fort Worth, Texas, 76104, United States|Houston Methodist Hospital, Houston, Texas, 77030, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|USO - Texas Oncology - San Antonio, San Antonio, Texas, 78240, United States|USO - Texas Oncology Gulf Coast, Sugar Land, Texas, 77479, United States|USO - US Oncology Research Network, The Woodlands, Texas, 77380, United States|University of Virginia Health System, Charlottesville, Virginia, 22903, United States|VCU Health Adult Outpatient Pavillion, Richmond, Virginia, 23219, United States|Swedish Cancer Institute - Edmonds, Edmonds, Washington, 98026, United States|Swedish Medical Center, Seattle, Washington, 98104, United States|Cancer Care Northwest - Vercler, Spokane Valley, Washington, 99216, United States|Northwest Cancer Specialists PC, Vancouver, Washington, 98684, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States|Tamworth Hospital, North Tamworth, New South Wales, 2340, Australia|Icon Cancer Centre Wesley, Auchenflower, Queensland, 4066, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, 4575, Australia|ICON Cancer Centre - Kurralta Park, Kurralta Park, South Australia, 5037, Australia|Austin Health, Heidelberg, Victoria, 3084, Australia|Goulburn Valley Health, Shepparton, Victoria, 3630, Australia|Latrobe Regional Health, Traralgon, Victoria, 3844, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, 6009, Australia|Ordensklinikum Linz GmbH Elisabethinen, Linz, OberÃ¶sterreich, 4020, Austria|Medizinische UniversitÃ¤t Graz, Graz, Steiermark, 8036, Austria|Klinik Floridsdorf, Wien, 1210, Austria|Antwerp University Hospital, Edegem, Antwerpen, 2650, Belgium|CHIREC - site delta, Auderghem, Bruxelles-Capitale, RÃ©gion De, 1160, Belgium|UZ Leuven, Leuven, Vlaams-Brabant, 3000, Belgium|AZ Delta vzw, Roeselare, West-Vlaanderen, 8800, Belgium|Centro de Pesquisa ClÃ­nica do Instituto do CÃ¢ncer do CearÃ¡, Fortaleza, CearÃ¡, 60430235, Brazil|Oncocentro de Minas Gerais, Belo Horizonte, Minas Gerais, 30180-060, Brazil|Hospital de Cancer de Londrina, Londrina, ParanÃ¡, 86015-520, Brazil|CTO - Centro de Tratamento OncolÃ³gico, Belem, ParÃ¡, 66063-495, Brazil|Liga Norte Riograndense Contra o CÃ¢ncer, Natal, Rio Grande Do Norte, 59075-740, Brazil|Hospital Tacchini, Bento GonÃ§alves, Rio Grande Do Sul, 95700-084, Brazil|Hospital SÃ£o Lucas da PUCRS, Porto Alegre, Rio Grande Do Sul, 90610-000, Brazil|FundaÃ§Ã£o Pio XII - Hospital de CÃ¢ncer de Barretos, Barretos, SÃ£o Paulo, 14784400, Brazil|Centro de Pesquisa Sao Lucas, Campinas, SÃ£o Paulo, 13060-803, Brazil|Instituto D'Or de Pesquisa e Ensino (IDOR), Sao Paulo, SÃ£o Paulo, 04543-000, Brazil|Centro de Tratamento de Tumores Botafogo para Oncoclinicas Rio de Janeiro SA, Rio de Janeiro, 22250-905, Brazil|Instituto D'Or Pesquisa e Ensino, Rio de Janeiro, 22271-110, Brazil|Icesp - Instituto Do CÃ¢ncer Do Estado de SÃ£o Paulo, SÃ£o Paulo, 01246-000, Brazil|Hospital Santa Catarina - Paulista, SÃ£o Paulo, 01310-000, Brazil|Centro Paulista de Oncologia ClÃ­nica, SÃ£o Paulo, 01452-000, Brazil|K2 Oncology, Providencia, RegiÃ³n Metropolitana De Santiago, 7520426, Chile|FALP, Santiago, RegiÃ³n Metropolitana De Santiago, 7500921, Chile|Bradfordhill, Santiago, RegiÃ³n Metropolitana De Santiago, 8420383, Chile|Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, 100021, China|China-Japan Friendship Hospital, Beijing, Beijing, 100029, China|Peking University People's Hospital, Beijing, Beijing, 100034, China|Beijing Cancer hospital, Beijing, Beijing, 100142, China|The Second Affiliated Hospital Chongqing Medical University, Chongqing, Chongqing, 400072, China|The First People's Hospital of Foshan, Foshan, Guangdong, 528041, China|Guangdong Provincial People's Hospital, Guangzhou, Guangdong, 510120, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China|Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, 515000, China|ShenZhen People's Hospital, Shenzhen, Guangdong, 518020, China|Cancer Hospital Chinese Academy of Medical Sciences. Shenzhen Center, Shenzhen, Guangdong, 518127, China|Zhongshan Peoples Hospital, Zhongshan, Guangdong, 528403, China|Liuzhou People's Hospital, Liuzhou, Guangxi, 545006, China|Guangxi Medical University Affiliated Tumor Hospital, Nanning, Guangxi, 530021, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China|Anyang Cancer Hospital, Anyang, Henan, 455000, China|The First Affiliated Hospital of Henan University of Science &Technology, Luoyang, Henan, 471003, China|Tongji Hospital Tongji Medical,Science & Technology, Wuhan, Hubei, 430030, China|Hubei Cancer Hospital, Wuhan, Hubei, 430079, China|Xiangya Hospital Central South University, Changsha, Hunan, 410008, China|Xiangya Hospital Central South University, Changsha, Hunan, 410008, China|Hunan Cancer Hospital, Changsha, Hunan, 410013, China|Hunan Cancer Hospital, Changsha, Hunan, 410013, China|ZhuZhou Central Hospital, Zhuzhou, Hunan, 412007, China|The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 215006, China|Jilin Cancer Hospital, Changchun, Jilin, 132000, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China|Jinan Central Hospital, Jinan, Shandong, 250013, China|Shandong Cancer Hospital, Jinan, Shandong, 250117, China|Shanghai Chest Hospital, Shanghai, Shanghai, 200030, China|Fudan University Shanghai Cancer Center, Shanghai, Shanghai, 200032, China|Shanghai Pulmonary Hospital, Shanghai, Shanghai, 200433, China|West China Hospital, Sichuan University, Cheng Du, Sichuan, 610041, China|The Third People's Hospital of Chengdu (CDTPH), Chengdu, Sichuan, 610031, China|Sichuan Cancer hospital, Chengdu, Sichuan, 610041, China|The Second People's Hospital of Neijiang, Neijiang, Sichuan, 641000, China|Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, 300060, China|Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China|Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, 310014, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, 310022, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, 310022, China|The Second Affiliated hospital of Zhejiang University school of medicine, Hangzhou, Zhejiang, 310052, China|Taizhou Hospital of Zhejiang Province, Linhai, Zhejiang, 317000, China|Nemocnice AGEL Ostrava - Vitkovice a.s., Ostrava, Ostrava MÄsto, 703 00, Czechia|Fakultni nemocnice Bulovka, Prague, Praha 8, 180 81, Czechia|Centre Antoine-Lacassagne, Nice, Alpes-Maritimes, 06189, France|CHU Bordeaux Haut-Leveque, Pessac, Aquitaine, 33600, France|Assistance Publique HÃ´pitaux de Marseille - HÃ´pital Nord, Marseille, Bouches-du-RhÃ´ne, 13915, France|CHU de Toulouse - Hopital Larrey, Toulouse, Haute-Garonne, 31059, France|Centre Hospitalier Universitaire de Rennes - HÃ´pital Pontchaillou, Rennes, Ille-et-Vilaine, 35033, France|Chu Grenoble Alpes, La Tronche, IsÃ¨re, 38700, France|Institut de CancÃ©rologie de l'Ouest, Saint Herblain, Loire-Atlantique, 44805, France|HÃ´pital Robert Schuman, Vantoux, Lorraine, 57070, France|Institut Jean Godinot, Reims, Marne, 51726, France|Centre Leon Berard, Lyon Cedex08, RhÃ´ne-Alpes, 69373, France|Hospices Civils de Lyon - Hopital Louis Pradel, Bron, RhÃ´ne, 69677, France|Gustave Roussy, Villejuif, Val-de-Marne, 94800, France|Centre Hospitalier Universitaire de Poitiers, Poitiers, Vienne, 86021, France|Institut Curie, Paris, 75248, France|Groupe hospitalier Paris saint Joseph, Paris, Ãle-de-France, 75014, France|HÃ´pital EuropÃ©en Georges Pompidou, Paris, Ãle-de-France, 75015, France|Thoraxklinik-Heidelberg gGmbH, Heidelberg, Baden-WÃ¼rttemberg, 69126, Germany|Robert Bosch Krankenhaus GmbH, Stuttgart, Baden-WÃ¼rttemberg, 70376, Germany|Universitaetsklinikum Tuebingen, TÃ¼bingen, Baden-WÃ¼rttemberg, 72076, Germany|Onkologiezentrum DonauwÃ¶rth, DonauwÃ¶rth, Bayern, 86609, Germany|Asklepios Fachkliniken MÃ¼nchen-Gauting, Gauting, Bayern, 82131, Germany|Klinikum NÃ¼rnberg Nord, NÃ¼rnberg, Bayern, 90419, Germany|MV-Zentrum fÃ¼r Onkologie und HÃ¤matologie, Cologne, Nordrhein-Westfalen, 50677, Germany|Florence-Nightingale-Krankenhaus, DÃ¼sseldorf, Nordrhein-Westfalen, 40489, Germany|Klinikum KÃ¶ln-Merheim, KÃ¶ln, Nordrhein-Westfalen, 51109, Germany|Krankenhaus Martha-Maria Halle-DÃ¶lau, Halle, Sachsen-Anhalt, 06120, Germany|Klinikum Chemnitz, Chemnitz, Sachsen, 09116, Germany|St. Elisabeth-Krankenhaus Leipzig, Leipzig, Sachsen, 04277, Germany|LungenClinic Grosshansdorf, Grosshansdorf, Schleswig-Holstein, 22927, Germany|HELIOS Klinikum Erfurt, Erfurt, ThÃ¼ringen, 99089, Germany|Vivantes Klinikum im Friedrichshain - Landsberger Allee, Berlin, 10249, Germany|Evangelische Lungenklinik Berlin, Berlin, 13125, Germany|DRK Kliniken Berlin Mitte, Berlin, 13359, Germany|Franziskus-Hospital Harderberg, GeorgsmarienhÃ¼tte, 49124, Germany|Asklepios Klinik Harburg, Hamburg, 21075, Germany|University Hospital of Patras, Patras, Achaá¸¯a, 26504, Greece|Agios Savvas Regional Cancer Hospital, Athens, AttikÃ­, 115 22, Greece|Errikos Dunant Hospital Center, Athens, AttikÃ­, 115 26, Greece|Thoracic General Hospital of Athens ""I Sotiria"", Athens, AttikÃ­, 115 27, Greece|University General Hospital of Heraklion, Heraklion, IrakleÃ­o, 715 00, Greece|Agios Loukas Clinic, Thessaloniki, KentrikÃ­ MakedonÃ­a, 552 36, Greece|European Interbalkan Medical Center, Thessaloniki, ThessalonÃ­ki, 570 01, Greece|University General Hospital of Larissa, Larissa, ThessalÃ­a, 41110, Greece|Farkasgyepui Tudogyogyintezet, Farkasgyepu, VeszprÃ©m, 8582, Hungary|OrszÃ¡gos OnkolÃ³giai IntÃ©zet, Budapest, 1122, Hungary|Budapesti Uzsoki Utcai KÃ³rhÃ¡z, Budapest, 1145, Hungary|Savera Cancer & Multi Speciality Hospital, Patna, Bihar, 800020, India|Rajiv Gandhi Cancer Institute And Research Centre, New Delhi, Delhi, 110085, India|Hemato Oncology Clinic, Ahmedabad, Gujarat, 380054, India|Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak, Haryana, 124001, India|Malabar Cancer Centre - Thalassery, Thalassery, Kerala, 670103, India|Regional Cancer Centre - Thiruvananthapuram, Thiruvananthapuram, Kerala, 695011, India|Galaxy Superspeciality Hospital, Aurangabad, Maharashtra, 431001, India|Sir H. N. Reliance Foundation Hospital and Research Centre, Mumbai, Maharashtra, 400004, India|Deenanath Mangeshkar Hospital & Research Centre, Pune, Maharashtra, 411004, India|Medipoint Hospitals Pvt. Ltd., Pune, Maharashtra, 411007, India|Pacific Medical College & Hospital, Udaipur, Rajasthan, 313001, India|Rajiv Gandhi Government General Hospital, Chennai, Tamil Nadu, 600003, India|Thangam Cancer Center - Namakkal, Namakkal, Tamil Nadu, 637001, India|Tata Memorial Centre - Homi Bhabha Cancer Hospital, Varanasi, Uttar Pradesh, 221002, India|Meir Medical Center, Kfar Saba, HaMerkaz, 4428164, Israel|Sheba Medical Center, Ramat Gan, HaMerkaz, 5265601, Israel|Rambam Health Care Campus, Haifa, HaTsafon, 3109601, Israel|Shaare Zedek Medical Center, Jerusalem, Yerushalayim, 9013102, Israel|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Emilia-Romagna, 47014, Italy|Ospedale San Gerardo-ASST Monza, Monza, Lombardia, 20900, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milan, Milano, 20162, Italy|Azienda Ospedaliera Dei Colli, Naples, Napoli, 80131, Italy|Azienda Sanitaria Ospedaliera S Luigi Gonzaga, Orbassano, Piemonte, 10043, Italy|Instituto Tumori Giovanni Paolo II, Bari, Puglia, 70124, Italy|Istituto Nazionale Tumori Regina Elena, Rome, Roma, 00144, Italy|Policlinico ""G. Rodolico"", Catania, Sicilia, 95123, Italy|Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Trento, Verona, Veneto, 37126, Italy|Ospedale San Martino, Genova, 16132, Italy|Aichi Cancer Center Hospital, Nagoya, Aichi, 464-8681, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, 277-8577, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, 060-8648, Japan|Himeji Medical Center, Himeji, Hyogo, 670-8520, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, 920-8641, Japan|Kanagawa Cardiovascular and Respiratory Center, Yokohama, Kanagawa, 236-0051, Japan|Kanagawa cancer center, Yokohama, Kanagawa, 2418515, Japan|Miyagi Cancer Center, Natori, Miyagi, 981-1293, Japan|Niigata Cancer Center Hospital, Niigata-shi, Niigata, 951-8566, Japan|Kansai Medical University Hospital, Hirakata, Osaka, 573-1191, Japan|NHO Kinki Chuo Chest Medical Center, Sakai, Osaka, 591-8555, Japan|Saitama Medical University International Medical Center, Hidaka, Saitama, 350-1298, Japan|Shizuoka Cancer Center, Nagaizumi-cho,Sunto-gun, Shizuoka, 411-8777, Japan|Tokyo Metropolitan Komagome Hospital, Bunkyo ku, Tokyo, 113-8677, Japan|Juntendo University Hospital, Bunkyo-ku, Tokyo, 113-8431, Japan|The Cancer Institute Hospital of JFCR, Koto, Tokyo, 135-8550, Japan|Tottori University Hospital, Yonago, Tottori, 683-8504, Japan|Kyushu University Hospital, Fukuoka, 812-8582, Japan|University Hospital,Kyoto Prefectural University of Medicine, Kyoto, 602-8566, Japan|Wakayama Medical University Hospital, Wakayama, 641-8510, Japan|Chungbuk National University Hospital, Cheongju-si, Chungcheongbuk-do [Chungbuk], 28644, Korea, Republic of|The Catholic University of Korea, Incheon St. Mary's Hospital, Bupyeong-gu, Incheon-gwangyeoksi [Incheon], 21431, Korea, Republic of|Chonnam National University Hwasun Hospital, Hwasun-gun, Jeonranamdo, 58128, Korea, Republic of|National Cancer Center, Goyang-si, KyÇnggi-do, 10408, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, KyÇnggi-do, 13620, Korea, Republic of|The Catholic University Of Korea St. Vincent's Hospital, Suwon-si, KyÇnggi-do, 16247, Korea, Republic of|Pusan National University Yangsan Hospital, Yangsan, KyÇngsangnam-do, 50612, Korea, Republic of|Pusan National University Hospital, Busan, Pusan-KwangyÇkshi, 49241, Korea, Republic of|Gangnam Severance Hospital, Yonsei University Health System, Gangnam-gu, Seoul-teukbyeolsi [Seoul], 06273, Korea, Republic of|The Catholic University of Korea, Eunpyeong St. Mary's Hospital, Seoul, Seoul-teukbyeolsi [Seoul], 03312, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Seoul-teukbyeolsi [Seoul], 03722, Korea, Republic of|Konkuk University Medical Center, Seoul, Seoul-teukbyeolsi [Seoul], 05030, Korea, Republic of|Asan Medical Center, Seoul, Seoul-teukbyeolsi [Seoul], 05505, Korea, Republic of|Samsung Medical Center, Seoul, Seoul-teukbyeolsi [Seoul], 06351, Korea, Republic of|The Catholic Univ. of Korea Seoul St. Mary's Hospital, Seoul, Seoul-teukbyeolsi [Seoul], 06591, Korea, Republic of|The Catholic University of Korea, Yeouido St. Mary's Hospital, Seoul, Seoul-teukbyeolsi [Seoul], 07345, Korea, Republic of|Korea University Guro Hospital, Seoul, Seoul-teukbyeolsi [Seoul], 08308, Korea, Republic of|Keimyung University Dongsan Hospital, Daegu, Taegu-KwangyÇkshi, 42601, Korea, Republic of|Kyungpook National University Chilgok Hospital, Deagu, Taegu-KwangyÇkshi, 41404, Korea, Republic of|Yeungnam Univeristy Medical Center, Nam-gu, Taegu-KwangyÇkshi, 42415, Korea, Republic of|Ziekenhuis St. Jansdal, Harderwijk, Gelderland, 3844 DG, Netherlands|Amphia Ziekenhuis, locatie Breda Molengracht, Breda, Noord-Brabant, 4818 CK, Netherlands|ETZ Elisabeth, Tilburg, Noord-Brabant, 5022 GC, Netherlands|Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, Noord-Holland, 1066 CX, Netherlands|Amsterdam UMC, locatie VUmc, Amsterdam, Noord-Holland, 1081 HV, Netherlands|Isala, locatie Zwolle, Zwolle, Overijssel, 8025 AB, Netherlands|St. Antonius Ziekenhuis, locatie Utrecht, Utrecht, 3543 AZ, Netherlands|Sorlandet Sykehus Arendal, Arendal, Aust-Agder, 4838, Norway|Drammen Sykehus, Vestre Viken HF, Drammen, Buskerud, 3004, Norway|Haukeland Universitetssjukehus, Bergen, Hordaland, 5021, Norway|Sykehuset Innlandet HF GjÃ¸vik, GjÃ¸vik, Oppland, 2819, Norway|Oslo Universitetssykehus UllevÃ¥l, Oslo, 0450, Norway|Wielkopolskie Centrum Pulmonologii i Torakochirurgii, Poznan, Wielkopolskie, 60-569, Poland|One Day Med, Szczecin, Zachodniopomorskie, 70-419, Poland|Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Kielce, ÅwiÄtokrzyskie, 25-734, Poland|Centro Hospitalar E UniversitÃ¡rio De Coimbra, Coimbra, 3040, Portugal|Hospital da Luz Lisboa, Lisboa, 1500-650, Portugal|Hospital CUF Porto, Porto, 4100-180, Portugal|Instituto PortuguÃªs de Oncologia do Porto Francisco Gentil, EPE, Porto, 4200-072, Portugal|Lotus-Med, Bucharest, BucureÈti, 012292, Romania|SC Memorial Healthcare International SRL, Bucharest, BucureÈti, 013812, Romania|Ovidius Clinical Hospital OCH, Ovidiu, ConstanÈa, 905900, Romania|Institutul Oncologic, Cluj, 400015, Romania|Fakultna nemocnica s poliklinikou F.D.Roosevelta Banska Bystrica, Banska Bystrica, BanskobystrickÃ½ Kraj, 97517, Slovakia|UniverzitnÃ¡ nemocnica Bratislava - Nemocnica RuÅ¾inov, Bratislava, BratislavskÃ½ Kraj, 821 01, Slovakia|Vychodoslovensky Onkologicky ustav a.s., Kosice, 041 91, Slovakia|CHUS - Hospital Clinico Universitario, Santiago de Compostela, A CoruÃ±a [La CoruÃ±a], 15706, Spain|Hospital Universitari Son Espases, Palma, Balears [Baleares], 07120, Spain|Parc de Salut Mar - Hospital del Mar, Barcelona, Barcelona [Barcelona], 08003, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Barcelona [Barcelona], 08035, Spain|Instituto Catalan de Oncologia - Hospital Duran i Reynals, Hospitalet, Barcelona [Barcelona], 08907, Spain|Hospital ClÃ­nic de Barcelona, Barcelona, Catalunya [CataluÃ±a], 08036, Spain|Hospital Jerez de la Frontera, Jerez de la Frontera, CÃ¡diz, 11407, Spain|Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Las Palmas, 35016, Spain|Hospital General Universitario Gregorio MaraÃ±on, Madrid, Madrid, Comunidad De, 28009, Spain|Hospital Universitario RamÃ³n y Cajal, Madrid, Madrid, Comunidad De, 28034, Spain|Hospital Universitario 12 de Octubre, Madrid, Madrid, Comunidad De, 28041, Spain|Hospital Universitario Quironsalud Madrid, Pozuelo de Alarcon, Madrid, 28223, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, 31009, Spain|Hospital Clinico de Valencia, Valencia, Valenciana, Comunitat, 46010, Spain|Hospital Infanta Cristina, Badajoz, 06006, Spain|H.R.U MÃ¡laga - Hospital General, MÃ¡laga, 29011, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, 41013, Spain|Hospital ClÃ­nico Universitario Lozano Blesa, Zaragoza, 50009, Spain|Sahlgrenska Universitetssjukhuset Ãstra, GÃ¶teborg, VÃ¤stra GÃ¶talands LÃ¤n [se-14], 413 45, Sweden|Kantonsspital Baden, Baden, 5404, Switzerland|HFR Fribourg - HÃ´pital Cantonal, Fribourg, 1708, Switzerland|UniversitÃ¤tsSpital ZÃ¼rich, ZÃ¼rich, 8091, Switzerland|Changhua Christian Hospital, Changhua County, Changhua, 50006, Taiwan|Hualien Tzu Chi Medical Center, Hualien City, Hualien, 970, Taiwan|Chang Gung Memorial Hospital at Kaohsiung, Kaohsiung Niao Sung Dist, Kaohsiung, 83301, Taiwan|Far Eastern Memorial Hospital, New Taipei City, New Taipei, 220, Taiwan|New Taipei Municipal TuCheng Hospital, New Taipei City, New Taipei, 236, Taiwan|Chung Shan Medical University Hospital, Taichung City, Taichung, 402, Taiwan|Chi Mei Medical Center, Tainan City, Tainan, 71004, Taiwan|Chi Mei Hospital - Liouying Branch, Tainan City, Tainan, 73657, Taiwan|National Taiwan University Cancer Center (NTUCC), Taipei City, Taipei, 106, Taiwan|National Taiwan University Hospital Yun-Lin Branch Dou-Liou Region, Douliu City, Yunlin, 640, Taiwan|Buddhist Dalin Tzu Chi General Hospital, Chiayi, 622, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, 807, Taiwan|E-Da hospital, Kaohsiung, 82445, Taiwan|Taichung Veterans General Hospital, Taichung, 407, Taiwan|National Cheng Kung University Hospital, Tainan, 704, Taiwan|National Taiwan University Hospital, Taipei, 10002, Taiwan|Taipei Veterans General Hospital, Taipei, 11217, Taiwan|Chang Gung Medical Foundation-Linkou Branch, Taoyuan, 333, Taiwan|Marmara Universitesi Pendik Egitim Arastirma Hastanesi, Pendik, Ä°stanbul, 34899, Turkey|Sakarya University School of Medicine, Adapazari, Sakarya, 54290, Turkey|Baskent University Dr. Turgut Noyan Research and Training Center, Adana, 01250, Turkey|Adana City Hospital, Adana, 01370, Turkey|Antalya Egitim ve ArastÄ±rma Hastanesi, Antalya, 07100, Turkey|Trakya University, Edirne, 22030, Turkey|Gaziantep Universitesi Sahinbey Arastirma ve Uygulama Hastanesi, Gaziantep, 27310, Turkey|Ä°.A.Ã VM Medical Park Florya Hastanesi, Istanbul, 34295, Turkey|Izmir AtatÃ¼rk Training and Research Hospital, Izmir, 35360, Turkey|Samsun Medical Park Hastanesi, Samsun, 55200, Turkey|University Hospitals Sussex NHS Foundation Trust, East Sussex, Brighton And Hove, BN2 5BE, United Kingdom|Torbay Hospital, Torquay, Devon, TQ2 7AA, United Kingdom|Huddersfield Royal Infirmary, Huddersfield, England, HD3 3EA, United Kingdom|Royal Marsden Hospital (Chelsea), London, Kensington And Chelsea, SW3 6JJ, United Kingdom|Royal Marsden Hospital (Sutton), London, Sutton, SM2 5PT, United Kingdom|Heartlands Hospital, Birmingham, B9 5SS, United Kingdom|The Christie NHS Foundation Trust, Manchester, M20 4BX, United Kingdom",
NCT06469879,A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients,https://clinicaltrials.gov/study/NCT06469879,,NOT_YET_RECRUITING,"This study is a randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy and safety of TQB2450 in combination with anlotinib as maintenance therapy in patients with limited-stage small cell lung cancer who have not progressed after chemoradiotherapy.",NO,Small Cell Lung Cancer Limited Stage,DRUG: TQB2450+Anlotinib|DRUG: TQB2450 placebo + Anlotinib placebo,"Progression-free survival (PFS) evaluated by the Independent Review Committee (IRC), Random to the time of disease progression or death., up to 33 months","Progression-free survival (PFS) evaluated by researcher, Random to the time of disease progression or death., up to 33 months|Overall survival (OS), Time from random to death., About 5 years|Objective mitigation rate (ORR), The proportion of patients whose tumor volume shrinks to the predetermined value and can maintain the minimum time limit is the sum of the proportion of complete remission (CR) and partial remission (PR)., up to 33 months|Remission duration (DOR), The period when the first judgment is complete or partial remission until it is found to be the progress of the disease., up to 33 months|Disease control rate, The number of cases with remission (PR+CR) and disease stability (SD) after treatment as a percentage of the number of evaluable cases., up to 33 months|No progress survival PFS rate in 12 or 24 months, If the tumor progresses or dies in 12 or 24 months, the time is from the beginning of the follow-up to the event. The proportion of all subjects who have not yet occurred at a certain time is called (no progress) survival rate., up to 33 months",,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,358,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-09,2026-09,2026-09,2024-06-24,,2024-07-01,"Anhui Provincial Hospital, Hefei, Anhui, 23002, China|Lanzhou University Second Hospital, Lanzhou, Gansu, 730030, China|Guangxi Medical University Cancer Hospital, Nanjing, Guangxi, 530021, China|Tangshan People's Hospital, Tangshan, Hebei, 63001, China|Harbin Medical University cancer hospital, Harbin, Heilongjiang, 150081, China|AnYang Tumor Hospital, Anyang, Henan, 455001, China|Xiangyang Central Hospital, Xiangyang, Hubei, 441021, China|Hunan Cancer Hospital, Changsha, Hunan, 410013, China|The First Hospital of China Medical University, Shenyang, Liaoning, 110002, China|Qilu Hospital of Shandong University, Jinan, Shandong, 250063, China|Shandong Cancer Hospital, Jinan, Shandong, 250117, China|Shanxi Provincial Cancer Hpspital, Taiyuan, Shanxi, 030000, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, 710061, China|The Second People's Hospital of Neijiang, Neijiang, Sichuan, 641199, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, 310022, China|Beijing Chest Hospital, Capital Medical University, Beijing, 101149, China",
NCT06629779,A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.,https://clinicaltrials.gov/study/NCT06629779,,RECRUITING,This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naÃ¯ve.,NO,Metastatic Castration-Resistant Prostate Cancer,DRUG: PF-06821497|DRUG: Placebo|DRUG: Enzalutamide,"Radiographic Progression Free Survival (rPFS), rPFS is defined as the time from the date of randomization to first objective evidence of radiographic progression as assessed in soft tissue per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or in bone per Prostate Cancer Clinical Trials Working Group 3 (PCWG3) guidelines by BICR, or death, whichever occurs first., Randomization up to approximately 3 years","Overall survival (OS), OS is defined as the time from the date of randomization to the date of death due to any cause., Randomization up to approximately 5 years|To demonstrate that PF-06821497 in combination with enzalutamide is superior to placebo in combination with enzalutamide in prolonging TTPP, TTPP (alpha protected): assessed using time to first â¥2-point increase from baseline score on BPI-SF Item 3 (Worst Pain) observed at 2 consecutive visits or the initiation of short- or long-acting opioid use for pain, Randomization up to approximately 3 years|Duration of Response (DoR) in measurable soft tissue disease, The DoR is defined as the time from the first objective evidence of soft tissue response (CR or PR, whichever is earlier) to radiographic progression or death due to any cause whichever occurs first., Randomization up to approximately 3 years.|Time to prostate specific antigen (PSA) progression., Time from the date of randomization to the date of the first PSA progression. PSA progression is defined as a â¥25% increase in PSA with an absolute increase of â¥2 ng/mL above the nadir (or baseline for participants with no PSA decline), confirmed by a second consecutive PSA value at least 21 days later., Randomization up to approximately 3 years|Prostate Specific Antigen Response, Proportion of participants with PSA response â¥50% in participants with detectable PSA values at baseline., Randomization up to approximately 3 years.|Time to initiation of antineoplastic therapy., Time from randomization to first use of new antineoplastic therapy., Randomization up to approximately 3 years.|Time to initiation of cytotoxic chemotherapy., Time from randomization to first use of new cytotoxic chemotherapy., Randomization up to approximately 3 years|Time to first symptomatic skeletal event, Time from randomization to first symptomatic skeletal event (symptomatic bone fractures, spinal cord compression, surgery or radiation to the bone whichever is first)., Randomization up to approximately 3 years.|Progression free survival on next line of therapy, the time from the date of randomization to the first occurrence of investigator-determined disease progression (PSA progression, progression on imaging, or clinical progression) or death due to any cause, whichever occurs first, while the participant was receiving first subsequent therapy for prostate cancer., Randomization up to approximately 3 years|Incidence of Adverse Events, Type, incidence, severity \[as graded by National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) v5.0\], seriousness and relationship to study medications of AEs., Randomization up to approximately 5 years|To assess circulating tumor DNA (ctDNA) at baseline and on treatment to evaluate tumor burden., Evaluation of ctDNA burden at baseline and on study., Baseline up to approximately 3 years.|To evaluate the PK of PF-06821497 when dosed with enzalutamide, PK characterized by pre-dose trough and post-dose plasma concentrations of PF-06821497 at selected visits, Cycle 1 Day 15 to last PK draw at Cycle 6 Day 1 (cycle length is 28 days)|Change from baseline in patient reported pain symptoms per Brief Pain Inventory-Short Form (BPI-SF), Analysis of Brief Pain Inventory-Short Form (BPI-SF) will be based on the pain severity score (mean of individual BPI-SF items 3, 4, 5 and 6), the pain interference score (mean of items 9A-9G), and the single BPI-SF Item 3 which asks the patient to rate pain at its worst in the last 24 hours., Randomization up to approximately 5 years|Change from baseline in BPI-SF Item 3 (Worst Pain) at Cycle 7 Day 1 (Week 25), Analysis of Brief Pain Inventory-Short Form (BPI-SF) will be based on the pain severity score (mean of individual BPI-SF items 3, 4, 5 and 6), the pain interference score (mean of items 9A-9G), and the single BPI-SF Item 3 which asks the patient to rate pain at its worst in the last 24 hours., Randomization up to Week 25|Change from baseline in health-related quality of life (HRQoL) per Functional Assessment of Cancer Therapy - Prostate (FACT-P), Change from baseline in HRQoL (FACT-P total score) will be presented. The FACT-P total score will be calculated based on the participant responses to the 39 items in the FACT-P questionnaire. Each item is rated on a 0 to 4 Likert-type scale and then combined to produce the FACT-P total score (0-156), with higher scores representing better health-related quality of life., Randomization up to approximately 5 years|Change from baseline in patient reported health status per European Quality of Life 5-Dimension 5 Level (EQ-5D-5L), Participants will self-rate their current state of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression by choosing 1 of 5 possible responses that record the level of severity (no problems, slight problems, moderate problems, severe problems, or extreme problems) within each dimension. The questionnaire also includes a visual analog scale to self-rate general health state on a scale from ""the worst health you can imagine"" to ""the best health you can imagine."", Randomization up to approximately 5 years|Symptomatic toxicity as measured by items from the Patient-Reported Outcome CTCAE (PRO-CTCAE), Each selected PRO-CTCAE items will be assessed related to one or more attributes that include counts for the frequency, severity, and/or interference with usual or daily activities., Randomization up to approximately 5 years|Time to definitive deterioration in patient-reported health related quality of life (HRQoL) per FACT-P, Defined as the time from randomization to onset of definitive deterioration in FACT-P total score, which is defined as \>10 point decrease from baseline and no subsequent observations with a \<10 point decrease from baseline FACT-P total score, Randomization up to approximately 5 years",,Pfizer,,MALE,"ADULT, OLDER_ADULT",PHASE3,900,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-10-22,2026-07-24,2028-11-30,2024-10-08,,2025-06-06,"Ironwood Cancer & Research Centers, Chandler, Arizona, 85224, United States|Ironwood Cancer & Research Centers, Gilbert, Arizona, 85297, United States|Palo Verde Hematology Oncology, Glendale, Arizona, 85304, United States|Ironwood Cancer & Research Centers, Glendale, Arizona, 85306, United States|Ironwood Cancer & Research Centers, Mesa, Arizona, 85202, United States|Ironwood Cancer & Research Centers, Mesa, Arizona, 85206, United States|Ironwood Cancer & Research Centers, Phoenix, Arizona, 85028, United States|Ironwood Cancer & Research Centers, Scottsdale, Arizona, 85260, United States|Arizona Urology Specialists (East Side Location), Tucson, Arizona, 85715, United States|Arizona Urology Specialists (AUS)-Orange Grove, Tucson, Arizona, 85741, United States|Highlands Oncology, Fayetteville, Arkansas, 72703, United States|Highlands Oncology, Rogers, Arkansas, 72758, United States|Highlands Oncology Group, Springdale, Arkansas, 72762, United States|Adventist Health Physicians Network, Hidden Valley Lake, California, 95467, United States|Adventist Health Physicians Network, Napa, California, 94558, United States|Adventist Health St. Helena, Saint Helena, California, 94574, United States|Duly Health and Care (Bone Scintigraphy), Lisle, Illinois, 60532, United States|NextStage Clinical Research-Chicago-(04), Lisle, Illinois, 60532, United States|Blessing Hospital, Quincy, Illinois, 62301, United States|Blessing Physician Services, Quincy, Illinois, 62301, United States|Duly Health and Care (CT and MRI), Westmont, Illinois, 60559, United States|Adult & Pediatric Urology, PC, Omaha, Nebraska, 68114, United States|Montefiore Medical Center - Medical Park, Bronx, New York, 10461, United States|Salisbury VA Medical Center, Salisbury, North Carolina, 28144, United States|AUC Urologists, LLC, Myrtle Beach, South Carolina, 29572, United States|Carolina Urologic Research Center, LLC, Myrtle Beach, South Carolina, 29572, United States|Grand Strand Medical Center, Myrtle Beach, South Carolina, 29572, United States|Parkway Surgery Center, Myrtle Beach, South Carolina, 29572, United States|USA Clinical Trials, San Antonio, Texas, 78229, United States|Harborview Medical Center, Seattle, Washington, 98104, United States|Fred Hutchinson Cancer Center, Seattle, Washington, 98109, United States|University of Washington Medical Center - Montlake, Seattle, Washington, 98195, United States|Centro de UrologÃ­a (CDU), Caba, Buenos Aires, C1120AAT, Argentina|Hospital Sirio Libanes, Capital Federal, Buenos Aires, C1419AHN, Argentina|Imagenes Mdq, Mar del Plata, Buenos Aires, B7600FZO, Argentina|Instituto de Investigaciones ClÃ­nicas Mar del Plata, Mar del Plata, Buenos Aires, B7600FZO, Argentina|Centro Medico Privado CEMAIC, Capital, CÃ³rdoba, X5008HHW, Argentina|Hospital Privado Universitario de CÃ³rdoba, Cordoba, CÃ³rdoba, 5016, Argentina|IMAXE, Buenos Aires, C1120, Argentina|AsociaciÃ³n de Beneficencia Hospital Sirio LibanÃ©s, Buenos Aires, C1419AHN, Argentina|Centro Medico Fleischer, Buenos Aires, Argentina|Liga Norte Riograndense Contra o CÃ¢ncer, Natal, RIO Grande DO Norte, 59062-000, Brazil|CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia, Santo AndrÃ©, SÃO Paulo, 09060-650, Brazil|Hospital Alemao Oswaldo Cruz, Sao Paulo, SÃO Paulo, 01327-001, Brazil|FundaÃ§Ã£o Faculdade Regional de Medicina de SÃ£o JosÃ© do Rio Preto, SÃ£o JosÃ© do Rio Preto, SÃO Paulo, 15090000, Brazil|IBCC - NÃºcleo de Pesquisa e Ensino, SÃ£o Paulo, 04014-002, Brazil|Multiprofile Hospital for Active Treatment Dr. Tota Venkova AD, Gabrovo, 5300, Bulgaria|""University Multiprofile Hospital for Active Treatment - Dr. Georgi Stranski"" EAD, Pleven, 5800, Bulgaria|Complex Oncology Center - Plovdiv EOOD, Plovdiv, 4004, Bulgaria|Complex Oncology Center Stara Zagora EOOD, Stara Zagora, 6003, Bulgaria|Cross Cancer Institute, Edmonton, Alberta, T6G 1Z2, Canada|QEII Health Sciences Centre - Victoria General Site, Halifax, Nova Scotia, B3H 2Y9, Canada|Lakeridge Health, Oshawa, Ontario, L1G 2B9, Canada|Centre Hospitalier de l'UniversitÃ© de MontrÃ©al, MontrÃ©al, Quebec, H2X 3E4, Canada|Wannan Medical College Yijishan Hospital, Wuhu, Anhui, 241001, China|Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, 100021, China|Fujian Cancer Hospital, Fuzhou, Fujian, 350014, China|Guangzhou First People's Hospital, Guangzhou, Guangdong, 510180, China|The Second Affiliated Hospital of Shantou University School of Medicine, Shantou, Guangdong, 515000, China|The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, 541199, China|The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, 453003, China|Henan Cancer Hospital, Zhengzhou, Henan, 450008, China|Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, 430022, China|Hunan Cancer Hospital, Changsha, Hunan, 410013, China|Inner Mongolia People's Hospital, Hohhot, Inner Mongolia, 010017, China|Huai'an First People's Hospital, Huai'an, Jiangsu, 223300, China|Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, 210000, China|Nantong Tumor Hospital, Nantong, Jiangsu, 226361, China|The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 215004, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China|Shaanxi Provincial People' Hospital, Xi'an, Shaanxi, 710068, China|Shandong Provincial Hospital, Jinan, Shandong, 250021, China|The Affiliated Hospital of Qingdao University, Qingdao, Shandong, 266003, China|Weifang People's Hospital, Weifang, Shandong, 261041, China|Yantai Yuhuangding Hospital, Yantai, Shandong, 264099, China|Tongji Hospital of Tongji University, Shanghai, Shanghai, 200065, China|West China Hospital, Sichuan University, Cheng Du, Sichuan, 610041, China|The First Hospital of Jiaxing, Jiaxing, Zhejiang/nanhu, 314001, China|Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou City, Zhejiang, 310016, China|The first affiliated hospital of Ningbo university, Ningbo, Zhejiang, 315010, China|The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China|Peking University Third Hospital, Beijing, 100191, China|First Affiliated Hospital of China Medical University, Shenyang, 110001, China|FakultnÃ­ nemocnice Ostrava, Ostrava - Poruba, MoravskoslezskÃ½ KRAJ, 708 52, Czechia|Fakultni nemocnice Ostrava, Ostrava, MoravskoslezskÃ½ KRAJ, 708 52, Czechia|Fakultni nemocnice Olomouc, Olomouc, OlomouckÃ½ KRAJ, 779 00, Czechia|Multiscan, Pardubice, PardubickÃ½ KRAJ, 53203, Czechia|Fakultni nemocnice Kralovske Vinohrady, PRague, Praha 10, 10034, Czechia|Urocentrum Praha, Prague, Praha 2, 120 00, Czechia|Fakultni Thomayerova nemocnice, Prague, Praha 4, 14059, Czechia|NÃ¦stved Sygehus, NÃ¦stved, SjÃ¦lland, 4700, Denmark|Vejle Sygehus, Vejle, Syddanmark, 7100, Denmark|Tampereen yliopistollinen sairaala, Tampere, Pirkanmaa, 33520, Finland|Oulun yliopistollinen sairaala, Oulu, Pohjois-pohjanmaa, 90220, Finland|Kuopion Yliopistollinen Sairaala, Kuopio, Pohjois-savo, 70210, Finland|Turku University Hospital, Turku, Varsinais-suomi, 20520, Finland|Helsinki university hospital, Helsinki, 00290, Finland|Institut de cancÃ©rologie Strasbourg Europe (ICANS), Strasbourg, Alsace, 67033, France|Institut BergoniÃ© - Centre RÃ©gional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest, Bordeaux, Aquitaine, 33076, France|CHRU de Brest, Brest, FinistÃ¨re, 29609, France|Centre Hospitalier PrivÃ© Saint-GrÃ©goire, Saint GrÃ©goire, Ille-et-vilaine, 35760, France|Institut de CancÃ©rologie de l'Ouest, Saint Herblain, Loire-atlantique, 44805, France|Institut Jean Godinot, Reims, Marne, 51726, France|Clinique Victor Hugo Le Mans, Le Mans, Pays-de-la-loire, 72000, France|Centre Leon Berard, Lyon Cedex08, RhÃ´ne-alpes, 69373, France|Centre Hospitalier Lyon Sud, Pierre-BÃ©nite, RhÃ´ne, 69310, France|Centre Jean Perrin - Centre RÃ©gional de Lutte contre le Cancer d'Auvergne, Clermont-Ferrand, 63011, France|Institut Godinot, Reims, 51100, France|Studienpraxis Urologie, NÃ¼rtingen, Baden-wÃ¼rttemberg, 72622, Germany|Universitaetsklinikum Tuebingen, TÃ¼bingen, Baden-wÃ¼rttemberg, 72076, Germany|UniversitÃ¤tsklinikum MÃ¼nster - Albert Schweitzer Campus, MÃ¼nster, Nordrhein-westfalen, 48149, Germany|Universitaetsklinikum Hamburg-Eppendorf, Hamburg, 20246, Germany|University Hospital of Patras, Patras, Achaá¸¯a, 26504, Greece|Alexandra General Hospital of Athens, Athens, AttikÃ­, 115 28, Greece|Athens Medical Center, Athens, AttikÃ­, 151 25, Greece|Attikon General University Hospital, Chaidari, AttikÃ­, 124 62, Greece|University General Hospital of Larissa, Larissa, ThessalÃ­a, 411 10, Greece|Borsod-AbaÃºj-ZemplÃ©n VÃ¡rmegyei KÃ¶zponti KÃ³rhÃ¡z Ã©s Egyetemi OktatÃ³kÃ³rhÃ¡z, Miskolc, Borsod-abaÃºj-zemplÃ©n, 3526, Hungary|Petz Aladar Egyetemi Oktato Korhaz, Gyor, GyÅr-moson-sopron, 9024, Hungary|IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) ""Dino Amadori"", Meldola, Emilia-romagna, 47014, Italy|Istituto Nazionale Tumori Regina Elena, Roma, Lazio, 00144, Italy|Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UniversitÃ  Cattolica del Sacro Cuore, Roma, Lazio, 00168, Italy|Azienda Socio Sanitaria Territoriale di Cremona, Cremona, 26100, Italy|Ospedale San Raffaele, Milano, 20132, Italy|Azienda Ospedaliera Santa Maria Terni, Terni, 05100, Italy|APSS- Presidio Ospedaliero S. Chiara, Trento, 38122, Italy|Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Roma, Verona, 37134, Italy|Chiba cancer center, Chiba-shi, Chiba, 260-8717, Japan|National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, 791-0280, Japan|National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, 003-0804, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, 060-8648, Japan|Kobe University Hospital, Kobe, Hyogo, 650-0017, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, 920-8641, Japan|Yokohama City University Medical Center, Yokohama, Kanagawa, 232-0024, Japan|Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, 238-8558, Japan|The University of Osaka Hospital, Suita, Osaka, 565-0871, Japan|Keio university hospital, Shinjuku-ku, Tokyo, 1608582, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, 811-1395, Japan|National Hospital Organization Kumamoto Medical Center, Kumamoto, 860-0008, Japan|Osaka International Cancer Institute, Osaka, 541-8567, Japan|Yamagata University Hospital, Yamagata, 990-9585, Japan|Chonnam National University Hwasun Hospital, Hwasun, Jeonranamdo, 58128, Korea, Republic of|National Cancer Center, Goyang-si, KyÇnggi-do, 10408, Korea, Republic of|Seoul National University Hospital, Seoul, Seoul-teukbyeolsi [seoul], 03080, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Seoul-teukbyeolsi [seoul], 03722, Korea, Republic of|Asan Medical Center, Seoul, Seoul-teukbyeolsi [seoul], 05505, Korea, Republic of|Samsung Medical Center, Seoul, Seoul-teukbyeolsi [seoul], 06351, Korea, Republic of|Kyungpook National University Chilgok Hospital, Daegu, Taegu-kwangyÇkshi, 41404, Korea, Republic of|Chungnam national university hospital, Jung-gu, TaejÇn-kwangyÇkshi, 35015, Korea, Republic of|Tauranga Hospital, Tauranga, BAY OF Plenty, 3112, New Zealand|MICS Centrum Medyczne Torun, Torun, Kujawsko-pomorskie, 87-100, Poland|Clinical Best Solutions, Lublin, Lubelskie, 20-011, Poland|Centrum BadaÅ Klinicznych JagielloÅskie Centrum Innowacji sp. z o.o., KrakÃ³w, MaÅopolskie, 30-348, Poland|Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie, KrakÃ³w, MaÅopolskie, 31-826, Poland|Provita Profamilia, PiotrkÃ³w Trybunalski, ÅÃ³dzkie, 97-300, Poland|CUIMED, s.r.o., Urologicka ambulancia, Bratislava, 851 05, Slovakia|Univerzitna nemocnica Martin, Martin, 036 59, Slovakia|Privatna urologicka ambulancia, s.r.o., Trencin, 911 01, Slovakia|Cancercare Langenhoven Drive Oncology Centre, Port Elizabeth, Eastern CAPE, 6045, South Africa|Wilgers Oncology Centre, Pretoria, Gauteng, 0081, South Africa|Wits Clinical Research, Soweto, Gauteng, 2013, South Africa|TASK Eden, George, Western CAPE, 6529, South Africa|Hospital Universitario 12 de Octubre, Madrid, Madrid, Comunidad DE, 28041, Spain|FundaciÃ³n Instituto Valenciano de OncologÃ­a, Valencia, Valenciana, Comunitat, 46009, Spain|Hospital Universitario HM Sanchinarro, Madrid, 28050, Spain|SÃ¶dersjukhuset, Stockholm, Stockholms LÃN [se-01], 11883, Sweden|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, 807, Taiwan|Taichung Veterans General Hospital, Taichung, 407, Taiwan|National Cheng Kung University Hospital, Tainan, 704, Taiwan|National Taiwan University Hospital, Taipei, 10002, Taiwan|Taipei Veterans General Hospital, Taipei, 11217, Taiwan|KoÃ§ Ãniversitesi Hastanesi, Ä°stanbul, Ä°Ìstanbul, 34010, Turkey|SbÃ¼ GÃ¼lhane EÄitim Ve AraÅtirma Hastanesi, Ankara, 06010, Turkey|Memorial Ankara Hastanesi, Ankara, 06520, Turkey|Royal Blackburn Hospital, Blackburn, Blackburn WITH Darwen, BB2 3HH, United Kingdom|The Beatson West of Scotland Cancer Centre, Glasgow, G12 0YN, United Kingdom",
NCT04385368,Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT04385368,MERMAID-1,COMPLETED,"This is a Phase III, randomized, parallel-arm, placebo controlled, double blind, multicenter study assessing the efficacy and safety of durvalumab versus placebo following SoC chemotherapy in patients with completely resected stage II-III NSCLC who are MRD+ post surgery",YES,"Carcinoma, Non-Small-Cell Lung",DRUG: Durvalumab + SoC chemotherapy|OTHER: Placebo + SoC chemotherapy,"Disease-free Survival (DFS) in FAS (Using Investigator Assessments According to Response Evaluation Criteria in Solid Tumors 1.1 [RECIST 1.1]), DFS was defined as the time from the date of randomization until either of the following events, whichever occurred first: disease recurrence using Investigator RECIST 1.1 assessments (i.e., local or regional recurrence, distant recurrence, second primary NSCLC) or death from any cause., Every 12 weeks (q12w) Â± 1 week until appearance of RECIST 1.1-defined disease recurrence or until primary DFS analysis, up to 33.28 months","DFS in Minimal Residual Disease-positive (MRD+) Analysis Set (Using Investigator Assessments According to RECIST 1.1), DFS was defined as the time from the date of randomization until either of the following events, whichever occurred first: disease recurrence using Investigator RECIST 1.1 assessments (i.e., local or regional recurrence, distant recurrence, second primary NSCLC) or death from any cause., Every 12 weeks (q12w) Â± 1 week until appearance of RECIST 1.1-defined disease recurrence or until primary DFS analysis, up to 33.28 months|OS in FAS, OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive., From the date of randomization until death due to any cause, up to 35 months|Overall Survival (OS) in MRD+ Analysis Set, OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive., From the date of randomization until death due to any cause, up to 35 months",,AstraZeneca,,ALL,"ADULT, OLDER_ADULT",PHASE3,89,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-07-17,2023-08-31,2023-08-31,2020-05-12,2024-08-30,2024-08-30,"Research Site, Birmingham, Alabama, 35294, United States|Research Site, Long Beach, California, 90806, United States|Research Site, Santa Rosa, California, 95403, United States|Research Site, West Hollywood, California, 90048, United States|Research Site, Miami, Florida, 33136, United States|Research Site, Silver Spring, Maryland, 20910, United States|Research Site, Minneapolis, Minnesota, 55407, United States|Research Site, Lincoln, Nebraska, 68510, United States|Research Site, Albuquerque, New Mexico, 87131, United States|Research Site, New York, New York, 10032, United States|Research Site, Durham, North Carolina, 27710, United States|Research Site, Spartanburg, South Carolina, 29303, United States|Research Site, Sioux Falls, South Dakota, 57105, United States|Research Site, Houston, Texas, 77090, United States|Research Site, Seattle, Washington, 98108-1532, United States|Research Site, Rosario, S2000CVB, Argentina|Research Site, Camperdown, 2050, Australia|Research Site, St Leonards, 2065, Australia|Research Site, Aalst, 9300, Belgium|Research Site, Bruxelles, 1200, Belgium|Research Site, Hasselt, 3500, Belgium|Research Site, Leuven, 3000, Belgium|Research Site, Roeselare, 8800, Belgium|Research Site, Belo Horizonte, 30110-022, Brazil|Research Site, Blumenau, 89010-340, Brazil|Research Site, Fortaleza, 60336-045, Brazil|Research Site, SÃ£o JosÃ© do Rio Preto, 15090-000, Brazil|Research Site, SÃ£o Paulo, 04501-000, Brazil|Research Site, Vitoria, 29043-260, Brazil|Research Site, Panagyurishte, 4500, Bulgaria|Research Site, Sofia, 1113, Bulgaria|Research Site, Sofia, 1618, Bulgaria|Research Site, Victoria, British Columbia, V8R 6V5, Canada|Research Site, Saint John, New Brunswick, E2L 4L2, Canada|Research Site, Kingston, Ontario, K7L 2V7, Canada|Research Site, Toronto, Ontario, M5G 2M9, Canada|Research Site, Montreal, Quebec, H4A 3J1, Canada|Research Site, Olomouc, 77900, Czechia|Research Site, Ostrava, 703 00, Czechia|Research Site, Praha 2, 128 08, Czechia|Research Site, Praha, 140 59, Czechia|Research Site, Copenhagen, 2100, Denmark|Research Site, Odense C, 5000, Denmark|Research Site, Bordeaux, 33000, France|Research Site, Marseille, 13915, France|Research Site, Saint Herblain, 44805, France|Research Site, Strasbourg Cedex, 67091, France|Research Site, Toulouse, 31000, France|Research Site, Villejuif Cedex, 94805, France|Research Site, Esslingen, 73730, Germany|Research Site, Gauting, 82131, Germany|Research Site, Regensburg, 93049, Germany|Research Site, Athens, 11526, Greece|Research Site, Athens, 11527, Greece|Research Site, Heraklion, 711 11, Greece|Research Site, Holargos, Athens, 155 62, Greece|Research Site, Thessaloniki, 54645, Greece|Research Site, Hong Kong, Hong Kong|Research Site, Budapest, 1121, Hungary|Research Site, GyÃ¶ngyÃ¶s - MÃ¡trahÃ¡za, 3200, Hungary|Research Site, GyÅr, 9024, Hungary|Research Site, Szolnok, 5004, Hungary|Research Site, TÃ¶rÃ¶kbÃ¡lint, 2045, Hungary|Research Site, Bengaluru, 560099, India|Research Site, Delhi, 110029, India|Research Site, Mohali, 160055, India|Research Site, Haifa, 3109601, Israel|Research Site, Kfar Saba, 95847, Israel|Research Site, Petah Tikva, 49100, Israel|Research Site, Ramat Gan, 5265601, Israel|Research Site, Meldola, 47014, Italy|Research Site, Orbassano, 10043, Italy|Research Site, Roma, 00144, Italy|Research Site, Akashi-shi, 673-8558, Japan|Research Site, Bunkyo-ku, 113-8677, Japan|Research Site, Hiroshima-shi, 734-8551, Japan|Research Site, Kashiwa, 277-8577, Japan|Research Site, Koto-ku, 135-8550, Japan|Research Site, Nagoya-shi, 464-8681, Japan|Research Site, Nagoya-shi, 466-8560, Japan|Research Site, Osaka-shi, 534-0021, Japan|Research Site, Osaka-shi, 541-8567, Japan|Research Site, Sendai-shi, 980-0873, Japan|Research Site, Sunto-gun, 411-8777, Japan|Research Site, Yokohama-shi, 241-8515, Japan|Research Site, Cheongju-si, 28644, Korea, Republic of|Research Site, Seoul, 05505, Korea, Republic of|Research Site, Seoul, 06351, Korea, Republic of|Research Site, Seoul, 06591, Korea, Republic of|Research Site, Suwon, 442-723, Korea, Republic of|Research Site, Culiacan, 80040, Mexico|Research Site, Mexico, 01710, Mexico|Research Site, Breda, 4818 CK, Netherlands|Research Site, Maastricht, 6202 AZ, Netherlands|Research Site, Zwolle, 8025 AB, Netherlands|Research Site, Lima, Lima 32, Peru|Research Site, Bydgoszcz, 85-796, Poland|Research Site, GdaÅsk, 80-214, Poland|Research Site, TomaszÃ³w Mazowiecki, 97-200, Poland|Research Site, Warszawa, 02-781, Poland|Research Site, WrocÅaw, 53-413, Poland|Research Site, Floresti, 407280, Romania|Research Site, Kazan, 420029, Russian Federation|Research Site, Krasnodar, 350086, Russian Federation|Research Site, Krasnoyarsk, 660133, Russian Federation|Research Site, Moscow, 105229, Russian Federation|Research Site, Moscow, 115478, Russian Federation|Research Site, Novosibirsk, 630108, Russian Federation|Research Site, Saint Petersburg, 191036, Russian Federation|Research Site, Saint Petersburg, 197758, Russian Federation|Research Site, Saint-Petersburg, 197758, Russian Federation|Research Site, Singapore, 169610, Singapore|Research Site, Barcelona, 08041, Spain|Research Site, Madrid, 28041, Spain|Research Site, MÃ¡laga, 29010, Spain|Research Site, Oviedo, 33011, Spain|Research Site, Pamplona, 31008, Spain|Research Site, Santiago De Compostela (A CoruÃ±a), 15706, Spain|Research Site, Stockholm, 17176, Sweden|Research Site, Lausanne, 1011, Switzerland|Research Site, ZÃ¼rich, CH-8091, Switzerland|Research Site, Chiayi, 613, Taiwan|Research Site, Taichung, 40201, Taiwan|Research Site, Taipei 112, Taiwan|Research Site, Taipei City, 114, Taiwan|Research Site, Taipei, 10002, Taiwan|Research Site, Taipei, 10449, Taiwan|Research Site, Taipei, 235, Taiwan|Research Site, Tao-Yuan, Taiwan|Research Site, Bangkok, 10300, Thailand|Research Site, Bangkok, 10330, Thailand|Research Site, Chiang Mai, 50200, Thailand|Research Site, Khon Kaen, 40002, Thailand|Research Site, Phisanulok, 65000, Thailand|Research Site, Adana, 01120, Turkey|Research Site, Ankara, 06010, Turkey|Research Site, Istanbul, 34010, Turkey|Research Site, Istanbul, 34214, Turkey|Research Site, Malatya, 44100, Turkey|Research Site, Hanoi, 100000, Vietnam|Research Site, Ho Chi Minh, 70000, Vietnam","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/68/NCT04385368/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/68/NCT04385368/SAP_001.pdf"
NCT06206733,ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma,https://clinicaltrials.gov/study/NCT06206733,,RECRUITING,"This study is a multicenter, randomized, double-blind, standard-of-care controlled phase III clinical study conducted in China. The purpose of this study is to evaluate the efficacy of ASKB589 plus CAPOX and PD-1 inhibitor compared with placebo plus CAPOX and PD-1 inhibitor (as first-line treatment) as measured by Progression Free Survival (PFS).",NO,Gastroesophageal Junction Adenocarcinoma|Gastric Adenocarcinoma,DRUG: ASKB589|DRUG: Oxaliplatin|DRUG: Capecitabine|DRUG: Tislelizumab|DRUG: Placebo,"Progression Free Survival (PFS), PFS is defined as the time from the date of randomization until the date of radiological progressive disease (per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 by Independent Review Committee (IRC)) or death from any cause, whichever is earliest., up to 18 months","Overall Survival (OS), OS is defined as the time from the date of randomization until the date of death from any cause., up to 24 months","Objective Response Rate (ORR), ORR is defined as the proportion of participants who have a best overall response of Complete Response (CR) or Partial Response (PR) as assessed by Independent Review Committee (IRC) per RECIST 1.1., up to 18 months|Duration Of Response (DOR), DOR, defined as the time from the date of the first response (CR/PR) until the date of progressive disease as assessed by IRC per RECIST 1.1 or date of death from any cause, whichever is earliest., up to 18 months|Safety and tolerability assessed by adverse events (AEs), An AE is any untoward medical occurrence in a subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product., up to 18 months|Number of participants with laboratory assessments abnormalities and or adverse events, Number of participants with potentially clinically significant laboratory values., up to 18 months|Number of participants with vital signs abnormalities and or adverse events, Number of participants with potentially clinically significant vital sign values., up to 18 months|Health Related Quality of Life (HRQoL) measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core Questionnaire (EORTC-QLQ-C30), EORTC-QLQ-C30 is a cancer-specific 30-item questionnaire. Participants rate items on a four-point scale, with 1 as ""not at all"" and 4 as ""very much."" A change of 5 - 10 points is considered a small change. A change of 10 - 20 points is considered a moderate change, up to 18 months|Health Related Quality of Life (HRQoL) measured by the Global Pain (GP) questionnaire, The GP instrument is a single assessment of overall pain where 0 equals no pain and 10 equals extreme pain. Low pain scores are considered a better outcome than a high pain score, up to 18 months|Health Related Quality of Life (HRQoL) measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) questionnaire, The EQ-5D-5L is a standardized instrument developed by the EuroQol Group for use as a generic, preference-based measure of health outcomes. The EQ-5D-5L is a 5-item self-reported measure of functioning and wellbeing, which assesses 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension comprises 5 levels (no problems, slight problems, moderate problems, severe problems, extreme problems). A unique EQ-5D-5L health state is defined by combining 1 level from each of the 5 dimensions. This questionnaire also records the respondent's self-rated health status on a vertical graduated (0 = the worst health a participant can imagine to 100 = the best health a participant can imagine) visual analogue scale. Responses to the 5 items will also be converted to a weighted health state index (utility score) based on values derived from general population samples., up to 18 months|Pharmacokinetics (PK) of ASKB589, Ctrough will be derived from the PK serum samples collected., up to 18 months|Number of anti-drug antibody (ADA) Positive Participants, Immunogenicity will be measured by the number of participants that are ADA positive., up to 18 months","AskGene Pharma, Inc.","Jiangsu Aosaikang Pharmaceutical Co., Ltd.",ALL,"ADULT, OLDER_ADULT",PHASE3,780,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-01-25,2026-12-30,2028-12-30,2024-01-16,,2024-03-25,"Beijing cancer hospital, Beijing, China",
NCT04493853,Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency,https://clinicaltrials.gov/study/NCT04493853,CAPItello-281,ACTIVE_NOT_RECRUITING,"This study will assess the efficacy and safety of capivasertib plus abiraterone (+prednisone/prednisolone) plus androgen deprivation therapy (ADT) versus placebo plus abiraterone (+prednisone/prednisolone) plus ADT in participants with mHSPC whose tumours are characterised by PTEN deficiency. The intention of the study is to demonstrate that in participants with mHSPC, the combination of capivasertib plus abiraterone (+prednisone/prednisolone) plus ADT is superior to placebo plus abiraterone (+prednisone/prednisolone) plus ADT in participants with mHSPC characterised by PTEN deficiency with respect to radiographic progression-free survival (rPFS) per 1) Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for soft tissue and/or Prostate Cancer Working Group (PCWG3) for bone as assessed by the investigator 2) death due to any cause.",NO,Hormone-Sensitive Prostate Cancer,DRUG: Capivasertib|OTHER: Placebo|DRUG: Abiraterone Acetate,"Radiographic Progression-free Survival (rPFS), rPFS is defined as the time from randomisation to radiographic progression, as assessed by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST) for soft tissue and/or Prostate Cancer Working Group 3 (PCWG3) for bone, or death due to any cause for each study arm., Up to approximately 55 months","Overall survival (OS), Overall survival is the length of time from randomisation until the date of death due to any cause., Up to approximately 80 months|Time to Start of First Subsequent Therapy or Death (TFST), TFST is defined as time from randomisation to the earlier of: the start date of the first subsequent anticancer therapy after discontinuation of randomised treatment (capivasertib/placebo), or death due to any cause., Up to approximately 55 months|Symptomatic Skeletal Event-Free Survival (SSE-FS), SSE-FS is defined as time from randomisation until any of the following: use of radiation therapy to prevent or relieve skeletal symptoms; Occurrence of new symptomatic pathological bone fractures (vertebral or non-vertebral); Occurrence of spinal cord compression; Orthopaedic surgical intervention for bone metastasis; Death due to any cause., Up to approximately 80 months|Time to Pain Progression (TTPP), TTPP is defined as the time from randomisation to clinically meaningful pain progression base on a 2-point increase from baseline in the Brief Pain Inventory-Short Form (BPI-SF) Item 3 (""worst pain in 24 hours"") score and/or initiation of/increase in opiate analgesic use., Up to approximately 80 months|Time to PSA progression, The time from randomisation to PSA progression, as determined by PCWG3 criteria., Up to approximately 55 months|Time To Castration Resistance (TTCR), TTCR is defined as the time from randomisation to the first castration-resistant event (radiographic disease progression, PSA progression, or SSE), whichever occurs first, with castrate levels of testosterone (below 50 ng/dL)., Up to approximately 80 months|Fatigue intensity, severity and interference domains assessed by the Brief Fatigue Inventory (BFI), BFI endpoints may include: Time to deterioration in fatigue intensity; Time to deterioration in fatigue interference; Change from baseline in fatigue severity and fatigue interference domain scores., Up to approximately 80 months|Overall Pain Severity and Pain Interference as assessed by BPI-SF questionnaire, BPI-SF: Change from baseline in pain severity and pain interference domain scores., Up to approximately 80 months|Disease-Related Symptoms and HRQoL using the Functional Assessment of Cancer Therapy - Prostate Cancer (FACT-P) questionnaire, FACT-P endpoints may include: Time to deterioration in FACT-P scores; Change from baseline in FACT-P scores., Up to approximately 80 months|Progression-Free Survival after next-line treatment (PFS2), PFS2 is defined as time from randomisation until progression on next-line treatment, as clinical progression, PSA progression, or radiographic progression determined by RECIST version 1.1 (soft tissue) and/or PCWG3 criteria (bone), as assessed by the investigator, or death due to any cause., Up to approximately 80 months|Plasma concentration of capivasertib pre-dose, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 15|Plasma concentration of capivasertib 1h post-dose, Cycle 1 Day 1|Plasma concentration of capivasertib 4h post-dose, Cycle 1 Day 1","Incidence and Severity of Adverse Events (AEs), Percentage of participants with an adverse event (AE), graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5.0, including analysis of pre-specified AEs., Up to approximately 80 months|Systolic and diastolic blood pressure, millimetre or mercury (mmHg), Up to approximately 80 months|Pulse rate (heart rate), Beats per minute (BPM), Up to approximately 80 months|Body Temperature, Celsius (Â°C), Up to approximately 80 months|Weight, Kilograms (kg), Up to approximately 80 months|Changes in Targeted Laboratory Results, Change from baseline in selected laboratory test results, Up to approximately 80 months|QT interval (QTc) by electrical activity, Milliseconds (msec), Up to approximately 80 months",AstraZeneca,,MALE,"ADULT, OLDER_ADULT",PHASE3,1012,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-07-13,2024-10-07,2027-03-29,2020-07-30,,2025-04-10,"Research Site, Tucson, Arizona, 85723, United States|Research Site, Tucson, Arizona, 85741, United States|Research Site, La Jolla, California, 92037, United States|Research Site, Orange, California, 92868, United States|Research Site, San Diego, California, 92123, United States|Research Site, Denver, Colorado, 80211, United States|Research Site, Lakewood, Colorado, 80215, United States|Research Site, Norwich, Connecticut, 06360, United States|Research Site, Fort Myers, Florida, 33901-8101, United States|Research Site, West Palm Beach, Florida, 33401, United States|Research Site, Chicago, Illinois, 60637, United States|Research Site, Geneva, Illinois, 60134, United States|Research Site, Lisle, Illinois, 60532, United States|Research Site, Baltimore, Maryland, 21201, United States|Research Site, Detroit, Michigan, 48201, United States|Research Site, Grand Rapids, Michigan, 49503, United States|Research Site, Troy, Michigan, 48084, United States|Research Site, Bronx, New York, 10461, United States|Research Site, Syracuse, New York, 13210, United States|Research Site, Asheville, North Carolina, 28805, United States|Research Site, Durham, North Carolina, 27710, United States|Research Site, Columbus, Ohio, 43210, United States|Research Site, Lancaster, Pennsylvania, 17601, United States|Research Site, Philadelphia, Pennsylvania, 19111, United States|Research Site, Pittsburgh, Pennsylvania, 15232, United States|Research Site, Charleston, South Carolina, 29401, United States|Research Site, Myrtle Beach, South Carolina, 29572, United States|Research Site, Chattanooga, Tennessee, 37404, United States|Research Site, Houston, Texas, 77090, United States|Research Site, Norfolk, Virginia, 23502, United States|Research Site, Roanoke, Virginia, 24014, United States|Research Site, Seattle, Washington, 98104, United States|Research Site, Madison, Wisconsin, 53792, United States|Research Site, Berazategui, B1884BBF, Argentina|Research Site, Buenos Aires, 1426, Argentina|Research Site, Buenos Aires, C1120AAT, Argentina|Research Site, Caba, 1425, Argentina|Research Site, Caba, C1012AAR, Argentina|Research Site, Caba, C1280AEB, Argentina|Research Site, La Plata, 1900, Argentina|Research Site, Mendoza, 5500, Argentina|Research Site, Rosario, S2000DEJ, Argentina|Research Site, San Salvador de Jujuy, 4600, Argentina|Research Site, Birtinya, 4575, Australia|Research Site, Darlinghurst, 2010, Australia|Research Site, Kingswood, 2747, Australia|Research Site, Orange, 2800, Australia|Research Site, South Brisbane, 4101, Australia|Research Site, Graz, 8036, Austria|Research Site, Linz, 4020, Austria|Research Site, Salzburg, 5020, Austria|Research Site, Anderlecht, 1070, Belgium|Research Site, Gent, 9000, Belgium|Research Site, Kortrijk, 8500, Belgium|Research Site, LiÃ¨ge, 4000, Belgium|Research Site, Belem, 66073-005, Brazil|Research Site, Belo Horizonte, 30110-022, Brazil|Research Site, FlorianÃ³polis, 88020-210, Brazil|Research Site, Fortaleza, 60135-237, Brazil|Research Site, JaÃº, 17210-120, Brazil|Research Site, Joinville, 89201-260, Brazil|Research Site, Porto Alegre, 90035-000, Brazil|Research Site, Porto Alegre, 90050-170, Brazil|Research Site, Porto Alegre, 90160-093, Brazil|Research Site, RibeirÃ£o Preto, 14051-140, Brazil|Research Site, Rio de Janeiro, 20230-130, Brazil|Research Site, Santa Maria, 97015-450, Brazil|Research Site, Sao Paulo, 01327-001, Brazil|Research Site, SÃ£o JosÃ© do Rio Preto, 15090-000, Brazil|Research Site, Tres Lagoas, 79601-001, Brazil|Research Site, Pleven, 5804, Bulgaria|Research Site, Plovdiv, 4004, Bulgaria|Research Site, Plovdiv, 4109, Bulgaria|Research Site, Sofia, 1407, Bulgaria|Research Site, Sofia, 1527, Bulgaria|Research Site, Sofia, 1756, Bulgaria|Research Site, Sofia, 1797, Bulgaria|Research Site, Varna, 9000, Bulgaria|Research Site, Calgary, Alberta, T2N 5G2, Canada|Research Site, Edmonton, Alberta, T6G 1Z2, Canada|Research Site, Kelowna, British Columbia, V1Y 5L3, Canada|Research Site, Vancouver, British Columbia, V5Z 1H7, Canada|Research Site, Brampton, Ontario, L6R 3J7, Canada|Research Site, Oshawa, Ontario, L1G 2B9, Canada|Research Site, Toronto, Ontario, M4N 3M5, Canada|Research Site, Toronto, Ontario, M5G 2M9, Canada|Research Site, Montreal, H3T 1E2, Canada|Research Site, Santiago, 7500653, Chile|Research Site, Santiago, 7500787, Chile|Research Site, Santiago, 8420383, Chile|Research Site, Temuco, 4781156, Chile|Research Site, ViÃ±a del Mar, 2540488, Chile|Research Site, Beijing, 100034, China|Research Site, Beijing, 100036, China|Research Site, Beijing, 100050, China|Research Site, Beijing, CN-100730, China|Research Site, Changchun, 130021, China|Research Site, Changsha, 410003, China|Research Site, Changsha, 410008, China|Research Site, Chengdu, 610000, China|Research Site, Chengdu, 610072, China|Research Site, Chongqing, 400030, China|Research Site, Chongqing, 400038, China|Research Site, Fuzhou, 350001, China|Research Site, Fuzhou, 350005, China|Research Site, Guangzhou, 510060, China|Research Site, Guangzhou, 510180, China|Research Site, Guangzhou, 510515, China|Research Site, Guiyang, 550002, China|Research Site, Hangzhou, 310003, China|Research Site, Hangzhou, 310014, China|Research Site, Hangzhou, 310052, China|Research Site, Kunming, 650118, China|Research Site, Nanchang, 330006, China|Research Site, Nanjing, 2100008, China|Research Site, Nanjing, 210009, China|Research Site, Nantong, 226361, China|Research Site, Ningbo, 315000, China|Research Site, Shanghai, 200032, China|Research Site, Shanghai, 200080, China|Research Site, Shanghai, 200127, China|Research Site, Shengyang, 110004, China|Research Site, Tianjin, 300211, China|Research Site, Wenzhou, CN-325000, China|Research Site, Wuhan, 430030, China|Research Site, Xi'an, 710061, China|Research Site, Yantai, 264000, China|Research Site, Zhengzhou City, 450000, China|Research Site, Zhengzhou, 450008, China|Research Site, Brno, 656 91, Czechia|Research Site, Horovice, 268 31, Czechia|Research Site, Hradec Kralove, 500 05, Czechia|Research Site, Praha 10, 100 34, Czechia|Research Site, Praha 8, 180 81, Czechia|Research Site, Praha, 120 00, Czechia|Research Site, BesanÃ§on Cedex, 25030, France|Research Site, Bordeaux, 33076, France|Research Site, Marseille, 13273, France|Research Site, Montpellier, 34298, France|Research Site, Nice, 06100, France|Research Site, Paris Cedex 14, 75674, France|Research Site, Pierre Benite, 69495, France|Research Site, Quimper Cedex, 29107, France|Research Site, Rennes Cedex 9, 35033, France|Research Site, Strasbourg, 67033, France|Research Site, Suresnes Cedex, 92151, France|Research Site, Villejuif Cedex, 94805, France|Research Site, Berlin, 10117, Germany|Research Site, Duisburg, 47169, Germany|Research Site, Hamburg, 20246, Germany|Research Site, Herne, 44625, Germany|Research Site, Mettmann, 40822, Germany|Research Site, MÃ¼nster, 48149, Germany|Research Site, NÃ¼rnberg, 90419, Germany|Research Site, NÃ¼rtingen, 72622, Germany|Research Site, Wesel, 46483, Germany|Research Site, Hong Kong, Hong Kong|Research Site, HongKong, 00000, Hong Kong|Research Site, Lai Chi Kok, Hong Kong|Research Site, Ahmedabad, 380060, India|Research Site, Bangalore, 560022, India|Research Site, Bangalore, 560027, India|Research Site, Delhi, 110085, India|Research Site, Faridabad, 121001, India|Research Site, Kanpur, 208005, India|Research Site, Kolkata, 700160, India|Research Site, Madurai, 625107, India|Research Site, Manipal, 576104, India|Research Site, Meerut, 250001, India|Research Site, Mohali, 160055, India|Research Site, Nagpur, 440001, India|Research Site, New Delhi, 110005, India|Research Site, New Delhi, 11029, India|Research Site, Thiruvananthapuram, 695 011, India|Research Site, Varanasi, 221005, India|Research Site, Haifa, 3109601, Israel|Research Site, Jerusalem, 91120, Israel|Research Site, Kfar Saba, 95847, Israel|Research Site, Petach-Tikva, 4941492, Israel|Research Site, Ramat Gan, 52621, Israel|Research Site, Zerifin, 70300, Israel|Research Site, Bunkyo-ku, 113-8431, Japan|Research Site, Chiba-shi, 260-8677, Japan|Research Site, Chuo-ku, 260-8717, Japan|Research Site, Fukuoka, 812-8582, Japan|Research Site, Hamamatsu-shi, 431-3192, Japan|Research Site, Hirakata-shi, 573-1191, Japan|Research Site, Hirosaki-shi, 036-8563, Japan|Research Site, Isehara-shi, 259-1193, Japan|Research Site, Kanazawa-shi, 920-8641, Japan|Research Site, Kashihara-shi, 634-8522, Japan|Research Site, Kawagoe-shi, 350-8550, Japan|Research Site, Kisarazu-shi, 292-8535, Japan|Research Site, Kita-gun, 761-0793, Japan|Research Site, Kobe-shi, 650-0047, Japan|Research Site, Kumamoto-shi, 860-0008, Japan|Research Site, Kyoto-shi, 606-8507, Japan|Research Site, Miyazaki-city, 889-1692, Japan|Research Site, Morioka-shi, 028-3695, Japan|Research Site, Nagano-shi,, 381-8551, Japan|Research Site, Nagasaki-shi, 852-8501, Japan|Research Site, Nagoya-shi, 466-8560, Japan|Research Site, Nagoya-shi, 466-8650, Japan|Research Site, Natori-shi, 981-1293, Japan|Research Site, Osaka-shi, 541-8567, Japan|Research Site, Osakasayama-shi, 589-8511, Japan|Research Site, Ota Shi, 373-8550, Japan|Research Site, Sagamihara-shi, 252-0375, Japan|Research Site, Sapporo-shi, 060-8648, Japan|Research Site, Shinjuku-ku, 160-8582, Japan|Research Site, Toon-shi, 791-0295, Japan|Research Site, Tsu-shi, 514-8507, Japan|Research Site, Ube-shi, 755-8505, Japan|Research Site, Yokohama-shi, 232-0024, Japan|Research Site, Yokosuka-shi, 238-8558, Japan|Research Site, Yufu-shi, 879-5593, Japan|Research Site, Daegu, 41404, Korea, Republic of|Research Site, Goyang-si, 10408, Korea, Republic of|Research Site, Seongnam-si, 13620, Korea, Republic of|Research Site, Seoul, 03080, Korea, Republic of|Research Site, Seoul, 03722, Korea, Republic of|Research Site, Seoul, 05505, Korea, Republic of|Research Site, Seoul, 06351, Korea, Republic of|Research Site, Seoul, 06591, Korea, Republic of|Research Site, Culiacan, 80040, Mexico|Research Site, Culiacan, 80230, Mexico|Research Site, Guadalajara, 44680, Mexico|Research Site, Mexico City, 0 3100, Mexico|Research Site, Monterrey, 64460, Mexico|Research Site, Nuevo Leon, 66278, Mexico|Research Site, Amsterdam, 1066 CX, Netherlands|Research Site, Den Haag, 2545 CH, Netherlands|Research Site, Hilversum, 1213 XZ, Netherlands|Research Site, Roosendaal, 4708 AE, Netherlands|Research Site, Tilburg, 5042AD, Netherlands|Research Site, Utrecht, 3543 AZ, Netherlands|Research Site, Callao, CALLAO 02, Peru|Research Site, Lima, 0051, Peru|Research Site, Lima, LIMA 29, Peru|Research Site, Lima, LIMA 31, Peru|Research Site, Lima, Lima 32, Peru|Research Site, Lima, LIMA 34, Peru|Research Site, San Isidro, 27, Peru|Research Site, Baguio City, 2600, Philippines|Research Site, Cebu City, 6000, Philippines|Research Site, Davao City, 8000, Philippines|Research Site, Iloilo City, 5000, Philippines|Research Site, Quezon City, 1101, Philippines|Research Site, Quezon City, 1112, Philippines|Research Site, San Juan, 1500, Philippines|Research Site, Bydgoszcz, 85-796, Poland|Research Site, GdaÅsk, 80-952, Poland|Research Site, Koszalin, 75-581, Poland|Research Site, Olsztyn, 10-228, Poland|Research Site, PoznaÅ, 61-731, Poland|Research Site, Rzeszow, 35-055, Poland|Research Site, ToruÅ, 87-100, Poland|Research Site, Warszawa, 02-781, Poland|Research Site, Warszawa, 04-073, Poland|Research Site, ÅÃ³dÅº, 90-242, Poland|Research Site, Moscow, 105077, Russian Federation|Research Site, Moscow, 117997, Russian Federation|Research Site, Moscow, 121205, Russian Federation|Research Site, Novisibirsk, 630082, Russian Federation|Research Site, Novosibirsk, 630007, Russian Federation|Research Site, Saint-Petersburg, 190103, Russian Federation|Research Site, St.Petersburg, 191014, Russian Federation|Research Site, Yaroslavl, 150054, Russian Federation|Research Site, Bratislava, 81102, Slovakia|Research Site, Bratislava, 851 05, Slovakia|Research Site, Martin, 036 59, Slovakia|Research Site, Nitra, 49401, Slovakia|Research Site, Presov, 08001, Slovakia|Research Site, Sala, 92701, Slovakia|Research Site, TrenÄÃ­n, 911 01, Slovakia|Research Site, Cape Town, 7570, South Africa|Research Site, Johannesburg, 2013, South Africa|Research Site, Johannesburg, 2193, South Africa|Research Site, Parow, 7505, South Africa|Research Site, Port Elizabeth, 6045, South Africa|Research Site, Pretoria, 0084, South Africa|Research Site, Badalona (Barcelona), 08916, Spain|Research Site, Barcelona, 08041, Spain|Research Site, Las Palmas de Gran Canaria, 35016, Spain|Research Site, Madrid, 28007, Spain|Research Site, Madrid, 28034, Spain|Research Site, Madrid, 28040, Spain|Research Site, Madrid, 28041, Spain|Research Site, Oviedo, 33011, Spain|Research Site, Santander, 39008, Spain|Research Site, Sevilla, 41009, Spain|Research Site, Kaohsiung, 807, Taiwan|Research Site, Kaohsiung, 81362, Taiwan|Research Site, Taichung, 404, Taiwan|Research Site, Taichung, 43503, Taiwan|Research Site, Tainan, 710, Taiwan|Research Site, Taipei, 112, Taiwan|Research Site, Taipei, 11490, Taiwan|Research Site, Taoyuan City, 333, Taiwan|Research Site, Bangkok, 10210, Thailand|Research Site, Bangkok, 10400, Thailand|Research Site, Bangkok, 10700, Thailand|Research Site, Chiang Mai, 50200, Thailand|Research Site, Hat Yai, 90110, Thailand|Research Site, Lampang, 52000, Thailand|Research Site, Muang, 22000, Thailand|Research Site, Ankara, 06010, Turkey|Research Site, Ankara, Turkey|Research Site, Antalya, 07059, Turkey|Research Site, Eskisehir, 26040, Turkey|Research Site, Istanbul, 34098, Turkey|Research Site, Izmir, 35100, Turkey|Research Site, Izmir, 35575, Turkey|Research Site, Kayseri, 38039, Turkey|Research Site, Cambridge, CB2 0QQ, United Kingdom|Research Site, Guildford, GU2 7XX, United Kingdom|Research Site, Manchester, M20 4BX, United Kingdom|Research Site, Plymouth, PL6 8DH, United Kingdom|Research Site, Sutton, SM2 5PT, United Kingdom|Research Site, Whitchurch, CF14 2TL, United Kingdom|Research Site, Ha Noi, 100000, Vietnam|Research Site, Hanoi, 100000, Vietnam|Research Site, Ho Chi Minh, 700000, Vietnam",
NCT05009290,A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy,https://clinicaltrials.gov/study/NCT05009290,,RECRUITING,The study is being conducted to evaluate the efficacy and safety of SHR3680 plus androgen deprivation therapy (ADT) vs. placebo plus ADT in patients with high-risk localized or locally advanced prostate cancer using pathologic complete response (pCR) rate and metastasis-free survival (MFS).,NO,Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy,DRUG: SHR3680|DRUG: Placebo,"pCR rate (assessed by pathology BICR), Defined as the proportion of subjects with no residual tumor detected in prostatectomy specimens by H\&E staining and ancillary immunohistochemistry (if necessary) as assessed by pathology BICR., 36 months since the first subject will be enrolled.|MFS (assessed by imaging BICR)., Defined as the time from the date of randomization to the date of first occurrence of BICR-confirmed radiographic distant metastasis, accidental pathologic finding of distant metastasis, or death from any cause (whichever occurs first), regardless of whether the subject reveives any other anti-tumor therapy or has missing (or unevaluable) tumor assessments., 84 months since the first subject will be enrolled.","MFS (investigator-assessed)., Defined as the time from the date of randomization to the date of first occurrence of investigator-assessed radiographic distant metastasis to the bone or soft tissue, accidental pathologic finding of distant metastasis, or death from any cause (whichever occurs first), regardless of subsequent anti-tumor treatment or missing (or unevaluable) tumor assessments., 84 months since the first subject will be enrolled.|PSA response rate., Defined as the proportion of subjects with a â¥ 90% decrease in PSA levels from baseline on Day 1 of Cycle 4., 25 months since the first subject will be enrolled.|PSM rate., Defined as the proportion of subjects without tumor cells detected in the margin of prostatectomy pathological specimens following H\&E staining and ancillary immunohistochemistry (if necessary), as assessed by local pathologists., 31 months since the first subject will be enrolled.|Time to BCR., Defined as the time from the date of randomization to the time of BCR (i.e. two consecutive PSA rise â¥ 0.2 ng/mL following radical prostatectomy)., 42 months since the first subject will be enrolled.",,"Jiangsu HengRui Medicine Co., Ltd.",,MALE,"ADULT, OLDER_ADULT",PHASE3,1256,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-11-01,2027-10-30,2031-10-30,2021-08-17,,2022-01-13,"Fudan University Shanghai Cancer center, Shanghai, Shanghai, China",
NCT06784752,Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET,https://clinicaltrials.gov/study/NCT06784752,NETTER-3,RECRUITING,"The purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive (SSTR+), well differentiated Grade1 and Grade 2 (G1 and G2) (Ki-67 \<10%) advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with high disease burden",NO,Somatostatin Receptor Positive (SSTR+)|Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET),RADIATION: [177Lu]Lu-DOTA-TATE|DRUG: Octreotide LAR,"Progression Free Survival (PFS) centrally assessed by Blinded Independent Review Committee (BIRC), PFS is defined as the time from randomization to the first occurrence of progression (centrally assessed by Blinded Independent Review Committee (BIRC) according to RECIST v1.1) or death due to any cause., After observing approximately 88 PFS events as per BIRC assessments, expected after approximately 33 months from study start","Time to Deterioration (TDD) (Key Secondary), Time to deterioration is defined as the time from randomization to the first occurrence of a deterioration compared to the baseline scores or death from any cause for each of the following domains (tested separately) of EORTC QLQ-GI.NET21 \[gastrointestinal scale (GI scale)\] and EORTC QLQ-C30 questionnaires (fatigue, diarrhea, and global health scale)., After observing approximately 88 PFS events as per BIRC assessment, expected after approximately 33 months from study start|Progression Free Survival (PFS), PFS is defined as the time from randomization to the first occurrence of progression (Investigator assessed according to RECIST v1.1) or death due to any cause., After observing approximately 88 PFS events as per BIRC assessment, expected after approximately 33 months from study start|Objective Response Rate (ORR), ORR: Rate of participants with best overall response (BOR) of partial response (PR) or complete response (CR) as per RECIST v1.1 (both Investigator and centrally assessed by BIRC)., After observing approximately 88 PFS events as per BIRC assessment, expected after approximately 33 months from study start|Disease Control Rate (DCR), DCR: Rate of participants with BOR of PR, CR or stable disease (SD) as per RECIST v1.1 (both Investigator and centrally assessed by BIRC)., After observing approximately 88 PFS events as per BIRC assessment, expected after approximately 33 months from study start|Duration of Response (DOR), DOR: The time from initially meeting the criteria for response (CR or PR) until the time of progression according to RECIST v1.1 or death due to underlying disease only., After observing approximately 88 PFS events as per BIRC assessment, expected after approximately 33 months from study start|Overall Survival (OS), OS: Time from the randomization date until the date of death due to any cause., Until 60 month from randomization|Time to Deterioration (TDD), TTD is the time from randomization to the first occurrence of a deterioration compared to the baseline scores or death from any cause for EORTC QLQ-G.I.NET21 and EORTC QLQ-C30 domains not included among key secondary endpoints., At the time of primary PFS analysis after observing approximately 88 PFS events per BIRC assessment|Absolute change from baseline in EORTC QLQ-G.I.NET21 domain, Quality of Life assessed by EORTC QLQ-G.I.NET21 (excluding GI scale) (domains not included as key secondary objectives), After observing approximately 88 PFS events as per BIRC assessment, expected after approximately 33 months from study start|Absolute change from baseline in the EQ-5D-5L index at each time point, Quality of Life assessed by EQ-5D-5L, After observing approximately 88 PFS events as per BIRC assessment, expected after approximately 33 months from study start|Absolute change from baseline in EORTC QLQ-C30 domain, Quality of Life assessed by EORTC QLQ-C30 (domains not included as key secondary objectives), After observing approximately 88 PFS events as per BIRC assessment, expected after approximately 33 months from study start.|Dosimetry, Absorbed radiation dose in selected organs, tumor lesions and total body, After observing approximately 88 PFS events as per BIRC assessment, expected after approximately 33 months from study start|Pharmacokinetic (PK) parameter: Area Under Curve (AUC) from [177Lu]Lu-DOTA-TATE blood radioactivity data, The AUC from time zero to the last measurable concentration sampling time (tlast) (mass x time x volume-1).

The AUC from time zero to infinity (mass x time x volume-1), After observing approximately 88 PFS events as per BIRC assessment, expected after approximately 33 months from study start|PK parameter: Clearance from [177Lu]Lu-DOTA-TATE blood radioactivity data, Clearance is the total body clearance of drug from the plasma or blood (volume x time-1)., After observing approximately 88 PFS events as per BIRC assessment, expected after approximately 33 months from study start|PK parameter: Distribution volume (Vz) from [177Lu]Lu-DOTA-TATE blood radioactivity data, The apparent volume of distribution during terminal phase (associated with Î»z) (volume), After observing approximately 88 PFS events as per BIRC assessment, expected after approximately 33 months from study start|PK parameter: half-life (T1/2) from [177Lu]Lu-DOTA-TATE blood radioactivity data, The elimination half-life associated with the terminal slope (Î»z) of a semi logarithmic concentration-time curve (time). Use qualifier for other half-lives, After observing approximately 88 PFS events as per BIRC assessment, expected after approximately 33 months from study start",,Novartis Pharmaceuticals,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,240,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2025-05-29,2030-09-27,2034-01-05,2025-01-20,,2025-06-04,"Highlands Oncology Group, Fayetteville, Arkansas, 72703, United States",
NCT05884255,An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.,https://clinicaltrials.gov/study/NCT05884255,,RECRUITING,"The study is being conducted to evaluate the efficacy, and safety of Lutetium (177Lu) Oxodotreotide Injection in Subjects With advanced gastrointestinal pancreatic neuroendocrine tumors.",NO,Advanced Gastroenteropancreatic Neuroendocrine Tumor,DRUG: Lutetium (177Lu) Oxodotreotide Injectionï¼long-acting Octreotide|DRUG: long-acting Octreotide.,"Progression-free survival (PFS) assessed by BICR, up to 1 years follow-up","Overall Survival(OS), up to 5 years follow-up|Objective Response Rate(ORR), up to 1 years follow-up|Duration of Overall Response(DoR), up to 1 years follow-up|Disease Control Rate, up to 1 years follow-up|Incidence and severity of AE and SAE, up to 5 years follow-up",,"Jiangsu HengRui Medicine Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,220,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-07-06,2026-12,2030-10,2023-06-01,,2023-08-09,"Tianjin University Cancer Institute and Hospital, Tianjin, Tianjin, 300060, China",
NCT04550260,Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC,https://clinicaltrials.gov/study/NCT04550260,KUNLUN,ACTIVE_NOT_RECRUITING,"This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study to assess the efficacy and safety of durvalumab administered concurrently with dCRT in patients with locally advanced, unresectable esophageal squamous cell carcinoma (ESCC).",NO,Esophageal Squamous Cell Carcinoma,DRUG: Durvalumab|DRUG: Placebo|DRUG: cisplatin + fluorouracil|DRUG: cisplatin + capecitabine|RADIATION: Radiation,"Progression free survival (PFS) per RECIST 1.1 as assessed by BICR, To assess the efficacy in terms of PFS in PD-L1 High population, up to approximately 56 months","Overall survival (OS), To assess the efficacy in terms of OS in all randomized patients and in PD-L1 High population until the date of death, up to approximately 72 months|Progression free survival (PFS) per RECIST 1.1 as assessed by BICR, To assess the efficacy in terms of PFS in all randomized patients., up to approximately 56 months","Adverse events (AEs), To assess the safety and tolerability profile of durvalumab + dCRT compared to placebo + dCRT in patients with ESCC, up to approximately 72 months",AstraZeneca,,ALL,"ADULT, OLDER_ADULT",PHASE3,640,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-10-19,2025-11-28,2026-11-30,2020-09-16,,2025-06-05,"Research Site, Atlanta, Georgia, 30308, United States|Research Site, Louisville, Kentucky, 40217, United States|Research Site, Dallas, Texas, 75390, United States|Research Site, Fairfax, Virginia, 22031, United States|Research Site, Morgantown, West Virginia, 26506, United States|Research Site, Brussel, 1090, Belgium|Research Site, Charleroi, 6060, Belgium|Research Site, LiÃ¨ge, 4000, Belgium|Research Site, Namur, 5000, Belgium|Research Site, Barretos, 14784-400, Brazil|Research Site, Fortaleza, 60430-230, Brazil|Research Site, Porto Alegre, 90050-170, Brazil|Research Site, Porto Alegre, 91350-200, Brazil|Research Site, Rio de Janeiro, 20231-050, Brazil|Research Site, SÃ£o JosÃ© do Rio Preto, 15090-000, Brazil|Research Site, Vitoria, 29043-260, Brazil|Research Site, Barrie, Ontario, L4M 6M2, Canada|Research Site, Sudbury, Ontario, P3E 5J1, Canada|Research Site, Anyang, 455000, China|Research Site, Beijing, 100021, China|Research Site, Beijing, 100036, China|Research Site, Bengbu, 233004, China|Research Site, Changsha, 410013, China|Research Site, Changzhi, 46000, China|Research Site, Chengdu, 610042, China|Research Site, Chongqing, 400030, China|Research Site, Fuzhou, 350001, China|Research Site, Fuzhou, 350014, China|Research Site, Guangzhou, 510000, China|Research Site, Guangzhou, 510060, China|Research Site, Hangzhou, China|Research Site, Hefei, 230031, China|Research Site, Huai'an, 223300, China|Research Site, Jieyang, 522000, China|Research Site, Jinan, 250117, China|Research Site, Kunming, 650118, China|Research Site, Liangyugang, 222002, China|Research Site, Nantong, 226361, China|Research Site, Qingdao, 266042, China|Research Site, Quanzhou, 362000, China|Research Site, Shenzhen, 518116, China|Research Site, Tianjin, 300060, China|Research Site, Xi'an, 710061, China|Research Site, Xuzhou, 221000, China|Research Site, Yangzhou, 225001, China|Research Site, Zhengzhou, 450008, China|Research Site, Zhenjiang, 212002, China|Research Site, BESANCON Cedex, 25030, France|Research Site, Lille, 59000, France|Research Site, Lyon, 69008, France|Research Site, Montpellier, 34070, France|Research Site, Reims, 51100, France|Research Site, Rouen Cedex, 76031, France|Research Site, Strasbourg, 67033, France|Research Site, Villejuif Cedex, 94805, France|Research Site, Bunkyo-ku, 113-8431, Japan|Research Site, Chuo-ku, 104-0045, Japan|Research Site, Hidaka-shi, 350-1298, Japan|Research Site, Hirakata-shi, 573-1191, Japan|Research Site, Hiroshima-shi, 730-8518, Japan|Research Site, Kashiwa, 277-8577, Japan|Research Site, Kitaadachi-gun, 362-0806, Japan|Research Site, Koto-ku, 135-8550, Japan|Research Site, Kumamoto-shi, 860-8556, Japan|Research Site, Maebashi-shi, 371-8511, Japan|Research Site, Matsuyama-shi, 791-0280, Japan|Research Site, Niigata-shi, 951-8566, Japan|Research Site, Okayama-shi, 700-8558, Japan|Research Site, Osaka-shi, 541-8567, Japan|Research Site, Osaka-shi, 545-8586, Japan|Research Site, Ota-shi, 373-8550, Japan|Research Site, Sendai-shi, 980-8574, Japan|Research Site, Shinagawa-ku, 142-8666, Japan|Research Site, Yokohama-shi, 232-0024, Japan|Research Site, Yokohama-shi, 241-8515, Japan|Research Site, Daegu, 41404, Korea, Republic of|Research Site, Seoul, 06273, Korea, Republic of|Research Site, Seoul, 06351, Korea, Republic of|Research Site, Seoul, 138-736, Korea, Republic of|Research Site, Suwon, 16247, Korea, Republic of|Research Site, Chihuahua, 31210, Mexico|Research Site, Cuernavaca, 62290, Mexico|Research Site, Monterrey, 66220, Mexico|Research Site, MÃ©rida, 97134, Mexico|Research Site, Veracruz, 91851, Mexico|Research Site, Katowice, 40-074, Poland|Research Site, KrakÃ³w, 31-115, Poland|Research Site, Siedlce, 08-110, Poland|Research Site, Warszawa, 02-034, Poland|Research Site, ÅÃ³dÅº, 90-513, Poland|Research Site, Chelyabinsk, 454087, Russian Federation|Research Site, Ekaterinburg, 620905, Russian Federation|Research Site, Krasnodar, 350040, Russian Federation|Research Site, Moscow, 115478, Russian Federation|Research Site, Obninsk, 249031, Russian Federation|Research Site, Saint Petersburg, 197758, Russian Federation|Research Site, Sankt-Peterburg, 197758, Russian Federation|Research Site, Tyumen, 6250041, Russian Federation|Research Site, Ufa, 450054, Russian Federation|Research Site, Barcelona, 8035, Spain|Research Site, CÃ³rdoba, 14004, Spain|Research Site, Madrid, 28007, Spain|Research Site, Madrid, 28034, Spain|Research Site, Madrid, 28046, Spain|Research Site, Pamplona, 31008, Spain|Research Site, Santander, 39008, Spain|Research Site, Zaragoza, 50009, Spain|Research Site, Changhua, 50006, Taiwan|Research Site, Kaohsiung, 80756, Taiwan|Research Site, Kaohsiung, 82445, Taiwan|Research Site, Kaohsiung, 83301, Taiwan|Research Site, Taichung, 40443, Taiwan|Research Site, Taichung, 407, Taiwan|Research Site, Tainan, 710, Taiwan|Research Site, Taipei, 10002, Taiwan|Research Site, Taipei, 11217, Taiwan|Research Site, Tao-Yuan, 333, Taiwan|Research Site, Bangkok, 10210, Thailand|Research Site, Bangkok, 10300, Thailand|Research Site, Bangkok, 10330, Thailand|Research Site, Bangkok, 10400, Thailand|Research Site, Chiang Mai, 50200, Thailand|Research Site, Hat Yai, 90110, Thailand|Research Site, Khon Kaen, 40002, Thailand|Research Site, Mueang Chanthaburi, 22000, Thailand|Research Site, Ankara, 06800, Turkey|Research Site, Diyarbakir, 21280, Turkey|Research Site, Erzurum, 25240, Turkey|Research Site, Goztepe Istanbul, Turkey|Research Site, Izmir, 35575, Turkey|Research Site, Van, 65080, Turkey|Research Site, Hanoi, 100000, Vietnam|Research Site, Ho Chi Minh, 700000, Vietnam|Research Site, Ho Chi Minh, Vietnam",
NCT06129864,A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy,https://clinicaltrials.gov/study/NCT06129864,eVOLVE-HNSCC,RECRUITING,The main purpose of this study is to assess the efficacy and safety of volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) who have not progressed after receiving definitive concurrent chemoradiotherapy (cCRT).,NO,Locally Advanced Head and Neck Squamous Cell Carcinoma,DRUG: volrustomig,"Progression-Free Survival (PFS) in participants with unresected LA-HNSCC with PD-L1 expressing tumors, PFS is defined as time from randomization until first objective radiological progression per RECIST 1.1 as assessed by Blinded Independent Central Review (BICR), or death due to any cause (in the absence of progression).

The analysis will include all randomized participants with PD-L1 expressing tumors., Up to approximately 7 years","Progression-Free Survival (PFS) in the unresected LA-HNSCC intent-to-treat (ITT) population, PFS is defined as time from randomization until first objective radiological progression per RECIST 1.1 as assessed by BICR, or death due to any cause (in the absence of progression).

The analysis will include all randomized participants., Up to approximately 7 years|Landmark Progression-Free Survival (PFS) Rates, PFS is defined as time from randomization until first objective radiological progression per RECIST 1.1 as assessed by BICR, or death due to any cause (in the absence of progression).

These analyses will include participants with PD-L1 expressing tumors and all randomized participants., Up to approximately 7 years|Overall Survival (OS) in participants with unresected LA-HNSCC with PD-L1 expressing tumors, Overall survival (OS) is defined as the time from randomization until the date of death due to any cause.

The analysis will include all randomized participants with PD-L1 expressing tumors., Up to approximately 7 years|Landmark Overall Survival (OS) Rates, OS is defined as the time from randomization until the date of death due to any cause.

These analyses will include participants with PD-L1 expressing tumors as randomized and all randomized participants., Up to approximately 7 years|Overall Survival (OS) in the unresected LA-HNSCC ITT population, OS is defined as the time from randomization until the date of death due to any cause.

The analysis will include all randomized participants., Up to approximately 7 years|Progression Free Survival 2 (PFS2), PFS2 is defined as the time from randomization until the earliest of the progression event (following the initial investigator-assessed progression), after the start of the first subsequent therapy, or death from any cause, whichever occurs first. The date of the second progression will be recorded by the investigator in the eCRF and defined according to local standard clinical practice.

These analyses will include participants with PD-L1 expressing tumors as randomized and all randomized participants., Up to approximately 7 years|Presence of Anti-Drug-Antibodies (ADAs) against volrustomig in serum, To investigate the immunogenicity of volrustomig., Up to approximately 7 years|Participant-reported physical functioning, Change from baseline of physical functioning as measured by scores on the Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form v.20 - Physical Function 8c are reported on a T score metric (mean = 50 and SD = 10), with higher scores reflecting better physical functioning.

The analysis will include all randomized participants., Up to approximately 7 years|Participant-reported global health status (GHS)/quality of life (QoL), Change from baseline of Global Health Status/Quality of Life subscale scores as measured by the European Organization for Research and Treatment of Cancer (EORTC) Item Library 172 are transformed to a 0-100 range; a higher score represents higher quality of life.

The analysis will include all randomized participants., Up to approximately 7 years|Percentage of participants with Adverse Events, Adverse Events as assessed by Common Terminology Criteria for Adverse Events (CTCAE)., Up to approximately 7 years|Area under the curve (AUC), The concentration of MEDI5752 in serum will be determined. Area under the curve is the integral of the concentration-time curve. The AUC reflects the actual body exposure to drug after administration. The AUC is dependent on the rate of elimination of the drug from the body and the dose administered., Up to approximately 7 years|Maximum plasma concentration of the drug (Cmax), The concentration of MEDI5752 in serum will be determined (Cmax will be derived)., Up to approximately 7 years|The time taken to reach the maximum concentration (Tmax), The concentration of MEDI5752 in serum will be determined (Tmax will be derived)., Up to approximately 7 years",,AstraZeneca,,ALL,"ADULT, OLDER_ADULT",PHASE3,1145,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-12-14,2029-01-19,2030-05-23,2023-11-13,,2024-10-03,"Research Site, Birmingham, Alabama, 35233, United States|Research Site, Prescott Valley, Arizona, 86314, United States|Research Site, Springdale, Arkansas, 72762, United States|Research Site, Los Angeles, California, 90024, United States|Research Site, Orange, California, 92868, United States|Research Site, San Francisco, California, 94143, United States|Research Site, Santa Rosa, California, 95403, United States|Research Site, Aurora, Colorado, 80045, United States|Research Site, Lone Tree, Colorado, 80124, United States|Research Site, Fort Myers, Florida, 33901, United States|Research Site, Gainesville, Florida, 32610, United States|Research Site, Miami, Florida, 33125, United States|Research Site, Palm Bay, Florida, 32909, United States|Research Site, West Palm Beach, Florida, 33401, United States|Research Site, Niles, Illinois, 60714, United States|Research Site, Des Moines, Iowa, 50309, United States|Research Site, Kansas City, Kansas, 66160, United States|Research Site, Louisville, Kentucky, 40202, United States|Research Site, Baton Rouge, Louisiana, 70817, United States|Research Site, Shreveport, Louisiana, 71101, United States|Research Site, Baltimore, Maryland, 21231, United States|Research Site, Hyattsville, Maryland, 20782, United States|Research Site, Towson, Maryland, 21204, United States|Research Site, Upper Marlboro, Maryland, 20774, United States|Research Site, Boston, Massachusetts, 02215, United States|Research Site, Ann Arbor, Michigan, 48105, United States|Research Site, Ann Arbor, Michigan, 48109, United States|Research Site, Minneapolis, Minnesota, 55417, United States|Research Site, Columbia, Missouri, 65211, United States|Research Site, Saint Louis, Missouri, 63110, United States|Research Site, Saint Louis, Missouri, 63110, United States|Research Site, East Brunswick, New Jersey, 08816, United States|Research Site, Hackensack, New Jersey, 07601, United States|Research Site, New Brunswick, New Jersey, 08901, United States|Research Site, Albuquerque, New Mexico, 87108, United States|Research Site, New York, New York, 10065, United States|Research Site, New York, New York, 10075, United States|Research Site, Stony Brook, New York, 11794, United States|Research Site, Charlotte, North Carolina, 28204, United States|Research Site, Winston-Salem, North Carolina, 27157, United States|Research Site, Cleveland, Ohio, 44106, United States|Research Site, Portland, Oregon, 97213, United States|Research Site, Portland, Oregon, 97239, United States|Research Site, Philadelphia, Pennsylvania, 19107, United States|Research Site, Pittsburgh, Pennsylvania, 15261, United States|Research Site, York, Pennsylvania, 17403, United States|Research Site, Sioux Falls, South Dakota, 57105, United States|Research Site, Nashville, Tennessee, 37212, United States|Research Site, Austin, Texas, 78745, United States|Research Site, Dallas, Texas, 75251, United States|Research Site, Flower Mound, Texas, 75028, United States|Research Site, Houston, Texas, 77030, United States|Research Site, Odessa, Texas, 79761, United States|Research Site, Tyler, Texas, 75702, United States|Research Site, Salt Lake City, Utah, 84112, United States|Research Site, West Jordan, Utah, 84088, United States|Research Site, Fairfax, Virginia, 22031, United States|Research Site, Norfolk, Virginia, 23502, United States|Research Site, Richmond, Virginia, 23230, United States|Research Site, Spokane, Washington, 99204, United States|Research Site, Tacoma, Washington, 98405, United States|Research Site, Tacoma, Washington, 98415, United States|Research Site, Graz, 8036, Austria|Research Site, Innsbruck, 6020, Austria|Research Site, Linz, 4010, Austria|Research Site, Salzburg, 5020, Austria|Research Site, Wien, 1080, Austria|Research Site, Charleroi, 6000, Belgium|Research Site, Edegem, 2650, Belgium|Research Site, Jette, 1090, Belgium|Research Site, La LouviÃ¨re, 7100, Belgium|Research Site, Namur, 5000, Belgium|Research Site, Barretos, 14784-400, Brazil|Research Site, FlorianÃ³polis, 88034-000, Brazil|Research Site, Fortaleza, 60336-045, Brazil|Research Site, IjuÃ­, 98700-000, Brazil|Research Site, Ipatinga, 35162-189, Brazil|Research Site, Londrina, 86015-520, Brazil|Research Site, Porto Alegre, 91350200, Brazil|Research Site, RibeirÃ£o Preto, 14051-140, Brazil|Research Site, Rio de Janeiro, 20231-050, Brazil|Research Site, Sao Paulo, 01509-900, Brazil|Research Site, Sao Paulo, 04538-132, Brazil|Research Site, Teresina, 64049-200, Brazil|Research Site, Calgary, Alberta, T2N 4N2, Canada|Research Site, Edmonton, Alberta, T6G 1Z2, Canada|Research Site, Kelowna, British Columbia, V1Y 5L3, Canada|Research Site, Kingston, Ontario, K7L 2V7, Canada|Research Site, London, Ontario, N6A 5W9, Canada|Research Site, Toronto, Ontario, M4N 3M5, Canada|Research Site, Montreal, Quebec, H2X 0C1, Canada|Research Site, Montreal, Quebec, H3T 1E2, Canada|Research Site, Montreal, Quebec, H4A 3J1, Canada|Research Site, Regina, S4T 7T1, Canada|Research Site, Beijing, 100142, China|Research Site, Beijing, 100210, China|Research Site, Bengbu, 233060, China|Research Site, Changchun, 130000, China|Research Site, Changsha, 410008, China|Research Site, Changsha, 410013, China|Research Site, Chengdu, 610000, China|Research Site, Chengdu, 610042, China|Research Site, Chengdu, 610072, China|Research Site, Chongqing, 400016, China|Research Site, Chongqing, 400030, China|Research Site, Fuzhou, 350014, China|Research Site, Guangzhou, 510060, China|Research Site, Guangzhou, 510080, China|Research Site, Guangzhou, 510095, China|Research Site, Guiyang, 550002, China|Research Site, Hangzhou, 310022, China|Research Site, Harbin, 150049, China|Research Site, Hefei, 230001, China|Research Site, Jinan, 250117, China|Research Site, Kunming, 650118, China|Research Site, Nanchang, 330029, China|Research Site, Nanning, 530021, China|Research Site, Shanghai, 20032, China|Research Site, Shenyang, 110004, China|Research Site, Tianjin Shi, 300060, China|Research Site, Tianjin, 300060, China|Research Site, Urumqi, 830000, China|Research Site, Wuhan, 430030, China|Research Site, Wuxi, 214122, China|Research Site, Xiamen, 361003, China|Research Site, Xian, 710061, China|Research Site, Zhengzhou, 450008, China|Research Site, Avignon Cedex 09, 84918, France|Research Site, Bordeaux, 33075, France|Research Site, Lyon, 69373, France|Research Site, Saint Herblain, 44805, France|Research Site, Toulouse Cedex 09, 31059, France|Research Site, Villejuif, 94805, France|Research Site, Berlin, 12200, Germany|Research Site, Essen, 45122, Germany|Research Site, Greifswald, 17475, Germany|Research Site, Hamburg, 20246, Germany|Research Site, Hannover, 30625, Germany|Research Site, Leipzig, 04103, Germany|Research Site, LÃ¼beck, 23538, Germany|Research Site, MÃ¼nchen, 81675, Germany|Research Site, Rostock, 18059, Germany|Research Site, TÃ¼bingen, 72076, Germany|Research Site, Ulm, 89075, Germany|Research Site, WÃ¼rzburg, 97070, Germany|Research Site, Budapest, 1083, Hungary|Research Site, Budapest, 1122, Hungary|Research Site, Budapest, 1145, Hungary|Research Site, GyÅr, 9024, Hungary|Research Site, KecskemÃ©t, 6000, Hungary|Research Site, Miskolc, 3526, Hungary|Research Site, NyÃ­regyhÃ¡za, 4400, Hungary|Research Site, PÃ©cs, 7624, Hungary|Research Site, SzekszÃ¡rd, 7100, Hungary|Research Site, Bengaluru, 560027, India|Research Site, Hyderabad, 500032, India|Research Site, Jaipur, 302022, India|Research Site, Kanpur, 208005, India|Research Site, Kochi, 682027, India|Research Site, Kolkata, 700099, India|Research Site, Lucknow, 226003, India|Research Site, Madurai, 625107, India|Research Site, Mohali, 160055, India|Research Site, New Delhi, 110076, India|Research Site, Thiruvananthapuram, 695011, India|Research Site, Vadodara, 391760, India|Research Site, Varanasi, 221005, India|Research Site, Aviano, 33081, Italy|Research Site, Firenze, 50139, Italy|Research Site, Milano, 20133, Italy|Research Site, Modena, 41124, Italy|Research Site, Napoli, 80131, Italy|Research Site, Padova, 35128, Italy|Research Site, Pavia, 27100, Italy|Research Site, Rozzano, 20089, Italy|Research Site, Bunkyo-ku, 113-8519, Japan|Research Site, Chiba-shi, 260-8717, Japan|Research Site, Chuo-ku, 104-0045, Japan|Research Site, Fukuoka, 811-1395, Japan|Research Site, Hiroshima-shi, 734-8551, Japan|Research Site, Kashiwa, 277-8577, Japan|Research Site, Kobe-shi, 650-0017, Japan|Research Site, Koto-ku, 135-8550, Japan|Research Site, Nagoya-shi, 464-8681, Japan|Research Site, Nagoya-shi, 466-8560, Japan|Research Site, Niigata-shi, 951-8520, Japan|Research Site, Okayama-shi, 700-8558, Japan|Research Site, Osaka-shi, 541-8567, Japan|Research Site, Osakasayama-shi, 589-8511, Japan|Research Site, Sapporo-shi, 060-8638, Japan|Research Site, Sendai-shi, 980-8574, Japan|Research Site, Shiwa-gun, 028-3695, Japan|Research Site, Sunto-gun, 411-8777, Japan|Research Site, Yokohama-shi, 236-0004, Japan|Research Site, Yokohama-shi, 241-8515, Japan|Research Site, Goyang-si, 410-769, Korea, Republic of|Research Site, Gyeonggi-do, 13620, Korea, Republic of|Research Site, Incheon, 21565, Korea, Republic of|Research Site, Seoul, 06351, Korea, Republic of|Research Site, Seoul, 5505, Korea, Republic of|Research Site, Suwon, 16247, Korea, Republic of|Research Site, George Town, 10450, Malaysia|Research Site, Johor Bahru, 81100, Malaysia|Research Site, Kuala Lumpur, 50586, Malaysia|Research Site, Kuala Lumpur, 59100, Malaysia|Research Site, Kuching, 93586, Malaysia|Research Site, Selangor, 62250, Malaysia|Research Site, BiaÅystok, 15-027, Poland|Research Site, Bielsko-BiaÅa, 43-300, Poland|Research Site, Gliwice, 44-102, Poland|Research Site, PiotrkÃ³w Trybunalski, 97-300, Poland|Research Site, TomaszÃ³w Mazowiecki, 97-200, Poland|Research Site, Warszawa, 02-781, Poland|Research Site, Badalona, 08916, Spain|Research Site, Barcelona, 08035, Spain|Research Site, Barcelona, 08036, Spain|Research Site, JaÃ©n, 23007, Spain|Research Site, Madrid, 28007, Spain|Research Site, Madrid, 28034, Spain|Research Site, Madrid, 28040, Spain|Research Site, Valencia, 46026, Spain|Research Site, ValÃ¨ncia, 46014, Spain|Research Site, Changhua, 500, Taiwan|Research Site, Kaohsiung City, 833401, Taiwan|Research Site, Taichung, 404, Taiwan|Research Site, Taichung, 40705, Taiwan|Research Site, Taipei City, 11217, Taiwan|Research Site, Taipei, 10002, Taiwan|Research Site, Bangkok, 10400, Thailand|Research Site, Bangkok, 10700, Thailand|Research Site, Chaing Mai, 50200, Thailand|Research Site, Hat Yai, 90110, Thailand|Research Site, Khon Kaen, 40002, Thailand|Research Site, Ankara, 06230, Turkey|Research Site, Ankara, 6200, Turkey|Research Site, Antalya, 07059, Turkey|Research Site, Istanbul, 34722, Turkey|Research Site, Karsiyaka, 35575, Turkey|Research Site, Yenimahalle, 06170, Turkey|Research Site, Aberdeen, AB25 2ZN, United Kingdom|Research Site, Cambridge, CB2 0XY, United Kingdom|Research Site, Hampshire, SO16 6YD, United Kingdom|Research Site, Leeds, LS9 7TF, United Kingdom|Research Site, London, EC1A 7BE, United Kingdom|Research Site, London, SE1 9RT, United Kingdom|Research Site, London, SW3 6JJ, United Kingdom|Research Site, Manchester, M20 4BX, United Kingdom|Research Site, Northwood, HA6 2RN, United Kingdom|Research Site, Sutton, SM2 5PT, United Kingdom|Research Site, Taunton, TA1 5DA, United Kingdom|Research Site, Wirral, CH63 4JY, United Kingdom|Research Site, Hanoi, 100000, Vietnam|Research Site, Ho Chi Minh City, 700000, Vietnam|Research Site, Ho Chi Minh, 700000, Vietnam|Research Site, Vinh, 460000, Vietnam",
NCT06475599,Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer,https://clinicaltrials.gov/study/NCT06475599,,NOT_YET_RECRUITING,To demonstrate that anlotinib hydrochloride capsules combined with TQB2450 injection can significantly prolong progression-free survival (PFS) compared with chemotherapy in patients with recurrent or metastatic endometrial cancer that is non- microsatellite instability high (non-MSI-H) or DNA mismatch repair deficient (non-dMMR).,NO,Endometrial Cancer,DRUG: Anlotinib hydrochloride capsule + TQB2450 injection|DRUG: Chemotherapy drug,"Progression-free survival (PFS) assessed by independent imaging review committee (IRC), Progression-free survival (PFS) as assessed by independent imaging review committee (IRC) according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST1.1) criteria.

Time from subject randomization (first treatment) to first disease progression or death from any cause, whichever occurred first., Up to 36 months after study start","Overall survival (OS), Time from randomization to death from any cause., Up to 36 months after study start|Progression-free survival (PFS) assessed by investigators, Time from subject randomization (first treatment) to first disease progression or death from any cause, whichever occurred first, was assessed by the investigator according to RECIST 1.1., Up to 36 months after study start|Objective mitigation rate (ORR), According to RECIST 1.1 criteria, proportion of patients with confirmed tumor volume reduction to pre-specified values and maintained minimum requirements, namely the proportion of patients with complete response (CR) and partial response (PR)., Up to 36 months after study start|Duration of Response (DOR), From the time of tumor first evaluated as complete or partial response to the time of first disease progression or death from various causesï¼if the tumor remission is not confirmed, it can not be used., Up to 36 months after study start|Disease control rate (DCR), According to RECIST 1.1 criteria, proportion of patients with confirmed tumor volume reduction to pre-specified values and maintained minimum requirements, namely the proportion of patients with CRï¼PR and stable disease (SD)., Up to 36 months after study start|Incidence and severity of abnormal laboratory values, Incidence and severity of laboratory inspection indicators exceed the normal range, Up to 36 months after study start|Incidence and severity of adverse event rate Adverse events (AE), serious adverse event (SAE), The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs), Up to 36 months after study start|Incidence of dose interruptions, dose reductions, and dose discontinuations due to study-drug-related toxicity during the trial, Incidence of dose interruptions, dose reductions, and dose discontinuations due to study-drug-related toxicity during the trial, Up to 36 months after study start|Immunogenicity of TQB2450, Incidence of anti-drug antibodies (ADAs) and neutralizing antibodies (NAbs), Before administration (-15 minutes) in cycles 1, 2, 5, and 9, and 90 days after the last dose (Â±7days), each cycle is 21 days|European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30), Questionnaire: EORTC Quality of Life Questionnaire (QLQ-C30):For questions 1 to 28, choose a number from 1 to 4, 1 means none and 4 means very good. For questions 29 and 30, choose a number from 1 to 7, with 1 being very poor and 7 being very good., Up to 96 weeks|European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L), Questionnaire: European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) : The scale has numbers from 0 to 100. 100 represents the best health imaginable. 0 is the worst health imaginable., Up to 96 weeks|European Organization for Research on Treatment of Cancer Endometrial cancer Specific scale QLQ-EN24, Questionnaire: European Organization for Research on Treatment of Cancer Quality of Life questionnaire 24 (QLQ-EN24)ï¼From questions 1 to 24, choose a number from 1 to 4, where 1 means none and 4 means very much., Up to 96 weeks",,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,420,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-07,2027-12,2029-06,2024-06-26,,2024-06-27,"Anhui Provincial Hospital, Hefei, Anhui, 230001, China|Fujian Cancer Hospital, Fuzhou, Fujian, 350014, China|First Hospital of Lanzhou University, Lanzhou, Gansu, 730000, China|Gansu Provincial Cancer Hospital, Lanzhou, Gansu, 730050, China|Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, 510289, China|The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, 510630, China|Huizhou Central People's Hospital, Huizhou, Guangdong, 516008, China|Jiangmen Central Hospital, Jiangmen, Guangdong, 529030, China|Meizhou People's Hospital, Meizhou, Guangdong, 514031, China|Guigang City People's Hospital, Guigang, Guangxi, 537100, China|Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, Guangxi, 541000, China|Liuzhou People's Hospital, Liuzhou, Guangxi, 545006, China|Liuzhou Municipal Liutie Central Hospital, Liuzhou, Guangxi, 545007, China|Guangxi Medical University Cancer Hospital, Nanning, Guangxi, 530021, China|Hainan Ceneral Hospital, Haikou, Hainan, 570311, China|Tangshan People's Hospital, Tangshan, Hebei, 063000, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China|The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, 450018, China|Nanyang first People's Hospital National Third Class A Hospital, Nanyang, Henan, 473000, China|The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China|Hubei Cancer Hospital, Wuhan, Hubei, 430079, China|Hunan Cancer Hospital, Changsha, Hunan, 410031, China|The Central Hospital Of Shaoyang, Shaoyang, Hunan, 422000, China|Inner Mongolia Autonomous Region People's Hospital, Hohhot, Inner Mongolia Autonomous Region, 010017, China|Changchun Tumor Hospital, Changchun, Jilin, 130012, China|The first hospital of Jilin University, Changchun, Jilin, 130021, China|Liaoning Cancer Hospital, Shenyang, Liaoning, 110000, China|Shengjing Hospital Of China Medical University, Shenyang, Liaoning, 110000, China|General Hospital Of Ningxia Medical University, Yinchuan, Ningxia, 750001, China|Qinghai Red Cross Hospital, Xining, Qinghai, 810000, China|The Second Affiliated Hospital of Air Force Medical University, Xi'an, Shaanxi, 710038, China|The First Affiliated Hospital of Xi 'an Jiaotong University, Xi'an, Shaanxi, 710061, China|Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, 712038, China|Binzhou Medical University Hospital, Binzhou, Shandong, 256600, China|Binzhou People's Hospital, Binzhou, Shandong, 256601, China|Shandong Cancer Hospital, Jinan, Shandong, 250117, China|Affiliated Hospital of Jining Medical University, Jining, Shandong, 272001, China|Linyi Cancer Hospital, Linyi, Shandong, 276000, China|Weifang People's Hospital, Weifang, Shandong, 261000, China|Yidu Central Hospital Of Weifang, Weifang, Shandong, 262500, China|Yantai Yuhuangding Hospital, Yantai, Shandong, 264000, China|Tengzhou Central People's Hospital, Zaozhuang, Shandong, 277500, China|Shanxi Cancer hospital, Taiyuan, Shanxi, 030000, China|Shanxi Bethune Hospital, Taiyuan, Shanxi, 30000, China|Affiliated Cancer Hospital of Xinjiang Medical University, ÃrÃ¼mqi, Xinjiang, 830054, China|Yunnan Cancer Hospital, Kunming, Yunnan, 650118, China|Maternal Health School of Medicine Zhejiang University, Hangzhou, Zhejiang, 310006, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, 310022, China|The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, 315201, China|Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, 100006, China|Beijing Chaoyang Hospital, Capital Medical University, Beijing, 100020, China|Chongqing University Cancer Hospital, Chongqing, 400032, China|The Southwest Hospital of Amu, Chongqing, 400038, China|Chongqing University Three Gorges Hospital, Chongqing, 400040, China|The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400072, China|The Affiliated Hospital of Southwest Medical University, Chongqing, 646000, China|Fudan University Shanghai Cancer Center, Shanghai, 200032, China|Shanghai Tenth People's Hospital, Shanghai, 200040, China|Obstetrics & Gynecology Hospital of Fudan University, Shanghai, 200090, China|Tianjin Medical University Cancer Institute & Hospital, Tianjin, 300181, China|Tianjin Central Hospital of Gynecology Obstetrics, Tianjin, 300199, China",
NCT06970639,A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases,https://clinicaltrials.gov/study/NCT06970639,,RECRUITING,"This study is a Phase III, international, multicenter, randomized, controlled, open-label clinical trial. The primary objective is to evaluate the efficacy and safety of furmonertinib plus platinum-based doublet chemotherapy (Arm A) versus osimertinib monotherapy (Arm B) in patients with EGFR sensitizing mutation-positive non-squamous non-small cell lung cancer (NSCLC) and brain metastases. Additionally, a proportion of subjects will receive furmonertinib monotherapy (Arm C) to further explore its efficacy and safety profile.

Stage 1 is the safety run-in phase, planned to enroll approximately 30 subjects who will be randomized at a 1:1 ratio to receive either furmonertinib 80 mg QD plus platinum-based chemotherapy or furmonertinib 160 mg QD plus platinum-based chemotherapy, aiming to evaluate the safety and tolerability of different furmonertinib doses in combination with platinum-based chemotherapy.

Stage 2 is the randomized controlled phase, in which approximately 350 subjects will be randomized in a 3:3:1 ratio (Arm A : Arm B : Arm C) to receive the investigational treatments.",NO,NSCLC Patients With Brain Metastasis,DRUG: Furmonertinib Mesilate Tablets|DRUG: Carboplatin Injection|DRUG: Cisplatin for injection|DRUG: Pemetrexed Disodium for Injection|DRUG: Osimertinib Mesylate Tablets,"Adverse Events (AE), Safe import period, Up to 4 years|Serious Adverse Event (SAE), Safe import period, Up to 4 years|Progression-free survival (PFS), Randomized Controlled Phaseï¼PFS assessed by BICR based on recist1.1; PFS was defined as the time from the date of randomization to the date of first documented disease progression (assessed according to RECIST v1.1 criteria) or death from any cause, whichever occurred first., Up to 4 years","Progression free survival (PFS) evaluated by researchers based on RECIST 1.1, Both the safe introduction period and randomized controlled trials require evaluation of progression free survival (PFS), Up to 4 years|Objective response rate (ORR), Both the safe introduction period and randomized controlled trials require evaluation of objective response rate (ORR), Up to 4 years|Disease control rate (DCR), Both the safe introduction period and randomized controlled trials require evaluation of disease control rate (DCR), Up to 4 years|Duration of Relief (DOR), Both the safe introduction period and randomized controlled trials require evaluation of Duration of Relief (DOR), Up to 4 years|Overall survival (OS), safe introduction period, Up to 4 years|InterPlanetary File Systemï¼iPFSï¼ by researchers and BICR based on RECIST 1.1 evaluation, Randomized Controlled Phase, Up to 4 years|Depth of Responseï¼DepORï¼ by researchers and BICR based on RECIST 1.1 evaluation, Randomized Controlled Phase, Up to 4 years|adverse events (AE), Randomized Controlled Phase, Up to 4 years|serious adverse events (SAE), Randomized Controlled Phase, Up to 4 years|Patient Reported Outcomes by EORTC QLQ LC13 questionnaire, Randomized Controlled Phaseï¼To assess the impact of firmonertinib on patients' disease-related symptoms and health related quality of life (HRQoL)., Up to 4 years|Patient Reported Outcomes by EORTCQLQ-C30 questionnaire, Randomized Controlled Phaseï¼To assess the impact of firmonertinib on patients' disease-related symptoms and health related quality of life (HRQoL)., Up to 4 years|Peak Plasma Concentration (Cmax), Randomized Controlled Phase, Up to 4 years|Steady-state oral clearanceï¼CLss/Fï¼, Randomized Controlled Phase, Up to 4 years|Steady-state minimal concentrationï¼Cmin,ssï¼, Randomized Controlled Phase, Up to 4 years|Steady-state area under the curveï¼AUCssï¼, Randomized Controlled Phase, Up to 4 years",,"Allist Pharmaceuticals, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE3,380,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-09-26,2029-03,2029-09,2025-05-14,,2025-05-14,"Guangdong Provincial People's Hospital, Guangdong, Guangzhou, China",
NCT06170788,Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) â¥ 50% (MK-2870-007),https://clinicaltrials.gov/study/NCT06170788,TroFuse-007,RECRUITING,"The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS). The primary hypothesis is that the combination of sacituzumab tirumotecan and pembrolizumab is superior to pembrolizumab alone with respect to OS.

All participants who have completed the first course of pembrolizumab may be eligible for up to an additional 9 cycles of pembrolizumab monotherapy if there is blinded independent central review (BICR)-verified progressive disease by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) after initial treatment.",NO,Non-small Cell Lung Cancer (NSCLC),BIOLOGICAL: Sacituzumab tirumotecan|BIOLOGICAL: Pembrolizumab,"Overall Survival (OS), OS is defined as the time from randomization to death from any cause., Up to approximately 48 months","Progression free survival (PFS), PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on BICR or death due to any cause, whichever occurs first, Up to approximately 48 months|Objective Response (OR), The OR is defined as a confirmed complete response (CR) or partial response (PR) per RECIST 1.1 as assessed by BICR., Up to approximately 48 months|Duration of Response (DOR), For participants who demonstrate confirmed CR or PR per RECIST 1.1 as assessed by BICR, duration of response is defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first., Up to approximately 48 months|Change from Baseline in Global Health Status/Quality of Life (QOL) [European Organisation for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30) 29 Items and 30] Score, Change from baseline in the score of EORTC QLQ-C30 Items 29 and 30 will be presented. The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to Items 29 and 30 (""How would you rate your overall health during the past week?"" and ""How would you rate your overall quality of life during the past week?"") are scored on a 7-point scale (1=Very Poor to 7=Excellent). A higher score indicates a better overall outcome., Baseline and up to approximately 24 months|Change From Baseline in Dyspnea (EORTC QLQ-C30 Item 8) Score, Change from baseline in the score of EORTC QLQ-C30 Item 8 will be presented. The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant response to the question ""Were you short of breath?"" is scored on a 4-point scale (1=Not at All to 4=Very Much). A higher score indicates a worse level of dyspnea., Baseline and up to approximately 24 months|Change From Baseline in Cough (EORTC QLQ-LC13 Item 31) Score, Change from baseline in the score of EORTC QLQ-C13 Item 31 will be presented. The EORTC QLQ-C13 is a lung cancer specific health-related quality-of life (QoL) questionnaire. Participant response to the question ""Have you coughed?"" is scored on a 4-point scale (1=Not at All to 4=Very Much). A higher score indicates more frequent coughing., Baseline and up to approximately 24 months|Change From Baseline in Chest Pain (EORTC QLQ-LC13 item 40) Score, The EORTC QLQ-LC13 is a lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQ-C30. Participant responses to the question ""Have you had pain in your chest?"" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The change from baseline in chest pain (EORTC QLQ-LC13 Item 40) score will be presented. A lower score indicates a better outcome., Baseline and up to approximately 24 months|Time to Deterioration (TTD) Based on Change From Baseline in Global Health Status (GHS)/ QOL Score (EORTC QLQ-C30 Item 29 and 30), The TTD in GHS/QOL score (EORTC QLQ-C30 Items 29 and 30) will be presented. Participant responses to Items 29 and 30 (""How would you rate your overall health during the past week?"" and ""How would you rate your overall quality of life during the past week?"") are scored on a 7-point scale (1=Very Poor to 7=Excellent). A higher score indicates a better overall outcome. TTD as assessed based on a negative change (decrease in score) from Baseline in GHS/QOL score. A longer TTD indicates a better outcome., Up to approximately 24 months|Time to Deterioration (TTD) Based on Change From Baseline in Dyspnea Score (EORTC QLQ-C30 Item 8), The TTD in Dyspnea score (EORTC QLQ-C30 Item 8) will be presented. Participant response to the question ""Were you short of breath?"" is scored on a 4-point scale (1=Not at All to 4=Very Much). A higher score indicates a worse level of dyspnea. TTD is assessed based on the time to a negative change (increase in score) from baseline. A longer TTD indicates a better outcome., Up to approximately 24 months|Time to Deterioration (TTD) Based on Change From Baseline in Cough Score (EORTC QLQ-LC13 Item 31)., The TTD in Cough score (EORTC QLQ-LC13 Item 31) will be presented. Participant response to the question ""Have you coughed?"" is scored on a 4-point scale (1=Not at All to 4=Very Much). A higher score indicates more frequent coughing. TTD is assessed based on the time to a negative change (increase in score) from baseline. A longer TTD indicates a better outcome., Up to approximately 24 months|Time to Deterioration (TTD) Based on Change From Baseline in Chest Pain Score (EORTC QLQ-LC13 Item 40), The TTD in Chest Pain score (EORTC QLQ-LC13 Item 40) will be presented. Participant response to the question ""Have you had pain in your chest?"" is scored on a 4-point scale (1=Not at All to 4=Very Much). A higher score indicates a worse level of chest pain. TTD is assessed based on the time to a negative change (increase in score) from baseline. A longer TTD indicates a better outcome., Up to approximately 24 months|Percentage of Participants That Experience at Least 1 Adverse Event, An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The percentage of participants who experience an AE will be presented., Up to approximately 27 months|Percentage of Participants Who Discontinue Study Treatment Due to an AE, The percentage of participants who discontinue study treatment due to an AE will be presented., Up to approximately 24 months",,Merck Sharp & Dohme LLC,,ALL,"ADULT, OLDER_ADULT",PHASE3,614,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-12-15,2028-01-25,2030-05-27,2023-12-14,,2025-06-13,"Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0130), Burbank, California, 91505, United States|Cancer Centers of Colorado St. Mary's Regional Hospital ( Site 0132), Grand Junction, Colorado, 81501, United States|Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0106), Marietta, Georgia, 30060, United States|The University of Louisville, James Graham Brown Cancer Center ( Site 0121), Louisville, Kentucky, 40202, United States|New England Cancer Specialists ( Site 0143), Scarborough, Maine, 04074, United States|University of Massachusetts Chan Medical School-Division of Hematology/Oncology ( Site 0144), Worcester, Massachusetts, 01655, United States|Allina Health Cancer Institute - Abbott Northwestern Hospital ( Site 0115), Minneapolis, Minnesota, 55407, United States|Hattiesburg Clinic Hematology/Oncology ( Site 0104), Hattiesburg, Mississippi, 39401, United States|Renown Regional Medical Center-Renown Health Medical Oncology ( Site 0134), Reno, Nevada, 89502, United States|University Hospitals Cleveland Medical Center ( Site 0119), Cleveland, Ohio, 44106, United States|Good Samaritan Regional Medical Center-Samaritan Pastega Regional Cancer Center ( Site 0117), Corvallis, Oregon, 97330, United States|Oncology Consultants P.A. ( Site 0129), Houston, Texas, 77030, United States|Instituto Alexander Fleming ( Site 0306), Ciudad AutÃ³noma de Buenos Aires, Buenos Aires, C1426ANZ, Argentina|Hospital BritÃ¡nico de Buenos Aires-Oncology ( Site 0304), Ciudad autÃ³noma de Buenos Aires, Caba, C1280AEB, Argentina|Centro Privado de RMI RÃ­o Cuarto S.A. II ( Site 0310), RÃ­o Cuarto, Cordoba, X5800ALB, Argentina|Instituto de OncologÃ­a de Rosario ( Site 0301), Rosario, Santa Fe, S2000KZE, Argentina|Hospital Aleman-Oncology ( Site 0300), Buenos Aires, C1118AAT, Argentina|Port Macquarie - Mid North Coast Cancer Institute-Medical Oncology ( Site 3002), Port Macquarie, New South Wales, 2444, Australia|Westmead Hospital ( Site 3000), Westmead, New South Wales, 2145, Australia|Grampians Health-Medical Oncology ( Site 3001), Ballarat Central, Victoria, 3350, Australia|Northern Hospital ( Site 3003), Epping, Victoria, 3076, Australia|Irmandade da Santa Casa de MisericÃ³rdia de Porto Alegre ( Site 0409), Porto Alegre, Rio Grande Do Sul, 90020-090, Brazil|Clinica Viver ( Site 0400), Santa Maria, Rio Grande Do Sul, 97015-450, Brazil|FundaÃ§Ã£o Pio XII - Hospital de CÃ¢ncer de Barretos ( Site 0402), Barretos, Sao Paulo, 14784400, Brazil|FundaÃ§Ã£o Faculdade Regional de Medicina de SÃ£o JosÃ© do Rio Preto ( Site 0406), SÃ£o JosÃ© do Rio Preto, Sao Paulo, 15090000, Brazil|Instituto Nacional de CÃ¢ncer - INCA ( Site 0405), Rio de Janeiro, 20230-130, Brazil|NÃºcleo de Pesquisa ClÃ­nica da Rede SÃ£o Camilo ( Site 0401), Sao Paulo, 04014-012, Brazil|William Osler Health System ( Site 0203), Brampton, Ontario, L6R 3J7, Canada|Trillium Health Partners - Credit Valley Hospital ( Site 0202), Mississauga, Ontario, L5M 2N1, Canada|McGill University Health Centre ( Site 0200), MontrÃ©al, Quebec, H4A 3J1, Canada|Clinica Universidad Catolica del Maule-Oncology ( Site 0501), Talca, Maule, 3465584, Chile|Bradfordhill-Clinical Area ( Site 0507), Santiago., Region M. De Santiago, 8420383, Chile|Orlandi Oncologia-Oncology ( Site 0504), Santiago, Region M. De Santiago, 7500713, Chile|FALP-UIDO ( Site 0509), Santiago, Region M. De Santiago, 7500921, Chile|Bradford Hill Norte ( Site 0516), Antofagasta, 1263521, Chile|Second Affiliated hospital of Anhui Medical University ( Site 3133), Hefei, Anhui, 230000, China|Beijing Cancer hospital-intrathoratic deparmtment II ( Site 3101), Beijing, Beijing, 100142, China|Beijing Peking Union Medical College Hospital-pneumology department ( Site 3100), Beijing, Beijing, 100730, China|Fujian Provincial Cancer Hospital ( Site 3131), Fuzhou, Fujian, 350014, China|The First Affiliated hospital of Xiamen University-Breast Surgery ( Site 3107), Xiamen, Fujian, 361003, China|The First Affiliated Hospital of Guangzhou Medical University ( Site 3134), Guangzhou, Guangdong, 510140, China|Southern Medical University Nanfang Hospital-Depatrment of Respiratory and Critical Care Medicine ( Site 3108), Guangzhou, Guangdong, 510515, China|Affiliated Hospital of Guangdong Medical University ( Site 3123), Zhanjiang, Guangdong, 524004, China|The Second Hospital of Hebei Medical University ( Site 3135), Shijiazhuang, Hebei, 050000, China|Harbin Medical University Cancer Hospital-oncology of department ( Site 3132), Harbin, Heilongjiang, 150000, China|Henan Cancer Hospital ( Site 3116), Zhengzhou, Henan, 450008, China|Tongji Hospital Tongji Medical,Science & Technology ( Site 3117), Wuhan, Hubei, 430000, China|Wuhan Union Hospital ( Site 3130), Wuhan, Hubei, 430048, China|Hubei Cancer Hospital ( Site 3106), Wuhan, Hubei, 430079, China|Xiangyang Central Hospital-oncology department ( Site 3136), Xiangyang, Hubei, 441106, China|The Second Xiangya Hospital of Central South University ( Site 3138), Changsha, Hunan, 410011, China|Affiliated Hospital of Jiangnan University(Wuxi Fourth People's Hospital ) ( Site 3113), Wuxi, Jiangsu, 214122, China|The Affiliated Hospital of Xuzhou Medical College ( Site 3112), Xuzhou, Jiangsu, 221002, China|The First Affiliated Hospital of Nanchang University-Respiratory Medicine Department ( Site 3127), Nanchang, Jiangxi, 330006, China|The Second Affiliated Hospital of Nanchang University-Oncology Department ( Site 3121), Nanchang, Jiangxi, 330006, China|Jiangxi Provincial Cancer Hospital ( Site 3143), Nanchang, Jiangxi, 330029, China|Jilin Province Tumor Hospital-oncology department ( Site 3126), Changchun, Jilin, 130000, China|Jinan Central Hospital-oncology department ( Site 3122), Jinan, Shandong, 250013, China|Shandong Cancer Hospital ( Site 3119), Jinan, Shandong, 250117, China|Shanghai Changhai Hospital ( Site 3125), Shanghai, Shanghai, 200082, China|West China Hospital, Sichuan University ( Site 3124), Cheng Du, Sichuan, 610041, China|Sichuan Cancer hospital. ( Site 3105), Chengdu, Sichuan, 610042, China|The Second People's Hospital of Neijiang ( Site 3140), Neijiang, Sichuan, 641099, China|Yunnan Province Cancer Hospital ( Site 3139), Kunming, Yunnan, 650107, China|The first Affiliated Hospital, Zhejiang University School of Medicine ( Site 3115), Hangzhou, Zhejiang, 310003, China|Sir Run Run Shaw Hospital of Zhejiang University School of Medicine ( Site 3111), Hangzhou, Zhejiang, 310016, China|Taizhou Hospital of Zhejiang Province-Respiratory ( Site 3114), Taizhou, Zhejiang, 317000, China|IMAT S.A.S ( Site 0602), Monteria, Cordoba, 230002, Colombia|FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 0600), Bogota, Distrito Capital De Bogota, 110131, Colombia|Oncologos del Occidente ( Site 0603), Pereira., Risaralda, 660001, Colombia|Nemocnice AGEL Ostrava - Vitkovice a.s.-Plicni oddeleni ( Site 1103), Ostrava, Ostrava Mesto, 703 00, Czechia|Multiscan-Onkologicke a radiologicke centrum Multiscan Pardubice ( Site 1105), Pardubice, Pardubicky Kraj, 532 03, Czechia|Vseobecna fakultni nemocnice v Praze-Onkologicka klinika ( Site 1106), Praha, Praha 2, 128 08, Czechia|Fakultni nemocnice Olomouc-Klinika plicnich nemoci a tuberkulozy ( Site 1102), Olomouc, 779 00, Czechia|Regionshospitalet GÃ¸dstrup-KrÃ¦ftklinikken ( Site 1204), Herning, Midtjylland, 7400, Denmark|Aalborg Universitetshospital, Syd-Department of Oncology ( Site 1201), Aalborg, Nordjylland, 9000, Denmark|Odense Universitetshospital ( Site 1200), Odense C, Syddanmark, 5000, Denmark|HÃ´pital Saint Joseph-ONCOLOGY ( Site 1308), Marseille, Bouches-du-Rhone, 13008, France|Institut RÃ©gional du Cancer Montpellier-Medical Oncology ( Site 1309), Montpellier, Herault, 34298, France|Centre Hospitalier Universitaire de Limoges - HÃ´pital Dupuyt-UnitÃ© d'oncologie thoracique et cutanÃ© ( Site 1303), Limoges, Limousin, 87042, France|Centre d'Oncologie de Gentilly ( Site 1301), Nancy, Meurthe-et-Moselle, 54000, France|Centre Hospitalier de la CÃ´te Basque ( Site 1300), Bayonne, Pyrenees-Atlantiques, 64109, France|L HOPITAL NORD OUEST ( Site 1310), Gleize, Rhone, 69400, France|Clinique de l'Europe-Service de pneumologie ( Site 1304), Amiens, Somme, 80000, France|Centre Hospitalier Universitaire de Poitiers-PÃ´le rÃ©gional de cancÃ©rologie ( Site 1305), Poitiers, Vienne, 86021, France|Klinikum der Ludwig-Maximilians-Universitaet Muenchen-Medizinische Klinik V ( Site 1409), MÃ¼nchen, Bayern, 80336, Germany|Klinikum Bogenhausen-Klinik fÃ¼r Pneumologie und Onkologische Pneumologie ( Site 1406), MÃ¼nchen, Bayern, 81925, Germany|Klinikum NÃ¼rnberg Nord-5. Med. Klinik ( Site 1407), Nuremberg, Bayern, 90419, Germany|UniversitÃ¤tsklinikum Marburg-Comprehensive Cancer Center ( Site 1412), Marburg, Hessen, 35043, Germany|Medizinische Hochschule Hannover-Department of Pneumology ( Site 1411), Hannover, Niedersachsen, 30625, Germany|Bethanien Krankenhaus Moers ( Site 1400), Moers, Nordrhein-Westfalen, 47441, Germany|UniversitÃ¤tsklinikum MÃ¼nster - Albert Schweitzer Campus-Medizinische Klinik A ( Site 1410), MÃ¼nster, Nordrhein-Westfalen, 48149, Germany|UniversitÃ¤tsmedizin Johannes Gutenberg UniversitÃ¤t Mainz-3. Medizinische Klinik und Poliklinik ( Site 1404), Mainz, Rheinland-Pfalz, 55131, Germany|LungenClinic Grosshansdorf-Onkologie ( Site 1401), Grosshansdorf, Schleswig-Holstein, 22927, Germany|SRH Wald-Klinikum Gera-Zentrum fÃ¼r klinische Studien ( Site 1403), Gera, Thuringen, 07548, Germany|CharitÃ© Campus Virchow-Klinikum-Department of Infectious Diseases and Pulmonary Medicine ( Site 1402), Berlin, 13353, Germany|IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) ""Dino Amadori""-Oncologia Medica ( Site 1807), Meldola, Emilia-Romagna, 47014, Italy|P.O. ""S. Maria della Misericordia"" Azienda Sanitaria Univers-Oncology Department ( Site 1803), Udine, Friuli-Venezia Giulia, 33100, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1800), Milan, Lombardia, 20133, Italy|Instituto Tumori Giovanni Paolo II-SSD Oncologia Medica per la Patologia Toracica ( Site 1804), Bari, Puglia, 70124, Italy|AOU Renato Dulbecco ( Site 1801), Catanzaro, 88100, Italy|Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Medical Oncology ( Site 1806), Roma, 00168, Italy|Fujita Health University Hospital ( Site 3411), Toyoake, Aichi, 470-1192, Japan|National Hospital Organization Shikoku Cancer Center ( Site 3415), Matsuyama, Ehime, 791-0280, Japan|National Hospital Organization Kyushu Cancer Center ( Site 3417), Fukuoka,, Fukuoka, 811-1395, Japan|Kurume University Hospital ( Site 3418), Kurume, Fukuoka, 830-0011, Japan|Gunma Prefectural Cancer Center ( Site 3402), Ota, Gunma, 373-8550, Japan|National Hospital Organization Himeji Medical Center ( Site 3426), Himeji, Hyogo, 670-8520, Japan|Iwate Medical University Hospital ( Site 3428), Shiwa-gun, Iwate, 028-3695, Japan|St. Marianna University Hospital ( Site 3421), Kawasaki, Kanagawa, 216-8511, Japan|Yokohama Municipal Citizen's Hospital ( Site 3425), Yokohama, Kanagawa, 221-0855, Japan|Kanagawa Cancer Center ( Site 3408), Yokohama, Kanagawa, 241-8515, Japan|Matsusaka Municipal Hospital ( Site 3422), Matsusaka, Mie, 515-8544, Japan|Tohoku University Hospital ( Site 3424), Sendai, Miyagi, 980-8574, Japan|Sendai Kousei Hospital ( Site 3400), Sendai, Miyagi, 981-0914, Japan|Kansai Medical University Hospital ( Site 3412), Hirakata, Osaka, 573-1191, Japan|Osaka Medical and Pharmaceutical University Hospital ( Site 3413), Takatsuki, Osaka, 569-8686, Japan|National Hospital Organization Ureshino Medical Center ( Site 3427), Ureshino, Saga, 843-0393, Japan|Niigata Cancer Center Hospital ( Site 3409), Niigata, Saitama, 951-8566, Japan|Shizuoka Cancer Center ( Site 3410), Suntogun, Shizuoka, 411-8777, Japan|Dokkyo Medical University Hospital ( Site 3401), Shimotsugagun, Tochigi, 321-0293, Japan|Tokyo Metropolitan Komagome Hospital ( Site 3405), Bunkyo, Tokyo, 113-8677, Japan|Cancer Institute Hospital of JFCR ( Site 3404), Koto, Tokyo, 135-8550, Japan|Toho University Omori Medical Center ( Site 3420), Ota, Tokyo, 143-8541, Japan|Tokyo Medical University Hospital ( Site 3407), Shinjuku, Tokyo, 160-0023, Japan|National Center for Global Health and Medicine ( Site 3406), Shinjuku, Tokyo, 162-8655, Japan|National Hospital Organization Yamaguchi Ube Medical Center ( Site 3423), Ube, Yamaguchi, 755-0241, Japan|National Hospital Organization Kyushu Medical Center ( Site 3416), Fukuoka, 810-8563, Japan|Saiseikai Kumamoto Hospital ( Site 3419), Kumamoto, 861-4193, Japan|Osaka International Cancer Institute ( Site 3414), Osaka, 541-8567, Japan|Chungbuk National University Hospital-Internal medicine ( Site 3804), Cheongju-si, Chungbuk, 28644, Korea, Republic of|Wonju Severance Christian Hospital ( Site 3808), Wonju, Kang-won-do, 26426, Korea, Republic of|National Cancer Center ( Site 3801), Goyang-si, Kyonggi-do, 10408, Korea, Republic of|The Catholic University Of Korea St. Vincent's Hospital-Medical Oncology ( Site 3800), Suwon-si, Kyonggi-do, 16247, Korea, Republic of|Ajou University Hospital-Hematology-Oncology ( Site 3806), Suwon-si, Kyonggi-do, 16499, Korea, Republic of|Keimyung University Dongsan Hospital CRC room 1 ( Site 3807), Daegu, Taegu-Kwangyokshi, 42601, Korea, Republic of|Asan Medical Center-Lung Cancer Center ( Site 3805), Seoul, 05505, Korea, Republic of|Samsung Medical Center-Division of Hematology/Oncology ( Site 3802), Seoul, 06351, Korea, Republic of|Higiea Oncologia ( Site 0721), Mexico City, Distrito Federal, 11819, Mexico|CIO - Centro de Inmuno-OncologÃ­a de Occidente ( Site 0715), Guadalajara, Jalisco, 44630, Mexico|Axis Heilsa S. de R.L. de C.V. ( Site 0719), Monterrey, Nuevo Leon, 64060, Mexico|Centro de AtenciÃ³n e InvestigaciÃ³n Cardiovascular del PotosÃ­ ( Site 0713), San Luis PotosÃ­, San Luis Potosi, 78200, Mexico|Oaxaca Site Management Organization S.C. ( Site 0718), Oaxaca, 68000, Mexico|Clinica Integral Internacional de OncologÃ­a ( Site 0714), Puebla, 72530, Mexico|Amphia Ziekenhuis, locatie Breda Molengracht-long oncologie ( Site 1901), Breda, Noord-Brabant, 4818 CK, Netherlands|ETZ Elisabeth-Department of Pulmonary Diseases ( Site 1902), Tilburg, Noord-Brabant, 5022 GC, Netherlands|Isala, locatie Zwolle-Poli Longziekten ( Site 1903), Zwolle, Overijssel, 8025 AB, Netherlands|Clinica Vallesur - AUNA ( Site 0854), Arequipa, Ariqipa, 15036, Peru|Detecta ClÃ­nica ( Site 0853), Surquillo, Muni Metro De Lima, 15038, Peru|IPOR Instituto Peruano de OncologÃ­a & Radioterapia-Centro de InvestigaciÃ³n ( Site 0851), Lima, 15036, Peru|INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS ( Site 0850), Lima, 15038, Peru|Hospital Cayetano Heredia-Oncology ( Site 0855), Lima, Lima 31, Peru|Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 2003), Bydgoszcz, Kujawsko-pomorskie, 85-796, Poland|Regionalny Szpital Specjalistyczny im. dr. WÅadyslawa BiegaÅskiego ( Site 2013), Grudziadz, Kujawsko-pomorskie, 86-300, Poland|Wojewodzki Szpital Zespolony im Ludwika Rydygiera w Toruniu ( Site 2016), Torun, Kujawsko-pomorskie, 87-100, Poland|SPZOZ Uniwersytecki Szpital Kliniczny Im. Wojskowej Akademii Medycznej UM W Åodzi Centralny Szpital ( Site 2012), ÅÃ³dÅº, Lodzkie, 90-549, Poland|Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie-Oncology Department ( Site 2015), KrakÃ³w, Malopolskie, 31-826, Poland|Instytut GruÅºlicy i ChorÃ³b PÅuc w Warszawie-3rd Dep of Lung Diseases and Oncology ( Site 2011), Warszawa, Mazowieckie, 01-138, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier ( Site 2000), Warszawa, Mazowieckie, 02-781, Poland|Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 2001), Przemysl, Podkarpackie, 37-700, Poland|Instituto PortuguÃªs de Oncologia de Lisboa Francisco Gentil ( Site 2104), Lisbon, Lisboa, 1099-023, Portugal|Unidade Local de Saude de Santa Maria - Hospital Pulido Valente ( Site 2101), Lisbon, Lisboa, 1769-001, Portugal|Unidade Local de Saude Gaia/Espinho - Hospital Eduardo Santos Silva ( Site 2103), Vila Nova de Gaia, Porto, 4434-502, Portugal|Hospital Dr. NÃ©lio MendonÃ§a ( Site 2105), Funchal, Regiao Autonoma Da Madeira, 9004-514, Portugal|Hospital CUF - Tejo ( Site 2100), Lisboa, 1350-352, Portugal|Hospital Jerez de la Frontera-UGC OncologÃ­a ( Site 2333), Jerez de la Frontera, Cadiz, 11407, Spain|CHUAC-Hospital Teresa Herrera-MEDICAL ONCOLOGY ( Site 2335), A CoruÃ±a, La Coruna, 15006, Spain|HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID-ONCOLOGIA MEDICA ( Site 2331), Pozuelo de Alarcon, Madrid, 28223, Spain|H.R.U Malaga - Hospital General ( Site 2332), MÃ¡laga, Malaga, 29011, Spain|FundaciÃ³n Instituto Valenciano de OncologÃ­a-Oncologico ( Site 2336), Valencia, Valenciana, Comunitat, 46009, Spain|Hospital Universitari Vall d'Hebron-Oncology ( Site 2330), Barcelona, 08035, Spain|HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO-Medical Oncology ( Site 2337), Sevilla, 41013, Spain|Chang Gung Memorial Hospital at Kaohsiung ( Site 3902), Kaohsiung Niao Sung Dist, Kaohsiung, 83301, Taiwan|Chi Mei Hospital - Liouying Branch ( Site 3908), Tainan City, Tainan, 73657, Taiwan|National Taiwan University Cancer Center (NTUCC) ( Site 3907), Taipei City, Taipei, 106, Taiwan|National Taiwan University Hospital - Hsinchu branch ( Site 3901), Hsinchu, 300, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital ( Site 3904), Kaohsiung, 807, Taiwan|Taichung Veterans General Hospital-Chest ( Site 3905), Taichung, 40705, Taiwan|National Cheng Kung University Hospital-Clinical Trial Center ( Site 3903), Tainan, 704, Taiwan|National Taiwan University Hospital-Oncology ( Site 3906), Taipei, 10002, Taiwan|Chulalongkorn University-Medicine ( Site 4003), Bangkok, Krung Thep Maha Nakhon, 10330, Thailand|Faculty of Medicine Siriraj Hospital ( Site 4000), Bangkok, Krung Thep Maha Nakhon, 10700, Thailand|Maharaj Nakorn Chiang Mai Hospital-Chiang Mai Clinical Trial Unit (CM-CTU) ( Site 4001), Chiang Mai, 50200, Thailand|Medipol Mega Universite Hastanesi-oncology ( Site 2508), Stanbul, Istanbul, 34214, Turkey|Ege Universitesi Hastanesi-Chest Diseases Department ( Site 2503), Bornova, Izmir, 35100, Turkey|Erciyes University ( Site 2511), Talas, Kayseri, 38039, Turkey|Adana Medical Park Seyhan Hastanesi-Medikal Onkoloji ( Site 2507), Adana, 01140, Turkey|Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve ArastÄ±rma Hastanesi-oncology ( Site 2506), Ankara, 06200, Turkey|Hacettepe Universite Hastaneleri-oncology hospital ( Site 2501), Ankara, 06230, Turkey|Memorial Ankara Hastanesi-Medical Oncology ( Site 2505), Ankara, 06520, Turkey|Ankara Bilkent Åehir Hastanesi ( Site 2500), Ankara, 06800, Turkey|Pamukkale University Medical Faculty, Fahri Goksin Oncology Centre-Oncolgyy-Hematology ( Site 2510), Denizli, 20070, Turkey|TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 2502), Istanbul, 34722, Turkey|Ondokuz MayÄ±s Universitesi ( Site 2509), Samsun, 55139, Turkey|Royal Free Hospital ( Site 2601), London, England, NW3 2QG, United Kingdom|Queen Alexandra Hospital-Oncology Department ( Site 2603), Portsmouth, Hampshire, PO6 3LY, United Kingdom|Kent and Canterbury Hospital-Oncology Research ( Site 2606), Canterbury, Kent, CT1 3NG, United Kingdom|Guy's & St Thomas' NHS Foundation Trust-Oncology & Haematology Clinical Trials ( Site 2605), London, London, City Of, SE1 9RT, United Kingdom|James Cook University Hospital ( Site 2604), Central Middlesbrough, Middlesbrough, TS4 3BW, United Kingdom|K Hospital - National Cancer Hospital ( Site 4174), Hanoi, Ha Noi, 100000, Vietnam|National Lung Hospital-Oncology Department ( Site 4175), Hanoi, Ha Noi, 100000, Vietnam|Tam Anh General Hospital ( Site 4179), Hanoi, Ha Noi, 100000, Vietnam|Thong Nhat Hospital ( Site 4170), HCM, Ho Chi Minh, 700000, Vietnam|Cho Ray Hospital ( Site 4171), Ho Chi Minh, 700000, Vietnam|Ho Chi Minh City Oncology Hospital - Tan Phu Ward ( Site 4173), Ho Chi Minh, 700000, Vietnam",
NCT06422143,Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023],https://clinicaltrials.gov/study/NCT06422143,,RECRUITING,This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT; MK-2870) in first-line treatment of metastatic squamous non-small cell lung cancer. It is hypothesized that pembrolizumab with maintenance sacituzumab tirumotecan is superior to pembrolizumab without sacituzumab tirumotecan maintenance with respect to overall survival (OS).,NO,Non-small Cell Lung Cancer|NSCLC,BIOLOGICAL: Pembrolizumab|BIOLOGICAL: sac-TMT|DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Nab-paclitaxel,"Overall survival (OS), OS is the time from randomization to death due to any cause., Up to ~50 months","Progression-Free Survival (PFS), PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1)., Up to ~79 months|Number of Participants With â¥1 Adverse Event (AE), An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention., Up to ~79 months|Number of Participants Discontinuing from Study Therapy Due to AE(s), An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention., Up to ~79 months|Change in Score from Baseline to a Predefined Timepoint in Participant-Reported Global health status/Quality of Life (QoL) Score (EORTC QLQ-C30 Items 29 and 30), European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) is a 30-item scale to assess the overall quality of life in cancer patients. The global health status and QoL scores are based on participant responses to items 29 (""How would you rate your overall health during past week?"") and 30 (""How would you rate your overall quality of life during the week?"") that are scored on a 7-point scale (1 = ""Very poor"" to 7 = ""Excellent""). Higher scores indicate better overall health status., Baseline and up to ~79 months|Change in Score from Baseline to a Predefined Timepoint in Participant-Reported Dyspnea (EORTC QLQ-C30 Item 8), EORTC QLQ-C30 is a 30-item scale to assess the overall quality of life of cancer patients. The dyspnea score is based on participant responses to item 8 (""Were you short of breath?"") that is scored on a 4-point scale (1 = 'Not at All' to 4 = 'Very Much'). Higher scores indicate worse dyspnea symptoms., Baseline and up to ~79 months|Change in Score from Baseline to a Predefined Timepoint in Participant-Reported Cough (EORTC QLQ-LC13 Item 31), EORTC QLQ-C13 is a 13-item addendum to EORTC QLQ-C30 to assess the overall quality of life of lung cancer patients. The cough score is based on participant responses to item 31 (""How much did you cough?"") that is scored on a 4-point scale (1 = 'Not at All' to 4 = 'Very Much'). Higher scores indicate worse cough., Baseline and up to ~79 months|Change in Score from Baseline to a Predefined Timepoint in Participant-Reported Chest Pain (EORTC QLQ-LC13 Item 40), EORTC QLQ-C13 is a 13-item addendum to EORTC QLQ-C30 to assess the overall quality of life of lung cancer patients. The chest pain score is based on participant responses to item 40 e (1 = ""Not at All"" to 4 = ""Very Much"")., Baseline and up to ~79 months|Time to First Deterioration (TTD) in Global Health Status/QoL Scores (EORTC QLQ-C30 Items 29 and 30), EORTC QLQ-C30 is a 30-item scale to assess the overall quality of life in cancer patients. TTD in global health status and QoL scores are based on participant responses to items 29 (""How would you rate your overall health during past week?"") and 30 (""How would you rate your overall quality of life during the week?"") that are scored on a 7-point scale (1 = ""Very poor"" to 7 = ""Excellent""). Higher scores indicate better overall health status., Up to ~79 months|TTD in Dyspnea Score (EORTC QLQ-C30 Item 8), EORTC QLQ-C30 is a 30-item scale to assess the overall quality of life of cancer patients. TTD in dyspnea score is based on participant responses to item 8 (""Were you short of breath?"") that is scored on a 4-point scale (1 = 'Not at All' to 4 = 'Very Much'). Higher scores indicate worse dyspnea symptoms., Up to ~79 months|TTD in Cough Score (EORTC QLQ-LC13 Item 31), EORTC QLQ-C13 is a 13-item addendum to EORTC QLQ-C30 to assess the overall quality of life of lung cancer patients. TTD in cough score is based on participant responses to item 31 (""How much did you cough?"") that is scored on a 4-point scale (1 = 'Not at All' to 4 = 'Very Much'). Higher scores indicate worse cough., Up to ~79 months|TTD in Chest Pain Score (EORTC QLQ-LC13 Item 40), EORTC QLQ-C13 is a 13-item addendum to EORTC QLQ-C30 to assess the overall quality of life of lung cancer patients. TTD in chest pain score is based on participant responses to item 40 (""Have you had pain in your chest?"") that is scored on a 4-point scale (1 = 'Not at All' to 4 = 'Very Much'). Higher scores indicate worse chest pain., Up to ~79 months",,Merck Sharp & Dohme LLC,,ALL,"ADULT, OLDER_ADULT",PHASE3,851,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-06-10,2029-01-12,2031-02-12,2024-05-20,,2025-06-13,"Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0122), Burbank, California, 91505, United States|Exempla Lutheran Medical Center ( Site 0119), Golden, Colorado, 80401, United States|Intermountain Health St. Mary's Regional Hospital ( Site 0116), Grand Junction, Colorado, 81501, United States|Mid Florida Hematology and Oncology Center ( Site 0109), Orange City, Florida, 32763, United States|Centricity Research Columbus Cancer Center ( Site 0111), Columbus, Georgia, 31904, United States|Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0001), Marietta, Georgia, 30060, United States|University of Chicago Medical Center ( Site 0145), Chicago, Illinois, 60637, United States|Allina Health Cancer Institute - Abbott Northwestern Hospital ( Site 0146), Minneapolis, Minnesota, 55407, United States|New Mexico Oncology Hematology Consultants Ltd. ( Site 0123), Albuquerque, New Mexico, 87109, United States|Thomas Jefferson University - Clinical Research Institute ( Site 0147), Philadelphia, Pennsylvania, 19107, United States|Oncology Consultants P.A. ( Site 0124), Houston, Texas, 77030, United States|Mays Cancer Center ( Site 0132), San Antonio, Texas, 78229, United States|Instituto Alexander Fleming ( Site 0203), Ciudad AutÃ³noma de Buenos Aires, Buenos Aires, C1426ANZ, Argentina|Instituto de Investigaciones ClÃ­nicas Mar del Plata ( Site 0200), Mar del Plata, Buenos Aires, B7600FZO, Argentina|Instituto MÃ©dico RÃ­o Cuarto ( Site 0204), Rio Cuarto., Cordoba, X5800AEV, Argentina|Fundacion Intecnus ( Site 0205), San Carlos de Bariloche, Rio Negro, R8402APU, Argentina|Sanatorio Parque ( Site 0201), Rosario, Santa Fe, S2000DVC, Argentina|Hospital Aleman-Oncology ( Site 0202), Buenos Aires, C1118AAT, Argentina|Ordensklinikum Linz GmbH Elisabethinen-Department of Pneumology ( Site 0720), Linz, Oberosterreich, 4020, Austria|Klinik Hietzing ( Site 0740), Wien, 1130, Austria|Standort Penzing der Klinik Ottakring-Abteilung fÃ¼r Atemwegs-und Lungenkrankheiten ( Site 0730), Wien, 1140, Austria|Klinik Floridsdorf-Abteilung fÃ¼r Innere Medizin und Pneumologie ( Site 0710), Wien, 1210, Austria|Hospital de CÃ¢ncer de Recife ( Site 0312), Recife, Pernambuco, 50040-000, Brazil|OncoclÃ­nica Oncologistas Associados ( Site 0309), Terezina, Piaui, 64049-200, Brazil|Irmandade da Santa Casa de MisericÃ³rdia de Porto Alegre ( Site 0311), Porto Alegre, Rio Grande Do Sul, 90020-090, Brazil|Hospital Nossa Senhora da ConceiÃ§Ã£o ( Site 0300), Porto Alegre, Rio Grande Do Sul, 91350-200, Brazil|Instituto de Oncologia Saint Gallen ( Site 0304), Santa Cruz do Sul, Rio Grande Do Sul, 96830-180, Brazil|Hospital de Base de SÃ£o JosÃ© do Rio Preto ( Site 0310), SÃ£o JosÃ© do Rio Preto, Sao Paulo, 15090-000, Brazil|Hospital Paulistano ( Site 0307), Sao Paulo, 01321-001, Brazil|Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 0100), Kingston, Ontario, K7L 2V7, Canada|Grand River Hospital ( Site 0153), Kitchener, Ontario, N2G 1G3, Canada|St. Marys Hospital Center ( Site 0105), Montreal, Quebec, H3T 1M5, Canada|McGill University Health Centre ( Site 0103), MontrÃ©al, Quebec, H4A 3J1, Canada|Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-centre-du-quebec ( Site 0106), Trois-RiviÃ¨res, Quebec, G8Z 3R9, Canada|Centro de InvestigaciÃ³n del Maule ( Site 0419), Talca, Maule, 3481349, Chile|FALP ( Site 0409), Santiago, Region M. De Santiago, 7500921, Chile|Pontificia Universidad Catolica de Chile-Hemato-Oncology ( Site 0402), Santiago, Region M. De Santiago, 8330024, Chile|Bradfordhill-Clinical Area ( Site 0407), Santiago, Region M. De Santiago, 8420383, Chile|ONCOCENTRO APYS-ACEREY ( Site 0400), ViÃ±a del Mar, Valparaiso, 2520598, Chile|Bradford Hill Norte ( Site 0420), Antofagasta, 1240000, Chile|Beijing Cancer Hospital ( Site 2411), Beijing, Beijing, 100142, China|Beijing Cancer hospital-intrathoratic deparmtment II ( Site 2410), Beijing, Beijing, 100142, China|Peking Union Medical College Hospital ( Site 2412), Beijing, Beijing, 100730, China|Army Medical Center of People's Liberation Army-respiratory ( Site 2426), Chongqing, Chongqing, 400042, China|Fujian Provincial Cancer Hospital ( Site 2419), Fuzhou, Fujian, 350014, China|The First Affiliated hospital of Xiamen University-oncology ( Site 2420), Xiamen, Fujian, 361003, China|The First Affiliated Hospital of Guangzhou Medical University ( Site 2417), Guangzhou, Guangdong, 510160, China|Southern Medical University Nanfang Hospital-Depatrment of Respiratory and Critical Care Medicine ( Site 2416), Guangzhou, Guangdong, 510515, China|Harbin Medical University Cancer Hospital-oncology of department ( Site 2415), Harbin, Heilongjiang, 150000, China|Henan Cancer Hospital-Pneumology department ( Site 2423), Zhengzhou, Henan, 450008, China|Tongji Hospital Tongji Medical,Science & Technology ( Site 2424), Wuhan, Hubei, 430000, China|The Second Xiangya Hospital of Central South University-Oncology ( Site 2418), Changsha, Hunan, 410011, China|First Huai'an Hospital Affiliated to Nanjing Medical University ( Site 2402), Huai'an, Jiangsu, 223300, China|Northern Jiangsu People's Hospital-General Surgery Department ( Site 2403), Yangzhou, Jiangsu, 225001, China|The Second Affiliated Hospital of Nanchang University-Oncology Department ( Site 2405), Nanchang, Jiangxi, 330006, China|The First affiliated hospital of Nanchang University (Xianghu campus) ( Site 2404), Nanchang, Jiangxi, 330209, China|Jilin Province Tumor Hospital-GCP office ( Site 2413), Changchun, Jilin, 130000, China|The First Hospital of Jilin University-Oncology ( Site 2414), Changchun, Jilin, 130021, China|Shanghai East Hospital ( Site 2428), Shanghai, Shanghai, 200120, China|Shanghai Pulmonary Hospital ( Site 2427), Shanghai, Shanghai, 200433, China|West China Hospital, Sichuan University ( Site 2422), Cheng Du, Sichuan, 610041, China|Sichuan Cancer hospital. ( Site 2421), Chengdu, Sichuan, 610042, China|The Affiliated Cancer Hospital of Xinjiang Medical University ( Site 2425), Urumqi, Xinjiang, 830000, China|The first Affiliated Hospital, Zhejiang University School of Medicine-Respiratory Department ( Site 2406), Hangzhou, Zhejiang, 310000, China|Sir Run Run Shaw Hospital of Zhejiang University School of Medicine-Medical Oncology ( Site 2407), Hangzhou, Zhejiang, 310016, China|Zhejiang Cancer Hospital-Breast Oncology ( Site 2408), Hangzhou, Zhejiang, 310022, China|Taizhou Hospital of Zhejiang Province ( Site 2430), Taizhou, Zhejiang, 317000, China|The First Affiliated Hospital of Wenzhou Medical University-Respiratory department ( Site 2409), Wenzhou, Zhejiang, 325015, China|Centro CancerolÃ³gico del Caribe (CECAC) ( Site 0509), Barranquilla, Atlantico, 080001, Colombia|Sociedad De OncologÃ­a y HematologÃ­a Del Cesar SAS-Oncology ( Site 0501), Valledupar, Cesar, 200001, Colombia|FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 0500), Bogota, Distrito Capital De Bogota, 110131, Colombia|Oncologos del Occidente ( Site 0504), Pereira., Risaralda, 660001, Colombia|FundaciÃ³n Valle del Lili-Oncology CIC ( Site 0505), Cali, Valle Del Cauca, 760032, Colombia|Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 0800), Brno, Brno-mesto, 656 53, Czechia|Nemocnice AGEL Ostrava - Vitkovice a.s.-Plicni oddeleni ( Site 0803), Ostrava-Vitkovice, Ostrava Mesto, 703 00, Czechia|Clinique Clairval ( Site 0904), Marseille, Bouches-du-Rhone, 13009, France|HÃ´pital Robert Schuman ( Site 0907), Vantoux, Lorraine, 57070, France|Institut de CancÃ©rologie de l'Ouest ( Site 0908), ANGERS cedex 02, Maine-et-Loire, 49055, France|Sainte Catherine Institut du Cancer Avignon Provence ( Site 0902), Avignon, Vaucluse, 84000, France|CHD Vendee ( Site 0901), La Roche-sur-Yon, Vendee, 85000, France|HÃ´pital Saint-Louis ( Site 0906), Paris, 75475, France|GEFOS Gesellschaft f. onkologische Studien ( Site 1005), Dortmund, Nordrhein-Westfalen, 44309, Germany|SRH Wald-Klinikum Gera-Zentrum fÃ¼r klinische Studien ( Site 1006), Gera, Thuringen, 07548, Germany|CharitÃ© Campus Virchow-Klinikum-Department of Infectious Diseases and Pulmonary Medicine ( Site 1003), Berlin, 13353, Germany|Bacs-Kiskun Varmegyei Oktatokorhaz ( Site 1100), KecskemÃ©t, Bacs-Kiskun, 6000, Hungary|Petz Aladar Egyetemi Oktato Korhaz ( Site 1101), Gyor, Gyor-Moson-Sopron, 9024, Hungary|JÃ¡sz-Nagykun-Szolnok VÃ¡rmegyei HetÃ©nyi GÃ©za KÃ³rhÃ¡z-Onkologiai Kozpont ( Site 1103), Szolnok, Jasz-Nagykun-Szolnok, 5004, Hungary|Reformatus Pulmonologiai Centrum ( Site 1102), Torokbalint, Pest, 2045, Hungary|Zala Megyei Szent Rafael KÃ³rhÃ¡z ( Site 1110), Zalaegerszeg, Zala, 8900, Hungary|OrszÃ¡gos KorÃ¡nyi PulmonolÃ³giai IntÃ©zet ( Site 1104), Budapest, 1121, Hungary|St. James's Hospital ( Site 1200), Dublin, D08 A978, Ireland|Rambam Health Care Campus-Oncology Division ( Site 1302), Haifa, 3109601, Israel|Shaare Zedek Medical Center ( Site 1300), Jerusalem, 9103102, Israel|Rabin Medical Center ( Site 1303), Petah Tikva, 4941492, Israel|Sheba Medical Center ( Site 1301), Ramat Gan, 5265601, Israel|Istituto Nazionale Tumori IRCCS Fondazione Pascale-Oncologia clinica sperimentale Toraco-Polmonare ( Site 1401), Napoli, Campania, 80131, Italy|Azienda Ospedaliera S. Giovanni Addolorata-Oncologia Medica ( Site 1409), Roma, Lazio, 00184, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1404), Milan, Lombardia, 20133, Italy|Fondazione IRCCS San Gerardo dei Tintori-Oncologia ( Site 1412), Monza, Lombardia, 20900, Italy|Istituto Clinico Humanitas-U.O di Oncologia medica ed Ematologia ( Site 1408), Rozzano, Milano, 20089, Italy|Istituto Nazionale Tumori Regina Elena-Oncologia Medica 2 ( Site 1402), Rome, Roma, 00144, Italy|Azienda Ospedaliera Spedali Civili di Brescia-Oncology ( Site 1414), Brescia, 25123, Italy|Ospedale San Martino ( Site 1407), Genova, 16132, Italy|Fondazione IRCCS Policlinico San Matteo-Oncology ( Site 1410), Pavia, 27100, Italy|Ospedale di Circolo e Fondazione Macchi Varese-Oncology ( Site 1413), Varese, 21100, Italy|Aichi Cancer Center ( Site 2502), Nagoya, Aichi, 464-8681, Japan|Nagoya University Hospital ( Site 2519), Nagoya, Aichi, 466-8560, Japan|Fujita Health University Hospital ( Site 2515), Toyoake, Aichi, 470-1192, Japan|Hirosaki University Hospital ( Site 2514), Hirosaki, Aomori, 036-8563, Japan|Ehime University Hospital ( Site 2511), Toon, Ehime, 791-0295, Japan|Gunma Prefectural Cancer Center ( Site 2510), Ota, Gunma, 373-8550, Japan|Takarazuka City Hospital ( Site 2508), Takarazuka, Hyogo, 665-0827, Japan|Kanazawa University Hospital ( Site 2513), Kanazawa, Ishikawa, 920-8641, Japan|St. Marianna University Hospital ( Site 2521), Kawasaki, Kanagawa, 216-8511, Japan|Kanagawa Cardiovascular and Respiratory Center ( Site 2518), Yokohama, Kanagawa, 236-0051, Japan|Kanagawa Cancer Center ( Site 2504), Yokohama, Kanagawa, 241-8515, Japan|Matsusaka Municipal Hospital ( Site 2522), Matsusaka, Mie, 515-8544, Japan|Sendai Kousei Hospital ( Site 2507), Sendai, Miyagi, 981-0914, Japan|Kansai Medical University Hospital ( Site 2503), Hirakata, Osaka, 573-1191, Japan|Saitama Prefectural Cancer Center ( Site 2512), Kitaadachi-gun, Saitama, 362-0806, Japan|Cancer Institute Hospital of JFCR ( Site 2500), Koto, Tokyo, 135-8550, Japan|Toho University Omori Medical Center ( Site 2520), Ota, Tokyo, 143-8541, Japan|National Center for Global Health and Medicine ( Site 2516), Shinjuku, Tokyo, 162-8655, Japan|Chiba University Hospital ( Site 2517), Chiba, 260-8677, Japan|National Hospital Organization Kyushu Medical Center ( Site 2509), Fukuoka, 810-8563, Japan|Niigata Cancer Center Hospital ( Site 2505), Niigata, 951-8566, Japan|Osaka International Cancer Institute ( Site 2506), Osaka, 541-8567, Japan|The Catholic University of Korea, Incheon St. Mary's Hospital ( Site 2106), Bupyeong-gu, Incheon, 21431, Korea, Republic of|Pusan National University Yangsan Hospital ( Site 2104), Yangsan-si, Kyongsangnam-do, 50612, Korea, Republic of|Pusan National University Hospital ( Site 2100), Busan, Pusan-Kwangyokshi, 49241, Korea, Republic of|Kyungpook National University Chilgok Hospital-Pulmonology ( Site 2102), Deagu, Taegu-Kwangyokshi, 41404, Korea, Republic of|Chungnam national university hospital-Department of Internal Medicine ( Site 2107), Daejeon, Taejon-Kwangyokshi, 35015, Korea, Republic of|Kyung Hee University Hospital ( Site 2101), Seoul, 02447, Korea, Republic of|Asan Medical Center ( Site 2105), Seoul, 05505, Korea, Republic of|Korea University Guro Hospital-Internal Medicine ( Site 2103), Seoul, 08308, Korea, Republic of|ClÃ­nicas AUNA Sede Chiclayo ( Site 0604), Chiclayo, Lambayeque, 14001, Peru|Oncosalud-Clinical Research ( Site 0600), Lima, 15036, Peru|Hospital Militar Central Coronel Luis Arias Schereiber ( Site 0602), Lima, 15076, Peru|Wielkopolskie Centrum Pulmonologii i Torakochirurgii-Oddzial Onkologii Klinicznej z Pododdzialem Dz ( Site 1510), PoznaÅ, Dolnoslaskie, 60-569, Poland|Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 1503), Bydgoszcz, Kujawsko-pomorskie, 85-796, Poland|Regionalny Szpital Specjalistyczny im. dr. WÅadyslawa BiegaÅskiego ( Site 1513), Grudziadz, Kujawsko-pomorskie, 86-300, Poland|Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie-Oncology Department ( Site 1515), KrakÃ³w, Malopolskie, 31-826, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier ( Site 1500), Warszawa, Mazowieckie, 02-781, Poland|Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 1501), Przemysl, Podkarpackie, 37-700, Poland|Szpital WojewÃ³dzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 1517), Koszalin, Zachodniopomorskie, 75-581, Poland|Centrul Medical Medicover Victoria ( Site 2000), Bucharest, Bucuresti, 010626, Romania|Cardiomed SRL Cluj-Napoca ( Site 2002), Cluj-Napoca, Cluj, 400015, Romania|SC Radiotherapy Center Cluj SRL-Oncologie Medicala ( Site 2001), FloreÈti, Cluj, 407280, Romania|Centrul de Oncologie Sfantul Nectarie-Medical ( Site 2004), Craiova, Dolj, 200542, Romania|Cabinet Medical Oncomed ( Site 2005), Timisoara, Timis, 300239, Romania|SC ONCO CARD SRL ( Site 2007), Brasov, 500052, Romania|Clinica Polisano ( Site 2008), Sibiu, 550253, Romania|CHUS - Hospital Clinico Universitario-Servicio de Oncologia ( Site 1703), Santiago de Compostela, Galicia, 15706, Spain|Hospital Insular de Gran Canaria-Oncology ( Site 1701), Las Palmas de Gran Canaria, Las Palmas, 35016, Spain|Hospital QuirÃ³n MÃ¡laga ( Site 1704), MÃ¡laga, Malaga, 29004, Spain|Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 1700), Barcelona, 08035, Spain|Hospital Universitario FundaciÃ³n JimÃ©nez DÃ­az-Oncology & Hematology ( Site 1702), Madrid, 28040, Spain|Hospital Universitario Virgen de Valme-Departamento de Oncologia ( Site 1705), Sevilla, 41014, Spain|Chang Gung Memorial Hospital at Kaohsiung ( Site 2207), Kaohsiung Niao Sung Dist, Kaohsiung, 83301, Taiwan|National Taiwan University Cancer Center (NTUCC) ( Site 2209), Taipei City, Taipei, 106, Taiwan|Taoyuan General Hospital ( Site 2203), Taoyuan City, Taoyuan, 33004, Taiwan|Taichung Veterans General Hospital ( Site 2204), Taichung, 407, Taiwan|National Cheng Kung University Hospital ( Site 2205), Tainan, 704, Taiwan|National Taiwan University Hospital-Oncology ( Site 2208), Taipei, 10002, Taiwan|Mackay Memorial Hospital-Chest Medicine ( Site 2201), Taipei, 10449, Taiwan|Chang Gung Medical Foundation-Linkou Branch-Clinic of Chest Medicine ( Site 2202), Taoyuan, 333, Taiwan|Prapokklao Hospital ( Site 2306), Mueang, Chanthaburi, 22000, Thailand|Faculty of Medicine - Khon Kaen University ( Site 2305), Muang, Khon Kaen, 40002, Thailand|Faculty of Medicine Siriraj Hospital ( Site 2301), Bangkok, Krung Thep Maha Nakhon, 10700, Thailand|Bangkok Metropolitan Administration Medical College and Vajira Hospital ( Site 2300), Dusit, Krung Thep Maha Nakhon, 10300, Thailand|Lampang Cancer Hospital ( Site 2304), Mueang Lampang, Lampang, 52000, Thailand|Songklanagarind hospital ( Site 2303), HatYai, Songkhla, 90110, Thailand|Maharaj Nakorn Chiang Mai Hospital ( Site 2302), Chiang Mai, 50200, Thailand|Medipol Mega Universite Hastanesi-oncology ( Site 1811), Stanbul, Istanbul, 34214, Turkey|Hacettepe Universite Hastaneleri-oncology hospital ( Site 1801), Ankara, 06230, Turkey|Gazi University Health Research and Application Center Gazi Hospital-Oncology ( Site 1804), Ankara, 06560, Turkey|Ankara Bilkent Åehir Hastanesi-Medical Oncology ( Site 1800), Ankara, 06800, Turkey|Memorial Kayseri Hastanesi ( Site 1805), Kayseri, 38010, Turkey|Mersin Sehir EÄitim ve AraÅtÄ±rma Hastanesi-Oncology ( Site 1808), Mersin, 33240, Turkey|Samsun Medical Park Hastanesi-medical oncology ( Site 1806), Samsun, 55200, Turkey|Burjeel Medical City ( Site 2600), Abu Dhabi, Abu Zaby, 92510, United Arab Emirates|St Bartholomew's Hospital ( Site 1901), London, London, City Of, EC1A 7BE, United Kingdom|City Hospital, Nottingham University Hospitals NHS Trust-NCCTT ( Site 1911), Nottingham, Nottinghamshire, NG5 1PB, United Kingdom",
NCT06571461,Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer,https://clinicaltrials.gov/study/NCT06571461,,NOT_YET_RECRUITING,"This study will evaluate the efficacy and safety of adjuvant therapy with liposomal irinotecan in combination with oxaliplatin, and S-1 compared with capecitabine combined with capecitabine in participants with pancreatic ductal adenocarcinoma after radical surgery.",NO,Pancreatic Cancer,DRUG: Liposomal Irinotecan|DRUG: Oxaliplatin|DRUG: S-1|DRUG: Gemcitabine|DRUG: Capecitabine,"Disease-free survival (DFS), Disease-free survival is defined as the time from the date of randomization to the date of disease recurrence or death from any cause (whichever occurs first). Disease recurrence is defined as evidence of disease recurrence demonstrated by imaging assessment with CT or MRI scan and/or pathological diagnosis indicated by biopsy., Approximately 3 years.","Overall survival (OS), Approximately 5 years.",,"CSPC Ouyi Pharmaceutical Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,408,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-09,2028-01,2029-03,2024-08-26,,2024-08-27,,
NCT06095583,Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC),https://clinicaltrials.gov/study/NCT06095583,,RECRUITING,"The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination with tifcemalimab as consolidation therapy in patients with limited-stage small cell lung cancer without disease progression following chemoradiotherapy.

Tifcemalimab is a monoclonal antibody against B and T lymphocyte attenuator (BTLA). Toripalimab is a monoclonal antibody against programmed death protein-1 (PD-1). Neither drug is approved for treatment of This combination regimen is investigational in limited stage-small cell lung cancer in any country.",NO,Limited-stage Small Cell Lung Cancer (LS-SCLC),DRUG: Tifcemalimab injection|DRUG: toripalimab injection|DRUG: Placebo for Tifcemalimab|DRUG: Placebo for toripalimab,"Overall survival (OS), To compare and evaluate the efficacy of tifcemalimab and toripalimab (Arm A) versus placebo (Arm C) as consolidation therapy after chemoradiotherapy (CRT) for patients with LS-SCLC as measured by OS, up to 3years|OS, To compare and evaluate the efficacy of toripalimab (Arm B) versus placebo (Arm C) as consolidation therapy after CRT for patients with LS-SCLC as measured by OS"", up to 3years|Progression-free survival (PFS), To compare and evaluate the efficacy of tifcemalimab and toripalimab (Arm A) versus placebo (Arm C) as consolidation therapy after CRT for patients with LS-SCLC as measured by Blinded Independent Review Committee (BIRC)-assessed PFS., up to 2years|Progression-free survival (PFS), To compare and evaluate the efficacy of toripalimab (Arm B) versus placebo (Arm C) as consolidation therapy after CRT for patients with LS-SCLC as measured by OS and BIRC-assessed PFS., up to 2years","PFS, To compare and evaluate the efficacy of tifcemalimab and toripalimab (Arm A) versus placebo (Arm C) as consolidation therapy after CRT for patients with LS-SCLC as measured by Investigator-assessed PFS, up to 2years|1-year OS rate, To compare and evaluate the efficacy of tifcemalimab and toripalimab (Arm A) versus placebo (Arm C) as consolidation therapy after CRT for patients with LS-SCLC as measured by 1-year OS rate, up to 1year|2-year OS rate, To compare and evaluate the efficacy of tifcemalimab and toripalimab (Arm A) versus placebo (Arm C) as consolidation therapy after CRT for patients with LS-SCLC as measured by 2-year OS rate, up to 2 years|objective response rate (ORR), To compare and evaluate the efficacy of tifcemalimab and toripalimab (Arm A) versus placebo (Arm C) as consolidation therapy after CRT for patients with LS-SCLC as measured by ORR, up to 2 years|disease control rate (DCR), To compare and evaluate the efficacy of tifcemalimab and toripalimab (Arm A) versus placebo (Arm C) as consolidation therapy after CRT for patients with LS-SCLC as measured by DCR, up to 2 years|duration of response (DoR), To compare and evaluate the efficacy of tifcemalimab and toripalimab (Arm A) versus placebo (Arm C) as consolidation therapy after CRT for patients with LS-SCLC as measured by DoR, up to 2years|PFS, To compare and evaluate the efficacy of toripalimab (Arm B) versus placebo (Arm C) as consolidation therapy after CRT for patients with LS-SCLS as measured by Investigator-assessed PFS, up to 2 years|1 year OS rate, To compare and evaluate the efficacy of toripalimab (Arm B) versus placebo (Arm C) as consolidation therapy after CRT for patients with LS-SCLS as measured by 1-year OS rate, up to 1 years|2 year OS rate, To compare and evaluate the efficacy of toripalimab (Arm B) versus placebo (Arm C) as consolidation therapy after CRT for patients with LS-SCLS as measured by 2-year OS rate, up to 2 years|ORR, To compare and evaluate the efficacy of toripalimab (Arm B) versus placebo (Arm C) as consolidation therapy after CRT for patients with LS-SCLS as measured by ORR, up to 2 years|DCR, To compare and evaluate the efficacy of toripalimab (Arm B) versus placebo (Arm C) as consolidation therapy after CRT for patients with LS-SCLS as measured by DCR, up to 2 years|DoR, To compare and evaluate the efficacy of toripalimab (Arm B) versus placebo (Arm C) as consolidation therapy after CRT for patients with LS-SCLS as measured by DoR, up to 2 years|safety, To compare and evaluate the safety of tifcemalimab and toripalimab (Arm A) versus placebo (Arm C) as consolidation therapy after CRT for patients with LS-SCLC as measured by the incidence of adverse events (Percentage of participants with treatment-related adverse events as assessed by CTCAEv5.0.) and abnormal laboratory parameters., up to 2 years|safety, To compare and evaluate the safety of toripalimab (Arm B) versus placebo (Arm C) as consolidation therapy after CRT for patients with LS-SCLC as measured by the incidence of adverse events (Percentage of participants with treatment-related adverse events as assessed by CTCAEv5.0.) and abnormal laboratory parameters., up to 2 years",,"Shanghai Junshi Bioscience Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,756,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-11-15,2027-07-31,2029-07-31,2023-10-23,,2024-06-21,"Banner MD Anderson Cancer Center, Goodyear, Arizona, 85338, United States|Banner University Medical Center, Tucson, Arizona, 85713, United States|Genesis Cancer and Blood Institute (Hot Springs, AR), Hot Springs, Arkansas, 05001, United States|SCRI Nashville, Davis, California, 95616, United States|Zangmeister Cancer Center (Columbus, OH), Los Angeles, California, 43219, United States|Los Angeles Hematology Oncology, Los Angeles, California, 90033, United States|University of Southern California Norris Comprehensive Cancer, Los Angeles, California, 90033, United States|Florida Cancer Specialists Pan Handle, Fort Myers, Florida, 32310, United States|Florida Cancer Specialists South, Fort Myers, Florida, 33908, United States|USA029 University of Miami Sylvester Comprehensive Cancer Center 1550 NW 10th Avenue 33173 Miami FL Ikpeazu Chukwuemeka N, Miami, Florida, 33173, United States|Mid-Florida Hematology Oncology, Orange City, Florida, 55905, United States|Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital, Marietta, Georgia, 30060, United States|Norton Cancer Institute, Downtown, Multidisciplinary Clinic, Louisville, Kentucky, 40241, United States|American Oncology Partners of Maryland, PA, Bethesda, Maryland, 20817, United States|Dana Farber Cancer Institute-Hematology/Oncology, Boston, Massachusetts, 461099, United States|Karmanos Cancer Center, Detroit, Michigan, 48201, United States|Henry Ford Health System, Detroit, Michigan, 48202, United States|Cancer and Hematology Centers of Western Michigan, Grand Rapids, Michigan, 49502, United States|Washington University School of Medicine - Siteman Cancer Center, Saint Louis, Missouri, 63101, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, 03756, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, 07101, United States|North Shore Hematology Oncology Associates DBA NY Cancer and Blood Specialists, New York, New York, 11776, United States|University of Stony Brook, Stony Brook, New York, 11794, United States|Toledo Clinic Cancer Center - Toledo, Toledo, Ohio, 97391, United States|Oncology Associates Of Oregon, P.C., Eugene, Oregon, 97401, United States|Oregon Health and Science University, Portland, Oregon, 97239, United States|Millennium Physicians - Oncology, Houston, Texas, 77090, United States|Texas Oncology, P.A. - Oncology, Tyler, Texas, 97402, United States|Virginia Cancer Specialists, Fairfax, Virginia, 22030, United States|Algemeen Ziekenhuis Klina, Antwerpen, Belgium|Grand HÃ´pital de Charleroi - Site Notre-Dame, Charleroi, Belgium|AZ Groeningen, Kortrijk, Belgium|Jessa Ziekenhuis - Campus Virga Jesse, Limbourg, Belgium|CHU UCL Namur - Site Sainte-Elisabeth, Namur, Belgium|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China|Xiangya Hospital Central South University, Changsha, Hunan, China|The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China|The First Hospital of China Medical University, Shenyang, Liaoning, China|Shandong Cancer Hospital & Institute, Jinan, Shandong, China|Anyang Tumor Hospital, Anyang, China|Beijing Cancer Hospital, Beijing, China|Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China|Jilin Cancer Hospital, Changchun, China|Hunan Cancer Hospital, Changsha, China|Sichuan cancer hospital, Chengdu, China|Chongqing University Cancer Hospital, Chongqing, China|Peking University Shenzhen Hospital, Guangdong, China|Sun Yat-sen University Cancer Center, Guangzhou, China|No. 1 Bandong Road, Gongshu District, Hangzhou, Hangzhou, China|The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China|The First Affiliated Hospital of Ustc, Hefei, China|Henan Cancer Hospital, Henan, China|Affiliated Hospital of Jining Medical University, Jining, China|The First Affiliated Hospital of Nanchang University, Nanchang, China|The Second Affiliated Hospital of Nanchang University, Nanchang, China|The Affiliated Hospital of Qingdao University, Qingdao, China|Fudan University Shanghai Cancer Center, Shanghai, China|Liaoning cancer hospital, Shenyang, China|Shanxi Cancer hospital, Taiyuan, China|Taizhou Hospital of Zhejiang Province, Taizhou, China|Tianjin Medical University Cancer Institute & Hospital, Tianjin, China|Hubei Cancer Hospital (Hubei Cancer Research Institute), Wuhan, China|Zhongnan Hospital of Wuhan University, Wuhan, China|The First Affiliated Hospital of Xiamen University, Xiamen, China|General Hospital of Ningxia Medical University, Yinchuan, China|Centre Hospitalier Universitaire D Angers, Angers, France|Institut Bergonie, Bordeaux, France|Centre Hospitalier Intercommunal De CrÃ©teil, CrÃ©teil, France|CHU de Grenoble, Grenoble, France|Centre Leon Berard - departement d'oncologie medicale, Lyon, France|Centre de CancÃ©rologie du Grand Montpellier, Montpellier, France|Hopital Arnaud De Villeneuve - Oncologie/Pneumologie, Montpellier, France|Hopital Haut-Leveque - Maladies respiratoires, Pessac, France|Chu HÃ´pitaux De Rouen, Rouen, France|Institut de CancÃ©rologie de l'Ouest (ICO), Saint-Herblain, France|Chru De Tours, Tours Cedex 9, France|Institut Gustave Roussy, Villejuif, France|""TIM - Tbilisi Institute of Medicine"" LTD, Tbilisi, Georgia|ICO-Institute of Clinical Oncology - Hospital, Tbilisi, Georgia|ISR-GEO Med Res Clin Healthycore, Tbilisi, Georgia|LTD ""Israel-Georgian Medical Research Clinic Healthycore"", Tbilisi, Georgia|LTD ""New Hospitals"", Tbilisi, Georgia|Ltd New Hospitals, Tbilisi, Georgia|Multprofil Clinic Consilium Medulla, Tbilisi, Georgia|Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic, Tbilisi, Georgia|Evangelische Lungenklinik Berlin, Berlin, Germany|Klinikum Esslingen GmbH Klinik fÃ¼r Kardiologie, Angiolgie und Pneumolgoie, Esslingen, Germany|UniveristÃ¤tsklinikum Giessen und Marburg GmbH, GieÃen, Germany|Klinikum Kassel GmbH Klinik fÃ¼r Onkologie uind HÃ¤matologie- Onkologisches Studiensekretariat, Kassel, Germany|Gemeinschaftspraxis fuer Haematologie und Onkologie, MÃ¼nster, Germany|UniversitÃ¤tsklinikum Regensburg, Regensburg, Germany|PO G. Rodolico, AOU Policlinico-Vittorio Emanuele Catania, Catania, Italy|Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori IRCCS, Cesena, Italy|Azienda Ospedaliero Universitaria Careggi, Firenze, Italy|Azienda Ospedaliero-Universitaria di Modena, Policlinico di Mod, Modena, Italy|Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli, Napoli, Italy|Iov, Irccs, Padova, Italy|IRCCS Policlinico San Matteo, UniversitÃ  degli studi di Pavia, Pavia, Italy|AO S. Camillo-Forlanini, Roma, Italy|Regina Elena, Istituto Nazionale dei Tumori, IFO, IRCCS Feasibility survey: PO di Livorno, AUSL Toscana Nord Ovest, SST, Roma, Italy|Chungbuk National University Hospital, Cheonju, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Rijnstate Ziekenhuis, Arnhem, Netherlands|Jeroen Bosch Ziekenhuis, Herzogenbusch, Netherlands|Erasmus Medisch Centrum, Rotterdam, Netherlands|Isala Klinieken Zwolle, Zwolle, Netherlands|Uniwersytecki Szpital Kliniczny w Bialymstoku, BiaÅystok, Poland|SPZOZ MSWiA z Warminsko-Mazurskim Centrum Onkologii, Olsztyn, Poland|Wielkopolskie Centrum Pulmonologii i Torakochirurgii im. E. i J. Zeylandow, PoznaÅ, Poland|Instytut Gruzlicy i Chorob Pluc, Warszawa, Poland|Institutul Oncologic ""Prof. Dr. Ion Chiricuta"" Cluj-Napoca, Cluj-Napoca, Romania|Medisprof, Cluj-Napoca, Romania|Centrul de Oncologie Sf. Nectarie, Craiova, Romania|Oncolab, Craiova, Romania|Radiotherapy Center Cluj, FloreÅti, Romania|Oncomed, TimiÅoara, Romania|Hospital Universitari Dexeus Grupo Quironsalud, Barcelona, Spain|C.H. Provincial de CastellÃ³n, CastellÃ³n De La Plana, Spain|Centro OncolÃ³gico de Galicia, CoruÃ±a, Spain|Complexo Hospitalario Universitario A CoruÃ±a, CoruÃ±a, Spain|Complejo Hospitalario de JaÃ©n, JaÃ©n, Spain|Fundacion Jimenez Diaz, Madrid, Spain|Hospital ClÃ­nico San Carlos, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Complejo Hospitalario Universitario de Orense, Orense, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Hospital Universitario Donostia, San SebastiÃ¡n, Spain|Hospital Universitario Virgen De La Macarena, Sevilla, Spain|Hospital Arnau De Vilanova De Valencia, Valencia, Spain|Hospital Universitario Y PolitÃ©cnico La Fe, Valencia, Spain|H.C.U.Lozano Blesa, Zaragoza, Spain|Taipei Veterans General Hospital, Taipei city, Taipei, Taiwan|No.123,DAPI Rd. Niaosong Dist, Kaohsiung City 83301 Taiwan, R.O.C., Kaohsiung, Taiwan|China Medical University Hospital - Internal Medicine - Taichung, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan City, Taiwan|Chi Mei Hospital, Liouying - Department of Oncology, Tainan, Taiwan|National Taiwan University Hospital - Internal Medicine, Taipei, Taiwan|Taipei Medical University - Shuang Ho Hospital, Taipei, Taiwan|Taipei Medical University - Taipei Medical University Hospital, Taipei, Taiwan|Taipei Medical University - WanFang Hospital - Hematology and Oncology, Taipei, Taiwan|Chang Gung Medical Foundation - LinKou Chang Gung Memorial Hospital, Taoyuan, Taiwan|Ankara City Hospital, Ankara, Turkey|Ankara Liv Hospital, Ankara, Turkey|Gulhane Training and Research Hospital - Medical Oncology, Ankara, Turkey|Memorial Ankara Hospital, Ankara, Turkey|Trakya University Medical Faculty, Edirne, Turkey|BakirkÃ¶y Dr. Sadi Konuk EÄitim ve AraÅtirma Hastanesi - Oncology, Istanbul, Turkey|Istanbul Goztepe Prof. Dr. Suleyman Yalcin City Hospital - Medical Oncology, Istanbul, Turkey|Ege University Medical Faculty - Pulmonary, Ä°zmir, Turkey|Ä°zmir Ekonomi Ãniversitesi Medical Point Ä°zmir Hastanesi, Ä°zmir, Turkey|Katip Celebi University Ataturk Research and Training Hospit, Ä°zmir, Turkey|Kocaeli University Research and Practice Hospital, Kocaeli, Turkey|Necmettin Erbakan University Meram, Konya, Turkey|Inonu University Turgut Ozal Medical Center, Malatya, Turkey",
NCT06111235,A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT,https://clinicaltrials.gov/study/NCT06111235,,RECRUITING,"This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followed by surveillance for the treatment of participants with IR-NMIBC.",NO,Non Muscle Invasive Bladder Cancer|Urologic Cancer|Bladder Cancer|Urothelial Carcinoma,DRUG: Cretostimogene Grenadenorepvec|OTHER: n-dodecyl-B-D-maltoside,"Recurrence Free Survival (RFS), Recurrence free survival (RFS) of cretostimogene after TURBT versus surveillance after TURBT, 51 months","Recurrence Free Survival (RFS) at 12 months and 24 months, Recurrence free survival (RFS) of cretostimogene after TURBT versus surveillance after TURBT at 12 months and 24 months, 51 months (RFS at 12 months) and 63 months (RFS at 24 months)|Incidence of Adverse Events, Safety of cretostimogene following TURBT, 52 months",,"CG Oncology, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE3,364,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-12-14,2028-01,2030-01,2023-11-01,,2025-05-29,"Urology Centers of Alabama PC, Homewood, Alabama, 35209, United States|Banner MD Anderson Cancer Center, Gilbert, Arizona, 85234, United States|Mayo Clinic, Scottsdale, Arizona, 85259, United States|Arizona Institute of Urology PLLC, Tucson, Arizona, 85745, United States|Arkansas Urology PA, Little Rock, Arkansas, 72211, United States|Michael G. Oefelein MD Clinical Trials, Bakersfield, California, 93301-2284, United States|USC/Keck Department of Urology, Los Angeles, California, 90033, United States|Tower Urology, Los Angeles, California, 90048, United States|Sun Kim Urology, Orange, California, 92868, United States|University of California Irvine Medical Center (UCIMC), Orange, California, 92868, United States|University of California Davis Cancer Center, Sacramento, California, 95817, United States|Stanford University School of Medicine, Stanford, California, 94305, United States|Colorado Clinical Research, Aurora, Colorado, 80012, United States|Urology Associates, PC, Lone Tree, Colorado, 80124, United States|Hartford HealthCare Medical Group, Hartford, Connecticut, 06106, United States|MedStar Washington Hospital Center, Washington, District of Columbia, 20010, United States|Advanced Urology Institute, Daytona Beach, Florida, 32114, United States|Mayo Clinic Cancer Center, Jacksonville, Florida, 32224, United States|Lakeland Regional Health, Lakeland, Florida, 33805, United States|Advanced Urology Institute, LLC, Largo, Florida, 33771, United States|University of Miami, Miami, Florida, 33136, United States|Emory Winship Cancer Center, Atlanta, Georgia, 30322, United States|Velocity Clinical Research- Savanah Urological Associates, Savannah, Georgia, 31405, United States|Rush University Medical Center, Chicago, Illinois, 60612, United States|University of Chicago, Chicago, Illinois, 60637, United States|UroPartners LLC, Glenview, Illinois, 60026, United States|Duly Health and Care, Lisle, Illinois, 601152, United States|Urology of Indiana, LLC, Carmel, Indiana, 46032, United States|Urology of Indiana, Greenwood, Indiana, 46143, United States|Urology Center of Iowa Research, West Des Moines, Iowa, 50266, United States|Wichita Urology Group, Wichita, Kansas, 67226, United States|First Urology, PSC, Louisville, Kentucky, 47130, United States|Southern Urology, Lafayette, Louisiana, 70508, United States|Regional Urology, LLC, Shreveport, Louisiana, 71106, United States|Chesapeake Urology Associates, LLC, Baltimore, Maryland, 21204, United States|Johns Hopkins Hospital Green Spring Station, Baltimore, Maryland, 21287, United States|Brigham and Women's Hospital, Boston, Massachusetts, 02215, United States|Cancer Center at Beth Israel Deaconess Medical Center - Research, Boston, Massachusetts, 02215, United States|Henry Ford Hospital, Detroit, Michigan, 48202, United States|Comprehensive Urology, Roseville, Michigan, 48066, United States|Michigan Institute of Urology, PC, Troy, Michigan, 48084, United States|Mayo Clinic, Rochester, Minnesota, 55905, United States|The Urology Group, Southaven, Mississippi, 38671, United States|SSM Health Saint Louis University Hospital, Saint Louis, Missouri, 63104, United States|Objective Health - Specialty Clinical Research of St. Louis, Saint Louis, Missouri, 63141, United States|Urology Nevada, Reno, Nevada, 89511, United States|Garden State Urology, LLC- Morristown Medical Center, Morristown, New Jersey, 07962, United States|Rutgers Cancer Institute of New Jersey - Cancer Center, New Brunswick, New Jersey, 08901, United States|Montefiore Medical Center, Bronx, New York, 10461, United States|Integrated Medical Professionals PLLC, New York, New York, 10016, United States|NYU Langone Health, New York, New York, 10016, United States|Icahn School of Medicine at Mount Sinai, New York, New York, 10029, United States|University of Rochester Medical Center, Rochester, New York, 14642, United States|Stony Brook University, Stony Brook, New York, 11794, United States|Associated Medical Professionals of NY, Syracuse, New York, 13202, United States|SUNY Upstate Medical University, Syracuse, New York, 13210, United States|Duke Cancer Center, Durham, North Carolina, 27710, United States|Urology Group, Cincinnati, Ohio, 45212, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, 43210, United States|University of Toledo, Toledo, Ohio, 43614, United States|Oregon Urology Insititute, Springfield, Oregon, 97477, United States|Midlantic Urology, Bala-Cynwyd, Pennsylvania, 19004, United States|Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, 17033, United States|Keystone Urology Specialists, Lancaster, Pennsylvania, 17604, United States|University of Pennsylvania - Perelman School of Medicine, Philadelphia, Pennsylvania, 19104, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, 19107, United States|The Miriam Hospital, Providence, Rhode Island, 02905, United States|Medical University of South Carolina, Charleston, South Carolina, 29425, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, 29572, United States|Lowcountry Urology Clinics, North Charleston, South Carolina, 29406, United States|The Conrad Pearson Clinic, Germantown, Tennessee, 38138, United States|Urology Associates, P.C., Nashville, Tennessee, 37209, United States|Vanderbilt University Medical Center, Nashville, Tennessee, 37232, United States|Amarillo Urology Research, LLC, Amarillo, Texas, 79106, United States|Urology Associates of North Texas, Arlington, Texas, 76017, United States|Urology Austin, PLLC, Austin, Texas, 78745, United States|Houston Methodist Research Institute, Houston, Texas, 77030, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|Michael E. DeBakey VA Medical Center, Houston, Texas, 77030, United States|Houston Metro Urology, Houston, Texas, 77074, United States|Urology San Antonio PA, San Antonio, Texas, 78229, United States|UT Health San Antonio, San Antonio, Texas, 78229, United States|University of Utah- Huntsman Cancer Institute, Salt Lake City, Utah, 84112, United States|Urology of Virginia (UVA) - Virginia Beach (Devine-Tidewater Urology), Virginia Beach, Virginia, 23462, United States|Benaroya Research Institute at Virginia Mason, Seattle, Washington, 98101, United States|University of Washington Medical Center, Seattle, Washington, 98195, United States|Spokane Urology- Southside, Spokane, Washington, 99202, United States|Charleston Area Medical Center, Charleston, West Virginia, 25304, United States|University of Wisconsin Medical Foundation, Madison, Wisconsin, 53705, United States|Vancouver Prostate Centre, Vancouver, British Columbia, V5Z 1M9, Canada|Nova Scotia Health Centre of Applied Urology Research, Halifax, Nova Scotia, B3H 2Y9, Canada|London Health Sciences Centre, London, Ontario, N6A 5W9, Canada|University Health Network (UHN) - Princess Margaret Cancer Centre, Toronto, Ontario, M5G 1Z5, Canada|McGill University Health Center - Montreal General Hospital, MontrÃ©al, Quebec, H4A 3J1, Canada",
NCT05232916,Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects,https://clinicaltrials.gov/study/NCT05232916,FLAMINGO-01,RECRUITING,"This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have completed both neoadjuvant and postoperative adjuvant standard of care therapy. Treatment consists of 6 intradermal injections, Primary Immunization Series (PIS), over the first 6 months of treatment and 5 booster intradermal injections spaced 6 months apart. A third open-label arm will explore GLSI-100 immunotherapy in non-HLA-A\*02 positive and HER2/neu positive subjects.",NO,Breast Cancer,BIOLOGICAL: Placebo|BIOLOGICAL: GLSI-100,"Invasive Breast Cancer-free Survival (IBCFS), IBCFS is defined as the time from the first dose of study medication until the date of ipsilateral invasive breast cancer recurrence, ipsilateral local-regional invasive breast cancer recurrence, distant recurrence, contralateral invasive breast cancer, or any cause mortality., Median 4 years of follow-up (interim analysis planned)","Invasive Disease-free Survival (IDFS), IDFS is defined as the time from the first dose of study medication until the date of ipsilateral invasive breast cancer recurrence, ipsilateral local-regional invasive breast cancer recurrence, distant recurrence, contralateral invasive breast cancer, second primary non-breast invasive cancer, or any cause mortality., Median 4 years of follow-up (interim analysis planned)|Distant Disease-free Survival (DDFS), DDFS will be defined as the time from the first dose of study medication to the time of distant disease recurrence or death., Median 4 years of follow-up (interim analysis planned)|Overall Survival, Overall survival will be defined as the time from the first dose of study medication until death from any cause., Median 4 years of follow-up (interim analysis planned)|Quality of Life Questionnaire Core 30 (QLQ-C30), European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30), Baseline and 36 months|Quality of Life FACT-GP5, FACT-GP5 to assess global side effect impact, Baseline and 36 months","Immune Response Measurements, Immune response will be measured by Delayed-Type Hypersensitivity (DTH) tests and immunologic assays., Screening, Baseline, Month 4, Month 6, Month 12, Month 13, Month 18, Month 24, Month 25, Month 30, Month 36, Month 37, Month 42, Month 48","Greenwich LifeSciences, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE3,750,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-08-11,2026-12,2026-12,2022-02-10,,2025-06-04,"Arizona Oncology Associates - Tucson, Tucson, Arizona, 85745, United States|Providence St. Jude Medical Center - Virginia K. Crosson Cancer Center, Fullerton, California, 92835, United States|University of California San Diego - Moores Cancer Center, La Jolla, California, 92093, United States|University of Southern California - Norris Comprehensive Cancer Center, Los Angeles, California, 90033, United States|Stanford Medicine Cancer Center - Stanford Women's Cancer Center, Palo Alto, California, 74304, United States|University of California San Francisco - Helen Diller Family Comprehensive Cancer Center, San Francisco, California, 94158, United States|University of California Los Angeles - Hematology / Oncology Parkside, Santa Monica, California, 90404, United States|PIH Health Hospital - Whittier Hospital, Whittier, California, 90602, United States|Rocky Mountain Cancer Centers, Denver, Colorado, 80220, United States|Yale Cancer Center - Smilow Cancer Hospital, New Haven, Connecticut, 06511, United States|Johns Hopkins Medicine - Kimmel Cancer Center-Sibley Memorial Hospital, Washington, District of Columbia, 20016, United States|University of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida, 33146, United States|Moffitt Cancer Center, Tampa, Florida, 33612, United States|Northwestern University - Northwestern Memorial Hospital, Chicago, Illinois, 60611, United States|Maryland Oncology Hematology, Annapolis, Maryland, 21401, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, 02114, United States|Minnesota Oncology - Maple Grove Clinic, Maple Grove, Minnesota, 55369, United States|Siteman Cancer Center - Washington University Medical Campus, Saint Louis, Missouri, 63110, United States|Nebraska Cancer Specialists, Omaha, Nebraska, 68114, United States|Nebraska Medicine - University of Nebraska Medical Center, Omaha, Nebraska, 68198, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, 89052, United States|Cooper University Health Care, Camden, New Jersey, 08103, United States|New York Oncology Hematology, Albany, New York, 12065, United States|Columbia University Medical Center, New York, New York, 10032, United States|Stony Brook University Cancer Center, Stony Brook, New York, 11794, United States|Oncology Hematology Care, Cincinnati, Ohio, 45211, United States|Compass Oncology - Northwest Cancer Specialists, Tigard, Oregon, 97223, United States|Redeemer Health - Holy Redeemer Hospital, Meadowbrook, Pennsylvania, 19046, United States|Sidney Kimmel Comprehensive Cancer Center - Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, 19107, United States|Texas Oncology - Austin, Austin, Texas, 78745, United States|Texas Oncology - Dallas Presbyterian Hospital, Dallas, Texas, 75231, United States|Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, 75246, United States|The University of Texas Southwestern Medical Center, Dallas, Texas, 75390, United States|Baylor College of Medicine - Dan L. Duncan Comprehensive Cancer Center, Houston, Texas, 77057, United States|The University of Texas Health Sciences Center at San Antonio - Mays Cancer Center, San Antonio, Texas, 78229, United States|Texas Oncology - San Antonio, San Antonio, Texas, 78240, United States|Texas Oncology - Gulf Coast, Sugar Land, Texas, 77479, United States|Texas Oncology - Tyler, Tyler, Texas, 75702, United States|University of Utah - Huntsman Cancer Institute, Salt Lake City, Utah, 84112, United States|Virginia Cancer Specialists, Fairfax, Virginia, 22031, United States|Sainte-Catherine - Institut du Cancer Avignon-Provence (ICAP), Avignon, France|Centre Hospitalier Simone Veil de Beauvais, Beauvais, France|Clinique Pasteur-Lanroze, Brest, France|Centre FranÃ§ois Baclesse (CLCC), Caen, France|Centre LÃ©on BÃ©rard, Lyon, France|Centre Antoine Lacassagne, Nice, France|Centre Hospitalier PrivÃ© Sainte-Marie Osny, Osny, France|Institut Curie, Paris, France|HÃ´pital NOVO (Nord-Ouest Val-d'Oise), Pontoise, France|Centre Hospitalier Intercommunal de Cornouaille Quimper Concarneau (CHIC), Quimper, France|Institut Godinot (CLCC), Reims, France|Institut Curie, Saint-Cloud, France|Centre Hospitalier PrivÃ© Saint-GrÃ©goire, Saint-GrÃ©goire, France|Centre Hospitalier Universitaire de Saint-Ãtienne, Saint-Ãtienne, France|Institut de cancÃ©rologie Strasbourg Europe, Strasbourg, France|HÃ´pital privÃ© DrÃ´me ArdÃ¨che, Valence, France|HÃ´pital Robert Schuman, Vantoux, France|Institut Gustave Roussy, Villejuif, France|HÃ¤matololgisch Onkologische Praxis Heinrich Bangerter Augsburg, Augsburg, Germany|Klinikum Bayreuth GmbH, Bayreuth, Germany|DBZ Onkologie GmbH, Berlin, Germany|HELIOS Klinikum Berlin-Buch, Berlin, Germany|Marienhospital Bottrop gGmbH, Bottrop, Germany|Evangelisches Diakonie-Krankenhaus Bremen, Bremen, Germany|Klinikum Chemnitz gGmbH, Chemnitz, Germany|StÃ¤dtisches Klinikum Dessau, Dessau, Germany|St.-Johannes Hospital Dortmund, Dortmund, Germany|UniversitÃ¤tsklinikum Carl Gustav Carus, Dresden, Germany|Zentrum fÃ¼r GynÃ¤kologische Onkologie DÃ¼sseldorf, DÃ¼sseldorf, Germany|Studienzentrale fÃ¼r das MVZ Eggenfelden e.K., Eggenfelden, Germany|Kliniken Essen-Mitte, Essen, Germany|Klinikum Frankfurt HÃ¶chst GmbH, Frankfurt, Germany|Praxis fÃ¼r InterdisziplinÃ¤re Onkologie & HÃ¤matologie, Freiburg, Germany|Helios Klinikum Gifhorn GmbH - Brustzentrum, Gifhorn, Germany|UniversitÃ¤tsmedizin GÃ¶ttingen, GÃ¶ttingen, Germany|Krankenhaus St. Elisabeth und St. Barbara Halle (Saale) GmbH, Halle, Germany|GynÃ¤kologische Praxisklinik Hamburg-Harburg, Hamburg-Harburg, Germany|Mammazentrum Hamburg, Hamburg, Germany|UniversitÃ¤tsklinikum Heidelberg, Heidelberg, Germany|Elisabeth Krankenhaus Kassel, Kassel, Germany|MVZ GynKrefeld GmbH am Helios Klinikum Krefeld, Krefeld, Germany|Gemeinschaftspraxis fÃ¼r HÃ¤matologie und Onkologie Langen, Langen, Germany|Studienzentrum UnterEms Leer, Leer, Germany|RKH Klinikum Ludwigsburg, Ludwigsburg, Germany|UniversitÃ¤tsmedizin Mainz, Mainz, Germany|UniversitÃ¤tsfrauenklinik Mannheim, Mannheim, Germany|MÃ¼nchen Klinik gGmbH, Munich, Germany|TUM MÃ¼nchen, Munich, Germany|Klinikum SÃ¼dstadt, UniversitÃ¤tsfrauenklinik, Rostock, Germany|GPR Klinikum RÃ¼sselsheim, RÃ¼sselsheim, Germany|Diakonissen-Stiftungs-Krankenhaus Speyer, Speyer, Germany|Klinikum Mutterhaus der BorromÃ¤erinnen gGmbH, Trier, Germany|UniversitÃ¤tsklinikum Ulm AÃ¶R, Ulm, Germany|Marienhospital Witten, Witten, Germany|Klinikum Worms - Frauenklinik, Worms, Germany|Helios UniversitÃ¤tsklinikum Wuppertal, Wuppertal, Germany|Azienda Ospedaliero Universitaria di Bologna Policlinico di Sant'Orsola IRCCS (Istituto Di Ricerca E Di Cura A Carattere Scientifico), Bologna, Italy|Ospedale Policlinico San Martino IRCCS (Istituto Di Ricerca E Di Cura A Carattere Scientifico), Genova, Italy|Humanitas Research Hospital, Milan, Italy|Azienda Ospedaliera Universitaria Federico II Di Napoli, Naples, Italy|Istituto Nazionale Tumori Fondazione Pascale IRCCS (Istituto Di Ricerca E Di Cura A Carattere Scientifico), Naples, Italy|Azienda Ospedaliero Universitaria Maggiore della CaritÃ  di Novara, Novara, Italy|Istituto Oncologico Veneto, Padova, Italy|Istituti Clinici Scientifici Maugeri Spa SocietÃ  Benefit IRCCS (Istituto Di Ricerca E Di Cura A Carattere Scientifico), Pavia, Italy|Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Istituto Di Ricerca E Di Cura A Carattere Scientifico), Rome, Italy|Przychodnia Lekarska KOMED Roman Karaszewski, Konin, Poland|Samodzielny Publiczny ZakÅad Opieki Zdrowotnej (ZOZ) Szpital Uniwersytecki w Krakowie, KrakÃ³w, Poland|Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie, KrakÃ³w, Poland|Samodzielny Publiczny ZakÅad Opieki Zdrowotnej (SPOZOZ) Opolskie Centrum Onkologii im. prof. Tadeusza Koszarowskiego w Opolu, Opole, Poland|Uniwersytecki Szpital Kliniczny w Poznaniu, PoznaÅ, Poland|Centrum Medyczne MrukMed, RzeszÃ³w, Poland|Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka w SÅupsku, SÅupsk, Poland|Narodowy Instytut Onkologii im. Marii SkÅodowskiej-Curie, Warsaw, Poland|Wojskowy Instytut Medyczny, PaÅstwowy Instytut Badawczy, Warsaw, Poland|Complejo Hospitalario Universitario de Albacete, Albacete, Spain|Hospital General Universitario Dr. Balmis, Alicante, Spain|Hospital Universitario de Badajoz, Badajoz, Spain|Hospital ClÃ­nic De Barcelona, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital San Pedro de AlcÃ¡ntara, CÃ¡ceres, Spain|Hospital Universitario Reina SofÃ­a, CÃ³rdoba, Spain|Hospital ClÃ­nico Universitario Virgen de la Arrixaca, El Palmar, Spain|Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain|Hospital Galdakao-Usansolo, Galdakao, Spain|Hospital Universitario ClÃ­nico San Cecilio, Granada, Spain|Hospital Universitario de JaÃ©n, JaÃ©n, Spain|Hospital Universitario de Jerez de la Frontera, Jerez De La Frontera, Spain|Hospital Universitario de Canarias, La Laguna, Spain|Hospital Universitari Arnau de Vilanova (Lleida), Lleida, Spain|Hospital General Universitario Gregorio MaraÃ±Ã³n, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario FundaciÃ³n JimÃ©nez DÃ­az, Madrid, Spain|Hospital Universitario HM Sanchinarro, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain|Althaia, Xarxa Assistencial UniversitÃ ria de Manresa, Manresa, Spain|Hospital General Universitario Morales Meseguer, Murcia, Spain|Hospital ClÃ­nico Universitario Virgen de la Victoria, MÃ¡laga, Spain|Hospital Regional Universitario de Malaga, MÃ¡laga, Spain|Hospital Universitari Son Espases, Palma De Mallorca, Spain|Hospital Universitario San Juan de Alicante, San Juan De Alicante, Spain|Hospital Universitario Donostia, San SebastiÃ¡n, Spain|Hospital Universitari General de Catalunya - Grupo QuirÃ³nsalud, Sant Cugat Del VallÃ¨s, Spain|Hospital Universitario Nuestra SeÃ±ora de Candelaria, Santa Cruz De Tenerife, Spain|Hospital ClÃ­nico Universitario de Santiago, Santiago de Compostela, Spain|Hospital Universitario Virgen del RocÃ­o, Sevilla, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Universitario de Toledo, Toledo, Spain|Consorcio Hospital General Universitario de Valencia, Valencia, Spain|FundaciÃ³n Instituto Valenciano de OncologÃ­a, Valencia, Spain|Hospital ClÃ­nico Universitario de Valencia, Valencia, Spain|Hospital Universitari Arnau de Vilanova (Valencia), Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain",
NCT05862337,Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.,https://clinicaltrials.gov/study/NCT05862337,,RECRUITING,The primary objective of this study was to evaluate the efficacy of anlotinib hydrochloride capsules combined with penpulimab injection (test group) versus placebo (control group) for adjuvant therapy after radical surgery or ablation in HCC patients with high risk of recurrence by assessing recurrence-free survival (RFS).,NO,Hepatocellular Carcinoma,"DRUG: Anlotinib hydrochloride capsules, Penpulimab injection|DRUG: Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo","Recurrence-free survival (RFS), RFS assessed by the Blinded Independent Image Review Committee and the investigator is the time from randomization to the first local, regional recurrence or distant metastasis, or death from any cause, whichever occurred first., Baseline up to 3 years.","Time to recurrence(TTR), TTR assessed by the Blinded Independent Image Review Committee and the investigator is the time from randomization to the first local, regional recurrence or distant metastasis, whichever occurred first., Baseline up to 3 years.|Time to extrahepatic metastasis or macrovascular invasion, Time to extrahepatic metastasis or macrovascular invasion as assessed by the investigator., Baseline up to 3 years.|Overall survival (OS), OS defined as the time from the date of randomization until the date of death due to any cause., Baseline up to 3 years.|Objective response rate (ORR) after first recurrence, subjects with evaluable tumor lesion status who were cross-treated with Anlotinib hydrochloride capsules combined with Penpulimab injection developed complete response or partial response after a first HCC relapse as assessed by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1., Baseline up to 3 years.",,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,480,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-05-10,2024-08,2026-12,2023-05-17,,2023-05-17,"The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, 233000, China|Anhui Provincial Hospital, Hefei, Anhui, 230000, China|The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230000, China|Peking Union Medical College Hospital, Beijing, Beijing, 100005, China|Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, 100020, China|Peking University People's Hospital, Beijing, Beijing, 100044, China|Beijing Friendship hospital of Capital Medical University, Beijing, Beijing, 100050, China|Beijing YouAn Hospital,Capital Medical University, Beijing, Beijing, 100069, China|Chongqing University Cancer Hospital, Chongqing, Chongqing, 400030, China|Chongqing University Three Gorges Hospital, Chongqing, Chongqing, 404199, China|Mengchao Hepatobiliary Hospital of Fujian Medical, Fuzhou, Fujian, 350001, China|Fujian Cancer Hospital, Fuzhou, Fujian, 350011, China|Gansu Provincial Cancer Hospital, Lanzhou, Gansu, 730000, China|Lanzhou University First Hospital, Lanzhou, Gansu, 730000, China|Lanzhou University Second Hospital, Lanzhou, Gansu, 730030, China|Gansu Provincial Hospital, Lanzhou, Gansu, 730700, China|Guangdong People's Hospital, Guangzhou, Guangdong, 510000, China|Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, 510280, China|The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, 510630, China|Guangxi Medical University Affiliated Tumor Hospital, Nanning, Guangxi, 530000, China|Guizhou Provincial People'S Hospital, Guiyang, Guizhou, 550002, China|The Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou, 550008, China|Affiliated Hospital Of Zunyi Medical University, Zunyi, Guizhou, 563000, China|Hainan Provincial People's Hospital, Haikou, Hainan, 570311, China|The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan, 570311, China|Affiliated Cancer Hospital of Harbin Medical University, Harbin, Heilongjiang, 150081, China|The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, 471000, China|The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450000, China|Henan Cancer Hospital, Zhengzhou, Henan, 450003, China|Hunan Cancer Hospital, Changsha, Hunan, 410000, China|Hunan Provincial People's Hospital, Changsha, Hunan, 410000, China|The Third Xiang Ya Hospital of Central South University, Changsha, Hunan, 410000, China|Xiangya Hospital of Central South University, Changsha, Hunan, 410000, China|Chifeng Municipal Hospital, Chifeng, Inner Mongolia, 240000, China|The First People's Hospital of Changzhou, Changzhou, Jiangsu, 213000, China|Jiangsu Province People's Hospital, Nanjing, Jiangsu, 210000, China|Affiliated Hospital of Nantong University, Nantong, Jiangsu, 226006, China|Nantong Tumor Hospital, Nantong, Jiangsu, 226361, China|Ganzhou People's Hospital, Ganzhou, Jiangxi, 341099, China|The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330000, China|Jilin Cancer Hospital, Changchun, Jilin, 130012, China|The Second Hospital of Dalian Medical University, Dalian, Liaoning, 116027, China|The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, 121012, China|Shengjing Hospital of China Medical University, Shenyang, Liaoning, 110000, China|The Sixth People's Hospital of Shen Yang, Shenyang, Liaoning, 110000, China|Liaoning Cancer Hospital, Shenyang, Liaoning, 110801, China|Binzhou Medical University Hospital, BinZhou, Shandong, 256699, China|Shandong Cancer Hospital, Jinan, Shandong, 250117, China|The First Affiliated Hospital of Naval Medical University, Shanghai, Shanghai, 200433, China|Third Affiliated Hospital of Naval Medical University, Shanghai, Shanghai, 200433, China|Baoji Central Hospital, Baoji, Shanxi, 721000, China|Heping Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi, 46000, China|The Second Affiliated Hospital of Air Force Medical University, Xi'an, Shanxi, 710038, China|First Affiliated Hospital of Xian Jiaotong University, Xi'an, Shanxi, 710061, China|Xi'an International Medical Center Hospital, Xi'an, Shanxi, 710117, China|West China Hospital of Sichuan University, Chengdu, Sichuan, 610000, China|Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, China|Affiliated Hospital Of North Sichuan Medical College, Nanchong, Sichuan, 637000, China|Tianjin Third Central Hospital, Tianjin, Tianjin, 300000, China|Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, 300181, China|Tianjin Cancer Hospital Airport Hospital, Tianjin, Tianjin, 300308, China|The First Affiliated Hospital of Xinjiang Medical University, ÃrÃ¼mqi, Xinjiang, 830000, China|Sir Run Run Shaw Hospital Zhetiang University School of Medicine, Hangzhou, Zhejiang, 310000, China|Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang, 315000, China|Shaoxing People's Hospital, Shaoxing, Zhejiang, 312000, China|Taizhou Hospital of Zhejiang Province, Taizhou, Zhejiang, 317000, China|The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China",
NCT06746116,A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain,https://clinicaltrials.gov/study/NCT06746116,DUoENDE,RECRUITING,"This is a phase IIIb, interventional, single arm, multicentre study assessing the safety profile of durvalumab in combination with carboplatin-paclitaxel chemotherapy followed by durvalumab with olaparib as first-line treatment for patients with pMMR aEC as the primary endpoint.

The study will include approximately 85 patients distributed in approximately 20 sites in Spain.

The planned duration of patient recruitment is approximately 12 months. Each patient will be followed up from screening for 36 months, until end of study period, death, withdrawal from study or loss to follow-up; whichever occurs first.

Enrolment will be opened to all eligible patients treated with durvalumab in combination with carboplatin-paclitaxel chemotherapy followed by durvalumab with olaparib as first-line treatment for patients with pMMR aEC. In addition, adequate tumour tissue before study entry, stool and blood sample collected will be required for central analysis to monitor the status of relevant biomarkers.",NO,Advanced or Recurrent Endometrial Cancer,DRUG: Durvalumab + Chemotherapy phase|DRUG: Durvalumab + Olaparib phase,"Number of patients with Adverse Events, Safety and tolerability will be evaluated in terms of Adverse Events (AEs), Serious AEs (SAEs), and immune-mediated AEs (imAEs), Time from enrollment up to at least 90 days after last dose of study treatment","Progression Free Survival (PFS), Defined as the time from the date of first dose of treatment until the date of objective disease progression or death (by any cause in the absence of progression). The measure of interest is the median PFS., From date of enrollment through to disease progression, death, withdrawn from study, or end of study (approximately 48 months)|Objective Response Rate (ORR), Defined as the percentage of patients with a confirmed investigator-assessed response of CR or PR and will be based on a subset of all included patients with measurable disease at baseline per the site investigator., From date of enrollment through to disease progression, death, withdrawn from study, or end of study (approximately 48 months)|Duration of Response (DoR), Defined as the time from the date of first documented response (which is subsequently confirmed) until date of documented progression or death in the absence of disease progression., From date of enrollment through to disease progression, death, withdrawn from study, or end of study (approximately 48 months)|Overall Survival (OS), Defined as the time from the date of first dose of treatment2 until death from any cause., From date of enrollment through to disease progression, death, withdrawn from study, or end of study (approximately 48 months)|Change in EORTC QLQ-C30 score, Change from baseline (enrollment) in EORTC QLQ-C30 score every 12 weeks until end of treatment or disease progression., From date of enrollment through to disease progression, death, withdrawn from study, or end of study (approximately 48 months)|Change in EORTC QLQ-EN24 score, Change from baseline (enrollment) in EORTC QLQ-EN24 score every 12 weeks until end of treatment or disease progression., From date of enrollment through to disease progression, death, withdrawn from study, or end of study (approximately 48 months)|Clinically meaningful deterioration, Percentage of patients having absolute change in EORTC-QLQ-C30 and EORTC-QLQ-EN24 score from baseline of â¥10 at 6, 12, 24 and 36 months after LSI., From date of enrollment through to disease progression, death, withdrawn from study, or end of study (approximately 48 months)",,AstraZeneca,Apices Soluciones S.L.,FEMALE,"ADULT, OLDER_ADULT",PHASE3,85,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-12-30,2028-11-30,2028-11-30,2024-12-24,,2025-06-06,"Research Site, Alicante, 03010, Spain|Research Site, Barakaldo, 48903, Spain|Research Site, Barcelona, 08035, Spain|Research Site, Cordoba, 14004, Spain|Research Site, El Palmar, 30120, Spain|Research Site, Girona, 17007, Spain|Research Site, L'Hospitalet de Llobregat, 08908, Spain|Research Site, La CoruÃ±a, 15006, Spain|Research Site, Las Palmas de Gran Canaria, 35016, Spain|Research Site, Madrid, 28034, Spain|Research Site, Madrid, 28041, Spain|Research Site, Madrid, 28046, Spain|Research Site, Madrid, 28807, Spain|Research Site, MÃ¡laga, 29010, Spain|Research Site, Pamplona, 31008, Spain|Research Site, Salamanca, 37007, Spain|Research Site, San SebastiÃ¡n, 20014, Spain|Research Site, Santander, 39008, Spain|Research Site, Sevilla, 41013, Spain|Research Site, Valencia, 46009, Spain|Research Site, Valencia, 46010, Spain|Research Site, Valencia, 46026, Spain|Research Site, Vigo, 36312, Spain|Research Site, Zaragoza, 50009, Spain",
NCT06624059,A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT06624059,HORIZON 2,RECRUITING,"The objective of this study is to evaluate the efficacy and/or safety of multiple therapies in patients with early-stage resectable NSCLC. Cohort B1 is a phase II cohort that will evaluate the safety, and efficacy of alectinib in combination with up to four cycles of platinum-based chemotherapy in the adjuvant setting post complete surgical resection. Cohort B2 is a phase II cohort that will evaluate the efficacy and safety of perioperative alectinib in combination with chemotherapy in the neoadjuvant setting.",NO,Non-Small Cell Lung Cancer,DRUG: Alectinib|DRUG: Cisplatin|DRUG: Carboplatin|DRUG: Pemetrexed,"Cohort B1: Incidence, type, and severity of adverse events (AEs) with onset up to 28 days after the last dose of chemotherapy, Up to 28 days after the last dose of chemotherapy treatment (up to 4 cycles, cycle length = 3 weeks)|Cohort B2: Investigator-assessed pathologic complete response (inv-pCR), At the time of surgical resection (approximately weeks 14-17)","Cohort B1: Investigator-assessed disease-free survival (DFS), From initiation of study treatment to the first documented recurrence of disease or new primary NSCLC or death from any cause, whichever occurs first (up to approximately 5 years)|Cohort B1: Overall survival (OS), From initiation of study treatment to death from any cause (up to approximately 8 years)|Cohort B1: Incidence, type, and severity of AEs with onset up to 28 days after the last dose of study treatment, From first dose to up to approximately 5 years|Cohort B1: Time to first onset of selected AEs, From first dose to up to approximately 5 years|Cohort B1: Change from baseline in target safety parameters, From first dose to up to approximately 5 years|Cohort B2: Investigator-assessed major pathological response (inv-MPR), At the time of surgical resection (approximately weeks 14-17)|Cohort B2: Pathologic complete response (pCR) by independent review, At the time of surgical resection (approximately weeks 14-17)|Cohort B2: Major pathologic response (MPR) by independent review, At the time of surgical resection (approximately weeks 14-17)|Cohort B2: Investigator-assessed overall response rate (ORR), Up to approximately Week 17|Cohort B2: Investigator-assessed event-free survival (EFS), From first treatment to the first documented disease progression that prevents surgery, local or distant disease recurrence, or death from any cause (up to approximately 5 years)|Cohort B2: Overall Survival (OS), From initiation of study treatment to death from any cause (up to approximately 8 years)|Cohort B2: Incidence, severity, and type of AEs, From first dose up to approximately 5 years|Cohort B2: Change from baseline in target safety parameters, From first dose to up to approximately 5 years|Cohort B2: Frequency of surgery completion, defined as participants who have successfully completed surgery without treatment-related delays (> 60 days) from the last dose of neoadjuvant treatment, At the time of surgical resection (approximately weeks 14-17)|Cohort B2: Length of treatment-related surgical delays, incidence of operative and post-operative complications, and/or reasons for surgical cancellations, Approximately weeks 14-24",,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE3,150,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-11-18,2028-06-13,2033-03-31,2024-10-02,,2025-05-25,"Clinical Research Alliance, Westbury, New York, 11590, United States|Royal North Shore Hospital, St. Leonards, New South Wales, 2065, Australia|Calvary Mater Newcastle, Waratah, New South Wales, 2298, Australia|Peter Maccallum Cancer Centre, Melbourne, Victoria, 3000, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, 6009, Australia|Hospital Sao Lucas - PUCRS, Porto Alegre, Rio Grande Do Sul, 90610-000, Brazil|Hospital de Cancer de Barretos, Barretos, SÃ£o Paulo, 14784-400, Brazil|Hospital de Base de Sao Jose do Rio Preto, Sao Jose do Rio Preto, SÃ£o Paulo, 15090-000, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SÃ£o Paulo, 01246-000, Brazil|K2 Oncology, Providencia, 7500000, Chile|RedSalud Vitacura, Santiago, Chile|Beijing Cancer Hospital, Beijing, 100142, China|Xiangya Hospital of Centre-South University, Changsha, 410008, China|The third people's hospital of Chengdu, Chengdu, China|Guangdong General Hospital, Guangzhou, 510080, China|Jinhua municipal central hospital, Jinhua, China|Yunnan Cancer Hospital, Kunming, 650118, China|Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan City, 430030, China|Zhejiang Cancer Hospital, Zhejiang, 310022, China|Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia, Perugia, Umbria, 06156, Italy|St. Vincent's Hospital, Gyeonggi-do, 16247, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, 03722, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|Hospital Regional Universitario Carlos Haya, Malaga, 29010, Spain|Oncology Unit, Faculty of Medicine, Vajira Hospital, Dusit, 10300, Thailand|Srinagarind Hospital, Khon Kaen, 40002, Thailand",
NCT06123754,Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC,https://clinicaltrials.gov/study/NCT06123754,,RECRUITING,"This is a randomized, controlled, double-blind, multicenter Phase 3 clinical study to assess the efficacy and safety of envafolimab plus platinum-based doublet chemotherapy versus placebo plus platinum-based doublet chemotherapy as neoadjuvant/adjuvant therapy in subjects with resectable stage IIIA and IIIB (N2) NSCLC. Primary study endpoints are MPR rate assessed by BIPR and EFS assessed by BIRC.",NO,Non-small Cell Lung Cancer,DRUG: Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection|DRUG: placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection,"MPR by BIPR, MPR rate is defined as the percentage of participants having â¤10% viable tumor cells in the resected primary tumor and all resected lymph nodes following completion of neoadjuvant therapy (evaluated by BIPR), Up to 5 years|EFS by BIRC, EFS is defined as the time from randomization until the occurrence of events leading to inoperable disease progression, post-operative disease progression (BIRC assessment based on RECIST 1.1) or recurrence/metastasis, or death from any cause., Up to 5 years","pCR, pCR rate is defined as the percentage of participants having an absence of residual invasive cancer in resected lung specimens and lymph nodes following completion of neoadjuvant therapy, assessed by BIPR;, Up to 5 years|DFS, DFS is defined as the time from post-surgery to radiographic disease progression, local or distant recurrence, or death from any cause, assessed by BIRC;, Up to 5 years|OS, OS is defined as the time from randomization until death from any cause.;, Up to 5 years|EFS, EFS is defined as the time from randomization until the occurrence of events leading to inoperable disease progression, post-operative disease progression or recurrence/metastasis, or death from any cause., assessed by investigator;, Up to 5 years|Explore the quality of life for subjects by EORTC QLQ-C30, All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.

Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems., Up to 5 years|Explore the quality of life for subjects by EORTC QLQ-LC13, All of the scales and single-item measures range in score from 0 to 100. A high score for the scales and single items represents a high level of symptomatology or problems., Up to 5 years|PD-L1, ctDNA, To explore the correlation between clinical efficacy and tumor tissue sample biomarkers (such as PD-L1 level, etc.) and blood sample biomarkers (such as ctDNA level, etc.), Up to 5 years",,"3D Medicines (Sichuan) Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,390,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-11-17,2025-12-30,2027-09-30,2023-11-09,,2025-05-20,"Tianjin cancer hospital, Tianjing, Tianjin, 300060, China",
NCT05718167,TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.,https://clinicaltrials.gov/study/NCT05718167,,NOT_YET_RECRUITING,"This is Phase 3, randomized, double-blind, parallel controlled study designed to evaluate the Progression Free Survive (PFS) of TQB2450 injection combined with Paclitaxel Injection and Carboplatin Injection Followed by TQB2450 injection combined with Anlotinib Hydrochloride Capsules versus Tislelizumab injection combined with Paclitaxel Injection and Carboplatin Injection followed by Tislelizumab injection in locally advanced (stage â¢B/â¢C) and metastatic or recurrent (Stage IV) squamous NSCLC subjects.The primary endpoint is PFS assessed by IRC.",NO,Advanced Squamous Non-Small Cell Lung Carcinoma,DRUG: TQB2450|DRUG: Anlotinib hydrochloride capsule|DRUG: Tislelizumab injection,"Progression Free Survival (PFS), Progression Free Survival (PFS) assessed by Independent Review Committee (IRC), Base line up to 2 years. The curative effect was evaluated every 6 weeks (42 days) in the first 54 weeks of treatment period; After 54 weeks, the efficacy was evaluated every 9 weeks (63 days).","Overall survival (OS), Overall survival is the time from randomization to the time of death from any cause., Baseline up to death event, assessed up to 2 years.|Progression free survival (PFS), Progression free survival (PFS) assessed by investigators according to The Response Evaluation Criteria In Solid Tumors 1.1 (RECIST) and iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics., From randomization to Progression disease, assessed up to 2 years.|Objective response rate (ORR), Objective response rate (ORR), assessed by investigators according to The Response Evaluation Criteria In Solid Tumors 1.1 (RECIST) and iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics., From randomization to Progression disease, assessed up to 2 years.|Disease control rate (DCR), Disease control rate (DCR)assessed by investigators according to RECIST 1.1 and iRECIST criteria, From randomization to Progression disease, assessed up to 2 years.|Duration of response (DOR), Duration of response (DOR) assessed by investigators according to RECIST1.1 and iRECIST criteria, From randomization to Progression disease, assessed up to 2 years.|The occurrence of all adverse events (AEs), The occurrence of adverse events (AEs) is to evaluate safety profile, Baseline up to 2 years.|The severity of all adverse events (AEs), The severity of adverse events (AEs) is to evaluate safety profile, Baseline up to 2 years.|The occurrence of abnormal heart rate in 12 lead Electrocardiograph (ECG), The occurence of abnormal heart rate is to evaluate safety profile, Baseline up to 2 years.|The severity of abnormal heart rate in 12 lead Electrocardiograph (ECG), The severity of abnormal heart rate is evaluated in accordance with the standard of common toxic reactions of the National Cancer Institute \[NCI CTC v5.0\]., Baseline up to 2 years.|The occurrence of abnormal PR interval in 12 lead ECG, The occurrence rate of abnormal 12 lead ECG is to evaluate safety profile. The results of PR interval were divided into low, normal and high according to the normal value range., Baseline up to 2 years.|The severity of abnormal PR interval in 12 lead ECG, The results of PR interval were divided into low, normal and high according to the normal value range, and the relative baseline change was described with a cross table. The minimum or maximum observed value after the baseline is used to calculate the results after the baseline.

Descriptively summarize the results of PR examination at each visit, classify them as normal, abnormal without clinical significance, and abnormal with clinical significance, and compare them with the results of baseline, and describe them with cross classification table. The severity is evaluated in accordance with the standard of common toxic reactions of the National Cancer Institute \[NCI CTC v5.0\], Baseline up to 2 years.|The occurrence of abnormal QRS interval in 12 lead ECG, The occurrence of abnormal 12 lead ECG is to evaluate safety profile. The QRS interval results were divided into low, normal and high according to the normal value range., Baseline up to 2 years.|The severity of abnormal QRS interval in 12 lead ECG, The QRS interval results were divided into low, normal and high according to the normal value range, and the relative baseline change was described with a cross table. The minimum or maximum observed value after the baseline is used to calculate the results after the baseline.

Descriptively summarize the results of PR examination at each visit, classify them as normal, abnormal without clinical significance, and abnormal with clinical significance, and compare them with the results of baseline, and describe them with cross classification table. The severity is evaluated in accordance with the standard of common toxic reactions of the National Cancer Institute \[NCI CTC v5.0\], Baseline up to 2 years.|The occurrence of abnormal QT interval in 12 lead ECG, The occurrence rate of Abnormal 12 lead ECG is to evaluate safety profile. The results of QT interval were divided into low, normal and high according to the normal value., Baseline up to 2 years.|The severity of abnormal QT interval in 12 lead ECG, The results of QT interval were divided into low, normal and high according to the normal value range, and the relative baseline change was described with a cross table. The minimum or maximum observed value after the baseline is used to calculate the results after the baseline.

Descriptively summarize the results of PR examination at each visit, classify them as normal, abnormal without clinical significance, and abnormal with clinical significance, and compare them with the results of baseline, and describe them with cross classification table. The severity is evaluated in accordance with the standard of common toxic reactions of the National Cancer Institute \[NCI CTC v5.0\], Baseline up to 2 years.|The occurrence of abnormal QTc interval in 12 lead ECG, The occurrence of Abnormal 12 lead ECG is to evaluate safety profile. The results of QTc interval were divided into low, normal and high according to the normal value., Baseline up to 2 years.|The severity of abnormal QTc interval in 12 lead ECG, The results of QTc interval were divided into low, normal and high according to the normal value range, and the relative baseline change was described with a cross table. The minimum or maximum observed value after the baseline is used to calculate the results after the baseline.

Descriptively summarize the results of PR examination at each visit, classify them as normal, abnormal without clinical significance, and abnormal with clinical significance, and compare them with the results of baseline, and describe them with cross classification table. The severity is evaluated in accordance with the standard of common toxic reactions of the National Cancer Institute \[NCI CTC v5.0\], Baseline up to 2 years.|The occurrence of serious adverse events (SAEs), The occurrence of serious adverse events (SAEs) is to evaluate safety profile, Baseline up to 2 years.|The severity of serious adverse events (SAEs), The severity of serious adverse events (SAEs) is to evaluate safety profile, Baseline up to 2 years.|European organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ-C30), QLQ-C30 is a quality of life questionnaire to help understand the physical condition of the subjects. The subjects need to answer them in person and circle the number that best reflects their situation. Among them, 1 represents no, 2 represents a little, 3 represents some, and 4 represents a lot. Questions 29 and 30 need to choose the most suitable number from 1 to 7 and draw a circle. The other 1 represents very poor, and 7 represents very good. Questions 29 and 30 need to choose the most suitable number from 1 to 7 and draw a circle. The other 1 represents very poor, and 7 represents very good., Baseline up to 2 years.|Quality of life questionnaire lung cancer module (QLQ-LC13), QLQ-LC13 is a quality of life questionnaire to help understand the physical condition of the subjects. The subjects need to answer them in person and circle the number that best reflects their situation. Among them, 1 represents no, 2 represents a little, 3 represents some, and 4 represents a lot., Baseline up to 2 years.|EuroQol Five Dimensions Questionnaire (EQ-5D) assessment pro, EQ-5D assessment pro is a quality of life questionnaire, which has five questions that need to be answered by the subjects themselves, choose the answer that best reflects their health, and mark the point on the set scale that best represents their health, of which 100 represents the best condition and 0 represents the worst condition., Baseline up to 2 years.|Incidence of Antidrug antibody, It's a parameter to evaluate the immunogenicity of TQB2450 injection, Baseline up to 2 years.|Incidence of neutralizing antibody, It's a parameter to evaluate the immunogenicity of TQB2450 injection, Baseline up to 2 years.",,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,570,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-02,2024-10,2025-10,2023-02-08,,2023-02-14,"Chinese Academy of Medical Sciences Cancer Hospital, Beijing, Beijing, 100021, China|Beijing Chest Hospital, Capital Medical University, Beijing, Beijing, 101149, China|TianJin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, 300060, China|Yunnan Cancer Hospital, Kunming, Yunnan, 650118, China",
NCT06497985,A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients,https://clinicaltrials.gov/study/NCT06497985,,RECRUITING,"A randomised, open-label, multicenter phase III study to evaluate the efficacy and safety of tucidinostat in combination with sintilimab and bevacizumab versus fruquintinib monotherapy in MSS/pMMR colorectal cancer patients.",NO,Colorectal Cancer,DRUG: Tucidinostat|DRUG: Sintilimab|DRUG: Bevacizumab|DRUG: Fruquintinib,"Overall Survival (OS), From randomization to the date of death from any cause., Up to approximately 2 years","Progression Free Survival (PFS), PFS assessed by investigator per RECIST v1.1, measured from the date of randomization until progression or death, whichever occurs first., Up to approximately 2 years|Overall response rate (ORR), Proportion of participants who achieved complete response (CR) or partial response (PR) assessed by investigator according to RECIST v1.1., Up to approximately 2 years|Duration of response (DOR), From the first occurrence of PR or CR until the date of first documented progression according to RECIST 1.1, or death, whichever occurs first., Up to approximately 2 years|Disease control rate (DCR), Proportion of participants who achieved CR or PR, or stable disease (SD) assessed by investigator according to RECIST v1.1., Up to approximately 2 years|Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life (QOL) Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status/Quality of Life Scale Score, EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire, contains 30 items across 5 functional scales (physical, role, cognitive, emotional, and social), 9 symptom scales (fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial difficulties) and global health status/QOL scale.Change from baseline in the EORTC QLQ-C30 Global Health Status/Quality of Life Scale scores will be presented., Up to approximately 2 years|Change From Baseline in EuroQoL 5 Dimension 5 Level (EQ-5D-5L) Health Utility Index Scores, The EQ-5D-5L is a self-reported health status questionnaire that consisted of 2 components: health state profile and optional VAS. EQ-5D health state profile had 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each dimension has 5 levels: no problem, slight problem, moderate problem, severe problem, and extreme problem. Change from baseline in health utility index scores will be presented., Up to approximately 2 years|Change From Baseline in EuroQoL 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scale (VAS) Score, EQ-5D-5L consisted of 2 components: health state profile and optional VAS. The VAS records the respondent's self-rated health on a vertical visual analogue scale. The VAS 'thermometer' has endpoints of 100 (Best imaginable health state) at the top and 0 (Worst imaginable health state) at the bottom. Change from baseline in EQ-5D-5L VAS scores will be presented., Up to approximately 2 years|Safety and Tolerability, Number of Participants Who Experience an Adverse Event (AE) assessed by CTCAE v5.0., Up to approximately 2 years|Plasma concentrations of tucidinostat, Plasma samples were collected from the participants at the defined time points. Plasma concentrations were measured using a validated, specific, and sensitive method., Up to approximately 6 months",,"Chipscreen Biosciences, Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,430,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-11-27,2028-05-31,2028-09-30,2024-07-12,,2024-12-03,"Rui-Hua Xu, Guangzhou, Guangdong, 510050, China",
NCT06947967,Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype,https://clinicaltrials.gov/study/NCT06947967,,NOT_YET_RECRUITING,"A Randomised, Double-blind, Multicenter Phase â¢ Study to Evaluate the Efficacy and Safety of Tucidinostat versus Placebo in Combination with CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma with Follicular Helper of T Cell Phenotype",NO,"Lymphoma, T-Cell, Peripheral","DRUG: CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)|DRUG: Tucidinostat|DRUG: Placebo","Progression-Free Survival (PFS), Defined as the duration from the date of randomization to the date of progression, relapse from CR, or death, whichever occurred first., Up to approximately 60 month","Complete Response Rate(CRR), Up to approximately 36 months|Overall response rate (ORR), Defined as the proportion of subjects with measurable disease who achieve CR or partial response (PR), Up to approximately 36months|Event Free Survival (EFS), Defined as the duration from the date of randomization to the date of disease progression, initiation of subsequent systemic antilymphoma therapy for residual disease, or death, whichever occurs first., Up to approximately 60 month|Disease-Free Survival (DFS), Defined for participants achieving CR as the period from the date of the initial CR until the date of relapse or death from any cause., Up to approximately 60 month|Overall Survival (OS), defined as the duration from the date of randomization to the date of the participant's death, Up to approximately 60 month|Safety and Tolerability, Number of Participants Who Experience an Adverse Event (AE) assessed by CTCAE v5.0., Up to approximately 78 months|Plasma concentrations of tucidinostat, Plasma samples were collected from the participants at the defined time points. Plasma concentrations were measured using a validated, specific, and sensitive method., Up to approximately 60 month",,"Chipscreen Biosciences, Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,224,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2025-06,2031-12,2032-12,2025-04-27,,2025-04-27,"Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510050, China",
NCT04513925,"A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)",https://clinicaltrials.gov/study/NCT04513925,SKYSCRAPER-03,ACTIVE_NOT_RECRUITING,"The purpose of this study is to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab in participants with locally advanced, unresectable Stage III non-small cell lung cancer (NSCLC) who have received at least two cycles of concurrent platinum-based chemoradiotherapy (CRT) and have not had radiographic disease progression.",NO,Non-small Cell Lung Cancer (NSCLC),DRUG: Atezolizumab|DRUG: Tiragolumab|DRUG: Durvalumab,"Independent Review Facility (IRF)-assessed Progression Free Survival (PFS) in the PD-L1-positive Analysis Set (PPAS), From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 114 months)|IRF-assessed PFS in the Full Analysis Set (FAS), From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 114 months)","Overall Survival (OS) in the PPAS, From randomization to death from any cause (up to approximately 114 months)|Investigator-assessed PFS in the PPAS, Time from randomization to the first occurrence of disease progression or death from any cause, whichever occurs first first (up to approximately 114 months)|IRF-assessed Confirmed Objective Response Rate (ORR) in the PPAS, From randomization up to approximately 114 months|Investigator-assessed Confirmed ORR in the PPAS, From randomization up to approximately 114 months|IRF-assessed Duration of Response (DOR) in the PPAS, From first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first (up to approximately 114 months)|Investigator-assessed DOR in the PPAS, From first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first (up to approximately 114 months)|Time to Confirmed Deterioration (TTCD) Assessed Using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core (QLQ-C30) Score in the PPAS, TTCD using EORTC QLQ-C30 is an initial 10-point decrease in global health status (GHS) and physical functioning from baseline that must be held for all subsequent assessment timepoints or followed by death attributable to cancer progression. EORTC QLQ-C30: a self-reported measure, consisting of 30 questions that assess 5 aspects of participants functioning (physical, emotional, role, cognitive and social), 3 symptom scales (fatigue, nausea and vomiting and pain), GHS and quality of life (QoL), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties) with a recall period of the previous week. Functioning items are scored on a 4-point scale: 1=Not at all to 4=Very much, with higher score indicating worse outcome. Symptom items (GHS and QoL) are scored on a 7-point scale: 1=Very poor to 7=Excellent. Scores will be linearly transformed with a minimum score of 0 and maximum score of 100. Higher score indicates better outcome., Up to approximately 114 months|OS in the FAS, From randomization to death from any cause (up to approximately 114 months)|Investigator-assessed PFS in the FAS, Time from randomization to the first occurrence of disease progression or death from any cause, whichever occurs first first (up to approximately 114 months)|IRF-assessed Confirmed ORR in the FAS, From randomization up to approximately 114 months|Investigator-assessed Confirmed ORR in the FAS, From randomization up to approximately 114 months|IRF-assessed DOR in the FAS, From first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first (up to approximately 114 months)|Investigator-assessed DOR in the FAS, From first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first (up to approximately 114 months)|TTCD Assessed Using EORTC QLQ-C30 Score in the FAS, TTCD using EORTC QLQ-C30 is an initial 10-point decrease in global health status (GHS) and physical functioning from baseline that must be held for all subsequent assessment timepoints or followed by death attributable to cancer progression. EORTC QLQ-C30: a self-reported measure, consisting of 30 questions that assess 5 aspects of participants functioning (physical, emotional, role, cognitive and social), 3 symptom scales (fatigue, nausea and vomiting and pain), GHS and quality of life (QoL), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties) with a recall period of the previous week. Functioning items are scored on a 4-point scale: 1=Not at all to 4=Very much, with higher score indicating worse outcome. Symptom items (GHS and QoL) are scored on a 7-point scale: 1=Very poor to 7=Excellent. Scores will be linearly transformed with a minimum score of 0 and maximum score of 100. Higher score indicates better outcome., Up to approximately 114 months|IRF-assessed PFS Rates at 12 Months, 18 Months and 24 Months in the PPAS, 12, 18 and 24 months|IRF-assessed PFS Rates at 12 Months, 18 Months and 24 Months in the FAS, 12, 18 and 24 months|Investigator-assessed PFS Rates at 12 Months, 18 Months and 24 Months in the PPAS, 12, 18 and 24 months|Investigator-assessed PFS Rates at 12 Months, 18 Months and 24 Months in the FAS, 12, 18 and 24 months|OS Rates at 12 Months, 24 Months, 36 Months and 48 Months in the PPAS, 12, 24, 36 and 48 months|OS Rates at 12 Months, 24 Months, 36 Months and 48 Months in the FAS, 12, 24, 36 and 48 months|Investigator-assessed Time to Death or Distant Metastasis (TTDM) in the PPAS, From randomization until the first date of distant metastasis or death in the absence of distant metastasis (up to approximately 114 months)|Investigator-assessed TTDM in the FAS, From randomization until the first date of distant metastasis or death in the absence of distant metastasis (up to approximately 114 months)|Percentage of Participants With Adverse Events, Up to approximately 114 months",,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE3,829,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-24,2025-08-31,2027-12-30,2020-08-14,,2025-06-04,"Stanford University, Palo Alto, California, 94305, United States|Banner MD Anderson Cancer Center, Greeley, Colorado, 80631, United States|Florida Cancer Specialists, Fort Myers, Florida, 33901-8101, United States|Cancer Care Centers of Brevard, Palm Bay, Florida, 32901, United States|Woodlands Medical Specialists, P.A., Pensacola, Florida, 32503, United States|Florida Cancer Specialist, North Region, Saint Petersburg, Florida, 33705, United States|Northwest Georgia Oncology Centers PC - Marietta, Marietta, Georgia, 30060, United States|Illinois Cancer Care, Peoria, Illinois, 61615, United States|New England Cancer Specialists, Brunswick, Maine, 04011, United States|Southcoast Health System, Fairhaven, Massachusetts, 02719, United States|Minnesota Oncology Hematology, Minneapolis, Minnesota, 55404, United States|HCA Midwest Health, Kansas City, Missouri, 64132, United States|Cox Health Systems, Springfield, Missouri, 65807, United States|Optum Health Care, Las Vegas, Nevada, 89106, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, 89128, United States|Titan Health Partners LLC, d/b/a Astera Cancer Care, East Brunswick, New Jersey, 08816, United States|San Juan Oncology Associates, Farmington, New Mexico, 87401, United States|New York Oncology Hematology,P.C.-Albany, Albany, New York, 12208, United States|Montefiore Medical Center, Bronx, New York, 10461, United States|Mount Sinai Medical Center, New York, New York, 10029, United States|Prisma Health ? Upstate, Greenville, South Carolina, 29615, United States|Tennessee Oncology Chattanooga, Chattanooga, Tennessee, 37403, United States|Sarah Cannon Research Institute / Tennessee Oncology, Nashville, Tennessee, 37203, United States|Virginia Cancer Specialists, Fairfax, Virginia, 22031, United States|Virginia Oncology Associates, Norfolk, Virginia, 23502, United States|CEMIC, Buenos Aires, C1431FWO, Argentina|Hospital Britanico de Buenos Aires, Ciudad Autonoma Buenos Aires, C1284AEB, Argentina|Clinica Universitaria Reina Fabiola, Cordoba, X5004FHP, Argentina|Sanatorio Parque S.A., Rosario, S2000QGB, Argentina|Blacktown Hospital, Blacktown, New South Wales, 2148, Australia|Macarthur Cancer Therapy Centre, Campbelltown, New South Wales, 2560, Australia|St George Hospital, Kogarah, New South Wales, 2217, Australia|Flinders Medical Centre, Bedford Park, South Australia, 5042, Australia|Fiona Stanley Hospital, Bull Creek, Western Australia, 6149, Australia|Monash Health Translational Precinct, Victoria, 3168, Australia|Tiroler Landeskrankenanstalten Ges.M.B.H., Innsbruck, 6020, Austria|Kepler UniversitÃ¤tskliniken GmbH - Med Campus III, Linz, 4020, Austria|Klinik Penzing, Wien, 1140, Austria|GHdC Site Les Viviers, Charleroi, 6000, Belgium|AZ Maria Middelares, Gent, 9000, Belgium|Jessa Zkh (Campus Virga Jesse), Hasselt, 3500, Belgium|Crio - Centro Regional Integrado de Oncologia, Fortaleza, CearÃ¡, 60336-550, Brazil|Centro Integrado de Oncologia de Curitiba, Curitiba, ParanÃ¡, 80810-050, Brazil|Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda, Ijui, Rio Grande Do Sul, 98700-000, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, Rio Grande Do Sul, 90610-000, Brazil|Hospital de Cancer de Barretos, Barretos, SÃ£o Paulo, 14784-400, Brazil|Hospital de Base de Sao Jose do Rio Preto, Sao Jose do Rio Preto, SÃ£o Paulo, 15090-000, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SÃ£o Paulo, 01246-000, Brazil|BC Cancer ? Abbotsford, Abbotsford, British Columbia, V2S 0C2, Canada|BC Cancer - Victoria, Victoria, British Columbia, V8R 6V5, Canada|Royal Victoria Regional Health Centre, Barrie, Ontario, L4M 6M2, Canada|William Osler Health System Brampton Civic Hospital, Brampton, Ontario, L6R 3J7, Canada|Ottawa Hospital Research Institute, Ottawa, Ontario, K1H 8L6, Canada|Beijing Cancer Center, Beijing City, 100142, China|Beijing Chest Hospital, Beijing, 101149, China|Jilin Cancer Hospital, Changchun, 132013, China|Xiangya Hospital Central South University, Changsha City, 410008, China|Sichuan Provincial Cancer Hospital, Chengdu, 610041, China|Chongqing Cancer Hospital, Chongqing, 400030, China|Fujian Medical University Union Hospital, Fujian, 350001, China|Fujian Provincial Cancer Hospital, Fuzhou City, 350014, China|Cancer Center, Sun Yat-sen University of Medical Sciences, Guangzhou, 510060, China|Hangzhou Cancer Hospital, Hangzhou City, 310002, China|Shandong Cancer Hospital, Jinan, 250117, China|Zhongda Hospital Affiliated to Southeast University, Nanjing, 210009, China|The affiliated hospital of Qingdao university, Qingdao City, 266042, China|Shanghai Chest Hospital, Shanghai, 200000, China|Cancer Hospital of Shantou University Medical College, Shantou, 515041, China|Shanxi Provincial Cancer Hospital, Taiyuan, 030013, China|Tianjin Cancer Hospital, Tianjin, 300060, China|The First Affiliated Hospital of Xiamen University, Xiamen, 361003, China|The Affiliated Hospital of Xuzhou Medical College, Xuzhou, 221000, China|Henan Cancer Hospital, Zhengzhou, 450008, China|CHU Angers, Angers, 49933, France|Centre Francois Baclesse, Caen, 14000, France|Hopital Nord AP-HM, Marseille, 13015, France|Clinique ClÃ©mentville, Montpellier, 34070, France|Hopital Robert Schuman, Vantoux, 57070, France|Institut Gustave Roussy, Villejuif cedex, 94805, France|Klinikum Braunschweig, Braunschweig, 38114, Germany|Thoraxklinik Heidelberg gGmbH, Heidelberg, 69126, Germany|Klinikum Koeln-Merheim, KÃ¶ln, 51109, Germany|UniversitÃ¤tsklinikum Regensburg, Regensburg, 93053, Germany|General Hospital ""G.Papanikolaou"", Asvestochori, 570 10, Greece|Sotiria Hospital, Athens, 11527, Greece|Agioi Anargyroi Cancer Hospital, Kifisia, 145 64, Greece|Princess Margaret Hospital, Oncology, Hong Kong, DUMMY_VALUE, Hong Kong|Queen Elizabeth Hospital, Hong Kong, DUMMY_VALUE, Hong Kong|Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong|Tuen Mun Hospital, Hong Kong, Hong Kong|PÃ©csi TudomÃ¡nyegyetem, PÃ©cs, 7623, Hungary|Szent Borbala Korhaz, TatabÃ¡nya, 2800, Hungary|Tudogyogyintezet Torokbalint, Torokbalint, 2045, Hungary|Soroka Medical Center, Beer Sheva, 8410100, Israel|Rambam Medical Center, Haifa, 3109601, Israel|Shaare Zedek Medical Center, Jerusalem, 9103102, Israel|Rabin Medical Center, Petach Tikva, 4941492, Israel|Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale, Napoli, Campania, 80131, Italy|IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola, Meldola, Emilia-Romagna, 47014, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Emilia-Romagna, 43100, Italy|Policlinico Universitario Campus Biomedico, Roma, Lazio, 00128, Italy|IRCCS Istituto Regina Elena (IFO), Roma, Lazio, 00144, Italy|IRCCS AOU San Martino - IST, Genova, Liguria, 16132, Italy|A.O. Spedali Civili Di Brescia-P.O. Spedali Civili, Brescia, Lombardia, 25123, Italy|Azienda Socio Sanitaria Territoriale Niguarda (Ospedale Niguarda Ca' Granda), Milano, Lombardia, DUMMY_VALUE, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, Lombardia, 27100, Italy|Azienda Ospedaliera Universitaria Pisana - Ospedale Cisanello, Pisa, Toscana, 56124, Italy|Azienda ULSS 8 Berica, Vicenza, Veneto, 36100, Italy|Aichi Cancer Center, Aichi, 464-8681, Japan|National Cancer Center East, Chiba, 277-8577, Japan|National Hospital Organization Himeji Medical Center, Hyogo, 670-8520, Japan|Kitasato University Hospital, Kanagawa, 252-0375, Japan|Kyoto University Hospital, Kyoto, 606-8507, Japan|Sendai Kousei Hospital, Miyagi, 981-0914, Japan|Niigata Cancer Center Hospital, Niigata, 951-8566, Japan|Kindai University Hospital, Osaka, 589-8511, Japan|Saitama Cancer Center, Saitama, 362-0806, Japan|Shizuoka Cancer Center, Shizuoka, 411-8777, Japan|National Cancer Center Hospital, Tokyo, 104-0045, Japan|The Cancer Institute Hospital of JFCR, Tokyo, 135-8550, Japan|Wakayama Medical University Hospital, Wakayama, 641-8510, Japan|Chungbuk National University Hospital, Cheongju-si, 28644, Korea, Republic of|Kyungpook National University Chilgok Hospital, Daegu, 41404, Korea, Republic of|National Cancer Center, Gyeonggi-do, 10408, Korea, Republic of|Seoul National University Bundang Hospital, Gyeonggi-do, 13620, Korea, Republic of|St. Vincent's Hospital, Gyeonggi-do, 16247, Korea, Republic of|Ajou University Medical Center, Gyeonggi-do, 16499, Korea, Republic of|Pusan National University Yangsan Hospital, Gyeongsangnam-do, 50612, Korea, Republic of|Gachon University Gil Medical Center, Incheon, 21565, Korea, Republic of|Chonnam National University Hwasun Hospital, Jeollanam-do, 58128, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|Seoul St Mary's Hospital, Seoul, 06591, Korea, Republic of|Korea University Guro Hospital, Seoul, 08308, Korea, Republic of|Ulsan University Hosiptal, Ulsan, 44033, Korea, Republic of|Meander Medisch Centrum, Amersfoort, 3813 TZ, Netherlands|Amphia Ziekenhuis, Breda, 4819 EV, Netherlands|Medisch Centrum Haaglanden, locatie Antoniushove, Leidschendam, 2262 BA, Netherlands|Zuyderland Medisch Centrum - Sittard Geleen, Sittard-Geleen, 6162 BG, Netherlands|Auckland City Hospital, Cancer and Blood Research, Auckland, 1023, New Zealand|Uniwersyteckie Centrum Kliniczne, Gda?sk, 80-214, Poland|Szpital Kliniczny MSWiA z Warmi?sko-Mazurskim Centrum Onkologii, Olsztyn, 10-228, Poland|Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy, Otwock, 05-400, Poland|Narod.Inst.Onkol. im. M.Sklodowskiej - Curie-Panst.Inst.Bad, Warszawa, 02-781, Poland|Dolnoslaskie Centrum Onkologii, Pulmonologii i Hematologii, Wroc?aw, 53-413, Poland|IPO de Coimbra, Coimbra, 3000-075, Portugal|Hospital da Luz, Lisboa, 1500-650, Portugal|Hospital CUF Porto, Porto, 4100-180, Portugal|IPO do Porto, Porto, 4200-072, Portugal|Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, 08916, Spain|Hospital Provincial de Castellon, Castellon de La Plana, Castellon, 12002, Spain|Hospital Son Llatzer, Palma de Mallorca, Islas Baleares, 07198, Spain|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Complejo Hospitalario Universitario A CoruÃ±a (CHUAC), La Coruna, 15006, Spain|Hospital General Universitario Gregorio MaraÃ±on, Madrid, 28009, Spain|Hospital Universitario La Paz, Madrid, 28046, Spain|Hospital Regional Universitario Carlos Haya, Malaga, 29010, Spain|Hospital Universitario Virgen del Rocio, Sevilla, 41013, Spain|China Medical University Hospital, Taichung, 40447, Taiwan|Taipei Veterans General Hospital, Taipei, 112, Taiwan|Vajira Hospital, Bangkok, 10300, Thailand|Rajavithi Hospital, Bangkok, 10400, Thailand|Ramathibodi Hospital;Medicine/Oncology, Bangkok, 10400, Thailand|Songklanagarind Hospital, Songkhla, 90110, Thailand|Adana Baskent University Medical Faculty, Adana, 01220, Turkey|Ankara University Medical Faculty, Ankara, 06100, Turkey|Hacettepe Universitesi Tip Fakultesi Hastanesi, Ankara, 06100, Turkey|Gazi University Medical Faculty, Oncology Hospital, Ankara, 06500, Turkey|Ege University Medical Faculty, Bornova, ?zm?r, 35100, Turkey|Dicle University Faculty of Medicine, Diyarbakir, 21280, Turkey|Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi, Edirne, 22030, Turkey|Istanbul University Cerrahpasa Faculty of Medicine, Istanbul, 34098, Turkey|Medipol University Medical Faculty, Istanbul, 34214, Turkey|Inonu University Faculty of Medicine Turgut Ozal Medical Center, Malatya, 44280, Turkey|Birmingham Heartlands Hospital, Birmingham, B9 5SS, United Kingdom|Addenbrooke's NHS Trust, Cambridge, CB2 0QQ, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, G12 0YN, United Kingdom|Leicester Royal Infirmary, Leicester, LE1 5WW, United Kingdom|Christie Foundation Trust, Manchester, M20 4BX, United Kingdom|Weston Park Hospital, Sheffield, S10 2SJ, United Kingdom",
NCT04873362,A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy,https://clinicaltrials.gov/study/NCT04873362,Astefania,ACTIVE_NOT_RECRUITING,"This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in participants with HER2-positive primary breast cancer who have received preoperative chemotherapy and HER2-directed therapy, including trastuzumab followed by surgery, with a finding of residual invasive disease in the breast and/or axillary lymph nodes.

As of June 4, 2024, this study is no longer accepting any newly screened participants.",NO,Breast Cancer,DRUG: Atezolizumab|DRUG: Trastuzumab Emtansine|DRUG: Placebo|DRUG: Trastuzumab,"Invasive Disease-free Survival (IDFS) in the Full Analysis Set (FAS), IDFS event is defined as the time from randomization to the first occurrence of the following events: ipsilateral invasive breast tumor recurrence, ipsilateral local-regional invasive breast cancer recurrence, contralateral invasive breast cancer, distant recurrence, death from any cause., From baseline until the first occurrence of iDFS event or death, through primary analysis data cut off (approximately 7 years)","IDFS Including Second Primary Non-breast Invasive Cancer, From baseline until the first occurrence of iDFS event or death, through the end of study (approximately 10 years from last participant in [LPI])|IDFS in the PD-L1-positive and the PD-L1-negative Population, Defined as all randomized participants from the ITT population with a centrally assessed PD-L1-positive \[i.e., PD-L1 status of IC1/2/3\] or PD-L1-negative status \[i.e.,PD-L1 status of IC0\] at randomization as per corresponding stratification factors recorded in the interactive web-based response system (IWRS)., From baseline until the first occurrence of iDFS event or death, through the end of study (approximately 10 years from LPI)|Disease-free Survival (DFS), From baseline until the first occurrence of DFS event or death, through the end of study (approximately 10 years from LPI)|Overall Survival (OS), From baseline to death from any cause through the end of study (approximately 10 years from LPI)|Distant Recurrence-free Interval (DRFI), From baseline until distant disease recurrence, through the end of study (approximately 10 years from LPI)|Number of Participants with Clinically Meaningful Deterioration in Global Health Status/Quality of Life (GHS/QoL) Physical, Role, and Cognitive Function, Clinically Meaningful Deterioration will be Measured by Scales of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer (EORTC QLQ C30), From baseline until 2 years after study treatment completion/discontinuation visit (approximately 3 years)|Mean Absolute Scores in GHS/QoL, Physical, Role, and Cognitive Function, as Assessed Using the EORTC QLQ-C30, The European Organisation for Research and Treatment of Cancer Quality of Life-Core 30 Questionnaire (EORTC QLQ-C30) is a self-reported measure. Functioning and symptoms items are scored on a 4-point scale: 1=Not at all, 2=A little, 3=Quite a bit, 4=Very much. GHS and QoL items are scored on a 7-point scale: 1=Very poor, 2, 3, 4, 5, 6, 7=Excellent. Scores will be transformed to a range of 0 to 100, with higher scores (i.e. closer to 100) reflecting better functioning, better GHS/QoL, and worse symptoms., From baseline until 2 years after study treatment completion/discontinuation visit (approximately 3 years)|Mean Change From Baseline Scores in GHS/QoL, Physical, Role, and Cognitive Function, as Assessed Using the EORTC QLQ-C30, The European Organisation for Research and Treatment of Cancer Quality of Life-Core 30 Questionnaire (EORTC QLQ-C30) is a self-reported measure. Functioning and symptoms items are scored on a 4-point scale: 1=Not at all, 2=A little, 3=Quite a bit, 4=Very much. GHS and QoL items are scored on a 7-point scale: 1=Very poor, 2, 3, 4, 5, 6, 7=Excellent. Scores will be transformed to a range of 0 to 100, with higher scores (i.e. closer to 100) reflecting better functioning, better GHS/QoL, and worse symptoms., From baseline until 2 years after study treatment completion/discontinuation visit (approximately 3 years)|Percentage of Participants with Adverse Events (AEs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0), From baseline up to 10 years|Maximum Serum Concentrations (Cmax) for Atezolizumab, Day 1 of Cycles 1 and 4 after 30 minutes post-infusion (a cycle=21 days)|Minimum Serum Concentrations (Cmin) for Atezolizumab, Pre-infusion on Day 1 of Cycles 1, 2, 3, 4 and 8 (a cycle=21 days) and at study treatment completion/discontinuation visit (approximately 11 months after Cycle 1 Day 1)|Cmax for Trastuzumab Emtansine, Day 1 of Cycles 1 and 4 after 30 minutes post-infusion (a cycle=21 days)|Cmin for Trastuzumab Emtansine, Pre-infusion on Day 1 of Cycles 1 and 4 (a cycle=21 days) and at study treatment completion/discontinuation visit (approximately 11 months after Cycle 1 Day 1)|Cmax for Total Trastuzumab, Day 1 of Cycles 1 and 4 after 30 minutes post-infusion (a cycle=21 days)|Cmin for Total Trastuzumab, Pre-infusion on Day 1 of Cycles 1 and 4 (a cycle=21 days) and at study treatment completion/discontinuation visit (approximately 11 months after Cycle 1 Day 1)|Cmax for DM1, DM1 = a thiol-containing maytansinoid anti-microtubule agent; N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine, Day 1 of Cycles 1 and 4 after 30 minutes post-infusion (a cycle=21 days)|Percentage of Participants with Anti-drug Antibodies (ADAs) to Atezolizumab, Pre-infusion on Day 1 of Cycles 1, 2, 3, 4 and 8 (a cycle=21 days) and at study treatment completion/discontinuation visit (approximately 11 months after Cycle 1 Day 1)|Percentage of Participants with ADAs to Trastuzumab Emtansine, Pre-infusion on Day 1 of Cycles 1 and 4 (a cycle=21 days) and at study treatment completion/discontinuation visit (approximately 11 months after Cycle 1 Day 1)",,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE3,1188,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-05-04,2028-08-31,2034-10-02,2021-05-05,,2025-06-10,"Alabama Oncology, Birmingham, Alabama, 35205, United States|Roy and Patricia Disney Family Cancer Center- Providence Saint Joseph Medical Center, Buena, California, 91505, United States|UCLA Medical Center, Santa Monica, California, 90404, United States|Innovation Clinical Research Institute, Whittier, California, 90603, United States|Florida Cancer Specialists, West Palm Beach, Florida, 33401, United States|Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital, Carrollton, Georgia, 30117, United States|University of Iowa, Iowa City, Iowa, 52242-1086, United States|New England Cancer Specialists, Westbrook, Maine, 04092, United States|The Valley Hospital, Paramus, New Jersey, 07652, United States|Levine Cancer Institute, Charlotte, North Carolina, 28204, United States|Abramson Cancer Center; Univ of Pennsylvania; Clinical Research Unit, Philadelphia, Pennsylvania, 19106, United States|The West Clinic, Germantown, Tennessee, 38138, United States|Thompson Cancer Survival Center, Knoxville, Tennessee, 37916-2305, United States|Mays Cancer Center at UT Health San Antonio MD Anderson Cancer, San Antonio, Texas, 78229, United States|Hematology Oncology Associates of Fredericksburg, Inc., Fredericksburg, Virginia, 22408, United States|Virginia Oncology Associates - New Port News, Newport News, Virginia, 23606, United States|Virginia Oncology Associates, Norfolk, Virginia, 23502, United States|Virginia Cancer Institute, Richmond, Virginia, 23229, United States|Virginia Oncology Associates - Virginia Beach, Virginia Beach, Virginia, 23456, United States|Providence Regional Cancer Partnership, Everett, Washington, 98201, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, 99336-7774, United States|Northwest Medical Specialties, Tacoma, Washington, 98405, United States|Macarthur Cancer Therapy Centre, Campbelltown, New South Wales, 2560, Australia|Royal North Shore Hospital, St Leonards, New South Wales, 2065, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, 4102, Australia|Tiroler Landeskrankenanstalten Ges.M.B.H., Innsbruck, 6020, Austria|Ordensklinikum Linz Barmherzige Schwestern, Linz, 4010, Austria|Lkh Salzburg - Univ. Klinikum Salzburg, Salzburg, 5020, Austria|Cliniques Universitaires St-Luc, Bruxelles, 1200, Belgium|Jessa Zkh (Campus Virga Jesse), Hasselt, 3500, Belgium|Clinique St. Elizabeth, Namur, 5000, Belgium|Hospital Sao Rafael - HSR, Salvador, Bahia, 41253-190, Brazil|Crio - Centro Regional Integrado de Oncologia, Fortaleza, CearÃ¡, 60336-550, Brazil|Hospital Araujo Jorge, Goiania, GoiÃ¡s, 74605-070, Brazil|Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda, Ijui, Rio Grande Do Sul, 98700-000, Brazil|Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, 90020-090, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, Rio Grande Do Sul, 90610-000, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, Rio Grande Do Sul, 91350-200, Brazil|Hospital de Base de Sao Jose do Rio Preto, Sao Jose do Rio Preto, SÃ£o Paulo, 15090-000, Brazil|Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda, Sao Paulo, SÃ£o Paulo, 01317-001, Brazil|NÃºcleo de Pesquisa SÃ£o Camilo, Sao Paulo, SÃ£o Paulo, 03102-002, Brazil|COC Plovdiv, Plovdiv, 4004, Bulgaria|Medical Center ""Nadezhda Clinical"" EOOD, Sofia, 1330, Bulgaria|University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna - ISUL EAD, Sofia, 1527, Bulgaria|Sichuan Cancer Hospital, Chengdu City, 610041, China|West China Hospital - Sichuan University, Chengdu City, 610047, China|Chongqing Cancer Hospital, Chongqing, 400030, China|Guangdong Provincial People's Hospital, Guangzhou City, 510245, China|Sun Yat-sen Memorial Hospital, Guangzhou, 510000, China|The First Affilicated Hospital, Sun Yat-sen University, Guangzhou, China|Harbin Medical University Cancer Hospital, Harbin, 150081, China|Zhongshan Hospital Fudan University, Shanghai, 200032, China|Tianjin Medical University Cancer Institute & Hospital, Tianjing, 300060, China|Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan City, 430022, China|First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, 710061, China|Zhejiang Cancer Hospital, Zhejiang, 310022, China|Henan Cancer Hospital, Zhengzhou, 450008, China|Masaryk?v onkologickÃ½ Ãºstav, Brno, 656 53, Czechia|Fakultni Nemocnice Hradec Kralove, Hradec Kralove, 500 05, Czechia|Nemocnice AGEL Novy Jicin a.s., Novy Jicin, 741 01, Czechia|Fakultni nemocnice Olomouc, Olomouc, 779 00, Czechia|Fakultni Poliklinika Vseobecne Fakultni Niemocnice, Praha 2, 128 08, Czechia|Fakultni Thomayerova nemocnice, Praha 4 - Krc, 140 59, Czechia|Vejle Sygehus, Vejle, 7100, Denmark|Institut Sainte Catherine, Avignon, 84918, France|CHRU BesanÃ§on, BesanÃ§on, 25030, France|Polyclinique Bordeaux Nord Aquitaine, Bordeaux, 33300, France|Hopital Morvan, Brest, 29200, France|Centre Francois Baclesse, Caen, 14076, France|Groupe Hospitalier Public Du Sud De L'Oise GHPSO, Creil Cedex 1, 60109, France|CLCC Leon Berard Lyon, Lyon, 69008, France|Centre Hospitalier Uni Ire Caremeau, Nimes, 30029, France|Groupe Hospitalier Diaconesses, Paris, 75020, France|Institut Curie, Paris, 75231, France|Pole Regional De Cancerologie, Poitiers, 86021, France|HOPITAL RENE HUGUENIN, Institut Curie, Saint-Cloud, 92210, France|Klinikum Augsburg, Augsburg, 86156, Germany|Hochwaldkrankenhaus, Bad Nauheim, 61231, Germany|Onkologische Schwerpunktpraxis KurfÃ¼rstendamm, Berlin, 10707, Germany|GynÃ¤kologisches Zentrum Bonn, Bonn, 53111, Germany|Marienhospital Bottrop, Bottrop, 46236, Germany|StÃ¤dtisches Klinikum Dessau, Dessau-RoÃlau, 06847, Germany|Gynonco DÃ¼sseldorf, MVZ Medical Center GmbH, DÃ¼sseldorf, 40235, Germany|Frauenarztpraxis Dr. Apel, Dr. Kolpin, Erfurt, 99084, Germany|Klinikum Essen-Mitte Ev. Huyssens-Stiftung / Knappschafts GmbH, Essen, 45136, Germany|AGAPLESION Markus-Krankenhaus, Frankfurt, 60431, Germany|Klinik Johann Wolfgang von Goethe Uni, Frankfurt, 60596, Germany|Praxis fÃ¼r InterdisziplinÃ¤re Onkologie und HÃ¤matologie GbR, Freiburg, 79110, Germany|Diakovere Henriettenstift, Frauenklinik, Hannover, 30171, Germany|UNI-Klinikum Campus Kiel Klinik fÃ¼r GynÃ¤kologie und Geburtshilfe, Kiel, 24105, Germany|StÃ¤dtische Klinik LÃ¼neburg, LÃ¼neburg, 21339, Germany|Klinik & Poliklinik fÃ¼r Frauenheilkunde und Geburtshilfe, Campus Innenstadt, MÃ¼nchen, 80336, Germany|Klinikum Ernst von Bergmann, Potsdam, 14467, Germany|Leopoldina Krankenhaus der Stadt Schweinfurt GmbH, Schweinfurt, 97422, Germany|Gemeinschaftspraxis fÃ¼r HÃ¤matologie und Onkologie Dr. Reichert/Dr.Janssen, Westerstede, 26655, Germany|Anticancer Hospital Ag. Savas, Athens, 115 22, Greece|Alexandras General Hospital of Athens, Athens, 115 28, Greece|University General Hospital of Heraklion, Crete, 711 10, Greece|University Hospital of Larissa, Larissa, 411 10, Greece|Metropolitan Hospital, Piraeus, 185 47, Greece|European Interbalkan Medical Center, Thessaloniki, 570 01, Greece|Queen Mary Hospital, Hong Kong, 852, Hong Kong|Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong|Tuen Mun Hospital, Hong Kong, Hong Kong|Budapesti Szent Margit Korhaz, Budapest, 1032, Hungary|Orszagos Onkologiai Intezet, Budapest, 1122, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, 4032, Hungary|Rajiv Gandhi Cancer Institute & Research Center, New Delhi, Delhi, 110085, India|Max Super Speciality Hospital, North WEST Delhi, Delhi, 110088, India|Hemato Oncology Clinic Ahmedabad Pvt Ltd, Ahmadabad, Gujarat, 380054, India|Manipal Hospital, Bangalore, Karnataka, 560017, India|Tata Memorial Hospital, Mumbai, Maharashtra, 400012, India|HCG Manavata Cancer Centre, Nashik, Maharashtra, 422002, India|Sahyadri Super Specialty Hospital Hadapsar, Pune, Maharashtra, 411028, India|Christian Med Clg & Hspt, Ratnagiri Kilminnal, Tamil NADU, 632517, India|TATA Medical Centre, Kolkata, WEST Bengal, 700156, India|AORN'S.G.Moscati, Avellino, Campania, 83100, Italy|U.O.C. Oncologia Medica Senologica, Napoli, Campania, 80131, Italy|UniversitÃ  degli Studi Federico II, Napoli, Campania, 80131, Italy|A.O. Universitaria Policlinico Di Modena, Modena, Emilia-Romagna, 41100, Italy|Irccs Centro Di Riferimento Oncologico (CRO), Aviano, Friuli-Venezia Giulia, 33081, Italy|Policlinico Universitario Agostino Gemelli, Roma, Lazio, 00168, Italy|Asst Degli Spedali Civili Di Brescia, Brescia, Lombardia, 25123, Italy|Ospedale San Raffaele, Milano, Lombardia, 20132, Italy|Irccs Istituto Nazionale Dei Tumori (Int), Milano, Lombardia, 20133, Italy|Ospedale Civile - Livorno, Livorno, Toscana, 57124, Italy|Azlenda Ospendaliero-Universitaria Pisana, Pisa, Toscana, 56100, Italy|International Cancer Institute (ICI), Eldoret, 30100, Kenya|Aga Khan University Hospital, Nairobi, 00100, Kenya|Kyungpook National University Medical Center, Daegu, 41404, Korea, Republic of|National Cancer Center, Goyang-si, 10408, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, 13605, Korea, Republic of|Samsung Medical Center, Seoul, (0)6351, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, 03722, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Gangnam Severance Hospital, Seoul, 06273, Korea, Republic of|Seoul St Mary's Hospital, Seoul, 06591, Korea, Republic of|Korea University Guro Hospital, Seoul, 08308, Korea, Republic of|Investigacion Oncofarmaceutica, La Paz, BAJA California SUR, 23040, Mexico|Health Pharma Professional Research, Cdmx, Mexico CITY (federal District), 03100, Mexico|Centro Medico Dalinde, Cdmx, Mexico CITY (federal District), 06760, Mexico|Instituto Nacional De Cancerologia, Distrito Federal, Mexico CITY (federal District), 14000, Mexico|Filios Alta Medicina, Monterrey, Nuevo LEON, 64460, Mexico|Centro de Investigacion Clinica de Oaxaca, Oaxaca de JuÃ¡rez, Oaxaca, 68020, Mexico|Auckland City Hospital, Cancer and Blood Research, Auckland, 1023, New Zealand|Bialostockie Centrum Onkologii, Bialystok, 15-027, Poland|Uniwersyteckie Centrum Kliniczne, Gda?sk, 80-214, Poland|Narodowy Instytut Onkologii Odzia? w Gliwicach, Gliwice, 44-102, Poland|Szpital Uniwersytecki w Krakowie, Oddzia? Kliniczny Kliniki Onkologii, KrakÃ³w, 30-688, Poland|Wielkopolskie Centrum Onkologii, Poznan, 61-866, Poland|Centrum Onkologii Instytut im.M. Sklodowskiej-Curie, Warszawa, 02-781, Poland|Hospital CUF Tejo, Lisboa, 1350-352, Portugal|Hospital de Santa Maria, Lisboa, 1649-035, Portugal|Hospital Beatriz Angelo, Loures, 2674-514, Portugal|IPO do Porto, Porto, 4200-072, Portugal|Filantropia Clinical Hospital, Bucuresti, 021164, Romania|Amethyst Cluj, Cluj County, 407280, Romania|Cluj-Napoca Emergency Clinical County Hospital, Cluj-Napoca, 400006, Romania|Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj-Napoca, Cluj-Napoca, 400015, Romania|Centrul de Oncologie Sfantul Nectarie, Craiova, 200347, Romania|Oncomed SRL, Timisoara, 300239, Romania|Republican Clinical Oncological Dispensary of the Ministry of Healthcare, Kazan, Karelija, 420029, Russian Federation|FSBI Russian Oncology Research Center n.a. Blokhin of MOH RF, Moscow, Moskovskaja Oblast, 115478, Russian Federation|MEDSI Clinical Hospital on Pyatnitsky Highway, Moscow, Moskovskaja Oblast, 143422, Russian Federation|SBIH ""Moscow Clinical Scientific and Practical Center named after A.S. Loginov of DHM"", Moskva, Moskovskaja Oblast, 111123, Russian Federation|Nizhny Novgorod Regional Clinical Oncology Center, Nizhny Novgorod, Niznij Novgorod, 603126, Russian Federation|S-Pb clinical scientific practical center of specialized kinds of medical care (oncological), Saint-Petersburg, Sankt Petersburg, 197758, Russian Federation|Medical Clinic ""AB Medical group"", Sankt-peterburg, Sankt Petersburg, 196006, Russian Federation|SBI of Healthcare Leningrad Regional Oncology Dispensary, St PETERBURG, Sankt Petersburg, 191104, Russian Federation|FSBI?National Medical Research Center of Oncology named after N.N.Petrov? MHRF, St Petersburg, Sankt Petersburg, 197758, Russian Federation|SBIH Kaluga Region Clinical Oncology Dispensary, Kaluga, 248007, Russian Federation|LLC Medical and Sanitary Unit ""Clinician"", Novosibirsk, 630099, Russian Federation|Regional Oncology Dispensary, Tomsk, 634063, Russian Federation|Regional Clinical Oncology Hospital, Yaroslavl, 150040, Russian Federation|National Cancer Centre, Singapore, 168583, Singapore|Hospital General Universitario de Elche, Elche, Alicante, 03203, Spain|Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, 08916, Spain|Corporacio Sanitaria Parc Tauli, Sabadell, Barcelona, 08208, Spain|Hospital de Jerez de la Frontera, Jerez de La Frontera, Cadiz, 11407, Spain|Hospital Alvaro Cunqueiro, Vigo, Pontevedra, 36213, Spain|Hospital Universitario de Canarias, La Laguna, Tenerife, 38320, Spain|Hospital de Basurto, Bilbao, Vizcaya, 48013, Spain|Hospital Universitario ClÃ­nico San Cecilio, Granada, 18016, Spain|Hospital Juan Ramon Jimenez, Huelva, 21005, Spain|Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico, Jaen, 23007, Spain|Hospital General Universitario Gregorio MaraÃ±on, Madrid, 28007, Spain|Hospital Clinico San Carlos, Madrid, 28040, Spain|Hospital Quiron de Madrid, Madrid, 28223, Spain|Hospital Clinico Universitario Virgen de la Victoria, Malaga, 29010, Spain|Hospital Clinico Universitario de Salamanca, Salamanca, 37007, Spain|Hospital Universitario Virgen Macarena, Sevilla, 41009, Spain|Hospital Universitario Virgen del Rocio, Sevilla, 41013, Spain|Hospital ClÃ­nico Universitario de Valencia, Valencia, 46010, Spain|Hospital Universitario Miguel Servet, Zaragoza, 50009, Spain|Chia-Yi Christian Hospital, Chia-Yi, 600, Taiwan|China Medical University Hospital, Taichung, 404, Taiwan|National Cheng Kung Uni Hospital, Tainan, 704, Taiwan|National Taiwan University Hospital, Taipei 100, 100, Taiwan|Taipei Veterans General Hospital, Taipei, 00112, Taiwan|Mackay Memorial Hospital, Taipei, 104, Taiwan|Chulalongkorn Hospital, Bangkok, 10330, Thailand|Ramathibodi Hospital, Bangkok, 10400, Thailand|Srinagarind Hospital, Khon Kaen, 40002, Thailand|Songklanagarind Hospital, Songkla, 90110, Thailand|Adana Baskent University Hospital, Adana, 01120, Turkey|Hacettepe University Medical Faculty, Ankara, 06100, Turkey|Ankara Bilkent City Hospital, Ankara, 06490, Turkey|Gazi University Medical Faculty, Oncology Hospital, Ankara, 06500, Turkey|Memorial Ankara Hastanesi, Ankara, 06520, Turkey|Antalya Training and Research Hospital, Antalya, 07100, Turkey|Ege University Medical Faculty, Bornova, ?zm?r, 35100, Turkey|Dicle University Faculty of Medicine, Diyarbakir, 21280, Turkey|Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi, Edirne, 22030, Turkey|Istanbul Faculty of Medicine, Istanbul, 34093, Turkey|Istanbul University Cerrahpasa Faculty of Medicine, Istanbul, 34098, Turkey|Medeniyet University Goztepe Training and Research Hospital., Istanbul, 34730, Turkey|Katip Celebi University Ataturk Training and Research Hospital, Izmir, 35360, Turkey|Inonu University Medical Faculty of Medicine, Malatya, 44280, Turkey|Medical Park Seyhan Hospital, Seyhan, 01140, Turkey|Ac?badem Altunizade Hastanesi, ÃskÃ¼dar, 34662, Turkey|Uganda Cancer Institute, Kampala, 00256, Uganda|Uzhgorod Central City Clinical Hospital, Uzhhorod, Katerynoslav Governorate, 88000, Ukraine|Municipal Noncommercial Institution Regional Center of Oncology, Kharkiv, Kharkiv Governorate, 61070, Ukraine|Municipal non profit enterprise of Sumy Regional Council Sumy Regional Clinical Oncology Disp, Sumy, Kholm Governorate, 40005, Ukraine|CI Dnipropetrovsk CMCH #4 of Dnipropetrovsk RC SI Dnipropetrovsk MA of MOHU Ch of Oncology and MR, Dnipropetrovsk, 49102, Ukraine|Municipal Institution Kirovograd Regional Oncology Dispensary, Kirovograd, 25011, Ukraine|Kyiv City Clinical Oncological Center, Kyiv, 03115, Ukraine|Blackpool Victoria Hospital, Blackpool, FY3 8NR, United Kingdom|Royal Sussex County Hospital, Brighton, BN2 5BE, United Kingdom|Addenbrookes Hospital, Cambridge, CB2 0QQ, United Kingdom|Cheltenham General Hospital, Cheltenham, GL53 7AN, United Kingdom|Barts & London School of Med, London, EC1A 7BE, United Kingdom|University College London Hospital, London, NW1 - 2PG, United Kingdom|Royal Free Hospital, London, NW3 2QS, United Kingdom|Royal Marsden Hospital - London, London, SW3 6JJ, United Kingdom|Christie Hospital NHS Trust, Manchester, M20 4BX, United Kingdom|Mount Vernon Cancer Centre, Northwood, HA6 2RN, United Kingdom|Royal Preston Hospital, Preston, PR2 9HT, United Kingdom|Royal Cornwall Hospital, Truro, TR1 3LJ, United Kingdom",
NCT05489289,A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection,https://clinicaltrials.gov/study/NCT05489289,,RECRUITING,The efficacy and safety of AK104 as adjuvant therapy in hepatocellular carcinoma of high recurrence risk after curative resection.,NO,Hepatocellular Carcinoma,BIOLOGICAL: AK104|BIOLOGICAL: placebo,"Recurrence free survival (RFS) by BICR, The time comfirmed by BICR from randomization to recurrence or death., Up to 48 months","12-months recurrence free survival (RFS-12), The proportion of patients without recurrence or death at 12 month., 12 months|24-months recurrence free survival (RFS-24), The proportion of patients without recurrence or death at 24 month., 24 months|Time to recurrence (TTR), The time from randomization to recurrence., Up to 48 months|Overall survival (OS), The time from randomization to death for any reason., Up to 48 months|Types and proportions of adverse events (AEs), Up to 48 months",,Akeso,,ALL,"ADULT, OLDER_ADULT",PHASE3,570,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-01-05,2026-01-28,2027-01-01,2022-08-05,,2025-03-12,"Zhongshan Hospital, Fudan University, Shanghai, Shanghai, 200032, China",
NCT04691063,The Study is Being Conducted to Evaluate the Efficacy and Safety of SHR-1316 in Combination With Chemo-radiotherapy in Patients With LS-SCLC.,https://clinicaltrials.gov/study/NCT04691063,,UNKNOWN,The study is being conducted to evaluate the efficacy and safety of SHR-1316 in combination with chemo-radiotherapy in patients with LS-SCLC.,NO,Small-cell Lung Cancer,DRUG: SHR-1316; Carboplatin; Etoposideï¼Radiotherapy|DRUG: Palcebo; Carboplatin; Etoposideï¼Radiotherapy,"OS, Overall Survival, up to 36 months",,,"Jiangsu HengRui Medicine Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,486,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-01-22,2025-05-15,2025-05-15,2020-12-31,,2021-02-26,"Jilin Cancer Hospital, Changchun, Jilin, 130000, China",
NCT06149286,A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma,https://clinicaltrials.gov/study/NCT06149286,OLYMPIA-5,RECRUITING,"This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come back after treatment (called ""relapsed""), or did not respond to treatment (called ""refractory""). FL and MZL are subtypes of Non-Hodgkin 's lymphoma (NHL).

This study will be made up of two parts (Part 1 not randomized, Part 2 randomized - controlled).

The aim of Part 1 of the study is to see how safe and tolerable the study drug is when used in combination with lenalidomide, in participants with FL or MZL, and to determine the dose of the study drug to be used in Part 2 of this study. This combination is considered ""first-in-human"" as it has not been tested as a combination treatment in humans before.

The aim of Part 2, of the study is to assess how the combination of the study drug and lenalidomide works compared to the combination of rituximab (called ""the comparator drug"") and lenalidomide. The combination of comparator drug and lenalidomide is the current standard-of care treatment for FL and/or MZL. Standard of care means the usual medication expected and used when receiving treatment for a condition.

The study is looking at several other research questions, including:

* What side effects may happen from taking the study drug in combination with lenalidomide
* How much study drug is in the blood at different times
* Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
* The impact from the study drug on quality of life and ability to complete routine daily activities",NO,Relapsed/Refractory Follicular Lymphoma|Marginal Zone Lymphoma (MZL),DRUG: Odronextamab|DRUG: Lenalidomide|DRUG: Rituximab,"Incidence of dose limiting toxicities (DLTs) for odronextamab in combination with lenalidomide, Part 1, Up to 35 days|Incidence of treatment emergent adverse events (TEAEs) for odronextamab in combination with lenalidomide, Part 1, Up to 2 years|Severity of TEAEs for odronextamab in combination with lenalidomide, Part 1, Up to 2 years|Progression-free survival (PFS) as assessed by independent central review (ICR) in participants with R/R FL and participants with indolent lymphoma, Part 2, Up to 5 years","Odronextamab concentrations in serum, Part 1 and Part 2, Up to 30 months|Incidence of anti-drug antibodies (ADA) to odronextamab over the study duration, Part 1 and Part 2, Up to 30 months|Titer of ADAs to odronextamab over the study duration, Part 1 and Part 2, Up to 30 months|Incidence of neutralizing antibodies (NAbs) to odronextamab over the study duration, Part 1 and Part 2, Up to 30 months|Best overall response (BOR) as assessed by investigator review, Part 1 and Part 2, Up to 30 months|Duration of response (DOR) as assessed by investigator review, Part 1 and Part 2, Up to 5 years|PFS as assessed by investigator review, Part 1 and Part 2, Up to 5 years|Complete response (CR) as assessed by ICR, Part 2, Up to 30 months|BOR as assessed by ICR, Part 2, Up to 30 months|Overall survival (OS), Part 2, Up to 5 years|Event free survival (EFS) as assessed by ICR, Part 2, Up to 5 years|EFS as assessed by local investigator review, Part 2, Up to 5 years|DOR as assessed by ICR, Part 2, Up to 5 years|Time to next anti-lymphoma treatment (TTNT), Part 2, Up to 5 years|Incidence of TEAEs for odronextamab in combination with lenalidomide versus R2, Part 2, Up to 2 years|Severity of TEAEs for odronextamab in combination with lenalidomide versus R2, Part 2, Up to 2 years|Overall change in patient reported outcomes (PROs) as measured by scores of European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQC30), Part 2 The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a global health status (GHS)/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and global health status/QoL, scores range from 1 = ""very poor"" to 7 = ""excellent"" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = ""not at all"" to 4 = ""very much"" higher scores indicate higher symptom burden., Up to 5 years|Overall change in PROs as measured by scores of Functional Assessment of Cancer Therapy-Lymphoma Subscale (FACT-LymS), Part 2 The FACT-Lym lymphoma subscale (LymS) includes 15 items to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from ""not at all"" (0) to ""very much"" (4). Higher scores are associated with a worse quality of life., Up to 5 years|Overall change in PROs as measured by scores of Patient Global Impression on Severity (PGIS), Part 2 The PGIS includes a single-item to assess how a patient perceives the overall severity of cancer symptoms over the past 7 days. Patients will choose the response that best describes the severity of their overall cancer symptoms with options on a 5-point scale ranging from 1 (No symptoms) to 4 (Very Severe)., Up to 5 years|Overall change in PROs as measured by scores of Patient Global Impression on Change (PGIC), Part 2 The PGIC item includes a single-item to assess how a patient perceives their overall change in health status since the start of study treatment. Patients will choose from response options on a 7-point scale ranging from 1 (Much Better) to 7 (Much worse); 1- Much Better, 2-Moderately Better, 3-A Little Better, 4-About the Same, 5-A Little Worse, 6-Moderately Worse, 7-Much Worse., Up to 5 years|Overall change in PROs as measured by scores of EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L), Part 2 The EQ-5D-5L consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: ""no problems"", ""slight problems"", ""moderate problems"", ""severe problems"" and ""extreme problems"". The EQ VAS records the participant's self-rated health on a vertical visual analogue scale where the endpoints are labeled ""Best imaginable health state"" and ""Worst imaginable health state""., Up to 5 years|Overall change in score of the global population item 5 (GP5) items of the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire, Part 2 A single item (GP5) of the validated FACT-G questionnaire will be used to assess from the participant perspective the overall impact of treatment side-effect. The question item is on a 5-point scale ranging from ""not at all"" (0) to ""very much"" (4)., Up to 5 years",,Regeneron Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,470,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-12-28,2029-01-23,2029-01-23,2023-11-28,,2025-05-31,"David Geffen School of Medicine at UCLA, Los Angeles, California, 90095, United States|Boca Raton Clinical Research (BRCR) Global, Plantation, Florida, 33322, United States|Indiana University and Comprehensive Cancer Center, Indianapolis, Indiana, 46202, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, 39401, United States|Stony Brook University Hospital, Stony Brook, New York, 11794, United States|Clinical Research Alliance Inc, Westbury, New York, 11590, United States|Prohealth Care Inc, Waukesha, Wisconsin, 53188, United States|Liverpool Hospital, Liverpool, New South Wales, 2136, Australia|Calvary Mater Newcastle, Waratah, New South Wales, 2298, Australia|Pindara Private Hospital, Benowa, Queensland, 4217, Australia|Epworth Freemasons, East Melbourne, Victoria, 3121, Australia|Ordensklinikum Linz, Linz, Osterreich, 4010, Austria|Kepler University Hospital, Linz, Upper Austria, 4020, Austria|Medical University Vienna, Vienna, 1190, Austria|Klinikum Wels Grieskirchen, Wels, 4600, Austria|Universitair Ziekenhuis (UZ) Gent/ Ghent University Hospital, Gent, Oost-Vlaanderen, 9000, Belgium|Az Delta, Roeselare, West Vlaanderen, 8800, Belgium|Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp, 2060, Belgium|Institut Jules Bordet, Brussels, 1000, Belgium|Centre Hospitalier Universitaire at Universite Catholique de Louvain Namur, Yvoir, 5530, Belgium|University Hospital Hradec Kralove, Hradec Kralove, East Bohemia, 50005, Czechia|University Hospital Kralovske Vinohrady, Prague, 10034, Czechia|Vseobecna Fakultni Nemocnice V Praze, Praha, 12808, Czechia|Institut Paoli-Calmettes, Marseille, Bouches Du Rhone, 13009, France|Centre Hospitalier Universitaire de Rennes, Rennes, Bretagne, 35033, France|Centre Hospitalier Regional Universitaire de Tours, Tours, Centre Val De Loire, 37044, France|Polyclinique Bordeaux Nord Aquitaine, Bordeaux Cedex, Gironde, 33077, France|Centre Francois Magendie, Pessac, Gironde, 33600, France|Hopital Victor Dupouy Argenteuil, Argenteuil, Ile De France, 95100, France|Avicenne Hospital, Bobigny, Ile De France, 93000, France|Hopital Saint Vincent de Paul, Lille, Nord, 5900, France|Centre Henri Becquerel, Rouen, Normandie, 76038, France|Nantes University Hospital, Nantes, Pays De La Loire, 44093, France|Centre Hospitalier Metropole Savoie, Chambery, Savoie, 73000, France|Gustave Roussy, Villejuif, Val De Marne / Ile De France, 94805, France|Centre Hospitalier d'Avignon, Avignon, 84000, France|Centre Hospitalier Universitaire (CHU) Montpellier, Montpellier, 34290, France|Hopital Saint Louis, Paris, 75010, France|Assistance Publique-Hopitaux de Paris (AP-HP), Paris, 75571, France|Stauferklinikum, Mutlangen, Baden-Wuerttemberg, 73557, Germany|Robert-Bosch-Krankenhaus, Stuttgart, Baden-Wurttemberg, 70376, Germany|Clinic Frankfurt (Oder), Frankfurt, Hesse, 15236, Germany|Stadtisches Krankenhaus Kiel, Kiel, 24116, Germany|Assuta Ashdod Medical Center, Ashdod, 7747629, Israel|Hadassah Medical Center, Jerusalem, 91200, Israel|Galilee Medical Center, Nahariya, 2210001, Israel|Rabin Medical Center, Petah Tikva, 49100, Israel|Chaim Sheba Medical Center, Ramat-Gan, 5265601, Israel|Assuta Medical Centers, Tel Aviv, 6971028, Israel|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Forli Cesena, 47014, Italy|S Gerardo Hospital, Monza, Monza E Brianza, 20900, Italy|Centro Di Riferimento Oncologico (CRO), Aviano, National Cancer Institute, Aviano, Province Of Pordenone, 33081, Italy|Candiolo Cancer Institute, FPO, IRCCS, Candiolo, Torino, 10060, Italy|University of Bologna Dipartimento di Medicina Specialistica Diagnostica e Sperimentale, Bologna, 40138, Italy|Azienda Ospedaliera Spedali Civili di Brescia, Brescia, 25123, Italy|Ospedale Policlinico San Martino IRCCS, Genova, 16132, Italy|Istituto Europeo di Oncologia, Milano, 20141, Italy|ASST Grande Ospedale Metropolitano Niguarda - Main Address, Milan, 20162, Italy|A.O.U. di Modena, Modena, 41124, Italy|Federico II University, Napoli, 80131, Italy|AOU Maggiore della Carita, Novara, 28100, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, 27100, Italy|Azienda Ospedaliera di Perugia, Perugia, 06132, Italy|Ospedale Santa Maria delle Croci, Ravenna, 48121, Italy|Santa Maria della Misericordia, Udine, 33100, Italy|St. Vincents Hospital - The Catholic University of Korea, Suwon-si, Gyeonggi-do, 16247, Korea, Republic of|Jeonbuk National University Hospital, Jeonju, Jeollabuk, 54907, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Namdong-Gu, 21565, Korea, Republic of|Inje University Busan Paik Hospital, Busan, 47392, Korea, Republic of|Pusan National University Hospital, Busan, 49241, Korea, Republic of|Yeyungnam University Medical Center, Daegu, 42415, Korea, Republic of|Yonsei University Health System, Seoul, 03722, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|Yeouido St. Marys Hospital, Seoul, 07345, Korea, Republic of|Seoul St Marys Hospital, Seoul, 137-701, Korea, Republic of|Seoul National University Hospital, Seoul, 3080, Korea, Republic of|Ulsan University Hospital, Ulsan, 44033, Korea, Republic of|Hospital Sultanah Aminah Jhor Bahru, Johor Bahru, Johor, 80100, Malaysia|University of Malaya Medical Centre, Kuala Lumpur, Negeri / Wilayah Persekutuan, 50603, Malaysia|Hospital Queen Elizabeth, Kota Kinabalu, Sabah, 88586, Malaysia|Hospital Ampang, Ampang, Selangor, 68000, Malaysia|Subang Jaya Medical Center, Subang Jaya, Selangor, 47500, Malaysia|Uniwersytecki Szpital Kliniczny, Wroclaw, Dolnoslaskie, 50-367, Poland|Specjalistyczny Szpital im A. Sokolowskiego w Walbrzychu, Walbrzych, Lower Silesian, 58-309, Poland|Pratia MCM Krakow, Krakow, Malopolska, 30-510, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, Pomorskie, 80-952, Poland|Pratia Poznan Medical Center, Poznan, Wielkopolska, 60185, Poland|Aidport, Skorzewo, Wielkopolska, 60185, Poland|Szpital Uniwersytecki Nr2 Bydgoszcz, Bydgoszcz, 85-168, Poland|Pratia Onkologia Katowice, Katowice, 40-519, Poland|Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. Mikolaja Kopernika w Lodzi (Copernicus Memorial Hospital), Lodz, 93-513, Poland|Uniwersytecki Szpital Kliniczny Nr 4 w Lublinie, Centrum Innowacyjnych Terapii, Lublin, 20-090, Poland|Narodowy Instytut Onkologii - Clinical Study Location -, Warsaw, 02-781, Poland|University Hospital of Santiago de Compostela, Santiago de Compostela, A Coruna, 15706, Spain|Hospital Universitario Central de Asturias, Oviedo, Asturias, 33011, Spain|Son Espases University Hospital, Palma, Balearic Islands, 07120, Spain|Hospital Universitario Marques de Valdecilla, Santander, Cantabria, 39008, Spain|Hospital Universitario Quironsalud Madrid, Pozuelo de Alarcon, Madrid, 28223, Spain|University Hospital Vall d'Hebron, Barcelona, 08035, Spain|Hospital Clinic de Barcelona, Barcelona, 08036, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, 08041, Spain|Hospital Virgen De Las Nieves De Granada, Granada, 18014, Spain|Hospital Universitario Ramon y Cajal, Madrid, 28034, Spain|Fundacion Jimenez Diaz University Hospital, Madrid, 28040, Spain|Hospital Universitario12 de Octubre, Madrid, 28041, Spain|Hospital Universitario HM Sanchinarro, Servicio de Hematologia, Madrid, 28050, Spain|Hospital Universitario de Salamanca, Salamanca, 37007, Spain|University Hospital Virgen del Rocio, Seville, 41013, Spain|Instituto Valenciano de Oncologia, Valencia, 46009, Spain|University Hospital Doctor Peset, Valencia, 46017, Spain|Chang Gung Medical Foundation Chia Yi Branch, Puzi City, Chiayi County, 613, Taiwan|Changhua Christian Hospital, Changhua city, 500-06, Taiwan|Show Chwan Memorial Hospital, Changhua City, 50008, Taiwan|Kaohsiung Medical University Hospital, Kaohsiung, 80756, Taiwan|Taipei Medical University - Shuang Ho Hospital, New Taipei City, 23561, Taiwan|National Cheng Kung University Hospital, Tainan City, 701, Taiwan|National Taiwan University Hospital, Taipei City, 10002, Taiwan|Tri-Service General Hospital, Taipei City, 114, Taiwan|Taipei Veterans General Hospital, Taipei, 11217, Taiwan|Taipei Municipal Wan Fang Hospital, Taipei, 116, Taiwan|Chang Gung Memorial Hospital, Taoyuan City, 333, Taiwan|Chulalongkorn University, Bangkok, Krung Thep Maha Nakhon [Bangko], 10330, Thailand|Sriraj Hospital, Bangkok, 10700, Thailand|Chiang Mai University, Chiang Mai, 50200, Thailand|Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Yenimahalle, Ankara, 06200, Turkey|Gazi University, Ankara, Central Anatolia, 06100, Turkey|VM Medical Park Mersin Hospital, Mezitli, Mersin, 33200, Turkey|Tekirdag Namik Kemal University Hospital, Tekirdag, Suleymanpasa, 59100, Turkey|Istanbul University, Istanbul Medical Faculty, Istanbul, 34093, Turkey|Ege University, Izmir, 35100, Turkey|Dokuz Eylul University, Izmir, 35340, Turkey|Sakarya University Medical Faculty, Sakarya, 54290, Turkey|Ondokuz Mayis Universitesi Tip Fakultesi Hastanesi, Samsun, 55270, Turkey|Zonguldak Bulent Ecevit Univesity, Zonguldak, 67600, Turkey|Royal Cornwall Hospital NHS Trust, Truro, Cornwall, TR1 3HD, United Kingdom|Derriford Hospital and the Royal Eye Infirmary, Plymouth, Devon, PL6 8DH, United Kingdom|University Hospitals Dorset, Bournemouth, Dorset, BH7 7DW, United Kingdom|Barking, Havering and Redbridge University Hospitals NHS Trust, Romford, Essex, RM7 0AG, United Kingdom|Salisbury Foundation Trust, Salisbury, Hampshire, SP6 2ND, United Kingdom|The Hillingdon Hospital, Uxbridge, Middlesex, UB8 3NN, United Kingdom|James Paget University Hospitals Nhs Foundation Trust, Great Yarmouth, NR31 6LA, United Kingdom|South Warwickshire NHS Foundation Trust, Warwick, CV34 5BW, United Kingdom",
NCT07000149,A Study to Investigate the Efficacy and Safety of Volrustomig Â± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC,https://clinicaltrials.gov/study/NCT07000149,eVOLVE-RCC02,NOT_YET_RECRUITING,"This is a Phase Ib/III, randomized, multicenter, global study evaluating the efficacy and safety of volrustomig in combination with casdatifan for the first-line (1L) treatment of participants with advanced clear cell renal cell carcinoma (ccRCC).",NO,Advanced Clear Cell Renal Cell Carcinoma,DRUG: Volrustomig|DRUG: Casdatifan|DRUG: Nivolumab|DRUG: Ipilimumab,"Phase Ib: Number of participants with adverse events (AEs) and serious adverse events (SAEs), Number of participants who received at least one dose of study treatment will be assessed., Approximately 39 months|Phase III: Progression-free Survival (PFS), The PFS is defined as the time from randomization until radiological progression or death due to any cause (in the absence of progression)., Approximately 38 months|Phase III: Overall Survival (OS), The OS is defined as the time from randomization until the date of death due to any cause., Approximately 67 months","Phase Ib: Objective Response rate (ORR), The ORR is defined as the proportion of participants who have a confirmed complete response (CR) or confirmed partial response (PR)., Approximately 39 months|Phase Ib: Duration of Response (DoR), The DoR is defined as the time from the date of first documented confirmed response until date of documented progression or death due to any cause., Approximately 39 months|Phase Ib: Progression-free Survival (PFS), The PFS is defined as the time from randomization until radiological progression or death due to any cause (in the absence of progression)., Approximately 39 months|Phase Ib: Disease Control Rate (DCR), The DCR is defined as the percentage of participants who have a confirmed CR or PR or who have stable disease (SD) after randomization., Approximately 39 months|Phase Ib: Volrustomig concentration in serum, To assess the serum concentration of volrustomig when administered concomitantly with casdatifan., Up to 27 months|Phase Ib: Casdatifan concentration in plasma, To assess the plasma concentration of casdatifan when administered concomitantly with volrustomig., Up to 27 months|Phase Ib: Time to Response (TTR), The TTR is defined as the time from randomization until the first documentation of a subsequently confirmed objective response., Approximately 39 months|Phase III: Overall Survival, The OS is defined as the time from randomization until the date of death due to any cause., Approximately 67 months|Phase III: Number of participants with AEs and SAEs, Number of participants who received at least one dose of study treatment will be assessed., Approximately 67 months|Phase III: Time to second progression or death (PFS2), The PFS2 is defined as the time from randomization to the earliest progression event after the start of the first subsequent therapy, or death from any cause, whichever occurs first., Approximately 67 months|Phase III: Objective Response rate (ORR), The ORR is defined as the proportion of participants who have a confirmed CR or confirmed PR., Approximately 67 months|Phase III: Duration of Response (DoR), The DoR is defined as the time from the date of first documented confirmed response until date of documented progression or death due to any cause., Approximately 67 months|Phase III: Progression-free Survival, The PFS is defined as the time from randomization until radiological progression or death due to any cause (in the absence of progression)., Approximately 67 months",,AstraZeneca,"Arcus Biosciences, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE3,1116,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2025-07-08,2030-02-21,2032-07-29,2025-06-02,,2025-06-02,,
NCT06789796,a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy.,https://clinicaltrials.gov/study/NCT06789796,,NOT_YET_RECRUITING,"The study is being conducted to evaluate the efficacy and safety of QL1706 versus QL1604 monotherapy as consolidation treatment in patients with limited-stage small cell lung cancer (LS-SCLC) who have not experienced disease progression after concurrent or sequential chemoradiotherapy.

QL1706 (Iparomlimab and Tuvonralimab) is a single bifunctional MabPair product against PD-1 and CTLA-4. QL1604 is a monoclonal antibody against PD-1.",NO,Small-cell Lung Cancer,DRUG: Iparomlimab and Tuvonralimab (QL1706)|DRUG: placebo for QL1604|DRUG: QL1604|DRUG: placebo for Iparomlimab and Tuvonralimab (QL1706),"Progression-free survival (PFS), To compare and evaluate the efficacy of QL1706 versus QL1604 as consolidation therapy after chemoradiotherapy (CRT) for patients with LS-SCLC as measured by Blinded Independent Review Committee (BIRC)-assessed PFS, up to 2 years|Overall survival (OS), To compare and evaluate the efficacy of QL1706 versus QL1604 as consolidation therapy after CRT for patients with LS-SCLC as measured by OS, up to 5 years","objective response rate (ORR), To compare and evaluate the efficacy of QL1706 versus QL1604 as consolidation therapy after CRT for patients with LS-SCLC as measured by ORR, up to 2 years|disease control rate (DCR), To compare and evaluate the efficacy of QL1706 versus QL1604 as consolidation therapy after CRT for patients with LS-SCLC as measured by DCR, up to 2 years|duration of response (DoR), To compare and evaluate the efficacy of QL1706 versus QL1604 as consolidation therapy after CRT for patients with LS-SCLC as measured by DoR, up to 2 years|PFS, To compare and evaluate the efficacy of QL1706 versus QL1604 as consolidation therapy after CRT for patients with LS-SCLC as measured by Investigator-assessed PFS, up to 2 years|1-year OS rate, To compare and evaluate the efficacy of QL1706 versus QL1604 as consolidation therapy after CRT for patients with LS-SCLC as measured by 1-year OS rate, up to 1 year|2-year OS rate, To compare and evaluate the efficacy of QL1706 versus QL1604 as consolidation therapy after CRT for patients with LS-SCLC as measured by 2-year OS rate, up to 2 years|adverse events, To compare and evaluate the safety of QL1706 versus QL1604 as consolidation therapy after CRT for patients with LS-SCLC as measured by the incidence of adverse events (Percentage of participants with treatment-related adverse events as assessed by CTCAEv5.0.) and abnormal laboratory parameters., up to 2 years",,"Qilu Pharmaceutical Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,636,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2025-02,2028-03,2030-03,2025-01-23,,2025-02-11,,
NCT04316364,A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC,https://clinicaltrials.gov/study/NCT04316364,,RECRUITING,"This trial is designed to evaluate the efficacy, safety and immunogenicity of neoadjuvant treatment with monoclonal antibody SHR-1316 or placebo in combination with platinum doublet chemotherapy in participants with resectable Stage II, IIIA, or selected IIIB non-small cell lung cancer (NSCLC) followed by adjuvant SHR-1316 or placebo and monitoring.",NO,Non-Small-Cell Lung Cancer,DRUG: SHR-1316ãPaclitaxel (Albumin Bound)ãCarboplatin|DRUG: SHR-1316ãChemotherapeutic|DRUG: PlaceboãChemotherapeutic,"Major pathological response rate (MPR), At time of surgery|Event free survival (EFS), Approximately 66 months","Overall survival (OS), Approximately 96 months|Pathology complete response (pCR), At time of surgery|Objective response rate (ORR), prior to surgery|Disease-Free Survival (DFS), Approximately 66 months",,"Jiangsu HengRui Medicine Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,537,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-07-14,2023-04-15,2026-12-15,2020-03-20,,2021-11-04,"Beijing Cancer Hospital, Beijing, Beijing, 100000, China|Guangdong Provincial People's Hospital, Guangzhou, Guangdong, 510000, China|Henan Cancer Hospital, Zhengzhou, Henan, 450000, China|JiangSu Cancer Hospital, Nanjing, Jiangsu, 210009, China|Zhongshan Hospital, Fudan University, Shanghai, Shanghai, 200032, China|West China Hospital,Sichuan University, Chengdu, Sichuan, 610041, China|ZheJiang Cancer Hospital, Hangzhou, Zhejiang, 310022, China",
NCT04691804,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer",https://clinicaltrials.gov/study/NCT04691804,,ACTIVE_NOT_RECRUITING,To evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line treatment by assessment of radiographic progression-free survival (rPFS) in mCRPC subjects unselected for deoxyribonucleic acid (DNA) damage repair deficiencies (DRD) status (Cohort 1) to evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line treatment by assessment of rPFS in mCRPC subjects harboring DRD (Cohort 2).,NO,Metastatic Castration-Resistant Prostate Cancer (mCRPC),"DRUG: Fuzuloparib , Abiraterone acetate and Prednisone|DRUG: Fuzuloparib Placeboï¼ Abiraterone acetate and Prednisone","rPFS by blinded independent central review (BICR) using RESIST1.1 and PCWG3, progression-free survival, up to 3 years","OS, time from randomization to death due to any cause, up to 4 years|ORR, The percentage of subjects with measureable disease at baseline who achieved a complete or partial response in their soft tissue disease using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, up to 3 years|Time to PSA progression, Time from randomisation to the first time of PSA progression according to the criterion of PCGW3, up to 3 years|Time to skeletal-related events, Time from randomisation to the first occurrence of a fracture or treatment for the fracture. The skeletal-related event is defined as the occurrence of either pathological or clinical fracture, spinal cord compression, bone-related radiotherapy or surgery., up to 4 years",,"Jiangsu HengRui Medicine Co., Ltd.",,MALE,"ADULT, OLDER_ADULT",PHASE3,496,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-03-18,2026-12-31,2026-12-31,2020-12-31,,2024-12-31,"Alaska Oncology and Hematology LLC, Anchorage, Alaska, 99508, United States|Urological Associates of Southern Arizona PC, Tucson, Arizona, 85741, United States|Desert Hematology Oncology Medical Group Inc, Rancho Mirage, California, 92270, United States|San Bernardino Urological Associates Medical Group, San Bernardino, California, 92404, United States|UF College of Medicine - Jacksonville, Jacksonville, Florida, 32209, United States|Hematology Oncology Clinic, Baton Rouge, Louisiana, 70809, United States|VA Maryland Health Care System, Baltimore, Maryland, 21201, United States|Johns Hopkins, Baltimore, Maryland, 21287, United States|Henry Ford Health System, Detroit, Michigan, 48202, United States|GU Research Network LLC, Omaha, Nebraska, 68130, United States|John Theurer Cancer Center, Hackensack, New Jersey, 76011, United States|Weill Cornell Medicine, New York, New York, 10021, United States|Messino Cancer Centers, Asheville, North Carolina, 28806, United States|Gabrail Cancer Center Research, Canton, Ohio, 44718, United States|Carolina Urologic Research Center, LLC, Myrtle Beach, South Carolina, 29572, United States|Tennessee Oncology, Chattanooga, Tennessee, 37404, United States|Center for Onology and Blood Disorders, Houston, Texas, 77030, United States|Bendigo Health, Bendigo, Australia|Concord Repatriation General Hospital, Concord, Australia|St Vincents Hospital Melbourne, Fitzroy, Australia|Gosford Hospital, Gosford, Australia|Ashford Cancer Centre Research, Kurralta Park, Australia|The Alfred Hospital, Melbourne, Australia|Western Health, St Albans, Australia|Macquarie University, Sydney, Australia|Riverina Cancer Care Centre, Wagga Wagga, Australia|Sydney Adventist Hospital, Wahroonga, Australia|UZ Gent, Gent, Belgium|Centre Hospitalier de Jolimont, Haine Saint Paul, Belgium|AZ Groeninge, Kortrijk, Belgium|Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China|Beijing cancer hospital, Beijing, China|Beijing Friendship Hospital, Beijing, China|Beijing Hospital, Beijing, China|Cancer hospital Chinese academy of medical science, Beijing, China|Hunan Cancer Hospital, Changsha, China|XiangYa hospital central south university, Changsha, China|Sichuan Provincial People's Hospital, Chengdu, China|West China Hospital of Sichuan University, Chengdu, China|Chongqing Cancer Hospital, Chongqing, China|The First Affiliated Hospital of Chongqing Medical University, Chongqing, China|Fujian Medical University Union Hospital, Fuzhou, China|The First affiliatared hospital of Fujian medical university, Fuzhou, China|Cancer Center, Sun Yat-sen University, Guangzhou, China|Sun Yet-Sen Memorial Hospital,Sun Yet-Sen University, Guangzhou, China|Affiliated Hospital of Guizhou Medical University, Guiyang, China|Guizhou Cancer Hospital, Guiyang, China|Urology Ward 2ï¼Harbin Medical University Cancer Hospital, Ha'erbin, China|The First Affiliated Hospitalï¼ZheJiang University School of Medicine, Hangzhou, China|ZheJiang Provincial People's Hospital, Hangzhou, China|Anhui Provincial Hospital, Hefei, China|The First Affiliated Hospital Of Anhui Medical University, Hefei, China|The Second Hospital Of Anhui Medical University, Hefei, China|The First Hospital of Jiaxing, Jiaxing, China|Qilu Hospital of Shandong University, Jinan, China|Shandong Provincial Hospital, Jinan, China|Yunnan Cancer Hospital, Kunming, China|The First Affiliated Hospital of Nanchang University, Nanchang, China|The Second Affiliated Hospital of Nanchang University-DepartmentDepartment of Urology, Nanchang, China|JiangSu Cancer Hospital, NanJing, China|Jiangsu Province Hospitall, NanJing, China|Nanjing Drum Tower Hospital, NanJing, China|The first affiliated hospital of guangxi medical university, Nanjing, China|ZhongDa hospital southeast university, Nanjing, China|Qingdao Municipal Hospital, Qingdao, China|Changhai Hospital of Shanghai-Department of Urology, Shanghai, China|Shanghai Tenth People's Hospital-Department of Urology, Shanghai, China|The Urology Surgery department of Zhongshan Hospital, ShangHai, China|Liaoning Cancer Hospital, Shenyang, China|The Fourth Hospital of Hebei Medical University, Shijiazhuang, China|First Hospital of Shanxi Medical University, Taiyuan, China|Shanxi Provincial Cancer Hospital, Taiyuan, China|The Second Hospital Of TianJin medical University, Tianjin, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, China|The Affiliated Tumor Hospital of Xinjiang Medical University-Department of Urology, Urumqi, China|The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China|The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China|Tongji Hospital of Tongji Medical College,Huazhong University of Science and Technology, Wuhan, China|Union Hospital of Tongji Medical College,Huazhong University of Science and Technology, Wuhan, China|Wuxi People's Hospital-Department of Urinary Surgery, WuXi, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China|The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China|The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China|Northern Jiangsu People's Hospital, YangZhou, China|Henan Cancer Hospital, Zhengzhou, China|Henan Provincial People's Hospital, Zhengzhou, China|Nemocnice Novy Jicin a.s., Novy Jicin, Czechia|Thomayerova Nemocnice, Prague, Czechia|Centre Hospitalier Departemental Vendee CHD, La Roche-sur-Yon, France|CHRU de Lille Hopital Claude Huriez, Lille, France|Centre Leon Berard, Lyon, France|Centre Hospitalier Universitaire de Nimes, Institut de Cancerologie du Gard, Nimes, France|Hopital Europeen George Pompidou, Paris, 75908, France|Hopital Lyon Sud, Pierre-Benite, France|Centre Eugenie Marquis, Rennes, France|Centre de Lutte Contre le Cancer (CLCC) - Institut de Cancerologie de l'Ouest (ICO) - Rene Gauducheau, Saint-Herblain, France|Strasbourg Oncologie Liberale- Clinique Sainte Anne, Strasbourg, France|Institut Univ du Cancer de Toulouse-Oncopole, Toulouse, France|National Institute of Oncology, Budapest, Hungary|Semmelweis Egyetem, Budapest, Hungary|Bekes Megyei Kozponti Korhaz, Gyula, Hungary|BKMK Hospital, KecskemÃ©t, Hungary|Szent Borbala Korhaz, Tatabanya, Hungary|National Cancer Center, Goyang, Korea, Republic of|CHA Bundang Medical Center CHA University, Seongnam, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of|Szpitale Pomorskie Sp.zo.o, Gdynia, Poland|Regionalny Szpital Specjalistyczny im.dr. Wladyslawa Bieganskiego, Grudziadz, Poland|Clinical Research Center Sp. z o.o., Kobylniki, Poland|Szpital Wojewdzki w Koszalinie im. Mikoaja Kopernika, Koszalin, Poland|University Hospital, Krakow, Poland|Szpital Kliniczny Nr Pozna?, Poznan, Poland|Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie w Warszawie, Warszawa, Poland|Dolnoslaskie Centrum Onkologii - Lower Silesian Oncology Center, Wroclaw, Poland|Ivanovo Regional Oncology Dispensary, Ivanovo, Russian Federation|Hertzen Moscow Oncology Research Center, Moscow, Russian Federation|Institution of the Russian Academy of Medical Sciences Russian Oncological Research Center n.a. N.N. Blokhin, Moscow, Russian Federation|Budgetary Healthcare Institution of Omsk Region - Clinical Oncological Dispensary, Omsk, Russian Federation|Bashkortostan Republican Clinical Oncology Dispensary, Ufa, Russian Federation|Hospital Provincial de CastellÃ³n, CastellÃ³ de la Plana, CastellÃ³n, 12002, Spain|Hospital del Mar, Barcelona, 08003, Spain|Hospital Clinico de Barcelona, Barcelona, Spain|Hospital Universitari Parc Tauli, Barcelona, Spain|Hospital Universitario Reina SofÃ­a, CÃ³rdoba, 14004, Spain|Instituto CatalÃ¡n de OncologÃ­a - Hospital Universitario Dr. Josep Trueta, Girona, 17007, Spain|Hospital Clinico Universitario San Carlos, Madrid, Spain|Hospital General Universitario Gregorio Marano, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Virgen de la Victoria, MÃ¡laga, 29017, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Fundacion Instituto Valenciano de Oncologia IVO, Valencia, Spain|Changhua Christian Hospital, Changhua, Taiwan|Kaohsiung Medical University - Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|Tungs Taichung Metro Harbor Hospital, Taichung, Taiwan|Chi Mei Medical Center, Tainan, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital NTUH, Taipei, Taiwan|Chang Gung Memorial Hospital CGMH - Linkou Branch, Taoyuan, Taiwan|Imperial College Healthcare NHS Trust, London, United Kingdom|Sarah Cannon Research Institute UK, London, United Kingdom|University College London Hospital, London, United Kingdom|Genesis Cancer Care-CHURCHILL Hospital Headington, Oxford, OX4 6LB, United Kingdom|Royal Marsden Hospital, Sutton, United Kingdom",
NCT06581380,JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT06581380,,NOT_YET_RECRUITING,This study was designed to compare the efficacy and safety of JK-1201I with Topotecan in patients with relapsed extensive stage small cell lung cancer (ES SCLC).,NO,Small Cell Lung Cancer,DRUG: JK-1201I|DRUG: Topotecan,"Overall survival (OS), Overall survival is defined as the time interval from randomization to death due to any cause., From the date of randomization to the date of death due to any cause; Up to approximately 3.5 years.","Objective Response Rate (ORR) Assessed by Independent Response Evaluation Committee (IREC) and Investigators, Confirmed ORR is defined as the proportion of participants who have achieved a best overall response of confirmed complete response (CR), confirmed partial response (PR) per IREC and investigator per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1., From the date of randomization to documented progressive disease, death, lost to follow-up, or withdrawal by the participant; Up to approximately 3.5 years.|Disease Control Rate (DCR) Assessed by Independent Response Evaluation Committee (IREC) and Investigators, Disease control rate is defined as the proportion of participants who have achieved a best overall response of confirmed CR, confirmed PR, or SD (or non-CR/non-PD) per IREC and investigator per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1., From the date of randomization to documented progressive disease, death, lost to follow-up, or withdrawal by the participant; Up to approximately 3.5 years.|Duration of Response (DoR) Assessed by Independent Response Evaluation Committee (IREC) and Investigators, Duration of response (DoR) is defined as the time from the date of the first documentation of objective response (complete response \[CR\] or partial response \[PR\]) to the date of the first documentation of progressive disease (PD) or death., From the date of first documentation of confirmed response (CR or PR) to the first documentation of progressive disease or death due to any cause, whichever occurs first; Up to approximately 3.5 years.|Progression-free Survival (PFS) Assessed by Independent Response Evaluation Committee (IREC) and Investigators, Progression-free Survival (PFS) is defined as the time interval from the randomization to disease progression as per Independent Response Evaluation Committee (IREC) and Investigators assessment or death due to any cause., From the date of randomization to documented progressive disease, death, lost to follow-up, or withdrawal by the participant; Up to approximately 3.5 years.|Incidence and Grade of Participants with Adverse Events (AE), Adverse Events (AEs) are assessed based on NCI CTCAE v5.0., From the date of first dose to the end of safety follow-up; Up to approximately 3.5 years|Pharmacokinetic Parameter Area Under the Plasma Concentration-Time Curve for JK-1201I, Irinotecan, SN38 and SN38G, Area under the plasma concentration-time curve up to the last quantifiable time point (AUClast) and area under the plasma concentration-time curve dosing interval (AUCtau) will be assessed using Non-linear mixed effect modeling in 80 participants randomized to JK-1201 group., Cycle 1 before infusion, and 12, 168, and 240 hours (hrs) post dose; every 2 cycles before infusion, and 12 hrs post dose thereafter up to 3.5 years (each cycle is 21 days)|Pharmacokinetic Parameter Maximum Concentration for JK-1201I, Irinotecan, SN38 and SN38G, Maximum concentration (Cmax) will be assessed using Non-linear mixed effect modeling in 80 participants randomized to JK-1201 group., Cycle 1 before infusion, and 12, 168, and 240 hours (hrs) post dose; every 2 cycles before infusion, and 12 hrs post dose thereafter up to 3.5 years (each cycle is 21 days)",,"JenKem Technology Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,394,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-09-16,2027-11-16,2028-04-16,2024-09-03,,2024-09-03,,
NCT03573401,Study to Evaluate the Safety and Efficacy of BF-200 ALA (AmeluzÂ®) and BF-RhodoLEDÂ® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).,https://clinicaltrials.gov/study/NCT03573401,,ACTIVE_NOT_RECRUITING,The aim of this study is to test the safety and efficacy of photodynamic therapy (PDT) with the medication AmeluzÂ® performed with the PDT-lamp BF-RhodoLEDÂ® in comparison to the respective placebo treatment for superficial basal cell carcinoma (BCC).,YES,Superficial Basal Cell Carcinoma,"COMBINATION_PRODUCT: Photodynamic therapy (PDT) (ALA-PDT, AmeluzÂ®-PDT)|COMBINATION_PRODUCT: Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)","Composite Clinical and Histological Response of the Subject's Main Target Lesion as Assessed 12 Weeks After the Start of the Last PDT Cycle That Included Treatment of the Main Target Lesion., Each subject had one Main Target Lesion. The composite clinical and histological response rate of the subjects' Main Target Lesions is the percentage of subjects with a clinically and histologically cleared Main Target lesion 12 weeks after the start of the last PDT cycle that included treatment of the Main Target Lesion (Visit 5 or Visit 8)., 12 weeks after the start of the last PDT cycle that included treatment of the Main Target Lesion","Main Target Lesion Clinical Response Rate (According to Clinical Assessment Only) Assessed 12 Weeks After the Start of the Last PDT Cycle, 1. Key secondary endpoint: Percentage of Main Target Lesions with complete clinical clearance (i.e. according to clinical assessment only) 12 weeks after the start of the last PDT cycle., 12 weeks after the start of the last PDT cycle|Main Target Lesion Histological Response Rate (According to Histological Assessment Only) Assessed 12 Weeks After the Start of the Last PDT Cycle, 2. Key secondary endpoint: Percentage of Main Target Lesions with complete histological clearance (i.e. according to histological assessment only) 12 weeks after the start of the last PDT cycle., 12 weeks after the start of the last PDT cycle|Subject Complete Clinical Response (Complete Clearance of All Target Lesions According to Clinical Assessment Only) Assessed 12 Weeks After the Start of the Last PDT Cycle., 3. Key secondary endpoint: Percentage of subjects with complete clinical clearance of all Target Lesions (i.e. according to clinical assessment only) 12 weeks after the start of the last PDT cycle., 12 weeks after the start of the last PDT cycle|Subject Complete Response (Clinically and Histologically Cleared Main Target Lesion (See Above) and Complete Clinical Remission of All Additional Target Lesions) Assessed 12 Weeks After the Start of the Last PDT Cycle., 4. Key secondary endpoint: Percentage of subjects with complete clinical and histological clearance of the Main Target Lesion and complete clinical clearance of all Additional Target Lesions 12 weeks after the start of the last PDT cycle, 12 weeks after the start of the last PDT cycle|Lesion Complete Clinical Response Rate Per Treatment Arm (Complete Clearance of Individual Lesions (Main and Additional Target Lesions)) According to Clinical Assessment Only, Assessed 12 Weeks After the Start of the Last PDT Cycle., Further secondary endpoint: Percentage of Individual Target Lesions that are completely clinically cleared per treatment arm 12 weeks after the start of the last PDT cycle., 12 weeks after the start of the last PDT cycle|Main Target Lesion Complete Response (Clinically and Histologically Cleared) Assessed 12 Weeks After PDT-1., Further secondary endpoint: Percentage of Main Target Lesions that are clinically and histologically cleared 12 weeks after PDT-1., 12 weeks after PDT-1|Main Target Lesion Clinical Response (According to Clinical Assessment Only) Assessed 12 Weeks After PDT-1., Further secondary endpoint: Percentage of Main Target Lesions that are clinically cleared 12 weeks after PDT-1., 12 weeks after PDT-1|Main Target Lesion Histological Response (According to Histological Assessment Only) Assessed 12 Weeks After PDT-1., Further secondary endpoint: Percentage of Main Target Lesions that are histologically cleared 12 weeks after PDT-1., 12 weeks after PDT-1|Lesion Complete Clinical Response Rate Per Treatment Arm (Complete Clearance of Individual Lesions (Main and Additional Target Lesions)) According to Clinical Assessment Only, Assessed 12 Weeks After PDT-1., Further secondary endpoint: Percentage of Individual Target Lesions that are completely clinically cleared per treatment arm 12 weeks after PDT-1, 12 weeks after PDT-1|Subject Complete Clinical Response (Complete Clearance of All Target Lesions According to Clinical Assessment Only) Assessed 12 Weeks After PDT-1., Further secondary endpoint: Percentage of subjects with complete clinical clearance 12 weeks after PDT-1., 12 weeks after PDT-1|Subject Complete Response (Clinically and Histologically Cleared Main Target Lesion (See Above) and Complete Clinical Remission of All Additional Target Lesions) Assessed 12 Weeks After PDT-1.., Further secondary endpoint: Percentage of subjects with complete clinical and histological clearance of the Main Target Lesion and complete clinical clearance of Additional Target Lesions 12 weeks after PDT-1., 12 weeks after PDT-1|For All Target Lesions, Assessment of Esthetic Appearance by the Investigator 12 Weeks After the Start of the Last PDT Cycle, But Prior to Surgical Excision of the Main Target Lesion and Any Alternative Treatment of Additional Target Lesions., Further secondary endpoint: Investigators assessment of the esthetic appearance of all Target lesions but prior to surgical excision of the Main Target Lesion or alternative Treatment of Additional Target Lesions, 12 weeks after the start of the last PDT cycle|Subjects' Satisfaction Regarding Esthetic Outcome and Treatment 12 Weeks After the Start of the Last PDT Cycle, But Prior to Surgical Excision of the Main Target Lesion or Alternative Treatment of Additional Target Lesions, Further secondary endpoint: Subject's assessment regarding the esthetic outcome and the Treatment 12 weeeks after the start of the last PDT cycle but prior to surgical excision of the Main Target Lesion or alternative Treatment of Additional Target Lesions, 12 weeks after the start of the last PDT cycle",,Biofrontera Bioscience GmbH,,ALL,"ADULT, OLDER_ADULT",PHASE3,187,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-09-25,2024-03-19,2029-02,2018-06-29,2025-04-29,2025-04-29,"Medical Dermatology Specialists, Phoenix, Arizona, 85006, United States|Alliance Dermatology & Mohs Center, Phoenix, Arizona, 85032, United States|First OC Dermatology, Fountain Valley, California, 92708, United States|Cosmetic Laser Dermatology, San Diego, California, 92121, United States|AboutSkin Research, LLC, Greenwood Village, Colorado, 80111, United States|Dermatology Associates PA of the Palm Beaches, Delray Beach, Florida, 33445, United States|University of Florida Dept of Dermatology, Gainesville, Florida, 32606, United States|Laser and Skin Surgery Center of Indiana, Indianapolis, Indiana, 46260, United States|Henry Ford Health System, Detroit, Michigan, 48202, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, 03756, United States|The Narrows Institute for Biomedical Research and Education, Inc., Brooklyn, New York, 11209, United States|Skin Search of Rochester, Inc, Rochester, New York, 14623, United States|Rochester Dermatologic Surgery, Victor, New York, 14564, United States|Clinical Research Center of the Carolinas, Charleston, South Carolina, 29407, United States|Austin Institute for Clinical Research Inc., Houston, Texas, 77056, United States|Austin Institute for Clinical Research Inc., Pflugerville, Texas, 78660, United States|Jordan Valley Dermatology, West Jordan, Utah, 84088, United States|Virginia Clinical Research, Inc., Norfolk, Virginia, 23502, United States","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/01/NCT03573401/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/01/NCT03573401/SAP_001.pdf"
NCT04619433,A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.,https://clinicaltrials.gov/study/NCT04619433,,UNKNOWN,The study is being conducted to evaluate the efficacy and safety of SHR-1210 in combination with Famitinib plus chemotherapy in subjects with NSCLC.,NO,Non-squamous Non-small-cell Lung Cancer,DRUG: Camrelizumab;Pemetrexed and Carboplatin; Famitinib;|DRUG: Camrelizumab;Pemetrexed and Carboplatin;Placebo,"Part 1ï¼Serum concentrations of Camrelizumab, Cycle 2; each cycle is 21 days (up to 42 days)|Part 1ï¼Plasma concentrations of Famitinib, Cycle 2; each cycle is 21 days (up to 42 days)|Part 1ï¼Area Under the Plasma Concentration Versus Time Curve (AUC) of Famitinib., Cycle 2; each cycle is 21 days (up to 42 days)|Part 1ï¼Maximum Concentration (Cmax) of Famitinib., Cycle 2; each cycle is 21 days (up to 42 days)|Part 1ï¼Time to Maximum Concentration (Tmax) of Famitinib., Cycle 2; each cycle is 21 days (up to 42 days)|Part 1ï¼Half-life (t1/2 z) of Famitinib., Cycle 2; each cycle is 21 days (up to 42 days)|Part 1ï¼Apparent Clearance (CL/F) of Famitinib, Cycle 2; each cycle is 21 days (up to 42 daysï¼|Part 1ï¼Vz/F of Famitinib., Cycle 2; each cycle is 21 days (up to 42 days)|Part 2: Progression-free Survival (PFS) as Assessed by BICR according to RECIST 1.1., up to 24 months","Part 1:Objective Response Rate (ORR) as Assessed by investigators, Cycle 2; each cycle is 21 days (up to 42 days)|Part 1:Duration of Response (DOR) as Assessed by investigators, Cycle 2; each cycle is 21 days (up to 42 days)|Part 1:Progression-free Survival (PFS) as Assessed by investigators, Cycle 2; each cycle is 21 days (up to 42 days)|Part 1:Overall Survival (OS)., Up to approximately 60 months|Part 2:Overall Survival (OS), Up to approximately 60 months|Part 2:Progression-free Survival (PFS) as Assessed by investigators according to RECIST 1.1., up to 24 months|Part 2:Objective Response Rate (ORR) as Assessed by investigators and BICR according to RECIST 1.1, up to 24 months|Part 2:Duration of Response (DOR) as Assessed by investigators and BICR according to RECIST 1.1, up to 24 months|Part 2:Disease Control Rate(DCR) as Assessed by investigators and BICR according to RECIST 1.1, up to 24 months|Part 2:Number of Participants With Adverse Events and Serious Adverse Event as Assessed by CTCAE v5.0., up to 24 months",,"Jiangsu HengRui Medicine Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,560,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-02-01,2022-12-15,2023-10-15,2020-11-06,,2021-03-16,"Beijing Cancer Hosipital, Beijing, Beijing, 100089, China|Beijing Cancer Hosipital, Beijing, Beijing, 100089, China|Henan Cancer Hospital, Zhengzhou, Henan, 450003, China|Hubei Cancer Hospita, Wuhan, Hubei, 430079, China|Shengjing Hospita of China Medical University, Shenyang, Liaoning, 110022, China|Shanghai Lung Hospital, Shanghai, Shanghai, 200433, China|West China Hospitalï¼Sichuan University, Chengdu, Sichuan, 610000, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, 300060, China",
NCT05899608,Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients,https://clinicaltrials.gov/study/NCT05899608,,RECRUITING,"This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival assessed by investigator. The key secondary endpoints include response and safety.",NO,Non-Small Cell Lung Cancer,BIOLOGICAL: Ivonescimab Injection|BIOLOGICAL: Pembrolizumab Injection,"Overall Survival (OS), Overall Survival (OS) in the ITT population, approximately 6 years|Progression Free Survival (PFS), Progression Free Survival (PFS) assessed by investigator based on RECIST V1.1, approximately 3 years","Adverse Event (AE), incidence and severity of adverse events (AEs) and clinically significant abnormal laboratory test results, From the subject signs the ICF to 30 days (AE) and 90 days (SAE related to ivonescimab/pembrolizumab ) after the last dose of study treatment or initiation of other anticancer therapy, whichever occurs first, up to 2 years.",,Summit Therapeutics,,ALL,"ADULT, OLDER_ADULT",PHASE3,1080,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-10-26,2027-12-31,2028-12-31,2023-06-12,,2025-06-03,"Clinical Study Site, Tucson, Arizona, 85711, United States|Clinical Study Site, Little Rock, Arkansas, 72205, United States|Clinical Study Site, Cerritos, California, 90703, United States|Clinical Study Site, Los Angeles, California, 90033, United States|Clinical Study Site, Los Angeles, California, 90067, United States|Clinical Study Site, Sacramento, California, 95816, United States|Clinical Study Site, Sacramento, California, 95817, United States|Clinical Study Site, Santa Monica, California, 90404, United States|Clinical Study Site, Santa Rosa, California, 95403, United States|Clinical Study Site, Lone Tree, Colorado, 80124, United States|Clinical Study Site, Hartford, Connecticut, 06053, United States|Clinical Study Site, Fort Myers, Florida, 33901, United States|Clinical Study Site, Jacksonville, Florida, 32256, United States|Clinical Study Site, Ocala, Florida, 34474, United States|Clinical Study Site, Palm Bay, Florida, 32901, United States|Clinical Study Site, Pembroke Pines, Florida, 33028, United States|Clinical Study Site, Pensacola, Florida, 32503, United States|Clinical Study Site, Petersburg, Florida, 33709, United States|Clinical Study Site, Plantation, Florida, 33322, United States|Clinical Study Site, Saint Petersburg, Florida, 33705, United States|Clinical Study Site, West Palm Beach, Florida, 33401, United States|Clinical Study Site, Peoria, Illinois, 61615, United States|Clinical Study Site, Westwood, Kansas, 66205, United States|Clinical Study Site, Lexington, Kentucky, 40503, United States|Clinical Study Site, Baltimore, Maryland, 21187, United States|Clinical Study Site, Burlington, Massachusetts, 01805, United States|Clinical Study Site, Ann Arbor, Michigan, 48109, United States|Clinical Study Site, Detroit, Michigan, 48202, United States|Clinical Study Site, Saint Paul, Minnesota, 55101, United States|Clinical Study Site, Billings, Montana, 59102, United States|Clinical Study Site, New York, New York, 10029, United States|Clinical Study Site, New York, New York, 10065, United States|Clinical Study Site, Chapel Hill, North Carolina, 27514, United States|Clinical Study Site, Charlotte, North Carolina, 28204, United States|Clinical Study Site, Cincinnati, Ohio, 45242, United States|Clinical Study Site, Cleveland, Ohio, 44106, United States|Clinical Study Site, Cleveland, Ohio, 44195, United States|Clinical Study Site, Eugene, Oregon, 97401, United States|Clinical Study Site, Charleston, South Carolina, 29425, United States|Clinical Study Site, Greenville, South Carolina, 29605, United States|Clinical Study Site, Germantown, Tennessee, 38138, United States|Clinical Study Site, Nashville, Tennessee, 37203, United States|Clinical Study Site, Austin, Texas, 78745, United States|Clinical Study Site, Dallas, Texas, 75246, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|Clinical Study Site, San Antonio, Texas, 78216, United States|Clinical Study Site, Tyler, Texas, 75702, United States|Clinical Study Site, Norfolk, Virginia, 23502, United States|Clinical Study Site, Reston, Virginia, 20190, United States|Clinical Study Site, Seattle, Washington, 98103, United States|Clinical Study Site, Spokane, Washington, 99202, United States|Clinical Study Site, Madison, Wisconsin, 53792, United States|Clinical Study Site, London, Ontario, N6A5W9, Canada|Clinical Study Site, Ottawa, Ontario, K1H8L6, Canada|Clinical Study Site, Regina, Saskatchewan, S4T7T1, Canada|Clinical Study Site, Beijing, 100000, China|Clinical Study Site, Beijing, 100044, China|Clinical Study Site, Beijing, 101149, China|Clinical Study Site, Changsha, 410013, China|Clinical Study Site, Fuzhou, 350014, China|Clinical Study Site, Gansu, 730050, China|Clinical Study Site, Guangxi, 530021, China|Clinical Study Site, Hanzhou, 310006, China|Clinical Study Site, Hanzhou, 310022, China|Clinical Study Site, Harbin, 150081, China|Clinical Study Site, Hebei, 050010, China|Clinical Study Site, Henan, 450003, China|Clinical Study Site, Hengyang, 421205, China|Clinical Study Site, Hubei, 434000, China|Clinical Study Site, Hubei, 44102, China|Clinical Study Site, Jiaxing, 330029, China|Clinical Study Site, Jiyuan, 250117, China|Clinical Study Site, Nanchang, 330209, China|Clinical Study Site, Qingdao, 266042, China|Clinical Study Site, Shanghai, 200030, China|Clinical Study Site, Shanghai, 200031, China|Clinical Study Site, Shanghai, 200032, China|Clinical Study Site, Shanghai, 200437, China|Clinical Study Site, Taizhou, 31700, China|Clinical Study Site, Yunnan, 650107, China|Clinical Study Site, Brest, 29200, France|Clinical Study Site, Caen, 14033, France|Clinical Study Site, Caen, 14059, France|Clinical Study Site, CrÃ©teil, 94010, France|Clinical Study Site, Le Mans, 72000, France|Clinical Study Site, Marseille, 13915, France|Clinical Study Site, Montpellier, 34295, France|Clinical Study Site, Paris, 75000, France|Clinical Study Site, Pierre-BÃ©nite, 69495, France|Clinical Study Site, Quimper, 29107, France|Clinical Study Site, Rennes, 35033, France|Clinical Study Site, Saint-Herblain, 44805, France|Clinical Study Site, Strasbourg, 67033, France|Clinical Study Site, Tours, 37044, France|Clinical Study Site, Villejuif, 94800, France|Clinical Study Site, Esslingen, 73730, Germany|Clinical Study Site, Frankfurt, 60488, Germany|Clinical Study Site, Gauting, 82131, Germany|Clinical Study Site, Giesen, 35392, Germany|Clinical Study Site, Heidelberg, 69126, Germany|Clinical Study Site, Jena, 07747, Germany|Clinical Study Site, Kempten, 87435, Germany|Clinical Study Site, Luebeck, 23538, Germany|Clinical Study Site, Athens, 11526, Greece|Clinical Study Site, Athens, 11527, Greece|Clinical Study Site, Athens, 11528, Greece|Clinical Study Site, Athens, 15562, Greece|Clinical Study Site, Athens, 57010, Greece|Clinical Study Site, Patra, 26443, Greece|Clinical Study Site, Patra, 26504, Greece|Clinical Study Site, ThessalonÃ­ki, 54622, Greece|Clinical Study Site, ThessalonÃ­ki, 57010, Greece|Clinical Study Site, Dublin, D08 NHY1, Ireland|Clinical Study Site, Dublin, D09V2N0, Ireland|Clinical Study Site, Galway, H91 YR71, Ireland|Clinical Study Site, Ancona, 60126, Italy|Clinical Study Site, Aviano, 33081, Italy|Clinical Study Site, Cremona, 26100, Italy|Clinical Study Site, Lucca, 55100, Italy|Clinical Study Site, Monza, 20900, Italy|Clinical Study Site, Pesaro, 61122, Italy|Clinical Study Site, Peschiera Del Garda, 37019, Italy|Clinical Study Site, Verona, 37134, Italy|Clinical Study Site, Aichi, 470-1192, Japan|Clinical Study Site, Fukuoka, 810-8563, Japan|Clinical Study Site, Hiroshima, 734-8551, Japan|Clinical Study Site, Hokkaido, 003-0804, Japan|Clinical Study Site, Miyagi, 981-0914, Japan|Clinical Study Site, Okayama, 700-8558, Japan|Clinical Study Site, Osaka, 569-8686, Japan|Clinical Study Site, Osaka, 573-1191, Japan|Clinical Study Site, Shizuoka, 411-8777, Japan|Clinical Study Site, Tokyo, 104-0045, Japan|Clinical Study Site, Tokyo, 135-8550, Japan|Clinical Study Site, Yamaguchi, 755-0241, Japan|Clinical Study Site, Yokohama, 241-8515, Japan|Clinical Study Site, Guadalajara, 44670, Mexico|Clinical Study Site, Monterrey, 64060, Mexico|Clinical Study Site, Monterrey, 64460, Mexico|Clinical Study Site, Monterrey, 64710, Mexico|Clinical Study Site, PoznaÅ, 60-693, Poland|Clinical Study Site, ÅÃ³dÅº, 90-302, Poland|Clinical Study Site, Belgrade, 11000, Serbia|Clinical Study Site, Belgrade, 11040, Serbia|Clinical Study Site, Belgrade, 11080, Serbia|Clinical Study Site, Kamenica, 21204, Serbia|Clinical Study Site, Kragujevac, 34000, Serbia|Clinical Study Site, NiÅ¡, 18000, Serbia|Clinical Study Site, Badajoz, 06080, Spain|Clinical Study Site, Badalona, 08916, Spain|Clinical Study Site, Barcelona, 08003, Spain|Clinical Study Site, Barcelona, 08025, Spain|Clinical Study Site, Barcelona, 08028, Spain|Clinical Study Site, Barcelona, 08035, Spain|Clinical Study Site, Barcelona, 08107, Spain|Clinical Study Site, Girona, 17007, Spain|Clinical Study Site, JaÃ©n, 23007, Spain|Clinical Study Site, Lugo, 27003, Spain|Clinical Study Site, Madrid, 28040, Spain|Clinical Study Site, Madrid, 28046, Spain|Clinical Study Site, Pamplona, 31008, Spain|Clinical Study Site, Sevilla, 41013, Spain|Clinical Study Site, Valencia, 46010, Spain|Summit Therapeutics Research Center, Valencia, 46206, Spain|Clinical Study Site, Vigo, 36312, Spain|Clinical Study Site, London, EC1A 7BE, United Kingdom|Clinical Study Site, Manchester, M20 4BX, United Kingdom",
NCT06686576,A Study of Perioperative QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer,https://clinicaltrials.gov/study/NCT06686576,,RECRUITING,"The goal of this clinical trial is to evaluate the efficacy of perioperative QL1706 in participants with untreated T4N0 or Stage III (resectable), microsatellite instability high/ defective mismatch repair (MSI-H/dMMR) colon cancer",NO,Colon Cancer,BIOLOGICAL: QL1706|DRUG: CAPEOX,"Pathological Complete Response(pCR), defined as the proportion of subjects with no residual tumor in the primary tumor removed and in all lymph nodes removed after neoadjuvant therapy., 1 month after surgery|Event Free Survival, EFS(EFS), defined as the time from randomization to either disease recurrence or death due to any cause or treatment related toxicity that results in the participant not being suitable for surgery., Up to approximately 5 years","Overall Survival (OS), OS is defined as time from randomization to death from any cause, Up to approximately 5 years|R0 tumor resection rate, R0 tumor resection rate is defined as the proportion of subjects with R0 excision, 2 week after surgery|Number of Participants with treatment emergent adverse events (AEs), serious adverse events (SAEs), Immune-mediated Adverse Event (imAEs), AEs leading to death and AEs leading to discontinuation of study treatment, Up to approximately 5 years",,"Qilu Pharmaceutical Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,288,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-12-12,2030-12,2030-12,2024-11-13,,2025-02-11,"Affiliated Cancer Hospital of Sun Yat-sen University, Guangzhou, China",
NCT06764875,A Phase â¢ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer,https://clinicaltrials.gov/study/NCT06764875,,RECRUITING,"This is a Phase â¢, randomized, open-label, Sponsor-blinded, 3-arm, global, multicenter study assessing the efficacy and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) compared to trastuzumab, chemotherapy, and pembrolizumab (Arm B) in HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma participants whose tumors express PD L1 CPS â¥ 1. Rilvegostomig in combination with trastuzumab and chemotherapy will be evaluated in a separate arm (Arm C) to assess the contribution of each component in the experimental arm.",NO,HER2-positive Gastric Cancer|Gastroesophageal Junction Adenocarcinoma,DRUG: Rilvegostomig|DRUG: Trastuzumab deruxtecan|DRUG: Trastuzumab|DRUG: Pembrolizumab|DRUG: 5-fluorouracil|DRUG: Capecitabine|DRUG: Cisplatin|DRUG: Oxaliplatin,"Progression free survival (PFS), PFS is defined as time from randomization until progression per RECIST v1.1, or death due to any cause., Up to approximately 6 years|Overall Survival (OS), OS is defined as time from randomization until the date of death due to any cause., Up to approximately 6 years","Objective Response Rate (ORR), ORR according to RECIST v1.1. ORR is defined as the proportion of participants who have a complete response (CR) or partial response (PR)., Up to approximately 6 years|Duration of Response (DoR), DoR according to RECIST v1.1. DoR will be defined as the time from the date of first documented response until date of documented progression per RECIST v1.1 or death due to any cause., Up to approximately 6 years|Proportion of all randomized participants alive and progression-free at 6 months (PFS6), Proportion of all randomized participants alive and progression-free at 6 months calculated for progression., Up to 6 months|Proportion of all randomized participants alive and progression-free at 12 months (PFS12), Proportion of all randomized participants alive and progression-free at 12 months calculated for progression., Up to 12 months|Time to second progression or death (PFS2), PFS2 is defined as the time from randomization to the earliest of the progression event (following the initial progression), after the first subsequent therapy, or death, where the first objective progression includes progression occurring after 2 missed visits., Up to approximately 6 years|Occurrence of adverse events (AEs) and serious adverse events (SAEs), Occurrence of AEs and SAEs will be graded according to the revised NCI CTCAE v5.0., Up to approximately 6 years|Pharmacokinetics (PK) of rilvegostomig, T-DXd, total anti-HER2 antibody, DXd, 5-FU, and capecitabine in serum, Concentration of rilvegostomig, T-DXd, total anti-HER2 antibody, DXd, fluoropyrimidine, and capecitabine in serum or plasma., Up to approximately 6 years|Immunogenicity of rilvegostomig and T-DXd assessed by the presence of antidrug antibodies (ADAs) for rilvegostomig and T-DXd, Presence of antidrug antibodies (ADAs) for rilvegostomig and T-DXd (confirmatory results: titers and neutralizing antibodies for confirmed positive samples)., Up to approximately 6 years|Increase in enteral feeding assistance and eating difficulties, Time to first-confirmed worsening of eating symptoms or initiation of feeding assistance among all participants, as randomized., Up to approximately 6 years|Proportion of time on study intervention with high side-effect bother, Proportion of time on study intervention with high side-effect bother relative to low side-effect burden as measured by the Patient Global Impression of Treatment Tolerability (PGI-TT)., Up to approximately 6 years|Overall Survival at 12 months (OS12), Proportion of all randomized participants alive at 12 months., Up to 12 months|Overall Survival at 24 months (OS24), Proportion of all randomized participants alive at 24 months., Up to 24 months|Pharmacokinetics (PK) of rilvegostomig, T-DXd, total anti-HER2 antibody, DXd, 5-FU, and capecitabine in serum, PK parameters (peak and trough concentrations)., Up to approximately 6 years",,AstraZeneca,,ALL,"ADULT, OLDER_ADULT",PHASE3,840,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2025-03-01,2029-04-02,2030-11-12,2025-01-09,,2025-04-27,"Research Site, Anchorage, Alaska, 99508, United States|Research Site, Duarte, California, 91010, United States|Research Site, Los Alamitos, California, 90720, United States|Research Site, Los Angeles, California, 90089, United States|Research Site, Santa Monica, California, 90404, United States|Research Site, Walnut Creek, California, 94598, United States|Research Site, Aurora, Colorado, 80045, United States|Research Site, Marietta, Georgia, 30060, United States|Research Site, Arlington Heights, Illinois, 60005, United States|Research Site, Chicago, Illinois, 60637, United States|Research Site, Dyer, Indiana, 46311, United States|Research Site, Louisville, Kentucky, 40217, United States|Research Site, Silver Spring, Maryland, 20904, United States|Research Site, Boston, Massachusetts, 02114, United States|Research Site, Grand Rapids, Michigan, 49503, United States|Research Site, Burnsville, Minnesota, 55337, United States|Research Site, Kansas City, Missouri, 64111, United States|Research Site, New York, New York, 10065, United States|Research Site, Cincinnati, Ohio, 45220, United States|Research Site, Nashville, Tennessee, 37232, United States|Research Site, Dallas, Texas, 75246, United States|Research Site, Webster, Texas, 77598, United States|Research Site, Fairfax, Virginia, 22031, United States|Research Site, Richmond, Virginia, 23235, United States|Research Site, Madison, Wisconsin, 53792, United States|Research Site, Buenos Aires, 1264, Argentina|Research Site, Ciudad AutÃ³noma Buenos Aires, C1430EFA, Argentina|Research Site, Rosario, 2123, Argentina|Research Site, Rosario, S2000DEJ, Argentina|Research Site, Viedma, R8500ACE, Argentina|Research Site, Darlinghurst, 2010, Australia|Research Site, Heidelberg, 3084, Australia|Research Site, Murdoch, 6150, Australia|Research Site, Westmead, 2145, Australia|Research Site, Linz, 4010, Austria|Research Site, Salzburg, 5020, Austria|Research Site, Wiener Neustadt, 2700, Austria|Research Site, Wien, 1090, Austria|Research Site, Edegem, 2650, Belgium|Research Site, Gent, 9000, Belgium|Research Site, Leuven, 3000, Belgium|Research Site, LiÃ¨ge, 4000, Belgium|Research Site, Barretos, 14784-057, Brazil|Research Site, Brasilia, 71681-603, Brazil|Research Site, Campo Grande, 79020-180, Brazil|Research Site, Natal, 59075-740, Brazil|Research Site, Porto Alegre, 91350-200, Brazil|Research Site, Recife, 50040-000, Brazil|Research Site, Salvador, 40170-110, Brazil|Research Site, Sao Paulo, 05652-9000, Brazil|Research Site, VitÃ³ria, 29043-272, Brazil|Research Site, Calgary, Alberta, T2N 5G2, Canada|Research Site, Edmonton, Alberta, T6G 1Z2, Canada|Research Site, Barrie, Ontario, L4M 6M2, Canada|Research Site, Hamilton, Ontario, L8V 5C2, Canada|Research Site, Toronto, Ontario, M5G 2M9, Canada|Research Site, Montreal, Quebec, H3A 1A1, Canada|Research Site, Puerto Montt, 5480000, Chile|Research Site, Rancagua, 2852424, Chile|Research Site, Santiago, 7500653, Chile|Research Site, Santiago, 7620002, Chile|Research Site, Temuco, 4810218, Chile|Research Site, ViÃ±a del Mar, 2520598, Chile|Research Site, Anyang, 455000, China|Research Site, Beijing, 100050, China|Research Site, Beijing, CN-100730, China|Research Site, Bengbu, 233004, China|Research Site, Changchun, 130021, China|Research Site, Changsha, 410013, China|Research Site, Chengdu, 610041, China|Research Site, Fuzhou, 350001, China|Research Site, Fuzhou, 350014, China|Research Site, Guangzhou, 510060, China|Research Site, Guangzhou, 510655, China|Research Site, Guangzhou, 510700, China|Research Site, Hangzhou, 310016, China|Research Site, Harbin, 150081, China|Research Site, Hefei, 230022, China|Research Site, Hefei, 230031, China|Research Site, Jinan, 250021, China|Research Site, Kunming, 650118, China|Research Site, Lanzhou, 730000, China|Research Site, Lanzhou, 730000, China|Research Site, Linfen, 041099, China|Research Site, Linyi, 276001, China|Research Site, Nanchang, 330008, China|Research Site, Nanjing, 210009, China|Research Site, Nanjing, 210029, China|Research Site, Shandong, China|Research Site, Shanghai, 200025, China|Research Site, Shanghai, 200032, China|Research Site, Shanghai, 201114, China|Research Site, Shenyang, 110004, China|Research Site, Shenyang, 110042, China|Research Site, Shijiazhuang, 050000, China|Research Site, Tianjin, 300060, China|Research Site, Wenzhou, 325000, China|Research Site, Wuhan, 430030, China|Research Site, Xi'an, 710068, China|Research Site, Xian, 710061, China|Research Site, Xining, 810001, China|Research Site, Yinchuan, 750004, China|Research Site, Zhengzhou, 450008, China|Research Site, Bordeaux, 33076, France|Research Site, Caen Cedex 5, 41076, France|Research Site, Clermont-Ferrand, 63003, France|Research Site, Dijon, 21079, France|Research Site, Lyon, 69373, France|Research Site, Marseille, 13273, France|Research Site, Poitiers, 86021, France|Research Site, Rennes, 35000, France|Research Site, Toulouse, 31059, France|Research Site, Villejuif Cedex, 94805, France|Research Site, Augsburg, 86156, Germany|Research Site, Bad Saarow, 15526, Germany|Research Site, Berlin, 10249, Germany|Research Site, Berlin, 10707, Germany|Research Site, Berlin, 13353, Germany|Research Site, Braunschweig, 38114, Germany|Research Site, Chemnitz, 9116, Germany|Research Site, DÃ¼sseldorf, 40225, Germany|Research Site, Essen, 45122, Germany|Research Site, Frankfurt, 60488, Germany|Research Site, GÃ¶ttingen, 37075, Germany|Research Site, Hamburg, 20246, Germany|Research Site, Leipzig, 04103, Germany|Research Site, Ludwigshafen, 67063, Germany|Research Site, Mannheim, 68167, Germany|Research Site, Ulm, 89081, Germany|Research Site, Hong Kong, 150001, Hong Kong|Research Site, Hong Kong, 999077, Hong Kong|Research Site, Hong Kong, Hong Kong|Research Site, Shatin, 00000, Hong Kong|Research Site, Budapest, 1122, Hungary|Research Site, Budapest, 1145, Hungary|Research Site, Gyula, 5700, Hungary|Research Site, GyÃ¶ngyÃ¶s, 3200, Hungary|Research Site, GyÅr, 9024, Hungary|Research Site, Zalaegerszeg, 8900, Hungary|Research Site, Bangalore, 560027, India|Research Site, Delhi, 110029, India|Research Site, Delhi, 110085, India|Research Site, Hyderabad, 500034, India|Research Site, Kolkata, 700016, India|Research Site, Mumbai, 400012, India|Research Site, Varanasi, 221005, India|Research Site, Cagliari, 09124, Italy|Research Site, Firenze, 50134, Italy|Research Site, Milano, 20162, Italy|Research Site, Napoli, 80131, Italy|Research Site, Padova, 35128, Italy|Research Site, Rozzano, 20089, Italy|Research Site, Torino, 10126, Italy|Research Site, Tricase, 73039, Italy|Research Site, Akashi-shi, 673-8558, Japan|Research Site, Chuo-ku, 104-0045, Japan|Research Site, Fukuoka-shi, 811-1395, Japan|Research Site, Hidaka-shi, 350-1298, Japan|Research Site, Shiwa-gun, 028-3695, Japan|Research Site, Yokohama-shi, 241-8515, Japan|Research Site, Daegu, 41404, Korea, Republic of|Research Site, Goyang-si, 410-769, Korea, Republic of|Research Site, Gyeonggi-do, 13620, Korea, Republic of|Research Site, Jeonnam, 519-763, Korea, Republic of|Research Site, Seoul, 03080, Korea, Republic of|Research Site, Seoul, 03722, Korea, Republic of|Research Site, Seoul, 06351, Korea, Republic of|Research Site, Seoul, 06591, Korea, Republic of|Research Site, Seoul, 5505, Korea, Republic of|Research Site, Georgetown, 10450, Malaysia|Research Site, Ipoh, 30450, Malaysia|Research Site, Kuala Lumpur, 50586, Malaysia|Research Site, Kuala Lumpur, 59100, Malaysia|Research Site, Sabah, 88996, Malaysia|Research Site, Amsterdam, 1105 AZ, Netherlands|Research Site, Arnhem, 6815 AD, Netherlands|Research Site, Arequipa, AREQUIPA54, Peru|Research Site, Lima, 15036, Peru|Research Site, Lima, LIMA 29, Peru|Research Site, Lima, Lima 32, Peru|Research Site, Lima, Lima 34, Peru|Research Site, San Isidro, 15073, Peru|Research Site, BiaÅystok, 15-027, Poland|Research Site, GdaÅsk, 80-219, Poland|Research Site, Koszalin, 75-581, Poland|Research Site, Olsztyn, 10-228, Poland|Research Site, Przemysl, 37-700, Poland|Research Site, Warszawa, 02-034, Poland|Research Site, WrocÅaw, 50-556, Poland|Research Site, Rio Piedras, 00935, Puerto Rico|Research Site, Badalona, 08916, Spain|Research Site, Barcelona, 08035, Spain|Research Site, Madrid, 28034, Spain|Research Site, Madrid, 28041, Spain|Research Site, Orense, 32005, Spain|Research Site, Santander, 39008, Spain|Research Site, Sevilla, 41013, Spain|Research Site, Valencia, 46010, Spain|Research Site, Kaohsiung, 80756, Taiwan|Research Site, Kaohsiung, 824, Taiwan|Research Site, Taichung, 40447, Taiwan|Research Site, Tainan, 704, Taiwan|Research Site, Taipei, 100, Taiwan|Research Site, Taipei, 112, Taiwan|Research Site, Taoyuan, 333, Taiwan|Research Site, Bangkok, 10330, Thailand|Research Site, Bangkok, 10400, Thailand|Research Site, Bangkok, 10700, Thailand|Research Site, Banphaeo, 74120, Thailand|Research Site, Dusit, 10300, Thailand|Research Site, Khon Kaen, 40002, Thailand|Research Site, Ankara, 06100, Turkey|Research Site, Antalya, 07100, Turkey|Research Site, Diyarbakir, 21280, Turkey|Research Site, Erzurum, 25240, Turkey|Research Site, Istanbul, 34010, Turkey|Research Site, Izmir, 35965, Turkey|Research Site, Mezitli, 33200, Turkey|Research Site, Cambridge, CB2 2QQ, United Kingdom|Research Site, Coventry, CV2 2DX, United Kingdom|Research Site, Dundee, DD1 9SY, United Kingdom|Research Site, London, EC1A 7BE, United Kingdom|Research Site, London, W1G 6AD, United Kingdom|Research Site, Manchester, M20 4BX, United Kingdom|Research Site, Sutton, SM2 5PT, United Kingdom|Research Site, Hanoi, 100000, Vietnam|Research Site, Ho Chi Minh city, 700000, Vietnam|Research Site, Vinh, 460000, Vietnam",
NCT06692738,A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT06692738,,RECRUITING,The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1).,NO,Non-small Cell Lung Cancer,DRUG: Rilvegostomig|DRUG: Pembrolizumab|DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Nab-paclitaxel,"Overall survival (OS), OS is defined as the time from randomization until the date of death due to any cause., Up to approximately 5 years|Progression-free survival (PFS), PFS is defined as the time from randomization until radiological progression per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1) or death due to any cause (in the absence of progression)., Up to approximately 5 years","Landmark overall survival (OS) rates, OS is defined as the time from randomization until the date of death due to any cause., Up to approximately 5 years|Landmark progression-free survival (PFS) rates, PFS is defined as the time from randomization until radiological progression per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1) or death due to any cause (in the absence of progression)., Up to approximately 5 years|Time to second progression or death (PFS2), PFS2 is defined as the time from randomization until the earliest of the progression event (following the initial progression event), after the start of the first subsequent therapy, or death from any cause, whichever occurs first. The date of the second progression will be recorded by the investigator in the electronic Case Report Form (eCRF) and defined according to local standard clinical practice., Up to approximately 5 years|Overall response rate (ORR), ORR is defined as the proportion of participants who have a confirmed complete response (CR) or confirmed partial response (PR), by using Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1)., Up to approximately 5 years|Duration of response (DoR), DoR is defined as the time from the date of first documented response until the date of documented progression using Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1) or death due to any cause (in the absence of progression)., Up to approximately 5 years|Pharmacokinetic (PK) of rilvegostomig, Concentration of rilvegostomig in serum., Up to approximately 5 years|Immunogenicity of rilvegostomig, Presence of antidrug antibodies (ADAs), titer, and neutralizing antibodies for rilvegostomig., Up to approximately 5 years|Patient-reported physical functioning, Proportion of participants with maintained or improved physical functioning as measured by Patient-Reported Outcomes Measurement Information System Physical Function - Short Form 8c - 7 day (PROMIS PF-SF 8c - 7 day) at each time point., Up to approximately 5 years|Patient-reported global health status (GHS)/quality of life (QoL), Time to deterioration (TTD) of GHS/QoL as measured by the European Organization for Research and Treatment of Cancer Item Library 172 (EORTC IL172). TTD is defined as time from randomization to the date of first deterioration. Deterioration is defined as a worsening change from baseline that reaches a clinically meaningful change threshold., Up to approximately 5 years|Patient-reported lung cancer symptoms of non-small cell lung cancer (NSCLC), Time to deterioration (TTD) in pulmonary symptoms as measured by the Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ).

TTD is defined as time from randomization to the date of first deterioration., Up to approximately 5 years",,AstraZeneca,,ALL,"ADULT, OLDER_ADULT",PHASE3,880,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-11-18,2029-02-05,2029-10-08,2024-11-18,,2025-06-13,"Research Site, Tucson, Arizona, 85724, United States|Research Site, Springdale, Arkansas, 72762, United States|Research Site, Beverly Hills, California, 90211, United States|Research Site, Glendale, California, 91204, United States|Research Site, Los Alamitos, California, 90720, United States|Research Site, Redlands, California, 92373, United States|Research Site, San Francisco, California, 94121, United States|Research Site, Walnut Creek, California, 94598, United States|Research Site, West Haven, Connecticut, 06516, United States|Research Site, Newark, Delaware, 19713, United States|Research Site, Bay Pines, Florida, 33744, United States|Research Site, Fort Lauderdale, Florida, 33308, United States|Research Site, Gainesville, Florida, 32608, United States|Research Site, Gainesville, Florida, 32610, United States|Research Site, Jacksonville, Florida, 32224, United States|Research Site, Athens, Georgia, 30607, United States|Research Site, Atlanta, Georgia, 30341, United States|Research Site, Boise, Idaho, 83712, United States|Research Site, Chicago, Illinois, 60637, United States|Research Site, Decatur, Illinois, 62526, United States|Research Site, Quincy, Illinois, 62301, United States|Research Site, Waterloo, Iowa, 50702, United States|Research Site, Lexington, Kentucky, 40509, United States|Research Site, Lexington, Kentucky, 40536, United States|Research Site, Louisville, Kentucky, 40202, United States|Research Site, Louisville, Kentucky, 40207, United States|Research Site, Alexandria, Louisiana, 71301, United States|Research Site, Baton Rouge, Louisiana, 70808, United States|Research Site, Covington, Louisiana, 70433, United States|Research Site, Shreveport, Louisiana, 71103, United States|Research Site, Shreveport, Louisiana, 71105, United States|Research Site, South Portland, Maine, 04106, United States|Research Site, Baltimore, Maryland, 21202, United States|Research Site, Bethesda, Maryland, 20817, United States|Research Site, Detroit, Michigan, 48202, United States|Research Site, Grand Rapids, Michigan, 49503, United States|Research Site, Duluth, Minnesota, 55802, United States|Research Site, Rochester, Minnesota, 55905, United States|Research Site, Bridgeton, Missouri, 63044, United States|Research Site, Columbia, Missouri, 65212, United States|Research Site, Kansas City, Missouri, 64108, United States|Research Site, Omaha, Nebraska, 68130, United States|Research Site, Camden, New Jersey, 08103, United States|Research Site, Buffalo, New York, 14221, United States|Research Site, East Syracuse, New York, 13057, United States|Research Site, Westbury, New York, 11590, United States|Research Site, Cincinnati, Ohio, 45267, United States|Research Site, Bend, Oregon, 97701, United States|Research Site, Medford, Oregon, 97504, United States|Research Site, Salem, Oregon, 97301, United States|Research Site, Hershey, Pennsylvania, 17033, United States|Research Site, York, Pennsylvania, 17403, United States|Research Site, Sioux Falls, South Dakota, 57105, United States|Research Site, Chattanooga, Tennessee, 37404, United States|Research Site, Nashville, Tennessee, 37203, United States|Research Site, Fort Worth, Texas, 76104, United States|Research Site, Houston, Texas, 77090, United States|Research Site, Kingwood, Texas, 77339, United States|Research Site, Lubbock, Texas, 79410, United States|Research Site, Round Rock, Texas, 78665, United States|Research Site, Fairfax, Virginia, 22031, United States|Research Site, Fredericksburg, Virginia, 22408, United States|Research Site, Olympia, Washington, 98506, United States|Research Site, Seattle, Washington, 98101, United States|Research Site, Silverdale, Washington, 98383, United States|Research Site, Spokane, Washington, 99208, United States|Research Site, Tacoma, Washington, 98405, United States|Research Site, Wenatchee, Washington, 98801, United States|Research Site, Buenos Aires, C1431FWO, Argentina|Research Site, Caba, 1425, Argentina|Research Site, La Plata, 1900, Argentina|Research Site, Pilar, B1629ODT, Argentina|Research Site, Rosario, S2000DEJ, Argentina|Research Site, Darlinghurst, 2010, Australia|Research Site, Hyde Park, 4812, Australia|Research Site, Southport, 4215, Australia|Research Site, Wollongong, 2500, Australia|Research Site, Innsbruck, 6020, Austria|Research Site, Krems, 3500, Austria|Research Site, Rankweil, 6830, Austria|Research Site, Wien, 1160, Austria|Research Site, Wien, 1210, Austria|Research Site, Anderlecht, 1070, Belgium|Research Site, Brussels, 1160, Belgium|Research Site, Charleroi, 6060, Belgium|Research Site, Kortrijk, 8500, Belgium|Research Site, Sint-Niklaas, 9100, Belgium|Research Site, Barretos, 14784-400, Brazil|Research Site, FlorianÃ³polis, 88034-000, Brazil|Research Site, IjuÃ­, 98700-000, Brazil|Research Site, Londrina, 86015-520, Brazil|Research Site, Porto Alegre, 91350-200, Brazil|Research Site, Salvador, 40050 410, Brazil|Research Site, Sao Paulo, 01246-000, Brazil|Research Site, Sao Paulo, 05652-900, Brazil|Research Site, TaubatÃ©, 12030-200, Brazil|Research Site, Saint John, New Brunswick, E2L 4L2, Canada|Research Site, Sydney, Nova Scotia, B1P 1P3, Canada|Research Site, Hamilton, Ontario, L8V 1C3, Canada|Research Site, Sault Ste. Marie, Ontario, P6A 0A8, Canada|Research Site, Montreal, Quebec, H4A 3J1, Canada|Research Site, MontrÃ©al, Quebec, H2X 0A9, Canada|Research Site, Beijing, 100021, China|Research Site, Beijing, 100029, China|Research Site, Beijing, 100142, China|Research Site, Beijing, 101149, China|Research Site, Beijing, CN-100730, China|Research Site, Changchun, 130012, China|Research Site, Changde, 415003, China|Research Site, Changsha, 410013, China|Research Site, Chengdu, 610041, China|Research Site, Chengdu, 610072, China|Research Site, Chongqing, 400030, China|Research Site, Dalian, 116001, China|Research Site, Guangzhou, 510062, China|Research Site, Guangzhou, 510100, China|Research Site, Hangzhou, 310003, China|Research Site, Hangzhou, 310016, China|Research Site, Hangzhou, 310022, China|Research Site, Harbin, 150081, China|Research Site, Hefei, 230001, China|Research Site, Hefei, 230601, China|Research Site, Jinan, 250117, China|Research Site, Kunming, 650118, China|Research Site, Linhai, 317000, China|Research Site, Linyi, 276001, China|Research Site, Nanchang, 330008, China|Research Site, Ningbo, 315010, China|Research Site, Shanghai, 200030, China|Research Site, Shanghai, 200032, China|Research Site, Shanghai, 200433, China|Research Site, Shenyang, 110004, China|Research Site, Shenzhen, 518020, China|Research Site, Taiyuan, 030000, China|Research Site, Tianjin, 300050, China|Research Site, Wenzhou, CN-325000, China|Research Site, Wuhan, 430030, China|Research Site, Xi'an, 710061, China|Research Site, Yangzhou, 225001, China|Research Site, Yueyang, 414000, China|Research Site, Zhengzhou, 450008, China|Research Site, Zhengzhou, 450052, China|Research Site, Avignon, 84902, France|Research Site, La Rochelle Cedex, 17019, France|Research Site, Lyon, 69008, France|Research Site, Nimes, 30029, France|Research Site, Rennes, 35033, France|Research Site, Strasbourg Cedex, 67091, France|Research Site, Suresnes, 92150, France|Research Site, Toulon Cedex 9, 83800, France|Research Site, Bad Berka, 99437, Germany|Research Site, Berlin, 13125, Germany|Research Site, Berlin, 13585, Germany|Research Site, Esslingen, 73730, Germany|Research Site, Frankfurt, 60488, Germany|Research Site, Gauting, 82131, Germany|Research Site, Giessen, 35392, Germany|Research Site, GroÃhansdorf, 22927, Germany|Research Site, Hamburg, 20251, Germany|Research Site, Hannover, 30459, Germany|Research Site, Hannover, 30625, Germany|Research Site, Heidelberg, 69126, Germany|Research Site, Hemer, 58675, Germany|Research Site, Homburg, 66424, Germany|Research Site, Kassel, 34125, Germany|Research Site, Kiel, 24105, Germany|Research Site, Krefeld, 47805, Germany|Research Site, KÃ¶ln, 51109, Germany|Research Site, Minden, 32429, Germany|Research Site, Moers, 47441, Germany|Research Site, MÃ¼nchen, 81925, Germany|Research Site, Regensburg, 93053, Germany|Research Site, WÃ¼rzburg, 97067, Germany|Research Site, Budapest, 1083, Hungary|Research Site, Budapest, 1121, Hungary|Research Site, Budapest, 1122, Hungary|Research Site, Debrecen, 4032, Hungary|Research Site, GyÃ¶ngyÃ¶s, 3200, Hungary|Research Site, GyÅr, 9024, Hungary|Research Site, PÃ©cs, 7624, Hungary|Research Site, SzÃ©kesfehÃ©rvÃ¡r, 8000, Hungary|Research Site, TÃ¶rÃ¶kbÃ¡lint, 2045, Hungary|Research Site, Calicut, 673601, India|Research Site, Delhi, 110029, India|Research Site, Kolkata, 700054, India|Research Site, Madurai, 625107, India|Research Site, Mumbai, 400012, India|Research Site, Nashik, 422002, India|Research Site, New Delhi, 110075, India|Research Site, Pondicherry, 605006, India|Research Site, Surat, 395017, India|Research Site, Varanasi, 221005, India|Research Site, Firenze, 50134, Italy|Research Site, Monza, 20900, Italy|Research Site, Orbassano, 10043, Italy|Research Site, Padova, 35128, Italy|Research Site, Peschiera Del Garda, 37019, Italy|Research Site, Roma, 00168, Italy|Research Site, Amagasaki-shi, 660-8550, Japan|Research Site, Bunkyo-ku, 113-8603, Japan|Research Site, Chuo-ku, 104-0045, Japan|Research Site, Fukuoka-shi, 812-8582, Japan|Research Site, Fukuoka-shi, 814-0180, Japan|Research Site, Hiroshima-shi, 734-8551, Japan|Research Site, Kawagoe-shi, 350-8550, Japan|Research Site, Kitaadachi-gun, 362-0806, Japan|Research Site, Kitakyushu-shi, 807-8555, Japan|Research Site, Kobe-shi, 650-0017, Japan|Research Site, Koto-ku, 135-8550, Japan|Research Site, Kumamoto-shi, 860-8556, Japan|Research Site, Matsusaka-shi, 515-8544, Japan|Research Site, Osaka-shi, 541-8567, Japan|Research Site, Osakasayama, 589-8511, Japan|Research Site, Ota-shi, 373-8550, Japan|Research Site, Saitama-shi, 338-0001, Japan|Research Site, Sendai-shi, 981-0914, Japan|Research Site, Shinjuku-ku, 160-0023, Japan|Research Site, Yokohama-shi, 236-0024, Japan|Research Site, Yokohama-shi, 241-8515, Japan|Research Site, Cheongju-si, 28644, Korea, Republic of|Research Site, Incheon, 21565, Korea, Republic of|Research Site, Seoul, 03080, Korea, Republic of|Research Site, Seoul, 03722, Korea, Republic of|Research Site, Seoul, 05505, Korea, Republic of|Research Site, Seoul, 06351, Korea, Republic of|Research Site, Suwon-si, 16247, Korea, Republic of|Research Site, Suwon-si, 16499, Korea, Republic of|Research Site, George Town, 10450, Malaysia|Research Site, Johor Bahru, 81100, Malaysia|Research Site, Kuala Lumpur, 59100, Malaysia|Research Site, Alkmaar, 1815 JD, Netherlands|Research Site, Ede, 6716 RP, Netherlands|Research Site, Groningen, 9713 GZ, Netherlands|Research Site, Leidschendam, 2262 BA, Netherlands|Research Site, Veldhoven, 5504 DB, Netherlands|Research Site, Zwolle, 8025 AB, Netherlands|Research Site, Lima, 15036, Peru|Research Site, Lima, 15102, Peru|Research Site, Lima, 34, Peru|Research Site, Lima, L27, Peru|Research Site, Lima, LIMA 29, Peru|Research Site, Lima, Lima39, Peru|Research Site, BiaÅa Podlaska, 21-500, Poland|Research Site, BiaÅystok, 15-027, Poland|Research Site, Bydgoszcz, 85-796, Poland|Research Site, Bystra, 43-360, Poland|Research Site, PoznaÅ, 60-569, Poland|Research Site, Warszawa, 04-141, Poland|Research Site, ÅÃ³dÅº, 93-338, Poland|Research Site, San Juan, 00909, Puerto Rico|Research Site, San Juan, 00918, Puerto Rico|Research Site, Barcelona, 8035, Spain|Research Site, Las Palmas de Gran Canaria, 35016, Spain|Research Site, LÃ©rida, 25198, Spain|Research Site, Madrid, 28007, Spain|Research Site, Madrid, 28034, Spain|Research Site, Majadahonda, 28222, Spain|Research Site, Sevilla, 41013, Spain|Research Site, Kaohsiung, 80756, Taiwan|Research Site, Kaohsiung, 824, Taiwan|Research Site, New Taipei City, 23561, Taiwan|Research Site, New Taipei, 220, Taiwan|Research Site, Taichung, 402, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan City, 73657, Taiwan|Research Site, Taoyuan, 333, Taiwan|Research Site, Bangkok, 10700, Thailand|Research Site, Chiang Mai, 50200, Thailand|Research Site, Dusit, 10300, Thailand|Research Site, Nakhon Ratchasima, 30000, Thailand|Research Site, Songkla, 90110, Thailand|Research Site, Antalya, 07058, Turkey|Research Site, Istanbul, 34098, Turkey|Research Site, Yenimahalle, 06170, Turkey|Research Site, Aberdeen, AB25 2ZN, United Kingdom|Research Site, Cambridge, CB2 0QQ, United Kingdom|Research Site, Edinburgh, EH4 2XU, United Kingdom|Research Site, Exeter, EX2 5DW, United Kingdom|Research Site, Greater London, SW3 6JJ, United Kingdom|Research Site, London, EC1A 7BE, United Kingdom|Research Site, London, SE1 9RT, United Kingdom|Research Site, Manchester, M20 4BX, United Kingdom|Research Site, Newcastle upon Tyne, NE7 7AF, United Kingdom|Research Site, Preston, PR2 9HT, United Kingdom|Research Site, Can Tho, 900000, Vietnam|Research Site, Hanoi, 100000, Vietnam|Research Site, Ho Chi Minh City, 700000, Vietnam|Research Site, Ho Chi Minh, 700000, Vietnam|Research Site, Vinh, 460000, Vietnam",
NCT06627647,A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC,https://clinicaltrials.gov/study/NCT06627647,,RECRUITING,"The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with non-squamous mNSCLC whose tumors express PD-L1.",NO,Non-squamous Non-small Cell Lung Cancer,DRUG: Rilvegostomig|DRUG: Pembrolizumab|DRUG: Carboplatin|DRUG: Cisplatin|DRUG: Pemetrexed,"Overall survival (OS), OS is defined as the time from randomization until the date of death due to any cause., Up to approximately 5 years|Progression-free survival (PFS), PFS is defined as the time from randomization until radiological progression per RECIST 1.1, or death due to any cause (in the absence of progression)., Up to approximately 5 years","Landmark overall survival (OS) rates, OS is defined as the time from randomization until the date of death due to any cause., Up to approximately 5 years|Landmark progression-free survival (PFS) rates, PFS is defined as the time from randomization until radiological progression per RECIST 1.1, or death due to any cause (in the absence of progression)., Up to approximately 5 years|Time to second progression or death (PFS2), PFS2 is defined as the time from randomization until the earliest of the progression event (following the initial progression event), after the start of the first subsequent therapy, or death from any cause, whichever occurs first. The date of the second progression will be recorded by the investigator in the eCRF and defined according to local standard clinical practice., Up to approximately 5 years|Overall response rate (ORR), ORR is defined as the proportion of participants who have a confirmed CR or confirmed PR, using RECIST 1.1., Up to approximately 5 years|Duration of response (DoR), DoR is defined as the time from the date of first documented response until the date of documented progression using RECIST 1.1 or death due to any cause (in the absence of progression)., Up to approximately 5 years|Pharmacokinetic (PK) of rilvegostomig, Concentration of rilvegostomig in serum, Up to approximately 5 years|Immunogenicity of rilvegostomig, Presence of antidrug antibodies (ADAs), titer, and neutralizing antibodies for rilvegostomig, Up to approximately 5 years|Patient-reported physical functioning, Proportion of participants with maintained or improved physical functioning as measured by PROMIS PF-SF 8c - 7 day at each time point., Up to approximately 5 years|Patient-reported global health status (GHS)/quality of life (QoL), TTD of GHS/QoL as measured by the EORTC IL172. TTD is defined as time from randomization to the date of first deterioration. Deterioration is defined as a worsening change from baseline that reaches a clinically meaningful change threshold., Up to approximately 5 years|Patient-reported lung cancer symptoms of non-small cell lung cancer (NSCLC), TTD in pulmonary symptoms as measured by the NSCLC-SAQ. TTD is defined as time from randomization to the date of first deterioration., Up to approximately 5 years",,AstraZeneca,,ALL,"ADULT, OLDER_ADULT",PHASE3,878,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-11-27,2029-05-10,2030-03-25,2024-10-04,,2025-06-08,"Research Site, Mobile, Alabama, 36608, United States|Research Site, Phoenix, Arizona, 85054, United States|Research Site, Anaheim, California, 92801, United States|Research Site, Beverly Hills, California, 90211, United States|Research Site, Redlands, California, 92373, United States|Research Site, San Diego, California, 92123, United States|Research Site, San Francisco, California, 94121, United States|Research Site, Santa Rosa, California, 95403, United States|Research Site, Walnut Creek, California, 94598, United States|Research Site, Lone Tree, Colorado, 80124, United States|Research Site, Stamford, Connecticut, 06902, United States|Research Site, West Haven, Connecticut, 06516, United States|Research Site, Newark, Delaware, 19713, United States|Research Site, Bay Pines, Florida, 33744, United States|Research Site, Fort Lauderdale, Florida, 33308, United States|Research Site, Gainesville, Florida, 32610, United States|Research Site, Jacksonville, Florida, 32224, United States|Research Site, Miami, Florida, 33125, United States|Research Site, Ocala, Florida, 34474, United States|Research Site, Saint Petersburg, Florida, 33709, United States|Research Site, Atlanta, Georgia, 30342, United States|Research Site, Boise, Idaho, 83712, United States|Research Site, Chicago, Illinois, 60637, United States|Research Site, Decatur, Illinois, 62526, United States|Research Site, Quincy, Illinois, 62305, United States|Research Site, Waterloo, Iowa, 50702, United States|Research Site, Lexington, Kentucky, 40509, United States|Research Site, Lexington, Kentucky, 40536, United States|Research Site, Louisville, Kentucky, 40207, United States|Research Site, Alexandria, Louisiana, 71301, United States|Research Site, Baton Rouge, Louisiana, 70808, United States|Research Site, Shreveport, Louisiana, 71103, United States|Research Site, Shreveport, Louisiana, 71105, United States|Research Site, South Portland, Maine, 04106, United States|Research Site, Baltimore, Maryland, 21202, United States|Research Site, Grand Rapids, Michigan, 49503, United States|Research Site, Duluth, Minnesota, 55805, United States|Research Site, Rochester, Minnesota, 55905, United States|Research Site, Saint Paul, Minnesota, 55102, United States|Research Site, Bridgeton, Missouri, 63044, United States|Research Site, Columbia, Missouri, 65212, United States|Research Site, Lincoln, Nebraska, 68506, United States|Research Site, Camden, New Jersey, 08103, United States|Research Site, Buffalo, New York, 14221, United States|Research Site, Westbury, New York, 11590, United States|Research Site, Canton, Ohio, 44710, United States|Research Site, Medford, Oregon, 97504, United States|Research Site, Portland, Oregon, 97239, United States|Research Site, Salem, Oregon, 97301, United States|Research Site, Pittsburgh, Pennsylvania, 15212, United States|Research Site, York, Pennsylvania, 17403, United States|Research Site, Providence, Rhode Island, 02903, United States|Research Site, Pierre, South Dakota, 57501, United States|Research Site, Sioux Falls, South Dakota, 57105, United States|Research Site, Chattanooga, Tennessee, 37404, United States|Research Site, Nashville, Tennessee, 37203, United States|Research Site, Nashville, Tennessee, 37203, United States|Research Site, Fort Worth, Texas, 76104, United States|Research Site, Houston, Texas, 77090, United States|Research Site, Kingwood, Texas, 77339, United States|Research Site, Lubbock, Texas, 79410, United States|Research Site, Palestine, Texas, 75801, United States|Research Site, Round Rock, Texas, 78665, United States|Research Site, Fairfax, Virginia, 22031, United States|Research Site, Norfolk, Virginia, 23502, United States|Research Site, Roanoke, Virginia, 24014, United States|Research Site, Seattle, Washington, 98101, United States|Research Site, Seattle, Washington, 98104, United States|Research Site, Silverdale, Washington, 98383, United States|Research Site, Spokane, Washington, 99208, United States|Research Site, Tacoma, Washington, 98405, United States|Research Site, Wenatchee, Washington, 98801, United States|Research Site, La Crosse, Wisconsin, 54601, United States|Research Site, Buenos Aires, C1431FWO, Argentina|Research Site, Caba, 1425, Argentina|Research Site, La Plata, 1900, Argentina|Research Site, Pilar, B1629ODT, Argentina|Research Site, Rosario, S2000DEJ, Argentina|Research Site, Darlinghurst, 2010, Australia|Research Site, Hyde Park, 4812, Australia|Research Site, Southport, 4215, Australia|Research Site, Wollongong, 2500, Australia|Research Site, Brussels, 1160, Belgium|Research Site, Charleroi, 6060, Belgium|Research Site, Kortrijk, 8500, Belgium|Research Site, Sint-Niklaas, 9100, Belgium|Research Site, IjuÃ­, 98700-000, Brazil|Research Site, Londrina, 86015-520, Brazil|Research Site, Passo Fundo, 99010-260, Brazil|Research Site, Porto Alegre, 91350-200, Brazil|Research Site, Salvador, 40050 410, Brazil|Research Site, Sao Paulo, 01327-001, Brazil|Research Site, SÃ£o Paulo, 01246-000, Brazil|Research Site, SÃ£o Paulo, 05652000, Brazil|Research Site, TaubatÃ©, 12030-200, Brazil|Research Site, Vitoria, 29043-260, Brazil|Research Site, Saint John, New Brunswick, E2L 4L2, Canada|Research Site, Sydney, Nova Scotia, B1P 1P3, Canada|Research Site, Hamilton, Ontario, L8V 1C3, Canada|Research Site, Kingston, Ontario, K7L 2V7, Canada|Research Site, Sault Ste. Marie, Ontario, P6A 0A8, Canada|Research Site, Montreal, Quebec, H4A 3J1, Canada|Research Site, MontrÃ©al, Quebec, H2X 0A9, Canada|Research Site, St-Jerome, Quebec, J7Z 5T3, Canada|Research Site, Beijing, 100021, China|Research Site, Beijing, 100029, China|Research Site, Beijing, CN-100730, China|Research Site, Changchun, 130012, China|Research Site, Changsha, 410013, China|Research Site, Chengdu, 610041, China|Research Site, Chongqing, 400030, China|Research Site, Fuzhou, 350007, China|Research Site, Guangzhou, 510062, China|Research Site, Guangzhou, 510180, China|Research Site, Hangzhou, 310003, China|Research Site, Hangzhou, 310016, China|Research Site, Hangzhou, 310022, China|Research Site, Harbin, 150081, China|Research Site, Hefei, 230601, China|Research Site, Jinan, 250117, China|Research Site, Jingzhou, 434000, China|Research Site, Kunming, 650118, China|Research Site, Linhai, 317000, China|Research Site, Nanchang, 330008, China|Research Site, Ningbo, 315010, China|Research Site, Shanghai, 200030, China|Research Site, Shanghai, 200433, China|Research Site, Wenzhou, CN-325000, China|Research Site, Wuhan, 430000, China|Research Site, Xi'an, 710061, China|Research Site, Xiangyang, 441000, China|Research Site, Zhengzhou, 450008, China|Research Site, Zhengzhou, 450052, China|Research Site, Avignon, 84902, France|Research Site, La Rochelle Cedex, 17019, France|Research Site, Lyon, 69373, France|Research Site, NÃ®mes Cedex 9, 30029, France|Research Site, Rennes, 35033, France|Research Site, Strasbourg, 67091, France|Research Site, Suresnes, 92150, France|Research Site, Toulon Cedex 9, 83800, France|Research Site, Bad Berka, 99437, Germany|Research Site, Berlin, 13585, Germany|Research Site, Esslingen, 73730, Germany|Research Site, Frankfurt, 60488, Germany|Research Site, Gauting, 82131, Germany|Research Site, Giessen, 35392, Germany|Research Site, GroÃhansdorf, 22927, Germany|Research Site, Hamburg, 20251, Germany|Research Site, Hannover, 30459, Germany|Research Site, Hannover, 30625, Germany|Research Site, Hemer, 58675, Germany|Research Site, Homburg, 66424, Germany|Research Site, Kassel, 34125, Germany|Research Site, Kiel, 24105, Germany|Research Site, Krefeld, 47805, Germany|Research Site, KÃ¶ln, 51109, Germany|Research Site, Minden, 32429, Germany|Research Site, Moers, 47441, Germany|Research Site, MÃ¼nchen, 81925, Germany|Research Site, Regensburg, 93053, Germany|Research Site, WÃ¼rzburg, 97067, Germany|Research Site, Budapest, 1083, Hungary|Research Site, Budapest, 1121, Hungary|Research Site, Budapest, 1122, Hungary|Research Site, Debrecen, 4032, Hungary|Research Site, GyÃ¶ngyÃ¶s, 3200, Hungary|Research Site, GyÅr, 9024, Hungary|Research Site, PÃ©cs, 7624, Hungary|Research Site, SzÃ©kesfehÃ©rvÃ¡r, 8000, Hungary|Research Site, TÃ¶rÃ¶kbÃ¡lint, 2045, Hungary|Research Site, Calicut, 673601, India|Research Site, Kolkata, 700054, India|Research Site, Madurai, 625107, India|Research Site, Mumbai, 400012, India|Research Site, Nashik, 422002, India|Research Site, New Delhi, 110075, India|Research Site, Varanasi, 221005, India|Research Site, Firenze, 50134, Italy|Research Site, Monza, 20052, Italy|Research Site, Peschiera Del Garda, 37019, Italy|Research Site, Rome, 00168, Italy|Research Site, Amagasaki-shi, 660-8550, Japan|Research Site, Bunkyo-ku, 113-8603, Japan|Research Site, Chuo-ku, 104-0045, Japan|Research Site, Fukuoka-shi, 812-8582, Japan|Research Site, Fukuoka-shi, 814-0180, Japan|Research Site, Hiroshima-shi, 734-8551, Japan|Research Site, Kawagoe-shi, 350-8550, Japan|Research Site, Kitaadachi-gun, 362-0806, Japan|Research Site, Kitakyushu-shi, 807-8555, Japan|Research Site, Kobe-shi, 650-0017, Japan|Research Site, Koto-ku, 135-8550, Japan|Research Site, Kumamoto-shi, 860-8556, Japan|Research Site, Matsusaka-shi, 515-8544, Japan|Research Site, Osaka-shi, 541-8567, Japan|Research Site, Ota-shi, 373-8550, Japan|Research Site, Saitama-shi, 338-0001, Japan|Research Site, Sendai-shi, 981-0914, Japan|Research Site, Shinjuku-ku, 160-0023, Japan|Research Site, Sunto-gun, 411-8777, Japan|Research Site, Yokohama-shi, 236-0024, Japan|Research Site, Yokohama-shi, 241-8515, Japan|Research Site, Gyeonggi-do, 13620, Korea, Republic of|Research Site, Seoul, 03080, Korea, Republic of|Research Site, Seoul, 03722, Korea, Republic of|Research Site, Seoul, 06351, Korea, Republic of|Research Site, Seoul, 06591, Korea, Republic of|Research Site, Seoul, 07061, Korea, Republic of|Research Site, Songpa-gu, 05505, Korea, Republic of|Research Site, Kuala Lumpur, 59100, Malaysia|Research Site, Kuching, 93586, Malaysia|Research Site, Petaling Jaya, 47500, Malaysia|Research Site, Alkmaar, 1815 JD, Netherlands|Research Site, Ede, 6716 RP, Netherlands|Research Site, Groningen, 9713 GZ, Netherlands|Research Site, Leidschendam, 2262 BA, Netherlands|Research Site, Veldhoven, 5504 DB, Netherlands|Research Site, Lima, 15036, Peru|Research Site, Lima, 15102, Peru|Research Site, Lima, LIMA 29, Peru|Research Site, Lima, Lima 34, Peru|Research Site, BiaÅa Podlaska, 21-500, Poland|Research Site, BiaÅystok, 15-027, Poland|Research Site, Bydgoszcz, 85-796, Poland|Research Site, Bystra, 43-360, Poland|Research Site, PoznaÅ, 60-569, Poland|Research Site, Warszawa, 04-141, Poland|Research Site, ÅÃ³dÅº, 93-338, Poland|Research Site, San Juan, 00918, Puerto Rico|Research Site, San Juan, 00935, Puerto Rico|Research Site, Barcelona, 8035, Spain|Research Site, CastellÃ³n, 12002, Spain|Research Site, Las Palmas de Gran Canaria, 35016, Spain|Research Site, Madrid, 28034, Spain|Research Site, Madrid, 28046, Spain|Research Site, Majadahonda, 28222, Spain|Research Site, Sevilla, 41013, Spain|Research Site, Kaohsiung, 80756, Taiwan|Research Site, Kaohsiung, 824, Taiwan|Research Site, New Taipei City, 220, Taiwan|Research Site, New Taipei City, 23561, Taiwan|Research Site, Taichung, 40201, Taiwan|Research Site, Taichung, 40705, Taiwan|Research Site, Tainan, 736, Taiwan|Research Site, Taoyuan City, 333423, Taiwan|Research Site, Bangkok, 10700, Thailand|Research Site, Chiang Mai, 50200, Thailand|Research Site, Dusit, 10300, Thailand|Research Site, Nakhon Ratchasima, 30000, Thailand|Research Site, Songkla, 90110, Thailand|Research Site, Ankara, 06010, Turkey|Research Site, Antalya, 07070, Turkey|Research Site, Antalya, 07100, Turkey|Research Site, Edirne, 22030, Turkey|Research Site, Izmir, 35965, Turkey|Research Site, Seyhan, 1060, Turkey|Research Site, Aberdeen, AB25 2ZN, United Kingdom|Research Site, Cambridge, CB2 0QQ, United Kingdom|Research Site, Edinburgh, EH4 2XU, United Kingdom|Research Site, Exeter, EX2 5DW, United Kingdom|Research Site, Greater London, SW3 6JJ, United Kingdom|Research Site, London, EC1A 7BE, United Kingdom|Research Site, London, SE1 9RT, United Kingdom|Research Site, Manchester, M20 4BX, United Kingdom|Research Site, Newcastle upon Tyne, NE7 7AF, United Kingdom|Research Site, Torquay, TQ2 7AA, United Kingdom|Research Site, Can Tho, 900000, Vietnam|Research Site, Hanoi, 100000, Vietnam|Research Site, Ho Chi Minh City, 700000, Vietnam|Research Site, Ho Chi Minh, 700000, Vietnam|Research Site, Vinh, 460000, Vietnam",
NCT04969731,Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer,https://clinicaltrials.gov/study/NCT04969731,,RECRUITING,PURPOSE: This phase III clinical trial evaluates the efficacy and safety of adjuvant Immuncell-LC therapy combined with gemcitabine versus adjuvant gemcitabine single therapy after R0 or R1 resection in patients with pancreatic ductal adenocarcinoma.,NO,Pancreatic Ductal Adenocarcinoma,DRUG: Immuncell-LC|DRUG: Gemcitabine,"Recurrence free survival (RFS) by independent review, Recurrence free survival is defined as the time from randomization to the date of the recurrence confirmed by independent reviewer, Up to approximately 36 months after Last Patient In","Overall survival (OS), Overall survival is defined as the time from randomization to death due to any cause., Up to approximately 36 months after Last Patient In|Recurrence free survival (RFS) by investigator, Recurrence free survival is defined as the time from randomization to the date of the recurrence confirmed by investigator, Up to approximately 36 months after Last Patient In|Carbohydrate antigen 19-9 level, Carbohydrate antigen 19-9 level, Up to approximately 36 months after Last Patient In|Quality of Life (QoL) EORTC QLQ-C30, The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items. Each of the multi-item scales includes a different set of items - no item occurs in more than one scale. All of the scales and single-item measures range in score from 0 to 100. A higher score represents a higher (""better"") level of functioning, or a higher (""worse"") level of symptoms., Up to approximately 36 months after Last Patient In|Quality of Life (QoL) EORTC QLQ-PAN26, The module comprises 26 questions assessing pain, dietary changes, jaundice, altered bowel habit, emotional problems related to pancreatic cancer, and other symptoms (cachexia, indigestion, flatulence, dry mouth, taste changes). The answers range is the following: not at all - 1 point, a little - 2 points, quite a bit - 3 points, very much - 4 points. Minimum score is 26, maximum is 106. The higher total score represents the worse quality of life., Up to approximately 36 months after Last Patient In",,GC Cell Corporation,,ALL,"ADULT, OLDER_ADULT",PHASE3,408,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-09-07,2026-12,2027-06,2021-07-21,,2021-11-22,"Seoul National University Hospital, Seoul, Daehak-ro, Jongno-gu, 03080, Korea, Republic of",
NCT06616532,PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT06616532,,RECRUITING,PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study will evaluate the efficacy and safety of PM8002 in combination with Paclitaxel as second-line treatment for SCLC,NO,SCLC,DRUG: PM8002|DRUG: Paclitaxel|DRUG: Topotecan,"Overall survival (OS), Overall survival is defined as the time from randomization to death due to any cause. Participants without documented death at the time of the analysis are censored at the date of the last follow-up., Up to approximately 32 months from first patient in","Progression-Free Survival (PFS) assessed by evaluated by investigator, PFS is defined as the time from randomization to the first documented PD per RECIST 1.1 based on assessments by investigator or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as â¥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of â¥5 mm. The appearance of one or more new lesions is also considered PD., Up to approximately 32 months from first patient in|Objective response rate (ORR) evaluated by investigator, ORR is defined as the percentage of participants in the analysis population who have a complete response (CR: disappearance of all lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions). The percentage of participants who experienced a CR or PR as assessed by investigators based on RECIST 1.1 is presented., Up to approximately 32 months from first patient in|Disease control rate (DCR), DCR is defined as the sum rate of CR, PR and Stable Disease (SD), as determined by investigators based on RECIST v1.1, Up to approximately 32 months from first patient in|Time to response (TTR), Time to response(TTR) is defined as the time from randomization to the first documented PR or CR assssed by investigator based on RECIST v1.1, Up to approximately 32 months from first patient in|Duration of response (DOR), DoR is defined as the time period from the date of initial CR or PR until the date of PD or death due to any cause, whichever occurs first., Up to approximately 32 months from first patient in|6 month PFS rate, PFS rate corresponding to the 6th month of the progression-free survival curve, Up to approximately 32 months from first patient in|12 month PFS rate, PFS rate corresponding to the 12th month of the progression-free survival curve, Up to approximately 32 months from first patient in|12 month OS rate, OS rate corresponding to the 12th month of the overall survival curve, Up to approximately 32 months from first patient in|Incidence and severity of Adverse Event (AE) according to CTCAE 5.0, An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment., Up to 30 days after last treatment|Anti-drug antibody (ADA), To evaluate the incidence and characteristics of ADA to PM8002, Up to 30 days after last treatment|Health related quality of life (HRQoL), Differences in the scores of health-related quality of life (HRQol), Up to 30 days after last treatment",,Biotheus Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE3,404,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-11-13,2027-01-25,2028-12-25,2024-09-27,,2024-12-19,"Affiliated Hospital of Nantong University, Nantong, Jiangsu, China|Jilin Cancer Hospital, Changchun, Jilin, China|The First Affiliated Hospital Of Ningbo University, Ningbo, Zhejiang, China|Binzhou Medical University Hospital, Binzhou, China|Hunan Cancer Hospital, Changsha, China|Sichuan Cancer Hospital, Chengdu, China|First People's Hospital of Chenzhou, Chenzhou, China|The First Affiliated Hospital of Army Medical University, Chongqing, China|The Second Hospital of Dalian Medical University, Dalian, China|The First People's Hospital of Foshan, Foshan, China|Fujian Cancer Hospital, Fuzhou, China|The Affiliated Hospital Of Guilin Medical University, Guilin, China|Zhejiang Cancer Hospital, Hangzhou, China|Harbin Medical University Cancer Hospital, Harbin, China|Anhui Province Hospital, Hefei, China|Shandong Cancer Institute, Jinan, China|Jingzhou First People's Hospital, Jingzhou, China|Affiliated Hospital of Jining Medical University, Jining, China|Yunnan Cancer Hospital, Kunming, China|Liuzhou People's Hospital, Liuzhou, China|The First Affiliated Hospital of Henan University of Science & Technology, Luoyang, China|Meizhou People's Hospital, Meizhou, China|Mianyang Central Hospital, Mianyang, China|Jiangxi Cancer Hospital, Nanchang, China|The First Affiliated Hospital of Nanchang University, Nanchang, China|Nanchong Central Hospital, Nanchong, China|Jiangsu Province Hospital, Nanjing, China|Nanjing Drum-Tower Hospital, Nanjing, China|Guangxi Medical University Cancer Hospital, Nanning, China|Nanyang Central Hospital, Nanyang, China|Qujing NO.1 Hospital, Qujing, China|The Fourth Hospital of Hebei Medical University, Shijia Zhuang, China|Taizhou Enze Medical Center (group), Taizhou, China|Weifang NO.2 People's Hospital, Weifang, China|Weihai Municipal Hospital, Weihai, China|Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China|Zhongnan Hospital Of Wuhan University, Wuhan, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China|Xiangyang Central Hospital, Xiangyang, China|Xuzhou Central Hospital, Xuzhou, China|The Second People's Hospital Of Yibin, Yibin, China|Yongzhou Central Hospital, Yongzhou, China|Yuncheng City Center Hospital, Yuncheng, China|Zhangzhou Municipal Hospital of Fujian Province, Zhangzhou, China|Zhoukou Central Hospital, Zhoukou, China",
NCT05211895,A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC,https://clinicaltrials.gov/study/NCT05211895,PACIFIC-8,RECRUITING,"This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in adults with locally advanced (Stage III), unresectable NSCLC whose disease has not progressed following definitive platinum-based cCRT.",NO,Non-Small Cell Lung Cancer,DRUG: Durvalumab|DRUG: Domvanalimab|OTHER: Placebo,"Progression Free Survival (PFS), Defined as time from randomisation until progression per RECIST 1.1 as assessed by Blinded Independent Central Review (BICR), or death due to any cause in participants with PD-L1 TC â¥ 50%., Up to 8 years after randomization","Progression Free Survival (PFS), Defined as time from randomisation until progression per RECIST 1.1 as assessed by Blinded Independent Central Review (BICR), or death due to any cause in participants with PD-L1 TC â¥ 1%, Up to 8 years after randomization|Overall Survival (OS), Overall Survival (OS), Approximately 8 years after randomization|Objective Response Rate (ORR), Objective Response Rate (ORR) per RECIST 1.1 as assessed by BICR, Approximately 8 years after randomization|Duration of Response (DoR), Duration of Response (DoR) using BICR assessment according to RECIST 1.1, Approximately 8 years after randomization|Time from randomization to second progression (PFS2), Time from randomization to second progression (PFS2), Approximately 8 years after randomization|Time from randomization to first date of distant metastasis or death (TTDM), Time from randomization until the first date of distant metastasis or death in the absence of distant metastasis (TTDM)., Approximately 8 years after randomization|Time to first subsequent therapy (TFST), Time to first subsequent therapy (TFST), Approximately 8 years after randomization|Concentration of Durvalumab and Domvanalimab, The pharmacokinetics (PK) of Durvalumab and Domvanalimab as determined by concentration, Approximately 12 weeks after last IP dose|PFS6, PFS12, PFS18, PFS24, PFS at 6, 12, 18 and 24 months (proportion per Kaplan-Meier), Approximately 6, 12, 18 and 24 months after randomization|Anti-Drug Antibodies (ADAs), The immunogenicity of Durvalumab and domvanalimab as assessed by presence of Anti-Drug Antibodies (ADAs), Approximately 12 weeks after last IP dose.|Time to deterioration in pulmonary symptoms (TTFCD), Time to deterioration in pulmonary symptoms (TTFCD), Approximately 8 years after randomization|PFS investigator, Defined as time from randomisation until progression per RECIST 1.1 as assessed by Investigator or death due to any cause in participants, Up to 8 years after randomization|OS 24, Overall Survival (OS) at 24 months, Approximately 24 months after randomization",,AstraZeneca,"Arcus Biosciences, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE3,860,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-02-18,2028-06-27,2030-08-30,2022-01-27,,2025-04-10,"Research Site, Chandler, Arizona, 85224, United States|Research Site, Phoenix, Arizona, 85054, United States|Research Site, Fountain Valley, California, 92708, United States|Research Site, Santa Rosa, California, 95403, United States|Research Site, Washington, District of Columbia, 20016, United States|Research Site, Jacksonville, Florida, 32224, United States|Research Site, Orlando, Florida, 32804, United States|Research Site, Saint Augustine, Florida, 32086, United States|Research Site, Macon, Georgia, 31217, United States|Research Site, Elmhurst, Illinois, 60126, United States|Research Site, Maywood, Illinois, 60153, United States|Research Site, Naperville, Illinois, 60540, United States|Research Site, Louisville, Kentucky, 40202, United States|Research Site, Baltimore, Maryland, 21224, United States|Research Site, Silver Spring, Maryland, 20910, United States|Research Site, Detroit, Michigan, 48202, United States|Research Site, Minneapolis, Minnesota, 55407, United States|Research Site, Rochester, Minnesota, 55905, United States|Research Site, East Brunswick, New Jersey, 08816, United States|Research Site, Florham Park, New Jersey, 07932, United States|Research Site, Buffalo, New York, 14221, United States|Research Site, Johnson City, New York, 13790, United States|Research Site, Asheville, North Carolina, 28805, United States|Research Site, Asheville, North Carolina, 28806, United States|Research Site, Charlotte, North Carolina, 28204, United States|Research Site, Winston-Salem, North Carolina, 27157, United States|Research Site, Columbus, Ohio, 43219, United States|Research Site, Oklahoma City, Oklahoma, 73102, United States|Research Site, Pittsburgh, Pennsylvania, 15212, United States|Research Site, Charleston, South Carolina, 29401, United States|Research Site, Nashville, Tennessee, 37232, United States|Research Site, Fort Sam Houston, Texas, 78234, United States|Research Site, Kingwood, Texas, 77339, United States|Research Site, Arlington, Virginia, 22205, United States|Research Site, Fort Belvoir, Virginia, 22060, United States|Research Site, Spokane Valley, Washington, 99216, United States|Research Site, Appleton, Wisconsin, 54911, United States|Research Site, Brussels, 1160, Belgium|Research Site, Edegem, 2650, Belgium|Research Site, Haine-Saint-Paul, 7100, Belgium|Research Site, Leuven, 3000, Belgium|Research Site, Liege, 4000, Belgium|Research Site, Sint-Niklaas, 9100, Belgium|Research Site, Barretos, 14784-400, Brazil|Research Site, Londrina, 86015-520, Brazil|Research Site, Porto Alegre, 91350200, Brazil|Research Site, Porto Velho, 76834-899, Brazil|Research Site, Rio de Janeiro, 20231-050, Brazil|Research Site, Santo Andre, 09060-650, Brazil|Research Site, Sao Paulo, 01221-900, Brazil|Research Site, Sao Paulo, 01236-030, Brazil|Research Site, SÃ£o Paulo, 01310-000, Brazil|Research Site, SÃ£o Paulo, 04556-100, Brazil|Research Site, TaubatÃ©, 12030-200, Brazil|Research Site, Calgary, Alberta, T2N 4N2, Canada|Research Site, Kelowna, British Columbia, V1Y 5L3, Canada|Research Site, Laval, Quebec, H7M 3L9, Canada|Research Site, Montreal, Quebec, H4A 3J1, Canada|Research Site, Las Condes, 7560908, Chile|Research Site, Puerto Montt, 5500243, Chile|Research Site, Santiago, 7500713, Chile|Research Site, Santiago, 7520426, Chile|Research Site, Santiago, 7630370, Chile|Research Site, Santiago, 8241479, Chile|Research Site, Temuco, 4810218, Chile|Research Site, Aix en Provence, 13616, France|Research Site, Angers, 49055, France|Research Site, Bobigny, 93000, France|Research Site, Clermont-Ferrand, 63000, France|Research Site, Lille, 59000, France|Research Site, Paris Cedex 14, 75014, France|Research Site, Pau cedex, 6400, France|Research Site, Quimper, 29000, France|Research Site, Saint Gregoire, 35760, France|Research Site, Saint-Quentin cedex, 02321, France|Research Site, Vantoux, 57070, France|Research Site, Villeurbanne, 69100, France|Research Site, Berlin-Zehlendorf, 14165, Germany|Research Site, Berlin, 12351, Germany|Research Site, Braunschweig, 38114, Germany|Research Site, Chemnitz, 09116, Germany|Research Site, Erlangen, 91054, Germany|Research Site, Essen, 45147, Germany|Research Site, Georgsmarienhuette, 49124, Germany|Research Site, Giessen, 35392, Germany|Research Site, Halle, 06120, Germany|Research Site, Hamburg, 21075, Germany|Research Site, Homburg, 66421, Germany|Research Site, Koblenz, 56073, Germany|Research Site, Krefeld, 47805, Germany|Research Site, KÃ¶ln, 51109, Germany|Research Site, LÃ¶wenstein, 74245, Germany|Research Site, Moers, 47441, Germany|Research Site, MÃ¼nchen, 81675, Germany|Research Site, Regensburg, 93049, Germany|Research Site, Regensburg, 93053, Germany|Research Site, TÃ¼bingen, 72076, Germany|Research Site, Athens, 11526, Greece|Research Site, Athens, 11527, Greece|Research Site, Athens, 12462, Greece|Research Site, Athens, 18547, Greece|Research Site, Holargos, Athens, 155 62, Greece|Research Site, Thessaloniki, 55236, Greece|Research Site, Thessaloniki, 56 429, Greece|Research Site, Thessaloniki, 57001, Greece|Research Site, Hong Kong, 150001, Hong Kong|Research Site, Budapest, 1121, Hungary|Research Site, Budapest, 1122, Hungary|Research Site, Deszk, 6772, Hungary|Research Site, GyÅr, 9024, Hungary|Research Site, SalgÃ³tarjÃ¡n, 3100, Hungary|Research Site, SzÃ©kesfehÃ©rvÃ¡r, 8000, Hungary|Research Site, TÃ¶rÃ¶kbÃ¡lint, 2045, Hungary|Research Site, Ahmedabad, 380054, India|Research Site, Bangalore, 560027, India|Research Site, Bangalore, 560064, India|Research Site, Delhi, 110085, India|Research Site, Gurgaon, 122001, India|Research Site, Howrah, 711103, India|Research Site, Hyderabad, 500032, India|Research Site, Jaipur, 302022, India|Research Site, Kolkata, 700160, India|Research Site, Marg Jaipur, 302004, India|Research Site, Mohali, 160055, India|Research Site, Namakkal, 637001, India|Research Site, New Delhi, 110005, India|Research Site, New Delhi, 110029, India|Research Site, Varanasi, 221005, India|Research Site, Bergamo, 24127, Italy|Research Site, Roma, 00144, Italy|Research Site, Rozzano, 20089, Italy|Research Site, Udine, 33100, Italy|Research Site, Bunkyo-ku, 113-8431, Japan|Research Site, Bunkyo-ku, 113-8603, Japan|Research Site, Bunkyo-ku, 113-8677, Japan|Research Site, Chiba-shi, 260-8717, Japan|Research Site, Fukuoka-shi, 812-8582, Japan|Research Site, Hidaka-shi, 350-1298, Japan|Research Site, Hirosaki-shi, 036-8563, Japan|Research Site, Itabashi-ku, 173-0003, Japan|Research Site, Kashihara-shi, 634-8522, Japan|Research Site, Koto-ku, 135-8550, Japan|Research Site, Kumamoto-shi, 860-8556, Japan|Research Site, Matsuyama-shi, 791-0280, Japan|Research Site, Nagoya-shi, 464-8681, Japan|Research Site, Osaka-shi, 545-8586, Japan|Research Site, Osakasayama-shi, 589-8511, Japan|Research Site, Sapporo-shi, 003-0804, Japan|Research Site, Sunto-gun, 411-8777, Japan|Research Site, Tokyo, 104-0045, Japan|Research Site, Yokohama-shi, 221-0855, Japan|Research Site, Yokohama-shi, 241-8515, Japan|Research Site, Daegu, 42415, Korea, Republic of|Research Site, Goyang-si, 10408, Korea, Republic of|Research Site, Incheon, 21431, Korea, Republic of|Research Site, Incheon, 21565, Korea, Republic of|Research Site, Jinju-si, 52727, Korea, Republic of|Research Site, Seoul, 02841, Korea, Republic of|Research Site, Seoul, 03722, Korea, Republic of|Research Site, Seoul, 06273, Korea, Republic of|Research Site, Seoul, 06351, Korea, Republic of|Research Site, Seoul, 07061, Korea, Republic of|Research Site, Suwon, 16247, Korea, Republic of|Research Site, Johor Bahru, 81100, Malaysia|Research Site, Kuala Lumpur, 59100, Malaysia|Research Site, Kuching, 93586, Malaysia|Research Site, Selangor, 46050, Malaysia|Research Site, Aguascalientes, 20230, Mexico|Research Site, Cdmx, 03810, Mexico|Research Site, Chihuahua, 31203, Mexico|Research Site, Guadalajara, 44280, Mexico|Research Site, Guadalajara, 44638, Mexico|Research Site, Monterrey, 64460, Mexico|Research Site, Oaxaca, 68020, Mexico|Research Site, San Pedro Garza Garcia, 66220, Mexico|Research Site, Sonora, 83207, Mexico|Research Site, Veracruz, 91900, Mexico|Research Site, BodÃ¸, 8092, Norway|Research Site, GjÃ¸vik, 2819, Norway|Research Site, Oslo, 0379, Norway|Research Site, Trondheim, 0730, Norway|Research Site, Bacolod, 6100, Philippines|Research Site, Iloilo City, 5000, Philippines|Research Site, Muntinlupa City, 1780, Philippines|Research Site, Pasig City, 1605, Philippines|Research Site, Quezon City, 1100, Philippines|Research Site, Quezon City, 1112, Philippines|Research Site, BiaÅystok, 15-027, Poland|Research Site, Gliwice, 44-102, Poland|Research Site, Gliwice, 44-102, Poland|Research Site, Katowice, 40-074, Poland|Research Site, Wroclaw, 53-413, Poland|Research Site, Zielona GÃ³ra, 65-046, Poland|Research Site, ÅÃ³dÅº, 93-513, Poland|Research Site, Bucuresti, 022328, Romania|Research Site, Bucuresti, 050098, Romania|Research Site, Craiova, 200542, Romania|Research Site, Floresti, Romania|Research Site, Iasi, 700483, Romania|Research Site, Oradea, 410001, Romania|Research Site, Sibiu, 550245, Romania|Research Site, Suceava, 720214, Romania|Research Site, Timisoara, 300166, Romania|Research Site, Amanzimtoti, 4126, South Africa|Research Site, Amanzimtoti, 4126, South Africa|Research Site, Cape Town, 7570, South Africa|Research Site, Johannesburg, 2196, South Africa|Research Site, Parktown, 2193, South Africa|Research Site, Pretoria, 0084, South Africa|Research Site, Bilbao (Vizcaya), 48013, Spain|Research Site, Castello de la Plana, 12002, Spain|Research Site, Cordoba, 14004, Spain|Research Site, El Palmar, 30120, Spain|Research Site, Palma de Mallorca, 07010, Spain|Research Site, Sabadell (Barcelona), 08208, Spain|Research Site, Basel, 4031, Switzerland|Research Site, Bern, CH-3010, Switzerland|Research Site, Lausanne, 1011, Switzerland|Research Site, Hsinchu, 300, Taiwan|Research Site, New-Taipei, 220216, Taiwan|Research Site, Taichung, 40447, Taiwan|Research Site, Taichung, 40705, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, 10002, Taiwan|Research Site, Taipei, 10449, Taiwan|Research Site, Taipei, 11217, Taiwan|Research Site, Taoyuan, 333, Taiwan|Research Site, Bangkok, 10300, Thailand|Research Site, Bangkok, 10400, Thailand|Research Site, Bangkok, 10700, Thailand|Research Site, Hat Yai, 90110, Thailand|Research Site, Adapazari, 54290, Turkey|Research Site, Ankara, 06340, Turkey|Research Site, Ankara, 6100, Turkey|Research Site, Antalya, 07058, Turkey|Research Site, Edirne, 22030, Turkey|Research Site, Istanbul, 34098, Turkey|Research Site, Istanbul, 34662, Turkey|Research Site, Izmir, 35360, Turkey|Research Site, Konya, 42080, Turkey|Research Site, Ãankaya, 06680, Turkey|Research Site, Birmingham, B9 5SS, United Kingdom|Research Site, Brighton, BN2 5BE, United Kingdom|Research Site, Cambridge, CB2 0QQ, United Kingdom|Research Site, Cardiff, CF14 2TL, United Kingdom|Research Site, Cheltenham, GL53 7AN, United Kingdom|Research Site, High Heaton/Newcastle Upon Tyn, NE7 7DN, United Kingdom|Research Site, Leeds, LS 9 7TF, United Kingdom|Research Site, London, SE1 9RT, United Kingdom|Research Site, Nottingham, NG5 1PB, United Kingdom",
NCT05317819,Study of ADI-PEG 20 Versus Placebo in Subjects with High Arginine Level and Unresectable Hepatocellular Carcinoma,https://clinicaltrials.gov/study/NCT05317819,,RECRUITING,Evaluate efficacy and safety of ADI-PEG 20 in patients with high-argininephenotypic and HCC,NO,Hepatocellular Carcinoma|Advanced Hepatocellular Carcinoma,DRUG: ADI-PEG20|OTHER: Placebo,"Overall Survival (OS), Time from study enrollment to death, Approximately 18 months","Progression free survival, Time from study enrollment to progressive disease or death, Approximately 18 months",,Polaris Group,,ALL,"ADULT, OLDER_ADULT",PHASE3,300,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-03-14,2025-09,2025-10,2022-04-08,,2025-01-13,"Changhua Christian Hospital (CCH), Changhua, 500, Taiwan|Ditmanson Medical Foundation Chiayi Christian Hospital (CYCH), Chiayi City, 600, Taiwan|Chang Gung Medical Foundation-Chia-Yi (CGMF-CY), Chiayi City, 613, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH), Kaohsiung, 807, Taiwan|Chang Gung Medical Foundation-Kaohsiung(CGMF-KS), Kaohsiung, 833, Taiwan|Chi Mei Medical Center (CMMC-YK), Tainan, 710, Taiwan|Chi Mei Hospital, Liouying (CMMC-LY), Tainan, 736, Taiwan|Chang Gung Medical Foundation-Linkou (CGMF-LK), Taoyuan, 333, Taiwan|Bach Mai Hospital, Hanoi, 100000, Vietnam|Hue Central Hospital, Hue, 49000, Vietnam|K Hospital, HÃ  Ná»i, 100000, Vietnam",
NCT04672928,A Phase Ib/III Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above Chemotherapies,https://clinicaltrials.gov/study/NCT04672928,,COMPLETED,This study is a phase Ib/III clinical study to evaluate the efficacy and safety of recombinant fully human anti-programmed cell death receptor 1 (PD-1) and anti-programmed cell death ligand 1 (PD-L1) bispecific antibody injection (IBI318) in combination with paclitaxel versus placebo in combination with paclitaxel in subjects with small cell lung cancer who have failed first-line or above chemotherapies.,NO,Small Cell Lung Carcinoma,DRUG: paclitaxel|DRUG: IBI318,"Adverse events, The incidence rate of all treatment-emergent adverse events (TEAEs), immune-related adverse events (irAEs) and serious adverse events (SAEs), treatment-related adverse events (TRAEs) and the severity., 3 months|Objective remission rate, Proportion of subjects with complete response (CR) or partial response (PR)., 12 months","Continuous remission time (DOR), For subjects with CR or PR, it is defined as the time from the first documented objective tumor response (CR or PR) to objective disease progression (PD) or death., 12 months|Disease Control Rate (DCR), Proportion of subjects with complete response (CR), partial response (PR), or stable disease (SD)., 12 months|Time to response (TTR), Time from randomization to first objective tumor response (CR or PR)., 12 months|Progression-free survival (PFS), Defined as the time from randomization to the first occurrence of objective disease progression or death., 12 months|Overall survival (OS), Defined as the time from randomization to death due to any cause., 12 months",,Innovent Biologics (Suzhou) Co. Ltd.,,ALL,"ADULT, OLDER_ADULT",PHASE1,20,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-12-14,2023-01-31,2023-01-31,2020-12-17,,2023-02-27,"Jilin Povince Cancer Hospital, Changchun, Jilin, China",
NCT02448173,A Multicenter Study of Active Specific Immunotherapy With OncoVaxÂ® in Patients With Stage II Colon Cancer,https://clinicaltrials.gov/study/NCT02448173,,UNKNOWN,"OncoVAXÂ® is the first cancer vaccine that both prevents cancer recurrence and

addresses the diversity of cancer cells. In this pivotal randomized, multicenter Phase

IIIb study in patients with Stage II colon cancer, OncoVAX is designed to use a patient's

own cancer cells to mobilize the body's immune system to prevent the return of colon

cancer following surgery.",NO,Stage II Colon Cancer,BIOLOGICAL: OncoVAX and Surgery|PROCEDURE: Surgery,"Disease-Free Survival, Defined as time from randomization to the date of the first objective test confirming tumor recurrence or death due to any cause, Up to Five years","Overall Survival, Defined as the time from randomization to death due to any cause, Up to Five Years|Recurrence-Free Interval, Defined as the time from randomization to the first objective test confirming tumor recurrence, Up to Five Years",,Vaccinogen Inc,,ALL,"ADULT, OLDER_ADULT",PHASE3,550,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015-05,2020-07,2022-07,2015-05-19,,2015-07-27,"Halifax Health Medical Center, Port Orange, Florida, 32127, United States",
NCT05868707,OH2 Injection in Melanoma,https://clinicaltrials.gov/study/NCT05868707,,RECRUITING,"To evaluate the efficacy of OH2 injection in patients with unresectable or metastatic melanoma who have failed at least second-line standard therapy, using investigator-selected salvage chemotherapy or best supportive care (BSC) as controls.",NO,Melanoma,DRUG: OH2|DRUG: Salvage chemotherapy or best supportive care,"Overall survival (OS), Overall survival is defined as the interval from first dose to death from any cause., From date of randomization until the date of death from any causeï¼assessed up to 3 years","Objective response rate (ORR), Determination of the ORR is calculated based on the proportion of patients achieving CR or PR using the RECIST v1.1 and iRECIST as assessed by investigators., Tumor assessments were performed every 8 weeks in first year and every 12 weeks thereafter until confirmed PD, start of new anticancer treatment, death, withdrawal of informed consent, loss of follow-up, or the end of the study, assessed up to 3 years|Disease control rate (DCR), DCR is defined as the percentage of participants with a best overall response of CR, PR, or SD., Tumor assessments were performed every 8 weeks in first year and every 12 weeks thereafter until confirmed PD, start of new anticancer treatment, death, withdrawal of informed consent, loss of follow-up, or the end of the study, assessed up to 3 years|Progression-free survival (PFS), Progression-free survival is defined as the time from first dose to the earlier event of confirmed PD or death from any cause., From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years|Durable Response Rate (DRR), DRR is defined as the percentage of participants with a best overall response of CR or PR using the RECIST/iRECIST assessment with a duration of response of at least 6 months., Tumor assessments were performed every 8 weeks in first year and every 12 weeks thereafter until confirmed PD, start of new anticancer treatment, death, withdrawal of informed consent, loss of follow-up, or the end of the studyï¼assessed up to 3 years|Duration of Response (DOR), DOR is defined as the time from the first recording of remission (CR or PR) to the first recording of disease progression or death (whichever comes first), Tumor assessments were performed every 8 weeks in first year and every 12 weeks thereafter until confirmed PD, start of new anticancer treatment, death, withdrawal of informed consent, loss of follow-up, or the end of the studyï¼assessed up to 3 years",,"Binhui Biopharmaceutical Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,340,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-03-08,2025-03,2026-03,2023-05-22,,2024-04-02,"Peking University Cancer Hospital, Beijing, Beijing, 100010, China|Chongqing University Cancer Hospital, Chongqing, Chongqing, 400000, China|Fujian Cancer Hosptial, Fuzhou, Fujian, 350000, China|Dermatology Hospital of Southern Medical University, Guangzhou, Guangdong, 510000, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510000, China|Guangxi Medical University Cancer Hospital, Nanning, Guangxi, 530000, China|Hainan Cancer Hospital, Haikou, Hainan, 570100, China|The Fourth Hospital of Hebei Medical University and Hebei Tumor Hospital, Shijiazhuang, Hebei, 050000, China|The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, 150000, China|The Third People's Hospital of Zhengzhou, Zhengzhou, Henan, 450000, China|Hubei Cancer Hospital, Wuhan, Hubei, 430000, China|Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, 430000, China|Hunan Cancer Hospital, Changsha, Hunan, 410000, China|Nanjing Drum Tower Hospital, Nanjing, Jiangsu, 210000, China|The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330000, China|Jilin Cancer Hospital, Changchun, Jilin, 130000, China|The first hospital of Jilin University, Changchun, Jilin, 130000, China|The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, 116000, China|Liaoning Cancer Hospital ï¼ Institute, Shenyang, Liaoning, 116000, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710000, China|The Affiliated Cancer Hospital of Shandong First Medical University, Jinan, Shandong, 250000, China|Weifang People's Hospital, Weifang, Shandong, 261000, China|Fudan University Shanghai Cancer Center, Shanghai, Shanghai, 200000, China|Shanxi Bethune Hospital, Taiyuan, Shanxi, 030000, China|West China Hospital of Sichuan University, Chengdu, Sichuan, 610000, China|Tianjin Medical University Cancer Institute ï¼ Hospital, Tianjin, Tianjin, 300000, China|The Affiliated Cancer Hospital, Xinjiang Medical University, Urumqi, Xinjiang, 830000, China|Yunnan Cancer Hospital, Kunming, Yunnan, 650000, China|Cancer Hospital Of The University Of Chinese Academy Of Sciences Zhejiang Cancer Hospital, Hangzhou, Zhejiang, 310000, China|Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, 310000, China",
NCT04073537,Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy in Subjects With Squamous Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT04073537,,UNKNOWN,"Anlotinib hydrochloride is a multi-targeted receptor tyrosine kinase inhibitor that targets angiogenesis-related kinases such as VEGFR1/2/3, FGFR1/2/3, and other tumor-associated kinases involved in cell proliferation such as PDGFRÎ±/Î², c-Kit, and Ret have significant inhibitory activities.",NO,Squamous Non-small Cell Lung Cancer,DRUG: Anlotinib|DRUG: Placebos|DRUG: Paclitaxel|DRUG: Carboplatin,"Progression Free Survival (PFS) evaluated by IRC, PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause; IRC defined as Independent Review Committee., up to 24 months","Progression Free Survival (PFS) evaluated by investigator, PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause., up to 24 months|Overall Survival (OS), OS defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive., up to 24 months|Overall Response Rate (ORR), Percentage of participants achieving complete response (CR) and partial response (PR)., up to 24 months|Disease Control Rateï¼DCRï¼, Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD)., up to 24 months|Duration of Overall Response (DOR), The time when the patient first achieved complete or partial remission to disease progression., up to 24 months|PFS rate at month 6, The percentage of PFS at month 6., up to 6 months|PFS rate at month 12, The percentage of PFS at month 12., up to 12 months|OS rate at month 6, The percentage of OS at month 6., up to 6 months|OS rate at month 12, The percentage of OS at month 12., up to 12 months|OS rate at month 18, The percentage of OS at month 18., up to 18 months|Adverse Event (AE), Safety data, up to 24 months|Serious Adverse Event (SAE), Safety data, up to 24 months|Abnormal laboratory test index, Safety data, up to 24 months",,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,386,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-10-31,2021-07-31,2022-06-30,2019-08-29,,2019-08-29,"Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, 100083, China|The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 50011, China",
NCT06953999,A Phase III Study of Ivonescimab + Chemo With/Without AK117 vs Chemo in Metastatic Pancreatic Cancer,https://clinicaltrials.gov/study/NCT06953999,,NOT_YET_RECRUITING,"This is a Phase 3, randomized, double-blind clinical trial aimed at evaluating the efficacy and safety of Ivonescimab plus chemotherapy with or without AK117 versus placebo plus chemotherapy in patients with metastatic pancreatic cancer. The study seeks to determine whether the addition of Ivonescimab and/or AK117 improves clinical outcomes compared to standard chemotherapy alone. Participants will be randomly assigned to receive either Ivonescimab with/without AK117 or placebo, both in combination with chemotherapy.",NO,Pancreatic Cancer,"DRUG: Ivonescimab, AK117, Albumin-bound Paclitaxel, Gemcitabine|DRUG: Ivonescimab, AK117 Placebo, Albumin-bound Paclitaxel, Gemcitabine|DRUG: Ivonescimab Placebo, AK117 Placebo, Albumin-bound Paclitaxel, Gemcitabine","Overall response (OS), Overall Survival (OS) is defined as the time from randomization to death due to any cause., Up to approximately 2 years","Progression Free Survival (PFS) assessed by investigator per RECIST v1.1, PFS is defined as the time from randomization to the first documented disease progression (per RECIST v1.1 criteria) assessed by investigators or death due to any cause, whichever occurs first., Up to approximately 2 years|Objective Response Rate (ORR) assessed by investigator per RECIST v1.1, ORR is the proportion of subjects with complete response(CR) or partial response(PR) , assessed by investigators based on RECIST v1.1., Up to approximately 2 years|Disease Control Rate (DCR) assessed by investigator per RECIST v1.1, Disease control rate (DCR) assessed according to RECIST v1.1., Up to approximately 2 years|Duration of response (DoR) assessed by the investigator per RECIST v1.1, Duration of response (DoR) assessed according to RECIST v1.1., Up to approximately 2 years|Time to response (TTR) assessed by the investigator per RECIST v1.1, Time to response (TTR) is defined as the time to response based on RECIST v1.1., Up to approximately 2 years|Adverse Events (AEs), An AE is any untoward medical occurrence in a participant, temporarily associated with the use of study treatment, whether or not considered related to the study treatment., Up to approximately 2 years|Cmax and Cmin, AK112 serum drug concentrations in subjects at different time points after AK112 administration., Up to approximately 2 years|Anti-drug antibodies (ADA), Number of subjects with detectable anti-drug antibodies (ADA)., Up to approximately 2 years",,Akeso,,ALL,"ADULT, OLDER_ADULT",PHASE3,999,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2025-05-14,2027-05-14,2028-05-14,2025-05-01,,2025-05-01,"Fudan University Shanghai Cancer Center, Shanghai, Shanghai, 20032, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, 310022, China",
NCT05568095,"A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body",https://clinicaltrials.gov/study/NCT05568095,STAR-221,ACTIVE_NOT_RECRUITING,"This randomized Phase 3 open-label study will compare the efficacy of the T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT) monoclonal antibody domvanalimab, the anti programmed cell death protein 1 (PD-1) monoclonal antibody zimberelimab, and multiagent chemotherapy versus the anti PD-1 monoclonal antibody nivolumab and multiagent chemotherapy in the first-line treatment of participants with locally advanced unresectable or metastatic gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma.",NO,Advanced Upper Gastrointestinal Tract Adenocarcinoma,DRUG: Domvanalimab|DRUG: Zimberelimab|DRUG: Capecitabine|DRUG: Fluorouracil|DRUG: Leucovorin|DRUG: Oxaliplatin|DRUG: Nivolumab,"Overall survival, From date of randomization until date of death from any cause (Approximately 15 months)]","Progression-free survival (PFS), From date of randomization to date of the first documentation of disease progression or date of death from any cause, whichever comes first (Approximately 15 months)|Objective response rate (ORR), Proportion of randomized participants who achieved a confirmed best overall response of complete response (CR) or partial response (PR) (Approximately 15 months)|Duration of response (DOR), From the date of first confirmed response (CR or PR), until the date of first documented disease progression or date of death from any cause, whichever comes first (Approximately 15 months)|Incidence and severity of adverse events (AEs) and serious adverse events (SAEs), From on or after the date of first dose of any study treatment to the date of last study treatment specific safety follow-up or date of initiation of subsequent systemic anti-cancer therapy, whichever occurs first (Approximately 15 months)|Time to first symptom deterioration in the FACT-Ga gastric cancer subscale., From the date of randomization to change from baseline in subscale greater than or equal to the deterioration threshold, or death from any cause, whichever comes first (Approximately 15 months)",,"Arcus Biosciences, Inc.","Gilead Sciences|Taiho Pharmaceutical Co., Ltd.",ALL,"ADULT, OLDER_ADULT",PHASE3,1040,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-11-21,2026-12,2027-02,2022-10-05,,2025-06-03,"Genesis Cancer Center and Blood Institute - Hot Springs, Hot Springs, Arkansas, 71913, United States|Kaiser Permanente - Los Angeles Medical Center, Los Angeles, California, 90027, United States|Norris Comprehensive Cancer Center, Los Angeles, California, 90033, United States|University of California Irvine Health Chao Family Comprehensive Cancer Center, Orange, California, 92868, United States|UCLA Health - Santa Monica Cancer Care, Santa Monica, California, 90404, United States|UCLA Ronald Reagan Med Ctr, Santa Monica, California, 90404, United States|Smillow Cancer Hosp, New Haven, Connecticut, 06520, United States|Yale Cancer Center, New Haven, Connecticut, 06520, United States|Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, 22057, United States|SCRI - Florida Cancer Specialists - South Region Research Office, Fort Myers, Florida, 33901, United States|SCRI - Florida Cancer Specialists - North Region Research Office, Saint Petersburg, Florida, 33705, United States|SCRI - Florida Cancer Specialists - Panhandle Research Office, Tallahassee, Florida, 32308, United States|SCRI - Florida Cancer Specialists - East Region Research Office, West Palm Beach, Florida, 33401, United States|University of Louisville James Graham Brown Cancer Center, Louisville, Kentucky, 40202, United States|Norton Cancer Institute - Poplar Level Road, Louisville, Kentucky, 40217, United States|Ochsner Cancer Institute, New Orleans, Louisiana, 70121, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, 48109, United States|HealthPartners Cancer Center at Regions Hospital, Saint Louis Park, Minnesota, 55426, United States|Regions Hospital, Saint Louis Park, Minnesota, 55426, United States|Perlmutter Cancer Ctr NYU, Mineola, New York, 11501, United States|Perlmutter Cancer Center - 38th Street, New York, New York, 10016, United States|Memorial Sloan Kettering Cancer Center - New York, New York, New York, 10065, United States|Duke University Medical Center, Durham, North Carolina, 27710, United States|Cleavland Clin - Taussig Cancer Ctr, Cleveland, Ohio, 44106, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, 44106, United States|Cleveland Clin - Fairview Hosp, Cleveland, Ohio, 44111, United States|Mark H. Zangmeister Cancer Center, Columbus, Ohio, 43219, United States|Cleveland Clin-Hillcrest Hosp, Mayfield Heights, Ohio, 44124, United States|Prov Care Clinic - Westside, Portland, Oregon, 97225, United States|Providence Cancer Center Oncology and Hematology Care Westside Portland, Portland, Oregon, 97225, United States|Providence Cancer Institute, Portland, Oregon, 97225, United States|Prisma Health Cancer Institute - Faris Road, Greenville, South Carolina, 29605, United States|Tennessee Oncology - Chattanooga - Memorial Plaza, Nashville, Tennessee, 37203, United States|Tennessee Oncology - Nashville - Centennial, Nashville, Tennessee, 37203, United States|Vanderbilt - Ingram Cancer Center, Nashville, Tennessee, 37232, United States|University of Texas Southwestern Medical Center, Dallas, Texas, 75390, United States|The Center for Cancer & Blood Disorders - Fort Worth, Fort Worth, Texas, 76104, United States|Baylor College of Medicine, Houston, Texas, 77054, United States|Harris Health System, Houston, Texas, 77054, United States|USOR - Virginia Cancer Specialists - Fairfax Office, Fairfax, Virginia, 22031, United States|Fred Hutchinson Cancer Center - Seattle Cancer Care Alliance (SCCA) Location, Seattle, Washington, 98109, United States|Froedtert Clinical Cancer Center, Milwaukee, Wisconsin, 53226, United States|Hospital BritÃ¡nico de Buenos Aires, Buenos Aires, Argentina|Instituto de Investigaciones ClÃ­nicas Mar del Plata, Mar del Plata, Argentina|Monash University, Clayton, Australia|Gosford Hospital, Gosford, Australia|Liverpool Hospital, Liverpool, Australia|Oncology West - Murdoch, Murdoch, Australia|FundaÃ§Ã£o Pio XII - Hospital de CÃ¢ncer de Barretos - Hospital de Amor, Barretos, Brazil|ONCOSITE - Centro de Pesquisa Clinica Em Oncologia Ltda., IjuÃ­, Brazil|Liga Contra o CÃ¢ncer - Centro AvanÃ§ado de Oncologia, Natal, Brazil|Hospital Ernesto Dornelles, Porto Alegre, Brazil|Instituto Nacional de CÃ¢ncer - Brazil, Rio de Janeiro, Brazil|Queen Elizabeth II Health Sciences Centre-Victoria General, Halifax, Canada|CHUM, Montreal, Canada|HÃ´pital Notre-Dame, Montreal, Canada|Ottawa Hospital - General Campus, Ottawa, Canada|Princess Margaret Cancer Centre, Toronto, Canada|Sunnybrook Health Sciences Centre - Bayview Campus, Toronto, Canada|Icegclinic, La Florida, Chile|Oncovida - Santiago, Providencia, Chile|Hospital Puerto Montt, Puerto Montt, Chile|Bradford Hill Centro de Investigaciones Clinicas, Recoleta, Chile|Centro de Estudios ClÃ­nicos SAGA, Santiago, Chile|Pontificia Universidad Catolica de Chile - Escuela De Medicina - Clinica UC San Carlos de Apoq, Santiago, Chile|ClÃ­nica Universidad CatÃ³lica del Maule - Talca, Talca, Chile|Institut BergoniÃ©, Bordeaux cedex, France|HÃ´pital Morvan, Brest, France|Centre de Lutte contre le Cancer - FranÃ§ois Baclesse, Caen Cedex 5, France|HÃ´pital Claude Huriez, Lille Cedex, France|Centre LÃ©on BÃ©rard, Lyon, France|HÃ´pital de la Timone, Marseille, France|Institut RÃ©gional du Cancer de Montpellier, Montpellier, France|Centre Armoricain de RadiothÃ©rapie, d'Imagerie MÃ©dicale et d'Oncologie, Plerin, France|Centre Hospitalier Universitaire de Poitiers, Poitiers, France|Institut Gustave Roussy, Villejuif, France|Evex Hospitals - Kutaisi Referral Hospital, Kutaisi, 4600, Georgia|LLC Todua Clinic, Tbilisi, 112, Georgia|Ltd Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic, Tbilisi, 144, Georgia|New Vision University Hospital, Tbilisi, 159, Georgia|Multi-profile Clinic ""New Hospitals"", Tbilisi, 186, Georgia|Evgenidion Clinic SA - Agia Trias, Athens, Greece|General Oncology Hospital of Kifisias ""Agioi Anargyroi"", Nea Kifisia, Greece|Metropolitan Hospital, Neo Faliro, Greece|BioClinic Thessaloniki, Thessaloniki, Greece|Medi-k CayalÃ¡, Guatemala city, Guatemala|ClÃ­nica Privada Dr. Rixci RamÃ­rez, Guatemala, Guatemala|Grupo Medico Angeles, Guatemala, Guatemala|INTEGRA Cancer Institute, Guatemala, Guatemala|Centro Regional de Sub Especialidades MÃ©dicas (CRESEM) SA, Quetzaltenango, Guatemala|Hong Kong Sanatorium and Hospital, Happy Valley, Hong Kong|Humanity & Health Clinical Trial Centre, Hong Kong, Hong Kong|Queen Mary Hospital - Hong Kong, Hong Kong, Hong Kong|Tuen Mun Hospital, Tuen Mun, Hong Kong|DÃ©l-pesti CentrumkÃ³rhÃ¡z - OrszÃ¡gos HematolÃ³giai Ã©s InfektolÃ³giai IntÃ©zet, Budapest, Hungary|OrszÃ¡gos OnkolÃ³giai IntÃ©zet, Budapest, Hungary|BÃ¡cs-Kiskun Megyei OktatÃ³kÃ³rhÃ¡z - KecskemÃ©t, Kecskemet, Hungary|PÃ©csi TudomÃ¡nyegyetem Klinikai KÃ¶zpont, Pecs, Hungary|Hadassah University Hospital Ein Kerem, Jerusalem, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Davidoff Cancer Center, Petah Tikva, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Azienda Ospedaliero - Universitaria Careggi, Firenze, Italy|Istituto Europeo di Oncologia, Milano, Italy|Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele, Milan, Italy|Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Istituto Clinico Humanitas, Rozzano, Italy|Azienda Sanitaria Universitaria Friuli Centrale ? P.O. Santa Maria della Misericordia, Udine, Italy|Hyogo Cancer Center, Akashi City, Japan|University of Tokyo Hospital, Bunkyo-ku, Japan|Tokyo Metro Ctr, BunkyÅ-Ku, Japan|Chiba Cancer Center, Chiba, Japan|Kyushu Cancer Center, Fukuoka-shi, Japan|Saitama Cancer Center, Ina, Japan|Nat Cancer Ctr-Kashiwa Campus, Kashiwa-shi, Japan|St. Marianna Uni Hosp, Kawasaki, Japan|Cancer Inst Hosp of JFCR, Koto, Japan|Kumamoto University Hospital, Kumamoto, Japan|Shikoku Cancer Center, Matsuyama-Shi, Japan|Shizuoka Cancer Center, Matsuyama-Shi, Japan|Aichi Cancer Center, Nagoya, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Kindai University Hospital, Osakasayama-shi, Japan|Osaka Prefectural Hosp Org, Osaka, Japan|Gunma Prefectural Cancer Ctr, Ota-shi, Japan|Teine Keijinkai Hospital, Sapporo, Japan|National Cancer Ctr Hosp, Tokyo, Japan|Kanagawa Cancer Center, Yokohama-Shi, Japan|Dong-A University Hospital, Busan, Korea, Republic of|Kyungpook Nat Uni Chilgok, Daegu, Korea, Republic of|Cha Bundang Medical Center, Seongnam, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul Nat Uni Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Kauno Klinikos, Kaunas, Lithuania|Klaipedos Universitetine Ligonine, Klaipeda, Lithuania|Nacionalinis VÄÅ¾io Institutas, Vilnius, Lithuania|Vilniaus Universiteto LigoninÄ SantariÅ¡kiÅ³ Klinikos, Vilnius, Lithuania|Hospital Pulau Pinang, George Town, Malaysia|Hospital Kuala Lumpur, Kuala Lumpur, Malaysia|Pusat Perubatan Universiti Malaya, Kuala Lumpur, Malaysia|Hospital Umum Sarawak, Kuching, Malaysia|CLIMERS Clinical Medical Research, Colonia Centro, 94300, Mexico|Centro de AtenciÃ³n e InvestigaciÃ³n ClÃ­nica en OncologÃ­a, Merida, 97134, Mexico|Centro Especializado en Investigacion y Tratamiento Oncologicos SC, Mexico DF, 3100, Mexico|Hospital Zambrano Hellion TecSalud, San Pedro Garza GarcÃ­a, 66278, Mexico|Centro Hemato - OncolÃ³gico Privado (CHOP), Toluca de Lerdo, 50120, Mexico|Hospital Nacional Daniel Alcides CarriÃ³n, Bellavista, Peru|SANNA - ClÃ­nica El Golf, San Isidro, Peru|Hospital Maria Auxiliadora, San Juan De Miraflores, Peru|Instituto Nacional de Enfermedades NeoplÃ¡sicas, Surquillo, Peru|Dr Pablo O. Torre Memorial Hospital - Riverside Medical Center, Bacolod City, Philippines|Baguio General Hospital and Medical Center, Baguio, Philippines|Cebu Doctors' University Hospital, Cebu City, Philippines|Manila Doctors Hospital, Manila, Philippines|Centrum Onkologii Ziemi Lubelskiej im. Åw. Jana z Dukli, Lublin, Poland|Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublinie, Lublin, Poland|Szpital Miejski w Tychach, Tychy, Poland|Narodowy Instytut Onkologii im. Marii SkÅodowskiej-Curie - PaÅstwowy Instytut Badawczy, Warszawa, Poland|Centro Hospitalar e UniversitÃ¡rio de Coimbra, Coimbra, Portugal|FundaÃ§Ã£o D. Anna de Sommer Champalimaud e Dr. Carlos Montez Champalimaud, Lisboa, Portugal|Instituto PortuguÃªs de Oncologia do Porto Francisco Gentil, Porto, Portugal|Spitalul Judetean de Urgenta, Baia Mare, Romania|Institutul Clinic Fundeni, Bucharest, Romania|Institutul Oncologic Prof. Dr. Ion Chiricuta, Cluj-Napoca, Romania|Medisprof, Cluj-Napoca, Romania|Centrul De Oncologie Sf Nectarie, Craiova, Romania|Centrul de Radioterapie Amethyst Cluj, FloreÈti, Romania|Centrul de Oncologie Euroclinic, Iasi, Romania|Clinica SIGMedical, Suceava, Romania|Institute of Oncology and Radiology of Serbia (Institut za onkologiju i radiologiju Srbije), Belgrade, Serbia|University Hospital Medical Center (KBC) Bezanijska Kosa, Belgrade, Serbia|Clinical Center Kragujevac, Kragujevac, Serbia|Hospital Universitari Vall d'HebrÃ³n, Barcelona, Spain|Institut CatalÃ  d'Oncologia - Hospital Duran i Reynals (ICO L'Hospitalet), Barcelona, Spain|Hospital General Universitario Gregorio MaraÃ±Ã³n, Madrid, Spain|Hospital Universitario HM Sanchinarro, Madrid, Spain|Hospital Universitario RamÃ³n y Cajal, Madrid, Spain|Hospital Universitario MarquÃ©s de Valdecilla, Santander, Spain|Hospital ClÃ­nico Universitario de Valencia, Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Faculty of Medicine Siriraj Hospital, Bang Phlat, Thailand|Songklanagarind Hospital, Hat Yai, Thailand|Sunpasitthiprasong Hospital, Ubon Ratchathani, Thailand|T.C. Saglik Bakanligi Adana Sehir Egitim ve Arastirma Hastanesi, Adana, Turkey|Memorial Ankara Hastanesi, Ankara, Turkey|Trakya Universitesi Tip Fakultesi, Edirne, Turkey|T.C. Saglik Bakanligi - Istanbul Il Saglik Mudurlugu - Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi, Istanbul, Turkey|Kocaeli Ãniversitesi AraÅtÄ±rma ve Uygulama Hastanesi, Izmit, Turkey|InÃ¶nÃ¼ Ãniversitesi Turgut Ãzal TÄ±p Merkezi, Malatya, Turkey|Ankara Ãniversitesi TÄ±p FakÃ¼ltesi - Cebeci AraÅtÄ±rma ve Uygulama Hastanesi, Mamak, Turkey|Van YÃ¼zÃ¼ncÃ¼ YÄ±l Ãniversitesi Dursun OdabaÅ TÄ±p Merkezi, Van, Turkey|Ataturk Universitesi Arastirma Hastanesi, Yakutiye, Turkey|BaÅkent Ãniversitesi Adana Dr Turgut Noyan Uygulama ve AraÅtirma Merkezi, YÃ¼reÄir, Turkey|Barts Health NHS Trust, London, United Kingdom|Sarah Cannon Research Institute London, London, United Kingdom|The Royal Marsden NHS Foundation Trust, London, United Kingdom|University College London Hospitals NHS Foundation Trust, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom|The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom",
NCT01954992,Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer,https://clinicaltrials.gov/study/NCT01954992,,RECRUITING,The study is designed to assess whether glufosfamide provides additional survival benefit as compared to bolus 5-FU in patients with metastatic pancreatic cancer who have already progressed or failed therapy on a gemcitabine based first line regimen.,NO,Metastatic Pancreatic Adenocarcinoma,DRUG: Glufosfamide|DRUG: Fluorouracil,"Overall Survival, Time from Randomization to death from any cause, Approximately 3-6 months",,,Eleison Pharmaceuticals LLC.,,ALL,"ADULT, OLDER_ADULT",PHASE3,480,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2014-04,2026-06,2026-12,2013-10-07,,2024-12-31,"Innovative Clinical Research Institute, Whittier, California, 90603, United States|Moffitt Cancer Center, Tampa, Florida, 33612, United States|Gabrail Cancer Center Research, Canton, Ohio, 44718, United States",
NCT06928389,Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT06928389,NSCLC,NOT_YET_RECRUITING,"This is a Phase 3 Randomized, double-blind, Multicenter Study of Ivonescimab Combined with Docetaxel Versus Placebo Combined with Docetaxel in Patients with Locally advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) that has progressed on or after PD-(L)1 inhibitor-based therapy. The purpose of this study is to evaluate the efficacy and safety of ivonescimab versus placebo, combined with docetaxel in patients with advanced NSCLC.",NO,Non-Small Cell Lung Cancer,"DRUG: Ivonescimab, docetaxel|DRUG: Placebo, docetaxel","Overall Survival (OS), Overall Survival (OS) in the FAS population, approximately 5 years","Progression Free Survival (PFS), Progression Free Survival (PFS) assessed by investigator based on RECIST V1.1, approximately 3 years|Adverse Event (AE), Incidence and severity of adverse events (AEs) and clinically significant abnormal laboratory test results, From the patient signs the ICF to 30 days (AE) and 90 days (SAE) after the last dose of study treatment or initiation of other anticancer therapy, whichever occurs first",,Akeso,,ALL,"ADULT, OLDER_ADULT",PHASE3,536,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2025-06,2027-05,2030-06,2025-04-15,,2025-05-01,,
NCT04073550,Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT04073550,,UNKNOWN,"Anlotinib hydrochloride is a multi-targeted receptor tyrosine kinase inhibitor that targets angiogenesis-related kinases such as VEGFR1/2/3, FGFR1/2/3, and other tumor-associated kinases involved in cell proliferation such as PDGFRÎ±/Î², c-Kit, and Ret have significant inhibitory activities.",NO,Small Cell Lung Cancer,DRUG: Anlotinib|DRUG: Placebos|DRUG: Topotecan,"Progression Free Survival (PFS) evaluated by IRC, PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause; IRC defined as Independent Review Committee., up to 24 months","Progression Free Survival (PFS) evaluated by investigator, PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause., up to 24 months|Overall survival (OS), OS defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive., up to 24 months|Overall Response Rate (ORR), Percentage of Participants Achieving Complete Response (CR) and Partial Response (PR)., up to 24 months|Disease Control Rate (DCR), Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD)., up to 24 months|Duration of Overall Response (DOR), The time when the patient first achieved complete or partial remission to disease progression., up to 24 months|PFS rate at month 6, The percentage of PFS at month 6., up to 6 months|OS rate at month 6, The percentage of OS at month 6., up to 6 months|OS rate at month 12, The percentage of OS at month 12., up to 12 months|The efficacy of intracranial lesions, To evaluate the efficacy of of intracranial lesions., up to 24 months|Adverse Event (AE), Safety data, up to 24 months|Serious Adverse Event (SAE), Safety data, up to 24 months|Abnormal laboratory test index, Safety data, up to 24 months",,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,184,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-10-31,2021-07-31,2022-07-31,2019-08-29,,2019-08-29,"Beijing Cancer Hospital, Beijing, Beijing, 100083, China|Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, 100083, China",
NCT06921785,Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma,https://clinicaltrials.gov/study/NCT06921785,ARTEMIDE-HCC01,RECRUITING,"This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will be conducted in participants with advanced HCC who are not amenable to curative therapy or locoregional therapy",NO,Hepatocellular Carcinoma,DRUG: Tremelimumab|DRUG: Rilvegostomig|DRUG: Bevacizumab|DRUG: Atezolizumab,"To demonstrate the efficacy of Arm A relative to Arm C by assessment of OS in participants with advanced HCC, OS is defined as the time from randomisation until the date of death due to any cause., Up to approximately 6 years","To demonstrate the efficacy of Arm B relative to Arm C by assessment of OS in participants with advanced HCC, OS is defined as the time from randomisation until the date of death due to any cause., Up to approximately 6 years|To further demonstrate the efficacy of Arm A relative to Arm C and Arm B relateive to Arm C in participants with advanced HCC, PFS according to RECIST 1.1, Up to approximately 6 years|To further demonstrate the efficacy of Arm A relative to Arm C and Arm B relateive to Arm C in participants with advanced HCC, ORR according to RECIST 1.1, Up to approximately 6 years|To demonstrate the efficacy of Arm A relative to Arm B in participants with advanced HCC, OS, Up to approximately 6 years|To demonstrate the efficacy of Arm A relative to Arm B in participants with advanced HCC, PFS, Up to approximately 6 years|To demonstrate the efficacy of Arm A relative to Arm B in participants with advanced HCC, ORR, Up to approximately 6 years|To demonstrate the efficacy of Arm A relative to Arm B in participants with advanced HCC, DoR, Up to approximately 6 years|To demonstrate the efficacy of Arm A relative to Arm C in the population defined by PD-L1 expression subgroups, Association of PD-L1 expression level with:

â¢ OS, Up to approximately 6 years|To demonstrate the efficacy of Arm A relative to Arm C in the population defined by PD-L1 expression subgroups, Association of PD-L1 expression level with:

â¢ PFS per RECIST 1.1, Up to approximately 6 years|To demonstrate the efficacy of Arm A relative to Arm C in the population defined by PD-L1 expression subgroups, Association of PD-L1 expression level with:

â¢ ORR per RECIST 1.1, Up to approximately 6 years|To demonstrate the efficacy of Arm A relative to Arm C in the population defined by PD-L1 expression subgroups, Association of PD-L1 expression level with:

â¢DoR per RECIST 1.1, Up to approximately 6 years|To demonstrate the efficacy of Arm B relative to Arm C in the population defined by PD-L1 expression subgroups, Association of PD-L1 expression level with:

OS, Up to approximately 6 years|To demonstrate the efficacy of Arm B relative to Arm C in the population defined by PD-L1 expression subgroups, Association of PD-L1 expression level with:

PFS per RECIST 1.1, Up to approximately 6 years|To demonstrate the efficacy of Arm B relative to Arm C in the population defined by PD-L1 expression subgroups, Association of PD-L1 expression level with:

ORR per RECIST 1.1, Up to approximately 6 years|To demonstrate the efficacy of Arm B relative to Arm C in the population defined by PD-L1 expression subgroups, Association of PD-L1 expression level with:

DoR per RECIST 1.1, Up to approximately 6 years|To investigate the immunogenicity of Arm A and Arm B, Presence of ADAs for tremelimumab and rilvegostomig, Up to approximately 6 years|Occurrence of adverse events (AEs) and serious adverse events (SAEs), Occurrence of AEs and SAEs will be graded according to the revised NCI CTCAE v5.0., Up to approximately 6 years",,AstraZeneca,,ALL,"ADULT, OLDER_ADULT",PHASE3,1220,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2025-05-06,2029-03-16,2030-03-15,2025-04-10,,2025-05-31,"Research Site, Phoenix, Arizona, 85054, United States|Research Site, Palo Alto, California, 94304, United States|Research Site, Jacksonville, Florida, 32224, United States|Research Site, Atlanta, Georgia, 30322, United States|Research Site, Grand Rapids, Michigan, 49503, United States|Research Site, Rochester, Minnesota, 55905, United States|Research Site, New Brunswick, New Jersey, 08901, United States|Research Site, Oklahoma City, Oklahoma, 73104, United States|Research Site, Arlington, Virginia, 22201, United States|Research Site, Milwaukee, Wisconsin, 53226, United States|Research Site, Porto Alegre, 91350-200, Brazil|Research Site, Sao Paulo, 05652-9000, Brazil|Research Site, VitÃ³ria, 29043-272, Brazil|Research Site, Halifax, Nova Scotia, B3H 1V7, Canada|Research Site, Barrie, Ontario, L4M 6M2, Canada|Research Site, Cambridge, Ontario, N1R 3G2, Canada|Research Site, Ottawa, Ontario, K1H 8L6, Canada|Research Site, Toronto, Ontario, M5G 1X6, Canada|Research Site, MontrÃ©al, Quebec, H2X 0A9, Canada|Research Site, QuÃ©bec, Quebec, G1J 4Z1, Canada|Research Site, Beijing, CN-100730, China|Research Site, Changchun, 130021, China|Research Site, Chengdu, 610041, China|Research Site, Deyang, 618000, China|Research Site, Guangzhou, 510515, China|Research Site, Lishui, 323000, China|Research Site, Luoyang, 471000, China|Research Site, Nanchang, 330008, China|Research Site, Nanchang, 330029, China|Research Site, Shanghai, 201114, China|Research Site, Shanghai, 201114, China|Research Site, Wenzhou, 325000, China|Research Site, Clichy Cedex, 92118, France|Research Site, Lyon Cedex, 69317, France|Research Site, Nantes Cedex 1, 44093, France|Research Site, Nice, 06200, France|Research Site, Pessac Cedex, 33604, France|Research Site, Rennes, 35000, France|Research Site, Toulouse, 31059, France|Research Site, Aachen, 52074, Germany|Research Site, Berlin, 13353, Germany|Research Site, Bonn, 53127, Germany|Research Site, Dortmund, 44137, Germany|Research Site, Dresden, 01307, Germany|Research Site, Essen, 45122, Germany|Research Site, Frankfurt, 60488, Germany|Research Site, Frankfurt, 60590, Germany|Research Site, GÃ¶ttingen, 37075, Germany|Research Site, Hamburg, 20246, Germany|Research Site, Hannover, 30623, Germany|Research Site, Leipzig, 4103, Germany|Research Site, LÃ¼beck, 23538, Germany|Research Site, Magdeburg, 39120, Germany|Research Site, Moers, 47441, Germany|Research Site, MÃ¼nchen, 81377, Germany|Research Site, Regensburg, 93053, Germany|Research Site, Ulm, 89081, Germany|Research Site, Hong Kong, 999077, Hong Kong|Research Site, Hong Kong, Hong Kong|Research Site, Pisa, 56126, Italy|Research Site, Roma, 00168, Italy|Research Site, Chiba-shi, 260-8677, Japan|Research Site, Kashiwa, 227-8577, Japan|Research Site, Kyoto-shi, 602-8566, Japan|Research Site, Morioka-shi, 028-3695, Japan|Research Site, Musashino-shi, 180-8610, Japan|Research Site, Osakasayama-shi, 589-8511, Japan|Research Site, Tokyo, 104-0045, Japan|Research Site, Yokohama-shi, 241-8515, Japan|Research Site, Barcelona, 08035, Spain|Research Site, Barcelona, 08036, Spain|Research Site, Madrid, 28007, Spain|Research Site, Madrid, 28027, Spain|Research Site, Madrid, 28040, Spain|Research Site, Santander, 39008, Spain|Research Site, Taipei, 10002, Taiwan|Research Site, Taipei, 112, Taiwan|Research Site, Taoyuan, 333, Taiwan|Research Site, AltÄ±ndaÄ, 06230, Turkey|Research Site, Ankara, 06530, Turkey|Research Site, Erzurum, 25240, Turkey|Research Site, Istanbul, 34180, Turkey|Research Site, Izmir, 35100, Turkey|Research Site, Hanoi, 100000, Vietnam|Research Site, Ho Chi Minh City, 700000, Vietnam|Research Site, Ho Chi Minh, 700000, Vietnam",
NCT06097728,MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma,https://clinicaltrials.gov/study/NCT06097728,eVOLVE-Meso,RECRUITING,"This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator's choice of platinum + Pemetrexed or Nivolumab + Ipilimumab in participants with unresectable pleural mesothelioma.",NO,Unresectable Pleural Mesothelioma,DRUG: Volrustomig|DRUG: Pemetrexed|DRUG: Carboplatin|DRUG: Cisplatin|DRUG: Nivolumab|DRUG: Ipilimumab,"Overall Survival (OS) in experimental arm relative to comparator arm, OS is defined as the time from randomization until the date of death due to any cause., up to approximately 61 months","Overall Survival (OS), OS is defined as the time from randomization until the date of death due to any cause., up to approximately 61 months|Progression Free Survival (PFS), PFS is defined as the time from randomization until progression per mRECIST 1.1 and/or RECIST 1.1 as assessed by the investigator at local site, or death due to any cause., up to approximately 61 months|Landmark OS, Landmarks of OS12, OS18, OS24, and OS36., 12, 18, 24, 36 months|Landmark PFS, Landmarks of PFS6, PFS12, PFS18, and PFS24, 6, 12, 18, 24 months|Overall Response Rate (ORR), Proportion of participants who have a confirmed Complete Response or confirmed Partial Response, as determined by the investigator at local site per mRECIST 1.1 and/or RECIST 1.1., up to approximately 61 months|Duration of Response (DoR), DoR defined as the time from the date of first documented response until date of documented progression per mRECIST 1.1 and/or RECIST 1.1 as assessed by the investigator at local site or death due to any cause., up to approximately 61 months|PFS2, PFS2 defined as the time from randomization to the earliest of the progression event (following the initial investigator-assessed progression), after first subsequent therapy, or death., up to approximately 61 months|Patient-reported physical functioning, TTD in physical functioning as measured by PROMIS (Patient Reported Outcomes Measurement Information System) Physical Function Short Form 8c. There are 8 questions each from a scale of 1 (unable to do) to a scale of 5 (With a little difficulty). The higher the scores the better the patient-reported physical functioning is., up to approximately 61 months.|Disease-related symptoms using EORTC IL305 (Q1), Change from baseline in disease-related symptoms as measured by individual symptom items from the EORTC (European Organisation For Research And Treatment Of Cancer) IL305 (Item Library 305) (Q1). It is scored from a 1 (not at all) to a 4 (very much). The higher the score the higher the disease-related symptoms., Up to approximately 61 months.|Disease-related symptoms using PRO-CTCAE (Q1, 5, 6, 9), Change from baseline in disease-related symptoms as measured by individual symptom items from the PRO-CTCAE (Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events) (Q1, 5, 6, 9). PRO-CTCAE responses are scored from 0 to 4 (or 0/1 for absent/present). The higher the score the higher the disease-related symptoms., Up to approximately 61 months|Patient-reported role functioning using EORTC QLQ-C30 RF subscale (IL305 Q2 3), Change from baseline in functioning will be assessed by the following measure:

Role functioning: EORTC (European Organisation For Research And Treatment Of Cancer) QLQ (Quality of Life Questionnaire) -C30 RF (Role Functioning) subscale (IL305 Q2 3) (Item Library 305). The questions are from a scale of 1 (not at all) to 4 (very much). The lower the score the higher the patient-reported role functioning is., up to approximately 61 months|Patient-reported HRQoL (Health-related Quality of Life) using EORTC QLQ-C30 HRQoL subscale (IL305 Q7-8), Change from baseline in functioning will be assessed by the following measure:

HRQoL: EORTC (European Organisation For Research And Treatment Of Cancer) QLQ (Quality of Life Questionnaire) -C30 HRQoL subscale (IL305 Q7-8) (Item Library 305). The questions are from a scale of 1 (very poor) to 7 (excellent). The higher the score the higher the HRQoL., Up to approximately 61 months|Immunogenicity of volrustomig, Incidence of Anti-Drug Antibodies against volrustomig., up to approximately 61 months|Incidence of Adverse Events (AEs) AEs graded by CTCAE version 5.0, Incidence of Adverse Events (AEs) AEs graded by CTCAE (Common Terminology Criteria for Adverse Events) version 5.0. Grade refers to the severity of the AE. The CTCAE displays grade 1 (mild) through 5 (death related to AE). Grade 2 (moderate), Grade 3 (Severe) and Grade 4 (Life-threatening consequences)., Up to approximately 61 months|Area under the curve (AUC), The concentration of MEDI5752 in serum will be determined. Area under the curve is the integral of the concentration-time curve. The AUC reflects the actual body exposure to drug after administration. The AUC is dependent on the rate of elimination of the drug from the body and the dose administered., Up to approximately 61 months|Maximum plasma concentration of the drug (Cmax), The concentration of MEDI5752 in serum will be determined (Cmax will be derived)., Up to approximately 61 months|The time taken to reach the maximum concentration (Tmax), The concentration of MEDI5752 in serum will be determined (Tmax will be derived)., Up to approximately 61 months",,AstraZeneca,,ALL,"ADULT, OLDER_ADULT",PHASE3,825,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-11-09,2027-03-15,2028-03-13,2023-10-24,,2025-06-11,"Research Site, Phoenix, Arizona, 85054, United States|Research Site, Duarte, California, 91010, United States|Research Site, Santa Rosa, California, 95403, United States|Research Site, Aurora, Colorado, 80045, United States|Research Site, Jacksonville, Florida, 32224, United States|Research Site, Atlanta, Georgia, 30322, United States|Research Site, Chicago, Illinois, 60637, United States|Research Site, Baltimore, Maryland, 21231, United States|Research Site, Rochester, Minnesota, 55905, United States|Research Site, Saint Louis, Missouri, 63110, United States|Research Site, East Brunswick, New Jersey, 08816, United States|Research Site, Commack, New York, 11725, United States|Research Site, Valhalla, New York, 10595, United States|Research Site, Cleveland, Ohio, 44111, United States|Research Site, Cleveland, Ohio, 44124, United States|Research Site, Cleveland, Ohio, 44195, United States|Research Site, Columbus, Ohio, 43210, United States|Research Site, Independence, Ohio, 44131, United States|Research Site, Portland, Oregon, 97213, United States|Research Site, Portland, Oregon, 97225, United States|Research Site, Portland, Oregon, 97239, United States|Research Site, Philadelphia, Pennsylvania, 19104, United States|Research Site, Houston, Texas, 77030, United States|Research Site, Fairfax, Virginia, 22031, United States|Research Site, Chermside, 4032, Australia|Research Site, Clayton, 3168, Australia|Research Site, Melbourne, 3000, Australia|Research Site, Nedlands, 6009, Australia|Research Site, Westmead, 2145, Australia|Research Site, Anderlecht, 1070, Belgium|Research Site, Antwerpen, 2020, Belgium|Research Site, Gent, 9000, Belgium|Research Site, Hasselt, 3500, Belgium|Research Site, Leuven, 3000, Belgium|Research Site, Sint-Niklaas, 9100, Belgium|Research Site, Barretos, 14784-400, Brazil|Research Site, Fortaleza, 60336-045, Brazil|Research Site, Joao Pessoa, 58013-140, Brazil|Research Site, Porto Alegre, 91350-200, Brazil|Research Site, Rio de Janeiro, 22281-100, Brazil|Research Site, Santo Andre, 09060-650, Brazil|Research Site, SÃ£o Paulo, 01246-000, Brazil|Research Site, Edmonton, Alberta, T6G 1Z2, Canada|Research Site, Hamilton, Ontario, L8V 1C3, Canada|Research Site, London, Ontario, N6A 5W9, Canada|Research Site, Ottawa, Ontario, K1H 8L6, Canada|Research Site, Toronto, Ontario, M5G 1X6, Canada|Research Site, Montreal, Quebec, H2X 0C1, Canada|Research Site, Quebec, G1V 4G5, Canada|Research Site, Beijing, 100142, China|Research Site, Beijing, 100210, China|Research Site, Changchun, 130021, China|Research Site, Changsha, 410013, China|Research Site, Chengdu, 610042, China|Research Site, Chongqing, 400030, China|Research Site, Guangzhou, 510060, China|Research Site, Guangzhou, 510100, China|Research Site, Guangzhou, 510180, China|Research Site, Hangzhou, 310022, China|Research Site, Harbin, 150049, China|Research Site, Kunming, 650118, China|Research Site, Lanzhou, 730000, China|Research Site, Nanchang, 330006, China|Research Site, Ningbo, 315100, China|Research Site, Qingdao, 266003, China|Research Site, Shandong, China|Research Site, Shanghai, 200032, China|Research Site, Shenyang, 110044, China|Research Site, Taiyuan, 030000, China|Research Site, Taiyuan, 030032, China|Research Site, Tianjin, 300050, China|Research Site, Tianjin, 300060, China|Research Site, Wuhan, 430030, China|Research Site, Xi'an, 710061, China|Research Site, Zhengzhou, 450008, China|Research Site, Zhengzhou, 450052, China|Research Site, Aarhus N, 8200, Denmark|Research Site, Copenhagen, 2100, Denmark|Research Site, Brest, 29200, France|Research Site, Creteil Cedex, 94010, France|Research Site, Le Mans Cedex, 72037, France|Research Site, Lille, 59037, France|Research Site, Lyon, 69373, France|Research Site, Marseille Cedex 20, 13015, France|Research Site, Montpellier, 34298, France|Research Site, Paris, 75877, France|Research Site, Rouen, 76031, France|Research Site, Saint Herblain, 44800, France|Research Site, Strasbourg, 67091, France|Research Site, Toulouse, 31059, France|Research Site, Berlin, 13125, Germany|Research Site, Berlin, 14109, Germany|Research Site, Bochum, 44791, Germany|Research Site, Essen, 45122, Germany|Research Site, Essen, 45130, Germany|Research Site, Gauting, 82131, Germany|Research Site, Georgsmarienhuette, 49124, Germany|Research Site, Grosshansdorf, 22927, Germany|Research Site, Hamburg, 21075, Germany|Research Site, Heidelberg, 69126, Germany|Research Site, Kiel, 24105, Germany|Research Site, KÃ¶ln, 51109, Germany|Research Site, Muenster, 48153, Germany|Research Site, Regensburg, 93049, Germany|Research Site, Alessandria, 15100, Italy|Research Site, Bari, 70124, Italy|Research Site, Bergamo, 24125, Italy|Research Site, Milan, 20141, Italy|Research Site, Monza, 20052, Italy|Research Site, Orbassano, 10043, Italy|Research Site, Padova, 35128, Italy|Research Site, Parma, 43100, Italy|Research Site, Rozzano, 20089, Italy|Research Site, Varese, 21100, Italy|Research Site, Amagasaki-shi, 660-8550, Japan|Research Site, Hakodate-shi, 040-8611, Japan|Research Site, Hiroshima-shi, 734-8551, Japan|Research Site, Kitaadachi-gun, 362-0806, Japan|Research Site, Kitakyushu-shi, 807-8555, Japan|Research Site, Matsuyama-shi, 791-0280, Japan|Research Site, Nagoya-shi, 466-8560, Japan|Research Site, Nishinomiya-shi, 663-8501, Japan|Research Site, Okayama-shi, 702-8055, Japan|Research Site, Osakasayama-shi, 589-8511, Japan|Research Site, Tokyo, 104-0045, Japan|Research Site, Ube-shi, 755-0241, Japan|Research Site, Cheongju-si, 28644, Korea, Republic of|Research Site, Seoul, 03080, Korea, Republic of|Research Site, Seoul, 06351, Korea, Republic of|Research Site, Seoul, 06591, Korea, Republic of|Research Site, Amsterdam, 1066CX, Netherlands|Research Site, Eindhoven, 5623EJ, Netherlands|Research Site, Rotterdam, 3015 GD, Netherlands|Research Site, LÃ¸renskog, 1478, Norway|Research Site, Oslo, 450, Norway|Research Site, Bydgoszcz, 85-796, Poland|Research Site, Bystra, 43-360, Poland|Research Site, Olsztyn, 10-357, Poland|Research Site, PoznaÅ, 60-569, Poland|Research Site, RzeszÃ³w, 35-241, Poland|Research Site, Warszawa, 02-781, Poland|Research Site, Amanzimtoti, 4126, South Africa|Research Site, Cape Town, 7570, South Africa|Research Site, Johannesburg, 2013, South Africa|Research Site, Johannesburg, 2193, South Africa|Research Site, Kimberly, 8301, South Africa|Research Site, Polokwane, 0700, South Africa|Research Site, Pretoria, 0002, South Africa|Research Site, Pretoria, 0081, South Africa|Research Site, Barakaldo, 48903, Spain|Research Site, Barcelona, 8035, Spain|Research Site, Madrid, 28041, Spain|Research Site, Oviedo, 33011, Spain|Research Site, Baden, CH-5405, Switzerland|Research Site, Basel, 4031, Switzerland|Research Site, Bern, 3010, Switzerland|Research Site, Fribourg, 1700, Switzerland|Research Site, St. Gallen, 9007, Switzerland|Research Site, Kaohsiung, 80756, Taiwan|Research Site, Taichung, 40705, Taiwan|Research Site, Tainan City, 70403, Taiwan|Research Site, Taipei, 10002, Taiwan|Research Site, Taoyuan, 333, Taiwan|Research Site, Adana, 01060, Turkey|Research Site, Ankara, 06280, Turkey|Research Site, Ankara, 06800, Turkey|Research Site, Diyarbakir, 21280, Turkey|Research Site, Izmir, 35110, Turkey|Research Site, Cambridge, CB20QQ, United Kingdom|Research Site, Cardiff, Wales, CF5 6NF, United Kingdom|Research Site, Leeds, LS9 7TF, United Kingdom|Research Site, Leicester, LE1 5WW, United Kingdom|Research Site, London, NW1 2PG, United Kingdom|Research Site, London, SE1 9RT, United Kingdom|Research Site, London, SW3 6JJ, United Kingdom|Research Site, Manchester, M23 9LT, United Kingdom|Research Site, Middlesborough, TS4 3BW, United Kingdom|Research Site, Newcastle-upon-Tyne, NE2 4HH, United Kingdom|Research Site, Portsmouth, PO6 3LY, United Kingdom|Research Site, Taunton, TA1 5DA, United Kingdom",
NCT06109779,Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01),https://clinicaltrials.gov/study/NCT06109779,,RECRUITING,A global study to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator's choice of chemotherapy in participants with BTC after surgical resection with curative intent.,NO,Biliary Tract Cancer,DRUG: Rilvegostomig|DRUG: Placebo|DRUG: Capecitabine|DRUG: Gemcitabine/Cisplatin|DRUG: S-1 [Tegafur/Oteracil/gimeracil],"Recurrence free survival (RFS) for Arm A vs. Arm B, Recurrence-free survival (RFS) is defined as the time from randomization until the date of radiological recurrence guided by RECIST 1.1 or death due to any cause, whichever occurs first., Approximately 5 years","Overall Survival (OS) for Arm A vs. Arm B, Overall survival is defined as the time from randomization until the date of death due to any cause., up to 7 years","Patient-reported tolerability Arm A vs. Arm B., Patient-reported tolerability is a multi-component endpoint defined as the proportion of participants in each arm reporting side effect bother, clinically meaningful impact on physical functioning and descriptive data on treatment-related symptoms., Up to approximately 7 years.|Progression Free Survival (PFS) following recurrence Arm A vs. Arm B., Progression-free survival following recurrence is defined as the time from randomization until the earliest progression event after the start of the first subsequent therapy or death., Up to approximately 7years",AstraZeneca,,ALL,"ADULT, OLDER_ADULT",PHASE3,750,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-12-04,2029-06-29,2030-09-30,2023-10-31,,2025-06-04,"Research Site, Birmingham, Alabama, 35233, United States|Research Site, Phoenix, Arizona, 85054, United States|Research Site, Duarte, California, 91010, United States|Research Site, Los Angeles, California, 90089, United States|Research Site, Newport Beach, California, 92663, United States|Research Site, Orange, California, 92868, United States|Research Site, Stanford, California, 94305, United States|Research Site, West Hollywood, California, 90048, United States|Research Site, Aurora, Colorado, 80045, United States|Research Site, Denver, Colorado, 80206, United States|Research Site, Littleton, Colorado, 80129, United States|Research Site, Washington, District of Columbia, 20007, United States|Research Site, Washington, District of Columbia, 20010, United States|Research Site, Altamonte Springs, Florida, 32701, United States|Research Site, Gainesville, Florida, 32611, United States|Research Site, Jacksonville, Florida, 32224, United States|Research Site, Atlanta, Georgia, 30322, United States|Research Site, Chicago, Illinois, 60637, United States|Research Site, Iowa City, Iowa, 52242, United States|Research Site, Kansas City, Kansas, 66160, United States|Research Site, Lexington, Kentucky, 40506, United States|Research Site, New Orleans, Louisiana, 70121, United States|Research Site, Baltimore, Maryland, 21201, United States|Research Site, Grand Rapids, Michigan, 49546, United States|Research Site, Rochester, Minnesota, 55905, United States|Research Site, Saint Louis, Missouri, 63110, United States|Research Site, Commack, New York, 11725, United States|Research Site, Mineola, New York, 11501, United States|Research Site, Philadelphia, Pennsylvania, 19111, United States|Research Site, Philadelphia, Pennsylvania, 19144, United States|Research Site, Nashville, Tennessee, 37232, United States|Research Site, Dallas, Texas, 75246, United States|Research Site, Tyler, Texas, 75702, United States|Research Site, Vancouver, Washington, 98684, United States|Research Site, Camperdown, 2050, Australia|Research Site, Clayton, 3168, Australia|Research Site, Murdoch, 6150, Australia|Research Site, Reservoir, 3021, Australia|Research Site, Westmead, 2145, Australia|Research Site, Brussels, 1070, Belgium|Research Site, Bruxelles, 1200, Belgium|Research Site, Edegem, 2650, Belgium|Research Site, Leuven, 3000, Belgium|Research Site, Natal, 59075-740, Brazil|Research Site, Porto Alegre, 90035-000, Brazil|Research Site, Porto Alegre, 91350-200, Brazil|Research Site, Santa Maria, 97015-450, Brazil|Research Site, Santo Andre, 09060-870, Brazil|Research Site, Sao Paulo, 01246-000, Brazil|Research Site, Sao Paulo, 01327-001, Brazil|Research Site, VitÃ³ria, 29043-260, Brazil|Research Site, Vancouver, British Columbia, VSZ 4E6, Canada|Research Site, Moncton, New Brunswick, E1C 6Z8, Canada|Research Site, Halifax, Nova Scotia, B3H 2Y9, Canada|Research Site, Brampton, Ontario, L6R 3J7, Canada|Research Site, Kingston, Ontario, K7L 2V7, Canada|Research Site, London, Ontario, N6C 2R5, Canada|Research Site, Mississauga, Ontario, L5M 2N1, Canada|Research Site, Ottawa, Ontario, K1H 8L6, Canada|Research Site, Toronto, Ontario, M4N 3M5, Canada|Research Site, Toronto, Ontario, M5G 2M9, Canada|Research Site, Montreal, Quebec, H4A 3J1, Canada|Research Site, Quebec, G1J 1Z4, Canada|Research Site, Beijing, 100142, China|Research Site, Beijing, CN-100730, China|Research Site, Changchun, 130021, China|Research Site, Changsha, 410013, China|Research Site, Chengdu, 610000, China|Research Site, Chengdu, 610072, China|Research Site, Deyang, 618000, China|Research Site, Fuzhou, 350005, China|Research Site, Guangzhou, 510060, China|Research Site, Guangzhou, 510515, China|Research Site, Guiyang, 550044, China|Research Site, Hangzhou, 310009, China|Research Site, Harbin, 150081, China|Research Site, Hefei, 230001, China|Research Site, Hefei, 230601, China|Research Site, Kunming, 650101, China|Research Site, Lanzhou, 730000, China|Research Site, Lishui, 323000, China|Research Site, Nanchang, 330006, China|Research Site, Nanjing, 2100008, China|Research Site, Nanjing, 210029, China|Research Site, Nanning, 530021, China|Research Site, Shandong, China|Research Site, Shanghai, 201114, China|Research Site, Shenyang, 110004, China|Research Site, Tianjin Shi, 300060, China|Research Site, Wuhan, 430071, China|Research Site, Wuhan, 430079, China|Research Site, Xi'an, 710061, China|Research Site, Zhengzhou, 450008, China|Research Site, Herlev, 2730, Denmark|Research Site, Marseille, 13273, France|Research Site, Montpellier, 34295, France|Research Site, Paris Cedex 5, 75248, France|Research Site, Pessac, 33604, France|Research Site, Rennes, 35000, France|Research Site, Strasbourg, 67033, France|Research Site, Toulouse Cedex 9, 31059, France|Research Site, Villejuif, 94800, France|Research Site, Berlin, 13353, Germany|Research Site, Bonn, 53127, Germany|Research Site, Dortmund, 44137, Germany|Research Site, Dresden, 01370, Germany|Research Site, Erlangen, 91054, Germany|Research Site, Essen, 45122, Germany|Research Site, Esslingen A. N., 73730, Germany|Research Site, Frankfurt, 60488, Germany|Research Site, Hamburg, 22763, Germany|Research Site, Heidelberg, 69120, Germany|Research Site, KÃ¶ln, 50937, Germany|Research Site, Leipzig, 4103, Germany|Research Site, LÃ¼beck, 23538, Germany|Research Site, MÃ¼nchen, 81377, Germany|Research Site, MÃ¼nchen, 81737, Germany|Research Site, MÃ¼nster, 48129, Germany|Research Site, Stuttgart, 70174, Germany|Research Site, Tuebingen, 72076, Germany|Research Site, Ulm, 89081, Germany|Research Site, Hong Kong, 00000, Hong Kong|Research Site, Hong Kong, 0000, Hong Kong|Research Site, Hong Kong, 999077, Hong Kong|Research Site, Shatin, 00000, Hong Kong|Research Site, Delhi, 110088, India|Research Site, Kolkata, 700094, India|Research Site, Mumbai, 400012, India|Research Site, Mysuru, 570017, India|Research Site, New Delhi, 110076, India|Research Site, New Delhi, 110085, India|Research Site, Vadodara, 391760, India|Research Site, Varanasi, 221005, India|Research Site, Firenze, 50134, Italy|Research Site, Milano, 20133, Italy|Research Site, Milano, 20162, Italy|Research Site, Padova, 35128, Italy|Research Site, Pisa, 56126, Italy|Research Site, Rozzano, 20089, Italy|Research Site, Tricase, Lecce, 73039, Italy|Research Site, Chuo-ku, 104-0045, Japan|Research Site, Hiroshima-shi, 734-8551, Japan|Research Site, Kashiwa, 227-8577, Japan|Research Site, Kitaadachi-gun, 362-0806, Japan|Research Site, Koto-ku, 135-8550, Japan|Research Site, Mitaka-shi, 181-8611, Japan|Research Site, Nagoya-shi, 464-8681, Japan|Research Site, Nagoya-shi, 466-8560, Japan|Research Site, Osaka-shi, 541-8567, Japan|Research Site, Sendai-shi, 980-8574, Japan|Research Site, Suita-shi, 565-0871, Japan|Research Site, Toyama-shi, 930-0194, Japan|Research Site, Ube, 755-8505, Japan|Research Site, Wakayama-shi, 641-8510, Japan|Research Site, Yokohama-shi, 236-0004, Japan|Research Site, Yokohama-shi, 241-8515, Japan|Research Site, Seongnam-si, 13620, Korea, Republic of|Research Site, Seoul, 03080, Korea, Republic of|Research Site, Seoul, 03722, Korea, Republic of|Research Site, Seoul, 05505, Korea, Republic of|Research Site, Seoul, 06351, Korea, Republic of|Research Site, Seoul, 06591, Korea, Republic of|Research Site, Oslo, 0379, Norway|Research Site, Bydgoszcz, 85-796, Poland|Research Site, Katowice, 40-514, Poland|Research Site, Koszalin, 75-581, Poland|Research Site, KrakÃ³w, 31-501, Poland|Research Site, Lublin, 20-080, Poland|Research Site, Przemysl, 37-700, Poland|Research Site, TomaszÃ³w Mazowiecki, 97-200, Poland|Research Site, Warszawa, 02-034, Poland|Research Site, Barcelona, 08036, Spain|Research Site, Barcelona, 8035, Spain|Research Site, L'Hospitalet de Llobregat, 08908, Spain|Research Site, Madrid, 28007, Spain|Research Site, Madrid, 28040, Spain|Research Site, Madrid, 28041, Spain|Research Site, MÃ¡laga, 29011, Spain|Research Site, Pamplona, 31005, Spain|Research Site, Santander, 39008, Spain|Research Site, Kaohsiung, 82445, Taiwan|Research Site, Kaohsiung, 83301, Taiwan|Research Site, Taichung, 40447, Taiwan|Research Site, Taichung, 40705, Taiwan|Research Site, Tainan City, 70403, Taiwan|Research Site, Taipei, 10002, Taiwan|Research Site, Taipei, 112, Taiwan|Research Site, Taoyuan, 333, Taiwan|Research Site, Hat Yai, 90110, Thailand|Research Site, Khon Kaen, 40002, Thailand|Research Site, Muang, 34000, Thailand|Research Site, Muang, 50200, Thailand|Research Site, Naimuang, 30000, Thailand|Research Site, Sisaket, 33000, Thailand|Research Site, Ankara, 06100, Turkey|Research Site, Ankara, 06230, Turkey|Research Site, Ankara, 06620, Turkey|Research Site, Antalya, 07100, Turkey|Research Site, Erzurum, 25240, Turkey|Research Site, Fatih-Istanbul, 34098, Turkey|Research Site, Istanbul, 34722, Turkey|Research Site, Samsun, 55139, Turkey|Research Site, Cambridge, CB2 0QQ, United Kingdom|Research Site, Edgbaston, B15 2WB, United Kingdom|Research Site, Glasgow, Scotland, G12 0YN, United Kingdom|Research Site, London, NW3 2QG, United Kingdom|Research Site, London, W12 0HS, United Kingdom|Research Site, London, WC1E 6BT, United Kingdom|Research Site, Manchester, M20 4BX, United Kingdom|Research Site, Sutton, SM2 5PT, United Kingdom",
NCT05690945,A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT05690945,,RECRUITING,"The purpose of this study is to evaluate the efficacy and safety of QL1706 combined with platinum-based chemotherapy versus tislelizumab combined with platinum-based chemotherapy in PD-L1 negative, locally advanced or metastatic Non-small Cell Lung Cancer Patients. The subjects were randomly divided into two groups according to 1:1, with about 304 subjects in the experimental group and the control group.",NO,Lung Cancer,DRUG: QL1706|DRUG: Tilesizumab,"PFS, Progression Free Survival in the intent to treat (ITT) population, as determined by the investigator according to RECIST v1.1 criteria, Informed consent until disease progression or death, which ever occurs first (up to approximately 2 years)|OS, Overall Survival (OS) in the ITT population determined by the investigator, From date of randomization until the date of death from any cause, which ever came first, assessed up to 2 years","ORR, Objective Response Rate assessed by investigator according to RECIST v1.1 criteria, First administration until disease progression or death, which ever occurs first (up to approximately 24 months)|DOR, Duration of Response assessed by investigator according to RECIST v1.1 criteria, First administration until disease progression or death, which ever occurs first (up to approximately 24 months)|DCR, Disease Control Rate assessed by investigator according to RECIST v1.1 criteria, First administration until disease progression or death, which ever occurs first (up to approximately 24 months)|PFS, Progression Free Survival in the intent to treat (ITT) population, as determined by the investigator according to RECIST v1.1 criteria, Informed consent until disease progression or death, which ever occurs first (up to approximately 2 years)",,"Qilu Pharmaceutical Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,608,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-02-15,2029-06,2029-12,2023-01-19,,2025-04-30,"Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China",
NCT05712694,Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC),https://clinicaltrials.gov/study/NCT05712694,,RECRUITING,To compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.,NO,Soft Tissue Sarcoma,DRUG: ADI PEG20|OTHER: Placebo,"Primary End Point of PFS, The primary objective is to compare the primary endpoint of PFS in subjects treated with the arginine degrading enzyme ADI-PEG 20 plus Gem and Doc (ADIGemDoc) or PBO plus Gem and Doc (PBOGemDoc) in the 2nd or 3rd line setting using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 assessed by blinded independent central review committee (BICR), Subjects will receive triplet combination treatment followed by weekly monotherapy ADI-PEG 20 or PBO (Each cycle is 21 days). Subjects tolerating chemotherapy may continue chemotherapy beyond 8 cycles and up to 104 weeks (~2 years).","Secondary End Point of ORR (CR+PR), The secondary objectives are to compare ADIGemDoc versus PBOGemDoc with respect to:

Objective response rate (ORR) (complete response \[CR\] + partial response \[PR\]) The secondary endpoint of ORR will be assessed by BICR using RECIST 1.1 and tested using a CMH test stratified by the stratification factors used during the randomization based on the ITT population., Subjects will receive triplet combination treatment followed by weekly monotherapy ADI-PEG 20 or PBO (Each cycle is 21 days). Subjects tolerating chemotherapy may continue chemotherapy beyond 8 cycles and up to 104 weeks (~2 years).|Secondary End Point of Overall Survival (OS), The secondary objectives are to compare ADIGemDoc versus PBOGemDoc with respect to:

OS

The secondary endpoint of OS will be tested using a log-rank test stratified by the stratification factors used during the randomization based on the ITT population. A stratified Cox model will be used to estimate HR and 95% CI, and KM curves will be used to estimate OS median and 95% CI., Subjects will receive triplet combination treatment followed by weekly monotherapy ADI-PEG 20 or PBO (Each cycle is 21 days). Subjects tolerating chemotherapy may continue chemotherapy beyond 8 cycles and up to 104 weeks (~2 years).|Secondary End Point of Safety and Tolerability, All clinically significant abnormalities and deteriorations will be followed and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE V5)., Subjects will receive triplet combination treatment followed by weekly monotherapy ADI-PEG 20 or PBO (Each cycle is 21 days). Subjects tolerating chemotherapy may continue chemotherapy beyond 8 cycles and up to 104 weeks (~2 years).",,Polaris Group,,ALL,"ADULT, OLDER_ADULT",PHASE3,300,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-11-29,2027-12-30,2027-12-30,2023-02-03,,2025-03-12,"Mayo Clinic Arizona, Phoenix, Arizona, 85054, United States|USC Norris comprehensive cancer center, Los Angeles, California, 90033, United States|UCSF, San Francisco, California, 94158, United States|UCLA, Santa Monica, California, 90404, United States|University of Colorado Cancer Center/ CU Anschutz Medical Campus, Aurora, Colorado, 80045, United States|Mayo Clinic Florida, Jacksonville, Florida, 32224, United States|University of Miami/ Sylvester Comprehensive Cancer Center, Miami, Florida, 33136, United States|Moffitt Cancer Center, Tampa, Florida, 33612, United States|Northwestern, Chicago, Illinois, 60611, United States|Indiana University, Indianapolis, Indiana, 46202, United States|University of Iowa, Iowa City, Iowa, 52242, United States|Mass General Brigham Cancer Center, Boston, Massachusetts, 02114, United States|University of Michigan, Ann Arbor, Michigan, 48109, United States|Mayo Clinic Rochester, Rochester, Minnesota, 55905, United States|Washington University School of Medicine - Siteman Cancer Center, Saint Louis, Missouri, 63110, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Duke Cancer Institute, Durham, North Carolina, 27710, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, 44106, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|Ohio State University Wexner Medical Center/ The James Cancer Hospital and Solove Research Institute, Columbus, Ohio, 43210, United States|UPenn (Abramson Cancer Center, Pennsylvania Hospital), Philadelphia, Pennsylvania, 19106, United States|UPMC Hillman Cancer Center, Pittsburg, Pennsylvania, 15232, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|Medical College of Wisconsin/ Froedtert Hospital, Milwaukee, Wisconsin, 53226, United States|UHN - Princess Margaret Cancer Center (Ontario), Toronto, Ontario, M5G 2M9, Canada|McGill University Health Centre (Quebec), MontrÃ©al, Quebec, H4A 311, Canada|Chang Gung Medical Foundation Kaohsiung, Kaohsiung City, Niaosong District, 83301, Taiwan|National Taiwan University Hospital, Taipei, 10002, Taiwan|Taipei Veterans General Hospital, Taipei, 11217, Taiwan",
NCT04385550,A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma,https://clinicaltrials.gov/study/NCT04385550,,UNKNOWN,"This is a randomized, controlled, open-label, multicenter study to evaluate efficacy of AK105 injection combined with Anlotinib Hydrochloride Capsules versus standard second-line chemotherapy. Patients are treated with AK105 injection combined with Anlotinib Hydrochloride Capsules or standard second-line chemotherapy, with 1:1 random ratio.",NO,Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma,DRUG: Anlotinib hydrochloride capsule|DRUG: AK105 injection|DRUG: Paclitaxel injection|DRUG: Docetaxel injection,"Overall survival (OS), OS defined as the time from randomization to death from any cause. Subjects who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive., up to 45 weeks","Progression-free survival (PFS), PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause., up to 45 weeks|Overall response rate (ORR), Percentage of subjects achieving complete response (CR) and partial response (PR)., up to 45 weeks|Disease control rate (DCR), Percentage of subjects achieving complete response (CR) and partial response (PR) and stable disease (SD)., up to 45 weeks|Duration of response (DOR), DOR defined as time from earliest date of disease response to earliest date of disease progression based on radiographic assessment., up to 45 weeks",,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,528,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-20,2023-10-31,2023-12-31,2020-05-13,,2020-05-13,"The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230022, China|Beijing Shijitan Hospital Affiliated to Capital Medical University, Beijing, Beijing, 100038, China|The Sixth Medical Center of PLA General Hospital, Beijing, Beijing, 100048, China|Peking University Shougang Hospital, Beijing, Beijing, 100144, China|Beijing Luhe Hospital Capital Medical University, Beijing, Beijing, 101100, China|Beijing Tsinghua Changgung Hospital, Beijing, Beijing, 102218, China|Fujian Provincial Cancer Hospital, Fuzhou, Fujian, 350011, China|Quanzhou First Hospital, Quanzhou, Fujian, 362000, China|The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, 362000, China|The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, 361003, China|Zhongshan Hospital Xiamen University, Xiamen, Fujian, 361004, China|The First Hospital of Lanzhou University, Lanzhou, Gansu, 730000, China|Gansu Wuwei Tumour Hospital, Wuwei, Gansu, 733000, China|Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510000, China|The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, 510610, China|Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, 524000, China|Guangxi Medical University Affiliated Tumor Hospital, Nanning, Guangxi Zhuang Autonomous Region, 530021, China|The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050010, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150040, China|AnYang Tumor Hospital, Anyang, Henan, 455000, China|Xinxiang Central Hospital, Xinxiang, Henan, 453000, China|The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450003, China|Henan Cancer Hospital, Zhengzhou, Henan, 450008, China|Union Hospital,Tongji Medical College,Huazhong University of Science and Technology, Wuhan, Hubei, 430022, China|Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei, 430030, China|Hubei Cancer Hospital, Wuhan, Hubei, 430079, China|Xiangya Hospital Central South University, Changsha, Hunan, 410008, China|The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011, China|Hunan Cancer Hospital, Changsha, Hunan, 410013, China|Jiangsu Cancer Hospital, Nanjing, Jiangsu, 210009, China|Jiangsu Province Hospital, Nanjing, Jiangsu, 210029, China|Nantong Cancer Hospital, Nantong, Jiangsu, 226361, China|Wuxi People's Hospital, Wuxi, Jiangsu, 214023, China|Hospital of Jiangnan University, Wuxi, Jiangsu, 214062, China|The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, China|Liaoning Cancar Hospital, Shenyang, Liaoning, 110042, China|People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, Ningxia Hui Autonomous Region, 750021, China|Shandong Cancer Hospital, Jinan, Shandong, 250117, China|Shanghai General Hospital, Shanghai, Shanghai, 200080, China|Shanxi Provincial Cancer Hospital, Taiyuan, Shanxi, 030013, China|The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, 710004, China|First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, 710061, China|Tianjin Medical University General Hospital, Tianjing, Tianjing, 300050, China|Tianjin Medical University Cancer Institute and Hospital, Tianjing, Tianjing, 300060, China|The First People's Hospital of kashi region, Kashi, XinJiang Uighur Autonomous Region, 844000, China",
NCT04365374,Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study),https://clinicaltrials.gov/study/NCT04365374,,RECRUITING,This trial will be a randomized controlled study comparing the efficacy and safety of intraoperative radiation therapy using GammaTilesTM (GT) versus SRT 3-4 weeks following metastatic tumor resection which is the current standard of care.,NO,Brain Metastases,DEVICE: Gamma Tile-Surgically Targeted Radiation Therapy (STaRT)|RADIATION: Stereotactic Radiation Therapy,"Surgical bed recurrence-free survival (SB-RFS) from the time of randomization up to 2 years post radiation., Surgical bed control is defined as the absence of new nodular contrast enhancement in the index lesion surgical bed., up to 2 years post-radiation","Overall Survival, Survival of subjects, up to 3 years|Functional Assessment of Cancer Therapy-Brain (FACT-Br), An assessment of quality of life (QOL), up to 9 months|Linear Analog Scale Assessments (LASA), An assessment of quality of life (QOL), up to 9 months|Hopkins Verbal Learning Test (HVLT-R), An assessment of neurocognitive status, up to 24 months|Controlled Oral Word Association Test (COWAT), An assessment of neurocognitive status, up to 24 months|Trail Making Tests (TMT) Parts A and B, An assessment of neurocognitive status, up to 24 months|Barthel ADL, An assessment of physical functioning status, up to 24 months",,"GT Medical Technologies, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE3,180,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-04-06,2025-12-30,2027-12-30,2020-04-28,,2025-05-11,"HonorHeath Scottsdale Osborn Medical Center, Phoenix, Arizona, 85027, United States|University of Arkansas Medical Center, Little Rock, Arkansas, 72205, United States|Keck Hospital of Usc, Los Angeles, California, 90033, United States|Baptist MD Anderson Cancer Center- Jacksonville, Jacksonville, Florida, 32207, United States|HCA Florida First Coast Neurology- Orange Park, Orange Park, Florida, 32073, United States|Advent health Orlando, Orlando, Florida, 32804, United States|Orlando Health, Orlando, Florida, 32806, United States|Florida Health Sciences Center, Inc. d/b/a Tampa General Hospital, Tampa, Florida, 33606, United States|Piedmont Hospital, Atlanta, Georgia, 30309, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, 30322, United States|RUSH University, Chicago, Illinois, 60607, United States|Indiana University, IU Health Methodist Hospital, Indianapolis, Indiana, 46202, United States|The University Of Kansas Cancer Center, Kansas City, Kansas, 66016, United States|University of Louisville, Louisville, Kentucky, 40202, United States|Henry Ford Health, Detroit, Michigan, 48202, United States|Abbott Northwestern Hospital, Minneapolis, Minnesota, 55407, United States|University Of Minnesota, Minneapolis, Minnesota, 55414, United States|Ellis Fischel Cancer Center at University of Missouri, Columbia, Missouri, 65212, United States|SSM Health Saint Louis University Hospital, Saint Louis, Missouri, 63110, United States|Dartmouth-Hitchcock, Lebanon, New Hampshire, 03766, United States|HMH Jersey Shore University Medical Center, Neptune, New Jersey, 07753, United States|Albany Medical Center, Albany, New York, 12208, United States|Memorial Sloan Kettering, New York, New York, 10065, United States|Westchester Medical Center, Westchester, New York, 10595, United States|University of North Carolina Health, Chapel Hill, North Carolina, 27599, United States|ECU Health, Greenville, North Carolina, 27834, United States|Mayfield Brain and Spine, Cincinnati, Ohio, 45209, United States|Allegheny Health Network, Pittsburgh, Pennsylvania, 15212, United States|Brown University Health, Providence, Rhode Island, 02906, United States|Vanderbilt University Medical Center, Nashville, Tennessee, 37232, United States|UT Southwestern Simmons Cancer Center, Dallas, Texas, 75235, United States|Baylor St. Luke's Medical Center | Baylor College of Medicine, Houston, Texas, 77030, United States|Houston Methodist, Houston, Texas, 77030, United States|The University of Texas M. D. Anderson Cancer Center, Houston, Texas, 77030, United States|UT Health San Antonio, San Antonio, Texas, 78249, United States|SCRI with Texas Oncology, The Woodlands, Texas, 77380, United States|Virginia Mason, Seattle, Washington, 98101, United States",
